0001213900-25-05789320-F PSYENCE BIOMEDICAL LTD. 2025062520250625171653171655171655 0
0001213900-25-057893
20-F
117
20250331
20250625
20250625


PSYENCE BIOMEDICAL LTD.
0001985062
2834
000000000
A6
0331


20-F
34
001-41937
251074496


121 RICHMOND STREET WEST PENTHOUSE
SUITE 1300
TORONTO
A6
M5H 2K1
27744604171


121 RICHMOND STREET WEST PENTHOUSE
SUITE 1300
TORONTO
A6
M5H 2K1



20-F
1
ea0246623-20f_psyence.htm
ANNUAL REPORT











 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 20-F
 
(Mark One)
 
☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
 
OR
 
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended March 31,
2025
 
OR
 
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
OR
 
☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of event requiring this shell company report:
 
Commission File Number: 001-41937
 
Psyence Biomedical Ltd.
(Exact name of Registrant as specified in its
charter)
 
Not applicable Ontario, Canada (Translation of Registrant’s
name into English) (Jurisdiction of incorporation
or organization)
 
121 Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1
+1 (416) 346-7764
(Address of principal executive offices)
 
Copy to:
Neil Maresky
121 Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1
+1 (416) 346-7764
(Name, Telephone, Email and/or Facsimile number
and Address of Company Contact Person)
 
Securities registered or to be registered pursuant
to Section 12(b) of the Act:
 
Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common shares, without par value   PBM   The Nasdaq Stock Market LLC Warrants, each exercisable to purchase one Common Share at an exercise price of $6,874.13 per share   PBMWW   The Nasdaq Stock Market LLC
 
Securities registered or to be registered pursuant
to Section 12(g) of the Act: None
 
Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None
 


 
 

 
The number of the issuer’s outstanding common shares as of March 31,
2025 was 568,021 common shares.
 
Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act. Yes ☐   No ☒
 
If this report is an annual or transition report, indicate by check
mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ☐   No☒
 
Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒   No ☐
 
Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒   No ☐
 
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, or a non-accelerated filer, or an emerging growth company. See definition of “accelerated filer,”
“large accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒         Emerging growth company ☒
 
If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐
 
† The term “new or revised financial accounting standard”
refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
 
Indicate by check mark whether the registrant has filed a report on
and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of
the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
 
If securities are registered pursuant to Section 12(b) of
the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an
error to previously issued financial statements. ☐
 
Indicate by check mark whether any of those error corrections are restatements
that required a recovery analysis of incentive based compensation received by any of the registrant’s executive officers during
the relevant recovery period pursuant to §240.10D-1(b). ☐
 
Indicate by check mark which basis of accounting the registrant has
used to prepare the financial statements included in this filing:
 
U.S. GAAP ☐ International Financial Reporting Standards as issue by the International Accounting Standards Board ☒ Other ☐
 
If “Other” has been checked in response to the previous
question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐
 
If this is an annual report, indicate by check
mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
 
 
 


 
 

 
TABLE OF CONTENTS
 


 
 
Page

 
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
ii

PART I
 
1

ITEM 1.
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
1

ITEM 2.
OFFER STATISTICS AND EXPECTED TIMETABLE
1

ITEM 3.
KEY INFORMATION
1

ITEM 4.
INFORMATION ON THE COMPANY
28

ITEM 4A.
UNRESOLVED STAFF COMMENTS
56

ITEM 5.
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
56

ITEM 6.
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
61

ITEM 7.
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
75

ITEM 8.
FINANCIAL INFORMATION
78

ITEM 9.
THE OFFER AND LISTING
78

ITEM 10.
ADDITIONAL INFORMATION
79

ITEM 11.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS
93

ITEM 12.
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
93

 
 
 

PART II
 
99

ITEM 13.
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
99

ITEM 14.
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
99

ITEM 15.
CONTROLS AND PROCEDURES
99

ITEM 16.
[RESERVED]
100

ITEM 16A.
AUDIT COMMITTEE FINANCIAL EXPERT
100

ITEM 16B.
CODE OF ETHICS
100

ITEM 16C.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
100

ITEM 16D.
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
100

ITEM 16E.
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
100

ITEM 16F.
CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT
100

ITEM 16G.
CORPORATE GOVERNANCE
100

ITEM 16H.
MINE SAFETY DISCLOSURE
101

ITEM 16I.
DISCLOSURE REGARDING FOREIGN JURISDICTION THAT PREVENT INSPECTIONS
101

ITEM 16J.
INSIDER TRADING POLICIES
101

ITEM 16K.
CYBERSECURITY
101

 
 
 

PART III
 
102

ITEM 17.
FINANCIAL STATEMENTS
102

ITEM 18.
FINANCIAL STATEMENTS
102

ITEM 19.
EXHIBITS
102

 
Except as otherwise indicated or required by context, references in
this Annual Report on Form 20-F (the “Report”) to “we,” “us,” “our,” “Psyence
Biomedical” or the “Company” refer to Psyence Biomedical Ltd., a corporation organized under the laws of Ontario,
Canada.
 


i
 

 
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
 
This Report and the documents incorporated by
reference herein include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements relate
to, among others, our plans, objectives and expectations for our business, operations and financial performance and condition, and can
be identified by terminology such as “may,” “should,” “expect,” “intend,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue”
and similar expressions that do not relate solely to historical matters. Forward-looking statements are based on management’s belief
and assumptions and on information currently available to management. Although we believe that the expectations reflected in forward-looking
statements are reasonable, such statements involve known and unknown risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied
by forward-looking statements.
 
Forward-looking statements in this Report and
in any document incorporated by reference in this Report may include, but are not limited to, statements about:
 

●the ability of Psyence Biomedical to maintain the listing of the Common Shares
or the Warrants on Nasdaq;
 

●volatility in the price of the securities of Psyence Biomedical due to a
variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence
Biomedical operates, variations in performance across competitors, changes in laws and regulations affecting Psyence Biomedical's business
and changes in Psyence Biomedical’s capital structure;
 

●Psyence Biomedical’s success in retaining or recruiting, or changes
required in, its officers, key employees or directors;
 

●factors relating to the business, operations and financial performance of
the Company, including, but not limited to:
 

othe Company’s ability to achieve successful clinical results;
 

othe Company currently has no products approved for commercial sale;
 

othe Company’s ability to obtain regulatory approval for its product candidates, and any related restrictions or limitations
of any approved products;
 

othe Company’s ability to obtain licensing of third-party intellectual property rights for future discovery and development of
the Company’s product candidates;
 

othe Company’s ability to commercialize product candidates and achieve market acceptance of such product candidates;
 

othe Company’s success is dependent on product candidates which it licenses from third parties;
 

othe Company’s success is dependent on the supply of materials necessary to perform its clinical trials; and
 

othe ability to respond to general economic conditions;
 
Forward-looking statements are subject to known and unknown risks and
uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected
or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements
for many reasons, including the factors discussed under the “Risk Factors” section below and in the Company’s other
filings with the SEC. Accordingly, you should not rely on these forward-looking statements, which speak only as of the date of this Report.
We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this
Report or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks described in the reports
we will file from time to time with the SEC after the date of this Report.
 
Although we believe the expectations reflected
in the forward-looking statements were reasonable at the time made, we cannot guarantee future results, level of activity, performance
or achievements. Moreover, neither we nor any other person assume responsibility for the accuracy or completeness of any of these forward-looking
statements. You should carefully consider the cautionary statements contained or referred to in this section in connection with the forward-looking
statements contained in this Report and any subsequent written or oral forward-looking statements that may be issued by the Company or
persons acting on its behalf.
 


ii
 

 
PART I
 
ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
 
Not Applicable.
 
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
 
Not applicable.
 
ITEM 3. KEY INFORMATION
 
A. [Reserved.]
 
B. Capitalization and Indebtedness
 
Not applicable.
 
C. Reasons for the Offer and Use of Proceeds
 
Not applicable.
 
D. Risk Factors
 
Investing in our securities involves a high
degree of risk. You should carefully consider the following information about these risks, together with the other information appearing
elsewhere in this Report, including our financial statements, the notes thereto and the section entitled “Management’s Discussion
and Analysis of Financial Condition and Results of Operations,” before deciding to invest in our securities. The occurrence of any
of the following risks could have a material adverse effect on our business, reputation, financial condition, results of operations and
future growth prospects, as well as our ability to accomplish our strategic objectives. As a result, the trading price of our securities
could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that
we currently deem immaterial may also impair our business operations and the market price of our securities.
 
We are a clinical-stage biotechnology company and have incurred
significant losses since our inception. We anticipate that we will incur significant losses for the foreseeable future.
 
Investment in biotechnology product development
is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate
will fail to demonstrate effectiveness or an acceptable safety profile, gain regulatory approval and become commercially viable. All of
Psyence’s product candidates will require substantial additional capital expenditures and development time, including extensive
clinical research and resources, before it would be able to apply for and then receive marketing authorization and begin generating revenue
from product sales.
 
Since its inception, Psyence has invested most
of its resources in establishing strategic partnerships, securing intellectual property licensing rights, advancing its clinical trial
program, raising capital, building its management team and providing general and administrative support for these operations. Psyence
has incurred losses in each year since its inception and expects to incur significant losses for the foreseeable future. Psyence’s
net profit/(loss) for the years ended March 31, 2025 and March 31, 2024 was $1 million and ($50.96 million), respectively. The March 31,
2025 net profit was driven by the fair value gains on conversion of debt into equity and warrant liability fair value remeasurement. To
date, no products have been approved for commercial sale and Psyence has not generated any revenue. Psyence has financed operations solely
through the sale of equity securities and convertible debt financings. Psyence continues to incur significant research and development
and other expenses related to ongoing operations and expects to incur losses for the foreseeable future.
 
Due to the numerous risks and uncertainties associated
with the development of its product candidates, Psyence is unable to predict the timing or amount of its expenses, or when it will be
able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, its expenses could increase beyond
current expectations if Psyence is required by the Therapeutic Goods Administration in Australia (“TGA”), the U.S.
Food and Drug Administration (“FDA”), the European Medicines Agency (“EMA”), Medicines and Healthcare
products Regulatory Agency in the UK (“MHRA”), or other comparable foreign regulatory authorities, to perform preclinical
studies or clinical trials in addition to those that Psyence currently anticipates, or if there are any delays in any of Psyence’s
or its future collaborators’ clinical trials or the development of the existing product candidates and any other product candidates
that Psyence may identify. Even if Psyence’s existing product candidates or any future product candidates that Psyence may identify
are approved for commercial sale, Psyence anticipates incurring significant costs associated with commercializing any approved product
and ongoing compliance efforts.
 


1
 

 
Psyence has a limited operating history and expects a number
of factors to cause its operating results to fluctuate on an annual basis, which may make it difficult to predict the future performance
of Psyence.
 
Psyence is a clinical stage biotechnology development
company with a limited operating history. Consequently, any predictions made about Psyence’s future success or viability may not
be as accurate as they could be if Psyence had a longer operating history and additional definitive partnership agreements in place. Psyence’s
operating results are expected to significantly fluctuate from quarter-to-quarter or year-to-year due to a variety of factors, many
of which are beyond its control. Factors relating to Psyence’s business that may contribute to these fluctuations include, but are
not limited to:
 

●any delays or issues in finding, and establishing successful business arrangements
with, pharmaceutical and product development partners to assist in moving its product candidates through the development and commercialization
processes;
 

●delays in the commencement, enrolment and timing of clinical trials;
 

●the success of its preclinical trials;
 

●potential side effects of its product candidates that could delay or prevent
approval or license-out agreements or cause an approved product candidate to be eliminated;
 

●supply chain interruptions, which could delay Psyence in the process of developing
its product candidates;
 

●its ability to obtain additional funding to develop its product candidates;
 

●its ability to attract and retain talented and experienced personnel to manage
its business effectively;
 

●competition from existing psychedelic analogs companies or new psychedelic
analogs companies that continue to emerge;
 

●assuming market authorization has been obtained for our product candidates,
the ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for such products;
 

●its ability to adhere to clinical study requirements directly or with third
parties such as clinical research organizations (“CROs”);
 

●its dependency on third-party manufacturers to manufacture products and key
ingredients;
 

●its ability to establish or maintain collaborations, licensing or other transactions;
 

●its ability to defend against any challenges to its intellectual property,
including claims of patent infringement;
 

●its ability to enforce its intellectual property rights against potential
competitors;
 

●its ability to secure additional intellectual property protection for its
product candidates and associated manufacturing methods currently under development;
 

●a biological or chemical effect that Psyence does not predict;
 

●adverse economic circumstances; and
 

●potential liability claims.
 
Accordingly, the results of any historical financial
periods should not be relied upon as indications of future operating performance.
 


2
 

 
Psyence has never generated revenue and may never be profitable.
 
Psyence may never be able to develop or commercialize
marketable products or achieve profitability. Revenue from the sale of any product candidate for which regulatory approval is obtained
will be dependent, in part, upon the size of the markets in the territories for which Psyence gains regulatory approval, the accepted
price for the product, the acceptance of the product by physicians and patients, the ability to obtain reimbursement at any price and
whether Psyence owns the commercial rights for that territory. Psyence’s growth strategy depends on its ability to generate revenue.
In addition, if the number of addressable patients is not as anticipated, the indication or intended use approved by regulatory authorities
is narrower than expected, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment
guidelines, Psyence may not generate significant revenue from sales of such products, even if approved. Even if Psyence is able to generate
revenue from the sale of any approved products, Psyence may not become profitable and may need to obtain additional funding to continue
operations. Even if Psyence were to achieve profitability in the future, it may not be able to sustain profitability in subsequent periods.
 
Psyence’s failure to achieve sustained profitability
would depress the value of the Company and could impair its ability to raise capital, expand the business, diversify its research and
development pipeline, market its product candidates, if approved, and pursue or continue operations. Psyence’s prior losses, combined
with expected future losses, have had and will continue to have an adverse effect on shareholders’ equity and working capital.
 
The Company will require substantial additional funding to achieve
its business goals, and if it is unable to obtain this funding when needed and on acceptable terms, it could be forced to delay, limit
or terminate its product development efforts.
 
Psyence’s clinical trial and product development
pipeline currently consists of an approved Phase IIb Study in Australia. We have also obtained approval from the MHRA to conduct a Phase
IIa study in the UK, which was not initiated due to certain cost-effective incentives provided by Australia. Once the Phase IIb Study
in Australia is completed, a Phase III pivotal study program will begin, of which the size and number of trials will depend on the results
of the Phase IIb Study, the advice given to Psyence from the regulatory authorities and whether the FDA will assess the program as being
fast-tracked or eligible as a breakthrough therapy. If the assessment is the latter, the Phase III program could be smaller than anticipated
and less than the usual required two pivotal studies to support market authorization.
 
Conducting clinical trials and developing biopharmaceutical
products is expensive and time consuming, and we expect to require substantial additional capital to conduct research, preclinical studies
and clinical trials for the current and future trials, seek regulatory approvals for our product candidates and launch and commercialize
any products for which Psyence may receive regulatory approval, including building our own commercial sales, marketing and distribution
organization. Our management and strategic decision makers have not made decisions regarding the future allocation of certain resources
among Psyence’s pipeline of trials, but continue to evaluate the needs and opportunities with respect to each of these trials routinely
and on a case-by-case basis. Because the outcome of any preclinical or clinical development and regulatory approval process is highly
uncertain (including the size and quantum of the Phase III registrational program), Psyence cannot reasonably estimate the actual amounts
necessary to successfully complete the development, regulatory approval process and potential commercialization of its product candidates
and any future product candidates it may identify.
 


3
 

 
Psyence expects that the existing available cash
will be sufficient to fund operations beyond 12 months from the date of this filing. However, Psyence’s operating plan may change
as a result of many factors currently unknown, and Psyence may need to seek additional funds sooner than planned, through public or private
equity or debt financings, sales of assets or programs, other sources, such as strategic collaborations or license and development agreements,
or a combination of these approaches. Even if Psyence believes that its funds are sufficient for its current or future operating plans,
it may, subject to obtaining the necessary contractual consents, opportunistically seek additional capital if market conditions are favorable
or for specific strategic considerations. Psyence’s spending will vary based on new and ongoing product development and business
development activities. Any such additional fundraising efforts for Psyence may divert management from their day-to-day activities, which
may adversely affect Psyence’s ability to develop and commercialize product candidates that Psyence may identify and pursue. Moreover,
such financing may result in dilution to shareholders, imposition of debt covenants and repayment obligations, or other restrictions that
may affect Psyence’s business. Changing circumstances, some of which may be beyond Psyence’s control, could cause Psyence
to consume capital significantly faster than currently anticipated, and Psyence may need to seek additional funds sooner than planned.
Psyence’s future funding requirements, both short-term and long-term, will depend on many factors, including, but not limited:
 

●the time and cost necessary to complete ongoing and planned clinical trials;
 

●the outcome, timing and cost of meeting regulatory requirements established
by the TGA, FDA, the EMA, the MHRA and other comparable foreign regulatory authorities;
 

●the progress, timing, scope and costs of preclinical studies, clinical trials
and other related activities for ongoing and planned clinical trials, and potential future clinical trials;
 

●the costs of obtaining clinical and commercial supplies of raw materials
and drug products for Psyence’s product candidates, as applicable, and any other product candidates Psyence may identify and develop;
 

●Psyence’s ability to successfully identify and negotiate acceptable
terms for third-party supply and contract manufacturing agreements with contract manufacturing organizations (“CMOs”);
 

●the costs of commercialization activities for any of Psyence’s product
candidates that receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution and
manufacturing capabilities, or entering into strategic collaborations with third parties to leverage or access these capabilities;
 

●the amount and timing of sales and other revenues from Psyence’s product
candidates, if approved, including the sales price and the availability of coverage and adequate third-party reimbursement;
 

●the cash requirements of developing Psyence’s programs and Psyence’s
ability and willingness to finance their continued development;
 

●the cash requirements of any future acquisitions or discovery of product
candidates;
 

●the time and cost necessary to respond to technological and market developments,
including other products that may compete with one or more of Psyence’s product candidates;
 

●supply chain interruptions, which could delay Psyence in the process of developing
its product candidates;
 

●the costs of acquiring, licensing or investing in intellectual property rights,
products, product candidates and businesses;
 

●the costs of maintaining, expanding and protecting Psyence’s intellectual
property portfolio;
 

●its ability to attract, hire and retain qualified personnel as Psyence expands
research and development and establishes a commercial infrastructure; and
 

●the costs of operating as a public company in the United States and maintaining
a listing on Nasdaq.
 
Psyence cannot be certain that additional funding
will be available on acceptable terms, or at all. Market volatility resulting from the introduction of significant instability and uncertainty
into global supply chains, pricing structures, and international trade relationships due to the geopolitical and trade policy uncertainty,
including U.S. tariff measures and escalations in the Middle East, could adversely affect global economic conditions and our business.
Other factors could also adversely impact the ability to access funds as and when needed. If adequate funds are not available to Psyence
on a timely basis, Psyence may be required to delay, limit or terminate one or more research or development programs or trials or the
potential commercialization of any approved products or be unable to expand operations or otherwise capitalize on business opportunities,
as desired, which could materially affect Psyence’s businesss, prospects, financial condition and results of operations.
 


4
 

 
We depend on our current key personnel and our ability to attract
and retain employees.
 
Our future growth and success depends on our ability
to recruit, retain, manage and motivate our employees. We are highly dependent on our current management and scientific personnel, including
Dr. Neil Maresky (Chief Executive Officer), Jody Aufrichtig (Executive Chairman), Warwick Corden-Lloyd (Chief Financial Officer),
Dr. Clive Ward-Able (Medical Director) and Taryn Vos (General Counsel). The inability to hire or retain experienced management personnel
could adversely affect our ability to execute our business plan and harm our operating results. Due to the specialized scientific and
managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial
personnel. The competition for qualified personnel in the pharmaceutical field is intense and we may be unable to continue to attract
and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.
 
Our historical financial results may not be representative of
our results as a separate, stand-alone company.
 
Some of the historical financial information we
have included in this Report has been derived from the financial statements and accounting records of PGI (as defined below) and does
not necessarily reflect what our financial position, results of operations or cash flows would have been had we been a separate, stand-alone
company during the periods presented. The historical information does not necessarily indicate what our results of operations, financial
position cash flows or costs and expenses will be in the future.
 
The psychedelic therapy and biotechnology industries are undergoing
rapid growth and substantial change, which has resulted in an increase in competitors, consolidation and formation of strategic relationships.
Acquisitions or other consolidating transactions could harm Psyence in a number of ways, including by losing strategic partners if they
are acquired by or enter into relationships with a competitor, losing customers, revenue and market share, or forcing Psyence to expend
greater resources to meet new or additional competitive threats, all of which could harm Psyence’s operating results.
 
The psychedelic therapy and biotechnology industries
are intensely competitive and subject to rapid and significant technological change. Psyence has competitors in Canada, the United States,
Europe and other jurisdictions, including major multinational pharmaceutical companies, established biotechnology companies, specialty
pharmaceutical and generic drug companies and universities and other research institutions. Many of its competitors have greater financial
and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations than
it does. Large pharmaceutical companies, in particular, have extensive experience in, and substantial capital resources for, conducting
research, molecular derivative development, obtaining regulatory approvals, obtaining intellectual property protection and establishing
key relationships. These companies also have significantly greater sales and marketing capabilities and experience in completing collaborative
transactions in Psyence’s target markets with leading companies and research institutions.
 
Psyence’s competitors may introduce new
psychedelic analogs or develop technological advances that compete with Psyence. Psyence cannot predict the timing or impact of competitors
introducing new psychedelic analogs or technological advances. Such competing psychedelic analogs may be safer, more effective, more effectively
marketed, licensed or sold or have lower prices or superior performance features than Psyence’s psychedelic analogs, and this could
negatively impact Psyence’s business and results of operations. Established pharmaceutical companies may also invest heavily to
accelerate discovery and development of novel compounds or to in-license novel compounds that could make the psychedelic analogs that
Psyence develops obsolete. As a result of any of these factors, Psyence’s competitors may succeed in obtaining patent protection
or discovering, developing and commercializing psychedelic analogs before Psyence does or may develop psychedelic analogs that are deemed
to be more effective or gain greater market acceptance than those of Psyence.
 
Smaller or early-stage companies may also prove
to be significant competitors, particularly through collaborative transactions with large, established companies. In addition, many universities
and private and public research institutions may become active in the development of novel compounds. Psyence’s competitors may
succeed in developing, acquiring or licensing on an exclusive basis, technologies and psychedelic analogs that are more effective or less
costly than any of the psychedelic analogs that Psyence is currently developing or that it may develop, which could render its psychedelic
analogs obsolete or non-competitive. If Psyence’s competitors’ market psychedelic analogs that are more effective, safer or
less expensive or that reach the market sooner than Psyence’s psychedelic analogs, if any, Psyence may not achieve commercial success.
In addition, because of its limited resources, it may be difficult for Psyence to stay abreast of the rapid changes in each technology.
If Psyence fails to stay at the forefront of technological change, it may be unable to compete effectively. Technological advances or
products developed by its competitors may render its technologies or psychedelic analogs obsolete, less competitive or not economical.
 


5
 

 
Current and future preclinical and clinical studies will be conducted
outside the United States, and the FDA may not accept data from such studies to support any NDAs submitted after completing the applicable
developmental and regulatory prerequisites (absent an IND).
 
Psyence is conducting a clinical study outside
the United States. Psyence has received full approval of a study in the UK from the MHRA, which was not initiated due to certain cost-effective
incentives provided by Australia. Psyence has received full approval from the Australian Human Research Ethics Committees (HRECs), the
body responsible for the review of research proposals involving human participants to ensure that they are ethically acceptable. The protocol
under review in Australia will be reviewed as part of a Pre-IND (Investigational New Drug) application by the FDA. To the extent Psyence
does not conduct these clinical trials under an IND, the FDA may not accept data from such trials. Although the FDA may accept data from
clinical trials conducted outside the United States that are not conducted under an IND, the FDA’s acceptance of these data is subject
to certain conditions. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in
accordance with ethical principles and all applicable FDA regulations. The trial population must also adequately represent the intended
U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically
meaningful. There can be no guarantee that the FDA will accept data from trials conducted outside of the United States. If the FDA does
not accept the data from such clinical trials, this would likely result in the need for additional trials and the completion of additional
regulatory steps, which would be costly and time-consuming and could delay or permanently halt the development of Psyence’s product
candidates.
 
There is a high rate of failure for product candidates proceeding
through clinical trials.
 
Psyence has no registered products on the market,
and its new potential psilocybin-based product candidates are currently either in the preclinical or clinical development phase. Psyence’s
ability to achieve and sustain profitability with respect to its product candidates in which psilocybin is featured as the active pharmaceutical
ingredient depends on obtaining regulatory approvals for and, if approved, successfully commercializing, its product candidates, either
alone or with third parties. Before obtaining regulatory approval for the commercial distribution of its current or future product candidates,
Psyence or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety,
purity and potency of its product candidates.
 
Generally, there is a high rate of failure for
product candidates proceeding through clinical trials. Psyence may suffer significant setbacks in its clinical trials similar to the experience
of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving promising results in earlier trials.
Further, even if Psyence views the results of a clinical trial to be positive, applicable international regulatory authorities may disagree
with Psyence’s interpretation of the data. In the event that Psyence obtains negative results from clinical trials for product candidates
or other problems related to potential chemistry, manufacturing and control issues or other hurdles occur and its current or future product
candidates are not approved, Psyence may not be able to generate sufficient revenue or obtain financing to continue its operations, its
ability to execute on its current business plan may be materially impaired and its reputation in the industry and in the investment community
might be significantly damaged. In addition, Psyence’s inability to properly design, commence and complete clinical trials may negatively
impact the timing and results of its clinical trials and ability to seek approvals for its product candidates.
 
The testing, marketing and manufacturing of any
new drug product for use in the U.S. will require approval from the FDA. Psyence cannot predict with any certainty the amount of time
necessary to obtain such FDA approval and whether any such approval will ultimately be granted. Preclinical and clinical trials may reveal
that one or more product candidates are ineffective or unsafe, in which event further development of such product candidates could be
seriously delayed or terminated. Moreover, obtaining approval for certain product candidates may require testing on human subjects of
substances whose effects on humans are not fully understood or documented. Delays in obtaining FDA or any other necessary regulatory approvals
of any proposed drug and failure to receive such approvals would have an adverse effect on the drug’s potential commercial success
and on Psyence’s business, prospects, financial condition and results of operations. In addition, it is possible that a proposed
drug may be found to be ineffective or unsafe due to conditions or facts that arise after development has been completed and regulatory
approvals have been obtained. In this event, Psyence may be required to withdraw such proposed drug from the market. To the extent that
its success will depend on any regulatory approvals from government authorities outside of the U.S. that perform roles similar to that
of the FDA, uncertainties similar to those stated above will also exist.
 


6
 

 
Because the results of preclinical studies and earlier clinical
trials are not necessarily predictive of future results, Psyence may not have favorable results in its planned and future clinical trials.
 
Successful development of therapeutic products
is highly uncertain and is dependent on numerous factors, many of which are beyond Psyence’s control. Product candidates that appear
promising in the early phases of development may fail to reach the market for several reasons, including, but not limited to:
 

●preclinical or clinical study results that may show the product to be less
effective than desired (e.g., the study failed to meet Psyence’s primary objectives) or to have harmful or problematic side effects;
 

●failure to receive the necessary regulatory approvals or a delay in receiving
such approvals. Among other things, such delays may be caused by slow enrollment in clinical studies, length of time to achieve study
endpoints, additional time requirements for data analysis or regulatory requests for additional preclinical or clinical data or unexpected
safety or manufacturing issues;
 

●manufacturing costs, pricing, or reimbursement issues or other factors that
make the product not economical; and
 

●the proprietary rights of others and their competing products and technologies
that may prevent the product from being commercialized.
 
Any positive results from preclinical testing
of Psyence’s prospective product candidates may not necessarily be predictive of the results from planned or future clinical trials
for such product candidates. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical
trials after achieving positive results in preclinical and early clinical development, and Psyence cannot be certain that it will not
face similar setbacks. These setbacks have been caused by, among other things, preclinical findings while clinical trials were underway
or safety or efficacy observations in clinical trials, including adverse events. If Psyence fails to produce positive results in its planned
clinical trials for its product candidates as described in the section titled “Business”, or its future clinical trials, the
development timeline and regulatory approval and commercialization prospects for such product candidates, and, correspondingly, Psyence’s
business and financial prospects, would be materially adversely affected.
 
Negative results from clinical trials or studies of others and
adverse safety events involving Psyence’s psychedelic analogs could have a material adverse effect on Psyence’s business.
 
From time to time, studies or clinical trials
on medical-grade psilocybin mushroom products may be conducted or sponsored by academics, research institutions or others, including government
agencies. The publication of negative results of studies or clinical trials related to Psyence’s proposed products or the therapeutic
areas in which Psyence’s proposed products will compete could have a material adverse effect on Psyence’s business, prospects,
financial condition and results of operations.
 
Supply chain interruptions could delay Psyence in the process
of developing its product candidates.
 
There are few licensed suppliers of input materials
for the manufacture of Psyence’s product candidates. Any loss of stored materials or facilities through fire, theft or other causes
could have an adverse effect on Psyence’s ability to procure the product candidate materials and continue product development activities.
Furthermore, Psyence is largely dependent on Filament Health Corp ("Filament"), for the supply of PEX010 (a capsule containing
25mg naturally sourced psilocybin and product being used in Psyence’s Phase IIb Study), and any interruption in Filament’s
supply chain (or the supply chain of any other suppliers engaged by Psyence) will lead to delays in Psyence’s drug development timelines.
Furthermore, Filament, as well as any other suppliers engaged by Psyence, will be required to continue to meet regulatory requirements
applicable to the PEX010 product candidate and maintain GMP compliant standards which dictate the minimum requirements for the methods,
facilities and controls used in manufacturing, processing and packing of a drug product. There can be no assurances that Filament or any
CMOs will be able to meet Psyence’s timetable and requirements or carry out their contractual obligations in accordance with the
applicable regulations. In addition, the drug product supplied to Psyence may not meet its specifications and quality policies and procedures
nor may they be able to supply the drug product in commercial quantities when the time comes. If Psyence is unable to arrange for alternative
third-party supply sources on commercially reasonable terms or in a timely manner, it may delay the development of its product candidates
and could have a material adverse effect on Psyence’s business operations and financial condition.
 
Further, the failure of CMOs to operate in compliance
with GMP or other applicable quality related regulations could result in, among other things, certain product liability claims in the
event such failure to comply results in defective products that caused injury or harm. In general, Psyence’s dependence upon third
parties for the supply of Psyence’s drug product may adversely affect profit margins and Psyence’s ability to develop and
deliver viable end products on a timely and competitive basis.
 


7
 

 
Psyence’s proprietary information, or that of its strategic
business partners, may be lost or Psyence may suffer security breaches.
 
In the ordinary course of its business, Psyence
collects and stores sensitive data, including valuable and commercially sensitive intellectual property, clinical trial data, proprietary
business information and that of Psyence’s strategic business partners, as well as the personally identifiable information of clinical
trial subjects, employees and patients, in and on Psyence’s networks. Despite security measures, information technology and infrastructure
may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise
Psyence’s networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure
or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information,
regulatory penalties, disruption of operations, damage to Psyence’s reputation, and cause a loss of confidence in Psyence’s
ability to conduct clinical trials, which could adversely affect Psyence’s business, prospects, financial condition and results
of operations.
 
Costs associated with compliance with numerous laws and regulations
could impact our financial results. In addition, we could become subject to increased enforcement and/or litigation risks associated with
the psychedelic therapeutics industry.
 
The manufacture, labeling and distribution of
products containing psilocybin or other psychedelic analogs is governed by various federal, state and local agencies. To the extent we
are able to successfully commercialize any of our currently contemplated product candidates via the FDA’s NDA approval pathway,
the presence of psychedelic analogs as active or inactive ingredients, as applicable, may give rise to heightened regulatory scrutiny
and greater risk of consumer litigation, either of which could further restrict the permissible scope of our marketing claims about such
products or our ability to sell them in the United States at all. The shifting compliance environment and the need to build and maintain
robust systems to comply with different psychedelic-related regulations in jurisdictions may increase costs and/or the risk that we may
violate one or more applicable regulatory requirements. If our operations, or any of our activities or prospective products, are found
to be in violation of any such laws or any other governmental regulations that apply to the manufacture, distribution, or sale of prescription
drug products, generally, and to products containing psychedelic analogs, we may be subject to penalties, including, without limitation,
civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, any of which could adversely affect
our ability to operate our business or our financial results.
 
Failure to comply with any applicable regulatory
requirements, relating to psilocybin or otherwise, may result in, among other things, injunctions, product withdrawals, recalls, product
seizures, fines and criminal prosecutions. Additionally, advertising and labeling laws are often enforced by governmental officials, and
any action based on potentially misleading or deceptive advertising is often followed by costly class-action complaints under consumer-protection
laws.
 
Psyence may acquire businesses or products, or form additional
strategic alliances, in the future, and may not realize the benefits of such acquisitions.
 
Psyence may acquire additional businesses or products,
form additional strategic alliances, or create joint ventures with third parties that it believes will complement or augment its existing
business. Any of these relationships may require Psyence to incur non-recurring and other charges, increase Psyence’s near and long-term
expenditures, issue securities that dilute Psyence’s existing shareholders or disrupt Psyence’s management and business. In
addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and
complex. If Psyence acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring
such businesses if it is unable to successfully integrate them with its existing operations and company culture. Psyence may encounter
numerous difficulties in developing, manufacturing, and marketing any new products resulting from a strategic alliance or acquisition
that delay or prevent it from realizing their expected benefits or enhancing its business. There is no assurance that, following any such
acquisition, Psyence will achieve the synergies expected in order to justify the transaction, which could result in a material adverse
effect on its business and prospects.
 


8
 

 
We will need substantial additional financing to develop our
product candidates and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development
and commercialization of our product candidates.
 
We expect to spend a substantial amount of capital
in the development and manufacturing of our product candidates, and we will need substantial additional financing to do so. In particular,
we will require substantial additional financing to enable commercial production of our product candidates and initiate and complete registrational
trials for multiple products in multiple regions. Further, if approved, we will require significant additional capital in order to launch
and commercialize our product candidates.
 
As of March 31, 2025, we had USD$6,171,130 in
cash and cash equivalents and restricted cash. Changing circumstances may cause us to consume capital significantly faster than we currently
anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may also need
to raise additional capital sooner than we currently anticipate if we choose to expand more rapidly than we presently plan. In any event,
we will require additional capital for the further development and commercialization of our product candidates.
 
We cannot be certain that additional funding will
be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable
to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or
other research and development initiatives. We could be required to seek collaborators for our product candidates at an earlier stage
than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable
terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.
 
Any of the above events could significantly harm
our business, prospects, financial condition and results of operations and cause the price of our securities to decline.
 
In addition, future changes in regulations, changes
in legal status of psilocybin-containing products, more vigorous enforcement thereof or other unanticipated events could require extensive
changes to Psyence’s operations, increased compliance costs or give rise to material liabilities, which could have a material adverse
effect on the business, results of operations and financial condition of Psyence.
 
We rely on third parties to conduct our clinical trials. If these
third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain
regulatory approval of, or commercialize, our product candidates.
 
Psyence relies on Southern Star Research Pty Ltd
("Southern Star Research"), full-service Australian CRO, to conduct clinical development activities with Psyence’s
product candidates, which activities involve trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring,
clinical data management and analysis, safety monitoring and project management.
 
Additionally, we expect to utilize and depend
upon independent investigators and collaborators, such as medical institutions, CROs, CDMOs and strategic partners to conduct our preclinical
studies under agreements with us and in connection with our clinical trials. We expect to have to negotiate budgets and contracts with
CROs, trial sites and CDMOs, which may result in delays to our development timelines and increase costs. We will rely heavily on these
third parties over the course of our clinical trials, and we control only certain aspects of their activities. As a result, we have less
direct control over the conduct, timing and completion of these clinical trials and the management of data developed through clinical
trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each
of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards and our
reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with
good clinical practices (“GCPs”), which are regulations and guidelines enforced by the FDA and comparable foreign regulatory
authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of
trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations,
the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may
require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection,
such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. Our failure or any failure
by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical
trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates
federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.
 


9
 

 
Any third parties conducting our clinical trials
are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot
control whether or not they devote sufficient time and resources to our product candidates. These third parties may also have relationships
with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development
activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual
duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they
obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical
trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully
commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would
be harmed, our costs could increase and our ability to generate revenue could be delayed.
 
Switching or adding third parties to conduct our
clinical trials involves substantial cost and requires extensive management time and focus. In addition, changes in manufacturers often
involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical
supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical
supplies which could require the conduct of additional clinical trials. Additionally, there is a natural transition period when a new
third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development
timelines.
 
We are dependent on licensed intellectual property. If we were
to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing our product candidates,
if approved. If we breach any of the agreements under which we license the use, development and commercialization rights to our product
candidates or technology from third parties or, in certain cases, we fail to meet certain development deadlines, we could lose license
rights that are important to our business.
 
We do not currently own any patents, and we are
heavily reliant upon a number of license agreements under which we are granted rights to intellectual property that are important to our
business and we may need or choose to enter into additional license agreements in the future.
 
Specifically, our business and active Phase IIb
Study is highly dependent on the Research IP Agreement with Filament for the rights to PEX010, which expires in April 2027 and covers
the Phase IIb Study only. Until we develop our own product candidates, the termination, non-renewal or hinderance of use of the license
granted under the Research IP Agreement could have a material adverse effect on our ability to develop our product candidates. Furthermore,
following the completion of the Phase IIb Study, we will be required to enter into agreements with alternative suppliers for the supply
and licensing of alternative drug products for use in our pivotal Phase III studies in palliative care, and there can be no guarantees
that such agreements will be finalized. The Company continues to evaluate its bridging program into Phase III in this regard, which bridging
program will require regulatory agency approval, and there can be no guarantees that such approvals will be obtained.
 
Our existing license agreements impose, and we
expect that future license agreements will impose on us, various development, regulatory and/or commercial diligence obligations, payment
of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, the licensor may
have the right to terminate the license, in which event we would not be able to market products covered by the license. Our business could
suffer, for example, if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed
patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms.
 


10
 

 
Licensing of intellectual property is of critical
importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors
regarding intellectual property subject to a license agreement, including:
 

●the scope of rights granted under the license agreement and other interpretation-related
issues;
 

●whether and the extent to which our technology and processes infringe on
intellectual property of the licensor that is not subject to the licensing agreement;
 

●our right to sublicense patent and other rights to third parties;
 

●our diligence obligations with respect to the use of the licensed technology
in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;
 

●our obligation to pursue, or license others to pursue, development of indications
we are not currently pursuing;
 

●the ownership of inventions and know-how resulting from the joint creation
or use of intellectual property by our licensors and us and our partners;
 

●our right to transfer or assign the license; and
 

●the effects of termination.
 
If disputes over intellectual property that we
have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully
develop and commercialize the affected product candidates.
 
We may enter into additional licenses to third-party
intellectual property that are necessary or useful to our business. Our current licenses and any future licenses that we may enter into
may impose various royalty payment, milestone, and other obligations on us. Under some license agreements, we may not control prosecution
of the licensed intellectual property, or may not have the first right to enforce the intellectual property. In those cases, we may not
be able to adequately influence patent prosecution or enforcement, or prevent inadvertent lapses of coverage due to failure to pay maintenance
fees. If we fail to comply with any of our obligations under a current or future license agreement, the licensor may allege that we have
breached our license agreement, and may accordingly seek to terminate our license. Termination of any of our current or future licenses
could result in our loss of the right to use the licensed intellectual property, which could materially adversely affect our ability to
develop and commercialize a product candidate or product, if approved, as well as harm our competitive business position and our business
prospects. Under some license agreements, termination may also result in the transfer of or granting in rights under certain of our intellectual
property and information related to the product candidate being developed under the license, such as regulatory information.
 
The agreements under which we license intellectual
property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple
interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope
of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations
under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations
and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current
licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product
candidates.
 
In addition, if our licensors fail to abide by
the terms of the license, if the licensors fail to prevent infringement by third parties, if the licensed patents or other rights are
found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms, our business could suffer.
Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject
to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor’s rights.
 
Similarly, if we are unable to successfully obtain
rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have
to seek alternative options, such as developing new product candidates with design-around technologies, which may require more time and
investment, or abandon development of the relevant research programs or product candidates and our business, financial condition, results
of operations and prospects could suffer.
 


11
 

 
We (or Southern Star Research in conducting our clinical trials)
will depend on enrollment of patients in our clinical trials for our product candidates. If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
 
Identifying and qualifying patients to participate
in clinical trials of our product candidates will be critical to our success. We may experience difficulties in patient enrollment in
our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among
other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of
patients depends on many factors, including:
 

●the patient eligibility criteria defined in the protocol;
 

●the number of patients with the disease or condition being studied;
 

●the perceived risks and benefits of the product candidate in the trial;
 

●clinicians’ and patients’ perceptions as to the potential advantages
of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the
indications we are investigating or drugs that may be used off-label for these indications;
 

●the size and nature of the patient population required for analysis of the
trial’s primary and secondary endpoints;
 

●the proximity of patients to study sites;
 

●the design of the clinical trial;
 

●our ability to recruit clinical trial investigators with the appropriate
competencies and experience;
 

●competing clinical trials for similar therapies or other new therapeutics
not involving psychedelic therapies;
 

●our ability to obtain and maintain patient consents;
 

●disruptions to health care systems caused by the coronavirus pandemic or
outbreaks of other infections;
 

●the risk that patients enrolled in clinical trials will drop out of the clinical
trials before completion of their treatment; and
 

●other public health factors, including the coronavirus pandemic or outbreaks
of other infections.
 
Moreover, because our product candidates represent
a departure from more commonly used methods for Adjustment Disorder ("AjD") treatment, potential study participants and
their doctors may be inclined to use conventional therapies, such as pure psychotherapy, rather than participate in our clinical trials.
 
Delays in patient enrollment may result in increased
costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these clinical trials and
adversely affect our ability to advance the development of our product candidates. In addition, many of the factors that may lead to a
delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product
candidates.
 


12
 

 
Psyence’s insurance coverage may be inadequate or expensive.
 
Psyence’s business is subject to a number
of risks and hazards generally, including adverse clinical trial results, accidents, labor disputes and changes in the regulatory environment.
Such occurrences could result in damage to assets, personal injury or death, environmental damage, delays in operations, monetary losses
and possible legal liability.
 
Psyence’s insurance may not cover all the
potential risks associated with its operations. Psyence may also be unable to maintain insurance to cover these risks at economically
feasible premiums. Insurance coverage may not be available (or generally available on acceptable terms) or may not be adequate to cover
any resulting liability. The successful assertion of one or more large claims against us that exceed available insurance coverage, or
the occurrence of changes in our insurance policies, including premium increases or the imposition of large retention, or deductible,
or co-insurance requirements, could have an adverse effect on our business, financial condition and results of operations.
 
Certain significant personnel may allocate their time to other
businesses, which may cause conflicts of interest in their determination as to how much time to devote to our affairs and potentially
competitive fiduciary and pecuniary interests that conflict with our interests.
 
Certain of Psyence’s directors and officers
do not devote their full time to the affairs of Psyence and certain of Psyence’s directors and officers are also directors, officers
and shareholders of other biotechnology and research and development companies or other public companies in general, and as a result they
may find themselves in a position where their duty to another company conflicts with their duty to Psyence. Although Psyence has policies
which address such potential conflicts and the Business Corporations Act (Ontario) has provisions governing directors in the event of
such a conflict, there is no assurance that any such conflicts will be resolved in favor of Psyence. If any such conflicts are not resolved
in favor of Psyence, Psyence may be adversely affected.
 
We have received research and development incentives from
the Australian government. If we don’t qualify for future research and development incentives, we may encounter difficulties
in funding research and development projects, which could harm our operating results.
 
We have previously received a research and development
(R&D) cash rebate through the Australian Government’s Research and Development Tax Incentive program, which provides up to a
43.5% rebate on qualifying R&D expenses in Australia.
 
For Psyence Australia Pty Ltd.’s ("Psyence
Australia") fiscal year ended June 30, 2023, our subsidiary, Psyence Australia, received a cash refund of AUD $1,336,622.
To receive this research and development cash rebate, we qualified for certain conditions under the R&D Tax Incentive legislation
(Income Tax Assessment Act 1997 (Cth), Division 355) in Australia including, but not limited to, having a company incorporated under Australian
law, all R&D activities being conducted solely within Australia; the Company’s aggregated group turnover not being equal to,
or more than, AU$20M for relevant period; all R&D activities are conducted by, or will be conducted for, the Company; and all CRO
expenditures have been physically undertaken in Australia.
 
Entitlement to tax benefits under the Research
and Development Tax Incentive for eligible R&D purposes is based on an annual application to the Australian Government. We believe
that we continue to be eligible for the tax benefits. If these tax benefits are reduced, cancelled, or discontinued, or if we fail to
meet certain conditions, we may encounter difficulties funding further funding R&D projects, which could harm our operating results.
 


13
 

 
Risks Related to Regulatory Matters
 
If we fail to comply with healthcare regulations, we could face
substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be
adversely affected.
 
The research and development, studying, manufacturing,
packaging, labeling, advertising and distribution of Psyence’s planned product candidates are subject to regulation by one or more
governmental authorities, and various agencies of the federal, provincial, state and localities in which Psyence intends to commercialize
its products. These governmental authorities may attempt to regulate any of its products that fall within their jurisdiction. Such governmental
authorities may not accept the evidence of safety for any ingredients that Psyence may want to market, may determine that a particular
product or product ingredient presents an unacceptable health risk and may determine that a particular statement of nutritional support
that Psyence wants to use is an unacceptable claim. Such a determination would prevent Psyence from marketing particular products or using
certain statements of nutritional support on its products. Psyence also may be unable to disseminate third-party literature that supports
its products if the third-party literature fails to satisfy certain requirements. In addition, governmental authorities could require
Psyence to remove a particular product from the market. Any recall or removal would result in additional costs to Psyence, including lost
revenues from any products that it is required to remove from the market, any of which could be material. Any such product recalls or
removals could lead to liability, substantial costs and reduced growth prospects, all of which could be material.
 
Our prospective products will be subject to the various federal
and state laws and regulations relating to health and safety and failure to comply with, or changes in, these laws or regulations could
have an adverse impact on our business.
 
We are in the process of developing an investigational
new drug for which we intend to pursue FDA approval via the New Drug Application (“NDA”) process.
 
In connection with our development and future
commercialization (if applicable) of the above- described prospective products, we and each contemplated product candidate are subject
to the Federal Food Drug and Cosmetic Act (FDCA). The FDCA is intended to assure the consumer, in part, that drugs and devices are safe
and effective for their intended uses and that all labeling and packaging is truthful, informative, and not deceptive. The FDCA and FDA
regulations define the term “drug,” in part, by reference to its intended use, as “articles intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease” and “articles (other than food) intended to affect the structure
or any function of the body of man or other animals.” Therefore, almost any ingested or topical or injectable product that, through
its label or labeling (including internet websites, promotional pamphlets, and other marketing material), that is claimed to be beneficial
for such uses will be regulated by FDA as a drug. The definition also includes components of drugs, such as active pharmaceutical ingredients.
Drugs must generally either receive premarket approval by FDA through the NDA process or conform to a “monograph” for a particular
drug category, as established by FDA’s Over-the-Counter (OTC) Drug Review. If the FDA does not award premarket approval for our
product candidates through the NDA process, this could have a material adverse effect on our business, financial condition and results
of operations.
 
The FDA will accept data from studies performed
in other countries, as long as the study complies with GCP and ICH guidelines. FDA will review the Phase IIb protocol prior to the start
of the study to provide advice on what and how aspects of the trial will be captured. Advice from a pre-IND meeting with the FDA was received
in July 2023, which informed the Phase IIb Study design and may also inform the phase III program we plan to do.
 
Clinical trials are expensive, time-consuming, uncertain and
susceptible to change, delay or termination. The results of clinical trials are open to differing interpretations.
 
Clinical testing is expensive, time consuming,
and uncertain as to outcome and may be more costly than anticipated due various factors including, but not limited to, regulatory environment,
legal compliance, supply and demand of services and inflationary costs. We cannot guarantee that any clinical trials will be conducted
as planned or completed on schedule, or at all. Failures in connection with one or more clinical trials can occur at any stage of testing.
 
Regulatory agencies may analyze or interpret the
results of clinical trials differently than Psyence. Even if the results of the clinical trials are favorable, the clinical trials for
the product candidates are expected to continue for several years and may take significantly longer to complete. Events that may
prevent successful or timely completion of clinical development include:
 

●delays in reaching a consensus with regulatory authorities on trial design
and other trial related matters;
 

●delays in reaching agreement on acceptable terms with prospective third party
service providers assisting the CROs in the conduct of the trial;
 

●actual or perceived lack of effectiveness of the product candidate during
clinical trials;
 

●discovery of serious or unexpected toxicities or side effects experienced
by trial participants or other safety issues, such as drug interactions;
 


14
 

 


●slower than expected rates of subject recruitment and enrollment rates in
clinical trials;
 

●difficulty in retaining subjects for the entire duration of applicable clinical
studies (as study subjects may withdraw at any time due to adverse side effects from the therapy, insufficient efficacy, fatigue with
the clinical trial process, death or for any other reason;
 

●delays or inability in manufacturing or obtaining sufficient quantities of
materials for use in clinical trials due to regulatory and manufacturing constraints;
 

●inadequacy of or changes in manufacturing process or product candidate formulation;
 

●delays in obtaining and maintaining regulatory authorizations, including
“clinical holds” or delays requiring suspension or termination of a trial by a regulatory agency, such as the TGA, before
or after a trial is commenced;
 

●changes in applicable regulatory policies and regulation, including changes
to requirements imposed on the extent, nature or timing of studies;
 

●uncertainty regarding proper dosing;
 

●delay or failure to supply product for use in clinical trials which conforms
to regulatory specification;
 

●unfavorable results from ongoing pre-clinical studies and clinical trials;
 

●failure of the CRO, or other third-party contractors to comply with all contractual
requirements or to perform their services in a timely or acceptable manner;
 

●failure by Psyence, its employees, the CRO or its employees to comply with
all applicable regulatory requirements relating to the conduct of clinical trials;
 

●scheduling conflicts with participating clinicians and clinical institutions;
 

●failure to design appropriate clinical trial protocols;
 

●regulatory concerns with administering a psychoactive product, generally,
and the potential for abuse;
 

●insufficient data to support regulatory approval;
 

●inability or unwillingness of medical investigators to follow our clinical
protocols; or difficulty in maintaining contact with patients during or after treatment, which may result in incomplete data.
 
Any of the foregoing could have a material adverse
effect on our business, financial condition and results of operations.
 
Psyence may be subject to federal, state and foreign healthcare
laws and regulations and implementation of or changes to such healthcare laws and regulations could adversely affect Psyence’s business
and results of operations.
 
If Psyence successfully completes the requisite
preclinical and clinical testing, makes the required regulatory submissions and obtains any corresponding authorizations or licenses (as
applicable), fulfills all other applicable development-related regulatory obligations, and, eventually, obtains FDA approval to market
one or more of its current or future product candidates in the United States, Psyence will be subject to certain healthcare laws and regulations.
In Australia, the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the
healthcare system in ways that could impact Psyence’s ability to commercialize Psyence’s product candidates. If Psyence were
found to be in violation of any of these laws or any other federal, state or foreign regulations, Psyence may be subject to administrative,
civil and/or criminal penalties, damages, fines, individual imprisonment, exclusion from federal health care programs and the restructuring
of its operations. Any of these could have a material adverse effect on its business and financial results. Since many of these laws have
not been fully interpreted by the courts, there is an increased risk that Psyence may be found in violation of one or more of their provisions.
Any action against Psyence for violation of these laws, even if Psyence is ultimately successful in its defense, will cause Psyence to
incur significant legal expenses and divert management’s attention away from the operation of the business. In addition, in many
foreign countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to government control.
 


15
 

 
Serious adverse events or other safety risks could require Psyence
to abandon development and preclude, delay or limit approval of its current or future product candidates, limit the scope of any approved
label or market acceptance, or cause the recall or loss of marketing approval of products that are already marketed.
 
If any of Psyence’s current or future product
candidates, prior to or after any approval for commercial sale, cause serious or unexpected side effects, or are associated with other
safety risks such as misuse, abuse or diversion, a number of potentially significant negative consequences could result, including:
 

●regulatory authorities may interrupt, delay or halt clinical trials;
 

●regulatory authorities may deny regulatory approval of future product candidates;
 

●regulatory authorities may require certain labeling statements, such as warnings
or contraindications or limitations on the indications for use, and/or impose restrictions on distribution;
 

●regulatory authorities may withdraw their approval, require more onerous
labeling statements, or require Psyence may be required to change the way the product is administered or conduct additional clinical trials;
 

●Psyence’s relationships with its collaboration partners may suffer;
 

●Psyence could be sued and held liable for harm caused to patients; or
 

●Psyence’s reputation could suffer.
 
Any of these events could prevent us from achieving
or maintaining market acceptance of our product candidates, if approved, and could significantly harm our business, financial condition,
results of operations and prospects.
 
Psyence may voluntarily suspend or terminate a clinical trial
if at any time its believes that any of its product candidates presents an unacceptable risk to participants, if preliminary data demonstrates
that the product candidate is unlikely to receive regulatory approval or unlikely to be successfully commercialized, or if sufficient
funds to proceed to the next phases of clinical trials are not raised.
 
After obtaining the requisite regulatory authorizations
to commence or advance clinical trials, Psyence may voluntarily suspend or terminate any of its clinical trials for any number of reasons,
including if it believes that a product candidate’s use, or a person’s exposure to such product candidate, may cause adverse
health consequences or death. In addition, regulatory agencies may at any time recommend the temporary or permanent discontinuation of
a clinical trial or request that Psyence cease using investigators in the clinical trials if the agency believes that a clinical trial
is not being conducted in accordance with applicable regulatory requirements, or that it presents an unacceptable safety risk to participants.
If Psyence elects or is forced to suspend or terminate a clinical trial of any of its product candidates, the commercial prospects for
that product will be harmed and its ability to generate product revenue from such product candidate may be delayed or eliminated. Furthermore,
any of these events may result in labeling statements such as warnings or contraindications. In addition, such events or labeling could
prevent Psyence or its partners from achieving or maintaining market acceptance of the affected product candidate and could substantially
increase the costs of commercializing its future product candidates and impair its ability to generate revenue from the commercialization
of these product candidates either by Psyence or by its collaboration partners.
 
The clinical trial is divided into stages and
progression of each stage is dependent on governmental approval to proceed to the next stage being furnished by Psyence. Accordingly,
if Psyence believes that it does not have sufficient funds to progress with the next phases of the clinical trials, or for any other reason,
Psyence is entitled to exercise this discretion in accordance with applicable laws and regulatory compliance and approvals, taking patient
risk and safety into account.
 
The success of Psyence’s product candidates and future
approved products, if any, is subject to a number of constantly-evolving state and federal laws, regulations, and enforcement policies
pertaining to psilocybin containing products.
 
Local, state, federal, and international psilocybin
laws and regulations remain highly restrictive and subject to evolving interpretations, which could require Psyence to incur substantial
costs associated with compliance requirements. Psyence seeks independent local legal opinions confirming the lawfulness of Psyence’s
existing and proposed activities as well as its compliance with legal, regulatory and governmental developments as they pertain to and
affect Psyence’s operations. In addition, violations of these laws, or allegations of such violations, could disrupt Psyence’s
business and result in a material adverse effect on Psyence’s operations. In addition, it is possible that regulations may be enacted
in the future that will be directly applicable to Psyence’s proposed business regarding the administration of psilocybin or psilocybin-assisted
psychotherapy. Psyence cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can it determine
what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on its
activities in the psychedelics industry.
 


16
 

 
There can be no assurance that Psyence’s
product candidates containing psilocybin (as the active pharmaceutical ingredient) will be approved for commercialization in Australia,
the U.S. or any other target jurisdiction at any time in the near or distant future. Any regulations the FDA issues relating to the sale,
marketing, and/or other activities involving administration of psilocybin or psilocybin-assisted psychotherapy could have a material adverse
effect on Psyence’s business, financial condition and results of operations.
 
We may seek fast track and breakthrough therapy designations
or priority review for one or more of our product candidates, but we might not receive such designation or priority review, and even if
we do, such designation or priority review may not lead to a faster development or regulatory review or approval process, and does not
assure FDA approval of our product candidates. Even if a product qualifies for such designation or priority review, the FDA may later
decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will
not be shortened.
 
We may seek fast track, breakthrough therapy,
and/or regenerative medicine advanced therapy designations or priority review for one or more of our product candidates.
 
The FDA may issue a fast track designation to
a product candidate if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious
or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition.
Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor
of a new biologic may request that the FDA designate the biologic as a fast track product at any time during the clinical development
of the product. For fast track products, sponsors may have greater interactions with the FDA during product development. A fast track
product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the
complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to
accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission
of the first section of the BLA. However, the FDA’s goal for reviewing a BLA fast track application under the Prescription Drug
User Fee Act (“PDUFA”) does not begin until the last section of the application is submitted. Fast track designation
may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.
 
A breakthrough therapy is defined as a product
candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition,
and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product
candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial
can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control
regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical
data at the time of the submission of the BLA.
 
Fast track designation, priority review, and breakthrough
therapy designation are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the
criteria for any such designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt
of such designation may expedite the development or approval process, but do not change the standards for approval. Even if a product
qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification
or decide that the time period for FDA review or approval will not be shortened.
 


17
 

 
We may seek approval of our product candidates, where applicable,
under the FDA’s accelerated approval pathway. This pathway may not lead to a faster development, regulatory review or approval process
and does not increase the likelihood that our product candidates will receive marketing approval.
 
A product may be eligible for accelerated approval
if it is designed to treat a serious or life-threatening disease or condition and generally provides a meaningful advantage over available
therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that
is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or
mortality (“IMM”), that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA considers
a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as IMM. For
the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical
sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical
endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be
used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically
important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s
agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical
benefit. Under the Food and Drug Omnibus Reform Act of 2022 (“FDORA”), the FDA is permitted to require, as appropriate,
that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of accelerated
approval was granted. FDORA also requires sponsors to send updates to the FDA every 180 days on the status of such studies, including
progress toward enrollment targets, and the FDA must promptly post this information publicly. FDORA also gives the FDA increased authority
to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies
in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug’s predicted
clinical benefit. Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with
due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. In addition, the FDA currently
requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving accelerated approval,
which could adversely impact the timing of the commercial launch of the product. Thus, even if we seek to utilize the accelerated approval
pathway, we may not be able to obtain accelerated approval and, even if we do, we may not experience a faster development, regulatory
review or approval process for that product. There can be no assurance that the FDA would allow any of the product candidates we may develop
to proceed on an accelerated approval pathway, and even if the FDA did allow such pathway, there can be no assurance that such submission
or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. Moreover,
even if we received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such
benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval does not assure that the product’s
accelerated approval will eventually be converted to a traditional approval.
 
Risks Relating to the Psychedelic Therapy Market and Biotechnology
Industry
 
The psychedelic therapy industry and market are relatively new,
and this industry and market may not continue to exist or grow as anticipated.
 
Psyence operates its business in a relatively
new industry and market. In addition to being subject to general business risks, Psyence must continue to build brand awareness in this
industry and market through significant investments in its strategy, operational capacity, quality assurance and compliance with regulations.
In addition, there is no assurance that the industry and market will continue to exist and grow as currently estimated or anticipated
or function and evolve in a manner consistent with management’s expectations and assumptions. Any event or circumstance that adversely
affects the psychedelic therapy industry and market could have a material adverse effect on Psyence’s business, financial conditions
and results of operations.
 
Psilocybin is considered scientifically to be
the safest of the psychedelics and/or drugs of abuse potential. In fact, psilocybin has been described as being anti-addictive and has
been studied for the use in substance addictive disorders, such as alcohol use disorder, smoking cessation and opioid addiction. Notwithstanding
the foregoing, the psychedelic therapy market will face specific marketing challenges given the products’ status as a controlled
substance, which has resulted in past and current public perception that the products have negative health and lifestyle effects and have
the potential to cause physical and social harm due to psychoactive and potentially addictive effects. Any marketing efforts by Psyence
would need to overcome this perception to build consumer confidence, brand recognition and goodwill.
 


18
 

 
Negative public opinion and perception of the psychedelic industry
could adversely impact Psyence’s ability to operate and Psyence’s growth strategy.
 
Consumer perception of Psyence’s products
may be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity
regarding the consumption of naturally derived, medicinal-grade psilocybin mushroom products. There can be no assurance that future scientific
research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the
naturally derived medicinal-grade psilocybin mushroom market or any particular product, or consistent with earlier publicity. Future research
reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or
that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for Psyence’s
envisaged products and Psyence’s business, results of operations, financial condition and cash flows. Psyence’s dependence
upon consumer perception means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention
or other publicity, whether or not accurate or with merit, could have a material adverse effect on Psyence, the demand for Psyence’s
products, and Psyence’s business, results of operations, financial condition and cash flows. Further, adverse publicity reports
or other media attention regarding the safety, efficacy and quality of naturally derived medicinal-grade psilocybin mushroom in general,
or Psyence’s products specifically, or associating the consumption of naturally derived medicinal-grade psilocybin mushroom’s
negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise
even if the adverse effects associated with such products resulted from consumers’ failure to consume such products appropriately
or as directed.
 
The expansion of the use of psychedelics in the medical industry
may require new clinical research into effective medical therapies.
 
Research in the UK, Canada, Australia and internationally
regarding the medical benefits, viability, safety, efficacy, addictiveness, dosing and social acceptance of psychedelic and psychoactive
products remains in early stages. There have been relatively few clinical trials on the benefits of such products. Although Psyence believes
that the articles, reports and studies support its beliefs regarding the medical benefits, viability, safety, efficacy, dosing and social
acceptance of psychedelic and psychoactive products, future research and clinical trials may prove such statements to be incorrect, or
could raise concerns regarding, and perceptions relating to, psychedelic and psychoactive products. Future research studies and clinical
trials may draw opposing conclusions to those stated in this Report or reach negative conclusions regarding the medical benefits, viability,
safety, efficacy, dosing, social acceptance or other facts and perceptions related to psychedelic and psychoactive products, which could
have a material adverse effect on the demand for Psyence’s product candidate and psychedelic therapies and a material adverse effect
on Psyence’s business, financial condition and results of operations.
 
The psychedelic therapy industry is difficult to quantify and
investors will be reliant on their own estimates of the accuracy of market data.
 
Because the psychedelic therapy industry is in
a nascent stage with uncertain boundaries, there is a lack of information about comparable companies available for potential investors
to analyze in deciding whether to invest in Psyence and, few, if any, established companies whose business model Psyence can follow or
upon whose success Psyence can build. Accordingly, investors will have to rely on their own estimates in deciding whether to invest in
Psyence. There can be no assurance that Psyence’s estimates are accurate or that the market size is sufficiently large for its business
to grow as projected, which may negatively impact its financial results.
 
Risks Related to Intellectual Property
 
Psyence may not be able to adequately protect or enforce its
intellectual property rights, which could harm its competitive position.
 
Psyence relies upon a combination of patent, copyright,
trademark and trade secret laws, as well as nondisclosure agreements, know-how of the scientific team, and other methods, to protect its
proprietary technologies and processes. The strengths of patents in the pharmaceutical field involve complex legal and scientific questions
and can be uncertain. Where appropriate, Psyence will seek patent protection for certain aspects of its products and technology. Filing,
prosecuting and defending patents in a wide range of countries can be prohibitively expensive. If Psyence fails to adequately protect
its intellectual property, it may face competition from companies who attempt to create a generic product to compete with its future product
candidates. Psyence may also face competition from companies who develop a substantially similar product to its future product candidates
that are not covered by any patents.
 


19
 

 
While Psyence will apply for a number of patents
upon the discovery or creation of something novel, there can be no assurances that any patents will be issued. Specifically, naturally
occurring substances arising from botanical sources, e.g Psilocybin, cannot be patented. As such, we will be required to rely on other
processes such as extraction, purification, or formulation in order to establish patents and such processes are not guaranteed to receive
issued patents. Even if patents are issued, the claims allowed may not be sufficiently broad to protect all of Psyence’s intellectual
property. In addition, any future patents issued to Psyence may be challenged, invalidated or circumvented. As such, any rights granted
under these patents may not provide Psyence with meaningful protection. If Psyence’s patents do not adequately protect its intellectual
property, competitors may be able to offer products similar to Psyence’s products.
 
Psyence will be further dependent, to an extent,
on Filament’s wholly-owned subsidiary, Psilo Scientific LTD. (“Psilo”), to maintain and defend the intellectual
property currently being licensed to Psyence under the Research IP Agreement, and which is relevant for use in Psyence’s Phase IIb
Study. Any failure on the part of Psilo or Filament, as applicable, to adequately maintain or defend its intellectual property will have
a direct effect on the viability of Psyence’s Australian palliative care clinical trial initiatives.
 
Psyence’s strategy is to patent technologies
with commercial potential in jurisdictions with significant commercial opportunities. However, patent protection may not be available
for some of the products or technologies Psyence is developing, such as in the areas of methods of treatment (which are not patentable
in most jurisdictions).
 
The patent positions of pharmaceutical products
are complex and uncertain. The scope and extent of patent protection for future product candidates are particularly uncertain. Protection
of Psyence’s future product candidates will be sought in respect of, among other things, composition-of-matter for specific formulations,
methods of use, and delivery mechanisms, bearing in mind that patent protection is not available for naturally derived psilocybin alone.
If any of Psyence’s products are approved and marketed for an indication for which it does not have an issued or licensed patent,
Psyence’s ability to use a patent to prevent a competitor from commercializing a non-branded version of its commercial products
for that non- patented indication could be significantly impaired or even eliminated.
 
Many companies have encountered significant problems
in protecting, defending and enforcing intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents and other intellectual property rights, particularly
those relating to pharmaceuticals, which could make it difficult for Psyence to stop the infringement of patents or marketing of competing
products in violation of its proprietary rights generally. Proceedings to enforce patent rights in foreign jurisdictions may not be successful,
could result in substantial cost and divert Psyence’s efforts and attention from other aspects of its business.
 
If third parties claim that intellectual property owned or used
by Psyence infringes upon their intellectual property, Psyence’s operating profits could be adversely affected.
 
There is a substantial amount of litigation, both
within and outside the U.S., involving patent and other intellectual property rights in the pharmaceutical industry. Psyence may, from
time to time, be notified of claims that Psyence is infringing upon patents, trademarks, copyrights or other intellectual property rights
owned by third parties, and Psyence cannot provide assurances that other companies will not, in the future, pursue such infringement claims
against it, its commercial partners or any third-party proprietary technologies it has licensed. If Psyence were found to infringe upon
a patent or other intellectual property right, or if Psyence failed to obtain or renew a license under a patent or other intellectual
property right from a third party, or if a third party that Psyence were licensing technologies from was found to infringe upon a patent
or other intellectual property rights of another third party, Psyence may be required to pay damages, suspend the manufacture of certain
products or reengineer or rebrand its products, if feasible, or it may be unable to enter certain new product markets. Any such claims
could also be expensive and time-consuming to defend and divert management’s attention and resources. Psyence’s competitive
position could suffer as a result. In addition, if Psyence has declined or failed to enter into a valid non-disclosure or assignment agreement
for any reason, Psyence may not own the intellectual property, and its products may not be adequately protected. Thus, Psyence cannot
guarantee that any of its future product candidates, or its commercialization thereof, does not and will not infringe any third party’s
intellectual property.
 


20
 

 
We may infringe the intellectual property rights of others, which
may prevent or delay our product development efforts and stop us from commercializing, or increase the costs of commercializing our product
candidates.
 
Our success will depend in part on our ability
to operate without infringing the proprietary rights of third parties. We are not aware of any third-party proprietary rights that our
planned products will infringe or misappropriate, but we have not conducted any freedom to operate study as we are in the earliest stages
of development. We thus cannot guarantee that our product candidates, or manufacture or use of our product candidates, will not infringe
third-party patents. Furthermore, a third party may claim that we are using inventions covered by the third party’s patent rights
and may go to court to stop us from engaging in our normal operations and activities, including making or selling our product candidates.
These lawsuits are costly and could affect our results of operations and divert the attention of managerial and scientific personnel.
Some of these third parties may be better capitalized and have more resources than us. There is a risk that a court would decide that
we are infringing the third party’s patents and would order us to stop the activities covered by the patents. In that event, we
may not have a viable way around the patent and may need to halt commercialization of our product candidates. In addition, there is a
risk that a court will order us to pay the other party damages for having violated the other party’s patents. In addition, we may
be obligated to indemnify our licensors and collaborators against certain intellectual property infringement claims brought by third parties,
which could require us to expend additional resources. The pharmaceutical and biotechnology industries have produced a proliferation of
patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of
use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.
 
If we are sued for patent infringement, we would
need to demonstrate that our product candidates or methods either do not infringe the patent claims of the relevant patent or that the
patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity
requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are
successful in these proceedings, we may incur substantial costs and diversion of management’s time and attention in pursuing these
proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may
be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court.
Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion.
In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully
or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product
candidates to market and be precluded from manufacturing or selling our product candidates.
 
Some of our competitors may be able to sustain
the costs of complex patent litigation more effectively than us or the third parties from whom we license intellectual property because
they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation
could have a material adverse effect on our ability to raise the funds necessary to continue our operations.
 
If Psyence is not able to adequately prevent disclosure of trade
secrets and other proprietary information, the value of its products could be significantly diminished.
 
Psyence relies, to an extent, on trade secrets
to protect its proprietary licensed intellectual property, especially where it does not believe patent protection is appropriate or obtainable.
However, trade secrets are difficult to protect. Psyence relies in part on confidentiality agreements and restraints of trade with its
current and former employees, consultants, outside scientific collaborators, sponsored researchers, contract manufacturers, vendors and
other advisors, as well as similar confidentiality protections benefiting its strategic partners and licensors to protect Psyence’s
owned and licensed trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential
information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, Psyence
cannot guarantee that it, nor its strategic and business partners, have executed these agreements with each party that may have or have
had access to owned and licensed trade secrets. Any party with whom Psyence or strategic and business partners have executed such an agreement
may breach that agreement and disclose proprietary information, including owned and licensed trade secrets, and adequate remedies for
such breaches may not be available.
 
Enforcing a claim that a party illegally disclosed
or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts
inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of Psyence’s owned or licensed trade
secrets were to be lawfully obtained or independently developed by a competitor, Psyence would have no right to prevent them, or those
to whom they disclose such trade secrets, from using that technology or information to compete with it. If any of Psyence’s owned
and licensed trade secrets were to be disclosed to or independently developed by a competitor or other third-party, Psyence’s competitive
position would be harmed.
 


21
 

 
Risks Related to Ownership of Our Securities
 
Future sales of our securities by existing holders could
cause our stock price to decline.
 
If we or our existing holders sell, or indicate
an intent to sell, substantial amounts of our Common Shares or securities convertible into our Common Shares in the public market, or
if the public perceives that such sales could occur, this could have an adverse impact on the market price of our Common Shares, even
if there is no relationship between such sales and the performance of our business. We also intend to register all Common shares that
we may issue under our Incentive Plan. Once we register these shares, they can be freely sold in the public market upon issuance, subject
to volume limitations applicable to affiliates.
 
If we fail to meet applicable continued listing requirements,
Nasdaq may delist our Common Shares from trading, in which case the liquidity and market price of our Common Shares could decline.
 
We cannot assure you that we will be able to meet
the continued listing standards of Nasdaq in the future. On March 11, 2024, we received two letters from the Nasdaq staff, one notifying
the Company that for the last 30 consecutive business days, the Company’s Market Value of Listed Securities was below the minimum
of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A), and the other
notifying the Company that for the last 30 consecutive business days, the Company’s Market Value of Publicly Held Shares was below
the minimum of $15 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C). Additionally,
on June 27, 2024, we received a notification letter from the Nasdaq staff notifying the Company that the Company’s closing bid price
per share was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement
set forth in Nasdaq Listing Rule 5450(a)(1). On November 20, 2024, we announced the favorable outcome of the Nasdaq Listing Qualifications
Hearing that was held on October 31st, 2024. The Nasdaq Hearings Panel granted the Company an extension until December 31st,
2024, to demonstrate compliance with all Nasdaq continued listing rules. During the Company’s Nasdaq Listing Qualifications Hearing,
we presented a comprehensive plan to regain and maintain compliance with Nasdaq’s continued listing requirements, including 5550(a)(2),
the $1 minimum bid price requirement, 5550(a)(5), the $1.0 million minimum market value of publicly held shares requirement, and 5550(b)(1),
the $2.5 million minimum stockholders’ equity requirement.
 
As part of its plan, we requested to be transferred
from The Nasdaq Global Market to The Nasdaq Capital Market pursuant to a panel exception, effective November 15th, 2024. Furthermore,
as previously announced, we obtained shareholder approval during the Annual Meeting held on November 12th, 2024, to effect
a 75-for-1 share consolidation, which became effective on November 26, 2024, and we obtained stockholder approval during a Special Meeting held on April 16, 2025, to effect a 7.97-for-1 share consolidation, which
became effective on May 5, 2025, in each case to satisfy Nasdaq’s $1 minimum bid price requirement.
 
On April 16, 2025, the Company received a notification
letter from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”)
indicating that the Company was not in compliance with the $1.00 Minimum Bid Price Rule. The Staff’s determination was based on
the closing bid price of the Company’s common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through
April 15, 2025. On June 17, 2025, the Company announced it had received formal notification from the Nasdaq Hearings Panel confirming
that the Company has regained compliance with all applicable Nasdaq continued listing requirements, following a successful compliance
hearing held on May 29, 2025.
 
If we fail to comply with the applicable listing
standards and Nasdaq delists our Common Shares, we and our shareholders could face significant material adverse consequences, including:
 

●a limited availability of market quotations for our Common Shares;
 

●reduced liquidity for our Common Shares;
 

●a determination that our Common Shares are “penny stock”, which
would require brokers trading in our Common Shares to adhere to more stringent rules and possibly result in a reduced level of trading
activity in the secondary trading market for our Common Shares;
 

●a limited amount of news about us and analyst coverage of us; and
 

●a decreased ability for us to issue additional equity securities or obtain
additional equity or debt financing in the future. 
 
The National Securities Markets Improvement Act of 1996,
which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as “covered
securities.” Because our Common Shares and Public Warrants are listed on Nasdaq, such securities are covered securities. Although
the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies
if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered
securities in a particular case. Further, if we were no longer listed on Nasdaq, our securities would not be covered securities and we
would be subject to regulations in each state in which we offer our securities.
 


22
 

 
The market price and trading volume of the Common Shares may
be volatile and could decline significantly.
 
The stock markets, including Nasdaq, on which
the Company lists its securities, have from time to time experienced significant price and volume fluctuations. Even if an active, liquid
and orderly trading market develops and is sustained for the Common Shares, the market prices of the Common Shares may be volatile and
could decline significantly. In addition, the trading volumes in the Common Shares may fluctuate and cause significant price variations
to occur. There can be no assurance that the market prices of the Common Shares will not fluctuate widely or decline significantly in
the future in response to a number of factors, including, among others, the following:
 

●the realization of any of the risk factors presented in this Report;
 

●actual or anticipated differences in our estimates, or in the estimates of
analysts, for the Company’s revenues, results of operations, cash flows, liquidity or financial condition;
 

●announcements by the Company or its competitors of significant business developments;
 

●changes in customers;
 

●acquisitions or expansion plans;
 

●the Company’s involvement in litigation;
 

●sale of Common Shares or other securities in the future;
 

●market conditions in the Company’s industry;
 

●changes in key personnel;
 

●the trading volume of Common Shares;
 

●actual, potential or perceived control, accounting or reporting problems;
 

●changes in accounting principles, policies and guidelines;
 

●other events or factors, including but not limited to those resulting from
infectious diseases, health epidemics and pandemics (including but not limited to the COVID-19 pandemic), natural disasters, war, acts
of terrorism or responses to these events; and
 

●general economic and market conditions.
 
In addition, the stock markets have experienced
extreme price and volume fluctuations. Broad market and industry factors may materially harm the market price of the Common Shares, regardless
of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities
class action litigation has often been instituted against that company. If the Company were involved in any similar litigation it could
incur substantial costs and our management’s attention and resources could be diverted.
 
Our Warrants are exercisable for Common Shares, which would increase
the number of shares eligible for future resale in the public market and result in dilution to our shareholders.
 
An aggregate of 281,950 Common Shares are issuable
upon exercise of warrants, including 19,808 Common Shares issuable upon exercise of Public Warrants, 954 Common shares issuable upon exercise
of Private Warrants, 837 Common shares issuable upon exercise of Addendum Private Warrants, 125,471 Common Shares issuable upon exercise
of Series A Warrants, 125,471 Common Shares issuable upon exercise of Series B Warrants, and 9,409 Common Shares Issuable upon exercise
of the Placement Agent Warrants. These Public Warrants and Private Warrants are currently exercisable at an exercise price of $6,874.13
per share, the Addendum Private Warrants $298.88 per share, the Series A Warrants and Series B Warrants at $15.94 per Common Share, and
the Placement Agent Warrants at $19.93 per Common Share and each contain 4.99% beneficial ownership limitations that may be waived at
the option of each holder upon 61 days’ notice to the Company, but in no event may such beneficial ownership limitation exceed 19.99%
of the number of outstanding Common Shares. To the extent such warrants are exercised, 281,950 additional Common Shares will be issued,
representing approximately 49.6% of our current outstanding Common Shares and could result in dilution to the holders of Common Shares
and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public
market or the fact that such Warrants may be exercised could adversely affect the market price of Common Shares. Notwithstanding the foregoing,
because the Nasdaq official closing price of our Common Shares was $4.92 on June 18, 2025, the Private Warrants and Public Warrants are
currently “out-of-the-money” and it is unlikely that any of the Warrants will be exercised by holders anytime in the near
future.
 


23
 

 
If securities or industry analysts do not publish research, publish
inaccurate or unfavorable research or cease publishing research about the Company, its share price and trading volume could decline significantly.
 
The trading market for Common Shares depends,
in part, on the research and reports that securities or industry analysts publish about the Company or its business. The Company may be
unable to sustain coverage by well-regarded securities and industry analysts. If either none or only a limited number of securities or
industry analysts maintain coverage of the Company, or if these securities or industry analysts are not widely respected within the general
investment community, the demand for Common Shares could decrease, which might cause its share price and trading volume to decline significantly.
In the event that the Company obtains securities or industry analyst coverage or, if one or more of the analysts who cover the Company
downgrade their assessment of the Company or publish inaccurate or unfavorable research about the Company’s business, the market
price and liquidity for Common Shares could be negatively impacted.
 
The requirements of being a public company may strain the Company’s
resources, divert the Company management’s attention and affect the Company’s ability to attract and retain qualified board
members.
 
The Company has incurred and will continue to
incur additional legal, accounting and other expenses since becoming a public company. The Company is subject to the reporting requirements
of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, the Nasdaq listing requirements and other applicable securities rules and
regulations. These expenses may increase even more if the Company no longer qualifies as an “emerging growth company,” as
defined in Section 2(a) of the Securities Act. The Exchange Act requires that we file annual and other material reports with
respect to our businesses, financial condition, and results of operations. In addition, we must establish the corporate infrastructure
necessary for operating a public company, which may divert our management’s attention from implementing our growth strategy, which
could delay or slow the implementation of our business strategies, and in turn negatively impact our financial condition and results of
operations.
 
Changing laws, regulations and standards relating
to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance
costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in
many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided
by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated
by ongoing revisions to disclosure and governance practices. The Company expects these laws and regulations to increase its legal and
financial compliance costs and to render some activities more time-consuming and costly, although the Company is currently unable to estimate
these costs with any degree of certainty.
 
The Company’s management team has limited
experience managing a publicly traded company, interacting with public company investors and complying with the increasingly complex laws
pertaining to public companies. The Company’s management team may not successfully or efficiently manage the transition to being
a public company subject to significant regulatory oversight and reporting obligations under the federal securities laws and regulations
and the continuous scrutiny of securities analysts and investors. The need to establish the corporate infrastructure demanded of a public
company may divert the management’s attention from implementing its growth strategy, which could prevent the Company from improving
its business, financial condition and results of operations. Furthermore, the Company expects these rules and regulations to make
it more difficult and more expensive for the Company to maintain director and officer liability insurance, and consequently the Company
may be required to incur substantial costs to obtain such coverage. These additional obligations could have a material adverse effect
on its business, financial condition, results of operations and prospects. These factors could also make it more difficult for the Company
to attract and retain qualified members of its Board, particularly to serve on the Company’s audit committee, compensation committee
and nominating and corporate governance committee, and qualified executive officers.
 
As a result of disclosure of information in this
Report and in filings required of a public company, the Company’s business and financial condition will become more visible, which
may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, the Company’s
business and operating results could be adversely affected, and, even if the claims do not result in litigation or are resolved in the
Company’s favor, these claims, and the time and resources necessary to resolve them, could have an adverse effect on its business,
financial condition, results of operations and prospects.
 


24
 

 
The Company is an “emerging growth company,” and
it cannot be certain if the reduced SEC reporting requirements applicable to emerging growth companies will make the Company’s Common
Shares less attractive to investors, which could have a material and adverse effect on the Company, including its growth prospects.
 
The Company is an “emerging growth company”
as defined in the JOBS Act. The Company will remain an “emerging growth company” until the earliest to occur of (i) the
last day of the fiscal year (a) following the fifth anniversary of the date of the first sale of our common equity securities
pursuant to an effective registration statement under the Securities Act, (b) in which the Company has total annual gross revenue
of at least $1.235 billion or (c) in which the Company is deemed to be a large accelerated filer, which means the market value of
Common Shares held by non-affiliates exceeds $700 million as of the last business day of the Company’s prior second fiscal quarter,
and (ii) the date on which the Company issued more than $1.0 billion in non-convertible debt during the prior three-year period.
The Company intends to take advantage of exemptions from various reporting requirements that are applicable to most other non “emerging
growth companies” including, but not limited to, an exemption from the provisions of Section 404(b) of the Sarbanes-Oxley
Act requiring that the Company’s independent registered public accounting firm provide an attestation report on the effectiveness
of its internal control over financial reporting and reduced disclosure obligations regarding executive compensation, and exemptions from
the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments
not previously approved.
 
Furthermore, even after the Company no longer
qualifies as an “emerging growth company,” as long as the Company continues to qualify as a foreign private issuer under the
Exchange Act, the Company will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies,
including, but not limited to, (i) the rules under the Exchange Act requiring the filing of quarterly reports on Form 10-Q
and current reports on Form 8-K with the SEC; (ii) the sections of the Exchange Act regulating the solicitation of proxies,
consents, or authorizations in respect of a security registered under the Exchange Act; (iii) the sections of the Exchange Act requiring
insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made
in a short period of time; and (iv) the selective disclosure rules by issuers of material nonpublic information under Regulation
FD As a result, the Company shareholders may not have access to certain information they deem important. The Company cannot predict if
investors will find Common Shares less attractive because it relies on these exemptions. If some investors do find Common Shares less
attractive as a result, there may be a less active trading market and share price for Common Shares may be more volatile.
 
The Company qualifies as a foreign private issuer within the
meaning of the rules under the Exchange Act, and as such the Company is exempt from certain provisions applicable to United States
domestic public companies.
 
Because the Company qualifies as a foreign private
issuer under the Exchange Act, the Company is exempt from certain provisions of the securities rules and regulations in the United
States that are applicable to U.S. domestic issuers, including, but not limited to: (i) the rules under the Exchange Act requiring
the filing of quarterly reports on Form 10-Q and current reports on Form 8-K with the SEC; (ii) the sections of the Exchange
Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act; (iii) the
sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for
insiders who profit from trades made in a short period of time; and (iv) the selective disclosure rules by issuers of material
nonpublic information under Regulation FD.
 
The Company is required to file an annual report
on Form 20-F within four months of the end of each fiscal year. Press releases relating to financial results and material
events will also be furnished to the SEC on Form 6-K. However, the information the Company is required to file with or furnish to
the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers. Accordingly,
if you continue to hold Common Shares, you may receive less or different information about the Company than you would receive about a
U.S. domestic public company.
 


25
 

 
The Company may lose its foreign private issuer status which
would then require it to comply with the domestic reporting regime of the Exchange Act and cause us to incur significant additional legal,
accounting and other expenses.
 
As discussed above, the Company is a foreign private
issuer and therefore is not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange
Act and may take advantage of certain exemptions to Nasdaq’s corporate governance rules. The determination of foreign private issuer
status is made annually on the last business day of an issuer’s most recently completed second fiscal quarter, and, accordingly,
the next determination will be made with respect to the Company on September 30, 2025. In the future, the Company would lose its
foreign private issuer status if (1) more than 50% of its outstanding voting securities are owned by U.S. residents and (2) a
majority of its directors or executive officers are U.S. citizens or residents, or it fails to meet additional requirements necessary
to avoid loss of foreign private issuer status. If the Company loses its foreign private issuer status, it will be required to file with
the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms
available to a foreign private issuer. The Company would also have to mandatorily comply with U.S. federal proxy requirements, and its
officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16
of the Exchange Act. In addition, it would lose its ability to rely upon exemptions from certain corporate governance requirements under
the listing rules of Nasdaq. As a U.S. listed public company that is not a foreign private issuer, the Company could incur significant
additional legal, accounting and other expenses that it will not incur as a foreign private issuer.
 
Psyence currently reports financial results under IFRS® Accounting
Standards as issued by the International Accounting Standards Board, which differs in certain significant respects from U.S. GAAP.
 
Psyence currently reports financial results under
IFRS. There are and there may in the future be certain significant material differences between IFRS and U.S. GAAP. As a result, financial
information and reported earnings of Psyence for historical or future periods could be significantly different if they were prepared in
accordance with U.S. GAAP. In addition, the Company does not intend to provide a reconciliation between IFRS and U.S. GAAP unless it is
required under applicable law. As a result, you may not be able to meaningfully compare our financial statements under IFRS with those
of companies that prepare financial statements under U.S. GAAP.
 
If we are classified as a passive foreign investment company,
United States taxpayers who own our Common Shares may have adverse United States federal income tax consequences.
 
A non-U.S. corporation such as ourselves will
be classified as a passive foreign investment company, which is known as a PFIC, for any taxable year if, for such year, either
 

●At least 75% of our gross income for the year is passive income; or
 

●The average percentage of our assets (determined at the end of each quarter)
during the taxable year which produces passive income or which are held for the production of passive income is at least 50%.
 
Passive income generally includes dividends, interest,
rents, royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition
of passive assets.
 
If we are determined to be a PFIC for any taxable year
(or portion thereof) that is included in the holding period of a U.S. taxpayer who holds our Common Shares, the U.S. taxpayer may be subject
to increased U.S. federal income tax liability and may be subject to additional reporting requirements.
 
Depending on the amount of our cash and other
assets held for the production of passive income, it is possible that, for our current taxable year or for any subsequent year,
more than 50% of our assets may be assets which produce passive income. We will make this determination following the end of any particular
tax year. Although the law in this regard is unclear, we treat our consolidated affiliated entities as being owned by us for United
States federal income tax purposes, not only because we exercise effective control over the operation of such entities but also because
we are entitled to substantially all of their economic benefits, and, as a result, we consolidate their operating results in our consolidated
financial statements. For purposes of the PFIC analysis, in general, a non-U.S. corporation is deemed to own its pro rata share of the
gross income and assets of any entity in which it is considered to own, directly or indirectly, at least 25% of the equity by value. Our
status as a PFIC is a fact-intensive determination made on an annual basis, and no opinion of counsel has or will be provided regarding
our classification as a PFIC.
 
For a more detailed discussion of the application
of the PFIC rules to us and the consequences to U.S. taxpayers who own our Common Shares if we were determined to be a PFIC, see
“Material U.S. Federal Income Tax Considerations for U.S. Holders — Passive Foreign Investment Company Rules.”
 


26
 

 
You may face difficulties in protecting your interests, and your
ability to protect your rights through U.S. courts may be limited, because the Company is incorporated under the laws of Canada, the Company
conducts substantially all of its operations and a majority of its directors and executive officers reside outside of the United States.
 
The Company is a corporation incorporated under
the laws of Canada, and conducts a majority of its operations through its subsidiary, Biomed II, outside the United States. Substantially
all of the Company’s assets are located outside the United States. A majority of the Company’s officers and directors reside
outside the United States and a substantial portion of the assets of those persons are located outside of the United States. As a result,
it could be difficult or impossible for you to bring an action against the Company or against these individuals outside of the United
States in the event that you believe that your rights have been infringed upon under the applicable securities laws or otherwise and it
will be difficult to effect service of process within the United States upon the Company’s officers or directors, or enforce judgments
obtained in United States courts against the Company’s officers or directors. Even if you are successful in bringing an action of
this kind, the laws of Ontario could render you unable to enforce a judgment against the Company’s assets or the assets of the Company’s
directors and officers.
 
The Articles of Incorporation and certain Canadian legislation
contain provisions that may have the effect of delaying or preventing a change in control.
 
Certain provisions of the Articles of Incorporation,
together or separately, could discourage potential acquisition proposals, delay or prevent a change in control and limit the price that
certain investors may be willing to pay for our common shares. For instance, our Articles of Incorporation contain provisions that establish
certain advance notice procedures for nomination of candidates for election as directors at shareholders’ meetings.
 
In addition, a non-Canadian must file an application
for review with the Minister responsible for the Investment Canada Act and obtain approval of the Minister prior to acquiring control
of a “Canadian Business” within the meaning of the Investment Canada Act, where prescribed financial thresholds are exceeded.
Finally, limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). The Competition
Act (Canada) establishes a pre-merger notification regime for certain types of merger transactions that exceed certain statutory shareholding
and financial thresholds. Transactions that are subject to notification cannot be closed until the required materials are filed and the
applicable statutory waiting period has expired or been waived by the Commissioner. The Commissioner of Competition still retains the
authority under the Competition Act (Canada) to review any acquisition or establishment, directly or indirectly, including through the
acquisition of shares, of control over or of a significant interest in us, whether or not it is subject to mandatory notification. Otherwise,
there are no limitations either under the laws of Canada or Ontario, or in our articles on the rights of non-Canadians to hold or vote
our common shares. Any of these provisions may discourage a potential acquirer from proposing or completing a transaction that may have
otherwise presented a premium to our shareholders. We cannot predict whether investors will find our company and our Common Shares less
attractive because we are governed by foreign laws.
 
It is not expected that the Company will pay dividends in the
foreseeable future.
 
It is expected that the Company will retain most,
if not all, of its available funds and any future earnings to fund the development and growth of its business. In addition, the Company
is a holding company and its subsidiaries are located abroad. Part of the Company’s primary internal sources of funds to meet
its cash needs will be its share of the dividends, if any, paid by the Company’s subsidiaries. The distribution of dividends to
the Company from the subsidiaries in certain markets where the Company operates is subject to restrictions imposed by the applicable laws
and regulations in these markets. As a result, it is not expected that the Company will pay any cash dividends in the foreseeable future.
 
The Board has complete discretion as to whether
to distribute dividends. Even if the Board decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on the future results of operations and cash flow, capital requirements and surplus, the amount of distributions, if any,
received by the Company from subsidiaries, the Company’s financial condition, contractual restrictions and other factors deemed
relevant by the Board. There is no guarantee that the Common Shares will appreciate in value or that the trading price of the Common Shares
will not decline. Holders of the Common Shares should not rely on an investment in Common Shares as a source for any future dividend income.
 


27
 

 
ITEM 4. INFORMATION ON THE
COMPANY
 
The following terms, as used in this section shall have the following
meanings:
 


 
AjD
Adjustment Disorder

 
PEX010
Capsule containing 25mg naturally sourced psilocybin

 
PAP
Psilocybin Assisted Psychotherapy

 
API
Active Pharmaceutical Ingredient

 

A.Corporate History and Development
 
The Business Combination
 
On January 25, 2024 (the “Closing
Date”), Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada (“Psyence,”
“Psyence Biomedical” or the “Company”), consummated the previously announced business combination
pursuant to the Amended and Restated Business Combination Agreement (as amended, the “Business Combination Agreement”),
dated as of July 31, 2023, by and among the Company, Newcourt Acquisition Corp, a Cayman Islands exempted company (“NCAC”),
Newcourt SPAC Sponsor LLC, a Delaware limited liability company (“Sponsor”), Psyence Group Inc., a corporation
organized under the laws of Ontario, Canada (“PGI”), Psyence (Cayman) Merger Sub, a Cayman Islands exempted company
and a direct and wholly owned subsidiary of Pubco (“Merger Sub”), Psyence Biomed Corp., a corporation continued under
the laws of Ontario, Canada (“Original Target”), and Psyence Biomed II Corp., a corporation organized under the laws
of Ontario, Canada (“Biomed II”).
 
The following transactions occurred pursuant to
the terms of the Business Combination Agreement (collectively, the “Business Combination”) at the effective time of
the Merger (the “Effective Time”):
 

●PGI contributed Biomed II to the Company in a share for share exchange (the
“Company Exchange”).
 

●Following the Company Exchange, Merger Sub merged with and into NCAC, with
NCAC being the surviving company in the merger (the “Merger”) and each outstanding ordinary share of NCAC was converted
into the right to receive one common share of the Company (“Common Share”).
 

●Each outstanding warrant to purchase NCAC Class A ordinary shares was converted
into a warrant to acquire one Common Share on substantially the same terms as were in effect immediately prior to the Effective Time under
their terms.
 
On January 15, 2024 and January 23, 2024, the
parties to the Business Combination Agreement entered into letter agreements (the “Closing Letter Agreements”) pursuant
to which, among other things, the Company, PGI, Biomed II, Original Target and Merger Sub (collectively, the “Psyence Parties”)
agreed, (X) on a conditional basis, to waive the closing conditions contained in the Business Combination Agreement that, at or prior
to the Closing, (i) NCAC shall have no less than $20,000,000, net of liabilities, as of the Closing (the “Minimum Cash Condition”)
and (ii) the PIPE Investment in the PIPE Investment Amount shall have occurred or shall be ready to occur substantially concurrently with
the Closing (the “PIPE Investment Condition”) and (Y) to waive certain deliverables under Section 3.6 of the Business
Combination Agreement (the “Closing Deliverables”). Upon the closing of the Business Combination (“Business
Combination”), the Psyence Parties waived in full the Closing Deliverables, the Minimum Cash Condition and the PIPE Investment
Condition. Although we did not satisfy the PIPE Investment Condition, we were able to close on a convertible debt PIPE financing with
the Investors, in an aggregate principal amount of $3,125,000, with an original issue discount of 20%, for gross proceeds in the aggregate
amount of $2,500,000 (the “Harraden PIPE Financing”). While the First Tranche Notes issued by us to the Investors in
the Harraden PIPE Financing are initially convertible into Common Shares at a conversion price of $5,977.50, due to the several adjustment
provisions in the conversion price under the terms of the First Tranche Notes, and the applicable Conversion Floor, the documents entered
into in connection with the Harraden PIPE Financing required us to register for resale, on behalf of the Investors, an amount of Common
Shares equal to the aggregate principal amount of the First Tranche Notes converted at an assumed conversion price of $298,88 and multiplied
by 300% of the result thereof. In addition, the documents entered into in connection with the Harraden PIPE Financing required us to register
for resale, on behalf of the Investors, an amount of Common Shares equal to the aggregate principal amount of any issued Second Tranche
Notes converted at an assumed conversion price of $298.88 and multiplied by 300% of the result thereof.
 


28
 

 
The Investors were also issued, as a structuring
fee, an additional 2,175 Common Shares and entered into call option agreements (collectively, the “Call Option Agreements”)
with Tabula Rasa Limited, which was the sole manager of Sponsor (“Tabula”), and Launchpad Capital Opportunities Fund
LP, which was a member of the Sponsor (“Launchpad”), pursuant to which the Investors may purchase up to an additional
2,844 Common Shares (in the aggregate) from Tabula and Launchpad, at a purchase price of $0.06 per Common Share (such 5,019 Common Shares
collectively referred to hereafter as the “Structuring Shares”).
 
The Common Shares and the Public Warrants are
traded on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbols “PBM” and “PBMWW,” respectively.
 
Psyence Biomedical Ltd was incorporated as a corporation
under the laws of Ontario, Canada on June 29, 2023.
 
Psyence Group Inc.
 
Prior to the completion of the Business Combination
(as defined below), we were the therapeutics division of PGI, a life science biotechnology company listed on the Canadian Securities Exchange
(CSE:PSYG), with a focus on natural psychedelics. We refer to PGI and its subsidiaries and affiliates prior to the consummation of the
Business Combination as the “Psyence Group.”
 
The Psyence Group was created through various
corporate transactions, including a prior business combination of Mindhealth Corp. with Cardinal Capital Partners Inc., a public
company, in January 2021, resulting in the Psyence Group’s public listing in Canada. MindHealth Biomed Corp. (“MindHealth”)
was a private corporation incorporated under the laws of British Columbia on May 21, 2020. Mind Health (Pty) Ltd (“MindHealth
Lesotho”) is a private entity incorporated under the laws of the Kingdom of Lesotho, which in May 2020, was granted permission
by the Minister of Health (Lesotho) to import, cultivate, produce, manufacture and export psilocybin mushrooms. The governmentally licensed
commercial psilocybin cultivation and production facilities operated by MindHealth Lesotho under the name “Psyence Production”
are situated in the Kingdom of Lesotho. On May 22, 2020, MindHealth Lesotho became a subsidiary of MindHealth.
 
Prior to the Business Combination, the Psyence
Group had three key divisions: Psyence Therapeutics, Psyence Function and Psyence Production. Pursuant to the Business Combination,
the Psyence Therapeutics business was separated from the Psyence Group and became a wholly-owned subsidiary of the Company, while the
other two divisions of the Psyence Group (Psyence Production and Psyence Function) remained under the Psyence Group.
 
Canadian Restructuring
 
Prior to the date of the Business Combination
Agreement, (i) PGI formed Biomed II and Psyence Biomedical as wholly-owned subsidiaries, (ii) promptly after entering into the
Business Combination Agreement, PGI and the Original Target, a corporation continued under the laws of Ontario, Canada, were amalgamated,
and thereafter (iii) PGI (x) transferred the shares of Psyence Australia and its related business assets to Biomed II while
(y) retaining the shares of Good Psyence (Pty) Ltd (RF) (South Africa), Psyence Jamaica Ltd (Jamaica), Psyence UK Group Ltd.,
Psyence Therapeutics Corp. (Ontario, Canada), Mind Health (Pty) Ltd (Lesotho), and Psyence South Africa (Pty) Ltd (South Africa) (collectively,
the “Excluded Assets”) (such transactions, collectively, the “Canadian Restructuring”).
 
Other Information
 
Our registered address and principal executive
office is 121 Richmond Street West, Penthouse Suite 1300, Toronto, Ontario M5H 2K1, and our telephone number is +1 (416) 346-7764.
 
Our U.S. transfer agent and registrar is
Continental Stock Transfer & Trust Company, located at 1 State Street, 30th Floor, New York, NY 10004.
 
We file reports and other information with the
SEC pursuant to the SEC’s rules and regulations that apply to foreign private issuers. The SEC maintains an Internet site that
contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our
electronic filings are available for viewing on the SEC’s website at http:// www.sec.gov). The website address of the Company is www.psyencebiomed.com.
The information contained on the website does not form a part of, and is not incorporated by reference into, this Report.
 


29
 

 

B.Business Overview
 
We are a life science biotechnology company that,
through our operating subsidiary, Biomed II, is developing natural psilocybin products for the healing of psychological trauma and its
mental health consequences in the context of palliative care. We have commenced the clinical trial process to evaluate the safety and
efficacy of its product candidates.
 
We strive to set the global standard for excellence
and consistency in drug development using nature-based psilocybin products. Psyence’s priority is developing pharmaceutical grade
psilocybin to help heal psychological trauma and the diagnosable disorders that can result therefrom, including AjD, alcohol use disorder
(“AUD”), other substance use disorders (“SUDs”), anxiety, depression, post-traumatic stress disorder
(“PTSD”), and grief and bereavement, especially in the context of palliative care. Our focus includes therapeutic protocols
for medical and scientific research including observational studies.
 
Our lead product candidate is PEX010, a capsule
containing 25mg naturally sourced psilocybin and which is being used in our Phase IIb Study. Psyence has entered into the Research IP
Agreement with Filament, a Canadian company that produces natural psilocybin capsules and the proprietary owner of PEX010, for the licensing
of PEX010 with respect to Psyence’s designated fields of use: anxiety and depression, including associated ailments, such as PTSD,
stress, grief, and adjustment disorder within the context of palliative care. See “— Licensing of PEX010”
below.
 
We have contracted Southern Star Research, a full-service
Australian CRO, to conduct a Phase IIb double-blind, randomized, low-dose controlled clinical trial to assess the efficacy and safety
of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. Outsourcing the study to a CRO assists
the company in operating in a more capital efficient manner without the overhead of handling in-house.
 
Corporate Structure
 
Psyence Biomedical conducts its operations through
its subsidiaries based in Ontario and Australia and also owns a subsidiary in the Cayman Islands, as listed below:
 


Name 
Country of Incorporation and Place of Business 
Proportion of Ordinary Shares Held
by Psyence Biomedical 

Psyence Biomed II Corp 
Ontario, Canada 
 100%

Psyence Australia Pty Ltd. 
Australia 
 Indirect 100%

Newcourt Acquisition Corp 
Cayman Islands 
 100%

 


30
 

 
The diagram below depicts a current version of
Psyence Biomedical.
 

 
The Company is subject to certain of the informational
filing requirements of the Exchange Act. Since the Company is a “foreign private issuer,” it is exempt from the rules and
regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and the officers, directors and principal
shareholders of the Company are exempt from the reporting and “short-swing” profit recovery provisions contained in Section 16
of the Exchange Act with respect to their purchase and sale of Common Shares. In addition, the Company is not required to file reports
and financial statements with the SEC as frequently or as promptly as U.S. public companies whose securities are registered under the
Exchange Act. However, the Company is required to file with the SEC an Annual Report on Form 20-F containing financial statements
audited by an independent accounting firm. The SEC also maintains a website at www.sec.gov that contains reports and other information
that the Company files with or furnishes electronically to the SEC.
 
The website address of the Company is www.
psyencebiomed.com. The information contained on the website does not form a part of, and is not incorporated by reference into, this
Report.
 
Phase IIb Study - Palliative Care Clinical Trial
 
On January 9, 2023, Psyence and iNGENū
CRO Pty Ltd ("iNGENū") signed a letter of intent to further develop Psyence’s licensed natural psilocybin
drug product, starting with a Phase IIb Study in order to lead a pre-IND meeting with the FDA. In May 2025, the Company transferred
all clinical trial execution duties from iNGENū to Southern Star Research and entered into a Master Services Agreement (the “MSA”)
with Southern Star Research. Under the MSA, Southern Star Research will provide comprehensive CRO services for the Phase IIb Study.
 
The product to be used in this Phase IIb
Study will be the proprietary botanical drug candidate PEX010 (25mg), which Psyence sources from Filament. The planned randomized double-blind
study will evaluate the use of psilocybin-assisted psychotherapy versus psychotherapy alone and will test 87 patients utilizing the HAM
- A scale as the primary endpoint, which is an FDA validated endpoint, and safety data will be collected throughout the study.
 
For safety, there are no specific endpoints as
all safety findings are captured as adverse events. The primary and secondary efficacy endpoints are all established in the protocol before
it is reviewed and approved by the Ethics Committee before the study can start.
 


31
 

 
The HAM-A is a rating scale developed to measure
the severity of anxiety symptoms and is widely used in both clinical and research settings. The scale consists of 14 items, each defined
by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical
complaints related to anxiety). During the Phase IIb Study, the HAM-A scale will be used to measure change in anxiety levels over time
as the primary endpoint.
 
The 87-patient Phase IIb Study being conducted
by the CRO, Southern Star Research, in Australia is the one that has been referred to in discussions with the FDA in the pre-IND process,
which is in the late planning stage, and estimated to commence enrollment in the second half of 2025.
 
The estimated costs of this Phase IIb Study were
initially $5,575,000 made on the basis of milestones completed. Included in this original estimate were costs for 75 participants; an
end of Phase II meeting preparation and attendance after the completion of the Phase IIb study with the FDA as well as psychotherapy training,
psychotherapy sessions and therapist fees for participants. Subsequently, the Phase IIb Study was increased to 87 patients, and we anticipate
the estimated cost of this study to be increased by approximately 5%.
 
On September 15, 2022, we received full approval
of a study (the “UK Trial”) in the United Kingdom from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) using
natural psilocybin in the field of palliative care with oncology patients. For this study, we had partnered with Clerkenwell Clinics Limited
(“Clerkenwell Health”), which would have been responsible for jointly designing and delivering the UK Trial. Following
such approval, we opted to forego proceeding with the UK Trial in order to pursue the opportunity to conduct the Phase IIb Study
in Australia, as Psyence could benefit from the Australian Federal Government’s Research & Development tax incentive program,
which could provide up to a 43.5% rebate on Psyence’s R&D expenses in Australia, making it a more cost-effective endeavor. In
addition, the Phase IIb Study adds a dose-finding arm, which allows us to accelerate our development strategy, seeking input from
the FDA with our pre-IND application. On March 5, 2024, Psyence received full approval of the Phase IIb Study from to the Australian Human
Research Ethics Committees (HRECs), the body responsible for the review of research proposals involving human participants to ensure that
they are ethically acceptable. If the outcome of the Phase IIb Study is positive, we believe we may be able to proceed directly to a Phase
III trial in the United States, subject to FDA review and the opening of an IND; however, there is no guarantee that the FDA will accept
data from trials conducted outside of the United States.
 
Licensing of PEX010 - Palliative Care
 
In April 2022, Psyence entered into a research
licensing agreement with Filament for the licensing of PEX010 and its associated intellectual property, as well as for the supply of PEX010
for the specific intention of the clinical development of the product for use in palliative care patients ("Research IP Agreement").
Pursuant to the Research IP Agreement, Filament grants to Psyence an irrevocable, royalty free, worldwide license (with the right to sub-license,
subject to certain restrictions) to use and distribute PEX010 and certain related intellectual property (such as delivery mechanism, preparation
methods and know-how) solely for use in connection with pre-clinical and clinical studies and trials to be conducted in Canada, the UK
and world-wide in the treatment of anxiety and depression, including associated ailments, such as PTSD, stress, grief, and adjustment
disorder within the context of palliative care. This license is granted in respect of the clinical trial phase of Psyence’s activities,
specifically phase II clinical trials which, at present, consists of the Phase IIb Study. The license is granted on an exclusive basis
solely within the territory of the UK with respect to the designated fields of use, and Psyence has a right of first refusal to extend
its exclusive license beyond the territory of the UK. Psyence does not have any rights to use PEX010 for any profit-making or commercial
purposes under the Research IP Agreement. Any results of testing, research, conduct of and any information derived from the clinical studies
and trials using PEX010 shall be the sole property of Psyence. Under the Research IP Agreement, Filament is entitled to receive milestone
payments of up to CAD$250,000 in aggregate based on four distinct phase II clinical trial milestones to be achieved by Psyence. Should
Psyence pursue a second or multiple indications, such aggregate milestone payments will increase accordingly. For the year ended
March 31, 2024, Psyence incurred $167,306 costs under the Research IP Agreement related to milestone payments, which was accounted
for as research and development costs.
 


32
 

 
In addition to the licensing rights described
above, per the terms of the Research IP Agreement, Filament has undertaken to support Psyence’s clinical trial efforts through the
supply of the required quantities of PEX010 to Psyence, for no additional charge, based on Psyence’s good faith forecasts of its
needs. Filament will also create and provide such information, assistance and support for the execution of the dossiers, IMBP and
other documents required to conduct Psyence’s clinical trials in accordance with the trial schedules. The license term is 5 years,
expiring in April 2027, however the license may be terminated early (a) by either party upon notice to the other party, where
Psyence notifies Filament in writing that all of its clinical trials have been completed or abandoned; (b) by a party upon notice
to the other party, if the other party becomes subject to bankruptcy proceedings; (c) by a party if the other party commits a breach
of a material term of the Research IP Agreement and fails to remedy such breach; or (d) by a party upon notice to the other party,
if the other party has a licence, permit or approval revoked by competent authorities which compromises its ability to grant the licenses
contemplated in the Research IP Agreement or its ability to perform under the Research IP Agreement. On July 22, 2024, the parties
concluded an addendum to the Research IP Agreement (“Filament Addendum”) whereby Filament undertook to provide a sufficient
supply of PEX010 to Psyence in order to facilitate the substitution of an alternative drug candidate for use in Phase III trials and for
commercialization purposes following the conclusion of the Phase IIb Study (“Proposed End Product”).
 
In December 2022, Psyence entered into a
royalty-bearing, binding term sheet for the commercial licensing of intellectual property (with the right to sub-license) from Filament,
which was subject to the terms of a definitive license agreement, and granted Psyence the worldwide right to commercialize PEX010 within
the designated fields of use, being anxiety and depression, including associated ailments, such as PTSD, stress, grief, and adjustment
disorder within the context of palliative care. The term sheet remained subject to further negotiations between the parties and the execution
of a subsequent definitive agreement within a predefined time period. Following further discussions, Psyence and Filament mutually agreed
to terminate the term sheet by way of the Filament Addendum. Psyence has engaged two alternative suppliers of drug product for its pivotal
Phase III studies as well as for future studies in other indications. Filament agreed to continue to support the supply PEX010 for the
upcoming Phase IIb Study.
 
Psyence has successfully negotiated and executed
supply agreements and licensing agreements for the use of third - party intellectual property with two licensed suppliers operating in
the United Kingdom and North America within the indications of AUD and other SUDs, and anxiety, depression, PTSD, and grief and bereavement,
especially in the context of palliative care, respectively. See “Recent Developments—Psylabs License Agreement and
Recent Developments—Optimi License Agreement”.
 
Psyence has not performed any pre-clinical or
clinical trials on PEX010. PEX010 is owned and has undergone clinical trials directed by Filament. PEX010 has received regulatory approval
to proceed into Phase I and II clinical trials in several jurisdictions worldwide. The FDA, Health Canada, MHRA, and the EMA have reviewed
the chemistry, manufacturing, and controls and quality information of PEX010 through its associated filed DMFs/ IMPDs. The DMF for PEX010
is also on file with the Therapeutic Goods Administration (the “TGA”) in Australia. In addition to clinical trials,
PEX010 is also already being administered to real-world patients via the Health Canada Special Access Program (“SAP”).
Through the SAP, PEX010 is being prescribed for end of life distress as well as Major Depressive Disorder.
 
In addition to clinical trial exposures, PEX010
is also being administered to real-world patients via the Health Canada Special Access Program (SAP). Through the SAP, PEX010 is being
prescribed for End of life Distress as well as Major Depressive Disorder. As of July 17, 2024, 156 doses of PEX010 have been administered
to 132 patients. Despite the serious condition of many of these patients, no serious adverse events or unexpected adverse events have
been reported in any SAP administration.
 
Licensing of additional API for use in AUD
and SUD
 
In September 2024, the Company entered into an
exclusive, royalty-bearing IP licensing agreement with Psyence Labs Ltd. ("PsyLabs"), a privately-held company specializing
in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development,
following an initial investment whereby the Company acquired a minority stake in PsyLabs. Under the terms of this agreement, PsyLabs will
supply the Company with pharmaceutical-grade, EU-GMP, nature-derived (non-synthetic) psilocybin for use in future clinical trials and
eventual commercialization in SUD, including AUD.
 
In parallel with an additional financial commitment
in PsyLabs in April 2025, the Company has secured an exclusive right of first refusal in respect of the worldwide supply of pharmaceutical-grade,
nature-derived ibogaine. Under this agreement, PsyLabs will grant the Company the right of first refusal to acquire the exclusive rights
to a dedicated supply of ibogaine for evaluation in the treatment of SUD, including AUD.
 
These exclusive partnerships further strengthens
the Company's integrated development strategy, ensuring access to high-quality psychedelic compounds to support its growing clinical pipeline
and diversification into multiple therapeutic areas.
 


33
 

 
Relationships with Third Parties
 
Psyence’s Australian-based research and
development will be conducted by its CRO partner, SSR, in Australia. As stated above, Filament’s PEX010 will serve as the product
candidate under investigation during the Phase IIb Study.
 
Psyence’s R&D capabilities
 
Psyence’s CEO (Dr. Neil Maresky) and
Medical Director (Dr. Clive Ward-Able) are both medically trained physicians with close to 60 years of experience between them
within the pharmaceutical industry related to R&D and the commercialization of new products. This experience provides the foundations
for an excellent understanding of the clinical development, regulatory and commercialization needs of various pharmaceutical markets to
design the optimal development program.
 
Psyence plans on working with various CROs and
consultancy agencies to prepare and operationalize their protocols for the various phases of the clinical development program.
 
Intellectual Property
 
Psyence engages a team of lawyers and advisors
that helps strengthen the protection of its IP assets. As psilocybin is a naturally occurring substance, it cannot be patented. However,
patents may be granted on formulations, methods of use, compositions of matter and formulation processes, provided that such items are
novel, non-obvious and have significant improvements to existing inventions.
 
Psyence’s IP strategy is built around:
 

●Establishing and maintaining a competitive advantage on formulation, dosage
and administration of psilocybin, as well as psychedelic-assisted therapy modules for palliative care indications; and
 

●Ensuring business flexibility through directing its research in areas which
maintain freedom to operate (relative to third party patent positions) and secures the most favorable commercial terms in agreements with
other companies in collaborating on later research, and the commercialization of Psyence’s IP assets.
 
Psyence has a specialist, experienced in-house
team focused on delivery of this strategy, including internationally recognized patent professionals working directly with Psyence’s
board on these issues.
 
Specific actions are being taken towards delivery
of this strategy include:
 

●Ongoing patent landscaping on the competitor patent landscape. Psyence has
completed a patent landscaping review and has ongoing patent watching searches in place on the back of this to identify any new filings
made in this space;
 

●Actively considering potential patent filings, with the intention to identify,
file, prosecute and eventually maintain Psyence’s patent portfolio. This patent portfolio is intended to be built out incrementally
across the proprietary formulation and treatment technologies that are under development by Psyence;
 

●Active management of key know-how and trade secrets (in order to supplement
the patent portfolio); and
 

●Thoughtful negotiation of in-licensing arrangements of third-party IP rights
that can enhance or accelerate the building of our business.
 
Psyence does not currently hold any patents. PEX010
is protected by a portfolio of patents comprising five patent families. A patent family is a group of patent applications covering the
same or similar technical content, or a group of patents registered in several countries to protect an invention. This occurs when a patent
application is made in one country and then obtains priority. This priority is then extended to numerous countries. In other words, applications
in a family are related to each other through priority claims. Filament holds a worldwide, exclusive, and sub-licensable license from
its wholly-owned subsidiary, Psilo, for the intellectual property portfolio relating to PEX010, and Psilo is responsible for maintaining
and defending the intellectual property currently being sub-licensed to Psyence under the Research IP Agreement, and which is relevant
for use in Psyence’s proposed Australian palliative care clinical trial. Below is a summary of the five patent families that are
relevant to Psyence’s licenses granted by Filament based on the most recent information made available to us by Filament.
 


34
 

 

●Filament patent family 1 is focused on extraction methods, and consists of
eleven (11) total granted patents, of which six (6) were issued by the Canadian Intellectual Property Office (“CIPO”) and
five (5) were issued by the United States Patent and Trademark Office (“USPTO”), as well as thirteen (13) pending patent applications.
Issued patents in this family are scheduled to expire twenty years from the earliest nonprovisional filing date, which in this case indicates
an expiry date in July of 2040.
 

●Filament patent family 2 is focused on purification processes, and consists
of one (1) granted Canadian patent as well as five (5) patent applications. Issued patents in this family are scheduled to expire twenty
years from the earliest nonprovisional filing date, which in this case indicates an expiry date in October of 2040.
 

●Filament patent family 3 is focused on the standardization processes, and
consists of one (1) allowed patent application and five (5) pending patent applications. Issued patents in this family are scheduled to
expire twenty years from the earliest nonprovisional filing date, which in this case indicates an expiry date in December of 2040.
 

●Filament patent family 4 is focused on chemical processes for stabilizing
psychoactive alkaloids. This family consists of two (2) granted patents, of which one was issued by the CIPO and one was issued by the
USPTO, as well as eleven (11) pending applications. Issued patents in this family are scheduled to expire twenty years from the earliest
nonprovisional filing date, which in this case indicates an expiry date in December of 2040.
 

●Filament patent family 5 is focused on methods and formulations for delivering
psychoactive alkaloids. This family consists of six granted patents, of which five (5) were issued by the CIPO and one (1) was issued
by the USPTO, as well as four pending patent applications. Issued patents in this family are scheduled to expire twenty years from the
earliest nonprovisional filing date, which in this case indicates an expiry date in March of 2041.
 
A summary table of Filament’s patent portfolio
relevant to Psyence’s licenses is provided below based on the most recent information made available to us by Filament:
 



 
 
Internal
 
 
 
 
 
 
 
 
 
 
 
 
 
 

●
@
 
Reference
Number
 
Family
 
Patent
Number
 
Status
 
Title
 
Jurisdiction*
 
Filing Date/
Appl.
No.
 
Issue
Date

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

1
 
PSU001a-AUNE
 
●
1
 
N/A
 
Pending
 
Extraction of psychoactive compounds from psychedelic fungus
 
●
AU
 
16-Dec-22;
2021291583
 
N/A

2
 
PSU001a-BRNE
 
●
1
 
N/A
 
Pending
 
Extraction of psychoactive compounds from psychedelic fungus
 
●
BR
 
16-Jul-21;
112022025777
 
N/A

3
 
PSU001a-CADIV1
 
●
1
 
3123908
 
Issued
 
Ethanol extraction of psychoactive compounds from psilocybin fungus
 
●
CA
 
29-Jul-20
(exam requested 5-Jul-21); 3123908
 
22-Mar-22

4
 
PSU001a-CADIV2
 
●
1
 
3124367
 
Issued
 
Aqueous extraction of psychoactive compounds from psilocybin fungus
 
●
CA
 
29-Jul-20
(exam requested 9-Jul-21); 3124367
 
26-Apr-22

 


35
 

 


 
 
Internal
 
 
 
 
 
 
 
 
 
 
 
 
 
 

●
@
 
Reference
Number
 
Family
 
Patent
Number
 
Status
 
Title
 
Jurisdiction*
 
Filing Date/
Appl.
No.
 
Issue
Date

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

5
 
PSU001a-CANE
 
●
1
 
3161623
 
Issued
 
Extraction of psychoactive compounds from psychedelic fungus
 
●
CA
 
16-Jun-21
(exam requested 13-May-22); 3161623
 
4-Apr-23

6
 
PSU001a-CANP
 
●
1
 
3088384
 
Issued
 
Extraction of psychoactive compounds from psilocybin fungus
 
●
CA
 
29-Jul-20;
3088384
 
3-Aug-21

7
 
PSU001a-EPNE
 
●
1
 
N/A
 
Pending
 
Extraction of psychoactive compounds from psychedelic fungus
 
●
EP
 
6-Jan-23;
EP20210827107
 
N/A

8
 
PSU001a-ILNE
 
●
1
 
N/A
 
Pending
 
Extraction of psychoactive compounds from psychedelic fungus
 
●
IL
 
30-Oct-22;
297791
 
N/A

9
 
PSU001a-JMPC
 
●
1
 
N/A
 
Pending
 
Extraction of psychoactive compounds from psilocybin fungus
 
●
JM
 
29-Sep-21;
18/2/000123
 
N/A

10
 
PSU001a-MXNE
 
●
1
 
N/A
 
Pending
 
Extraction of psychoactive compounds from psychedelic fungus
 
●
MX
 
16-Dec-22;
MX/a/2022/016531
 
N/A

11
 
PSU001a-USCON1
 
●
1
 
US11510952
 
Issued
 
Ethanol extraction of psychoactive compounds from psilocybin fungus
 
●
US
 
28-Jan-22;
17587731
 
29-Nov-22;

12
 
PSU001a-USCON2
 
●
1
 
US11571450
 
Issued
 
Aqueous extraction of psychoactive compounds from psilocybin fungus
 
●
US
 
17-Mar-22;
17697798
 
7-Feb-23;

13
 
PSU001a-USPC
 
●
1
 
US11382942
 
Issued
 
Extraction of psychoactive compounds from psilocybin fungus
 
●
US
 
17-Jun-21;
17351149
 
12-Jul-22;

 


36
 

 


 
 
Internal
 
 
 
 
 
 
 
 
 
 
 
 
 
 

●
@
 
Reference
Number
 
Family
 
Patent
Number
 
Status
 
Title
 
Jurisdiction*
 
Filing Date/
Appl.
No.
 
Issue
Date

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

14
 
PSU001b-AUNE
 
●
1
 
N/A
 
Pending
 
Methanol-based extraction of psychoactive alkaloids from fungus
 
●
AU
 
16-Dec-22;
2021291726
 
N/A

15
 
PSU001b-BRNE
 
●
1
 
N/A
 
Pending
 
Methanol-based extraction of psychoactive alkaloids from fungus
 
●
BR
 
16-Dec-22;
CA2021050823; BR112022025778
 
N/A

16
 
PSU001b-CADIV1
 
●
1
 
N/A
 
Pending
 
Hydro-methanol extraction of psychoactive compounds from fungus
 
●
CA
 
16-Jun-21
(exam requested 28-Apr-23); 3198238
 
N/A

17
 
PSU001b-CANE
 
●
1
 
3163795
 
Issued
 
Methanol-based extraction of psychoactive alkaloids from fungus
 
●
CA
 
13-Jun-23
(exam requested 3-Jun-22); 3163795
 
13-Jun-23

18
 
PSU001b-CANP
 
●
1
 
3089455
 
Issued
 
Methanol-based extraction of psychoactive compounds from fungus
 
●
CA
 
7-Aug-20
(exam requested 5-Jul-21); 3089455
 
5-Jul-22

19
 
PSU001b-EPNE
 
●
1
 
N/A
 
Pending
 
Methanol-based extraction of psychoactive alkaloids from fungus
 
●
EP
 
6-Jan-23;
EP20210825822
 
N/A

20
 
PSU001b-ILNE
 
●
1
 
N/A
 
Pending
 
Methanol-based extraction of psychoactive alkaloids from fungus
 
●
IL
 
24-Nov-22;
298561
 
N/A

21
 
PSU001b-MXNE
 
●
1
 
N/A
 
Pending
 
Methanol-based extraction of psychoactive alkaloids from fungus
 
●
MX
 
16-Dec-22;
MX/a/2022/016530
 
N/A

22
 
PSU001b-USNE
 
●
1
 
N/A
 
Pending
 
Methanol-based extraction of psychoactive alkaloids from fungus
 
●
US
 
15-Jun-22;
17841323
 
N/A;

23
 
PSU001c-USCON1
 
●
1
 
11642385
 
Issued
 
Basic extraction of psychoactive compounds from psychoactive organisms
 
●
US
 
23-Mar-22;
17702701
 
9-May-23;

24
 
PSU001c-USNE
 
●
1
 
11331357
 
Issued
 
Methods and compositions comprising psychoactive compounds from psychoactive organisms
 
●
US
 
15-Jun-21;
17348697
 
17-May-22

25
 
PSU002-AUNE
 
●
2
 
N/A
 
Pending
 
Process for obtaining a purified psychoactive alkaloid solution
 
●
AU
 
5-Dec-22;
2021290454
 
N/A

 


37
 

 


 
 
Internal
 
 
 
 
 
 
 
 
 
 
 
 
 
 

●
@
 
Reference
Number
 
Family
 
Patent
Number
 
Status
 
Title
 
Jurisdiction*
 
Filing Date/
Appl.
No.
 
Issue
Date

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

26
 
PSU002-BRNE
 
●
2
 
N/A
 
Pending
 
Process for obtaining a purified psychoactive alkaloid solution
 
●
BR
 
16-Dec-22;
BR112022025782
 
N/A

27
 
PSU002-CANP
 
●
2
 
3097246
 
Issued
 
Process for obtaining a purified psychoactive alkaloid solution
 
●
CA
 
23-Oct-20
 
28-Mar-23

28
 
PSU002-EPNE
 
●
2
 
N/A
 
Pending
 
Process for obtaining a purified psychoactive alkaloid solution
 
●
EP
 
6-Jan-23;
EP20210881426
 
N/A

29
 
PSU002-ILNE
 
●
2
 
N/A
 
Pending
 
Process for obtaining a purified psychoactive alkaloid solution
 
●
IL
 
25-Dec-22;
299448
 
N/A

30
 
PSU002-MXNE
 
●
2
 
N/A
 
Pending
 
Process for obtaining a purified psychoactive alkaloid solution
 
MX
 
13-Apr-23;
MX/a/2023/004350
 
N/A

31
 
PSU003-AUNE
 
●
3
 
N/A
 
Pending
 
Standardized psychoactive alkaloid extract composition
 
●
AU
 
19-Dec-22;
2022291410
 
N/A

32
 
PSU003-BRNE
 
●
3
 
N/A
 
Pending
 
Standardized psychoactive alkaloid extract composition
 
●
BR
 
16-Dec-22;
CA2021050813; BR112022025780
 
N/A

33
 
PSU003-CANP
 
●
3
 
N/A
 
Pending
 
Standardized psychoactive alkaloid extract composition
 
●
CA
 
18-Dec-20;
3103707
 
N/A

34
 
PSU003-EPNE
 
●
3
 
N/A
 
Pending
 
Standardized psychoactive alkaloid extract composition
 
●
EP
 
6-Jan-23;
EP20210825817
 
N/A

35
 
PSU003-ILNE
 
●
3
 
N/A
 
Pending
 
Standardized psychoactive alkaloid extract composition
 
●
IL
 
25-Dec-22;
299449
 
N/A

36
 
PSU003-MXNE
 
●
3
 
N/A
 
Pending
 
Standardized psychoactive alkaloid extract composition
 
●
MX
 
16-Dec-22;
MX/a/2022/016533
 
N/A

37
 
PSU004-AUDIV1
 
●
4
 
N/A
 
Pending
 
Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
 
●
AU
 
19-Dec-22;
2022291416
 
N/A

38
 
PSU004-AUDIV2
 
●
4
 
N/A
 
Pending
 
Predominantly phosphorylated psychoactive alkaloid extraction using alkali
 
●
AU
 
19-Dec-22;
2022291413
 
N/A

 


38
 

 



 
 
Internal
 
 
 
 
 
 
 
 
 
 
 
 
 
 

●
@
 
Reference
Number
 
Family
 
Patent
Number
 
Status
 
Title
 
Jurisdiction*
 
Filing Date/
Appl. No.
 
Issue Date

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

39
 
PSU004-AUDIV3
 
●
4
 
N/A
 
Pending
 
Psychoactive alkaloid extraction and composition with controlled dephosphorylation
 
●
AU
 
19-Dec-22;
2022291414
 
N/A

40
 
PSU004-AUNE
 
●
4
 
N/A
 
Pending
 
Psychoactive alkaloid extraction and composition with inhibited dephosphorylation
 
●
AU
 
19-Dec-22;
2022291411
 
N/A

41
 
PSU004-CADIV1
 
●
4
 
N/A
 
Pending
 
Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
 
●
CA
 
14-Jun-21
(exam requested 25-Jul-22); 3169140
 
N/A

42
 
PSU004-CADIV2
 
●
4
 
N/A
 
Pending
 
Predominantly phosphorylated psychoactive alkaloid extraction using alkali
 
●
CA
 
14-Jun-21
(exam requested 7-Sep-22); 3173030
 
N/A

43
 
PSU004-CANE
 
●
4
 
3137016
 
Issued
 
Psychoactive alkaloid extraction and composition with inhibited dephosphorylation
 
●
CA
 
16-Aug-22
(exam requested 29-Oct-21); 3137016
 
16-Aug-22

44
 
PSU004-CANP
 
●
4
 
N/A
 
Pending
 
Psychoactive alkaloid extraction and composition with controlled dephosphorylation
 
●
CA
 
4-Dec-20;
3101765
 
N/A

45
 
PSU004-ILDIV1
 
●
4
 
N/A
 
Pending
 
Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
 
●
IL
 
25-Dec-22;
299450
 
N/A

46
 
PSU004-ILDIV2
 
●
4
 
N/A
 
Pending
 
Predominantly phosphorylated psychoactive alkaloid extraction using alkali
 
●
IL
 
25-Dec-22;
299451
 
N/A

47
 
PSU004-ILDIV3
 
●
4
 
N/A
 
Pending
 
Psychoactive alkaloid extraction and composition with controlled dephosphorylation
 
●
IL
 
25-Dec-22;
299452
 
N/A

48
 
PSU004-ILNE
 
●
4
 
N/A
 
Pending
 
Psychoactive alkaloid extraction and composition with inhibited dephosphorylation
 
●
IL
 
25-Dec-22;
299453
 
N/A

49
 
PSU004-USNE
 
●
4
 
US11298388
 
Issued
 
Psychoactive alkaloid extraction and composition with controlled dephosphorylation
 
●
US
 
23-Sep-21;
17483601
 
12-Apr-22

50
 
PSU005a-CADIV1
 
●
5
 
N/A
 
Pending
 
Process for transmucosal psychoactive alkaloid composition
 
●
CA
 
24-Mar-21
(exam requested 18-Apr-23); 3197443
 
N/A

51
 
PSU005a-CANE
 
●
5
 
3152326
 
Issued
 
Preparation of transmucosal psychoactive alkaloid composition
 
●
CA
 
29-Nov-21
(exam requested 12-Mar-22); 3152326
 
9-May-23

 


39
 

 


 
 
Internal
 
 
 
 
 
 
 
 
 
 
 
 
 
 

●
@
 
Reference
Number
 
Family
 
Patent
Number
 
Status
 
Title
 
Jurisdiction*
 
Filing Date/
Appl.
No.
 
Issue
Date

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

52
 
PSU005a-CANP
 
●
5
 
N/A
 
Pending
 
Transmucosal psychoactive alkaloid composition and preparation thereof
 
●
CA
 
24-Mar-21;
3113240
 
N/A

53
 
PSU005a-USNE
 
●
5
 
N/A
 
Pending
 
Transmucosal psychoactive alkaloid composition and preparation thereof
 
●
US
 
14-Jun-22;
17840482
 
N/A

54
 
PSU005b-CANP
 
●
5
 
3123774
 
Allowed
 
Transdermal psychoactive alkaloid composition and preparation thereof
 
●
CA
 
1-Jul-21;
3123774
 
Forecasted Issue Date: 8-Aug-23

55
 
PSU005b-USNE
 
●
5
 
N/A
 
Pending
 
Transdermal psychoactive alkaloid composition and preparation thereof
 
●
US
 
28-Jun-23;
18259697
 
N/A

56
 
PSU005c-CANE
 
●
5
 
3161491
 
Allowed
 
Vaporizable psychoactive alkaloid composition and preparation thereof
 
●
CA
 
22-Dec-21
(exam requested 3-Jun-22); 3161491
 
25-Jul-23

57
 
PSU005c-USNE
 
●
5
 
N/A
 
Pending
 
Vaporizable psychoactive alkaloid composition and preparation thereof
 
●
US
 
14-Jun-22;
17840502
 
N/A

58
 
PSU005d-CANE
 
●
5
 
3157550
 
Issued
 
Injectable psychoactive alkaloid composition and preparation thereof
 
●
CA
 
17-Dec-21
(exam requested 27-Apr-22); 3157550
 
3-Jan-23

59
 
PSU005d-USNE
 
●
5
 
US11491138
 
Issued
 
Injectable psychoactive alkaloid composition and preparation thereof
 
●
US
 
16-Mar-22;
17/696,584
 
18-Nov-22

 
Legend: CA: Canada; IL: Israel, AU: Australia; US: United States; BR:
Brazil; MX: Mexico; EP: Europe; PCT: Patent Cooperation Treaty International Patent System; JM: Jamaica
 
Competitive Environment
 
There are currently no pharmaceutical agents with
FDA regulatory approval for the treatment of AjD within palliative care or any other arena. The current treatment of AjD is empirical,
with either psychotherapy or off-label pharmacological agents, such as anti-depressants or anxiolytics, or a combination of both.
 
We believe that the competitive landscape analysis
of other commercial psychedelic-assisted treatments in clinical trials strongly suggests that Psyence’s clinical asset has a first-mover
advantage in both the palliative care and cancer-related AjD market upon approval. PEX010 and its associated IP has been licensed to Psyence,
giving it exclusivity for the indications of anxiety and depression within the context of palliative care in the UK for R&D purposes.
Psyence plans to expand their targeted indication of cancer-related AjD to address different types of AjD and other secondary indications
both in a palliative and non-palliative context.
 
In 2019, the FDA designated psilocybin therapy
as “breakthrough therapy” for the treatment of severe depressive disorder. This precedent provides the possibility that psilocybin-based
drug candidates, such as the Proposed End Product, may be eligible for a number of processes that could result in expedited marketing
approval of such psilocybin-based drug candidates, such as Fast Track, Accelerated Approval, Priority Review and Breakthrough Status.
Breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.
The criteria for breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial
improvement on at least one clinically significant endpoint over available therapy.
 
A breakthrough therapy designation conveys all
of the fast track program features (see below for more details on fast track designation), more intensive FDA guidance on an efficient
drug development program, an organizational commitment involving senior managers, and eligibility for rolling review and priority review.
 


40
 

 
Additionally, even if we are granted an accelerated
approval pathway, that may or may not lead to a faster development or regulatory review or approval process and may or may not increase
the likelihood that our other product candidate will receive marketing approval. The European Medicines Agency (EMA) PRIME program, similar
to the Food and Drug Administration (FDA) breakthrough therapy designation program, was launched in March 2016 to enhance support
for the development of medicines that target an unmet medical need. PRIME and the U.S. breakthrough therapy designation share the same
objective (timely patient access to innovative medicines).
 
Business Objectives
 
Psyence intends to further expand the development of its product candidates
for additional indications. While Psyence’s initial focus will be on the development of PEX010 for the treatment of AjD in patients
with a recent diagnosis of cancer in its Phase IIb Study and the development of the Proposed End Product thereafter, indication expansion
will focus on other causes of AjD potentially leading to an increased opportunity within the indication. Further indications will be considered
once the AjD program is ongoing in areas such as Alcohol Use Disorder and potentially with the use of other in-licensed candidates, however
no such agreements have been reached at this stage.
 
Psyence’s Psilocybin Asset
 
In order to accelerate clinical development of
a palliative care, psilocybin-based asset, Psyence has initially licensed Filament’s proprietary botanical drug candidate, PEX010,
and its associated IP. Filament has developed innovative technology to extract and standardize stable doses of natural compounds from
mushrooms. PEX010 is currently covered by up to ten patents (five patents by the USPTO and five by the Canadian Intellectual Property
Office). The product candidate has also previously received authorization from the FDA and Health Canada to enter into Phase 1 and
Phase 2 human clinical trials. The license granted to Psyence in respect of the early trial phases grants Psyence exclusivity in
the UK to use PEX010 in future Phase 2 clinical trials for the indications of depression and anxiety, including associated ailments, such
as PTSD, stress, grief, and AjD within the context of palliative care. Pursuant to the license, Psyence will own all the data, results
of testing, research, any information and any other IP derived or arising from any clinical trials, with the exclusion of IP related to
the manufacture, processing or production of the Filament input material, which will vest in Filament.
 
PEX010 is a pharmaceutical-grade, natural psilocybin
drug candidate. It is an oral capsule containing 25mg of naturally derived psilocybin. PEX010 will be used as an adjunct to psychotherapy
for the treatment of AjD due to an incurable cancer diagnosis versus psychotherapy alone within a palliative care context.
 
Description of PEX010
 
PEX010 is extracted and purified from the psilocybes
species of mushroom. Psilocybin is rapidly metabolized in the body to form psilocin, a psychoactive molecule. There has recently been
a resurgence in the study of the use of psychedelics in a multitude of potential indications such as depression, anxiety disorders, PTSD,
addictions and within palliative care, which is the focus area for Psyence’s development of PEX010.
 
PEX010 is being tested in patients with a recent
cancer diagnosis and who have developed AjD which can severely affect their quality of life as well as those closely related to them.
 
Natural versus synthetic psilocybin
 
Naturally extracting psychedelic compounds for
medicinal use has the exciting opportunity of exploring the ‘entourage effect’, which refers to the synergistic interaction
of two or more psychoactive molecules that are present in low concentrations in the final product after psilocybin extraction, resulting
in a smoother, more tolerable onset and offset of the psychedelic experience. There are other active molecules within the mushrooms that
have psychedelic effects, although less than psilocybin (see diagram below). A small amount of these additional active molecules is contained
in the extracts derived from natural mushrooms, which contribute to the entourage effect. In the case of ‘magic mushrooms,’
psychedelic effects are achieved either by ingesting natural psilocybin-containing extracts or engineered formulations of psilocybin derivatives.
It is important to note that the pharmacological properties of the psilocybin molecule remain unchanged whether the drug is synthetically
or naturally derived. Current synthetic versions of psilocybin exist as distinct polymorphic structures and are synthesized via reactions
using certain substrates and enzymes that direct the production of psilocybin. Naturally derived psilocybin is obtained by cultivating
and processing psilocybin-containing mushrooms into a crude API for further use.
 


41
 

 
What distinguishes naturally derived psilocybin
formulations from synthetic formulations is the potential to explore the ‘entourage effect’ by varying the amounts of different
tryptamines yielded in the host mushroom during the growing process. The ‘entourage effect’ has important ramifications for
the overall therapeutic effectiveness of psilocybin-assisted psychotherapy due to the potential of modulating the psychedelic effects
and the neuroplastic processes, which help form connections between multiple neurons, typically induced by psilocybin. This is because
the subjective effects derived from the type or intensity of ‘mystical experiences’ occasioned by psilocybin, might additionally
contribute to the overall effectiveness of the treatment. Whilst this area of research is still largely unexplored, a few preclinical
studies have shown that different species of magic mushrooms procure nuanced changes in psychedelic experiences due to their differing
levels of psilocybin, psilocin and other tryptamine derivatives. As the psilocybin industry continues to evolve, we believe that it is
likely that there will be demand for both naturally derived psilocybin formulations as well as synthetic psilocybin (and derivatives)
due to both the increasing demand in psilocybin-based research and more importantly, patient accessibility of psilocybin medicines. Whole
Psilocybe mushrooms contain tryptamine derivatives that may contribute to a synergistic therapeutic effect.
 

 
Figure 1 Source: ChemDraw
 
Psilocybin, 4-phosphoryloxy-N,N-dimethyltryptamine
(4-PO-DMT) is a naturally occurring tryptamine derivative found in over 100 species of mushrooms.2 Psilocybin quickly
dephosphorylates into psilocin upon ingestion. Psilocin is a partial-agonist of serotonin receptors in the brain. Tryptamine derivatives
and serotonin share many similarities in their chemical structure. Psilocin binds with high affinity to the serotonin 2A receptors (5-HT2A).3
 
Psilocybin
reliably induces profound changes in sensory perception, emotion, thought, and sense of self, characterized by marked alterations in
all mental functions, including perception, mood, volition, cognition and self-experience.4 These profound changes are
often referred to as “mystical-type” experiences. Measures of mystical-type experience occurring during psilocybin treatment
have been repeatedly observed to predict later effects on behavior and emotions, including reductions in depressive and anxious symptoms.5,
6
 

 



2 Daniel J, Haberman M. Clinical potential of psilocybin
as a treatment for mental health conditions. Ment Health Clin. 2017;7:24 – 28


3 PubChem. Psilocybine. https://pubchem.ncbi.nlm.nih.gov/compound/Psilocybine.
Accessed 25 February 2021.


4 Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute,
subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol.
2011;25:1434 – 1452.


5MacLean KA, Johnson MW, Griffiths RR. Mystical experiences
occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25:1453 – 1461.


6Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T,
Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening
cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165 – 1180.
 


42
 


 
Oral
psilocybin has about a 50% bioavailability and psilocin is detectable in plasma within 15 minutes of administration of the parent compound.7,
8 The
half-life of psilocin in blood is 2-3 hours. Onset of noticeable psychoactive effects for a 25 mg dose typically occur within one hour,
peaks at two hours after a dose and finishes at six hours after the dose.
 
The investigational medicinal product PEX010 is
a capsule for oral administration that contains the herbal drug substance PYEX; a Psilocybe cubensis mushroom extract containing Psilocybin
4-phosphoryloxy-N,N-dimethyltryptamine (4-PO-DMT)). The drug product PEX010 is manufactured with the drug substance PYEX (12.5 - 14.0%
psilocybin), excipients, and hydroxypropyl methylcellulose capsules.
 
Indication and Treatments
 
Adjustment Disorder
 
Incurable
cancer is predictably associated with challenges and burdens that may lead to symptoms of depression, demoralization, and fears of suffering,
dependency, and mortality.9 Up to 50% of individuals with advanced cancer report symptoms that are sufficiently severe
to reach clinical levels, exacerbating physical symptoms and impairing quality of life.10,
11 Multiple physical symptoms, dramatic alteration
in support needs and personal relationships, difficulty navigating a complex health care system, and the threat of impending mortality
all may constitute pathways to distress.12
 
AjD is defined in International Classification
of Diseases 11th Revision (ICD-11) as a maladaptive reaction, which usually emerges within one month of a significant life-stressor,
such as illness, family or partnership problems, job-related issues, or financial difficulties. 13 There
are two core categories of symptoms that characterize AjD: a preoccupation with the stressor or its consequences, and failure to adapt.
Preoccupation includes recurring distressing thoughts about the stressor, constant worry, and rumination. Failure to adapt describes a
generalized stress-response (e.g., sleep disturbances or concentration problems) that results in significant impairment in social, interpersonal,
occupational, educational, or other significant areas of functioning
 
AjD
is also defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnostic criteria,14 and
while there is great overlap with the definition and symptomatology compared to the ICD 11 classification, the DSM definition separates
AjD into 6 different subtypes, Both the ICD and DSM have had substantial impact on global psychiatric practice and research. While the
DSM has been used more often in research around the world,16 a study of nearly 5,000 psychiatrists in 44 countries demonstrated
that the majority of psychiatrists outside the U.S. utilize ICD classifications in their daily clinical practice.17 The
DSM-5 conceptualizes AjD as a stress-related syndrome in a separate chapter of “Trauma and Stress Related Disorders”,18 representing
the most significant change from DSM-IV.19 However, the current diagnostic construct is crucially dependent on an exclusion
criterion, so that a diagnosis of AjD is rarely applicable when another mental disorder is present.
 

 



7 Brown
RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, et al. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy
Adults. Clin Pharmacokinet. 2017;56:1543–1554.


8 Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider
FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous
psilocybin in man. Pharm Acta Helv. 1997;72:175 – 184.


9 Lo C, Zimmermann C, Rydall A, Walsh A, Jones JM, Moore
MJ, et al. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. J Clin Oncol. 2010;28:3084 – 3089.


10 Hopwood P, Stephens RJ. Depression in patients with
lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol. 2000;18:893 – 903.


11 Delgado-Guay M, Parsons HA, Li Z,
Palmer JL, Bruera E. Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting. Support
Care Cancer. 2009;17:573 – 579.


12 Rodin G, Lo C, Mikulincer M, Donner
A, Gagliese L, Zimmermann C. Pathways to distress: the multiple determinants of depression, hopelessness, and the desire for hastened
death in metastatic cancer patients. Soc Sci Med. 2009;68:562 – 569.


13Maercker A, Brewin CR, Bryant RA, Cloitre M, van Ommeren
M, Jones LM, et al. Diagnosis and classification of disorders specifically associated with stress: proposals for ICD-11. World Psychiatry.
2013;12:198 – 206.


14Casey P, Doherty A. AjD: implications for ICD-11 and
DSM-5. Br J Psychiatry. 2012;201:90 – 92.


15Printer to align footnotes with paragraphs as appropriate.


16Clark LA, Cuthbert B, Lewis-Fernández R, Narrow WE,
Reed GM. Three Approaches to Understanding and Classifying Mental Disorder: ICD-11, DSM-5, and the National Institute of Mental Health’s
Research Domain Criteria (RDoC). Psychol Sci Public Interest. 2017;18:72 – 145.


17Reed GM, Mendonça Correia J, Esparza P, Saxena S,
Maj M. The WPA-WHO Global Survey of psychiatrists’ attitudes towards mental disorders classification. World Psychiatry. 2011;10:118 – 131.


18Kangas M. DSM-5 Trauma and Stress-Related Disorders: Implications
for Screening for Cancer-Related Stress. Front Psychiatry. 2013;4:122.


19Strain JJ, Friedman MJ. Considering AjDs as stress response
syndromes for DSM-5. Depress Anxiety. 2011;28:818 – 823.

 


43
 

 
Treatment Plans
 
Traditional Treatments
 
Evidence suggests that addressing psychosocial,
emotional, and physical symptoms early in the cancer trajectory, through such steps as palliative care or psychological interventions,
may positively influence survival outcomes.20,21,22,23 Comorbid depression with cancer leads to worsened quality of life,
increased sensitivity to pain, difficulties with treatment, communication difficulties, caregiver burnout, increased risk of suicide,
longer periods of hospitalization, and a reduced expectation of survival.24,25,26,27,28 The National Institute for Clinical
Excellence Palliative Cancer Care Guidelines29 recommend that if experiencing more severe types of psychological distress — which
would include moderate to severe AjD — patients should be offered specialist psychological interventions such as
psychotherapy, including cognitive behavioral therapy (“CBT”).
 

 


20Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S,
Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733 – 742.


21Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, et
al. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled
Trial. J Clin Oncol. 2015;33:1438 – 1445.


22Giese-Davis J, Collie K, Rancourt KMS, Neri E, Kraemer HC,
Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary
analysis. J Clin Oncol. 2011;29:413 – 420.


23Spiegel D, Giese-Davis J. Depression and cancer: mechanisms
and disease progression. Biol Psychiatry. 2003;54:269 – 282.


24Skarstein J, Aass N, Fosså SD, Skovlund E, Dahl AA.
Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for
Research and Treatment of Cancer Core Quality of Life Questionnaire. J Psychosom Res. 2000;49:27 – 34.


25Depression as a predictor of disease progression and mortality
in cancer patients: a meta-analysis. Centre for Reviews and Dissemination (UK); 2009.


26Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera
E, et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation.
J Clin Oncol. 2002;20:1907 – 1917.


27Misono S, Weiss NS, Fann JR, Redman M, Yueh B. Incidence
of suicide in persons with cancer. J Clin Oncol. 2008;26:4731 – 4738.


28Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart
A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326 – 1327.


29Nice N. Improving supportive and palliative care for adults
with cancer. London: NICE. 2004. 2004.

 


44
 

 
Psilocybin-assisted psychotherapy
 
CBT has been shown to improve anxiety in patients
diagnosed with incurable cancer, but appears to be less effective at improving depressive symptoms.30 Several recently
published trials have examined the efficacy of psilocybin, a classic serotonergic psychedelic drug that induces its acute subjective effects
through the agonism of serotonin 2A (5-HT2A) receptors, to treat depression and anxiety in patients with life -threatening cancer,
amongst other psychiatric conditions.31,32,33,34 Psilocybin-assisted psychotherapy is a course of therapy involving single
or multiple sessions in which a dose of psilocybin is administered in conjunction with psychotherapy, delivered by a suitably trained
therapist in a controlled setting. This intervention consists of three therapy stages: (1) preparation, (2) dosing session(s),
and (3) integration, which allow for a more patient-centric approach compared to other therapy models. The pharmacological effects
of psilocybin, in synergy with the psychotherapy, are considered to give rise to increased neuroplasticity, which facilitates rapid and
deep psychological transformation that may accelerate and augment the effects of the psychotherapy process.34
 
PAP has been demonstrated in various academic
studies to cause expeditious, substantial, and sustained improvements in cancer-related anxiety and depression, existential distress,
quality of life, and orientation toward death.32,33 For example, in an academic study 15 of 29 patients with
cancer-related depression and anxiety, at the 6.5-month follow up, psilocybin was associated with enduring anxiolytic and anti-depressant
effects (approximately 60-80% of participants continued with clinically significant reductions in depression or anxiety respectively),
sustained benefits in existential distress and quality of life, as well as improved attitudes towards death.35 In another
study of 51 patients,33 similar results were reported. At 6-month follow-up, these changes were sustained, with about
80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements
in attitudes about life/self, mood, relationships, and spirituality to the “high” experience resulting from the psilocybin,
with over 80% endorsing moderately or greater increased well-being/life satisfaction.36,37,38,39,40,41,42
 

 


30Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance
and commitment therapy: model, processes and outcomes. Behav Res Ther. 2006;44:1 – 25.


31Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner
A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384:1402 – 1411.


32Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt
AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71 – 78.


33Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards
WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening
cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30:1181 – 1197.


34Brouwer A, Carhart-Harris RL. Pivotal mental states. J Psychopharmacol.
2021;35:319 – 352.


35Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté
KL, Guss J, et al. Long-term follow-up of PAP for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol.
2020;34:155 – 166.


36Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe
D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet
Psychiatry. 2016;3:619 – 627.


37Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts
R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology.
2018;235:399 – 408.


38Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND,
Johnson MW, et al. Effects of PAP on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78:481 – 489.


39Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa
PCR, Strassman RJ. Psilocybin- assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29:289 – 299.


40Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot
study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983 – 992.


41Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability,
and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735 – 1740.


42Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards
WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening
cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30:1181 – 1197.

 


45
 

 
A number of factors provide rationale for focusing
on patients with AjD following a diagnosis of incurable cancer as the target population. The size of the cancer population, which generally
makes up approximately 30% of target country palliative patients, provides justification for research, in regard to both the magnitude
of needs and the access to participant recruitment. Additionally, previous clinical trials have demonstrated the feasibility and efficacy
of PAP for people with depression and anxiety symptoms, both within and outside of the palliative care setting, highlighting the versatility
and universality of this intervention. Moreover, the sustained reductions in anxiety and depression amongst palliative care patients suggest
the longevity of positive outcomes mediated by PAP and the potential to dramatically improve patient quality of life, in what remains
of their life.
 
Classic psychedelics, a term referring to naturally-derived
psychedelics including mescaline, lysergic acid diethylamide and psilocybin, all share a common mechanism of action via the serotonergic
pathways. Psilocybin is a prodrug that, when ingested, is metabolized into the psychoactive compound psilocin. Psilocin acts as a partial
agonist at the serotonergic 5-HT2A receptor, and research has demonstrated that activation of the 5-HT2A receptor subtype is integral
to the mechanism of action leading to subjective psychedelic experience.43,44,45,46,47
 
The pharmacological effects of psilocybin, in
synergy with psychotherapy, are considered to give rise to increased neuroplasticity and create a ‘pivotal mental state,’
which facilitates rapid and deep psychological transformation that may accelerate and augment the effects of the psychotherapy process.34 This
is thought to underlie the transdiagnostic efficacy of PAP for a wide range of difficult to treat psychiatric conditions, including treatment-resistant
depression, PTSD, substance use disorders, psychological distress with a life-threatening illness and obsessive-compulsive disorder.
 
Clinical Studies
 
In recent palliative care clinical trials conducted
at New York School of Medicine and Johns Hopkins University School of Medicine, in which participants received PAP at doses of 22 mg/70
kg, 30 mg/70 kg, and 0.3 mg/kg, no serious adverse events (“SAEs”) were reported. Adverse effects of PAP amongst
participants had all been previously described for psilocybin and were mild and transient, and included physical discomfort, psychological
discomfort, increased systolic and diastolic blood pressure without criteria for medical intervention, increased heart rate with a mild
sympathomimetic effect, nausea and vomiting, transient anxiety and headaches or migraines. None of the participants experienced prolonged
psychosis or hallucinogen persisting perception disorder (“HPPD”).
 

 


43Willins DL, Meltzer HY. Direct injection of 5-HT2A receptor
agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther. 1997;282:699 – 706.


44Glennon RA, Teitler M, Sanders-Bush E. Hallucinogens and
serotonergic mechanisms. NIDA Res Monogr. 1992;119:131 – 135.


45Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler
A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897 – 3902.


46Ray TS. Psychedelics and the human receptorome. PLoS One.
2010;5:e9019.


47González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic
L, Ang R, et al. Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior. Neuron.
2007;53:439 – 452.

 


46
 

 
There are currently 16 registered studies in Clinical
Trials.Gov in the investigating the efficacy of PAP to treat depression, anxiety and demoralization in patients with incurable illnesses:
 


NCT
Number
 
Study
Title
 
Study
Status
 
Conditions
 
Sponsor

NCT06001749
 
Psilocybin
in Cancer Pain Study
 
RECRUITING
 
Opioid-Related
Disorders|Pain Management|Pain Management and Care|Advanced Cancer|Advanced Cancers
 
Yvan
Beaussant, MD, MSci

NCT06430541
 
Study
of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
 
RECRUITING
 
Breast
Cancer|Ovarian Cancer
 
University
of Colorado, Denver

NCT04522804
 
Study
of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
 
COMPLETED
 
Cancer
 
University
of Utah

NCT05220046
 
Palliadelic
Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
 
RECRUITING
 
Pancreas
Cancer|Biliary Tract Cancer|Psychological Distress|Gastrointestinal Cancer
 
University
of Nebraska

NCT05847686
 
Psilocybin-Assisted
Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
 
COMPLETED
 
Hematopoietic
and Lymphatic System Neoplasm|Metastatic Malignant Solid Neoplasm
 
University
of Washington

NCT06416085
 
Psilocybin-assisted
Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
 
RECRUITING
 
Advanced
Cancer|Stage IV Solid Tumor Cancer|Stage IV Sarcoma of Bone|Stage IV Lymphoma|Stage IV Melanoma|Endocrine Cancer
 
University
Health Network, Toronto

NCT04593563
 
The
Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder
 
UNKNOWN
 
Major
Depressive Disorder
 
Maryland
Oncology Hematology, PA

NCT00465595
 
Psychopharmacology
of Psilocybin in Cancer Patients
 
COMPLETED
 
Depressive
Symptoms|Anxiety|Cancer
 
Johns
Hopkins University

NCT00957359
 
Psilocybin
Cancer Anxiety Study
 
COMPLETED
 
Cancer
 
NYU
Langone Health

NCT06319378
 
Cancer
Related Major Depression Treated With a Single Dose of Psilocybin
 
RECRUITING
 
MDD
 
Section
for Affective Disorders; Northern Stockholm Psychiatry

NCT05947383
 
A
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin
for the Treatment of Major Depressive Disorder in Adults With Cancer
 
RECRUITING
 
Cancer|Major
Depressive Disorder
 
Sunstone
Medical

NCT04950608
 
Pilot
Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
 
ACTIVE_NOT_RECRUITING
 
Hospice|Psilocybin|Demoralization|Terminal
Illness|Cancer-related Problem/Condition|Psychotherapy|Terminal Cancer|Cancer Terminal
 
Yvan
Beaussant, MD, MSci

NCT06200155
 
Psilocybin-Assisted
Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
 
RECRUITING
 
Depression,
Anxiety|Psilocybin-Assisted Psychotherapy|Advanced Cancer
 
M.D.
Anderson Cancer Center

NCT06644170
 
A
Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
 
RECRUITING
 
Hematopoietic
and Lymphatic System Neoplasm|Metastatic Malignant Solid Neoplasm
 
University
of Washington

NCT05506982
 
Psilocybin
Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
 
ACTIVE_NOT_RECRUITING
 
Hematopoietic
and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm
 
Emory
University

NCT05398484
 
Psilocybin
Therapy in Advanced Cancer
 
RECRUITING
 
Advanced
Cancer
 
NYU
Langone Health

 


47
 

 


Known and Potential Risks of Psilocybin
 
Abuse Potential
 
To date, there have been no confirmed reports
of an overdose of pharmaceutical psilocybin. Currently, psilocybin is placed in Schedule 1 in the UK Misuse of Drugs Regulations 2001,
defined as having no medical use, possessing high abuse liability, and lack of accepted safety when used under medical supervision. However,
in preclinical studies using non-human primates, psilocybin, mescaline and N,N-Dimethyltryptamine did not serve as positive reinforcers
in 3,4-Methylenedioxy methamphetamine (MDMA) experienced rhesus monkeys. This suggests that non-human primates do not find the psychoactive
effects of the 5-HT2A receptor agonists addictive.
 
Analysis of long-term follow-up data from eight
pooled experimental trials with healthy volunteers indicated no subsequent drug abuse, no changes to overall drug consumption habits (including
alcohol, nicotine, cannabis and MDMA) or functional impairment following exposure to psilocybin in the laboratory. Where changes in drug
consumption habits were noted, most respondents described decreased consumption, particularly with reference to psilocybin use. Large-scale
survey research indicates that hallucinogens are selected as a primary substance of abuse in only a fraction of responders.
 
In clinical studies with psilocybin, exposing
individuals with either no history of hallucinogen use, or a history of minimal use (less than ten times in total and not within the previous
five years) have not resulted in reported instances of subsequent illicit hallucinogen abuse. Additionally, studies have shown side
effects that are potentially predictive of low abuse potential, such as elevations in fear and anxiety. Based on available literature,
it is not expected that either psilocybin-naïve or experienced individuals will develop dependence after exposure.
 
Safety
 
Psilocybin has been found to be of very low toxicity
in humans and research animals.
 
In recent palliative care clinical trials conducted
at New York School of Medicine and Johns Hopkins University School of Medicine, in which participants received PAP at a dose of 22 mg/70
kg, 30 mg/70 kg, and 0.3 mg/kg, no serious adverse events (“SAEs”) were reported. Adverse effects of PAP amongst participants
had all been previously described for psilocybin and were mild and transient, and included physical discomfort, psychological discomfort,
increased systolic and diastolic blood pressure without criteria for medical intervention, increased heart rate with a mild sympathomimetic
effect, nausea and vomiting, transient anxiety and headaches or migraines. None of the participants experienced prolonged psychosis or
hallucinogen persisting perception disorder (“HPPD”).
 
The clinical safety of psilocybin has been extensively
studied in open-label and double-blind, controlled trials, both as a single agent and as adjunctive treatment in a number of clinical
and non-clinical adult populations. Dosing regimens used in previous clinical trials with psilocybin have ranged from 0.014 mg/kg to 0.6
mg/kg, administered orally as either a single dose, or multiple doses weeks apart. Thousands of participants have received psilocybin
under controlled conditions in a clinical setting for various indications, with results published in peer-reviewed journals. Knowledge
gained from previous clinical trials with psilocybin and discussions with researchers leading other randomized control trials in this
area has directed the design of Psyence’s planned Phase IIb Study.
 


48
 


 
Psilocybin (also known as ‘magic mushrooms’)
is rated as one of the least harmful recreational drugs. Commonly cited risks include prolonged psychotic reactions, flashback phenomena/HPPD,
and bad trips. Prolonged psychotic responses are extremely rare in clinical studies with psilocybin (<1%), even at very high doses,
and none have been reported in modern studies or studies with patients. The risk of flashback phenomena is minimal (or even negligible),
and no cases have been observed in other studies with psilocybin. Periods of psychological challenge (for example, increased anxiety)
are more commonly reported, but may be predictive of positive clinical outcomes.
 
Psilocybin Related Adverse Events by Incidence (at 25 mg)
 


Common
>20%
 
Less common
<15%
 
Rare
< 2%

1)
 
1)
 
1)

 
 
 
 
 

Increased anxiety, particularly at the onset of the drug effects
 
Paranoia or suspiciousness.
 
HPPD/flashbacks

 
 
 
 
 

2)
 
2)
 
2)

 
 
 
 
 

Mild-moderate increase in heart rate
 
Nausea
 
Worsening of mental state after the drug experience

 
 
 
 
 

3)
 
3)
 
 

 
 
 
 
 

Visual hallucinations
 
Dizziness
 
 

 
 
 
 
 

4)
 
4)
 
 

 
 
 
 
 

Transient headaches, lasting for one to two days (maximum) post-dosing
 
A ‘bad trip’ i.e. negative thoughts and mood during the acute drug effects
 
 

 
It is not uncommon for people to experience some
negative psychological content during a psilocybin ‘trip’, particularly if they suffer from ongoing psychological distress,
as is characteristic of depression. Typically, this is managed by ensuring good preparation before, support during, and integration after
the experience. While challenging episodes have been relatively commonly reported in previous trials, some of these have contributed to
a psychological ‘breakthrough’ on the part of the participant. Recent evidence indicates that challenging psychological experiences
can produce therapeutic benefits, improving psychological well-being in the long-term.
 
Negative aftereffects of challenging psychological
experiences under psychedelics are thought to be a consequence of inadequate ‘set and setting’ and post-session integration
work — and they may also relate to the duration of the challenging period. In the Phase IIb Study and further
studies, such risks will be reduced via thorough psychological preparation and integration, good patient-staff rapport and a positive,
supportive environment. Challenging experiences/periods will be managed principally through psychological support, but oral and injectable
lorazepam and olanzapine, as rescue medications, will be available. These would only be used in cases of severe panic that were unresponsive
to psychological intervention, and where the patient’s behavior was putting themselves and/or staff in danger. Consent for such
medication will be sought from the patient ahead of study participation.
 


49
 

 
Before, during and after the dosing session, patients
will receive psychological support from therapists who have been specifically trained to deliver PAP in the context of research studies,
including clinical trials. An onsite psychiatrist will also be available to support where needed. Monitoring of participants’ vital
signs, behavior and mood will be conducted prior to the psilocybin being administered, and prior to the participant being discharged.
On the dosing day, patients will only be allowed to return home only once the study psychiatrist is confident they are fit to do so, and
authorizes the patient’s release. 24-hour emergency contact numbers will be provided for a member of the study team, and localized
support and crisis services will also be provided.
 
Due to the psychoactive nature of psilocybin,
the safety of participants in clinical trials can be enhanced by testing psilocybin within a “set and setting” protocol. By
addressing the set (the emotional, cognitive, behavioral states, mindset and expectations of study participants just prior to psilocybin
exposure) and setting (the physical environment in which the exposure occurs) of the experience, the risk of the subject reporting an
event which is distressing or injuring themselves can be reduced. This approach generally incorporates three components: (1) preparation,
(2) drug session and (3) post -session meetings to integrate the classic psychedelic experience.
 
During the preparation phase, participants undergo pre-exposure sessions
designed to build rapport with the therapist who will be present during the drug dosing session and to identify personal themes and struggles
that might be especially likely to impact the session experience. The drug session itself is conducted by a trained therapist (the gender
of which is selected by the participant) and an appropriately trained member of the study team, who are present throughout the session.
Sessions are typically conducted in a room designed to be quiet, comfortable, and aesthetically pleasing, and participants are encouraged
to wear eyeshades and listen to a program of music through headphones during the drug exposure to aid them in focusing their attention
inwards. In the third phase, participants are engaged in a series of drug-free therapy sessions to discuss their dosing session experience
thoroughly, with the goal of maximizing its therapeutic benefit.
 
Suicide
 
While most trials with psilocybin have demonstrated
reduced suicidality following dosing, one recent large-scale study conducted by Compass Pathways with 233 participants on the efficacy
of psilocybin in a treatment-resistant depression (TRD) population reported that suicidal ideation and intentional self-injury were seen
in all treatment groups, as is common in TRD studies. Most cases occurred more than a week after the COMP360 psilocybin session. There
was no mean worsening of suicidal ideation scores on the MADRS scale in any treatment group. Suicidal behaviors were reported at least
one month after COMP360 administration for three non-responders in the 25mg arm.
 
It is important to note that subjects with AjD
and patients with a cancer diagnosis are also at increased risk of suicide. As such, in the Psyence Phase IIb Study, the risk of suicide
and other AE’s will be assessed by thorough and regular screening using the Sheehan-Suicide Tracking Scale (S-STS) at every study
visit. Participants with suicidal tendencies and histories of suicide attempts will be excluded from the study. The study psychiatrist
and psychotherapist contact details will be provided to patients in case of emergency, in addition to providing localized information
for support services and crisis management. A standard operating procedure for dealing with both AEs and any unexpected suicide attempt
has been prepared. As such, we believe that the risk of suicide and other AEs will be reduced by thoroughly screening participants for
any suicidal tendencies, by excluding patients with histories of suicide attempts and by regular monitoring of suicidal ideation and behavior.
 
Target Population and Market — Palliative Care
Patients
 
Previous trials have demonstrated that PAP is
well tolerated in samples of palliative care patients, with no SAEs. Recruitment of palliative care participants may require screening
of large samples in order to achieve the intended sample size. In previous PAP trials with palliative care participants, 10%-27% of screened
individuals were enrolled in the study. Recruitment for trials of psychiatric disorders is complex, as such conditions may affect motivation
and adherence, relating to both the physical and mental health of participants with a cancer diagnosis. Moreover, there is an exogenous
risk of participant death during the trial for clinical trials in the palliative care setting. Similarly, as cancer may metastasize further,
diligence must be paid to exclude participants with metastatic cancer to the brain, considering the potential impact on cognitive function.
Together, this indicates that the success of recruitment and screening relies on the selection of participants with appropriate life expectancy,
extent of cancer, and post-diagnosis time for the inclusion/exclusion criteria in PAP trials with palliative care patients.
 


50
 

 
Targeted Market for First Indication (AjD in Patients with a
Cancer Diagnosis)
 
The total Palliative Care Market is large, with
an expected robust CAGR of 9.4% over the next 7 years. The figures below are drawn from commissioned market research performed by
Insight Ace Analytic (insightaceanalytic.com) in September 2022.
 
The total market value was calculated using two
approaches simultaneously; namely top-down and bottom-up approaches.
 
In the top-down approach, the total market revenue
is calculated by conducting the parent market analysis for deducing the revenue for global palliative care market revenue. Analyst perspective
and subject-matter-expert based heuristic form of market sizing also plays an integral role in this step. For forecasting the current
estimates, the following key sources were considered:
 

●American Cancer Society International Association for Hospice & Palliative
Care,
 

●UK Palliative Medicine Association National Hospice and Palliative Care Organization
(NHPCO),
 

●Worldwide Hospice Palliative Care Alliance (WHPCA), International Association
for Hospice & Palliative Care (IAHPC),
 

●Investor presentation of palliative care providers,
 

●Psychedelic drug development companies,
 

●Hospice care providers and associations
 

●Worldpopulationreview gco.,iarc.fr, webmed.com, acsjournals,.onlinelibrary.wiley.com,
NCBI, www.cancer.org, ecancer.org, canadian-cancer-statistics-2021, www150.statcan.gc.ca cancer.ca, canceratlas.cancer.org, bmcmedicine,
biomedcentral.com, www.who.int, ascopubs.org, www.jpsmjournal.com,OECD
 
In the bottom-up approach, we used different mathematical
models to estimate the market sizes of different economies and segments, which we then summed up to define the total market. The key data
points that enabled the estimation of global palliative care market are as follows:
 

●Palliative Care Service Revenues from major service providers
 

●Palliative care different disease and treatment penetration by region and
key countries
 
As a part of the market engineering, both ‘top-down’
as well as ‘bottom-up’ approaches were extensively utilized along with data triangulation models to derive & verify
the market sizes & forecast through 2028. Market forecast was performed through proprietary software that analyses various qualitative
and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across
various data points provided accuracy in different market segments in the report.
 
A holistic approach was used to ensure that the
granular and uncommon parameters were taken into consideration to ensure accurate results. The information from the paid databases were
further combined to the raw data in order to standardize it.
 
Data validation is the most crucial stage of the
research process. Primary interviews were conducted to validate the data and analysis, which provides first-hand information on the market
dynamics, outlook, and growth parameters. Industry experts validate the estimates, which helps the company to cement the on-going research
study and primary research includes online surveys and telephonic interviews with different distributors and manufacturers.
 


51
 

 

 
Figure 2 The estimated year of launch
of the Proposed End Product in the treatment of Adjustment Disorder in palliative care patients is 2027. Robust growth of the total palliative
care market continues through 2030.
 

 
Figure 3 Robust growth in the palliative
market across major regions of the world continue through 2030
 


52
 

 

 
Figure 4 The initial indication within the
cancer segment of palliative care is about 37% of the total market which provides a large segment of other chronic illnesses to be targeted
with label expansion opportunities.
 

 
Figure 5 There will be approximately 2.25 million
patients in North America and Europe with distress related to cancer in 2030
 


53
 

 

 
Figure 6 This table gives a directional indication
of what the size of the revenue could be with very conservative estimates of percentage of number of cancer patients with distress
on PAP and the costs charged for PAP or just the psilocybin. Growth in percentage market obtained will be dependent on awareness
and ability to provide PAP in sufficient clinics. Whichever scenario is considered, the Serviceable Obtainable Market could be three times
higher when other chronic disease sources of distress are available.
 
Business Model
 
Psilocybin-assisted psychotherapy, once approved,
will have to be delivered to patients in a guided manner over a period of 6 – 8 weeks, including the intention setting
meetings, the psychedelic event (dosing session) and the subsequent integration meetings. This implies having trained guides who will
spend a long time with patients over the course of the PAP, suitable clinic settings and psychologists’ oversight.
 
The final business model for the provision of
the Proposed End Product will depend on a number of aspects, including the final outcomes of the studies, the indication(s) that
will be allowed by the regulatory agencies and the state of the environment and market to provide psychedelic therapy at the time of approval.
It is expected that the number of clinics available to be able to provide PAP will increase dramatically once the first psychedelic is
approved for any indication.
 
Our possible business models will take into consideration
of whether to merely supply the Proposed End Product for clinics to administer, through including a premium price for the intellectual
property of a proprietary PAP, to enter into partnerships with clinics to administer PAP, or even to own dedicated clinics for administration
of PAP.
 
The target audience for the initial indication
will be oncology sites, including their oncologists and other health care professionals to create awareness of the effectiveness of PAP
for cancer patients who have AjD. The principal marketing message will be to offer patients a better quality of life for their remaining years
with a single administration of the Proposed End Product within a PAP. It has been shown that patients in palliative care who are less
anxious or depressed utilize fewer healthcare resources, which is an aspect that will help justify the costs of the PAP.
 


54
 

 
Alcohol Use Disorder (AUD)
 
Psyence Biomed have intentions to study the use
of psilocybin in the treatment of AUD and possibly Substance Use Disorder (SUD). There are a number of academic studies showing the efficacy
of PAP in the treatment of both disorders although they have tended to be smaller studies. In the current planning phase, the creation
of a steering committee for the AUD study has been initiated and preliminary market research is being conducted to identify the best patient
to target in the study, to help identify the appropriate design, as well as to choose which endpoints should be used.
 
There is a big unmet medical need for an
effective therapy to treat AUD despite the fact that there are a few products authorized regulatorily. However, those treatments
have low long-term efficacy, and their indications are not particularly broad.
 
The deleterious societal and economic impact of
AUD is enormous and to develop an effective, sustainable treatment for the disorder would be a great advance for patients, their families
as well as the general public.
 
Legal and Regulatory Framework
 
Current Regulatory Landscape of Target Markets
 
Psyence will focus on the initial countries and
regions to perform their clinical development and to commercialize the final product, being North America (US & Canada), EU,
UK and Australia. Introductions into other regions will be contemplated at a later phase.
 
In the United States, foods, drugs and dietary
supplements are subject to extensive regulation. The U.S. Food, Drug, and Cosmetic Act (the “FDCA”) and other federal
and state statutes and regulations govern, among other things, the research, development, testing, manufacturing, storage, recordkeeping,
approval, labelling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of
pharmaceutical products. We must ensure that all promotion and marketing, distribution, and labeling of any pharmaceutical products comply
with the U.S. regulations, including the FDCA and the U.S. Food and Drug Administration (the “FDA”).
 
Psilocybin and psilocin are strictly controlled
under the U.S. Controlled Substances Act (“CSA”) as Schedule I substances. By definition, Schedule I substances
have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential
for abuse. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas,
security requirements and criteria for importation. Anyone wishing to conduct research on substances listed in Schedule I under the
CSA must register with the DEA and obtain DEA approval of the research proposal. A majority of state laws in the United States also classify
psilocybin and psilocin as Schedule I controlled substances. For any product containing psilocybin or any Schedule I substance
to be available for commercial marketing in the United States, such substance must be rescheduled, or the product itself must be scheduled,
by the DEA to Schedule II, III, IV or V. Scheduling determinations by the DEA are dependent on FDA approval of a substance
or a specific formulation of a substance.
 
Prescription drugs are classified and regulated
under the federal Food and Drugs Act (Canada). Labeling, marketing and selling of any prescription drug must comply with Health Canada.
The regulations in the European Union are similar to those in the U.S. and Canada.
 
Psyence will focus the phase IIb portion of its
clinical development program in Australia. The TGA is Australia’s government authority responsible for evaluating, assessing and
monitoring products that are defined as therapeutic goods, and the use of therapeutic goods supplied in clinical trials in Australia under
the therapeutic goods legislation. Such legislation includes The Therapeutic Goods Act 1989 (“TG Act”), Regulations
and Orders which set out the requirements for inclusion of therapeutic goods in the Australian Register of Therapeutic Goods (ARTG).
 
For a prescription medicine to be registered in
the ARTG, a sponsor of the product (usually a pharmaceutical company such as Psyence) is required to submit a dossier of evidence on the
clinical efficacy, safety and manufacturing quality for evaluation by the TGA. Clinical trials of medicines and biologicals regulated
under the Clinical Trial Notification (CTN) or Clinical Trial Approval (CTA) schemes are subject to the TGA’s Good Clinical Practice
(GCP) Inspection Program. The TGA has issued a handbook which provides guidance on the legislative, regulatory and good clinical practice
(GCP) requirements when conducting clinical trials in Australia using ‘unapproved’ therapeutic goods in order to assist trial
sponsors, Human Research Ethics Committees (HRECs), investigators and approving authorities (institutions) in understanding their roles
and responsibilities under the therapeutic goods legislation.
 
Until recently, psilocybin
was included in Schedule 9 (Prohibited Substances) of the Poisons Standard which, because of interaction with state and territory regulation,
largely restricted the lawful supply of goods containing psilocybin to clinical trial settings only. However, effective as of July 1,
2023, the TGA made the decision to down schedule psilocybin to Schedule 8 in the Poisons Standard when used in respect of certain conditions,
namely for the treatment of treatment-resistant depression.
 
To import products that
contain a controlled substance (such as psilocybin), the importer requires both an exemption, approval or authority under the TG Act and
a license and/or permit to import from the Office of Drug Control under the Customs (Prohibited Imports) Regulations 1956. Licenses and
permits to import psilocybin are only granted by the Office of Drug Control where the use of the substance is permitted by the relevant
state or territory under their respective medicines and poisons legislation and the use of the of psilocybin is to be prescribed by an
Authorized Prescriber or for an authorized clinical trial.
 


55
 

 
Psyence will monitor
the evolution of Australia’s regulations as they pertain to psilocybin and the conduct of clinical trials in Australia.
 
Regulatory Changes on the Horizon for
Therapeutic Psychedelics
 
With the reintroduction
of the Breakthrough Therapies Act in March 2023, there appears to be momentum to develop a legal-regulatory framework for therapeutic
psychedelics. Congress also announced on November 17, 2022, the bipartisan Congressional Psychedelics Advancing Clinical Treatments
Caucus (the PACT Caucus). The PACT Caucus will focus on exploring psychedelic research to alleviate the U.S. mental health crisis.
 

C.Organizational Structure
 
The information set forth above in Item 4.
A. is incorporated herein by reference.
 

D.Property, Plants and Equipment
 
Headquarters and Operational Office
 
Psyence’s headquarters address is 121 Richmond
Street West, Penthouse Suite 1300, Toronto, Ontario, M5H 2K1, Canada. The Company has an operational office in South Africa at Unit
A210 The Old Biscuit Mill, 373-375 Albert Road, Woodstock, Cape Town, 7925.
 
ITEM 4 A. UNRESOLVED STAFF COMMENTS
 
None.
 
ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS
 
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
 
Unless the context otherwise
requires, all references in this section to the “Company,” “we,” “us” or “our” refer to
the business of Psyence Biomedical and its subsidiaries.
 
You should read the following
discussion and analysis of our financial condition and results of operations in conjunction with our historical condensed consolidated
audited financial statements for the years ended March 31, 2025 and March 31, 2024 and the related notes included elsewhere
in this Report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results
and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various
factors, including those set forth under “Risk Factors” and elsewhere in this Report.
 
The numbers presented here are presented
in USD.
 
Overview
 
Psyence Biomedical Ltd.
(the “Company” or “PBM”), is the world’s first life science biotechnology company traded on Nasdaq (NASDAQ:
PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The Company
is working towards developing safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders.
The Company is initially focused on mental health disorders in the context of Palliative Care. The Company is currently conducting research
through clinical trials to evaluate the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with
a cancer diagnosis in a palliative care context.
 


56
 

 
Operating Results
 
Sales and marketing costs
 
For the year ended March
31, 2025, the Company incurred sales and marketing expenses of $483,530 (2024 – $80,603; 2023 – $7,029). The significant increase
in the current year reflects the Company’s strategic focus on investor awareness and brand positioning following its listing on
the NASDAQ in January 2024.
 
The increase was primarily
driven by expanded investor relations efforts, increased participation in investor conferences and roadshows, travel to support capital
markets outreach, and enhancements to the Company’s website and promotional materials. These initiatives were aimed at strengthening
the Company’s visibility among institutional and retail investors and aligning its communication strategy with the expectations
of a U.S.-listed public company.
 
Research and development
 
For the year ended March
31, 2025, the Company incurred research and development expenses of $342,168, compared to $954,593 for the year ended March 31, 2024 and
$1,608,895 for the year ended March 31, 2023. The year-over-year decrease primarily reflects the timing of milestone activities related
to the Company’s clinical trial for the treatment of adjustment disorder.
 
In the current year, $237,168
was incurred in relation to the clinical trial, with the remaining $105,000 relating to licensing fees. The overall decrease in R&D
spending is also attributable to the transition to a new contract research organization (CRO) during the year, which resulted in a temporary
slowdown in trial activity and associated costs.
 
The Company anticipates that
R&D expenditure will increase in future periods as the new CRO advances the clinical trial toward its next development milestones.
 
In the prior year, R&D
expenses included $785,720 related to the adjustment disorder trial, $167,306 in licensing fees, and $1,567 for general research.
 
General and administration costs
 
For the year ended March
31, 2025, the Company incurred general and administrative expenses of $1,209,847, compared to $557,904 for the year ended March 31, 2024
and $366,435 for the year ended March 31, 2023.
 
The significant increase
in general and administrative expenses in 2025 reflects the scaling of corporate operations following the Company’s NASDAQ listing
in January 2024. Key cost drivers included increased payroll and related costs, higher professional and regulatory fees, as well as expanded
operational support functions required to meet the obligations of a U.S.-listed public company.
 
In prior years, general and
administrative costs consisted primarily of bank fees, salaries and wages, and operational overhead. The Company expects general and administrative
costs to remain elevated relative to historical periods as it continues to operate within a U.S. public company environment.
 
Professional and consulting fees
 
For the year ended March
31, 2025, the Company incurred professional and consulting fees of $1,623,209, compared to $1,158,484 for the year ended March 31, 2024
and $1,252,510 for the year ended March 31, 2023.
 
The increase in professional
and consulting fees during the current year was primarily driven by higher legal costs associated with ongoing corporate, regulatory,
and transactional matters following the Company’s NASDAQ listing. Consultant fees amounted to $927,109 (2024 – $848,955),
reflecting continued use of external advisors for business strategy, financial reporting, and administrative support. Legal fees increased
significantly to $508,638 (2024 – $105,962) due to increased regulatory compliance, corporate governance, and securities-related
legal work. Accounting and audit fees totaled $187,462 (2024 – $203,567), remaining consistent with prior year levels.
 
The increase reflects the
expanded complexity and regulatory requirements of operating as a U.S.-listed public company, and the Company expects to continue incurring
elevated levels of professional fees in line with its listing status and strategic initiatives.
 


57
 

 
Other Gains and Losses
 
For the year ended March
31, 2025, the Company earned interest income of $95,787, compared to $2,134 and $1,554 for the years ended March 31, 2024 and 2023, respectively.
The increase in interest income during the current year was primarily driven by higher cash balances resulting from equity financings
completed during the period.
 
The Company recorded a foreign
exchange loss of $7,317 in 2025, compared to a loss of $2,696 in 2024 and a gain of $26,912 in 2023. Fluctuations in foreign exchange
rates during the year impacted the translation of foreign currency denominated cash and liabilities.
 
Research and Development Rebate
 
For the year ended March
31, 2024, the Company received its first R&D rebate from the Australian Tax Office (ATO), amounting to $879,344, recognized as other
income. This rebate represented 43.5% of the qualifying R&D expenditure incurred in Australia during the period.
 
No R&D rebate was received
for the year ended March 31, 2025, as clinical trial expenditure in Australia was lower compared to the prior year, resulting in reduced
qualifying costs for the rebate.
 
Investment in Psyence Labs
 
During the year the Company’s
invested in PsyLabs, which was valued at $745,000 based on independent third-party transactions. The investment was followed up by an
additional investment of $500,000 into PsyLabs in April 2025 to further support the Company’s strategic focus on advancing its portfolio
in psychedelic pharmaceutical manufacture and to benefit from PsyLabs’ growth prospects in the development of a pharmaceutical API.
 
Fair value movements
 
Convertible
note
 
During the year ended March
31, 2025, the Company recognized a total fair value gain of $5,052,708 related to its convertible note liability, compared to a fair value
loss of $5,157,397 in the prior year. The gain reflects changes in the fair value of the liability as a result of market conditions, extinguishment
terms, and conversion into common shares.
 
As part of the extinguishment
of the convertible notes, the Company entered into amendments and a termination agreement with the investor, resulting in the issuance
of additional shares and warrants. The fair value of these instruments, totaling $1,695,080, was recorded as an expense in profit or loss.
After accounting for this expense, the net fair value gain recognized in profit or loss was $3,357,628 for the year.
 
This marks the full conversion
and termination of the Company’s convertible note obligations during the financial year.
 
Promissory Notes
 
During the year ended March
31, 2025, the Company fully extinguished its convertible promissory notes issued to Psyence Group Inc. and the NCAC Sponsor. These notes
were originally issued in January 2024 for a combined principal of $3.2 million and classified as financial liabilities at fair value
through profit or loss (FVTPL) due to variable conversion features. Both notes were converted into common shares during the year under
debt-for-equity agreements, including additional shares issued under make-whole provisions.
 
As a result of these conversions,
the Company recognized a total fair value gain of $705,565 in profit or loss—$327,668 on the PGI note and $377,897 on the NCAC note.
The fair value of the notes was reduced to nil at March 31, 2025 (2024 – $2,790,492), reflecting the full settlement of these liabilities.
 


58
 

 
Liquidity and Capital Resources
 
Since incorporation, the
Company has financed its operations through shareholder investments, a loan facility secured against its expected Australian Tax Office
(ATO) R&D rebate, and the rebate itself. The Company’s primary uses of liquidity include funding scientific research, clinical
studies, salaries, and professional and consulting fees.
 
As of March 31, 2025, the
Company had a cash balance of $6,171,130 and a positive working capital position of $5,965,908, a significant improvement from the prior
year’s cash balance of $762,799 and negative working capital of $10,978,027 as of March 31, 2024.
 
The Company’s ability
to continue funding its operations and meet planned expenditures depends on various factors, including economic conditions, access to
capital markets, regulatory developments, and other factors beyond its control.
 
The Company’s current
obligations include funding commitments for its Phase IIb palliative care clinical trial. These are expected to be met using existing
cash and cash equivalents; however, the Company remains subject to risks, including the potential inability to raise additional funds
through equity, debt, or other financing to meet its development plans, operating requirements, and liabilities as they become due.
 
The Company has incurred
operating losses and cash outflows since inception and, given the nature of its business, will require ongoing financing to support its
research and development activities. Its ability to access capital depends on factors such as market conditions, investor sentiment, and
the trading price of its securities. There can be no assurance that additional financing will be available on acceptable terms, or at
all.
 
The Company’s primary
capital needs include funding research and development, clinical trials, staffing, professional and consulting fees, and general working
capital. Access to future financing remains uncertain, and may not be available on terms as favorable as those previously secured.
 
Research and Development
 
Expenditures on research
activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements
of net loss and comprehensive loss as incurred.
 
Development expenditures
are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future
economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and
to use or sell the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct
and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are
expensed as incurred.
 
Critical Accounting Estimates
 
The preparation of financial
statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual
results may differ from these estimates. The Company’s management reviews these estimates, judgments, and assumptions on an ongoing
basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical
accounting policies as these require a high level of subjectivity and judgement and could have a material impact on the Company’s
financial statements.
 
Fair value of Convertible Debt
 
Management exercised significant
judgment in determining the fair value of the convertible promissory notes classified as financial liabilities measured at fair value
through profit or loss (FVTPL) due to their conversion features. Fair value was assessed using valuation techniques incorporating observable
and unobservable inputs, including share price volatility, risk-free interest rates, and conversion terms. Changes in these assumptions
had a material impact on the profit or loss recognized during the year.
 
Quantitative and Qualitative Disclosures About
Financial Instruments and Financial Risk Management
 
In the normal course of business,
the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These
financial risks are subject to normal credit standards, financial controls, risk management, as well as monitoring. Our Board has overall
responsibility for the establishment and oversight of the Company’s risk management framework.
 


59
 

 
Credit risk
 
Credit risk arises from cash
and cash equivalents held with banks. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The
objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash
and cash equivalents by depositing with only reputable financial institutions. The Company also assesses the credit quality of counterparties,
taking into account their financial position, past experience and other factors.
 
Liquidity risk
 
Liquidity risk is the risk
that the Company will not be able to meet its financial obligations as they fall due.
 
The Company manages liquidity
risk through an ongoing review of future commitments and cash balances available. Historically, the Company’s main source of funding
has been through investments from its parent. The Company’s access to financing is always uncertain and there can be no assurance
of continued access to significant equity or debt funding on terms satisfactory to the Company, or at all.
 
Foreign exchange risk
 
Foreign currency risk is
the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies
that differ from the respective functional currency.
 
The Company operates internationally
and is exposed to foreign exchange risk from the South African Rand, Great British Pound, Australian Dollar and United States Dollar.
Foreign exchange risk arises from transactions as well as recognized financial assets and liabilities denominated in foreign currencies.
 
A 10% adverse change in exchange
rate would have resulted in a loss of $8,861 as of March 31, 2025.
 
Management mitigates the
risk of adverse exchange rate movements by holding funds in US dollars.
 
Interest rate risk
 
Interest rate risk is the
risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The
Company has no significant interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially
independent of changes in market interest rates.
 
Capital Management
 
The Company’s objectives
when managing its capital are to safeguard its ability to continue as a going concern, to meet its capital expenditures for its continued
operations, and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. The
Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying
assets. To maintain or adjust its capital structure, the Company may issue new shares, issue debt, or acquire or dispose of assets. The
Company is not subject to externally imposed capital requirements.
 
Management reviews its capital
management approach on an ongoing basis. The Company considers its shareholders’ equity balance as capital.
 
Off-Balance Sheet Arrangements
 
We have no obligations, assets
or liabilities, which would be considered off-balance sheet arrangements as of March 31, 2025. We do not participate in transactions
that create relationships with entities or financial partnerships, often referred to as variable interest entities, which would have been
established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.
 


60
 

 
Contractual Obligations
 
We do not have any long-term
debt, capital lease obligations, operating lease obligations or long-term liabilities.
 
JOBS Act
 
On April 5, 2012, the
JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying
public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised
accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption
of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates
on which adoption of such standards is required for non- emerging growth companies. As such, our financial statements may not be comparable
to companies that comply with public company effective dates.
 
Additionally, we are in the
process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain
conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not
be required to, among other things, (i) provide an auditor’s attestation report on our system of internal control over financial
reporting pursuant to Section 404 of the Sarbanes-Oxley Act, (ii) provide all of the compensation disclosure that may be required
of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any
requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing
additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive
compensation related items such as the correlation between executive compensation and performance and comparisons of executive compensation
to median employee compensation. These exemptions will apply for a period of five years following the completion of our IPO or until
we are no longer an “emerging growth company,” whichever is earlier.
 
ITEM 6. DIRECTORS, SENIOR MANAGEMENT
AND EMPLOYEES
 

A.Directors and Senior Management
 
The following sets forth certain information,
as of the date of this Report, concerning the directors and executive officers of the Company. All executive officers are appointed by
the Board to serve in their roles. Each executive officer is appointed for such term as may be prescribed by the Board or until a successor
has been chosen and qualified or until such officer’s death, resignation or removal.
 


Name
 
Age
 
Position(s)

Jody Aufrichtig
 
51
 
Chairman of the Board and Strategic Business Development Officer

Dr. Neil Maresky
 
61
 
Chief Executive Officer and Director

Warwick Corden-Lloyd
 
45
 
Chief Financial officer

Marc Balkin
 
50
 
Director

Christopher (Chris) Bull
 
56
 
Director

Dr. Seth Feuerstein
 
52
 
Director

 
Executive Officers
 
Dr. Neil Maresky has
served as the Company’s Chief Executive Officer since January 25, 2024 and Director since June 29, 2023. Dr. Maresky has also served
as PGI’s chief executive officer and director from July 1, 2021 until his resignation in March 2024. Dr. Maresky brings more than
25 years of enterprise leadership and biopharmaceutical expertise and currently oversees the strategy and operations of Psyence. From
2010 to 2021, Dr. Maresky, spent more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs. Dr. Maresky is a South
African trained doctor. In Canada, he has held various executive leadership positions in “Big Pharma”, including leading research
and development and driving scientific strategy at Bayer Pharmaceuticals (1998-2002) as well as Wyeth Pharmaceuticals (2002-2008), where
he was interim President and general manager in 2008. Dr. Maresky is a South African trained doctor where he was trained in emergency
room medicine and cardiology, and practiced as a family physician. In the mid-1990s, Dr. Maresky emigrated to Canada and began his career
in the pharmaceutical industry. During the course of his career, Dr. Maresky has positively impacted the health of millions of patients
across Canada. With extensive experience and relationships with academic institutions, health authorities and decision-making bodies across
Canada, Dr. Maresky has contributed to many innovative medical therapies and technologies, including over 50 approvals of new medicines
and new indications. One of Dr. Maresky’s most recent achievements was the approval of the AstraZeneca Covid-19 vaccine by Health
Canada. Dr. Maresky holds a Medical Degree M.B.,B.Ch. from the University of Witwatersrand (1987).Dr. Maresky is an experienced research
scientist and entrepreneur, and has experience in both big pharma and technology driven startups, both at the board and operating levels,
in a broad variety of areas.
 


61
 

 
Warwick Corden-Lloyd has
served as the Chief Financial Officer of the Company since January 25, 2024. Mr. Corden-Lloyd has also served as Chief Financial
Officer of PGI from May 21, 2020 until his resignation in January 2024. Mr. Corden-Lloyd is a Chartered Accountant and Certified
Project Manager. He has over 19 years of experience working in public accounting, consulting and listed financial services companies
in the UK, US and South Africa. Mr. Corden-Lloyd has listed company financial and regulatory reporting experience in international
and emerging markets. From May 2020 to January 2021, Mr. Corden-Lloyd was the Corporate Finance Advisor and Chief Financial
Officer of MindHealth Biomed Corp, the predecessor company prior to PGI. Mr. Corden-Lloyd was previously the Vice President of Operations
and Finance at Canopy Growth Africa, (a wholly owned subsidiary of Canopy Growth Corporation (NYSE: CGC / TSX: WEED) from May 2019
to May 2020. Whilst at Canopy Growth, he oversaw the Finance, Legal, Supply Chain, Human Resources, Quality Assurance and Regulatory,
Project Management and Country Manager divisions. Prior to that he was Head of Financial Accounting at Capitec Bank, South Africa’s
largest customer retail bank, from February 2015 to May 2019 where he was responsible for managing the financial and regulatory
reporting, budgeting and financial accounting for the bank. Before working at Capitec Bank, he worked for PricewaterhouseCoopers International
Limited in South Africa, US and the UK and for The Bank of New York Mellon Corporation in the UK. Mr. Corden-Lloyd received a Bachelor
of Accounting from the University of Stellenbosch, South Africa in 2002, a Bachelor of Accounting Honours from the University of Natal,
South Africa in 2003 and registered with the South African Institute of Chartered Accountants in 2006. He is also registered with The
Institute of Chartered Accountants in England and Wales.
 
Jody Aufrichtig has
served as Strategic Business Development Officer and Chairman of the Board since January 25, 2024, and a Director of PGI since May 21,
2020. He has served in the same roles at PGI since May 21, 2020. Mr. Aufrichtig is a chartered accountant and experienced entrepreneur
with extensive experience in emerging markets. Mr. Aufrichtig is the founder of MindHealth Biomed Corp and has built multiple award-winning
businesses and created substantial shareholder value in cannabis, commercial and residential property, private equity, tourism, leisure
and other industries. Prior to founding MindHealth Biomed Corp, he was the Managing Director of Canopy Growth Africa (a wholly owned subsidiary
of Canopy Growth Corporation (NYSE: CGC / TSX: WEED)) from May 2018 until he led a management buyout of the African operations in
April 2020. Mr. Aufrichtig founded Daddy Cann Lesotho (Pty) Limited in July 2017 and was granted a license by the Ministry
of Health (Lesotho) to cultivate, manufacture, supply, hold, import, export and transport cannabis. Daddy Cann Lesotho (Pty) Limited was
subsequently acquired by Canopy Growth Corporation in May 2018. In 2000, Mr. Aufrichtig co-founded Indigo Properties, a business
focused on commercial and residential property, tourism and leisure. Mr. Aufrichtig holds a Bachelor of Accounting and a Bachelor
of Accounting Honours from the University of Cape Town, South Africa and is registered with the South African Institute of Chartered Accountants.
He is well-qualified to serve as a director because of his extensive commercial and corporate experience in a broad variety of areas including
finance and mergers and acquisitions and has served as a director and chairman of other publicly traded companies.
 
Marc Balkin has
served as a director of the Company since January 25, 2024. He served as the Chief Executive Officer and served as a member of the
board of directors of NCAC from March 2021 until January 25, 2024. Mr. Balkin is a founder of Balkin and Co, an advisory
firm that has advised private equity firms and family offices on mergers, acquisitions and investments in Africa since 2015. Clients have
included HP Bet (part of the family office of Dr. Hasso Plattner, a founder and current Chairman of SAP), Omidyar Network (part of
the family office of Pierre Omidyar, the founder of eBay) and Rand Merchant Bank. Prior to founding Balkin and Co, Mr. Balkin was
the Managing Partner of Hasso Plattner Ventures Africa, a Venture Fund in which Dr. Plattner was the key limited partner. Mr. Balkin
also held responsibility for managing the Emerging Market portfolio of private equity and venture capital assets of Dr. Plattner’s
family office. Mr. Balkin is currently a partner at DiGame, a growth fund focused on Africa and the Middle East in which the key
investor is Abu Dhabi Investment Counsel (“ADIC”). Mr. Balkin represents DiGame on the board of direct-to-consumer
asset manager 10X Investments. Since 2004, Mr. Balkin has served on and chaired a range of venture capital and private equity fund
investment committees as the representative of the limited partners or investors. These include Enablis, First National Bank Vumela Fund,
Telkom Future Makers and Alithea IDF. Between 2000 and 2007, Mr. Balkin was the founding partner of O2 Capital, a private equity
fund manager for the Msele Nedventures Fund. The LPs in the fund included a range of development finance institutions such as Proparco
(France), DEG (Germany) and IDC (South Africa) and the fund invested primarily in technology businesses in South Africa. Mr. Balkin
obtained his BA in 1995 and his LLB in 1997 from University of Witwatersrand in Johannesburg. He is well-qualified to serve as a director
because of his experience at board and committee level as well as his legal, finance and financial markets background.
 


62
 

 
Chris Bull has
served as a director of the Company since January 25, 2024 and has served as a strategic advisor of PGI since December 2022.
Chris is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his thirty year
career, Mr. Bull has been an investor, director, founder and advisor to a range of successful companies in Europe and North America
with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies.
Mr. Bull has served as a Chairman and director of a venture capital firm (Knife Capital). Mr. Bull has also been recognized
through receipt of a number of international awards, including IAM Strategy 300, IAM Patent 1000, IAM Licensing 250; Euromoney
Expert Guides: World’s Leading Patent Attorneys; Chambers and Partners’ Global Guide to the World’s Leading Lawyers
Legal 500 Guide to Outstanding Lawyers, in recognition of his skills in relation to the development and execution of venture capital investment,
patent and intellectual property strategies for high-technology companies. He is well-qualified to serve as a director because of his
prior Chairman and director experience and his chemical engineering, attorney and patent attorney qualifications.
 
Dr. Seth Feuerstein has
served as a director of the Company since January 25, 2024. Dr. Feuerstein has expertise across multiple areas of medicine including
Suicide Prevention, Technology and Suicide, Telehealth, Social Media and Mental Health, Digital Medicine, Suicide, Digital Health, Digital
Therapeutics, Healthcare Innovation, Emerging Medical Technologies, forensic psychiatry, technology transfer, technology investment, intellectual
property and the intersection of technology, law and medicine. He is a founding board member of the Center for Biomedical and Interventional
Technology at Yale and Executive Director of the Center for Digital Health, Innovation and Excellence. He has been teaching at the
Yale School of Medicine, Department of Psychiatry, since 2004 and is the faculty advisor for Innovation in Healthcare at the medical school.
He works across multiple sectors in healthcare including health insurance, healthcare startups, healthcare investing, clinical care delivery
innovation and early stage emerging medical technologies. He is the founder and CEO of Oui Therapeutics, Inc. Since 2019, which is
developing a prescription digital therapeutic for suicide attempt reduction. Dr. Feuerstein has been appointed senior advisor/Highly
Qualified Advisor (HQE) for the Department of Defense, advising on behavioral health innovation, since June 2019. From 2014 to August 2018,
he was the chief medical and innovation officer at Magellan Healthcare. He has also co-founded and/or held leadership roles in a number
of biotechnology and healthcare companies. Dr. Feuerstein received his Bachelor of Science from Cornell University, a J.D. from New
York University School of Law, and an M.D. from New York University School of Medicine. We believe that Dr. Feuerstein is well-qualified
to serve on the Board as result of his prior board experience and extensive experience in the fields of psychiatry and biotechnology.
 
B. Compensation
 
The following tables and discussions relate to
the compensation paid to or earned by our executive officers and directors who were serving during the financial year ended March 31,
2025.
 
Dr. Neil Maresky currently serves as
chief executive officer of the Company following his resignation as chief executive officer of the PGI. Warwick Corden-Lloyd
currently serves as chief financial officer of the Company following his resignation as chief financial officer of PGI. Jody
Aufrichtig currently serves as Director and Executive Chairman of PGI and the Company’s Director and Strategic Business
Development Officer. Dr. Maresky, Mr. Corden-Lloyd and Mr. Aufrichtig are referred to collectively in this
information statement as our “named executive officers.”
 
Prior to the Business Combination, Psyence was
part of the Psyence Group and not an independent company and, as such, the historical compensation shown below was determined by PGI.
Following the Business Combination, compensation arrangements for the Company’s executive officers have been determined based on
the compensation policies, programs and procedures established by the Compensation Committee, which entailed: (i) for executive directors
and officers (a) market related base annual salaries or fees, (b) annual cash bonuses based on a target percentage of such
base annual salaries or fees based on the achievement of performance metrics approved by the Compensation Committee, (c) a sign-on
award in the form of RSUs, which may be converted into Common Shares and which are subject to a trading lock-up period as well as a clawback
policy and (d) long-term equity awards in the form of RSUs based on a multiple of such base annual salaries or fees, and (ii) for
non-executive directors (y) a fixed monthly fee and (z) long-term equity awards in the form of RSUs based on a multiple
of such fixed monthly fee. The Company’s Compensation Committee approved the named executive officers’ compensation at
its first meeting.
 


63
 

 
Summary Compensation Table
 
The following table summarizes the compensation
awarded to, earned by, or paid to our named executive officers for the fiscal year ended March 31, 2025 and March 31, 2024.
 


  
   
   
   
   
   
Nonequity  
   
  

Name and 
   
   
   
Option  
Stock  
incentive plan  
All other  
  

principal 
   
Salary  
Bonus  
awards  
Awards  
compensation  
compensation  
Total 

position 
Year  
(US$)  
(US$)  
(US$)(2)  
(US$)(3)  
(US$)  
(US$)  
(US$) 

Neil Maresky 
 2025  
 360,000  
 30,000  
 -  
 -  
 -  
 -  
 390,000 

(Chief Executive Officer) 
 2024  
 231,228(1) 
 —  
 70,458  
 55,000  
 —  
 —  
 356,686 

  
    
    
    
    
    
    
    
   

Jody Aufrichtig 
 2025  
 200,000  
 16,667  
 -  
 -  
 -  
 -  
 216,667 

(Executive Chairman) 
 2024  
 110,302(1) 
 —  
 31,924  
 42,773  
 —  
 —  
 184,999 

  
    
    
    
    
    
    
    
   

Warwick Corden Lloyd 
 2025  
 180,000  
 15,000  
 -  
 -  
 -  
 -  
 195,000 

(Chief Financial Officer) 
 2024  
 98,346(1) 
 —  
 5,395  
 19,588  
 —  
 —  
 123,329 

 


(1)
This includes salary earned from April 1, 2023 to January 25, 2024 as part of Psyence prior to the Business Combination and salary earned from January 26, 2024 to March 31, 2024 from the Company.

 


(2)
The amounts reported in the “Option awards” column represent the aggregate grant date fair value of the stock options granted to the named executive officers by PGI during 2023 computed in accordance with IFRS. The option awards value was calculated using the Black-Scholes valuation model. The options vested as follows: 50% on March 31, 2023 and 50% on September 30, 2023. Note that the amounts reported in these columns reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by the named executive officers from the stock options.

 


(3)
The amounts reported in the “Stock awards” column represent the aggregate grant date fair value of the restricted stock units (RSUs) granted to the named executive officers by PGI during 2023 computed in accordance with IFRS. The stock awards value was based on the share price on the date of grant of RSUs. The RSUs vest as follows: 33.33% on March 31, 2024, 33.33% on March 31, 2025 and 33.34% on March 31, 2026. Note that the amounts reported in these columns reflect the accounting cost for these RSUs and do not correspond to the actual economic value that may be received by the named executive officers from the stock RSUs.

 
Other than as set forth in the foregoing table,
the named executive officers and directors have not received compensation pursuant to any standard arrangement for the compensation of
directors for their services in their capacity as directors, including any additional amounts payable for committee participation or special
assignments, any other arrangement, in addition to, or in lieu of, any standard arrangement, for the compensation of directors in their
capacity as directors, or any arrangement for the compensation of directors for services as consultants or experts.
 
Share Ownership
 
Outstanding Equity Awards at Fiscal Year-End
 
As of March 31, 2025, our executive officers
have not received any equity awards from the Company, but as described above, have previously received equity awards from PGI.
 
Employment, Consulting and Management Agreements
 
As of the date of this Report, the Company had
the following employment, consulting and management agreements in place with its named executive officers:
 
Jody Aufrichtig – Executive Chairman
& Chief Development Officer
 
The Company, its wholly-owned
subsidiary, Biomed II, Jody Aufrichtig (as principal) and Aquacap Limited (as consultant) entered into a consulting agreement dated January
25, 2024 (the “Aufrichtig Agreement”), pursuant to which Mr. Aufrichtig shall perform the services of the Executive
Chairman of the Board and Chief Development Officer. Mr. Aufrichtig’s base fee is $200,000 per annum.
 


64
 

 
Mr. Aufrichtig shall
be eligible to receive 335 restricted share units (“RSUs”) as an initial award, which may be converted into Common
Shares. Any Common Shares issued pursuant thereto will be subject to a lock - up period ending January 25, 2025, and a clawback at the
option of the Company should Mr. Aufrichtig’s appointment be terminated by the Company for cause (as defined in his agreement) or
should Mr. Aufrichtig resign without good reason (as defined in his agreement). For each completed fiscal year of the Company, Mr. Aufrichtig
shall be eligible to receive an annual cash bonus based on a target bonus opportunity of 50% to 100% of Mr. Aufrichtig’s annual
base fee, based on the achievement of performance metrics approved by the Compensation Committee. Mr. Aufrichtig is further entitled to
2,316 RSUs for the 2024 fiscal year as well as an allocation for the 2025 fiscal year to be determined by the Compensation Committee,
both of which shall vest in tranches.
 
Mr. Aufrichtig or the
Company may terminate the Aufrichtig Agreement at any time upon no less than sixty (60) days’ written notice to the other party.
Additionally, the Company may terminate the Aufrichtig Agreement at any time without prior notice, for cause, subject to a ten business
day cure period by Mr. Aufrichtig.
 
The Company may terminate
the Aufrichtig Agreement without cause, or in relation to a change of control at any time and Mr. Aufrichtig may terminate the Aufrichtig
Agreement for good reason (as defined in the agreement), and in each such case the Company shall pay Mr. Aufrichtig severance pay (in
lieu of notice) equal to 12 months of Mr. Aufrichtig’s base fee (as at the date of notice of termination) plus an additional amount
equal to the aggregate annual bonuses paid to Mr. Aufrichtig over the preceding 12 months (from the date of notice of termination) plus
a prorated payment on account of any annual bonus targets already met by Mr. Aufrichtig as of the date of notice of termination for all
active services rendered up to that date (calculated at target). Mr. Aufrichtig shall be entitled to exercise any vested stock options
until the earlier of 1) the option expiry date or 2) a date which is 12 months from the effective date of termination, and if so required,
the Company shall extend the option expiry date accordingly.
 
In the event of termination
by the Company for cause or by Mr. Aufrichtig without good reason, Mr. Aufrichtig shall not be entitled to any severance pay or any other
payments, and none of the unvested equity incentives granted to Mr. Aufrichtig shall vest.
 
Mr. Aufrichtig shall
not be entitled to any minimum termination entitlements required by the Ontario Employment Standards Act, 2000 (“ESA”),
and no minimum termination entitlements contemplated in the ESA shall apply to the Aufrichtig Agreement.
 
All equity incentives
granted to Mr. Aufrichtig will be subject to accelerated vesting upon a change of control, upon termination by the Company without cause,
or death of Mr. Aufrichtig.
 
Dr. Neil Maresky – Chief Executive
Officer
 
The Company, its wholly-owned
subsidiary, Biomed II, and Dr. Neil Maresky entered into an employment agreement dated January 25, 2024 (the “Maresky Agreement”),
pursuant to which he shall perform the services of Chief Executive Officer of the Company on a full time basis in consideration for a
base salary of $360,000 per annum. Dr. Maresky shall be entitled to an initial award of 335 RSUs. Any Common Shares issued pursuant thereto
will be subject to a lock-up period ending January 25, 2025, and a clawback at the option of the Company should Dr. Maresky’s appointment
be terminated by the Company for cause or should Dr. Maresky resign without good reason. For each completed fiscal year of the Company,
Dr. Maresky shall be eligible to receive an annual cash bonus based on a target bonus opportunity of 50% to 100% of Dr. Maresky’s
annual base salary, based on the achievement of performance metrics approved by the Compensation Committee. Dr. Maresky is further entitled
to 4,168 RSUs for the 2024 fiscal year as well as an allocation for the 2025 fiscal year to be determined by the Compensation Committee,
both of which shall vest in tranches.
 
The Company may terminate
the Maresky Agreement without cause, or in relation to a change of control at any time and Dr. Maresky may terminate the Maresky Agreement
for good reason (as defined in the agreement), and in each such case the Company shall pay Dr. Maresky severance pay (in lieu of notice)
equal to 24 months of Dr. Maresky’s base salary (as at the date of notice of termination) plus an additional amount equal to the
aggregate annual bonuses paid to Dr. Maresky over the preceding 12 months (from the date of notice of termination) plus a prorated payment
on account of any annual bonus targets already met by Dr. Maresky as of the date of notice of termination for all active services rendered
up to that date (calculated at target). Dr. Maresky shall be entitled to exercise any vested stock options until the earlier of 1) the
option expiry date or 2) a date which is 12 months from the effective date of termination, and if so required, the Company shall extend
the option expiry date accordingly.
 


65
 

 
In the event of termination
by the Company for cause or by Dr. Maresky without good reason, Dr. Maresky shall not be entitled to any severance pay or any other payments,
and none of the unvested equity incentives granted to Dr. Maresky shall vest.
 
All equity incentives
granted to Dr. Maresky will be subject to accelerated vesting upon a change of control, upon termination by the Company without cause,
or death of Dr. Maresky.
 
Dr. Maresky shall be
entitled to continuation of benefits (if any) for the minimum period required by the ESA and the greater of: (A) all other minimum requirements
of the ESA and (B) the severance pay and other payments set out in the Maresky Agreement.
 
Warwick Corden-Lloyd – Chief Financial
Officer
 
The Company, its wholly-owned
subsidiary, Biomed II, Warwick Corden-Lloyd (as principal) and CordenLloyd Consulting (Pty) Ltd (as consultant, and an entity controlled
by Mr. Corden-Lloyd) entered into a consulting agreement dated January 25, 2024 (the “Corden-Lloyd Agreement”), pursuant
to which Mr. Corden-Lloyd shall perform the services of Chief Financial Officer of the Company in consideration for a base fee of $180,000
per annum. Mr. Corden-Lloyd shall be entitled to 134 RSUs as an initial award. Any Common Shares issued pursuant thereto will be subject
to a lock - up period ending January 25, 2025, and a clawback at the option of the Company should Mr. Corden-Lloyd’s appointment
be terminated by the Company for cause or should Mr. Corden-Lloyd resign without good reason. For each completed fiscal year of the Company,
Mr. Corden-Lloyd shall be eligible to receive an annual cash bonus based on a target bonus opportunity of 30% to 80% of Mr. Corden-Lloyd’s
annual base fee, based on the achievement of performance metrics approved by the Compensation Committee. Mr. Corden-Lloyd is further entitled
to 1,302 RSUs for the 2024 fiscal year as well as an allocation for the 2025 fiscal year to be determined by the Compensation Committee,
both of which shall vest in tranches.
 
The Company may terminate
the Corden-Lloyd Agreement without cause, or in relation to a change of control at any time and Mr. Corden-Lloyd may terminate the Corden-Lloyd
Agreement for good reason (as defined in the agreement), and in each such case the Company shall pay Mr. Corden-Lloyd severance pay (in
lieu of notice) equal to 12 months of Mr. Corden-Lloyd’s base fee (as at the date of notice of termination) plus an additional amount
equal to the aggregate annual bonuses paid to Mr. Corden-Lloyd over the preceding 12 months (from the date of notice of termination) plus
a prorated payment on account of any annual bonus targets already met by Mr. Corden-Lloyd as of the date of notice of termination for
all active services rendered up to that date (calculated at target). Mr. Corden-Lloyd shall be entitled to exercise any vested stock options
until the earlier of 1) the option expiry date or 2) a date which is 12 months from the effective date of termination, and if so required,
the Company shall extend the option expiry date accordingly.
 
In the event of termination
by the Company for cause or by Mr. Corden-Lloyd without good reason, Mr. Corden-Lloyd shall not be entitled to any severance pay or any
other payments, and none of the unvested equity incentives granted to Mr. Corden-Lloyd shall vest.
 
Mr. Corden-Lloyd shall
not be entitled to any minimum termination entitlements required by the Ontario Employment Standards Act, 2000 (“ESA”),
and no minimum termination entitlements contemplated in the ESA shall apply to the Corden-Lloyd Agreement.
 
All equity incentives
granted to Mr. Corden - Lloyd will be subject to accelerated vesting upon a change of control, upon termination by the Company without
cause, or death of Mr. Corden - Lloyd.
 
Christopher Bull, Marc Balkin, Dr Seth Feuerstein –
Letters of Appointment (Non-Executive Directors)
 
Each of Christopher Bull,
Marc Balkin, and Dr Seth Feuerstein have entered into letters of appointment on identical terms in their positions as non-executive directors
(“NED”). Each NED’s appointment under this letter is for an initial term commencing January 25, 2024 until
the date of the first annual general meeting of the Company, unless terminated earlier by either party giving to the other one month’s
prior written notice. Each NED’s appointment is further subject to the Company’s articles of association, and re-election
to the board by the Company’s shareholders at the first annual general meeting of the Company.
 
Each NED is compensated
for their services as a non-executive director in accordance with the compensation, annual bonus and long-term incentive policy adopted
by the Board on February 2, 2024, as supplemented by the performance metrics to be approved by the Compensation Committee of the
Company in accordance with the Company’s rules and policies governing performance and bonus schemes (still to be adopted).
Each of Mr. Balkin and Dr. Feuerstein earn US$2,500 per month / US$‎30,000.00 per annum and have been allocated 973
and 347 RSUs respectively as equity / long-term incentive awards, and Mr. Bull earns £6,250 per month / £75,000 per annum
and has been allocated 1,182 RSUs as equity / long-term incentive awards. Each NED shall be entitled to a further allocation of RSUs for
the 2025 fiscal year to be determined by the Compensation Committee, which shall vest in tranches.
 


66
 

 
Cash and Equity Compensation
 
The Company’s Compensation
Committee approved the named executive officers’ compensation at its first meeting. Following the Business Combination, compensation
arrangements for the Company’s executive officers was determined based on the compensation policies, programs and procedures established
by the Compensation Committee, which entailed: (i) for directors and executive officers (a) market related base annual salaries or fees,
(b) annual cash bonuses based on a target percentage of such base annual salaries or fees based on the achievement of performance metrics
approved by the Compensation Committee, (c) a sign-on award in the form of RSUs, which may be converted into Common Shares and which are
subject to a trading lock-up period as well as a clawback policy and (d) long-term equity awards in the form of RSUs based on a multiple
of such base annual salaries or fees, and (ii) for non-executive directors (y) a fixed monthly fee and (z) long-term equity awards in
the form of RSUs based on a multiple of such fixed monthly fee.
 
For information regarding
share options granted to Psyence’s directors and executive officers, see the section entitled “— Equity Incentive Plans”
below.
 
Indemnification Agreements
 
The Company has entered
into indemnification agreements with each of its officers and directors. Under these agreements, the Company may agree to indemnify its
directors against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a
director of the Company.
 
Equity Incentive Plans
 
The 2023 Equity Incentive Plan
 
The Company has adopted
the Psyence Biomedical Ltd. 2023 Equity Incentive Plan (as amended by the Board on June 28, 2024 and November 12, 2024, and
rectified by the Board on June 17, 2025), which is referred to herein as the “Incentive Plan.” The following is a summary
of the material features of the Incentive Plan.
 
Purpose
 
The purpose of the Incentive
Plan is to enhance the ability of the Company to attract, retain, and motivate persons who make (or are expected to make) important contributions
to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities that
are intended to motivate high levels of performance and align the interests of directors, employees, and consultants with those of the
Company’s shareholders.
 
Eligibility
 
Persons eligible to participate
in the Incentive Plan are employees, non-employee directors, and consultants of the Company and its subsidiaries as selected from time
to time by the plan administrator in its discretion, including prospective employees, non-employee directors and consultants. Any awards
granted to such a prospect before the individual’s start date may not become vested or exercisable, and no shares may be issued
to such individual, before the date the individual first commences performance of services with the Company or its subsidiaries. As of
the date of this prospectus, approximately 11 individuals are eligible to participate in the Incentive Plan, which includes approximately
2 officers, 4 non-employee directors, and 5 consultants.
 
Administration
 
The Incentive Plan will
be administered by the Board, the Compensation Committee of the Board, or such other similar committee pursuant to the terms of the Incentive
Plan. The plan administrator, which initially will be the Compensation Committee of the Board, will have full power to select, from among
the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants,
and to determine the specific terms and conditions of each award, subject to the provisions of the Incentive Plan. The plan administrator
may delegate to one or more officers of the Company, the authority to grant awards to individuals who are not subject to the reporting
and other provisions of Section 16 of the Exchange Act.
 


67
 

 
Share Reserve
 
The number of the Common
Shares that may be issued under the Incentive Plan is equal to 15% of the aggregate number of the Common Shares issued and outstanding
immediately after the Closing (calculated on a fully-diluted basis), or 3,362 Common Shares. On November 12, 2024, shareholders approved
the increase of the number of Common Shares reserved for issuance under the Plan to 13,635 (post-share consolidation figure). All of the
shares initially available under the Incentive Plan may be issued upon the exercise of equity incentives.
 
The number of shares
available for issuance under the Incentive Plan also will include an automatic annual increase, or the evergreen feature, on the first
day of each calendar year, beginning January 1, 2025 and continuing until (and including) January 1, 2034, equal to 15% of the
issued and outstanding number of shares of the Company calculated as of December 31st of the calendar year immediately preceding the date
of such increase, or a lesser number of shares as determined by the Board. Shares issuable under the Incentive Plan may be authorized,
but unissued, or reacquired the Common Shares.
 
Shares underlying any
awards under the Incentive Plan that are forfeited, cancelled, held back upon exercise of a share option or settlement of an award to
cover the exercise price or tax withholding satisfied without the issuance of the Common Shares or otherwise terminated (other than by
exercise) will be added back to the shares available for issuance under the Incentive Plan and, to the extent permitted under Section
422 of the Code and the Treasury Regulations promulgated thereunder, the shares that may be issued as incentive stock options.
 
Types of Awards
 
The Incentive Plan provides
for the grant of share options, share appreciation rights, restricted shares, restricted share units, and other stock-based awards (collectively,
“awards”). Unless otherwise set forth in an individual award agreement, each award shall vest over a three (3) year period,
with one-third (1/3) of the award vesting on the first annual anniversary of the date of grant and the remaining portion of the award
vesting annually thereafter.
 
Share Options. The Incentive
Plan permits the granting of both options intended to qualify as incentive stock options under Section 422 of the Code and share
options that do not so qualify. Share options granted under the Incentive Plan will be nonqualified options if they fail to qualify as
incentive stock options or exceed the annual limit on incentive stock options. Incentive stock options may only be granted to employees
of the Company and its subsidiaries. Nonqualified options may be granted to any persons eligible to receive awards under the Incentive
Plan.
 
The exercise price of
each share option will be determined by the plan administrator, but such exercise price may not be less than 100% of the fair market value
of one the Common Share on the date of grant (which shall be the volume weighted average trading price during the thirty (30) preceding days)
or, in the case of an incentive stock option granted to a 10% or greater shareholder, 110% of such share’s fair market value. The
term of each share option will be fixed by the plan administrator and may not exceed ten (10) years from the date of grant (or five
(5) years for an incentive stock option granted to a 10% or greater shareholder). The plan administrator will determine at what time
or times each share option may be exercised, including the ability to accelerate the vesting of such share options.
 
Upon exercise of a share
option, the exercise price must be paid in full either in cash, check or, surrender of other the Common Shares which meet the conditions
established by the plan administrator to avoid adverse accounting consequences to the Company. Subject to applicable law and approval
of the plan administrator, the exercise price may also be made by means of a broker-assisted cashless exercise. In addition, the plan
administrator may permit nonqualified options to be exercised using a “net exercise” arrangement that reduces the number of
shares issued to the optionee by the largest whole number of shares with fair market value that does not exceed the aggregate exercise
price.
 


68
 

 
Share Appreciation Rights.
The plan administrator may award share appreciation rights subject to such conditions and restrictions as it may determine. Share appreciation
rights entitle the recipient to the Common Shares or cash, equal to the value of the appreciation in the Company’s share price over
the exercise price, as set by the plan administrator. The term of each share appreciation right will be fixed by the plan administrator
and may not exceed ten years from the date of grant. The plan administrator will determine at what time or times each share appreciation
right may be exercised, including the ability to accelerate the vesting of such share appreciation rights.
 
Restricted Shares. A
restricted share award is an award of the Common Shares that vests in accordance with the terms and conditions established by the plan
administrator. The plan administrator will determine the persons to whom grants of restricted share awards are made, the number of restricted
shares to be awarded, the price (if any) to be paid for the restricted shares, the time or times within which restricted share awards
may be subject to forfeiture, the vesting schedule and rights to acceleration thereof, and all other terms and conditions of restricted
share awards. Unless otherwise provided in the applicable award agreement, a participant generally will have the rights and privileges
of a shareholder as to such restricted shares, including without limitation the right to vote such restricted shares and the right to
receive dividends, if applicable.
 
Restricted Share Units.
Restricted share units are the right to receive the Common Shares at a future date in accordance with the terms of such grant upon the
attainment of certain conditions specified by the plan administrator. Restrictions or conditions could include, but are not limited to,
the attainment of performance goals, continuous service with the Company or its subsidiaries, the passage of time or other restrictions
or conditions. The plan administrator determines the persons to whom grants of restricted share units are made, the number of restricted
share units to be awarded, the time or times within which awards of restricted share units may be subject to forfeiture, the vesting schedule,
and rights to acceleration thereof, and all other terms and conditions of the restricted share unit awards. The value of the restricted
share units may be paid in Common Shares, cash, other securities, other property, or a combination of the foregoing, as determined by
the plan administrator.
 
The holders of restricted
share units will have no voting rights. Prior to settlement or forfeiture, restricted share units awarded under the Incentive Plan may,
at the plan administrator’s discretion, provide for a right to dividend equivalents. Such right entitles the holder to be credited
with an amount equal to all dividends paid on one Common Share while each restricted share unit is outstanding. Dividend equivalents may
be converted into additional restricted share units. Settlement of dividend equivalents may be made in the form of cash, Common Shares,
other securities, other property, or a combination of the foregoing. Prior to distribution, any dividend equivalents shall be subject
to the same conditions and restrictions as the restricted share units to which they are payable.
 
Other Share-Based Awards.
Other share-based awards may be granted either alone, in addition to, or in tandem with, other awards granted under the Incentive Plan
and/or cash awards made outside of the Incentive Plan. The plan administrator shall have authority to determine the persons to whom and
the time or times at which other share-based awards will be made, the amount of such other share-based awards, and all other conditions,
including any dividend and/or voting rights.
 
Prohibition on Repricing
 
Except for an adjustment
pursuant to the terms of the Incentive Plan or a repricing approved by shareholders, in no case may the plan administrator (i) amend
an outstanding share option or share appreciation right to reduce the exercise price of the award, (ii) cancel, exchange, or surrender
an outstanding share option or share appreciation right in exchange for cash or other awards for the purpose of repricing the award, or
(iii) cancel, exchange, or surrender an outstanding share option or share appreciation right in exchange for a share option or share
appreciation right with an exercise price that is less than the exercise price of the original award.
 
Tax Withholding
 
Participants in the Incentive
Plan are responsible for the payment of any federal, state, or local taxes that the Company or its subsidiaries are required by law to
withhold upon the exercise of share options or share appreciation rights or vesting of other awards. The plan administrator may cause
any tax withholding obligation of the Company or its subsidiaries to be satisfied, in whole or in part, by the applicable entity withholding
from the Common Shares to be issued pursuant to an award a number of shares with an aggregate fair market value that would satisfy the
withholding amount due. The plan administrator may also require any tax withholding obligation of the Company or its subsidiaries to be
satisfied, in whole or in part, by an arrangement whereby a certain number of the Common Shares issued pursuant to any award are immediately
sold and proceeds from such sale are remitted to the Company or its subsidiaries in an amount that would satisfy the withholding amount
due.
 


69
 

 
Equitable Adjustments
 
In the event of a merger,
consolidation, recapitalization, share split, reverse share split, reorganization, split-up, spin-off, combination, repurchase or other
change in corporate structure affecting the Common Shares, the maximum number and kind of shares reserved for issuance or with respect
to which awards may be granted under the Incentive Plan will be adjusted to reflect such event, and the plan administrator will make such
adjustments as it deems appropriate and equitable in the number, kind, and exercise price of the Common Shares covered by outstanding
awards made under the Incentive Plan.
 
Change in Control
 
In the event of any proposed
change in control (as defined in the Incentive Plan), the plan administrator will take any action as it deems appropriate, which action
may include, without limitation, the following: (i) the continuation of any award, if the Company is the surviving corporation; (ii) the
assumption of any award by the surviving corporation or its parent or subsidiary; (iii) the substitution by the surviving corporation
or its parent or subsidiary of equivalent awards; (iv) accelerated vesting of the award, with all performance objectives and other
vesting criteria deemed achieved at targeted levels, and a limited period during which to exercise the award prior to closing of the change
in control, or (v) settlement of any award for the change in control price (less, to the extent applicable, the per share exercise
price). Unless determined otherwise by the plan administrator, in the event that the successor corporation refuses to assume or substitute
for the award, a participant shall fully vest in and have the right to exercise the award as to all the Common Shares covered by the award,
including those that would not otherwise be vested or exercisable, all applicable restrictions will lapse, and all performance objectives
and other vesting criteria will be deemed achieved at targeted levels.
 
Transferability of Awards
 
Unless determined otherwise
by the plan administrator, an award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner, except
to a participant’s estate or legal representative, and may be exercised, during the lifetime of the participant, only by the participant.
If the plan administrator makes an award transferable, such award will contain such additional terms and conditions as the plan administrator
deems appropriate.
 
Term
 
The Incentive Plan became
effective when adopted by the Board, and, unless terminated earlier, the Incentive Plan will continue in effect for a term of ten (10) years.
 
Amendment and Termination
 
The Board may amend or
terminate the Incentive Plan at any time. Any such termination will not affect outstanding awards. No amendment or termination of the
Incentive Plan will materially impair the rights of any participant, unless mutually agreed otherwise between the participant and the
Company. Approval of the shareholders shall be required for any amendment, where required by applicable law, as well as (i) to increase
the number of shares available for issuance under the Incentive Plan and (ii) to change the persons or class of persons eligible
to receive awards under the Incentive Plan. We have opted out of Nasdaq requirements to receive shareholder approval in connection with
an amendment to the Incentive Plan.
 
Form S-8
 
On July 30, 2024, the
Company filed with the SEC a registration statement on Form S-8 covering the Common Shares issuable under the Incentive Plan.
 
Material United States Federal Income Tax
Considerations
 
The following is a general
summary under current law of the material U.S. federal income tax considerations related to awards and certain transactions under the
Incentive Plan, based upon the current provisions of the Code and Treasury Regulations promulgated thereunder. This summary deals with
the general U.S. federal income tax principles that apply and is provided only for general information. It does not describe all U.S.
federal tax consequences under the Incentive Plan, nor does it describe state, local, or foreign income tax consequences or employment
tax consequences. The rules governing the tax treatment of such awards are quite technical, so the following discussion of tax consequences
is necessarily general in nature and is not complete. In addition, statutory provisions are subject to change, as are their interpretations,
and their application may vary in individual circumstances. This summary is not intended as tax advice to participants, who should consult
their own tax advisors.
 


70
 

 
The Incentive Plan is
not qualified under the provisions of Section 401(a) of the Code and is not subject to any of the provisions of the U.S. Employee
Retirement Income Security Act of 1974, as amended.
 
The ability of the Company
or its subsidiaries to realize the benefit of any tax deductions described below depends on generation of taxable income as well as the
requirement of reasonableness and the satisfaction of tax reporting obligations.
 
Incentive Stock Options.
No taxable income is generally realized by the optionee upon the grant or exercise of an incentive stock option. If the Common Shares
issued to an optionee pursuant to the exercise of an incentive stock option are sold or transferred after two years from the date
of grant and after one year from the date of exercise, then generally (i) upon sale of such shares, any amount realized in excess
of the option exercise price (the amount paid for the shares) will be taxed to the optionee as a long- term capital gain, and any loss
sustained will be a long-term capital loss, and (ii) neither the Company nor its subsidiaries will be entitled to any deduction for
U.S. federal income tax purposes; provided that such incentive stock option otherwise meets all of the technical requirements of an incentive
stock option. The exercise of an incentive stock option will give rise to an item of tax preference that may result in alternative minimum
tax liability for the optionee.
 
If the Common Shares
acquired upon the exercise of an incentive stock option are disposed of prior to the expiration of the two-year and one-year holding periods
described above (a “disqualifying disposition”), generally (i) the optionee will realize ordinary income in the year
of disposition in an amount equal to the excess (if any) of the fair market value of the Common Shares at exercise (or, if less, the amount
realized on a sale of such the Common Shares) over the option exercise price thereof, and (i) the Company or its subsidiaries will
be entitled to deduct such amount. Special rules will apply where all or a portion of the exercise price of the incentive stock option
is paid by tendering the Common Shares.
 
If an incentive stock
option is exercised at a time when it no longer qualifies for the tax treatment described above, the share option is treated as a nonqualified
option. Generally, an incentive stock option will not be eligible for the tax treatment described above if it is exercised more than three months
following termination of employment (or one year, in the case of termination of employment by reason of disability). In the case
of termination of employment by reason of death, the three-month rule does not apply.
 
Nonqualified Options.
No income is generally realized by the optionee at the time a nonqualified option is granted. Generally, (i) at exercise, ordinary
income is realized by the optionee in an amount equal to the difference between the option exercise price and the fair market value of
the Common Shares issued on the date of exercise, and the Company or its subsidiaries receive a tax deduction for the same amount, and
(ii) at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long- term capital
gain or loss depending on how long the Common Shares have been held. Special rules will apply where all or a portion of the exercise
price of the nonqualified option is paid by tendering the Common Shares. Upon exercise, the optionee will also be subject to Social Security
taxes on the excess of the fair market value of the Common Shares over the exercise price of the share option.
 
Share Appreciation Rights,
Restricted Shares, Restricted Share Units, and Other Share-Based Awards. The current U.S. federal income tax consequences of other awards
authorized under the Incentive Plan generally follow certain basic patterns: (i) share appreciation rights are taxed and deductible
in substantially the same manner as nonqualified options; (ii) nontransferable restricted shares subject to a substantial risk of
forfeiture result in income recognition equal to the excess of the fair market value of the Common Shares over the price paid, if any,
only at the time the restrictions lapse (unless the recipient elects to accelerate recognition as of the date of grant through a Code
Section 83(b) election); and (iii) restricted share units, dividend equivalents, and other share or cash based awards are
generally subject to tax at the time of payment. the Company or its subsidiaries generally should be entitled to a U.S. federal income
tax deduction in an amount equal to the ordinary income recognized by the participant at the time the participant recognizes such income.
 


71
 

 
The participant’s
basis for the determination of gain or loss upon the subsequent disposition of the Common Shares acquired from a share appreciation right,
restricted share award, restricted share unit, or other share-based award will be the amount paid for such shares plus any ordinary income
recognized when the shares were originally delivered, and the participant’s capital gain holding period for those shares will begin
on the day after they are transferred to the participant.
 
Parachute Payments. The
vesting of any portion of an award that is accelerated due to the occurrence of a change in control (such as a sale event) may cause all
or a portion of the payments with respect to such accelerated awards to be treated as “parachute payments” as defined in the
Code. Any such parachute payments may be non-deductible to either the Company or its subsidiaries, in whole or in part, and may subject
the recipient to a non-deductible 20% U.S. federal excise tax on all or a portion of such payment (in addition to other taxes ordinarily
payable).
 
Section 409A. The
foregoing description assumes that Section 409A of the Code does not apply to an award under the Incentive Plan. In general, share
options and share appreciation rights are exempt from Section 409A if the exercise price per share is at least equal to the fair
market value per share of the underlying share at the time the share option or share appreciation right was granted. Restricted share
awards are not generally subject to Section 409A. Restricted share units are subject to Section 409A unless they are settled
within two and one-half months after the end of the later of (1) the end of the Company’s fiscal year in which vesting
occurs or (2) the end of the calendar year in which vesting occurs. If an award is subject to Section 409A and the provisions
for the exercise or settlement of that award do not comply with Section 409A, then the participant would be required to recognize
ordinary income whenever a portion of the award vested (regardless of whether it had been exercised or settled). This amount would also
be subject to a 20% U.S. federal tax and premium interest in addition to the U.S. federal income tax at the participant’s usual
marginal rate for ordinary income.
 
New Plan Benefits
 
No awards have been previously
granted under the Incentive Plan. The awards that are to be granted to any participant or group of participants are indeterminable at
the date of this prospectus because participation and the types of awards that may be granted under the Incentive Plan are subject to
the discretion of the plan administrator. Consequently, no new plan benefits table is included in this prospectus.
 
C. Board Practices
 
Corporate Governance
 
We have structured our corporate governance in
a manner we believe will closely align our interests with those of our shareholders. Notable features of this corporate governance include:
 

●we have a majority of independent directors on our Board, and our independent
directors will meet regularly in executive sessions without the presence of our corporate officers or non-independent directors;
 

●we have an audit committee that consists of three independent directors,
at least one of whom qualifies as an “audit committee financial expert” as defined by the SEC; and
 

●we have implemented a range of other corporate governance practices, including
implementing a robust director education program.
 
Number and Terms of Office of Officers and Directors
 
Our officers are appointed by the board of directors.
Our board of directors is authorized to appoint officers as it deems appropriate. Our Board currently consists of 5 members, and pursuant
to our Articles of Incorporation, may consist of a maximum of 10 members and a minimum of 3 members.
 
Independence of our Board of Directors
 
Three of our five directors are independent directors
and our Board has an independent audit committee. The Board determines which members are “independent.” The Board has determined
that each of Messrs. Balkin, Bull and Feuerstein is “independent” as such term is defined under the Exchange Act and
the rules of Nasdaq.
 


72
 

 
Committees of the Board of Directors
 
The Board directs the management of our business
and affairs and conducts its business through meetings of the Board and standing committees. The Company has audit, compensation and nominating
and governance committees, each of which operates under a written charter.
 
In addition, from time to time, special committees
may be established under the direction of the Board when the Board deems it necessary or advisable to address specific issues. Current
copies of the Company’s committee charters will be posted on the Company’s website, as required by applicable SEC and Nasdaq
rules. The information on or available through any of such website is not deemed incorporated in this Report and does not form part of
this Report.
 
Audit Committee
 
Our audit committee (the “Audit Committee”)
consists of Marc Balkin, Chris Bull and Dr. Seth Feuerstein. Mr. Balkin is an “audit committee financial expert”
within the meaning of SEC regulations. Mr. Balkin serves as the chairperson of the Audit Committee. Each member of the Audit Committee
can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations,
the Board will examine each Audit Committee member’s scope of experience and the nature of their employment.
 
The Company has adopted an audit committee charter,
which details the principal functions of the Audit Committee, including:
 

●evaluating the independence and performance of, and assesses the qualifications
of, our independent auditor, and engages such independent auditor;
 

●approving the plan and fees for the annual audit, quarterly reviews, tax
and other audit-related services, and approves in advance any non-audit service to be provided by the independent auditor;
 

●monitoring the independence of the independent auditor and the rotation of
partners of the independent auditor on our engagement team as required by law;
 

●reviewing the financial statements to be included in our Annual Report on
Form 20-F and Current Reports on Form 6-K and reviews with management and the independent auditors the results of the annual audit and
reviews of our quarterly financial statements;
 

●overseeing all aspects of our systems of internal accounting control and
corporate governance functions on behalf of the board;
 

●reviewing and approving in advance any proposed related-party transactions
and report to the full Board on any approved transactions; and
 

●providing oversight assistance in connection with legal, ethical and risk
management compliance programs established by management and our Board, including Sarbanes-Oxley Act implementation, and makes recommendations
to our Board of directors regarding corporate governance issues and policy decisions.
 
Compensation Committee
 
Our compensation committee (the “Compensation
Committee”) consists of Marc Balkin, Chris Bull and Dr. Seth Feuerstein. The chair of the compensation committee is Chris
Bull.
 
The Compensation Committee is governed by a written
charter approved by the Board. The charter of the Compensation Committee permits the Compensation Committee to engage outside consultants
and to consult with human resources consultants when appropriate to assist in carrying out its responsibilities. Compensation consultants
have not been engaged by the Company to recommend or assist in determining the amount or form of compensation for any current executive
officers or directors of the Company. The Compensation Committee may also obtain advice and assistance from internal or external legal,
accounting, or other advisers selected by the Compensation Committee. Our Compensation Committee is responsible for overseeing and making
recommendations to our board of our directors regarding the salaries and other compensation of our executive officers and general employees
and providing assistance and recommendations with respect to our compensation policies and practices.
 
Nominating and Corporate Governance Committee
 
Our nominating and corporate governance committee
(the “Nominating and Corporate Governance Committee”) consists of Marc Balkin, Chris Bull and Dr. Seth Feuerstein.
The chair of the Nominating and Corporate Governance Committee is Marc Balkin.
 
The Nominating and Corporate Governance Committee
is governed by a written charter approved by the Board. Our Nominating and Corporate Governance Committee is responsible for identifying
and proposing new potential director nominees to the Board for consideration and reviewing our corporate governance policies.
 


73
 

 
Corporate Governance Practices and Foreign Private Issuer Status
 
The Company is a foreign private issuer within
the meaning of the rules under the Exchange Act and, as such, the Company is permitted to follow the corporate governance practices
of its home country in lieu of the corporate governance standards of Nasdaq applicable to U.S. domestic companies. For example, the Company
is not required to file periodic reports and financial statements with the SEC as frequently or within the same time frames as U.S. companies
with securities registered under the Exchange Act, although it may elect to file certain periodic reports and financial statements with
the SEC on a voluntary basis on the forms used by U.S. domestic issuers. The Company is not required to comply with Regulation FD,
which imposes restrictions on the selective disclosure of material information to shareholders. In addition, the Company’s
officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions of Section 16
of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of the Company’s securities.
 
In addition, as a “foreign private issuer”,
the Company is permitted to follow certain home-country corporate governance practices in lieu of certain Nasdaq requirements. A foreign
private issuer must disclose in its annual reports filed with the SEC each Nasdaq requirement with which it does not comply followed by
a description of its applicable home country practice. The Company currently intends to follow some, but not all, of the corporate governance
requirements of Nasdaq. With respect to the corporate governance requirements of the Company that it does follow, the Company cannot give
assurances that it will continue to follow such corporate governance requirements in the future, and may therefore in the future, rely
on available Nasdaq exemptions that would allow the Company to follow its home country practice. Unlike the requirements of Nasdaq, the
Company is not required, under the corporate governance practice and requirements in Ontario, to have its board consist of a majority
of independent directors, nor is the Company required to have a compensation committee, a nominating or a corporate governance committee
consisting entirely of independent directors, or to have regularly scheduled executive sessions with only independent directors each year.
Such home country practices may afford less protection to holders of Common Shares.
 
The Company intends to rely on this “foreign
private issuer exemption” with respect to the quorum requirement for shareholder meetings and with respect to Nasdaq shareholder
approval rules. Whereas under the corporate governance rules of Nasdaq, a quorum requires the presence, in person or by proxy, of
holders of at least 331∕3% of the total issued and outstanding voting power of our shares at each general meeting, pursuant to our
bylaws, the quorum required for a general meeting will consist of at least two shareholders present in person or by proxy who hold or
represent at least 25% of the total outstanding voting power of our shares.
 
Limitation on Liability and Indemnification of Officers and Directors
 
Section 136 of the Business Corporations
Act (Ontario) (the “OBCA”) governs the indemnification of directors and officers of a corporation and provides that
a corporation may indemnify a director or officer of the corporation, a former director or officer of the corporation or another individual
who acts or acted at the corporation’s request as a director or officer, or an individual acting in a similar capacity, of another
entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred
by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved
because of that association with the corporation or other entity. A corporation shall not indemnify an individual unless the individual
acted honestly and in good faith with a view to the best interests of the corporation or, as the case may be, to the best interests of
the other entity for which the individual acted as a director or officer or in a similar capacity at the corporation’s request.
If the matter is a criminal or administrative action or proceeding that is enforced by a monetary penalty, a corporation shall not indemnify
an individual unless the individual had reasonable grounds for believing that the individual’s conduct was lawful.
 
The Company has entered into indemnification agreements with each director
and officer of the Company in accordance with the provisions of the OBCA cited above, which are incorporated into such agreements. Under
the indemnification agreements the termination of any proceedings by any judgment, order, settlement, conviction or the entering of a
nolle prosequi does not, by itself, create a presumption that the individual did not act honestly and in good faith and with a view to
the best interests of the corporation or that the individual had reasonable cause to believe that his or her conduct was unlawful. To
the extent permissible by law, there shall be a presumption that the individual acted honestly and in good faith and with a view to the
best interests of the corporation and that the individual had no reasonable cause to believe that his or her conduct was unlawful in the
absence of fraud unless a question of law is involved.


74
 

 
D. Employees
 
As of March 31, 2025, we had 12 employees
and consultants, of which 11 individuals provide services to us through consulting agreements. These employees and consultants are located
in Canada, Australia, the US, South Africa and the United Kingdom.
 
E. Share
Ownership
 
Information regarding the ownership of the Common
Shares by our directors and executive officers is set forth in Item 7.A of this Report and is incorporated herein by reference.
 
F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation
 
Not applicable.
 
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY
TRANSACTIONS
 


A.
Major Shareholders

 
 

The following table sets
forth information regarding the beneficial ownership of Common Shares on the date of this prospectus, based on information obtained from
the persons named below, by:
 

●each person known by Psyence to be the beneficial owner of more than 5% of
the outstanding Common Shares;
 

●each of Psyence’s executive officers and directors; and
 

●all of Psyence’s executive officers and directors as a group.
 
Unless otherwise indicated,
Psyence believes that all persons named in the tables below have sole voting and investment power with respect to all shares beneficially
owned by them. Except as otherwise noted herein, the number and percentage of Common Shares beneficially owned is determined in
accordance with Rule 13d-3 of the Exchange Act, and the information is not necessarily indicative of beneficial ownership
for any other purpose. Under such rule, beneficial ownership includes any Common Shares as to which the holder has sole or shared voting
power or investment power and also any Common Shares which the holder has the right to acquire within 60 days of the date of this
prospectus through the exercise of any option, warrant, convertible security or other right. As of June 19, 2025, there were 713,232
Common Shares issued and outstanding.
 


 
 
 
Number of
 
 
 
 
 

 
 
 
Company
 
 
 
% of Company
 

 
 
 
Common
 
 
 
Common
 

Name of Beneficial Owner(1)
 
 
Shares
 
 
 
Shares
 

5% Holders
 
 
 
 
 
 
 
 

Directors and Executive Officers
 
 
—
 
 
 
—
 

Dr. Neil Maresky
 
 
—
 
 
 
—
 

Warwick Corden-Lloyd
 
 
—
 
 
 
—
 

Jody Aufrichtig
 
 
—
 
 
 
—
 

Marc Balkin
 
 
—
 
 
 
—
 

Christopher (Chris) Bull
 
 
—
 
 
 
—
 

Dr. Seth Feuerstein
 
 
—
 
 
 
—
 

All Directors and Executive Officers as a group (six individuals)
 
 
—
 
 
 
—
 

 
Notes:
 

(1)Unless
otherwise noted, the business address of each of those listed in the table above is 121 Richmond Street West, Penthouse Suite 1300,
Toronto, Ontario M5H 2K1.

 
To the knowledge of the Company, we are not
directly or indirectly owned or controlled by any other corporation, by any foreign government or by any other natural or legal
person either severally or jointly. As far as is known to the Company, there are no arrangements regarding the operation of which
may, at a subsequent date, result in a change in control of the Company.
 


75
 

 
Rule 144
 
Pursuant to Rule 144, a person who has beneficially
owned restricted Common Shares of Psyence for at least six months would be entitled to sell their securities provided that (i) such
person is not deemed to have been one of Psyence’s affiliates at the time of, or at any time during the three months preceding,
a sale and (ii) Psyence is subject to the Exchange Act periodic reporting requirements for at least three months before
the sale and have filed all required reports under Section 13 or 15(d) of the Exchange Act during the 12 months (or
such shorter period as we were required to file reports) preceding the sale.
 
Persons who have beneficially owned restricted
Common Shares or warrants for at least six months but who are Psyence’s affiliates at the time of, or at any time during the
three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within
any three-month period only a number of securities that does not exceed the greater of:
 

●1% of the total number of Common Shares then outstanding); or
 

●the average weekly reported trading volume of the Common Shares during the
four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.
 
Sales by Psyence’s affiliates under Rule 144
are also limited by manner of sale provisions and notice requirements and to the availability of current public information about us.
 
Substantially all of the present Psyence shareholders
will be able to sell shares either pursuant to the registration statement of which this prospectus is a part or, commencing three months
after Psyence becomes a reporting company, which will be prior to the Closing date, pursuant to Rule 144, although Psyence’s
executive officer and directors and other affiliate will be subject to the limitation described above with respect to sales pursuant to
Rule 144. These restrictions do not affect sales pursuant to this prospectus.
 
B. Related
Party Transactions
 
On January 25, 2024,
the Company issued an unsecured convertible promissory note to PGI (the “PGI Note”), in the principal amount of $1,610,657,
which is equal to the total amount owed to PGI in connection with loans that PGI had previously made to the Company. The PGI Note bore
no interest, and (i) $150,000 of the principal balance of the PGI Note was paid on the Closing Date and (ii) $1,460,657 of the principal
balance of the PGI Note was payable on the date that is the one-year anniversary after the Closing Date, or January 25, 2025. The proceeds
from this loan were received by the Company prior to the Closing Date. This note is convertible into shares at the option of PGI.
 
On January 25, 2024,
the Company issued an unsecured convertible promissory note to the NCAC Sponsor (the “NCAC Note”), in the principal amount
of $1,615,501, which is equal to the total amount owed to NCAC Sponsor under certain existing promissory notes previously issued by NCAC
to the NCAC Sponsor (the “Existing Notes”). The NCAC Note bore no interest, and (i) $100,000 of the principal balance of the
NCAC Note became owing on the Closing Date and (ii) $1,515,501 of the principal balance of the NCAC Note was payable on the date that
is the one-year anniversary after the Closing Date, or January 25, 2025. This note is convertible into shares at the option of NCAC Sponsor.
 
Both notes were designated
at FVTPL due to the embedded conversion features, as the conversion prices were not fixed.
 
At inception on January
25, 2024 the fair value of the PGI Note was $1,418,675 and the NCAC note was $1,413,529.
 


76
 

 
PGI Note:
 
On September 30, 2024,
the Company entered into Debt for Equity Exchange Agreement with PGI pursuant to which the Company issued 3,473 of common shares to extinguish
$1,307,960 of PGI Note, representing a conversion price of $298.88 per share.
 
On October 25, 2024,
the Company entered into Debt for Equity Exchange Agreement with PGI pursuant to which the Company issued 1,414 of common shares to extinguish
the remaining balance of PGI Note representing, a conversion price of $298.88 per share.
 
In accordance with the
Debt for Equity Exchange Agreements entered into on September 30, 2024 and October 25, 2024, as amended, the Company will need to issue
additional shares to PGI if the Company’s volume weighted average share price for the 10 days prior to November 26, 2024 is lower
than $298.88 per share (“PGI make whole payment”).
 
In December 2024, the
Company issued 42,378 common shares to extinguish the PGI make whole payment. The issuance of shares pursuant to the Debt for Equity Exchange
Agreements resulted in a fair value gain of $327,668 which was recorded in the consolidated statements of income/(loss) and comprehensive
income/(loss).
 
NCAC Note:
 
On September 30, 2024,
the Company entered into Debt for Equity Exchange Agreement with NCAC Sponsor pursuant to which the Company issued 5,405 of common shares
to extinguish the outstanding balance of NCAC Note, representing a conversion price of $298.88 per share.
 
In accordance with the
Debt for Equity Exchange Agreements, as amended, the Company will need to issue additional shares to NCAC Sponsor if the Company’s
volume weighted average share price for the 10 days prior to November 26, 2024 is lower than $298.88 per share (“NCAC make whole
payment”).
 
In December 2024, the
Company issued 46,870 common shares to extinguish the NCAC make whole payment. The issuance of shares pursuant to the Debt for Equity
Exchange Agreements resulted in a fair value gain of $377,897 which was recorded in the consolidated statements of income/(loss) and comprehensive
income/(loss).
 
The fair value of the
notes was calculated using a credit adjusted market borrowing rate as at March 31, 2024. The fair value of both notes was $nil as at March
31, 2025 (March 31, 2024 - $2,790,492). A fair value gain of $705,565 was recognized during the year in the statement of comprehensive
income (March 31, 2024 ($108,288)).
 
The foregoing description
of the Swap Agreements does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Swap
Agreements.
 
Equity Incentive Plans
 
See “Management  — Equity
Incentive Plans.”
 
Employment Agreements and Indemnification Agreements
 
See “Executive Compensation — 
Employment, Consulting and Management Agreements” and “Management – Limitation on Liability and Indemnification
of Officers and Directors.”
 
Related Party Transaction Policy
 
The Board has adopted a written related party
transaction policy, which sets forth the policies and procedures for the review and approval or ratification or related person transactions.
 
A “Related Person Transaction” is
a transaction, arrangement or relationship in which the Company or any of its subsidiaries was, is or will be a participant, the amount
of which involved exceeds $120,000, and in which any related person had, has or will have a direct or indirect material interest.
 


77
 

 
A “Related Person” means:
 

●any person who is, or at any time during the applicable period was, one of
the Company’s officers or one of the Company’s directors;
 

●any person who is known by the Company to be the beneficial owner of more
than five percent (5%) of its voting stock;
 

●any immediate family member of any of the foregoing persons, which means
any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, daughter-in-law, brother-in-law or sister-in-law
of a director, officer or a beneficial owner of more than five percent (5%) of its voting stock, and any person (other than a tenant or
employee) sharing the household of such director, officer or beneficial owner of more than five percent (5%) of its voting stock; and
 

●any firm, corporation or other entity in which any of the foregoing persons
is a partner or principal or in a similar position or in which such person has a ten percent (10%) or greater beneficial ownership interest.
 
The Company has policies and procedures designed
to minimize potential conflicts of interest arising from any dealings it may have with its affiliates and to provide appropriate procedures
for the disclosure of any real or potential conflicts of interest that may exist from time to time. Specifically, pursuant to its charter,
the audit committee will have the responsibility to review related party transactions.
 
C. Interests of Experts and Counsel
 
Not applicable.
 
ITEM 8. FINANCIAL
INFORMATION
 


A.
Consolidated Statements and Other Financial Information

 
Financial Statements
 
Our consolidated financial statements begin on
page F-1.
 
Dividend Policy
 
Psyence has not paid any cash dividends on its shares to date and does
not intend to pay cash dividends in the foreseeable future. The payment of cash dividends in the future will be dependent upon the Company’s
revenue and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends is within the discretion
of the Board. Further, our ability to declare dividends may be limited by the terms of financing or other agreements entered into by us
or our subsidiaries from time to time.
 
B. Significant Changes
 
Except as disclosed elsewhere in this Report,
no other significant changes to our financial condition have occurred since the date of the financial statements contained herein.
 
ITEM 9. THE OFFER AND
LISTING
 
A. Offer and Listing Details
 
Nasdaq Listing of Common Shares and Warrants
 
The Common Shares and the Warrants are listed
on Nasdaq under the symbols “PBM” and “PBMWW,” respectively. As of June 18, 2025, the closing price of our Common
Shares was $4.92 and our Warrants was $0.019.
 
B. Plan of Distribution
 
Not applicable.
 
C. Markets
 
Refer to "Offer and Listing Details"
in Item 9.A.
 
D. Selling Shareholders
 
Not applicable.
 
E. Dilution
 
Not applicable.
 
F. Expenses
of the Issue
 
Not applicable.
 


78
 

 
ITEM 10. ADDITIONAL
INFORMATION
 
A. Share Capital
 
Not applicable.
 
B. Articles
of Association and By-Laws
 
The following description of the material terms
of the securities of the Company includes a summary of specified provisions of the Articles of Incorporation and amended and restated
by-laws (“bylaws”) of the Company. This description is qualified by reference to the Articles of Incorporation and
by-laws, copies of which are attached as exhibits to this Report and incorporated in this Report by reference. In this section, the terms
“we,” “our” or “us” refer to the Company, and all capitalized terms used in this section are as defined
in the Articles of Incorporation and bylaws, unless elsewhere defined herein.
 
We are a corporation organized under the laws
of Ontario, Canada and our affairs are governed by our Articles of Incorporation, as registered on June 29, 2023 and the Business
Corporations Act (Ontario).
 
The following is a summary of the rights of our
Common Shares as set forth in our Articles of Incorporation and bylaws and certain related sections of the OBCA. This summary does not
purport to be complete and is qualified in its entirety by the full text of the Articles of Incorporation, which is filed as an exhibit
to this Report.
 
Our authorized share capital consists of an unlimited
number of Common Shares, each without par value. As of June 19, 2025, we have 713,232 issued and outstanding Common Shares.
 
The following description of our share capital
and provisions of our Articles of Incorporation and bylaws are summaries of material terms and provisions and are qualified by reference
to our Articles of Incorporation and bylaws, copies of which have been filed with the SEC as exhibits to this Report. The description
of our Common Shares reflects amendments to our Articles of Incorporation and bylaws.
 
Common Shares
 
The holders of our Common Shares are entitled
to one vote for each share held at any meeting of shareholders. The holders of our Common Shares are entitled to receive dividends as
and when declared by our Board. In the event of our liquidation, dissolution or winding-up or other distribution of our assets among our
shareholders, the holders of our Common Shares are entitled to share pro rata in the distribution of the balance of our assets. There
are no preemptive, redemption, purchase or conversion rights attaching to our Common Shares. There are no sinking fund provisions applicable
to our Common Shares. Our Common Shares are issued in fully registered form.
 
C. Material Contracts
 
Material Contracts Relating to the Company’s
Operations
 
The information set forth in Item 4.B. —
Licensing of PEX010 is incorporated herein by reference.
 
Southern Star MSA
 
On May 21, 2025, Psyence Australia, a wholly-owned
subsidiary of the Company, entered into a Master Services Agreement (the “MSA”) with Southern Star Research. Under
the MSA, Southern Star Research will serve as the Company’s CRO for its Phase IIb clinical trial of PEX010 (psilocybin) in patients
diagnosed with cancer who are experiencing adjustment disorder. 
 
Pursuant to the MSA, Southern Star Research will
provide comprehensive CRO services for the registrational Phase IIb study, including:
 

●Trial Management & Oversight: Clinical monitoring, site initiation, site
management and close-out activities.
 

●Project Management: Development and maintenance of a detailed project plan,
coordination of cross-functional teams and regular status reporting to Company senior management.
 

●Data Management & Biostatistics: Design, build and maintenance of the
electronic data capture (EDC) system; data cleaning, database lock and generation of interim and final statistical reports.
 


79
 

 


●Regulatory & Ethics Support: Preparation of submissions to the Therapeutic
Goods Administration (TGA) in Australia and local ethics committees; management of regulatory correspondence and amendments.
 

●Pharmacovigilance & Safety Oversight: Collection, processing and reporting
of adverse events, serious adverse events and safety follow-up as required under applicable regulations.
 

●Patient Recruitment & Retention: Assistance with site selection, patient
screening strategy and patient retention programs to ensure timely enrollment of the target 87 participants in the double-blind, placebo-controlled
study.
 

●Transitional Handover: Coordination with the Company’s prior CRO (iNGENū)
to facilitate a seamless transition of all clinical deliverables, data, documentation and site-related activities.
 
The Company will pay Southern Star Research aggregate
fees in accordance with the MSA Exhibit A to the MSA. Fees are structured as follows:
 

●Payments: Payment terms consist of an upfront deposit, being a percentage
of the total project costs, as well as monthly invoices in accordance with services delivered per the work order.
 

●Expense Reimbursements: In addition to monthly invoices, Southern Star Research
will be reimbursed for all reasonable out-of-pocket costs incurred in performing the services.
 
The MSA includes mutual representations and warranties
customary for CRO engagements.
 
Material Contracts Relating to the Business Combination
 
Consummation of the Business Combination
 
On January 25, 2024,
we consummated the transactions contemplated by the Business Combination Agreement, pursuant to which (i) PGI contributed Biomed
II to the Company in a share for share exchange, (ii) following the Company Exchange, Merger Sub merged with and into NCAC, with
NCAC being the surviving company in the Merger, and each outstanding ordinary share of NCAC was converted into the right to receive one
Common Share of the Company, and (iii) each outstanding warrant to purchase NCAC Class A Ordinary Shares was converted into
a warrant to acquire one Common Share on substantially the same terms as were in effect immediately prior to the Effective Time under
their terms. The figures in this section are presented on a post-split basis.
 
Securities Purchase Agreement
 
On January 15, 2024,
in connection with the Business Combination, the Company and Biomed II entered into the Securities Purchase Agreement with the Investors
and the Sponsor, relating to up to four senior secured convertible notes obligations under which are guaranteed by certain assets of the
Company and Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up
to $12,500,000 in exchange for up to $10,000,000 in subscription amounts.
 
The two First Tranche
Notes, for an aggregate of $3,125,000, were delivered by the Company to the Investors on January 25, 2024, in exchange for an aggregate
of $2,500,000 in financing, which occurred substantially concurrently with, and was contingent upon, the consummation of the Business
Combination. On the original issuance date of the First Tranche Notes, interest began accruing at 8.0% per annum based on the outstanding
principal amount of the First Tranche Notes, and is payable monthly in arrears in cash or in Common Shares (at the Conversion Price).
The initial Conversion Price of the First Tranche Notes was $5,977.50; provided, however, that such Conversion Price is subject to
certain adjustments according to the terms and reset dates included in the First Tranche Notes and may be reduced to a Conversion Floor
of $597.75, until the First Reset Date (as such term is defined in the First Tranche Notes), then to $298.88 on the Second Reset Date
(as such term is defined in the First Tranche Notes) (the “Conversion Floor”). The provisions relating to the reset
dates are as follows: Downward adjustments in the conversion price occur on five reset dates. The First Reset Date occurs five days prior
to the date on which the Registration statement of which this prospectus is a part is declared effective. The Second Reset Date occurs
on April 25, 2024, which is the three-month anniversary of the closing of the Business Combination. The third reset date (the “Third
Reset Date”) occurs on July 25, 2024, which is the six-month anniversary of the closing of the Business Combination. The fourth
reset date (the “Fourth Reset Date”) occurs on October 25, 2024, which is the nine-month anniversary of the closing
of the Business Combination. The fifth reset date (the “Fifth Reset Date” and collectively with the First Reset Date,
the Second Reset Date, the Third Reset Date and the Fourth Reset Date, the “Reset Dates”) occurs on January 25, 2025,
which is the 12-month anniversary of the closing of the Business Combination. On each of the Reset Dates, the conversion price of the
First Tranche Notes will be reset to the lower of (i) the $5,977.50 initial conversion price of the First Tranche Notes and (ii) the average
daily VWAP for the previous ten Trading Days prior to such applicable Reset Date, but in no event less than the Conversion Floor.
 


80
 

 
In addition to the downward
adjustments made to the conversion price on each of the Reset Dates, the conversion price of the First Tranche Notes will also be adjusted
in connection with the conversion of the First Tranche Notes, or the determination of the payment of interest in Common Shares, upon a
conversion or a payment of interest, at any time after the date of the closing of the Business Combination and prior to the First Reset
Date, in the event that at such date the Investors have not recouped at least an aggregate of $5,000,000 of their investments, to the
lower of (i) $5,977.50 and (ii) the lowest daily VWAP of the Common Shares, during the period from the date of the closing of the Business
Combination until the earlier of (a) the date of conversion or payment of interest or (b) the First Reset Date.
 
Furthermore, if the average
VWAP for the 30 Trading Days (the “30-day VWAP”) after a conversion is lower than the conversion price on the date
of conversion, the Company is also required make a “make whole payment” in cash or Common Shares, at its election but subject
to certain limitations, as described in the First Tranche Notes, determined as follows: The “make whole payment” equals the
difference between (i) the principal amount converted on the date of conversion divided by 30-day VWAP and (ii) the principal amount converted
divided by the conversion price on the date of conversion. The “make whole payment” is due no later than 35 Trading Days after
the applicable date of conversion.
 
On May 31, 2024,
the Notes (the “Initial Second Tranche Notes”) for the initial portion of the second tranche of the Financing (the
“Second Tranche”), for a total of $312,500 of principal in exchange for a total of $250,000 in subscription amounts,
were issued to the Investors.
 
On June 14, 2024,
the Company issued two additional Notes (the “First Subsequent Second Tranche Notes”, and together with the Initial
Second Tranche Notes and the Second Subsequent Second Tranche Notes (as defined below), the “Second Tranche Notes”)
for an additional portion of the Second Tranche, for an aggregate total of $312,500 principal in exchange for $250,000 provided by the
Investors. The Investors were not obligated to fund any of the Second Tranche because the Company was not in compliance with all of the
covenants under the Securities Purchase Agreement. Notwithstanding the foregoing, the Investors agreed to fund an additional portion of
the Second Tranche on such date and may continue to do so at its discretion.
 
In
July 2024, the Company issued two additional Notes (the “Second Subsequent Second Tranche Notes”) for an
additional portion of the Second Tranche, for an aggregate total of $625,000 principal in exchange for $500,000 provided by the Investors.
The Investors were not obligated to fund any of the Second Tranche because the Company was not in compliance with all of the covenants
under the Securities Purchase Agreement. Notwithstanding the foregoing, the Investors agreed to fund an additional portion of the Second
Tranche on such date and may continue to do so at its discretion.
 
The
Second Tranche Notes are substantially the same as the First Tranche Notes, except that the first and second reset dates have been
removed, as these applicable dates have passed. Interest on the Subsequent Second Tranche Notes accrues at 8.0% per annum, based
on the outstanding principal amount of the Subsequent Second Tranche Notes, and is payable monthly in arrears in cash or in the Common
Shares (at the applicable conversion price).
 
The initial conversion
price for the Second Tranche Notes is the lowest daily VWAP during the period commencing on January 25, 2024 until the earlier
of (i) the date of conversion of the Second Tranche Notes and (ii) the date on which the registration statement for the
shares underlying the First Tranche Note is declared effective (or May 14, 2024) and is subject to reset on July 25, 2024,
October 25, 2024, January 25, 2025 in respect of the Initial Second Tranche Note and the First Subsequent Second Tranche
Note and July 25, 2024, October 25, 2024, January 25, 2025, July 25, 2025, October 25, 2025 in respect of
the Second Subsequent Second Tranche Note, at which time the conversion price will be reset to the lower of (i) the initial conversion
price and (ii) the average daily VWAP for the previous ten (10) trading days prior to such reset. The current conversion
price floor for the Second Tranche Notes is $224.22.
 


81
 

 
Providing any financing
with respect to the Third Tranche Notes and the Fourth Tranche Notes is at the sole discretion of the Investors. With respect to any financing
relating to the Third Tranche Notes, the Investors may issue a commitment letter to the Company on or before the 30th day
following the last funding of the Second Tranche Financing, assuming that the Second Tranche Financing has been provided. With respect
to the Fourth Tranche Notes, the Investors may issue a commitment letter to the Company on or before the 90th day after
the last funding of the Second Tranche Financing, assuming that the Second Tranche Financing is provided. The Third Tranche Notes would
be in an aggregate principal amount of $3,125,000 and would be delivered in exchange for an additional $2,500,000 in financing. This would
be the same for the Fourth Tranche Notes. Additionally, in consideration of the willingness of the Investors to enter into the transactions
that are the subject of the Securities Purchase Agreement and the Notes, including providing the financing, Psyence Biomedical agreed
that it or certain of its shareholders would pay the Investors a structuring fee by delivering to the Investors an aggregate of 5,019
Structuring Shares. At the initial closing of the financing under the terms of the Securities Purchase Agreement, and concurrent with
the closing of the Business Combination, 2,175 of the Structuring Shares were delivered to the Investors. The remaining 2,844 Structuring
Shares are subject to the terms of Call Option Agreements, by and among the Investors and certain members of the Sponsor, pursuant to
which such Common Shares are deliverable to the Investors no later than two business days after requested by the Investors; provided that
no amounts shall be requested at any time that the Investors own in excess of 9.9% of the Company. Pursuant to the provisions of the Call
Option Agreements, the Investors have been granted the option to require Tabula and Launchpad to each sell to the Investors such remaining
2,844 Structuring Shares they own at a price of $0.06 per Common Share. The number of Common Shares which the Investors may purchase pursuant
to the terms of the Call Option Agreements are subject to adjustments for share dividends and split ups. As of the date of this prospectus,
the Investors have purchased all of the 2,844 Structuring Shares.
 
In order to secure the
repayment of the Notes by the Company and Biomed II, pursuant to the terms and conditions of a General Security Agreement, dated
January 25, 2024 (the “Security Agreement”), each agreed to grant to the Investors a security interest, subject
to certain exceptions, in all of the Collateral (as such term is defined in the Security Agreement) in each of their possessions, including
a pledge of all equity securities owned by either of them, provided that no Common Shares are pledged equity securities.
 
Pursuant to a Guaranty,
dated January 25, 2024. Biomed II also agreed to guaranty all of the Company’s obligations to the Investors under the Notes including,
without limitation, payment of all installments of principal and interest thereunder.
 
In connection with the
foregoing, on January 25, 2024, the Company and the Investors entered into a registration rights agreement (the “Registration
Rights Agreement”), pursuant to which the Company has agreed to file a registration statement covering the resale of the Common
Shares issuable upon conversion of the First Tranche Notes (the “Initial Resale Registration Statement”) and any
additional registration statements required to be filed to register the resale of the Common Shares issuable upon any of the other Notes,
as applicable, and to use its best efforts to have the Initial Resale Registration Statement and such registration statement(s), as applicable,
declared effective by the SEC as soon as practicable, but in no event later than the applicable Effectiveness Deadline (as defined in
the Registration Rights Agreement for such applicable registration statement). The Registration Rights Agreement contains certain penalty
provisions, subject to certain conditions and cure periods, for the Company failing to (i) file a registration statement by certain
deadlines set forth in the Registration Rights Agreement, (ii) cause a registration statement to be declared effective by certain
deadlines set forth in the Registration Rights Agreement, (iii) maintain certain circumstances and conditions allowing the resale
of certain securities or (iv) satisfy the requirements of Rule 144(c)(1) under the Exchange Act if a registration statement
is not effective. The Registration Rights Agreement also provides the Investors with customary piggyback registration rights under certain
circumstances.
 
In connection with the
foregoing, on January 25, 2024, NCAC and the Company entered into a lock-up agreement with certain shareholders of the Company (the
“Lock-Up Agreement”), pursuant to which such shareholders agreed not to, during the period (the “Lock-Up Period”)
commencing from the Closing and ending on the earliest of (x) one hundred eighty (180) days after the Closing; provided, however,
that in the event that the Investors delay investment of the Subscription Amounts (as defined in the Securities Purchase Agreement) with
respect to the Second Tranche Note (as defined in the Securities Purchase Agreement) due to the occurrence of an event outlined in
Section 2.1(b) of the Securities Purchase Agreement, such period shall be extended by 60 days or such earlier date as the
deficiency is resolved, and (y) subsequent to the Closing, the date on which the Company consummates a liquidation, merger, share
exchange or other similar transaction with an unaffiliated third party that results in all of Psyence Biomedical’s shareholders
having the right to exchange the Common Shares for cash, securities or other property, (i) lend, offer, pledge, hypothecate, encumber,
donate, assign, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares issued or issuable to the applicable
shareholder pursuant to their respective agreements (“Restricted Securities”), (ii) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Restricted Securities,
or (iii) publicly disclose the intention to do any of the foregoing, whether any such transaction described in clauses (i), (ii) or
(iii) above is to be settled by delivery of Restricted Securities or other securities, in cash or otherwise (any of the foregoing
described in clauses (i), (ii) or (iii), a “Prohibited Transfer”). The lock-up provisions provide for certain
exemptions for transfers to permitted transferees.
 


82
 

 
The foregoing descriptions
of the Securities Purchase Agreement, the Guaranty, the Registration Rights Agreement, the General Security Agreement, the Lock-Up Agreement
and the Note are qualified in their entirety by the full text of such agreements (or their forms), which are incorporated by reference
as Exhibit 2.3, Exhibit 10.1, Exhibit 10.12, Exhibit 10.13, Exhibit 10.14 and Exhibit 10.15 to the registration
statement of which this prospectus is a part, respectively, and are incorporated herein by reference. Furthermore, as described above
under “Addendum to Securities Purchase Agreement,” certain provisions of such agreements were amended.
 
Amendment to CCM Engagement
Letter
 
On January 25, 2024,
NCAC and CCM entered into an amendment to engagement letter (the “CCM Amendment”), which amended that certain Engagement
Letter dated as of February 9, 2023, by and among NCAC and CCM (the “Initial Engagement Letter”). Pursuant to
the CCM Amendment, NCAC agreed to pay CCM a revised transaction fee, in lieu of (i) $982,500 owed to CCM as deferred underwriting
commission and (ii) fees outstanding under the Initial Engagement Letter, in connection with the Business Combination in an amount
equal to 251 CCM Fee Shares, plus reimbursable expenses incurred as of the Closing Date, which was paid from NCAC’s trust account
at the Closing of the Business Combination.
 
In addition to the obligation
to deliver the CCM Fee Shares to CCM, the terms of the CCM Amendment also include registration rights obligations on the part of the Company,
which include obligations to use reasonable best efforts to file a resale registration statement covering the CCM Fee Shares and to maintain
the effectiveness thereof while CCM continues to hold the CCM Fee Shares, in accordance with the terms of the CCM Amendment.
 
The foregoing description
of the CCM Amendment is qualified in its entirety by the full text of the CCM Amendment, which is incorporated by reference as Exhibit 10.9
to the registration statement of which this prospectus is a part, and is incorporated herein by reference.
 
Modified Cantor Deferred
Underwriting Fee Payment Obligations
 
Pursuant to the Underwriting
Agreement, dated as of October 19, 2021 (as amended or modified, the “Underwriting Agreement”), entered into in
connection with NCAC’s IPO, NCAC previously agreed to pay to Cantor, in Cantor’s capacity as representative of the underwriters,
deferred underwriting commissions in an aggregate amount of $5,567,500 (reflecting Cantor’s portion of the $6,550,000 deferred underwriting
commission, after giving effect to the waiver of 50% of the original $13,100,000 deferred underwriting fee) (the “Cantor Deferred
Fee”).
 
On January 25, 2024,
NCAC and Cantor, in consideration of redemption levels by NCAC public shareholders, among other factors, entered into that certain fee
modification agreement (the “Cantor Fee Modification Agreement”), pursuant to which, among other things, Cantor agreed
to accept, in lieu of payment of the Cantor Deferred Fee in cash at the Closing, an aggregate of 251 Cantor Fee Shares, payable and delivered,
at Closing at an effective price of $5,977.50 resulting from a waiver of a portion of the Cantor Deferred Fee.
 
In addition to the Company’s
obligation to deliver the Cantor Fee Shares to Cantor, free and clear of specified restrictions, the terms of the Cantor Fee Modification
Agreement also include registration rights obligations on the part of the Company, which include obligations to use commercially reasonable
efforts to file a resale registration statement covering the Cantor Fee Shares and to maintain the effectiveness thereof while Cantor
continues to hold the Cantor Fee Shares, in each case in accordance with the terms of the Cantor Fee Modification Agreement. The Cantor
Fee Modification Agreement also includes a penalty provision that will require the Company to deliver to Cantor $5,567,500 in cash in
the event that Cantor is unable to timely sell or transfer Cantor Fee Shares or the shares and warrants purchased in the private placement
by Cantor in connection with NCAC’s IPO, due to continuing restrictions thereunder resulting from a failure by the Company to satisfy
certain post-closing registration-related covenants and agreements in accordance with terms of the Cantor Fee Modification Agreement,
following notice and reasonable opportunity to cure on the part of the Company.
 


83
 

 
The foregoing description
of the Cantor Fee Modification Agreement is qualified in its entirety by the full text of the Cantor Fee Modification Agreement, which
is incorporated by reference as Exhibit 10.10 to the registration statement of which this prospectus is a part, and is incorporated
herein by reference.
 
MWE Fee Agreement
 
On January 25, 2024,
NCAC and MWE entered into that certain fee agreement (the “MWE Fee Agreement”). Pursuant to the MWE Fee Agreement,
NCAC agreed to pay MWE a fee (the “MWE Amended Fee”) for the legal services provided by MWE to NCAC, in lieu of outstanding
legal fees due to MWE. The MWE Fee Agreement provides that the MWE Amended Fee is comprised of (i) $100,000 due upon the Closing,
(ii) an additional $100,000, payable on or prior to the 90th day after the Closing and (iii) 209 MWE Fee Shares,
payable and delivered, at Closing.
 
In addition to the obligation
to deliver the MWE Amended Fee, the terms of the MWE Fee Agreement also include registration rights obligations on the part of the Company,
which include obligations to use commercially reasonable efforts to file a resale registration statement covering the MWE Fee Shares and
to maintain the effectiveness thereof while MWE continues to hold the MWE Fee Shares, in accordance with the terms of the MWE Fee Agreement.
 
EGS Fee Modification
Agreement
 
On January 26, 2024,
the Company and EGS entered into that certain fee modification agreement (the “EGS Fee Modification Agreement”), pursuant
to which the Company paid to EGS, for services provided prior to the Closing, (i) $50,000 upon the Closing, (ii) $50,000 payable
to EGS within ninety (90) days following the Closing, and (iii)  167 Common Shares, which were issued promptly following the
date upon which the SEC declared the Initial Registration Statement effective (the “Issuance Date”). Additionally,
the Company paid EGS (i) $25,000 in connection with the filing of the Initial Registration Statement and (ii) 84 Common Shares,
to be issued upon the Issuance Date.
 
Amendments to RNA Engagement
Letter
 
On January 25, 2024,
NCAC and RNA Advisors, LLC, entered into that certain amendment to engagement letter (the “RNA Amendment”), which amended
that certain Engagement Letter dated as of February 2, 2023, by and among NCAC and RNA. Pursuant to the RNA Amendment, NCAC agreed
to pay RNA a revised transaction fee (the “RNA Amended Fee”) in connection with the Business Combination, comprised
of (i) $25,000 due upon the Closing, (ii) an additional $25,000, payable on or prior to the 90th day after the
Closing and (iii) 35 RNA Fee Shares, payable and delivered, at Closing.
 
In addition to the obligation
to deliver the RNA Amended Fee, the terms of the RNA Amendment also include registration rights obligations on the part of the Company,
which include obligations to use reasonable best efforts to file a resale registration statement covering the RNA Fee Shares and to maintain
the effectiveness thereof while RNA continues to hold the RNA Fee Shares, in accordance with the terms of the RNA Amendment.
 
Amendments to Maxim Engagement
Letter
 
On January 25, 2024,
NCAC and Maxim entered into that certain amendment to engagement letter (the “Maxim Amendment”), which amended that
certain Engagement Letter dated as of April 28, 2023, by and among PGI and Maxim. Pursuant to the Maxim Amendment, PGI agreed to
pay Maxim a revised transaction fee in connection with the Business Combination in an amount equal to 251 Maxim Fee Shares.
 


84
 

 
In addition to the obligation
to deliver the Maxim Fee Shares to Maxim, the terms of the Maxim Amendment also include registration rights obligations on the part of
the Company, which include obligations to use reasonable best efforts to file a resale registration statement covering the Maxim Fee Shares
and to maintain the effectiveness thereof while Maxim continues to hold the Maxim Fee Shares, in accordance with the terms of the Maxim
Amendment.
 
The foregoing description
of the Maxim Amendment is qualified in its entirety by the full text of the Maxim Amendment, which is filed as Exhibit 10.11 to the
registration statement of which this prospectus is a part, and is incorporated herein by reference.
 
Lock-Ups
 
In connection with the
Closing, the following parties are subject to lock-ups as set forth below: the Sponsor, MWE, NCAC, J.V.B., Cantor, Maxim, EGS and RNA
(each, a “Lock-Up Party”) entered into lock-up arrangements which are substantially identical to each other, pursuant
to which the applicable Lock-Up Party agreed not to, during the period (the “Lock-Up Period”) commencing from the Closing
and ending on the earliest of (x) one hundred eighty (180) days after the Closing; provided, however, that in the event that
the Investors delay investment of the Subscription Amounts (as defined in the Securities Purchase Agreement) with respect to the Second
Tranche Note (as defined in the Securities Purchase Agreement) due to the occurrence of an event outlined in Section 2.1(b) of
the Securities Purchase Agreement, such period shall be extended by 60 days or such earlier date as the deficiency is resolved, and
(y) subsequent to the Closing, the date on which the Company consummates a liquidation, merger, share exchange or other similar transaction
with an unaffiliated third party that results in all of the Company’s shareholders having the right to exchange the Common Shares
for cash, securities or other property, (i) lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, any shares issued or issuable to the applicable Lock-Up Party pursuant to their respective
agreements (“Restricted Securities”), (ii) enter into any swap or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of the Restricted Securities, or (iii) publicly disclose the intention
to do any of the foregoing, whether any such transaction described in clauses (i), (ii) or (iii) above is to be settled by delivery
of Restricted Securities or other securities, in cash or otherwise (any of the foregoing described in clauses (i), (ii) or (iii),
a “Prohibited Transfer”). The lock-up provisions provide for certain exemptions for transfers to permitted transferees.
 
Warrant Exchange
 
On May 16, 2024,
Psyence entered into a Warrant Exchange Agreement (the “Warrant Exchange Agreement”) with an unaffiliated third-party
investor (the “Holder”) of Public Warrants. Pursuant to the Warrant Exchange Agreement, the Company issued to the Holder
1,104 Common Shares (the “Exchange Shares”) in exchange for the surrender and cancellation of 1,104 Public Warrants
held by the Holder (the “Holder’s Warrants”) (such transactions, collectively, the “Exchange”).
 
The foregoing description of the Warrant Exchange
Agreement does not purport to be complete and is qualified in its entirety by reference to the Warrant Exchange Agreement, which is included
as Exhibit 4.26 to this Report and incorporated by reference herein.
 
The issuance by the Company of the Exchange Shares
in the Exchange was made in reliance upon the exemption from the registration requirements provided by Section 3(a)(9) of the
Securities Act of 1933, as amended. The Company did not receive any cash proceeds from the issuance of the Exchange Shares pursuant to
the Exchange.
 
D. Exchange
Controls and Other Limitations Affecting Security Holders
 
Limitations on the ability to acquire and hold shares of the Company
may be imposed by the Competition Act (Canada) (the “Competition Act”). This legislation permits the Commissioner of
Competition to review any acquisition of a significant interest in us. This legislation grants the Commissioner jurisdiction, for up to
three years, to challenge this type of acquisition before the Competition Tribunal if the Commissioner believes that it would, or
would be likely to, result in a substantial lessening or prevention of competition in any market in Canada.
 


85
 

 
E. Taxation
 
Material U.S. Federal Income Tax Considerations for U.S. Holders
 
The following discussion summarizes the anticipated
U.S. federal income tax considerations generally applicable to a U.S. Holder (as defined below) of the ownership and disposition of the
Common Shares. This discussion addresses only holders who acquire and hold Common Shares as “capital assets” (generally, assets
held for investment purposes).
 
This summary is based on the Internal Revenue
Code of 1986, as amended (the “Code”), U.S. Treasury regulations, administrative pronouncements and rulings of the
United States Internal Revenue Service (the “IRS”), and the US Treaty, all as in effect on the date hereof, and all
of which may be repealed, revoked or modified (possibly with retroactive effect) so as to result in U.S. federal income tax consequences
different from those discussed below. This summary does not describe any state, local or foreign tax law considerations, or any aspect
of U.S. federal tax law other than income taxation (e.g., alternative minimum tax, the 3.8% Medicare tax on certain net investment income,
or estate or gift tax). Except as specifically set forth below, this summary does not discuss applicable income tax reporting requirements.
U.S. Holders should consult their own tax advisers regarding such matters.
 
No ruling from the IRS has been requested, or
will be obtained, regarding the U.S. federal income tax consequences of the ownership or disposition of the Common Shares. This summary
is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the discussion
set forth in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations,
the IRS and U.S. courts could disagree with one or more of the positions taken in this summary.
 
This summary does not purport to address all U.S.
federal income tax consequences that may be relevant to a U.S. Holder as a result of the ownership and disposition of the Common Shares,
nor does it take into account the specific circumstances of any particular holder, some of which may be subject to special tax rules,
including, but not limited to, tax exempt organizations, partnerships and other pass-through entities and their owners, banks or other
financial institutions, insurance companies, regulated investment companies, real estate investment trusts, qualified retirement plans,
individual retirement accounts or other tax-deferred accounts, persons that hold the Common Shares as part of a straddle, hedging transaction,
conversion transaction, constructive sale or other similar arrangements, persons that acquired the Common Shares in connection with the
exercise of employee share options or otherwise as compensation for services, persons that are resident or ordinarily resident in or have
permanent establishment in a jurisdiction outside the United States, dealers in securities or foreign currencies, traders in securities
electing to mark to market, U.S. persons whose functional currency (as defined in the Code) is not the U.S. dollar, U.S. expatriates,
or persons that own directly, indirectly or by application of the constructive ownership rules of the Code 10% or more of the Company’s
shares by voting power or by value.
 
As used herein, a “U.S. Holder”
is a beneficial owner of the Common Shares who, for U.S. federal income tax purposes, is: (1) an individual who is a citizen or resident
of the United States; (2) a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) that is created
or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate whose income
is subject to U.S. federal income tax regardless of its source, or (4) a trust (A) if a U.S. court is able to exercise primary
supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions
of the trust, or (B) that has validly elected to be treated as a U.S. person for U.S. federal income tax purposes.
 
If a partnership (or other entity or arrangement
treated as a partnership for U.S. federal income tax purposes) holds the Common Shares, the tax treatment of a partner in or owner of
the partnership or other entity or arrangement will generally depend upon the status of the partner or owner and the activities of the
entity. Prospective investors who are partners in partnerships (or other entities or arrangements treated as partnerships for U.S. federal
income tax purposes) that are beneficial owners of the Common Shares are urged to consult their own tax advisors regarding the tax consequences
of the ownership and disposition of the Common Shares.
 
This summary is of a general nature only and is
not intended to be tax advice to any prospective investor, and no representation with respect to the tax consequences to any particular
investor is made. Prospective investors are urged to consult their own tax advisors regarding the application of federal income
tax laws to their particular circumstances, as well as any state, provincial, local, non-U.S. and other tax consequences of investing
in the Common Shares and acquiring, holding or disposing of the Common Shares.
 


86
 

 
Passive Foreign Investment Company Rules
 
A non-U.S. corporation is considered a PFIC for
any taxable year if either:
 

●at least 75% of its gross income for such taxable year is passive income;
or
 

●at least 50% of the value of its assets (based on an average of the quarterly
values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income (the
“asset test”).
 
Passive income generally includes dividends, interest,
rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition
of passive assets. We will be treated as owning our proportionate share of the assets and earning our proportionate share of the income
of any other corporation in which we own, directly or indirectly, at least 25% (by value) of the shares. In determining the value and
composition of our assets for purposes of the PFIC asset test, the value of our assets must be determined based on the market value of
our Common Shares from time to time, which could cause the value of our non-passive assets to be less than 50% of the value of all of
our assets on any particular quarterly testing date for purposes of the asset test.
 
We must make a separate determination each year
as to whether we are a PFIC. Depending on the amount of our cash and other assets held for the production of passive income, it is possible
that, for our current taxable year or for any subsequent taxable year, more than 50% of our assets may be assets held for the
production of passive income. We will make this determination following the end of any particular tax year. Although the law in this
regard is unclear, we treat our consolidated affiliated entities as being owned by us for United States federal income tax purposes, not
only because we exercise effective control over the operation of such entities but also because we are entitled to substantially all of
their economic benefits, and, as a result, we consolidate their operating results in our consolidated financial statements. In particular,
because the value of our assets for purposes of the asset test will generally be determined based on the market price of our Common Shares
and because cash is generally considered to be an asset held for the production of passive income, our PFIC status will depend in large
part on the market price of our Common Shares and the amount of our cash and other assets held for the production of passive income. Accordingly,
fluctuations in the market price of the Common Shares may cause us to become a PFIC. In addition, the application of the PFIC rules is
subject to uncertainty in several respects. We are under no obligation to take steps to reduce the risk of our being classified as a PFIC.
As stated above, the determination of the value of our assets will depend upon material facts (including the market price of our Common
Shares from time to time) that may not be within our control, and no opinion of counsel has or will be provided regarding our classification
as a PFIC. If we are a PFIC for any year during which you hold Common Shares, we will continue to be treated as a PFIC for all succeeding years
during which you hold Common Shares. However, if we cease to be a PFIC and you did not previously make a timely “mark-to-market”
election as described below, you may avoid some of the adverse effects of the PFIC regime by making a “purging election” (as
described below) with respect to the Common Shares.
 
If we are a PFIC for your taxable year(s) during
which you hold Common Shares, you will be subject to special tax rules with respect to any “excess distribution” that
you receive and any gain you realize from a sale or other disposition (including a pledge) of the Common Shares, unless you make a “mark-to-market”
election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions
you received during the shorter of the three preceding taxable years or your holding period for the Common Shares will be treated
as an excess distribution. Under these special tax rules:
 

●the excess distribution or gain will be allocated ratably over your holding
period for the Common Shares;
 

●the amount allocated to your current taxable year, and any amount allocated
to any of your taxable year(s) prior to the first taxable year in which we were a PFIC, will be treated as ordinary income, and
 

●the amount allocated to each of your other taxable year(s) will be subject
to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on
the resulting tax attributable to each such year.
 
The tax liability for amounts allocated to years
prior to the year of disposition or “excess distribution” cannot be offset by any net operating losses for such years,
and gains (but not losses) realized on the sale of the Common Shares cannot be treated as capital, even if you hold the Common Shares
as capital assets.
 
A U.S. Holder of “marketable stock”
(as defined below) in a PFIC may make a mark-to-market election for such stock to elect out of the tax treatment discussed above. If you
make a mark-to-market election for the first taxable year during which you hold (or are deemed to hold) Common Shares and for which
we are determined to be a PFIC, you will include in your income each year an amount equal to the excess, if any, of the fair market
value of the Common Shares as of the close of such taxable year over your adjusted basis in such Common Shares, which excess will
be treated as ordinary income and not capital gain. You are allowed an ordinary loss for the excess, if any, of the adjusted basis of
the Common Shares over their fair market value as of the close of the taxable year. However, such ordinary loss is allowable only
to the extent of any net mark-to-market gains on the Common Shares included in your income for prior taxable years. Amounts included
in your income under a mark-to-market election, as well as gain on the actual sale or other disposition of the Common Shares, are treated
as ordinary income. Ordinary loss treatment also applies to any loss realized on the actual sale or disposition of the Common Shares,
to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such Common Shares. Your
basis in the Common Shares will be adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market election, the
tax rules that apply to distributions by corporations which are not PFICs would apply to distributions by us, except that the lower
applicable capital gains rate for qualified dividend income discussed above under “— Taxation of Dividends and Other Distributions
on our Common Shares” generally would not apply.
 


87
 

 
The mark-to-market election is available only
for “marketable stock”, which is stock that is traded in other than de minimis quantities on at least 15 days during
each calendar quarter (“regularly traded”) on a qualified exchange or other market (as defined in applicable U.S. Treasury
regulations), including Nasdaq. U.S. holders should consult their own tax advisors regarding the availability and tax consequences of
a mark-to-market election in respect to our Common Shares under their particular circumstances.
 
Alternatively, a U.S. Holder of stock in a PFIC
may make a “qualified electing fund” election with respect to such PFIC to elect out of the tax treatment discussed above.
A U.S. Holder who makes a valid qualified electing fund election with respect to a PFIC will generally include in gross income for a taxable year
such holder’s pro rata share of the corporation’s earnings and profits for the taxable year. However, the qualified electing
fund election is available only if such PFIC provides such U.S. Holder with certain information regarding its earnings and profits as
required under applicable U.S. Treasury regulations. We do not currently intend to prepare or provide the information that would enable
you to make a qualified electing fund election. If you hold Common Shares in any taxable year in which we are a PFIC, you will be
required to file IRS Form 8621 in each such year and provide certain annual information regarding such Common Shares, including
regarding distributions received on the Common Shares and any gain realized on the disposition of the Common Shares.
 
If you do not make a timely “mark-to-market”
election (as described above), and if we were a PFIC at any time during the period you hold our Common Shares, then such Common Shares
will continue to be treated as stock of a PFIC with respect to you even if we cease to be a PFIC in a future year, unless you make
a “purging election” for the year we cease to be a PFIC. A “purging election” creates a deemed sale of such
Common Shares at their fair market value on the last day of the last year in which we are treated as a PFIC. The gain recognized
by the purging election will be subject to the special tax and interest charge rules treating the gain as an excess distribution,
as described above. As a result of the purging election, you will have a new basis (equal to the fair market value of the Common Shares
on the last day of the last year in which we are treated as a PFIC) and holding period (which new holding period will begin the day
after such last day) in your Common Shares for tax purposes.
 
You are urged to consult your tax advisors regarding
the application of the PFIC rules to your investment in our Common Shares and the elections discussed above.
 
Distributions on Common Shares
 
In general, subject to the PFIC rules discussed
above, the gross amount of any distribution received by a U.S. Holder with respect to the Common Shares (including amounts withheld to
pay Canadian withholding taxes) will be included in the gross income of the U.S. Holder as a dividend to the extent attributable to the
Company’s current and accumulated earnings and profits, as determined under U.S. federal income tax principles. Because the Company
does not expect to maintain calculations of the Company’s earnings and profits in accordance with U.S. federal income tax principles,
U.S. Holders should expect that a distribution will generally be treated as a dividend for U.S. federal income tax purposes.
 
The amount of any distributions paid in Canadian
dollars will equal the U.S. dollar value of such distributions determined by reference to the exchange rate on the day they are received
by the U.S. Holder (with the value of such distributions computed before any reduction for any Canadian withholding tax), regardless of
whether the payment is in fact converted into U.S. dollars at that time. A U.S. Holder will have a tax basis in Canadian dollars equal
to their U.S. dollar value on the date of receipt. If the Canadian dollars received are converted into U.S. dollars on the date of receipt,
the U.S. Holder will generally not be required to recognize foreign currency gain or loss in respect of the distribution. If the Canadian
dollars received are not converted into U.S. dollars on the date of receipt, a U.S. Holder may recognize foreign currency gain or loss
on a subsequent conversion or other disposition of the Canadian dollars. Such gain or loss generally will be treated as U.S. source ordinary
income or loss.
 


88
 

 
Subject to applicable limitations and provided
the Company is eligible for the benefits of the US Treaty or the Common Shares are readily tradable on a United States securities market,
dividends paid by the Company to non-corporate US Holders, including individuals, generally will be eligible for the preferential tax
rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including
that the Company is not classified as a PFIC in the tax year of distribution or in the preceding tax year. Any amount of distributions
treated as dividends generally will not be eligible for the dividends received deduction available to certain corporate U.S. Holders in
respect of dividends received from U.S. corporations.
 
Distributions to a U.S. Holder with respect to
the Common Shares may be subject to Canadian non-resident withholding tax. Any Canadian withholding tax paid will not reduce the amount
treated as received by the U.S. Holder for U.S. federal income tax purposes. However, subject to limitations imposed by U.S. law, a U.S.
Holder may be eligible to receive a foreign tax credit for the Canadian withholding tax. The rules governing the foreign tax credit
are complex. U.S. Holders are urged to consult their own tax advisors regarding the availability of the foreign tax credit under their
particular circumstances, including the impact of, and any exception available to, the special income sourcing rule described in
this paragraph. U.S. Holders who do not elect to claim a foreign tax credit may be able to claim an ordinary income tax deduction for
Canadian income tax withheld, but only for a taxable year in which the U.S. Holder elects to do so with respect to all non-U.S. income
taxes paid or accrued in such taxable year.
 
Sale, Exchange or Other Taxable Disposition of Common Shares
 
Subject to the PFIC rules discussed above,
upon a sale, exchange or other taxable disposition of the Common Shares, a U.S. Holder will generally recognize a capital gain or loss
equal to the difference between the amount realized on such sale, exchange or other taxable disposition and the adjusted tax basis of
such Common Shares. If any foreign tax is imposed on the sale, exchange or other disposition of the Common Shares, a U.S. Holder’s
amount realized will include the gross amount of the proceeds of the disposition before deduction of the tax. A U.S. Holder’s initial
tax basis in the Common Shares generally will equal the cost of such Common Shares. Such gain or loss will be a long-term capital gain
or loss if the Common Shares have been held for more than one year and will be short-term gain or loss if the holding period is equal
to or less than one year. Such gain or loss generally will be considered U.S. source gain or loss for U.S. foreign tax credit purposes.
Long-term capital gains of certain non-corporate U.S. Holders are eligible for reduced rates of taxation. For both corporate and non-corporate
U.S. Holders, limitations apply to the deductibility of capital losses.
 
Information Reporting and Backup Withholding
 
In general, dividends paid to a U.S. Holder in
respect of the Common Shares and the proceeds received by a U.S. Holder from the sale, exchange or other disposition of the Common Shares
within the United States or through certain U.S.-related financial intermediaries will be subject to U.S. information reporting rules,
unless a U.S. Holder is a corporation or other exempt recipient and properly establishes such exemption. Backup withholding may apply
to such payments if a U.S. Holder does not establish an exemption from backup withholding and fails to provide a correct taxpayer identification
number and make any other required certifications.
 
Backup withholding is not an additional tax. Any
amounts withheld under the backup withholding rules will be allowed as a refund or credit against U.S. federal income tax liability,
provided that the required information is timely furnished to the IRS.
 
In addition, U.S. Holders should be aware of reporting
requirements with respect to the holding of certain foreign financial assets, including stock of foreign issuers which is not held in
an account maintained by certain financial institutions, if the aggregate value of all of such assets exceeds U.S.$50,000. U.S. Holders
must attach a complete IRS Form 8938, Statement of Specified Foreign Financial Assets, with their return for each year in which
they hold the Common Shares. U.S. Holders should also be aware that if the Company were a PFIC, they would generally be required to file
IRS Form 8261, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund, during any
taxable year in which such U.S. Holder recognizes gain or receives an excess distribution or with respect to which the U.S. Holder
has made certain elections. U.S. Holders are urged to consult their own tax advisors regarding the application of the information reporting
rules to the Common Shares and their particular situations.
 


89
 

 
Material Canadian Federal Income Tax Considerations
 
The following is a summary of the principal Canadian
federal income tax considerations generally applicable to a person (a “Holder”) who acquires as a beneficial owner
our Common Shares, and who, at all relevant times, for purposes of the application of the Income Tax Act (Canada) and the regulations
adopted thereunder (collectively, the “Canada Tax Act”): (i) deals at arm’s length with the Company; (ii) is
not affiliated with the Company; (iii) holds our Common Shares as capital property; and (iv) has not entered into, with respect to any
of our Common Shares, a “derivative forward agreement” or a “dividend rental arrangement,” each as defined in
the Canada Tax Act. Generally, our Common Shares will be capital property to a Holder provided the Holder does not acquire or hold such
Common Shares in the course of carrying on a business or as part of an adventure or concern in the nature of trade.
 
This summary is based upon the current provisions
of the Canada Tax Act, and an understanding of the current administrative practices published in writing by the Canada Revenue Agency
prior to the date hereof. This summary takes into account all specific proposals to amend the Canada Tax Act publicly announced by, or
on behalf of, the Minister of Finance (Canada) prior to the date hereof (the “Proposed Amendments”) and assumes that
all Proposed Amendments will be enacted in the form proposed. This summary does not otherwise take into account or anticipate any changes
in law or administrative policy, whether by legislative, governmental or judicial decision or action, and does not take into account or
consider any provincial, territorial or foreign income tax considerations.
 
This summary is of a general nature only and is not exhaustive of
all possible Canadian federal income tax considerations. It is not, is not intended to be, and should not be construed to be legal or
tax advice to any particular Holder. Accordingly, Holders are urged to consult their own tax advisors having regard to their own particular
circumstances.
 
Currency Conversion
 
Generally, for purposes of the Canada Tax Act,
all amounts relating to the acquisition, holding or disposition of our Common Shares must be expressed into Canadian dollars. Amounts
denominated in another currency must be converted into Canadian dollars based on exchange rates as determined in accordance with the Canada
Tax Act.
 
Holders Not Resident in Canada
 
The following portion of the summary is generally
applicable to a Holder who, at all relevant times, for purposes of the Canada Tax Act: (i) is not, and is not deemed to be, a resident
of Canada, and (ii) does not use or hold, and is not deemed to use or hold, our Common Shares in a business carried on in Canada (a “Non-Resident
Holder”). Special rules, which are not discussed in this summary, may apply to a Non-Resident Holder that is an insurer that
carries on an insurance business in Canada and elsewhere.
 
Dividends
 
Dividends paid or credited, or deemed under the
Canada Tax Act to be paid or credited, by the Company to a Non-Resident Holder on our Common Shares will generally be subject to Canadian
withholding tax under the Canada Tax Act at the rate of 25% of the gross amount of the dividend, subject to any reduction in the rate
of withholding to which the Non-Resident Holder is entitled under any applicable income tax convention.
 
Dispositions
 
A Non-Resident Holder for whom our Common Shares
are not or are not deemed to be “taxable Canadian property” for purposes of the Canada Tax Act will generally not be subject
to income tax under the Canada Tax Act on the disposition or deemed disposition of such shares.
 
Generally, provided that our Common Shares are
listed on a “designated stock exchange” (which includes the Nasdaq), our Common Shares will not be taxable Canadian property
to a Non-Resident Holder at a particular time unless at any time during the 60-month period that ends at that particular time, both of
the following conditions were satisfied: (a) one or any combination of (i) the Non-Resident Holder, (ii) persons with whom the Non-Resident
Holder did not deal at arm’s length (for purposes of the Canada Tax Act), and (iii) partnerships in which the Non-Resident Holder
or a person with whom the Non-Resident Holder did not deal at arm’s length held a membership interest directly or indirectly through
one or more partnerships, owned 25% or more of the issued shares of any class or series of a class of the capital stock of the Company,
and at that time (b) more than 50% of the fair market value of our Common Shares was derived directly or indirectly from one or any combination
of real or immovable property situated in Canada, “Canadian resource properties” (as defined in the Canada Tax Act), “timber
resource properties” (as defined in the Canada Tax Act) or options in respect of, interests in, or for civil law rights in, any
such property, whether or not such property exists. Notwithstanding the foregoing, our Common Shares may otherwise be deemed to be taxable
Canadian property of a Non-Resident Holder in certain circumstances. The Non-Resident Holders for whom Common Shares may constitute taxable
Canadian property should consult their own tax advisors.
 


90
 

 
Holders Resident in Canada
 
The following portion of the summary is generally
applicable to a Holder who, at all relevant times, for purposes of the Canada Tax Act, is or is deemed to be resident in Canada (a “Canadian
Resident Holder”). Certain Canadian Resident Holders may be entitled to make, or may have already made, the irrevocable election
permitted by subsection 39(4) of the Canada Tax Act the effect of which may be to deem to be capital property any of our Common Shares
(and all other “Canadian securities”, as defined in the Canada Tax Act) owned by such Resident Holder in the taxation year
in which the election is made and in all subsequent taxation years. Resident Holders whose Common Shares might not otherwise be considered
to be capital property should consult their own tax advisors concerning this election.
 
This portion of the summary is not
applicable to a Canadian Resident Holder (i) that is a “specified financial institution”, (ii) an interest in which is,
or for whom the Securities would be, a “tax shelter investment”, (iii) that is a “financial institution” for
purposes of the “mark-to-market” rules in the Canada Tax Act, (iv) that reports its “Canadian tax results”
in a currency other than Canadian currency, or (v) that is a corporation resident in Canada that is, becomes, or does not deal at
arm’s length for purposes of the Canada Tax Act with a corporation resident in Canada that is or becomes, as part of a
transaction or event or series of transactions or events that includes the acquisition of our Common Shares, controlled by a
non-resident person (or a group of such persons not dealing with each other at arm’s length) for purposes of the
“foreign affiliate dumping” rules in section 212.3 of the Canada Tax Act.
 
Dividends
 
A Canadian Resident Holder will be required to
include in computing its income for a taxation year any dividends received (or deemed to have been received) on our Common Shares. In
the case of a Canadian Resident Holder that is an individual (other than certain trusts), such dividends will be subject to the gross-up
and dividend tax credit rules applicable to taxable dividends received from “taxable Canadian corporations”, including the
enhanced gross-up and dividend tax credit applicable to any dividends designated by the Company as an “eligible dividend”
in accordance with the provisions of the Canada Tax Act. A dividend received (or deemed to have been received) by a Canadian Resident
Holder that is a corporation will generally be deductible in computing the corporation’s taxable income. In certain circumstances,
however, a taxable dividend received (or deemed to have been received) by a Canadian Resident Holder that is a corporation will be deemed
to be either proceeds of disposition or a gain from the disposition of a capital property. Canadian Resident Holders that are corporations
should consult their own tax advisors having regard to their own particular circumstances.
 
A Canadian Resident Holder that is a “private
corporation”, as defined in the Canada Tax Act, or any other corporation controlled, whether because of a beneficial interest in
one or more trusts or otherwise, by or for the benefit of an individual (other than a trust) or a related group of individuals (other
than trusts), will generally be liable to pay a refundable tax under Part IV of the Canada Tax Act on dividends received (or deemed to
have been received) on our Common Shares to the extent such dividends are deductible in computing the Canada Resident Holder’s taxable
income for the taxation year.
 
Dividends received or deemed to be received by
a Canadian Resident Holder who is an individual (other than certain trusts) may result in such Canadian Resident Holder being liable for
alternative minimum tax under the Canada Tax Act.
 
Dispositions
 
Generally, a Canadian Resident Holder who disposes
of, or is deemed for purposes of the Canada Tax Act to have disposed of our Common Shares will realize a capital gain (or a capital loss)
in the taxation year of the disposition equal to the amount by which the proceeds of disposition of the Common Shares exceed (or are less
than) the total of (1) the adjusted cost base to the Canadian Resident Holder of the Common Shares determined immediately before the disposition,
and (2) any reasonable costs of disposition.
 


91
 

 
Subject to the Capital Gains Proposal (as defined
and discussed below), (i) one-half of any capital gain (a “taxable capital gain”) realized by a Canadian Resident Holder from
a disposition of our Common Shares must be included in the Canadian Resident Holder’s income for the taxation year of disposition,
and (ii) subject to and in accordance with the provisions of the Canada Tax Act, a Canadian Resident Holder will generally be required
to deduct one-half of any capital loss (an “allowable capital loss”) realized in the taxation year of disposition against
taxable capital gains realized in the same taxation year. Any unused allowable capital losses for the taxation year of disposition may
generally reduce net taxable capital gains realized in any of the three prior taxation years or in any subsequent year in the circumstances
and to the extent provided in the Canada Tax Act.
 
On June 10, 2024, the Minister of Finance released
draft legislation to increase the proportion of a capital gain that must be included in income, or the proportion of a capital loss that
constitutes an allowable capital loss, as discussed above, from one-half to two-thirds, effective for dispositions on or after June 25,
2024 (the “Capital Gains Proposal”). The Capital Gains Proposal provides that the one-half proportion would continue
to apply to resident individuals (other than trusts) with respect to up to $250,000 of capital gains (net of capital losses) per year,
and also provides for adjustments of carried forward or carried back allowable capital losses to account for changes in the relevant inclusion
rates. However, the draft legislation to implement the Capital Gains Proposal is complex and incomplete and subject to potential changes.
Canadian Resident Holders that realize capital gains in connection with their Common Shares should consult their own tax advisors in this
regard.
 
A Canadian Resident Holder that is an individual
(other than certain trusts) that realizes a capital gain on the disposition or deemed disposition of our Common Shares may be liable for
alternative minimum tax under the Canada Tax Act.
 
If a Canadian Resident Holder is a corporation,
any capital loss realized on a disposition or deemed disposition of our Common Shares may, in certain circumstances, be reduced by the
amount of any dividends which have been received or which are deemed to have been received on such Common Shares. Similar rules may apply
where a Canadian Resident Holder that is a corporation is a member of a partnership or a beneficiary of a trust that owns our Common Shares
directly or indirectly through a partnership or a trust. Canadian Resident Holders to whom these rules may be relevant should consult
their own tax advisors.
 
Additional Refundable Tax
 
A Canadian Resident Holder that is a “Canadian-controlled
private corporation” (as defined in the Canada Tax Act) throughout the relevant taxation year or a “substantive CCPC”
(as defined in the Canada Tax Act) at any time in the year, may be liable to pay an additional tax (refundable in certain circumstances)
on its “aggregate investment income” (as defined in the Canada Tax Act) for the year, including taxable capital gains realized
on the disposition of our Common Shares. Canadian Resident Holders that are “Canadian-controlled private corporations” or
“substantive CCPCs” should consult their own tax advisors regarding their particular circumstances.
 
Eligibility for Investment
 
Provided that our Common Shares are listed on
a “designated stock exchange” for the purposes of the Canada Tax Act (which currently includes the Nasdaq Global Market),
our Common Shares will be, at such time, “qualified investments” under the Canada Tax Act for trusts governed by a registered
retirement savings plan (“RRSP”), a registered retirement income fund (“RRIF”), a registered education
savings plan (“RESP”), a deferred profit sharing plan, a registered disability savings plan (“RDSP”),
a tax-free savings account (“TFSA”), or a first home savings account (“FHSA”), each as defined in
the Canada Tax Act.
 
Notwithstanding the foregoing, if our Common Shares
held by a TFSA, RRSP, RRIF, RDSP, FHSA, or RESP (a “Registered Plan”) are “prohibited investments” for
purposes of the Canada Tax Act, the holder of the TFSA, FHSA or RDSP, the annuitant of the RRSP or RRIF, or the subscriber of a RESP (as
the case may be) will be subject to a penalty tax as set out in the Canada Tax Act. Our Common Shares will generally be a “prohibited
investment” if the holder of a TFSA, FHSA or RDSP, the annuitant of a RRSP or RRIF, or the subscriber of a RESP (as the case may
be): (i) does not deal at arm’s length with the Company for purposes of the Canada Tax Act; or (ii) has a “significant interest”
(within the meaning of the Canada Tax Act) in the Company. In addition, our Common Shares will not be a prohibited investment if such
Common Shares are “excluded property”, as defined in the Canada Tax Act, for the Registered Plan. Holders who intend to hold
our Common Shares in a Registered Plan should consult their own tax advisors in this regard.
 


92
 

 
EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT
ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN COMMON SHARES IN LIGHT OF THE INVESTOR’S OWN CIRCUMSTANCES.
 
F. Dividends
and Paying Agents
 
Not applicable.
 
G. Statement
by Experts
 
Not applicable.
 
H. Documents on Display
 
We are subject to the informational requirements
of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports on Form 20-F
and reports on Form 6-K. The SEC maintains an Internet site at www.sec.gov that contains reports, proxy and information statements
and other information we have filed electronically with the SEC. As a foreign private issuer, we are exempt under the Exchange Act from,
among other things, the rules prescribing the furnishing and content of proxy statements, and our executive officers, directors and
principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently
or as promptly as U.S. companies whose securities are registered under the Exchange Act.
 
We also make available on our website, free of
charge, our annual reports and the text of our reports on Form 6-K, including any amendments to these reports, as well as certain
other SEC filings, as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Our website address
is www.psyence.com. The reference to our website is an inactive textual reference only, and information contained therein or connected
thereto is not incorporated into this Report.
 
I. Subsidiary
Information
 
Not applicable.
 
J. Annual
Report to Security Holders.
 
Not applicable.
 
ITEM 11. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISKS
 
The information set forth under Item 5 above
is incorporated into herein by reference.
 
ITEM 12. DESCRIPTION OF SECURITIES OTHER
THAN EQUITY SECURITIES
 
A. Debt Securities
 
The information pertaining to the Notes and
set forth in Item 10.C herein under the section titled “Material Contracts—Securities Purchase Agreement”
is incorporated herein by reference.
 
B. Warrants and Rights
 
Warrants
 
Public Warrants
 
Each the Public Warrant shall entitle the registered
holder thereof to purchase one whole Common Share at a price of $6,874.13 per share, subject to adjustment as discussed below, at any
time commencing on February 24, 2024 and will expire on January 25, 2029, at 5:00 p.m., New York City time.
 
The Company will not be obligated to deliver any
Common Shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration
statement under the Securities Act with respect to the Common Shares underlying the warrants is then effective and a prospectus relating
thereto is current, subject to the Company satisfying its obligations described below with respect to registration. No warrant will be
exercisable and the Company will not be obligated to issue Common Shares upon exercise of a warrant unless Common Shares issuable upon
such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the
registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with
respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and
expire worthless.
 


93
 

 
The Public Warrants and the Common Shares issuable
upon exercise of the Public Warrants have been registered on the Form F-4 filed in connection with the Business Combination. The
Company will use its best efforts to maintain the effectiveness of such registration statement, and a current prospectus relating thereto,
until the expiration of the warrants in accordance with the provisions of the warrant agreement. Notwithstanding the above, if the Common
Shares are at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition
of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders
of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of
the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement,
but the Company will be required to use its best efforts to register or qualify the shares under applicable blue sky laws to the extent
an exemption is not available.
 
Once the warrants become exercisable, we may call
the warrants for redemption:
 

●in whole and not in part;
 

●at a price of US$0.01 per warrant;
 

●upon not less than 30 days’ prior written notice of redemption (the
“30-day redemption period”) to each warrant holder; and
 

●if, and only if, the reported last sale price of Common Shares equals or
exceeds US$10,759.50 per share for any 20 trading days within a 30-trading day period ending three business days before we send the notice
of redemption to the warrant holders.
 
If and when the warrants become redeemable by
us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable
state securities laws.
 
We have established the last of the redemption
criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise
price. If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled
to exercise its warrant prior to the scheduled redemption date. However, the price of Common Shares may fall below the US$10,759.50 redemption
trigger price as well as the US$6,874.13 warrant exercise price after the redemption notice is issued.
 
If we call the warrants for redemption as described
above, our management will have the option to require any holder that wishes to exercise its warrant to do so on a “cashless basis.”
This redemption feature may differ from the warrant redemption features used by other blank check companies. In determining whether to
require all holders to exercise their warrants on a “cashless basis,” our management will consider, among other factors, our
cash position, the number of warrants that are outstanding and the dilutive effect on our shareholders of issuing the maximum number of
Common Shares issuable upon the exercise of our warrants. If our management takes advantage of this option, all holders of warrants would
pay the exercise price by surrendering their warrants for that number of Common Shares equal to the quotient obtained by dividing (x) the
product of the number of Common Shares underlying the warrants, multiplied by the difference between the exercise price of the warrants
and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean
the average reported last sale price of the Common Shares for the 10 trading days ending on the third trading day prior to the date
on which the notice of redemption is sent to the holders of warrants. As an example, if we elect to call the warrants for redemption on
a “cashless basis” in accordance with the redemption criteria described above and the “fair market value” is determined
to be US$10,759.50 per share, then a holder of warrants for the purchase of 100 shares of our Common Shares would receive 36 shares of
our Common Shares upon such exercise. The “fair market value” for these purposes may be higher or lower than the US$10,759.500
redemption trigger price and will only be determinable when we elect to send a notice of redemption to holders of the warrants. If a holder
does not exercise his or her warrants within the redemption period, then he or she will be forced to accept the nominal redemption price
of US$0.01 per warrant which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than
the market value of such warrants. If we call our warrants for redemption and our Private Warrants and their permitted transferees would
still be entitled to exercise their Private Warrants for cash or on a cashless basis using the same formula described above that other
warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis,
as described in more detail below.
 


94
 

 
A holder of a warrant may notify us in writing
in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent
that after giving effect to such exercise, such person (together with such person’s affiliates), to the warrant agent’s actual
knowledge, would beneficially own in excess of 9.8% (or such other amount as a holder may specify) of the Common Shares outstanding immediately
after giving effect to such exercise.
 
If the number of outstanding Common Shares is
increased by a share dividend payable in Common Shares, or by a split-up of Common Shares or other similar event, then, on the effective
date of such share dividend, sub-division or similar event, the number of Common Shares issuable on exercise of each warrant will be increased
in proportion to such increase in the outstanding Common Shares. A rights offering to holders of Common Shares entitling holders to purchase
Common Shares at a price less than the fair market value will be deemed a share dividend of a number of Common Shares equal to the product
of (i) the number of Common Shares actually sold in such rights offering (or issuable under any other equity securities sold in such
rights offering that are convertible into or exercisable for Common Shares) multiplied by (ii) one (1) minus the quotient of
(x) the price per share of Common Shares paid in such rights offering divided by (y) the fair market value. For these purposes
(i) if the rights offering is for securities convertible into or exercisable for Common Shares, in determining the price payable
for Common Shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable
upon exercise or conversion and (ii) fair market value means the volume weighted average price of Common Shares as reported during
the ten (10) trading day period ending on the trading day prior to the first date on which the Common Shares trade on the applicable
exchange or in the applicable market, regular way, without the right to receive such rights.
 
In addition, if the Company, at any time while
the warrants are outstanding and unexpired, pays a dividend or make a distribution in cash, securities or other assets to the holders
of Common Shares on account of such Common Shares (or other shares of the Company’s capital stock into which the warrants are convertible),
other than (a) as described above, (b) certain ordinary cash dividends, or (c) to satisfy the redemption rights of the
holders of Common Shares in connection with a proposed initial business combination, then the warrant exercise price will be decreased,
effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or
other assets paid on each share of Common Shares in respect of such event.
 
If the number of outstanding Common Shares is
decreased by a consolidation, combination, reverse stock split or reclassification of Common Shares or other similar event, then, on the
effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of Common Shares
issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding Common Shares.
 
Whenever the number of Common Shares purchasable
upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant
exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of Common Shares
purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the denominator of which will be the
number of Common Shares so purchasable immediately thereafter.
 
In case of any reclassification or reorganization
of the outstanding Common Shares (other than those described above or that solely affects the par value of such Common Shares), or in
the case of any merger or consolidation of the Company with or into another corporation (other than a consolidation or merger in which
the Company is the continuing corporation and that does not result in any reclassification or reorganization of outstanding Common Shares),
or in the case of any sale or conveyance to another corporation or entity of the assets or other property of the Company as an entirety
or substantially as an entirety in connection with which the Company is dissolved, the holders of the warrants will thereafter have the
right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the shares of
its Common Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and
amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger
or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such
holder had exercised their warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of
Common Shares in such a transaction is payable in the form of Common Shares in the successor entity that is listed for trading on a national
securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following
such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure
of such transaction, the warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes value
(as defined in the warrant agreement) of the warrant.
 


95
 

 
The warrants will be issued in registered form
under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and the Company. You should review
a copy of the warrant agreement, which is filed as an exhibit to the registration statement of which this prospectus is a part, for a
complete description of the terms and conditions applicable to the warrants. The warrant agreement provides that the terms of the warrants
may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by
the holders of at least 50% of the then outstanding Public Warrants to make any change that adversely affects the interests of the registered
holders of Public Warrants.
 
The warrants may be exercised upon surrender of
the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse
side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless
basis, if applicable), by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant
holders do not have the rights or privileges of holders of Common Shares and any voting rights until they exercise their warrants and
receive Common Shares. After the issuance of Common Shares upon exercise of the warrants, each holder will be entitled to one vote for
each share held of record on all matters to be voted on by shareholders.
 
No fractional shares will be issued upon exercise
of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company
will, upon exercise, round down to the nearest whole number of Common Shares to be issued to the warrant holder.
 
Private Warrants
 
The Private Warrants were assumed by the Company
upon the consummation of the Business Combination, and after the Business Combination, each warrant is exercisable for one Common Share
and will expire on January 25, 2029, at 5:00 p.m., New York City time.
 
The Private Warrants may be exercised on a cashless
basis and will not be redeemable by the Company so long as they are held by the initial holders thereof or their permitted transferees.
Otherwise, the Private Warrants have terms and provisions that are identical to those of the Public Warrants. If the Private Warrants
are held by holders other than the initial holders thereof or their permitted transferees, the Private Warrants will be redeemable by
the Company and exercisable by the holders on the same basis as the Public Warrants. If holders of the Private Warrants elect to exercise
them on a cashless basis, they would pay the exercise price by surrendering their warrants for that number of Common Shares equal to the
quotient obtained by dividing (x) the product of the number of Common Shares underlying the warrants, multiplied by the difference between
the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair
market value” shall mean the average reported last sale price of the Common Shares for the 10 trading days ending on the third trading
day prior to the date on which the notice of warrant exercise is sent to the warrant agent.
 
Investor Private Warrants
 
On January 15, 2024, the Company issued warrants
in connection with the SPA Addendum. The holders of such warrants are entitled to purchase Common Shares for cash at an exercise price
of $298.88 per Warrant Share, subject to adjustment. Such warrants are exercisable at any time from the issuance date to the date that
is the two year anniversary of the issuance date. Adjustments may occur if the company undergoes share dividends, splits, or fundamental
transactions. The warrant can be exercised in part, and no fractional shares will be issued. Additionally, there are beneficial ownership
limitations and provisions for buy-in compensation in case of a failure to deliver shares. The warrant holders do not have the rights
or privileges of holders of Common Shares and any voting rights until they exercise their warrants and receive Common Shares. After the
issuance of Common Shares upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all
matters to be voted on by shareholders. The foregoing description of the such warrants is qualified in its entirety by the full text of
the warrants, which is attached as Exhibit 4.3 to this registration statement of which this prospectus is a part, and is incorporated
herein by reference.
 


96
 

 
Series A Warrants
 
On December 27, 2024, in connection with the closing
of the PIPE Transaction, the Company issued the Series A Warrants to purchase up to 125,471 Common Shares at an exercise price of $15.94
per share to certain of the Selling Securityholders. Such warrants are exercisable at any time from the issuance date to the date that
is the five year anniversary of the issuance date. Adjustments may occur if the Company undergoes share dividends, splits, or fundamental
transactions. The warrant can be exercised in part, and no fractional shares will be issued. Additionally, there are beneficial ownership
limitations that may be waived at the option of each holder upon 61 days’ notice to the Company, but in no event may such beneficial
ownership limitation exceed 19.99% of the number of shares of outstanding Common Stock. The warrant holders do not have the rights or
privileges of holders of Common Shares and any voting rights until they exercise their warrants and receive Common Shares. After the issuance
of Common Shares upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters
to be voted on by shareholders. If holders of the warrants elect to exercise them on a cashless basis, they would pay the exercise price
by surrendering their warrants for that number of Common Shares equal to the quotient obtained by dividing (x) the product of the number
of Common Shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair
market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported
last sale price of the Common Shares for the 10 trading days ending on the third trading day prior to the date on which the notice of
warrant exercise is sent to the warrant agent.
 
The foregoing description of the Series A Warrants
is qualified in its entirety by the full text of the warrants, which is attached as Exhibit 4.5 to this registration statement of which
this prospectus is a part, and is incorporated herein by reference.
 
Series B Warrants
 
On December 27, 2024, in connection with the closing
of the PIPE Transaction, the Company issued the Series B Warrants to purchase up to 125,471 Common Shares at an exercise price of $15.94
per share to certain of the Selling Securityholders. Such warrants are exercisable at any time from the issuance date to the date that
is the two year anniversary of the issuance date. Adjustments may occur if the Company undergoes share dividends, splits, or fundamental
transactions. The warrant can be exercised in part, and no fractional shares will be issued. Additionally, there are beneficial ownership
limitations that may be waived at the option of each holder upon 61 days’ notice to the Company, but in no event may such beneficial
ownership limitation exceed 19.99% of the number of shares of outstanding Common Stock. The warrant holders do not have the rights or
privileges of holders of Common Shares and any voting rights until they exercise their warrants and receive Common Shares. After the issuance
of Common Shares upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters
to be voted on by shareholders. If holders of the warrants elect to exercise them on a cashless basis, they would pay the exercise price
by surrendering their warrants for that number of Common Shares equal to the quotient obtained by dividing (x) the product of the number
of Common Shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair
market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported
last sale price of the Common Shares for the 10 trading days ending on the third trading day prior to the date on which the notice of
warrant exercise is sent to the warrant agent.
 
The foregoing description of the Series B Warrants
is qualified in its entirety by the full text of the warrants, which is attached as Exhibit 4.6 to this registration statement of which
this prospectus is a part, and is incorporated herein by reference.
 
Placement Agent Warrants
 
On December 27, 2024, in connection with the closing
of the PIPE Transaction, the Company issued the Placement Agent Warrants to purchase up to 9,409 Common Shares at an exercise price of
$19.93 per share to the Placement Agent or its designees. Such warrants are exercisable at any time from the issuance date to the date
that is the five year anniversary of the issuance date. Adjustments may occur if the company undergoes share dividends, splits, or fundamental
transactions. The warrant can be exercised in part, and no fractional shares will be issued. Additionally, there are beneficial ownership
limitations that may be waived at the option of each holder upon 61 days’ notice to the Company, but in no event may such beneficial
ownership limitation exceed 19.99% of the number of shares of outstanding Common Stock. The warrant holders do not have the rights or
privileges of holders of Common Shares and any voting rights until they exercise their warrants and receive Common Shares. After the issuance
of Common Shares upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters
to be voted on by shareholders. If holders of the warrants elect to exercise them on a cashless basis, they would pay the exercise price
by surrendering their warrants for that number of Common Shares equal to the quotient obtained by dividing (x) the product of the number
of Common Shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair
market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported
last sale price of the Common Shares for the 10 trading days ending on the third trading day prior to the date on which the notice of
warrant exercise is sent to the warrant agent.
 
The foregoing description of the Placement Agent
Warrants is qualified in its entirety by the full text of the warrants, which is attached as Exhibit 4.7 to this registration statement
of which this prospectus is a part, and is incorporated herein by reference.
 


97
 

 
Pre-Funded Warrants
 
On December 27, 2024,
in connection with the closing of the PIPE Transaction, the Company issued Pre-Funded Warrants to purchase up to 77,792 Common Shares at
an exercise price of $0.000797 per share to certain of the Selling Securityholders. Such warrants are exercisable at any time from the issuance
date. Adjustments may occur if the company undergoes share dividends, splits, or fundamental transactions. The warrant can be exercised
in part, and no fractional shares will be issued. Additionally, there are beneficial ownership limitations that may be waived at the option
of each holder upon 61 days’ notice to the Company, but in no event may such beneficial ownership limitation exceed 19.99% of the
number of shares of outstanding Common Stock. The warrant holders do not have the rights or privileges of holders of Common Shares and
any voting rights until they exercise their warrants and receive Common Shares. After the issuance of Common Shares upon exercise of the
warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders. If holders
of the warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering their warrants for that
number of Common Shares equal to the quotient obtained by dividing (x) the product of the number of Common Shares underlying the warrants,
multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y)
the fair market value. The “fair market value” shall mean the average reported last sale price of the Common Shares for the
10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent.
 
The foregoing description
of the Pre-Funded Warrants is qualified in its entirety by the full text of the warrants, which is attached as Exhibit 4.4 to this registration
statement of which this prospectus is a part, and is incorporated herein by reference.
 
C. Other
Securities
 
Not Applicable.
 
D. American Depository Shares
 
Not Applicable.
 


98
 

 
PART II
 
ITEM 13. DEFAULTS, DIVIDEND ARREARAGES
AND DELINQUENCIES
 
Not applicable.
 
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY
HOLDERS AND USE OF PROCEEDS
 
On January 15, 2024, in connection with the
Business Combination, Psyence Biomedical entered into a securities purchase agreement (the “Securities Purchase Agreement”)
by and among (i) Psyence Biomedical, (ii) Biomed II, (iii) Sponsor and (iv) certain investors (the “Investors”)
relating to up to four senior secured convertible notes (collectively, the “Notes” and the transactions pursuant to the Securities
Purchase Agreement, the “Financing”), obligations under which will be guaranteed by certain assets of Psyence Biomedical and
Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up to $12,500,000
in exchange for up to $10,000,000 in subscription amounts.
 
If an aggregate of $10,000,000 in subscription
amounts are received, proceeds raised are planned to be allocated as follows: $2.5 million for research and development costs net of government
rebates for the Phase IIb study and Phase III study initiation for the treatment of AjD; $3.0 million for research and development costs
net of government rebates in areas such as Alcohol Use Disorder; $1.7 million for salaries and consulting fees business strategies, financial
and administrative services; $0.6 million for professional fees and consulting fees; $0.5 million for sales and marketing; $1.4 million
for general and administration costs and $0.3 million for drug licensing fees. To date, $3,125,000 has been received in subscription amounts
and has been allocated as follows: $0.4 million for research and development costs for the Phase IIb study; $1.0 million for salaries
and consulting fees business strategies, financial and administrative services; $1.0 million for professional fees and consulting fees;
$0.1 million for sales and marketing; $0.3 million for general and administration costs and $0.3 million for drug licensing fees.
 
ITEM 15. CONTROLS AND
PROCEDURES
 
Disclosure Controls and Procedures
 
At the end of the period covered by this Report,
an evaluation of the effectiveness of the design and operation of the Company’s “disclosure controls and procedures”
(as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) was carried out by the Company’s
principal executive officer (the “CEO”) and principal financial officer (the “CFO”). There are inherent
limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the
circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide
reasonable assurance of achieving their control objectives. Based upon their evaluation, the Company’s CEO and CFO have concluded
that, as of the end of the period covered by this Report, the design and operation of the Company’s disclosure controls and procedures
were not effective to ensure that (i) information required to be disclosed in reports that the Company files or submits to regulatory
authorities is recorded, processed, summarized and reported within the time periods specified by regulation, and (ii) is accumulated
and communicated to management, including the Company’s CEO and CFO, to allow timely decisions regarding required disclosure.
 
This Report does not include a report of management’s
assessment regarding internal control over financial reporting or an attestation report of the Company’s registered public accounting
firm due to a transition period established by rules of the Securities and Exchange Commission for newly public companies.
 
Changes in Internal Control over Financial Reporting
 
There has been no change in the Company’s
internal control over financial reporting during the fiscal year ended March 31, 2025 that has materially affected, or is reasonably
likely to materially affect, its internal control over financial reporting.
 

99
 

 
ITEM 16. [RESERVED]
 
ITEM 16A. AUDIT COMMITTEE FINANCIAL
EXPERT
 
The Company’s Audit Committee consists of
Marc Balkin, Chris Bull and Dr. Seth Feuerstein. Mr. Balkin is an “audit committee financial expert” within the
meaning of SEC regulations. Mr. Balkin serves as the chairperson of the Audit Committee. Each member of the Audit Committee can read
and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the Board
will examine each Audit Committee member’s scope of experience and the nature of their employment. For a description of the education
and experience of each member of the Audit Committee, see “Item 6A. Directors, Senior Management and Employees.”
 
ITEM 16B. CODE OF ETHICS
 
We have adopted a code of ethics that applies
to all of our executive officers, directors and employees in accordance with the rules of the Nasdaq and the SEC. The code of ethics
codifies the business and ethical principles that govern all aspects of our business. You will be able to review these documents by accessing
our public filings at the SEC’s website at www.sec.gov. The code of ethics is also available on the Company’s website at www.psyencebiomed.com.
 
ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND
SERVICES
 
The aggregate fees billed by the Company’s
external auditors in each of the last two fiscal years are as follows.
 


  
March 31, 2025  
March 31, 2024 

Audit fees 
$152,253  
$203,567 

Audit-related fees 
$-  
$— 

Tax fees 
$-  
$— 

All other fees 
$-  
$— 

Total 
$152,253  
$203,567 

 
Notes:
 
The policy of the Company’s Audit Committee
is to pre-approve all audit and non-audit services provided by MNP LLP, its current independent registered public accounting firm, including
audit services, audit-related services, tax services, and other services as described above. Pursuant to this policy, the Audit Committee
pre-approved all of the services provided to us by MNP during the year since the Closing.
 
ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT
COMMITTEES
 
Not applicable.
 
ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE COMPANY
AND AFFILIATED PURCHASERS
 
Not applicable.
 
ITEM 16F. CHANGE IN REGISTRANT’S
CERTIFYING ACCOUNTANT
 
Not applicable.
 
ITEM 16G. CORPORATE GOVERNANCE
 
The information set forth in Item 6B above
under the caption “Corporate Governance Practices and Foreign Private Issuer Status” is incorporated herein by reference.
 


100
 

 
ITEM 16H. MINE SAFETY
DISCLOSURE
 
Not applicable.
 
ITEM 16I. DISCLOSURE REGARDING FOREIGN
JURISDICTIONS THAT PREVENT INSPECTIONS
 
Not applicable.
 
ITEM 16J. INSIDER TRADING
POLICIES
 
Our Board has adopted insider trading policies
and procedures governing the purchase, sale, and other dispositions of our securities by directors, senior management, and employees that
are reasonably designed to promote compliance with applicable insider trading laws, rules, and regulations, and any listing standards
applicable to us. A copy of the insider trading policy is filed herewith as Exhibit 11.2.
 
ITEM 16K. CYBERSECURITY
 
The Company has developed and implemented cybersecurity
risk management measures intended to protect the confidentiality, integrity, and availability of its critical systems and information.
The Company’s cybersecurity risk management measures are integrated into its overall enterprise risk management program, and shares
common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal,
compliance, strategic, operational, and financial risk areas.
 
The cybersecurity risk management measures set
out the foundation of the process for assessing, identifying and managing material risks from cybersecurity threats and provide guidance
for response plan when facing cybersecurity threats. The Company has not engaged assessors or other third parties in connection with such
processes.
 
There can be no assurance that the Company’s
cybersecurity risk management measures and processes, including its policies, controls or procedures, will be fully implemented, complied
with or effective in protecting the Company’s systems and information. The Company has not identified risks from known cybersecurity
threats, including as a result of any prior cybersecurity incidents, that have materially affected the Company, including its operations,
business strategy, results of operations, or financial condition. The Company faces risks from cybersecurity threats that, if realized,
are reasonably likely to materially affect it, including the Company’s operations, business strategy, results of operations, or
financial condition. Many of the laws and regulations regarding cybersecurity, information security, privacy and data protection applicable
to the Company are subject to change and uncertain interpretation, and any failure or perceived failure to comply with such laws and regulations
could result in negative publicity, legal proceedings, suspension or disruption of operations, increased cost of operations, or otherwise
harm the business of the Company.
 
Cybersecurity Governance
 
The Board has general oversight power over cybersecurity
issues and has delegated daily supervision responsibility to the Company’s Finance department. The Finance department, consisting
of personnel with relevant expertise in cybersecurity management, overseas the implementation of the Company’s cybersecurity risk
management measures and reports to the Board any material cybersecurity incidents. The Finance department supervises efforts to prevent,
detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal and
external security personnel, threat intelligence and other information obtained from governmental, public or private sources, and alerts
and reports produced by security tools deployed in the IT environment.
 


101
 

 
PART III
 
ITEM 17. FINANCIAL STATEMENTS
 
See Item 18.
 
ITEM 18. FINANCIAL STATEMENTS
 
Financial Statements Filed as Part of this Annual Report:
 
Audited carve-out consolidated financial statements
as at March 31, 2024 and audited consolidated financial statements as at March 31, 2025.
 
ITEM 19. EXHIBITS
 


Exhibit No.
 
Description

2.1#
 
Amended and Restated Business Combination Agreement, dated as of July 31, 2023, by and among Newcourt Acquisition Corp, Newcourt SPAC Sponsor LLC, Psyence Group Inc., Psyence Biomedical Ltd., Psyence (Cayman) Merger Sub, Psyence Biomed Corp. and Psyence Biomed II Corp. (incorporated by reference to Exhibit 2.2 to the Company’s Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).

2.2
 
First Amendment to the Amended and Restated Business Combination Agreement, dated as of November 9, 2023, by and among Newcourt Acquisition Corp, Newcourt SPAC Sponsor LLC, Psyence Group Inc., Psyence Biomedical Ltd., Psyence (Cayman) Merger Sub, Psyence Biomed Corp. and Psyence Biomed II Corp. (incorporated by reference to Exhibit 2.3 to the Company’s Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).

2.3#
 
Securities Purchase Agreement, dated as of January 15, 2024, by and among Psyence Biomedical Ltd., Psyence Biomed II Corp. and the investors party thereto (incorporated by reference to Exhibit 10.1 to Newcourt Acquisition Corp’s Form 8-K (File No. 001-40929) filed with the SEC on January 16, 2024).

2.4
 
Description of Registered Securities (incorporated by reference to Exhibit 2.3 to the Annual Report on Form 20-F filed with the SEC on July 29, 2024).

3.1
 
Certificate of Incorporation of Psyence Biomedical Ltd. (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).

3.2
 
Amended and Restated Bylaws of Psyence Biomedical Ltd. (incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).

4.1
 
Specimen Share Certificate of Psyence Biomedical Ltd. (incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form F-4 (File No. 333-268525) (File No. 333-273553) filed with the SEC on November 13, 2023).

4.2
 
Specimen Warrant Certificate of Psyence Biomedical Ltd. (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form F-4 (File No. 333-268525) (File No. 333-273553) filed with the SEC on November 13, 2023).

4.3
 
Form of Common Share Purchase Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form F-1 (File No. 333-282468) filed with the SEC on October 2, 2024).

4.4
 
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 6-K filed with the SEC on December 31, 2024).

4.5
 
Form of Series A Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 6-K filed with the SEC on December 31, 2024).

4.6
 
Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to the Current Report on Form 6-K filed with the SEC on December 31, 2024).

4.7
 
Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.4 to the Current Report on Form 6-K filed with the SEC on December 31, 2024).

10.1
 
Form of Guaranty (incorporated by reference to Exhibit 4.4 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on January 31, 2024).

10.2
 
Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).

10.3
 
Sponsor Support Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).

10.4
 
PGI Support Agreement (incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).

10.5†
 
Psyence Biomedical Ltd. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Report of Foreign Private Issuer on Form 6-K filed with the SEC on June 25, 2025).

10.6†
 
Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 4.9 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on January 31, 2024).

10.7#
 
Research IP Agreement, by and between Psyence and Filament (incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).

10.8#
 
Commercial IP Term Sheet, by and between Psyence and Filament (incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form F-4 (File No. 333-273553) filed with the SEC on November 13, 2023).

10.9
 
Amendment to Engagement Letter, dated as of January 25, 2024, by and between J.V.B. Financial Group, LLC, acting through its Cohen & Company Capital Markets division and Newcourt Acquisition Corp. (incorporated by reference to Exhibit 4.12 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on January 31, 2024).

 

102
 

 


10.10
 
Fee Modification Agreement, dated as of January 25, 2024, by and between Cantor Fitzgerald & Co. and Newcourt Acquisition Corp. (incorporated by reference to Exhibit 4.13 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on January 31, 2024).

10.11
 
Amendment to Engagement Letter, dated as of January 25, 2024, by and between Maxim Group LLC and Psyence Group Inc. (incorporated by reference to Exhibit 4.14 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on January 31, 2024).

10.12
 
Form of Registration Rights Agreement, dated as of January 25, 2024, by and among Psyence Biomedical Ltd. and the investors party thereto (incorporated by reference to Exhibit 4.15 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on January 31, 2024).

10.13
 
Form of General Security Agreement, executed by Psyence Biomedical Ltd. and Psyence Biomed II Corp. (incorporated by reference to Exhibit 4.16 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on January 31, 2024).

10.14
 
Form of Lock-Up Agreement, dated as of January 25, 2024, by and among Psyence Biomedical, Newcourt Acquisition Corp. and the other parties thereto (incorporated by reference to Exhibit 4.17 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on January 31, 2024).

10.15
 
Form of Senior Secured Convertible Note, dated as of January 25, 2024, issued by Psyence Biomedical Ltd. to the Investors (incorporated by reference to Exhibit 4.18 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on January 31, 2024).

10.16
 
Promissory Note, dated January 25, 2024, issued by Newcourt Acquisition Corp to Newcourt SPAC Sponsor LLC (incorporated by reference to Exhibit 10.3 to Newcourt Acquisition Corp’s Form 8-K (File No. 001-40929) filed with the SEC on January 31, 2024).

10.17
 
Form of Call Option Agreement (incorporated by reference to Exhibit 10.17 to the Company’s Amendment No.3 to Registration Statement on Form F-1/A filed on May 10, 2024).

10.18
 
Warrant Exchange Agreement (incorporated by reference to Exhibit 4.26 to the Company’s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on July 29, 2024).

10.19
 
First Addendum to the License Agreement and Commercial Term Sheet, dated as of July 22, 2024, by and among the Company, Psyence Group Inc. and Filament Health Corp (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 6-K filed with the SEC on July 24, 2024).

10.20
 
Common Stock Purchase Agreement, dated July 25, 2024, by and between the Company and White Lion (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 6-K filed with the SEC on July 31, 2024).

10.21
 
Registration Rights Agreement, dated July 25, 2024, by and between the Company and White Lion (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 6-K filed with the SEC on July 31, 2024).

10.22
 
First Addendum to the Securities Purchase Agreement and Senior Secured Convertible Notes (incorporated by reference to Exhibit 10.22 to the Company’s Registration Statement on Form F - 1 (File No. 333 - 281644) filed with the SEC on August 19, 2024).

10.23
 
License Agreement, dated September 3, 2024, by and between the Company and Psyence UK Group Ltd. (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 6-K filed with the SEC on September 5, 2024).

10.24
 
Share Purchase and Sale Agreement, dated September 17, 2024, by and between the Company and Psyence Group Inc. (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 6-K filed with the SEC on September 20, 2024).

10.25
 
Debt-for-Equity Swap Agreement, effective as of September 30, 2024, by and between Psyence Biomedical Ltd. and Newcourt SPAC Sponsor, LLC (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 6-K filed with the SEC on October 8, 2024).

10.26
 
Debt-for-Equity Swap Agreement, effective as of September 30, 2024, by and between Psyence Biomedical Ltd. and Psyence Group. Inc. (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 6-K filed with the SEC on October 8, 2024).

10.27
 
First Addendum to Share Purchase and Sale Agreement, dated as of September 27, 2024, by and among Psyence Biomedical Ltd., Psyence Group. Inc. and Psyence Labs Ltd (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 6-K filed with the SEC on October 8, 2024).

10.28
 
Termination Agreement, by and between the Company and the Signatories thereto, dated November 21, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 6-K filed with the SEC on November 22, 2024).

10.29
 
First Addendum to Debt-for-Equity Swap Agreement, effective November 26, 2024, by and between Psyence Biomedical Ltd and Newcourt SPAC Sponsor, LLC and Newcourt Acquisition Corp. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 6-K filed with the SEC on December 4, 2024).

 


103
 

 


10.30
 
First Addendum to Debt-for-Equity Swap Agreement, effective November 26, 2024, by and between Psyence Biomedical Ltd and Psyence Group, Inc. (incorporated by reference to Exhibit 10.4 to the Current Report on Form 6-K filed with the SEC on December 4, 2024).

10.31
 
Second Addendum to Share Purchase and Sale Agreement, effective November 26, 2024, by and between Psyence Biomedical Ltd., Psyence Group, Inc., and Psyence Labs Ltd. (incorporated by reference to Exhibit 10.7 to the Current Report on Form 6-K filed with the SEC on December 4, 2024).

10.32
 
IP and Mutual Exclusivity Agreement, dated December 5, 2024, between the Company and Optimi Health Corp. (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 6-K filed with the SEC on December 19, 2024).

10.33
 
Quality Agreement, dated December 5, 2024 between the Company, Psyence Australia PTY Ltd., and Optimi Labs Inc. (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 6-K filed with the SEC on December 19, 2024).

10.34
 
Supply of Goods Agreement, dated December 5, 2024, between the Company and Optimi Health Corp. (Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 6-K filed with the SEC on December 19, 2024).

10.35
 
Form of Securities Purchase Agreement, dated December 23, 2024, by and among Psyence Biomedical Ltd. and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Current Report on Form 6-K filed with the SEC on December 31, 2024).

10.36
 
Form of Registration Rights Agreement, dated December 23, 2024, by and among Psyence Biomedical Ltd. and the Holders named therein (incorporated by reference to Exhibit 10.2 to the Current Report on Form 6-K filed with the SEC on December 31, 2024).

10.37
 
Letter Agreement between the Company and H.C. Wainwright & Co., LLC, dated July 25, 2024 (incorporated by reference to Exhibit 10.37 to the Registration Statement on Form F-1 (File No. 333-284444) filed with the SEC on January 24, 2025).

10.38
 
Amendment and Extension to the Letter Agreement between the Company and H.C. Wainwright & Co., LLC, dated December 9, 2024 (incorporated by reference to Exhibit 10.38 to the Registration Statement on Form F-1 (File No. 333-284444) filed with the SEC on January 24, 2025).

10.39
 
At the Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC, dated March 4, 2025 (incorporated by reference to Exhibit 10.39 to the Registration Statement on Form F-3 filed with the SEC on March 4, 2025 (File No. 333-285542)

10.40#^
 
Exit Deed between Psyence Australia Pty Ltd. And iNGENu CRO Pty Ltd., dated April 3, 2025 (incorporated by reference to Exhibit 99.2 to  the Current Report on Form 6-K filed with the SEC on  April 11, 2025).

10.41#^
 
Master Services Agreement between Psyence Australia Pty Ltd and Southern Star Research Pty Ltd, dated May 17, 2025 (incorporated by reference herein to Exhibit 99.2 to the Current Report on Form 6-K filed with the SEC on June 11, 2025).

11.1
 
Code of Ethics (incorporated by reference to Exhibit 11.1 to the Annual Report on Form 20-F filed with the SEC on July 29, 2024)

11.2
 
Insider Trading Policy (incorporated by reference to Exhibit 11.2 to the Annual Report on Form 20-F filed with the SEC on July 29, 2024)

12.1*
 
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

12.2*
 
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

13.1**
 
Section 1350 Certification of the Chief Executive Officer and Chief Financial Officer

21.1
 
List of Subsidiaries of Psyence (incorporated by reference to Exhibit 21.1 to the Company’s Registration Statement on Form F-1 (File No. 333 - 276973) filed with the SEC on February 9, 2024).

23.1*
 
Consent of
MNP LLP

97.1*
 
Compensation Clawback Policy

101.INS*
 
Inline XBRL Instance Document.

101.SCH*
 
Inline XBRL Taxonomy Extension Schema Document.

101.CAL*
 
Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*
 
Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*
 
Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*
 
Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104*
 
Cover Page Interactive Data File (formatted as Inline
XBRL and contained in Exhibit 101).

 




#
The exhibits and schedules to this Exhibit have been omitted in accordance with Item 601(b)(2) of Regulation S-K. The Registrant agrees to furnish supplementally to the SEC a copy of all omitted exhibits and schedules upon its request.

 


†
Indicates a management contract or compensation plan.

 


*
Filed herewith.

 
 

**
Furnished herewith

 
 

^
Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit.    

 


104
 

 
SIGNATURE
 
The registrant hereby certifies that it meets
all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this report on
its behalf.
 


Dated: June 25, 2025
PSYENCE BIOMEDICAL LTD.

 
 
 

 
By:
/s/ Neil Maresky

 
Name:
Neil Maresky

 
Title:
Chief Executive Officer

 


105
 

 

INDEX TO FINANCIAL STATEMENTS
 
Consolidated Financial Statements for Psyence Biomedical Ltd. as
of and for the Years ended March 31, 2024 and 2023
 
    Page Independent Auditor’s Report (PCAOB ID: 1930)   F-4 Consolidated Statements of Financial Position as at March 31, 2025 and March 31, 2024   F-5 Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss) for the fiscal years ended March 31, 2025, March 31, 2024 and March 31, 2023   F-6 Consolidated Statements of Changes in Shareholder Equity (Deficit) for the fiscal years ended March 31, 2025, March 31, 2024 and March 31, 2023   F-7 Consolidated Statements of Cash Flows for the fiscal years ended March 31, 2025, March 31, 2024 and March 31, 2023   F-8 Notes to the Consolidated Financial Statements   F-9
 


F-1
 

 

 
Psyence Biomedical Ltd.
 
Consolidated Financial Statements
  
For the years ended March 31, 2025, 2024 and 2023
 
Expressed in United States Dollars
(USD $)
 

F-2
 

 
Management's Responsibility for Financial
Reporting
 
The accompanying consolidated financial statements
of the Company have been prepared by management in accordance with International Financial Reporting Standards. These consolidated financial
statements contain estimates based on management’s judgment. Management maintains an appropriate system of internal controls to
provide reasonable assurance that transactions are authorized, assets safeguarded, and proper records maintained.
 
The Audit Committee of the Board of Directors
reviews the results of the annual audit and the consolidated financial statements prior to submitting the consolidated financial statements
to the Board for approval.
 
The Company’s auditors, MNP LLP, are appointed
by the audit committee to conduct an audit and their report follows.
 


“Dr. Neil Maresky”
 

Chief Executive Officer
 

 
Toronto, Canada
June 25, 2025
 

F-3
 

 

 

Report of Independent Registered Public Accounting
Firm

 
To the Board of Directors and Shareholders
of Psyence Biomedical Ltd.
 
Opinion on the Consolidated Financial
Statements
 
We have audited the accompanying
consolidated statements of financial position of Psyence Biomedical Ltd. (the “Company”) as at March 31, 2025 and 2024, and
the related consolidated statements of net income (loss) and comprehensive income (loss), changes in shareholders’ equity (deficit),
and cash flows for each of the years in the three-year period ended March 31, 2025, and the related notes (collectively referred to as
the “consolidated financial statements”).
 
In our opinion, the consolidated
financial statements present fairly, in all material respects, the consolidated financial position of the Company as at March 31, 2025
and 2024, and the results of its consolidated operations and its consolidated cash flows for each of the years in the three-year period
ended March 31, 2025, in conformity with IFRS® Accounting Standards as issued by the International Accounting Standards
Board.
 
Basis for Opinion
 
These consolidated financial
statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 
We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required
to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness
of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
 
Our audits included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts
and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that
our audits provide a reasonable basis for our opinion.
 

 
Chartered Professional Accountants

Licensed Public Accountants
 
June 25, 2025
 
Toronto, Canada
 
We have served as the Company’s
auditor since 2023.
 
MNP LLP 1 Adelaide Street East, Suite 1900, Toronto ON, M5C 2V9 1.877.251.2922   T: 416.596.1711   F: 416.596.7894
 


F-4
 

 
Consolidated Statements of Financial Position
 
As at March 31, 2025 and March 31, 2024
 


USD $ 
Note  
As at
March 31, 2025  
As at
March 31, 2024 

  
   
   
  

ASSETS 
   
   
  

Current assets 
   
   
  

Cash and cash equivalents 
 6  
 6,135,166  
 733,188 

Restricted cash 
 6  
 35,964  
 29,611 

Other receivables 
    
 137,348  
 41,747 

Prepaid expense 
    
 251,796  
 322,126 

Total current assets 
    
 6,560,274  
 1,126,672 

Non-current assets 
    
    
   

Equipment 
 7  
 11,096  
 5,487 

Investment in Psyence Labs Ltd 
 13  
 745,000  
 - 

TOTAL ASSETS 
    
 7,316,370  
 1,132,159 

LIABILITIES 
    
    
   

Current liabilities 
    
    
   

Accounts payable and accrued liabilities 
 8  
 394,270  
 755,202 

Convertible note liability 
 9  
 -  
 7,657,397 

Derivative warrant liabilities 
 10  
 200,096  
 901,608 

Due to NCAC Sponsor 
 11  
 -  
 1,474,256 

Due to Psyence Group Inc 
 11  
 -  
 1,316,236 

TOTAL LIABILITIES 
    
 594,366  
 12,104,699 

SHAREHOLDERS EQUITY/(DEFICIT) 
    
    
   

Share Capital 
 15  
 61,752,305  
 46,125,397 

Warrants Reserve 
 9,14  
 1,065,705  
 - 

Accumulated Deficit 
    
 (56,447,204) 
 (57,458,994)

Reserves 
    
 351,198  
 361,057 

TOTAL SHAREHOLDERS EQUITY/(DEFICIT) 
    
 6,722,004  
 (10,972,540)

TOTAL LIABILITIES AND NET EQUITY 
    
 7,316,370  
 1,132,159 

 
Nature of operations (note
1)
Subsequent events (note
19)
 
Approved on behalf of Board of Directors
 


“Dr. Neil Maresky”
 
“Jody Aufrichtig”

Chief Executive Officer and Director
 
Executive Chairman and Director

 
The accompanying notes are an integral part
of the Consolidated Financial Statements
 

F-5
 

 
Consolidated Statements of Net Income/(Loss) and Comprehensive
Income/(Loss)
 
For the years ended March 31, 2025, 2024 and 2023
 


USD $ 
Note  
2025  
2024  
2023
(Carve-out)
(Restated Note 3) 

  
   
   
   
  

Expenses 
   
   
   
  

Sales and marketing 
    
 483,530  
 80,603  
 7,029 

Research and development 
    
 342,168  
 954,593  
 1,608,895 

General and administrative 
    
 1,209,847  
 557,904  
 366,435 

Professional
and consulting fees 
    
 1,623,209  
 1,158,484  
 1,252,510 

Loss before other items 
    
 (3,658,754) 
 (2,751,584) 
 (3,234,869)

Other items 
    
    
    
   

Other income 
 16  
 -  
 879,344  
 - 

Depreciation 
 7  
 (4,268) 
 (240) 
 - 

Interest income 
    
 95,787  
 2,134  
 1,554 

Interest expense 
 16  
 (9,270) 
 (52,941) 
 - 

Foreign exchange (loss)/gain 
    
 (7,317) 
 (2,695) 
 26,912 

Listing expense 
 5  
 -  
 (41,481,605) 
 - 

Transaction expense 
 5  
 -  
 (2,461,025) 
 - 

Gain on debt settlement 
 15  
 -  
 281,500  
 - 

Fair value gain/(loss) on convertible
note 
 9  
 3,357,628  
 (5,157,397) 
 - 

Fair value gain/(loss) on warrant
liability 
 10  
 694,516  
 (306,250) 
 - 

Fair value gain/(loss) on promissory
notes 
 11  
 705,565  
 (108,288) 
 - 

Fair value loss on warrant
exchange 
 10  
 (185,064) 
 -  
 - 

Fair
value gain on investment in Psyence Labs Ltd 
 13  
 22,967  
 -  
 - 

NET INCOME/(LOSS) 
    
 1,011,790  
 (51,159,048) 
 (3,206,403)

Other comprehensive income/(loss) 
    
    
    
   

Foreign exchange gain/(loss)
on translation 
    
 (9,859) 
 3,715  
 (89,828)

Other
comprehensive income 
    
 -  
 191,982  
 - 

TOTAL COMPREHENSIVE INCOME/(LOSS) 
    
 1,001,931  
 (50,963,351) 
 (3,296,231)

Income/(Loss) per share -
basic and diluted 
    
 5.24  
 (4,674.25) 
 (394.06)

Weighted average number of outstanding shares
- basic and diluted 
    
 193,043  
 10,903  
 8,365 

 
The accompanying notes are an integral part
of the Consolidated Financial Statements
 

F-6
 

 
Consolidated Statements of Changes in Shareholders’
Equity/(Deficit)
 
For the years ended March 31, 2025, 2024 and 2023
 



USD $ 
Note  
Number of shares  
Share capital  
Warrants Reserve  
Reserves  
Accumulated Deficit  
Total shareholders’ equity (deficit) 

  
   
   
   
   
   
   
  

Opening balance as at April 1, 2022 Restated (Note 3) 
    
 -  
 4,537,055  
 -  
 255,188  
 (3,093,543) 
 1,698,700 

Psyence Group Inc contribution 
    
 -  
 1,397,086  
 -  
 -  
 -  
 1,397,086 

Net loss for the year 
    
 -  
 -  
 -  
 -  
 (3,206,403) 
 (3,206,403)

Other comprehensive loss 
    
 -  
 -  
 -  
 (89,828) 
 -  
 (89,828)

Balance, March 31, 2023 Restated (Note 3) 
    
 -  
 5,934,141  
    
 165,360  
 (6,299,946) 
 (200,445)

  
    
    
    
    
    
    
   

Opening balance as at April 1, 2023 
    
 -  
 5,934,141  
 -  
 165,360  
 (6,299,946) 
 (200,445)

Issuance of shares to Psyence Group Inc 
 15  
 8,365  
 -  
 -  
 -  
 -  
 - 

Issuance of shares to NCAC shareholders 
 5  
 13,040  
 37,336,416  
 -  
 -  
 -  
 37,336,416 

Issuance of shares for debt settlement 
 15  
 251  
 718,500  
 -  
 -  
 -  
 718,500 

Issuance of shares to third party advisors 
 15  
 746  
 2,136,340  
 -  
 -  
 -  
 2,136,340 

Net loss for the year 
    
 -  
 -  
 -  
 -  
 (51,159,048) 
 (51,159,048)

Other comprehensive income 
    
 -  
 -  
 -  
 195,697  
 -  
 195,697 

Balance, March 31, 2024 
    
 22,402  
 46,125,397  
 -  
 361,057  
 (57,458,994) 
 (10,972,540)

  
    
    
    
    
    
    
   

Opening balance as at April 1, 2024 
    
 22,402  
 46,125,397  
 -  
 361,057  
 (57,458,994) 
 (10,972,540)

Issuance of shares to third party advisors 
 15  
 586  
 241,379  
 -  
 -  
 -  
 241,379 

Issuance of shares for convertible note 
 9  
 38,156  
 4,617,286  
 -  
 -  
 -  
 4,617,286 

Issuance of warrants 
 9  
 -  
 -  
 682,482  
 -  
 -  
 682,482 

Issuance of shares for ELOC, net of issuance costs 
 12  
 222,292  
 6,410,395  
 -  
 -  
 -  
 6,410,395 

Issuance of shares for warrant exchange 
 10  
 1,104  
 192,060  
 -  
 -  
 -  
 192,060 

Issuance of shares for promissory notes 
 11  
 99,540  
 2,084,927  
 -  
 -  
 -  
 2,084,927 

Issuance of shares for Psyence Labs Ltd shares 
 13  
 35,594  
 722,033  
 -  
 -  
 -  
 722,033 

Issuance of units for PIPE financing, net of issuance costs 
 14  
 47,679  
 273,179  
 1,468,872  
 -  
 -  
 1,742,051 

Issuance of shares for warrant conversion 
 9,14  
 100,668  
 1,085,649  
 (1,085,649) 
 -  
 -  
 - 

Net profit for the year 
    
 -  
 -  
 -  
 -  
 1,011,790  
 1,011,790 

Other comprehensive loss 
    
 -  
 -  
 -  
 (9,859) 
 -  
 (9,859)

Balance, March 31, 2025 
    
 568,021  
 61,752,305  
 1,065,705  
 351,198  
 (56,447,204) 
 6,722,004 

 
The accompanying notes are an integral part
of the Consolidated Financial Statements
 

F-7
 

 
Consolidated Statements of Cash Flows
 
For the years ended March 31, 2025, March 31,
2024 and March 31, 2023
 


  
Note  
2025  
2024  
2023
(Carve-out)
(Restated Note 3) 

Net profit/(loss) 
    
 1,011,790  
 (51,159,048) 
 (3,206,403)

Non-cash adjustment: 
    
    
    
   

Fair value (gain)/loss on convertible note 
 9  
 (3,357,628) 
 5,157,397  
 - 

Fair value (gain)/loss on warrant liability 
 10  
 (694,516) 
 306,250  
 - 

Fair value (gain)/loss on promissory notes 
 11  
 (705,565) 
 300,270  
 - 

Fair value loss on warrant exchange 
 10  
 185,064  
 -  
 - 

Fair value gain on Psyence Labs Ltd 
 13  
 (22,967) 
 -  
 - 

Gain on debt settlement 
 15  
 -  
 (281,500) 
 - 

Share based compensation 
 16  
 -  
 317,882  
 221,287 

Third party advisors share issuance 
 15  
 241,379  
 -  
 - 

Depreciation 
 7  
 4,268  
 240  
 - 

Foreign exchange 
    
 (9,860) 
 3,660  
 (84,499)

Listing expense 
 5  
 -  
 41,481,605  
 - 

Transaction expenses 
 5  
 -  
 2,100,830  
 - 

  
    
    
    
   

Changes in working capital: 
    
    
    
   

Other receivables 
    
 (95,601) 
 107,622  
 (109,858)

Prepaids 
    
 70,330  
 (245,075) 
 (71,665)

Accounts payable and accrued liabilities 
 8  
 (360,932) 
 (1,035,498) 
 1,659,058 

Cash used in operating activities 
    
 (3,734,238) 
 (2,945,365) 
 (1,592,080)

  
    
    
    
   

Additions to equipment 
 7  
 (9,877) 
 (5,727) 
 - 

Increase in restricted cash 
 6  
 (6,353) 
 -  
 - 

Cash used for investing activities 
    
 (16,230) 
 (5,727) 
 - 

  
    
    
    
   

Proceeds received from convertible note 
 9  
 1,000,000  
 2,500,000  
 - 

Payment of promissory note 
 11  
 -  
 (150,000) 
 - 

Proceeds received from Psyence Group Inc 
    
 -  
 -  
 1,172,923 

Net proceeds received from ELOC 
 12  
 6,410,395  
 -  
 - 

Net proceeds received for unit issuances 
 14  
 1,742,051  
 -  
 - 

Cash provided from financing activities 
    
 9,152,446  
 2,350,000  
 1,172,923 

  
    
    
    
   

Change in cash and cash equivalents 
    
 5,401,978  
 (601,092) 
 (419,157)

Cash and cash equivalents, beginning of year 
    
 733,188  
 1,334,280  
 1,753,437 

Cash and cash equivalents, end of year 
    
 6,135,166  
 733,188  
 1,334,280 

 
The accompanying notes are an integral part
of the Consolidated Financial Statements
 


F-8
 

 
Notes to the Consolidated Financial Statements
 
1. Nature of operations and going concern
 
Psyence Biomedical Ltd. (the “Company”
or “PBM”), is a life science biotechnology company traded on the Nasdaq exchange (NASDAQ: PBM) that is focused on the
development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The Company is working towards developing
psychedelic therapeutics to treat mental health disorders. The Company is currently conducting research through clinical trials to evaluate
the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with a cancer diagnosis in a palliative
care context (the “Clinical Trials”).
 
The Company’s registered office is at 121
Richmond Street West, PH Suite 1300, Toronto, Ontario M5H 2K1.
 
On November 26, 2024, the Company consolidated
its common shares and warrants on the basis of 75:1.
 
On May 5, 2025, the Company consolidated its common
shares and warrants on the basis of 7.97:1. All prior share capital information has been presented based on these ratios.
 
Business Combination Agreement and NASDAQ listing
 
On January 9, 2023 Psyence Group Inc. (“PGI”
or “Psyence Group”) entered into a definitive business combination agreement, as amended (the “Business Combination
Agreement” or “BCA”) with Newcourt Acquisition Corp. (NASDAQ: NCAC), a special purpose acquisition company
(“SPAC”). The agreement aimed to create a public company leveraging natural psilocybin for palliative care treatment.
PGI is a listed Canadian company that contributed its clinical trial activities to the Company as described below.
 
The transaction concluded on January 25, 2024,
with PBM's listing on NASDAQ. This transaction involved PBM acquiring the SPAC through a merger, thereby making the SPAC a wholly-owned
subsidiary of PBM.
 
Transaction Overview:
 
On January 25, 2024 (the “Closing Date”),
the Company, a corporation organized under the laws of Ontario, Canada, completed the previously announced business combination (the “RTO
Transaction”) as per the BCA (Note 5). The parties involved in the BCA included:
 

-Psyence Group Inc.
 

-Newcourt Acquisition Corp., a Cayman Islands exempted company (“NCAC”).
 

-Newcourt SPAC Sponsor LLC, a Delaware limited liability company (“NCAC Sponsor”).
 

-Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of Psyence
Group.
 

-Psyence Biomed Corp., a corporation organized under the laws of British Columbia, Canada (“Original
Target”).
 

-Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (“Psyence
Biomed II”).
 

-Psyence Australia (Pty) Ltd (“Psyence Australia”)
 
Key Transactions (collectively, the “Business
Combination”):
 
Formation of Subsidiaries: Prior to the
Closing Date, PGI formed three wholly owned subsidiaries: Psyence Biomed II, Psyence Australia and PBM.
 
Amalgamation: Prior to the Closing Date,
PGI amalgamated with the Original Target. Consequently, PGI transferred shares of Psyence Australia and related business assets previously
owned by the Original Target to Psyence Biomed II.
 
Share Exchange: PGI contributed Psyence
Biomed II to PBM in a share-for-share exchange (the “Company Exchange”).
 


F-9
 

 
Merger: Following the Company Exchange,
Psyence (Cayman) Merger Sub merged with Newcourt Acquisition Corp., with Newcourt Acquisition Corp. being the surviving entity. Each outstanding
ordinary share of Newcourt Acquisition Corp. was converted into the right to receive one common share of PBM.
 
Warrant Conversion: Each outstanding warrant
to purchase Newcourt Acquisition Corp. Class A ordinary shares was converted into warrants to acquire one common share of PBM on substantially
the same terms as the original warrants.
 
These Consolidated Financial Statements provide
historical financial information of PBM, reflecting PBM as if it had been historically operating the Clinical Trials conducted by PGI
prior to the Closing Date. The Financial Statements are carve-out statements up to January 25, 2024, the date of listing of PBM.
 
2. Basis of presentation
 
Statement of compliance
 
The Consolidated Financial Statements, including
comparatives, have been prepared in accordance with IFRS® Accounting Standards as issued by the International Accounting Standard
Board (“IFRS”) on a going concern basis.
 
The Consolidated Financial Statements were authorized for issue on
June 25, 2025 by the directors of the Company.
 
The Consolidated Financial Statements up until
January 25, 2024 were presented on a carve out basis (“Carve-out Financial Statements”).
 
The Consolidated Financial Statements have been
prepared on a carve-out basis from the PGI consolidated financial statements for the purpose of presenting the historical financial performance
and cash flows of the Company on a stand-alone basis. The accounting policies applied in the Carve-out Financial Statements are, to the
extent applicable, consistent with accounting policies applied in the PGI consolidated financial statements, and as a result, reflect
the carrying amounts that are included in PGI’s consolidated financial statements.
 
In determining the perimeter of the Carve-out
Financial Statements, the activities related to the Company’s clinical trials were considered to include the operations of Psyence
Biomed Corp. and Psyence Australia (Pty) Ltd carried out through PGI directly as well as through legal entities of PGI as detailed above.
 
In the Carve-out Financial Statements, all intercompany
balances and transactions have been eliminated. The transactions and balances with the remaining PGI operations that are not part of these
Carve-out Financial Statements have not been eliminated.
 
The Carve-out Financial Statements present the
expenses and cash flows attributable to the clinical trial activities from April 1, 2022 to the Closing Date, and include allocations
of certain transactions and balances.
 
The Company believes the allocation assumptions
applied in the Carve-out Financial Statements to be a reasonable reflection of the utilization of services provided by PGI. However, different
allocation assumptions could have resulted in different outcomes. The allocations are therefore not necessarily representative of the
financial performance or cash flows that would have been reported if the Company operated on its own or as an entity independent from
PGI during the periods presented.
 
The Company believes the basis of preparation
described above results in the Carve-out Financial Statements reflects costs associated with the functions that would be necessary to
operate independently.
 


F-10
 

 
Basis of consolidation
 
These Consolidated Financial Statements incorporate
the accounts of the Company and its subsidiaries performing Clinical Trials. A subsidiary is an entity controlled by PBM and its results
are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.
 
Control exists when an investor is exposed, or
has the rights, to variable returns from the involvement with the investee and has liability to affect those returns through its power
over the investee.
 
The subsidiaries of the Company have been consolidated
commencing the Closing Date and on March 31, 2025 for the purpose of these Consolidated Financial Statements are as follows:
 
Name of entity  Place of incorporation  % ownership   Accounting method Psyence Australia Pty Ltd.  Australia   100%  Consolidated Pysence Biomed II Corp.  Canada   100%  Consolidated Newcourt Acquisition Corp.  Cayman Islands   100%  Consolidated
 
 
Inter-company balances and transactions are eliminated
upon consolidation.
 
The financial results of subsidiaries up to January
25, 2024 were presented on a carve out basis.
 
Basis of measurement
 
These Consolidated Financial Statements have been
prepared on a historical cost basis, except for certain financial instruments, which are classified as fair value through profit or loss
(“FVTPL”).
 
Functional and presentation currency
 
These Consolidated Financial Statements are presented
in United States Dollars (“USD $”), which is also the Company’s functional currency. The Company’s
functional currency before the Closing Date was Canadian Dollars.
 
This changed upon consummation of the BCA at which
time the USD $ represents the currency of the Company's funding and is the currency of the primary economic environment in which the Company
operates in, except for the Company’s Australian subsidiary which has an Australian Dollar functional currency.
 
See change in accounting policy in note 3 for
further details on the change in the Company’s presentation currency.
 
3. Material accounting policies
 
Financial instruments
 
Financial assets and financial liabilities, including
derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument
or derivative contract.
 
Summary of the Company’s classification
and measurements of financial assets and liabilities:
 
Financial Assets and Liabilities   Classification   Measurement Cash and cash equivalents   Amortized cost   Amortized cost Restricted cash   Amortized cost   Amortized cost Other receivables   Amortized cost   Amortized cost Investment in Psyence Labs Ltd   FVTPL   Fair value Accounts payable and accrued liabilities   Amortized cost   Amortized cost Derivative warrant liability   FVTPL   Fair value Convertible note liability   FVTPL   Fair value Due to NCAC Sponsor   FVTPL   Fair value Due to Psyence Group Inc   FVTPL   Fair value
 


F-11
 

 
Classification
 
The Company classifies its financial assets in
the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (“FVTPL”);
ii) those to be measured subsequently at fair value through other comprehensive income (“FVOCI”); and iii) those to be measured
at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual
terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as
those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair
value, gains and losses are either recorded in net loss or other comprehensive income (loss).
 
The Company reclassifies financial assets only
when its business model for managing those assets changes. Financial liabilities are not reclassified.
 
Amortized cost
 
This category includes financial assets that are
held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments
of principal and interest ("SPPI") criterion. Financial assets classified in this category are measured at amortized cost using
the effective interest method.
 
Fair value through profit or loss
 
This category includes derivative instruments
as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL.
This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest
(“SPPI”) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or
to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized
in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives
are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.
 
Financial assets at fair value through other
comprehensive income
 
Equity instruments that are not held-for-trading
can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through
net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable
transaction costs are included in the carrying value of the instruments.
 
Financial assets at fair value through other comprehensive
income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).
 


F-12
 

 
Compound financial instrument and derivative
liability
 
The Company determined that the warrants, including
public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured
at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized
in net loss.
 
Each embedded derivative is measured and presented
separately unless the whole hybrid financial instrument is designated as at FVTPL.
 
Measurement
 
All financial instruments are required to be measured
at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that
are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial
assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered
in their entirety when determining whether their cash flows are solely payments of principal and interest.
 
Financial assets that are held within a business
model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal
and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All
other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with
any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial
liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value
are attributable to changes in own credit risk which is recorded in other comprehensive income.
 
Cash and cash equivalents
 
Cash and cash equivalents include cash on hand
and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three months
at the date of their acquisition.
 
Restricted cash
 
Restricted cash comprises a collateral agreement
with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment
certificate with the bank.
 
Related party transactions
 
Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered
to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be
a related party transaction when there is transfer of resources or obligations between related parties.
 
Change in accounting policy
 
Pursuant to completion of the Business Combination
Agreement and NASDAQ listing as explained in Note 1, on January 25, 2024, the Company decided to change the presentation currency of its
consolidated financial statements from Canadian Dollars to United States Dollars.
 
The Board of Directors believe that US Dollar
financial reporting provides more relevant presentation of the Company’s financial position, funding and treasury functions, financial
performance and cash flows.
 
A change in presentation currency represents a
change in accounting policy in terms of IAS 8 – Accounting Policies, Changes in Accounting Estimates and Errors, requiring
the restatement of comparative information.
 


F-13
 

 
In accordance with IAS 21 – The Effects
of Changes in Foreign Exchange Rates, the methodology followed in restating historical financial information from CDN $ to USD $.
 
The average and closing rates used in translating
the historical financial information from CDN $ to USD $ for the various periods were as follows:
 
The closing rate used as at March 31, 2024 was
$0.7380, as at March 31, 2023 was $0.7389 and as at March 31, 2022 was $0.8003.
 
The average rate used for the year ended March
31, 2024 was $0.7415. and for the year ended March 31, 2023 was $0.7559.
 
The change in presentation currency is a voluntary
change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated
to United States dollars which is disclosed in the tables below:
 


Change in presentation currency 
March 31, 2023 Reported CAD $  
Foreign Currency Translation  
March 31, 2023 Restated
USD
$ 

EQUITY 
    
    
   

Net equity 
 (271,275) 
 70,830  
 (200,445)

NET DEFICIT 
 (271,275) 
 70,830  
 (200,445)

 


Change in presentation currency 
March 31, 2022 Reported CAD $  
Foreign Currency Translation  
March 31, 2022 Restated
USD
$ 

EQUITY 
    
    
   

Net equity 
 2,122,696  
 (423,996) 
 1,698,700 

NET DEFICIT 
 2,122,696  
 (423,996) 
 1,698,700 

 


Change in presentation currency 
March 31, 2023 Reported CAD $  
Foreign Currency Translation  
March 31, 2023 Restated
USD
$ 

Expenses 
   
   
  

Sales and marketing 
 9,292  
 (2,263) 
 7,029 

Research and development 
 2,126,762  
 (517,867) 
 1,608,895 

General and administrative 
 484,382  
 (117,947) 
 366,435 

Professional and consulting fees 
 1,655,663  
 (403,153) 
 1,252,510 

Loss before other items 
 (4,276,099) 
 1,041,230 
 (3,234,869)

Other items 
    
    
   

Interest income 
 2,054  
 (500) 
 1,554 

Foreign exchange gain 
 35,574  
 (8,662) 
 26,912 

NET LOSS 
 (4,238,471) 
 1,032,068 
 (3,206,403)

 


F-14
 

 


Change in presentation currency 
March 31, 2023 Reported CAD $  
Foreign Currency Translation  
March 31, 2023 Restated
USD
$ 

Net loss 
 (4,238,471) 
 1,032,068  
 (3,206,403)

Non-cash adjustment: 
    
    
   

Share based compensation 
 292,756  
 (71,469) 
 221,287 

Foreign exchange 
 -  
 (84,499) 
 (84,499)

  
    
    
   

Changes in working capital: 
    
    
   

Other receivables 
 (152,778) 
 42,920  
 (109,858)

Prepaids 
 (97,547) 
 25,882  
 (71,665)

Accounts payable and accrued liabilities 
 2,258,967  
 (599,909) 
 1,659,058 

Cash used in operating activities 
 (1,937,073) 
 344,993  
 (1,592,080)

  
    
    
   

Proceeds received from Psyence Group Inc 
 1,551,744  
 (378,821) 
 1,172,923 

Cash provided from financing activities 
 1,551,744  
 (378,821) 
 1,172,923 

  
    
    
   

Change in cash and cash equivalents 
 (385,329) 
 (33,828) 
 (419,157)

Cash and cash equivalents, start of year 
 2,191,095  
 (437,658) 
 1,753,437 

Cash and cash equivalents, end of year 
 1,805,765  
 (471,486) 
 1,334,280 

 
Research and development
 
Expenditures on research activities, undertaken
with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and
comprehensive loss as incurred.
 
Development expenditures are capitalized only
if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits
are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell
the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect
operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as
incurred.
 
Provisions
 
Provisions are recognized when the Company has
a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle
the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required
to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations.
Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash
flows.
 


F-15
 

 
Foreign currency translation
 
The Consolidated Financial Statements are presented
in USD $ which is the Company’s functional currency.
 
In each individual entity, a foreign currency
transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency
and the foreign currency at the date of the transaction.
 
At the end of the reporting period, monetary assets
and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary
assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.
 
The resulting exchange gains or losses arising
on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial
recognition, are included in the consolidated statements of net income/(loss) and comprehensive income/(loss) in the year in which they
arise.
 
For the purpose of presenting these Consolidated
Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end
of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries
is recorded in reserves.
 
Income/(loss) per share
 
The Company presents basic and diluted income/(loss)
per share data for its common shares. Basic income/(loss) per share is calculated by dividing the profit or loss attributable to common
shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined
by adjusting the income or loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted
for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.
 
Share based compensation
 
The Company operates equity settled share-based
remuneration plans for its eligible directors, officers, employees and consultants. All goods and services received in exchange for the
grant of any share-based payments are measured at their fair value unless the fair value cannot be estimated reliably. If the Company
cannot estimate reliably the fair value of the goods and services received, the Company shall measure their value indirectly by reference
to the fair value of the equity instruments granted. For transactions with employees and others providing similar services, the Company
measures the fair value of the services by reference to the fair value of the equity instruments granted. Equity settled share-based payments
under share-based payment plans are ultimately recognized as an expense in profit or loss with a corresponding credit to contributed surplus,
in equity. If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available
estimate of the number of share options expected to vest. Non-market vesting conditions are included in the assumptions about the number
of options that are expected to become exercisable. Estimates are subsequently revised if there is any indication that the number of share
options expected to vest differs from the previous estimate. Any cumulative adjustment prior to vesting is recognized in the current period.
No adjustment is made to any expense recognized in prior period if share options ultimately exercised are different to that estimated
on vesting. Market conditions are considered in the estimate of the fair value of share-based compensation on a grant date.
 
Income taxes
 
Income tax comprises current and deferred tax.
Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders’ equity,
in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also
recognized directly in equity or other comprehensive income.
 


F-16
 

 
Current tax is the expected tax payable on the
taxable income for the year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect
of previous years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the
amounts and the Company.
 
Deferred tax is recognized in respect of all qualifying
temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Consolidated Financial
Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively
enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax
assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate
to the same taxation authority.
 
Deferred tax assets are recognized to the extent
future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable
that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.
 
Accounting Standards Effective January 1, 2024
and issued but not yet effective
 
IFRS 18 Presentation and Disclosure in Financial
Statements
 
In April 2024, the IASB issued IFRS 18 –
Presentation and Disclosure in Financial Statements which will replace IAS 1, Presentation of Financial Statements. The key
new concepts introduced in IFRS 18 relate to the structure of the statement of earnings (loss), required disclosures in the financial
statements for certain earnings or loss performance measures that are reported outside an entity’s financial statements and enhanced
principles on aggregation and disaggregation which apply to the primary financial statements and notes in general. IFRS 18 will apply
for reporting periods beginning on or after January 1, 2027, and also applies to comparative information. The Company is still in the
process of assessing the impact of this standard on its consolidated financial statements.
 
Classification of liabilities as current or non-current
(amendments to IAS 1, presentation of financial statements)
 
On January 23, 2020, an amendment was issued to
IAS 1 to address inconsistencies with how entities apply the standards over classification of current and non-current liabilities. The
amendment serves to address whether, in the statement of financial position, debt and other liabilities with an uncertain settlement should
be classified as current or non-current. This amendment is effective on January 1, 2024. The Company adopted the amendment on the effective
date and the adoption did not have a material impact on the Company’s consolidated financial statements.
 
Non-current liabilities with covenants (amendments
to IAS 1)
 
The amendments to IAS 1 specify that only covenants
with which an entity is required to comply on or before the reporting date affect the classification of a liability as current or non-current.
In addition, an entity has to disclose information in the notes that enables users of financial statements to understand the risk that
noncurrent liabilities with covenants could become repayable within twelve months. The amendments are effective for annual reporting periods
beginning on or after January 1, 2024, and are to be applied retrospectively. The Company adopted the amendment on the effective date
and the adoption did not have a material impact on the Company’s consolidated financial statements.
 
4. Critical accounting estimates and judgements

 
The preparation of consolidated financial statements
in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results
may differ from these estimates. The Company’s management reviews these estimates, judgments, and assumptions on an ongoing basis,
based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical
accounting policies as these require a high level of subjectivity and judgement and could have a material impact on the Company’s
consolidated financial statements.
 


F-17
 

 
Reverse takeover transaction
 
The determination of fair values of consideration
paid and net assets acquired is subject to significant estimation. The Company treated the RTO Transaction as a capital transaction equivalent
to the issue of shares of the Company in exchange for the net monetary assets of NCAC. The Company determined that the original shareholders
of PGI became the single largest shareholder of the Company after the RTO Transaction, therefore the Company was the acquiror and NCAC
was the acquiree.
 
The Company has determined the RTO Transaction
did not constitute a business combination as defined under IFRS 3, Business Combinations, as NCAC is a non-operating entity that did not
meet the definition of a business under IFRS 3. The excess of the consideration paid over the net liability acquired together with any
transaction costs incurred for the Transaction is expensed as a listing expense in accordance with IFRS 2 Share-Based Payments. The fair
value of the consideration paid was estimated by the closing trading price $2,863.22/share of the Company’s common shares listed
on the NASDAQ on January 25, 2024.
 
Convertible instruments
 
The valuation of convertible debt instruments
is subject to significant management estimation. Convertible notes are compound financial instruments which have been designated at FVTPL.
 
The identification of convertible debenture components
is based on interpretations of the substance of the contractual arrangement and therefore requires judgment from management. The separation
of the components affects the initial recognition of the convertible debenture at issuance and the subsequent remeasurement. As the Company
has designated the entire convertible financial instrument as FVTPL given the embedded derivate liability that was contained by the convertible
financial instrument, the debentures have not been separated into debt and derivative components. The fair values attributed to the different
components of a financing transaction, and/or derivative financial instruments, are determined using valuation techniques. The Company
uses judgement to select the methods used to make certain assumptions and in performing the fair value calculations in order to determine
(a) the values attributed to each component of a transaction at the time of their issuance; (b) the fair value measurements for certain
instruments that require subsequent measurement at fair value on a recurring basis; and (c) for disclosing the fair value of financial
instruments subsequently carried at amortized cost. These valuation estimates could be significantly different because of the use of judgement
and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market.
 
Contingencies
 
From time to time, the Company is named as a party
to claims or involved in proceedings, including legal, regulatory and tax related, in the ordinary course of its business. While the outcome
of these matters may not be estimable at the reporting date, the Company makes provisions, where possible, for the estimated outcome of
such claims or proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates, the
difference will be accounted for as a charge to profit or loss in that period. The actual results may vary and may cause significant adjustments.
 
The rebate over the tax claim is subject to inherent
uncertainty and could be subject to being denied and clawed back by the Australian Tax office at a future date. The Company expects that
a claw back of the rebate is highly unlikely.
 
Deferred taxes and Income taxes
 
Significant estimates are required in determining
the Company’s income tax provision. Some estimates are based on interpretations of existing tax laws or regulations. Various internal
and external factors may have favourable or unfavourable effects on the Company’s future effective tax rate. These include, but
are not limited to, changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, and results
of tax audits by tax authorities.
 


F-18
 

 
Provisions for taxes are made using the best estimate
of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these
provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from
audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded,
such differences will affect the tax provisions in the period in which such determination is made.
 
Share-based compensation
 
Valuation of share-based compensation requires
management to make estimates regarding the inputs for option pricing models, such as the expected life of the option, the volatility of
the Company’s stock price, the vesting period of the option and the risk-free interest rate are used. Actual results could differ
from those estimates. The estimates are considered for each new grant of stock options.
 
Government grants
 
Government grants are recognized when there is
reasonable assurance that the Company will comply with the conditions attached to them and the government grants will be received. Grants
are recognized as income when they are received. The Company has recognized the government grant received during the period as research
and development grants as other income in the consolidated statement of income/(loss) and comprehensive income/(loss).
 
5. Reverse takeover transaction with NCAC
 
On January 25, 2024 the Company completed the
RTO Transaction (See Note 1). As disclosed in Note 4, the RTO Transaction did not constitute a business combination as defined under IFRS
3, Business Combinations, as NCAC is a non-operating entity that does not meet the definition of a business under IFRS 3. The excess of
the consideration paid over the net liability acquired together with any transaction costs incurred for the Transaction is expensed as
a listing expense in accordance with IFRS 2 Share-Based Payments. The fair value of the consideration paid was determined by the closing
trading price $2,863.22/share of the NCAC’s common shares listed on the NASDAQ on January 25, 2024.
 
Accordingly, upon consummation of the BCA the
Company issued 13,040 common shares in exchange for the outstanding ordinary shares held by NCAC stockholders.
 
The calculation of listing expenses is as follows:
 


  
Listing Expense 

Consideration paid: 
  

Shares issued to NCAC shareholders 
 13,040 

Total consideration shares issued 
 13,040 

Fair value of the common shares 
$2,863.22 

Deemed consideration amount for the common shares issued 
$37,336,416 

  
   

Net identifiable liabilities acquired: 
   

Cash and cash equivalent 
$203 

Accounts payable and accrued liabilities 
$(2,136,505)

NCAC promissory note (Note 11) 
$(1,413,529)

Derivative warrant liabilities (Note 10) 
$(595,358)

Net liabilities acquired 
$4,145,189 

  
   

Listing expense 
$41,481,605 

 
The listing expense has been included in the consolidated
statements of net loss and comprehensive loss.
 
Transaction expenses included in the consolidated
statements of net loss and comprehensive loss are others costs of $2,461,025 in connection with the RTO Transaction composed of legal,
banking, professional fees and costs related to the settlement of carved-out assets and liabilities from Psyence Group. Some payments
to brokers and advisors were in the Company’s shares upon RTO at the closing trading price on January 25, 2024 (Refer Note 12).
 


F-19
 

 
6. Cash, restricted cash and cash equivalents
 
Cash and cash equivalents include the following
amounts:
 


  
March 31,
2025  
March 31,
2024 

Unrestricted cash held with chartered banks 
 6,135,166  
 733,188 

Restricted cash 
 35,964  
 29,611 

Total 
 6,171,130  
 762,799 

 

●unrestricted
cash held with chartered banks and
 

●the Company entered into a cash collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited Canadian Dollars $50,000 in a guaranteed investment certificate with the bank. Amounts are presented as restricted cash on the consolidated statements of financial position.
 
7. Equipment
 


  
Computer equipment 

Cost 
  

At March 31, 2023 
 - 

Additions 
 5,727 

At March 31, 2024 
 5,727 

Additions 
 9,877 

At March 31, 2025 
 15,604 

  
   

Accumulated Depreciation 
   

At March 31, 2023 
 - 

Charge for the year 
 (240)

At March 31, 2024 
 (240)

Charge for the year 
 (4,268)

At March 31, 2025 
 (4,508)

  
   

Carrying Value 
   

At March 31, 2024 
 5,487 

At March 31, 2025 
 11,096 

 
8. Accounts payable and accrued liabilities
 
Accounts payable and accrued liabilities include
the following amounts:
 


  
March 31,
2025  
March 31,
2024 

Trade payables 
 261,937  
 562,352 

Accrued liabilities 
 50,481  
 125,951 

Provisions 
 81,852  
 66,899 

Total 
 394,270  
 755,202 

 


F-20
 

 
9. Convertible note liability
 
On January 15, 2024, in connection with the RTO
Transaction (Note 5), the Company and Psyence Biomed II entered into the Securities Purchase Agreement with the Investors and the NCAC
Sponsor, relating to up to four senior secured convertible notes obligations under which are guaranteed by certain assets of the Company
and Psyence Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up
to $12,500,000 in exchange for up to $10,000,000 in cash subscription amounts (the “Convertible Note Financing”).
 
The First Tranche Notes, for an aggregate of $3,125,000
principal, were delivered by the Company to the Investors on January 25, 2024, in exchange for an aggregate of $2,500,000 in financing,
which occurred substantially concurrently with the consummation of the RTO Transaction. On the original issuance date of the First Tranche
Notes, interest began accruing at 8.0% per annum based on the outstanding principal amount of the First Tranche Notes and is payable monthly
in arrears in cash or in common shares of the Company. The maturity date of the First Tranche Note was January 25, 2027.
 
The Second Tranche Notes, for an aggregate of
$1,000,000 principal, were delivered by the Company to the Investors between May and July 2024, in exchange for an aggregate of $1,250,000
in financing. On the original issuance date of the Second Tranche Notes, interest began accruing at 8.0% per annum based on the outstanding
principal amount of the Second Tranche Notes and is payable monthly in arrears in cash or in common shares of the Company at the Conversion
Price. The maturity date of the Second Tranche Notes is May 31, 2027.
 
The Company designated the entire instrument as
FVTPL.
 
On August 20, 2024, the Company and the Investor
entered into an addendum to the Securities Purchase Agreement (the “Addendum”). Under the provisions of the Addendum, the
First and Second Trance Notes would be extinguished by the Company issuing common shares within the conversion limits detailed in the
Securities Purchase Agreement.
 
As a consideration to the Investor entering into
the Addendum, the Company issued to the Investor 1,673 common shares valued at $523,000 based on the market price of the common shares
on the date of issuance and 837 warrants to acquire common shares of the Company with a two-year expiry, exercisable at $298.88 per share.
The warrants were valued at $42,528 using the Black-Scholes pricing model with the following assumptions:
 
   Warrant Inputs at August 20, 2024  Share price  $312.62  Expected dividend yield   Nil  Exercise price   298.88  Risk-free interest rate   3.93% Expected life   2.00  Expected volatility   17.7% Expiry date   August 20, 2026 
 


F-21
 

 
The fair value of shares and warrants issued pursuant
to the Addendum as detailed above, was recorded in the consolidated statements of income/(loss) and comprehensive income/(loss) as part
of the fair value gain on convertible note.
 
On November 27, 2024, the Company and the Investor
entered into the Termination Agreement pursuant to which all obligations, covenants and liabilities of the Company and the Investor under
the Securities Purchase Agreement will be fully and finally terminated.
 
As a consideration to the Investor entering into
the Termination Agreement, the Company issued to the Investor 18,947 common shares valued at $489,598 based on the market price of the
common shares on the date of issuance and 22,876 warrants to acquire common shares of the Company with nominal exercise price for a one-year
period. The warrants were valued at $639,954 by the reference to the Company’s common share price.
 
The fair value of shares and warrants issued pursuant
to the Termination Agreement as detailed above, was recorded in the consolidated statements of income/(loss) and comprehensive income/(loss)
as part of the fair value gain on convertible note.
 
Between May and September 2024, the Company converted
all outstanding balance of the First and Second Tranche Notes into common shares by issuing 17,536 common shares. The total additions
to equity on conversion were $3,604,688.
 
The Company measured the fair value of the convertible
loan liability before each conversion using Monte Carlo valuation model with the following main assumptions: expected dividend yield 0%,
exercise price $224.22- $320.45, risk free interest rate 3.63%- 5.23%, expected life 0.1 – 2.7 years.
 
The change in fair value resulted in a fair value
gain of $5,052,708 (2024 – loss of $5,157,397, 2023- nil) which was recorded in the consolidated statements of income/(loss) and
comprehensive income/(loss) as part of the fair value gain on convertible note.
 
As at March 31, 2024, the fair value of the convertible
notes was estimated at $7,657,397 using a combined discounted cash flow approach and Monte Carlo simulation with the following assumptions:
 


  
Inputs 

Share price 
$681.44 

Note principal amount 
$3,125,000 

Prepayment Amount 
 130%

Discount rate shares 
 4.43%

Discount rate cash 
 20.83%

Volatility annual 
 100%

Volatility daily 
 6.30%

Risk free annual 
 4.43%

 
10. Derivative warrant liabilities
 
The Company has two classes of warrant liabilities
outstanding: Public Warrants and Private Warrants. As of March 31, 2025, there were 20,762 warrants issued and outstanding, consisting
of 19,808 Public Warrants and 954 Private Warrants (March 31, 2024 – 20,912 Public Warrants and 954 Private Warrants). Each warrant
is exercisable to purchase one common share at a price of $6,874.13 per share.
 
During the year ended March 31, 2025, the Company
entered into the Warrant Exchange Agreement. Pursuant to the Warrant Exchange Agreement, the Company issued to the Holder 1,104 Common
Shares in exchange for the surrender and cancellation of 1,104 Public Warrants held by the Holder. The warrants exchange resulted in a
loss of $185,064 which was recorded in the consolidated statements of income/(loss) and comprehensive income/(loss).
 


F-22
 

 
Public Warrants: The fair value of the Public
Warrants is determined based on the observable market price, as they continue to be traded on the Nasdaq under the symbol “PBMWW.”
Changes in fair value during the years ended March 31, 2025 and March 31, 2024, have been recognized in the consolidated statements of
income/(loss) and comprehensive income/(loss).
 
Private Warrants: The Company utilizes a Black-Scholes
options valuation model to value the private warrants at each reporting period, using the following main assumptions:
 
   Warrant Inputs at March 31, 2025   Warrant Inputs at March 31, 2024  Share price  $4.78   $681.44  Expected dividend yield   Nil    Nil  Exercise price  $6,874.13   $6,874.13  Risk-free interest rate   4.21%   4.21% Expected life   4.00    5.00  Expected volatility   59.98%   59.98% Expiry date   January 25, 2029    January 25, 2029 
 
At March 31, 2025 the fair value of the Public
and Private Warrants was $200,096 (March 31, 2024 - $875,000) and $nil (March 31, 2024 - $26,608), respectively. A fair value loss of
$694,516 was recognized on the consolidated statements of income/(loss) and comprehensive income/(loss).
 
The expected volatility was based on implied volatility
of the Public Warrants.
 
As at March 31, 2025, the derivative warrant liability
was $200,096 (March 31, 2024 – $901,608 ) reconciled as follows:
 


Derivative warrant liability – Public and Private Warrants 
Number  
Amount
($) 

At listing January 25, 2024 
 21,866  
 595,358 

Fair value loss 
 -  
 306,250 

Opening balance April 1, 2024 
 21,866  
 901,608 

Warrant exchange 
 (1,104) 
 (6,996)

Fair value gain 
 -  
 (694,516)

Balance as at March 31, 2025 
 20,762  
 200,096 

 
Warrant transactions and the number of warrants
outstanding are summarized as follows:
 


  
Public Warrants  
Private Warrants 

  
Number of Warrants  
Weighted Average Exercise Price  
Number of Warrants  
Weighted Average Exercise Price 

Balance, April 1, 2023 
 -  
 -  
 -  
 - 

Issued 
 20,912  
$6,874.13  
 954  
$6,874.13 

Balance, March 31, 2024 
 20,912  
$6,874.13  
 954  
$6,874.13 

Warrant exchange 
 (1,104) 
$6,874.13  
 -  
$6,874.13 

Balance, March 31, 2025 
 19,808  
$6,874.13  
 954  
$6,874.13 

 


F-23
 

 
The following warrants were outstanding and exercisable
at March 31, 2025:
 
Issue Date  Expiry Date  Exercise Price   Number of Warrants Outstanding   Number of Warrants Exercisable  January 25, 2024  January 25, 2029  $6,874.13    20,762    20,762 
 
11. Promissory Notes
 
On January 25, 2024, the Company issued an unsecured
convertible promissory note to PGI (the “PGI Note”), in the principal amount of $1,610,657, which is equal to the total
amount owed to PGI in connection with loans that PGI had previously made to the Company. The PGI Note bore no interest, and (i) $150,000
of the principal balance of the PGI Note was paid on the Closing Date and (ii) $1,460,657 of the principal balance of the PGI Note was
payable on the date that is the one-year anniversary after the Closing Date, or January 25, 2025. The proceeds from this loan were received
by the Company prior to the Closing Date. This note is convertible into shares at the option of PGI.
 
On January 25, 2024, the Company issued an unsecured
convertible promissory note to the NCAC Sponsor (the “NCAC Note”), in the principal amount of $1,615,501, which is
equal to the total amount owed to NCAC Sponsor under certain existing promissory notes previously issued by NCAC to the NCAC Sponsor (the
“Existing Notes”). The NCAC Note bore no interest, and (i) $100,000 of the principal balance of the NCAC Note became
owing on the Closing Date and (ii) $1,515,501 of the principal balance of the NCAC Note was payable on the date that is the one-year anniversary
after the Closing Date, or January 25, 2025. This note is convertible into shares at the option of NCAC Sponsor.
 
Both notes were designated at FVTPL due to the
embedded conversion features, as the conversion prices were not fixed.
 
At inception on January 25, 2024 the fair value
of the PGI Note was $1,418,675 and the NCAC note was $1,413,529.
 
PGI Note:
 
On September 30, 2024, the Company entered into
Debt for Equity Exchange Agreement with PGI pursuant to which the Company issued 3,473 of common shares to extinguish $1,307,960 of PGI
Note, representing a conversion price of $298.88 per share.
 
On October 25, 2024, the Company entered into
Debt for Equity Exchange Agreement with PGI pursuant to which the Company issued 1,414 of common shares to extinguish the remaining balance
of PGI Note representing, a conversion price of $298.88 per share.
 
In accordance with the Debt for Equity Exchange
Agreements entered into on September 30, 2024 and October 25, 2024, as amended, the Company will need to issue additional shares to PGI
if the Company’s volume weighted average share price for the 10 days prior to November 26, 2024 is lower than $298.88 per share
(“PGI make whole payment”).
 
In December 2024, the Company issued 42,378 common
shares to extinguish the PGI make whole payment.
 


F-24
 

 
The issuance of shares pursuant to the Debt for
Equity Exchange Agreements resulted in a fair value gain of $327,668 which was recorded in the consolidated statements of income/(loss)
and comprehensive income/(loss).
 
NCAC Note:
 
On September 30, 2024, the Company entered into
Debt for Equity Exchange Agreement with NCAC Sponsor pursuant to which the Company issued 5,405 of common shares to extinguish the outstanding
balance of NCAC Note, representing a conversion price of $298.88 per share.
 
In accordance with the Debt for Equity Exchange
Agreements, as amended, the Company will need to issue additional shares to NCAC Sponsor if the Company’s volume weighted average
share price for the 10 days prior to November 26, 2024 is lower than $298.88 per share (“NCAC make whole payment”).
 
In December 2024, the Company issued 46,870 common
shares to extinguish the NCAC make whole payment.
 
The issuance of shares pursuant to the Debt for
Equity Exchange Agreements resulted in a fair value gain of $377,897 which was recorded in the consolidated statements of income/(loss)
and comprehensive income/(loss).
 
The fair value of the notes was calculated using
a credit adjusted market borrowing rate as at March 31, 2024. The fair value of both notes was $nil as at March 31, 2025 (March 31, 2024
- $2,790,492). A fair value gain of $705,565 was recognized during the year in the statement of comprehensive income (March 31, 2024 ($108,288)).
 
12. ELOC
 
On August 28, 2024, the Company entered into a
$25 million equity line of credit (ELOC) agreement with White Lion Capital, LLC, which was declared effective by the U.S. Securities and
Exchange Commission (SEC). This agreement allows the Company to sell up to $25 million in shares over a 24-month period, subject to specific
conditions outlined in the Purchase Agreement.
 
As part of the consideration for entering into
the ELOC, the Company issued 3,392 common shares to White Lion at a fair value of $187,500 as a commitment fee. These shares were accounted
for as share issuance costs in the Consolidated Statement of Changes in Shareholders’ Equity/(Deficit).
 
During the year ended March 31, 2025, the Company
issued 218,900 common shares for total consideration of $6,692,495. The Company incurred $282,100 in cash settled share issuance costs.
 
13. Psyence Labs Ltd. Share Exchange
 
On October 28, 2024, the Company acquired 1,000
shares in Psyence Labs Ltd. (PsyLabs) from PGI, the Company’s parent company. PsyLabs is a private company headquartered in the
British Virgin Islands. PsyLabs is focused on the production of psychedelic active pharmaceutical ingredients and extracts. The Company
issued 3,346 common shares in exchange for the shares in PsyLabs. There was a make whole provision which entitled the PGI to a top-up
in shares if the share price at November 26, 2024 was lower than the issuance price on October 28, 2024. The share price was lower which
triggered the top-up leading to the issuance of an additional 32,248 shares to PGI. The total consideration was 35,594 shares. Based on
the listed share price of PBM’s common shares at the respective dates of issuance, the total fair value of shares issued was $722,033,
which was recorded as the cost of the investment in PsyLabs.
 
Fair Value Assessment
 
As at March 31, 2025, the Company determined the
fair value of its investment in PsyLabs to be $745,000, based on a recent arm’s length subscription transaction by a third-party
investor at $745 per PsyLabs share. This price was considered to represent a Level 2 input under the fair value hierarchy in accordance
with IFRS 13 – Fair Value Measurement, as it reflects observable market-based pricing for an identical equity instrument
in an active negotiation with a market participant.
 


F-25
 

 
As a result, the Company recognized an unrealized
fair value gain of $22,967 in the statement of profit or loss and other comprehensive income for the year ended March 31, 2025, in accordance
with IFRS 9 – Financial Instruments, as the investment is classified as a financial asset measured at fair value through
profit or loss (FVTPL).
 


Summary of transaction 
  

Description 
Amount 

Number of shares in PsyLabs acquired 
 1,000 

Total PBM shares issued 
 35,594 

Total fair value of shares issued 
$722,033 

Fair value of investment at March 31, 2025 
$745,000 

Fair value gain recognized 
$22,967 

 
14. PIPE Financing - Private Placement and
Warrants
 
Private placement
 
On December 24, 2024, the Company completed a private
placement with HC Wainwright & Co., LLC (“HCW”), raising gross proceeds of $2,000,000
through the issuance of:
 

●47,679 common shares,
 

●77,792 pre-funded warrants (each exercisable into one common share at a nominal exercise price of $0.000797), and
 

●250,942 common share purchase warrants, comprising:
 

o125,471 warrants with an exercise price of $15.94 and a 5-year term (expiring December 24, 2029), and
 

o125,471 warrants with an exercise price of $15.94 and a 2-year term (expiring December 24, 2026).
 
The proceeds were allocated between the common
shares and the warrants based on their relative fair values on the date of issuance. The fair value allocation was as follows:
 


Fair value allocation 
  

Component 
Allocated Amount 

Common shares 
$313,628 

Pre-funded warrants 
$511,690 

Warrants 
$1,174,682 

Total gross proceeds 
$2,000,000 

 


F-26
 

 
Fair value allocation assumptions
 
The common shares were estimated using the share
price on date of issuance - $19.37.
 
The pre-funded warrants and the warrants were
estimated using a Black Scholes valuation model using the following estimates:
 
   Pre-funded
warrants   Warrants with
5 year expiry   Warrant with
2 year expiry  Share price  $19.37   $19.37   $19.37  Expected dividend yield   Nil    Nil    Nil  Exercise price  $0.00   $15.94   $15.94  Risk-free interest rate   3.63%   3.63%   3.63% Expected life   -    5.00    2.00  Expected volatility   100%   100%   100% Expiry date   -    December 24, 2029    December 24, 2026 
 
Share Issuance Costs
 
The Company incurred $257,949 in cash settled
share issuance costs, which were allocated proportionately to the equity instruments issued. The portion related to the common shares,
$40,449, was deducted from share capital, and the portion related to the warrants, $217,500, was deducted from the warrant reserve. The
Company also incurred $137,778 in warrant settled issuance costs, 9,409 warrants, which was allocated to warrant reserve.
 
Pre-funded Warrant Exercise
 
During the year ended March 31, 2025, all 77,792
pre-funded warrants were exercised. An amount of $511,690, representing the fair value originally allocated to the pre-funded warrants,
was reclassified from warrant reserve to share capital upon exercise. An amount of $66,003 of share issuance costs was reallocated to
share capital upon exercise.
 
All instruments issued in the private placement
were classified as equity instruments, as they did not contain any contractual obligations to deliver cash or other financial assets and
met the fixed-for-fixed condition.
 
15. Share capital
 
a) Authorized
 
The Company is authorized to issue an unlimited
number of Common Shares, each without par value.
 
b) Issued and outstanding
 
On November 26, 2024, the Company consolidated
its common shares on the basis of 75:1.
 
On May 5, 2025, the Company consolidated its common
shares and warrants on the basis of 7.97:1. All common shares and value per share amounts have been updated to reflect the share consolidations.
 


F-27
 

 
As at March 31, 2025, there were 568,021 (March
31, 2024 – 22,402) issued and outstanding Common Shares.
 


 
2025 

Common shares 
Number  
Amount ($) 

Opening balance April 1, 2024 
 22,402  
 46,125,397 

Shares issued on conversion of convertible note 
 38,156  
 4,617,286 

Shares issued on conversion of convertible note warrants 
 22,876  
 639,954 

Shares issued for ELOC 
 218,900  
 6,692,495 

Commitment shares ELOC 
 3,392  
 187,500 

Share issuance costs for ELOC 
 -  
 (469,600)

Warrant exchange 
 1,104  
 192,060 

Shares issued to third party advisors 
 586  
 241,379 

Shares issued on conversion of PGI promissory notes 
 47,265  
 988,569 

Shares issued on conversion of NCAC promissory notes 
 52,275  
 1,096,358 

Shares issued for PsyLabs share exchange 
 35,594  
 722,033 

Shares issued for PIPE financing 
 47,679  
 313,628 

Share issuance costs for PIPE financing 
 -  
 (40,449)

Shares issued for PIPE pre-funded warrants exercised 
 77,792  
 511,690 

Shares issuance costs for PIPE pre-funded warrants exercised 
 -  
 (65,995)

Balance as at March 31, 2025 
 568,021  
 61,752,305 

 
On January 25, 2024, because of the completion
of the RTO Transaction, the Company issued 8,365 Common Shares to PGI, 13,040 to the previous shareholders of NCAC and 997 to third party
advisors (see Note 5).
 
Payments to advisors of NCAC was settled in the
Company’s shares upon RTO Transaction at the closing price. Accounts payable of $2,136,340 acquired from NCAC as part of the RTO
Transaction was settled through the issuance of 746 shares at a fair value of $2,863.22 per share on January 25, 2024.
 
An amount of $1,000,000 owing by the Company for
services provided in relation to the RTO Transaction was settled through the issuance of 251 common shares at a fair value of $2,863.22.
A gain on settlement of $281,500 was included in the consolidated statements of net loss and comprehensive loss relating to this advisor
settlement.
 
The opening balance of equity is the net parent investment which represents
the net financings that the Company received from PGI to fund its operations through contributions to the clinical trials, cash extended
to the Company’s subsidiaries and the net effect of cost allocations from transactions with PGI, all of which did not require repayments.
 
c) Income/(Loss) per share
 
The calculation of basic and diluted income/(loss)
per share is based on the income/(loss) for the year divided by the weighted average number of shares in circulation during the year.
In calculating the diluted loss per share, potentially dilutive shares such as options, convertible debt and warrants have not been included
as they would have the effect of decreasing the loss per share, and they would therefore be anti-dilutive.
 


F-28
 

 
d) Warrant Reserve
 
As at March 31, 2025, there were 261,188 (March
31, 2024 – nil) issued and outstanding Warrants.
 


  
2025 

Warrants 
Number  
Amount ($) 

Opening balance April 1, 2024 
 -  
 - 

Warrants issued for convertible note Addendum 
 837  
 42,528 

Warrants issued for convertible note Termination Agreement 
 22,876  
 639,954 

Convertible note Termination Agreement warrants exercised 
 (22,876) 
 (639,954)

PIPE financing warrant issuance 
 328,734  
 1,686,372 

PIPE financing warrant issuance costs 
 9,409  
 137,778 

Issuance costs for PIPE financing warrants 
 -  
 (355,278)

PIPE pre-funded warrants exercised 
 (77,792) 
 (511,690)

Issuance costs for PIPE pre-funded warrants exercised 
 -  
 65,995 

Balance as at March 31, 2025 
 261,188  
 1,065,705 

 
The following warrants were outstanding and exercisable
at March 31, 2025:
 
Issue Date  Expiry Date  Exercise Price   Number of Warrants Outstanding   Number of Warrants Exercisable  August 20, 2024  August 20, 2026  $298.88    837    837  December 24, 2024  December 24, 2029  $15.94    125,471    125,471  December 24, 2024  December 24, 2026  $15.94    125,471    125,471  December 24, 2024  December 24, 2029  $19.93    9,409    9,409 
 
16. Other income
 
In the prior year ended, March 31, 2024, the Company
received a research and development rebate of AUD $1,336,622 ($879,344) from the Australian Taxation office. The Company benefits from
the Australian Federal Government’s Research & Development tax incentive program, which provides up to a 43.5% rebate on research
and development expenses in Australia.
 
This rebate represents a government grant aimed
at supporting research and development activities. Therefore, in accordance with IAS 20, Accounting for Governmental Grants and Disclosure
of Government Assistance, the grant is recognized as income when there is a reasonable assurance that the grant will be received and
that the Company will comply with the conditions attached to it. These conditions were satisfied when the Company received the rebate
on October 5, 2023.
 
On August 21, 2023 the Company entered into a
loan agreement via its Australian subsidiary Psyence Australia (Pty) Ltd (the "Borrower"), to borrow up to AUD $1,100,000
by way of a secured loan from RH Capital Finance Co., LLC (“Lender”). The Loan is secured by way of a General Security
Agreement and company guarantee against the assets of the Borrower and the Company.
 
The loan was granted to the Borrower after it
successfully registered its research and development activities with the Australian Federal Government. The Borrower benefits from the
Australian Federal Government’s Research & Development tax incentive program, which provides up to a 43.5% rebate on research
and development expenses in Australia. The Loan bears interest at 16% per annum subject to a minimum interest chargeable period of 91
days and is repayable at the earlier of: (a) 21 business days after the notice of assessment (in respect of R&D refunds) is issued
by the Australian Taxation Office to the Borrower for the financial year ended June 30, 2023 (b) an event of default and (c) 30 November
2023.
 
The loan with the Lender was repaid in full on
October 5, 2023 when the Company received the research and development rebate from the Australian Taxation office, which was utilized
to settle the loan payable.
 
$nil (March 31, 2024 - $29,697) in interest expense
was incurred during the year ended March 31, 2025, on this loan. The loan and all outstanding interest was repaid.
 


F-29
 

 
17. Capital management
 
The Company’s objectives when managing capital
are to safeguard the Company’s ability to continue as a going concern to pursue the development of natural health business, to maintain
a flexible capital structure which optimizes the cost of capital at an acceptable risk level.
 
The Company manages its capital structure and
adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its
capital structure, the Company may obtain additional funding from equity financing, issue new debt, acquire or dispose of assets or adjust
the amount of cash and cash equivalents on hand. The Company defines capital as the aggregate of its capital stock and borrowings.
 
Total managed capital is as follows as at March
31, 2025 and 2024:
 


  
2025  
2024 

Borrowings 
 -  
 10,447,889 

Share capital 
 61,752,305  
 46,125,397 

Total 
 61,752,305  
 56,573,286 

 
To facilitate the management of its capital requirements,
the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment
and general industry conditions. The annual and updated budgets are approved by the Board of Directors.
 
Management considers its approach to capital management
to be appropriate given the relative size of the Company. There were no changes in the Company’s approach to capital management
during the period.
 
18. Transactions with related parties
 
All related party transactions are measured at
the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from
or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments.
The Company incurred the following transactions with related parties during the years ended March 31, 2025 and March 31, 2024:
 
Compensation to key management personnel
 
Key management personnel are those people who
have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management
personnel include the Company’s executive officers and Board of Directors.
 


Key Management Personnel 
 March 31,
2025  
March 31,
2024 

Short term benefits 
 984,697  
 465,702 

Share based compensation 
 -  
 233,295 

Total 
 984,697  
 698,997 

 
Short term benefits consist of consulting fees,
director’s fees, payroll and other benefits paid to key management personnel. Share based compensation is options granted to key
management personnel.
 


F-30
 

 
19. Share based compensation
 
During the year ended March 31, 2025, $nil (Year
ended March 31, 2024 - $317,882) was recognized for options and restricted stock units (“RSU’s”) granted by Psyence
Group under professional and consulting fees expenses and general and administrative expenses on the consolidated statements of net loss
and comprehensive loss. No options are outstanding as of March 31, 2025.
 
This share-based compensation relates only to
the historic carve out pre-combination period and does not relate to options or RSUs in the Company. No share options or RSUs have been
issued by the Company during the year.
 
20. Income tax note
 
The reconciliation of the combined Canadian federal
and provincial statutory income tax rate of 26.5% (2024 – 26.5%) to the effective tax rate is as follows:
 


  
2025  
2024 

Net Income/(Loss) before recovery of income taxes 
 1,011,790  
 (51,159,048)

  
    
   

Expected income tax (recovery)/expense 
 268,124  
 (13,557,148)

Difference in foreign tax rates 
 6,871  
 966 

Listing expense 
 -  
 10,992,625 

Non-taxable fair value gain adjustment 
 (1,722,146) 
 - 

Non-deductible loss on loan settlement 
 449,196  
 - 

Share issue costs booked to equity 
 (246,802) 
 - 

Other permanent expenses 
 1,787  
 2,061,001 

Change in tax benefits not recognized 
 1,242,970  
 502,556 

Income tax (recovery)/expense 
 -  
 - 

 
Unrecognized deferred tax asset
 
Deferred taxes are provided as a result of temporary
differences that arise due to the differences between the income tax values and the carrying amounts of assets and liabilities. Deferred
tax assets have not been recognized in respect of the following deductible temporary differences:
 


Unrecognized deductible temporary differences 
2025  
2024 

Equipment 
 4,508  
 240 

Restricted interest and financing expenses – Canada 
 764,297  
 - 

Share issuance costs and others 
 722,097  
 124,132 

Non-capital losses carried forward-Canada 
 4,248,226  
 1,357,347 

Non-capital losses carried forward-Australia 
 431,349  
 164,861 

  
 6,170,477  
 1,646,580 

 
The Company’s non-capital loss carry forwards
will expire as noted in the table below:
 


Year of expiry 
Canada  
Australia 

2044 
 1,357,347  
 - 

2045 
 2,890,879  
   

Indefinite 
 -  
 431,349 

Total 
 4,248,226  
 431,349 

 


F-31
 

 
21. Financial instruments and financial risk
management
 
a) Financial instrument classification and
fair value measurement
 
Financial instruments that are recorded at fair
value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance
of the inputs used in making the measurements.
 
The fair value of hierarchy has the following
levels:
 

●Level
1 – quoted prices in active markets for identical financial instruments.
 

●Level
2 – quoted prices for similar instruments in active markets; quoted prices for identical
or similar instruments in the markets that are not active; and model-derived valuations in
which all significant inputs and significant value drivers are observable in active markets.
 

●Level
3 – valuations derived from valuation techniques in which one or more significant inputs
or significant value drivers are unobservable.
 
The table below presents the carrying value of
the Company’s financial instruments:
 


  
Level 1  
Level 2  
Level 3  
Total 

Investment in Psyence Labs Ltd 
 -  
 745,000  
 -  
 745,000 

Derivative warrant liabilities – public warrants 
 200,096  
 -  
 -  
 200,096 

Balance, March 31, 2025 
 200,096  
 745,000  
 -  
 945,096 

 


  
Level 1  
Level 2  
Level 3  
Total 

Derivative warrant liabilities – private warrants 
 -  
 26,608  
 -  
 26,608 

Derivative warrant liabilities – public warrants 
 875,000  
 -  
 -  
 875,000 

Convertible notes 
 -  
 -  
 7,657,397  
 7,657,397 

NCAC Sponsor promissory note 
 -  
 -  
 1,474,256  
 1,474,256 

PGI promissory note 
 -  
 -  
 1,316,236  
 1,316,236 

Balance, March 31, 2024 
 875,000  
 26,608  
 10,447,889  
 11,349,497 

 
The face value of the other financial instruments
approximates the fair value due to the short-term maturity nature of the financial instruments.
 
There were no transfers in and out of level 3
during the year.
 
b) Risk management
 
In the normal course of business, the Company
is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial
risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company’s Board of
Directors has overall responsibility for the establishment and oversight of the Company’s risk management framework.
 
Credit risk
 
Credit risk arises from cash and cash equivalents
held with banks. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing
counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents
by depositing with only reputable financial institutions.
 


F-32
 

 
Liquidity risk
 
Liquidity risk is the risk that the Company will
not be able to meet its financial obligations as they fall due.
 
The Company manages liquidity risk through an
ongoing review of future commitments and cash balances available. Historically, the Company’s main source of funding has been through
investments from its parent. The Company’s access to financing is uncertain. There can be no assurance of continued access to significant
equity or debt funding.
 
The following table set forth the maturity of
the contractual obligations as at March 31, 2025 and after
 


  
Carrying Amount  
Contractual Cash Flows  
Less than 1 year  
Between 1 and 3 years 

Accounts payable & accrued liabilities 
 394,270  
 394,270  
 394,270  
          - 

Total contractual obligations 
 394,270  
 394,270  
 394,270  
 - 

 
Interest rate risk
 
Interest rate risk is the risk that the fair value
of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has no significant
interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially independent of changes in market
interest rates.
 
Foreign exchange risk
 
Foreign currency risk is the risk that the fair
values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective
functional currency.
 
As at March 31, 2025, a 10% fluctuation in foreign
exchange rates would result in a $8,861 impact to net loss and comprehensive loss.
 
22. Subsequent Events
 
On April 15, 2025 the Company issued an additional
15,242 common shares to a third-party consultant.
 
On April 15, 2025 the Company signed a subscription
agreement to subscribe for an additional 250 shares in Psyence Labs Ltd for total consideration of $500,000 in cash.
 
On April 17, 2025 the Company granted 12,711 restricted
stock units (“RSU’s”) to consultants and an employee of the Company. This was granted pursuant to an equity incentive
scheme implemented by the Company to incentivise consultants and employees.
 
On May 5, 2025, the Company consolidated its common
shares on the basis of 7.97:1.
 
Subsequent to year end the Company issued 130,000
shares for gross proceeds of $607,050 under the ELOC.
 


F-33





























































































































































































0001985062
false
FY




0001985062


2024-04-01
2025-03-31



0001985062

dei:BusinessContactMember



2024-04-01
2025-03-31



0001985062

pbm:CommonSharesWithoutParValueMember



2024-04-01
2025-03-31



0001985062

pbm:WarrantsEachExercisableToPurchaseOneCommonShareAtAnExercisePriceOf1150PerShareMember



2024-04-01
2025-03-31



0001985062


2025-03-31



0001985062


2024-03-31



0001985062

pbm:NcacSponsorMember



2025-03-31



0001985062

pbm:NcacSponsorMember



2024-03-31



0001985062

ifrs-full:ParentMember



2025-03-31



0001985062

ifrs-full:ParentMember



2024-03-31



0001985062


2023-04-01
2024-03-31



0001985062


2022-04-01
2023-03-31



0001985062

ifrs-full:OrdinarySharesMember



2022-03-31



0001985062

ifrs-full:IssuedCapitalMember



2022-03-31



0001985062

ifrs-full:WarrantReserveMember



2022-03-31



0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2022-03-31



0001985062

ifrs-full:RetainedEarningsMember



2022-03-31



0001985062


2022-03-31



0001985062

ifrs-full:IssuedCapitalMember



2022-04-01
2023-03-31



0001985062

ifrs-full:WarrantReserveMember



2022-04-01
2023-03-31



0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2022-04-01
2023-03-31



0001985062

ifrs-full:RetainedEarningsMember



2022-04-01
2023-03-31



0001985062

ifrs-full:OrdinarySharesMember



2023-03-31



0001985062

ifrs-full:IssuedCapitalMember



2023-03-31



0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2023-03-31



0001985062

ifrs-full:RetainedEarningsMember



2023-03-31



0001985062


2023-03-31



0001985062

ifrs-full:WarrantReserveMember



2023-03-31



0001985062

ifrs-full:OrdinarySharesMember



2023-04-01
2024-03-31



0001985062

ifrs-full:IssuedCapitalMember



2023-04-01
2024-03-31



0001985062

ifrs-full:WarrantReserveMember



2023-04-01
2024-03-31



0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2023-04-01
2024-03-31



0001985062

ifrs-full:RetainedEarningsMember



2023-04-01
2024-03-31



0001985062

ifrs-full:OrdinarySharesMember



2024-03-31



0001985062

ifrs-full:IssuedCapitalMember



2024-03-31



0001985062

ifrs-full:WarrantReserveMember



2024-03-31



0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2024-03-31



0001985062

ifrs-full:RetainedEarningsMember



2024-03-31



0001985062

ifrs-full:OrdinarySharesMember



2024-04-01
2025-03-31



0001985062

ifrs-full:IssuedCapitalMember



2024-04-01
2025-03-31



0001985062

ifrs-full:WarrantReserveMember



2024-04-01
2025-03-31



0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2024-04-01
2025-03-31



0001985062

ifrs-full:RetainedEarningsMember



2024-04-01
2025-03-31



0001985062

ifrs-full:OrdinarySharesMember



2025-03-31



0001985062

ifrs-full:IssuedCapitalMember



2025-03-31



0001985062

ifrs-full:WarrantReserveMember



2025-03-31



0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2025-03-31



0001985062

ifrs-full:RetainedEarningsMember



2025-03-31



0001985062

pbm:PsyenceAustraliaPtyLtdMember



2024-04-01
2025-03-31



0001985062

pbm:PysenceBiomedIICorpMember



2024-04-01
2025-03-31



0001985062

pbm:NewcourtAcquisitionCorpMember



2024-04-01
2025-03-31



0001985062

pbm:CashAndCashEquivalentMember



2024-04-01
2025-03-31



0001985062

pbm:RestrictedCashMember



2024-04-01
2025-03-31



0001985062

pbm:OtherReceivablesMember



2024-04-01
2025-03-31



0001985062

pbm:InvestmentInPsyenceLabsLtdMember



2024-04-01
2025-03-31



0001985062

pbm:AccountsPayableAndAccruedLiabilitieMember



2024-04-01
2025-03-31



0001985062

pbm:DerivativeWarrantLiabilitiesMember



2024-04-01
2025-03-31



0001985062

pbm:ConvertibleNoteLiabilityMember



2024-04-01
2025-03-31



0001985062

pbm:DueToNCACSponsorMember



2024-04-01
2025-03-31



0001985062

pbm:DueToPsyenceGroupIncMember



2024-04-01
2025-03-31



0001985062

ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember



2023-03-31



0001985062

ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember



2023-03-31



0001985062

ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember



2022-03-31



0001985062

ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember



2022-03-31



0001985062

ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember



2022-04-01
2023-03-31



0001985062

ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember



2022-04-01
2023-03-31



0001985062


2024-01-25



0001985062

pbm:NcacMember



2024-01-25



0001985062

pbm:NcacMember



2025-03-31



0001985062

pbm:RTOMember



2024-04-01
2025-03-31



0001985062

pbm:NcacMember



2024-04-01
2025-03-31



0001985062

pbm:NcacMember



2025-03-31



0001985062

ifrs-full:ComputerEquipmentMember



2023-03-31



0001985062

ifrs-full:GrossCarryingAmountMember
ifrs-full:ComputerEquipmentMember



2023-04-01
2024-03-31



0001985062

ifrs-full:GrossCarryingAmountMember
ifrs-full:ComputerEquipmentMember



2024-03-31



0001985062

ifrs-full:GrossCarryingAmountMember
ifrs-full:ComputerEquipmentMember



2024-04-01
2025-03-31



0001985062

ifrs-full:GrossCarryingAmountMember
ifrs-full:ComputerEquipmentMember



2025-03-31



0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2023-03-31



0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2023-04-01
2024-03-31



0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2024-03-31



0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2024-04-01
2025-03-31



0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2025-03-31



0001985062

ifrs-full:ComputerEquipmentMember



2024-03-31



0001985062

ifrs-full:ComputerEquipmentMember



2025-03-31



0001985062

pbm:InvestorsMember
ifrs-full:TopOfRangeMember
ifrs-full:ConvertibleInstrumentsMember



2024-01-15



0001985062

pbm:FirstTrancheNoteMember
pbm:InvestorsMember



2024-01-25



0001985062

pbm:FirstTrancheNoteMember
pbm:InvestorsMember



2024-01-25
2024-01-25



0001985062


2024-07-31



0001985062


2024-07-31
2024-07-31



0001985062

pbm:SecondTrancheNotesMember



2024-07-31



0001985062

pbm:InvestorsMember
ifrs-full:OrdinarySharesMember



2024-08-20



0001985062

pbm:InvestorsMember
ifrs-full:OrdinarySharesMember



2024-08-01
2024-08-20



0001985062

pbm:InvestorsMember
ifrs-full:WarrantsMember



2024-08-20



0001985062

pbm:InvestorsMember



2024-08-20



0001985062

pbm:InvestorsMember



2024-08-20
2024-08-20



0001985062

pbm:InvestorsMember



2025-03-31



0001985062

pbm:InvestorsMember



2024-04-01
2025-03-31



0001985062

pbm:InvestorsMember
ifrs-full:WarrantsMember



2025-03-31



0001985062

pbm:FirstTrancheNoteMember



2024-09-30



0001985062


2024-09-30
2024-09-30



0001985062

ifrs-full:ConvertibleInstrumentsMember



2024-09-30
2024-09-30



0001985062

ifrs-full:BottomOfRangeMember
ifrs-full:ConvertibleInstrumentsMember



2024-09-30
2024-09-30



0001985062

ifrs-full:TopOfRangeMember
ifrs-full:ConvertibleInstrumentsMember



2024-09-30
2024-09-30



0001985062

ifrs-full:ConvertibleInstrumentsMember



2024-04-01
2025-03-31



0001985062

ifrs-full:ConvertibleInstrumentsMember



2023-04-01
2024-03-31



0001985062

ifrs-full:ConvertibleInstrumentsMember



2022-04-01
2023-03-31



0001985062

ifrs-full:ConvertibleInstrumentsMember



2024-03-31



0001985062

pbm:SharePriceMeasurementInputMember



2024-08-20



0001985062

pbm:ExpectedDividendYieldMeasurementInputMember



2024-08-20



0001985062

pbm:ExercisePriceMeasurementInputMember



2024-08-20



0001985062

ifrs-full:InterestRateMeasurementInputMember



2024-08-20



0001985062

pbm:ExpectedLifeMeasurementInputMember



2024-08-20



0001985062

ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember



2024-08-20



0001985062

pbm:ExpiryDateMeasurementInputMember



2024-08-20



0001985062

pbm:SharePriceMeasurementInputMember



2024-03-31



0001985062

pbm:NotePrincipalAmountMeasurementInputMember



2024-03-31



0001985062

ifrs-full:ConstantPrepaymentRateMeasurementInputMember



2024-03-31



0001985062

pbm:DiscountRateSharesMeasurementInputMember



2024-03-31



0001985062

ifrs-full:DiscountRateMeasurementInputMember



2024-03-31



0001985062

pbm:VolatilityAnnualMember



2024-03-31



0001985062

ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember



2024-03-31



0001985062

ifrs-full:InterestRateMeasurementInputMember



2024-03-31



0001985062

pbm:PublicWarrantsMember



2025-03-31



0001985062

pbm:PrivateWarrantsMember
pbm:DerivativeWarrantLiabilitiesMember



2025-03-31



0001985062

pbm:PublicWarrantsMember
pbm:DerivativeWarrantLiabilitiesMember



2024-03-31



0001985062

pbm:PrivateWarrantsMember
pbm:DerivativeWarrantLiabilitiesMember



2024-03-31



0001985062

pbm:PublicWarrantsMember



2024-04-01
2025-03-31



0001985062

pbm:PublicWarrantsMember



2024-03-31



0001985062

pbm:PrivateWarrantsMember



2024-03-31



0001985062

pbm:DerivativeWarrantLiabilitiesMember



2024-04-01
2025-03-31



0001985062

pbm:DerivativeWarrantLiabilitiesMember



2025-03-31



0001985062

pbm:DerivativeWarrantLiabilitiesMember



2024-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:SharePriceMeasurementInputMember



2025-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:SharePriceMeasurementInputMember



2024-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExpectedDividendYieldMeasurementInputMember



2025-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExpectedDividendYieldMeasurementInputMember



2024-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExercisePriceMeasurementInputMember



2025-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExercisePriceMeasurementInputMember



2024-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
ifrs-full:InterestRateMeasurementInputMember



2025-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
ifrs-full:InterestRateMeasurementInputMember



2024-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExpectedLifeMeasurementInputMember



2025-03-31



0001985062


ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExpectedLifeMeasurementInputMember



2024-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember



2025-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember
ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember



2024-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember



2025-03-31



0001985062

ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31



0001985062


2024-01-24



0001985062


2024-01-25
2024-03-31



0001985062

pbm:PublicWarrantsMember



2023-03-31



0001985062

pbm:PrivateWarrantsMember



2023-03-31



0001985062

pbm:PublicWarrantsMember



2023-04-01
2024-03-31



0001985062

pbm:PrivateWarrantsMember



2023-04-01
2024-03-31



0001985062

pbm:PrivateWarrantsMember



2024-04-01
2025-03-31



0001985062

pbm:PrivateWarrantsMember



2025-03-31



0001985062

ifrs-full:WarrantsMember



2024-04-01
2025-03-31



0001985062

ifrs-full:WarrantsMember



2025-03-31



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
ifrs-full:ParentMember



2024-01-25



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
ifrs-full:ParentMember



2024-01-25
2024-01-25



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
ifrs-full:ParentMember



2025-01-25
2025-01-25



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-03-31



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-01-25
2024-01-25



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2025-01-25
2025-01-25



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-01-25



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-09-30



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-09-30
2024-09-30



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-10-25



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-11-26
2024-11-26



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-12-31



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-04-01
2025-03-31



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-09-30



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-09-30
2024-09-30



0001985062

pbm:NCACNoteMember



2024-12-31



0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember



2024-04-01
2025-03-31



0001985062

pbm:NCACNoteMember



2025-03-31



0001985062

pbm:NCACNoteMember



2024-03-31



0001985062

pbm:NCACNoteMember



2024-04-01
2025-03-31



0001985062

pbm:NCACNoteMember



2023-04-01
2024-03-31



0001985062

pbm:ELOCMember



2024-08-28
2024-08-28



0001985062

pbm:WhiteLionMember



2025-03-31



0001985062

pbm:ELOCMember



2024-04-01
2025-03-31



0001985062

pbm:ELOCMember



2025-03-31



0001985062

pbm:PsyenceLabsLtdMember



2024-10-28



0001985062

ifrs-full:OrdinarySharesMember



2024-10-28



0001985062


2024-10-28



0001985062


2024-10-28
2024-10-28



0001985062

pbm:PrivatePlacementAndWarrantsMember



2024-12-24



0001985062

pbm:PrivatePlacementAndWarrantsMember



2029-12-24
2029-12-24



0001985062

pbm:PrivatePlacementAndWarrantsMember



2029-12-24



0001985062

pbm:PrivatePlacementAndWarrantsMember



2024-04-01
2025-03-31



0001985062

pbm:PrivatePlacementAndWarrantsMember



2025-03-31



0001985062

pbm:PrivatePlacementAndWarrantsMember



2026-12-24
2026-12-24



0001985062

pbm:FairValueAllocationAssumptionsMember



2025-03-31



0001985062

pbm:PrefundedWarrantsMember
pbm:SharePriceWarrantMember



2025-03-31



0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:SharePriceWarrantMember



2025-03-31



0001985062

pbm:WarrantWith2YearExpiryMember
pbm:SharePriceWarrantMember



2025-03-31



0001985062

pbm:PrefundedWarrantsMember
pbm:ExpectedDividendYieldWarrantMember



2025-03-31



0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExpectedDividendYieldWarrantMember



2025-03-31



0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExpectedDividendYieldWarrantMember



2025-03-31



0001985062

pbm:PrefundedWarrantsMember
pbm:ExercisePriceWarrantMember



2025-03-31



0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExercisePriceWarrantMember



2025-03-31



0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExercisePriceWarrantMember



2025-03-31



0001985062

pbm:PrefundedWarrantsMember
pbm:RiskfreeInterestRateWarrantMember



2025-03-31



0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:RiskfreeInterestRateWarrantMember



2025-03-31



0001985062

pbm:WarrantWith2YearExpiryMember
pbm:RiskfreeInterestRateWarrantMember



2025-03-31



0001985062

pbm:PrefundedWarrantsMember
pbm:ExpectedLifeWarrantMember



2025-03-31



0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExpectedLifeWarrantMember



2025-03-31



0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExpectedLifeWarrantMember



2025-03-31



0001985062

pbm:PrefundedWarrantsMember
pbm:ExpectedVolatilityWarrantMember



2025-03-31



0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExpectedVolatilityWarrantMember



2025-03-31



0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExpectedVolatilityWarrantMember



2025-03-31



0001985062

pbm:PrefundedWarrantsMember
pbm:ExpiryDateWarrantMember



2025-03-31



0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExpiryDateWarrantMember



2025-03-31



0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExpiryDateWarrantMember



2025-03-31



0001985062

ifrs-full:OrdinarySharesMember



2025-03-31



0001985062

ifrs-full:OrdinarySharesMember



2024-03-31



0001985062

pbm:PGIMember



2024-01-25



0001985062

pbm:NcacMember



2024-01-25



0001985062

pbm:ThirdPartyAdvisorsMember



2024-01-25



0001985062

pbm:RTOTransactionMember



2024-01-25



0001985062

ifrs-full:OrdinarySharesMember



2024-03-31



0001985062

ifrs-full:WarrantsMember



2025-03-31



0001985062

ifrs-full:WarrantsMember



2024-03-31



0001985062

pbm:IssuedAndOutstandingWarrantsMember



2024-03-31



0001985062

pbm:IssuedAndOutstandingWarrantsMember



2025-03-31



0001985062

pbm:IssuedAndOutstandingWarrantsMember



2024-04-01
2025-03-31



0001985062

pbm:AugustMember



2025-03-31



0001985062

pbm:DecemberTwenteyFourMember



2025-03-31



0001985062

pbm:DecemberTwentyFourOneMember



2025-03-31



0001985062

pbm:DecemberTwentyFourTwoMember



2025-03-31



0001985062

pbm:ResearchAndDevelopmentExpensesMember



2023-04-01
2024-03-31



0001985062

pbm:PsyenceAustraliaPtyLtdMember



2023-08-21



0001985062

pbm:RHCapitalFinanceCoLLCMember



2024-04-01
2025-03-31



0001985062

pbm:RHCapitalFinanceCoLLCMember



2025-03-31



0001985062

pbm:RHCapitalFinanceCoLLCMember



2023-04-01
2024-03-31



0001985062

country:CA



2024-04-01
2025-03-31



0001985062

country:CA



2023-04-01
2024-03-31



0001985062

ifrs-full:ComputerEquipmentMember



2025-03-31



0001985062

ifrs-full:ComputerEquipmentMember



2024-03-31



0001985062

country:CA
ifrs-full:OtherTemporaryDifferencesMember



2025-03-31



0001985062

country:CA
ifrs-full:OtherTemporaryDifferencesMember



2024-03-31



0001985062

pbm:OtherMember



2025-03-31



0001985062

pbm:OtherMember



2024-03-31



0001985062

country:CA
pbm:NonCapitalLossesCarriedForwardMember



2025-03-31



0001985062

country:CA
pbm:NonCapitalLossesCarriedForwardMember



2024-03-31



0001985062

country:AU
pbm:NonCapitalLossesCarriedForwardMember



2025-03-31



0001985062

country:AU
pbm:NonCapitalLossesCarriedForwardMember



2024-03-31



0001985062

pbm:TaxYear2044Member
country:CA



2025-03-31



0001985062

pbm:TaxYear2044Member
country:AU



2025-03-31



0001985062

pbm:TaxYear2045Member
country:CA



2025-03-31



0001985062

pbm:IndefinitePeriodMember
country:CA



2025-03-31



0001985062

pbm:IndefinitePeriodMember
country:AU



2025-03-31



0001985062

country:CA



2025-03-31



0001985062

country:AU



2025-03-31



0001985062

pbm:InvestmentInPsyenceLabsLtdMember
ifrs-full:Level1OfFairValueHierarchyMember



2025-03-31



0001985062

pbm:InvestmentInPsyenceLabsLtdMember
ifrs-full:Level2OfFairValueHierarchyMember



2025-03-31



0001985062

pbm:InvestmentInPsyenceLabsLtdMember
ifrs-full:Level3OfFairValueHierarchyMember



2025-03-31



0001985062

pbm:InvestmentInPsyenceLabsLtdMember



2025-03-31



0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level1OfFairValueHierarchyMember



2025-03-31



0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level2OfFairValueHierarchyMember



2025-03-31



0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level3OfFairValueHierarchyMember



2025-03-31



0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember



2025-03-31



0001985062

ifrs-full:Level1OfFairValueHierarchyMember



2025-03-31



0001985062

ifrs-full:Level3OfFairValueHierarchyMember



2025-03-31



0001985062

pbm:PrivateWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:PrivateWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:PrivateWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:PrivateWarrantsMember
pbm:WarrantLiabilitiesMember



2024-03-31



0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember



2024-03-31



0001985062

pbm:IfrsConvertibleDebtMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:IfrsConvertibleDebtMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:IfrsConvertibleDebtMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:IfrsConvertibleDebtMember



2024-03-31



0001985062

pbm:NcacSponsorMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:NcacSponsorMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:NcacSponsorMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:IfrsPromissoryNoteMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:IfrsPromissoryNoteMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:IfrsPromissoryNoteMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:IfrsPromissoryNoteMember



2024-03-31



0001985062

ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31



0001985062

ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31



0001985062

pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember



2025-03-31



0001985062

pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember
ifrs-full:NotLaterThanOneYearMember



2025-03-01



0001985062

pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember
ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember



2025-03-31



0001985062

ifrs-full:NotLaterThanOneYearMember



2025-03-01



0001985062

ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember



2025-03-31



0001985062

ifrs-full:OrdinarySharesMember
ifrs-full:MajorOrdinaryShareTransactionsMember



2025-04-15



0001985062

ifrs-full:MajorOrdinaryShareTransactionsMember



2025-04-15



0001985062

ifrs-full:MajorOrdinaryShareTransactionsMember
ifrs-full:RestrictedShareUnitsMember



2025-04-17



0001985062

ifrs-full:MajorOrdinaryShareTransactionsMember



2025-05-05
2025-05-05



0001985062

pbm:ELOCMember



2025-03-31



0001985062

pbm:ELOCMember



2024-04-01
2025-03-31


xbrli:shares

iso4217:USD



iso4217:USD


xbrli:shares



xbrli:pure

iso4217:CAD

iso4217:AUD







EX-12.1
2
ea024662301ex12-1_psyence.htm
CERTIFICATION






Exhibit 12.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
EXCHANGE ACT RULE 13A-14(A)/15D-14(A)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
 
I, Neil Maresky, certify that:
 

1.I
have reviewed this annual report on Form 20-F of Psyence Biomedical Ltd.;

 

2.Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;

 

3.Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f) for the company and have:

 

(a)Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;

 

(c)Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and

 

(d)Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered
by the annual report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control
over financial reporting; and

 

5.The
registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing
the equivalent functions):

 

(a)All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.

 


 
 

Date: June 25, 2025
/s/ Neil Maresky

 
Neil Maresky

 

Chief Executive Officer and Director
(Principal Executive Officer)

 
 





EX-12.2
3
ea024662301ex12-2_psyence.htm
CERTIFICATION






Exhibit 12.2
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
EXCHANGE ACT RULE 13A-14(A)/15D-14(A)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
 
I, Warwick Corden-Lloyd, certify that:
 

1.I
have reviewed this annual report on Form 20-F of Psyence Biomedical Ltd.;

 

2.Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;

 

3.Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f) for the company and have:

 

(a)Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;

 

(c)Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and

 

(d)Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered
by the annual report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control
over financial reporting; and

 

5.The
registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing
the equivalent functions):

 

(a)All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.

 


 
 

Date: June 25, 2025
/s/ Warwick Corden-Lloyd

 
Warwick Corden-Lloyd

 

Chief Financial Officer
(Principal Executive Officer)

 
 





EX-13.1
4
ea024662301ex13-1_psyence.htm
CERTIFICATION






Exhibit 13.1
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual
Report of Psyence Biomedical Ltd. (the “Registrant”) on Form 20-F for the fiscal year ended March 31, 2025, as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certify pursuant to 18 U.S.C.
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 

1.The
Report, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Registrant.

 
Date: June 25, 2025
 


 
/s/ Neil Maresky

 
Neil Maresky

 

Chief Executive Officer and Director
(Principal Executive Officer)

 


 
/s/ Warwick Corden-Lloyd

 
Warwick Corden-Lloyd

 

Chief Financial Officer
(Principal Accounting Officer)

 
 





EX-23.1
5
ea024662301ex23-1_psyence.htm
CONSENT OF MNP LLP






Exhibit 23.1
 

 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
 
We consent to the inclusion in the Annual Report
on Form 20-F of our auditor’s report dated June 25, 2025 relating to the consolidated financial statements of Psyence Biomed Ltd.
(the “Company”) consisting of the consolidated statements of financial position as at March 31, 2025 and 2024 and the related
consolidated statements of income (loss) and comprehensive income (loss), changes in shareholders’ equity (deficit) and cash flows
for each of the years in the three year period ended March 31, 2025, 2024, and 2023, as filed with the United States Securities and Exchange
Commission.
 

 
/s/ MNP LLP
 
Chartered Professional Accountants
Licensed Public Accountants
June 25, 2025
Toronto, Canada
 

MNP LLP

1 Adelaide Street East, Suite 1900, Toronto ON, M5C 2V91.877.251.2922   T: 416.596.1711   F: 416.596.7894

 





EX-97.1
6
ea024662301ex97-1_psyence.htm
COMPENSATION CLAWBACK POLICY






Exhibit 97.1
 
PSYENCE BIOMEDICAL LTD.
 
EXECUTIVE COMPENSATION CLAWBACK POLICY
 
The Board of
Directors (the “Board”) of PSYENCE BIOMEDICAL LTD (the “Company”) has adopted the following
executive compensation clawback policy (this “Policy”). This Policy shall supplement any other clawback or compensation
recovery policy or policies adopted by the Company or included in any agreement between the Company, or any subsidiary of the Company,
and a person covered by this Policy. If any such other policy or agreement provides that a greater amount of compensation shall be subject
to clawback, such other policy or agreement shall apply to the amount in excess of the amount subject to clawback under this Policy.
 
This Policy shall
be interpreted to comply with Securities and Exchange Commission (“SEC”) Rule 10D-1 and Listing Rule 5608 (the “Listing
Rule”) of The Nasdaq Stock Market LLC (“Nasdaq”), as may be amended or supplemented and interpreted from
time to time by Nasdaq. To the extent this Policy is any manner deemed inconsistent with the Listing Rule, this Policy shall be treated
as having been amended to be compliant with the Listing Rule.
 
1. Definitions.
Unless the context otherwise the following definitions apply for purposes of this Policy:
 
(a) Executive
Officer. An executive officer is the Company’s chief executive officer and/or president, chief financial officer, principal
accounting officer (or if there is no such accounting officer, the controller), chief operating officer, any vice-president of the Company
in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs
a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the
Company’s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy making functions for
the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an
executive officer for purposes of the Listing Rule would include at a minimum executive officers identified in the Listing Rule.
 
(b) Financial
Reporting Measures. Financial reporting measures are measures that are determined and presented in accordance with the accounting
principles used in preparing the Company’s financial statements, and any measures that are derived wholly or in part from such measures.
Share price and total shareholder return are also financial reporting measures. A financial reporting measure need not be presented within
the financial statements or included in a filing with the SEC and may be such financial measures as may be determined by the Board or
the Compensation Committee thereof (the “Compensation Committee”).
 
(c) Incentive-Based
Compensation. Incentive-based compensation is any compensation that is granted, earned or vested based wholly or in part upon
the attainment of a financial reporting measure.
 
(d) Received.
Incentive-based compensation is deemed “received” in the Company’s fiscal period during which the financial reporting
measure specified in the incentive-based compensation award is attained, even if the payment or grant of the incentive-based compensation
occurs after the end of that period.
 
2. Application
of this Policy. This recovery of Incentive-Based Compensation from an Executive Officer as provided for in this
Policy shall apply only in the event that the Company is required to prepare an accounting restatement due to the material
noncompliance of Company with any financial reporting requirement under the United States securities laws, including any required
accounting restatement to correct an error in previously issued financial statements that is material to the previously issued
financial statements, or that would result in a material misstatement if the error were corrected in the current period or left
uncorrected in the current period.
 


 
 

 
3. Recovery Period.
 
(a) The
Incentive-Based Compensation subject to recovery is the Incentive-Based Compensation Received during the three (3) completed fiscal years
immediately preceding the date that the Company is required to prepare an accounting restatement as described in Section 2 above, provided
that the person served as an Executive Officer at any time during the performance period applicable to the Incentive-Based Compensation
in question. The date that the Company is required to prepare an accounting restatement shall be determined pursuant to the Listing Rule.
 
(b) Notwithstanding
the foregoing, this Policy shall only apply if the Incentive-Based Compensation is Received (i) while the Company has a class of securities
listed on Nasdaq and (ii) on or after October 2, 2023.
 
(c) The
provisions of the Listing Rule shall apply with respect to Incentive-Based Compensation received during a transition period arising due
to a change in the Company’s fiscal year.
 
4. Erroneously
Awarded Compensation. The amount of Incentive-Based Compensation subject to recovery from the applicable Executive Officers under
this Policy (“Erroneously Awarded Compensation”) shall be equal to the amount of Incentive-Based Compensation Received
that exceeds the amount of Incentive Based-Compensation that otherwise would have been Received had it been determined based on the restated
amounts and shall be computed without regard to any taxes paid. For Incentive-Based Compensation based on share price or total shareholder
return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information
in an accounting restatement: (a) the amount shall be based on a reasonable estimate by the Company’s Chief Financial Officer (or
principal accounting officer, if the office of Chief Financial Officer is not then filled) of the effect of the accounting restatement
on the share price or total shareholder return upon which the Incentive- Based Compensation was received, which estimate shall be subject
to the review and approval of the Compensation Committee; and (b) the Company must maintain reasonable documentation of the determination
of that reasonable estimate and provide such documentation to Nasdaq if requested. Notwithstanding the foregoing, if the proposed Incentive-Based
Compensation recovery would affect compensation paid to the Company’s Chief Financial Officer, the determination shall be made by
the Compensation Committee.
 
5. Timing
of Recovery. The Company shall recover any Erroneously Awarded Compensation reasonably promptly except to the extent that the
conditions of paragraphs (a), (b), or (c) below apply. The Compensation Committee shall determine the repayment schedule for each amount
of Erroneously Awarded Compensation in a manner that complies with this “reasonably promptly” requirement. Such determination
shall be consistent with any applicable legal guidance by the SEC, Nasdaq, judicial opinion, or otherwise. The determination of “reasonably
promptly” may vary from case to case and the Compensation Committee is authorized to adopt additional rules or policies to further
describe what repayment schedules satisfy this requirement.
 
(a)
Erroneously Awarded Compensation need not be recovered if the direct expense paid to a third party to assist in enforcing (or making
determinations in connection with the enforcement of) this Policy would exceed the amount to be recovered and the Compensation
Committee has made a determination that recovery would be impracticable. Before concluding that it would be impracticable to recover
any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company shall (i) make a reasonable attempt to
recover such Erroneously Awarded Compensation, (ii) document such reasonable attempt or attempts to recover, and (iii) provide
appropriate documentation to the Compensation Committee or Nasdaq, if requested.
 


2
 

 
(b) Erroneously
Awarded Compensation need not be recovered if recovery would violate home country law where that law was adopted prior to November 28,
2022. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on a violation
of home country law, the Company shall obtain an opinion of home country counsel, in form an substance that would be reasonably acceptable
to Nasdaq, that recovery would result in such a violation and shall provide such opinion to Nasdaq, if requested.
 
(c) Erroneously
Awarded Compensation need not be recovered if recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits
are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the
regulations thereunder (as such provision may be amended, modified or supplemented).
 
6. Compensation
Committee Decisions. Decisions of the Compensation Committee with respect to this Policy shall be final, conclusive and binding
on all Executive Officers subject to this Policy.
 
7. No
Indemnification. Notwithstanding anything to the contrary in any other policy of the Company or any agreement between the Company
and an Executive Officer, no Executive Officer shall be indemnified by the Company against the loss arising from the recovery of any Erroneously
Awarded Compensation.
 
8. Agreement
to Policy by Executive Officers. The Company shall take reasonable steps to inform Executive Officers of this Policy and obtain
their express agreement to this Policy, which steps may constitute the inclusion of this Policy as an attachment to any award that is
accepted by an Executive Officer. This Policy shall be deemed to apply to each employment or grant agreement between the Company or any
of its subsidiaries and any Executive Officer subject to this Policy.
 
# # #
 
 
3
 





GRAPHIC
7
image_001.jpg
GRAPHIC

begin 644 image_001.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" &/ >0# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]/Q7^8K^:'_ (*T,P_:ETX*
M[+_Q:WPN"0S#KJ6OGH"!V/XFOZ7CT_%?YBOYG_\ @K1_R=-IW_9+O"W_ *^&W_ "4T/^Q?CORH'XMX]?\ )!2_['>3[?\ 7S''YD;YQTGD'_ G_HXH
MWW'_ #\2?]]/_P#'***_H,_B@-]Q_P _$G_?3_\ QRC??:%O_3CX@K^F ]/Q7^8K^9__@K1_P G3Z%OTU'7_\:^^\-O\ DIH?]B_'?E0/Q;QZN^ Y);O.\G2_\&8X_,BBNZ^'
M7PT\;_%GQ+!X-^'FB#Q)XINX+FYL="BU+2]/U#4(;.![J].GQZK>627KVEK&
M]U<10R&2.W5I=K*C8V_%?P0^*W@GP_<>+=?\'70\)V.MS^&-3\4Z-J>A^)]!
MT?Q+;3BWN/#^MZCX9XW!PK1P\\50C
M7GRO;W]*;35KIKFTC=-)O>R;5KVU=VK)I
MMH=M%*S2?5QDK.W,XO2Z<8VE*ZLDU9MW22BC@YY' S^77\N_T/I1Z>_ ]_\
M/?T[TNB>K3;2:3DKJ]U>*E=JSVNM-Q=-TFE=IM))>I>&_@E\6O%NL?$#P]
MH?@76)M?^%6A:EXC^(>B7OV?2-3\+Z3H[F/4);ZTU2>V>2YB96:*RMC+/<1)
M)-;K)$$)\K1U=5D0[D<*Z,,X*LH93DCNI!R>^1CL+I5Z%>52%&M2JSI*G*I"
ME.-1PC6I^UHMN#E&U:C:K2M-\]-\R[&-7"XFA"E5KX;$4*=>5:%"=:A5I1JS
MPU98?$PA*I""<\/7O0KP=I4JJ=.HH2LI.HH_S]>G3UZBC_$C\1U%:[;W775.
M-XK>:;2BXKK9MK2\;-&%G\DTFW92I#:V[W=[+!:P-<3.
ML$;W$T,9FDC0N-P-*4HQBYR:C%1%)?''C#PZU_HXN=$\+1VEM>KJ4MP-0:RG:>WO+:2WM+6XGNIGFCA2+
M?N(\,C=98TE0ADD19$89P48 J><=00<$ @DJ>16-'%8;$W^KXBA7M&C4?LJL
M)VIXB$JE"H^5OW*L(N=-[SBG**:C-QZL3@,=@U3>,P6+PJJ5,11A]8PU>C>O
MA:JH8JBN>FKU\MM/\7^((+_ $W;X?N[Z2WBL8[[3GNX]3 O'N[=;>2*UEBE
M\P,LA ?;=6K3H1C*M.-*,ZD*474:@I5:DE"G37-:\YS:C"*NY2DDKMF-"A7Q
M,IQPU"MB)4Z56O.-&E.C0P])5L16=EI2H4FJE6;TA!J35G=-
M?BOXFMO!GP]T9/$7BN^AN9M.T%-2TO3M0U%+*WDN[Q=/35+RSBO);6TAFNKB
M*&9I(H$>4H8U)K&\4^&=;\%^(M5\*>([6"RU_0[RXT[5[""_L=1.FZC:2M#=
M:?=W&G7%U:I>VLJF*Z@69VAD!1\$$4EB*#KRPJK4GB(P]K*BI7J*ESSIJKRV
M^"4X2C&6TGHM;I6\)BEA8XYX:O\ 4IUI8>GB_95'A9XB$(U)X=8A1]DJT:&Q%P5$37HM
M'2[:V5O-2VD25E",&KO? _PJ^('Q*LO%VH>!O#S^(;7P'H<_B7Q<+;4=+M[K
M1= M(9I[G6)K*]O+:[N+")+>8/-9PW&V51"09656*M>A1INK6JTZ5*+474J3
M4(*3FJ:3E+W4W4DH)-KWFD[7%0PV)Q56-'#8>MB*TXU9TZ-"E.K5J0HTZM6K
M.%.">@K^M?_@G]_P F=? C_L4I_P#T^ZO7
MYMXI?\BC+O\ L9/9IK_=*W573]4VGNFU8_>/H[N_%.<_]B%_AF&&/L6BBBOP
MT_L$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** $/3\5_F*_F?_P""M'_)T^G?]DM\+?\
MIQU^OZ8#T_%?YBOYG_\ @K1_R=-IW_9+O"W_ *&O_ "4\+6O_ &?C
M;7VVH;^6I^*^/?\ R04K6_Y'>3[MI?'CMVDVKJZND[7V/(O^"<0!_;2^#_'_
M "S\;G/?CP1KF#GIQV.!SNZYP.B\8_M >"_AGX!_:E^ ?A'3?%'B/7/CA\:_
M$M_XZ\4ZYIFEZ9HWA;1[/Q(MK-9>$-"M=0U:]UO7O(L)3;ZI?26,5;0
M?9X(S\H_"#XM^*_@=XYT_P"(_@6'0O\ A+]'M[Z#1]1U[3)=7ATL:E:2V%]+
M;6 O;2U>>XLYY;N^(_!+>'?&/A_Q%XG37H;&
MWT^YC\8?#[XI0-K[O)K?BB\$MQIOB;1X-%U#0]5B&@:CIMD(;>.YY_\ :F^#
M'PR^%%[^$;&[^"/Q3^#W@S4_@@;W4_$5Y);>/?%-S"-1EGU-M9-Q?Z
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MS_$_3/">>3H-(_;!^,&A:O\
M![7=*MO MKJ?P%\,:IX-^&$Q\,SS+HOA[5],M=)O+6\236&&L2O9VD0CN+[=
M+#,TLZDM)@8U*II*7H87B/@JCG%7$O*Z$LL3R2>$HULCI5\32IT,XP..S7#8EU\
M15C7K4\#2Q^!PF*I."KTL3:,O#U"YO[>TL/AYH&JWUKXEU0II.HZ2Z^,/$2Q0Z;HE_>W'V#2+B2"
MXCM9IKG)U_#?P?\ @E/\&?B;^TIIEO8_\(,O[0V@?#7P%H'Q9U'Q'-:>&/AW
M<26-[XAN=>'@<7FHZCXSU.UO&TP_<33R6.F*(;J26XU-_-;POP3^TY\2O N
MG?$[P[96'@;Q!X)^+NK7GB#QE\/?&7A9/$G@F77[VY:]DU?3-(N[Q9M/NENO
M*D 2]=&^S69($EG;/'#X"_:5^)?@'2/B%X8MK;P1XH\$_%":"[\6^ ?&7A'3
MM5\%37]I''!87^EZ#:MIT&BS6%O;64$$>G/%;F'3[ 21/-:QSCKK9=GLGB9*
MO*=1XO"SIU(YC*E#$9:I86I5P;I3INGAL31]G5I_67*2KQO"3M5-K+X1Z]=>)_AE'JTLO@K6M0M[ZWO+C1;FUBN(;
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MCQ4*->;Q.45\O4_:.A.,ZM2M54JLN2,72=1P4&X+O"^DRZ7!I\VFZ!97
M":=J>G7&LZ:]II5NFN:-XG@OXKS5; S%9+62%:\5^'W[-GPLMC^PMX+\3^'X
MO%.I_M6Z!XL\2^/_ !5)J&K6>J^';,Z1:W?A6P\!-I]];:;HLFARW2W&HSWN
MGZNVMSH\%RL=D1$/E[0?VLOC9HGBOXG^.;K7=+\5^+?C%X;;P=X[UOQ=I/\
M:C7 6XL=C#:?.AD>?4J,J4<31BH8?!4:=/"UZF'I*KA\AKY?&I25FX4:&93P
MF*<)N4L1"C6JRUC&C5]VKQ5P7B<2L3B(J>TC0Q6*Q&28;&8!UZ=&A]6J8A8:4E1J5<2OH'3_ (,_#+P+^SS^U!XT
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M##7BW*4E/AHY[PG16%5++U1=/(J-&E6EESQ%? YY#^S*>(KRG5Q4Z6,P^+6
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MPGAY58X7*\7@\4Z6(ITG[*-'&5<-BJ5H-5U1?-%."A4]+,>*.$\=B+R:GBZ-.MF/$.6YGERQ^"EBTL0JN7T,QP56[E]5^LPM*:JU*
ME/Z2_9<^#'P=^(Q^ MAKO@G4=0M_B/\ $'X@^"OB%XC^(ESJ.BV.JI;:/J&H
M>#])^!%]H.M6EQJ7B?0;6QBU#Q;?_P!BW>F6;F\@U34[+=I]A<[GPWT2V\-_
ML7?\%%?#=E)-/9>'/BQX2\/6'OA=X;T/4?"#VGP=U[5_$'@2_U;P1HFJZ[IMQK[WLF
MLV+ZS=1FZ73=3;4;Q;Q+ :?>W$,D<,E\8X(1'SO_ TA\1!X2^,7@A;+P3#X
M=^._B(^*?B);6GADV4MUK*7$-W9S:*]IJ,4>APZ?=V\=U;PVT4GG7$EQ-?/=
MO<2L^M3)\YKXFK*K.,Z#Q^6XFC&KCW6488'._K+G*,J*E&<\NC"*C24;3C"E
MS3474ER8/B'A7 X7"JA0K0QD,GSW XBK1R?#X5RJ9OP?1RN%%RH8N<9TH9Y3
MJ5ZM2H_\$[5!_;3^"&[YL7WC(J2/NG_ (5_XFSMX&!D
MD\'NW4-SX[\Q6\M+>2YFT^[GM1)=+.L*22/"D)CJ_BNU\'W;:O%>>,+:\M/$.JZ3]JUZYL-)U:]@O[M4O[2Q66V-Q(
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M^&6H7>H_#_5#H=JOC+PD]]?1ZG)5836MM)?PPW&\6QOE6*.W6\$"[#Z
MX_[;GQO;6O&/B86GPR7Q3\1O!-IX!^(OB4^ +*35O'&AV=JUC"^O.UYY#WIL
M'>QE:SAL[.:!A)+9O<1V\L/A8KA_-YX>MAJ,X3I5,1F=;DGF%6$'6KY[@\QP
MF*G3E&2DEE]&K@_J[_+=VVOH?8M%%%?AI_8
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 (>GXK_ #%?S/\ _!6C_DZ;3O\ LEWA;_TX
M^(*_I@/3\5_F*_F?_P""M'_)TVG?]DN\+?\ IQ\05]]X;?\ )3P_[%^-_*@?
MBWCU_P D%+2__"WD_P#ZW8$A3P#]#7T[/X$@^'7[*.A?&-[>"?QS\;OB+KG@7PE=7
M<$4Z^&/AYX/L+L^*;S2UG66.WUSQ?K7D:5<:LL8O-/\ #T,]GILEM+J%U,>7
M%8R&$6'4DYU,5B887#TTTN>M.G5JSE*3UC"-&A6JU97M:"T3DCNP6 KXY8R=
M%0C#+DGAA ,T
ML<6[)42.JE@,C< 3DC((R.X]QEZ.LBAT970Y*NK!E8>H9201GC/3/'8U^D?[
M7/@ZS_9(\(?L_?";X8);Z)XC\5^ [CXB?%#XC6]G83^+_%VNS3V%E9Z6NKWM
MK=W&F>&-(G;47L]&TTVME,BV1NXYWAE,\_Q?^!_ACXD?LV_LH?M&Z9Z/X(\
M<_%;Q1H_PE^)MQHNCI;Z#K^NZEK>K>&=(\=R^'-,^QVMOJSZAH@GUTZ4MHE_
M:ZA-,86FM(M_BT>)<+5IY?BIT:M+!9IB\9A,)7YH5)J6$CB'&I6H0A"<*>)>
M$KRHN$JCA&*C5BY:+Z;$<#XZABSK5L'/-LO5=>QIJNJM=X5J.'4L1^:]-# C.>^,=\\]OP]>M?;?CG]B7
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M-M8*02K>C '*GV8 CG(X.)*_07X@_ ;XK_%&Y_8G^'6C1?#"6Y^(_P (?/\
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M&==483FJ=*G1PU-5,1B:\TI35.DI0C&%.$JE6I-0BERS:YRHU
M/S1CECE!,;JXQG*LK C. 05)&"<@$XS@XI]?1WAR#Q#^TWK7PO\ A7:P^"?#
MWC2QD^(-SK'CR]M]$\*67B/2I+33]=BU+Q,^F6UC'JWB;1[#1;[3X)Y4CN-8
M2:QC>2.2.]O*M^*/V:M0T+PM^S_X_P!/\86VI>!/VAM?D\+>'M4OO#=]HVO>
M'-&QLHX7
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M3=VN2UO->K>PSVD.,>(Q@X*51T,1%\M3#PQ<*JIRI\WLI86<:Z
MG\+A=IM1=NR?!W$M/%T\#/*JRQ51S4:/M,--SG3QE;+9X>G.EC'!XI9CAZ^$
M]C)J2JP49NG"4*T_D%B$7C:5X-TV?4;;PMH$4^DVVL
M:_J=S,&@T^.XLTFD8S7-RFY0RJ9[@Z>/^I\UXPH8VKB,2FW1HU,#5P-*IAXK
MV,I5I\^88>,G!WC4DZ;491;54N$Q%?4/BWX77W[-OCCX-:MKESI/C[P%\7O"7A?QHEA
MJ.AW.BOX@^'7B:_LK;7_ WXK\/:F;B[T#6K>VN!)!H>.-?[I_#^8K^M7_@G]_P F=? C
M_L4I_P#T^ZO7\E3_ '3^'\Q7]:O_ 3^_P"3.O@1_P!BE/\ ^GW5Z_,?%+_D
M49=_V,G_ .HE8_?_ */'_)59S_V(7_ZL,,?8M%%%?AI_8(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (>GXK_,5_,_\ \%:/^3IM._[)=X6_]./B"OZ8#T_%?YBOYG_^
M"M'_ "=-IW_9+O"W_IQ\05]]X;?\E-#_ +%^._*@?BOCW_R04O\ L=Y/_P"G
M,=Z'YD4445_01_%(A ((/U_ )
M-3UG1H@QO;GX9_$BVNFM_%]K$C&:YL=#\2/'HVNW$"$:,+S3[V],5E<"<_)&
M,_R^H/4'U![@\&I+>::SE6XLY[BSN4CGB2YM)Y;:=8;J%[:ZA66!XW\BYMY)
M(+F L89X7:*5'0E3QXO!PQ3P%?VC?A]\(M+^*5[KO@[XI?!_0KGP;%XYTSP^/%OA_P >>#I4
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MGX?^)=#\:/KWP"EU71/$NCV2Z7%X<\8>$=3QB[4TW"6 FJ4K.,E*"J0G3G[RZ<=QKG>8K$QQ*R]PQ='$X
M>O!8&').&+SVGQ+5ERRK2_>K.*:KTZDG)0HSJX5TYT:LDOT@^('[5?P&UGX7
M_M-_"OP3H'Q2T7P[\6!X#F^&6E7&F^$;+PQX)B\(162#PKIOA_3+R.'0?#QN
M["34;S4_,U+6-:O-4O;N[7[3''-<^&_M*_&WP+\7? '[-WA;PBOB2'4O@M\+
MD^'WB Z_H]MIMEJMX+31@=4T::UU2_TP^(EBZ;J8B51?6)X"GEM2I-2A[
M[GAJ=IU_;8\$^$?&G['GC#PAH_B?7/^&??
MAEJ?PJ\?Z5K.EVFCGQ'HNOZ5INFZMJ7AB\35KX)=6S6C76GP:BMMYLD-O'-(
ML4TP3S";X\?#2W^$/AS]G#3]-\;^-/A]KG[1-_\ :G;:2GAWQ5J/AR]U
M59M*\ >#],&H:G/+XA$'V=K[5SRRCBHN4[JG6=%X=XFI*/K/[0&@?#30OBQXST'X
M3R:Q_P *_@72'TJSUZ[2]UG0KS4/#VG77B'PU?:A#-=)=WGAS7+B^TB:=;N[
M:*ZLYX&N[HV_G/[Q\4OV@_ W[2?PY^%ND_%VY\3>"OBW\(M%;PE;>/=!\/6_
MC#P]X]\)NMLD2Z]I2ZKI&KZ+X@MWL8+LW5K+>V-Q=S7TCI''=+%;_%:HJ *B
MA548 P,=>G3J3TQU[]:7 ].X/XCI7>#
M_$_Q'^&GARVU>;7X]4L=*-]K_B2>VD/A[6(O!'[HQ^5H6HZO?RZ
ME+F^U1G6)=.KW'X@_M0?"_QS\,_V=?!F[XJOK?P2^-.I^.=4UWQ5:^'M8N/$
M/AB_\33:XUQ*^F7]HD&L+;-#8Z9H%C;PZ=IL<45H+X65O$3\"TA53V'X?YS6
M-?(<#B<32Q=:6+E7HQC"$EBII**I8NC-\B@HTWPZGAAM&\6^-?%6F6UL?'U_/+/\ "C:.>!SG/X]1]/:N1\*Y6\/+#.6-=&:I
M*4/KPP$K_ ,1 X@^NPS%K*WC*53%U
M:5:66PE*E4QV>(O#^D:)JEQXD\.ZAJ^H:CJ'AGQ';3ZI:6V@
MZU(NJW@BU6 ZM81 PJ(I3'()O4/&'[47[-_CO]I_XK?''Q'X-^(5WIGBGX4V
M?AGXEZ%'X>L_&6GZ/J.J7.AW=TEI''5N$JN7
M4JLZBR;#9K@\LC7)PM*N?;OQ=^)?AG]J'5O
MV4_"7@FS\>0>)? ?@W1OAOXNN?'5UI5W:&PTO5+*_P!5\::EXHMKAGGCM]/L
M[[6_$>LW]MIUA8VT&)#-X3FGTOPWX4N
M]KI_:6@>$],MM#L]6"RA95BU66VN=0M1*J2FUG@>106*CYPBGN($NHH+BX@B
MO;5K*]C@N)H8[VS>1)7LKQ(G1;JSDEBBDEM9P\$TD4+2QN8DQ%Z_GQ^0_H/?
M\:Z,)DV%P5:A4I2FZ6#PV+PV$C*HZDH+'XF6+QL
MHOS'Q2_Y%&7?]C)_^HE8_?\ Z/'_ "56
M<_\ 8A?_ *L,,?8M%%%?AI_8(4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>GXK_ #%?
MS/\ _!6C_DZ;3O\ LEWA;_TX^(*_I@/3\5_F*_F?_P""M'_)TVG?]DN\+?\
MIQ\05]]X;?\ )30_[%^._*@?BOCW_P D%+?_ )'>3[?]?,OS'Q2_Y%&7?]C)_^HE8_?_H\?\E5G/\ V(7_ .K##'V+1117X:?V
M"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% #') &.N?J._4=_\<'M7X!?\%,/V?/CC\3O
MVC+#Q'\._A5XS\::#%\//#NFR:QX?THWEBM_;7^M23VC3"5/W\*3Q.Z8.U9$
MR?FK]_V4,,'Z_0^HIIC4G.6![D,PS^1Q^6.?H*]C(LZQ&09@LPPU"CB*BHUJ
M*AB'44$JOLES)TG&=TH.UVU=[.Z2^2XSX1PG&N32R7&XO$X*A+%X3%^VPD:4
MZW/A'5E&-JZ=-1DZK4FO>LEZ'\?O_#''[5O_ $;[\3__ GS_P#'Z/\ ACC]
MJW_HWWXG_P#A/G_X_7]@6P?WG_[[-&P?WG_[[-?;?\13SC_H6Y;_ .#<;_F?
MD_\ Q+KPY_T4&>?^"LN_^0/X_?\ ACC]JW_HWWXG_P#A/G_X_1_PQQ^U;_T;
M[\3_ /PGS_\ 'Z_L"V#^\_\ WV:-@_O/_P!]FC_B*>VFG:98PI+<7EY<100QL[BL?QW\=/A!\,O$GAKP?
MX\^(?A_POXE\6F)M$TG4[R6.>6VN-6L] M=0OWBBF@T+2;[7]0L= L-8UV;3
M=*O]>O+;1;.\GU.:.U)_Q%/.?^A;EO\ X-QO^8?\2Z\.?]%!GO\ X*R__P"0
M/Y6/^&./VK?^C??B?_X3Y_\ C]'_ QQ^U;_ -&^_$__ ,)\_P#Q^OZI6^.G
MPA3XE2?!Y_B)X>7XEQ1!IO"IO7%W#<_V._B+^R9KLQ_V7%XB/AN.3Q/_ ,(S
M)?+XA_X1A&\1#3/[%!OAE>%?VCO@;XW\%>,?B-X5^*?A76? W@&&>Y\7^)K?
M49(=,T"RATB#Q!'JEY+=10R/H^I:#=6NMZ'K%M'/I>OZ5&
M>-98F:&=(YX6:-U8Q31QRH3MD17!46=@_O/_ -]&C_B*><+7^S,M_P#!N-_S
M#_B77AS_ **#//\ P5EW_P @?Q^C]CC]JPYQ^S]\36QU"Z$'*'@D,%N3L8 C
M*M@@'I1_PQQ^U9_T;[\3_P#PGS_\?K^DG]EIY)?$O[7'FRS2"']JSQ>D0DFE
M<1QK\/OADZQ1!W811!F8B*,*@))VY9B?K=@D:EF=E5022TA ))))P ,DG
M@#). "1U8WQ*S?"8FIAUE^6U'"-"HZG-C8RLM_9*;]
MZHS'#_1[X^_=W/X_\ _ACC]JW_
M *-]^)__ (3Y_P#C]'_#''[5O_1OOQ/_ /"?/_Q^OZG=+_:"^".N?#SQ+\6]
M&^*G@W5?ACX/U7Q'H?B3QUI^O6UWX:TK6O"6KR:!XATB74X7DMYM2TS78I-#
MFL;5I[F36 NF6T/5M!@TC5;G6+.RM]-O98.
M7_B*>*_#?B34/$NE:'K=KJU_P"#M6BT'Q/!8RO*NBZW
M+IMEJ_\ 9-W,%\@7\>G:C8W-Q:QRR2VJW,27202L(Z/^(IYS_P!"W+?_ ;C
M?\P_XEUX<_Z*#/?_ 5E_P#\@?R1?\,?\ [[-&P?WG_P"^S1_Q%/./^A;EO_@W&_\ R0?\
M2Z\.?]%!GG_@K+O_ ) _C]_X8X_:M_Z-]^)__A/G_P"/T?\ #''[5O\ T;[\
M3_\ PGS_ /'Z_L"V#^\__?9HV#^\_P#WV:/^(IYQ_P!"W+?_ ;C?\P_XEUX
M<_Z*#//_ 5EW_R!_'[_ ,,?\ [[-&P?WG_P"^S1_Q%/./^A;EO_@W&_YA_P 2Z\.?]%!G
MG_@K+O\ Y _C\;]C?]JTJ_?\^O-/ "C _4D_SKY_B'C''<1X:CAL5A,+AX4*
M[Q$)8>IB)2(YX^PBI*2E3Y5]EQ;3Z66BBBOD3]0"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
MX'XI^/[#X5?#;QU\2]5L+[4]-\!^%M;\57VFZ8;<:C?VNAV$]_-:61NY8+5;
MJX2 Q0FYFA@5V#2R(@+#Y\L?VA?CUJ%E9W]M^Q9\4GMKZUM[RW<_%#X#J6@N
MH4GA8JWQ!5E)BD0LK*&5B5(R#79A\!BL52=>C"G[*-5T74JXG"X>+JJFJKA'
MZSB:',U3E&3Y5))-7=]#EK8S#T)JG4E-3J^3G=/F?L:-7E3FG%V%_\.65_P#SQ,_[1PO>O_X18[_YC/K>BODC_A?/[0'_ $95
M\4?_ Z/P&_^>'1_POG]H#_HRKXH_P#AT?@-_P#/#H_LG&]L+_X(?V
MCA>]?_PBQW_S&?6]%?)'_"^?V@/^C*OBC_X='X#?_/#H_P"%\_M ?]&5?%'_
M ,.C\!O_ )X=']DXWMA?_#EE?_SQ#^T<+WK_ /A%CO\ YC/K>BODC_A?/[0'
M_1E7Q1_\.C\!O_GAT?\ "^?V@/\ HRKXH_\ AT?@-_\ /#H_LG&]L+_XV%_\.65_P#SQ#^T<+WK_P#A%CO_ )C/'O\
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MLG&]L+_XL+<)##KQ?P,@
M&IVK62^K^(OA/9?LW^%_BGJ7PT77_BMX)^"6H?LS^#O%^J>-[51H&MZ[\,7\
M#?"GX3:!KFG^&K3(]:^'/[*/@'7&^-'Q>U2(Q77B_Q9I]A97M[9IX;UBQM/
MT=_X7I\? _F#]BGXH[]GE[O^%G_ ,'9G.S
M/_AB;XG^7(9#)'_PL[X!>7)Y^3/YB#XA!9/.+,TN\,92S&0MDT?V3C>V%_\
M#EE?_P \1_VGA;;UWO\ \P6._P#F,[C]EKXL^)/C;\&-"^(?BG1;/1=6O_$'
MC[0R^F1WD.B>)--\&^/O$O@_1O'/AV'4&DO8?#_CO2="L_%NC1SS7(2QUB$6
M][?VGV>^N/H>OD2+XY_'N!$CA_8G^)\4<<:11QQ_$_X"1QQQQ@+''&B?$,(D
M:* JHJA550H %2?\+Z_: _Z,J^*/X?%'X#$_E_PL/GZ4?V3C=K87_P .65__
M #Q%_:6%[U__ BQW_S&0?LK?\C+^UY_V==XQ_\ 5>?#&OKN3:%RQ 4$$[B
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MTI8$GU3P]I>FW&C^.YI;>&>SN= T:?5;8W,-N );JVOE\+:5/XF_9E^!OP^TOXFA5A*V_AWXB>-/A?\
M%W1?#FOI"UEKVI:K%<6$LW_"7VMT_X1_0[WP+X@^.NL?!/
MQK\18I;<>(?#OAS]GSX/?&VYN?%/@ZVN[ Z[K6F>%/ LOV7498H9OMK]C/XV
M^*6^,_CK]F>7P0EGX6\"V?QDU6[\274>JMXZM/$_@CXQZ?X)C\0_%W4KF233
M]4\4?M)V^MZK\9_#I:5%:W4'T(?CC\>F<2-^Q1\43(
MJLBR'XG_ #9PC%695<_$+/\ 8E^)RS3E
M//E7XF_ )9)O*39%YLB_$(/*8D^2,R,Y1"54A>*/[)QO;"_^'+*__GB-YGA7
M?6OKU^I8_P#^9#Z]HKY(_P"%\_M ?]&5?%'_ ,.C\!O_ )X='_"^?V@/^C*O
MBC_X='X#?_/#H_LG&]L+_P"'+*__ )XB_M'"]Z__ (18[_YC/K>BODC_ (7S
M^T!_T95\4?\ PZ/P&_\ GAT?\+Y_: _Z,J^*/_AT?@-_\\.C^R<;VPO_ ('1_9.-[87_P .65__ #Q#^T<+WK_^$6._^8SZ
MWHKY(_X7S^T!_P!&5?%'_P .C\!O_GAT?\+Y_: _Z,J^*/\ X='X#?\ SPZ/
M[)QO;"_^'+*__GB']HX7O7_\(L=_\QGUO17R1_POG]H#_HRKXH_^'1^ W_SP
MZQ_$/[2WQO\ "^@:WXEUC]C#XJ6VD>'='U/7=5N$^)GP*G:#3-(LIM0OYDAA
M^($DLSQ6EO-(L,:-)*RB.(,[ 4UD^/DXQC##2E*48QC',,LE*4IRC",8QCF#
M>UL/%WAK0O%%C;77E_:[:SU_2[75;6WNO*9X?M,,-VD4_DN\8
ME5@CLH#'J*\Z<)4YSISBXSISG3G%[QG3G.G.+LVKQG3G%V;5XNS:LWV1E&<8
MSB[QE&,HOO&48RB[.S5XRB[-)J]FD[H****DH**** "BBB@ HHHH **** "B
MBB@ HHHH **3=[-^1HW>Q^F#_P#J_6@!:*3=[,/J#_3-)N]F^N#_ /K_ $H
M=13=WLQ_ _UQ2[O8G\#_ %Q0 M%)N]C],'_]7ZTF[V8?@?Z9H =13=WLWUP?
M_P!?Z4I;V8_@?ZXH 6BDW>Q^F#_^K]:-WL1^!_IF@#YM_;"(/[*O[177 ^#G
MQ!STZ_\ "-WP'7KTKVSP:H/@_P )GG_D6M"Z?]@NU]J\1_;"(_X95_:+]_@[
MX_X^OAS4,#ZY(&/>O;O!; ^#_">,D?\ "-:#R!D-K6O_X#IZ,Z38/4_I_A1L'J?T_P
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M_+_@ [;OSU]-7TZ+4-@]3^G^%&P>I_3_ I=P/8X]<'%&[V8_@?ZXI6]?O"W
MJ)L'J?T_PHV#U/Z?X4[=[$_@?ZXHW>Q^F#_^K]:+>OWA9#=@]3^G^%&P>I_3
M_"G;O9A]0?Z9I-WLWY46]?O"R$V#U/Z?X4;!ZG]/\*<6]F/X'^N*-WL?I@__
M *OUHMZ_>%D-V#U/Z?X4;!ZG]/\ "G;O8C\#_3-)N]F'X'^F:+>OWA9";!ZG
M]/\ "C8/4_I_A2[O9OK@_P#Z_P!*4M[,?P/]<46]?O"R&[!ZG]/\*\I^/"@?
M [XS8S_R2CXB?^HAK'^?J!7K&[V/TP?_ -7ZUY/\>6'_ H[XS9RN?A1\1 -
MPQ_S*&L5UX!+Z_@+W_W_ '5[_7L%;\;&&)TPV)=]L/B/_3%V0Y5BIZ^'?4&D_X?-V'_ $;[J&/^Q]L?Y_\ "._TK\+6_P!=?PA_Q&?Q'_Z'\/\ PUY7_P#,Y^Z9_P""
MS=AV_9]U'\?'MB?_ '711_P^;L/^C?=1S_V/UC_+_A'?ZU^%E%'^H'"O_0M?
M_A7C/_EX_P#B,_B/_P!#^'_AJRO_ .9S]T_^'S=AW_9]U'_POK$?^ZZ:3_A\
MW8=_V?=0_P#"]L1_[KIK\+:*/]0.%=?^$U_^%>,_^7B_XC/XCZ?\+\/_ U9
M7_\ ,Y^Z7_#YNP_Z-]U#'_8^V/\ /_A'?Z4O_#YNP[?L^ZC_ .%]8G_W717X
M644?Z@<*_P#0M?\ X5XS_P"7A_Q&?Q'_ .A_#_PU97_\SG[I_P##YNP_Z-]U
M'/\ V/UC_+_A'?ZT?\/F[#O^S[J/_A>V(_\ ==-?A911_J!PK_T+7_X5XS_Y
M>/\ XC/XC_\ 0_A_X:LK_P#F<_=+_A\W8?\ 1ONH8_['VQ_G_P ([_2C_A\W
M8=OV?=0_\+VQ/_NNBOPMHH_U X5_Z%K_ /"O&?\ R\7_ !&?Q'_Z'\/_ U9
M7_\ ,Y^UOC+_ (*V>#_'_A3Q'X(\6?LX:GJ7AGQ9HVH>']>T]?B)':F]TG4[
M>2UO;47-IH,-Q!YT$DD?FP2QRH7WHRD9K/_ (C/XC_]#^'_ (:LK_\ F<_=+_A\W8=O
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MNH_^%]8__,[1_P /F[#O^S[J/_A?6(_]UTU^%E%+_4#A7_H6O_PKQG_S0/\
MXC/XC_\ 0_A_X:LK_P#F<_=+_A\W8=_V?=0_\+VQ'_NNFN]^%G_!6&S^)_Q+
M\ _#F/X'WVCOXX\6:+X835)/&MI=KIS:O=I:B]:U30[=KD6V_P PP":(R %0
MZG&?Y\*]_P#V4?\ DYWX ?\ 96?!O_IUBKDS'@7ABA@,=7I99_8N,#CH>?3)Z<^O./YYZ4ZF'[Z_3_&GU_/
MD=M>[7W-K^O0_MT****8!7PA^V/^VG!^R3<> X+CX=W/C@>-TUUU:W\00Z&=
M._L5[%2#YNGWYN!#%Y>P$AMV!]WU^$?_!9?_C^^ ?\ U[^.O_0]!KZ/
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M%]8__,[7X644O]0.%?\ H6O_ ,*\9_\ +Q_\1G\1_P#H?P_\-65__,Y^Z?\
MP^;L._[/NH_^%[8C_P!UTTG_ ^;L/\ HWW4,?\ 8^V/\_\ A'?Z5^%M%/\
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M&M2M'LH-.T^V\^XT"2:;R+6WAB\R61Y9=F^1V=F:MG_A\W8?\ 1ONHY_['ZQ_E
M_P ([_6OPLHHEP%PM.4IRRZ4I2DY3D\9C6Y3DW*'_$9_$?7_A?A_X:LK_^9S]T_P#A\W8?]&^ZCG_L?K'^
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MSE)O]=DSDD>G^3^6>:^R/RX6BCZSN
M 4444P"BBB@ HHH_+\QG\!W_ H **,<9].O^/T]^E% !1110 4444 %>_\
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M)\0Z=\2=(\"^.=(7Q)H":UI\2Z?#=MI5\^HF)I/.MKA]%FF>WDD,)5"K!MTTZE.,%+W
MVU]QP<\JHX;BK&9GA\%B8X'*$I8NG@JU:=:'$>4_6Z.#I8ZM2HSJXC+?
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MD\3#4WT/0]-OK:\LY+4:C?P7O6L,^I1+K6C7UO-;3V.H:')J$%W%
M=V ]'_ E?ZW:M(GA[P9X7U",:?%XI.EV&
M+5_$5I;?86?;9Q7DL=M#<7!BLYSB@\PA#"4:D\%2PTX4IX?%S==UH9?4E7IP
MHTY*I253$8O#UG'$+V=7"1G"E^\FHF5\,<.8R.15:N9XB%'-ZV.56I2Q.64J
M> 6#_MKGP=5XJLJ]'%0A@L>!#X@TV.WTN_U+1]/FN+D#2I)QJ$P
MM(KA[9]/FCRMPD"R>$/%TGQT\*?$WX!+^T9_P +IT7PEX&\
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M2\5U(25E_X)Z>,_"GP]
MU_X\ZUXQ\=>%/ 'A5]I2=
M;%4ZRA3J)*G)RJN7.C/*&_AM\+O@KX^\#ZKK/@'P_K*>"?%7B/1/$VKWTT5C?
MS^(/&0US3M6U#1=/\*F*RENWO+[5+2TM(;2YO)+?3XKB"TC]H\5?$/P3/^PW
M)\,?C'XV\+?%S]I*Z\7(WPKN+#Q'8^/?$GPR\-S:EI'FQ>(?B3#)/8V&D2QV
M^MN^C2Z]?0F+4[.*50L#S:?]1>(_V@/@UIW[4&K7_P#PFW@O5=!^(7[%?_"D
M]$\>:=KNFZIX?\+_ !#@COW;2-;U&TFF&C6NJ3+;V$NI74<=DDC6#R3BTEN9
M8/,IYGFN%E4J0I8O&*K+B*680QG[^IA<'F
M>)J8; 4JT'([_5/B?#'/\
M#:YTW6=#OO#OCV*6X>U0^%/%4.HCP]JC?:HWL9(4U&.X@O\ 9:SPQRRPA^TU
M+]E+]HG2K#7=1OOA;JL$'A?7+;P]XIA76/#-Q?\ AB_O%\RUN/$5A;:U+<:'
MH,\)-Q'XEU,6VA_85?46U#[ OVJOK3PQ\3/ /ACPS_P3B^$FK^(_#,7BKX+_
M !+O/'WQ4UI-W&BW%_):R1ZK?6NE:A>"'['
M;1L'NIX81T/CSQ]\/=3\'?\ !4JSL?'W@>ZO/C3XQ\*:I\+[6'Q;H33_ ! T
MS31;7M^^C*;Y6NXX;,FW-O.T/FS(VGQH\B-&.ZIG^;JK3C#"P]G[3EE4J8'%
M.5>#XB>51K05*48T54P,J>/]DG+D5)2O["K[27D4N%.&'AL16GF=6594O:0H
MT\?EE)82M+@A<25,)46)3G7JX;.*:RCVTI1]K/$4J3C4QU*>&G^?_BCX%_%[
MP?X^\/\ POUSP)JH\=^+;;2[[PGH6E3:?KG_ D]AK$7NF7UQI&J6\]CK4(NT?2I(FEO?)M]LS?JX?
MCU\%O#/[2W['GBC5_''A74O">A?LJW'P;\6>(M&U/3]>LOA_XVU32X;,'74L
M)Y9+*V@W-875]L^R+;W]Q*)S!!=F/R/X._&*Q^ W[1?P/\+?%+XF?!GQ#\)_
MAQX@^)J>$[GX0V6G7GAGP79?$31KO38?&NMZ[IMN/L$NM7T]O)?^'OM&H76C
MQ"[U>_DM8UM$E5/B#.94936 C.O3RNMB_9^QQ,FN9-X93NOP=PQ3Q7LWGE2&$KY]A\J>)6)RJN\MPV)I\.UZ%?&
M3EB*"J0Q%',LXC3Q=.C6P\<1ERA5C3Y<;&AXI?\ [-NE^&/V1OBA\3?&7AT:
M?\4O ?Q?\/\ @33=9T/QK9>(?#NH:7?R:5%K=G>P:)J.JZ$=:T34;C4M&OX8
MI;>[L;BV5+FUCFC$DW&?L5_"WP-\;?VB/"?PJ^(FE7FI>&?%&F>)Y9YM,UC4
M-$U.PN=$T&[U:TFM+FRDVR++-;>5(/VC=.\;:%H'A[QG8ZS>:]X9L+C1IEU/3Y[2-[.]O=1L5.HI
M86UQ+/;*!9:A):ZD6ME\U_X)^^*?#/@7]J;P-XZ\;^)?#_A#PCX=TKQB=8UW
MQ)K-AH]E;2:GX;O],T^WC^V313WES=7UPD*0V<,VP*[SM'$H=M%B\6^$[Y?!_@?2?B-J/AK^R?%>OV.JVC^!_%]
MAX=LXKR^-Q+_ &C'J%ISDN+C$DUVUI865O-=O+.=/UKP^FDS0W\[W:7NEPRWD
MLBQJEFB"*Z,5PWDU^8D4VH>'/$45]:R6G]J>']?AU2T>*ZM=0T]KW3-4CU.R
M9+NPGN+2[M)9((6\ZVFEB>%\HS$A1V935Q^$O#_Q)UCX;^'_ (#>#O$DOBOQ!X?U>7Q=
MX0N-7?79=-\1Z?JVHSW$]KK5_!IMO:^$+;PQ!:ZJM_JCH=,MA(O"?[8&M^ OCO\*?$_A"V\22> M-\*?%#X9>+_ !?H'@KQ9X4UO1KJ
M\O(+^P'BW4='TOQ#X?D_M.\MX]2T;4)V*06]Q) &GEAMN,_8^\:5>I:P:=J/
MBBSA70XM5>*WCN[C3T;43QX/&8JCDSQU7ZU7S[#T,36QF!K+$*^)=:>'E1EA
MU!1A@\/3K0J826'NYTJ*G"K7E.=0[LRR[*Z_%3RO#/+L'PABL5@L+EN:488.
M4E@(818FC7IY@J]2K+'X^I2JX;'SQTHNEB<34I5J-!X;#1J?,LOP<^)4?B+P
M/X8B\.1W^H_$Y1+\-[O3-:T*_P##OCQ&N6L"OA7Q3!J+>'M3ECOXSI\MLNI1
MW4-^T=O-%')/").QO?V6/VA=-%D=4^&&JZ6VH^/_ /A5>G1ZEJ?A^Q?4?B T
M,LT7AZP%WJ\0N9+H030V5_&S:9>7<;6MI>SRK@_6/ASXC>!/"WA#_@G9\'M8
M\2>&(_%GP=^*U]\0_BGJ\>OZ/>>'?A]H=_K=[,FD:AXIL[VXT*YO[BTEBU:\
MM=-OKSR8K&VCFS>W%O$_*:QXLA\8_P#!2W1O$&B>*(O%'A3Q'^TWX&UKP_J6
ME:XFL:%J6EH=(L=(NK06MW/9;K6U@:PC5TCN[..)X&2)6VO7]M9M4J5HJC0H
MT/Q&*Q./S?AW*H8;"YCE].>$J9YD^!Q6.^M15'$8C$2R?&XBK@U*G3PM*
MLY4J6*G#$T<0G\T>+/V;_CCX%\/>)O%/BSX>W^DZ/X)U2ST?QH5U;P_J>H^$
M;K4&VZ/XDTC2=6O]4TG2]38JFG:Q=VD6FWA9)8[DV[K*=+]E'_DYWX ?]E9
M\&_^G6*OT ^(7BKPG\'_ !C_ ,%-M8\7>+/!NI3?&0W/@#P)X-TS7[75/%&N
M>)[VWO()FU3PZA34M#B\)QWT4E_?ZM;VUD(8]VD7EW'Y1D_/W]D\%?VG/V?E
M)W$?%?P8"WJ1JD()P?7K_/M6F'S'%YGDV>5<32I*,,NE*C6HT:U"G5CB,B6,
MKTDJTY^T>#Q%9TG.F[351)M^S:2QN29?D?%7#5# UZLY5)9=)U+5]-UO1[/PYHUS
MJS:II;Z5>6QNC"8?].LKA9A-9+(UL$N43S/HWXT?LKZ#\#OC5X9N+;38/B;^
MSG\6=#\1^(_A=XBDUC5(H62U\':MXGL_#]YKFAWEI,^J:?)9VMS:73NT&O\
MAZ9I?+2]M[XP?)WPDMK>YUCQ<+G6O#6AQS?"_P").DVUSXF\0Z9X>M[O5M;\
M*:AIFCZ99RZE/$+F\U#4)DMX1$/)B/SW4L$9#M]6?LT_M4Z=X?\ A%\1?V'=:&GZ-:7)+&WTC6+JZN!HEQ#(8=-
MU6[N;)2=-U5A!^QYLLRIXZMC<#+$8BE2IT,)C\L3JQA/#XG?&X5ZE@\'B*E?'9CE>?3IX>4Z>-P')?)\
MVC&I4GB"DUJ]CN/$?B&WTN*2Y72[26>:.!8H[JY
M-[)/%@M_B]:V,(U/3_$-[/J<7B[P;>7^EZJLGB#3C-9Q_9+*RN[Z
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MQSWVD4J[II9IEE/V^&PG$^193_:4JM>2IPHXS)!KS6-0^$-\^F_$72K'4-(FU;PW>+=361BDTT:@
MMSJ2-=VMU:QW&DK?0-<6TR>:%C=E]D\*_L3_ !7OKCXS0>.$T#P;/\'/AI_P
MFVH:;=>,O")N=1U+7=&;4?!=DUZ=5;3-,T6[.^XUKQ!J-U;Z;8Q6LEC'\)>(?
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MZ#\5]+MKD7'_ AR:\MG<^ K"^MHRPL-2L;588]),"&.OG[X6
M^&]!\0>/].L_$6O>%=/\*Z%-=Z]JEYXCUNU\-:7XBL?#T']-GU?[+(]
MYXQO+:ST:T@ECCDM;?49;V_2TBMY0OW_ /LL?'7X<>,]#_:2^"WQM_X0?X5^
M ?C1HNI^(K[Q%?\ C?5+ZRL_BE<31V\%QIL7B#5M0)B\N.SOK>;0HFM8SX>M
MEGE5'MMW?G>.QU#V%7 NK7CEU7#8O,J="DZDL3@ZTYT*U.,(1599CZF,P6:SH8:KG6!S++#CBZN)H2ER0G+X'^'_P?^(7Q/R_@[1K6XM?[?T;PE#J
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M8*,'@L9.I2PM>O0<'[CQ5HOA"^U?0+'4]1T"VEO4>_MWN=
M36QPPBZ,T^F1'4(8WMV5CS-W\&_B39>!+/XFWGAZ"W\ WGC63X>+X
ME?7-#6RA\8VU]<6-WX?U!!?/>:7=0S65W'-=WUJEC;JL=TTS6[H7_7CXD?$'
MP;\*/^"DO[/'C+QQKUEHOA.R^ /AW2+SQ%,)H]+LY-;\-^+-*TZ]NI)(4DMM
M.FNYK>-[FYBB%JDZ272P*KE/EWXCZWX"L?V+KGX/:=\5/AAXH^(,/[7>L^/+
MG1?#?BJ"YB@\,:OK6I&UU2#4+^+3[6_L(;>]L[G4-0L3/862S3VXN)3I]XT?
M)AN((:2Y7
M]?'<%9!@XY]!9A5^M91B>(:-.A4Q^ IRJU,MP_"N(RNG/"MQKU'CIYOFU*:P
MR<:OU%1P\K4:KEX=\>/@;?67Q?\ %7AWP)\)-6^#&@>#OAOX?\;^*]'^(?CS
M0=2L?">B-$+6^\8>(/&0U2]TG3]+UK4VCM].MFU">YN+H,\5G;+.UI:1?#?X
M*W$6C?M%VWC?X1:SX[U_P!\,K'6[&^\+?$#PW9VWPSNM5T^;7M-\;ZO;P:NR
M>*]!O-(\BZM'T;^VH)4M+VQCM#<7BS6_W)\5OVC=-T;]K?QI\5?A%XX^#?Q$
M\*:Q\&_AQX.UWP7XD\4Z#!X5^+6EPZG>V'B?P?:Z[J3KI^B>)]"21=:TS^V1
M%I^HV;W,$XGBF\AN4\)>-_V<_"WBG]OFR^'7C7PMX8\#_$'X,Z7X/^&&DZWX
MGM8+;4_%YT#7)]<\,^#)+^8O<^&=)U6\32]&N@R:1&C);Z9*VG1PF/CIYMG'
MU"C1JX2O;ZAE%>%2#QLZTJLLQRZEBJ6)JU.3%TZG[REF>#2>;\1X6="O+*XX26'CDF<8K*Z^78:#EEV*PE1X>A1J6EA*
MV!Q=6G*E[66(PM2E\@^)/V6/$O@SX4_ OXG:SJ'AK4YOC!KEY&['QAJO@SQ?XKT?5O\ A!/#%KH%KJ&M^*?%/C,Z
MK=Z+IF@RL\E^CSZO=<2I:Q^M_$/QA\/?'G[.?[!NE:)X^\&6WB/
MX-7UWH?CSPKJVJ#2_$>AWEYXF\,7*7;V<]O]G30H['3+_4+KQ!+=PZ9':Q1A
M)YKJYCMQ](?%OX^?"/7_ (X?MN:5HOC7P=J%C^T-^SWX4\,?#+QY;:UI[>';
MSQ1X7\-7-A=>#M0UMI!;^'Y-8OIVM[>XUE[&P:\MH3-/''+!*=8YKF\:M.I.
MG4Q%:V?0G%T,52IT*=+B'+\!0G*E"2IU7#+ZM;$TI23FHQDZ'HY3B::<<)1
MK8BG*O&AB*.$4_S+L_@/\5]1\>>&/AKI_A9+WQ?XYT2#Q-X$M(=:T4:5XY\.
MW5E-J5KK/A#Q#-?P:+KMC^>/LEU#-#%<0/ )O&_[/_P 8/AUX
M/B\>>,?![:5X6/BF\\$7FH0ZUH6K2Z+XML0YDT'Q%9:3J%[=:!?S(A>VAU-(
M'E4IE5>>W5_T$\&?&[X5Z7\8_P#@GOX?O_%_A.SL_P!G+X;ZY:_%?QU-K6G)
MX7TG6==\*W-N/"UIX@#-9ZY/HU^L-OV3:A>-':RND%U*GGGCGQS\/Y
M/V.?V@? 5IX[\$WOC+Q)^V%XC^)6A^'--\1:9>:MK/@R;Q!I[IXDTZWCES+
M@U"A;!X;#8MPDFJ4:\9R:C.G.7GSX4X967YI6IYLY8G#X?,:N#7]J9?RPKX3
MASAK-H864)24L5.>/S/->-_B+K]BD,NIV^@V3;8=-TD3J\$>HZO(D\:W4J.EE:6UW<
MB.69(4//Z3XT_9[UGQ_I=GK'P8'AKX1R:]% =2TCQOXNG^(MIX>>XVVNL:WJ
M5_>W^B:Q.T AN]+_"GC+2_%6H>)M+C+_P!G-H?@
MG3)SXG76M1@-O%+IVM6>B6>EW+3R:CJL5K;---VU)UI9OF5',*V)HX=X#!/*
M/8.M&E/VL*CQE2-;#QE3>.I8ATXH_(IQPM/A;(L5E%++L5F
M3S#-ZG$D,5#+JM:FJ%3"QR>%>EC,33J4DZ'/X\\3:7;7&HWOASP)9:
MQ=VUUXGU.RL(3)<06:M&KJMF+F34I([9Y/!OP)^+WQ!T+Q/XC\&^!]0U[3?!
M6M67A[Q=%;W>G6^K^'=9U&Y6SLK'5-"OKJTU>U::X=XWG>T^RVJV]W+>2P16
M=R\?V[\.OBK\._$W@K_@G^)_%?A;P<_[+OQ+\2ZA\7M-\1:S9:/=V6ARWMOK
M^G^,=&M+EDNO%5OJ@M)-/^SZ#%J6K1:Y*OA%_P4@U
M'3_$^@^$M5^/WQ TW6_AIX/U76K'1_$WB/1+2^9]8:+2Y;B*:!M0L9Y99X93
M +VXN+JRA,[J4;EK9YFU.=>G#!PM#%QP\93PN*DJ,7GCRV,<0URK$5*N BLV
M]M3E2A3YG&2]C8]3#\,\,5(86K5SB4U5R[&8R4*.,R[#RQ+I<)4\]D\.JJDL
M)&GGBJLWT^N0VUMI,^E7T&HMJQD-A!:KL_"^)=3\4ZLUEIK7
M"3V36MOJ>L7:SQV8O'BAT^"]U$I8PS2VPO9[.R1I8/-/VO\ XA>#_$FB_LS_
M X\,:]H_BW5/@M\$]*\'^-?$_A^[&IZ)+XCGCTYY] TS6(\V^L6^A_8&6:]
MLVDLO/N3%!+(1(B;X3-\SJYQ++:LG8'D]!^M*W^NN
M/^NTO_HQZ* _K^M^EUZ-K9N[656^\ <8(R <,.=V/[V><^OMQ7IX^+?BL?"V
MV^$(MO#2>&;+5M)7LY-=T4>)%E6>31-6FT^S-Y9R6\D[P
MV\=F+H6.ZV;S*D9@@W,0%&22QVJ%'WF). HY8D@ 9)(K&KAZ%;V7M:<)JA5
M5>ES*RIU8J7[Q6<4MWS)\T)7]^$KG10Q6)PJK?5\15PZKX>IA<1*$^15,/6G
M3E4IU&U*\9SITFY^[43A"U:$58-JD8(##'(89!'N.XSR/?)[G(0#U53C@< <
M8QCCJ!V'0<#'%>C2?";QNM_\/_#\.DS7GC?XHPZ;?^$/ 5G%--XEN=%UUY4\
M.ZSJ$15;;3(O$1AFN]*L[F477]C0R:W>K::>\#S>F/\ LSZDGQ47X&M\3? "
M_&-KM=$_X14KX@;0%\6O:BZ7P2_CU=-;0!XD)_T/:(CI0U,C3VU,3\CGGF.
MII*>(HI.E5K.RY[8?#3=.KB)N$9N.&I34J\_P!U\34IVER]=#(\TKJU+!5V
MEB,-@5S\M%O&8NC'$87 0=65)O&5\/*G6AA(R5=PE3E.$7.DI_-H50M 4+G 4 DD@*!DGJ3V)/\3>'=4N=$UG1=3"07MCJ=FZI-;.I:"YM7FAE1VQ(I5
MG*K!FXD>2.&.&U'VF>6>9UCAMX88=TDUS-*R0P6\:M+-*ZQQ*S,!79&<)4XU
M8R3IS3G&2:Y91E'VKJ*S<7!QDJGM&^5*<9\Z4E(\^<)PJ2IU%.%6G.=*<)J=
M.I3JW=.=.<9QA.G6YU*DXN,:OM.>G;GIYYZ?=^
M6D(!ZJA(P =HR!UQGTR2<# !Z5M>*?#VK^"O$.L^%?$]I_96O^';Q-/UW3II
M8FETN_:W@N7L;LJVV.[A2XC2X@9@\$XDA<;XV%8'VBW,9E$\7E X\WS%$>[^
M[O)V[B> ,Y/I1"<9QA4@U*,HQ<7!-_NY)VE[BE^[LW)SNXJ+4^;E<9M34Z%2
M5&<9T:M.4J4Z
M.G.>>,TF%&0$7!ZC:,$9Z$'@C!(QTP<>F.I^'WAF'X@>.?"G@C_A*/#?@_\
MX2K6;72/^$G\67\=AX;T(72RO'?ZQ>9S;VK"+RX2"GG7$T$(D3S"Z9WBO2H?
M"GB/Q!X>;6]%UU- UO4M%37]"O!=Z#K?]G74EM_:>BWKA/M6G7@B:>UF(4O$
M0?F^\85>BJ\L,II5HT8UY0Y)Q7LI3E251R=.--N4TXR]_P!I)V=2+3C)W[&I
M]7CCERN@\1+!QJQJTG+ZPJ-/%3H1I^U=>+5.5.3M0C2YTZ:J.K"4%C;%V[-H
M"_W0 !USTQQ^&!ZC/(-J@YVKQTR.G4XXP<>V<' S2JRL RD,K %6!!!!Y!!!
M((([@D>AK5T+0];\4ZYI'AGPSI-]KWB+7]2M=(T31M-@,]]J6I7K^7;6EM$"
M TDC99G9DBAB62>XDB@BDD72;C"$Y5)*$*<93FYR45"$(.4IR;DE&,:: HQR23],Y.2,'MD#.?H3QM\!
M;'X=>)S\._&?QB^'ND?$NWFLK/7/#4%GXHU30/">J7Z1O%HOB?Q_I^ESZ#I^
MI0":$:BUM!?:?ICRA;R^C"NR^.^-_#=UX \7>)_!FL7MA5.K!1E[2E7BN62E"3]I&=./.J%7&U54#@!1@8ZXXQWYXQSD
M]2Q*D C! (]QG'))(YX))//OZ "HFGB3R]TD8\[;Y9:15$FX@ QEB/,&#GY-
MQ/& 2<4)/%*"8W1P#@E)(W ;KM8JQ 8#)QGD E)?#FCZWX4\&:SXZGL]>74F34=&\/K$VJ1VL^F
M6UVMO?0F>W6.&\$,6XKGQ&(HX7#U,5B)>RP]&/M*M5PE*%.,Y1A>7
M)";BI.4+II+WXRE;FN=."P>)S+%T,#@J3Q.+Q3Y,/1@USU9.%2?)#G<+R<*-
M1VO%OE2?O2IJ?B[1H^-Z(X!X5D5@.,8 (/\ //)&<$BGGD$=B""..0<9!XY!
M P1TP3QFJBW<'EQM)+'&)45@)756PZ@@ $C>!N"EE.-Q*@\9KN].\#:SJW@G
M7?'6CO!JFG>$;O3X/&NGVRS#5/"EAK,YM-!\0WMNR%+KPWJEZK:8^K64DL>E
M:J;:SU5+87MK/)T/>C&DHRY4I\M))2E&+S
MA1J5G+V<'-PH5*K4$^9T*5/VE:22BISA2ITW.K%1DX0ISE.*Y)VXT(@ 4*H4
M=%"@#\@ /T[,=4^'/C;PKX_T&WTVYUWP9K=EXCT2/5[>:ZTQ-7T
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MC&",C!]C^&?4 Y HQG].P/3IU_3TZC!HHK^CK)IKHTT]]4]T];OMJ]M%9:
M'\(W;23;:6JB]8IM)-QB[QC?[7*ES?:N'&0<#(Y!ZX/MGIVH^OU';!P1D?@2
M/H2.]%%5=MMO=N[?6]V[WW6K;TM\@[KO:]];V;EK??5MN][W?-S78'DY/)^@
MYXP2?4GN3[8P0#0!@D@!@8QBBNS\(>!M5\81^)=1AFATGPS
MX)T9?$/C3Q3?1SR:;X?TR:ZBL-/C,5LK7&H:QKNIS0Z7H&CV@^TZE?2\O;VD
M%U=09U*E.E!U*LXPA#E7--J*3NH04=GS2E75."BN:4I^SC>RBM*-"KB:GLJ%
M.56I*,Y.,=U",?:5)2E)J,(*,'4J2E*$.6$IS=D[\6% .<#.,$X&XCC@MC)!
M]\_D!1@$Y(!.,=,9&(B\BMHG@KPKI'^FZU+:I#.U]J%Q=V&E6AMM#>.
M;6T34EDATZQEL],9=/NK74=2M]0E>X6*:)[&>,,C0J5J>)EAW)ITJCA:K'][2IU:*]LO,2H(Q_(#WQSUXSP<\8&,#BG
M<>@Z8P0",#IUST['J.NN[9V22;3:2BDFI>\VM(I\U^?K=OFNF
M[GF:O35ZO3^\HI62=K3C&46MIQ4U*&LKDYP>P[\8!'/;!!X[_4"DP,@X!(&,
MX]@,_7C)]2 >PJNUW;*S(T\*LAPP,J!E//RLI(8-\I^7!((.<8)#EN87?RTD
M1GX^174L1@,2%!+-M4ACM!PA#YVG-+F;T;;2:G[U^6+7PM.7NQO=J*M*\7RLGP#P55NZ]'HX1;BW%M)6A&49^
MZK5$TCV+XS?&OQK\>?$.D>*O'\?A[^V]%\.6'A.TG\/Z3)I$4FA:6\SZ;:W<
M!O;N.>6R^T3I#<*(Y6C?9,TFQ-OD>!V [].GXCVQ@ 8P..G%"D.H*,K;ONE6
M!5AG&Y6X5@>,$'!SC(-?1GC;]G#4_ _P'^&W[0<_C;0]6\*_%.^GTOPIHEGH
MVM6_B!+ZU_M3[='JXN@MAI\5J^C7J>?'<7?V@^1Y"%9B4X?:8'+%@L'&,,-'
M$5/JF"HPI2<9U.6I65*G:,^6\8U*B;DHRU?,^;7U94LUSRIFN93<\?6PF'_M
M'-L5*I1=2.'C.A@?K=9WI*I"-1X;"\\5-QG4HPT=1R/G,J"#E>&X.1D'ZYR&
M_'.<#.<#!CW/MTX[=@ < 8Y!'H*T?#UA!XB\0Z!H"ZA#8_V]K6E:,FH/'+>1
M64FKZC#I=K=SVEJXN9K:.[N(A.( TBQB0HKNFP^A?''X2ZS\ _BEXH^$WB?5
MM)UC6O"K:6EYJFB_:UTNZ?5M*M-6MQ:)?QQ78V07:1NLD:DRI(% 7:3O]9H+
M$QP:E%8FI1J8J-.,4G*CAZL(5:BG%*+C2JRA&2Y]&VN5KG.:."Q?U"MF4:3_
M +/H8N&!KUXR@J4,96I8FI&C4BI_Q)4\/B9N3@XIPDW551QYO+<#&,#N.!V)
MS@=_U]?4TF!R,##9##'!![>GMTZ #H!4/VF (9#+&(P<&0NJQ@@[64NQ50P;
MY=I(R>XI4N(9&9$D1W7!*HZLV,D'*J25VD8.?4=,C._,XW;35US:QLVN1O1-
M)R3C&5E&ZDT]YJZXTVM%)JRCISK^-/#_AGQ5H.A:OX*\#:
MU\0+FWUJVU":'5-$T PKJ4%G=:.;?47\->)[*.6&UFU/0[@6?B3PUJEM.6GTGQ-X
M>NV1+_3)WD6XLY[/5=.N+O3[N.5.+K2G4IUH-TYQG#FG3DD[]>R9A6HUJ$U3K0G3DZ=*M%2M:5&M!2H58.,I0G2K4Y*=*<92
MA4@W-7Y9K:2=]
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MNO"GB<_\% I?!K6-T?%I_:F2\%B 5O'M7\WI__ O/XS"W^SCXF>*MXTMM
M"&J&[MSXE_L)HC =$_X2\VI\6#2FMV-N;(:V(O(Q!@PC97RF%R3&X:$*M*6'
M>(GP]1R'$4L0ZCIQEA)XA0Q5&<(R!-+:S
MO]7CBO8)4EN=)\U/#EU=VDT/FG3[FS,S"-73Q*_FCD;_ ()._%>&ST*R\?>.
M[[1M(\6:]I?AKPUIO]O64/B7PY8QBXTVPTFWTCS8+2_NK2TNK>RAN]/BNMUE
M/;R!)4_,?P=\1/'WP\&L#P'XPU[PV6-;=_#*6\<,FCM"(8MAL9(I3C2Q5&I0I8:EA%*
MHL0ZE6A2R3'Y55C*+E*G'ZSB<71QJIM>SA3H1A)JK"*CWUO$/"XJCBZF(R^M
M3QV)QV-S)2P\L.L)1QE;C3*^)*$Z4I4WC'[+ X'$9>JLXPE.IBW4]A"A.M!_
MHYXQL_%_C?\ ;#_;)D;PA8^*;;P+X7^)XT?QI?VL6GR_!BP@-E./'GARRT7P
M_<7_ (X\66TT4UAHNG&*^URXNY7CBU;3X1-*OIWBWP9X7A_:W_X)YW[>&;-I
M?BG\+]"N/B,VM^$]+TZ7QS?_ -DW"/?>,_#K6TND?V_=1,)-4B,+WD-T^+OQ#B\8ZQHI\-ZMXHB\37\.MZCX>W+(-&NKZ!XG
M>P$H\X1A4=+C=/XU?&6&Y\'WJ?%7QVU[\/K:YM? M[/X@N[R[\)
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MQ!87MKHMW!.ESF4]+XG"$TZ;43BI<;X.5+&0Q>#Q.(Q%?-
M<]Q6$QG+@X3R_!YGELL#EU/"QA2H^SQ&5)N4'3]G34*M>5&O'&.->7U]^V;\
M KB#]H+QY'\$/ -[J.A:!\,/ WQ,^)^D>#]+0:1\/M1\0:;>S:Q/-80O''I5
MOJ,=@-<.EV$+&W6ZO)K>TBM(Y!'SO_!.7Q3X0\*_M>_#34?&4UG:66HV7B;P
M_H>HZ@\4=I9>*]=T@VFA,TLQ"12:@%N])LI6* 7=]%&IWS*1X1\/_CK\0_A_
MK_CGQ;9>+_%]WXF\=Z)JVE:_<3Z_/):>*;K6;2\L)-1\)$TJWO[JY
MTBP)B1=1%NTUQ'9VYMI_%HX4CA2'&5C1$7)YP@7:=P (8%5(8 %64,N"H-=M
M/*\;4RG%9)C*T)499;3P%''TY5W7E*I2J^WJ5HU&W*-.I4I0P_LW*?L82A6:
MDYRCY5;/\MPW$F XJRG >RQ5//<1F^)RG$1H+!4XT(E.ART,3*5>E1=%TDO;/VC_#FO^'OVC?C-X6\0VMT/$UQ\5/%T\=E+#//J
M&JQ>(]>N=2T.XT^W9#/J4>K6%_9OIS6L/C9>Z=:Z7>_%'Q=?6]C9IIMC=7U]
M#=Z[9Z9'&T2:?9^*;BUE\4VEHD3O$D,&LHJHS*NT$FN!?!?A[]L/_ (*">%[7P+X1D\*>&/@OXK\8
M>'O"6L>&M-U+PWI^KQ:'H6JKJ.G:3>VKQ6<7VW4=0PNFM;Q+%>7%O$8HPJIY
M-X]\/Q^._ G_ 3'\:CX:^'/B/\ $'XD07NF>)?"]O9Z)X*L/B=;Z)?V%Q9Z
M'KT^BV%AI5CIUK;"YGN;MK(V=K8QW*7$$]G--$WPT*T22.UT34;R:.22?2HDDD T["63N[330S2$DY=WE4^&\QC5IUY8K#RKT\)AW5.:^DK<71YJ =%O_ -E7Q!JGBK3P/$?A3]M&
M/P);>))?#DFCMX(\':YJD5MX@\%^$==N-.TK5-?\ ^&5N[BQTK7-2L[/3[F6
MQ^UZ?96MK!9M7T3X?@N/!7[:'QI^"_A30M*TCX4> _V1[V7P7HVE^&]*2WTN
MVU+POI4L^OVVN6FGC4Y;WQ1JLVIV^JWMUJ-R-^(-%\97\&J>+-)UCQ1J>H:?XAU"VCBBMKC5+6XE>.80)!"
MB6\8CLPD$"FV;RE:MBV_:&^/EE:Z7:6/QE^(ME#HNAOX9TD6OB2[@GLO#S@+
M_8R7L86]ELHT41VR7-Q,UG 6@M'MXY)EDPJ\*YG5P]2A5QF$J>U>96A-8N5'
M#RQG]CSI5J,5)I5:4LNQ$$HTVN7$N4FZDZDJG70\0LDP^88?&4LJS&BZ$.=+OM*GTSPQ
MX$\%/IOV/3]3O-39[[5;1!I&DH]U>WS<;^RCX8T"U_:J_:V^'\VF0V?@%_A7
M^TMX2ZS:6<,\<'VN6\F
MFNI%E5[9KF:>X-OYLSL>ATOXU^)=$T/XI74>K:[K'Q-^-6GOX7\>>/M:O6N+
MZ'P/+>6]]JVB:1/YC7D^J^,9[:VM]?U:Y,$5AHEFFDZ7:N]S)=P]5;(\RE/-
MI.K0<2S2GC(XN?MI2A"22C[\JT:-/#*&&?)'RL%Q9DE
M"GPW!8+%QEP]B98_%5*\<$WCE_JQC&V9+6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M;W&J_#SXGV&FV_BG2+66*'4-/UGP_>#4?"WC+P]+YD&/H9?B<>ZZ<8X_),YRF%9)-X;$9A@Z=/#8CEE&2<(U:7L*LN5\M'
M%U^B;7WC^TCW[(GBCP# MQX=^%6H7?@_XD6=A^\;PKXIN=$.G/
MG'^T+CP_?W["2WEL[7399I=7U"*VO8-+LKAX+
MC^._A_/?W/@7QEXC\*2ZK;-9:L=#U*>QMM9L\D"#5M-W3:?J
M,10G;'?V]V(@Q2-ARY34/'7C?5M>TSQ5J?B[Q%>>)=%>W?1-I0Q&(S.O1KUU
MB/;I9B\1BI4ZU*'(IRA7J*"Q$,11J.'LTE3K4U./HYGGV!S?,LKS>OA\7AL7
MA,%D&!Q6&PZR]X*NLCA@L&\3AIXBG6J4?;X'!1E#!U\)B*$,;.4FZF"E.G5_
M4O\ :%\(W^G_ +(_Q0UW5=*U%?'/P\_;%O+/PWKUUX(?#GBW6]'U3Q]I%WXQU
MJX_X2U-,DMT8W_VRZE@EOHM.@:TTR6='M[0K;$Q>7;JHUOBIXJ\!:E*OA+X0
MVWC#3?A1I_B37/%^CZ1XUN+:;6;?6?$=AI.GW,4J6MW?6[0Z7I^DP:?:WSS&
M]U%99[BZ6,>2@\K"9#BC",?=Y:DU)3J5)5OH6YY1E@L-3IUH87!X_%X#%QE4I59MX>FU7PE&@Z'ZE_#S5I="\ ?\$K
M6TFST"VN?B3XX\1^%?&^I3^&?#E]K/BCPS'>2V7_ C^HZO?:7=7[Z?+;B 7
M BF2ZG^QV/GW+" AN)^(%MIFK_L\_P#!2?0+W1O#5GH/P4^.^D6OPNL-(\,Z
M)I$7P^ADU^VM[LZ/)86,-\DUYYDTU_)>W=S+=SW5SN80W7VU\&/YO@ZVBU^_2#PG,;:6R\_PU$DH31)C:3S6SRZ>+>1HY'RQ
M)R2Z^+/Q4O;'Q)I=Y\1_&EYIGC.>2Z\8Z==:_?RV/BNZE@AM9+KQ):M(T6MW
M3VUM;P&YU%9YA'!$%==BXRAPKC*>(CB/K6&E..+ABN=?754]W/ZN:_%SM.:P
M526"C[C2C.4%%0E9:5>/L!5P+P4LNQK@\KJY=*,GELH2=;@FAPOS;T
M7G-5<\74M"M4J2Q48UG^PGP^^&>I/H7CGPEX^^%MMX5TJ]_82N/$-E\+]#T>
M^\0?#_3]9TS[?+HGC?4?$=]9PP1?&'7[M&U"ZTSP\UYJ6G10Q3ZOK=Y>M (O
M)/@_KE_X9_9,_8D\0:5:Z'!XDUO]KW3? VK:[?\ ACP_JFNW'AB_US5[34?#
MBW^J:9=7%O:7=NTVGW*1M'>"V+6T,L*[UK\WH?C1\9[6;2I[;XN?$J";0M!F
M\+Z)+#XTU]'TKP[D6VO7T>FZ!J\,DTT.L:19^88;#5DFNKJ?^TK=8
M[SS[B:4S%Y7:HCPICI0JTZV*PCA6QF$Q,H16+Y'&AALWH334JC:?]DQQ*EB\UX9S.-1U:%"%.*PS
MR;,,/35&G0H\F8P6%HT*<<4ZOJW[8>B:/X<_:H^/6B:!IUEH^D67Q#OOL6EZ
M= EI8V9O=/T[4+A+6VB"06T- -)^T[E$"ZJK&P,X91&MP\I(56=?S>\1>)/$OB
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M2KK6OB#XNU6ZT+5CK^C7-]K$\]Q8Z\46)=>2\:YU&"!$MX+
MJ*!$1;)^,7Q?;5M9U[_A:?Q!77/$>D0^'_$6M1^+=;BU?7M"@9S!I.L:C%=I
M=W]G!OD$"7$KM;I++' R)(ZGR8<,8^E"C&.+P\_8X?$X>G[:.)G-4J^89?C:
M<9U8.-2K*G#"5Z7/.2DW7HQJQJJGB77]^KQSE6(EB)56UJM&AB98K#X*.+KYOAZZPU"?L\+R8Q81X-XC"O ?L=?>#?#]C
M_P %'OV7XU\)VMK8_$#]GW3]6\96NIZ!800>*/$ \+^+%NKSQ%IGV4Z1<>(%
M&G:=)J1BA,R7-I%.Y#QQ2/\ .GQ&ATKQY^Q?>ZYXQ@T&TG\,_MYZI\/-)US2
M]"T3P])X4^'M]X@>PU+0]-ET>RL%M]*L]-N+B8I,9Y%:!+B>>:6!)5_/>+XN
M?%FWU#0-7@^)_CZ/5O"FC-X>\+:H/%6L'4/#>A2!5ETC1;QKIKC3K.94C69+
M62,S1QQPS,\4:**>H_$GXB:OH%_X4U7QUXKU'PMJNHW.L:IX:O=9NI]!U'6+
MR[:^N]8O=+=S:7.J75Z[W=QJ$L1NI)W>1Y2S')0X6QT*N D\;04L'3RZBZR>
M+4XK"XO-JM2<%.;4G4H9KAZ4FXNZPDE+W8I*\7Q[E6(HYQ0CE.*A1S6KGN(=
M*:RYX>$\VRSA3!TZ>(A1A[6<:&-X?QN*JO#N*DLTJ5J+]JZLI_NCH$.L>&OV
MQ_VC_A1X=T6/2_A%X(_9$EC\":#I/AZSCT30[&]T#25MKW2]3M;);G[7XCO'
MU4:C,=1DEUZXL4>X$\^FHUO\:? ZP\&?$C]F+0/ 'A;6I?A7\=_A_P#"3XE^
M-9?"OB?3;6;X??M$^ -;AU-M<\82SR6_S>(] @@?3M+U^.[AU?P9J.G+ MN^
MDS2_9_A:'XY_'"WL],T^W^,7Q+M[+1=%?PYI%O;^,=;@&G:!));N^CVLT-TD
MZ:>QM;<"!I&,4<*P0R) 6C; 'Q)^(R>'Y?"D?CKQ0OAN:SNM.?0O[7N1IW]F
MWUT][?::BG=<6^FZC>.]UJEC:SPVVJ7$C3:C'=N!6=+A7&TX7^M8.->']DU(
MU:4,5[]3+:.)HUY8B%:,XXNICXXB58
MRKA6^)HU<'B:F"?)A\^Q>!Q>&PV!Q&&E&K@O[,G@Z=+#U,.K5*<.2OA:N#K5
M<,?57ABVL;[_ ()L?$6?4T4/HG[4GA.Z\'3R(IF&K:IX0T>UUN"W1
M?,J^GRK"5L+_ &E*JN18S-<5C*5+W7R4JBHTJ5U&4HQDXX>52?+*5W6C=WN?
M!9UCJ.,634:"O_9?#^595B,0N7EQF+PDLPJXBI!1C"7LJ#QL<)0G./[RE04X
MW@X-E%%%>J>*%%%% %VS_P!6_P#UU;_T%**+/_5O_P!=6_\ 04HH I-_KKC_
M *[2_P#HQZ*&_P!=OP_P#\C_(O^QUE
M/_JSP!_8L?OK]/\ >P_?7Z?XT^OY-CL_\ %+_TIG^E(44450!7X1_\%F/^
M/[X!?]>_CS_T/P]7[N5^$?\ P68_X_O@%_U[^//_ $/P]7V' /\ R5F5_P"'
M'?\ J#7/RWQH_P"3<9__ (LL_P#5IA3\0Z***_I _A!;+T7Y(****!A1110
M4444 ']*,#CVZ444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 7;/_5O_ -=6_P#04HHL_P#5O_UU;_T%** *3?ZZX_Z[2_\ HQZ*_I0/
M_!)#]EXLS?VK\5,L22?^$NTX\L-=)CM=-B\#7'AFWN+.XMCX>,T\VH'
MQ-&UO)&ZQP)9R"4.9$*^IK_P21_9=QQJOQ5XP,'Q=IQ(( XR=![5K4\1N':4
M:,JBS&$<125>DW@XVG1E.I3C-6Q3TE.C5BNON.^Z)AX$\>3=11ADK=*I[.:6
M;T])\D9M/_9-&HSB_1G\V%%?TH?\.D/V7O\ H*_%3_PK=-_^4-'_ Z0_9>_
MZ"OQ4_\ "MTW_P"4-9?\1,X8_FQ__A&O_FDK_B O'_\ SZR;_P .]/\ ^9#^
M:^BOZ4/^'2'[+W_05^*G_A6Z;_\ *&C_ (=(?LO?]!7XJ?\ A6Z;_P#*&C_B
M)G#'\V/_ /"-?_-(?\0%X_\ ^?63?^'>G_\ ,A_-?17]*'_#I#]E[_H*_%3_
M ,*W3?\ Y0T?\.D/V7O^@K\5/_"MTW_Y0T?\1,X8_FQ__A&O_FD/^("\?_\
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M K=-_\ E#1_Q$SAC^;'_P#A&O\ YI#_ (@+Q_\ \^LF_P##O3_^9#^:^BOZ
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MAWXV\)^/O#^I?$F77/!NOZ;XCTE-0\3V-U8-?Z7<+_CW_T/P]7[N5\D_M*_L?\ PR_:FF\)
M2_$34_%UA)X.75UTE?"^IV>G+,NKFU-V;P76GW_G%#:1&$HT87+ JQ;CZ'A7
M,\-D^?8+,<9[7ZMAXXE5'1A[2HO:X>I1CRPYHWM*:;UT2U/A_$?(,PXGX/S7
M),K5&6.QCP;HJO5]C2:P^-H8FKS5'":C:G3DU=:O1'\CM%?TA_\ #HC]F<_\
MS)\6O_"GT<'_ -1X&C_AT/\ LSC_ )F3XL_^%1HY_GX?K]A_XB5PQ_S\QZ_[
MDO\ [N?R[_Q ;Q 6GL('_/G)?_#Q3_\ F,_F
M\HK^D/\ X=#_ +,X_P"9D^+7X^*-'/\ /P_2?\.A_P!F?K_PDGQ:_P#"HT?^
M7_"/XH_XB5PQ_P _,?\ ^$3_ /EX?\0&\0/^?.2_^'BG_P#,9_-[17](7_#H
M?]F<_P#,R?%K_P *C1Q_+P_2_P##H?\ 9G/_ #,GQ9_\*C1Q_+P_1_Q$KAC_
M )^8_P#\(G_\O#_B WB!_P ^'_ ! ;Q _Y\Y+_ .'B
MG_\ ,9_-[17](?\ PZ'_ &9S_P S)\6?_"HT('_ #YR7_P\4_\ YC/YO**_
MI#_X=#_LSC_F9/BU^/BC1S_/P_2?\.A_V9^O_"2?%K_PJ-'_ )?\(_BC_B)7
M#'_/S'_^$3_^7A_Q ;Q _P"?.2_^'BG_ /,9_-[17](7_#H?]F<_\S)\6O\
MPJ-''\O#]+_PZ'_9G/\ S,GQ9_\ "HT('_/G)?_ \4_P#YC/YO**_I#_X=#_LS]/\ A)/BS_X5&C_S_P"$?S2?
M\.A_V9Q_S,GQ:_\ "HT<_P _#]'_ !$KAC_GYC__ B?_P O#_B WB!_SYR7
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M,?\ ^$3_ /EX?\0&\0/^?.2_^'BG_P#,A_.39_ZM_P#KJW_H*45_1VG_ 2+
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M\J .@I:* "BBB@ HHHH *0JIZ@<^U+11Y@TGHTFO/7R$VKG.!_3\NE)M4]O
MZ?RIU% ";5/8?R_E1M7I@?Y]^M+10 FU1V'X\_SI-J^G\Z=10 A53V'\OY4;
M5Z8'^??K2T4 )M4=A_/^=)M4=OZ_SIU% #=J]P_E_*EHH 3:O3
M _S[]:-JCL/Y_P Z6B@!NU1V_K_.C:O7'^?ITIU% "%5/8?R_E1M7I@?Y]^M
M+10 FU1V'\_YTFU1V_K_ #IU% #=J]P_E_*EHH 3:O3 _S[]:-
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MO]J*P^$/Q.N[GQ#]LNK/X0Z5X4_9]FNOC_/ OCA:?%BV\'VUGH&G:S\-?AS??"/P[X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?)'CS_D
M\?\ 9V_[)!^T%_Z:;.\9\/Z^QCDFLIX)'B)16,;.4+*I*D@$?ST_\
M)?XQ_P"AQ\7_ /A4Z_\ _+&OON'>!*W$&60S*.94\(IUJ]'V4L+.LTZ$XQ-:FO>YOAY=+;N^GXKQQXQT."\_JY%/(:V8RI87"8EXFGCZ6&C+ZW3G44%3G
M0J/W%!)RYK2OHE9G]NF],]5^NY?\<_I2EU_O*?\ @2_U(K^(K_A+_&/_ $./
MB_\ \*G7_P#Y8T?\)?XQ_P"AQ\7_ /A4Z_\ _+&O<_XA3B/^AW1_\-]3_P":
MCY#_ (F/PW_1)8G_ ,.V'_\ F4_MUWK_ 'E^FY?\ _P"!+_0FC>O]X?7O\ >7Z;E_QQ
M^M?Q%?\ "7^,?^AQ\7_^%3K_ /\ +&C_ (2_QC_T./B__P *G7__ )8T?\0I
MQ'_0[H_^&^I_\U!_Q,?AO^B2Q/\ X=L/_P#,I_;KO7^\H_X$O]":3>O]X#_@
M2_T)K^(O_A+_ !C_ -#CXO\ _"IU_P#^6-'_ E_C'_H4_\ E_J17\17_"7^,?^AQ\7_P#A4Z__ /+&C_A+_&/_ $./B_\
M\*G7_P#Y8T?\0IQ'_0[H_P#AOJ?_ #4'_$Q^&_Z)+$_^';#_ /S*?VZ[U_O+
M]-R_XX_6C>O]Y1_P)?Z$U_$5_P )?XQ_Z''Q?_X5.O\ _P L:/\ A+_&/_0X
M^+__ J=?_\ EC1_Q"G$?]#NC_X;ZG_S4'_$Q^&_Z)+$_P#AVP__ ,RG]NF]
M?4?]]+_C1O7^\#_P)?ZD5_$7_P )?XQ_Z''Q?_X5.O\ _P L:/\ A+_&/_0X
M^+__ J=?_\ EC1_Q"G$?]#NC_X05/\ YJ#_ (F/PW_1)XG_ ,.V'_\ F4_M
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M_P#YE/[==Z_WE^FY?\!_P"!+_4BOXB_^$O\8_\ 0X^+_P#PJ=?_
M /EC1_PE_C'_ *''Q?\ ^%3K_P#\L:/^(4XC_H=T?_""I_\ -0?\3'X;_HD\
M3_X=L/\ _,I_;H9$'5E_[Z4?S(I5;=G&.,=#G.<\_3CKWK^(>7QAXR$;D>,_
M& .TC_D:=?Z$'G_D('H'
M5-1IT:?):WM.9RNTTK6/H&BBBOCC]8"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y(\>?\GC_L[?]D@_:"_]
M.7PIKZWKY(\>?\GC_L[?]D@_:"_].7PIKZWKU1+X9>C.];KU7YGY*_\%?_ /DWWP%_V5G3
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M\&?^F:VK^.B7_5/_ +IK^Q?]DW_DV?X$_P#9+/!G_IFMJ_*O%3_<)O^Q3@/_4YGT+1117XH?UN%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R1X\_Y/'_9V_[)
M!^T%_P"G+X4U];U\D>//^3Q_V=O^R0?M!?\ IR^%-?6]>KF?\#(O^Q)2_P#5
MAG!P8+^)F'_8?4_]1\$%,?\ I_5:?3&]^F/_ &9:\B7PR]&=ZW/R5_X*_P#_
M ";[X"_[*SIW_J.^(:_G4.>V?PZ__7]QW&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MW 8[,\+B,70HUO:4(X19>\,[N#7X-RV>$
MR.&!S.5//<[RSA_,,OR[&5<*X8N>;/.O[0H47*E3JX*C@8Y52EA:E;$3^M5<
M=2PEU5E":_*J@D#K_GV^OM7Z,_"C]G/X<>,/CE\8OV?#WQ1^).C_#GQ/I-SX:U'X=_!7Q9\5/C):-K=Y8:AK6MZ
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MVM[73=1@NI[21UT>""WCMHYD'SO+U[*MB:=7ZR\5A)1CB,+-2^#00>A_+KU].*6O
MN#X__"CX&_!GQ1\5/@'/I'B^/XL>%HOA3:_"GQTMY^/7[/7P4^#-_P#%_P"&>L>*
M_#^C>-?A[X$\ :W\/=;NO%UY?>,/B3X\O[.*_P#&7A[7_!,44VFZ'X?U2TNU
M'@^:-+&:R>QC:XO[];R5!<.(<'-X5*AC;XV"K85>P3E7PLUA.3&4U&=12PW-
MC*2J-.-2CRU74IJ-*3%2CE.*GAVVZ.)IRPSI3=3$TJ1\ ,=H)/0 DYP 2223P!CDX.!R1C)&CJ
MFD:KH=Q;V>M:==Z5>76F:5K-O:W\+6T\VDZY86^JZ-J4<;;RHV Q*KUWPM\%MX_\:Z?HLVEGA4WFK0A6+ (?T0_;K\(3_$OX(_ #]K&W\(VO@O6Y
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MQGM6O?'-S)"^EV6J:JMSHFG3644>J6L']K178Y)<49="-:+C&A"=2K*5%
M*,(1S2ME#J3JC0HU94[3_ #?"2N)&CBDD
M2%%DGD2.1T@C>18DDG=%9((WF>.%))BB/-(D2L9'56:"#QD9] [9@4Q_'?PU_9E^$WP?_9J^)'BOP#X]\4Z]\;/
MA1XHU75=#T#QO-I&DZ=XIL[33TT[Q0MQJ"SSM;Q:G=J@\/V]S;VR0W%Q=S-?
M?9;6PEI<0T_:SI/ XN4GF-;+<.J7L*KKU#S[&3Q-3%4(83"X_-\=DV'IZ8.O6KUI8K!6Y(
M4(7=917*JN:S#X;T?Q;%!
M%<:-J7B.XFDMX- MYK>:64:Q)/#+&NGRPQ7!90"J[E+?>7P&_9I^#GQ4LO#6
MDOIWB*:S\1?L]>,O&^H^/?$%WJG@WQ/'\7O"5Q U_9?#CP[/=_V9XT^'6CQ7
M*6VJ:U'H5SIBW+6L+^(I]1O)+*VS=),#_P#!,WX?_:[=+FWF_;4MH;NV2XN;
M(7$5R#;W*1W5G)%=6LQC=S;W5M*L]K*$FB??$"<*_$<'4A3PT)J49R]I1G0JR#X)KRH5L1C\12C0J9!FV;8
M&>"JQK*IB,KJ\.QGAZWM*,8NDZ6?TY.K!*G)Q_=2G*C457X8\<> _&GPR\37
MW@SXA^&M2\(>*].ALKF]T+6%A6^M[;4;9+RPN&^SRSV[PW5LZRQ/#-*!AXG*
MS12(O)U^F/[0WP5^'NE?M9_''P/J=Q\4?'6J^'O@YH?BOX=:;KNI:]XWF\2>
M,U\-V]ZR_$SQO)?V5_X?\!Z/8H'N=8U'6=$T;3+12;S5X8[?[+>>$_MA?!?P
M3\&]?^#]QX%22UTWXI?!CPU\1M2TF'6IO$>C:3KNH2R6^HP^&MNBU]?Z!=2
M*L^GO=R3L(QYD4\D,R!>C+>(,/CGEV'FIK%X_!1Q7-&GRT93EA%C:BA&56K5
MA!TW)1J5'RJK&5)/G2;Y,ZX1QF6K/<52G1>!R;,ZN J4ZF(C7QD+9F\KI^UE
M0PV&PU2HL1R2JNC&ES4IJM2HTHVIQ\1\*?!;XM^.?#]WXL\&^ -:\1^%].G^
MRZIXAL)=&&CZ3=$0E+;5[V\U2UCTFXD\^'RHM2^RO.)H# )$E5SROBWP;XR\
M ZP_A[QWX4\0>#=>2W@O!I/B33+G2[R6SNL_9KVT2=!%>65P01!=V(#;1F#1=LK:-:3VM
MQJ1#;(U@2XA/(9I45"P]/^''QE^%G[2G[2_[%GPEB\"7GBGP/\&?"LWABS\1
M?$&./3]<\4>(?#WA*WU"QUV^T+3;W483I&G7GA:VN;#0=6U"\ADN[I[F\@9;
M>)9N"?$.84<9F*PM/$TJD9<_OTW*<\,IV5\12E3Y4]#Y;,^'\1EN$IY@\5A,3@*V)S'"4<1
M0E63>(RW,*F KX>I3J4DZ6)BX0Q3I*=5?5*L:T:DHJ5KMO\ !WXIW?@J;XDV
MO@;5[CX>6\AAN/&Z3Z0/#-M.)(X3:76I/J:I;7XFFAA.FS*FH&>6*);9FD4'
MS5FPI?@*!N)8A<+C))S@9 Z@D=^17Z4>$47_ (=/_%/Y5;/[35FV,#!(NO!(
M#D#!W #.<@_*.>*^Z]9&Y%L0FIRV7V*"].C71:PNXF7[>LL)$,G+0S>I]6S[%8BE!QRC&8
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M;3-%MX;))KC1="FL[9Y)5BM9[>*$I)3_ &QY],N/V:/V I])TYM&TVX8>+I
M;+2I+^34O[/A=_#+&TCOYTBGNH86REO)<+]H, C6=I)5>1L(\0?6,9EN&HT/
M=Q-:%#&JJFE0JU,G><1IT)TZD6ZL*4J*J2*9\-8G$XBG6PMZ=*IB*=:%*BZ_MTJ3WU]?\M#Z%HHHK\4/ZV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#Y)\>#_C,?]G;V^$'[0(_/4OA5_A7
MUM7RW\9?A+\5O%/Q+^&OQ2^$OC/P)X7U_P ^'?'GABXM/'_ (0USQ9I>J:?
MXXE\,7$TUO%H7B?PQ=6MW8R^&XU1I+B>&6.X=3$"H8Y)\._MN]OBG^S-CW^#
M/Q'/Y8^+O^/K7N5Z5#'X?*Y4\SRW#SPF6PPM>EBZU>E5C5AB\PJNT88&O%Q<
M,13DI*IK[R:35GY=*I5P];&IX/&5%5Q2ZCOHX)()(8UMU>)Y'_!FOW7P\@J7#D::JTJRIYACX^THRE.E.
MU2B^:$I0HR<7?[5.FWV5TW_%7CC-SX^Q,^6<'+*-I14JL;Z
M-Z.2L[6NCWJ#]H?Q3:_ 2Z_9P7PQX-D^'=WXC7Q?/<20^)#XI;Q4EQ!$VY#MN\P\)>+(?#$.OVE[X5T/Q9I_B.RTVRO+?
M69M9T^[T]](U6#6;#5_#NM^']1TS5]!U^"ZMQ'!JMG<[X8))8O+D65R.4HS7
MUD,!A(0Q$(T(PCBJ\L1B.252+K5ZC3K5IOGYHSK145*,&H)144G%M/\ +JF9
MYA6J8.K6QL7-U>SP^:]P_D_@C]HKXF_#_XUZK\
M?O#M_;#QOX@UCQ-JFOVVL6W]JZ/K=EXNNY;K6/#NMV8EA^UZ7(C6\$9@GAFM
MGL;.YM)4DA /AI16*D@94Y4D9VG&,KZ$CCZ'W.7?Y_SFN>GEQ%.K2I5L-
M6PE/+Z>&EAZ$(8?+XM57@X2I*,YPAB$ZE.?"[P5J/AJ?7[W0/">B:%K,7A"QU7Q/;M9ZQK%S;MKW]
MKZG>RVK&WM8KK5AIFG0K''I^FVRQ\YVM?M$^,M;^$_B+X-'0?"6G>$O$OQ3U
M+XR75WID7B&'Q!8^.]3OS?R7FF:EGF.(I8?$2Q;K4:2PU.G-9C'#4\QBZ=/ TXVQE'!X6E5]FJ*4
M,/04%3=&,G](?%[]J/QI\;](T>'QWX1^&\_CG2M M_#-W\7K'P[_%RU\/7D/Q"UWPS:[A%I]_8TZ%/,?:PPDXXQ857H5*L?
MJ48>WHSYY0Q2B\FPV']I117]];7>FW:ZI/#;QWN^"UMXT],\!_M%^+
M?A]\&?'GP'L/#'@C6_AY\1[Q]2\36/B2T\0W=Z-2,5I'!J&BS6&OZ?;:)>63
MZ?87=O<6-I'(;VS@NY&>0'/@8P>5P1R,CD$C.0"."1@\#)H!! (Y!Z,.5/I@
MCCL>YS@XZ'&U? 83$Q:KT:56,Z]+%24N=VQ%%QE0KP2JJ4)PE"#CR2Y?=UBD
MWSH\%B,N@X.E!_4,53G3Q6$FY8:?/2Q-&=15U552K6II
MI3C*,)0^K/!?[8_Q*\#^'O@SH=IX8^'.O7GP"U/7;WX8>)_$^A:GJ&M:)9>(
MHI8M4TADM-9T_3KB*1)/+AU&2S_M6WA B@NXFS,W+Z#^T=XAT/QQ<_$>+P3X
M(N?%Y^*FJ_&32-7W>*].N_#OC+6;2UMM1M=.N=.\1VUU=^#[Z2UCO=0\(ZO/
MJ&G:A,QBFECMXU0_/=%K/ZC04J_.JTDZK]I"M4E7K4W!UE!0EB:M:
MJDHV]]MQO.2.Z7$O$$J>$ISS?%U(X"5*>$]HL/-4*E'#X3"4:E*$L&XTZU##
M8+"TJ5>4ZM2$,+AXJ5Z?-/W>Q_:0^(T'@+XG_#K5K?PQXMT'XL>-Y?B3X@E\
M3Z-)=WUAX[GN/M$_B71C:WMG9I<23>7+'8:E:ZCID,EO RVA02+)C_$?XV^)
M/BEX&^%GP^UW1/#.G:)\&]"N?#7@VYT:+6H=5;1[V*U6\AUJXU#6-2M]0GN)
M[.&\:\CM;:6*;S!#MAE>.O(./;IGMTZ9]>6(A4A&=Z=>6'6$E6C!S47.IAHJC.+7(XVNGRQMA5SS.*U"KAJV98RIAZV&I
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MF7>OS3V]S':3R6EW"EZVGZA&$>ZLFFBBE'E'Q@^/'
MC3XXV?PYM?&NG^$[>?X8^$(?!&A:EXWVA6K(UI;:K&ES+9"*R5 +>V
MTZTL;9':20HY8!/%0P9596#(P#*RG*L" 0593@@C'(-+D9QD9P2%)PQ ZD+D
M$['FE5IRHQAAWA8JTJTXJ2H#?BG/;W'C>?5XO$
M"9[.'Q/X0U![_2SJ%J;S3YQ:?UQ\-?%LK>/KW]K&'QK\,_AKXH^'WQ.LO$%U\+M)BO-,U77M)UF
M#5-0\0ZEX8L-1O[NX\00:Q>7\_AZ]TT7&HWLCZK)-&. 5C4 8&!G%%)!
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M5:^(3=2U:IB*;HXF4XNO*-ZV'MBCAE7PF'P>)I8S"TL+7^I>TH4Z&*I^WA3C4E3510;51-=&\9?
M%KQ1'X1^'UQH?QRTG4]%^*'PW;2M8A\$^(XM4N+Z_GU ^5K9\0VFNQ7^I7US
M;ZO!K(FA^TO;11Q6\=M'!S/Q6_:"\7_%_P %_##P!K_ASP-H7ASX1:9<:/X*
M3PMH^H:;>VFG7,5M#-:7,]SJU]'<6\J6=F61H%D,UJMR9WGEN9)/#*,_Y^O^
M?Y^M32RC+J5:CB(X.BJ]#V3I5%[2]-T<+/"4I*/M.67L>::MC=3B+/*V%Q&"JYIBIX3%>V^L4'[#EG'$8U9E7IM5I4:52=6=6.7B)QZ(17]B_[)O_)L_P "?^R6>#/_ $S6U?QT2_ZI_P#=-?V+
M_LF_\FS_ )_[)9X,_\ 3-;5^>>*EOJ.4V27^V5]KI7^J0N[-NUW=VN]S]Q^
MCG_R/>)_/*L"_OQ[?Z_J?0M%%%?BA_6P4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 )CG.<'\/Z@TM%% ?U^H
M4QNW'/;\U'T[]Z?3'_I_5:F7POT?5_Y@MUZK\S\E?^"OX'_#/O@+M_Q=K3C^
M/_".^(?7UQ7\ZE?T5_\ !7__ )-]\!?]E9T[_P!1WQ#7\ZE?T/X<)+A>BDK+
MZ]C]%M_%I'\0>.G_ "<'%_\ 8JR?_P!1JS_5_>%%%%?=GX\%%%% !1110 5]
M$?LS_"'2_BSXX\33^)UGD\!_"OX<^+/BSX[M;:9[:?5M'\*60DL/#D5U$5GM
MAXCUB>UT^ZN+2.Y\J1?G>OL+]B_P <:3X?\:?%3P#K-W!IR?'C
MX(>-OA/HFJ75EAABUO4(YM&BDD=(UOKVR1W4.2/*S
MNIB:658VIA.=5XTX6=._M(TW7PT<1*E9-^UAAI8B5.R;4HW2;2/=X7HX&OQ!
ME5+,G#ZG/$U'4C6E&-&I6CA,;/ T:DI.,50K9C# 4JRG.,90J.$Y1C.4E\Z^
M%K6#XB^-[:3Q-<6?AOPYM0K9M+T:VB'VBZU"2QA>2XO;EY)?IG]O/X*Z!\&/C-#J_@*UAC^$OQ8\+:3\0
M_AXVG@/IT%E/96EOK&EV#+E##!M^I6\/Q5UW5-.\,:IX3\2_#XZ[I=CX+T>>2XUS2I;O78+W14U_5/$MEI,UY;7
M&G!+'3]'-LMTE[> M5T7
MP!)9^%(_"\QELXO!FH7&EM8VNGB31I([.*YTS39-,M[C2M(D*F$7$P\W%U,=
M2S7+\7AZ=:MEM.I4RK%4J,7+EIXBG3G3S*-.5-M0HU849.LYR4L/4K\O+%S9
M[.6T\FQ'#F>9?C\1A,-G<\/AN(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ML0_KN:TL5#"U+SI*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M>O%PHRGBJ-&IFF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M#2/VBOA%:_#+]A'P?,OB"R>#]5EL[W3;O6+G79+3PW.D
MX.HW]L&@L&25;6VFGE:XBN!;1KYGFUJN?XN5">)PN+BJ&,JSIQ>#GAW/#UN'
M\X4HUH0K2]QYA'"TH4W.;A5KTE[6;E2G1^BPN&X/RVGC(8;,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M(+6;0M>U2WTC1_%M\'OBQX/U#Q#9>#]%MOA[XB^(5WXRTN+1%\&:5\*K675/$NHW>H_;KR*\L8;2
MUP^J.MG#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M]/"TL?CZ6!FZF"I8[&T\%4E>\\'#%XJ.%F[W;YL.J$E+:<7"M**** "BBB@".7_5/_NFO[%_V3?\ DV?X$_\ 9+/!G_IFMJ_CHE_U3_[IK^Q?
M]DW_ )-G^!/_ &2SP9_Z9K:ORKQ4_P!QRG_L,K_^HD#^B?HY_P#(]XF_[%.!
M_P#4YGT+1117XH?UN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4Q_Z?U6GTQ_Z?U6IE\,O1@MUZK\S
M\E?^"O\ _P F^^ O^RLZ=_ZCOB&OYU*_HK_X*_\ _)OO@+_LK.G?^H[XAK^=
M2OZ'\./^27H_]AV8?^G:1_$'CK_R<'%_]BK)_P#U&K!1117W9^/!1110 444
M4 %-90X*MT/MGOU'H1U!ZA@""" P=11O_7JOR;#^M/Z_JR[(M7M_?ZG=SW^I
MWMUJ-_011I&996>1U1?,=V&XU:**222222
M45%12T248>SBDE;2,/=2=TDEN.[U5VT^CE*2TO9^_*>J;M?X8_E^E%%%EYWTUN[^ZZ;B]]U[*FD^D816R$M-DEHUHDE9I1:=DKJ27O)WYF
MVY.5[(_#^0YZ>GIQ1_/M[9Z_I1157>EFU;1--IVZQO=^Z]FNJZH.VB=FVDU%
MI7O_ '?NWT45JHI"_P"?\_IWI***6UK>ZETBVEU6JN[WOKWWW2L/56E[VVLF
MV[IJ5]TKW2>VZ5K!4\5W>P6=]IT-[=PV&J&S_M.R@GDAMM16PE-Q91WT,;!+
MN*UN&,\$4X>))@DNPR1HX@HI.,6N5I-::.[2Y9N:LFVKM3FF^9-J3[GG_ !/YT444Q?\ !?WM
MR?RN]%LE9*R204444 %%%% !1110!'+_ *I_]TU_8O\ LF_\FS_ G_LEG@S_
M -,UM7\=$O\ JG_W37]B_P"R;_R;/\"?^R6>#/\ TS6U?E7BI_N.4_\ 897_
M /42!_1/T<_^1[Q-_P!BG _^IS/H6BBBOQ0_K<**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK9Z^@_
MJI_H:=2-T/T/\J35U;OI]^@?U^*/R3_X*_\ '[/W@+_LK.G_ /J.^(:_G4K^
MBS_@L"&/P \!*B[B?BSIYQD#_F7?$'M/_8=C_\ T[29_$'CK_R<'%^659/_ .HM4;13O+F_YY_^/K_C1YM_&OO#\>&T4[RYO\ GG_X^O\ C1Y
M7-_SS_\ 'U_QH ;13O+F_P">?_CZ_P"-'ES?\\__ !]?\: &T4[RYO\ GG_X
M^O\ C1Y7-_SS_\ 'U_QH ;13O+F
M_P">?_CZ_P"-'ES?\\__ !]?\: &T4[RYO\ GG_X^O\ C1YM!M%.\N;_ )Y_^/K_ (T>7-_SS_\ 'U_QH ;13O+F_P">?_CZ_P"-'ES?\\__
M !]?\: &T4[RYO\ GG_X^O\ C1Y
M7-_SS_\ 'U_QH ;13O+F_P">?_CZ_P"-'ES?\\__ !]?\: (9?\ 5/\ [IK^
MQ?\ 9-_Y-G^!/_9+/!G_ *9K:OXZY(9F1P(^2K?QIV&>Y'\Z_L5_9.4K^S1\
M"@1@CX6^#1V[:/;>A(].]?E7BI_N.4_]AM?_ -1(']%?1S_Y'O$W_8IP/_J<
MSZ$HHHK\4/ZV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end



GRAPHIC
8
image_002.jpg
GRAPHIC

begin 644 image_002.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" &6 @\# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH ***8QQC&<]AT!/8$XZ?3_"@!]%?+4G[8/P3@\??\
M*]?6]B(2/X,NO'36XT*'7XM\44MF;I@ES*EHT
MHN=T0^HD;<#UR"1R".G'(..^?3(&: 'T5Y%\6_C3X)^"NA6&N^-;ZZ']M:O:
M>'?#6AZ-I]SJ_B;Q9XCO_,-IH7AC1K1'N=4U.6**:8V\858XHFFEECCZX'P^
M_:4^$/Q*@TO^P?%*V&LZMXAU7PE%X1\2V=UH'C&S\4:'"UQJN@:IX;OXUU#3
M=4M;0+>O#MBBHY#\IZ\C' YQ_%U(YQTZ'/Z "F0#'N=O/R\D[0!D9.3QZ>]-$H+;>X(!YP
M 3T7) !;'.T$G&:^5]=^*?BO1-4^*/P^\::M:/IN@W=_,?"KA;B^LYI?+U*RB34M-9(RT5?%_[-'QL_:0\4^.OV
M)--^)FGC0_#7CGX.?$C6=3U2#QFOB*[^(NH:7H>GW6GZIXETE-"LUT6^LTEC
MU"W4:AM*** "BBB@ HHHH AF?8K$8+%7*!\^66"C:'Q_"6QG'2O%OAK\7%\7ZYX@\#>
M*=';P9\2O"4[R:MX2N;Q+K[?H4L\J:5XK\/70$3:MH.HPJ@:X2(FQO"]G,%D
M"L_MI4'.M/4I9K)&F&GS,=%U2^M2DEQH=_,L8NK2;S(A(J7,:+.@<@'T0)%/?CL2",\;O
MKP.3Z4NX<=><=O7^GTS7YK_![]MGQU\4-<\!>&9OA@UEXU3X2^*?%'Q=^&UO
M<1Q>*- ^(&AW'A[^R="T&6_OH89M!\1V.JR:QHNK7D:VNHZ2R2PW'G@Q-](1
M^+/VG_$4L;:/\+OAYX$TXR1,9O''C6^US5Y8/-3SX_['\,Z;':6MN5\T1LP,3-D ^FJ*KP&3 64H9!'$6V;L;BO[S:&^81EPVP'^&K% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5$[[6'?C[OTYR<\#Z]NO2GLP49/ZMYP3RH[@=2!DXSQ0!^4'C?X%?'GPI\-_''P9O-,\ ZA^SN?B9J/Q6U+XA:-MSJ?Q5LO!\OC:'XA:EX;T_P "P:2L6J^,(=4BN(;?7H];C5=((DC66^A2,_M@#XT:5KGAC2]4\&UU#Q7IL=EXNT(D2:1XCT$ZG+8:A):W]
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M35M&\%:/H&@6_AG0;"WUV]MK6YU+7[G3K9;CQ!J=O9V4%QM\5Z9X,TW1?@5K^D^,O#FM?#OPE'IVF:MXU5+W3_%WA;PC:V^FGQE!XOM"^CL
M+B&);V]L;N2SNM/=YD\IX82X[/XMTN[V:A':6LRVEQ>PP7"0/J&GPW+QQ/J&GK=6@>10)2IW4 >WJ % P ,8YX_
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M_1Y(X[:"XMP[I*T4N!M\2,SZ[\0?A_P##FU?RY%L/!?A>[\6:
MC$M%50\S(@"(96RY5/E4L57@5;' ]*3 SGN: %HHHH **** "BBB@ HHHH *K3
MW,4 =Y98X8HT9Y9IG6.*%5&YG>1R$554$L6("@$DXR*LU\7_ +<.A^)];^#E
MNFBZ3XH\0^%K#XB^ M8^+?ACP4\\/BWQ%\*-.UJUF\8:=I"V\T4]^#9*DVI:
M5;EI]5TF&]L[=#,!N /K>SUK2-4MUO=/U;3-0LGF:VCO+'4+2YM'N P @$]O
M+-$UQR (02^>-N16A'-"[R0I-&\D6T2JDB-)$S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M_$RW\5:393_#O1]?OO D6LZ9:^'+FPEN]2@MHM1N3>NEPBSQ7PB#QE&MAA@_XURMSX(\*7<.LVMSXU\1:A;:KK\$NG6KPZWJ-J;=H;W5(S%B]N8O
ML=J(Y;CS&06\(&0@H _(OQ=\8/&O]@^./C)_PT#X@M/BWI?QXNOAIHO[*UI>
M:*VA7GAJ/QG8>$[?X>W/@IK1?$UQXBUWPR\GB]_&%E>K):K<_:[=#9VLN?UW
M\*^%] \'Z%IWASPSI%IH.C:9 (+/2;*-8K>T!)>1ED7/GS2N[/-<2,\MR[&6
M5F8FN:G^#7PKN?',7Q-N/AUX+N?B)#'%#!XWF\.:4_B:%+=&2U*:LUN;M9+:
M-V@AF#^?' 3$CB,E3Z7&NU N,8[9+?D2*_M!?#C5OBW\$?BG\,]"
MU9]#UCQQX*UOP]INI,V(8KR_M7407+*KM'8ZESI^I.BLXLKNX95+8%?#GPP\
M(_$GXK_&+]GG6Y_@II'P-TK]DZ#Q+X1\ZCXPO)_!M03MX)%RT'B.[?6Y(?)0:>D5H+SS96_4EIUW8'0,JEL]&;[JE0"V3G& >Y(&
M37R]^SM=VC>(?VCO*ELB+?X\ZS#-]EO%OVCE/ASPX EY(LC^1<;G56MB5-OD
M(54G /J<=!WXZYSGWS2TP.2<8SV)R/SXXR>H&M+6].\-:1J_B'5YA;:5H6EWNKZE<-@I'8V%O)<7;D,0H:.*/>.>< 'K@_.>B_
M%;XW>/M-BU;P%\%K70-(U.,76DZ_\3/%UM8MJ>GSP)-INKQ:%H-KJ-VEM>V\
ML'PE9S?V
MYXVOX5P PMM L+BW9W+1>;>VZR+*K",_1UG;16EO;VUO&L-M:Q1V]O"@58XH
M((U@AC2-0$1$CC4(J@!5^7 Z4 ?+^M?"7XO?$P65A\6?B)X=M?!L6N:5K=]X
M*^''ARZMO[6_L>\AO['3-3\6:U?/?'2&OH8I-2MX=)!OH$\EI(4+-7U/& $
M"JH4!%50%554 !5 X"@<*!C &*DHH **** "BBB@ HHHH **** "BBB@ JO
M(OR/(#APD@W*3\N%., G!/ S[],9)/+^,?'?A+P%HT^O^,=>TWP_H\'R&ZO[
MA8Y+BXQN6SL;8!KF_O9!@16=G#/:?K'
M@AM6,4VE0IH<7BGXR^,-+=I8I1H7@-YH[+X>Z/-'Y-O'5Y:16EM,DUI8-
M=@H #Z._9DN;B]^!OP]GN7NGFFT_6#+)=?-.6'B+50%F+$L"RJ"O8H,5[V(\
M9^9CGDY+$9YY +$+G)SM !]*^*_!?@_XS_ 'PQI,'@JQO/B9\.;>RAGG^%?B
M/6+4_$[P.UT\MYJ$/AOQD/\ B6^,4CGEGD.F:N+2YEE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M8@'GGV.">: /D]_CCXB^$<45G^T=HMKHFF1SP66G?%KPI'MK35--B675O"NLZBIA2*TNHKBPEO9'@M+ME\L5L7'QD^(WBZ5K?X4?!?Q%>1?
MND'BSXG2_P#"!>%]DA#O);V4BW?B+4X/*#8FM-+V"1HU9PK9'DO[2%]>I\2E
MT_[23I4_@?X;3OIK$261QQ".*Y*!TB)57*DK7W@5#-N
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MCUOP!\)O GPQL)['P=H<6G7-^PEU?6YY9=1\1Z]M[7,SHKN6BCCPH'DOQ(\5:?X1^/?@+5-0M;F1W^%GQ"@TR."2VBN/$6K1ZEH=
MY#X8T%+V:WCO_$-Q!:7-U:ZM6>:RUG2;J*;3_$/A[5("HFTO7]$O(XK_ $ZYMB&BD^T6ZQ/*K&WEE0AJ /1S
M$^" [#@X*GG.,<@Y0>@VK@#J#UK\XOB5I.B_$;]IOP-H_CG0?#NN6?A[XJW^
MB:1'/HV+B[T0?"VWUW[#K4B#RM=M;;6))+R(:F9(;0A1#'N#9_2%V 0E2"1C
M ![Y Z$@$D*>,@$]#7YM_$J^TWX;_M1?#WQ!XT\0>'=#TOQ-\6-3U'3$O-8
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M)=W%L;C3_%6A.I"W?A;Q98+'K>BW,(V"&Z-G\TENS5[TC;E#!BM/P1^&-_X)TG4/$OBR>/4OBAXZ:SU3QYJ%JP6QLIH(/(TGPGX?A \NQ\,^$K
MII>DV,;-&OESW6XR74A/O &!RM **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KYN_:+T?Q)+I'@7Q-X;\/ZCXJ'@#XCZ+XVUG0-&=6\0W
MVAZ7#=1ZA_8%G)-!'JFHP?:%GATQYH_M81H5;M?\/_ -K'3KHR#XB6UEI^BM?SVEM\0O#L.H2^'=,)N4BM='^(VBW\$7B'X;>(
MD,DD=Y_;=HWAYGMYYX-9^SB.1OKVVO[+4K>"]TZ^MM0L+FW%Q;7MCM(H*3Q7-N\EO+"Z'>LJ2,C+R#@YKR/XD? WP?X]OH_$2_;O"?CBVADBM/&WA=
MHK34YTDMI+8Z?XFLF0Z;XPT%EM-\0/'&F6?PXAN[DCPC\(M(N? ,'BR.[G>\NKKQ5>17,FH:7'>32&*\\/>&KF
MVTV15=(YH[MI7ACX@:9XXU+4-<\6:@\>E1ZQ,FD-INEZ*7N)9;V:-3]G)W5[]X;_:+\":MJ
M]AX:\16_B?X9^+M1EMX+3PO\0]!NM!N+R[N5C9;;3-3 N=#OW,TBVZK#J8>6
M=E6.(E@*]=\+^%/#W@_1[/P]X8T33M T/3U$=II>E6T=I:P*!M.Y(E4SR/\
M?EGG:2>60L\DC-DUK7UG9W7D+>VEM>)%/%/$MW!%MJ2IL9'1&5E8 T ?/P_:6^%'B'PQK.K>"/'GAJ_U.V^(E[\%K9=2:]2TL/C#%
M-/9VG@[7X88C=Z?,U[$'(**LUNWFQ2%2K-V'P8^%S?#+PW=P:QJ:>)/'/B?5
M[SQ+X_\ �-#<>)O$5Z[XD D>2:/3-)LOL^D:-9O(R6>GV<*HD;22K7Y/:-
M^S#K.B:O\+OBAX4^*GPKL]/U#]K;5Y?C)I<6OW+Z'\1HK3X@ZYJW@:\TF]2S
M4)\:?#ES/_8%]:/"O]K:1YFESWB16,1?]P5ZMU^\>Y_E[?YZ4 .HHHH ****
M "BBB@ HHHH **** "D(R",XR,9I:* .*\;^ ?"/Q&T2X\-^-O#VF>(M&N.6
MM=0@W-;R[6VW>GW:;+K3+Z!MC0WUC/!=Q% T$-5M_%O
M@'4/$?BY=-@-M9ZI8:O#H_QO\'Z8BRB&#P[XK>--/^)&A6VYPWA+Q_'?/.DF
MV+4-R1@?H93"B$@[<$$$8R.0,#(! .!P,YXH ^/--U#]H7XM:?I^CZ,NJ?!G
MP=;V:Z;K_CWQEINGM\8/%,L5O K:IX5\*V,D_ASPI!?L95?4]6>XO+:;M114E'KW@SX#?"_P59:O;V7ABSUG4/$J_\57XC\5J?$_B3Q8Y4J\FOZQK/VFZ
MNHF)^6R5H[*!0J06\:@+7LGE@YW88'J"/KT.>.IZ8[^M/"A>@QT_08&?7CU^
MO6@#YLNO@'\/_ <>N>*?AUHVL^%;^Q\.^)I4\+>#M4O;'P]KM$K:6;LS$262V\-NXOS'-DMS7Y>?LTZ=\<_A]\4OV'/A3XWA^*WB;P-'X=^)7
MC_PC\0]8T[5HHM(T_7_#-5
M_;'QH\D/@_Q5- UW'-#XM@1\0/VF]5\5_\$_['XCW6EVG@OQ-X;^(%_/=:-XL\37>N^+[C3_"4CV1^(^D
MZGI]O;'4+ ".YL94NI;8WEQ%2JG+;MS,P.M3S4M10G* A-JD97D$#/8 = /3D#M4M !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ! /49^M( 1GGCL,8Q2T4 %1.2I3@;.A/&=W\.>#P2.
MP'S$'(Q4M(5#=>1S^HQ]?RH _'OPS^Q3\4])M_"_BDZKXPB\1Z=^V;JOQ9U'
MP%<>-K>Y^'/_ K[4?%U_J,FM6WAX0>7'J8TZYBN883=K<)=K)^Z4G:?V#4=
M?MH **** "BBB@"*1"Z[0H(+?,K8*NI!#!AT(8'!!'()R#5+^S;3S+=Q:V@>T#
MBR8V\#-9!E5<6I\L&W7:&1A$0"",\\5I44 ,1=H([9^7IP.<#@G)'J3DT^BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:64'&1DMX^M.KYK_ &JOB3XN^$'P.^(/Q1\$MHG]M^"-.MM:-MX@TV\U*QOK!+^TM+^V
MDAL;FWNXIOLMS++:21&0R20"+9MD8T ?26]?4?3OT!Q]<$'ZM?@9QZ\=>,U^>_@']L#7-)@OHOC7X=>.SUWQY#X:^#/BCP]X>U?0?^%J^&_[#
MTS4=9UN/P_XCEA&EWVB:S?7GA^#3#J!O/$8T\ZCH=G=0K*:S9_VC_%L7C7P5
MJ%M\0[)_ MO\>/BYX#^(^E:YX!_X1>[TCPEX1\$7OB:&U@GN-0O;V^O/# M!
M=SZ[;+&FJVKR*--C,8% 'Z. @C(.139)%1MFN4TVW:/Q9::QXDT_0=8\ >'[O0'@UGXCZ+XHNIK/P_JW@RW-QY5]:W\UO*I
M6ZFM)K+"?:HD\V+>V']J3PIXDO/%O@W3]&^(?ACQSHWA?1M9M+#7/!\EE?-#
MXP%_9Z#JEC87EPHO[>RU"RGCU8NJ0VAMRDO$\;4 ?6"R @DG@C(&1DCCD8QD
M!;C5_#6N^
M';'QU%X1UWQ#X;T73]3W7:V)E@%YIYN89[$S'4!'MMQ9^+K'6+;Q\/AC/K>IZ ;/PS-XQ?PU!XIL;"UU7SW2;^U=*G$]D BMO5X9%
MC=<$ ^F:*8A)7YL9'4@YSW!X '((/'K3Z "BBB@ HHHH **** "BBB@ HHHH
M *0LHQDCG..>N/3U^E#=.F>1QZ\U\V_M3?&#Q1\#?A!K?Q,\-:;XMX>M;ZV\475]8Z4FG:YKECHLU])=6*/+&=+%ZE_,6 C:"*8!@VU2 ?2.Y?[P_
M/VS^>.<=:"ZCDL,=MWX8M-;UC2OBKX>T2+23-\0_!]E>65MK;>&HKO51IUW=/:2J)[66ZMC+9;Y8\
M71?VK]83XA^$[#7=<\ 7/PZU'4/VAK+Q;XBT[1_%>CR>%(?@S9V^L1O?2:_%
M 6N[?3YI+;63;P3:;-<0N=-N)<%* /O_ ",9R,49'J/Q_P ^]?+W_#7?P7.B
M7FL-K.MPS6MYI%C;>&YO"^L+XPUP:]I\NK:)?^'_ P+=M4U?2=4TNWNM0M]
M1M8'MEM[:X$KI+'Y1YRW_:P\%Z=JGCC5O$OBFQ_X0K3_ !#\+O#?A6WT?PAX
MO7Q);WWQ(T&XU;0SXB2_LHX;J/Q \(32IM(@,%LY%G?&.\8(0#[%HKS_ .&O
MQ,\(_%KPE8>-_ ^HOJ>@:A/>V://:W&GWMKJ&F7MT%S:7,:2Q2(0R@;2?0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ ^M>1?&KX0Z'\'O$XLDU6Z\,:DNEZP8=/U"TU.WAM[
M]H+D1H]S9PK/$4!D0D9QD'UVB@#PSXB? GPG\4-&T70_%^H>)+_2=)M;.QN;
M,ZC$]OX@M[2>RNE;68)+5T^W"XT^!H]6L!I^KVQ>X%I?0+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MZR"@=@?J!FEH CCSMYP,_,<9ZMDYP<$#& %(! E%)D8)],_I0 M%1^:GS
MO!XP 2">@(!R03G'2GA@<<\GMWXZT +1110 4444 %%%% !1129 ZG'7
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M\=>+?'<^H:Q;:;;74-[XOU1]3N]/1=,CB@>VL96,=M,T0F="HF=GRQ]EHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ IDGW2< X(.#C!P<]\"GTA (((R".1UR/I0!_/A\2?^"A/[2_P!_X*1>._
MV<]-\-2_'OX>>+]=\$R>%?!#3V.C>)/"W_"4Z1$9;?P]XBDV:?%96-S;SW"Z
M;KF)M1\YH[#S)$+#^@"QDDN(()IH7M9Y((I)K:5UDEM9)8U>2VE>-WC>6!W,
M4CQNT;,I9#M(%>(_&3]GGX?_ !?\)^--$OM&TK0O$?BVRT_R_'NFZ39+XJTC
MQ#X=;[1X-\16NK[$OFN_#-]MFLP9TS')/ KQQ329X[]EOXQ>)?'_ (;\0> _
MBC%9Z?\ '3X,:JO@OXK:9;^4BZG.J,WAKQ_I-FDLGDZ!X^TB)=:T]3(_D227
M-J6S;D4 ?5]%-4Y4<\XS[\^O\OPIU !1110 4444 %0S8QG(SC 5ONMD]">W
M?D\?K4U>??$WXD>%OA1X'\3_ ! \9ZBFF>'/"NE3:IJ$QVM/<,K>79:9I\'^
MMN]6U>Z:'3M)LX0\M]?7,%O!'))(%(!^+/\ P52_X*&_M)_LW^(;#X0?"/X?
MVW@B/QEIJR:3\<-:EMM?DU""YNK2PNQX7T"S65-#GTNXO8[:36?%(CLGNIXE
ML$::/#?M?\,X]1C^'7@3^U[V\U'5W\'>&I-6U"_;?>WNIRZ/9R7]U=-LC_?S
M73RO(/+0*3M"*!BOE7]G7X*WOBO3O&OQO_:#\'Z=?_$KX_2Z7J.I^"_$$,&M
M:?\ #;XMPJH$4*$081%4;51!V55 51V H EHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHR/6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &LH88/L
M?7H0>0>#T[BOA7]J3PMKGPJ\4^'/VO\ X9:,VHZ]\/+)=!^-OAC3]\5W\1?@
M5-*)=898HV6'4/%'PZE0>*/#372EWLX=5TX3QJ\0K[LJOM0R6\\,\:303V\R-'-!-#(#'+%+&S))&ZE70E6!!H PO"7BC0O&?AW0_%?A?4
MK;6?#GB32[+6=$U:SD6:UOM,U"W6YM+B*1"5(>)URMPC\&O"J^!_ L-]8^&+?5=8U73M)O-0N-0@T9=9OI=1GTO2#MTV-C!91.T< 6,A1Z70 44A(&.O/3%-9CM!7.2?[I/KU !/X]J 'T5&D@8XYW
M#J""/T(!_2I* (I'*%0!N+' 4=2<$]<'' 8@G R,9YX_/IV'[8/QT >UCO\
M]F[]FSQBK%IC+_9WQ@^.NC,CVTD"JS6&J>$/A+=,LREC-'>>-HE=5(TW:/O/
M7=+AUS2-4T>YENH+?5=.O=-GN+&>2VOH(;ZVEM9I;.ZAQ+;74<M4.A# $MAI.G1O),X0R23W-U=W4S-/
M>:A?W4T][?WT[M<7=Y/+<3.SL30!W$08#)ZG))YR3GOZ=3MY/RX&2 *EI
M .@ ^@XI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYI_:'^/3?!/3O!UCH7A/4_
MB#\2OBCXJ7P-\,? NFW4.FKK_B0Z?/JEW)JVLW0:ST/0]'T>SNM1U#4YPXC2
M+RE0.ZU]+5\J?M)_ S7OBZGPU\7?#KQ3:>"?C!\%?&H\<_#?7]:TV35O#4\U
MW8S:)XH\*^*--@EMKFZT;Q/X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M6^([B"X6QT;1OM%HC6UK!/J5_/?#7Q[I'
MQE\&_!WXB:/JOBC2#H'AG_A.-%OM9T#XAZ-XHDC@L]7\&:M'8RBS,T=K=B3-
MI&]3^*FFWMO$=O%!XYTJ;2-.FM]=T73[?6K&PG\->)H)//DN;2X:*VFL[C*\G;_L0>.O&E
MU9>.?CIXV\$^/OB%XE^.?P_^*?Q)TB'PM,_PYB\&?#;0MMW5Y+::4^L?V@VJZQ+/<7NI[KAXHD C8 ^IOA=^T!X<^*_P 5/B[\/?"LFF:M
MI7PIL_ +]&URQUC2=?NO&>FW^H26L!T^61+>;2A9I;S(\KEI)!CY5&?H_
M_/\ G%?*WP=_9NT7X,_&#XU^.O"=GX:T#P=\5+#X>0Z5X/\ #>CQZ/%HE_X/
MT[4K+5KNZ2 BUN)=5N+U+E9HHXRFWRW!X-?5 R ,]<4 +112$XQGN0/;/_Z^
ME "T4W<.<>I'4=1P>I'?_(J&0DE3E=I'R^[A@ "02-K$@#T/Z@$X8'OQV/K[
MCUI>M>4?#OXE:9\1[GQP-&TS4[;3? _C34O!!U:Z5!9>(=0T>*V.J7&D'+2/
M96-],]C++(L;-OMSGT^M%0S$@='()YV '@XY.>3C_9'<>E [#()R,$=,!MS';WXZ$8]20#7Q!^
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M'NIPM)87'QBFO?B+\7A:39%M)GL](TG5$4&:2RN4#1+M1WWFNCM_P!B
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M4+_9J\2_!2RN;F*SM_CS\+WF^(WP(NWN)(X$DU>_LEGUCP@BEQ)MYE S72?MW^ _BC\/OB[\!_\ @H!\!O"5[\4M5^!^C:]X,^+?PU\.2K)X@\=_
M [Q7BKXMO^*6FR6^I:5=1:_\(?%WA/5KGX@>:(52]\+ZG\/+RPFU"?5W=VMTLDM9(Y9
M1 Y'S@ _2+P3XV\)_$/PSI'C/P+XDTCQ?X2U^UCO]%\1Z#?V^IZ7J=I,H=)[
M6[M9)(F0Y *$AXR"LJJP-=<"#R*_F#^!"_M3?LWK\4?VU/V8O@)XG\#_ +#V
MO^-+;5-2_8R\4'5IOB+K'P^2W@A\1_&[P!X:N3[TRS9
MA;+M=F_HJ^#?Q@\ ?';X;^%/BM\,?$%IXF\%>,-,AU'2=4M'#%"?W=SIU]#G
MS++5-.N%DM-0LYU26WN871DY6@#U*B@'/(HH **** "BBB@ HHHH **"<M&1 "20,=\C^6<_AC- #Z*3<..>O0_P"?K1GD#US^E "T4P."M'CD^A^M*74'!8 ]<$@'\B<_CT_6@!U%'7I10 4444 %%%% !1110 4444 %%
M'3K4?F#G ) QR!DE-\Q3P",^^/_BA
M0!)147G1D$AU( ))X.,$@YYZY!''3KTYIPD4@,#D,"01R,+][/...1P3T[]*
M 'T5'Y@QG!'7J". <$X&2,<9W8QU) YH\Q4=.M<]P1['//>EH H_VGIV+P_;[/&GL5OR;F$"Q81K,5O#OQ;,(G23$Y0[&#_=.:
MQM8\9^#?#T.G7&O^*?#>AP:Q.+?29]6UG3=.BU.X89$.GR7EQ"EY*1AMEN9&
M*X;&"#7XZ_$C3/C]/\4?^"FEQ\*_$'@72?!L7A'PNWB:R\=Z%XEU/5=1F/P.
MGFNV\%2Z7>VEG9YM\P/MG\"?^%$_\+,GO[CP+<> 8? UN?'#>$[R^ L[OXB#Q;=7EIJ$\1_X2][>.TBB
M0QO 90#]L_%'Q(^'WA*_\/Z5XH\4:'I>J^)-0L['PYH]SRF*T.F
MZ=")KV9)&)'VF*$01#M.GBZ+P=K4W[2"R>#]5T'5U'P]\82W-MI-I<:Q-I[Z/IDQ1K&WMKF\3RY?-./
MO/\ 8-\&W%_^SU\+O%OCKPW:;\)KCQ9JLO@
M2VO9M4\[5+!Y/#(TS;;RS1W8L5M8YMK@N?NR*U6!&$21Q%V+NL4:(IF8L7D(
M0#+,2K%VW2,57MPS/MV>7K>CW21RR+(59UU&R^T:?=;XVAGS\H[[0_''@KQ/&_%GAGQ!>
M:.RKJ]GHNMZ9JEUIC$D*-0M[*YGFLR65E47"1_,I4?,"!\V_MF>'O&:_LZ_'
M#Q+\'M'EE^,__"LM7TOP[K'A^VBC\:MI\ACEU6Q\/:B!]J751I@O9=('FMY6
MHB"2% ZJI_/OP=>_LR7WQ-_8R/[$TEM/\3+'5XE^*Q\'?;Y[FU^#8\.75M\1
M(/CPV19CQ.GB 6,=G%XGQKZ:]]MDT]5 PP!^WR[6^9=IY/(QUZ'GU[4ZHXP
M#P1N=B!D]CV]!QP,#CK4E !2$9'3N/J.1R.#C'6EKAO'7Q'\$_#/0Y/$OC_Q
M/H_A#P_'/#:'5M;O8K2TDO+H-]FL[=F8RW-W-M/E6UO')-(5;8K 9H \N_:(
M_:"T3]G?PWX>\1Z[X7\7>*(/$OC#0/"5O:^$M%NM6N;2YUJZ\EKJYCM5=E6-
M!OBC*AKJ3$,9WG%>J:UK6I2^$-@7UYHNDW3BSE?5I-,:ZTBR
MU 3X&FS-<-"MU%Z'\/
M=3C\/O>6L\(%S%KGB*'3+)); 2O*D]NLKAXW\ABPW#\M/C=XN^(7PN^.G[?/
MQU\.ZWXQUKX<:-H_@_X9_&_X!]+BD?[-K?A37
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M&FYS:07+*,J17UM-9\7_M#7MQXQTRYUOPC%=?#*UMD\,+XHTB%HY-3TZ:_O;I([6VE-PDK^<4$:
MA@ ?5W_!.G]EJ_\ V?O@XWC;XFS?VW^TQ\>IC\3OV@/&M_NFU?4?$NNA]0MO
M#WVF8^;#H7A*WNH],L+0"..$1R;T5S7B/[%OB*#XY_M]_MY?M$>#+B&^^$6G
M67PM^ 6A^(=/CD&C^-O$OP]L]2?Q/J5CM5!K/[+O_ 4L_:2TV3P7^T?^U-\/?@[\*]1=[/Q9H'[,WA6^TSX@>+-)*LL]
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M5KI(?^"FOQ7U_1;KXD^'_P#@GG^T=XC_ &M;Q-I_P .+L/JM_HD>FD7LTMPY^$Z/XHENA)XP\/^"="T?Q7IFJPNT>J:3K$<%J+W0=M922&(![3^S%X3\8> /V=O@GX-^(E_-J'CGPG\,O!VA^*[ZZG>>XDUC3]%M8+
MN.ZN"29Y[9D\F9R2&>-V 53@=1J'PG^#LFO?\)AJ?PX^&M-K$C0N+B!DU.XL3>/*DK&5'6(=;L
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MJ*A.T9VYYR!V.>GU SGWI]M2#0['4VCB!)(6)[EEVL2R?=))SCC/BQ^TI\#?@9J.CZ3\6OB-H/@;4/$%K/>
M:+;:R;M7U*WMI#%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M%UF:RE>:)XKF>$PV@,M/Q)OM$T^Y\>?$/Q%I5AJ7B+5M?O($N-5CL[FZMW;2M*CO)KA+>PM1&614>ZE
MGE+,0#X0;_@O[\#&1G'[.G[1;!)$4!?#432L3(R-LC"[I$4[3\O+QL&P ,U'
M-_P<"? &UFCM[OX!?'VSN9WG2"VN])T^"YN9+8@W$=I!-(LUPZ[E3$"-OM,F0$5^[(\+>&@5,?AS0$(8@D:/IP.T_?P1;+C/ .,9[U^!G_ 4ZTS3[;_@H
MM_P2]M+.QTVPM;OQWK,EW'%I]B+2]\O4;59(KZU-N4>-QY:)=S1RK;LZJNUY
MER ="_\ P7R^",;3Y_9M_:-0I(J"9/"\>R0-M,+%Q$/+:3S(_DG"2(T@4C&<
M=7X/_P""\W[).I:U:Z5\1O"/QE^#EO>2O;0>(/&?A">71]T8C:62:ZLE,BQ1
M&4+)+''*B(#*044FOVJ;POX;8N&\/:$5?@@Z1I[;^,DOFW(.2J]?[@[XQY]\
M2_@+\(/C%X6U3P/\2_AOX.\6^%=7M)[:YT_4]"L&:(3QM!))9W,<*75E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M^UI^S#(YC3]H7X+NX!.U?B/X5)P+DV9(QJG(6Z!MV(R%F&QB&XH ^AJ*^?\
M_AJW]F8D ?M _!O)(&/^%B>%>IE,( /]J_\ /7Y/KSTJ-OVL/V8T0._[0?P9
M5':%$=OB/X412]S,UM H8ZGC,MPIAC&27D!4?,,4 ?0991@$@9Z?R_G2U^8^
MN?\ !6;]C[PK\HZ+\78-2T_7/A/K,FK0&233Y/$^
ME33P:/?6-P#93I?!H7N8YE$ZB([OT=T'Q#HOB?1=+\0^'=4T_7M$UJQ@U+2M
M7TBZAOM.U+3[E ]O?65U [PW%M.A#12Q.RNIR#VH VZ*** (IMBPX)&<$@'G[IX-?EU\<-2_:'UG]J3Q7\-_@=XX\0P:M'\,O /C70;*]US18/
MA_X.OV\9?8O$.J>+-$NX?[4UG2-4T"&:VMM,TR0W!O'\W@!2?U(90P(Z>A'4
M'L?_ *U>'>+]/^&OPX\96/Q4N_!EY>?$+QI=Z)\-!XF\,>&K[6=?GL]1NI'L
M;?6'L1(MCX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MZ7X1U;2K5?-MO^$76VGLD6XGG,WS7BOMG4 ^FHA@OP1R.,#:,@9VGOSU.!S
M4M( !P*6@#._LJP$EW*MI:+)J(5=2<6T._4%2$6Z+>MLS=*EN/(19RZK#F,#
M82IR=5\&^$]:MK2TUGPUX>UBSTZ19=/M-6T;3]1M=/E0*L;V,%W;S1VACV($
M\A4"8! RJXZ>B@"O'"J!0I.54(,\ * 0H "XV@# P% & *L45#,S ;4*JS
M9 9NS8)&!D;LX/ [CUP* %< C[H9@N1U)R>#CD9R,X&?K@5\M_ ^&)/BO^TV
MD4%I;V]CX^\.VMI';Z=96<<,,GA.RN;F(26EK;RR^?=2MMWWQ,^._P]^%WV+3];OK[6?%6K316VB^ _"&FS>)/&^KW$LH@1K3P]IHFO(;2
M.1D-UJ=ZMMI]G&WF75Q$F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M(7 /IU;:*)/+BQ#&"-B1JJ1Q\[@(TC"*OS9/ [DGJ'=#*ZQYFCZ0R:\
MC1:\'T^V<:XGV8V@36%,6-21;7_1E2[\T+;CR5"QG%=!10!\5^*D\1_LT^+=
M2^(VGW5UK?[.GB Z;_PL#PEEY+CX*R6-K%IT'C3P/86\8CC\!B.*W;Q=H$$;
MR::A?6K#=!#/;U]B:7?V>JZ?9:IIUY!?Z;J-I!?:?>VTBS6]W9W<23VMS!,A
M*RPSP2))%(IPR,IP#D5)=V5O>036US#%M12(S*\4BM'(IVN"M/LK.UT^TM[&RMH+.SM(8[>UM+:-(;>VMXE"10P11A4BB
MC0!$C155 J@*!0!9I&&1C./\^GY?YZK10!\5_MJ_L]_&W]H7X9OX5^"/[0_
MB+X"Z[ EXUT=(L();#Q?')&RQZ3K6J1[-:TJR) 5KC290X+99"%%?GY^P/\
ML$_M:?"#X;>-_"/C7X]>,/@?JTGQ)U76([7P1:^%?&^G>,+6[M;9$\3W.O\
MB&WN=8EO+^6%FNH;YEDA^6W7Y *_=9AD$Q':FH@4LPSE@N[)R
M20".?P[]Z /A4?LM?M#<9_;N^,))R'_XH3X=#.[+$H/[. 0K(!L/S!8@8"&+
M;Z8?V6/VA2 &_;Q^,F!@_+X'^'2$[\.^2--/5U'ECI'$6BPV[>/O"B@#XJT+
M]FWXZZ1XBT36-0_;4^+&OZ7IFMV&IZIX=O\ P7X#CL==TZTXM-/BNK
M6VOP0MQ<6K?:54$QEME_P6A^'3ZT?*CU7]CCQ?:>#9)\1I<:A;>++&;7H+-Y !/,MJ(G>.)O-1M<5^NISCCK7YX_M[?LO?$;XR:?\,OC1^SQKFG>%_VH_VM%VFZA!]G\5_#/Q/<*C/#HGC#3H?LBW&2EI>*DK; Q=0#]"8E7JISAFX!X^8Y
M/ .,Y_D17X__ /!7$V$=O^Q=+\1(GG_9XC_:W^'W_"\(KE7?P\VELMS_ ,(P
MWBD)%)MT6+7ECEE:&?B)^R7\9
M-*MX8?%G@;XD>#M>FT!-5CC"7S^#_&&DV-[I/B31#+F2TU&%XS)%,BNK29-2
M_%/_ (*0_P#!+SXU^!/%7PI^*/QF\'^+/!/BW3Y-%\3>'=3T'Q,8+J"<*RJ9
M(],62UGAD:&XM[J%U>VF2.595() !^K-J+)[*V>P-LVF"VC:Q:T*&R:R>%6M
MC:/&QMC8M;%!#Y/^CB$CRQY>!7Y&_P#!-H^';C]HO_@H_=_"8VW_ HJX_:!
MT:+PZ^EQI'X9'Q"M/#\L7Q(/A5+;&GRV[\K=G&ZOS4.L_L%Z
M=9)\-=#_ ."NO[0^@_ 3S!:I\(8KW4KDV.A"X'D>%],\;MX?_MFVT#[&;JQ:
M42331VA2-+B(P[A^C_P,_P""@O\ P2>_9Q^'&A?"3X0?&?PGX:\%^'HW^S6E
MIHWBF[O-1OIF O\ 6M:U-M(>YU?6=4N,S7VIWC--S_ /!5/X5>
M,_B5^R=JFJ?#O0)O%7C3X._$#X?_ !PTGPQ9J9;S7[?X;Z_;ZWJVEV<*#-S=
M2Z5%T?7-.MIM4LHK
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M5-,N];U$-))$(K)+I+:)]N8D 8B7QKXF^+7_ 5AUGPQ\-/!7P_\;_"']A/2
M?$^D>)/B]\2/B#I;^'_%'QY3P[?+J5I\./!GAF8V^H6OA2_O;6V3Q!K$[XF@
M\RW,1$FP@'Z(_P#!/RSUC3_V)?V6['7H[B+5+7X*>!H9UNOEG,*:1 +*1TP
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MR17$445Y#M:W5M.ABGM[B"5'BFAFB=XY(I4:-U8A@.#7XD?%O_ ((E?"^^\=ZS\2OV7OC3
M\2/V4_$FOS27&IZ9X%O[F?PTES.SB232[%+VPNM+@,M@8 _<(EV+@H0!D*P()(QU [9.1ZCOZU_/Y_P5 1I?^"CW_!*R%5/GR^/=:,2
M^:$M05DF"Y,X6'Q B[I&X:%-L*)]QM>"9))O!GBC7/#ESJ&O>%IYWE#N[ J4^5@I+8)(!_1F2PZ#=DG
M.3MQ@=L@YS["]!U7Q3XKUC2_#GAO0[.;4=8UK6;V&QTW3M/M
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MH-/TX%I[R[DV_:-2U:^DS/)*P78NR,(@]E P,9/XT M^#/'=E;:;XV\*>'?%VGVEW'?VMAXET>PUNSMKZ$%8KR"WU&"XBBNH@2(IT19
M8\DHPS7"C]G7X!@J1\%_A=EM?L\? 4'*_!CX7 YS_P B)X:ZYSG_ )!P[Y;W?Y_OM_P"$$\-<$G((_P"):<$-\RD#*,=ZD-S7LE% 'YW:O_P3$_9.\4?'?6OCKXQ^
M'^F>*+C4=%T#1M*^'-SINFV?PV\.C0X)H1JEKX:TZVM[>^U2\EEDN9;B^:18
MY7EVQD.E:5IEK!8Z=INGVT5K8V-G;1K%;VMI;0J
MD4-O#$JI'%&HC4#"BM*B@!"< G_/M^9J/S&X^3K_ +0/'<].V#Q3I,;>1GD<
M'_#^?H.<$C%?F9\>OVC/C!IM]\>] \/V@\$6/P8\=?L[6GASQ9I?V?6M5\3V
MWQ!\0V%OK^CZWH5Q)*PL-9CF^QZ=+;?9)T5]YF^24J ?IDK[B1QE20P# EMY+]*^$\WP_T:36-;\)_&[X?^+=1\G7(M"ELO".
MEW5W'XMD$DZM%J,5WI%U+8S:3("MXMR"%+1*5\RU3]N?P'HUE]GO/ 'Q+E\8
MQ^)_B+X9N/A_H^A1:WK\;_"R73_^$IU(2:7^>Z$*HK
MHU:,G[85@->\=:,OPA^)4=KX!N]-TO6O$=V^@66B6NK^(M!TG7O"VF7\LFJ"
M[T^;55U./3;QY+*4:/?*T-R7WJ ?'WA7]F/]IK1HIK'PGX;D^'&M>)=*_:0
ML-9\:K\39=4ATZW\4^-]/\0_"[2[C21&SS0R:;#?65O>6(AF\,I>.D:O$!GN
MY_V5/$FM^*/@1&?A!>^$? !T_P")D/Q.T6#XQZUMMLNMZ3_PE.F-K$>EV#QM%/<">9@1=PR>WZ=^W!X;UK3?#=[HWPP\=ZS+K_@G
MQQXVO(+ :68=(LOACKL>@^.;*2]N)X+:\ETZ:0W&C30LD?B"S$DEJ$$M?MS_ ZUJ_\ $%OX$\-^-/'.F:!H5UJESK>CZ9/'ICW5CX/'C>YL);R\MXH;
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M#Q#W=S=WZZ-8Z?/?206X27[$_8V\!>,_A3\#=*\ ^.?">G^$-8T#Q/XX
MDMM/TW7?^$EAO-"U?Q9J^MZ)?R:F8HI7N6T_4H+&>"XWSJ]DTC/Y3HJR_%G]
MJSP1\(9_"NEZYH/C76/%GB[PMJ'CBV\&^'O#M_JGB+3_ QHJVT>J7.HV%E'
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M#//"=/NFTF2?2=2LYYX[^!DNF**X /KFBBB@!C\J1R.G(Z]17R!^T9\3/%7
MA[Q'X<\#Z/XPTSX8^&;[PSXC\<_$?XDW-B=6UO1/"&@2V=B]EX0TWF*/6+R\
MOHXY-6NH;Q-)B*7<=K*QPOV"0#C(S@Y'UK\YOVRED/B369HIHPR_LU_$D#?%
MO95/B3PXKFVE57:%ID)BN TM+Q+;6]WXB^(?B.Z?6O&WBZ25#,EYK>NW2^?(TJNI^SVJ6EFBI$$ME\M2*_Q1
M^!7@CXEWEAKMRNH>%/'>B!AX=^)'@^].A>+]#+C/E"_A1XM7TV1PHNM%UB&\
MTZZBWHT2ER:]7\. ?\(_H6 !G1=*Z>@L8 ,#G .!R?\=AL#&<#/')VYXZ<=
M>!W]* /S5LO@U\MY_!^:Z-I9:]>01FTB\8^$+BV6669I)(8RJQGOOA:W[0O[0_@+P_XV\7_ !.T
M3X8^%/%6FR72^&_A)HKKXJC2UOKFU\UO'/B":^:SM]0:U\^>#3]'M[J&)EM5
MO2S.Y^V-5*C3M3Z?\@V\ ^8*!MMI>C<[>V#C@MBM(FTFX71?&WQ4N-0\?WMOK20,=-N;U-9N)HXH([QHWN5T^*TE* F-U?::^8?@
MG\5IOA)XPOM#\66J^&/"_BOQDGAGXC>%2S2:;\$OCQK*_:;>\TN[+L+;X0?&
M.*-]2\*W$FRQT;5XWLQ+&MQ,:_34A=IVE>#_ +N,\GGKR2"M%_\ \+(O]3TCPYI4/AW5?#GQICU9672?'/PH:W::>TU*6%UDM_$7A&\1=:\#
MZWA[C1[\SPIO2Y !]8PG/).&[J&# CU!SR._P!>O&TFQ7S=^RCJ/BS5?@OX
M;O/%LNHWP6?5+;P?KNNCR_$?B;X>6U[)#X'\1>)+0JDEEKNI: MJ]_;RHLS,
MBW$JAYF ^D: "BBB@ HHHH **** "BBB@ HHHH *:R!OT[ ]..A!!XR!G(&2
M0,\TZB@#GM:\)>%O$FS_ (2+PUH'B 1(4B&M:+INJ^6I(++']NMI]H;"Y5<
ME0>HKXM_;K\*?#?P-^QS^TQXIT[P%X%TC4=+^#?CF2QU*#P;X>2>TO[O1;FR
MM+F*1;!&6:*>:-D<.K(P5PP*"OO,X[_Y_P __KK\X?\ @K7JEWI?_!/']I^>
MT9XY+CP+!IK/&X1OL^IZ[I=GM,=MK'P^\$WNJ+\%? [ZA>WOA/0)[NYNKO1K6ZN9KB>2RE>6:ZEF>:9B[>9(S
M,3SBOK3_ (53\+@ !\-O ( "@ >#O#N %;> !_9V WS #HWS#FN>^ FE:?X
M?^!_P;T73D2"RTSX8^!+*VC0*J!(O#&F8V\E0&;+#:2,OA>#7K] 'GQ^%'PM
M 8CX:> "2K9 \&^' 6!P2"3IW() )SU(7/3G\FO$/@KP9HO_ 64^'GA]?!_
M@\>&?''['?BB63P^/#>BC33JWA[Q89UU8:?_ &;]FDO!;R"T-W@RK!^[.$%?
MM&Q&&!(/3@\<' '/N?UXS7Y&_M(R#1O^"K?_ 3\U6P9X;OQ'\,_V@?#6IQP
MQ[I)M+ATNSOHVN&1L_91<$ %PT:LRLNUV)H _3:W^%OPRA*O#\.O 4,D;Y#0
M>$/#R,CJ^]65DTX%'#@."#D, PP:[A+>&-42*-(HXP%2*-5CC0#. B( $'/1
M<#T /-.B8$'MSP#U((!S[Y).6[D'DU+0 @ '3BEHHH **** "BBB@ HHKD_&
M$^H1^%?%$NEW[Z7JL.@:Q<:;J'D+MV* .LR/4?_KZ?G3"H)+<9!P3M .!U4D\D$=>WI7Y(_ C]J?XI2>#/!7Q$\?Z
M_P#$#QQ<>)-%\#>&$\$W?POTKP;I'C;XE?$+4=3M/#DOP[\7+=6J1Z/9PZ5<
M2^)I]6AN;6SCG@D0P;D4?0J_ME7M[?\ A_0?#/P/\=^*O%&HWGQ!T;Q'X>T_
M6O#MO>^$O$?PS\0:3HOBS29IKF6.VU:&!-7CU.QU6P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MUWPS=+;SM'>6)-I<6E[;2V]_"5/FQ)W44@Z=,=?T/]>M+0 444
M4 %%%% #74.I4D@'K@X/T^A[U\\>.?V8/A-\0-<\6>(_$6EZP=0\;KX('BI=
M+UR_TRVUE_AWJ)U3PG/MW+:A:67BB#61X]\2_$4:_%XHU.'6_P"W_&-K;V'BN!=1A>.4:)XAM+*SCU/2
M /LL_P!FA<*LJ[ZL:A^RI\'M2NOB3>7>DZW++\6/$'@[Q/XM!\0:EY0UWP'+
M:2>%=2T>%I&CTJXTU[*VPULH\Y8]L_F!F-?2F/K^9_QI: /@+7_V*M,O/BKX
M'O-&U&ST[X*:/H'Q0M?%O@QKWQ#_ ,)5X@\2?$_6[/7-;O(-M-=1TR6!A+'/U[1M&NM+'BO0HO#WB70].U2^M?
M"VMV,&AIX9@FOO#T=0@T!!ID=]!%#.826D+2JDB^W8'H/R]#D?D23]32
MT ?)T'[%OP'@TS6M,CT;Q R:]#X$AO;YO%>L'4H7^&4RR^!+JQO!^&X
M@;*QNX0LWV"26UG:9)&K?/[*WPE;4-0U>*S\26FM:AX^OOB0^MV?BC5+;5;3
MQ/JNEPZ-K3V%Y#(DEIINMZ9!%::MI47^@WB*)'B$N)!]'A%&>_/T_E3@ ,X[
MT >4>+_@QX)\:7_A#5M1M]3T[6? PN8/#NM^']7O-&U>VTV^M4L]0T2YO[5A
M/>Z+J-O'&MWI]R98GD19T\N<>97GE]^RA\'[[6]0UZYT_P 1_;]5^+&E?&K4
M!#XBU/[#<_$'2-%C\.6&I&U:1XUM(M(B%I)IB!;.97E>:)F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MZEX@\07C2ZGJ^H74Q,T\]S.0'+
MY)QSF@#Y:\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M T\=_"CQK:+>>$/B'X3UKPGKUN1N?['K%G):O/#AEV2VQ9;F+82QFBB"[=N
MZO3Z0@$^X]_R_P#K9]\=30!^''PR^/W[4'_!/;PQIG[/7[17[/7Q=_:*^'?P
M_L&T3X/_ +1?P(T1/&6H:_\ #[2I8K30=*^(GA9!:W/A[Q-I6FFWL6F%U/#?
M16WG,REBY]5?_@KCX*25E;]D?]M9D5S&\L?P5O'B)6#SR8PVIH9"^!;P@*&E
MN"(@!AF7];BN_P"/.,8!' (S2&!", )@$$#RTP".1T4<9Y_44 ?D
M9/\ \%9M#U-)[7PC^Q/^W#XIUXHD-AI#_!:71HKS49$$EO8S:E>:I);V,#C=
M))?7"&".%3(@EPZ+T?[*7P#^/'Q*_:$U_P#;L_:YT.W\">/;CPE<_#OX"_ 2
MTU*+68?@M\/+RZ>YU>_U[5(_]%N_'GBEV5=7ELECBAMT\G& OZHK$!D\*3U
MV9 .. 2>&) P!D\ # XIRC@%B"PX)7IW[?KVQT' H 1!U)7:0=H_P!T>G;D
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M)E:>YM9&BN&D &/HVB@#YMLQMM'
M\2CQAI$KPRO)&=T3%#OM^S)\&!M;XHV]H=4U5]-@\<:_976GZ]K$&F/>-81P:Y:WUXNKZ:+<:9>O<2//:L[%C]"
M4F![_F<_GG/>@#YP;]E;X*2Z--X>D\&E=*EN?"T\:IK.KKM+O5O3>Z7H7A_5"]WIND64T-C"S!1& JX]&^'WPJ\%?"]_%C>#-*FTZ7QUXJO
M_&WBNYN-0U#4Y]8\3ZJD4=_JMS+?W$Y2:XB@@C98O+C*PJ=F[)/I6/\ '],4
M4 (,X&<$]\>O?_/:EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I",C ./>EHH _.K]ORV\;W&J?LA0?#N71[/QBW[4
M'AEJ/#GB(7-SKMEI-U:74UD4*QJ#(8A<-"7*?*XPOV0;/X
MFV?[6_[:T7QMG;4"+J="TBM&(5;8WZ42V5K.T+SP13O;2B>V::))6MYPK()H#(K&*3:Q7?'M
M;!(S@FFQ6%I#+)<1P1)<3,CSSI&B2SM&I6/SI%4-*(E9EB#EA&K,J;5)% %S
M(/3M1110 4444 %%%% !1110 4444 %%%% !112?0CW[_P!10!#/($ W$(F<
MER0 NWDDGG &22.@->3?!CXQ^'_ (W>'=9\6>%-.UFU\.Z?XN\1^%-.U/5[
M6*TC\2?\(U>G3;S7-%BCEEDDT2XO8YXK&XG$;W"P/(B%"I/CG[9OC[6]"^%E
MM\-? ^K?V5\5_C]X@M/@[\-[F.$W%S87WB.*9O$/B5;>-@YLO#'AF#5-2N;G
M>JVTPMMY!=0?HCX8^ = ^%G@#PA\./"T!M_#W@KP_I?AS2HV.Z0VVF6D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M - ".6P-F"21U(''G3G%4[>]MIV<0W<,_DN\$PAEBF$=RA&^"0QLVR
M>,%=T3X=-;'1-4\1:EHFD7,NE:)HUA>:M?ZEK,B
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MGQ7D
MNDPRZ)XNTZS=-(N]-\E5\1RJTZY#I..ZD^(W[3__ CWC3P]IOB#XCW>E2>(
M/@;<:K\0=6\"SR:_X7T+QSX)N=3^(DGA+3["U2[OM.\.>);:RL[EEM;F\T:2
M6[A02H25 /U\9AV8#!P?8XSCO@XYZ="#T(SS^I>)M"TG5=#T;4]=TS3M5\33
MW5KXWO==N=/M_ME_%I4,CJ][):V@-Q<16ZR-%#B1P 0:_,35/&'[7
MGAWQ!H5EHVH>(OBIKD'PPEL[(V_A2Y\%:'=^+X]"U.[MO%?B73]1AO;+6/"^
MHO'8RM+;W^E:_;>(H[?3);+^S]3E\HFU3XH"Z^ 6N'Q#\6O',WB'6_B--J^H
M>+/A=IUEK'PYNKGX3--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MW3)OVCO!E]XG^%]SX;AN1JNH^)[3X96A>S\=&?3A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M4 %%%% !01GK110 TJ#GCKUZ<\$8.WN?IG
MBGT4 ,V(225Y(QGGISQUXZG&.G:N5\:>"O"WC[0Y/#OC#0K#Q#HLMQ:W;6&H
M1M)&EY8S+<65Y;NC)-;7EI.BS6US;R1S02+N1UR<];10!R?A?PCX>\&Z;<:;
MX8T6TT2QGO;C4)X+./;+>W]TZ&YO[Z=R\]W?7 1!+M!C@D'&<\GJ3DD\GN2!R:?10 P(.Y.?S'7/ (P!P"0, D9-&P9)RMZ< 8Z8XQBGT4 -V\YRV< =?3..W;/Y\]:<. !Z444 %%%% !1110 4444 %%
M%% !1110 4A4'&1G!R.O!P1_(FEHH :%48PH&.F![8_E3O\ /YT44 %%%% !
M1110 48[_P"?2BB@! . !Z 8I:** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBCI0!%)*(\Y[ ' &223@ #(SGIQT[XI#*>F
MQ@V!P1A<\$@.3S@=PIY_*OFG]K[XK^(?@E^SS\3/B-X1BB;Q/HFF:=::->7<
M*7%EHUYX@UK3] 3Q#?P3LL,MCX?&HMK%S'*?)>*S*291FKY1@O/BM^S-\M6_"^K?'WQK\=_#O[2VK^)O"'C'3_ !M:Z5?SZ=XDT_P?/XOM?'?@%]"L;!?#
MWAD2V\]K?V$R7^EV]C=VB1W$<@CR ?J0&^7)_P \XIK/M8 @!2"=Q([=@.O<
M<]*A$K#@;6 !(.U@3C)V] H! ';. Q!KY1_;*^)_CKX7?!V'4/AYJ.F^'_%
M/C+XB?#SX9:?XLU:&&YM/!D7C[Q/8Z!<^*FL;A&M;VZTJ&X=K&TN\6DMW)%]
MJ8Q@J0#ZP,V &*N,@$#Y>1GG:#@M@H-2*Y9BN,8 )R<%2>BD=^.=P.
M.U?F'IT/QT^!?Q^\*_L^>'_CWJOQ1C^,OPS\;^,=(UCXTV%IXFUSP'XR\(ZC
M9SWNL6ZZ$=%FD\':];WUQ9V^B3K'!IM\MO!:7KI&(1^F&G1WD=M;+?SQW-XM
MK EY<10&WAGNU11<301&24P022AFBMS+(T2%59V(R0#0HHHH *0Y .!DXX P
M,GZGC\Z6FN,J>OX=<=^G/Y ,XJ1)!(
M,@$=< ]< XR?3Z=17Y]?MBP?MES>+O@,/V<8_!TGA*+XG>';CQH-3DUZ&_VP
M6VL-<1^+7TZ)XH_AU/!Y8U*:V\S55U-;$^5Y)9Q](^'/CW\+;_P-9^-+KXF^
M![W2X_%(^'&K^(=,U(Q^'E^)D&J'0]2\*6;W#&Y6^37DETZVM9_](FD$8C!$
MJ9 /=Z*\FD^-OPLA\+S^-Y?'WAA/!]KXED\'W'B-[]4TV+Q3'JBZ+_PCQGSM
M.J+J[#3I(!E_MF;8*)1M'JJ/G.X@$<@M%%% !1110 45YS\5_B=X9^#_ ,/O%?Q)\77$EOX>\'Z8^IW_ -GC,UW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M<<]P/7@T /HHHH *8[[%+'H,8]\_3I432L""I5D/)(()4MKQ#]H?Q)\7?"OPE\7Z]\#_"FD>,?B%I^FWMQI6B:WJ%SI\+1I;3M)?67V6VN
MFU"_LW\F:STUDB2]=3"TR[R: /MXN>(?A%X)UCXX>&]-\)?$B\T.QG\0Z3I5Y]MA\Y[6*075TJQ(EE?W09IK_38
MMXL;II;=)'6,;?:O,;L4QU;/F!L$X&W(ZXP2.O; - %BBFA@3@\$\@'KCUQ^
MA]#P>:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 &_'_A?7/!?C'1[/Q!X7
M\2Z=/I.NZ+?H7L]1TZZ7;-;3JK*X#<,KHZNC*'C97 -?"VM?L6>'OAN+?Q1\
M'K36/&/B2QLI?"+:)\3/''B/Q%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M'Q'IGQ \)Z8UEMG\+DE?1/ /C3X:R'2H/"'A^R7'A_0/&?A#47>2V-I90KIXUW1KFXLIYD1I[2
M)IFEH UOA%^RG\*?@WXIU#QWH \7>)/'%_X?MO"">,?B%XNUOQMXCTSP?:W$
M-Y#X7TG4M0I=20P@2W$_P"\N)ICU^D44( O/.3RMGX'6'B:[TVXA^(,G@?3?&(^'U_\ &VW\&W\WP8L_&*SR65QIEWXPA\Q8(+/6
M%70[W5C:G1[?56%N]ZL8>4?;EM(DB*T3+)$\4.0$@J4VL#D
MAE=67 Z@%FBBB@ IK*&&#GJ#P<'(_I3J,CUZ]/>@"E=1A(I'0#?LDQN)^8F-
ML)P&^\<'."0 2,D8K^="R_9[^,'PO^'OPUU;PC\+?%^J^#OCO^U;H&I_&[X?
MSV\@U?X=>,="^-=YJWA;XXZ9I4B2W1\/ZWH%C':^+87>WM(K :9K*E9)3%7]
M"?C+Q+I_A#PIXB\6:H\::;X:TC4M;OFD=(U^SZ7937;+YDKQQ(SM&J#S9$7Y
MB-P)%>4?LT:=XBB^$7AS7?&-]?7_ (L\2:O;:/:1
MWSMI?V?]9OT\;?$8>%X_VO=5
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MBKXW_:!\2:YK<.A?"_Q!^TY%\8?#W@I/ WARWUOXDKX^T_XDW$L
MNIZ-XV]JUS]FCN8=J1SR[_ -!/"GQV\.ZIHOBO4?'6C:Q\(M4^
M'EI!?>/K#X@6XT_2?#]G-YCQ7]OXOP?#.O:5,(6:"^TG4+HJKQ)<16T[B$ #
M/V>'M=\4CQOXU\4^*_$?C_P"(WBR/3TT:R\1>,_%%V+C4KW3-
M"BEGAT738H(K.SM=-2>X\F*U5WF>5RU?0BKMSSG)XX P/3(ZBO&/A1\??A!\
M;3JG_"K_ ![HGB^?0)(4UNQL&FMM2TG[4@:SNKK2M0AM-3CT_4XR7T[43:M8
MWRJS6US(%)KVF@ I#T/)'N.M+1QW_P F@#X<_;1\??$7P%!^SQ>_"\SWNN:Y
M^T;X+\/7?AS^VX/#MAXKT:]TW7'O=&U;5+F"XBCTMS"DTD9C!DGBA"ME0&\/
M^''[5'CSP%X[_:>OOCAX<\4SVF@?%7P+HEAX-\'ZMIWCC1OA;XMI:%HNL2Z;/JFF6&HS:/?1ZK
MI4M[:QW4FGZC"KI#?63R!FM[J-9)%2>(K(JNP!P:^>_C%^SIX,^(^K>&?%]]
MX@UGP4W@GQ/'\0]83PQ#I-G9>,MMDH08X]@!^1\/[3'QW\#06.E>+_B5XIU3P9\;OVSA9?!7Q]8-'%JOANPT_P")
M,^B>+_V>_$,KVUS%;Z^!?V@/$6L:
MN]_\;-#\%^')-3WZ'H_@7P):7&JQZ4LLA6WO]?\ $ESUTWRTE6
M4*"A6LG]GM-+^*WPRMO&/B?PUXO?$+X:Z9<^&M,ABTO05U68^$
M=>-FUL(T\0W"K<:U_;(3[=))J9F6M-'?2Y?%7BOQA/->75[/K/C'4H=2U:22XD+F%9+>ULK>"SA)\NVMH+:..&)$3
MYBNX]S30@4DCJ>IXR><]<9Z\XIU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q/_P %"M>U
M[PO^R+\7?$7A?4IM(\1:5;>%KK1;V'5[C0&_M!?&>@K;VW]LVTL4EBM\\GV&
M:4L(O+GV2J\+,I^V*Y[Q%X9T/Q9I-]H'B71]-U_0]1%NE]I&KVD5[87@@FCN
M(OM%O.LD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M-<1[WCL&F"SKI]LT-HDBHRP*\:X /7D5<*2.<ML\$L+F,[7 E0H60]F4,2/]H*01CF< *N,\*.IZX'XR,^F
M: /Q=N?A/^TQ#\(-;_X)VVO@/P))H6KW6N?V9\<9?&>FA8_@AJ_CE]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MP^ 6]TGX3^&=2^+OB>W(=XK;Q#JCR^'OA\DTLM)^M%4$9Y^;DCISG/0<<^N3[&@#X[U/\ 9M^)7Q%M&T;XU?M Z_XL\)7MPW_"
M0^ _"7A/P]X)\.^)M*,BS?V'K%W;Q7VMS::\J1K=+'?QSW5JAMY)F260-]M,,=O#':QQ)#';1Q0PI&3L6"!%CA55QA%2-50+D]#@X J]10 4444 %%%% !1
M110 5X=^TCXDUKP;\!_C+XL\-ZPGA[Q#X9^&/C+7]$UV2"*YCTC4]+T2]N[7
M4#!-F.7[/-$DK+("C;>>N*]QK+U?1M-U_3=1T76;*UU/1]6LKK3M2TZ]A6XM
MKZRO8FANK6XCDW))!/&S))&5P58CTP ?BIXO_; _: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MO_@MX/T'X4S_ >TC2];U+PY>>*?B1J8\10ZKJ.HZC#X8O\ 4+.V\+>"KN"[
MT'0TO+@WL^H_:[F&*VLRL;?H8#D9KYC_ &24CC^"^C[4ECC'BKXDQPI<((YM
ML/Q$\2Q2NQ8#>&GC6,*Z^5(4 -?3:N&SCMU!R"/PQT]\T .K.O[J"SM+
MN]N9/)L[*WEN[J8Y4PPP1M//*#CI'%&S$#)X*C!(J^S!3R<9Z<=/KSW[=*^;
M?VHM4U4?#%O!OAZ20>)/BKXBT/X8Z0]N[QR6H\2WH35]1WQ?O(UTS1;?4;BX
ME7(A4;CDX% '-:7\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MF^"_ 6E0VGAS3?LT*PPMJ5S;7VI3O"LS7*D[ ?,OPP\&?$;XL:UXA^-/ACX
MH?$&V^*%IHY\->&OB1XI\&Q^'O@MXCTG^T)+VZ\$>'?A9>&+7Y/!5MJMI%=#
MQC=W$&O:J7-S!<,$2&OH3P]^T5>^$M;TKP-^T9X6C^%?BO5KAK#0_&-M>-J'
MPC\<74"DF;2/%;J$\+W-YG=;:!XM-A?DLL,$UQ)L#?5JVRH@C0L@"*B[-J[
MN-H10NU%C4;8U"[4!.!DYKPW]H_Q!:>#O@MXZU^\\+^'O&EK9V5LDGAOQ1:)
MG#5M9\1:%I6E-
M;BZCU/5-6T_3]-DMF3S5N8[ZYGBM7@,?SB192A3YPQ4@U\Z7O[6OP[U34I?#
MWPNTOQG\:/$,=^=,GMOAUX?NKO0K*Y2+S9&U'QAJ26?AFVM848&:XBU&ZV@Y
M6-R%!\2_9U_9R^#VJ^)_C.^O^$;?Q39> _BUJ?A3P+HOBG5]4\4Z%X,\.?\
M"/>&==71= T+5[B?3-,M;?4=2N'M8Q9L\%N(88)$CC"U^@UMI-AIME]BTZRL
M["S5"@L[.VBL[54P$"K#;)$BA8P$4A=VU0NXB@#XX_9IU^\U#XF?M 'XCZ/;
M>$/C1J_B30M:U#PD+V'5H[3X80Z8-*^'\FCZ[:P16OB*RQ;ZBVK3:MU/;3"%VC\S[:4@JI&"" 01P".V!S@>@[#BORI^(_PT\4_!OXK^&!X%U.UTIA
MK&L>(/V=M;UB6::R35-;8WGQ)_9B\::MJ&/B<476/AQ=27,]]H_B.WG
M6S!^S0(?T%^$GQ3T/XN>"-(\:>'HKFTBO&NK#5M"U*%K76?#/B+29OL6O^&M
M:MB,VNJ:)J"36EU$X&Y4BGC+1S*: /4Z*** "BBB@ HHHH **** "BBB@ HX
MZ\>Y_P#KT4C=#]#_ "H \S^)'Q8\"_"S2(-6\::TM@;\S6^BZ/:V\NH^)/$5
M_%$9CI_AS0+-)M3UJ_=0 MO96[["P:9XE(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MEBU#PZEY8F2#2]2U5)K^XCA>,G]!+33K33X%M;""VLK.' AM+.VAM;>!5 2
M.&!4C 50 !LX(XQ7S?\ M%?"&Z\8Z5%XU\(Z/I.I_$/PMIMY91Z3J@ TGXA>
M"]0*?\)1\.?$*XQ-::S9))-HES,'.C^((+&^MS'M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MP)X.NX(-5\="% S6VK2&R\/R7"QMY\\!*, =1^S? D.O?M(RI#Y+3?'O5C<
MP& 37B^"?!8F<@HCR$JT:O(_F&1U9LD$5]4\$8X^@[8].A!'X$?6OBWP]^S?
M\2/AW97>H?#/]H'Q,OBWQ!K4_B;QZWC_ $/1_$OA;QQXIOVMAJFJC2;>&TNO
M"L-Y#:6]C;6WA^\6"SL8(8D622/>>2_:#^.G[3WP4^ 7Q*\M/:CX/T[X=0V'B#5KOPAX[OO$7B.RT>31[VQN6LM:T/41%MEVPL' /ICX[CX76_PN\57_QCM["]\ :-:QZYJ5O=[S+]KTNXCO\ 1CH[1217
M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M%I:W$EEHYN8);A(P8?,D8(?6_AM\8/ WQ4M;NY\):NTU[I&]4M+C1_
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M8)@>+/VC/BEX9T;2/!-MJ'PTL+:RL;;Q-\8?BWX
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M4MKWP;\7>'?B5MSX.\1Z]XEUSXX?$VRFT_Q9XDCN](\"^#[J.&(_#;X>&:.2#2V6W)6;7_ !'-
M;QZSXEN9OW\$KII<;"&V99/J!<;5QP,#'TQQTJ+RT8EB &R<,OROM/(!(['/
M3H2,G))Q,.@SU[T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$
MC!Z?7'X?0]Q5:>VAF@DMY84F@EBECEAE198)(V0HTM(Q:HH ^7O^&1/V?6\22:\_P]M9(KC46UJ3PE)>:E_P *[_MN9_.EUS_A VNC
MX8;49) K22?V:(?.#2) DDDCM],P0)#%%"D<<444:110Q(L<4,<8"Q1Q1H%6
M..-%5450 H& , 3[1G./U/KG\L\XZ4M #%15Z =01@ 8Q] ,\\\U\C_ +;$
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M?P3O/AUX@T'1(;NWU+4O$ \4V>LZ9J4D+A9I-TFX,V/MY
M,[5R,' X."1[''&?7''IQ0 ZBBB@ HHHH **** "BBB@ HHHH **** "F&-2
M N/EY.WL2<\GUY.>O6GT4 1F-2P8DG';(P3QR>.3@ ?05)110!&X4G:W(.,J
M02#N.T9[<'V%?A'-\?/VF)?ACJ6H2>)K8?#Y?VZV\$'XOR^-Q%XSB\,I\4XM
M.'@(>'9-'$7]EQC9H$ M[M]^GE9(SN!D/[MN&.=J[CA2.<W4 C&1G.
M:YE_"/AF2S_LY_#.AR:<-536?L$VCV#V;:Q'<
M!*KB7Y@ =2N.<>ISZGGOWX.0">3C/>G4Q!M7!SGJMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "HRY!;*D ' .,Y['HP/'?CZ9J2O
M)_C3XU\4_#CX:>+_ !OX/\%CXA:]X;TY]3L?!:ZW!X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M?!";PAJOCD^/-/@T#1-<3PUJ8O+>\L]6MM]M;$Z-/;)J;/?Z2AUS362U
M*7FB?\36(M8_O@ ?0]%>"Q_M*_!6YUOPIH-K\0M#NY_&=MIEQH&I6M.NQK+X>LYO$4<;:19:KXAC0WNKLDBV,,C*5K(A_:P^!-UXB\/>%+
M+Q_I]_K/BGQ1%X.\/C3K74+W3=7URY.I0VL-GK<%I)IMWU>PN=,\S[7'Y+ 'T@3@@>N?T_3\R*8LH)4$$%AD#K^HXKYNUK]J[X,Z=9ZM
M/8>([CQ''M)U34I)+'1#?Q2V9DAM&AM=4O9M,OETRRO7BEO(
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M"=/TNQU#6M/\<7GA'QWX?.KW7C/S;^XET.-_"+V\J:CITL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M5WM-7M+FX@U61WLKNUM3]G/F5_\ L/7]WXMZ!=7:>']*\1)X@M-?>VN(GT^;7=L,>F3*]O]BEMRURT/VI(2A10!]!?!7X)W
MWPK\2?%;Q/?>,9?%,OQ2UOPWK?V231K#28O#R>'_ S9>&H;"UELRTU]#<06
M,5V\MZ[RQ3R211,+=8HT^@Z** "BBB@ HHHH **** "BBB@ I",@CCV_^O\
MCZ444 ?&FN?L6^"/$_C?QQXQUWQIXYO;;XC>/_ OQ%\3^&!=:3;:5)K'PVBA
M3PC;:;?6NEPZ[IMC83002SI;:FLE^(A%=.\;.K4C^PO\-9K?4X+WQ7X\U ZA
M:Z/$MY=W^D-J5OJ7A7QG=>.?!VO-?)HZ2WNL>&=;NYUM9KX3P7]B4M=4M[LH
MLH** .C\0_LB>#/$6IW.L7OBOQ=;:CXC\&Q> ?B/+I3Z'IMO\1_"L=^=5;3M
M9L;;1ULM'>6\:Y$MWX:@TFY>UNY[5G:-LUSGBCX%>'/A1X%\<^'_ H=3UKP
M-\4->;2KOX9:]KRZ?X0\.'QQ;1:/KE_H-Q9:!J.L1B$0QZEI^F33F&'40\L-
MY:LYD!10!T/_ R'X)OO#OPF\.:UXD\6:A9?"C2/#UGI;&^MEU&^U30;A;N/
MQ#<>(#9GQ#!K5^T8L]5OK34H6U335%K>I+N9ZI:7^QQX7T.W\,V.C_$3XBV=
MCX0\4?$_Q1X?LI+W1;V"R?XK6%_8ZWH\@NM'D-WH^E_VC=W.@V]P7EL[AXS/
M/=1QB,E% '9?"?\ 9LT'X2^(['Q)I7C#Q;KLUA\+/"7PFM;37WTJ:+^Q?"-Q
M=W=KJ=Q/9Z=:WEQJ][-=2?:Y9+C[*(PJ0VT848^DE&% XX ' 'X #'IQ11
M0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end



GRAPHIC
9
image_003.jpg
GRAPHIC

begin 644 image_003.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" $O B,# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^NG_@IG^V
M]HO_ 3P_8X^*?[3EWX=D\8ZYX9.C^&/ '@Q;E;%?%?Q'\7ZM_PCG@C0;NZ
MS9:-)KEVNY]KX1&";&(<_E'>?\1&GP^\!> /VCO^%N?L@?'7Q?KMUX7\1^,_
MV#;/X^/6M>*]W]N^'1JPY(P< 9\4L *_2S_@KO\
ML1:[_P % OV%OBS^SWX-UW3/"_Q)N+OPMX[^%>L:Q\NE?\+'\":Z=8\/:7K_
M W
MA#X=O\'?"_[3%S\<]*\#_LV?#W=JWAQ_$/Q$TCQ#HGBD>'_$^A>,O^$?PO@_
MQ$,XP23U(!^Z6K_ME?'^P_X+&_L__L>WUUX:\/\ P+^(G[ _BK]HGQ=X-GT3
M3;[Q5IOQ-T;QH/#@4>-MQ(T/PZBH&"X1Y 7V $I6CH__ 7:_P"";&O?&*U^
M$6F_&O7T35/'!^$NC?%_4/AM\1K/]GG7OB?D@>!=)^-YT#_A6/\ ;V,9']J
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MN/?^"N?[#/@3]G/X-?M/?\+8O?&?PX_:'U3_ (1OX':7\-?"?C+Q
MQ\3/BIXF.5U;PSX<^&GAG09/%[:]X<4'_A+$.FC_ (186I\S:&&?RDN="_;#
M_8@_X*F_MZ?M2>&OV#OCG^U=\%/B%^SK^R_\'O#OBOX9_P#"'7WC?Q5XH\!_
M#OPYH[CP_P"'=9\5(VM:$=M?L-^!-&^&GQVTSPQXW_:9_:0^,7[;G@;]C"R^'7B3]J;X,^%_BKKHU?X4^#?
MA1XAUD!=&Y7_ (N!K_@T$H/E#8)+ 'Z7?MG_ /!8GPMXA_X);_M:?M=?L%^/
M+S3?BM^SMXN\ ?#[Q#HGQ3^&&JZ3XD^''BC6/B?X#\,^(-#\M$
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MNTC7O$/@KQ+H@U];#Q%_S*I()U7&W:'P*_#W1OV%/VI(/V+/^#M/_A+/V9/VI?A]XR_:0\*?V9I>?A-X6L_^$D_X2+7_&]GTVXNUY4D9)!Y'/L'
MQ7^ ?_!0SP!^T5_P7W^.'[+'P;U1?B/\;/!7[(H_9:\6^+-,\&WGASXDW7@3
M0AHWQ6'@G2M:/_"/ZUXJ\&^%SJO_ B2^,B-WBO"G(.T@'ZJ_LO?\%>_V,OV
MN/B0WP<^'6M?%/PK\2KSP#J/Q5\)^%/C!\&/B/\ "75OB-\,-'(^U>.O R_$
M'0-+&MZ#U^M?_'3PYXD\1_ OQZWPZ\+3^ ?%&B^'?$&A>-]5UOPL/#Z^+ ^K6A'A[+#'B+0
M&R"Q"?'?[)/[-_[6GB3_ (*8?L>?M0>+/@7^W^GPWT_]E#X\?#3QY\3?VW?%
MO@[Q)XXL_B?XD\'?;#H \$>&/%8_X5)\.?[\)$^&O"__ GQP2#TKM_@
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MX-UGPGH7P?\ $AT?X'7DGP^^)]EJWBJP\(#61\6-3^)GB+Q*B>'_ 9K@\4G
M21X1\(!0W_"*JN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M('[4'PR\1Z-\./#?A[PS\OVMM0?]L3Q)^S9\2OV4-9^'W['GAS]OW_A7=C^UGKOQ?O/!VK+X@TJ\UGPQXH_M
MT?#QF=?!R)XU\4*S@Z&4!V:N ?97PQ_X*H^(/C[\.?^"4'Q"TGXW:#\#-7_
M &FOCE;?"7XP^ ?&/[-GQ&U>#XS>-M%\&>&M:\;?#'X5:O(O_%$:(CZL_P#P
MB/Q0/F>%/%*@.&Y9%^A/'7_!=W_@G-\--?\ 'OAS7_B5\14U'X4__@O\
M&&^TSX+?%'7?#OPF\4Z-K_\ 8UYKWC?Q#HFA#0M$\#G62ZKXA\PCQ+\NU7&5
MK\M_"7PE_:U^-/PS_P"#?*2__8V^._PQN_V)?VE?"_@CX[Z/\2]+TRRU#POX
M:\ _"[P-X;;XQ;%UK)^'?B'Q0O\ Q287<\1?L-?M777_!.W_@X
M#^&EC^S_ /$!_B?^U!^V=\0?&'P&\+1VVECQ%\6_ )\8_#9_#^N^'AD Z+LT
MC5W (R%#$84MD _=OX!?\%8/V)_VH/CU=?LT_"OXA>);WXD3>'-7\9> 9]?^
M'GC/P?X'^+?@C1L_VKXR^"?C?6M$C\/_ !#T/P^"=VN^'W,?RJ!D;C7EWA#_
M (+D_P#!/;QS\6_#'PD\.?$'Q_M\.?\()X<^-E[X8_X0_6-;_MX?V" LHP<$2$Y:OD?Q9^RS^TA#_P43_X(^_%#
MP?\ !?78_"?[/_\ P3W^-'PU\>>+;BU!\$?#CXG:O\$1X<\$^#/&H[#_ (2G
MY. &'WAR03^.WC;]G[_@J!^T3X(_9KF^/W[./[>_C;X\_ []NGX8?$SX\6GB
M76OASX=_8T\+>!]&^*&K_-^RU\$_A^W@G_A80'A3^R<^(3_R*V=>)(_X23D
M_=?]DO\ X+-^"OVAOV]?VU_V9_%VCZE\-_AS^SY:^3\-/%>L>"O&>EI=:/\
M"W0?$6K?&[QG\;O&FM%?#OP_"LJM\/O#_B+8?%/A/1W\7J069'^GOV;?^"Q_
M[#'[5_Q;\/?!CX1?$'QB/%7CJV\3W7P@U3QW\+_B)\./!/QXTCP>VWQ'KOP2
M\:^*M"TSP]\0+#300S'36#\$*N< _D7XP_9*_:Q\1_M>?\%Q?V<(_@+\3](\
M$_\ !2_X7Z-??!3]JFUBTD_!'0-9\!_ [_A'/^$>\<:O'KW_ ENB/XRUW&@
M-M+K@$*,,''B/[#W[('[1'BSXM_\$\O ?QH_91_X*1Z/JG[$E]I_BKQ;XS^.
M_P"T-\+O#O[+'P:\8> ]!7PSI!_9PTC1/!'B3Q!\7-"\1< ^$2=+ \*MT ?M1_P6._X*4:K_ ,$S_P!GOPE\0O"7A.#QAX_^)?Q+T#P!X1M]4\.>,M5\
M(>&K$ZD!XV\7^(AX9.2/#OA8EO"N@90^*/%)TU0KC<*Z_P",/_!8C]BCX)_#
MSX'>,O'OB'XES:K^TIX17QE\(/A!X?\ @Q\1O$/Q\\2>%B&_M;7-4^"(T,^,
M?#.C*5&X^(XXEVN"I8H5'DW_ 7R^ /QN_:'_P""?E_X1^ 'PX\0?%GQ]X/^
M.?P(^+)^'OA/)\4Z]H'@+QBFL>(+3P[R1JVM[ &$8.6#%BN02?C3XB+^U;\(
M?^"B'PN_X*X:#^P5^T1\;?AU\;_V+M.^ WCS]G_0]/\ !E]^U/\ LO>+]'\9
M'Q']J_X0@^*AH&L_\)'@#Q6/#OB7D$YP1R ?O!^RO^UC\!/VR?A!H?QL_9S^
M(5E\1/ 6J7=]HTFHV=KJ>DZKH_BG2,_V]X7\1Z!K@77_ WXIT X75?#VOHK
MJQ0 .K%Z_&3QK_P6+3]FG_@IG^WI\!?VDO$NM:K\!/@W\-?@/XH^"7@CX5_!
MC7_B9\1UU;6?!ND>)_BSKVO6OPPT'Q+X@;PKX?<(#KWB,HOA=Z_\
M!&3]ESX^_!_2OVU?V@OC_P##5?@%XD_;A_:K\4?M(:%^S?%K&AWM[\&_"VL#
M&DZ'XA;PVG]@MXJ\0@Y\6%2#NLP'/+ ?('BK_AL+]D#_ (*W_P#!17]K[PU^
MP)\;?VG?@9\8O@Q^S?\ #GPKJWPL_P"$,/BK6O%'AKP%HOVJT\/Z/XF\4(?$
MOP[_ +=^V:#XL=2!X"W1E0%4AP#]6?&O_!5O]A[P+^S-\+OVM[KXUV7B3X._
M&_5-.\.?!J/P+H>N^,?B!\2O%%Z_/@[P3\,M%T!O&.M>*XT%U_PE&@?V?N\,
MFT(D"D!J]N_9&_;;_9__ &W? NO>-_@1XHU36(_!OB2_\#_$3PGXF\/:[X(^
M(GPQ\;VA ;P=\0?!.N(OB#PSKZKNM3=^*=U\._C)J7C_]GO\ :E_:?^/GQG^ _P"RWXU\+Z5^T)\+?!/[5&I@Z2/@
MCXB\4$>#SXW\&)I-J?%F@*&&?$=^I'_$L8C]L?\ @CS^SUXP\">+?VPOVBO'
M'P8_:S^"^K_M&?$#X?V5O>_MB_%[P9\1OCA\6O#'@'0M6TGP[\1_&_@KX?\
MA;PXOPB\4_8/$#>'SIQ\2^*6Q\RLNQB0#TBT_;'^/\W_ 7$U3]AF77O#Z?L
M\6_[$EM\<[7P_P#\(AIQ\5?\)JWC0>&VU3_A-0=QT4KP-!.2')8C&5KPBW_X
M*._M/Z)^W#_P63^%"Z9IWQ3^''[#?[.OP^^+_P _A;X:\)BQ\5:_P"*-8^'
M7_"3>(O#^J^(-(#Z_K8DUP>7C[RQLPC9>#7(_MR?#_\ :T_96_X*S_#C_@I;
M\#?V6/B#^V+\(/$_[+5]^SA\5O 'PM72@R@Y0'Q62,,N[A?V*_@/\ \%%O'OQ:_P""K_\ P4'L_@W:?LM^!O!O[)/PR^/$VF>+]0\-W_PKT*]&DZ]\5O#^BK)_8__ D1_L<-8,!LW%F&
M%&X ^8OV/_\ @HG_ ,%0_P!HW3O@'\>O@K^V5^PA^V'KWCSQEX8_X7O_ ,$Y
M-&T;P=\ /B;\)/ _B4AO$0\$^(OB!XK_ .$Q\4:Y\+/OMX*&_\%!?VXKO_@I?)^QE^SE^TK\&/V1O^%:>(?@L?AQX?^,WA(ZJ?VH-9^*?
MPN\?>.O$&J^(-5UP[D^$'@WQ1X?TOX6LW@P"0^/O$OA)7.%7'P/^T-^RS^U#
M^VOX>^$7@/1?^"*GB3]E/_@I#IGQ$^&^H?$K]OOPI+X+^%OP1T#4/".N;?&?
MQ&\.ZQ\/M=7_ (2=?$C*?$'_ B+[W)8L&)4(?KC_@M+X5^/GC_]H'X8?!C]
MH'_@G=X<_;#^!>N>+O ^F?LN?%OX0_V'X5^,?BKQ1=_!OXD+XV^#OQ7\;:WX
MK_XI=&^(J:3\45_X1P>%O"A\*^ R>6W4&^A^NO[0WB/_ (+%>,;K]E3X4_ #
MP[\ OV?+WQA\-]0\8_M;_M/ZK$?C3X)^$GC?1M$+#X8?"GP3XE;P;XB\3_\
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M_9X\8*657T%M?^R9_P $DO%G_!)_P[\"/B-J'BC]I#XQZGXC\&>'++XC_!\8&K_!M? _P]P?
MB"OC(X)+'"ELLP4# ;Z']1W[3W[4'P8_9 ^#GB7X]?M!>-H/ GPT\*RZ/;7F
MKRV6J7UY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MQC^S_P"--,L/V7/@K^T)I?[05QK,>EK_ ,*9\4^)]""^'/\ A-M<=7X^]D&QXH_8E_:JO?V3?\ @XX\+VW[//Q N/'W[5G[3WCCQ'\ M-\K2SJ?
MQF\+#4O#?_"/ZKX)M02HT3/]J$$\$9P.I !^XG[3G_!5S]C?]DS5?AOX;^('
MCGQ;XX\6?%CP0/B7X+\'_!/X<>,?C1XVU+X8$'_BY^J>'_A]H>J/H_P[09#>
M(M0V(0P &X/C[0^!7QV^%7[2/PM\(_&?X*^,=)\?_##Q[IG]K^%_%.BDM87M
M@P R,_,&4Y5@RJ0>Q!4G^2SXR?L_L^_M.? S]JS3/A?^W5XI^'WCK_@G
M3\ /@'XIMOV"/&/@[P[^T)\)?B_\(/#.CD_#GQMI/Q!_X2('X=>(OF!/AS&/
M%>"5/0_NU_P2!_9TU#]ES]BKP9X"\0_"3QU\#M?U_P 6>-OB7K_PD^(OQ8TO
MXT>*? 6I>.]=;6?[*U3QOX9\,>&] 8N'&O?V#%$1X6.JNC2&3Y8P#"^/W_!;
M/_@GK^S1\8/$WP4^)/Q,\73^*? %UI%C\7M;\"?"OXC_ !$^'?P(N-7R-)/Q
M9\:^%]#U/0/!:L,.-[%AD;E5@/?A7^T'^QE^S7^RS\;KCX4
M:)\=$/COXA_M">'OV9M5_:A)^'FLZ"NL?#5OA3X;VKX>\?GQ$X8>*AX>+GPJ
MOS;P7*CY[M?AA^W%^PYX?_X*B_L?^'_^">WQ4_;#MOVZ_C)\=_B%\#OVB_A_
M<^#[WX=:EIW[0>@OX9&@_M!ZIXG\5KK_ ,/U^%I!*,P964;D!)5A[7\/?^">
M'[3?P!^+W_!O1X&?PKK'Q(T+]C3PC\>-&_:"^(WAF$WG@CP'K'CKX8X/_$U;
MG^PO[=U8:!X3;!##PZK LK T ?I'_P %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M3?VG_ G_ 43^#?Q._9__;?^(7Q"U;XL:AK/[.WA;X.>*?A?\-_V#=3^!&D^
M)O#NLZ1KOB/2-&/AKQ%^T#\8CH6D'_BGO&G_ G?_%4CPIQCPV:_1;2?V6OV
MC[S_ (*#?%7XOP_!7QW;?#CQ'_P1&L?@7X<\0W%MI8TF[^,(TW2,_"[()_XG
MHPP([D%3@9H Z/\ 9<_X*._'KXM_ S_@BM\0OBI^T?X ^'_CS]MGQ=\1M/\
MB5X/_P"%!Z[XD7X^_P#".,0?#_@?5?"['0?A&WAS[&"_B#Q&H!#KACAE7[1^
M+/\ P7 _X)X?!'XP^)O@SXZ^*WBF/4OAWXLL/ 7Q6^)&@?"OXB>(_@A\)/&^
MJLP7PA\2_BQH>A2>$?#6MN<,!))D @L ^]:_'7X ?L2?M=^%?A!_P;::)XA_
M9[\>:?JG[)_Q1^-^J_M(6=W:Z66^$.G^)2W_ C^J^-U&MYZ8VD$DG((7'S:
M_P $?#?_ 4*_P"">?AC]L']B#PC_P $S-=_;#\1_&_]KCX@_&CX,?'+6SX/
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M;'_@G3\=_"?AC4[JVM[*^TG7O".L6?Q.\$:2H&OG1/#?A;^UO#W_ D'+:5X
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M1:A\2[B+2X/#F@_& :]H]YJW@W !)UW )VXZC'/(H,#]MC1OCO^SMXTD\:_#O5]4UG0C=WFD:IXM09;!@!'OR& "E?SF^'G_ 41\6>%O^"B'_!4CX6_M%_$3P9X3_9/_8M^#OP*
M^)?AK5+CP\=)U/PAI_C+PMD_9X^ G[4'ACXX?#3Q'\*->\7?M]?M+_ !*\*Z)XAMOL5YK_ ()\7:[X;;P_
MXQTI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MJXU3P59>&/"VHG6SX>T,CQ#XL"E#X6TO(W>G077_ 5@_85L/V//#O[<\WQO
MA;]GCQCK1\+>%-=L_#'C&\\8^)?'_P#:5YH__"N]*^'W]BMXS/C@:WI6JZ:?
M")\-A]Z9 "DEOD?X ?LZ?&OP]_P6W_:"_:*\2_"77].^#GB3_@G[\"/A=X2^
M*EXFF)XM?$.P_9D\4^(/BS^P]_P4U^*W[4OB;]EG6+_0?#GC;XG_ OU?QE]L_M/P2>-
M _X2H6//A/..O!/0!@?K9^TK_P %FOAI\0/^"=W[M- U76/ 'QG^&VI>'/&_PWU#Q%XQTC2-'U+QM\,_'ZQO_ &'K^B'5S$<-P-YV
MOM->^_L>_P#!8#]E#]I#Q9\%/V=[SXAZ_P#\-$?$KX3:#XLTN?6_AAXP\'?#
M/XL>(='\,)K'Q 'P=\<>)M"TOPCX_'A[6QJI_P"*>[Z20"P7"_GU^U7?_MQ_
M\% /V(O^"GHMO^";>H?L]:=\2?AC\.O!W[/^@^--)T&P_;.^-_B_1_&/A!O$
M ^)/A[1-MQ)-X1_9D\(>-=(^/VJ6=MIAL?A+_ &O\&_ GAO2M,U8=O^)WI.JZ!M&022<9
M8D@']'M%%% '!^(/&?A'PDVD6?BGQ3X<\.2^(]4_L?PY'K>L:7I5QKFKAMM(&L7O\ Q.=:^4*516))'RDY-5H_'_@=M9UWPW#XP\*MKWA'3UUGQ/H:>)-)
M&J>&]((M\5OV8-:\#_M9_":]M+8?VG9>*_@/KZ>.=4N-*)PP=O"MKKX55ZDD')*D_P @
MOCSXY?M!F#XH_P#!2SP-HGBLZG_P7?L/VH/V)? 7A(XSX"W:]\(/ 7P%U\#J
M,^%/#WCD @@GYAS0!_ME?%WX)DD_X1]'?QCX<_XI6,7I\TJ8W*_"WB
M[_@N+\"(/V ]<_;U^$GPX\2_%#P?HWQ\T[X$3?#.X\9>&/!/C?\ XJ/XIGX6
M>'/&.JZ5(?$Q\,Z)XB&?%WAC0_$2AW\*L'W(0 OP9KG[)OPL^$7_ 5]_P""
M;O[&Q\'Z!XG^'/A#_@C1\>/@OK/A6XT@'2O%>G#^U_#?B$:MG/'B0#Q"&!&0
M=9;:G
MC]J'Q[HWP2/C;OD^%3JI^'V20,# ZT ?Z'7@WXH?#[QKJ'B+0/"'CKP7XG\1
M^%)18^+- T'QCH/B+5O"FH%1G3O$&DZ->N=&D7. LBH<@CD#-;'C#QIX0\!:
M!J'BKQKXH\.>#_#&E@G6-?\ %6LZ7X=\/6F ?EU35];9(XR1PI++GG)XK^9C
M0/V>/@5^R+_P<'?L3>!?V9_AWX?^$'A?XH?\$[?C5??$;0/ ]C]@L_'FH:-K
M[#P_KOC?["%_X2;74.DD?\)!XBRP"*=VMG\'OB5HWQ/\ VB]1/AOX@_M3^,_B+X<_9+^#?BCPWH.4\9?&WP]X 95\??\
M(?9?"?A[QH?^$3/_ !/6++@B@#]]O WCWP5\1] M_%7P]\8>%?'7AN]4I;:_
MX-\1Z'XE\/71]%U?13)&Q'.0AP,C@[@#^9W[<_\ P4^7]E[XQ?"K]E'X%?L]
M_$#]L']L/XR>']9\9>$_@K\/]7TKPU8^%_ ^C8%W\1OB9XWULG0/#'A3[: A
M9N6P2JA"C'\L?^#"[?X^_!?Q'X4L?@GX-U
M[X2?!"\T[Q)X,\2_VKXS^$_PQUKQ3XF_X1KP1XA.DJ/MX9!XI&D,Q)P >F_:
MF^*&A_\ !.?_ (+M:5^V]^TVFM^'OV5OVG/V.-._9XT;X\2^'=>UOP-\)?B?
MX;\0:-K)TOQL=$1_[%_X2%?#V!E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M"BVU#P)^T,W_ 5XE_:@'QI!_:3O?$&K_P#%=ZK_ &K\,O[$YT,?#HZ2&\'C
MQ-E?^$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MB/A?I(U/Q1\+=4^Q:M_97AW6O"PU]L\ KQR!R:_5_\ X)^_MP_#'_@H7^S)
MX)_:6^$VC^(?#>@^)+[Q-XM) ((P3@"OXW?V6_V0OVR_C=^R!_P4Q^,G[%O[7O[0GPT\?_ [_ &[/VH/M
M7[,'P_\ $8\.?#+XRZ?H^NG6/$.EC5]%_P"*AT7XC^--"O/[._X2#J?[(\)?
M6OZ;?^"&'Q%_9/\ 'O\ P3K^"R_LB>#;SX9>"O#/]LZ+\0?A/K>IWOB+QOX"
M^+RZLS?$#0?B!KVMF37]<\0?VS>#7SK]\H:7POJVA' 0!8P#].?%_P 8_A/X
M"U31O#WC_P")OP]\'>(/$NZ+PYH/BSQQX7\-ZMXC '!T'2-;UM'U=F/ $:L1
MC+8%?G/_ ,%*_P#@IS9_L)Z]^S[\+/!7POT/XV_';]I3QIJ'@WP9X(U7XR>#
M?@MX>\*V&D:9_:]WXR\<>-/$X>/1?#"KU<@[@&'&0&_G ^)4W_!/K3_VE?\
M@MI%_P %D--TJY_::U3QYXH'[*/_ MC1_&6JZKJ/[-X\'8^"2_LM J?^)X-
M<_LO(\&$$,H7&#X^(Q[_ /9R;Q[X0_X-E;7]N/X3V'C/XO\ QD\9_$+X3?&^
M+XKZ,=7\<>._@AHN@:QXA^"7@OXJ_P!LJ3K7_".^%M?\/Y7Q$"P8MQGB@WM_
M7]?MH>.3X=T;P[\,/!6O+Y?AWQ*6\6ZNN@'Q",:5*JGQ8!L&:^;_ -C?_@J+KW[0
M/[2/B3]D#]H_]E;XD?L8_M*0?"S3_CEX#^'?C_Q5X,\867Q&^$&K:\=&;7O#
M_B'PN2#XJ\&G:OBWP]M!TD[FW$X"[O\ P6+^%GP \8?\$TOCQX<^/=K\3='^
M$7@_P[X6\3_\)'\#_"0\8_$WX8W_ (/\0^'/^$5\:>'/"@S_ &S9>#AM;Q8I
M7_D0EU]2>=Z_@I_P3_\ %/BG]IW_ (+)_#_]JJ+]L,_MW?#_ /9D_89\MJ_:5\*_"8?"3X1^"Y]9O-9'P]^#>E:3EEUKXAOH6K:M\4?%H.<^*#KRLN[P4
M4 8']?\ \8?BWX!^ WPN\=_&3XJ>(-/\(?#?X:^'-7\6>,/$FJ\:;H.C:,"7
MO'PHV@<8Q_&RCY=PQ^)GPB_X+AZ!\;_V%KC]M+P?^S?XK@UKQ7^U]HO[&GP/
M^#^K^.M)L;_QKX[\8^(/#OASP7JOC;QP?"S:=\/M#<>(SKWBW">)V\*CPZ^7
M8L-OB?[=_C[]HS_@IMX1_8E^)G[ 'PM+\9?'/PM\9G1?AA\.?&J_$/_ (J!?ASX/\7:5_PEWQ \'GP.6\6'1U3)P%'S
MK_P0O^%>K?MD_LG_ +:G[/\ ^T[^S=IFE? 35_VV_C!\4=%^('AOXG7EEX@\
M/_M#_P#"QAXC\1>#O!3:&OAOQ?\ #SQ7\!_%.E>'SX1^)W@XJ9-I5#D%@ ?J
M9IG_ 5FFUS]F&P^(-A\!KE_VIM7_;$O_P!@O1_V8D^(&EWMEK_[3WAKQDOA
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M V"".A!;.?M0 4444 %%%% !1110!\%V_\ P3O_ &0;7]K+5?VWV^#UG?\ [3VI6HMQ\3=9
M\1^,?$C:/MTP:0-2\*>'=;US4?!WAK6FT,%6;P]X:1B.C!CY@^]*** "BBB@
M HHHH **** "BBB@ HHHH **** ,^:V@O(I89H8YK:?BZ@GSCMG([= >O;@^
MG))X$\'V]IH>GIX1\.II?AJY%SX>TT>'=*^QZ'?)DC4=!3:R:*M!DMWM% ')MX;T-M:B\0W.BZ;<^(+>U:VMM?GTK33JMI8%AG31JF#(!NSPK;2
M"MOE@2>0.OJ%% ')-XMPJL$ .<<[JI^*O!?A/QMI-QX>\9>&_#OB_1KRX^TG1/%NBZ9XBTN;//.E:RK
M1[@:9IFG6=[>6.D
MECI>EEOO;5R1&I**,!1L(0I/XA\/>'O%6ERZ)XIT#2/$FCW@QMJ\.",/I6LAU8C.0&4@') R376T4 <##X \ P^%_^$,B\!>%+?P8(B?\ A$%\
M-:$/#G;C^Q_L1T+)'/0CUZ5TW]F6'V7^ROL4'V#[+]E^R?9_]#^P=/LV,8Z<
MXQ^&:V** ./M_!GA6U\/IX0M_#.@0>&1:FV_X1ZWT;2X?#NTXR/[)"!0. "H
M!' ).[YJH>#OAYX*\ 6$NG> O!GA/P38SW N;JT\)>'=*\.V%XW0M]DT957/
M3JH'4!1DY[^B@#DM(\,>&_#:7*:!HND:)%?W)O[J+1]-TVP6[OVQG4B%PC$
M +NRRYR#RF_UC^PM(TS2_ME^PS_:6I!0#(0$
M)4D-(,D@G<178T4 >=^)?AWX%\6ZCH^L>*?!'A/Q7J_A^XN+K0=2\0>%M(\1
M:KH5PW?0-5UBS8Z*P;<MI>G7M_I%\% W:3>'<=)<< L",@C)^537744 9]Q##>1RV\T4=Q;3_P"CW4$^
M<$=QCN"#R!U_A/''(^%? 7@KP3I$N@^$/!OA/PCHT\GVFZTSPEXMP6&DZ,H4M@C&5 P2 .2#WU% ',Z#H6B^'=-M=*\/Z7I^CZ79Q$6VF:78C2[*
MU!S@C2TV@9ZCY0?09^:H]%\-:#X>2XBT'1=)TBWN[IK^^M],TRUL!=:@Q7.H
ME4P&( 4L&8_#+3OAKX#M?AM>6FHV-]\.=.\)
MZ"O@?4M/UB[?5]>M#X*5!X?*:]>M=DK)"ZJSACN*\])X-\%^$/A]X:T3PAX$
M\)>'_ GA70+(6&@^%?"'AS2O#GAC0]/3=BVT+1]"$>@Z.FXDA44 DD *#BN_
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_0W;_ZP!^@-%?G]-KWB2'_CYUO7
M,_\ 7U^'_P!;GT_"G?V[XD_Z#FM_^!Q_PH ^_P"BOS^_MWQ%_P!!S4?_ ._
M^M3O[=\2?]!S6_\ P./^% 'W_17P#_;WB2'_ %VNZY^-W]?Y<4W_ (2#Q+_T
M,VJ?^!U 'Z 45^>_]O>)?^@UKG_@=_\ 7JS_ &[XD_Z#FM_^!Q_PH ^_Z*_/
M3_A(];_Z#=__ .!1JY_;OB3_ *#FM_\ @MP//^%2_V]XDF_P"8WKGT^U=>GT]NW_U@#] :*^ /[=\2?]!S6_\ P./^%)_;
M'B3SO)_M;7,>OVK\>F?\_K0=!^@%%? ']N^)/^@YK?\ X''_ H_MWQ)_P!!
MS6__ ./^%!SGW_17Y_0Z]XDF_X]M;US/_7U]1_];CU_"HO^$D\1_P#0:US_
M ,#S_A0!^@U%?G__ ,)!XE_Z&;5/_ ZC_A(/$O\ T,VJ?^!U 'Z 45^>O_"2
M>(_^@[JG_@>?\:^W?!\TTWA?0;FXF^T37&F:?N. !D@?ICCGIMP:#H.MHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _.7_EM_P+^E.K^&B;_@Y\_;
MGANKG'P6_93Q_P!B;\1N?;_DHW\O\31_Q$^_MT?]$2_94_\ ".^*/_SQ:Z!^
MP?G^/_R)_M_P#SQ:/^(GW]NC_HB7[*G_A'?%'_ .>+0+V'G^/_ #^@GX4?&&\U+3?@7XU
M\:>+OBAXV^+G[0'AOX[:/\1KBS_:4;2=*^"?QYTCX7_&+6/$7P1\0_L2D[=&
M^'/PJ/@8>'_^$O'_ !5B^*CX1\7G[ZFNE^ _[7GQ&T?P+\#;:&_^%^I:#\.M
M&_X)S?"76?AEXL_M[5?VA?CQJ'[2'PO^#W_"0_%#P1XA_MS_ )DS_A./^A9\
M4?\ "?\ _"!_$O\ X3#Q7X7Q7\T/_$2!^U1_PE%_XY'[*_["?_"M\/>*O^&7/
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MXG6A_P#8Y_CQ@U-H_P#PMAS^P?[8_Y&$>'O[%^(__ !)>OA[WY["@/8>?X_\ /Z9X]>^,?\ PTI^U%\3
MK#Q5\0/"7PQ_9S_:1\477Q5^(GC3XJ_\))\$--_9O\!_LO\ @/QYXB^#?A[]
MG#1?%7]O_P!N_P!N>(O^$P_X3#P9X&\,?]C9VKCX?VGO'_QFU;P!H_B2_M[:
MY^'?[4OA?1;7Q!X3T;_A7/\ PGGA?XJ?\$^_CS\5?#W_ D/@C1?B-\6N/!G
M3_D>>,>$C_PKWPOXP K^>"'_ (.M\3[6.G_%0X^(V=:S]?SS6#H/_!R!^U1X5L;;2?#?[*_["?AO1[.Z^WVNC^'_
M (0:]X_X1[1?%1Q_P 4KXA\0^__ !4E >P\_P ?^ ?T;_"7
M]ISQ5X0^$/A72M*\5Z?;>/\ 5?@C^P?HO@W5_%FC>,OBWJOCS4=8_8N\2?%3
MQ#_Q3WB?XX?"7P_HN/[)_P"$P\5^,/\ A)_"_7G_ (2CXDX(YKQ3^U7^T/XZ
M\(>._BI_PG?PT\/_ WO?V%?V-OVFC\"(]+\8_\ "1P?\+4\8^)=(\;GP3\6
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M]H2S_9!_:H^(M_H>AZ;\8/A'HWQ0_P"%<>(/">C:#JW_ E6GZ/H/AO6?#WQ
M0/PGT7XC?%K^Q-<\&?\ "0^(?^+7_P#"<^*,_P#"!_\ 4[<_R@S?\'-7[9DQ
MUB:;X _L=W-SKEK]@\1WEY\.?&7_ !6&CC_B3_V#X@'_ L;_B=>O_%9]>?I
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M_D:J_F/A_P"#BC]H6STN_P##_LK7O%'_
M $'O$/A__A*O^)UK@_Z'#\.^*ZJT_P"#E[]LRSAN8;#]GC]B_3;:\M3HUU9V
M?PT\9:5I5YH__0!_Y*-_R _^*A\0_P#%'\>_6@/8>?X_\ _K'O/BU\8[S]DO
M]L#QAXYAT/PUXP^%_P .?CP? ?CCP/=^#?#G]O:/H_P;_P"$D\/>,O\ A'M%
M^(WQ:_X5]KG@SQ5U_P"*Y_YEOPEXN'M^>?C3]H?X_-^S]X8^ 5A\7OB!IOQ?
M_9?UKX#_ !!^/'QD&LC_ (3CXD?!_P >>,OA!_PSC_PD/B$?]'#Z'\6/$(^(
M?_9'_%W0U^&6@_\ !R/^U=X5T&Y\*^%?V8/V'_"7@^\_M#[5X3\/_"KQEX<\
M.:E_;/\ R,)_X1[1?B-_PC_^<5I3?\'+W[85Y#M.?&6-3T?1S_Q3V@^(O\ BXW_ #)G_-/?^A5YH#V'G^/_ #^ECXS?\% O'/@
M/Q=^TA_P@T/PW\;^&/ ?PJ_:@\9?#2\O/!NJ>!]*M/''[-_Q0\!^ _$'@WQ#
MXA_X6-XV\0?$'0_^$J\;^(?#_P 0O&'_ @OP;_XJKPW_P 6W_X3SI5_6/CE
M\5/@_P#ML>,/AUXYE\-^)+GQ1\$/@/?^(_%FEZ-KWASX9?\ "4:/H/[3GCW_
M (4W\)_!&M>*O&W]B_&+]HC_ (1[_A'O"?C#QF?^9#\6X_X2CXD?\('X5K^8
M#_B)!_:H^W>(-;_X97_83_MCQI_R.6L?\*@U7^U?%_'/_";^(?\ A*_^)U_W
M.=;%Y_P_YJ
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M:5JOCPGMXW_XJK_B=_\ ?\$^_^$&TNZ_MG
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M??XC8_SUYY ]AY_C_P _N@HK^&C_B)]_;H_Z(E^RI_X1WQ1_P#GBT?\1/O[
M='_1$OV5/_".^*/_ ,\6@/8>?X_\ _N0FZ'Z#^=?>7@K_D4O#O\ V"--_P#0
M17^;[_Q$^_MT?]$2_94_\([XH_\ SQ:_N;_X):?M-^-_VQ_V!OVM1X;\/^-?BAX-U#5]9T;P19ZG9>%M-GT?QCXB\-BTTA=8RVT?V!E@W(+$_<(-
MQ\_Q_X!^BE%%% !117S[^TK^T-\-_V6/@3\3_ -H;XLW&MVWPU^%'A>?Q
MCXNO/#>D-XAU=='M/LN]M(TI0#J\AW# 4ANI!4] #Z"HK^;W_B*F_P""3?\
MT-'Q\_\ ##^,O\*/^(J;_@DW_P!#1\?/_##^,O\ "@#^D*BOYO?^(J;_ ()-
M_P#0T?'S_P ,/XR_PH_XBIO^"3?_ $-'Q\_\,/XR_P * /Z0J*_F]_XBIO\
M@DW_ -#1\?/_ P_C+_"C_B*F_X)-_\ 0T?'S_PP_C+_ H _I"HK^;W_B*F
M_P""3?\ T-'Q\_\ ##^,O\*/^(J;_@DW_P!#1\?/_##^,O\ "@#^D*BOYO?^
M(J;_ ()-_P#0T?'S_P ,/XR_PH_XBIO^"3?_ $-'Q\_\,/XR_P * /Z0J*_F
M]_XBIO\ @DW_ -#1\?/_ P_C+_"C_B*F_X)-_\ 0T?'S_PP_C+_ H _I"H
MK^;W_B*F_P""3?\ T-'Q\_\ ##^,O\*/^(J;_@DW_P!#1\?/_##^,O\ "@#^
MD*BOYO?^(J;_ ()-_P#0T?'S_P ,/XR_PH_XBIO^"3?_ $-'Q\_\,/XR_P *
M /Z0J*_F]_XBIO\ @DW_ -#1\?/_ P_C+_"C_B*F_X)-_\ 0T?'S_PP_C+_
M H _I"HK^;W_B*F_P""3?\ T-'Q\_\ ##^,O\*/^(J;_@DW_P!#1\?/_##^
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MGAOX@^%)=9TJ[T[59/#WB_2;77M(:^L2";6X-C?P;XLG;QR^-O\
M@FG\'_ OP;^(6B0^!OVI?CG^TA\.OV0?#'[6GQ?\?_#3Q[^SYX'^$OP'_P"%
MI_"_Q)\7_!&A?\*G^('_ !=#XN:'X>\*\_&WQAX,.<'! .16G\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MK?&;_@E1%!^S;\&OBI\)OB!\-M%^,OA_]BGQ1^T9^T?^SUXX\=Z]_P +
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M\1:KX-7(+%?#*[F9LL?OC6/^".__ <5^)(?#T/B1/C!K=MX0\2:/XH\&_VQ
M^V'H.J_\(KXHT?\ Y%[7O#W_ !<;_B2ZYX=_Z'#GZUX3>?\ !N?_ ,%DM0N[
MK6-8_9OTO4K_ %"_^U7]Y>?&[X7WVJW>L8_Y#W'BKK[]NO; /PZHK]OO^(<
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M^!'C+Q'\,] (TK2OAO\ %#QW\'/ GCOXL>#O#WAY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MAB#X/ZI+X:_9G\6?%#X#VO@C1O ?QX\M\C!K7_"&DY/OX;\)$\FN9\*_\%7/V]O"NC^!K/\ X7]XD\;:Q\-_CM%?%7
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M +T;Q!H^B_V5XCU[P/\*_\ B3^"/^$WU;_F9_%7AS0_^*?_ .$PZX_4 \2K
M_5D_X-_?^4/'[#G_ &3GQ1_ZM+QY7^4W7^K)_P &_O\ RAX_8<_[)SXH_P#5
MI>/*!XC?Y_JS]C****#F"OR:_P""X_\ RB/_ &]?^R#>)_\ T^:/7ZRU^3'_
M 7+_P"41W[>W_9"-?\ _3_H] '^3M17KWQ2_9]^-GP2\._"OQA\8/A=XL^'
M?ACXY^$O^$\^$VJ:_:_8=*\:^!^/^)II/ID>(?#IQ[G\/&?,MO\ GK;_ )"@
M[]/+\"Q17T=\)/V/_C]\D?$7X=>%=#U+P3K?Q5U#X+VWB#6/'G@WP/I0
M\;Z1\+S\5-5T'_B=>*O!/_-.1_PD/ZG&>?FGSH?^>W_CW_UJ!Z>7X%BBNW\'
M_#'Q_P"/-/AUOPKX/UW4O#%QX[\+_#0>+/\ CQ\#Z9XX\=_\B1X-\0^-M:_X
MI_1=<\9G2M6_Y'/_ *%L "LKQ]X/U[X8^./&'PZ\9PZ?IOC#P'XCU#P;XCL[
M/6M!\1Z5INH:/KO]C^(3X>\0^&/^*>ULXP?^$P\&?_J T\OP.=HJO#-!-[<9
MXX_R/\]OK^.*2OVR_X
M(3^'_C]?_M1>+/%GPB\9Z7X(^'?PS\.>%_B#^T7!;^'/ASXC^)OQ'^'VD:]_
M;&E?L_?"?P]\0?\ F.?%37-)_P"$/SGPOCPL?^+D=Z /Q%\[_P !OI[?EU_7
MWH\['V;_ *?/^/ _7C_''KUYZU_9U\/;[3F^$OB+Q)KOPJ^$?P3_ &M%;/$_P#P4K^"AA^#8_X5O\;-7U+Q'J_[+?PQ\1$G_A(/[<\/>%M5^&G_ I+
M_A#/XO[=_P"$/S7SI^TL_P#P4$^&'[*G_!/'P"UMH/B3]J[5/COX6\4>%OVD
MM#\._ :R\$?LT#XU>#O^%0?#/]E?P1_8H4ZUNT3_ (2'Q!\;/$'_ @Q\*^%
M?%/!)/)##V[[/[F?RL45^K?_ 68^/UI\;?VQKOP/X?\5:7X_P##O[+_ ("\
M+?LUQ_%C1]%\&V/_ N7Q3X0_P"2L?$75O[%_P"*?\3CQ#\1?[6'_8JG0>G;
M\I*#<**** "J_G^WZ?\ UZWO#L6JS>(M!AT6PM]2UZX\1:?8:99WG_(*O-0&
MO?\ %/?\AG_BG^-M_;-U_P"$/[5=[HWP'\*^!O$7[:OCOX7_ /"1_ ?]FGX)?V*/[ UK_A1.B?VM
M_P (IX@\9^&?^$4'QH_Y%#/_ C?(!_$IYW_ !\]OL__ !]?]0W&<_Y]?KR>
M?[?I_P#7K^WK]G>;Q]#^W#X?N=>L);FYN/V6_P!FG1_V^?$'A*Z_94OO@Q9?
MM2_\*+\=?\)MJ?[;?_"3_P#$_P!9^'7@S^U=)_X2S_A5?B;PN1XI_MW'_%7G
MCY+\86'@_0?^";GC;2H;_P"$>M_L0_\ #L..UT#5/#?_ J_&O?\%-3^TH?[
M5U32>3\3_P#A<'_(6QV_X4QZ# H,/;OL_N9_*#5>\_X])_\ KU']:L57O/\
MCTG_ .O4?UH-GL_1_DS_ &)O^"M )1__L5_]FN_ [_U77AZB@X7N_5_FS_,K\2?\$A/VI-!C^!7B&_U7X7W/AC]
MHC]F3XP?M2>$_%EGKNOZKI6@Z?\ "OX7#X\>-_A?XWQX5_XDWQ&_X5R?#W_$
M@Z#GT./CW_AD7]JX^#?A=\19OV;/C9;>!OCAK.G^%_A!XL_X5SKW]E>//%&L
M'_BGM!\/>O\ PF?_ #3WMXJ^O3];?"/_ 6B\/>%=!^+OPZUOX(>)/$/PN\>
M?L'^!OV;O"6CW/B/0/\ A(OAO^T1X#_9]\2?LQ^(?V@M)_ZE7QE\.?&^K>'_
M (A>'Q_U*/:NAC_X+2?!_3/%FC_%32O@A\;/^%E_$GQY_P $_P#Q3^TCX?UC
MXC:7JWP=T'PQ^PW_ ,(V?#VA?LX>'O\ A%?^)-KGQ5/A[/\ Q6?_ "*ISQD\
M!T:^?XGP/X)_X)/_ +'?!_CSQC\$/&GPF^'7B#X\?"_]GWQ'XH^(GAS5
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MG=:IJOQ-T'4?'F/$GPFT'QOX>_Y@O_"UO"OA[^W_ GW]AVX36?V _VY_#>C
MZQXD\2?LA?M(:)X>T/P;K'Q!\1ZGK'P@\9:5I6@>!]'_ .1A\9>(O^H'_DFO
MU2U[_@MA\-/&&O?$[1/$G['GAOPW\'_^$\_8W^(/[/O_ KNZ_LKXQ>%=8_8
MS\9>&_\ A5'_ LW5M:\5?\ "/ZT/^%.Z3J_POQX=\,^%_\ D9/4U@Z=_P %
MG-*AU[1[_5? WQLUNQM_B_\ \%/_ (H:UI=Y\51JG]I:/^W'X-_X0/P/H/&,
M_P#"JO\ A(N3W_YIQG)R ?DO#^R7^U1-X7^%WC"']GSXR7/@_P".&LZ/HWP@
M\0?\(%KQTKXG:QK'/A[0?!'_ $,__"9X_P"+>_\ 0_\ \O2-9_8/_:,T'POX
M!^W_ Z^)/\ PNGXB?%_6/@MHW[-_P#PJ#XC:5\3=-U#_A#?#?CSP]KV?^$5
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MXP\>?"K]HCX+:/\ %CXB>//A?XX\<>,/"_QX\&^'/#GA[7O&_C?6O"O_ D&
MB_\ "%_\(]S\+_A5_P (OX4\5?\ M_P &>O\ R.E\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M\<^ O"?A;XJWOCO1_$?POU_X4Z+KA^*'B;XP?"W6_ RV++X=\4?\54/$*?\
M"8>$/ 3 ^%*]9TSXD_LB> =#_9F^&GP9_;L^#GPV^!_P&\)^*/"^I^$-!^,O
M@L>(/B,3X ;P'X(/B'Q'_;FX+X=.K>(OB86V,_BKQ_I/A([67)KG-)U+]B+P
M_HOB^/3/^"E-[;?%+QYKOAB_\1_M _\ #2WP9'Q9U'2/ >F>(M'\$>#6SX6/
MPQ/@CP]8>(O$)7P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MU=\&ZKJVO^#_ WK.O:%>>%=MH#W6QR %+9*HN2*^=/A/_P GE?MA?]BG^S%_Z8?']4?#_P"V?^QSI&C:7IT_
M[8OP0UJ?3-'T^VN];UCXP_#HZIJY6U &J:H1?C_BM;)_9,LOVK?VLM?O/VF/@7:Z/K?AW]G>UT?4[OXJ^#/L-Y_8_A_QZ-5"DZX.A
M/'3C/.,T ?1/Q*^-'Q>^'_[67[-OPCA\/>!9/@[\;XOB=HVI^)[O6-5_X6)!
MXH\!_##Q-X[#:3I./["TK1-F@6:2%G8$ZH'58VSCY]_9G_;2^,OQ7\?_ $O
M_'OAOX=:7\(OVP? GQI^(/P&@\(GQHWC_P %V'PLU7PTWA_3?BOJFL$^$-:_
MX3/X=>(CXM \.KX6_P"$2\4@^#T7QW%_Q7[5_BKXY_8G^+'QG^#_ ,;=0_X*
M):-X5U7X(7PNO!_A/P/\<_@S8^#+C4=:M=9\-ZS<^(M)UG0O$7B#6SXBT35C
MH#9\2 ,&X!.0/!#X4_88\#66OW7P)_X*!>%/!OB4Z1X@\$?!R[\1_'[P7XC\
M/?LR>!_C!X]\-^.OBQIOP1\/EE']N^(E\/!_"G_":-X\/A51H*A3\.<>%-4
M/IZW_:E^,NF_MS1_LO:A)\(?%>BZWX0^)WC.UT72M%^(G@?QOX-_X0_2O#>K
M^!CJOC;QC?MX ^+6L^,AXDV>+/"7PJ\,K)X!2,>+96DC!+6?A)^T/^U!\7?@
M9\;?$=^/V!_A4W_$_\4,#K?@OQ
M#K6N+HA&I%SJ7A?PNIRS,JJQ/ ?\)-^PKJGQGTGXU>*?^"@>E>/+KP7J?B?Q
M1\,?!'BW]H'X7:KX'^#GBCQYX?UCP#JOC'P1I"Z(NOC7--T+5=?T#PK_ ,)I
MXE\4+X63Q'XL15.3L\3_ .%:?\$]9_AC\1OA+J7_ 4KU_5_"?Q<^,&E?'/Q
M?J.J_M'_ +/AU;4O'X\0WFL:_DCX>CP_K'A7Q'K0\/\ _"5^#_$7AB3PJQTC
M0&81X*L ?H-\$?BW\>_C_P#L=?#+XP:#X<\"?"OXW_$/PCIOB2TT7XAZ3XR\
M1_#NS#:LP&J'2M%USPWXOO="\1>%A_PD'A/&IJ0-6T'<3FD_8D^-OQ4^/?P9
MU3XH_%.#X;S0ZK\1?B/H_P ,/$OPSM?%6E>&_B%\+O!NO?\ "->%/B*-)\3Z
MWXCUW1?^$SOM*U_7U4MC_A%;WPHX4[6#>#R_%3]CG4O#.N>$?%/_ 4BA\3V
MVN?"?Q/\(;W6-3_:7^#NE7]WI_CS4O[6_P"$Q/\ 8NB>&_#VD?$;!?0?"?B#
M:@7PJ5 4G+U[KX"_:K_8*^&'@KPC\.O!/[3'[.>B^$/!'A[1O!WA31+/XO>"
MMMGX?\.::NCZ3IG_ "&P28E154D+D*"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M-C7Y@S^3YESY-^=2MOM7^BWGV7_D):/_ -![^F>I_G^S/[-/_!4K1/@IX=\
M>!O'_A7XG_%'P_J@^,'B?X\ZIK&LZ!XB_L'Q1X[U[Q)XC^$^@_LX>!_B!_PF
MOPNT7X=?"K6Q_P +0/A#QF,_$#Q7XD).3X*\"5^5OQL\>>&_B=\9/BO\3O!_
M@#2_A=X8^)'Q&\4>,O#GP_T?_D%> ]'UC7CK'A[P;X>]/^$,]\'GF@#S>O\
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M 4F_P""=.H?%?QA>1>)-.B\%ZI^U[K_ ,2K^:[^"&JKX<\>C_AW5_PHCQ!^
MT$? _P#PBS?\(P?BI^T3C7SX0S_PGQ.L'Q> H(0>+^%?VQOV2]2UC]C"[L_V
MTKCX'?!#X7_ /POX7T7]F?P/^SQ_PCOCC]GS]I_1_@1XD\!^-OBCXW^-I^"'
MC;_B1_%3XBD#_A,/A4/%'BO.KD@>%_\ A"M67]G*.[_ &B=-^!G[3FC?#33M<^-?[!/QRE3_A0VO:KX<^.]AX#^'7_""?M=
M>#3_ &U\.>=;\1ZY_9/B#^W_ !GIGA<>*O['&<_\)'_Q-.'F_P""@7[ MXU0^%/B=X:\+_"#5/&?_ 4>/Q>_90/[-VJ?VK^VE??M'ZGX\_X8[^(ND^-C
MX5'A_P"'VA_"K0]6\$G'C/Q-X7_X4N=(X)9J_EFHH#ZO+S_'_(_?;]M?]OS]
MG7XZ_LO_ !^^ _A[QAX;\2:9HFB_\$\;_P#9ET:W^"W_ AVJZ;\0? GPZ_L
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M_P .;/\ @E?_ -&&?LS_ /AN=*_^)H_XMOP_X)_D<^;#Z_J?\:/M'_33_ #^5?ZXW_#FS_@E?_P!&&?LS_P#AN=*_^)H_
MXM7^I#\8_^"3__ 36\/?&3]E#1-$_8E_9SL-'\7_%7QQHOB[3++X::#MUVPT;
MX%^//$6@:5JC8 (37=(T#7>0&_T(%ADY/U+_ ,.;/^"5_P#T89^S/_X;G2O_
M (F@/K#\_P ?\S_(Y\RV_P">OZ"C[1_TT_S^5?ZXW_#FS_@E?_T89^S/_P"&
MYTK_ .)H_P"'-G_!*_\ Z,,_9G_\-SI7_P 30'UA^?X_YG^1S^Y_TG_I\_X^
M_P#I\_SCGU_&E_T7V_Y^N_Y?Y_*O]<7_ (M_#FS_@E?_P!&&?LS_P#AN=*_^)H#V[[?A_P3_(Y^T?\ 33_/Y56O)O\ 1;G'
M_/K_ )Y'M^G/6O\ 7/\ ^'-G_!*__HPS]F?_ ,-SI7_Q-4M0_P"".'_!*^.R
MOY?^&"?V9QBPU#/_ !;30N05+?W1W'J/3() ('UA^?\ 7S/;?^"MK_[-=^!W_JNO#U%6_P!BR.[TK]D/]F73M(LHK/3+/X&?#""RM0 1# OA#2=J
M=?(/['O\ PY\3/$'@
MW7M*\#Z]_;'_ "+P\/>(1_T.?TYKY^\RV_YZ_H*_J@\>?M%?L3>*OB-_P2I^
M*GCGXJ?L=^+?A-\&_ 7[#_P^_:!L[OQ)\>/$?[0MF? G@WQ)X#\;^#?''P1U
MH?\ "CS\./!GBGQ#X>\0?\)>/ P^('?/:O+K;XM?L3_LO_#5]*\$^._V)_CK
M\;_A?^P?^UA8>'/$%G\*O^%C>!]>_:@UC]M+PWX\^ VF?\7!^'/_ !<'7?!G
MP=_Y)[XP\9G_ (17_BF^!R*#I]O+L_N9_-A]LMO]3YW?_(QZ>_X>]'VR$?\
M+;'V?^OU^OX=*_JU\%_%#]A#Q[H/P&\#:/J?[)'C+P1\2-:_X)X>%_V>/V>_
M!WP@%C^U1X$_:P_X7=X#_P"&QO&7QO\ $)^''_)./&9/C<_\5EXF\>> /%7A
M7Q'H ^&_A,C(/I7Q'^)O_!-KP%^TMX/\#?&GQ+^QAJGQ7^&_CO\ X*,>%OAS
MXA^"?P?T#X-?#W_ L?P;XJ\/>-O^*P
M\9^!OC(/"G_-1QX['4#ZP_/^OF?R$Y\Z'SO.XX__ %^O/_U_>DK[6_X*)>+O
MA7XZ_:T\<^)/@_H_PGT?PQ>>'/ ]KK/_ I/Q'_PD?PRU[QQH_@W1_\ A-O&
M/A[Q#_PKGX2^#_[<\1:[_P C;_PAG@;POX5/BK_A+?\ A#\"OBF@W"BBB@ H
MHHH _KT_X-!]-T[4OVA_VTH=2L=/U&+_ (4O\+?^/BU%\>?&?B/C+!AC\,GH
MN#S7]P'Q7\2?"GX.?#GQA\3/'VFZ#H_@SP-X>U?Q/XDU"+0A?M'L[QRNF
M:59V+'6;XBT _L)3NRRXYY/\1W_!GK_R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MA.N>.0/B*?[8T/\ X2G9J0_X56/'Q'A1CXO ^]]%_&SXP?#;X)W/@+P[_PK
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MX&&R$OV7_LT!T?2^"=!^)/3@YYZ9 P
M.<]C[[\$? .H_"7X,_"GX6:SXNU'Q[JGP[^'?@CP1?\ CS7]O]J>*M2\-:%I
M&B/KNJ]/].\0NI9\_-N+#DDJ/'OA/_R>5^V%_P!BG^S%_P"F'Q_0!M_'SXI?
M"O\ 9Z\(Z+XK\4^ YO$L_B/QQX'^&'@GPKX0\.>'_P#A(O%'Q \8Z^-'\$>'
MM)_X2:_\,^#]&.I:V6(U_P 1^)?#'A90 TFK8:/=Y;)^U=^SUI_[+OB;]K'5
M_!&N>'?A]X4G\7Z-XS\-ZAX*TQ?&^@^,/!_C.[^%7B/POX>UG7%^(=
MFWA :[IWB3_A$V?D^+4TG,@Z3]N/X >-OVFO@B?ACX,U3PS-;/X[\$^(O''@
M3QT=3LO WQ?\$>&M4.KZQ\+_ !7JFAV3:_H^A^(F32C_ ,)!X>+2*VD[2!N8
M#XS\-?LN_M:Z?^SGXF_8BM[KP1HG@/4_AW\0-8A\9O?ZKJO@GPM!XR^-B:QX
M'_8X\&*%'Q!U?X/^'/@WIGC;X8?$+XF^)/\ BOPGB7PC)X1 VD( >X:=^VQ\
M&-0TV'2[/X"_$74OC-/\7O%'P-/[/=GX6^'._&@'B(_$0_
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M_:*T"V^(Q^-'P2U'PU\3_P#A)/M7[/5W_899MNOBCP@S>%V_6^@#_ "AO^"]4,-G_ ,%=OVV(;"&WMK:S\6_#_P#T>TM1_P!$
MO\!^F!DM?[.WQ]\8?"GQA\;_ ?\%_BAXD^"W@.Y^P^//BQX?\&Z]JO@?P?_ -C#XAXZ
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M'B')\*Y!^&X !P'.?DQ9_LT_M'7EK\'[^P^"'QM=O6/3P0<_P#$Z_#OT[UX_>6WMQ]?RK^E'
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M_IST>OUAK\X_^"L%AX U7_@GS^TII?Q;OAIOPHO_ [X7M_B5>CI:?#X_$;P
M*OC7ZDZ!_:PSSU].* /\B*&\AF_U,PN<_C^7J?<^N*LU_5_\?/V9/VI_C_\
MML^(_@=\;OV:?@^_[ W@3Q;\7O&?[(&E^$-&\'?"/PYXP^%_@3P8-8\$:5\$
MO&W[/WA3Q'\*A@^+/ 9I-3_P""7/\
MP3Q^'7QX\5^"O&'PN^*'C;PQX[_;I_8X_9<\!Z-;_M Z_P""3\)?#'[4_P"S
M3X;^*FK:Z -#_P"$AUO_ (55KG_(ICQD"3T^(XS0=/UB7G^/^9_*#17](_@K
M_@F)^RS>:1^Q)X/U7X=?$GQ)\/\ XZ?%8Z-\>/\ @H1;_&C2_#G@?X2>)_\
MAH'QW\+/^&8#X('A4>#]&UWQGX5\$^'M _X3 ?\ %5_\)5X[_P"$N'_%'UJ_
M%S]@[]@'X.W_ .TE\2O%7[.7[0EMIG[/_P"R/H'QDO\ ]GOQ9XQ^,GP"TK7_
M (H#]I32/A9X>_X0CQ#\6_"H^*&M?#KQGHFJCQ!\0_\ BF3_ ,53H_\ Q;?K
M0'UB7G^/^9_-'12N?G_T:V_T8YP/_K_I^/XTE!N%%%% !1110 4444 %%%%
M!1110 5_IE_\&N__ "B8^&O_ &5OX\?^K.UJO\S2O],;_@UT_P"43'PW_P"R
MP?'C_P!6AXDH,,1O\_U9^]/CG3?&&L^%-=TOP#XJL/!?BS4+#[-H/B?6/#'_
M F%CH>H,I U,^'3K?ALZR ,,5/B,8.WDD'/Y^?LP_&[]IOQ3^SM^T]\6]5N
MO"W[1-WX.\8_OV83X7\$_\*J/QFT_X6:#_P (WSI/_"5>-OL?_"9?&+P_
MXWT#PHVX-_PB_P#8.2(=$MO$&C:KH=WM-6V@C2M54@V)Z@$="MCE=H ;YHB_9DT'1K']GGP?\/\ Q9XD^&7PA_9\T/Q5
MX>TCX:^"[[5-#A\2_;/!Q\!^![;Q!KRG^WS8>#=$U77_ ! JE]__ G0T'Q:
MS;_#>U@YC\O/A]_P4M^)&B:7\4/ WCWQSX,\=?$F\\&?L]7'PM,EG!\7_VA&^*>C^(?AUXV\&?$##GP3\"3\,O$'C_ ,6>, X#>%=(U[PDV[QC
MI@KF]:_X*H?$.3]F;]D#Q1H'C_\ 9\N?CAXVT/X(_$O]H[6]6U#3-/\ VF_
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M-+&G?"T^!M'\/^$-(T$>+/#+,/$FM>.L^*M=R1%X7TMM!_LV? SXX:KH]OXMP2<8)\T^)/[#/P0^*OV<>*[WXJP:I9^+/&GB?3M>\,_%WXA>&O$/AK3_ (C:
M%I'AOQQ\/-)U?0];#:-\(?$FB>'_ \K_#!<>$5_LB/9$#N+?5?A/P?X?\">
M&O#WA#PGI]IH'A3PQH^D^'/#NA:8JPV.AZ!I&FC2=)TS2R ,"-%M44L?F_B9
MF 9@#YT_:#_Y+[^P_P#]EH^(_P#ZSO\ %^OI3Q%_;?\ PC^J_P#"*?V3_;_]
MEWO_ CW]O?:?[#_ +0^SO\ V9_:O]C\_P!B=?,_BQC9^\KYK_:#_P"2^_L/
M_P#9:/B/_P"L[_%^OI/Q!I-MKVDZGI$UYJ.F1:GIFH:;)=Z/=G2]5M/[54J3
MI>J9#:7K W*5/S?.R-C@$ 'Y#^!_VJ?VH_B1X0^ WPL/B[X;>&/CQ\6?VH/V
MN/@UKOQ?T+X5^(+WP-H7A?\ 9HUSXI9U[PI\,]:\5[O[<\0#PEX>\/@>,O$X
M3/\ PEC[2P5E^@?AO\=_B_\ &C]B'3?C"NMVG@3XLVO_ E>@>+M3^'?P>\8
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M%^(&@:?^S=XS\1^$=8O_ )\13X$'_#0FJCQ7N_8^T7P]H>E$_&YO$7/PM\5
M?V\23_PC9\+5WGAW]M3XY:G^WY_PH74-;\#Q?#'_ (6WKOP\T_2QX2NSX'U/
MP3I'P<_X3O2=4T#]H\>*1_;7[2Z^*B#XJ^ +>&#CP$NNLQRO_"5CZJU#_@GY
M^S[K/@?0_AA)_P +;TKP/I4OB ^+/"OA_P"-'Q2TJP^,O_"MXI/_ MQO&>M:EK+^+-9\8%Y/$W_ D.NK(R[TQT;?L(?L]Q_$V\^)T&F^,(
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M &2'P7_Z:(** /\ &XF\G^T+DB;_ )>OT_\ KG^6:K>=##]FS-_Q\?F/3_\
M5[(_^$;UG0=5_;2_
MMCQYXR_MGXL?"_Q#X(_Y' _#GP9^ROXW\$>(/"?3_BO_ U[YJMXX_X)Q?"G
MX4^'_P!IS3_@/HOQ#T3X;_%3]D+P/<_#D?$36M*_X6;\6M:'[8_P'^!'B$>-
M_#OQ;^!_AOQ!^S'XK_X2C5?^$1_XHS/@#'/_ L+_A#AXHH.GV[[?A_P3^7J
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MW>&/AQXV\8_%K7/&?Q&_X1WQA_Q1OP@\4^*SS_PA_48!'\>]5_MM^)K^E[XX?\$C?V>/A!9?M,^*O!GP?_:H_:<_X1>U_9?L/ ?[/?P;\9FQ\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M^+OB'6_B/K/Q/^ /B[XDVW[/FM_%2P^$7@#_ (1^U_X6O\3_ IX?T4>)?$>
MLGQIH3#PE\% /"OBSQ^(C\1BO@WPU*L@!]4']A;X-2_\SA^TP>__)V?[2HZ
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M^$OQZ^./A/X0:KXE\.6>L:O\./ 7AOP/X/\ ''QLT8#&B>')-)U@ OX4\*A
M0V[)VH ?;?CK]G7]D+X6OH8^)?QU^+'PX_X2[61H_A/_ (3/]N7]H/P[_;VH
M'D:#I/\ PD_QO_XG3<9\M=S %2?O+GTW_AA+X/?]#?\ M+_^)<_M+?\ SR*_
M,G]J>']I_P 0_M#0_M#_ /^&_Q]T+Q#XN_9J\/_ S_ &>/"FK_ '\">.-
M)_X7!H_QL\>?\+!\&_M"'X@^%?$O_#/_ ,.?$6A7O@?Q#_PF'A[Q/X$'C_PK
MX;S_ ,+#SX:\!^%:_?Z#SMD?G>1]IX^T^1_G=CUSWZ4 ?Y,O_!;/PCI_P_\
M^"IG[7'@_2M0U^]TS0_%GA6UM]1\3^(M4\7^(IS_ ,*N\!;CJNJ:TS^(-8&>
M0-[XX&YCS7Y;5^OO_!?'_E+S^VO_ -C[\/\ _P!5?X#K\DM-\[^U-'\G2O\
MA)+G^V='_P"*?_Z#Q_M[_D ?\27MXS^G3V%!Z"V^7Z&/YT/D^;Y_X<^OU_S^
ME'G0^7YW/V;'7/;/3/KVQ7]<'C#]G#6[/X__ \^*D/[$/@OP#\8++_@ASXG
M^-/[/WP&'[-W]D_#+7_VQ]&_X23_ (2'0?#WPH\3@CX@?$;X5>%?$/\ PD'_
M A_C,>*?'V?^$2_X3#/(/Q'^UM^RC\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MV#[9M-9U35>?RZ].??\H** "BBB@ HHHH **** "BBB@ HHHH **** "O]$G_ (-O
MO!'QZ\0_\$M/AM>?#K]H#2/A[H/_ M7X[?9?#EQ\%] \8_8_P#BY_B/IJQ\
M5KU.2/RR2,G_ #MJ_P!,O_@UW_Y1,?#7_LK?QX_]6=K5!AB-_G^K/UE_X53^
MUQ_T=UH?_B-OA'_YXM'_ JG]KC_ *.ZT/\ \1M\(_\ SQ:N_'/]I>P^ NK_
M (/"&CZ8/#G@O4?'>O:1X9TG5?&NJ^)M;T
M_9&=MT^)MJ/\ 9&T$^&V<.8W?^%4_MM //%K#\0?M46R?M'P?LX>!_ NM^//$6D1>%+SXG^(K7QC\.?#NG_ UMO'.G
M:QK>CC^QO&>OZ=XM\9:^OA;2KKQ=XIT+PWX:/_"+>%[OP^X+?\)"*\<\4_\
M!0F^^''C'QMX'^+7[,/Q@\!:[X1^'ND?$'2H(O$_P;\;KXHM_&'QC\._ GX9
M^#]*7P7\1=1?1M;^*OCC5T'A-/$90@:/XMR0?#9) /?_ /A5/[7'_1W6A_\
MB-OA'_YXM'_"J?VN/^CNM#_\1M\(_P#SQ:3X-?M(-\7O!WQ6O[CX4_$#P/\
M%#X,>([_ ,'?$?X*:Y=^#=4\;V?B6U\'>'?'6DZ9X>U7PSXHE\/:U_PE_A3Q
M%I&H^$]?_P"$D4,^K?/M3("_L]?M&W7QSUOXM>#_ !'\+/&7P;^)GP3U_P +
MZ-XR^'_BO7O!WBK['_PG/AH^,?"FJ:5XL^'VO^)/#NLVWB'PSJ]JTED-1!\,
M_=*C8#0!\Q_'#X8_M,0?&G]CV&^_:GT>^O[CXO\ Q&_LN\?]GSP:/L?_ !8#
MXI'C_BJL9_#)Z'.*^G/^%4_M+3?V@_\ DOO[#_\
MV6CXC_\ K._Q?KZ2UW6TT#2-5UF:PU758=)TR_U$V.@6S:GJMY_98+'3M*TO
M<6U;6MZT/_ ,1M\(__ #Q:\$D_X*)^$KCX,> OBMI?P9^*!\6?$7XV?$?X!>$_A9XM
MU;X=^#M=M/'/PMU/XC+XIM?'/C;6_%1^&'@%MII'[5^A^(/V6=*_:L\/?#CXIZ[X:USP?9>.M(^'&F>&#MO^$?+$D#^WSXF_X18@LPD(558 G_ .%4_M+1_P *I_:X
M_P"CNM#_ /$;?"/_ ,\6O O&7_!2#PAH'@_X?>./"WPB^*WQ"L_%/[->G_M>
M>,=/\,#P:=5^%G[/6JVQ?_A,=776/%:KK6N*6)_X1#P:/$\C_P#".ZYDC8KM
MZK(/B#X)U'Q[-XZTG3M+N/AYX7"Z5X<\7>
M'_!WB+Q +TO9^-_$7A;5!XP30%&X^%MNJ[?^*B\,!@#J/^%4_MM;X1_^>+52_\ A9^UD+&]\W]K?0@/LM]_S;?X/!QCL#\0^<=@2,\;BK8!\Z^*
M'[=_A/X;?M$0_ .Y\ >.=M+7/%>F>,/'VA_;% \6:YX*\,^)AX6W,64MX=\4_V9]]:C_R#;[_KQU'^1H ^
M5/V+%G_X9&_9K\^[\^;_ (4G\./,E 'SM_PB^F_-C=QZ8[8Q16S^P]_R:!^S
M?_V2'P7_ .FB"B@#_'7F\5>*_P"WM9UO_A*?$G_"17']H6%UX@_X2/7O^$CU
M+1_^1;_L#_A(??PK5C6/B%X_\275S?\ B3Q_\0-;N+C1M/\ "]U>>(/&6O:K
M]L\+Z/\ \B]H/_$Z\5MXH> O^"?]_X#^*_BSXM>#O''@;XD?'C]LO7_ /A&]7^#>K_!'1?"A^*'PDT/
MP9X5_M;QAX3^)_C/Q-_P@'BO^QSCH:X'P[^PO_P30^('Q&_:?^&/A^']JSPE
M#_P3S^/'P?\ !'[07Q$\TGP]X8\*_\
M%I-<\&:YJW_"8>$_^1H_XI4CZ4'0?@#XD\;>,/&,UM-XP\8>+/%MS;Y^RWGB
MSQ'KWB/^S>W_ #&^O_,O<_3Z40^*O%5GXBA\86'BKQ9;>,+.Z^WVOBRS\1:I
M_P )'_;'_0>_X2''_"0=<<>V*_I T?\ X(5^ _['^&_AOQ'XV\:V_P 9;C_@
MHE?_ O^+WA^SOQ]BT+]A#_A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MR?LK^,C>J>,G)_:.&T>P]?_ $
M?BSXU^'O['/QR^(5C\0?$'BB[US6OVA?B#^R#X%^*WC;_A8OQMY\,OA;JV[5Y?%_B?Q1*ND:Q\36\(:D_B7Q;X2\ >)$\&^+7W>#PR_ 7PV_:-
M\6:SI?P+^"WC;XB_$'P\GQJ\,?VC/V@/"G[7GC3XBV.O?##XJ?"_P#:
M$\2Z3H0\;D>"!^S)\1?&?Q%^$_A[P?XK\(_"C_A!!_PBNL:"/!QQ08'[9?\
M" _MY_\ 1RO[.G_B*_C3_P"B-IW_ @?[>?_ $MO_%/P7X2\)_M(>+_ (W>.OB_^SS\#=:_:(\"GP)I?[6GC/X6?&?XG^&/ ?[:
M6K^&?@E\8_#OA[PP2/VFO^+<^'A\,-OC/Q,!\:FTEF&6\2R&OT>_X*&?$'X=
M3_"E-)T'X\^.='^-6L^(_'/PP^ _@7X)_M##X4ZKK_QX;00WVGQOK^BZV-N@
M_ ;M^B-KY1^&G@G]LR;]JC]JN"P_: ^ =OXA@\.?L[_V[JD_[-WC+[#=YT#Q[_91
M&E#]HS@XXW9'< Y//Z=> (M:A\#^$4\0^(-/\6Z_:^%/"\6K^)M-@4:9XGU9
M-,5=5UW2>3N3Q"^Z1#D!0XVJ!@5\]?"?_D\K]L+_ +%/]F+_ -,/C^@"+_A
M_P!O/_HY/]GC_P 1:\9?_1&513X9_MQ17,EY#^T5^S>EU/%]GN[W_AE;QDMY
M=[<$9Q^TMVU@ZG\O@\?%FP/\ ;_AA/$0##/A[;JK'H1QG\_\ X7>,OB?\7/\ @ERWA/1?
MVFX/#/[3.N>#/BCX9TSXL>/_ (BVGAV_TS6? 7QCU;P%JRZ1\5_"P#>*?"O@
MU1I7PO'Q_P#!@D;Q8QT+XB97Q?XT56 /MW_A ?V\?^CD_P!G#_Q%OQG_ /1&
MT[_A _V\_P#HY/\ 9X_\1:\9?_1&5^4/B/XC^.O&7P5L-9\+>,-0\%:3^RQ\
M:_VCO"W[0W@/7O\ @HW\2/#I^,O_ COPPT3Q$-4^&?[4JZ$_C'XA:%X,;QQ
MI1.A>,QX67PEX]_XI+QGM'A@L>0U3]J3QQXS_:P^&?CW0?B%\5/#'P?/Q$_8
M8\,73:E\4M5TGQ!\)6^.WPYT7Q):?L_Z_P#LM-KML\ ?\)'XN(WCX0L?"X!^QO\ P@?[>?\ TM -'*_LZ?^(K^-/\ Z(VOS2_X**_%3XU>'O$NH_&;X/?$O4_&'A%/AK\+8OV9
M;/X._M'>#O!5AH/[05G\;/$FD:O_ ,)O\,_[90?M ^%/BJ?^$)^%X\/[?'2M
M_P (W\2O"?\ PB7A5G_X3VOW[CW;$\[&_P#3M^'Y\YH _P F'_@MM9^+]._X
M*G?M=V'Q$\2:3XM\66GBOX?'4_$'AGPVW@;P]J0/PO\ 1']E>'&\5>-GT0@
M'D-XX!!R&&:_+.&;R9+::&:>VFLN?MGU_$=OUK]?/^"^/_*7G]M?_L??A_\
M^JO\!U^1-F+#[58?VK-<6U@;K1O[9O+.U_M75=-T_P#YF$?Y%!Z"V7HOR.PO
M/BI\5-2U31];O_BI\4-2UCPO=?;_ YK%[X\\9:KJN@ZSS_Q/O#WB+_A*3_8
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MZ/#K?B37-;M=#T;^QO#EGK&LZ]JO]@Z/_P! 'P]_T!M#_0?3BOZ/?$7_ 2W
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MIZM\,M&\*?\ %OM<_MS5CXA^'N@>'O\ A)^<8SQ7:77_ 1\_9=U[_AI_P"
M_@#]ICPWH?Q.\!_\%+_A_P#LA_!?XX_$S1_B+C7=0\2_"_5_$G_#/GB+P1HG
MA8_\3T_$72O#W_"5_%!0?"GRG)Z _EE\9/\ @IY^VE\=O!LW@;QY\2_#=E8:
MYXC\#^//'GB#X=_"KX7?#+QQ\9?&_@/_ )$CQE\;O&_P^\*?\)!\0-;\&?\
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M>P_M=?M"67[5-_\ MI:5X_N-$_:0U/XBZA\6KKX@:7HV@V/_ !7&L ?VJ/\
MA'L?\(__ &'XAP/^*/R?7Z 'ZL? G_@F'^R]^T9\ M6TGX7?M<_##6_B=XC_
M &V_!'P#^"_[1.J>$OCOI7A3XC?\)W^S]K&L?\*;/PG_ +$SH_BIOB-G'C#Q
M"" %.3D@'P[P?_P23UCQ)X5^#/B'5?VI?@_X2UGXB?!WXH_M*>-_"=WX-^(V
MJWWP:_9X^ VJ>/-'^+'Q0\;^(?#&A_\ "/ZR/[;\$?\ "'^$] \/?\5]XJ_M
MBO!+G_@IE^UZ_B+0O%6E^*?AOX2F\(?'CP/^T9X3T?P/\$?A?X'\.:#\7_A7
MX-'@3P1KVE>"=%\*_P!@?V'_ &)G_BG_ 'YX-<9X;_X*!?M7>&/'/PH\?Z+X
M_P!//B'X)_##X@? [P;;WG@WP;?>'+SX0?%/7M7UCQM\,/&^DZUX5_X1_P"(
M.A^,]<\;:KC_ (3,9]J /MCPW_P1MN=8N+GQ/JO[:7P+\*_ W5;#]E#7_A5\
M;+CP%\9-5TKXL^%_VOSX[\-?"C_A'_!&BZ'_ ,)!HOBH:YX('@_Q9X/\9C'A
M;MSQ6OX@_P""3-YI?P\^'UQX_P#'/PC^ 4/PST/]M;Q9^U=\>+O6/B-\1OL7
MA;]EC]I31_@KS\)]&\*_]!O5M*T#PI_PAF?^$J_M@CXCG%?%'BK_ (*-?M>^
M-K[Q5>:W\1=#^S>*/$7[/'B+_A']&\!^#=*\.>%1^RQ_PD>L?!+0?!'A[PQX
M4_X1_P"'_P .?A7_ &MJI_X1_P &$];^Q
MGX[VNL^'_$'PJ^'/B/P/XJL/VC_B+_PM/XVZ%XW\$ZUX5_X1_6M#\9_$;_B?
M_P#"'^,_^15STZ4 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M7C[Q)\-OB1?%#Q?X-\">!-6\9>(=(UKPK
MC_D!^"?!/7_D0/[']J /I3P__P $8?C3X@^"/Q(^-=M\3O#>B6/A?6?VA[#P
M'X?\<> _BAX'U3QYI_[.'_([_P#";_VU_P F_:YXR_Y%_P *:!XRX\5>*M(S
MC%='9?\ !$SXEZQI'[,GBBS^/W@;3?#'[0_CS4/A]_:GQ$^%7Q0^$FJ:#XH_
MX4YJ_P 4_P#BB-*^(/A7P3K_ ,6SXRT32?$'A_PH/^*7_P"$I\?GVY^0?$?_
M 4G_:]\=>%_B1X5^)?BKX?_ !1MOB)XL^)_Q!NO$'Q,^$'PY\<>-_ ?BCXI
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M5\!^)_'G@W1_ >JZI\$!K7A7_BTG_$CTK2?#_P#Q1G_0'T&O%OC)^UU\M\-_AQ\(O'%_X+TSX;_">_P!7UGP[X'^'_P .?!OPYTK4_'&L:9I&CZMXR\0G
MX?>%<^)_B-XBT/2M*_XJ#\NU!)\XT444'0%?Z9?_ :[_P#*)CX:_P#96_CQ
M_P"K.UJO\S2OZY/^"//_ < ?LJ?\$[?V)O!O[-/Q>^%_P ?/%OC/PYXW^(_
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M%_\ \\:@YC]%?%G_ 3H^)?Q9^+>C?&GQ[K/P8T3Q/\ $V3]E?XC?'O7=)\!
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M;>:?K'P[\=^!!_97_%Q\D_VUJH&>,]!M!&/=?^(NW]@O_H@/[5__ (3OPO\
M_GC4 ?H--_P3\_:$\9_! ?#3XC^+_P!FOQ[9V'[2OQ7_ &A=3^%'B#P%\11\
M _BG8_&K7?%_CK5_ 7Q7\/MKO]O7UC\//B+XUN]?\)MS$Q\.:!_PEWA5@:]\
M^&7P8_:P\"_"#Q/^S?I_B3P)K6@>%/@KH7@CX=_%;X@VNM7U[XO\<>)-2UL^
M-1_9&C>*SXBT;X;_ M\#ZIX?^&?A+3]>!\6DZ0I/BL)Y@'X^_\ $7;^P7_T
M0']J_P#\)WX7_P#SQJ/^(NW]@O\ Z(#^U?\ ^$[\+_\ YXU [/L_N?\ D?H3
MXU_X)L?$3XJ?LY?L[?LY_$.7]F36+KX2_"BY^!/C/XQQ_#CXBK\1;/P"=+T?
M1?MOPISXJ&A'7/$.A:.$\5>$?&1\4^%&\4;?%V" OA<>MQ_\$XK?P5^T;\-O
MV@OA9\?OBSX"M?\ $_Q'\&Z/X#TMMIT)?$:Z
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M:WH_Q8^'/A?PYX;L_AGX?UK^DWQ
M-_P=2_\ !+[QCHNI>&_&'P>_:6\4^&=4M3;:OHNO_!SP%XB\.W6GL,8\0Z3K
M7Q%VL!UVNK*3@L"5%?YYE?H?_P $_?V=?V9OVF]4\?\ @;XTZK\=/"7B'0_
M?CCXH77Q8\#77@W2O@?\!_ _@/P;_P ))_PF7Q9.M?\ %0:U_P )GKG_ !1_
M_"'_ /%+_P#(R4'/8_J\TG_@XD_X(L^&/&'@#QKX5_9G^/'@R[^&E_\ $#7O
M!&G^#O@C\,?!OA?1O%'CW0O#GASQ'XH_L#1/B.- 'CC_ (132O\ A'E\0C!7
MPKXCUX@D>)-HZ>W_ .#DS_@C#9^%O$?@>S_9/^*<7@WQOM\(]XIU!MN=2U_P /CQ6/#_B76\KDC4MQ/R\\"OXU/&_P'^#>C_L)_!_]IGP-
MXP^(&M_$CQ1^T%XH^"WQ&T?Q!HVE^'? ^@ZQH_PO\-^//^*(_P"9@UK_ )&'
M_DME> _ _P'U[^Q_$/C+Q#X(UK_ (NA\6_^9A\8?$+P?\*O^15\*>G6@+']5-Q_
MP
M+&;PP%RP1/!;!%4A0H"Q[8/$W_!R;_P1G\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M)3XC*,_*I8*JJ3P,#BO&/ W_ =!_P#!/WPU\>?CU\4-0\!_M+OH'Q,T;X+6
M/AVWL_A[X-^W6?\ P@6@^/#X@.J@_$; (;5003GH.AP1_(]^W)^SK\$/@;I?
M[,'B3X.7_P 7/#=U\>/A!_PMKQ'\$_C9=>#=6^)OPET_^WO^$;\$:]XA\0^&
M/"O@G_DJOA7/C#X>^#_SKX%H"Q_H1>._^#H__@E!\3?#USX0^(WP)_:!\>^$
MM3'D7/ASQG\$?AAXB\/:GP0=_A[Q-\1]KX'WMF\1ZE^S5^T#K?_%JO^%&6OAO4_A#\,+[P!H_PP_M\:U_PAVD^"3\1CH&BZ%X
MBUW_ (1W_A+%_P"$9VXT?05(*^&\#^3K]G7]GK]FSXP?LJ_M/_$CQ5?_ !L\
M$_%']G_XMRW7K_P"WA^P'\'/V7?V<_AO\6O &N?%#4K_Q1XR\#>%]&\0>++K0=5\._$[P
MOK'P;\-^//$/C+_A'M&\*GQ!^S[KO@S7/$/_ A__"K_ (J_\55XJ_Y&V@+'
M]0.I?\'(O_!%[5_#OA+P?JO[)/Q-U+P?\.KDW'P\\+ZI^S-\'-5\.> M0]?!
M/AYO%9T[1B,?>\'!CU&<%JW=3_X.<_\ @D9JOCC2OBEK'[-WQIU3XHZ'I[6&
MC?$.]^ 7PYU?QMH=BPP-+TOQLWBH^(M%53R%21 M\%OCQX5A^-GQ)_MRU^ ]_P#M!?$3X=_%7]GWQ'X'^"6L_%37_P#A&_$/@WQ#
M\)_^2H?#[6\?\D]\8>,S_P (K_PE7B3ZX]F\>?\ !/'X ^#_ (\?LS>!H?"O
M[0&I6'QX^$'BCQE=?">\^/'[-.E?V#XHT;QE_8X/_#4O_)#]:T/_ (17_B?_
M !"\'^#/^$H\5>%3_P 4CSQ@"Q_1_#_PMUMX"\1V_[.OPH/B+P'8ZMC6=4TSP3J__ EF_1AG5=4WZ;X=D"R?-O7YWW>R
M_P#$6M_P3?\ ^B;?M6_^&X\&?_/'K^+S3?V,_A7-_P %.K_]A^_\?_$"V^%%
MG\;O%'P_M?'%YX-_LKXFWFCZ/H/_ DGA[_BGO\ F"_\)GKG_%/CQASX4_YF
MZN'_ &_/V;_ W[+OQD\,> / T/CC3?\ A(/A!\/_ (@^(_"?CC6=!\MHUC_ (23'@WP]\6/A\?^$?\ BWH?_(O?\5AX,Z?\BCF@"]_P4[_:<\"?MF?M
MV_M#_M,?"^S\26/@3XL>(O"^L^'8/%&G_P!E>(K,Z-X,\-^&\ZMX>))Z^'B>
MI(]37PQ9WGV.^L+^&&WN9K*ZT>_^QWEK_:VEZEQ_S,./\>1VQ4%%!T'Z7ZO_
M ,%;?VM]>\<^ /'/]E?LX:'?_#OX5>*/@9:^'_#_ .S+\.?#G@?Q5\!_'F@_
M\(UXA^#?C;P1_P (KCX@?#C_ *D\<>%>3U-MXD7?Q4\+_%JU\6CX0?##^UM"/@/X8'X6>'OA?X?!\*G^Q?@Z/ASCP\/A>,>%
M"%'4Y)O_ ?_ ."8_P 8_C!^SMH_QYTKXE_"CPWJ_CSP'\=_B7\!_@IX@UG7
M_P#A9GQX^'_[+&?^%\:]X(_XI7_A']%_X0P G_A#O&?CK/BK_A&C7G_[#G[!
M7Q:_;Z\7>-?#GPR\2>"/!.C_ \\'+XF\1^./B7MA@G6?B+XR/A_Q#_PK_PAC:J^&_%S,0H) MGP'\4?LW_#K2_AG\*O!OPX\.? GX8>/-=_X2/QOH7P2\/:+_ ,D_UWXJCQ#X
M@\/?$+Q@?^*K_P"%?>(_%@XX%<#^T)^V-\>/VG/#'PN\(?%G6]#U+0?A/I^H
M?\(Y9^'_ ;H/AO^T]0UC0? G@/Q#XR\;?V+SK7Q&\9Z'X(\$^'_ /A,#P/^
M$;/'6OI^S_X)._'/_A _V?OB=JOQ&^$?AOX>_&3P;I_Q+\>>+-8NO&6E>'/V
M=?A?K'PO\-_'C_A:'C?Q"/"O_"/ZUH?_ KKQ#X?'_%JO^$H_P"*K\2>$O"/
M_)2/&V:_,&;R?M=R;"_&I6'VK_1;S[+_ &4=2T?_ *#W3GMZY]N: *U?ZMG_
M ;^_P#*'C]AS_LG/BC_ -6EX\K_ "FZ_P!63_@W]_Y0\?L.?]DY\4?^K2\>
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M4!X#TG5/#WB'13_PCW]A\C_BL/M10!7HJQ10!7HJQ10!7HJQ10![/\ "O\ 9K_:*^.7A[QMXM^"OP*^+'Q:\,?#
MNU&H>/-?^'?@/5/$ECX5T\_\5)_Q-M6T7H<]_6N/O/A7\3M-^'.E?&"_^'7C
MC3?A1XC\1ZAX7\._$R\\.:]I7@?7?%!_Y@.E:L/^0UKFM \ ? J+XK_M":M^VQ\)_@G\:_ 5CXG\._LR_ ?XV?$;XC>!_A)J?Q!\=^#O^
M$#U7]H'XL'X>Z'XV_MGPKX,T/5O^$?\ "G@__A!C_P )3XI_*K^GZ,_[07_!
M-7X._LDK^V9\&/B=^T'K/[;?A;Q=\*_@9_PGGQ%\1^+](^'/CWP=I'PLTOP;
MX<\.CX<_V!HI&MZKJOQ/_L ^)@#X6(\6@DAL!SGY*^!OV=?C]\2_AWXV^,'@
M#X+?$CQM\*/A?S\1OB7X:\&ZKJO@?P&/^IAU;G\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M@"_[*_Q\'QOE\.'QD/A/_P *YU0>.#X7S_R.(\/9YT0<_P#%8=<\=:\O\,?
M?XT^.OBC-\%O!7PE^)'BKXP6]_J%A=?"?P_X,U.]\LZ/_ ,C#CP0?^*@S
MX,S_ (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MRZ%\8-4\!ZI8_#+5]0_["W;KWQ^-?T>?LU?&C_@G[\$_V]?B_P#&;X>_M&_
M;PS^SYX?AT:VGU?Q9\7_ -JH?%CXMB#6]5/A[PH/CL?%'BH?V1GTKY9\#?$K]G'0?^"7/[0/P/UO]J/X,:+XH_:!'
MP:T_P'>>&/'G[07C#]HW7O['^,FLZR?!W[4?PF^(/A,?"_X2_#KX6Z)JW_"0
M'_AGD^%_^0/\O_"39- >W?9_? ?XH>-OA3\-
M_P#D?/B7X;\&Z]JO@CP>/^9A_P"$AU;KT!Z_7K7@]Y_QZS?]>A_F*_J<_9+^
M.G['_P"SY^QKXG^!7BW]LSX-^(]>^&$__!03PI:_$[0[KQEI7Q8^''_"T_!G
M]D>"#^Q)X)'PX_L#XM>"?CK_ &5CQ6/BH1_PBIU?7N?"XS7\L\L,T.G20H?L
MW^C$_9P/J/IGN1[<<= V>S]'^3/]BO\ X)P_\H__ -BO_LUWX'?^JZ\/44?\
M$X?^4?\ ^Q7_ -FN_ [_ -5UX>HH.%[OU?YL_P [/]GO]M[QG\'_ (*_L\?
M'Q5^QW^TAXD\*_#OP'_P4 ^$GQ5\0>$]&\9>'/$>O>!_VY/^$;SKWPF\0_\
M"N?^)+\1O!G_ CW_,Y_\C36]XX_;>_X3;P/\;_@;JO[%O[7G_"C]<_9:_9/
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M *(Y\6/_ U'C'_YE:_VKMB^GZG_ !HV+Z?J?\: ^L>4?O/\5'_A3_Q@_P"B
M.?%C_P -1XQ_^96C_A3_ ,8/^B.?%C_PU'C'_P"96O\ :NV+Z?J?\:-B^GZG
M_&@/K'E'[S_%1_X4_P#&#_HCGQ8_\-1XQ_\ F5K[ ^ /QW_:N_9[^%/C_P""
MWAO]E?PWX_\ 'Q0\9:?XR\>:7\9/V5?&7CC^WM0T?0<^'O^$A\0_P#0#\&?
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MX33Q5_R6X_\ ,U=.*_UPJ* ]IY?C_P _P ?;]J+XI_M1?M=>++;Q_\ $[]F
M:W\->.;RZUC6?$?BSX9?LW>,O _B/QYK&L?]#O\ ]!GGP]_Q;W_H0,U\P?\
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M T/P9_:W_"0?\(AX-/A<>*03TX(_U9J*#/VGE^/_ #_ "']-^/W[6^@_"^P
M^$OA7]E?P7X2\,7EU\+[_P"(UYX>_9!U32M5^/'_ JK7O\ A)/!&@_&[_BE
M3_PL'0_[<_YD_P#YFKKGM74:O^U1^U=XDOO T.M?L9_"?4?A=\+_ YXH\+_
M Y_9[O/V,M?_P"%'^#_ .V?&7_">>(?&7A[P1W^(WC37/#W_(X?\)SR.E?Z
MW%% >T\OQ_X!_DH#]L;]OO\ X6A<_&F_^$MQK?Q7U3XJ^*/BCK/CC6/V5=>U
M75=>T[6/A?\ \*K\0_"_Q%_Q2H_XLX/AS_Q3W_"K^/QKY]^/7B;]IS]H;6O!
M6I^+?@5XD\*Z#\,_ >G_ T^%_P_^&?P'\9>!_ W@/P/H^O>)/$G]EZ3I/\
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M/^&??^%5^(=4\/?%C1?^$)\/_P!AG^UO$/\ Q1_C/P-XH_X0#P!XD\7M@%%!B?Y;'[+?[;GC_P#9]\.^ / %Y^RO^TAKG@G_ (NAK/Q?L[?PEJE]_P (
MKXH\><_ ;0?VM _\ "-^ Z_,?XV>&_B=\5/C)\5_B=X;_ &9?B1\-M!^)'Q&\4>,M&^'_ (?^
M%7C+^RO >CZQKW_"2?V#X>_XI7^?X<5_LKT4&GM/+\?^ ?XJ_P#PI_XP?]$<
M^+'_ (:CQC_\RM?ZD/\ P08TO4]%_P""2'[%NC:WIFJ:)K-C\._%$6H:/K>E
MZKI6J:9MFDZIXA_X),_MX:#HNE:IK>LZI\!_$-MI^CZ787.JZKJ1_M+2.+32=''F7AP2
M1MP< YP.#^L]% '^8O\ \-]P>/M*\0?#3XU?L,_M9W?P?\4_ +]@GX<79^%F
MJ:KX.^)G_"S_ -@4^(QX>U\ZMXF^')\(?\*Y^*G_ D/.@ ,? /89&*L:M_P
M4-F^+&O0^,/VBO\ @G1\;/']_I?_ 4#^(W[9EIX'\/_ /"96/PRO?"_Q3\&
M>'/ 7B'X8>-])\3_ X/]M^*O#VA>"?#WB#PGXPX\*^*?%7_ "-_A/ K_3@H
MH _S$OVHO^"@OB3XW_!WXS?!;PA^Q)^T1X2T;XH?LR?L\?LW>'-4U3PE]A_L
M'_A2O[0/COX[_P#"9_\ "$?#[X'^"O#^B_\ "9?VK_PC_P#PA_@S_A%SX6R:
M_#S_ (4_\8/^B.?%C_PU'C'_ .96O]J[8OI^I_QHV+Z?J?\ &@V^L>4?O/\
M%1_X4_\ &#_HCGQ8_P##4>,?_F5H_P"%/_&#_HCGQ8_\-1XQ_P#F5K_:NV+Z
M?J?\:^0?VIOVQ/@9^R9X8M=:^*OB"=]8U0'_ (1/P-X4MO\ A(OB'XJN5$@
M\/\ AQ6\R3#D!M:=ECVEL,77% ?6/*/WG^0?_P *?^,'_1'/BQ_X:CQC_P#,
MK1_PI_XP?]$<^+'_ (:CQC_\RM?[.7@7QSX;^)G@GPKX_P#!FHV^M^%O&N@Z
M1XH\.:I!RMYH^L::NK:3=?5@1QZY]\]YL7T_4_XT!]8\H_>?XJ/_ I_XP?]
M$<^+'_AJ/&/_ ,RM'_"G_C!_T1SXL?\ AJ/&/_S*U_M7;%]/U/\ C1L7T_4_
MXT!]8\H_>?XJ/_"G_C!_T1SXL?\ AJ/&/_S*T?\ "G_C!_T1SXL?^&H\8_\
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M^- ?6/*/WG^*C_PIGXP?]$=^+'_AJ?&/_P R='_"G_C!_P!$<^+'_AJ/&/\
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M .BVWC/5-%_X0?XBSYP03JV/^%7_ !!88('_ CA\+=MX*4_L?\ [09M;'P?\:=#\/\ B:?!3P-\2,?#KQ7,-N&5;/Q.L8U@DXP?#[N"
M20<+@#[V@N(KB&&:']]#/D>9['U^I!X]O6@"Y1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%?)'QO\ VV/V8_V>XKF'XH?&3P1H>M@ P^%--U >
M(_&]V3P<>"=$+^(<@=B@!_O'I7Y#_%?_ (++>/\ XF:O-\./V+_@]K=[K]P?
ML5KXH\6>'-5\=>-PW'_((^"/@#)R#P#XR\<>%0 M=^$!UCX8?\*PM/%NM1ZA:Z#J?Q \27)U4ZN06&E^"?AGHFB-X@^(.N88?V4N
M5\+JRG_A+LQLI?\ F6\-P_%KXP?$6PAFTKQ9\8_VG_BQS=6=YK/_ D?CC4O
M^QAU;_D7_A]\.?!G?_F5?"O(^OZ2_#'_ ()F?MD_M.>-/^%K_M/^-=4^&]QJ
M?_(0\6_$"ZT'XB_&^\T[G_B1>"/!.C'_ (5=\)=#XY )(R"?AX :_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M].U?0'AG_@I)^P?XTA_M6_!M[DX_T?5?%UKX5O9L9Z?\ "3_\(X,X].*^
MT=5T?3=8M_LVJZ=8:C;8'[B_L1?#\FS^@],FO)-<_9H_9W\3C'B/X$?!S7NG
M.J_#7P=?G'/=M#.?QH OZ-^T!\"O$*?\4Y\:/A1KW?&C?$;P?JA[?W-<)_S[
M5Z5I^NZ/J<)ET[4[&^3^]9W8ON<^QS^E?'.J?\$XOV#M?M67@/0M*/X'1U3^7^!Y@?\$NOV!RQN;;]G'PUID@[Z/KWC32OP_XDWBE?K_\
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M)M?L%::3?\ YZ:IX,M=5('TUD/G\J]BT']E+]F#PNO_ !3O[/'P
M7T3_ +!_PK\&PMI^)WB1OI\GA=5!!]"1Z>I\\E_P""JWC/Q;LA^ G_ 3Z_;(^**7,7^C:IXD\
M&?\ "LM*S_U]ZU_PD?0C'3Z]J_6G2?"WA_P_"(=#T'1]%A'(@TC2-,L,X[X4
M8/M74T ?B!=_&G_@M/\ %N-H?AU^RQ\#/V>=(OMUL#KQ_R+ '8"N3O?^"=W_!1#XZRNO[3_ /P4!U73=#O(?-O_ A\&M&U/2]*
MR/X=N?#6A%@,G 7&._I^]=% 'X__ F_X(O_ +&'@!A=>*-&\M0/$1L+&[SG#+H'@!?!:-CC"^(AJV,'=G( _3/X=?"WX:_"C0XO#OPR\ ^#/A
M]X>M_P#5:5X(\-Z5XM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%?-7PI_:K_9K^.?BSQAX%^#G
MQW^%7Q0\9^ )=OCCP_\ #_QWH/B6^\-D:F='SJ_]BLX0?VW9G0@2>2 A)=U5
MOI6@ HHHH ***^ ?A
MM_8W_"<>)LJI_P! \/GQ!I(D(+%?M8PI/ /HVBOF-/VJOV?QX2^.7C^3XH^
M&1X2_9MU'5;'XX:^[:E_9OPWO=%\&:+X^U8>)/\ 0U%DT7P]\1:#XB.TR)Y6
MKC!9V8#W+P]KND>+-#T7Q)H-]!J6@^(=+T_7]'U"W(:WN](U>U75])U(M$,N<M(TNV\2^/_$>F>'-*N[\[@-,%Y?C!.1R%RP)!8 $&@#W"BOB_Q-^WK^Q9X)U[
MPEX8\9?M1?!'PWXB\=Z)X5\4^$='UKXC^';>X\5^&O'A/_"$Z]X?*WC#6=$\
M2Y(\+LHQJ@),?S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M$GQ%IWA/P)\/_#>K>*?%GBC5SML-#T#1[;[7JNIW9&MO:/?07^D:WINGZSI=Y#S!=Z?K %WI-RIYX9?F&#U/S 'Y1T=
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M\=P7?P?TRX\)WAU)=6%_\;/&>L> _A4 !$^E.KL@P:]
M6^&/Q0\ _%SPK#XS^&WB32_%OA>[U#6M*M=M5JJ@D G!)'() /4:*\.\1_&[X2^%=1\,Z3K'COPY9W_C?XC+\)M @@OFO;C4
M?B.^A7NKCP:6TDM_9&NC1=)9MI.4RH*CY6/N- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MB?Q]\$^(OB/\$/C%\.O"&M'PYXO\>?##Q]X.\+^(,*?["\0>)?!^M:-I.NX/
MW?*O[I&+#DXXR00?;** /YE/#GA']IO1?V!?A?\ LU>'?^"9/COXMW]G_ ."7Q0\1V_B[P;I?ASQ5X?T;7M&T;XKZ_P#"8_L^_''P3\4/BUH7_$H/
MQ/;P=XS\<_!M?B =8#>,,,&+^"K^QE_P4P\:_LV:5IWC^7]J?3?B;\*?V!?V
MGS\,],\-_M!ZIXM ,)GXY\4>%6) ^(_BOQ2:_KBV#U/Z?X4;!ZG]/\ "@#^9[XJ? [_ (*%ZYK?
M_!0&;PUX+_:2_P"&G/'GAR_C_9D_: TCXT:7I?[/>@_ 8^#/A !\$=(\$_\
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MK^'3_P )&0G'YYZ5^S#_P %%=)^"WQ&T#XM\!_BO\:1\6OB;X[TCP?\+O'ND_M7ZEX)NM&_:.\%>(/^%=^,OB%J_P )B?!W
M@SXO^%SXK7P'KS>#U52/"@_I)B_:4\)S?M8:M^R2-"\1V_C?2OV?K#]H:Z\3
M[=-_X1X^&-9\>7?@$:6#G_D-C7-)8G*D$8(*@;CY_I'_ 4)_8BU_P +?$+Q
MQ8_M3_!V/PG\*]3T#1OB+XFN/&FE6.E>#K_QCKP\.>$[KQ%=:R=MIHGB/7+D
M#PEXB;=X8U,E]C[-/- 'PSXN^'/[3_AK_@E=\*?AE8^$OB]^T)\7(]9\#>'_
M !YIGQ$\5:[X'^+=G\.#\4]FOZYJ_A[X??' ^(/B$?!OP]&EJ/AM?Y/%_P 0_M\_V7\(_V8/&GAO\ ;*\:_M(R?L+?M07_ ,//!?PO
M_:0_X0?5OAQ\41^VAXC\-?LG_&3XL>(1\<0?$_P[^%6A:MX&Y/CKQ3_PBOA3
M QXHR,?U!Z1_P4!_8P\0>.-"^&>A_M*_"?4O'/B_0M/\7>'/#=GXH4ZMJOA;
M5_!J^/;35$&]0,^%"WBT%V3'AA02I3KZ)\%OVB/V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M16/Z/?MI:A\3_B5^R+X8N=%^#W[4.@?$7XFZ1I_]L:9^SYH_[-?CCXW_ )U
M'6O!>KMXBT#4Q\7?%/\ PJ]ER+[X8^*O$'AUI-JWI"N$PB_2.N_MJ?LG>'_B
M'\.OA+KG[1GPEL/B-\7],\,ZS\-/",P2OA
M'

M^GB.;PM\0M8&L?8[3QI_8@+:(H?23H19_G#C !5B% /@CX6_L7_M#^,_A;_P
M2,_94^,/[.W@?X;?#'X :%X6^,G[5VH>%)=!O?#8U_\ 9P%C_P ,X_L^H1XH
M\2>(/%/_ D7Q%_LGXI?$$G/A0MX$VD@?\2E?+_BK^Q5^TC\*/B/XF^,7[)O
MPF\>3:=\._BTOA[X0^#_ (E:CX.^+/BK4]1\,^#OB]K7@CXH#P1K.N^"= _X
M4WX,^)'C?_A5WP2'B/QUXI\?> ?"GCSXT_'%L^+CX$'AC]Y+S]K;]F?3;6&_
MO_CK\-+:SG'QAEMI[CQ1I.,?LX/_ ,7WY&>?A2 W_"P!Q_PBX^_M.,>'7_\
MP4)_9V\0:/X<\0? [XH_"KXY:-=_'GP/\$?'&I^%/B]X$TRR\"WWCO2M9\1C
M5+IM:=1XE?\ X1?2+CQ#I'A+P=N\5>/E4KX/74V8,H!\6?\ !33X9_M7?$3Q
M'\&[C3/AS\>OBS\*8O@!\7M%UKX9_LL?&,_"SQ3X5_;/UD_#8?!'XG^(/$/_
M L;X1'Q1\.O!P'CM,\8ZC\0OB'^SG^P_X6\1?$<_$#7M;\$_$SXH>&_@YK'AO]H_5?#WAS_A*2$/
M_"P])\/$;_#*XRNJ^$@O_"2D#ZT_9V_X*4?L7_M.> 8?'OPR^-OAB33;W3?B
MAXIBTOQ/MG6MSJ?ASQ5NT'_A)
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M]F3XN_%7QI\%_A7\#/"_BG3-4\1:0?#FOMX:\1[K1 _
M]JCP]K0&A>*&WC_A&9"(W*.R[^8UW]O[]B[PQX^\:?"OQ'^TO\)M"^(7PWT_
MQ3J_COPG>^,[,ZMX7T_P'IA\1^.+K5ESM5?!^A8U#Q5\Y/A92/,VLIH _%3]
MCS]EW]M73?BW^R[XE^+7PN^)%IX$^$_[=?[0WQ \.1^--8M/M'PX^ _CS]CG
M1_#GAX:5X>\3_&_XM^(=%\*#XX-XB/\ PA__ G/BCQ2N220"2>U_:D_9V_:
MT^(7Q0_X*3Z!KOP@_:.^+^O?&#X,>./#7[)'Q"\+_%[P_I7[-NC_ @UK]G_
M /X1W_A3OB'X4ZQ\2/!*#XBGXQ?\)&6/B+P+XI#MXET+Q>/%V =WZT/_ ,%"
M/V(XI_A?;-^U+\%E_P"%WWNH6WPI$OQ"TG;XW;2?$ \"W?\ PC_[P2-HD?BM
M1X?;7=Z1GQ,^P;^=OI4?[67[,[_8-GQS^&"?VI;_ !HO['RO%VD@7MA^SC=?
MV5\;B/NG'PK)V?$'@-X8;[PVG?0!^#=O^P?^UWHVM/\ S0;_P#:HM_V;=5_
M:>_82\2:]\;GXC'QAHOA7_A8A\)^'O%OA
M#PZ?FP6\&J 2%DG_ &%?VF=,\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MB\;?'?XF_%X^,O@!\5=>O/BAX\UGX4ZE\$/ X^)'C+^Q?"_AWP+JV@$$^!_
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M\0@$^%74A?$Y(2,O\^ #^=7XZ_ #_@IA*_#^E_$_Q
MG\.OB-X@\9ZGX'\<_![Q,?V@=(U?P/\ ##_A"!^UN= T70O!OPZ4_P#")?%#
MXK>.?VB_%)\+*?AT/AZ<8'J'QJ^ W_!1J^\9_MYVWP-\'?'34+'XC:YX(\6)
M\2OB)XM7PM\1=7\,?\+BT4^-OV:_@GI.B_M%GX8?$#X=#X.:3XA/A+Q!X=_X
M9S\?>%O"I/A/_A+#XO\ $F1_0+\-/VHOV>?C3>?$:P^%?QG^'GCZY^#>HFP^
M*D?A?Q1I6JGP%?E=7 TWQH$#?V+E] U;)M(?C3-^U-\&K;X8GQ[J_P]3QC_P )I9_V5=^-]'TMM:U;0M((8G62OA8CQ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MG_%OQ"M-%^)_@_P]9?"34/VMX:\"/I+'QBZ !2 ?'/CKP3^T/^R__P $K?\ @JEX?\1>(?BOX57X>>/OVKM;
M_9:\2>*/BMJOBOQQI'P0_P")/XC^%6J:/XW.M^-?%Y UTZ_G_A(6/BH%KXD#
M!#
MI'P)\2#XK_&[_BWW[1GAK_A8'PY^*WQP_P"$) \''XOCPKX7/_%\A\/2<^%*
M_4W7?^"M?[(6J>)_$OP7TS5O#7BGXTZ)\1O@5\+?%WP<\5^,O"_AS2-3UGX\
M6O@76-4'@KQMXH/_ A_Q!'@WPMXXWMIZ,@\5R:,WA7P@MQ^+7P^C_ &C?A /%OP+\.>*/%'Q=\/\ _"9Z5]J\!^&/ 3'_ (3?5/$ 5MJI
MX.55/BH!B?#"OME5=K!@#\%O"'[&_P"W9XEU3]G/Q;\7/A?XT\2^.+/P;_P1
MK'Q>\0>)/%'@V^U0^)_V*?
M^$DP3X[/ XKXH_ W_@JM?>!/V=-#\-?"KXYW/Q5\#:UXH\9:?\8O^%RZGJOB
M30-0;]N7QYJ^J>#=7T@?M&>"/AAHF[]G7_A']OB_QGX:^,?_ E7A;Q(?"*C
MPQ_PC=?ORO\ P43_ &(;CP'XA^+.F?M1_"#4? 'AGQY:_#;Q)XMT?Q9;ZMI&
MF^.-6T%/$>EZ 3H[.NK:R^@BTU]509/ATRPUK2KRWU'2
M-4L;&^TN\M"#9WNG:OC[(R@$A@00W&,!@& ;*@ _E[\$_P#!/SX[>#?VC/B'
M:>%?A?\ M%^ =-\4?\%,O'OCGQW\1_#7QXU72_AUX\_9 ^._P<\>6;:II6DC
MXC9/BGP_XI&E?\)4!X8_X2KPMC0\$Y%8-[^SK_P5E\3_ !UO7?B7H_Q//BW
MP%\1?V:OV;-;^'%GX['C&_\ C+^RE^SAIGCQ?''QETCP[HWQP^$QUGQ7^T/\
M1?$?@OQ;XLT ?%[PMXJ\4^%?#I\('J0?ZPM@]3^G^%&P>I_3_"@#\'?'/P8_
M:]C_ ."7WP5^'>@7G[2'Q0\>Z-\3?!&J?'+PS>:UI/PD_:F\;?LOK\9-7UCQ
MM\+M(U?_ (6/XV;1O%/_ KJ32O#X/\ PM\^/?$_A;2&_P"+A+XQ.'^9O$/P
MF_;?U7]KW]DKQ'\(?V<_VCO@]\'OAWXW_9@,FO>,OCIXR^(OC$_L]W7_ D/
MAWXU^#OB<=9_:9\3?##PM_PCAU71SXL^&7_",?&7Q7X]X\7+\0,^"17]/>P>
MI_3_ HV#U/Z?X4 ?R/^-/V+?^"@6@_LW?LS+G]I[Q%K?C?Q5^U!K'[7&@0?
M$SQC\7/B9HWC;6=7.B_LN>,/#WA[_AHWX2D:'\*O"XV^%5\&^)5\*^%_%8T'
MXA^+_"GB@J0/Z(/V:_$/Q6_X1]?AM\4_!GQ4BO\ X4^!/A%HY^-7Q O_ 7!
M-\>/$^M?#T7OCC5SI/P_\4^)/[%U[PWKEM_8/BW)&E'Q2S'P>LFDA:^P-@]3
M^G^%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKX%_:;_:%\=_"7]I+]@7X6>%AH!\,?M)?&KX
MG^!/B&=4M+J^OQI'@_X'^//'FDG2')(TA_\ A*?#^DJS [2I*<@ON /OJBOP
M,\-_\%7?B7X6U?X@>!-4_9_\6_M ?$UOVJO^"@'P]^&'@_X02^#_ /!9_"W
M]C7_ (035]6_X375_B!XK4+XM_L3QM9\@$^)_$^514#AJ]W^/_\ P4;\:^%?
M@K^PA\?/V:O@=JOQU\+_ +;'Q?\ @QX/T_2M8\1Z#\.=5T+PK\8/!_B/Q)I-
MLO\ ;>M 'QP#9@-][PNATB^R<,C$ _7RBOR>^&/_ 4^\(?$CX]^#?A7%\%O
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MK^G_ +)7[4'_ OC^T_$1^(7Q3\;8;XJZ'_Q1Y\.^#?^$7\!> ,'_A#_ EC
M./.]&_X*!?\ !2Z\\)QZ)8:?\(/BA\4?BS^R;^S?^W5X#G^&OPBUT_\ "FOA
MA\=]=\>:/X@^%^O^'-9^)!'Q _X0WQ1X=\$Z!_PL_P#X27PJ3X3\2>+?%[>$
M1_PA)KZ-^%/[>O[07[2OP_\ VA[CX(ZO\)XOVAM/^$/@?7_V?/V<[VTNA?:[
MJ.CV_ANV^)GQEU;QOXEO0-9^'7B#7?&UF?"'A''_ EGA3X6#X9_$;QAI1;X
MV>%_"U 'QOJ'[!'[4GQ*_;<_:O\ #GC#X+:]I7P#_:*\6_M6^%[[XCZAJVAG
MP]\&?A?\>_V?M&^&P^,GP23PQ\;O["UCXQ>,O^$?TGPAXN\/^-?V>5\51^%,
ME_B$J@GQ/^FO[)__ 3LOO@K\&?VAOAI\3O$?P_US7OC_P##GPQ\)O$GQ/\
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M ,%K/AMK.G_%*U?X%?$'5/''PV^(O[.WP^L/!?PR^(OP9^+C>/#^U/XS\1>
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M\>+'XJ?!^'Q9\'-(U;X$:3^S=\9=&^!'Q7\8^(?&VM^+/^$-\?QK\1-?TH>
M5\&-(?%P8D-"%P_D$?\ P76^ %^W[0^KZ3\+OB=X@\)?!7X<_%_XG^'O$/AK
M4/"&J7_Q%T3X$>,='\!>.[1- 77@?A[KC>*?$"#PA_PF)C_X3SPN/-^8JJ$
MP-8_X(Z_%;7]<\7Z;=?M/>##\*(+;_@HMI_P@\)P? ^2W\;:!_P\(TOQ*WB+
M5/''C@_$,KK)^%'BC7V_X5Z?!WAGPL/^$8"1,5++7K5C_P $F[RR^)/A7Q[8
M?&'1+'3=#^(__!-GQV/#^G_#E;+_ ),#\&^/?"&JZ9E?%+ #XJKXV!0GGP -
M(7.OCS\7_ OP=\,? '2O%/P
MPU3XBZ;XX^*)\1'P.OB#Q /%H^&(743I.D_VJO\ PD[)X5&L,'R?#QW?(_BW
M_@M7\-? ?PN^'/Q-\:_ WQMX9T?4/'/Q \"_%[PEJOQ%^#5C\3/@_P"*?A7\
M;5^!/Q!T/2/! ^(B^(/C-_PCGB 7WB$Z_P#"OS/"Y\!88.NL8\) ^:OC]_P
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M[?!X^#_P!_V0_&MM-\3_C=^
MU1\#?VB]"\4>+?AW+XV^"?C?]EG2O#NK>(!H#:)XK;P_\0P-"U;_ (3!O^$>
M+'Q3X7/_ BOA$#Q>4 ^I/V;O^"B'AC]I3]G_P".'[1]A\,]?\$^$?@I:>.M
M2O\ PQK'BWP9JWQ/NK'P!H?B36-6T+QMX&T;6SKWPD\;D:$4;PE\0\.,J#N!
M+1@'S+^T3_P2A\:_%KQ;XYC\ _'#P1X$^%_[0OP-_9Y_9]_:,\/7_P (7\4>
M-M-\,_L]Z[?>(O#^I?L^ZM8>*O#GA_P#K?B$ZL=-*^-/#/BO2?"; >+](7>@
MTH>+?';_ ((3ZC\5OBC\>/B)X6_:7O? ^(OQ%M=9^$MA:>!#JEQ\$_AA\5=
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MA?\ KXF>"O#'Q ^!_[7_P 7_A;\+/B1:_!S53^T%H_P)^#?ASQWX?\ &/B#
MQ;HWQ(/B#X2^%?#VNG6,<#Q1XI72 H7&I>&,]FW_ 6Q\+^"A^SMX/\ B]\!
M_%_AGXK?%#X5?!/XF?%GPEX>\7>#O$'_ JRP^-WC(>!?AZWA_2AKG]O_%D^
M(M0+>('\(>#$E\5>%O"V'\78)*D [;P'_P $R?'_ (4\=_#C5_%7QB\!^*O
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M-H^7Q*H]X_8R_P""BOA?]L7QK\=/AKI'P[O_ ;XU^"6D^"/%&H6EK\1?A?\
M4O#GB30?'9\1_P!D?V1XT^$OBGQ-X>_MH:YX)\0V'BG0,J\9106?MV!-*\ _L9?'C]D'Q#XU;4[;]H'7OVK[OQEX^\,:"OASQ$-._:D\8^/=7+ +N
M+:[X>\+>.%\/?V\>^CJ5 *L3\HR_\$WOVNUT+]G/Q1!^TE^SMP5\":H_[,/B&Y^$NN_ ?XI?"_P "_"O5U\0^!Q\;_P#A(6^,F? _A[QM$O\ P@@?_BD3X1'A$FO /V6/^"M/[1-WX!\:>)OBG\!?BO\ &;XK>,/'?[6'
MQ3\*_!+P/?\ P'\.Z3\(?V4?V6?B?_PJSQ#K^E^-?^$H#>)]NM@: /#_ (R<
M>/O%?C[2?%P\(?\ %(#PLP_2;]G7_@H-X9_:F^._B#X7?!WX*?%#5OA_X=^%
M/PC^*_B3X]:I=>"]*\$:=8?&SX<^'/BG\*M*7PZ_BO\ X6;K&N^)?"WB#)'_
M C*IX7?2"S]6:@#Y"\/?\$8;7P3X,UCP+X5^,MC>V,O@S_@F5X-\.ZKXH^'
M']J>(K+3_P!@?XGWOCWQ"=5+>*@&_P"%JG5 " 6/A0G)_P"$G'3A3_P1B^*-
M_<:UX57]I3X>-\*/#/@K]O\ \"?!O2[;X#FS^(VF6'[? UC6/$6I?$[XA_\
M"Q3_ ,)\?!OBG5&VG3_#'A9?%7A@;"RLZ[ON+X.?\%)/ ?Q-_;+\4_L8WO@*
M[\+^.-,\/?$_Q/X7\46?Q&^%OQ$TK7=.^%GC+1O#7C2TU72?A_XI\2:_\/\
M7?\ BH-)UL:!XQ5&*,H)+*C'PKQ/_P %>Y=/^+>O_";P5^Q;^T3\3M8L_C1\
M;OV>O!>M^'/$_P '=/TOXC_&?]G_ ,/Q^//&VEZ -<^(PDT/PL/ARMYXA_X2
MWQ"$56/_ B;Q>8JL #*U'_@E=\2+KQ/XZ^R?'+P7;> /'GC;_@GU\5)M+O_
M (5:L?%&F?$W]AQOA7HXM[36/^%B?\(X/!/Q4T+X5(=C>&AXJ\+>*/$C,C.J
M$GSN^_X(R?$/6/#&M_"+6_VB?!=S\)/!?PR_;F\$_LU'3/@W=:3\1O#E_P#M
MQCQ)_P )MJGQL\1#XC'3_B%_PCK>(=I'@WPSX"/C\9/C#C:6]3G_ ."S/PKN
M?#OA_P")G@GX"?&3QE\&M(^%?P ^-GQ\^(^G7/@/2C^S[X7_ &C]4/A[X;?\
M)#X>UK7AK_Q UMFTK6&\6+X,W_\ "+>%K(R,S'('1WO_ 6&^$WASQ+XAOO%
M?P9^,_AW]GM-;_:4\&_#_P#:/D/@[4_"GQ'\;?LLZ5XC\0_%C0-)\#Z/XJD^
M)^AJ(O!'C8>$]>U[PNB>+'T9B-AM?X@O^S1+X(\67OPS\9:5XC^ _B?]GSX$ZM\(/^%H?"CQO\/?B-X*U_1/B+NU
MB[\7>$N?^$68V1\)>+LKJ)8?M+\/O#VJ^%O _@SPSK?BC5O&VM>'/"_A_0=;
M\9ZY;)9:OXJUC1=+L])U;Q?K!#.!K7B%@VMN,L-Q8 _Q5^6_[$W[M:>_:MGC?X?>*?$BZSHGB+1/#GAX+H$FT>%G\.ZZH(9PI^'?B#_P %?/C'XRUOQ/\
M$+P-X-^)/[/G[.U[^PUXP_:*^$_B7QCX.^#GQ&\1?$XI^U/\"/A!X)^,GAS2
M#\1S_8NB'PMXWU8GX8^-#X89O^$CT#Q:6("[0#^G2BOQ>O?^"NO@S3]5_: T
M _!#Q]=Z_P#!?XK^#_@3X8\&S>)/AWI?Q:^+WQA\=^,#X$\#:'9_##6/%:>(
M? 7A3QEKX77_ M\3/&93PJWA/.KEQC:TVC?\%:=.U7Q3\-?AC!^RW\:T^-W
MB;XK_'#X3?$OX73>(_A,Q^#.O_LYZ3X'\2?$W7O&?CD^+!X?U?P3_P (3XY\
M/>+_ EXA\/;AXHC!C14#94 _9NBOYMO^'T5ZGQ.E^,/C/X5_$CXMQ-\^*?CQK.J?M*^ _A!\*?&7A_5=%\6,?A]_PD0U;GP_XT;P
MQ_PC*ZS_ ,)5(S(3CZ9^'_\ P6$\._%>^^#'A3X=?LS?&/QI\3?C#\5OB_\
M":/PQX:\1?#K_A'O#.H?!9? OB+QMXH_X67XFU[PSX=\2?#U?AUXUB\7_P#"
M1^'MX.IZ/+X-$M**** "BBB@ HHHH **** "BBB@ HHHH X[Q5XJ\->!]!U;Q5XMU[2/#GAW1+
M'[5JNMZ[?VVE:5IUNH"EM2U.1RJ $@^G3AB5)Y>R^+/PUU>'44T_X@>"+PZ'
M=ZSIFL"U\6Z#>?V;?^&VV^(M-U4K>M@^'5^;Q2A*MI>M>_9XUKPI\/+#^V/%&B?$#X%_$BWT*XU33=*A\4Z1\)_CA\/_ (J>)/"MNBTZ+Q=H7@O5/#\L\K*D8OE)8*Q-?%7[2O\ P24^&GQ4E%I\!]6M/VMJ_QI\0)_ ,VMZ7K/Q ^)?[2/PN'@)?$6OZI'+*9- E^:;Q]H2A1XIA= ZAU<
MD _5CQ)X]\ >#=(L-9\8>-/"7A#1M0NA;66N>(/$6E:7I5YJ%X/[44:5JNL,
MEA> @73*K:5?6^HZ9J%J+G3-2M+I;VSO+$A674%;
MA3C(&0S DD9ZX_"CQS_P2D_:!^(.K>*[37/C_P"&9O!DVLZ-J'A[3+U?B-XB
MM[\:1I?B/1_#IUKP3K?BH?"[X=CX5>%-7_X5CX3'PL\#@_$#PID_$4$\"A#_
M ,$M_P!J6^U3Q%I_BG]K>#2?AS?6'A#3[?P/\-]1^,_@2QN]&^&_PN^+?@6W
MU0G1_B(O_"+ZU9^*O'O@+Q#>'PZ=OB#_ (0>(7!C+(" ?N@?%OAH>*%\-
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M,F\5KXLDUF2-WA$8-?:WQ7_92_9B^(GPC^'7[-7B?2+?PMX,^!__ A/CSX-
MZ'X+\:ZI\._%'PP_X4G]ETGP-XQ\$:OHFNIXAT7_ (0U630!XAVE0-592Q=P
MY^,?@!^QG^UE^S)%<_$_3/'GPQ^-7Q7_ .%4^+O!>@^%O%5YXR71[G3M2^)/
MCGXM:'X-\+>.-99?$&FZ%'JFN>&]'=O%OF(D+:W,[*KQ,WT1XP_9D^+GQ/\
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MQ_XET-]3UX?$<^(RG@;0M=T/0)F\&*/%/B58Y&D*K&S _8/]H/P7\ OB]X!
MOO@1^T'-X0O?!WQGQX(_X03Q)XI7PWJOCS4=O]K_ -A^%0NLZ;X@.O@"TUT)
MX==O$X4*_+!17A_PZ_X)V_LQ_#J+PDVF>%?%/B+Q3X.^-NG?M%V/Q$^('Q+^
M*'C#XE^(/C#X<\":S\*?#OC3QOXWUKQ4_B_Q_P#\(_\ #O7_ /A'D\.>(9)/
M# 5AO7?7B'CC]B#XXR>-O@G\0]'^(7PA^+/BSP1^RYX5_9I\;^.OVC/ FN:_
MXGLO$^@%-<_X:%^%+>'->6/1/B-XS\331S^+;#?X8::/2O",D?BIO^$>16^?
M_AS_ ,$Q?VPM!/A74=;_ &V]>TSQ7X7_ +6/@^3PIKOQ2U'PWX&&N?$7QQXF
M\4G1O#_B7Q4?#WBK[-X2\>0^$O#@\8^&6^SIH,4DP2.5&(!^CGQ9_8C_ &>_
MC3\9]"^._C3PQXB_X6;I'A>#X>ZO>^$_'/C/PAI?Q&^'^D:[K/B+1? OQ/T#
MPUXGT_0?B!X5\/:[X@U_Q%IN@>(XY=CZRQ8.BG3*^?O"?_!-/]@'X-^9H,&D
MZC%J6ES?LX>(]/L_&GQQ\::IJN@^%_V;OB@WB3]G'0/#X\4>*RVB_#GP9XXU
M7_A'_"7A$+_PB;;U\)*&!P?F:Q_X)O?M8:MI%I;C]IN;P;'JW[,NJ?#"PC^'
MGQ8^.;:5X"\7Z['XYTS4O$_AEO$SGQ;XKTGQNGB3PWXQ\4SZ_P"*/#7B3PQX
MI\/(W@URCAJ]C_:3_P""9-[\9_C)\/OBKX ^(^F_#>^^&GPZ_9J^%&E66H:=
MK_C2]\0_![X9?'&7XG?%+X:>--4UO76?6H?'>D0^#!X,\9G=XH\#>/\ P%H7
MBR&5V!V@'NWB#_@F[^R1J'BKPKXE@\,>-/"'C'1/B?\ &#XM6FN^"?B_\1_!
M/B/6=8^/'CK1_'WQMT+5=6T/Q3I^H:U\./&GBG2/#VO^*_A><> ";,*-(.X9
M8?\ @FO^R\^E?&7P;_9WQ/7X5?'?0/%.C>/?@G_PN3XGK\$;1O'OC)?'GC77
M?!'PQ/BH>'_A[KOB+Q4UYKS>(/!P0[[S7<*H.!\.6'_!*GX_:A?^"?&/B[]I
MK4]:\>>$[K]J"UL?B#=?$+XL:OJ%@OQL^&$?AGP1\4_ VG*?#D?@#XAZ=\1M
M-\,^,?B%X0#^*/ 'BH2ZR -\D:LE[_P3'_;M?MT:MXQ\477C:+6Y
M[_5M<^+/A*TT;3O$?@OQMK?B#Q!I*>#O%0/]L_"O]HCXJ>,OB)\$/"1QX3/P
M]\/_ N^'OBXM'X/C=@#[L_;>_9:\!?M?>'O@C\#-:^)$/@B?X?_ !N^%O[1
M>H>'-&U37K+QSK_@7X6:F=(U-?#[>&/%/AKQ?X98:_XBT",?$V-G_P"$59U)
MR9*\<\6?\$J?^"> T/P9X*\3>&M<\/:1X;\':A\/I;%?C[\2/#^J?$?PQX[^
M,/\ PM6\'Q8UM3\//CAI7[1%]XBU_2-4^/4WQ#T[Q?XB^*$"?%W1OBE\2SXK\%:%J?B/1?%0U
M_P 'Z%\)_"%KH\GA;P?X'/AKP"GB72XY7\)+$X<=/\>/^"MQ5\1^"K;X9Z/\#/@%\'-:\/65[\1O$/BO51X6^-W@+XO?%+4C\0=:\3KXA E
M/PQ\/:=\./$#!O%;^+0WBSQ>6V[0 >S7O['W[#D'QIO?'E[>:>OCSXK_ !RT
M?]H*T\*3_&?7QXMD*/%P<@EN*\"?L3_ +!,?@#4/!'A+QOJ/C+X*W'B?P!XW\.?#2\_:F\=^,?A
M+\.+GX5?&31O'O@@?";P\/B.?#_P_P!#\'?&'2O#X \/!0&0^#R0'72Q\K^&
M/^"5_P =++P]XF\+^,/C+\(/B%J?Q3^#'Q(^"WQ1^/VM_#[4])^-WPVU'Q+X
MJ^._Q#TCXH?LZ?V*1X>\,>*O$=M\'HKK13L>-Q:\9?\$H/
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M!;XR^*/_ 2A^)OQ#^-'C?X]Z;XC^!=OXGN[SP3XGTCX3^+-/\>^-_@]\1O'
MJ7'@"T^+3_$\:T/^$@'A%+SP6EEX T,_\)0J7K#Q&W_"+W!$0]:^(7_!-?XK
MS?L@VO[-/@K]HZ_^)M[+\,_ 7P:U7PO^T1I'A?Q#\$-*\-V/A_P_X=\8ZC\-
M?#FB_#L>+_A_XLG\(Z/K6B?#C7)/$OBEO PU]Y8EMWP?\0/C%XYURY_9X^+'ACX[:5XW^)7[7/Q'U3XE_"7Q7JVF?\(WX?8^.-;^(
MY\0>%_"?B/PMA_&#]FW]E/XG?M'^"_B_XT
MUXZ+\>O!/@0I:6OA'XQZW\.=5\;?#'1==;Q%INF_$SP3X9\6>'!\0OAQXM/[>V^)%D\,+-D/NC^5/S(\:?\$<_B1XJG\:S:3XL^$FE!G\6WOPN^S0^,])U
M;0KWXKS>"H-1?QMJI_X2-OB%X1^!OASP!<>%_@9X2\0 IK/@_799O%K>&?%<
M;,/:/VBO^"8/C_XMQ_"#P9!XJ^$;?#KX-?LC:_\ L[>$?'FI^'->T_X\6OQ&
MUOX9^(_AIMU)H_[*'[!#?#[X%^'M,D\"ZE\.O@I\$?B_X-^$,4OQ7_ +4\-P?!#XI>'QX&
M^+&W5SXF(UKPH=#_ .*>;Q"Q*^%V;"2(V%KF?!O["'[&W@_1_A%\6O 7C;XB
M>%](^$?@OPAX5TCXG^$OVHOBG96'C;X/^$-8U?Q#X(\"_%;QM8_$0'XL^!_!
M_BKQ#X@;PJOB-F5%;_A%0_EJQD^P7/[+TD\7PU_;
M \*^*=*M/"GCG2K*VU7]J?XGZ)XL_P"%6^"/L+%M$^#_ ,*]1T30]/\ ">FL
M%D.H:]XG\1E1/+'&VC\.O^"I>&/&_PMBUKQ?>>&M;E\1?%_XR?%GQSX*U3X7,5\*/HOAO0/&.A>$S\38_"_AGXA_&=;
MCQ WQ(41>&? [ ^P+G]E3]B;3;?P-\-KRQ\,V\'ASXY^*?VB_"?A35_B)KH
MO+SXS_&L_%,:MK_]E/KO_$Z/C >-OB61H"Y#C<51B#LTOV:_V-/V4_V*-1N-
M8^$L&M>&M7^(N@^!O@[HU]\0_BSXJ\*M2*Z'X.
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MJ)*-E=3\>O\ @F/\+_#GA3P=
MXWTSP!XG\#KKU]X)\,L#X]\$>,O$,^A>+"LGCCPIXK\+R^&-&BA\UXG4 'UW
M\-OV!?V0OV8_B5J_[1GAC0M1\(ZYX;T[XOZC8:IXJ^*'C"^^'?PRT'XT>(!X
M[^+=SX?\*>)]>7P;X,T3Q+K6E+XM\5D(FPV3,6!* ==:?L:_LG>&M<@^,,GA
MJ/2M2T3XP?%?]ID^++OQSKVEZ59?$CXU>#?^$.^)OC(EM=&@?V'XP\+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M;"^+'Q/]/^%'AKQA\./@IXC^-WAK2=7M? ?B_X8>)M
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MS:?##XS>"]"\?_#[Q%JFL_MMZ!^V%X&_'T^CW.@V>J?#7]HK3-
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M/=$\-_$+P_I'B'X?-X,/A8>&' 90P->O:)\!?V2OA!XG\"^)_$7Q3UOQ/\
M$7]F;1?'WB?0_&WQP_:0UWQEX\\)^&OC6/#OASQ#J_BS5O'WBL.-"\1+X>TG
MP_X7_P"$BD'A0A%6(;V^;P?QI^PAXY\2?L3_ !=_9-T;1?@9IM^#K+Q5KGQ7^)'PX\&+X,\">'/!]OK\FE>)B5CO=%O_#S>(/!8\(>&O"IGU5+
M/Q=XK+^+4M\9?"SQM\3?#V@^ ](C\(>/+?6V\V+X:^$1X4U;_A$7T!4_X2T:OH7_"PO";K
MX=3> ?NSJ7BGPWH^CR>)-4U[1+'0H;;[1_PD&J:QIECI'D8R6_M5F"!0!DD'
M!Z9+$ \G'\6_A;]L\6:>GQ+\!C4/ MF+_P :V[^,M"^V>"K#&/M7C1?,SX8
M_P"IA$8)[YYK\IOB5_P3%^(5_P#L0:Q^RKX>_:)UGXHZU>_!?P'\)]'L?VB;
M?P_J?P0\%7WAC_A&UTOQIX*\#>#OAROB+1M:T0^'U3P8P\2-_P (T"AB+#[M
M;]H[_@E_K_[3-I^U%K7BCXB_#GX=>/\ XZ^#?A?\/K'_ (0[X4Z7XA\*+X/\
M)^&O%EQJ/@WXGOXF']N>/M"\<_M$>+;GQEXD#LCR>'_AU\/;8;KBWN%C /UW
MU3X@>!O#]_X9T[6_%WA?1[_QC=&U\+V&I>(]+LKWQ3?%0P70+4WN=9+=2L>X
MXVDGD9S]+^)OP[U:2)-)\<>#+Y[CQ%J'@RV73/%>AWOVSQ/I#2#5?# 96(&N
MZ!_I3'05W.@PS("Q"_GU\=?V+_C#\7?#?['7@N?5O@=XHT'X">*O#>K_ !5U
M3Q?X7UVQ\;^*6^'Q\-+X.U'X4>(=$R?A\\>NZ6/B=XOT#KXE\4^&_"?A%O%:
M^#_[2KY,^$__ 2T^,WPPUO]GK5X?$W[,\VJ?!G]I+X:?$;4[K2_ WC#1&U/
MP'\+_@+XF^ :3^'OL1_XDOQE^*_A'4Y/$?Q3UP?\4P_B70]%D4>*41B #]MM
M)^(G@S7-3L=#TCQIX7U;7M33Q/<:7I>E>(=.O+V\L/ FNV>D^(S:6UD[@CP]
MK6K:5H'B@ @(2%;)QCU6OQ5_9L_8B^./P1^*WP'DU_2O@U;^$/AQ\5/^"@WQ
MCCU#X.#5= M="T/]IKQ;X<2H/[54 %%%% !1110 4444 %%%% !1110!__V0$!

end



GRAPHIC
10
image_004.jpg
GRAPHIC

begin 644 image_004.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" $G CL# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]Q_BG^US_
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M0MFNC>&!;-9;H*A^+M!_9N_;4_8_^(?_ 2G_;JT7]DKX@_M%V_P1_X)N^&/
MV-_C]^SWX/U3PQ-(K*[\SQUX7T[6-6G\/W@MGN(_!&J6_A>-I&T.Q
MU/\ M)H]/::1?$/BW_P3H_;I^-7[%/\ P5/^*Y_9BOO _P 8/^"BW[8G[//Q
M-^&G[):^(/"VI^*O /P\^''CC3X!XI^)M_97-EX>T'Q=XDTO4KV]\9V^G7T;
MZ)I?FZA<^;';2H0:W7JOS/Z"?V9?^"LW[&O[2WQ4/P#\'^//%>E?%J/P#_PL
M?P_8?%#X5>/_ (/6WQ7\#Z9ID6I:SXT^&5QXY\)Z%9^-?#FBI]O-Q-X=&I16
MMA:W&H(_EPF9.%\#_P#!#/A!X<\=_$R%/B5\4KWX,?#KXN:
MU\&/B9H/P-\>_%*SNIM,NO!'A'XN:QH]IX?U'7H]2C&F0(D\=O/J$UO91,[7
M" _GQ>?#_P#;G_;-_P""B7['WQMUO]AWQ5^R5X=_X)]_!OXY:5K'BKQ_XB\#
MG1?BO\8_B9\.X?"GA?P'\,[GPGJVLW&O?!/PMXBT^UN8]8O[ 6VI:#J'B+3=
M0N]-M+FXU2U_.N?]G?\ X*>?'B/]B[Q7^T%^SQ^W+XL^.WP#_;M^$7Q-_:'N
M_&?CKX4:!^RAX3\'Z)X]U..UU#]E3X!?#G5=,TO7M$TG1[[2]6\2>-[S2)[_
M ,&:!9:OH$_B*\?7/LI#5I6?H?T/?\$[_P!K;XY?M$_M:_\ !5+X2?%'6-$U
M'P1^RG^TQX/^&OP5LM&\+VN@:AH'@_7O!FI:S<6GB'4](9AXIOS<#3Y&&H',
M48\W(\H8]4_:X_X*K_LG_L8?$/3?A#\2[KXG^+?BE+X U#XK:K\/?@O\(_%W
MQ<\3^#/AQIEQ]DD\?>.++P3;W?\ PB'A66[V(U]?(059VD5(6+K\Y?\ !,KX
M ?&GX._MC_\ !8GQ[\5?AOKG@WP/\?OVM?"?C/X2^(M6BL$T_P ;^$+#P9J%
MK=:WIL,6JSN^D)MVP?'7[(/C3]GFP\._ ;3?V-/B-\-O@U9>)OC1JUC=VOC31/VM_C5>75C\3?!
MOPZOIY=/M+:>XNH_"^B:-)+>V@DGA\MPQ/TD\_V"/ /P]_9J^+GB#XR
MW=S\,?VN;'QU=_ KQ9H/@OQ;K]MXXN_ UH9]9T.>'2-!.IZ1XC34%/A/2=(N
M(DN-1\075GI!'F7:XV/@=_P5:_8L^/GPP^/WQ>\/?$S7/A]X=_97FN%_:*TO
MXR^"_%?PB\7_ G%G9-?VQ\4>#/'>C1W=E::MIX_XEUSINZ74Y9H+>W'VBYA
M6OP@_9:_85_:VT#X>?\ !NSX8\=_LU^.-*U3]CCXV_M4:M^TQ%JB:);6'PSM
MM>N?%0\)^*M1,>OWKZII?B"XO]+ET&\%K*;H:;%.=BP>8O:?'[_@FU^U;^T5
MXP_X.%?!OASX<7OA.#]KJR_93U;]FOQMXBU"STSP5\6]5^#UOIOB?6]-?4[6
MZLI;&VU;5-'L]'N+LW,,4"W9DN-\*R1L >Z>./\ @N%X>^.'[77_ 3%^%/[
M&WBKQ!IW@']I'XX>)?#OQM\,_%_X">-O GB;QI\&;GP>^J^ /B%\/YO'VD6<
MD_P^UK5M.U.WTWQ5XM\0^%_#GQ-/QL^$7@:VUKQEX9@\7Z+IWA[QUXE&D:VDVD7%Q90O#;V^R9$DN(
M5B>-9/-39AORVN_#'[>'[7G[3W_!%3Q_XB_X)Q?%?]G/P#^P_P#$N^T#XS^)
MO&>I_#>2XL=2?X7Z'XMZ!.L<6FSRC]%O^#@_P#9N^-W[5'_ 3VG^$_P!^%VM_%[QW-\??@9XIN_!?A
MS^S_ +;>>&/#GBW[7XMN9/[3U+2;)DM])>3[1')J$$DL$DJ6XGN3#;R@UNO5
M?F?G[X]_;Z_X*+_L5?&_]C>S^)7[;G[#'[?W@/\ :4_:'\&_ _Q)\(O@=\,9
M/ 'Q>T6P\93W-I>>/?#:>!_&?CA=0T?P;Y8N=1@U'3K6WNM4D^RWIM[:6>XA
M_67XW_\ !9;]A']G+XP>*/@?\0OB)XMNO$/PPO-!T[XS>*_!/PN\9^.OA;\"
M-0\47,W_ C>C?&;XD>$M)/A7P'KNHQ"%9-,O+RX;39KFWEOD@1)I!^9?QF_
MX)F^(?\ @G+^W1^SG^WA_P $S_V3/#GC#X:^()8/A)^UK^S+X-\.^$+G6-!\
M'7ZV_P!B^,?P4U'Q!:S:UX>U_0K*XU2778_#_B6U75IK>#2G:ZMM0FLY?B#X
MM_L&?M?[0_PZ_;@^.WB#XJ?#MOV:/V@/!GPF^ 7Q
M"\"?&B\NYO%/A;]K*_\ $Z>)O$'A3Q7X8M+W4;2XU30-!ODF-II3RFTL]4FO
MK8-7:S]&?TN_M/\ _!4/]D7]E;QG\,?AC\0?%WC'Q-\1/B]H4GBSPGX0^"?P
MZ\5_&/Q1'X M[6*XE^).MZ?X(T[Q#=Z5\/8DOK:2/Q5J%F--3S!(Y1%>6+X\
M^/G_ 5D^"WQ4_9;T+]HC]D3]KG0/A=X,TW]M_X>?LS:S\5_%7[/'CWXFZ%X
MZU;5C9W-]\/_ OX4GM=*UJ"+QUI>M:8- ^+$%@^EZ'M._[!W_!3WX/?$WX!_!?P[^UKJ7B/_@G%\"_V7/$G[.>C_M#_ ELOVB/@3<^
M [^%]"\4WL/C--&U#Q-\(Y?[!3PUJGQ2L-%=O[.BU&YV1HAD3\WOV?/V>/V@
M?VE?^"6?Q,\+?"7X06OQ \>:5_P< 6OQ9\7^%?A7>:#KGA/0O"7@C6_!5YXX
MN?#.OSW=CI_B_P #^$91=Z=I.MV-S%]KT.*V@@WNZQN&)_4E^U/_ ,%@OV)/
MV.OBK??!7XI^-O&^N_$;P_X?@\;?$#P[\(_A?X^^+EY\(_!%V8+A?&WQ5E\)
MVMW<>#_#$LMOAO^URNO#]G_ ,=>$/#WBCQIX<\>1Z'X:M?$$-FEUX<\.WM[I^HZHE];:5H^
MC7]JUU=^(+NPTEQ'-M];\*^-OASXX^&.O>"DF\+^+(_"6O^&+OX=?%S2?'7BJ"Y\.?#JQN-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MCP\^KW7A@>,+.]T:/Q+)I4AT^^*)9S>,?LM_LQ_M?:U_P47^ G[3OB']GO\
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M?^"$OP,^,'[-O_!,SX#_ 8^.WP_U?X7?$SPCX@^,#:QX-U^6UCU32M.UWXS
M>-_$&CW$C6BM*(M6TB]75HE!"2#"SE;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M2XN?($4CKQ7_ 4J_P""='CM/A]^PE\3_P#@G9\+? %OX\_X)F_&C3_BG\)?
MV=/,TWP7X2\>?#R[%KIWCKX<>%M5U)Y[+1/&&HV6D6%S9ZCJTV^XN[5(E9K^
M:(/K? O]IG_@K#^UM^UO\&;F?]C_ ,3?L#?L<_#O1O$^H_M'6_[0)\%>/OB!
M\:/$FH64=KHO@GX=Q:,!?Z3INC:A&DC^,K9<7>EQ7-NZB.8I0!^E?[7/[9O[
M/7[#WPY\.?%?]H_QC=> O 'B;XA^#OA=#XIAT75=7T_2_$WCF9QIBZQ_8UI?
M-I&GM]GFU/4=3@M;B>"RM[BXA@EECCK\^I/^"^O_ 3RME^(5E=>(OCE_P )
MQ\-@EQJOPL?]G+XQ:?\ %OQ1X?2UN[^'Q[X,^'@\+Q>(-;\$#1[:?5-6\47;
MV]EH=HEI/+90QZAO$7_!=G]G7XT?M+?LK_ ?P3\#?AQK?Q.\0^%?VW?V;?B=
MXF\.Z3/%+)IW@'P9X@U^]\5Z_J,L]Q;I-9Z/97 1H'G!@&,,Y5$;F8?V:_C6
MG_!9;]N+]I&7X2Z^OPI\=_\ !-KPG\'_ (>_$L_V4=-USQ]I^OR7^M^#=)$F
MIRHNH6QM-, \ZV:%)E!F"PJ[@ ^KO'?_ 5O_8@^'WP!^ _[2X^(VM>.?A[^
MU!(K:8![
M*ZM9YYV$-K,3SEM_P65_81O?V9/'?[6EU\1?%^A?";X5?%+1/@_\6(O$'PQ\
M::#XX^&?Q!U[6M,T:V\*_$'P+JF@2:GHEREWJUHFKW2PLUKIDUS=(5,!9?PH
M^%/P+_X*??LT?\$YO^"7/P=\/_!G]I[PGX!\(>./VBK7]M7P-^R[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M%:_V'==_9[^+7[6%O\2="_%.E>$/'OBF*]32DT#
MX/7MS'+J'Q8DN]=M[;2["Z\%PS:/?W=S#:P/(0SM\ _\%D_^">_Q&_;@^*__
M 2L^&6F>#?B1<_ [PE\3/B5I7[1GCGX=W.FZ1K?PM\":YX+\'V=O<7&I76I
MSW5C!XHN;"[TC4[G3H+R*/3X;O[3!+:>9"WPC\2OV$/^"B_Q'_X)FZ=^PWJW
MPF\8:QX^_P"":G[7_P .?&_P"\0:3K_AGP-IG[8'[+7PRU/7(/"\GP\\065C
M:>&M*^+_ (6\)^(+I+.#Q/INDC5M5TV#4[:'5M2>'3[T _9G4O\ @M1^RIKG
M[-'[57QO^&EK\5+[QE^RUX B\9>-_@-\2/A'\1_AM\8;!?%UK:V?PWU36OAY
MXIT.P\36GPY\5ZSJ^CF7Q9IZRZ?H^C37>OW]S:Z987-POKO_ 2;_;CD_P""
MA/[(7PR_:!U73O[%\?75O+I?Q4TRU\$^-?"_@Z#QL=/L];OK/X;W_CMY=0\7
M^$M*M?$6FV6D^-M#U;6_#NH*=6M+=+9Y8C!^0_[-_P"Q[\:OC-K?[?/QGG_9
MW_;G^&GC?XA?L!_$']E?X6_$W]O']H;P'X\^+/Q1UGQMH-_<_P#".M\*O!?A
MJ./0_"7A7Q$87T7Q9??$M1J"7EO!)X(L!(\\?Z=_\$0D^,WAO_@GQ\!/@G\=
MOV=OBA^SAX]_9P\*Z;\%;_0/B:-"#^,X_!VCZ=;KXU\(G0M5NB?"U])=R6=F
M+Z!G#66=PMBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "J]WD0,5=D8-$R%,9+K*A2,J63
M>DK 1R1*ZO+&[11D2.M6** /@#]J7_@FQ^Q1^VKXH\(^,/VE/@'H'Q%\8^#;
M.ZT/P]XZMM:\<^ _&VFZ'=L]S>:''XO^&WB?PYXBGT.:M9+J!IK2Y^AOV?/V=?@Q^RU\.?#?P:_9Z^'_A[X7_ K\+)J"Z)X,\+Q20:1
MVH7!O+[5[FXN?MVIZWKUY>;5OM2U759KF9)'9Y'=0K>\T4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '\2TO_!X?H-E>W=M)^P;XGNI+:YOH)9+7XZZ%LN?L=X=
M-6\,,?@VYDL5E:U++&89#EMA(+O)2_\ $8YX=_Z,!\8?^'WTO_YW-?Q"ZI/]
MIU?6KCO=:UKUR?\ @6L3KGU[_P"/-4:#I^KOS_'_ "/[B/\ B,<\._\ 1@/C
M#_P^^E__ #N:/^(QSP[_ -& ^,/_ ^^E_\ SN:_AWHH#ZN_/\?\C^XC_B,<
M\._]& ^,/_#[Z7_\[FC_ (C'/#O_ $8#XP_\/OI?_P [FOX=Z* ^KOS_ !_R
M/[B/^(QSP[_T8#XP_P##[Z7_ /.YH_XC'/#O_1@/C#_P^^E__.YK^'>B@/J[
M\_Q_R/[B/^(QSP[_ -& ^,/_ ^^E_\ SN:/^(QSP[_T8#XP_P##[Z7_ /.Y
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MW-'_ !&.>'?^C ?&'_A]]+_^=S7\T(_X)F_&#Q5\/OV;/$GPMH?MB3>)=+:7_ (0;X5_#KPI^R;\0=&\$>(?BSK7Q*\7S::FF?#/Q#87]GK.I
M^*_B'::#:6*[X]/GO=3^PVMQV_PZ_P""//[2GCCPA^TE8:K:Z)X0^,_[.WC;
M]FSPWIWP[\9^+/A%I7PX^*7@C]HE?%LOASQQ:_%WQ7XWT_P)9:3=:)X;TMO5O"=TNK>,9/&.G6FGQ76IZA:VLP5_L'F?T3_P#$8YX=_P"C ?&'_A]]+_\
MGM8OB#X,\1?$GP9I?Q9OH_@'$J?&37M%^&6JZGI?Q \>6G@.'4-,@U[Q3I.E^(
M].N=/N+2X::WT^.>^M_:)_\ @FUID/\ P4E_9Y_8$C^,&J2VGQSTG]GWQ4/B
MG<>$TM[_ $P?'#X0I\4K*"'PH]W9+?S:1;,_A],743S-< Q[Y-L;@?[!YG]'
MG_$8YX=_Z,!\8?\ A]]+_P#GMM>%O#'P#\5_LM_$7X@?%C3_C+\2/B=\)H]!_:8^%NE_L:^*_#VO?!3PQ!XQ\
M0^/I]4^)?BL^&[GX01^$+J*:R^(+_P"I9(;BS"WZVP%;X._\$>/B5XCU"7PQ
M\:_%UU\(?&5A^UG^QC^SS%I.@:9X5^)FD:UX(_;#;Q-JOA'XR^#M?\,^)FT/
M7/"\FCZ=K&H:1<73VNG^*]0U&V:]U'2[66:_M0/]A\S]_O\ B,<\._\ 1@/C
M#_P^^E__ #N:/^(QSP[_ -& ^,/_ ^^E_\ SN:_FM\4?\$POB[=:[\-_#7P
M=FN-+=?\;_ !2UWX5_![X4Z+H/P4_:"\1_ ?1_$6@_$'QA\2?$
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MK_BSQGJ^G^&=/\&>&;\:CI7B+1+G0FGB\YIDS/VF?V+_ -I?]D"T\,ZE\?/
M-MX8L_%-QXCT[3]1\/>-O!GC33[?QOX.72;GQK\,?$.IZ+XF\;Q^%/BKX275
MM!DO_ .KPZ1XBTFWU&6]O(DM[>5 "OA?LM\W37KT/ZY/^(QSPW_T8'XL_P##
M\Z%_\[JE'_!XYX+3]/CSHA/Y)\.MWY?CQFOYT_BK^P!^S1\"O"%Q
MX#^-'[;.G_#;]MJU_9]\/?M&P_"K7_A+K-O^SC<:5XN\*:'XT\&? B/XMZ;X
MN_X2R+XT^)?"E[9ZDT&K>%KKP;JU\(M%MWTUK]-2M?(Q_P $M?VXI-(^%6J:
M9\(M*UT?&GQGX4\ >&O#VE?$_P"&&N>-='\>?$KPS<^//!O@[XH>$_#OCW6)
M_ %YXK\+:-JOB#PU+XLU#P\-0TS3$L;J&873V4X+W/M?#]KO;KU/ZB?^(QSP
M[_T8#XP_\/OI?_SN:/\ B,<\._\ 1@/C#_P^^E__ #N:_F#U[_@E)^W7XMXF:WJ7PDT21/A.=;7Q-INE?:YKNL7/A;PII_Q$^)NF> ['0/']S=_$_5
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M-0^(?A^R^+'Q4^):K]KTO1;G5;>.TNH5OS'>&R%CM8'XL_P##\Z%_\[JE'_!XYX+3]/CSHA/Y)\.MWY?CQFOPN?\ X);?
MLUZ'XP_:MM3X1_%;X%^-/$.AWFG^,?#6IS6FLQ77A'Q3+X8N]"UK2WADNT/V>?Y)^/O["
MME\(OVE/V:/@]X3^+UE\6/@]^V)I?P0\<_L__&+3_"9\*W?B'X6_&KQRW@+2
M;GQAX(_M35?['\>^'=>378-4T+^WK7RK>.X?[0FP,0/=^UMU].O7L?U$?\1C
MGAW_ *,!\8?^'WTO_P"=S0?^#QSPY_T8%XO'U^/&D@?B7^'.W\_PYQ7Y">./
M^"$_L;_ ;PY\:/A;X[B\%PF]_:#US5/AIXU^)&JZ
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M .=S1_Q&.>'?^C ?&'_A]]+_ /G'?\ HP'Q
MA_X??2__ )W-'_$8YX=_Z,!\8?\ A]]+_P#GM>'?^C ?&'_A]]+_^=S1_Q&.>'?\ HP'QA_X??2__ )W-?P[T4!]7?G^/^1_<
M1_Q&.>'?^C ?&'_A]]+_ /GM/^1_<1_Q&.>'?^C ?&'_ (??2_\ YW-'_$8YX=_Z,!\8?^'WTO\ ^=S7\.]%
M ?5WY_C_ )']Q'_$8YX=_P"C ?&'_A]]+_\ GM .=S7\.]% ?5WY_C_D?W$?\ $8YX=_Z,!\8?^'WTO_YW-'_$8YX=_P"C ?&'
M_A]]+_\ GM_HP'QA_X??2__G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M>Y^#VKR368NY8M1$'VM/$$;7)3^TMA<.N1R&O\ PS^O
M?_-53BKM+NTOO']8?G^/^9_-I17])?\ Q#LZ[_T=]X:_\,_KW_S54?\ $.SK
MO_1WWAK_ ,,_KW_S55T?5WY_U\@^L/S_ !_S/YM**_I+_P"(=G7?^COO#7_A
MG]>_^:JC_B'9UW_H[[PU_P"&?U[_ .:JCZN_/\?\@^L/S_'_ #/YM**_I+_X
MAV==_P"COO#7_AG]>_\ FJH_XAV==_Z.^\-?^&?U[_YJJ/J[\_Q_R#ZP_/\
M'_,_FTHK^DO_ (AV==_Z.^\-?^&?U[_YJJ/^(=G7?^COO#7_ (9_7O\ YJJ/
MJ[\_Q_R#ZP_/\?\ ,_FTHK^DO_B'8UULI_PUWX:D\P&+;_PI_7O^6O[O=_R-
M7\&[?_P&N>TC_@WVUS5=;\7Z,/VL?#=K_P (I=Z):_:S\(->_P")@=3\-Z)K
M6W'_ E7_+,:SO\ ^ @^E'U=^?X_Y!]8?G^/^9_.K17])?\ Q#LZ[_T=]X:_
M\,_KW_S54?\ $.SKO_1WWAK_ ,,_KW_S54?5WY_C_D'UA^?X_P"9_-I17])?
M_$.SKO\ T=]X:_\ #/Z]_P#-51_Q#LZ[_P!'?>&O_#/Z]_\ -51]7?G^/^0?
M6'Y_C_F?S:45_27_ ,0ZVN/A#^UWX:D#D)M'P?U[^,A=W_(U?P9WG_=K#TC_
M (-]]^\3Z6/VL?#=K_P (WK&EV8N_^%0:\1J']H>%M(US9_R-7_+,:QYG
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MBL?%?XM?^%1:_'_ *V1(]V__A*N/+W;_?;CO7.Z/_P;\:WK6J^+]+'[6/ANU/A/7M,T
MS[7_ ,*GUYQJ'V_PII.NE-G_ E7/E_VQO\ ;8#VH]@UKKIK]WR#VZ>D[\KT
MEZ/?KV/FS3_^"ONK:YHLW@#XP_ +0?'GPY^(.F_MM>'/VBM'\)^/O$?A'4/B
M/H7[9_QLT;XXZWMYB-Z]_X*N?"+QQH7COX/_%C]CBX\0?LRZMX=_9"\$?#;X<>%?CEJ6B^//A/X
M&_8W7QE)\-[>]^(#>"-0D^(WB;Q)K_BC6M0\6ZO;6Z>#KY6N[+3_ 3IU]/;
MW]K]3_\ $.SKO_1WWAK_ ,,_KW_S54?\0[.N_P#1WWAK_P ,_KW_ ,U5(?\
ML'F>81_\%V)KSP/^T%%J_P"R?X9T_P"*7[15]^UQ:_$?QGX%^)*>&- UWPM^
MU'H.IZ+I*?$"UO? WB;Q=XPUWX":0ND>'/!D6J_$'1O"]UX6TRQ_LKP%I]ZU
ML\?QD/\ @H_J:_\ !0G]GK]O*?X01-JWP'\*_ 7PA:?"Z/QFT$.NS_!+X2VG
MPLT34AXE7P=M?U[_ .:JC_B'9UW_ *.^\-?^&?U[_P":J@/]@\S\OO@1_P %#/'GAC]J[3OV
ME_VD=/\ &/[8-AI6@_$S0=!\$_%;XB:MXMO? ,7Q)M-?&G^(O@QJOQ/L]5T#
M0O$O@.XO;?4_#^H#P+J=CIVI7EI=L-.$ U.R^UO$W_!<75_$/Q-TKXE3?L]6
MMS<:9\9?V"OB_>1ZS\5X];UGQ-=_L$IXRT/3+36]O\
MB[^ZTR]07NF:=?^'[6XM)?9Y?^#=;7)(I(S^U_P"&AYB/'G_A3^N?\M%*
M8^?Q5M^;..?7CG%9>F_\&^6MZQJ7BVV'[6OAJV/AWQ,-*'_%H-7Q+]M\,^&M
M>R-GBK=C&K;N/3GC- ?[!YG@?@+_ (+$:5XM7>$/$^B?$#P]!X]\,>(/BG^TUK'[1<.O>"/$7BCX<>,M*\&J6U[_ (53KUK'
MH^L:SK?AS3M6UWPWJWA;Q$FE::G4C_@ME8:I\3;OXM>(/V64U'Q/H_\ P4!@
M_P""@?P^M[+XMO'I&A^)]4^#?A[X,_$+X=:L9?#2WOB'2?$FFZ!/J'A7Q'K&
MFZ=J>GZ@USJ'E+!:E#[7_P 0[.N_]'?>&O\ PS^O?_-51_Q#LZ[_ -'?>&O_
M S^O?\ S54!_L/F?GKI/_!5+XQ^'/V7/A-^S1X<\)>&8-3^$W[1OA#XR>'_
M (L:A//KWB/5? '@SXH:O\=/A'^SQXHL+3P]97EYX/\ !_Q?\6^)O%IOK.]L
MKRX2,Z)97EG?&OQ-
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M/VD_$'P:^)'@KXJZEX#.A7/[2E[]L\56GQ-T2S\#:WJ'C)_".N7'B%_#6I>
M_'7A)_$,&LP:1KJ:CH-]JFCWWEG[ ?\ P4NU_P#8*T#4M&T'X8:5\08]7_:/
M^$/Q[UIM1\2Q:9;W>B?#'P-\1? WB3X6:Q"+#5;V[M_%%A\3M;M+GQ)?:7J4
MF@QZ0\)TZ]=!;2_HU_Q#LZ[_ -'?>&O_ S^O?\ S54?\0[.N_\ 1WWAK_PS
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M_P &[.N $G]KWPT0%8X_X4_KW. 3C_D:N_2N>T+_ (-]=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M)\,O$6K^,_$EYXRN9[.PM(/".G_V,CIP_"'QP_;GU#XR?M&_L]_
M&31OA+X5^&GPQ_95T[X,>!_@5\"_#6O^(]7TOPW\,/A+XDT[QSIF@77CG4K/
M4;CQGK_B36?[8U/7_%/]E:09-6U5085!V5^KO_$.SKO_ $=]X:_\,_KW_P U
M5'_$.SKO_1WWAK_PS^O?_-50%\#TM:+JWA?\ ;Z\)S7EKXWU..^:T_;/O]M+K,>E@#[42?)/$G_ 4;T+]H+Q'\>O ?Q'\!Z-\(O ?[8NM?\$_=#^)GCR'Q
M5KVK7'P9\+?L41KX6U37+6VL= L;KQ=>^,?"TM_K=EHL5U$/!]W+#<2EXK&2
M-_M7_B'8USC/[7WAH8*GCX/Z]V(./^1J[XQ^-8>D?\&]^N:I=^(K$?M;>&[7
M_A&O$-YHN/\ A4&O?OL:-X9UK/\ R-7;_A(RP[\>E%KZ=]/O%S89:Q;YEK'7
MKT/QP_;:^/FG?M0?M@?M$_M :-8R:;X;^*'Q-\6ZMX2MI1?6M^OA"WN=(L/
MTFM6NI?Z0VH7?A#3[,_[*V08]#7R_7])?_$.SKO_ $=]X:_\,_KW_P U5'_$
M.SKO_1WWAK_PS^O?_-53^KOS_KY!]8?G_7S/YM**_I+_ .(=G7?^COO#7_AG
M]>_^:JC_ (AV==_Z.^\-?^&?U[_YJJ/J[\_Z^0?6'Y_C_F?S:45_24?^#=C7
M&Q&?VO?#1\YTM]W_ J+7(_+^TNL FWOXJV#R#)YW/7R\#DBN<\._P#!OQKF
MO2>)HA^U?X;M/^$<\57?A4 _"?5I/M7]E:1H][_;&V/Q5O/VG^V?(XZ>9D\
MT?5WY_C_ )!]8?G^/^9_.Q17])?_ !#LZ[_T=]X:_P##/Z]_\U5'_$.SKO\
MT=]X:_\ #/Z]_P#-51]7?G_7R#ZP_/\ '_,_FTHK^DO_ (AV==_Z.^\-?^&?
MU[_YJJ/^(=G7?^COO#7_ (9_7O\ YJJ/J[\_Z^0?6'Y_C_F?S:45_28/^#=C
M73E/^&O_ T/-5H<_P#"HM>C_P!>IAQO_P"$JXW;]OOG'>L'1_\ @WOUO6+K
MQ%&/VM_#=L?#_B6_\.X/PGUZ3S?[-TS0[O.W_A*N?^0V3[8SVH^KOS_'_(/K
M#\_Q_P S^=&BOZ2_^(=G7?\ H[[PU_X9_7O_ )JJ/^(=G7?^COO#7_AG]>_^
M:JCZN_/\?\@^L/S_ !_S/YM**_I+_P"(=G7?^COO#7_AG]>_^:JC_B'9UW_H
M[[PU_P"&?U[_ .:JCZN_/\?\@^L/S_'_ #/YM**_I,7_ (-U]<9D0_M>^&B'
M=$W?\*?US]WO8+Y_S^*MO[C/G<_\\^,'%MU7PAC_A3^KXN_P"QA W]K_)XKW_Z1]H\GCO)SQ1]7?G^/^0?6'Y_C_F?SL45
M_27_ ,0[.N_]'?>&O_#/Z]_\U5'_ !#LZ[_T=]X:_P##/Z]_\U5'U=^?X_Y!
M]8?G^/\ F?S:45_27_Q#LZ[_ -'?>&O_ S^O?\ S54?\0[.N_\ 1WWAK_PS
M^O?_ #54I4&DWKHF_N^0/$.W7Y_\.?S:K]Y/]]/_ $,5_H#?\$5_^48O[+/_
M &!OB1_ZN?XCU^(1_P"#=O7D!D'[7OALF(&;*_"#Q &41 R%P5\6(08PI?.X
M ;M (6OXYO_ +2L#ZW*\6X7FW:TC'*DYYKG(^L>4?O(/"&T>&/"A8*0/#7A@XMC)&E0E1+^XN/W1;'FCR6S'N&8\^8GT)HGPCCU0>'HAKUU+J>J6_@#7_$*6V@
M^;X?\.Z!XVU^#1)+[3+P>,4VW5K'.9L#PM=^:Z"+;:[_ +9;_/?A*-%\*>&2
MR[E/A3P\K =?GTV%,@9QP6#?A7I=MXV\D6FBVOB#Q)'IFF2QWMAIML^RU
M>ZM)$N[,LV./)NH89E]3$!WKH.$ZRT^"_B#^S?$%[K>K^&])M-!\+76I:E+=
MW?GW5C=7%G9:[H^F^)&_YE*/7] NIM5M;[^"Z$'][B6+X)^+5AU*_P!;O-+T
MV#1KKQ7I^K3V>I?:=5.N>%-/\0ZK:_;;7_E\T.\7P]KEO8^)/^7NYG@MO^6M
MM]/9BPG\6^(6MI%N+AK&2XWI#;ZE$\]ZK+W^T6VOS0^N9 >V::W7JOS XR*3S
M(XI/)V[HX6V?\\/M4;7'FC_KKM"_\#ZXJ6D%O(H3RXI$,<0@CMI/]?%8A@\<
MJ^\DP7=_LD]*/)N/^>$_^?PK$_^?PH 6BD\FX_
MYX3_ .?PH\N=?F\BE "G[LG_7&?\ ]$O7G_A?_D>OC-_V-7@3_P!5
M5X:KOV\YDD7[/,,Q3??QMXB<\\?Y-<#X8AF_X3SXT_NG7_BJ/ G*?>'_ !:W
MPST^O()ZX/UH [X@' ,;3 N@\A%\QK@EUQ;K%_RW-P<0BW_Y>-_D_P#+2O0O
M!OP_M?&UA?1+KT5IJYU;2]%TNPNM'\SPKJE[XBU2ST*U']N_:['[9J.L2ZBK
MZKX*^U1[;"PN1E_]6_GZ1W"L&0W =3E=Q.&(Z)SC[_W!SU85TMAXJ\9:7HL_
MAO2=5PD5[_P!L!0!WVK?#+0K:VU[4#X^U
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MX7UZ9'#-O7Y)W^8?*Y.T_7Z=1[@5YUX-AF_X2OXQ?N'3_BN]$^9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M %T ,?(>L35=8UKQ%?3ZIK5_JFK7LT%E:C4;H_:6E7381:B(W?;8,_[V-O\
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MF65_04)#?(6K0F^(7
MQ$FMKVU?Q;XDEL;O4UUJ6S_Y[ZO:.MRFM8]Y(%STX],5R^JZKK7B"_EU77K^
M]U76+Y%EGU&<_O98E(6./ZI@9] "*Q6Z]5^8&>WW)/\ KE+_ .BWK@?!'_(<
M^+?_ &4MO_4#\!5WK0S;)/EN6_=3<$GG]T_\NOM7!>"H9O[<^+6(KE1_PLQ^
MO2MP._P!H;Y2AD#$+Y:IO:7)QY2#^%Y<^6DG_ "R=A+_!7I?@
MSX>V?C?2EN(O$RZ/K,VJV>BV5MJV@?;M(U%;B\@M[G2]"U/[79?VOXBTBUDG
MU:73_M,7VE;)K;Y_-$;^:K%,&!"W#,.44DX:0#]VG/\ >DVJ/MGI>D0>'M-\0:YIVBV^I0:P=,MG*)8:Y!<17$5WO["">*.<=,^7@\&D]GZ/\
M(#U'3?@G9ZMJ TG1O&:P37&I>"/^$:O-7T,VUAJ>F>(=+TN[TF5;O_A(+W[)
MJNEVVJ:SJ)\-_99?LBVGVCY#$)$\I\6>'(O"FN7.D6MR^I68M=(O;+49K?8M
M_I>J:/9:KI&J6C?PK-IE[90GU1R.^*U)OB#\1YK>ZM7\6^(Y;>ZU:+6[NR^T
M;Q/JEG*EW%K17OF2!.^!C)Z5R^JZIK/B"^GUC6[^^U;5]0D\V[U&?_62Q!2(
MX_8HP&?8'\<5NO5?F!FR?M^5OE<_*>#USQQU'N!7 ^!X9O[:^+_P"X9/\ BZ\QW)PP_P"+?^ QQC\CCL3Q
MWK<#T#@\$%@>/+5-[2YX$*#^%YB?*23_ )9.XE_@KU'P+\.M/\;:?%>?\)*V
MC:HVK6MC;V>H:!]NL+Z&VN8I[S3/#.IF[LAJ_BS2K*.XU6#3OM47VF:R6V^?
MS?+?R]8I0P)6X8CE%8G#2@?N5_&78![D5U.E^,O&ND:5#H%EXAUNPT:VU!-6
M2PMY#$EGK,4JS)<^9_"('C6X]_+QWH [5OAGH%K%JE[>>+=1EMM-U/P/MX7\RY\5V7C"QT>^\,Z0A_P"$J_T?QEM6/ACQ1K'AO3=9N-=L]$N1IDNIWUG]AN;G4]*C\NYM!#_ &_>\^'[W4];TEA]
MEEP&.?+P)%TW\>_$.;3[JUG\5>(;FUU'5AJUWI\MX94N;^%UFM]9,?\ $'N(
MX0,]#@]L5QLCWUY<75Q=O)-MC?"?_(9^)_K_ ,+,U/\ ]1CPC79^3-@X6=CM;AR=I^4]?IU'OBN/\*PW']L?
M$[,;*#\2-2Y3[W'AKPCC&/UZ<$\4 =>ZEU**@E+C8(BN_P [?\IA4?PO*#Y<
MMNR&L:]I5JLVIW6G_ &F+[3;6M=59>,/&NG:1;:'IOB#6;#0+/48M5L-/M6V)::NDJ2"Y#]OL[HMQSU\O'4TGL
M_1_D!Z38?!C2[^_CT^/QF\$TM[X3%K>7?ALBTU/3?%>AV.OZ--IDG_"07PMM
M7TOP=,-1O_#GV63[%96ES>?)Y'F)YAXO\/KX7\3ZGX=6Y_M*#3TM[FSU' M?
M[0M;G3="OAJGV7^+SFUOR?\ 9W[ATK7?XB?$=[4V\_C/Q*D0U?\ ME85GWM+
MJJ8=M8V\Y$RKY3>BN3V-M=\ARN[_9W5BMUKU7Y@47^Z?P_F*\Z^'_ /Q_?$__ ++'XW_],O@:O1_)FPW^
MO_U,ON$[O\ D">!>G]?;-;@>A#)
MRH0R%P8O+5=[2^:#&8D'\+R!MB2?\LF82_P5Z9X0^'6G^--'N+T>(IM,N(M5
MGTZ<7N@?;M-N[&RTNYO-3TC1-3^UV/\ ;&N:;IT%UJ%[IWVJ+[3:6L]L=_FB
M-O,1%,"#MG;!!VN3M;'.TYXYZ#WQ75V/C'QQIFDVVC:5X@UG3]"L-0CUBPL+
M1MBV>K0RI,;D/GC[.8_M'/41D=^4]GZ/\@/2;;X.:4;V\L)_'%O826^K:)!#
M/J>A?9M+U&RU'0]/U73H_#]U_P )!>_9/$RZ#?V;?\(W]EE^R%?M)*"+S$\U
M\;^&)?!/BK5?"DERUU-IC64BW"V^RYFTK4])T[5[9M;;H+_S[^,CU [U87X
MA_$7RVM#XP\2-%-JY\2FU^T;Q-K)'RZR5'!\QL+C/&<]LUS.HW6HZM?W>IZE
M>7M_>W\OVF[OY^);O42-LR#_ '(M[GV7\:Q3U7J@*G=?]Y?_ $(5P?@S_CY^
M(W_94M?_ /4?\)UWT4,WFQ?+MN>!_Q)/"74=_;W(/>MP.KQN#KY8F#1R(83+Y'FAXV4Q++_ \@.R,]W*CO7K7
MA3X>:7XLTB&^_P"$H.G376N/I-YI]SX8\C3[G2K+1[J[UN]T34OM=E_PD&LV
MNCV]]XAU$?:HO(L-3NK@[_+\M_+?+D&2T4DHP?WM5U=AXR\=:=H^FZ'I_B75+/1=)U$:SIEC8L$TS2=4C;S3<:4_42Q8,EQSS$)0
M/O8H ]&LO@[:7]UJ]K'XL^U3Z5>^&]4U4#PYEE\ :[HVIZS#K$0'B"^_?RV,
MDD$!^RR@3O&3LQYB^6^+O#S>%M>O]":\^W&T6RNH;\C[*EYI>J:9IVJ:0DMK
M_%JL=KJ.^X'&V!9&Z"M#_A//'F&AD\8>)L/J[>)PJ3[V?7-I,6LA><^;+MB/
M/"N3Q@5S>HW.H:M?W>IZGHZKJ,O\ :&IZI=?\?-W?R+Y;H.^4C9BW^R&_
M$ H0_P"MB_ZZ)_Z$*X#X=_\ -0_^RO\ Q%_]*-#KT6.&;S8OEG;]['PY.W[Z
M]?IU^HKSKX?0S9^(?[IE_P"+Q?$?E/O#]_HG3TST..HS0!Z3;6\MW=6EE 4$
MU_>6FGQ-)'YL:R7]S%9H\D?\<:-.&=>Z@U['IWPEL-=\:3^!])\2:C<1V-MK
MMEXPU+_A"+B;3=-N-(B2TCM= L;2ZLKB\:_GO8].N[I+J(6%K=SZC)OCM7C?
MQ0PRXR1><%3NC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M=\-;K;=;@8S_ '3^'\Q7T5\$_P#DG\/_ &-WQ-_]69XOKYU,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M@2/XAQ6MU93?NM'2YT_4]'AAT!_^/(?@HNG>.O"GA31-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M:C[&!)]UP&7YU6@#PG_A4'A;
M_H._%#_P[WQ%_P#EY1_PJ#PM_P!!WXH?^'>^(O\ \O*]0HH \M?X/^%3'(K:
MY\4F5HY%<)\7OB1N*,C*^/+U^)_NDDXD7C.M?\0=8O\ 3OB5I5E9S7'QC^*L0>,;:5MT/\ *OT8_P""=7_((^/G_95] _\ 50?#*HJ.T)>GZI#6Z]5^9WO_ [T_9;_
M .A7\>?^'N^,O_SQ*/\ AWI^RW_T*_CS_P /=\9?_GB5],_&;Q/K7@GX3?$C
MQAXM'C'3//T?XF_$RUTZ_GT#X<_#>3P]\6=:TGQ);^,=4BM-,E\M5OB%K>EKI/AN_C3B-SWK_AWI^RW_ -"OX\_\/=\9?_GB4?\ #O3]EO\ Z%?Q
MY_X>[XR__/$KP7XK?M??&/P%J/QGTVXN_@7\/-2^'_\ PHZ7X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MMXY^/<%QX:\>FTTWXC:#96H_X7=\9*_4&-P&,?"
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MM&8P. >J_P##O3]EO_H5_'G_ (>[XR__ #Q*/^'>G[+?_0K^//\ P]WQE_\
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M:O\ LJUS_P"H+X#H ^?!_P $\/V6U(/_ B_C[CU^-OQFQZ=_B+BG_\ #O3]
MEO\ Z%?QY_X>[XR__/$KZB^)^M7/AOP#XU\1VFO:7X7F\/\ AC6M=/B+7-)F
MUS1M&@T>QN-1NM1U72H+[3)KS3[:UMII+M$U"S*0!YC/&(R:_/[Q;^TE\<_!
MO[,WP9\>>(/%?P4T3XT?%B5'T[X>>)/#VL:?JGC*]\4V^I>(O GP]\+>'O\
MA94Z>'==TKP@;*?XE^*+Z_\ $VD>%M/TSQ-XIU'1KC2])NK>0 ]?_P"'>G[+
M?_0K^//_ ]WQE_^>)1_P[T_9;_Z%?QY_P"'N^,O_P \2OD7XU_MM?M ?#)_
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M:_2V!(\(ZG 2%%V&'_CU>>$XC/. &. >@ ( KQOX._P#(>^.G_99[_P#]
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M="\ VGB+QK?_ !7F^)NIW&K3X-^)QI'B#2=%TZ#Q]HPU#Q?XDMFFU&
M&PT'Q7XS:[UG3M2M?"VE_%VTD6., ^J/^'>G[+?_ $*_CS_P]WQE_P#GB4?\
M.]/V6_\ H5_'G_A[OC+_ //$KX*\9_\ !3[XA'6_BC8_#KP?X5AT_P #?%JT
MTBUTOQ;!XITGQK>_#6R^&6G^+];U+Q+H_B?3_ T7A[7-:UJUU#3] TS1/$7B
M_P =GPQ>:8^A^!O%.KO:?8OLZY_:I\21?M4^'_A)I1\"2^!=2UW0/"Z:/<_V
MA+\3?$.?B7_PL#P^]OJ\-JO@[P_>>$H?"&JKJGA^]N&U^ZUMZC_96AS@'3-_P3R_9;=2O_",>.QD9!/QL^,K %?F!('Q$R>0/3GJ0.:\5^#O
M["'[,^N:A\:?MOAKQR?[-^.GC.TA ^-?QE!VC1_"P)!/Q%)^Z/0<$Y["OU"
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M 'KNJ6]]K+ZBUUJ'BJ\TO1KN=0#Z5_X=Z?LM_\ 0K^//_#W?&7_ .>)2'_@
MGG^RVP(_X1?Q[SZ?&WXRY]>WQ$S7Q7\0_P!O;XT>"(OB7:)'\&_'EUX)\1-J
MNB:GX#MM6\0Z-XY\,W7P_O\ Q3H/@7PS!I'Q"U.>_P!1\9^.=)U?P4-?NM=M
M_P#A'+[1M3U#Q7\-+/PUJG@?1]?^M]+_ &E?%T7[5^@_"K4X?"%I\.?$_A_0
MK+PPVDZMX<\1^.M3\93?#WQ!XW\3CQQHUAXSTO6?!-EH=GX?M]+L/$+> -M/6+I+?18M5TB[U!8$ -K_AW=^RYR/^$8\? $%6S\;?C/]U@5;_FHI_A)[&O'
M/A-^P=^S5K>J_&=;SPSX]/\ 9WQCUK3K;'QN^,N?LM!&2/U"D.%F0 !1"S?FI''Y9__7QX)\#F"ZC\=R2HS\>/$JY=@HR_A[P6@"D\
M>82P$0/WI"BY&.#_ ()X?LMJ0?\ A%_'W'K\;?C-CT[_ !%Q3_\ AWI^
MRW_T*_CS_P /=\9?_GB5WO[2_P 4?'/PC\.?#S7O".D^%M8M/$7Q<^%G@/Q7
M)XKOM1LI]+\.^.?&>C^#)[CPKINEO]OO_%WGZ^BV"PAUAN#'<36US;PO;M\R
M_"/]K#XA?$;P-\8-&M>O9]0M/"7@.X\?-K0OOA
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M_P#V6;XA_P#IT% '@O\ P[N_9<_Z%?Q]_P"'M^,W_P \6E'_ 3P_9;4@_\
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MQGX]LM.BG\7>+[V9+=?&_B!PLEU=ZUM-O_4JU>@#\]O"6/\ A%O"^1N_XICPWQYGE9_XE$7_ "TP=OK[_=[U
MT#W-V@7RKAE:.6&:*%+W+>?!,D\! /\ =GCC?Z+7BGA;X9S3^&/#LW_"WOCQ
M!]KT30[[[-9>/]+FLK7S-*C79:K_ ,(_)]D3G:%\MLK\AQG<-_\ X5=-_P!%
MD_:!_P#"\TS_ .92O0.<]4%_J$ER]W+JEX\DTKW"RQ77[R#4GC,=R%Z_>MWE
MC;C[K&B2[OBQD^VR&3:X,TEUB?:RE)%7G_EHA:-A_=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M;AU95^,/Q^8E6PO_ GFDM0.D&Q^*^G@1Z9X\T',F_X;^#4S+GP=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M?^%WX?\ _G=T?\,[:G_T<7^TQ_X7?A__ .=W0!].R?ZN3_<;_P!!->-?#?\
MY*+\?_\ LH'A7_U3?PQKA7_9SU)T9&_:+_:6VNK*=_CO0@IW C!,?@*W?DGC
M$R-/#]N"GCS2"S_\6Z\'9(\SP?<(
M<\DYA?C)&TC>H!]T:C:6U_8W=C>6]M=VEY!):W5K>6\5W9W-M<*8I[>[M9_W
M5S:S1.T=Q;OQ-"SQ]6%>8Q?";X;N%M3\/O"'V2'0_#?AZ&VD\.:-)IMKH_A3
M5;S7O#::7HTL4T6F1:=KNJ:GJ&FG839:C;VUZO[RW1QYS_PSMJ?_ $<7^TQ_
MX7?A_P#^=W1_PSMJ?_1Q?[3'_A=^'_\ YW= 'JUQ\-OAW?#68;WP/X0G7Q1J
M^GZWXC$^A:NZ[I*PG3+_5E6U2#5=4M1;Q2P7$C;X)85=,LN3U&F:)H6G7
M37&FZ3I=A>3@/<26&G6%EMVF/_ N_#_\ \[NC_AG;4_\ HXO]IC_PN_#_ /\ .[H ^GVZ'Z'^5>#?"7_D
MHO[2/_94O#?_ *IOX9US)_9UU+@-^T1^TPX+*I7_ (3O0 /F8+DD> ;<[5SN
M;$R?*#P_W&\:^&GP$U&^\<_'J$?'W]HNW.F_$G0K?[59^/-!!N?^+0_#$;91
M_P (=O,+MQ$M'5M!TAXP @TW0-7UC5;FTM0N+>[NHID("FO+/^&=M3_Z.+_:8_\ "[\/_P#S
MNZ/^&=M3_P"CB_VF/_"[\/\ _P [N@#W#6O"7AGQ'&MMKOAK0=8B2YTVX5=;
MTC3+^.273;F#4+"2U#I*8I[&\M;>]M',;&&XMXI$ V*RW[31=*M)X&M]+TV
M1W]U?6_V>PL;5;;49[2>UN+Z-8K>.4ZE<6DL]KM/_HXO]IC_P +OP__ /.[H_X9VU/_ *.+_:8_\+OP_P#_ #NZ /I\]/Q7^8KP
M+X/_ /(]?M#_ /97H/\ U4WPGKG?^&==2)4-^T5^TPRETR/^$[T _.O#$>
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M-?U:S\2:KO\ #FF3?VAX@M;JWN+#7M4MBI@U'5+&]@MKX:M)NMS\)^$TUC2=?A\,Z#;:SID.JV^C:G_96F?VCIUCK;+<:G9Z=>P'S[1=2GMOM=
MP(BRRQ":%@-T@7Q/_AG;4_\ HXO]IC_PN_#_ /\ .[H_X9VU/_HXO]IC_P +
MOP__ /.[H ^GG^XW^ZW\C7COPL_Y&/XU?]E6N?\ U!? =<'_ ,,YZDX*-^T7
M^TMA@RG?X[T+;R".=G@*W?Z8F3G&=PRC>9> /@-J%]KOQ9A'[0?[24!T_P"(
M\%OE/'FCEG_XM_X+!V^9X.N%P<9.87X'\)PR@'W!J-G;:A8W-E>PPW%I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M2PN,2';X?_PSMJ?_ $<7^TQ_X7?A_P#^=W1_PSMJ?_1Q?[3'_A=^'_\ YW=
M'T^>GXK_ #%>'_!W_D/?'3_LL]__ .H%X"KCV_9TU)AM;]HK]I@@D9'_ G>
MA 'D'!,?@*V?;_>VS)QG.X91O+/AM\ ]0O\ 6OC*5_:"_:+MS9_%Z]MA]C\>
M:1EPO@/P&,RB3P=<(3CUA< XQM.& !]OZYI6GZYI&H:1JUC;:GIFHVSVNH:=
M>6L=[;7UG+@7-I);2D1R"XBWQ*7.(W99<$IBO.9OA+\,[_Q;>^.;OP1X7OO$
MFH?\(DTVMWND:=?WL=WX$?6)? \ME,\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MA 'ZF/P#;OC/7$R>^X94^4?#/X!WU_K'QC*?M
M!?M%V[6GQ?O[;-GX\T@E]G@+P&"9A)X.N%SC/6%\-C&TX=0#[IU.TLK_ $^[
MLM1M8+ZPNX'MKRRNH8+BWO+:8>7-:SP7(,$T5PC-"\<@(=7*CYB*\RL/A/\
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M_P#SNZ/^&=M3_P"CB_VF/_"[\/\ _P [N@#Z!? O/\
M:?QWQU_X7MXIQ_X3?@VN>?\ 9TU)U*M^T3^TPP(P5_X3O0AGV)C\ V[X/\6)
MDXSG<,JWC7PD^ U_?ZQ\:POQ_P#VB[8VGQGUVV#6?CS2,N$\/>'L^:'\'7">
MG6%P&QC:2&4 ^]M0L+2]@6.\MK:\B6XLYQ#>6T=U!]HMKR"YM9Q%*#&)[6ZB
MAN;2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MFHZ?$7QIM_;6VH8#6_'CO_#.VI_]'%_M,?\ A=^'_P#YW='_ SMJ?\ T<7^
MTQ_X7?A__P"=W0!ZW:^ /!%A8PZ=IW@_PI9VEOK5SXCLK.RT#2[.P'B"ZAEA
MN=6AA15,NJW4$\MM?ZF 'O+*6YM2Q\YU.OX4\+^'/"&EZ;X>\+:'I?A_0-+@
M,>E:-HUA9Z9I6FQN]S,3:Z=" UK)=RW=[+(\:KYN7,GS/)N\-_X9VU/_ *.+
M_:8_\+OP_P#_ #NZ/^&=M3_Z.+_:8_\ "[\/_P#SNZ /J"ORM\6_\CEXX_['
MKQM_ZE6KU]7R?LZZH4*C]HW]IA2V%W?\)YX>4C>P4X+?#EANP?E&,EL %20P
M^1XM!ET&]\1Z._C3QEK+:?XV\>VS:IX@UW2Y]9O"GC77SYNH3)HELLDW.P,L
M$0,:I\O<@'Y_^$L'POX54[?WGAOPQ$N^.WE7?-I<$4>8[K]PQ#NN"_W3AE^<
M+7T)=?#72;C2_"-OI.OI>^+/$WA=/%E_;W]]8)IFE6#Z1K6NZA+)8Z9_ITDR
M:;X?NVLA!Q'>BWDD_MO_#7H@\8^+A9:;IW_"3^*8++1I!-96LFM_V9]@([VB?PHP^5AWC9E_BYZ5NO
M5?FLL
M-U;^)O"%M;RR6LMK#)+'->>7:)/*FM;?L]^.+R^72H=3\,G58PUY?VCWNH6Z
MZ5I;:GK?AZ+Q*=6?0++P[>F;5O#&JH(M#N8KI2X^U!XQ+&_E'_"5^*Y+^UU.
M3Q5XA.I6EV]S:ZM;ZULU&PBO(GLKE[;4N/+E-I<3Q!,?Z2'-MTFK1E\>^-;R
MST"VE\1:S%!H0O9]'@L-5_LB5KC4;O\ MYMM!CZ[I=YH>M:GI%[=6UU/IUPUE++9_P"DP7K1G=_:OVK/RB8KY0/\1;;_ !5E
M5- *]^(: "BBB@ H
MHHI/9^C_ " 1NA^A_E7Z,?\ !.K_ )!'Q\_[*OH'_JH/AE7YSMT/T/\ *OT9
M_P""=/\ R"/CY_V5;0?_ %3WPSKGE\+]/\AK=>J_,^Y_B9XY\-_#/P#XL^(7
MC"ZN+/PQX,T2^\1ZY-:6YO+LZ?I<+74]O:6:_->75X(Q:6]FO-U-.D YDK\S
M-3_X*-66B?L8^%?VBK_1/!%MXX\9^,/&?@;1O!R?$K[7X+T;4_"'CKQ5HFLW
MWC'XE*@^SZ?X+\#>&+CQ)XAN+7%_JNM1Q>%-/3[:UNR_K)=Q1S6\DM2,8(E175V@=2&$D4ZJ8IH2I$T3O$1AZ\G@^$7PXB?6)!X.T#R/$GA\^&M?TA
M-*M;70]4TU?$.O>)+A3X?G_TMXT7(_P!F#1/"/C6PT=S8
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MX(L?!.K>*-7\6^%-=\47OQ/\2?!;0?#VB^+_ 1&^I2WVH^)-)TN%_$$L;Q:
M-HS>(KJ]VP:!,1^F=VBO;R*RLX^0B-?,_>,KJRQN(B&:&1@$GC8^5)"9$G_<
MM(*\QL?A-\-K&]AU"R\$^&8S;IIKV,<6F6K:;9R:=XAU3Q78WVG6#YTK3-1M
M?$NM:]J-O=:6BW,=WJHEE?RR #\K?B)_P %.?%'PBTKXTM\0O WA>P\5^!K
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M_P#JF_AG0!V'QD\5:WX&^$_Q&\8^&= 3Q3XE\,^#/$.M>'/#MF7%QHNE/?W^I:/;6JWNI):P&5]4L' ?$%S'<&(U\*ZI^U?\ %"W_ &?]*^(V
MB6'PMO?BAH_Q"\3?#;QK\.-.
M];-K'I2WFGZGXBL+%;AO'NHZ7_9.AWMEIWZ.>(=%T?Q)H6K>'_$.G66KZ#K.
MGW6F:SI6HQ)/8:CI=Y$T%_9WL$H:*>UN+9Y8IX9@898V:.4>6S5X1=?LR?L]
MZE9Z59ZA\(/ =U9Z19Z7;>'M+3POH%KI.@+80^*D@N_"FGVRKI^B7-ZOBOQ*
MUW/I1$]S:ZQ^.:0D ^-OC9^VI\5_AA_PMQ%^#>A6 ^%WC#P[ID3W?B/Q
M%XKO=2\&7/P8UKXKZO+>V'A'3%U&UUCQ%J^AWGPW\"-;W4]EH^IW4OB?Q7=6
M/AW2]8T>?V.[_;(T&'X_?LY? ^RLM-BU#XQ>%;GQ=XNN?%NO:?H6M^$X-1^&
MFN^-O".CZ#X:,-?GT'6&U^QTS&G>%/#VE:C>NQDN./IGQ'\)/A=XP>
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MKX3^'%^&&J^&O$?P^\1>.?B*CV_BN#QIX:T;PLTF@+JUE=?VKMPOH_AG3;Z![B[TZV^(&I1D7.E0LGK^F?!WX5Z->ZEJNG?#;P9INI:[XIM?&N
MK75OX6T-//\ %EF\[6?B25X;2$_VY;-J.I:A)J@;S#=WVL7.\M?NS];HWA#P
MSH^MR:[IWAO2M/UF_MM0AN-9MK"SCU*6UU#59M=OK"[U&(M+=176MW=UJ8B0
MA$D0NRC.2 ==SM.=F-IV^7]W=L;=GOTSC]>:\B^%G_(Q_&K_ +*M<_\ J"^
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M"!?L7AB^NK#4;BVFN=(V3W$-Q)!MPQH-M\7]-T.+QGK]QXEF^$-KXO\ BG\/O%?AS5(=+T=?L7Q$\*ZK\)]1U+Q)
MXCL#<>%_#OA[4=3DCM+ZX\*BUNO>=7_:]U.P_:L\+_ FS\/Z5<^ +_3_ 9#
MXE\?7IOB)?$7Q4T'Q[XB\"Z#X5N;8R6=P\>B> +S4KZ75'N3J=EK%Q=PW6FW
M&GII%Q]%W'[.OP,U)M0%_P#"+X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M=J]C:7]]I,WAS6_#GBKQ'XBU#Q'!']
M:\-^)=,L=;\/:_IEYHNN:/JEFNH:9JNDZI ]EJ&G:E9.&BNM/O;6>6WO8)@8
M)+:259QY)>O%?"_[.OP/\&:Y8ZQX8^%W@/1+O3K#P?9:+%I'AK2]+TOPW%\.
M(/%%IX,G\*Z3 4L="BT&'QSXMMOM&C1I=L?$TLM[X^>()?"'[+?B1_AS^TG9_L_?"JRTGQQ\5M.U?XV^+#X8.JZY\*/!WA_4_#<
M&IW/Q-CUN_\ #_P\U#4K9SX#\(:[8?$'Q]KL,^A?#W4[>3W2Z_;MO[?]O7PE
M^R@WA'3]+\$S>#] FU[QY?WM]J5SJ?Q&\;>#_BEXQTKPGX9FT2W_ .$?@?PU
MIWPA\40^(+N_E>SU::]EATN:WGT2*R?ZZ\7?LY?L^>.M&L=&\>?!'X5>*?#^
MC>+=6\<6>E>)_ .@:SI]AXNUJ6^O];\8VEI?V]Q%8:SJ5_J.I7E]KM[NXMYF"3L];OA_X#?!GP[XRT3QSHGPH^'>B>,/#=GXLTWP[XDTOPCX;M=:T;
M3O%VKS:OXFMM+U2QTFVO--&N:GMWMT:A_Z@?@&@#J_B]XAU'PA\,/'7BW2M6\-Z#>>%?#6J>)3KGC"'6+GPOH]GH-
MK)JNI:IKMOH$T&K7&FV&G6EW=7$%G,AF2+RYB;=I@?@CQ_\ MK^)O@I\!?V>
M/&'Q<\.^#=)^+7QR\6?#ZSB\*6>N:SX2\%>'/"/B/QWX;L]2O;K5-9BEN;;6
M_"O@SQ5HEK-X7N[I(-1\8ZC9:7MPU+2]0@6XM-1LKH>3M?"\U]9ZGI]O65C-93M WV"\M8+M-CVZ,H!^
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M621++6O$7BOQ+I'A#P_I4B0_Z1>2W^LZ]8VMIIEI_IFK7M_MM?$#3?@U\(_B%IWA/P1:ZUXN\+_%_QMX[TGQ+XEUJ"PTS2O@3JFG:7XS\'
MZ'?11G4H_'^L2:K+IUA!J2R:;H6NZ)J%A>Q27>U7_27Q7XU/PSXIT
M;3?$/A_6H8[+5=$UBP34],U*UDN(2;:\L9 8[B%G5"5E'DHRK)+^[1J\DC_9
MX^"$D5E;3_"SP9YM+6
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MKH=U,\MSI,.MV\?VE8/-+1/$K B#= V4=]P!Z1)M$,#Z1EOY?R/X>
M#? L9U/X[C_JNWBG_P!1OP;7OLW^JE_ZYO\ ^@FO _@5_P A3X[_ /9=O%/_
M *C?@V@"U^TG\5-3^#'P9\9_$/0]&L_$&N:-'H5CHFC7]P\%K?ZUXH\3:+X3
MTF&18GBFOB-0URVDATB">UN-;F1-&M[RSFOTNH?ACQO^W;XY\+?!3X%>/%^'
M^@2^(_B0?'.H_$CPUJTGB?48/#>@?"BZ32OB3MPI;M(9]*UVWB:\;]/_%'AS0?%WA_5?#/BC0]-\2>']:M6L-6T+6+*TU'3-3L
MYG3S+:\LKX-:7,1(#".=67>JL 6"BO&X/V=/@E#)IT$GPK\$W=E8WOAK4-+L
M+SPYHUSH_A_6O!EEX)$-T?L\D[. ?FQ
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MPFTFT7[7);@?I?\ 7XK^&?C7\./!OQ&\*^(_#_BO3]?L+DW^L^#;O5+OPNW
MB33I/[)\5V5G)J@&HF'3?$]AK&F:2;X>5_9MB!;G_5BMV?X3?#.Z22WF^'O@
M^6VE\8/\0);5O#FE-9OX\FT^;0YO%%Y9"T1;K6IM,NKBUO-7?YYK1YHRQWMO
MU?A[X!\$_"_PWH_@CX=^%=%\%^#='CO$T/P]X?L[*PTG3HKF[N;^9+:WAPZM
MJ-U=76HOY>1N#;\'?N /0:_*WQ;_ ,CEXX_['KQM_P"I5J]?JE7Y6^+?^1R\
M-O_4JU>@#\I/"_@;XAR>&/#T\7[07C^SMI=$T-H+,^!/@WITJ
M,B.UN8_ 6J2A,?N_]/O@[*2 6D*JV[_P@OQ%_P"CC_B!_P"$'\&__G<5VW@_
M_D4O"?J/#?AHJ?-EAV.-*C,M;36-Q<>*-9LHET744O[2STZRNK[Q7#HNMR:Q-F*!KW4- UFU@#?\?,\\5JOS
M3@'T#G/E3_A!?B+_ -''_$#_ ,(/X-__ #N*/^$%^(O_ $M[BOK#_A37C.66.QMTLI[[[3XRL;BPNM6_L\7MVF=&Q\M5/#WPQN=<\ S^./\ A((X(@_B&WA-Q91#2+VY\-PZ-&6NM>G_ '5G
MK'B1]M ! _\(/X-_\ SN*^J-1^$WC72)PFL1Z#81WEQHRV-P_B2PFLM336=.+KI.AW
MM9HT5_<^+89;W6-8/_'O:6<7A&2ZN>OGQPO;_ /+4B@#XX_X07XB_]''_ ! _
M\(/X-_\ SN*/^$%^(O\ T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M:MMJ"6^E7@!W?\ PH[XTG '[8?Q:))&,^!/@.1U'.!\-LG'4 =QT/2O*_ GP<^+
M]QXY^-5M%^UI\6(;FV\5^$OM-\/ GP'S/NN.0,
M7&4;","8PT:&1OM*S')_X^#OMNN 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M?&'PO^*.MZCH]KXV>3Q'+H-Y')X1@TXWGQ%T"RO/$%Q;ZK\U
MJ$?0OCSXX^(_A]\7OAC\-3\,[W7O#WQ.U1M#T[Q%8^,]%N/$-I=P:/K>M^(-
M03X?6UM>:UJGA+P>-'T>P\:^,-0U6&WL=5\7Z3:Q^M\6T9BJAO^$$^ [8W,!T'PWR20<#'.3Q7C'PQ^#GQ>N_'7QXBM_VL?BS9W%E\
M1=!@N[P> O@/F^*_"+X8A2#_ ,*X.W:<-GN,C/.*_0&VE1F"*MM%;6QGM(@S V7S[>IQ(ZD$CFO&?A+_R47]I'_LJ7AO\ ]4W\,Z .._X4?\:?
M^CP_BW_X0OP'_P#G;4?\*/\ C3_T>'\6_P#PA?@/_P#.VKZ$\::AK.E>$O$>
MH^'-$/B3Q!9:-?SZ)X?&I6&CKK6K);N=/TR75M3N+2RTV"]NO*@N+Z:XC-K
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MQSX9?!WXOW?B[XYP6_[6?Q8L9[+XI6$-UM?+C!!./T'3=G )"JZG.XR[U*_$_!_\ Y'K]H?\ [*]!
M_P"JF^$] ')?\*/^-/\ T>'\6_\ PA?@/_\ .VH_X4?\:?\ H\/XM_\ A"_
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ME:(=(O;?ZQUO]H&^\-?%SX->#KGP-H6.A?%6R\1VE[9VWB>T\):
MMXZ73)M)TFSUO39-"DT?1[A++6KSQG;3W&H:M9Q^#[+QAX?D\0:SX= )O^%(
M?&@=?VPOBT0?EP? GP'(._Y<8_X5OUYX]#@UYGX"^#7QCN?$7Q>CB_:Z^+-N
M;3XBVT#D> _@1EB/A_X*Z9^&Y'4]3@G'3J1]VJ&"N&.]@SHSXY"%"ZYY//W0
M?M"C_C3_T>'\6__"%^ _\ \[:OH/QKJFMZ)X4UW5?#?AP^+=?L;"2;2/#?]K6.
M@Q:O?@JMO:W>M:D?L6E:>782:C?S).;:P2YEBM;R98[6;\^-=_;VB\+_ 3^
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M CME<>$K/2]1M?#J:>-;N?$FIRZIIE_-J*:SIFB)X3D^S1?9]M_ [XU,N!^V)\6ADJ#GP)\!R"-PW+C_A6X^\,J/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M.Q-?H&I.\'>/G4'RSC<.">,'W_+/7&:\1^#G_(=^._\ V6F__P#4$\ 4 M ,*/^-/_ $>'\6__ A?@/\ _.VH_P"%'_&G_H\/XM_^$+\!_P#YVU>U?%7X
MA^&?A/\ #[Q/\0_&&IVVD>'/"]@M]J-Y=7UAIJ,9;F"RL["&]U.\L+&"]U:_
MNK72M.,]W#OU"]MHHB\SQQO\A7/[7?B#5?V>_@E\>/ _PRL->N_C9JW@O0;;
MP!JWQ%TKPWK-CK7BO5KC2K/2=+OH/#GBBPUK5K58]3U364+CR-#\/ZE/'+;2
M1"ZA /4_^%'_ !I_Z/#^+?\ X0OP'_\ G;4?\*/^-/\ T>'\6_\ PA?@/_\
M.VKQK3OVRM7N8]7MM:^!WBFRU"R^,?P]^&C^$;C6+BPUW3_A[\2/BWK'PJT#
MXQ^(;#Q]X5^']M)\/]9N]!U+4-+3P'J7CZ75[LP>%[B*RL[:XOK7V[5OBYXO
MT/\ :'^'?P5TOP-HFO:+XS\+>,?%>I>,+/QSY.O^#_#WA:&*(Z]J_@Z_\/O/
MJ>EZ[XCO_"WABUU#3]MX#LJL48*Y7_A6XSY;$.!GJHKQ+X,_!OXN7=]\9_L7[6'Q6TX0?&;Q3;W07P!
M\!T:\O$TKPP9-1#?\*X/^M *$<9#FOT1'F>0_F8W;&^OW3UKY^^ 7_(4^/\
M_P!E^\5_^HWX.H YS_A1_P :?^CP_BW_ .$+\!__ )VU'_"C_C3_ -'A_%O_
M ,(7X#__ #MJ]/\ CIX]U+X8_"GQGXYT;P-KWQ+U;0--MY=-\">&K34;_6?$
MU[>ZE9:9;Z=:V>D:;J^HW$1EO5FOH[33+V0Z?#=$P.@;'SKXQ_:KU[0O@_X2
M^+OACX'+W3O$L'B.Y\%W/@K0]'US0M(\4>*OB;+
MXHCN/#:>#[_P_P"'H1K.C:C_ ,32U2$W*@'=_P#"C_C3_P!'A_%O_P (7X#_
M /SMJ/\ A1_QJ[?MA_%O/;_B@_@.WZ#X;\_Y-?)_B;_@I=X)TK3?%.O>#/A]
MK'Q \/Z#\69?AMIU_9>*--\O6O#.B?#W0_%6J_%"RL_"VG>*KG1-#34+S5O#
MNFP:Q;^';!;K2+;6]M(FG_ !!O-0\+PZ$\WA+6/"&CZIX5BTO3]6U'7M1UF&3Q=9W<^L#3-'\+O;QN
M+/4M;O&CE8 YAO@A\;MIQ^V)\61D8+-X ^! " \,Y/\ PKC^!27'NHKQ7X0?
M!WXPW>K?&C[+^U?\5M/$/QCUNWN&3P'\!]UVR>&?"K#4 ?\ A7! ,S#9T!(8
M\8Z?HG-_JI?^N;_^@FO _@5_R%/CO_V7;Q3_ .HWX-H Y3_A1_QI_P"CP_BW
M_P"$+\!__G;4?\*/^-/_ $>'\6__ A?@/\ _.VKU7XX>/=7^&/PK\7^.?#_
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MEBSTO6/&UWJ=[964'CO4_ 6J_$VS\+:9IMN8_!DFFPS^(+< Z5O@=\:B,#]L3XL DJ#YG@/X#NI4L RE?^%;C.Y"0>
MU>2_";X-_&"\C^(_V/\ :S^*6G&V^+OCZWG\OX?? ?=<,FIJ=RD?#?C#M \:\4^"G^J^)__ &6;XA_^G04 <#_PH_XV=_VP_BUC
MO_Q0'P(7]3\-^/\ (I?^%'_&G_H\/XM_^$+\!_\ YVU?4%]&DUL\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M$^C7'B'2]4^)OBWQ-?V/C7Q[!=:]=^'O ]KMMM;Q1X0';DDG]7:_*WQ;_P CEXX_['KQM_ZE6KT ?GKX3"-X5\+K(2(SX8\-
MARK;"J'2(0S!CTVKD^^,=Z].7X@^,;:3?'XJU.6-K:PT];5[B*2TBTS2+R#4
MK%G6?]T?)N[."5-_22-2OS "OF?PQH'Q4;PUX;EM?BQH$-JVB:(8+.X^#\4D
MELITF/"?:YO$$4=U@<;V=M_P#$M9[F[C\;ZC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M@?N?&-M)\Y&SY9T^]\VY&;.=?BQI_VEG^#
MV]9!_P *W\&;6*_\+&&M?%.GMJWAGQAH.J^&O$&DK>7NGMJFBZU8SZ?J>FB^TZZLKVT^W6<\UJ9[>ZA>
M,2EMQ4,K?.D_[(_P*F\/:3X/U'PIJVJ>"- L[6V\.^&]2\:^.[G3/"\=B-6:
M-M"U*^\6P:OI>ERZ-K=WX6UK3K!SINH>%9;?PMJEM=Z)9W]K)WO_ A/[0/_
M $73PE_X9?\ _&11_P (3^T#_P!%T\)?^&7_ /QD5Q&YYYJ7[''[-NMWNLW=
MU\*=$AO-?N$NKV]T^]\0Z!#I-/UA)OA];7O\ ;GB%M4TOPC%H
M*>(H=:U2XOIK^">[@N>UC_9P^#D_BCPOXNOO 6FW/B'P6HMO#-Z/[8C@TY4O
M]X\-Z5>:YJ%QX8T'4;22'PMM3PE_X9?_ /&11_PA/[0/_1=/"7_AE_\ \9% 'LT4>T ,Z22&.YGDRGDLTAS&
M+F.(@D!D8QD[@-C DDG!\L^&_P#R47X__P#90/"O_JF_AC66W@K]H$*2/CIX
M1R!G!^"XP?;_ )*1WZ5Y/X \(_'67QS\;UM_C3X0M9E\>:%YK#X+\R@?#CP?
M@Y/Q(YS]XD$],GK0!]0_$7P5X9^)'@7Q7X!\::=/K'A+QAHE[X>\2:3;W.J6
MMJ?A75]6\&:+::1#HOA*Y\?>-+OP_9+H\^H7=N^G@^*#??8OL^L:EH.I:3,MQ
MI^M>'[NWT?6+2XTBZOK>7L_^$)_:!_Z+IX2_\,O_ /C(H_X0G]H'_HNGA+_P
MR_\ ^,B@#'MOV7_@1;6_CJR'PUTOP:1IU
MM<:R%\/:#:Z[?WVL1Z)X?MM.TA)[H3)9)(F5TA^SY\)Y/BQ8?&27P],?B=::
M3<:&OBB/Q1XL>6;1)]3U+7KG1+O0YM6GT*XT>#5==N]1LEGM'6WO;Z"X@$<\
M5NXF_P"$)_:!_P"BZ>$O_#+_ /XR*/\ A"?V@?\ HNGA+_PR_P#^,B@#W4J<
MMSCYVM+\O_ IG;N^8<;O^%CG&?IST[UXE\+/"GQOG\<_M!K:?&?PG;72_%/0OM;'X
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MCP:G)=^)+S5M,?$EEXU\1:^DFJ^-;&.VL-=<6-JCKWW_"
M$_M _P#1=/"7_AE__P 9%'_"$_M _P#1=/"7_AE__P 9% '$ZM^QU^S1J,>M
M3W?P3^']N_B/4_#NL>)Y/#^D-X7?5[[PSI=UX:L7N(_#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M]LUS;3VUQ;,[!?+N()TF@D"2Q;G15;YP3]D[X$S6MIXMP]J6O^,#I-EXB%[KR:IXBC0:Y_:%[=^+5U?4H/'DVOB;2?B+'9V=U?0SV5C*
MDG??\(3^T#_T73PE_P"&7_\ QD4?\(3^T#_T73PE_P"&7_\ QD4 <#JG['G[
M-6HV_B*ZE^$NAW,GB?Q'_P )=KBK>:_ UQ?L^K"\M+..PUO$.DZB-=U]-0\)
MZ08?"_B)]MO#XM%T\)?^&7_P#QD4?\(3^T#_T73PE_X9?_ /&10![T>GXK_,5X?\'?^0]\=/\
MLL]__P"H%X"JH?!/Q_Q\WQS\),HP6 ^#.W*@\C=_PLMM?&K[#\:O"ENR_%^]$I/P>+AF_X0/P&,[?\ A8PS^.,9S]0#ZR\:^%O#?C;P
MKK7A7Q?H6@>)?#>LVGV;5=#\4Z-9>(?#M_"DL=Q&FLZ)J0-AJ>GQ7$,-Q<6=
MX/L\J0D2D)DCXVA_X)[_ +)$6BZ)X:7X*Z._@SP?!X=M/!'P[&IZ_:^"?!:^
M&+[Q=?6L&CZ'I#Q3)XLU ^-X+\7<'C'3+F"Q\7VE]:V=K93^[?\(3^T
M#_T73PE_X9?_ /&11_PA/[0/_1=/"7_AE_\ \9% 'C^H_L$_LB:EIOBC0Y_@
M!X'FTCQ?\1X/B3XDMPE];1:CXSEBU:*XUCR4O8VTRPGL]>UFQF\.:));>'=:
M7Q1K]G=^'[>UUFXN1TGA7]D']G7PM\9-,^-_ASX:P:3\6-+T"\\-67C&T\4^
M/"+?PW'KO44BTI(=1MK26'O
M/^$)_:!_Z+IX2_\ #+__ (R*/^$)_:!_Z+IX2_\ #+__ (R* />@ ,#^Z /T
MP/TKPWX.';KGQW/_ %6B_P#U\"> !_6JQ\$_M '/QS\),,'*_\ "F=N1W&[
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MK]H!8I2WQR\).HCMPE:LGQV\4B8_\*>\S+#0/"V>#\1@3D\9.#W]J /KOQ_X-\.?$'PGK7@[Q99-
MJ'A_6[6*&_MTO+W3IT-M=0WUG>6>IZ=/:ZAI6H:=?6MKJ&GZM8W,%WI=]:V^
MH6\T#S-X6U:*R^'>HC4_ .G6/C/QW86/@_5Y-/N;?4M2
M\-0V/B&.477B"&XN3XLU.83ZQXE:6\DU>\NM-FN;:7O?^$)_:!_Z+IX2_P##
M+_\ XR*/^$)_:!_Z+IX2_P##+_\ XR* .2UC]D;]F[7FOS<_!GP78SZMK=OK
M^N2:):77AR35]6?0;#PB\OB9_#YT.\\3V>H^&K&'1=4L]:-_::MI\=S8:INM
M;FY=?4M%\ >&-/\ $GAGQ!:^'Q_:7AO1?$FA:%K=S=WNH:EIVC>+KW3]8UVP
MAOM:U&YU-]+O]0T#1VN[&XC-YH]W9:58:?C11<%.:_X0G]H'_HNGA+_PR_\
M^,BC_A"?V@?^BZ>$O_#+_P#XR* /=YO]5+_US?\ ]!->!_ K_D*?'?\ [+MX
MI_\ 4;\&U(W@GX_@$M\<_";* 2RK\&=A([@-_P +'./Z].]>)_![PA\<9=8^
M-ZV?QG\*VKK\:-=\UC\'MX8_\(_X>!X_X6,-PW'KD>#?#WQ \
M):SX/\5Z5'K>@:U#;Q:AI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M_P"$)_:!_P"BZ>$O_#+_ /XR* />Z\1^"G^J^)__ &6;XA_^G052_P"$)_:
M!4M\<_";*'0LH^#.PE0Z[AN_X6.<9&1[].]>1_"+PC\<)HOB8+'XS^$K1E^,
MGQ \YO\ A3ID$C#45!./^%C#.3SVZ9ZC% 'VC/GRS@,Q#Q$!51V)$J'@2?(,
M8R7/^K ,@Y45\J^(?V1_V%M6UK3/B-J/QGLM6FAUJY0?$O
M6;;0EU'Q?-/%=6ECJ<\D/ACPD]M%)+$(7\,Z;+"K30A&[7_A"?V@?^BZ>$O_
M R__P",BC_A"?V@?^BZ>$O_ R__P",B@#S#1_V*?V9-$\=:W\2M ^&UO9>
M/_$/@/\ X5IK_B6R\9>.;6[U[X>IHLFA6F@ZK%'XEDLKBWT_0]1N[.&\CC:\
MT^34?^$@T\IJ-];.OH_PI_9U^#'P:\3>)O$OPO\ AOHW@?5_&QT>+Q1>:;=7
M;S:A'X5TF72-(M9XFU.ZM[?;;7!G>TM8VM;]XAJ^J ZU'!*MC_A"?V@?^BZ>
M$O\ PR__ .,BC_A"?V@?^BZ>$O\ PR__ .,B@#WNORM\6_\ (Y>./^QZ\;?^
MI5J]?:K>"?V@L3E>'^"N]<;AGY1\3(CG&=I#C:V&P^-C?$$NF^*[35
M?%-MJNOV.JZA#XY\?K=ZC!X0^QQ7M ?G]X4*KX5\+NV2$\,>&I.&O4;,>DPNNU]/_P!)5PR@HQ_T8-@WW^@_:*^A
M[;X'^)K[1O"FH66I6$C^*'\-?9[+4K76-(TZ,>)(;R\>^TN[A_XDGB/4=+CL
MVU/6X/#_ /I*Z19WTEX3 LU?//A,9\*^& " 6\+^&T4M/]F3>^D1*@DD[QER
MHDB_Y>$+6_\ RUKU*V^('C2""TM;;Q!-!!9KX7BM"]FL5EI#^&;6]M_"=YH;
M/^YT^.WTBYU>74TG_P!&U/3DN]/NO]'NY,^@M/AKQ 5M(=;LTU9+1H9)-036M0N+&Z_<:?IGA74-+'@NSED_UU[XFMXT^=U->
M>>*O#>I^%-332=::%;^;3]+U:ZLK/_CWTB?5DOM2T_03[:!IE])&!V.K#\;=
MS\1O%]S%J\!U@Z5:ZSHEQH%Q8Z)H6AZ!I%AHLNHPZI<6]I8Z?_Q*UN-5UFWM
M_$$\_AO%U,MN_P!N_P!%:XSAZ]XBU7Q7KVI^(=YU._F/[V\DEM
M[*'3$'_7/3M-9CVPIP>U &91110 4444 %%%%)[/T?Y (W0_0_RK]&?^"=/_
M ""/CY_V5;0?_5/?#.OSF;H?H?Y5^C/_ 3I_P"01\?/^RK:#_ZI[X9USR^%
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M.>M?\%&_"EY8?&6_^&_PQ\1?$^R^$FHOI[3V7BWP)HG_ GUM'XNUOX;2R>#
MX-:U33A=7NH?$>VC^'GAG2KBP,6O:YK.GW4OEPM*Y^F/%_[1H^'GQ/\ @_\
M#CQ#\/?$R6/QFN%TRS\5#7O#=YI6A^,;_2O$FO7WA2>+^UKC6-:NM$M_#TT.
MHW^@V\GAW2QK_AJPADVREHLS2_V.?@5X?UPZSHG@J[L;N+6_#&MZ-IL?B+Q'
M>>%?"EUX.\81?$'1+30/"4VO1^'_ QX:'Q%7_A8&M>']!:*;Q!XBDN-1NMX
MWH.VUG]GCX;>+O&7A?QIX@A\::S?^$-9M_$^G:=J_P 0_%]_X?.OZ5?SZYX:
MFUWPI=Z_>Z'K-WX8NM:O+OPS=75G*NA02006^)8H74 ^@%D#H0RX(%THW??+
M6[&#<"#@[D8G//!/O7DOPW_Y*+\?_P#LH'A7_P!4W\,:]7A1XY!DAI&14F+'
M:',2W$D\\$?HUQM-JFH>3?7 L+&YO6@TN-9M2E2UB:=X]/@<&.YOF2-A:6TH\FYG\N";]U(]?%O
MB/\ :MDLOV7O"G[1OA'X.>*_$-IXCM=%Q\.]6UCPWX.\6Z?_ &OK%[X9T33'
MCO;VTT.^UJ\\6#1]#C\,6-Y%/>G7!;N")C"WW%/@PR!O-VE2"83()0#QF,Q
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M6H:+X)\3MXK\37OB3P=93P^&YWU&XMX]/C,R2)N6?[*_PM_!MI#IFBP2>+O%Q\/FST6+6+?PC#>^%6UV[T;4;;P-IGBWQ-IO@BXUBUE;PG
MIWB'5-,LPMUJT4D0!].1OYCX 4&*/=(1R-\KW*3Q@_[,\"DGVZX(KQ+X2_\
M)1?VD?\ LJ7AO_U3?PSKVV-G++\R,A6M\E%_:1_[*EX;_P#5-_#.@#V/7]0.DZ)JNJ+97NI_V?8W%X=-TV*.XU+4%MXV
ME>QTZWEQ#-VGC^$O&7[>O@;P7\$?AK\=]2^'_
M (XLM*^)T/B"_70M>NO"7AW5O">B>#],\0Z]XLE\0ZG>ZV-%_M^#0_"FJ7&B
M^#]'UG5-6U[5QIVB6@LKR_AFA^^[TS+:SM;[//5"T1E)$0=2"IF(^<0*1F;R
M_P!]Y0?R09=@KY'U;]D?X/Z_X:T?P)J4?BP_#30H=.&A> +?Q1KMIH-G)IVL
M^,-4U*[ELUMOA;X+_$+QE>?";Q-\.O#UQHVH:AX=\"ZAXSC^)7AZQU30;KP'IFOZVE[X@NK
MSQ)XH\*^!(-%N8XKG6_$VJV,=O'+'&;L>Q>*_P!H,^!/C!\)?AEXB^'WBBTT
M_P"+$>K66D^+Y]2\/RZ3IWBVST?Q1XCE\+R6<&K7%[=_8]&\(:S+>ZI8V\J6
M,NJ^%K*4K%J&(H]7F\7_#GQRSVMW>6^ECQ-\)]&
MDT7P'MKUW7?"^HRZWI=OK/Q \6W_A2ZUT7.JZGH&N7?A:XU6XT+5Y/"D&MZKIW@BZN
MK:0:!I>H:E:0(D\4+J ?1"X!*C!9'56]E(W)_,?UKPCX/_\ (]?M#_\ 97H/
M_53?">O;HHT1XFC"\M.Q&\ ,MRXN)[B-.6(:YV)@GA6)S_>\1^#_ /R/7[0_
M_97H/_53?">@#U+QUK6K^'?".O:WH'AC6/&FMZ=9&XTKPGH%UH]CJ_B&_$D:
M6VE65_X@U31M#TY[N5EBDU'5=3M;"P@,MY'_ (_W
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M3=#EUO38/'TDSK_Q4D.IP^'M&A)UP2Z!?37:BQ:=CY7<_L*?!'4K2^B34
M_C @U3XMR?'246?QI^*=GO8YWM-1U:\N-.T36;9TT2[A
MM9-+:"_\,6,\?LD/[-OP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M_A=J/AK0?!%T?B#!\/O#.CZ'X?T'X?6?Q$\6:#HMGXM!O&>D>,=,U"XTGQ?HGC'5O$&F7^E0:99S6]M&_FH > 7O_!1'1+:Z^(-I9?"
M7Q/K=]X+\0>.+2QT:R\2:!IGB'4/A]\-H=>U#Q[\3);'Q4NBM:>'5TKPS+K7
M@U]%NM>D\:PZI96=F;:6V6XC^C=8^/NO:3\:_A1\++#X9:GXCTGXN:+K7B;3
M?'%GXAT&SCT#2/#VAOK.OZEK/@>\NI/%>GZ5I,UY\/\ PY+J"Q_9Y_$WQ$TP
M>6D2RD\AK?[#W[/WB"6^N]W4T$=]-\2/B7+=V7A:2'6+.]^%VAW
M,'B=[SPY\'M2T_6?%&EW_P ,K%#X2O+#Q'=6E@@O+FW9/>?"_P +/".C^-X?
MB!:P:G>>+8?#.J>#TUS5M0UO4)8O"NJ^)9O&CZ#;)JVJ7$EI86FO:C+'H]KY
M#+HVE:G!KQ3X._\A[X
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M?\$\?V?O$FAZ#X2\
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M^"+]?%?B.TB\-0O%_CIHO[0.CM\2(_B-H7@L^ (+BY^*'Q
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M#^C>*+CX@>(-#\'V;:/X>)(Y[;PO*$M-<\$:U?6NN>=XI\'^,[>&V@
M\4Z+JUZL&I>'=#\*^&[R-K;3I$< ^8]9_P""I7PJT1_%5K<_#GQT!X6^,+?"
M.X,=SX-$$BVP\0K$YG2)+272'N'^SF53]+:E^UQX/
MT#]I#0OV=]7\.ZW#K&KRZ9IUKXFFU'PS;6@\1>)O!/B[XCV6A0^'KK7[OQ+J
M.DVWA3P/J#7_ (IT"UFT"V\0I:Z,-D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M-;BU^WLF,<0M=WK]MX5\!0G2[>;QE/I^C64^K7_V2>+[#I\]UJ$H,=I)&<&/]B;X$Z?I6J>'
M;?1_&=OHGB341=:[8Z=\2?B7'INH:-;VMW9K\-;FSA\4RN?A%>V>K:F4^'4:
MMX:LEU+5[",%M:.?2=(_9X^'-IXZ\/>/3;^*-3U+PO;!O#UOJ/COQCJ7A/3-
M3.A7_AZVUW3/ ^IZM<>'=*UVV\)>(M:\):=JME;/-:^%[F\T@N#-O !]#2G,
M,A]8G/YH:\#^!7_(4^.__9=O%/\ ZC?@VO=G!$;<^6HBD58AT("-_(#/X5X3
M\"O^0I\=_P#LNWBG_P!1OP;0!Z5\1_$&H^%?!'B'7])\+:KXTU/3;-)+'PSH
ME[IVF:CJ5S+MZ_!EG\+?V=_B[8^"/$$NF?'[4Y;>"ZUBZL]'T7X:Z5!9J_B?6?&_BNW&HZ-H
M/AFQN8+)X[J74(TUBY,%[ 'E$49^W/'_ (2TGQWX0UKPGK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MTO1KO5[C1+34+O2_$6HZ);ZC96CRVF@&?1BZ^:Y4 ^A%.'9.P4,OT.0M\UXK\%/]5\3_ /LLWQ#_ /3H*]N' ]*\1^"G^J^)_\ V6;XA_\ IT% 'LE\
M'-I.J!B[)L0JK.4=R$678EQ:RL(6(E*P7,-P0A%O(L_EFORNUC_@J=\,=+NI
MK>^^$WQDL8;#XM^-/AIXK@UK2=$\.:SX.\+^!/%?P^\#:M\5M>T>YUE-1@\(
MZEXM^+WP\L-"TORH_$O_ C=[J?BZ[AL[73I([C]4KT.;681M*DFS]V\+()D
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MM.N+<]W\#_V5O@G\ /$_C'Q3\*?"C>&-5^(%KX7M_%(%[?7$M(DG9H[8"#4[[4-5M'+?VCJUTNKYWPJ: /IRORM\6_P#(Y>./^QZ\;?\ J5:O
M7ZI5^5OBW_DDL-3^!46GC1-"^RI
M>^'?B-<\,PVK\Q6MCR?C]_T%OV?_P#PGOBA_P#+
MNNV\(Y/ACPHJQQSR2>&_#$4-O+%<3+=W$VE016UF([6UO9_,O+AX[:)TM9?*
MEE25MB(TB>OVGPV\07]IX9O])U#3_&$?BU[G^S=*\-S:OXC\57MA93&VUJ^U
M6.ZT"Q@L8= G#Z4V^ZC\N+MGX_?]!;]G_\ \)[XH?\ R[KZ"F^'OCZ&PL+D^%M9::]\,Q>-HA8?\3"6WTZ]
MN+VVA:]N./[-@CEL5:[C_CMUE@_Y:5C:]I%UX>\0:MH-[-9F]T74)M'NQ9?\
M>+_8[6RN5CM.?^/F-K\&?_85\>M 'BWD_'[_ *"W[/\ _P"$]\4/_EW1Y/Q^
M_P"@M^S_ /\ A/?%#_Y=UZQ10!Y/Y/Q^_P"@M^S_ /\ A/?%#_Y=T>3\?O\
MH+?L_P#_ (3WQ0_^7=>L44 >3^3\?O\ H+?L_P#_ (3WQ0_^7='D_'[_ *"W
M[/\ _P"$]\4/_EW7K%%)[/T?Y >3-!\?V5E&L?L]*2K8,WAWXH>6, GG_B?Q
M?-QA/WB_/MZ]#]X_L)V7[5!TCXU#PKKO[.B$_$W1_MSZKX8^*TKC'PW\(%?L
MR0^,;:1E+X!(F0!M>^&9!([X(!_#VKGE\+]!K=>J_,]W73_VUMPSXE_9? YR3X,^,..A_O?$7'Y_
MAS4OV#]M/_H:/V7?_"+^+G_SQ:Z7]H;]HGX9_LP_#J[^)_Q1GUF'P[!KNB>'
M+:+PWH=]X@UO4]:\3ZC8V&GVUEI>G(\[^=?W4 N;UFBM-*M5GU/4+FTL+*YN
MX/,-+_;!^%^H^+/VE?!]YIGQ$T#6OV4/#L'B_P"(XU;P'J\,-[X.N5\8RZ5K
MWA4V$&HKJND:S%X(\4OH^EZE;Z?J>M6%E8>*/#MK?>&=6T+Q+/@;G5?8/VT_
M^AH_9=_\(OXN?_/%H^P?MI_]#1^R[_X1?Q<_^>+7R7I?_!6+]E'Q#+X+MX[O
MX@:?9^,OA=\4/BYJNLR^&]!2R\ _#OX.ZCXCT#QYXB\3WUIXGFN9?L>L^$]2
MLM(N? \?BJXUS4K"SET2QN;32M=DL/7KG]OKX#6/[+UA^USKUMX\T?X2ZK>1
MZ-%9?\(-K&L>,9K[5/%:>'Y8K32=!CO+F[M&O8KF^O[NPNY].T_2;2\U#7;J
MPO[.326 /4I;#]M;RW\OQ/\ LN%]IP#X,^+WXXV_$7=NVYVX_BQ7EG@6P_:_
M_P"$[^,XT_Q-^S0+D>,] ^W_ &OP9\8<'_BW'@[:80WQ%V8WXZ8&TG':ONB%
MU8!ANS)&&8["BF18)HGW,H\QI@8B)8;TEXF!&?,C KRKX>Y_X6!^T'M&6_X3
M[PL5_P!X?!KX8E3^!P?PH X/[!^VG_T-'[+O_A%_%S_YXM'V#]M/_H:/V7?_
M B_BY_\\6M_]I#]HSX;_LO?#;4/BG\4;K6;/P]:ZKHWAJT7P_H=_P"(M6O]
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M-MKU_IM/>%]7\ 7$GQ!M]%^$\GBV_\ B7\0M;\.VEUJ=C8^%?"F@>!_$'CBZ\4SWKFY
M\*VVDZI$S-K<<) />7L/VT@N3XE_9=?D;5_X0WXLH2^X>60TGC^Y0$2;6&Z%
M^0,;3AU\:^&5E^UV?'/QY&G>(_V:_M/_ L70?[1:\\(_%1@EY_PJ/X8[_*6
M/QC;.5*Y7B9,9R0P!4_>UA)#=);7=O+%/!/:I/#MD$(#K'+=YSE01XS\+&"_$#]I5R,A/BCX:M?MI_]#1^R[_X1?Q<_P#GBT?8/VT_^AH_9=_\(OXN?_/%KH/VA_VC/AK^S/X+
ML_''Q0OM:M](U'QEX1\"Z3;:!H5_KVJZAXE\8Z]I.B:,$L=.9)OL<-[JMM<:
MM?33VVG:5I4-]JFK75KI5G>W,7CG@S]N;X!^-[+]I?7_ [J^O-X7_94;Q2?
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M ]Q:P_;6 )/B/\ 9?/!V@^#OB\OSD8CPTWCZXC!#[2NZ%\M@+M8AE\?^&=E
M^UT?&'QV&E^(OV;!='XH:=_:!N_"/Q48"['PW\%[_)6'QC;2,"O0K,N%W9)7
M*-]R^'M635;+2[W[+J&FRZA9VM]-IFL0"SU/3YM1@-]+I^I6_GZA]BU>W8YN
MM&6](LU#.6?R]M>3?"9@GC7]HMR&8)\78'(4*6PGPG^$[$@.0IV@;L$Y.,#D
MB@#EET_]M;<,^)?V7P.M_/%K?^._[0'P]_9ST3PUXE^(^H:S;V?C'XA>!?AGH-OHNBZKXAO=1\5^//$F
MC^&M!B-L&32M LHM2UFSGU34K^2"UL]+2\NY+B 6YDC\(\-_\% _V<]>A_:C
MN_[7\865K^R5-?K\6KO4_#-];Q6DNE7&N:-JL7A)K&,WVMR7?B+P9J5AI>FP
M0IJ?BK4KBTUCP[9:SX3UW0M+1]@_;3_Z
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M7QR\\C=MQ]L:7>6EY;V]U9W%M<6E
M]9)?VL]N0]M=Q:B);R&_LI1PT6H1"2Y>($["NX,R@._F7PU=8]<^-LC@E8_B
MK<.V$=SM3P/X!8_)'\QX'^[W?Y U '!?8/VT_P#H:/V7?_"+^+G_ ,\6C[!^
MVG_T-'[+O_A%_%S_ .>+70_'?]H;X;_LZZ%X8\3_ !+U;6K/2_$WQ$\%?#31
MQHWA_5/$ES=>)?'GB/2/#.CBXBT8#3])TK3KS6(=1UN_U3'V70[+4;N'=M!_(/A9^W1\&_C%IOQ=NOA?HOQ#\3ZC\%;.34+WPAI_A*^B\3>,_#C^)/%GA+
M1O$OP[MKF>TM_$/A_P 0Z]X \6:?I^HSWMI9RW&AL+NXM+?=.@!WWV#]M/\
MZ&C]EW_PB_BY_P#/%H^P?MI_]#1^R[_X1?Q<_P#GBU\MVO\ P5/_ &>W\'>#
M/&/B7P/\??ASX<^(OP^\<>/O"-]XS^%MU8-KDOP]OKN+7_"F@16^KW5SK?BN
MZ:R2]T"_M+:Z\.WLFO>&[VV\0SR:Y#;MZ%XC_P""B?[//AGX'>"_CS=+X_O_
M WX[\3>.?!4?AG0?!^H:QX\T/7_ (27'C.3XVC7_#MNV/^B:?H>HW*AC M 'K[V7[:B*6'B;]EUB"H"_\ "&?%D98L N/,^(VS.2"N
M>^,M&!SM_P!G-?<6CWMOJ%K87MM=6MU:7]K%J-K/9N7M+N*]:6:TOK23(#1ZA:F6
MZ:'YO+8$@L!YC^4_"0$ZU\=<;@?^%TWARI(QCP+X .YL$9C7K*NM XW[!^VG_P!#1^R[_P"$7\7/_GBT?8/VT_\ H:/V7?\ PB_BY_\ /%J[^T9^
MTOX*_9D\*6GC3Q_H/Q'U/PO+<.FMZUX(\'7GB#3_ -ID+ 77BOQIJJWUEI/
MAGPY;QY,+7D[7>IW;6^FZ9::CJEY:6%QP;_MM? 6+P?^TYXXO-9UC2_"G[*&
MK2^'_B]J&M^$]<\/QP:Y'X7T/Q)_9VG6VLZ?INHZE:_9=\EC
M>+40@2Z0 Z_[!^VG_P!#1^R[_P"$7\7/_GBT?8/VT_\ H:/V7?\ PB_BY_\
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M,D2:5&"E?M3 C/)\:^$/_(:^._!/_%ZKS.&VX'_"#_#[+,M0Q! .)73_P!M;<,^)?V7P.M+^+G_P \6M#]HS]I?P-^S)X8L?&7Q!T/XB:IX4GNR-;UKP7X-U;Q+I7@K2[=
ME>\\4^.M2L9$LO#GA6W@!_>7 FNM0F:.PTZSO=1NK:SF\KM?VZ_@5%X;_:.\
M5Z__ ,)WX0TO]E2Y?3_BS;^-?!5YI&J0V=YH5IK.B:EI=B+TKJT7C6Q;2_\
MA$K6>2U\0W@O;>&YT"R@DDN8@#T3[!^VG_T-'[+O_A%_%S_YXM'V#]M/_H:/
MV7?_ B_BY_\\6OD[4/^"L_[*&EWV@:7K"_$K2]3\1_"RU^*VDZ;>> );^_O
MK6_UJ]T'PYH"7&FZU?3WOBKQ1J6G3Z%X?GT>+4O"EOK>HZ=H5[XMM?$5U::%
M-ZQXF_;Y^"WAG]G;PS^U!>Z#\5M1^&FM+K__ D&H>'_ (;ZOJNI?# >%=5U
M/2_']Y\0X+E%@\)V7@[Q%HEYINI339677M,MK1/,,R,0#U@V'[:8&?\ A)?V
M79.1\G_"'?%I"3D8PS^/[A00>1F%\D8&TD,OB7P9LOVMC>_&0:+K_P"S7&?^
M%S^)O[0>]\(_%1@+\:-X=\PQ+'XQMF*D9 Q,F MPQ_N_P!YYDKAW PDXDD1Y8^-K.5P><>#_ C=_:'[0(498_'_ ,4J,KN4;O#O
M@U=SKYD1:-,[Y%#J6C5@,YP0#$^P?MI_]#1^R[_X1?Q<_P#GBT?8/VT_^AH_
M9=_\(OXN?_/%JS^TC^TKX&_9E\.^'O$_Q#T'X@:EX9U;Q!IWA_5=<\#^#V\2
M:/X+_M;4;+2++7/'<_\ :$1\/^%[O4+^RL()5,LEY=W45A'%++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M\-ZKHVLJKR:S&DH![BUA^VF!G_A)OV76Y&%'@WXLJ2M ;3AE\7^$5E^UR=5^- TOQ'^S4KGXSZY]L:\\(_%-@+[_A%_"WG>2L?C*V<@
MJ".)EPO)R,JWWO;R6\\0GM0CV[P,(+A#A)[9H&N;8V\@ $UK&MR\8B'$4B94
M )D^+? [_D(_'?\ [+OXG]R"?#O@S# =RI^8#N1B@#FOL'[:?_0T?LN_^$7\
M7/\ YXM'V#]M/_H:/V7?_"+^+G_SQ:M_M$?M*>"/V9]'\/\ BCX@^'_'^H^$
M=6\0:;H^K^(?!/@N7Q)HO@4:IJ-KI5EXD\93V_\ I&F6+:E?V5M&]O'MR0VME=7#PP3^!^%_^"DO[-WC'X6?M(?&O0;SQ9;^"/V6IO$<7Q0N]5\*7MO>
M*NE67]L0W7AFPN]0TVUOX=:@C2XL[&[U'2]>N)]L%UHUE%)]IC /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MOB'_ .G04 < NG_MK;AGQ+^R^!SDGP9\8<=#_>^(N/S_ YJ7[!^VG_T-'[+
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M?_A/6'\2:1X?\1"RO--CUO1[/6!I.I03V6IZMX*70U3:6484 \%DL/VTPC'_A*?V70P4[#_PA?Q:(\W_ED"&^(P7!DV@YSP3P
MQ^4_)-JGC-+GQ"OB^]\'2^)AXU\>_P!LR>'='\90Z(][_P )KKYD;3XI]:N9
M4@*[=V#@?K#7Y6^+?^1R\@#\]/"I8>%/"[J55X
MO#/AF9"Z[UWP:5#,@*]\L@ ]"0>U>KZ5X[UK1--M]'M+30KK1M/T_P 2Z,NE
MZU9>;I]SHWBC6]+\3_:'3[78[KBP\0Z79:C8 746+^UM3E\>6_JNC_L&?M0Z
M=I6E:7'JO[/[KI=I8Z9%*VO_ !"L/M%OI]A]DC5X;'PO?6OVA!"K2;K60$JQ
M38P\Q-;_ (87_:E_Z"'[/G_A6_$?_P"=O6_-%-7:.<\\C^-OCB.XU>[^Q>$9
M]=U?2[_1+C6K_0_,U:5+^Y\032P7*?\ "07I-O'>:]K:P_Z++M.UODQYB>=:
MYJ\_B#6M7\0WWD?;==H_A.&ZJ:^B/^&%_
MVI?^@A^SY_X5OQ'_ /G;T?\ #"_[4O\ T$/V?/\ PK?B/_\ .WK3VE/R^Y ?
M,5%?3O\ PPO^U+_T$/V?/_"M^(__ ,[>C_AA?]J7_H(?L^?^%;\1_P#YV]'M
M*?E]R ^8J*^G?^&%_P!J7_H(?L^?^%;\1_\ YV]'_#"_[4O_ $$/V?/_ K?
MB/\ _.WH]I3\ON0'S%17T[_PPO\ M2_]!#]GS_PK?B/_ /.WH_X87_:E_P"@
MA^SY_P"%;\1__G;TG4IV=K?<@/F%NA^A_E7Z,_\ !.G_ )!'Q\_[*MH/_JGO
MAG7@J_L-?M21/'*;W]GF012Q2['\5?$>128Y%<$H?AP 2I4,.>& 8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MP9;>*=1LM L/#T'A3P]?6=W!R>J:%^P)\+] ^#'CKX #QQ\
M5-9^&_Q3LO$L/CW^WM<\.?VMXCUG7O$-QKFI^+K[4](\'>&/)U=(;;3-!MET
MMK+1Y_#-IMX<7XB_\ SN* /;8U\N+R]YD*IL9F;S)R%BE53<2C_6MF-\L1G?\ KY/\-_\
MDHOQ_P#^R@>%?_5-_#&LDW?[3?!/A7X&##*<_P#"P_B*_1@<;/\ A7'.<8[@
M9S@XKC/#FA?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M\/\ Q?<:Q:Z'/XH^'OBV2?0KNTLM034OAI\0O"WQ+T$&:^L=1M&T^37_ CI
MD>L6L]E,E]I#WUE^[-P)4^&8_P#@FI\&K*\^*K:3XK^)=KI'QXU/QG_PM?PK
M<:Y9:KIVK>$_%>M_$CQBGA'P]'<>'R- @L?BQ\2=6^)^B:QKAU?QQH6LV-CX
M;A\5-\/]+U/PMJ/V!]K_ &F_^A4^!G_AQ?B+_P#.XH^U_M-_]"I\#/\ PXOQ
M%_\ G<4 ?'6E_P#!+;]FS2O$WA#XAZ7X@^.%M\6?"FF_$*#4?B_HGQA\1Z'X
MZ\;Z_P#%#3?%%IJWQ&\4S:-)8^%+[QM9S^,/$^L>'=;T3PEILT/BO4));M[F
MV2:.2QJ?_!-#X)>(?A_IWPOU3QK\9;W1+#6_%'B/^T8?%=CIFL:EJGQ*MO%V
MF?&FXO;G0_#6AV=_;_&WPA\1]:\,^,[+='X7T_0[+1],\*>&/#DNF:F^I?7O
MVO\ :;_Z%3X&?^'%^(O_ ,[BC[7^TW_T*GP,_P##B_$7_P"=Q0!Z_IMG!8VM
MG9VL<5O;V=I%;6\%J<16]C;031:?9K)D_:;:UA=XE;KYT2R$#FO.?A9_R,?Q
MJ_[*M<_^H+X#K#DN_P!IKRY WA3X&$%'!_XN'\1'ZJ0/E/PX.>2/<=1@C-MX8T?]I?P_J'C>[7PS\#)6\5>,7\2#_BOOB(AC\SPSX;T,J6_X5R2/^1?QQW.
M,G/(!Z9\;?A+X8^.'@&\^'7C&?6+;0+WQ+\/O$T\V@WMGIVI+J'PZ^(?A?XC
M:$JW=]:W<"6%--BU6)8DNKG2GO;:QNK&^FM[VW^3O#7[ 'PX\ >-/C)X
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MFM_&JZ%\$M)^$GA/P_:,]G-!X8L/"DWOC/3M+L]5TK5M(N;
MS2KOWG[7^TW_ -"I\#/_ XOQ%_^=Q1]K_:;_P"A4^!G_AQ?B+_\[B@#Y]M_
M^">/[/1\(>#?!/B)/&WC'0/!VG_&JTO%\3>++VRU#QM<_'[Q)H_BOXGZSXNO
MO"T'AN\LK_6=?\-V^K6USX1E\)Z5:W\\LXTB55,4O!2_\$R/A!'\,_AQ\&/#
MGQH_:/\ #OPS^%GCZQ^)/A?PO'\2M%\5)J?C:S\4>-O$\]UXTU/XE^"_'VI^
M,8;S7_&:ZI/8ZZMP=,U7P_X=U/39[34-/M[J/Z_^U_M-_P#0J? S_P .+\1?
M_G<4?:_VF_\ H5/@9_X<7XB__.XH ]CLHYH6M;>6YN+J6%522XNCIZW=XD%J
M8)=0NEMHH8=TUQL#?V?9Z='YC@^2(/W0\@^$AC_M;X^"4!HV^,NHI)N^X$?P
M'X!1FD/\,:!B\C_P1JS=JB-Y^TT,$^%/@80"I/\ Q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M\8WOC+6]",!\+Z3XQ\.^&=M1]K_ &F_^A4^!G_AQ?B+_P#.XH ]?L;>6&&)'NKBY>*';+->+&+V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M=XEQ8/8+HTOT)]K_ &F_^A4^!G_AQ?B+_P#.XH^U_M-_]"I\#/\ PXOQ%_\
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MB+_\[BC[7^TW_P!"I\#/_#B_$7_YW% 'K^F1K"MHD"W'EHL]N[W#_:M$_%RTWG)MENK\"\F\ADU4MJ3(:\O^"G^J^)__99OB'_Z=!6>;S]ID#+>%?@7
MC(X/Q#^(+ACD;4VR_#G82[80$\@ME?F KF/A_P"'OV@O"<7BAK[1?A!?W7B7
MQKXC\62RV_COQD$LEUA[/;IPS\.MBDD1)1B)6D(,3.&V;&"Y(EA/[U/B+Q-^PU\(/%O[0VN_M,:GK'C>R^*NK>&+
M+PA'JVEWGA"T70M!,?A6R\3Z9ICKX7EUN*Q\5>&/#EEX5\1R:OKFKWT>@ZWJ
MKZ%=Z#K/]G:Q8?0OVWX[_P#0M?"C_P +WQC_ /.YH^V_'?\ Z%KX4?\ A>^,
M?_G(_$U
MK-?^$/".D^&-)\,:7=^-[SQ#+HO@X:)X?\*Q75EX?GTK5[V'2GT[4-=O])N[
MO2KGZ-_9F^!/AG]FKX4^%_@QX3UCQ5KV@^%I-7FL-7\9:N^KZ]?G5-1O=1D:
MYN2=L%C%]M>UT/2U5!;Z98*Q!>$FNG^V_'?_ *%KX4?^%[XQ_P#GM -"U\*/_ O?&/\ \[F@#V.ORM\6_P#(Y>./^QZ\;?\ J5:O7W7+??'D1OL\
M+_"65B-H23QYXT,9+$+\PC^&LS$+G=Q&1Q\Q5MI?ZUX@\2:S"(EPWRXP2 ?<-%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>Z3S(63#D.\2
MGRSMM'B/PH/VW_ /PJ^"T/PPT3Q/J?@_Q'^RSX9\6Z]X?\=?%KQCK_CW2?%VEWGQ+
MTW0-/^*FBV6D_!G4OAUK/P]U?1]#?QK9^)=2LM6LOZ99O]6WR[L[05(9@P+
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M_P (1:I?6VG:O-O"VG?
M%.UU+Q#\/?B-\+M$^/U]I^FS6EG\/K;PGJGPZ\6#]G3Q_;6?C.W\3Z;XDM[2
M^T2YOO XM89D?]L+OP/X3U%;:*_\(>&+]+6RTW1;99M T67[)I&E:A;:GI=I
M;"6WG2'1M+U*SM-2TS23&Z6>H6EM=(JO"LBL7GPW^'FH:W;V
M^HZ?!K$_@OPY)JEG8ZQYMSK6GV&H1Z5;W%O%KT^J:MJ%_LG59[[6+Z-Q*DS"
M@#\.KC_@LCXT^&7COXP/\8/@SJD.A:=^S-\,OVE/"?P^TCQ+IEW)X:TK6/AC
M-XLUSX<:9\1?["MA\4OB7J^H>*/"/B+4]"71]-7P+\,8/$GC,1:P/#YTR^^G
M/V6O^"@GQ@_:%_: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M ,?_ 2^'.H:UXVN#\*_ _PZ^'?Q9LM/\.>(/B/KO[>5W^Q]X;U/Q?XI\8>#
M)M7^'5SX=DB2\U?PI#<^/M%UVTOI[RTM-(NY8-+'[M2? SX-2:G>:R_PD^&5
MQK5SXTM?']QJ9\ ^&DOKSQKI:1)I_C"XO'LTO9_%L")';IXF63SE\QW=BGF
M[<'PP^'-A//?P>!/"4=[MK3999EC4-@JR@'X6R?\ !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M$:4(XM(\&7/@[P]=>$-&CM8G:#3]-\+7%O=:-8RC[1M_P"RG_P5!A_:O^.7A[X3^&?V?O&OA_PWJ7P[\*>*=3\?:CXMT0S>%?$'C#X2
M>"?B_;^';[PLFFV0O_"2:!XUTW1])\?:%XKNU\4>(]*U2[LO#%CIA\/ZI=?+
M5Q_P4M_:6\2_#WP7I7PMU;]G._\ V@;W1?\ @HK+XL\'^*M1LO".D>"=2_9Y
M^/%C\+/@)8^-H_$'BO2C\-KOQ1I6HZ9'H=MXZU?1/#_CCQ)M5M/W8L?AM\.['Q-#XTL_ W@RU\;6.B1>%[+Q=:>%O#,'B6P\-V/SVGA6R\1Q
M:1%J-OH>GF-9;?1'E6&V*;U0JA%9]U\&OA-=W7C;4+OX;?#^[O/B)9QZ?XYO
M)O!FB377CFS5!(MAXNNY+%O^$BM&GCCD%K.'7S(XR ",4 ?A/\//^"A_Q1\5
M?%/]E75M6^/.D>'_ (%^-_A-\0O"L^K'X0_#R'5?%'Q^T^T^*<6JW/[0'P]T
M3XT:[XE^$'@'X8Z=\*#JG@?XA_!O4/&7PK\>:KH_Q%;_ (3&W\*:CXM+_P40_:*U7X1?LQ_$;Q-\:OV7/$W@[XP_MV7GP#L_B+IOAZ3PAXJ^,O[/OB%
MM3LOAI\4- \"3_$>YT+X0^,=26S.M16WB>_\46%[X:-,GB)H)?VE3]
MGSX&0>+-*\>P?"GX>Q>,?#_PW?X/Z-XGB\*:''J.E?"I[A;N[^'^GW1TZ5;3
MPJCI(&\/[/):,R1N DCL.4O/A7^R_I=S'X;N_A'\%["VT[6);_2+%_AQX5N-
M/L]9?3M&EOKVPTY=#%IH]T$_L%WNK8>9,P'F,,LQ /S0_:9_X*3>+/A]^V/X
M7^$/P]\0>$9O@_:^!?!UTWB'PS;>"?&\WQ+^+'Q=UWXX^"/#OAR[U&?Q[I&M
MZ#X1\ >*/@[]F\::SX(\+>--0\/W>HS:IXTN-(TNPBMAS'[!_P#P4U\>^/\
M]F3]IGXP?M*:W\/;B^_9_P# WP@^)ZZS;6=A\/?"[>&OB_\ "VV\9V5EK^M_
M#[Q+\E>(X=9\/:19Z)K/BCXE:1H5AH^K_ !$\!:1KNH:7H\GZW0Z+
M\"H+[1-:F\*_#VWO[&._C\+:N_AGP[-J&E6'C(3R:Q8Z1=Q:,SZ;%XCM=2GU
M"\MUVK?VGB"YLW58[IE%7PXOP,TKPS>>#/#_ (*\)>&/"7BBY\1Z7KG@W3_
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M%'XML\']F*(S>-BS(*S*1+:P_ 2SEO;FTT;X>VUSJ5S:^*+B\MO"FEVLVHW]U=07
M]AXBFF_L,?VAX@EU#6[>\CF/[SS=363KDT ?CA%_P6UU>V\ Z'K-Y^R1K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M201&UD.GR1>9;.UDQ9)3'0!^-VO_ +MUKX >%CX2\'Z1\7[?PO\,[KX[>+/A)X?TKX:^ K:W^%-]XW\:QZ?X;,4.B?$
M#Q#!XAN_$IOKV\+0'^PM*XKXP?\ !6_X^> O VO_ C\6>"_A_\ #W]JOPW^
MSIIOCSQ]J7A3Q)!XTTGX=_%O3F^%&J>*?"&M^$=>\.OX3BMAX.^(-IJ&F1>&
M_B5XY-N^KC4+](+2*6:+]Z&/PV72M&@?2/#2Z*==&N:';W.CZ4?-UZVN]2N3
MX@LM.DL'6SN1=V\EW:^((HS///.D5N\=Q<1LW(7MI^SQ=ZIJOBG7= ^'=YXB
MU[3I/#GB#Q)JWA'39O$NK:;IAM8XK/Q)K4VE0:G>6,=I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M9?$GB"^UOSO++6VK76IZM&T/QM\<)X_\
MB.OBBQ3Q0/$/BO3_ AHW@#2=8FM/$7VN+3+C1_">A6?AS04LA:F#2X]L0!.
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M%;.WT*^U%=&:^O+".1DCC@N&,=M$MNMW.FZE>^%=#O]2L[S7[3[%XA^SWG]EPM93^(]/ L=2*SQ"XC2&*02*RH #\
MROAM_P %)-0M/V1?BS\?_C'\+3X%_'7
M@;X)_$S6_C%H>MP:)8:?JVB>%OA)\:M.^)7C?27L-$;3Y_#OB;3(;B[N-*2"
M?Y5UC_@M#XE^(OAAM?\ @[\'_$GAGQ/X+'Q.MO$WA'Q_?Z;_ &%J?Q+\*_L_
M?M._&S1_A;XNDFA?Q%X1\_P;\(O ?Q7:[T8PK<^!/BGX2MKR\LK">YO(?WT7
MP3X3CTK7M!M_"WAJ/2/$]M=66LZ8NBZ;/HNMP?V7!H,*ZMINX?;K*#1[2STB
M>S/R3Q2FW"A6&&0?#WP=!=SWUIX7\,VE[)J!U:*Y3PUI@N(KW^Q&\/V]_ML%Q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MBF.-];\2Z1X7TZPUK674CR!KVMV2B[UB-9MCO&SM&<9EQ#O! /YYO'__ 5"
M_:'\#_LB?"[XP>&/CE^S-\>OV@?V@IO#OQ+\,_#;X:?"KQEX@TWX,?#S0? &
MM?&3XM> ?$FB^ O&?C[QQK%S'I>F>%_A1H/C/Q78_#S^PO&OB(:]K\>H&PTK
M2;_M[_\ X*J>*=>^-5CK'AGXF^#/!_PDU#QY\//AK\-OAM !*_9YT3XS^$OBKX^\12_%/P3XQ^&WPY^(&IZQ-X>\(>./!OPX\;^$+6^\ Z
MK#XMLLO>3P_N1H7PH^&'A&^U'6_"/P]\$^&+W4)]9O-3O/#WA70=*N]:N=M8+_4[W4;_2+>2XGAU&>T-M?27<3O-;S31R#:22P?![X3)JFB:Z/AG\/I-?\
M#&FW>C>&]9N?!>AW.J^']-N0T=_;:-JMQ:I?VVD.]_)'>K;R1K-;2W<;EA/(
M6 /QH_8S_P""F'QFUO\ 96_:C^/_ .T[I<&O:C^SSX#^%?Q%@\+^'?!&G?#3
MXCZCI7Q#^#WA_P")%B^H^"M,\=?%'PU'\.-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M5!!XEN+>:>.?Q&I$EY%)+;%F^TE6N3> O!M[J4^KW'A'PGM29[V6?6].GT3Q KRR(Z27NIZ/IVFZ!JES*S?:].@N;9SY<[H@!Y!^Q[\7'^.
MGP#^&GQ-_P"$KM?&TVMZ1>V7B'Q-9^&]0\&VE_XR\-ZC=^%O%L.G^&-3EN;C
M2-.LO$>AZOI\=A]KG$3Z>M]]KUA=1&H0_5%'O"VEZ5H'A;2=*\/Z'
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M;49(,!1YHC0@!6>O6Z* //9?!VD71L));S7)?L=CM_)&8X5@,EN?^>R1YZ@&&R^'?A:R F:UNIRMO%&T]QJ>H7/G6UK*EW"'BE8Q.
M$EBC8!AP5#JP8*:](HH R-&L(-,L+#3;88M].L++3X!_=73H38@?@L07/L>M
M:]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !17XNS?\%9/B9:7-Y!'_P $E?\ @J;,;&\:
MV::R^ _@/^R[E(9M0LHSI-S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M>Y_$_P#Z1&_\%5/_ PW@W_YXM'_ ]S^)__ $B-_P""JG_AAO!O_P \6@#]
MI**_%O\ X>Y_$_\ Z1&_\%5/_##>#?\ YXM*/^"N7Q/8X_X=&_\ !53G_J@W
M@W_YXM '[1T5^,=M_P %:?B=.PB/_!)'_@JC&&)^9_@3X(0# +??F^)440Z
M?,ZY/"@M@'=A_P""IWQ(EVG_ (=4?\%/87Z!+CX*_#F+M_%(?BH=N!SWR<+G
MF@#]?Z*_*.R_X*8?$6]"F3_@F)_P4@M-W)-S\(OA\@7@D;FA^*,D@SC;\J-R
M<-AG?UH _3&BOS
MJM_V\O&UP5#_ + G[^>^:V8?VV/&,^,?
ML/?MD0$_P77P\\((WXNGC^Y88'I X)XRH)=0#[\HKX4A_;&\9. [?L9_MMO&_@/PSL/;G9XIW<=1CN!GC(K5B_:[\4S $_LA_M6P-CA9/ >A;..N=GBG=Z
MXQWZ\"@#[6HKXV3]J_Q*XPW[)W[4BD_WO NCHO'JS^*<+G'&>O3KC-I/VIO$
MC8'_ RG^T\@/\3^#-#(&/\ <\5%O8 #KU &30!]?T5\B?\ #47B/_HUK]IG
M_P (S2?_ )IZ/^&HO$?_ $:U^TS_ .$9I/\ \T] 'UW17R)_PU%XC_Z-:_:9
M_P#",TG_ .:>C_AJ+Q'_ -&M?M,_^$9I/_S3T ?7=%?(G_#47B/_ *-:_:9_
M\(S2?_FGH_X:C\2+R/V6?VF21V_X0S1_I_'XH"_F?ISB@#Z[HKY#_P"&IO$O
M_1JW[3'_ (1F@?\ S54?\-3>)NW[*W[3!/\ V)F@_P#S5&@#Z\HKY#_X:E\4
M?]&J?M,?^$9H/_S44U_VIO$X4D_LJ?M-$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M\&Z!@__"&:%]?X/%);\A]>,T]/
MVH/$C,%'[+?[2ZDY^9_!NCA1@$\EO$KCGH,J>2.AY !]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M?XFT;0L#OS_Q/N_8]ZLQ_%#5V<+_ ,*G^*"9S\SZ-H6T8!//_%01]>@^<M>A /8:*\F_X61JS_ "M\+_B.JGJ7TC10HQR,E/$-RW)&!B!^<9VC+J]?'^HL
MP!^&WQ 0'/S?V5I?& 3_ ,_HZ].O>@#U:BO,%\>7P()^'WC\ =WTJP*CCN(+
MN27Z;4;G&["Y(F7Q[>L0!X#\;+G/)TC:!@9^]D8]/?IWH ])HKSQ?'%\6 _X
M0CQB.O+Z?A>AZGM!H_X36__ .A*\5?^ - '?45P/_":W_\ T)7BK_P!H_X36_\ ^A*\5?\ @#0!
MWU%< WC74,<>"?%).1]ZS"#&1DECP !D^^,=375VES]JMH;A[:^MVF0.T,L9
M$D9)/RL/44 :E%?RS?M>_M_?'SP9^W9^W+\$9?\ @IE\$?V#/AK^SE\'/@EX
MY^$FB_$[X._"7QU^,=5T;Q3XBDL+_2K.^@TK0K^*
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M#_&ZUUPZ'!\+?$>J>%9=)U.P'A+3?&][XXT#XN6^KS?#?Q)\.]+TFZM],O\
M7M)U/5M?T#QJ^G>%/$&@Z5J.JZ+9ZR ?=E%>!?!GXJGXHOJY
MU/POXLM-8O=$NKCPOXWT6\BM]7\$7[Z9X@U-=1F^QS:9XNT+6M,COM(N_"_B
M'35DN=*OBVFO[[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !12,54$L0%'4GIUP,Y]\5"9H,?ZR+\2,4 3T57$T.?
M]9#^##-*9H,?ZR+\2,4 3T56\^'_ )ZQ?\!8;OP_K[9IPF@S_K0?8GC\M>BHUDB8@*Z%CG !&>F3T]LU)0 4444 %%1RDB-BIVG& V =FXX\P@\$1@[R#
MP0I!KY:U+]K7X%:!?W]KXI\7R^$S9:KJ&DVS:WI=TD>H2Z)J>J:-JJ:+'907
M-S<1VFI:-J<=Z4AD"V6DW$KA45G4 ^J:*^/KO]MK]F+3H?.O?BII=@&N+:U5
MY=+\2QQ"[O+Y-.MH+Q_[+A"ROJHNM.P\L>=1LM10Y<-'7O'PX^)/@WXL:#9>
M,/A_XAM?$GAN[N+Z"/5;.WN4B>>P9K2\L2UTJNIAN2LN!QE"HSG- 'I-%%%
M!14-Q*L$,DSR1Q)$N]I)3B-54@DLWN88[B"2-X9E$D;I
M@JP;G(.>YS^.: /RX\-_\$[/ 4O[=W[6W[7OQ1T_X7?%OPY\??!OP'\-^&/
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M \0R7>BZ]JEA'?AO-
MJWA35-1T:?XH^'?B7X>\0Z/K?C#3(->BNM3^''B30HO%?@?7O!^G7FF:K::3
MXQO+K1M=T75;:TU>PT;_ /9I^/?Q'N[7XI_%_7_@;\0_&VG:[>IX2^$UWXMRZ^!/A[X9ZMX772=6\.VNKZMIA\MNYLCJ6IZD44 ?5OP#^'FI_#+P[-X;U.;PH-1N_$?B#Q5J6G>!?"FD>#?"OAY
M?$31-I_AW2K+3M/ANO$%K;06AEA\4>()IO%>H"'_ (FUW:1&+2#]"T44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M1U.W-WI]Y:++- ;NWEM?.MY1!<1?:%,)>"9H;A8IE#DQ2-#($D"L0 ,CXIT[
M]C;P+8^(O"_B"V\:>.O.\,ZMIM]8:=Y^BII6L3:1)>7L8\5Z?!I-M'KFI?9;
M^2YGUF:=)Y;^;5;I%\Z]1&** -G7/V,_AAK7B36_$_\ :WCNSU/Q/XB\7ZWX
MG;3O%=^J7=[XQ2&)K>&:=TNM/TK3;B*TU"VT[3Y! ]Q:1PSB2V>6-YG_ &3?
M#,OAW5O"R^,_&O\ 8FM'6KN"PN9]+FAL9-=OO!FK6L%W9I9KIFOZ?ITW@2..
M^TW7+74+;5["]NK"9D$YF4HH PM5_8J^'NM));:7XJ\>>'8;BW%Q>"SO= OK
MG4KNYU"[O/[:N;G4-!=IIK\7FHB_-P&NM5U)- UG5@UYX5T5E;IW[$?POTWP
M=X?\#7_B3XD:QIWASQ/XO\7Z9'JGBI+.YEU;QS:2Z#MM[7S8H!.L0NEDM3-&2B@ ;]B#P#YGU>
MQM]!TS1#:Q"2/9X?MK@Z?]MU Z*JW&J#6]?L+S-K?R _9>EVL%@L.G6:J+*Q
MM4MK:)5,<=E:PQVUM96<*')9$@MB6?\ O#MN"@HH V:*** (;C'DN3G"@.M>PC!SL)(VO\ +^[;(V/M;(Q7P+J^@_M*V/B#QI=VGP1^ /Q!TSQ#KWB"2TW7
MZ>%-=7P1J4&NV>G6GB;4+BVNX-MTVNE-.G[*'P%6VMM5M[.'P_'XOT2YFO'31Y;'2;A;JYTBULXI[>]FM-*,LDT
M;0Z5/71_&L#QZ4-4\27=
MM<:7H^CV6;2:ZM(2T[ZLP<7(1HPADD&2B@#[*@4[UW;L1S7,8$C&61WR3"XD
M))"K;[UVDY&X DD'-ZBB@#G/&&B2^)?"?B?PY!>-I\VO^']8T6'4%L[/4&L)
M=5T^XL8[T6&H?Z#??9&G%P;2[_T>Y$9AE^1S7GWPM^&-M\-?A[X3\"Z??RZE
M;^&M)BT\ZBLUSX?6^N0\D]]=C1=(_P")9I@N+Z:XF^R6/^C1;\1Y6BB@#__9

end



GRAPHIC
11
image_005.jpg
GRAPHIC

begin 644 image_005.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" #X CT# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#ZC^%G_!0+
M_@L5\8/V0_VG_P!NOPQ^W#^QEX(\'_L^_%3]H#PUIWP,^+7P0T71M4\8:1\(
MM7MKC1-"A\>R^-;);76/%%E*FBZ+)'IV-A9H+R[AD3]DO!'_!;']G
M+3/V4_V-/C-\M^+-&\(>%]*U/6H_!.G7T%U>VNHZU>I;+X<.F3P23.HW?G-_P2N_X(4_LZ>)_
M@W\6/''_ 46_8LCO?C:_P"U9\<=;\.?\+-U[6A#KOPP@\207_@37]3\/Z%X
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M%BDO;=;&QT*[MY+9;N\MWEV64,[K^:7PZ_X)Z?MP>'_^"??[/?P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M_C[P1\-]'GMI+5)_"OB[3_#VB3"*^<7]LES87OREX3_9"_;?^ W_ 3_ /\
M@C-XF;]CSXR>.?B)^P9^W3\3_BQ\:_@!X-?0]1^)UYX>O?&7CZ?1-6\(07>K
M:K;:AI.N17T%]->OK<1L5UZXMPT[2)#(">S]'U/V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M'K=M#*V%7
MK/::C/??"BT7Q)]M^-FE?8P9H(O$DE_X<2: #;+::=<0R@PM**#$_5GX6_\
M!:;_ ()]_&#XVZ#\#?!7Q1\72:KXW\:ZU\,/A[\3M;^&GC_P]\$?BC\1M O)
M8=:\!_#WXOW.@V7@C7_%.G7=Q+;?9+>\CEDNE2U5Y+B:-9/??^"BG[9&C?L!
M_L8_'3]JW6= G\4W?PQ\)I<^%/" >:UE\8>/M9U>R\+?#[PUJ$UNS7,MKJWB
M+5+,ZY-;'SH-$M[^>%2Z1[_Y5_V3_P#@GQ^U';^'/V//V)OCI^R;^WWJ$W[-
M_P ?] \7^*_'VH?M3>"O!G[ 7@72/A7XMU;Q%X>^.WP=CT/0_$>K:]KNM?VY
M;75K\.Y]&N9##/J\3RV2[[ZV_IZ_X*E_L9ZM^W]^PG\=OV7_ [X@M?"_C3Q
MKI&D:AX%US5"DVG:=X[\):UIOBCPS_:OF1SK;6FKW&F0:5<_Z%;&RCUMM1-I
M=26XM)0#\Q-$O_\ @X@\*>$/@E^U$?'G[,O[2=E\1-;\&ZQ\2/V(/"_P[TKX
M:R>!OAQX_N=/U%D\"?';Q+>6/B37?$GA'2=8#:B_B&YCMHX+&\6R6>Y:*%_O
M7]IO_@L%^QA^R#\3?$?P;^)VH_%37/'OP^\$6'Q ^+FC_"+X/?$'XM67P9\'
M^)K:+4=*UKXH^*/"NFZKHOA2&ZMHI+Z=Y]0*:A:L=5M\3/A_P# G]E;X6_\$_?$'[+'Q\\.:[\-_"GQL_:S^*'B;X?>-/V<--^'/@4:
M9IOC?4?AUI6I+?7OBJY\;Z=H"AM#M9#?Q'50NF:IM2/XO?M)?MN_"3Q#\)/VQ_B+\$O'WP2T_0_V/H/V2_'_@#X%? /Q+JMW\/K_3
M_'>I?M8>-Q?)\2=O
M^"Q_[!7[.NG?!C6O'WQ7\0:A9?M(?"?4?C+\$)? _P ./&_CV;XC^#[.ZTZ*
MUL_#NG^$M N;F]UB]&OVUM;Z+>(E\]U(L$9%Y@GE?BS_ ,%M/V#_ (,:IX1T
MGQCXG^+5]K7B7X4>"?CMXITKPE\$?B;XJU+X,_"3XDZ=I^I^"_%_Q[BTGPRD
M'PABU+2]462[L]<>/7M,@LVNM0B6SMW=_P M?V1OV*OVF_#W[1G_ 0(\5^-
M_P!G?QEH7AC]E']B#X\?#KXVZCJMCI5K8_"SXM2>&[C0=!L-3M3JEP8(=8UT
M!]"=(99/LTR7\>R1 R>9?M6?L8?M6?!G]NW_ (*%_$7P_P# []O+X^_"S]O'
M1_!^L_#*;]BOXU>$OA?X7UC7H? \7@KQ)\+?VI?^$J$EWX9\(Z499K?P]XNT
MZ&<_\(5?Z_"+>;SO(8 _I*UW]NK]FKP[XW_9/\"_\)S<:UJ_[;JZT?V<]9\)
MZ'K/B3PGXQTS0O"=EXONM>N/%UGIT6DZ7IMQI6J:0MIVVEP*U]
M=Q1MQ?\ P4\_;=T[_@GO^Q;\6?VG6\-CQ=XA\-VND>&OAMX,=XK"+Q%\3?&N
MLV'ASP5!J5W,R^1HNG:K?'6=?\G_ $F71-/U"&T_TN2 5X;^S1I?Q4_8O^$7
M_!-W]DKP1^Q]XU\4^![_ ,'>(O"WQ7\91?%GP_XWL?V0M/T[0$\4Z7H/BG6Y
M-%L=3^)4FO:QJC>#](US2++08X8M+^USSWMI#)!-VO\ P5Z_8A\0_P#!07]@
M_P"+/[.W@+6]-T?XI23>%OB-\);_ %:6.+2KKX@_#/6K#Q+XGQZ
M\RGP^NK.2-(FU.'5<[;3( /S_P##L?\ P<._#>#X%_''Q-XQ_9=_:J\/?$;Q
M1X>B^./['_A?X;6/PEN?A/\ #WQ<3<7M[\./B[K=Y:7GB;4/!&DRO'<0>*KB
M*'4W^T:=IT<]]>V44OVK^TQ_P62_8=_98^*WC'X)_$/Q'\4M=\7?"W2-#U_X
MT7OPQ^#GC[XHZ#\"[#Q"EN^D:O\ %C7_ IH>L:5X/6XM;O^U_[1FG,3%8O-
MM^#$GP^T)+T_$1/AEI<\4FH^+]1\>M%!?6.HVRQW37HACBN;6;_2HOEG_ (*%
M?"/_ (*3_M"_&C_@H?\ !3Q'\&/VP?B#X(\?>!;?0?V+-/\ V:/B/\-_@9^R
M;X@\)CP-?V6N:K^U5X\%_8_$#QOXOM/$FF*%\%:MKVK6T^D7Q\&1P01:P&B
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M"P__ VM\#?"7BZ[T+1U_:+^&G@[Q3'JUM%HM]'<6FG"W\16U]JT^A6>L7$/
M]I:OIECIJ.)[N/(!^]W[.7_!77]B/]J"\^)6A^$O&_BGX=^)/A%X!B^+OC?P
M=\>?A?XT^"'BO3_@_+;/J$?Q0TK1/'^B6[^(?"$JI%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MI,/Y=\9K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MPLKN>XMHS=)'#%=VDTD$R@UNO5'R!\7OVF/^"K/_ 2R\5_L^?%G]MWX[? C
M]L;]D?XS_%;P1\%?B_+\/_A#'\&/'_P)\2?$J6>W\,^+/!NH^'[^\3Q+X1T^
M>SU*VCAU:&.XOES:_:]-N+N+4+?T7PQ_P6?O?B7^V5_P47_97T'PKJ?AJ?\
M9E^#GC-?@%X@N/AEX^EN_%GQ+^&/P^\<^*OBOX@^(VL:E'<>$O#/AK_A(_#=
MCHWPK\.:AH]X/&EKHNHZE!XBN;CQ):VS>"?M/V?_ 4%_P""TT_[/G[+OB;_
M ()__%']A']G+P?\9/AO\8_VG?BM\=O%/AB_U;4+3P'=75P/A[\'_#^F-87G
MB.6:]N&-CXJB%JFR1+B6UTB"&6UUCOS\(_VJOA]_P4J_X*Z:>?V8_C%XV^%7
M[?'[,^F6GPQ^.'A=_#MY\+](\1?#/]G;QKX;MO"OBI)=5FU*TUOQ#K&H67@[
MPPB6\F;V>XCD5(F=T#5[/T>QVG_!-S_@N_\ ;XK? ;]B[PM^U7\2_$$G[3?
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M 6!_8A_8\\MKU[I^D/X.U+PMI;Z5XFENK*#5_$R66F7MO-IGA30]3U34MUM9W,#>S?MP?ML
M>%?V-OV'OBY^V7JFA:GXAL? /P]TOQ7H?A"ZMY]&U/6/%/C&70=+\"^%]?L4
M_P!.TF]O-9\4Z#;ZU97/^E6FGF\D0&>)17Y?? #]BKXQ?"W_ (*\?LI?$8?"
M7Q3!\!O@A_P2ET[]G6+XCZIK&A>,]!\-_$33O$VE3MX);QI)#H>I^)/%%KH6
M-*LO$^D^$M(2_P##=G?03.;6::*OTP_X*@?L<7?[>W[#'[0G[+>DZQ:>&?%?
MQ&\)1)X&\0Z@GF:?8>+O#_B#1O&'AQ;\[)?)LK[6?#UEIUY=>1[%K
M=>1]GE /R3\-:S_P<06?@#X+?M<6/C7]EGX^P_$^X\$>+/&/[".A?#O3_AE+
MX9^''Q&ET^^M/['^/FM:EI>JZGXH\%^'[HO=WFNWUO8V9MI)]ET$-O)W'Q*_
MX*W:A^S1_P %6?VEO@=^T1K'B2;X >"OV2OA!X]^%GP<^&7PMB#4M-G\?*C_#70==\1>(],\+^'Y=1U;5=0U/4T\+^'M#.H20F22_C1O(M(_:
ME_X+C>,?A7\#OV2/A;_P3XUW]F[]HKPEJ?PZ\"?%?]KWXB^+/ 'B[]FG1_ 7
MP].D6'BWQ?X&TV^FGU;Q1-XITG0A%-HMM+/=(=3*6UUJ[!9M)^OO@K^SG\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M_N+K_1E/F 'VU;_\%>_V"+G]E.U_;43XTM-^S]_PL+PO\*]?UW_A$?&#^(/
M7Q+U_5TT)_#_ (^\#OH0\8^#[O1;J>*YU>35(\06T%PT>5C5Y;'P%_X*N_L?
M_M3_ !.\>? /X0>-_&VA_&'PMX#U+X@Z!9?$_P"$'CSP-;^,O $,4BK\4?AZ
MGC'2K"?Q]\/XID%X][I4T<]Y;P206@,SQJ?YU?B]_P $X/VX?B;^P_\ M[_%
M&Y_9DUGPE\6_V]?^"A'P4_:%\+?LC:9JOAS7O$GPI^%G@[QA;_;M4\9C1=<'
MA6W\;Z_ILUWK?B)]!+W5KIL=]8W;>5*]?L3\MXCNO@[X1_P"".6^M(E^
MSNOVNXA0D1D2@ TOV_CSXC>,?AUX6
M\=?#']GGQ]\,-<^+WC2V\8ZSI^G?#;X>_L]W=M=^/M1\2Z!IFFG3I)=/@FM-
M8A@G\3W(CTV"YE7[S_8]_;R_9M_;LT3QCJ7P(\1Z[)JGPRUY/#/Q1^''CWPC
MK_P[^*/PX\27\#36NC>,_ ?B'2[35M%N;FP>0PW*R[9%)21F#%7_ )??A3^P
M;^W5\#_V,/\ @D_\:K3]F+Q?\0?BC_P3[_;!_:;^*WQ(_9@:;PUI?Q#U_P"'
M7Q8\6]U+:ZO=&P6:\$,9_H?_ & O
MB?\ M._&[Q!^T!\4?CA^QCH7[&/@GQ1XITG_ (5#I7B"STBW_:/^(.FVVCQZ
M?J'CCX_Z;HNI:A96NK6-[8&Q\//+.;QM*=5D(A!8 'Y^_M8_M'_\%*_B#_P5
MWN?V!?V/?VDOA%\!O"-C^R+H/[0]Q/\ $OX'Z7\3AJ>K#QQ>>'=;TDSI<6VL
M1K_9USI&S[/.A1RC2AH5EC;+^#G_ 41_;!\++_P4P_9 _;2\=_"#P%^UI^P
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M$/QOC^!WABVN]?\ AKX GU"8 7NO0F&PC62Q#9&?
MVT[KXNW(^"'BGQ-8^ /"*VG@WQ==_$+Q/\5+V:XLX?A1HWPTCT"7QI>^/?M"
M26K:796Y,TOX(_P#!,2X\=_L6?MJQ^,_@U^QO
MX2^$FO?M&_L ?&NW\&_M>_ 7QSIP@N;GX3:]\*Y-8T#P=XZ^&%WJ21:I>^(X
M]7M8HO$+17MZL]O;S6EQ@?$3]B/_ (*H_%O]A']BKXL?&S1_C9\4/C/^R%^V
MEXJ^,VC_ TT3Q=\/?!/[7FK_LM7^FZ1H7@O4[75M*@\3_#T_M->&392Z^DZ
MW\=R)]4D!NHKHF>( _H$^''_ 5G_8E^(WP ^-?[1P^)^M> / W[-#[/VAM%
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MQG\3]7:XA_X0_P >6?@KQ-=67P"^'?BM9]:\-:MCKVF '[6_ W_ (++_L4_M"_%#X<_"OP;K'QC\.:C\:KS6K+X$^.OB'\"OB/\
M/OA;\<;GP^;YM03X3?$KQ7HUOX4\5PNNG7B6:I/&MS<>7#:;[N2VC:GXY_X+
M7_L ?#SXX>(O@/XD^)GBO^UO!WCNU^%OCSXG:+\-?'^L_ 3X??$R_N$L;/X?
M>/OC7I_AZ?PCX7\7M>S6UG-IU]=JMO/=01Q,;EXD/X1?L/\ [+O[>?P>_:;_
M &2-$_9<^!__ 4._9)^&GAGXJPW/[7_ ,!_VF?BM\._C?\ L+^!OA)87EZN
MN:?^S)XUOKRR\6^*-2UNR+V_A"YT[2Y+O2_M=E_\ !.3]KOX9
M:7^T]^P_XN_9@_;Z^/O@WXY_M3>-?&7@O6O@E^TYX*^&7[$_Q!^&OQ,\7>'/
M&T7Q ^+FNW^EZWXJ\+_$3PI/91ZA$FMZ3=PW6L>'-,L+-[::>.YB /Z:?VDO
M^"NG['W[+?Q-\7_";QM<_&'QCXJ^%OA;2_&_QG?X(_!#XE_&'PW\#/"FOVL=
M]IFO_%C6_ _AV[L_"FGZCI%P?$%JM]&Z3Z)%+K9 2WW)^@_PP^)G@WXQ>"/!
M7Q/^&^O6'BGX?>/_ _IWB[P=XCTS^T$LM9\-ZQ8FYTO4[>&YL+*:V2ZB97>
MTU!$E@D)4J)T5:_D_P#^"@W[&_Q=\/?M.^/?&WP:_92_X*!>!_'UU\'_ (?>
M#/A%^U?_ ,$\/CSX8\167Q[U_P +>#M.\-6?AK]L[X9>-[/PYI&@Z=XS
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !11D>H_P __K'YT9'J/\__ *Q^= !11D>H_P __K'YT9'J/\__
M *Q^= !11D>H_P __K'YT9'J/\__ *Q^= !11D>H_P __K'YT9'J/\__ *Q^
M= !11D>H_P __K'YT9'J/\__ *Q^= !11D>H_P __K'YT9'J/\__ *Q^= !1
M1D>H_P __K'YT9'J/\__ *Q^= !11D>H_P __K'YT9'J/\__ *Q^= !11D>H
M_P __K'YT9'J/\__ *Q^= !11D>H_P __K'YT9'J/\__ *Q^= !11D>H_P _
M_K'YT9'J/\__ *Q^= !11D>H_P __K'YT9'J/\__ *Q^= !11D>H_P __K'Y
MT9'K_G_)% !1110!_FM_M=_\' /_ 5;^$O[5W[37PK\#?M(:)I7@SX=?'GX
MG^#?"MA-\%OA+>RZ=X>\+>-?$NB:1IG]H:KX?EU"Y,.EPZ:[2!&+[27PI9A\
M\?\ $2%_P6#_ .CH-"_\,E\'/_F5K\[O^"@/_)^G[9W_ &=%\MT'706CT6SW7KY'[B_P#$2%_P6#_Z.@T+_P ,E\'/_F5H_P"(D+_@L'_T=!H7
M_ADO@Y_\RM?AU10:V79?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MVCOVE/&_P \6>%O@UX$TKPXT.M_!/1-%\<65G\5/BCHNF:EJ][::)%XM2$106Z2M%(H!\S_\1(7_ 6#_P"CH-"_\,E\'/\ YE:/^(D/_@L&.1^U!H6?
M^R)?!S^OA7%9G@S_ ()2>$_BO^SG\7_VKOAM\:/&H\+^"A\4?C#\,_"_CCX2
MWVD>"/B+\!/ _P MX0TBQ1K36/B0-2!+#^P_^"B?[4OP8
MT.'QWK/Q6U_PU'\&?@]_P3NL/COI?@YK;PCX]TGQ'YVG>,R^KZ5K.EW4LFK:
MK:V.E3:;K5K>3Z1?@:?:OR]?3K^!^?O_ !$B_P#!87_HZ#0__#(_!K_YE:/^
M(D7_ (+"_P#1T&A_^&1^#7_S*UK_ E_X(W^#]7^#_[-7Q[\=_'#Q]IOACQM
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M ;]FGX>_$;^ROASIM;T[XA>,YHH)8O$-_XHT2T^'C7GA>"-OEO]A_]F+X:#QY^WSXJ_:'\#6OQU@_
M8!^ 7Q'^)\GP&_C%\0?"OCZR^'6B?VUKOAN.QUR\^"WA:[UO4_&
M_C:\\,1:'O^(D+_@L'_P!'0:%_X9+X
M.?\ S*T?\1(?_!8,!_$W@3X"
M_%W]A#P7K'[/=O\ %;QEH_@7P5XC^+_PU\9>)K#QQ:> (O'_ .SEXJ^)OB3P
MO!X&^%&OW$T%WJ6I?&CXJV^B_P#"<:/KL6E2Q:Q+IL;^@>*?^")=CX$\1_\
M"M=;_:Z\.-\7?%G[9&N?L,_L]>#[+X0^)!HOQ'^)'AJ?X;Z[?^,?%'C%O$0T
M[P/X-C^'WQ!LO$'B.U^QZOK%AXK\/6FA^#O#OC30?$;ZD06GVOAZ^G7\+F7_
M ,1(O_!87_HZ#0__ R/P:_^96C_ (B1?^"PO_1T&A_^&1^#7_S*U\V_M\_\
M$[HOV)=6^"-]X>^+T/Q5\&?%?Q5XC\(22^(=#\/^ OB)X0\5_#WQA:Z-XA7Q
M+X'\-?$KQ$VE>#O%/]HMXL\!>)XKO3/[6TZ.#PC>>%?#GB;1;.T7^D+5/^"0
M'_!/NR_:G^)'C^#X,QZ3^S,OP7U?X*_#WX=3>*_&$-AX?_;F\(VGQ!\:Z]J$
M^KV_BY/$\JZ1\)OA_:_$4:-K+B&P?7EO++;-!$ #OA>[_$_$_P#XB1?^"PO_
M $=!H?\ X9'X-?\ S*T?\1(O_!87_HZ#0_\ PR/P:_\ F5K'\)_\$M?"K]H.P^-WBCP]K?B[Q'^ROH/B'P7XL^$%SX2T/2=)_:I^)FF_"SP]K/PVU;
M5_B);^)O$T_@>_U/3]7NO%EWX TGP!J5G'<6O@;Q7J=_M >,OV>/VJM$^'?QSMO'?C/\ 9&_:=U;0OCS^U%)\*/$&F7OA;P)\*_@-\0O&
MWQ<^&7P=^!VH>)9C\:=6O_'&@^%+O0[V)8=-%JVM:QJEW8Z1I][>0@[X7^]^
M)\W?\1(O_!87_HZ#0_\ PR/P:_\ F5H_XB1/^"PIX/[4&AX_[(C\&_Z>%M\%_\$7].O?V??@[\??B7^T'%X9B^)_AGX+?';Q!X&U/PM;MI8_9\^*_Q+TSX
M=V&A^&_&DWQ(AU77_P!H:W\+ZM=>._$'AJP^':^$;;1=0U*UL?&^HW>CPVLW
M"O\ L,?L_P"J_P#!:[Q7^Q3X-UKQ=JG[.?PX^,WQ"D\;)KULFE>-9O!GP%\*
M^,_B3\4?AW)>OJDX\0ZE=_\ "+:KX1M/&XMS)XM^WIJ,:I)=*Z@KX;[-^;IO
MOT.J_P"(D+_@L'_T=!H7_ADO@Y_\RM'_ !$A?\%@_P#HZ#0O_#)?!S_YE:]3
M^#G[(G[*7Q.^._\ P0KL;WX(Z#8^!_VW;'X[:[\<_!4'B7Q)8:?XJCT;XK?$
MO2/ ^AW-S.5U!=,\.^"=)M-#TF+16$ESHV@_95(68UUG[/G[*'[&_P 7_P!D
M_2?!?@;X%?"[XG?M4ZG\)/VA/%_C/P'\2?BW\6/@/^V_J>N>#]>\;:A\-_'W
M[&UAXH*?!CXI_!OP]X;\/V-QJVE7KIXJU&ST'4X;:2/49+-P"/ /^(D+_@L'
M_P!'0:%_X9+X.?\ S*T?\1(?_!8,\=^
M./V9OV%A^R3HOACQ_P#'S_@F'X6_:FG_ &O?!?Q0^*EC\3O WQAA^"_CWXLW
M^LZUX"U3Q3XD^'+?#E]I\?]H16:GY3_ ."4O[&'
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M'QGX2^WZ_H&C>+M#U?7?"OB>V.A:C-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M44!9=E]R_P C]Q?^(D+_ (+!_P#1T&A?^&2^#G_S*T?\1(7_ 6#_P"CH-"_
M\,E\'/\ YE:_#JB@++LON7^1^XO_ !$A?\%@_P#HZ#0O_#)?!S_YE:/^(D+_
M (+!_P#1T&A?^&2^#G_S*U^'5% 679?M_,K1_P 1(7_!8/\ Z.@T+_PR7P<_^96OPZHH"R[+[E_D?N+_ ,1(7_!8/_HZ
M#0O_ R7P<_^96C_ (B0O^"P?_1T&A?^&2^#G_S*U^'5% 679?M+_@L'_T=!H7_ (9+X.?_ #*T?\1(7_!8/_HZ#0O_ R7P<_^96OPZHH"R[+[
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M??\ !8*T-JEQ^TGH7RY%\G_A%>C1_9R.PP< 9-?B
MVW0_0_RK#\1?ZRV^ES_Z4-086\OP/M/_ (* ?\GY_MH_]G2?&[_U/M=KY)K^
MYCQG_P $K/V%_B]X[^)'Q3\<_"?6=6\:^/OBO\7O$WB;6+7XA>+-'34+O6OB
M?XJDP+2QNK&U&UM.#X-U$!C*[R!$_.-_P1G_ ."=>#YGP7\2%.,_\76\9GOQ
MQ_PE7KBG&AJM>JZ^?H2L1JM(_)G\15%?VX?\.9_^"M31_PYG_X)Q_]$6\2?^'4\9__ #4UT?5WY_C_ )%_6'Y_C_F?Q'T5_;A_PYG_
M ."M0?6'Y_C_ )G\1]%?VX?\.9_^"M?^'4\9__ #4T?5WY_C_D'UA^?X_YG\1]%?VX?\.9_P#@G'_T1;Q)_P"'4\9_
M_-31_P .9_\ @G'_ -$6\2?^'4\9_P#S4T?5WY_C_D'UA^?X_P"9_$?17]N<
M7_!&7_@G&TL0_P"%*^)&7S8C(/\ A:OC,9A#J9_^8_>](1(?^/67I_!_K$XD
M?\$@/^"?K?$NT\/S_!WQ(-,F^$K^)[F#_A:OC/YM6_X333M+L^/M5D>-,GD;
MFZBZ?\M/]6Y]7?G^/^0?6'Y_C_F?QA45_;A_PYG_ ."MU-'_ YG_P""M.9_^"M'UA^?X_YG\1]-=MJEO3'ZD"O[M?NY/^8]?=$9C_P >LO3^#_6)RT__ 1__P"">R_$2ST"3X.^)!ILWPXUK7+J
M#_A:OC+G7(_&F@:?;8_TNRZ:3),Q_P!*CY'\?^K<^KOS_'_(/K#\_P"OF?QU
M_"_XG?$+X+_$#PK\6/A3XPU?P%\0_ VJ1Z[X6\7:#=2V6JZ/J$,4L;RVLT14
M8N;2:YL;B"XS8W5K=36NHQRV$US&WW%XV_X*P_MZ>,/%'PZ\4W7QETSPMJ'P
MC\::S\1_!>A?#[X4_"3P)X+L_B?J&@:KX7UOXJ:MX*\'>%].\/\ CGXEZUHO
MB74M/U+7]6M=5NYX[V6=GBF19XOZ6O\ AS/_ ,$X_P#HBWB3_P .IXS_ /FI
MH_XMOVNH_@&G[-8^+"P_"G2M"MO!]J\OA7P-/\1Y/A=8^*[CQAX<^#*_%33-"T_X
MAR_";2=9TNV\1WWPEO[I?"$.JW,<*0W4;&TF]0\0_P#!7+_@H?XD\6^!?&NM
M_'VX;QA\.?B?;?&+3_$>@?#SX=^&;WQ/\4['P_J7@BRUOQ^WA'P1X>TWXK0:
M'X,US5O ?D>,[77HH_#.HWNASS1MMFC_AS/\ \$X_^B+>)/\ PZGC/_YJ:/J[\_Q_R#ZWAWI%^\]%J]^A_+!\1?\
M@H9^UC\5-)\6^'O%/Q&T#_A'O&OPC/P-N] \&_#+X.>!O#D7P0O_ !U;_$^U
M^&WA[1?"?A^RT_PQX/T[XB:;!KWAZ+0[F+5GF?47DWLS1OX#K'QN^)6M_!WP
M%\ ]6\42W_P8^&WCWQG\1?A_X.DTB!H=$\=^/QIZ>*/%$^N1SVWB74;?Q#!I
MD:7%EJ\RK<0VLEMIH>[EMHW_ +'E_P""-7_!..-DE_X4KXD9872:4?\ "U/&
M?,$+"2X_YFGM LAKGYO^".W_ 3TB\;Z1H0^#WB0:;+X*\1ZG>0?\+5\9#.K
MZ+XMT;2;,?\ (U8XTS5Y&Z?P_C1]7?G^/^0?6'_7_#G\Q'AS_@HU^V%X4^!>
MB?LZ>'OB?%;?"G1OA[XG^$MM9S_#KX?7?C67X2^+=635?$'P;U#QSK7@/4?B
M"G@&YUI8?$VB>&-8\0006NIV-G+&9POD2V!_P4O_ &W#XDU+Q7-\=+L:YK_Q
M2^('QBU;5U\+^ Y?M/CWXI?"[_A0?CSQ+)%=^%?)E@\2_".[N/!MQ&O^DO 9
M%LO],,&?ZEG_ .",_P#P3DVG/P7\2$)
M/_#J>,__ )J:/J[\_P ?\@^L):R^'>7IUZ]C^8#7/^"FW[;GB3P'X;^&=[\6
MH[;0?#=G\(H[2]TKX;?"S2?&4UW^SMXIAU3X'7GC/XD6?A7_ (3OQKJ/P?U7
M2O#DWA:75C]CT2&>'2V/D,]87C/_ (*(_M>?$'XB>"?B?>_$NWT/Q?X)_:'U
M']I_P:?!'@7PCX TKPK\;O$EKX5TKQ+\0)=$\/>%=][/XL@\-:-<>*](U']W
MXON9Y9K@>5<25_4Y_P .9_\ @G'_ -$6\2?^'4\9_P#S4T?\.9_^"MQ)_X=3QG_P#-31]7?G^/^0/%X=W4;M#OQ3M-5\3_M ^,!\7OB5<^/OAO\ #CXF6FI?%.VDO;W1_B[X=\.>/O!USX?\
M(?$SP9J_B/Q!H_@WQ-X0A;5-%DU"ULKM !'\0_#_ .+BSZ_>7OBS1A'>MJS>,;JXO?%T&LV>H7=OI_B_1/%5S=75QXI\
M-^(?#%_I*ZI*L=K;":.W=/[ U_X(T_\ !.-&#_\ "E?$C*A#R#_A:GC/F)3N
MF_YC][_RR#_\NLO_ #_ %BD?C;0-$'P=\2#2Y_!GB;5KZ#_A
M:OC/G7M,\5:1I5L/^/JR^[I6H3-_Q]1?=S\^3&Q]7?G^/^1"Q$4[M1LM79]%
MN?S6C_@J'^W')X_\=?$[7/C6/$?B/XA?"W1?@;XAT?Q5\./A_K_@"T^&'AK4
M)=;\!^!/#WPJF\(1>!_#\WPXU@MXBT--)TK1KG2?$']G:X]QM>?[7?Q?\1^&?%?Q!^,WB/5/%'A#XZZQ^TGX7\0:+H?A?PUK>@?'/5-)\%>'=
M6\?6FI^$-"T^XN-:O-(\'^$GM+,W2Z;$;!$UF&YT;[?:S?U=_P##FC_@G(O*
M_!;Q)D=/^+J>,_I_T-/I1_PYL_X)TCG_ (4SXB3_ &G^+'C*-1]7_P"$JXST
M'J2!WH]@XZZZ:_=\B_K>&?9_,_D>_:+_ &NOCO\ M4>(/"WB#XQ^(_"^J:GX
M %ZGA6T\"?#7X:_#_1;74M4OX]%O$?C;Q#K$$>J^*_&%U
M:Z]J%]?"2.66*>3[5%[->?\ !43]O#4-3N=7E_:"UF\O;[XJ^,OC=;I-X?\
M =SI\OQ1^(/PMO/@EK_B*XM[SPKY,T,_PXU34? 9C7_2&.KC['B\\BOZ>_\
MAS=_P3I/'_"G=>D_V$^,/C+M=WQE)[_<_P"$K.>?;CKVI6OIWT^_03Q.'M[J5^GKT/YBKG_@J%^VU?>!_!OP
MWN/C!#+X4\(Z=\']%TR\/PN^$MKXLUK3?V>_'-GXI^!LOC3QT/"G_"9?$.3X
M4ZQX8LKC0K;7P=,L=-3^P9_]$N)<>>>#OV^_VO/!&J7?B3PE\:=0T77=;_:,
M@_:^UG4;?P_X.7^TOVC7\+Z_X:U/QO=D>%=SZ7J_@OQWK&CZQX*)_P"$4FTF
M]O83PYK^KE/^"-7_ 3BB=9C\%?$C+ 1.X/Q5\9\I ?-D_YC][T1&/\ Q[2]
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M1?\ @C/_ ,$YM;G\QOPY_X*>_M??!/X>>)/@M\!/B?J7@/X/2ZUX^NOAEH_BWP7X$\8>._@MX
M=^)\NHC7/"/PJ^*'B+PHGC'X>'Q+X;N[;3_$\OAWQ;97.H7*ZSJ/^FQ^9976
M9X#_ ."G'[;WPQ^!MK^SYX$^,CV?@+1]"\5^%?!^L:YX"^'VK_$KP/X2\;-<
M2^./ 7@/XQZYHT'Q5\"^%_&=Y)3'XAM4O!>7>HPBZB#6EQ_40W_!&?\
MX)UX/F?!?Q(4XS_Q=;QF>_''_"5>N*B_X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M"ZTT6#P_92PMI^NWEMKFJ>*%NHO[1TO0/!-FQ<7!C?\ J5_XM\2;=S?\ -5?&??)_Z&KU'Z>M,_XM_(/K.'^RES=/7H?Q%J0FQ!_$"2/H,_T^O]9*_MP_XMQ=3QE^/_ #-/IFC_ (M(/K#\_Q_S/XCZ*_MR7_@C/\ \$Y0P"?!3Q(SM^[5?^%J^,ADR?N^O]OWO3=G
M_CVEZ?P?ZQ.,U3_@D#_P3[MOB%\.M#MO@[XE&G^(]/\ B/+JL'_"U?&7S?\
M".Z3X;N;?_E[L?NW.K0MC[3%T_C'[MSZN_/\?\@^L/S_ !_S/XP**_MP'_!&
MK_@G.P1&^"WB0!(L$?\ "U?&7]X8_P"9I]?2C_AS/_P3C_Z(MXD_\.IXS_\
MFIH^KOS_ !_R#ZP_/\?\S^(^BO[,__FIH_P"'
M,_\ P3C_ .B+>)/_ ZGC/\ ^:FCZN_/\?\ (/K#\_Q_S/XCZ*_MQ7_@C9_P
M3DMV%POP7\2*UL1M+H=O\&O$D%MJ,'C"WU&V_P"%J^,O](70?#6CS0G_ )&K^">[BD(/]W/'-'U=
M^?X_Y!]8?G^/^9_%=17]N _X(U?\$YV"(WP6\2 )%@C_ (6KXR_O#'_,T^OI
M3E_X(S_\$YM_;JW_!&?_@G7@^9\%_$A3C/_ !=;QF>_''_"5>N*B_XM.IXS_P#FIH^KOS_'_(/K#\_Q_P S^(^BO[MX6IXSZ@Y _Y&GN0!^--!J=M_PM;QE
M_I L_"^DWT!_Y&O^">VADY_N>_)]7?G^/^0?6'Y_C_F?Q7T5_;@/^"-7_!.=
M@B-\%O$@"18(_P"%J^,O[PQ_S-/KZ4?\.9_^"M:?3-'U=^?X_Y!]8?G^/^9_$?17]N'_#F?_@G?_T1;Q)_X=3QE_\ -31_PYG_
M ."=G_+3X+>)-G?_ (NIXR_#_F:?7%'U=^?X_P"0?6'Y_C_F?Q'T5_;<_P#P
M1G_X)SB.7R?@OXD60Q2JI_X6IXS_ (HV4C_D:1]X$K^-M7_#G3K+X-^)+?3_$&M>.[+6+;_A:OC+_ $C^S_#%]J5N?^1J_@N;2"3GKM]*
M/J[\_P ?\@^L/S_'_,_BWHK^V\?\$:O^"M_I4B?\$9_P#@G'N&/@MXD!Y_YJKXS'8]_P#A*:/J[\_Q_P @^L/S_'_,_B,H
MK^WD_P#!&?\ X)SX.SX,>)-W;_BZWC+\?^9J],U&W_!&?_@G7@^9\%_$A3C/
M_%UO&9[\N*/J[\_Q_R#ZP_/\ KYG\0\GW&^EM[F4_X(T?\$Y@28?@KXD,ZJ[6X_X6WXRML7(1C;-YQU^]";9Q&V/LLN_&SY-W
MF)YE\3O^"//_ 3WTB'0Y=/^%'B6P$]QJ]K(?^%D^,KWSQ96NA2;O.(.=EQ?
M70[?>H^KOS_'_(/K#\_Z^9^OFFA"?$PE&Z$^./BSYRXSF'_A9/C+SA_WZW\]
MNO:OH3PWX%\-ZK\.[J74=5TRU^).MR:EK>D1'68'N[72K36='M+[0+;2;G]S
M?77B#/B3Q3:V1RUS/HD<,?SNE?(4'Q.^&&F7GB33=6^(WPYT[5;7XC?%>WN-
M.O/&'A2PN;+9\3?&#?OX;ZZL;O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MI\+\'_J?/!G;GU]JW ^ZK/X->!K)=._M/7GU76-2_P"$/#V#ZGX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M)/\ HKGPX_\ "\\&_P#S5T =_17 ?\+7^$G_ $5SXM"3_HKGPX_P#"\\&__-70!WDO^IG_ .N$_P#Z*>O/9/\ DMD/_9&-9_\ 5KVV
M*?+\6?A(L4W_ !=OX;'=#+'A_'7A)U_>QM'RL'B"^E/WN-MK+@X)V*#(G"S?
M%'X73_&A;F/XD^!91!\%]7M"\/B[0Y8OE^+5H>8T^9L]MN=I.X\ T >]G:1A
MEWJ?E*GH=W +=,JI(9QW4$=Z]-^&_AFP\1+XNDU/P[_;&GZ)H=R[RVNOG1]6
MAGF@>"R;PWI NK+[>R7LENVH,;J/R-/%W<_/Y7EO\Y_\+2^&+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M_3/^R/ZY_P"I_P"'/Z5:/Q3^&2C/_"R/ PP1S_PD>C\MOPZ_X6YITI\?^!_)'P?UK=/_ ,)'HGRY^(/AT#A!N^9B%X]>>* />C_NL^.=
MJ]\O3OAKX9L_$:^,O[8\/KJ^DZ-X>O[RZFL=?_ +'U2$3V
M4T,/_"/:1]JLA?N)Y(OM[?:XA#8&[N/G\KRW^^(W@7;WW^(M+V
M\\#/XXQ[XI#\3/A6PW_\+#^'[>W_ D>D<]O^6AV=\\GW'.* /NJ[^&_@5M2
MO6L]#MM1TJT\*:WJ=\]EXN_XG+67]IW_ /PAGB'PU:CQ4W_%4ZKHW]GO>/Y-
MYY-G87,O]GZD4&GW/COC[0-)T73OA[/8Z?8:/J.J>$[BY\1Z5IVM_P#"2V\F
MJ_VBGV#63=?\)!>?V?9W.EAX?#:^7!OMI/$$7_"':3O_ +3M/G7_ (6;\+/^
MA_\ '_A1^'_ /&GQ_$[X6JX*_$'P"C#.&7Q'H61P0<;#NY'!QV//&: ._;H
M?H?Y5Q%W_P E1T3_ +)SXS_]3SPS2-\4_A@-I?XC^!]OF19QXCT?/^L3'W_E
MZXSGMTYQ7$7'Q.^&?_"QM D7XC>"O+7X:^+.3XCT,CGQ5\/%Y\OYNI'3\>.H
M![@5W?+@G/8=..MQ]06=[>2*S3PGI'VNR^WS->/;I?G[5$(-/:[N?G,/E/\W_\ "U/AD.?^%C>!
M?^!^(M)"_CO&WZ9[XQSB@_$SX7L-Y^(G@!@.2/\ A(] [\#KVY!Z^E 'W/M#;P++<7+Z=HEGK&F6OA+6[QWA\2F\UJ6R9+5?"/B;1M,_M^]\SQ%KM\US/?2
M?9I?LUEHUU%KN[UO4M.UHZVNHZ\W
MB36!/K+_ //C!KL9=]'3IY&D:K'U-?. ^)OPLS_R4'X?K_M'Q'H6!_WQE^>G
M'KSQFG_\+/\ A:O*_$;P!D=-GB+2MW/'''IU]LT?,#OCT_%?YBN%N?\ DI/A
M3_LF7B__ -2;X?TQ/BI\,!)$6^)/@B-?-BRP\1:6"/WBXP<=S@?C7&W/Q-^&
M9^(WA>5?B%X*9%^'OC/,S>(]+PN?$?@%1U_O$X],GB@#V\KOXRPY#91-[ (0
MY(7T 7);^ O_#7J/PWUW0="7QE?:]KN@:69]!N8-.TG7=#N-M=:U:VEY<:4FGM(-2"I' +A[1;1]0TJ.=M4L_GC_A:7PR_P"BC^!O_"CTJC_A
M:7PR_P"BC^!O_"CTJD]GZ/\ (#[:U/QS\/93XBN+'5]#L4M?"7BC3[32M7\#
M2SIJ\MQ=:I;^"O!7BF\MO"K:VD?@?PY*FIZD;:&\#7L^B"X\9:E;--87/F'Q
M5\2Z#XCG\+R:)M%U$0#IV[>,QM\Z?\+2^&7_11_ W_ (4>E4?\+2^&7_11_ W_ (4>E5BMUZK\
MP.TD_P!7)_N-_P"@FO.M6_Y+#\/_ /L0_BE_Z>?AU6B?BC\,B''_ LCP.OR
M2=ZM\2?ATOQ@\!3'Q[X*,*^!/BENG/B/2"%!UKX=JN=
MXV\E@O/K@MLM'\/7S-+:Z^=!U:&:6UEALCX;TS_E]87KV_V]L 1:=]KF_Y9X/SI_PM+X8M
M&H_X6)X'Y9O^9CT3Z_P?-V[>V>*C/Q.^&&/F^(?@5AW#>(](VGTSYAV<'D9[
M].<4 ?=ES\.? 8N[RYT_0K/5M*T_PQKFHSI!XX^T:CMJS\[6M;NC=KK?SSB/1[+4)1I^J[!I=YYG\8/"WA/PK>>%X/!US:3Z??Z9?S3
M+#J?VBXGBLY;"/3O$%S#_;]YO?Q$MY>D_)!M.E%_^$.TK;_:=G\O#XF_"S/_
M "4'X?K_ +1\1Z%@?]\9?GIQZ\\9J5/B=\+58%?B-X W#.-GB/2MW0@XX].O
MMF@#O&^Y)_URE_\ 1;UYWK1)^+'PUR<_\4A\6O\ T\^":N/\4OAEYMP,O[N3G_ (2/2.R-_?\ EYZ<^O'.*\_U?XG_ Z?XI_#Z8^/? YAB\._%4-/
M_P )'H/R[KCP$@S]2P4@^N: /=EX"';(^UMVV*3R7.W+?++_ 8QDMV4&O2?
MA/X9L/%/B26QU/1['6].@T634+\W^M_V2^FV@N0UQ]GC^U67_"27\L2O#IJ_
M:XOL>H/:WOS_ &?RW^?/^%I?#%HU'_"Q/ _+-_S,>B?7^#YNW;VSQ49^)WPP
MQ\WQ#\"L.X;Q'I&T^F?,.S@\C/?ISB@#[IT/X9^"-6N/!?V+0;;5DU6.\O-8
MLM;\=WMKJ>J:5_9FE:KXVU%K73_%7VEO$L/B/5I/A[HBG_1AJEI8F^_T$7%>
M->-%\-P:%X+CTCP_'I.M7MA]U#0]"T_Q!(^OWOA\^+Q!
MX8CUB\_L2VFN/LFKR&X$A=N?^69W_E^/
M&:=_PM'X61_(OQ!\ HW9D\1Z66XQTX].#[9H [V3[C?2O-]8_P"2L?!S_L ?
M&?\ ],WP^JX/BC\-'$BI\1/!#L89_E'B+2M'!^+'PEGC^(/@JX@AT?XQB>Y/B/0<6^ZR\'HHX_ONRQ_5OH* /?86V1POG&P
M1O\ ?\O.V56V[O\ :QMV_P#+3.S^*O0OA/X>M?$OB^STR_TBQO;$V]QJ-[<:
MCJ9\-P:39QR/-=7L5D!_Q.+^"!'ETNVQBZU-+.$G$E>!'XJ?#':O_%Q? X_=
M#_F8]#S]X=1'\W;G'ID\$XB/Q1^&###?$7P*X/56\1:0%..>?,PG!Y&>XXYQ
M0!]SZ5\._ R\,_VE!=M>B\TG4?&!DU"\T6UM-&G\5W)47VF9\2^&O$
MD-U\.=#\("_MMNJ7=BQDPI5O/_'_ (5\':+X'\%:IX=C":IJ%S<6]_<'6?[4
MEU>TB_M-KFZ+B^'VQ]$O%TW1=6O/[ T#^S-3=-(V:SYG]J+\K?\ "S?A9_T/
M_@#_ ,*/P_\ XT^/XG?"U7!7X@^ 489PR^(]"R."#C8=W(X..QYXS0!Z"O4?
M4?SKA]:_Y'[X4?\ 7#XG_P#IBT*F2?%+X9>5+_QMHX/L:XS6?BA\,7\??#*:#XB^"GAC_P"%B>=(?$>DXRWA70T7._Y>68#GOT^;
MB@#VP!3A7#E6B"G9U^9]H+CO$"09Q_%")!WKU#X:>&-.\1_\)@^K:-#JFEZ%
MX?OII[NR\0'1KVQM/B+X%_U2_?\ $>@[>6'WOR].H![G$9^)GPO8;S\1/ # W(/7
MTH ^Z-1^'/@)]8N?L7AZ#5="M?#&NZYJ%O:_$$MK$NFG4-1_X0>ZT>0W5C'J
M>O\ Q!T/[-K&HQ7%U%:0:?I%U+=[[:.6)_-OBUX8\&^'SX2G\+M%'=ZQI=UJ
M.M6*7GVZ2TWO;)X(+Z0:OJNE_V@]QY%K+X?,=B_P!CV7)AD3Y=_P"%
MF_"S_H?_ !_X4?A_P#QI\?Q.^%JN"OQ!\ HPSAE\1Z%D<$'&P[N1P<=CSQF
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ML='TKQ-KXU'Q%::N_B'QH/#X\):%!HFG2>$O$=M+_ ]QXA2^M((M^^Y^<4^*'PP0Q,WQ&\$ "'&9/$>E[!DXY_$C'/!Q^#&^)GPN9_,C^(_P_+@G
M _X2/2#U!!^_\G0YY_#G& #[3?X;?#J'^Q?[/U6SUW4M)TJ_\/:M80>+;:)/
M%'Q&L/"]EJGAJ;4[^ZNK*+1K75[I]8T_S4NHKF_'A\6=EYE[=01OL2> OAG8
MVE[!>KX6;5KV36I+/2+&^UV,Z2R> XO%5GX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MG_9ND_\ 0+T+_P $NE_XU7TS/F>(<,J_\5_\4MF1>O;[2+PS/X#L8(+SX?Z;J4UOXI@\:'Q"-0/C(:]+K6F1^&[CPZVE_Z;'I-
MOX8;1[AY8OW<-M'--M]G^Q=(.?P<[>.O/IQSBOIG7_ G\"+&XO;6R\2SW*7YN;2WOM.\0:??Q:#=0
MZ'XMN?[8CLK2TOKK7)=3\2166E06U[:RR6TU\ER=C0"1*H\(_!;S_$$*>*"B
MV^G6Z>%Y-,^(GVX7JW%SKD#>)[Z\_P"$?LO(U=II/#^KW'A+[5%_9L6LR7?S
M_9_+=K=>J_,#YO\ [,TK_H!Z'_X(]!H_LS2O^@'H?_@CT&NR\90>&+;Q7JUO
MX*E:?PO:W-Q::3>37GVZ75K1$L2VJB;K^\OENT)[ACGK7.UN!G_V9I7_ $ ]
M#_\ !'H-']F:5_T ]#_\$>@UH44 9_\ 9FE?] /0_P#P1Z#1_9FE?] /0_\
MP1Z#6A10!GG3=*"N?[%T-?W,U]8_L+Z3I,O[1
MOC('2=%(_P"%&6Q^72M/B)Q\2+C^./+X[X (/ /K7RU+_JG_ -TU];_L(Y_X
M:6\<9_Z(5:?^K(FQ_P#7]ZBI\$O1_H-;KU7YGZS_ -@:-_T!])_\!(/_ (FC
M^P-&_P"@/I/_ ("0?_$U=U:%9]-NXW#$"+S1LECMW#0,LZ-'M=!5>VD59XI89(TFC_&WP=XQ^+'@CX,?&KPI\1])_:S^)6OZQK$&H^";KP]HG
MQ-\)?&GXDZLFL:-?>-_">AZ?XPUSQG:?#+X;^%+OQ'H/AW7/%_@%='\&7WA'
M4]MP?N)O$?_ AL^I^!/BCKGCO4O UWXPTJ2#Q7XKTCQB_AGP]J5_IK7GBW4_$5
MA=Z_Q%O/CSJ7[-_P4MO"7A_]I3P]\:]"U'2VTZQ\,Q>/KFWU^YBU'2FT>W^,
MVH^*=?U76[>]\>>!/*E1?BSKGC#X9?#OQ#?WVB?&#['>^&M.NH #]6F\/Z%M
M.[2=/"]S]E7CGCHH[X[BO Y-'T<_M/Z-$-,L"C? ?QAE?LJG.WXF>$SC.",!
MAGH.>AQQ7O6G$RQQ3R1-'<31-<3#M N("/&9O^3JM$_[-_P#%O_JR_"- 'M7_ CVB?\ 0)T__P !5_\ B:/^$>T3
M_H$Z?_X"K_\ $U>U(RK87;0%1,L#O'N#[2RC<%8I+ Z*^-IE6>$Q F7S4";A
M^+_A?7OVE=(_9[^)7PZN;CX]ZE\2O$OBCP[J>@_$7Q?X/^)]I\1?$ND6NM>
M-7_:)M])^'^H:_XJ3P^GAKPUKWB2'P+H/@7Q+X1\->-XH;?1_AK>6VM6,A !
M^R7_ CVB?\ 0)T__P !5_\ B:/^$>T3_H$Z?_X"K_\ $U^%?A[4/VSM!O=;
MUOXE^%/VL?$/A:V^&1TZU\,?#:\\36_BV[\)0>'?")
M/'2ZII'BSP]=PS?&+X=>$]0UO5)O'DR:68W]&^)W_#6[_"?]EG1_ 'B+X\ZE
MXQT :A?>-]7TGPUXJT>^U?Q)=W7A*?P5X7\1S>)XH-4U>UTBSN?$_A^W\<_%
MA;?P!XNM?"6N>(?BY:ZGX@\7>&=90 _8Q] T-58MI.G;0#G=:0DM>-W?ISBO$=0TC1W_ &D?"L:Z1I>QO@G\0\C[%8 ''CKX6'DH-^.G8\@9&.:]
MSMF+2!G$D3RK%*8I!+LB0I.([5!,=HN4(DDN/( ;Y6$N$\G/DEY_RMCX__ /4W^&- 'JW]A:*.6T;26 ZC[%:MG\) $/KR?<A,=HT/2E)_B6
MPL5(QSPT69!GH=HY!P?ES5S5TN9=+U".R\H7DEI.EF9RJP"[:-EMC.[VUZL<
M(G,9FE-I="*,-)Y$NW8WY!_L\ZA^TU)\$_C5X+^*NK_&_P +?&[Q[X-UK6/"
M.O3Z=XB;7]/^)=E\/3=_%'1/AII7B:76_!FD:;X6\57:V/A/QE93:/\ #GQS
MK>LZ=K'A#PJD^DWJD _7$^']%'(TC32?]JT3'X[EQ^??WI!H&C'@Z/I0'^S:
M0Y_#:N?R[>U?CQ\%> /A=J<
MOPU\,W'B;XGV&LR^+-1^'/Q)^*B>,-1\3VNK:3K'@?P?\0!KVGVPLI[GP5'?
M12]%K'B+]MV\_9T_9)T;POX&^*%M\1-+T[]G>^_:5U"^UWPVOQ:C5?$?P^M-
M5T&6;Q$!XMK64+@\C'RS+Y9P<$;NA&1\P%>,:CH^D?\-!^#XET+2U1OA!\222=.T]0,>-?
MA><;H_G'( X')Z@ FO;XWDW%&RI=;F=U6=[@%7W" !Y@'$ 0D_N@(1-Q'A3@
M^1ZA_P G(>#?^R)_$;_U-_A;0!ZFV@Z.%)71M)8CD+]BM6W$MW.X<@5@17/@:YL[[5()?"LUII+W UB_6XTF:UT>2SB>6\M[Z\;]WIL5M"DDD
MTC%/)C1WVC )Z77[=KO1]4M%D:%KG3KN 3*9@T)FADC\X"!XY6,6[S/+66'S
M-OEM-"K-(GXY^#_V,?CYX*^ 'B_X%7+:-JB>+]:^%M]J'B*T\;:M/!5_XGU#Q#XIN?A_I=_8O^T3_P (CJWV319-#\:6OPNO=2@@U#5-8LKV>RF
M/UIM)_!5[ZNKK2X_$%O!8W6B3W<_A^=A$FL6\"$M<:)*SB(:P 5
MG#F'<=^*?='P)8)I[W"^&;2'4[O[-I9>#2_*O[AP5DBL !AY-I<3;,D)OR,<
MC\=/#'_!/[]H+3=?L;_3/'?@KX:SIX0U>*;5[:&Z\3ZUM^Q=(\ :S:>&-&\%Z1I=K_P )%HWC3PSI=[X]$WQ)T[PI9WUQ"XZ'QI^Q)\M$OP2_9&^%-S/\.S>?LZ> M.\.:M/X9UK4_"ND73V6G_#F&UNM'L;W0=7N;K0
MM$LO E]HUQXMDB+8Z:45-I9'9-H'S$+A3A@?FP,9KQO6M&T@_'[X=Q#2M,$;?#'XI;E&G6*D
M[?$OPV(PT0\Q<$#[H^8 [L9;'M5@;D%/M3B2X?S!.1$EO'YD@EWF&WD(EMT+
M68V1+<:D2GSFYN5!OI/)]:_Y.(^'7_9+_BE_ZD?PXH ]8_X1[1/^@3I__@*O
M_P 30?#^BCD:1II/^U:)C\=RX_/O[UJ708V\BH6!8*N4:1& =E5B'A1Y4PI)
MW1A64?,)(L>:GY2)#XN^&?P6^-6H>)F_:Z\4^(_B9\0O&GB#X;?"/P?XT\=:
MG\4M%\ ?#?Q3HG@CPYX9T+7;ZXU?4_ VF>.;")/B5X]U#PGJ6F>(8?#/B:Y'
MAFUO-<73].O0#]1?[ T;_H#Z3_X"0?\ Q-*- T8\'1]* _V;2'/X;5S^7;VK
M\*-7LOVW;+7D6V\6?M(^(M)L/@[X6TO59X] ^(^C-XDT;3M)\#>)==UO2O[$
MBBU2S\1:EK*^+?ATL=OI6C?M(Z/FWDO
M[2%I^T1I&JI)8VW@G1[W6-,U>&]\3:=J?AGPY\8-3E L-8EN?A5"GAK4?$GC
M+/PNTWQ]J&H7_P 6V_X22S4* ?K:V@Z(FUCI.G\/'UM(6&2Z@<2KLZD=>1U7
M+A:\<\0Z1I(^-WPE@&DZ?YM]ENWVS3PM'=/%:R20M=/<>4Q#J96DD/V:[F1"EO->V&9':7RY_W"QFO,O$7_
M "73X/?]D_\ B]_Z6_"Z@#U+_A'M$_Z!.G_^ J__ !-!\/Z*.1I&FD_[5HF/
MQW+C\^_O6AJ!9;.=D3S715DCCVJQ:2-U>,(SD1PR;U7R[F7]S:/MN9OW<+U^
M/,_A[XT^!/$W['?$&K^,_BIH/AGQE;?"+
MQ-\5KKXO>"_".O7^E:1X&T;7/&FM:GX"\(:?!J-GX3T^;P9X*TR&;S-=C1P#
M]=/[ T;_ * ^D_\ @)!_\31_8&C?] ?2?_ 2#_XFOYU/A_XC_P""N>E2?LY7
M^G?!SXJ^+OA[H/C_ ./6NV_AWQ/\2O#<.M>.M"\1>"?BAIOP7\)?M"ZQ\0[7
MPA\0?#?A+P+JEIH%WI]U(_V_[C]B[P
M?X1^(&A_MBV_QMTSXS?%#7_B9XF\"Z5I%M\6O%/PSO?$?QNTSX/W?@Z^\+ZG
M<:;INCVGCVV^#J>(_!%C%+K6G?!NZ36?$ CT.\U-R ?OF^@Z(%);1]*"XP2M
MG:DC/ QYB[.I'7\.<5X7XUT/1U^._P "8QI.G>7)H_QBR!8V"C(TWPL_6)1*
M,$?PCGHV!N ]#^$/_":_\*U^'_\ PLG[)_PLG_A!_"W_ L3[!]E^P?\)E_P
MC^G_ /"2?9/[*_XE/V;^UM_]E^7^_P#[(^R[^,UQ_CC_ ). ^ G_ &!OC1_Z
M9_!5 'LI\/Z*.1I&FD_[5HF/QW+C\^_O3?[ T;_H#Z3_ . D'_Q-:MX[1VTK
MH'++M.$5W8#>NY@DD^(OVM/#/BW]L/4=:_
MX6<]]XJT;QOH7P'T[Q'IM_<>%=&^+']J^-3\&_#_ (8NKKR=*G.M>"%\/WB^
M*/AYIVD?#^P;R]$\82W_ ,;)]9MKD _7?^P-&_Z ^D_^ D'_ ,32C0-&/!T?
M2@/]FTAS^&U<_EV]J_!_P_8?MT#6O#-E:ZC^T:GA2UTOQ):^"-4O='^(MK>ZFOCFU\;>*?B%X>\9^+[N33I/AV+G1[WP)X/\ B?K6N#XDS:;I^D>![SPR
M^L:=!#[-?ZG^V-IW[$_B[PG\+_"OQ=U?XPQQ^-K72/'&O77C'PW\5=?\!66C
M7VHW'CK2=&^+_B#QH="^*/B3Q;;+X:\-_#G5_$\CZ7IFI_\ "6>$[>*QO((Z
M /UZ.@:&H);2M/"CJ1:KQGC^[ZFO!_'VBZ,OQS_9^A72M/,M^%M+9>Q'\(ZC/3/(S7L?A,ZJV@^'7UFVEM-8?1-*;5X9)(9IX;[^S8OM5K>2
MDE6ECOS>,#8@1D+'D"(G/F'C[_DN_P"SU_UP^+7_ *B>FT >RGP_HHY&D::3
M_M6B8_'M6-Q)"+B*WO)4,=M/- 4D$T$,S)+/&R,KPHZL,$D?C;\&/$O[9FA_"GXL>#[C
M3O'FI_$;Q;_8^A_!>^^*-YXBLO%GG:5X=TFQ^-GQ+DU'XCV]K::)+I6H7K>*
MOA_X.U6ZM_ 4>MWAT;P&BS(,]#M'(.#\N:_"/PPW[>)L=,OO
M&=C^TGIUP_PL^$=GXOTJPO-:O?$ND_#+3?#/P@/Q/\46.J>'8H_A_P"(?VB]
M1\06GQ)AU#PEX6T73OBOINK:O_:/A[Q1JGARTN=/NO2_';_MA7'PJ_9]@\%1
M?'23QMI]_P".+*6RUVT\4:!?;-4\=Z)J_P '=<^-.MZ6!HFH)HWPCL[[0O'.
MB>(2=)M?$6LZM/>'_A.H=' /V0?0-"5&+:3IX7:MU^-O[/4(TJP*S77Q5+#[*.J^$[9\]OXASCCTXKZ$L@\?RR@B5PWF/)@R2RA7
M\U';@N4*JUL<8^PB(C@"O$_B/_R7+]G;_KO\5?\ U$;"@#V<^'M$Y_XE-A][
MO:KZ=>G/Y8_G0?#^BCD:1II/^U:)C\=RX_/O[UQWQHT_Q+JWPD^)&F>#=MPUXMOO!?B&U\-:YX5CTZ7Q-IVMS:;<)IDN@1ZL#I[:P]V8H=/^TC NI8FC(E
M$9'YA?"[Q#^T7X/^-7A7Q%\3)?C\GAC3_!'A^+QY+X@LKW4_AI<>"[GX(_"7
M0_#$*:1IDM1O\ H#Z3_P" D'_Q-*- T8\'1]* _P!FTAS^&U<_EV]J_%'4H/VF[*Z\:_\
M"+_\-H7D%M\;/!FJ?!M-?A\1V3W:+'X7LOBOX+^(<]S+,@MRFE:W;^&/B!?:
MEXA^ .HS>+;^^\)Z8^FZ+8QGHOAE=_M;'X"_'VP\:']H63QOJ_B#PIK'A;[9
MIGBNR\6+;6\UE>?%#P1X2U.0KKNA1WEC;ZKX4T[Q5X"DM_"HN=33Q+\#O#UE
M?6K740!^QIT#15!8:3IXQW^RKT/!_A'4$BO!/B/H^D+\7?V>(8]*L#%-XC^(
M6\?95QA?AMJ+J1@=[L-?GOVU
MW3?#;Z]JL?@;2]8DU,#6M1UG2O K>&+/Q#J?B G6M8\1?VIJ6M@:FJD]!\1?
M^2O_ +./_8P?$'_U6NHT >T'P]HG/_$IL/O=[5?3KTY_+'\Z#X?T4MVK1,?CN7'Y]_>M><*T,@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MG%?&+[WAW_M<:M%;R?P_"?X6ZO
MJ/B:^UGX7?#;4M8U/XE?%!YM9NO _A36)YKB;XI^+$L[BZN[ZTOKKS;:[:&Y
M5OLLI,L2[M@S(O;Z7^R[\/\ 6-)L];TKX-_!B5;ZQU>^TK1;GPQX-L]?\1Z=
MH[R)KVKZ9;?\(KDI%)'-#72MUZK\SG+/\ :6E?PZKH0;M_Q.M)
M_'[^%Z>OX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MU)Y]"TV'09_A5X<;4C>ZWIFIZT9M/TV;PJ8I4CCT=KB;=_JK>.68?-&,\IM!+X36MY>6-Y\&?AG:2Z=.UGI'\(R>QH
M[7^TM)_Z"FA?^#K2_P#"C^TM)_Z"FA?^#K2_\*X;_A3'P<_Z)'\*_P#PVO@W
M_P"92C_A3'P<_P"B1_"O_P -KX-_^92@#N3J>EJDA35-"W>5-C_B=:7WB<'M
MZ$U]2_L,:[H=I^TAXS%QK.A0AO@9;;G.LZ60O_%R)\9Y[G Z]2>*^(&^#/P<
M"N3\)/A8 (Y"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M/@OE65E)^&G@W <,"A_Y ?9@,>]>#R?L[? 4_M+Z-I/_ H_X2'2Q\!O$-Z;
M?_A6G@W[,UZ_Q%\.B3?C0S]T'

MT?\ "4^%O^AF\/\ _@XTO_&O,O\ AF/]G3_H@?P8_P##:>#?_E)1_P ,Q_LZ
M?]$#^#'_ (;3P;_\I* /3?\ A*?"W_0S>'__ <:7_C1_P )3X6_Z&;P_P#^
M#C2_\:\R_P"&8_V=/^B!_!C_ ,-IX-_^4E'_ S'^SI_T0/X,?\ AM/!O_RD
MH ]-/BGPN0P'B70#\K=-8TO/W3T^;_/H>E>*:CXC\/#]H_PHY\2:&(A\$_B)
MNSK&EXY\=?"P#(SQSC!SC)QGM6Z?V8_V<^"?@'\%_E=&7/PT\&XWHZLG_,#[
M.%(]Z\4N/VE_\ "C?A'_9J?!3QK>+;_P#"M?!OV8WLGCGP()-^
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M)K3?]F3]G,*Q;X!_!O&KW]G#]GR+X_^#]*7X&_
M"3[$?A!\2;I+?_A6G@W[*S-XU^%YP^-$_A/S)URX4@T ?6G_ E/A;_H9O#_
M /X.-+_QH_X2GPM_T,WA_P#\'&E_XUY@W[,?[.FT_P#%@O@P>G'_ K3P:>_
M_8!D_P#0#^'41?\ #,?[.O\ T0#X+_\ AL_!G_S,T >J?\)3X6_Z&;P__P"#
MC2_\:/\ A*?"W_0S>'__ <:7_C7E@_9E_9U4Y_X4#\&%QW'PS\& CMV\-I_
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M&B/0_#7P;C_TQTG_ S'^SI_T0/X,?\ AM/!O_RDH ]-_P"$I\+?]#-X?_\
M!QI?^-'_ E/A;_H9O#_ /X.-+_QKS+_ (9C_9T_Z('\&/\ PVG@W_Y24?\
M#,?[.G_1 _@Q_P"&T\&__*2@#TX>*?"V?^1GT!>^1K&E9&.>[ <]#[5X]XB\
M2>'6^-7PIE.OZ$8H_!/Q7W3G6-,P-T_PO SDG[S, #D9SP ,*-,_LQ_LZ=_@
M)\&#?
M*?R[CX721[O^)'_"R(X]& ^E 'U;_P )3X6_Z&;P_P#^#C2_\:/^$I\+?]#-
MX?\ _!QI?^->9?\ #,?[.G_1 _@Q_P"&T\&__*2C_AF/]G3_ *('\&/_ VG
M@W_Y24 >F_\ "4^%O^AF\/\ _@XTO_&C_A*?"W_0S>'_ /P<:7_C7F7_ S'
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MX/P&^#1'H?AKX-Q_Z8Z3_AF/]G3_ *('\&/_ VG@W_Y24 >F_\ "4^%O^AF
M\/\ _@XTO_&C_A*?"W_0S>'_ /P<:7_C7F7_ S'^SI_T0/X,?\ AM/!O_RD
MH_X9C_9T_P"B!_!C_P -IX-_^4E 'IP\4>&"<+XGT$'GE=8TO<,#)QD^F<^V
M:\(\?>(_#K_''X 3+XBT*2&*W^*_FS'6-+PF[POI2KGYCDL[*!SCYL\8P.H;
M]F7]G1%9O^%"_!A< G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M@XY_Z ?^37A/Q!_9Y^ 5K\9/@!IUO\$OA)#9:AMA=?[#.-LD22KU^9%QV- 'V*?%'A;D_\ "2>'OO=?[8TO.<8Z;C_7ZTG_ E/
MA;_H9O#_ /X.-+_QKS,_LR?L[D\_ ;X-$8'!^&G@W^FA],]/SI/^&8_V=/\
MH@?P8_\ #:>#?_E)0!Z;_P )3X6_Z&;P_P#^#C2_\:/^$I\+?]#-X?\ _!QI
M?^->9?\ #,?[.G_1 _@Q_P"&T\&__*2C_AF/]G3_ *('\&/_ VG@W_Y24 >
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MX?\ _!QI?^->9?\ #,?[.G_1 _@Q_P"&T\&__*2C_AF/]G3_ *('\&/_ VG
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M.Z,9R,UW=G\<_%=A964EU&6\U34-2EGTFST^2SCL+_ .R7
MWV>-[K1X8[BR^RS?VG:-/IGR"[\Q'67QS\06QTJWM/!*+;Z9HNN>'5M8]5U2
M6TOH+B/PK%>/J4?]@6.Y(M5T2*=O!_VJ(@QYR^!&X!QY^(_BJ[E(T[PYIEG%
MJMWKGB410Z!KURU]!XAT/4+3Q+K5S#_')+_PE%PJGJDK*_\ #3[/XU>,[6\N
M]4A@T)=4GUGQ!J_]J:C8:M::II]SXGGT>;Q$EA;77[@B==$L+27S.!;S2LOS
MA:[&#XZ^)8KG2)YO!@FM;/0(/"MIO\ CTP;E>8A7SZ]A?S3M)_9DUMYIO[CRH;7[7%:>;?C_B3&Y[?9MWG#^\8L
M=Z:W7JOS ],B^,'BS[+<:6]MH5SINI!XM1M;NUS;ZC87Q\91:G;./^GBQ\87
M$2?]-'7M7FE_?#5-3O=4D@L+*;5+K4]2-E80;(M/ANYK"+3=+#=O*L-/>7_@
M&.AI/[,O_P#GRN/_ !_^O1_9E__ ,^5Q_X _P#UZW KT58_LR__ .?*X_\
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MW_:1(MK!L],]_4$>E34 >:?R9),,LGV6&Y2U
M%NOE+9&%K02Z@;8M8^.S?\G5:)_V;_XM_P#5E^$:^@Y1F*0>L;C\U-?/TR@?
MM4:,W_5 ?%7X9^)/A.@#W/5_MATN_&GF%;\VLPLFN?,^SK=%"+=Y_)5I_)64
MHTOV=7N=@;[.CS^6I_''X+_M!?M4P?"GXNZ=KND^+O%_Q6UC^P]/^#$'B33=
M$T+Q'?\ B^[\/:-'\=?$EGX5\1^'O">G:'\-OA#XFU^SU^V^'6J75WK=G'8/
MX)O;N*&,S+^SCC*G[W8_)][@@\?U]LU UO!+-%/)"GGQ!A%*V/,3M0WLU 'X@_#OXT_MGSMX=O[KP]\5OB)XX\5_L^^$(1\+=;\$2_#.]^&_CE? ?
MAV&Z^*'Q,LK^TT_X9^,8_$?CJ_\ $&J7/A'P_P#$Z1['3/[.\%%3)X?$3=]X
MF^,7Q@G_ &>?V5K&3XB?';X>_M"^,]#\*6&LZKJWPRMM%LE\7SZ3HFL:OXP^
M/>C+X#^(&E>&+3[#>ZM?>&OA%X6BB;Q%XMUW1_ ES/I%MIURWA7]AFC!!&3_
M )/TIJ1;6#9Z9[^H(]* ,JV2-)D6.*,)$)T@*DR/!#-*[RQ*Y"?9[1I(81%;
MK),"R"W6UMTTW*>37G_)R'A/_LB/C_\ ]3?X8U[D_P!T_A_,5X;>?\G(>$_^
MR(^/_P#U-_AC0!UOQ@'BH_"SX@?\(/K3^'?& \)ZVWAS7(M$_P"$DN-+U=+&
M5K.\L]!^U6G]JWT4H!L+/?/YMYY ^P:IC^S;O\T/A#\;_CCI_P 5OA\WQA\3
M^-M*TR3P?X:3XA:+XA^')\,_#W2]"U+X,?"I] ^(,.JCP1I36OCWQ+^T#X@\
M3>%;K1$UB0Z7&S>!!H5L= ^U1?KM4%S!#<0O#/$DT3%&:-_NDQR+*A/^XZ*X
M]U% 'X<:I\7?VE;+7-;70O%7QI\5^"= ^+NDW?AS3=;^'VL:%XT^+%Q-I$$>
ML_ C3_$MC\+=!T;P/XKT7Q.WB>35[==(L/!6GW4OAW1M ^(MK#X8U>]B]V\
M?&3X_67@O]I9/#/_ L[XS:[8>*K&+X!-XG\&#P]J\]_K>A:4?%]AJD&L^'_
M (46%Q;_ I\7S:]KFI>'#]HT.#PE'I'@;2O%/BC55M)9OU/2/+;Q*[(PPL:
MX\M HZ=_3 /K]:G" '//^?PH ^;/V4/%/CGQC^SK\(->^*%IXKM?B+>^ -&/
MC.'QQXVT+4M4RVK&T6[;=;7]O)N^?8.CU#
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MU>Z?::O-%_\ "RO 3?$7XJ_$.PLM
M%_9\\ ZQ\>=!^)/@C2?"?AR]\>>,_ 7@*R\-Z;\.M:M/!GAZZ@\5?\)MJ'B+
M7?B+J-OK(\-Z'JFN:%X#BFMY+!=.T#];JAN(8;B)HKB-)(F*EDD^X2CJZ9^C
MJK#W H _$&[_ &@_^"@ AUR.;X+_ !@T6]N/VK_ALNH21> _AKKD'@OX2:J/
MA>__ K3PY%IFN7.H^(_#]^_B+66\>_%_P#M+5]2T.X'C&STR/3=0CM+RT])
M^$/Q:_:$U#X5?M*S_%:X^+5U>>#]&O+_ .'NNZ+H,_A_Q[XJ\<>&=#U7Q%\6
M/"_@30Y?A[IT6D>'$\5:9IFF^#-*\1Z/XKUGP[H.MZ]X:'B>3^SDFC_755"E
M%"LBH,*JX\O&T@9QZ \>_P!*FH \6^!OAOQOX.^%?PZ\.?$CQ9JGCCQ]9>&-
M,7QKXJU5+(7&J^*S%;3Z^ZF#3-'<6D>HW4UCHP6S4?V)I5D7 )+5%XB_Y+I\
M'O\ LG_Q>_\ 2WX75[8^,#/3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M'2M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M-+OHM/G%K?2VTD5G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M(M1LO'/B/2]!US6=/>--6\+0VUAM0WFU&SNK#0K6Z\/:=9Z[J/L7C[_DN_[/7_7#XM?^HGIM>_2*K(RM]TXS^!!'
MZ@5X#X]5O^%[_L]E?N+;_%D''_8J:8!^'(_*@#J?CM+XUM_@Q\4+GX<:Q-H'
MCRU\#^([OPGK%MX;3QA=6&N6FFW%Q82VGA9X;K_A(+LS1+'::5'9W\]YM;Z=J$[1V4_YM?#'XW?M#:?\ M!^'W^-^J>*](^&4/PR^'\5W!>>&I?#.A(VN
M?"?P#
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M?0$G^KD_W&_]!-> ?$:/=\)/[D_Q3_7PI:C^M '<_&.'Q7/\*?B'%X%U
MN+PYXQ/A#76\,ZY-X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M![SM?L]:EXHL?%%MX[T6/Q"G@?PQ>^(_&.I^%_[,\2166F>%$O/!?Q$T3PW=OXNG
M\%G6=:O_ ?J5GJOAU-:TEKO0C?Q:WIOZ-44 ?@S\9/C]^W3JOQ2_8K\,?#2
M?QYX4U'Q-X%LO#'Q]AT'X+Z]K'@#3/C;J)\.:+XN2[GO/ ^L69T3X8RZQ>>,
M[U]2\7>$?!X\)6&H-X8UWQSXD_LCPXWO7[%/QY^/+_%^?X&_'(_$SX@W,W@N
M^NO"GQ2/@:TT+X;WNF> ==U70]4UZXNU\*>%=6DUSQ9K=Q>V7]NZB#;ZII>B
M>%+^+PQX
MGU[FV,?-TR/YC'ZXKQ/XN^;_ ,4]Y73_ (F^?^^]/Q[]/6@#^=A/@S\+]6O_
M !;JFK^#=/N=4O?B+\5+FZN)-6\5V\DF_P"*'BX!A#8Z_':')(ZR '*Y8 &
M3_A1?P@_Z$;3O_!SXQ_^:JO0]+#;O$NTD,/'/Q88.J;S$5^)7C)O/"_9;W_C
MWQYV?LLNWR]WR8\Q/??"?@OPYXK\)6LPM]4TWQ!=^,[K0)-6/B#[5 UGHOA+
M4_%^HWJ^%_\ A'[+^UY];TW1[O1;33?M47VJZOX8L/N\M^E;KU7YG.?'_P#P
MHOX0?]"-IW_@Y\8__-51_P *+^$'_0C:=_X.?&/_ ,U5?>-A^SN^IS>'].L_
M$>J2ZQJE_P"((M7N6\(F6PT6>UF\$2^&M*OM/(_XDUZ3XNMTO-$_YMR!7B7C7P[:^&=8TW3+%YGAD\)>%=9>5I_M1FDUW28M3U)HX_^8?I7]HW*&WC
M/6<11]ZW ^>_^%%_"#_H1M._\'/C'_YJJ/\ A1?P@_Z$;3O_ <^,?\ YJJ]
M9HH \F_X47\(/^A&T[_P<^,?_FJH_P"%%_"#_H1M._\ !SXQ_P#FJKUFB@#R
M;_A1?P@_Z$;3O_!SXQ_^:JC_ (47\(/^A&T[_P '/C'_ .:JO6:* /)'^!/P
M>96W>!M-VJ#(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M"?A[Q9KOQ%U.WT>_XC<_1'_AD']G3_HF\'_A1^,O_E]1_P ,@_LZ?]$W@_\
M"C\9?_+ZOPO\$?\ !5/]I[7_ (5^#_&GB:Z^#EA9+^T3#X:^)4VBZ#)J'C.]
M^&.K^#_!FJZ=X#^#WPTU3XC7;>,OC#-KWB*ZT>^\ ZSXF?XU>&-+T>^OO%_P
ML>_N+NSD^L/V-?V]OC/^T3\(?V@-0\16?PM\/_'OP]JOB:;X6?#7Q%M3[F'3M9UIO OB[5=*\6W]]KOC3P5:^'YM9^(^@+X5\+^)-#LYKY[[2TLM8FN
MH@#]'S^R%^SJN"/AO!PRD_\ %1^,CQN&[C^WN<#)Q7A4O[*WP _X:6T;2!\/
MKM\6O%L%E:^)_B7\&/A_X^\1V^E6MU::-'K_B[PIIFMZP-*MM0QJ,6F"\O&&BS
M7.?-TPC &]"99O\ DZK1/^S?_%O_ *LOPC0!G?\ #(/[.G_1-X/_ H_&7_R
M^H_X9!_9T_Z)O!_X4?C+_P"7U>A_'+7O'WA7X.?$WQ-\+;+POJ/Q%\/^"?$.
ML^#++QM-JGKXE.B07&M3:*LT0?4;/2%AU2_MEDLM/O-/N[B
M&^M_R.^"'_!0#XE^*_CO\#]$^+OC#X1^&OA/\2/V1_A;\4[D:!'H]WJEKXX\
M1?"2R^(GC7Q5\38-;\:P>-?A%\,+6\UNWT7P!MK<M[8W[55K\1AXF?"SQ1\%O"/C_PG;^$
MS>"QCU[XAZUKGB*:Z\4^(?$:D_;"_:!\#
M?LX?&GXD>.?B_P#!S6=4U']H>_\ A#\ ?&FJ?#>X\#:/H_PB\)_&[P?\$/C)
M^T3X^\$:5\7=7U37O!?PW\1:EXP\7:F]KK'A!=*\!:'X4U>ZU'3X?%[SH ?I
M$?V0?V=@,K\.(%*E6!_X2/QEQM8-_P!#"GI_>'X]#XY??LI? _'_P ,:6WP
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M/@/X>^*/V>?@_P"+H+B'2Y=%U;6/&/COX*_#;XD7?B>9=8\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M+635I=+T[26OM<(M]%AUJWTW4I/[6(;5;1=27MU-_A;0!S _9 _9U4[O\ A6EN_';Q*__ *"?PZA?^&1?V=O^B9V_
M_A1>,O\ Y?5T/[3^D^/=<_9Z^,^E_"[Q5XJ\$_$.Y^&WB\^#_$W@;3=#U?QG
MINN6^BW=S9+X5L/$EEJ.AS>(+]X3INDR:CI][!:WUY#=BTN)8(XG_'WX7>)_
MVV?AI^U]X$\=?&>V_:2N_@/8_LT_![PSXZT*6"]\9>#W\?\ B+P#\,?"X\0N
M^GW<-G/X[N?C?J_BFQ\8^#=*\+'XBQ&PG^)6N>.+7X>:GX>\)7P!^L/_ R+
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MI;\%6_Y&/QCU1@X_YF5^ZC^$_AU'D.L?LI_L]Q_'3P!I?_"M+M_A(_&7.WQ+\-Y!_S'T'51_&..YR%/IO[&L?Q:C_9R^$:?'+_ (2K_A:"^&KT
M:]_PF\^FW'C@Z5_:M[_PB7_"M3#S17MFE?_ -!/X=0[_AD']G3_ *)O!_X4?C+_ .7U=A\?_$_CGP5\%_BMXP^&EGX2
MOO'GACP%XGU[PQ;^.[G6;3P:-3TO2[J\2X\2/X>TS6-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MC/7[+P?I>K6_P^@#//%6^&O_ 4P^.6I_L\_M0>)?&>G_#/3_BG\*?'/P^\)
M> ]7CMR? \?\ AC]D;3/%6J7WC#Q/8W6A:EK7
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M2A:_;=?FL]2LIX=*ANI8YT*9K\COVMVM9?$7Q6T0SZ%KS^&?@=I/\ ;_@;Q/XG\-2>(=3T/X1VVI>$;>'Q3\5=#\2^
M*M1UGP?K5Y:^&;^.VA$DR 'Z1_\ #(/[.G_1-X/_ H_&7_R^H_X9!_9T_Z)
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MJ\(+XF\<#P%XVUNV\[5-6\")XJO]3\/:?>:1)X@_LG4-1;2&]X\M + WQH_],_@J@#+/[(/[.O\ T3>V_#Q'XPS^FO9IO_#(/[.G_1-X/_"C\9?_
M "^KUCXI^)8_!OPW\>^+YO$&@>$X/"O@WQ)XCN/%7BL3MX8\,6VBZ1>:E<^(
M?$$5M+=7_ &3=
M9\5_%K]FOQ;X(^,_BOXCZ#XRL?#6CRZ3XLNOA//9_$+5?AY\>)_#R>-_%.I^
M M"F3P9I4?Q"\(2#QCH_PTLVU75_BCX_T26^L+) #];/^&0?V=/^B;P?^%'X
MR_\ E]1_PR#^SI_T3>#_ ,*/QE_\OJ_"_P".W_!6[]HGP=XB_: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M-_X9!_9T_P"B;P?^%'XR_P#E]57]LCXQ+\ _VM7QSXT\+W7C?2M$ANM=TK2YA;^#K/Q3X)D\3^(]4BOWT;P=HM'::E=G3I;J&7\V/@?_P4 ^,>N_'_ .%/@[XT>)?@1I'@SX@_LY>%O$\6E_#;
M7?"_B33['XG:KX$T;7-\4
MW^I>"[/QC=:A;P/0!^F/_#(/[.G_ $3>#_PH_&7_ ,OJ/^&0?V=/^B;P?^%'
MXR_^7U?@98_\%G?M#6O@C5];M_"VJ-H&N^&Y?#?@/5
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M^O:O#OB)^RG\ ;?XL? '3XOAW!Y&I>(?B +R/_A(_&.76'P)KES%_P S2O\
MRVB0XY'!]<+ZG^Q1\8O%7Q]_9F^#OQ<\M:5K6K:&UUH]A)J&OV":=J*6+7L5[I7B/5]#UAE&H>'=1U?1?L5^.U^(O_)7_
M -G'_L8/B#_ZK74: ,D?L@?L[ _\DV@QDG/_ D?C+N.O_(S/W_V#]!]X/\
M^&0?V=/^B;P?^%'XR_\ E]7TCM\]?^"CO[1?Q-_9>^ 4'Q0^%MJ.A>$KCQA\/CXPU75?$NF^&-#U#2[3Q9!J6F:1JFI:YI6B^+-3TNS\,:R >\
M_P##(/[.G_1-X/\ PH_&7_R^H_X9!_9T_P"B;P?^%'XR_P#E]7YP_&7_ (*4
M?$3P[>_L3^#OAGX%TRS\:?M#7?AW2OBH_BC0?'7B3PE\+_'/B7P+X@N-.^$G
M]O>$=.OQ9_%&T^*!\-+X[\.^-M0TW5]&^'D5[XC73VGO8YZ]@_8T_;2\6_$W
MXJS_ 2^.U]X/LOB]'X,EFTW3OA_HWBBZ\'Z[JW@75M6T7XGZQHOBF[EG\.3
M:/#XE-SX7TNUTI[W;K'@3QJ@\5>(],.AI8 'UZ?V0OV= #GX;6Y!!5L^(_&.
M-K?*Q_Y#W923VZ=1UKR#XG_LM_ #23H367@"V@:YBU!)7/B+QCF6.V:T%OG&
MN'E%ED/;AQUWN.0#ZUX5\8OO>'?\ MU:7BVM7MZMK&L:W=P6/Q1^($%L-2UO5M4U[57^RV/B".TM@VK:SJ1$>X $A5)(P9_P#A
M@S]G,MCS?W9"CG@A\'MM)HWK(=S%I7[233[Y?Y(R">PR:_6[_A@[]G#_H">-_\
MPZWQ'_\ FIH_X8._9P_Z GC?_P .M\1__FIJ_K#\_P ?\S _)*BOUM_X8._9
MP_Z GC?_ ,.M\1__ )J:/^&#OVMM_X8._9P_P"@)XW_ /#K?$?_ .:FC_A@[]G#_H">-_\ PZWQ'_\ FIH^L/S_
M !_S _)*BOUM_P"&#OV-_P#PZWQ'
M_P#FIH^L/S_'_,#\CI?]4_\ NFOK?]A'/_#2WCC/_1"K3_U9$V/_ *_O7UR?
MV#_V-MR21N WQ6^(Y5MDBML/_ !5(_P!9C9U_BK1\*_L9_!?P5K\N
MO^$&^)?AW6[C0VT*YU#3?BU\1X9WT=]1BU)=/CE_X2DE!%=PQLV 0R!E_BXF
M5=RBXZZJW]:^0UNO5?F?6=U$D]M-!)''+'/&T,D4J"6&6.4>6\M4$$>66..*XO7/ _A/Q'9G3_$7AK0M8LI3HT2VE_I<$T*R>'-7L?$6AK'',GE
M?9M(US2M.U?2V( @U*SLYDPZ)CB?^%$Z%_T//QL_\/3\2/\ YJ*/^%$Z%_T/
M/QL_\/3\2/\ YJ*P-STP:#HH B72-,"1W[:N=NF:;' -::%H7U<1A5)U3R'>
M.>\!)> R1ALMQ)%H&AQ3"5-&TQ)FFENFEBL;**9KJ[ADM+F_66(F16N+>>6!
MV7YF21E9L$FO+_\ A1.A?]#S\;/_ ]/Q(_^:BC_ (43H7_0\_&S_P /3\2/
M_FHH ]E@@AM8?(A1(X8P\4*#KD*S-S^#?D>N:\&F_P"3JM$_[-_\6_\ JR_"
M-:9^!6B+AE\<_&OM_P 8#KUOH"
M6"58WBG0PRI*NZ.2.7]W)$ZY&1(C&/&?XNAZ'C?$/@3P=XITVYT3Q#X:T76]
M,O+>PTVXL;VU#VTMA8:A:ZE:V<@!.19W=I!>0C((FMXB0,8KA?\ A1.A?]#S
M\;/_ ]/Q(_^:BC_ (43H7_0\_&S_P /3\2/_FHH ]/73]/+F1;:SD:6YM=0
MC)M B?:(K<6^F-$P("FVMK1;=<#A3C";@M"Z#I:+&GV&P9K:"\MXF:,8CM-1
ME$VHJ.^'DW< CGDX+$5YA_PHG0O^AY^-G_AZ?B1_\U%'_"B="_Z'GXV?^'I^
M)'_S44 >S6MM!;)!#;I''%#"(8$B3"BW 7: >F,@'CJ>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M#TL^']$B(;^RM+2+^T#K&XNU!,MNTL;$J[@
MOBT'3!]G$EE82M9I=&$FW"^4+^?SF ;G (W#'.23TR37F/\ PHG0O^AY^-G_
M (>GXD?_ #44?\*)T+_H>?C9_P"'I^)'_P U% 'LRQQ0Q!(E2)0DB".+[GRH
MQZ8[ 9]>E>,ZA_RM4+SXHQ\Y(3G^]U'6LD?L[^#I]9M]>;Q3\7FUBWTZ^TRTU4?&7XD+=#1]4O;?
M4Y]/5_\ A*3D1WEC"Q.T'8I!)S@ 'T517AO_ HG0O\ H>?C9_X>GXD?_-11
M_P *)T+_ *'GXV?^'I^)'_S44 >Y45X;_P *)T+_ *'GXV?^'I^)'_S44?\
M"B="_P"AY^-G_AZ?B1_\U% 'N+=#]#_*O#-:_P"3B/AU_P!DO^*7_J1_#BFR
M_ ;0'C='\;_&QT=2LB?\+I^)'[R-N'CY\4 ?O$RAYZ-QS64?V=/!MQK5KKS^
M*/B\^K65MKEC8:@OQH^(XN+.SUV^TZ\UBPBQXI/RK>Z)8!BN5QN7)(- 'T-/
M&DT3Q2HDD<@V21R+O1T8@,A4\'M+K^R3=6VJ:;!=V5TF@:K9Z]HD4T$V8I#I.MZ9INKVX9?W=S80RJ R?+PG_"B
M="_Z'GXV?^'I^)'_ ,U%'_"B="_Z'GXV?^'I^)'_ ,U% 'IM?8KY;_3H?L%C#'87T:&.'4+6)2I4Y*1AU;S,'<6&T8BA\,:';HD2:1IB1QF_
M#_Z#91;_ .TV,NJ7BF(>9&;DM)"VW!)DP^8R2/.?^%$Z%_T//QL_\/3\2/\
MYJ*/^%$Z%_T//QL_\/3\2/\ YJ* /7K:VMK*.WM[6.."VB2*&TMH4VI!;JZD
M'KPK$ >X&22:\E\1?\ )=/@]_V3_P"+W_I;\+J@E^!&AF-U'CGXV LC*I'Q
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MYU^>"XNO+9O%.WY[:WFAH6L%]97-E%+B&
M2.8B-DEADRDD;!L,K#H21R!7$7'@;P7?:5-H;^%_#BZ1>V%]:WVG?V-IQL+W
M3?$%K-:ZQ9VZ1A<+J>G)=V5YC[]IM^%$Z%_T//QL_\/3\2/\ YJ* .]M_"OABTLQHEOH&F)I;6>GZ5]BBT^T2$Z=H
MT,9T5%C9BG]FZ1%%';VFY6*W"IM&1\T\OAW1IKB>:;2-)G:]N(KF\=]/L+@3
MW=M:_8HXGB?)D8:>94!;MZ6UGY&@ZM8ZWHELEJ+5!]BTO6].T_5-+M-RK;ZG9VDX!,5MXV?^'I^)'_S44?\ "B="_P"AY^-G_AZ?B1_\U% 'I(\/Z3Y=O%_8^F+#;:DN
MJV\%O8V5M#!J<"LT=\D4*^8-2=5$4TBM@P-(&^4E?NT>PT^1(8[V.(O
M;_-'9:BYEU!%ZX\V0E2!@ -R 2<^7?\ "B="_P"AY^-G_AZ?B1_\U%'_ HG
M0O\ H>?C9_X>GXD?_-10!Z_:VT%FL$%M%'!:Q0&&TMH8=D<$"KD'<#\NX@#!
M')(R,G->'_$?_DN7[.W_ %W^*O\ ZB-A5]_@1H94@>.?C4,X^_\ &?XD.I&1
MD%3XH )89"^C$'G&*QKC]FKP3J&IZ7K=_P")?C#>:MH4ETVA:A/\8OB0MWI!
MO+2>PNS:2?\ "4C N;.YN+5S@YBGD SD 'ONJZ?8ZKI]SIVIVEG?V%VJ17-
MG?VL=[:7,9E0^5-;3?NY-S!=F[[DFR0M+^SYM(TS['_Q(M4L]=T:W$'3S]+UC3;#4[)N/(O+.WN%P8P:X_\ X43H7_0\
M_&S_ ,/3\2/_ )J*/^%$Z%_T//QL_P##T_$C_P":B@#TL>'=$1(HET32(XXK
MU]0@A&E:8L=MJ#Q/$=01 #G4O+;;/=JM-L4>2:XADM[R]WQ?O ;BTDFMSCYCYN&&TM7FO_"B="_Z'GXV?^'I^)'_ ,U%
M'_"B="_Z'GXV?^'I^)'_ ,U% 'K]I;6UC##:VD"6]K#;F&TMX(=D5O;JI89/
M\(8@ XR2."237AWQ%_Y*_\ LX_]C!\0?_5:ZC6@_P "-"*L/^$Z^-*@C!+_
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M^ZD%]<:5%+ WF(MW>*-4=4!#*AW DGA_P#A2N@_]#I\9/\ P[WQ%_\ E[1_
MPI70?^AT^,G_ (=[XB__ "]H ]FKP_XP?ZSP_P#[NJ_^AV%6&^"VA!3M\9_&
M)CP-K_ JI!(###M)V_.OS8Y['-O/@%X/U%D.J:S\1M6$(9;4:M\3
MOB/=36J-@R)'+_PE(RLA52>/X1]: />J*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **AN&5(7=\!4VNS,_EH@1U?S)')&R./'F2-_#&K'!
MQBOF7XQ?M2_ OX!:QX&T+XO?$C0/ GB/XCZH=-\%^'-0BU+4-=U^\L=1?2M8
MNM+\/:5&]_%I0O-0T_'B!5,+IJ/F79%I'*0 ?4%%V^N:/<6E
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MO]E^)[(Z%X.\>:??:GX0U.X:\TJ"YNQKMI8W,9'F^79K;/MZ'*-*\G6M(G&K2W4.F1KJ-K.=6:T@:^GCTHR,)=3FL[6&XDD2S+M;1O+-,#'
M"YH ZJBN;?Q!HL>HSZ;-K&G6^HV-I'J%W937\,-]9V$_R13W<,A9?*>210C2
MD*K,"I9B"1?$.@LUJJ:WI?F7YD%F8]0TYI;WR(I+F8(!PPB@BEDM0!TE%20ID)&C
M,W"FK%YJ=EY5ZXOX8DT]=][( \AA40PZD)8TB#L\J:=%--#A)1O 9H9D5XG
M-ZBOSWU'_@I?^Q)H?@W7/'NN_M#>%[#PMX;\*;#PK
M8>-;NP\4:1_PC2:YH>GR^%KF/Q"OBW7](T?P6]K=V1BNKAF6.;U3P;^V'^S1
MXYU9/#_A7XP>%O$.KW'CZ'X8VVD:)]M+ZKXTU/1O%'C"SL=&0:5;W6KW#^&/
M"/BW5-0U'2YCHP7P_K[!C+"\; 'UI17E7Q&^*7P^^&'A3Q=XQ^('B_2/"OAC
MP%X0U[QWXOU74IK9;;1/"OAFTEN]8U*]M9XYK^6&+3X;@R0P1MM(U@^$/CG\+/&2> 5TCQAID&N?$GP!/\ $[P1X2\0M_PC7C?6? $=WI8O_$J>
M%?$4D/B2#1+.;6-(36-0>Q:WA6]T^XC*(@( /M3Q+J?A+4/&VF:,WB333JFH^$+"\73M1\66^GMC5AZ/\7_ (:Z[\2=9^$>C>,+?4/B#H7PZ\'?%/4-)L[6>[DC\ ^/M>\5>%?"
M7C"/5[!#H%YHVJZWX$\0V:'3Y#Y+Z$TUZ([:)S0![;17B6G?&_X5ZG\3F^#E
MIXMTBY^(,?@+2_B0/#B30$#PCJ6M:WX9M]0T^_).E:@T.J>'M>M9H=-=IH8]
M*F>=1&C,?1G\1^'VEALEUS1Y+FY:>&VM5U.T:YO!:0275VD<-N3,1!;03S2;
M!M2*)Y)AY88$ Z>BO+=:^(W@W1M:\)Z-=:VLM]XO\0WO@_2?[/TO4=3AN-M] U+Q/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M30_!W[KQ+-I]IJ>M2Z;MGBCDLVT[15GU&;4OWRKM16!:ZIIM[=2I;7MO<3Q")[BW2;;- LC7$5NM_ MLDML6EBN8(XKTJWFVX0!I
M>=8$TH.R-NN#(ZK;08W3W)A@7#2
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M@ HHHH **** *MZ6%K(R!693&ZHS;5E*2HWDD^15]^R(I(R.OP
M!\:/V;OBQK_[4/@3]JCX(?$/P3X-\0Z/\'M9^ 7CK2/BGX*U;Q-HFH_#+7_&
M^B>.+SQ-X:AT/Q5X>U6P\;:%J>C0101^(XVT34+..6QU6(Z=-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MZYXCN->\2:1;:QH/BOQ7I=GJO[FVO/%$#Q8>%)%^/?AI_P $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MP1W^-=E\>-"DNM:^"7A_XC>/[;Q]X-\":GX=N?AGX\G_:6^*/QDO_A'
M^R?X1MO'^J:A\#_!-IX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MB_:O\3>.;B[_ &H_"@GFD^(VFZ%?Z1+#3\()_
MBSH7Q2^'-C%XGU^+Q5K?ASQ"/C%XM\;:_?:"-*U?Q[XJNM=U&T\3V?AC1K?4
MO!5F)[+\T=)_X*&_M]-\7/A5\(++PY9>+-?U6QMM>L
M- _X9=^*7ASQ1\>_ 6H_M=>)O@=:?$C7;=/%6[]E#PM-\&=._P"%K)KWQ)SI
MMW>^$=6L(")]0MU'HOPT_:N_X*&/'OQ.\
M0?LI_$K2]/\ V;]0UCX4_''Q9\9/@_%X8\2>.M*B^*6G_"7Q;\/_ (9>'O#G
M[0-E?)X \1^(/B1I>F)!?FZCLIP#U[PK_P $S?BU+X5^.7A/QQ\:_# \/?M/
M?M$?"3XG?&KPSX1T/XE7UI?_ U^&FG6Y\3?#_3/&7Q/^)WC;XCW%S\9]3T;
M0+7QM:>(/$V?5:O\ \$Z?&\/[3T?[3?PI
M^+&F?!6]O/BZNN>)_#OP^\-SQ0Z]\$I;[0/$FN^&WN[ZYU.WU+QG\2/$%AKM
M]XZNAI\FAZN?$^EP6"VU_P""[2Y7X^^#O[9O_!1;PGX%^ O@7XC_ ^^(/Q3
M^)'C;0?AAHWB3Q5K7[*GCK29-%\=P_MEM\*/VAO _C\^'-:GT?0K+P#\ ;6V
MU[PO\0-2BTWPWX^NM5T[QG:0:_>ZI!HNHUM0^/G_ 5,\>>'?!.F7_A34],\
M=>)+"#X@^"O''@KX+_%3P[IWPPNO'7[)'[8NHQ^#_$_A;4?%2Z/\2KGP-\3/
MA_\ ":/2-2^(\UG;7NM>/-/BU?P;INI'P_?VP!]"?'7_ ())ZQ\=?C%\?O'F
MJ?%#X'?A3XP\60^,M*T7Q-^S
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M]K.+PM+8/V
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M@=8LK%*GU#]I#_@I[8?$O1?A79^&M#U3QY=_#/PX85N_V8?B/%X \3ZOXT^
M_P 1/B1XA^+]U\3[7Q=#X/\ !6G_ >^+NF>"/V>I/A9XHN+;Q?XCO[B]U:6
MXM6\11W$(!:T[_@D#J-P_P */$VJ>*?@3X(\?_![PQ\"/"GA'5OA!\'_ !%X
M;T[PL/@]^T@?BSXU\0^%;2[\4:A>6OB3XX^!([7PK\4YM,N-*AU3Q'-<6UPL
MMG";_\ 9IM_#OQ#^'5IH_PI\ _"/0/&VKQ_"V__ .$TTGQ]
M\+_BEJ'QA\9?%W]GK5--\1S0>"?&_P"TAJ>HW/@GXZWFHQ74FH>!-*TFTCM+
MJ6Y%N_J7[&G[6W[*?@3\*K+X7^(_C%X<;Q?X&U'3-?U_
MPG\25\'67P-^'8U^;Q1;V^F_%;PI)X.^+&J_&CPU,-.B']N> 5FF\,1%I[WX
MZN?CW_P5@3X+6NA> O"?B+PG=3_ C2_!.@:?=_ OQ_XK^)FA?%.\_8IN/C5>
M^/+_ ,=?$SQ6TFIS>'_BYI&F_!VW\,ZW;WET=<\2:\NJ>,=2U\>#+"< ]7\+
M?\$7]8\+>&8?"'ACX[P>!=*U/X9^&/#GBP>#_"&H:-<:Y\28?@5\?_@UXP^*
M6H"7Q5E>%K[2(M0O;C4(-0T;W_XQ_P#!.'QA
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M/X>_:JT?XQ?LY7'B+X^^(-?^'OV;5O#7AW3]4\,VE_I=P\>HVP!Z!IW_ 2;
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M=PG[.DQ\-ZUXBUCQVOAO4?'6CW/['_Q8\$V_B#XI:A\4O!G@OXD_LLIMUE\*9/V>O!FJ>+_%L/[2'C&"X\%?$B7P\EMY$J>'?*DYW5OVQO\ @IU:>&;^
MQ\3_ ]O-&T/QW:^!M9?XG>$?V3OC/XFUCX&:!K?BW]HSP!=>![?P!X?\<:C
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M2^&[SPMX@L_VD7H/H/Y4 ?SU_%;_ ((U>,?&MX?>*= U?3?!&F62W>G^+_P!HSPW\1FTO6%U+5?"GQG^(MCI_BLM9)97?P\33
MX[*".[DOO[(_
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M^6^M[@ ^,8_^"OOPGU3XD7&E^'/#&O6_P<:'X=:AHGQ5\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M_!KXO>';;6/"_P :-3O/L_P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M%^-;6R\6Z3I'BW3=M,NI^*?BZOB#3- \1Z;\ O&5IXE\7_"+X:+I']H?'EM07189M0_9ZT^_\;Z1#
MH7Q-@=O#USJ/B"RM[%3MK\'_ (B:_?3Z;\5?A3JOQF\(7B:#IFB:C>6>CV?PT\,:_P"*]56.UD3PO9:7
M=W%Y)#;7DMQ'TGA;_@G+^ROX1G^'EQX:\(^,-&O/A;JNO:CX$G3XK?$^8Z'H
MGBF[T.74_AO%!;^*_LES\%KVX\*Z%>6_PE+0>!+:/1["2'PY8SQ)M3N_9*^ ]WH>I_#7X<:SX?UC1]9MO$'AO7)?B%\1/$&K:/=6?PW\9_"OP_96%
M[?>);J*PTGP1\-_'7B'P/X,TV)5T?PUIM?!/]MGPE\,_"NL?\+%^(.@_##P/\3_'WA.PT;XBPZ)XBU74=(N+SPUK6G>'?
M%'B\6SPZ?JMII>C&*QEU._>#2)DACO9C75_#S_@I#^S!\1O@K\7/COX5USQ;
M8^"?@UX=\'^)_$>G>,/ &M_#WQ3J?AOXA^%K3QI\*-3\-:-XY@\+#5;#XSZ+
MK&E6GPR>%K6/5M;U*.V9D6
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MQI;_ XO_ANWPB\>:+X2UO4?'7A3QKXRTO3O$^F:S9:Q;G3=$\&>$+O1=*\<
M:TEUX3OM,\9^-[W5-.\,1?#D:GX8T>&+7I-3746Z_P )?\$UOV,? FM_#_Q1
MX*^"$'@V?X7:WJWB?PWI7AG7_&NB>&I-=OOB+XF^*-CK?B3PS'X@LM,\=ZSX
M.^(^O:UXP\#7OBC3+NX\'7>J6,WA.2R@L+2 >B^!?V-?V=/A[\2/#GQ9\-^
MY[+Q[X"T;Q-H^D^)F\4^)[Y[R36]5\4:CXD\4^(8-3U>7P[XF\9:Q>^.?&[:
MGXLUJ*3Q!IZ>+-?TA)XK&5Y$ /COXN?\%:OAI;Z7;:+^SYX*\=?%CXE:Q\6/
MA!X#\'V6K^"?&_A;PGXP\*_$CXHM\-)_C'X0UF.SN]2\6?#/PWXDT?6_"=_J
MNFVLMG<^,9]/MKX)I7EC
M\+?&%[X*O_%_B+X3ZS\:?"W@ >/+/0+3PF_C_P 2?##PCX@U+0O#C7T=Y-::
M>-/B!JUMX4U
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MO;6:%T:WDEC//6__ 2O_8>M)[Z[A^#-H\-Q\)M1^"=SI%QXR\?S:"WPWUOX
M;6_P=U2S31;CQ/)'I>IZE\-=-TWP5<:NJK/I^GZ#;:A T-Y:1S Y?P3_P %
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MAG5/$/C'PEH-XGTKPQH.N>*$T34&5KG25E-BSW;6\9W?A5_P43_9H
M^,WQGT7]F[POK?CG1?B[K/A*X\4V_A3QGX&\3>&=:TR\LO#>A>,K_P #^)Y=
M7@GD\.?$/3/"/B;PCXQN]/UF!ECT+6;)[&3[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MD_X+ ?L_ZEXZLM%TW0/'^B?#;_A+=$TR_P#V@/&_A'Q#H7PMI_3]:^&GB33]/\3&7Q/=^#=)-S8>#_&:>$$U&VT76=2TV:_U*.SLKOI_ W_!
M(G]DO2/#7B*Q\?Z1XN^*'B?Q3X[\0?$.7QWK'C'Q%H&HZ#JVK_&+QS\8+'3?
M UEX>\0Q:/X)TZV\0_$#4HS#X?98M>0/=:Z#JM]I5AH_AK1[#PQJOBOQUJ'A!H/ 7PE\5?L_>&+N\\*W_B6:TO+W3_ (.>*M0\
M"7&MRJ9;G1VTQH'6X$M'?'NJZ=\/XM-\0^ /"5WX@\>W%OHJZ=X=\-C5/B7X(N&U&ZF2U=-3'GRP1,T
MR]+\ /\ @IA\%_CQXB^&7A?2O 7QH\$^._B_K_QOTWPYX1\?_#S4=%NH-(^
M7B_6/ _B_P 43>(C-)X=N?#>H^)+.[M?#4VAZIK-S-P7-O:1L\D7=Z;_P
M3[_9BM?"]KX6G\(>)?%FCZ9X,UKP%H[>*/B7XX\1:O;>#]6\9?#_ .(EMXMM>UCQ9=S6UE'XF^&O@O4O#7(ZOH^'_P!@3]FG1/%'P^\4
M6_@O7+B;X9?$KX@?%WX?Z)=^/O'<_@GPO\1OB!?:EJ'B7Q!I7@*\U^[\.VJ-
MJ/BCQM>:/#<6/Q/%6*SX
M(HUDBDC .6N\%"-A%S*+FXG7J2&G"H!G/S YP:T* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\6(/^"\?_!-\[;I?'/QQD\T
M!PDG[*/[4D9B+P0S6@M+:[^&IMXE:RN7\R>R(CF4$@[6VFW_ ,/ZO^"M?'3_ ,12_:5_^=M0!^SE%?C'_P /ZO\ @G+_ -#I\=/_ !%+]I7_ .=M1_P_
MJ_X)R_\ 0Z?'3_Q%+]I7_P"=M0!^SE%?C'_P_J_X)R_]#I\=/_$4OVE?_G;4
M?\/ZO^"M]I7_ .=M1_P_J_X)R_\ 0Z?'3_Q%+]I7_P"=M0!^SE%?C'_P_J_X)R_]#I\=
M/_$4OVE?_G;4?\/ZO^"M -#I\=/_ !%+]I7_ .=M1_P_J_X)R_\ 0Z?'3_Q%+]I7_P"=M0!^SE%?C'_P
M_J_X)R_]#I\=/_$4OVE?_G;4UO\ @O9_P3B12S^-?CF%'4G]E']I7 R<#/\
MQ;;U(Q[T ?L]17XSVO\ P7E_X)T7!Q!XT^.$F3PH_90_:6YX)_Z)K(>@_N]N
M<=1T%O\ \%P_^"?MT 8O%OQO()[_ +*?[2ZCID9;_A5GR^W7)P,\T ?KQ17Y
M5VG_ 66_84OPK6WBGXT-N' E_9?_:2@3U^:2?X7QQ+QTWN"3A1EBJGI+;_@
MK3^Q9>(##XF^+0#8QYG[.7Q]B3L>7G^'(B7VW]3@#YBM 'Z845^=EM_P5"_9
M"O,"'Q+\47W D+)^S_\ &Z-. 3R__"N1C&#CGD@#G-;4/_!2+]E>? AU[XD<
M]!_PHKXUQ],_QR?#^V1<8_BG3/0;F(1@#[YHKX7C_P""AG[,C#>NN?$4C_II
M\&/B\B<\#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MNC]GK_H,>./_ U?Q(_^96@#["HKX]_X;H_9Z_Z#'CC_ ,-7\2/_ )E:0_MT
M?L] '.K^.2/0?"GXE,3^">%2Q_#ZGC- 'V'17QS_ ,-T_L[_ /04\>?^&E^*
M'_S)TA_;K_9W4%CJGCP ?]4D^*#=>.G_ B@S^= 'V/17QNG[=W[.SL%75O'
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MOA<1]OXC]/FQ4\7[5GP9EP8]6\6_^&\\9IV_O'PV@'_?Q<].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MZT!T/4LFW\^_3G% 'JE%>8'XL>%#UN-2'NWA[5MJJ'T^]MP.OU/3VH ].HKSV/XC^%Y!D7&IX]M'U4G\!Y4F??@_AU$G_"Q/#'_
M #\:M_X)=5_^0J .^HK@?^%B>&/^?C5O_!+JO_R%1_PL3PQ_S\:M_P""75?_
M )"H [ZBN!_X6)X8_P"?C5O_ 2ZK_\ (5'_ L3PQ_S\:M_X)=5_P#D*@#O
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M'*)* /TXHK\^M$_X*'?L^Z]H5YMXZLO#%OX[_LI/A)=>'+7QC:Z1>^")_\ A-9O%GB26ST!=%:\U#4K^UTZ*Z>+
MN=(_;)^#GBCPGI7C#P9'\0/&:ZG#XDU"^T#PG\./%VO>+?!:^#M;U3PQXOC^
M(OADZ/::CX.UGPYXDT/6O"6I^'M5-MKU[J>D>)=.\/Z?K"Z-?Z@@!]F45YCX
M \YU#P]?VUK=Z9KW]FSVFCZYH6H:?%JN@ZSH>KC=8^)-+U>
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MP=P #VRBO*K[XU_"'3XTDO?BG\.K..3;LD;QEX? ;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M*^/-!N)$EGM]7U==>U&6)+N,V^HWMS;)XLTN\E;3Y)S>V@DOX;A+J&&77#M#I<3RW?[.'Q@F\'>#/#E[^U#\1Y_$7A;PWXBT:ZU>Q$.FVOC'5=7U.SDA\1Z
M]"^NW>O20>'M/>;1%@L=8MKQVU)$CN%8@,44 :8_9V^*5SKFEWEQ^T;\0)=(
MAN1>:Y:K;W]IJU_:IK+:U%HUB]QK]];:1H<\=EI>ES275I=:_>6UA+;W6HO!
M<2J/L:U5@P.&"D(R(S&5(84B\H1QRMFX_+A=PVF3-_P!@'Q5>W-W+
MJITRX\"ZU_PD^IZ?H<<22,+>+5K_ $G5O"-V84?1$T+3;V*"9K@VURLEE-<0
M2%% &;J6E?#>;2M/-S_P37\6WOAV#4@VB6$^C:#+J9N+6R?P]IZ0:98&_MK*
MRNM&UA([.?4=0C9]-EUL('G")+]1_!KXJ^(-*C\$?#73?V5/B'\,O"T6E);R
M/%%I%IX:\&($OI[>U:WM3YYDGN(XK0",Y$MPC,-BL244 ?:$04,3D.PMO-A2VV8]H7IG!LT44 <'\4?#^L>*_AWXS\-:!?'3-9USP_J.FZ=?K/>V
MQM;FZ@:))//T\B\3 8@B$_."4DS$SBJW@'2?$GAOP/X/T76-9_X2W7]+\-:1
EINN>)GFEF?7]0L;5(;C6FDNY/.8ZI,);SEG&93M8J5)** /_V0$!

end



GRAPHIC
12
image_006.jpg
GRAPHIC

begin 644 image_006.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" %2 E@# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#\'YIY_,N?
M]*N/^/KG_2?T_GR/\*K?;+C_ )[3_P#@92WG_'W/_P!?0_K5>N@"?[9M_P#P,H^V7'_/:?\ \#*@I>0?0B@";[9M^V7'_/:?_P #*/MEQ_SVG_\ RH** )_MEQ_SVG_ / RC[9M@"?[9MH** )_MEQ_SVG_\ RC[9M\#*@HH G^V7'_/:?_P #*/MEQ_SVG_\ RH** )_MEQ_SVG_ / RC[9M_P#P,J"B@"?[9MSVG_ / RH** )_MEQ_SVG_\ RC[9M7'_/:?\ \#*@HH G^V7'_/:?_P #*/MEQ_SVG_\ RH** )_MEQ_SVG_ / R
MC[9M\#*/MEQ_SVG_ / RH** )_MEQ_SVG_\ RC[9M_P#P,H^V7'_/:?\ \#*@HH G^V7'_/:?_P #*/MEQ_SVG_\ RH** )_MEQ_
MSVG_ / RC[9M7'_/:?\ \#*/MEQ_SVG_ / RH** )_MEQ_SVG_\ RC[9M?[9M* )_MEQ_SVG_ / RC[9M*@HH G^V7'_/:?\ \#*/MEQ_SVG_ / RH** )_MEQ_SVG_\ RC[9M ,J"B@"?[9MG_\ RH** )_MEQ_SVG_ / RC[9M_/:?_P #*@HH G^V7'_/:?\ \#*/MEQ_SVG_ / RH** +MO<7+7$/[^X),O_
M #]?3W]?\ 'W/_ -?0_K5>
M@ KZ%_9]_9)_:0_:PUS7M!_9X^%&N?$6Y\-QV]UXHUR/4+7PYX.\*V]Y_P >
MEUJWBSQ./^$>T6^_ZA^>_K7SXGWA^/\ (U^T6JVGB>X_X("_#>/X)IXEO]*L
M_P!M+QA+^US9^ SJG]N36UW;7G_"*'QM_P (QGQ#>^%1GP[D]!E<=<4 ?F#\
M>OV>OC=^S)XV3X=?'WX9>)/A?XMDTPZQHUGJ_P#IUCKVD X.NZ1XBT3_ (I_
MQ/H@.<_\([T/7G(KQ2.XMIEWPW-O,G&9(Y;6<=?ZY_'TZ5^Q?PG^ ?[=OQ@^
M(7_!-WX=?M&_#N3X^_"+Q1H/CCQ1^S=\$_C9\1]*\#G_ (5/X/TJ\U?QO=^-
M]6L[ _$#1?!&G6/V34/[/\1_\335=*L]!T?2!_R"Q7V5^TM\&?V8_B%^R_\
MLZ_'+PWH/[)>M_$+2_\ @I/\+_V;O$?C#]DOX7^,OAE\'=>\#ZQXHL]'\0_"
M75M)\:#/Q!_LVQ_XE_BSQAIW_(6U8^U '\U2W%O(VQ+FW=^28XY?\_\ UNU+
M)M\-?"W[(/P#U_XT_"'XE^!]+U2+XJ6GQ!T>STF]O+C4]7O;Y=/;PMJ%]=$_\
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M,G[3EO+M[X8_L8:#\-?VV_#>B>%/V/\ PW\2/V-_&_A>7]FG2OV>_ ?Q:@^('ANX\'^*
M,:M\)?VN[OQ/H?\ PAWB;_A8FAZ3=Z?_ ,)!J&I_\QC_ (DYQ_R% #^:K[1#
MY:3>=;^3)_RT\W,'0<=?\]NG)]HMEN%MGN;=)I,?Z/+=?O\ V_\ U>FM\2?V7OV8_A3X:_:!_P""JI^$'P^NOV2O'_[#/PO\7?LW?!:>TM=4\'Z-^UM\
M8K8^#M4\+Z5I!8_;?^$-OM(.OY.!I9\1ZB0!TKU;]A+]E/X*7=O^RG^S!^T_
M\ _V,/#.J_M$?LW^*/BA_P *_ET7XB_%3]KSXLV]WX6U;Q):?':Y^+-CI^F^
M#_@7H.IM#Q'K'A+X<>-+C5-+G_M[Q!X;_MC_ (2&U^QV7_$PZ:3JO_(1KR6.XAF#F&:.
M;R_];Y /VBOV.?^"/G[/'Q%O[S_ (5UXP_X*$_M
M8>'-9M_M7]E:KKWA_P !_P#"R+S^P?M9_P")A>_\)%8^'[3P_P#;_P#D*_\
M$X]%OC1\!_VI/"'@/X0Z9^R'X.^+6AV4
M/PX'CS1?#?BKX(?M-7/C/0=-\/:W\138_;=1TK4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M[X \(:_?:-_PS3\,[;X?66IW_AGXQ:=8@#^W\#&"_;-^&7PL^'O[6
MOQK^&/[/EUKFI?">R^(/A[3_ (5V%_#JND^(K.#Q@+/[+X$NAK=EIVHV(T_7
M;O\ X1\7^I:XLW\O_CZC^U?OX;?_ )>_7_/H*]=^
M)GP2^+/P?T/X7^)_B5X/G\,:%\;_ G_ ,+%^%>J7&JZ7?0>+O ]GM;31/^/&QP;,XU'G%Z#W%?TI^)/V7_P!GG5?@E^VQ\ ?BK\#/V-?AE\4_V=?V
M);?XO:7\*_@/X<^(?BOX^_!#Q?9^'_MO]O?&/]IK6K'PYX1\::UJ&H-]O_X0
M_3AJ3'3;G4.#&1OY_P /_L^?#+]J7Q1_P1D\)?%_0Y/'7@SP?_P2L\;?&Z7X
M7V>JW6GS__ AT;5]*^'5I=V0-_P#8=0O23JPQ\VE_*.3P ?RY)MUO,D?^MDCE\_R3T_SG'/Y5&MU;,R1I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M>7-\NG=2UZ 3Q7Q1\8_!/[+WQ'^$/\ P7]\6_"KX-?#_P -^#OV>[;X'_#G
MX!R>%]/NM+AT?_A#M=O?!_Q"\3V?V&__ +.O+_QGKMIJNH9((_LF\L1C)! !
M^6,W[#7[6=IXQ\5?#VX^#NJ3^-O _P #;?\ :0\9>'[;6M!-QIOP0N[:T!^(
MMW]MO_[/^PZ@1@Z?_P A4$'@$M_8O^)?U_XE_J:_L5U"1X_P!N;]K'?-OF_P"(?SPO+=1_\\+C^R^G^//X5^$?
M_!%/X3?#CXX_MX_"+X8_%OP%H'Q3\":Q\)OC/?7_ (#\26@OM*UVXTGX=W>K
M6C7@++]CO$O;6T?3+\,&TO4P0H9L*0#\R8YH9M_D31S^7S+YM8BN+:9MD-S;S.8O-_=R^>/L_7\O;ZYXK]T(?"?P9_:R_8L^+OQHU+]D[X8?L
MK^//V4/VY?@O\%_ \_PS\/Z_XM/V-[=#5M?+#.J7=@5 PQK[8^*7P6_8P^,O\ P5G'_!-WP[^R+\+/A+\+O@Y?
M:O\ &[Q1K_@BZN])^(WQ^UC2/A)>>,?^%-VPL\'1/ ^H7UY:$Z=IV&_XD]^-
M' /0 _E7CNK:17=+FW=(\^;)'+_J>_T[GCKWXIDU]9VMN]Y;+<>;
MGKC_ (],?\OWZ5^WEQK'P9_:/_8J_:E_;#U[]CSX&?L\>//V!/V@?A?:^"-+
M^%WA;5?"O@?XS?#?5_&0L_$/[/GQ.\*:U?:EI_C3Q5I^AVG]G:MJ!/\ :W]J
MWEC_ &O_ &7@Z37T9^T[^R?^S?\ LS> OVX_^"B>G?#7P!XE_9U^-?[/GPG_
M .&"_AYJUK9WWA;2/C3\>- _XJPZ3I"JHS\*[W2;O4=*P -*^V7^!@\ 'X*?
M%CX)_$[X%OX,MOBUX;D\&/\ $OP1I_Q%\!B76=!UR?4OA_K L_LFJ7?_ C'
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MKX&? S4/&WBSQ9^TYK.O:5\$/@=M_LS.!UH _.!;BV,/VE+FW>V'_+S'*?([?\O>.?\ /TH6:&1G2.:-WBXECCE/
MVB ?Y_3\:_JE?]F']D;QU^W1_P $>_$6@?#CX)>*O"'[6GPP^,VL?&+1_A_\
M,]5^'7P.^*=QX/\ "][=^'_'?A3X-^-+\:AX:L?M_.DXTT' L-7!4\U\+?%"
MU^ _[0'_ 3J_;B^(^B?LH_!/X ^+_V.OVO/"'PK^#?B3X-V&OP:[-X \2:]
M9V=WH7Q-\0ZU?ZCJ'C2]_P!*(^WZB#_:O^@?V.>!D _'+P'X-\4_$CQUX0^'
M7@309_%7CCQYXCL/"_A+PW9R^1?:]K]YS::7:78_XE]EQ_S$-1SI7ZUO_&+X
M._%']GOXB^(?@[\9?!FN>"?B+X4ET>/Q'X8O)=+OKZT_MC2[.\TG_CRSI][_
M &E8W=I_9)TX?\OF,U^O_P#P1"^"+ZU\3OVA?VO-2U7P/X6LOV6_A-X@TSX6
M>*?B'KUIX5\ 0?M'_%/0;S1_"9U;Q#?'^S]%L?#UE_I_M_P ^,9[;_@EW_P4-\7:E\"/VA/BIH7Q"^%_[-_[66J> ->M/'/P<\8?$:S\
M3@>"==U6[T,?8/MJFZU4Z5N&[2M6M-#P2, '\^"_ ?XZ_\ "?\ B3X4#X4>
M.)OBCX4\.:CXM\8^ _[&\_7/"'A>ST*S\27?BCQ9:67_ !Y:&?"H.H?VAJ/I
M89Z&O'%O--"[H;^RFADE\J*2.Z_UW_'GFZN_MO\ Q,/MVH_:[3_P#.*_M6TG
MX_QI_P %3/\ @K5X5/P(^ QE^&G[#7B;Q#)XI3P=JD'C'XIG2?!OASQ%M02;[^S_$^BZD=6NM-U33_O-IFD:",9TZOR";Q_\ LY_!S_@DW^S5^TC?_L.?
M #XB?'W]I[XF?M#^ X]?U?2[JRTGX:YXPN[2Y\/Z2?[3_MF]\.DZ3H/A
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MU;>,K;X:?\+ N+"ZL? ]YX_O,WFD^#?[6O;[^S[W7.WIGBM[XQ?!WXB_L_\
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M#X=^&/['W[3/QG^#7Q"_: ^%WPHU3QE\'?A1)K'_ F_C./5-!@@\-_\(Y;?
M;-6M?[)^W?\ "07H^Q$:A_Q+O[4QD'//+_"'[(_[2'CO]G;Q;^UQX.^%>H:Q
M^S=X'DU Z]\3_P#A(]!L;'3;;1_L=GJ]K:6E[??VA>_Z=JUGG_B6$M/^",7Q.TKX9?L'7VA>)+JW_X0;X[_P#!0>?]FKQE]L/[B\T?XV?#K6='L[J\
M_P"W[[(>_P"5>U_&GP@O[)'_ 3)_;!_X)P:5J=G->?LU_L/^$O%'C'5-,B$
MT&I^/_C5\;+V\M+H6G?_ (D0TJP]QDC(Y)_7]?@!_'DUU"TWV;[;;OMQR_Z[CGCG_/&MW"^N[3/]H^]?UD?";]D[]G>]\->,_P!E;X[? O\ 8N^&/C70/V$M7^-EA\(/
M FE?$_X@_M3^!/$&C>#QJVE_&3X@_M,WEEIGA^QLM1OLWVD^']//RM=G2<%M
M,VGX'\>^)/V=?V>?^"<__!,O4K3]D7X-^.OCI^UW\,H;#Q'\=_%-MM-_$71_LGC&TM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MOQ3>V=IXS^'OV$9T74/B+_95F/B$"Q&JC5MM.GQ%\:?"+X4SZ5\"(O&_CSP'IEUKGCCP?I_]O:Q_I6DZ397VFZA>W^HWQM-/
M/(_XE5YUQ0!^3O[0O[)/[2W[*.J:%HG[17P<\2?"ZY\3Q7%UX7U#4+K2]MQ5!9BS^U_P#"/>+-%O\ 4M/UK^SQ=VAU;3O^85]M'!SFOF];RSV7,R36M7FRR>:/(A_TK['_I=W9#_0K'_F(?]N?/?']"GAKQ[^R'^V/KG_!-S_@E#\+/
M&_QW^(/P(\(_'GQ/XR^(WQX^/?VOPK\1?&H&@^(_$=G\+_!%I?#4=0T6RU(7
M8T ZA_:0P?L !.,G+U6P^ _[3_PY_P""HOAO7OV)_@I^S"W_ 3LTO6?'?P7
M^(7@?0=>\.7 N/AOXQUC2+7X3_&XWO'Q _X6)8^'K3^U22NJ_P"F]>@H _#+
MQ;X%\;_#O_A%5\>>#_$'@P>.?#%OX\\&IXDL/[*OO$G@^\NKRSM?&-G:9/\
MQ(_$5]:W?]E7^?\ B:&S[<5R7VB&17=+BWFAM_\ 6R1R^?!%VQFO[!_C=X(^
M%G[:?_!1C_@G]\#_ (V?!_X5Z5X&T#_@GIH'[4FJ6FCZ7JFAZYXUN++P;J]G
MI/P'U;5K(_VC>?!WP]?7G_"0'P?IW_$U_P")..X(KX7^(7P]_8_^+DO[$WCN
MRTK]D^Y^,-_^W=\/_@MX[T;]DOP;\4/#O[.OQ9^"&L:]B[\&^.+7X@Z'INGW
MOCCP9]E_L_5>VJ_8[_- '\[L3]CM/MGVJ[M+(?Z
M;8_8<\C_ .M7M'A3]GSXV>,_%?PC\#Z#\.MMGFD6?_,3M;O6O^)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M?8VA_LGX@:EJ7KJW:MWXJ?"GP'\"_@5_P<3_ C^%NC6WA[X=>"/BS\ ;;PO
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MTZ]SJ&JZ?T\5:K>&OBRB@#Z3'[87[2B?$+X^_%/XB_M0^$KCP'\>_$?
M]@:!/-\0/!]X+1=6T'5-)^P_V?X6L0MK:+_:&F@:K@D=#7;_ J_X*$?MI?
M_P"$NG_!#X7_ +0/B/PQ\-/#VEZAX<\&V#=<\8?#'0-7M?LFJZ9X'\;Z
MWH?_ F'@NQU$@:?_9^G:GVXYKXUHH ^N_@1^WQ^V'^S+X/O/AY\$_C?JGA7
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M0CCI[/!'BR?X@>$_AIJGV3^
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M=_BGX-N/AIXV^($OA?03-XD\#C3!H]UH/]D_81X?LB-$M!I_]HMV^OVQOV9_ANGP>^"'QOU3P-\/=+EU"Z\,>'[SPOX7\57WP]U"\MKP:M=?#+Q
M#XGL=3U#P7_:-C=W?_$P\._\@KZ<5\>T4 ?6OP'_ &[/VP/V:]+\0Z/\&?CE
MK&@Z/XT\4:A\0=9TOQ9HV@_$:W/C^\'^E^//^*TL=2_X1CQQJ/\ T.&G?\A7
M\*^:?%7C#Q;X^\7:WX_\;>)/$'C#QSXHUZX\4>(_''B35+J^\5>)/$'VK[7=
MZI_:O_+[_9WV2T_LD9QI7V/K6!10!]Z:I_P5$_;_ -MP]U#X7^*+>X\&^#9Y_'G@?6-*.CW=KXWN_[#_M#Q/KOV'.G?\)!J/&E#ZUX9
M/^U7^T9+?_L]ZO8_%GQ!I&N_LJ>%O^$,_9^U_0(M+T35?AEX>/\ I=KI5KJN
MBV)&MV!_Y!Q_X2/K_P @@U\_44 ?5?QP_;A_:P_:2E\"2_&/XP7?B>T^&GB>
MV\=^#M TOPWX6\#>%=-\?V5V=8'C'5O"G@NQTW3]:\4B_MK4C7]1_P"0KDGG
MDFNO[;7[5$?Q@^*_[0*_%VX?XQ_'3P'#_A,/ ]Y;#1]6\+
MW>D_8?\ A'[&Q^PVF?[0T[&J\"OERB@#['^%/_!0K]M+X'_"6'X)_"7X]^(/
M#'PUT>V\0:7X-T^3POH.N>,?A[I_B2U^QZM_PKWQOK7_ !6'ABQYZ:=J?7]/
MC:[5+I)OM,UQMB@#[*B_X*$_MJP?&;PQ^T"O[0?B.3XT>!_A7/\#?"WCB72M!N)],^&%W=B]N
MO#%WI)L?[.O<7_V/41XAU'_B:YN\^F?#?"_QP^+7@?X9_&_X.>&_&=QI7PQ_
M:0M='B^/'AN/2]+N(/B%;Z/JEYK%I=76K7W_ !,-$OA?7=V/^)=^M>3T4 ?6
MC_MT_MM3V))\0_\A8Y.>378?\$T_P!J#P/^Q3^U]X"_:&\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MU+_D% ?'>G_$OXM^$_[&M?\ BMO&
M]G/44 >M2?'7XM+\!=1_9?A\4O
M;? #6_'=A\3M>^'-OHNE>5KOQ'M?L9M=2\07G_(P7@T\V5GG3A_Q*C]BYY J
M?P?^T!\8/A_\&_'G[/'@[QG_ &#\$/BAXHT#QWXM^']OHV@SV,WCCPY=:1J^
MD^,M)N_L/]H>&-<^W>'O#VH?VAIW_/GZFO'J* /N)O\ @I-^W''^
M.4B?&#PU\.;CX2Q>-/\ A O!L$&I?#^]NK,7>E^-])-C_P 7!_M&^M+3_B8>
M(O\ B:C5;2P]\^(?$3]H[XW_ !A\#^%OA=\0O&L6L?#WPAXW\3_$;PGX3&@Z
M#I.E>'/&'Q(U2]_X2O5+6TT6QTW/]H7UY=XT_P#YE7[98'HM52_X*"QZ3H^CQ_M(:Q_9NE>#9_ J>$O!NJZKXD\'WFE_V/::7\0O$-[H?
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M\:_/$.J_M1^&_!_A']H&XD\-Z!8WWCOPMX#M?^*3T&S/V'_BF?^$=Z:3J
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M]_Q,++^SL7? _P"0K]L_&O(:* -/3]6U+0]4TW7O#^JZIX?U[1+^WU[0=MZNK'7-"UC1[K[9I.J:5X@LO^/+^SKZTM!_:'Y^_U7\=?V^OVPOVDOA^_PO\
MC3\M,Z4/$7!(&[]F"7/P,\1Z7I^@Z7X
M^\*V]II=YX;TG2[OQO96/_"0>)K'^P[O^S_^$?\ $/\ Q*NG]L=ZN?%#]OG]
ML;XR>*_A9XJ^)'QHN-8U+X&>,K;XB_"?3-/\+^#?!O@?PM\2++/_ !7EYX)T
M6QTW0-;\5"_-Y_Q,-2XZ]]3S7Q_10!]"_P##5O[0D>H_M'ZO!\29/[:_:ZT:
MXT']HJYN-&T"?_A9VG:SGKFN^T7]OW]L7P]H'P1\.Z9\
M:Y(=-_9BU#SO@=<:IX6\&ZKXC^'T%GI5WI%I;'Q9>V/]H:U8_8;NZT_^S]1/
M]E<>E?'E% 'V#\-O^"@G[9_P6\'>*_ ?PQ^.NN>%?#/BWQEJ_P 5=0M_^$7\
M&ZKJNA?$#Q?J@O/$'C+PIJVM6.I#P7>ZC??\3#_B7#_E\ KE?&/[9G[3OCNV
M_: T[Q5\5?[8M?VIK[PO<_M H?#F@V4/Q.O_ ):C1_#US=W8L?]"OM.L;2T
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M4=S;3*CPW-O,DD7F^9'+Y_\ GI_^JIMK[MFSY\X\O(S]/IC_ H 2BFLVU4=
M_D23_5>9_G/X^E"R))-]F1XWN1^Y-O'+_I'_ !Z_;?\ CTQ_SX^_]: '44UF
MVML_CXX_SCG_ #VHXV;\?)CS?,]L]<^G^>M #J*;E/\ GI_TS_#_ #VZ4]HW
M4_.DB>ID_P# SW'^3F@!**;&R3;S"_G>7+Y4QB_Y8W'\L]OKSQ3_ .%W_@CE
M\HR8'_'QZ_T_#\0 )1369%.QWV/YOE?X_C^/O1&R3+OA?SD_UHDC_P!(]<]_
MZ>W/< =12K^\;8GSR?Z/+YGIZ?AZ4;9-WE[/G_3\_KV_6@!**:K
MHW\8YB^U<]K;C_2N.U"LC,B(^]Y/^>?7&?7_ /70 ZBF^8BC[\>/*\T?O?\
MEW_Y^^3_ (41R)(K/"\;I'-Y7F1D^OMC_//K0 ZBBB@ HHHH **** "BBB@
MHHHH **** "BFYVKYGTSSWP/\\4,=I??C]WTZ_E[>OIGF@!U%*OSMXY]P/QS2-\NS?E/,_=1=/P/?-/VA?QE\K
MD?\ +Q^% "44U9$;?L>-_+_UO[P_N?\ /^>.0+(DD:31NCPR?ZJ2/B#_ #Z^
MGYT .HIGF)_>%+O^7?\ P?\ /3/?'\\^V?PH =139)$A_P!<\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MK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M(-?_ +'TN\O;2U^U_P#$R^VWWV&T_P"$?TG3R?[*U75;VPTCI7TGX3_9#\MFL2:)XPU71_ <-Y?^#]&MM4O-4\^"&W\2_V/K%WJGV2RT/\ X\=._P"$ATGP
M_JQ_Z"MG?Z1_R&* /H'6/A!\$/ ]CK=GI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M>%_$']@R7%KH,$^I^,-'U31_#=WI?VNROQI_]A_\ $V/B#_A#_P#DJGA7
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M>>-O'D-AI?@_PQ>>%_"\OA*/PGXHM=#_ .$5U#1_!NCC[5=^'O[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M/?C--_PKKP]X>UB27QQ]@U34)?!MC?:#K'ANU\'V?A.ZN])LMM7UIXA\0?#WP?\._[4\*_\5)8:1XP_P"0;_Q*_@_QMX+A\,_\(Q,_EW^D^,-!
MM]?T;]U=6/\ 9M_9ZI>>&_%F@_\ ']_H1\.^*M)N]/\ ^)=G^UA9V.KZQ[M]GA\R1W2-OWOFRW$>?WUQ_T]].] 'Z+_ M\$_"AO OP*AU[1/!\-_'XH^'Y
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M6VOGZ[C_B2WVG7VK:MI^=._LS)LQI-?,:QHOR;Y'2/UEN
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M4-!U635!:ZI;V_BC2]M\'>#_"^O>'[S4M2UC7-'U:SU_1_"\-QI^GVL^AS>(/$EU_HFEV?VW_B8?VYI
MUC_Q,,_SK;\8?"6P\(Z/\4=8FUNXN;#P7KVCVOA>..+CQMH__'GXAUZ[_P"G
M[3K[[)P/^8K[B@"SX3O/".DW7QCO]D>@Z?IT.GQ>'/MFEZ#X_P!M[O[)_;7_ !+]:.HV-I9\9_XE7K79V?@[X=>(K*\\?_V5]@MM4\1Z??Z-IM"">'3_[>T?1M6\+W>DB^_L^ROM0_Y"/]GZ;IG_$J^V#->8Z?\/=*&M1Z#K&O
M:G9>)(_#FG^(_P#B5Z7:WUCH]QK&E7FL?:M6U:]_XE]EH?V$_P!GZM_U^=ZF
MN/ASX5T]D^V>)[SR='UG3]!\;^7I=K]@L]0UC03K'A[^R;N]OAIU[H?V&\_L
M_5M0U'G2C_Q-Z /3KKX<^ +J'Q#=W+WEGJ6EVMQ:_P!CZ'?VOG^ ]/\ [+UG
M6+/5-6N_[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M3[;X>>!M!T_PWJMUM3[O^S_\ B7:9I?%GVKY4DCAD^^GVKUDD_P!?-V'VL#/^@X]*8LM][_Q]'_1SQ=VMIGFRYQZC2O?- 'LWCSPKX;TW1W\5::^R7Q!XNU#0=+TN.Z$
M\&FZAX;NKS_A+;JT[FQ-C=>'O[)/_7_GV\?^3RT_OQ_NL>4?_ KCZ?E^MRXU
M"_O(;"VN;^YFMM+B\JPLY/\ 4:;;\]/^G[Z>N/053+[F?\.?R/\ 3F@!****
M "BBB@ HHHH **** "BBB@ HHHH ?#_Q]6W_ %U'\J*(?^/JV_ZZC^5% $MY
M_P ?<_\ U]#^M5ZL7G_'W/\ ]?0_K5>@ HHHH **** "BBB@ HHHH **** "
MDW!1O]O\3C]3_G%+10!K:'K6L>%=?T'Q;X;OO[*\2>$]4T_7]!UC_7_8]8L[
MK[9:77V3_E]L=.ON?[/S]3WKTN']H#XQP:AINI0^,[B:;1_]!T>/Q!86NJ^3
MI]EXRO/B1:?:^/[/O<^*KN[U ?\ 4*O-/TCKIU>/44 ==XF^(GC#Q=8ZWINL
M7]G-I&N:IX7U34-.M]+M=*@^T>#]!O/#?A.Z_P")+8_\>.G:'=W>G_V?T]\U
MM:Q\6O'_ (DM]'L-8U73[VP\/6MQ%I=G)H.@Z69KB\M?L=IKVK'1;'3?MOCC
MP[8VEI_Q4&HG5-5TK['_ ,2?5@=2KSA5W-Y:'>WITS^/3VS3)&2/[^4'_33K
M^/\ ^OIZ4 >G:Y\8_B%XFU;0=;U+5=/O-6\+_P!L2^'+NST;0?#GDW_B2U^Q
M^(?%'V2RL?[/'CC4;'_B8:MXP_LS^U?^@/JU4]:^*OCG7[[P9JM_XADCU+X=
MQ6]K\/M4LM+M=*OM-_L>ZL[S2=4_T*^_Y#OV[2-)_P")AJ/_ #YV&/\ F*8Y
M7PWX;\3^,KC['X/\,>+/%MSQ%]G\+Z#JFN?^F2Q^G^>*^D/#?[#_ .V!XLM4
MO=!_9[^(GV.3_57&L16NAP<_]C1KFFZA^G]: /,=>^.7Q.\5:'K?AZ_U71]!
M\/:Y:W/]LZ'X/\.:#X L=2GUC5+/6/$-U_Q1=B/].U'7+3^T-6U#_B5_VKJM
MG_Q)]6_L>KEC^T!\48+B"YN=;T/Q)./!'A?Q'_9&K^&]*_L?2
M?%%I:7MCJ7V+Q7]A_P"0MX@T[4]4_M4V=A_;/;/O?_#MW]MAHT=/@?J'^Y_P
MEO@SS_;IXJ]/_P!5M^O- 'B$WQ:^)=QK3^(;SQ+<7^I7'@/6/AIJEQJEKI=]_;'@?Q)=7EYJV@^(;
M3_D'ZW_:-]=W?B#&H_\ (*U7[ ='QWV_!?QN\9_#G1]$L/!O]EVVI>'X?&&E
MZ-KFJ6%KXCGA\'^,/L=YXL\+ZM:7MCIOV(ZC?6G]H?VAIV?^7_2.QKAO%7@_
MQGX(D>'QSX,\6^#WCE\J'_A+/"^J:'Y./^?2[OK'_3?IU/XURJSPR1^M_P"6D?Y=_P##].* /7;'XX?$O3=+31-'U[2_#>FR:I_;-K%X?\&:#I4^@_\
M$_/B2[T'P]=_8<:+X'_MRT'B >#]._XE7]J_\PG-7X_VBOC!:ZA>:E9^(=+T
MVXN-+M]+L+.R\&^&(-#\-_8_MMY::IX3\/65C_PC_A?7-.OM6U;4#K^G?V7J
MO_$XOS_:W:O&5^9MB??,0E\O_IW_ *=>.G:DH ZCQ5XF?Q)_PC%M#9_V;IO@
M_P ):?X3T:W$OGSS6_VN\O-6U35N/^/[Q%KEW=ZA^%M110 4444 %%%% !1110 4444 %%%% !1110 444UOE4.^!U/\N>?\]<4 ;?A
M_7M2\*ZU8>)-$FLX=7T?[1+I=Q>6%KJL$-Q>6GV/_D$WMC_9][V%6;KQ7K%U
M>:W>;[.PO/$FEG1M:^QV&EV,&I6_VK[9=_Z)96/^@V/V[_B8?\3'_P#5SVW#
M)_TT[Y]./?\ SZT*VZ8VR))--)^Z-M;_ +^>;IG\/KU'- '0_P#"4:\K0I#<
M_9_L>O?\)1:V_E6OD6?B"SM?L?\ :@_Y_?\ 0./%>N:;_9NIZE_:
M5A)I?]E_V?)%_KK?^WKSQ)_Q]_\ 8;N[O4?[0/'I6]HOPA^*_B)81H/PU\<7
M<$G[WS)-&NK+O_S]WMCQT[UW\?[*/[0DR[X?AI>(G_3YK.@P3]/3[< /K^I%
M 'G;?$S7HM/O-,MK;1VAUC1O#^C>*/[4TNTU7_A*;?PW_P @FZ_ZMCE^)7CF;^S4FUB.9-+^T?99+S0=!G_M@7EKU\0VGV'3?^$GOC89T_2=0U&O1
M9OV4_P!H>%-[_#&\F3_GG9Z]H-Q/U/\ RZ?;OI_DUY[KGPG^*/AE7?6_AIXX
ML(8^);C^P;JX@Y_Z>[/Z?Y- %:_^(7BW5K&_T?5=2DN=*URZN+K68[C]_JL.
MGWEU9WEWH.DZL/\ CRT/_1/^0>?^)5[<5@^(-;N?$VLW^O7B1I+C
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M_P#A)^SZEGK]S9Q^/_B=Y0^U>,-#0;C ^UVO@CP\!_9]G8_]1#43_:O
MYT ?FM\"_P#@G;\MXENH67/_ #$-1_/&:_6CX0_\$_?V5/A?]@O-5\'R?%?Q5;_9Y9M=^*&J?;M*
M^T?]0GP]96/_ C]E8_]0_4=,Y[:K7T:VM;I'=W^>X%O*8X_^6./^GO_ -QX
M_$T]=:?<MQ_\ )/\ LWG_ +"78U?D\0.TJ.]S)(^/]7)+S_\ K'O^/2O'FUU.CO\ )T[^
MO'I_^KM6G);Z]'H+^*?^$>UA_"L=U]EE\41Z7='0XK@7/V/_ )"W_(/_ ./[
MG_\ 7R >H_\ "0?[M;:2_N=+^T7$7D0?VA9VGVR[TOVOOL/\ Q,#^%5O^$@A\OSOM*>3YOE>9YO'V
MCU_+]>U 'K5YK%GJUH^G:E;:?JNE2?NI=/UBPM9X)L8_Y=+VQ[_R[5\;?%;]
MA_\ 91^+'VJ_F^'MO\/?$]Y]H/\ PE'PKENO!U]#<')^U7=I9'^S];X_GTKW
M)]=W+]_/_;7C\\?Y.*8=8_OOGT__ %#C^72@#\,/CA_P3+^,'PZAFUCX7:EI
M_P :?"5G+<2PZ7;Q?V'XXTVW_P"GSP]_S&L>FG?\37UZ5^<$UK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M'^E>++O_ )MGK_]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M*\6?#_X>^.K>:'QAX,\/Z]Y^/-N+BU\C5?7_ $35K+_CRZ ?\2[G^OQSX_\
MV'?#UPMU<_#+Q5>Z"_\ K8O#?BB7[=H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MM^LZYJG]C:79R?ZB>_Z_Z7G_ )M,:4\=SK%Y*->\9>)9(O].\2>*+RU^QW=UU_T*QTZQ_XE^DZ?_/B@#V/X4_#G
MP3\$?!]MX)\ 6'V.SS;W6O:I>?Z=KGBK6,?Z7JOB'5O^?[T_YA0TK_B4"O2%
MUA]_X?GQ[8?VQ#_>?]*?_ &K#_P ]?U/^%=!SGJ?]MG^^/R-']MO_
M 'C_ -_:\L_M6'_GK^I_PIK:Q"J[]X<]HY(O/_S_ #!QV% 'I=QKB21S0^=M
M>3[1"?\ 2O(_TC[,<_Z7QFOM[3/V@OA[:V?AWQO_ ,)Y>36WA_X#V_PJ'[-\
M>C:I/8Z]XPO-+O+/_A*/]-L?^$/'A74?M=IXPU;4MO _Q[N? W@SP'XY^)VAR_"^+P1H_CRPT'5;&;1[SQ0;/QO=?9/$]]IOV+^SM
M#']H:OJ&G?\ (*TKGFO;+?X3_ 'QYXR'A[3?,O/#UQXW^+%AI>G^#]4M18_V
MAH^E^#[R[M+OQ#96.I>(/^%<^'=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MV2:]X)
MUR6XE\$>,)(O(GUC3_\ C\N]+\0]/L7BK3NNK ?\A6OW+?5H1]Q_R_SV_+^5
M<3\1O"OA7XI>$=5\&>*H?.TW5(OW5YY>)]!U#_ETU321_P!0Z^^R:@1_TYT
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M3,:5]L]ZX_XI?"/]J+P!KGB3Q_XYL_$%X_P?U[3_ '=?%C3_$?V\V8\!_8_
M#FD_\(]_S^_\([FTL.-,]?:@#UNX_9[\#>%_@M\6/C+KWCFX\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MO:#JD>O>%X-*UBXT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M?$7P];;]!U2Z$OBBRC/D?V;K%Y_S%.O^A#4?KV]ZQ+AN_3]4?*=%+N=F??\
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M? ?PQ\0^#H]MN[_LG3]._P"$HTO5=*_XF_\ :W:O9M%_9X_9WFM]5UC7M!\>>$IO#_P'U#XJ
MZIX$^)GC>[TJ^M-/_M[1[/PGXH\;^(=%T/4O[%/C.QN[OQ!_PA_]F:IC['85
M^=VH?&[XKZI:Z5INI?$;Q1?VWA_1KCPYHT%Q?VL\&FZ/> V=Y:W=W_S&_P#0
M;2TT_H?^)5US75?\-5?M#MK%GKP^-GCR?6-/L-0T&PUB\NM+GOCX>O/L?VO2
M[NT^PY^PZC]D_P"X5C%!]'^%/QD\9^#/#;ZP_A2.U\+ZSH-SK%_:
MW]]-H^L:79ZQ:7=IJUE_Q^V/VZZN_P"R=0_LS2Q_97MS7CG]H)_ST_\ 'A7/
M^(O&&O>+M>O/$_B?6]4\2>)-4_>W_B#6+HF^FS_Q]VO_ %X_8?\ B7Z1U_/B
ML?[?_M_Y_.N@#N/[03_GI_X\*/[03_GI_P"/"N'^W_[?^?SH^W_[?^?SH [C
M^T$_YZ?^/"D_M =%FV/_ ,]!_,]O\_6N(^W_ .W_ )_.C[M\^&\/CCP6GCG1[;?XJ\#Q7,LOEQ?O]8\+_\ ,6M;OM]NT[_D(#_J%6?:ORL6
M33'D36]Y_H?\ /VS7
MXW_%+P5-X#^('B3PPZ2?9K._^WZ-MZ***#H"BBB@ HHHH **** "BBB@ HHHH *Z[P+X1N?'7BC3?#ELXAAO/L]UJ
ML_3['H_7[4.!Z<]:X]EW*Z#_ *Y'/Y_AW_/WX^QOVM7V72Y)#_ *G1[/Z]/3Z$XH,ZG3YGU=:_9M-M;?3;"&.STK3[6WL-+MXS_P N
M]G_R]?CSQ^%3?;_]O_/YUS"W"+_'O?G]X?\ /\N_/%/^V?[?Z_\ UJZ#,Z:*
M^W/G[[_Z3*/\D_G7M_[/_P 6M!^#OC'Q/XK\5^$-0\<:1X@^$'Q/^'W_ C@
M^U0:5J5QXPT&\T>T_M:[_P"@'_I8_P"0MR<__ *Z_0[X!_MJ?#KX7?"O1/ /C[X5W'C_Q#H\OB#2_^$DD_LS]]X'T>ZO/
M&'P=TK_3>FN>'?C%>?V_JO./^$5M+#2.M!^!O@^_F^*EA;^"=!\0:/HVJ06]GX?\ &'A>SL_"?@3_ *??[/T/P1_Q2?\
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M\/Z/'K'A/6-"TO6-4BU3^W-2T?X\>.[/Q?:7-I:7M]_PD'&N>"?[/TD=
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M0UFRTZ^M#I^K>'_[+'BK5?MGTK@/^&ROBTMQ'JK^ /#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M^.QXO^(7CS_3=M9O#VL?\ "'Z@GPL\#^._@1'XH\6?#S0?MVNZ;J%GXRUC6/!7@[2;36KX>'_M
MWQ#USQ;=Z!C4?^)II6E7?6OCWPAX\T3PO\'/B'X$2PO$\9_$CQE\.)/$7BBS
MENX()OA?X/\ ]+O/"^D\?V@;_P 0ZW=_;]6T_P#XE>E?VK:6&?2OJWXM"[X=?"/7/@:GP?UG5?#%I\0/ 'C'PYXO3Q'_ &3XP\57'@_XBV?C#5O$_P 3
M=)L?^*?_ .$W&B?:]/TG_A'!QBQTD>E!F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M2\9>%[SP5XFU7PQ>/Y[:/+Y5K<.W;_/7O7U[^TA
MX=2^TO2O&%LD?VS2Y?L&J>7QYUO>?8[.TZ$__JO,^E?(LBE9)OG$G[WRL_TY
M_'C' K$U(Z*** "BBB@ HHHH **** "BBB@ HHHH ?#_ ,?5M_UU'\J*(?\
MCZMO^NH_E10!+>?\?<__ %]#^M5ZL7G_ !]S_P#7T/ZU7H **** "BBB@ HH
MHH **** %#;]?2?[+NBIJ'CR_\ $ES;;X?"^E^;"/\ GCJ&L=O_
M !Z?RSBOFSO_?\ SR?Y<_I7V?\ LUVZ:?X1UZ__ .6FL:]9_T[Z./L5H
M,=AG\^* /L/^UG_YZ)^=']K/_P ]$_.N$^V_[7_D6C[;_M?^1:Z#G.[_ +6?
M_GHGYT?VL_\ ST3\ZX3[;_M?^1:/MO\ M?\ D6@#N_[6?_GHGYT_^TYF'W_,
M\O\ YY_3IQ]>>/<5P"WOF-L3YWY_=^;^'O\ Y]:]I^#/P+^*/QZU)(? VE1I
MHEF#%KWC36/M5CXMI(=4N;IBEFEQJ4W_ #STNUNM5GQ_VY?E_P#J&?V ^&/[!GP?\%V]M>>,_P"T
M/BCKT<7VJ6/6)?[*\*V=Q_TZ:39?\?OM_:..>E?8&A^$_"OA>W2S\,>&/#_A
MZVMXOW4>EZ-I=CQ_U]V=C_:&>,?A^- '\[J:/XS:/[3_ ,(=XH>VZ>9_PCFI
MC_VQ_P ]?88EYJCZ?O%_9WFFO'_T$+"ZL?(P. ?MMC^GU]:_IA^V7FW:]R=G
M_3,G'I_G_.,34M#T36HWAU[1/#^MPR1>48]0T'2KX3?]??VW\MGD5'2>-T_P">AE_P'IGUZT]=4F91\\?X=?Y'T_3TK]F/B-^P_P# WQXLUSH.
ME7GPT\0R?:91JGA/]_I,]QW_ +6TF]_T"]L/^P=_]:ORX^.G[-/Q3^ >S4M>
ML+?Q/X&N/W5KXX\-Q75]8PW'&+75K3']H:+?'V_XE7IF@#RO^U9O^>B?D?\
M&C^UG_YZ)^=<&M\F[8F__5>=U_Y=O^?KZ=.,^U+]M_VO_(M '=_VL_\ ST3\
MZ/[6?_GHGYUPGVW_ &O_ "+1]M_VO_(M '=_VL_]^/\ =_O>3_D>A_GWKXM_
M:RT6'[3X2\6P_.\EKJ'A>_DC_P"G.Z^V6=T/KC/?WKZ6:^W+)\^SZR_3_'_"
MO&?C]"FJ?#74F0^<^CW^GW\4G_;U9V=Y^N??]: /@ZBI&_C_ ._7_P!;_P")
MQ^51USG0%%%% !1110 4444 %%%% !1110 JQO<20VR?.]Q+;Q1?]?'//MW_
M _7]%]#L8=#T'1]+MOD32[7[+Y?_/:X'^F7?MG[=],DG\?A+P/8_;O&7ANS
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M]?\ 59CCU*X_P!3INJ3#G_56%U/G_Z_;M^5??.B^ ?!/AV/9I/AC3T3R?*^
MT:A%_:NJS>O^E^W?KGBNNC9XU5(3Y*1_ZJ..+[./\_X^] 'YL30ZE:_\?.FZ
MI;G?Z=J_2]F\[?YR6]UYG_ #\Q>?!W
M_7/^'8FN/UKP#X)\01NFJ^&]/DFDQ_I&EQ?89\<\?:^@'2@#X#^T.O/\?KYO
M;'^?7\:;]I?W_P"_M>[^,/V>=3M;>:\\$W_]I)$/-_X1^\B_T[[./^?35O\
ME][8_P Y^;+R>:QF>SO(;BPO+?\ =7=GMOY1]K?\ NO\ ]_*Y_P"V?+O_ (,=/-XQZ?7_ #TH^VGT?_O\/\* .@^UO_=?
M_OY1]K?^Z_\ W\KG_MI]'_[_ _PH^VGT?\ [_#_ J:O7_%_F7#=^GZHL^)
M-/C\1>&];T&9-XU2PN8HNG_'Q9VOVRT_\GK0CGVQ7YW-&\:HC_ZZ.+RKKVN,
M?Z7^/^<5^A<=]MD1_P#GG^'^>?RX]L?"OBZS33_%'B&P3[EOJEP(L]<
M?E]1Q[5B:G.T444 %%%% !1110 4444 %%%% !1110 ^'_CZMO\ KJ/Y440_
M\?5M_P!=1_*B@"6\_P"/N?\ Z^A_6J]6+S_C[G_Z^A_6J] !1110 4444 %%
M%% !1110 UNGR=,^W3O[=:^TO@G,D/P]TW8_^LO]8D&?3[4:^,%ZCZC^=?5W
MPGNDA\!Z.GF?/]JU',?_ &]7G7Z_7GVH ]Y^W_[?^?SH^W_[?^?SKB_MG^W^
MO_UJ/MG^W^O_ -:N@YSL/M^SG?U]_P#ZPI_VSB3?\Z1R^5+Y?^)]M>7\Z>7OC_P">G^H_+O\ EVKW+]GGX.ZG^T%\7/#WPQTJYN+/1[R6XO\ Q3KD
M?_,M^#](^QWFK:I:?]/VH_\ (/TGCUH ^G/V0/V3;S]H*\_X3/QM]ITKX.:'
M?W%MYFGR_8;[QMJ%E_Q]Z7X>N_\ H!Y/_$VU#\_?]VM%T+1_#>BV'A[P]IMA
MHF@Z/%;VNEZ'H\7V'0[.W_Y^[2T_Y_L?\A;'.J\CM4/AWPWH/A'P[HGA7PKI
MUOHGA[POI>GZ#H.EVT7-GH]G_P POM_R_#^T/[0^M;5 !1110 4444 -*HPV
MN/D[\_4TR2.&ZM;^TO+.WFTW5/W5_I\\7V[2KRV_Z>])[=>.]2TN[;_!O_Z9
M_P"(] ,CK[4 ?BM^V9^QN/A7#?\ Q6^$5AM7O5-)N_^7WP/_P!0_P#YA5?F]]L^5'W_ "21>;%)YO..^?\ ./:OZQ)K6VNK
M6\T^ZACO+#4+6XM;_2]4_?V-Y;WEKB[M;O\ ZM1-$2[F^'7C2*X\4?#ZXN(C_H>G_:L7?A>[NS_P OWAV^N[L:3_U"KSH* /"/
MM_\ M_Y_.C[?_M_Y_.N+^V?[?Z__ %J/MG^W^O\ ]:@#L/MG^W^O_P!:N/\
M'TGV[P'XMM?O^9HUQ+Y?/_+G_IF>?\CDT\7V!@/T_P ^MMA=Q#_P"!>?\ /US0!\8*WRH_4R?ZWC_EX_T/'3C]>/PIU-4?;%D_]
M>?\ /_)Q3JYSH"BBB@ HHHH **** "BBB@ IK+N&/\_YQ3J* /1OA>L+>-M)
M=W_X][6XE&/Z_E7TRMY(RI^\_?>5^]Y/OW_SBOEGX;R)'XPL'=PB?9+B(_Y_
M/WQ^OT1]H_N<_NK?CT_#^?IZ<"@#H?M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M#4Z'[7+_ )-'VN7_ ":Y[[4_H/\ /X4?:G]!_G\*SJ=/G^@'0_;'17^MU_G'\_IBOE?XF0I'XXUMT_U=Q]GNO-['_1?RQQ_GO]#_ &CM^=?B+/'/XNU#8^_RXK>'G_)Z8/\ G%9@<11110 4444 %%%% !1110 4444
M%%%% #X?^/JV_P"NH_E11#_Q]6W_ %U'\J* );S_ (^Y_P#KZ']:KU8O/^/N
M?_KZ']:KT %%%% !1110 4444 %%%% "KU'U'\Z]]^%NH;O#]Y9O]_3[KS8H
M_P#ZXSVXQ^%> UZ!X!U7[+?7EGOV)>1>;%ZS>_?TYY/MZ4 ?0GVS_;_7_P"M
M1]L_V_U_^M7')>;OXSUQQ_G]/K_\ KZ>M
M?OG_ ,$N?A6GA?X+ZW\6M2MMFO?%?6?LMK)M_:^H'GM^7\Z-YJ7DVLT^_:?*_P!;Z<#\*_L5^"?@V'X>_!OX4^!K/RT3P_\
M#[P?:77_ $VN/[!L[S5KKW_M&^N^E=!SGJ%%%-9D5=[_ '/\_P"- #^=VS^/
M/^KY_P ^WK0ZR+]_Y,8_=R?R_P _H*Z'P;X9F\5>(K/1!ML3?>3I^C6OVW5O\ 1/\ E].G6.<>A]ZU=/\ ]MXKOH;;X=:K_;UA<6%O*)-
M8M?[#U6;4,?\@N[_ .8?>_VCG_B4_P!G:G0!PV]?7]#_ (4GF)_>%>@0_"WQ
MA=6MA=6=AI\W]H2Z?]ELX[^U\^&WUBZO+.TU2[[?8/MUI=YS_P ^?T%30?"W
MQ;?+JLVFPZ7J5M9Q6]U_:&CZ]:WWVRW^RWEY]EM/^GXV-I=^_P#H?Y@'G6]?
M7]#_ (4ZMSQ!X3UCPI-90Z]_9]M???9[S_CTNKO/_'ET)YK
M#H ;_P"@<^;Z=.W^>N:^+?V_OA9_PM3]F?Q5J5G#+_PE7PO_ .*\\.7D<7^H
MM[/_ $3Q#I8_ZMI&]GX@TO4-!NHY,B#[/K%K>6?_MW_3% '\;*ZDDBI,C_ +F3/E1]NO\ Q]>G
MTR>U/^V?[?Z__6K$UZQF\+^(O$_A6Y^2;PWXC\0:!*3C_F#Z]>6?(_//6LW[
M6/4_D?\ &N\EM[7TS_I7_ -?'
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M%X-O?8S=6G_"+ZYXDT_[#X=^RMI^)_PIU=I\3/!I^'/Q&\;> $U$ZI#X/U[4-!BU0VHL?[2-GC_2OLF?\ 0N+O
M^SAIXZXS7%T -+(/WM>%X7+V=O?_;]+D_Y[:?K&+RT[_\ 3WG//6OUTDD>-=Z)O>/][%^/^AY]N;O^
MGG[:FDO8^*/ VMIY?_$PTNXT"62/'[ZXT?\ TPW7.?\ EQO*FKU_Q?YE
MPW?I^J/E'[8?0_F?\:/M0]!^O^%8/VH??W_YS_CSUH^TG^^?S'^-8FIT*W3M
M\GU_^N1_G\^E?/?B2Z2\U[6+K?O_ -/N(NX'V?\ Q/'7VKUVZU V]G>7.\;+
M>+'/''^1Z?E7A4LGF2.Y^_)^]E_+ZG/_ .N@".BBB@ HHHH **** "BBB@ H
MHHH **** 'P_\?5M_P!=1_*BB'_CZMO^NH_E10!+>?\ 'W/_ -?0_K5>K%Y_
MQ]S_ /7T/ZU7H **** "BBB@ HHHH **** ')]X?C_(U/8WDFGWMG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M6VN+M.3^*+#3]4^S>&])TWP_977]C_P!J6EW]M_M#[=_I?_DY7*^)/B)H_B&QTJP/
MA[4+/[/=6^LZI))?VL\&I>*-'T&ST?2=4^R=/L.;/_D'^E=A#\>OM4B3:KX5
M_LVYN/"^L>'+_4/!]_:Z5?0?;=4^V6G]D_;K'4M/^P_Z)V^M 'D7C:'Q!'XH
MO_\ A+?+_P"$A^R:?%?_ &>+-C,+.U_T2ZM+NR_Y+
MO$U_XH^QQV;WD6GVOV>7_3K[_0[7[']JN]6X)^O]EURU= !5JQ8K>6;_ /3U
M;C\?M0/\_P#(JMR3ZDU6NM6MM!L=2\0WDGDV?AO2]0\1W4DG^H^SZ/:7FL=N
MW^B=O7WH _C+^-ETB_&[XTHGSI;_ !:\<>5^.OZQ^7 ^O;Z>M$'BQ_%GB;Q5XJF.RY\4^*/$'BB6/_L,:]K%YCI_UZ>WK65]N'O\ K7.=!U1O
M,?.[[(X^>GY?G^'N*\HUR^;4M2FN?^FGE1?]>X__ %?YXK>U+4DAMYT3_721
M?NO;_P"N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MPO\ \*]^(.G^++K0=*_X61H_AO0?^*ATK_A$_P#D(>--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MS_(G/OQZ8&?_ *]?"O[?\ ITT?MQ^'X]\U]V[4
M?Y'^Y)+;Q>8?T&?Y_E]?S0_;L\0?:/%/PZ\/>=&D-GXMV_X].F1FIJ]?\7^9<-WZ?JCXVW/&W^L_E['_ [4C7&U=YDX]/3^OZ?_ %^?
M>Z[!]_F#W'K^/\_RIGV_RVWNYV1_K_D?B<_C6)J'B;4G6R^QH_SW _>8_P"?
M?\?_ *_]:X,KM79_SS_Y:?GCM[__ %^XLWEV]YM* "BBB@ HHHH **** "BBB@ HHHH ?#_ ,?5M_UU'\J*(?\ CZMO^NH_E10!
M+>?\?<__ %]#^M5ZL7G_ !]S_P#7T/ZU7H **** "BBB@ HHHH **** "BBB
M@">&9X6WI_RTZ^_.._\ G]:N_:O]G_/YUETU6?M/K$?QQV^OXU_3)_P1Q^.$/CCX ^(?@GJ5YO\5? O7KC^R[>X_P"/Z\^&_C"Z
MO-8TGG_J':Y=ZMG_ *_+"OYC]KK]PQ?]M,_IS[U]%?LF?M&:W^RG\=O"7Q=T
MI+S5=!L_M'ASQYX?MYM_P 4BMEN+&\\/WEM]LM/M>/^7[3K[_ (E_:M[M4444 +_$CCCRY?-_S^)K\^O^"FWQV3X)_LC^-H;"\DL_&WQ@EM_A+X(BBE_?
MV9UC_3/%FJ6EI_SX:=H?_$O_ .WP=Z_0"XN+:SM;G4KR\CL--T^UN-4O]4N9
M?(L--T^S_P!,N[J[N_\ GQTZQM/Y#M7\?W_!0/\ :N_X:P^/4VL>'+O?\'_A
MO8:AX(^$L<MQR_NO_ 6SM/_ *XX[?2D^V;1V_S]:I5&S K]>OMCK_3\*YSH'W$R3-O,?Z^O
M^?R%0444 %%%% !1110 4444 %%%% !1110 4444 %%%% &A#?3;=C_C^!_'
M'7_ZWK9:9W7YQ\GX?U[]_L
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M\;>/;6WBNKBWE_T[PWX7O/\ C[NKOKG^T*_("/\ =QPI_!'%Y7^-W_W$
M1G4/TYK.IT^?Z%PW?I^J+_VI_0?Y_"JTUYNC9/;Z]/<_Y_E3&D0?3T__ %X)
MJH_WC^'\A69J1I]T?C_,TZBB@ HHHH **** "BBB@ HHHH **** "BBB@!\/
M_'U;?]=1_*BB'_CZMO\ KJ/Y44 2WG_'W/\ ]?0_K5>K%Y_Q]S_]?0_K5>@
MHHHH **** "BBB@ HHHH **** "BBB@"3S7]?U/^-/W_ -P?.?\ GGWX]/\
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M>?$RSE^PWWQ4N+/FTT'PGWL?ASX=O[3_ (FVH<_VKJM?C,JO$OR)&DM+R.?^O3&;+_N'?THW(J_)\G_ "UB2"+R((>Y_P!$_P"7/_N'4QI6;O\ Y_E^
MF:YSH!F!7Z]?;'7^GX5'110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !2JVUAZ_TR.?\ /6DHH M1M\WW-Z?\M8_KU/OCU/ZXS73^#_%7B3P'
MXHT;QIX1U+^RO$/A^Z\W2]0_Y;S?].FK6G_+[8ZB/^)?JWXXSTKD%;;3O,_O
MIO/3,G?CO].E!G4Z?,_=WX$?'WPE\/1_%VE\^(_!=Q+^_T&X_
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MUU'\J* );S_C[G_Z^A_6J]6+S_C[G_Z^A_6J] !1110 4444 %%%% !1110
M4444 %%+QP421W _UM2[7VAWAD3/[W]Y%Y!'^?Y8YH9=BH^M.WFB_P"FUO\ _6R..W6AI478=Z?O/]5^]_UW_7IV^@__ %4 3;D7Y-@^S?\
M/O)%Y_?^7OI_M18W5SI-R]SHESJ&@WGF_:OMGA^_NO#E]]I/_3WHM]IH'&>-
M1[8J%61M^QHW\O\ =?NY?4]^F.?7]*7=N7>B2/\ O?*,<>?/^T<_X_KZ4 =W
M'\4OBC#&B)\4?B@M&N:SJFN3_P#E:OM2_3Z#'>AYT+2/#'-;N\<7FRQQS?ZFW_ ^_P"?/84]629O
MW3QW*=I+?]_!,.P%WC- #VV*J0)GR8_]5';RG[##S_SZ?K^@ I*;YB9\SS(]
MG_/3_EA]<_Y^G:@,B[T=XT>**XE^SR?Z_P#3]#[=J '44WM %W3Z_YQ]:%9)/\ 4NDW[KS?W?\ S[^_X?\ $OYZ8XS0 ZBFLR1[(WDCWR2W
M$44>?W\WV/\ X^_LA_[>_P#&CS$._8_G>7]H\WR^XY/O_P#J]S0 ZBFHT95'
M23>DG[R*2,_Y]O\ ZU.H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HIK,BXWO&G7_ %G_ ->G[=G[R0A$_P!;]HD_U'V?_GZ'?_'- "4]7V_Q
MR)[Q]WV/_C[^R?_ %^^
M?J 94D;Y_+_ .F4GV7R/_2+M_.MNR\2>)--7R;/Q/XDLX?^>>GZ]JEC /\
MR>Z_EGTYYQ]N=_\ JWV<8CE_UP_I^'Z"AOD3>_R)_P ].??WQ_G\P#>O_$GB
M'4H_)O\ Q)XHOX?^??4/$>NWT!_\GOR]^O:N>C6VA^>"VCWR'][OCM9YS_V]
M]O\ /7L]1F/SW_M>3SN_F2?Z_O_ )]_TIM*L;M_ ^_RO-\OCS_Z#//?_P"O0J[]FSRW=_W44<M,W3_ #^5 "44UY$C,F]XT\N7RI?^F.?3\._M3V7:SI]]X_WX_Y]?7O0
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MG/3Z4 )132VYY/\ IGT^G3Z4[: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M0#^T;[/_ !,/AWIG]JZKJO\ R&#_ &.4(Y(O(@YM?^/7
M[)9>EC=_^2?K59K6VN&=YHXK_P OG[1<16D\]G]C_P"/2ZM+O_H._P#06[>E
M 'Z':'KO[/&H:7\+O!/Q7^'OPGU76)/V?;CQ;\6OBQ\._P#BE8/A[K'B75+/
M_A'M!M-)LK__ (J?XC:=X5TG^S]7T_\ Y"O_ E7B2_-O?M%>-
M?!^I>*O!_B'PE9_#31_%OPY\-_#OQE:_#GPYXJUC[5H^CVG@.T^(6M?VEI^C
M:YIUA_Q4&KZAJ(_XFFJV=_I'']I5\/-'MV)-;1PIYMQMOJ'_ %"C^-$EK9M;S0W,%G]CCE_>VO8 ^]
MOB9>? KP%KG[)W@SX76?@?QOX;\+^-_'$?Q!\4>+#:^*['QM;WGQ&L_#?VKX
MA6G_ !+=0LK[3M#^U_V3_P PK2O^0OH_I7LVH?"W]D7Q)XP_X3_Q;J7A.V\)
M7'Q?.@RZ!X'\;Z7X.\$0Z?\ \+0O/!_A[X2_\*]%_J6H&Q'A7_BL-6^.']I_
M_7_*GRX89ODADAN9(OLLL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MB^'WPG\;Z-XXUSQOI<'_ FWCB\T'QYK%W\+_"5Y_P T^T/P[8_9/^$LU#_D
M*ZKJMG8:0?\ D)8J;XD?!']E3P7X)^)UGX/U76/B1XYL_A=8>+?!&N:I\2]!
MTJQ_M"S\>:/9W>O>%-)LNE]J.AW?_$V\'C_F%6?_ !)Q_P A2OS<:WMF;>Z6
M_G?ZWS/L&E_N;CJ?]$'7_CSM-0YST%$-O;0[!##';>7^]_T>*U_X^/LO_'U=
M\C_3C_I>G_VASGK] ";S'D^1YUQC_CZ_P"G+_L'\\X_!*5L
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M']J6=E::7XA\)_\ +[_H/VO_ (J#3O\ B58[5\*R6=LT;[+:W=Y)3+^\//\
M_'\G_B859:.%9/.\F-[F/][:W$D5K/Y-QUX],9N^?;GO0![WX\\%_#'P_:_#
MJ_\ "_B&XUA_$'B/3X=9U"2Z\_PY>:?>:I:7EV?LG.H67]G?Z78?]@H'K7L6
ML>'_ (#ZA)XVFT&3P?;7/C>*WDT'3OM_V>Q^''_"'ZIH_AKQ#;:3=D'[%?>,
M_M>KZA_: Q_QYDXR*^(?)AC:?[,D<(D-Q^\BB\B?_CZ_X^NW^<<4WR(59_\
M1H_WDIEECDB\_P [UM./IUSZ\T ?8=OX)^!7A?QIH[_VW)K&FR>)-.L+"WU#
M6;75=#T'3KSP'>:QJ^J>(;7C4/$_]G:Y=_\ $I_ZBMG89Z\/T;X5_ K3V^V:
MKXDO/$EG!XR_L&ZM[/Q'I?V";PN=4T?[)=:M_P!./B*QN_M__05TK_D$_P#,
M-P?CQ8H?XTC=\6\4MP(A!YW^E?;!_D'_ .NQ;>V^3_1K>'R_L\40M[6UGG]/
MM1^V_3O_ #H V->M;:Q\0:]9V=M'9VUOK.L0VME'?_VKY-O_ &I>_P#,5LO^
M)=>_]P\FLRE54C78GR9Q^[C_ -0?^GK[)_S_ &?IQV]$H **** "BBB@ HHH
MH **** "BBB@ HHHH **** 'P_\ 'U;?]=1_*BB'_CZMO^NH_E10!+>?\?<_
M_7T/ZU7JQ>?\?<__ %]#^M5Z "O1/A'X.\/>/OB9X*\$^+?$FL>$O#'B36?L
M&L^+/#_AS5/&-]H-N.+2UM-)T6QU+4,ZB/\ B7?VAINF:IR:\[IMG>^*M'U2
M'6/#?B3_ (1[4M/NK?4-&UC2XKJQUS1[C'^F?9-6L[[F^[G4/8B@#[2\0?L)
M?&_1IM51(=+2_P!/NKB[B\%7EU=:KXXAT>\_MC_A%+N[N]%L1X/\:^*M0L=)
MN]0U;P_X,_XFNE_Z!_;&DZ6*RKW]B_XG:?=7FDW7BKP'_P )/I]AX7N=4\/Z
M7+KU]?:;<>,/&5YX#\$6MW]BLMF^)=NVE?9OB%X@MDT/5-1UG0?+U[Q1Y^CZOK'_(PZKI/V*^Q97WB+_H(:M7RH8]<^(4W7VS^R]6N[*_\ [0O<_P#0
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MJM_I^J:S)M$\5>&]2UZ\\+W&LZSI>L>'/&6E3^&O%!U[Q)X;TGP;]K^PZEI]X=1_X1Z[U#
M5O&&H_\ $J\*_P"@:1K'_(2Q7"?$;]DGQG\.=!;7IO&_PS\3YU[POXMW6O?VKIO_"2>,O\ A6_VJ[N[VQ_L\?\ %<9T_5O[._YA7_$W]Z^;/^$F\?K#
M>0_\)_XD=+RUU"*ZCDU[7H/[2_MC_3-6M;O[%??\>.HWW_(7T_KJI_XF^>:I
MS:EXJNO/2\\3W]S#)+;RQ1W$NJ3F&X^U?;/[4M,7W]GV5]IW_,)_\&YH ^WH
MOV _BU<6>@ZK8>/_ (1W^B>(/&7BCX?:7>6=_K\\^L:AX/\ [8L]6U32=)^P
M_P!H?8=.USP]=^'_ /A'\ :KJWV#5^F*FL_^">?[0DG_ CT+S>#[/5=;^'W
MB'XERZ''JEU/JN@Z/X;T'_A)+32_%FK?8?[/T77-2L?^8A_Q-/\ B:_\4CVY
M^*K/Q1X\T]=^F^.?$&CS1W]QK,4FGZIJOGV?B"\M?L=WKUI_IW^A7VHV/VO3
M]6STQVI]MXH\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MUCPF_AN76?%%AXM^1IU4V=__P 2BO(=>^*FO^+O%6I>//%7B'Q[JOC/Q!JG]O:SX@_X2V[@OIM8
M_P"/S^U+3K]B_P"@?G3O^05Q_8_0U4TWQI9Z3:PZ;I5_\2-'TVWU3^V;6ST+
MQYJFE06>L6?_ !YZK:6EE_Q+_P"W.FH?VA_]>@#UW7/V1?B1HL/P**:QX&U7
M4OVC-9^R_#3PG'?Z_I7BK_A%Q:ZQ>:3\1]6TF]L?]"T+4AI-W_:^G_\ $TU7
MFP_XE/\ Q,LUWZ_\$_?C,MYM_:VO6FDC0_[0LO\ A'?^$ATG3]6\/_\ (5U75;S_ (D_K7S8WC309IM*FN4^
M(]S-H=U<7_ARYD\>77V[PMJ%Y=?;;O5/#UWG_0K[4K[!U;^SO^8K_P 3?&!5
M]OB!X;EU)-5GA^+#ZK]J^WRZI'\5=4^W3:A_H=Y_:GVO']H?;M.OK3^T* /H
MK4OV"_'-KH]M]B\9^#WUC3]>_P"*RU"2ZU32O#GAOX?ZS=>&]'\#^,A:7I_M
M"]OO$6N>(?\ A']6T_\ Y"O]J_\ $H-M3Q1X-M=<_P"$7\46'_"5>(/#=U]C_LO2M)^PC4/!?^G6FK?\CGJ?]E:K]C/]
MC^WGB_%#PJ^CZKX=O-,^*%_I7B#6='U[7K>\^(WG_P!L:QX;_P!,TG5+N[^P
M?VA_Q+K[_B8:1I__ $%;/^U_^0QS44GC[X=7EO?VNJZ/\9-5MM8^S_V]9WGQ
MDU2>Q\27%GB\M+K5K3_E]OM.OKN[U#2?[1Y_'J >(*N[9\_^MQ_RRX]/?]/;
MK0V5[R?]^KK_ .OS[5[!_;GP!54_XMC\0.,\_P#"QCS_ .2'<>_\JFC\0?L\
M;DW_ K^(C_7XC>G8?Z#[?R- 'BV_P#ZZ?\ ?J[_ ,*>N6./WGX176?ZXZ?I
M7M__ D'[-Z_?^$OQ(=#_P LS\2^W;@V/&/_ -?0T^/Q)^S,6_Y(Y\4'_P"F
M?_"T,<^X^P=._P#6@#Q#8_\ F$T>7[_I_P#7KWAO$W[,2_\ -$OB@F?^>?Q5
M_P#N'IU_/IS4?_"6?LR?]$8^+'_AU;;_ .4= 'A?E^_Z?_7IFQ_;\O\ [*O=
M_P#A+/V9/^B,?%C_ ,.K;?\ RCI?^$J_9@S\_P %OBP_'7_A9]J><_\ 8"H
M\'VO_P \W_+_ .O2;/\ IG)_WZ_^O7O+>)OV8)
M..,=:9_PD'[,O_1$/BA_X=6U_P#D.@#PKG^X_P"8_P *9O\ ^NG_ 'ZN_P#"
MO>&\0?LT#[GP3^*">A_X6A;=?_ &C_A(OV;(_G_X4Q\4.G_+3XH?U^P_GV^M
M '@_R_\ /.3_ +]'_&DY_N#\Q_A7NW_"5_LT_P#1&/B7_P"'0M?_ )7T+XH_
M9FD^1_@M\3.>O_3CCV_G0!X:%=L_)]1_@,4,KKCY"MN'_X4M\4/_#H6N?7G_0/0?7^CO\ A)OV8Y/DC^"?Q4]/^2HVOIQ_RX_TXXH
M\(VO_P \W_+_ .O0%?\ YY[!V^OT->\_\)'^S''\[_!/XJ;.W_%T+7_Y!_#.
MM (2S]F3_ *(Q\6/_ ZMM_\ *.C_ (2K]F3_ *(M\6/_ ZEM_\ **@#P?9_
MMQ_]_J5B5_CCQT_U@'_ZOQKWC_A+/V8O^B+_ !9_\.G:_P#R!3U\6?LQD?\
M)%OBP/>/XJVO;V^PX_PH \ R?^>L7_?ZUI<^GSX[>;:]_0DM9CX_XLM\7$/_ &5:U/\ [8]/PIC>+/V8&_YHM\6''_96K7KZMOU_Z:VO/ZT;O]K_R):5[TOBO]EW^/X)_%QS[_%JU_/\ Y ?UJS#XJ_97S_R1
M#XN?^'?M<_\ I#_3^7 !\^+\W;_R+C_&G9]H_P#OY_\ 7KZ(_P"$N_94C^_\
M#?C#)G_GG\7[6#\/^0'_ "]!TQ3_ /A,_P!DYN'^ GQED_[K3;9].?\ B1C_
M #US0!\ZC>/5S[R\_P"?PHVO_M3/XTVO\ \H^??C^N;"^,/V/_ ./]GKXV'_KG\;K7^NA_T]O>@#YJ9 O_ .]Q
M_3^>*11NQBOJ"/QE^QM'_K_V=?CA,,#)_P"%YVOK_P!@/_.>U3+XT_8M;_7?
MLV?'0=?]7\>+3_Y1CT[<>G% 'RS17U9'XV_8ACXF_9I_: ;(S^[_ &@K7^7]
MA]>E6HO'7["N?G_9@_:$?Z_M#VO3_P $?K].M 'R5M9AQGV)_P#KG_ZU&UE'
M.?Q^.OV#$_UW[+7[1CX/_++]I&U@YQS_ ,P/_)[=:F7X@?L
M+_KOV4?VCW]?^,EK;KU_Z ?Z]^O% 'QXBLW89]O\GGZ4*KM]Q)/\^Y(XZ5]F
M1_$+_@GUSN_9+_:4?_KG^TW:P?\ N#]N_'K[65^(O_!.M?\ 7?LA?M./_P!W
M2V@]A_S ^/\ .* /BHQ.O^L21/?)_K2JNZOMC_A9'_!.4=/V./VH'_ZY_M56
MHS_Y0^?_ *QJ6'XE?\$W%(-S^QM^U1Z_N_VK[6 ^G/\ Q2O_ -?D]Z /B#_@
M>S^O^>>].*G^_O/M_3'.*^YO^%E_\$S3G/[%_P"U8_\ UT_:TM/P_P"95_.I
MH_B9_P $RE/S_L5?M6/GIY?[6EK[>OA7M[__ *@#X1I6.WOV_P">6?\ /TP:
M^\X_BA_P3!7[_P"Q/^UI_P")=6O/M_R*O^>*?_PM#_@EW_'^Q/\ M<#'K^U]
M:_U\*G_.* /@7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M-YM;BTO[.\C^P7VFSV>/M=KJ]K>_P"GV7I_Q,?>GM&ZKO<<WUK^F
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MM3#\^QTDCD3S3%YGFVN/M'_/KCU_[!W2OM+4O"OPBA^$NB?M"7GPN\#_ E7
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MHH DW=ON?AG_ Q^7_UU\U_^>C_Y_&HJ* )?-?\ YZ/_ )_&D:1\GY_4Y[?Y
M_'\:CHH 59'QC?G'I_G_ J3S7_YZ/\ Y_&HJ* )/,[Y\SWSC\/PZ]>]'F>W
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MOC.S'TXS_/FA.I^G]17TDW[+?Q+_ .$SU[P'18W
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M !QH^JV%[7[#9W'VJRL[2UTG^VK'^T+W-]Q_P PO_B5<5:C\/\
M['#:/JKI\;_BX^L1C4(_#EG%X(THV-Y<6=K_ *(?M?V$9.I:Y=_V>!_T"CCB
M@#YL94'\$;_]L1^7I1\O_/./_OT?\:9#<0W&U$N;.:8?\^I'_
M !+OJ:F8;?\ 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M5>*_VB?B?:6HL[7Q1XL.M7W]GZ*#@:CJVG:=UU6R_M?L*^0]_P#O?]_J-_\
MO?\ ?Z@#WR^_:H_:M.T^R?\_M]IUC>?V?I.H:D3JVE:5_R!Z\_P#"OQ6^*G@2/1T\&_$7Q9X5A\/^
M*-0\;Z-;^']9NK&"S\8:Q:WEG=Z]T_L__B8V-W=Z?J^/^0KI7_(8ZUP>_P#W
MO^_U&_\ WO\ O]0!ZI+?$NEZ?HWB/7-0N[6^GU
M[1]'_P!,\/:7=VE[8ZEX>LK'3K[_ )%/3]/TS_BE>?[(Z\^;ZAJ&JZMJ5YK>
ML:KJ&MZWJ$MQ=:IKFH75U/JNL:A>9^UZIJUW>_VE]M/_ ##^/^?/_B3_ -EF
MJ>__ 'O^_P!1O_WO^_U #J*;O_WO^_U&_P#WO^_U #J*;O\ ][_O]1O_ -[_
M +_4 .HIN_\ WO\ O]1O_P![_O\ 4 .HIN__ 'O^_P!1O_WO^_U #J*;O_WO
M^_U&_P#WO^_U #J*;O\ ][_O]1O_ -[_ +_4 .HIN_\ WO\ O]1O_P![_O\
M4 .HIN__ 'O^_P!1O_WO^_U #J*;O_WO^_U&_P#WO^_U #J*;O\ ][_O]1O_
M -[_ +_4 .HIN_\ WO\ O]1O_P![_O\ 4 .HIN__ 'O^_P!1O_WO^_U #J*;
MO_WO^_U&_P#WO^_U #J*;O\ ][_O]1O_ -[_ +_4 .HIN_\ WO\ O]1O_P![
M_O\ 4 .HIN__ 'O^_P!1O_WO^_U #J*;O_WO^_U&_P#WO^_U #J*;O\ ][_O
M]1O_ -[_ +_4 .HIN_\ WO\ O]1O_P![_O\ 4 .HIN__ 'O^_P!1O_WO^_U
M#J*;O_WO^_U&_P#WO^_U #J*;O\ ][_O]1O_ -[_ +_4 .IK?=_ZZ?NI?3[/
M_+I^F:-_^]_W^HW_ .]_W^H L_:+DO#_ *9J")%]G/[O5-4@_P"/,G_I^Z_8
M?P_.H8Y)MWG2/<1W-Q_Q_P D
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M_A&XKB+2_P#A#_#EIH?G?;,_:QJWV+'VW_L(:CUKRZ)8XU1$0IY<7E?7O_\
MK^OYF_\ WO\ O]1O_P![_O\ 4 2*VVHRNUGV33I#)$8I8HY;KR)OK:?\@_MT
M_P#KT;_][_O]1O\ ][_O]0 ]F>21G?[\G[V7/_/Q^>??].">4IN__>_[_4;_
M />_[_4 2P_\?5M_UU'\J*6W^:XA_P"NO_/7C_//U/U')0!UM]G_EDG_Q-1?9[?\ YX0_]^D_^)HHH /L]O\ \\(?^_2?_$T?9[?_ )X0_P#?
MI/\ XFBB@ ^SV_\ SPA_[])_\31]GM_^>$/_ 'Z3_P")HHH /L]O_P \(?\
MOTG_ ,31]GM_^>$/_?I/_B:** #[/;_\\(?^_2?_ !-'V>W_ .>$/_?I/_B:
M** #[/;_ //"'_OTG_Q-'V>W_P">$/\ WZ3_ .)HHH /L]O_ ,\(?^_2?_$T
M?9[?_GA#_P!^D_\ B:** #[/;_\ /"'_ +])_P#$T?9[?_GA#_WZ3_XFBB@
M^SV__/"'_OTG_P 31]GM_P#GA#_WZ3_XFBB@ ^SV_P#SPA_[])_\31]GM_\
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MA_[])_\ $T?9[?\ YX0_]^D_^)HHH D@MX/.A_#'__9

end



GRAPHIC
13
image_007.jpg
GRAPHIC

begin 644 image_007.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" $\ E4# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H
MHHH *R[^_M--L;O4;^>.WLK*VGN[J23@0VMM;MM=/X?S%?FA_P5?M_VI->_85^-/P[_ &0/ =]\0?CE\7-&L/A3X<_L_5-,T,^&
M](\>W0T7Q9XQN;R_OAA?#WA:ZU2_P!AB01S0!^0O[ 7_ 6,_:5^//\ P4+L
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MJOQC\6:+\-[FS'BSQW9_#U;)?$">" +NU(\07P1-3+#8NM_!-+X)_L2^+?V0/%FC^-OV8_^"D_P]^)6J:QJGC3P)JWA/XM?"?6/BWXQ\8^
M*_&/A(&_VCPMX>L;VS_M;3_$(#,+U020J@?KQ_P5!\"_MW>)?VJ?V<[KX6>"
M?CQ\2/V+CX(\4:-\1_!'[*GQ&\%_!WXQ'XL7EWCPE<^*_&^L-X=\7V7P=-AQ
MXKL/#OBG32>"?##0=+C\)
M>*+CXFZO\7K.\:RO/A-9_#0Z>-?O/'5C=[D;P^O*]B#M-?&'[4'_ 7Q^!W@
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M<*K ,-?V>M:_9^\9
M0?$WXF:[\*M"LKWQ!XG\(ZOK2)J/A>P\/WJ:HWA;P8M?\%9/V,6_98^"?[8&G^-_$FM?"O]H3XA>'_A7\*K#1_"6JWWC_Q+\1_$GB"]
M\(VO@S_A!QC7[+7-/URTO!JVGD;M*%F22>-WYW?"GX*_M5_%;]N/_@D5^TSX
M[_9C\8_!OPK\$?V0?CS\'/C)H?C#6O#&JZK\//%1TGPUX:\)VNJ?V-?,+O\
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M;=Z_IV_:D^"?BW6?^"(/&MY^RMXA^$O@WPN=:\_[;J]K\.1
MX;TG3!XAUH::+OU _,?G)W?*0#^=O]E[_@M?\ MEZ__P $L?VO?BQ\
M:V\&:O\ MP_#CQ9\(/"?P2_L;P=IFDZ1XC/[3EMI!^"%U_PC8.V]LFOY-9+-
MC)(4L3M7'W'^P%_P6 UG3/\ @F]X+_:8_P""A6M:IKWQG\8?M&?%#X#:1X6^
M#'PFU/6_%/C7Q?X0UYM(M?"_A+P/X*74SJ%_IYL[I6OB57;;,Q)(VG\Z?A__
M ,$BOVR_^&DO^"5.I>(OAOJNC? BS_9P_9^'[)6^&
M=MX@M?[>_M+6KX7VJV@%_P"'1_99PQ.-H+=KX$_91_X*E_L__L!_ +X>^$/A
MC\7?#T<'[?G[3'Q,_:X^'?P&\8_#O1/VD-?^!_Q%\?ZOK'@FY^"7BW6SJ6F:
M$=0%]:ZCJW]G:GI>L-C']J:8JED#?0_;+3/^"S?[#FH_LZ?&7]I_6?%/Q(\%
M^"/V=OB#H'PU^.?A;QO\+_%/AKXG?"SQEXENK.QTC3/%GP^O;+^WM'74!>'4
M/MS(1_9GVUARHKY%^+/_ 6 E^)?QE_X)VS_ +)FMZSX?^ OQM_:^\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M[6W_ EWBW2OV=?A9\0-0^'-K\4=8\!Z_9:'\5/&!U4Z1:Z7\$;7[$=1^)RZ
MEKEK_9VDWWAS3M3_ +3U3A<=1XKXZ_X+7_LW_P##)/[5G[0'PFT#XDR_%#]E
MSPEI]_XH_9_^*GPK\9?#CXG:!J'C"V)^'>J^-O!-Y8CQ#8_#KQ!?8OQXCTX_
MV9_9:WK%MRYK\HOBI_P3@_X*&>.O^">[?L2W_P /;_7O$/\ P3L_:Y\&_$']
ME#Q+H?C+PMX.@_:C_9G\.:]>ZQX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MW]\2O^"AG['/AKQCXA\.?&_P#\0>,=8N=6@U?X0:Q:V5]I%U:Z5X8UX
M: +$ZW]L']G^(4?J#@*,, ?6'P(_X+9_!Q_^"?'[(_[7O[4VF:QX+^*'[3EI
M/H7A+X-_#3PAKOCCQM\3?'.C7EYI&J7?PR\$Z*-2\0WWA:_-D=16_P!0P$TH
MV3-R8ZYO]K#_ (+I? OP?_P3S^+_ .V)^RO;:W\3O'?@/Q;8_"9OAAXW\$^,
MO#>O?#'XLZS=@V>D_&[PG>:=_P )!X+6PL3=ZCI9U KI>JE$723("<4_V^?V
M2?CQ\)/VN_V!?VZ/V-?V_$CX):_^S!X4U30? &JV?@7QY:?
M\2KQ1\*?[;_XI[^V_#O.GG3R>0/:O@CX@_\ !.O]NG]HS]EW_@LY\=];^!^F
M_"7XW?\ !1$_"\?"#]E$>)]"N?$6F>&/@]KNCWMIKOCGQ%9'^P/^%C^(["TO
M#G3\ GY2P9D# 'ZXW7_!9']F#P/\"OV:_B3XZLOC+XA^(O[1'@R;Q'X5^#'P
M_P#@EX\UWXS^)+?PU:-9^-_&0^$ME9'7['X=Z;?VMY_9?B+4472M74H-'+;<
M+Z%XR_X*_?L)>#/@?\ _VB]:^+5]-\&_VD/&]S\-/AYXOT/PIXGU2>'QM:6E
M]=:KX7\6Z39:<=?\,:YI]]:'03IS1MJ8U8[0K[0P_$SX\?LG?MK^,_C%^QK_
M ,%!E_98_:EMFTS]D%OV9OC'^SI\#?CQX8^'/[4'PD\3^&]6LCX4\8Z3XN&M
M_P#".^)O"OC*QMKO_A*=-T\_VOI:75B=6!",1LP?\$QOVC=%^ W_ 35TKPI
M^RU/X$UKPM_P4VM_VM/C[\+Y_C3:_&*?X;^$-8MKX7NN^(?%OB8^&_[;US42
M+/7_ !9X>\.C4\:L#\Q.0H;GZ-^/O^"Y7[-C_LT?ME?%_P"#OAWXH:S\5_V1
M_#\%_P"(_@O\3/A?XQ\ ^,8M0\39LOA]XEUGP[?6']HV7PXU'7#G5?&%]QI6
ME66H:J0H5=WF7P8_X*B^+OC_ .!/^"3OQ!3XD:9\$M4_:J^*'B#X>?%3X:>)
M/@)XSN;+XM>+]&\-6\'?#/Q%J )\%^%M.OQ=W^D_$#4BVE^*]*YT@DL0.
M*_:%_8+_ &G/B5^V1_P6>\9^&/AQ'%X,_:G_ ."??PV^#_P,\87FJ:!8V7C#
MXHZ/X7O+35M!(7_3[(_;C::?_:&H<M7COX5W7[!OQEU_PC\<].\6>+O!NJWVF>"?"'P;LO >D?$^VO+&_S=Z'XCUNV
M!&G8_M7_ $1>.108'Z6:_P#\%Q/V$O"WQ6O_ (8ZOJWQCCT72/BO;_ W6OCI
M_P *2\?']GK3?B_>WEGI-KX#U7XL_P!B#0%UQKZ\M;$CH&/<#G9_9<_:V^,W
MQ4_X*@_\%%?V7_&&M^'[_P"#?[.O@[]FW7/A)I5EX<%AJUEM6\5YQXF74+U;0Z6-W_$K"[1EMH/\[G[3'[&/_!5[]I+P3\5/"?QI_9__ &A/
MBI\:O"W[8>C_ !0TOQ79_&_P'X5_9*F^ ^C?% :QX?M?@Y\$-%UWPV?$_P 1
MAX5ME)U'Q%IFJ:KI.Z^_XFPS_91_?+]D#]F_XY?#_P#X*H?\%'_VA/&?@.\T
M'X2_&WX:?LC:-\+O%XU33)H/%6H> _ =YI'BRU.E"]_M"QO?#M]=?V?JW]I8
M4FS"Z0>10!\??\%&_P#@IW\;_ /_ 4N_9I_X)_? GXA:_\ !+1_%N@7-_\
M%;XD2_LQZ_\ '#6[WQ!K.IZ/9^"M*^'ND,VGV%YH1LKP_P#"6>+]/)TGPH/M
MVJZP<:97V7\2?^"X_P#P3Z^$WQ:\4_"'Q9\1_&^H)\-_%VG_ Y^*GQLT'X1
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M,=$T>[&JZ!?8'VO[!JI#(RYTT^FP@_)G[)_[!7QH^ /_ 5;\)?$;7?"#^)_
M@K\*O^"7?P:_9:T'XXWMWI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M/Z%^!/\ @F=^RA^Q/\)M9_:$_9._8?\ 3?M@^%_@OJ)\%_V6+O6_%EY\4+G
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MS4/BOK%YI5KXM8)^+OBGQ'X>\(>,OB ND?#_P[\5_$?Q0^(&K_"[Q3H?PR^%EM\(+FZM/%FF^
M-O&U]8C3K#7-UI=G1]/TXR'5% VL2V!X5^T#\&_VH?!G_!;7]GK]KCP%\ /$
MGQF^!GBK]ES4/V7?''B?PKXH\*Z4?A+JVL^-/^$CN?$WC?2-:O?M^M:?86-R
M;T?V>,D @$M\P^4OV?O^"7'[2GBG_@B?^VW^Q1XP\,V_PJ^.?QQ^.G[1/CCP
MO!K^H:;GWK+9Z)XPM-'M=/9FP84NW)94,A !^L/
M[,'_ 5H_8]_:S^($WPP^'VK_$CP3XON?!MQ\2O!.F_%_P"&GBGX6P_%/X9Z
M/]J75?'OPP/B?3_L'BCPIIRVK7SZEI_0!20HW$<#\,O^"W'[#7Q8^+O@7X4:
M#J7QGT8?%;QEJ_@+X/?%?Q1\#O'OA?X)_%_QQHPQ=^%OA[\3[_3_ .P=M:FQ^P81F(&XJ"M&_%3]IW]K2U^*GA70?C/XE\!GPA9>&/@W\,M$.IC6OA5J5[9VFH:KJ'B+4]+
M&EZ5]@_XE/6OESPA^QS_ ,%._BCXZ_8%^(OQ[_9X_:;\4?&/]G7]LS0/B-^T
MSX\\=_'WP'>_"N?1O[=U@C5/V9?@CX8USPWX/\,^"/L-U::AJVH'3-+\5:5]
MC_LG^R=3_M$9 /OWX7?\%N=:_:&T7_@JQI-DUY^S[/\ LD:/XPUKX(_$OQ%\
M!_B+XKT+PMX*\ Z9,_BOI%^-.%YXXOM>N59?AB#I>J:II@W:,=4)!K[
MEN/^"M_[,7P%\+?L[>!OC?X\\:_$+XX_&;]E?PC^T%X;M_A7\"_'M[>_%_3[
M[2[0WA\$^!M$L=3U#1]0U*2\.I:5X.U$I_9NE,MK\ C^R_XHU_0OVW(/B!\6OV??C)HGBWPLO@[Q3J%WX6M/#GA_P"')TAK[_A(
M;+Q5J'VLL;_40-,'V/G !%?2_P"SO^Q=^TGX0_X*)?\ !,SXP^*?A-=Z5\-_
M@/\ \$KH?@/\2_%#ZKH%_8^"?C NA^&[$^&,&];7_MU^;2\5O[.!TI22#TH
M^ZM+_P""PO["FJ_L?W_[SO!H[
M_# ?#0:)_P )!>^*_MEW\NF@#+7?+8/R[O[,O_!5K]DG]JKXUZ5^SO\ #5_B
M9H'QNO/AKV\766MV"KHE]?_:VO]*L<
MDZD@W!@69:_G%^-G[$GQZ^#G['WQ/\1?$6/X5_"#Q]X$_P""TWBC]KWX#^"O
MCU\1O"OA7P9^T%X8U;7[J[\/>%6\5WK#PC9:[XUL;S_B4?V@K :I8G)!*@_6
MW[)7Q.^,?QP_X."9OB%\8?@_X4^"WBR+_@G1;^;\.?"?Q!T#XN:YX*T>\\96
M7]DGXG>+/"P/AX>*-1^UW7]E6&FZEJ@72?L+' U&@#]=O^"N7[9?C+]BK]D'
M6O&WP=M]%U/]HSXG^,/!OP1_9OT'7;(ZI8ZO\6/B+K]KI.D-=Z2.;ZRT"R-W
MK\EAN(<60!!YSYO_ ,$EOV\_&W[3?[)GQ#U?]K6\\,>#/VE/V5/B+\0?A!^U
MC';QVVA:%H7BCP)=7=Y_PDYL\[='T74="Y4$%L63E<#<#\N_\%&?V(/VN?\
M@H?_ ,%"?VMMO"GA[6[S4/MA\':>HSKYTO&DO>7ZDL1D_,/A+_@D]^VE^S_ /M2?M??"W3O
MBI\1?VC_ -G;_@I+^R9XZ\,?%;]I;QY_PB^B>)?AO^T;9:#>:-X3\0>+/#NA
M_P!G?;K'4K'[)8"_TXDXO;X%0W /1OVJ?\ @O3X-\6I^RS:?L.>)/%=H?BE
M^V7\-OA+K'BSXF?!;Q/8^"/B_P#"/6-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M;/A[%/H5U_8C?#_P=I=IJ_B#5-6U8%5L386%T&^88!..HKY@^$__ 6;_8M^
M,GQ+\"?#CPC)\<+?1_B_XMU;P%\'?C/X@^"WCW1/@=\6_&.CW=U97>A_#_XG
M_8&T*_D^U6ETN6;2]Q4#Y>2/S;\#?";]O?\ :-_;Y_8"_:4^(_[$>I_ 'X3_
M *_9&^.'P,U[3?B#XX\*:IJMWXQ\3>!K31?L?BO2?!5[J%_HO@CQ%J%J=.T
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MO#/PN^'GCD_"SQ=H?BSP;XFTCXE:+\4#M))J;-Q\N2L?@#_@KO^Q[X_\ @O\ M"_&.WU'XH>#4_99\/V_BCX[_#3XE_##
MQ1X!^-W@7P_>*+K2=4O?AUXGLEUZ]L-2&[^R[U!M."20QQ7X!_$7_@DW^VUX
MZ^ 7[8+Z=\+M0LO'&B?\%>1^VM\*O MIXVTOPKJOQE^$-CI=E9ZM_P (1XKL
MO^18\;_8<_\ "*:AJ.?^)K9\\5ZI8?L(?M+?&/X$?\%1?B1IW[(7[0'PR^*W
M[0?[(T'[._PF/[3G[3>E_%OX^?%ZXM+@WG]E>+/#N=2\'^"]"\/7_P#R*?B
M>)?[6U0F^[9- 'Z_?![_ (+3_L)?&?XQ_#SX.^!_$GQ,&N?&/P=J_C7X-^*?
M$'PE\9^'? 'Q?MM'TMM6U_0?AIXNUW1M.T_Q/KVF"UN_,T+3MS-J888)(4>9
M_P#!)?\ X*RS_P#!1+XC_M9>#]7\!:QX+N?A#\6-8TWX<6T?@3QEI-CMNAH]E<^-_$6M@ZJZ3I7V G2B,Y\&\1_L3_ +1EUXO_
M .#?S4=(^#LL.G_L>F>/]HR>WU70H3\,H!\&K/PX;6X'V[-\3XI4D#3<@D$C
M)R!Z-_P2#^"G[5'[+W[07_!0?X3?&C]GSQ)X9^'OQ2_:=^(/[17PY^/D/BCP
MMJW@'Q3I'B^ZLK&T\+Z3I%G>MXOL[X65H-08ZD"J\EA@$4 ?T!T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>&_'WX[?##]FOX3>
M-/C?\9O%,?@SX9?#W2CKWC'Q))8ZE?PZ;IP(M#=A=(5KX@$J"2C8!49Z8]RK
M\?\ _@O4W_&H?]NP]!_PI34L^O\ R%;'(_2@#=^!W_!:[_@FA^T+\2?"WPF^
M&?[3FAS_ !!\;R_8O!&A^*_#GC3P$?&.H!MDG%?9GA?]J#X/^,OVA/B3^ROX:\37-Y\:OA-X-\+>//'GA>30M=M[/1_#/B^
MY^QZ1J=IXAOK!= O]W.;"P=F#$?LAV&FS_#>;]I
M6XB_8?\ ^%!1>%UT(?$W_A9&/ 1U;_A%+7PS_P 5!:7W]AG5AJNW"C[NLY*G
M'LWCGX\_M?V_[9?_ 5<^&/@;X]:'\.O'7PY_P"";W[/WB#X::K\3]:\*^'?
MAQ\,?C1XDM?[)U3Q7=ZMK9_L^RO=1OUNMNI>(-2;2QJY4@ D ']4E%?QR_\
M$ZOVIOC9\%_VI/!/PK_:6\0_\%"/!/Q=^)7[//Q(\1^$O@W^T)XW\!?'_P#9
MZ_:<\<> _"__ DEY\1O@Y\6/#(T[4/#']I"UQI/A_PYIFJ>%2">A.:^:H/V
ME_VPD_X)M6?_ 6Q;_@HU\1F_:(O/C;;F7]D.34] 'P A\+GXH_\('_PS1=_
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M_#7A_P"$EI\/AH?_ D%CXK^PW@U#^WSCQ41_P A;=A@ #^_+PSXBTGQ7X=T
M'Q7HEVE_HGB?1[#Q)I-Y#'C[9I&L6EIJVDW0QV-A=VIY'(8<>G45_%3\;_V@
MOVN?CI^V!\2/V9O 7CC]KCP9\/?V2/V)/@!XS^$WAO\ 9'\;_"7XM%VC:Q_PMKXVZK\3[[PWJ'C/X=?;B?#^E>'_#IQI9M+\X!)SVGCOXM_\ !0O]
MI+XH?\$6_@%XZ_:<\=?LQ_$G]J7]GG]H>/\ :6US]G[Q'X,\0P>)3X"15L_'
M>@WME_:GA W^I6"V=^-2T\9TG4[R]71P0 2 ?V145^9O[:/Q"^)'[!?_ 3$
M^.7Q$^'>O>)/BS\4?V<_V<]8N_#/C/QQN\0^*O%?B#PWH8M%\4>*VL@@OKWG
M^T95PW-MM8L.OY??L5Z3X@^$][^Q'^T;X\_X+%>,/'FN?M1_ SQ!X[^)'P#^
M..M>#?'WASXQ>(+SP8/'FK:_\$=*T0>'#\/+WX5'C5M/T[2M5TO5/L7]DC53
MP* /ZM?6/A?X'^!'QW^&_B/7M8L[S0?A/^RWX8O]2\8>%]#\.BTNK#2/'^H :KJ?V(
MXZX'V_:?M=?&_2?@A_P]U?Q;;"^^#^GG
MX7_;/#VE^"#G_B36']N<:2,8)QT()H _K2HK^++XY?%#_@H1\1/AS_P3TU[P
ME\0/VC/C3\)=8_8*\#^-_BM\)_V2_CQX#^&7[9?_ MG6+6S^U_&[Q9I/B>Q
MU+Q!\0? ^G=M/T[^R])SSK%9_P 4/^"B7QF^+7[,W_!*GX+? 'X^_MM^TY\9/BS\*OCG\7+/2/AU\'OVO?%5_\ !079U?X-VGB'6K__ (0[POXX-\MW
MI^K>,--U,_VII-F2#EF /[6W^Z?P_F*^8/$'[3_ ,"_"O[2/@7]DO6O&T=A
M^T%\3/ 7B'XG^#?!!TO5&GUWPAX2N?LGB'7/[7^PGP^!8%/[/VW[KJ;;M(_D^^)'[97_!1K]F7_@G_P#M8^#_ !#\1?B!X)AT?]M+X#?L\? ?]H#XN>*?
MAA\1OCO\)?@_\;-4L[/QO:_%C_A"[[Q)I]EXJ^'9^UZ?I/B#Q%_Q-?\ 3!TK
MW+X5?!^;X#?\%_OV(/AF/VK_ (D_M5VUK^PS\=-8T_7/C!XBT/QC\0/!5OJU
MW:W5U;#Q5HU@AOM#\2;?^$ATC^T.-,TF\&DHS*58@']*OQG_ &H_@A\"?'WP
M$^&'Q2\8IX;\:_M*>.[GX+O&%E:#5[G0UNK*-H[/-GC(U$(F
M3T/*U]-U_,I_P7LLK_5/VE_^"-.CZ;\6/^%'7?B7]LGQ1X>A^*$$FA#5/!$]
M]X#^Q7>IZ0VMC^SK/7-1LKHZ#I-_DE=5O=/& -M?*6H3?MLZ=\3?^"O'_!.S
MX _ML?&_XOWG[/?[.?PG_:P_9J^,_B7Q9INN_$[X>_%>]N+SQ+XA^"'B#Q9H
MUBI\2Z'XBLM)NM/TGP_J2DZ4+NQ!0$Y !_8L_P!T_A_,5^>_[77_ 4P_8T_
M82\1>#?"O[3_ ,5+KX=ZQXXT:YU[PHD7@WQIXH@N]'LKK[%MSQ>VAS_:,B],C*G"_D%^P)^W1\5/^"HG[=/[.7C/X<_$CQ;H?[/'[-/[$'A#
MQO\ M)>#/#M_=6.A>*?VKOBKG2#X,\6VH7;K%YX*32-7OUT\@#3, ,V]BQ_8
M?_@IEI&B7G[ '[8NH7^EZ5>7=A^S1\8/L=_J.DVM_-9_\47K!_T4[=R]?^7
MC)XZ\$ Y[]DO_@JE^Q!^W!X\UKX=_LS_ !@N?B+XLT;PW!XSNK-/ WCWP_IG
M_"/FZ^Q?:K+7_$N@Z?H%^/^"(?_ 1L
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M_P!+O-0TFPU'C^UKPZMDD''E7BG1OVO-*\4_\%G/@59?\%'/VN+;X??\$\O
MGA_XY?!;5#XHT&]^(^L>./%_@O6O&=GI7Q"\;WV@_P!HZWX'TV^TC^S_ /A'
MCMTK5=*O23SIN& /ZVO$W[3GP>\(_M"?#7]F'Q#XHGT_XT?%GPMXI\=^"/#"
M^']=O+'5_"O@ZZ^Q:_=CQ!:6!\/Z-?)>DD6&HZI_:3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ML0<5^(G[4S(O[,'_ 7[YSY?_!9/X+_N^G'_ E_PWZ]._6@#^\33[N"]M+*
M\M9([J*\MK>ZBN(H_)\Z"[4$7.!P,KAL#GG/I6O7\JWQ!TO]HK]IS_@J=^W7
M^ROI/[9?[1'P-^"'PS_8G_9_^*OAWPW\']>M=#N+/QO>^%_]$U32=6O-#U*_
M\,6.HWWVO4/%FGZ< =5U0V&-5U
M?]J;Q]^T?X:^-OQ(^ FJ> O _P"T9\6='_9OUV]T?P_X$\)>+/$XTW0/#'BO
M4;&T%_XLU YU3519\#.20#^YNBOXY;KXN?\ !5-OV%?VD?A7H/Q7U31/&'P[
M_;'^'_@/X*^,/C)\<_@/X<_::^(_P'U@WEYXM_9]N_B%HM]J7@#1?C]X>OM)
M.GZ3J&HZ9_:VJZ5=X!R!/CK^U1^SQ^V%X(
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M^=,_LK5-+P?[6(XK[@_X+!7C^*OVJ?\ @C5\$=843_"CX@?MSZ?XP\9Z?/\
M\>&KZC\*_!VL>)/!.EW@R?\ 0M0UNZ%_U7_D#]!P* /TS\&?MO\ [-WCO]IC
MQQ^QUX:^)VG3?M)> /"VC>./%'PLU2QU/2M?LO#'B73;+6+35+.ZO[ :;K,8
MT_5M,9K#3R7TKG^UAD+GL?@S^U/\%/VA?%/QM\#?"/QG_P )3XD_9X^(7_"K
M/C!9_8-3L9?"GC<6HO!I?VN]L18WS,AZZ=D @YQA<_R&?MA_!+XR^(/^"P'_
M 4@_;!_98O=_8!\-_LC_&WP/X0L[EA8_%/XM ,)%X(M+N_TG<1SA
./V@-/\
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M6>_UC43C&F<[>25 ,#P7^V7_ ,$S/^"J\/BG]EF+4?"OQWTW7= _X3%OA?\
M%/X;Z_X;L?B)X1LKM;+_ (3WX=GQKHOAT>,M.T^]#9\6^#-28Z9GY6!!+>Q>
M#_V?OV O^"6?PM^,'QM^'WPE\ _L[?#[1]!/BOXO^-?#FC:YJFI7>@:-S]LO
M;PWGB3Q'>V6G\#[ I9>AV\;J_DN_9#\;>-O^"3'[L-1_:J^.VL
M?#7X;_!C_@GCX[^'?Q4\+0_ GX;_ ^*>OY^)N@?\3L:;J%E>^'KWC2O$'B
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M(;J_^'<'P?U:Q^-$_@ :!I!M=!M/%H\5?V?9_$4Z$;33M5U#^S#R/[PKJO\
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M7[18Z]IX\4?\?=I'[?7_!2+X8^)_V[?BS
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MQI.=,SQ]* /[9/#7B&T\6^&M$\5:#M_9/^/ZSS975J>2"!MP.I/E&K?M$_"CP[^T)X1_9DU?Q-+IOQB\=^!=9^(W@O
MPQ?6-U90>*?"7AK5+.P\0W.D:I>?\2W4+_PZ+VV.K:?9DZG'IUTCE#LRG\V/
MQT_;?^*?_!,O]H ?$[XD>+=4_9E_:=_X)A6'B?X"> ]
M O#EG9^#O"=GP-'O?B)87FDZA_9_S+N^WY^9>.0^,'AK]H/X$_LT?\$#_C3\
M;/B'XL^)'[7/_#9O@>\\6^(_%&J?;O$DNC?M(:%K%WXU^')NNMYH?A[0[K2M
M/_L_H3HW''! /[":*IQ^2)GV9WR?ZV/T/\AU]<>^.ER@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O%/C;\$/A?\ M%_"
MOQC\&/C+X/L_'GPS^(&CSZ+XQ\+7ESJ=O9:]IQG7=9W=WHS6&H8R"Q"-U4=<
M%F]KHH _+;X(?\$MPK<8!-YX=MO&FN^([#1=9YVYT]$?C( R!7T3J_[$O[+?BCX@_&_XL>)O@GX2
M\3^-_P!I#XMIR2,@?8%% 'YP_LV?\$KOV&/V3?'Z_%7X*_!-/#WCS3M!G\.^%M?\2>+?&?C
MVY^'OA>\YNO"_P /1XTUWQ'8>"]#R,'3O#VT$=7B_P"".O\ P3=M?C^O
M[2MM^ROX'3XHGQ9=?$',EWKTO@C_ (6!>'-U\1/^%97FMM\/QXJQP=1'AD,.
MH!)R/U&HH ^MU'Q3I'A"U-GX>TV[W7QTZS&G9 46"<%22'#MC^RMX3U;Q-\7DGN_'L)U7Q/8^'=8\0-=?;;OQA:^$]&UL:!8^*]1O&']I^(-
M.TQ=6)";F(+;OU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MVUYI7Q"M_B?X2>7QO\1IX/ GCBSU0ZQ9W?P]TJ\\6'3_ 4/M_73_#PTO2^.
MF378_%C_ ()(_P#!/CXW?&+Q[\=OBC^SAX8\5?$/XI:/-I?Q&N;O4_%$/AOQ
MN!IO]D#4_%?@K2=9TWP[KFN6&G+_ &;INOW^F-JZ;F <-MDK].** /S,^*G_
M 2@_8-^-GA_X3^'O%_P'M[>!_''AGX<6=FMG_PA
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MA\2>"/'GAC5O!_BSP]M* /B?Q7^P3^R)XQ_9;\._L9>)?@?X;UC]FOPAI>C:%X2^%]YMQ\/7'A_5[S4!X@L=0\/7=UC2M1_M,ZFCD8,@P#Y3X'_X)2_L$_#SX&?%[]G;
MPY^SQHDCQ=XWO\ 76\7WXTTVMLV
ME6(U6/2]*V* A.=_Z744 ?*/Q#_8[_9R^*D7P#L/'_POT[Q';_LN>*-&\:_
MB"YOM3@/@3Q!X:TNTTC2=2TC['J :\;3[&VM+!1J6\ G8=V3AW_ .Q#^RYJ
M6N?M+>)]2^$VBW.N?M@>%K#P9^T?J O]?CF^*GAC1M)OO#MEIFJV@UQ;'2#I
M^G:K=V'VW2_[,?!)Y!W#[*HH ^*O"O[!_P"RAX(\4_ ;QIX;^#FBZ?XG_9H^
M%VL? WX(ZJFJ>*);CP%\,-:MOL6I^'[13KAT\V6HV-J VH:EIVHZKDC&JY;
MYG_AVQ^Q2/V/!\2YOAW_;/BFWL/\ A.#XH_X2_P#X2;^U
M;36_^$A^W_V\1J'_ "$AIN<#')6OONB@#\SOBW_P28_8#^.'Q;\4_'#XH_L\
M:'XH\;_$'0K;PY\08I-?\8:5X7^(>GV5I9:3I5QXW\$:+K>G^'=;O_#UC9VJ
MZ5X@U#33JNEC<58$ U[!X$_89_9>^&OC;X(?$3P?\+;+3/''[.7PFOO@/\'/
M%4NM^)[W4_!/PHOKH75UX3M6O=9-CK%BQMAM_M-=3?3#]WC(K[1HH ^:?C/^
MRY\#OV@_$_P5\9?&3X=Z?XV\0_ #QW;?%'X2ZE>ZAJUI-X)\MO].6]O>0%_M#3W0$XVX7#>.>)?\ @FY^Q?XR\-?'/P9XG^!/A[5_"_[27Q@T
MGX^?&G1KC6O%,,'C?XO:1*]6O++74U#[;I]]I-M?\ ]GZ;J.G:3D$+
MI@&<_?-% 'S!HW[*7P#T'XU?$O\ :&T;X::7IWQF^+?P^\/_ J^(WCB*_UZ
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M/[$G[(OCL?$[X)?!MM&^(EOH]SX9T/Q?XD\8>,_'^H^#O"MYM7M5T[P;X8SP=!\.Z?I0./E4YR,K_ (*6?LE>._VG_A9\*/$7P:FT>T_:._9D
M^.?PW_:,^"%QKMZ=,T34O$_@35!_PD'@W5M5&XZ-HGC/PM=:MX>U6_4<+>#
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MM:QX7N;869TEKO1K[3]0%B;. ;BNH!NS9X!]GHH _'31?^"#7_!)_PWJN@Z]H
M7[)?A^PUCPUK5AXBT:YC^('Q1QIVL:1=B]LKH9\<M^"3?[ _[;'C+3_B;^T9^SYH_BKXCV=A!HTOC_2-9U[P1XJU?PO9_:_LF@:_J
M_@O7-,.M:$!=$_V?J.>>00%VU^F5% 'A7P.^ 7PB_9I^&7ASX._ GX>>'_A9
M\,/"%H;3PYX,\+VILM)TV&[YNKK[^H7U]?Y!W7VHGM$/VQ_'^E?$S]H7]GK0/'WCJSL(-$NO%EMK?BSPKJFO>%[9B;;POXV?P;XI\/
M'QGH0R2L?B+^U H 0*B 8_1^B@#X\U#]B3]E>_\ $/[./B,_!;PQ::Q^R2;^
MW_9RDTF75=(@^%9O-)_L:Z'A_2+*_P!-T^[LA8!0?[0&I@D[L%MQKFO%O_!/
M+]COQS8?M.:=XS^!>A^(+3]LB^\,7W[2MO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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^D=/@C_Q+CX<_P#RNH _3^BOS _X:)_X*M_I'3X(_\2X^'/_RNH _3^BOS _X:)_X*M!3C_ *1T^"/_ !+CX<__ "NH _3^BOS _P"&B?\ @IQ_TCI\$?\ B7'PY_\
ME=1_PT3_ ,%./^D=/@C_ ,2X^'/_ ,KJ /T_HK\O_P#AHK_@IS_TCH\$_P#B
M7'PX_P#E?1_PT5_P4Y_Z1T>"?_$N/AQ_\KZ /U HK\P/^&B?^"G'_2.GP1_X
MEQ\.?_E=1_PT3_P4X_Z1T^"/_$N/AS_\KJ /T_HK\P/^&B?^"G'_ $CI\$?^
M)M?](Z?!'_ (EQ\.?_ )74?\-$_P#!3C_I'3X(_P#$N/AS_P#*Z@#]/Z*_,#_A
MHG_@IQ_TCI\$?^)M^&B?^"G'_2.GP1_XEQ\.?_E=1_PT3_P4X_Z1T^"/_$N/AS_\KJ /T_HK\P/^
M&B?^"G'_ $CI\$?^)M_HK\P/\ AHG_ (*M<_EI] 'Z?T5^8'_#1/\ P4X_Z1T^"/\ Q+CX<_\ RNH_X:)_X*M7'PY_P#E=0!^G]%?F!_PT3_P4X_Z1T^"/_$N/AS_ /*ZC_AHG_@IQ_TCI\$?
M^)M_B7'PY_^5U 'Z?T5^8'_ T3_P %./\ I'3X(_\ $N/AS_\ *ZC_ (:)_P""
MG'_2.GP1_P")MX:)_X*MC_AHG_@IQ_TCI\$?^)M_AHG_@IQ_P!(Z?!'_B7'PY_^5U 'Z?T5^8'_ T3_P %./\ I'3X(_\ $N/A
MS_\ *ZC_ (:)_P""G'_2.GP1_P")M"/\ Q+CX<_\ RNH/[0__ 4W*G=_P3H\%_3_ (:X^'(';TL!G\2/\0#]/=Z^
MOZ'_ HK^?7]JC_@KE^U)^QC>^"[+X__ + -EHG_ L"TUN?PE_PC/[2/P[\
M1&Z_X1B32HM?-V([ ?8((7UW2!IT;#,L4D_.86 * /Z#**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBF>8G]X4 /I P;IVK!\0:
M[HGAO1]1UOQ'K&E^']$T^VEN+_6-8OK;3-+LK8 DW%U>WI6Q0#&29&QSC!+!
M3^,O[0'_ 5_^''APZQX5_9;\.2_'+Q5;RG2I?'>IR77AWX.Z#?G'7Q%SJ/B
M?;C']G^'--]?^)L>P!^R7B/Q%H/A31;_ %WQ1K6E>'M$TZVFN=1UO6[^UTO2
MK*V S]HN[N\VV"DCGYB>H&WG%?C)^T'_ ,%AO .EC5?#'[+'A67XQ>(8);BQ
ME^)>N1W.A_![0-0M!SMQ$U3XA);S>;I?@NSBNO#GPL\.9_Y=K3P197W_$Z_[?[4^M< JI&D,?E?9
MH8XO*M?W7D6-F,_\>MI:67'\ZZ5AY>?X_P"1SG<_%WXJ?%W]H?77\1_'KXA:
MQ\2+D2_:=+\+F+^ROASX:'8^'O!%EFP)Z?\ $QU'^U-6SZG-<,S/MA3?^YMO
MW5KYD7D06>/^76SM.@]^G?VI:*WL@/U\_P""5?\ R13_ (*"_P#7:;_U35?H
MS_P2C_Y1Q_L9?]D*\&_^DUU7YR?\$K(FG^"?_!02W5-[7$T\,,9_Y;D_!O:,
M=\DD*/K6Q_P3E_X*D_\ !/7X6_L+?LL> /'_ .UG\*_#'C#PC\(= T;Q'X?U
M#4-4%]I&HV:W8N[6[M1HA/&,$X&. .G/+7_BR^1T']!U%?F9_P /B?\ @F'_
M -'H_"#_ ,&NN?\ RFH_X?$_\$P_^CT?A!_X-=<_^4U8@?IG17YF?\/B?^"8
M?_1Z/P@_\&NN?_*:E_X?%?\ !,7=Y?\ PVG\'MW_ &%-4_G_ &)C_/I0!^F5
M%?FA_P /AO\ @F/OV?\ #9OPDW_W/M^N_P#RDSGVZYIO_#XC_@F+_P!'H?"3
M_P #]<_^4E 'Z8T5^9C?\%B?^"8D:;V_;0^$:H/XWO\ 71_/1!^='_#XG_@F
M(>G[:'PBY]-3UW'ZZ)0!^F$GW&^E?@7_ ,%+?C+\8- _;N_8Q^"GA+XJ>/?
MWPT^('PL^,WB?QUH'@?X]_#S]G2YU/4/"7BCP'9Z3KS_ ! ^(%AJ-CK!\.Z-
MJ^KZB?!^G :GJBC)*C.W[";_ (+$_P#!,1AL_P"&T/@_SW_M77,G\?[$_3^E
M?"W[2G[5O_!*C]I_Q1X?\6^)_P#@H[X)T&'PWHT%CH.@6FA^%-M[O7=(/C/X=^)-1LK_45^QV.J?8-27(LU#,K%@ #RC]J/_@IC^UGX7C_:N^&/
M@SQ+^SW\&?B%\#_B?\()?AP/%G]N^./[9^ &L?&/PW\.-6^*'B'QMHO_ !1_
MV+Q"=5M-/\5^'Q_97BKPL+R_.#@8_;;Q?\38_%7P)^,%O\./C?\ "+1OB[X(
M^'&K:?XB^(MKJEIK?@'X7?$C5_!AUK2?$_B*U^VYLM"!O;;Q"HU Y_LHV9P0
M37X='XG_ /!+>2/QE$G_ 5F4P_$B)8O'EO)H?PYG@\:VY8W=N?%EI_PJC_B
M=;4^9?[1^]JV=5(76/FK9LOC[_P36\/V'B.VTK_@LGJ/A[2_%%I;CQ1:69^'
M&EZ3XDM[2UM/#G_%66I^%@L-:']A65GX/_XF('_$JM!I'8[0#Q#X2?\ !3#X
MV?L^_"C3_@C8P^-OB=^U0WQOT?X5_$7QQ\:OBOI?Q\^!VG:N?A-J_P 5+/Q/
M\'OB%X*.F_VUX4^*EEH]T=)\'ZCJ?]J^ =4O+]=8^2PTU6^OK[_@I9^VWJUS
M\;M5\,?L[_!#2=+_ &/\ 4M0^*FA>([SQ#X-\
M)7GAC^TO#][9>'K'P_JVHZ3X@_YBO_((/3GP^+QG_P $HH?!+?#2+_@J=I]M
M\.OM_P#:I\!V^A_#FQ\&P:_SC7AX>_X54+"SO_L.-/&H$+P>N1MKL-,_:'_X
M)UZ"LZZ1_P %C=3T&&?0K#PY?1Z-;^ ],AU/PMHPO+3P[H-W]C^&ZB\\+^'K
M*[U;3M)TW.!]LOSO/( !D>(_^"N6MZWXB\-_M/>$O!FH>)_@M9?"S]M;QW\
M]/\ "_CWQ!8Z+\7_ 1\$_"_@.T_X3'QOX4&B#3[X:AXXU;Q#_96H:><>%O"
MNCW^K-Q76_$__@JI^UA\/;[X*_#'PQX1_9=^./Q5\8?#GQ1\:-3\0?"#Q3K^
MH?";QMHVCZGX0LA\)O!7B+6K_3O[&\+?[1U7Q!J>IG2]+TNRT\MI .HC'
M-:=\:O\ @F?HNEZ1I>G?\%>[_3-.T#2-1\.>'=,LK'X<6.E>'-'UA<:_H?A_
M2C\*A8:-H?B,!5U;3\'2]3R ,@$CD3XK_P""2O\ 86A>%!_P5'T?_A&?"FIG
MQ'X7\.Q^&/A:-)\-^(-6^Q_VIKFE:5_PITV5C?>(][?VKA"-3_T(]=.4, :'
M[4/_ 5/^)>O^)/VGO@)X9U/P3I_AR]_9]_:=70_&?@>?Q5HGQ$^"GQ/^"7P
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MC3@=?TZR"Z?I>O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M[4 &,"N"_:Q_P""J/Q0^(W@+]MOX1>"/%O@2'P]X1^&FH_%#X3?&?X9W?C+
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MPT^_W_V6IYP210!^?<7_ 4'_;<_X8NB_9R_X:;\?2?M/>%O!&@?MM>(?VDH
M-*TO_A(M0_8Y\26WAW6/"MM_:GV'_A'A?ZEXVU=OA@Q R?LG.:_2KQ/_ ,%B
M_B+X)^,OCWP!HEI\)_BOX/\ "'P2^-NO65W86WBCPYXC\*_%C]GWX2>&_'>K
M:%XLU76[\Z?XE_X2*_U6ZT_5O^$=TO\ XI8DG^UM4!YQ;CX\_P#!,R"T>VN?
M^"OMQ;:>-!T;X?\ V:ZLOAS#92Z#9Y^R^!+L'X5*+WPIP/[(\([O[+TL'_B4
M MKO5?^%5?;KRQO=.M?L6KV <_VOI@*ZMGAB 87B;]OW]J?X9_M7?LH>*OBO<^
M =,US]IK]DWX82ZG;>'O$WBJ]_92^!'_ M+XM"\TCQYXX:^(\1'7-1T53X
M\+:B=-.E:OX^O;'2&U;3=&)SC>-/^"M'[;'Q2_9N_:L^)WPJ\ _##X/:+X%\
M!^(?&/P_^(NKW-S?ZK\+-0^''QKL_AQJ_A?QOX3OKTZCK.M>(]%NQXB_M!=-
M7PMX6TNZO?[9)52K>F:G\=_^";>KPI;7W_!875-1@BTC3_#J6W@'58CH%
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M%OV//B'XO\)_MM\3?'/A36-$;7?VM+W3?"MWJW@_2_#_P[T[2QXJU3_B:@G(SZSH_[2WQK^+G[
M6-MIUQ^U#\0WNOBO^V#\5?V/O$?[-FCZQI?AO2M$_99/[.FK>(_#_P 8]*\$
M_8?^$Q\&_$;3KVZM/%W_ L ZH=*TK5=6&D< 5TDWCO_ ()17D/@_3[_ /X*
MG:-J5A\.#!+\/]+U3PQ\+[[2O!(R1='PG:?\*I_L_1K/4KW&HE=/ )(#,!F
MM&^^*7_!,G4=:U[Q?J/_ 5ZUI_&?B?PO<^"=<^(EO'X"LO'^H^&+FWO;2XT
ML^-[3X4CQ"#]A"V/RZDVW3+.Q'\(9@#];_\ @EO\4/&'Q<_8+_9O\;^/]2N=
M;\6W?@^ZT+5/$-Y<_;KSQ%_PC/B#5?#=GK][>\?;+_7['2K34=5OMYQ^AE?B-^S+_ ,%!?^"5/[,'P5\ ? [PC^WQX"\3>$/AQIG]@^%K_P 6ZU=7
MNNQ: "?[+TV\OK#0[ 7JV(V_Z<(PVI?,3G("_1'_ ^(_P""8O\ T>A\)/\
MP/US_P"4E 'Z8T5^9G_#X?\ X)B'I^VA\(__ 9ZZ/R_XDF:3_A\9_P3"V^9
M_P -K?![9CK_ &GJG\O[#Z]NN* /TTHK\SO^'Q'_ 3%_P"CT/A)_P"!^N?_
M "DI%_X+$_\ !,1EWI^VA\(W3U_M#7?Y_P!B9_#'XXH _3*BOS,_X?#_ /!,
M7;O_ .&T/A%Y><;_ .T]<_+']B8]^M+_ ,/B?^"8FU'_ .&SOA'LD_U1^WZ[
MSQV_XDF1^(H _3*FO]T_A_,5^9__ ^)_P""8O\ T>G\'_\ P9ZM_P#*.F-_
MP6+_ ."8FW_D]#X/CW_M37>/Q_L3/Y]* /R$_P"#DA'?Q'^R*5Z'1/C5@YQG
M_3/A9^=%?(G_ 7C_;T_8U^/>K_LQ7/P@_:&^'GQ A\*Z?\ &&R\02:1>ZQ)
M_9-QJ5[\.9]/@NC-IELPDN8;6Y91L/$#<],E ']M=%%% !1110 4444 %%%-
MWKZ_H?\ "@!U%,\Q/[PJ&:6&"-I9I$BAC&9)))?)BC [DD@#G'7&MX3XJ_:0_9_\ !)>+QA\M!1+]BC33Y%U^T=\/YI#_ - ^YU352./^H/HT@_(=<M*._L22_)_P -">$$3^_<6'BBW&?3_3-"'4],Y]*[+P_^VM^R-XJE6VTK]H_X
M-R2[^(+_ ,>:#I,^?^O76FTUL],?*,>O:@#ZOHKG-"\5>&O%-H+[PQK^B>)+
M C)O?#^LZ;JUF/\ MZL+N1.O?.#FNCH **9YB?WA2[U]?T/^% #J;O7U_0_X
M5F:KJ>FZ+I]YJFLZE8Z1IFGP_:;W5-3N[>RL;*!.#M,@5^/W[0_P#P5Z^$O@6[UGP;^SSH@^/7CBSS#?\ B"VEN]+^$OARXRNTZOXM
MX&L?Q!E\.A\Y4AQC:0#]?-:UC2]"TR^UG6]4L-%TK3[9KJ\U/5;ZVT_3;.
MXN+J[O-L=HH.1N8[ <#+,0*_'C]H;_@K[\)?!=QJ7A+]F[0H_CUXRL_]%O\
MQ9%/[6\6_P#'_P")[[M_9_AX'@\ZN._XH?&[X[?'7]I;4)]2
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MDNO\_I6]EV1SD/!'J#2UJ6?AWQ)?0Z5PZY+J$6ER1V%UY&I?8_\
MC[_LKK]M_LX_] [\JS;FSN;.&&:YMI++[9:V]U%)<2^1YUO_ ,>9NK3[;_RX
M^NH8^E #-WR[\?)U\S/'\^GOCK[4M7X]%U*;0YO%J6%V_AZWO_[+EUSS;6"P
M_M#G_1?LF/\ 3;[_ $NT_P ]:%#V?H_R8'[ _P#!*?Y?@Q^W]\VW_3)B9/\
MNCH.?P'S<>GO7X%_LZZ?IK? /X..^CZ&[R>#+?S?,T;2YYYO]*O,W5W=_8?K
MV[5^^G_!*/S/^%/?M_;/O_;SC_PTA_I_]>OYL?@'^T-\"M'^"?PNT36/B3I=
MGJNE>$K>+5+>32_%,]]9W']J:Q_TX?V?^/;G\,:>[]$!]@?8=/\ ^@5I'_@F
MTO\ ^5]+]ALO^@3H?_@FTK_Y!KQC_AI+]GY7V/\ %?0]_P#V#_$__P H_P#/
M\V?\-*?L];MG_"V-#_\ #Q1Z?\ 8#_3/X5L![3_ &?8$[/['T=_,R/+CT;2
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M_P /_P!N3]C/X>^"[_P3HG[6-GJMG>VOBCRMMJUE?G^VK[[#_ ,@G^T?^05JOV_UITG[&-0\+?
M$;4+GX&?%#_BYVGZQX7L_#>K7/B'_F(>&+XV.DVFH?\ $NX_M6N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ME0!WOV&R_P"@3H?_ ()M*_\ D&C[#9?] G0__!-I7_R#7C'_ TG^S]OC3_A
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M['9K\\.E:-O_ .67_$ATNX[#_ET%C_C_ "KWKX7_ &T?QIHZ>)]>_L_3=$N
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M?$5]D#^T1_Q*JYP)OC5\#]$^"36^FZ]>:?>^)-CCPEH,$%Y\-[S0
M;/6/^$RU>[^P#_3M1UR[NM/TCP_IW_,*T>_U<4:A^S3\2+*/3-GA+P/JNI:C
M+X/M?^$?T:Z\+ZWXJTA^,S_X*N_I7)?$#]L+]B3XE
M:+>:9XA_:ZL_+CU0:SX7O+/X!>///\'F\TNS\-ZMH/AZ[O?^)A9>%?$5C::5
MJ!\/ZC_S%;/_ *B5>HZE_P %!OV)+/6K#7_AU^TAH_@#6+*U^&]KK/B#_A1G
MCS5?$?BFW^%>@V>CZ3:^(/\ F'66A_;K3_F'<#KF@#F+C]FGQY8-K$UYHGP[
ML-!TOPY;^,K_ ,4:A+H-CXFZC>G3M<_XE_]G\:K_P!
M?&:V_A/^S_X>^)'@FZ\37]Y>:',_C;4/ =K<>'_A]H.J^'-(^R>%]8\8'Q1\
M0=6O;'_B2^%?L-I]@.HX
M^$'Q1\1_8_['UZS\26G]D_VW_P >/^G6?_(/_P"02..G6N9M?VJ/V)[+P/\
M\*W3]LF\_P"$5E\96_CO6K./X+?$6"^\2:A_9?V/^R_$/V*^_P!,T/4;'_B8
M:MI^.GZ] 'LL_P"SA9PQ_!$S:EH[ZE\2_$>G^#?'NECP;:F#X8ZOXDM#>>%+
M7FQ']M?VCH=I_: ]KWJ.E*(_%$-KH7CSP1H/A3
MQQH7_"'Z]_PCEV=6\/65B?\ 0/$-]_I^DZA_S%=*X%;M &U?^$DLM1\6>%_&-MX>UG]GCQD+'P3J_@^ZL[SPG=>$_L7_ "XZ;8_\2#U_
MLK_B4>E?+OQ"_:6_97N-4?6=$_:@_P"%D:KKEUJ%UKVJ>)/!'C+PY/#<&[O+
MRTM;2[UJQU+4+VQ_TO']G]N] '4?8;+_ *!.A_\ @FTK_P"0:M/GC_ )@VE>AP?^/'GKWYR/P'BG_#2W[/?_16-$_\!?$__P HZ3_AI+]GLC9_
MPMK0O3_CT\4]NO\ S _\]NU &)^TW9Z:O@WP%-_9NCI-)\>_A/YGEV&E^1-;
M_P!O7?/_ !XY]?I[&OI"^T_39+J\=]'T?_C_ -0_UFEZ7^O^@^G\J^%?VB_V
MAO@AK'@SP1:Z3\3O#]S-!\M[2W[/TEY>3?\+8T?RY+O][&;#7OW-QW_ .8'0!Z[_9^FM]_2M#0M'_+W]A_R/:OI#X9_L[Z1XO\ #>E>)/$*6\+^(/M$7A?0-/TOP'X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MR?[.'_$J-F>*I^'_ -M;]A*S^*VI?$OQ9^U!)XC_ +4\)^(/!'_")O\ SQE
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MW%X6U72O$EOXC/VO2;KP]J_V'_3;'[";/C41_P 2K['G_F&UULG[>/['+-M;?M5Z'86;Q3Q:+H]O^SQX\.DZ-HX^'?_ JVTT'2MQ-=5U3I@FN+A_:]_8SL_$'PT\6:;^V3;VVM_"OP[X8\,>$I/^&>/'D\,UAX<
MM;RT_P")M:#_ )<=0^U7>G\C_D%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MB_LX?:__ "Z5R*_M*?L_,VQ/BOH[O\ ],[#Q1M:6D=Q\(3;Z=8Q^9:>.FDGL-)T>R-RPO/#>)+B.W^1I%&0">@)QU-%><_MX_&
MOX2>+)OA9+X<\2Z\.M''C4+#SB65'/' QSVHK&
M7Q/Y?D=!_J-4445R@%%%% !3=Z?WE_[Z'^-)N5E^1D/X@CGV!_'WKX.^*_[9
M&G:1XOU+X*?LZ>"KS]HSX\V4OE:SX>\+WUK8_#GX97!S_I7QC^)A \/^%L?*
M?[ ']J>*CSG2!P: /M[4M3TS1M/N]3U74[#2M*L+;[3>ZCJ%W;6-A9VX&#M5Y>2+9VEK@ ?B!^U7XKLSF_N/A98>
M3\+-'G&05\0?&/6-O@ZR!X8'P^VKG)P0" 1YVO[+7B/XM7MGXH_;/^)T_P ;
M-0MY;:^L/@IX3&J>#OV=/"LX)(M?^$3LK[^T/B#>C)(\0>--3U3!W8TG2\U]
M&]+_X\=#\/V%KX]O^0C@>
MV2: /ER[L/V\_BLXG\8?%OX6?LN^')XC#)X8^$_AD_%/XBX8YQJ_Q \3$>'=
M&OE 4^']*+ \Y+$T3^Q!\(?$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M]$T6_&G@GL>GL3R(+7X&?M#_ ]DGG^!W[8OC=K.WVF+P+^TGX8TSXM>'HST
M^RVWC>Q&F>,+(#M_9S$$$Y QS\+_ +.__!4;Q[XT^+W@/X9?'WX8_#_PWI7Q
M=\40>#?"_P 0/AGK.NS6.C^*+S'_ CV@^+-*\3_ -I:A>Z)XAOOMFGCQ!GO
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M>M?1OAOX)^'M<^'O@SQ)%-2G_P"$HO-(N_!N
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ML+;Q!XT_MOP7KWCF7Q'9R6%K_9?_ B_C"ULO^)#X>N_^8(?MVDVNG_VAIV1
M_IE_5G6OBMX#UKXA>%?'C^$M8TUY/"^L6OBB3[+I=]_8WB#[+>:/X3U3P1X=
MO?\ B7ZU_P (8?\ B8'^T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M'L_1_DP/U^_X)4L%^#'_ 4"<;^+N8_)_K^/@XO(]Q_#GHP&>E?@+\)?C/#\
M-?A'^SKH.K^#K._\/7/PET?5->\21Z-_Q-9K>\NO$EG=VNDW?V#4M/\ ^)=?
M:3I.GZL-1_Y"NJ^,-!_LM_.;\(_C5^S!KG[/OP-\'^//C9H>E?\(W\/\ 4+#5/ TEKKT$'_"0:Q:WFC_V
MIJUW9:'_ *;?>';&[N_[(T__ )!7]J_\3?\ Y#&G:6*QI[OT0'V'X@^(M_H/
MP1\0_%6V\)>$_$.O:7H-Q?V'A/1Y=!OM*O-8O->L]'TG0;SQ#9?\OQ_M;^S]
M6[Z5JMG?_AS$W[0UA=7W[/UGX?\ !VEZM_PNR73_ .WH[B+3//\ AOI]Y]LL
M_LMW:?86'PY\2?#K_AH'2YK#QA?_ -O:
MSK$FEZ]8>(YM0.J6>L?:K.TLM#_L^QYTFTT\Z?IW32KS^U\U6L_B%^Q58^(/
M$/B2S^/>EVU_X@^*&C_%66WN(O%'V*'4='TO6-'_ ++\/_8O"G_$E\*_;O$.
MK>(/[/Z?VK>7^KUL!]"7G[07PNTFS\0W-_9ZQH]SX3U3P_IM'-J'B^ZN]'\):7I/AZRLM2_MK_A(OLEW_P A'_D$ZKZUEZ7\>O 46H?%2P\8
M6^EZ)'\._%NL:-=6=OX7TL7T/@>SM='_ +)U3Q9:?\P7Q5XBUS5KO3])T_\
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M'O@#X?\ BJS^$>EZ/JGBB\\27]KX _! _L/4C_ &YIVAV?
M_"0:MJ&H_P#$I_M6]KPG3_C)^RUI=UX#U)/VF=#37O >J>(-4BU31_"5WH<'
MB31_&&EV>C^(=+\0Z39>%18?8=1^QZ3_ ,3#^S/^$J_ZBW2E\5?%K]EGQ)XD
M\5:WI7[5#QYH]G:WEG:77_$Z\*_VAHM]_8=WJ
MWA_^T=-_XFI_T"@#T[P7^TAX/\2>)M;T2_T>33=$EUCP1:^ _$%OX-TN>"\_
MX3#P;9>,/#VE^+/$/V'^S[+Q5J-]=W>GZ3I^G?\ (5^R:#_R"QJ5:6A_M&>
M-0^&OA7XHZQX5\2>$O#?B"74?](UCP'I<_\ 8.GV>O?8_P"U-6U;_E]L3]KM
M/^0?_:G_ !YW_7%>"6?Q _8VL_$R:QIO[2]G9^$KCQ'X'\;R_"^WM=>_X17_
M (2#X;Z79^&_!%U]K_X17^T#_P ([8Z3I.H<"N8\0:Y^QYXCT'3?#>J_M47E
MSI6CVOBC1K"WN+#5;[R='\8:]_PD?]EVGVWPKS?>';__ (E__"8?\A75=*O/
M[(YZ4 ?6FI?'KX>>&KC4K/Q)9W%S>?V]\0-/M;/P7X-_X2J^_P"$?^&_V/\
MX2'7]5N_L/\ H5\/^$A_M#5O[._YA7_('_XG!K2N?CI\'K'Q%#X;N=>T-+F2
M*W_XG$>C:#!X.AU#6/"__"86F@_:_P#D(V5]J/A3_BH/^09_Q*O^01_:V=2K
MYX7XI_LO3_9(/C!_8]GXAM;3_BE?[/_
M .)P[5@V?C+]BW2]4U*:'XY:!>:/K&C0:-XC\-WF@W5]_PDEQ9^
M%_\ A _[4TGQ;K7A74O$'AB^_L.TTG_D''_ERXQTH ^G/ /Q:T?XD>.O%OA[
M1/#A^#? _BBUN-8\$6NAWU[_P )?=:Q]DNK2TO;'_3K'[#I.D_\3#_I
M\O\ IUK'_:NCAC_9D^/#Q6VG)-'\/O$'E21Z7:P3Y^U_]>/]?IS7DO@'XW?L
MP> ]4U+6+S]JC_A/-2O/!O@?X_LG[%X5_ZBW_
M !-O^O/WXYO]I[]J+]F_Q!^SK\;-*T?XQ^#[K4M4\$:Q86%G]E\403WEQ>77
M^B6OVO\ L//I_+Z 'WCIMO;+I>C[+#3]\>EZ/_H]OHVES^=_Q*K/_2KN[^P_
M7VY^M:/E0?\ 0,L/_!/I?_R#7S39_MM3Z;<6>EV?VNU^UV6A_E_^NKO_#7W[+O_ $6WP?\ ^"KQ/_\ *2@#Z)\J#_H&
M6'_@GTO_ .0:/*@_Z!EA_P""?2__ )!KYV_X:^_9=_Z+;X/_ /!5XG_^4E'_
M U]^R[_ -%M\'_^"KQ/_P#*2@#Z)\J#_H&6'_@GTO\ ^0:/*@_Z!EA_X)]+
M_P#D&OG;_AK[]EW_ *+;X/\ _!5XG_\ E)2?\-??LNLVS_A=G@_?Q^[_ ++\
M4_\ RD_SVZ< 'T5Y4'_0,L/_ 3Z7_\ (-'E0?\ 0,L/_!/I?_R#7SDG[8'[
M+K-L3XV>#W_ZYV'BCH/^X'_+I3_^&OOV7=J/_P +L\'[))?*\PV'BCBYX]=#
MP?T]^* /HG[.O_0,T_\ \$^E?_(-+Y4'_0,L/_!/I?\ \@U\Y+^V!^RZRH__
M N_P?LD^T9D^P>*/^7+_C[_ .8'_+CT[T\_M??LN_/_ ,7L\'_NY?*E_P!
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MZN)O^0-I?_/U>?\ 3CW/^>MFYCCT_7H(+/1[3Q3>MCS_M'VKD?\@+_/IF@#Z$\J#_ *!EA_X)]+_^0:/*@_Z!EA_X)]+_ /D&OG;_
M (:^_9=_Z+;X/_\ !5XG_P#E)1_PU]^R[_T6WP?_ ."KQ/\ _*2@#Z)\J#_H
M&6'_ ()]+_\ D&CRH/\ H&6'_@GTO_Y!KYV_X:^_9=_Z+;X/_P#!5XG_ /E)
M1_PU]^R[_P!%M\'_ /@J\3__ "DH ^B?*@_Z!EA_X)]+_P#D&CRH/^@98?\
M@GTO_P"0:^=O^&OOV7?^BV^#_P#P5>)__E)2?\-??LN_)CXV>#_WG^J_T#Q1
M^^_\H?XY['ZT ?17E0?] RP_\$^E_P#R#1Y4'_0,L/\ P3Z7_P#(-?.K?M>_
MLNC_ %GQL\'@#_J%^*/?_J!_X]Z7_AK[]EW_ *+;X/\ _!5XG_\ E)0!]$^5
M!_T#+#_P3Z7_ /(-'E0?] RP_P#!/I?_ ,@U\[?\->?LP8W?\+L\'[,>;YG]
ME^*.G7_H!X]L^M'_ UY^R[_ -%L\'_^"_Q/_P#**@#Z)\J#_H&6'_@GTO\
M^0:/*@_Z!EA_X)]+_P#D&OG)?VP/V66QCXW^#^N/^/#Q1_\ */\ &I/^&OOV
M7?\ HMO@_P#\%7B?_P"4E 'T3Y4'_0,L/_!/I?\ \@T>5!_T#+#_ ,$^E_\
MR#7SM_PU]^R[_P!%M\'_ /@J\3__ "DH_P"&OOV7?^BV^#__ 5>)_\ Y24
M?1/E0?\ 0,L/_!/I?_R#3)K>V:)Q-I^EHG3S)-+TN#_VQ[?3\>*^>?\ AK[]
MEW_HMO@__P %7B?_ .4E(O[7_P"S!A]GQO\ ":/Y7_+.P\40?3_F5>/?T% '
MQE_P4ZC/G_ YX[.U17L/B$1/#'8Z2MSC4/"WSE+>RV3[M?\=?@E\09?A!>>#_ (E:!XACT^#Q];:C<:7!KD5M#<27WAEHT"ZCI=I-EE1R
M,1D87DYHK*I\M?6MAIFCZ?:0-=WEUJ=Y=%;.RL[*TP[R.VT+AF(RS!->\0:%X:T?4]>\0:QIV
MB:)HEAVMC8:3I]F&:\U*[N;UD2TL['[,Y9R0@8#(R,U^4\-OK7[
M?&O6_C7QC9:SX;_8A\/:O/J'PU^'$HO-#U3]IS5]*NC=GXG_ !+MR/MUE\'?
MM\>?A_X,4C5?'Q"ZSK2C1G72V -O5?B!\5?VXKB_L?A;JWB?X*?L> SZ-JWQ
MCCLQI/QA_:-T^[!6\T/X-F]']I?#[X=ZF&*GX@ZCIH\5:JO&C+I6'+?47PU^
M&7P\^#OA"P\ _"[PCH_@GP;90X_L?3!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M'K[/_%/Z&[CP?\ $NSB_P")7\:/AG+:
M^'/'&FW'_/KJ_P#H T_Q/8_]0_Q%IFJ:5^?/UXV5/SY_SZ9!_E2_=;9_'%^Z
MQV_#Z>_^- '\Q_QX_8-_:;_9S74->31#^T/\*+>6XE_X6)\+]+\CQ_H^G_\
M4V?#(_VEJ'_<0\&?\2G_ *A&E]_CS1-:T?Q!9IJ6B7]EJ4,=U]E^T:?+Y%Q#
M<=/LNK:3>_\ $PL[['_,/U'_ K^S"WDFMY/M-M-)"_KS_GCG^GM$_OV>/VC+^_\57FB:A\*_BS<1_Z-\6/A?+:Z'KFIS\X_X3;P]]B'A_QG9 D'
M_BHM,.JXR/[6!(- '\XNU_\ GF_Y?_7I?NIO_@_YZ8_/!Z#OZ9_*OH?X]?L7
M_M,_LUQW.J^)_"O_ N;X56]U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MK]*_8?\ X)3AC\&/V_T7EY+R8 ?[1^#H ^G)'ZU_/U^SI^UE^S9X6^ OP?\
M#>O?&/P_HFMZ7X,M[75-+DTOQ1]NBN/[4O/]%^UV7A7^S^W'^<8T]WZ(#[R^
MP6?_ $#=*_\ !%I/_P @4?8+/_H&Z5_X(M)_^0*^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MM?L>K6MI]M\*_P!GV7]HV-V#_ -XG_:6T_Q/H/@_
M0=8T:.SU#PYKUC!>7%YH/_"'V>O:M_8GA73?].\&:']KT_PGI^G'_D*_\3?6
M/^)P: /LSP3J4/B3PKI6MWVF^"X;S6+7[5?Q>%XM!USPY9W/VK_1+6SN[+_C
M]_L[_1/#_P#Q+N/[5O,_\PT5TWV"S_Z!NE?^"+2?_D"OC?X=_M'?LC_#?P_>
M:+8?'O2]5>XUFX\47]QK'AS7H+[^T+RU_LM]!CFNY_X;-_93_Z+=X;_ /!#XR_^9:@#Z/\ L%G_ - W2O\ P1:3_P#(%'V"
MS_Z!NE?^"+2?_D"OG#_AL[]EC_HM?A?_ ,$/C3_YE:/^&SOV6/\ HM?A?_P0
M^-/_ )E: /H_[!9_] W2O_!%I/\ \@5X+^UA#9P_LQ_'B:&STN&:/X?>()8I
M(]&TN">'/X_Y]JRO^&SOV6/^BU^%_P#P0^-/_F5KPW]IK]K7]FSQ!^SO\:=!
MT?XN^&[_ %76/!&L6&EV<>E^*()[S4+RZ/V2T^UWOA7_ $+WS@_A0!][Z79V
M$.DZ.XTW0W\W1M'B_=Z+:_OOMFF6?^E?;+VQ_P!-]_IUJU]@L_\ H&Z5_P""
M+2?_ ) KYGL_VR/V5UL[,3?&SPVEY;V&GV$OF:#XR\^RN;/2[/[7I=W_ ,4K
M_9__ '$,\9JS_P -G?LL?]%K\+_^"'QI_P#,K0!]'_8+/_H&Z5_X(M)_^0*/
ML%G_ - W2O\ P1:3_P#(%?.'_#9W[+'_ $6OPO\ ^"'QI_\ ,K1_PV=^RQ_T
M6OPO_P""'QI_\RM 'TC]CLU^?[!I:>DG]@Z7G\?]![^]>'^,O']_H_Q2\$_#
MVPTKX=:)H^H6MOJFLZSXXM?L,_C:WO+K^QKOP'\,KO[#_P (_P#\)QIU]GQ!
MJVGZCJ?_ !-=*_XE&C]JYUOVS/V5V79_PNOPGQSG^QO&7\O^$5'I^GXUY'\1
M/CY^S'\2-0TJRUO]I^WA^&,D5O%XM^%\>@^*+ZQU[4/#8^V>$]4TGQ#_ ,(I
M_:.BGOJ^HZ=_Q-=5H ^D['QQKE]XJ^+OA*Y^'_@_2W^'>@^%]?\ #FH:A=:7
M<6.O:?K']L?9+K5OL6AG4/#%CIW]DW@U7Z8KQ]OVDKJ3P;X8\21^#OA/)#KG
MQ!\*-)N]&T/4O$%EH?B&^_XE_]G>(],TOM
M_:Y-<9#\?/V8E\8>/_'EM^U[>6U_\1- T_0;FWL_!MU_96CVWANZ_P"*>NO#
MQ/PY_P"8<;J[_P"0D=4[=:IP_&S]F./1_%6E:9^V'>:5K'CC7M8U3XC>)-/\
M&W?G^-OMFEV?AK5M+_X1Z]\#_P#"/^&/[.L;3G_A'?[+].: /?K'XWZ"OQ:\
M2?#WQ#X>\+V&@Z%\/M'\;P_$#2XM+GT/7M0O/"__ DGB'0;2T/_ $#K&T_M
M#2?$&G9_M4>E=)\%?B)'\6O [^+;_P #:?X)N8_%'B#PO%H$D5K?3PZ?X;^Q
MWFDZI=@V./MWB+1+NTU'_.:^/M6\;_L&:QI,.B/\=;?3]*M[KX8:II>EZ5%X
MR^T0V_PLTO\ L?2M!^U_\(I_R!-1L?M?_"6:?UU7[8<''%>P^%?VHOV1?!D.
MO6&C_&_0TAUSQEX@\47]O"SUC6/L?VNTM/^*5YL=.^R6FG\T ?6WV"
MS_Z!NE?^"+2?_D"C[!9_] W2O_!%I/\ \@5\X?\ #9W[+'_1:_"__@A\:?\
MS*T?\-G?LL?]%K\+_P#@A\:?_,K0!]'_ &"S_P"@;I7_ ((M)_\ D"I$L[;<
MGDZ5I;S?\L8X]&TP?^V/^?TKYL_X;._98_Z+7X7_ /!#XT_^96D;]LK]E>1'
M3_A=GAM -GCQ1=_Z+=_Z#]?\XKZBO+&SCO+R'^Q]'AACNKB(^9HVE^?-_I0_P"G'IV_
ME7YM_M)?M8?LY>)/ GP^@T3XP>&[^:T^/GP7UFZC_L;Q1!!9Z/9^*;O_ *E7
M';^I[X^D;K]LS]E1KJ\F3XW^&UADNM1\WS-!\9<7'VKG_F5: /H;[!9_] W2
MO_!%I/\ \@4?8+/_ *!NE?\ @BTG_P"0*^M_P"&SOV6/^BU^%__ 0^-/\ YE: /H_[!9_] W2O_!%I/_R!1]@L_P#H&Z5_
MX(M)_P#D"OG#_AL[]EC_ *+7X7_\$/C3_P"96C_AL[]EC_HM?A?_ ,$/C3_Y
ME: /I!K.P7#OINC[#_K?,T'2_(^S\Y_YMCV'A+^V-!L?"&J16ME\5/$GB"TN?]$^(HM+ZQ'A^]\#^(;'[)I_A3^SL_P!E
M?9+_ /MC%8Z?MG?LK[DW_&SPN,?]0'QE^YZ_]2IQ7C-O\?/V;+GXA6?CGQ#^
MU7;^(8_"'M
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MN-9^.>F:WX&TZP?X47WV;PO+'%I<\WQ.L/[3_P"$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ME?\ @BTG_P"0*&L[!5??8:.G[K_EII=K!GT_TLV/;Z>V*^M_P#P0^-/_F5I_P#PV?\ LKIO?_A=_AN']UD26^C>,H9Q_P"6K0!\<_\ !3D6
MT5S\$2EM;0A['XA-YJZ98VXN?]/\+_/LM_D^7.,]>:*\:_X*%_M"_!/XBR?"
M"[\&?$;0?$L.F0>/[74+JRTS7;>.*XEOO#31QE-0\/6DWS+&Y&(R.#DYQDK*
MI\?V
MC[K4-!\.:Q%%Y\WPS^'NCFT/Q-^-EY:'Y@/!6AWGV'2!TU+Q5>Z"J-MW \@'
MAWQ$U&7]M_XKZY\*K"=Q^Q]\#/%$%K\6-7L[JZAA_:'^,ND70O/^%26E[8\7
MOPL^'I ;XB;01XJ\5_V?X/!8)J;'[<58XUAAA2WLT2UM[6TL[.VM8/L=O9_\
M@G2])M++_B7V5CIW/Z5QGPY^'/@_X0^ ?"/PQ\!Z;_9OA+P7HO\ 8-A;RR^?
MJLW^BC^UM>U6\'_(:USQ%>_\3#5M0[ZK7:4 %%%%= !1110!GZUJM\0S)YR>&_#FH>(Y8XY?(GFM]'TN\O+NUZ_\ 3IV].M?#WP0_X*$?"CX\>!_@
M#XRT?P?XP\)?\+\\1>/_ OKWAOQI%I4&J?!G6? GPY_X6IJ_P#PL'DF]LM0
M\*VEIJ&DZAIV/[5_MG3]7&<5]I>+M'?Q'X3\9^'H9HX9O%'@WQAXM<:QH-YH]I=79[?\ 'W^5?F;X9_X)R^)?"_Q-_9>\86'Q2T*VT3X;_L\7'PJ_
M:!\+Q:+=367Q'^(%G\$=8^"7@CXM>">O]C7^G:'XAU?P_P"+-/U$#^U?"G]@
M#'_$M)(!]\ZM\?/@;H.@_P#"8:W\6OA_I7A[_A7.G_%7_A)-0U[R-*A^%]Y=
M6=G:>/-6N_\ D'_\(/J-]=V>GG4!_P Q6\L.U>)O"7@_PK^T
M'\.->\3^.=?N=!\,:-9ZI=%UL\#2=/\0Y/BK2B-7T@:
MF F_\$_?VA->\!ZQ\.OB%\0O@6]GH7[*O@C]E#X<_P#"-Z!XI_XF6C^#
MOBUX/\8:3XH^(5W>WV?^*BT3P\=.U7P=IO\ Q*]+U7_F+=*^A_$G[&FIZQ\0
MOB;XYTO7_!^E0^/_ -L+]G?]INQ$>BW,&JZ=X0^ ^EZ-H^K>#KN[LKW-CKNH
M_P!D7G]D:AIN!_IW.>,MH^%=YKUK?3^&_"_PW\=^)/!]WJMW=WMCIVG_ &'[!I-KX@U;^SM3_M7PK]LL
M#K'OW:I=:'I6F>(/$F+SP]
M:W=I?:'_ &A>WWB+[)_Q2?B#_D%>*A_R!O[4/7X)MO\ @G=\8_%VB:7\+/B=
M\0OA1H/PU\&#]K>_\$^)_A=H?BJR^)FI:Q^TW=>,;.S_ .$UN3?Z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MGQ%?C(T#4=3\+Z3I:V=\VKYU8C2SW7[1OP>^(GC_ ,;_ !^,GPBNOA[_P )
MY^S[XH^).L:%X5^*]O=P?#KQKHWQ(\*_\(UXAMKJ]\,66HZEHFN^'!=6>H:3
MJ(TS.XW^D^IKQC]G#]BOQ%\"_B1\(?'FH>,_"7B%/!?PE_: \.>-M+T;PY=:
M5#>?$?X\?%FR^*EWJGP^^W7^-%\$: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ML/S_ !_S.<_+[_AH3PQ:V/BJYL]?^,$/Q+\#;Z#4M'T?5
M?MGA/2[3P]?#^S]$OM.OKN[U G3M,_XFO_((UBNMT[]K;P!X9U:\\2>&_AIX
M@MM2TO7KCQ=H.GQW6EZ5H?CSQAXD\+V?AKQ#JGQ-TG1?^)?HMCJ/V2[\0:3I
M_AW^U-*_TWVQ7S-\=OV??CK^RK_I/QR\'V?_ @<=U]EL/C9X#NKO7/A'>?;
M+K[':?VMQ_:'@N^U&^_YAWC/33I)_P"8/JU>46\T-U"ES9S1W-M)%YL5Q!*)
MX)>/Z//"7B+2?"OB2\T'PW+\6-4U32O&FH>??ZEX@^*E
MK>?:]!TG[%_S(_AW[7_9_?5?[)^W_0MT7]I:PFTOPWHGBWP?>7_V._\ "_B/
M6-4T^_-CY/CCP?XH_MCP]_9.DY_L\Z'IVAVEWX?_ +0S_:O]E?8*^4&4K]_Y
M/,SG_/XZ:Q\9(O%'A7QYH_B'2I+9]8^S1?#[1_#EA:
MV&A^#]/L]4-Y=VMW=WW_ !,+W_3KN[_M;P_J/]J?VKJMY_:_]K?\2TUX7110
M]GZ/\F!^OW_!*CCX,_\ !0'YL_Z7/^\./^B. Y/TX/X?6OQ^_9;AA3]FOX&N
M]AI_F2> [?\ =W%A:_O_ /2KS_2O^8EJ/X_IVK]A/^"4A;_A3?[?VS!?^T..
M/(_YI&?P'N?P[\_@=^SC^TM\ ?#_ .S_ /!S1-8^*_AO3=8TOP1;VNJ:?M]<:K#<]\9QI[OT0'W)Y5O_P! S3__ 3Z9_C1Y5O_ - S
M3_\ P3Z9_C7@W_#57[.'_18_"W_@+KW_ ,HZ/^&JOVM=; >\^5;_P#0,T__ ,$^F?XT>3;-\G]E6#^8?]7_ &-I?[X_R'^0.U>#?\-5
M?LX?]%C\+?\ @+KW_P HZ5?VJ?V%]\G_ #TM=>SZ=?[#YQ@\\_K0
M!Z[XD_MY='F_X0_1_!>I:Q_RSM_&G_$C\*0Z?_R]ZIJ]WHECQ_9W]/QKYHL_
MVFI(;/P-K&M_#>WTKPWX@T&WU[5)+.TNKZ?_ )"GB3PW]J\)G[#_ &?>Z']N
MTG2?[*_M'4_[5U7_ (3#PE47Q*^.'[,'Q.\&ZQX)O_VA+/PEI^L?V?+JFH>&
M[75/[5FM[.Z_TO0+O[;X5_L^]\*ZBM_P!HJS\1:#X?TOQ#:VNGW-K=:5;S7.L:7>6>DZI=VGACP/INGV6N>#+&[U;3
M])T[3O\ B5#5;S^UR?\ B6Z70!]4>$=63Q#X9T36+S3/":7FJ6OVJZC\+_V#
MKFAZ;J'VK_1+7[79?\?M]]ASI^J_]16\_P"H;STGE6__ $#-/_\ !/IG^-?)
MW@'XU?LP?#?P]<^'M-^-^CZJ]QKUQXCU2YU2PU[]]K%Y:_8_M7V2QT/_ $*Q
M^P_\P_3O^8KSK'?'M_P :/*M_^@9I_P#X)],_QKP;_AJK]G#_ *+'X6_\!=>_^4='_#57[.'_ $6/
MPM_X"Z]_\HZ />?+MN/^);IZ#_L#:5G/X8_2OG[]K 0Q_LQ_'ATMK-'_ .%>
M^(/*DM[#2X)_^/K_ )^\^G^>M3?\-4_LY-@_\+@\+GT_T;7A_P"X.O$?VH/V
ME/@'K'[.?QLTK2OBOX7O-2U#P1K%AI]GY6O0?;+B\NO]$M?^0'T/3_(H ^VM
M-M[/^S]*":;I\W_$FT>6UDL]+TS]R/[+LS=_:\>GZ]:O^5;_ /0,T_\ \$^F
M?XU\\V?[4G[.4=CIMM<_&#PNDUG8:?:RV\MKKWGPW%GI5G_R]G0SVZ_7UJ[_
M ,-5?LX?]%C\+?\ @+KW_P HZ />?*M_^@9I_P#X)],_QHV6_P#T#=-_\$VE
MUX-_PU5^SA_T6/PM_P" NO?_ "CIG_#5'[.7_18O#?\ X":]_P#*.@#WU8[;
M=_R"M/F_Z9_V7I?&?3M_(^E>$^-OB)JN@_%CP3X T^S\!^'M*U"+3[_7O$'C
MBU^P_P#">6]Y=?V/=_#GX>W?V'_A']%\<:=?8\0:M_:.J#^U=*_XE&CBF-^U
M-^S>HY^,GA?W\RUUZ?\ EH?Z=>*\B^('Q2_9[^(FK:/INL?M+:?#\.HXO-\6
M_#>/2]5GL?%6H>&]4^V>$_LFK?V'_:&B_P!G7W&K:AIW_$UU7VH ]Q;QG\0D
M^)FN_#&;P9\,[G5+CP'J'COP;JEO=:I?8T^R\46GAO2=+^+%I]@_XDO]HV-V
M/[)U#3?^?/D=<^<:5\:O'OB"1/#FF_#WX5W_ (LO/%'Q/TKPY>27^J3^!]2\
M+_"#0;/6/&^J_P!K7MC_ ,)!]N^W7?\ PA^DG_D%?Z'GZ\KX5^+7[/?A/6OB
M+KD/[5UYK'_"Q+K4-0UFWU2P^T3V>H7G^A:3JFDW=EX'TW4+*RT[[7_9_A/P
M_J.IZII7;_D,<&G?>.OV5XO#?P]T3PQ^T#'X O\ X9Z-X@\+Z#XH\/Q:I/KE
MYHWB0_8_%G]K?;M$_L_^W/$7VO/K_:M 'HO@C]I;1/$OC*YT36?!EGX4\)7G
MPOT_QY8>)+P:7Y\VL6>EZQK'BSP;=VGV$6%E?>'=#TG5O[)U '^U-5_T#MS7
MH7P3^(EW\6/ \WBW5?!.G^"[R/Q1K'A?_A'_ "K6?SM/T?['>>']4N_]!_X_
MM1T.ZM-0U;3_ *^QKY:U34OV)=3TM-!3XP6%MIL&J?#>ZL(]/.O0SPZ?\*]+
MO#::7_R _P"T,^(K&ZN]/^(61_Q-?MG/6O7?"_Q\_96\&KK=OH_QC\-I#X@\
M9>*/&5U;R1:[/Y.H>)#9_:]+M,:'S8Z=]DM-/]_IT /J+RK?_H&:?_X)],_Q
MH\JW_P"@9I__ ()],_QKP;_AJK]G#_HL?A;_ ,!=>_\ E'1_PU5^SA_T6/PM
M_P" NO?_ "CH ]Y\JW_Z!FG_ /@GTS_&B..%63R--T]W _Z!>E_3GMG_ ":\
M&_X:J_9P_P"BQ^%O_ 77O_E'36_:H_9R9?\ DL'AM_\ IG':Z\?7_J!_G]10
M!@_M8K;+X!^&\Z0Z=;/'^T5\#XOM%OI5I!/#;_\ "4W?^C77/X?3UKZ?O(+-
M;Z\3^Q]'1(Y;F*+R]+M?^?O_ (^L^AZ__7%?GU^TW^T5\!->\#> H=*^*_A?
M5;RW_: ^"^L70CM=>,%GI_\ ;]W_ *5_R \WOKSR?:OHJ\_:L_9O:ZN7_P"%
MP>&_.^U:A%-_HNO&#(NKS_J!@\=<4 >Z^5;_ /0,T_\ \$^F?XT>5;_] S3_
M /P3Z9_C7@W_ U5^SA_T6/PM_X"Z]_\HZ/^&JOV
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MHM_X+B\,:A)JGA+5+K7-#%OXPQ]D\+ZM=WMC_:'_ E6G&T_XFW_ #"M*-YZ
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M96E3_#BWN_MFD$W=J;'_B=7VH>*=)N] _L_4?[,_P"/._'>O+]8\=?L
MM>+;S6+SQM^TY<>)+[4_"\'A?2]0N+"[L1X/\,'Q/9^([O0O#PT3P/\ VC?$
M7NDZ5_Q,-1)&JZ5SH_:K=GXL_8VT_7O$OB33?C'I=M?^)/B3X?\ B=JEO;R^
M*)['3O$'ANVU>SL],TG[9X5_Y FI7VK7?B#[!IQ_Y"MYZ\D ^X&M88V>'^S=
M+WQR^5YG]EZ7_P >]G=7G?GCD?J:3RK?_H&:?_X)],_QKP1OVJOV;V9_^+Q^
M$RGF_NC]EUX\?Z9>?] /_I[_ )T[_AJK]G#_ *+'X6_\!=>_^4= 'O/E6_\
MT#-/_P#!/IG^-'E6_P#T#-/_ /!/IG^->#?\-5?LX?\ 18_"W_@+KW_RCH_X
M:J_9P_Z+'X6_\!=>_P#E'0![SY5O_P! S3__ 3Z9_C1MME5W_LW2_\ 5?\
M+QI=K!!QT_X\K''IG_ZU>#?\-5?LX?\ 18_"W_@+KW_RCIK?M4?LY;7_ .+P
M>&^>T=KK_/N?^)'Q^(^IH ^'?^"G<,$5U\$I$M[2 36/Q";S8K*RC%SC4/"X
MWD6WR94''///%%>9_P#!1;XZ_![Q7-\'I/!_Q"\.:]%86_C^#4)[.;6=)CAN
M)+[PRT:%+CP]:/.65'(D$9QC!(SR5E4^.7J=!_IAW^HV&F6=YJ%_=0VECIUO
M-=7MW.XCAM+>UMSMW\9[FX\&? O3;L #PU^SMX"NKP>'=3M!P+&]^*NM_P!K>/\ 50!C5-)O- _
MY!N*],_;Z\2ZU=?"?P]\"/!VJOI?CG]J3XA>'O@CHVHV4I^VZ-X0U8G5OB=X
MFZM@:;\.M)\1#[;T1KRQ.-QS7L&DZ#H_A;2=$\,>&+"WT?PWX3TJW\-^'-/M
M_P#40Z/9Z7_8^D^WU]?PXY -.BBBN@ HHHH ***13NZ=?3_..U "TZ&.2:9(
M(?GGDE\J)/;^7\J9SN1!DO)@>7GG_#/Z=?K3[>1X9X9D^1_];%(.?\_E^&:
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M"[OQ1)X$^"/_ DMH_V7I7_0'_LOC2ZYP/V-M_\ @IQ^QM=>!?%7C]/'GC2:S\%?$;P_\%M4^'__
M JKXC6/Q;UCXD>,-+_X23X>^%_"?PRO=#_X3#6O^$S\*_:_$'A/4-.TS_D%
M>^,=-??\%$OV0M)\7>#O VI?$+7+#6_%D?P_BEU"Y^'/CRQT3X>?\+4U2\T?
MX9:7\8]6O;'^S_ACXJ\1:Y:7?A_2=/\ &?\ 9>JG5?\ B;\5^9GQ6_9A^*_C
M3XI?$;X^_#WX.?MB?#'XV:Y\/AAXDD\!_L^^(O"O@/Q1\$_A?>?#?^
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M5["\TK5=+L]3TR_M3;7^G:G:V][97=NQQM ,$AOA=XTDU;QG^S=J@^!'CF[EN;^Z\(SV(UWX.>)-1!.ZYO/":YU#PO?7W
M;4?!NIZ4!D9TH\TOK'E'[SG/Y^_X=_\ !ZX[_7/_ -;WI:[[XR_!?XS?LTZY
M-HGQX^'6H> [.67RK#X@:?\ :M<^%7B3_KT\661_XDM\?^@?XBZ?I7 ;D:'S
MD??#Y7FBX_Y8"WSSQ_GK72VK/7H_R _7_P#X)4#;\&/^"@7SY_TN?M_U1P'/
MKQU_#!.>*_(#]EED_P"&;?@A^YLT?_A [?\ =7$7^N_TJ\_TG-D?_3CQ7[!?
M\$ID9_@W^W_%$H>66[$44IX[U^!'[//[3GP'\)_ ?X5^%?
M$_Q(M]!U[POX8_LSQ%H>J:#XR^W:/K%GJEY9W=K=_P#%*C_E^'I7+#[7K_F!
M]T[!_P ^]E_X 6M+Y1_YY:?_ . %M_C7SG_PUQ^S/_T5G1__ 0>,O\ YE:/
M^&N/V9_^BLZ/_P""#QE_\RM=8'T9Y1_YY:?_ . %M_C1Y:?\^UF_I'_9]IS^
M./KWKYS_ .&N/V9_^BLZ/_X(/&7_ ,RM)_PUU^S-_P!%:T1_^F?]@^,C]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M0/B1_IGB'QYJUW_PBO\ INN:=_:WB'4-)T__ )!7A75;P?V/_P PL ^T_!N
MLS>(O"FCZQ>6?A.VN;VU\V_LO#=WI>N:5IMQ9W0^R:7::K9'^S[W^SK'_B7Z
MMT_XFO;_ (EM=)Y1_P">6G_^ %M_C7QY\/?C]^RC\.]!O-!TWXS1ZFE[K.H>
M([_4-4T'Q1_IFLZQ]C^UW5I:'PKBQ_T&TM/^)?\ ]!47]=O_ ,-M='_\$'C+_P"96@#Z,\H_\\M/_P# "V_QH\H_\\M/_P# "V_QKYS_ .&N/V9_
M^BLZ/_X(/&7_ ,RM'_#7'[,__16='_\ !!XR_P#F5H ^B]@_Y][+_P +6O
MOVL%\O\ 9C^/$B6UO"W_ KGQ!Y4EO:VL$\/^E?KZ''2J/\ PUQ^S/\ ]%9T
M?_P0>,O_ )E:\5_:3_:<_9^\3?L^_&/P]X>^)&GZQKVN>"-8L-&TNST'QE]N
MU/4+RZ_T2UL_^*5_#\: /NJPA2/3=*A2VLU231M'EMH[>UM?W)_LNS^U_:[O
M\>,_EQ5SRC_SRT__ , +;_&OFRS_ &MOV:4TW3;:;XKZ4_V.PT^UECN-!\93
MSPW']EV?_+V?"O\ GI])_P#AKC]F?_HK.C_^"#QE_P#,K0!]&>4?^>6G_P#@
M!;?XT>4?^>6G_P#@!;?XU\Y_\-MC_\ @@\9?_,K0!]&!4_Y]K-^<&+^R[6?_/<9_*O$/&7Q#UO2?BSX#^&^CV?@
MO1+/Q!%!JEUJOC27^RH/&UO]J_L?5O!OP]U;^PQI]EXJ\._\A#5M/U'_ )&K
M2O\ D#"N>D_:X_9F:-_^+KZ&_/230?&0]?\ J!]L>P!XKR3Q]\;OV=?B1JVF
MVVL?M(?8/AI)%IUUXM^'MB;?V?J>EZKJI % 'L_@?XU3?%35_$^D^!4^%\TVEW7BC2_!OA_7)=4@US4KC
MPWJG_"-W>J:M:?V'_9__ BNHZY_:W/A[^U-5\*_\A?61FN&OOVC_&&CZ/;:
ME?\ A+X9^'H;SXH>*/AS_P )A)K7BB?XG^#]!^V:MXHN]5LO"O_"067]H
M^*OM7@_2?[1_XE?^AG'(Q7$Z/\4?V4=(\0)K=G^T'J#VVCQ_$";P'H]YX;UZ
M"P^&^H?%3[9>^++O2OL7A7^T+[^T1=W?]D?VC_R"OME_5]OC;^S39_#_ ,-_
M#KP?^TGJG@+PWH_ARX\.2QZ'X2U2^O=>T?6.-6_M?^VO"O.N>(OM>K9U#_F%
M?:ZYP/;+?XW6$/Q@\0_#'6]'T?2M!T/XMS0;2SO=#_P!"_L[0\ZCI/B ZG_:NK9Z5O?!/XF7GQ<\$3>*K_P )6_@^:/Q1
MX@\.1:'<2^?/#I_AO['>:3JEWTS?:EH>K6G]K:?^5?)6L>*/V(]8L_[''QCU
M'2M'CU3X875K;Z?8>,YY]-T_X66O]D>'M!L[L^%?[0^P^(K&[_L_Q9_T%1GU
MKU[PM^T=^RCX1M]>M]*^+6EI;>(/&7B#QM+')H/BC_0[CQ']C^UZ7C_A%B/L
M.G?9+33]*X_#M70!]8^4?^>6G_\ @!;?XT>4?^>6G_\ @!;?XU\Y_P##7'[,
M_P#T5G1__!!XR_\ F5H_X:X_9G_Z*SH__@@\9?\ S*T ?1GE'_GEI_\ X 6W
M^-.C7YCLMK-^_E_9;6#\AG\>>/7BOG'_ (:X_9G_ .BLZ/\ ^"#QE_\ ,K3E
M_:X_9FW?/\7=#7_N7/&7K[^%>W.!TR: *'[6+0CP'\-O)2-'_P"&BO@?%#<6
M]KY$_P!G_P"$HO/]%XZ=QU'>OJ*\\E;V\1+/3H?+EN(HH_L%K.?^/K_C[[\^
MO\J_.C]I#]ICX#^)O!W@*PT'XD6>JWMI\MV3_A%?\ CQT[_F+?YS]%7G[7W[,TEU,B?%K1WS=7'[PZ!XI\B;_2O;PK_GGK
MB@#Z$\H_\\M/_P# "V_QH\H_\\M/_P# "V_QKYS_ .&N/V9_^BLZ/_X(/&7_
M ,RM'_#7'[,__16='_\ !!XR_P#F5H ^C/*/_/+3_P#P MO\:/*/_/+3_P#P
M MO\:^<_^&N/V9_^BLZ/_P""#QE_\RM'_#7'[,__ $5G1_\ P0>,O_F5H ^B
M67:I=(=/_=YE_>6%K_Q[_P#+WC/X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MJ7FL>(=5-W_P@^?L7Q#_ +6SXK[_ -E6?_$H)[M 9HOQ#T?6-=U3Q)XHU34X/"L7_"-^,;OP?]F\)W=EX5Z>(K'_3](_X2(?\
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M_P" %M_C7SG_ ,-MK0!]&>4?^>6G_P#@!;?XT>6F7WVVGO\ NA_K+"U]>?Y_C^E?.?\ PUQ^S/\
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M>7?AB^./^$P\,:Y]A\)?\)!I/B#_A&=4TK5=5L_[(%>D2?\$V_@#9>+O"
MOB3PWJOQ$\*Z5X/_ .%'W]KX/LM4\,:KI6L:Q^SW=?VQ\,M4U;Q#XG\*ZEXP
M^P_;O^)AXM\/Z=J?A?PKXJ_YC%=Y8?L2_"NWU$KJ7B?X@>)_"UI\7OB/\8]'
M\ >(-4TK_A'-!U_XO^%_$OA#QMX7TG[%H8U#_A!_$/\ PEGB+4/^0GC2LG'6
M@#Q;P[_P50^ GB3P?XM\:6'@SXH7EGX;\.?#_P 4Z!H_ANZ\&^,?$?CSP/\
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MR?M(#]I:U\2:'JFE_P"A^.-8^'-G\*_%GA?^R;S0]2T__A!O$7@:T_L_5M.
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M_'EYX#U;3/&]V-=U/^Q=MT?\ 9Y\/1?9-9M3!!8?LS:J=:^'MS9VEY8#_ $W4,D>*^,ZJ !H^3DFK^S;^
MS%_PI7XX?M>_&^\M]-AU7]HCXQZ?XG\):19ZS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M&=@N\=#G!S@@FN[KX)_X)P:]>7W[)?P]\,ZJ\CZK\+M4\MQEK'ANUN\6:1=Z%XF\/Z1XDT6\AGAO\
M1]?TO3]9TV\M[HM]JMKJROE>R<'/S!RPP,G<,Y_&;]HG_@COX(UAK_Q/^RCK
MX^#_ (A>2XU _#/Q!'D \^'=3_LKK_Q*>./W
M HH _&O_ ()0? /XU? I?VH=$^-?PXO/ >I:Q\3/"MUHLL]W:ZWI7BJPL_!M
MG9W6O>'_ !#8?\AFP-^I7&I#^T]+(*$G.#^MC>'=#C+;]$TCR?3^S-,$$4 R
M<'-E^A[=^*ZBFL<+Q]!_GZ4 8W]AZ-_T!],_\%MK_P#(5(NC:*WW-'TAL=?]
M M?UQ9_RKA?BG\6OAW\'/"-_X[^)'BS2_"?A:RFLK235=2MK.S5[Z]O]29"FF6.GH9=0.]4 Y(\FUO]L?\ 9E\-:]X#\,Z[\7_"NFZ]\2M,
M\,ZSX7M[V>Y@BET[QA=_8_"5UJ@(*^&?^$COO] TG^U&TO\ M+4_E4M_P!CZ)C?_9.D;?7[!:8]?^?+.,?C[T_^Q-&_Z VD?^ -K_\ (=>)WW[3O[/=
MGX/^+'Q#O/B]X#M/!WP)\1ZQX1^,/B6[U^SATKX<>)_#EU9C6-"\6W;L!HNL
MZ;]MLR=.OP'S>6/#;Z]ELMMFM2W_/\ V8#J006 R W2@"?^P]%7 _L?2_\ P7VG_P ATC:+HB+N?1M(1$'7
M[!:8'YV?'X8Y[5;^WV+++LNX':WD\F39+;RR17(7FW(#L!='IL8$YX(KS>Q^
M*7@34/'/C+X>6WB.R_X3/P!H?ACQ/XNT\X@.@:+XPN;^TTBZNKJ[! &H'P]J
M@&>UH0?FQ0!WK:+HJ_>T;2!];&U_^0Z4Z'HRKSH^E@#O_9]IZ>UF?Y9]Z\=T
M+]H/X/\ B#2/A!K^D^-]/N=%^.*$M&L
MM"T?5;YOMP!O_LI()( /M[WUJLGD&X@\X0^=Y/G+YWD9QYX!^; ZYQCWR: *
M7]AZ-_T!],_\%MK_ /(5']A:1_T!M*_\ +3_ .0J\B\-?M ?"'Q9\4_$WP5T
M/QQI%[\2/"%I_:>L>%";BROX["V-H+ZYTR>]01ZS9:9>7=FFIMIKO_9OVZS5
MPHQN]4UGQ%HF@:-J^OZMJ-I;Z5HVCWVO:I>&59X;32+.V>ZO+MN3FT$=K.6(
MX;: N/X0"Q_8NBJ/^0-I '_7C:_TLZ;_ &+H3?\ ,&T=_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MW4#6FGWGB#Q)X0M;KD*+RS.N^%/$.G@@D!M)SD'J >Q_V%I'_0&TK_P M/\
MY"I/[%T5A_R!M((_Z\;7^MG6+K7C?P5HB::-;\5>'=(;6]5ET+1DO]:TZU;6
M-96VO;UM)TH-=(]]K L[2[OAI^GDZDRVK?*N!G(^'WQ*\%?$KPEIWCSP9XCL
MM?\ #&IK18H9OL5U>V5XMUG'V+[#>6MV&RP"XZX.2 =E_8FC_] 72O
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MFXAE\B7R9?+E$IBGXS 0O(/MPW)X&. "C_86D?\ 0&TK_P +3_Y"H_L+2/^
M@-I7_@!:?_(52C5=,9E5=1L'=YIK6-%O;;)N0>;8 .2;H=#&,N/FSG(R\ZGI
MRG9]OLP_FQVWEBZM\^>M]A:1_P! ;2O_ M/_D*K6B&=]D?F7,$8F..BG.6[X !/(SU%<[
MKWC;P;X6MDO/$7BSP[H5I/J]AX>AN=7US3=,MY=?U9MNEZ(+F\NT7^T=2,F=
M,T\$2R#.Q", &LNBZ*WW=&T@_2QM?\ Y#I?["TC_H#:5_X 6G_R%7.^%/'7
MAGQI9G5/#^JQ7]F-5UG0?.F_T!@2N<8) . *T=7\
M8^$O#<%I<:]XET+1X+_5]/\ #]E<:EJ^G64-YX@U9L:5H=J]W>*&U+4RMRL991RBMW -'^PM(_P"@-I7_ ( 6G_R%1_86D?\ 0&TK_P +3_Y"J\+RS/G
MXN[9C9'%U_I%O_HIVDXN@"#;' /#;3@$XZU$NI::\<,R7]H\,\GEQR)<6[12
MS=P&#'MHNOV&I>+?"%AH&J^*-'MMQ.G:?XEM6N]*NKJ[!-C=_VA96V%VME0 <5:\6?
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M2/H.C,.-&TG\=-M&_0V9_EWKMLGDISY8ZC+9SG)*Z:B@#\O/V#YO[0_9-^%/B%_\ CY\>77CCXH74G_/[J'C#
MQYXDUC_]77I7UW7R/^P3&B_L2_LJ['WB/X-^'_\ 5_\ /S_Q./\ 1?S_ /U]
M:^N*Z "BBB@ HHHH *MVL,0DCS6_
MVB+]W%Y\_P#QZG[7_P"E?OQ0!^%GPE_;<_:7DC\#>"?B=XVTN\\;?%S]KGPO
M+\$?'%GX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M_J(.K7^E6&H\-I5Y8D X'?_ !F_9"^ _P =O%^I>,_B7X:UN\UC7?"7_"OO
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MH'XD>&/AKX,LW.CW%[X0\'_"[P?XP_X0Z[U5B3=7VHZYJVK?Z<M7_['?P6\0> ].\ >)[SXL>)]+T?QO;_$OPOXL\4?%_QYKGQ-\$^.-'M?['TG
M5/A[XW%^/$'AC_0;N[T[5M/TX_V5JNE7@]P?9?@[\&_!?P,\(P^ _A=H6H6&
MCG6=8\1ZI>:IJ&J^(_$7BKQ!XDNO^*AU[Q#XAO?^)AXGUS4?LG_$V\0>(N=*
M_P! R1B@#X5T#_@IAX,\2>+;SP=X)^%GB'Q!JLF@_LW2_"^1]>M++2OB=X@_
M:/N[*T\6>"])NCD6-]\";W5K0?$/@'2@3_:Q4@$>=^"/VL/V@?%GQ(^&W@GP
MSH^F>)_A=XO^$'[8'C+QE\2/B'KVEGXJ>&]8^#_Q1\1^ ])U3P]9>&/"NFZ=
M]AT[[):#2; C2_[4'V'^V-7&L9K[%\!_L,_LM?#?5/A=XD\%_",Z?J7P'\;_
M !0^(WPOO!K.O7\/A;QS\:S>'XA:G=VE]?$7H(R-)_M%?[+TH$[2IYK3C_8U
M^ >DS?#34[/P9X@T2Y^%MQ/X5\1:YJ]WJ \/ZC_Q*M*U;/]CT ?.W["G[4?Q1^)ND?!_X7?&_P)-HOCSQ
M1^S-IWQS\.>/[KQ9I?BF]^(_A>S\3+X/\0W/C6TLM/7_ (1KQ1J5]=Z3J7V#
M3CJVE:IIK,O]L:5MVK^D%>0^#?V=/A1\.]<\#Z]X2\'R:/XA^'?PFN/@MX.N
M9+_5!]C^#]YKUGXDN_"__3[_ ,3RTL]0&H'C_0^*]=_A1\_)(/W>?^6Q_P#U
M&@!:*** "BBB@ ITM\"_888:/K7[8W@="$LO"_P"V#\4+W3( /^/.Q\8VVC>,%M>3D*#>-P2M:_0:OSW_ &-?^2T_M^-PT1_:@M_*QV/_ KGP?T^G;K^ K]"*YP"BBB@ J*5
M=T;(>A7',9E]ON_Q'V(YJ6B@#Y'_ &M_A1K7Q=^#UUX7T7X>67C_ %>/6?#V
MO:5H=Y\1]4^%=_H.LZ/=7=W:>)_"?Q!T6PU+4-%\5>';XV6HZ03IITLM:XXR
MN?@#4/V+_P!KZ?P'\6?A3XEUSX7_ !+_ .&M/!WPOT7XV_&O7+^ZLO&7P_\
M$/@_PMX<\'^(;K2/#HT(Z?XUL?["\/'4O">H#4_"YTGQ[=W^LG2 -2)K]MZ*
M /P7\?\ _!+?XO>*7^+F@6/C3P&OPX^-5Q\>/$'Q-\&ZF-5N3XU\MRSK]YMX4^(FA?"OX>CP/KO@OQ3XAU7PQ8^"OB!>7G@R[L_V@O"?V+3M3T_6O%/@T>'
M]5&FZ??C3-3C6\L_[(=?M^J,OZ=T4 ?@_P" OV"_VI_A_/8>+](D\$V?BWP!
M=?"B76=&L_B5XIGL?VK/&/@+Q-XQUGQ%\8OB#JUYH0_X0W7O&=AXJM6_LQ=-
M=SJFD7^EZOJQT3^RR*^G_P#!.S]HW2]#\,3>)[CX;?%4VVC_ @TKX@_#+4_
M'OCS1-$^),'@VZ^/!O=)\0>*AH9U$Z)XMJ_>BB@#\%/A5\7=7_9P*_\ "?>!O%/B?Q/X5\#^
M*@/A=XQ\"6O_ COB*RT/4?$##P]KGB#2M1VZEI>F-XITJS8ZPW]K%0N%^SO
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M?#3P_M:MJ0T8,P&KE<^8?!?_@GYXY^+_PZO]3O? "?#WQ#X;\._M#Z7X2U3QI?^,O!
MMA>_'#Q[:_"NZ^'OQ9^'OA3^P_\ A(/#'@CP;9>%-5T :?XBTS2]6_X2JSO_
M !:HU4ZD0?Z2G^Z?P_F*C4!=@5?D]#_RRXZ =N3_ )% 'X0WG_!-O]H;7KK]
MH"'Q1X\N-=UOXHWPBB\>7OQ0U_3]*\5>#]:^*'@_Q?=>%O$/A31="_X2"RO_
M [X6TK5O!^DWY\3:GI>E:40-'&=3U.OI3]M/]A?Q#^T/X1T#X9_#U/!^@?#
M+0_@=\4/AB_@CQ!J'B#3/#AU763X/'P[N?[*T5-0%Y9^';[P]=WXO+_<1A26
M=FY_5"B@#\H?VS?V1OCU\9M=_9[MO@[>> ?"O@_X7_V/=F]O+G5-*\;^$=7T
M;7/#5Y:-I.KV5EJ?_%*#0M(NM-.@>'O[*U4ZM]@_XFHT8ZE6A\!_V,_B_P#"
M[7?CSJ6H>,-#T5OB5\)M7\$^$];\.76J7NJ^&_%&L_%OXU^/%U7%\,BRTVS^
M('A[:0-V^RO<< X_4ZB@#\!_#O\ P39^,<[_ S\1^)_ /P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M &=?>+-)SJ!&E_\ $KLR-(TG_B6Z77'>._\ @F?^TM\4]6^-M3X)6'P]L/#_]L:^/#GCWQ1X:U3X<:OX3UWQM9G0_[1^W9\)ZO8ZKX@U#^U P
MO-/8>%-,4ZF3_0I10!^)5E_P3V^-UC>VD'@_Q!X?^%W@7Q]\5/&L/Q0^'WA_
MQCXSFA\+?L\>)3X<\7:3X7\$W5IBP/C?P_\ $?P[=[6TX:7I!\+:Q?Z2&/\
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M;4]4L?!_C7Q#\'_B+^,-7M;"Q:^TC6O&'P\O!ILFI7[:MXG76;3:6&D\
M5_09L7T_4_XTZ@#\&]'_ .";'QYTGQY\&K[4_&$]YX,^'UUK\?AZR\)_%#5=
M$O\ X2_;?B-K'B[2+O2;K6O"NI:CK6AG1+JT\/:KI^G:GIFJ_P!E@Z.O_$HS
MBMJ'_!+?Q[%HGA*%['X<>,XM%U3X$_$_QEX/U_Q/XSN=,^(?QG^%GQ:\7^)/
M$'B>]N]9L#865]_PA&OZ5IWA3Q 1_:N[2/['']EZ01J=?O;3=B^GZG_&@#\R
M/@?^S3\=/A?X8_:UT+3_ /A"M-7XL:QXGUCX2Q>-];U_XCZY'K^KZ5>VMU<_
M$KQJ/[,U_7/"VHWMQ;6&D:< ^J^%=)20+JFJ?\2_'R3\'_\ @FE^T)9:%I5G
MX_\ &NAZ(= F_:>U_P $V.E^*/%%]#\+?'_Q>\+:1I'P^\3^'M)T:RTWP_>G
MP;KEKJOB 9.I_P#'Y8YQJ_\ :E?O?10!^/?P/_8B^+O@;]D?X_?"&YU+5/#O
MQ0^*6GP6&F7^I_$$^)-$L]?T?0+32!XRTFYT/0O#G_"-'QG>VMUX@U9=/_XF
MS:K>@ZO@J,^?:U_P3A^,K:1XIU7P[XO\/V?Q"\;VWQ8@^(6J1^+?'HA^(&@>
M(O'/@3Q)X)^'6K7=]@V6A'0_#OB+PEJ;:>-OAA/$@?1B5.I&OW%HH _%.?\
M8J_:&T'Q#I?Q+^&/@WX4?#V;3)?A_=6'P/TSQ]XJ_P"$6L]'T;X=>,/ VK:%
M>>-[+0O[0N[W3KWQ!:Z_I-A8:8-)#6:J=7W-@^5:'_P33_::@U;P!'J7BGP1
M/XJ\+:/H,NC?M(R>-O&!/"7A-K 6-]8V'CCQ!_PG\?
MB+4-3&IZR&OCJIT[5F0U_0#10!_/39_\$V?C_!\$K;P/?Z9HOC*\N-8\M^&_C[XNZLW@#Q!KWB+X8VG@/P_\ &+P]=^%O NG'1M=T_7+6[\8:EX>\0Z9J
MK:Q_PD6H?VIJNFZNI_M+]J_@1X"UOX9_!OX5?#O7[BPOM8\"^!- \+:G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M_M!?";5/ GBBQOO"&G^)/A?XE\8>'O 7B"[OK\#Q-9?8=)QX3\8^'MND^/\
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M#FGF[N[W[,=)O=;^P>)[_4-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M[[07SZK:V&J_9Y+9]M7GPM\0_"'P3X%TGX1^!/B!XQ\,>)_B+9?#^RQ>>-=-\(:HFL6N@:M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MI=:C86TD@WQQW-U;PD@]QEA[\_,?M != &U16+_;VA?\ 09TG_P &%G_\71_;VA?]!G2?_!A9_P#Q= &U16+_ &]H
M7_09TG_P86?_ ,71_;VA?]!G2?\ P86?_P 70!M45B_V]H7_ $&=)_\ !A9_
M_%T?V]H7_09TG_P86?\ \70!M45B_P!O:%_T&=)_\&%G_P#%T?V]H7_09TG_
M ,&%G_\ %T ;5%8O]O:%_P!!G2?_ 86?_Q=']O:%_T&=)_\&%G_ /%T ;5%
M8O\ PD6A_P#09T?_ ,&=K_\ %T?V]H7_ $&=)_\ !A9__%T ;5%8O]O:%_T&
M=)_\&%G_ /%T?V]H7_09TG_P86?_ ,70!M45B_\ "1:'_P!!G1__ 9VO_Q=
M'_"1:'_T&='_ /!G:_\ Q= &U16+_;VA?]!G2?\ P86?_P 71_;VA?\ 09TG
M_P &%G_\70!M45B_V]H7_09TG_P86?\ \71_;VA?]!G2?_!A9_\ Q= &U16+
M_;VA?]!G2?\ P86?_P 71_;VA?\ 09TG_P &%G_\70!M45B_V]H7_09TG_P8
M6?\ \71_;VA?]!G2?_!A9_\ Q= &U16+_;VA?]!G2?\ P86?_P 71_;VA?\
M09TG_P &%G_\70!M45B_V]H7_09TG_P86?\ \71_;VA?]!G2?_!A9_\ Q= &
MU16+_;VA?]!G2?\ P86?_P 71_;VA?\ 09TG_P &%G_\70!M45B_\)%H?_09
MT?\ \&=K_P#%T?\ "1:'_P!!G1__ 9VO_Q= &U16+_;VA?]!G2?_!A9_P#Q
M=']O:%_T&=)_\&%G_P#%T ;5%8O]O:%_T&=)_P#!A9__ !=']O:%_P!!G2?_
M 86?_Q= &U16+_;VA?]!G2?_!A9_P#Q=']O:%_T&=)_\&%G_P#%T ;5%8O_
M D6A_\ 09T?_P &=K_\70OB+0W^[K6C'_N*6O\ \70!M45C?\)!H7_0;TS_
M ,#K3_XNB@#\[]4A/PR_;Z\364BO%H/[4GP(T?7+!,F&";XC_ ;7S9:K:VIZ
MG4-1\#^*[/4&/_0+\-GDU]1LNTX_S_G->!_M^Z+?:+\.O!O[1_ANSGN_%/[*
MGQ%TWXLO96\>;C6? &UO#?Q9T#GDV>H?#?7O$-^.3_Q,["PZM.U70;F.\\/:Q8:?JFEWEO+Y\%[I^L6MG>:3=6EV>/L.HV-W9_F.>>0"2BBBN
M@ HHHH *0_,O'IQ_.EHH ^;/VM_B[\8_@A\#O$7CK]GS]G_7/VI_B_/K/@_P
MGX)^#FAZJ/#=O>3^([H:0=>U?5FR-%\*>'0+N_U?4<\ ]C@C\:?V=?\ @KQ^
MV9I7_!0[P'_P3L_X**?L?^ /@/\ $+XVZ+M2;75LYT_6]#U&^TF[T_5M0&!I6J?A7[3?M3_ +47P@_8Q^ _CG]HKX[^)HO"
MWPX\!Z8!J#VA\[7-=U>]./"O@[PGI6"?[=\17F; # R1@E>H_ K_ ()A^ ;_
M /;2_;"OB%XQT4_#[]@_]EB7XE^%IO$?PW^%]Y]KT?P]K
MNKZ3]N_M'_A*]3L;O5_[)T\#^U!JNKZAJYVZ/_90(!_2AXX\0:AX1\$^.?&>
ME>&-9\;:KX;\+ZQKVC>!]'E_XGGC#Q!H^E_;-)\,:3Q_Q_>(KZT&GXZ_E7\S
M_P 9/^"VG_!2+]C7XA_ OQ=^W;_P3@\"?!G]FCX^>*;;POH#^$_B#_PD?QA\
M'VUY=6OV72_$5X"/#_\ PE>FV-V+_5M.P*OC9X/
MT?\ :!^&^I>+?V8]*U#6?VA_#]OKUK?:K\)=&L[8WEWJGC>T'-E_9UB,>QS[
MU_,J?'W@W_@N]^V]\/\ XT_$3Q[X(^$G_!+/]B3QR9OA7X?^(GQ!\,>%/&W[
M7'Q=LKL7EMXUN_#]Y>Z?_8OA;[9:VNR\U!M9/P:_;6^%?[%O[$G[+'PO_:9\;?%3X!:Q\??M/Q!^(-SX OH=/L]>^Q:MQG^
MS_\ CP^R?4^N:]=;]K[]M7X1?L _M4?M:?MA_LH_#?X*_&SX#^'/$'BCPG\'
M_"?Q!_X3'PYXJ\'Z/:6?]DW5WXA_Y@O]HZY]KY_Z<^1Z^?\ [<'[!?[,O[7W
M[4.B_'C6/V]?'?[*OQW^%_P5MO 8@^"GQ<\!^!]=T+X8>)/MWB32O$]Z-:O/
M[?N]"\1#[3A@6TO5M*M&^5=H+_B9^SM^U1^T1\>O^"/O_!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M;:\\,_!O0;SYM+\&^'O"]K&G8:/I5G9?7_EU/Y^F*]"HHKG **** &O\ =/X?S%?EC?\ P(^%
M?Q\_;N_:)TWXO>%I/&VF^$/A'\#G\+6=_P")/$UC8Z#_ &R?&(U@V>DZ-K>F
MJ6O_ +';,;_:22I4>WZH5\(?"_'_ W_ /M8[,;_ /A3?[.WYY\>>G_Z\^U
M%;Q#^PK^PQX3T35?%'BGX8>%_#OAO0["XOM8UO7/&_CO2]'TO3K0YNKR[N[[
MQHEE96@&TM>EL -G<3@UH:?^P/\ L2ZK8V6H:=\(=!O[#4;2WO[*[M/%OCJY
MM+NQNE#6D]M?MV0PQ&]>3]F_X@^79
MQQ7$XG!TLD6I^QG/^G@;>#_%R#U'Y+?'K_@H5\'=:_9)_8A\#?L\?M+?%"'6
M-4\)#P'XB\2? _QQX7^%?ASPWXQ\!_!'PWXD_L'XQ_$SQIX4U+3_ O?:=?
M?V3X/T[3?[5\5:J;_1\#&: /W$7_ ()Y_L9OC9\%=,;W/BCXB=?_ K,5)_P
M[U_8T_Z(IIW_ (4_Q$_^:NOP"_94_:6_;5_:K^(?[#>F^,/VJ?BQ\.=$M_\
M@F]?_M7_ !:T[P7X#TJ&#XM?$CX;_&_Q'X;M-,\;W=]8B_LK#Q#H?]DMXMT_
MP[_9A\5"R.D#^S#J(S\P_!;]NS]N#Q3\$?VC_P!I3PA^U)XT\9_$;P/^QEXA
M\8Q? /7/%O@/QQJVK_&?6/B.+3Q%\9/A[\'-$\*Z;J/ACXM4\4?V7JMF 7_ "-'Q$ZYZ?\ (UXS^/XT?\.]
M?V--JO\ \*5TP;QC)\4?$7![8'_%5_KC\Z_/S_@CW\6OCM\4]7^/1\:_M%^$
M_CW\)(M"^$^M_#VTN/BMH7QB^*GPV\4^(] O;WQOI?BWQ=X7\+>&K :%XBO1
MI6O^%/#^I::-4\+ ZAHIR-/(/YS?!3]N?]J3Q=^T'\$=M_@H;\1O@/\:_^"=\GA+2?^%??"O]E_PU=?$BT'BC[(-#_M#PO?>&_ ^D>$_B
M"/B!J/B4#Q3JNL+I(SC /Z'O^'>7[&[?\T4TP_]S1\1/Y?\)94/_#OC]C'Y
M!_PI?2/WG^J_XJCXB'/X_P#"6<]>^VOYB?V5?V__ -ISQMX^_98U+1_VX_B/
M\M_A3PF1XPU'5,>*3K&H:2 !6-^RK_ ,%$_P!LG5=-^%7COX1?M8_$/]M#XR>+
MOV"_VG_BQ\>_V>]<\$6@\-_ WXC_ LT#[5\&[JR^PZ'IH&N>(M<:ZTT:=J.
MIC_A8'V3^U@,=0#^I/\ X=Z?L9[MO_"EM+W8\O;_ ,)3\1,9Z_\ 0V?Y'\55
M&_8$_8G6XMK-OA#X?6[NXC=6UK)XO\M=T?]N3]H_P /?#;XUZU\!?VY?BI^U/I[_P#!+?QS^T3\8_&'BCPY9W _9D_:
MML]3T;_A$]!\.76B>%M..AWNHW]WX@TW_A5VI?VGJNE:7HW]KXVX)]B\8^ _
M'WPY_;8_X(T?$3]H/]O7]HC4)?BW\._B]XBU/XB>(;KP_P"%?"D/C[QAX?\
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M^)_#>M^'OB%XQU6PU[P[>[/LNOZ6;/QHXO-'O>=M\"4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M&?\ D:OZ9[YK^8_Q_JOQH_9:^,G_ 59^*GP^^._Q4\/'Q/_ ,% ?V9_@G\9
M_C'JOAC0?$5[\&?@A\2/#'@_5_&_QNTD67A4"SOO!>AW?_" >$[_ /XFNE:7
MIF&U?2 1D=K??M7?M=^(=(OO@_\ ?\ ;7^+GBWX(ZS_ ,%/?@-^S+\&/VS[
MGPEI?B3XB^*?AUX[^'-[J_QB\,?VK>:)IOAWX@V7P\UIBNE_$%=,TO2_[3 5
MF(50 #^C=?\ @GQ^QC)(R1_!?27=/X/^$H^(G')Y/_%5]>>P/\JE_P"'>?[&
M?_1%='_\*GQ[_P#-57D_[5=S\5_@I\$_V;? O@GXR>.X?%6J?&;X/?"'Q'\5
M[VRTO7_&/BC0=9N!HVLZWK]K]A_L_P"VZA@7YU *HTLDM]XMCX\\*?$7]I7P
MIXJT#6+C]HKXD>,M(\!_MW#]F;_A$/$&@Z4=+\;_ XO+2SN]5U3Q;=V6A_V
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MPO\ !O1]\G^JC_X2GQYWY'_,UD>W)'^'P/!AX
M/_:!T?P5HGP\\5^,M*\*Z%K_ ,&&TRS.K'2?!%[H9O\ Q1KOB(F[_LGQB-2
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MJC_D$^%3=WQ^]C !^CJ_\$^/V,69XT^#&CEH_P#6Q_\ "4^/.OO_ ,54./3
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MOX*\5Z'/%GA;Q[XYU;1M>L&X%WI>JV7C5EO+/((P"RD@G&*ZA/V _P!B
MB6[GLX?A!H#7EM")KJU3QEXY$T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MXK.J:_IVI:7_ ,*__P"$;LMP/X7NK"Q\1^*/$'Q"\96&BZ/J&K7=GH^EVVJ77_"4_Z'>:A?:M:6"V1QN%Z,
MK@C/HEM^P!^QE=V]O/:_!;1)+:\BMKJ*2+Q/X[(EMKL VER/^*JYR"".HYSD
M9P/Y-?V@=)N?#?@#_@O3X!\2_';XIZU\5+CX^?!#Q1:_!OQQ"/$6E0Z!XE\=
M_!2]TKXUZ1X?-C_IEAX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M[_\ !/7]C9%9W^"NF(D?[W/_ E'Q%X]SGQ6/TZ=A7G_ ,/_ -D7_@GC\6=$
MU#Q'\-/!G@3QSH.EZ]K/A:_UGPOX]\8ZM9V7B'PY=FRU_0KNZL_&C*+W3;P&
MRU2P9@0Q5'7#5^%/ACXI_MS_ M\=P>(=6_;D^-WQ(\.? __ (*_>'?V&HO!
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MUBQN=+U2SNXQ/#>:==VOV.\MKKD9%]9-M8$ CDMHFDFU_\ 9PO_ +5\,[S43^_\8?LX>,/MEY\)]4%T>;T^#+W[9\+_ !9J '_$
MJ_L;0B?^0ES^HU?G]^V=\./%NFMX"_:J^$.EW>N?%G]G:76;C6?!]CCSOBU\
M$/%QM%^)_P +B!D7E^+*TM/%_A,;B1XK\-6(QG422 >\?=V=O-^O7C].]+7.
M^"?&OA+XD^"O#/Q$\#:K!K?@GQOH-MXB\.ZQ:0&W_MC1[RY%I_9=T_;
MB-/RI(!XZA@.BKH **** "BBB@#PG]HS]F7X _MM6=/\42^$]8NM4L;'_A(/#=U]LM-4^UZ+G4/MW_4/QWS7QS\//^"+W_!+;X2?
M$7P9\6OAS^QUX+\-?$?X>:[I_BSP5XGM_$?C.^OO#GB?PWSX>N;6TO-=&G7M
MCN"G^SSD<# S@C]/** /DK1OV"?V-M"\7?M/>/-(^ _A2Q\5?MBZ-MB76O_P#%TM'O+5K.[T'59
MHTA?]ACX?W/V>*W\G[1XH\>?ON?^/6\N_P"W.V<_VA]:_76B@#\Z/VC/^"2G
M_!.[]JWQ#X5\7_'7]FGP[XR\5>"_!WACX=:#X@TO7->\*ZW_ ,*X\(VIL_#W
MAC5KJQU!?[:L?#MF?L.E:>/O<]"VX?0>C_L;_LK^'_V9_$/[&WAOX(>"O"7[
M,'BSPWJ'A+7OA/X7BNM*T/7=(\2?\C#_ &M=_P#(P?;]1_Z=3'^/TI10!
M\D?$G]@S]CWXP_LX>!OV1?B9\"_#GBS]G/X:#PP/ ?PXN]5U2WL?#8\(@C0!
M::N+_P#M#&GJ;S3M7'<$@\9%='\8/V1/V9_CSH_P1T'XN?"#0_&6A_LV>*/#
M_C'X):,+K5-#@^'&O^#]+LM'\/7.DVFB7X^W#PYHEG96&DYX) XR 1]*44 2
MR2O-<33/\[7DOFRR>O\ 7'Y=\5%110 4444 %%%)\@1W?YT_U4L<M.N/?KW(!R_C;QKX9^%W@[QA\1O&]W'IWA#P!X=U?Q/XCNWVG&GZ1;"[-O:Y*
MYO+\&TL=+ .XZG=V(0,V >!_85^'GB31_ 'B/XW_ !+T^33OC!^T_P")[CXO
M>-M/F0F?PWH%[:BS^'?@3D$V=GX+\$+I&G_83\RZJ;\@G)QXAXYM?^&MOVAM
M+_9OM6DO_@A\ M>T+XE_M0:@J#^R_&/Q.0_VO\*/@ ;L$K>+X>_T3QE\0=/R
M2$M/#^D.$T.UD$2")4'E1O&!^Z'?CICMSCTKG OT444 %%%% !7P?\
M+_\ D_[]K/\ A_XLW^SMS_X7O/2ONY_NG\/YBOA#X7?\G_?M8?\ 9(/V=O\
MW>Z /K7Q9K7A#2--AB\:W_A?3-)U^_L?#%E;^);O2[/3-M?7^IW6X:9IR$OJ; )&C\FN/T/PE\&O$6F7EEX>\/_"WQ!HUEXCSD:/X.U
M;2H?%.C76VZ-W;6-G_9]GXHTX!K A\ZKIAM5S@J17\EW[3/[5WQE_:1^.6D:
M;\1_VC/AEX5\'_##_@M?^S_^S]X$_8HD\):##\3M(\/_ X\96A\/?%N\\6?
M;CXQLK[Q%]KN]? _LS_A%-4TB\L%&K # Z(_MP?'WX,?L_ZQ\4? /C#X;_ O
MX%>%OV]OV^+;]I76/@GX,^%]Q\8K+2/!_P ;OL7@CQGX3^$_Q!US3=/^)VA_
M;_[6_P"%V_\ "._VIXJU7[78?V/I/04 ?UE>(/A]X,U_0-=\/ZCX9T?^Q=?\
M,ZUX+U)+*T@TR\F\,^)+1K+5]+MM5L/[,U#1K'4!=78/V A=X_M0,'(KX@_9
MG_X)?_LQ_LM_$+PC\2/ Y^)GB_Q'\./AKJWP@^%,OQ,\8_\ "5Z7\(_A=XDU
M*SO=9\&> ++^Q=-6SLM1.D:2FJ-KK:OJO]FVRC^U&"DM^2EY_P %%?V]?B?^
MW!\0_!_P0U+PI#\/OA!^T1\&/A7'\*_'6H_"?P%H?Q'^"'CW0?!^L>(OB-JO
M_":W^F_&$?$7Q%8^(3K_ ,/-.\%Z9J>D ?\ $GU<#.*S/AW_ ,%.?VA?&/[;
M7@GPS\+_ -H;1_B5\'?CA_PVOX7T>#XR?#KP+\+/!/@OQA^S=H%[=^';K0+;
MPSKNI?%'1_ ^F^*;6UT_Q7XP^(NFZ8/%.E6=_K.C=B #^FK1/!GA?PA#>6W@
MKPUX8\'I>W(OK^+PSH>EZ)]LN$Z75U::-9Z=]M;K89U $G +'(%36W@_PC'K
M%[XOM/#'AJV\5W]I]@O_ !7I^CZ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M^V;^T%\?_P!GGQ1^QIX7^''AF;QA^R/X6\"6_P 2++P[\1EO?MO_ E]]KO@
MW_A$M*\0>+;[XAMIGA;5/[8T_2=) ##(!_3-<6'PH\&SKXMZ;_8%Q8^%O#\OQ \4-9W=_=:?_9+6L;>*=8U&SM+N^8;=2E?3!?' 4!JZW4O
M"GA?5?[/AUCP]H&JII%_]KT*WUC1M-O8-!N;3Y;6Z\/VM[8XL67_ $4?;M/&
M00.05R/X@_@OJ/QS^*?[.G_!*'3)/VQ[/XA?%^__ ."G_P 5_#'@WQCXQ\.Z
M3XJUK]G#6='TSXV:/>:5X@\.WM^=1UK7-0L;.Z\0>%/#_C0!?"OVT:0I.D;@
M/KJ__P""GW[/@J?BAI,WQ$\2?M._ML?L_?$#]H_P1X;^%_AW5/%5
MO^RA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MN/#&
M_B)9>$=9_L2S^,'QN\7_ !C^(/BCXE^++:?4O%WQ0^*EW:76K7=YJE^--!O
M;+2]!T?0M_P# 7]J_XF>*/ 'C>_\ A-I%E\#O&/PJN]7_ .%3Z9X(\/\ @J^U+XP^)['3
MAI']G?%G3_B'X9TS5&U.\.JZ3P2*\NO?VL?VL?BU^RSXQ^+OQK^*/@/XV?!R
MX_: _8"\,?"KPM\9/A+\'+?7!XP\=?$7PW>_%?Q/JWA[X?>*M3%E8>'KZ\_X
M1_X>W_B/G5=)SV!- ']A!\,>&)X-;BGT/0GMO$@@_P"$BAN-'TQH]>#VHM+<
M>( 0?[8'V(#3U&HEN !!IW@SPKI=II>G:?X5\,:5I'A^6"[T#2H-!TRR
MLM"N;0$_:=)L[.S%AHQ]+[3L8& .V/YAA_P4L_:MN?C9'\2H/C[\-U1_^"FB
M?L0'_@G'%X-\,3>/[CX0#75\-W?Q/_M@7X^(%GXKQMFU7:>:W[//\ P4"_;SU3XH_LI?$/XB_M ?#7QK\(_P!H;]M+]KS]C/\ X5"G
MPKTKPM8Z#I_PBM?B/=_#[XB:IXWLK[4M1N]<6]\(Z0=7"J-(.EWN02VZ@#^J
M2\L["]54O+.SO5M[F"YC2[M1>F*<'BM227W]J2?\2RUBGDU')-M=$L03K0XQ?\ #M'P;_ &G_ (KR>-?VB/AQI_AKQUXB\%^%M(^'5[\"/#OA?Q+KWB*S\)^)_@G\
M5?ACK>I+K?A;Q#H=E:?VIX1\:#_A+-(U0,-6.UW!^)O"?_!4;XZ:O^VUX>\.
M> _C[?\ Q7^!WQ3U7]L?P/\ V)XT^&?PY\ V/@GQ!^SAX,\7^(]*NOAGI6BZ
MWJ7Q0OO^$>US1QX?U;Q!\0],TO2?'^EJ-7T@G:* /Z?+7PWX>M+^^OX=$T:"
M\O)9;F_N(](TV"_FGNK?['=&]N[2S+7K:B#^\8G=( =V[A:J-JW@IM?L_!":
MCX83Q?8:8=>TOPJ9=*@UNST<7)LCKEGI(/\ :-G8@YL3J-@-HW<$L !_*/\
M!?\ X*=_\% _!?A#X+_&CXJ?%KX?_M 6O[2O_!-?]IC]JCPQ\'_#WPOTKPM!7Q _9[L[2[\/7?A[5]%OM2U'QG9>(AJH7Q7I_!&!C QW__ 38^*'CGXP?
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M#=]JUMKMQH.AWVJQP"*VU&YTC3)]4@M[HDG[+JEY9&^7Y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M#[QYK(^'&N:K!XA^(NO6>D^*M*U;P1X+US4OL6ABRN\Z0-1QJP^QYVM^U
M!\1_C;^S)^QOJOC8_$C1?$GQ3\.:CX1CO_'^J^$;7^PI8/$7BFTLKHW>@+>D
M65C8V-YG[<7# $(#OP ?<=]X6\,:FRC4]!T._1+HWT4=_H^F7O_ !,.?^)H
M#>6)(O\ W!SQQT%6!IVE7:WSS:993#48K>UO_M%A;?\ $QAP<"[PI%X, YL2
M?10"2 /Q#U_]M;]H'P+HGQ[\.Z;\3?"?QHD\-_%CX ^%/#WQK\+^'=!L-#\*
MP?&"UN[KQMIAL[N^/AYCX-6S']D:CJ6I'3 MV!K&.0>TMOCS^U_+#\!_AW/X
M^\)^$M?^*_[0/Q'^%=M\2+BP\&_$#7-8^'^D>#O[8\/Z[J^D>%[T^$-&\<:?
M?9_XEVFZD=*.2"#G% '[ 6'A[0+*QLK"PT/2(++3[KS+&SM]+TVRL=.N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MXT"&--"TR#_BGR3=_P!@V@-B0=#Y'_$O).EGIC(%1OX3\+)=Z9K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MJ*3:1HDAU>**RU5)=,TRX.MV%GFU%KJ@8%K^QL S "_R$'R 84_D!_P4U^+
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MM3FV%U:7@U&Q/V [B3CD],'BOXW?V6?VO/VH?@Y^S/X.^'R?MR:9>ZQ\>?\
M@IC\7OV:O%GQB^*'ASPOXCU7]COPQ:>,?B/JUYK^JC6==&;SXJ7NE6EA\/M-
M^(@TS2O"NF:O8'1\:0 1^U/_ 3^_;$^)WQ+_9V_;%\2_&[XL^'/B3HO[)/Q
M@^-OPU\.?M5>$/!UI;Z'\6/A_P##?0?[8_X6':>$M#)T[6=<\.E[O3]6L?#>
MI'2O%6J:,/[).-06@#]8I_!'@^?Q+9^*9?!_A>;Q+I]K]BL/%=QXMO:Q;0-$6PM[\7UE8'3-+^P6FH&[
M6Z%W:V84V*W_ -OR1J U$:FS.3SQ_(AX0_X*=_MT^*;/]H*?X.?'*X^,%MX
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M;U+0]6^WZ5?_ [TW^R_"VJ_8/[7!QJF0#^K.RT[X1>-7FL-+TSX;^*8? .O
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M:AY0&310!]M53PS*0ZADD!.#CH?^7?'7&<\],]>E7** /R8\2V,7["/QM%:V_8R_:!\9K?9+VZNV"LVC?![XQW;,VIWS :3X"^(.
M-6)1=4+#[AD7R9-C]+_!7AKXA>%?$7@GQSH-EXI\(>+-+
MOM%\2>'-;M;6]TO6='O+4VEW:7=J0 RZ@I)QSC)("L!7YE:!K7BK]B7Q5H/P
M7^,OB'5?$?[+_B"[A\/_ +//Q_UYVO+GX8F[.W2?@/\ 'C5CC_B7Z<0?^%3?
M%'405?2"OA3Q:YU;&K, ?M!1110 4444 %%%% !1110 4444 %(S;5/I_7!Y_SUI:=OV_.GWXP?]7^_GY_
MZ=#_ #_,T ,;G>C$O@S\$[.P\0_M.
M?&?^T(OASIMM3FKGQX^/5O\(1X7\'^#- D^)W[0/Q,S:_"#X2:'-B?7=0[>)_%FJV7/ACX6
M>#"?[0\6>,-1&.NDZ.=4Z'T/]F+]FBZ^#;>*/B)\2_$8^(_[1_Q8DT^^^+OQ
M-2S$-E/!:$G1_AYX'TD'_BF_AQX.6Y-CHNFKAFV2:MJ^6U!ECYP/2?V>/@)X
M;_9P^%>A?#;PM->ZO/:74^N>,?%VL,9_$GQ!\M.H.PWA5QIF["@K]"T44 %%%% !1110 U_NG\/YBOA'X7G=^W]^UFO_5&_P!G
M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MC+79VMVLIS=^(K*P74"&M!LOXA\/?
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M'P\72_ _@W3M/\-G7?#^H?9KQ_&!T[_A*-1U*S,IE0D%?UM_%>Y^.MM\%OA?;_&:\M?LTOQ33P1X?@\?S6Q^S?:1=>*Q8'4V)QW;M]8_ ?X,Z7!XM::YX@_M:\&K:@N-3U,73%G(#-7M5% 'A/PM_9]^#'P(MM8M?@I\)? 'PLMM?
MU.?6M=B\!>%]*\-Q:]J)'_'UKYTBQ6]O[XFYNB"S-AMP) (%9FE_LP_L\:-X
MQUGXB:/\!?A1I7COQ'=7%]K_ (PL_ ?ABR\2:GM"\N[#5V# ZG]J^9CSCZ)HH \9TCX(_"'1?\ A%IM'^%'P_TQ_ ?A[6/"'@K[
M#X2TFW;POX0\1X_X2#PQH 6R/V'1-37']J:=IX73=4& 5'0MQ;GX3?!;X6_#&\C@U"(ZAX&\#^'_ MJ'D:QJ?VW5[5M6T^R%Z;/4K[_ (F!
ML%(4GH<$9^@Y_P#5M]_I_!UZC_/YU_.Y^WO_ ,%'OVP_@G^T5^UI\+?@(G[-
M.C^"OV3?V3? /[6FLW'QL;Q"?$7CNPN]5UBU\0_#GPHVBWVFV%E>ZE9Z0<>(
M-2&IKI>IWFGJ %(! /W,USX0_"?Q%KS^*O$/PZ\%ZYXIGL5TJ7Q'K/AS2K[7
M)["SS=VRG56LCJ 53AAM8-@;><89EW\(/A3J/C&R^)%S\._!ES\0[>*WFM?&
MMYX*H39_\>MR-6-B=0^VZ?V!.1G ( P/Y\?C1_P6$^-GA7XF?"/Q%\,+
MWX<>+_AKKGB;]DGPQ\7_ (.?\*P\>'Q'\-KG]J?2[+5K73/B#\;;[7-.\/>%
M_B+IUCX@L]1\)^#M.TO5%U;2[/<0"Q)^./$_QJ_;DUKPI^TKJ7QW^*_P<^/'
MP<^&?_!7CP-\$KKP/K'_ G?@[Q_H/VSXB^#[3PG<^"/$/AC7--'ACP1X=L=
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MOCY^U7_P@&O_ !3USX$?"[PY/_#H
M!\*:4;$ZOI.2<_U%?#OQ+8>-/!?@KQCI.L:1XATWQ3X8T/Q%8>)-!BF_L37]
M.UC3K75[/5-'%W_IW]GZD+H:A'N.[85$N'WB@#.TKX,_"K1O"FJ>!]/^&O@R
MS\(:X/-U[PQ!X,=H8[U)!+?[M1Z'\'/ACX5L/#NF
M>%?AYX-T*P\*:O=:UX=T[3]!LH+?0M6O/EO=4TL6@'V+6KZR(!U!M?7J* /&=7^"'PD\2: OA77_A9X#U/PU!K%_K-IH&H>'-*O=*AU:]+&ZU.UM/
ML.VSO-1+?\31@H)P-Q?J=.3X2?#*Y_X1::]^'O@JXE\"1"/P0'\-Z7_Q2D'V
M-K0P>'R+$_8%(N;L V 4;KH@$DC/J=% 'DFJ_!KX7>(M%T+PQKOPV\(ZIX9\
M.7(OM"T34/#NEW&EZ/J .?M6DV9!2R))))"Y/&>@PMQ\(?AI/_PB_F?#SP;,
M_@@W$W@L3^&],;_A&A>;_M)TDBQ_XEXS;.P&T_:2 3QZU10!XOK7P*^$
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MPT^!GPK\"?\ "06.KZ;K4GA7P-X8TF75M(UBY:ZO-(U-K*P0WNBZA)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MT/4$' SP3@@].WIK_=/X?S% 'Y+ZAHGQ3_8/)LKF#QA\<_V,;0W)TW5X_M'
MBOXX?LLP7>%LM.^RC.H?$_X.Z>JC:2=4\6>%4VAEU/1U 7Z]\$>*_!_Q!\,Z
M+XY^'OBK1_&O@GQ':_:M&\4^'[XWVDZE;D G_2R +.]Y_P"/#4#_ &H#D9SQ
M7T[Y;-&B.F]#^[,?F' AQWSG[5\O4'&MMK\#OB+KUR=4\9_#V\T\ZM\ ?C!< 9W^./A\ %T3Q2<''C+P8=*U4G']K#5>
M2 #Z"W)_ST3\_P#ZU+7R-HW[6NF^&-;L_A[^U5X$U3]F'XEW&8;#6?$%^=;^
M"'C KP1X)^,8LAI_V(-D'P_XT'A;!RIU7(Q7UPK(T,-S#-!-9W$7FVMY;W5K
M/8S6_P#S]6EW9?\ $OO>G3/H.M[[_O/W']/?\ IZ4 +13=Z^OZ'_"G4 %%%% !13MC>GZC_&C:&_\ CO6#\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MVD?B1I_1A\0/B'8@Z=\,]$U#:Q/AWP86U=<$-K"J=P^ZOA=\&_ 'P4\(:3X
M^%/A32O!'A/2$9H=.TB%!Y]\2?M.IZI>#%]K&MZED?VEJ.J-J3N5&6;!KG \
MB_9O_92\/_ R?Q-XU\0>(]5^*_QW^)0MKCXJ_&SQ-';CQ)XDFM"19^&M(M54
MV7A;P+H)RND>%--(4*H;59-1<9'U[110 4444 %%%% !1110 U_NG\/YBOS1
MT#XI_#/X<_M_?M/#XA_$?P)X#.J_!W]GF72_^$S\6Z!X6.H"U_X3,71M#K=_
MIQO, J,J&QZ; >"
MO$^IBS-B-4\1^%]"UR_6W4BYM[5;R_L'O/L:DW("84%\Y!.30!R7_#4O[,__
M $<3\"/_ [W@'_Y>T?\-2_LS_\ 1Q/P(_\ #O> ?_E[6U_PH+X%_P#1%?A1
M_P"&^\*__*6C_A07P+_Z(K\*/_#?>%?_ )2T 8O_ U+^S/_ -'$_ C_ ,.]
MX!_^7M'_ U+^S/_ -'$_ C_ ,.]X!_^7M;7_"@O@7_T17X4?^&^\*__ "EH
M_P"%!? O_HBOPH_\-]X5_P#E+0!B_P##4O[,_P#T<3\"/_#O> ?_ )>T?\-2
M_LS_ /1Q/P(_\.]X!_\ E[6U_P *"^!?_1%?A1_X;[PK_P#*6C_A07P+_P"B
M*_"C_P -]X5_^4M &+_PU+^S/_T<3\"/_#O> ?\ Y>T?\-2_LS_]'$_ C_P[
MW@'_ .7M;7_"@O@7_P!$5^%'_AOO"O\ \I:/^%!? O\ Z(K\*/\ PWWA7_Y2
MT 8O_#4O[,__ $<3\"/_ [W@'_Y>T?\-2_LS_\ 1Q/P(_\ #O> ?_E[6U_P
MH+X%_P#1%?A1_P"&^\*__*6C_A07P+_Z(K\*/_#?>%?_ )2T 8O_ U+^S/_
M -'$_ C_ ,.]X!_^7M'_ U+^S/_ -'$_ C_ ,.]X!_^7M;7_"@O@7_T17X4
M?^&^\*__ "EH_P"%!? O_HBOPH_\-]X5_P#E+0!B_P##4O[,_P#T<3\"/_#O
M> ?_ )>T?\-2_LS_ /1Q/P(_\.]X!_\ E[6U_P *"^!?_1%?A1_X;[PK_P#*
M6C_A07P+_P"B*_"C_P -]X5_^4M &+_PU+^S/_T<3\"/_#O> ?\ Y>T?\-2_
MLS_]'$_ C_P[W@'_ .7M;7_"@O@7_P!$5^%'_AOO"O\ \I:/^%!? O\ Z(K\
M*/\ PWWA7_Y2T 8O_#4O[,__ $<3\"/_ [W@'_Y>T?\-2_LS_\ 1Q/P(_\
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MOB,+L>-],\/$^*,)9^(3>7?]JJ<[OM9./O8^R/\ A07P+_Z(K\*/_#?>%?\
MY2T?\*"^!?\ T17X4?\ AOO"O_REH _,B3]DS_@CO_PAT?P\MH?V5[3P3:>,
M_$'Q!M_"FG_&S2['PZ?$_B^X(\5DZ59>.0!HGB(X.K:!M;2CZ8RR_?&B?M#?
MLKZ!I^G:+I/QV_9]TC1]$M;+2=*TO2_BK\.[:ST[3=)"VNEVEG:VNO!;2RT^
MT L$L@H15^0;1ECW_P#PH+X%_P#1%?A1_P"&^\*__*6C_A07P+_Z(K\*/_#?
M>%?_ )2T 8O_ U+^S/_ -'$_ C_ ,.]X!_^7M'_ U+^S/_ -'$_ C_ ,.]
MX!_^7M;7_"@O@7_T17X4?^&^\*__ "EH_P"%!? O_HBOPH_\-]X5_P#E+0!B
M_P##4O[,_P#T<3\"/_#O> ?_ )>T?\-2_LS_ /1Q/P(_\.]X!_\ E[6U_P *
M"^!?_1%?A1_X;[PK_P#*6C_A07P+_P"B*_"C_P -]X5_^4M &+_PU+^S/_T<
M3\"/_#O> ?\ Y>T?\-2_LS_]'$_ C_P[W@'_ .7M;7_"@O@7_P!$5^%'_AOO
M"O\ \I:/^%!? O\ Z(K\*/\ PWWA7_Y2T 8O_#4O[,__ $<3\"/_ [W@'_Y
M>T?\-2_LS_\ 1Q/P(_\ #O> ?_E[6U_PH+X%_P#1%?A1_P"&^\*__*6C_A07
MP+_Z(K\*/_#?>%?_ )2T 8O_ U+^S/_ -'$_ C_ ,.]X!_^7M'_ U+^S/_
M -'$_ C_ ,.]X!_^7M;7_"@O@7_T17X4?^&^\*__ "EH_P"%!? O_HBOPH_\
M-]X5_P#E+0!B_P##4O[,_P#T<3\"/_#O> ?_ )>T?\-2_LS_ /1Q/P(_\.]X
M!_\ E[6U_P *"^!?_1%?A1_X;[PK_P#*6C_A07P+_P"B*_"C_P -]X5_^4M
M&+_PU+^S/_T<3\"/_#O> ?\ Y>T?\-2_LS_]'$_ C_P[W@'_ .7M;7_"@O@7
M_P!$5^%'_AOO"O\ \I:/^%!? O\ Z(K\*/\ PWWA7_Y2T 8O_#4O[,__ $<3
M\"/_ [W@'_Y>T?\-2_LS_\ 1Q/P(_\ #O> ?_E[6U_PH+X%_P#1%?A1_P"&
M^\*__*6C_A07P+_Z(K\*/_#?>%?_ )2T 8O_ U+^S/_ -'$_ C_ ,.]X!_^
M7M'_ U+^S/_ -'$_ C_ ,.]X!_^7M;7_"@O@7_T17X4?^&^\*__ "EH_P"%
M!? O_HBOPH_\-]X5_P#E+0!@-^U!^S7G$?[1?P/7&-Q_X6Y\.E))52H;S-M=F5-N2VTD$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MCQ!<>-M=^V7WB73]'U[2-&O/ ?PGO-%UW3M!\2^*?L-Y=ZB-0#:GI8/]G_\
M$KZUY?XV_P""FOA/2?#FO:E\/?AIJWC"^M?#6K:EX;:\\6^%]#\.^(O$&B^%
MO ?C"Z\(6>J6G]J70D^Q^.6;5]2U")=)TP:-K:OJC:O&NE4 =1-\0_VQOA7Y
MW_"X/V8-/^+.E6\7FR_$3]EOQE:C5M1Z@?:_A-\01INH6/\ UX>'?$VJ<=^]
M&G_MS?LP27":;XS\;:Y\%M;D_P"/K1_CQ\/O%'PJGL_;_A(=:T+_ (0Z]_[A
MVI\\9%8.K?\ !2[PGIVJ7^DZ7\)?%_B+4[?7]1T+3+;1_$_A>>?4[CPY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M_$W0])_9-U3XA^"-*3X$?$*;X4>,-1O_ OJOB&/]H3QGKGB+PYJ]Y\4='^&
M_A^Y\5Z19>+?]!T4ZW=W8'A$Y\4Z5I?_ !.-G_,)K3TS6/V#?AOXP^*>C_$W
M]CWP_?/\._'WB#P;'XHT>^'Q&@.G67BC2/!_A1?%>DZWKAO_ OKGB/7=7M-
M.TH^(QIG]JK>'5EVZ3A@ ?H]XG_:^_92\%R>3KW[0GPPO=5_T@?\(_X3UD^/
M]M_ CX?^?35_&G_ !6%[9'_ *AWADGN*Y/Q'^TM\&OV;/B)-\-_!?[,^EL^
MCZ7X0NO$FG_#_P -^#=*UWP3;ZSI?]L^(?[5(OO^)R=,^U6FGC3].!!U2\(.
MJ'((CU'_ (*@^$+&%-8MOA[K%U:?\5$)=(O=>T&PN+.?PYXU/AW51>>++R^'
MA^SOUT2UN_$"^$=/&JMJG^@Z3I&L%BS, >E0_ /]L'XQ+)_PNGX]:!\"/"MP
M+>.Z^'G[+^EW/_"57E@#C[)XA^,?C0ZEXA!/KX=TO2UQ@DU]*?!?]E_X$_L^
MPW4_PR\!Z7I>O:Q()=>\M&-?%WPD_;W\6_$#QMX*\ W'P9E^V^/?C%J&@:!KDOB33/#NGV7P?_LO6-9'C
M*[L;QM0O[W7=._LF[T__ (1 8;51_P 3;<.*U=*_X*5> ]=\:ZIX1\*_#W7=
M3M[76;NQT'Q$?%'ABQTK7=(\.W.J_P#"675S:WA7_A&+[3;'1[S4=)\'OYGB
MWQ1]E"QZ9%&O]I$ _4)714=Q\XQYG$OG?_JX_IBI?-B_O]_*_'\OUK\QHO\
M@HKX2G^!\7QX?X7^+-*\-ZYXZN/"?@"WU[Q!X7TB+QH+6UO;L:\=7O-06R\+
MV-C8Z1>_VGH/B!1JG]JW-EI&C-J;8SRM[_P5"\&Z=9WMTWP>\;PZ?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M8U)-0!0VC 9#,!^MX.FOM3\/#[6PT/53>:]J/VW3LW7-@Q56&5.0<']KM0U33])L[N_U&[M["PL;
M4WM[?7MMX?-FTOPEXW\,>([^&#'WVM-%U"_O0!CGY,%O3@ _(^U_8T_P""N%M<6MS;
M?\% _P!E6VN[+3+#1XM1MOV"O!@O8=.L1_H6F6A_X2P?9-/\/@YTBP&Y?[Y4
MY B/[%G_ 5I,HNW_P""@'[*CWCZZOB*6XF_8+\'&Y_MXVGV*YU\W=IXKTYS
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MO[(M/[(TG[;=+XI/VLZ?8 :V0K;_P#!1K]F
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M=[]D\59O-0^V$:G]O8ACJ9R163J?[#7_ 5:U][XZ]^WG^RIK/\ :FL>'O$>
MJ2:A^PAX/:;6-?\ #-V;O2=4U@V7BK3AK!TXBV&E'5/[4.FD$ L1@?NM10!^
M)C_LD?\ !82>YENKC_@HI^S9/+MIDYM5XP>.*US_@G_ /\ !4+Q'H^G:#KW[?L'>#K'2
M[/5]'N?MNCW6VS\5?Z5_9]\#?C(3+ ]\U^]%% 'X@M^R%_P6!GGM;F;_ (**
M_LSR7]A=M>VNJ#]ACP;#<66HJ=MMJEKCQ4<7PL;N[5B3@' )Y&76W[%__!5Z
MTN)+D?MY_LHM,=:/B6.2+]@WPM;F;7S;?9CJEV;7Q:O_ !.N3_Q4 )U-5^4
M*,#]O** /QGT_P#8^_X*?6NC2>'=0_;A_9@O?#RWJZG;:!%^P]X7MM+AOS=&
M[N=2^RWGCG4;#^T/M[&_6^_LSMFTZYBLY?V-_#36\%Q93B\%W:,WBH@7FG7J"_TIAIN-^2QW,S']:** /RCLOV
M2OVXDU37-=NOVEOV=&U[Q/I>GZ'XDU3_ (96TNXGUG1M'OFN](TRZM;KQ6=.
M^PV!N#J 3^S=W]J85E!)U,=MI?[/7[<^E:I<:[:_M.? R#7YM(@TB6^M/V9-
M"L;B>QLKE7L[6YU:UUT7[6 W7)6PSL4[3D%1C])J* /A6'X6?MYK_K_VJOA;
M+S_T0.S!_37ABM6V^&7[;JC_ $G]I_X=S#TC^"&F#^>MCI[D?2OM6B@#XU7X
M;_MHY_Y.6^'O_AE=-Y^F-MY&_X5Y^V)_T<7\/O_#-VG_R\IW_"O?VO/^CAOA]_X:"U_P#EW7UO10!\D?\
M"O?VO/\ HX;X??\ AH+7_P"7=+_PKW]L#_HX?X?_ /AG[?\ ^7E?6U% 'R-_
MPKS]L3_HXOX??^&;M/\ Y>4?\*\_;$_Z.+^'W_AF[3_Y>5]MO^CC/AY_X9JU_P#E[1_PKG]L;_HXSX>?^&:M?_E[7U_10!\@?\*Y_;&_Z.,^
M'G_AFK7_ .7M+_PKG]L?_HX[X?\ _AG+3_Y=5]?44 ?(7_"N_P!L;_HY#P!_
MX96S_P#E[3?^%=_MD?\ 1R'P^_\ #*VG_P O:^OZ* /C[_A7/[9?_1Q_P\_\
M,W;?_+RI/^%=_MC?]'(> /\ PRMG_P#+VOKVB@#Y"_X5W^V-_P!'(> /_#*V
M?_R]IA^'7[9)_P";D?A^,>GP6M!_[G37V!10!\??\*Y_;+_Z./\ AY_X9NV_
M^7E,_P"%MM:?_ "[IW_"N?VS?^CDOAW_X96T_^7U?85% 'Q[_ ,*Y_;-_Z.2^'?\ X96T
M_P#E]2_\*Y_;+_Z./^'G_AF[;_Y>5]@T4 ?'B_#G]LPM,<_I[U,/AU^V-G)_:-^'^/\ LC=IV_[CG\\U]>T4 ?(W_"O/VQ/^CB_A]_X9
MNT_^7E.7X>_M>Y^?]H?P B@#Y17X?_ +6@?Y_V@_ ;
MH/\ EF?A!:?_ "]Z?AQZUM'S*O@?\ :@#<_''P8WO_ ,*PM ?S&H8_7^E3CP7^TSNR_P :_!A3T_X5K:Y_
M6_'\Z^DZ* /G9?!W[2&[Y_C+X0*>@^'-KGK[WP'I5I?"'[08_P!9\8?"[_\
M=.K3K[XO_P#/\O?%D0_QH?H%KX3^/>[Y_BSX89/3_ (5_
M:@_^G#^OMC:^&_C0#E_B7H&/^Q,MOZWO.,U83P]\8E;Y_B)H+H/\ J3[LK,
MC-P_;@8^G?K3]Z^OZ'_"@#RS^P?BS_T/^B?^$E;_ /R;3UT'XI[OF\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MHHH ^6/VRF1/V0_VH6N#Y21_L^?%^4R']S#"/^$#UK#9!_Y<".I Z'C.M_L5_L>?'[QW^S]_P31_:(^"G[&OP)_9#@_9O\&K\=_%'[MAOP)K/V3PSXV\/>%UTW4K+PK\5[XV@\6ZCXU;55TG25! 7YR?[@?%/A[1/&7
MA_Q!X1\3Z;:ZQX;\3:;=^&M=TB[C#VFI:+KUM-I^K6-R@P6BO+6>2.3# \C!
M'(/&^$/A+\-/AK\.-&^#7@CP5H&@?"S0/"4OAO1O =K9+)X9TWPT+=;+_A'+
M;2K@S6J:+]F8QFP,9B(ZY!8, ?R9-_P4;_X*4>#_ 7XIL_$_P :-7LOVD[/
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M>KI4PTX3F%M>_!OQ'X_^(6H_#GXC^#O!OP\UWQ#I-EKGC;P?\/O%6GV7BR[T[XK^#].XU75
M='OQH_\ PB]>T?L[_'K]I#]JWX.>*OC9KW[3WACX$:E\$?"_A"RN](B\(^%O
M^%?^)/$-EH \1^*_B-\6;36;'4O$%EX'\9C:-(\/>'?$WA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MOVZF:^.BVGB?4,?;?%MEX<-U_8%EXJN?^6NOVNG0ZDW:<5[S0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D^XWTI],?H#
M[_Y_E0!Y'\3OBIX<^%=EI%_X@74WAUBZN;&PM])M;9F!M+7[7=?:A>,H"X&!
MMZY)X.XGR'0OVP_A=XE\->*_%&A:=XUU"P\*76CZ?=6EMX=>75M2O]8S]CM=
M)TM6S>DM[5/I>F:7;B)[32].LFGDF\W[)96\._[.2(MVV//R_7Z8H ^6[/\ ;.^$>H6U
MA,EIXTMOME_!I<::QX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MV7B5)/"\HM=9O=8TM8+ 7_ -K:7EI>/I][>8)9S8!MHR_P!8NEV-E:P1
MI:6MM9I<(+J=+."&T62X8J#*XMDBRQ!Y[>U;5 !4,K.(W\O'F>6?+W]">^<<
M^F??VJ:F/T_'_&@#YN^,6N?&?2M2\(GX6:5HNM6TT^L1Z_I>L:CIUC+J5R8U
M_LNU!O[X Z>0;O46_LS.I%[*QTLXTW4F(\IM/'G[:=Q?7ED_P,^&L,=O+:QR
MZI>>/;F"QF#'%SQ_R$+T&R_XF"_] L_\2Q?%OX$^!_C/J?A>;QE)
MXB2?PSIWBF71KC0=>N]#FM+NZGT".2^5[+;F\"0N$EQA1M@9AIDLGQ1_:"EMH(8"=+D^+&J-I4^!9G_2+/[&%D_!EH [/X/^*OVIM7\9WD
M/QD^&'@'P9X&DTMV;9OP_\ M^S_\>><;9&YSU/IQ7VWX!\&:=X \-Z1X0TN_US5+'0XIK2SU#Q+JUSKNN/#N
M/%UJEWF6X/3[ZX&!A10!WE1R]/O[/\_X?YZYDJ*;_5G!(Y XXX_*@#QSP'\6
M]!\?>-OB7X&T^RU.TUCX5ZYIVDZQ)J*VT0U$ZMIHO4O+- #FS! L>,-D*01@
M8]HKG-/TS2K/7-7FL]+T^SO+U+>XO[^VM8X;[4)3T-[<* ]QCH-^3CJ371T
'%%%% '__V0$!

end



GRAPHIC
14
image_008.jpg
GRAPHIC

begin 644 image_008.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" "* DL# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@#G
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M%LVUPH2XMYHCYD,9+(2 5PQ[7"E'648)>:2/E88C,*K<:5?&
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M$32/%.BW-Q)ILD\5GXAT02[;77-'FE'VJPGC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MVK7%C9G$7/+L0HS4&O9RUO[Z52/[I6NV
MZC<8Q23YIMECE215:*6-A+%*J21,LB(P_M (2..VUMVLX@VK01Q>#KJ)(]1(^UJL5Q-$/-_=R,FTUYW\,/^"8EKI6N:5K'
MQ(\;P:KIMJMK=W?A_0[*X@FN+I?+EEL9-5GF18;4/YD$MQ;VLEQ(@WVLEG,R
M3Q?K+9VEKI]I:V%C;Q6ME96T%I9VL""."VM;:)8;>WAC4!4BAB1(XT4 *BA0
M,"MJU6G+EM%3:O=OF27DK6;_ "/+RK+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MD0*DHRCSQBHN+M**;:L_ADKW>]T^SMW%1G6H8GZMB:SKQKP]IAJTH0IRM6H25-*',HN-6GI>4>=?9/L*BBBLST0HHHH **** "BBB@ HHHH **** "BBB
M@ K^=_\ X*(_\G*^)_\ L&^&_P#U&=$K^B"OYW_^"B/_ "MG1*Z,-_%_P"W9?H>#Q#_ +E3_P"PFG_Z15/A>OZ9OV,/^3:OAG_UYZW_ .I-
MK-?S,U_3-^QA_P FU?#/_KSUO_U)M9K?%?!'_'_[:SR^'O\ ?:O_ _P#3
MM,^HJ9)''-&\4J)+%*C1R1R*KQR1NI5T=&!5T=2596!5E)!!!I]%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M=)TNPA:>]U'4;J&RLK6%/O2W%SMR6[A\C^U-;\0:C"&8'?;QW,6E+-GH!))IDK 9.%QD@Y _+C]M3]IGQ!\7/B#
MJWA71]1N;/X>^$]2N-.TC3[>62*+5+FRF:";7[U5($]Q>2QM-I[ON^QZ:]M%
M (9YM0>ZX_9^TK32=DI-M[VUZ=VW>WWGU']H1P.5X*I.+J5:E"G&E3OR\S4+
M\TGJU",.1R:3;O&*U=U^F?C[_@H=\ ?!L\]GI-SKOCB[MY%C<^'[*&WL3DD,
M\5YK%Q8/<1IP3+:VT\3J08GD) KPVZ_X*H>%EF867PIU.: 'Y9+KQ6EM,1GJ
M8H?#5VBG'83L,\;\#)_&C2-(U37]3LM'T:QNM3U34;F*TLK&S@EN;JZN9W6.
M*&&"%7EEDDD941(T9W=@JJS, ?LK1_\ @GU^TIJNG+?R>$;;2V= Z66I:WH-
MO>D, 0&@.J[XG.>8YQ%(G(D1&!6MW1H0MSO5]92M?Y(\=9KG&)M95%'LG*2F[^K3>]C[V\._P#!4#X5ZA(?!'BK0DE<++=65YIFKV\"X)+N
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MN^+]:2]DTCP[IT^JZD-.M6O;Q+*U7?M40_9K5F5M9\4AE)5@?"]UD$'!!_?]01BO0OV8OC78?M)_!XZCK=O:-KMO'/X
M6\=:;%'Y=IMBGXT\#7BO_Q(M;O+:TEMX3NI1[-;;/\ &VO9GIYCF=>A2PN)PCI3P^(BU>I3TX2
M5S^@WX7_ +8?P2^+WBVR\$^#]7U>37M0BNY;.'4]'ETZ"X-E:S7LT,<\LK S
M_9;:XF2/;\RPN,AMJM]1U_*)\&_'-W\-OB=X+\:V;%9/#^OZ??NH4LTUM%<)
M]LM54,I)OK,SV#<_ZNZ<$,"5/]5^G7]KJNGV.IV,JSV6I6=M?VMXMY5()!62&1'!!(P1@FE7I*FXVNXM=>ZW_"S-LHS"ICJ=95E!5:4XZ0BXITY
MQ]UV%?&7]HSX7_ '?0X?B#J5_:3^(([V;3K?3=.DU&8P6
M#V\<\\R1NGE1F6ZBCB)):1A)M7;%(R^ZU_.W_P % _B.?'/[0&MZ5;7#RZ5X
M&MK7PI:('5X?M5AYLVK2H%)VR#6+S4;24$C*VD)*@C+31IJI.SO9)MM;]E^)
MMFN-E@<,JE/E=6=2-.FIIRCUE-M)QO:$>ZU:/T^_X>(_LT_]!KQ1_P"$Q=?_
M !^OJ#X6_%+PO\8?"D7C3P<=2?0;B]N[&VN-3L&T^6XELF1+AX87>0O DK&
MR;AB>*>%E62%U'\JF@:1=Z_K6EZ+80/=7FJ7]K8VMLAP]Q<7,R0PVZ-@XDGE
M=(8S@_O'4 $D _U8?"WP18_#'X;^$/!%J46#PSH-G9W4^45)[X1FXU:^=@$4
M?:]1EN[MV( 'FDD\9JZ]*%-1LY.3?6UK+?IWL<>49AC,=5J^V5%4:4%=PIN+
M=2;]U65TBBB1I)))&5(XXT4L[N[$*B(H+,S$*J
M@DD 5\;_ !._;M^ 7PVGNM.BURZ\:ZO:>8LEEX1BM[RU$T'^V+RYL]+F
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MRH^3[G_@EMCM^RO\5?V?KN*Z\16 OO#T\Q33_%FAR2W6DR2@N5ADN!%!<6%YL3S1;W]M9R
MR+N:U%S'#-*E*GAY^[&34NFKO]TE9^FYA/&Y[A%[7$T8SI)KFO3IN*3?6=";
ME3[*33BG:[[_ --B.DB))&ZR1R*KHZ,&1T8!E=&4E65E(*L"00002#3J_$_]
M@_\ :[U71M;TOX,_$;5GO?#>KSQ6'@_5M0FS-X>U.=TBM-)-Q(M;NQ&F7DT)M=FGRW$=K^V%M*G.U[.V\6O>A))*4>B:DE\I?$;]L[X'_ L\7ZMX(\7:EK]OKNBR01WL=GH,
M]Y;![BTM[V,17"2J) (+J'<=H ";#X@^'[R2/PSJ$
M-]<1WFJQ#36@ATZYN+2\ENUG?9;Q0RVLS-*\OE>4HEW[#FOY]_V\?^3FOB'_
M -?.D_\ J.:+4>O_ +0/BWQ9\(/AI^SO\.XM52RM;>[7Q'#81S&^\4:UJNO7
M]Y:::L%MOFETZQBN;2."T"L;[4I'F>!Y+?3MO1]73C3<6[RLY-[17+=OIUVU
M_5GB_P!N5:6)QE.O&$X49584(4X.-2I4C65.$7+FDKMK_@H)\!O %[/I>FW6K^.]0MI%BF/AJ"W73%8@[BFIZC<6J7<:$ -/IT%[;MN
M!BEDP17C5O\ \%2_AVTQ%U\-?%$5N"?WEMK&G7,Y';$$UI919/I]JP.,MCD?
M/GPW_P""9OQ*\2Z;:ZOX]\2Z5X'>[$5P='D@FUS6HXI8Q(R7T-I<6MG:7(9L
M,@U2ZD4JPFBB?*+W'C#_ ():ZO;:9-<>"?B-IVJZG#;R/%INL:33CE8
MDU"/4-82'?R$\VV1-Q4/-$F7!RX9>ZY.3ZN[M^"LOQ)>(XAJ+VL*"IP?O*FJ
M5'FMO;EJU/:MV[\LG_*F['WW\'OVN/@M\:;F#2O#OB!])\27'EK#X<\11Q:?
M?W,KQ[S!83QSW.G:A.F&4VUM>/=DJ6%ML^:OINOY*_$WAGQ?\+/%][H.O6=_
MX=\3^';\)-"Y>WN;:YMI$FAFBEB<94E8KFUN;>5HY$,%W:3/$\$[?T.?L7?'
M"^^-WP=L[_7[AKKQ;X5N_P#A'/$%U(!YNHF*WBGTW5I2JHKS7EH_D7DJJHFU
M&RO90J!PHBM14$IP=XNV]G:^S36Z?]:'7E>:SQ=26&Q,(PKQ4G&44X*?([3C
M*#;<*D-VD[-)Z1<;/ZXJ.::*WBEN+B6."""-YIIIG6**&*)2\DLLCE4CCC16
M=W=@J*"S$ $T]F5%9W8*J@LS,0JJJC)9B< $DD@ #)K\(OVR?VN=?^+'B:
M]^%'PQO;J/P+:WITJXETTR^?XUOTF\EIG$(,ESI#S+C2[%5>&ZB\O4)4GN+B
MUBT_.G3=25EHEJV]DCT,?CJ6 H^TFG.M'Z!_$_\ ;Z^ WPZN;C3;'4=0\=ZI;2".6+PK';2Z:C[S&X&L7MQ;6MRL; [W
MTU;^, ,-V[:K?/3?\%3_ QYY$?PGU)K3=Q*WBQ5GV9^\85\,O%NQSM^T8SQ
MN[UG?L^?\$X=+ETJP\5?':YU"34K^&.\7P3IUT;1[-9MLJ)X@U2,/[<>=
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M%<6DQNQTH3BYT6[QU<);_+]-T[;WT"GF.+PF(IX7,X4[57:EB:6D&VU%MVYG%2:4)PBD) !)( )))P !R22> .II:^+/%&J^)OVE/'VL_
M#3P=KEUX<^#/@:^.G_$SQ9H\P34_&6O1$^=X)T6[4,D%A;,I35Y!O$BAVNHI
M;*?3H=3QC'FOK9+63[+;YMO1+J_FUZ]>LJ*BE%U*M27)1I1:4JD[7=V](0A'
MWZE27NP@KVE)PC+O_&'[5GPJ\,ZI<>'M&FU[XC^)[8/YF@?#G1I_$]RDB,\?
ME27<#1Z;Y@F1HGBAO)YHG#^9$JQRE.7?]J;Q#!:Q7]W^S5\>HK&0QEGB\,0W
M%U#&^-SR6:W"-^[!RRK(Q.&VDXY^B_!/P_\ !GPYT:'0?!7AW3?#^FPJH:.Q
M@5;B[D'6YU"]??>:C=NM[T\5"DW]BCAX3A'R"_#[]I/X4?$75#X=T[6KK0/%0D6
M$^%/&&GS^'-<>=UWK!;0WG^BWMP5^;[-97=Q7_$WX.> /BU
MIAL/%^AV\]Y"%?3/$%HD=KXBT6XC99(;C3-52,SQ^5*DM"UX_\(?&WB[P/X[N?V??BMJDFM:M%I\FL?#'QQ
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M[Z;6_N].^VI\XZ-^T;J:U>>
M%_!8MXFN)))+J\\5V-SH6I%)$$,D:SM'#'(M>]_"GQ/J7C3X:^!O%FL1VT6K
M>(O#&D:OJ45FC1VL=[>V<4US';H\DS+$DK,J RN=H'S&N%_X9Y\%OKWACQ%/
M=ZO<7_A7Q%XZ\268>>!+>]NO&^J7FM&WU."*!$O;7PYJUX^H>'5E!DLKN-)V
M>20N6]2\$^%++P+X0\-^#M.N+J[L/#6CV.C6EU>F(W<\%C"L$M&M)>]&,O9)WMRP3:O(ZBBH#=6H)4W-N&4E6!FC!5AU4@MD$=P>12?:[3_GYM_^
M_P!'_P#%5!UW7=?>O\QM]>VFFV5YJ-_<16EAI]K<7M[=SN(X+6TM8GGN;B9S
MPD4,,;R2.>%123P*_.GX!V5[^TA\?O%G[1^OV\__ A/@BX;PM\*]/NUF6-I
M[=)!'J"P2@1B2QLKN75+@JIQK.O1J'\W1T"=5^V=\1M5U:W\+_LY?#R>.\\;
M_%J^M+/5X[:56;3O"LMQM=+MD+&"WU66&634&(ROAW3M99U"SPLWUW\,OA_H
MOPM\">&O F@H!8>'].BM6G**DNH7SDSZCJ=R$ !N=1OI;B\F[*TVQ,(B@:KW
M(7^U4NEW4%\3_P"WG[J\DSSI_P"UXR-):X? N-6K_+4QC3?1JA!^VFM;5
M)4D]8Z=W7\VFHZM\:/B%\?M=^'/@[Q_XIMM3UOQSX@TS2;>?QGK^G:=$T=]J
M$RHSQ7K1V\20V[A1'"5&%1$Y45_277\[_P $F5?VZ]&+,J@?%7Q'DL0H'SZY
MU)(')X'/)P!R:TP[LJKLFU!-75]4WY'%GBM6MI.S=[/6Q[!_P ,@S@9ZD#)KB4^,W[6
M'[(7CS3M#^(^IZUJ^DSK%='1_$^K2^(M"UK3'D2.6;3-6>YU.2U\LPRP^=IM
MU!M\&>']2T[6_$/AX:Y<:S-IMQ#>#3!JDFC?9-,FFMVD074HL);B>V#>9;JUL95
M4W" U3J.K+DG"#BT[VC:W6]UM]Z\C#,,#2P&'EBM5%O5VO*UI*T6I1Y7<_77P'XRTGXA>#?#7C?0VM ' N;*<2VERHX6>&0#@"O@SX_P!C>_LX?'OPI^TEX>M[@^"_&=PGA;XJZ=9K
M(T?G7"1*^HF")&1I;ZRLXM2MRP7.M:%M+^9K$@?Z&_8ZTV_TO]F_X8P:CYHF
MN-*O]1A252KI8ZGK6I7U@0" =DUG/#<1G'S1S*>]>P?$OP#HWQ0\"^)/ FO(
M#I_B'3I;03A%DEL+U2)M.U.V#C N=.OH[>\@S@,\(1LHS X)J%22>L;RC)=X
MWM]ZT:\T>M4ISQF!HU%:&)5.CB:,K6Y,1&G&:TZ0FW*G-;ME9ZEI]S#>6&H6MO?6-W;N)(+JSNX4GMKF"1MQ%U31XO%/[.'Q#N([7QM\)[Z[MM'2YD6,ZEX52YVJEF7(,UMI4LT,NGG[S>'
M]2TAD79;RE?N[[7:?\_-O_W^C_\ BJF4>636_9]T]4UZK]3HPV(CB:$*J7*Y
M)JI!MSN6**K_ &NT_P"?FW_[_1__ !5'VNT_Y^;?
M_O\ 1_\ Q52;W7=?>O\ ,L457^UVN0/M-ODD #SH\DDX 'SM%%%% !1110 4444 %%%% !7\[_\ P41_Y.5\3_\ 8-\-_P#J,Z)7]$%?SO\
M_!1'_DY7Q/\ ]@WPW_ZC.B5T8;^+_P!NR_0\'B'_ '*G_P!A-/\ ](JGPO7Z
M*?"/_@H5XI^$_P //#GP_L? >@:E:^'H+R&.^N9=1$]Q]LU&\U%FD$>I1)E7
MNVC&V-!M0<$Y)_.NNHL?!/B_4[6*^T_PWK-Y9SAC#M2IP>""*[IQA)+G2:3TN[*_WH^4P]>OAYN>'G.G-Q<7*"4FXMIM-.$]+I/9;;
M]#]-#_P5.\:8X^&WA@'L3-JA'Y?VL,_F*\K\=_\ !2#XZ>*;.[T[01H'@NVN
MXVC^TZ%ITPU:%7&"(M1U"^U-H&QTFM([6Z0_-%MP6W/_P ;JQ:_##XB7LRV]IX)\474[D!8K70]2NI"20!A+:VE;DG'3ZUFJ=!.
MZ4-/._YRL=,LQS.HG%XG$M/2T8N+=^EX48RU\FFWMD]S=74LD]Q<32NTDLTTTK/)+++(S2222,SR2,TCLSLS'L?AI\/\ Q#\3O&N@
M>"_#-B]_JFMZC;V<484^3$LC%I;BZ<8$-G:P)-=7LVMPO\ '_XAWEL+CPG<>#]&E,;3ZUXM#Z+##"TA5RECMRQABZ?M!^SC^ROX$_9XTEGTS_B?>,K^V6'6/%=W;K%*R-L>:RTBV+S'3M/>5
M%:0&::[N_+A^U7#QP6T%NJE>$$TFI2M9):I>K6B2[;]-#7 Y3B<74BZE.=&A
M=.=2I%PE*-[M4XS2G*4M5S.*C&[DW)I)^J:+X0MOAQ\([;P9H!>2/PIX(GTN
MQE.X2W5W9Z3,'O)#EF$U[>^9=2G)/FS-@FOY3]0:1[VY:4L9&E8L6)+$]B22
M2>,M/=:[\.M8NIM2SIT,EQ<^%Y;B4O-INJ6\2LT%C;,Y73]3*BR:R6*&[FAO8S]J
MQPTTI34GK*S3;W>MUZN]_,]?/\)4E1PU2C!RI8:,ZM632?*K-Z-M?/_P"RA\3_ Q\(OC9X2\9^+[1[C0[*>[M[N>* 7,^G+J&FWVF
MKJ,%OL9YGLGO4NC'"5G=(76WWSM'&_\ 29X1\>>#/'VFQ:OX,\4:)XET^:-9
M!/I.H6]VT08D;+JW1_M-G,K!E>"[AAGC92LD:L"!_)/)%+"P66-XV(R ZE20
M>C#(&5/9AD'L:UM(\1Z_H%PMWHFL:EI5W&H6.ZT^[GM;F)1NP(KB%TFB WOC
MRG0@LQ'))K:K051J2E9I6VNFOT^1Y.79M/ 0E2]E&K2G/VGQMFHK22T>S2;1_5!\9?AO9?%OX9^+O %Y]CC?7]*G@TV]O;?[3#IFLQ 3Z3J@C
M ,FZROHX96,6'>(21'M<#)KY3\&_ML_M&>#&@6U^(6J:M9VZ+&MCXA\C7H'1(S&BO)K$-]=J ""P@N8
M-S*&RK9-?;GPJ_X*?)<75IIGQ<\'6\%O)Y44WB/PFTL3PNS,KS7&A7\]Q'+$
MJ[7=K;58),;Q#9R.%1\E3KTD^1QDGJTE=_).S^YGI5,;DV8U(2Q<*U&I&/(I
M2DXPLW=*4Z/,K)MVM>+]6MK[3+FYDAN-MU:VT2HT%_>1R%=\C,8<;55L_(O\ P4_^%WV76?!WQ9L+
M?$6KVK>%],?#/CWP_
MI_BGPAK%GKNA:G&7M;^RDWH64[98)XV"S6MW;N#%MVH/AFOQ8^"'CGPK#;BXU:+3'UWP^@)#MK6AAK^UMXV 8JVI11W&DN<$>5?R
MC!-8PJ2593ENW:6EM'H[KRT?R/2Q. HRRNIAL,G*$8NOA_?=2\XMU5RS;=U-
M<\59VM.RT/Y=U9D974E65@RL.JLI!4CT((!![$5_2+^PQ\2$^(?[/GA>.:X6
M;5?!6$)<[@\MO-\[,K&OYOIHF@FDA?[T
M;LAX(SM) .#@@$<@$9P17ZB?\$Q/B0VD>/\ Q3\.+RX86?BW1AJ.FQ.RB-=9
M\/O-EW>JO*5!W#3[=>, 'KQ$>:FWUBU+Y;/\'?Y'S>28CV&/IQ
M;M#$1E1EVYI>]3?_ ('&W_;Q^R'C_P 767@+P1XL\::@5^R>&- U369$8D><
M]C:2S06RX!)>[N%BMHP 29)5 Y-?R@>(]8O/$&O:QK>H3"XOM5U*]U"]N!G%
MQ=WEQ)<75QR2MY$64:/HACU&[M](_\%O[CJXAK\^)IX=/2A3YI?]?*NOWJG&/_ ($?>O\ P3S^%W_">?'.R\17
MMOYNC?#VT?Q-=$A3&VIHZVV@6[A@V&;4I5U*'&"XT:X4':'%?JA^W)\5)OA?
M\!=>_L^Y^S:WXTG3P?ILBR/',D-_;W-SK,D+1_.KG1[2\M4D#(8Y;N)PP917
M(?\ !//X7CP)\#8?$MW;B+5_B'?OK+N0AD_L2P,MCH\8=1N:&:3^T=3AW'!B
MU&,@ $_/O\ P52U:9;#X2Z("1;RMXMU)UYVM-')XMPQJ&_:8E)ZQB[+_MV[?WR_(ZZ4)8'(:M1>[6Q$/:-[-?6)1IT]=TXT7==G/N
M? '[*7PDC^-OQL\,^&-4#R:)'<2ZYXD97:.232-,4WEY$DBJ2CWLBPZ<)4*/
M!+?Q3QMNC /]-%A866EV-GIFFVEO8:?I]M!96-E:1)!:VEI;1K#;VUO#&%CB
MAAB18XXT4*B*% %?RR_!CXX^-O@3X@OO$G@>6QAU._TN?2)I+ZQM+Y5M+BX
ML[F41I=P3HCM)8P#>JA@H=0VUW!^E_\ AX]^T7_T$M!_\$&C?_*ZKKTJE22M
M;E2T5WN]WMZ''E.8X+ T9JK"LZU2HW*4*<9+DBDJ<5)SB[+WI-62YG?7<_H.
MKF_%_A+0/'7AK6/"7B>PBU/0]=LI;&_M)0.8Y!E)H7P6@NK:4)<6ES'B6VN8
MHIHF5T4C\%?^'CW[1?\ T$M!_P#!!HW_ ,KJ/^'CW[1?_02T'_P0:-_\KJQ^
MKU5JK?>_\CTWG^7R3C*GB)1DG&2=񑘕JV::;33W3/EKXL^![_X0?%7Q
M7X,EFMW_$9_BM\%/ /C.YG2XU2[T==/UR1#G?K>BS2Z3J4S#)VM>7%FU\%R=J72#/:
MOYK?BI\3_$OQ@\9:EXY\6&R;6]56S6\>QL[>RBD:RL+33HG,-K%#%O-O90!V
M$89G#.Q9F8G]L_\ @FGK4NH? C5M-DD+C1/&U[#"I&/*BO-&T6Z,8]C,9I?]
MZ1CWR=L1%NE!R^*+2;7FK/\ %7/-R.M&.8UJ5+F5"M"JX*6C2ISYZ7,KNTE"
MMU\-^$_M$6Y+6\DM$N]8U2$,Q0W$=C=V%G9S*@>%;W4UR&9"OR+^WC_RM^OG2?_4)?%$LQ[N\=[':(Q]Q!;0QCV0#M15;
M6'A;JH)^CC=_?8,!2A5SROSI-4JN+K135USQJM@?BO_P %2O"^FV?BWX<^*[>"*+4=;T+5-.U&1(PLER-"O;/['-*X(WNL.KO;
MLS L8K>V0-MB &Q_P2LU>Y_M3XMZ&78VC:5X5U)$).U9X+_7;=V4= 62\4,>
MIVKG@"KO_!5/[_PC_P"O3Q?_ .E?AJN;_P""5O\ R-_Q5_[%C0O_ $[W5=N^
M$UZ+\IJQ\GI'B2T=+U=;:7Y\)>7WO5]WJ?>G[:WQ-F^&7P!\57=AM/PAIDB3>3.@U:*X?59;=P0XFCT6VU!870AXYY(G!4CM?BCX@M$N]/\ H@?2$F0-#+XHU%YC9W!4G:S:5!;W5\J,I\J\?2KE"K1"O>?
M^"INH2)X,^&&E!V$-QK7B'47C!^5YK.VTBT@=AZQQ:C=J,]IC7K?_!-_1K33
M_P!G@:E!"B7&N>,=;N+J08<\DUFOM\D_O9U58K%9_"G/WJ>$HJHHO5FOLXKH??E%%%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MZ>%3++)'''G>[HJEA4834HODE:ZOIT>CZ]FS#$XK!5M(ISIRCI?FC4A3<;:W7GK]PZ+JMMKFCZ3K=D=UGK&FV.J6K9!)MM0M8KN DC(
M),4RY(./2M*O%/V<)KB;X#?"8W0F$\7@;0K5_M"LLQ^Q6B6:F0. P9D@5CD=
M\\CFO:ZS:LVNS:^YM'=2G[2E2J6LZE.G-KLYPA)KY.304444C0^(O$_["OP\
M\5>(M;\27GCCXCVMUKFJZAJT]M9ZEH@M;>;4;R:]EAM_M&A7$_D123ND*RS2
M,D*I&&VHH&%_P[V^&7_0_P#Q0_\ !GX>_P#F6X!M
MMX6DVVVW[^K;;;_B]6V_F?DAXK^%5K^Q1\:_AK\7M*O=8\4_#O7'E\(^*KS7
MX[2]U709+Z"2"ZN(9[*TLH(Q_9O_ !,K%T@6YE72M3TMY'2\A4_K1;7-O>VU
MO>6DT5S:W<$5S;7$+K)#/;SQK+#-%(I*O%+&ZO&ZDJRL&!(-<#\6/AOHWQ:^
M'WB7P%K:JMMKE@T=I>&-9)-+U:W87.DZM &!_?:=J$4%R%&/.C22W<^7,X/R
M_P#L7?$?5WTCQ'\!/'>;7Q]\'KR;2XK>=R9+[PO'<&WM6@9TC,\>CSLEI'(@
M*'1[O09@2)\U4FZD%)ZRAI)]XM^Z_D[IVZ69C0A' 8IX>*4<-C+U,.EM3Q,(
MKVU&[;=JM-*K33D]8U(I[(^Y:_F*/@76OB7^TUJ_@CP]J=MH^L^(/B#XBLK#
M4;R2>*VM9A>ZG/YDLEM;W4ZC9"Z@QV\K;F V@9(_IUK^>'X(JW_#=>BG:M+5\1M5/4]X/\ P3D^/1!!^*?A$@C!!U/Q!@C_ ,)FO3/A1_P3-TW1=?LM=^*WC.'Q
M+;6,L4Z^'= M[J*VO7BW%8;[5[X03K99*;[>STZWN2%(AO[<&OU:HJ'7JM-<
MR5^JBD_O1U0R3+X24_93FXM-*K6J3C=.^L79-7MH]'U36C@M;6VLK:WLK."*
MUM+2"&UM;:"-8H+>VMXUB@@AB0!(XH8D6..- %1%"J !27=W;6%KMV=G;S7=WM\ _ 0>\\>_%VZM]/N+:VN7@:SDED41+I=IK#2LL?S
M#.,7.2BNN[[+=M^BNSNQ->.%H3K25^1)0@MZE234*5.*76M#_AC%^VW\;_B1\6]7O=8\+?#G03'X5\,76@1V=CJNLO:11V]B;B>]M+R-Y1I
MJOJ>J-+;-WPR_Z'_P"*'_@S\/?_ #.5]7?![X9:
M1\(/AUX9\ Z/LD31;%!J-\J!'U;6KG_2-7U64!5(:]OGFDBC(_T>V\BV3$<"
M WN;>0"V*[X9XY
M(GVLRAT9K^9Y]/ 8*G2C4Q\:$L36E*I6J
M59J"E5J/GG"%ZM./+334(I)OEA=MWN?/W_#O;X9?]#_\4/\ P9^'O_FM[?#+_H?_ (H?^#/P]_\ ,Y7N?_#67[.'_17_ A_X%W'_P BUV7A#XY?!_Q]
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MI&000000<$MK*![FZN)6_ACA@C>1SR=JG )XH!M)-MV23;;T22U;;[))ME^BOD?]E_XO_$3
MXVW7Q'\9ZQ:V-C\,1XB?2_AW;O8FWUK9:/)]J$]RGEIM3
MZA;0W7V>U\B+ZXIRBXMQ>ZM>W31.WJKV?F94*T,12C6I\W)/FY'*/*Y14I14
MTKOW)\O-!ZM^3E?$_\ V#?#?_J,Z)6^&_B_]NR_0\;B'_MOAEDYQ9:V![#_A)M9XK^9BOZ9OV,/^3:OAG_ ->>M_\ J3:S6^*^"/\ C_\
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M>RL:^/O''_!+_P"'FIBYN/ OCG7O#MRZY@L]=L;+6]/1@ JR:>=#NH@QR3)
M(+S':(U\T_L"_M*:;X&\<:]X7^)7B&6WTGQK:Z?;V&MZK=2&QTS5],FNWM!>
MRR.8;6UOXK^YMI[YU58)8K 7$BVHDEM_W5@N(+J"*YM9X;FVGC66"X@D2:":
M)P&22*6-FCDC=2&5T8JP(()!IR=6A+E4Y6T:?V6O1W7DUMJM[ [[G7?#<\E]'9VV8U%QJ5G+!::E8QAI LL[V3V, &9+[D9^."""0000<$'@
M@CJ".Q%?U3?'3XE>"?AE\-_%.K^-=0T^*VN=#U:QLM'NI83=>(;NZL9X(]*L
M[)W$ET+DR>7Y>."-W'\L%W(DUU/+& J22NR@9'!8G.&)8;OO88
MDC/))YKJH5)5(MR2T:2:T3T[=UY::GS^;X+#X*M3A0J2DJD)2E3E)3E2M)*/
MO*SY9IOE4US>ZW=Q=S]+?^":OQ6UO1OB?>?#&XO)9O#GB_3+VX@LI7D>.UUS
M2+.6_MKNW3=LA:33[.]L[EPN;A#8QR,5L[94_=.OY\_^"MF^P^&-$US5;ZX6/="HETZ?1X89).B-)M=?TL>_D$IRP%I-N,:]6-._\ ):#:7DIRE9;)MI=C^9_]LGX7#X5_'CQAI-K!
MY.C:S=?\)-H:C>4&F:XSWD<2%E $=E=&[TN-5+ #3FP0/E7RKX*>/;CX9?%+
MP3XVMV*_V#KUA>W "LYELDF5=0M@J@L3>6#7-E\H+8N6P.2#^N?_ 4V^%O]
MN> O#'Q0L+??>^$K\Z#K+J2"=&UAC+I]Q( I#BSU:(V40)!#ZXQ&1D'\.@2"
M""00<@C@@CH0>Q%=5*7M*2OKHXR^2M^*LSYO,:$L%CZJA[J52.(HNVBC.2J1
MMMI":E&W9)'W_P#\%$_B?;^._C3!H6EWD=YHG@G0=-TZUDBYADO=4M8MMB?/S^:-1L[*4@!1)I:K\Q0X^0/A5X(U#XC_$3PAX)TL-]L\1:[IVFQN@5C;I
M<7,:37C*WRF*PA,E[< @@6]O*2" 17"3W$]U*TUS-+/*P4&261Y'(4!5&YRS
M850 HSA0 !BOU&_P""8_PM_MGQSXD^*-_;[[+PAIQTO2'=49#KNN)) TJ$
M@NLMEI":BDBC "ZG;2'GRR&[4:+M]F-EYR>BT\V[DTU/,\Q7,FOK-?FFD[\E
M)6E))]HTHM0 2L42AFP-S98\DU^7?_ 5-T%YO"'PP\2+&S)8ZSX@T.:0#(634[73-2M@W
MH#'HM^MDTEE &_Y;ZAISWUA 03-8T'6P&(HPC>7LK
MTXI=:3C.,4O2FXI+R74_'']@GXMBPO[2_T8B1&TZZM)9&2SDOCL:0KM+-L;9E?UU_X8F_9F_P"B:P?^%!XI_P#E
MU7X#_!'XG:K\#OBMX;\;6\4DC:%J:KJE@',7V_3)EDM=2LB6**/M5A<7,4$L
MO[N"66*Z*MY(4_TX^ ?'_A3XF^%M+\8^#-6M]7T358%DBEB9?/M9]JF?3]0M
MPQDLM1M';RKJTF"R1.,C=&R.^^(YXR4E*2C)+9M)->FFN_F>-D4<%7H3HU:-
M"=>G.4_WE.G*MJ/\ AB;]F;_HFL'_ (4'BG_Y=5]5UB>)/$>A^$="U3Q+XDU*UTC0]%LYK[4M
M1O)5B@MK>%2S$LQR\CG$<,,8::>9XX84>61$;GYZG\\__ I?YGN/!8&*;>%P
MJ23;;HTDDDKMMN*222;;;LD?-_\ PQ-^S-_T36#_ ,*#Q3_\NJ]F^&_PG\ _
M"/2[_1OA]H$>@:=J=\-2OK=+S4+TSWBVT5HLS2ZC=7M_P ZOQB_:)^('Q$^*GB[Q-H'B[Q9H>DZSK<_]D:98>)-:LK:STJ%A:Z9%]GM
M+Z&VA>.PA@-V88Q$UU]IG#,)"Y_?G]FCPGKO@WX)> ]*\4WFJWWB2ZTHZYK<
MNM7]WJ6H0WVO3RZK]@GN+V:><-IMO=06#1&5EB>V=5XK2K"<(QMEWNVM+V]3S\NQ6$Q.)JQPV!IT?8QD_K$8THWBY\D4E&G&:]JDY).7PK6Y^&7
M[>/_ "?\ R;)X:_[&'Q7_ .G:2OR;_;Q_Y.:^
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MI 0P#*05(!!!!!!&001P01R"."*6N4^C"O,_&?QE^%GP\U/&_CKP]X9U.
MYM8[V"QU2]$%S):3230Q3B,*Q$MS3SS.L4,,,2EY)99'*I''&BL[N[!44%F( )K^<7]I/QWMQJND>"_!XB5W2_M;.Y6QL;@B,,PM]3U2YNM0C68GVZTJ?M)--M
M12;;5M.V^G?Y(\W,\?+ T: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M^UGO=0;3[&RMHS+;9%$@) +.ZKD@9YK0KY*_:\UZ[N?!
M7A[X2^'KAU\8_&'Q5HWAK2XK8QM=VFDV>HV>HZUK)1I8G6SL?*LH+N:/<\,-
MY).$9()=M17-)+N]7V6[?R2;,L155"C4J\JDX1?)#;GJ-J-.FG:]YU)0@K)O
M5V6A]7VTMO/;P3VDD,UK/#'-;36[I);RP2HKPRP21DQO#)&RO&\9*.C!E)4@
MU-6?I.FVVC:5IFD6:E;32M/L]-M5/5;:QMH[6!3[B*)16A4FJO97LG972V3L
MKV\KWMY6"BBB@84444 %?G?^U?X=U7X0?$;P/^U9X*M'D?2+ZR\._$G3[;*)
MJ>CW0^PVUU=?O(X]E[9N^A3SRAA%?+X:N ";4L/T0KG_ !7X8T?QIX:USPGX
M@M5O=%\0Z9=Z5J-NP'SVUY$T3-&2#Y<\)*S6\H&Z&>..5"'12*A+EDGNMI+O
M%Z-?=MYI,YL70^L4)0C+DJ1<:E"IUIUZ;YJ4UYM@:-XGT"[2_T77]-M-5TR[C(VSV=["D\+%M$&D>(XO%^F?#GPI8^)X+V34H==M]*@CU*._E,ADNTN0-XFM&/Q"^/'[,,'B;X/WOP:\8?%'0/#OB34)/"/B/2K3Q EL=(OI6N/+AGL_#6K6
MDUK=LRZK'#%.K6%SJ%W9."(52/U#_AL/XO?]&I?$/_OWXH_^8:K]G--\CO%[
M-3BKI[77,GL]4UORK1?+/DFL/4C;FC>,X2UB
MXOF/T#HK\XK[]M3XRVUPT4?[*/CDH%0@RQ^, ^6&3GR_ 3+C/3#$XZX/%4_^
M&W/C1_T:CXU_[X\9_P#S TO93_N?.I#_ .2-'FN"6G-7_P#"3%__ #.?H7XH
M\2Z/X.\.:WXJ\07:6.B^'],N]6U*ZM/Y]_LD^&]7^,GQ-\=?M6^.+5@-0U&\T'X;V-Q^\BT^R@0V5UM0Z!;7$2H+B^?7KB11/AS\_?'?]H_XG?&FR\&_"CQ/\.=5^"7ACQAXNTJVUSQ
M!KXU^.WO+6*]M(XXI'U7P[HD?V#39[E-6OHXGF9VM+0N]O&A\[]?O!OA31O
MWA70/"'AZW6VT;P[I=II=A$,%FBMHPK3S,/]9M3AK;FJ75TTTH+>S3:O)VO9[*W4QIU89CC(RAS/#8%1JSDZ=2
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M*.W#2*S-Y\MS%I3^L4<'&/UER@J3IJM
M"TN>-W*5648*/+>[;5G9IQMS+]B/V1OB+K?Q1^ ?@?Q3XDGDN]<6+4=%U"_F
M97N-1?0M2N=,@U"Z=5027EU:6]O+>R[09;LSRD N0.R^//PGT_XT?#'Q%X'N
MQ%%?W,'V_P .W\@/_$L\1V"O+I=UN4AE@DD+V-^%.9-.O+R$?ZRKGP0\'^$/
M GPJ\%^&? NJ6^N^&K+2(YK+7[62WEAUZ:^DDOK_ %E7M6:W!U&_N+FY,,3%
M+8.+93B&O5JY6[3M7YKW5IIN[2FGJF_C?]C3XLW_ (S\"WWPZ\7F:V^(GPCN5\+Z[9WIQ?7&E6LD
MUEI-](&=WDEM39W&BWTA)8W.G)M-=\3?$73YM-\6_#O3TNC=Z_$+BQTI+SR["RO)0^MXMOLK+!++_;'APW,<-P9
MKN-_1S^U[\:,G_C%#Q[P2.1XHSP<<_\ %#5MFKJSMT.'#XZGAXSPF)G4E5PL_8\\*-:LJE-1C*C.4J-.HHU'2E"-2,G&7/!N
MS4DS] Z*_/S_ (:]^-'_ $:AX]_+Q1_\PU'_ U[\:/^C4/'OY>*/_F&J?93
M[+_P.'_R9O\ VGA/YJW_ (28O_YF/MSQ;XT\)> ])DUWQEXBTCPSI$;K$;[6
M+Z"RA>9^$@@\YU>YN'_@M[=99G )6,@''Y__ +2OQTTGXVV_A#X _ KQ)9^)
M-5^)FKQ6_B?4]-%P]MI/A^TE29[6]WK;2QPW#1R:CJ0PN-(TJX@?M[8?QI^(/Q5^(^WQ?XMIQ%[JZM]7T[6;26!+9R&NX
M]^VXL)4(99;:_MVELKJ)E(EM;B>(%2^X=%/#VBIMWDDY):.*=GRW:WL[/33U
M/#QN=NM4J8:%-PPLIQI5*BYXXB5/G@JO)&2BJ;G'F@HRCSJ+=^64DE_41\/O
M ^B?#;P7X;\#>'H?*TGPWI=OIUNS >;9+FXE?
MO78U'$[211R,AC9XT=HV^\C,H8HWNI.T^XJ2N-N[N]6]7ZL^JC&,8QC%*,8Q
M48Q2LE&*2BDNB2227D%?SQ_\%#8I9?VE/%!CBDD T[PXI*(S@,/#&B$J2H(!
MP0<'G!!Z$5_0Y7G'B+X/_"OQ;JL^N>*/AYX.\0:S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MY[H4444 %?B_^V;^P]KT&NZQ\4_A#I,NKZ-JN7GO;S
M3+*$--?Z5FRN\*P/IHA>Q_:"BKIU)4Y?Z/I^!R8W!
M4<=2]E5NFGS4ZD;<].5K7C?1IK247[LEO9I27\@=S97VG3O'=6]Q:3P2M&XD
M1XWCFB8JR[N,21N"" %[5;'P[XZ\6:'9(A1;32/$6L:7
M:JIQTM]/O;:'=P/F*%AV-?TX>-O@9\(?B-,UWXS^'OAG6[]Q(K:I)IT=IJ["
M4;7W:M8&UU%\CION6P>1C)KP:_\ V OV9;Z3S!X0U>S]4L_%6O*AZ]1/>7#9
MYQG=GWSS76L53:]Z#]+*2_KY'S<^'\93E>AB*4EK:7-5HSMV?+S+UM*Q_/-K
MOBKQ+XHN?M?B+7=6UV[("&ZU;4+K4;IERI"O<7:Z/X??
M"SQW\4-?M/#?@OPYJ>M:E=.@*6ML[1VT+;LW5Y,VR"SM$"MON[N6WM$("R3H
M2,_T):%^P]^S1H,J31?#T:D\8( UC7=?OXF##!\RV?44MI1CM)"R]1C!(KZ2
M\,^$?"O@S3DTGPEX#++OD;DLY))
MI2Q44K0@[]+V2^Y:_D71X=KRGS8G$4XQO>2I<]2I+_M^HHQ3:ZOG:[,^>?V4
M?V;=-_9W\#/97+VVH>-O$0MKKQ5JMNNZ&,P*YM-%L9G59);+3VGN'>X98S>7
MD\\XBAMQ:VUO]445QVO?$/P%X6U.WT;Q-XS\+^'=4N[5;VUL=M62!9X4O[B#S(VEAEC4J3EHW ^Z<2/IJ5.CA:,*4.6G2I
MI0CS225_.4G&\I.[;;O*3;\E6^)W@BR^)'P^\7^!=0 $'B;0K[3$D/\ R[7D
MD1DTZ\4X.)++4([:[C;!*O"I'2OY2O$6CW/A_7=7T2]C$-WI.HWFGW4(8/Y-
MQ:3O!/ 6'#-!*CQ.?[R'@5_4)XZ_:'^#GP_\.:AXBUCX@^%+J.SM9IK;3=)U
M[2]4U;5)XX7EBLM/L;&YN+B::X*;5D,8MX5)FN)8H$DD7^8KQMXB;Q;XN\2^
M)FB$#:_KFJZRT*G%YDIW34=+75M=
M4[7\MSYGB*5"4\,X3A*LHU(S4)1DU3]V4'+E_SM^](ZHN>F78*,^V3R:_ID_8[^&(^%OP$\&:7<6Y@UCQ!:_P#"7:V)$19UNM=C
MBFLK:?;_ ,M;'1TTVRE4D[9X)C]YFS^#G[+GPN;XN_&OP5X3EA>;2FU.+4=>
M*JK(NAZ8&O\ 4TFW\+'=6EM+8HX&1<74 4AF4U_4$B)&JHBJB(JHB(H5410
MJJH "JH "J ,4L5/X8+_ !/\E^K*X=PUY5\7)?"E0I^LK3JM>D5"'S8Z
MBBBN,^J/Q]_;+_8:U74-5U7XJ?!O2OMJW\LVH^)O!EA$!>0WDTGF7FIZ%:Q@
M&[MKF1Y+NZTZW5KRVG:8V<-U;3)!I_YL> _BM\7/@?J]S-X/\1:_X2O$F$&H
MV2EA:3O ZAK;4=,O(Y]/NFB*>5Y=[:326I,@A$$I9J_JIKROQQ\$/A)\2)3<
M^-? 'AO7+XJRG5);!;75RK+L(.K6!M=290O"JUTRKV R:Z:>(LN6I'GCM?2]
MNS3T?X,\#&9(JE5XC!5OJU5RM4G_:)C@,32^#YG( 6XG\-1&Y'J2;>[M;4L>H/V(*IQE' (;Y[^*/[1'QI^.<
MJ6OC#Q1JFIZ=]I1[30;)(K'1;>=RL<6S3]/@M+.2?>=L5U=12WB^8T2W'EN4
M/[EM^PE^S(9/,_X0*Y7_ &%\3^)@G7.,'52WX[L^^:]:\#_L]_!;XM^'7AS3=2@1$AU:>T;5=7B$9+*8=3U:2^O8&#,QS!/%DL3W-4JU&.L:6O1V2_
M&[M\DG2V:]I6J77G!0IJ7_;\FN]S\MOV,?V(M?U+7='^*?Q;
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M8\.>$-+BT3PMH>E^'M'@DFFATS1[*#3[&.6XM2I64Z<8*+3CRZW5O=5CBPF65M>ANT445@>R?C]_P501Y)?A&L:,["S\7L512S!?M?AH9PH)QD@9Z9('>N<_X)
M8Q21^+_BIYD;Q[O#&A[=Z,F<:O-/!_
MAWQ2VG"9; Z]I-EJ9LUN3&9Q;_:X9?*$QAB,@3 [N
M?!G@OPUX6N+^*."]FT'1['3);N&%S)%%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MCLE[RD]%LN>:5K)VLE^=W[07[=?C[XXVM'B%)RB0V-[=Q10QV]K/(6632[.(K=.4AGO+ZW=K=OJG]AC]C[4_ -U#\7_BA
MIWV7Q1)#(?"7A^]C#7ND)=PM%-KFII)EK6_FMYI8+"RD"W-M'--=7J17;6L-
MG]P?#S]GKX-?"R:.\\%> M%TW4X5*1ZSWEJ#N(*VDL
M"LO!4\Y]GI2JKE<*4>2+W;^)_P!==6^AIALKJO$1QF85UB:\+.G"*:I4VM4T
MFHWY7K&,81@I>^^>2317Q%XAT/QG^S-XZUWX@^!-!O?&'P6\;7LFJ^/O!.D1
MJ^L^"M><$S^)_#UME5GTVZY^UP !($VVMW)::;::==Z=]NT5E&7+?2Z:LT^J
M]>C3U36S[JZ?IUZ"K*+4I4ZM.7/2JQ2M_ /QM^%?Q,L8;WP?XUT34))8XY)-*GO(M.UVT,L:2!+S1+]K?4K=@KKAVMS#
M)G=#+*A#'TR:\M+>(S3W5O!"HW-+-/%%$J_WC([*H'N3BO%/&W[-7P-^(,]Q
M>>)?AUH4NH7;QRW6I:6MSH&H7,T3M(DUS=:'<:?)=3*[,WFW)FD)/+<#'GZ?
ML1?LY[U,_A#5KV)&5A;7OC3QC<6OR'A3 VMA"F."AX*_*1CBG:F^LUYM:_%&:ECHZ.EA:G]^-:K23\W3E1JN/>T9R71,Z[Q[^TS\,?!TZZ)I&I_\+!\;
M7M&>I^,;SXY_&D6J>/]2L#IGA/P?93?:M)^&WAN0S$6,,N6CN=?NXIY4U&^B9Q
M&+B]CCE/VZ>&#V?P9\+_ (>?#N.6/P3X-T#PVT^?M%SIVGPQW]T#CB[U*19-
M0N@ +BYE &*[RCF2344]=')VNUV5M$GUW;V;MH$:%6I.-3$SA+V;4J="
MDI*C":O:I.4_?K5(W?(Y*%.FVY1@YM2B4445!UA1110 4444 %%%% !1110
M4444 >'_ +0_P@LOC9\+?$'@Z2.W76EA.J^%+V=%(L/$EA'(]@S.>8[:]#2Z
M9?D'FRO9S@LJ8\T_8Y^+UY\1/AS)X3\4O-%\0OA=.GA/Q/:WK*-0GMK0S6NE
M:E=)N9OM)2SN-+U)B2QU33+N5L+<19^NZ_-WXZ6=W^S5^T'X6_:(T*"9? ?Q
M N1X8^*5A:I*\45Y6UI#K4!VAWU;1+Q"Y;5V1]8>]%TWOK*
M'^)+6/\ V\E]Z1YV+_V:M3Q\5[B4'JR3D_^?52?2)^D5?S
MR>!+:VO/V\H[:\MK>[MIOC/K<MKJ%I:W]C<175E>V\%W:74#K)!M9X.^.O@W]HKQ5\2/!GPZ\6W-WI?Q$\1ZSHMXWA+5;ZRGQX@U">UN%!L)H)H9
M49)8V&Y7C=6'7C3#_P#+Q72;A97:6KNNK74X<\=O[/JM2>D5).ZB[7LGM?4_H#_X0KP;_P!"EX9_\$.E?_(E?"O[?GP@^&M[0=!\3>'-0T8:7J^FZ?;:;<72:AJ,5A/IMS]B2!;V)HKJ2[A2X$A@GMEDC9$
M,RR?,7_#5'[>'_1.M5_\-M>?_*>N \8:/^V]^U9+IVA>)?#'B6UT"VO59;.]
MT0>#_#UG<^7+&=0NWO+/1XKMDB>2/S99+^YC222.SB EECD<*4X2C*4X))W;
MY[Z+=6OU\]#/%9CAL5AZM"C@L54JU8.$$\(XJ,G91GSM_P#!,7Q7K&L?"_QGX=U"XN+FP\.>(K&YTGSOFCM4UJWNQ>6L#D B-KG3/MKI
MELW5Y=3G#S.6_1W7]ML4;%4&6=MJ("S 'PC]F'X!67[/7PXB\*B\BU/7]3O#J_B;4[<2+;3Z@T,5O#
M:60E"R&SL;>)8TD>.%KFYDN[PP6_VD6\7SY^V?XSUSQUXA\#_LM> )RVO^/=
M1L+_ ,830LY73]#AF^U65K>-#)&Z6R"VF\1ZH@=9%T[2[52KPWQ5LY)5*TK.
MT7)MOM%?%+\';U1W49U,ORNC[9.5>%.-.%*]Y2K59R5&BK-W:MT;F-^RUH.I?'CXQ>-_VJ?&-HPTNVOKGPY\,=.NDCD2SBMXS:-=095L?V-I;"
MS6:)VAN-9U76+I0EQ;
M6TOQ/#/;M<:@US!(DRWM_M=>,-4@TC7-.OY=.O?$FKW=K?1VEY%.]E-!=WTEM)%>)&UK*LR,AAFD##!-6J
M;KM-H)-?NZ<8I*Y_47165H6LV'B+1=(\0:5,MQIFN:98ZOI\ZD%9K+4;6*[MI 0
M2/GAF0D=B<=17G_QP^($/PN^$_COQS))''<:)H%V=+$CK&)=;O@NG:)""Q&?
M-U6[M%8+\VS>PP%)'.DVTNK=OG>Q[DZD(4Y59-M?VHOV./#'[1$MKXBM-6'A3QS86:6*ZJUF;W3]5LX69K>#5+>*:WG2:W$DD<%
M]!+(RPLL5Q:W:06@MO@+P-^S=I/[-/[37PNT[XR267B/PQXC\N?PQKUF7BT*
M'Q7'=QQ:;'JB7T$,C+INKC31/#A8S_:FG7M7ESW#$ ^*M=&49FP2HOPA;NQ"X+Y.,YK^@CX^_!U?C?\"H=&@02>+M)T;3?$
MGA&]D;%P-?L],1FM#?39I2W[N6XANV)>V0CK?/2483FG"?-'1:Q
MNMT]]&[V[77I\Q!X;,Y5\7A\&Z>+PSHXCEG-3AB'&3DZMF]6G?ZAHKY=_9+^,DOQ<^%UK'K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MIEV37,\J9SMDFD=<^NUF(S[XS3(8)KB588(WEEM)K]Y$_X)B_ Y9Q*WBGXB21ALF!KSPP$(_N[E\,!P.V0<_D*^@OAI^Q[\ _A9
M?0:MH7@V/5-:M94GM=6\37#:U<6D\:!%N+2TE2+2K6X7ETN8-/CN(W9FCE0L
M<];Q5-+12;[6M^+9\W3X?QTI)3="E&^LO:>T:7E"$$V^R;7FT?/_ /P3[_9P
MU'X7^%K[XD^,M/EL/%?C*SBMM'TV\A$5YI'AMGCN7N+B*1!-;76MS16THMY-
MLL.GV=K)(D,U[$H4Z%._+!.\G;FG.3
MO.-OV<[CP)%X2TKPYJ4?B>UU^>^.NVE
M_=O&^ESZ1#;K;BSU3351&74)FE+F5BR(% &31&+G)1CJW>VMME?<>(Q%/"T9
M5ZO,J<.7FY8N4O>DHJT4TWJU?71:GWA17X5+_P %/?C2V=OA+P V.NW1M>./
MKCQ2:=_P\[^-?_0H> O_ 2:_P#_ #4UK]6J]E_X$CS/[?R[^>M_X(E_\F?N
MG17XH>'/^"I/CJWOH5\6?#WPKJ.GF1!<#1Y-7T2\2,L/,9);J^U^)F"Y**;/
MYF !9021^I/P2^.O@3X]>%1XF\%WKZ)=3*S1Q7D4,LT4D
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MU@<$?#O[(O[6_B3XZ:]KGA?QYHVC:'JATA?$'A*;2;/4+--L[Z?3-:CVW
MVH:DL\EIM=;BW"UU*5[1;;M&Z]YZ+6U_OJBBBI.@***^)?VN/VG_$'P+F\+:#X%TG3-<\
M3:O!=:UK,>I6=WJ%OI'AV&>/3[:ZE@LM1TV2)[Z^>Y\F>6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M3\2Z%;:G>0V$XF*DD>8P ->F4VK-I[IM/U6@0
MG&I"%2-^6I",XW5GRSBI1NNCM)771Z!1112*"BBB@ HHHH **** "BBB@ KY
MB_;!\1> _#WP#\:_\+ MWO-.U:U32M'LX#$+V7Q))NNM&N;-YE=8I-+N;3^U
M9Y1'(5M+*=!%,9!!+].U\,?\%!OAQJ_C[X#7-_H[J9? FKIXLOK9G2/S]*AT
MZ_L+Z1&D=%+V:WB7CH-TKV\-PL*23&.)[IVM."G)4*EHM&O":VWA_Q#X4\-Q-9
M6UEJUC-_:+Z4)II+:Q&J6EU%+"ME'(EI92>3<+:VD,4/V:X6)$K]S/A#\5O#
MGQD\ :%X_P##I>"SU>&1;FPN71KK2]2M7,-]IUPRA5D:"8;H;A%5+NUDM[N-
M5CG51_*K;:5J-Y<06MK97$UQM?@1_P3]LK[X9Z%JGQ#\3^./"_B;5_/U.XT#29],MX=-M+AE6PBNH;[2KFYCO
MY;6..YN89'1[4SK9R1I+;R9ZJ].DDI7Y&W]E7YKWO[MUZW7ZGS>3XW,)3E2A
M&6+I0I+W:E54U2Y7&,.6M*$K77NJF^9R2NKB?]]+_ (T>9'_S
MT3_OI?\ &O@/_AWK\._^BC?$W_P.T#_Y14?\.]?AW_T4;XF_^!V@?_**N:U/
M_GY+_P %O_Y(]_V^8?\ 0OI_^%U+_P"4GV+\1_B#H'PQ\$>(_'7B"X1--\/:
M=->-"LB+/?76/+L=,M=QPUWJ5X\-G;+T\V96?"*[#XP_8K\!ZWXHO_&'[3WQ
M"C\[Q9\2KZ^A\-K,G&F^'Q=%;N>R$D,6YAOFW<;
M\3O^">FA#P+XAN?!?C7QMJ_BK3K-M4T32=M%)+:SF$ZQQ7\$6MIX-\1:1;P"S6
MTN=(M8[>PNX[( &VM]3L(H;E8MH6&[6]LQEK1\5I&G)P;E>2C-VY6HVNE:[T
MD]W?I8YXRK5\PH1QE*-!4J-2MAJ2J1K0JUKJ%2HYQC&//1I-.%/E;2FZB?;=
M_:N_Y-S^+O\ V*-U_P"E%M7X._#OX6P^./V??C'XJM+57UOX=:QX(UI9D55G
M?1M3E\3Z9JB&0X(AMI?[/U&4!OEALYFVFOWB_:N_Y-S^+O\ V*-U_P"E%M7Y
M[_\ !-'0=/\ %/A#X\^&M6B$^F>(-+\.Z-?Q$*V^TU*/QE:3@!@1N$MKA6'(%72DX4I272I!^JTNONN<>9T%BX+$13?27+6<)?]NS47]Y]2
M_P#!/KXECQW\!;#0KJ;?JOP]OY?#LJ,NUQI$X.H:(P7)_M @@>,_\ !3;XBO9^%?!'PKL+C;<^)-1D\1:Q&H#8L-/#V&E13 $L(Y[N?4+U
M,+Q+I$; @@$>'?L4:[J/P2_:A\8?!OQ%*T$7B&YUCPM*)04237-"N[FXTF[1
M581I%=M;:A#9MM_>KK-N5 5EPFI#_AJ+]O6.R3;?>$?"6NB"8@L(1X;\"[FN
M@0RL);?6-1M9H5<+L/\ PD,9#%6&ZE!1K2GHX1BZOWK2WS;_ ,GBZE;**&$
M3:Q56O'+9)_$O9S7.VM[*DH*3_NR/EK]H3X;V_PK\0?"WPNMHEKJ;_##PIK>
MOJ$VR_VYKLVKZC?0S,1N=[(2PV +?PVJ@<8K^DGPS_R+GA__ + FE?\ I!;U
M^%W_ 4=_P"3D--_[$OPU_Z4:S7[H^&?^1<\/_\ 8$TK_P!(+>IKMNG1;W:D
MW\]3IRBG&EC/Q-B;]E;]I?1OC!8JUK\*?C'
M.VB_$&"%%6STK79I%EN]2=%90A$I3Q- 0K22;?%,,8_?JM?I!%>6D\44\%U;
M303QI-#-%/%)%+%(H>.6.1&*/&Z$,CJ2K*05)!S7P!^V]XCN?',G@?\ 9D\(
M6]KJ7C#XB:WIFIZD\D<M\EI_P3O^&UO:VL$GQ!^)#R06\$,CQ7>@01.\42([QPG0Y3#&[J62(RR&-2$,
MCE=YAJ,HP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M>6+2]2TW5M2BTHH=/DDDM[6YMKN_MKE9K-8!+!'/#-'*[020?,W_ 31U[4[
M#X[W6BVUPZZ;KOA/6H=1M,DQS&S%OJ-I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M0$$9KA?@II7[-VGW^N/\"Y_!$^HO9VJ:]_PB>N?VO,ED9W:U^U*=0O?(B:ML8"/>ZX))4 >._\ !1)F7]F[5&5BK#Q3X>PRDAAE=0!P1@C()!QV)'0U\C_\
M$KY))/%7Q6\QW?'AS0,;V9L9U6\SC<3C.!G'7 STK*,+T93YI*S^&_NO5+5?
M,]2MBU#-\/A?JU"3G"+6(E&]>%X5G:,N5V2Y++WEI*7S_:"O,O'?QF^%?PS=
M(?'7COP]X=NY5WQ:==WJRZM(A"D2)I-FMSJ31L&!606NQADAB 2/G+]MK]I*
MZ^ _@2TTOPO.D7CWQFMW;Z1M,7\GO@#^S3\3?VKM;UKQ)J&O3:?H$%^&U_Q?K;76I27>I7"K*UK:P-
M<)<:KJ;6_ER3-+=1>1 ]O->7:^=:QW13I*474G+D@MG;5]-/GIW;^\,;FM(C@\'0^LXII.2;:A3NN9)V:;DHVE*\H0A%KFE>2B?M1I_P"U_P#LX:E=+:0_
M%+1+>1W\M9-1M=8TNUW_ .U>ZAIUM:1KZ/+.B'H&S@5]#:=J6G:O96^I:3?V
M6IZ==QB6TO\ 3[J"]L[F(D@26]U;/)!,A((W1NRY!&A3W
MGP[^(#:CX@M8'ECTO6M,&F0ZE+&FY8+;4HM2NX[.61QB(7-NT)8JLMU;J6G3
MY-_9R_:&^(/[,OQ+_P"$9\2OJG_"*'69-)\;>$+\3,;61+IK:]O[*T8DVVOZ
M?,LC+)$N^^>)M-O6DBDBEM*]C":;I3M4ZKM&M1DY1B[I-OWIQDHW3FE*,XQ]Y1DDS^A#QK_ ,B;XM_[%G7O_35=U^0W
MPRLK_P &_L\? C]H30H)Y;[X5>/O$&G^)8+-9VEU'P5XEUMK.^AEAMQFY>*X
MN9M/M1("EN?$%S=,0(05_7#Q1>6NH^ ?$6H6,\=U97_A#5[RSN86W17%K=:+
M<3V\\3?Q1S0NDB-W5@>]?''[&'A?3/&W[($/A'68A+I?B.3QKH]ZN,LL-]=S
MP&:/D%9K=G6>!P0TM6*G2GNHU:=;"5*,_13C&_>,I='K]TZ;J%GJVGV&JZ=.EUI^IV=KJ%C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M19?#?]C/4_!%B1)%X>TOP;93W 4WNH'Q9HD^JZ@P"J-^H:E-=WK_*/FG([5
MI3]WE?6?9UZM&K"A%]+TZ7M:MMTY
MP>FC/I'X*_\ )'?A3_V3CP3_ .HWIM>@:CJ>G:/97&IZO?V6EZ=9QF6[O]1N
MH+*RM8@0#)<75R\<$* D O(ZKD@9R17G?P;FBM_@O\+KB>1(8(/AIX,FFFD8
M)'%%%X9TYY))'8A51$4L[$@*H))P*^5O!WA^;]L#Q)J7Q&\MSI?PW\$6UW-967BJ;2;A5F\5:X]I-'/.CSHJK'OBGBG6XT<&"UL=1.N1RWMW:*;N]]6W9)=6]?))-O1:];KRITL-3IP52O6I05.#ERQ484:3G5JRLW&E33C
M=J+E*4HP@G*5X^_2?M1_L_172V9^*GAEY&SB6&2\N+$@=7_M*"TDTX1CO(;H
M1]?FX->QZ!XCT#Q5ID&M>&=:TK7](NAFWU+1[^VU&RE^56*K<6DLL6]0R[XR
MP="0'53Q7+VWPF^%MIIJZ/;?#CP+#I:0B 6">$]"%KY07:$:(V)5_EX)<,QR
M222M+-W=+"6T9K>W2-"D&E226UY:&VTN'5K&^:4):1RW5[)]R9
MUL7AX^UKQH5:,=:OL%6C4I0^U44:KDJL(+WII.%3D4I14N5Q?Z 5A^(?$WAW
MPEID^M>*-=TGP]I-L"9M2UG4+73;.,A6;:;B[EBC,A56*QJQD?!"J363>^//
M#5CX"G^)4M^I\)P>%SXO^WK@^9HW]FC5(Y8UW8:6:V*"./=EI76/.XU\>?"/
MX7S?M&2K\>/CK;/K>G:S<7M.'M]6@*:K?Q3IMQ=2/-)QI0I1Y4ZU245*7+>48PC!.523M%I*4E[U#^U#^S_/>&Q3XI^&4F! ,
MMQ+>6ECRVT'^TKJTAT[:3@!_M6PY!#8(-:GQPO['4_@)\4]0TV\M-0L+OX<>
M+)K6]L;B&[M+F)M%O-LMOM2Y(C"U@_A30OLWE%=NU8A8A4P.%*!67@J00#7P3\?_"-S^S!X9\7:AX).HS_
M 3^)NC>)O"OBCP?)=W%[#X*\4>(=*U'^Q_$.BFZ>:=;&\U%O(N8FF#('>TE
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M7RQ\$/V?=4^'WQ!^)_Q1\=:[8>+?&_CC5YTT[5[6"2)=.\.2/%MQG:1IUM!=S*9BUP:BW)[Q7NKO)Z)^D=W\CBQM.K7C3PT$U
M3KSY<3532Y,/%'
M=,LM+T[51HNF'6A#90+ DTVK?91?2W,VTRW$[3^9--))(Y+.:]$HHJ&V]VWZ
MZG7&$()1A&,(I))1BHK1)+1);))7=WIN%%%%!05^:OC0']E']J+3/']LAL_A
M%\=)FTSQ;'&JQV&B^(Y)Q-<7[JB;8VM;ZX&OQ,2#_9E_XHBA4BV0#]*J\@^.
MWPHT[XS_ R\1>![WRXKVZ@%_P"'K^0'.E^([ /+I5X&4JRPO*6LKY5(,NG7
M=Y!TE-7"2B[/X9+EDO)]?6+LUZ>9R8VA.M24Z5EB,/-5\.^]2"=Z;?\ )6@Y
M4IK:THO[.G,_M6,K_LY?%MD8.K^$+DHRD,KAKBU*E2,A@P(*D9!R,9S7PG_P
M2O!%C\7L@CYO!O48_P"6WBWUKZ/_ &4O'-O\6?A?XA^"OQ3TY+WQ7\.&;P;X
MLT+6,O+JN@V\\MKIEQ2A@YN-.@O'8&^A9_J'P)\*?AU\,5
MU)? 'A#1O"BZN;4ZD-)@:$7GV(W!M1*&D?B W=R4"[0&FD8@EB:MODA.DT[N
M2::VLDM>^JLUZG'&B\9B\#F=.<8TJ="<)TY*7M%.7M(RAHN5.G-RA)2L[Q>F
MJ/R#_P""B/@O6/AO\9_"OQE\(RW&DW'B6VM;W^T]/C6*6T\4>%WL[:2Y,P4J
M97LQH&]*N9MKR-96
M)COM8GCGVFE>/?"VD^*=/L;L
MWUG:ZM;^?';79B>!IX2&1T=H9'C&_"FCV.@Z
M%IPF%EIFG1"&U@-Q/)M:"IY7R9G/&\\72;G5A2][FC7J04)3_D2^.2:]Z\K/1'X:?\ !1T$_M'Z:0"0
M/!?AK) .!^_UGK7[4W_B[1O 7PP_X3+Q!/\ 9]'\.>$+35+UQS)(EOIL!CMK
M=?\ EI=7DYBM+2(?--M;/+CL"2#BOCO]IK5+WXT?%/P'^R=X(N&MM(M9['
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M,=9\>V>K7-]H^OV-A9/I^H16D:VT]@T[ATDL[DLQD7((90!QC/-?M9N_Z!?B;_P '5M_\JJ\;_P""7ES;0?#?XBB>X@A+>*]+VB6:.-F TJ3) =@2
M.>H&/RK]0/[1T_\ Y_K/_P "8/\ XNG6J352:4Y))Z)/R1SY9@<%5P&&J5<-
M0G4E"3E.<$Y2?M*B3;YE?1);;)'Y9?'3_@G%X$A\':WXA^$^HZWI_B#0],N]
M2BT+5)K.^LM82QA>YFM;:XBM+&XM;^6*-EM3-)<6TLVR%UM_--U%\>?L2?M!
M>)/A=\6-"\':CJ\\_@?QCJ]MH.JZ9<3R265O?ZG=)9V&L6:$.(KZ"_G@::>,
M(;K3WNH;DRE;-K;]IOCI\(-*_M%])O[?0] BO[635=;U2
M>TGCL[6ULDD>?R6FPUW>-']FL[9)9YG 0*W\Z7P.T34_%_QL^'NF:1"\]Y>^
M--"9 F(V6WBU.VDN+CH57[-9QS7DHX B@E;(5&8:TG*I2J*I=Q2=FUY-NSM=
MV:6O3:YYV94Z&"Q^#E@5&G5DHVDXJR9^W7
M_!1/_DVS5?\ L:?#W\K^OD7_ ()6_P#(U?%?_L7/#_\ Z=;VOKK_ (*)_P#)
MMFJ_]C3X>_E?U\B_\$K?^1J^*_\ V+GA_P#].M[41_W:IZ_K$ZL3_P E#A/^
MO4/_ $WBCRC_ (*3ZM=ZA^T%'I%?#]E:PL1Y40FBEU)WC &09)=5
ME\PDD,53 !7G]8OV//#FG>&_V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M:5ECBBB16>221E1$!9F !-?
MS7_M=?%"P^-_Q^UW5O#3&^T.VDL?#.@7-LDTKZCI^E1B#[;%$ SR)>7C7]]:
M+&F]K6Z@#()MZ*L*G[1OHHN_;6UC;B&=-8.G"37M)UX.$=Y6C&?.TM[6DHM]
M7)+5Z'[4? +5;C6/V0_"UUMG;TKFOV /^3:O#'_ &&_$W_ITDKU3X>^#;OX?_LV:/X0U%=FIZ/\,;Y-4CVA
M/)U2\TB\U#4X"H) \B^N[B'@D'9D<&O*_P!@#_DVKPQ_V&_$W_ITDK-VY:MM
MO:*WI>9U48RCBM9+5/AUXV^Y';1>)8A;Q:#JD^V$N\\\<.DQAWD"6]AI.LSGF9S7W#7AW[1GPU
M/Q5^$/BSPQ:QL^MPVG]N>&C'))#,-?T7=>6,$4\1$L)U)4FTF22,AE@OY>:\
MT\)?M'6LG[*K_&/5)XIM?\.^'9]&U2VN?]%:\\=V'EZ/8V\T5RRO!_;VI3:;
MJ2QR'=#8ZFLCG;&Q":MHXN*])1IU[?]/9/J/\ 7&DCG<,'
M^SW!LI(+A)$*F2SU#PO9R_*)P&[O]L__ )-R\??]=/"__J7:'5S]DWX?W7@?
MX0Z5?ZTLK^+/']S<>/?%-U=1I'>S7^O[)[1+P1Y N8M,%HUV@.T:A-?. #(Q
M-/\ ;/\ ^3U@EM&4(KSM)7?SE=_<9.$EEN,JU$U5Q
M-'$XBHGO'VE*7LJ;_P"O5%4H6Z/G[F1XHU>ZT/\ 8C.HV4DD-TOP%T"SAEB4
M-+&VJ>%=,TLO&K<&15O&*9Z, >U>/_!/]I1/ _PE^'OA>W_9]_:#U0:7X7TL
M7&JZ3X 6YTS5K^\A%_J6JV%PE]$L]IJ6H75S?6\HC3S(IT?:,U[\WA:\\;?L
M@Z=X6TX%M2UCX%Z%;Z:@02&34H_"%AM\!/A[/%<-->^'=%MO!VKI)&\-Q!J'AB*/3%%Q!)^\@>[T^*QU**-P#]GO86
MPPHNE"5X\UJCOJU:Z=MO1H7+4EBL.H5O8N66P4'[*G5YG&I1=2*51I)I2IR?
M+=N-KJRN<#_PV!+_ -&W_M*?^&Z_^^5M:UK14^T_#EOLZSZAI\]M;23;=09A'%<212LR*S*$W*I(K[YKSGXM?$.Q^%7P
M[\4^/+](;@:#ISRV-C/K7#I::3IHG8'8;W4)[>!G56,<;22E=L;$2I
M1;5J:O=6M.>]U;\3>K2KQI5'4QUJ:IS=1O"8>RAR2Y[^_P#R\WX)7;2?P;X]
MU'Q7X5_X)[6%EJFDWFAZV%TCPY-IFL6MQ9W5II?_ G;)9Q3V=TL=Q%&VE6]
MM'%!*B%K9D4J$;%?HIX-T>V\/^$?"V@V2)'::+X=T72K9$4*BP:?IMM:Q!0O
M &R('CKUKY@^..FZY\9/V0]7U'6M!;3O$.I>$=%\>2Z!82322VCZ7=67B1K2
M%I5$QNAI4$H,3#>MTQAW,!N;V[X(>.+/XB_"?P)XLM)DEDO_ ]I\&IHKH[6
MNMZ="NG:W9R^6S!9+;4[:ZCQGYD"2+F.1&9R;<+V_P"7L^:VR;2:_)V]",+&
M-/%*'-*2>6X14937+*5.E.<9MKI*\Z4IQW3:N>JUX%^U+H]MK?[/7Q;M;J*.
M46W@W4]7MQ(!M2]T-5UBQE!(.TQW5C$2P'W=P/!(KWVOD_\ ;6\=Z=X(_9Z\
M;17MR_-'3C)1CA,5*=N58>MS7\ZM_I7T!7S[^RD2W[.7P=9OO-X)TLG.:^@J)_%+_ !2_-E87_=<-
M_P!@]#_TS3"BBBI-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MSQ^/?@WQS\'OCIX7_:+^$GA/4O%<7B**;0/B1X3T6"Z:34R+:.,7DPL-/U"6
M)-1LK:VD^U-;21VVL:%93.))-1=)-/\ X;%^*7_1J/Q%_P# O7!_[H9K[[HK
M3G324H*32LGS23LMD[=MD^QY[P56%2K+#8RIAX5JCJRI*C0JP5222G*+J+FC
M[1I2E%:N?_,%1_PV+\4O^C4?B+_X%ZY_\P5?
M?=%'-#_GTO\ P.8?5<;_ -#.I_X283_(_/VY_;$^+1MK@6?[*7Q 6[,$HM6N
M+C7I(!<&-O(,R)X&B=HA+M,BI)&S(&570D,.Q_8[^$GB+POHGB7XK?$JWN%^
M*/Q5U.YU35EU".5+[2M'-W-<06;Q3_O;674[QY=3N+?;'Y=K_9-F\4;6 1?M
M&BAS7*XQBH\UN9IMMI;+797UTW95/!U%6IUL1BIXET5/V,94J-*-.=1*,JEJ
M7Q3Y$X1M%%% !1110 4444 %?F?_ ,%!O@?\3_C#=?#5OAYX4O?$D>BV?B:+4WLY]/B^
MQR7MSH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MKYQ_X)]_ ?XI_![Q#\0[OXA^$[[PY;:QHFCVNG37<^G2KM8%(Y%9C($ R "Q/'ZAT5*J24'3TY7J]-=T][^78WG@*53&T\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M=:->O6KXNI!IP]O).,7%WBVKRM[H.KVEK""H,MQ<:?<0PQ@L0H,DCJH+$*"!?%7PY^!>A>%O&>C
M7.A:[::MK\\^G7;6SSI#=:@\L$C&TN+F';*AW)B9CMP6"D[1]2T5CS/E<>C:
M?GI?_,]*5&,J]/$-RYZ=*K225N5QJRIRDWI>Z=-6LTK-W3TL5^8/BC]FCXF7
M?QSN_!.E:=M_9Q\7_$+3?BKXEEC%DMK'>6]E>OJNA3K)>-=D7]S<7>G0VT%A
MY26LFC3K,IT\A?T^HIQFX7M;56UZ=FO-7NB,3A*6*5-5')>SFIKD:3E%I*=*
M5T[TZL4HU(]4EJA%5454151%4*JJ JJJC"JJC "@ 8'%?/W[4GA/Q%X
MW^!_C+PUX4TJXUK7;]M!>STVU>!+BY6R\1Z3?7(A-S-;P%X[6VFD"/-'OV;5
M.X@'Z"HI)V:DMTT]?)W-:M.-:E4HR;4:M.=.3C:Z4XN+:NFKI/2ZMY'!_"S2
M=0T'X9?#O0]7MFL]5T?P/X5TO4K-V1WM;^PT.QM;NW=XF>-FAN(I(V:-V0E2
M58C!KYF\2?"GXH?!CQSXA^)W[/MEIOB7P_XMN9=5\=?!_4+F/3$O]39;B>;5
M?"U](\5K:7]QZB$&K6CV.GZ;]JT4U)IMV34KW3U33=_+KLUJM
MT9U,-"I"E%RG"5'E=&K!J-6G*,%#FB[.+4HKEG"490G%M2C:SC\>G]J;Q;'<
MKI4_[,7QS76#M1DM]"CN=&68J"0-9Q$7@5CM\\:?EAAUB*\CGE^''Q=_:-\4
M:#KOQNT2U^'?PI\,7XU;2?A3;ZDNJ:MXFU.&26.WNO%EY;B.(6GV<['@=+64
M6MS=ZM1HPFXM->U]DN:I%-)N#<82:7-&2]UQF*(Q& QQF$Q^482B^48MNSRS'C9Y>S
MY=F-NWY<8XKX5;X;?&#]FOQ/K6M_ [0[?XB_"?Q/J0U35OA9/?C3]6\,WLTL
M,4]QX9NIA(#:QVQ*1+!%>S-9VEII]QI-P]O#JJ?=U%*,G&^B:>\7L[;>::Z-
M--?>C:OAXU^27-.E5I-RI5J;2J4W)6DO>4HRA-64ZM*^FGTS3/V8?C=)K4<M!\&OBK\4="\:_$3XM66F2>,H_ /BK2/A7\+-&N(KS2O"&H:SH]W:_;KG4)I/
MLU_XFN?,C@6Z65H(Y MRTJ&'3K/2/NVBGSV^&*B^]VW;LF]D^ME=K2ZZXO"2
MJJV)Q%2O%)\L.2E2IJ3C)*7)&:4N1R2M./#7B&PETS6M&\,V=EJ6GSF)IK2YC:4M#*8))HMZJR[A'+(H)P&.,U[#114M
IW;;W;;^]M_J=5."I4Z=.+;5.$*:;M=J$8P3=K*[44W96O<****19_]D!

end



GRAPHIC
15
fin_001.jpg
GRAPHIC

begin 644 fin_001.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" L (D# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^]W4-1L](
MT^_U;4)DM[#2K*[U.^N)"%2"SL+>2[N9G9B%5(X87=F) !).!7^0E^T+\3K
MOXU_'WXX?&&^D:6Y^*7Q<^(OCYG:9K@"+Q3XMU;5[2*.9F8R006EU!!;G<56
MWCB1,(J@?Z>W_!5;XPM\"/\ @G1^V%\1K>ZEL]2M?@EXL\+:'M*W3P#HD]JQZ3VNH^)(+M2,L! Q ) %?Y55K;R2-:V<"&265[>T@C7J\LC)!#
M&ON[LJK[D5I!:W\C^:O'W,>?$<.Y/!MN%+&9C4BOYJ]2G@Z%TGOR4:K5T]'I
MKNQUWHZ'HRLI_P"! COQW[U_JG_\$F?&MW\0O^":?[$OBB]F:XN9OV?/ NBR
MRNVYBWA.Q;PF(R?6%-%6+';9C)QFO\L[Q-X&=7O]
M"UO3Y?\ 6V&K:7M9[M[B1I)?!6L_%3P-N9MVV#1_B-XAN[*-?[JQV&IVR*IYPN[HU$^G]/?_ASR
M/ >NZ/$V<8.:E&5?)YMP=U:>$QU"4HRB]I1]I+=75I+34_9S7=MO$>I6FC>'O#NDZCKNO:Q?RK!8Z5HVD6M>!7^5K_P4T_;5UW]OC]L7XJ?'JZNKP>!WU)O!OP>>S\,
M1PV[X6VN_$.;KQ;K2HB;]9UZ\#*%CC5?Z\_^#E[]O"/X&?LSZ/\ L@^!-;%M
M\4?VG8GG\:K93!;WP]\"='O"FM-<%07MV^(.N6\7A2TY'VO1;/Q;'\IC4M_!
MIIGA/7M7\/\ BGQ38:?)+X>\%KH?_"1:H2L=K83>)=0DTS0;+>V!+?:G<6]X
MUK:1YF>VL+^YV^3:2LI!=7_7];G?XW\43QN.P_"> G*I2P"6/S54FY*>+=-S
MHT)J-_=P>&DZ]5/2%7$1MK/1+NM*J.K-T5?Q; [\GH:_L9_X+&PR_LH?\$.O^">/[(.+:QU_P :2_#"Z\56(3R+
MIV\&^!KSQ_XQ#VI^;=_PGGBO2GU"9@#]M5<8$K"G/HOZOLO+^O,^&\/%]2P_
M&>?R5O[)X4QU"A)K18O.)PRRBDTTU+V=6NU;5KF:?NN_\M_05]Q?\ !-;]H _LO?MY?LM?&J>\>RT3PY\6?#NC>,)1-+#&? _C>5_!7B\W
M!B(,D-MH>O7>H"%@TMT31;%/,O-1NH+2YOI(+>,MZD89'C< @@AD=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MP_V6UF(ER0J!5' J]Y_\/T_#_/Y,_#<2UEOA;EM!6C5XDXGQF-J+3FEA,EP
MT,)1=KI\JQ.(JV=FE)-::'@DDL40!EDCC#$A3(ZH"0,D L1D@&/&G
MBKPEJ$&L>"O&'B3PMJMG*LUKJOA/Q%JN@ZC:S+\R2V]_HU[:7,,@ZJ\M'K7]?G_!JC^SOX9\3:3^UY\=_&7A/1/$, U+X=_"/PM)X@T?3]8M8WM+75?&
M/BT6L.I6US'%*#?^$A)-$%++F-B=A%?9/_!RC^R9^SG%^PI>_M"Z3\+_ +X
M.^,7PZ^)/PXTG0?&GA;P]I?AS6-:T/Q;KC:#K7A76Y=(MK1=M16XETZ]TV*>RE@1[J.X'+6S2:^=^OR_K?8[,%X98^OP2^-:.;4\/.GA,3F$<
M!*C6IU'AL)7E3+IU?=JU(4YU:2=-)\JBYIM-?@9_P3K_X+Z?M=?LK_$7P
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M.B6NH2R2,0L:(SL0!FOZ#?\ @ZS^,8\1_M1?LY? VSU&2:T^%OPM2(+;Q!\3O$SV=M+(,XDN/[!\%VC1L5!BBNY%0XFDS\;?\&X/PI'Q'_X*B_#G
MQ%<6RW&G_!KX<_$_XFW/F0^=$EX^@?\ "":,S%E9(I8]1\9I=VTA*LDUFK1G
M>HI+2+??^N_]?(]'C:7^LOB]A5"OC%HMKSQ/,GNT[M
M7T^&_P#@JEX4MO!7_!2/]MSP[90K;V<'[1?Q"U*SMU78D-KX@U/_ (2&"-%_
MN)'JBA3_ !+AN]?US_\ !M)\:_"_A7_@F%\9M2\=:Q;Z%X4^ WQO^*GB/Q-K
ME_,D5GI'A.;P3X3\:7MS*6*[$M(UU2<_,3*TBHB[\!OYJ?\ @OMX);P1_P %
M7_VHX]BQP>+9_AQX\ME4$?N_$GPS\*BY:74["_E9AQF0J.5-?,?PT_;@
M\6_"G]@/]H+]BGPE'J%BO[1GQF\&>-/&?B.&X2*VC^'OA?PY%;:MX1A1"+EK
MGQ9X@TSPV^I2 BW.AZ1>:?*LBZG(@&KQ5M?Z_I>6K/+R?/:7!7B'Q1CL0E&&
M&EQ30I4+-JOB*E6M/ 4%RJ\85,0Z+E+11I1GJGRG+_\ !0#]K_Q+^W+^UC\7
MOVDO$9NK73?%>MOIW@'0KI]Q\*?##P[OTWP1X?5% 2.>+28UU+5O+7$^NZGJ
MER2QFS7VA^V7^SRW[%W_ 37_8D^&'B2P_L_XU?M?^./%W[6WQ:M;E?)U?0/
M!WACPQIW@_X(>"[J XE6TM-$\<:[XBNH9T5K;Q-J>M6_S&W5EX?_ ((P_L.-
M^W9^W)\/O!?B+2VO_@_\*_)^,'QH>19/L5WX5\,:C:?V/X2GD1DS)XW\3R:9
MHLEN'\V31?[V30KHW[/WP=^'GP[L[>
MW2-((-1\0VEQ\1M72)8CL588_%6E6)BVH87L'B"A5 #ZJ*Z;^O\ 7^1Y]+"8
MB?"G$_&^:RE4QF>8^&39=4J*\JM;&8GZYG&*AS=(8?#PP<''2"J58PLH)+\>
M/V3?A+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M)L+/%U>TG'ZSB*::3DE))Z79[O\ \&[_ ,*H_B=_P5.^"^H7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MM+H_A#4WC\N\D;PKX&MOAWX4^SRN0)E'C[Q?JJ6$<8P+Y9U8.00/X^(E*1QH3
MDJBJ3ZD GTY.3QQ7]?G[>"/^RI_P;MY;^(;GQ!\?\ Q#<;/E6YG98+>*-6
M>26XF810QQHH+.[RNJ(J@LS$ #)HC]IZ^GX]WK^OD=GB!?"4>#.'HNW]D\+8
M"K6C=Z8S.ISS*LVG&+4N2M03;7,XI*2NM?[4/V#?VOO#G_!'O_@B/\"_VA/$
M7PMOOB7XI_:?^/\ XRU73/!T'B6U\(W>H6FJOKVG:;K[:I=:9JQ.FZ?X7^'>
MG7*6\.GRR3#68Y1+''@M^$/_ 4R_P""QO[17_!2U/#O@_Q=H'AWX2_!+PAK
M3>)-"^%'@^^OM774O$B075E9^(_&GB?4(K2Y\1ZEIMA>7-KI5M!IFD:1IQNK
MNYAT][R?[2O]-G[M'B+2/B##XSN+W7?B!KWAOPC9ZAK%G!X=T>_MD@LETO5DB-W/'=+)J]W$$$>9
M&^7/@=_P:M:Q1QYBM(G@N28 *4D5F.V4XJ[>K_ _5[_AW/T/B#AWQ*QV%P'"F2X6O0X9P
M^3Y/A*CE6P&$P^)KQP6'KXZIB,0ZBQ,Z3QM>K&5+DY)2P[?LIIJ_\RO[ ?[$
MWQ-_;Z_:6\#? 7X>:7?G2;W4K'5OBEXSBMI7TCX<_#6TO(F\1^)-7O0OV>VN
M9K-9=-\.6,KK<:QK]U965JC SR0_Z2/_ ["_8<_Z(9X7_\ *U_^1J]7_90
M_8U_9O\ V)?ANGPM_9M^&>C^ /#TTL%WK^I1F74_%OC/58(?)76?&?BO4&FU
MGQ%J(5I!;F]N39ZM&SIU<75J8>%;#X=4X2C3PV$]O3E)QASSE5K.,'6J--0C3A!/_+__ ."W?Q??
MXT?\%1OVL]=2[DN],\&>-=.^$6BA]I2VL?A9H&F^%+ZWMRO!MY/$EGK]^A/S
M%KV1B237[A?\&F7PF,FK?MC_ !WG6("UL?AK\'M)D,?[\M=S:MXV\0HDV.(2
MMOX9,D2L=SA&<#8I/\BWQ$\7Z[\0OB%X]^('BF[^W>)_'7C;Q7XR\1WN"HN]
M=\3Z]?ZWJUPJ,SLDM:OXU_:!^*6I^(+TX,MY/I$/AWP]IL>X*&%O::;IL*Q1,7VRRW,@8><56I:12
M]?Z_$_%_#-_ZP^*.(S>JV[5,\SF*FWS7J.K"A&WO:TXXR"Y6[1]GH_=2/Y[_
M /@YY\*7&A?\%*[+Q!)%L@\0?\MCHNJ>,/#DQ8X^\CZM2>"M?SLNRHK.Q 5%+,3T"J"23[ FOZK/^#L&SMH_P!JW]EK4$C5;J[_ &>=
M>M;B4 RQ6/Q&U1[8,0,L8S>W&"2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MUFXDN]7\:^)_$/B_5+J8YEN=0\3:Q>:W>3RD #S);B^D=\ ,2!P!7]>'[ L
M9^'O_!LQ^W-XU\*RS:;XC\7ZI\>!K.HH^)I$NHO WP^EB@>,1R0Q_P#"-H]N
MB^8Y2>XN)E(\TH/X[/NQ\<;4X'887BG'>3]7_7W?KW/A^,D\%PKX=Y1#X)Y/
MC<[JM/W98C-R;BEI<_T-O^#8[X1IX!_X)PS?$"XT]K35
M?C?\:_B!XM^UR B2^\/^%SIW@'1&PR@B!+GP[K,MORRLMR95P)"*[_\ X.-_
MV=8_CA_P38\;>-K"SAG\4?LW>+O#?QFTR<0/+>GP]#++X2\<6%LT:NT<4F@>
M(VUBYR A_L&!I'2.-C7V?_P2,\+:/X._X)F?L3:-H<#064WP"\&^()5=E=Y-
M4\603>*-:G9U1 ?M&KZO>RJ"N4C9(\MLW'[$^.?@WP_\1?@G\8? 'BRR&H^&
M/&WPO\>^%O$%B2%-UH^N^%M5T[4(4M(_IG 9!0Q'AQA,@:A[/$\+4J5VK15?$8#Z]"J[)MK6O^/U7
M;_#+P+J7Q1^)7P[^&>CP2W6J_$3QUX1\#:?;P F:6Z\5Z_I^AQ+'M5B&!OMP
M(4[=I..*XN2)8)9H$+%+>::W0L07*02O$A<@ %RJ L0 "Q) .*_33_@C'X:
MTGQ9_P %2_V*-*UJ%KBRM_B^/$4<2L%SJ?A#PGXF\5Z([Y5PT<.LZ-83R1X'
MF)&T>Y=VX;-^[\O^'_7^F?Q=D^"6/SG*\OE*T<9F>!PDI=HU\9AZ,GZ\DY-:
MZ.VNA^PO_!TQXXL?#_CS]B7]E;PXUI!X<^#_ ,&-=\6#3;23!LFUR\T?P'X=
MMI[8?ZJ.WT3P#<&Q+?-Y5S,%^4G/X _\$_OA$WQY_;A_9.^$FR9K;QC\>?AS
M%JI@A^T21:%HOB"U\2>(+DQ88-%;:+HU_<7!<;$@CD=_E4U]_P#_ <4>(]6
MU[_@K#\>;34K@S6WA;PC\&O#FAP_-LLM)'PTT'76MXPS-@2ZMKFJ7LFW:K37
M'-*\0?\ !5?X2W&J0&X?PO\ #?XR>)](!("0ZQ;^#IM*@N'!
M5BWE6NKWNP*482,K;L*5:%\#\W_7Y?UH?H6=16?^+KRZMA,+&FDMDZ."G&*5E::6EV?Z1+G+-Z9('T' 'X"FT45F?V6%%%% '_V0$!

end



GRAPHIC
16
fin_002.jpg
GRAPHIC

begin 644 fin_002.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" = 'L# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BOQY_X*
M%_\ !6;PA^QE^TS^Q%^QQX*\+:7\5?VB/VPOC1X(\)S^$YMM':Z+XH^)FMM9PW-PVH>7)>KX.T65;>/7+G2M5GEGCM-.D,GW]^UC^TY\+OV-
M?V=_BS^TS\9M772/AW\(?!^I>*=:*%3J.L74*K;Z'X7T.!C_ *9XB\5ZY<:?
MX=T&R4?Z5JNHVL3%(R\B?Q,_'O\ 9A^(_P -_P!K/_@CE_P51_:VA\1Q_MH?
MMQ_\%%_"S^//!NJ^(;R7P5\ /@IXMTFSM?@/^SQHVA>6T%MK7@;PU=Z>^L:G
M^XN;SQ7Y'UP2!_^JOPS_;R_X*M^(/A]^VC^R_\
M\$T?V*M'\*_%?]L'XR?$;PGK/QADUA)M6\%_L]_L]:5?PZ[\0]?\8KIMU!)%
MXUUGP59ZJ_AC3)YHH],1K?4=24RZEH-GJ6__ ,%$O^"@WQ=TGXN>$O\ @G3_
M ,$[M/\ #/C_ /;U^+.F'6/%'BG7$.J_#7]CGX0RDP:I\;_C!]E$T*ZK%'(&
M\#^"[PBZUW4/L\\MGML_&[Q!^S=\+OVA_'D-NVO_%:;PI-9ZM\>OBK8X$KV>E^/?'K:<_AT0W#B+PQ
M#!ILY\ZVF0 ']>WC7QSX+^&WAK4O&GQ#\7>&? G@_14@?6/%7C'7=+\->'=*
M2ZNH;*U;4=:UFZLM.LUN;VYM[2 W%S&)KF>&"/=+*BGI8)X+F"*YMYHI[>>.
M.:"XAD26&:&50\4T4L;-')%*C*\M_8!_9HTO4O&'P^_8I\&VW[4'[<'B;0;HC0O#-_=7VB^&/!'A3Q#<+&
M1XQT[5KK2IEDOIM9\1:9]CC,VA:F+;^V!_C#\,/VM^#W[.NB>/=8O+66%+&S\)^%/ %CJ26NDM+/Y4\MU:VT&GZ):BX>2_N[BSM('
MEEG3< ?F[_P4:^)/Q4_:F_::^!O_ 2W_95^)7B_X9^++C5O!G[2_P"VS\9?
MA[JNHZ'KOP3_ &9/!WB!+_PUX-T_Q#IDD&=.UG
M5-3C;29A%=];\9='_P""TGQ9^,/Q?T'X1_%#]D[]B/\ 9M^'NIVFD?#KXE^-
M/ >I?M&?%?XQ>&9=&AO=5\>WMO-XK\'^$_AN^D2"ZMGTS5M,OYEN@)I)+FUM
MI+BY\]_X(+>#O&_Q%^ 7Q<_X*1?&S238?'3_ (*9_%W6?V@+JVG82S^$/@+H
MHD\&?LX_#JSD*[ET?0/A]ID>JZ>\947UKK]K=72MMA3^P]^SAJ=MIW[3_ /P44\=W?[._@G6V1+R7X7_"BXT>>_\ C_\ &JYL/FMO@3X98[<>(==TE5F6Y6)6 /CSP/\ L6?\%,/VFOAYX"^,OP3_ .#A
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MY/!W[)'@/QKI;I-H.M>,3J,$/BKXUZGX6EB2319/%<=IIB7>Z[N+"Z,L\M^Z'P^\5KX[\!^"O'":7J&AIXR\)^'?%2:+J\7D:KI"^(=(L]673-2AY\J^L!
M=BUNX^J3Q2*>E=?3%5(D5$541 J(B@*JJ,!411@*JC 50 % %?/?P4_:
MI^!?[0_C/X^> O@_XXM_&?B+]F7XF/\ ![XRPV6FZK;V7A7XCP:7;ZM?>&$U
M2]LX-.UB]TJ&X%KJQTBXO(M.U&&>QNGCG3:0#Z'HKY&_:O\ VV?@=^QO!\((
MOBQ<^+M3\3_'OXI:'\'?A!\/OASX1U/QUX_\>>-M:;S)(-%\-Z7MF;2]!T]9
M=8\2ZMDZ7"\\DCRO#!+];H21DX['TQ\H)'4]#GO0 ZBOQJ_;R_X+/?"
M?]C'XJ:G\ O 7P _:%_;/^/'A#X>7/Q=^+'PT_9A\(+XPNO@C\,+>**>'Q;\
M6-5$KP>%8]2MI5OM-T^2VGO)=-V:A?VV?V:/A
M/^U'\+?$-WI'@CXM:'?ZIINB^+K06'B;0M0T+Q!K'A'Q+H&MVMI/>V:ZAH7B
MCP_K.DSRVEW<6ER;/[3;3/!-&Q /S#^*UR?^"J__ 5%M?V8/+&K?L0?\$O/
M$G@_XK_M%1/"+GP]\-O%.E2F6*Z\5
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M:Z%XT=TL!M)_5OBQ^QM\ /CIMCQWX=\.R^&M U[5?#5E<1:/K[Z!:W#7N@VFL6UY:Z/JT-KJ5C'%=VT4J@'XE
M_LR?\$9=:\)_\$A/VNOA-\5Y9/$'[>?_ 41^$_Q#^)G[3GQ&U*6.]UJ]^./
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M]A!&3_LECWK\'_\ @G1K7_#?O_!37]N[_@HI>W%OX@^#7[-FL7'_ 3X_8NO
MH95O=$:R\'R6GB#]I#XE>';A+B6VDN/&OC&YT?3+77+%!%JOA1;*TWD619_Z
M%Y$5T*,JLC#8R,H961AM*LI!!4@D%2,$9!&":\Z^%/P?^%GP-\(6_P /_@W\
M//!WPO\ !%G?ZEJEMX4\"^']-\-:%%J>LW37^JZ@NFZ7!;VQO-0NY7GN[DQF
M:>0@R.VU0 #TBBBB@#\E?^"R_P"V?^T+^QG^R%K>M_LE? OXE?'C]IGXI:C+
M\./A!I/@#P#KWCRQ\$:S?:9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MCPLX4MK.QL;.V2.WM+2UMXXX+:V@CCA@AC2*)%1547* /_]D!

end



GRAPHIC
17
ex23-1_001.jpg
GRAPHIC

begin 644 ex23-1_001.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" L (D# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^]W4-1L](
MT^_U;4)DM[#2K*[U.^N)"%2"SL+>2[N9G9B%5(X87=F) !).!7^0E^T+\3K
MOXU_'WXX?&&^D:6Y^*7Q<^(OCYG:9K@"+Q3XMU;5[2*.9F8R006EU!!;G<56
MWCB1,(J@?Z>W_!5;XPM\"/\ @G1^V%\1K>ZEL]2M?@EXL\+:'M*W3P#HD]JQZ3VNH^)(+M2,L! Q ) %?Y55K;R2-:V<"&265[>T@C7J\LC)!#
M&ON[LJK[D5I!:W\C^:O'W,>?$<.Y/!MN%+&9C4BOYJ]2G@Z%TGOR4:K5T]'I
MKNQUWHZ'HRLI_P"! COQW[U_JG_\$F?&MW\0O^":?[$OBB]F:XN9OV?/ NBR
MRNVYBWA.Q;PF(R?6%-%6+';9C)QFO\L[Q-X&=7O]
M"UO3Y?\ 6V&K:7M9[M[B1I)?!6L_%3P-N9MVV#1_B-XAN[*-?[JQV&IVR*IYPN[HU$^G]/?_ASR
M/ >NZ/$V<8.:E&5?)YMP=U:>$QU"4HRB]I1]I+=75I+34_9S7=MO$>I6FC>'O#NDZCKNO:Q?RK!8Z5HVD6M>!7^5K_P4T_;5UW]OC]L7XJ?'JZNKP>!WU)O!OP>>S\,
M1PV[X6VN_$.;KQ;K2HB;]9UZ\#*%CC5?Z\_^#E[]O"/X&?LSZ/\ L@^!-;%M
M\4?VG8GG\:K93!;WP]\"='O"FM-<%07MV^(.N6\7A2TY'VO1;/Q;'\IC4M_!
MIIGA/7M7\/\ BGQ38:?)+X>\%KH?_"1:H2L=K83>)=0DTS0;+>V!+?:G<6]X
MUK:1YF>VL+^YV^3:2LI!=7_7];G?XW\43QN.P_"> G*I2P"6/S54FY*>+=-S
MHT)J-_=P>&DZ]5/2%7$1MK/1+NM*J.K-T5?Q; [\GH:_L9_X+&PR_LH?\$.O^">/[(.+:QU_P :2_#"Z\56(3R+
MIV\&^!KSQ_XQ#VI^;=_PGGBO2GU"9@#]M5<8$K"G/HOZOLO+^O,^&\/%]2P_
M&>?R5O[)X4QU"A)K18O.)PRRBDTTU+V=6NU;5KF:?NN_\M_05]Q?\ !-;]H _LO?MY?LM?&J>\>RT3PY\6?#NC>,)1-+#&? _C>5_!7B\W
M!B(,D-MH>O7>H"%@TMT31;%/,O-1NH+2YOI(+>,MZD89'C< @@AD=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MP_V6UF(ER0J!5' J]Y_\/T_#_/Y,_#<2UEOA;EM!6C5XDXGQF-J+3FEA,EP
MT,)1=KI\JQ.(JV=FE)-::'@DDL40!EDCC#$A3(ZH"0,D L1D@&/&G
MBKPEJ$&L>"O&'B3PMJMG*LUKJOA/Q%JN@ZC:S+\R2V]_HU[:7,,@ZJ\M'K7]?G_!JC^SOX9\3:3^UY\=_&7A/1/$, U+X=_"/PM)X@T?3]8M8WM+75?&
M/BT6L.I6US'%*#?^$A)-$%++F-B=A%?9/_!RC^R9^SG%^PI>_M"Z3\+_ +X
M.^,7PZ^)/PXTG0?&GA;P]I?AS6-:T/Q;KC:#K7A76Y=(MK1=M16XETZ]TV*>RE@1[J.X'+6S2:^=^OR_K?8[,%X98^OP2^-:.;4\/.GA,3F$<
M!*C6IU'AL)7E3+IU?=JU(4YU:2=-)\JBYIM-?@9_P3K_X+Z?M=?LK_$7P
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M.B6NH2R2,0L:(SL0!FOZ#?\ @ZS^,8\1_M1?LY? VSU&2:T^%OPM2(+;Q!\3O$SV=M+(,XDN/[!\%VC1L5!BBNY%0XFDS\;?\&X/PI'Q'_X*B_#G
MQ%<6RW&G_!KX<_$_XFW/F0^=$EX^@?\ "":,S%E9(I8]1\9I=VTA*LDUFK1G
M>HI+2+??^N_]?(]'C:7^LOB]A5"OC%HMKSQ/,GNT[M
M7T^&_P#@JEX4MO!7_!2/]MSP[90K;V<'[1?Q"U*SMU78D-KX@U/_ (2&"-%_
MN)'JBA3_ !+AN]?US_\ !M)\:_"_A7_@F%\9M2\=:Q;Z%X4^ WQO^*GB/Q-K
ME_,D5GI'A.;P3X3\:7MS*6*[$M(UU2<_,3*TBHB[\!OYJ?\ @OMX);P1_P %
M7_VHX]BQP>+9_AQX\ME4$?N_$GPS\*BY:74["_E9AQF0J.5-?,?PT_;@
M\6_"G]@/]H+]BGPE'J%BO[1GQF\&>-/&?B.&X2*VC^'OA?PY%;:MX1A1"+EK
MGQ9X@TSPV^I2 BW.AZ1>:?*LBZG(@&KQ5M?Z_I>6K/+R?/:7!7B'Q1CL0E&&
M&EQ30I4+-JOB*E6M/ 4%RJ\85,0Z+E+11I1GJGRG+_\ !0#]K_Q+^W+^UC\7
MOVDO$9NK73?%>MOIW@'0KI]Q\*?##P[OTWP1X?5% 2.>+28UU+5O+7$^NZGJ
MER2QFS7VA^V7^SRW[%W_ 37_8D^&'B2P_L_XU?M?^./%W[6WQ:M;E?)U?0/
M!WACPQIW@_X(>"[J XE6TM-$\<:[XBNH9T5K;Q-J>M6_S&W5EX?_ ((P_L.-
M^W9^W)\/O!?B+2VO_@_\*_)^,'QH>19/L5WX5\,:C:?V/X2GD1DS)XW\3R:9
MHLEN'\V31?[V30KHW[/WP=^'GP[L[>
MW2-((-1\0VEQ\1M72)8CL588_%6E6)BVH87L'B"A5 #ZJ*Z;^O\ 7^1Y]+"8
MB?"G$_&^:RE4QF>8^&39=4J*\JM;&8GZYG&*AS=(8?#PP<''2"J58PLH)+\>
M/V3?A+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M)L+/%U>TG'ZSB*::3DE))Z79[O\ \&[_ ,*H_B=_P5.^"^H7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MM+H_A#4WC\N\D;PKX&MOAWX4^SRN0)E'C[Q?JJ6$<8P+Y9U8.00/X^(E*1QH3
MDJBJ3ZD GTY.3QQ7]?G[>"/^RI_P;MY;^(;GQ!\?\ Q#<;/E6YG98+>*-6
M>26XF810QQHH+.[RNJ(J@LS$ #)HC]IZ^GX]WK^OD=GB!?"4>#.'HNW]D\+8
M"K6C=Z8S.ISS*LVG&+4N2M03;7,XI*2NM?[4/V#?VOO#G_!'O_@B/\"_VA/$
M7PMOOB7XI_:?^/\ XRU73/!T'B6U\(W>H6FJOKVG:;K[:I=:9JQ.FZ?X7^'>
MG7*6\.GRR3#68Y1+''@M^$/_ 4R_P""QO[17_!2U/#O@_Q=H'AWX2_!+PAK
M3>)-"^%'@^^OM774O$B075E9^(_&GB?4(K2Y\1ZEIMA>7-KI5M!IFD:1IQNK
MNYAT][R?[2O]-G[M'B+2/B##XSN+W7?B!KWAOPC9ZAK%G!X=T>_MD@LETO5DB-W/'=+)J]W$$$>9
M&^7/@=_P:M:Q1QYBM(G@N28 *4D5F.V4XJ[>K_ _5[_AW/T/B#AWQ*QV%P'"F2X6O0X9P
M^3Y/A*CE6P&$P^)KQP6'KXZIB,0ZBQ,Z3QM>K&5+DY)2P[?LIIJ_\RO[ ?[$
MWQ-_;Z_:6\#? 7X>:7?G2;W4K'5OBEXSBMI7TCX<_#6TO(F\1^)-7O0OV>VN
M9K-9=-\.6,KK<:QK]U965JC SR0_Z2/_ ["_8<_Z(9X7_\ *U_^1J]7_90
M_8U_9O\ V)?ANGPM_9M^&>C^ /#TTL%WK^I1F74_%OC/58(?)76?&?BO4&FU
MGQ%J(5I!;F]N39ZM&SIU<75J8>%;#X=4X2C3PV$]O3E)QASSE5K.,'6J--0C3A!/_+__ ."W?Q??
MXT?\%1OVL]=2[DN],\&>-=.^$6BA]I2VL?A9H&F^%+ZWMRO!MY/$EGK]^A/S
M%KV1B237[A?\&F7PF,FK?MC_ !WG6("UL?AK\'M)D,?[\M=S:MXV\0HDV.(2
MMOX9,D2L=SA&<#8I/\BWQ$\7Z[\0OB%X]^('BF[^W>)_'7C;Q7XR\1WN"HN]
M=\3Z]?ZWJUPJ,SLDM:OXU_:!^*6I^(+TX,MY/I$/AWP]IL>X*&%O::;IL*Q1,7VRRW,@8><56I:12
M]?Z_$_%_#-_ZP^*.(S>JV[5,\SF*FWS7J.K"A&WO:TXXR"Y6[1]GH_=2/Y[_
M /@YY\*7&A?\%*[+Q!)%L@\0?\MCHNJ>,/#DQ8X^\CZM2>"M?SLNRHK.Q 5%+,3T"J"23[ FOZK/^#L&SMH_P!JW]EK4$C5;J[_ &>=
M>M;B4 RQ6/Q&U1[8,0,L8S>W&"2M+ISZSX&\:?&WPI9>)]'67R4U?3=/>XUMM+N7V.38:A/ID-KJ,2A7N+"6YMUD
MB:42HT[0OV_6WZO4^;X[RV>*\2LYRVC.*J8_/*%*G.;:C"68+ */,TFU&$L0
M[V3=EHF[7_NK_P"#?O\ 873]D']B'P]XY\8:&NG_ !I_:=;3/BOXYDN[4P:K
MHO@Z>S;_ (5EX+N#*JS0Q:7X=NI/$-[;.$:+6_$^IQ2J?L\0C_@N_;X^+K_'
MK]MK]JSXO%]UMXV^.WQ$N]*Q.;A$T#2]?N] \/1Q3%FW0KHFDV'EJI,:*=D9
M**I/^J%^T!J][X2_9^^./B#072PU'PO\&/B9K&B/"GEQV5[HG@C6KO36BCB,
M?EQVTUM"8TB,>Q454*X&/\@*&:6YBCN9W:6>Y47,\KG+RSW'[Z:1SU+22.SL
M3R68D\U,-6W_ %_6K/OO&3#4<@R'@SA? QY<'A*>+K-I*/MJM"G0PSK3BEK4
MJU:N*Q$W=^]54;R44S^N[_@UU\+Z?\//"_[?_P"U_P"(8Y1H_P -OAYH'A**
M01;1)I^AZ5XD^*/C 03L"KR+;Z+X<5HQCRRT;.&$J;?Y-?%OBK4O'?BWQ7XY
MUFXDN]7\:^)_$/B_5+J8YEN=0\3:Q>:W>3RD #S);B^D=\ ,2!P!7]>'[ L
M9^'O_!LQ^W-XU\*RS:;XC\7ZI\>!K.HH^)I$NHO WP^EB@>,1R0Q_P#"-H]N
MB^8Y2>XN)E(\TH/X[/NQ\<;4X'887BG'>3]7_7W?KW/A^,D\%PKX=Y1#X)Y/
MC<[JM/W98C-R;BEI<_T-O^#8[X1IX!_X)PS?$"XT]K35
M?C?\:_B!XM^UR B2^\/^%SIW@'1&PR@B!+GP[K,MORRLMR95P)"*[_\ X.-_
MV=8_CA_P38\;>-K"SAG\4?LW>+O#?QFTR<0/+>GP]#++X2\<6%LT:NT<4F@>
M(VUBYR A_L&!I'2.-C7V?_P2,\+:/X._X)F?L3:-H<#064WP"\&^()5=E=Y-
M4\603>*-:G9U1 ?M&KZO>RJ"N4C9(\MLW'[$^.?@WP_\1?@G\8? 'BRR&H^&
M/&WPO\>^%O$%B2%-UH^N^%M5T[4(4M(_IG 9!0Q'AQA,@:A[/$\+4J5VK15?$8#Z]"J[)MK6O^/U7
M;_#+P+J7Q1^)7P[^&>CP2W6J_$3QUX1\#:?;P F:6Z\5Z_I^AQ+'M5B&!OMP
M(4[=I..*XN2)8)9H$+%+>::W0L07*02O$A<@ %RJ L0 "Q) .*_33_@C'X:
MTGQ9_P %2_V*-*UJ%KBRM_B^/$4<2L%SJ?A#PGXF\5Z([Y5PT<.LZ-83R1X'
MF)&T>Y=VX;-^[\O^'_7^F?Q=D^"6/SG*\OE*T<9F>!PDI=HU\9AZ,GZ\DY-:
MZ.VNA^PO_!TQXXL?#_CS]B7]E;PXUI!X<^#_ ,&-=\6#3;23!LFUR\T?P'X=
MMI[8?ZJ.WT3P#<&Q+?-Y5S,%^4G/X _\$_OA$WQY_;A_9.^$FR9K;QC\>?AS
M%JI@A^T21:%HOB"U\2>(+DQ88-%;:+HU_<7!<;$@CD=_E4U]_P#_ <4>(]6
MU[_@K#\>;34K@S6WA;PC\&O#FAP_-LLM)'PTT'76MXPS-@2ZMKFJ7LFW:K37
M'-*\0?\ !5?X2W&J0&X?PO\ #?XR>)](!("0ZQ;^#IM*@N'!
M5BWE6NKWNP*482,K;L*5:%\#\W_7Y?UH?H6=16?^+KRZMA,+&FDMDZ."G&*5E::6EV?Z1+G+-Z9('T' 'X"FT45F?V6%%%% '_V0$!

end



GRAPHIC
18
ex23-1_002.jpg
GRAPHIC

begin 644 ex23-1_002.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" B )(# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)BM=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BOG[]JG
M]ISX0_L:_L^?%3]IKX[^(AX9^%OPA\+7?BCQ+?1Q+MVGXF\4:U=:?X=\-Z6)8OM^MZG8VS301R//'[^S!<9SSTZ=?3KU/:OX9?^"^.
MO?&3_@KI8?MK_"S]GCXG:/X&_87_ ."0_P .O%GQ6_:%^(,UCJVLZ/\ M!_M
MB>%O#>K:PWP+\.OI=U;07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M="\0Z]H,TKZKHX\6:N ?M[^R1_P %>1^W;_P4T^/G[*G[+GP_
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M^'=&U!/,^U7%G!/^B-E;M:6-M:FXN;Q[:U@MVNKQXY+RZ:&!(S<7ME?-G=(XT:5V9$52JC^:3X"^*=-_X*C_\%TOB]\<8&A\1?LK_ /!'?PMJ?P!^
M#$S&.[\/>+OVS/BN]W:?%[X@Z:OGSV5[+X \/Z'J7@JUGCB8VEUIOA7Q+IT\
M+W\4C 'J/A/Q!_P5'_X)R?L)_L2_L]>&?@YX]_X*6?MK__$NF?%GXP_$O
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M)U.S3P_K\.K.MZFG6H!]%:1^QC_PMA;5=%OK^"'R8+;4=(D\!:-=>&[:? FNM1T_Q%X@NEG9F%A.H53P^O?M]?\%F
M_P#@F)XY^#Z_X+^(7P[U_P")
M=W)IGA[Q!XP^&^N6^F6NJZ9:Z@DSZA9Z#X.TZVDL[1H[;7EU:ZT_3[_W;XG?
M\'+'_!/^>SN/#'[%FE?';_@HA\=+Z&RB\)?![]F;X)?%2Y?5-3U$E+4>(O&'
MB?P7I&E>'-'M6*-K-[:6?B'5-/BE5XM#NRDXA\X^#?[&G_!0O_@J+^T1\"?V
MM?\ @K+X1\'_ +,7[.G[-GBVP^+'[./_ 3J\!^)&\8:MJ_Q9TWR)_#?Q6_:
M2\7P2-I^JWOAF91M" 3D]STR?I29Y P><\]N #^NMXV-Y/IU[]CNK>Z%G?VS!;FQNO(DD\B\MRR^?:R[)X=RB1%R,@%^B@G )]!FO
MDSXD?MZ?L2?!WXDV?P<^*_[6_P"SC\./BO?7FFZ?#\.?&GQE\ >'/&<=[K$:
M2Z3:WOA[5->MM3TZ;4XI89+!-1M[4W<<\#P;UGB+@'UG148D# ,JLRL 59=K
M*P(R"K!L%2.01P1S10!^//\ P61_;C\=?LQ_ _P9\ _V8B-:_;W_ &X/%G_#
M/W[(GA.U$LE_I&OZX]G8^./C3J7DQ3_V7X7^#?AK5'\1W>NWD;V%AKM,NDQZK);])\(O^"6?P^^ O\ P2B\_$C6;
M=S??$;XU?&/PCK5GXS^*OBAI'DO;N?5?%NJI=VJ7UW=WFF^'=/T?0Q>2P:5
M]?/7[''[(G[1'Q;_ ."K7[97_!2O]LSP!=^ 5^&=SJ7[('_!/KX;:OK.F^(+
M;0?@3X?<'QC\?](DTO4K^TT^Z^-MU#3]:L]-\0^,]%U2U-FNE.?WJ
M(### $>AY_I_A0!_GC_\$YO&/_!7_P#:_P#V5O ?_!"CX:_!KQ?^Q3\.?V>)
M_B)\+OVY_P!M3Q7IGB*'Q3H_PUU3XC>+M;N?A-\.;2\TW1-.TOQAXAT;6KCP
MDEGI&KZYJWBG2XO[4CU7PCX-;6-0NOLK_@K5^S-\(O!GQ@_X(D_\&_G[+O@=
MO!W[/?CWXTZ=\<_C=H=A.9M1\;^!? .K&WU;7_'5_"D-YXG\0:]I.F?%[Q;X
MJUG4PLMM:U^(OQ'N+R)D687>LK/(0MS " ?KQ_P5G_X*!^$?^"8G["WQ0_:":#3+KQ[;
MZ?;_ W_ &>/ 3Q;D\:_&CQ3:7-AX!\/6>F6R^=>:5H@M[GQ5XBM+5$9?"WA
MS5HK9QGZEXS_ ."D'QN^)WP-
M_:\^,?B/7UL]4\3?#'1]/^,FBZT?"%U+<6LK'6;2Q\;>(O&GQMFC3_ &O3/ NFW-Q_03\=?V/OCA_P43_X+6?#SQ#^T%\+?%7A;_@GU_P3(\*>
M&/'_ ,'HO%=@MOX2_:@_:O\ B#:Z=XFA\5Z&GGSV_B/PA\+$LM(M-6:6%3I?
MB7P6NB7$$MAXQU2&OW>^-OPA\%_'[X-?%7X&?$BP.I> OC!\//&/PT\8V48A
M,\WAWQMH%_X>U8VCW$%Q##?Q6>H2S6%R\$OV6]BM[E5+Q+@ _'#_ (*B_P#!
M6C0/V3?^".4/[M%!%'+&EQ'\/=!?7_ !Y>VP4Q22^%UTJ58WO M=)_P;P?L<:U^QG_ ,$L?@'X
M=\=Z5<:=\8/C:NL?M)_&%M33.O2^+?B]-#K.BVOB&:4M=R:WHOP^@\&Z+JL=
MY(]Q;:I8WT4N)?-)_G5^%7_!'G_@JU\M\4^*_$G@KXUZ?=Z3+X;_ &C/A_:>+XO$_P /])U_29?$VHZEJOB?7M)T[P?\
M+YO"[^'=$C\"^!K/Q6M^U[_ODC38N H 55P%15 554 !5 P !P/
M6@#\C/\ @ME^W%XB_8B_8B\2WOPF,FH?M1?M&>)-#_9?_90\-V+J=9U+XW?&
M"23P]HVN:;;_ #/+)X'TV;4O%D),4EO-JVG:/I=P4.J1;OH3]@C]A3X:?L7_
M +$/P+_8\_L3P_XSTWX;^#]/;QUJ&MZ59:U:>.?BKK=Q/XF^)'CF^@U2UG%U
M<>(/'&JZUJ5E)>I+MD^'*_L*_L,> _&7C_P"&VA1>*-3N_'OC#]IWQE;QV%OK>O>$7TF/3+2P\&3:
M?X:UKP]J@U*8VTWAL/$SSZW<6]A^W_\ /O0!SGAKP=X1\&6;:?X/\*^'/"FG
ML0S6/AK0],T*S9@6(9K;2[6UA)!9B"4SEF/4G/1X&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MXXK4:G=-?7=OMP1I*Z!X8\'^'?VRKOP1X6T'0+>)K6PT'0=$\*^"M/LM!T>QLB+&&PTF.UA6V
M!C01AN #[<_X+-?MI:A^Q?\ L._$#5/A]?7B_M*?M WMA^S!^R1H.DW$%OX@
MUO\ :(^-$5UX6\$WNCR7$]O!;-X-6XOO&]Q>W,T-G#_8$%J\HNKZUCE]2_X)
MB?L!> /^"F_\+$^
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M,G@[4?A1<6-S/%=V.JZ9'J/A>VM=?N=M#^ ]O\!^0H ^>_V>?@EK/P5^ /P-^#>L_$CQ3XTUCX2_![X9_#+5?&-Y=1B\
M\6:EX#\%Z)X5OO$UV+B":X%SKUUI4NJ3^?-+-YMTWFRR/N8E?0M% $<8 !P
M.>P^E2444 %<1I7PU^'.A>.?%?Q,T3P!X)T?XD>.M.T+2_&WQ TKPKH6G^-_
M&.F>&8IK;PYIWBKQ7:6$.O>(;#P_;RRV^B6FKW]Y;Z5#))%81V\;LI** .U'
MWOS_ ))3B 1@@$'J#R#^%%% #"!GH.-F..GS9_G3Z** &8'' ^\W;_>I]%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end



EX-101.SCH
19
pbm-20250331.xsd
XBRL SCHEMA FILE













995301 - Statement - Consolidated Statements of Financial Position
link:presentationLink
link:definitionLink
link:calculationLink


995302 - Statement - Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss)
link:presentationLink
link:definitionLink
link:calculationLink


995303 - Statement - Consolidated Statements of Changes in Shareholders’ Equity/(Deficit)
link:presentationLink
link:definitionLink
link:calculationLink


995304 - Statement - Consolidated Statements of Cash Flows
link:presentationLink
link:definitionLink
link:calculationLink


995305 - Disclosure - Nature of Operations and Going Concern
link:presentationLink
link:definitionLink
link:calculationLink


995306 - Disclosure - Basis of Presentation
link:presentationLink
link:definitionLink
link:calculationLink


995307 - Disclosure - Material Accounting Policies
link:presentationLink
link:definitionLink
link:calculationLink


995308 - Disclosure - Critical Accounting Estimates and Judgements
link:presentationLink
link:definitionLink
link:calculationLink


995309 - Disclosure - Reverse Takeover Transaction with NCAC
link:presentationLink
link:definitionLink
link:calculationLink


995310 - Disclosure - Cash, Restricted Cash and Cash Equivalents
link:presentationLink
link:definitionLink
link:calculationLink


995311 - Disclosure - Equipment
link:presentationLink
link:definitionLink
link:calculationLink


995312 - Disclosure - Accounts Payable and Accrued Liabilities
link:presentationLink
link:definitionLink
link:calculationLink


995313 - Disclosure - Convertible Note Liability
link:presentationLink
link:definitionLink
link:calculationLink


995314 - Disclosure - Derivative Warrant Liabilities
link:presentationLink
link:definitionLink
link:calculationLink


995315 - Disclosure - Promissory Notes
link:presentationLink
link:definitionLink
link:calculationLink


995316 - Disclosure - ELOC
link:presentationLink
link:definitionLink
link:calculationLink


995317 - Disclosure - Psyence Labs Ltd. Share Exchange
link:presentationLink
link:definitionLink
link:calculationLink


995318 - Disclosure - PIPE Financing - Private Placement and Warrants
link:presentationLink
link:definitionLink
link:calculationLink


995319 - Disclosure - Share Capital
link:presentationLink
link:definitionLink
link:calculationLink


995320 - Disclosure - Other Income
link:presentationLink
link:definitionLink
link:calculationLink


995321 - Disclosure - Capital Management
link:presentationLink
link:definitionLink
link:calculationLink


995322 - Disclosure - Transactions with Related Parties
link:presentationLink
link:definitionLink
link:calculationLink


995323 - Disclosure - Share Based Compensation
link:presentationLink
link:definitionLink
link:calculationLink


995324 - Disclosure - Income Tax Note
link:presentationLink
link:definitionLink
link:calculationLink


995325 - Disclosure - Financial Instruments and Financial Risk Management
link:presentationLink
link:definitionLink
link:calculationLink


995326 - Disclosure - Subsequent Events
link:presentationLink
link:definitionLink
link:calculationLink


996000 - Disclosure - Accounting Policies, by Policy (Policies)
link:presentationLink
link:definitionLink
link:calculationLink


996001 - Disclosure - Basis of Presentation (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996002 - Disclosure - Material Accounting Policies (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996003 - Disclosure - Reverse Takeover Transaction with NCAC (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996004 - Disclosure - Cash, Restricted Cash and Cash Equivalents (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996005 - Disclosure - Equipment (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996006 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996007 - Disclosure - Convertible Note Liability (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996008 - Disclosure - Derivative Warrant Liabilities (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996009 - Disclosure - Psyence Labs Ltd. Share Exchange (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996010 - Disclosure - PIPE Financing - Private Placement and Warrants (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996011 - Disclosure - Share Capital (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996012 - Disclosure - Capital Management (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996013 - Disclosure - Transactions with Related Parties (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996014 - Disclosure - Income Tax Note (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996015 - Disclosure - Financial Instruments and Financial Risk Management (Tables)
link:presentationLink
link:definitionLink
link:calculationLink


996016 - Disclosure - Basis of Presentation - Schedule of Subsidiaries (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996017 - Disclosure - Material Accounting Policies (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996018 - Disclosure - Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996019 - Disclosure - Material Accounting Policies - ​Schedule of Change in Presentation Currency (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996020 - Disclosure - Critical Accounting Estimates and Judgements (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996021 - Disclosure - Reverse Takeover Transaction with NCAC (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996022 - Disclosure - Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996023 - Disclosure - Cash, Restricted Cash and Cash Equivalents (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996024 - Disclosure - Cash, Restricted Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996025 - Disclosure - Equipment - Schedule of Equipment (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996026 - Disclosure - Accounts Payable and Accrued Liabilities - ​Schedule of Accounts Payable and Accrued Liabilities (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996027 - Disclosure - Convertible Note Liability (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996028 - Disclosure - Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996029 - Disclosure - Derivative Warrant Liabilities (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996030 - Disclosure - Derivative Warrant Liabilities - Schedule of Private Warrants (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996031 - Disclosure - Derivative Warrant Liabilities - Schedule of Derivative Warrant Liability (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996032 - Disclosure - Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996033 - Disclosure - Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996034 - Disclosure - Promissory Notes (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996035 - Disclosure - ELOC (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996036 - Disclosure - Psyence Labs Ltd. Share Exchange (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996037 - Disclosure - Psyence Labs Ltd. Share Exchange - Schedule of Investment is Classified as a Financial Asset Measured at Fair Value (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996038 - Disclosure - PIPE Financing - Private Placement and Warrants (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996039 - Disclosure - PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996040 - Disclosure - PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996041 - Disclosure - Share Capital (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996042 - Disclosure - Share Capital - Schedule of Issued and Outstanding Common Shares (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996043 - Disclosure - Share Capital - Schedule of Issued and Outstanding Warrants (Details)
link:presentationLink
link:definitionLink
link:calculationLink



996044 - Disclosure - Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996045 - Disclosure - Other Income (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996046 - Disclosure - Capital Management - Schedule of Total Managed Capital (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996047 - Disclosure - Transactions with Related Parties - Schedule of Key Management Personnel (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996048 - Disclosure - Share Based Compensation (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996049 - Disclosure - Income Tax Note (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996050 - Disclosure - Income Tax Note - Schedule of Canadian Federal and Provincial Statutory Income Tax Rate (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996051 - Disclosure - Income Tax Note - Schedule of Deferred Tax Assets (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996052 - Disclosure - Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996053 - Disclosure - Financial Instruments and Financial Risk Management (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996054 - Disclosure - Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996055 - Disclosure - Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details)
link:presentationLink
link:definitionLink
link:calculationLink


996056 - Disclosure - Subsequent Events (Details)
link:presentationLink
link:definitionLink
link:calculationLink


000 - Document - Document And Entity Information
link:presentationLink
link:definitionLink
link:calculationLink
































































































































































































































































































































































EX-101.CAL
20
pbm-20250331_cal.xml
XBRL CALCULATION FILE



























































































































































































EX-101.DEF
21
pbm-20250331_def.xml
XBRL DEFINITION FILE















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EX-101.LAB
22
pbm-20250331_lab.xml
XBRL LABEL FILE





EX-101.PRE
23
pbm-20250331_pre.xml
XBRL PRESENTATION FILE









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































XML
25
R1.htm
IDEA: XBRL DOCUMENT








v3.25.2









































































































































































































































Cover
12 Months Ended

Mar. 31, 2025

shares

Document Information [Line Items] 
Document Type20-F
Document Registration Statementfalse
Document Annual Reporttrue
Document Transition Reportfalse
Document Financial Statement Error Correction [Flag]false
Document Shell Company Reportfalse
Entity Interactive Data CurrentYes
Document Accounting StandardInternational Financial Reporting Standards
ICFR Auditor Attestation Flagfalse
Amendment Flagfalse
Document Period End DateMar. 31, 2025
Document Fiscal Year Focus2025
Document Fiscal Period FocusFY
Entity Information [Line Items] 
Entity Registrant NamePsyence Biomedical Ltd.
Entity Central Index Key0001985062
Entity File Number001-41937
Entity Incorporation, State or Country CodeA6
Current Fiscal Year End Date--03-31
Entity Well-known Seasoned IssuerNo
Entity Voluntary FilersNo
Entity Current Reporting StatusYes
Entity Shell Companyfalse
Entity Filer CategoryNon-accelerated Filer
Entity Emerging Growth Companytrue
Entity Ex Transition Periodfalse
Entity Contact Personnel [Line Items] 
Entity Address, Address Line One121 Richmond Street West
Entity Address, Address Line TwoPenthouse Suite 1300
Entity Address, City or TownToronto
Entity Address, State or ProvinceON
Entity Address, CountryCA
Entity Address, Postal Zip CodeM5H 2K1
Entity Listings [Line Items] 
Entity Common Stock, Shares Outstanding568,021
Common shares, without par value 
Entity Listings [Line Items] 
Title of 12(b) SecurityCommon shares, without par value
Trading SymbolPBM
Security Exchange NameNASDAQ
Warrants, each exercisable to purchase one Common Share at an exercise price of $11.50 per share 
Entity Listings [Line Items] 
Title of 12(b) SecurityWarrants, each exercisable to purchase one Common Share at an exercise price of $6,874.13 per share
Trading SymbolPBMWW
Security Exchange NameNASDAQ
Business Contact [Member] 
Entity Contact Personnel [Line Items] 
Contact Personnel NameNeil Maresky
Entity Address, Address Line One121 Richmond Street West
Entity Address, Address Line TwoPenthouse Suite 1300
Entity Address, City or TownToronto
Entity Address, State or ProvinceON
Entity Address, Postal Zip CodeM5H 2K1
Entity Phone Fax Numbers [Line Items] 
City Area Code+1 (416)
Local Phone Number346-7764
































































































































































































XML
26
R2.htm
IDEA: XBRL DOCUMENT








v3.25.2

























Audit Information
12 Months Ended
Mar. 31, 2025
Auditor [Table] 
Auditor NameMNP LLP
Auditor Firm ID1930
Auditor LocationToronto, Canada
Auditor Opinion [Text Block]

Opinion on the Consolidated Financial
Statements

We have audited the accompanying
consolidated statements of financial position of Psyence Biomedical Ltd. (the “Company”) as at March 31, 2025 and 2024, and
the related consolidated statements of net income (loss) and comprehensive income (loss), changes in shareholders’ equity (deficit),
and cash flows for each of the years in the three-year period ended March 31, 2025, and the related notes (collectively referred to as
the “consolidated financial statements”).

In our opinion, the consolidated
financial statements present fairly, in all material respects, the consolidated financial position of the Company as at March 31, 2025
and 2024, and the results of its consolidated operations and its consolidated cash flows for each of the years in the three-year period
ended March 31, 2025, in conformity with IFRS® Accounting Standards as issued by the International Accounting Standards
Board.






























XML
27
R3.htm
IDEA: XBRL DOCUMENT








v3.25.2

















































































































































Consolidated Statements of Financial Position - USD ($)
Mar. 31, 2025
Mar. 31, 2024
Current assets 
 
Cash and cash equivalents$ 6,135,166
$ 733,188
Restricted cash35,964
29,611
Other receivables137,348
41,747
Prepaid expense251,796
322,126
Total current assets6,560,274
1,126,672
Non-current assets 
 
Equipment11,096
5,487
Investment in Psyence Labs Ltd745,000
TOTAL ASSETS7,316,370
1,132,159
Current liabilities 
 
Accounts payable and accrued liabilities394,270
755,202
Convertible note liability
7,657,397
Derivative warrant liabilities200,096
901,608
TOTAL LIABILITIES594,366
12,104,699
SHAREHOLDERS EQUITY/(DEFICIT) 
 
Share Capital61,752,305
46,125,397
Warrants Reserve1,065,705
Accumulated Deficit(56,447,204)
(57,458,994)
Reserves351,198
361,057
TOTAL SHAREHOLDERS EQUITY/(DEFICIT)6,722,004
(10,972,540)
TOTAL LIABILITIES AND NET EQUITY7,316,370
1,132,159
NCAC Sponsor 
 
Current liabilities 
 
Due to related party
1,474,256
Psyence Group Inc 
 
Current liabilities 
 
Due to related party
$ 1,316,236












































































































XML
28
R4.htm
IDEA: XBRL DOCUMENT








v3.25.2























































































































































































Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss) - USD ($)
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Expenses 
 
 
Sales and marketing$ 483,530
$ 80,603
$ 7,029
Research and development342,168
954,593
1,608,895
General and administrative1,209,847
557,904
366,435
Professional and consulting fees1,623,209
1,158,484
1,252,510
Loss before other items(3,658,754)
(2,751,584)
(3,234,869)
Other items 
 
 
Other income
879,344
Depreciation(4,268)
(240)
Interest income95,787
2,134
1,554
Interest expense(9,270)
(52,941)
Foreign exchange (loss)/gain(7,317)
(2,695)
26,912
Listing expense
(41,481,605)
Transaction expense
(2,461,025)
Gain on debt settlement
281,500
Fair value gain/(loss) on convertible note3,357,628
(5,157,397)
Fair value gain/(loss) on warrant liability694,516
(306,250)
Fair value gain/(loss) on promissory notes705,565
(108,288)
Fair value loss on warrant exchange(185,064)

Fair value gain on investment in Psyence Labs Ltd22,967

NET INCOME/(LOSS)1,011,790
(51,159,048)
(3,206,403)
Other comprehensive income/(loss) 
 
 
Foreign exchange gain/(loss) on translation(9,859)
3,715
(89,828)
Other comprehensive income
191,982
TOTAL COMPREHENSIVE INCOME/(LOSS)$ 1,001,931
$ (50,963,351)
$ (3,296,231)
Income/(Loss) per share - basic (in Dollars per share)$ 5.24
$ (4,674.25)
$ (394.06)
Income/(Loss) per share - diluted (in Dollars per share)$ 5.24
$ (4,674.25)
$ (394.06)
Weighted average number of outstanding shares - basic (in Shares)193,043
10,903
8,365
Weighted average number of outstanding shares - diluted (in Shares)193,043
10,903
8,365




























































































































XML
29
R5.htm
IDEA: XBRL DOCUMENT








v3.25.2

















































































































































































































































































































































































Consolidated Statements of Changes in Shareholders’ Equity/(Deficit) - USD ($)
Number of shares
Share capital
Warrants Reserve
Reserves
Accumulated Deficit
Total
Balance at Mar. 31, 2022 
$ 4,537,055
$ 255,188
$ (3,093,543)
$ 1,698,700
Balance (in Shares) at Mar. 31, 2022
 
 
 
 
 
Psyence Group Inc contribution 
1,397,086


1,397,086
Net profit (loss) for the year 


(3,206,403)
(3,206,403)
Other comprehensive income (loss) 

(89,828)
(89,828)
Balance at Mar. 31, 2023 
5,934,141
165,360
(6,299,946)
(200,445)
Balance (in Shares) at Mar. 31, 2023
 
 
 
 
 
Issuance of shares to Psyence Group Inc 




Issuance of shares to Psyence Group Inc (in Shares)8,365
 
 
 
 
 
Issuance of shares to NCAC shareholders 
37,336,416


37,336,416
Issuance of shares to NCAC shareholders (in Shares)13,040
 
 
 
 
 
Issuance of shares for debt settlement 
718,500


718,500
Issuance of shares for debt settlement (in Shares)251
 
 
 
 
 
Issuance of shares to third party advisors 
2,136,340


2,136,340
Issuance of shares to third party advisors (in Shares)746
 
 
 
 
 
Net profit (loss) for the year 


(51,159,048)
(51,159,048)
Other comprehensive income (loss) 

195,697
195,697
Balance at Mar. 31, 2024 
46,125,397
361,057
(57,458,994)
(10,972,540)
Balance (in Shares) at Mar. 31, 202422,402
 
 
 
 
 
Issuance of shares to third party advisors 
$ 241,379


241,379
Issuance of shares to third party advisors (in Shares)586
586
 
 
 
 
Issuance of shares for convertible note 
$ 4,617,286


4,617,286
Issuance of shares for convertible note (in Shares)38,156
38,156
 
 
 
 
Issuance of warrants 
682,482

682,482
Issuance of shares for ELOC, net of issuance costs 
6,410,395


6,410,395
Issuance of shares for ELOC, net of issuance costs (in Shares)222,292
 
 
 
 
 
Issuance of shares for warrant exchange 
$ 192,060


192,060
Issuance of shares for warrant exchange (in Shares)1,104
1,104
 
 
 
 
Issuance of shares for promissory notes 
$ 2,084,927


2,084,927
Issuance of shares for promissory notes (in Shares)99,540
 
 
 
 
 
Issuance of shares for Psyence Labs Ltd shares 
$ 722,033


722,033
Issuance of shares for Psyence Labs Ltd shares (in Shares)35,594
35,594
 
 
 
 
Issuance of units for PIPE financing, net of issuance costs 
$ 273,179
1,468,872

1,742,051
Issuance of units for PIPE financing, net of issuance costs (in Shares)47,679
47,679
 
 
 
 
Issuance of shares for warrant conversion 
$ 1,085,649
(1,085,649)


Issuance of shares for warrant conversion (in Shares)100,668
 
 
 
 
 
Net profit (loss) for the year 


1,011,790
1,011,790
Other comprehensive income (loss) 

(9,859)
(9,859)
Balance at Mar. 31, 2025 
$ 61,752,305
$ 1,065,705
$ 351,198
$ (56,447,204)
$ 6,722,004
Balance (in Shares) at Mar. 31, 2025568,021
 
 
 
 
 
























































































































XML
30
R6.htm
IDEA: XBRL DOCUMENT








v3.25.2









































































































































































































Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Statement of cash flows [abstract] 
 
 
Net profit/(loss)$ 1,011,790
$ (51,159,048)
$ (3,206,403)
Non-cash adjustment: 
 
 
Fair value (gain)/loss on convertible note(3,357,628)
5,157,397
Fair value (gain)/loss on warrant liability(694,516)
306,250
Fair value (gain)/loss on promissory notes(705,565)
300,270
Fair value loss on warrant exchange185,064

Fair value gain on Psyence Labs Ltd(22,967)

Gain on debt settlement
(281,500)
Share based compensation
317,882
221,287
Third party advisors share issuance241,379

Depreciation4,268
240
Foreign exchange(9,860)
3,660
(84,499)
Listing expense
41,481,605
Transaction expenses
2,100,830
Changes in working capital: 
 
 
Other receivables(95,601)
107,622
(109,858)
Prepaids70,330
(245,075)
(71,665)
Accounts payable and accrued liabilities(360,932)
(1,035,498)
1,659,058
Cash used in operating activities(3,734,238)
(2,945,365)
(1,592,080)
Additions to equipment(9,877)
(5,727)
Increase in restricted cash(6,353)

Cash used for investing activities(16,230)
(5,727)
Proceeds received from convertible note1,000,000
2,500,000
Payment of promissory note
(150,000)
Proceeds received from Psyence Group Inc

1,172,923
Net proceeds received from ELOC6,410,395

Net proceeds received for unit issuances1,742,051

Cash provided from financing activities9,152,446
2,350,000
1,172,923
Change in cash and cash equivalents5,401,978
(601,092)
(419,157)
Cash and cash equivalents, beginning of year733,188
1,334,280
1,753,437
Cash and cash equivalents, end of year$ 6,135,166
$ 733,188
$ 1,334,280




































































































































XML
31
R7.htm
IDEA: XBRL DOCUMENT








v3.25.2













Nature of Operations and Going Concern
12 Months Ended
Mar. 31, 2025
Nature of Operations and Going Concern [Abstract] 
Nature of operations and going concern

1. Nature of operations and going concern



 



Psyence Biomedical Ltd. (the “Company”
or “PBM”), is a life science biotechnology company traded on the Nasdaq exchange (NASDAQ: PBM) that is focused on the
development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The Company is working towards developing
psychedelic therapeutics to treat mental health disorders. The Company is currently conducting research through clinical trials to evaluate
the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with a cancer diagnosis in a palliative
care context (the “Clinical Trials”).



 



The Company’s registered office is at 121
Richmond Street West, PH Suite 1300, Toronto, Ontario M5H 2K1.



 



On November 26, 2024, the Company consolidated
its common shares and warrants on the basis of 75:1.



 



On May 5, 2025, the Company consolidated its common
shares and warrants on the basis of 7.97:1. All prior share capital information has been presented based on these ratios.



 



Business Combination Agreement and NASDAQ listing



 



On January 9, 2023 Psyence Group Inc. (“PGI”
or “Psyence Group”) entered into a definitive business combination agreement, as amended (the “Business Combination
Agreement” or “BCA”) with Newcourt Acquisition Corp. (NASDAQ: NCAC), a special purpose acquisition company
(“SPAC”). The agreement aimed to create a public company leveraging natural psilocybin for palliative care treatment.
PGI is a listed Canadian company that contributed its clinical trial activities to the Company as described below.



 



The transaction concluded on January 25, 2024,
with PBM's listing on NASDAQ. This transaction involved PBM acquiring the SPAC through a merger, thereby making the SPAC a wholly-owned
subsidiary of PBM.



 



Transaction Overview:



 



On January 25, 2024 (the “Closing Date”),
the Company, a corporation organized under the laws of Ontario, Canada, completed the previously announced business combination (the “RTO
Transaction”) as per the BCA (Note 5). The parties involved in the BCA included:



 




-Psyence Group Inc.


 




-Newcourt Acquisition Corp., a Cayman Islands exempted company (“NCAC”).


 




-Newcourt SPAC Sponsor LLC, a Delaware limited liability company (“NCAC Sponsor”).


 




-Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of Psyence
Group.


 




-Psyence Biomed Corp., a corporation organized under the laws of British Columbia, Canada (“Original
Target”).


 




-Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (“Psyence
Biomed II”).


 




-Psyence Australia (Pty) Ltd (“Psyence Australia”)


 



Key Transactions (collectively, the “Business
Combination”):



 



Formation of Subsidiaries: Prior to the
Closing Date, PGI formed three wholly owned subsidiaries: Psyence Biomed II, Psyence Australia and PBM.



 



Amalgamation: Prior to the Closing Date,
PGI amalgamated with the Original Target. Consequently, PGI transferred shares of Psyence Australia and related business assets previously
owned by the Original Target to Psyence Biomed II.



 



Share Exchange: PGI contributed Psyence
Biomed II to PBM in a share-for-share exchange (the “Company Exchange”).

Merger: Following the Company Exchange,
Psyence (Cayman) Merger Sub merged with Newcourt Acquisition Corp., with Newcourt Acquisition Corp. being the surviving entity. Each outstanding
ordinary share of Newcourt Acquisition Corp. was converted into the right to receive one common share of PBM.



 



Warrant Conversion: Each outstanding warrant
to purchase Newcourt Acquisition Corp. Class A ordinary shares was converted into warrants to acquire one common share of PBM on substantially
the same terms as the original warrants.



 



These Consolidated Financial Statements provide
historical financial information of PBM, reflecting PBM as if it had been historically operating the Clinical Trials conducted by PGI
prior to the Closing Date. The Financial Statements are carve-out statements up to January 25, 2024, the date of listing of PBM.


















XML
32
R8.htm
IDEA: XBRL DOCUMENT








v3.25.2













Basis of Presentation
12 Months Ended
Mar. 31, 2025
Basis of Presentation [Abstract] 
Basis of presentation

2. Basis of presentation



 



Statement of compliance



 



The Consolidated Financial Statements, including
comparatives, have been prepared in accordance with IFRS® Accounting Standards as issued by the International Accounting Standard
Board (“IFRS”) on a going concern basis.



 



The Consolidated Financial Statements were authorized for issue on
June 25, 2025 by the directors of the Company.


 



The Consolidated Financial Statements up until
January 25, 2024 were presented on a carve out basis (“Carve-out Financial Statements”).



 



The Consolidated Financial Statements have been
prepared on a carve-out basis from the PGI consolidated financial statements for the purpose of presenting the historical financial performance
and cash flows of the Company on a stand-alone basis. The accounting policies applied in the Carve-out Financial Statements are, to the
extent applicable, consistent with accounting policies applied in the PGI consolidated financial statements, and as a result, reflect
the carrying amounts that are included in PGI’s consolidated financial statements.



 



In determining the perimeter of the Carve-out
Financial Statements, the activities related to the Company’s clinical trials were considered to include the operations of Psyence
Biomed Corp. and Psyence Australia (Pty) Ltd carried out through PGI directly as well as through legal entities of PGI as detailed above.



 



In the Carve-out Financial Statements, all intercompany
balances and transactions have been eliminated. The transactions and balances with the remaining PGI operations that are not part of these
Carve-out Financial Statements have not been eliminated.



 



The Carve-out Financial Statements present the
expenses and cash flows attributable to the clinical trial activities from April 1, 2022 to the Closing Date, and include allocations
of certain transactions and balances.



 



The Company believes the allocation assumptions
applied in the Carve-out Financial Statements to be a reasonable reflection of the utilization of services provided by PGI. However, different
allocation assumptions could have resulted in different outcomes. The allocations are therefore not necessarily representative of the
financial performance or cash flows that would have been reported if the Company operated on its own or as an entity independent from
PGI during the periods presented.



 



The Company believes the basis of preparation
described above results in the Carve-out Financial Statements reflects costs associated with the functions that would be necessary to
operate independently.

Basis of consolidation



 



These Consolidated Financial Statements incorporate
the accounts of the Company and its subsidiaries performing Clinical Trials. A subsidiary is an entity controlled by PBM and its results
are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.



 



Control exists when an investor is exposed, or
has the rights, to variable returns from the involvement with the investee and has liability to affect those returns through its power
over the investee.



 



The subsidiaries of the Company have been consolidated
commencing the Closing Date and on March 31, 2025 for the purpose of these Consolidated Financial Statements are as follows:



 



Name of entity  Place of incorporation  % ownership   Accounting method
Psyence Australia Pty Ltd.  Australia   100%  Consolidated
Pysence Biomed II Corp.  Canada   100%  Consolidated
Newcourt Acquisition Corp.  Cayman Islands   100%  Consolidated




 



 



Inter-company balances and transactions are eliminated
upon consolidation.



 



The financial results of subsidiaries up to January
25, 2024 were presented on a carve out basis.



 



Basis of measurement



 



These Consolidated Financial Statements have been
prepared on a historical cost basis, except for certain financial instruments, which are classified as fair value through profit or loss
(“FVTPL”).



 



Functional and presentation currency



 



These Consolidated Financial Statements are presented
in United States Dollars (“USD $”), which is also the Company’s functional currency. The Company’s
functional currency before the Closing Date was Canadian Dollars.



 



This changed upon consummation of the BCA at which
time the USD $ represents the currency of the Company's funding and is the currency of the primary economic environment in which the Company
operates in, except for the Company’s Australian subsidiary which has an Australian Dollar functional currency.



 



See change in accounting policy in note 3 for
further details on the change in the Company’s presentation currency.


















XML
33
R9.htm
IDEA: XBRL DOCUMENT








v3.25.2













Material Accounting Policies
12 Months Ended
Mar. 31, 2025
Material Accounting Policies [Abstract] 
Material accounting policies

3. Material accounting policies



 



Financial instruments



 



Financial assets and financial liabilities, including
derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument
or derivative contract.



 



Summary of the Company’s classification
and measurements of financial assets and liabilities:



 



Financial Assets and Liabilities   Classification   Measurement
Cash and cash equivalents   Amortized cost   Amortized cost
Restricted cash   Amortized cost   Amortized cost
Other receivables   Amortized cost   Amortized cost
Investment in Psyence Labs Ltd   FVTPL   Fair value
Accounts payable and accrued liabilities   Amortized cost   Amortized cost
Derivative warrant liability   FVTPL   Fair value
Convertible note liability   FVTPL   Fair value
Due to NCAC Sponsor   FVTPL   Fair value
Due to Psyence Group Inc   FVTPL   Fair value

Classification



 



The Company classifies its financial assets in
the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (“FVTPL”);
ii) those to be measured subsequently at fair value through other comprehensive income (“FVOCI”); and iii) those to be measured
at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual
terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as
those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair
value, gains and losses are either recorded in net loss or other comprehensive income (loss).



 



The Company reclassifies financial assets only
when its business model for managing those assets changes. Financial liabilities are not reclassified.



 



Amortized cost



 



This category includes financial assets that are
held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments
of principal and interest ("SPPI") criterion. Financial assets classified in this category are measured at amortized cost using
the effective interest method.



 



Fair value through profit or loss



 



This category includes derivative instruments
as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL.
This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest
(“SPPI”) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or
to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized
in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives
are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.



 



Financial assets at fair value through other
comprehensive income



 



Equity instruments that are not held-for-trading
can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through
net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable
transaction costs are included in the carrying value of the instruments.



 



Financial assets at fair value through other comprehensive
income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).

Compound financial instrument and derivative
liability



 



The Company determined that the warrants, including
public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured
at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized
in net loss.



 



Each embedded derivative is measured and presented
separately unless the whole hybrid financial instrument is designated as at FVTPL.



 



Measurement



 



All financial instruments are required to be measured
at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that
are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial
assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered
in their entirety when determining whether their cash flows are solely payments of principal and interest.



 



Financial assets that are held within a business
model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal
and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All
other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with
any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial
liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value
are attributable to changes in own credit risk which is recorded in other comprehensive income.



 



Cash and cash equivalents



 



Cash and cash equivalents include cash on hand
and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three months
at the date of their acquisition.



 



Restricted cash



 



Restricted cash comprises a collateral agreement
with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment
certificate with the bank.



 



Related party transactions



 



Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered
to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be
a related party transaction when there is transfer of resources or obligations between related parties.



 



Change in accounting policy



 



Pursuant to completion of the Business Combination
Agreement and NASDAQ listing as explained in Note 1, on January 25, 2024, the Company decided to change the presentation currency of its
consolidated financial statements from Canadian Dollars to United States Dollars.



 



The Board of Directors believe that US Dollar
financial reporting provides more relevant presentation of the Company’s financial position, funding and treasury functions, financial
performance and cash flows.



 



A change in presentation currency represents a
change in accounting policy in terms of IAS 8 – Accounting Policies, Changes in Accounting Estimates and Errors, requiring
the restatement of comparative information.

In accordance with IAS 21 – The Effects
of Changes in Foreign Exchange Rates, the methodology followed in restating historical financial information from CDN $ to USD $.



 



The average and closing rates used in translating
the historical financial information from CDN $ to USD $ for the various periods were as follows:



 



The closing rate used as at March 31, 2024 was
$0.7380, as at March 31, 2023 was $0.7389 and as at March 31, 2022 was $0.8003.



 



The average rate used for the year ended March
31, 2024 was $0.7415. and for the year ended March 31, 2023 was $0.7559.



 



The change in presentation currency is a voluntary
change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated
to United States dollars which is disclosed in the tables below:



 
























Change in presentation currency  March 31, 2023
Reported CAD $		   Foreign Currency
Translation		   March 31, 2023
Restated

USD

$		 
EQUITY               
Net equity   (271,275)   70,830    (200,445)
NET DEFICIT   (271,275)   70,830    (200,445)





 
























Change in presentation currency  March 31, 2022
Reported CAD $		   Foreign Currency
Translation		   March 31, 2022
Restated

USD

$		 
EQUITY               
Net equity   2,122,696    (423,996)   1,698,700 
NET DEFICIT   2,122,696    (423,996)   1,698,700 




 



























































Change in presentation currency  March 31, 2023
Reported CAD $		   Foreign Currency
Translation		   March 31, 2023
Restated

USD

$		 
Expenses            
Sales and marketing   9,292    (2,263)   7,029 
Research and development   2,126,762    (517,867)   1,608,895 
General and administrative   484,382    (117,947)   366,435 
Professional and consulting fees   1,655,663    (403,153)   1,252,510 
Loss before other items   (4,276,099)   1,041,230   (3,234,869)
Other items               
Interest income   2,054    (500)   1,554 
Foreign exchange gain   35,574    (8,662)   26,912 
NET LOSS   (4,238,471)   1,032,068   (3,206,403)



























































































Change in presentation currency  March 31, 2023
Reported CAD $		   Foreign Currency
Translation		   March 31, 2023
Restated

USD

$		 
Net loss   (4,238,471)   1,032,068    (3,206,403)
Non-cash adjustment:               
Share based compensation   292,756    (71,469)   221,287 
Foreign exchange   
-
    (84,499)   (84,499)
                
Changes in working capital:               
Other receivables   (152,778)   42,920    (109,858)
Prepaids   (97,547)   25,882    (71,665)
Accounts payable and accrued liabilities   2,258,967    (599,909)   1,659,058 
Cash used in operating activities   (1,937,073)   344,993    (1,592,080)
                
Proceeds received from Psyence Group Inc   1,551,744    (378,821)   1,172,923 
Cash provided from financing activities   1,551,744    (378,821)   1,172,923 
                
Change in cash and cash equivalents   (385,329)   (33,828)   (419,157)
Cash and cash equivalents, start of year   2,191,095    (437,658)   1,753,437 
Cash and cash equivalents, end of year   1,805,765    (471,486)   1,334,280 





 



Research and development



 



Expenditures on research activities, undertaken
with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and
comprehensive loss as incurred.



 



Development expenditures are capitalized only
if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits
are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell
the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect
operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as
incurred.



 



Provisions



 



Provisions are recognized when the Company has
a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle
the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required
to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations.
Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash
flows.

Foreign currency translation



 



The Consolidated Financial Statements are presented
in USD $ which is the Company’s functional currency.



 



In each individual entity, a foreign currency
transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency
and the foreign currency at the date of the transaction.



 



At the end of the reporting period, monetary assets
and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary
assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.



 



The resulting exchange gains or losses arising
on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial
recognition, are included in the consolidated statements of net income/(loss) and comprehensive income/(loss) in the year in which they
arise.



 



For the purpose of presenting these Consolidated
Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end
of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries
is recorded in reserves.



 



Income/(loss) per share



 



The Company presents basic and diluted income/(loss)
per share data for its common shares. Basic income/(loss) per share is calculated by dividing the profit or loss attributable to common
shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined
by adjusting the income or loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted
for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.



 



Share based compensation



 



The Company operates equity settled share-based
remuneration plans for its eligible directors, officers, employees and consultants. All goods and services received in exchange for the
grant of any share-based payments are measured at their fair value unless the fair value cannot be estimated reliably. If the Company
cannot estimate reliably the fair value of the goods and services received, the Company shall measure their value indirectly by reference
to the fair value of the equity instruments granted. For transactions with employees and others providing similar services, the Company
measures the fair value of the services by reference to the fair value of the equity instruments granted. Equity settled share-based payments
under share-based payment plans are ultimately recognized as an expense in profit or loss with a corresponding credit to contributed surplus,
in equity. If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available
estimate of the number of share options expected to vest. Non-market vesting conditions are included in the assumptions about the number
of options that are expected to become exercisable. Estimates are subsequently revised if there is any indication that the number of share
options expected to vest differs from the previous estimate. Any cumulative adjustment prior to vesting is recognized in the current period.
No adjustment is made to any expense recognized in prior period if share options ultimately exercised are different to that estimated
on vesting. Market conditions are considered in the estimate of the fair value of share-based compensation on a grant date.



 



Income taxes



 



Income tax comprises current and deferred tax.
Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders’ equity,
in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also
recognized directly in equity or other comprehensive income.

Current tax is the expected tax payable on the
taxable income for the year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect
of previous years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the
amounts and the Company.



 



Deferred tax is recognized in respect of all qualifying
temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Consolidated Financial
Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively
enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax
assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate
to the same taxation authority.



 



Deferred tax assets are recognized to the extent
future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable
that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.



 



Accounting Standards Effective January 1, 2024
and issued but not yet effective



 



IFRS 18 Presentation and Disclosure in Financial
Statements



 



In April 2024, the IASB issued IFRS 18 –
Presentation and Disclosure in Financial Statements which will replace IAS 1, Presentation of Financial Statements. The key
new concepts introduced in IFRS 18 relate to the structure of the statement of earnings (loss), required disclosures in the financial
statements for certain earnings or loss performance measures that are reported outside an entity’s financial statements and enhanced
principles on aggregation and disaggregation which apply to the primary financial statements and notes in general. IFRS 18 will apply
for reporting periods beginning on or after January 1, 2027, and also applies to comparative information. The Company is still in the
process of assessing the impact of this standard on its consolidated financial statements.



 



Classification of liabilities as current or non-current
(amendments to IAS 1, presentation of financial statements)



 



On January 23, 2020, an amendment was issued to
IAS 1 to address inconsistencies with how entities apply the standards over classification of current and non-current liabilities. The
amendment serves to address whether, in the statement of financial position, debt and other liabilities with an uncertain settlement should
be classified as current or non-current. This amendment is effective on January 1, 2024. The Company adopted the amendment on the effective
date and the adoption did not have a material impact on the Company’s consolidated financial statements.



 



Non-current liabilities with covenants (amendments
to IAS 1)



 



The amendments to IAS 1 specify that only covenants
with which an entity is required to comply on or before the reporting date affect the classification of a liability as current or non-current.
In addition, an entity has to disclose information in the notes that enables users of financial statements to understand the risk that
noncurrent liabilities with covenants could become repayable within twelve months. The amendments are effective for annual reporting periods
beginning on or after January 1, 2024, and are to be applied retrospectively. The Company adopted the amendment on the effective date
and the adoption did not have a material impact on the Company’s consolidated financial statements.


















XML
34
R10.htm
IDEA: XBRL DOCUMENT








v3.25.2













Critical Accounting Estimates and Judgements
12 Months Ended
Mar. 31, 2025
Critical Accounting Estimates and Judgements [Abstract] 
Critical accounting estimates and judgements

4. Critical accounting estimates and judgements



 



The preparation of consolidated financial statements
in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results
may differ from these estimates. The Company’s management reviews these estimates, judgments, and assumptions on an ongoing basis,
based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical
accounting policies as these require a high level of subjectivity and judgement and could have a material impact on the Company’s
consolidated financial statements.

Reverse takeover transaction



 



The determination of fair values of consideration
paid and net assets acquired is subject to significant estimation. The Company treated the RTO Transaction as a capital transaction equivalent
to the issue of shares of the Company in exchange for the net monetary assets of NCAC. The Company determined that the original shareholders
of PGI became the single largest shareholder of the Company after the RTO Transaction, therefore the Company was the acquiror and NCAC
was the acquiree.



 



The Company has determined the RTO Transaction
did not constitute a business combination as defined under IFRS 3, Business Combinations, as NCAC is a non-operating entity that did not
meet the definition of a business under IFRS 3. The excess of the consideration paid over the net liability acquired together with any
transaction costs incurred for the Transaction is expensed as a listing expense in accordance with IFRS 2 Share-Based Payments. The fair
value of the consideration paid was estimated by the closing trading price $2,863.22/share of the Company’s common shares listed
on the NASDAQ on January 25, 2024.



 



Convertible instruments



 



The valuation of convertible debt instruments
is subject to significant management estimation. Convertible notes are compound financial instruments which have been designated at FVTPL.



 



The identification of convertible debenture components
is based on interpretations of the substance of the contractual arrangement and therefore requires judgment from management. The separation
of the components affects the initial recognition of the convertible debenture at issuance and the subsequent remeasurement. As the Company
has designated the entire convertible financial instrument as FVTPL given the embedded derivate liability that was contained by the convertible
financial instrument, the debentures have not been separated into debt and derivative components. The fair values attributed to the different
components of a financing transaction, and/or derivative financial instruments, are determined using valuation techniques. The Company
uses judgement to select the methods used to make certain assumptions and in performing the fair value calculations in order to determine
(a) the values attributed to each component of a transaction at the time of their issuance; (b) the fair value measurements for certain
instruments that require subsequent measurement at fair value on a recurring basis; and (c) for disclosing the fair value of financial
instruments subsequently carried at amortized cost. These valuation estimates could be significantly different because of the use of judgement
and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market.



 



Contingencies



 



From time to time, the Company is named as a party
to claims or involved in proceedings, including legal, regulatory and tax related, in the ordinary course of its business. While the outcome
of these matters may not be estimable at the reporting date, the Company makes provisions, where possible, for the estimated outcome of
such claims or proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates, the
difference will be accounted for as a charge to profit or loss in that period. The actual results may vary and may cause significant adjustments.



 



The rebate over the tax claim is subject to inherent
uncertainty and could be subject to being denied and clawed back by the Australian Tax office at a future date. The Company expects that
a claw back of the rebate is highly unlikely.



 



Deferred taxes and Income taxes



 



Significant estimates are required in determining
the Company’s income tax provision. Some estimates are based on interpretations of existing tax laws or regulations. Various internal
and external factors may have favourable or unfavourable effects on the Company’s future effective tax rate. These include, but
are not limited to, changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, and results
of tax audits by tax authorities.

Provisions for taxes are made using the best estimate
of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these
provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from
audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded,
such differences will affect the tax provisions in the period in which such determination is made.



 



Share-based compensation



 



Valuation of share-based compensation requires
management to make estimates regarding the inputs for option pricing models, such as the expected life of the option, the volatility of
the Company’s stock price, the vesting period of the option and the risk-free interest rate are used. Actual results could differ
from those estimates. The estimates are considered for each new grant of stock options.



 



Government grants



 



Government grants are recognized when there is
reasonable assurance that the Company will comply with the conditions attached to them and the government grants will be received. Grants
are recognized as income when they are received. The Company has recognized the government grant received during the period as research
and development grants as other income in the consolidated statement of income/(loss) and comprehensive income/(loss).


















XML
35
R11.htm
IDEA: XBRL DOCUMENT








v3.25.2













Reverse Takeover Transaction with NCAC
12 Months Ended
Mar. 31, 2025
Reverse Takeover Transaction with NCAC [Abstract] 
Reverse takeover transaction with NCAC

5. Reverse takeover transaction with NCAC



 



On January 25, 2024 the Company completed the
RTO Transaction (See Note 1). As disclosed in Note 4, the RTO Transaction did not constitute a business combination as defined under IFRS
3, Business Combinations, as NCAC is a non-operating entity that does not meet the definition of a business under IFRS 3. The excess of
the consideration paid over the net liability acquired together with any transaction costs incurred for the Transaction is expensed as
a listing expense in accordance with IFRS 2 Share-Based Payments. The fair value of the consideration paid was determined by the closing
trading price $2,863.22/share of the NCAC’s common shares listed on the NASDAQ on January 25, 2024.



 



Accordingly, upon consummation of the BCA the
Company issued 13,040 common shares in exchange for the outstanding ordinary shares held by NCAC stockholders.



 



The calculation of listing expenses is as follows:



 

















































   Listing Expense 
Consideration paid:    
Shares issued to NCAC shareholders   13,040 
Total consideration shares issued   13,040 
Fair value of the common shares  $2,863.22 
Deemed consideration amount for the common shares issued  $37,336,416 
      
Net identifiable liabilities acquired:     
Cash and cash equivalent  $203 
Accounts payable and accrued liabilities  $(2,136,505)
NCAC promissory note (Note 11)  $(1,413,529)
Derivative warrant liabilities (Note 10)  $(595,358)
Net liabilities acquired  $4,145,189 
      
Listing expense  $41,481,605 




 



The listing expense has been included in the consolidated
statements of net loss and comprehensive loss.



 



Transaction expenses included in the consolidated
statements of net loss and comprehensive loss are others costs of $2,461,025 in connection with the RTO Transaction composed of legal,
banking, professional fees and costs related to the settlement of carved-out assets and liabilities from Psyence Group. Some payments
to brokers and advisors were in the Company’s shares upon RTO at the closing trading price on January 25, 2024 (Refer Note 12).


















XML
36
R12.htm
IDEA: XBRL DOCUMENT








v3.25.2













Cash, Restricted Cash and Cash Equivalents
12 Months Ended
Mar. 31, 2025
Cash, Restricted Cash and Cash Equivalents [Abstract] 
Cash, restricted cash and cash equivalents

6. Cash, restricted cash and cash equivalents



 



Cash and cash equivalents include the following
amounts:



 




















   March 31,

2025		   March 31,

2024		 
Unrestricted cash held with chartered banks   6,135,166    733,188 
Restricted cash   35,964    29,611 
Total   6,171,130    762,799 




 




●unrestricted
cash held with chartered banks and


 




●the Company entered into a cash collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited Canadian Dollars $50,000 in a guaranteed investment certificate with the bank. Amounts are presented as restricted cash on the consolidated statements of financial position.

















XML
37
R13.htm
IDEA: XBRL DOCUMENT








v3.25.2













Equipment
12 Months Ended
Mar. 31, 2025
Equipment [Abstract] 
Equipment

7. Equipment



 


























































   Computer equipment 
Cost    
At March 31, 2023   
-
 
Additions   5,727 
At March 31, 2024   5,727 
Additions   9,877 
At March 31, 2025   15,604 
      
Accumulated Depreciation     
At March 31, 2023   
-
 
Charge for the year   (240)
At March 31, 2024   (240)
Charge for the year   (4,268)
At March 31, 2025   (4,508)
      
Carrying Value     
At March 31, 2024   5,487 
At March 31, 2025   11,096 

















XML
38
R14.htm
IDEA: XBRL DOCUMENT








v3.25.2













Accounts Payable and Accrued Liabilities
12 Months Ended
Mar. 31, 2025
Accounts Payable and Accrued Liabilities [Abstract] 
Accounts payable and accrued liabilities

8. Accounts payable and accrued liabilities



 



Accounts payable and accrued liabilities include
the following amounts:



 
























   March 31,

2025		   March 31,

2024		 
Trade payables   261,937    562,352 
Accrued liabilities   50,481    125,951 
Provisions   81,852    66,899 
Total   394,270    755,202 

















XML
39
R15.htm
IDEA: XBRL DOCUMENT








v3.25.2













Convertible Note Liability
12 Months Ended
Mar. 31, 2025
Convertible Note Liability [Abstract] 
Convertible note liability

9. Convertible note liability



 



On January 15, 2024, in connection with the RTO
Transaction (Note 5), the Company and Psyence Biomed II entered into the Securities Purchase Agreement with the Investors and the NCAC
Sponsor, relating to up to four senior secured convertible notes obligations under which are guaranteed by certain assets of the Company
and Psyence Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up
to $12,500,000 in exchange for up to $10,000,000 in cash subscription amounts (the “Convertible Note Financing”).



 



The First Tranche Notes, for an aggregate of $3,125,000
principal, were delivered by the Company to the Investors on January 25, 2024, in exchange for an aggregate of $2,500,000 in financing,
which occurred substantially concurrently with the consummation of the RTO Transaction. On the original issuance date of the First Tranche
Notes, interest began accruing at 8.0% per annum based on the outstanding principal amount of the First Tranche Notes and is payable monthly
in arrears in cash or in common shares of the Company. The maturity date of the First Tranche Note was January 25, 2027.



 



The Second Tranche Notes, for an aggregate of
$1,000,000 principal, were delivered by the Company to the Investors between May and July 2024, in exchange for an aggregate of $1,250,000
in financing. On the original issuance date of the Second Tranche Notes, interest began accruing at 8.0% per annum based on the outstanding
principal amount of the Second Tranche Notes and is payable monthly in arrears in cash or in common shares of the Company at the Conversion
Price. The maturity date of the Second Tranche Notes is May 31, 2027.



 



The Company designated the entire instrument as
FVTPL.



 



On August 20, 2024, the Company and the Investor
entered into an addendum to the Securities Purchase Agreement (the “Addendum”). Under the provisions of the Addendum, the
First and Second Trance Notes would be extinguished by the Company issuing common shares within the conversion limits detailed in the
Securities Purchase Agreement.



 



As a consideration to the Investor entering into
the Addendum, the Company issued to the Investor 1,673 common shares valued at $523,000 based on the market price of the common shares
on the date of issuance and 837 warrants to acquire common shares of the Company with a two-year expiry, exercisable at $298.88 per share.
The warrants were valued at $42,528 using the Black-Scholes pricing model with the following assumptions:



 



   Warrant Inputs at
August 20, 2024		 
Share price  $312.62 
Expected dividend yield   Nil 
Exercise price   298.88 
Risk-free interest rate   3.93%
Expected life   2.00 
Expected volatility   17.7%
Expiry date   August 20, 2026 

The fair value of shares and warrants issued pursuant
to the Addendum as detailed above, was recorded in the consolidated statements of income/(loss) and comprehensive income/(loss) as part
of the fair value gain on convertible note.



 



On November 27, 2024, the Company and the Investor
entered into the Termination Agreement pursuant to which all obligations, covenants and liabilities of the Company and the Investor under
the Securities Purchase Agreement will be fully and finally terminated.



 



As a consideration to the Investor entering into
the Termination Agreement, the Company issued to the Investor 18,947 common shares valued at $489,598 based on the market price of the
common shares on the date of issuance and 22,876 warrants to acquire common shares of the Company with nominal exercise price for a one-year
period. The warrants were valued at $639,954 by the reference to the Company’s common share price.



 



The fair value of shares and warrants issued pursuant
to the Termination Agreement as detailed above, was recorded in the consolidated statements of income/(loss) and comprehensive income/(loss)
as part of the fair value gain on convertible note.



 



Between May and September 2024, the Company converted
all outstanding balance of the First and Second Tranche Notes into common shares by issuing 17,536 common shares. The total additions
to equity on conversion were $3,604,688.



 



The Company measured the fair value of the convertible
loan liability before each conversion using Monte Carlo valuation model with the following main assumptions: expected dividend yield 0%,
exercise price $224.22- $320.45, risk free interest rate 3.63%- 5.23%, expected life 0.1 – 2.7 years.



 



The change in fair value resulted in a fair value
gain of $5,052,708 (2024 – loss of $5,157,397, 2023- nil) which was recorded in the consolidated statements of income/(loss) and
comprehensive income/(loss) as part of the fair value gain on convertible note.



 



As at March 31, 2024, the fair value of the convertible
notes was estimated at $7,657,397 using a combined discounted cash flow approach and Monte Carlo simulation with the following assumptions:



 































   Inputs 
Share price  $681.44 
Note principal amount  $3,125,000 
Prepayment Amount   130%
Discount rate shares   4.43%
Discount rate cash   20.83%
Volatility annual   100%
Volatility daily   6.30%
Risk free annual   4.43%

















XML
40
R16.htm
IDEA: XBRL DOCUMENT








v3.25.2













Derivative Warrant Liabilities
12 Months Ended
Mar. 31, 2025
Derivative Warrant Liabilities [Abstract] 
Derivative warrant liabilities

10. Derivative warrant liabilities



 



The Company has two classes of warrant liabilities
outstanding: Public Warrants and Private Warrants. As of March 31, 2025, there were 20,762 warrants issued and outstanding, consisting
of 19,808 Public Warrants and 954 Private Warrants (March 31, 2024 – 20,912 Public Warrants and 954 Private Warrants). Each warrant
is exercisable to purchase one common share at a price of $6,874.13 per share.



 



During the year ended March 31, 2025, the Company
entered into the Warrant Exchange Agreement. Pursuant to the Warrant Exchange Agreement, the Company issued to the Holder 1,104 Common
Shares in exchange for the surrender and cancellation of 1,104 Public Warrants held by the Holder. The warrants exchange resulted in a
loss of $185,064 which was recorded in the consolidated statements of income/(loss) and comprehensive income/(loss).

Public Warrants: The fair value of the Public
Warrants is determined based on the observable market price, as they continue to be traded on the Nasdaq under the symbol “PBMWW.”
Changes in fair value during the years ended March 31, 2025 and March 31, 2024, have been recognized in the consolidated statements of
income/(loss) and comprehensive income/(loss).



 



Private Warrants: The Company utilizes a Black-Scholes
options valuation model to value the private warrants at each reporting period, using the following main assumptions:



 



   Warrant Inputs at
March 31, 2025		   Warrant Inputs at
March 31, 2024		 
Share price  $4.78   $681.44 
Expected dividend yield   Nil    Nil 
Exercise price  $6,874.13   $6,874.13 
Risk-free interest rate   4.21%   4.21%
Expected life   4.00    5.00 
Expected volatility   59.98%   59.98%
Expiry date   January 25, 2029    January 25, 2029 




 



At March 31, 2025 the fair value of the Public
and Private Warrants was $200,096 (March 31, 2024 - $875,000) and $nil (March 31, 2024 - $26,608), respectively. A fair value loss of
$694,516 was recognized on the consolidated statements of income/(loss) and comprehensive income/(loss).



 



The expected volatility was based on implied volatility
of the Public Warrants.



 



As at March 31, 2025, the derivative warrant liability
was $200,096 (March 31, 2024 – $901,608 ) reconciled as follows:



 
































Derivative warrant liability – Public and Private Warrants  Number   Amount

($)		 
At listing January 25, 2024   21,866    595,358 
Fair value loss   
-
    306,250 
Opening balance April 1, 2024   21,866    901,608 
Warrant exchange   (1,104)   (6,996)
Fair value gain   
-
    (694,516)
Balance as at March 31, 2025   20,762    200,096 




 



Warrant transactions and the number of warrants
outstanding are summarized as follows:



 












































   Public Warrants   Private Warrants 
   Number of Warrants   Weighted Average Exercise Price   Number of Warrants   Weighted Average Exercise Price 
Balance, April 1, 2023   
-
    
-
    
-
    
-
 
Issued   20,912   $6,874.13    954   $6,874.13 
Balance, March 31, 2024   20,912   $6,874.13    954   $6,874.13 
Warrant exchange   (1,104)  $6,874.13    
-
   $6,874.13 
Balance, March 31, 2025   19,808   $6,874.13    954   $6,874.13 

The following warrants were outstanding and exercisable
at March 31, 2025:



 



Issue Date  Expiry Date  Exercise Price   Number of Warrants Outstanding   Number of Warrants Exercisable 
January 25, 2024  January 25, 2029  $6,874.13    20,762    20,762 

















XML
41
R17.htm
IDEA: XBRL DOCUMENT








v3.25.2













Promissory Notes
12 Months Ended
Mar. 31, 2025
Promissory Notes [Abstract] 
Promissory Notes

11. Promissory Notes



 



On January 25, 2024, the Company issued an unsecured
convertible promissory note to PGI (the “PGI Note”), in the principal amount of $1,610,657, which is equal to the total
amount owed to PGI in connection with loans that PGI had previously made to the Company. The PGI Note bore no interest, and (i) $150,000
of the principal balance of the PGI Note was paid on the Closing Date and (ii) $1,460,657 of the principal balance of the PGI Note was
payable on the date that is the one-year anniversary after the Closing Date, or January 25, 2025. The proceeds from this loan were received
by the Company prior to the Closing Date. This note is convertible into shares at the option of PGI.



 



On January 25, 2024, the Company issued an unsecured
convertible promissory note to the NCAC Sponsor (the “NCAC Note”), in the principal amount of $1,615,501, which is
equal to the total amount owed to NCAC Sponsor under certain existing promissory notes previously issued by NCAC to the NCAC Sponsor (the
“Existing Notes”). The NCAC Note bore no interest, and (i) $100,000 of the principal balance of the NCAC Note became
owing on the Closing Date and (ii) $1,515,501 of the principal balance of the NCAC Note was payable on the date that is the one-year anniversary
after the Closing Date, or January 25, 2025. This note is convertible into shares at the option of NCAC Sponsor.



 



Both notes were designated at FVTPL due to the
embedded conversion features, as the conversion prices were not fixed.



 



At inception on January 25, 2024 the fair value
of the PGI Note was $1,418,675 and the NCAC note was $1,413,529.



 



PGI Note:



 



On September 30, 2024, the Company entered into
Debt for Equity Exchange Agreement with PGI pursuant to which the Company issued 3,473 of common shares to extinguish $1,307,960 of PGI
Note, representing a conversion price of $298.88 per share.



 



On October 25, 2024, the Company entered into
Debt for Equity Exchange Agreement with PGI pursuant to which the Company issued 1,414 of common shares to extinguish the remaining balance
of PGI Note representing, a conversion price of $298.88 per share.



 



In accordance with the Debt for Equity Exchange
Agreements entered into on September 30, 2024 and October 25, 2024, as amended, the Company will need to issue additional shares to PGI
if the Company’s volume weighted average share price for the 10 days prior to November 26, 2024 is lower than $298.88 per share
(“PGI make whole payment”).



 



In December 2024, the Company issued 42,378 common
shares to extinguish the PGI make whole payment.

The issuance of shares pursuant to the Debt for
Equity Exchange Agreements resulted in a fair value gain of $327,668 which was recorded in the consolidated statements of income/(loss)
and comprehensive income/(loss).



 



NCAC Note:



 



On September 30, 2024, the Company entered into
Debt for Equity Exchange Agreement with NCAC Sponsor pursuant to which the Company issued 5,405 of common shares to extinguish the outstanding
balance of NCAC Note, representing a conversion price of $298.88 per share.



 



In accordance with the Debt for Equity Exchange
Agreements, as amended, the Company will need to issue additional shares to NCAC Sponsor if the Company’s volume weighted average
share price for the 10 days prior to November 26, 2024 is lower than $298.88 per share (“NCAC make whole payment”).



 



In December 2024, the Company issued 46,870 common
shares to extinguish the NCAC make whole payment.



 



The issuance of shares pursuant to the Debt for
Equity Exchange Agreements resulted in a fair value gain of $377,897 which was recorded in the consolidated statements of income/(loss)
and comprehensive income/(loss).



 



The fair value of the notes was calculated using
a credit adjusted market borrowing rate as at March 31, 2024. The fair value of both notes was $nil as at March 31, 2025 (March 31, 2024
- $2,790,492). A fair value gain of $705,565 was recognized during the year in the statement of comprehensive income (March 31, 2024 ($108,288)).


















XML
42
R18.htm
IDEA: XBRL DOCUMENT








v3.25.2













ELOC
12 Months Ended
Mar. 31, 2025
ELOC [Abstract] 
ELOC

12. ELOC



 



On August 28, 2024, the Company entered into a
$25 million equity line of credit (ELOC) agreement with White Lion Capital, LLC, which was declared effective by the U.S. Securities and
Exchange Commission (SEC). This agreement allows the Company to sell up to $25 million in shares over a 24-month period, subject to specific
conditions outlined in the Purchase Agreement.



 



As part of the consideration for entering into
the ELOC, the Company issued 3,392 common shares to White Lion at a fair value of $187,500 as a commitment fee. These shares were accounted
for as share issuance costs in the Consolidated Statement of Changes in Shareholders’ Equity/(Deficit).



 



During the year ended March 31, 2025, the Company
issued 218,900 common shares for total consideration of $6,692,495. The Company incurred $282,100 in cash settled share issuance costs.


















XML
43
R19.htm
IDEA: XBRL DOCUMENT








v3.25.2













Psyence Labs Ltd. Share Exchange
12 Months Ended
Mar. 31, 2025
Psyence Labs Ltd Share Exchange [Abstract] 
Psyence Labs Ltd. Share Exchange

13. Psyence Labs Ltd. Share Exchange



 



On October 28, 2024, the Company acquired 1,000
shares in Psyence Labs Ltd. (PsyLabs) from PGI, the Company’s parent company. PsyLabs is a private company headquartered in the
British Virgin Islands. PsyLabs is focused on the production of psychedelic active pharmaceutical ingredients and extracts. The Company
issued 3,346 common shares in exchange for the shares in PsyLabs. There was a make whole provision which entitled the PGI to a top-up
in shares if the share price at November 26, 2024 was lower than the issuance price on October 28, 2024. The share price was lower which
triggered the top-up leading to the issuance of an additional 32,248 shares to PGI. The total consideration was 35,594 shares. Based on
the listed share price of PBM’s common shares at the respective dates of issuance, the total fair value of shares issued was $722,033,
which was recorded as the cost of the investment in PsyLabs.



 



Fair Value Assessment



 



As at March 31, 2025, the Company determined the
fair value of its investment in PsyLabs to be $745,000, based on a recent arm’s length subscription transaction by a third-party
investor at $745 per PsyLabs share. This price was considered to represent a Level 2 input under the fair value hierarchy in accordance
with IFRS 13 – Fair Value Measurement, as it reflects observable market-based pricing for an identical equity instrument
in an active negotiation with a market participant.

As a result, the Company recognized an unrealized
fair value gain of $22,967 in the statement of profit or loss and other comprehensive income for the year ended March 31, 2025, in accordance
with IFRS 9 – Financial Instruments, as the investment is classified as a financial asset measured at fair value through
profit or loss (FVTPL).



 

























Summary of transaction    
Description  Amount 
Number of shares in PsyLabs acquired   1,000 
Total PBM shares issued   35,594 
Total fair value of shares issued  $722,033 
Fair value of investment at March 31, 2025  $745,000 
Fair value gain recognized  $22,967 

















XML
44
R20.htm
IDEA: XBRL DOCUMENT








v3.25.2













PIPE Financing - Private Placement and Warrants
12 Months Ended
Mar. 31, 2025
PIPE Financing Private Placement and Warrants [Abstract] 
PIPE Financing - Private Placement and Warrants

14. PIPE Financing - Private Placement and
Warrants



 



Private placement



 



On December 24, 2024, the Company completed a private
placement with HC Wainwright & Co., LLC (“HCW”), raising gross proceeds of $2,000,000
through the issuance of:



 




●47,679 common shares,


 




●77,792 pre-funded warrants (each exercisable into one common share at a nominal exercise price of $0.000797), and


 




●250,942 common share purchase warrants, comprising:


 




o125,471 warrants with an exercise price of $15.94 and a 5-year term (expiring December 24, 2029), and


 




o125,471 warrants with an exercise price of $15.94 and a 2-year term (expiring December 24, 2026).


 



The proceeds were allocated between the common
shares and the warrants based on their relative fair values on the date of issuance. The fair value allocation was as follows:



 






















Fair value allocation    
Component  Allocated Amount 
Common shares  $313,628 
Pre-funded warrants  $511,690 
Warrants  $1,174,682 
Total gross proceeds  $2,000,000 

Fair value allocation assumptions



 



The common shares were estimated using the share
price on date of issuance - $19.37.



 



The pre-funded warrants and the warrants were
estimated using a Black Scholes valuation model using the following estimates:



 



   Pre-funded

warrants		   Warrants with

5 year expiry		   Warrant with

2 year expiry		 
Share price  $19.37   $19.37   $19.37 
Expected dividend yield   Nil    Nil    Nil 
Exercise price  $0.00   $15.94   $15.94 
Risk-free interest rate   3.63%   3.63%   3.63%
Expected life   
-
    5.00    2.00 
Expected volatility   100%   100%   100%
Expiry date   -    December 24, 2029    December 24, 2026 



 



Share Issuance Costs



 



The Company incurred $257,949 in cash settled
share issuance costs, which were allocated proportionately to the equity instruments issued. The portion related to the common shares,
$40,449, was deducted from share capital, and the portion related to the warrants, $217,500, was deducted from the warrant reserve. The
Company also incurred $137,778 in warrant settled issuance costs, 9,409 warrants, which was allocated to warrant reserve.



 



Pre-funded Warrant Exercise



 



During the year ended March 31, 2025, all 77,792
pre-funded warrants were exercised. An amount of $511,690, representing the fair value originally allocated to the pre-funded warrants,
was reclassified from warrant reserve to share capital upon exercise. An amount of $66,003 of share issuance costs was reallocated to
share capital upon exercise.



 



All instruments issued in the private placement
were classified as equity instruments, as they did not contain any contractual obligations to deliver cash or other financial assets and
met the fixed-for-fixed condition.


















XML
45
R21.htm
IDEA: XBRL DOCUMENT








v3.25.2













Share Capital
12 Months Ended
Mar. 31, 2025
Share Capital [Abstract] 
Share capital

15. Share capital



 



a) Authorized



 



The Company is authorized to issue an unlimited
number of Common Shares, each without par value.



 



b) Issued and outstanding



 



On November 26, 2024, the Company consolidated
its common shares on the basis of 75:1.



 



On May 5, 2025, the Company consolidated its common
shares and warrants on the basis of 7.97:1. All common shares and value per share amounts have been updated to reflect the share consolidations.

As at March 31, 2025, there were 568,021 (March
31, 2024 – 22,402) issued and outstanding Common Shares.



 











































































  2025 
Common shares  Number   Amount ($) 
Opening balance April 1, 2024   22,402    46,125,397 
Shares issued on conversion of convertible note   38,156    4,617,286 
Shares issued on conversion of convertible note warrants   22,876    639,954 
Shares issued for ELOC   218,900    6,692,495 
Commitment shares ELOC   3,392    187,500 
Share issuance costs for ELOC   
-
    (469,600)
Warrant exchange   1,104    192,060 
Shares issued to third party advisors   586    241,379 
Shares issued on conversion of PGI promissory notes   47,265    988,569 
Shares issued on conversion of NCAC promissory notes   52,275    1,096,358 
Shares issued for PsyLabs share exchange   35,594    722,033 
Shares issued for PIPE financing   47,679    313,628 
Share issuance costs for PIPE financing   
-
    (40,449)
Shares issued for PIPE pre-funded warrants exercised   77,792    511,690 
Shares issuance costs for PIPE pre-funded warrants exercised   
-
    (65,995)
Balance as at March 31, 2025   568,021    61,752,305 




 



On January 25, 2024, because of the completion
of the RTO Transaction, the Company issued 8,365 Common Shares to PGI, 13,040 to the previous shareholders of NCAC and 997 to third party
advisors (see Note 5).



 



Payments to advisors of NCAC was settled in the
Company’s shares upon RTO Transaction at the closing price. Accounts payable of $2,136,340 acquired from NCAC as part of the RTO
Transaction was settled through the issuance of 746 shares at a fair value of $2,863.22 per share on January 25, 2024.



 



An amount of $1,000,000 owing by the Company for
services provided in relation to the RTO Transaction was settled through the issuance of 251 common shares at a fair value of $2,863.22.
A gain on settlement of $281,500 was included in the consolidated statements of net loss and comprehensive loss relating to this advisor
settlement.



 



The opening balance of equity is the net parent investment which represents
the net financings that the Company received from PGI to fund its operations through contributions to the clinical trials, cash extended
to the Company’s subsidiaries and the net effect of cost allocations from transactions with PGI, all of which did not require repayments.


 



c) Income/(Loss) per share



 



The calculation of basic and diluted income/(loss)
per share is based on the income/(loss) for the year divided by the weighted average number of shares in circulation during the year.
In calculating the diluted loss per share, potentially dilutive shares such as options, convertible debt and warrants have not been included
as they would have the effect of decreasing the loss per share, and they would therefore be anti-dilutive.

d) Warrant Reserve



 



As at March 31, 2025, there were 261,188 (March
31, 2024 – nil) issued and outstanding Warrants.



 



















































   2025 
Warrants  Number   Amount ($) 
Opening balance April 1, 2024   
-
    
-
 
Warrants issued for convertible note Addendum   837    42,528 
Warrants issued for convertible note Termination Agreement   22,876    639,954 
Convertible note Termination Agreement warrants exercised   (22,876)   (639,954)
PIPE financing warrant issuance   328,734    1,686,372 
PIPE financing warrant issuance costs   9,409    137,778 
Issuance costs for PIPE financing warrants   
-
    (355,278)
PIPE pre-funded warrants exercised   (77,792)   (511,690)
Issuance costs for PIPE pre-funded warrants exercised   
-
    65,995 
Balance as at March 31, 2025   261,188    1,065,705 




 



The following warrants were outstanding and exercisable
at March 31, 2025:



 



Issue Date  Expiry Date  Exercise Price   Number of Warrants Outstanding   Number of Warrants Exercisable 
August 20, 2024  August 20, 2026  $298.88    837    837 
December 24, 2024  December 24, 2029  $15.94    125,471    125,471 
December 24, 2024  December 24, 2026  $15.94    125,471    125,471 
December 24, 2024  December 24, 2029  $19.93    9,409    9,409 

















XML
46
R22.htm
IDEA: XBRL DOCUMENT








v3.25.2













Other Income
12 Months Ended
Mar. 31, 2025
Other Income [Abstract] 
Other income

16. Other income



 



In the prior year ended, March 31, 2024, the Company
received a research and development rebate of AUD $1,336,622 ($879,344) from the Australian Taxation office. The Company benefits from
the Australian Federal Government’s Research & Development tax incentive program, which provides up to a 43.5% rebate on research
and development expenses in Australia.



 



This rebate represents a government grant aimed
at supporting research and development activities. Therefore, in accordance with IAS 20, Accounting for Governmental Grants and Disclosure
of Government Assistance, the grant is recognized as income when there is a reasonable assurance that the grant will be received and
that the Company will comply with the conditions attached to it. These conditions were satisfied when the Company received the rebate
on October 5, 2023.



 



On August 21, 2023 the Company entered into a
loan agreement via its Australian subsidiary Psyence Australia (Pty) Ltd (the "Borrower"), to borrow up to AUD $1,100,000
by way of a secured loan from RH Capital Finance Co., LLC (“Lender”). The Loan is secured by way of a General Security
Agreement and company guarantee against the assets of the Borrower and the Company.



 



The loan was granted to the Borrower after it
successfully registered its research and development activities with the Australian Federal Government. The Borrower benefits from the
Australian Federal Government’s Research & Development tax incentive program, which provides up to a 43.5% rebate on research
and development expenses in Australia. The Loan bears interest at 16% per annum subject to a minimum interest chargeable period of 91
days and is repayable at the earlier of: (a) 21 business days after the notice of assessment (in respect of R&D refunds) is issued
by the Australian Taxation Office to the Borrower for the financial year ended June 30, 2023 (b) an event of default and (c) 30 November
2023.



 



The loan with the Lender was repaid in full on
October 5, 2023 when the Company received the research and development rebate from the Australian Taxation office, which was utilized
to settle the loan payable.



 



$nil (March 31, 2024 - $29,697) in interest expense
was incurred during the year ended March 31, 2025, on this loan. The loan and all outstanding interest was repaid.


















XML
47
R23.htm
IDEA: XBRL DOCUMENT








v3.25.2













Capital Management
12 Months Ended
Mar. 31, 2025
Capital Management [Abstract] 
Capital management

17. Capital management



 



The Company’s objectives when managing capital
are to safeguard the Company’s ability to continue as a going concern to pursue the development of natural health business, to maintain
a flexible capital structure which optimizes the cost of capital at an acceptable risk level.



 



The Company manages its capital structure and
adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its
capital structure, the Company may obtain additional funding from equity financing, issue new debt, acquire or dispose of assets or adjust
the amount of cash and cash equivalents on hand. The Company defines capital as the aggregate of its capital stock and borrowings.



 



Total managed capital is as follows as at March
31, 2025 and 2024:



 




















   2025   2024 
Borrowings   
-
    10,447,889 
Share capital   61,752,305    46,125,397 
Total   61,752,305    56,573,286 




 



To facilitate the management of its capital requirements,
the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment
and general industry conditions. The annual and updated budgets are approved by the Board of Directors.



 



Management considers its approach to capital management
to be appropriate given the relative size of the Company. There were no changes in the Company’s approach to capital management
during the period.


















XML
48
R24.htm
IDEA: XBRL DOCUMENT








v3.25.2













Transactions with Related Parties
12 Months Ended
Mar. 31, 2025
Transactions with Related Parties [Abstract] 
Transactions with related parties

18. Transactions with related parties



 



All related party transactions are measured at
the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from
or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments.
The Company incurred the following transactions with related parties during the years ended March 31, 2025 and March 31, 2024:



 



Compensation to key management personnel



 



Key management personnel are those people who
have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management
personnel include the Company’s executive officers and Board of Directors.



 





















Key Management Personnel   March 31,

2025		   March 31,

2024		 
Short term benefits   984,697    465,702 
Share based compensation   
-
    233,295 
Total   984,697    698,997 




 



Short term benefits consist of consulting fees,
director’s fees, payroll and other benefits paid to key management personnel. Share based compensation is options granted to key
management personnel.


















XML
49
R25.htm
IDEA: XBRL DOCUMENT








v3.25.2













Share Based Compensation
12 Months Ended
Mar. 31, 2025
Share Based Compensation [Abstract] 
Share based compensation

19. Share based compensation



 



During the year ended March 31, 2025, $nil (Year
ended March 31, 2024 - $317,882) was recognized for options and restricted stock units (“RSU’s”) granted by Psyence
Group under professional and consulting fees expenses and general and administrative expenses on the consolidated statements of net loss
and comprehensive loss. No options are outstanding as of March 31, 2025.



 



This share-based compensation relates only to
the historic carve out pre-combination period and does not relate to options or RSUs in the Company. No share options or RSUs have been
issued by the Company during the year.


















XML
50
R26.htm
IDEA: XBRL DOCUMENT








v3.25.2













Income Tax Note
12 Months Ended
Mar. 31, 2025
Income Tax Note [Abstract] 
Income tax note

20. Income tax note



 



The reconciliation of the combined Canadian federal
and provincial statutory income tax rate of 26.5% (2024 – 26.5%) to the effective tax rate is as follows:



 




















































   2025   2024 
Net Income/(Loss) before recovery of income taxes   1,011,790    (51,159,048)
           
Expected income tax (recovery)/expense   268,124    (13,557,148)
Difference in foreign tax rates   6,871    966 
Listing expense   
-
    10,992,625 
Non-taxable fair value gain adjustment   (1,722,146)   
-
 
Non-deductible loss on loan settlement   449,196    
-
 
Share issue costs booked to equity   (246,802)   
-
 
Other permanent expenses   1,787    2,061,001 
Change in tax benefits not recognized   1,242,970    502,556 
Income tax (recovery)/expense   
-
    
-
 




 



Unrecognized deferred tax asset



 



Deferred taxes are provided as a result of temporary
differences that arise due to the differences between the income tax values and the carrying amounts of assets and liabilities. Deferred
tax assets have not been recognized in respect of the following deductible temporary differences:



 
































Unrecognized deductible temporary differences  2025   2024 
Equipment   4,508    240 
Restricted interest and financing expenses – Canada   764,297    
-
 
Share issuance costs and others   722,097    124,132 
Non-capital losses carried forward-Canada   4,248,226    1,357,347 
Non-capital losses carried forward-Australia   431,349    164,861 
    6,170,477    1,646,580 




 



The Company’s non-capital loss carry forwards
will expire as noted in the table below:



 
























Year of expiry  Canada   Australia 
2044   1,357,347    
-
 
2045   2,890,879      
Indefinite   
-
    431,349 
Total   4,248,226    431,349 

















XML
51
R27.htm
IDEA: XBRL DOCUMENT








v3.25.2













Financial Instruments and Financial Risk Management
12 Months Ended
Mar. 31, 2025
Financial Instruments and Financial Risk Management [Abstract] 
Financial instruments and financial risk management

21. Financial instruments and financial risk
management



 



a) Financial instrument classification and
fair value measurement



 



Financial instruments that are recorded at fair
value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance
of the inputs used in making the measurements.



 



The fair value of hierarchy has the following
levels:



 




●Level
1 – quoted prices in active markets for identical financial instruments.


 




●Level
2 – quoted prices for similar instruments in active markets; quoted prices for identical
or similar instruments in the markets that are not active; and model-derived valuations in
which all significant inputs and significant value drivers are observable in active markets.


 




●Level
3 – valuations derived from valuation techniques in which one or more significant inputs
or significant value drivers are unobservable.


 



The table below presents the carrying value of
the Company’s financial instruments:



 




























   Level 1   Level 2   Level 3   Total 
Investment in Psyence Labs Ltd   
-
    745,000    
-
    745,000 
Derivative warrant liabilities – public warrants   200,096    
-
    
-
    200,096 
Balance, March 31, 2025   200,096    745,000    
-
    945,096 




 














































   Level 1   Level 2   Level 3   Total 
Derivative warrant liabilities – private warrants   
-
    26,608    
-
    26,608 
Derivative warrant liabilities – public warrants   875,000    
-
    
-
    875,000 
Convertible notes   
-
    
-
    7,657,397    7,657,397 
NCAC Sponsor promissory note   
-
    
-
    1,474,256    1,474,256 
PGI promissory note   
-
    
-
    1,316,236    1,316,236 
Balance, March 31, 2024   875,000    26,608    10,447,889    11,349,497 




 



The face value of the other financial instruments
approximates the fair value due to the short-term maturity nature of the financial instruments.



 



There were no transfers in and out of level 3
during the year.



 



b) Risk management



 



In the normal course of business, the Company
is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial
risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company’s Board of
Directors has overall responsibility for the establishment and oversight of the Company’s risk management framework.



 



Credit risk



 



Credit risk arises from cash and cash equivalents
held with banks. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing
counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents
by depositing with only reputable financial institutions.

Liquidity risk



 



Liquidity risk is the risk that the Company will
not be able to meet its financial obligations as they fall due.



 



The Company manages liquidity risk through an
ongoing review of future commitments and cash balances available. Historically, the Company’s main source of funding has been through
investments from its parent. The Company’s access to financing is uncertain. There can be no assurance of continued access to significant
equity or debt funding.



 



The following table set forth the maturity of
the contractual obligations as at March 31, 2025 and after



 






















   Carrying Amount   Contractual Cash Flows   Less than 1 year   Between 1 and 3 years 
Accounts payable & accrued liabilities   394,270    394,270    394,270    
         -
 
Total contractual obligations   394,270    394,270    394,270    
-
 




 



Interest rate risk



 



Interest rate risk is the risk that the fair value
of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has no significant
interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially independent of changes in market
interest rates.



 



Foreign exchange risk



 



Foreign currency risk is the risk that the fair
values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective
functional currency.



 



As at March 31, 2025, a 10% fluctuation in foreign
exchange rates would result in a $8,861 impact to net loss and comprehensive loss.


















XML
52
R28.htm
IDEA: XBRL DOCUMENT








v3.25.2













Subsequent Events
12 Months Ended
Mar. 31, 2025
Subsequent Events [Abstract] 
Subsequent Events

22. Subsequent Events



 



On April 15, 2025 the Company issued an additional
15,242 common shares to a third-party consultant.



 



On April 15, 2025 the Company signed a subscription
agreement to subscribe for an additional 250 shares in Psyence Labs Ltd for total consideration of $500,000 in cash.



 



On April 17, 2025 the Company granted 12,711 restricted
stock units (“RSU’s”) to consultants and an employee of the Company. This was granted pursuant to an equity incentive
scheme implemented by the Company to incentivise consultants and employees.



 



On May 5, 2025, the Company consolidated its common
shares on the basis of 7.97:1.



 



Subsequent to year end the Company issued 130,000
shares for gross proceeds of $607,050 under the ELOC.


















XML
53
R29.htm
IDEA: XBRL DOCUMENT








v3.25.2













Insider Trading Policies and Procedures
12 Months Ended
Mar. 31, 2025
Insider Trading Policies and Procedures [Line Items] 
Insider Trading Policies and Procedures Adoptedtrue
















XML
54
R30.htm
IDEA: XBRL DOCUMENT








v3.25.2













































Cybersecurity Risk Management and Strategy Disclosure
12 Months Ended
Mar. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items] 
Cybersecurity Risk Management Processes Integrated [Text Block]The Company’s cybersecurity risk management measures are integrated into its overall enterprise risk management program, and shares
common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal,
compliance, strategic, operational, and financial risk areas.
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]

The Company has developed and implemented cybersecurity
risk management measures intended to protect the confidentiality, integrity, and availability of its critical systems and information.
The Company’s cybersecurity risk management measures are integrated into its overall enterprise risk management program, and shares
common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal,
compliance, strategic, operational, and financial risk areas.

The cybersecurity risk management measures set
out the foundation of the process for assessing, identifying and managing material risks from cybersecurity threats and provide guidance
for response plan when facing cybersecurity threats. The Company has not engaged assessors or other third parties in connection with such
processes.

There can be no assurance that the Company’s
cybersecurity risk management measures and processes, including its policies, controls or procedures, will be fully implemented, complied
with or effective in protecting the Company’s systems and information. The Company has not identified risks from known cybersecurity
threats, including as a result of any prior cybersecurity incidents, that have materially affected the Company, including its operations,
business strategy, results of operations, or financial condition. The Company faces risks from cybersecurity threats that, if realized,
are reasonably likely to materially affect it, including the Company’s operations, business strategy, results of operations, or
financial condition. Many of the laws and regulations regarding cybersecurity, information security, privacy and data protection applicable
to the Company are subject to change and uncertain interpretation, and any failure or perceived failure to comply with such laws and regulations
could result in negative publicity, legal proceedings, suspension or disruption of operations, increased cost of operations, or otherwise
harm the business of the Company.


Cybersecurity Risk Management Processes Integrated [Flag]true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]The Company has not identified risks from known cybersecurity
threats, including as a result of any prior cybersecurity incidents, that have materially affected the Company, including its operations,
business strategy, results of operations, or financial condition
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]false
Cybersecurity Risk Board of Directors Oversight [Text Block]

Cybersecurity Governance

The Board has general oversight power over cybersecurity
issues and has delegated daily supervision responsibility to the Company’s Finance department. The Finance department, consisting
of personnel with relevant expertise in cybersecurity management, overseas the implementation of the Company’s cybersecurity risk
management measures and reports to the Board any material cybersecurity incidents. The Finance department supervises efforts to prevent,
detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal and
external security personnel, threat intelligence and other information obtained from governmental, public or private sources, and alerts
and reports produced by security tools deployed in the IT environment.


Cybersecurity Risk Management Expertise of Management Responsible [Text Block]The Finance department, consisting
of personnel with relevant expertise in cybersecurity management, overseas the implementation of the Company’s cybersecurity risk
management measures and reports to the Board any material cybersecurity incidents.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]The Board has general oversight power over cybersecurity
issues and has delegated daily supervision responsibility to the Company’s Finance department.
Cybersecurity Risk Management Third Party Engaged [Flag]false
















































XML
55
R31.htm
IDEA: XBRL DOCUMENT








v3.25.2

























































Accounting Policies, by Policy (Policies)
12 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract] 
Financial instruments

Financial instruments

Financial assets and financial liabilities, including
derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument
or derivative contract.

Summary of the Company’s classification
and measurements of financial assets and liabilities:

Financial Assets and Liabilities   Classification   Measurement
Cash and cash equivalents   Amortized cost   Amortized cost
Restricted cash   Amortized cost   Amortized cost
Other receivables   Amortized cost   Amortized cost
Investment in Psyence Labs Ltd   FVTPL   Fair value
Accounts payable and accrued liabilities   Amortized cost   Amortized cost
Derivative warrant liability   FVTPL   Fair value
Convertible note liability   FVTPL   Fair value
Due to NCAC Sponsor   FVTPL   Fair value
Due to Psyence Group Inc   FVTPL   Fair value

Classification

The Company classifies its financial assets in
the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (“FVTPL”);
ii) those to be measured subsequently at fair value through other comprehensive income (“FVOCI”); and iii) those to be measured
at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual
terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as
those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair
value, gains and losses are either recorded in net loss or other comprehensive income (loss).

The Company reclassifies financial assets only
when its business model for managing those assets changes. Financial liabilities are not reclassified.

Amortized cost

This category includes financial assets that are
held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments
of principal and interest ("SPPI") criterion. Financial assets classified in this category are measured at amortized cost using
the effective interest method.

Fair value through profit or loss

This category includes derivative instruments
as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL.
This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest
(“SPPI”) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or
to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized
in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives
are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.

Financial assets at fair value through other
comprehensive income

Equity instruments that are not held-for-trading
can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through
net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable
transaction costs are included in the carrying value of the instruments.

Financial assets at fair value through other comprehensive
income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).

Compound financial instrument and derivative
liability

The Company determined that the warrants, including
public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured
at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized
in net loss.

Each embedded derivative is measured and presented
separately unless the whole hybrid financial instrument is designated as at FVTPL.

Measurement

All financial instruments are required to be measured
at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that
are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial
assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered
in their entirety when determining whether their cash flows are solely payments of principal and interest.

Financial assets that are held within a business
model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal
and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All
other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with
any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial
liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value
are attributable to changes in own credit risk which is recorded in other comprehensive income.


Cash and cash equivalents

Cash and cash equivalents

Cash and cash equivalents include cash on hand
and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three months
at the date of their acquisition.


Restricted cash

Restricted cash

Restricted cash comprises a collateral agreement
with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment
certificate with the bank.


Related party transactions

Related party transactions

Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered
to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be
a related party transaction when there is transfer of resources or obligations between related parties.


Change in accounting policy

Change in accounting policy

Pursuant to completion of the Business Combination
Agreement and NASDAQ listing as explained in Note 1, on January 25, 2024, the Company decided to change the presentation currency of its
consolidated financial statements from Canadian Dollars to United States Dollars.

The Board of Directors believe that US Dollar
financial reporting provides more relevant presentation of the Company’s financial position, funding and treasury functions, financial
performance and cash flows.

A change in presentation currency represents a
change in accounting policy in terms of IAS 8 – Accounting Policies, Changes in Accounting Estimates and Errors, requiring
the restatement of comparative information.

In accordance with IAS 21 – The Effects
of Changes in Foreign Exchange Rates, the methodology followed in restating historical financial information from CDN $ to USD $.

The average and closing rates used in translating
the historical financial information from CDN $ to USD $ for the various periods were as follows:

The closing rate used as at March 31, 2024 was
$0.7380, as at March 31, 2023 was $0.7389 and as at March 31, 2022 was $0.8003.

The average rate used for the year ended March
31, 2024 was $0.7415. and for the year ended March 31, 2023 was $0.7559.

The change in presentation currency is a voluntary
change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated
to United States dollars which is disclosed in the tables below:






















Change in presentation currency  March 31, 2023
Reported CAD $		   Foreign Currency
Translation		   March 31, 2023
Restated

USD

$		 
EQUITY               
Net equity   (271,275)   70,830    (200,445)
NET DEFICIT   (271,275)   70,830    (200,445)





















Change in presentation currency  March 31, 2022
Reported CAD $		   Foreign Currency
Translation		   March 31, 2022
Restated

USD

$		 
EQUITY               
Net equity   2,122,696    (423,996)   1,698,700 
NET DEFICIT   2,122,696    (423,996)   1,698,700 
























































Change in presentation currency  March 31, 2023
Reported CAD $		   Foreign Currency
Translation		   March 31, 2023
Restated

USD

$		 
Expenses            
Sales and marketing   9,292    (2,263)   7,029 
Research and development   2,126,762    (517,867)   1,608,895 
General and administrative   484,382    (117,947)   366,435 
Professional and consulting fees   1,655,663    (403,153)   1,252,510 
Loss before other items   (4,276,099)   1,041,230   (3,234,869)
Other items               
Interest income   2,054    (500)   1,554 
Foreign exchange gain   35,574    (8,662)   26,912 
NET LOSS   (4,238,471)   1,032,068   (3,206,403)



























































































Change in presentation currency  March 31, 2023
Reported CAD $		   Foreign Currency
Translation		   March 31, 2023
Restated

USD

$		 
Net loss   (4,238,471)   1,032,068    (3,206,403)
Non-cash adjustment:               
Share based compensation   292,756    (71,469)   221,287 
Foreign exchange   
-
    (84,499)   (84,499)
                
Changes in working capital:               
Other receivables   (152,778)   42,920    (109,858)
Prepaids   (97,547)   25,882    (71,665)
Accounts payable and accrued liabilities   2,258,967    (599,909)   1,659,058 
Cash used in operating activities   (1,937,073)   344,993    (1,592,080)
                
Proceeds received from Psyence Group Inc   1,551,744    (378,821)   1,172,923 
Cash provided from financing activities   1,551,744    (378,821)   1,172,923 
                
Change in cash and cash equivalents   (385,329)   (33,828)   (419,157)
Cash and cash equivalents, start of year   2,191,095    (437,658)   1,753,437 
Cash and cash equivalents, end of year   1,805,765    (471,486)   1,334,280 

Research and development

Research and development

Expenditures on research activities, undertaken
with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and
comprehensive loss as incurred.

Development expenditures are capitalized only
if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits
are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell
the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect
operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as
incurred.


Provisions

Provisions

Provisions are recognized when the Company has
a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle
the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required
to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations.
Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash
flows.


Foreign currency translation

Foreign currency translation

The Consolidated Financial Statements are presented
in USD $ which is the Company’s functional currency.

In each individual entity, a foreign currency
transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency
and the foreign currency at the date of the transaction.

At the end of the reporting period, monetary assets
and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary
assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.

The resulting exchange gains or losses arising
on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial
recognition, are included in the consolidated statements of net income/(loss) and comprehensive income/(loss) in the year in which they
arise.

For the purpose of presenting these Consolidated
Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end
of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries
is recorded in reserves.


Income/(loss) per share

Income/(loss) per share

The Company presents basic and diluted income/(loss)
per share data for its common shares. Basic income/(loss) per share is calculated by dividing the profit or loss attributable to common
shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined
by adjusting the income or loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted
for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.


Share based compensation

Share based compensation

The Company operates equity settled share-based
remuneration plans for its eligible directors, officers, employees and consultants. All goods and services received in exchange for the
grant of any share-based payments are measured at their fair value unless the fair value cannot be estimated reliably. If the Company
cannot estimate reliably the fair value of the goods and services received, the Company shall measure their value indirectly by reference
to the fair value of the equity instruments granted. For transactions with employees and others providing similar services, the Company
measures the fair value of the services by reference to the fair value of the equity instruments granted. Equity settled share-based payments
under share-based payment plans are ultimately recognized as an expense in profit or loss with a corresponding credit to contributed surplus,
in equity. If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available
estimate of the number of share options expected to vest. Non-market vesting conditions are included in the assumptions about the number
of options that are expected to become exercisable. Estimates are subsequently revised if there is any indication that the number of share
options expected to vest differs from the previous estimate. Any cumulative adjustment prior to vesting is recognized in the current period.
No adjustment is made to any expense recognized in prior period if share options ultimately exercised are different to that estimated
on vesting. Market conditions are considered in the estimate of the fair value of share-based compensation on a grant date.


Income taxes

Income taxes

Income tax comprises current and deferred tax.
Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders’ equity,
in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also
recognized directly in equity or other comprehensive income.

Current tax is the expected tax payable on the
taxable income for the year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect
of previous years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the
amounts and the Company.

Deferred tax is recognized in respect of all qualifying
temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Consolidated Financial
Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively
enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax
assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate
to the same taxation authority.

Deferred tax assets are recognized to the extent
future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable
that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.


Accounting Standards Effective January 1, 2024 and issued but not yet effective

Accounting Standards Effective January 1, 2024
and issued but not yet effective

IFRS 18 Presentation and Disclosure in Financial
Statements

In April 2024, the IASB issued IFRS 18 –
Presentation and Disclosure in Financial Statements which will replace IAS 1, Presentation of Financial Statements. The key
new concepts introduced in IFRS 18 relate to the structure of the statement of earnings (loss), required disclosures in the financial
statements for certain earnings or loss performance measures that are reported outside an entity’s financial statements and enhanced
principles on aggregation and disaggregation which apply to the primary financial statements and notes in general. IFRS 18 will apply
for reporting periods beginning on or after January 1, 2027, and also applies to comparative information. The Company is still in the
process of assessing the impact of this standard on its consolidated financial statements.

Classification of liabilities as current or non-current
(amendments to IAS 1, presentation of financial statements)

On January 23, 2020, an amendment was issued to
IAS 1 to address inconsistencies with how entities apply the standards over classification of current and non-current liabilities. The
amendment serves to address whether, in the statement of financial position, debt and other liabilities with an uncertain settlement should
be classified as current or non-current. This amendment is effective on January 1, 2024. The Company adopted the amendment on the effective
date and the adoption did not have a material impact on the Company’s consolidated financial statements.

Non-current liabilities with covenants (amendments
to IAS 1)

The amendments to IAS 1 specify that only covenants
with which an entity is required to comply on or before the reporting date affect the classification of a liability as current or non-current.
In addition, an entity has to disclose information in the notes that enables users of financial statements to understand the risk that
noncurrent liabilities with covenants could become repayable within twelve months. The amendments are effective for annual reporting periods
beginning on or after January 1, 2024, and are to be applied retrospectively. The Company adopted the amendment on the effective date
and the adoption did not have a material impact on the Company’s consolidated financial statements.






























































XML
56
R32.htm
IDEA: XBRL DOCUMENT








v3.25.2













Basis of Presentation (Tables)
12 Months Ended
Mar. 31, 2025
Basis of Presentation [Abstract] 
Schedule of Subsidiaries

The subsidiaries of the Company have been consolidated
commencing the Closing Date and on March 31, 2025 for the purpose of these Consolidated Financial Statements are as follows:



 



Name of entity  Place of incorporation  % ownership   Accounting method
Psyence Australia Pty Ltd.  Australia   100%  Consolidated
Pysence Biomed II Corp.  Canada   100%  Consolidated
Newcourt Acquisition Corp.  Cayman Islands   100%  Consolidated

















XML
57
R33.htm
IDEA: XBRL DOCUMENT








v3.25.2

















Material Accounting Policies (Tables)
12 Months Ended
Mar. 31, 2025
Material Accounting Policies [Abstract] 
Schedule of Classification and Measurements of Financial Assets and Liabilities

Summary of the Company’s classification
and measurements of financial assets and liabilities:



 



Financial Assets and Liabilities   Classification   Measurement
Cash and cash equivalents   Amortized cost   Amortized cost
Restricted cash   Amortized cost   Amortized cost
Other receivables   Amortized cost   Amortized cost
Investment in Psyence Labs Ltd   FVTPL   Fair value
Accounts payable and accrued liabilities   Amortized cost   Amortized cost
Derivative warrant liability   FVTPL   Fair value
Convertible note liability   FVTPL   Fair value
Due to NCAC Sponsor   FVTPL   Fair value
Due to Psyence Group Inc   FVTPL   Fair value

​Schedule of Change in Presentation Currency

The change in presentation currency is a voluntary
change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated
to United States dollars which is disclosed in the tables below:



 
























Change in presentation currency  March 31, 2023
Reported CAD $		   Foreign Currency
Translation		   March 31, 2023
Restated

USD

$		 
EQUITY               
Net equity   (271,275)   70,830    (200,445)
NET DEFICIT   (271,275)   70,830    (200,445)





 
























Change in presentation currency  March 31, 2022
Reported CAD $		   Foreign Currency
Translation		   March 31, 2022
Restated

USD

$		 
EQUITY               
Net equity   2,122,696    (423,996)   1,698,700 
NET DEFICIT   2,122,696    (423,996)   1,698,700 




 



























































Change in presentation currency  March 31, 2023
Reported CAD $		   Foreign Currency
Translation		   March 31, 2023
Restated

USD

$		 
Expenses            
Sales and marketing   9,292    (2,263)   7,029 
Research and development   2,126,762    (517,867)   1,608,895 
General and administrative   484,382    (117,947)   366,435 
Professional and consulting fees   1,655,663    (403,153)   1,252,510 
Loss before other items   (4,276,099)   1,041,230   (3,234,869)
Other items               
Interest income   2,054    (500)   1,554 
Foreign exchange gain   35,574    (8,662)   26,912 
NET LOSS   (4,238,471)   1,032,068   (3,206,403)



























































































Change in presentation currency  March 31, 2023
Reported CAD $		   Foreign Currency
Translation		   March 31, 2023
Restated

USD

$		 
Net loss   (4,238,471)   1,032,068    (3,206,403)
Non-cash adjustment:               
Share based compensation   292,756    (71,469)   221,287 
Foreign exchange   
-
    (84,499)   (84,499)
                
Changes in working capital:               
Other receivables   (152,778)   42,920    (109,858)
Prepaids   (97,547)   25,882    (71,665)
Accounts payable and accrued liabilities   2,258,967    (599,909)   1,659,058 
Cash used in operating activities   (1,937,073)   344,993    (1,592,080)
                
Proceeds received from Psyence Group Inc   1,551,744    (378,821)   1,172,923 
Cash provided from financing activities   1,551,744    (378,821)   1,172,923 
                
Change in cash and cash equivalents   (385,329)   (33,828)   (419,157)
Cash and cash equivalents, start of year   2,191,095    (437,658)   1,753,437 
Cash and cash equivalents, end of year   1,805,765    (471,486)   1,334,280 





















XML
58
R34.htm
IDEA: XBRL DOCUMENT








v3.25.2













Reverse Takeover Transaction with NCAC (Tables)
12 Months Ended
Mar. 31, 2025
Reverse Takeover Transaction with NCAC [Abstract] 
Schedule of Listing Expenses

The calculation of listing expenses is as follows:



 

















































   Listing Expense 
Consideration paid:    
Shares issued to NCAC shareholders   13,040 
Total consideration shares issued   13,040 
Fair value of the common shares  $2,863.22 
Deemed consideration amount for the common shares issued  $37,336,416 
      
Net identifiable liabilities acquired:     
Cash and cash equivalent  $203 
Accounts payable and accrued liabilities  $(2,136,505)
NCAC promissory note (Note 11)  $(1,413,529)
Derivative warrant liabilities (Note 10)  $(595,358)
Net liabilities acquired  $4,145,189 
      
Listing expense  $41,481,605 

















XML
59
R35.htm
IDEA: XBRL DOCUMENT








v3.25.2













Cash, Restricted Cash and Cash Equivalents (Tables)
12 Months Ended
Mar. 31, 2025
Cash, Restricted Cash and Cash Equivalents [Abstract] 
Schedule of Cash and Cash Equivalents

Cash and cash equivalents include the following
amounts:



 




















   March 31,

2025		   March 31,

2024		 
Unrestricted cash held with chartered banks   6,135,166    733,188 
Restricted cash   35,964    29,611 
Total   6,171,130    762,799 

















XML
60
R36.htm
IDEA: XBRL DOCUMENT








v3.25.2













Equipment (Tables)
12 Months Ended
Mar. 31, 2025
Equipment [Abstract] 
Schedule of Equipment






















































   Computer equipment 
Cost    
At March 31, 2023   
-
 
Additions   5,727 
At March 31, 2024   5,727 
Additions   9,877 
At March 31, 2025   15,604 
      
Accumulated Depreciation     
At March 31, 2023   
-
 
Charge for the year   (240)
At March 31, 2024   (240)
Charge for the year   (4,268)
At March 31, 2025   (4,508)
      
Carrying Value     
At March 31, 2024   5,487 
At March 31, 2025   11,096 

















XML
61
R37.htm
IDEA: XBRL DOCUMENT








v3.25.2













Accounts Payable and Accrued Liabilities (Tables)
12 Months Ended
Mar. 31, 2025
Accounts Payable and Accrued Liabilities [Abstract] 
​Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities include
the following amounts:



 
























   March 31,

2025		   March 31,

2024		 
Trade payables   261,937    562,352 
Accrued liabilities   50,481    125,951 
Provisions   81,852    66,899 
Total   394,270    755,202 

















XML
62
R38.htm
IDEA: XBRL DOCUMENT








v3.25.2













Convertible Note Liability (Tables)
12 Months Ended
Mar. 31, 2025
Convertible Note Liability [Abstract] 
Schedule of Using the Black-Scholes Pricing ModelThe warrants were valued at $42,528 using the Black-Scholes pricing model with the following assumptions:
   Warrant Inputs at
August 20, 2024		 
Share price  $312.62 
Expected dividend yield   Nil 
Exercise price   298.88 
Risk-free interest rate   3.93%
Expected life   2.00 
Expected volatility   17.7%
Expiry date   August 20, 2026 

As at March 31, 2024, the fair value of the convertible
notes was estimated at $7,657,397 using a combined discounted cash flow approach and Monte Carlo simulation with the following assumptions:



 































   Inputs 
Share price  $681.44 
Note principal amount  $3,125,000 
Prepayment Amount   130%
Discount rate shares   4.43%
Discount rate cash   20.83%
Volatility annual   100%
Volatility daily   6.30%
Risk free annual   4.43%

















XML
63
R39.htm
IDEA: XBRL DOCUMENT








v3.25.2

























Derivative Warrant Liabilities (Tables)
12 Months Ended
Mar. 31, 2025
Derivative Warrant Liabilities [Abstract] 
Schedule of Private WarrantsThe Company utilizes a Black-Scholes
options valuation model to value the private warrants at each reporting period, using the following main assumptions:
   Warrant Inputs at
March 31, 2025		   Warrant Inputs at
March 31, 2024		 
Share price  $4.78   $681.44 
Expected dividend yield   Nil    Nil 
Exercise price  $6,874.13   $6,874.13 
Risk-free interest rate   4.21%   4.21%
Expected life   4.00    5.00 
Expected volatility   59.98%   59.98%
Expiry date   January 25, 2029    January 25, 2029 

Schedule of Derivative Warrant Liability

As at March 31, 2025, the derivative warrant liability
was $200,096 (March 31, 2024 – $901,608 ) reconciled as follows:



 
































Derivative warrant liability – Public and Private Warrants  Number   Amount

($)		 
At listing January 25, 2024   21,866    595,358 
Fair value loss   
-
    306,250 
Opening balance April 1, 2024   21,866    901,608 
Warrant exchange   (1,104)   (6,996)
Fair value gain   
-
    (694,516)
Balance as at March 31, 2025   20,762    200,096 

Schedule of Warrant Transactions

Warrant transactions and the number of warrants
outstanding are summarized as follows:



 












































   Public Warrants   Private Warrants 
   Number of Warrants   Weighted Average Exercise Price   Number of Warrants   Weighted Average Exercise Price 
Balance, April 1, 2023   
-
    
-
    
-
    
-
 
Issued   20,912   $6,874.13    954   $6,874.13 
Balance, March 31, 2024   20,912   $6,874.13    954   $6,874.13 
Warrant exchange   (1,104)  $6,874.13    
-
   $6,874.13 
Balance, March 31, 2025   19,808   $6,874.13    954   $6,874.13 

Schedule of Warrants Outstanding and Exercisable

The following warrants were outstanding and exercisable
at March 31, 2025:



 



Issue Date  Expiry Date  Exercise Price   Number of Warrants Outstanding   Number of Warrants Exercisable 
January 25, 2024  January 25, 2029  $6,874.13    20,762    20,762 





























XML
64
R40.htm
IDEA: XBRL DOCUMENT








v3.25.2













Psyence Labs Ltd. Share Exchange (Tables)
12 Months Ended
Mar. 31, 2025
Psyence Labs Ltd Share Exchange [Abstract] 
Schedule of Investment is Classified as a Financial Asset Measured at Fair Value





















Summary of transaction    
Description  Amount 
Number of shares in PsyLabs acquired   1,000 
Total PBM shares issued   35,594 
Total fair value of shares issued  $722,033 
Fair value of investment at March 31, 2025  $745,000 
Fair value gain recognized  $22,967 

















XML
65
R41.htm
IDEA: XBRL DOCUMENT








v3.25.2

















PIPE Financing - Private Placement and Warrants (Tables)
12 Months Ended
Mar. 31, 2025
PIPE Financing Private Placement and Warrants [Abstract] 
Schedule of Fair Value AllocationThe fair value allocation was as follows:


















Fair value allocation    
Component  Allocated Amount 
Common shares  $313,628 
Pre-funded warrants  $511,690 
Warrants  $1,174,682 
Total gross proceeds  $2,000,000 

Schedule of Pre-funded Warrants

The pre-funded warrants and the warrants were
estimated using a Black Scholes valuation model using the following estimates:



 



   Pre-funded

warrants		   Warrants with

5 year expiry		   Warrant with

2 year expiry		 
Share price  $19.37   $19.37   $19.37 
Expected dividend yield   Nil    Nil    Nil 
Exercise price  $0.00   $15.94   $15.94 
Risk-free interest rate   3.63%   3.63%   3.63%
Expected life   
-
    5.00    2.00 
Expected volatility   100%   100%   100%
Expiry date   -    December 24, 2029    December 24, 2026 





















XML
66
R42.htm
IDEA: XBRL DOCUMENT








v3.25.2





















Share Capital (Tables)
12 Months Ended
Mar. 31, 2025
Share Capital [Abstract] 
Schedule of Issued and Outstanding Common Shares

As at March 31, 2025, there were 568,021 (March
31, 2024 – 22,402) issued and outstanding Common Shares.



 











































































  2025 
Common shares  Number   Amount ($) 
Opening balance April 1, 2024   22,402    46,125,397 
Shares issued on conversion of convertible note   38,156    4,617,286 
Shares issued on conversion of convertible note warrants   22,876    639,954 
Shares issued for ELOC   218,900    6,692,495 
Commitment shares ELOC   3,392    187,500 
Share issuance costs for ELOC   
-
    (469,600)
Warrant exchange   1,104    192,060 
Shares issued to third party advisors   586    241,379 
Shares issued on conversion of PGI promissory notes   47,265    988,569 
Shares issued on conversion of NCAC promissory notes   52,275    1,096,358 
Shares issued for PsyLabs share exchange   35,594    722,033 
Shares issued for PIPE financing   47,679    313,628 
Share issuance costs for PIPE financing   
-
    (40,449)
Shares issued for PIPE pre-funded warrants exercised   77,792    511,690 
Shares issuance costs for PIPE pre-funded warrants exercised   
-
    (65,995)
Balance as at March 31, 2025   568,021    61,752,305 

Schedule of Issued and Outstanding Warrants

As at March 31, 2025, there were 261,188 (March
31, 2024 – nil) issued and outstanding Warrants.



 



















































   2025 
Warrants  Number   Amount ($) 
Opening balance April 1, 2024   
-
    
-
 
Warrants issued for convertible note Addendum   837    42,528 
Warrants issued for convertible note Termination Agreement   22,876    639,954 
Convertible note Termination Agreement warrants exercised   (22,876)   (639,954)
PIPE financing warrant issuance   328,734    1,686,372 
PIPE financing warrant issuance costs   9,409    137,778 
Issuance costs for PIPE financing warrants   
-
    (355,278)
PIPE pre-funded warrants exercised   (77,792)   (511,690)
Issuance costs for PIPE pre-funded warrants exercised   
-
    65,995 
Balance as at March 31, 2025   261,188    1,065,705 

Schedule of Warrants were Outstanding and Exercisable

The following warrants were outstanding and exercisable
at March 31, 2025:



 



Issue Date  Expiry Date  Exercise Price   Number of Warrants Outstanding   Number of Warrants Exercisable 
August 20, 2024  August 20, 2026  $298.88    837    837 
December 24, 2024  December 24, 2029  $15.94    125,471    125,471 
December 24, 2024  December 24, 2026  $15.94    125,471    125,471 
December 24, 2024  December 24, 2029  $19.93    9,409    9,409 

























XML
67
R43.htm
IDEA: XBRL DOCUMENT








v3.25.2













Capital Management (Tables)
12 Months Ended
Mar. 31, 2025
Capital Management [Abstract] 
Schedule of Total Managed Capital

Total managed capital is as follows as at March
31, 2025 and 2024:



 




















   2025   2024 
Borrowings   
-
    10,447,889 
Share capital   61,752,305    46,125,397 
Total   61,752,305    56,573,286 

















XML
68
R44.htm
IDEA: XBRL DOCUMENT








v3.25.2













Transactions with Related Parties (Tables)
12 Months Ended
Mar. 31, 2025
Transactions with Related Parties [Abstract] 
Schedule of Key Management PersonnelKey management
personnel include the Company’s executive officers and Board of Directors.
















Key Management Personnel   March 31,

2025		   March 31,

2024		 
Short term benefits   984,697    465,702 
Share based compensation   
-
    233,295 
Total   984,697    698,997 

















XML
69
R45.htm
IDEA: XBRL DOCUMENT








v3.25.2





















Income Tax Note (Tables)
12 Months Ended
Mar. 31, 2025
Income Tax Note [Abstract] 
Schedule of Canadian Federal and Provincial Statutory Income Tax Rate

The reconciliation of the combined Canadian federal
and provincial statutory income tax rate of 26.5% (2024 – 26.5%) to the effective tax rate is as follows:



 




















































   2025   2024 
Net Income/(Loss) before recovery of income taxes   1,011,790    (51,159,048)
           
Expected income tax (recovery)/expense   268,124    (13,557,148)
Difference in foreign tax rates   6,871    966 
Listing expense   
-
    10,992,625 
Non-taxable fair value gain adjustment   (1,722,146)   
-
 
Non-deductible loss on loan settlement   449,196    
-
 
Share issue costs booked to equity   (246,802)   
-
 
Other permanent expenses   1,787    2,061,001 
Change in tax benefits not recognized   1,242,970    502,556 
Income tax (recovery)/expense   
-
    
-
 

Schedule of Deferred Tax AssetsDeferred
tax assets have not been recognized in respect of the following deductible temporary differences:




























Unrecognized deductible temporary differences  2025   2024 
Equipment   4,508    240 
Restricted interest and financing expenses – Canada   764,297    
-
 
Share issuance costs and others   722,097    124,132 
Non-capital losses carried forward-Canada   4,248,226    1,357,347 
Non-capital losses carried forward-Australia   431,349    164,861 
    6,170,477    1,646,580 

Schedule of Non-Capital Loss Carry Forwards

The Company’s non-capital loss carry forwards
will expire as noted in the table below:



 
























Year of expiry  Canada   Australia 
2044   1,357,347    
-
 
2045   2,890,879      
Indefinite   
-
    431,349 
Total   4,248,226    431,349 

























XML
70
R46.htm
IDEA: XBRL DOCUMENT








v3.25.2

















Financial Instruments and Financial Risk Management (Tables)
12 Months Ended
Mar. 31, 2025
Financial Instruments and Financial Risk Management [Abstract] 
Schedule of Carrying Value of the Financial Instruments

The table below presents the carrying value of
the Company’s financial instruments:



 




























   Level 1   Level 2   Level 3   Total 
Investment in Psyence Labs Ltd   
-
    745,000    
-
    745,000 
Derivative warrant liabilities – public warrants   200,096    
-
    
-
    200,096 
Balance, March 31, 2025   200,096    745,000    
-
    945,096 




 














































   Level 1   Level 2   Level 3   Total 
Derivative warrant liabilities – private warrants   
-
    26,608    
-
    26,608 
Derivative warrant liabilities – public warrants   875,000    
-
    
-
    875,000 
Convertible notes   
-
    
-
    7,657,397    7,657,397 
NCAC Sponsor promissory note   
-
    
-
    1,474,256    1,474,256 
PGI promissory note   
-
    
-
    1,316,236    1,316,236 
Balance, March 31, 2024   875,000    26,608    10,447,889    11,349,497 

Schedule of Maturity of the Contractual Obligations

The following table set forth the maturity of
the contractual obligations as at March 31, 2025 and after



 






















   Carrying Amount   Contractual Cash Flows   Less than 1 year   Between 1 and 3 years 
Accounts payable & accrued liabilities   394,270    394,270    394,270    
         -
 
Total contractual obligations   394,270    394,270    394,270    
-
 





















XML
71
R47.htm
IDEA: XBRL DOCUMENT








v3.25.2

































































Basis of Presentation - Schedule of Subsidiaries (Details)
12 Months Ended
Mar. 31, 2025
Psyence Australia (Pty) Ltd [Member] 
Schedule of Subsidiaries of PBM [Line Items] 
Place of incorporationAustralia
% ownership100.00%
Accounting methodConsolidated
Pysence Biomed II Corp. [Member] 
Schedule of Subsidiaries of PBM [Line Items] 
Place of incorporationCanada
% ownership100.00%
Accounting methodConsolidated
Newcourt Acquisition Corp. [Member] 
Schedule of Subsidiaries of PBM [Line Items] 
Place of incorporationCayman Islands
% ownership100.00%
Accounting methodConsolidated




































XML
72
R48.htm
IDEA: XBRL DOCUMENT








v3.25.2




























Material Accounting Policies (Details)
12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2022
Material Accounting Policies [Abstract] 
 
 
Closing rate0.738
0.7389
0.8003
Average rate0.7415
0.7559
 




















XML
73
R49.htm
IDEA: XBRL DOCUMENT








v3.25.2





















































































































































Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details)
12 Months Ended
Mar. 31, 2025
Cash and cash equivalents [Member] 
Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items] 
ClassificationAmortized cost
MeasurementAmortized cost
Restricted cash [Member] 
Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items] 
ClassificationAmortized cost
MeasurementAmortized cost
Other receivables [Member] 
Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items] 
ClassificationAmortized cost
MeasurementAmortized cost
Investment in Psyence Labs Ltd [Member] 
Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items] 
ClassificationFVTPL
MeasurementFair value
Accounts payable and accrued liabilities [Member] 
Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items] 
ClassificationAmortized cost
MeasurementAmortized cost
Derivative warrant liability [Member] 
Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items] 
ClassificationFVTPL
MeasurementFair value
Convertible note liability [Member] 
Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items] 
ClassificationFVTPL
MeasurementFair value
Due to NCAC Sponsor [Member] 
Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items] 
ClassificationFVTPL
MeasurementFair value
Due to Psyence Group Inc [Member] 
Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items] 
ClassificationFVTPL
MeasurementFair value
























































XML
74
R50.htm
IDEA: XBRL DOCUMENT








v3.25.2















































































































































































































































































































































































































































































































































































































































































































































































































































Material Accounting Policies - ​Schedule of Change in Presentation Currency (Details)
12 Months Ended

Mar. 31, 2025

USD ($)


Mar. 31, 2024

USD ($)


Mar. 31, 2023

USD ($)


Mar. 31, 2023

CAD ($)


Mar. 31, 2023

CAD ($)


Mar. 31, 2022

USD ($)


Mar. 31, 2022

CAD ($)

EQUITY 
 
 
 
 
 
 
Net equity 
 
$ (200,445)
 
 
$ 1,698,700
 
NET DEFICIT$ 6,722,004
$ (10,972,540)
(200,445)
 
 
1,698,700
 
Expenses 
 
 
 
 
 
 
Sales and marketing483,530
80,603
7,029
 
 
 
 
Research and development342,168
954,593
1,608,895
 
 
 
 
General and administrative1,209,847
557,904
366,435
 
 
 
 
Professional and consulting fees1,623,209
1,158,484
1,252,510
 
 
 
 
Loss before other items(3,658,754)
(2,751,584)
(3,234,869)
 
 
 
 
Other items 
 
 
 
 
 
 
Interest income 
 
1,554
 
 
 
 
Foreign exchange gain(7,317)
(2,695)
26,912
 
 
 
 
NET LOSS1,011,790
(51,159,048)
(3,206,403)
 
 
 
 
Non-cash adjustment: 
 
 
 
 
 
 
Share based compensation
317,882
221,287
 
 
 
 
Foreign exchange(9,860)
3,660
(84,499)
 
 
 
 
Changes in working capital: 
 
 
 
 
 
 
Other receivables(95,601)
107,622
(109,858)
 
 
 
 
Prepaids70,330
(245,075)
(71,665)
 
 
 
 
Accounts payable and accrued liabilities 
 
1,659,058
 
 
 
 
Cash used in operating activities(3,734,238)
(2,945,365)
(1,592,080)
 
 
 
 
Proceeds received from Psyence Group Inc

1,172,923
 
 
 
 
Cash provided from financing activities9,152,446
2,350,000
1,172,923
 
 
 
 
Change in cash and cash equivalents5,401,978
(601,092)
(419,157)
 
 
 
 
Cash and cash equivalents, beginning of year733,188
1,334,280
1,753,437
 
 
 
 
Cash and cash equivalents, end of year$ 6,135,166
733,188
1,334,280
 
 
 
 
Reported [Member] 
 
 
 
 
 
 
EQUITY 
 
 
 
 
 
 
Net equity 
 
 
 
$ (271,275)
 
$ 2,122,696
NET DEFICIT 
 
 
 
$ (271,275)
 
$ 2,122,696
Expenses 
 
 
 
 
 
 
Sales and marketing 
 
 
$ 9,292
 
 
 
Research and development 
 
 
2,126,762
 
 
 
General and administrative 
 
 
484,382
 
 
 
Professional and consulting fees 
 
 
1,655,663
 
 
 
Loss before other items 
 
 
(4,276,099)
 
 
 
Other items 
 
 
 
 
 
 
Interest income 
 
 
2,054
 
 
 
Foreign exchange gain 
 
 
35,574
 
 
 
NET LOSS 
 
 
(4,238,471)
 
 
 
Non-cash adjustment: 
 
 
 
 
 
 
Share based compensation 
 
 
292,756
 
 
 
Foreign exchange 
 
 
 
 
 
Changes in working capital: 
 
 
 
 
 
 
Other receivables 
 
 
(152,778)
 
 
 
Prepaids 
 
 
(97,547)
 
 
 
Accounts payable and accrued liabilities 
 
 
2,258,967
 
 
 
Cash used in operating activities 
 
 
(1,937,073)
 
 
 
Proceeds received from Psyence Group Inc 
 
 
1,551,744
 
 
 
Cash provided from financing activities 
 
 
1,551,744
 
 
 
Change in cash and cash equivalents 
 
 
(385,329)
 
 
 
Cash and cash equivalents, beginning of year 
 
 
2,191,095
 
 
 
Cash and cash equivalents, end of year 
 
 
$ 1,805,765
 
 
 
Foreign Currency Translation [Member] 
 
 
 
 
 
 
EQUITY 
 
 
 
 
 
 
Net equity 
 
70,830
 
 
(423,996)
 
NET DEFICIT 
 
70,830
 
 
$ (423,996)
 
Expenses 
 
 
 
 
 
 
Sales and marketing 
 
(2,263)
 
 
 
 
Research and development 
 
(517,867)
 
 
 
 
General and administrative 
 
(117,947)
 
 
 
 
Professional and consulting fees 
 
(403,153)
 
 
 
 
Loss before other items 
 
1,041,230
 
 
 
 
Other items 
 
 
 
 
 
 
Interest income 
 
(500)
 
 
 
 
Foreign exchange gain 
 
(8,662)
 
 
 
 
NET LOSS 
 
1,032,068
 
 
 
 
Non-cash adjustment: 
 
 
 
 
 
 
Share based compensation 
 
(71,469)
 
 
 
 
Foreign exchange 
 
(84,499)
 
 
 
 
Changes in working capital: 
 
 
 
 
 
 
Other receivables 
 
42,920
 
 
 
 
Prepaids 
 
25,882
 
 
 
 
Accounts payable and accrued liabilities 
 
(599,909)
 
 
 
 
Cash used in operating activities 
 
344,993
 
 
 
 
Proceeds received from Psyence Group Inc 
 
(378,821)
 
 
 
 
Cash provided from financing activities 
 
(378,821)
 
 
 
 
Change in cash and cash equivalents 
 
(33,828)
 
 
 
 
Cash and cash equivalents, beginning of year 
$ (471,486)
(437,658)
 
 
 
 
Cash and cash equivalents, end of year 
 
$ (471,486)
 
 
 
 




















































































































XML
75
R51.htm
IDEA: XBRL DOCUMENT








v3.25.2












Critical Accounting Estimates and Judgements (Details)

Jan. 25, 2024

$ / shares

Critical Accounting Estimates and Judgements [Abstract] 
Trading price per share$ 2,863.22
















XML
76
R52.htm
IDEA: XBRL DOCUMENT








v3.25.2












































Reverse Takeover Transaction with NCAC (Details) - USD ($)
12 Months Ended
Mar. 31, 2025
Jan. 25, 2024
NCAC [Member] 
 
Reverse Takeover Transaction with NCAC [Line Items] 
 
Trading price 
$ 2,863.22
Common shares issued13,040
 
RTO [Member] 
 
Reverse Takeover Transaction with NCAC [Line Items] 
 
Transaction expenses$ 2,461,025
 
































XML
77
R53.htm
IDEA: XBRL DOCUMENT








v3.25.2





















































Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details) - NCAC [Member]
12 Months Ended

Mar. 31, 2025

USD ($)

$ / shares

shares

Consideration paid: 
Shares issued to NCAC shareholders (in Shares) | shares13,040
Total consideration shares issued (in Shares) | shares13,040
Fair value of the common shares (in Dollars per share) | $ / shares$ 2,863.22
Deemed consideration amount for the common shares issued$ 37,336,416
Net identifiable liabilities acquired: 
Cash and cash equivalent203
Accounts payable and accrued liabilities(2,136,505)
NCAC promissory note (Note 11)(1,413,529)
Derivative warrant liabilities (Note 10)(595,358)
Net liabilities acquired4,145,189
Listing expense$ 41,481,605




























































XML
78
R54.htm
IDEA: XBRL DOCUMENT








v3.25.2












Cash, Restricted Cash and Cash Equivalents (Details)

Mar. 31, 2025

USD ($)

Cash, Restricted Cash and Cash Equivalents [Abstract] 
Deposit made in a guaranteed investment certificate with the bank$ 50,000
















XML
79
R55.htm
IDEA: XBRL DOCUMENT








v3.25.2

























Cash, Restricted Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) - USD ($)
Mar. 31, 2025
Mar. 31, 2024
Schedule of Cash and Cash Equivalents [Abstract] 
 
Unrestricted cash held with chartered banks$ 6,135,166
$ 733,188
Restricted cash35,964
29,611
Total$ 6,171,130
$ 762,799
























XML
80
R56.htm
IDEA: XBRL DOCUMENT








v3.25.2









































































Equipment - Schedule of Equipment (Details) - Computer Equipment [Member] - USD ($)
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Schedule of Equipment [Line Items] 
 
Beginning balance$ 5,487
Ending balance11,096
5,487
Cost [Member] 
 
Schedule of Equipment [Line Items] 
 
Beginning balance5,727
 
Additions9,877
5,727
Ending balance15,604
5,727
Accumulated Depreciation [Member] 
 
Schedule of Equipment [Line Items] 
 
Beginning balance(240)
Charge for the year(4,268)
(240)
Ending balance$ (4,508)
$ (240)




































XML
81
R57.htm
IDEA: XBRL DOCUMENT








v3.25.2






























Accounts Payable and Accrued Liabilities - ​Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)
Mar. 31, 2025
Mar. 31, 2024
Accounts Payable and Accrued Liabilities [Abstract] 
 
Trade payables$ 261,937
$ 562,352
Accrued liabilities50,481
125,951
Provisions81,852
66,899
Total$ 394,270
$ 755,202




























XML
82
R58.htm
IDEA: XBRL DOCUMENT








v3.25.2





































































































































































































































































































































































































































































































































































































































































Convertible Note Liability (Details)
1 Months Ended12 Months Ended

Sep. 30, 2024

USD ($)

$ / shares

shares


Aug. 20, 2024

USD ($)

shares


Jul. 31, 2024

USD ($)


Jan. 25, 2024

USD ($)


Aug. 20, 2024

USD ($)

shares


Mar. 31, 2025

USD ($)

shares


Mar. 31, 2024

USD ($)

shares


Mar. 31, 2023

USD ($)


Jan. 15, 2024

USD ($)

Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Aggregate principal amount 
 
$ 1,000,000
 
 
 
 
 
 
Proceeds from convertible debt 
 
$ 1,250,000
 
 
 
 
 
 
Interest rate 
 
 
8.00%
 
 
 
 
 
Common shares valued 
 
 
 
 
$ 241,379

 
Equity on conversion$ 3,604,688
 
 
 
 
 
 
 
 
Fair value 
 
 
 
 
$ 945,096
11,349,497
 
 
First Tranche Note [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Common shares, issued (in Shares) | shares17,536
 
 
 
 
 
 
 
 
Second Tranche Notes [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Interest rate 
 
8.00%
 
 
 
 
 
 
Investors [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Common shares, issued (in Shares) | shares 
 
 
 
 
18,947
 
 
 
Common shares valued 
 
 
 
 
$ 489,598
 
 
 
Exercisable per share 
298.88
 
 
298.88
 
 
 
 
Warrants valued 
$ 42,528
 
 
 
639,954
 
 
 
Investors [Member] | First Tranche Note [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Aggregate principal amount 
 
 
$ 3,125,000
 
 
 
 
 
Proceeds from convertible debt 
 
 
$ 2,500,000
 
 
 
 
 
Convertible Instruments [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Expected dividend yield0.00%
 
 
 
 
 
 
 
 
Change in fair value 
 
 
 
 
$ 5,052,708
5,157,397
 
Fair value 
 
 
 
 
 
$ 7,657,397
 
 
Convertible Instruments [Member] | Top of Range [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Exercise price (in Dollars per share) | $ / shares$ 320.45
 
 
 
 
 
 
 
 
Risk free interest rate5.23%
 
 
 
 
 
 
 
 
Expected life2 years 8 months 12 days
 
 
 
 
 
 
 
 
Convertible Instruments [Member] | Bottom of Range [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Exercise price (in Dollars per share) | $ / shares$ 224.22
 
 
 
 
 
 
 
 
Risk free interest rate3.63%
 
 
 
 
 
 
 
 
Expected life1 month 6 days
 
 
 
 
 
 
 
 
Convertible Instruments [Member] | Investors [Member] | Top of Range [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Aggregate principal amount 
 
 
 
 
 
 
 
$ 12,500,000
Subscription amount 
 
 
 
 
 
 
 
$ 10,000,000
Waarants [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Common shares, issued (in Shares) | shares 
 
 
 
 
261,188
 
 
Waarants [Member] | Investors [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Common shares, issued (in Shares) | shares 
837
 
 
837
22,876
 
 
 
Ordinary shares [member] | Investors [Member] 
 
 
 
 
 
 
 
 
Convertible Note Liability [Line Items] 
 
 
 
 
 
 
 
 
Common shares, issued (in Shares) | shares 
1,673
 
 
1,673
 
 
 
 
Common shares valued 
 
 
 
$ 523,000
 
 
 
 








































































































XML
83
R59.htm
IDEA: XBRL DOCUMENT








v3.25.2
















































































































































































































































Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details)
Aug. 20, 2024
Mar. 31, 2024
Share price [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input312.62
681.44
Convertible note, measurement input312.62
681.44
Expected dividend yield [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input
 
Convertible note, measurement input
 
Exercise price [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input298.88
 
Convertible note, measurement input298.88
 
Risk free annual [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input3.93
4.43
Convertible note, measurement input3.93
4.43
Expected life [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input2
 
Convertible note, measurement input2
 
Volatility daily [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input17.7
6.3
Convertible note, measurement input17.7
6.3
Expiry date [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement inputAugust 20, 2026
 
Note principal amount [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input 
3,125,000
Convertible note, measurement input 
3,125,000
Prepayment amount [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input 
130
Convertible note, measurement input 
130
Discount rate shares [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input 
4.43
Convertible note, measurement input 
4.43
Discount rate cash [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input 
20.83
Convertible note, measurement input 
20.83
Volatility annual [Member] 
 
Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items] 
 
Warrants, measurement input 
100
Convertible note, measurement input 
100




































































XML
84
R60.htm
IDEA: XBRL DOCUMENT








v3.25.2













































































































































































Derivative Warrant Liabilities (Details) - USD ($)
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Jan. 24, 2024
Derivative Warrant Liabilities [Line Items] 
 
 
Number of warrants issued20,762
 
 
Warrants outstanding20,762
 
 
Exercise price of warrants per share (in Dollars per share)$ 6,874.13
 
 
Common shares issued1,104
 
 
Cancellation of public warrants1,104
 
 
Fair value of warrants (in Dollars)$ 945,096
$ 11,349,497
 
Derivative warrant liability (in Dollars)$ 200,096
901,608
$ 595,358
Public Warrants [Member] 
 
 
Derivative Warrant Liabilities [Line Items] 
 
 
Number of warrants issued19,808
 
 
Exercise price of warrants per share (in Dollars per share)$ 200,096
 
 
Fair value loss (in Dollars)$ 185,064
 
 
Fair value of warrants (in Dollars)
875,000
 
Private Warrants [Member] 
 
 
Derivative Warrant Liabilities [Line Items] 
 
 
Fair value of warrants (in Dollars) 
26,608
 
Derivative warrant liability [Member] 
 
 
Derivative Warrant Liabilities [Line Items] 
 
 
Fair value loss (in Dollars)694,516
 
 
Derivative warrant liability (in Dollars)$ 200,096
$ 901,608
 
Derivative warrant liability [Member] | Public Warrants [Member] 
 
 
Derivative Warrant Liabilities [Line Items] 
 
 
Number of warrants issued 
20,912
 
Derivative warrant liability [Member] | Private Warrants [Member] 
 
 
Derivative Warrant Liabilities [Line Items] 
 
 
Number of warrants issued954
954
 
























































XML
85
R61.htm
IDEA: XBRL DOCUMENT








v3.25.2









































































































Derivative Warrant Liabilities - Schedule of Private Warrants (Details) - Level 2 fair value measurements [Member]
Mar. 31, 2025
Mar. 31, 2024
Schedule of Private Warrants [Line Items] 
 
Warrant, expiry dateJan. 25, 2029
Jan. 25, 2029
Share price [Member] 
 
Schedule of Private Warrants [Line Items] 
 
Warrants, measurement input4.78
681.44
Expected dividend yield [Member] 
 
Schedule of Private Warrants [Line Items] 
 
Warrants, measurement input

Exercise price [Member] 
 
Schedule of Private Warrants [Line Items] 
 
Warrants, measurement input6,874.13
6,874.13
Risk-free interest rate [Member] 
 
Schedule of Private Warrants [Line Items] 
 
Warrants, measurement input4.21
4.21
Expected life [Member] 
 
Schedule of Private Warrants [Line Items] 
 
Warrants, measurement input4
5
Expected volatility [Member] 
 
Schedule of Private Warrants [Line Items] 
 
Warrants, measurement input59.98
59.98
















































XML
86
R62.htm
IDEA: XBRL DOCUMENT








v3.25.2










































































Derivative Warrant Liabilities - Schedule of Derivative Warrant Liability (Details) - USD ($)
2 Months Ended12 Months Ended
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Schedule of Derivative Warrant Liability [Abstract] 
 
 
 
Number of shares, Opening balance21,866
21,866
 
 
Amount, Opening balance$ 595,358
$ 901,608
 
 
Number of shares, Warrant exchange 
(1,104)
 
 
Amount, Warrant exchange 
$ (6,996)
 
 
Number of shares, Fair value gain (loss)

 
 
Amount, Fair value gain (loss)$ 306,250
$ (694,516)
$ 306,250
Number of shares, Balance ending21,866
20,762
21,866
 
Amount,Balance ending$ 901,608
$ 200,096
$ 901,608
 




































XML
87
R63.htm
IDEA: XBRL DOCUMENT








v3.25.2












































































































Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details) - $ / shares
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Public Warrants [Member] 
 
Schedule of Warrant Transactions [Line Items] 
 
Number of Warrants, Beginning20,912
Weighted Average Exercise Price, Beginning$ 6,874.13
Number of Warrants, Issued 
20,912
Weighted Average Exercise Price, Issued 
$ 6,874.13
Number of Warrants, Ending19,808
20,912
Weighted Average Exercise Price, Ending$ 6,874.13
$ 6,874.13
Number of Warrants, Warrant exchange(1,104)
 
Weighted Average Exercise Price, Warrant exchange$ 6,874.13
 
Private Warrants [Member] 
 
Schedule of Warrant Transactions [Line Items] 
 
Number of Warrants, Beginning954
Weighted Average Exercise Price, Beginning$ 6,874.13
Number of Warrants, Issued 
954
Weighted Average Exercise Price, Issued 
$ 6,874.13
Number of Warrants, Ending954
954
Weighted Average Exercise Price, Ending$ 6,874.13
$ 6,874.13
Number of Warrants, Warrant exchange
 
Weighted Average Exercise Price, Warrant exchange$ 6,874.13
 












































XML
88
R64.htm
IDEA: XBRL DOCUMENT








v3.25.2

























Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details) - Warrant [Member]
12 Months Ended

Mar. 31, 2025

$ / shares

shares

Schedule of Warrants Outstanding and Exercisable [Line Items] 
Exercise Price (in Dollars per share) | $ / shares$ 6,874.13
Number of warrants Outstanding20,762
Number of Warrants Exercisable20,762
Expiry DateJan. 25, 2029
































XML
89
R65.htm
IDEA: XBRL DOCUMENT








v3.25.2






























































































































































































































































































































































































































































































Promissory Notes (Details) - USD ($)
12 Months Ended
Jan. 25, 2025
Nov. 26, 2024
Sep. 30, 2024
Jan. 25, 2024
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2024
Oct. 25, 2024
Jul. 31, 2024
Promissory Notes [Line Items] 
 
 
 
 
 
 
 
 
 
Principal amount of debt issued 
 
 
 
 
 
 
 
 
$ 1,000,000
Fair value 
 
 
 
$ 945,096
$ 11,349,497
 
 
 
 
Fair value gain on promissory notes 
 
 
 
(705,565)
108,288
 
 
 
Unsecured Convertible Promissory Notes [Member] 
 
 
 
 
 
 
 
 
 
Promissory Notes [Line Items] 
 
 
 
 
 
 
 
 
 
Fair value gain on promissory notes 
 
 
 
377,897
 
 
 
 
 
Parent [member] | Unsecured Convertible Promissory Notes [Member] 
 
 
 
 
 
 
 
 
 
Promissory Notes [Line Items] 
 
 
 
 
 
 
 
 
 
Principal amount of debt issued 
 
 
$ 1,610,657
 
 
 
 
 
 
Notes paid$ 1,460,657
 
 
150,000
 
 
 
 
 
 
Fair value 
 
 
1,418,675
 
 
 
 
 
 
NCAC Note [Member] 
 
 
 
 
 
 
 
 
 
Promissory Notes [Line Items] 
 
 
 
 
 
 
 
 
 
Shares issued (in Shares) 
 
 
 
 
 
 
46,870
 
 
Fair value gain on promissory notes 
 
 
 
705,565
(108,288)
 
 
 
 
Fair value of notes 
 
 
 
2,790,492
 
 
 
 
NCAC Note [Member] | Unsecured Convertible Promissory Notes [Member] 
 
 
 
 
 
 
 
 
 
Promissory Notes [Line Items] 
 
 
 
 
 
 
 
 
 
Principal amount of debt issued 
 
 
 
 
$ 1,615,501
 
 
 
 
Notes paid$ 1,515,501
 
 
100,000
 
 
 
 
 
 
Fair value 
 
 
$ 1,413,529
 
 
 
 
 
 
Shares issued (in Shares) 
 
5,405
 
 
 
 
 
 
 
Conversion price (in Dollars per share) 
 
$ 298.88
 
 
 
 
 
 
 
Weighted average share price (in Dollars per share) 
 
$ 298.88
 
 
 
 
 
 
 
PGI [Member] 
 
 
 
 
 
 
 
 
 
Promissory Notes [Line Items] 
 
 
 
 
 
 
 
 
 
Shares issued (in Shares) 
 
 
8,365
 
 
 
 
 
 
PGI [Member] | Unsecured Convertible Promissory Notes [Member] 
 
 
 
 
 
 
 
 
 
Promissory Notes [Line Items] 
 
 
 
 
 
 
 
 
 
Shares issued (in Shares) 
 
3,473
 
 
 
 
42,378
1,414
 
Extinguishment amount 
 
$ 1,307,960
 
 
 
 
 
 
 
Conversion price (in Dollars per share) 
 
$ 298.88
 
 
 
 
 
$ 298.88
 
Weighted average share price (in Dollars per share) 
$ 298.88
 
 
 
 
 
 
 
 
Fair value gain on promissory notes 
 
 
 
$ 327,668
 
 
 
 
 
































































XML
90
R66.htm
IDEA: XBRL DOCUMENT








v3.25.2
































































ELOC (Details) - USD ($)
12 Months Ended
Aug. 28, 2024
Mar. 31, 2025
ELOC [Member] 
 
ELOC [Line Items] 
 
Equity line of credit$ 25,000,000
 
Purchase agreement$ 25,000,000
 
Common stock shares issued (in Shares) 
218,900
Fair value amount 
$ 187,500
Total consideration amount 
6,692,495
Issuance costs 
$ 282,100
White Lion [Member] 
 
ELOC [Line Items] 
 
Common stock shares issued (in Shares) 
3,392












































XML
91
R67.htm
IDEA: XBRL DOCUMENT








v3.25.2

























































































Psyence Labs Ltd. Share Exchange (Details) - USD ($)
12 Months Ended
Oct. 28, 2024
Mar. 31, 2025
Mar. 31, 2024
Psyence Labs Ltd Share Exchange [Line Items] 
 
 
Issuance of additional share32,248
 
 
Consideration of shares35,594
 
 
Fair value of shares issued$ 722,033
$ 313,628
 
Fair value of investment 
745,000
 
Third-party investor 
745
 
Unrealized fair value gain 
$ 22,967
 
Psyence Labs Ltd. [Member] 
 
 
Psyence Labs Ltd Share Exchange [Line Items] 
 
 
Common shares issued1,000
 
 
Ordinary shares [member] 
 
 
Psyence Labs Ltd Share Exchange [Line Items] 
 
 
Common shares issued3,346
568,021
22,402
















































XML
92
R68.htm
IDEA: XBRL DOCUMENT








v3.25.2




























Psyence Labs Ltd. Share Exchange - Schedule of Investment is Classified as a Financial Asset Measured at Fair Value (Details)

Mar. 31, 2025

USD ($)

shares

Investment is Classified as a Financial Asset Measured at Fair Value [Abstract] 
Number of shares in PsyLabs acquired (in Shares) | shares1,000
Total PBM shares issued (in Shares) | shares35,594
Total fair value of shares issued$ 722,033
Fair value of investment at March 31, 2025745,000
Fair value gain recognized$ 22,967
































XML
93
R69.htm
IDEA: XBRL DOCUMENT








v3.25.2

























































































































































PIPE Financing - Private Placement and Warrants (Details) - USD ($)
12 Months Ended
Dec. 24, 2029
Dec. 24, 2026
Mar. 31, 2025
Dec. 24, 2024
Private Placement and Warrants [Member] 
 
 
 
Private Placement and Warrants [Line Items] 
 
 
 
Gross proceeds 
 
 
$ 2,000,000
Issuance of shares 
 
 
47,679
Pre-funded warrants 
 
 
77,792
Exercise price of warrants per share$ 15.94
 
$ 15.94
$ 0.000797
Purchase of common shares warrants 
 
 
250,942
Number of warrant purchased125,471
 
125,471
 
Warrant outstanding term 
2 years
5 years
 
Share settled issuance costs 
 
$ 257,949
 
Share capital 
 
40,449
 
Warrant reserve 
 
217,500
 
Share settled issuance costs 
 
$ 137,778
 
Share warrant issued 
 
9,409
 
Common shares issued 
 
77,792
 
Pre-funded warrants 
 
$ 511,690
 
Issuance costs 
 
$ 66,003
 
Fair Value Allocation Assumptions [Member] 
 
 
 
Private Placement and Warrants [Line Items] 
 
 
 
Exercise price of warrants per share 
 
$ 19.37
 
















































































XML
94
R70.htm
IDEA: XBRL DOCUMENT








v3.25.2






























PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details) - USD ($)
Mar. 31, 2025
Oct. 28, 2024
Schedule of Fair Value Allocation Component [Line Items] 
 
Common shares$ 313,628
$ 722,033
Pre-funded warrants511,690
 
Warrants1,174,682
 
Total gross proceeds$ 2,000,000
 




























XML
95
R71.htm
IDEA: XBRL DOCUMENT








v3.25.2
































































































































































































































































PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details)
Mar. 31, 2025
Pre-funded warrants [Member] | Share price [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants19.37
Pre-funded warrants [Member] | Expected dividend yield [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants
Pre-funded warrants [Member] | Exercise price [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants0
Pre-funded warrants [Member] | Risk-free interest rate [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants3.63
Pre-funded warrants [Member] | Expected life [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants
Pre-funded warrants [Member] | Expected volatility [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants100
Pre-funded warrants [Member] | Expiry date [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants
Warrants with 5 year expiry [Member] | Share price [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants19.37
Warrants with 5 year expiry [Member] | Expected dividend yield [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants
Warrants with 5 year expiry [Member] | Exercise price [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants15.94
Warrants with 5 year expiry [Member] | Risk-free interest rate [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants3.63
Warrants with 5 year expiry [Member] | Expected life [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants5
Warrants with 5 year expiry [Member] | Expected volatility [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants100
Warrants with 5 year expiry [Member] | Expiry date [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrantsDecember 24, 2029
Warrant with 2 year expiry [Member] | Share price [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants19.37
Warrant with 2 year expiry [Member] | Expected dividend yield [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants
Warrant with 2 year expiry [Member] | Exercise price [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants15.94
Warrant with 2 year expiry [Member] | Risk-free interest rate [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants3.63
Warrant with 2 year expiry [Member] | Expected life [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants2
Warrant with 2 year expiry [Member] | Expected volatility [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrants100
Warrant with 2 year expiry [Member] | Expiry date [Member] 
Schedule of Pre-funded Warrants [Line Items] 
Fair value of pre-funded warrantsDecember 24, 2026




























































XML
96
R72.htm
IDEA: XBRL DOCUMENT








v3.25.2
























































































































































































































Share Capital (Details) - USD ($)
12 Months Ended
Mar. 31, 2024
Mar. 31, 2025
Oct. 28, 2024
Jan. 25, 2024
Share Capital [Line Items] 
 
 
 
share price (in Dollars per share)$ 2,863.22
 
 
 
Owned amount of service (in Dollars)$ 1,000,000
 
 
 
Gain on debt settlement (in Dollars)$ 281,500
 
 
 
Common Shares [Member] 
 
 
 
Share Capital [Line Items] 
 
 
 
Common shares issued251
 
 
 
PGI [Member] 
 
 
 
Share Capital [Line Items] 
 
 
 
Common shares issued 
 
 
8,365
NCAC [Member] 
 
 
 
Share Capital [Line Items] 
 
 
 
Common shares issued 
 
 
13,040
Accounts payable (in Dollars) 
 
 
$ 2,136,340
Third Party Advisors [Member] 
 
 
 
Share Capital [Line Items] 
 
 
 
Common shares issued 
 
 
997
RTO Transaction [Member] 
 
 
 
Share Capital [Line Items] 
 
 
 
Common shares issued 
 
 
746
share price (in Dollars per share) 
 
 
$ 2,863.22
Warrants [Member] 
 
 
 
Share Capital [Line Items] 
 
 
 
Common shares issued
261,188
 
 
Number of shares outstanding
261,188
 
 
Common Shares [Member] 
 
 
 
Share Capital [Line Items] 
 
 
 
Common shares issued22,402
568,021
3,346
 
Number of shares outstanding
568,021
 
 
































































XML
97
R73.htm
IDEA: XBRL DOCUMENT








v3.25.2













































































































































































Share Capital - Schedule of Issued and Outstanding Common Shares (Details) - Issued Capital [Member] - USD ($)
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Share Capital [Line Items] 
 
Opening balance22,402
 
Opening balance$ 46,125,397
 
Number of Common shares, Shares issued on conversion of convertible note38,156
 
Amount of Common shares, Shares issued on conversion of convertible note$ 4,617,286
 
Number of Common shares, Shares issued on conversion of convertible note warrants22,876
 
Amount of Common shares, Shares issued on conversion of convertible note warrants$ 639,954
 
Number of Common shares, Shares issued for ELOC218,900
 
Amount of Common shares, Shares issued for ELOC$ 6,692,495
 
Number of Common shares, Commitment shares ELOC3,392
 
Amount of Common shares, Commitment shares ELOC$ 187,500
 
Number of Common shares, Share issuance costs for ELOC
 
Amount of Common shares, Share issuance costs for ELOC$ (469,600)
 
Number of Common shares, Warrant exchange1,104
 
Amount of Common shares, Warrant exchange$ 192,060
 
Number of Common shares, Shares issued to third party advisors586
 
Amount of Common shares, Shares issued to third party advisors$ 241,379
$ 2,136,340
Number of Common shares, Shares issued on conversion of PGI promissory notes47,265
 
Amount of Common shares, Shares issued on conversion of PGI promissory notes$ 988,569
 
Number of Common shares, Shares issued on conversion of NCAC promissory notes52,275
 
Amount of Common shares, Shares issued on conversion of NCAC promissory notes$ 1,096,358
 
Number of Common shares, Shares issued for PsyLabs share exchange35,594
 
Amount of Common shares, Shares issued for PsyLabs share exchange$ 722,033
 
Number of Common shares, Share issued for PIPE financing47,679
 
Amount of Common shares, Share issued for PIPE financing$ 313,628
 
Number of Common shares, Share issuance costs for PIPE financing
 
Amount of Common shares, Share issuance costs for PIPE financing$ (40,449)
 
Number of Common shares, Shares issued for PIPE pre-funded warrants exercised77,792
 
Amount of Common shares, Shares issued for PIPE pre-funded warrants exercised$ 511,690
 
Number of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised
 
Amount of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised$ (65,995)
 
Number of Common shares, Ending balance568,021
22,402
Amount of Common shares Ending balance$ 61,752,305
$ 46,125,397








































































































































XML
98
R74.htm
IDEA: XBRL DOCUMENT








v3.25.2

























































































Share Capital - Schedule of Issued and Outstanding Warrants (Details) - Issued and Outstanding Warrants [Member]
12 Months Ended

Mar. 31, 2025

USD ($)

shares

Schedule of Issued and Outstanding Warrants [Line Items] 
Number of warrants shares opening balance | shares
Amount of warrants opening balance | $
Number of shares Warrants issued for convertible note Addendum | shares837
Amount of Warrants issued for convertible note Addendum | $$ 42,528
Number of shares Warrants issued for convertible note Termination Agreement t | shares22,876
Amount of Warrants issued for convertible note termination agreement | $$ 639,954
Number of shares warrants convertible note Termination Agreement warrants exercised | shares(22,876)
Amount of Convertible note Termination Agreement warrants exercised | $$ (639,954)
Number of shares warrants PIPE financing warrant issuance | shares328,734
Amount of PIPE warrants financing warrant issuance | $$ 1,686,372
Number of shares PIPE warrants financing warrant issuance costs | shares9,409
Amount of PIPE warrants financing warrant issuance costs | $$ 137,778
Number of shares warrants Issuance costs for PIPE financing warrants | shares
Amount of warrants Issuance costs for PIPE financing warrants | $$ (355,278)
Number of shares warrants PIPE pre-funded warrants exercised | shares(77,792)
Amount of warrants PIPE pre-funded warrants exercised | $$ (511,690)
Number of shares Issuance costs for PIPE pre-funded warrants exercised | shares
Amount of warrants Issuance costs for PIPE pre-funded warrants exercised | $$ 65,995
Number of warrants shares ending balance | shares261,188
Amount of warrants ending balance | $$ 1,065,705
































































































XML
99
R75.htm
IDEA: XBRL DOCUMENT








v3.25.2




































































































Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details)

Mar. 31, 2025

$ / shares

shares

August 20, 2024 [Member] 
Share Capital [Line Items] 
Expiry DateAug. 20, 2026
Exercise Price (in Dollars per share) | $ / shares$ 298.88
Number of Warrants Outstanding837
Number of Warrants Exercisable837
December 24, 2024 [Member] 
Share Capital [Line Items] 
Expiry DateDec. 24, 2029
Exercise Price (in Dollars per share) | $ / shares$ 15.94
Number of Warrants Outstanding125,471
Number of Warrants Exercisable125,471
December 24, 2024 [Member] 
Share Capital [Line Items] 
Expiry DateDec. 24, 2026
Exercise Price (in Dollars per share) | $ / shares$ 15.94
Number of Warrants Outstanding125,471
Number of Warrants Exercisable125,471
December 24, 2024 [Member] 
Share Capital [Line Items] 
Expiry DateDec. 24, 2029
Exercise Price (in Dollars per share) | $ / shares$ 19.93
Number of Warrants Outstanding9,409
Number of Warrants Exercisable9,409












































XML
100
R76.htm
IDEA: XBRL DOCUMENT








v3.25.2




































































































































































































Other Income (Details)
12 Months Ended

Mar. 31, 2025

USD ($)


Mar. 31, 2024

USD ($)


Mar. 31, 2024

AUD ($)


Mar. 31, 2023

USD ($)


Jul. 31, 2024

USD ($)

Jan. 25, 2024

Aug. 21, 2023

AUD ($)

Other Income [Line Items] 
 
 
 
 
 
 
Other income
$ 879,344
 
 
 
 
Percentage of rebate 
43.50%
43.50%
 
 
 
 
Borrowed amount 
 
 
 
$ 1,000,000
 
 
Loan bears interest rate 
 
 
 
 
8.00%
 
Psyence Australia (Pty) Ltd [Member] 
 
 
 
 
 
 
Other Income [Line Items] 
 
 
 
 
 
 
Borrowed amount 
 
 
 
 
 
$ 1,100,000
RH Capital Finance Co., LLC [Member] 
 
 
 
 
 
 
Other Income [Line Items] 
 
 
 
 
 
 
Percentage of rebate43.50%
 
 
 
 
 
 
Loan bears interest rate16.00%
 
 
 
 
 
 
Number of repayable days91 days
 
 
 
 
 
 
Number of business days for notice of assessment21 days
 
 
 
 
 
 
Interest expense
$ 29,697
 
 
 
 
 
Research and Development Expenses [Member] 
 
 
 
 
 
 
Other Income [Line Items] 
 
 
 
 
 
 
Other income 
$ 879,344
$ 1,336,622
 
 
 
 




















































XML
101
R77.htm
IDEA: XBRL DOCUMENT








v3.25.2

























Capital Management - Schedule of Total Managed Capital (Details) - USD ($)
Mar. 31, 2025
Mar. 31, 2024
Schedule of Total Managed Capital [Abstract] 
 
Borrowings
$ 10,447,889
Share capital61,752,305
46,125,397
Total$ 61,752,305
$ 56,573,286
























XML
102
R78.htm
IDEA: XBRL DOCUMENT








v3.25.2




























Transactions with Related Parties - Schedule of Key Management Personnel (Details) - USD ($)
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Schedule of Key Management Personnel [Abstract] 
 
Short term benefits$ 984,697
$ 465,702
Share based compensation
233,295
Total$ 984,697
$ 698,997
























XML
103
R79.htm
IDEA: XBRL DOCUMENT








v3.25.2

































Share Based Compensation (Details)
12 Months Ended

Mar. 31, 2025

USD ($)


Mar. 31, 2024

USD ($)


Mar. 31, 2023

USD ($)

Share Based Compensation [Abstract] 
 
 
Share based compensation expense
$ 317,882
$ 221,287
Share option issued 
 
Restricted stock units issued 
 
























XML
104
R80.htm
IDEA: XBRL DOCUMENT








v3.25.2























Income Tax Note (Details)
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Canada [Member] 
 
Income Tax Note [Line Items] 
 
Percentage of statutory income tax rate26.50%
26.50%




















XML
105
R81.htm
IDEA: XBRL DOCUMENT








v3.25.2































































Income Tax Note - Schedule of Canadian Federal and Provincial Statutory Income Tax Rate (Details) - USD ($)
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Schedule of Canadian Federal and Provincial Statutory Income Tax Rate [Abstract] 
 
Net Income/(Loss) before recovery of income taxes$ 1,011,790
$ (51,159,048)
Expected income tax (recovery)/expense268,124
(13,557,148)
Difference in foreign tax rates6,871
966
Listing expense
10,992,625
Non-taxable fair value gain adjustment(1,722,146)
Non-deductible loss on loan settlement449,196
Share issue costs booked to equity(246,802)
Other permanent expenses1,787
2,061,001
Change in tax benefits not recognized1,242,970
502,556
Income tax (recovery)/expense





















































XML
106
R82.htm
IDEA: XBRL DOCUMENT








v3.25.2


























































































Income Tax Note - Schedule of Deferred Tax Assets (Details) - USD ($)
Mar. 31, 2025
Mar. 31, 2024
Schedule of Deferred Tax Assets [Line Items] 
 
Unrecognized deferred tax asset$ 6,170,477
$ 1,646,580
Computer equipment [member] 
 
Schedule of Deferred Tax Assets [Line Items] 
 
Unrecognized deferred tax asset4,508
240
Restricted interest and financing expenses [Member] | Canada [Member] 
 
Schedule of Deferred Tax Assets [Line Items] 
 
Unrecognized deferred tax asset764,297
Other [Member] 
 
Schedule of Deferred Tax Assets [Line Items] 
 
Unrecognized deferred tax asset722,097
124,132
Non-capital losses carried forward [Member] | Canada [Member] 
 
Schedule of Deferred Tax Assets [Line Items] 
 
Unrecognized deferred tax asset4,248,226
1,357,347
Non-capital losses carried forward [Member] | Australia [Member] 
 
Schedule of Deferred Tax Assets [Line Items] 
 
Unrecognized deferred tax asset$ 431,349
$ 164,861












































XML
107
R83.htm
IDEA: XBRL DOCUMENT








v3.25.2
























































































Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details)

Mar. 31, 2025

USD ($)

Canada [Member] 
Schedule of Non-Capital Loss Carry Forwards [Line Items] 
Non-capital loss carry forwards$ 4,248,226
Canada [Member] | 2044 [Member] 
Schedule of Non-Capital Loss Carry Forwards [Line Items] 
Non-capital loss carry forwards1,357,347
Canada [Member] | 2045 [Member] 
Schedule of Non-Capital Loss Carry Forwards [Line Items] 
Non-capital loss carry forwards2,890,879
Canada [Member] | Indefinite [Member] 
Schedule of Non-Capital Loss Carry Forwards [Line Items] 
Non-capital loss carry forwards
Australia [Member] 
Schedule of Non-Capital Loss Carry Forwards [Line Items] 
Non-capital loss carry forwards431,349
Australia [Member] | 2044 [Member] 
Schedule of Non-Capital Loss Carry Forwards [Line Items] 
Non-capital loss carry forwards
Australia [Member] | Indefinite [Member] 
Schedule of Non-Capital Loss Carry Forwards [Line Items] 
Non-capital loss carry forwards$ 431,349




































XML
108
R84.htm
IDEA: XBRL DOCUMENT








v3.25.2

















Financial Instruments and Financial Risk Management (Details)
12 Months Ended

Mar. 31, 2025

USD ($)

Financial Instruments and Financial Risk Management [Abstract] 
Percentage of fluctuation in foreign exchange rate10.00%
Impact to net loss and comprehensive loss$ 8,861




















XML
109
R85.htm
IDEA: XBRL DOCUMENT








v3.25.2




































































































































































































































































































































































































































Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details) - USD ($)
Mar. 31, 2025
Mar. 31, 2024
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value$ 945,096
$ 11,349,497
Investment in Psyence Labs Ltd [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value745,000
 
NCAC Sponsor promissory note [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
1,474,256
Level 1 [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value200,096
875,000
Level 1 [Member] | Investment in Psyence Labs Ltd [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value
 
Level 1 [Member] | NCAC Sponsor promissory note [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
Level 2 [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value745,000
26,608
Level 2 [Member] | Investment in Psyence Labs Ltd [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value745,000
 
Level 2 [Member] | NCAC Sponsor promissory note [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
Level 3 [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value
10,447,889
Level 3 [Member] | Investment in Psyence Labs Ltd [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value
 
Level 3 [Member] | NCAC Sponsor promissory note [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
1,474,256
Warrant Liabilities [Member] | Derivative warrant liabilities – public warrants [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value200,096
875,000
Warrant Liabilities [Member] | Derivative warrant liabilities – private warrants [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
26,608
Warrant Liabilities [Member] | Level 1 [Member] | Derivative warrant liabilities – public warrants [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value200,096
875,000
Warrant Liabilities [Member] | Level 1 [Member] | Derivative warrant liabilities – private warrants [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
Warrant Liabilities [Member] | Level 2 [Member] | Derivative warrant liabilities – public warrants [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value

Warrant Liabilities [Member] | Level 2 [Member] | Derivative warrant liabilities – private warrants [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
26,608
Warrant Liabilities [Member] | Level 3 [Member] | Derivative warrant liabilities – public warrants [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value

Warrant Liabilities [Member] | Level 3 [Member] | Derivative warrant liabilities – private warrants [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
Convertible notes [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
7,657,397
Convertible notes [Member] | Level 1 [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
Convertible notes [Member] | Level 2 [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
Convertible notes [Member] | Level 3 [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
7,657,397
PGI promissory note [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
1,316,236
PGI promissory note [Member] | Level 1 [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
PGI promissory note [Member] | Level 2 [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
PGI promissory note [Member] | Level 3 [Member] 
 
Schedule of Carrying Value of the Financial Instruments [Line Items] 
 
Financial instruments at fair value 
$ 1,316,236
























































XML
110
R86.htm
IDEA: XBRL DOCUMENT








v3.25.2




































































































Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details) - USD ($)
Mar. 31, 2025
Mar. 01, 2025
Schedule of Maturity of the Contractual Obligations [Line Items] 
 
Carrying Amount$ 394,270
 
Contractual Cash Flows394,270
 
Accounts payable & accrued liabilities [Member] 
 
Schedule of Maturity of the Contractual Obligations [Line Items] 
 
Carrying Amount394,270
 
Contractual Cash Flows394,270
 
​Less than 1 year [Member] 
 
Schedule of Maturity of the Contractual Obligations [Line Items] 
 
Contractual Cash Flows 
$ 394,270
​Less than 1 year [Member] | Accounts payable & accrued liabilities [Member] 
 
Schedule of Maturity of the Contractual Obligations [Line Items] 
 
Contractual Cash Flows 
$ 394,270
​Between 1 and 3 years [Member] 
 
Schedule of Maturity of the Contractual Obligations [Line Items] 
 
Contractual Cash Flows
 
​Between 1 and 3 years [Member] | Accounts payable & accrued liabilities [Member] 
 
Schedule of Maturity of the Contractual Obligations [Line Items] 
 
Contractual Cash Flows
 
































XML
111
R87.htm
IDEA: XBRL DOCUMENT








v3.25.2





































































































































































































Subsequent Events (Details) - USD ($)
12 Months Ended
May 05, 2025
Mar. 31, 2025
Apr. 17, 2025
Apr. 15, 2025
Oct. 28, 2024
Mar. 31, 2024
Subsequent Events [Line Items] 
 
 
 
 
 
Total consideration (in Dollars) 
$ 722,033
 
 
 
 
Common Shares [Member] 
 
 
 
 
 
Subsequent Events [Line Items] 
 
 
 
 
 
Common shares issued 
568,021
 
 
3,346
22,402
ELOC [Member] 
 
 
 
 
 
Subsequent Events [Line Items] 
 
 
 
 
 
Common shares issued 
130,000
 
 
 
 
Gross proceeds (in Dollars) 
$ 607,050
 
 
 
 
Subsequent Events [Member] 
 
 
 
 
 
Subsequent Events [Line Items] 
 
 
 
 
 
Additional shares 
 
 
250
 
 
Total consideration (in Dollars) 
 
 
$ 500,000
 
 
Common shares basis ratio7.97:1
 
 
 
 
 
Subsequent Events [Member] | RSU [Member] 
 
 
 
 
 
Subsequent Events [Line Items] 
 
 
 
 
 
Common shares issued 
 
12,711
 
 
 
Subsequent Events [Member] | Common Shares [Member] 
 
 
 
 
 
Subsequent Events [Line Items] 
 
 
 
 
 
Additional shares 
 
 
15,242
 
 
















































XML
112
Show.js
IDEA: XBRL DOCUMENT

// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}



XML
113
report.css
IDEA: XBRL DOCUMENT

/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}

.report table.authRefData a {
display: block;
font-weight: bold;
}

.report table.authRefData p {
margin-top: 0px;
}

.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}

.report table.authRefData .hide a:hover {
background-color: #2F4497;
}

.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}

.report table.authRefData table{
font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}

/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}

.report hr {
border: 1px solid #acf;
}

/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}

.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}

.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}

.report td.pl div.a {
width: 200px;
}

.report td.pl a:hover {
background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}

/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}

.report .reu td {
border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}

.report .rou td {
border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}

.report .nump {
padding-left: 2em;
}

.report .nump {
padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}

.report .text .big {
margin-bottom: 1em;
width: 17em;
}

.report .text .more {
display: none;
}

.report .text .note {
font-style: italic;
font-weight: bold;
}

.report .text .small {
width: 10em;
}

.report sup {
font-style: italic;
}

.report .outerFootnotes {
font-size: 1em;
}



XML
115
FilingSummary.xml
IDEA: XBRL DOCUMENT




3.25.2

html
295
372
1
false
109
0
false
6


false
false
R1.htm
995100 - Document - Cover
Sheet
http://xbrl.sec.gov/dei/role/document/Cover
Cover
Cover
1


false
false
R2.htm
995300 - Document - Audit Information
Sheet
http://xbrl.sec.gov/dei/role/document/AuditInformation
Audit Information
Cover
2


false
false
R3.htm
995301 - Statement - Consolidated Statements of Financial Position
Sheet
http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet
Consolidated Statements of Financial Position
Statements
3


false
false
R4.htm
995302 - Statement - Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss)
Sheet
http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement
Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss)
Statements
4


false
false
R5.htm
995303 - Statement - Consolidated Statements of Changes in Shareholders??? Equity/(Deficit)
Sheet
http://www.psyencebiomed.com/role/ShareholdersEquityType2or3
Consolidated Statements of Changes in Shareholders??? Equity/(Deficit)
Statements
5


false
false
R6.htm
995304 - Statement - Consolidated Statements of Cash Flows
Sheet
http://www.psyencebiomed.com/role/ConsolidatedCashFlow
Consolidated Statements of Cash Flows
Statements
6


false
false
R7.htm
995305 - Disclosure - Nature of Operations and Going Concern
Sheet
http://www.psyencebiomed.com/role/NatureofOperationsandGoingConcern
Nature of Operations and Going Concern
Notes
7


false
false
R8.htm
995306 - Disclosure - Basis of Presentation
Sheet
http://www.psyencebiomed.com/role/BasisofPresentation
Basis of Presentation
Notes
8


false
false
R9.htm
995307 - Disclosure - Material Accounting Policies
Sheet
http://www.psyencebiomed.com/role/MaterialAccountingPolicies
Material Accounting Policies
Notes
9


false
false
R10.htm
995308 - Disclosure - Critical Accounting Estimates and Judgements
Sheet
http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgements
Critical Accounting Estimates and Judgements
Notes
10


false
false
R11.htm
995309 - Disclosure - Reverse Takeover Transaction with NCAC
Sheet
http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCAC
Reverse Takeover Transaction with NCAC
Notes
11


false
false
R12.htm
995310 - Disclosure - Cash, Restricted Cash and Cash Equivalents
Sheet
http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalents
Cash, Restricted Cash and Cash Equivalents
Notes
12


false
false
R13.htm
995311 - Disclosure - Equipment
Sheet
http://www.psyencebiomed.com/role/Equipment
Equipment
Notes
13


false
false
R14.htm
995312 - Disclosure - Accounts Payable and Accrued Liabilities
Sheet
http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilities
Accounts Payable and Accrued Liabilities
Notes
14


false
false
R15.htm
995313 - Disclosure - Convertible Note Liability
Sheet
http://www.psyencebiomed.com/role/ConvertibleNoteLiability
Convertible Note Liability
Notes
15


false
false
R16.htm
995314 - Disclosure - Derivative Warrant Liabilities
Sheet
http://www.psyencebiomed.com/role/DerivativeWarrantLiabilities
Derivative Warrant Liabilities
Notes
16


false
false
R17.htm
995315 - Disclosure - Promissory Notes
Notes
http://www.psyencebiomed.com/role/PromissoryNotes
Promissory Notes
Notes
17


false
false
R18.htm
995316 - Disclosure - ELOC
Sheet
http://www.psyencebiomed.com/role/ELOC
ELOC
Notes
18


false
false
R19.htm
995317 - Disclosure - Psyence Labs Ltd. Share Exchange
Sheet
http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchange
Psyence Labs Ltd. Share Exchange
Notes
19


false
false
R20.htm
995318 - Disclosure - PIPE Financing - Private Placement and Warrants
Sheet
http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrants
PIPE Financing - Private Placement and Warrants
Notes
20


false
false
R21.htm
995319 - Disclosure - Share Capital
Sheet
http://www.psyencebiomed.com/role/ShareCapital
Share Capital
Notes
21


false
false
R22.htm
995320 - Disclosure - Other Income
Sheet
http://www.psyencebiomed.com/role/OtherIncome
Other Income
Notes
22


false
false
R23.htm
995321 - Disclosure - Capital Management
Sheet
http://www.psyencebiomed.com/role/CapitalManagement
Capital Management
Notes
23


false
false
R24.htm
995322 - Disclosure - Transactions with Related Parties
Sheet
http://www.psyencebiomed.com/role/TransactionswithRelatedParties
Transactions with Related Parties
Notes
24


false
false
R25.htm
995323 - Disclosure - Share Based Compensation
Sheet
http://www.psyencebiomed.com/role/ShareBasedCompensation
Share Based Compensation
Notes
25


false
false
R26.htm
995324 - Disclosure - Income Tax Note
Sheet
http://www.psyencebiomed.com/role/IncomeTaxNote
Income Tax Note
Notes
26


false
false
R27.htm
995325 - Disclosure - Financial Instruments and Financial Risk Management
Sheet
http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagement
Financial Instruments and Financial Risk Management
Notes
27


false
false
R28.htm
995326 - Disclosure - Subsequent Events
Sheet
http://www.psyencebiomed.com/role/SubsequentEvents
Subsequent Events
Notes
28


false
false
R29.htm
995447 - Disclosure - Insider Trading Policies and Procedures
Sheet
http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc
Insider Trading Policies and Procedures
Notes
29


false
false
R30.htm
995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure
Sheet
http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure
Cybersecurity Risk Management and Strategy Disclosure
Notes
30


false
false
R31.htm
996000 - Disclosure - Accounting Policies, by Policy (Policies)
Sheet
http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy
Accounting Policies, by Policy (Policies)
Policies
http://www.psyencebiomed.com/role/MaterialAccountingPolicies
31


false
false
R32.htm
996001 - Disclosure - Basis of Presentation (Tables)
Sheet
http://www.psyencebiomed.com/role/BasisofPresentationTables
Basis of Presentation (Tables)
Tables
http://www.psyencebiomed.com/role/BasisofPresentation
32


false
false
R33.htm
996002 - Disclosure - Material Accounting Policies (Tables)
Sheet
http://www.psyencebiomed.com/role/MaterialAccountingPoliciesTables
Material Accounting Policies (Tables)
Tables
http://www.psyencebiomed.com/role/MaterialAccountingPolicies
33


false
false
R34.htm
996003 - Disclosure - Reverse Takeover Transaction with NCAC (Tables)
Sheet
http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACTables
Reverse Takeover Transaction with NCAC (Tables)
Tables
http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCAC
34


false
false
R35.htm
996004 - Disclosure - Cash, Restricted Cash and Cash Equivalents (Tables)
Sheet
http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsTables
Cash, Restricted Cash and Cash Equivalents (Tables)
Tables
http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalents
35


false
false
R36.htm
996005 - Disclosure - Equipment (Tables)
Sheet
http://www.psyencebiomed.com/role/EquipmentTables
Equipment (Tables)
Tables
http://www.psyencebiomed.com/role/Equipment
36


false
false
R37.htm
996006 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)
Sheet
http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilitiesTables
Accounts Payable and Accrued Liabilities (Tables)
Tables
http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilities
37


false
false
R38.htm
996007 - Disclosure - Convertible Note Liability (Tables)
Sheet
http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityTables
Convertible Note Liability (Tables)
Tables
http://www.psyencebiomed.com/role/ConvertibleNoteLiability
38


false
false
R39.htm
996008 - Disclosure - Derivative Warrant Liabilities (Tables)
Sheet
http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables
Derivative Warrant Liabilities (Tables)
Tables
http://www.psyencebiomed.com/role/DerivativeWarrantLiabilities
39


false
false
R40.htm
996009 - Disclosure - Psyence Labs Ltd. Share Exchange (Tables)
Sheet
http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeTables
Psyence Labs Ltd. Share Exchange (Tables)
Tables
http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchange
40


false
false
R41.htm
996010 - Disclosure - PIPE Financing - Private Placement and Warrants (Tables)
Sheet
http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsTables
PIPE Financing - Private Placement and Warrants (Tables)
Tables
http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrants
41


false
false
R42.htm
996011 - Disclosure - Share Capital (Tables)
Sheet
http://www.psyencebiomed.com/role/ShareCapitalTables
Share Capital (Tables)
Tables
http://www.psyencebiomed.com/role/ShareCapital
42


false
false
R43.htm
996012 - Disclosure - Capital Management (Tables)
Sheet
http://www.psyencebiomed.com/role/CapitalManagementTables
Capital Management (Tables)
Tables
http://www.psyencebiomed.com/role/CapitalManagement
43


false
false
R44.htm
996013 - Disclosure - Transactions with Related Parties (Tables)
Sheet
http://www.psyencebiomed.com/role/TransactionswithRelatedPartiesTables
Transactions with Related Parties (Tables)
Tables
http://www.psyencebiomed.com/role/TransactionswithRelatedParties
44


false
false
R45.htm
996014 - Disclosure - Income Tax Note (Tables)
Sheet
http://www.psyencebiomed.com/role/IncomeTaxNoteTables
Income Tax Note (Tables)
Tables
http://www.psyencebiomed.com/role/IncomeTaxNote
45


false
false
R46.htm
996015 - Disclosure - Financial Instruments and Financial Risk Management (Tables)
Sheet
http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementTables
Financial Instruments and Financial Risk Management (Tables)
Tables
http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagement
46


false
false
R47.htm
996016 - Disclosure - Basis of Presentation - Schedule of Subsidiaries (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable
Basis of Presentation - Schedule of Subsidiaries (Details)
Details
47


false
false
R48.htm
996017 - Disclosure - Material Accounting Policies (Details)
Sheet
http://www.psyencebiomed.com/role/MaterialAccountingPoliciesDetails
Material Accounting Policies (Details)
Details
http://www.psyencebiomed.com/role/MaterialAccountingPoliciesTables
48


false
false
R49.htm
996018 - Disclosure - Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable
Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details)
Details
49


false
false
R50.htm
996019 - Disclosure - Material Accounting Policies - ???Schedule of Change in Presentation Currency (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable
Material Accounting Policies - ???Schedule of Change in Presentation Currency (Details)
Details
50


false
false
R51.htm
996020 - Disclosure - Critical Accounting Estimates and Judgements (Details)
Sheet
http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgementsDetails
Critical Accounting Estimates and Judgements (Details)
Details
http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgements
51


false
false
R52.htm
996021 - Disclosure - Reverse Takeover Transaction with NCAC (Details)
Sheet
http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails
Reverse Takeover Transaction with NCAC (Details)
Details
http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACTables
52


false
false
R53.htm
996022 - Disclosure - Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable
Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details)
Details
53


false
false
R54.htm
996023 - Disclosure - Cash, Restricted Cash and Cash Equivalents (Details)
Sheet
http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsDetails
Cash, Restricted Cash and Cash Equivalents (Details)
Details
http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsTables
54


false
false
R55.htm
996024 - Disclosure - Cash, Restricted Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable
Cash, Restricted Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)
Details
55


false
false
R56.htm
996025 - Disclosure - Equipment - Schedule of Equipment (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofEquipmentTable
Equipment - Schedule of Equipment (Details)
Details
56


false
false
R57.htm
996026 - Disclosure - Accounts Payable and Accrued Liabilities - ???Schedule of Accounts Payable and Accrued Liabilities (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable
Accounts Payable and Accrued Liabilities - ???Schedule of Accounts Payable and Accrued Liabilities (Details)
Details
57


false
false
R58.htm
996027 - Disclosure - Convertible Note Liability (Details)
Sheet
http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails
Convertible Note Liability (Details)
Details
http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityTables
58


false
false
R59.htm
996028 - Disclosure - Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable
Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details)
Details
59


false
false
R60.htm
996029 - Disclosure - Derivative Warrant Liabilities (Details)
Sheet
http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails
Derivative Warrant Liabilities (Details)
Details
http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables
60


false
false
R61.htm
996030 - Disclosure - Derivative Warrant Liabilities - Schedule of Private Warrants (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable
Derivative Warrant Liabilities - Schedule of Private Warrants (Details)
Details
61


false
false
R62.htm
996031 - Disclosure - Derivative Warrant Liabilities - Schedule of Derivative Warrant Liability (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable
Derivative Warrant Liabilities - Schedule of Derivative Warrant Liability (Details)
Details
62


false
false
R63.htm
996032 - Disclosure - Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable
Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details)
Details
63


false
false
R64.htm
996033 - Disclosure - Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable
Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details)
Details
64


false
false
R65.htm
996034 - Disclosure - Promissory Notes (Details)
Notes
http://www.psyencebiomed.com/role/PromissoryNotesDetails
Promissory Notes (Details)
Details
http://www.psyencebiomed.com/role/PromissoryNotes
65


false
false
R66.htm
996035 - Disclosure - ELOC (Details)
Sheet
http://www.psyencebiomed.com/role/ELOCDetails
ELOC (Details)
Details
http://www.psyencebiomed.com/role/ELOC
66


false
false
R67.htm
996036 - Disclosure - Psyence Labs Ltd. Share Exchange (Details)
Sheet
http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails
Psyence Labs Ltd. Share Exchange (Details)
Details
http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeTables
67


false
false
R68.htm
996037 - Disclosure - Psyence Labs Ltd. Share Exchange - Schedule of Investment is Classified as a Financial Asset Measured at Fair Value (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofInvestmentisClassifiedasaFinancialAssetMeasuredatFairValueTable
Psyence Labs Ltd. Share Exchange - Schedule of Investment is Classified as a Financial Asset Measured at Fair Value (Details)
Details
68


false
false
R69.htm
996038 - Disclosure - PIPE Financing - Private Placement and Warrants (Details)
Sheet
http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails
PIPE Financing - Private Placement and Warrants (Details)
Details
http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsTables
69


false
false
R70.htm
996039 - Disclosure - PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable
PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details)
Details
70


false
false
R71.htm
996040 - Disclosure - PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable
PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details)
Details
71


false
false
R72.htm
996041 - Disclosure - Share Capital (Details)
Sheet
http://www.psyencebiomed.com/role/ShareCapitalDetails
Share Capital (Details)
Details
http://www.psyencebiomed.com/role/ShareCapitalTables
72


false
false
R73.htm
996042 - Disclosure - Share Capital - Schedule of Issued and Outstanding Common Shares (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable
Share Capital - Schedule of Issued and Outstanding Common Shares (Details)
Details
73


false
false
R74.htm
996043 - Disclosure - Share Capital - Schedule of Issued and Outstanding Warrants (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable
Share Capital - Schedule of Issued and Outstanding Warrants (Details)
Details
74


false
false
R75.htm
996044 - Disclosure - Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable
Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details)
Details
75


false
false
R76.htm
996045 - Disclosure - Other Income (Details)
Sheet
http://www.psyencebiomed.com/role/OtherIncomeDetails
Other Income (Details)
Details
http://www.psyencebiomed.com/role/OtherIncome
76


false
false
R77.htm
996046 - Disclosure - Capital Management - Schedule of Total Managed Capital (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable
Capital Management - Schedule of Total Managed Capital (Details)
Details
77


false
false
R78.htm
996047 - Disclosure - Transactions with Related Parties - Schedule of Key Management Personnel (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable
Transactions with Related Parties - Schedule of Key Management Personnel (Details)
Details
78


false
false
R79.htm
996048 - Disclosure - Share Based Compensation (Details)
Sheet
http://www.psyencebiomed.com/role/ShareBasedCompensationDetails
Share Based Compensation (Details)
Details
http://www.psyencebiomed.com/role/ShareBasedCompensation
79


false
false
R80.htm
996049 - Disclosure - Income Tax Note (Details)
Sheet
http://www.psyencebiomed.com/role/IncomeTaxNoteDetails
Income Tax Note (Details)
Details
http://www.psyencebiomed.com/role/IncomeTaxNoteTables
80


false
false
R81.htm
996050 - Disclosure - Income Tax Note - Schedule of Canadian Federal and Provincial Statutory Income Tax Rate (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable
Income Tax Note - Schedule of Canadian Federal and Provincial Statutory Income Tax Rate (Details)
Details
81


false
false
R82.htm
996051 - Disclosure - Income Tax Note - Schedule of Deferred Tax Assets (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable
Income Tax Note - Schedule of Deferred Tax Assets (Details)
Details
82


false
false
R83.htm
996052 - Disclosure - Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable
Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details)
Details
83


false
false
R84.htm
996053 - Disclosure - Financial Instruments and Financial Risk Management (Details)
Sheet
http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementDetails
Financial Instruments and Financial Risk Management (Details)
Details
http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementTables
84


false
false
R85.htm
996054 - Disclosure - Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable
Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details)
Details
85


false
false
R86.htm
996055 - Disclosure - Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details)
Sheet
http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable
Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details)
Details
86


false
false
R87.htm
996056 - Disclosure - Subsequent Events (Details)
Sheet
http://www.psyencebiomed.com/role/SubsequentEventsDetails
Subsequent Events (Details)
Details
http://www.psyencebiomed.com/role/SubsequentEvents
87


false
false
All Reports
Book
All Reports



ea0246623-20f_psyence.htm
pbm-20250331.xsd
pbm-20250331_cal.xml
pbm-20250331_def.xml
pbm-20250331_lab.xml
pbm-20250331_pre.xml


fin_001.jpg
fin_002.jpg
image_001.jpg
image_002.jpg
image_003.jpg
image_004.jpg
image_005.jpg
image_006.jpg
image_007.jpg
image_008.jpg


http://xbrl.sec.gov/cyd/2024
http://xbrl.sec.gov/dei/2024
http://xbrl.sec.gov/ecd/2024
https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full

true
true





JSON
117
MetaLinks.json
IDEA: XBRL DOCUMENT

{
"version": "2.2",
"instance": {
"ea0246623-20f_psyence.htm": {
"nsprefix": "pbm",
"nsuri": "http://www.psyencebiomed.com/20250331",
"dts": {
"inline": {
"local": [
"ea0246623-20f_psyence.htm"
]
},
"schema": {
"local": [
"pbm-20250331.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
"https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
"https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
"https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://xbrl.sec.gov/country/2024/country-2024.xsd",
"https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
"https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
"https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
"https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
"https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
"https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
"https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
"https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
"https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
"https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
"https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
]
},
"calculationLink": {
"local": [
"pbm-20250331_cal.xml"
]
},
"definitionLink": {
"local": [
"pbm-20250331_def.xml"
],
"remote": [
"https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
]
},
"labelLink": {
"local": [
"pbm-20250331_lab.xml"
]
},
"presentationLink": {
"local": [
"pbm-20250331_pre.xml"
]
}
},
"keyStandard": 201,
"keyCustom": 171,
"axisStandard": 23,
"axisCustom": 3,
"memberStandard": 30,
"memberCustom": 66,
"hidden": {
"total": 188,
"https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 100,
"http://www.psyencebiomed.com/20250331": 85,
"http://xbrl.sec.gov/dei/2024": 3
},
"contextCount": 295,
"entityCount": 1,
"segmentCount": 109,
"elementCount": 863,
"unitCount": 6,
"baseTaxonomies": {
"https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 598,
"http://xbrl.sec.gov/dei/2024": 50,
"http://xbrl.sec.gov/cyd/2024": 9,
"http://xbrl.sec.gov/ecd/2024": 1
},
"report": {
"R1": {
"role": "http://xbrl.sec.gov/dei/role/document/Cover",
"longName": "995100 - Document - Cover",
"shortName": "Cover",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "c0",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"b",
"p",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"b",
"p",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R2": {
"role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
"longName": "995300 - Document - Audit Information",
"shortName": "Audit Information",
"isDefault": "false",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "2",
"firstAnchor": {
"contextRef": "c0",
"name": "dei:AuditorName",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "dei:AuditorName",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R3": {
"role": "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"longName": "995301 - Statement - Consolidated Statements of Financial Position",
"shortName": "Consolidated Statements of Financial Position",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "3",
"firstAnchor": {
"contextRef": "c4",
"name": "ifrs-full:CashAndCashEquivalents",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "ifrs-full:OtherCurrentReceivables",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R4": {
"role": "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"longName": "995302 - Statement - Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss)",
"shortName": "Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "4",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:SalesAndMarketingExpense",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DepreciationExpense",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R5": {
"role": "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3",
"longName": "995303 - Statement - Consolidated Statements of Changes in Shareholders\u2019 Equity/(Deficit)",
"shortName": "Consolidated Statements of Changes in Shareholders\u2019 Equity/(Deficit)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "5",
"firstAnchor": {
"contextRef": "c13",
"name": "ifrs-full:Equity",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c13",
"name": "ifrs-full:Equity",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R6": {
"role": "http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"longName": "995304 - Statement - Consolidated Statements of Cash Flows",
"shortName": "Consolidated Statements of Cash Flows",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "6",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:ProfitLoss",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:FairValueAdjustmentsOnPromissoryNote",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R7": {
"role": "http://www.psyencebiomed.com/role/NatureofOperationsandGoingConcern",
"longName": "995305 - Disclosure - Nature of Operations and Going Concern",
"shortName": "Nature of Operations and Going Concern",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "7",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R8": {
"role": "http://www.psyencebiomed.com/role/BasisofPresentation",
"longName": "995306 - Disclosure - Basis of Presentation",
"shortName": "Basis of Presentation",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "8",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R9": {
"role": "http://www.psyencebiomed.com/role/MaterialAccountingPolicies",
"longName": "995307 - Disclosure - Material Accounting Policies",
"shortName": "Material Accounting Policies",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "9",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R10": {
"role": "http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgements",
"longName": "995308 - Disclosure - Critical Accounting Estimates and Judgements",
"shortName": "Critical Accounting Estimates and Judgements",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "10",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R11": {
"role": "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCAC",
"longName": "995309 - Disclosure - Reverse Takeover Transaction with NCAC",
"shortName": "Reverse Takeover Transaction with NCAC",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "11",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:ReverseTakeoverTransactionWithNcacTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:ReverseTakeoverTransactionWithNcacTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R12": {
"role": "http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalents",
"longName": "995310 - Disclosure - Cash, Restricted Cash and Cash Equivalents",
"shortName": "Cash, Restricted Cash and Cash Equivalents",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "12",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R13": {
"role": "http://www.psyencebiomed.com/role/Equipment",
"longName": "995311 - Disclosure - Equipment",
"shortName": "Equipment",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "13",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R14": {
"role": "http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilities",
"longName": "995312 - Disclosure - Accounts Payable and Accrued Liabilities",
"shortName": "Accounts Payable and Accrued Liabilities",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "14",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R15": {
"role": "http://www.psyencebiomed.com/role/ConvertibleNoteLiability",
"longName": "995313 - Disclosure - Convertible Note Liability",
"shortName": "Convertible Note Liability",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "15",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R16": {
"role": "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilities",
"longName": "995314 - Disclosure - Derivative Warrant Liabilities",
"shortName": "Derivative Warrant Liabilities",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "16",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R17": {
"role": "http://www.psyencebiomed.com/role/PromissoryNotes",
"longName": "995315 - Disclosure - Promissory Notes",
"shortName": "Promissory Notes",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "17",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:PromissoryNotesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:PromissoryNotesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R18": {
"role": "http://www.psyencebiomed.com/role/ELOC",
"longName": "995316 - Disclosure - ELOC",
"shortName": "ELOC",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "18",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:EquityLineOfCreditDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:EquityLineOfCreditDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R19": {
"role": "http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchange",
"longName": "995317 - Disclosure - Psyence Labs Ltd. Share Exchange",
"shortName": "Psyence Labs Ltd. Share Exchange",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "19",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfPsyenceLabsLtdShareExchangeExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfPsyenceLabsLtdShareExchangeExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R20": {
"role": "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrants",
"longName": "995318 - Disclosure - PIPE Financing - Private Placement and Warrants",
"shortName": "PIPE Financing - Private Placement and Warrants",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "20",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R21": {
"role": "http://www.psyencebiomed.com/role/ShareCapital",
"longName": "995319 - Disclosure - Share Capital",
"shortName": "Share Capital",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "21",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R22": {
"role": "http://www.psyencebiomed.com/role/OtherIncome",
"longName": "995320 - Disclosure - Other Income",
"shortName": "Other Income",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "22",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R23": {
"role": "http://www.psyencebiomed.com/role/CapitalManagement",
"longName": "995321 - Disclosure - Capital Management",
"shortName": "Capital Management",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "23",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:CapitalManagementDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:CapitalManagementDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R24": {
"role": "http://www.psyencebiomed.com/role/TransactionswithRelatedParties",
"longName": "995322 - Disclosure - Transactions with Related Parties",
"shortName": "Transactions with Related Parties",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "24",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R25": {
"role": "http://www.psyencebiomed.com/role/ShareBasedCompensation",
"longName": "995323 - Disclosure - Share Based Compensation",
"shortName": "Share Based Compensation",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "25",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R26": {
"role": "http://www.psyencebiomed.com/role/IncomeTaxNote",
"longName": "995324 - Disclosure - Income Tax Note",
"shortName": "Income Tax Note",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "26",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R27": {
"role": "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagement",
"longName": "995325 - Disclosure - Financial Instruments and Financial Risk Management",
"shortName": "Financial Instruments and Financial Risk Management",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "27",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R28": {
"role": "http://www.psyencebiomed.com/role/SubsequentEvents",
"longName": "995326 - Disclosure - Subsequent Events",
"shortName": "Subsequent Events",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "28",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R29": {
"role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
"longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
"shortName": "Insider Trading Policies and Procedures",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "29",
"firstAnchor": {
"contextRef": "c0",
"name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R30": {
"role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
"longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
"shortName": "Cybersecurity Risk Management and Strategy Disclosure",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "30",
"firstAnchor": {
"contextRef": "c0",
"name": "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R31": {
"role": "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy",
"longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
"shortName": "Accounting Policies, by Policy (Policies)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "policies",
"menuCat": "Policies",
"order": "31",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R32": {
"role": "http://www.psyencebiomed.com/role/BasisofPresentationTables",
"longName": "996001 - Disclosure - Basis of Presentation (Tables)",
"shortName": "Basis of Presentation (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "32",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R33": {
"role": "http://www.psyencebiomed.com/role/MaterialAccountingPoliciesTables",
"longName": "996002 - Disclosure - Material Accounting Policies (Tables)",
"shortName": "Material Accounting Policies (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "33",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R34": {
"role": "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACTables",
"longName": "996003 - Disclosure - Reverse Takeover Transaction with NCAC (Tables)",
"shortName": "Reverse Takeover Transaction with NCAC (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "34",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:ScheduleOfListingExpensesTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"pbm:ReverseTakeoverTransactionWithNcacTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:ScheduleOfListingExpensesTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"pbm:ReverseTakeoverTransactionWithNcacTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R35": {
"role": "http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsTables",
"longName": "996004 - Disclosure - Cash, Restricted Cash and Cash Equivalents (Tables)",
"shortName": "Cash, Restricted Cash and Cash Equivalents (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "35",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R36": {
"role": "http://www.psyencebiomed.com/role/EquipmentTables",
"longName": "996005 - Disclosure - Equipment (Tables)",
"shortName": "Equipment (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "36",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R37": {
"role": "http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilitiesTables",
"longName": "996006 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
"shortName": "Accounts Payable and Accrued Liabilities (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "37",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R38": {
"role": "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityTables",
"longName": "996007 - Disclosure - Convertible Note Liability (Tables)",
"shortName": "Convertible Note Liability (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "38",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R39": {
"role": "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables",
"longName": "996008 - Disclosure - Derivative Warrant Liabilities (Tables)",
"shortName": "Derivative Warrant Liabilities (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "39",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfPrivateWarrantExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfPrivateWarrantExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R40": {
"role": "http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeTables",
"longName": "996009 - Disclosure - Psyence Labs Ltd. Share Exchange (Tables)",
"shortName": "Psyence Labs Ltd. Share Exchange (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "40",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R41": {
"role": "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsTables",
"longName": "996010 - Disclosure - PIPE Financing - Private Placement and Warrants (Tables)",
"shortName": "PIPE Financing - Private Placement and Warrants (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "41",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfCommonSharesWarrantsInputsUsedInFairValueMeasurementExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfCommonSharesWarrantsInputsUsedInFairValueMeasurementExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R42": {
"role": "http://www.psyencebiomed.com/role/ShareCapitalTables",
"longName": "996011 - Disclosure - Share Capital (Tables)",
"shortName": "Share Capital (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "42",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R43": {
"role": "http://www.psyencebiomed.com/role/CapitalManagementTables",
"longName": "996012 - Disclosure - Capital Management (Tables)",
"shortName": "Capital Management (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "43",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfTotalManagedCapitalTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"pbm:CapitalManagementDisclosureTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:DisclosureOfTotalManagedCapitalTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"pbm:CapitalManagementDisclosureTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R44": {
"role": "http://www.psyencebiomed.com/role/TransactionswithRelatedPartiesTables",
"longName": "996013 - Disclosure - Transactions with Related Parties (Tables)",
"shortName": "Transactions with Related Parties (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "44",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"ifrs-full:DisclosureOfRelatedPartyExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"ifrs-full:DisclosureOfRelatedPartyExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R45": {
"role": "http://www.psyencebiomed.com/role/IncomeTaxNoteTables",
"longName": "996014 - Disclosure - Income Tax Note (Tables)",
"shortName": "Income Tax Note (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "45",
"firstAnchor": {
"contextRef": "c0",
"name": "pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R46": {
"role": "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementTables",
"longName": "996015 - Disclosure - Financial Instruments and Financial Risk Management (Tables)",
"shortName": "Financial Instruments and Financial Risk Management (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "46",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R47": {
"role": "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable",
"longName": "996016 - Disclosure - Basis of Presentation - Schedule of Subsidiaries (Details)",
"shortName": "Basis of Presentation - Schedule of Subsidiaries (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "47",
"firstAnchor": {
"contextRef": "c48",
"name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c48",
"name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R48": {
"role": "http://www.psyencebiomed.com/role/MaterialAccountingPoliciesDetails",
"longName": "996017 - Disclosure - Material Accounting Policies (Details)",
"shortName": "Material Accounting Policies (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "48",
"firstAnchor": {
"contextRef": "c5",
"name": "ifrs-full:ClosingForeignExchangeRate",
"unitRef": "pure",
"xsiNil": "false",
"lang": null,
"decimals": "4",
"ancestors": [
"p",
"ix:continuation",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c5",
"name": "ifrs-full:ClosingForeignExchangeRate",
"unitRef": "pure",
"xsiNil": "false",
"lang": null,
"decimals": "4",
"ancestors": [
"p",
"ix:continuation",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R49": {
"role": "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable",
"longName": "996018 - Disclosure - Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details)",
"shortName": "Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "49",
"firstAnchor": {
"contextRef": "c51",
"name": "pbm:ClassificationOfFinancialAssetsAndLiabilities",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"pbm:ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock",
"ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c51",
"name": "pbm:ClassificationOfFinancialAssetsAndLiabilities",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"pbm:ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock",
"ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R50": {
"role": "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable",
"longName": "996019 - Disclosure - Material Accounting Policies - \u200bSchedule of Change in Presentation Currency (Details)",
"shortName": "Material Accounting Policies - \u200bSchedule of Change in Presentation Currency (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "50",
"firstAnchor": {
"contextRef": "c26",
"name": "ifrs-full:EquityAttributableToOwnersOfParent",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c26",
"name": "ifrs-full:EquityAttributableToOwnersOfParent",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R51": {
"role": "http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgementsDetails",
"longName": "996020 - Disclosure - Critical Accounting Estimates and Judgements (Details)",
"shortName": "Critical Accounting Estimates and Judgements (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "51",
"firstAnchor": {
"contextRef": "c66",
"name": "pbm:TradingPricePerShare",
"unitRef": "usdPershares",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c66",
"name": "pbm:TradingPricePerShare",
"unitRef": "usdPershares",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R52": {
"role": "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails",
"longName": "996021 - Disclosure - Reverse Takeover Transaction with NCAC (Details)",
"shortName": "Reverse Takeover Transaction with NCAC (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "52",
"firstAnchor": {
"contextRef": "c67",
"name": "ifrs-full:ParValuePerShare",
"unitRef": "usdPershares",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"pbm:ReverseTakeoverTransactionWithNcacTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c67",
"name": "ifrs-full:ParValuePerShare",
"unitRef": "usdPershares",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"pbm:ReverseTakeoverTransactionWithNcacTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R53": {
"role": "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable",
"longName": "996022 - Disclosure - Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details)",
"shortName": "Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "53",
"firstAnchor": {
"contextRef": "c70",
"name": "pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfListingExpensesTableTextBlock",
"pbm:ReverseTakeoverTransactionWithNcacTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c70",
"name": "pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfListingExpensesTableTextBlock",
"pbm:ReverseTakeoverTransactionWithNcacTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R54": {
"role": "http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsDetails",
"longName": "996023 - Disclosure - Cash, Restricted Cash and Cash Equivalents (Details)",
"shortName": "Cash, Restricted Cash and Cash Equivalents (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "54",
"firstAnchor": {
"contextRef": "c4",
"name": "ifrs-full:ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"span",
"td",
"tr",
"table",
"ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "ifrs-full:ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"span",
"td",
"tr",
"table",
"ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R55": {
"role": "http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable",
"longName": "996024 - Disclosure - Cash, Restricted Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)",
"shortName": "Cash, Restricted Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "55",
"firstAnchor": {
"contextRef": "c4",
"name": "ifrs-full:BalancesWithBanks",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
"ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "ifrs-full:BalancesWithBanks",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
"ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R56": {
"role": "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable",
"longName": "996025 - Disclosure - Equipment - Schedule of Equipment (Details)",
"shortName": "Equipment - Schedule of Equipment (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "56",
"firstAnchor": {
"contextRef": "c82",
"name": "ifrs-full:PropertyPlantAndEquipment",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
"ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c83",
"name": "ifrs-full:PropertyPlantAndEquipment",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
"ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R57": {
"role": "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable",
"longName": "996026 - Disclosure - Accounts Payable and Accrued Liabilities - \u200bSchedule of Accounts Payable and Accrued Liabilities (Details)",
"shortName": "Accounts Payable and Accrued Liabilities - \u200bSchedule of Accounts Payable and Accrued Liabilities (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "57",
"firstAnchor": {
"contextRef": "c4",
"name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock",
"pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock",
"pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R58": {
"role": "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"longName": "996027 - Disclosure - Convertible Note Liability (Details)",
"shortName": "Convertible Note Liability (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "58",
"firstAnchor": {
"contextRef": "c87",
"name": "ifrs-full:NotionalAmount",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"p",
"pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c88",
"name": "pbm:ProceedsFromIssuanceOfFinancingDebt",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"p",
"pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R59": {
"role": "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable",
"longName": "996028 - Disclosure - Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details)",
"shortName": "Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "59",
"firstAnchor": {
"contextRef": "c107",
"name": "ifrs-full:SignificantUnobservableInputLiabilities",
"unitRef": "pure",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c113",
"name": "pbm:SignificantUnobservableInputEntitysOwnEquityInstrument",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R60": {
"role": "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"longName": "996029 - Disclosure - Derivative Warrant Liabilities (Details)",
"shortName": "Derivative Warrant Liabilities (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "60",
"firstAnchor": {
"contextRef": "c4",
"name": "pbm:NumberOfWarrantsIssued",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"p",
"ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "pbm:NumberOfWarrantsIssued",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"p",
"ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R61": {
"role": "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"longName": "996030 - Disclosure - Derivative Warrant Liabilities - Schedule of Private Warrants (Details)",
"shortName": "Derivative Warrant Liabilities - Schedule of Private Warrants (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "61",
"firstAnchor": {
"contextRef": "c144",
"name": "pbm:WarrantExpiryDate",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c144",
"name": "pbm:WarrantExpiryDate",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R62": {
"role": "http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable",
"longName": "996031 - Disclosure - Derivative Warrant Liabilities - Schedule of Derivative Warrant Liability (Details)",
"shortName": "Derivative Warrant Liabilities - Schedule of Derivative Warrant Liability (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "62",
"firstAnchor": {
"contextRef": "c146",
"name": "pbm:NumberOfShareIssuedWarrantLiability",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c146",
"name": "pbm:NumberOfShareIssuedWarrantLiability",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R63": {
"role": "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable",
"longName": "996032 - Disclosure - Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details)",
"shortName": "Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "63",
"firstAnchor": {
"contextRef": "c127",
"name": "pbm:NumberOfWarrantsOutstanding",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"td",
"tr",
"table",
"pbm:DisclosureOfWarrantsExplanatoryTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c150",
"name": "pbm:WarrantsIssued",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"td",
"tr",
"table",
"pbm:DisclosureOfWarrantsExplanatoryTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R64": {
"role": "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable",
"longName": "996033 - Disclosure - Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details)",
"shortName": "Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "64",
"firstAnchor": {
"contextRef": "c155",
"name": "pbm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights",
"unitRef": "usdPershares",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"pbm:DisclosureOfWarrantsOutstandingAndExercisableExplanatoryTableTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c155",
"name": "pbm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights",
"unitRef": "usdPershares",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"pbm:DisclosureOfWarrantsOutstandingAndExercisableExplanatoryTableTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R65": {
"role": "http://www.psyencebiomed.com/role/PromissoryNotesDetails",
"longName": "996034 - Disclosure - Promissory Notes (Details)",
"shortName": "Promissory Notes (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "65",
"firstAnchor": {
"contextRef": "c87",
"name": "ifrs-full:NotionalAmount",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"p",
"pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c172",
"name": "pbm:FairValueAdjustmentOnPromissoryNote",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R66": {
"role": "http://www.psyencebiomed.com/role/ELOCDetails",
"longName": "996035 - Disclosure - ELOC (Details)",
"shortName": "ELOC (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "66",
"firstAnchor": {
"contextRef": "c177",
"name": "pbm:EquityLineOfCredit",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "-6",
"ancestors": [
"p",
"pbm:EquityLineOfCreditDisclosureTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c177",
"name": "pbm:EquityLineOfCredit",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "-6",
"ancestors": [
"p",
"pbm:EquityLineOfCreditDisclosureTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R67": {
"role": "http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails",
"longName": "996036 - Disclosure - Psyence Labs Ltd. Share Exchange (Details)",
"shortName": "Psyence Labs Ltd. Share Exchange (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "67",
"firstAnchor": {
"contextRef": "c183",
"name": "pbm:IssuanceOfAdditionalShare",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"p",
"pbm:DisclosureOfPsyenceLabsLtdShareExchangeExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c183",
"name": "pbm:IssuanceOfAdditionalShare",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"p",
"pbm:DisclosureOfPsyenceLabsLtdShareExchangeExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R68": {
"role": "http://www.psyencebiomed.com/role/ScheduleofInvestmentisClassifiedasaFinancialAssetMeasuredatFairValueTable",
"longName": "996037 - Disclosure - Psyence Labs Ltd. Share Exchange - Schedule of Investment is Classified as a Financial Asset Measured at Fair Value (Details)",
"shortName": "Psyence Labs Ltd. Share Exchange - Schedule of Investment is Classified as a Financial Asset Measured at Fair Value (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "68",
"firstAnchor": {
"contextRef": "c4",
"name": "pbm:NumberOfSharesInPsyLabAcquired",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "pbm:NumberOfSharesInPsyLabAcquired",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R69": {
"role": "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails",
"longName": "996038 - Disclosure - PIPE Financing - Private Placement and Warrants (Details)",
"shortName": "PIPE Financing - Private Placement and Warrants (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "69",
"firstAnchor": {
"contextRef": "c185",
"name": "pbm:FairValueAllocationGrossProceeds",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"span",
"p",
"pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c185",
"name": "pbm:FairValueAllocationGrossProceeds",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"span",
"p",
"pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R70": {
"role": "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable",
"longName": "996039 - Disclosure - PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details)",
"shortName": "PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "70",
"firstAnchor": {
"contextRef": "c4",
"name": "ifrs-full:IssuedCapitalOrdinaryShares",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "pbm:PrefundedWarrants",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R71": {
"role": "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable",
"longName": "996040 - Disclosure - PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details)",
"shortName": "PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "71",
"firstAnchor": {
"contextRef": "c192",
"name": "ifrs-full:SignificantUnobservableInputEntitysOwnEquityInstruments",
"unitRef": "pure",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"td",
"tr",
"table",
"pbm:DisclosureOfPrefundedWarrantsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c192",
"name": "ifrs-full:SignificantUnobservableInputEntitysOwnEquityInstruments",
"unitRef": "pure",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"td",
"tr",
"table",
"pbm:DisclosureOfPrefundedWarrantsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R72": {
"role": "http://www.psyencebiomed.com/role/ShareCapitalDetails",
"longName": "996041 - Disclosure - Share Capital (Details)",
"shortName": "Share Capital (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "72",
"firstAnchor": {
"contextRef": "c5",
"name": "ifrs-full:ParValuePerShare",
"unitRef": "usdPershares",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c5",
"name": "ifrs-full:ParValuePerShare",
"unitRef": "usdPershares",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R73": {
"role": "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"longName": "996042 - Disclosure - Share Capital - Schedule of Issued and Outstanding Common Shares (Details)",
"shortName": "Share Capital - Schedule of Issued and Outstanding Common Shares (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "73",
"firstAnchor": {
"contextRef": "c34",
"name": "ifrs-full:NumberOfSharesIssued",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c39",
"name": "pbm:IssuanceOfSharesForConvertibleNote",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R74": {
"role": "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable",
"longName": "996043 - Disclosure - Share Capital - Schedule of Issued and Outstanding Warrants (Details)",
"shortName": "Share Capital - Schedule of Issued and Outstanding Warrants (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "74",
"firstAnchor": {
"contextRef": "c223",
"name": "pbm:NumberOfSharesWarrantsIssuedForConvertibleNoteAddendum",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfIssuedAndOutstandingWarrantsTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c223",
"name": "pbm:NumberOfSharesWarrantsIssuedForConvertibleNoteAddendum",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfIssuedAndOutstandingWarrantsTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R75": {
"role": "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable",
"longName": "996044 - Disclosure - Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details)",
"shortName": "Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "75",
"firstAnchor": {
"contextRef": "c225",
"name": "pbm:WarrantsExpiryDate",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfWarrantsWereOutstandingAndExercisableTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c225",
"name": "pbm:WarrantsExpiryDate",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfWarrantsWereOutstandingAndExercisableTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R76": {
"role": "http://www.psyencebiomed.com/role/OtherIncomeDetails",
"longName": "996045 - Disclosure - Other Income (Details)",
"shortName": "Other Income (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "76",
"firstAnchor": {
"contextRef": "c10",
"name": "ifrs-full:OtherIncome",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c230",
"name": "ifrs-full:NotionalAmount",
"unitRef": "aud",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"p",
"ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R77": {
"role": "http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable",
"longName": "996046 - Disclosure - Capital Management - Schedule of Total Managed Capital (Details)",
"shortName": "Capital Management - Schedule of Total Managed Capital (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "77",
"firstAnchor": {
"contextRef": "c5",
"name": "ifrs-full:Borrowings",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"pbm:DisclosureOfTotalManagedCapitalTableTextBlock",
"pbm:CapitalManagementDisclosureTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c5",
"name": "ifrs-full:Borrowings",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"pbm:DisclosureOfTotalManagedCapitalTableTextBlock",
"pbm:CapitalManagementDisclosureTextBlock",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R78": {
"role": "http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable",
"longName": "996047 - Disclosure - Transactions with Related Parties - Schedule of Key Management Personnel (Details)",
"shortName": "Transactions with Related Parties - Schedule of Key Management Personnel (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "78",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"ifrs-full:DisclosureOfRelatedPartyExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"ifrs-full:DisclosureOfRelatedPartyExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R79": {
"role": "http://www.psyencebiomed.com/role/ShareBasedCompensationDetails",
"longName": "996048 - Disclosure - Share Based Compensation (Details)",
"shortName": "Share Based Compensation (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "79",
"firstAnchor": {
"contextRef": "c10",
"name": "ifrs-full:AdjustmentsForSharebasedPayments",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": null
},
"R80": {
"role": "http://www.psyencebiomed.com/role/IncomeTaxNoteDetails",
"longName": "996049 - Disclosure - Income Tax Note (Details)",
"shortName": "Income Tax Note (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "80",
"firstAnchor": {
"contextRef": "c234",
"name": "ifrs-full:ApplicableTaxRate",
"unitRef": "pure",
"xsiNil": "false",
"lang": null,
"decimals": "3",
"ancestors": [
"p",
"pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock",
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c234",
"name": "ifrs-full:ApplicableTaxRate",
"unitRef": "pure",
"xsiNil": "false",
"lang": null,
"decimals": "3",
"ancestors": [
"p",
"pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock",
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R81": {
"role": "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable",
"longName": "996050 - Disclosure - Income Tax Note - Schedule of Canadian Federal and Provincial Statutory Income Tax Rate (Details)",
"shortName": "Income Tax Note - Schedule of Canadian Federal and Provincial Statutory Income Tax Rate (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "81",
"firstAnchor": {
"contextRef": "c0",
"name": "ifrs-full:AccountingProfit",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock",
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c0",
"name": "ifrs-full:AccountingProfit",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock",
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R82": {
"role": "http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable",
"longName": "996051 - Disclosure - Income Tax Note - Schedule of Deferred Tax Assets (Details)",
"shortName": "Income Tax Note - Schedule of Deferred Tax Assets (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "82",
"firstAnchor": {
"contextRef": "c4",
"name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ix:continuation",
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R83": {
"role": "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable",
"longName": "996052 - Disclosure - Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details)",
"shortName": "Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "83",
"firstAnchor": {
"contextRef": "c251",
"name": "pbm:NonCapitalLossCarryForwards",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"pbm:SummaryOfOperatingLossCarryForwardsTableTextBlock",
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c251",
"name": "pbm:NonCapitalLossCarryForwards",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"pbm:SummaryOfOperatingLossCarryForwardsTableTextBlock",
"ifrs-full:DisclosureOfIncomeTaxExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R84": {
"role": "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementDetails",
"longName": "996053 - Disclosure - Financial Instruments and Financial Risk Management (Details)",
"shortName": "Financial Instruments and Financial Risk Management (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "84",
"firstAnchor": {
"contextRef": "c4",
"name": "pbm:PercentageOfReasonablyPossibleChangeInRiskAssumption",
"unitRef": "pure",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "pbm:PercentageOfReasonablyPossibleChangeInRiskAssumption",
"unitRef": "pure",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R85": {
"role": "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"longName": "996054 - Disclosure - Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details)",
"shortName": "Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "85",
"firstAnchor": {
"contextRef": "c4",
"name": "ifrs-full:FinancialLiabilitiesAtFairValue",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
"ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c256",
"name": "ifrs-full:FinancialLiabilitiesAtFairValue",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
"ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
},
"R86": {
"role": "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable",
"longName": "996055 - Disclosure - Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details)",
"shortName": "Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "86",
"firstAnchor": {
"contextRef": "c4",
"name": "ifrs-full:FinancialLiabilities",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c4",
"name": "ifrs-full:FinancialLiabilities",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true,
"unique": true
}
},
"R87": {
"role": "http://www.psyencebiomed.com/role/SubsequentEventsDetails",
"longName": "996056 - Disclosure - Subsequent Events (Details)",
"shortName": "Subsequent Events (Details)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "87",
"firstAnchor": {
"contextRef": "c4",
"name": "ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred",
"unitRef": "usd",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
"ix:continuation",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "c293",
"name": "ifrs-full:NumberOfSharesIssued",
"unitRef": "shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"p",
"ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ea0246623-20f_psyence.htm",
"unique": true
}
}
},
"tag": {
"country_AU": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/country/2024",
"localname": "AU",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable",
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Australia [Member]",
"label": "AUSTRALIA"
}
}
},
"auth_ref": []
},
"pbm_AccountingMethodOfSubsidiary": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AccountingMethodOfSubsidiary",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accounting method",
"documentation": "The accounting methods used in subsidiaries are classified as consolidated or unconsolidated.",
"label": "Accounting Method Of Subsidiary"
}
}
},
"auth_ref": []
},
"us-gaap_AccountingPoliciesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccountingPoliciesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_AccountingProfit": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AccountingProfit",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Net Income/(Loss) before recovery of income taxes",
"label": "Accounting profit"
}
},
"en": {
"role": {
"documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
}
}
},
"auth_ref": [
"r28",
"r29"
]
},
"pbm_AccountsPayableAndAccruedLiabilitieMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AccountsPayableAndAccruedLiabilitieMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accounts payable and accrued liabilities [Member]",
"label": "Accounts Payable And Accrued Liabilitie Member"
}
}
},
"auth_ref": []
},
"pbm_AccountsPayableAndAccruedLiabilitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AccountsPayableAndAccruedLiabilitiesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Accounts Payable and Accrued Liabilities [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_AccrualsClassifiedAsCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AccrualsClassifiedAsCurrent",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": {
"parentTag": "pbm_CurrentAccountsPayableAndAccruedLiabilities",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accrued liabilities",
"label": "Accruals classified as current"
}
},
"en": {
"role": {
"documentation": "The amount of accruals classified as current. [Refer: Accruals]"
}
}
},
"auth_ref": [
"r331"
]
},
"ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AccumulatedDepreciationAndAmortisationMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accumulated Depreciation [Member]",
"label": "Accumulated depreciation and amortisation [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
}
}
},
"auth_ref": [
"r39",
"r336",
"r338",
"r339",
"r340"
]
},
"ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofInvestmentisClassifiedasaFinancialAssetMeasuredatFairValueTable",
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Total fair value of shares issued",
"verboseLabel": "Total consideration (in Dollars)",
"label": "Consideration transferred, acquisition-date fair value"
}
},
"en": {
"role": {
"documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]"
}
}
},
"auth_ref": [
"r125"
]
},
"ecd_Additional402vDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Additional402vDisclosureTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Additional 402(v) Disclosure [Text Block]",
"terseLabel": "Additional 402(v) Disclosure"
}
}
},
"auth_ref": [
"r252"
]
},
"dei_AdditionalSecurities462b": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AdditionalSecurities462b",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Additional Securities. 462(b)"
}
}
},
"auth_ref": [
"r315"
]
},
"dei_AdditionalSecurities462bFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AdditionalSecurities462bFileNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Additional Securities, 462(b), File Number"
}
}
},
"auth_ref": [
"r315"
]
},
"dei_AdditionalSecuritiesEffective413b": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AdditionalSecuritiesEffective413b",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Additional Securities Effective, 413(b)"
}
}
},
"auth_ref": [
"r313"
]
},
"ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Additions",
"label": "Additions other than through business combinations, property, plant and equipment"
}
},
"en": {
"role": {
"documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
}
}
},
"auth_ref": [
"r34"
]
},
"dei_AddressTypeDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AddressTypeDomain",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Address Type [Domain]",
"documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
}
}
},
"auth_ref": []
},
"ecd_AdjToCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustment to Compensation Amount",
"terseLabel": "Adjustment to Compensation, Amount"
}
}
},
"auth_ref": [
"r265"
]
},
"ecd_AdjToCompAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToCompAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustment to Compensation [Axis]",
"terseLabel": "Adjustment to Compensation:"
}
}
},
"auth_ref": [
"r265"
]
},
"ecd_AdjToNonPeoNeoCompFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToNonPeoNeoCompFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
"terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
}
}
},
"auth_ref": [
"r265"
]
},
"ecd_AdjToPeoCompFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToPeoCompFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustment To PEO Compensation, Footnote [Text Block]",
"terseLabel": "Adjustment To PEO Compensation, Footnote"
}
}
},
"auth_ref": [
"r265"
]
},
"ifrs-full_AdjustedWeightedAverageShares": {
"xbrltype": "sharesItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AdjustedWeightedAverageShares",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Weighted average number of outstanding shares - diluted (in Shares)",
"label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
}
},
"en": {
"role": {
"documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
}
}
},
"auth_ref": [
"r63"
]
},
"ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 13.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other receivables",
"label": "Adjustments for decrease (increase) in other operating receivables"
}
},
"en": {
"role": {
"documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
}
}
},
"auth_ref": [
"r343"
]
},
"ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 14.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Prepaids",
"label": "Adjustments for decrease (increase) in prepaid expenses"
}
},
"en": {
"role": {
"documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
}
}
},
"auth_ref": [
"r345"
]
},
"ifrs-full_AdjustmentsForDepreciationExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AdjustmentsForDepreciationExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 9.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Depreciation",
"label": "Adjustments for depreciation expense"
}
},
"en": {
"role": {
"documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
}
}
},
"auth_ref": [
"r345"
]
},
"pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 15.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accounts payable and accrued liabilities",
"documentation": "Adjustments for increase (decrease) in accounts payable and accrued liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.",
"label": "Adjustments For Increase Decrease In Accounts Payable And Accrued Liabilities"
}
}
},
"auth_ref": []
},
"ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accounts payable and accrued liabilities",
"label": "Adjustments for increase (decrease) in trade and other payables"
}
},
"en": {
"role": {
"documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
}
}
},
"auth_ref": [
"r345"
]
},
"pbm_AdjustmentsForListingExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AdjustmentsForListingExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 11.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Listing expense",
"documentation": "Adjustments for listing expense to reconcile profit (loss) to net cash flow from (used in) operating activities.",
"label": "Adjustments For Listing Expense"
}
}
},
"auth_ref": []
},
"ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AdjustmentsForReconcileProfitLossAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Non-cash adjustment:",
"label": "Adjustments to reconcile profit (loss) [abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_AdjustmentsForSharebasedPayments": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AdjustmentsForSharebasedPayments",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 7.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable",
"http://www.psyencebiomed.com/role/ShareBasedCompensationDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share based compensation",
"verboseLabel": "Share based compensation expense",
"label": "Adjustments for share-based payments"
}
},
"en": {
"role": {
"documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
}
}
},
"auth_ref": [
"r344"
]
},
"pbm_AdjustmentsForTransactionExpenses": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AdjustmentsForTransactionExpenses",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 12.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Transaction expenses",
"documentation": "Adjustments for transaction expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.",
"label": "Adjustments For Transaction Expenses"
}
}
},
"auth_ref": []
},
"ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 10.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Foreign exchange",
"label": "Adjustments for unrealised foreign exchange losses (gains)"
}
},
"en": {
"role": {
"documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
}
}
},
"auth_ref": [
"r169",
"r344"
]
},
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
"terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
}
}
},
"auth_ref": [
"r306"
]
},
"ecd_AggtErrCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtErrCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Erroneous Compensation Amount",
"terseLabel": "Aggregate Erroneous Compensation Amount"
}
}
},
"auth_ref": [
"r215",
"r226",
"r242",
"r277"
]
},
"ecd_AggtErrCompNotYetDeterminedTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtErrCompNotYetDeterminedTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
"terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
}
}
},
"auth_ref": [
"r218",
"r229",
"r245",
"r280"
]
},
"ecd_AggtPnsnAdjsSvcCstMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtPnsnAdjsSvcCstMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Pension Adjustments Service Cost [Member]",
"terseLabel": "Aggregate Pension Adjustments Service Cost"
}
}
},
"auth_ref": [
"r307"
]
},
"ecd_AllAdjToCompMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllAdjToCompMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "All Adjustments to Compensation [Member]",
"terseLabel": "All Adjustments to Compensation"
}
}
},
"auth_ref": [
"r265"
]
},
"ecd_AllExecutiveCategoriesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllExecutiveCategoriesMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "All Executive Categories [Member]",
"terseLabel": "All Executive Categories"
}
}
},
"auth_ref": [
"r272"
]
},
"ecd_AllIndividualsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllIndividualsMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "All Individuals [Member]",
"terseLabel": "All Individuals"
}
}
},
"auth_ref": [
"r219",
"r230",
"r246",
"r272",
"r281",
"r285",
"r293"
]
},
"ecd_AllTradingArrangementsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllTradingArrangementsMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "All Trading Arrangements [Member]",
"terseLabel": "All Trading Arrangements"
}
}
},
"auth_ref": [
"r291"
]
},
"dei_AmendmentDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AmendmentDescription",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Description",
"documentation": "Description of changes contained within amended document."
}
}
},
"auth_ref": []
},
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AmendmentFlag",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesAmountOfCommonShares": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesAmountOfCommonShares",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Share issued for PIPE financing",
"documentation": "Amount of Common shares, Amount of Common shares.",
"label": "Amount Of Common Shares Amount Of Common Shares"
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesCommitmentSharesELOC": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesCommitmentSharesELOC",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Commitment shares ELOC",
"documentation": "Amount of Common shares, Commitment shares ELOC.",
"label": "Amount Of Common Shares Commitment Shares ELOC"
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesShareIssuanceCostsForELOC": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesShareIssuanceCostsForELOC",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Amount of Common shares, Share issuance costs for ELOC",
"documentation": "Amount of Common shares, Share issuance costs for ELOC.",
"label": "Amount Of Common Shares Share Issuance Costs For ELOC"
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesShareIssuanceCostsForPIPEFinancing": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesShareIssuanceCostsForPIPEFinancing",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Amount of Common shares, Share issuance costs for PIPE financing",
"documentation": "Amount of Common shares, Share issuance costs for PIPE financing.",
"label": "Amount Of Common Shares Share Issuance Costs For PIPEFinancing"
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesSharesIssuanceCostsForPIPEPrefundedWarrantsExercised": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesSharesIssuanceCostsForPIPEPrefundedWarrantsExercised",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised",
"documentation": "Amount of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised.",
"label": "Amount Of Common Shares Shares Issuance Costs For PIPEPrefunded Warrants Exercised"
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesSharesIssuedForELOC": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesSharesIssuedForELOC",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Shares issued for ELOC",
"documentation": "Amount of Common shares, Shares issued for ELOC.",
"label": "Amount Of Common Shares Shares Issued For ELOC"
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesSharesIssuedForPIPEPrefundedWarrantsExercised": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesSharesIssuedForPIPEPrefundedWarrantsExercised",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Shares issued for PIPE pre-funded warrants exercised",
"documentation": "Amount of Common shares, Shares issued for PIPE pre-funded warrants exercised.",
"label": "Amount Of Common Shares Shares Issued For PIPEPrefunded Warrants Exercised"
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesSharesIssuedOnConversionOfConvertibleNoteWarrants": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesSharesIssuedOnConversionOfConvertibleNoteWarrants",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Shares issued on conversion of convertible note warrants",
"documentation": "Amount of Common shares, Shares issued on conversion of convertible note warrants.",
"label": "Amount Of Common Shares Shares Issued On Conversion Of Convertible Note Warrants"
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesSharesIssuedOnConversionOfNCACPromissoryNotes": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesSharesIssuedOnConversionOfNCACPromissoryNotes",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Shares issued on conversion of NCAC promissory notes",
"documentation": "Amount of Common shares, Shares issued on conversion of NCAC promissory notes.",
"label": "Amount Of Common Shares Shares Issued On Conversion Of NCACPromissory Notes"
}
}
},
"auth_ref": []
},
"pbm_AmountOfCommonSharesSharesIssuedOnConversionOfPGIPromissoryNotes": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfCommonSharesSharesIssuedOnConversionOfPGIPromissoryNotes",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Shares issued on conversion of PGI promissory notes",
"documentation": "Amount of Common shares, Shares issued on conversion of PGI promissory notes.",
"label": "Amount Of Common Shares Shares Issued On Conversion Of PGIPromissory Notes"
}
}
},
"auth_ref": []
},
"pbm_AmountOfConvertibleNoteTerminationAgreementWarrantsExercised": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfConvertibleNoteTerminationAgreementWarrantsExercised",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Convertible note Termination Agreement warrants exercised",
"documentation": "Amount of convertible note termination agreement warrants exercised.",
"label": "Amount Of Convertible Note Termination Agreement Warrants Exercised"
}
}
},
"auth_ref": []
},
"pbm_AmountOfIssuanceCostsForPIPEFinancingWarrants": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfIssuanceCostsForPIPEFinancingWarrants",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of warrants Issuance costs for PIPE financing warrants",
"documentation": "Amount of issuance costs for PIPE financing warrants.",
"label": "Amount Of Issuance Costs For PIPEFinancing Warrants"
}
}
},
"auth_ref": []
},
"pbm_AmountOfIssuanceCostsForPIPEPrefundedWarrantsExercised": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfIssuanceCostsForPIPEPrefundedWarrantsExercised",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of warrants Issuance costs for PIPE pre-funded warrants exercised",
"documentation": "Amount of issuance costs for PIPE pre-funded warrants exercised.",
"label": "Amount Of Issuance Costs For PIPEPrefunded Warrants Exercised"
}
}
},
"auth_ref": []
},
"pbm_AmountOfPIPEFinancingWarrantIssuance": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfPIPEFinancingWarrantIssuance",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of PIPE warrants financing warrant issuance",
"documentation": "Amount of PIPE financing warrant issuance.",
"label": "Amount Of PIPEFinancing Warrant Issuance"
}
}
},
"auth_ref": []
},
"pbm_AmountOfPIPEFinancingWarrantIssuanceCosts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfPIPEFinancingWarrantIssuanceCosts",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of PIPE warrants financing warrant issuance costs",
"documentation": "Amount of PIPE financing warrant issuance costs.",
"label": "Amount Of PIPEFinancing Warrant Issuance Costs"
}
}
},
"auth_ref": []
},
"pbm_AmountOfPIPEPrefundedWarrantsExercised": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfPIPEPrefundedWarrantsExercised",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of warrants PIPE pre-funded warrants exercised",
"documentation": "Amount of PIPE pre-funded warrants exercised.",
"label": "Amount Of PIPEPrefunded Warrants Exercised"
}
}
},
"auth_ref": []
},
"pbm_AmountOfWarrantsEndingBalance": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfWarrantsEndingBalance",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"periodEndLabel": "Amount of warrants ending balance",
"documentation": "Amount of warrants ending balance.",
"label": "Amount Of Warrants Ending Balance"
}
}
},
"auth_ref": []
},
"pbm_AmountOfWarrantsIssuedForConvertibleNoteAddendum": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfWarrantsIssuedForConvertibleNoteAddendum",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Warrants issued for convertible note Addendum",
"documentation": "Amount of warrants issued for convertible note addendum.",
"label": "Amount Of Warrants Issued For Convertible Note Addendum"
}
}
},
"auth_ref": []
},
"pbm_AmountOfWarrantsOpeningBalance": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AmountOfWarrantsOpeningBalance",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Amount of warrants opening balance",
"documentation": "Amount of warrants opening balance.",
"label": "Amount Of Warrants Opening Balance"
}
}
},
"auth_ref": []
},
"ifrs-full_AmountsPayableRelatedPartyTransactions": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AmountsPayableRelatedPartyTransactions",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accounts payable (in Dollars)",
"label": "Amounts payable, related party transactions"
}
},
"en": {
"role": {
"documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]"
}
}
},
"auth_ref": [
"r47",
"r50"
]
},
"dei_AnnualInformationForm": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AnnualInformationForm",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Annual Information Form",
"documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
}
}
},
"auth_ref": [
"r222"
]
},
"ifrs-full_ApplicableTaxRate": {
"xbrltype": "percentItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ApplicableTaxRate",
"presentation": [
"http://www.psyencebiomed.com/role/IncomeTaxNoteDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Percentage of statutory income tax rate",
"label": "Applicable tax rate"
}
},
"en": {
"role": {
"documentation": "The applicable income tax rate."
}
}
},
"auth_ref": [
"r29"
]
},
"dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
"xbrltype": "dateOrAsapItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Approximate Date of Commencement of Proposed Sale to Public",
"documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
}
}
},
"auth_ref": []
},
"ifrs-full_Assets": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "Assets",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "TOTAL ASSETS",
"label": "Assets"
}
},
"en": {
"role": {
"documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
}
}
},
"auth_ref": [
"r12",
"r102",
"r103",
"r105",
"r145",
"r147"
]
},
"ifrs-full_AssetsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AssetsAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "ASSETS",
"label": "Assets [abstract]"
}
}
},
"auth_ref": []
},
"dei_AuditedAnnualFinancialStatements": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AuditedAnnualFinancialStatements",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Audited Annual Financial Statements",
"documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
}
}
},
"auth_ref": [
"r222"
]
},
"dei_AuditorFirmId": {
"xbrltype": "nonemptySequenceNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AuditorFirmId",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Auditor Firm ID",
"documentation": "PCAOB issued Audit Firm Identifier"
}
}
},
"auth_ref": [
"r200",
"r203",
"r222"
]
},
"dei_AuditorLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AuditorLineItems",
"lang": {
"en-us": {
"role": {
"label": "Auditor [Line Items]"
}
}
},
"auth_ref": []
},
"dei_AuditorLocation": {
"xbrltype": "internationalNameItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AuditorLocation",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Auditor Location"
}
}
},
"auth_ref": [
"r200",
"r203",
"r222"
]
},
"dei_AuditorName": {
"xbrltype": "internationalNameItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AuditorName",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Auditor Name"
}
}
},
"auth_ref": [
"r200",
"r203",
"r222"
]
},
"dei_AuditorOpinionTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AuditorOpinionTextBlock",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Auditor Opinion [Text Block]"
}
}
},
"auth_ref": [
"r311"
]
},
"dei_AuditorTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AuditorTable",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Auditor [Table]"
}
}
},
"auth_ref": []
},
"pbm_AugustMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "AugustMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "August 20, 2024 [Member]",
"label": "August Member"
}
}
},
"auth_ref": []
},
"ifrs-full_AverageForeignExchangeRate": {
"xbrltype": "decimalItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "AverageForeignExchangeRate",
"presentation": [
"http://www.psyencebiomed.com/role/MaterialAccountingPoliciesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Average rate",
"label": "Average foreign exchange rate"
}
},
"en": {
"role": {
"documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
}
}
},
"auth_ref": [
"r327"
]
},
"ecd_AwardExrcPrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardExrcPrice",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Exercise Price",
"terseLabel": "Exercise Price"
}
}
},
"auth_ref": [
"r288"
]
},
"ecd_AwardGrantDateFairValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardGrantDateFairValue",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Grant Date Fair Value",
"terseLabel": "Fair Value as of Grant Date"
}
}
},
"auth_ref": [
"r289"
]
},
"ecd_AwardTmgDiscLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgDiscLineItems",
"lang": {
"en-us": {
"role": {
"label": "Award Timing Disclosures [Line Items]",
"terseLabel": "Award Timing Disclosures"
}
}
},
"auth_ref": [
"r284"
]
},
"ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgHowMnpiCnsdrdTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing, How MNPI Considered [Text Block]",
"terseLabel": "Award Timing, How MNPI Considered"
}
}
},
"auth_ref": [
"r284"
]
},
"ecd_AwardTmgMethodTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMethodTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing Method [Text Block]",
"terseLabel": "Award Timing Method"
}
}
},
"auth_ref": [
"r284"
]
},
"ecd_AwardTmgMnpiCnsdrdFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing MNPI Considered [Flag]",
"terseLabel": "Award Timing MNPI Considered"
}
}
},
"auth_ref": [
"r284"
]
},
"ecd_AwardTmgMnpiDiscTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing MNPI Disclosure [Text Block]",
"terseLabel": "Award Timing MNPI Disclosure"
}
}
},
"auth_ref": [
"r284"
]
},
"ecd_AwardTmgPredtrmndFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgPredtrmndFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing Predetermined [Flag]",
"terseLabel": "Award Timing Predetermined"
}
}
},
"auth_ref": [
"r284"
]
},
"us-gaap_AwardTypeAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AwardTypeAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Type [Axis]",
"terseLabel": "Award Type"
}
}
},
"auth_ref": []
},
"ecd_AwardUndrlygSecuritiesAmt": {
"xbrltype": "decimalItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardUndrlygSecuritiesAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Underlying Securities Amount",
"terseLabel": "Underlying Securities"
}
}
},
"auth_ref": [
"r287"
]
},
"ecd_AwardsCloseToMnpiDiscIndName": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardsCloseToMnpiDiscIndName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Awards Close in Time to MNPI Disclosures, Individual Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r286"
]
},
"ecd_AwardsCloseToMnpiDiscTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardsCloseToMnpiDiscTable",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Awards Close in Time to MNPI Disclosures [Table]",
"terseLabel": "Awards Close in Time to MNPI Disclosures"
}
}
},
"auth_ref": [
"r285"
]
},
"ecd_AwardsCloseToMnpiDiscTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardsCloseToMnpiDiscTableTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
"terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
}
}
},
"auth_ref": [
"r285"
]
},
"ifrs-full_BalancesWithBanks": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "BalancesWithBanks",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable": {
"parentTag": "ifrs-full_RestrictedCashAndCashEquivalents",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Unrestricted cash held with chartered banks",
"label": "Balances with banks"
}
},
"en": {
"role": {
"documentation": "The amount of cash balances held at banks."
}
}
},
"auth_ref": [
"r346"
]
},
"ifrs-full_BasicEarningsLossPerShare": {
"xbrltype": "perShareItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "BasicEarningsLossPerShare",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Income/(Loss) per share - basic (in Dollars per share)",
"label": "Basic earnings (loss) per share"
}
},
"en": {
"role": {
"documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
}
}
},
"auth_ref": [
"r61",
"r62"
]
},
"pbm_BasisOfPresentationAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "BasisOfPresentationAbstract",
"lang": {
"en-us": {
"role": {
"label": "Basis of Presentation [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_BasisofPresentationScheduleofSubsidiariesDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "BasisofPresentationScheduleofSubsidiariesDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable"
],
"lang": {
"en-us": {
"role": {
"label": "Basis of Presentation - Schedule of Subsidiaries (Details) [Table]"
}
}
},
"auth_ref": []
},
"ifrs-full_Borrowings": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "Borrowings",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable": {
"parentTag": "ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost",
"weight": 1.0,
"order": 1.0
},
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": {
"parentTag": "ifrs-full_NetAssetsLiabilities",
"weight": -1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable",
"http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Borrowings",
"negatedLabel": "NCAC promissory note (Note 11)",
"label": "Borrowings"
}
},
"en": {
"role": {
"documentation": "The amount of outstanding funds that the entity is obligated to repay."
}
}
},
"auth_ref": [
"r329"
]
},
"ifrs-full_BorrowingsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "BorrowingsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Convertible Note Liability [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_BorrowingsByNameAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "BorrowingsByNameAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/OtherIncomeDetails",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Borrowings by name [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r350"
]
},
"ifrs-full_BorrowingsByNameDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "BorrowingsByNameDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/OtherIncomeDetails",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Borrowings by name [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
}
}
},
"auth_ref": [
"r350"
]
},
"ifrs-full_BorrowingsInterestRate": {
"xbrltype": "percentItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "BorrowingsInterestRate",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Interest rate",
"verboseLabel": "Loan bears interest rate",
"label": "Borrowings, interest rate"
}
},
"en": {
"role": {
"documentation": "The interest rate on borrowings. [Refer: Borrowings]"
}
}
},
"auth_ref": [
"r350"
]
},
"pbm_BorrowingsMinimumInterestChargeablePeriod": {
"xbrltype": "durationItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "BorrowingsMinimumInterestChargeablePeriod",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of repayable days",
"documentation": "The minimum interest chargeable period of borrowings in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Borrowings Minimum Interest Chargeable Period"
}
}
},
"auth_ref": []
},
"pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment": {
"xbrltype": "durationItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "BorrowingsPeriodToRepayAfterNoticeOfAssessment",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of business days for notice of assessment",
"documentation": "The period to repay the borrowings after the notice assessment received related to the research and development refunds.",
"label": "Borrowings Period To Repay After Notice Of Assessment"
}
}
},
"auth_ref": []
},
"ifrs-full_BottomOfRangeMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "BottomOfRangeMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Bottom of Range [Member]",
"label": "Bottom of range [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for the bottom of a range."
}
}
},
"auth_ref": [
"r78",
"r107",
"r114",
"r121",
"r175",
"r176",
"r350"
]
},
"dei_BusinessContactMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "BusinessContactMember",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Business Contact",
"label": "Business Contact [Member]",
"documentation": "Business contact for the entity"
}
}
},
"auth_ref": [
"r203",
"r222"
]
},
"country_CA": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/country/2024",
"localname": "CA",
"presentation": [
"http://www.psyencebiomed.com/role/IncomeTaxNoteDetails",
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable",
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Canada [Member]",
"label": "CANADA"
}
}
},
"auth_ref": []
},
"pbm_CancellationOfPublicWarrants": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "CancellationOfPublicWarrants",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cancellation of public warrants",
"documentation": "The number of public warrants.",
"label": "Cancellation Of Public Warrants"
}
}
},
"auth_ref": []
},
"ifrs-full_CapitalCommitmentsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CapitalCommitmentsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule of Total Managed Capital [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_CapitalManagementDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "CapitalManagementDisclosureTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/CapitalManagement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Capital management",
"documentation": "The entire disclosure on capital management.",
"label": "Capital Management Disclosure Text Block"
}
}
},
"auth_ref": []
},
"ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r33",
"r36",
"r68",
"r69",
"r71",
"r72",
"r73",
"r74",
"r75",
"r126",
"r132",
"r133"
]
},
"ifrs-full_CarryingAmountMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CarryingAmountMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"label": "Carrying amount [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
}
}
},
"auth_ref": [
"r36",
"r69",
"r71",
"r73",
"r74",
"r126",
"r132",
"r133"
]
},
"pbm_CashAndCashEquivalentMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "CashAndCashEquivalentMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cash and cash equivalents [Member]",
"label": "Cash And Cash Equivalent Member"
}
}
},
"auth_ref": []
},
"ifrs-full_CashAndCashEquivalents": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CashAndCashEquivalents",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_CurrentAssets",
"weight": 1.0,
"order": 1.0
},
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": {
"parentTag": "ifrs-full_NetAssetsLiabilities",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable",
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Cash and cash equivalents, beginning of year",
"periodEndLabel": "Cash and cash equivalents, end of year",
"terseLabel": "Cash and cash equivalents",
"verboseLabel": "Cash and cash equivalent",
"label": "Cash and cash equivalents"
}
},
"en": {
"role": {
"documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
}
}
},
"auth_ref": [
"r8",
"r79",
"r97"
]
},
"ifrs-full_CashAndCashEquivalentsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CashAndCashEquivalentsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cash, Restricted Cash and Cash Equivalents [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_CashEquivalentsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CashEquivalentsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule of Cash and Cash Equivalents [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Increase in restricted cash",
"label": "Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents"
}
},
"en": {
"role": {
"documentation": "The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
}
}
},
"auth_ref": [
"r341"
]
},
"ifrs-full_CashFlowsFromUsedInFinancingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CashFlowsFromUsedInFinancingActivities",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Cash provided from financing activities",
"terseLabel": "Cash provided from financing activities",
"label": "Cash flows from (used in) financing activities"
}
},
"en": {
"role": {
"documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
}
}
},
"auth_ref": [
"r76",
"r81"
]
},
"ifrs-full_CashFlowsFromUsedInInvestingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CashFlowsFromUsedInInvestingActivities",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Cash used for investing activities",
"label": "Cash flows from (used in) investing activities"
}
},
"en": {
"role": {
"documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
}
}
},
"auth_ref": [
"r76",
"r81"
]
},
"ifrs-full_CashFlowsFromUsedInOperatingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CashFlowsFromUsedInOperatingActivities",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Cash used in operating activities",
"terseLabel": "Cash used in operating activities",
"label": "Cash flows from (used in) operating activities"
}
},
"en": {
"role": {
"documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
}
}
},
"auth_ref": [
"r76",
"r81"
]
},
"ifrs-full_CashTransferred": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CashTransferred",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Total consideration amount",
"label": "Cash transferred"
}
},
"en": {
"role": {
"documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]"
}
}
},
"auth_ref": [
"r124"
]
},
"ifrs-full_CategoriesOfRelatedPartiesAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CategoriesOfRelatedPartiesAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails",
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails",
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Categories of related parties [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r49"
]
},
"ifrs-full_CategoriesOfRelatedPartiesDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CategoriesOfRelatedPartiesDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails",
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails",
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Categories of related parties [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
}
}
},
"auth_ref": [
"r49"
]
},
"ecd_ChangedPeerGroupFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ChangedPeerGroupFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Changed Peer Group, Footnote [Text Block]",
"terseLabel": "Changed Peer Group, Footnote"
}
}
},
"auth_ref": [
"r263"
]
},
"pbm_ChangesInOperatingAssetsAndLiabilitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Changes in working capital:",
"label": "Changes In Operating Assets And Liabilities Abstract"
}
}
},
"auth_ref": []
},
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
"terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
}
}
},
"auth_ref": [
"r260"
]
},
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
"terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
}
}
},
"auth_ref": [
"r258"
]
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CityAreaCode",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"pbm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails",
"http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Exercise Price (in Dollars per share)",
"verboseLabel": "Exercise price of warrants per share",
"documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
"label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights"
}
}
},
"auth_ref": []
},
"ifrs-full_ClassesOfFinancialAssetsAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfFinancialAssetsAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails",
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of financial assets [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r116",
"r138",
"r139",
"r152",
"r153"
]
},
"ifrs-full_ClassesOfFinancialInstrumentsAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfFinancialInstrumentsAxis",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/OtherIncomeDetails",
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails",
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable",
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable",
"http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of financial instruments [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r132",
"r134",
"r135",
"r136"
]
},
"ifrs-full_ClassesOfFinancialInstrumentsDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfFinancialInstrumentsDomain",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of financial instruments [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
}
}
},
"auth_ref": [
"r132",
"r134",
"r135",
"r136"
]
},
"ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfFinancialLiabilitiesAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of financial liabilities [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r138",
"r139",
"r152",
"r153"
]
},
"ifrs-full_ClassesOfFinancialLiabilitiesDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfFinancialLiabilitiesDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of financial liabilities [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
}
}
},
"auth_ref": [
"r138",
"r139",
"r152",
"r153"
]
},
"ifrs-full_ClassesOfOrdinarySharesAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfOrdinarySharesAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of ordinary shares [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r61"
]
},
"ifrs-full_ClassesOfOrdinarySharesDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfOrdinarySharesDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of ordinary shares [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for the standard value for the 'Classes of ordinary shares' axis if no other member is used."
}
}
},
"auth_ref": [
"r61"
]
},
"ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfPropertyPlantAndEquipmentAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of property, plant and equipment [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r37"
]
},
"ifrs-full_ClassesOfShareCapitalAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfShareCapitalAxis",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails",
"http://www.psyencebiomed.com/role/ShareCapitalDetails",
"http://www.psyencebiomed.com/role/SubsequentEventsDetails",
"http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of share capital [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r20"
]
},
"ifrs-full_ClassesOfShareCapitalDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClassesOfShareCapitalDomain",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails",
"http://www.psyencebiomed.com/role/ShareCapitalDetails",
"http://www.psyencebiomed.com/role/SubsequentEventsDetails",
"http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Classes of share capital [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
}
}
},
"auth_ref": [
"r20"
]
},
"pbm_ClassificationOfFinancialAssetsAndLiabilities": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ClassificationOfFinancialAssetsAndLiabilities",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Classification",
"documentation": "Classification of financial assets and liabilities.",
"label": "Classification Of Financial Assets And Liabilities"
}
}
},
"auth_ref": []
},
"ifrs-full_ClosingForeignExchangeRate": {
"xbrltype": "decimalItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ClosingForeignExchangeRate",
"presentation": [
"http://www.psyencebiomed.com/role/MaterialAccountingPoliciesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Closing rate",
"label": "Closing foreign exchange rate"
}
},
"en": {
"role": {
"documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
}
}
},
"auth_ref": [
"r327"
]
},
"ecd_CoSelectedMeasureAmt": {
"xbrltype": "decimalItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CoSelectedMeasureAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Company Selected Measure Amount",
"terseLabel": "Company Selected Measure Amount"
}
}
},
"auth_ref": [
"r264"
]
},
"ecd_CoSelectedMeasureName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CoSelectedMeasureName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Company Selected Measure Name",
"terseLabel": "Company Selected Measure Name"
}
}
},
"auth_ref": [
"r264"
]
},
"pbm_CommonSharesBasisRatio": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "CommonSharesBasisRatio",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Common shares basis ratio",
"documentation": "Ratio applied to the Common Shares Basis Ratio, for example but not limited to, one share converted to two or two shares converted to one.",
"label": "Common Shares Basis Ratio"
}
}
},
"auth_ref": []
},
"pbm_CommonSharesIssued": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "CommonSharesIssued",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Common shares issued",
"documentation": "The number of common share issued.",
"label": "Common Shares Issued"
}
}
},
"auth_ref": []
},
"pbm_CommonSharesWithoutParValueMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "CommonSharesWithoutParValueMember",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Common shares, without par value",
"label": "Common Shares Without Par Value Member"
}
}
},
"auth_ref": []
},
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
"terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
}
}
},
"auth_ref": [
"r269"
]
},
"ecd_CompActuallyPaidVsNetIncomeTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsNetIncomeTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Compensation Actually Paid vs. Net Income [Text Block]",
"terseLabel": "Compensation Actually Paid vs. Net Income"
}
}
},
"auth_ref": [
"r268"
]
},
"ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsOtherMeasureTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Compensation Actually Paid vs. Other Measure [Text Block]",
"terseLabel": "Compensation Actually Paid vs. Other Measure"
}
}
},
"auth_ref": [
"r270"
]
},
"ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
"terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
}
}
},
"auth_ref": [
"r267"
]
},
"ifrs-full_ComponentsOfEquityAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ComponentsOfEquityAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"label": "Components of equity [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r3"
]
},
"ifrs-full_ComponentsOfEquityDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ComponentsOfEquityDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"label": "Components of equity [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
}
}
},
"auth_ref": [
"r3"
]
},
"ifrs-full_ComprehensiveIncome": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ComprehensiveIncome",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "TOTAL COMPREHENSIVE INCOME/(LOSS)",
"label": "Comprehensive income"
}
},
"en": {
"role": {
"documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
}
}
},
"auth_ref": [
"r0",
"r22",
"r88",
"r91",
"r96",
"r171"
]
},
"ifrs-full_ComputerEquipmentMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ComputerEquipmentMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable",
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Computer Equipment [Member]",
"verboseLabel": "Computer equipment [member]",
"label": "Computer equipment [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
}
}
},
"auth_ref": [
"r335"
]
},
"pbm_ConsiderationOfShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ConsiderationOfShares",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Consideration of shares",
"documentation": "Represent the consideration of shares.",
"label": "Consideration Of Shares"
}
}
},
"auth_ref": []
},
"pbm_ConsiderationPaidAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ConsiderationPaidAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Consideration paid:",
"label": "Consideration Paid Abstract"
}
}
},
"auth_ref": []
},
"pbm_ConsolidatedStatementsOfChangesInShareholdersEquityDeficitAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ConsolidatedStatementsOfChangesInShareholdersEquityDeficitAbstract",
"lang": {
"en-us": {
"role": {
"label": "Consolidated Statements Of Changes In Shareholders Equity Deficit Abstract"
}
}
},
"auth_ref": []
},
"ifrs-full_ConstantPrepaymentRateMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ConstantPrepaymentRateMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Prepayment amount [Member]",
"label": "Constant prepayment rate, measurement input [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for the constant prepayment rate used as a measurement input."
}
}
},
"auth_ref": [
"r172",
"r176"
]
},
"dei_ContactPersonnelEmailAddress": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ContactPersonnelEmailAddress",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Contact Personnel Email Address",
"documentation": "Email address of contact personnel."
}
}
},
"auth_ref": []
},
"dei_ContactPersonnelFaxNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ContactPersonnelFaxNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Contact Personnel Fax Number",
"documentation": "Fax Number of contact personnel."
}
}
},
"auth_ref": [
"r203"
]
},
"dei_ContactPersonnelName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ContactPersonnelName",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Contact Personnel Name",
"documentation": "Name of contact personnel"
}
}
},
"auth_ref": []
},
"dei_ContainedFileInformationFileDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ContainedFileInformationFileDescription",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Contained File Information, File Description",
"documentation": "The description of the contained file."
}
}
},
"auth_ref": []
},
"dei_ContainedFileInformationFileName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ContainedFileInformationFileName",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Contained File Information, File Name",
"documentation": "The name of the contained file."
}
}
},
"auth_ref": []
},
"dei_ContainedFileInformationFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ContainedFileInformationFileNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Contained File Information, File Number",
"documentation": "The SEC Document Number of the contained file."
}
}
},
"auth_ref": []
},
"dei_ContainedFileInformationFileType": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ContainedFileInformationFileType",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Contained File Information, File Type",
"documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
}
}
},
"auth_ref": []
},
"ifrs-full_ConvertibleInstrumentsMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ConvertibleInstrumentsMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Convertible Instruments [Member]",
"label": "Convertible instruments [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for convertible instruments."
}
}
},
"auth_ref": [
"r337"
]
},
"pbm_ConvertibleNoteLiability": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ConvertibleNoteLiability",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Liabilities",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Convertible note liability",
"documentation": "Value of convertible note liability.",
"label": "Convertible Note Liability"
}
}
},
"auth_ref": []
},
"pbm_ConvertibleNoteLiabilityDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ConvertibleNoteLiabilityDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Convertible Note Liability (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_ConvertibleNoteLiabilityMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ConvertibleNoteLiabilityMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Convertible note liability [Member]",
"label": "Convertible Note Liability Member"
}
}
},
"auth_ref": []
},
"pbm_ConvertibleNoteLiabilityScheduleofUsingtheBlackScholesPricingModelDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ConvertibleNoteLiabilityScheduleofUsingtheBlackScholesPricingModelDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"label": "Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details) [Table]"
}
}
},
"auth_ref": []
},
"ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CountryOfIncorporationOrResidenceOfSubsidiary",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Place of incorporation",
"label": "Country of incorporation of subsidiary"
}
},
"en": {
"role": {
"documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Total for all subsidiaries [member]]"
}
}
},
"auth_ref": [
"r55",
"r58",
"r92",
"r93"
]
},
"dei_CountryRegion": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CountryRegion",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Country Region",
"documentation": "Region code of country"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"ifrs-full_CreationDateAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CreationDateAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"label": "Creation date [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r82",
"r83",
"r86"
]
},
"pbm_CriticalAccountingEstimatesAndJudgementsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "CriticalAccountingEstimatesAndJudgementsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Critical Accounting Estimates and Judgements [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CumulativeEffectAtDateOfInitialApplicationAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"label": "Cumulative effect at date of initial application [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r325"
]
},
"pbm_CurrentAccountsPayableAndAccruedLiabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "CurrentAccountsPayableAndAccruedLiabilities",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Liabilities",
"weight": 1.0,
"order": 1.0
},
"http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Total",
"terseLabel": "Accounts payable and accrued liabilities",
"documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
"label": "Current Accounts Payable And Accrued Liabilities"
}
}
},
"auth_ref": []
},
"ifrs-full_CurrentAssets": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CurrentAssets",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Assets",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Total current assets",
"label": "Current assets"
}
},
"en": {
"role": {
"documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
}
}
},
"auth_ref": [
"r15",
"r95",
"r171"
]
},
"ifrs-full_CurrentAssetsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CurrentAssetsAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Current assets",
"label": "Current assets [abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_CurrentDebtInstrumentsIssued": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CurrentDebtInstrumentsIssued",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Liabilities",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Due to related party",
"label": "Current debt instruments issued"
}
},
"en": {
"role": {
"documentation": "The amount of current debt instruments issued. [Refer: Debt instruments issued]"
}
}
},
"auth_ref": [
"r329"
]
},
"ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CurrentFinancialLiabilitiesAtAmortisedCost",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Total",
"label": "Current financial liabilities at amortised cost"
}
},
"en": {
"role": {
"documentation": "The amount of current financial liabilities measured at amortised cost. [Refer: Financial liabilities at amortised cost]"
}
}
},
"auth_ref": [
"r141"
]
},
"dei_CurrentFiscalYearEndDate": {
"xbrltype": "gMonthDayItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CurrentFiscalYearEndDate",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Current Fiscal Year End Date",
"documentation": "End date of current fiscal year in the format --MM-DD."
}
}
},
"auth_ref": []
},
"ifrs-full_CurrentLiabilitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CurrentLiabilitiesAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Current liabilities",
"label": "Current liabilities [abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_CurrentPrepaidExpenses": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CurrentPrepaidExpenses",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_CurrentAssets",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Prepaid expense",
"label": "Current prepaid expenses"
}
},
"en": {
"role": {
"documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
}
}
},
"auth_ref": [
"r327"
]
},
"ifrs-full_CurrentProvisions": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CurrentProvisions",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": {
"parentTag": "pbm_CurrentAccountsPayableAndAccruedLiabilities",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Provisions",
"label": "Current provisions"
}
},
"en": {
"role": {
"documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
}
}
},
"auth_ref": [
"r10"
]
},
"ifrs-full_CurrentRestrictedCashAndCashEquivalents": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CurrentRestrictedCashAndCashEquivalents",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_CurrentAssets",
"weight": 1.0,
"order": 2.0
},
"http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable": {
"parentTag": "ifrs-full_RestrictedCashAndCashEquivalents",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Restricted cash",
"label": "Current restricted cash and cash equivalents"
}
},
"en": {
"role": {
"documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
}
}
},
"auth_ref": [
"r329"
]
},
"ifrs-full_CurrentWarrantLiability": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "CurrentWarrantLiability",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Liabilities",
"weight": 1.0,
"order": 3.0
},
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": {
"parentTag": "ifrs-full_NetAssetsLiabilities",
"weight": -1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable",
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Amount, Opening balance",
"periodEndLabel": "Amount,Balance ending",
"terseLabel": "Derivative warrant liabilities",
"negatedLabel": "Derivative warrant liabilities (Note 10)",
"verboseLabel": "Derivative warrant liability (in Dollars)",
"label": "Current warrant liability"
}
},
"en": {
"role": {
"documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]"
}
}
},
"auth_ref": [
"r329"
]
},
"cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]",
"label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
}
}
},
"auth_ref": [
"r210",
"r303"
]
},
"cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
"label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
}
}
},
"auth_ref": [
"r210",
"r303"
]
},
"cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
"label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
}
}
},
"auth_ref": [
"r211",
"r304"
]
},
"cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
"label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
}
}
},
"auth_ref": [
"r206",
"r299"
]
},
"cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]",
"label": "Cybersecurity Risk Management Processes Integrated [Flag]"
}
}
},
"auth_ref": [
"r207",
"r300"
]
},
"cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cybersecurity Risk Management Processes Integrated [Text Block]",
"label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
}
}
},
"auth_ref": [
"r207",
"r300"
]
},
"cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
}
}
},
"auth_ref": [
"r205",
"r298"
]
},
"cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
}
}
},
"auth_ref": [
"r205",
"r298"
]
},
"cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
}
}
},
"auth_ref": [
"r205",
"r298"
]
},
"cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cybersecurity Risk Management Third Party Engaged [Flag]",
"label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
}
}
},
"auth_ref": [
"r208",
"r301"
]
},
"cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
"label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
}
}
},
"auth_ref": [
"r209",
"r302"
]
},
"cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
"presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
"label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
}
}
},
"auth_ref": [
"r209",
"r302"
]
},
"pbm_DebtInstrumentConvertibleInitialConversionPrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DebtInstrumentConvertibleInitialConversionPrice",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Conversion price (in Dollars per share)",
"documentation": "The price per share of the conversion feature embedded in the debt instrument.",
"label": "Debt Instrument Convertible Initial Conversion Price"
}
}
},
"auth_ref": []
},
"ifrs-full_DebtInstrumentsHeldMeasuredAtFairValueThroughOtherComprehensiveIncome": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DebtInstrumentsHeldMeasuredAtFairValueThroughOtherComprehensiveIncome",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value of notes",
"label": "Debt instruments held measured at fair value through other comprehensive income"
}
},
"en": {
"role": {
"documentation": "The amount of instruments representing indebtedness held by the entity that are measured at fair value through other comprehensive income. [Refer: Debt instruments held; Financial assets measured at fair value through other comprehensive income]"
}
}
},
"auth_ref": [
"r329"
]
},
"pbm_DecemberTwenteyFourMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DecemberTwenteyFourMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "December 24, 2024 [Member]",
"label": "December Twentey Four Member"
}
}
},
"auth_ref": []
},
"pbm_DecemberTwentyFourOneMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DecemberTwentyFourOneMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "December 24, 2024 [Member]",
"label": "December Twenty Four One Member"
}
}
},
"auth_ref": []
},
"pbm_DecemberTwentyFourTwoMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DecemberTwentyFourTwoMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "December 24, 2024 [Member]",
"label": "December Twenty Four Two Member"
}
}
},
"auth_ref": []
},
"ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Unrecognized deferred tax asset",
"label": "Deductible temporary differences for which no deferred tax asset is recognised"
}
},
"en": {
"role": {
"documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
}
}
},
"auth_ref": [
"r30"
]
},
"dei_DelayedOrContinuousOffering": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DelayedOrContinuousOffering",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Delayed or Continuous Offering"
}
}
},
"auth_ref": [
"r234",
"r235",
"r249"
]
},
"ifrs-full_DepreciationExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DepreciationExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": -1.0,
"order": 7.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Depreciation",
"label": "Depreciation expense"
}
},
"en": {
"role": {
"documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
}
}
},
"auth_ref": [
"r327"
]
},
"ifrs-full_DepreciationPropertyPlantAndEquipment": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DepreciationPropertyPlantAndEquipment",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Charge for the year",
"label": "Depreciation, property, plant and equipment"
}
},
"en": {
"role": {
"documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
}
}
},
"auth_ref": [
"r35",
"r38"
]
},
"pbm_DerivativeWarrantLiabilitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DerivativeWarrantLiabilitiesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Derivative Warrant Liabilities [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_DerivativeWarrantLiabilitiesDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DerivativeWarrantLiabilitiesDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Derivative Warrant Liabilities (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_DerivativeWarrantLiabilitiesLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DerivativeWarrantLiabilitiesLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Derivative Warrant Liabilities [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_DerivativeWarrantLiabilitiesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DerivativeWarrantLiabilitiesMember",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Derivative warrant liability [Member]",
"label": "Derivative Warrant Liabilities Member"
}
}
},
"auth_ref": []
},
"pbm_DerivativeWarrantLiabilitiesScheduleofPrivateWarrantsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DerivativeWarrantLiabilitiesScheduleofPrivateWarrantsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Derivative Warrant Liabilities - Schedule of Private Warrants (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_DerivativeWarrantLiabilitiesScheduleofWarrantTransactionsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DerivativeWarrantLiabilitiesScheduleofWarrantTransactionsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_DerivativeWarrantLiabilitiesScheduleofWarrantsOutstandingandExercisableDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DerivativeWarrantLiabilitiesScheduleofWarrantsOutstandingandExercisableDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"label": "Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details) [Table]"
}
}
},
"auth_ref": []
},
"ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Income/(loss) per share",
"label": "Description of accounting policy for earnings per share [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's material accounting policy information for earnings per share."
}
}
},
"auth_ref": [
"r328"
]
},
"ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Financial instruments",
"label": "Description of accounting policy for financial instruments [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
}
}
},
"auth_ref": [
"r328"
]
},
"ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Foreign currency translation",
"label": "Description of accounting policy for foreign currency translation [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's material accounting policy information for foreign currency translation."
}
}
},
"auth_ref": [
"r328"
]
},
"ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Income taxes",
"label": "Description of accounting policy for income tax [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's material accounting policy information for income tax."
}
}
},
"auth_ref": [
"r328"
]
},
"ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Provisions",
"label": "Description of accounting policy for provisions [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
}
}
},
"auth_ref": [
"r328"
]
},
"ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Research and development",
"label": "Description of accounting policy for research and development expense [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
}
}
},
"auth_ref": [
"r328"
]
},
"ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Restricted cash",
"label": "Description of accounting policy for restricted cash and cash equivalents [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
}
}
},
"auth_ref": [
"r328"
]
},
"ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share based compensation",
"label": "Description of accounting policy for share-based payment transactions [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
}
}
},
"auth_ref": [
"r328"
]
},
"ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Related party transactions",
"label": "Description of accounting policy for transactions with related parties [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's material accounting policy information for transactions with related parties. [Refer: Total for all related parties [member]]"
}
}
},
"auth_ref": [
"r328"
]
},
"ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cash and cash equivalents",
"label": "Description of accounting policy for determining components of cash and cash equivalents [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
}
}
},
"auth_ref": [
"r80"
]
},
"ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
"presentation": [
"http://www.psyencebiomed.com/role/MaterialAccountingPoliciesTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "\u200bSchedule of Change in Presentation Currency",
"label": "Description of nature of change in accounting estimate [text block]"
}
},
"en": {
"role": {
"documentation": "The description of the nature of changes in accounting estimates that have effects in the current period or are expected to have effects in future periods."
}
}
},
"auth_ref": [
"r85"
]
},
"ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
"xbrltype": "percentItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Risk free interest rate",
"label": "Risk free interest rate, share options granted"
}
},
"en": {
"role": {
"documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
}
}
},
"auth_ref": [
"r122"
]
},
"ifrs-full_DescriptionOfVoluntaryChangeInAccountingPolicy": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DescriptionOfVoluntaryChangeInAccountingPolicy",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Change in accounting policy",
"label": "Disclosure of voluntary change in accounting policy [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of a voluntary change in accounting policy."
}
}
},
"auth_ref": [
"r84"
]
},
"ifrs-full_DilutedEarningsLossPerShare": {
"xbrltype": "perShareItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DilutedEarningsLossPerShare",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Income/(Loss) per share - diluted (in Dollars per share)",
"label": "Diluted earnings (loss) per share"
}
},
"en": {
"role": {
"documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
}
}
},
"auth_ref": [
"r61",
"r62"
]
},
"ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgements"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Critical accounting estimates and judgements",
"label": "Disclosure of accounting judgements and estimates [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
}
}
},
"auth_ref": [
"r323"
]
},
"pbm_DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilitiesTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "\u200bSchedule of Accounts Payable and Accrued Liabilities",
"documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
"label": "Disclosure Of Accounts Payable And Accrued Liabilities Explanatory Table Text Block"
}
}
},
"auth_ref": []
},
"pbm_DisclosureOfAccountsPayableAndAccruedLiabilitiesTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfAccountsPayableAndAccruedLiabilitiesTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilities"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accounts payable and accrued liabilities",
"documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
"label": "Disclosure Of Accounts Payable And Accrued Liabilities Text Block"
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule of Key Management Personnel [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/BasisofPresentation"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Basis of presentation",
"label": "Disclosure of basis of preparation of financial statements [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of the basis used for the preparation of the financial statements."
}
}
},
"auth_ref": [
"r323"
]
},
"ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Cash and Cash Equivalents",
"label": "Disclosure of cash and cash equivalents [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
}
}
},
"auth_ref": [
"r323"
]
},
"ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accounting Standards Effective January 1, 2024 and issued but not yet effective",
"label": "Disclosure of changes in accounting policies [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of changes made to accounting policies by the entity."
}
}
},
"auth_ref": [
"r323"
]
},
"ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfClassesOfShareCapitalAbstract",
"lang": {
"en-us": {
"role": {
"label": "Share Capital [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfClassesOfShareCapitalLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable",
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Share Capital [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"pbm_DisclosureOfCommonSharesWarrantsInputsUsedInFairValueMeasurementExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfCommonSharesWarrantsInputsUsedInFairValueMeasurementExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Fair Value Allocation",
"documentation": "The disclosure of Common Shares Warrants inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value.",
"label": "Disclosure Of Common Shares Warrants Inputs Used In Fair Value Measurement Explanatory"
}
}
},
"auth_ref": []
},
"pbm_DisclosureOfConvertibleNoteLiabilityTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfConvertibleNoteLiabilityTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiability"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Convertible note liability",
"documentation": "The entire disclosure of Convertible note liability.",
"label": "Disclosure Of Convertible Note Liability Text Block"
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilities"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Derivative warrant liabilities",
"label": "Disclosure of derivative financial instruments [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]"
}
}
},
"auth_ref": [
"r323"
]
},
"ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Convertible Note Liability [Line Items]",
"terseLabel": "Promissory Notes [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Maturity of the Contractual Obligations",
"label": "Disclosure of detailed information about financial instruments [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]"
}
}
},
"auth_ref": [
"r131",
"r134",
"r140"
]
},
"ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/EquipmentTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Equipment",
"label": "Disclosure of detailed information about property, plant and equipment [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
}
}
},
"auth_ref": [
"r37"
]
},
"ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEvents"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Subsequent Events",
"label": "Disclosure of events after reporting period [text block]"
}
},
"en": {
"role": {
"documentation": "The entire disclosure for events after the reporting period."
}
}
},
"auth_ref": [
"r26"
]
},
"ifrs-full_DisclosureOfFairValueMeasurementOfEquityLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfFairValueMeasurementOfEquityLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Fair Value Allocation Component [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Derivative Warrant Liability",
"label": "Disclosure of fair value measurement of liabilities [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of the fair value measurement of liabilities."
}
}
},
"auth_ref": [
"r106"
]
},
"ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Carrying Value of the Financial Instruments",
"label": "Disclosure of fair value of financial instruments [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]"
}
}
},
"auth_ref": [
"r323"
]
},
"ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfFinancialInstrumentsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Financial Instruments and Financial Risk Management [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfFinancialInstrumentsLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Carrying Value of the Financial Instruments [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfFinancialRiskManagementExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Financial instruments and financial risk management",
"label": "Disclosure of financial risk management [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of the entity's financial risk management practices and policies."
}
}
},
"auth_ref": [
"r323"
]
},
"ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/NatureofOperationsandGoingConcern"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Nature of operations and going concern",
"label": "Disclosure of general information about financial statements [text block]"
}
},
"en": {
"role": {
"documentation": "The entire disclosure for general information about financial statements."
}
}
},
"auth_ref": [
"r6"
]
},
"ifrs-full_DisclosureOfGeographicalAreasLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfGeographicalAreasLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Non-Capital Loss Carry Forwards [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfIncomeTaxExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfIncomeTaxExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/IncomeTaxNote"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Income tax note",
"label": "Disclosure of income tax [text block]"
}
},
"en": {
"role": {
"documentation": "The entire disclosure for income taxes."
}
}
},
"auth_ref": [
"r32"
]
},
"ifrs-full_DisclosureOfInformationAboutExpectedRecognitionOfContractualServiceMarginInProfitOrLossLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfInformationAboutExpectedRecognitionOfContractualServiceMarginInProfitOrLossLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Maturity of the Contractual Obligations [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/TransactionswithRelatedPartiesTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Key Management Personnel",
"label": "Disclosure of information about key management personnel [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
}
}
},
"auth_ref": [
"r323"
]
},
"ifrs-full_DisclosureOfIssuedCapitalExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfIssuedCapitalExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapital"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share capital",
"label": "Disclosure of issued capital [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of issued capital. [Refer: Issued capital]"
}
}
},
"auth_ref": [
"r323"
]
},
"ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/MaterialAccountingPolicies"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Material accounting policies",
"label": "Disclosure of material accounting policy information [text block]"
}
},
"en": {
"role": {
"documentation": "The entire disclosure of material accounting policy information applied by the entity."
}
}
},
"auth_ref": [
"r4"
]
},
"ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
"lang": {
"en-us": {
"role": {
"label": "Subsequent Events [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Subsequent Events [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfOtherOperatingIncomeExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncome"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other income",
"label": "Disclosure of other operating income [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
}
}
},
"auth_ref": [
"r323"
]
},
"pbm_DisclosureOfPrefundedWarrantsUsedInFairValueMeasurementOfLiabilitiesExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfPrefundedWarrantsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Pre-funded Warrants",
"documentation": "The disclosure of pre-funded Warrants inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value.",
"label": "Disclosure Of Prefunded Warrants Used In Fair Value Measurement Of Liabilities Explanatory"
}
}
},
"auth_ref": []
},
"pbm_DisclosureOfPrivatePlacementAndWarrantsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfPrivatePlacementAndWarrantsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrants"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "PIPE Financing - Private Placement and Warrants",
"documentation": "The entire disclosure for private placement and warrants.",
"label": "Disclosure Of Private Placement And Warrants Explanatory"
}
}
},
"auth_ref": []
},
"pbm_DisclosureOfPrivateWarrantExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfPrivateWarrantExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Private Warrants",
"documentation": "The disclosure of private warrant.",
"label": "Disclosure Of Private Warrant Explanatory"
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/Equipment"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Equipment",
"label": "Disclosure of property, plant and equipment [text block]"
}
},
"en": {
"role": {
"documentation": "The entire disclosure for property, plant and equipment."
}
}
},
"auth_ref": [
"r40"
]
},
"pbm_DisclosureOfPsyenceLabsLtdShareExchangeExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfPsyenceLabsLtdShareExchangeExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchange"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Psyence Labs Ltd. Share Exchange",
"documentation": "Disclosure of psyence labs ltd share exchange explanatory.",
"label": "Disclosure Of Psyence Labs Ltd Share Exchange Explanatory"
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Investment is Classified as a Financial Asset Measured at Fair Value",
"label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
}
}
},
"auth_ref": [
"r168"
]
},
"ifrs-full_DisclosureOfRelatedPartyExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfRelatedPartyExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/TransactionswithRelatedParties"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Transactions with related parties",
"label": "Disclosure of related party [text block]"
}
},
"en": {
"role": {
"documentation": "The entire disclosure for related parties."
}
}
},
"auth_ref": [
"r51"
]
},
"ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalents"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cash, restricted cash and cash equivalents",
"label": "Disclosure of restricted cash and cash equivalents [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
}
}
},
"auth_ref": [
"r323"
]
},
"ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/ShareBasedCompensation"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share based compensation",
"label": "Disclosure of share-based payment arrangements [text block]"
}
},
"en": {
"role": {
"documentation": "The entire disclosure for share-based payment arrangements."
}
}
},
"auth_ref": [
"r117"
]
},
"ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/BasisofPresentationTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Subsidiaries",
"label": "Disclosure of subsidiaries [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]]"
}
}
},
"auth_ref": [
"r57",
"r60",
"r101"
]
},
"ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Subsidiaries of PBM [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Pre-funded Warrants [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Using the Black-Scholes Pricing Model",
"label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities."
}
}
},
"auth_ref": [
"r104"
]
},
"ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Fair Value of Convertible Notes Estimated Using Combined Discounted Cash Flow Approach [Line Items]",
"terseLabel": "Schedule of Private Warrants [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
"xbrltype": "textBlockItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
"presentation": [
"http://www.psyencebiomed.com/role/IncomeTaxNoteTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Deferred Tax Assets",
"label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]"
}
},
"en": {
"role": {
"documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
}
}
},
"auth_ref": [
"r31"
]
},
"ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Deferred Tax Assets [Line Items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
"lang": {
"en-us": {
"role": {
"label": "Share Based Compensation [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_DisclosureOfTotalManagedCapitalTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfTotalManagedCapitalTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/CapitalManagementTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Total Managed Capital",
"documentation": "Schedule disclosing information related to total managed capital.",
"label": "Disclosure Of Total Managed Capital Table Text Block"
}
}
},
"auth_ref": []
},
"pbm_DisclosureOfWarrantsExplanatoryTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfWarrantsExplanatoryTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Warrant Transactions",
"documentation": "Tabular disclosure of the warrants transactions and the number of warrants outstanding.",
"label": "Disclosure Of Warrants Explanatory Table Text Block"
}
}
},
"auth_ref": []
},
"pbm_DisclosureOfWarrantsOutstandingAndExercisableExplanatoryTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DisclosureOfWarrantsOutstandingAndExercisableExplanatoryTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Warrants Outstanding and Exercisable",
"documentation": "Tabular disclosure of the warrants outstanding and exercisable.",
"label": "Disclosure Of Warrants Outstanding And Exercisable Explanatory Table Text Block"
}
}
},
"auth_ref": []
},
"ifrs-full_DiscountRateMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "DiscountRateMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Discount rate cash [Member]",
"label": "Discount rate, measurement input [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation."
}
}
},
"auth_ref": [
"r347"
]
},
"pbm_DiscountRateSharesMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DiscountRateSharesMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Discount rate shares [Member]",
"documentation": "This member stands for a discount rate, shares used as a measurement input used in valuation techniques based on a present value calculation.",
"label": "Discount Rate Shares Measurement Input Member"
}
}
},
"auth_ref": []
},
"dei_DividendOrInterestReinvestmentPlanOnly": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DividendOrInterestReinvestmentPlanOnly",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Dividend or Interest Reinvestment Plan Only"
}
}
},
"auth_ref": [
"r234",
"r235",
"r249"
]
},
"dei_DocumentAccountingStandard": {
"xbrltype": "accountingStandardItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentAccountingStandard",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Accounting Standard",
"documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
}
}
},
"auth_ref": [
"r203"
]
},
"dei_DocumentAnnualReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentAnnualReport",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Annual Report",
"documentation": "Boolean flag that is true only for a form used as an annual report."
}
}
},
"auth_ref": [
"r200",
"r203",
"r222"
]
},
"dei_DocumentCopyrightInformation": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentCopyrightInformation",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Copyright Information",
"documentation": "The copyright information for the document."
}
}
},
"auth_ref": []
},
"dei_DocumentCreationDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentCreationDate",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Creation Date",
"documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
}
}
},
"auth_ref": []
},
"dei_DocumentDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentDescription",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Description",
"documentation": "The description of the document."
}
}
},
"auth_ref": []
},
"dei_DocumentDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentDomain",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document [Domain]",
"documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
}
}
},
"auth_ref": []
},
"dei_DocumentEffectiveDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentEffectiveDate",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Effective Date",
"documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
}
}
},
"auth_ref": []
},
"dei_DocumentFinStmtErrorCorrectionFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentFinStmtErrorCorrectionFlag",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Financial Statement Error Correction [Flag]",
"documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
}
}
},
"auth_ref": [
"r200",
"r203",
"r222",
"r273"
]
},
"dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
"documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
}
}
},
"auth_ref": [
"r200",
"r203",
"r222",
"r273"
]
},
"dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentFiscalPeriodFocus",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Period Focus",
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
}
}
},
"auth_ref": []
},
"dei_DocumentFiscalYearFocus": {
"xbrltype": "gYearItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentFiscalYearFocus",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Year Focus",
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
}
}
},
"auth_ref": []
},
"dei_DocumentInformationDocumentAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentInformationDocumentAxis",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Information, Document [Axis]",
"documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": []
},
"dei_DocumentInformationLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentInformationLineItems",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Information [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"dei_DocumentInformationTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentInformationTable",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Information [Table]",
"documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
}
}
},
"auth_ref": []
},
"dei_DocumentInformationTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentInformationTextBlock",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Information [Text Block]",
"documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
}
}
},
"auth_ref": []
},
"dei_DocumentName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentName",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Name",
"documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodStartDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentPeriodStartDate",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period Start Date",
"documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
}
}
},
"auth_ref": []
},
"dei_DocumentQuarterlyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentQuarterlyReport",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Quarterly Report",
"documentation": "Boolean flag that is true only for a form used as an quarterly report."
}
}
},
"auth_ref": [
"r201"
]
},
"dei_DocumentRegistrationStatement": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentRegistrationStatement",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Registration Statement",
"documentation": "Boolean flag that is true only for a form used as a registration statement."
}
}
},
"auth_ref": [
"r189"
]
},
"dei_DocumentShellCompanyEventDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentShellCompanyEventDate",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Event Date",
"documentation": "Date of event requiring a shell company report."
}
}
},
"auth_ref": [
"r203"
]
},
"dei_DocumentShellCompanyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentShellCompanyReport",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Report",
"documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
}
}
},
"auth_ref": [
"r203"
]
},
"dei_DocumentSubtitle": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentSubtitle",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Subtitle",
"documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
}
}
},
"auth_ref": []
},
"dei_DocumentSynopsis": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentSynopsis",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Synopsis",
"documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
}
}
},
"auth_ref": []
},
"dei_DocumentTitle": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentTitle",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Title",
"documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
}
}
},
"auth_ref": []
},
"dei_DocumentTransitionReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentTransitionReport",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Transition Report",
"documentation": "Boolean flag that is true only for a form used as a transition report."
}
}
},
"auth_ref": [
"r250"
]
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentType",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_DocumentVersion": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentVersion",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Version",
"documentation": "The version identifier of the document."
}
}
},
"auth_ref": []
},
"dei_DocumentsIncorporatedByReferenceTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentsIncorporatedByReferenceTextBlock",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Documents Incorporated by Reference [Text Block]",
"documentation": "Documents incorporated by reference."
}
}
},
"auth_ref": [
"r192"
]
},
"pbm_DueToNCACSponsorMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DueToNCACSponsorMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Due to NCAC Sponsor [Member]",
"label": "Due To NCACSponsor Member"
}
}
},
"auth_ref": []
},
"pbm_DueToPsyenceGroupIncMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "DueToPsyenceGroupIncMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Due to Psyence Group Inc [Member]",
"label": "Due To Psyence Group Inc Member"
}
}
},
"auth_ref": []
},
"ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
"terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
}
}
},
"auth_ref": [
"r262"
]
},
"pbm_ELOCAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ELOCAbstract",
"lang": {
"en-us": {
"role": {
"label": "ELOC [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_ELOCDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ELOCDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails"
],
"lang": {
"en-us": {
"role": {
"label": "ELOC (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_ELOCLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ELOCLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails"
],
"lang": {
"en-us": {
"role": {
"label": "ELOC [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_ELOCMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ELOCMember",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails",
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "ELOC [Member]",
"label": "ELOCMember"
}
}
},
"auth_ref": []
},
"dei_EffectiveAfter60Days486a": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EffectiveAfter60Days486a",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Effective after 60 Days, 486(a)"
}
}
},
"auth_ref": [
"r319"
]
},
"dei_EffectiveOnDate486a": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EffectiveOnDate486a",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Effective on Date, 486(a)"
}
}
},
"auth_ref": [
"r319"
]
},
"dei_EffectiveOnDate486b": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EffectiveOnDate486b",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Effective on Date, 486(b)"
}
}
},
"auth_ref": [
"r320"
]
},
"dei_EffectiveOnSetDate486a": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EffectiveOnSetDate486a",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Effective on Set Date, 486(a)"
}
}
},
"auth_ref": [
"r319"
]
},
"dei_EffectiveOnSetDate486b": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EffectiveOnSetDate486b",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Effective on Set Date, 486(b)"
}
}
},
"auth_ref": [
"r320"
]
},
"dei_EffectiveUponFiling462e": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EffectiveUponFiling462e",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Effective Upon Filing, 462(e)"
}
}
},
"auth_ref": [
"r318"
]
},
"dei_EffectiveUponFiling486b": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EffectiveUponFiling486b",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Effective upon Filing, 486(b)"
}
}
},
"auth_ref": [
"r320"
]
},
"dei_EffectiveWhenDeclaredSection8c": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EffectiveWhenDeclaredSection8c",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Effective when Declared, Section 8(c)"
}
}
},
"auth_ref": [
"r322"
]
},
"us-gaap_EmployeeStockOptionMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeStockOptionMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Employee Stock Option [Member]",
"terseLabel": "Employee Stock Option"
}
}
},
"auth_ref": []
},
"dei_EntitiesTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntitiesTable",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entities [Table]",
"documentation": "Container to assemble all relevant information about each entity associated with the document instance"
}
}
},
"auth_ref": []
},
"dei_EntityAccountingStandard": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAccountingStandard",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Accounting Standard",
"documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressAddressDescription",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Description",
"documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressAddressLine2",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine3": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressAddressLine3",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Three",
"documentation": "Address Line 3 such as an Office Park"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCountry": {
"xbrltype": "countryCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressCountry",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Country",
"documentation": "ISO 3166-1 alpha-2 country code."
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityAddressesAddressTypeAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressesAddressTypeAxis",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Addresses, Address Type [Axis]",
"documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": []
},
"dei_EntityAddressesLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressesLineItems",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Addresses [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"dei_EntityAddressesTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressesTable",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Addresses [Table]",
"documentation": "Container of address information for the entity"
}
}
},
"auth_ref": [
"r191"
]
},
"dei_EntityBankruptcyProceedingsReportingCurrent": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityBankruptcyProceedingsReportingCurrent",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Bankruptcy Proceedings, Reporting Current",
"documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
}
}
},
"auth_ref": [
"r195"
]
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r191"
]
},
"dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCommonStockSharesOutstanding",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Common Stock, Shares Outstanding",
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
}
}
},
"auth_ref": []
},
"dei_EntityContactPersonnelLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityContactPersonnelLineItems",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Contact Personnel [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCurrentReportingStatus",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": []
},
"dei_EntityDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityDomain",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity [Domain]",
"documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
}
}
},
"auth_ref": []
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r191"
]
},
"dei_EntityExTransitionPeriod": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityExTransitionPeriod",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Ex Transition Period",
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
}
}
},
"auth_ref": [
"r321"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityFileNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityFilerCategory": {
"xbrltype": "filerCategoryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityFilerCategory",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Filer Category",
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": [
"r191"
]
},
"dei_EntityHomeCountryISOCode": {
"xbrltype": "countryCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityHomeCountryISOCode",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Home Country ISO Code",
"documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationDateOfIncorporation": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityIncorporationDateOfIncorporation",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, Date of Incorporation",
"documentation": "Date when an entity was incorporated"
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityInformationFormerLegalOrRegisteredName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInformationFormerLegalOrRegisteredName",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Information, Former Legal or Registered Name",
"documentation": "Former Legal or Registered Name of an entity"
}
}
},
"auth_ref": []
},
"dei_EntityInformationLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInformationLineItems",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Information [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"dei_EntityInteractiveDataCurrent": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInteractiveDataCurrent",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Interactive Data Current",
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
}
}
},
"auth_ref": [
"r310"
]
},
"dei_EntityInvCompanyType": {
"xbrltype": "invCompanyType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInvCompanyType",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Inv Company Type",
"documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
}
}
},
"auth_ref": [
"r309"
]
},
"dei_EntityLegalForm": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityLegalForm",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Legal Form",
"documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
}
}
},
"auth_ref": []
},
"dei_EntityListingDepositoryReceiptRatio": {
"xbrltype": "pureItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingDepositoryReceiptRatio",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Listing, Depository Receipt Ratio",
"documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
}
}
},
"auth_ref": []
},
"dei_EntityListingDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingDescription",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Listing, Description",
"documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
}
}
},
"auth_ref": []
},
"dei_EntityListingForeign": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingForeign",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Listing, Foreign",
"documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
}
}
},
"auth_ref": []
},
"dei_EntityListingParValuePerShare": {
"xbrltype": "perShareItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingParValuePerShare",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Listing, Par Value Per Share",
"documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
}
}
},
"auth_ref": []
},
"dei_EntityListingPrimary": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingPrimary",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Listing, Primary",
"documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
}
}
},
"auth_ref": []
},
"dei_EntityListingSecurityTradingCurrency": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingSecurityTradingCurrency",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Listing, Security Trading Currency",
"documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
}
}
},
"auth_ref": []
},
"dei_EntityListingsExchangeAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingsExchangeAxis",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Listings, Exchange [Axis]",
"documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": []
},
"dei_EntityListingsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingsLineItems",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Listings [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"dei_EntityListingsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingsTable",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Listings [Table]",
"documentation": "Container for exchange listing information for an entity"
}
}
},
"auth_ref": []
},
"dei_EntityNumberOfEmployees": {
"xbrltype": "decimalItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityNumberOfEmployees",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Number of Employees",
"documentation": "Number of persons employed by the Entity"
}
}
},
"auth_ref": []
},
"dei_EntityPhoneFaxNumbersLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityPhoneFaxNumbersLineItems",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Phone Fax Numbers [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"dei_EntityPrimarySicNumber": {
"xbrltype": "sicNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityPrimarySicNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Primary SIC Number",
"documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
}
}
},
"auth_ref": [
"r222"
]
},
"dei_EntityPublicFloat": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityPublicFloat",
"crdr": "credit",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Public Float",
"documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityRegistrantName",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r191"
]
},
"dei_EntityReportingCurrencyISOCode": {
"xbrltype": "currencyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityReportingCurrencyISOCode",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Reporting Currency ISO Code",
"documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
}
}
},
"auth_ref": []
},
"dei_EntityShellCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityShellCompany",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Shell Company",
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
}
}
},
"auth_ref": [
"r191"
]
},
"dei_EntitySmallBusiness": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntitySmallBusiness",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Small Business",
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
}
}
},
"auth_ref": [
"r191"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r191"
]
},
"dei_EntityTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityTextBlock",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity [Text Block]",
"documentation": "Container to serve as parent of six Entity related Table concepts."
}
}
},
"auth_ref": []
},
"dei_EntityVoluntaryFilers": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityVoluntaryFilers",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Voluntary Filers",
"documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
}
}
},
"auth_ref": []
},
"dei_EntityWellKnownSeasonedIssuer": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityWellKnownSeasonedIssuer",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Well-known Seasoned Issuer",
"documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
}
}
},
"auth_ref": [
"r312"
]
},
"ecd_EqtyAwrdsAdjFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Awards Adjustments, Footnote [Text Block]",
"terseLabel": "Equity Awards Adjustments, Footnote"
}
}
},
"auth_ref": [
"r256"
]
},
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
"terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
}
}
},
"auth_ref": [
"r305"
]
},
"ecd_EqtyAwrdsAdjsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjsMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Awards Adjustments [Member]",
"terseLabel": "Equity Awards Adjustments"
}
}
},
"auth_ref": [
"r305"
]
},
"ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
"terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
}
}
},
"auth_ref": [
"r305"
]
},
"pbm_EquipmentScheduleofEquipmentDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "EquipmentScheduleofEquipmentDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"label": "Equipment - Schedule of Equipment (Details) [Table]"
}
}
},
"auth_ref": []
},
"ifrs-full_Equity": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "Equity",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_EquityAndLiabilities",
"weight": 1.0,
"order": 2.0
},
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "TOTAL SHAREHOLDERS EQUITY/(DEFICIT)",
"periodStartLabel": "Balance",
"periodEndLabel": "Balance",
"terseLabel": "NET DEFICIT",
"label": "Equity"
}
},
"en": {
"role": {
"documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
}
}
},
"auth_ref": [
"r12",
"r17",
"r87",
"r90",
"r102",
"r103",
"r105"
]
},
"ifrs-full_EquityAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "EquityAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "SHAREHOLDERS EQUITY/(DEFICIT)",
"verboseLabel": "EQUITY",
"label": "Equity [abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_EquityAndLiabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "EquityAndLiabilities",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "TOTAL LIABILITIES AND NET EQUITY",
"label": "Equity and liabilities"
}
},
"en": {
"role": {
"documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
}
}
},
"auth_ref": [
"r12"
]
},
"ifrs-full_EquityAttributableToOwnersOfParent": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "EquityAttributableToOwnersOfParent",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable": {
"parentTag": "ifrs-full_Equity",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Net equity",
"label": "Equity attributable to owners of parent"
}
},
"en": {
"role": {
"documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
}
}
},
"auth_ref": [
"r11"
]
},
"pbm_EquityLineOfCredit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "EquityLineOfCredit",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Equity line of credit",
"documentation": "The amount of equity line of credit.",
"label": "Equity Line Of Credit"
}
}
},
"auth_ref": []
},
"pbm_EquityLineOfCreditDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "EquityLineOfCreditDisclosureTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/ELOC"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "ELOC",
"documentation": "The entire disclosure of equity ine of credit.",
"label": "Equity Line Of Credit Disclosure Text Block"
}
}
},
"auth_ref": []
},
"ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EquityValuationAssumptionDifferenceFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
"terseLabel": "Equity Valuation Assumption Difference, Footnote"
}
}
},
"auth_ref": [
"r266"
]
},
"ecd_ErrCompAnalysisTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ErrCompAnalysisTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Erroneous Compensation Analysis [Text Block]",
"terseLabel": "Erroneous Compensation Analysis"
}
}
},
"auth_ref": [
"r215",
"r226",
"r242",
"r277"
]
},
"ecd_ErrCompRecoveryTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ErrCompRecoveryTable",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Erroneously Awarded Compensation Recovery [Table]",
"terseLabel": "Erroneously Awarded Compensation Recovery"
}
}
},
"auth_ref": [
"r212",
"r223",
"r239",
"r274"
]
},
"dei_ExchangeDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ExchangeDomain",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Exchange [Domain]",
"documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
}
}
},
"auth_ref": []
},
"ecd_ExecutiveCategoryAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ExecutiveCategoryAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Executive Category [Axis]",
"terseLabel": "Executive Category:"
}
}
},
"auth_ref": [
"r272"
]
},
"pbm_ExercisePriceMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExercisePriceMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Exercise price\t[Member]",
"documentation": "This member stands for exercise price used as a measurement input.",
"label": "Exercise Price Measurement Input Member"
}
}
},
"auth_ref": []
},
"ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
"xbrltype": "perShareItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ExercisePriceOfOutstandingShareOptions2019",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Weighted Average Exercise Price, Beginning",
"periodEndLabel": "Weighted Average Exercise Price, Ending",
"label": "Exercise price of outstanding share options"
}
},
"en": {
"role": {
"documentation": "The exercise price of outstanding share options."
}
}
},
"auth_ref": [
"r121"
]
},
"ifrs-full_ExercisePriceShareOptionsGranted2019": {
"xbrltype": "perShareItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ExercisePriceShareOptionsGranted2019",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Exercise price (in Dollars per share)",
"label": "Exercise price, share options granted"
}
},
"en": {
"role": {
"documentation": "The exercise price of share options granted."
}
}
},
"auth_ref": [
"r122"
]
},
"pbm_ExercisePriceWarrantMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExercisePriceWarrantMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Exercise price\t[Member]",
"label": "Exercise Price Warrant Member"
}
}
},
"auth_ref": []
},
"dei_ExhibitsOnly462d": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ExhibitsOnly462d",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Exhibits Only, 462(d)"
}
}
},
"auth_ref": [
"r317"
]
},
"dei_ExhibitsOnly462dFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ExhibitsOnly462dFileNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Exhibits Only, 462(d), File Number"
}
}
},
"auth_ref": [
"r317"
]
},
"ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
"xbrltype": "percentItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ExpectedDividendAsPercentageShareOptionsGranted",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expected dividend yield",
"label": "Expected dividend as percentage, share options granted"
}
},
"en": {
"role": {
"documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
}
}
},
"auth_ref": [
"r122"
]
},
"pbm_ExpectedDividendYieldMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExpectedDividendYieldMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expected dividend yield [Member]",
"documentation": "This member stands for expected dividend yield used as a measurement input.",
"label": "Expected Dividend Yield Measurement Input Member"
}
}
},
"auth_ref": []
},
"pbm_ExpectedDividendYieldWarrantMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExpectedDividendYieldWarrantMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expected dividend yield [Member]",
"label": "Expected Dividend Yield Warrant Member"
}
}
},
"auth_ref": []
},
"pbm_ExpectedLife": {
"xbrltype": "durationItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExpectedLife",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expected life",
"documentation": "Expected life.",
"label": "Expected Life"
}
}
},
"auth_ref": []
},
"pbm_ExpectedLifeMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExpectedLifeMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expected life [Member]",
"documentation": "This member stands for expected life used as a measurement input.",
"label": "Expected Life Measurement Input Member"
}
}
},
"auth_ref": []
},
"pbm_ExpectedLifeWarrantMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExpectedLifeWarrantMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expected life [Member]",
"label": "Expected Life Warrant Member"
}
}
},
"auth_ref": []
},
"pbm_ExpectedVolatilityWarrantMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExpectedVolatilityWarrantMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expected volatility [Member]",
"label": "Expected Volatility Warrant Member"
}
}
},
"auth_ref": []
},
"ifrs-full_ExpenseByNatureAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ExpenseByNatureAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expenses",
"label": "Expenses by nature [abstract]"
}
}
},
"auth_ref": []
},
"pbm_ExpiryDateMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExpiryDateMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expiry date [Member]",
"label": "Expiry Date Measurement Input Member"
}
}
},
"auth_ref": []
},
"pbm_ExpiryDateWarrantMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExpiryDateWarrantMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expiry date [Member]",
"label": "Expiry Date Warrant Member"
}
}
},
"auth_ref": []
},
"dei_Extension": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "Extension",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Extension",
"documentation": "Extension number for local phone number."
}
}
},
"auth_ref": []
},
"pbm_ExtinguishmentOfDebEquitytAmount": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ExtinguishmentOfDebEquitytAmount",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Extinguishment amount",
"documentation": "Amount of debt equity Extinguised.",
"label": "Extinguishment Of Deb Equityt Amount"
}
}
},
"auth_ref": []
},
"pbm_FairValueAdjustmentOnConvertibleNote": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueAdjustmentOnConvertibleNote",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 2.0
},
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": -1.0,
"order": 11.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value (gain)/loss on convertible note",
"negatedLabel": "Fair value gain/(loss) on convertible note",
"documentation": "Amount of expense (income) related to adjustment to fair value of convertible note.",
"label": "Fair Value Adjustment On Convertible Note"
}
}
},
"auth_ref": []
},
"pbm_FairValueAdjustmentOnPromissoryNote": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueAdjustmentOnPromissoryNote",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": -1.0,
"order": 13.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Fair value gain/(loss) on promissory notes",
"terseLabel": "Fair value gain on promissory notes",
"documentation": "Amount of expense (income) related to adjustment to fair value of promissory note.",
"label": "Fair Value Adjustment On Promissory Note"
}
}
},
"auth_ref": []
},
"pbm_FairValueAdjustmentsOnPromissoryNote": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueAdjustmentsOnPromissoryNote",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value (gain)/loss on promissory notes",
"documentation": "Amount of expense (income) related to adjustment to fair\r \n value of promissory note.",
"label": "Fair Value Adjustments On Promissory Note"
}
}
},
"auth_ref": []
},
"pbm_FairValueAllocationAssumptionsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueAllocationAssumptionsMember",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair Value Allocation Assumptions [Member]",
"label": "Fair Value Allocation Assumptions Member"
}
}
},
"auth_ref": []
},
"pbm_FairValueAllocationGrossProceeds": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueAllocationGrossProceeds",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails",
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Total gross proceeds",
"terseLabel": "Gross proceeds",
"documentation": "It represents fair value allocation on gross proceeds.",
"label": "Fair Value Allocation Gross Proceeds"
}
}
},
"auth_ref": []
},
"pbm_FairValueGainOnInvestment": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueGainOnInvestment",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": 1.0,
"order": 6.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value gain on investment in Psyence Labs Ltd",
"documentation": "The amount of fair value gain on investment.",
"label": "Fair Value Gain On Investment"
}
}
},
"auth_ref": []
},
"pbm_FairValueGainOnPsyenceLabsLtd": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueGainOnPsyenceLabsLtd",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 6.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value gain on Psyence Labs Ltd",
"documentation": "Amount of income related to adjustment to fair value of psyence labs ltd.",
"label": "Fair Value Gain On Psyence Labs Ltd"
}
}
},
"auth_ref": []
},
"pbm_FairValueGainRecognized": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueGainRecognized",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofInvestmentisClassifiedasaFinancialAssetMeasuredatFairValueTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value gain recognized",
"documentation": "Fair value gain recognized.",
"label": "Fair Value Gain Recognized"
}
}
},
"auth_ref": []
},
"pbm_FairValueLossOnWarrantExchange": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueLossOnWarrantExchange",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 5.0
},
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": -1.0,
"order": 14.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value loss on warrant exchange",
"negatedLabel": "Fair value loss on warrant exchange",
"documentation": "Amount of expense (income) related to adjustment to fair value of warrant exchange.",
"label": "Fair Value Loss On Warrant Exchange"
}
}
},
"auth_ref": []
},
"pbm_FairValueOfInvestment": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValueOfInvestment",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofInvestmentisClassifiedasaFinancialAssetMeasuredatFairValueTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value of investment at March 31, 2025",
"documentation": "Fair value of investment.",
"label": "Fair Value Of Investment"
}
}
},
"auth_ref": []
},
"pbm_FairValuegainlossOnWarrantLiability": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FairValuegainlossOnWarrantLiability",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value (gain)/loss on warrant liability",
"verboseLabel": "Amount, Fair value gain (loss)",
"documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
"label": "Fair Valuegainloss On Warrant Liability"
}
}
},
"auth_ref": []
},
"ifrs-full_FeeIncomeAndExpenseAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "FeeIncomeAndExpenseAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expenses",
"label": "Fee income and expense [abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_FinanceIncome": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "FinanceIncome",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Interest income",
"label": "Finance income"
}
},
"en": {
"role": {
"documentation": "The amount of income associated with interest and other financing activities of the entity."
}
}
},
"auth_ref": [
"r333"
]
},
"pbm_FinancialInstrumentsandFinancialRiskManagementScheduleofCarryingValueoftheFinancialInstrumentsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FinancialInstrumentsandFinancialRiskManagementScheduleofCarryingValueoftheFinancialInstrumentsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_FinancialInstrumentsandFinancialRiskManagementScheduleofMaturityoftheContractualObligationsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FinancialInstrumentsandFinancialRiskManagementScheduleofMaturityoftheContractualObligationsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details) [Table]"
}
}
},
"auth_ref": []
},
"ifrs-full_FinancialLiabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "FinancialLiabilities",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Carrying Amount",
"label": "Financial liabilities"
}
},
"en": {
"role": {
"documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
}
}
},
"auth_ref": [
"r130"
]
},
"ifrs-full_FinancialLiabilitiesAtFairValue": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "FinancialLiabilitiesAtFairValue",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails",
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Financial instruments at fair value",
"verboseLabel": "Fair value",
"netLabel": "Fair value of warrants (in Dollars)",
"label": "Financial liabilities, at fair value"
}
},
"en": {
"role": {
"documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
}
}
},
"auth_ref": [
"r130"
]
},
"pbm_FinancialLiabilitiesFairValuePerShare": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FinancialLiabilitiesFairValuePerShare",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Exercise price of warrants per share (in Dollars per share)",
"documentation": "Fair value per share of financial liabilities.",
"label": "Financial Liabilities Fair Value Per Share"
}
}
},
"auth_ref": []
},
"pbm_FinancialLiabilitiesUndiscountedCashFlows": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FinancialLiabilitiesUndiscountedCashFlows",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Contractual Cash Flows",
"documentation": "The amount of contractual undiscounted cash flows in relation to financial liabilities.",
"label": "Financial Liabilities Undiscounted Cash Flows"
}
}
},
"auth_ref": []
},
"pbm_FirstTrancheNoteMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "FirstTrancheNoteMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "First Tranche Note [Member]",
"documentation": "This member stands for First tranche note.",
"label": "First Tranche Note Member"
}
}
},
"auth_ref": []
},
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
"terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
}
}
},
"auth_ref": [
"r219",
"r230",
"r246",
"r281"
]
},
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery due to Expense of Enforcement, Amount",
"terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
}
}
},
"auth_ref": [
"r219",
"r230",
"r246",
"r281"
]
},
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery due to Violation of Home Country Law, Amount",
"terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
}
}
},
"auth_ref": [
"r219",
"r230",
"r246",
"r281"
]
},
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
"terseLabel": "Forgone Recovery, Explanation of Impracticability"
}
}
},
"auth_ref": [
"r219",
"r230",
"r246",
"r281"
]
},
"ecd_ForgoneRecoveryIndName": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryIndName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery, Individual Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r219",
"r230",
"r246",
"r281"
]
},
"dei_FormerAddressMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "FormerAddressMember",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Former Address [Member]",
"documentation": "Former address for entity"
}
}
},
"auth_ref": [
"r202",
"r233"
]
},
"dei_FormerFiscalYearEndDate": {
"xbrltype": "gMonthDayItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "FormerFiscalYearEndDate",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Former Fiscal Year End Date",
"documentation": "Former end date of previous fiscal years"
}
}
},
"auth_ref": []
},
"ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
"terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
}
}
},
"auth_ref": [
"r261"
]
},
"pbm_GainOnDebtSettlement": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "GainOnDebtSettlement",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": 1.0,
"order": 5.0
},
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": -1.0,
"order": 16.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Gain on debt settlement",
"negatedLabel": "Gain on debt settlement",
"documentation": "Represents the value of gain on debt settlement.",
"label": "Gain On Debt Settlement"
}
}
},
"auth_ref": []
},
"ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "GainsLossesOnChangeInFairValueOfDerivatives",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Change in fair value",
"verboseLabel": "Fair value loss (in Dollars)",
"label": "Gains (losses) on change in fair value of derivatives"
}
},
"en": {
"role": {
"documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
}
}
},
"auth_ref": [
"r333"
]
},
"ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": 1.0,
"order": 3.0
},
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Foreign exchange (loss)/gain",
"verboseLabel": "Foreign exchange gain",
"label": "Foreign exchange gain (loss)"
}
},
"en": {
"role": {
"documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]"
}
}
},
"auth_ref": [
"r5",
"r42"
]
},
"ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": {
"parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
"weight": -1.0,
"order": 7.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Non-taxable fair value gain adjustment",
"label": "Gains (losses) on financial assets at fair value through profit or loss"
}
},
"en": {
"role": {
"documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
}
}
},
"auth_ref": [
"r128"
]
},
"ifrs-full_GeneralAndAdministrativeExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "GeneralAndAdministrativeExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLossBeforeTax",
"weight": -1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "General and administrative",
"label": "General and administrative expense"
}
},
"en": {
"role": {
"documentation": "The amount of expense relating to general and administrative activities of the entity."
}
}
},
"auth_ref": [
"r327"
]
},
"ifrs-full_GeographicalAreasAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "GeographicalAreasAxis",
"presentation": [
"http://www.psyencebiomed.com/role/IncomeTaxNoteDetails",
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable",
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical areas [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r151",
"r162",
"r177",
"r179"
]
},
"ifrs-full_GeographicalAreasDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "GeographicalAreasDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical areas [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
}
}
},
"auth_ref": [
"r151",
"r162",
"r177",
"r179"
]
},
"ifrs-full_GrossCarryingAmountMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "GrossCarryingAmountMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Cost [Member]",
"label": "Gross carrying amount [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
}
}
},
"auth_ref": [
"r33",
"r68",
"r72",
"r75",
"r126",
"r133",
"r135",
"r181"
]
},
"pbm_GrossProceeds": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "GrossProceeds",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Gross proceeds (in Dollars)",
"documentation": "The amount of gross proceeds.",
"label": "Gross Proceeds"
}
}
},
"auth_ref": []
},
"ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "HistoricalVolatilityForSharesMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expected volatility [Member]",
"verboseLabel": "Volatility daily [Member]",
"label": "Historical volatility for shares, measurement input [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for the historical volatility for shares used as a measurement input."
}
}
},
"auth_ref": [
"r174"
]
},
"dei_IcfrAuditorAttestationFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "IcfrAuditorAttestationFlag",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "ICFR Auditor Attestation Flag"
}
}
},
"auth_ref": [
"r200",
"r203",
"r222"
]
},
"pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IfrsAccountsPayableAndAccruedLiabilitiesMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accounts payable & accrued liabilities [Member]",
"documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
"label": "Ifrs Accounts Payable And Accrued Liabilities Member"
}
}
},
"auth_ref": []
},
"pbm_IfrsClassOfWarrantOrRightAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IfrsClassOfWarrantOrRightAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Ifrs Class of Warrant or Right [Axis]",
"documentation": "Information by type of warrant or right issued.",
"label": "Ifrs Class Of Warrant Or Right Axis"
}
}
},
"auth_ref": []
},
"pbm_IfrsClassOfWarrantOrRightDomainDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IfrsClassOfWarrantOrRightDomainDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"label": "IfrsClassOfWarrantOrRightDomain [Domain]"
}
}
},
"auth_ref": []
},
"pbm_IfrsConvertibleDebtMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IfrsConvertibleDebtMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Convertible notes [Member]",
"documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
"label": "Ifrs Convertible Debt Member"
}
}
},
"auth_ref": []
},
"pbm_IfrsFairValueAdjustmentOfWarrants": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IfrsFairValueAdjustmentOfWarrants",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": -1.0,
"order": 12.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Fair value gain/(loss) on warrant liability",
"documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
"label": "Ifrs Fair Value Adjustment Of Warrants"
}
}
},
"auth_ref": []
},
"pbm_IfrsGainLossOnExtinguishmentOfDebt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IfrsGainLossOnExtinguishmentOfDebt",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Gain on debt settlement (in Dollars)",
"documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
"label": "Ifrs Gain Loss On Extinguishment Of Debt"
}
}
},
"auth_ref": []
},
"pbm_IfrsPromissoryNoteMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IfrsPromissoryNoteMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "PGI promissory note [Member]",
"documentation": "This member stands for promissory note.",
"label": "Ifrs Promissory Note Member"
}
}
},
"auth_ref": []
},
"pbm_IfrsTaxPeriodAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IfrsTaxPeriodAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable",
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "IFRS Tax Period [Axis]",
"documentation": "N/A",
"label": "Ifrs Tax Period Axis"
}
}
},
"auth_ref": []
},
"pbm_IfrsTaxPeriodDomainDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IfrsTaxPeriodDomainDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"label": "IfrsTaxPeriodDomain [Domain]"
}
}
},
"auth_ref": []
},
"ifrs-full_IncomeStatementAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IncomeStatementAbstract",
"lang": {
"en-us": {
"role": {
"label": "Profit or loss [abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_IncomeTaxExpenseContinuingOperations": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IncomeTaxExpenseContinuingOperations",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Income tax (recovery)/expense",
"label": "Tax expense (income)"
}
},
"en": {
"role": {
"documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
}
}
},
"auth_ref": [
"r23",
"r27",
"r28",
"r29",
"r53",
"r100",
"r144"
]
},
"pbm_IncomeTaxNoteDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IncomeTaxNoteDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/IncomeTaxNoteDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Note (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_IncomeTaxNoteLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IncomeTaxNoteLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/IncomeTaxNoteDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Note [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_IncomeTaxNoteScheduleofDeferredTaxAssetsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IncomeTaxNoteScheduleofDeferredTaxAssetsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Note - Schedule of Deferred Tax Assets (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_IncomeTaxNoteScheduleofNonCapitalLossCarryForwardsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IncomeTaxNoteScheduleofNonCapitalLossCarryForwardsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details) [Table]"
}
}
},
"auth_ref": []
},
"ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Reported [Member]",
"label": "Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for the financial effect of changes in accounting policy for cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. [Refer: IFRSs [member]]"
}
}
},
"auth_ref": [
"r325"
]
},
"ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IncreaseDecreaseInCashAndCashEquivalents",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Change in cash and cash equivalents",
"terseLabel": "Change in cash and cash equivalents",
"label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
}
},
"en": {
"role": {
"documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
}
}
},
"auth_ref": [
"r79"
]
},
"pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Impact to net loss and comprehensive loss",
"documentation": "The increase (decrease) in profit and loss as a result of an change in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations.",
"label": "Increase Decrease In Profit Or Loss Due To Reasonably Possible Change In Designated Risk Component"
}
}
},
"auth_ref": []
},
"pbm_IncreaseDecreaseInWorkingCapitalAbstractAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IncreaseDecreaseInWorkingCapitalAbstractAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Changes in working capital:",
"label": "Increase Decrease In Working Capital Abstract Abstract"
}
}
},
"auth_ref": []
},
"ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Equity on conversion",
"label": "Increase (decrease) through conversion of convertible instruments, equity"
}
},
"en": {
"role": {
"documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
}
}
},
"auth_ref": [
"r324"
]
},
"ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of warrants",
"label": "Increase (decrease) through exercise of warrants, equity"
}
},
"en": {
"role": {
"documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
}
}
},
"auth_ref": [
"r324"
]
},
"ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IncreaseDecreaseThroughOtherContributionsByOwners",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Psyence Group Inc contribution",
"label": "Increase through other contributions by owners, equity"
}
},
"en": {
"role": {
"documentation": "The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note."
}
}
},
"auth_ref": [
"r2"
]
},
"pbm_IndefinitePeriodMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IndefinitePeriodMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Indefinite [Member]",
"documentation": "Represents the indefinite period.",
"label": "Indefinite Period Member"
}
}
},
"auth_ref": []
},
"ecd_IndividualAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "IndividualAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Individual [Axis]",
"terseLabel": "Individual:"
}
}
},
"auth_ref": [
"r219",
"r230",
"r246",
"r272",
"r281",
"r285",
"r293"
]
},
"ecd_InsiderTradingArrLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTradingArrLineItems",
"lang": {
"en-us": {
"role": {
"label": "Insider Trading Arrangements [Line Items]",
"terseLabel": "Insider Trading Arrangements:"
}
}
},
"auth_ref": [
"r291"
]
},
"ecd_InsiderTradingPoliciesProcLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTradingPoliciesProcLineItems",
"lang": {
"en-us": {
"role": {
"label": "Insider Trading Policies and Procedures [Line Items]",
"terseLabel": "Insider Trading Policies and Procedures:"
}
}
},
"auth_ref": [
"r204",
"r297"
]
},
"ecd_InsiderTrdPoliciesProcAdoptedFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTrdPoliciesProcAdoptedFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
],
"lang": {
"en-us": {
"role": {
"label": "Insider Trading Policies and Procedures Adopted [Flag]",
"terseLabel": "Insider Trading Policies and Procedures Adopted"
}
}
},
"auth_ref": [
"r204",
"r297"
]
},
"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
],
"lang": {
"en-us": {
"role": {
"label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
"terseLabel": "Insider Trading Policies and Procedures Not Adopted"
}
}
},
"auth_ref": [
"r204",
"r297"
]
},
"ifrs-full_InterestExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "InterestExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": -1.0,
"order": 8.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Interest expense",
"label": "Interest expense"
}
},
"en": {
"role": {
"documentation": "The amount of expense arising from interest."
}
}
},
"auth_ref": [
"r99",
"r143",
"r149"
]
},
"ifrs-full_InterestExpenseOnBorrowings": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "InterestExpenseOnBorrowings",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Interest expense",
"label": "Interest expense on borrowings"
}
},
"en": {
"role": {
"documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
}
}
},
"auth_ref": [
"r327"
]
},
"ifrs-full_InterestRateMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "InterestRateMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Risk-free interest rate [Member]",
"verboseLabel": "Risk free annual [Member]",
"label": "Interest rate, measurement input [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for an interest rate used as a measurement input."
}
}
},
"auth_ref": [
"r173"
]
},
"dei_InvestmentCompanyActFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "InvestmentCompanyActFileNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Investment Company Act File Number"
}
}
},
"auth_ref": [
"r235",
"r236",
"r237",
"r238"
]
},
"dei_InvestmentCompanyActRegistration": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "InvestmentCompanyActRegistration",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Investment Company Act Registration"
}
}
},
"auth_ref": [
"r251"
]
},
"dei_InvestmentCompanyRegistrationAmendment": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "InvestmentCompanyRegistrationAmendment",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Investment Company Registration Amendment"
}
}
},
"auth_ref": [
"r251"
]
},
"dei_InvestmentCompanyRegistrationAmendmentNumber": {
"xbrltype": "sequenceNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "InvestmentCompanyRegistrationAmendmentNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Investment Company Registration Amendment Number"
}
}
},
"auth_ref": [
"r251"
]
},
"pbm_InvestmentInPsyenceLabsLtdMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "InvestmentInPsyenceLabsLtdMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Investment in Psyence Labs Ltd [Member]",
"label": "Investment In Psyence Labs Ltd Member"
}
}
},
"auth_ref": []
},
"ifrs-full_InvestmentPropertyFairValueUsedAsDeemedCost": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "InvestmentPropertyFairValueUsedAsDeemedCost",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value of investment",
"label": "Investment property fair value used as deemed cost"
}
},
"en": {
"role": {
"documentation": "The amount of investment property, for which fair value was used as deemed cost in the opening IFRS statement of financial position. [Refer: Investment property]"
}
}
},
"auth_ref": [
"r89"
]
},
"ifrs-full_InvestmentsInAssociates": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "InvestmentsInAssociates",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Assets",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Investment in Psyence Labs Ltd",
"label": "Investments in associates reported in separate financial statements"
}
},
"en": {
"role": {
"documentation": "The amount of investments in associates in an entity's separate financial statements. [Refer: Total for all associates [member]]"
}
}
},
"auth_ref": [
"r54"
]
},
"pbm_InvestorsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "InvestorsMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Investors [Member]",
"documentation": "This member stands for investors.",
"label": "Investors Member"
}
}
},
"auth_ref": []
},
"pbm_IssuanceCosts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IssuanceCosts",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails",
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance costs",
"documentation": "The amount of issuance costs.",
"label": "Issuance Costs"
}
}
},
"auth_ref": []
},
"pbm_IssuanceOfAdditionalShare": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IssuanceOfAdditionalShare",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of additional share",
"documentation": "Issuance of additional share.",
"label": "Issuance Of Additional Share"
}
}
},
"auth_ref": []
},
"pbm_IssuanceOfSharesForConvertibleNote": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IssuanceOfSharesForConvertibleNote",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Shares issued on conversion of convertible note",
"documentation": "Represent the amaount of issuance of shares for convertible note.",
"label": "Issuance Of Shares For Convertible Note"
}
}
},
"auth_ref": []
},
"pbm_IssuanceOfSharesForPsyenceLabsLtdShares": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IssuanceOfSharesForPsyenceLabsLtdShares",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Shares issued for PsyLabs share exchange",
"documentation": "Represent the amount of issuance of shares for Psyence Labs Ltd shares.",
"label": "Issuance Of Shares For Psyence Labs Ltd Shares"
}
}
},
"auth_ref": []
},
"pbm_IssuanceOfSharesForWarrantExchange": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IssuanceOfSharesForWarrantExchange",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Common shares, Warrant exchange",
"documentation": "Represent the amount of issuance of shares for warrant exchange.",
"label": "Issuance Of Shares For Warrant Exchange"
}
}
},
"auth_ref": []
},
"ifrs-full_IssueOfEquity": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IssueOfEquity",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares to Psyence Group Inc",
"verboseLabel": "Deemed consideration amount for the common shares issued",
"label": "Issue of equity"
}
},
"en": {
"role": {
"documentation": "The increase in equity through the issue of equity instruments."
}
}
},
"auth_ref": [
"r2"
]
},
"pbm_IssuedAndOutstandingWarrantsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "IssuedAndOutstandingWarrantsMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issued and Outstanding Warrants [Member]",
"label": "Issued And Outstanding Warrants Member"
}
}
},
"auth_ref": []
},
"ifrs-full_IssuedCapital": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IssuedCapital",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Equity",
"weight": 1.0,
"order": 1.0
},
"http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable": {
"parentTag": "ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails",
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Opening balance",
"periodEndLabel": "Amount of Common shares Ending balance",
"terseLabel": "Share Capital",
"verboseLabel": "Share capital",
"label": "Issued capital"
}
},
"en": {
"role": {
"documentation": "The nominal value of capital issued."
}
}
},
"auth_ref": [
"r158"
]
},
"ifrs-full_IssuedCapitalAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IssuedCapitalAbstract",
"lang": {
"en-us": {
"role": {
"label": "Capital Management [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_IssuedCapitalMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IssuedCapitalMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share capital",
"verboseLabel": "Issued Capital [Member]",
"label": "Issued capital [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a component of equity representing issued capital."
}
}
},
"auth_ref": [
"r3"
]
},
"ifrs-full_IssuedCapitalOrdinaryShares": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "IssuedCapitalOrdinaryShares",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable": {
"parentTag": "pbm_FairValueAllocationGrossProceeds",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails",
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Common shares",
"verboseLabel": "Fair value of shares issued",
"label": "Issued capital, ordinary shares"
}
},
"en": {
"role": {
"documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]"
}
}
},
"auth_ref": [
"r330"
]
},
"ifrs-full_KeyManagementPersonnelCompensation": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "KeyManagementPersonnelCompensation",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Total",
"label": "Key management personnel compensation"
}
},
"en": {
"role": {
"documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
}
}
},
"auth_ref": [
"r46"
]
},
"ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "KeyManagementPersonnelCompensationSharebasedPayment",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable": {
"parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share based compensation",
"label": "Key management personnel compensation, share-based payment"
}
},
"en": {
"role": {
"documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
}
}
},
"auth_ref": [
"r45"
]
},
"ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable": {
"parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Short term benefits",
"label": "Key management personnel compensation, short-term employee benefits"
}
},
"en": {
"role": {
"documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
}
}
},
"auth_ref": [
"r44"
]
},
"ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "\u200bBetween 1 and 3 years [Member]",
"label": "Later than one year and not later than three years [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a time band of later than one year and not later than three years."
}
}
},
"auth_ref": [
"r182",
"r183",
"r185"
]
},
"dei_LegalEntityAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LegalEntityAxis",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Legal Entity [Axis]",
"documentation": "The set of legal entities associated with a report."
}
}
},
"auth_ref": []
},
"dei_LegalEntityIdentifier": {
"xbrltype": "legalEntityIdentifierItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LegalEntityIdentifier",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Legal Entity Identifier",
"documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
}
}
},
"auth_ref": [
"r188"
]
},
"ifrs-full_Level1OfFairValueHierarchyMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "Level1OfFairValueHierarchyMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Level 1 [Member]",
"label": "Level 1 of fair value hierarchy [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
}
}
},
"auth_ref": [
"r41",
"r66",
"r67",
"r103"
]
},
"ifrs-full_Level2OfFairValueHierarchyMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "Level2OfFairValueHierarchyMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Level 2 fair value measurements [Member]",
"verboseLabel": "Level 2 [Member]",
"label": "Level 2 of fair value hierarchy [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
}
}
},
"auth_ref": [
"r66",
"r67",
"r103"
]
},
"ifrs-full_Level3OfFairValueHierarchyMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "Level3OfFairValueHierarchyMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Level 3 [Member]",
"label": "Level 3 of fair value hierarchy [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
}
}
},
"auth_ref": [
"r66",
"r67",
"r103"
]
},
"ifrs-full_LevelsOfFairValueHierarchyAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "LevelsOfFairValueHierarchyAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Levels of fair value hierarchy [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r41",
"r103"
]
},
"ifrs-full_LevelsOfFairValueHierarchyDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "LevelsOfFairValueHierarchyDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Levels of fair value hierarchy [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
}
}
},
"auth_ref": [
"r41",
"r103"
]
},
"ifrs-full_Liabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "Liabilities",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_EquityAndLiabilities",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "TOTAL LIABILITIES",
"label": "Liabilities"
}
},
"en": {
"role": {
"documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
}
}
},
"auth_ref": [
"r12",
"r102",
"r103",
"r105",
"r145",
"r148"
]
},
"ifrs-full_LiabilitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "LiabilitiesAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "LIABILITIES",
"label": "Liabilities [abstract]"
}
}
},
"auth_ref": []
},
"pbm_LineOfCreditAtFairValueAmount": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "LineOfCreditAtFairValueAmount",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value amount",
"documentation": "The amount of line of credit at fair value.",
"label": "Line Of Credit At Fair Value Amount"
}
}
},
"auth_ref": []
},
"pbm_ListingExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ListingExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": -1.0,
"order": 9.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Listing expense",
"documentation": "The amount of listing expense.",
"label": "Listing Expense"
}
}
},
"auth_ref": []
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LocalPhoneNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
"lang": {
"en-us": {
"role": {
"label": "Income Tax Note [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_MajorOrdinaryShareTransactionsMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "MajorOrdinaryShareTransactionsMember",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Subsequent Events [Member]",
"label": "Major ordinary share transactions [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
}
}
},
"auth_ref": [
"r161"
]
},
"pbm_MaterialAccountingPoliciesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "MaterialAccountingPoliciesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Material Accounting Policies [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_MaterialAccountingPoliciesScheduleofChangeinPresentationCurrencyDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "MaterialAccountingPoliciesScheduleofChangeinPresentationCurrencyDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"label": "Material Accounting Policies - \u200bSchedule of Change in Presentation Currency (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_MaterialAccountingPoliciesScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "MaterialAccountingPoliciesScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"label": "Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details) [Table]"
}
}
},
"auth_ref": []
},
"ifrs-full_MaturityAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "MaturityAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Maturity [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r14",
"r109",
"r110",
"r111",
"r112",
"r113",
"r114",
"r115",
"r129",
"r137",
"r164",
"r182"
]
},
"ifrs-full_MaturityDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "MaturityDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Maturity [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
}
}
},
"auth_ref": [
"r14",
"r109",
"r110",
"r111",
"r112",
"r113",
"r114",
"r115",
"r129",
"r164",
"r182",
"r184"
]
},
"pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram": {
"xbrltype": "percentItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Percentage of rebate",
"documentation": "The maximum percentage of rebate for the research & development expenses under the research & development tax incentive program.",
"label": "Maximum Percentage Of Rebate On Research Development Tax Incentive Program"
}
}
},
"auth_ref": []
},
"ecd_MeasureAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MeasureAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Measure [Axis]",
"terseLabel": "Measure:"
}
}
},
"auth_ref": [
"r264"
]
},
"ecd_MeasureName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MeasureName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Measure Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r264"
]
},
"pbm_MeasurementsOfFinancialAssetsAndLiabilities": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "MeasurementsOfFinancialAssetsAndLiabilities",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Measurement",
"documentation": "measurements of financial assets and liabilities.",
"label": "Measurements Of Financial Assets And Liabilities"
}
}
},
"auth_ref": []
},
"ecd_MnpiDiscTimedForCompValFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MnpiDiscTimedForCompValFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "MNPI Disclosure Timed for Compensation Value [Flag]",
"terseLabel": "MNPI Disclosure Timed for Compensation Value"
}
}
},
"auth_ref": [
"r284"
]
},
"ecd_MtrlTermsOfTrdArrTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MtrlTermsOfTrdArrTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Material Terms of Trading Arrangement [Text Block]",
"terseLabel": "Material Terms of Trading Arrangement"
}
}
},
"auth_ref": [
"r292"
]
},
"pbm_NCACNoteMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NCACNoteMember",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "NCAC Note [Member]",
"label": "NCACNote Member"
}
}
},
"auth_ref": []
},
"dei_NameChangeEventDateAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "NameChangeEventDateAxis",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Name Change Event Date [Axis]",
"documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
}
}
},
"auth_ref": []
},
"dei_NameChangeEventLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "NameChangeEventLineItems",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Name Change Event [Line Items]",
"documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
}
}
},
"auth_ref": []
},
"dei_NameChangeEventTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "NameChangeEventTable",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Name Change Event [Table]",
"documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
}
}
},
"auth_ref": []
},
"ecd_NamedExecutiveOfficersFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NamedExecutiveOfficersFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Named Executive Officers, Footnote [Text Block]",
"terseLabel": "Named Executive Officers, Footnote"
}
}
},
"auth_ref": [
"r265"
]
},
"pbm_NatureOfOperationsAndGoingConcernAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NatureOfOperationsAndGoingConcernAbstract",
"lang": {
"en-us": {
"role": {
"label": "Nature of Operations and Going Concern [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_NcacMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NcacMember",
"presentation": [
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails",
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable",
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "NCAC [Member]",
"documentation": "This member stands for Newcourt Acquisition Corp (NCAC).",
"label": "Ncac Member"
}
}
},
"auth_ref": []
},
"pbm_NcacSponsorMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NcacSponsorMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "NCAC Sponsor",
"verboseLabel": "NCAC Sponsor promissory note [Member]",
"documentation": "This member stands for Newcourt Acquisition Corp (NCAC) Sponsor.",
"label": "Ncac Sponsor Member"
}
}
},
"auth_ref": []
},
"ifrs-full_NetAssetsLiabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NetAssetsLiabilities",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"negatedTotalLabel": "Net liabilities acquired",
"label": "Assets (liabilities)"
}
},
"en": {
"role": {
"documentation": "The amount of assets less the amount of liabilities."
}
}
},
"auth_ref": [
"r170",
"r327"
]
},
"pbm_NetIdentifiableLiabilitiesAcquiredAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NetIdentifiableLiabilitiesAcquiredAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Net identifiable liabilities acquired:",
"label": "Net Identifiable Liabilities Acquired Abstract"
}
}
},
"auth_ref": []
},
"us-gaap_NetIncomeLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLoss",
"crdr": "credit",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Net Income (Loss)",
"terseLabel": "Net Income (Loss)"
}
}
},
"auth_ref": []
},
"pbm_NetProceedsReceivedFromELOC": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NetProceedsReceivedFromELOC",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Net proceeds received from ELOC",
"documentation": "The cash inflow from received from the of (ELOC) ordinary shares.",
"label": "Net Proceeds Received From ELOC"
}
}
},
"auth_ref": []
},
"dei_NewEffectiveDateForPreviousFiling": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "NewEffectiveDateForPreviousFiling",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "New Effective Date for Previous Filing"
}
}
},
"auth_ref": [
"r235",
"r236",
"r237",
"r238"
]
},
"pbm_NewcourtAcquisitionCorpMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NewcourtAcquisitionCorpMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Newcourt Acquisition Corp. [Member]",
"label": "Newcourt Acquisition Corp Member"
}
}
},
"auth_ref": []
},
"dei_NoSubstantiveChanges462c": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "NoSubstantiveChanges462c",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "No Substantive Changes, 462(c)"
}
}
},
"auth_ref": [
"r316"
]
},
"dei_NoSubstantiveChanges462cFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "NoSubstantiveChanges462cFileNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "No Substantive Changes, 462(c), File Number"
}
}
},
"auth_ref": [
"r316"
]
},
"dei_NoTradingSymbolFlag": {
"xbrltype": "trueItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "NoTradingSymbolFlag",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "No Trading Symbol Flag",
"documentation": "Boolean flag that is true only for a security having no trading symbol."
}
}
},
"auth_ref": []
},
"pbm_NonCapitalLossCarryForwards": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NonCapitalLossCarryForwards",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Non-capital loss carry forwards",
"documentation": "Amount of non-capital loss carry forwards.",
"label": "Non Capital Loss Carry Forwards"
}
}
},
"auth_ref": []
},
"pbm_NonCapitalLossesCarriedForwardMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NonCapitalLossesCarriedForwardMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Non-capital losses carried forward [Member]",
"label": "Non Capital Losses Carried Forward Member"
}
}
},
"auth_ref": []
},
"ecd_NonGaapMeasureDescriptionTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonGaapMeasureDescriptionTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-GAAP Measure Description [Text Block]",
"terseLabel": "Non-GAAP Measure Description"
}
}
},
"auth_ref": [
"r264"
]
},
"ecd_NonNeosMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonNeosMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-NEOs [Member]",
"terseLabel": "Non-NEOs"
}
}
},
"auth_ref": [
"r219",
"r230",
"r246",
"r272",
"r281"
]
},
"ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonPeoNeoAvgCompActuallyPaidAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-PEO NEO Average Compensation Actually Paid Amount",
"terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
}
}
},
"auth_ref": [
"r255"
]
},
"ecd_NonPeoNeoAvgTotalCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonPeoNeoAvgTotalCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-PEO NEO Average Total Compensation Amount",
"terseLabel": "Non-PEO NEO Average Total Compensation Amount"
}
}
},
"auth_ref": [
"r254"
]
},
"ecd_NonPeoNeoMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonPeoNeoMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-PEO NEO [Member]",
"terseLabel": "Non-PEO NEO"
}
}
},
"auth_ref": [
"r272"
]
},
"ecd_NonRule10b51ArrAdoptedFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrAdoptedFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
"terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
}
}
},
"auth_ref": [
"r292"
]
},
"ecd_NonRule10b51ArrTrmntdFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrTrmntdFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
"terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
}
}
},
"auth_ref": [
"r292"
]
},
"ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NonadjustingEventsAfterReportingPeriodAxis",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Non-adjusting events after reporting period [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r25"
]
},
"ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NonadjustingEventsAfterReportingPeriodDomain",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Non-adjusting events after reporting period [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
}
}
},
"auth_ref": [
"r25"
]
},
"ifrs-full_NoncurrentLiabilitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NoncurrentLiabilitiesAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Non-current assets",
"label": "Non-current liabilities [abstract]"
}
}
},
"auth_ref": []
},
"pbm_NondeductibleLossOnLoanSettlement": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NondeductibleLossOnLoanSettlement",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": {
"parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Non-deductible loss on loan settlement",
"documentation": "Represent the amount of non-deductible loss on loan settlement.",
"label": "Nondeductible Loss On Loan Settlement"
}
}
},
"auth_ref": []
},
"ifrs-full_NotLaterThanOneYearMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NotLaterThanOneYearMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "\u200bLess than 1 year [Member]",
"label": "Not later than one year [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a time band of not later than one year."
}
}
},
"auth_ref": [
"r13",
"r110",
"r111",
"r115",
"r182",
"r185"
]
},
"pbm_NotePrincipalAmountMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NotePrincipalAmountMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Note principal amount [Member]",
"label": "Note Principal Amount Measurement Input Member"
}
}
},
"auth_ref": []
},
"ifrs-full_NotionalAmount": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NotionalAmount",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/OtherIncomeDetails",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Aggregate principal amount",
"verboseLabel": "Principal amount of debt issued",
"netLabel": "Borrowed amount",
"label": "Notional amount"
}
},
"en": {
"role": {
"documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
}
}
},
"auth_ref": [
"r327"
]
},
"pbm_NumberOfCommonSharesCommitmentSharesELOC": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfCommonSharesCommitmentSharesELOC",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Common shares, Commitment shares ELOC",
"documentation": "Number of Common shares, Commitment shares ELOC.",
"label": "Number Of Common Shares Commitment Shares ELOC"
}
}
},
"auth_ref": []
},
"pbm_NumberOfCommonSharesShareIssuanceCostsForELOC": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfCommonSharesShareIssuanceCostsForELOC",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Common shares, Share issuance costs for ELOC",
"documentation": "Number of Common shares, Share issuance costs for ELOC.",
"label": "Number Of Common Shares Share Issuance Costs For ELOC"
}
}
},
"auth_ref": []
},
"pbm_NumberOfCommonSharesShareIssuanceCostsForPIPEFinancing": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfCommonSharesShareIssuanceCostsForPIPEFinancing",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Common shares, Share issuance costs for PIPE financing",
"documentation": "Number of Common shares, Share issuance costs for PIPE financing.",
"label": "Number Of Common Shares Share Issuance Costs For PIPEFinancing"
}
}
},
"auth_ref": []
},
"pbm_NumberOfCommonSharesSharesIssuanceCostsForPIPEPrefundedWarrantsExercised": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfCommonSharesSharesIssuanceCostsForPIPEPrefundedWarrantsExercised",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised",
"documentation": "Number of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised.",
"label": "Number Of Common Shares Shares Issuance Costs For PIPEPrefunded Warrants Exercised"
}
}
},
"auth_ref": []
},
"pbm_NumberOfCommonSharesSharesIssuedForELOC": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfCommonSharesSharesIssuedForELOC",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Common shares, Shares issued for ELOC",
"documentation": "Number of Common shares, Shares issued for ELOC.",
"label": "Number Of Common Shares Shares Issued For ELOC"
}
}
},
"auth_ref": []
},
"pbm_NumberOfCommonSharesSharesIssuedForPIPEPrefundedWarrantsExercised": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfCommonSharesSharesIssuedForPIPEPrefundedWarrantsExercised",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Common shares, Shares issued for PIPE pre-funded warrants exercised",
"documentation": "Number of Common shares, Shares issued for PIPE pre-funded warrants exercised.",
"label": "Number Of Common Shares Shares Issued For PIPEPrefunded Warrants Exercised"
}
}
},
"auth_ref": []
},
"pbm_NumberOfCommonSharesSharesIssuedOnConversionOfConvertibleNoteWarrants": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfCommonSharesSharesIssuedOnConversionOfConvertibleNoteWarrants",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Common shares, Shares issued on conversion of convertible note warrants",
"documentation": "Number of Common shares, Shares issued on conversion of convertible note warrants.",
"label": "Number Of Common Shares Shares Issued On Conversion Of Convertible Note Warrants"
}
}
},
"auth_ref": []
},
"pbm_NumberOfCommonSharesSharesIssuedOnConversionOfNCACPromissoryNotes": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfCommonSharesSharesIssuedOnConversionOfNCACPromissoryNotes",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Common shares, Shares issued on conversion of NCAC promissory notes",
"documentation": "Number of Common shares, Shares issued on conversion of NCAC promissory notes.",
"label": "Number Of Common Shares Shares Issued On Conversion Of NCACPromissory Notes"
}
}
},
"auth_ref": []
},
"pbm_NumberOfCommonSharesSharesIssuedOnConversionOfPGIPromissoryNotes": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfCommonSharesSharesIssuedOnConversionOfPGIPromissoryNotes",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Common shares, Shares issued on conversion of PGI promissory notes",
"documentation": "Number of Common shares, Shares issued on conversion of PGI promissory notes.",
"label": "Number Of Common Shares Shares Issued On Conversion Of PGIPromissory Notes"
}
}
},
"auth_ref": []
},
"ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
"xbrltype": "decimalItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
"presentation": [
"http://www.psyencebiomed.com/role/ShareBasedCompensationDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Restricted stock units issued",
"label": "Number of other equity instruments granted in share-based payment arrangement"
}
},
"en": {
"role": {
"documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
}
}
},
"auth_ref": [
"r123",
"r349"
]
},
"pbm_NumberOfShareIssuedWarrantLiability": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfShareIssuedWarrantLiability",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Number of shares, Opening balance",
"periodEndLabel": "Number of shares, Balance ending",
"documentation": "The number of share issued in warrant liability.",
"label": "Number Of Share Issued Warrant Liability"
}
}
},
"auth_ref": []
},
"ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
"xbrltype": "decimalItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Exercisable per share",
"label": "Number of share options exercisable in share-based payment arrangement"
}
},
"en": {
"role": {
"documentation": "The number of share options exercisable in a share-based payment arrangement."
}
}
},
"auth_ref": [
"r119"
]
},
"ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
"xbrltype": "decimalItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
"presentation": [
"http://www.psyencebiomed.com/role/ShareBasedCompensationDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share option issued",
"label": "Number of share options granted in share-based payment arrangement"
}
},
"en": {
"role": {
"documentation": "The number of share options granted in a share-based payment arrangement."
}
}
},
"auth_ref": [
"r118"
]
},
"pbm_NumberOfSharesConvertibleNoteTerminationAgreementWarrantsExercised": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesConvertibleNoteTerminationAgreementWarrantsExercised",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares warrants convertible note Termination Agreement warrants exercised",
"documentation": "Number of shares convertible note termination agreement warrants exercised.",
"label": "Number Of Shares Convertible Note Termination Agreement Warrants Exercised"
}
}
},
"auth_ref": []
},
"pbm_NumberOfSharesInFairValueGainloss": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesInFairValueGainloss",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares, Fair value gain (loss)",
"documentation": "The number of share in Fair value gain loss.",
"label": "Number Of Shares In Fair Value Gainloss"
}
}
},
"auth_ref": []
},
"pbm_NumberOfSharesInPsyLabAcquired": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesInPsyLabAcquired",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofInvestmentisClassifiedasaFinancialAssetMeasuredatFairValueTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares in PsyLabs acquired (in Shares)",
"documentation": "Number of shares in PsyLabs acquired.",
"label": "Number Of Shares In Psy Lab Acquired"
}
}
},
"auth_ref": []
},
"pbm_NumberOfSharesIssuanceCostsForPIPEFinancingWarrants": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesIssuanceCostsForPIPEFinancingWarrants",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares warrants Issuance costs for PIPE financing warrants",
"documentation": "Number of shares Issuance costs for PIPE financing warrants.",
"label": "Number Of Shares Issuance Costs For PIPEFinancing Warrants"
}
}
},
"auth_ref": []
},
"pbm_NumberOfSharesIssuanceCostsForPIPEPrefundedWarrantsExercised": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesIssuanceCostsForPIPEPrefundedWarrantsExercised",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares Issuance costs for PIPE pre-funded warrants exercised",
"documentation": "Number of shares Issuance costs for PIPE pre-funded warrants exercised.",
"label": "Number Of Shares Issuance Costs For PIPEPrefunded Warrants Exercised"
}
}
},
"auth_ref": []
},
"ifrs-full_NumberOfSharesIssued": {
"xbrltype": "sharesItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NumberOfSharesIssued",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/ELOCDetails",
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails",
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails",
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails",
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable",
"http://www.psyencebiomed.com/role/ShareCapitalDetails",
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Opening balance",
"periodEndLabel": "Number of Common shares, Ending balance",
"terseLabel": "Total consideration shares issued (in Shares)",
"verboseLabel": "Common shares issued",
"netLabel": "Common shares, issued (in Shares)",
"label": "Shares issued (in Shares)",
"totalLabel": "Common stock shares issued (in Shares)"
}
},
"en": {
"role": {
"documentation": "The number of shares issued by the entity."
}
}
},
"auth_ref": [
"r324"
]
},
"ifrs-full_NumberOfSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "NumberOfSharesOutstanding",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalDetails",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Balance (in Shares)",
"periodEndLabel": "Balance (in Shares)",
"terseLabel": "Number of shares outstanding",
"label": "Number of shares outstanding"
}
},
"en": {
"role": {
"documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
}
}
},
"auth_ref": [
"r19"
]
},
"pbm_NumberOfSharesPIPEFinancingWarrantIssuance": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesPIPEFinancingWarrantIssuance",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares warrants PIPE financing warrant issuance",
"documentation": "Number of shares PIPE financing warrant issuance.",
"label": "Number Of Shares PIPEFinancing Warrant Issuance"
}
}
},
"auth_ref": []
},
"pbm_NumberOfSharesPIPEFinancingWarrantIssuanceCosts": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesPIPEFinancingWarrantIssuanceCosts",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares PIPE warrants financing warrant issuance costs",
"documentation": "Number of shares PIPE financing warrant issuance costs.",
"label": "Number Of Shares PIPEFinancing Warrant Issuance Costs"
}
}
},
"auth_ref": []
},
"pbm_NumberOfSharesPIPEPrefundedWarrantsExercised": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesPIPEPrefundedWarrantsExercised",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares warrants PIPE pre-funded warrants exercised",
"documentation": "Number of shares PIPE pre-funded warrants exercised.",
"label": "Number Of Shares PIPEPrefunded Warrants Exercised"
}
}
},
"auth_ref": []
},
"pbm_NumberOfSharesWarrantsIssuedForConvertibleNoteAddendum": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesWarrantsIssuedForConvertibleNoteAddendum",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares Warrants issued for convertible note Addendum",
"documentation": "Number of shares Warrants issued for convertible note Addendum.",
"label": "Number Of Shares Warrants Issued For Convertible Note Addendum"
}
}
},
"auth_ref": []
},
"pbm_NumberOfSharesWarrantsIssuedForConvertibleNoteTerminationAgreement": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfSharesWarrantsIssuedForConvertibleNoteTerminationAgreement",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares Warrants issued for convertible note Termination Agreement\tt",
"documentation": "Number of shares warrants issued for convertible note termination agreement.",
"label": "Number Of Shares Warrants Issued For Convertible Note Termination Agreement"
}
}
},
"auth_ref": []
},
"pbm_NumberOfWarrantExercisable": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfWarrantExercisable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Warrants Exercisable",
"documentation": "Represents the number of warrants exercisable.",
"label": "Number Of Warrant Exercisable"
}
}
},
"auth_ref": []
},
"pbm_NumberOfWarrantOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfWarrantOutstanding",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Warrants Outstanding",
"verboseLabel": "Warrants outstanding",
"documentation": "Number of warrants outstanding.",
"label": "Number Of Warrant Outstanding"
}
}
},
"auth_ref": []
},
"pbm_NumberOfWarrantPurchased": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfWarrantPurchased",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of warrant purchased",
"documentation": "Number of warrants purchased.",
"label": "Number Of Warrant Purchased"
}
}
},
"auth_ref": []
},
"pbm_NumberOfWarrantsExercisable": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfWarrantsExercisable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Warrants Exercisable",
"documentation": "Number of warrants exercisable.",
"label": "Number Of Warrants Exercisable"
}
}
},
"auth_ref": []
},
"pbm_NumberOfWarrantsIssued": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfWarrantsIssued",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of warrants issued",
"verboseLabel": "Pre-funded warrants",
"documentation": "Number of warrants issued.",
"label": "Number Of Warrants Issued"
}
}
},
"auth_ref": []
},
"pbm_NumberOfWarrantsOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfWarrantsOutstanding",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails",
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable",
"http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Number of Warrants, Beginning",
"periodEndLabel": "Number of Warrants, Ending",
"terseLabel": "Number of warrants Outstanding",
"verboseLabel": "Purchase of common shares warrants",
"documentation": "Number of warrants outstanding.",
"label": "Number Of Warrants Outstanding"
}
}
},
"auth_ref": []
},
"pbm_NumberOfWarrantsSharesEndingBalanceinShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfWarrantsSharesEndingBalanceinShares",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"periodEndLabel": "Number of warrants shares ending balance",
"documentation": "Number of warrants shares ending balance.",
"label": "Number Of Warrants Shares Ending Balancein Shares"
}
}
},
"auth_ref": []
},
"pbm_NumberOfWarrantsSharesOpeningBalance": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "NumberOfWarrantsSharesOpeningBalance",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Number of warrants shares opening balance",
"documentation": "Number of warrants shares opening balance.",
"label": "Number Of Warrants Shares Opening Balance"
}
}
},
"auth_ref": []
},
"ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Foreign Currency Translation [Member]",
"label": "Opening balance after adjustment, cumulative effect at date of initial application [member]"
}
},
"en": {
"role": {
"documentation": "This member indicates the opening balance after the cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard."
}
}
},
"auth_ref": [
"r325"
]
},
"ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"label": "Opening balance before adjustment, cumulative effect at date of initial application [member]"
}
},
"en": {
"role": {
"documentation": "This member indicates the opening balance before the cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. It also represents the standard value for the \u2018Cumulative effect at date of initial application\u2019 axis if no other member is used."
}
}
},
"auth_ref": [
"r325"
]
},
"ifrs-full_OrdinarySharesMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OrdinarySharesMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails",
"http://www.psyencebiomed.com/role/ShareCapitalDetails",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3",
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares",
"verboseLabel": "Ordinary shares [member]",
"netLabel": "Common Shares [Member]",
"label": "Ordinary shares [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
}
}
},
"auth_ref": [
"r332"
]
},
"dei_OtherAddressMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "OtherAddressMember",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Other Address [Member]",
"documentation": "Other address for entity"
}
}
},
"auth_ref": []
},
"ifrs-full_OtherComprehensiveIncomeAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OtherComprehensiveIncomeAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"label": "Other Income [Abstract]",
"terseLabel": "Other comprehensive income/(loss)"
}
}
},
"auth_ref": []
},
"pbm_OtherComprehensiveIncomeLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "OtherComprehensiveIncomeLoss",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ComprehensiveIncome",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other comprehensive income",
"documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]",
"label": "Other Comprehensive Income Loss"
}
}
},
"auth_ref": []
},
"ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ComprehensiveIncome",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Foreign exchange gain/(loss) on translation",
"label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
}
},
"en": {
"role": {
"documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
}
}
},
"auth_ref": [
"r16",
"r24"
]
},
"ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other comprehensive income (loss)",
"label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
}
},
"en": {
"role": {
"documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
}
}
},
"auth_ref": [
"r159",
"r160"
]
},
"ifrs-full_OtherCurrentReceivables": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OtherCurrentReceivables",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_CurrentAssets",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other receivables",
"label": "Other current receivables"
}
},
"en": {
"role": {
"documentation": "The amount of current other receivables. [Refer: Other receivables]"
}
}
},
"auth_ref": [
"r157"
]
},
"ifrs-full_OtherIncome": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OtherIncome",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other income",
"label": "Other income"
}
},
"en": {
"role": {
"documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
}
}
},
"auth_ref": [
"r52",
"r154",
"r155"
]
},
"pbm_OtherIncomeDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "OtherIncomeDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Other Income (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_OtherIncomeLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "OtherIncomeLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Other Income [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_OtherItemsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "OtherItemsAbstract",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other items",
"label": "Other Items Abstract"
}
}
},
"auth_ref": []
},
"pbm_OtherMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "OtherMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other [Member]",
"label": "Other Member"
}
}
},
"auth_ref": []
},
"ecd_OtherPerfMeasureAmt": {
"xbrltype": "decimalItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OtherPerfMeasureAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Other Performance Measure, Amount",
"terseLabel": "Other Performance Measure, Amount"
}
}
},
"auth_ref": [
"r264"
]
},
"pbm_OtherReceivablesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "OtherReceivablesMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other receivables [Member]",
"label": "Other Receivables Member"
}
}
},
"auth_ref": []
},
"dei_OtherReportingStandardItemNumber": {
"xbrltype": "otherReportingStandardItemNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "OtherReportingStandardItemNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Other Reporting Standard Item Number",
"documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
}
}
},
"auth_ref": [
"r203"
]
},
"ifrs-full_OtherReserves": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OtherReserves",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Equity",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Reserves",
"label": "Other reserves"
}
},
"en": {
"role": {
"documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
}
}
},
"auth_ref": [
"r158"
]
},
"ifrs-full_OtherTemporaryDifferencesMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "OtherTemporaryDifferencesMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Restricted interest and financing expenses [Member]",
"label": "Other temporary differences [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]"
}
}
},
"auth_ref": [
"r334"
]
},
"ecd_OutstandingAggtErrCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OutstandingAggtErrCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Outstanding Aggregate Erroneous Compensation Amount",
"terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
}
}
},
"auth_ref": [
"r217",
"r228",
"r244",
"r279"
]
},
"ecd_OutstandingRecoveryCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OutstandingRecoveryCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Outstanding Recovery Compensation Amount",
"terseLabel": "Compensation Amount"
}
}
},
"auth_ref": [
"r220",
"r231",
"r247",
"r282"
]
},
"ecd_OutstandingRecoveryIndName": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OutstandingRecoveryIndName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Outstanding Recovery, Individual Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r220",
"r231",
"r247",
"r282"
]
},
"pbm_OwnedAmountOfService": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "OwnedAmountOfService",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Owned amount of service (in Dollars)",
"documentation": "Owned amount of service.",
"label": "Owned Amount Of Service"
}
}
},
"auth_ref": []
},
"pbm_PBMSharesIssued": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PBMSharesIssued",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofInvestmentisClassifiedasaFinancialAssetMeasuredatFairValueTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Total PBM shares issued (in Shares)",
"documentation": "Represent the amount of PBM shares issued.",
"label": "PBMShares Issued"
}
}
},
"auth_ref": []
},
"pbm_PGIMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PGIMember",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotesDetails",
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "PGI [Member]",
"label": "PGIMember"
}
}
},
"auth_ref": []
},
"pbm_PIPEFinancingPrivatePlacementandWarrantsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PIPEFinancingPrivatePlacementandWarrantsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"label": "PIPE Financing - Private Placement and Warrants (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_PIPEFinancingPrivatePlacementandWarrantsScheduleofFairValueAllocationDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PIPEFinancingPrivatePlacementandWarrantsScheduleofFairValueAllocationDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable"
],
"lang": {
"en-us": {
"role": {
"label": "PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_PIPEFinancingPrivatePlacementandWarrantsScheduleofPrefundedWarrantsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PIPEFinancingPrivatePlacementandWarrantsScheduleofPrefundedWarrantsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"label": "PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details) [Table]"
}
}
},
"auth_ref": []
},
"ifrs-full_ParValuePerShare": {
"xbrltype": "perShareItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ParValuePerShare",
"presentation": [
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails",
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable",
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value of the common shares (in Dollars per share)",
"verboseLabel": "Trading price",
"netLabel": "share price (in Dollars per share)",
"label": "Par value per share"
}
},
"en": {
"role": {
"documentation": "The nominal value per share."
}
}
},
"auth_ref": [
"r18"
]
},
"dei_ParentEntityLegalName": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "ParentEntityLegalName",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Parent Entity Legal Name",
"documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
}
}
},
"auth_ref": []
},
"ifrs-full_ParentMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ParentMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Psyence Group Inc",
"verboseLabel": "Parent [member]",
"netLabel": "PGI [Member]",
"label": "Parent [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for an entity that controls one or more entities."
}
}
},
"auth_ref": [
"r48"
]
},
"ecd_PayVsPerformanceDisclosureLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PayVsPerformanceDisclosureLineItems",
"lang": {
"en-us": {
"role": {
"label": "Pay vs Performance Disclosure [Line Items]",
"terseLabel": "Pay vs Performance Disclosure"
}
}
},
"auth_ref": [
"r253"
]
},
"ecd_PeerGroupIssuersFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeerGroupIssuersFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Peer Group Issuers, Footnote [Text Block]",
"terseLabel": "Peer Group Issuers, Footnote"
}
}
},
"auth_ref": [
"r263"
]
},
"ecd_PeerGroupTotalShareholderRtnAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeerGroupTotalShareholderRtnAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Peer Group Total Shareholder Return Amount",
"terseLabel": "Peer Group Total Shareholder Return Amount"
}
}
},
"auth_ref": [
"r263"
]
},
"ecd_PeoActuallyPaidCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoActuallyPaidCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "PEO Actually Paid Compensation Amount",
"terseLabel": "PEO Actually Paid Compensation Amount"
}
}
},
"auth_ref": [
"r255"
]
},
"ecd_PeoMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "PEO [Member]",
"terseLabel": "PEO"
}
}
},
"auth_ref": [
"r272"
]
},
"ecd_PeoName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "PEO Name",
"terseLabel": "PEO Name"
}
}
},
"auth_ref": [
"r265"
]
},
"ecd_PeoTotalCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoTotalCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "PEO Total Compensation Amount",
"terseLabel": "PEO Total Compensation Amount"
}
}
},
"auth_ref": [
"r254"
]
},
"pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption": {
"xbrltype": "percentItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PercentageOfReasonablyPossibleChangeInRiskAssumption",
"presentation": [
"http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Percentage of fluctuation in foreign exchange rate",
"documentation": "The reasonably possible percentage of the change in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations.",
"label": "Percentage Of Reasonably Possible Change In Risk Assumption"
}
}
},
"auth_ref": []
},
"dei_PhoneFaxNumberDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "PhoneFaxNumberDescription",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Phone Fax Number Description",
"documentation": "Description of Phone or Fax Number"
}
}
},
"auth_ref": []
},
"ecd_PnsnAdjsPrrSvcCstMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnAdjsPrrSvcCstMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pension Adjustments Prior Service Cost [Member]",
"terseLabel": "Pension Adjustments Prior Service Cost"
}
}
},
"auth_ref": [
"r256"
]
},
"ecd_PnsnAdjsSvcCstMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnAdjsSvcCstMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pension Adjustments Service Cost [Member]",
"terseLabel": "Pension Adjustments Service Cost"
}
}
},
"auth_ref": [
"r308"
]
},
"ecd_PnsnBnftsAdjFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnBnftsAdjFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pension Benefits Adjustments, Footnote [Text Block]",
"terseLabel": "Pension Benefits Adjustments, Footnote"
}
}
},
"auth_ref": [
"r255"
]
},
"dei_PostEffectiveAmendment": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "PostEffectiveAmendment",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Post-Effective Amendment"
}
}
},
"auth_ref": [
"r189"
]
},
"dei_PostEffectiveAmendmentNumber": {
"xbrltype": "sequenceNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "PostEffectiveAmendmentNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Post-Effective Amendment Number",
"documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
}
}
},
"auth_ref": [
"r189"
]
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r196"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r198"
]
},
"dei_PreEffectiveAmendment": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "PreEffectiveAmendment",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-Effective Amendment"
}
}
},
"auth_ref": [
"r189"
]
},
"dei_PreEffectiveAmendmentNumber": {
"xbrltype": "sequenceNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "PreEffectiveAmendmentNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-Effective Amendment Number",
"documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
}
}
},
"auth_ref": [
"r189"
]
},
"pbm_PrefundedWarrants": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PrefundedWarrants",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable": {
"parentTag": "pbm_FairValueAllocationGrossProceeds",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails",
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Pre-funded warrants",
"documentation": "It represents fair value of allocated pre funded warrants.",
"label": "Prefunded Warrants"
}
}
},
"auth_ref": []
},
"pbm_PrefundedWarrantsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PrefundedWarrantsMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Pre-funded warrants [Member]",
"label": "Prefunded Warrants Member"
}
}
},
"auth_ref": []
},
"pbm_PrivatePlacementAndWarrantsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PrivatePlacementAndWarrantsAbstract",
"lang": {
"en-us": {
"role": {
"label": "PIPE Financing Private Placement and Warrants [Abstract]",
"documentation": "N/A"
}
}
},
"auth_ref": []
},
"pbm_PrivatePlacementAndWarrantsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PrivatePlacementAndWarrantsLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Private Placement and Warrants [Line Items]",
"documentation": "N/A"
}
}
},
"auth_ref": []
},
"pbm_PrivatePlacementAndWarrantsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PrivatePlacementAndWarrantsMember",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Private Placement and Warrants [Member]",
"label": "Private Placement And Warrants Member"
}
}
},
"auth_ref": []
},
"pbm_PrivateWarrantsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PrivateWarrantsMember",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Private Warrants [Member]",
"verboseLabel": "Derivative warrant liabilities \u2013 private warrants [Member]",
"documentation": "This member stands for private warrants.",
"label": "Private Warrants Member"
}
}
},
"auth_ref": []
},
"ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Proceeds received from convertible note",
"label": "Proceeds from borrowings, classified as financing activities"
}
},
"en": {
"role": {
"documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
}
}
},
"auth_ref": [
"r167"
]
},
"pbm_ProceedsFromContributionsOfParent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ProceedsFromContributionsOfParent",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Proceeds received from Psyence Group Inc",
"documentation": "The amount of proceeds from contributions of parent.",
"label": "Proceeds From Contributions Of Parent"
}
}
},
"auth_ref": []
},
"ifrs-full_ProceedsFromExerciseOfWarrants": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ProceedsFromExerciseOfWarrants",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount of Warrants issued for convertible note termination agreement",
"verboseLabel": "Warrants valued",
"label": "Proceeds from exercise of warrants"
}
},
"en": {
"role": {
"documentation": "The cash inflow from the exercise of share purchase warrants."
}
}
},
"auth_ref": [
"r342"
]
},
"pbm_ProceedsFromIssuanceOfFinancingDebt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ProceedsFromIssuanceOfFinancingDebt",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Proceeds from convertible debt",
"documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
"label": "Proceeds From Issuance Of Financing Debt"
}
}
},
"auth_ref": []
},
"ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ProceedsFromIssueOfOrdinaryShares",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 8.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Third party advisors share issuance",
"verboseLabel": "Common shares valued",
"label": "Proceeds from issue of ordinary shares"
}
},
"en": {
"role": {
"documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
}
}
},
"auth_ref": [
"r342"
]
},
"ifrs-full_ProceedsFromIssuingShares": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ProceedsFromIssuingShares",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Net proceeds received for unit issuances",
"label": "Proceeds from issuing shares"
}
},
"en": {
"role": {
"documentation": "The cash inflow from issuing shares."
}
}
},
"auth_ref": [
"r166"
]
},
"ifrs-full_ProfessionalFeesExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ProfessionalFeesExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLossBeforeTax",
"weight": -1.0,
"order": 4.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Professional and consulting fees",
"label": "Professional fees expense"
}
},
"en": {
"role": {
"documentation": "The amount of fees paid or payable for professional services."
}
}
},
"auth_ref": [
"r327"
]
},
"ifrs-full_ProfitLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ProfitLoss",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ComprehensiveIncome",
"weight": 1.0,
"order": 1.0
},
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
"weight": 1.0,
"order": 1.0
},
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow",
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "NET INCOME/(LOSS)",
"terseLabel": "Net profit (loss) for the year",
"verboseLabel": "Net profit/(loss)",
"netLabel": "NET LOSS",
"label": "Profit (loss)"
}
},
"en": {
"role": {
"documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
}
}
},
"auth_ref": [
"r1",
"r21",
"r77",
"r88",
"r91",
"r145",
"r146",
"r171",
"r178"
]
},
"ifrs-full_ProfitLossBeforeTax": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ProfitLossBeforeTax",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": 1.0,
"order": 1.0
},
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Loss before other items",
"terseLabel": "Loss before other items",
"label": "Profit (loss) before tax"
}
},
"en": {
"role": {
"documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
}
}
},
"auth_ref": [
"r127",
"r154",
"r155",
"r186",
"r187"
]
},
"pbm_PromissoryNotesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PromissoryNotesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Promissory Notes [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_PromissoryNotesDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PromissoryNotesDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Promissory Notes (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_PromissoryNotesTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PromissoryNotesTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotes"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Promissory Notes",
"documentation": "The entire disclosure on promissory notes.",
"label": "Promissory Notes Text Block"
}
}
},
"auth_ref": []
},
"ifrs-full_PropertyPlantAndEquipment": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "PropertyPlantAndEquipment",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Assets",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"periodStartLabel": "Beginning balance",
"periodEndLabel": "Ending balance",
"terseLabel": "Equipment",
"label": "Property, plant and equipment"
}
},
"en": {
"role": {
"documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
}
}
},
"auth_ref": [
"r7",
"r36"
]
},
"ifrs-full_PropertyPlantAndEquipmentAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "PropertyPlantAndEquipmentAbstract",
"lang": {
"en-us": {
"role": {
"label": "Equipment [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
"xbrltype": "percentItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ProportionOfOwnershipInterestInSubsidiary",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "% ownership",
"label": "Proportion of ownership interest in subsidiary"
}
},
"en": {
"role": {
"documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
}
}
},
"auth_ref": [
"r56",
"r59",
"r94"
]
},
"pbm_PsyenceAustraliaPtyLtdMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PsyenceAustraliaPtyLtdMember",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncomeDetails",
"http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Psyence Australia (Pty) Ltd [Member]",
"label": "Psyence Australia Pty Ltd Member"
}
}
},
"auth_ref": []
},
"pbm_PsyenceLabsLtdMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PsyenceLabsLtdMember",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Psyence Labs Ltd. [Member]",
"label": "Psyence Labs Ltd Member"
}
}
},
"auth_ref": []
},
"pbm_PsyenceLabsLtdShareExchangeAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PsyenceLabsLtdShareExchangeAbstract",
"lang": {
"en-us": {
"role": {
"label": "Psyence Labs Ltd Share Exchange [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_PsyenceLabsLtdShareExchangeDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PsyenceLabsLtdShareExchangeDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Psyence Labs Ltd. Share Exchange (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_PsyenceLabsLtdShareExchangeLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PsyenceLabsLtdShareExchangeLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Psyence Labs Ltd Share Exchange [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_PublicWarrantsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PublicWarrantsMember",
"presentation": [
"http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails",
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable",
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Public Warrants [Member]",
"verboseLabel": "Derivative warrant liabilities \u2013 public warrants [Member]",
"documentation": "This member stands for public warrants.",
"label": "Public Warrants Member"
}
}
},
"auth_ref": []
},
"pbm_PurchaseAgreement": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PurchaseAgreement",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Purchase agreement",
"documentation": "The amount of purchase agreement.",
"label": "Purchase Agreement"
}
}
},
"auth_ref": []
},
"ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
"weight": -1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Additions to equipment",
"label": "Purchase of property, plant and equipment, classified as investing activities"
}
},
"en": {
"role": {
"documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
}
}
},
"auth_ref": [
"r165"
]
},
"ecd_PvpTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PvpTable",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pay vs Performance Disclosure [Table]",
"terseLabel": "Pay vs Performance Disclosure"
}
}
},
"auth_ref": [
"r253"
]
},
"ecd_PvpTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PvpTableTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pay vs Performance [Table Text Block]",
"terseLabel": "Pay vs Performance Disclosure, Table"
}
}
},
"auth_ref": [
"r253"
]
},
"pbm_PysenceBiomedIICorpMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "PysenceBiomedIICorpMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Pysence Biomed II Corp. [Member]",
"documentation": "This member stands for Pysence Biomed II Corp.",
"label": "Pysence Biomed IICorp Member"
}
}
},
"auth_ref": []
},
"pbm_RHCapitalFinanceCoLLCMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "RHCapitalFinanceCoLLCMember",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "RH Capital Finance Co., LLC [Member]",
"label": "RHCapital Finance Co LLCMember"
}
}
},
"auth_ref": []
},
"pbm_RTOMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "RTOMember",
"presentation": [
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "RTO [Member]",
"label": "RTOMember"
}
}
},
"auth_ref": []
},
"pbm_RTOTransactionMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "RTOTransactionMember",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "RTO Transaction [Member]",
"label": "RTOTransaction Member"
}
}
},
"auth_ref": []
},
"ifrs-full_RangeAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RangeAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Range [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r78",
"r107",
"r114",
"r121",
"r175",
"r176",
"r350"
]
},
"ifrs-full_RangeDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RangeDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Range [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
}
}
},
"auth_ref": [
"r78",
"r107",
"r114",
"r121",
"r175",
"r176",
"r350"
]
},
"ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule of Canadian Federal and Provincial Statutory Income Tax Rate [Abstract]"
}
}
},
"auth_ref": []
},
"ecd_RecoveryOfErrCompDisclosureLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RecoveryOfErrCompDisclosureLineItems",
"lang": {
"en-us": {
"role": {
"label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
"terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
}
}
},
"auth_ref": [
"r212",
"r223",
"r239",
"r274"
]
},
"dei_RegistrationStatementAmendmentNumber": {
"xbrltype": "sequenceNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "RegistrationStatementAmendmentNumber",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Registration Statement Amendment Number",
"documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
}
}
},
"auth_ref": [
"r189"
]
},
"ifrs-full_RelatedPartyTransactionsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RelatedPartyTransactionsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Transactions with Related Parties [Abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_RepaymentsOfBondsNotesAndDebentures": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RepaymentsOfBondsNotesAndDebentures",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow": {
"parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
"weight": -1.0,
"order": 5.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedCashFlow"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Payment of promissory note",
"label": "Repayments of bonds, notes and debentures"
}
},
"en": {
"role": {
"documentation": "The cash outflow for repayments of bonds, notes and debentures."
}
}
},
"auth_ref": [
"r342"
]
},
"ifrs-full_RepaymentsOfCurrentBorrowings": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RepaymentsOfCurrentBorrowings",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Notes paid",
"label": "Repayments of current borrowings"
}
},
"en": {
"role": {
"documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]"
}
}
},
"auth_ref": [
"r342"
]
},
"ifrs-full_ResearchAndDevelopmentExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ResearchAndDevelopmentExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLossBeforeTax",
"weight": -1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Research and development",
"label": "Research and development expense"
}
},
"en": {
"role": {
"documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
}
}
},
"auth_ref": [
"r70"
]
},
"pbm_ResearchAndDevelopmentExpensesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ResearchAndDevelopmentExpensesMember",
"presentation": [
"http://www.psyencebiomed.com/role/OtherIncomeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Research and Development Expenses [Member]",
"label": "Research And Development Expenses Member"
}
}
},
"auth_ref": []
},
"ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ReserveOfExchangeDifferencesOnTranslationMember",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Reserves",
"label": "Reserve of exchange differences on translation [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
}
}
},
"auth_ref": [
"r43",
"r156"
]
},
"ecd_RestatementDateAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDateAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Restatement Determination Date [Axis]",
"terseLabel": "Restatement Determination Date:"
}
}
},
"auth_ref": [
"r213",
"r224",
"r240",
"r275"
]
},
"ecd_RestatementDeterminationDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDeterminationDate",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Restatement Determination Date",
"terseLabel": "Restatement Determination Date"
}
}
},
"auth_ref": [
"r214",
"r225",
"r241",
"r276"
]
},
"ecd_RestatementDoesNotRequireRecoveryTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDoesNotRequireRecoveryTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Restatement Does Not Require Recovery [Text Block]",
"terseLabel": "Restatement does not require Recovery"
}
}
},
"auth_ref": [
"r221",
"r232",
"r248",
"r283"
]
},
"ifrs-full_RestrictedCashAndCashEquivalents": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RestrictedCashAndCashEquivalents",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Total",
"label": "Restricted cash and cash equivalents"
}
},
"en": {
"role": {
"documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]"
}
}
},
"auth_ref": [
"r329"
]
},
"pbm_RestrictedCashMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "RestrictedCashMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Restricted cash [Member]",
"label": "Restricted Cash Member"
}
}
},
"auth_ref": []
},
"ifrs-full_RestrictedShareUnitsMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RestrictedShareUnitsMember",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "RSU [Member]",
"label": "Restricted share units [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for restricted share units."
}
}
},
"auth_ref": [
"r337"
]
},
"ifrs-full_RetainedEarnings": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RetainedEarnings",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Equity",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accumulated Deficit",
"label": "Retained earnings"
}
},
"en": {
"role": {
"documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
}
}
},
"auth_ref": [
"r158",
"r160"
]
},
"ifrs-full_RetainedEarningsMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RetainedEarningsMember",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Accumulated Deficit",
"label": "Retained earnings [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
}
}
},
"auth_ref": [
"r3",
"r156"
]
},
"ifrs-full_RevenueFromInterest": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "RevenueFromInterest",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Interest income",
"label": "Interest income"
}
},
"en": {
"role": {
"documentation": "The amount of income arising from interest."
}
}
},
"auth_ref": [
"r98",
"r142",
"r149",
"r327"
]
},
"ifrs-full_ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Deposit made in a guaranteed investment certificate with the bank",
"label": "Reverse repurchase agreements and cash collateral on securities borrowed"
}
},
"en": {
"role": {
"documentation": "The amount of instruments purchased for resale in reverse repurchase agreements and cash collateral on securities borrowed. [Refer: Repurchase agreements and cash collateral on securities lent]"
}
}
},
"auth_ref": [
"r329"
]
},
"pbm_ReverseTakeoverTransactionWithNCACLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ReverseTakeoverTransactionWithNCACLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Reverse Takeover Transaction with NCAC [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_ReverseTakeoverTransactionWithNcacAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ReverseTakeoverTransactionWithNcacAbstract",
"lang": {
"en-us": {
"role": {
"label": "Reverse Takeover Transaction with NCAC [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_ReverseTakeoverTransactionWithNcacAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ReverseTakeoverTransactionWithNcacAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Reverse Takeover Transaction with NCAC [Axis]",
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.",
"label": "Reverse Takeover Transaction With Ncac Axis"
}
}
},
"auth_ref": []
},
"pbm_ReverseTakeoverTransactionWithNcacTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ReverseTakeoverTransactionWithNcacTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCAC"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Reverse takeover transaction with NCAC",
"documentation": "Reverse takeover transaction with NCAC",
"label": "Reverse Takeover Transaction With Ncac Text Block"
}
}
},
"auth_ref": []
},
"pbm_ReverseTakeoverTransactionwithNCACDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ReverseTakeoverTransactionwithNCACDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Reverse Takeover Transaction with NCAC (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_ReverseTakeoverTransactionwithNCACScheduleofListingExpensesDetailsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ReverseTakeoverTransactionwithNCACScheduleofListingExpensesDetailsLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"label": "Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details) [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_ReverseTakeoverTransactionwithNCACScheduleofListingExpensesDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ReverseTakeoverTransactionwithNCACScheduleofListingExpensesDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"label": "Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_RiskfreeInterestRateWarrantMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "RiskfreeInterestRateWarrantMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Risk-free interest rate [Member]",
"label": "Riskfree Interest Rate Warrant Member"
}
}
},
"auth_ref": []
},
"ecd_Rule10b51ArrAdoptedFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Rule10b51ArrAdoptedFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 10b5-1 Arrangement Adopted [Flag]",
"terseLabel": "Rule 10b5-1 Arrangement Adopted"
}
}
},
"auth_ref": [
"r292"
]
},
"ecd_Rule10b51ArrTrmntdFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Rule10b51ArrTrmntdFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 10b5-1 Arrangement Terminated [Flag]",
"terseLabel": "Rule 10b5-1 Arrangement Terminated"
}
}
},
"auth_ref": [
"r292"
]
},
"ifrs-full_SalesAndMarketingExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "SalesAndMarketingExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLossBeforeTax",
"weight": -1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Sales and marketing",
"label": "Sales and marketing expense"
}
},
"en": {
"role": {
"documentation": "The amount of expense relating to the marketing and selling of goods or services."
}
}
},
"auth_ref": [
"r333"
]
},
"pbm_ScheduleOfCarryingValueOfTheFinancialInstrumentsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfCarryingValueOfTheFinancialInstrumentsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Carrying Value Of The Financial Instruments Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfChangeInPresentationCurrencyAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfChangeInPresentationCurrencyAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Change In Presentation Currency Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfChangeInPresentationCurrencyLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfChangeInPresentationCurrencyLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable"
],
"lang": {
"en-us": {
"role": {
"label": "\u200bSchedule of Change in Presentation Currency [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Classification And Measurements Of Financial Assets And Liabilities Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/MaterialAccountingPoliciesTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Classification and Measurements of Financial Assets and Liabilities",
"documentation": "The description of the entity's classification and measurements of financial assets and liabilities.",
"label": "Schedule Of Classification And Measurements Of Financial Assets And Liabilities Text Block"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfDeferredTaxAssetsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfDeferredTaxAssetsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Deferred Tax Assets Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfDerivativeWarrantLiabilityAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfDerivativeWarrantLiabilityAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule of Derivative Warrant Liability [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/IncomeTaxNoteTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Canadian Federal and Provincial Statutory Income Tax Rate",
"documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
"label": "Schedule Of Effective Income Tax Rate Reconciliations Table Text Block"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfEquipmentAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfEquipmentAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Equipment Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfEquipmentLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfEquipmentLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofEquipmentTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Equipment [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfFairValueAllocationAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfFairValueAllocationAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Fair Value Allocation Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfInvestmentIsClassifiedAsAFinancialAssetMeasuredAtFairValueAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfInvestmentIsClassifiedAsAFinancialAssetMeasuredAtFairValueAbstract",
"lang": {
"en-us": {
"role": {
"label": "Investment is Classified as a Financial Asset Measured at Fair Value [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfIssuedAndOutstandingCommonSharesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfIssuedAndOutstandingCommonSharesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Issued And Outstanding Common Shares Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Issued and Outstanding Common Shares",
"documentation": "Tabular disclosure of issued and outstanding common shares.",
"label": "Schedule Of Issued And Outstanding Common Shares Table Text Block"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfIssuedAndOutstandingWarrantsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfIssuedAndOutstandingWarrantsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Issued And Outstanding Warrants Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfIssuedAndOutstandingWarrantsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfIssuedAndOutstandingWarrantsLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Issued and Outstanding Warrants [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfIssuedAndOutstandingWarrantsTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfIssuedAndOutstandingWarrantsTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Issued and Outstanding Warrants",
"documentation": "Tabular disclosure of issued and outstanding warrants.",
"label": "Schedule Of Issued And Outstanding Warrants Table Text Block"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfListingExpensesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfListingExpensesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule of Listing Expenses [Abstract]"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfListingExpensesTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfListingExpensesTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Listing Expenses",
"documentation": "The tabular disclosure of calculation of listing expenses.",
"label": "Schedule Of Listing Expenses Table Text Block"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfMaturityOfTheContractualObligationsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfMaturityOfTheContractualObligationsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Maturity Of The Contractual Obligations Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfNonCapitalLossCarryForwardsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfNonCapitalLossCarryForwardsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Non Capital Loss Carry Forwards Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfPreFundedWarrantsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfPreFundedWarrantsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Pre Funded Warrants Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfPrivateWarrantsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfPrivateWarrantsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Private Warrants Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfSubsidiariesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfSubsidiariesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Subsidiaries Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfUsingTheBlackScholesPricingModelAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfUsingTheBlackScholesPricingModelAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Using The Black Scholes Pricing Model Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfWarrantTransactionsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfWarrantTransactionsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Warrant Transactions Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfWarrantTransactionsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfWarrantTransactionsLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Warrant Transactions [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfWarrantsOutstandingAndExercisableAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfWarrantsOutstandingAndExercisableAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Warrants Outstanding And Exercisable Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfWarrantsOutstandingAndExercisableLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfWarrantsOutstandingAndExercisableLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Warrants Outstanding and Exercisable [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfWarrantsWereOutstandingAndExercisableAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfWarrantsWereOutstandingAndExercisableAbstract",
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Warrants Were Outstanding And Exercisable Abstract"
}
}
},
"auth_ref": []
},
"pbm_ScheduleOfWarrantsWereOutstandingAndExercisableTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ScheduleOfWarrantsWereOutstandingAndExercisableTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Warrants were Outstanding and Exercisable",
"documentation": "Tabular disclosure of Warrants were outstanding and exercisable.",
"label": "Schedule Of Warrants Were Outstanding And Exercisable Table Text Block"
}
}
},
"auth_ref": []
},
"pbm_SecondTrancheNotesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "SecondTrancheNotesMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Second Tranche Notes [Member]",
"label": "Second Tranche Notes Member"
}
}
},
"auth_ref": []
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "Security12bTitle",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r190"
]
},
"dei_Security12gTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "Security12gTitle",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(g) Security",
"documentation": "Title of a 12(g) registered security."
}
}
},
"auth_ref": [
"r194"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "SecurityExchangeName",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r193"
]
},
"dei_SecurityReportingObligation": {
"xbrltype": "securityReportingObligationItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "SecurityReportingObligation",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Reporting Obligation",
"documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
}
}
},
"auth_ref": [
"r199"
]
},
"srt_SegmentGeographicalDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024",
"localname": "SegmentGeographicalDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Domain]"
}
}
},
"auth_ref": []
},
"ifrs-full_SegmentsAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "SegmentsAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable"
],
"lang": {
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r65",
"r108",
"r145",
"r163",
"r180"
]
},
"ifrs-full_SegmentsDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "SegmentsDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable"
],
"lang": {
"en": {
"role": {
"documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
}
}
},
"auth_ref": [
"r65",
"r108",
"r150",
"r163",
"r180"
]
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "All Award Types",
"terseLabel": "All Award Types"
}
}
},
"auth_ref": []
},
"pbm_ShareCapitalDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ShareCapitalDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Share Capital (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_ShareCapitalScheduleofIssuedandOutstandingCommonSharesDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ShareCapitalScheduleofIssuedandOutstandingCommonSharesDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable"
],
"lang": {
"en-us": {
"role": {
"label": "Share Capital - Schedule of Issued and Outstanding Common Shares (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_ShareCapitalScheduleofIssuedandOutstandingWarrantsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ShareCapitalScheduleofIssuedandOutstandingWarrantsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Share Capital - Schedule of Issued and Outstanding Warrants (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_ShareCapitalScheduleofWarrantswereOutstandingandExercisableDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ShareCapitalScheduleofWarrantswereOutstandingandExercisableDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"label": "Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_ShareIssueCostsBookedToEquity": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ShareIssueCostsBookedToEquity",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": {
"parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
"weight": -1.0,
"order": 8.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Share issue costs booked to equity",
"documentation": "Share issue costs booked to equity.",
"label": "Share Issue Costs Booked To Equity"
}
}
},
"auth_ref": []
},
"pbm_SharePriceMeasurementInputMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "SharePriceMeasurementInputMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share price [Member]",
"documentation": "This member stands for share price used as a measurement input.",
"label": "Share Price Measurement Input Member"
}
}
},
"auth_ref": []
},
"pbm_SharePriceWarrantMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "SharePriceWarrantMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share price [Member]",
"label": "Share Price Warrant Member"
}
}
},
"auth_ref": []
},
"pbm_ShareSettledIssuanceCostsCostsSettled": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ShareSettledIssuanceCostsCostsSettled",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share settled issuance costs",
"documentation": "The amount of share settled issuance costs settled during the period.",
"label": "Share Settled Issuance Costs Costs Settled"
}
}
},
"auth_ref": []
},
"pbm_ShareWarrantIssued": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ShareWarrantIssued",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share warrant issued",
"documentation": "Share warrant issued.",
"label": "Share Warrant Issued"
}
}
},
"auth_ref": []
},
"ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "SignificantInvestmentsInSubsidiariesAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable"
],
"lang": {
"en-us": {
"role": {
"label": "Subsidiaries [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r57",
"r60",
"r101"
]
},
"pbm_SignificantUnobservableInputEntitysOwnEquityInstrument": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "SignificantUnobservableInputEntitysOwnEquityInstrument",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrants, measurement input",
"verboseLabel": "Fair value of pre-funded warrants",
"documentation": "The value of significant unobservable input used in the measurement of the fair value of entity's own equity instruments.",
"label": "Significant Unobservable Input Entitys Own Equity Instrument"
}
}
},
"auth_ref": []
},
"ifrs-full_SignificantUnobservableInputEntitysOwnEquityInstruments": {
"xbrltype": "decimalItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "SignificantUnobservableInputEntitysOwnEquityInstruments",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value of pre-funded warrants",
"label": "Significant unobservable input, entity's own equity instruments"
}
},
"en": {
"role": {
"documentation": "The value of significant unobservable input used in the measurement of the fair value of entity's own equity instruments."
}
}
},
"auth_ref": [
"r104"
]
},
"ifrs-full_SignificantUnobservableInputLiabilities": {
"xbrltype": "decimalItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "SignificantUnobservableInputLiabilities",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrants, measurement input",
"verboseLabel": "Convertible note, measurement input",
"label": "Significant unobservable input, liabilities"
}
},
"en": {
"role": {
"documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities."
}
}
},
"auth_ref": [
"r104"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "SolicitingMaterial",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r197"
]
},
"srt_StatementGeographicalAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2024",
"localname": "StatementGeographicalAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Axis]"
}
}
},
"auth_ref": []
},
"ifrs-full_StatementOfCashFlowsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "StatementOfCashFlowsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Statement of cash flows [abstract]"
}
}
},
"auth_ref": []
},
"ifrs-full_StatementOfChangesInEquityLineItems": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "StatementOfChangesInEquityLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"label": "Statement of changes in equity [line items]"
}
},
"en": {
"role": {
"documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
}
}
},
"auth_ref": []
},
"ifrs-full_StatementOfChangesInEquityTable": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "StatementOfChangesInEquityTable",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"label": "Statement of changes in equity [table]"
}
},
"en": {
"role": {
"documentation": "Schedule disclosing information related to changes in equity."
}
}
},
"auth_ref": [
"r3"
]
},
"ifrs-full_StatementOfFinancialPositionAbstract": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "StatementOfFinancialPositionAbstract",
"lang": {
"en-us": {
"role": {
"label": "Statement of financial position [abstract]"
}
}
},
"auth_ref": []
},
"pbm_StatementsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StatementsLineItems",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"label": "Statement [Line Items]"
}
}
},
"auth_ref": []
},
"pbm_StatementsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StatementsTable",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet"
],
"lang": {
"en-us": {
"role": {
"label": "Statement [Table]"
}
}
},
"auth_ref": []
},
"ecd_StkPrcOrTsrEstimationMethodTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "StkPrcOrTsrEstimationMethodTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Price or TSR Estimation Method [Text Block]",
"terseLabel": "Stock Price or TSR Estimation Method"
}
}
},
"auth_ref": [
"r216",
"r227",
"r243",
"r278"
]
},
"us-gaap_StockAppreciationRightsSARSMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockAppreciationRightsSARSMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Appreciation Rights (SARs) [Member]",
"terseLabel": "Stock Appreciation Rights (SARs)"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodShareIssuanceOfUnitsForPIPEFinancingNetOfIssuanceCostsinShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodShareIssuanceOfUnitsForPIPEFinancingNetOfIssuanceCostsinShares",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of units for PIPE financing, net of issuance costs (in Shares)",
"verboseLabel": "Number of Common shares, Share issued for PIPE financing",
"documentation": "Number of shares issuance of units for PIPE financing, net of issuance costs.",
"label": "Stock Issued During Period Share Issuance Of Units For PIPEFinancing Net Of Issuance Costsin Shares"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForConvertibleNoteinShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForConvertibleNoteinShares",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for convertible note (in Shares)",
"verboseLabel": "Number of Common shares, Shares issued on conversion of convertible note",
"documentation": "Number of shares Issuance of shares for convertible note.",
"label": "Stock Issued During Period Shares Issuance Of Shares For Convertible Notein Shares"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForDebtSettlement": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForDebtSettlement",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for debt settlement (in Shares)",
"documentation": "NUmber of issuance of shares for debt settlement.",
"label": "Stock Issued During Period Shares Issuance Of Shares For Debt Settlement"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForELOCNetOfIssuanceCostsinShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForELOCNetOfIssuanceCostsinShares",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for ELOC, net of issuance costs (in Shares)",
"documentation": "Number of shares issuance of shares for ELOC, net of issuance costs.",
"label": "Stock Issued During Period Shares Issuance Of Shares For ELOCNet Of Issuance Costsin Shares"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForPromissoryNotesinShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForPromissoryNotesinShares",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for promissory notes (in Shares)",
"documentation": "Number of shares issuance of shares for promissory notes.",
"label": "Stock Issued During Period Shares Issuance Of Shares For Promissory Notesin Shares"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForPsyenceLabsLtdSharesinShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForPsyenceLabsLtdSharesinShares",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for Psyence Labs Ltd shares (in Shares)",
"verboseLabel": "Number of Common shares, Shares issued for PsyLabs share exchange",
"documentation": "Number of shares issuance of shares for psyence labs ltd shares.",
"label": "Stock Issued During Period Shares Issuance Of Shares For Psyence Labs Ltd Sharesin Shares"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantConversioninShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantConversioninShares",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for warrant conversion (in Shares)",
"documentation": "Number of shares issuance of shares for warrant conversion.",
"label": "Stock Issued During Period Shares Issuance Of Shares For Warrant Conversionin Shares"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchange": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchange",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Warrants, Warrant exchange",
"documentation": "Represent the stock issued during period shares issuance of shares for warrant exchange.",
"label": "Stock Issued During Period Shares Issuance Of Shares For Warrant Exchange"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchangeinShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchangeinShares",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for warrant exchange (in Shares)",
"verboseLabel": "Number of Common shares, Warrant exchange",
"documentation": "Number of shares issuance of shares for warrant exchange.",
"label": "Stock Issued During Period Shares Issuance Of Shares For Warrant Exchangein Shares"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchanges": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchanges",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of shares, Warrant exchange",
"documentation": "Number of shares issuance of shares for warrant exchange.",
"label": "Stock Issued During Period Shares Issuance Of Shares For Warrant Exchanges"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesToNCACShareholders": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesToNCACShareholders",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares to NCAC shareholders (in Shares)",
"documentation": "NUmber of issuance of shares to NCAC shareholders.",
"label": "Stock Issued During Period Shares Issuance Of Shares To NCACShareholders"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesToPsyenceGroupInc": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesToPsyenceGroupInc",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares to Psyence Group Inc (in Shares)",
"documentation": "NUmber of issuance of shares to Psyence Group Inc.",
"label": "Stock Issued During Period Shares Issuance Of Shares To Psyence Group Inc"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesToThirdPartyAdvisors": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesToThirdPartyAdvisors",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares to third party advisors (in Shares)",
"verboseLabel": "Number of Common shares, Shares issued to third party advisors",
"documentation": "Number of issuance of shares to third party advisors.",
"label": "Stock Issued During Period Shares Issuance Of Shares To Third Party Advisors"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Shares issued to NCAC shareholders (in Shares)",
"documentation": "Number of stock issued during the period for reverse takeover transaction.",
"label": "Stock Issued During Period Shares Issued For Reverse Takeover Transaction"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodSharesNewIssue": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodSharesNewIssue",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares",
"documentation": "Number of new stock issued during the period.",
"label": "Stock Issued During Period Shares New Issue"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForConvertibleNote": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForConvertibleNote",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for convertible note",
"documentation": "Represent the amaount of issuance of shares for convertible note.",
"label": "Stock Issued During Period Value Issuance Of Shares For Convertible Note"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForDebtSettlement": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForDebtSettlement",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for debt settlement",
"documentation": "Value of issuance of shares for debt settlement.",
"label": "Stock Issued During Period Value Issuance Of Shares For Debt Settlement"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForELOCNetOfIssuanceCosts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForELOCNetOfIssuanceCosts",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for ELOC, net of issuance costs",
"documentation": "Represent the amount of issuance of shares for ELOC, net of issuance costs.",
"label": "Stock Issued During Period Value Issuance Of Shares For ELOCNet Of Issuance Costs"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForPromissoryNotes": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForPromissoryNotes",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for promissory notes",
"documentation": "Represent the amount of issuance of shares for promissory notes.",
"label": "Stock Issued During Period Value Issuance Of Shares For Promissory Notes"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForPsyenceLabsLtdShares": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForPsyenceLabsLtdShares",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for Psyence Labs Ltd shares",
"documentation": "Represent the amount of issuance of shares for Psyence Labs Ltd shares.",
"label": "Stock Issued During Period Value Issuance Of Shares For Psyence Labs Ltd Shares"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForWarrantConversion": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForWarrantConversion",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for warrant conversion",
"documentation": "Represent the amount of issuance of shares for warrant conversion.",
"label": "Stock Issued During Period Value Issuance Of Shares For Warrant Conversion"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForWarrantExchange": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForWarrantExchange",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares for warrant exchange",
"documentation": "Represent the amount of issuance of shares for warrant exchange.",
"label": "Stock Issued During Period Value Issuance Of Shares For Warrant Exchange"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfSharesToNCACShareholders": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfSharesToNCACShareholders",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares to NCAC shareholders",
"documentation": "Value of issuance of shares to NCAC shareholders.",
"label": "Stock Issued During Period Value Issuance Of Shares To NCACShareholders"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfSharesToThirdPartyAdvisors": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfSharesToThirdPartyAdvisors",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable",
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of shares to third party advisors",
"verboseLabel": "Amount of Common shares, Shares issued to third party advisors",
"documentation": "Value of issuance of shares to third party advisors.",
"label": "Stock Issued During Period Value Issuance Of Shares To Third Party Advisors"
}
}
},
"auth_ref": []
},
"pbm_StockIssuedDuringPeriodValueIssuanceOfUnitsForPIPEFinancingNetOfIssuanceCosts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "StockIssuedDuringPeriodValueIssuanceOfUnitsForPIPEFinancingNetOfIssuanceCosts",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Issuance of units for PIPE financing, net of issuance costs",
"documentation": "Represent the amount of issuance of units for PIPE financing, net of issuance costs.",
"label": "Stock Issued During Period Value Issuance Of Units For PIPEFinancing Net Of Issuance Costs"
}
}
},
"auth_ref": []
},
"pbm_SubscriptionAgreementOfAdditionalShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "SubscriptionAgreementOfAdditionalShares",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Additional shares",
"documentation": "Subscription agreement of additional shares.",
"label": "Subscription Agreement Of Additional Shares"
}
}
},
"auth_ref": []
},
"pbm_SubscriptionAmount": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "SubscriptionAmount",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Subscription amount",
"documentation": "Represents the subscription amounts.",
"label": "Subscription Amount"
}
}
},
"auth_ref": []
},
"pbm_SubsequentEventsDetailsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "SubsequentEventsDetailsTable",
"presentation": [
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Subsequent Events (Details) [Table]"
}
}
},
"auth_ref": []
},
"pbm_SummaryOfOperatingLossCarryForwardsTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "SummaryOfOperatingLossCarryForwardsTableTextBlock",
"presentation": [
"http://www.psyencebiomed.com/role/IncomeTaxNoteTables"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Non-Capital Loss Carry Forwards",
"documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carry forwards, including an assessment of the likelihood of utilization.",
"label": "Summary Of Operating Loss Carry Forwards Table Text Block"
}
}
},
"auth_ref": []
},
"ecd_TabularListTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TabularListTableTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Tabular List [Table Text Block]",
"terseLabel": "Tabular List, Table"
}
}
},
"auth_ref": [
"r271"
]
},
"pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "TaxEffectFromChangeInTaxBenefitsNotRecognized",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": {
"parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
"weight": 1.0,
"order": 6.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Change in tax benefits not recognized",
"documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to change in tax benefits not recognized.",
"label": "Tax Effect From Change In Tax Benefits Not Recognized"
}
}
},
"auth_ref": []
},
"ifrs-full_TaxEffectOfForeignTaxRates": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "TaxEffectOfForeignTaxRates",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": {
"parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Difference in foreign tax rates",
"label": "Tax effect of foreign tax rates"
}
},
"en": {
"role": {
"documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
}
}
},
"auth_ref": [
"r28"
]
},
"pbm_TaxEffectOflistingExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "TaxEffectOflistingExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": {
"parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Listing expense",
"documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to listing expense.",
"label": "Tax Effect Oflisting Expense"
}
}
},
"auth_ref": []
},
"pbm_TaxEffectOfotherPermanentExpenses": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "TaxEffectOfotherPermanentExpenses",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": {
"parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
"weight": 1.0,
"order": 5.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Other permanent expenses",
"documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to other permanent expenses.",
"label": "Tax Effect Ofother Permanent Expenses"
}
}
},
"auth_ref": []
},
"ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "TaxExpenseIncomeAtApplicableTaxRate",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": {
"parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expected income tax (recovery)/expense",
"label": "Tax expense (income) at applicable tax rate"
}
},
"en": {
"role": {
"documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
}
}
},
"auth_ref": [
"r28"
]
},
"pbm_TaxYear2044Member": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "TaxYear2044Member",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "2044 [Member]",
"documentation": "Identified as tax year 2044.",
"label": "Tax Year2044 Member"
}
}
},
"auth_ref": []
},
"pbm_TaxYear2045Member": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "TaxYear2045Member",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "2045 [Member]",
"label": "Tax Year2045 Member"
}
}
},
"auth_ref": []
},
"ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Temporary difference, unused tax losses and unused tax credits [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r31"
]
},
"ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDeferredTaxAssetsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Temporary difference, unused tax losses and unused tax credits [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
}
}
},
"auth_ref": [
"r31"
]
},
"pbm_ThirdPartyAdvisorsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ThirdPartyAdvisorsMember",
"presentation": [
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Third Party Advisors [Member]",
"documentation": "This member stands for third party advisors.",
"label": "Third Party Advisors Member"
}
}
},
"auth_ref": []
},
"pbm_ThirdPartyInvestor": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "ThirdPartyInvestor",
"crdr": "credit",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Third-party investor",
"documentation": "Represent the amount of third-party investor.",
"label": "Third Party Investor"
}
}
},
"auth_ref": []
},
"ifrs-full_TopOfRangeMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "TopOfRangeMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Top of Range [Member]",
"label": "Top of range [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for top of a range."
}
}
},
"auth_ref": [
"r78",
"r107",
"r114",
"r121",
"r175",
"r176",
"r350"
]
},
"ecd_TotalShareholderRtnAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalShareholderRtnAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Total Shareholder Return Amount",
"terseLabel": "Total Shareholder Return Amount"
}
}
},
"auth_ref": [
"r263"
]
},
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalShareholderRtnVsPeerGroupTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Total Shareholder Return Vs Peer Group [Text Block]",
"terseLabel": "Total Shareholder Return Vs Peer Group"
}
}
},
"auth_ref": [
"r270"
]
},
"ifrs-full_TradeAndOtherCurrentPayables": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "TradeAndOtherCurrentPayables",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": {
"parentTag": "ifrs-full_NetAssetsLiabilities",
"weight": -1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Accounts payable and accrued liabilities",
"label": "Trade and other current payables"
}
},
"en": {
"role": {
"documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
}
}
},
"auth_ref": [
"r9"
]
},
"ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "TradeAndOtherPayablesToTradeSuppliers",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": {
"parentTag": "pbm_CurrentAccountsPayableAndAccruedLiabilities",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Trade payables",
"label": "Trade payables"
}
},
"en": {
"role": {
"documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
}
}
},
"auth_ref": [
"r331"
]
},
"ecd_TradingArrAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement [Axis]",
"terseLabel": "Trading Arrangement:"
}
}
},
"auth_ref": [
"r291"
]
},
"ecd_TradingArrByIndTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrByIndTable",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangements, by Individual [Table]",
"terseLabel": "Trading Arrangements, by Individual"
}
}
},
"auth_ref": [
"r293"
]
},
"pbm_TradingPricePerShare": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "TradingPricePerShare",
"presentation": [
"http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgementsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Trading price per share",
"documentation": "Price of a single share of a number of closing trading price of a company.",
"label": "Trading Price Per Share"
}
}
},
"auth_ref": []
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "TradingSymbol",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"pbm_TransactionExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "TransactionExpense",
"crdr": "debit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": {
"parentTag": "ifrs-full_ProfitLoss",
"weight": -1.0,
"order": 10.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement",
"http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails"
],
"lang": {
"en-us": {
"role": {
"negatedLabel": "Transaction expense",
"terseLabel": "Transaction expenses",
"documentation": "The amount of transaction expense.",
"label": "Transaction Expense"
}
}
},
"auth_ref": []
},
"ecd_TrdArrAdoptionDate": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrAdoptionDate",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement Adoption Date",
"terseLabel": "Adoption Date"
}
}
},
"auth_ref": [
"r294"
]
},
"ecd_TrdArrDuration": {
"xbrltype": "durationItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrDuration",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement Duration",
"terseLabel": "Arrangement Duration"
}
}
},
"auth_ref": [
"r295"
]
},
"ecd_TrdArrExpirationDate": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrExpirationDate",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement Expiration Date",
"terseLabel": "Expiration Date"
}
}
},
"auth_ref": [
"r295"
]
},
"ecd_TrdArrIndName": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrIndName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement, Individual Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r293"
]
},
"ecd_TrdArrIndTitle": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrIndTitle",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement, Individual Title",
"terseLabel": "Title"
}
}
},
"auth_ref": [
"r293"
]
},
"ecd_TrdArrSecuritiesAggAvailAmt": {
"xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrSecuritiesAggAvailAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement, Securities Aggregate Available Amount",
"terseLabel": "Aggregate Available"
}
}
},
"auth_ref": [
"r296"
]
},
"ecd_TrdArrTerminationDate": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrTerminationDate",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement Termination Date",
"terseLabel": "Termination Date"
}
}
},
"auth_ref": [
"r294"
]
},
"ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "TypesOfAntidilutiveInstrumentsAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/ShareCapitalDetails",
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Types of antidilutive instruments [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r64"
]
},
"ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "TypesOfAntidilutiveInstrumentsDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/ShareCapitalDetails",
"http://www.psyencebiomed.com/role/SubsequentEventsDetails"
],
"lang": {
"en-us": {
"role": {
"label": "Types of antidilutive instruments [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
}
}
},
"auth_ref": [
"r64"
]
},
"ecd_UndrlygSecurityMktPriceChngPct": {
"xbrltype": "pureItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "UndrlygSecurityMktPriceChngPct",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Underlying Security Market Price Change, Percent",
"terseLabel": "Underlying Security Market Price Change"
}
}
},
"auth_ref": [
"r290"
]
},
"ifrs-full_UnobservableInputsAxis": {
"xbrltype": "stringItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "UnobservableInputsAxis",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable",
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"label": "Unobservable inputs [axis]"
}
},
"en": {
"role": {
"documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
}
}
},
"auth_ref": [
"r104",
"r348"
]
},
"ifrs-full_UnobservableInputsDomain": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "UnobservableInputsDomain",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"label": "Unobservable inputs [domain]"
}
},
"en": {
"role": {
"documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
}
}
},
"auth_ref": [
"r104",
"r348"
]
},
"pbm_UnrealizedFairValueGain": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "UnrealizedFairValueGain",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/PsyenceLabsLtdShareExchangeDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Unrealized fair value gain",
"documentation": "Represent the amount of unrealized fair value gain.",
"label": "Unrealized Fair Value Gain"
}
}
},
"auth_ref": []
},
"pbm_UnsecuredConvertiblePromissoryNotesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "UnsecuredConvertiblePromissoryNotesMember",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Unsecured Convertible Promissory Notes [Member]",
"documentation": "Represents information pertaining to unsecured convertible promissory note.",
"label": "Unsecured Convertible Promissory Notes Member"
}
}
},
"auth_ref": []
},
"pbm_VolatilityAnnualMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "VolatilityAnnualMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Volatility annual [Member]",
"label": "Volatility Annual Member"
}
}
},
"auth_ref": []
},
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
"terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
}
}
},
"auth_ref": [
"r259"
]
},
"pbm_WarrantExchange": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantExchange",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amount, Warrant exchange",
"documentation": "The amount of Warrant exchange.",
"label": "Warrant Exchange"
}
}
},
"auth_ref": []
},
"pbm_WarrantExpiryDate": {
"xbrltype": "dateItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantExpiryDate",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrant, expiry date",
"documentation": "Warrant, expiry date.",
"label": "Warrant Expiry Date"
}
}
},
"auth_ref": []
},
"pbm_WarrantLiabilitiesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantLiabilitiesMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrant Liabilities [Member]",
"documentation": "This member stands for warrant liabilities.",
"label": "Warrant Liabilities Member"
}
}
},
"auth_ref": []
},
"ifrs-full_WarrantLiability": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "WarrantLiability",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable": {
"parentTag": "pbm_FairValueAllocationGrossProceeds",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrants",
"label": "Warrant liability"
}
},
"en": {
"role": {
"documentation": "The amount of warrant liabilities."
}
}
},
"auth_ref": [
"r329"
]
},
"ifrs-full_WarrantReserve": {
"xbrltype": "monetaryItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "WarrantReserve",
"crdr": "credit",
"calculation": {
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": {
"parentTag": "ifrs-full_Equity",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet",
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrants Reserve",
"verboseLabel": "Warrant reserve",
"label": "Warrant reserve"
}
},
"en": {
"role": {
"documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]"
}
}
},
"auth_ref": [
"r330"
]
},
"ifrs-full_WarrantReserveMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "WarrantReserveMember",
"presentation": [
"http://www.psyencebiomed.com/role/ShareholdersEquityType2or3"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrants Reserve",
"label": "Warrant reserve [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]"
}
}
},
"auth_ref": [
"r326"
]
},
"pbm_WarrantSettledIssuanceCosts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantSettledIssuanceCosts",
"crdr": "debit",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Share settled issuance costs",
"documentation": "The amount of share settled issuance costs settled during the period.",
"label": "Warrant Settled Issuance Costs"
}
}
},
"auth_ref": []
},
"pbm_WarrantWith2YearExpiryMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantWith2YearExpiryMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrant with 2 year expiry [Member]",
"label": "Warrant With2 Year Expiry Member"
}
}
},
"auth_ref": []
},
"pbm_WarrantsAndRightsTerm": {
"xbrltype": "durationItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantsAndRightsTerm",
"presentation": [
"http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrant outstanding term",
"documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Warrants And Rights Term"
}
}
},
"auth_ref": []
},
"pbm_WarrantsEachExercisableToPurchaseOneCommonShareAtAnExercisePriceOf1150PerShareMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantsEachExercisableToPurchaseOneCommonShareAtAnExercisePriceOf1150PerShareMember",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrants, each exercisable to purchase one Common Share at an exercise price of $11.50 per share",
"verboseLabel": "Warrants, each exercisable to purchase one Common Share at an exercise price of $11.50 per share [Member]",
"label": "Warrants Each Exercisable To Purchase One Common Share At An Exercise Price Of1150 Per Share Member"
}
}
},
"auth_ref": []
},
"pbm_WarrantsExercisePrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantsExercisePrice",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Exercise Price (in Dollars per share)",
"documentation": "Represenst the exercise price of warrants.",
"label": "Warrants Exercise Price"
}
}
},
"auth_ref": []
},
"pbm_WarrantsExpiryDate": {
"xbrltype": "dateItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantsExpiryDate",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expiry Date",
"documentation": "Represents the date of warrants expires.",
"label": "Warrants Expiry Date"
}
}
},
"auth_ref": []
},
"pbm_WarrantsIssued": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantsIssued",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Number of Warrants, Issued",
"documentation": "Number of warrants issued during period.",
"label": "Warrants Issued"
}
}
},
"auth_ref": []
},
"ifrs-full_WarrantsMember": {
"xbrltype": "domainItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "WarrantsMember",
"presentation": [
"http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails",
"http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable",
"http://www.psyencebiomed.com/role/ShareCapitalDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrant [Member]",
"verboseLabel": "Waarants [Member]",
"netLabel": "Warrants [Member]",
"label": "Warrants [member]"
}
},
"en": {
"role": {
"documentation": "This member stands for warrants."
}
}
},
"auth_ref": [
"r337"
]
},
"pbm_WarrantsOrRightsExpirationDate": {
"xbrltype": "dateItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantsOrRightsExpirationDate",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Expiry Date",
"documentation": "Date which warrants or rights is set to expire, in YYYY-MM-DD format.",
"label": "Warrants Or Rights Expiration Date"
}
}
},
"auth_ref": []
},
"pbm_WarrantsWith5YearExpiryMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WarrantsWith5YearExpiryMember",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Warrants with 5 year expiry [Member]",
"label": "Warrants With5 Year Expiry Member"
}
}
},
"auth_ref": []
},
"pbm_WeightedAverageExercisePriceWarrantExchange": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WeightedAverageExercisePriceWarrantExchange",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Weighted Average Exercise Price, Warrant exchange",
"documentation": "Represent the weighted average exercise price warrant exchange.",
"label": "Weighted Average Exercise Price Warrant Exchange"
}
}
},
"auth_ref": []
},
"ifrs-full_WeightedAverageSharePrice2019": {
"xbrltype": "perShareItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "WeightedAverageSharePrice2019",
"presentation": [
"http://www.psyencebiomed.com/role/PromissoryNotesDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Weighted average share price (in Dollars per share)",
"label": "Weighted average share price"
}
},
"en": {
"role": {
"documentation": "The weighted average share price. [Refer: Weighted average [member]]"
}
}
},
"auth_ref": [
"r120"
]
},
"ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
"xbrltype": "perShareItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "WeightedAverageSharePriceShareOptionsGranted2019",
"presentation": [
"http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Weighted Average Exercise Price, Issued",
"label": "Weighted average share price, share options granted"
}
},
"en": {
"role": {
"documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
}
}
},
"auth_ref": [
"r122"
]
},
"ifrs-full_WeightedAverageShares": {
"xbrltype": "sharesItemType",
"nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
"localname": "WeightedAverageShares",
"presentation": [
"http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Weighted average number of outstanding shares - basic (in Shares)",
"label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
}
},
"en": {
"role": {
"documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
}
}
},
"auth_ref": [
"r63"
]
},
"pbm_WhiteLionMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.psyencebiomed.com/20250331",
"localname": "WhiteLionMember",
"presentation": [
"http://www.psyencebiomed.com/role/ELOCDetails"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "White Lion [Member]",
"label": "White Lion Member"
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "WrittenCommunications",
"presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r314"
]
},
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
"terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
}
}
},
"auth_ref": [
"r257"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "106",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "106",
"Subparagraph": "d",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "106",
"Subparagraph": "d",
"Clause": "iii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "106",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
"URIDate": "2024-03-27"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "117",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
"URIDate": "2024-03-27"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "35",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
"URIDate": "2024-03-27"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "51",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
"URIDate": "2024-03-27"
},
"r7": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "54",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r8": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "54",
"Subparagraph": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r9": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "54",
"Subparagraph": "k",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard",
"URIDate": "2024-03-27"
},
"r10": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "54",
"Subparagraph": "l",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_l&doctype=Standard",
"URIDate": "2024-03-27"
},
"r11": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "54",
"Subparagraph": "r",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_r&doctype=Standard",
"URIDate": "2024-03-27"
},
"r12": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "55",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
"URIDate": "2024-03-27"
},
"r13": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "61",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r14": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "61",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard",
"URIDate": "2024-03-27"
},
"r15": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "66",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
"URIDate": "2024-03-27"
},
"r16": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "7",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
"URIDate": "2024-03-27"
},
"r17": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "78",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r18": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "79",
"Subparagraph": "a",
"Clause": "iii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r19": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "79",
"Subparagraph": "a",
"Clause": "iv",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard",
"URIDate": "2024-03-27"
},
"r20": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "79",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r21": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "81A",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r22": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "81A",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r23": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "82",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r24": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "91",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r25": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "10",
"IssueDate": "2024-01-01",
"Paragraph": "21",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
"URIDate": "2024-03-27"
},
"r26": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "10",
"IssueDate": "2024-01-01",
"Section": "Disclosure",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
"URIDate": "2024-03-27"
},
"r27": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "79",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
"URIDate": "2024-03-27"
},
"r28": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "81",
"Subparagraph": "c",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r29": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "81",
"Subparagraph": "c",
"Clause": "ii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r30": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "81",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r31": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "81",
"Subparagraph": "g",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard",
"URIDate": "2024-03-27"
},
"r32": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "12",
"IssueDate": "2024-01-01",
"Section": "Disclosure",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
"URIDate": "2024-03-27"
},
"r33": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "73",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r34": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "73",
"Subparagraph": "e",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r35": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "73",
"Subparagraph": "e",
"Clause": "vii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r36": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "73",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r37": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "73",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
"URIDate": "2024-03-27"
},
"r38": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "75",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r39": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "75",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r40": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Section": "Disclosure",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
"URIDate": "2024-03-27"
},
"r41": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "19",
"IssueDate": "2024-01-01",
"Paragraph": "142",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard",
"URIDate": "2024-03-27"
},
"r42": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "21",
"IssueDate": "2024-01-01",
"Paragraph": "52",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r43": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "21",
"IssueDate": "2024-01-01",
"Paragraph": "52",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r44": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "24",
"IssueDate": "2024-01-01",
"Paragraph": "17",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r45": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "24",
"IssueDate": "2024-01-01",
"Paragraph": "17",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r46": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "24",
"IssueDate": "2024-01-01",
"Paragraph": "17",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
"URIDate": "2024-03-27"
},
"r47": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "24",
"IssueDate": "2024-01-01",
"Paragraph": "18",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r48": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "24",
"IssueDate": "2024-01-01",
"Paragraph": "19",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r49": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "24",
"IssueDate": "2024-01-01",
"Paragraph": "19",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
"URIDate": "2024-03-27"
},
"r50": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "24",
"IssueDate": "2024-01-01",
"Paragraph": "20",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
"URIDate": "2024-03-27"
},
"r51": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "24",
"IssueDate": "2024-01-01",
"Section": "Disclosures",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
"URIDate": "2024-03-27"
},
"r52": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "26",
"IssueDate": "2024-01-01",
"Paragraph": "35",
"Subparagraph": "b",
"Clause": "iv",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard",
"URIDate": "2024-03-27"
},
"r53": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "26",
"IssueDate": "2024-01-01",
"Paragraph": "35",
"Subparagraph": "b",
"Clause": "viii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r54": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "27",
"IssueDate": "2024-01-01",
"Paragraph": "10",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
"URIDate": "2024-03-27"
},
"r55": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "27",
"IssueDate": "2024-01-01",
"Paragraph": "16",
"Subparagraph": "b",
"Clause": "ii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_ii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r56": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "27",
"IssueDate": "2024-01-01",
"Paragraph": "16",
"Subparagraph": "b",
"Clause": "iii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r57": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "27",
"IssueDate": "2024-01-01",
"Paragraph": "16",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r58": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "27",
"IssueDate": "2024-01-01",
"Paragraph": "17",
"Subparagraph": "b",
"Clause": "ii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_ii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r59": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "27",
"IssueDate": "2024-01-01",
"Paragraph": "17",
"Subparagraph": "b",
"Clause": "iii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r60": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "27",
"IssueDate": "2024-01-01",
"Paragraph": "17",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r61": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "33",
"IssueDate": "2024-01-01",
"Paragraph": "66",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
"URIDate": "2024-03-27"
},
"r62": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "33",
"IssueDate": "2024-01-01",
"Paragraph": "67",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
"URIDate": "2024-03-27"
},
"r63": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "33",
"IssueDate": "2024-01-01",
"Paragraph": "70",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r64": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "33",
"IssueDate": "2024-01-01",
"Paragraph": "70",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r65": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "36",
"IssueDate": "2024-01-01",
"Paragraph": "130",
"Subparagraph": "d",
"Clause": "ii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r66": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "36",
"IssueDate": "2024-01-01",
"Paragraph": "130",
"Subparagraph": "f",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r67": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "36",
"IssueDate": "2024-01-01",
"Paragraph": "134",
"Subparagraph": "e",
"Clause": "iiA",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard",
"URIDate": "2024-03-27"
},
"r68": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "38",
"IssueDate": "2024-01-01",
"Paragraph": "118",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r69": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "38",
"IssueDate": "2024-01-01",
"Paragraph": "118",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r70": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "38",
"IssueDate": "2024-01-01",
"Paragraph": "126",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
"URIDate": "2024-03-27"
},
"r71": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "40",
"IssueDate": "2024-01-01",
"Paragraph": "76",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard",
"URIDate": "2024-03-27"
},
"r72": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "40",
"IssueDate": "2024-01-01",
"Paragraph": "79",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r73": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "40",
"IssueDate": "2024-01-01",
"Paragraph": "79",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r74": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "41",
"IssueDate": "2024-01-01",
"Paragraph": "50",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
"URIDate": "2024-03-27"
},
"r75": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "41",
"IssueDate": "2024-01-01",
"Paragraph": "54",
"Subparagraph": "f",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
"URIDate": "2024-03-27"
},
"r76": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "10",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
"URIDate": "2024-03-27"
},
"r77": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "18",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r78": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "44H",
"Subparagraph": "b",
"Clause": "iii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r79": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "45",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
"URIDate": "2024-03-27"
},
"r80": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "46",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_46&doctype=Standard",
"URIDate": "2024-03-27"
},
"r81": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "50",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r82": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "28",
"Subparagraph": "f",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_f_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r83": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "29",
"Subparagraph": "c",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_29_c_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r84": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "29",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_29&doctype=Standard",
"URIDate": "2024-03-27"
},
"r85": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "39",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_39&doctype=Standard",
"URIDate": "2024-03-27"
},
"r86": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IAS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "49",
"Subparagraph": "b",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_49_b_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r87": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "24",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r88": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "24",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r89": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "30",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_30&doctype=Standard",
"URIDate": "2024-03-27"
},
"r90": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "32",
"Subparagraph": "a",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r91": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "32",
"Subparagraph": "a",
"Clause": "ii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r92": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "12",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r93": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "19B",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r94": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "19B",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r95": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "B12",
"Subparagraph": "b",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r96": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "B12",
"Subparagraph": "b",
"Clause": "ix",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r97": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "B13",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r98": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "B13",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r99": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "B13",
"Subparagraph": "f",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r100": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "B13",
"Subparagraph": "g",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r101": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "B4",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r102": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "93",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r103": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "93",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r104": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "93",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r105": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "93",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r106": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "93",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
"URIDate": "2024-03-27"
},
"r107": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "14",
"IssueDate": "2024-01-01",
"Paragraph": "33",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r108": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "15",
"IssueDate": "2024-01-01",
"Paragraph": "115",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_115&doctype=Standard",
"URIDate": "2024-03-27"
},
"r109": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "15",
"IssueDate": "2024-01-01",
"Paragraph": "120",
"Subparagraph": "b",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r110": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "94",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
"URIDate": "2024-03-27"
},
"r111": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "97",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard",
"URIDate": "2024-03-27"
},
"r112": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "17",
"IssueDate": "2024-01-01",
"Paragraph": "109",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard",
"URIDate": "2024-03-27"
},
"r113": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "17",
"IssueDate": "2024-01-01",
"Paragraph": "109A",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard",
"URIDate": "2024-03-27"
},
"r114": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "17",
"IssueDate": "2024-01-01",
"Paragraph": "120",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
"URIDate": "2024-03-27"
},
"r115": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "17",
"IssueDate": "2024-01-01",
"Paragraph": "132",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r116": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "17",
"IssueDate": "2024-01-01",
"Paragraph": "C32",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
"URIDate": "2024-03-27"
},
"r117": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "2",
"IssueDate": "2024-01-01",
"Paragraph": "44",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard",
"URIDate": "2024-03-27"
},
"r118": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "2",
"IssueDate": "2024-01-01",
"Paragraph": "45",
"Subparagraph": "b",
"Clause": "ii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_ii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r119": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "2",
"IssueDate": "2024-01-01",
"Paragraph": "45",
"Subparagraph": "b",
"Clause": "vii",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard",
"URIDate": "2024-03-27"
},
"r120": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "2",
"IssueDate": "2024-01-01",
"Paragraph": "45",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r121": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "2",
"IssueDate": "2024-01-01",
"Paragraph": "45",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r122": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "2",
"IssueDate": "2024-01-01",
"Paragraph": "47",
"Subparagraph": "a",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r123": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "2",
"IssueDate": "2024-01-01",
"Paragraph": "47",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r124": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "3",
"IssueDate": "2024-01-01",
"Paragraph": "B64",
"Subparagraph": "f",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r125": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "3",
"IssueDate": "2024-01-01",
"Paragraph": "B64",
"Subparagraph": "f",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r126": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "3",
"IssueDate": "2024-01-01",
"Paragraph": "B67",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r127": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "5",
"IssueDate": "2024-01-01",
"Paragraph": "33",
"Subparagraph": "b",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r128": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "20",
"Subparagraph": "a",
"Clause": "i",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a_i&doctype=Standard",
"URIDate": "2024-03-27"
},
"r129": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "23B",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r130": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "25",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
"URIDate": "2024-03-27"
},
"r131": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "31",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
"URIDate": "2024-03-27"
},
"r132": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "35H",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
"URIDate": "2024-03-27"
},
"r133": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "35I",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
"URIDate": "2024-03-27"
},
"r134": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "35K",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
"URIDate": "2024-03-27"
},
"r135": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "35M",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
"URIDate": "2024-03-27"
},
"r136": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "36",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard",
"URIDate": "2024-03-27"
},
"r137": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "42E",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r138": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "42I",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42I&doctype=Standard",
"URIDate": "2024-03-27"
},
"r139": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "6",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard",
"URIDate": "2024-03-27"
},
"r140": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "7",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
"URIDate": "2024-03-27"
},
"r141": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "8",
"Subparagraph": "g",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_g&doctype=Standard",
"URIDate": "2024-03-27"
},
"r142": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "23",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r143": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "23",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r144": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "23",
"Subparagraph": "h",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
"URIDate": "2024-03-27"
},
"r145": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "23",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
"URIDate": "2024-03-27"
},
"r146": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "28",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r147": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "28",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r148": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "28",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r149": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "28",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r150": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "28",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
"URIDate": "2024-03-27"
},
"r151": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "33",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
"URIDate": "2024-03-27"
},
"r152": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "9",
"IssueDate": "2024-01-01",
"Paragraph": "7.2.34",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.34&doctype=Standard",
"URIDate": "2024-03-27"
},
"r153": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "IFRS",
"Number": "9",
"IssueDate": "2024-01-01",
"Paragraph": "7.2.42",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.42&doctype=Standard",
"URIDate": "2024-03-27"
},
"r154": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "102",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
"URIDate": "2024-03-27"
},
"r155": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "103",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
"URIDate": "2024-03-27"
},
"r156": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "108",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
"URIDate": "2024-03-27"
},
"r157": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "78",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r158": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "78",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r159": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "82A",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82A&doctype=Standard",
"URIDate": "2024-03-27"
},
"r160": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "IG6",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
"URIDate": "2024-03-27"
},
"r161": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "10",
"IssueDate": "2024-01-01",
"Paragraph": "22",
"Subparagraph": "f",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22_f&doctype=Standard",
"URIDate": "2024-03-27"
},
"r162": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "19",
"IssueDate": "2024-01-01",
"Paragraph": "138",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r163": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "19",
"IssueDate": "2024-01-01",
"Paragraph": "138",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r164": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "19",
"IssueDate": "2024-01-01",
"Paragraph": "147",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r165": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "16",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r166": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "17",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r167": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "17",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r168": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "44D",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44D&doctype=Standard",
"URIDate": "2024-03-27"
},
"r169": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Section": "A Statement of cash flows for an entity other than a financial institution",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
"URIDate": "2024-03-27"
},
"r170": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "IG63",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
"URIDate": "2024-03-27"
},
"r171": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "B10",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r172": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "93",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r173": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "B36",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r174": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "B36",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r175": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "B6",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r176": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "IE63",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
"URIDate": "2024-03-27"
},
"r177": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "15",
"IssueDate": "2024-01-01",
"Paragraph": "B89",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r178": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "17",
"IssueDate": "2024-01-01",
"Paragraph": "113",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r179": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "17",
"IssueDate": "2024-01-01",
"Paragraph": "96",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r180": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "17",
"IssueDate": "2024-01-01",
"Paragraph": "96",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r181": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "35N",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
"URIDate": "2024-03-27"
},
"r182": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "B11",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r183": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "B35",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r184": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "B35",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
"URIDate": "2024-03-27"
},
"r185": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "IG31A",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
"URIDate": "2024-03-27"
},
"r186": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "23",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
"URIDate": "2024-03-27"
},
"r187": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Name": "IFRS",
"Number": "8",
"IssueDate": "2024-01-01",
"Paragraph": "28",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r188": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "Global LEI Foundation"
},
"r189": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12"
},
"r190": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r191": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r192": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-23"
},
"r193": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r194": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "g"
},
"r195": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12, 13, 15d"
},
"r196": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r197": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r198": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r199": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "15",
"Subsection": "d"
},
"r200": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-K",
"Number": "249",
"Section": "310"
},
"r201": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-Q",
"Number": "240",
"Section": "308",
"Subsection": "a"
},
"r202": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-Q",
"Number": "249",
"Section": "308",
"Subsection": "a"
},
"r203": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Number": "249",
"Section": "220",
"Subsection": "f"
},
"r204": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "16",
"Subsection": "J",
"Paragraph": "a"
},
"r205": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "16K"
},
"r206": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "16K",
"Subsection": "b",
"Paragraph": "1"
},
"r207": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "16K",
"Subsection": "b",
"Paragraph": "1",
"Subparagraph": "i"
},
"r208": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "16K",
"Subsection": "b",
"Paragraph": "1",
"Subparagraph": "ii"
},
"r209": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "16K",
"Subsection": "b",
"Paragraph": "2"
},
"r210": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "16K",
"Subsection": "c",
"Paragraph": "1"
},
"r211": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "16K",
"Subsection": "c",
"Paragraph": "2",
"Subparagraph": "i"
},
"r212": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1"
},
"r213": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i"
},
"r214": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "A"
},
"r215": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "B"
},
"r216": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "C"
},
"r217": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "D"
},
"r218": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "E"
},
"r219": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "ii"
},
"r220": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "iii"
},
"r221": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "2"
},
"r222": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Number": "249",
"Section": "240",
"Subsection": "f"
},
"r223": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a"
},
"r224": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1"
},
"r225": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "i"
},
"r226": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "ii"
},
"r227": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "iii"
},
"r228": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "iv"
},
"r229": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "v"
},
"r230": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "2"
},
"r231": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "3"
},
"r232": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "b"
},
"r233": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 8-K",
"Number": "249",
"Section": "308"
},
"r234": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form F-3"
},
"r235": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-2"
},
"r236": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-3"
},
"r237": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-4"
},
"r238": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-6"
},
"r239": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a"
},
"r240": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1"
},
"r241": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "i"
},
"r242": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "ii"
},
"r243": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "iii"
},
"r244": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "iv"
},
"r245": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "v"
},
"r246": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "2"
},
"r247": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "3"
},
"r248": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "b"
},
"r249": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form S-3"
},
"r250": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Section": "13",
"Subsection": "a-1"
},
"r251": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Investment Company Act",
"Number": "270"
},
"r252": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v"
},
"r253": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "1"
},
"r254": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "ii"
},
"r255": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii"
},
"r256": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "B",
"Clause": "1",
"Subclause": "ii"
},
"r257": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "i"
},
"r258": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "ii"
},
"r259": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "iii"
},
"r260": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "iv"
},
"r261": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "v"
},
"r262": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "vi"
},
"r263": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iv"
},
"r264": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "vi"
},
"r265": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "3"
},
"r266": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "4"
},
"r267": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "5",
"Subparagraph": "i"
},
"r268": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "5",
"Subparagraph": "ii"
},
"r269": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "5",
"Subparagraph": "iii"
},
"r270": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "5",
"Subparagraph": "iv"
},
"r271": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "6"
},
"r272": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "6",
"Subparagraph": "i"
},
"r273": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w"
},
"r274": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1"
},
"r275": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i"
},
"r276": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "A"
},
"r277": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "B"
},
"r278": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "C"
},
"r279": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "D"
},
"r280": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "E"
},
"r281": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "ii"
},
"r282": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "iii"
},
"r283": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "2"
},
"r284": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "1"
},
"r285": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2"
},
"r286": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "A"
},
"r287": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "C"
},
"r288": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "D"
},
"r289": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "E"
},
"r290": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "F"
},
"r291": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a"
},
"r292": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "1"
},
"r293": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "2",
"Subparagraph": "A"
},
"r294": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "2",
"Subparagraph": "B"
},
"r295": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "2",
"Subparagraph": "C"
},
"r296": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "2",
"Subparagraph": "D"
},
"r297": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "b",
"Paragraph": "1"
},
"r298": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "106"
},
"r299": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "106",
"Subsection": "b",
"Paragraph": "1"
},
"r300": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "106",
"Subsection": "b",
"Paragraph": "1",
"Subparagraph": "i"
},
"r301": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "106",
"Subsection": "b",
"Paragraph": "1",
"Subparagraph": "ii"
},
"r302": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "106",
"Subsection": "b",
"Paragraph": "2"
},
"r303": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "106",
"Subsection": "c",
"Paragraph": "1"
},
"r304": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "106",
"Subsection": "c",
"Paragraph": "2",
"Subparagraph": "i"
},
"r305": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "402",
"Number": "229",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1"
},
"r306": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "A",
"Number": "229"
},
"r307": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "B",
"Clause": "1",
"Number": "229"
},
"r308": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "B",
"Clause": "1",
"Subclause": "i",
"Number": "229"
},
"r309": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-T",
"Number": "232",
"Section": "313"
},
"r310": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-T",
"Number": "232",
"Section": "405"
},
"r311": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-X",
"Number": "210",
"Section": "2",
"Subsection": "2"
},
"r312": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "405"
},
"r313": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "413",
"Subsection": "b"
},
"r314": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
},
"r315": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "462",
"Subsection": "b"
},
"r316": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "462",
"Subsection": "c"
},
"r317": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "462",
"Subsection": "d"
},
"r318": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "462",
"Subsection": "e"
},
"r319": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "486",
"Subsection": "a"
},
"r320": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "486",
"Subsection": "b"
},
"r321": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "7A",
"Section": "B",
"Subsection": "2"
},
"r322": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Section": "8",
"Subsection": "c"
},
"r323": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "10",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r324": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "106",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r325": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "106",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
"URIDate": "2024-03-27"
},
"r326": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "108",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
"URIDate": "2024-03-27"
},
"r327": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "112",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r328": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "117",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
"URIDate": "2024-03-27"
},
"r329": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "55",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
"URIDate": "2024-03-27"
},
"r330": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "78",
"Subparagraph": "e",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
"URIDate": "2024-03-27"
},
"r331": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "78",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
"URIDate": "2024-03-27"
},
"r332": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "79",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r333": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "1",
"IssueDate": "2024-01-01",
"Paragraph": "85",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
"URIDate": "2024-03-27"
},
"r334": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "12",
"IssueDate": "2024-01-01",
"Paragraph": "81",
"Subparagraph": "g",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard",
"URIDate": "2024-03-27"
},
"r335": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "37",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
"URIDate": "2024-03-27"
},
"r336": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "16",
"IssueDate": "2024-01-01",
"Paragraph": "73",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r337": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "33",
"IssueDate": "2024-01-01",
"Paragraph": "70",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r338": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "38",
"IssueDate": "2024-01-01",
"Paragraph": "118",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r339": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "40",
"IssueDate": "2024-01-01",
"Paragraph": "79",
"Subparagraph": "c",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
"URIDate": "2024-03-27"
},
"r340": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "41",
"IssueDate": "2024-01-01",
"Paragraph": "54",
"Subparagraph": "f",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
"URIDate": "2024-03-27"
},
"r341": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "16",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
"URIDate": "2024-03-27"
},
"r342": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "17",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
"URIDate": "2024-03-27"
},
"r343": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "20",
"Subparagraph": "a",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
"URIDate": "2024-03-27"
},
"r344": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "20",
"Subparagraph": "b",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
"URIDate": "2024-03-27"
},
"r345": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "20",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
"URIDate": "2024-03-27"
},
"r346": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IAS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "45",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
"URIDate": "2024-03-27"
},
"r347": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "93",
"Subparagraph": "d",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard",
"URIDate": "2024-03-27"
},
"r348": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IFRS",
"Number": "13",
"IssueDate": "2024-01-01",
"Paragraph": "93",
"Subparagraph": "h",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h&doctype=Standard",
"URIDate": "2024-03-27"
},
"r349": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IFRS",
"Number": "2",
"IssueDate": "2024-01-01",
"Paragraph": "45",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
"URIDate": "2024-03-27"
},
"r350": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "IFRS",
"Number": "7",
"IssueDate": "2024-01-01",
"Paragraph": "7",
"URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
"URIDate": "2024-03-27"
}
}
}



ZIP
118
0001213900-25-057893-xbrl.zip
IDEA: XBRL DOCUMENT

begin 644 0001213900-25-057893-xbrl.zip
M4$L#!!0 ( !>*V5H\LZ/!"'0# .[N' 9 96$P,C0V-C(S+3(P9E]P
MR]>7/;2+8G^C\^!9YN]VTY'D5K\5(N5WN"I<56MRWY2G)7
MUYN8> $221)M$&!CDMLS2\5$69Y-E?_[+3W_Y+J+)1'B?9Y*]_&9SO'Q__Y7^]"G[Y?[:VPMMJ3@<+L+]?#8_'R7A11%EY3@O9N%F-7L4;H73JIK__/CQU=55?P37E*.D4&5>
M%R-5X@?AUI;<;K]0>+.?P]_@CG^KLW#W:;B[_?/N3S_O;HM8) PT*S\6>[YUPUY3MMY.)%[%T8JZ3[0OC"O[ JS(4X)71Q7DP>PQ>/J\5M\(5W\V1MM[?W'LL5Y@>?EEV[ ]=F:9*I?_YZ]M9>7G5?;R]]7&DIBBJ00QSN]M;V[M;.
MKG.3+9@&[T9Z6E;=9^?IUO9/SMS"E1]7O"E^/8Q*I2^?#V?>U?-R ;M##9-\
MIF(4-1SJT^T]^X"RL&\[CLHAW1L^]!:N+K=P[MI7MILFHIL[**X W,]>F*B__Y%J;#7MFM/]^]/1]-U2S::HVD3&[^J^7C096Q@:I#1?&K(,3_]TN55*EZ%?[RF/\(@E]F
MJHK"49Y5*H-EJ]2GZC']D+38EOIWG5S^=6.?O]^Z@(79> SW?,PW_668QXM7
MO\3)95A6BU3]=6,,5_X<[FS/J_ BF:DR/%%7X5D^B[(>?] +SU61C#?H5S
M&,)C_(L4XE&B4E"'9W6JMMY'$X6ZS[W[51)74[S]]I\W6H_=*I/_*/AR7KT,
MAWD1JV*KRN<_A[^FT>ACN LC*O,TBM:W"/6Z-[9=YA?M-I>!GBC&]%:3+)?@Y',,>J>!G.HF*29#SZ;7P=^4"/&#ZS
MHYS_\3'P[>F^X7;7D&"RAZ\^G!Q?'!Z$YQ>#B\/S7QX/7WW#9Y\?[G\X.[XX
M/CP/!R<'X>$_]]\,3EX?AONG[]X=GY\?GYY\XP']-CA_]/?[
M<%0_??+B&P]"B\ W?>C1Z=F[\)?DT\]9GIW4,_CIB/7'I^I,C?^Z,=K>"+-H
M!D\&2^#G@WP$UV05:8XP@6,]^72Y!:?2]N[&*SCBCGYY[-WJU8\PA9OOHN)C
M>)JI1W?Q;;LTTDT'\AG=]1GQ8?,%185,GI^'>9X.HS3-JV'^J4NZSM0D*<'R
M09/GO *;&C^TXK;WD[S]B^=/GLCK^U(7_E+.H\P[3<;1+$D7/W_N?=V3A]]M
M^.KL\/7Q^<79X +T$NO+=XM_'$47KPY#!UU9U3=8/\"O]YYL?>$WP!'[*[C'1&?K_W0T[,?=9-\39'\VCMN
MD&5UE)ZI>5Y4OE[?V^"-]NQE:Y,-3DX^#-Z&9X?O3\^6;(<]V@M/-^,_N!=N
M54B^N>EUE!=A-57A."E'4M6WBC+95UK?)[N%\>'V;Q ?S,7^8G-]'B78_UG[A?%P4\\(A>\'<84>=#GVZ\
M@J-S- WW=IK"U0MN;)/8AQW!)Z7_J&=HGNP^;9LG/YZY\N-JX*^L-"E2F*"1
MTE2^K84"QLG)^3&IW.MHXX.U9;+>%[>W+\ZG*DTQG!YEB^;.^.G9M]T9
MYV\.W[[%N,+[P
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M?J6'WNPDEMH^^YZ[SGDSTV&^#>T[PN57A>)Y7BQ=O9V][^SC;#E[WK/OQY6ESD5YFO\V!-
M+_("[I&WXG WU;PE'@UXEGQ&]](1MZ?^7S/W3"I^UL_'JW=,WX>[?6S'(;VQA_;\[X>:3G6>/PKTGS[:>/W_VY%NG
M,66N4)?.P;D;)?,H#=4G-:JKY!)-TW$R4N5=,CQOT;&;+\(J_[9.[ K)WO&"
MZ_ -. SO55'F6:;2AL/S;)
M/L^W[^WIL_Q=EYP^.[M?>/KLW-+IL_=EI\_R%U]Q^CRY*Z?/];4/OE>AHO:[
M/-TP9]B73]S;'#RF]],\ZXJ([<#VMZ?C=YVO3=2Z\%.5JCF.MA<>SB+0N%$6
M/P:WXR@:E1[JD+%
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M=]_[K5N1?A#SMFFLY>10-H'O4&*AU%=6:W!@GT1E'/T;G+<_MV
M_W,3=KUM]Y4WU=XU-]7NUY:@WZ(" _-PD2@I58R2DFP+<)9(58&-!(L&'B+8
MH*%LPG/M?/T=^MMOW_N]O\H>W7MRY_:HEU7Y'KBF;X[K_3J>S:3MV80GL+OOD'OS+680
MMH4883 +H,Z2,HP$6X3 HWP(/Z:L7J G,VQ-)J*Y?M3);#W'*7K$7<+-_
MUXB)@6?:VD>J*^4?. 69[GY#?$]KPSUSRC27>@(;G]G_-]W59IC+ACTL5/1Q
M:ZA EN MY_36[D.>=3P$7\\=J#/7UWBX6UGZU8I*O[^,;=!YP*&L4/924I:U
M*C1H( 1K'RN9\>!&**!U!A#%!#\AI#^/<6^G%Q 7PA5\):?C41%Q)M\['I]L
MA+$:);,H+?^Z<7QRY)VA^C\(INH/+6#W BQ7$!18*;.
M$GX@C]B/.8+U^_393[WM71.BU6-]Y;]H_S;F_;8.L8U7QQG"X"J%Y!>CJ8*M
M.L,ZQH17M[ H--*\5RI-MSYF^16\K8I*4*&Q2$ O@%6,U3C)&*2&!=4\ZB?;
M3[6P.(H=='"?O_]=E?R'P('U/^Q_;YCM_0T&^7<M?6<,PN6SD58K@__#@BZR/4R5@ES1@T5JK'RP?.6S7,-]877A
M@!UC3)MO5(;+3]X]?'3[_'7$0!NR* \H)0BIOBVY^$>>UIC1(:1MT=C?+[KE
MX3Y*0O>.OIHJ-*$:B_MSN+DCBP/^(ZUK'$9I&NC%=5=]J.0"N//76.@PK@4^
MCCZI&BDZ-G9V^1Y4658&FW!GM ++&HS M'\LK/>IA>B;>PA^%EPT_!>\%?Z(KH=?XGCD9EC34 9C*=J;1V45OMCF
M.\31HNQ_D4A*A=R9-F@Q(]DH6MN%)86ML%)5M;?&2>[MG0MPTFEL(1%GF$T*%T$ZE(5B_ 8S2,\K2]5>!!5$>/T&Z)M[^$JM-8Y=J8FM> F
MS[M$TMGOG"Z1$I]L=Q9B^5*L21[*84[J# :C4 LB6,LP&4I>G0XVT]#^11D((*S
M-MM:\ET6@AK",4W"29%?55-=;M.'(2LVOQ*-A$6;?'?[9?M6],7.RT N:(W1
MOXS$2BY=\G1]I6?V[>P.MW:UX>=J_WZXN4^S!Z;9HY^_I0CM[$AONY>J%9#4!0M_WK U=MV7T&T'7_&&NWC-32L/2.G0DW%_3?+NX@,RV_;E
M E\9[:+UUK%MEH9RE[W8LY=F_<9?GC&P6O;U(<
MR@NI1_.:!B,@&(?9!2D!OMZ[FW7]@['JNW@BC5><"6PZ@-$QI_A+4J%YGT79
M* &7L-2$.F60T%$$N@H)Z"AE&W[HG_?#UX/!^PXO<5E\ ,TP,KY@[Z&["'8)
M0A;Q*A 5YK1PO% Q;]#LP?&F"[22Z.$X] PF +XIU&52TE[6X\:1@A.';TLA
MG*B(2SI^GKP,$?&7Q W[K>&G;$:^A^(=3->RE6XJZY\L00 S;_B::\_1J+>-
MY+Q-4=2+@!%",!YGVF2XR4IJPZ108_#/MN9:(\-<<_@=O@%+?><5^'B=CE&P4QFB,%O=@7B12#_JT%^+B/(Q8W@J_2?Q]
M'37*,T(H1N %H8+ J9$YA(='$U(8)M0;E:4J2_Q(6WEJ/%;D-&2";\1?)NA+
M9%%*&ZG(TS"'L]21 YO,J4%'%/Z&?;+]Q,'XD1=U'A7#"!ZP=?HI50L*)VSN
M/"65M=\/G^\^0U3@(RTG7K9MF,)^=N1NG("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MO*.DVZ=64)<<]Q*MO7R_^[L[*65[KX,.UPPZ[""JVS@#X6=<_^M"\X:?MKN\U7C,Q1'LDYP0X/H6*O21.2MR=BJ9@'[B=2^MC7\>RVW2Y=YW6:)
M;W<:F_YP]RA^NMU!G)+2-@*UNAC_7N@U$W"E5],A49-<(EW'F@C.H3F<28C>
MU*DO,B."?]=P0N'1LM2^22BPW])T8*RJV2J''/-@H"+RJWYX#)>*MW_QTRV%Z@:_ >RK\_79_]VF2?8OTN)<7_TPF?%5@WR>[VER&?5@:!(?CNSN_
MK3,D-^#A'">?5 P[,<4&#\WX@TO#YFN_YTLY7;\O$=TR(;CE7@*F5\ 2!)OI
M-? #]A+XXC'<"'^XN\8?WF7\X5T0Q.MA("\&O[X]1(+&_=.3B\.3BV_=V.+.
MUX0&(56%LLCM6D^EXJ&;$*[]]+5YX7#/=I8:\L*9][U&76%SCI9Y?RNF]49+=9O^7Q1."S2
M_BOZ_[>W=S9>[0\^(&OKX.SW\.3TXC \.WP].#LX/GD='IV>_09_;KT]/?T[
M_MOT:P!5$'G3^D4O>UT)V7B5),L6;]D$MI?L,Q/QU0L6!V<7X;$G?M&UY^KF
M@O2-2WYW/K.GEBW+E^RU6WR-8Q!G4&TWEN1OMCWW8(P'L.&.+W['D_C@^.QP
M_^+T[!Q^?WAR?'H6OAN<#%YS#Q7L_C0X^,?Q^>'9E^W/>R)#WUY"=N^PA#S9
M>'5Z='1X1LKY^/SB>%_W 7L/HG)X$%XM\/?P^ 0[C%'OI/4&_YIK_^0.KSV&U^VZA_!_R*ME><;KSZG[[]!W>C/#JB-I!?;+%_8TEY^NS>:(RG=U@,?@*3X/TA]M@#
MGPUM@:/CD\')_C'U%_O'\>%O].'[L]-S-!$>MF3<11WR[ [+SHN-5Y]U,@[?
MO7][^OOAX;V0G&?WQPIY?G?E EFDWPW^!K)P_F9P=OCF].T!>)DD#6>';P?H
M9V# X_>0NF<-J W0+8K'\ZV?CE3TU[IG?\?Q+#M()7P&TP 870!=_I;#"^ \UQ8M[HREV
M[G"8&IFW_P>; !YC#/(?AZ0MX(.W^M\'Q^?[;T_//X!O&@Y^/?UP 2;EV=\/
M+\*SX_._WPLS\L7>0U(H=SB@C=>3VCCR%$^DLO'@S. D/
M_^<#9D7LEP]:C*R0W# UN#*5V/7VG[O'_95]9.;W1.W9AJ1ICUEVAC>5GSN?
MIWUQCPZX.YR 0=ZR@\.CP8>W%^<].,W^@4G9@W!P=G8X.!N\/F1/^.#P[?')
M_WPX!*?I-K41KNF]WH>\W'M\>LW%^?.X?1[Z,9$/IP3<.[]V>G^X>'!_3B9[I&FN,/!=V1 0[SDV>G;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M4'28[+P(WY\=_@/AE\M>G_Z]OAVM$0\6&;&SO?N0CJ8[7#NPM^=BR?\@A\2]D9+O( -WN)X 6^K^>#)P)S7%'2XY
MV'N*T?XWQ[\>WV_)\&@W[P'KYN&GD8*_L+87=SS>88<]\!87A&:L><
M.!1[(?470,XY9 @.B!=RP(R09YH'/SS*"R'#W-W>.@HWDMS/3%E3)-D^23NFQ^DM=%\Z/WY0('$_R:Y#.%8T_U!=)L3J[;][LMT5O@T^7W
MH?M['/C;*N[WP@AYL&' $3.8%Y,H T&(A6T?;Y]&5T2Z?(K-$9.\%^Q'611'
MM]#\H)LQ[1OSP]V$DG#O97@Z)P;QG_&APDW_,OQ'E-:XF;X]8R'/18;TG^FU
MIN3+N1N=>=$S\C*\6,SAQ=_F5ZJ@Q[T,L0<]S]Q)CO.1>/2#^I(?
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M\OG[B1A(8Z39'.8P#F#?+%=DMVM_AC77HZ+'FB]BD0.=UX*.Y.I_'O>AAKF=74+#4WXO_WG\.Z-"=GZW *LI#CV
MB(MO.K:5%NLRLN,5X0ZXW0;XN:WF%_*&CU\M_:K#%[?^M3CM?A,,_/]?YNQOO$+E%@V3-*FH)U';.V0U"2HH$H,C!1TN!@?^$_S,&7:WGF+?
MR$!\T-^B KL?E*B&3Z(RCO[=;MOQRZUT[5A+XDTE\3L)'AQ]<)R2W(E@S<$P
M4%JLG/9OW6(9UW2"1\%E5"2*I5?.Q9[H1-L0"CV6L$0114./W.2(C3VV4$L]
M!NK95274?@O/VVDRF::H@*F-.YWX<5U61<(_X1XK[9",V)WXNC@\L1N2S#<[
M1T5>EN:1-'!G.!1HP3$4IH<\_)N;)L*+M:?D+Z4Q?,DDMVL,4]0C/^O5.7>]4[WXKA M!!Z24(M%[G#7"S^J1:C 9,P7"K=\ ;8HMN.#3;&6Q[4\>O?3W@]YEZ3CN3/6
M#;U^:1$J<7+GS&!+VK>B?_Z60KA#,_XC"N'G9# WTN,LG>TQ+'8LF@7LEVH%
M-:[3<)2">AI1(R_R95^NU_+NK:43J,&.=!FV[?8LEV9+O S57!?
MNRA5Z[6\@VO9M2_S(?F18M+FV$&7EA76$9<5;0)9< S!QFBFXVM3A"];2$ Q
MIN:\X"VPBH??D:)FC1]0V^6%%1M% 4Z<77A4(=/"_#4*DX!2,PR3DK3I3D.8S@.TGPN'>B#KC&T)6\M,_=$9NQY
MD/Q'=2PD:Q Q"K!?IZJP;;2:5V(+>*)@YCCAT"P*&:
MI!*] I]0CH,42XB*)5DO]OU<; H7UO-Y2C% GMT84O43FL5_X.K;RCV+G]-?6DGJ@,W/HT5*,\RV?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M34T BG"4%*-Z5I(-1GX<6&M#W\W<]4+I_D5?%ST:,"P"=U%I8P+[8]8E:,B&2JS3MP!O@RN%"Q*"AYK GJ9
M)0RV+X4A\7_=!5OR*GIB'RK\H1M+LPQ&$\C\K@*\*0]+$PHLA^9[%B'Z 9X$
MUAYN@TD=8?)9J19X)44?$-<@0@09G# >GB5HX%GZX;N\4#D)2J820MYM).$,Q8'?PYA8(RHYKNYJD"M8JFC,0J>.NU]VS@:CPK
MP/"B,'9.@1N@8+7"'=0D 6%M V61.LE^#=MC!2O #C96[=!+?1B< J5!.FMPJLBJ>"M<1!YP>&>98MM8$V(P(.)M2>"CA+F
M1< 37])28HP@(]-NJ*91.EZ#T7\.GZQQYRMQYVO@^>T SW>_#? W
M R6_Z7OO?=7WIJ<[+*3]\ O[(]_&U-!_?VK([&VX6VQ,G,"9/@#W'CQ-./IO
M0;??=*F?W.92[_;#:SM:W&IXO[_N<]O\FL_W&<<7/(?=FO1@CT&KV8(_@F:ZNO-=G=6:[\/?@9%9HR'
M=4J!'URT#R5YV>^+?*14O%ZW.[1N![!N3ESLFY8 _I*8]TN^Z5./LTO%@'GP
MD;%"QT$V2P$0.+$$- YB-2D4B2]&H*[C\H_S-,VO^.ZVVHG*/"2D(*5$53Y1
M','0?CW'+[R?S>'8NY%0?!>+K'.CBWCW+,>D&SY"(1Q+
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MSHC TRCCIV:PITC'B/Z#@?&.0RM-0V]P:M*0?M Z]^F9!1% Y0U8P#J598 >IB^9-:!&]J(JN-ELZ.BR/#](-[),*:(F3M
M4@4NV!C.5*P5ITJ>$C;("*5"3B-8HRO2ED/,>G-1:)V440538I!+
M^*BHKJ9YX7HK0U#GF23)Z9("4U^U"BA#I:M <5\]H#A,(+!S,+'M$2UTD5&)/30&\(#'7[0 * '\;E)$,SCQHX1^)<*'A0A)&NM?V6)U>/EH1HN.
M>X/-&8V.H-1+/(,'T."32P;'8%9&-"LZ2.;5O!:%^-\1""\"Y!A
MT?#>Y#H4#"4;5#=7ZF%CQP89';^@#JK'F_CS1^;7.(PR9**)=[2K]G9ZX>[V
M[E,:B/?1D_ *7NA/.^$,=KL>ZN:?GF[W7SS3GSTB(VO.ZBE=L-EG[A+0C>UH
MZ(9Q@9K,(!30HKC$- OI+:IW!0L.#3_B3QJ'&$% *M-.=&!2QQ5-:%T!)*A4MA(53\]RI9^RHZP@E 94DX[H>Y>Q
M-8H)0VL>,8=#4$T+RNN2,8^/@%>4%W/\&B'4('@0KC1-@MBXV<3*7*A))98(
MCZ<\W8//4B&0?D8)T]!P!!!GDYP\%-^Z:\GI=0R.AZDG#[AXEARU&D0F!VMZ
MF?T=E64.(H5Y>N,[^F#JI;!]O$3G[Z5B,)KEM;V97E6J'KS"
M$Q"W'Q[;0Q7H&VE))D$6&APL]!&9=N@I0@+T2 T[;V;9>'!ZCQ$B4O3#X\R<
M_SUO$.+/@,P@ 'WW0*ML9J:4_ #+"^.0#.$F^(<@\E^\7J =J\FT6'G[$/_O!\M*\G7.'
MHX...QS6>&*!/?8.EP1=HG LSI:N+\\?-?XI;T8G_M&16DUQ?!$8-33F37?
MY'Z"\/CP=_?.[]Z<-6Z-X #:UN1Z%+P585N"3O!L0C9^4#Q[+K@31$L?K4%9
M@4W&J*(&WA,'HU>:=P%ZJF3D&KUDZ6*,^\+"F(PYJ,'^$Y)V@-Y9\#TSET+!
M'&=2UB(^^RA/TVB(U!Z"#(-K6@,4A=3890R@$?:%91!W"TQI71!XKTC4(4QO
M! ??(1YJ26OP*Y\G.!AYL8X+ECXOH,E;<7)9U>',OU@G9)MRRT(('NYHR2(CQ$Y+#@\0M4 X+$@SNO!:O\;X4B>KDD-.\$E ]!.R:@-+-E9
MXTJ^M]CK*)=KTT:FF%NL0MCRS$:V\(S#" VBH2H"2R="]44242F=GSL(YW&*
MW!D$\,PHOL$$L<.H3 S:%A7@#/&S8,H@4#D9P:^;!I%6IBXJT6CE!Q__M&YH,NT*3KC.@PY2D]U>LMTKANN*[@6"%=(,J9Q$0DX]AQLF(<*!P]<%!WRZ,3BHH5N$Y,2>-$
M(<((M4* OCI]3:$"3\81=9#PS29WP-J#Z K*@.10" E3D:5\G!3U6A^8RF+B]);[#
MGR?#NM+^#()HY1V$<\=G1PM:O ZWE+G]VH4^WZ*V)Z2JG+]N8#71@Z<1<8QW
M--$19TP[:8R4X,@"0L>"%PVT9!)&$BF2,Y'"$=1 O7 ^C4!UC\C-DX!<1_#>
M[&7:."4<%!3TG^67.M[7:5';\(M[+PZX6(N7A!_],1RO^M84.FO1O^.B;WU6
MX3R;H9I%2>J%*@-U;(1*!VC&K:+)M4BM1:K!(VG,(QT15&NA60O-BOO9?#(B
MFB137"Z/*+O%IJ3#"%M"\=XJ,(EBXH.A&O\MM.4=.QD#35RCFK6"0?8QPHNL
MT$K,,**T%MNUV+KW$[*!T30BMG[PBHJ:0V3:UW=%U#BUFN4TUTI2+#@$W'7+
M^UKPUH+GWB^INHB2G%#!N,XTME&$:XDF74O66K)62%94544TJ@2TQ-3?48JA
M\]A$2XM$$4B "W$SE=J&"J3.C(ML &#I8BUV:[%S[V?HMO., XXVWU@N1E,%
M)V@R HF+TGQ2"AY5DKH9W-.Y*&A?),8B(TQ0.,$*+";?FM]Z+8-W7 :)N@%%
M3M/">U)Z$\.<6(JQ#P'
M7%K6F!W"7X+R36;#NB@9]C>F+RU/W?H87\ORRF,\)J@*YB]M,JV.%QJ8Q%XQ
M,ZVGY$P+PBLIXD X\4RGJS:D6=I#2J9% WOVSTXUY=&CM7RNY;,IGYJ[;R1<
M59;8%7Y08]:P+D0W.A\X/-!@?WY4BP"F$).W*,)K,5N+V0HU:))X'@[4(O$X
MM+=(+; '1*(V262FF(Y>!C1'P2"?U6@+7$KA*RV$EMRG064&1KF749%\"IP75
M6LC60K9"R*C(1[DAYVY1@S\JJ?67O@[!,L2Z!6Y;%PZ6'QF675P
M+VMA70NK%\I!E&B:3[@%'_8=4S/Z6S@8O(*$.+?D H@!70O36I@\8=+\'89N
MW&4K%M+XM<2L):8#SF(+>]FB[W\C2;D;,'Z/HYR)LPV3#3I&3A=X0WR#?+X)
M'O<.G_D0?TF$\/6<.):Q^RK\3-H^C34LWX+IT'JV+L9:
M5HRUNR[&^NY<0QX! 99:.Q0$NE0;'0&JHZ'OA\H4::<_3M&3]_ZZQEVC>+P2
MV>0_*N!D)5UF(N-.P;M7Y(YTB3S/T@[#M ZG)MPUY>E2,%"%5'"EM>ACVY)("9AZWP9XC=@[C#HGP,'@-M853HV,,/4VK
MK^;(2\!D79K'0=['O48W^7*^QIK\^711)C"C0A"AT[7RRXZNA6XR5G,BT;.1
ME>UJR@Q[>O3Y%;5'<>F*W"YUY(SH]U^T2KMP.M'2Z6%.@C2546%05RL>,[9Z;ZK*?KW$U?AX59TG">SZ7I.4\67"/$6.9V]% '
M0=*SZPF>7T[\;MI:=JQ@9E15"LVI"MUI7M\0H1EE63C@H5$I15X$"-B@E<(J#FN*\D=]RI4_0&
M9A,,"3.NRS;F!/W4:0XCA]V"K[5NUI%&2UO[,RC3QBMN)"JX$1HST
MAZQ*F")(--F^P\\G'"7,<=C0#T@KI2RI%.P_379HV2AA!I"T:+S0C%B&>"?P
MBM:2.6VAGD;++*-^<78$5]+-07$R*8N!9'6P4#FT;4FN&7IZN,N'MJV+_ZZN(%8EJ:Y%C"4\F%_W%_)Q9!R]G.8T*-ML:#G7#C"M0#@59R7I%%,]3;F-F$VB-%KTN(87R57P8JK3\&31%5K+Y_%#6))F#_G55\L*
M40.]IYU(.W$,E]ICMP?2^RD2(!T?#\-SPA&Y?$7$]LF;#.E6#5[.-GC69QWR
M_L@I1(.)^+[!\7$D^"1#%Z0+*JZ$O8P*XMVHZL!6>PIWC$X4,:[Q1X'$Q):1HVH1XS%Q^#)KS,*P.H$@H_S5$%2]4+3ML8%Q!:P9)F0_]!,V[G0W2XF7:+[AQ@C%/(TOT<*9$!V=K96WL]QMCK%&$TL5
M+SLZ&/ 0(E2BI3:1Z6T(^XCE*>,(9AMSQ[SX/FVVG3#3V!0%?;4U)A >#YJDON!2AL
M6]55[BU/PAEX38/8A?-\L-;'/N\Q!A?X+%,.J1Y^/4QROW+=\GDEF@PMN52Z
M+)C(^Q@YRYK_2O-*<'>^:[&K.DI FQP]KVY4EH_6O#E^[>]I(C:\1BP"O@)Y
M.M7'+O^Q7('BI?ND49T)[Z#O=SL.^(PD-2ZP8%5
M:AN+Z:NPNV7)7!=8V^]B+T&9U85+#THLOH:Z%!G/B8X2V6<*(8]$94J$)_I;
M\K.CPC:YY)F$/9AKWV]LM*UA3 VB60X_:%EO^D@Q:HX).#PT/MJR3 NMR!3@
MF<]ID]89:RNR]X2CDWZ$;*2F79X( B@>N"O24VI3 I:S5%O#Q=:("/N0AJM_BJ\R$1^7U?D0)D0B!4YES"NR;'0%0[1!7V&C-DV50TW_<:AYA#X=PU[HIZ%
M#05_C \P]'U\;U2*CZP#*#T.'9<9NPO,]#Q*\U5F4T0J5:<%LJ6O2!?F5&M2
M2?16OB.9$";+T6*<6%ZY&VARNN5L<>)!&DZZAZJ1;Q3;?[Z.[2^+[>^M8_MW
M5,*UKC*$NU-IUVJJNZ++*$DY-QV54Q-%=@I?D%2MSCP*8F&-VMD-XM=;W6NMPWN1^^T4U^FX>3DRY,HXQII*9(XA-$MO\%MY)'A26\5"X,B9I0]#QZ
M93?T1E9'PWU&!N4\T^8L/CCC\"I;S=Q"F>D,DDN,$$H (B^:[,D]&XI$VYKC
M_G)0($MZ?TK(L TJ#@7W*'<++9 Q(PE!_]LIW9ARF ><0-)@MVJHM61;?*JFM $9"4/8O<;RFZSJ6-KK4I%TQ#6+\E_B+%Z&3UL;4Q69 +7A1 'QA
MU#SS$ABA=W %F8*!E6M1ZJV6@#A&"^1]B[&OBGF6^.D!=5OA !M&\SG$UGQW
M#S;-^:V6H7TC/EDGP.@T;0[HU89G&2UIH!V T ]C"(FI>)%G+:
M?5B=AUW%I3VXFD<+9N4U?=!+A[P8'@*6J; *4H<:FI;NR="+V _W40F1H^8"
MC4#4Q5"U-))#0Z'7"ODPG5Y/W&@V>#7#/WM;U*A:RWB#_0_M\_JM#AVRU75HT*U- Z\AQQP8..K5%@;ZV#F#C4'_ZC6#)Z[&=GPM=CXMH/V[X=&[1F9]:W8JBEFPGBFKT/.,C#.D-2[I$Y;7/TQ\YBU1>X'6(G)W1$2B
M CU->V>D!8U!I81'U;C'7A6M*3)3<:#I_E\/>AA?%;+]=_('A;]M!XMK4]VO
M)>_A2A[9[Y2(9=W\$MJ^10*X):P=&>TWUY+1&T1U1K)7&4<_/Z[A>(]"C
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ML,1&M)8V4H7$CJ*9-BQ8Q#5R%&W"?DUPWXY3@NP90Q'^H#'XM9O=;S!P@132"K\K$
MY/+@E"8EQ?R#+0VX%I6'*RHK MR(H,)T$?9(TDVTC"\O24Y'H90N)Y'G='NM
ME[#R1K$!EV?<9!5[FB\W7/\( ?5:$.^%(-Y=;ORU -T+ ?(<93K="G(_/7J^
M)+M4C"02*5M&=M4S(.;>,JBO3L"O1>J'$"G-_TA"Q:5P)ALBI%4=UKLK8X%E
MNM$\@E0^UT@@4Y(*.R*FHBPOTBXJ&UN-T+Z0BZC1J;G
ME3G.'/T68#-M%2/0%=;!],-W["E=YLA,0$J!\80XPP:,G" "CVJN&$#H,@H@[Z8;ZS&5(A76
M'2)!0)H/=4Y5K&BR7!)",!HEH(MMT;[.=+$(Z*982?]GR;S459(XKHG*
MYSD&SK7?Q]?C9Z.%.Q+7^?O0/^^'502K@ B8J,1GB[:"VT2ZQR[C6I(XAFD[
M!%VE\8M:VQJ'G7%,=4FFNBM1203_X41!EM3&5!)$;K7Z4+W]'8SSL13I6L/_0+ET"M0
M=KUDAT7?;PNKXX3$74'U35SG%GRF\*:3.0)_"\.SQ=A2_._ ZC5L]MELP6>'M%63W$R<>JQ/?UG3J=^E\._=5W9'.M^ON;%/_\M"[^65;\\V1=_//=621^4P[R&C6W+M_XJ!:N'2QZO6U'!XX%K6;S
M-%\H]?!9&K!65X+W0O%$Y;K2.]=A>7(F+: 8[JBH$RK0Q!GK27D&&WUY155#
M]!L[EM_C11X_#PDQK5Q,%PBO4]JGC4"_^6Q\B], 8S9EHEDW#37K0/)@X2-L)5OT5P
M!H%"VD(]5V/S EA[FJ'L9_BG>#G\=8 C[G-=TCH"]<>4&>;O'A$
MKW41%8LL_$=>AINOB8M/ W)5_3BRC-TN P-1XCE]UP.;FQ_.0+[X8&UY*CMCL:[#^MAG7Z! YRJZ#))%PU)6]+]SSJX]H$]SB4X>03][,!,"T^LU^8-YK3+
M7=8A8(^" "P#A;1&'(#1-6I7QNRR=HU;6=ZA7KJ>:#,DFDG M<,:\T9&F-F$
ML%V%=JM0L'JCAC#<;Q.%GH-:JHNGU=AD#MM70015, ,1;>E\'.#,Z0O)>RT5
M8MPKU0NQK"D&.P%M87%F'[S*/Y<*+I2QSDE-,J*MI0URI0)B:&!]J^)0=
M*:(O,1WIP)1+T-8WGJ>]7XGQ $X7$U)E-$(T#>L3Y.8ED_K]Z^-PDTSY,1'U
M#$'VKUA5(C=Z@*NK]P@JBD*-,0(*%G_$>LT^3Q?,];I-=FZ\74[#,3RA#)G6
MC%Z27@0INZ[D[R6B$NBX1\QH,U(5PA@LPH=^W84_P>ZT&KIW]Y6$V5#9=^H<
M?\_E*=:U@0SY3W %0#3K+;GE,8?SB9DN0FP4S3BTQ*
M1#M4*.[?0,4' ?P@B7W[QQ+%<#6V=BU1WGE5>"]$F/$9(0$&3:W3NZ1'Y8WH
MR$3&A;0"@*$8 T+THB3]8-! 4>C*'',W%#FG&93XNW1>.SG,R&%WNHH6I4?W
MLD">.HGBR"@0,I8A)0M3="Z"2",Z"N:KTC!*QE#ZH1W*NT?.^_?T T8PZ:!Q
M<$)\@EV*7E&Q*X6UD%/-279(> !,Q&""I)E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M$_P67Q+%@NX4[N#9Y*G])N^6] H*!6^GX2B#*#CVZ0(\,+\)C<\G8NL?4
M#\]K.CKI?DL:HHL77$9CY+EA!:(I,)O_3A?"&8]!>V%\(2Y',''H?VD?I$33
M32#XDEM1DY5=N)TUPK&BT((0,+:P?NV!]@10GXCA%&1J$O&@]-PM2Q2LR .$
MA\Z1L4S=T1S1/F?,D E[5'F ::*4:;\M;+:IH.&9&7S#M\PI5\2A@"3;TL0Y
MS0M$GC@E\I$YUKK6C[A!3#\J?BB2Z\.2P#KUPX'/1R3'$A?"&):+SVT0BBRR
MZ6S5J;27M/HS<+##7.YCH>Q-M"+4OO7@?[ 9@5+,F\;3T_L(&FIMI+I&H>MX1LZ#S=1=,38&&F"WZZ(76,CMFF7&ILC<#:'%?B>Q1U:>BQ!45#_ K!PR5:2
M7+#5X')"KY3RMF CF6V 02:>XH%ZXV^_%9.=P%+U>-L6MUA0F@5Y1L_7ULH
MZJA( %O[G, <3J*(\%Y9GFTY?@>ET%=,KJ91EVUZ@PGI\7$&SPR(Y-<2S^HW
M*H@$U#83\5B&KG4:):1+VUT5-!^_5]U.>9E&2XVA4(F*DR"L0J[]+]..K5$2
MS%B@"G=IMJ@D$KM+G+>#UV.GSLV-W[.UH]C+X"]W&TNP=(8?('(%8MR%R/*9Y=5Y>DL#+8D?O.Q'\3),"+-1)@&1+@Z1H)\-TCPOMM!FZ7J\8C[]:$
M[#HZ+I$#L/ORND+*Q(Z@DZG'1;)ZJZS1]$/NST@Z]*##U,'WCJ?IR0'8TF4]
M!#U-E#CC2IB7Q%GQP\>O#Q
M2]?NL-SRD;_ BU 6,V@MIA]W%.8"%!ML0:#YIM'9"1NM(/S^$5_8&"+X?&.(
M:PS/C,3\+ O?U#"AX9DV7P_!VQV5V&6%1 X%YM_25=&RX3#+&/K26,T:Z\1" @N+!Y>HGS/:6GL=6>S(F9DEK E\1^+WR["S*O
M%(Z$,7D&V\J9,O3^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M0RK!\^#!*:FYO-*-W41+U=H/=26Z2$BME%9='O_G23_NMY>@,^X%]Q$D*%]8"-^Y;B4WSCM9T:B<5A%DSX1T?&GX8:P5
M:CZ;2WL-57@(^)^7B9I/EH,T0D@FNZN8M+";:&E$DH)
MFLKFSS<8F6,7D%;(*O#J&C@^P4FYKM:*S7XIW;73I.!H8]KW0O&2P#Z=\M)-
M!!WO1EL@D"?,@N"07;3JRE2>L%K%#0:>9DL2-\3<6]I;D*MLQ>*1:\T@9.,]'LN5S@&W:.D[1F7B^/2BMM6!_9$-IU):O+16CLV^NG("
M=Q5(4=,:H2*3&:A.0I((>]%88>G.O"YT<1%)[\ADLMMC?K#!<8'W2OOYSZG.
M8*7J#)>I3B]ZB,T,,&'LQ-=+50VCT4?:;"1%C44LDUF"N?%*6\(ZC1R0;6V1
M1 Y-,$7VNY&RJ_ CTJ66O5[V:83K;<:- '2"C0*.19HH77O4#X[J I]O&]WJ
MUT:'H!2?Q:3GHJ81RGD'!LUA<-MOA1D!5$.@N;VDHU()VS.B@'5/&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M(0+2(@8_OU\6M&Z6[-]8=/H,2H25U27L*7#Z&HYAJV=AIY>+8<9[QIL,B'4_AM^75%%E!1<2!
M,XFLX(X+!-V&B:TK0@_P*Y?F:JM0V4ZE@$Y9Y3F--\Y']4S@YP?X&J6/M,#%
MU8RN-$M6#+H,YM3:Y[*2X#YOR! EY?ZW*[:'A9#H1R%,V\?T#O+X?$&+/Z8E)TBJ8)_MJR\IPK
MR$UX#JN
M'LXR&V7#.JT9)26X$*IZ72S8Z'Z#M&()QHAK6*@PC-T&HGL,=D#2OQ/U$Q2AX@L$ ) *&@3[RD.YW<.8F*=R=[74.
M=UD.]]DZA_O=8XQN=UQ';7?T'&'4L[B)^LM VZIR5+I55F(F<6V@]EOD&6W?
MA-2K:;'GNJ9DY4K'$B?5_*/%-,]-T*QI<7$M"44$3'PS,'V)K9YFMZGT"\(S
M,&,*,,=0Q.TNVD?'$4@,($-.(CA3=!%#GRZK(\S+DI?
MD,W#!D\#\D5=%XDC/I5>R.6J?F]PCUMH^<;_[<.B-%9J:]W][2[1:BT+OC/
M0"L80VQ;3O,K34?*26@R. FE:6U.0AL*"TZXJ?J3/B=A^:8HN&SO4=5<.TL%
M#AQR-),;@FB$1X(J)^V'D3WX1U67C?<
M3L> NOIROC7);&0X\!W+?CB8Y88)NL+J*EWA%K/'*WX.61 $(RA3V$,J@T,A
M)66.T(56Z[)491/DCN;XB)O@HDT4P-DTSQ-J ^KFHO%:CQ$=#P/*>B.(=%$F
M)?-V>'WZ*)?2R&HO3H6K&=P $T=MUYMQO1G=^S4ZXR U
M@"'QZ[%P.EU"6J%_S7@GK8-U 9&<1CX&^HOH0-?B]Z#%3Z0%!$Y5I/J)"MND
M$@V.)RG<^D*-AZ O':1^8 RC>:$3:58:*;0T5%*E:OMWQ]^*:/1N^&38:5TG
M.?U48C.CC\=K-VZ)@JD, NB,9C?=ZJ%J>-:NZ\[/%F?9P2 TNH62']4=IYM^#^2=Y;::LJ-JWAI=KP50Z#P+-L"))K-B:6(OY_L8$^R"U?C]RQ?0@^;5!R9
MA.\"4+_*1#'U.'7QN!FWC0(;JZ>'&9^6G>2.=)P0]2QF&I*TG2R\4IHEY2I:
M8';9FAT*D[,1HCF&I2HN(U-'WL+W60(&DP' 75NZ)5NV=&@NQ=-=<^S$6UJ
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MI4V&KM%=*/#[]"V%SCQL/<"0&BYKW=MK
M-OOJAV@?IWDI>Y+T@;FOI.@UIX[&6XZ3@NM:QI5#R8:V5AF,/H-T6-$7&J6
MBZ0Z#&UG4!J;1T W?:'7L\.T[#4@2832V(16(NQ/3>;=(S LZ0YO5)164^2[
MG8>;&R#:^AL4O(U'/8-/EG8 .->'_]S>V0XW(^0A@LU-VE:W>]A].ILP[2O9
M&%R+'KLZFTD7^%W8:2/3M8..Z#WF9,+CXV%XCK&X1[8)N[O?\)=ZT,8B\EJ
M;?JOP!]J+A-:4BMR*IL@*@]/"AG.(U::R(-DF/4[V9,(/M%E&C871X^6>LQ3
M913U![C.8'I.-9S%<[C$LQ3K;P0>=90R:!>42E)Q'QA
M61PA@R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M#'Y/V]!O?6##1JGG!)V$C1#H!O4=YW+7>:3?BRJ,F\3P7+M%OK)Z/'"S<++A)9!97XQF]EQ&I>N^5.(K>A^6_\W MSMK %WRP!WS]> N^_N
MQ'8%#'3&QB$N[QG>*SD<#7VT#3UJ'NF>#L&DV ':89MR2]34B$L$AP2J^@%<
M72D"@\T+YWV!&0W,O.KIM $534*!=9I*9\+(685)Q_I,YJ^-JLB-3EV"BC&F
MJ6<1V=]TDM?VFJ5R?&='#.P"NT3VG+R+.JO?+;5XAVPX#D_%]/EHL%'%5M/:0LS^-,]Y,SIG*B9]O,B%]0)=0Y/!0WL\,.RU1UE1>82SE0Y3RIE!5&W5NN
MYSW>22IQH9?;"#,06;^L4SS$M25;592>&2)EP.@C13(*+>N&'$://01/%NF+
M04F/8021U.^RF1(GI0XK<0"#+!"^E1@X>+P2IE$%RU[6D":X+R8A$"Y.U?4P
MTK8.Z_4XLIE2Z>,HS>DSO:?AMZG*G!'QSWKZ6IP:\PXZYN(^O&&;@7<]01.8
M32Z&G$GM*V)TC$W&/"9I="56E7"'2B EN8RXU%B+E:?#7&((,*S Q2 D)WA
M9K\%+M#KBLW:8D .23!J.3)O"J;\.(EUW&]%,;TNOFYEF5R&Q);9]C7*88*'
M%H_=Y^8799F/F(.)_ ;K1_"_#<"89,A)V>$L2$A/,RE[W45,#R3/);^R.X>(
M01T6?-T?(@;C&)L7I@S\U+_Q
M+VB":(@1-0X#-6@2+!^D#4>Z<4=;*-V1LTM*2?%PM.TRHJK < R7D6]&]4/T
M5+@=.OPV">251UTI[I]A(B9+N"64YE=U6J#1)7!*@\22('2DM<'=:K$WG;B5
MFW $3J^B12\0PH]2":M3UTMCU-$4KX&D:U9;3:W!Y[7UMMFTFU!Z"TO8$"JL
M$->C,N7EOLM1 :N2+2AB8OIX@*"+ ]8::WGL3A3
M"O7*$?:!D&ET^/'Y'(F&&)##\\G*!DJ!WVFL1'L$;CQ;TL]8^NZB+);39%QI
M,GQ1*RJ[3(H\,XWK#'T1(K;K)(V]2&I0Y$-DW2@7986U^C:&0.H)>5H5%:@[
MZ[75%=R L7I-+T+FH9>>-*83T&--Z8:33T
M.A!2A5!521QGH.LJ0Q^.TD26S@K2T5[EJ$[&6KT'W
MGZ :#Z)5;Z:(>IZRH"%C7P4I+D*<"%D @1LR@7%.+(='Q$6?W3JF@][7]H=S
MS@3'['#J1'#E45"I3D1LE1',H4!'"JS1QZWMV"QDF? AKTHA7JLQD)7JX#9M
MF=JI06^NFE=7TVUH!(V=HN-SS9YTW2?E0SV4CEKA/U-ZW[F! G<#]:0=")-8
M=)Q.V &Y)X7C*P.7&$G,=,,;?53HPEZR(0N%'''VVZ!4R7_8P2&Y:8@7[%1J
MB,FNAD&HD_#'!%$U"1AS#+,515%<. 2TI4-'J+=1M@"A=!XYQ^J34;4>H<0;RRE&C(6<M-6>C/H"VG,X#^"(/P AV8RW2P\OL5*.01;EQ\ZV92YUG77=8!CK>V)>N3.NX
MGIQFG&2"PX9L&?Q^"+IRG CBA5U"V\_LP5NJ71/O5'DL68.@L0!AYP)@>I%L
MJ/!?6(D28B:"6I^T.<<,D!3WI[I4#N G52;O64\8\E^5AB+,A'G8ISM-Y?/PB&1A[.L9G;^ F,IAE9(X!)3!"#PD3+M'H/%"3I08UXS!CU]F6,^HR=PT3V,)P(BGW_I!H_.PG8GC+/!M" H!27$,/MML!5]W'R&OPXC0$:+$P=NYF,,=V'@BNRG,'2N
MT#5SH;J_)C8JP#:57N@8_D F&U4$QHYVSV@@"/S^6?@0XE;4UAR?
MM?@5P46CCHU(.\>J-*Y(L#2A4I:02#4"SZ6P>B=%J(NX'#6);16G0FCE!H$U
MB"$I/0 #R7Q/3CO]$N3;.*.RP!]A>>52-LH3+D#XJ.N!&0N9'7@BPL+]"[R2
M9,S9<*?+2K-7AX[7M7/?@W
M%'\3%4&A"K>YHF.->(1[.OL/SEX7627E1JR5X?6/Q_H-#AU<*4.G(.1C78_K
M+>FN+O1V#<=-(,.CI9=1+9=<\H
M'Z]7-Y8H&%U. 76G%6B@;Z/MS.O<2;&0." T&>1*09!\'O=L\!D4F:.9;1-;
M$S;6K63A(FL[4!F"?(B_8UY\#77RJ(9;[^;8DFXW8^EOZI[/:03>_K0EZVJY
MD#],X1Z0@_F.RC;V=GKA[O;N4YI8;.#^X?S@3\]Z.\]W>CM[V]@N@/JCM_L!9OXQ2TY)>AY45?]\/][$Y%<5WDV)4SS0E'ZHB3O'5$K&E ()9)Y_7MNS=SM*07-AO.;^*3(=H9/"JA!,Q'0M07.;6+F#CVT0T>!QJ^F>5[J;MV1'C=U#M,-
MY*YT @)O@$< Y\XRJ:IJ[_2. 6F06Q>[X\W5_L/<$;\M+2AUU65-Q8,TX0'Z
M?)=P#)/2S#.G)PO#9CFD+WD//K6CPCV*EPH0L8D:"E\^9SA$G DBUSX+);&V
MD7*"U.(V\$ERT<'JA>4(H_58]!KJ'J$:\=Y$[Q8W$0IL(]=HPQTU>J_* 8'\
M.+2;#%+"!> 3':[+KMH,X2E=%=F&_8WLM?;GS5-,G099S:SI(D!W5F[A0(?KHN=.4^FFS=KT-X?>D8
M39XKK&CS36B",.)=%QC*^?R*(3PJO7S V]:&V8254FI-6;[\78!8X<#-NGPY
M\:F#5Q'0S,@D4-T &QK\B$IYN-UK/2"'KO:V32^=W&)/?QX8I!+B 6HF)[1=
M.=RM@:$X.6M.#V,[8S>7;R(Z&F]%L4(W_K.D["'PZ7VMD"Z7P"Z9?4@=DQTWN\"$
MJH;OVT"]!7^1O=9L[' L$?C _QGX3$SZ+43PW(7%!9FL*$2*:YV6I^H@8U#&
M*HI3SB1?=?+SLZ\>=+$;Y.->4X.#>?N#>MXZ^(HG+)M[ZM%^+:* ZJX[+[&U%_"LFXAW08J:J?7W_[9::\30MA='QIV]:WH".3H#>_\
MDMD/=,,TW7K A?M@3\NR%%6IQR%H7$Q#%W52<<%CLSU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M70?R,Y=6ICVQ$1N$0%[),&T=\I+1RG?X0[9#
MR55SGR9O*H8M'E="H?2HY[ UNQ ]0H/622P;QD4+":C5IH'9G\4,#YPV7@\$IV_ DIZ#+B.5
MLU?[<+9V]G>2@M](P.IUC(9-=RZ!2)!R^S<@8#]+P3POKZIZ=NJ,0YWK86T=D5["=*[6%)W'0%
MD5Z,O%B]%LTF61KI)F%2W;S!C1,UAL$Y/+$F*M:\F*RRFGEZC'4(4E(Y6.%=SD13?[<-#8K;:[=A5P9AK3WP]/$?ZHJYEY8>6?
M 4MV:X$;:ZNA-G:G, ^S6$Z4O3%!-=N339<[>; MLNL%D.+UOW%AGR) F/+#%4))&Z^2:<$;EX% ZKF*",_I<1'5#)*.AA36QME,
MZ50A%'=7I0854!-SR2@J;.D/:55=SG5+D+Z[803>#(NPM\8B+,,BO%AC$>ZH
MB&. U-M(3X*0> ;?@KW'QI5@=#@%VHK6#=3R@@9"9"I@C>1^FT-B1I%HK;":+(VT
M:_Y/?U9,>H_L>0^PR=P9IG>G3HXKX6=Q2X@Y:MN-"FQ:LH=:L-+J3 .B*-XD8.';*W(A:#MGOIP%'3*!W;>%C+&*;)O6X(++ A
M,)>59U5$+!GS#)B:'ISC.2@\YA;DKPT/"8$$X0"20M2V98;W"@3[DI1.\:ZI
M"W;)4;"8.*:Y] M\>I/!RC%"%SFYX7MK:
M#Q$:Z(1/I:.[YG7:&!S[=MMG C>&*6)Q!L77SPUMT#&]#'5S4M'-HU'T_E@[9%ST#2CJ11L,+WZRH!WB\M7
M@HREA_?!>7?IMDJG2[436S Z=)R/ZF:)KI/2<0K""JD>"71PL_,RR>0(+Y:E
MR4+TI<1.O^JP2&)"E.AXPE!55]2VC\0O<3A!-6>=YD#K\D5M8G;?RN ]"#EG=Q;'L'2W;H$E&^>.Y=?E61!FL7+).]KWPW$L=>^:9425[8,M
M#($,->;T#[O:S!D6X9LY\;&%Z72+.[3XV% !$IZC-L5F7:BOK]?05P*2SH8E
MK<\A/6ZBTQ4W""R/W[V&+^N$%-I)'AFD8=[LY C1,0L,O2%F ZD@&L" U3=8
MEE4R& Z'";612M*624>>(G"0=7J(PHL1.:EU:[JQ/2<>L#*X![RJQIJ[SV.+
M.I$0@8E"I).F%^,MJ)Y*AVLQL%GV7%0L":3^VAV1GZ/C#4DK(>\1Z,%I
M9 @(?%Z@(M7C_6'HI4'$Q2RT #8,#%-+VZB2PG:V9&"F AV7YY!KQ<&DR FT
M:%%9+DPXX=(#V9&2SMVP?(5\&G<7'8B[P@+NT"/&>^>NZNT8HU>X]W M#\UO
M24>,%Z.BF!+7GALJV8"H9$/;D-#3A#A?)DE[_#XMAP\X$F2NP!(,X)1/>4YVMW>?BVI!W 3%;1LM2R4[8J.3R<.5>'""MS;OMW$;N](H)^/@P+WJDQS:7A$AW+">CFV#DLJ?]%(^T=E)'M"*Z[PUG9-VWX/=%
MKX?[W! [Q;XNGY-SE>12$3<8XG:Q*$M;HS!V6/09SX\=:"(=I,%9BXI8"[/^
M5:!_Y:%V7<<.25&L?_>YEPN=E[/]P^7=3%OKAZJW,&M@"B&[M/<,J?OU017H
M3#=.F8#5.GY$L\>_)$ G#$E3V7C=:-Q%8Y(0QT^.8>=.F#?&QDAZ(+H+LH9A
M+\R25)55+EEO_'F1+YBM%J;0B8Y4N.JM9_LC<(WFE0:E-NQ1:>OJ4'QMICY%J+1Z.B$B1HC3 $GN5-KQZC"3>4&;! 1%&BL]!D'ECAOOY_T;*6(K'?Z1
MT \?4X9VQ;2OARV7Q-)FD).@S//#@:T6[MM1JK:IHWF;#B3Y@]V]-\N_/%GG
M7Y;E7W:VUPF8.RKC;UWSI]N729CN$!/K&#;2'LU(-9U.04=)C$_X#!@GT_,O
MBB@FL:.(Q6&\2,59T!FR_MZW[^M1M82A](["WY,OP6W2Q_A :6AEY.#M"VH]22'L?^H28E\T(QIY=F<0N^
M2[O>M;S==7G3Z6*=N!)"2=!1;+NBBFMP$9M,1I?.RWW[4HB"
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M/ 6%W,4PU,7PYR&!G6Z##<8SPG71"GM(-DT'A_HB!5MXL4HX>FOL>1YJ=2MF=.T32:M7G<6F5/:B([!\&N)#7?:.7 /;:AK,1QR^Z#I-R[!+$H/7+R+232/DZ*L[.GD
MU(TNA4YFXB!:J)_<-7 RSU&L_HT@#>),'J>< 9-0BC-TY@PV!#(]CW@X8W)\
M6J-H3OG8,:>P,44EM05.70',.N]BE5&;U;%2*]/T3H5D.UL?+<]RNXF59@H?
M&<;4Q**F<:(#TR?-VH_>330!/5=B@[:A-G=,+V4! ,Z/^^&%/01,WV^O]4Y'
MM;? *?J@SJVG6EY>60\I5!(&EM2K<& 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M(.<)F7>\1ZFX@5>#>W& :C4M4:3*QQ*$2NMK%WH$B9/NV@:/G.R6,"[]?B6B('\B.QN48F,,A $\LI?B=[UN'H#37OK N/S
MN8"%M?'DE'8Y#5>\@EOJ>TBDM89XUDR;>06C(?@71[G9E:A+$7__$\UOJ^HU/_%U]K\L(;X1\?;I&OBY%ONZL
MD:]WH1QV$_;^$II.9B)+NS[$#(IS$J58ZAJ%I23GWM7:_\9E?\&*KDD4<$W8_PV1Z6<8,V:0K\ [H9H*"BG(==0GH<$P9YH4D/B=Z#
M_VG6E&)HA>9K#ES2.2TCKG*<6_*^+'JITA(+32;G6EZ54?B
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ML[GHQ7(OPC^C>8.<4%-=(>]":9,S0V7RFYJ^(7# L384J1F9=4/YUFV(MC[>HL[V^&>6YS.W6.VB]@UJ*N=3M%HC0S!0E:%MRGL^%LMC&:LD=DW86M,)J0][Q(9E%AZ(QSI(9',$T\1PSN6A#7@MAA(13YIV0F/'YNC(+]96*?7PO.
M6G!:@L.IEQ99[=IH7 M,-SC?">+I!@6-KDY^"PSC^]H::RD:8,LI'.
MM="MA<[W5!BEV$$WCJ94R0ETZSA81 >Z#/RQJF%6R@ A$$Q"0I'\M(_OKM?2MI6^5RA,Z<:(H ,
MRT59J5G)+7D-U]PH+_(LNDR*&KQ!D#4U QV%O:KKBK+^G%L4EIFQ]*5:B]U:
M[%KF/<:+.=1EG$+.D'(HKGFB,IRA(+;6JND4!'[7KA8Y:P*G,-8'$V/,NC9S
M+9"MLY0TUISH8K06;"?B5VG T&C H$,#_E@5GA8:/%3
MQ$%$!84JJ3!C)AMY1FU$Z0B:J6J:QVQ<#^)_U8RM1!(^$MF0>A8/_G7 #8KM
MCN\Y:0$..AEXC'2\#%A'Q#FMN(Z]X[I3;EU*J<"*$E("5$LV': AI7,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MA*4;]H8-S-#&HBU3!O:::->!Q-,-5
MQEMY//D:DGXDXIFT_#!6B_+MY>E<\ "41 -2II;M(&R4F>1^*/>W![57QVFB>?:QQ(!P:9H1R%/ J (3-9]QRYE@#%94PNW?P4>I
M9V1X=.H%W6[ 8%VP\L (N_-Y1XW@(Y>/ F^BU8L>8X#VC:7MLM)"H&BG$QP*
M;F$(#S-24.0%I+!$INER-(&I*"MJ)XU6$C9,Q?Z/9HQMW8?55U2_:3<0F4EV
MZW']OO[='$[@40/H(W-HK%-NJ37E7DE"2X -F6BHA:K83^CQKJ,Z#:S,#,A6
MV[*/JKA# 64G*92C5I1SZ2
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M=0'K #;#YBDM1$:5+7B<[NNGTM:KQ+81%*\>1Y=YX4@.UMW_%.H:/T!V<@.3]OZ7Z QBE!228+\1@(1WN@QI;R&*C1!$!LIRE6C'.,]G*
ME2Z9HS B4RM=^Y$]RQ_65?U(:UEG9# LO1N(*GH;C:B483Z2(YOO@.?X@]?Q
M6@ P,(?T:]3P4HH*HJ7S&&R>_7(0,9LC#/>23OR#ETY"(UT8BC$8_
M+%$T,KUS/.2[W9*__],_ZZ:!(G8),&:!XV:QR
MS9CN_P9>\K@CV%9:?9FW#=]7"Q['VRKNFS6@B+U<')B+)7X_3LI1) TJ%[!4
M(36 #_]69[)A][9[X>[V[EY/*E2'91*C =5K/[_GBI3("^Y45+J##P?AGW9Z
M>WO/>L]V=_O!1:XOUCT'EQW-5NY(,?#2)X*D-JUTM7%>NFTL131\60-_.BD9
ME1ULPL<8VL8K!FBUEO1,//IV7KQX'F[N5]-'O? @X7,OW'OZ])$G8-9YP3Y&
M%1TZ*0)Q*:'1PSU'X0MSO,/UM4\+.YX[H);VZ-(,T,A!-)LC<@K^;P-Z%;547&3FW[%'BK=&EQ%)DMTCGX\*?=[7MST-<56J^3LJ+^&OFTT7)SC?/7Q5]5-F/L>L/08*K5#C*P,@&J35E8.WNK<%J
MG4O-"JG8-;5;95X72-))$;MA1&4Q&;G)68;"$6&[5"Z(T59^I_ZG"G;A+ LT
M+Y!I^,W,2N;9NO6J^SID4G#$,G $ #29/"%VV)F$
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M65_6<^P7&W@OM[['%O;8/S9C+)8-&L]@7*Q/BQD!UBR86-ERI3'-RR]:8(L$,UP[3-,CM2T]F
M-7GIDA^B;N=:SXA[DNFW#3S44O'7*6_Z9:!?BC;"+"=ZX/8$VBY!/,W]
M<$#92'320O(:9P1RNFJDTYW^!8Q"LQ%N]UA)X;N %K5&@QR?A7O!WX4)M;.T
MC)AFP(VQ]?1&=LWU(7[+I,<\=@Z9R]OQBZ"4!/(F>IHTOLND6WNA>USR2W'B
M@5P6]+VOJJGEA61G?\5H[K_]<MTK-IK!4ADT#4L"FLH%^PWB2[PC8]<*P?\A!MMNITP?O!6R6^:5$.S?8R$"MBA>HTREW0#]W>@Z3OH)#-T\GQBVUYWX='!P&(B
M+Y.('H+C/<#?#ISHPR;:*KOPXL-7)P<#G''Z8.?E(SVH^^]I+^?4'F$Z?L2'
MGLY7-UM<ZW.3&$#B5<#H]TI97- 1UN84%X6"]#U7M;F@HL0_59GYQ3,5 =O<1[^KP*,]C7E2\V7Y>SN!T'G'.\>A@?_"(@2OX)^IU
M%A36ZY0Y5(+0S!&;.1EIJQ5T JD3QGKH&!C;;.8)M>YN
MPY8,Z"AM1@M#CIC7.*RJ@)-S7*<]VQKB4KK7<'J> J&&:7
M"S7Y>2BBC6_1$ZFV+SC$DW6L"GTN)U7I#9[(O.4.=%*GRKE@+(W[>/\&<1)-
MLKQ,$!8#DXI%;-9^YJ3D@01V,8;D?^:MHD>;@
MBM0CDE6Q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M0KV;IQ?[CU@/G8&F4%M7#!:<-M@M+MQ_EW(\M!6$+\9YCQB4Y^)QDK,4*$X,?9#0VQ@U0L.0<#VSE&E
MEPZK+)F'B1+DS>O]]S2YQ_MOPDF=(%% AG4EYM$%20S]_OT461W_+WOOVN2V
MD;2)?J]?@?#QG)#BL'O4NEC6>,81;^G#9 NS$""0Y =HOS
MZT\]>:G* D!VRV/9)$.D>>[R56*=+X
M9=2Z@M+V"FT,E<MGF5(=T#3!/H-&C;U,^(4+9;E'YM:$L:M<"](<]#7SS2E#WL!T21R@IM;X,\\[5MS8O8_Q!4.'\FT0;KM_DCM[I3$]+K8OLT$Z;#!AX]%Q46% SO>"EYHI]VPL#&*\X
MF#C&]K/>R2GL@0!0O17;=<$PR*PK6S%CN=$9&XY L5*(@;*M_NK!6\\W.5JI
ME097-UKD;?/P+H\1WUCGQKG?#API&^EWPP:Q5X'L4G?"D)^Z(@93WG_S# 8<
MX.&90O[ ')-^A-,@/\IV2:5DTN6^9Z#SX>]7 ;A#&#(
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M6.H8BA62F9W_;BC3/I(_\F$0SB\/$,Z=$,Z'!PCG)^IS'^C>?EMUW]7-E28
M@X)O*7X _2^P#R&1#FEK0UG%WZV6M\VP.$C:+VY82,7&EKTL!'>IZ0S+6!=*
M3)# ;LE>S35@%)$0D>A297&L6D('/!A2V:PDM,
MEX!!"XQU(*<(C0]+_%<^\W^>^V&=;[C%HAO&Y&(2D4AF8/ H,E2:F%-KQ\/Y
M.)R/L0@$!9F55*]:ILAQLIZG\>0$Z?SW!LD/-LGG3G/5G862#"+4F])@IQOA
MWDA?A]C;NLT/'6T.\CIXGO*GSMZ5E6?R[9[.<#&$%IBYZ<()6""@0-3:=P)2*FHAM_71+K QITG ;0QFP#=[^_70B9-R$G)L#T:0/((P1\Y<>>HH>A#]]GE&GQOPU
MXJ9,0CVX?5+LQ\]P=,_'.A.F:F/L %G<[]>$(%U*@[PV$ O/%:IU$,^#>";/
M"P"=-;#.YWDKY(# -F9%@TJM@\P<9&9XGY-#',M]!$L5JM1V.RQ:?D5 1M%I
M01DB#4MXE8,A>1"\$6458%0!M)FGWIZ]?3F**T]8" WW7:E.#E.,!]4OZ\2:O76*J,3Y=@/)2!Q6@IL1<*1 [
M>!<1I+( 4K0]B.M!7$?%U;NNL8@;>7LOCM7UO[VX,['73K05CWYB89UBZ!:$NX&_L'Q9:C5;[L7=E@1Z_6F]\+BN0@7+^%
M)B2^>UU&SLEV*BLJ+A1>A;LT57[ET0\N3
M2OV)Z:/BE.@[DH!3VGCJO>&#U!VDKI=[,[E?*JN52 I8CT9:EQT$Z"! _>2M
M0 P(VHMJ0S]Y!9 ORD(,*"6($:]UWM1U+BY]NX(
MC6Z+@&O@U)CALXBM29*6B%* 1F+_QVHF>FK:(S;^E#>\K'M("MRA8T[2%DY+
MAPV=5> RC/R%6%P8A)%[TXW26E&A+Z21*-I"OZ:(A""E/$M(/$MJU.;V[=3M[N2_"RVJ8EUIK&^M.RDK/;?FPJ$+RA*#:9\&L[E6F80,+ZSOP(O
MG4TK;*:+JNO"=C,.H>.2[:;UF[!JF&LZ!1\0(TTUXV8'=W*_99'+:8(N//,*
M;'5$+,=,.3&28HIBC[1LT0RIF=;"_L.\-1-NYK(A*S(,,"'I"GR3SA9^"U$F
M-P(CADEFHQJK)99:M1^75"W_!D>EB\T%1ECBM'K_&M$_=F=+VYN 7G+\YCAI
M0J3GT5)V=MJI)G+.:\="ZCZF_0,N2_M*2IM[)Z_I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MR:'T;&?IV:-#Z=EO;OV_D3+6MYJ:P%%%$*Y0TCK^II361WQ('VMW,[H6,S6M92",=J$7-[#Y\$:-5UC;PB0F=<*N]'HG>Q]%F891?28PS*0?+K9
MK)EL^K$F]_82;:A@.Q/Y"JNLM-.V09E^/,:>WXXLX.='#IEGX&^?(59YZ\.(
M.\AX8,V24=QN5FNC%B^\K?\;9_T/(O7[%2F_7]NQ[ 8TVMS:=QIT I'3N-Q.*>JYQ:*W?)!E>X)(-#
M'A+BPL]L$Z"#*!]$^8:B'*K?.5BDFG(29)R#2M7&( %;'2A'H*4:\ @E#64@;_V:8R!W/@(..[G]?WQQA.ZI7C1;42I VYUDWM
MA;B1."'"?4NP[D%@@93XU9'0![GZ?2L
MMR*%!H).28IL1-@DD(.YPO^\TSP <
M<]G4&[_P;44)0) @%)8! :G5U&)S6'!#L43956XJKA'E05-.BRS8V<*2DZ1-
MPAY)V^M_45,BVMN]A'TLR@7SU*Q1ZHY7CC.@(KVYK*MW2&Y2]2@WPAF-*+3)
M5Z=#N$E,\H=&YA&3Z="!O)/V(;.2;PX,:NF/"/??V-DN LEE[TQV?X"P^RF%
MRB.W1X+=VM;_NB/Y3"<#N0\\^=DKRIVBS#!^7[5=.%ZFC3XS(\@]O&<@)!D7X*I+ !>V(V
MR=<7O41YG[(D=M2-Q]@?#EKA0CJ>+5;>N&ZWPD#L]YN0Q^"*I:8"FI]W??6@
M;F39K5/$PPQ0".[HVL.9*B]V;Q.D90*3K S6N:^4N"?4M!3D*??0H'K)VM*CG#EH#3O[:$C79)^Y?N5%MZ1$14TWAFI)&$?DZ_$I!6[@+Q?3%0PV4B8L3UE&52G]7Z>$T*IH:(Z"8/SO]
MHJV11\R>;UIDK1!]0,7#T#1(X;XC@8E! "X;"\#U))Y^$[.^X;'<-;3?C%@J
M'X,7F5HGV4VL$Y)4:8(^UG0QVB6Q%6V]=0H1DFWLI+>(N6WHN& [=T+U!)6:
M5^W._4SV,948T;$N[,O(&Z217*PAQ9+X?^UVQ&]MRYBW0_K'"LU?P/H/=8.3
MC?8YM"V. &YEUPF6B=ISM.7-*2L]_CD(C _A*M:A7;Z&;'L'H3)&)-6AH#K%I6<^F&='=DUTDF!-GH&?(
M1*]KGEOY'N)(!X'6L_/G@B1JOP;O0TRY+$L;-]$GNIC0E?D[;C9.'KT+S=*5
MF1R[AY=YN^$66/D053%BQX ..S2)-*A5E\KTF*WH+IKT<' 674#LD>1P'97>
M_+H,BIR?+ A0AB(F^%2F&*;+D5 VRG3E5IR9D7+R55?5S6P[Y097^D'H]G[;
MK>?OFUF ^DXB])?;CZ'Q::Y]3L,ZC=M-TE:H_>S!FMJ; ID:+SKG+1=[T%:S%FU%MAQ!/V7Y3M8B%%9UE@% 9JBL[44
M5"SG5;M0G\+/VOMMRW')=^5[ZMJ]H_*-'@!C+6"3/@-A-AIE/C+X<=11\6[IS8- '5V_5AO5"T=5V>QT_)_HD_
MF,A.>;T*A,9@11)T=+3&]J*J;SSNBC)#?I$[[K"(F\=*HQB0I3>NU]P!DPJ>
MV-ZA;ZOE6GCYF"&<8VX OY@CFHVW-$PK\I61G68P[WPQ&\4"?R?\ZXB[^/A1
M<36O,$5'\93^?BMTXI7&RNR?2O$9TW.%)-* J1/RP)W;>D:[ID)Z%T
MU(Q4=L%DU1+ILZM+[K+%^*%&@;B#-='T
MSAP6;3J/!2K1CW5&YQ4E'MM;:P9^$%SZ_KT#7'HG7/J+ USZ$Y5QZMU."FB*
M("7N[DU+MZ"-ZX0[9,2>M$9:U+!WA"GWNK;F=X/>#\9HBJL5UQ4:*%:4N5!1
MEK@?:S]A[[3;BK(TBKT4UR9O&3Y+AHNH;ZX[LEI5>S=S,Z,!YQ$!?EU 7P?,
MCY3^6>6I%M;/N)2RY%*Z<6'PKBK3/UZ1\$\M*\R\,1*3)G+S"ABW6KJP5^A%?^==[$YP;$VMR@BPW\Z)L^![Q
ME[B6R_FG%,WD)K^CR5(3Y#(OV'?#K$'?:BH<*'YKXJ+TRR9"BF*["ZKNDOB!
M(^U0IF6H.^M:8L6[%T@)JLB-D_>/PNOZS^+] 2ZG36LB/#FD>6!TI*"P:R[:-IUN?P#9';&
MC])D]!P1]MGJ-UXT:25)+,JCIR2_S3"W('^+JJ97$I[+*8*C'^H+$XWVXQ8*3]?0+%!W/I
M2P6,(\CLO#SRTN$_+\E,\/)*T#HPF
MR[(LC$;)1]]P[)Z/+Q;Y8\SK(%'SJ6D+8!6,5C K+;&!_M+;.5["2\R!6R:=
M+8XSBM.M_,R:UM$"+;TH3+WOWIS[YRA..>335.GI.#EW$+[OC:MD[\, DZY(
MK?K"8YVY73JWX^PY,3CW'PEL- ^;?7BR/,YI+]NDH6.,'-.X0X\0&I=YKS>S
MS&N"04F9RKJCI+QW+\\K!6JA)1EWA.#KX(H,5GLI("")=KS\==8673D+81)\
M]YOO3ZG?;WC<-.]HD^!1$%% 8* Q[KE$01?5FCQDR57*>F@;8&R%MA@D=PMD*P&NX!_V,9_QPQ:A6->M5T8C!G+\V$*P= \;Z0TCG>":=(P?&M[
MF27>+(N2U^R5K<9^UF[.W8\8W_.RS$Z]A-R1=A_>JGOU[,?GI[AHI=G'W9CA
MF)9>C_J'KJM:@H3#">S:87\&1C6$D^"5PJ^7R@= SL$\_&>:=\%?K9JAY+4:
M*,+JQ0D=@KN4WM\YYRCL2+)%[;%;>[F=CAOCE$$#"47!.F]0IBDY+GNE?>!5
M1G7_$]+^4&OQ[LIN?'24T!&7"^*:PPC&>93?WGPVM$^^&=X_Y
MAO4G+PL!;EXK)%(@XF9^.HI>&:A?IE53)64O]D7Q(M<>>LT4U-1^"TIB6K D
M_HEB?QY;09DZ6IYP)'0)5QIMZMSG9=QU _UU1R@)25\WY^"Z:3CH 4C)TA;Y^%'P8F1WN=A!P^T\6G*^G2$*L
MN14 <;:J\QEC4KS4:@]O98]PWACV1P/1\U?#2,I-5L:J'B[J]G=F"
ML!EM$RC>2.U8MT=OJL'=!8U_6Q7/N,J?C+OC=D_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M](,78[OJ0A2.[TJ!_?U,WX-1*MK*0 0!X, 0DC[G95+G("2\>$DQ_ZIO5W*SY4#X.=,#S1VP ) 7_X!EX!7#M!_V@MEDLT%#$1?C9U$]T7M%SZ97CS]-TIE\!I"O8;ZGHT %HT0(HVS).Q=L&
MTZI@QF3G_['."59K8@UG+U[82,,D.)Q[1YPLC7]$9*7JSX5#@[ &-([56;B]
MSIC+57(@;"KR*'CK**&JK]*1&;_/"('&%;SX ]I)0M-.MJTP)H0Z&H,7F>C&]]13((A=#&!^>9P(BAEF1[1%WE107#;'6!L"K8)[T)
M?K'MN"D\B/_""LKOPG37%S#'U_L$ABU+*1^HUEU9S_F$=(+B&>[*Z7)<=%TZ
MPY\C@8EP[!3'+(KC4.3<-2)WDZ=>(Y+[;B11=H[*9Q$/()@PF%4I L[XJZ!S
M--R-2$M/ X5 CUYJ).0, 4M$/#PN;&5NY-R!9Z.E9+Z-DS#$7WUSAD)MIOXF
M5H)2U.BLV$4GQE8O@$L*]8Y.'I5F'3'R9EP@M$(2W*RI_1^ 3;NM)#E3B0W;^F,T/7"OX^>(LV8O%\MJZB^=UR6U(SOE1D[W[]V_;S7A\VM=:$B)*A^B**H66Q+.Z$S'QNP3)S63^V?))OYYJ6
MP1",LR4,]!?$+5_VM)B+CI<
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M,9-]11Z/UDW+H 0;HZQ(
MUS'@>XT9'&M+AC']A!I5$'U?ZQ/#356&#;CQ$FD<6&^WGM,8XA! &1]QS):36._IE6.[1"P
MX'["X!HI)0"RAOL@BL2$'CY*$$@##!\MRO2:2%]?]]"FKR+TGHXMC.874J3J
M=_V;JEF7LXLE;N6M.Q-H_L>-A?V:-6ZF\B FAV66M !:L-N6 M2]Q"'T;H?V
M8*NZT1_HL9"2]Y+K%*N.@@SG+30>(AW2F/(/ /(+U;\$ BZ[M+,"F6-Q@1W\
MNI%E3:P'#EX0',I0ZW/,RI3O0.P-N\.F2S=ENJG Z=12N:M)D]M\IM)";AD2_H?<++]'&U6%/<,4RH'Y=':_Y52.]Y?CC>,)*23>K%^^Y/$
M=.)N$>,7[-C(N1/#0"(IUBMF%.WI@0W9C'2P('IJ_-(DH,Y+%:F5P?7V2,J6;6SS:);QPD&DTP*X032=\/#
M?-/>'Q\$=M_?:.FVGNE095!U(= (2G*"/M#AJ)44QW%QPQQ@1+7T;-V7X'JY
M7P9L Z(C#S!-.OKS'-$.4]R >+'"/RA>P1B'DBLTU]41SDLL3_5?=_1U 5 &
M8-V&W L%K. LAM\554>Y/H-KR>M9<]'4]"O]V'^Z:*A$G'S'<#J:5=7 UBRD
MM&C*@N*D 2&I_K,/U.Q;9YQ8XD2%>XF-X
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MS_CO^Z8:TGEA ?5Y5$ZETP\QJWE^V;0:G 20<##U&\UC-T
M,S0=&D8%#C%:&!V\DS#U+[8J<0%"0R027XZ]=1F%L,V:7.!L*+L:5>;0\W7D
M89$'XTQ7^Z8N#,,C%]*H=LAFLKP$;M-0]8QJHNCXC/HWNXM_9WGGY:5NKB(K
M2WBHLK)X0XM0(K.1XP^<09>X?*-'^I?95#?MZ\F'NI23ZS8FEDE]M/T0=KU)&&64+EG/N"!]\4]U'5-@31CSGL_8U];PQICR
MNY$&\/\MP9R)&ZY0%%AU@Z2E;1MX@FZJBF\RFK QP94)50RM< 4F0B %@SLD
MX3A[0Y_O6OALY\*+A=%6J,HW*8WT^4.N),N_:+PZ0C+HP0L.(G*$0BDJG_5^
M;W+O]99R()V *W[OH.(0&"[?K[SJ,08?]4:;]ZEJN.!#ZD6#'6C[PR"2&9(F
M06,175RLX] G!.#5H#7\\9^3[&F^S(M\$@DYAO1D==_.TI63I%,'
MJBNQKR<#Q32)80!6GT73*9>7!!129DYKY9,?8$(,SARG!;71]E/A4B9F<52C
M+=8HF0S"W(J%D-;*?:U3":".: 6>UHQ*&W R1B9KLI3JDNX&5B8T.\GN2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MVFV6VH)NBH;P.3TOM
MC?U=O/T/Y4RH(@W*1UTEHO#$=_&I7E0$19JCX%&I8/T7_%N8?CB^_8JT8,C>
M+AJ_()8QT0^*4#M>PY/7R-]7JEK[18K)]XHB>_))2HAPI?5VEX1>-T,E);XV
M1-/7,?$55'!K',MPE\M1Z( /(T8!+2I&<0"PF[1%-I&.O=%4KM>0_R*37#4O
M81+D HG122((#UI.]-IM0+GPW73FS<<:-/K>'T5U-(A4;PF Q7:LZ*$"O1OK
M%3/<,XC!FJ[45FF2B86SLNNRDG7)6G"*]2AZ*<>F7+;ENA(BT([I;VZ[BM9%
MQD46"YIZ;#X 1BPI#+3:TA).'+!C)0XP@ZLIL-"5*-L60E=#%+R$:='-:N[D
M$2#^_DOOELW5$9!U6D0?HU_K,E],3"1ZX7534S#EA.XY-II=]7(-.'/ MKETGS@IR#>7R?'W1Q4E%DM:4:W&.Y(]P$/+U49?OA5J9O($X4@US,D1"%&2X
MMHZSG[28,0#Z@R(G-4U061Z-SDRID?3JRZ5Q1=KL@N<8 6S>8J] TS/!HOC-
MV 0FYZ*A3(%J6G=9\Z P"
M#'UX)%VU9H*1P3DDXF,<:TKTAW.'27/$QER7%!U:K+@@A*KZ4(&%R!ER\V(E
MM71*D9+J53 !MSZV%U'Q83OW!(:>^,Z?^Y)!3_T1E_"?BO$E4/$#T6ZYM3MEO
M<-C9TE?BDX:*H:#[H>SD NX:7'_0WTO_>;T'QV_ZS*FJ5U^5V ^]R_ FR2B$
M?(%K8*.W CAEK%1'L7@JNX%"]'*0<\RJ:S;>TD+)Q_%Y%G%R$V5]Q^U!K\<+
M3[E1$15G1,MO\(Z< ,'#CC*&U0+GV]RJD70\5""T_&"!9T?5HN.Z"^1=
MHMV:N#;3MN%B 35C_ _&D #VZG1Z=?8*C R/?KC9>=21_%]K[ -ZKB!/T6NJ
M0O&O#$&][.\7T=Z1R:RU&I&'H8MOU(E*&;T1?M8N/W#0H7#0J]O)5QT980H=&H2:C)?3W>'4';I=S.ZS=12D S<)(T]EN:< <.
M'#G\"\%#;U/F";39&T->71PU5R!A@*JHBLI;WQ/6 ]F;8!GSY+Y_^^PXH2'$
MMWH%L:!.XBYBQEP5G/?(=AL8-V-AZ\I?N%TJ]9$Q)"1CSEYEI^I]L&\AW*,4
M[BTOB=;<'P>!R_;%XQ7Z.F5G9U/W!D6"#+'4;**H<$ Y^#!C+M:-*SFJOM/ <@B)C^F5D'\"YK6N*XFXY^V /K$"I),^
MOO5'(JR.XM&((Z%1O\QZED[;\X3&@B:(F-#H"[VKK:0P/VLH5[59$MV]X08=
MNH(V A)82(BXMXD$=$'!(<1F'6'35DQ\&,Z(:&'M4A)K94X.ICC:]-A :GB'
M#XK>ESQ$&@90!"BB3N9]]]:*"R409(,D1L31A#1\$%!\=*HD>@"%8^("%)&8
M^2/-92:D<:-9V \%[&ERV)8&0>9UB7G'J_ 0-Z()=C]3+XB.24(J)'MZ#79HD%Q, >++QAYA$G*@APU\Z,%W'8F%PY ?F.J=1-GY(S:O[+BKRNR?QMF.RJ#HQS4Z^\A>)U42V%6&FX2,)3DL;WAV@8@WXARE-J2"KEN3M!.+D&<"ZE
M.RB'KJ7" O0X.RBMTQZ"^");9T14)'>61-=<_^T&1TO-;8,N(O82JA[*C=T3
M8A9)?\P)KFJ"RPH=P9OPM&O)T@ATV'T%3JLREM3F$I
MFUZGMU4;O(#@Q# 1;;+?0P32N%#(:'Z_PEXJ%\3-H&(+/1QC<['5G_:5VQ7!
MQEF XPZ>3QLE;A,&6W[=;^?13:DSAB"/%-7*(Q]/-X/YBOJD%.,$^Z*VP_
M0A-)C<':_=%W^VK'N #;)295I;UH/5%LXF"%)*W)GA/)R+I9B>4XA]H8C!)L
M/J$LACO*KN@?$?'B5R(TB#,QUQ!G5I]("<1(SRH(DYQ/R43(B;UFTU)/45NK
M3Q3C$7K.6;YA] QDE0F%.9)^DWH?P@8$?!VI".FTDX:4-<-V"W+\9["'JK9@
M.4,X&WZYT$&-"B:[,FSX%\[T\E49DL0()U!WA+1W-/UC/O\YJUM1G+&$0OLB
MW_H\T]N8L+=B["V)#1]/BUR>>A%U2E $I;)9=TP+R_VK)J8YE!RQF^F>'
MT)//ADPF=%HM3#+-X&'WC=VQE!(YC)'N!$(=FRYR)*8?%A3FLIC7$-[M$D7*,W9*OP-P>-^2T%;A4MQ HSW"7[>)$DU\E&I-]9AJ$R4I)O "><6Y61:,
M3.#1T,JZ8!3=9 F5V\CFKJ3X<:J^-PKDKX JX9%(%&'_:USZ&B50B]NTU3M?TS%AF;);Z5[T*X./1!46^.K$(;G;B1(S$P2K/M;J7Q&:\.-@#0*2,@&Q+..J-M6>(LE%QFT)9<,FKSF(2:F7O_LZ+("($^=!2;
MI<;Q**423!5L4R01Q7TN-:\DLR*F@B?7#BF:P>2\J3_01PP %\-#XB[F5ATI
M[$^KI/SES)'P80&(@1,X]8Q"HWL*25*),E_O_;ZP44AQ+(H2@1F^HJ+0\GIP
M9^Z,PKEDLYM4.U<+>'N#CFY(O#OE/)?&X\G&0WT (M0/OIF;KK]]27QB$+7E
M/CX;0U+!2LJ%H'M,68@QLM,O%=GH$CM0^7#Z%Q_W];0!^5:'QYRK;MRK??O'7*MO[E5+Q3BX1SOU$_FEJ,[3AU(QP#[
M0+M2>)=SFQ!TVT8+UG\BEW+3C0986"-9"G#NYLZ.91**,:^R:)3;;OF_I&[W
M#& E=/P (#C->:T!+K[GGC3<_F.LY_*$*PFVB.E
M8]MECM,=-CIDG"R7$JF2]=KI7M! 3=(6Z;] OZ"6*VZ=34[]VBNQCU*>IA3+56*[YV
M4O#W;TZ7+)WFQ*7,$MU")CWSEKK,1==;9KGI.+AUR5949Q%0Q#PYO)O3,(KC
M^.LV.V\8]^5'$ (_>DJ]Q9EK7S#,4*Z66,O @9'0;=@PRB+$1,?5BVW);>]V
MM,QT;RD-#KSCII(H,4Y_O16N*S(^)3&W:<>+*JRY27F86(0]%_N3JSI2T"$X
MF!LOH?6Q>Q.30%V9G@,UHJ-G^:H"C?5_)(I-LDJ-7H(=2R7
M.TC&Q$B3]6;N&-.MQ04A3L[J[MWDB?-S&+2QZ9+XG6D%W1.1('QG0LDCG76N
M2J>6J-3?( _JG0>0(.N$TV6G"
MH<)8I"*;#HPX6!31]!/ &G(8DAN^VN_V%[,W%B84=5.03=8(JY3B-1;E8HEJ
M%LR(G4T )EA:Z\ RWT5Z7?&VQF_:D<@ T"V4,AK$*1+262T?Y<4@QZRPA-[&
MKWH[C-=04RE+W:@1G!"$Y]V"F.,_0<84FH>[$(UA/R8DCNHK$$_/ZC*7$@@I
M3N%P=;7*Z4=13VQ":%HEFN34NV+M+.T?%8EZVX4)Y?0NO>M])Y;?R^>R5X:U,Q9W.]82C!1L4]?,ZME#(&
MC4KT]-C;UH'[>K:8S2LK1LTTJ6MI=(LMUC\4#=5/4M[A4NY3_ ;I0EO!QMT%R_M(EA'+/U/*#L56C2FU&$X>:6E(PC#*I?_:K:LPW?AZGC_7$R!R("Y_U@DN;A2
M5V!&IF6:%#$7:I?MEV#+ZQNT29;(^BU!C=M8''=1T@AE4OW4PXA,8D@KU=72(A+(/P4%,FY(=TLQ
M);%:@)3-L7O%8XW1>J9&#$8/+6R(JI&UFMS)$0EI;8[&7QMAW3/MC4R!+2,-
ML2BXQQ6J]-\M G=Y2^ES.=,[9=MB/[ S^!D7;>&D!HN^_C$[1G-3@69%8'"HQZJX9U)CGTU$[G
M"/\%_D\9<@_C1M>4BVHQCJV>*5N/HFW&C0DU@ P'A-":.='AEP24-YL2C/P+
M?62)5#<8Q'A&G*N[J58T?C[AK(F]@--.2W^MQKX43,W"/+[XT:VJ03>I+371
MQLH:.5!EH_ESSA\ZKK.S> L;R3!UT!-5ZIMR4#JV \53 +-#5MD,^$I#55C9U+ZPZ3)0]0KAT)$X+.\>GDSH86&:;M:T<1;2;"%*\OB,NQB[WD
M[3#)WD@8#.2!,;7?42TET$:OTS([IVRY0F0!
MAK/2ZT1OZY64Y%Y"M[#KI&E\$\9(O,Z)-KM0OQ7)ZB6XA*$Q6G]J2+^^].,2]TIG0@9Q)'='($636/
M7R^+_A9==V[)+>QLJ6PPHNR-,JXC["Q=0HJPC#4I 2"P#$H'/#]EL0UAR$O!
M37GCE3L<(6JT^U7I^),;1PF'QR.6@! L):T7EYU,%J5)T#V8",+N/6I;.2B2
MKI+0)))+'C+LF#,WWF [S5WDW#>$FD9EUVT79Y7Y>?1\NJ8#WW][W:![8V;8
M]=)D8\G.8/X;CAF%'FCLR="*E[MU?(Q(7#<5=BG3#9>VSX[&Q<,HNU%OXM8:
M@-\&S&5N ]:Y;'I5$YZ2+D?>"VH2D,;_"^FG$JK@K1L^V0L]B $MO*6TT:*53\\3H?XY^.,/>,?G>(B2HJN@UK2+V/B;I?[#:+">O.\&1 >@7"I?
MP2(A$ O35=7Y%7E'H=T-)\I"I5$=^AU)];.QO4V!?+0LEXW :PS^V4]U,6&+
MNH%)W/#A)-,X'!R2[-XY($.74Q$M\>)$#)))R SAAZ/PDRLU^A!/_7ADAA^9!N6#< V/#KB&G;B&DP.NX5/A\7EY
M!5OAHEI!JR!E_L;;"RVEOVX'FX^0"7:YOY'XG1)RZ<)$H>FH90_4\D53HRN)
M\.DQCQA]?=WX\^8O78X]"S3NUCNK'$R&ZM^TPT5"Y$Z0*%2F4[J<M#W'7G8:]GC:+A;\>WOAK@3,=9E.D:1SU1":PX? 'BJKFS@(<="262J'OM9U4
MI(MJ:#8(>9!@!!$03)@9TH:4EB&4))Q>4N4JT4V6A;&9<'=(&47H)L6U)M[Z
MPFF;ENLKZI@3!Z/6F!\NF0'+^/10)4'X$L!*:9&%->"\HAZ3*.>7872\/IH@
MI\@ODA\"*\8CSY;0\[ ,7]6Y]YQ>,A@X/HZ=G$XF1*:-\#X 4P("FJ8N1K>
MP<%X(?>]D80BS*3+I@;O,2JT0I.J4)M,D1!ONJ(T^*/$?7^#B-M5&2+[BQ(A
M\3A;C33"9N-C)=D6)JER/^1=D?\;FR?]B4M\3W38X"QP"!6=%6'9A^;>,X6'
MU95_-N583,NNW2(L!^&/HN9^"B4,TO-RVVP"?"BT'Q49Q49*.+Z_@]1]*F^Y
MO%0V,"EQP$%#)TB_-2MVN?J*5562-Q!FV_5:"SUX![%PHB4Z](P0*+9-8=IY;?!@)MQBZ@BH!I";I(TH;5LEIL%L"+??[HGO^G=_.(RUXRAW/N*-%;*%&E,K&_U\W4
MWP[R:DJ'YGR%R!>^EY^]WO@M>/3PT;T[T[MW[M^]+%$XQ(6)OO8"_-*
MNG5GWX&R38Y-6!MGU@;?_OSDT:^\-D_O'F>G =I2;XE5XQ\;+SSW'X])7BXE
M1E)NRT(X+H/9GE4>6SKXF_CRM"I8Y[@5THM8,B--GY\MDKU/WTI-B'&42>':;0BOMYK6=26)QII(TW>N:7[WSLE=.KT_-)6
M$=IC0PURZ+"'UB0:6Y',=N_Y_POM''3)._>=E)RSYO$+M)W_M-JNON_5?_XS_Y?>+(_HO+^U+.O0Z]BNCV8;"*?@S3%_/3WS0K 8
M>X'C"?;P*OUVFC ]Y/TCMYI?0V^Y/-NT/7D)XK%W471&$U@R0'EP83B')MKR
M0N); ,Z*.:1T+H';I#]R]B$V@\]$CEH3[=R=TOC\_V2];D_"+1W=9
MJ4#&@Q[0W\IM'!)F*]4LM/UBS"6/Q?3HT5.(I0SF_O&CP:/);1%S71M1X$'K
MK7W@K0VQGG:!&8>29W6^%*5'[)GL _NKW8OULIN7K5?*CC3>VUT*V'_??/:4
MD:UCVAEA7)S \KUPNT],9XJ@0TX>T7E;7Z0'VL*;'9$.EY< ]Q':110-321$
M.4E*>*--)^]XYDZ72R0'7Y1<@*Z*)0[D_LA Z. +GWN>/7YTY/7DT8DH;FCE
MALB\&/M)]B90 @L#0$C>M_YO'QT\>7SM<-S;<%]Y;>J2/I.83P8[V+JW_>3??]E7(=8K@UAZPER.[8*Z:
M'<:%ZQL7HOJ[ONY_5N+X,A40OA?IO-[ #K%T7KT;]@W%:^1M/W;*,Q("\V825WDG@,O!3:(J_5[V0K;_&[_]KVC[83OPU4QC-1VZ_-072G-,
MYD^.:'PC&)^^K:03&QA5B:_/A&1]0VJO\42KS[Z(R'LF3;B=[*G\F

LAQ/
M'H_MQ4+)7:S/N1OL!/?./6>=,6:$&/=ZMSV2
M7.Y,?,]Z)L'\ZMYY!%-Q8AN]+D86NO+HT[<"=F S\MFS7'>GK[(/'=K>K$S(%76K'.EE_/']
M5Y_Y\;3ZN='WW]5_^6I5WBHWGNK=#M
M7_;/!*OVY(O'3_RRX0%?__7/ZP)O^?G/RSFLB,N&H0.!B5#LZW]O&@TZSB6B
MG0AE.I0_KUO\'VSA+H%*]F*X$P?!^#0$PQOU5),30Z"'[?\#;7_>L[A"L4T:
M\(:/(";BJER"T ,6I!B(ZB]<)55DT[9YASM+PNY:])D^E_"U%P*_('0V"L:6
MYU2*L-'$SZKIP$*R-;1;X.@0P04F0S&0N&RE1C& YKR!U^#VW8:AB,H["/H?
M2M##!1CHK9;E52=MJ392?(P>4]TZJ?[;=%_ALX-M)R6&30VLA =-*CX@P-WP:\1H,5UKKRO6@B;?I2+P89+UWYGJCW\KAMX?MDRWC$$27G2V(QY5B&:/.^7]/GCSY0BN5J?1]7A;@>$2Z9;T!S8- #[EA
M.8"Z*Z*-D-:6XLQ+>VZ-^0%78&DXXY9JN"ZG&GP.?-)-U>D=*+7O+O[F6.["
M3-OKC=RAH(1C*,!/>8O4 ]^K-><0&\VO" NT$3&.T'&YO7EE:,WJS%2)>)B7
M0&O*=DP\Q?EPT**WLEP00;T3['*&7G14Q1ZIZQ)01TZ49-5,JI/F;;[A\ME)
MEGY-&JB'+_EK7VKZ+JD!K/_JTKX=0 N9$H%OIGF;;NA@<]A@B RG%+ TWM5)%0H,LFJQMO?[0CV](#1K&Y(X#LX?9(&-<%>*MD"Q]Z^\;^/%!(-$O#B#1G2#1^P>0Z&\.8'K;1[MITSWB"&$L5XQ.FXM RLMBDNZ'1D)X8RT6>6@?$4Q)I >#J!2D9*YR B@R(%T
MPQ-+Y1YM55(H/N4 U\V339O7&Q0+"G>W$B$ \4AIL(G$2JBB@%1*/7 MI5"
M+P&B#>DDF:M502? 10JP*+7=J6]X5P#V54<"7HCUF)6CTPWDTIPH:J4!@F(A7/..7;Y0KTB
M520&04L:**@UI.F/CQM.YG?P,,[R-2G+%,Y%Z,3XR_36*VICA<&/R7M-%H:&G9+(0%7 9M6]DXB5I2L
M;4=3X>0;;_"(4:X[M ?L+KR2;= A.*8!0&L<6G0C@DJ7R$&4#Z*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M.UP1 #C,[5(;*&22%0(,2("TN+8LVV!F)>[9#7@B.X!" 2M)I!T]&ZG?]VYYC7>DG_YO\^>'9T\"3^Z.\F6N?<&4<9;=3D8A0 ZS%OHT35U
ME_)_:INVZA:L3CF+WM-"!& QA,@C=2-N" #W+^&2B"O0X;]$W;Y&%M">JC_8D4$@ DC99G@K,B;Q>C
M-&DCD"#4\K8%N&*=H'5-]_)(@R8=M\!5WJUMR2ZSQ%#&3?!"IBBF__Y<4+PQ
MWF 15?&_W:S.NTX[;IC6"J@^;N;>2,RFH&Y#HZIJ3>3*VK:*L#_R%J)K3M2VZR@^@KP2?P1^4(MXU-UD(^N*_1#-9JI+_,CB[!D76_H(YO'X^"]5<$)X*M
M,D&9E^_10:TC30RD0+_BF$''M!+:.9.P5!$S);7TW@H[K_0I@K3R?\_KT"PQ
MY;N3M9:ZK:*J-TKAVR]OOO5 QU,PC)_C7*_IT-W_\F3RY-&]D5H[X@?TB^R(
M+5#VCGYS)9MJS9N3)Y,O[WW9YW^41V2#1_2*$";9DT^2(XS^&'GK55I<8
M?OSUEP\>W^C7>/5IX5>DV"Q&'G-R_]'DX>.3&\T" \&Z^R^<_LQ'9/$1WYA'
M0%J?3![>>])[R-G.<4#B7]7Y3(I7J'11GZ<] P9E'\MBL )M$7<<>5#:GW\Q^?+QP^.3!Y$QC&^WGM3QX=/WE(#[!+1$OG]BT&__C)\9,'@Q_3VYA*IF%6JH?'3Y[\21I $ *I"5R\
MEA\S]!*8@BN-R528?K )W<[HN4*?0[OWQ0E1?"CC$_@WF+?67$C<.I:Z4DG7
M!;R%^?CW#XHXC?PX,-,G?U()B6H4C/"@@\#!363,"PL/@;N=\,NN1G0XV(U4
M=9B:LQ'T[+24OFX3UY:"3B0V#[ (O2<0F1>UAT^.O_A3:+8DK4-V#M/ UM.J:@A!7]^*)C(\ET9MY_O^RY6(ZS-\0,BU\:*X"?)W]&6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MN+E)-W'2>&RB_+IQX*O$065@<&.*1HX\K6_-1_R9>MB5U8IF8I4
M#-,M-0\[XKC(L-9V,!0*,DA;X"5XH8'.6>+>#A%:8WW8:;GAM Q?:J2&2.01
MT].&[]9VWG[S-DNMB@;KK'1XV\5/
M3G96Z$9+G7K8TKC!X8F-''HGQYW9;F0#'CIF0^BN60.SCER!+1M$)#"RM&&Y
MKBX:Z>-M7N0*;WZ?4R,?_]>J19F9%ZN%M$CK29Z*Y0T4T4!R0P1)1=?6Z[FX
M@"F'TMB6H!X.[C_WBN/.";1
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MMZM-Z-V:5=-RP0:\S;WZF5##4E=;%],;%\A@=(70=NQ
M7=3.M5D$*C&OT&MZ(7$5_$1V1AI0ZH-#E7:=TW74*:5*^'VN\2J[7/H8RL*P
MD9/Y>2V'MPC];&1E>POK/FK7YD]#HSV%"&,[ZOR*\VB!; 6+$D0N'0;
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M;A+9"..CY^JT>\X.KH494U3)ULDQC;M''$MR7\!8#Z+CQD3')#^)7H@Z6=U
M>B28VWFSWN^BT$DE5Q(6-D0%HW>F-ML33CM>%_DR_(KA*7TT68 7_-WD9")"+\W1SEP '%)OJOT?KVK&GV#J7AMG!1
MA^_2!1/4CW\Z?5Z^)Y%#T@A[4TG?V9[B2B1VY\RT)W%D!V=^CI+"URPU_!ME
M'UE*VU/J+4%\G?TI&35E2X6-%L !Z\B;C>$)NG_]<\[E '$WMX34+!H\8T?.
M::\D41Q @76S=N/_>]N+$$0_GJYDV0%>L67)R*^;&2CBPY<%@S D/V%=)>,$
M?: U K4Q;HV(KC0=>\-YU\= _?K-L0&;4M/PS67J%[,]^235N:+LX] @3^L41M"F_( I'#=BL>0A1OZA)62V&HF<@Q$O[T
M=9T4M#M)"84>5:RE1X$H,'RGS"RXH17G<$=H(Q]=*"NUML5B-N!UEVXCA(.Y
M9E]VL#VP2=,V9)P'-T712I+@0@]%+'LV7/;>&KOK?&GQHK7'S#=PK2>&BJ_>
M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M>^'@UI4W>[BT[J0TI;M/\]"Z#RBZ_E[FV]"8;4,F[I$/BTC3>X[[C
M?&=F1!1-'GAT<=-8_B2[,Y4!!SYIZQ@A'+%NUB3<%,SW2]@%HCCD5?*U/S%8
ME<]/CN\_>)1-I7.FMSSNS/8]NL*>^M%I[\CMW,M\V5D(G3;Z=&G^E!J,31%L6![%/N@"MNRRSQ_?BZU#\\ H2CMK&[OMZA>W
M:JNFE58ALO_P#%JO!";D6=RIC,3(!H\O /"6$FN[\+M(34UU_0A0ND3\C2J/
MH.*H08#I1MCE8$,W:H6P;NM65/[RZ\%RL6LA]R_]2YOC;6M.)5@V29M]?#>PR#,FKA*TGLNIJK&&A1:_@P"NY0<2@*[.SP7<5I,_A(-]C3\
M3-:N]Q4[2<_P$NH%$ [H4HITH/XI8+=DVQ>UT1SFCB9QW 6VOODZM!Z8"0?$
M8'5T3JW[R_9\;\/=>B09#\ EAQHA@%/AW/=R4W6(J%TV+-#CK^%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M?;1KVGW -9W].M>TN]DUG7WT:]K=Y)K.?H5KVMWLFLZ>/[NU3DMU$@/;[]+3L?]>T?/]2J9-YN6_^KOV_5%D+*2TN9<2]L/CQUGK]J2XD8$
M7!V_/SJ^G !B?)OLG=#VD,5">>M$UQ]VVGO:I F(/(">@]@S?H6=7;(/*$Z7$(6D/"3M>:W1F T>:L#S-?).Z8,
ME"T2C8/0U:@>/?;G=M:0CU]O)^B@MVTV%G)-GGN?K@'?X4PH$;'QX- 61UI(
MK),%&9;B4&0*#]&>O?P8_F+N]GAH'P/(]:DFZ9XM&P&+[G 7J*MGEW3K7J.YIK;LKBCSP!C"J+V"'K#QX_,J=K=++)#8+&S3&7B4
MP?$-BD?MNF5LB_5@[0,K>I J&#./^3K?CN0AU$MVZAL.Y'M2NQ.-G> 15WN3@3Y.Y!_'>&M2'K@-B3D'Z-EUUQJ.I(8$O"[O;_7
MA !]O^Z-6^T*&AMMAJF/L9N-.[Y+Z9'Z 5IZ3#K^7?[
MS[^W,>ZM\G\UY.;(@Q6%*?TY^G [>C0]T3M8U7]*[N,1GLXEMM[)R*N:H:%EF:B31%8#
MFHDPBI=-1>O3[18A69X!-1E6M;M>K:(@/>SSJ,T9K,QP^M09$^]\),=+CNR8
MX8C!+#K;JIJ1F@!@UE*]%PU8VF$2'OS*Y9?^2^K>[XHN]9+P$1I*X4L"URX+
MX+$K/2JB9VBX"KJ&>[Q-=D8*F:B C_=]8@2# 6'$ @O(M@V?6FA@KT*0/,RC
M[DHHA^&*]C2;?S[TRW9?KO'DB[&:PEX!&G8Y.6VVKK2%=Z 444D25I7AN+ZS
M@DN.*\E**$J,+K ?'RO08XXYTUI+J^H>C)X<$[D2=NUQJD5F2O^6WMCN0\L]
M^=5MR4+.%;+Z.D>NL MB5B)O!&#-6H&]06Z;I5WNDX(*!BBQ@)(D_?WT
M]-6M-[@^>*<<=DK;VBI=64QH) U>+.3-+G9(*MDNC]-R?06V3#R?'AHW(4TI
MA8&YQ*\/Q2] K^=4$T=:36>(U,E%A9P-2&ZS2-BHW* !FISVT35AA#FGHHB?
M<^5?1F&/:NG8ZB'M%94^CWQ MJKZI6C*3O0!X"M4=:0X"U+0?HHUMQ/>LS2@
MG((11_Q3+MRT?*9,Y+K.KWJKJ%$3028&I NG3KAV24([O7):M@!&82/I/%FO?0^R1^[VK/V\T74EI+!ABN:*"-/X*_^3R'-+\*9\)X1I

MKL3[5;[5T+*W-4M[$HD^P"/VZ .X5) M.A&_S-V36X9;V*\6V*3Z'>OGI\]Y5ZT9(/D[W'*#)2R
MFO.G&$G\\T1X>@Y]MO^PM.6G"CE]_"B043(N5M/XB4?1[\UUQ8IJAG30A--1NFB_)7\1V-U!!W["#9);&>N\Y =$6KL22R$O1V
M#("-#JK2 .0$M1
MP6@$<1W#;?W-!(9;"BZTS3:O*5!U1^O[M1#WELO$[C1W>98H'8C@+ORRJ;M5P7;LSF\D2=FNSSM'D,T=(8?^P W:; >X.
MJ%(08N;X;%LV\[LA8B'[',I"%+L<$002^%!#D>Q$?*L;6HKL@J1?%P"9!)&<
MX=HHTNB5,1\C^$$CWM,D#)7$(<>BY[=6#IX1KI[P.KQ?^0*!B5#NDG<7,4KD
M1.W>6!=.A&C8'S J!"8I81O2\E4/+B
MXWOC.\Y^*I-2-"J!L<'_M&A(+A<,*Y;!.S]\"Z@XM50LWI'5.FPI"&#BY5E-
MEO,5$)1EOI;:HB5EDJG0)M3)%!DH(=:"0V->OA#"WU!@NP<%&SD JXWW(XC
M"_XS$6DJ@/0JLCN;JJ6D (3"76_@9T[# L(,L%_T".=:!;Z0LUZQ7 LH)(@
M9+.J-O:Z87)V"3+WB(FN2KL\\LMAN7:U'*RD&W/BCP%(":NBN3'2>\P/4M'U
MI/?71$HO!CY94C(%/PHQ92]KF?\\5W@6/=PE]C#C-TD^19YHL2@>)9X9'1Q,
M!$"M\ (-MS-3"RI!^%^3:'/<9QN.3)*6_08\H
MMD/G(ST%E/JBH)5BD:8Y+1'S-OB-J)8B&HAK>O>4>\JT(:FBE%"Q*L;11HGG
M*F1384RW5M]"[/)>NDSLFF2"5X<-EU@!+#QD0#[O$DHIB([
M@"*$.PP!=! JG12W_+7Z^H4&0^D=ST77G+%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M_@5M6)MXE!/\*):4LEC)FW-P_7.$+?HNY.9%HH*A$S5,H\D3Q/>G(9ENV6";Y)8(C12
M:HTPYF\DH:.<&N8>[=52CXX)Z ?!1'6SMIJ6ELX2[#T=YR.X;R-(BLKBV#WW
M7ZEQ-FT32XV:F_8D,R[((#IRE'\-CHL>+;*0(D+PJ3!<0FJQ<'=XP'M=?;3>&Q*@GZTY1$(2(CY9QTC:U+U,:=&77RZUMZ_YF),_C[Q.^M2!P"A\3A' X1<4 OQY?/CWOPQ!Z3?3)$0SM7T[I$&K %%,D'N_-/*"E$6"U
MIEH8Z55>K4WZ"5')\OV*>4];MOVD]VCM&@47#Z^WQHC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M?4F$AZ&_)A6 '8*<@%7MDF4PQ09,Z-.)I92$9RBV5G:]:P!7AOM<\,C*PUP+@9G-QL]N[?SS$(6J)R$+!ZMA:0;S9]4\8O\ILDEXK@1#HN.$<,8
M[UF'!Q;EK"HXRX@6DUI2D6A+/H;K:D$,,P(ID7:7"SX>W$!C(.\<06.V1[W>
MYM*7^41)T,+Z&Y3PY+K,+27@Z,*7 @Y4!-KHZ"-D!K6>A$9.>;')VZRS(Y$?U>
M\G"\_+9Q"Q-E:6WC3Y0S)O0I'SS'A7HPZ2L:\KFC7T=1'P(87-+,I;QY D1'
M_"EM38\3SQHT8']Z8J*HG8]D'.@9_10ROR>'S._.S._C0^;WPP68_D^>5<7?
M/LO_[[U[7T @\Z]_R;>?O?WVA?#^>IOLA^M\>KTA__Y:.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M/0A=TYY[J_(_H[C'D$V1!,N=^')Y!=ZKS0K
MY!S *Y/>$LME@T[/123ZFD7Y2+KK$*)B45+C59R9U]3AP_]C3+*R4W0S)L/I
M#B(,_+M);[3[?YE,PDEY#JWF/S:U[.B#$]K1!Q/$:BBXO6BD:"BTFO(B1,"K
M[-0DYZ 'L(%/\ZT7KNRLJW.$+)F"*#83MAOUP]/3I^F8PI/?O#I]FKU!9M[O
MR/??/\63GY5^\RG +0S/L1INY.'RXW'I^WO;;%8\X;/EK"]X[N<*WM_/QE]W
MAQ?E;O:",]1O-M,;+)5C""1G2&DOKBX:HI.CJJF( 26VEM;8.#I\RO8\#5/?-_V5;GP!9D;]%N*14W&G_OW6=GXZ_?M?QN_^O#4^V+;W5D
MW/CM%J% #<:XKU#0-K2'Y-UKG/,Z+3/S#^M#!'-WIWQ;?@N%L,^[2\'1HX_+'V"UZF<<*",3F%41X^T4DC>"4[3**-\J11Z
MD#4U O07RJ]G5,6!NN,@>_%YSY.:Z;[83,QMSM S85OG_M1@F?7VS819-_&?
M4O/,R>KVLKJTV?R ^AM3C?RB5,&B+ ?<()8GE2A@<\6U0='3>Z\H=4K=_LK"
MT= "VH@SWLR\WBS+!%;4@YR'N];FNPZ'YW!X1I_W;5\XO>G>BN?C[1)_AKJ2
MQ?,I:J>STY[T=F-BF]NG*$ 58FM%,B..,5OY1DM08*L1PPO?I4:)=$Z_]F)>OY01/I'N(WX(YF+3KK9ZU)>8V]2
MMK44S5F7:\"I<_VTVQ%@R+[G+X;'=(F25/O7$4*DFEU,Q)U54AZDK":I<^L-
MCJ2FKN?4T'R-XM]K)JN_\XI7PH[-T=R\ W_G_]PE4$%$6$16 @P[KR39-I,I
MA^]U&NZ/)#77K#&SEN1KKJ[P8N[4B.)G4U]#/I0FTP>H*_4=H4ZR]^]-[MWC
M_Y\M2\*>J!].,)+8]U;WJ'^95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M)X_XB/8%Y#O2GBZIFE?.!-4>
M5@"DO/C#CO<0/-5O 5.NP"QW7B FHZ_-'DR>/'Q\_\@M8<'LB
MNN#1B DK'5+,SN#@9;D&CXL1IB0X,C+S21!%@P)]&I_WO&X:X3(OFMF&KRVY
MU=AZX?JUI9SR4(NT:[$BJW#'5CIW:M:9TL;8F>@+IP^\5UEQP$RXSV"3C,;K.@X.7(AMU_\N7DRR^9M S$"G[]_*)X
M&7IP[UX@^6%<9+9F)K81./1@6;-?<%G=?[&LV8LCRNI^WO,>#
MYN!.>^.4!GOB)ROC;Y,YE P:\=:Q0A'&N6[>;V9H(
M8]V\+%EQ17[(^Y.3QX_Z-^ZR2%7KC(A"5L)P$9VQ?4[/4_SFY2JU5%/?AW3T
MVWRZJ?/L==[EV?=*@L.<<5?24]Z?&)12+/-SKEC4A* Q3/DIPU33]_G&:]-5
M7GA[DI'T+U<@$-DLF?GBN;_XW?>O[!OS;$$MCU1ACKPM/#5]HM'<9M2_KEDQRPL92>$>\&NX=W_L"1:-I
MA.0.$1]Z(_3D20\>;W?67QGSLA7./EP;^9R\\JZWXV^BI,EC=F3@;MTA'!X?
M\C>X!\Y/'*JBHBQ''+Y4"8+?M%].F[G0/7GWS0@$,&$/\ZT\_*0)"&ZW0QM[:RW\([LB^7Q=TNA,^IKS'UN2N
MS_/[G?O'9BG?,$KB%I21[H!$W'8DTRL;Y=5RYT@N-18/<0#>%.6< F[3
MLFZN[L8 GF0!/LDF"+3@RL5)L44\ZRNYO[HSBI:[VD%FKB+95,WYQ' (EVT
ME#1)>2+>1,JFT/?PSM,WW_[EU9O_^?M=C2-XSW"VH6)RP?UF*\!12X2:9EQ[
M31H=TT9>=;R"=&DX>[LT&AYP3W&EW&CD*+TB$A'[>.27GX9@O35Q,)HPYS%
MCDQH,:8VN(1NV>"Z5?2D17!8,H1.$'<%'F]?J"P30L"T^)F]9+
M@%H_",DM VNI@IZX6YL+S52J/K[OWOV3B7B.W- ]B?.)SM R8K[VM&&<$C/E
MQS3&[WB,%G:4P)7"5U)+D?O 2)^V_?QZB?K^!L>% HGUQJ\7Z>\7N4Z+06[W
M>&29#.W.J_7V+MT7H^-RWY==L[YHDBNYLL,+U,=[1X;__J=?H**A"E)Y:FAD
M8X?IAS@A\3FGVL@"AIQ0>#@II0S4,_Y1.@]Y) 6=4<#MLMZ@4E/;$Y;O\5U3(@!.'2^PS4*JLIE- ?8\Q>_\;J/77@'Y68!YFS1.^+&^
M4J.XAF#=OU42!EJ%3>$*(RAKE57BD CV)F*5:;^B1(J[#U3[V
MU[M9Y_LL#I.Q 8!0 D37/;Q=_.;M-::LZA]3\TG0W[&RN\A)R95E]J[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M2R(.X9FB:.FH)7VX PNY].R&\7UR_R1[[>WF!3)H;]8MFK'_A$Y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MQ^1"2QT=! ^5EH5XM=E5.:4[^A1?K]>HO?_YS=G5U==R5LV/O]@IY:?B2**@>0+J2%?>&+'Z[XDMS
M2F;"L7>2J?F+PX/LM".*3X:E;PFMJHEM*J=67?Z5O'R5=K$VP8:II&SHJJY(
MQ1%]QVO:F8]P= 2-_3/ V!__S1\&!'AP +L! (\.0 !?H[\WM?&.22EI=8$H)7UZBKT1Y%;]PV^'T/S%'[8T20P3==IH^@(T:FP;NZ 9#/?V(
MA@%?BBFA$*"5@&P7B,^11Q!0,&6., 0*&7B#;[,(/K'C"' F:8>D9UO$66+*
MW$FS1BZ)L,]^NI2&(GPV18VI5)X!R=52WD5Q9.DL@N89X/F39HE9E\]+;G_J
M2G@!^2STRI'I& ;]VVPL@G?QDL"OWHNFI3FOFRDWAUP6(+BD]@'OH5HH/BN=
MAHBH9CFCBK.BW9PG[+2;+HA*>32E5K0C\G*LX0#+(,MM(,%*ZA4)TFZ)HZ!8E9\OFXZ492'$46(>SJBSM@]4L_-Z9-,_IC\]22 ];IU(> )QP9U]L>09^?-;UX4?O*R^CZ&0!6NR.(N6K
MIEL?\:3\8F#W(-UC0WGU]LVS(9[IO*W*N<2D_75Z*2$V G54TICZVI,'QXYS
MQ*&+MR9M;4'6%A0[@0I*/03<2)CJ4N\Y8R5;K"S10M@7(!EG5K_]=;
M?/:PB'69%T-] ^EG>C *;S(GE_I'-^+D$I8'2@1JCUPEXH/.?T7HKK.SJ?>6
M-\4V'$3N!V"1>Q"%U[I59Z]BT)A=I^?>*6()RB/*P-XUL9G\R,4A4XN()Y#'
M>P%=4TKD2OH+Z%+H[<+I0NJ8JA_R8 2:1+"$GF+Q(NJ-#T[3P)XCE\NOR%_T
ME'%;,7/03.:\ZYH9=Q[V/J!XGA1@](N%4S9Q? PG?+KXH,7R@7 Z;5N.?M31EBD](6-+B#W^OM="0MQEP(QR^SIZ]?4D&<-,M#4U<MZ>JH0%V/M(Q LXV>N0%$9M=QE1O15K!E0;J/+ XCL[@)PUDXRI7Z;66IWX+0
M4U=LDB;_ '\5:<5*A4HSMOUQO[10SFM2""%M@!-. \/<,WY/YQ2O)$7CT0HD
M @1JR*OMO/5IQ&&N+[26'&\FZ0;P+S;ZO"QI;!Q'(,V*$=3<:_DN!454BEFSI$:$11=0
M&RFYC\#E\H&+O]?C%A<9.2=_Q_EK1O\KX8;]$(: \>)_9H+<3ZWXV8""\;J8
M4AH8JLOY6D@5KTIP/>#!=?'9UPCPJ NNCY:UB/$7/'4\T#3RQ#U$EA\VYCWO
M>(K2*89<#%L!OJIS!KQK..'CSP^&LM?"?_OL?E]Z_ONYOD(SGM#M]*42(PC.
M_#MO"-$PIMN1_/Y'F[FA,+V.$W3J)W[N-MN?_HT=VA<,OY>O#@3T,Q[NLVI0[KSU7/Z)_VBN3^-_4RY/_5*TY&WV#7=#BJ
M>[W?$$W+9U][O;-S*&,O^=.'[MEP1W;O0KP07GD3'*B#$-(;692OP]?W?6OW
M6\?7:V2-?C99R9GT(R+/V]QT_OZ(V_0B!!?
MNZYI 'A@-.S28[]8W/P7->-^?N+F@[)9#P_9K%W9K ?W#MFL_VK1?X-Z"D1_
MVWS!'@2B/15M5BV\Q/S?>_=.CO^U.D>6[I-9C8]2CBDX#-O031EW!*QAH!=Y[1@KDK;9DB]J
MI15:G1YG;ZKEK.RA/6)'WW$432B^K*3U( A^(]X\Q>@XB]&)*%@[BM#H5V-$
M\TV[K+H+[E1?<'"20TV,P>EC;BCP(RWB)UG:.CX [9SMV-F'N#"K9F\>!"_1
M0M )H#=W4YX.C8W651$36!'P3@*(/(ZO4'CDN;@)$0[YBW=*E(C]N<,I."I.X8
M6">E4AS'(Z:D"\0GNUCFEU.CN("(#/+@4JG\KKD"[M&!D$X-%S?RBT[.CHN>TD,C9GEV^*2B!'U ^-.]T12G!&W$7\RW81@604-S)H
M,@NY,E KR>KU4&7CD#$W:)^(RMP%KVJP/6W$<#K/WJU=5IPHY?>^3-T9 Z>HJ3_E2S$6^1C;CM<>I^%XDGVG)
MC3<2EQ_^_NT/_^__\^"+!U\YY#\DT)#=^M#*D3;TN:0Z )@RRC%C*.Y#H=820DU3N!!N2;3BJN>SDHVF1*RU#>D)@L<^F)
M?73VPS/JHAM^3M1:ST[I2GJ1;[$(CU)-;@I6'&A5>EDK0<3[4UALZ-:@*]DL
M#D8PGFH;M@O-;W@)!QA0GQ.]^IV/2O-K8PM]J5:YH@S5*4M/N?.E:.!9"[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M\K@S\GARB#Q^HC+^EN^(HU,.ZBBNFFX+,1K9EUZ4>;C$;K
MMM[1;Q:=>CQ7WIRIM^&Z]KMR$8TX+LP2 ZCS=BO4(>L[?K7 =1<+
MS7FI[8/P$($&)(=U5'&%L;Z?[RD9;?GU3IFTE,8+K65
M]YXC$UEW#:-7PQ-6%]L.WR,&F3HG#:P%TT1R1]^[>YP]8W:X8+E%EVBB%_21
M7L]ZH]*BQ37/).Y!*$E^?XVMZ0C*1 V&W(Z;_=;J9HC*EX^/Q.KI+ZT 2 4#
MQ,)"W@6@=+L0>.AF&K*[%:\G3"V*M !F.BW+9<(,""!YU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MJ8 =(YIOA(<6",Q,*V:!TTY53^NR?5M&.@M5T0' MU*:Z__A9O8JR"&]&NV2-I@J'&@FX(92/,MQY!]V5":2K.2"P&6
M\'FC31&2P)H^*8G&4<4\NV]-H />6ECYKMB2L_4_+98GD5A 5
M UU_7A;4F>#O@3XM1![UWK54":9W7"]/OG-&C037N'L
MX8/C1W_RJS\E'J'E(-CYFM[R#&QO"'IV63JS1?Z.D.#K@"9'Y5)LY(@L3W[9
MM+@57)I(&PV&^J_ I ;^_DA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MX7.A:BT2X*M0&.KG.(R1G&(+5C=*9]I!@%/0? ==4P]M3^(JG;>JI&*6+ZN\#WG94"N=2=8V6V];0+^B6\%5T]8%PB>:GMBN-(/IZX$ZM$I(RXH(FVV7K/1G$
M)JIN,;'.C%MXS=L4;"B^6S971UYMW:6F!O76[D*_>PUNKR1(%/XAM;6L&EF#
ML5\0]5B@W9V(&42X%5K-(UI.4<%)8=HO44R9[2VF=!]:3/D6UJMN?14I<'E7
M"?;3EWEA#J K+'+Z!<,'C'*7W*7.Z0FB:W&E'FGZI"[T#&3@%MO1L9-OFV*,>O-Y34)(_;B2R8)?%*J*W(=]"+Z)]C6*>=A;$I7=\%T2?SMSZF/4UO.-QW7//K%]_8<58'%H>GHI^6VD2MX9%2Q]CB@/LCV1]J:7MCI>9,#
M!H''AXP".Q([T_\QL@<[;Y][M+IOG>LD(8O'/9Y-/#?;^(7/FD#$O@DPD]!(D58P6)4$U1*FS>>_K5&/5,75T
MS4Z-MN,-L1BWRK
MPXHDGUW P"M,;=%Q]N8"GD; UHH7E6O0#60!W'8*VJ40@SOHAS"V\+(L3(B,
M,PUJ$'2,",#JK;JPXD]L_0*2ZU&X%]%?>G#2M^2KI?1\_/SDB\>3!_>^D)C4
M-?)D@];#429-8AC=YLMC!NDL%Z[T<:7.ZY@0#;P6=,&3O)JK)WD=3< [FE24>O\7;EDRY;B4P,CIH\
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M 1"=HK)@"ZUK9=GJKTT,^(:$$:'>IX"#+M!D?:N'G^'>_:S6H]VYH0<.??.!N^<>2),XK-P4*&#O6^/B4+D$YA3A!LWKX#
M3(+II;^61J*+LMBR)//SOL)"W"GVSGYL>]S(6-F2)X&8L9;Q0Z>%UF@E/.EW
M;+AA)TH"O^8;[X)*28$&C11KV(%KR/RHA*I?=-.8WPM
M_%!ZC_-C)!SXM;8\\,";.FW&P3WD,^DACW%("I(;YWE3<+/8&WJP29<@UZ?R
MRR3G0X?!KUKX%FOBIGDG<4W24."Z4#X5UX_,V+"&S3=(GY- 7@M4H-0EQW?'B#31 C4RSS34T>2U[2F\TKU'_9K@@LUUP2*NMKDWXWE3SG4:RG(
M*.#L%_M;^)(<-OK(I.J?S(W_S'M?,<6X+T;H)&#E;:^\)>=S*OD-TAS=!M];XR+7*2..&.$-/>4-?=%(:KZ2#J:A*58V*$Y P8HD!^N%;R:(DPQ1R'*G2V
M>$",PH6!6)$K+8^7]/[>'9E@.,HG&6LJ[9Z%/BMF-;6$8%F>>[TM57K3MF\]HJI"U" :*I* #8L#N1!I2)@8GOR#:8PZ0)FC1JBE,/C16,T3035HZ$139
M8@.Q0N('[RGHIE4;(LB'3'H*S$*P&@<:LT\U=^[M_H+:VU@-1GJQDK)!6SE!
MYX!(.JO+9IW7+FJT$--, ^#S#?6ETD^A5==<_14"#,:XY F*34>=1*P1;8+I
M)A@%6WFS\N),L9U>'.^V:CB[B_Y( 8V%I.M\Q:"[/<"W1;9D=I?HXJ.]9R7HE""8T3(4)NY$50&QO&#W]Z+[-0K)#0D,MB DQK_WXS%00@K-3E,885R>KF-VLF^Y#6#=5D 2&HCNY<5^7B#+8O'\G
M_(%^M^I\"E &:^S$]'2[?X?VRXMJ^#.YP(6(^?9+.*+28H:6A42?36X%!E3/
MG8&32RKB.-#]=1GW2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MF<^-!O"MI E*76N4)'^6D@C:);%?Q+B9 A5J-&[ M*?#Q;1MT;=T.Y87.VUXT?@)E448]=N=C<-C#YO-Q80C!Y^--UJ<(>0+G+E!M
M$4);WN3M8SC>3A&:_/A-$F1)^P-R4K$G#L=]ML8??CT88!,JYM8K..2^D5MRT NEX1^UV139&34=4X)&-_FIA8&=I'X2C%EA*.=4[_3T)QB1%W
MHUF.-R=,-8F]@9Y(,X:3JFFGQQ;'*,2QOV=B1Y_0[QG%+#J-()GZ4_A&R&-9
MACYUL+M6$0O60 92DUJ>CD"@S,8>Y<- );L5J&0EJ*1=@4J>F\>U'7XA55,_
M$DBD(*\H,GK.&8--M[KGP15YR8R:,&4CZ!Q;!N>M532X&5C*
MY84W%\WI)=RJ#JP&!N7H8)Q9A$E;83\2&=]836'(U';R-"RGK]G0]4<*/#I7
MSO[TC8A*;URVHFIL(*:M'*N^FM:'C[!2P/U3Q,-:KQ_(;2K,HJX,JDMMH$J3L?L1-56 ^Z&DQ2# WI!@
M$>PT+!@16GD8'XG5U, \%3EQK#S(@FM@?.MMRN0!%^A:[2 6.0Q2#8T8^@4MH)&U*G(Q*JJ%:\0(Z>(\_RR"&&&S[@1
M'$.:VRR<\1=).'2'D]*JG RKK(L5,JJPM[-IBD0-8GP)KEW'T]\!G?#@7MW"2V0R381Q ROU7]00YDPNTCD;%%E>6*3W=
M(90M/$_M7.>YRG6^$FFIL &(5DNE( !=(&YG4G49%L,;C$,GW+D5IS\FEG.F
M57 J3;0+]?WIN>J2G"02Q4\O*=3(X[ORJ7K1 $L ]%Q40I!Z6,X,&AW3@7V*
M/Z,!/LS;YSK\JT0C+:VJ'M1/)P=!250P96,NX5^_J@1G!"L%8"#(N'M:A_PW'Q4!754]4\NHB(SYQ0GS).
MNU,=#Q5ZC,A,"1D%\9K3RZ;EQUBE9DOE!"L1$)?0$PZ;4W.?='QAY?N?@
MJ1^<+O7C_L[A_.35_Y\>>=Z : NM.$[CQ-/RN(K$)A
M#6_@4J'/6;SO'B;$X-<."ZY"=KG0N=);Z#?#\:"\HV6JVLQ,(D*)JY8RQ>);
M"[*"_7*&!5(\W2SLBJ-?"D?K0&1?CTR_#D#P:\"URA\S!H5;>%C5:9@?Q=@A
MH\ =?1FHV'K(_2S8HI/N%OD&:K@T@[@8PL5*TC4*;UNWXZ0>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MG\K!.*2NO62)8M7) 8(^M;=K$C(57HFPX71!79?[MR:BNN6WC>U1B]UO0Z"^S2.JZ,K%D8RSC&
MYM_6?#YP2VOLEH*#IZ%3-#D,\TWAF$KU,?N4]Y0D\P,DKDX]88<<[4N_3N?0
MM&Y2DS1!R^'^((.M67^PF/?[LQ8H#8PM"+W"K]0811R+/,T?8S?NQ$?F'6*=1$SH7!,?OBUBUGR42U+3#STZ]?DG)O8T
M/:MTAKKYQ":_1?MC@*L*I"ME3ED%C)[(T-C%CK5*W(:V6*DT2$VK5Z$*^&6?
MY]D!<0@'JXT$]:-JM1ZJEEQL(8391,8,IE>KI$H5#IF ,SU$L*Y%*8M>8*@R?+2U #^I@X5F7M!IYNX1'!K,:54YB(\8>^P%JBB8_N+PL,.*$76',W@,SV\I
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M5M/85#F["+Z((/*'NM) /;;0>_\V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MBAI,C2N^O_=**+0:!=8&;_Q&(3+F\>1+;WI-*C3XC]&]8TB
MV<^X&A@7H>4AI>>I\E#[;=F>J]_]V._N1_M#*KX:46L$=*FC^,"-1_VM5J/C
MM=I[7JO;W;;.YX=9I;GLLBS=P@^_XOSRYX\G3_\V9<.[+%=*V-['
M-[T2:,@QT*=_T4F.;=+MBW5X.&^821%3NY?F=1:.T* I]W![GY_^C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MSPSN>;#Y]M/&V0-MS\<[F(>0O5IDMMW&GNM$I /Y26LW]!H)\R:*7%NS73L3LUJK1MZW=*E1OGFR@W&GM[[;T20 _K*#=>4XI>O[2T V_7>MD(Y-7Z8@5+0"-HZ7%R
M7J+5H5&A%MAM,/&^F/5)+AN23#Z8MDAK/[(K\?E:**W(IIW;9TMZ;UIL&\',9H8IGM"::C?($P]F_*D=CHP3#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MUX5=JH+GJN"Y*GBN"IZK@NZ7._ND@@3^
MV(O.)$-Y:CQ-^(XM4LF&5R$;2AJ!4I0-1SVJ3>PV]EKM0UB"-1*E!"#/>J.'2^N2T"][)DHE47[L
M1;_-AG%4F\@'PXM:#=WVKO[)5AS9:'^7HHA4J;8:+/8:*\0&^K/JBM3.>Q@UO3@0'5I)DEI#1;Z
MY39N*E&X-/;V.]U7*5Q>C4VRRRV4[C.?K2QN4.]\MO%LS=*:+/2KIDTOP95Y
M*3;).O1MZNZU2JA!6>M@2*NT7@S]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M%<*AE.IE ]\SUM?M-H=-IE#/]^1ENB75;+@_:S5 *44U&Z02+A,A7A4,1#_]O*ZZ\J%>WRHDTL
M &CN+U8 M%K[S4YS?25"269$62T.VL^2[ZADQF;)C/7H2-^M1%F]#MK/TMNUDA&;)2/*;!:]QS*B86S49J.]VR@A2;C>1D59W0S:SY+QJ 3&
M9@F,]>CD6L9\ANWZCA+S@>ML090$QV\_2OK62
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M=)]F 3_5[VZYD'I0 [P5K1&6[.^;\,(6>I/W=MCTFT^[7-VP"B/5HSO8KY'HUH]VO"5Q&M0+1[]>JK:%:@V8-:^CT[[7Y^ 27V
M_UM.<&H(R*^Y1T? =:7XL_$K]0;)3VEY[\#EUNYC$>VA-N03OK=Z3O6M^YQ!%* $^>]?6K_\[#/7*3^Z1("VEV+3'E&P/::TMS.O2_-3:[KN EQL:0;W
MH0M_Q,6M2/>N*2GOR!L_(PW/OY='GAO[Y][ZZ=BUH"W#>=S+"SJ2 GMX]&LSG _RD4LB<;/!M);LI;.T@K)-26<41G+8<%KNNI*850*8XG"\,.QW_?3
M2E\\B[Y8BAY>4QJO,4ASF49Y2:15&N6HMPI0OJ;KKG3*ANN4Y>
MWB[@.95*1\TT5SIE2WX5$S=&U&*"ZKR%,\\#4#K;AVZ[N0/:YB79V&OEG"Q%
MY*\IX6Q5\I+67:F2#5MY1Z,CJD"8(^6,VNV=QO+2RW7E)RKYZ=4,;#GY^_UTS4[M5XV F6RREW9YYDP
M35(V+^TRY+M;&Z?E):6BM.TM[R*TI?5^8?_*22*O4R>F'*IU2*91UHF&53M'3=YE4>?H]_<[
MRP?"K"E]URIE\I*<-UM=5"F32EVL#0VKE,D+41,OR:TI:6Y&\
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MHYL[-$N+-0_7'[XTQM^'Q<] +2ZJE[]7PZAX&%6[&D:UM1-UM2BZ.A[IC5LSWIKW<<[#+$PU]>MB,IY]?Z_<&\;R$-Y1PHD__BJM6#[1Z*&7]_NM[E?UM%_1 O_1IAT]?+C1,F(]J%'_G4?QXY1Z\O%&#Q@H\Z)H
M]!/4N-^8HA=%C4<;2%2QRP(U[C=8Z+50XUX3@UX+,1XT"NA%$>4IIOODPWQH
M\?>8Y?.B2/8SC@;&%6EYJR?T/-A\^VGC[(&VY^,=S$/(7BVR6F2UR&J1Z['(
M'W.T*TE=+;):9+7(:I'K):F?#QKSDDKF+&C,BVUXMV[0F IN^?.KNGH0$(9
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MYAXW:ES>7GT#NAG^\H\/MDL:@O^%/GR\/W,^AC_8,]CJ1R:'[]N+ >1N+;WYPZ)[]Z\ ]DU_]073HGIP?
MN"=9'$WEH7M^=(5-_K#MC'L4P:_4A;V*I4AGKFJ>AK\2@?[M@?N[F BP(IZ" '_O_^/OOB&P_P_NJ/!4[SD"Z253GT3:27CCQU$XH5X\3_7B
M]6B/>86"V17POT$6QY+&NH:1.QV+> *7.2,3T17 BFE"(S"<=\<]L)U'62#2
M*)ZY8CJ-HQOX##5$'TLW1M RX@%'475J/7L?@M%$0C:R>>FV2#L2L26$+JUX82=%62"-PC+>NK'P4SV#I\$']&U=;W^1K@:OKP
MKOJFM 3)R"$\:U$0"GT+)9,XT<8$C!H$?TJ&D,7PC@>W I1L! R;9: 2N6<(+.$]F
MV$3M;_^UUVKN'B;YU^"Q,G7'>(KNM1\G:6T2@5?CB.$-'"7V^X27X%G1'N;Y
MC^:["'AP7(LE#S!&+@,2?8&G9E.T8A1OU]WSDW\UF@WZC@_K@C='L$N"_9W3
M"OI2AB[L588)[C/2J_:K#7I"Q$N0L9#T)
M?\87*:[4LV?\4!U%B,>&'Y[?D?K$YS_HZ1=_$Y/IX;$[S6(PRV12=]22W"D<
M88)KE%^G^"+XD@^K =Z0N*-\2?B2)22";XKA$-?F#OUKZG$';#*;RD1?57PJ
M\$MA%-;L;?%F-_:NG89NJ]'<]^C<4+ .90+.
MN)JF[0?18-;G4T7)Y@"?X2UH-0ZIEVXZCJ-L--9_IC\U#Y<+X@3N,["(YBF@
M[=!/J'422ET0K?#[@<35NM^D,T.W+1BE\_!RLCPAMQ H<+/PRS0>H!:69P85R0#2,?_8EK$K(A-:PCQN89
M&U()@$&4!4/0.4D6I,@UP+9R2)8.7U:X7HY10[A77,#\.MV5ZWPG$CC,6 R^
M@%$U&,@ ;2!D=?5(#Q;N1S%2X$+>^'#>R*EO[1/@[G)UY^V28S%GBA?*1\$'
M1M20A83>"=%J"$<41%,Z,7Q#S"^##>'2>>)( KP59:2E O]:UN!=$HTRE#!X
MTM4J02GS*1%@]U+("QDJR?I*A71>#X$Z2A9"Z$^YZZ@41R1Z$T3T>!#\OPK^$'
M^!@09QKY^/D;- QNA!^0TZD6O;&RH/?],X(3OI$S4#]!@#H727^-U,2995_P
MUHQB,7&O@2,RN"WN5B))ET>WQ *3B 1 "@1-\#"LKUHOV?;X@\2F)"A0+HTR
MN#7( .3;N_(:#LN'Y?/MMSE7K<+#CT7Q2(3^-^T^H'7@LT3RPYLH(+V8 //B
MXL"8&,DX\8CU63*PU,&EX\@U_'"MJ!K8KRF/]X:LN5 9>*!MP);VK]U;=DQ!G(2HCT&@B%P]YQI_*M+QK9AYK)Q0
M#9$\03^6U UI6D'B#A2*+:M0LN2>K-:W<>[3*D.$!,[<@_UP .R02 >E<.!_
M 9$UCJ(A+R+*8F7_3MGFR0T/L.6#P$5C"V6K,6 L7P-U-X=G8,=G8!\,_! (
MW //=3!SMT[.>MON^<7IV4DN:Q/0V(&('=@H69*X$%SS,4KGWA#4N4_Z&I7(
M%LCS[>_K&O/L6S"1 I&%Z,VA]74FXL&8^0-LUQTR8\(Q*8M];4[,7MAQY(<#CS6+)S /^C/0/10RF%=[5"Y)^[G^F7]^VM.QL@O^/D$[KX3
M]3%BC63>2H$EPM(7G*ESZ5O.#_^N$*N:$]6K:IZ4"OLY@N7N[;SK,A.O +US(AIA5&#MGN:MW]
M<^R#!3H?B(!;A48N6"B#+.%[W2<+:C
M,$K\)/?&\=.XB_,Q""#W]+0/#D@VG+DK-KS*$>.LC+@&L>C97C^1#N,.#NV)
MMX?1 ([QB"S)/?UIA"%AGZQXE+4HRE#M['"()BA8O0FX'S'(_(A]$,FO5O8N4B8<111D"5%C@,#2OETO&$3C*' _ YV.
MEM2XJ?^1C: NV] 6)E_@JMXQ(4Q?2T<*%@HA(L>*4T![X#_8Y/-90'[@<7"+PYL%S V!3J_84@AZ?$CNM#5S6S5/IK6KMI.6-4DSE8!QB]'S&\0H:CTTW"'W\H8B'_C>)_T87?1@IR1"B
M!\H>WQ1QEHE['4<39Y(EH+VC26("JG U\KS# #U^>'U_YF93?!U<492*=+>V
MKG$Y^J?^C,V"R_.K3[0:^JOZ+67+?!!!F+T* E!_&2:OT***TYGS"9U7N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M:W ?AD!.+:-R@3P7RJZ[IRD] &4^"C,Q!0YAYA,^A5Q;WMZ[0]D['4)W]V^!M@Z[J$BTHIB=,M:@Y3WS\3V:<',MD$/M3?2&8YIMLBN0M:"?-B^#DH*[P64=K95RWC3AX&C"+/P1.!I=<]*, U/M09Q;[T9#, !2#ZJD^
MK%T4 6&3"%0N7!327C$K5/9E@AE9QXX@81N/M XCCYT\&"7*E"%NY9 33A=.
M0$3[\$G^L[;A"UI(F_ZY*O),6E7GO(#2I&H<=/@&_#VDW7*H@I:@/F<[V!]"
M/X.TX+Q)O-3Q>P5RMB_)]V-(M>7.N@5WUED05D3W<<3.4VZ#DL8GL@\0,T;I
M2^ ?<7TMV7/U8_=_P:Y#,P;(C-DP//5;,/@X^0BV*"A>^"_9;UJMXCM>,*7TF!*W">S$#8'.LY2/ILL #\:I:L$(/*?)3)L[R.*'17> WJA=!FK!#48
M8#Y]T0Y2 #_)K], #'WD:/@47>Z=0WA]!*\<24R 1NJ.Z_E0XSS_A)M=\)Q
M2-A$@@>"\2E:8122?7D;N3HAMU1TJ@BIX'QLPD:=BXF\ 89 0A7+3;3PO*9]
M:5^&(CHV?D#3!T4AF[F8,B>!FDPBLA!4UB^-T*-%HP*>+MG1BZZO\9]*--L$
MQO0UV.BP(BWK"=C%B*[Y'5GFN_$#:9L.W?S"M47X3!0E&@2C/"4Y=#[:$AKV8P-'K5<.!6Z&]A:6A%\I&G1PZ:HV*9HFQZ$B=
M:J/1[$"?/7X_]OM9*O7YSS,+F)/*>1&LW1133<0(MIP_4#&5LX0@1%XQ&",X
M:ZC!;WUT3$;LL2PQ:FN6N6KV!,PG0[A@DOQM5.>8!-%.G$5BVCQIPJ3NL#GL
M3_"B* M-[SP#JQ_P>2NNT<*.9@+0I2,2W8EO\*U)!L!KR<:X-,HF,$%F,)9HON9#3B#
M3EY>+-43$[*%;GQ!X3U&,F7DCX%&0QHS](%Q$93&#K_-)OHR#_U8::XYW\UV
M%3[>X4A0H+//7(JG/L![C(>#\!?*B!O_. A+"'<1H2?7.3\F0T9%S
M$(]/D4TOPPUX4*J\6Z7*5Z;*FU6JO'P&7@7(9>E! C[S$Y!#=\8;G((X)ZV5
M"\3"WWP-\=-N%"/2@D@E4>^V>E $W8AXIFTD5K@-9]-43"CI.\/3
MR9U),-!3(Y+<86:,K5$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MT+<=NFS'D'&^W%I.+";R8_425.,!NK]S?.B92(L%J\[O5<%$MR8PL5#_,)"._$7Z'@8TYL+^/)IY#<):9L>MB:6*70[#5PB$C2A'#?9<@*@H;
MRS=?YJBZ6PQY-WO9=A2-#(!?)93Q@JEE^+8[H-)IA@,(LT-(1BT7$%M41(!H
MC&'1/#1 $.0QL%(='2"S/1=E5ZTXB1R+5.1O47 +%R71TT4F%F<#/V7:^$Z;
M9,6*_,D(';[__N47-XD'__V+#_=,_M]&HU7_:SKZYM\@X- ^/1K+R7$L;C<]I7YN2;I.;0IF ?POG@71UUGMH_>Q-H0G
MIN-9D%\T9ZM3._]4.SZ[VN8$3RZ%0/6 $T@Z>-F]!*;(6&X0N+S9:+A+(N))
M_>])-OT'UI;"_V-R6#'R_\W\P1?07$.9+Y9M(D;#H29&$6+SN$0CCE+X*:10Z32-8A/?Z<>"%/E264-F1?YE!L%-,.^H8($^
M>>#\*% WH) FI+J-HVLM#C8X5"';,2AKC+?Z%!/342WSGE;/6N=6M_;;5:NW
MS91K,^4VE6,?L8=$;K5CV87H&R..K KF5LN<2, .0Z@J&!)(>0KHR4G$_^!0
M6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MDPW 7U C9O_[E\8O3V2+JL,#6^!7BI_X>@@+_$[7))N6?X&WY5_/
M?L&9@L,Y!F$%LFSVMVUP<"^+Y9-W^=/NL0B!*=S?/?!!*%[5G>/-,RH
M$)>P(D-4*9U#2J@HC*7]F(%K5@DAB%'XB :T!6A^M!K@W>\>M#K,J.3N@_!M
M[7%+D+_?:Y+B(]&J?6]:G6=]-*5MF ,8/.,TG28';]Y,LS[:0_5PT/?K80#_
M\,?U473S1BQ,",>(R!JUR
MXKE_1&!4@\8Z0PY* OC7.\_]9Q0$,KR5"+9VW_VK[O8&X+9Z3I+U!?Z+5%,0
MA:,:?'6R+(14]*/A_YBO9@QO3 [0\(W HQZ:W@$JUPKW57&BBL34W=\163$8
M1R:I5'> 9N'K>Y!L]/N_* 21"F[!\\Y5'I/,?$C/:W9Z;:>@PFZ]V6",S'X
M@&5%?_0\]_=H#-8D2(X_/?<];.8:C/[$O;B J[\DN.<4HWH4P05S,0,Y&8UD
M(2^K:ZYT!8!Q8^!A"8;]T)\81I3U0[C]5(8A!7H7C]S-C[S;7M,CWWF6>[]S
MWR._B)+$O?3MWR)UL2+M B%A;-;#@CD!J4S3W(X%=8+#%E;9TESDO[R]Q0)::+ZV7:&&4'[$
M\-UH0FX,A=909@T96+N*@78.VXV#9G/G1PWG)V:@YEZCGO>O*C:OVB0S_&%9
MRP>EJ5.[*5&ZK2N4^,B=64:QB%.%3+ +'DOE40=./,E >;K?QJ]OW(]7&
M@[,M!%:QHJ%#,$559TG4!(%()D+#Q9I==^*'6MNX\9+-DK!DL>L;6D"H@Y8%)=UPC+:DQI-J3[ =9T [%:M;8[CK(8S*5/H<+E
MA1&8&7*Q-:\X4[GQ"U8NW$;].H0H%
M/X!+KD)&(\#'$O]KX6,$W8H(2*0HMIF7Z(KRDEA5XX^$@A?F0%,-R#0@:4>8
M*A(\$RHKF>-IU?&(DHN>FQQD?4S3)SFH
M0I?K61@P*^)\OV2+FR=;5,D<+61A:W:MTC O<%JR:G>KV:IWW9K;[-0;OUJ"
M8]LC..[4YZ(PY+'Q;!C#VA!(.$/*XMHP+)0%!.]F6B8OMFCE-"^ZQMU>F?9X
M3UO%6U:U<&^(#@Y9_[KX>M.SF8_9;UG5=^F2"6[2AND&RA-9A91TVP;HCDO.
MH0 O]3,@=V@!$;17KG,*Q7)-C[IZ82]9KFWEZWMS-,8BY1<>L[Q[-LYGL]4QHLV /9= &:_\8<9EH]R30CV:1Q(W881M!@./;^=^4]@KC$I!L-4)%=GGQ94,GD$9(@8H,KD>8#Q+.-FIGTK DMF2LA*=@.S<9C&@_-YI-:#V<:%[:P8SC:6 ZL!*]SF$5J::!VJXPG31 1HN
MF,$X\-B?X@,P.H1XXYD;BAM2=5C*2R97(+^:\#%CI;$[L&>:4; ;3PPPF?*H
MJYQG../(,)D$*[M2J?OY$$X)88_(HMH8D:X(@%)2!=.=#6;*:J-P^V*J3@RM;IT7&MV=RFDE-X?R"&8DKFH4:Q:^!A
MEF1<3C.1\2BOV "KD!\Y@5V.R0PO-.RC8 T?4Q1CM)CK[_P@"*F,F_F::I9%
MG(; 8L!4:$" ;$/N_"OJF_:B/G;$YZZ[6-,24BM9PWT4%V9.:,^EDD$B4.\?
M,%<'"/H"VLA1%"MD1U&DV,EPK#.CL'0LT12>LC(VYHO>%L$@4T)])M-3@V6M1'4BKKOOYMZ-S9 &L8_Q/.&,9"A)GF.PCAY9PUX!N %W2]9'=<]- BFGM)P,
MY"4!$Z.X6&)DSFF;::>JY F,8/$ "U15?>Z28@H\+GO2,L5SM=+\L^Z'9M[Y1QQY^]>QXZL6%I8(0M#*QWSA>><1Y&&VR)NW5\>;:M"S;QN[JQJ%=0EIVGT6O8*>.6VB\Q$M7'AA:D
M4, ,",34PFJ*A&;&E 7I")(2[ >;%G*C7AAO_;#$AYC
M(1.'&S7! W9L8'#6I]['&&%7*\%G4_LU>!!!2,9B:+=%I>LRH(ZHHR#JZV[9
M8,S%! A'L3R0J@DLPUEU#RIXO,./53VGJ9L X5P9-<,M010$EH;MCT]JQY:=(J^\#KEY2-=K-!K6BA*^[IT.-N)%,"OBE_,6L$/'U']-Q%_M;IOO@VS#'DYY+[M@>&FEY?J$>8
M*Z)@2(J\>_:Z8JD*.#&+033"L@=;RC'PB5'WN(/3?ZK]%2SIW[CK%#.H;I%O
MWTDZ#O3(L9@1_N$K5#8;ZZENW*K[C3CJ$B//)Y$RM8N]QI09$@LNO)Y. U@P
MQIAN,3LD0A;8*FVK*^N5EY)P;Y%Y,^T%=)Q[31B@EX;#^?GMC>^96_U[?D'Y*V_CZ#9T+JX\]R-8U!$(-O?HPG./HF_??/?C/SWW/8@Z@NL<
M>6K>BOO'F>>"]X8@C&.3R),$]LNNU['NM(6Q]T(#CU!A
M=F9.;XB6&L."BL]34)[NSD&SVVFK=&:SV^T\;B)[!;WV[HU8R:$I;Z,L_M\,
M]@$4>ALC7@ \GM %TK[]VW^U6GN'L7M5!+ X"& Y1I#+Q)K<42BEZ=14>!&,
ML0CN5;LF!E26 DPWM%(1_9G[V_F'H]J)4NO3XMD0AM4/^#PXI$L8<]".-S*,
MLL0I8F+@^-7YNKU!*N"\@INZV]S?WSW<;1TT=]M\7'D""P_Q)\N9D.,*/0\]T\P@,_FDGV(PA%VDZ%@
MO3&#+"RN\1L7$ K8'2=)*:@R$CBX!'T=+-%4QQ]DX4C%M1"60'?P4Z@1"8W#
MUMY!N[&WGB@F6-A^*6>-#9KN*PJBZ2UFP,YAS:F?$[WO"5*!+'.H,#
MZN8G DI]DUWM)U]<3%=@]4*A\E%%!&N12L1A=[C%(VPT#IM[!WO[ZPE*VF^T
MRSG Y@]KRF,9C,0PJKW/Q QAB.<"PP2)^QMM%NY)W;U4L",=0R'S?2Z./-=Y:"7F*%TR%2B1*2I8>)'J97V$OSU2%QG.??^P
MN7O0W5W/<^_NEG1Q[PU57CCWBPC$+<+-6'R?^5\RN%@#QJ(>8\%S["!&38P"
M'PM$/A1%?!V'T"V$AP]46QD5 A]JM:_KT:TTQQAL+NPFP[')O&-R@L-/,"D[
MQC[QV AF* 5/*;)D_1R' 9M$ _=RX&.?=L4>.WL'W9W6>K+'3DGL<6]T]IF0
M\> +4+1'=MTM4!OMY;?Q#%WC"_CM41#Y<,;('7#+W4_("C)TSK1B_W!FU/EQ
MH:=8,:K ;0ET2(N*_JX5!&(^D:99:DHMLW6S4XZBU]T_,9#",$.,;LP(E=P^
M;(+EMK^WEJ?>:NR4<^KWAJ(?B43.4)4?1V-LR>OVZAR']R<49#!]&Q35J5TN
M17?JP!H:Y4QQ>MC9R4PL1(V"@6TS$5[=-MU-[).$3'L'L8#N4W]!,_BAA\<_?/$\^YD'#5WY\AFB66DN=\8;MV4BF?0Y00
MV-N:4IP@2%2ZC1J=S 7'#Q2#>A2YZ^;ZY*/.U9V:M&8>6F<'73>,A.6H<.TQ
M0^*/]-RNK8OCZ&B[KC#- >F9\ZR/O20H(0C^AO+DP13=;2FV4]RK?FIVNN4<
MV[UC)HKZ'E)C&.$IM9N'PCV*XEC"IL$[.X%[$W\39.N+KS(4[J7GG(F_W#,&
M(/UYWJO]^=LG]SW'SB^S^$8NQIQU-Q*1M(HI\;SF9VX]MPY_8##9?Y.?4W7Q;X<4B@.W,@C
M-6,"=PJ:B"2?M!<XYS<)W[ADT-,0>Z;QJ=/C2]=
M#RC%B1Y66APCK486FR;!D4*I.*H[ \)0.+H_CQCDM+@>/<$1 - C6/P:Q31W
MCD>2$?(I2>64U,>2>>?\7MT=E:SP&TP-8VL(!U%PX&_2D&UZW760J6W$-SZ-
MMLW2 >H?U9ZFX;6:7JOEM0I8J*-H$L5]?V%\M%XXPD#)T+V-X@3C'/,02,_)
M)S-9X5@MPN!37IL.)9"7VB^\FC&9Q9JI]O^J$=D&/G8>*>?Q2'LQK.&
M1%% EI"F_@#.SW.PT!A#+9BD'E(8!]'J?CH'415<@8C]<+_B(!3C[6NR*6IU
MO%;7:^UXK5VO5T>WA3KYB#I1.XSP_5C:'7(H0OL]\[/(6RH1?
M5TC>QY(&HX=J.J!_G1?6*C2DU .:S1CM(J_H0)=M4K2T24'H/>>6IB0KN!EV
M(^311(CXY4>#7;/TZR9U2WWG4*C1+O9B>H-
M0\U4N"^*T'T89^Z6 EJ L#IZ>X622>$IGF@.WWQ$LL(0O"8,05F]/.Z1VC*/
MOY(3[.9QB77X$E,>/40$?/._@/WQ948EVR!UQ CQ-B<7'D[T%*%$K_AW.'RL
MX?]GST1!3TA;S6N?ZV@^+V)%M<,HK%'7]!H>4S%W^=$]"4>P.!WA;C8.VSOM
M@]UV>ZE[L]MI?=^]>:4L<8]DF7G\6_$%5!WX[W"P5Q$8%7C*5\M_0-^_BV#$_O]O?Z#3)V<"?[)@R&.P5^?X<0W&BNG]2.XO!I'9NDT2G B7A*U
M&OHFW"[SDS(]M!5T\K'W]L.)>WIZZE[D!?E'IB#?N=(%^7.9[^YANXW].U:$
M43K%<%7%/A;[W"/G9A[_'G-GM6-0M=3IX0CGITOW#P]/:Q!E<>K^<0;BYB-0
M@MK!Q )!_^YO1YYS.?7E",31,08WV#JS.Y0A(-:@(I*%Y(FRVHS->A=P KW5
M)'7SW@Z)Q 9$(IXYNCW,$@YJ'K;V#SK-Y>*GTVI4_+."?^Z1E#./-TP JL=F
MI0+@@K)LZO F$G&L?C+A=I1#+DCA&:W\\;K[UH^"N3!AHWW8[1RT=O:7GF9K
MKU(FJT[S'LFV_#2_B!A4" 8^P7B *^M^]-QW$;H3K=;^H8M#%R^_1#M'!R+<>#V>G6GMQ([,9<(/S 58Z91.:J)WY3'YMH/LCCH$J@C3=+$##W_%(^
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M/-P+E9KSW']G%9 P[K.GF0D*Q+R;A!*\:Y!*VY=]C:.>CLMIO+K<;=
M]EYUIBO.]!X99_-X]#-D%/IX<&M"PS^E"!_43 <^W$"DJ2W8&<.Y0BQ&EA\/,#R+NHF0AV!_LINJ(QJED9I]!6D
M +8< 9WP 3^2*BW?QEJ'=FMG1?*^55WI5<=_C]2Z>?Q'K%K\6$<801RQW&44
MK>YKO2PJ):A,Q2GMN9S;MT85K!B,MMCS>=4H,=G'(D><:I&7J%7=5\(T>7U"2I41L-.]%X*6EVEAFW[4P1+IB,=8=4
M->!*?J767NQU2TS1BL'<$"0^8%CBP:%B5;4W(M3FFIH!?;(X%[1
MB]VA'9TGIVEQ-/=D4IQ[TNJ902+Y;!&/*O:IY']8M F6T#UO'\L$L9O(:M([
MY#C@S!4J8+9+[ZW^YTS=IM=N>>VVURZ,KOCN7> 9+QAHY2$M"20.,C55"PEOC6+LW)!%-=N;ZZJ=F)9QE*-%!SD*_U(M,A2$MYB(Q=.ZH0_W
M9QAFS7QN(45@."K@QP]BEI>*X:V^NJ8M<-.WFMM,+S@U*J^GI/U62_T6]D:4X&UO)=L>A0ZWVNKO^+:1_I8B"'885NT,
M>7HRGWN-&I9@Y:;"\A;:/41ZFBRM#C/C@9HJ.#^P5G/JW%7 EB8TMFN6=YN8
M(S%:,P,%(N2WCJC%CI](NQ7VL##[#WQ=O;-K,.X".!9$8<>ZW;(SQ/XLQM^:\X64WD[0(1.H)F<< I?[H;V8A"9.J&Z^[L"RLW4Q:9WSM/E1)?#SE^WCO/
MY;C=PP*/^$;$-'1%#,00)R29H8!P?C0XD5 ;)!\R>*W5S\.;ZXVM% ,AK?)@
MJ6D]L;PBS>.QQ&IP@P9\>,X\/(>G ")X1&%=&-;L4KF2.D:46;; >H<#GT'H
M@Y@A;@;76N^2ZU[Y8\TN_W]X56M_KIAR;@_+1;'GJDX@._5NC=M%<5=P-YMZ
MMA"[%8NI(QFJ43PT_2:8Z38U2..:>A_\V]'LO$67_:L/-P$!4SN-VAXWFJ/9
M6@-_2N5?>NRA[I*G(#W82,YJPK%\&@\F2O.FY0@$9HT6S+:QSY4^[KX,Y;7/
M1[WL#&D7B\>8#T14_#)<@E6W3[5K'^FI:<'AF,KE;M,<&OCC=
M(BJ(F^YA;K^7NCN%0ZOAH?'T=#V=B;YB=NZI"DML7>7<07QJ=!61X;3J (;2
MFA6@Z$^-;:*AS6!8_F<]'^C%LQ6+=XY&VQM2ML9^J@U)]@A0X"8>A+4Z;4J0D?+R>FFHI#G9J:=0<4@?K'>*$$5^,SN*V:-3/
M"%NG&"6!C 'N"7ST#=4@)[#2Y)J[M2EFV/':NUY[SVOO>YV&UVEZG=83PIDJ
MS%2%F7KR6%/[WNT ?A,SV/?ED>=^R&#C[N]OL44(W.!W?V+@,MK'7/! W)QD0XII]J PGMH .V"[U\'#/K60VY==\BMHMRJ8"RK#OG>+0..1 SF>5K[3<1@1F,-WWL0SWT1#'TL]/L3)#S]]JWX KOA
M:F!JI1-/Q[/:6Y">7$K.O\!/JJ0389-05UE]$R'V,*
M+$+A0!>T]X #.HU5M7?-9L4&*]C@WAT$WL=1WSVZ1%1"""<""K7WP7./QGA&
M[OM+'& UHB)B//O!'^ *807Y;R+H4QWG,'7P\SK?" >>NL9@^NZ@FH70@NXU
M42,GUP2L>PA.> ].Q4+1X,[>P>YR&;%;Y9Q6,<>]^P?8H!)CYT9
M0 1\GO1C\+)35 H7/O9_'2;.G]8/[ENK]5;.%-SE7B:%YHU%7V^9X7JO -72
M^48]>[[1,,K@]&M]L)CO-^%H;SFC-9O[57YK%:O=NVG!VSC*;KE3Q;QF^H""
MY29*A9F>FU D9\40.]0;W8-V/0X*H\U.K=EF[K]% *+Z
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MG1#?]*-$..?HWV(C$^XDC%TPK82T:S+2;")GQ/9+'7D31-;:Z5%W3
MM3I9[F9TL?2FM;>B6&._XHL5?-&Y=V"S,)-9Q -?U( ,B.OPQ8/Q8'-%-;(
M\T"8AF MRG=9Q0/WCGN>1;&$4WY'MU^.J 796]B]\%,\_1-0(:IYJGL.GN>EN*;,:QIA
M^I^M0D92+$?VX/'/)7?=J)^PUJ@A;B(+2('H_E@&3CU7NK5SN+-[T-QMK_!(
M=CM5*=XJ7GA \+.*;SU2?&NM\94/0@;O5\C@EM.KK'.B%9A]*-5:L=!O]?1X,,$1%.-"]"3HL@&C)I8'$@
MY:81Z# N[R*8'\( M%VD:\3,1S0"3\U+"V;.1'P!"F13MP@P:C/ 1;V#9R$5
M&FT8[(W>;**4A&Z'A#O6PYD\GM0T0N@6XG_U[*B)P%8YV9#JG/+)C(29'6!F
MFALQ&1 , F7CC)/9=;\)TF9&*-DHX +^#9]OAY5L^\&Q0YTR
M0JPJ'=$*;9#/G:1-J2F"*IM.4Z#,W.ZEO=<]%\$V(##&*4_(DY2=%:G/$R/A
M05GHTZ\THBJ=1Z?67;2B(C,Q*==G1:37BN;P&B$\O\*\51*W%J.)3M3RX$:/
MO5(=O QR@,9!$XG[,Z*B/LUII$/$V,A<3>@D7)3&E:NW+4+'""!,P_BP82S!
M57E@EAIANIG@S2,%1[<0Z(C;M ,F!+SPWF"4,<*?A+T.?1DV+";)K/J]>(>.#P$W&R \T 15X)6]_P!5J=-MO
M?,&\9\'G'3WMH^U. ]_TE!O]$F1TC!9Q_37*#A$XVC%4B,T"R)^=1X/!]PJCZ A!.R<\L+\>
M+L)TE\E=4/,4/2G/57=U!$?DJ'TLHQ]VJM/(P;R8P*X_R(%X#(KKM+U.Q^MT
MOMW7TNJ+MN N@G.#53C6/%?6?8"!R[YG"L!)9BC=NS76NM&@5ZF&C@X#@_ZFV@
MFA_F!2S+:TWL3GE+HOJ.C1$_O\)F'FFD;6WHFN@@JXL9AS5C%Y6
MSG?& %YJ^U,3[KYD,/\F5ZF=AJKP:\%NF;?_D/? "@+%"$R)[_QW%']Q+X%U
M(C4#=@A7/.3[15$'',#T!6P-]S.;7GC_%S_OY;5+!1PX-V( $4(&4$IE371)
M6RUW,GJSVW"^@-G7;O /+OZ ;V[4V_@;_#'$-I:J/F.("X"[?D.FF-4^\K)W
MDMC](YG^\S!W_?5B"D69?$YAW3BW%;4]U8MH:YK&:O*M@.4:20Z?>J/R6#CJSVFUF84K!A<.D6USU]>Q_V+U9)TE:10HI &()/53/T"H
M/ D*' F--QYA[WI6+RT43='Y[IWVH\>@WU.7!*N2&+@-!PUZ,%NB"7"D$GY
M.3@3+(KAEO(W\$>VWM&UN9<>P$XJ">(,B ZS"50FT@<)8Q=O>5,1HMZT\#H5]<8 6JMR1D,?1:P>R5E7S?Z/.?B)\'F7_\ =%20?H-6P3^&PM8E$RRMG@GS/VM7N1Y+X*.<(XQ5E>X\ (^.< 1?+7/ HM2$[44A ^H$',M'H,
ME(B4T73:XG5/ODX5$I\F9[;V6@<[*_ +NXT*'+6*%^X-?WP?R#"$H\:97%?2
M3P.>V'8I:%Y.[6V6C'$^WV^64":[TBDXEGF;0)#]I\<]*J@XB^#C?) M#.8?
M-%?TZ6FVJ[**50=Y;VBD/237??>OXM3<&MAT,I[*<)S-OB&6[9V9L M4I7**
M?T;8&/(W#^?64I?0PO1AE4X"+^=;- 5/(_1%+?"_:%M_Z^U3+9:E;K!\8#+R;8;\X?Y!>V]_1<.^_4:5?E[%'_=&05Z AWUUJ:!B
M.F2F@Y9T<$;(1Q,)G_L07;J?0DE LL9A]T#N-YH5%&35.=P;6O@^"K_Q"+-
M?JN="9E$A![$9FFIR/HT3OQ_P,BGQGH@5=US3Y4&W_@#!U1V#XSAO.JI*)DO
M.&N@VH:H<8C81I-VKK7YA3KHVID.8E_""C%B.BK,X>R11\ UM=@^[[8-.>P6T\#Y@]_7-?STP<]MM5)G;E9G;G2IS^_R96[2H)4>$N3=\,'.;
M.YBGU.UF=%,,'%2HQZ,0E#2IOX]N-+;,#V^P]^Y(F!3>?,1T25,?;RX=-\$Q
M(;H-\ +&),\!JRBF3 Z>/;+W2$K-TE>_(,M9RLEVP>D"SFLKYNU?%*?F&N9[
MHH)C&_=X]+*H@UXP!0Q^;&[JPOLI?OOQZ(HV\I$ !1R]I;&JK#7F]KBP W4*
M^87'_>;+7;I:>P4F8+/RE4]$5BUOU4K;C<M*M(L>;6D;3VZ-#@R.;-72]1FY]'Y%:-LT8)LY9&MCZ-[%KZXJ$&6.%V/N4_0
M(XV=1J.YV]E_ -O\/%,\_\[S\ RM#>TVAL"=XR1<$E;/2Y'ONMM\ QZ3)AM1Q>?3Z]./[Y_9I'_E!/<*;UF?'/_R&&.!,AN#*(0)C_F8>A@V_PGYYJ
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MZW"5*ONU-+;ZC4:43B,?JR=H>1A)_3";3,?$#IMF?6-5G#6<
MBL'89"8NU#P/\<'=.C_I77S8+LCMHC">RUB\.E'\:LUB??"V67Q)K=Q/_ZED
M[%4V 7Y9^)N(!SAJ F3/VRB4^1](CL-?\M^< 2>&^)N3VZI
M_9L4 5R]CS*]C>(O\.T(RX"BS9;?G>Y^N[O3?F4G#X*7 5#4FX[$\XF-_RPT
MHS-PA(*UO*J=Z:L3U9\__O'QTY\?7QD'T?DS/F'=>. 9:!'/ BREPY713/MH
M-'/9J\!_>NYY;[.E:*.ST^WNOSXK>+Y9]Y+,V:( ?742\K7&%7+)R,I6]5W[
MCPI!_>=5&IW4K83MS86.)1LN)/>[N^WN*X>W*EFHH["O$][Z6@7BJQ1X'__]
MF1;U080C[*;#;O9FB[J==G._O;OWRDZ:V9O6I;--13M* #'*4IDT6Y\=3+QU48\SXY?FQJXY*Y$M# ,_7-W CN D!RZ'W&4J(RQ B8:
M?!E'P<2:;[#9TK.[W]EM[[VVF&2/EG0^%B *6YXU$LD#\4B#"-[B( +//0_$
M0/:CVA$\(<;>.$,V(Q&.=7(C@@S[XR$,P(0T,;ZI0IT@9+,I?O+J-B*QFQ3E
MKF'*!1S!RH@GNOB]81:\M\^8'Y:24]KN-G<9#C-]'+7.^/T':C:M"^I3BRU+?HN2J3^05.^X-I2^I]1]JMX&O:.KTW^>_-^/GZ[^[P\)XV=BPU8)
M]U*QRW]RWOM/D)H:1^GW+%&16AKL?+FSN,([)#)&]/FX#^%0ACS
M# U.4,$N_>OU/XIFY^F/XA57X[8:C6;W]67)EH-VOU-#-H< XQ&J"'M4AB5E?U:V"B/H7FT.)U$6V9-%*7R6F$)RP\OU8_KBF!#*D72%^J(>'/#)>Y.
MI]/<;;RR(^=(RJ7$*1(V%(%K=W^X6(+&$F%#Z&E$K%253;QRD5S53?PL!5]O
MW42WV]C9WVN]LO.>!T-$DSX-/61)F@6ICS-E_&D [F(\<\_S,4$8YT Q;+S6
MW#*^S.(;_R;2 OEH'$M3^!6L0Q^+6BT;GM_K[/WVOK;S G@JSSZL%9>8F7%/FO%V2NCP ,0:H7Y#R]H
MT.2#ID TJRD0*Z= [%93(![.P#:AP;9/:Y>21N)J^C8:%J,](=,_RD;_"*-;
M'J1Y;B:D7_C)EV0>P/A$5QD>ZQMJ^_]XVO?T^CC UVSTZ5ZX'A-JKR)WB .A
M,3 (_N98@.=)LU7#"&?27OOQ1 [5K%8::P\:* +M-%3X554+)3.>4I0/7JV[
M1WI>B6?/8_43=XIP+AR\BO-JY3 +)&^ZJ6>5?/[#/?.3C-]P'&MD/"',;/F.4-Y3>ZTP,FP!!. =>NAJO >'64T!1E^-/8'XU=0><+3G8?1U[/
M> 8LB6>:7*2326XX E-1/LMNI5 $<_Q:2*M
MF>RKY[)D":\KK/&LKFGL3W#4ME<8"3[1@^]I01^]C[5C.$P<>9_&LVD*BC[$
MX<]#>%"* ]K@GL#N?H@6Q]$.0L-A1#-?1]CJU,_JV!/+XT=<93JL?"_ (
MI7K6UMGQ66^[,-8U'DN@NCN)PB]REM1=G,$->QWAS/N$IWTO;L,=1K0F.(BA
M->*;AL]+9V[\]_P >C.3$F>8*[U>MRT7BB"&0W*O79Q>&X-]/8$3+,@
MB&YKV12OH7"OXVCB2N#3U)E&$0(=^7S4\'8U+)JF[8S)9INY-U&0@0V X7EX
M)7 >\B\.9\[Z"2GKU!W"%6+&I['-./ 1CA0QD7B5<9PR?0)'SF<3GM,[AON!
MHYS-''1'!(-H' 7P!'\0I31:>B#"$#['P^B8G>!,K[.0T+XXUG@R%2A!8 V\
M4;P)L*.()B+#^Z>%LDGDD$" [22 -V9U]T^227JY\ %M*$G5I-(A)9?ST=!#J>M@-,M*AW8QXVNDB =CM6 _RA# S76.3B]G8>W(:N@LBE [%EI;$0\B52/ ;?YB9:R%]U&3(YB"\D(V0
M;(7!U'0-4/;8GP"1Z$]89[A; 79R3'& 'U@!;DI[0O:,\ XBKZ.\P[MR)UK$&!,KAGP0[+-^A0_#0>7!2EK/3WY'/[-ITXRP;JO..1WX!?9A]D"AZ4S
M$ G^!,I+$XC>DXS13DO\82YVB0N1[Z;:H &6@N4J8M!6Z]8:V+"[_&9NFX?S45K.Z^I=L$O"ENA!_0J*T QYN+%"XX:,04]3WN'\48
M\3VM2!U2?J*U4/SMOUKM_4-<4UQ02L431ED%VC:(ICBF3"+OP*T1U_!.(UA>
M_M70QBA#V#?=!K42UF/@.3(_KZ,,S8D(?D(F!34U(TY-HZ]X-69./K,6&=((
M8$'7>*.E(QI/("2F>:IH0.,!M=!41@)B 3*\<@Y<.'SGOZ/X"UK<8%=0=0,*
M 6UO4HWVDOKL)9_W4!+[
M#>?+R'/;#?[!Q1_PU8UZ&W^#/Z+5 J0 20KV(*Y NG#7\>%;.)VT!73N_^.R
M=T*SIN@WS<-M5OY:IJ* 5-_,+4]:$5BUHR0MK-D9"Y!E(%*(Y;04!PF9FPR(
MF; , %PPO6_B!T.>P1L##R**C7?#]A)\<3H&8P^/ _-[T02>DWK*--:=7:V_
M #MKTR29@5("^<\C%WVA?NH'431T"1&%MA-JGRA+75@FB#Y?T$*U>X*@N1@)
M1^9-_F@P&>,4)[?S]^&(:!O)#,PT>-P$'0Y_H)0''(< K2!H'3?P1QP7[
M+8R&Q"GQ IRY!*7WQ!_% C@%)XIC=%'9_@5NL27\-([0(,9_F9'44>P4M-\4
M^3&AV97P3_0>T"(:ZH(M,X=-!C)$(E"@-=#:DJV:(1==];GH"N2'+K9BB>)A?FO,AFO"5:QBI'O]X6^'
M?Y'E#P(I-0@CO#-N2*,B<7%ZO0Y;46'-;$!@/168(%/MYM>Q6 O/&T>=3M!^
M)D?M:$/%;!A%&AF/$TS=3]5OT &17X "R.+H-L/B8(,D>PIM S-7CTF8'[1,Z1;@?<=I)4@'Y77@ISWMP"14GC:%$_63L:*;)&3[C2]OX1=_
M15D564XE@XRPFHE9 "ED=$L#$ ZX9,)GXGFH
M,C^]7_U@LJ;]Q %M)HAWAWZLC4:),MD?A1QRG*'@H+G5NX<43PIQV51)J 9N
MG_:Y_,2^_2\P)/F@+$:KRF*LS&+L55F,4A(&ZZ$:+8]B"R1+Y'[A%$;BDM#8
M.9P(,,% B"?C.(HFB1(EVPY8'K%0X1G+= EP4)2+H>[K+$ !COJ-0UP8D@(9
M>A1-)A2O ><$(ZF4'E'&X(*!@WA(>,) 2>SK0"3C/MZMZ5B&$>@Z\0:M&(^T
M9%^0 I["2\Z7/@ML'PL>_%4L!T"M+#YJ_;'MG::+F3
MLT7!M *XGE".0$3X8)MMZ(>#O)#KF08N)^A009YN&E,R*S=9Q.(M(*Z[=4T1"#$!]6Y;S\K>W4;]!'M&ETL?NJ8&F$A@DT_$#-W68IC%1.K-@8#Y
M#@^03^&KEI%@[]NWS,#'E?-UPFY;?^:>A@.?@S1;P%JM+EA?V]]94T$++.J
M,F>]&QV83 6X(B/<_M?#^0GP/SCPO;\XCUC/1$84"+S+#^<%'/Y&%_-2+2F.
M8$8N_'L_?O,/YV^C]+#5^)4)O 1ZH@LP?\V)N.13=XT];_VZ8!MJ -[;2AGNFNQM@NL(3:+@E>:12V!_2V%9J'D&L48I*IA(\CXP(U'_:U6H^.U
MVGM>J]O=7CS^N<.M-U%9S1UP3?WZEW\TMPO[7T:3AWSFOAO[V64O6\(C_6Y]
MSN9T7BG,)9% TJ'9@'HYU38$I=A44.K[VSX7X"=%OB!MFF$I,_IB6*)<__Z7
MT7AX8Q1L4IW_8Y]_ZQ[W[@&?J<[F$<_FS ^&-3)),W]I%B
MG]__W)\1F#LA13>N796EQXHGG9/*;[X)>%9'_MA'WK['5;O/9WY@<]7YW&.3
M__23#.Z%#NASI/+[>SGVOWW#-,(]/EJ=W-.<7.<>M^8^GZG.YVG.Y\IDXTP&
MSG/!\#,I HS:I)&;WB+.M?EW6,4;#B6C,28[&*>?D)YBP'&8Q+@75H!ADZ4/-X&5$+U0D/%[PX*D2]@8"
MDX7L#7-.&:ONZ&ARPP M('S,^9TH'$643IW/2=.T4<\1"2Y\,!8(/X,5)AAM!"-G:-IRU#'HCM]")!)F
M;BB )T*!$ME1 6Z ?2!.P(4CCU$[#XDD* ,B R8DAV/DQ72"+JY"827_EJB8IT4G[*[V>4
M@HH<,4M@%"X$8TCYM8G!,.&_8?RVD]A3_X$_GZS^)1;&02UOL0_:-BE1J1N;+K\H[Y7
MQ%06.F0EL1V+V H 3G^7-!F: ^Y*XBFDDB!@J4XNP;/!V!G"C^@/*&[!B "R
MN1
MJ8ND>+"P58J$U]U39H!ER5-:U75&;7D5;B!1V$!.KX\I;63"H7OC"Z0(
M784YEK.O_]PU]Y2 X#Q!#=RGZVMPTU@T$+C 1,\]1XD,/$@9WOAQ%*+757>/
M;'&0G]N;J0KXZZ5J^30%B8.W$1/]ZO+.K5B]B6/Z" E0Z_X+& M74WH#U$@PF]B2@@I@7"H9)!)!@P%+4DH$I,UME 5#QOO"GS7.@=,<
M" W%^@*4(%CE3P*",$A9J)(_"+0GH+*]_"((B(!+!*=F642D-AGTOL3J"5!+
MMUA3D#'" #XX261P(TF=OZ&T#IX,XK 14Q%CU@NXG<#=,;&%DV_7;#;A"T(Z
MQWJW*]!BH=T1JQGQB%_>6"'TL(1^NTKHKTSH[U<)_37E\;?*N-.6*@KP/!;&
MF"ZEY3R3''9(7"AHU')!;$0(J :J&;H=1Y;!ETSEP+]F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M)9>)NW3\T.N.\QB;[65-T:/SBJQ(7NPHPL_5# ,I&B8.0VQ9A/MJ/ %1OV2]LT%J4RLX)1)>A6U/==+P/G@OOWK&8'Z"42'O,5N!E (OC@*9.*0
MHS/!6EB2 Z3?B:T"_PN&=?!)DRG*=;[%_ X[4'2EUV&M:>P%LSVZA2,L,(NQ[-U<#U/ B?*HJ#RW56T<7P6X\,""EBVR6KT@*:E(3Y%1
M^:-8WV%MK>YMJ7K0%#6H"<05&(? A7"=LQB]9_0V;[$84,YD,A9#=78!VAA8)TFEK1'M1;.$_%9VLM'MFXY!!B0+[&)7!@N?3F-"=8?1(-/BV@=-G:;LUH*M=BOB86*"
M&* +XN%2QN?UC\CU)RIAH1%[U_CJVC4*)]V:6E\(,D 8V:Y>/ML5!S6T:1H-HI"KK[WRC>1E69"\&ZIP(!EM@YXS+S$>JWZ=6*''VF*O.[RDZ&
M8$V$(,P0%NGH^%A")!+8>,(JB&>F\BA7HXK[@KS&7$F*@L Z BT*6@T;J(]O
M,:U#2VBUVT6F5U%HJ:8B.<7J(+H&IE*G!K+'QW+DU(KPNUM7%\?;5E5.'D(G
MZ:SW@R*]&-H+%3P:Y6V-;(@9!ZT2\-6P>!/+[O(R(MSPS])J"Y"HJAS8.E.H3#I5)M044XEJN),S?;.PU[RXE)7*!#YF"TB_J%P-=O
M;2#'XKX2L&2DH>A9[_CBTN7CH0J8V?Q>ZNZE?H8V()-BI2*"Q A7[L"Y,P_#
MIK' BG:@5Z]]-Z74N8!XD<]%I*/B(T?
M-#^2?:ON0^^O8X<5F7%7J>AQP%U4A[X8A51LB,J!?#:16GAO;3@S,V#I?4)!
M3D_36M4AJ0EF)FI>-+O5MVDAC$WOG1B?U02$J4>--BI4_)SKFK'M30RL!D=.
MW&D4H7LYEL!984W)7?4V[DD2HI_DB(-=:](Z-_?6
M=SL9KV
MH\FEW?2A3(4?+''3T7O29ZGBX[@HX^C3R0C5(($^3=]$FACOW:4^.1-.K'#<
MFDUM$F44SL#V-DT0YLCHF$)-MM^IC%DSVRW&MP)?WB@>7\)MJ: K8/T.KG()&WB4S/VJPV+%ZW0W>U !R\RP\:00^5JN/;2X?+%E$5>HNU/W
M/%>:U!Y'Q%]DNC2+-]?TV=%C43;9BCHOIM\7;29F=@K:)@[FJ^$^!Y+_A)J<
MRG-4A6VQ$8+F3V6'@X+'E@&4MV['>B.K/T6$!X<:75+(%-*0^8OA!%WMODI-B4 >XL8+Y>,=J/*#ZK[76[J]T
M:6@U8%,6^J)(M3)EF2IZ[&"[C[C DSL5PS$V3/ 6^"*G(FN1@(:1%<6R&RG(3JX5PX I%C29@
M++%GE>Y71[VG0#9ACP!LP*,%HQW21N$RMGU-H@#18C[FJ/OYS!V&BLR!30=>
M'"%JB#1J>4B1"0\ZP'/6"7//&?J!/R(+88(10-1DY-5&6ELNV?0DGYB@'J_B
MJWV,(E!5/C;XR0,^IB.CBH6 N#'!2].*J^Y< 85H50JH4\2;<&QP,,"2'4J*
MY"Q#,1FC,F+41,8,YEB(PA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MHS^,@JB/$,V1><=2J-D&W.:Y14@',1=6R*U/0
M:[Q>G$N@IR:<3J"PU33 &+ PH-$ +C]')LG82U(YK;OOL#4KZ*J!J@Z@W"BW
M:'8PKZYZ$N.O\]#T%P2-1UE,T 9JQJKL3SD\>/Q3YO_6=Y=6/-S-8'>6_A<*
M^A^ZMCMMCU7] >ZN#/GE'\YBW;O:X9M_K/S3X@"(!YA72+K]G=W]PF0*++'X
MP:D2O_RC-X'_CU /94J&E _N%.TW+C("U;62Q+X?1Z\UF.\_P:>\:&EUAQ4
M:][""(KO5'NL&:.5P5O<[>"_?T%N?AV,]OD/V_PQ?2MMSOJHV4VS%TTKF+.9
M/L4C$:KIW\[6Q]_.CSYM5QQ7<=SB\_Z,XF!XBY%LS4_SO-3#'ZFKS9_ 1[UM
M;[78<^X2>_RTK=,>/*5BQHH9ESSO-+R1F&/1\""11]SF ER<)XN3BH\J/EI\
MWKD%@&1T'C=2IS OAOQ!.6?(\K;Z*M!L3N:!#5/5_$@_IUC""'_D0.,1[HN6*0Z-[$7CT*<292X/=C$<_JMWX@9_0I
MY^/1VU/XWNUMG?-']2@>>:ZT?X!_BR%8:37^98WR:AA+26JM1JM)WVYV&W7\
M/7RD/AK LU0Z"O[EJ7^*-!!)X2W]R6"BN^$[?3^"'S!?$8N =X"KNAU'=9^Z
MPB<#V'L_X:_BG_Z:)A.U0_K\IY.CXY)NSEJ%[19#E81VH?+7H7]-(W@P$HM8$%WP\&^3@'AM-:R$"L9PIMA"!)$CY!@0PTE-SC3R0SU@189X5-RF6JU+F6AW1P8)=Y:H<%OR
M@@)JE:!\$@-MSBN\9$2:>\$!Y(33,!/Q%Z+6U-^,+JY4;\51=W$4R9U<+@[]
MA-KB\0@3#5V>RE!JI#'#]A1\S4&Y-X@R[(DU(
MR8UK".2DV_"H;)1"^6(C'<*OY=W'C>(SW3_R'!]#N?)Y'6Z6^@Q<%=BCA5/A
M-"L0L2ZAGHKIYIH1T4%Z#!F'FVYPMS-G7E/:']&9(5.F Q;27MW*TO-?J3^$
M2?6:OAD$\Y$IC;*+KM-;[HPB=/X,MJ5'5?QOAM4/PN2^X.M_3Z.;G&(!/51A$]1$ILIH]1^_G+"VB&M0"9B+@\7H4J<:;:>3E'7W>-%JHE!
M'"6)HU='=%6:W:".!=8:B '-C+?-$B:DLB@T=(S1_1N;<.VYXRC@?*2I]T2>
M()L-K;*0Z[<4J,P9Q2(DY"^>B&F A26*$_G_L_=FRVTCV;KP?3X%PE']!Q4!
MJ30/5;L=(MDDCDL'+-ZUM5K$LBJNAK3,'+W,07(YW"+2/R(52Q[FS"VIB3R^T"C"1#.LE^
M5,J%4I*3AVZ.O@8&H..*KOG0W4Q.G>>-R7SW4IGU-,Z2KL,57,MV30H9EALB5MQJ5&QE$WVP*SWDAH2\!UCK!DPZVR46(J58#OE%:Q1TV9S1CQ'
MUK4J+M<-E!S,!EH=1KIX;S#"3@ )[.9U6:YU\Y??"2^8:E+TRZ
M'<[*JIASK5Y5^M-Q M\\C7&<3DL!B4"/&)69#J@$0""=5QDV36^&*@U24IWC
MZ/X/F"])G7VY6RB;(E6ZS!:B7
MA'?OA%E[V]U2''>6*8Z=*8X;RQ3'ITGAF J)=7II]?=78 (5@[^_ M9Q&?_?
M]?6MM?^=7J*)<9]IC0^[^@8(5O+Z'24:!ILDQ8U.9_,1J3%M! K#6(G6?08Z
M9HY:QC%&]@GUL-)*ES5@X,>'0\3;H+_>ZO: B/?8D0V.8@]TW;TU6 \E3(H,
MD=>R!\@^K%S_#1:L)6296ZUY:WV-LU*?Q='=@7"W'X)P'QN^K>\0[U:-8AK%
M(TJ[^6?)H5W<MPRD? 7KHOD3YMACD"1>C90X.*"%TH0$I%6WB,VE+8<%ZOC[BWFQQM6,CC;MF
M+$:Z(-,.R770 V"D9%NE*780B$L!PJFD_D21I<6];\$R1!1U-#*I%'R&BZ"L
M^62/-I:)ZN_-YA%! +PH .K6^DB:;S8!,>$50.^![3^%SH@4]
M)N- ,J#),C^>@8(::P.>(=0$C9F\($+[\.Q2MONR?6\IVSME^]92MC]-"N]B
MH'L/S$#O&=#B1K&_R^"/'-N]3 @L7/IVM7Y@H8=80G'YQQ1J"<=;"@P($&1>X$>*C=MK,,[/UD4HT5U8YUXH+>#Z\ \&$
M!>^6:E3P6_@_PNWT 75-:"K)&C,0#27O5XSWI^7*,)X2E K5YD<8&T.-A"$3
M^@EA@1FHFEC#%&.GCF1 0.D,4E!2WXO!&+%\@A+>B2$K03*4BBPNWI*L 3J0
M4YH+_?.C=EG('C.(5(5'K[#7+XQZC:DPOOJDP\2Z!HQR:T2X4?:*0;*_'V7I
M81!;WF"U)2[I(P91G[,#P[;L7454U+**?1BF>MVDTTIBBXG%&\%*:6X35$0HVDS002SJX+?K.AP6_V";:M# .+NVT05!AYC<$W
ME$9X#2WM
MJ31@IZK$NXQF!\;B\?;X/:YMA35"99:&Q<&MQL89B>3 T(W6*^/(CH4\+RT.
M.(Y&1=//-@C)5>ME^H>W"XJ:Z++8*WHZI6"/(R!;64,!@$\%R18!KFJMTIF#>L2:'2'@4K<&)17!232'RZ(;&J5KBA'Q3-V_ 71QQ"%+$!^;'A<@_W1E
M#RW.=,T<%I&D7KH@[A2B]2:9E$JS# 93S^;.]CU;ZCV=%0A94V)[^AH!"PP;
MIC:T9#:P+D2(/'@ 8$>BS8E0=.F\.]QA(8O(G6%A_4,G&T83.4+PQI-D-L&X
M],"%T0'[%G%[9E&J,',G+AB0/?+R>(AC4?Y%168KCI.IJ%2MD^%'
MX6W(E_$KK,P?MH5P \D@H4<'C8TFAOZ>6&!8(4)"U=,'&B*5BQ"EB>+LQM4HKHX8S$; 7R'?]
M(1P'E2\V%&K=>N/P?]]R*H[IIR3L#.<'&U2B9JQ7@K1 #>C,.!%\C* 'DA=&
M=$A04;(O"09,)B"*"M[NFJ-74/I<;J3EF'_T9Y8P0.0:"YF$7."7O!*+XVYT"/PO>L1H<63AR!:TE
M\9M9VXK3*1D?B)%N+12K2CS;&W(WQ]'^TG'4Z3C:7CJ.'IO&Z;^KNKM#ES_Z
M,!WDH/<'7T#;,OD*O<,O;U>>MQW*T,EOJ'B*18DQ^4I.PJ3^"&.J!VHBES?3
M/KZ\U0B"J([-@W,P^RHJT?>W]ARV5@# V87AV@J#: @ZTT#; 204M,7@PJ@[
MS:2\65 >N,721-9/:EF%;8W8BF9@4%; 2V >*?IS-,2Y5$8)+@\"^V0,UM#>B[(C;:$DC BE/0&9T+1*E5*7!'>!>-C&,M@\#'*5\1='>0G*CN36IX7DDI
MK:"\5$[3N8/*M^+2B$IL""&JC8L^2AHDB3/O21<8DAM5$)ZFSI)'!66MD<0D[)CD9,-QB/L*$XZ?K1B\,-BF03^Y#&9@*E;223*E+F)B8RFCKQDK$<\!
M"81.'_9VFDBFZRC2.D;ED#[H*-)"%I4QW6!K:&W9))VO!7^ F2N@JW@JAN)+
M122-6'&F?ZRY)J$V?I/"T6K9;8CMD+T&Q?TBCY[U>:+?##.225TL"2E)D'"E
M0G%@ %Q'"L\.37K4+O#WTC='ZO4)\58?/'J52N/DM;Q(,P'-BZ3%*/6HO20"
MB897D;9 +&0RGQ>5%P%#M'#OMWF^7E(?JQG(D(L19X0=8<3F(IN0_$I1R#@N4SQU(4^L;9%]1.R%=4* -
M;U/<1N5N.DL/O1Y<[B0WPR!&N^ 9=C,)@0Y&H?NY [\NY
M6X=UA#7KT4H8''\)U9?_IJ$/L8 !!HU0/ZAX,)H=>678W-<3=EI#(@0_IQ_@
M;0_PGP4K$L^6T8KZ] 7.%)9]+NWZ1GD^A/]#S!/FI4/V<5$CQS3F^BW"^9;V
M>(30K:O*1!3JMC'!E[5S!%/,AV'P%D9D,7>4EQ-LHQ4<#J1UF/0CA,OX[NW1
M(=XMZ46XXCAI1C$Z!%-&@207,?YW5HGGV+ZZ#"XQ%H!ZT@0C#_PXNC)T0$1K
M;J%+F:%NF1@ZE2/T)P(*19<$U3X ?$UCJ?XN=)NY9!SHU+Z,7S$K1$==S5]
M8>I3N)#[P6:3D8,BB^:3/&K5QT+\6M!4S=+30#'?JV4Z0N9;@P:4&!?NJ.=S$*_ER99EYT\,Z1U",*>,[&X6^HA#Y!
M0@D.?2\54HG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MX&I1BNU_*']??-3,K-/HNFP]9X;EYMDM6:X3:-UJ+X[EO)U[J!6)&,UTM8+?DC4.*^TC8EBMTN..F
M_JG]H9*H*6X_3*LVYY-0_\/\ZY\X]#\-D5/C/+2HT('!(M(9D< .W+P;X*S>
M*4?.KE#S9]T^G'"6=7FX_\/GRX[Q!(MD2FNVW$+H-Q%WD8@^CQV+ N-+.F'%
MHLJN@=W! C=T"(S1>%)/#M=GP53#8IBO[Q\M-Q>APHU;F/'E#G=&<4(*' _Y;$^X:?_0+36=ZT@Y8XJ'*ZM:S1S=TA7VSC%)
M\! NWA^BP\)\:AKMK/+1_1Y1BD[D-U2]9&U?*V(SDX3C_X*#[0G+D98^0&8M+%0H]:0Y2(K215L'
MY\@>G4]L_3?MD?/P>WH8;\G&P?Z!J[5/7<4EU"8\M6C&99VRM7#<*]H0NR5G=,J=]"^02F*5F^"J6EN@A:$RX=_CYXOWSU4I)R/IL2,.\B;]>
M*Q-$-402N",AB0\XG=QT=];BKS(SE'M])DD:+\/,;#!)Q-CM@Y>YUSJ:C3Y6M^K*)4^9@#>(QUH=R\>H_U4?)%!O:[=
M!FPZ(/L@'?T22C@8X)=M4L$,<$&=MCZ!838RO5V.+CZMH"BO_>A0"V?XP>$*
M*0IXH"U:*\S1\!>D2SO260'+3$"B]]X?G:T$)QFW6MHX9%]?/\:[VZ")/_(KO/]FY?D>%LT[T0>@)G8@YBZL_$NYB49NMTG5C,?(@7
M"F[0+--)5CI!L/5.VY9TE.+)XRJA4+@2?\PF=-5%QSVNQIB/M?%2NH/J/T,/)960 *'@"Q)^%GZ/+#'N[5$E%1G9)'5V(& A(Q2:J8%,*YF!&
M F#Z,PY@:6K.?WX-7K+V#-I=+^&?O+6;6>VA2+*/&LG@ D!Q#V&+:Q
M\DSA%9,KDB1"$8"'XD&IE1/3!N&*"F*A C<*EFAHH*[
ME*0XFX\L9\$6&LU2G<*&T(=T>.V&"MIX'M7;7-@\\R).-L(5$2/ZQRR=\]EL
MA&IS?7,KU#P!]GDH&#.@R9<"'T1M8;3549N"V<=]T]&WN5]P5PG<*,F(:N,!
M]ZR+"S(>;6/$4$DW'AUY\>+"B]ML/Q19(YT].&%?Y-K%YZEP2B@#VSRVV+Q!
M3PM&>V8KDI9+HY'/F[AJR5%WZGV%76?956)LO<+1/"V;83V+E,PH2(%39PR&
M]RM&P]"H)'$C$S?04JM,N(7<\R!7XLQ!SXCO6N.\Z"(Z7X$"*M5VMH!1DE9*$Y<)A F:5E)2G.QC55(.IW"!7#6ZJXD$MGT-7YXKNU><)19DZM"'I
M,_U=$7 G(\J=L]_[#.597ZF[IMIOT53:^#ZQ-B[\ <61V)&XSH^NY8SK!EC[,IEFA7Q^^%JSQ49H!]DY,3< 2V
MSV5LHN%_(#/E3EW*M?^=WA$/G2OP*)3WIPX6%''BA-PU&-4;O/:ZY(+W*9$(
M%)#+1S2K3"?++=VK&E02S%T743?)41V<3;S$'A2;4;KJF)8CG96B]4I]),HI
MORDI)';)59D8>8BR+)_!S:%BJ$]@,-K>FAM[(>)=;;(NU4\H#:O$+FXR I?M
MN@<>'%*J$.KPCM%NM@O8KZ(17B<9J)%^MWS<<] %L"WYOP.D+4*YO=V=?!N8U)QRMV6W0N-7]UV[/
M-3BW\ZJ8$7JE_=USQX^^J.'4EHRGC!9+/Z>TY^"DBB<\J^TU=;@64(/V05Z
M_D_Y.\@^$D'D)F30>XE%+6G^SC3_MI7FSZ2H+@S.TDC'OX_!5J4PRD-0_L.D
M4?X11\-_SZ*BTJV 3J=2W@@WG6W2%Y!3:+3.L;<=PR&)8[C*&YL;P>=D, 8%
M=JB <; /Z,RPK( \8;YV@6G\^22F+?&UOKZS"=O(#)YF%P"O*N2. ?'W?^
M"#;_>R/4H4J2KD<214!W=H3X5?8 M'09ODG( ,P@^@H .@ZV]K=6MO9W@,.UC(^+/>30,@S_1G5?E@Z\X@6D,$[R&
M7=L[V-QYC#1@^D\4),._OXH0=05MXNCUCWS[R<7Q1^') ;#D+Y\^'Y^??OCG
M\=O@_.+PW;O@Z/3CQ^-/%^?/F<(_Y=E]")J[GN[^?9[NSEIP>G;\^?#BY-/[
MX/#3V^#=R:?#3TMPK/.@[G+YS]N'H]-/;DPOXC<+?P#WX\N&"
M?B(;=_KI?F^!2&NIB.V&)'(5DT>>RI<,ZX.U:P%_Q2F[UTF)./KLMPXI<]6H
M=*5MV"Y12PEX2G: \/I0$@/TQ]=Q_9-9J3\ DU$^RV>%_I!>"&.3)\6 %F!1
MFU>41V8>)>ABX=6L7R;#)"H>"A?Q"1UV&H^J[GG\*Y_ILC0PB=F;Q V]$+1F
MB(*5;&JOZ0'A5,X*J@_(!EQ^(($D2;6B)A?T,RW2B3S@9_\+AKV-UN$H0#*8
M)#.083"B0)#"Y(RET#S"#: A8=]'_GV;*&)RD:F\/N :1<>/L;5!7H,=FAU]
M'LA'V\:'IL$.L[R*G8!EG)8Q12*4)N_/W".%<7><'9*($,WH.BJ&J]C8@2!]
M[&0I^R?)KO(44_.3$I&#T--!SKU*0ZY$93GC2% )[!VV*"*X"[VO2D^YPO)'
M2D KXY3A4PA,J!2<+.[$$"#H&#H#,;K'H:"M!OA&Z3FCI.F-GTV.XUM#D2,O)F
M_^;>^R6]U00N# Y.J=LGBST=,#"&?(2T^>7\[7/=JZZW]E^?7G'KD0<4X \%
M6G@S^VX*/)[6AVJXIGI-T=L4JV=O/MH\/6F@0Y#NQBIDK"3"-"D'C/G23X!#
M#L89H[J8/C-%-!2';50.HW\'O4^'YV\/_^Y#C8_D^O/
M(W;0]K((_6S2#8P3L[,\6RWG8'-BJ=**$P=9Q59)0\\/:\*ZGJ&I8 ;HC>9$
M?>1TI9X"<;MHQ*DC3GTJSV-5YM$";47N[-)6+D=<#1P4&)G@Y#/7YVNJZSG_
M5UO Y#.C4C[*P3";U/&PSO@PVAFH/Y'7?M$WL!%HT=1[.,E;I@V0C@;4PT=8
M2\9I=NS%=A+S&F@[M%68/>9#'5#!/V9M?'4<&UGXO?<06JS(/0QJZPW*Y%VBZ3#;932]*YJ^NXRF_SRW@<4_6Q? 7#ZS
M:OQ\]0!7USJ/TE@W5-,5*02R]?BF[MR44L8VSN*8)24GX;"+=?MO>WPIVM]:!'5J.@P :_[*^'N^M;O^/06_;3O7!]
M\T!"R @00PGDA.#*R)0J\9%R:+9%/$(KKG0G:!0Q*KR-+ZG"2R+0G-Z,F60&
M"(_2VPL!$B*#'-=A#'IRAE #3#0;N02 U324LO^(LAF"Z> "7X1@74!&'/84
M&%%J&TO=$9-TKH:H"5(XDSIO<%:SG 0Y$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MN$H_',;"KPRO\D6*=1=.DA1O7(:-B>%VM- 5]&/RRN;6']*)K8YC4J$9#DL[E$/Q-#RWC,["RP2\;ZSOA^OJZ/,L0!%P2
M0+(_UCX0))2(<,:%3.!]GPFVYRWCPA/3U2EX%<..:(QM/FKL,Z6G%P49[!05
M/T0>V(&3,A7TCCZ?K@1#KMW3%*WQ8]F9S N/ L3[R0O"M0%EA0I?R'N Q"94
M.M?>\7S ,("D]+YT"G/]/-:I+V4J!SKGF(X7
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M(XTA@\'!*/LJAUA&::3!+H/KZ%(+.B^!%*@(MJ*:TBH7D$FXEY22M.&I3XC55SV4^L6W;0$4@/GFX_71>@#0^J]]0/&TP [3&
MLI3&WRV-&\ROMK4BBGMAKR=@U)M!^48S%Z$P'-$!]81+=*/RN^$B3I6,F?:99M'PVL,YA* >XBUJF0#U>"2@>M))H@,+'VAVWNA1OK!XT0RO9^>+"SLQ(JT3<$
MN)_XZ%#7W2.D;4&4/;Q"^XMJ$_IG)75]?UP=VN_/GMTOQSL;J*7@R2#55<6)X,?Z4$>4(
M?A($VZIVQO&18L[*6G X()1GC3]'69$\;>HQCK;CQOY>N+V[69_CYOH66H K
MH>,WTE(VJZ0'H)'10$=@Q;]XJ]V[M:XFK$SY!)-@\6CZY<
MJ"U:Z+>ZRL+(HG0IA.>C(FVT$SXT@J9PY8"0-=S03)H]NC% PFMF-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M^>KUVYH\;?&4*M>NPTYR?!)[2C@H^^[0AS851$J$M!$'G_-;5"5VUM?IK=252R9(]PM1\KA0/AB-"O(EM!ALENF*D<&@@O9.3X)4TMR# .Z%54UD'$+_1WK)F7].(M'
MB6":RBPUFO1ED5^3(RLOV6.2M!:9-;#,#\].7L %?AMZ.-4Q=]U5C*EHSPCW*5^&BLL#0^6[*[![FXVG%UUB[W5PMZ_MN\A/G@9M3H )]8V_,ZW:3'589$VHGW-@!8^M@3W,$*^^9;=($C(MW(*"2
M\F-GHJ+[F9?7B^(Y)=^%U<:P!>S5+"G'>.,4=OR18#6OJ>1: .F_B$GNP)R6
M*7.')95+Z!VO[:)\6J>*LN:MR72O"Z0,>'!H^WEAOJGIO11$ET7,GM2J@IA/156M_GJH%6%Q(Y0,$$[Y.3J$"&(0J!BI?$T=CA!2/+(1(E90DU(_%$I.9]6X>,[=
M; Q,L_AE*]R"^[.[N>_YKUX$B2Z> UF*>.DY0VHT2U/G6BOI0F#(3,BVD5E?
M9VYNG0.>G0[=UBM.%]<
M\IS:?1:<'&Y"PR8#F83OBQRLC9-LL&8BF9^.#H^"MI^%TKH>K90\JU-VN;F&N>:O0AM^];Z5P:QT6)9I:C
M*&CP@QKOZ[W[Y\79!Q/81\0;Q@:U@GL4$SP$-N#$)@Z\)[0HV34M?CSAWO"_
MM&:KO4%;WUG?"G=V=IM DQK[Y^R];FR T=_M%<%O.=#3U#F%M$@I()\4DF0&EGE4U7QBC>2/<.]@/=P^V*3T#Y-@8P06]J[A
M-M)V;Q[!G?^$Q?S=L@0VEUD"G5D"^\LL@9_G-A#"Q8<$A-%09S@=<>TYPFWD
MLV(0/R3@QE,5+N<)M2,RB.?4P G3Q%QT8U9#1*-RBB:TZD&B'*0V@R)IQVQ)
M';=S,/U&T8 ]#I0CB)()Y5!)'8HE0PP^;(V$*8J$U>(L-LU,XB[M"JMD$"+M1?8]'K@RZC ER%1L,-(&2,& AXBT[
MV(7_K>]38U"WBFA"W1M)4S#!5W*E*=1BK3U;G\?>+NH@!S2+++Z,6N= R>GK
MX<'>?KB^N2?]\OSQQFL(W 8+F*9P-&A'.9'24OJ-
M4[1&L#V#%FQ/4(TQ^V/@^3BCP8#@@G.E#U.P2;PVHTX81I?K4"A)WA+TXWF>
M&9,36\ MS[O%6<2Y7GY
M Z3##5WC;U+&9_)_Z!]HMX+1@N_]/1CK'IB^:36A)$2G)ZZ@X+KPLM3RA*J7WM^-LHP:E9"QA77!K[G>WF,$!#FA CAM;3=].ZPG.)FF7/U8,N\>+ '@)Z!4[DTLZ2_*;FE*.:>66/)9-4KS:Z %K3_%
M4XT@'0:7E*9(AB\#@7)G=U/O$3**@9R3J6[QCEK'J+$C?">,BP5 60M.*L-/
M*9C$;$WS-(=!:I:EFWRVQ'T,MA,F#R7X*J(C)1EV0VX*+WTO":/<%'_0%<2+
M"6I<'RU_ H0N2)QR^WCG I@%TW[ SZ.K*$G)3X5[.M)-NIZ!HQEL7QL,E>NV@IK*.GAEA? 3HX%B#=I.0RE]%EJ:(M80]>\U2#(QX*C!WY:!LD071 GM'H"LP5_)3X64[ 0?$52O[4V!DO@DI<>[MM?/Y(DLNN"/'KH*89Q8NV'+-D/W.5?0USFST5.?@4"=M*3A#/!G'/J3FO(,Q
MWY>O67Z=QL-+=HYZW==#4D7\("7!$1AH>HS#8F"3G/9\M(@W(E^=:.
M3'H1)+TH,%0',9,#5J0,,L.AC:9>SMC93P& ;21\H<=CK7AS2)BX$@7L-(&& *A;TI8V=(PEMA3.'6JA$P1?S\'M43,H9^D20")&8V8>UZ"&TJZ@ %04Y"%A"X@%%IEH+N*BF
M 0FGKXM6H*F=A4M^01=*7U ' Z(&*T/0;P85Q9+A).D/1U$UCXBR8Q1HW:P<
M;HOS"O;O\"&Z*B2*GDXB*<5,8GH%I7]!(NE,N;CU!/H\Q!
MFV]Q#%\C?N;2(\JJ%3#@:538*A(=AE5.2Q'N"(.])5'C)N%Q\N[SN=;J4:_.
MHDMV.*'I!C(F$!T'*9;W.X3=&%XZF3VV>0J.#K_/;+@+KR8J4]A.1>DV-:@I
M2:L4[=:"&V]>T.X3=::&2E-\7=:?MPT_B>6,<^%/:9=8-I0D,VPKP=Q_8M$=?4YUA"Q]0!0"^)1F,@,L:;L 5J)K6.ZAKP+\YMINPM[WGMMX=X8J8YD%NFG*RF:9XB]]8F.!5FLP4844$;5T%31QSV,%C80#R,V,@";I S
MCJ[P28U[*W50.B9;S^!N:S_TLA*'85^=?%A0C_M+:-E7KS]:5A!_0Y4&;['C
M.%>:#[ PYHPPPY,:D?Z%^3:W26XQ:MGW9+G #)*B/<7%(03,0T UJ"P)H ,7
MPUU""!R4-+U_SV*W#S AA_7+N+A"QJ-8S;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M=%\K''_)FCW(@L5W I;.U5\!*,92 3E[@C:K)M@QMIBCKY
M!)0[P3EWQD/ V\[-Z&-B ^?/4!".H/:H\\)4T//M:YT.*+67,^8^*]3>!*CP
MG&6ZLU[TNZLJ^LI%21RJQ&]%>[=OU(D](;"2LEKH5WCV,BYQM3W034/RW(O^1JW!2B%G'%*4QA,FGL$3GIJ;H5(D1N;*7B1(>QR%-L[3JN*(C
MT':Z]0^*A]'Q\+D9/H8M&10G$^]="_XP.,4Z.M-T9()AS)$0?@%%W11JV/V8
M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MV/ B(T0_ 3?(:'B;&56.6Z_K +%?G\^->F>8\)!Q%_L)GU)BRFZI:]
MNP3[4NY%@:=-'8,(G%^B4LY-;*FTLC6;R,W@M]AY$PX8R&90:AMQLWI; ?:N_3N]LGYY3J8&47H$IR\2W 3H7QBBFRB@=1@%-B8$%5IVA_'?^L$
M+-%[Y(0)8VGJ@?E#$];"]93<$IP7P8!NEV&BD\V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MH8)D>S HKV4>5MS$6@\W5QH!0HH2$,DY$B%J\VI0"#'M08]45EI02I#^PWBX4EL:U1(:X+X<]*T4+'.J11SFE,G.-;#NU%PP8"?_E@N1
M#!PB:*>Q*17O7F?K8'IQ!?4@!.,3UP;*OB[]T7/CMSXKVX)"Q%H"CS5S%W*DE<\K=&1"M E-'KID*N8A"Z;I>[,LJA1]2#F'J=>$K((RYSL3 GNET[S5\9<=-)YZ!2+7]
MN7*@+.+8?
MSYB"XV^QKN"S]T;UX\!I$M_.YGK)"I^H+!"G0QU<ME_,2")V@0C)I@ROI\Y35[I17VFT%4PMQRFG#SF.R?WD&V^O;VEEX'A7]*(O+
MU=-O:3SG[>HEC:FFJ2U.FF !,,]Q: H]^&[A?CA[03P)+G9]N^OM_\2WGE<%&JR?40&?, (APF; @,%9D5>\*C-M/6_WCL.Y*H? O(D2
M@[*D=G9T>/H&$:N 1>%T)\BM*&E(6NTF, =X*R^>((FQZCHU!:K$D&MG*N?(
M6TE.6;<#"RZ+AXNP4,:.8%R]KMG.K9;_%@)MWNG0/571<2>)%%M^%S+[2[!':NNL;,,#.(3Q4$Z1<7M#2=:M.2FE3K7]246>_R$F3< M2_-Y['^OH:G<2XCAN&B*I\T8T5)^2B4P5S&OGILM
M^GVLI=Y?I!->L9.S4SQ3%'*I$FZ7Y:0C([+^[9D'RCY$OJ+4DJA(D_@^ZL-N
MM%+H/U&0#/_^*OJ_Z^L'Z%:(7O_(MY]<''_D&>RN!6]//A\?79Q^/H<'CC^=
MG'X./AY^.GQ__/'XTX4Z_/0V./YX]N'T7\?'Y_>C9TM[%]O=18NS5>-56;Q?
M',L9Q&DZQ2N:7?[]U?JK[YW40E^&\;"4TPB]M9EL5^N54#3J(4BVS8>Q7K]5_54/] WK0".Y?7W=^A7MPN,;KKX;X._SD+8%*
M()X57M7S.,/F*/70)_[TUZK _^!&W8]2\L Z4%N\T[()"KZS2J'9IL.P0Q69
MD!OI]/1ON/*?B>&'=>R!H;?)E@'FA-%:F+$D/ ,J;YJV_8Q,D^DT3S*67)2C
MR$5Q&'&-BRNMI"6@:^4I:L_'$:LN_EB4C&M&0O9)#)_\ 5&I922V/QP42=^*
M27Z99I4D!"DM-R]LTO X:18%+!9A@7+YA%ZC\S"",IA'%5CZK8"1&Y$+$CM
M_.H^(TZW);D?Q![D/N(=[V #Z V$RR].07N3;_+*_A[4^03_U+QS<_=OQ #0
M26KN=/TMLCCKS,07-(<&%F3'_9O=M981;YYWFTOXAK7L\5(.+W_ZE>QN\5+.
MI%*G5Z[X#)?)P->3?M
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MO:'VSM63=+ND+T-MF]9J.]Q6P1/*^C>S+ XV#^@'6VL!3DCF0JGK5*_.M^.S]B06HIW<#Y6QMB&8XI,&0M0+!DN04$M7_PIM''
M''G$AV'O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MT+['_*9 WJ2_0[<[^HZQ/%,5.5P =':#Y2^$AU$'T"M)@D0Y70\+^&9**-S1,J<),-5V)+UTJ,V>%5R6>@6RIJBD/[C2Y@OWC-L_A 7
M2N,V^I<".!.6,,YAY1;JS )2V>?#!F_0768XISOB!A)(:7&4(CK&2'=KI-LS
MA8M$(,[1H,#Z.9[J6O GI6-^JP3$N89%5PGQY%V4CU&^-X+3RPE;0
MP,VCS(35":-H]/,A?4634/I^U)=&,;>D/Y-MG3#R<)9?171AZ#PC @DNHJDI
MUD$X/#Q8RH&T5X0"=SOKG+)]A=0J,7Q-%J7BACG7!/P[B 0WY#2C(W#F9FOY
ML70!6"R1,S)B72YW+8)"OTM;P![;P0@5D!)P@@%197\>_$&[I_2A>/N1IT,D
MS(^RZ+@MQC&!D[U&O+VRH"#5QL'^WLI:
M_7ZY&*A#RT6$4Y1\6^&?13P%=AW/BM! /#ND K3=Q[ZMQM:*:H;9O?1[*1/K&_^ FT@%E%V&BBI"^D4>#5WM+#-5.S-5-Y:9JK-"]EKUNXZXDO'4VI1S6NN&*V*^^$>7S/GL;1Z#HRQ
M6../W!?7]7!\8>UERGD9=I\EAOPQTN.SZKW>K7J[/9B[9D'*T!'P5JXZ$$3T
M2/2I(]2L,?BCSHJM[:+"B >$3.TD3<#>)(B)8[)-M,+SY;]#K!@G[Z^CRRW:;1E=YXLYE0NDDIA.
M9S8'QY=%'OX$"7>33,!UMR4;$M29FS';: 3CX"\;/4#]XD.:)QXU"ZL4,,>A.%^LPF4/\_ZO_]_J1K[W!23FL9
M'*IIV9P:HTI98%BRC4#[R*=S;"Q^;8XI#'I1@&VNT5"[1O4:*YR388+TBC#5
MWC-'MC5GT/OTK_/CWX*C]T?!K\'%^?_Y+?CS^/CM2OURK&\<8#Z*=Q*@E8Z3
M%)6/VJ3(DB)[,;JFYM?9YP"SX;B@IKU\=84$=X$6#%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MQ(QCU/D6 5/*@+LD2Q(1AO6!L?[X=D,=9Y3Z]OA'^[
M59O;!4Q%V+1%71<3-(
M4PER+I?= %9N!H9@(E^Y<2U4UQ15UYV^"^T#\D1^QYN)]^6<&]LIF(W5VY\E
M:15,4!>:8DNW:]CDU>LDRZB_B)R1>"2X_G7H@H)X#:@9&04QR*(,VV^6H=.M
M2:XO"VZJ#BV0&R(RORYIT'TX*^ 023D)P6A.,$M86=!1\2]1M)41[U,8Q2SS\K4LE;9K" D5!?8^BT*(I[&L5&GVFW$_ 2.G^;(Z)O=K?(LS-
M\2 GF7)J;KIID4EA&+R-AG!+8=H9*!],ZJ^4K@R!_TK)O9[=&)X;Y=
M4LTN3A#4:&SCI%.Z8+\3]/;AALB^]V3P%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M-^MCCQTP/;>'K\/>N]CY(7"L4[>'@4]5Y%:L75\,\/&62B &$ZD;:(-1SJ&6LV-
MU&0C>;_BQ )4J-XMJ=Q*N5,-Y<[&ZBLGB&JH6+HT.MD;^%C*KE)7C;../#&6 YM\^9*\,W>*LNXN
MHZR=4=;-993UYZ%Z>CVE0$L&=+<[\KL,D%9CL#2.3='K/>]C\#8>D.UAS(G-
M-<53)$/!LDJPVB><7IC!6BE1"A2OO,AB=)111VWS@1\J#3Z0
M':%_:&_[][7@% .F8_(/)D4UMX%3I1.RK*" 70M,35Z4&5T@--L5>BJ^7C*U
M$S0R4NK[1K/4J=E'A_D,?1[TX"[R8_&6&,Y,S)7WZZ
M7HC9F58:XMSR(6<'4IC,[*G 3U#HASVQA!EEFH_*"]=4;2N#/
M=26-;+O>?V?)*-8JBJ=OZN%)MZ?MMN#\IO,J16JF%;\AFVD;U@L+L^?62Q0[
M.?RH_>WS8&M]/>1WXL=G3$@;Z]ZGEH V=^!^X3E-M/_,B'9KDL0^2LBEC'@IQEK_C/N%<6><3^\F@A+Y/\SY,F\;4( CM W^(KN?P
MH**8:+ #6J)YZ'16$3B,\S/< ;V)NDX?R;[\FJ1IR5\*((&\M9Y>*IFL_&C]
M0*UV'2I]':7A98I(.S/'IV>8@H /8Z?I54=KM,QB^#2Y+J;,9F9'.)'Q!"I3.JN<9-(I$?K!@6;/FMGV+S4WD7'-.=[4!&_)F
M8G*L3@JVGLWS&7PRI'P))&/JYW9AR8]26/@G^'D:<\XKNGY)=\8,33;#/Z+!
MF(J+'PR8Y))ASN65H1U&?U7[J;J@U%9BV' (_"W*';"1.0T6YV;=%I(;>N&E
MP*+R!.QI$$S+^6"<1%6!7G.['@H:C%"2.1\Z]]6[I,I<4FUI$3LM!1H&#\T1
M*&ET+?YA7K$)'5MSE.T5S\,(LAG'I+O/\2A:%5E\^(4<"FZ/M/9IOZ]1D1ZYMN;!SLZTRT(!B]H/8!#RY25>,Z;Z"W
M,9K;$\FY.7,.H#1^#1TE8.\=QG[F1C/ B3IS K)V:$#29O7^E/1^BA.@6[!L
MT'PIWEJ\''84*_@D=QOL<M% %:D+^C9FTCLSJ/V]4EA%)<;R6I;<>GY+F8)8%W-_3Q#:S':.- 8P$#MQ=A
M16>F01:F@JK$=%#9X02=@;D HD1-IA4#:3$N3A>[8;W/8#R4#.TA9_GK'R#&
MTKGZ'R.G=(I8[X__.5XQ+A:?9-[&(XPM_Y%$-_CG-HK'P]GEK*QL["[491I4=D!1 ??6.8=HRHLP-^H2+D?DDJ2Y):27
M.2$_&.57E.3HA77J7#A5@.)-K)]AV,U32EG^6HIS9'_;*9CD''+2.(&^<]9J
MV3-SA/(9-$CKH4'_US_6WDH2/8@_1?E!C@O'WFY0F"1E(@L^NL\$W<]\- SP
M3\1L2[%4@&,7;:MHJ#3*J#3B4)52^E)@!;6RQCH-L]2:#M.5'U&S$ R'TM5;
M]B@>#A3D80!A6][Z9HWT#8V ]:"O?U3P':IHE5(=@W%6"D 9< S5 *.;1@EI
MVJ@M1T7&V0(([-4&HN/HUB5FAP!Y%QR,Q)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M!Z"T'H[F<)+&P]\L/.LH=R6&$1*-FXN1A4ADZC\HHQ5PE
M;B42X[1[?7E*?L%-F_-LAN$^ Q<=@>PK+F-1AD$SPJA(9#RQ8[7H)3[JM%,"
M2KJ4 \HYB:L"FT9Q0>C-^]4;Z+D3^/M&<)9:+QP'!3&/J=F4IR:R&C1W*5.0_Q&E&Y%%9?YX.LJW &!]G2BAA$8>=$U
MA@05$0?KB+VA3-7"V^L4B6L&GVY.V=U^8YYJV.K%I\I(JP[Y*,*\;9)0T)N;
M/1PEW^*AD!!PG#'BE\:L%_?^\V.FK_3TV]_5WK.[_?@ME>"+NYBY=@C[O*%2
MW!P>4PRPK1N-;]
M4^N%69; &7$GG)Z/#@PU\5F!F)'>OTC8FJ+9=;-!H0".P6V^T&ZEY&2O@
MC<^W']^>7(AZ*BP)K8)H6L)5U/^JP9S>?JJ+ %%O@L;2$%HNK%;M3X.R!1.%
M=V1_?[5I%M-D@:\6C+0<^$$&=HE]]3K&+JEXX.FP'3RMY96-)]N$W:O7G_*,
ME:R[O?DGW-0FGN&-%THP@Y%+>=#AC[7R^WSZP2CN=,H.W3N2VX/-[[P"L^OI
M3@]#2EEE6CQ,T^@)[^5A*FH %13]%H&HWWN[/X
M!YO?&_0%/=WIL?_AZ<[O\(G/;^!%\I:S_"NSO,BK*+WC].[."VN6S@+D_Y97
M&]#,&Z?Y>]#:K.#6>_8=TVO?U7^!F5J?;4\GA;^ZVENMY38.L]Z7\U]6
MELM]SLOM;;ZX%6^]M!4OE[M<[DW+O:WH_SWXGNX.>D[8GN"W8!USSG5'(?1_
MUCL8O'K=Z/SB#*9=IXM[$9E?M0OR]J,VS9/:'T)7=.=LVI:Q\"W?MX!;#%R?
M?H&'_NKUUNYZN+Z^_A,OX">?_^IRZLNIOY"I;QW\M;'H=
M6#M&X-ZM(T[7-G;(F>U%OVL[EMO.9M&1MISCYM9&N+FY?_-L>AMWWI@[3H72
M9S87_O(!-V9O/=S>N<6^/,AD=G;:+MLC3>9IG=/3FLW6SFZXN[][M]G
M+3F8YF>5D'F\R#Z"W>>]N:\A[W[I9PP?P6+K9>JN._4BS
MV0#)MKOW1";3L)R6\UC.P[TZWT.M#\W;>LTJN)=E?&YLK(=;ZYM+X[-A1FR$
M!T_FE+8WP[V]K2M(.T.7Y %NK'_I"S0I^0%?RJ6SG(>3W,>&P??0:T/;H%V-&=]66;HP7ZXM7V+
MF,U+LT)WPJV#)R.)#L*=_:<2CGU:Q_2T9K.QN15N;7ZG$?HKE5O_\,)__:H[
M%7??_FU>K?>"FO!%Q=W-C)UQ4L7TVQB1+*Z+:/I[4)<&53XUKS>@>9B.ZBYB
ME1O<_';3,NBW9?*?F%^T1R0]\PP5BC4E7DI*A9>8:<8 P')W&@ P)
ML-5L!FW [,M XT=I[*CI3?!3W%BK^5[_#;OR!NKAVP IL"WH!$QFS=VU=MI>
MDO8CD_;F_9-V'$03[!582CMTVY150.&X EI0C00(#O=T-G$:-S&.U>5E$5\B
M\"-UL R&^,]1E.A.I0*95F+)X8EL#-9,+8
M\[48$F86M34X>??YG+&3MG.3#.'7'@R^Y15!4"FA)^5NPL_XW!'=JWCYNIBQ?G\?3RFE.L;7./UD+/N65
MU$D3PFO5?39E+"> WXQ2PN(B(#'3>'*0EY6&."GK>TZXFCDAU<&N<7M@^K'@SS+)\E =HQF)$AA!BQ7P,BZ(58TR_%>OV0\3Y_Q;#T!QD/0!C^0[\ 3
M"*9'"-LT]"Q#S+,>(K.MW#\?*IWE.&S(0P*D[LZH#PP,8C,M!E; 2Q,@.1Z1
M(.60#7E,:&MK;6NK@P]MAPN_9H0C_,5VQR]V[Y5+T8(>B3G1MCX89WH:B%NG
MU#@7=H_@<[&=XH@:!%GHPO@R-V!MC)#]LR%!DUN04H/0Y3V9CY1]B_P";CIA0@],\R+X9! AMT4\QM+.R^W70XBL
MP/QU0Q\AXFDT)^& 8]M6>*BS)XBUP9. %TYC]$5A&TI@R 2J&M*0W(W860=U
MR-$O(K0R:O<8I$D\@^6$G1L0=NV L\]ZN:ICN01%/+_-M@;^MIH-154)>VZF
MU$XZT%UNJOMH3/- \'K$94^O,^XF<&]O\COIW,L+W(9,QPP_RO :V&CAG8-L
MAY !J\>(#'4?-;D47A8?Q[5N-X=!?T82=TC-0/KX
M4#^_PJXG.!HH)E=)/BO3N1VT94"$M4,H8;/HY@U8RS;F*&J*M!Y])$PH][/IQ-.1.VP;C,G8VM%"Q4T2U1>^T2Q[_=QPX\0(<->D4MG9H,@@W0_IN9B.K_BR;3WZ4A?0NX_@,W
M,'M0XL,77KA\">GA>@S4-5_-0;@-53GKE\DPB;!O%#?$"DY.PJ"^O;V(.L P
ME!BW0C[\]RP"C2+X()VJ>YX6L!)0>$Q#A4<>\6IJI0LQU#Y*91R@/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M MA1YG,G8Z-IB&5UI A??4;Z0N&5$0CF8%.4 0]K5*R:&J-L.MC5WV[FGG XMG0UU^X7 )H"*S/UOW2=VO"* NXWQO7RW>(3(N\I^E"P<>4X
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M@J@!U;.(6M]9&[# AAYHK(*.0[L428BPYZ0 X"'0;%8:0LW*M."Q*4@&\*+?"$!=U!Z;FQ0GW(=Q88<['2E/\;9J BL7+*H+-%>QCCG_H]L/.
M69BCB$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M9:O?ZRP+%CK+G(6U>MYW+7W.+D4C#5[7!C=_]G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M?G\QFC]*^[I>6U-0NQY_UP=\JK4G@
MGU<#?84?QH^FK.+DI3;YT[DGI\N-)]&ZH7_AA4?C(@').$4V]F:6PC8AW$#P
M)DJ_)N1@AB=A#][%L[@ 1I9D/$/QT*@/,:CJ!2D!ATX-5.]3GJW:/)JW&HAC
MY3D3]3'JL.13J&VI\K:4X^OU;66L!<][DMJ]=>O+@' 3?#6"9Q$Y.Q QT[Q,
M!!&M1#FT:NOH#1B*MA#(39P/'SU##C"3M2[EJ(_Y[E!0(_<1ZZ&6"
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MSFQ29R'Q9PZ;1+38X,OY+YOA#F=1.MW7W%1+&I3X;#^.
MC98"3V_I]
M-]S<:9DK?[FWX^>#*IYD69_C1KBQOVG\Q+>8D.5;'5FEAF\YOCN!XR-[_4?X
M\![:=_<0>$%WR5O96U_FK73FK>PN\U8>"?#J",,9R&@$8LV]O2\HNFJ$F[M^
M926E$:C(X;J J71)N(<^"!H9!FY9(Q,5#(-5&BB+Y'\+,'KH#:,MO@6Z\IJ<[I9'NS$E'[92Q'B('F*POR>LQ, ?@W@XPV@C\.RHGR;EV"HNBWD]
MS#5*0,;\%O023JNP.(PX=LMT>]$*'M[7N.) A4Q9*U>4I8NZ!HPUBF&RJM=?
M:4;FXK;8',A59&01^P(HPK!HZ+N&W]3M=*XPZ W0?8QQS%6-W>V@DDZTX+T-
M4(J. ^-F\J_A3^4# !01!0QJQ1UNR,Y&>K5VBCDIPQ5'H_!1_EIFZ^[W!,/\
MH*RJVVPS*TN]1 BDPU(->G/,.S
M-H_>D6U#E$Q4BG$IBBM )T8Y?4LC3*-CJWZ,?#+GSJ_Z02V?Y(EL"V\V8\"(OG8)D26U;
M'$A(LD!C,0M1B+8#,J\%7\0=A4#;]ODFU I]%S@OG>.P#NAR=!DE& F(
M+BPJ 84U3:HDUO2-+)V@F >S0@(,Q#B KY9X53@_*!-:IQ4 >TU FDZB88P_
MEV@XV]Y) KU@-EOA^WW3!1O%6.^.ZSQD\U7NM
MO5I(O;H!$._8/V;:5[NYKUL.P:7\!%H7
M]AP!B\XXS+*APML$;*5CG&!CC]/=5D(;Q2_B44RW&E@$IM(E!![O)"/ZDUW3
MK1LNQB[T+:*M 5.83! ;5"[S!-.#T2L^BJ.*M&GYHC;B/1'L_<)URRO.9L4T
M+^,'A.%^-*J?\E(;AZB(AA-RP\;9F.P#,A](BLSKR9.HH5>@H6/@N8A1XK Z
M/,EA, R':*ER/M!(%W W!4*.
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M??U0)Y/:[\5G)B%D3)!T> ,:[#IT5X]44:9K[9!@1_ P:Y'FI#1[,MMP2%-5C_&QL>:R0":B>YH)7DC&*AVRMZPZM-QT;>7DB/.][1_LQMGS>CNFAR(4Q=4A3VY(V(BYI^&B[P'7K [I261#>*\QC*9)*DD=?7QX&]P<M0Z159>&F6TT694F8MP^ ILT1BJ_4?4;T/#L$./ST_87JA5I H;W#@]!W%U M^Q+W+IOH5/C1NM85,DN*^RC<)PAY)D Z.1HT(PKFOY'Z1QE?J'+6I_Q_8K9*%#V"A*%X?!*)^T
M .6I<'SF]7P84CAGH/84J,7!4]Q?S:[64_A LT3.ALR]-FMN>8;>0*<4T5O)
M.;LYI#WLKFU)(#EWAX-[*TE\ '9UI^CNQC*ZVQG=W5M&=[\OQ?.O71#N!?8Y
M1CWI15CEV8S<0)8?VEX"@=M'4M[6"FD@FZP5BQC$:5O/@HS:D_KUOC8C#EYJO#))U)"#0I5TCB;X5;NYO^*]>"
MTZS-">8G!DIT4H3L +W01E3;]?AK*9AVAB2 <6&D>MM]H]VBNM5P=VLGZ$WS
MLEKET!%JK,BFI.@GN9P5\0HHX5@8SZ:X6 E6M8BN(M!@4-YWGDSM *<2G35%
M/BB&Z\GDSQT2S!X>[ZBR^]AQ;'7+."VE9%@L%2IBFP$;A<,;Z,"MIIE0P/6Q
M&J? >$JF?9JA#I:3W49H\UHM O*.LM:?6X2%!LY!53NTP/;0'-M]Q;U7XC&_M6-_7=LC/&#HL'?,6V-LI*_UJOC'/B
MW%MNB_6TS6D"XMY>1M1C (9M3*B6NN%8"6LNM[G5E1&%\#]89H9-_F89;PM-
M 28SD(*9!D-[U@%PV47:O'0NG5.5:,J=6TJR!)D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M73^K^!_DRA;Q)$JX3 #="Q92A-ZA]#MXV'3.-YA4YN
M6%H2EF(>!L>05"TWQH:Z$.:X=',VG\ORFMM8+1&XT@]Q;3[WL2_-:T0G:22-
M=;)_+4^R/.,A4'Z9== ,YL$H2E)_+:IK+12-&,2BQ A9IMCEDRKE.GB[,RM_
M.)0.>9;.'6\BA75U+$;E-X>&UL N:UF<"!YG5!Q@VA+7,O@SG2J)NK>\@:=R
M,RY:5*"18IP05YO2]-34F=L&]I&NIS>7QJKF[A>E!0Z1_D*77Y(
M"'D6-U0LS29]-MASZV#$D7Z5IS-L[16CM$%A@?@"E[%)WN69#6>%MB:00V,S
MLJWU%6MG\,%@;[(5A2N4H-1 #/VHZPYX= A+_1O>)(UHYS@1PF!C@[>!]HV^
M,;'"QJX0"U.4DJNMP-;3XHS;[B I=XSF,]'7&VS.WL:Z(\,MWH[_MSA2D);-[./>JOSX5[O"EP\82:16V65"364D7G!!WX)I09$HJA3&!,RK'8-&-
M8Z2( J,Y!:/3X/#:.JJ;4Y*M'\>5U%;HV)!RZB86T#F>Z54.\XF&J$;%&I0'
M3Q6=:>(U+VLUQ2!UG73_Z31-!F2!I=$UY\^0WR]*M;1J8X5M.X39LN@7ZLM<7421QSVB8)^D7^-B]6H+!-*!, =(VZIAT&Q:H"00O-FY:\9W\):3;L2P"6&
MYCH$,W*61CH;+XLK\Z5.Q7/J9%A/*>+AC+;-=949YR.;?KH@G%X;FY2-% M'
MRHI %YM^-DX[:/ ]K1W%I<>R//^QGK2BS7[6U_-N4;3-912M,XJVOXRB/6$Z
M9XWOT/4=?";?P9KJT!&(Q6HSO=WOX$;D&1+/9APP5 2[(#3.1\(^+:-X:)/,
M'5K)T%*&(R;Y()DF<>8"5OB>0A:)'HX=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MHR@![ JS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MFG%+LB@%-EL]G:RXU+:<_%:$T:P3&;K/!5@E$*_I-O4SX,
MY&;M,-GE5;;] @:BJUSI;.7VH@T?;FS!):$O'0^W>YL[E0)D? 3EKPATHY8[G??3
MY-+371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MK_F6\:-)](TZ-HFP0"[_-M$9:%2$;R5:S;[7;8:S0$P5K@ \H:D3H-9!C'$RGZ!2V?FPU*ZS&B9U$3>0M"
M6G^H$5Q;C -?DE)E&FMW;HFSZ[WI6OQ/+,R2UT>&[HZXD]2+8P49H<>AJ3ST
M;B&W#FUI\.F?_DJXD* KC=,2,7IJ!REK4!K^%64.F"AE,_P=BCM:T!E_L[X.
M2=/UNL$;C3"4"A3;^)F=RV#F7W$7(M0=F5^(IM[TWCN]/&K\">F+G-RUI'50M&U=7R['<7+H:ONM+.H):F:KX7A\V.
M-/6ANL:% DA8=*QHC^4@=6=UI[P;X8#U(VH=;19H,NE#$)\
M^4Z'3S.O8*HC#@/!5]#%VD2RRI(LF;@]O=YZ+:X^-FTM-RE>,F30OU*O9+6V
M7ZA]SB(*_>Q?6^[G1"IMPLF""I;$O9W&-@>!,(#1*!QNB0OD"\'BH]&#Q!EK
M4B JBDUII)RKG[K"3G6"I#"=6TP#'2_GH>4L.'$%!U@H2.S+E9OHEI>>W8K)
M!\[>= /1I:EK?'M1(F(U:30M8^N%;R=?!_>H0;ZVV.@F,OZI1=X%*#/E*"X<
M -.744>\X$ZJ!7?2^&B<,C+T)83PZWAXBM'^:6DTE)@I; SS/N>QIE&:IK,840%)4G.1?5]@$A_QVY[^)+BAA/4:7-4")>
M"=DW$TR=^K(T&<4<#).J$?N24(HBY_4OUM1)5XD)J:I.DF5EJ HO*X-2TA=T
MJY"YHC.'/[=Q[]:\%(GYMF3U-O2&G_LBPN*?^YV[:-I*?;@=DUC97MK78^R%
MQD#C->!$@I/H; 89=IIBH@.28.<72?A%9YFWU!O^U+1TB$$^4G/P,EW8/K@O
M@< 8!9Z\V+@-&-HSQ-)&(IBLB1YN>!VCZA);M3N=.N<\+3%$;:6K8>&"X"9@A2>&F#&N#S.7-0OZ36<7@"92.[.F3<76-F$TU
MYJV=##F?/[2I#=L][L2"_/C%TNQ!9JRPW\$C*
MS['\?I09USS+M1KO)H*@MIQ&I48@]\KPU:W*\"4MY<^8M6+F3VB)PHB?HG(8
M_5OO!+MIG$&]-&^]Z\T^(HKB!YJ&Q-AX1MZ5=Z" \VO.5_>?.RMUC5:GW/Y@A%V3;,9TN?'1Y3M<6F0DSE JYM >SO'1E6K^_-FM+"?FH ^ZAX;
MF*B/6?NX1V7PCH/:N%*$+K^(OL$^9YA;QGOY[$V9BW&C.XD4HRCI4B+T0"V-
M@*0P9%_O6_)E[7Q-YP<@@\:MQ*COP-M*T[0/31.I0$)]7<*SI/=' Q=ZIBGY
M0FG09A(%]+2:*,H&G^8.,& 8V$Y*W9\%##S=]H*DC>Z5W;5ME&@"_5+:XB"RD% ZZ>&<)FMKP8E3'CZ,RT&18# @Y9M@D=,G $EA8/R-T))UXZQET;M\,SXZ$,A;!M*1JM_S?D 3NMGV^V9M9&COF37J."4$(P^8TC889PG-J,Q]QRSE>,_*4FM$M?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MYT/,IF9M1@MV,*2Q%2K\/:5J)(2K(EE86+O
MJ?^T3CG@K#0)PXHT-NT@G.R^YRUG[-T[)W0P#M*V146D$@+7S@JBX\,E!C6M(PE 4OPHQS_8YZ%<&MWL!:$.8\HF_*!B(T5/UU
MWHF&H3R 3_Y]KOLT$KYH SQ#3XF,WLS9..,$HHVB/$L/Q:(,Q<=$691FFSEQ
M'NA7@US)HFJY+#VG0,=#,>"Q+< Q9CLW0:&H53;UF6;'L"0_!9>F;1_.+M&N6L1'LG'MI<'Z=#M7X0?QK6W%.95%NYF0=9&^_0 \>ZF[(P;L,Q<'6JTXSA
M>H?R=VNSD#FCT."
M8LM$\&!.3#1KFE+CSCC3)0^HB,.)@GI,D;,4MCVCT%> :+);$+FC6[N.S>$
MH,_Z>7.U-EYB\-];T_,7\PTW4&DR+WB(:>+()224ZWR5> )%UK.8_] YSYS@
M42HKZJ(^6)E!SR"^P:L$"%8L1GAQPGH.8R>';=S$N\9$3%KLYMCMG"TV9N.T
M=LN[%!72FK?X6=P>&A(S( N6T@46VIY1%UD@.X2LI.0C22HQ/$L9?D<=0CSN
MV!AQ)3#H\>W,L')K_[V=6I3%KMN7N5R'.8X8_#33M> 0'5A_ >T[NTLX
M,$#\ \-L-1CH]@S$=OI#KP"QY>3\%_9):V1CX1,(=H; ^
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MOVVCK/H\:]Q&M.9R#**$E6PJ7:SKZ@IU=?Z*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MZQW![Z5;U8[9_MP:M1GW71@3$'/;75>.B0N='Y>BIUAX-)^_>XW7HGOD;8@9'<@? 76D2=!LB5
MURJ^[G9W?/K!-)V5''3T6:AR6"@Y+*RO/KB."PM9DU*3](1JB9RRV9;""-=G
M7W,[RN[GI7T'SQ]>H8RUY#3O90PY-UBBN[T[-1'/F6F?144T&,] ESAC$MJ7)*!2D_V5I M@!$@(G<"L/A+#:R=,#Z[4 :NK24FK*[L=2.4"J"6[%(+VB
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MW%BUK9>IKD[N(217,4S%7P!/$5=,JF <#=FS:,,59F7#%/.5[
M\Z(FUR8SF="KXDDRFW "JZ[<=MBSR>AJ<2%I5.86-6I6PC56S 71CT)X8Z@)
M^OOS4U<3X(_)$_:&T[*>?9G )Y.R;QW>0#]723XK063?!&O#?DFM-.D.Z:P]
MU1N=.C>..BOFLRE[>>5#@P(;!6%%4_,PP+
M5N$FE>Z#[4[QMI ]/D?G61A(V,ED% LA3
M:A 3T1J]M?W(FW23UZ%O2*__(^G]YM<&1VOXSN"_2J ]S6KHV@"6N-O-[V(
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MX=ABMJ ZMR*=<_)K/)AQ&DUMZ&_+KU6!_T&:6E+XDL)1XYF!/8'6%H'A2@8NE866E;#+(H[;J9]ZO[!K +NI
MD'&43YQDM(A08\3E5G_3*$&NFY"7"MN1M#C@)/1V?GQ$8M17<"NGD#0IFVF1.MTGZJM4JG 9\RPW"KZB+O8[-Q3?$!NEK9, 'M'NR.R=H#
MT>2]V\UL-5M,U0O=ON*4I(S]5\$^Q[>:"3R@8?W@*NSIK+!25ER3>9(YX$7]
M7-J.&J:XIO"IYN?D2;6I.]SO'0=SWM".F+D6G&H50V<.@>;@\N@=4"OPY"1!
M0Q<1(?8)J@R'>/=3UGZQT,\ "X8<MP4MT?U:L^X(3(]&L;O5&GYI#W<_70+L@R2Y+'W&G4$VLVG_3D/E*Z[B\5V,6
M\?^/O3=M;AM)UH6_UZ] ].UY0XJ >"39\M+=IR-D2>[6C+M8Y#@ *!ESJ]_*[?: )"46Y1EFE]FVB*60E565BY//NE>&ISS%%FBJYW^C11H
M-O*E7\=F@O.HGI@$]@DW7D] A=8*MFS3G_%6F\]:(&D67R7Y1ZCL>C4#$*4>
M\^MTIM]4IQF",YLO<\P/PQ$%5XHM8J-+9]+F!8IDI?F4 RMV1;-TXGF.=RB>;Z2M"'*ZEJ-S!O=!C%NN,F!3"&)H SF87$Q%"W6>T?\,>1;X QX8<$)@IP"M>RL;
MZ)\4!)L"-GK]3\=6MT^+C;KG[GY3!'P(P4X2W99PX010)Z7>WP^%47CP)?:X
M<:A(&]/J!?Y_3 VD@;_&3)UT:7<;V]M3C03%28C0HAKHEIS@8)Q"[1FS^2"@
M!7EK$L:\Z%&5("S05LM/2V(+GK2
M>N-MVJ^RFLA_.F@+D8I-2Q8=SPK/;!)/A^(I(BR")2HT$&MBUD#K@%\F_!O,
M(YT9X]K) UT@\P*!YP7[@6U;(=-%53[FJF_48NC_>HQ&GU&[FZQ;P1D+8UE(
M3L V9?ML2(FS_6T9$OV,JUO'.NU%[TM/1L7'M1MD,6 6.A329,.(/-DAI2=B:[\+.*H:W6>_0K"3&3=G.P:?WHK/$V/D=UZA!
M A3W"9T@J)'P&(E&^K^!> 8PG_8[#'DBM>4:Z"TWQ$."VAFXO/&6S8"XQ,J2
M6BP0.*(*L+I5K!R]!SHG_9Q@UUD\MG[E,;1M[/#7.?"9];@DYLYZ/%9WH>DVTYJVDT 8(^V#]9Q,NHVD7(B>(M[[\
MW?-M3/A;B FG@$=,3!.IS(WT8'S,[1?!) I)!=FWE,2.,Q@4Z@5>FCA,ZY$0
M4\^ 891.KK5A;0I^&E<]I0^.03": N66/2M:$JLB/^4I;? ,))\=AJ=X'5[0N,*AS4E.%#"JM^S+<0ASJWLKU5JY7DNMQ,0'A:%6_A@^F(4O&6"J+FOVPD0(7:8(0A^[[&()!
M.IC8U=-D''J!>7*[E=:MM#:?1YI4A+75S>">S@[ $[-JI)K9O2\F"HCMO=BQ.9DVW0(NI2- Y%[F9+N"<$9B/DP1SB
MLV=&V[=M]\1V3S2?5V#OUQ1=920?G6(,62"6\ZI."1R 2$PH(@ W?$:H"2GR
M UEL!5XXKAP J:%&1H09T^9;F=S*Y"(];8U9[(C@6[/2X%1Z&>R!"3'W>AM4K^HMJ68#:)NG"*B9FUL+0^].[\""FTKG=^$=)*SA%%4T)U8M BM JEO0$L_
M(.KM%T=I?8/4JRB36?51.:8 UL!E#%9#N%GE)6_Z\]!P<+#(M@_G95+VDTE:
M[;W_G*=$[6U@;@P#HE+CCT0.5HR![)MC'PPA>M7$,U%9G-NQU@?38]:'XBU%
MG@V@RG] !8$/")I[F%RS36-^-QD0+WG;F0AQYT:UYD.BOYX/N9),A"EM;1^;
M?AH^4\$S-S[PWA1)Y$+$#M$F!%0%<=.^UEPU1ZH4#=(+5F*>1/I"EO9F-,$%5:$0$AFG,]-Y2T6$END9Q1
ML>P@*4LL/X=B"A@7,$: O"&19X9):5]6[$@054PTIE#ABT,V$R.9#:XO'G,O
M0N?5DED2QY++@*F3#T(H/2F5!GS"#&>*0I1;Y>'4G7C)M'RG@N#L-![WEA$($@3'GD=N>_YL.*F4M?(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M/!SD(I)-(^QY5"9CPB7B@,TX$>>HO1.D2B?R>^C#G):=%3TQ=!RZ0MZ-J8SQ F[;M]CI+/P>XOGXIMLVP[71+(UZ>"L6RW!FB3#Z$S'EY$7%^$734=@%3 /_HD>[X6'3
M6[#:QJF-W9(S-$,$[^@=4:'1H6P8:\8'WI05]OJBU
MXL$S:3H6;M$5-W/HTA&^M$JL55*-L1E!\>Z+X%NM*5R_*[:SY?,#PL2A_%2C_,96$X[; T#ZR!E(:7I1!
M2P]X!!$WWT07\;9T>DOS1J8/18V@$H]SDG6^HZX]]2\?[&L,6S],38LK9S*K
M NI&^K.:Z"ES:#S=?7:HL%D/SS\J!GG#@
M>H00&;!OEMB?V=Q'S$$%Q*N(F%:^$1":RT?#Y\MH!KAMR\0*\2(T-<,+RC2?
M \VP+1KAA2:M16$J&)K0 ,JY[@02>82-<]PNY!^3//LHC07:)C]FOMK6TR%V
M#KR%6X1].'\ZWL-YE14QC)0(%Z PC&K2_?IQHLQ1790YU/ \J[S/=T\PYMYI
M#^+'2'IKG%]DLUT22N'AP>7@U,)2=?+Y8&A3QF!9>JK!33JM%$&P[RW)9D]=@@BVKC 1"2O1?I4':US7'K;ZB
M)>3R*O\L"76UV7]2WMUR8$?_GA7E;.PIY5'A48G9BD?8&^$S>*\[URN*W4B;
M(:T407,DU;(MV%9%#B+OCU!J(X@8"MFCI0BG!,M1O_KS')2W7*@
M)^/YX='/3_YF.CL64&/#S:4HD5R;4LY/!6Z>J3Z&2H]FC3H?PK$F@7&>IMCK
M8ZNO5_UYGMQR0T3_8RB(E(2/,!KM8A343=/@U 280;1_]1'UER
MK7G:X5$P":M]^3<:M^K_^B;3:C&1.L?+YH8 ?/_@
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MJ@JA6C?>2K#&]"*:37"+W)^U-LRIVZVN'"$AP;@I](X"9P3600__
MNH!.'@DZ1%C,&4$B08[I/E%@"_=GJT#&IC0UJ5(F"(X['X NIOMY>!:U3B)+
M8*.(@=47>]*@B-_SMI+2XX4PC(#R2AI$S'%
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MS0$_Q-FU H7_Z1HH_,\$*]=.WK_FKVK,XIJ]QV,#M.*8WY.#.#KM'6K)"^"##N@TMKQ6!P>.%JW$W3,EW: _9Y:0BY^!KHMSKE\AR8EY712\#LV#
MO!B 90#=?$^223),XNAX!L9FGB44K_GC4D]!,=.'PO&HU(:!28]!OV-]G/Q#
MOW98C!TMN[%-+LYZ][@Y,'BKWM]"@?---C5[XR&_Z:'WQ[F3-O:1N87,@]\"
M4W$+3&WR^+A>\>F_8/#R46M6ZR%#"85
M-,J&I,0HQ3:&#]N_)?I*LOUZ#MV+>(NJ:G0P\S_ET<).^X0R"E=M=@P7)]X>&"^L(E>A;_)XFRX7__D/R__0.T
MB9-?'W1XYU=G;Z/GO>CM\=_?7T27OQ]?G/W^_LWIV<5E=/SN-+HX>W-\=78:
M?3B^N/I?=75Q_.[R^.3J_/V[R_5$L%<8]!?5;'+I(Y13TCY;;6SL(PRT1PVM
MY[4MS__54;8)-NXO=://>;PV!3?BMDRF/TMFG]%DQSWO&U?#\TH[_<];R%_37E5SB^%[\6"Q;\X4U8.W ]Q_F9>XA5&/D2#
M:X(AX*F,(JE/4^S@B,=IU^%-[= 0^.:=XWX;:].'N;4#7!Q1^^EBXK-Q8M42
M][[&@ @E^:IHD@#G9C]%;$A__C5HWQ:U^GO(*NQM&38SOT%DE9/ '_7^0SON
M0S7'@ +W@FX15T0V JRGOM'OQ8PPI0:<7+ GRH^&HF(K@(]0 +4TLC
MH-"VZ7I,S!);H7I<0@7A_2^0*#S]ME1P(G("0AK=ZEGW3@D&>.%$5&1KX#!091#@=P\ L<(*Q0BQ.#9#)FR
M9P] 1F]MF[-Q#Z#EZ13!$';-S%=FFA6]: A2)]0QRO?Y'+?%M';
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M[&^M?E[HU2^YJLVE7.W6MC3>HL>]_!N5[<^(V)RV/;F_7S[\=7_DL@^ZG[M3O^JTK#,Q5]A-/>QNH:C2*N*QEH^IC'^S1PT7:-==13?_F*-)J8XAK
M7""3[/=Q#_T6W(/68% 7J@7IE344,,VV<["[TK2N>0H;Z(WVKZ C]['*P5_[
MB'5N9?W6H[]%O[O1VS5-U:K7KWO)[OOZE6=="X%>=,)_0IZA*'^*RNO^SN'^
M4VT\OH@/CXYV_94Y]1*X9\:%E4*#!]N?: 9W2#:;E7MXS4_1$TH :K?[\&'7
M];['NX;U=U;WM.QI8SO+ ?Z25A_GW\RT;)?Q;MOXSZ2\S;2N/X$#8++W)B_F
MPV]F\K:+[>[9OQ?#>70\ US739U=?S.SLEW%NVU9AX+MFYFS[1J[.Q7Y^NIB
M"B&\'?S'+K+W?3/3LUW.NVU9,*<",L9O9NZV:QWY;L]QGD?+7!\G7Q?M5-EG
M%P#^<'&+[?*OL/QK2IZN,T^*D-*TND^4U%TALU\!0K!"CFMU'98P4),@?^M^@:HKO*LJH.T.)6;0K[WX/ @NM!>Q+C0RNVR+M.TCOY,JSJ./J03(-33#[B<
MZ?TEJ>7]_5A=%:4>8A$+O5#T]NCWZ/ ?!QY>0?W2 EAXQ(562SAMJ!8=T&EY
M.KQ.@YI?K!."NAR],HJ@'$1["(>!_ OS^$2]"ZV6*@
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M02)6]+UV,AFDS 64#<[Z_W)(X1I(MY#Q%U[JL21Z\]D<"ND$1;S%/!"M!8B@H403&E&BBPLHJ6 "#HYVAKN+D7GNQ!P<>D/9*4J%>#JDS06L'7X:'.*W
M#/]JT#?SD';ME$;R*1O+/_B!X:"TT3ZE;7!*N],"J!PP"1$BKUJ\U8!Q%4FS
M]+3?QS90B[9!1-L@MAOMAD&K@J@A868B6%8MPXY"03UBB'#3S\ O@]]^C;POM:!NM(/F[L(8&80Y4=?=GO7$>2Z'%5J(>D42!+"7@X5[#$9A^S.=\YE$36"8$
MS6?CU&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MD-<;9%@0C]YH! ]I/"%M\RKVWD^BOR>3&="50BG2X?[AT[ '"-<>::6/WD(Z]$J=M/@!0V*A'P!I#1#+
M#[^=>Z3,\&](@PDCM>LH=M^0!P3O:^GT7B32!@"N "FP*C?*(YV:<#-,@;DZ-.V3$8*6E:E(8%L:8
M(QF[>IQ'^_'^_KY5Q/(M_21/F"VQ=I\%S(I(;,R,#*+)3I%5DP,D\/U/G^'W
M-YZL%C]YCFK>I7L0?EH,\T_2/6B% #U3,NCP"DM.*CD<#'JY@50MN".0?CA,L40O!FGFM$X4$6K5W_ B>"8%J3 6Y(H54:8:OGM*5$B60G_X0YWT
M&[,IX?9W)\Y0_&&E+:IDBQ[%1_L'M*R08>.7N5OYH+5SP)+7LF\[DF9B!EP\C,3;?BQL\ZMC@^RMM<.4\+!U@#0QU
MX5RRRX]H"I?J#_OX1=M,V_Y(MZ2[#1N_-5]HT9-E$I:?M/NV1HQ6A)^7U
M/Z\^O-%.J=ERZ5B;A$.S/2ML.YY"RA?>++3I]CM'D,V&2KPN3L&2Z02S4>>.W1"_@3IT];##P[-@Q?QL^='IC >!7+B7? D/CI\
MN=%S>:>,](O];4:Z,R/];)N1?L1R+IM_#0F)Q_.1V@J\U&HQQ1#[D_TV.]!K
M@'":]JF%UMF_9Q RLRTSA9R8?"*8/#>*8"DT O/R2?ST^1.,O%'(E<]^?8L>
ML+8B9EEUH[1F?;+_/'[Y;)\MM=;->SO>#NH#%;#?JU[N8< ^7;:8% $<:Y,<5LTQ1,UIZRYKO%W7B!JM-MN%
MJ.4+&/0O*=JV.YHS#;%!S/H8>AX._?Z<&*:VM<3G9
MAM\3$[.X,V\QB/N(7*P'R&-CG'PWQ6?:/R'SWC\&""XQ3XGVEMM2$:T
MX\2(QLG'%'+RX, F-US>VNLGBMOWZ6'\Y/F+19O76,7-
M:22G%YXD^YD?$$;_NX16.4)+"%!")">N80X-OW#[/SE\'C][]D*B^$F%7:&1
M49JC"D"'#P8AMULKY@H/1BPNM=$(>Q4_WCQHGI&IN,I>@U#DCS7IMC9][/"3O=)PGM
MIYY:TZD7+3GU<&A67ZOML1<>>\_B%\_WEQY[P3S^U7-/M1EK*YQ[SY_'+UX^
MWYY[]\"''L;[%(=<]:0.DGPPP[QM-*M8P>KC(:OU]H?JK13:QIMX['EB!U.LMR]5TEWH6C'?U:TI[=Z_/SE?OST
MY>$N-.ULDY+G^T?QT;,C(Q_7D^P_>L@.;ACC]RPQ'@2C32(:@]CY\6#_17SX
MXL7N=R F19E>%P@'0?@%!I$51X@O;Y.INX$-MA4Y3LN:J(IUR
M09#7RD89;>*,O+:L3/5IU:M\/E\/H'(*T!G/FBSIUK?>Q\)ZBHUV<2WR22A^CG\R_[!SUS2S/_B@R.8H!Z?
MY!L@ -C.#+_?V5)M_. 2<+Y98&5NVZ1685%V-F-]M>TBIZ?3$30[
MDT:,LE_Q(OM6>SE]/+[HX.?H#AWG56?'^9[SWC6)UCIKV:ALC2!>40/B%7W0
MEMA@OLD""D?DJR(IAUBPE@R+*?HVT6V9U74*[61H;@"_.5>U,S=3G!N!=T W
M&F[NAE %^#%+25@0$32$=+9QD "RH8>-K-U3P/Q2=3. 2HV6@'_+VZFPQ7G]
MYN)XC^4\,6))'^_()>\Y;8JHQ)V4V"WB-O,'LT5$["V!#6%V'Z'= K7MRHP,VSBB[K\&)8QRD $(!?020K -YH=Q/MS;E\N#(*]^B""96+H:MWIM$N^\@AO)&+.V2ONYNK;V>2&A-G>0&E+.QXG"W?/W!-E_?F:]_OLW7/U(9
M[U!YHN;&J=9PV\+"[[P,#&'"MKX^JQ85G-L.G5)"C:<9U;2KEO"N;=4#_3@F
M(?N+NM'[>2N)7$=DG,QN-TB,5I=),^2:48FXW^VHN0GPW$6R@,%-EFO;O*K3
M*?^G]@,P- %_,O\]!3(Q_?]9/T?LSQAKY+28[.7);:P'X?USF,P@DV;_T"_=
MZ['[$Q";R1\4%N6* HY-:1Z< DLZ1ZZTC\A!<7;P#I7XX1.TGY5.$O2J5(JA
MF33=Q5R1'#G(I 9EE9A$ CJ&UJ'>PT ?54_"[:9_9)M^E)7CV&6:LQW&D ]D
M[OO@74I F;+="0FNK3Y!1QSX2C(]J$3_4E29O,@\VR4DP= 2;" KV@?[(-NE
M80[I:!UGG/OOJ+K^RC$48.:Z8FE45I(. 7XRSB9Z,?X#@;M.J:9C+2^PH0H%N?!&X9I LJZTEI&CVY.,1=$7X#:<6ENJ.R>2:4H;*=E DX7
M.R@E ;YA5@WRHM)_D]-&+S2*SK(18D4BC 0KOFB@:-Y#(E[_?R^ZG*8##!/F
M^=RO[X8A#[1.UH\B?% R@Z0O8 ,@G)DZ826*0E: ^<@X\*T?P'%)+^JYMK#C
MHRV@CDZPJ?L]5E'KAY[S N-JGWW6FH"S0R<%5"CF7COWKT:%N^:]_0YJ]8UO
MNER87OS%UZY !XC_DT39\+]_2/[?_L$!A!R37]\ZNSM]&+7O3Z_-WQ
MNY/SXS?J_-WK]Q=OCZ_.W[];2=SO8V*^R'#QB(M7GQ4V4 9%GB?32N\+^:_%
M'2Y78<+^.6JE1^:!'CZ=?KY/IF+@3.]Y>]7E$K_7]YRX4*A+"X5"P#L:-*\S
M;9.CT7!NJ5["P;63@]^/6*W/., 9L-]G/_]!ML?7L7S>STH?_S8RW^\@X?KI
M->"D)@I"\#3"UWL']Z]+'R;Y? J=!%(MT7?(-:]!2EL15%_\7<+@ ^8KPJF
MTP(#"4D%?C%]<@6X TP[&M#F4$K@ 8D%@#ZT"]GR3!KW,P(.G)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MYM&_MC#9%W;&6J/8G-PG6>5;+&JZ&S/EMRDA%RD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M>/U?A<0I;(I,!.ON)^I_6I*1/H I1VF)YS+3$RTM!CMHODOQ:R4OQ2E_'%6V8 UQWN<>6+ ?IY+WAU90MU.<
M3E^\JK1:<33##NU. I*?8K-_#[@='C@.\BM/M9'Z"09)B8UD(R [H@2&M3OG,09?NMM)$U> >&37BEU8I]01=!V=8=']6"<1U\EE6159!9H-D0\ WE=Q9FM9A('0%@M6A1G;Q 3&;?I$.0T;SFC.M^_.CEFO29#$K(EM9AL:1&Y4CNWT@))
M,KU(N+XEN4)!+ +_+&*2-O6,8(J0Z^GC&
M49I@'S;HI 9 +R8S\Y.*+R6I>)L2X.+YP9/X\,FA[5(S]"@SO5=L[$(LM&@0
M3N4NC>+R#\W<#"T.VV"M?4:79R<++!!"R044;C8;+3I,#S)/H:($C3$"ZMQAN.NB85L[BM2;A4WG*^($
M5-0J 2"W*?>]1DG5^N<3T-)#91+J*MI5-VD^%/: <9H*#,5MCDDRM_+;J'X(
M^YLY2,NDPHU["^V.&8=I3!Z&;9Z3'0K(TEI>DV?_G@$(&D^M(?2[HAP*<>.@
MEMR;32T\<^@ !.09286L3(D>[S6>]^['Q5RT>H>/$Z;; GB:DLBB4;TW8U6[
MI3RV \'I+%/L CN!0K(T'4\!@@)DR$/\;_A8;0T,;I(JA6]S6)'9MB^:0^141OT);@A^QV&T6Z#<3D%#M3WG?.A=\6.GO!I-C[MJD4'RP+0W[TOC4
M6SF-3O2/93*H[P1Z^V:+P0@*U_SX"&EP6,;;0.COIRD[-IO.GXCDS$X79\]!
M 6Q']+3WJA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M_,E!6535GG;A!JP+ZS3AD)56DC,@H(%+%:RMP*\
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M$E2V$U8QH)LP;T -:R$BO9.]^^WLW?_W?YX\>_+S+J3)1WI:MB(>MS=LPJ -87 DW#M,\@QZY6@(JP""[R!3;
MI?S%Y YPG75D$I+K:WWZZ>E2(VT (A-SLVTRY"*B,X)21<=.@J(7O4X9SJ"5
MV6P L0G$0=+!NVVS\KVKCP]$1%=!7( HZ0@BR,!0P85.1V4!F;X4R;_CJ)]2
MFUTF^-8NB11@U 7@2B7&.R@J;MA]JU<5_G^LGW.3S[%Q&*; 6B3:I,=8IU#/
M,'S\;5%^C"C;N*7$W\ISXWE<4:[U9S;NS[33P=(-[>:Y%3RHQU *NQ*Y2K@B
M2WD>@K_PY"O3I-*G+BRQOG>O&.U-BP$TF4:AAY0MDM>G!.F4*L\:R>43P;^#S92B#W\)9(I;1EH :S2DLY0#1&;*NDDVN.@:P#PMW<5LK;NE;LLK5X")2>D+F!)]-O76"1![ !P3O@+;WX['B8LP[?[6!Q'>K]+.
M_/TD^GLRF6G)Y]JG(^KG'JO;%,]GG*24ZJ#^K
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MAX26;/S[I,[GN&%B-M7)X- /$"I]9I-=8,M5FYO2B.>4M-&JJ\_#@,)Y0PC$W7THK?_-PP;))/); R'"1TQ^"9[]JHV<>]\
M'Q4_M0AS2\MVDEJ7E=3[/0!^'9W>XK*'[*:
M[7[OYP7#HF$@_>Y1_/+Y\]Z1%E &'T.+]>(V_02F#[;:PD9MC8=CG78?0S;:
MBC!ZR&"\*X[1..Z'+26% [S&M:K$N1N*V=4Y7,)3SM490HM$>'P$U0YWESL,O\/6G("H[4-0.'PB#BS+#_;!@-+LHK!@4^/'P
MY8O>BQ/5ESP^K ]PIAX_S2T6X-X0MG*M#%P^G&E%,\WL%A+(
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MS#[=(F:[$+,O]K>(V4M.J(1$!%96XC#>? B%T0Z[J9@A#J%,Z@Q;5LQXQF%#DA,WME!F :W(B"JY?ML(1Q80S3MC0.9L5:>O,9<5 3T6<%7R9[_HBJPRTBROU:3Z;
MIDCMD:<)=#P.'>PC$Y"@$6;@D\&#Q@12I!$I[XRSYYMW5L$U%9@HYJBR@5YW
M@H*F:+(3='6VWF7-_8<7:T8YEG/,1DUWN8OY)M0J#_O-/?;36+-OG@
MXPYY8ZUML6N?:W!XIL:3?=_ " S0)_M[VNO!)?=L/-H1B;L VJ@C43*61IN&
MD=53WNKY 4WPB4!U&%CL./D(8"P>%OX+JMG-MA>3V(D^!(*I=PE2JC'F$4TD
M]OO!EQ._'TG *&(9$X,B1/'Z"QW=V&@D'V"$!O[2(:? /87FL!IF(R&[[*?U
M+5!'B=G9"-78[(MI.M8;)X<^>*(ML*@ \600SVZ/U(KNK_E^MS@V'1PLCZY 8MKQ%8;QXTX7#DH0>/'6EPZI3FI;;PAB)>EJ=B&0CZ Z[E+/
M,UKY]3))HN!P75RG<.2X&264*]5VNPV%.J&)):_DP5IB6ZTFM:;=#>,2RP1?
M26; 3D8@^OX36O(735'NEF,CO!*89HVJK("BPK1&'@HS&'F<0".91G(O6,_6
M0>JY&"2S*O4.TEMN2XQV]UCK3XLT!!P71T,&Q2M_/J&FA-?%YA-";)R<)_[">TSKUH^"O/U8@E+X)QR+C-T9(:%]J3E=+?]@M>W
MY=GA!HMMHS2AMW NVFG,6J*^YU2*SU=17W6K.1ZGM5KN746BQ6G30(2]M*_"(H0FMCD5*G:$Q
M*(#KCA=A-0F]RDU &L)95:9C+6=#@3U4#>.9+YX"W )Y.<59YOS?*NMJIEPCBGCK)H9YU: Q0HO_,+LLXU/J" #[4Q'Z-8\&&GZ5T-I-!,7BAPZ\0>Z
MUYSS-LUH4#/N Z7;3)C6!==HAG@41:'HLJXX3ZM*#HQ*"[BT3W&SM&5[EI9G
M@/ACV1S*Y_)ES2UJ9J69N(UV]+.,VR:&^:Y(LL4<\![F[&@(>.4T9(AS:9O/
MHPAIZ3&Q++.TP!?T+? E-K_R[V@9:727D<;-)QRU/R'X*-=&7*PT,.3#"PXA
MW-80QM*.LT7+$GL[!_MR%X4\Z!_#9IX/QT=> @.16G8OY/(6
M[F&0NQ\/#Y_V#@\W.?1YMYS?T3;GUYGS.]CF_!ZQG'] 'X?H*.86RZC0YQ"5
M:=A8 .31!",X.(^&JF!;J8+0K37W[M!J" &1.,H:X;O9$B2OV0D'%&XY=J-OVUOOGEO^#_C5)5?NU%#CDS\)*<1%2@
M-5];?*BVE&=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MOWCZU'V.MG&(YQO(QK#KL(>&08C17V<_Y0?RQ+Q,Y-%D_3/^F5=T2Q;,@;U1%2C^/,T$@
MEF+3R]TNDL-H+J>:X';"JH.WZR[\U.A6&'-C-IHDPXZIEQOVWV;9 UUC_
M0ENUF ITAW/>T572G^5$B?8FF6G5,TU04JBS"U *-&:57046&]40&UD>?=<<
MOQHFQD)Y?MSO[3_#,(Z[FB2,'4VQ'(_:/[1,+9_(BPKE4V:L*:.A6+OX)5M<
M.;2-9R M1 3X_N8NK9,3< G*=8)JK6FP<6SU!)@.F6F>ET2_(15L+JIY[NKC(389;0\C
M-;,4P>U^,AIWD V47Y?.X+R32YYC,6$MB!$*T1)@!,P8*SW '0=*3G_1LO*)
MYI"1&=%!XV4EU(=6*9$L.H>ZTCLX3X?7J= 2@?ZHYUX[V%ON/IEFF*"E)XYC
M7XF"4FZJ<7KVL/G4C0Z3NLI>RR65*LYCK#\9M@TX))H*7' GC^WWA\/FH
MW%+)ABQ:$\:-Q8H$Q$J:$EKT4NQBX>"UV:2J$R)FJWS8!9>64P( Y"/%UVWT
M^IZWXE"5DU;K+C$,59V_5*G?/,6+,TMGKZX&*F[ID+J@BSMT6).SP!T6>*!.
M)C#+TW H-N0-&4D3N]ZE&'Y
M6$-*QKI)Y/:/<8@TJ<4J=5Y$JXHZF'5^9=3ZE4X*F+K/D4NE$K>UFL!?H!4S
M>D9]V$GI"-HWX69& \.-QB_\=+)GR)1K^\@=*-SS!Z!:T@]\*'.SR:J KP$K
M"-Q+'G:C3,0QR?TDF>$Z0!/]-$V&VJVEHD-[DJ%9Y7U3*,-DO@6%*^U?R16!
MBQ\'V6E]!E?F,)ZF6CCJN;+&>>Q:DG*98WB@'0)&#J6M*EL6+IMIE&0YNZHF
M(;!X2]EZ=KTP-%5!Q^&E,^52AA#6H/-M).GM$G OPY!Q8 \ G#Z9QJPM+-JPZ!(WUD8[#B&_?*]KGI3Z+9_X)94>2#6:\UVXF
M;[+GHQ"I8!_L;-0Y:RHCM$909[E8W/!89YNI"O0^=8TRA$W3[/IZWH?(?]L)
M0..5Q?&F<7OL=AR[2 HCYZWLS>"TA:82R*CLLUL8F7,C5KX=%H)9W\"3_IBN
M?ORB5O->P BO/(#_NKA%9UM9]XBP(1SH^4.501(H?[D@Q>2?W2"+LZSVTKI.2#8*%GQ=\,PS9.Y4VSBXCP,
M=O>8(S;^*;(\.$>=Y520X>C,<-_]\<.9"5DQ(82T\IE([]I9GM.]CIRY2O%&A$P6&),+$KO7WTFI+3]FS?62,Y/Z4DAL!:7#Z@/W( 3>JP@$)/
M3Y$3" @2U'/1KS9I+ND#X4BQ(9-)BTUI:;? -_:Z]HZ98 K%7YD0O&G96VFW
M!+H7.>%M8;72JC 9Z=,T8SHOR!% ,?R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MMO2$H/GXKQIV?5-&FK45N7%0BV.U]%J9RA)'WM)&+1/MJ:VH;$3MDVE8-C
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MJH;QY.1:#SF9LE^/AY"YG(UAR$N(,+-?8ZF7-4$N+_,M6'I\81/4D[?1F2''5F\0(+7)7]]-D6P")3 G?H!D8ANC$?I()DP092%CFWZ"
MF6;?M&950')&5K/(9V,=*'D+&T/+Z^NT7]IAO\11/PE@*=XG=*0/[%LB66W7
MMG,R>%0+ZWZ*1)-,B@2 2W %A OUWA)3C@WF44HL'=KCGGFX\!]?ON ZYEMZ
M#CX#PPUI:=IYW<+VUI8L O@P?QM@QK&]B5LF8^.9G5\KF+.5Z&(%7XM S#:PZ,#'/'K-#4\"=,<^PL3Y3\Z;BGU%7!H_1,;/>,@%!&9D$Q (=PTR9CY
M R;:>.AU.8/RI<$ QR%LD"L0?6WR3FZA[K')8$ :L(\5B1C;Y6*1BUN0-:ZX
M4^":^2E; ])N]IFCB$A)&+!Y"WL;/RG(64.6PND,$6;!3,X$MFZ0A<%NG7F(*L]=TT.=TN]0O4AZNR(MB30KB^S,%G5L6 $[[MZ#_EXTO]X1Q?N&&D4])[N_,W>6)"S*<['RH$I_&QZ!6Q'9!]M><9#Y@IOPKO@:ZY)!^G#P CP3MSS#^_9V)'*LWP>V#UPAN"ZHQZD_S3W#Q+H
MJ@30I,B9.6%0 16BR?R%H^50/J[P#\C^*C9\_1GMK1&P^9FO3-
MP8B"(O8?G\5'3*^QS.J*.<-U35TRN+\#+^UM@FMKP$;L4EX'&PGO8,\(W63M\[[!OFKYYI8@6O43>B9XEBK]DJT)UZ!(B81QHBX
ME^>)V6.@$/-(&^P%_#'U>R XSHE>)T6[;T!O[$1C\>J!VGOKWK!J2M@?FCZ"
M)M=Z9/Q4J:Z 5B6 '_7\BP!I&X@1CD@"Z+X-'3?*)]#$MQ]BK'RJH\>U,'4(
M,5CD)JV,?((63&)1XH8@D))S)BF=.'LH";=IRS=LM/BW&/4!XE-9ZSD*C?QP
MP5P=/=*"0UB;/$UPLL&JH?.[Y P, 9^:)FR[1*L X7(/CD*TU%% 2$,Y("X,
MZS6HO^8P-"8N\!FBI3X#/D%UN W-C20@;6PLLI(;L4RK4%J*Q]%]F;=4:,X2
M],U&!TGO886[U)2X^7Q7YD2ZW"-8-(PX6A;JP==F@&,RJ=T,NS]C!MO)C[6L
M"*/K*KL^G(FNG!H,7BFM=#YA.2"TA<: DCX*Y/7-\$?3\F$D!R\GB(F[11RT
MP/<('-7B0,43.](K!OD]2%N6)JNOU:@BV,<=E@;9O$W$E:8J>H=5+4
MPD?@-FB<@BJ>3<"(@ZF8E>F"G;O12OEN:M^<*@SE)M17:!NFN@YV"_+;GWUR,]ZKN+]/QYALOS77;::_%#83X6^HK=[F'+
M5';DGU!P&Y?+*+Q8#%R5X'M;WG;,\:,@C& *%G+M]>6V@[A+@0BWU](\U/$T
MW6Y@=#OFHMALTG>1-=H8O(N"9Q!!+#&;YB7-3"!EQE4VK@>K;%HL
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M4V.GE^F5.I E(ZJ##)@E%Q2QVD5Y\328.$5(AVRT"C/);]3]%^^.
MM_"UP#:'.3D>?LHJS.B\>7.R**US-UP;/GH%7)OJP+5%2W%MAXMQ;7H 31?!
M&Y4'45/L'L 5G1"USH]L<1GNU&K.Z\HBU8K/NJTXJ7C\U\RXE6'$?_D
M"*=H>:9K:\.WV/"!P+38\)Z$?JNH,E]"[HPJ@]O;[?90]%:QV[T9W6A1] ^\
MM\GG;+P]\L)P%,[*?9UR]+25\=MJM7,.VTWS%[QH/>4^_'9NOZ8E$N8/*Z;K
M)0RF, R&EW2?=%\*?8X\Z#.]Q>[8C=Y^=\M]O=CFOCIS7T^WN:]'+.=WBUH&
M&L"<3&WQ2U]M_17KQW7#5X#*W*OU$WZRNBM"AA[0$;D,'KYB[!+N4M^'%;0T
M-1N*V1M6S4S+U1(3V=8R;"CXT\4'A7.Z;=_GL6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MK_0,N^Y3< ]/096Q214^_W<\[;QG 8IDZB _V
M@W1_ U,BSZ6?P]2DU\0)[JS0N!JBNAIJO:#G'%HK<'T9O3#X*'63YJ9O#(VL
M?7*,>2!W>J/9"75C!0=SGEN6H/8O^R[J/!>$,T1+AY+DU)H-BY0XF/7)#B4J
M?'1@\^R46U OBWY8U/@*DNN2#$"L;=C@JGK:.WQ&3])77:0X*FJ/T 56I^C&
M0ZWP5UG?3# Y0244KW"PEQ7[3N;/0 NQ^K%4EP+<
M131[[M23G61WYZ5'NZL< ^.8&J<=O'SRA)CSF1V+*NWX':6DV1=!2<
M&;! ]%L'VD.O[ C-C+1/@=ME&B?;O[3LG?@M57VGY2&](/1H^H$?)8BISS]>S03WY@N)WII*5(-G9F$+8_4
MNE;C,)A?01$[TW!?^V6%&6[5T%_\.O>C>>\D?6T*4%5?,J "3Y@DC,:SG^5[
MP@HZMB8,!R\.5^Z2ZP#2OG@9$KL*'5)D<(4D$'C'B3B$6+EUJM"J952WOO*8ZTL8K
M_Z4EHQI2U2=!3[4]CYM3'PZTD'/H'Q]CA21$5U(* X!#,Y]24,<9F=-CT_V4
M*^V%S #EE(V:8^AKW9=^DHJ)K*:6B>#2*=/*,L\^0A4MQ $II($1#3?PJ#^W
MJE+L"HBP*8PS\60-G*%DU+M$"]''M&9>#[VF#ZB!?NF;+=*_3]=@V6OOE.=^
MNO/,>CU[]T*OD,RI4^AH^1[_&&?K%3T;XD]X@
MH#+_Z%WVHM?I$$EUS[4I/X;NFI^U>G:89RAJ@Y<: ^)>E_+1V?4V00?APQD1
M4V+LOM320*5B6,297"^9
M@RF_7<.Y9$*A"-G%N'+FN)3*BRRP$>!\03(MC)U!,M7&5@X!^;2NA']WQWQ:S+]0D&&$T5Z3PT)W5K__P?S^KR ]6<62@CFD
M/G)V2 D'G$L3+ S1MLD,UFN8DOOUXIGK?C7-RV'J!^=18*X _C(KP>F^GI&=
M!ZQ/PW$V83<1V8F*23&;#*2!+%!@S*!:14Q@]<<$P[Q8H%(U!@E?#Z5(C<*:
MBTM_2,*T_<M*5=\]-GAHAUH^9GUM1AS*E.[0@E5 -&[=B-H-%F1$2T&XZ*-*DD'I=^ ,8Q:
MW%I('_ VDCW)FTM6V@1L).!.R8,:M0D;^3]JY[,.VXA#@9( MCH--./E- [DGOQ=^BM]@?
MIJ2/+VS;L@E:Q&:_TO.Q^T:*'P-#O,Y&-=RG/9LS;/"** 4B6AJ@=@L@"S%Y
M"\VYHBEUE:&S)"7&F(@WQ@8Z>LH]A[0OA_X!9E;SFI-?T+X9GI! A0Q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MFPV.;CEF5C36PJK/"6P9&'%6XZ)QQHP(P2G5PSHV:"Z)J)HY0MZP-PG$;AL>I('SZ03Q:M,6 4MG,RMD"%V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MV/V[FG[4+6F;X(6"G>9,)EI %&5G $7Q;WWBAKE+R),FJ
M,-0.7NM&=%T.@ _8/WE"*D^.MNNW?2IP@J;%+>&BX$\08-S8P^BX@AH%@7G[
ML%OG\'"\*(6 \;[VI0&'"$[#+:4%6K:F%J38!F9:CC%QMO7"5S]%IB$PN@U&
MJX'OCR\=:#G^3XH;2_:9X.Z]W:)]_4-Y4B2I7_0]C,I!-:^-*W ""5'O7[G*
MH'>- 3>@QRC4!7CDT/Z 3(7I!:+](F.$!IO;.&)2K!$+S^9I1I KN/&DR&?C
M?I;$TI5$J-##,$=KU'61#0T8"G@[)GDH;< /"">X\-3-(;3]V
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M]1=//@< -KD3H*.$P*KT.$F-)!_473]RP"S\Z"&3-"#O4B;4O\DOW:+O!?
M+CZ!9>BK$,61R,KBS1WGTW-.,:A]FU(8V F)(EP)'3P.C\9ZCB9[N(.L\]@6
M9J*O@[(=8R-[.P:"R>C/H \+ZHT! 2SKEJ4IE/0L!,1\"[F\NZ3T7^YO4_J=
M*?UGVY1^>ZYX+$1+&4
M(P*;(_KP^OP$3 VL=(*LC_8-+$8+L%5I!IKSI_L?./UO[SE"];QOV%LV9S6Z
M,(!+GT+\?'+]WS_L_[ 6V(?12!6T9IIM*2_77A/6J8J:T<_^X5?U2SV4"_!<S_]6OG3[\V0"9WT'4P=2^?/7_YLP&4
MU$-X5?.AJR%7?O@U >*;1/M\SX_^)@[HM;81*O$"1E(&R5(4D0!5&+ E*P*N
M^UF[W=Z@_JLNX7_@EJV ;06L=EN"831/I(U0(-&. 4 TY">#CBH^/I_S[35
MF);Y7.&=Q@?B6[G<._%$%*.A25T#G+0V^!FZ ;TK;5D.9X.4'#< &3 *!3U)
M_$V,6E_2$=Z@.$"'#]1"6-5.HNJFJ0X&$+4[A#D9@A['
MJK0(DV*>Y.A [SAP!?H=(HSF9[V7](N&-E/-& ZH1)\-..B (7<,&3.+U2Z^
MY#K))D[I@>/,*F=Y23AZT9]I)*ENQXG7?A"Z!#.J5*;.7!#SXVR&)Y%(%)"4
MJ]S!GA+GYF@.O)-]8OAQ80P+*H-EHQUJ3;XC,7,#":LXE7X.E:E '9--Q(>C
M[0BEZY![<=Q\&#I_$>P,"4_((]'(L#L@]O>V<_,8@HK]U+P8L#$NW(D1UG*K
M@EM];XW6+AN;/DE2B41I;IMA]UX/II*_NNR2YT3)HR6M32M1^;MR/J"8A)E3
MHY+PTQ$ "$O;-DUVAC8V2J*W#*[Q&-+1252E>J9@.F3!292!X,,:H8H@5U)#
MK<4;=@69KKWH%"-]#K[#MKB$=:&^?<;_YV5:68?'D#L'&X:@82ERU%*2!)^.
MF;:ZQ7"F5!\7?%MVA_"ZF.+FKH2YVX'RZRV#5HL&;3433C/"-/P)]BFX(5+:
M3/GKL=IQ]J+CO+[!E#LG1P0 HBC,0PW*L$M>#$N$"I'F"'AE\HQ9#6U%K4W=
M X@(%_!V0G4R,XY^>BC"A?FH25$KC*X)B.8VM>D-R^0MR0>3W F"1.3(A(/
M&1: %9!VS'DD4FG !3E%P'R2&E8'%+\R[ ,4F*TQ;S2,75P'3I0S/1)(HS%1
M^S1AVFC,I,4S&-8H4MIV"6/E0HK:].UB+10&U9MLN.3DN(%VPX'M"B_%HX:C_3A\S@1 &Q:MG_3&063$BJ.VB8'[5"IZ,R%+
MFUYBH(D?Y?K"&0.ZL_:1-<.2H!MH-F=\6.&V$+7H(M /@BA+.>$S+A$VX_CC"3^8/A8$R93HK(;[&)@*.J3J>,ET43ND8"F.JC3"3M
M^T$.TX-X&=P=^ 7JN"+)UG\$N@N&U7EJ+#R/'M)9*@N@R+70OD0I1A*ET/>*N"HC&Q^F*JK2@I')M-JC3'/"8PO[ %:M'\1SPVTW[/Q$YR/_*)3SQCF$V-\A VA>S%IP^*B#< Q",MB63+7/QZSM $IT
M]9.=8CZUPKL GL"$51D.?I ";0YO>+82]7S!W5(@[#329IL!YE[_B_TJ6#CM
M7^_1 @KH@; S8(Q5#F$)0X?A\;!JR:="OT00;93J!BR4'!B^^0J%TF,LRQX+
M,I2'H!4HXJKDI::"(=&SXK^\G27K^TB0M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MT6AY)D0ZZ$XRV[ K ZY3Z>HF-[@Z\G&&Y0H6_$!;J>2F%Z,1!):PB\HMQ"TOL)A=MQ@.4O5SR4)OJ,!Y[]7!Z-AWG)Z5-5=7%X*.X/RTL!^C:H+,)#C_[4+[S9-QV
M"V# I^*&S;'"?&8J\'SXLO6Q,$*%(1F]M6^*5\'SJ_,[^MA.T=6,MCNMFC(1NM9B-2D4RHG3V$.1N+O>V-7)\%^SJJ88=$9U4W!+:[=05@GPF6JAL<*A
MNMIL+]CKO>A_]1QAT (R)G#CQ-X(V]\L9\M(!9%?WZMN/,]0S%OB"&#NRF@W+E_/ PNF*2^(,H>KX@\M(>9$'. ALM"*2B%[WWYM'N
M?LP-H:E@<=5X27@8!.-:7K?KKXSI^6YS$+B^^"Y3D S2Q_66G6OHQ%+-RAFE
M%T1JM=B7RFRO[CB+$6\,\H]081J6:UY0_0H<+)_VHB=%'V,Q3_=J0[8SB.%1
M:$I//584>7$G.-8=5(3;40*F"?1>161P"QXPTV*1$A&%F7W8_:5R3$-7351D
M@8O3">*B;-G)48/-:>
MI<^%S\=/WEB#X6[0]8,M=+T3NOY\"UU_I#)^QMJ]DA:F:SEXMD$2%'9;$6;C=D]A]BBC85;1.+*3LXMM(X@K@4$2.$K+7M]3>8IBA66VDNOT"I&PV>:DF%L'4)B^HCMI8W7YL":@0PQCZ
MAB2\QM]3CK_'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MF86%9?9+$#4['J0&U1PS-1*FQTD1@56 @C F6:K/2.UC:,.-45;4$M*8 (?U:3OO:$5TJ,M1U_A"?(: ;EVBY*-T!BJ*7@'U:'SJYH?5\O.E[V)&(K
M@2.#0W\27(;I48'0BZ72#".QY.=@I&GC3,0>_KU ,S108-3&@3?5H+A&\A3%
MW/;A)[3!M)GJ/4?!CQPMUMDQKB_90]S37NX8[UX&][- ],,+@%Y[LZTP84>>*ND=2N(@'
MLVN"=4'A!$7K-I\/10*Z#1H#R8ZWF/=J102M9.@]PM,%L&*1P*IA.:ZI,GKM
MI=<^S$Q_L??AFUQP?3X1@SP.]5TH)F:QE0-M)L/=!GFI38Z#/#+V#F0NFY;O
M(E"I!SKD\#OMH'Y<.\R.U\0V[C41%:0+<7!H-Y=9&=ML^)C OB;5169\)U]1"60ATQQBW:^<
M*@EIWN($UF563=/V09(/Q 7H(*EK]S):^K,O'U_MR_%=LV)=>0F5<*]!T7HV-)U<]*Y01)'(B0\V"FX\^D1K$>"!ZS_/+9QIZ:1F
M@ELE]_KE$QS^?\X,EK3[Q=;R^/V%1G/A$*!FMN\+BS QT2NKQT*(B> RU>\,*BXB(16OIT^C,$YNI\#\9%L,$NLR:82"))@=E
M!B9/P450AC"H924<:G@])3B#TQH]9MRRX0.-@H7Y7C3^]@<3Q7+C6^Q.9."'
MZUD;&SHD!F7'55)G3FR0%8Z/90X^2;5^$H8I[OY9P6$#D;45AZT*::C$]8\.
MV^S"#&VP,KWH$L39FQ$GO=7$(>)XB1[1)'25GXW<6,UVMRS8X38+UID%>['-
M@CU2&;^T]K43I\V=KGU.#'*H' ,-CJA4"Q 4M/,PX9\61:M"37L6RP_S,Q,W*D%R0@1$T^:P+9"(P[4]A(&SWN0DK2[:K_]S4
M@XW/F[*Y47/,19444/)@KGDQN=X#&R4 -HP0LF*H.4R9H@1V@R"$K8H%O@WN
M&( M"O3"5!#(=D.[!EWAK Z>4BT5H>)S>'7I# 7URC/X.J^FR*MDMR#YX.[*
MY3ZU2Q5,,1_CC6FV-]BZ)V->V90&1!QX[IR%=DW\;**Z)
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M6?5G5$4SCXW;A@D*+0ELR@MRZGO$7TW$=3+%:.F3 BAD->!2JWC%GB0% ZM %>Y+5;7S?Q3"/CY'H9(FD.
M!1WMAG#':3/M.<)/]0H,V@+=9*QQVW<;W3 OYW"5U5L6>A,$CTST-=-V> ;!(3>
MU+0+ L/.1O4&166!UL&D-D,1!@O=840K$\5I*X# 6!=V43,$,I83JIBD ;#"
MI%2ACI[>Y4>*Z!V!69XYX3*XTM":>2]8+<[BM!["D2/M WQ\*;0;/""<3# NQ4ZG42R@^]AJH_@K !YEG4;F'\W0OSA[[WJ1
MQ5$V21"MR2&#IVJP;_98.G>P.1>F52),TZMD\'$VC?ZT]M\F'T-N(B_PUQN^
MA^^JM:.0//W6G<0SK)-?JI 5\P^A*>8%(M"0IX9ILJ_@S=KQR0,N,41BC/4V
M3M_NARW-0LEJY;@KP^L%F5(#=-Y:YMA,-#LBD^>0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M-^"W+Y^\B$F]2R>E2^KEJ<FP$?\]Q(GC@#I5-KT42[*2CS%9]>8>ZY
MO0R]U[J\3)?):TR5)!X\PB<0P><3]MF#*X308Q5\^^&S@SCRK17\%CQ2<7PW
MIBY OVMY,P@]!_]C<-9G@K-^/0.^3N$,UVIH0?BC 48W7F-E#&,^^KO@BT0&
MZ M_:VQ% 7,@M.HQDFE@9/<756MBW5K/?.6#WSH-(+]D11LQL[6=<8^G.M;6ZU,[?ZM(EW<3&P*H7C.C'6U^+8SULDFE$A/RAVW=VNC;>LNM1:D-LH5V:UAA[\F^SWE
M*;"-:X+$2DY_<9J85L+GIJ[_)?O5$8;C00V]S*(=_/YDUWBU3BF42H;%M"8&
M@C(E^WQGH.>5F+>A9@_NL)],S[+/MY_^4[23[6('942*)7#NM<#<^P'_6=V2[TE7/X1AOO3"3'I4MN&Q+KD,>:*UO@:_=R3[M(F,O^HM8KD (
MJKB9V="60AN7M-.M%UM48"TC+,@MT*ML:E?1'O1K815)GEGIKD7_29R&;=\OHGP!7- @LN6C>,"I0U7FB46FVF#X=A2
MH\(1"NA&2VPF _TY*(BH@W
MUL,*NTP2";MI2T"1'&M*?XE^Y3W$[_WX"/0B=5*",>3JC
MD PFYVX!XJ)O%BP+O>@"RJRT%W1\#:A C\B+ (;4.1ERR,X7U5@M<9I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M8&\*)B*9,!!2EDX>&&#P&W4(IK.*5Q52!?5-+<5$=FJ4&'S?JKR+3GBGMMX/.D"B399-'W'5+N!F>:L]GSP7B8*O0P+=O(G?Q ?U.1%R;'@G/F6 )*/!@B
M04^"I4F/B-EE B].#GVHKV.GH.-IWA7-W9AYS@'X#!EM$B,4ODO]KICLB>"H
MIG_=HW@Y-+3!K&7 $V>Q1MSF2F8^MBE&FFSW/3+SPJ&$L+I*']ST)T6CYBYQ
M]!-N7O-9]ENP,6!>I;=@<:YK%VLW7X1[?:W*Z3VGDDA?WZL>Q_8]]1$#)LL(
MP'30)3!;X+&5/-6YN5 NVBU\8(V%(1V@*%5B&^V299@S%*YI/KQ)R.
M(&W0+@E>>-!EO_:0W1P$X>B[O(&X29"V#P9DDW1D8^:>B1=T\^U>""$ >& 3
M=I2Q7S9^4QVW+CT1'1?CMFYSK,>9-#D\M^2<$)BE,<$DXN72N"P^)SN*/!UV
M>D< .[=4&R^141:!I4K TM$&/:M.=B%(#T'T8%@U2 NYVQ4:%N[Q(;U:F7L4S?[:Z9(=,Q(:7::9*>[>_I
M]VNSGC&<^/U$!\OUT\'S8H(X,L6TM2&=2BS,OYM2+&WC)<"S2+VM(2I4C/M.
MS&\7JI/I*$;Q/4[POH[RW?;KK$MX>7Z\[685#?9
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MIMW J;$!Y'[JGY:L[U1#WY'$M9IE$UOEZ 7AL&BLY8[*'N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M:W7B=]MF4HET,M;$ JCX6P\Q;[W@<#)271X<-A[TKX>&Q%Q_DYR.,?="E<0
M6DZ-BG*Z+Q#'HK0::'1A,&M4KG@Q/!RDT/FD=+OM7I-_/:ZG%4UM$IA+DD9; >I-^9^]F93C"H9Q*I3]TV[
MQ3_:+,]!.\E15YS>Y3TRAXS'WJ+2R4V"V#\96-0UL."T]5;&"2,'*3CB(9?&
MHU*'+G>ZIT<+2L,"-#NT171LAWH'Z< 2J,;:JW#MO5.AF1V4"O<\D&G"[38;
M@LCR2,N\\X[@3ZQNA,8H:2S]7__,AH@W/]-$MMAF33.4>Y=^(LC!)%2_9:JS
M@V1,TC![>PN\(:+K+;U9K-1J=O)*B+?OI1O0*HLO?140:Y^J0'!7MI9T5)VNJ.!A9)I)&N7#*-1P#VXO]DX8UI?#@66&FGTUOK&\F:D*&P'=H[(2>
MM$OR*E7]QD1R^ +Y-H6W&07?U !0\DSJ$*C!I6::_F;RF!_ 2#S_9X?]J>=H
MV0&G5CW@ NKPX$!*RL4JRT#2/4D)M9=R3NN&M[VQ.^FTN42>]NU;YFDMF6J!
MUH6"I;O8%4PDC"K/=/#M>G@_Q>[<))7@&":V'QBUI)N-%V;8-\+\_GX 'T[^
M?XG(T7D,35=&L1_H7,%'%O."'S+LR&IF&'I%/JN0!(R\49UA>O:B*T\
MXC &36GM;Z-ZG69)&]4,=P"6/N& +$ U3RG\NL ZC5&TM9H[:IKOUM2XB>8S,,76*9\B(\LC>)U/*>>=PEP%@B?;:J9EN4=7A9VZLSKU;
M4N]HF]3K3.H=;)-ZCU3& R['$U:0OR&_VPM9-[CHCV"C'@*. F#!.[/I@3/T!$N=AW!S5/)ZK4A84.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MR4PF;E-K"E_ZQ^IJD5 NR>+&P!NKU%8)M#!])<.9Q+.'YPE1/(7%BCN!.3&9.H1MT0S:(G6=J9]N@[*G(+F)
MSI<,8L:-PC4FMY,6$-;\$.#0
M8TOW>F%S#%HO;')T\R[I*[ERSR:<%*>TPESLBH4)++#%K/:-C<#U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M$@X$0G+O >>O%SP K#6JF.LH+67M-3J
M?,-I\ :%D)Z]$02WY";Q<9W[KEY?'OLCPY-FE)7:_+K!QEG=-[_^/;QY-=K#
M3=W)2^K\LK;R!2Q;1:&&I8@C$%;XW_/7^G]/X;]AEG%90(K\LI +*R,?M$#X
M+'?VQ-(2=J/U:MV^_=J W6&D&OYVXZ4=:;0P-AP:CA03F9/)+(-#3BZ$#\)+
M\)-8)\%)B+W7V"'@3ZLL;)(,DMTV>"/4#6N#!(@PX7B$SIZ@-^N.*&OT?@4&
MCJ0Y5ZH!G'>[^M].F"W2\FM4%,&4O3Z6TR3I.)PU89VFVVTQ,,!\&(MBG!XKK^)&H57%B%%B)3
M1][U24@!X( _8A6$F9R:P=;R>P$2'Q_ZU/JO+:MS[99]\ZL^^$VZ[ZRT*W7B>E^Z]GQR>_1AXOWEQ_.3J[._WD6G;_[Y]GEU?N+
MZ/PR^N/BM[/3Z.I]=/+^W>4?;Z[4^=5E]/[/=]'5\?^-CD__>7ZIKSM^]?Z/
MJ^CJ]S/\*UQY]C]_G+T[.;N$.\^OHO>OH^-W_-RW9^^N]'_JR]Z^??\NNOS]
M6!\M\('MY=0R/OF^.SB7B?^\J:-EVTR9L
M+_JEFH)RMF_8&R7C+)__M.P=>&V5_2>E(3GH34Q7?4B01ALHEX& &-X2@@0W
M2Z4#.:0MWOB&3Z[E8O/;?8J-Z1NDM!]P]ADLEJV\K'D!UW(,+']M]#NJU'L4
M'OW0TV(PXQSX!+L5Y\FM4VF72WY]2X\,>UZ9*F50[)37=1LP&:_K\NS$#4Z#$XACH)OUE;9OUN'^WFL\
M)UI_?;;W#\)RZ"=&T@ -,\SG8$\"7J+* "!00W>0V]O;7I4.>M?%)VP-@I%$
M"$]S,!Q?@-QMGYFPW!E\)>J'CJV6KTLI=0@3,21"@+*8Z%U+;6CMI^NYK)R.
MZ!(4ISYO9FZYPZ2-^KG+@2":&%*>X%)R AWB3^15._VM@ 4:G&<3:*'6?M(2
M$KX^)>^;/MM^)I&6@=.FAS*8,5^[=G6QT2QE$L$3TUMZ35II8; %=&-4(0/FI!]2LNYBPSD12)_])( &?1]!\^B0%P5BJOG0/.4@L-L
M1+9C8D62B;XN&W@B;2O_[31Y2PN>\Z@D"%P^5]P-1'_Z%$+&"7700Q1+,D%.
M F2NL.0;O*N,0]P^R&_89EBNJ0"]1*U&/R59CDDK+JZZ3?NPF0%!EF+K #TC
MY75*\9% ATBS'WB-I+*Z-(BOBN;4HH/6EG1EE5KED =(1"W5Y+64[3_8/6A
MXAXW(43;"D _5+9>8"Z]2/";",=60S-!:@GMJ0O2(2A94%87MN-$)?+>3@F(
M.K"]JZP2/3>MYN#?]K2L@:XC+5FFTN8=.FH[]PLJ)R'L'MM-L2IB"ECH$,F0((+ORQ+FQ[!M.UFDGD,8)#79L?T*[Y"H;P^;T:PC.]:-#L
M>*ZM0_+_]@^>0K0W^75-8^$(V_G5V=OHX* 7_<\?Q^^NSJ^.,MSR]/WKR__ /"8111>WM\\8^SJ^CB_/(?EP\3%?Q*['>>R9]BMCX9T1&!V.&^;IQH?A?VY/3\?0-A6"-P& G?T< )WV(M.SRY/+LX_7)V_?P>1
M56W"_'%Q?G6N)>S]U>]G%^KJ]^-WT=G__'%^];_.CU]1UM:OY>\SNG&L9SCM
MUP[A67ML8[-4>KACIV22.XV4M-(75Q@<5;NE]0ZU^_E@OWM BC(G&ZT@&W31C.B! X.?W;HYC[,2NV?5-!,D)MD@AUN&'8"Q;%FG?%X(WVO
MUA#I^Q-;C;(7>('$U.O=#&LE4T8:!?FD]1,V/!0QQ ?L=QFM_\,>AZ8Z2Y@>
MP?]NB)?EN3#-MYT][!T^P1 Q#M@X<]G &5DGZ>8B_=2?3W9$+7'.$U+_&!1S_M[T?3WK@7XWS^;U%^C$[ $X&W
M?'V;?(WGE$"-7.Q.H67A&@\ +%?.LT_4"B@ [>A5KV:(=I>ZV;0<9,+9=,NB
M9)8 P]"30I[.-7;ZZ ,10]2IW&(>)$T]6/I*!FI*E-,Y%)TCSA!V.C6,3:X-
MO#6?2P#Z5I1SA@"NB5/RB=6+$"[%I\UL5T0WDL0(W#C,9\CT4I^0N; 9VCE
M6CS$D;& -\;N?CNT(S#3Q.@ZQ=-% 3QIX[ML63&N'\[)%!LEMJTBKT0 E-+/
MP+?"C:I]"0&6QF5+HD#BR"**0X*D1G[!B4+GR:U!P:$,1-CD A'_ ^GNH9PX
MM0]ZE"7&*#S*ZR1Z6J>UB]32WQ8>$MMXFYO#E$8GH3YBZ4R_!M)M*[FDI+G3\8_F^]P:BI"-B5K/5NP;2$]=M8378W
M0-KS+2"M$Y#V9 M(>Z0R?M4PTRI7W;?H9=50Z$U3K_(J2XWJY-(KFY%ZO?>4
M\S_M]>?1*VF\>6*[$&%^1WEG$7 ZP@G8!PY'?M[D%H4YWQ_\_>NS:WB6T)P]_Y%8S/Z7FB2=+M*L>6TSCBVQW9.3]=;
M;W4A"=FMA#F1K%-FK!#1:$1'@(4F0-Z1,($TYKYT^K8@-F'"BH[\$B*%STS_H$'+^H33
ME3"HA^AZ-IO724249+#GF/;Q8 MDJ)UH=3I645M\3510-(X);NA(8F'X>(M/
M/+_=.1Y^.%8^T'\Q<,1M,"EFAV#?-)[%8ZN<))[T9AH1"SR2M GUV@$L:,UU
M@":P38G]Z,16U8T,#S4=3&&S@BZ)%(S&7D<[-CX<=X.W$5(L2@.V;EIQPR%B
MWCDT5THXVHKK\H5B%%S6P6C=XG9FPL2-4+MV8O8P-&1S4,P'+P?K]34BHW#$0R;&6>L*1S>+TB&OUG#XAK3TE'I0$?[BQ&C
M&RLY<+46<9J%V,70D$!PQ,#VJ?ACTS\;;7+8Q!NET!C4I]L-O
M1_)1*3&UP$#R9@;XZO#AS\]'A)3'_N-O1XHL_T+4O^_RA\-&=R@YX%8/N??1
MJ?"K/^87X \#)'T\S?QJ,9J]AND%H.NVVMW/08C.'\.C-@V1'YWB4A"'N6FT
M^ ;@>-/^.B[\ >@IZ:6=TPM\:C9][N_RPU9P9@9DR\UV=1DLW@_-/K15#3I
M7#1;U&1Q;+QZK%>$SM*8Q(,((:=)]!RM446E/HHAJ&R863*1(!2ZQ9Z>&!PX+KJMEA)F8SOQO
MG%WGN *=T^R!;%1DJ:UW&[H<)A7HE#EB,JLR+%9"?PS80&0-L ;ABY/(%WPY
MM,E=-RCH''*W%G_)1C&_0%R2N=Z4?80X^S#3.MT],L: "7^43]CE=A[@5F=.C\SJ/6,UWFB\X7^-*L>GIN\Z$W6M-I#(F!,$Q;.!(T13#,G8\YMUR1OSVIZ">20$YES'^)!&!&8 *?8
MR2F:F ITJ7=L1#$'CA%/(6 L!DM[XV$/VC8/:!"CW>OD?D_6_"G)49Q&!)01
M#7$PB0]LB$;SC>B>=DJ3K*\!8BAIVB\1$9+2U%O@B/-HO1"-UH,WSJ]GXVGI
M"W@C MWY%$>7!,\;$VI+#*3,D'W 'Q,#'PRY(K@R)OPB:/()OSS@0AZX4Z1"
MG/THR,(NY&S8+W@M>/2D#%R6Q[:HOUF>&*"$08)P0!^(+?)4
MXX$F*MI>S8FDS8E.X89RU>[HDX[WG(5_<,IX;]0R1T//H1-HU@5HTO,,"=@6R1C^\(
MP9L"(,)Q?5F!O>P7DX*Q7"D@YDM4)3':@#0QL!\(L2+ W<1@)CA5WW,^V3 ,
M+/*98<[<#P*Y/-(^MJ:TZ8AOPJ5=(+$&(]@31+B#QW^?C)\XMC-XE+ DC;J0
M2<>&B#!U.4F^NV_\@#CR&.;.0?8#99<51EFC0(^^)8X*%F!27.R)E/=Q>R[$
MT\G/PIEE,29 *(702S'1N,C[]YP(#6SG&K*^C"&;A FW/O[)XJ[@<MGR20DRMY+XE/\ZEO$2T>KIBC9(XYK*'IOYBFG?:^"8$O<&SS[96&!3"'^5DT
MNQK,ON,#2>B,?7CH\6OX/N+"#VG'RZK;TO(;&,Z"X40B.UQ [3(3>3$+Q(>A
M*('U2\^%ABRS<1F]X9QK,68*1W46J"<8QA=N4TG5FI:'>7'^JQ2BHSV&$$@V
M8$:RQ.PX#)W#SU:*V^@,M=RA_H0*8^:+$2F\H-9+7J1;T4TM;/E=N@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M,8]KC4$,DXQ"!9NC>/=087#EC]<)1T3 2*XZE0CX.H**,">3Q?Y
MG(YJ!.M 2#CHC,&B&?%XDNW1H.OJD[];N'BI;9,P:H2H$0D"#!<:$MXP+&;G
MOUDK>[VZG4Y=MY-9M].LZW8J2N.]V,C!:,$>:+;)*Q$LP/00CH>BTEB-@>6S
MNH)0KH>#%"/3,:A,0TD>C4Z X@L\3QH^RRHIE!+I?NH$80C@P<)MNM-2JDZ-IX\=AW'JC?AZ97Y*M@V&&P A[6I2;".L8#&]A(KQQ!O[?PPW9>B(:
MGGHJG\-UL#!!_H764?PSA?5T"C^.2&0 @1 H1#!P(=T
M SJJA"-EH$(>J+Q9B3U(>F91*"7]6H$O 6)34FE8?LRW5!/GDP\CC_T29VS2
M'Q!?SC^AJW<3R&&+?D6/K3M AJ'&FL3]FJ".3!BSMQ5MF>J*![YXHM(L%#+G%&$ #F#RRM8<33[ RBMPAU'(PNNBH1?N..1',499IW#!&*J+YM8 [Z(7Q1XN4($S.\'*_G8BOC/63^F
MDF$*A5?3<;#R-@F28]QARH,K-,X?+* &X0DSF<,8?_1>P@)XPW7C-B;F*.'"
MQ HW6@R$1FKLL!\240F8ULHJS6Q3#(KHB-\P]Q+QDHD0C8XPK(3YK06PS PK
M&QH4+>,\,8J+!1=0"-#"RAB3=[=82B4$Y]J POJZ: @Q\LY44@@IOZ'Y!$Z*
M$ VSZ>/XS&MMPU
M"I&\R#80UZ&8?G:F\R=()\+C@8-8H"8HS4QH
M\F!/5IB'S@VGDC(:[$FL#R<_-_F](BFSH/#4"3;L12H+*0"@YO,!=QZ\0#TH
MF C!Z@QNG?#H1@0O;U>91L=!A?7!4.ME,^(R&*7S2^"I)U/7,TYC=G9Z(U*4<8-5*OA>68P;BA:IIM0Q7; :US#QB\X
M#I5U$-R*O&I@[_$U('0E C)Q2(7Q,$@H6V"A@1_LZCHV&!O$?&J6F#D>LB_Y
MZA,<'0?-@!A5X+"B]L?QB#.4P[NWD@&B0 ;"%T*F]DTIF#>H^O?0W[=P*5Q0
M:# *Z^=9["DM\;BV"D%#B.LC
MBU-!4[TMME_K4LZ0#!U# &A081"D8F
M,9J!#+P+[AVR$9K0(@;O1E."#TRL\RSW^C:UD$$^:QY(2CG..H:WL);A'0(O
MW?#FW\/7V4;W6R7$/PAZ 4-+'1WF+83&3S)/&9/14-Z!7=R@BM)$<0Z1QF\
M!,\LZ&3&3TC\--ZLR4P;Q'"DIQSY9X)#[R!@\3/N;H"-Z-!,#:J>P+!<0HL1
MV*3G<..PR7%(6A\7,],)SC"WD'4Z(0MSGA-%7NSQ:#NC9GBSQ#VPZ3(.IJ32
MI(YK.NZ#85O_:_"6J*7.=WQI+H[*3&88>'J<2$2J>RMJ/T<[E)A!R>$^4!S;S%)FS"E@N&,U .RZ4FCZQRCAS>2]W+Y8RQF_PO1>UML
MMPG=+DR+K,(;T[P/>>D@Y49>!U9EL"W"F1>N[HX !M/@W %[-=@8
MR;17!_\3 B'!]G!FG01JCV\<20+5H$EK&U9-^3@_-9Y?BW^?9N_%G"D.3&*(
M$^ _F^-H8_A"/I/R>,BI04!7"%RF((5,)Q*C_R2%DH@FQ] _X!^!C^WQ4;N\
M3HY&0ZUPOM+[DS9%'85,_A*X7:#\O&FK[(HM70R: &1VC6Q'R< -O'X:!5,'8_+)R+=9_&
MZ5=*4*_$>$=(LBAR--['8"BGKM?$@8W6?+PK#4PR6N;Y4DD,IA.DSS*()BR#
MJ 9?L<-^ CE+#E6>FLVAC*CQ#>G@, S8EG\)2C53(BJLEC=!SM4\.6%XT&^[24\RG52T#JFX\@W!]R--_UR=ICZ?(Y@X<]PE99(:U5%L.$&':C
MM _,'"F%A;;8$_+4$_1Q33<(9M#?LM8+0[#6NEO=C703V#A?N3@JJ?D.1FM-$6"GBGCC=WL4"!M@R'6,EEIO%]QT:V
M D;I$$6A=WEF&\]N1M!2YQ'M6+:'M2%NWQ(@./-&B_KI<>[=7H\,SVNU^GQ
MBM+X_8*M,V35^6,:$PI$(6@$@:5QTD0+*^\\0_N4?$((\0X-@'NF3NF;_:?Q
M-"/T@CO*PV"K%\]!2\E)2@WQ3V?.M\"YYK-EO@A@/\]>D[(Y.)'$S#Y(C>#D
M#&8G_L2U>#RLFM[W'[IX6,P;&6J!"ZVA:9BNNS,$*,&>FC[W0F(=#*EV7B0L
M'T^_>[1 M'UH/F)-#"\IU<2X"^0*6K=*(4S""0Q)A+ (K@/!XLH%\"X'45R%A3AO0"PDE
MLWIHOV!@->IM)$=/^'S@/Z2/J)U M3,VH(K1!F5'-ZLM%-G"#DQT$YZF537MX,"(H>8EK_E$E I@T"9O$#T-YS3:1$3WCU"V)N^/ET"T:\1[(C!R-9D3B49,
M6\[4L4-02^HX6M#D,3"UDX>F)"("#>L9-23<3\*.N9B+<'"OS,+ A.Z2&\].S@2![V^V @SVMF
MR20X=SPIF*R"")(:& ZVTY*FJ3.0$IU=&1U=N(_"AC2MCP0C1/(7N/H7:Y*A
MV!SQ!R7[AN^S\HHA_1U^!>T4D0:1-\OVQ-CB@56^=&=!I\?P(3B+Q=O2*I0%
M)5R\&BR&,$XJ1O0H7#S3W:YA;3[G#P$.F7@P
M61%7BGWVOJFMP"50P,XGY2:JL]_ZJ%P0B@L5Z2]0>V(01#^%'4>M?GJ*Q6O3IJ6Q26:!3$N_)I;@LKR%DAH06%%R%.H9N&NC=<%B25'/83=+,.DK
MTL\>B_5"; @Z$FGO+5VMQ%?'4^.1E@ $Q7ELLC)5V5F=% WA&BY\05'EI[T&
M5=:!"Q 98!=4LT'! PZ9H'+*R1P3&+18)Y\B1-\FT/[1#,FF+YCQ5I' 4V1^
M0"Q>;X]C;)$,2;(8(O2(,%1ZF:^M*_LN:4)J!RV70LJK)B/9V[5M^6TA#)MHMXQY/&_ OAC8S\32%ZN=F?)8F,RR#J$O&0-:[
MFY[8&T-!V_R),D)$EL6:_NBNOX@-'204%VF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MD>4Z5Y>9JVO5N;J]6U_P'?E1[SU97>=$MDC%:-Y$PU] D2T(U9FS-9_!/1=6E9EM)JL04BPN$[=\5O=%M"F%/&&34>'<#
M'\L^Q=8_OETUT"REV5X3T+]%&%]G;\SX0M^=!9=>#"S6XNFK0*5'K0PT2%I*
M;'@K\PB3^1W(AUHPGXUUCF-[,R X/)00'$H,#R72&9JBTFUTN[\L1@&BXV@6
M2S,AO;Z.$0B=(54P @,J7.QFVJ41R/-%PBHC<#$0]9(9@!*W"$ )NQW\E1V
M2L%+R3._T@)0J>&BK0)0*\9]I0:@A+("4.F3OC("4,*F :@W92:L],865+RP
MKD>6(.\5'IF>UR,3UO/(=K0O^BAIU);R (:4+PEKMK9DM[5DO[QQ2[:H*&)M
MR-:&;&W(UH9L;<@>L"'[MLR$O);LEUU9LJW:DEW]@)NI,:+0Z %UU@9M409M
M%F!3[-JNU)2[^:Q:X>]@CD06W7,9DWPK"AN*M0FU;@[9&%1F??
M6FJ\-FIKH[8V:FNCMC9J#]946&G4)O2N$*CYM%A^Q7@V-4M?09-;0M.L:FKU1,?1&F2<7<^R!WH.#!H?8J=R%!Z8Z:5FERM$]=QTE)@FN*;M=M2NZLN.&=">LI!;LBRW.ZVQ5UG'80RW2LQOWLEE.M>B>NX
M5T*I[E7JH5+=*Z%$]VJ-"FBA?/;NO,BM%N5>Y>^^$DITK];HOA+*G-Z/M/#"B*N*7JZ7.>JF>I<
M"5LW)93M7*VP^PM'[2H_8WAZUA W7.H.:P/)M9[UOR8]$K$(P380[H)Y>\'R
M\U@1^=N*/UP1K=\+1K8<<)AE-:V(YPU 98$$0V[:>R+?@9%Z;N*:7L=]92*>
MD@VCH)IZMGIN+ JQN[=<>Z*A(JMUB"M\9>LM(!&C=-2&8ZT]/-1B4VE:U^.@U@-$N QA)Y SN^]_HF12M(9[W
M+WK?+^_O)/%\\,_!>?_J7.S=WO9[M[VO_3NA1_YYWK\<7/WW]_[5V:!_]Y9;
MTD =&&6J@W7)H5,H.221WVR(WWKW_=M![U+\=GT^N!B<]>X'UU=WXOVU>/][
M7[P=?/W]_DZ\OA#O^F??;P?W?PJ_7U^>]V_O1*"+[W=]^.[F]OJLWS]_TY01
MCHA@L-.75\4(Z:.D;KQ75!E?+ >&4\,4(!03Z*3ABM'(M.QPR'PP%O0X$C$(
M[7SQAE_9XUM/2<6.UEL>(@7.R,?*>(%YW'-J>&S[8DT@#R!I=;$L[?X,CMS'-MD9SL^><7C
MD3.=TJ&D+ K*GW$%W_/8!H^J1 .R $@(OP6A@Q!RPB+D8O>^()BS1^2X_/R2
MZ R)?&-#'#Q\\<$DC00@]AB!>;!HAQTW ")$;P$!
M05CQC$;U)3Y."0=(T(!O.'_2>""O]@"1EIE+G&UK%N[6(\>A./B[HDJZ+$NR
M+ MTM2N=OSK!0?KT"OP6_D<'R@_#3"^]V]L=L@CK[>T('+%W(A,<;"\"S4_P
M%0$2!$$@\NV)KH%E5O#M;&K8-@WDPA#?Z=3!D:: 3CHXWOLD_EUMZ")Q[Z9T
M@P&L\/!,PQWABC!Q;!)^<&8H'$8.3,.U3<3K \S0MS'3[9I#V/T;$,0-$OQ@
M,"30FH^I?."?#=AG='Z8SY])6%H(C\:< CL
M@V*+"CRQ-QTYC\Y4_$Y.=6YYZ$.0!RJ-=NR!GC$UL&:6#5R&]2<@7":P]S[8
M[X8!*O/! K1/*$<;4YS29XQA\24-8,$&1--]AIFVGR%1U8H]B:!O0NY%$S5X
M^Y1'XN_TY G9M3042R[%]VCRJW##YH-IFRZ5!+$S.3;#*GQ![JW%[CUVYP\B
M,59,V^,G:(CW#H95)8(="?J!@$()<@F!F9$]G!DLC$ )KLX@2#D\?!Z"S" [
MA(*23\F%3(*^JY,!F$B_%87,W(8(L<9HP1KL[]DWTAGAV
M?75_>WV)YJ: =N;Y]]NR?)!=3_PX#U:!X 1]UYE2RK@!33&>8PCN;8\ Z=%L
M--MM[ ?)+:C,V M7L^#&K0 ?LP ?S K$E2ET=8OI/N%BJ7!_RNU\:G+GVCA1]&.3
M[TM1^>SNS%['#(._6L@*6[0LC?D/P\%:M;/+V(_QXPCJT>P;/@K,3AB-0A..HYP
M2NNKYYNXM%QD0E4NSP4ZP4RGM80T"_!&NJGT 9P-*'*)+7%<>%JL^'!LW/.$>!P&,&Z)L
ML$R%F/M$4'N"K SQ]B6@.X"YYV\K+MJZ]P"04WF]F#^/(2.&UD;0:O:8)](%@/0LR>)XM6,M'5V)#R$(RY_^@P;QK3
MFH#^P&SW8,VOB".E7>M_V3:"(%\>['XR:>T1!61T.1/F,_%9P=#IT-N&E.B(
M$"I\;8Z9[?/T-+?I?@.Z%L,V'IAW&F>#):B7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M]KP 1;+,7;SKGT6,>&_Q61!N-(/-%D256BZYJQ=Z2(G7;8A]J-=^,GD!MZ$@2@47= @P28%%\K/D@?(^@ )-&U-&'14\3TY*1+83,ZL=+&\0:$B'$@&XH
M=9MPPSH$-UCFDFT&^>(0PU=@JVT,\J5):\Z3IZ;O%.#9&Q%O$7NY
MJ"/W!V^/OC[XMD^SJ?-*1]5?@-63,,$-)
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M?G7?N[H7+_I]FHT!^VYPEC,7TSE(3K^/54_0+"0A]87%MH9@"%!)C56RM@1&'2;>85@N$:=;5U%M4))CS#SB1O&_@?$T]A]QW\(OM. \'SK8';V9 =4V<.2?GX_ B_K5=_E3L2*(
M0(W[FM0[.V*^EC\.WH7\E?PS5B'_8D)#'_QF.OXLLE<*_3OPA(^BO^?WA#>#
M$OC?CM2C)3=,EQ6SA\]Q]%;@4"S& A\]-U<
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MPF+Y$9'7JLQ+\!_1:5K1*;NNW[8R^%=(^@:;*#Z]<5]^1FAF])I5
M:),8,R+I,&PO J.KO'/J'_XH7&O-H+XP/?KF[$R\L;FHH>
MX9 3*#89FS,3C[:TQ$.$$H](K8\0?Y!$CQ$8HN'G/C&&(E=!H1;JYN"(AL<"
MZD,(70[):S6@?2C2'P,#&Q!04EKP7(@ 9,Q#FW#=(A"@P\?CH A+ B*U )X%
MH_T-.^PN!W?W@ZNOXMU][^J\
M=WM.OKJ^I8E"(4@4ON48V[HMEX6+SP09Z.6209]PV_?;L]][=WWLJ^S_]_?!
M_9^\O7) /OSR)Q(&0?Y-[^I/[+_M75P,+@>]^_YY\./;FB:*>\OU,VRE]*PO
M"\=?-$2"]ZNO?7%P)=[VOQ*Q<=N[NF?*ZTXXZ]_>#R[^!%$2!NMK$MDCB>RZ
MD[_U%9*PMS?7MT10B%^O_]F_A>J2_ALF K#IHH7AGNE#W:K_B"6>86+_"S5T
MA+#)8F30>@(L.\4Z@#,^A$K\BEE/3+K>X&S&$2N3O7!<$\K?;USK&2XM5[SS#7_N!>4 UFDQ4ZUV0+%E/'&]0L=F7>B85>BHR/+;KW3M>T/\-KCJBW>]B_[]G\+YX.[L\OKN^^U;%LS5U\Z[[F5M#;!@3.M^#@D [#CB
M\H'-1IR^_N#KE? /X@74$SVWO
MFG*T8FNG#.W*7EIM@1\JOU
M\Y/MV%=SG%:(#1WD1[?FY+>CD7PD4A/PMR/KI_]I8OTTQR>^.S>/1)OHU-^.
MS-'XT\#V+&(8W+OC&XAM6:8'7=8]6L)W,34>CA#!UL_G$U560$NP\CYBT$4?
M38P[>J=@J.V,W4](M(#2XKF@797-F9%PA$ T,C>V/!R\B'UYK+PN,@0(1Q@'
M1:EL3$ZT'S!>-(C3DNG@$=XHPU=M4&*-CT$5M!2L)9I:'@8NL3R9H(W ([PE1@(;8H\\=A8NODH#) R?QUY-:C73
MLP6C9QE+* VUBI*AH):"%;:DF! /_\45R]F?7_JW?$Y7MW!SW".O^=?8Z-%U&^*^WEOMB'2>AE $>P)C"ANV>/\6+R
MU_M'F%+CW9/G?)DZHQ\G(_DO>,Y?RI%H>L3M@]1V1#:,7L>?RGER*% 45=;T
M1<>CA,X*E)5L @OK4K8(G^.KP%2MZ(L*+GG3B"2!@> >2B[HF[/'@;SP<> [
M;9:?6/CN!K3=2WCA@XM_13% *V^#GGQ,?( 8@]IBVNM/'>F(S]X05A#)-D@;
MX/G !4_!"HCY;GI?2@Q.8B:<0,QNI9C6?X\%307FB!5\G:*L" X!#Z",(%F#
M7NO,A7GJR?:*XI'L8A!&=^?YD^H_.V)DZ=.I.V.@)#:.VR3K['\+
M">^:CQ3#0_&WZW@>&SNPZABXW 5Y-1\,*:2$&HLH@;9"*"1%,XA@!%VV!D3
M]G?"G7&L5",)&.K#)C[;HQ%%3L*DH<'&!.U0-*J4HLJ7P*6*P)Q,ZYF^ (-4
ML#<9*D^,:&,1HUOL?C?X>Q)!%[XI&_Y$WS7H/,;G>73K3/P@/@4''WT!F5'Q
M86YA4X? IF?!8$4Z#$Y\>31M<8)%T.DWHKT/47F_M@B:&%,OKPRZAP4.-X;K
MO_;M!_)9B@0B>,49'O3[!1%$P0BU\#"!!3F:;H6 +0 6[7-)#M"$V3I"($,:
M ;=&>:12_+H+_E%+Y1_7Y*N*;"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MB3JQUY42V3W^*:ST,D9T<"G1WT; [3#(,H@Z"/&=96BN>W.M'4XQ1KO4I#-ZPNC&A'@VV*;LPHP=-D.3?P@W V'T&BJOU-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M?01&:MD@"3/V"&%B%>F'1O\J@_C*N'NI?%=^&&-#L(F"G._.%1?#:(03;W<->@Q[?*
MP7QZ/G1OZ%HP.?6!&3O!Q"Z8B!\T4P>/"M F,4,(?S"=6@_!2!'J8$;-AF 9
M)#XAG#T.\2)6=\VVA,*[><[<#4JGC2FA!IK8X4BAVR-IA7=HE3G@NA 0Q)F
MS,>G#>Z)3_QLN8[-V&9MC;IA"G>WRZ:2ZV[6*P#2ZP*@[ (@Y>T7 .UCR9)6
MRGRO7019E6MZ99J0*
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M ,V'R9_B&1ITH4_\B\& ?7<MLZ4_OSAIBL=@B8A$G#!P:MJ)VM9T7?O "BZ#$9,PZI;\_,IY9G-MC8"4C?4X6ZQ&6 .Y#:F"TLS4[QFFB^ZXY4CMXCJRDKM3V
MI"L[S6ZSK4>9MBG+6D=M =,V-;7;'BM_F3\5PKK M46^]-)5O@E]F+Z%.,:
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MMJ^5.G)C:52>FPCW70(U-R6NA^=)[@#_7I:EF%6AJYQ0#V9?*D(PL=SIM%4FF
MJ2LJIM!*HIB@N/+KW R>5W/"MI>!Q6KQ"D1G,WGZ&$
MVI3BZG1$.319F3!$-DT6KH]OO@ZVIL=2\@IO7@+J.(F^^;D8HBNNN'N;6A95
MT;JRK.JRWFX3^C4-8C"UNG)+5F@]UE]L@S>EXJ5Y 4"HV/_W'/IV!S84L<,
MCAN8O;5!@5,Z=5([<9*U,"!&I]DNR#_FMBFJM,)+YR4Q;Z(>GD"O52B5EN:G
M=$LU$?GH"ZPTN)Y,K!&ACH$]-I]LFN:*%>*NY\UT#]2;V0M*?'6]$SHAQ,'-]%:4U9(.C3]%].T@QPK[C^QIL8&:EP_>#5>31':.0"J;15-
MM9 \-5UL[R1T>V^Z3^+=HVF60KBM@R?M:?J^Z2XIWU>3Y?N<>/_1^&?C2T,,^\FQ*4:BC3(&'VM)9^S ?,(SY]&TZ3W_
MTW@BB.63WW\SW!\FN7!LL>E/\+3,ZOQUJV
M.M&F54^TR9YHH]83;=;84'L8G?.;V4>1[OH=I,/DP^B_R%)9Q6?K35/\YHQ3
MO,Q-U-6988,7>V'Y__L DPK'<574*%;;9(:I]ZUM*FB,*55/!"N%1YZ+M\:^
M&3^M)VJ"@046:R!.="NO2M7<1%-@L3/L@,$56<#_9"Y95)<6=1>>%!GWAQ#YN&?,>GKT9(W/Q)/F0$MY)\
M"Y@!04@W,TA4<=*MJ BO3*X\B[C;NRT:*D)L2\ML;R[(Z>!DOI-G,S'>/E!>
MV NE5Z>;((/2.Z52^AW=9(I2'$?SV(B:(=(!S!S/0?MNG.@5%U1"5]":T2NMV['9.LE16IM4_>UT4,^!"NS]MV&$+:NRKLAARZJ"+:N*/"['.L&F55@>>CW;
MI")%1.!E"M$@7$.H"6EQ=0/KQQXC,P>",Z_D 6]45G8J1')I4Z2:8[5P9X_W
M^/1_L@U=ZY);LZ&NYY2)<6TMKE;4R6%5!R3%*I2>[ZB:3IO)E*[2Z6(S6;=;
M0FLBG84Y'A-),W_BI'%IC4P[.FM'*M&^=TTIH2P4*'G(^UN-[M(?^T6-_H>S;M)J'SPIO_^6 )WQG]6#)'DN(]*]D1VYA(/O\#0$68QMJ%8H]99!@8570N7*0)1/?YGU2/NBOXK*R/WGRR+FI:YTD^8E\6C4XILT4ZV!
MI1-XD1!7!*SR#DE%N&\ZNT<\$1/3>\@G:D=I-9M9MFIO_D"(1U0*M%8+IL(*
MY;.Z;?(_*B>UIM(I35,OV)Y<-MZ9,Y_-'<@I'[F1^?V_>(5"[NEGQ:KJ\.CZ
M&Q67UE2PE7::U)NQ#W:*]FJ6T>1]D*5
MU>T2JRAG$
MN9A $H-"@=1(NY0_U%XLP?*!?)TW*F4K-#HK@YX+-TEW3,\QP=M84_(6YUL5
M1LA[(=/]9X-6D>D.XJBYS8,DW:I)(R&K=D6,[RR)DFR4E"^-H0>7[B..^M8%
M\OZ34 &EJTJG*5-*[RI-M;1]/!#Z3UF$M<*@19H@F#!\QXT447$>X,V=HLIW
MF.9/GVX\QRY\Z.$-\ 7BJTZZ2E%UC<\^E!4YJ!;908 JOWT0HKNUEF&PRLXM
MHH%'C TUVW@@X^J$U?*NS\*[] K8'KU>AVF[[C#-[C#5Z@[3NL-T]QVF6ED=
MIM&C3\V)'ZXH*ZKG-$NQ%3^C=5^*+>8]2.LXO+$I="6JK J:7EHA^>LL,BZ7
M= LO@[PS1PXAI#5]W^W)-^GZ4N*54GW?-6BZ70&:KJ:WJQ62$R^;ZKO=KLRF
ML.MJ>6[PX 8)[=O.^K,E01/QD18O?".$.
MUG:$MXW:! N:@RC2A#"=N;0^W%U#+$F_L_
MF?2-4"S*66H[Y"77XH+E!9)K105O(=GU_1!T\1.]Y[/9]!5"YE\=9YQ20[M<5MMCU%U*V\UZ%;!\[>]6 C(NI!D^W[(NK1E9[F*F+]6 8@O)
MNY=#L:R862=_EYM*6,S@0ZTBE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M$BQ-[3ES<-)01+IBL#N%71)*XU?>_[*4M2S61,X:C*,JXA!;_L0DQBK[_:(URMYPJ80QLR0"4/+-.#L<<58K90+LGPBD\
MN#4@GM28",![UX R+_'&F5JCG N2@8#4/1-0%663VE#^[XYHC&X\;*G47U&3
M&P\+%# _& K *Q@)^[*R)IA_A^&ZT(U"U]5-YN[WMR@D];OH-*%_$235?@9
M$H#A#@W;]$ZN?T[-5[$WPJ6(*E':AR-&U(:Z+QRK>\!QN'%H;SBN(J=KA-/W
M0P9:>:S.L:D0ITY#X6RUTI9E,)%"4;NJALDO
M7>O0@@-5*6,@A8>,>SM\B[,H8O!TK=8$*-J>[(MU!(%SIEC>XCSB?#MZD:\O+Q)QYA0D+#HMA&(.X1>
MMYV$'K"!:7N4[,^FQ@L0&[.^X;7%R'L72:>%1I:4QN#J+I4<]Q4Y&MA3RS;%
M__ER>RD2U\8W0!*=.Z,Y")7&=@&[@D%W=_9[94%W;_QT;.?I-9)KNQL]FD_&
M=K#<(Z&>]2X/"=IGQG0TGU+I<&G9/X900U5-.C[O7QP29,_-B65;!0)VCT1]
MV?MR2*"_-(;FM.KD?'/;/R28WK@FV$Y%2HJ]$72S4H _M8^NM\>U\:IY$>XP#@YCVE*HZ])1&/H]"*](ICIW0:6WB](F+?M>Y\16'!/,>M3IM[R ^!\-PD)#
M2*LZ3Q:R#N$,8S0B,$13'9WY@6^RE2(M63D>?CA6/T1W&3*[B'YT=_)?;-?(
M?:1H!2K%()&+!YC,7=OR'D4/FBM^8Q(6OC8A1D"7H:,C?'R(;?K5YBN(8:D-I=6-90MN0_Z0G1<\O>(HS^;&G9-+_NBEZ6!LY(IY0)CE5#? 2)N [OL:&V#*'B+R/5K
M/ZM Z.\5_%0'1%#P#C&PN@@L]?"0 B)6+$BUB34F\@W2.I#E)Q(-2TVH#,3P
M_Y"(O1\FTYE86F5Y/[P/*7I_XCI/U#9@>K;!*NW$-&"5(1[31A 1FAL&V!JF
M6) E/72]04^=>M!3]J"G9CWHJ=*D/CR]&WR]ZMU_O^V7^EPBETSX/;MEO$X<$?M4)FUN$>4]@S2VSP:GCB&BJJ1,?=,6IMJS/U'QR4*@+86SFWH+"3(@'\[(OR-
M"F"7UVP)X-8,S4=C.FDL 52,>1=9]Z"GBM&W*$7]GH.2_$2+M^/2W([709:-W?_:OSOKBE\'UM_[YX*QW*5[>GZ]KB2;ADS#:6_+RJ67L,CW7
M55KBL@V.ES[ULS"8?GG]M,RM8:G#@<:]Y4]+!T=&T=;.HA%5LD'6,[>[M;F=;6[KM;F=D^IRY&'N9E/+/[DS
M'\#ZX]"6934\8MG,.+@Z[_^/>'\M7@RN>E=G V(EW-WW[OO?^E?W=SOV$\H4
M#/@ *#P#?L/H15BR&E0A4OL[0,N'Z:!
MEY&_:&6]3:5-[M6J%A+Z*PKQX@-N(PHYQ7)4LJ]8)7O)8]*>G295@T'"A?8^
M#D]1*%%"2>CF*" 7T_1_.SOK]R\N)80O_FWXR_Y*:">1)S9J*'+/;F
M8\MWW$@!,'J?QS=GO>LOXN#\D_BK]?.3[=A7\R=R_Q%F4PCT;^&&(T*\,!KG
MMZ.Q:7UBM[JPW*?!^$BTQK\=63^?3U19T5I'ITH7AB_'[G7Z(=D#&055EA68
M16MY(,O).TW$79PTXZA=>IHR<03@B@G#B ATHM7\-PZ;[V]XHN''A9Q.AX+&
MY%ZUP*UOQ4E,@)Y H0G$>10(]"2B/R?!QSM%7WLI^JY,'^93$NWU\?C2\;P/
M?*/YS#4?H8[HV4Q\SQ7:Q/) W;UFZ35=2M-SL8^T:I% :PG'96 R ^\[17!G
M*8+/'@W[@=S=LNGTZ4<<(B:RX>G'4/(XLORWC-;V8>M(K;LMS:*PP%3O22?5;JH6QIO$9J?KH8.^J!6^R%O%5C<%6[NMAMGUHAZ%N+PP?I=@
M_!,\@C5BKL,46 ]/8C&U/_MZ$CTW!'QP)[(V_XE
MRYW&OV8/1Q^+C'9L<+R2L[Z+0:N,:-$;"IVE/S2'_MK-0>BK[Q;O%\PJ6V:.
M)<* NP3&KI[6_TD\2L^C5=W?;2NP9#WQ'$*$[LZ(X/C[W;GX]P\[B;3F4OE*
MK=VSM;M::_<=FJMQ]+*VJ6'M4&MHX:(5\$X#V2_0R*YE/P06?OGJ*'B=W6E ^DBH]X)&%IQN ?5:HZA"G 0*
MT0L4HL"GJ;#AKF&-+)&B,\.E%;61MH*T5AG@31MQ%)O2$X >Y*\]-MRQUQ#)
M$3TSXUQ">"[>MB::GD^,.9#>T%0XA@JT\#1!_/Y?\S&F*QMB2!GD.@OO 87
MHC&;N<[,MM;XRU;E!.YQDC6GP,F];"*C<)KH7B8\^8F ]S\M+X&5&Y\'S3)7<%Z'G!ZMLC*W HECEZP,A(B)$2 L++8V>6GA%X? !/YQ;A%0^([K":[Y;)DO'JL\].93
M&G&"?QITHIN!]^+["592-8&U!=:0(WKS(3P>B##7+P46":&G!%&"A/-L3-\H
MEI*C< R:SB)W86-0)$K@LYD#S#(6B#A Q"!&1@%V"=Q@"^%\Y".W1?%EN;RZ
MM2E!3MKJ6,M\PF*RS9]=_!<]/>5@I+MJ+5?DNV7U#O#JQ9UQ)4'*4%'8D_\)M*]>I<^C(==1,\.+"6CHRY1:QHQTM=4E/\.-/@5 9GO+1PQ,Q6FY$1P*8X$W=
MS(=3:R3VB \UM\$N%:!R*%EH):#J*UCSK2J]+MS0QW[^8=LIEM>0T9_-NRY^:X1V3(7ZR.['IFV82R[LF%7Z;.Z,?)2/X++OQ+
M.2*^\,B8 16ZM%92CY( ,?R@)UD2F2G&3 ^F[>5UJ'OYATO@/>F^L82\:3A)B[K,7*P\)G>D9
M+\_+YDSQ&&[-?)*(!TI!C5G
MHUC-6>Q[21R%54Q>1,HP]U@T6373F%4S20+>$4IC)D%IC&F0D[/X!4W&6)3^
M_4?7-$_@(W%&$.6,,[(T/,[!7]'&&HUC\$1-' U93-N7=I%:7A"!)XK8QP<
MTHV U:*4? C,EHMWU)WRSH#0^]P5'7H::2':)&3$J7!RFC@Q+'?Z*F%T=3H5
M(>#IPJ7DZQE!N;=XOPR&BRWJ2F$D(<9(R8B;10.OX4,@8FFP,"M"^F4SR8\$&<,V(Q&ER]N[W[UYC,@CC8.VB%_C]A/87 97MCRO#F-6<-CXY'I
MM-\(:&)4CQ.J9(R1LWPQ/(NBF+%;!8ZU3QMIC<:XO7<3?[*PFH]DV:Y(=;J)(VLV.V$U<'R(+$" @QUO]<0B2V <5]Q1AT6
M(V2>"7%8V%@!=&F"X>?,M^'R)\)OU\_8]?_H4WX3CV.)^0_B,=-=V'\16@(P
M/\ -IA&@KAN"R@X]*WPVDY*)Z>YIJ2KX^GOCKB%,3*+6 0SAFO"I\>(%0M&8
MS%TS&!9.+S;SIR2RC+-'R9/
M% #1!107QY808,L+I#N#. 6C>/_H>-%O&8W0_-R+B5/.:-K-=$&?1)(6A$R<
M(2874S-\QM"9DUL\FK!33M6<,EI\*\:$BX'IA\4;(7P"Z7($I)WHT\B[R@:3\0,8$\P5Y1"C,O3)MCA,-W\#E&=J&V"/&B$$C%R%2)'A0E .%$';D6728!Z 9X,LIE,SGR>)0P)C
M>$E>2SZ;NS/ *+D+DVUPST7Q9DXFU :VR25"A@A=Y[V1YLA?P?P"L#+!:D/N
M$*P9^OB:;Z^CK#J:SL%\8X0'KN',=4;F>.[28G+(@7LLH0O#MS+Y@G/U2A9;
MP4#4+PS/(T;/ R*!:M$QU1% :'BNAG@'2(Y<'+R;^=,@-T):!2%.(.+YH"HM
M^9[1ZKO&9"-J>=$3O-L3,$J
MY4\*5>N,[D?"J:!\Z Z,U<&%.;8OA 443\;8C%=S0+$"(7KB<9#_)AX!+ .^
MR"PZW#DOMM!^&)I3RWRF(EF(2'I>7V%$Y>\PL# C;E3-=1E)!K7:28:='N+L
MD>@M&EMWG8F)1E?H[1D05ARZ'\GA+JV1:7L+,7BCV+K@@X5C6MEP[=4!9O F^GY/H3T>T:UD'HV3/=9SK+/LV79<5)1+^!\H4:]JIJB!R9U,[N
M$JG1=M1(]UL'?IX_LQHM#TK>)2P72M5BLZS?Q=XP;8S?NDP(Y1.QQ%='P0A6
ML-1KN)A=(M@3MSBB(O;&YM0 D^;.)TZ@+_8-C]A6=W/+-T6E*\L$KU0$B-=7
MDOA-/Q/5?W9IS#'1%;D*.VD-D5B/$"_W4AJ==KNAZDI#[:IJM!M%O">7**V&
MWFTUE+:BQ+Z["+]K=[K-S&[(:O':SELGM;I>*;M>J1Y]NTZ]4KPM]MQDL=8PEIVW5^RR6+.7=]#,(98UQ^R'_.M[+>C2BNA4>._Y,-4 O$!3TH?!AL9@UO887E_((Q>2)XV]6@I=XP791_"VR(/
M44\\9!O\-W,X:T P(5($(+8;+YNU7B(%+,L:?A?O=( WWGP<=0J*>G=W?1AA
M>9B@. P8G\U=%S(+M _O4$&R=UAOMGJM2Q^AF?$PY9=T09NN&(*!F>D_:F4>99DM5N#I<]PX>?:@(0'#&AM1R*Q\BWB-'IH%]*]D1 E\3_9\Z>3L8-N %S HRK6Q/5.)O/I]!/@K6>/X3_]
M$&F$ @G5F'B[N6W1!\V]Q!#,#H&II&BZI+1://+"CWCZ1H&M[PO8W:/3MJ9)
M2J=3'*CS"XQ%<;!XYUO3\UUKQ(L'EPJ[W )NV94+#+T*_^OM>EU]D/*YDRJ\
M$+);4!",A".\VFTU5Q)0%>&X'>,5"4?EZ%3M2BU%V1*.Y:KKE#(/K+%PS9%)
MWG6[$I0C:@L0"^^MVM%I4Y':S?;.^' UEV6&(FY@YHH%M4>PKC5?<&BIV5,&8V8$)/*2SOHOL5X7
MY[)GKW>G72ENAO4^17I.NFX2_:(3PNZN-JIKA!5L(6R$,)T85JHJ*6I)"-NM
MH9 IPNX='^IN4V,PM1RK+%L4(<=ZB.Q\W-""J(#>DB6UO=K3J#%5L !;!U-M
M8GF"U)):;77?DBM'_#?M85>.?9(ND=Z)4W/PARE'N9V"5S^#HH;RZ:%=$>B7
MIP5N<+ZA_WHS-8B$L<MP'XV/9]/$N7C(2Z-H0>#(?9M*"I:;7J4)1Y"S'L#FQ@@S@AFL>8S0G29"-"F
M+LFR7!N+28Q%:B=//'-T8OT\>;3&8Y-<0O][,B&@.B$@/&&58M5W-W.8=8LB
M1F4>Z/5][U*,5UIDO:I:"<]3W8Y$5[]$*F$U"5F-G?EP:FY)H5DWX@0Z+%&J
MK.')Z H1(I*FM"2MG29&ABL9XWWC:2L39QT\J>AQ:JJDZ-WR\%2HUWET>CGH
M?1E<#NX'_>7E7;5S6;G#[#K%"DN?631B:ADXUL4RO2AAUY1S&(M((Y7.I,$YM^,1BY,M(I12ME4TJD(3HJV&V;#IR $RH!]0V%-O.X>A?1E".A\
MZDH[.M6Z1 *D&A75!^,&:KT4,#:)=:;KDBJOCC)72YR?.38^ #@6)C4&K/I:
M/J-VJT)A.9U0)=,)?4NL$1($M/AP3GC-QP"DMG7@JW2I%](Y.STW7>C9P
M;<.+X;I&TGPIF]85^1!HIHA$ZA\4O&L23NOH5)7E]QE!WPIP;2)'945JR=O6
MUNU:\YS325A79[TS\0YF1#KN#MA0J0HUY=0YZD'IG'8!;'!N#OV![?GNG(;;
M<29N/EZ +)S4;!,ZU+<5(SO))S$6X(FDKX2G9N+ 'NT]D[3 )75>(IT]M6+S
M$H<,L65RH;M?N= %N0"QL92\\KK1N^:,E'
MIWJW*6FI38ZK4Q;O'5E;6?]K(TLATDR5%"(Q6MW-4DS5*&R\^[UWV__]^O*\
M?WLG]O_[^^#^SX_'Y_V+P=G@_D.=3#BLPY14XXC+LL0S8V;YQG0'[N'"))M>EG;53*AW<0@FD_@$!^TI4AM794T67]_X9D-( 9]>RU)4?7*Q4%9D GWSL.T
MTAU$^25E82Q0%6ED*ZYB8&5 S4M:4X7DYW3-6COS-(X+H\);DW8K6&.^X8+JP=BYBP,]2MK&[ $&O;C(5";BL5LR7D6@1R;:FI=Z1N=PO(;:-I,GPZ)A#K)LIJ^+'ECH?@
MR,ZG_MHPJT61E.[JQ%6-IT*G4:R'IP[!$S'_97VU(?LF0Z>YPA2U7*MR?&XK
MT=;'K;GY>*4+C>%M597D5 NFCJ023)5H1BVB:K7QU(8="++4;:N2WMRLLR(3
M:>1M/X0W*#&@RK8,K.@JBB2!Q-[5N7C5OV<";=4;UIU&^^]@*4"(]>RU*UO;
M==_1_OJ.-L?:;KN05JQ7"98"A+_.7#6P:)P5NIP%$79E^',7EW5&-H0?0_6S
MH'PH; ?$XIOD/=_=?.CAYA%?-)]Q:04[7'?OIUN)O])/T)O!!D:Z\GEH/AK3
M"2"2+F8F?SFW7'/D.^ZRI7BET]@"E(1\>RZV6V:1MAYCV9Z+'#H\:X43O"*N
MO#YW&^1CU>V_3HFI]N-7KTK0?V1#%I8V6I
M"<3<"F.5GX0OI8(IREFG$L\>+7,B]G^:HSF6EU]/)M;(=+'_B5-CZKNSNZO+
M9S^7=.SPO&>/AD5TDKUXX SY7LIV&&X)_FH%P+#VM%LPMPW1A-@$8+&I^@#WLL'LZW.8!Z?4V
ML,VW@;4+W096U.ZO*].'"FOGR?QX?.EXW@<4>["JTS4?3=LC$E&(??^F5X-=
ML/WUKZ;A>J)IP[+N^*(PNAL,@00;2^LE88D03DI@9L=[PV),03=PPM^Y7$7&
M8;O%@(09-<>]O_S[IE8\+7%F?@2.T/#A 3#*7%:5!S1TCUDF9/(OL"H*,C5:
M3NE*M1H?%<)'L\9'I?"AL1U\Y/^.SPSWV3QQYOX',?(I; )! P@DG*A]J X"
M-UCO5R#Q[(06-D#K7MZA;'A4\J#U2[^;ERYT-^-*NM9$.IKOY23'0@X[WNC"F$N>TQQ&I^F#XQ$#/,Q\@"R\)QG7S$1M;R)G[%BBVK
MY3TQ?9]EN<\KT=)?@LD2B3MU85 8UI'DW0MK99G;4JIB?7M$ZNR1VIM'IUV9*DE:S6QUL2:BUB5_1$KCCZ4
MU;1RNVK1:NF#'38[*72E8.H1S,ZQ^6Q.';;=J&278C<.]!X?4QK+[U# [4NJ
M'::1R'F)"+/SD)/6$F>MHU.MJ4I**ZT];Q-0U51X@%2XG?57 !G">%.]*>G=
MW#9@97!4DV%%[+H"R! GB[;DCM3IILWJJ A[KV-=M-W^6K:)A31XKZ(\9-E
M6Y[OXJ3NVO*K+;]W*.RV4KF,FV"518R7UI)V."]5E;M2IYG6]%\!:5=38O6M
MOR)(L0.32?6VU$WMIZ\)\;T0XE;V7R&$J, 8E);4U [>_BMV2,IF+W#C.A/3
M\PCTC"F>!JP_@G)O/H7 JS@Q%ZIH^#-V5>'Y)HW#_*,K=B(]=HS+W71<; *;
MK4]647,TRN<7A*?7$KDXQ*"E:F"*YA6Z>D9J=
MW"9O3?0UT>_;R-Z*Z'$4LJJKDJ[D+DRJ!-$O6MTISZ_*/,.5]>O0\"S2=G71
M@4F1HN6;3UF&^/[9? 4P2K2C*_7DVJA_U[)^U63JK6T9RP?!\ 7EPKWQ<[WY
MBAW]Z%236L2@:>M5,&APVG5-RH=)RMO;Y=O1,FRI)72L2'HEC/.:E@^9EKMM[>C99B_3@S-IM1I52&ZDJ3E?5>I'IU>9UK =;!Y_Y4(.\%!:3*H,(^^1D"-
M@!H!^T# P1;<,;V&0^XJ7\MPJ#$MKW@8R4&4OG3":+[<2.?HM-/N2EJSKH"KX"MN)V):!R=B"G7+-SW7N3ES"7_A
MW-_*T^*A6C#M2M!;%3%:)>F2^\$EYHBB[+A6VK][=$I\H$ITF.8.I-=45QS5
M;6=);4IV7?GH5$U=]583796);IDAU7[#AE3%PD<#,"I,ST^/(-6ID7W')6LQ
M4OFJ^%M8ZS8W+USGB7-3/LVEP#0$J=VINS(K^(J'$7_:F/94J'U1M#H*5<%7
M/(P2\8U)#WLB]/SE@U6UY/9CIYG4-ZH\NQQJH*Q.]57@%0\C4L9YM?9*:NGV[#EB\ XK;SM[;B.3THU-=E;I-I::Y Z.Y94&R3ATDVQ5:+QR7?&(3
MVVOT:-@/IG@\A66B'Q\,*YFQK"-F=<2LVC*E"I;35\(X'K0[F-ZUW6=<=6Y-
M)D2YV2/X\-XU;&^*V:!;<^0\V)9GC@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M"2JN(D:K)+2*498;ZDK@U'\"H_;&_YI[/JC*:_LL9-(KPI]K%:R0_X
MEEIJ%:9 U!1Y:.&I=6DRFQ2UHU-=4@@I:MVZXN_0J'"I,7=X@_PJ&K#*-M5>
M#-M7FDQ\0Z/3EO=IJ1#M^O>E6--C(=FIZU%CME4",N$Y):DZE4(NM4F6F$FVEL>
MA'HP\;:9ZSQ9GN>XKT&X+??NO]J&6]>&4RI!QE5$:96D5O4";CM1EF7]%85:G)JM&Y\K47G*/5CSK ZQ[?\5JSR:(J8.H?/YVF:A#-XZG4\3=@BM=71);E5ANF&M
M"0O3A(20W"&$\1QK; :K+L9Y-Z*N2OXHWW"K,L
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MM! >E2:S"@H4U FH$U C8!P*J6E:5W,L3*8''8Q"SQ0^GW->:K6)D5=
M*K35T5X\BYJ+ [06KTS_>G)O_%RU6F)-"U^#]8@=O5N73[U56BTQ,E(DK6:3
M:!.M7^O$X6:)0Z5:B<.Z$F)GE1!%3+*N1"5$36![([#]6;%0N9AE%N3/7K>.3I6N
M(G4[N7?QU13_OBE^J4@M8CYW)0BLLL5E]]?WO4OQ[/K;S6W_]_[5W>"?_;K8
MK"XVJTL;#K+8+$5WY]/;;:PZDXGFUI0*%#;4A'V0A%UFU=D*TLX1A>HJR
MU&W!B.@J$'E=?G:XI+Q5]'5[4NYB'5JW):F5$-?D@B$0\_!T0Z-W9\'5O&;Q
M@%6D7>(TNYE)WN#1<$WQ!$\Q-#QK)!KV6!Q;T[EO9C7^UD9R;237 KAL(UE=
M4_R>4Y[M&ZY-$.H!B]^8[AWP=Y:Q3+Y'_O=B8EB5RSSF%Q R!1P2JNX;:MH\
MF+WKC9HU#Y(UUS'S2V+.5!LI@P'4M:+EI;#I.L?5CDZ;4JO=;*1NNMT[S]9>
MR^%RIE(QSFRNXLRM#EPX9\*X^&ZS(:?M+*@<7VZ3<>#'A =_$N6&HNJ6SMV6-B\W\23X*/"^/[H],_\"[F6#3(88T'4R1('A+GRYF(SMSW?.)RD=M27\S#
M4Y]4U1G+X;[LUWFJ7;=:"^W;=5LWER?%6F4?<
M[FB0A^EJDMQ,:R_=NXZI^?'M\>-V69EB&+)3ZAFW.UL7IC=+W=1^[YHA:X8L
MGB&WRBT5PI#:JL#F=F?<[FS*T6E'TE)7CAP0/W+W[*-O$,HZ_75L/9\*@O#K
M1_C+K[/H(SZ)BDQH\-YZ,CWQRGP1;YTGPY;H!Y)X9[K6Y+/X9+@/%CDG7"JG
M'9T?8L8?5LJS J_".KU_-$5C!'T(AOT*;ANN@!(AC6; )%W??'"-*1$^KB\0
M!\\GEY\Y-E82&N #7EBV88\LP?%IV:^0 2[^L/\X.2%',Z?C
M3^(-H=[/Y([_GD.+#'DP+(?%T9_D[^+)"?LIBC_Z8_('/RL]P8GOS,C%*E @
M^X3390L^6U5S>;3P]I3H<@%A$7'!(?!8M,;1&G\4KPO<42%<.0*,5_=%'_BN$$X Y@% 6Q(:N:?PX&9I$V)#[SA#XT>.V
M4HX+D(W"*(+W&([3'QX]+[Q'B-,R2>_787"R80JUXQ\&RD3C+UD#X^FC<5KN
M>6)R#Z\@TMUQL1GLT]PF)#JU;//H-,; (=M" .<,.\H\F)N-$O^1B%C3]?[S
M;QU5:7\6^O^>6_[KQ^-S.BO'LU#=<330*_L?C-
M<$>/HJ9((M%R.O[9Q+ 6*+T]R[Q2J&KAE5 5$D$TG3(532.T,=MLY$RGQLPC
M_,__]EE\L<;^(YQ*_H4JX'PG9'M^/=-R]5#;$4M; (48!L,EF]^M'25#ONX"CGM8;QM$'FF1NC[>7.4SN+(F%F^
M,7T_K\U7!XNWIF>ZS^^(U-D+OR,2[XU&\Z?Y%*T49G"\GY>_=PA?4ZD6M\%$
M$VTP\7@M2YH!?3TSH;2!G&-J@!]M>*+AB[V9:Q'O'_T'%729CU+N&*PW45M@:?Z(7]+E
M4/*J=(F2+@'9C[J;_"CYI+A_4N KY+AQ\@5XE#<2F5C:Q-K$WE3T< [W99=&
M@[5MHL'4\<_5IJ:I4!NG:VU)UM/BOP<+W;RDI+]Y4M)W14K:T2D1T9*2NC/Z
M4&&[HOZO52QP5SMB T)>)NBP?5,F\5S\&6*7XE)-1,']@A!ZUK#.9V=NL3JRVWI;7=E&M'D/<\R
M@DNALI.*G&,YM7>VH7:"8=MF$ C:5UB(G32ZG2K =6\^KZ5J>^K?O+VP9Z\4[F3EU>)41(/MHOCP2JYXXLG
MO3)]$:9] ]2#A%ZMJJK-X-W*,7C.DT-9UH&>7*G:R9=[2NI>U@M!*<>R]4*K
M /=AKS#;STHFK5L(S/;G^&3.%TQ;E 2Z9E_J)?>@V_2?KRYD6_(^JW-?11TC
MU>=?4''O&!:Y1;Z:*?)KZ*V&GE9#;VVE7MS/&]0Q76M0LJBX_-7T]U->4E8_$WQ/E"E/20T9V;6;(S;#6S['1_1(G,HI3&
M+%4*,>1OSOI"L_Y2O&Y8R\[X[]M>S&P"3_]Y"B16M&>MSXQK]YRMP9X;M(WE
M%7?96>!M6IMJ-.0(MZJ[*G5H$O-9E[I:4U*::2,>R\9[J4@N#*,IZ*N%T0ZX
MH+DK+B!ND-+2):VU.LE=R[[ML;["P2JX.">'U4M3C7R$\C?>?%0D]@YJBQ+S>;J6K\"4+])"'C#7,6!9_SJP]2'>7>'J4Z4($_E
MO_;.1%)NW[EZ%575<#=;Z[B;54=R]8K/JN%-M?-[4]4LR]B] ])9QP&I6DG&
M'FSV;GZ;O8+%&$>G \^;HTX-&O]%WQ$7:M/+5Z^PW[T2++FM1N]\9_0#H&V.S^MFU>G5:\L.>_)#[;>LGFP]9;-RM5;YCYY=MG0H?AG^=7*U5GO+#:(H7RU4FN5
MJ%8!!$2'D>56*X2_%!C37%E#>CE\NYOM!\^ +DX\W!"X20-2)_ROM25-:TE-
MY> ;N)K997Q5/WEV35753YY='E%%7MQDMO6N>%$KD!M%*=4UC[=3K7OA>.>$P3?(!=8'8B-MM*1])SS!.H
MN@:H7I _[\FK%[G.>_+JQ2?VK74WY,-647QXB!ZQ_VBY8QP)_RH:XV?+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MI:;>D;K=9CVH99_8WWF/;(M(>$66NFU5TG/D0W&J9L#3X#6AZD/
M\^X.LZNP2)Y1+7L+?%2Q[F?_X8-N[O!!)>&W*X^[+:_E<5>]PJ-Z%8F5\.O:
M2GZ_KIJE,#MWA=KJ6JY0U#K("INQTVD''5[W9H-PFK5WC+
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MCXB5HHBX@LY@__+Z3!)MTX?/+7[-R/%VH9<4]1 (.(2 #&RGX=V> AW7]
MPXX*N5Q54KO5%;H5MS/OW$[=AR&9Q#%D==W$--ZFQF6?8: M96V
M3D J*?(FI1,5 /-N5'8"QOE$0PMZ355)KN[VI]Q:HWH)OKPG/]A8=+MZL>C]
M:^J-^+!=%!]6T(N>N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MY=L@7>D]6R%+DNIG 1+6MCQP2)M*VMO+)_[4*[!D0^^*X=%:+*\':#+GJV16UL?;!E IWIE 'E/OFG*:M\KVF8X
M7;Y>TK;_<^0FM8/-,7:JEV/,>_+J!;>7ZML2=K1EJTT%U:9"')GN8=9UE+"<
M+1M::G'0JK++M]9>-M@3NB^M\XZ7W-1;V3;0!-G)PAIZ*Z'7S4Y8OF/HK7">
M*[66+8<;K4&,K:.O=J%SHWQA+/\A8SLWKV2G"VI>*<.2VP.K-,MBE<-9S:97
MQ?"K5[-MLPVHN>?9ZIJL'YWJK8XDJZLS:?66H+*I84>3XC6Y=73:(KZTKDJ$
M FK$[QWQ!8_XSD8\IL[EEBZU:[Q7 .\[6AJ@R1TH2%QU8,U=
M;T#0Y"ZH>:G9;$MJCC;^>AEM_S&/?!8E"N*/R02V]]:3Z8E7YHMXZSP9MD0_D,0[T[4FG\4GPWVPR+/@4GG9
MXV?\::4\BWM%OUJG]X^F:(P@%F_8K[!("MNJ16);BX8M6N2Z!]>8X@X)P9E@
M@OC,L=$Y-WQS+++Z-W+)G4\^>#)QSJ9U6O8K9("+/^P_3D[(TM8K\S_SV'G@#R8*7U6<3Z$?)W\>2$_10YD_XX$IVA)SCQG1FY6 4J8I]PVFK!
M9ZNC*M*\*5%$A7#D"C'?W11_XKA!. .8!0%L2&KFG\.!F:1!20^\X0^-'CME*."Y"-
MPBB"]QB.TQ\>/2^\1XC3,DGOUV%PLF$*M>,?!LHPXR]9(RKKUX_&:;GG^=4C
M3!R+@A#9Z[@&",E/69XC^+%U'DA3 QW.TU_N\,5
M??19%Y%:%T\T"6C&B9!4)$0EP!(](@T3EVC[!0OJ)"(0IE.F[JCU%-/](VM-68>X4/^M\_BBS7V'^%L\B]4)>8[)[LCH0DH=H;S_OQ\E"N^F+D -=.F2C>9
MR"L 1?YVI"9?(7.YXKP*K*=846\=?EI-S 55T;=4UX\UVOE>5XT^OK>
M7GRA!/R]O+@F_CIT/YX*QV>&^VR>.'/_ __DUO1\5 O $:*VX/]L!J)RJU28
M1-/57Y97.'X\AB*3A5?B O&7I9Y:<%6Z $DG"/:C[B8_2CYIF:NWU2ODN''R
M!:I64:6L57]V. !>'GE12@#QZNB+ OLG%4G1NY+<7!V 6PJ38GFQ-#AO57VQ
M,9RUHU--4N66U)17-Z/G ?,V">%M'F8'U:UQM]"P7/$90D/B\8-AV1\^@L4@4H'P3E>Y%5YM UU= &@,P?4"27%M
M+UE?E$-<-D%<:GI;:JF;=""6WKE5M";?!(S9T(/*":+3VV]AV7IWTU;UK2NF
M<@H3WO(\M8RA-;7\U_*E266&B)M:(]X7O*N#!?"*/$AH6N*FL[1
M:5O6);VUR3Z-PQ8U.8&8#;LNR!I94MN'+VN:53-:DM9*O?&D6 ER&=6QZTSX
MUU284M'1);E5W9&L>M$TT6&S^ZGCF@*K!34.JV-G'#JS)^IGNP4QZZFTYY*%8-?V6,.C:'ONB9OC_%
M$IT=\.E"-4#5$5:YRMIG.NRU&WI]BD1G[BF6.<9&':'M;9[8!%6Q4A]/RXJ][4T_+RZA&?]L)QD4R0
M2FZ,5_PP']-"\E=I2YT*KW,O+V5># B;8$@IDMK9W0J6/*K]_M%RQUA/_RH:
MXV?+MD;0*S_G.+8:K-\(Y]]&K%8D_/3=G+B&\'6G\=E7051JSQB5^%+K]GV!:Y8R+
MM8Y.";H.= )QD6;'QA!L@[@[^&"Z(EM21Y-3$0&<1Y.AQB[Z8'OO&;UI=K!L3P;K= ]N)Q<46#-AB;DZ:16=1>#EUD
M7#:I:O+1::M%NM8+)I";#Y%:G84J95C"DSET5Y^5C%7D,(U;(_AF?'H#DJ'#H])JY?G*I])
M([3!?$:!!(D*"'3$=K;*&0'[4EY\H7"LBL1ET#MS!J ]3Y&%*[P\[0T/7
M$RU;?''<'V CHR9Y1O3NDVL/LSAM(G1_06N.3*M9YC"L;?%!97TE@L-8XZ(
MM^S!$&;V7P3]]+.AVH3:7>C
MJVS6>G>!GO)H5PN.3.L\7L3=_N3=@S@Z[E9+>@GD;3J
M^EAE3K78 J(Y. ^S8[HDMZO8JK-/T;8=6*$#2I%:VS1 [=8$S-QLU1N-R)U]
MCWS_BO/98&J<,1JYMC]+!94@&:_()9-%:LM355IM7[W.O3CFEU[O'=).N(=9TJ;G!C//W@>O"M5T9
MJ,[&,$XL:\$0K1QF_$:RN^1P7J8.Q!&RMF^Z8F^J+'OZ^SLW+#_4 G>"D8:C0_4[HA7C(G%IZ ;&L*3A5*#1I:VC,;MY6X&>$?DL9TK5PI]:)"#[!(?3LOA;=3T43)];.63ED(?$,&4]*XJR9W5\9,"
MZ*/.!M=YK&H>IMB"HA[A%. A3_0=T?SWW)KMII^Y*JT3)=I1-W-W]$B\D^O)
MC0OFMO]Z,S5LG_@F?0[GLV!E:<\;V,^FERTCLT6CCA71[2K.)2AU3O*.P-N"
M"8QMM8K@S5\4M6DS?D7"M]SA!\_5)6ATK1',PH>9QN6+JH6V[CIBNR.WM<1L@'RXGO [_ 7Y_)HRX_U.0WEYY8N2/03B'3-+?O 5
MO$Y^_Q%&POE$5C.-6X<8WV",H&A9O\(^RR',.S""A5@;.XD/U+2QR_CB]L31
MS6O%U[2Q+6WD5WO9#O*;N87
M?7%M#5U:(I7H7#C87YS8=U"^(*K,NH/\:&U6K6FY3"O_UIRQJ8'7DR^./?9@N8#7
ML\?GYI!\.L\["$Y786K>IHQ=F0B]LNE8B9W8$7PN^5M'1-1@:,?V,R$#2M)HT;&&;FA:PWGF "_GMP8;M[AS;H&IIK25J6NNCI[4"VM
MS!8OI_%Y__+Z; >J63T$ MNP*)U EY/8+8,MD!I -A]E-2$GU51D2>L>_M@<
M9=-I'!4X>ODY\RTRXAE,[+A(6<'$XEWL%6O6*;\]C$TF %YC7+(.OMLKZZM?X](S"O>%#KE/=6X-M;RGL3(VKKI#@1U<_6F)M9$Q[&JC/CAYGAVF5B
M?..89POJ0A5=E9K-UM9YW QN[3]'42OCY,<8?9=>B-#EJ$*G8H7<M>+98Q/JQIJQ(W79EMYB4F:[;!)JKR_):Q(EN$:#*W4T&TQWRX*:2X(E#U\'J
MWZ)=:2?QR[,L^2>)0_/!LFWPCIV)^&H:[H&ZQ@<=QUE&^?JVMNJ&0KBE'IVV
M-4U2.B5-9GD'N%-;^T(>9DPUF "R>0?_NT>?TMX7^IJ80- UJ:EM7$1_<"%<
M=:6R,LFG%5-3:CD1W":AVK$S'T[-];DG_&WQH9@U[IV'PYK[8C =\OZ*IDM*
M:_UPK;JSF-P[(8.]V3BMS6VF *^"//LQ0Q%SNJ2 (
M+$L[BQ()4>DR@?6]]61ZXI7Y(MXZ3X8MT0\D\M_VH%![#(\V?\F:4\DFM1\M#[1Q.F_SI/,\-^!4\3:M(]$79]&[9HD>L>7&.*
MR\ %HMU]2#)QJX*^,5LF%4Y",6COT?)R?D)M^)-X8SP0;KHC5@^4 )/[*^W/XC^-Z1S^+IZM*MDGG%9;\-EJO,_+J
M/=<86J//XA7A>@JD*P>@T8G^Z"/_%<()H!Q * MB0]M<5LIQP7(1F$406_(X9D/CYX7WB/$:?E$'#G2KP9*0.,ON8DD:9R6*7B&I[]Z
MA/ECUC:1Y(Z+JYD_$=?"=*>63?0;]B7 =*R<4@!N2XX^+%V>!6_"(9OV2*HZ
MKN9/Y':CA>@Z_-NRY^:X1Y3:7^>6-YHZWMPUKR=?3=LD(G!@4Y5'8-(;.G,_
M>.7PC?L_9U/#-GS'?3T9R7_!+?]2CD23J+D90-:=FXNZ<>M'A>I2:2E==5%"
M% 5M9([![18O_7%#/ :Z1RKKJ*K\^8PJ3?R7@D0G.&[D^YLOWR+??9!$B\#J_['W
M9LUM(\F_Z#L^!4)W^AX[ F)S7]PSBI!ENT?_TVWI6.KIN$\G0+(H80P"' "4
MFO/I;V96%5#82) N,CL![MI0LMK >>B0 IL,'PA5]-?VK^)QS0K;_[>OWPZ?K_@*3]^/M[^(2)&%M;H1_29NR%V:["UES!N+1=&@C[QQ^A'"I$2=KZ+!DN!:7_LJ![P76Y+V^\"W;
MG:S&*%9-?.;"7TV>V939<&^((" -_(;^2%* +QE6(.>E!>ZKZ4U]72P!?J2I
M#\ ),W =EO J+DM R@C#]DLG2P\H$&XGE3)<3:JKB
M,9^9WN09GNVYRZ=G?0+RBG8;>'!K>$,_,#J7<'LT)*EOSEBP(L9ELQE#7 #<
M/-]'4A%]T.()J8!)2EHEP=3"]MOA*O'W"_@MWDO]U8+UF_H$(<<>?,1\MHH%R)GS*MG'B_0O3)FAA"2'$&4MP#?#/C5S^(RT?N4M(6#[R?+!$D'6GMO=5I-F$-K@X<_:O[PN9CX*%VW]#;S7;7
M$&J7WX6)HGXU"Q@/A ?02O<)"4VL#=?0,Y$GA2"!RVP1BP]Z'TZ>/+^;*[U'
MA.GE$T:/"*,5(DQC- #2Z-M+BWY0WVFDW[T3YK0((P^+GV+9",0&(0AW_SU$UQ($H)(3ZZ00+-18YI3U_[
M7/]C.DO36^DC8K!.NN@3;(%(7-__>JN(:+0!E-^IWU0%N4[^%TT@ .UD@K:<
M@=!'U:"/)<4G"L5-27%#!\8#&])!$R&A.++.2@O/2GF]'EODQYOKV-)(AP$!
M)^[2"_3KR7^6ED^M<>&YWJ(162!?;ZYOP*XQ=7_!R/I?++V%ZV-$(?J.L&HT
MA6(/]]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MB&6 L 4!"FZ?WA-R#V.K%LV<%G?!MM(!H^/C+9J,-'TTP L7$]0FS;1%NYY"LW=:U-O(8QD/]A8D(;OSA7[]<@(*:
M!L__N&@UFS_!WM(),'YU,[ME/+-VU0CMR8*]BW?NO;8-OZ.ON+S1?48EOH=\6.0?LGX9V?3_]D
M3I_,AH<%^HN>_MMO-WCXGQBH";07;6MN!^MUW\G"U-_6(Z+B $:FRIL3IUL3CUA<_+G:Z0;SAQQ0AS!X_Z11BAJ67[T0)7X
MS_!%>PEFHBE-3%5DW'D6D,6TM4>@#PO.4N.T>>3V=GLV23@@L5"2D!GAT\_\
M<:+\<0T_\."7<+SWP>H])A S#CKZF'K01WO.-84V_C=;Z8KG[.OO)J!5>5K.
M7O'P?CK(J2E!3I5Z=0=%4@".^M[S)M&#K&.#%704$-C[$<0P4>]4%/B31#3W,QFCLU1]'V2-CKN6D_F7/!.TE:ZC%:
M4KS8E%\ E&($S\F=;G.=7F#,#$$M:K#)]'T6^$I$2N/'-UYEO1X7GSK*-W)>U-])_RP@$.+$@+QJD#ZE.XD@'W_G
MJ7THO@%(EPHS#OHWT3&BI>N1T,;#
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MI@$L/B.7!8Z7QC=S4 SM'6^19
MISR#F+D##ESR7M@EL!Y0,OS%M_1&17C@FERU,'JFYF]4!Y-[^/2J*NX,-R.O"<[4;^D>)=Q/0M="%KA=)%@?G
MU_>>D+ZX14KN6XC&/75MO[PIDH=;#[=?OCW 3@;=7T /@3YR2 H\H.(B4#>*-=]?1D[H+=K// @#"\GX
MCO;1A3_5V!>^(X:.0'A;O(* 0S)/1M$4/!S]E6%9W3)X!CWP7SD;%,D))-#^
M9PEZ6DCCGB3O%!3X!.0#75?%4G1H
M8PDPK\)N-Z$.S*Y2>E/@^DU4#:6 %DJ!B'Z7$?VH.2_RFXBR1(^-K"#%I$!&
M)O"4P']&ND6:.)EV%!A!9$AAV"9L*C'#]HT)=N>+)/L9=HT&+1<0NBQ?%4)G
M M3R(C%!6(M;2#T(HD4QS.Q*.27'..K_,Y+A7-.HD*P[?!F\)BBHUO/&D.OW7T
M*4/7Q'(D5P$#P3/@9R&_R(/6LK5C0/P20G=ER#4.X8WHF:@C(LE#W# E[#9\
M31P%]Y2BFC@E_Z]FDWD8?4V*",\X'K )7?S*;)L[9_SW-GN"
M)9(C;XGX,D:L$88M4V0/,<3Z.,@'7)[$/H;?"Q\21OX]-CMX+>2:SKE8WO<+'N%GA"R=\$<7YR6H@S,@$?Y*(I.A
MG9G7H9?(ZPN,XT[X&6*; [!!X>HX^:QP^JMLITR!5J/&:DTTP>G (],QD9XN 2?L03+SOIO&$'Q$<^.-RR<#L #'PW]G^XK
MUGH8( %G,X:UGUKV*D$N+^TIOT9M8; :WP0>6L'3(C_YA8D=:)E6#-;5*'Q+TN U6A==;7BMQ'U%& F9!XX(T^J8GE\PRM$3FU-ND
M[@03^ 6Y5K HLI$?4.K5A8_$TKVSI3-1I#P_5V!UR2O@L;F:.$7UI.S5@1*'
M>=&S(\@8CLX9P_R,8:MY3AG6FS(L%0>N+30;QF4C/Z[^P.S19%S %!, 2MZD
M07C9J5 F6WP8Q7$)'4PZL%$,J6A7ZO ;$M5IP0?0:@9MS+I2')KHT
M*!7E,K<9Z7^I:!+K#$,H88N),+LBWBLR,=F? 5;UE<^>M"*_$?ME?UFH7%^?
MP0RB[F*@T .*@<*O,'!$_4BT9Y%YI/2Q3Y&9%SAF84H&2\]1 E2B:FX>1F?$
M#^')C-%YXN.B,@Y,C!*QX8,8JI(/E-XTGOX"C$Y/ R/"BSUM;V>P/KU5/ WU
M "^P9G 9G."6]D W[=91H81Y.:A^73FH1\(?*'MM=?FW7W2!5$;T,V]V6&QQF5#JJ\UMA^DS1=L)A_CBS18:VD%X2EPZ%^C(F=-1
M7^GD6.EL)-DV\1Z^20N-5!;IZ:K6"P>+K=/^<=&^*$AD:91NIO%/! 'V_&=K
ML>L(HRU:IA[H@)0TY)R!F)]&B/JJFFKKZ4*!?O>G3-;/*@JX!TV$/<62-)0W
M^:=<(LE/M'[*WOLZY=$=9O1F14IYJ[O9KMH_J%A'>[\\9^6BM]KB];"M-;D$CL3@I1Q?@]6WN;[N61C\=BIEPV'=TY7ZG&Y?+-8,FV8.A LYF
MG*)7-7X1LR_?RL^JV,KJ4;^I/_U:MA1FTBUV8-;>D^H/?[AYTJKP'VZJL+?LB5$VS7K/2R]+%RZ*6:Q_+I>DUC^K2
M]([FTD0,L-VEZ1>_-+)W>^(CU"[\)*,H>TBR!^1@BHQ+;NJM/&1YTL&JQ[S@7BQH$0-1:]M@TTZ:.&J4>LY,##/)UH*GO*VB,>H\^)R";L/\
M(3]H XL,&;P2 U$24: 6$8#KM!3 E==G:_+,(?M8[&'-,-^.$2C3\G1L7M .7"MBP:<](=##8KH([[^"8.!GJ^_B_J/__'P2?^;VH$M\I+0L5[<\H-:Q@=UGGA,AVFQ7BELMBD6?-(L2NTL>07?5 _5X'(>E0;)/GZ(
M%T"B:X$UYY2ATXFP)3SC$9(P'A/_7W0@5#I&":KL#R\\,".]EX<+"[F
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MG*D(":X.Q0"ZO$1S"2"">$8[-W%:Y6;CTO)-;4V1^WIR8_M-?E6WK=P9ZMJRR9TE*U;)Q;-BC3F [%I'-U9+B>8^[JO]0RV0_"O6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MA^)SWXHQ9]XMW/K$AM4P;;=:&[,,T]9#FEV9N5=I^&A'F7UDLEGP?6KM?U0-\_M(Z4J1@QM %N4QW>&8+(JH*+[P@'U*@:'=.N;1)-$$%A7;QVYTZ_X<.H"!JL]
M#L/2'Y^Z$*705Y9#C;%FX2@A!:^EP]&R)Y=/]+/>B^9&O!>G^!B?^R?GTV%)
MPL;JHK"/.IDXLJSH%\TJ\0:7DFQ89>BQ9^;X&-G"1BISIKSM[N8V?!NO>MI88-=V,Q/EZH$H>W9:+9>(?&$)MT];XZ!P!N8M:@3:4HAXE*)U1\95)UM0>]:5CXU+A+2MZR)3YP%6$135]K=#9
MT)GJ[RS/8R\NM3K7F6S3:E)#7IVJ56 S OV*OWH/6Z&VI%F P-B*\>PU.GM#
M?S(MT4$7V4ILG%DRWXHV!W5K=5@@.I]Y:QD%/_/^L #8/0BQ0<5"K+\'(0:G
M&8FQU)5Q'7NE$18:)=SZ&X[I?YC@<#G]8,8_4-GK(
M2J5BWKX5,JKX<(:U76 L9.06Q$HV1<^XOK*]O?8,'@JU6Z3AJHE['+9A=,?_
M%ETM014]N_8T6X_"+\7 9U65IAIISQGC6@G\4(;I7B*31FV@8MAO[NXN'^_O;BO0ZT1U_"=50!(D5+I'VI(D\E!,J5=3H82UNU>/O.\.6\\=B;
M5U&M9L4L/JI/_GS99.[^""*IU:JZ<*NN&KL
M4\_\J#HO50)-IM?.6\43R5VLMQ$U,V#F(+ R$6K2T4?&CWH#2$'?N!-:%V$'8H F&U4@CJN4(P
M[ ^!HC"U-,7?1$PZ#<)>ERZ#\>8
M(:@SI7/H.\1]3=) PFA42OM(%;FEN_C*C&5[4>\H4=X#MY=>HYC\K!YB+V*[88^CHU!& [22/&LX%,Q7!>^
MM?5*]FL?9TSAW9.\J[Q0M<:)T>EBU?P0BI;E&?\0&JSJ LQ67168G],:*#8@
M"B7N)7B]ER *^M,Z<\:D5?TE0I:?E17$@L<&Y.&M$>SS+.-?O)UR^(B&?JW,?-*4]F-R0$MB#%YL8!ZGA0C"J4]]\U>CZH+55F=O
M9?E%@\4:9]Z?!?-R1K#X"/-4_%$\CJKQA#E @Y[0Q(E7]<-/\F_*SVL#CL?4
MF.4(4M*MZ7'1[;[GH5M7)Z%:=V6B0L AMRVQV
M0K(Z(H$H2A9BO746RS$L/_Q5F$9=
MT)DSY1>4U\R*]O XP;.MUV2^*1K!,Z BT)@?E7CS%FK5.M?)P<1N:B_#R&SFRF/Z_&GI4C\JPX>QTJ2',(=J@Z?=FJ,7_YN]KP^ >(LU2=
MO6S5E;Z\MNWLQLK"R8N'(!0%H AIBF:DXOV&OK"7I+UD9)[B"F8RB8F"/4OK
M8 @D"N:FPQBH*"D,' UXSYAU;2KS&&AM/UZHZF+Z3\SLCJ%W,J+WI ,SI*F 0+D.#GGPN#+D\2T>'0I6O'6>-"XPO ,_
MX)D''@=3L@?>%IF1(Y*MU=ZRNC*HJ3,-8YG9F2,M-W.DI(P2^+E8VH@;AO .
MBGJN@P9L.G@MA@L0>+^(+=QEX >F:+ ,CWIB#O-2\:1$]E]8N,R9RGL8F8"Q
M!J^,9G(W=)!2&@\Q92 [97(I3%J&XQI3* 3.]I'H\A-+6;L,@\Y)([BI#(B9
MWZDW)8^X%4/@R>C;CNC!2.AD@@M#)+ 2<&K?!)'L4]@8?!8S_*_1_W3U??F$^MH&W5N83<\NI^D>T?NN\,KB[#7
MV;4SQ?]]CAJ=5=3L=ZMWJF5,_5YMT8MQ?GNW???^+:E2=CW1>@B;3U6)F:!?
MP,[@6DY1GAMBCO!B ;O!2VM@1, ++G%3AOYL/3V#]+ M>!0:'-2)UU<&;0CX
M CZ6KCR()3)27,^"I8)LGIO!TN.2">M7GL+=Q\D=M0"+IL_:NGTO<5+8[>_7^.,]E0OO%.Z\CL?9#WD3-"2ZTZ+J@-X
M ]L K3#=?(+[1GVPZ7Z:\.!_NY3_]M"@F^ICT_F.&I@/3.2WV&-/)@)Z<-RW
MU-W@OX!K8TY$0) BMW'C%6?3_A/U]8W@>TWL@>GQJ>'7WO? KX[>]KJ@"W79:@6S1KJSOY"[^+N=9
M#UW%*Q..OXC.>(+BU@QT/>.$UYX% $Y$,HPH6H+1$$?^B\,QT4UT.4J2F^3\
M\. JS\WOZ DIWA5 $5JG6$-%K@M_R:?%C\_
MGXO '"RFH:N,1*Z.N2*@3XB?(7\+0Q[X:_ 58[$B1#TF"*69X1)2S!D.&_"X
MMXV_F0$AR!7SW:6'4_W0O1O#L1 +^?#$X)7!M[SX0D]1F/W+M8'W36]U0Q[<
MK9.\#3M*K(W/C8FE08VC9&[R1Q =DURJY(PRX9O;''%-0FSI81!67O:%S629
M*8W\DN!I,"G&."83?J==2SN&Y,[7ZX=/U_\'_!.?3@\AO2B#*7T*!_L5.V"U
M#'1XQ)!)70Z9-!+&RL2:MAJ_('#IW1)'42E@N$U^Z#ZZ'DMBU&J%#P1?]X$(>B
MJ2-,:8HPB@C/!6V#ZL>EH)G-7I"%8\R2,RTD/=+&B,VD"SP*WJW"D6^PL2C*
M!SJ6@#*8M B=?%X8_<9X)Q. N0WKU90A4^#"V;)!F41H:AMFW(5%[K?7#_I0
M)R9I_:)CB6?T\7LQV,S0;Z)(JO+[SR#XYB1&D",^>QXP,Z95#9&PD[5U&+(7
M@@E?2>.)/8D(">%79VAF$6AF^PS-7 /-[)RAF<<-S>Q6!\WL; ?-+"[!,X&8
MV^B/>L[LEHMR;THZF )6*+S;+55ZHX7QF4J9J:Q:D=M?@*7A:?KGOX1J^(:2
MFXMK%-*\VMFUW:>5Z$_#S5@NO%'<*R.R5:A&>$C"YOST5?\;&9HX'O>M&0>9
ML,YM6*L^P])\81X*$++.Q-!F/AMX*< =%$:PZ3!)+^]RH&'ISXOI6>[2EUEI
M_15C%3COG'CG1 ;+%3^Y3-#C-GQ3W\&KA\W/FN,/?S>]R;/>:7&?$V=W:W\3
M,9DO7@@B4AM07I O"LK=_\<%2&K."!@/"3XXR_GEU TNQ0?2@18Q)UR(&2EE
M4,A4OP/NEE"Q#]4;2EW>P,!A=7S<:@,VS*P(=<) BHC UU:!CY
M^@VU^P?=T5#L:)3:$<<%,CW-2PV>RD-O769'TFL'4;B5&_
MK(^NO!3+*V9B%!KC2<19FGK_-W%6LPQG7?,U[(V
M$@%[9QQPBRW:8J^7E@BG&*;_BO *=NU,K^=X!>YFZ3LA0P0[!NRW>(,:NA\0
MAKP6H9")J-Y&IM1H!VR(#UF8E7^12Y41HA ))^)$0I9X+/!MR(T2DUQZ"]?'U6XT*#$-.,8DE31%>38N'I.>BF!UN+(I=Q:C,G%"^%'M:X9F=CNF;1ATPX#B-9.&8Q.)BU,M>T"QIA<94I _@KB]3G #]G3
M(A&JF_6S]
M?*5_HYL&W']S#0Y88Q$C4?IQ&(7
MY",G14U\(=F"HNI3^I=&WCG_:T4L@CW]B]QAG*:U\19?7'W^/W_M%,R@6ESJQK>E?L[#5Q7Y8-8#SXO)?F!Q#B@R["2Y&:%L^MV?THHV]^)]98$H
ML$AN)1R@KBH:.M'RJ.[-U:3Z8?<]::6WHRO*^1VJ'GT;U[
M=9CGW\WN31"W@>K18&'K/RXN%==F8D[CGDW[XJH]:!GM0=I[V_:DLBC\_NT?
M]_K3;NWOM,-#7OJ)0^Y<7 V:QK"3#M%5<<9KR?J&#GK]O8['+/=]KU-'WH5[
MW6P:W6ZM][I26V,;=?+Y4?_T^UCM<9@5;;P.CXL_?"]Z9DM=4FON"XI
M:MH6TBD_SI'7KFN*Z9-^87U2YISKM_YUJM#"S%_A6T<:3#A?N<$>V#A?N%#[92X0LGCO>1[3P>&FQ]VCA\9(BFRUX
MM%#$"/]X^"3BAN=HX>D&Z(YJ,:<9+3R]\,%ZV[U]@#A1RH$;@H%GM-IMHS_J
M'R)4='J'NL$'[QQ53&AT<=5M=XQ138>;'^L]O7/= LEWH*#N"#R %ES4H3%H
MUA_7/85 W^E[_+6KB$)J8-3:1@WL(<)S^@=;OYK83A6,VL550;VAVM,_V]I5
M13%UT-E&'51U:0O%Z$XU1%>V_T'KM$-T)XGH*Q1IV1VY=5* OLIHMXCA"=,4"=+QIM+\V$*50<$WM4-HKWL'GW=JWZ)8Q4VC3U\[T=[EEP63%O(WNQ=7(:(_:V_BPM466JJ'U!G._
M5S>Q"S@ B-4PVOUT->!65"\?\MD#<[=*X2*V8NX4F1$I833;Z;JQG9F[3"0F
M_63078Q4&I_]],)L=\&G;-2:IZA1&,D=P9%]BO:SE40:\/A'WQCT-TNE V5Z
MZA0QA4E80,X,+ZYZK8$Q[ ]VH.3[0[)A.;&Q/1NF2#MTN_^E8]QX.7R4QP>X@>\_O!T!8O8$Q:UQG:TA6CI-IL75]UAU^@,?TC!L@4)
M-XJ6;K,%]P-$RZC[@XF671@Q13QPH3K]OM'M[$^T;!8?.F(\M@H50
MP4::2YO*F&5>S^@7M[M#J%)4%3JV B 3?&L[0:/4J/+R4SW=RYU:C;-[FLJ5.JX>7K=UK&[W6SBF<
M0]J!91+]O^'@*][ 432/MP(V3PGV,_J_*I5@!4CRCT3Q1_.OK4I]NLT^"!:C
M/>@;S='FV,:YV*<&-$AI[;*& ?)%U !%5+,+8JK>XI^??\PC7W_IRZNFK2Y]
MZO"'X#/ P7>-87\OE[YFT-G%U5U:T1P1,/N\F&,)9]W*^:5\JN3IQK#X(%EV
M2]LHY@&.,!C>['5_Q'A5+KDV"TLLT.L50&*]J$:O-'OM)0HE
M<3!,MN+&.79OVQLN&3+'.7]H<3#_+FR[^ME3L/OUM(3+4PGMDS>H/-C'2.4E48T*_Z@ L(UL[%U=#H%\C,GB-:E60;:KO#
MJ9/M@JG1-T:M"H_V-()?6.7RV]W#PX\;Z]A/M&N[(%>K1T$N./'NH'4.MD*N8^.E3;*L#WDY_>(YMG6AL:TMC8D AK6;?Z&8,1J@QI)5;,).<'IH[1DW[
M42>I=)ZD=]R2U<$I9%4/9TNM-5ZSM-NVAR).WJJ4[U\*=:^'>
M0 '8N19NRUJX0S6WK[ZV"[L2@<1.85*.L\CH,"[SM2K7<81S#=G,;Q[ ((]<.9OCJ.IPW/GWU\&QZ
M#+Z"<[AP$!AS_)BAM@]"&;6A80%R"?S=H&=T"N+ W!7C8B1-3Q.L )[9;1GNX2R%3?;7!2;A#W<>D
M1*$N?3:YM/ZZ?+:F4P8?X?^_G %5+EO(;)8:6
MDK5;7MWNQ=6P:W0+X+CW?W7K- UK)VRO/&%K,@F.U@0Z+Z8.T5[(?>#12A_#
ME:^N]QTK*R?FP@I,^^Q%G-)B]HV-YAAZCTV8]4+C?0^K:RMT+#ZQ">@$'^&L
MXO^TU[L%PWIKY^E;M.?MHF1M1!KTP/48; [C')FY7*4MLR-]\Q7N )N:&J/V
M+JCK([ 3JS1G*N/=%)&'P+O-D3'LE>#=7939U;W'%J8U?M+JY& Z-W>NTPZA4J:XB:R^6=)KCD/6-XJFU:ZA4E6[%IBK0M"A7U^[LT'JG5
M+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M L5Q=EO*1S:J]F(W,,1F?=1ME]9'Y[A&"1%1N2-;5$2D&*%3@9K;>8;H5F"
MHW7$SHLY%F!:5'[-JZ)P:@3^A?UG:;W 77""4X:2I!,P* BNG2G^[W.TQ>V"
MW-TNJ()AS^@4F%AV;&CPM N.TEU#939[(,>!1IA?H[DQ?,=-[VUY[OUW6LEG/,?ERC(_P&[6,9H'9:>M6>S0.O4>6H%KCET$.@.C7R4QX C^R%C8]EBGL%/
M_E@J9Y(.W0HW#NL-DS!@50J.=06&VAL-*!C[*:IM<"38.%Z\/-30#.
MH:_J14"[?R"MU6NC".AT0#'4#-7(4F3KNW_&?L(;?=;2=G,
MH_&C FHF>B&JK0"3G?^^N-[:"M='_/JNB;/UU]+-IQQIN]UG32\ICE$:]K<%GUH;9EN\OJN:6>8Z-73BWLF>GK
M0!\O/,,PF&Z 7 '9&)C?F:.]6L&S'CPS3)'Z"S8AUQX'@V!ZU(%E^!,+=F+-
MX$*Y'KQP\NR@Z:I_=]Q7FTV?>-D(/=$/X*_P/4/'ECT>;Z;_7XX>QE=0;SV"
M8.-+'-&/#K^O86ME3/P@$1]/)V0Z]@KS9JIMQRNE@\G-3$=?L4CA5+@^R5(;EFND2F
M\?"O$P;G9OD1E]@K,>YX#A)B8M$/9O D"_2'H<^6N!@=^,1QY\!?8^:PF17X
M&JX.'CMX"X]6-[:+\'OEC[#O?C,MC5\I^G[+&CHO$I\NHZ:C)_N-,:W>IX(E1^GS]K+
M*;S)MO6IY>$-Q,]:#O^'%L'NPZ_XRP5V+\6?*6= O0^45S3T1_@E/T2Y(/P(
MMK@-4<;GL@;OP";BC>S\2.M..XB94I]WO$@^"86[\639[Y^)C:
M'M:HMJ.W'Y.B+B0X-YU+/32+WII47*^@D6*R!^2*9LJ&R+H+]^B)MF? HYY
M*X+LP-GNP#:H;E%^Z"9*GZ5-BI6^^F*Y2U^'B^H$A@XRUPI09DIY!Z\S@]@[
M7RT0#6-<%W@)>(E!3H%4"FQ&(BI:!"_@E!*:X4VGOMBA##=!SL JXM_BM[MHQI>W3!\D( ,I9[E34"HF
M]6X!B>1B+2HMBCYI^=]]86I,T'B!3U@D"ST*F$EA&+W.;VBI@WVQV"L*M-A"
MF GR.;D23DLJ&N,4]]C,1N&,7^0]L(-\VDSP2T*]86Q-FR'$(4=XYLY(^#$'
M)'3/ Q+6#$CHG0 A'YU Q)Z8?BI&JM'M(:3O=^5KN^U6$&%7J=:11V<
MRUZ7523;0M!.XKDJT!-@CX-]BT_V]@N5F@U84-(RRI__?_&;9;@U]\T,P.14KA29(=CBC$
M4"<'=&KA@+K"%[<.-\[0&7ZQIDLX+XQ%!2L#S-Q9XD)K=*%%F-Y"G]<*>,0!
MC5IO&L6A,HX_--[$X\F,6O#*6^S!-1BR22Y2&YU0Q
M%Y55_R \V*V%!SLU\>!U :=E[CH,!PGQ<)%/YZ\TT)%?#!TZDDTHN*8,(U\.
M23=@S@2_6"*T)#55Y+GP%U_BHF*7DWXF?I?B1VPVHPB4
MPJ=A&,S77QE\TYQP?\](/?+7Q<5V#HD3@7 Q$\EJC, /MHV#@#7"8G2?-%2%[M^@Q_RV\"O&C%>4OA2A3B7()K(BC!XRS(O")F&@KTB6HEI+,,%@UT__D=;O&]
M#$@KZ8;X[\4S$?E"W63#)6I(&W9$S%T#]_5JXKXOF#M"P;7T%GCV<#+":!,:
MUH_;>EJ6K6>HLBA'QOK+L6]-+1+&<8:BD!(W#F7\1Q6=/H7F3'@M"/T&5HH#U] ZPLA\MK0V7YAGAJ^925*(Y^#%G$8#J<4-42Y5N"78IF;Y,7,&
M:>B]L+S0TJG%Y3^;'J8A_'O&IQ'4XI>N>4G,&VW7=1G &[V-B1Q@!=W'I1R3
M(UI(NA0[L#K]0VY2"6'BXZ 8X$+*MEGVDM][A=1:2&HT;LB) %WE4X82]DR_
M\1OZ1WJ*E7U(Z%Q,3'NRY)<<7 7R3I1TW,P*I$H%&<"KMGELWQ5OTNA)SZZ-
M:?.D?0A/Q']R: Z*$2$_G.5\#(N 3\>6J[O+0*;>]>G2"QM4Q8P#^Q/D+?H\%"T6WZ;;W[#-O38-J3;L\O"C3#8KDD!R6U1H@Y/CL(V4%TO
M7,Q1HFJ(/V
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M$H)0Q"&GO;559\!
M7R' !P(IX$62#^*/X2\2D 9(*JPMB(J=[3(GGT%4T(Y$VQM>N*P49A;<-&BG219*WZSU?NH:G'D4Y-?< I5OA&[C?N&C^9?M=AH64^/VV.C
MNMU>/3#_8D<%3JOP@(KF6#><M0K^!P<46@=3,\&(2#B@9+$25V21ZX;<\,*P\*C1/K+@W*9*U0@.2,A3^'<@!
MU4,5JS-MW\U[KC +0HV9%?XU]")OT$J\X0S_*@+_ZIWA7VO@7_TS_*M2^%=5
M4*W^Q49H61E]4!2VL4$SU4/K&Z$_A)B,86#Q9W*\#/MH2]]BC_"MT1DP3$G2B9E;1:>$+O.2K&!2>.H2^ 9DP755MEFFB_#B91L>Z&0Q:^)AF1'PWP<#17D9^F3!Z*Y62 DTLGZ](?!Z)P6'7?K+&
MY8B2C!5R<5'@QX:K4%>I5&3YI*T=P34R%OV?)7QWAN@@#>P98$3,-ZI)/)%&
MCR&%\,'HQ/"(=@XT@_,!>#\3T_,(?B19Q)*5"%F(."W*DC;T<"MQ^R6*]G/'
M"6SNRRF(/GP\YC%,'SXD+J!8+K^$M$CS57C;S^8+A@9@4_)R8L$4.-08G0-K
MQUYIQ6\MO[0)_YVB%U'MA6J3MU]Q6Y9K&I4'RM+*7.3:!<7F\#DU?&6[S37XZE[^@=0%8
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MS[+I4O%MZ+'J\6,542,2XZ!.;!,<Z=A#
M08;G/84#P;ZSE89=%X R&$]#JR^@\FYNALH5;KKTHJR9?#(O;Q1Z
MAN-8C*B.=!IN+[0N9R'K*C!*=-%$S67T-!GX [5)GC&&(91DGDC+MP)@_) 4X0,+FW>T,)^>/*84O,(NU!\)<#69
MD((^\/TY"MC<-X&(Y21X8IBKMALAH>E0Z6$$2TE:"SYH8>!"*IW'X_5TM=D*D#X1OBA%*?)85]2$P/9[[L:+P F>$L-D!&+M/Q%6 GV)*QK"T1+ 27$;L@AQ1#9H9=*I6UXZU>5NWMAP?-A5)10,,<M3Z&C)OZIO0.SQYF&P0TA9!8)(9-UP._?X 'WRA]P7>[*G1-*@7:'Q$ 3Q8 >
MGI_^:DK &9RD1B=)EO]TZE$?%8?RI'X@*D$(0? ,3@')3^(2+N2XP!=F)67V
M)RGF4G,\"CNI3$=R1XN6QX'%ZHK U47?V4CU\XFSW,+U!59_RL9!! J)<3C'
M0SA1-;]::N _NTM[JH&'(W?"$1;9=P(7CMY\N'+X1V@LH_Q+&-AQ 6M.W07%
M':@)@GR$0$"$C]&H%$9&Z>@[2-FI1#RF+L^JB
MM[[M]5S5K]D7@O,H>M@.P445T:M)T7M$0K4L=>NJO7Y4+U:DM'0,J%JS%;<5
M*8X>DIIW)1.6G#08>5 V:H%";9Q6PNSB&:U$B)'?65[11GB9E%@TE3!BOGS1
MP)7 %HJB "E<$#:9@H4(,SIFQ$D1R2U+CI!Q:*8TMICBD.],M)_0$#=94@$TG*#LE!@J((5(?^"E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M"H*:7<*+R&USPCJ#5)P\@$LFG89OCW>Z4A_'FW"*;LM59F;45E&ZT\T@,&O?;VYOHDO4<'?A/4DKFM!DP,]H -YX#5)M0Y4NKO'32!%+DWXD,BTX^TN,).AC1$=A)!1\Z[%D='K6C![$S36RD3N&_E%^
M^B;Z-)J:/E&7 Y PS*!T>.9Q!>(.L0!MSE@@\446;X+"(Q?A8M2WM,F_LWNET[\+Z+VK"'H5 )F%XY8E"O3),&V^NE>@I+2^">N4L/]80&^,L?J T
ML<:;A':C-Z7$8>1;M'4J=;W\2+:V*'85-C[*$RU6[Y>Q-63:J!)3E-*C2B O
MPS/),%^ YMI]%NIX9[_"Q*M&8Y@0RUOAZ)SBNR\+-?KQ\^7?\?-2#>[HF(^"E?;-"L-TJE
MOU+[^1:4*K*[ZK*K'0T"=;-:OLY4?&%5?:I4XW%*7IPW7V!#9<6#4LMIN=<8
M84"G#-\DN]U\^=?C_6\GS4U(M="8B]UT17@'>:HQU4$L*Q?^-5'48;)'1"AX$B/EZD0,W!M3=142U>::BD+RM@E8AO!*C)EM$/NA=?/PG,$ZH.OY3K6<5/CFC9D$8X&#BPO
M_K(L5D.U0>RD/UDO F++YF,VQ2IA$/E@N(%.CG07*4T4_DA6D]2Q%/[1F[2L
M-QE"O5$_I,*M,SGY7+52*3CUL^NI+\R\FX:(T81V#<=R1Q*$C^6 8XO'S+2E+]@K#.7Y+.QU
M/@=# ($N2Y_O(!;EBY5I.[PND..!PIB>VBF!]\SAG58P:4#!+3=:LO;.?,_+
MTK-H1WC=D&2<8JI9(DQJ$'#RBL&K)>O^HK\;OT^N2.'<&,I)4R4>,98,8RF,
MKWP97ZV6+#O4A1_-HS!Z^ O1Y]WD/;U'I(PRB*3FA6++B)6L8W& Q46N.MS'^I--KGPL!7U484W).)(54WV"NEEAO]C:4?RB?QUY QPF2+Y3SS+T2M^%=Z
M%//-WA4/!Z8(BRR+5^T_2UM& HS"\MF8_ZQ3X:PL/D1MKY"SWIBFQ;O%VDY+Z[]$E803QA#6SD6-*>:#$0I
M/J&P<#T>'J9J%$(]3D/\"0@0N"H>)HZ7'F=6A+I)QZBA__ELB6D4[C+ ?*@6
M,B+P:8!Y6$PNQ/JWH#X2DB2>28[O%,6@Z'+B<[_NEM >O4_"7*LI L"BD:X #1134YOE(,#PG[2. H(VR$)=Q ;"&1]1CI1,:[4,3S
M'X@GC(J6HCJ$B2P)H@0P!4^>,?" 9YXH^[9$;PRUF:$92]\0A5],<8SX#RYD
M5 -5J=@[Z=O^2.ICS-0/CQEQ(7-(Z..'
M;/.5:K8FWZ69BI_9EBN
M19N!E6/V!I3%TK&M[YBQ/^5C J&L%A.);&]6;XI3W>%#.F(:9O=DB-4)[2XJ
M8\P()BCE@Z&@ _%$O75B#UWG^E#9JRSJI2I"PE$_24NPH?_+]*@*E[[L8$*1
M6JKR?\BT*DD.,LQGY@N(>UY1[ %#*O\..P9FHSQD^C6$D,@21VDUB2Y$!M;=
M:-(RL:VYQ2U00^>A7R[VQ'8,=3/25/>X@*6/BW%&V]*%YZ1E#ASO(Y:B@8H,
MJ!D6_Q>O'[1R^[_^T)TD!N>LYIJLYO"MW[&!9C*0)$;#Q3NL\6![*/A-7A(?F&+J'5:F2&2X2751-GM!;23$>=P,41 Z
M8 L"*YKA1 Z?2E["*6X;"\H;^C_=5TRT&G*NGC#(A;N)5W7.5(N('$Z![H2[
M&D64N"&FV-]:3/P2*$:1P.!M,"_F;41N+WS\4G@OH>=A9;3%9V&U/P]G4:%Z
M:HZ)P=T'M=\ KU.*H*XQG1U6=R7!/_PQL;2MZ!IWZO;=0T[+N%,W[/ZEI@-R
M^^+)F+&6 ="++#MN0CSS#JX^; 6ND?@[F998W[@@OJD3)SX2JP79?RANHJ&OIQYC'&;"N45C>2A
MSIP$6XNC!\4MYG=%4Z9/)/"#<8-6Z5"(!*'((Y9EAEUD^>)%G\13ORR_HK/J
M$)?0!D_>_4EM*&^N*_4!T13 )0:T/4IU9(]A%44'X=1TM;-E$ ";A&'^>M3ZG51!-=>3/?AOXK_4)++-,,?3"YX)7$M6@-L/(>'74(SG5)UZG;_-I
MU5IR6K6DHB^PKF)5:\>O4#ANF\DK1^?#K$?49P'@,?\O8%Z/ N6EH"+^!*[Y
M.C$GC_"8CS8($!7NWAW4./RPAY/(\]%GG)\1E7+J-_\N#6Z(76(Y^YVNAY8$
MBKU[ +WRU05UTGI/J4Q9VD,V$_U"=!)(?K,D7$@K#Q=RF4\K*(47TJK""^FE
M\$):=7@AO0A>2,F9Q@%#VE: H<'V@*&H8N;>]"A:L2-DJ%L8,H3MO- UL1'B*5>&OESP4_27\WEH5^/F/]YMFHO?S>C\_5MZ8R8;9#% [^*JU3&:W6;J^!.'G(5A52?(A%DU\?EG9M.U("E$
M=J^ J>Z-"W;3PP]HC"UM=C?[CMDZ>%CG]#T%_\#[/<0D' 4$
M3%]4W/@?]D5,1S FLR%S[[H,N__0(B>!H\XX*:
M/_VB%U^<>**_,-&WQ$7^]M2J%+/GL(OV-/?]'%EJ( ) 9K+]3ORV?BSF!1#@GN_ =F16DWAX4% ^J" Y,+
MSUPE)VKL];&%PQ_>MG2[2:F_#W(M16FB$H Z)5XD3F.G-?Y"6<M!T]_&K\#P6:T.T.CW>N]C_:1I!MR-7!2H]7N64[(F,-(=<4
M^'WR>"2G_[05/Z6_O(E/UEW5S!6-MGZH.+&U6FS0W$6+D<1%Y<#5UB=R+^_)
MLU35V1?7R_>/"NNZ?JZNV_;L-M&\. .GV3-#"[@!32U3;Z&O\N/:VYC[V&PF
MV?K<6P>T7@:%3[2J\]I&X%Q]R? D%)NJD$!?*R9VD0U_2[ZV!EG0.J!+,USC
MTA14H?N\W)]X<73\=HO#C9+#*1N^M;V::&[)&B0>
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M:>U\JWZF3%'&U)%3301C3BX),T ,%55])P=2JQ@G=3:".^.8""R&2^.;\,MG2Q7,1I1HK(RVO#97 %-C.MR'28 J/*@@=1U3I!Y6>BOE4;F\YWX#R#*BIQC@.ASV>,25HA-21F7 [ZB%JD
M8U,*TWMATTL\3R>^YWI#^YK],7R\=J
M*X$\SRRC$M%+@D[@1LU ANQDH$?T=]^P^DX K=KO#]26\8@KEX;GRJ4U
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MOL5OV,E')^N[@2)3LM#1@KDXR62VISIB#0Z Y&3WLWGNHNL)AL";9QAA52DLNV>';M@J,:AFN1)A^T
M0)MOAJYFGE I*I_9H*SXJ88-VF!H]-O&8+0YJUD5$^PC+;.CF_UW]*AB+#HS
MYY:]^K#IY?19W_HOXVN--HP/O"KBMV^[T;41RARGG4< _G&!$0#8;+XR@&>#
ME$\;F8)./V?8GW60<-0?C"(:YL-TQ*E6^?*EXBN2V"GZWWJ_$B-/L0WA99 W
MXM&+MC'N[&=,RIR3_%^_;PRMZ8G8+/03+L?S-Z1=2]I:5/+UC2V6'NS-9]=RW[[0N#ZM*2-**6'$G36-9C.C AJ[!^A/2Q/1;(R. YL-$>&Q^2KO]<^B_"V2O:%?BUY<
MF*06$]:9[),2"X"YZ_J@)&:]RNG8C5P!=H )=97Q?F(&6"B_ZLE W7O8#"-8
MW=MPKMA;#^PV:EB3DP_I]VOLL3)HZ.'[3S&S](D%IF6SZ6TTQ?AZ["Z#K8F,
M7O@YN[*'_ (*]25.^V(1WQVFLGS;]V6:5;@AO]@6-M)ZY[C;'M&/X;:O SU*
M%;6;[4[-=5(J&.+29Y-+ZZ_+9VL*UNP'G?__$MMT7K;:H%(OA6P%.7OE^
M1"[1K/,DTDM@E90PG,*M4AG.X[/I/#X#QST]RV91:J^H7$%=S'SJ@OED#-J#
M0Z1*:KM*W;JOTMJS+V4TESS.7M'CW$^Z*W2=M(V,XV,P_1YA)*6ZR)>5%"IU2SOHKS$=5A]BW>7@AONT?4)1AT6_NG)8]
M1"71#U/CGD?<*78K)U'T@;>MN[5;_Y79?3=\0)7LL[)BIE4WP[+R$OU"I24G=A$9Z>N2A64:Q^%A;[A
MG':H)MI2KVTNBX5%[.N0*KIPN4;0FGMXL@;]>@X:ENJ#5-U-AW5M?[;$*['$-S!ML;Q8KP-#^W9Z(VP,F.7942>K9]=+O?;A A#P[JN>T1T>/!9VUJ_U1[J&I1(V
M)1FM:JH*HC77G8DVPL2KUHE#B&I)JI/!F3&7W1SPZ.Z9JW[5,:
M&SVRC/D @]KF \">ASBZK&A+P6.&E^Q";@5+DC^>83 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M>@9XJ,=2>W^$0=,C:&HZ.CFYK6GQS ?UL.")GK@(31_XUUUG0=
M,B7@1F-GXG#H11B*OIPT_R\^X?^VBL6]-SY0C6T/>W6UZ@2*C1JZLA@^O":<
MXK[/9$(=+[B+.DRW1(=I8TU?;DWMR\T'P?3>&[$B>0S^RZ[9'RT7I_K=WL9+
M^?'C49VZ?B_JVO7K>$$_?NR6:LU=T6%;3F#7'A98+>X9O,4"_YRY
M2[!NF6.Y^#]X"1\K&#L_7W?'0 5>ZL$1':+<'ZO5E5+W\8I*W$TL@>==PL4$
M2[%;+7.W!@TGI#2#V*VRC4"'A9DSK#RE!_'&WP96QE,9/!)B;J[T,3-")*#Y
M](1]"P*LI+><-#489W7]!>S+'#@4=OH
M-?.;"L0&J?/#JWX3-%IW.?8GGK6@JNPMMH )95I^[A:H@8&O/%YFL_1W>&[8
M];T-]W=\I4H0NC9?>$\#YPDE"'VN]M\<8Q!<-2OON>T<'?2/'^
MEL39H9H(;\&]YTY IOE?/'>.$T2Q)^C=+.3#3VQM=S)!QV5*5R4 V6J9MKW";4VX0P/_"$4^-@)9SGD/!2EN$R,A&OH=;QKB@J]E
MX>@'2VQ(GPH:!DENU 0W6J2)X.=CH+?#\]24A@[T]:,S8F3O[#PN[E:\_QLL
M-*3W95LA^&*)TWY5BOKH]-FI AR+(,D,QRDD1*8Z2(
MPZ\JZ5@KRN//8?_/]DI#[0?'A'UNI,P#KB4K09W(&U>-#1T% E (U?PJ_URX
M.'P%]9>X*(.3EX9@X[A T83,A7?+N+PS$+7G% T.\F-Q3_
M9PDWOQ*AN$/)4*5"<8@4:^>T4-)4H5A0>&4SSZ[2:S@ZG/0:[2Z]M#SIE46=
M'/&E[R2^Y& >;KAA"%^[QYD\:\1:YII@/MT] C'YQZM H<7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M<&1LV^BU,\Y_R8M1/=6K""XT@S)OE\6;7-"[^DZ'$F?S2*% %47 =0.@1:D/!)8[HZ
M4'Q5<,6M>BF2+N'60#%0=F% =FK&=@DL=JLY**-1U]V_37"3M.[L7UQU6NU&
MOV(\=C%(V\;V*CC;F!I33ZT7"ZUU?84Y^BQ0<56 8K5Y]/J&0CUQ$7;M+OW5
ML@OW<]_']J#L*OOS*CX[DR@UQSLYYS+'!*WRS_^^4,//DH'@EN
M\.&.J]4\GN,:@H1KC-(.\N;#^ND@]TU(/-N:'?#\6L=S?MA.JI$1"3C890N/
MZ,5%K M''1WJH&)1BM8A#ZJ%H:A!8Y<6O0>Z:);'\P7UGUYFT*'5ZL1 ,6L.
MXS,X?L'*OWMUL 5#L+H-P_HJZF[4[EKAYF.-
M#S%9_O HXT[SC#)>@S)NG5'&I1@\&5]"25(&1US/ZC$R.3,MCPMP@]#EB)M UH) _R!)O(W,L>#:,XP'6:.W1=F$,3%PT9BTS!%MF[HD>5,W#G[
M^1U0QG]/+X=_+SSVS!S?>F')WV/:VPLT$9%7-H#3K'2NR&,8V)-.P-TY^E<@
M*L;Z]?9@^\PL_N:1>7/1[EU)PMQ!HXTE@K G^&=X[A&)<(D\/'('H$_QZ(1;/I29_?3@G4S .K()M:#FQ:(O,&
M;L]5:VB,NAG)MQW3J64[S5>03@4?X:H['!F]44:"9%,Z54LD&'=.IY:#S)4Y
M5$P/MHWA(-V&;,>,JN/."2;&8K$Q#I(#"C%*MFH+N"WNE,.3=LRL5<8\.V;6
M6MV+JWYG9(QZZ6$%$I_BL1GL"7E 7')!*H3)M :_^#%ZMVR::L$WT'\0V^9C N#ZP12 LE925(C;.IAI9&0IL>VS:).EBD.DDHBM"&:)1
M$YMHY',VR#I2C6NOW4FX,GY[!/C_Q=CA"*D:,R-B6(G!84@ILAP7HO1SPCYG_3-
M4/&C@=69.GM5CY]"+W_&8]1O3LUUZ()=]
MN;"+N:CL"[$7B%G*2@&NOT.M9JD$A(SP?A*OO/;O07\"QX#+K@*9?J6RQ&DQ
MW'6O-;BXRD!=&UK"CEA_55K-4K%Y:0D0=CIC+^UF:Y1W+8 (65(#AW*TNXUV
M.H5\N7$O[2/;RPCN>KO9Z/92>S%TS_*_Z^DDVR9.C!U7=^N)"F$EX]T,LWQ?
MX/TJYG]W=FQCTY%&/YT8^^ERTY;:Q[HE!(XVVAE;,B(Y@HDU?6UMX,-TZ:%5KP;LI93X#1X87P8X7,U&*QG,)B!YJ_7+AI>W2[XMG[RV$O5(6+X3J2A@G*4=<$/95'ZA<7-V4ZE2JUFJ2?:O.)W^-S"LF7_GW-#Z
M% 0<3J+VK!=0>R\%W74<5-4SX/_&(&,@A?X.C=:0E="@+[+#4AC-RG=(TSQ;
MO8'1&:4C+7QL&,B@XD@M&N+C(8P"9BIO+(%L (H%.#LH$G-I-4L%742AHFDKM+H.0G(6NQ[ S@.CGW,]
MA%V-T5J3!GL_]
MO]]*_V]^N4^HYW6%(-^M.B]7"O1M=8\&1M4&Y[,_;#6ZF\?.[KWQM66&\6P?AU#EN?WBETE#5'MYP73>48^HFG'FL]QY;\-HN_;K$D58%F2NEX*L]
MU]'%5:NSRXG^5-,-_"1L"1[9X!&2PY[6\=1*=' F9:-;$DF\Y[L7/U"T#P][
MG,/C.<[6Q56[V1CNY3P+GM:_0D0Q]>&(NC8?YK!*966J/2SL7K>3[COMBHQ.!TS1QE&IO6]A:/\(KEW[>(HO.MVJ5-YZR'?\)WMH
M,+T&$KM3CX H!!I&@)0\<^GJ_\*/5\H!ADW,\-35A+?5;.C1JB3PY5!C_>I.
MCC]C,]A75Y_@,!B."LO8L:;@13[H]\NQ#3PD 5>\#R\1C(4_;.C7]+#X+%,*
M;GJ, R>*SR^X_?JE<)LU"1.1"]D.*-+IU3-7(;&JNXBB
M_P1:"T](.4*# V)][,F$..X-4KM]H+/ UH C8YB5*\IBP0V[Z!QH%\.+JTR4
M8?+&Z._BB8!D4C5O7X>Z*2/BQU$KS8^[G$[O,+OH-@N>SON&_MFDW!O]6[/\
M6*^AP$5$) ?7NTX<:HNI&3."'J_/TNQ@S"(5LK(S86[FGGD46MX.,=(%+[)O
M# ?=1BNC!U?4?NB4->&GI2>[Z/ V4@ZF5#-T5MB%/57;(=N/?)8=1:.^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M;@>Y]W:0<8E6#5SL+9#B-!IC#OHGWABS4ZH/F:_!YAY_A=%R1TKR
M4MV]JR5Y31#%'Z$7Z>! O4@/O>_AN0?K9L*7Q\)V^L
M)&-W5!D-WW 3V\[Q8!5[!#UMMW;'X1R"?L?3L[G7*DN_'[ )MO@GP(8AX/&"^7@>KX\^=E',.ZGA\SQY6@(\:&>W:CEG<=X_'D^SU2A/P1^M%
MW4VT\<"U7-+ 3CRIRZFYHJYVE\Q10^91_!;6_XE&D$;XTU:U[:@3TXA'E?2C
M/@"A>]43&JLCCIS0&QI_$]S[)!-8UT$R#YC=F4#D.[-0P 3\J ',4A/DK4<8
MVZ;1'&7TB4O",S>V@&J7:@Q:1;^%WN#B:CC(KJWER=>_%8](=6*]2'8@1ZGN
M?Y60 _MY]8U^!J#XO8%(++39K!=FKQKZM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ME=^#D'"O>JB?[WUM'\JNM/N,1"#+:S^==\=+1;7C\(7 GWSEO\X+A
M>RI6B,IF\2[+P21?7"],:?!-Q\)U/JP7--2&FS#(JS3=?)[OCX?&Q75&@F+K
M"9;B?\+-C3(B*86IM7=54,0N0_UY^C9&4;L,>Q">[;+ZKMB69EF!:[M"6Y]'W>\;6W. Q^%'69FA)@W[:&]&QMUX>BG[G)LLY)@(K9*Z9XQ%9A[
M@^::AD8%2+^[ '@S)[=/*W/0RL]85')>6?WT%%#&?G 4VV?1DO6U,H*NI,D>
M<4./3(R55I-F;1PQ5KW%&KSI6%'G+^?P#DH.
MGW,VV^1L,OV@6A,,_>H3#(DD]I%F5NK8>"H/ML_4RC%P4VWI.10W1\Y0==1@
MTS- BE[#D6/OEK#D[3ZK9OGM$N+,!#4SP0'"V<)],F)Q[$[=0=C"$856;D3A
M4/'CPDMOG^[2.Z>[].Z.2R\3KA F:Z^=#8S(E6'<^5Z39]X^[*5\N;H(F)+;
MKR%)V=LYJ+];O]A!.[?K[;9'L0/NX@"'NJXE1^WGN6VIE=2S0LU2D*JZ$MSA:UY6_C] ]RI5M[OM+=[!;0;_-$]WV?2Q4)UWR?>WN\SX>TSK,;?AUF LR@
M;.9!7O(=1B@,^H65=[6F:OD6*^U2+5:DNTEWYVZFD$Z]2#OM0_)CSFB(HV?&4NUC:F/&:EO_[ .$FP>/>J/(A42I[QXA6%LCL(;-H@BL;:$-
M^S[=U'6OPJ<-R=H'Z_=V
M:*Y3+^NWZV;]XP%+9GLXQ;H['_4-W=,\MAULUF$G=RC;6484.K!CL9>'W;..
MW%7H5S9+<)<;V"OF-9[$D>U%19=JWU;;]>OO2T_G "J/:SSQ$8S-:I_'9JT9
MF]4YC\VJMZ1AJV9FJ(UFU5$''CX5>+CK(
M&CT 8E171-\/2P-%X%<''*UQ=E.[^5/V[G/(6[C[S[;20WXQV69FPWK6]KSM
ME6DN[-]YW_!0?!)'I(CC#7#131ADM:U=WZ^V-(4JQI:T!C6!2WJ[Q5YO;-/W
M0WM*'$+"STL>T9;.W3:C7 X$+-H73&P_I[_O(,RHMM;]QD'*YPG!%$V7**[;WGSBW?!U?QJQLP/W1*BPRNS?MN
MS*$=U>5Y AU:K88>+4*G54BJG&J#XSLGU6&1M].5PWXMPEF 0PUWQ&>3I<>F
M&IP4V87HV2XB@CA $)SU>__KK?X.GR%F3P/I\$=(+R27&$+]WI 3HA>>Y4RL
MA6GK)O6R1 MW0WO;7JE&?[ 2>*1I\]:9A2K>1RW$@/1;3:/?&Z3D@*&_/EN3
M9YSNS?ZS-&GB,>XL< /3UN2N7H&.@CP6;M( Q[L=RE;Z_@(*=,/E4<38-&CDO*HMAE< 3A5#&#@B#OK/<;:5FJ-?TWMC!7
M% >ZFXF6 A]=SZ, 3;'>Y'AE6[UF9F-ZV4@[8A'9+4UVV);;QP[/"],*VY??
MV"Y-CT8C6E"B "E*M:6O@!284#6Z_6PNT[MN2- ',>"Z^RC##!G@1@?K]+/T%TO*29ZG/W@^D\8F_KZ#.0 ?!$>CHS,(W(>
MFS!X]%0;KV(R!38 #Y34;L'-P\9/
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M=;NCT<55Q^@.T@%VU$D3=SZ'Q0J5!?N#)8/R6UK^\\:[N4.//0Q6?0[?P&MP4GP,PB*&[C])A6>=)H#8]3/-J'@X#1D;9Q8!N:HSQRR*M+ 68+(*#W$2&PBWL"^323;@42J=LE3SI-['3X&C8&&8,$UK ):"OG+2 @CM]
M-PE8J*8UMW72C<9,>FX/OIG37U_AEX9:&>E>,
M'2_+CNG&>B]+YZU?EEM'-R<3UYN28T2==RNT\%;XL6N$YFE:D9+UEKZ+
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M\Q:NIUC&2BZA$R=H,8>P#VYN>V#T^QGBE9OX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M:AK=4;JTX'U#O][E(N^0L*GT(GM+G5XCX6%GKJT29;0WVTBR@ZPD1V(LG%,8K^%B,7FT&AGOWT>1SJQ.'"?3
MIH"KJ=\LA]W-;DC01+T$,HLVNM2%H*ZBC79#__S;WMUTUMTXV()0@N^\5Q#:G##6] ?QWCXSCO#(DP!X\)5\>X:6/#<^G6<_WT#@_N
MO6[&@Q-_/EN@G'[#K]V8"RLP;4/_[;<;0[$38.&VB=1@LQG66(#H$!#T/QH/
M#:#Y!$0/ J4PY:>%!A70$J\V/OG=P^>;]P(#&;W?I,EW,;HC%)*!V[=M(OO]$@2>Z;/0Y"M&]?YZJEMAZ /\10\,QW:7URNC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M!!2%MUE4'BS4VR;T9F9%KY"0<#73Q_@.?H3_>L_+2>]_O34RDR-@E:%"GM:/$US'*8F 6AL;WBM_HS,Z?_68(=)_PC*M?YB/8_2(9_67@6^JT/C#SU8T^:
MN9.ES\*"XH7G3I<3*<47_FKRS*8,)R.;W,-8P,;FYH0MJ6$2O.@);1:*1_)V
M= '2P(\)U((JKU2!2*ES[)!UV$V/>4\H/"J4%&Z43$O%3AJI2EOW>$V,&8OF
M>^Z+17X7]^$PGTH"6\+"T*>%/Q:7RX46>2TB=::FQ, N32>_\'U*]BM0X^XB
M39N^^0RF%
MJD#O9M?AJ^C@"Y]X%R$F1KN;D7*+85HY?;*,'*33AMWM6%5QH[Y'M9SVC-\J E/./-_2/)K_QY,O9%@7'519 %/G'WT,Y%+\#HA82_KH000?T '@V
M0AR+H90@Q[TGR=)<'A2H&MN%0R*AP,6 B)_<><"RIK=:0\^4V04J?M!N&\U.
MNN3&T#(R-F$%I!_ZTY;SPGA45941IZRX_VY=H8/*X9GZM>\SW^?Y9^ND#9+K
MC,1,W"*9,E"OMN.K7_B>,4TW1WRC&]P/@^VXOT[0Q]+$0'Z"LL/<%1@R]>2@M;.8\!<\84_,G
MGL7K9 -TUL2NQRM4MA"$1(1N3(8^60X1X!#72GU)3<(Q,B)Z"C?_&7IBMMX$[%LM ]&"(5PSKSQ:(
M?N#!%:6Y0_2.1F%AN'NW7[X]Z*T.-;EHM7[1E;LHMZ+'/O!>JJ.?)T$M^EKAR5.<4]4$P+)HF:-Z)B+45I@K1+D$-SR6_PY[M]CZF3++BT5I8X'^&MJ>A[=TSM'T-M+UWAK;7 FTO%42I9PNH<06J)ZYHE?PY
M=0."([7Q7]K66($==<8?X2M#3?HKO*^8XL (:ML8]3-0/EG9?_ +9R"E0?8B
M3(?<:!MWX>?@\2?"_P(JG'EE *.(=$2FWQ'K47V%_K?/LFO@&64B_,-&!-V;5O".5/;
M47@6 H^^>.YGA9\0;<#\OY'#NEH%\4
MV8,EAO!D="%7N2"<"KWKM)_"8]_25-G0#3V<\K99<7]BH1E=2?_V==2KK(<[
M3UM6UZN]OME[X@8-AS]EGI#:CCX5Z L#U+D-M856';_U:;+QH4*K3S N4K^DMO+F)<(4#BR^N'BE<=?_Q]WB0ZI"SNG<\,]C#
M+E'P3BLWMO-/.CVP>='+X!8\M1E&UR A-!>=.YU!C.-N[612O*W98G?QPW-%?S2\)CRUR
M[4[T^- /_!9NHM@!=G,]PMW.;_L!AZ?3/3\6I^!9[GLP,
MA9ZJNFF];IT=][L-_?[V_K,>NHWZI2[6J(>+)!"O7&;-V(_4@=:729+[7,A]
MGGH6Z4XM7NQFX5HPK&,S*G>5, XMW#Z/H__S1O\3Q,PKR3/]_S7GBU_@ZPV"
M@(>5H/^\^3/J:.V9%'W006;[?M2PG.)C:J42>5LSMFE\R+%V58]ONA.36K[B+>[&)8B(6L?>H(;/Q."(,E40K?!!%617Q _^ST;.<
M''^??F@YF%_YH%\V&VWX*)"UL@.2W*UN:FUP:=N-K@WYYT26>)CJ'Q<8IL)@
M5Z[M <\&HR+M#0HZ_9SA*-9!0E#3HXB&^>HY-'&._8(]!.[D.W<&.5SYG@H?
MN),(BZ-?%783^Q=7W8$!--J EC)B)$3+19HMYYMVOFEO\Z8E!W%M&8%!V,7
M&&25J2P\=CE;4KHG' C\CID((XR&?MBE=SU3YSL-\97EPU&Z#O!QD%]>]I@L19!IUET \N@[:?]=CO8 :[US1&W0T%
M<_I"4FXWHEQWM>7=+3[T_$2NVF#357.+W8GUG+QC
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MZ^(LVD_U%#/#\#.OWZ,_A!<(A?LD[\#$-MW)7KL#2H[XA!B*$H?4-PQ!LUPEX#[C"%KM@OY+"ZTLTN=OQI=8Q^.UWB>SR@
MP_MT5/>T4#&P ;Y^J7J*'_DRMW4-JO\Z".K)<8E6,348(&VX-ND9_F Y$%I3G!X$1QU$8IW6E*X%C])KKX!CE
M06]QD%MV<6F]F#M/ZQ?7,ZIPLH_=?#AXW,\]2^B2@R4TSSJC1[U$]+"QD#)P)"^L0/YJ'6L4= >
MIC]&C4X:%'#$]:9ID'+"LLX/Y\3*4',0S/W:VD_S(&8:G9(*4R(K:DE6-(4>
M>9A@CRR?;B>_EG-WRFR%87DP#O\EGX&!N?TM@/\^]GZ^TI)^<+EPS;%O_\]8,HI3H"=J^S%'LOJAR*!2H5T]%="1J"I4D!%1
MZW?SHG8/47.U8C&[@\3K6J/V]AH]M.KSYL])R(E.U+Y;8RT]5Z>T\E;YS,.](SZ!SO&?0^5'.H'N\9]"M_ R*2L6X
MS,N4^.O2^
M1S_FOKO- ^V[+BLCY\:IV*7M"5\ZR-P:#8]76/9X?4#)^/.>Z;D#N&Q?].SG
MHM](875YU&?Y<&*C\=CIY'[..-3I&>Q^NO]9MEZ;EG4T8X#[8UJU7>*%F\]19D
MZ^+J4N2YCL#R7<^&O>-E0R!C;[]66%5$[1\O47&L;GFBUN'[O[@(/T>0S^$.
M;E &JU3OP6$0;:=S.Z".*S6WL5YR=D^0G#N,C=L7.7LER;EOB\'R5@1=.(Z0
M4YL,AJ.)E:T!(;1;K5B'F)V82L47# ;-*DOC4P6A(5F3E3A'3N9VU63NUTGF
M?B5DYD(@IT>A5E\ON3A0K;[W\'2N'$*FTQC/MX M"Y7^$+\H!#/NT^SO@3'J9G2C2LQ%U;+FHH;SU./%EPO/7;@>#98+F+V2<^Y2
MXW!D>V$^)DY\A1=@\MD_01*09VP:6K\+47/*9HJ1<'!QU6T:W0P*&F+,/$Z$
MA.W0M$I.Q(D<22]!7CE;C[IZU+IK 1_YQE"B9G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MB'3C6?QMIU-O-):C]>$L@P5M[$\>C>Y=;=W*1=8 _?&8XW4%T[2FBQC2-7I^XA.KEGVW
M8-#53-(-73(MEW)?HQ,.9_3?D04>;*0U &)H53H=YHD#L9]Q/A=ZEY;M3^M:
M&(A%"^!K$\+&Y8Z,5Z*?@OBM?/#G;*UZ6NPNW&OG",K>?B=]C9ZF0X%<'YQI;Z6^YSZ!_J5#&')]7;'W5CAS
MX<+PH%(UP28(CHV) 4JR9H;SG'PH!6;.ZQ+%4L7Z<\NCXTN9E1)::P*O!V\E
M=I386,$Y%*3H?+\UI1OKV0]>=?@P^R;M+D#;6,/AS/'&.!\0:: Y!H7)5]L?
M9*&Y#3OR19M);=[@ZNA>2/.]B")*A;[GTL:\ZZFP-1+:X(51\/ SYLOA2&0?
M:YCZ5H[TI($O-D *V^J!ZZ=/XAXWG\8(0R-:S4J>+&)NU,U<:]IXE:K)NY,
M1P7OX-TIS#/;UB7
M]1^[..8^M[G&B\/*J$(&C4>O)NL3Q'*LINSJYK+(2$5K4_HZ6^I2H%.KX/:W
M.]UZ0UE&]UR^/;^A;*CY;&B%\X^3IW41RV3#ENR$C;,3NSITLEBKP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M'M>Y8IY;'GN\=/24D[-.LU?OM;/H>LW13L'.29^N;\_+P\XL#PTH3EQMQ'*Y;KV7<1^7Z.=BW38N27X+)+_>Z8%3W&N+9W1P"PR7SJCV\S^'=3KFZV/_
MO=7Q:(,W!E[XYKO.H1^.Q+NX=#H07*+++\@M@UU8K+XJRCPD[E9N9M*MG"'I
M;XK5R+&BNZWT,E; =WKU3BK)>[LWA1R4^9+7X9-F/A[)O=E?]2=_T=O>F[M=
M.E.@D2V&3=DU]>9]3'92L'T _)=&IYPZ.O3=:1FQ8>M8R.7.)$U_-AS+%O3^
MN]4)>; ><.%WN.Z^O^RD9Z/7.#EK[QP/*F\7STT/@PHM
MN=Y4EQM52N_W;P@VW7V^PG:Y"?S=LFMK2N=72^!9=C@O$),";=WZ:2!%]SK=NOM3G$G+9MS='/>/S_*@X0+3WN26F"P
ME+JB5B=I]_U=.DJ(!5)O]#KU9GOS#+V2FRV\K=\YLVMMX/B5Q\=U:X*U8VDL
MKO_:];^V[=6IUSDY:[;K[8SQ/\M^VA+N9K(SI9ZM"KK:L&&D+*S+ZIS,&?L-^$7Y"BN^#!9\0UQ671P&E;8^,%WJZ'5V]OK+L.N[
MF2?>9\E.3"_Y'-=RVB!>X+C8HY4XA-RJ0LBQ$'),'R015[716(FFDD,H>3?5
MS@,>"#$'RJ-X,LYZX]*7H X"I(RDU8UJ8S6@0TF.SK[2X2GV=^D0K<&4*+G.
M7UF*'3F#/%N0Z"RN+:;.?*0T7]+2S95.;(':*RU0JO'. N]9P:;/X=F^9.?8
M ;*!K^L.-**;M.N]!&4OB=FMC,F.HK;J08F&B.^OA4!MM-8U^B78\_3JX7!8EGL?@MH I=V1ZVI;J3<;VY_P
M1)SBS8"/@XJ*B]KPLV9ZFCV3E'8 8S$@0\USZ#QF'T!R.B:XF37_D_N'6^D!
M-++#]C@.]N#[^1M:5MM[/->=D[-NOMK#=:RYYJ!,OLV; \/^[\9(WAM#MAQ@>[MWCB$2)ACD-IOA493N=-F#&H,5AJN+F :(J^%$)D4+B6 :7=Y>H/3E B2R'8
M%DXK.A#T6(\M.MR:CFY[)_6'0P:=,M5FM$EZ(S[=@N1OJ^F9+^CM6MP0(391E$YM]$[.E+K<[-2;O).@#?_R##M [&-R[U#1D>8*K1;=HN@.NT]P
M+WM\HM\+[T_PNPU[T]W?L9$;)V=J:[F0)@3.<24M!H6XF=,[3=D#IM*"ECMB
MT^6LXBG\G;<:K%ZI=SO-=\IRM","_6,MFS*A5< V2)&-=->QVQ>3Z,&=#.AZ
M!DV0Z,#)"DW.-AKX?QS(R!?:MSR+^05 4\UA[W"PT@!'M%+]14&;<4V^Q5K4
M5QDR9TF+NUX(EMK3N2[6E]Z1!1+7!OE&NW9
MR$V&KV!1G^%]UY;CW)J?7A'KU3.<)WSK[>B"#-QD$@VW"*4K<^O_J00:YG#L
MZ7/4SQBFF>/"/YC!AH6:Q)7 N#*$,O2>P>\BIF,\$_8Q$WB$I*5NC!-8^-I\
MOX317 P"T5J *H!-" !/*<8IW1(PN"@)AOE,'-;(PZ"Q0Y1>IQ9\-M?R70(S89$MA*WYIC_1]L(\:)*+(<4&('4*F^KJ!0JL; "P%4F?=CF!BFD>!/
M('%UAJ8*>T71G6O^MY;<*F_@&+JAV8://Q<03$8C1):CW:^.&R *TQM2T-A'MG- D&CX3=L'P(86)M0=P7WQ?<"F3247QA6H$ .WTI7)IP#\OX-GM*W
MM^CT:FP\AQ]E M_P\!N51%A536I2EM%'&*S!AHU%J @_QB>6.=?8F.NPC/%*A]FVA.0.DBA?Y!#!Y @ W]S
MC=. [-*A'9< XE&M(![70#QV*XC'3"$>MP=I5/(#V=;?AK,J_-DM1=JC/) G
M@T392M3)7@/'RI81=5))X?]G=$/K; )8S)*V[1$G51FQK#IR7>[RBM!R0)R4
MMQD[V(83:AKC<'3;>MC'0$(KQ,MY,I:(JC'O=?G=LI6GYN<=#4EZ;O4]VP$^ S42[0T=@D\K8_+T+W)(MUEA*!4
ME%3@W-'26>8D!3L3EG4N0'X%FY+8@^J>G'6;&8)4EIT/*6IPHO5Y.^W_4FB]
M=W+64NKM!"T4.8"$9HUWLOZT/A![8ICLKMM_M D-YN^SU+JP(QE9>;CPI,<3
M[EM$IR2+:N;>>='V>'\O-WS1N]HJK+?X*7#U=SE<.T/H"O>Y1=.*@W*)@["*L5:
MY"(SG'&!B:U/Z^2LJ73K:E/,SO*=C]#6F[AT0BA60Z?;J3?573O2,C= &XX!
M:X4Z^,.P>A8P[T1T5LTU/_KSD'BFLJJHJX?=E[R-\.3L:E/3>&&@[HE#/-VR
M1:=R=GS6=HOS;@\)/)TN0JRTZTHJD(%715V:7GD*?'>#CWB@E\*
MLNP>;39V:0??E_N_,CNS2K-7+>#,C/2J%O!"G*ST#=^K3ZJ3JMD[
M>TL:"(Z/_D]K3OSMW!(^2VTJZZINJO;O9$Q,GWN*,2_9^6_2KB10 >I!-X+O
M6CD8[/!OQ":1MRLB24
M,V5(,/-YI#MLS"Y%&5?N:[X)^U?"+'M$,1WM'D34<7:E;5E=0CGE+4KCG_PB
MOA7;V_<>P16&GVV8:;RM\@A^N%@[LX&<=8954=IQ3P8;/T\G\)4G-+&GNC8[
MQ=:J4V)&C>[\(H-:")50W&-I+6Y"9]&ER'Q3N+4U_UCU&C55^5&*YN3X;C$5
M2#7@=KW)3>SC[77?)7#:-^UDBAJP3'FR_ET9,&:'"U:*+H9F9^L:O(HM6[(E
M8C 2LT4MABU)34_=B-[O)Z>YLL1_KU
MK[ 1V\MY9W]V 6>'M=\E&!Z0>YBWF!QX*E2R;#1]JP%[K;3K+75[X,0CW^T4
M"AP;.G/=[;PN#0>@V]4<='M+65[OQEM!"72[NC?=CK-GCTJWIX)DS$BWMXY.
MMV>UVVET>[LDNOW@-'YG%4!Z)+4J&"9J2Y
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M1\NVK1<$9!JMC=H,;;HF.63HV10V%O:&FJ'[GR0?SU%B_4BXV>_JTO7UN?0D"_!Z<7:.#
M07>%?B;_\)99J&M\D.&$#XZ^[#-8+31,7_%OACNKS0$$ JQMY.FCI^$A(W#^
M$(K<88<*SB)A -WX7P%;0AAG7R"$EO4'BHZK,.2BW^K6'&\X
M)(Z#0H*:X!'4'CL*KI-$)\\UTEK7@7$U?'O,\:"S2\KD>"A-N>2>1RM[SV-^
M[ ;P,_PCR@'"F+N;=DO990H!DPE$>;_RWWA/0VK)-@)#H\MX%_^DP-":"2]'
M3?TG(DA3MD\,$QDT7]P0KNV/A%KI*9W*'9DCP0\:HFQ$%HA]1!]T#]R06502
MYJOZPEX9+.X\?"&; AY?#K9-["<"LL4%+!C](;[2W
MV1+/:'RP[O&M?509:$=P7#DX2* U&+Y/= 6(4KJT FG@.88)WY?84JCNH:CY
M]&E4K8?/D][0<2#.U,?]OJ=G_4)B;4$.@HKZZ$LU'PF==]VYI=>=);47 *K[
M+;77.EGSR12L^'[!V\&;V'3)3@XIH\_/M*\,;,Q;X9OX8O2#6@HC!+5
MA/>/YC8C4.?,,E,;@C)GT)D7>&)!M]067,.-+N7ZL$"">VN@R)$M? 8V+,,'A(>?^8=#:%[\8PO8W684=M='_0WC--+I1I\R19M.9$RCK],^,8-R
M:\X51[)H1A?+-.L=SG"WMRAMH9;V+5;-'\'BV>B@+(PS\,_P(O0T':L &@.E
M@]DXYMR#)-*Y&Y&&DO!U5) MYH4L&920*^:%+#KI( 436W^
M1?.+9L("T+#,PSK!FSJ&,-5MYA]I^N
M%A7ID"V_AO-MT$9K(X*7\=@-.WP*G*0QSHB"+_KY*M;S+#U:]%D6'"";CH4#
M[Q\[S>B8FH@3@;.V--?#&^,3T<;@O@3>)@VS3.#N[\+_U31I-":O%(+0)Q#V
MR?:&\%/B>QM)K$.O?TO[Q*&)S4=.]?Q&W3Z&=RJJ1F&BY3YR.Z4!#ZW)NS\AC%*/[Y"MPPO
M76#GX8<.N/]A, :;_NWQC/9VTB@-V.LY_R3PW-F[D;C:$G'Q^<,3#!8-Z.\P
MM\IB7W1 & T)H\/ISR8+P8SJ[%8AF;"1.+6H'HP,Q3?KAC.UG/"F@A&D@!R:
M-YD/::0CQ&@M,T"9T>K,.E+IYZCJ=L'*U34P;R7U3W&2J^95X^Q-5?/>KBW&+=W_-YC
M)PJ\$,S1:-.-1]?ZN'J+TXUMZDYM8OD#NR=%*L)(\ JDHCVUT.T7]+Z]2SQCV_ %=A,UZJV66N]V-Q=Y9=$[
MEROPD,]+"I 3V,3#QJ_:";$]-K0NDUTL%.P
M2CXY:W7J6';?Y(0G"T822V,B-_@$F[0 ]9"S=5P2R\8&TG<3O T/SUUMG&/T
MVG0O@P34M<$B( 9Q^FY_@M50#LBJY20;6=Y1LM I.^QX)1.[ZZ>L90*NS>U.
MO:TVZTIW\S2(K&2B%+!H^40+)/"VD2$8D,'PS#RPNQB?\>>VTXGM]5HT)#7%
ME))-1\:;'GQSX.F/&$BB]7[HM(#6N93MU?WHV_G5>QA.2 C\=6W1V/"T!>?3+I@Q3QS3K+!*>8R$IGR[\;D!*
M0".2ITVQBF8^?_RCA2%=6/X%K)?2(W04=)X]"..:+ Q*UZT-GVB$>BFPCTGH
M@;\Y4]M 7DTGOULN$UPM#I.2C?^)D&8,R@Q8\6LK#C3M*(!5&Z8?#T5D60H
MJV,I6>8RJ]:/>]Q1HM]IMCM;T?+1;.45-<3L3A?X9FNFPW2I7_YF,ZK \-FH
MLT5/]O3'X]B2X+Q'EXS*8$(TAQ9F:BS^35Z9_/J!\*!M<=!4&,Z3/R.8EMS26D5?QRQL[#L)26-/N%GDD6_
M"(K6E+"LR!BADSV>850?)0O?3@^A>1K6 & 1'$T*>&90@XH4/FG/]+2.C%ME-@3FKZ@55E4Y[^K1:/[8;&"&P.U=#=)T&)Q@\.M;J 4Q4L^\HQ+_VB$HF?D
M*=_P'MP_8CI,2H"AW\DL:G-!Q3F6:9)QSI3D?M)^6;$N*H_N$V: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M.CG&],)7L!XN]5S"+HR5F8H2)79V:G[B*[.HDT%W!3?ETP0OS81\]/M?7+6Z[:XE:QKTD!;Y]]*Q ^YW SI8/@>1P!LGGN4P[CIY3.Y-MM7OQ<3N($=KL:M5..\Z9A-X:#L979RK'=2^<,VWV:S;JR_VD[1>;(E#4YLD,:
MXY*SS"43L6YRVUI-X"E,7R3C7>_DK-/KUGMY\8Z7M5&_, "X(/+>F^T&&,"I!/\:&. SZT( $"X.&3Z--?6N":^^D5>X)QG6Q5A[#
MEY$&M8_:MMUHGB9YTNTC4SKI-;W GWAO\!SRUQGGJYC;AW7R)/NV2H3)S:=E+,I7L
M0J\V3LZ:,A;:+E_HW_H-NR$H$V9! O/D)TE<. EHI5C[#+[&"6%H[K]^"XQF
M $(36K5!B.]3^PR7BREK4D(\D1%Q'-95Y"=7HN9XCK$1K;R@*4X=,2BPS9TF
M#,+O668 ZT3UM<:(A7],6._02#*)*\')=&H!R(U-GN"W^!3\^)T$VC-<]>*L
M//J$N# )7:U!L<8HYN8IQSUAV53MR7[F(X!0E (+?FY:KO\H]&Z"O07A HE9+-1X)VUQ,M6%*/WZ;\,%Z,8*0^WL
M--.E+Y%$$X0#0LP: \@(TNAALUE>9DHI?%.
M8@101"(0(5*D9=IU*NBGT8CU](:;B&@\]]C2B05P])PXJSOV6CC+++M1I"U9B<8A/T<>*TC=LB( 4A114F1GQC2"ZI3#X4A@.Q#!ME^C^4&G(S6]H!0
M$0LXG8Z-(9NG^KH%NI$JX_!A+LS3&VJXJ=F2?]A$?'LOQ"NKB'\;H/*00-CF
MG(BU8%9-EJO3U\)E4ZM&2M%RQ2LW\P8\468?WK^Y!M?SK<3NVE1! W44IW&N
M8TENS9;9)6PBF=#L[79]")-L[N'08R?(R*AN"+LMUM;<,W5G^3M'R,/9-
MGC?C-:QU@ @PL>MX#*Y66Z[+[5Z]T6
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MAKW;?0H/UW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MJQZ^K?>LE>V>[0M\K4!0F&]FI,97)R/"D'7@\%%(?M&Q8"XB*R*LA-M@1@VP1)C6O9&)E/+UNQ930]3&"&0G.&0 >)CLJ(?&- W!?B8Y-%$H T+C>?
MT3#4;)M-8?"!EN9##_ KXSDXX0Z(, _!$N9)F&^FY\ ]47ME,;6^J8>?G,.^
M&+&>@W0 ,;N^-6[EU#G3:J$8.@%&E$LK<:-UZ?&Y=G%(J$C<*>1NE'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M(XAZH!T.LMJHM]2MG=)9+.8C9FK.,?%WR3R:-2 ?G9:<(\C'XG %<\'Y8NG)P/%R:B_&>(SA,1S4
MKM&B+99IP_0:RR8-R-AZJ; D-F>PTNB='P=G""R&"4W*A!E#NTFM K,;@S X
M"Z[':0C:/_61*T6J!>QSR #\=BDC5LK\12M%8LGOJ/#'R2XISF0&JK?-+5F@
M;%'B2'8GR>#R(N-M(+-ASGH_ 9X4^90,9+';:&"]=K?7J'?5S=?E/<7&R@^N
ML*9*5"M")^Y:*?($66R=<'(84##OS\_D'N6XT*Y'X-R+U<@=QG
M(>=IZ\]#O(9[P_D^GW6RMZX'2R-R.G.&*E_B9WWNTM]SU2\.QYCAT"#0U5K ;M0@^B3_:NH"MR+VEA,]]
MOT^$P77:M+W$I0 M-;8!FZ'HY[(SM1R#;2(\+]A7^+[GT :2*.[+DT%L!*"?
M,0)L,AJ3HM"Y]OTI/F!"TBV4UT9M>*? 5W,85QM;U-IH_+8+7>L(K C%L[C^?Y]@7!_[6U;>AN#9
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M8/DH;J]:UIU:SYR?VUQ/:0Y5/"NB#P'H9"00<357JZNB$.V\HA /\2(M^'?0",Y 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M>'@R<=T)ZR43<>WN+*X[['(E!PR"?#=\B$SDH)?MIW.X]U,H@V_*-(OIO^^2A"5(7U0)8@.?<%5@NAP$D1)@X+T6V1E
M5+!DT>7$_M#J:2G'&7GO[-];D7'<>[VS'7#W8;$HL?BV*O&-B^_>$T>R4ICX
M'GK>*+<>Z,[>MB=S*^5P5!V.S22N?6R9]-88\$&AOSPHW\4$H$1A-(>M=79LFU'K7'_R=X- S
M.?A8KU/O((9;@A$-![3S^[^O=7+?^:(YP8#OS;C*K7
M7)(;V297=E)3JTL02YH8*L_>=;>N/=J!]C+IGOU?HU1$[FRIX%/E-=VZC#N_
M_WWOYK[OY7&T[SY?%6(,Q,AT)U:*6Q<7[MN@'-C^%UGI<6#UGMW]QS$8)+7<
M 1U60L-6;N[MO?Q1:>3.O5VN1+E4XRY!S!^13EXOCCL-Y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M.2=REFKT#12=S/$&?Y*AB]0$2V"O=5QX& Y!J$M&/\YL4 O6RBV],5+6%L?+7@L G%=&#:\V@+91QAB"^YY"(T(M&.BRJ#*GX[@
MHSL(*P*M:CA/['5X4A!B#;5SH"L67[1(X\@&6_-BV=_%/D7&V?E<,L#("'U\
M(DL!>31PZC7%[QMJSA/E,OT7 L(/QH.:EBM=KC0?( \1\Z/A.?N+P\DV#<\2ZAP"\9&PX&@_K,M>D*P2!"^1L4)T:WAI.-!
MFVHV".G"J^ E4QL4.-83LDG>X"+Q'^[+K#0Q3&-B_.U;R^CSX*6K-V,P U>+
MP:/#8NBN6.88E 29>JQI*&Y #=>C8(GOV 0&[D"1',M(DHU1V0G 5\8VTLO*^DGA>1T8(RSZYB7(;IMB:^&*N8GWU&B4,\1GT'" ;\U
MQ'T>$(GJ3=#A$T)MB[4M[Q$-4J\>O;4-KM_60XZ"/"77X\JW.]MXD&-R('_.DA82\P\9).7<4!(69 3LT(@0!]UP$Y!F89
M/N#[G]H0:*%&VN2G^%:]%,E :XI('!]FQ< C7&EC_M)_*@
M" )P#O0V6.:!&]!=F'!D!?)[06 OQD2_,EGX!D2^/X#+:6+$7Z71P-%H
M^04DK#$;-.)C_X)/A9<%\( 8IKL?3O !?^G-11NZWO(A!DT0AU^ADJN-P*A6
M ,#'T=]]'EP'^A-TZX^G"_@\MC\1]03,J4VW7I*O/B/'E[ ?O#^F5'7V#&56W_Z5-IC^@$;?1F$<:__+J$\VN
MN"3229I'G4GFI??)LC;MD[-F#UBOBHBL>\C,Q3&Y/+9^ ]?688$P':T'-1[)
M>-VI>%T KU-D8G/@M5KQ.A->)ZZ0;08D;/N_.4$N[+&FC\+"Z
M)5,3W>1JHBK=*0_KM",G(-?$%[[E:*M(1/=FVO")^PFU>"%B+I(TP]#A"I8 9%HU;]4=3=/ E#]TX
M%V?]#36/U5JQ$BB'#7#'<:CQ(JB%4@O,()GQG$WP]=,!T6B]'2O1P"1.%! *
M(V58]$C3V#3/9)A#:T)8.=*4P,OPQY'5^"566$SE&ICKDG!0ZI30::EMI(LL$R#HE[PZ-=%E/5C4T+-M8@[7Y9=1W&M4W!TI&WFG.6>4*Q A:P(_Q G)
M1DB,0?Q!QKHQ&F%]+J9$*5W$F;(ZIMK(,ZD%Q9N1OP2AY:S/2>+585N3N[I*
M8O?FCM@89-<>R>WHGF@.[.)@/+NS' M=:8@"7%?1\;^A24WYY^A$-#*$3.H_:S-SQ0MLWZQO+&.;/;&=":>)OUC[0:D
MZ 7%#;@RAS:LFUP0]L\K\\ZV1H9[:U_#)EQXY,%:O2\7!-4NBBSN$&IDRX3=
M3.8**B=GW7JW(R_MD&2 9O>+6 FKN6/5!_!\FSP1T\'J/?QX7O<6+M)NGZ3UAMZ/0Q:7U/II:-A@A$U;#T5ME=ZWIM2?VL98DMM^G4"T@,B TXXU(7#NP MFVK6VX8;52W<"<6>'MD%52__1
M)K12[';4#]_[]0GL _]^Y?A_BIXK;)MJUY66LGRPL)X'Z&:_8B7K[I-AZZ=^
MW:MEHK8!YT9H^[&>LZBQD+/4D0OVO:8%&T_K?]A?!H26J\=D8+T14GHIM7#6
M,@"W.J6];'L"SG-&K++*_""\ZA@Z=7]A@>#1K#<\J18]5WO]X5^>X=!EZF!)
M(M/(:;#W/$K,@]]>8Q,]F8T!I=C&^3ZM)QP"L'4#8M^.F(!>4;696$P[H*J4NBIS? "\,X$-!?)KCFL-O],'.=(;K/M3
M8$\'9_=?OP5%@&B+Z!_D'][27H%0D3'/ 8XPF4S'UHR0A>X2O$N"I_\"E\A@
MM\"1M1>S;((C>%VTFM0/_/+H!N&(,5['+#"R;&9Z:KWXLUF0UT!R#WIC6N4U*3XDJ
MRG/Z("9L'_'W]Z@8XE*EGIRI[WKJ!WDQU"3T?D<<,) OK.^1" M@+#HM&X[[
M3HW=.QUW1.-J\K5Q(!IHA1YM]/BGMC4D1'>2&*"4>8[/^*([_SW)#$KOY*S3
M4.L-GG'U3+!3E"&?KF_/"^C)R:\#9^M^&^4'Z99Z+\X'<"D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MZ:V=_;+8/5"RIR+%7C1C+J=FF+MZUCV1R->YH+=+41UR9U80@34!H^TD6]:4CDC::A2-V[678CVFVZO-A#%$^8N
MERA,%=V:_@9]\O-8A4A4;X_T)L2T\/4,3F/
MIO*8EX(\*\8N*,T\Z=E$D,(AB./(Q@,MMYY+$7S B'-B++L:#,YE2.$XM9]H
M)#0''O4X[^>XM(NIZ@?6,NXST'1M8\#@4#[.;E],8J=@WX84'T^X.8[O_@GE
M23W7,=XSH3+GIJGTE@EE-0DIC^3VTM?DA"9R)($G5TVYV%W@7?DY<8A5VO+A
M27-_,\;CC^2>#,>:XQ@C@^@/5K28Y(: %_6@O6;M[_(8R E7E)!TWCEMM&4GGV+$FQV@4:,>X)''L2)$DJ1R2.!8C+].J\,X&SQ!@T.YVE)*,]30T>=J-
MH^-SI8%ST%J\^'.>-'#$L\71\GG2P+NSM#AJOFAY:,5<\J^8\&=QY L*F,I*
MW^C]!3]&[)[@^#Y8. V-_ON3-=93^2B;3A%7>EJEII@G:^U24\R3BDY:BB\M
M>]?P5AJ94$M,+T\BNB6FERMT99+3##/F6ESC%>.UR2>5+8Y=XT\2>#)&>?.D.=]E<>(55G0M&>F\\\JY2Y21=$[ROLVYAN1U#>*^GW,%R>O]+8[4=ME#(3S!.)U+<@\,=VSYRFD8G4MZ!"*.8)1>I;4!$4-SF6M9,\%?+IE=A#PR'S
M9'5ZC99&&I+G0HJDE"<%R9,A15+*TPFI[SP@KUB'3$UZ\+=SRTE1P+"])*BI
MC5MA5'.D0DUMX0JCFB,A:FHS!U3O7".11D^HN]BY_"GF2<8N=BY_BGE2L8N=
MBQ<6Y5%^S9.*7:)]^5/,DXI=XGWY4\R3BETB?G[+*':,7KMZT)%:B&CL8@0+
M(ILC']U=K.#^=KN;P@Q^P^Y,I/KJ[M-E,(M. ;BE>3N.74SL(^Y$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M# :W;^J8')HBQ>>AV]EW6+L=\+<_1$PH-D2A&)TFM@W_>AP!<^'58&?[CTWQ8=3&MN3+'7(A$/@_*8YG\3.0C#7D;S,I'R[;I4$XG
M*LUA>"P_:KF2S+$T]V3J^PBWHX^6J3LTE@[M7,SP1!D<:_(#94;G[!:FFM1\R4I#4LS\W! WH.J>#(GQ3'2D#C.]1=G#>(-[
MP03Q=DCAV)-%3Q140U[Y"C[.![]7LBB:.CPP*86C^>/NS#<33-78 /@ ] '
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MOG.VFW'XL%ENKCP@S%+"42\T"[
MX1D:7E/^.D/SR70-=^;M#9Z#Q,,&*)Q@/B8[]V;8BE==I:)T)64!@'::<@VYQ35742AY^K^Q0B^_HCM[
M2! ^A:U4%,:*U?*Q WQRVXG(=7CTWMEDA$CI>MA.X1MI/0__3^&:L3BPP*+_
MXN/"3(D)N_I1&^,*"J0MGIB9X)C5B&^UBJJL &,4GGF- P4LSP!8*9,MMX]+ZKK+4/[BN GOB:?HVQS+E"E&T>:=Y(*UM 0 L0$[?FO-42M:Y$JY(<2Y#NU"0XO+/ P3XAMFT0+!):*/XK)D/ @ ,I2E<+K\8])O7^-_MMYF Y(A;2B]=2\ZJOXXT\;,4C(^9BP?M]=-H1(9@<,<[EHBDV+4.QP[$XK;A
M3;M/YQDOWV*CY:W%D!P/I%EH2+TAK6)EE8C7EF;F5^?&)2E^#0G<9F;T/UK6
M=ZP#3MO"N[V =;C&@=8H@[ QZ<)TIV%BBNIVZD^ZRR-UQB6/8RCR(F^C<>5=
M-3H<,W(1"MD#F4PM6[-G%W0\,I9UT@C9DS%\NK$N")L5"$NA)^8*LZ86W$N=
M5 -*-I#/CMX1<;3%3:O%A'=Y-6.=>%HNGBR;W*
M,0E%T\63>Y5C"XJFBROW'!-0-%U&HNGBGL?]ZWN5*_?[
MU_<(49Z6;DR+0_.
MP\7N=&!]8DN@<;HVV-KZ"B^7K+V3&J*?#6.6&HIZ<-1H-
MN==M-SKAM/LP4Y3\57VXF^IX/[T<:X_Q5W1/SD;:V"'+>:@MGG]A#6EHX]+
M$;,LNW\)GSGQ=_5.SB[_X"6\\"/&L?"]-@FN.V<_C@WS^PM;!HY&4Q.<3QSH]F4W[U2+M&_NK,IT.;0&=8G[QFO(H^M#DB.ZTX_O'__\O+R[G5@C]]9]N-[I=%HOC=,C+P.D?/X!^.#OQ_!#]E:86/8
M5562_*\1RNM*_+^*67'POMA*;9[H;GD#':O==J _R\'#YG_3?(?'UF+'ORH?=IHGC;E^9O9
M7Z+4A&]&%L?V;/T6ROO8POG6D$>4YMS.B)[NLZ")4#:IC]"T[-[;\:SLD9?N>CYQ@F?(HQ!] ;[$&,JJ7GG_ETO5\@
M[. 8K@C(\$B_"[:.$,M"!.OVC 6\1*D0M]B+X2Q9[T19M+UKY[45';&4"Q^/1L@W4)_=D#/]%89KQ6A=JE)NA-OPZM4S'
MLC>J@^R403&2K%;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M!P\^RK,_9Z_4"7'EX.,\I0COE8WMS8./\I0DO%M$=XK'=\//CA4BO!>C@6AS8,/#Y4@O)'#R"4I^R.5,%M(UIE"-#FR< JH'6D_>950*N(@%;9V-ZJ EK'>=Y;54!KOP&MT@E$%= Z3KY7
M 2W!.]1;54!+:'R/5A70$OT$5@&M?0:T\N1L%= 2G(&"![0B0Q6OS&?B3R>Z
M,K]Z \?0#N7EUZ V$0/,BUI3#,'!2&CX8U
M(?K5U;EE3ZLK#X4&%#SHM9T8W)"7H>79;G\(^M\QT$@G$(4CT@IMT4-A =AJ
MB.,>&:T60=W5G*>^2<'MBQX!2\9].GKQG@R)0<=R5^%/QGS1@V?)F#_W$ZY,_Y)PK0V#8Q$#T6-P
MR<2@/Z0C79P[;88Z -P!^,3VB#Z?_%+YA:%,B![52R83%[ ]SYIK/!,_3!N9
M E252?BB('H8,.$5P0(S8=,QJS>62P)!F%6N8B '@D<3DZH$CSQ8-^?]\V2@
M[,?"?,&CA]LPW_<1/]N6-[TRAY53$([2$#QV>.Y-O#&U]FSL?9_NYNWHR@2#
MKXW[4WP$S>0M)>'-H4TTAUP0_Y\H)^AM9U>7]U^=Y*_=)&K9R5DQ$ $=T:.+J07F=DHPH_A1&^.0P/[()79?_]-CU]#L
M!")3W5.03(@>;ZR4"$=@HCQ6)9*G3(@>N:R4"-?C+1N@94?TT.A1
MZ9YRBY)X\&^X?Z=*.Q<%+F10D262GXGMD ?M.['@WVCY)QOYCN-\<9I??+;?
MWC (=!>[^C"
MMSN5Q\);(6-KI>%M0>.+10]V!6F3.]N"/7!G=W =MN"R$7]B/$&07>:(?D&F-AD:[#HXL6S7<-B_
MF_K59*H9-N6WJ7^V+<=9>,J"%'"^DO0F>,@"6FIT/U7TF%HEUR50O#GB,ZFB
M!^,J 2V%XBV=)R]ZK64EUR50O'G>8H0,UA8KH*N>:NK1!R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M4FI>\0'!@[>K==A7 BO6(THL@>^2FPG*ZPSTA ]D[M4'%V1\!0A0]U1IY")
MPL<'*P%*:'>Z:9*&4;G+TN[T1 _R[5?NMKO*^]!R^S2 N>DOT0.+I;P%%<2[
M*H!8P TVRKW]JWW!@VWE9'DQ\?Z>X.&N'K;BLOK12J0_!BV*PC
MY3DX:;W39CY.VGX"A#OKT>A^)'9[HC_*4H_*#8S3"2K\HJ6-2RX)LKB2P"U9
M^&BYKC5)6+5026 ))% Y, FLBF;$D;VFN+(GNB24ZF8I-UJ5).Q%$LK6/B8W
MVI4D[$42R@90*CDWTQHXQ*8#&Z_,J1>=TT+3^7>V
M,02?4W,\F^";Z)<.,,DJ-[J'R<5/KU."$UDOC&>D0/_#(&-]2X:*Q\S>H3*3
MV$/#27DJA6.C+'!(<14;HU,&7&(3Q[W7W&/@IM\X'\R< DJ3'4QK]:.'D!)U->6G90UGCX/I L<.AJPQDU[-E%&CTK(A<%#CL)
M=Q_)[58I"QPR6L=%K" )II#8ZJ- Y#!;=DI'C<%#OML-ISG%MNK.YM,M1F^
MK%0^;7YMZ/6*F1][#S ,5/*07GZ\%#@:%*)=71JF!I<1;;R4RD2->^<-X%')
MR]9SX6&.5>NR(G#()RD/;>,9SN.VO0=;TK*B2YJZTX128#P'-%P;V@!5O[&Y
M6UH\@1(X^I2G4CA@<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M_=QL]GY^_^OO?^G7-\I_9C?]SW_=OF_V;O_UNSPSFI8Q^O/;=_7?'\][Y]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MEL#!7)'*I)MY*@2!8Z5BE4GGR<6VP,'(TI_$M_-+U1[0%CO0(P/R"+MEM@>,F";B89J3CT1Q@@>,KI6=]4<=7X(+,U9,\OYE
ME6<3/3*;X\ZV)H;C6/8,D3F3-3EM*5,;)M3.OPD?$S-!&#VO^%PT#I.M. E<
M?UF)4\&!O>B/LC5, @?V*BE,*87M-%+8SE,*!0Y-BB:%%'#[O'^>:&RW@'FO
MCL !TDJ6#L*H=@0.U%8B>! 6M2-PN+@2P7+=5#L"1Y]%E*6[SU=[%*/H$/1L
MQ4C@\'M;*O$8C_*5HE5.8.#EKZX$E-R"Y%50?^#%J-RUT)TJF#_L84FMJ=P72U7@8']I65Z0(Z164?*\,1C*[8NH H>V13B\>=9CJ@+'DT7@79Y%&JK
MT=C2\J[DJE;@R*D8+"]=SYHJ<+ARN>NA#_\=P[BZOCW?9R%Q]U3I;LWKZ(^R
MY;7 ,<7-O/[MR7#)-?SL /M:5('C<>4_I>4RPEV!XV7EXW5!![1[X!&F.V=&
MS"&YU@;.M:MO8&!>,:9&Q#!FRSV!8TSAD:/@=N?:U'#AU"TTL]S:.AQ(>Q8
MX!4562J*?\6'B$J[%<5'7':UO['-2%S T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M[-UQB-/1A,CW?;<[!F$Z_,!X66S,E-W%%)U-.'Q
M'FMWX*)T-#'QO9NX Q>D0XB#EQS)
M(5?^'4+0N>3\RQ$T4I%%#O:6<$Q ,>/C%%GDH&H2X,>A-MR'JM[.')L.FGL[[^;#B6O;?.R%RY*'+(, $7[Q]N'\#1=+2ANQF:43SN'4)H+NZ2
M[.:P".BR* *'PAYF4^1@'YZO&V//-9[)TN5S_NVD@;"\N)CGQ4$1.!@E%A=S
M/8L'%0=:Q#Z]+P\A%",0+W/5KH<0EBD[+TL-
MMJ4H(D=V;$)1=G WYFSO>X^>MB!S/V=[XE#-'OX!.[-!7DF
M8VN*7\!:)]-)$L_)R\$IVR0DI2EP'&CUH$E_<$,?/!U;&QO:G3O;/, AKZ/<
MI,.-\CG*38$#0*O9=_^3GT=FAYR<6]?7F^>G',N=I"EPN*B\/"_(]C8%C@^5
MEWDEM[$"QY$^$^O1UJ9/QE ;]\%K]GVLH>69KCW[<-ZO%++2%#A(5$+^EN_\
M"AQ9>B"3J65K]NS"&(V(C5[Q-]-SB/Z@O5Y;>)6"*U+X"=R+=6,Y^79N3::>
M2^Q/?WD&O4@=7!BJ*7 8ZH!8G&=FKBEM$[$Y3SK((HRF<.&T2K"$T%@M@6-S.W ;+Y24SP<8>F\)'*\3F*6YGE*!PW$[
MW_X*E: ;R_3#3.S+YYIM&T2_M.P7S=Y7=#]7;2%PL+ 2K7)KK<.-2?:_5:*U
M5ZUUN.'02K3VK+6$B\322EO@-[#OCJXZTNJGO2(D@M)HM1*R2L30?E%*1[@
M;GDE8[.6$THRA(O[)I*,=J4S=I8,X0*W:R3CRM3)R# -E["_5.*QJWBTA0N_
MEEP\#LNNM 4.Y1[7.3[< .V!G2B!PYU)4$&NS&?BN/B:*].O4+_6!DZ2RO04
M%%UCWP,V2FB&_:LV]LA/L&[LB9@M)E7I-V7>-P\P.M46./ IO) IQR)D H=
MA1>RYK$(F7#!T&*%3"A>"AN^I V9MR,?.>+6OC<>G]Q()YXW@ M+:'7AC9 */N8./DT1/Y6 EUU-%Z7L$'82KXKAR^!? L;2J[DN_(U-\MW1]A8
M^,'+MU!B)'#,O/+L^"P5.+I>*7L^2X6+PR=5]K;Q/)\"D[AGJ%3J_FB45IYU
MA!WAD@"5A!_>A317"1ME7LY2OD^&E>WRKTMYB)5E:/)ES"!4T%B2]BQN'JJ<)FI0Y&PHW&VA,L,%2AA0C%2N 3(]L/=OTXM
MT[$V@^I5+DYF4B5MFPM!0[S5LJ6S]+CB*OVAQ2:R[G39MI@3/JF#I_8'M&W22WGQ-X\6X:Z(D=;]\/>
M[8C\HKF>#7NZJ$3 IE]K+K$?GC3SUB0(#KLG[4'%JY&3>(D<=A59O!9E"TB*
M2MS#DTWHYYO($D^A"1R2/7)=(7#8LSJ&B\P\A!CCUR?-)OZ@CJ6!AK8.9L&>
MT>]L5.XIJ+BQ3$W_TW-MCC9TX?'[]&!;IW([%TGK"1QMK'B/M*'V835'K]6$G=&/LN<8S
MN0(NVMZ$4KU X3V!/QE#E^B4O&^FL;D4/$?!4_,1/(%CE,(K%^"C[5Z K^1S
M&?]_^.#P;]+BOA%37_&CX"_9B(; L:3]=WYX?FD/:.X0X9@G8%3N4
M+52]\^M@XD,9Y7*Z0^F!N8FSV*&.^$GX:O^+$Z(YGDW.? KIEX)G!G^;OP4?
MN_H5GJ.?G/$?;SA62Y'5#]^^7BP]78JN8^,;0"U'EC)_DVX\@X@M< .?< /V
MV=9<*V#SMK3%9&/A@4LONR"F-0';P/ZZXH5K]YK[RH7'1F4A7'?2/9S":S:(
M 7Z%NQ7)WC#4-LK!>7\G.="\C6_H?TOTAO?&ZP=@@^790^*P_WPBFDZ5 GP5
M=OM !E83 R-#8V,C,P,65X,3(M,5]PV:6V_;.!;'WPWX.Q &
M=I RL5I,P]Q)H!B*U,//(GAJ(/VD98HFQM*U)"4'>^GWW-(V98O;=U=)]EN
MW8?&$F_G4.?'_R&EZP_AG[V;>NWZ0^!WX"_!?]=A-^P%-]=G[B^4GI7%U[MG<_D,?S<"WYK)#(S5Z1YGAL2\I1IF>)) QI"T_[WMFN1
ME*H1SZX(5CUO$<.>S0D5? 2W%!^-3>/F^O8F>![S(3>D>7':O#Z[!;/[+SC@
M+]E0YZT7&B-BF6'*>M4.!F'WKMOVP^[#/7FX(_U!][[=[?L]$GP*VA_#[E\!
MW(8:P:!>ZW\M/FM>=MROUS'%?R1^YZ$?!AU2F0;R&+3MU+T[OW@=.^ 9A1\"\N@/;OW[X/'D
MX5,O^&SG!THNSE_%C!>-SG\6VO!DUKCI>M">"_(G54P_S3P87F$),6-JKEYZ
M]#4?0_\6HJ\=]'I]O]/IWO_^6^.\8:\?^WY[?OT?6G)B9&ZM6=P82F-D6MZ;
M\MB,L;_S?T (A(/Y,!.W0RQ><00G%Y<\6VT@6(*KW=T#
M!'?%EY.$IES,KK[EC:VK^;^8<[YQTSR]/L/.<)'OW%1LV&KE_L;MUFMC.F%$
ML0EG4Q9#R'!-:)855,#-7"I#9$;NI$J!F9,[(A/2US.618S<5]$Q\
MVJIZ@!H5#O WAL/-'J+O$&A[>> 7NP3:O@>]I9K%]1H$4CHC3YF<"A:/F.>"
MK8RR6$*7F30D@M:49Q"$,U)D1A6,:$,-2V%-Q?"C\$1@<>40=@F-X)8B,H5\
MPTA7;Z-"QB*F-54SK)+2)U:OF7&E4PTW8[ &QA285. @6"'B*BI2J ;!KL&4
MF"DR'?-H3'2!_RW;3YEB92?H09@FXS!3X@6
MG);AK#H1NV*T_KSBNPWOUO@<5(PC.(7*1@&:D>4!43"<6J4LZS!-9W
M:CCTP[-(%#$( =!0B4H/4.)*S$@.P8P@(J!"+$DK8UP[MI9] \TQQYX]K%((
MH 7PDL" '4];@R*JQR01(?DR(
MWK\%1.$8%&$9<+\H_7!#'/.A8!B?
MA %M0\'U&%M@M13$# 4-KV.N(R%U >U0YI04#H!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MPXH@J]">Q0<9_5EP'NZ.\QQ"!]3.M Z6XA4/ZJ$+B7(X*<'(ZY(*;&6:=V\;%E<%"8WEP3*]4K>P!K?8_EQ[EAM2&W3Y"B2*K86V-W@B&60_ HQJ]>@B.5(/-:!O:YC#U8&GH/ZM@[8_;]C%[V%
MB@83*@H4&LLO]:I,,[2*>[W+XEL[Q"0U ][39^0UD8' QD
M:YL)NZ@[7=1FN*]-MIROD-7C%3+$+3.>:=HUB+FY (-:@&,6'P3O)R$O?I/\
MU84TDK<&!VZBRNV7+=E*X'<()J:D,HH*A01LIG^K9X]L[<#?MAY3O4AJ(86D
M%E$6VXS:VETJ[(P(_L1$>;BZ5M_;U15(#K[@2XL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MNP>M!'8+9%G%3)U$4@B::W@V\U\-^V$GQ'WY@6MZ[U?JV7
MJW&Q9GLYPW/3;P6-GIP#Q)ZFOZC%9_ILY;.[%W7GO0+NO7:+LU_
M_?>(M\><)21X9E&!9TGDP>7W5H\[96;L%H ]#7C4=V>UL)!MC'J,(ZU-W NN
M9WOO\ R_+'>?FN,7Z?\&4$L#!!0 ( !>*V5J9RB:.K0< +(N =
M96$P,C0V-C(S,#%E>#$R+3)?<'-Y96YC92YH=&WMFM]SVK@6Q]^9X7_0,+,[
MR8Q)0MK28:P?_V>(QDPA+9T;VBVM^0A
M8%D_SA'GH^^1[*MWX>_]ZWKMZEW@=^&3X-]5V O[P?75J?N$NZ?E[:N;^^Y'
M\A!^[ >_-!*9F4O2.LL-"7G*-+EC,S*4*W:)*5J
MS+-+@E7/VL2P)].D@H^A2/'QQ#2NKVZN@Z<)'W%#6NG-V#V8(\#_IR-
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MQLBT+)OQV$RPO[.?(!3"X6*8*MP57O]AZ"O.)+,Z$I%_/++WECZVK^)W/.-ZY;)U>GV!DN]MWKB@W['+17KTWH
ME!'%IIS-6 SQPC6A6590 86Y5(;(C-Q*E0(XS5LB$S+0M37S2KIJ/0A4.\3O&PG4U]#;=<5;]C6 \Q-V+A,#Y:\3=#=4LKM<@M-(Y>M3+!XS#P7?F7M"(H4D2FD(4:Z>L\J9"QB6E,UQRHI?63UFIE4.M50&(,U,*; 7 ,'P0H15U&1
M0C4(?PVFQ$R1V81'$Z(+_+=J/V.*E9V@!RG7@M&89V,(%#,!#W7.(FLA]IN#
M;3(&/R%:<%I&\^I$',#Z/L%Z\\\"BY&$9Q"Y2,$J4CV@*B82;JO*?9XEL.)3
MPZ$?GD6BB$$:@(9*5'J $E=B3G((9@01 15B15H9X]JQM>H;:(XY]NQAE4(
M+8"7! ;L>-H:%%$](8F0,[U@3[$QUT91&(EBH3,M]C4@"B>@"*N ^UGI/PK9UB4F96J-B[E,$@Z71_K81F./4,5LX$,<\Y%@&)^$
M 6TCP?4$6V"U%,0,!0VO8ZXC(74![5#FE!0.@%S)B,50#/P<0<#'# AR41T\
M11.:C1GQ04&&A0#76F]HLW5QQ)P9K8O87;E+CAN2S)&' Q"4F0J0#A TYC,#
MU6MK(R5K(\$5.FHE4J8YZC3>QMT"\JGLW ODR3A]EA1 M02;)C$\S21@S <$.5>9\L%'0 LC/EVHH9U&(9]H."
M1\U*"*MBJIB@%K4R\ULM,EXIM'B3@R:",5H*'E-C+1UI'G.J.'K 77YJY3W#
MG@I-(&6TJY.V":;5/JG!%-!"$%MLE5.,N4)0%&UPS%JQ2CZAB4MEJRDX?!LQ
MK BR"NU9?)#1'P7GT>XX+R!T0.TL-QZDJ>LL[JY4.R,)&$]YC*!1+3.*FDPU
M4(I;.*2/*B3.Y:@ )ZJ!R
MU#9-CB*I8FN!W0V.60;)KQ#S>@UNL1R)QSJPUW7LPMT6!*18%"XSA@20(;-SZ%L-1;]E_+='@'Z727V[=DEE=H"*JGW<9O) N#@X%L
M;3-A%W6GR]H,][7)EO,5LGZ\0D:X9<933KL&,3<78% ;<,SB@^#](.3%KY*_
MNI!&\C;@P$U4N?VR=[82^!6"B2FIC*)"(0'/T[_ULT>V\0C MIY0O4QJ(86D
M%E$6VXS:VETJ[)P(_LA$>;BZ4=_;U15(#C[A2YLCW,NOJ_C'/ML+%XP
MZJVD J4KE=I 5.(#WXIJH.9\ 4LT9I$#/]\(+LVCL!DT4NEETFD+\(0EY<8P
M]AEE'DG(:_%^S,% V\D14 JL:Q1:^,0MZ3+Q97\4'!Q 1Y(BB^PQ[/'AY.9'
M4;Y7.;GQ!7" VS<.S.&I/AX\1IP!(67>N#Q F3'ZB'F@VSW93-!N_.R#OL5S
M@QVXJ\BA.^IPI[4+V:K75KI%8VBIV5*V/LEHN5V$)@ :[.H\EXUJ\%P7*406
MN&R]*95TZS.6@Z+]2+A]QSZ92
M3!GF>AD=EP_952F6+,V%G#.X.YM()X^45"D&ZG9)6.NU+R%ZLB,/+Q_]U6C?
MI.&K!ZT$=AMD6<5,-2,I!,TU_#:+;PW[OB?$??G>9R4HMA)0]OHOI&7A1]A]
MWKBL]W:CGIW,3XZ8TQC/Q): MDXN$-&MACR+LQ?<&D%87CJC?RLR1LXO/')^
M=GZQ'A<;MIZ_E
MVN+;_XY\9\)90FZ7B\V]R_?=&O!"8QP-W'$M=!\\L:C 0ZS%0,M>_$.3_&=<_<2.KZK_A=02P,$% @ %XK96EF$2E@Y! -10 !T !E
M83 R-#8V,C,P,65X,3,M,5]PU8;6_B.!#^7JG_881T52OQ
MWG9U6UBD0,*6$PN(I+KK1S=QP+>)G;6=;;E??^.\4-JR.O4*5'NZJA+!'L\S
M,WF>F9#NM?=EW#L^ZEX[EHV?8/ZZWL@;.[UN(__$W4:QW>U/[5MPO=NQ\ZD2
M"JZOH-5,-'@LI@HF]![F(B:\FB]4P:62A14\B$=GKSW7@9C(!>-78$R;'=#T
M0==(Q!:X)-EBJ2N];K_G/"S9'=/0.J^WNHT^ACW;!Z!/N::RTCOA=RKI[!D$
MTQHXH 8
MF^6"94]GGF,_">Q).!^;'V Z!._:.3YRK7G?FCAN;?K'V+D%:^#A5F[6;C;;
M/_M=BVBHBQ7& VH\-NN7C%=Z(PZ^X)SZF@D.]TPO02\I6)RG)#H^FM-$2 TB
MA)E:4>Y3Z#,1TX#Y)(*Q#NIP:LQ/HN!;*CISNF!*2\+UB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M&\;9BQCV">HM::G;*H1I%*U0X7$2&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M22'6?74%R_=%RC4*X)W:PLX=-LQKO_P]H'E=^#=02P,$% @ %XK96ICI
M>+:O P M P !T !E83 R-#8V,C,P,65X,C,M,5]PM6V_:2!1^1^(_'"$U2B5N=D(2"D$"8U)6YB)P=M6GU6"/\51FALZ,F["_OF=L
M:"!)JS8E63_8M;]+_!'/_D^=>ER+!]0>PZFL-/EM1!6-Z!S.Q(KR<+Y1A3B6+2LB(K-,=GZ;W
MND(2MN0?0+)EK%OPJZ):L")RR9#1D-9+G7:OX][';,$TV&=5JUWKH=K31X O
MEG["%VK=^A.!S]CZV(+AZ ;F,^>Z1._MLXKU;[UN53^OER7H>OYUJ?06]NQK
M&5"NJ=R%9"&2\#>0*EJL,[3O"PNAM5AE:Z6.,QG/W;$/DP$,QWUWZN(+IS/W
M9CCWW9G;A^EMSQLZT'6W8'XYOBH7!<#8ZF@\.(_(Y59I%FV,$^BM]G\H!((K]"YH 3JFP'B0I(H)CJ-LHM@:0ATT*>2/4E%2T%,J.%D&@:PE\IIV WRLAA-W K(9KQY0[.H(N$Y:01XX0'
M#-&4QH45JJ4,QE1M* \H])A8(9FGPVJQ<&K83Y+00#IBM29\M#K(_P3F4_H"Z%HII8SI10#2,B QB.+.VJA,>FL%Y-C R,UMH6"S\1#BZ$W6&
MTT0H]3[CQ/E:TIBBAE_IX7X9@ICP)484?:]B@F28Z52JK6>!?DF9WL!I2",6
M,+T52%0,42+N5+$0"0F4H-9;LS>42+6+I(XES9=@C?DA0J \1(T/[Y^6=
MN6=EXXV()4AXQW2<2;KES)@Z-Z8J3+8@E>@X'!HF]SZWHEC L*R8,LE4_;]J
MY7'*_TE7?]H3[;?NB2\66%,U&(VGX'G35U/S2$(=3'QL]IA?4RDBFN4/%FM"$3*-3&%U>[-$-%C>"PH0YMG@N.BZ'O]OMX>EV7ZJ5L/I]VG=W\ /3J*$=K"QM&J&-C0_T=EH<_VT>I*/8?
MS:!:\)5*S0*2["H5I?Z@SHT]_1^)V<)=U-\]=]8]>/9 ]Z>:9Q>X[\6RN[O!
M2Y_?P7TS) NZ(1Y?+*38Q?%8T. 2I3&Z>,!0L)KU.@8\SU"8C,LP:CA@_]TT
M"N(-O-_9B\+CX.4H>:/=C\XSM\YMP,Y->EC5J\O+JMVPJG;3MO,M46TT+ZK6I67!_N;@8>_RJGF>*6?^#?R94=2D_BN552_(>9OY1M02P,$
M% @ %XK96K/,9[(&$ #40 !T !E83 R-#8V,C,P,65X.3M5<66\;1Q)^)\#_T.O%&A) 4H=C)VMI!>A@$&%E2;#D[/JQ
M9Z9)=CR7NV=$*[]^JZJ/Z1D.*3F1-QMM DCBL(_JZCJ^.L:'/]V^NS@:#@Y_
MFAZ?P6^&_QW>GM]>3(\.=\QO^';'?GUXMKM'W=?'!V>'$V_+&0D*_;W[R=[ASLG0,CUAB5BD5="N37&55'".OYC5%15D='*
M+_-(EP>KBYES1$6:/.(P!^S!OR>G%T??-Q>GDZ92?G5^^F9^>GQQ?L
MXO9L\L<1]$F'V_.?I^STZMWU]/+F^/;\ZI*=7AS_Z^3X])_L^NKB
M_/3C.OH>0]HCR.BC_R'6/'[KGBU2,7-/9)X(7&]W\EKF+XYN%X*=%%PEK)@-
M!V=2B;@JE&9;%7SQ,DT^U\4!J <-0;UXJ>C1-@QG\+Q?OG!@=X73(BMY?M]:
M8\$UXTE15B)A.'I6I&FQE/E\.!!?1%Q7\DZP&":*7/-*%CF+4[Z,>/R)E44J
MXWO<1.I@EVMZ'&XR8;MW EU[S:% ?27% WYT3V=P)X2A\@\3NL$OI(Y[<+G2I@](U$MAM'6F92 Z[ 8?#$<,!SQ/&62F41DX@26YC?\ ).Y_9=>*%/5A#=4-"J8H[F0#]
MU8(#$QA\P4$(&<^*&KZ&K5ML-VR+!)+W"TC(<% 5GF&CAS8SLSGP'&@MZ%!V
M'V"-^!(+K=UA[7.[#0MV834(KFJ=]9NHRB^UKN3LOJLM#]NN;Z:@'>D=#N >
M))J,4@G2G((N"YB[E-4"MHIK)2L23A"8Z9=XP?,YR5$FM<;KW&H4YF9ZVE+)
M]W4JX"AGXSV:?2&!&_G'KEK; <,!CN@:"#0NEUPG_#.[J0JXPW=<
M?1(5N[@X#6DP0\+)(P:6(>/W*'(<9 C5"$2JT5OXC.2%;)BI(@.Y!'Z3D.%O
MT VS-A@!(W? 8)3(0(J8U*0P<%LYR%>",HL+QT6NX6PXFMB*LT-NC%J+> 6I
M2)$24%8-YNT.1T>HZ^X40%ID;%HJ^;JU>R2[*XT'[(FD[IN*]1IE,I(--[\W
M88M:*-K519:6-OB[^KM\S8;>\C:+;Z-WAEX.W5^=#BXFLUD+)1G,3M&Z^O<;&&^
M174(O,Y+I5$A-8L74LQZAH,6[B"OE0"W!02,[$BX$)['DJ=NY C&@%;)DH,%
MXW&,=A[OSBVTA2Z3G( 22$1>&+>R.G3D94*!! BU[?8LP#7R]DC4[#OX<^P)
M[+C5X0!\$%A(-<YZEF=Q^09MPR1FFF>
MXHWQ) -1U)4BQVG&$BO$]B@ &^[4RT6!#AW$-=/ %NL^QQG_A,=PNWAT8'VL
M00#A7*9E)E.NUBR@22&"8T_8M'N5S@MBFCH#J?M[=X[FLWU6KS01R\8\Y#@Z]Z3&5&IR!,X VN1UUI>&,P#I.-$#8HD
M@6 PQ@">4$+H$ZV- I&'6-1=VZIY:1MPMBSJ-/&$$,1"NMO,'S,UB1,U@_.L,!D$*4A2(VO!-WRPYCRHS([BN[6?_"WG0!,4' +
M%CN@13!( @$Z6!F5H)HV'KFQ/,.!M0J@XJS69@K,!\7 ??OL96/_= 6 #$+
M6@=$\ @V>HA3(!()*G6:VO@!%:\B7&-TQ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MW(?S1R"VPJ6?,DQV$<;(B]P%XS%% &YYM$1!YDX=)^1*NS?A"G([+.MI;P5!(+J5U%.9C\4Q"*6L:E;B31:V1/UK7R,L^
MW^O,KCNI._G*].&@'ZI0O !K&"0+A-5I9;RX7Q+329YM'XJ2C\:,P#B4U.$ @/GFH;^_7A'H"MNEGV!).SHRMDKR1"6*K]G2;_:7\1B@
MK4B3M^R:S\4!+/:Y%B":8!+8>&RK98=GYS\[JL)RP]Y^3[WA#3Z+ -T*Y9^=
MI)A1W9N\!JHT:%\")%RW5UPQ4X<[L&L/ 9$2_-,X$J#20&5)5(=$O>FA"0G]
MVBT#UNP@;PP[GN:"OMY /\4NYN[9*[+([YV!O2:1)RO\X]7E;;CM>"FP=OD6
ML+C*>/H"#32.\?+SK*$JW\:$MQ/4#GP+LNFM#;.MK[9-OM9DF0T2N@<4"YY+9H"E))A ,*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M]+H5&*TP/EU)$#65/1-O+#@,IL*I-SX+#AZP,@_#/"#15!BAM>X"@RK:W)3
M_0'1C=M3,6.P'1B6-1FS4,WY>H;@:A _+40\$/&%)/"S[A.S>"$^G?20(ID3N[<>^:U
M[O4M0X 5]F XKOF32:-/U54^?SZ71XW%?>
MLV[)?*:8?,U:ECMR ?K$9 EU]X0C^PLS[3>AAHCP7<2#!@5"DKT#U1!]1Q>35M"@1%YIA$"Z\M*>(:S^X+7 16K3J%^2!>]=ZVJ9P0YC3Y^O:"< KKZ>$2$=Y1
MBG?2A2FL@U)<=D\56%)+NIK73D8WMM+8"FZNNI5&1"5VENR1DCE:945S31E/
M4-(W51F>OR1W"2@0V05):G#D J^0'.&
M;J7T(-\W\9B(8CB("Y"JRN$H""/X7/%RH=&DC5 W*)V%L"L2:;$TD*HAM*=B
M9.CV;L:JILL^ZW@A$D1HF,84'!L R&820QZVZ":)1NU&= :3@(2[LH6QIJ.Q
MAQM(DTO1RESUX_@7;8-\EJ* WQ8.0+AW=89L*IWQQWHB;FF")-^4U%S_?U@@: &
M'Z[DKR9\I#Y,^&GD !UCC<7:L%431LUJA50/!RZH!KM,AJY[L]C/44D]L\V5
M(;.?L9J[/,MP\* 0AR5AJ]Z8H;#^A& (Z"F.%]X8M!8HP)4;/@'U IF,#;RF0*8WC0)9SFP+Q560S5]CRX'8KY#4>PJ#2$-R8-KR&
M\#YQ(Z]CY6U!-6ALY>@(NG64+8>$_9E9J7A<&16;L!/*CB+UK@1@\O/5FAE!
M1(!MO_=? Q@]7'/LATD!BT8MG&",!,;UP'/11G@<3IZ1U?4MT,;E/T3"R(3X
M#AF823T+8P+ _*F# X](!8" :0I 5Q+'!3L 6SHBU ,DSJO9M
MV/4Q987] W95DGZ]QMW&/%(QD?@-!DPO#JLD .[+?*#VX6?O-G*HW\":5[4^[SP:3,>B_5L=AWLDC1
MM"R*#*TTF%KX*N5+'[*#L::/P0LK8(TH5H38YDYDE+_\830<[._N[_\N@\]^
MJ[WG]A@NANL>IL_R%Q$%B#QWT(YU)^)O+5(L7S-JV^24M\)(+A9AB9A8[.$J
M1-R V/%H%-HZ(]SG+IO:LNFE;8X19&]:,:>C-5CX >O^S"!:_)3"G\I/6+^*
M>4VX.^RRYU_&F!,T[3M*5*[GH4SQ%*;SP60V(I&+F:RPB1GD/E(%3U *[KA,
MG7R#HT^+>R&ZC<$C0N8PD));0E0VVO*0FR;LOV$?)C>3TPG[;GM1PZ>[^%S!^40L\QM7DR;#D!#[Q8V:U/KLM1!/COZ$8?QT4/A.QJ5DT$;]_M#E5M5+$Z'V#!MM1P-P8TZDQ:8PW&DE;WT*K
M -[4N)!BO2IWA+[TUS9]W1EEP56QQ.1Y;Z'O;FD;@H.- _[=^<.0=,+%1B,
MV_<5V^_SM5OY[>L(&U]IM.\K]M2>1_ARQVI%VDN =$=8?:^2S\%=:6,ATD)K
M7\;R">^P4:V3;^JWD_\? O*#:?MS%T9.V6H>L'A5FS:E\RH,%8-X#GQNJM%X00>G2SW6)(&FV@!V54I<)@5>&[-HU(M=789=#-7FBP,:U5R:JNA.L 17/A
MDMK!7M0 @>VD\<(M3*)$G::V3XZZ\(1[D[=/:/O>(X[\VR^XIGN_E1*"QMFU
M>U4WJHO5*4)NX$<[[]G8]P9ZE.:Q1N]/@(!^PSOS?V7P_S?^MQK^^,5>]07R
MV"(P=M'>NMA\+3.7,JD6>#F[?WO1FDU]9EK^BAV'00Q/J_4$\.Z<&(W:GV$T
MVB*23K"#_YR'^?<]\)\!^0]02P,$% @ %XK96MNW2"?@&@ \1L L
M !F:6Y?,# Q+FIP9Z679U136[3O-TT0I/<:%!"E2E=$M"1*30X<@(%U X""]2XW44 ((J%2I2DBP@2 )S2UI-^>^-^[[\C[<<>_>G_9>
M:\RQ_FNM^9O_R5Q@K@)"-A;6%@ ;&QMPD_4"S&7 [-^O_]7S;Y#_;0PV9A\@
MS -H $D<;"< =F$V#F$V)AZ ;U_^9 /S?AXV=@Y/K"#?/45X^UH0V(8"=
MC8.#G9.#BXN3DS7ZE#4.< ISB1S7N7A$U/$6]XE@,=VH]!(>I4M-_>).4V1E
MO=LAT4=Y)22EI&543JJ>.JVF;V!H=/:=75QON+G?N7OO
MOH^OGW_HH[#'X8B()S&QM;SHZ!P;Q0\,C;T?'IF=F/\[-+RPN$4EK7[Y^^_YC?8.RL[NW?_ ;_'/XKRXV
M@.._I/]_=0FS=+%SM25/_424])[+X[9 I7@EE?:(*Y5]I_ZGLORM U" \3N,WV+":F9[/_#27>SKZ;J&_?,_DWBN1W\86+'MRBM\$7<]5MK,^*,R[!6K7Q/W$I: CJ+/)6;WIY!UA."25II^4MW7_#KBT&8ET^;IU(O7]?
M]R)7^:R01^&0R\K9]#.8?]"56)JXQQH?DH<)1#]"+<"$ZW^5M\S6HXXB6@:6
MY-]W)?[ZA\*-5W]$%DBZ4*N0N;1AJAR]937.QB%T%'#]X^R^/*KDOM@7;WTO
M,M)*R;M1X]ES,QEJ5W,--=W]8@!:Z4_MR*>18N'!#A/9(+&FO!2KQF^-3D4"
M<=.1.XXU'V>FUALVPU92$TK53S.!*/;S%$(/N@9-$_$9QJ*%<*OYZ"9MC/;]
M@.0\G,\$^X_FL:V.9(3]4/=))=4YL2D7C<>+SU[>QXV?QZ_(S2$AI N1 ]XG
MFC/M*=SQ89%T/H^9KTS XU:M7[BN&V%Q[(R.9ML[)S-%Q5N3%-BZ-!,XLHN8
MADLQ@?Y33,"G*S))QAHI7D>[3C;\%KA\I
MHVGQ#($AMV/"W?"#8A@MYO7AQWSS)Y*Z+:O=?5<4R+\RJWYV'C2AU?KOE/LNF;]M_?3)AJ 1?'D3(M%[H0]@F&*%AH9&[BB"$_P(36[RE_+S02(3
MB%.0+(J$'K/D[R(&-M#,"AHE?MHD%NP7/B'KQJ4:P'Y., 2\Z=U*H#15[P<3
M:!:,,F@*I%@>%"9]I]0L7I'X/4A@?Q0YD#_C*@P1,/:!Y
M0,;N.!'Z*_*(%R)=R4P @[QVJW)4.Z%;HA-"4W8O49>OCUU1F56>T9?5W(K2
M/*@,AB/FVM._^;2_QG4L?UFR&;L8AI[?[R"LH<4<9%,'R47L(=6V0 [4X'I!
M1I'F3&CI)7^CWP\1?L;[UZ;%@X5#6N)?;J%OXUX/"BX:,?AKZ V]QHT+>SA1
MQN0\1*)NS[9CU"U,RL2KR@_2,ASE'XMD GXQFTOTH?QH\:-ZST1^$49,GHVE
MCI6_.*U66FMD#AMZ?7[GB0QC&+W:]'J<>@K=+X!;+8(V"VC6A3$!&5ORP,\A
ME^,FR97P(Z#,[@A#1] ?%4@@%R$:;9Y>N@_0VURE1%Y7FB8?]HZ/'^Z:R@X.
M[6M I;_ON#!&B5?">$4"S),_J!YKQMCIS_84NF]YN'3DHW[B*!\PPN+M]ZX"=*ZG0TR R.U!0=+)9 GB]%##CJOQY&"JY%P/J]
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MGK6&#%8@=.E3L)QXNM=?W*J'K,#1]QB3Z]3KJ/[B9B8P7!UD.E6/2" &)92
M'?EA;UXBEOM(#ER(C@8O:_QOXU]1D4^M>X Q;( X@'[<4:;"BUMO](95R/#8O3]MSTLCZ[1ZC\\9('SB'F?E2XHHYJ)"
M,+]S&VGRQ:_V.NANI&\1-BB%J_7QU=1>Q<9L-<.@G<'9LA:U]"#->B7>AX4$
M;7T5^4>6F2PN2)GR8T>TP=/SFVG$M^[..[O/+.K1S)1 *V6E? W[ P;/%:R*T&ZS5EM(\I^OVI;7WT#'>0F $.758
M=VQR8MIMICHAG3O![]0KJ$FT-%PK8P>6Q+KQIBJ(:?6JJ!L5K^=-/&H^^]GQ9M@,TG/F
M;JN,\D9=?PC4KJ#)=*C@[A\]\B=;-WA<1R"7[T>2O>KP'7_-<^6QHP\G!QP?
M=R)K11-K?>YG9;K[(I0SAH2.N"D]TSE^);7J*(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MA EMD9XPR)("ZW\Q3@Q-^&Q&\WWHNO4U4O9A;G(>$Q"X6;,:K+\285DD,C .2<+;
M-(BHZ5XKYR7TU!I?0V8\4[.WR4P^"#Q]MG';AR'P'.PS$:5R@MQ$\^[F$30%
MMX:-WU*]\66A!8$FSN56(\8=4^]1IRT,7G3K$_]:D+_:P>V/I>A0)9"G,]>*
MM]#4,S1%6[\@(AA#F2<6)^SS'(>M)."0GW73ZQ@Z:<*,65A+;M_R!0OK>E,)FMR<27#M>HU5]#(>(MI]Y>#Q]%N]
M)"WH:Z2D[U33U=N87^9F2643PP1RD.! .@7"X$TF?\>[2HP'5])DP% *E!0X
MD2=8*.)M&L4$>$X^>^?F=B+G@N6P7WC@<;51@_Q6GR<86RLLX7";CDRS3"EG
M-(,]<6/S.)O4.YGW^+WT2Q*R><&A5TN[^%W5+OLMF$,\$UBM\19K)[O2Q-(.
M/I&WLM3A/MQ;DA0^IQ:L\\+S)3#F&A.(C>>90K])W\"(,0$18M?\_@3+74PC
M \BX./3J"YATF[9\@,2A9)PI!Q(.5I.@H@&YN\HN3RQCOY$=8FE^D:&G;W>)
M3!M\5(7JZ+9B$KO(LG^J6?R@(E2ZA9D %XQ>M;;0U$]:9,@A=A:O"U-Q(D@]
MK%/A \8+@030=@U11*+F-:_49AA]!
MS RCE.*))]K3B-MQM'/B[?5$*4>>CH!B"43,%?+RAA.[YH>$,F^_G;KDZK=_
M^U-M3E,663XUR$IMUD(!>B/-EAK"F(-*XORTA0MJO8R&GBROK[!--A0'DRL'!06V
M9Y#"Q'US-J4BS9,&LVUPS6#3KNJ-7.6F H.#A*UM*G3-=0N]EB:)FB-(U >YCG[<$^1&W!F4"8]A\""T-CB27*9G+E.&NTCJ53[F
M 7!1_R\"/^8FL+;O#&,PA?H8]:E8L%N2I*G9R!"DJ>^@SB!](R0MUT&9E,H#:&QENK2>:@K-X63>J]$@R/M,<\:G#O.[+5F-'V'DD.]#^R K%M>I
M7C#R[F1#"A6*E&>1_->'E<]*5HJS2#._8(JLJU6.4I.+%,VY_,:+]I*X307%
MDNO 855#P2$3@'V)V'O](HE<*4KI#3A]?=CG!7AW,M=8M,[N\?L5++OL-W2AFG +U+B,5"%-#^T,7EU:&>DEZ6XRN@5!)QL7#-BVK*
MTP90<;^DAMR'@KDROM5HY0SAQ"G;#/9ON'_20.,"4EMO#]6+!H J%>V?H:N_
M^ZH-EFOOYNIX;+"NIHEMB,AQ]A:-0(68U2VI^)O-S5?.[CR[UWN!E8QAO0+H
M@?G_K%K*MDBH,N8KYL\O@LZ.$,R1=:>+MU;X/<]/JG3Q!!A=D';M])__.E=2++L'>74$5XMZ1C3?Y&*S1$].3 AZ=KZ$M626)%O;VVM6K[XBPF0@U@HK&*HHONO]?)M2#[\
MLP0?0!]%VH/5R'J@2*+ CEPX'Z?_Z(5NLV6*S]"KZ
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M?=F\MU5M*2T'<>!/2KR?@@M82D&3C-*4(N3+6,0K
M&,IOJ+ZM8#&NIYDRU"QB37TCQP:S8^VK"?1!\L3"Q A. ?E7;F=*0R$%?7 5
MW";?+(]Y:XC XE=$\W\2YRJ5'6\5[FU+KA^<&3SY18*PI.O9E4AZB#9U%>HS
M$D%6Q9/LK1=P.JH=9U7UIUL+UNO;&5WTS^&FH5"2#ZO9.O(EM=+@09%;G8Y0
M5\A7YZJI\>4N++7>I@GSNY?+1SYM4XG!32@F.^*6-KX2I]O@B=PD
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M?6?TS-R=+%LYA"9HQH*<+BO[AQE3,++3+'D[AN;U#R*M;#>VAMI4XW1'W"D2\S@30FT#:QV<'"^A[(08XDS0_@XDVYZ-F,HV[K"B>F314'U\XG
M?PXG'>DAXG@6-V2&7BK(3VUO9?"I3._?3?P\(3\]6OL9+V29)_MU(HI ]OM0
M$%BS?IBVI4+U\/PI8R)2N^$M FJN.FQZU%\R..7.TQV\=L'L6H!8\#=UJR*^
MC)OL6>ENJ8OV:ELL! I^W ;#H68D 7F*NGQK#%
M#I("1K@2&E.K$_'&R:+&#K+>=?=L,S.M* 6_\._6/;-U87",MQYFR77:5(YFT-K-:OI)=MY[VHM;#?=;W!X1!&Z,_0RN
M"_CMXN)2U3>A#%U78IFS 7H"]$<\ L8$@'KT'YD>V,%5>@KZ/A-8R"5V(C7I
M!2CI'PR O#?=']ZXX9@7!I4 )YRC(2IAQ=)@XU6_MF)A_^/N%X/@079%+S.M
MX>5N"TMGL!"'Z9# S^$[+&8<%A_K>('H()UXFG
M9@9O7>@Y9STLMYOM_N%,6(W^K)*]D ,-QS([6+0D8MR&"F5]BWY""KO0ET^\>O5ZP7BU7OQV;BMHA:8@/SW&W^W-8$!Y$CKYR/4G?E0_Q5#"J_R DFDG2&M>[DN_*S%0\/3T+=8
MO(/D3YQ0[W'$;Q(W)HCQF8261RP/H70I\K]XDWO"\8?[#&RMIYK>>>40&,Q^
MRL*+5H6QD(H]@IL49/ GD!N27J'[];]2!(KO-_DS#.C_H$[[HQ1[SNJN.)29
M$0F"?DV_>*4\EOPZ'ZB+78$]:/[T5BIBR*6\S&F?@1.EH(\1#@=)J4I&-M5W;/80J0\U4; [&!VP'V9]]JN6Q!?$I_.T&+F !X[OM KHPD3:QA'"]BWBPH
MA_I X-OWB."FM1MK5:\)"ERYL;:MM#X6*UI88KU:CSZO-8;Y@.MX? :R&?4LIIFV?.^3,"?L!APU>IC4 ,3\"E\,D>Z"N@.W:'(7H^\B3_6]&SE
MT\V,AQ! (!2\Q\J6C^"U55PJ%+N]F4(N)FF]/)R(ZO:C8 =RO%6GYF J!D^-
M'")3 EN[^+/B+KC]?VM YY?KF=3RD5*[2=Q\#E"[>R?WO/C/AB*
M^KEQWP]J%5"3$IN7WY:>J;S08$_3LVZ3LA7:OOLY)ZD+1JUEN0 4$[CUB/X<
M?1LBB/@^+".SSNHAT7YS,Z;JX#?;KFM':E^!QI&LBAYW;[4K1JUNM(+2R?-8BV8-B6BE6@YH02@.UZ+VF6KB1QN6 @SJP&Q:&3>D]C[S<-=UT[LWE
M2?T>U/9?Y+W@*V[82YTG,V]]KM@/#1I,"\.M\TWHC@1>\?13QS#7MSF+//4)Z/9SPNW;%Z%BDN?K7A"/0MKW1Y
M!^9\WN?RHJ_F[W8ZQLM)<2"J(%&FU^)VB^K>>GAPTGL&XS]:Z-*@+&X5O.SMV9UV#-FR#!O,#
MA^C!"3X&@<4Q)I!X)XMUCOR]"KX*(IB+$E,GBTO6O97!TC4VSDW>[F3X*S#8
M72=-H_4!,;8:^\> L>PW#^('4*=FPM2[OI("R"AA4#<]M$29E@,EHD'99>!^@H_B0"^T->:WA0]RFR>I00Q'S \WO*\"THM_N7.Y#Z"8#F&^YFEL@[+!AFF!25_.V?]2^NDD\ET#+A);:(,SZX^EO(^/1(!
M=:4_)32&$L%1$TE>,#S+;+7((>7#1BM]\;:>YT"P_5Q7UBGB>C^V.>BT7RB=
M'[>ZL!WKMPH!58\1A+3T#UH_HHQH 6 4B=#VEB>#.LB0- [_^Y'%X*D3G!WD
M7RV:.(TZ[$GGON>8;18YUM"+<]!4"-DN31:Q-/!!FN9(-4)T#:*E6T?Q@IKK
MY#W=<:*VW T/??\M.2=?!:7 V]\5CS/ZH\H>I1H:'*!I(GH#2] 8W&I><9-A
M2DG?I)L=F:^_5S';*WO%[MK0M58(@S1Q4I23T*6@TRZ3%FP22<2.]$A2NI.-V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MFGEDM&W\/:0/)=]>M("N225<)O/W-VGN1KCJ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MCN9B;,S%_P!02P,$% @ %XK96G^=?R!@#P ?! L !F:6Y?,# R
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M=*##!L!M>[^_F&I@:&&YPWR]S_.0[V$__R,!@<>.?W?B
MY"D\(?I,3"PI+O[L)5KB#TGTY,O7;Z2E9V1FW;QS]Z?\@L)[1<4/RQ]55%8]
MKO[E26,3NYGS^Q\MG5W=O![^\Q&1T;'QB<$8HGT[;N_WL_,SD$?/RTM
MRU?@OU<_6=M+G!28(WMLN?'=>;?Y)4U=!ALW1L&HK^_.&!HLMZVAIFJ=C F !E6H7]%YE:*D&=&/!C(481;"JF]C 3VUSJE!^M_80>\XEQVX=
M^!\JL_NG[X9P8 I(_0ZRK6-)M4.CM%RLKLFA%*,-Y+8=)8K*P3?T]E A:;@9S'0-33:\B?'E\SI,WO+-Y%9.V
M]/4&-5!)9_$NO^LI%4_IO?!?/5'S6-#-V^JRA6F&M5,#L9A,-6"D!LA8>&NA
M$NTO;\[H3E ),!R,TIS8V2_MUYMKW]Q6V$$$? SIG(!&-HQ2>,<)+ O>A),C
M]<"1Z9+5GBH%ZWX_^L_Y$R.8%2_*/>NM7%%-2F;
MX*N*.%6O&@!#,.,U_F ]CSFI+W7HIAK,8S><&36EA'M]RV48=/#T@A2QXG+-7!T<$E<^9!)[;)M0'!+P752-54-=/AR10^$EK125HFI
M&DBE:9YX-:F!]; :D"_#C96VT3R['6/&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M$>8#B\ZTW\=#%D7RKU\)+"J=N,WZM9/^HBU-,FN,YI8,8!YR:"R _:FK\^UAO(IFB5_J0P,JXH_H@>3VH7X ?NJ#_
MUZ+2G"S!\7""^_)BV$8-(#AK^2GV=*ZXE.7L1M5+&50#S?T]Q(R6NO*R>2Y"
MXTNGXL)2R/0HM#(<*
M_37M&F3@X2Z(>1#VAP[)0]MU$D^I_D3O;Y#90:?7_5-G9M8Z@L/YA:=OU8!/G>AL5LA19
M\OKA'98]?=O&&1J/I18I(T:9<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M7/N6X:7GM/M=O"3+@FF"SO.$I$RWH))"WDBK/7L^;MQGF/9H>4(GYWP6#5,.'4GQ *'YL=7
MVD_/M[*0Y8[0*RU%&:C@D:5<+7@7WZ!BSMJ:WMN98@N%Q;6T1?K5/'+)I+'V
MXVE]@7:,FGFM'YS.2^?N\K:4Y(\-H<.V'3]\W-MM YHCC+T)V$'3E E(LI04FQNB3:,E;*85C!+'@/?4P/Z[7NZ8BKGFN61:#A7
MKY!:0Z1'N05-?NTJ^WXE,%U$F.,?^;V-%3H<5=(S*_W9_3:J;*8^CWM6#4R2
M1$D+5/W.=>V.I^'68Q"6S[U)P'0(;V!0[1MA_V/06*XR64J);WNQ:8#A42$K
M:GJJC\,GYIK.C>T]2'HT>Z'MXY&/;5\%+;>8^H5Z88(9#_*&E_8M'OCB(=>:
M2W6!'5-\2645B'Q&!+!QQ$FLE'_#Q^ZT,@)N (?D46 JW#DORNU"TA^6
M8"R4IT9\Z_73HH=K*\)E'K@[@BLO:%/%:2\%X1&SBU>6^0N)&C=IK94P*:43
MY6*LS!_D='M<]D_U<8I+6JV\_Q!N>7.*?O^;85<78[*=">3\8ZU @+L2VY*>
M)LE%S7L&?Q1$_$DX?1_;-!D,AM@8HUYA;XXYJ SK-:J'V6OWO!MJ4KHQ8%"_
M*1TKXMAV,L2EF62J1QJ$:J8Y\C4U0A;+2MZJC=*_ENI0-ULT0+SA-QLX4ZJKVSGE$C
M;%0&TM(8(;V^?!;_'OP&:L8J_]JG)0'H4X/?68',>ID 1)?9;0A.TWZDV4]!$^K$KF
M/DC4P'=/!;ZQ4>1X1$(X_B 50;:]D@,P/;C&W!A,&A$\1(2W\F634%!GY'8(
MUZT&!%[=1 2#5*.,6JMN(WJWY/+4 (MH[
M:B(_@^8B\[JWU!M'&G;^X)(8Q)K_&^+&]F<1L$J3()71.(R43AT[$'%,PN8\
MXQK!K(YI[:#DRE&?K:HA9A-OBL]JLQ65_B9X5%AMG:P^1Z"7&ZT^U?0#NY9]#BMZP&S ]. F/,+@ZTE@MY(G5@!V=W/WD;T_='K9XAAJYZF2_M!SO1J:QR67T@2E'O4'F";A!8<, X-D$
MA=L4XQ1X%FY5607Q/5VZA==;SJRFK15FN.;:PDE=3V#R@3$VT0A_^G#Y_.(#
MPI]N'Z['_QH>29A9;7)OR<].B)@\O/-:BKWJ52GH%T'N9()'<()YL0M+WNO>643& >A)"39/L@FK,!KZNR*-/=64PZ.%VD&,]ST/B$BK4"'3*KC4GQM
MKW&].?QQ":LS#9!
M7)K.Y+@75?712K;!6%'N1.!'HAY=T"OYXJ>*^B8C_V[+:<-6:('@SJ9LM,ZV
MMO\)LM,Y796H5JQRGBK,H-+JT@3/&JSY)_#4*H-CWE# EFEZZZG(!<"T;K)2$G@X9D
M+FS.]5?#VXL#ZB(OH*K:K90^8%4G)GU:&\:+M%'Q_HXF\'^G/_O8K[?!XN;$?3F&?>UF)^9ROR$10R 6/$2=;588[KB10):CK
MQ,;8A@3-:0ZOL>K+\JDTOR<@HZ!DT]HC'WOZ#V)G^^8[TI[VW7\,+/5&7.0A
M"/5I%B^'DBT.EZY:YJ'?E.]\\M7X\Y=6^ V4G2\/ZA[9AMZ*.&.22G[=;J[$
MP'C0H]-"#:!41DIO,*E3LPE>.$>HX*1Y(\5K'ET$Y!R_E"W:<-
M;Z;HB29:,&5(A97J.6&:H[!G(.%\
M2"HO@BL>]X)2L=Y=$0J8G_9N /T:KU:>GCZ+-6%$D,K&B?>:%I&SM_L3RR>(
MVWX0C&7>#_XM/Z>HE?\N0VF*E#=1)U#R2#A&\76\)M*&8N"=_&[<+1_W479]
MEAIHLNS!&*?T$I+2:/U9Q"9]WOZS(53^]%<0)L<["C(+^*UYL-:YBC/@NG:I
MV^.'O"YQ'RJ$7!EPXX8:..GZK?ZG@XI >JF\[PU6U&#M+]LEQ< .6)F9(E#5
MQVS$+8BIHOZ)L$71=!7X9 9F2M[WD/?KGX2G(!W\ ,G==J\3#0ES+K/@^T]
MX39W]7+TLI*2J[Q?U.V7IC17R;C;MM8X%#78]*[9KK/,7YZ+F""/3A95XNA??QZ,UL^CM/?Y*?LP\87N.)&3K<5 -9#;]O#?R36(K\NDN_$#B?9L(7,!(4R]L)U@)'5Z:
M'Z]J:F]HX]PYXESK7%9@($ZZ>6IJ0S6@VL,4%7%!7S5@H1*H 4.^TOR35 W(
MZA6:A ,+/X<1H@7C.-P+*D3^N:[<])8O6D%^CYW#:!6<*$:N$9P,I=WU%?ZB
M0^4XDG5$.#\J_@JZI,B(W632J 9."1L+%QI!%WD8C &%MKWI[B??;74@,'^9M0J-].M.N,B_F>UY.X(=J4C\!FEY%/YVOSYL:&AL;F(S*9
MDQ-%>@M)CMMZ:\/FG"U9:/3QTP]0ZHE_ E!+ P04 " 7BME:B?N5H:/?
M "\]P #0 &EM86=E7S P,2YJ<&?DNP=44UVW+AQ$I8M(KU&*=!#I1?(J
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MU+2M[2VM7=T=G4/8 >'AD?^?#F9V;
M7UC$$]8_?]G8_+JU3?I^\./GX1'PZ_@OO1A C/^J^G^H%Q==KU.G3S.>9OI+
M+X93D7\UX#I]YI+*V0O7K9CNAG"+7WW"S'/C:7ES/XN$JC61U^/A1U8^236\
M%.DOU?Y)L_^:8G'_+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MD5A;SJ&>J#=KVE)O)KZ'88CWMM0)A,FZ*RY;0Z<\!:=#T.-5*WXB2UL^@\?.3 97 I1S?<-^)UI6?P$.*TOCQ,
M&GLDICA'%@W3D_9LG,1G6@[I:*#* >3UCV2S0*V.3B*UHP8(M9TN_ZC^S%N<
M12$<^OJFM*S F,GYW*/GZP\>-(KHD6PEW.$EK5[6R)>0A'F
MTR6NLK7C6LCA/\9:6)^9>&ZMJ>1?L;(3:0Y[-5/W(:Z25\^@U#2D* YKD^?G
M(24U9L2-TLE)\+L1/%I3!3I&E!P=KF6MNLM";H5/@BTG.VK7'"QF>ZM))'R021G:!-*=/:H?=)V'39JJI+36YQ1;!^Q%ZU]_59%]L&O<'+M@Q@("G7K
MY\[2ZE2QN?-64Z!$V%1P].49=*#;XFO?]N1 GH:I&-=[#7OO"3^Z0S*KY.LE
M9XHC360JX\N,&2&%T#',AV.KK?VW=+.X1M&=^EK6J#'EJRU?O^PNY^ WZ=^H
MR6\^Y>M6/67RZ%W;N263[;U.*U-M+^L_GWNY3>D,I_?&,3T22+PYI[MB=(F7
MMS3EMGD,,\0+DHVB:<>0Y'C
M-8W"B,)3\C)?D%Z#3BG!9[MV",1.!P%"B!9<#S7^3FBF%O?P%TG
M)^C3*PN+=QH1^*N[6/">?F7UW)=U/>JL^?G2[D&EO'98P'VVXM#VTR_;
M[5&U\G&[.N])6X=:6/!:X1":;P=\7N]:.<#O6 P%[,K]W"6 Y IW"O+F-%GY
MY==OGM-2?:TSTNV/E#R\[J>-SH]=&S21G-V1O,[RO34\W.G\-V/6KU@MN5%!
MBYO?7HJ4_1+85-O7:]C6E)W(V_=:D"]]L19L5/;:*9FL5'>_ '
M'VO.=%6ZG"!KATX:O(URMRN_$5YC5R74@K5WA-^Z)/='7"AVKI>5&)$O5XNK
M*9>7U4F#3,ZA+-TKLDD2)%%#__8CMW +S;05W]8*0O=">VM/P,=$Y#NUX@C7
MQG>&RV[O9 ZD91]^']+M"F.5$=D4(95IDRG=!\Y"%H7137[=$>G5+Z]NZ[3M
MM1>C#$+" SW9C^9R7FJT[T=&*_"]4A^<>&5TQ&T@6'3S0^MUY*J;R,%*J%Y745ME#S0TMKZCMA"XW%99UGG
M;]89@>.293&\WUA.-. /&,YP9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MXO*=MY;3@:YIXN.J\G[G3\@,>AV#B 7XD,U8>*%KJ1W*&W2/QI^V7=Q5;?+"Q
MGOJQ9V!E)O](:9_?TMSZ^X3\N\# 2T7;!)G[ON)/Q*R3U"\W]]C@2X/[8\5G
MX+($74>%-LJY[^L6,[L7,D/N(DID.VY0Q>UHK2
MV#P!+]) +=1%CQ#?0WI%$=_,?^9W\RA%4:7%!9=Q,]\+]KMN;&AQ>0G/7K42VU$L61(*MQ5L4U4:67'\(/BI:+H4@]_^:4Q_S?IS#DK=PZ<
ML"'M=N?_\/*REYLK-RJN=V[4L:V8=C/-O1V76U2=F]<[O6PB([EX5&0QQ\NN
M(M-R3V5QJU#;&&7/WN#3T%V;6F,R#+[EZ$E'#^^CG4P^YZ>79\_BN[I-^T+L9=
M9=A\@=Z!4EDH--#E<*($=4B6!OIQ4C^WL2*+^+-2B09JSEVHQBS+ASM8SFB4
M;;5Y'F57OL'P;$(.+R&2[B;I#U6DR1-Q)Z?_5Y3MOTCI_H6L;=')&OPOLB8:
MBZEF_,^)W"K,GT[D]!3I6^_UP)CVA6K\2'^OBK3>X:O1
MU-24VW:HETYE&62@M/9QDF@@!7)0Z&KV:?]GVELCGD\FOG6]_=KC>?(;3!F/
M?(SP@SZ.Y<+!K0C70M>3AS$75H&=(9V-YU5;19J)K=&0"XH-L^[G/S2&MN0;-% "QKBC
M+]YX.GSOJIN[J(*??MRJ%N=*:R8M@XQ&FV;0%NAA!+#[Y64!)>7$P#[9F]J?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MMX:+"0<[S<)\9Y\#K9V:JRHJ5$RX"P?6&9_:3&G^\76K]%5@^[=7ELE%FL(?D
MH*/)G=76U']RKQ YM\IG%EMCDCNXR(>#M(QT.B<-^H+^<[K>9VI;EEMZV=R/?0MG]RCB NRK$]P=*Z?@]Z*VVJ6#%X OF
M=Y.:Y1<6?Y?H[%M64%5KJ56\?%;]899X;7P&W]6>D(+W;G[-XU(6)=N3C"F5
M<8TF5@ERAK9#,MYG)AJAGG=-6Q'FYP0\>Y1DM&,_"3 8]:+;D?S1HETW468=$T$ =MOPQ0UI4Y1DA7L0:46CP@&XK?N[%!79G"XC>>U*TZ X6VLB^W=M?RT\Z@#?F5*2C"/H.E5WO9LCKO;3'9T-61 H/C'U+3B$$..5]SA>P-6)?$](
MWE8DD=DR 2 R1"IS/R4H'+\6\JAF6U]U>B]8V(A(&<2]\ZR62=HV"5+7/' 9
M('.?6,!-B4JE)%ULN[W861)37*S2]ES915(A=E40YJ1GLO8\_&2IH#?7 :>6
M_F:HV++;!2WWVX6?'_O&[]^\X+2D]P!@.\P'"M=$)0C\28J-/5R$[-/DVT5L
M&#Z :=B="]<&/6..\!5YX C=BN*H]_W@T^+HLN1T_714Z%#07=SNZ:=ZL\T3
M.CM>"[MEETU[4%8$8@O*6CNCUH"KH/:NGUU_MTWU%KY9+:;4&>'T, MXSKWW%@+K_/PK4T2:ZF>VL.&T02\C72B7Z?"?N&5RL(-M$"S/%=:/\%W%FO)
M6U@E-Z_3@T/)I7/<4(MUPV[VM((PM&=;?+19K-(\S*G'UU*5>VI^VKZ\OK2;J&"+)%^H=
M@&+-C#W"%%D*KXOD?(=_II8:]N?/-3T.OG3EU,4OPVB^=#',Y8+%)Q\\M^M/Q/I+@87-/^YZY<+->J.V)VESDZY>YV$!_/B3*D,=$A,OW4(/OU(HPA]+L
MK$Q#0\/N()N_/P\=Y$K'QY:W*>A8:;]:8K.Z,CM<M/SKV>P5[2U5\VK%VV>;GJS3';<8%NK-M9!W.ZK[5QSV7=UV2&?;8\KI2J9,O
M%5>5E1F5S
MFX(RS3YLDI9JC"L7Z6Y29C32#K[P8<+;HEI(JY-PR2A)F+WV#O>0;3WK:VQW
M8=CV!#1ZAPY#=;1@+&ZU T1YL1M6G\VSA6B9F1Q$J^E'C
MU5_Y'%A0?E'APRW5O=7Y044;F028,J%G)H!]Z%Y;#B^:%XBALVV%=LBKCCBR
M)1[HL:FESG0SI>N9K=- O"8U?K-1Z.2 B:?^D7@73@8-9$Q@]=?7/@^7%8MKWU#UK=WZ.CQRXL^Y>(L; 4OCJW?3R5@4JG:W7-A&%Z@8YT_::E_17>6[/:2
M!O(=?X0W2G-$O%*K]S?KU9DTP!5HFQKP)C#/CCY-$63V^*7/2:G2EP8D;@(Q
M55L/81'433P+208P)'!$FA9;S_4)&1-.@E_OO()%K:T,^3[R>WM$Z7^UB5=-$,#J2,H%F.:46O,;20G .<5"B.V;=_=DNN$)_5!A?+RBQ.%!/.(
MSU L769_%\6
M!E IM7L2!KQI@_>>!=QGF$,9)<_4>? )6=OZV0VB7] Y13R$O8?M1(\Z+:9&
M@L;]H),,?1V Z<1@ :[R0=T);DAP$S:;;:VL]RV"UQ/8KG%:MW=@6L.+\%_2
MAA24W<"[J\&6RM+;I0:'UI32:DI5K#B1@LZ,\DP(F*_TPQ )8Q:8U
M$9(VW^\?[(W7+OW^CJ:BG]1Z[+_!,?A)(:.I.J.47E!7!K
M6^G88V0\]1)0-S?MY6H_W?2&ND#:5T<829?W"7/Y1!J(RAV]FAR/=QNB@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M+!\=[5X!VAX/>M\G[6\I0?/R6!\9,)L9=C5U?;#C,).QQ&&ZN&E)) N$.UFP]5@B2=A,9/M^Z?
M@46 7[NZPA!V.(O*2FA_V%B=3W=)9 3_L);>O+.:SRHA$X)?[0^.1S!AO! I
M-) G*V&?)UXM,>$1Z<4K6:%!TKM=KFYN!5;97UWL^;OZF#AJ*IX2^8G:W@/5P/(]>P,5>G'*-+JH.598[H!#PDE
ME)T_-;4_X,L3L8\R]#R+.ATR>:V5;Q;GIS2UJM[6V",O=]H[R 9+ [6B!Y&<
M<)DV0%&Q\#'984U4V+;8A>B5G06_Y$58VD_N+IE4;1N)WP_71N[>N-S5&>V(
M+I_VZ,AYE%8Y)#_PZ-7"Y<@;66+QM?PW>*X&Z%].5!B /;++XIM2N]6&@LZ<*15^:B[6<$_6K#R7E,82=.R%$U]KY)'G$K2Z=-,4YEG=U>^C$JO
MM&CW'-0.\BY4B&5U;&UF;8(:J/3;O2FM_SZ6Z7"VOR;Q?.Q%0)[ GT(5=]W64M!-HX^59I((_EK8*@X(LSZKJ*BS&)$YO8F M+6$1S))G' 1MA;7ZM,%E? 6:&
MG0UUY?5/#6A5YNNO6GCWX,^ZS >SA\UJW]+JO#[9V<(K-_:9J?-@$3JIW$]<
M$?[P$\Q\#=6_'.U 8GJB_#/XM$]1TYOJ3_[[T9=;/(['I^]OA2V;MPD/]9@Q
MH%8^&4@^> ?WC.,"Z]()VR72>9C9.G\M-:@9$>J#]JT9$DL^AXP,%IWIT?AHLNEJ$J)^L-P[V' \_>Z@""AZ7:\U$3_R
MI;-(I3X[/._NDPGJZTV9T;0\;[WN*VF94L(65ZK&U?FM79_I7\*[GN-GK;G=
MR'[O*OR(,:7>6!J+=ZV[3P8;RR?RRPET#8>5E]G4NC>:3#S,\Y\=EK:P\\-7
M;4.(%C-,ASC@TIN-H:.,M!S]+1HH$4$(V%N[@Z1J3U#27X\"DP
M6;&E\7IENP@Y#$W1F.5[ADU@H6E@"')
M9@AR&AY:!3M*ZFIB5E9J$);Z!,R^UHWLT,
M1;2BGD'=%L1OKBE K=3YD.VDS>S$C+=@_M/-P,&[SS3K%<1T"D)3WOM85UJ7
MNN:R/'F)[G^WEN7+QT5Q/WZ 7PJ2,XR DY1&%-H''@4:Y@^.%N>
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M:J;:)M**=:/E9X.=,34KZPV):AC-9U?\09%2"ZZ^6O%;"[\20A9Z%W,.([%N_1B= L
M$VL7RL#KV*D(E@:9;/#>97+NBXY__^!9+2[OWLL"J%$3Y_;>J%H=Q@<].0E^
M]38DF^/V\-WFGS4$68+,G==ZJO66LE@+U RQ1+3XGE,6U,(69;P0';#.E?1^
MV\/72)[7PK1DN58+DK77CL/CT5H=[:63.FI-G00%M'
M#NC/E1XC K_?KGDA5T>L>_&XKK)$+D,NHT2&\3*F$0%('Y&?S[W-/N%!T4"X
M;VCWX#3H=YFQQG :B-72^/X,,;^TV%FC">=O-%OD>*QM\_ENTJ(FO'9_+#(077ZHR&,%34+.7S+DN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MMZ0$?N0;RT[PU$[G_HHRP28_OUT;=L]Z+1/F
M%:8MM]V?GUSC)M;2 SV/LN))WLUC1^+3&_K*"[=Z]Q>?@Y/E,\8MI]T@AGWICW9[O1-^T5P5L'
M9"@ QF>G@EN"=\M/C+8*CB%Q>J$DER$AR TM4-(*:O@^!RF:=MYI1%?*C'R
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M(MLAE 1-[@E05Q8CAQ8.=K?ZU\)B:2#SYMDOW=,]LB]\^T2S[MDY$A&E6-"ID-DY$Q-3(=F9Y)^L]"SCG8.\(^HN56G1J%KH35>( ER\Y6WQU7
MU[F=BU*0Y!/GO73V97%<=_I3K$,\$,\A$D:"R>#M&5D4 NT<^..#PF:#S2[E
M"^E/]%KZIY073M@V+< (*4/<(GIOZQQT3ZK;*@SPH[4%SEO.5@KW%VWZT#M]$Z#>MOK/?M^UGNS.LL2^W^7)8V M"7O]2K"4@%X0XS\",WZYHD) CPM,_J786**-I9S@6VE0=^P9BTSEXA^OB2VQ/:9H*EC9F&;HIU=E@C2XD+5CZF&
M&[.(?'4VCZY2TTE.Y@9]N7 Y>UM?#Y%+%OF"IONM0:YP"87NL-XD3L[L1IUG):=E#=A2ACU> [9EXNU7"\04/5_!&B2GO:18@4B+
MJW7;N%)HEK7C9R6NF32-6=;KMKS0D#K@@Z0R+&4X#,:["H -SU N]+<3&$CZAOGHTW*&[P/^@QJ_;+6_8I3Y3
M\WV22TT3]1WW\O8[S"9$%'YVFJQ*G%A:!R?!#?DS]44X4\4N 5;U?B._OR%^
MJZV$S6%?OQ,T:Q0G[%MS?Q7:M6J;2*Q?6GDN'!8Q=Z@1>?7E/:PW3&B,4W 6
MQ3K_O',*)3C1$$#2>J\H%O6JTN)*K7LU$_=NK:E*7F_I36FKJ9*- S'^\0=0
MEUI+MA1T0K]5E7/39=NM#T>(EH<]6)X9)NM0BVH9*)?ZF;:U7K)E,1TD&"^R5+F_.G/3SYE/(9I:3-T7- +4:U(]N)H8PMP
M@)]/@S+YW!_89 K:&PQ)HUREU/8H8)I1\51FN 1POSW*.*O'=RT)>$(*)L"=
M@XI#"300UW:.Z])"/WYMJ):K!>,9BQ)_CQ;!.=N[VG5AM1^Q-G8J D4'IC:V6[(W5!*U3*N<M%RJ^J_,D:O?Y6O<\6(@PL3Q-"N_-JY^I37G?;,D2A[4J%\K+S3?!H>T;G>90
M9IS)Y=:MRR;1LJW9W##QL:F"<8SI@(2%_DSE@C(*'&L(>MJ+D!.K.+> 5(8U?4FG,)'!/-ZV-+,=P#!>X24R];<3_GVY2Y]9\'>HHU$@+%
ML(9]N+4RVZQU1Y,&ST<2.;I+HQV$[(7ZVQ]Z%$\@ UD24ILKUJS7!2&Y@ZL
MB,TH]VC&5/JOB,PIMI57N%[NPH],HPL.S*,SCR)TLG(;+$6_)'CMO_7*3UE\\^LL?D&K&7].B*]6YW4//R.K1J,+B2@#-N=6;OC4H75B5S'S/4>R
M.>O\^^[,@ C6!)GN9_D6 MX6X7YK5V8D'#AL>&VXWB4/W7?44W?"=2>Z&K*L
M5(LUH(PW_""6:!$:J$Q^;U\D=E#_(M&M8X\IF'\(R@0K'D*TQ*;C:2 >8&G@
MV#Z>(._Y"-\8;2F4X^9[O$P.\5VW;6MWVBR^Z?B-S9#G.OIBP3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MA:%^;F"#_W'I^_X7N/7.%I.7GNKCHT&W1ZNCXU'9QTCU=5:!Q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M]&/QL4<%&'8'"
M^$%IP9=X'<!$ C_TW6BHZN[-)?)%$PD@I\QHW*<92+1-=:U
MQ?7TI]S/9<+\"1NV]=?;ZPQ63>P2[N)_6!E&)6>I4[?(D&?H'8>_?R#[W98&
M"J."WSO\K*>!3E-IH%P=@(N>4^?1>63,S,X!F ?SV:H0,?^.!MJ6\OS7UZ,H
M*5!JP_\?KT>9HQ +2L0.:@G\.C0&WT'.^T #-[
M72HKR1N&=)+^P9AT,^$4,P3Z]J$E?J6OM^C5OHQ25WB[ FR2^N-5(AOI?4"G:&#$@28Q4^G>W'WS+WN%4Z'M57+?BY],TV)K1#^S1]4M^4$*FYTM73K"/$-U9,
M+G8];DZ"N57DB[+8C*3W8WF(H0]OE[$)6O*;C.$#;=#)]1;VLS-$H&BZJ2T]
M)"_C]^9PA^U2($
MV?WQY^00)-N=EU(9"X:+3U%EW7?ZS@%51,2-+F* NS9.3U_/A>[TQ& ZMBW^
MEGMN2AQFMV;"$!>V6K8^6.!^#VK=,T'U>?L($23C:*!,C&\OH^,4Y#XB08R[
MF70NG:A[&#E'UB;([JN;1;MD"\#V!YWO=X@U-P!%^T:M/2?G2G)[BBJ^1@E,
M5T<[M3DU*0<7CV;)4%7F.X<_CMRZ=T90BY6!E8>Q%72%B>>-@\!;&DB?XI^F
M?0YJ;IUPU\X::SML-_ AW*4RL3XS$V97*O"PNHJ9T&R:K5M9;IJ[22W<[A/C+=HTMB51TFRM[-G0^9=J]O9N.(K4^KWI,S1_@5?)GGM\UG#
MFYO[[ZZ[UUOEUA[[$C!+;&N'O6CJ4M1,+SK[;O9A)=$XB:R*U[I,7"G=@$4<
M&1)[5S)#-5-,88E_+)K'2"HS.O[ZKEYIHI B>59UK>\JL$!$C= ! ?%")E.E
M/I!]CH_>RH:[<0]V7\O9"H&%#HMQS:E3A*UFJCM(C% .Z^%?/S)U=BR3+;+-
MV>ES0FX2OM,9W-"
M]2\W]J9'>AY[YIHL=R[7FDY[I#/OF7;LASBYB.?5()"]&*(CH*
M/+00Z#E$7I@I5*@W.ZK7JJ['U4I+L:K6)X9M&C7D4"X"3T[LR&=G8_FI. 0K
MF?L%W/HC7)=T!W8N.,G9;K@8+ZS,#KNLS&QX+WZ@.SCYQ]B?^ ]PO:!=R>E@
M=8BJ]:QZ_;CUX;>]6)Q(J"L0O"=/ZGB+X8-6V7+Q1RGG
M,)5+ONW.C6NM'Y_,J/DVAIL=:2!\<9%K4<=12YPY#U;#*V
MEW0<(ZN1??V7S<"#0\8S]HE^5X>B;^F+.W8'58O;\<]*/T853->JRT1_@_E%
M%*H&+YK:B50INFZ(>)5LP +N<_.\8DW293)F!
M[-?#!/_O#W$Y66*HF2Y1F>L&/\KF#N>)E@EPWQ,Q&'9 ")+ZMP5O.$X6^E4BNK]W4_.JM[O8J?/K@##K.S46]TLV7Z"MQ>LC6#-$@KX(I42-HCE,50-BFF(_:M) OJ2?A&+IK#((>?L9.5PNV)3(E/\
MC_X:O] Q A?3PN*)@Z9&;4@TY_R/EX,$@G+J8?;U/R]2.)T?JAKM2 :1_DQ0
M>V@T+O+TU4FC<+F#D?M-KSM&43\:RK%.@;(W;->A11MN?F%:L2?JGJN->H")]JCI686MA55X9VKD*:ZNK8'6:6..G;BKVSS[B8UQKV[
M^BE(+,^UZIT9.!Z_^SI+3LFF&^7T$1:96BMS/+G'\ *N]J%/ 39Y';"\W$P#
ML5+/3(%-6^::IHZ>/3U+#Y
MI.E;)J:$2B*9'<83-?>DB9OXH%Q2Q.;@"BO004PW#&9Q@1U=)_[$9.A=6U]E
MZ5Z2-$/[FM5M"?6E$]@BF^-VEYW'HCU#(M5_9#T="6MV(=O7U)RJ2+03 +&S
MAV_A:J^IS&&<73DMUJ@259$*KTOP!:.-SKBA+P\WL.OK5@T.K?G29EQR^>J9
MP0W]2^?KIDJ\?195_)__^F,R1,W/6Y[#@,V H?3=B&!>G4CG&2.!H6RL42*S
M+4I/[14,9>UHFE[2-J,)UN2P'A4
MLF+;HS;@IYFHS*H_5;)LT0"_YZ%\9BSZ\G.^5/Q))3B_W$^GE]R=U]4W(S@K
MA:O_%'N1.@UF(X<2)P_#B??WT]"-Y L KA;8M)V#V_G3>Z\/Z@M@2&J+ZZZF
MQUZ4BNL-BBT&GM4^?!K$K<6 $$,?Y<3\GM_);#?M+.\"B))9]>\BYZ2YS?B=
M';L<*@4&+CC6OJRH]?@Z_EU&)M2V*J/>(M14.=_:1-E;./@Q 3ZB]-;C]2=%
MA>XR;D'MT1Z^LZPOITF"]I>OA,^$.PUG?(>#9SYM6MNZ#%IM0Q8A@=,@@8CSSBXPZD>([WYRK# 1D5#>29PM^0Z+MOY(5@ZM7/X$>SQ$.%4]
MZK(19W8?E_D>X^7K?'/6UBX*PD #^8,7-M=Z5D_MAR&9X38?I8FH)_#@M#JY3)A H/-2G3K)_'A@ CT'H=:CXQRI/*U9UY$P:XO:#PBB:V*B@\@M.;K(<;?Z+2J,;H4:63"134BVU8_#)N.!+A?L&/N7S+#[M;(&.Z&F[E@&D?;<
M(EO*D24;LPSTYFQVNUF1=>HV#33X&X&S":OB+P\;M5,)][4O<&$QS;\5$6JC
M/]@=.11JDWDKW 3%&HKB3T8X(-NJ7Y0?1A23UO%&;2?:/@B&GF!P=AB..+(>
M0,\'^L1@Z=ACH]0Z5U@NMCL)7>.GDYP$-P[4K_4-?+%CK50/$Y^YH].6\-M
MA>RMARR]!L/@-O[=U77,(H+0,0+F C0)O"O/"0N$\0
M*RPWQN] !'V/]2OK7+]&1IKXBD3J*)77JII4^,GAI)Y$I&V#)T3K<3[#*@ "
M>5!THRXZ%KI)IZ;.?<)CC^HF. 7-I[/D9&V&IN.J25-OIX=&D0H\T_73;VWR
MNE#6;(L.V2T/:J8^)PMNM[Q 7AJ^62I]T'1BSN=N)2;.9=AWN#ZVFQ@I2:L*#%RP'W%E:2)_%I(C@^+#@
M)*I2%VEF-C_2)T"MUWJ4!K(C55<1TOV3'JUWX';WVS!<.YJ'B^&)F:T/QQ0R
M+WU:"3F!DET_]FE2/R+/4R_"/ PT$S:09L351*7#;H2OCQ@W3K%5]YJC0KF7
M8YM38%,XFY7-G_Y^;7.(H']@)7?\W?1
M%Z0-NUMR'"MR7)RP_6I/;TP-;T@.NF.0X#^H\:NDIHS+YHG]]N76>=5;=XCS
M/1H7KM9LF[*!4PN4^75R0])+3MGSI$G]E5F4^AG)V,7/30#!9>B,>7,B$]&-
MX-R0/YZA@>(0B'>E<&8ZL31%4/2W?Y+S(BA\-U _!?)[H.XV8KX)0
MD>%1Y)$AY5\\7JN'5Q''J8YTJOV51 -)V8?2^30_#53/KO)_R'WC?_E")0TX
M^NN^<0<-]'3%LH,"'P$_IZN/N X>^M\1D!'ZG[\;:OEOGU[L_\V7%\ON&!62
MV;]\>5%A#T$V9700/.)]$0#RQZ3;LCC@$<=,EL9\H#^D3(BR9#5=9Q%
M,4:0^O>@CZ%$&\Z%@_7LP?W%J]A!Q#DJ+VQRN(@=RJFG6_VN 88PU2R01P0B
M&DVN5=Z2LEP=R!W\]DS7_O=WO^J/*'E7^H\IG#75SZ9+OCSY9G!E\G/(+T_D
M"[2G^$2SX-D[+>SJK%II:9E^<@+)5M?E^MZ%2IL,1YJ>FPMTV_V6\TM)%2\B
M+?1YZEU(9X\%:T(S[!:T?< H;R<4+^IDI-%4JBZHTVB"CGH7!1[9)ZN,[+G0
M0$8G) @-Q') XU\I8&2M"CUB*^KL=(T$%X? 5 0=UR8CI#4$[4 \ KB9'=N
M"3%H,P'YZE) ZU]"OZ%S*5[RF[B)H5'<)/*.H;YQ0A0_GX0,'$$W!9,$=X?
MI%N2-#TW!J-WV>Y0Z9=MA&CO1@/]^=^4EI[*<5EJT4#E0?2>\2$8\A^(OQ&6!OHO2TN/!P3O(
M+E.ZO@RPBETY15R>Z'H!W)]S)NG7GROT#"2=[@=\\NM>:8[V
M1?D67'G9P5]8R'6=/>";/'@$(:I_'GZ5))W4 UZ?3(D%$S&I<&>/0&Z3Z7VI
MK$>!3>K^UT[-W<; *HHXV$SZYGZRB9[".L[=QX754Z*^+QFV]"!MBG2M_UH$
MQ+\N0C+9#'T.\?%Z&7VW 4,#_0')SP8\LQ<[J)E'! 25F^[QL^E3P1YR8D\#
M?>PCT[$Q *>!2,?46I=UU /D"_=OPFDXK\ A3S7JXFUO2&1').'ND#ZR67_
M%O"AJ[NXOG"6)3>]EZK4=R"9RI40S,6A>L(CC,_'0Q=UUX(SR;SKX)057@"%
M=_-^N\*0%(WD!XI6K7)$57][G7PS?I!KNS!GV9 ]NW+;F6.FJ:-\A^_C9-7.
ML=UX7WGY\K9]+E852>(YR#[F^X(!-(6I=VF@"SM8Y(_;WAA 7ID&^LSY!4,5
M6#]LI($J8P ZZA-^T4#K/Q!8D=@9S(]@#%TT(A)"CL6@BV7Q?:UMO7$F[FQO
M8$%W(YQ>>"?!9AV?EY=*E/'Y+#L.J86,)NP]Y>VW\OYG^S/*!M(>#M5W_GZ@$G4.@N0@-5Q.O1]YTB::"+"'#E(=U"SH6<0.#F >%LY4PR,,DK+KG-
MCR7DYB^*Y?V3%,B_E>(E$WR?_RADE5B(@_\02?VV#%
M%,'UN^"SE$K6QSD17YXA&^M.DY\5O0LO/!+FXC$CM_O"T.4%<<\CWZ>QV"BQ\C;9/\ZWS#S?IZ*,L3Z[30/^E&:Q=5CZ, R2:X'HD
MY:%>80(J/AR:I,\Y S
MN09%PS.HKEQ'MFH78_6=ETQ*)X?/ "X4_!I.7W8%;O'A+E&CI<$-"#6;B?>S
M<5L&LBURJ(HNV*>P6#9!/1,ZIOE2PC(]S*-OY!IGVW^X,Z7N4NHQ,;IJWEMP
M#DI?HQ$*V\-5LG F#:0:_"]K=.VO-4+\M49*JW\'VLJ_U_MZS.D$[(3@O1<2!(W7I&4GZ@5FWOH]A,RN1UQ/Q6A!IBI<+9@S5NEZA0)H]EP
MRW,#P1M]Y0?[5;J4"KVJJ>![BV_Y_^3G[2UF)DY/M3P\)UBW:?!0I/3#1*55/$R>L2^
M\8D>%L^N(]Y#"&ZP4&H:.SU4GO&BJ_"$_/3O%N?O0#UW>.85XA$-M-]BU$^A
M'^@;!_\-C&B@=TS_XAD0:PUO_G(,V:O_-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M1$E,J:ZZKM-X1ZM(9-PF[]XOVQQSMU6#@G95SAM^=!ILCEV4&6XC9B
MAS/=;3=*'-2;9HO\8N(-X4]I(+;-P\=T$,H!E310LO&:)@VDIP/!PZD?P#^\
MH#P(XE?R61IH,]D%<6\]^BZ"^"6?!CH8G#PQ9EO!4+D\,;\RCE?2?DE0^2?W
MZ,FAD1W)F 8ZE_TVF H+0PS\HKR ?!WMDZ$'[H\ !PTT>2Y[MR0X0)DJ\AI#
MA24?9O'W(LCB(X@#P9^]O-^-RMNF%A*XETS)2)@A>T5N:A9&TO!)G$N2>B'$4# 899--"&ZDZ4_.=L II9:((
M.@R!R3H0!LPO_,?_1,G7(;VO,,!#>HKSBP!>U'+_20=&NB@-]-Y[]H?#.S"Q
M#^'#>7P5G08!PF(9$0?8RO]0R;^=%DCK@]X=NK)\NC30LTDQ.O-NF SFW+5:
MSW_N;"(%($]4VEI57"8CPR_A:"#?_?CC\9/%)1=#]<'JD9LX=0[K;SMNTK[U;*!_FJII. ])![--4(2IK(ZO=QV=J\G*+HM^I1)&D]C2/Y8H8YX/>G(0)$_#-%?5_1)'8EP[YI%ES&10R&ECF#"@KNHSNBW
MP[D?@^1(@#SD2!T"\[#)2ID E42>]8NU$I#S@)1CD[&6I/?IN%7 '0$^]YXZ
M!.'!1%S/IBHAWNH-]PM=HT_D$):R]"B(],T97\
M9ZSA%H25*NZZ@%Q #Y'\CN=&TOMK74(7#W"7^H$O,5>=;"PZY 0C!>%2NN=E.N!=/RUPMU5/"(MJA!K.$>5ATFO
M%92?J *Z0\>HS#U;'Z&5-\0A,@<1A==XTN1+%6K'2-A_:L
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MDKG#H'?Z;^:A3"(Z?T,S"X\+=<-(YBKX,^?Y<[&5?7T^2P5H$!6(Z
MTZ.X1CDG"K$Z($>>RKPACSRW;':QPS]%KSCEU*TIAMY(,?]YR @.W5C6%9!GEI"JY
M/PX>1'2WP#L5 ED=8485@S=<@63ON.$5W)"'G^%68O3 2ZDMJ9B@PB]N?;GU
M0/:A'8FO S^OK*[,!E>EXW+(#\.O+^?;'9CY^;49,10+:?M4)C/;UCY5M2SPLK/[D0]4M(9RM'))(VO?HX&((>+])RDC>3:462Y6TC@
M7#PY')SI$26XU/M_(;;G0U(Q]Z%/,)RMF-1R^POM5%$@==V2GL[RAT'/^6^Q
M.?DO%M3S#B6T( :@WNI'.UK )HG(SCF/(J0(WRB!6P)GS_*M^H"1$9"T1@Q\!WZ^,J03 7,29.SV$T^Z6T02N3U^>=VZ:T/EXQMR')7]K>X4
M[YG?+G+U4W(S]^B7PQ8XT/TM=^U].B;[QA%=GMTTT*?GOZZ?J,:^<[]$9'H+
M7F <7)PG112?F ##)P:S>L+$8O<.2\#XA^[J*2!^O:F9:#F,X?(H^ 1+QO:)
M4)#ZG/# KBZ297QCT^ZY-XV^93Q$!8S7M%>:8-\B)8.J 53UJ0([A]Z%_2S>
M^.!3"^1[,T%DDW"QNA6=5A(D3E]EB\J2/0CA#Y=_+HG[:M?6<7 ]OZ4KUJ77P_;CO;VG?5_0W+4B_?YGW9^OP:DT$&AA0,7>
MRP%ROD/F_N_W[2ZJRA5\LKV3O9X\\JRJ"$8#>4!3Q]2^Z/UR( 2_EMW/@3B[^1^'F[\/
M!"?2PDML]$BB@*8W$*=^'#BB5Q(<]ZF>^AW_W6$N42K_#84QP?\[L?G?NQ^#
M_V]B\PZ8'NXZANE"?A5:30W/GL<2JMJ?XI?!-G/A+@G 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M*X.Q3,?W'^L'4EZE0%ZC]WCG&-MAV[$_/]@[#W#FEJWKN&X+4C1B/0:%:47$9!.;'0A]"ID*R)-.DB D"B]LZ4J
M4C8B!(2 E-"+$(J @'0!(22A2$^H$4+XHGN?\YSW.>>\[_>#'ZR5W&O>MQICK6NN*],14D_9>NQ"-QW(O;I^B2J1IM/"/7M>HO^0PV]S8]A081A6)IZ/N
M['C8)Q[^98MP1#@HK]Q$%_G0&+FKVGFM_$C/J[]@N:2V1,FB/DVS\!63K
M;&J\E782E:]B$#9*R\5KM:T@(204YYX#!;0:JQ@,*@0> TIVR\5G6P.G'RO^
MO@M&48P_!.6.4,6FFZ.I?R7FYW[?SK;"K!E_G1']J@Y9IK$W-K]9I6=Q]4A,
M/UB6"MSMY-P];/_D\>L"^;\6,JW]Q_KY 17_7.3<7U]_*HC:.08PVM_"M]M>6SG'?^/GX3:'J C% -J "_H-7]R?I=N^),7- 1_G%K.>7DLU_G^!B*
MC\#MV2^S0K0)*L-#^_23T%MH:?]ZZ4L%I];*]I%J)9,:NOTFY;)U_S*QK# 2&M
M&4&J+7KSZ[()O[)I.+,&^1GX/XK^*\+_E<17(;=IK^FPP*7]RL__M0S_(3_/
M-A^!3Q[)Z39.1LTA"YW_/472_P-A%JHJ"3+7(.X"T]
MC2O(EM]5=D'4@;^/ J]%PKE,%Y
M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M?-C@'M>QW(C08W4DTL>/0\QP2-[>]E
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MGC:O].*C_OB*JRG0R%%SC9/X* ,3VF!NE:D_![B,^(##\K3!J#$LSE?%Y
MJ[C^XS]:"3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M/PI'?SIAM.*=N]3>? S8HSO,E&P*W=XY.K6U'OC'ULL)GL;'MJ9F[^L!*S>I=3;#CQ0PN%JEVJ+.-\B.8)&UAMS6F;<7L@#>[!F:"SW1[NQ-=>.D88L0G,_5KWD9BW-"*"TF@B_E@J4'F%.#@"
M=^5"!U].VZ^'])>O?J'-T'W1J]/PRX<.M"DO1(^BX,E0(GYF,)$A8<3.WPUY
MX6Y>MNHAQYI9V.+R_N+<@Y!J019[^X\Z[E]! 1-X$)432@.WT'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M(4F)=,W_1&:@T_P^_4AL\L!S5G[7'M
MM;N%_*:<)S?U0/]".I>N@Z2 @)48*#K5-.F$5_4UGF[I5$?. A[))PI*O5)Z
M%PT>L1G>B'_<1,#\2DRFJ_6NLN:,GHQX[[IH]4C<,MFHCP.\>&Y>5:6RZ>_-["/[33SZ!=Y1EML7V4HC>T]N=(]:&G!O%6LDM3G"WL
MT?:UEPL93WX(9+\NMIOADO8'%U8KIF7@<]H22WW0X%W#DFNK)QIO0>GMWC.,?M2Z"JHT/4?]"3_9?
M?]*3R+\S(32BVN07&],BZ!S.1,ZE-H'_,V7]JR!"_R;ZOYKF)]%+T+OFIP48
M^:<%^&5)H!3HO]-G(G(-44&#_BR9S7_U$O^*R%](HL.!]D]Y&/ZG/'#3Y6&O
M^P?]HZI'8I#_W3Y4R?^MW-C_3NO_&M?/OA.@U_8OX:*W0\,RO1AB_\MX@?]+
M8#\E"OBW1"7]W.$1WT9^TB'H*;T/1___MMWZ73J@4BI>Z\M\Y!O#M_A9#;100S4%Q=**AZ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M%:X?@JF,U221-:GR?M)T!V\-ZM#,K9+BUF6T+*A.EL(L1A\^79^P)/E7MF+[UK:=HQF;%R]XF3L?1[E-1E. OOAS1A[).\\#
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M4"?M=0&.0K 6J1OATZE\Z2$M,K)8ESPU\7E*+6=[KKN3#W@2%D6PPX5/R9R
M03IJ6UC((C'@FB8-DO.LQ,BNYE!9-?/TU;'SI9FQ*Y)_=')]M?:XDBY1Q*MO
M[?"ZY<-1@H;H5YBM'CT,#2$9+%*0*D I(/8K&E)*YL#1+=>&JD&LRQ:5+LQ>
M.%ZXQ>K4)8;^.[S%&J@%ND$CYFMMC26( 9 W-6@&-Z!F#)7$SWX;?96X/D2@NMU;1J6/#'_7T6U,O%UP/,JU9!J?GQ@>YJIY;LY7$:#R/VZE24]@UFQ=,?\IAE
M.YL:%3.VU8]D_5ER1[UZ2X/G\XKCUTP8)O48X#DVL&SR<;1K2%_XLR#H1O=\
MZF,4A$WEAX#5%^Q#<0?V9<)EFW??":(CF>V]K=VMQ)R(K1=6+KI-_0;SQ-JSC+JO;^P< ]A@*1U8TQ#@W1%/=+GD/(8W@MG(]Q<62=N)M/&P3Q434)25P4D;L4[U)7>VD2YTN&:#5+_'?I'=BN*A X@Q7H
MS&EV8SE(U4<[3XQOVT(M4-Y5*)!ZC@A.X@5'[B)/K$ O=KB0:(%-4KX!ZAG/=_OZ(CG3TVN>80UJ*_5?
M/*@,=!J+10YB5#;7J_P)FE2:W5N(Z+,V28Q@3ZX
M,$)7GZ&OP(+;7H^JL@AAGR^S
M7.--:3/!&K*CHCK[)_SS,D;3@KSR#?4*KIFRQF''O3MDG"P9>=HS-H7?.L)E
ML:\^S9N[+L*BC?M7'=)L4BN4'<5AI\-H4TMM8[#WOM$EV\46#H:V RK(=W$4LH;.^
M(;1?RD^__+R]:TU&0_+,@ZDVZ=?\7;N/Z\.Y:S[QZQ+H9 _F@#,7+JNT1C==
M5ED.FHCQA+,YA.2[JEC&X*'\RU5';XQ(4LND]8VWXQK7J^J GM(Q?L7/]ED-
M3NE+?OA4M:<2A=GAS5PH$R23,GQ/7[MTI[+AC@ALTY7<6:4)BGC11,DD#!14456&,@/*((UVI,6T+5['A%E,(=#0R6=
MS$4[B,W-ERUOGGJKOBW(>3*2Y6+6UF:>P-)5:=+FP#7Q_G?R9#JGO-?ZG>MM
MXUG7O]H,)0IE5ZLG/%(_$37"T9X&U+I9 Y-$JMK04U8%0X6SRY+DBIR=[E1>ZHBWBUZ^]X\2\1$#==.)0(C@!=H(&^=A=1JK!H
MU-=LQ&&[8D9Z9GI:J>WW6=GA]YT8/SK]W+^]@
M6>?W&-]G!HZ *A3;':-=H2"(NA.[(9R+!K;Z
M;SXEZ3?%07PY9B*Z6:8?Z7?Z7[[FZ(,I/K2&91[J9Q LPZ@R9,A<;AP"2-6G
M%+5R4A7?465K1OQE+KKQ)JSJ^S4< Q*DT0\5!;E;A]".O.83TS+QLT*ONFIJ
MA$\WUX<%TQB7B6 FN/H$36W57I8\$:'& (S18'2S9R$U[T=3C0LIB)"[G0T1
M4]^^3G^]NB^+$TFI$ FY_2AQZFOU58,E,4"W0P4EAZO306@0PN7*AH4PLIBY
M^?36F,V(:<%@YGNIV4_-57K95ZX6]_269*C(]?J49ISH_F%O:V/FK6RG0IE2
MHCSQZ7W_4$K_9-8R;PF7*:-)A&MUY9H%9Q.9?:77O+B+O7@XGL.#K0MW&L'[
MC=9-8SG*DY1?U\8S=&0CNX%X*X3 *DVHN76XR3=?8:A:0XJ$KHV]%-;!:U"0
MOM?4V%B?N:2M\]2S:;*]Q^WR DT!?K$UCB@22>.#2U,DB)LG5QH&G\/!I:A0
MN#E!G:UCJGEGR HW2 #RG/,U',.,@L01F
MG:/\3N@%*AMX35$$"XI'W"35=@Y.Z:UV?L(Q;4BJ:3L0<1?A-TC?IM)?+G82
M0#'7>]03(E]*/CN8;DF0;@YAC#.MBC5G/MF/.M(D@*=.SHUG'QJYTCTGZ0U,
MQOP+XC*B$TEZMP,1=)G:>/,>AFP_!ER82SR:UAG?Y=,MY%4H*[XQ_56_V$Y;
M(%EG''B5,&S[^O=ML<7 ,DYS\3OI,CP]T030HW<50*!) G"M('+OQCS*EBWL
M;0GA8G%<:$=7BV#U]M:QTNF]M:'-&V",M\]?2T^%#OTJ[A ZW?K [,*C2&LXX!PKBYB8X",N@%58(K
M2JAU3$,$RW\,.%?F-^-TMX6TF?0H';]N1#'M-%H1PD[EA[Q7K$AF'W6H"ST&
M.):2NB4_1*TKR$SJ[\4,ERK,:!WB/4I."7)-2#6I$UY96I'Z.X\!D3*;7)\Q
M=62.B!J,5%?4GX.,BJR4#%/.*=!7\UW.48V/K:[E:#59LMQ'#6[2()4M#B]<
M3@"S=!+*Z=>XN*D60C:U,?#5;"+AL.M\QN/E&Y9W1^'F+L'>;[]!>]RN!J%W
MR]**[,\BNMWY&!IRN+7O$@=!"V
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MM.409* EZNDGN4!_1G2,Z1O7&V^FW!W&ME7B3/#MSK@QAU,'VE10DT=U4/_*S
M@+^D2+J^A+.B0L38WF"E5/-1QUO?4UQ/P$(457)L]YSB.A<)W(YC;Q&&\Y"!
M[<@HP4N4S!RV>LI=1Y0]S*GM&915WJWY)HAW-6CCC8=&FS0F1+TI@R9XJ)7G
MG]\AO1O\0\K!]EZ:*8%ET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MO27W>D^GYUTK>VM/S+)T5T8A6\\DH/4)JVG:*HO](_MMM_Y8Q)[\V/9=K6WZ+.A1][;GRB9)24Q
ML%<0 M$; 'IR4Y])0-6!8CX%K,K+=[E1<#M/F."FPX+D?M)3'M9<\4D7$H2P70H1.P]Y:")P5WMK"U0!DH(%U*0A'%[5"D,^@HL<29QD .B8IZ
M2FAJ4;QX#'#N+K)YT*.PG'G-K_'VM?I8MGG+I>P>Q8/XGD*7MYR-HYF#!D-K
M\W5U'2EVF(*(M*8)3ZG/_?)HECNZ\TXNCGV ZQ*[S'MWR!,OU$X?.M"^T,#D
MW"0X([[U]&J#8F?&=Z?+N6!+D/$FCMUW3G4(E\#FR@PH\8]JFH*#5-CMW2]-RI'- $?DQ*4*+$[B[$;4;.+,FT\G'C
MAQS"\,:P]:6(IE67@A@\/%_VLO834TLNR6[9"+TTE"&/UFU3(!-MQH3.SOP/
MR/;]8S[[,S#LJEJ5NT'7#:-G\?"L@TA;EBBA+*$7D5<>:'?)>X]=+V$B>Y[0
M5NISG/^:>I^KB
MHQ&B5%>R3(0DU84X?>34H;*7,H<[9;,2<'':"@;%!LE$ELN7S%@:W9C"':'L
MQC!B;+T8:_MI!^.=?F@)E^]8Z]AC,KKWEP>+M4D>[KL?>U!?MZ(5$2OZ_[6MSM5D-WR]1""
M#"/M*R_N>8LJ58P,IG].5^1Y-8X);D1QI)M9KN^"3&2G"(5FWI6M+>;#$X09
M;>UAZEW\#W#UIA1QM-K]SC.QT\T=?YS)L7*O&_QZV T"(IBI%N2]&,(F%^P)
M'G&%RDQ&84L@O-9Z6Q3M=H32A(GJFW/7J/KR+J<7TX+2/[A,)<5*XNW.2YD3
M:A,WB!"M48@@D"ME>[#C26]V"SQB=0EHXW/E6MEK1QJY2Q;:Z"SCRJL)*5M,XTCSYM8G7W(*9P0
M%!A:;E):03E(?8^OV.[6DTX783-)M.A8N4A4;1Q303,< ;(N:5KW;;RTMY&Q*1?-1.MC93MY:P!0?65)0DT\\!E#,@_R"TE'X0ZY1Q"7Y&_U<4:6G9\LO
MU"=_ORU_TY)MX"[0Q%;(JP?J2U$(D'/ PM*-9RDL%BI;!*$/MK=-0S5GK.^F!P;PH%;+4V5@CQLP]CK%UF]@;=SM[BW;Y_TU5LD)A#--$(G+UTN\W&E0UW4C.;QH+#[+#%_&7Z!]=A;,&MM!W$8(
M].9%MB\JARCCQ9U>:S!P)!Z,FO-K";%*YO)%EX29H"#,>E5IXE;%6#;M"[G]
M@I)';VA*%"[LK# 9$JM70,1_=&O[UVF.F?>V;CC'Z>KIGBLB@T?I2+GEQ Y*0UR9.6_:C\"S#:7IR4
M2Y^??F;" )/$!:MJ:TC%\9P;?*[&.#M1 1V3*"XE?&]\3O<^RY<&=X_M""#N$DUCB,4V&E!Q!O$0>5F#GKY_@YCV^XJ
M]=#B%;R;Z_7\Y,(# W&]ZWT%X@I%0^@[V5:$&]?BRW7%1W*K86J:3KH#;ZK'
M[KU!]+^KJ!>&OB1;GC/Z.%&B;#Y0[ZT$-Q0"QJ CTZ&=@S)80_/K0PFBDMV,
MD?F)^>$N9MAR-[Z!U.+I0^Z_;M@5@EI:(634Q+;9,R0A@Y8ZN/GA;:SXM$HU9YA@ P@&0J[ANNGG\2%6G3&PL(%B1;8[' #H2YRX< U#_]UMW$V\DCP%C
M96S4H1\!ATK65)$62G)Z*]\.WTP OJ ULHF>JW0[$9.QG1E/[2K28H)ORM@I:TP*<>\<*@G56)B%<&CRL5/NBG0N2^XQ) E2UA)%6B9:2'5/57#6': )+3
M#\Q*2<('1+\;5]#)>XPA/4,3@L' 6;=,@85W@^]=MJRGODW9J5;S'@.B"EW@
MUMKYVD"]3N+&X;C0KKP^[=[8FF[INT\9S'62#ZP1C#;#I!AD-9D4[ ^#L3YB2[
MP7"XVWLJ]SCF>BV45(ZXC(KRST-]'\^X6E$[K!!74O+B[8.[EZ,,QCPVGJ9F
M*YH_9%@+K/Q<3"QQ\+K1\4C,!'67,:F/K80; HS!\44$^1"]4E)=>\V6SHZW
M=Q6H:GF99&Q%G1O[5+(P>J-I-AW($%T,%7BU$+BSC%]0@7UCN+8%GY(M-H%E
MEO)EC 8ID_GYE
MVV*D6@FN3V08*1R?;A-D,G#=4TUBI43B]&/UTX;7K^4XSUGE-]0KUMXD]S^3
M"46R.9*$7Y,5FM0]/>?L;+M8X>HUY-.T9OR1AH0GOT&(<&8+UUCI!D;4_QS0
M/':+YTI#G'5U)>=S1FE[^<=2>YY82(P@:*SUL6=8 UM()S,R+CQFNL)$ CYW-I!EKTTR7V!EO&^-.?22/RX]U%R;^_& <% Q>WD!1?)
M>]^0;:U3BEA.*/ 8X'8,8*":UL=U5L!V\91^TL'B1J??733UR1 5XKJGN*>B
M=ILPO#BV^6ZHR4 C@_M. R*N>.I^K(T5-L<]2S'>C_1'JMM[9(/O,HP/ U^SDIF!?:1-]-TS-%@HE%VGJ;!F 8(_PKI>)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M#^Z\J..[5Q+M2]43F& D[\JL$"G>YC[SW#& DR+._-"CX19M()9@ +%MK/DP_,1VU2]RK<]Q
M+SG2):O7VE'-@C.=MT:,0+0[LN2P2*K]2' >@NGYBQYZ/MQ=,>XD?/!?E88X
M,:D-&_FDYK/]X;4FMN3_P3KBO@=()O QR>M@$<@S2//7XG[_
M0]UZCA38Q0Q8Z347BLT6]TI^A]_2RB,)$09>XZ<'+\["#(BUPU21 OBM<3\=
MC/H-8I<-%_;()P SK.9=1KG)ET$^\QKO?L=16-V0\$G^PJNRS4LUU2^?E(R#
MJKJ[#$QD(C)XD6'$QAK*U#Z)*M8 885YNS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MM-A?KP!\4U%H&$7IZN?41L,5YX)Q?"N^+IDW444N
M81::0V4*)=$;PP,Z>4TU^JJZD1J#S5)7'C+?:YSHE^M]==_?2BN'5\ES30>;
M(=,QVF% S$\SZ^KEN";:V7U.S5":#<.;R)^857_M3'Y?V*MKET4FQE:S$G9D?\M?;MH91#@YC?>;LNXX;[QN*8A=.^+KHM$I]SM8!?Y\=IGT_D.'&.E(],/M"RL
MKJ6+:(-_I]X[2B\@):UEDZKVGG]H-M"W'85#2[Z#.78:W5YZ'P/.^KCU.?G.
M23"O.OM9Q!0[IJ1(S2^#E3P]
MAX'^%&^B.G OF2)%KJ5=0$8@3E"&WJX@KK20.8X!";OZJQ+@
M6$LV;<_376^XHA7<;[UJJEO;1"]^>>MF-1B%3@\T%YP.0 0D=AOM<7A)HV$+
M8UY?FWJSF0S?52BIC&0SC1+/:O:/%FCE=XK[A:"N%FLI/+B61_3*,4]W6'&X
M;EWZ_>'[)2O^/JE/9*O8]]<_+M:Y&G<9=8Z]?R^I(&[NBL]+-MG/4>_)'5PD!!DI $K@YJ:UBUFVT<=/V(K]UHQ6:@HH#BJ]-,3HKN2,!O,BP?
MI%?XNGD6P?)MK!X'G^,<>U#/=*G#;%]])F@>S*#"'
M@ C2)40IB"&I[,7A1ZU::YXZ;LJDWZV_8)@Q&T_=;B#JL_^Z,^
MQ;MKP*C]V9-DQ;44 O2Y =F-;DZPG@FY9VFJ]'_:[47&J18-,N'P0$\6UDEA
M%+Z5SV5HYO;>H>UCS[7)H2=-U6YV4A%U%P>D7*Q@?>V@"T@''-W!G2FCBMJ-9)Q,4D\I/#3MP%A<;!\[9PJR_WGMVTR:DJ7 TZ0DW[2QP)6Y5=TY>Z(^KO
M-LUG:QNGSYY,8[;:*LEVF'EJ$G%6TZA?[/=\AM NPP))J: =?E\G#9V1CH>N
M>)2TC49_D[JU@@*3U_L)'EIYJ+^W_X)-BV9MRMW0:MWN4/1$GD-Y+'M6.$(CB..:)8>AW(]AX"2*2/>GK'[(\/R/7,_H/@=^
M&W^8Q.'<M/L]0^2@ICG/ZX)C:',%0W$?%'(44/(&2MMM_[FD>.0&SVYF B]H]Q3486#!S
M5R'MFZ\=SJ8@H:$TP$#.MH'K"$9Y269H:V4"S[UKK>J.;_(NMW9N8:NDG,3/
M7-GN,&7,'UZ;'ZM$;]5',65(8 N. X-;E@^@06,F:TB]F5S81'BH8NB:K(EJS8O,6.71F4((^N>
M:Y=KFZOJ1Q68V=0CDOO5Z^I2E_<30,)\T;[W[_99CBXK.2P[IO%_QWNGQ#O$
MEN<8=RF-Z^E)QWLI,;8\*S @\.JG?=PE?^/XXW=B[NTG' A,ZB-89((*ARR%
MR:?$5 I+*A.20*E)>)<;$U%O%D<+/_1TE8^:>6UA>,OL!M/N8R*GB&\3*$M?!1D%TTB2':9M$W&&->YW@M_$_3G(D5TY,)[^$JY(D?#F3#C4G(;A\)Q5Q&;D1Q!+J7\CWR8S
M_!9I)KL6JXJVA+RQ'X%[EDRWE53"RF\W#:O%E6@/M=;\F28E\]2A6I$K3J'U
M6RY'J_.,HM81FNI"ML1S)6JMRVW;:]AXMXKZGB/R)5ESO'IP_25G;M%D\V>V&,*;3QZF[?:*1UE4*4+N]&(?
M?B(!+H5/.DF]39$KH(#QD2EH2LXXLSND<^G6A,B$FMQMJX$E\YYSCV>AWI0?W5DN+TYVCXH.E827>Q8YM7(:H31$%;O&7V:?-]5QE2Q-7FM2QWH.R"LM/8/(YGATPZR_EDF5*N@^)R4[<
MI64M=I%AZ7:Q[6:P('97&RN]K_QV-CX%ZX[1[:,%6\ 8L&/218H<'O*Q-69J
M( ^/-O2,YUU8Z(5Y#'8+LH]\MK\8NX^]:2-5$+$^_A9D2@9&>V!4*;MMG/!F(6JN6F+Y#9=;>5H8W6Y0$63<\Q8^ZF4R U95YAS,H[N+MSQ,#4IH!EG0
M!Q\V+&?#Z;(\- 75J2&G@IZ-*W2^4=6#2-(H]]E;5;M9$3AQL: 444L&=H&
M\,!#95I;@T4,MS:_OZ,YJQ\49;*&V&_M#DM0W6**1;$TA3HCG99IUL[=A@4:WF3R_[\J$+-'[84A,&C@V>UM77C]EUMY5)Y
M4R3][J%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M1!XLE':E L!T.]4!LF'EM[M?'JT>"E'F3R(_0%VR)UB^&B1HTHRV(QOTCU\"$LB6$3A^Q4[;!P7T:64&YX7
M7#9RKHZ@B1F*-_M7*PW 8Z[T?=^(B[,*.^I(-^Y.*]DUU2W+A]7.91RX#;>D,<:X6*3\W0A!HO?
MYJU3."K.V&IO88M2
MI0UHTVU$4K'S5%>%+[X\BG:&-+.40+NRNB?&TI#=$O9X^N&(WTN5)M85E:88
M-3=_<15K&UN[;]$+KR_?'5S6D#_*VM2*&BDK.)VF4 +W-:3%4238&M/TV)(IY3)5A.K=/XJ78D\\$7:L9E5C;Z(;[XC("LY:EOZ=<9IMISKE]\B&&7$L/1[+]D TG*^*E%Z R,!QM+"O(,Z.+-3S6L91Q8A2,ITV43'5
M=7WT4MZ,FLN^X4OP'\=PGVLR69X:RXEQ*OA6O>6J4FI1TR\_@Q&QL6YQU+Z.
MCLF/@K&P]:J'H7E-]SX4D=.$;($\IK 5JRA#?LRT]]OE:WH2.?E;8MW,D(A*
M20MC?>G.)Y#K_2O>5V6-^MZ/%Q:9M7>+1 19?3902?4IQHM9Q6;,\7M>@UZ%GZ!\IJ(5C2D$R/^4-MLQ3?C^DVG3.8B9A=58FS]S,N6)=HE94\D7X\^BYQMPC"JL*[89C.6$=5DQ]$\F^U90@FP'O6P&.CM-OM27H96"+;(Q,\J9J]K]+G6
M[/O,ZI^R") !3;>>;Q&GJI(50UOG<@E(#HIMV^"A-%6?+)U'#C8@M.OO,3J\>(./]W/33]MBFS341 =QP PS'0)-P%^1E//"ILU\ZU6YNL&+VCK[\8\O#M\$)=K#.?446.
MM5.D*:"YKJZA,GQ@Q;C>S>DU1GD"Q<(OQ?+ BYQ*JBL6EPTD]CGPWWU0PFI2
M]IO$S;W1!3WV'UF/FQ.23(%8-5D3;AN,;XR!>5_%JYX[B7+2V+Z+RUYI:GN0
M\^^+):^Z+,6B@%J)TFSHF(YACP0E0FHQ9+ZD=5*?N)[0W<'L5G[21@O'Y'].
MT8"2Y*4&Q9_Z0/)KZ,IU+'&9".K?.9B_.3YU_\!\AS?.M>ONP]/OOS55R4P6
MG.Q'7*7*D)?:95B[\=!H&V;G(/1 AD/9M,PZZ#4P$B4:Q^5L.?G]()+W9 $YB#7,[D!^BUH<*!TN6:RQ5M"NF9$XSJ*3;3*T&=4X,"KYI@>2-SS:-Z5ECYFO:]8-6K+K]O0Z:. 02N,*KN
M6]KG8\!Y-=ER9YK4F 8SG&VX"42$LE$0:ZY!5UN$MY7G27.4BV728PG[QT[WH-W@Y^$"9MV1-J1IU3)$>$X\A W]%
M98GXF/.(N2PL=M3\S(AQ/+]#PX/7&<#'J4JNB0%:A3(,M@)I<[[W.=2>*#+:
M**Q:$B2)4N5IIO'7JUT?N1KU;1UP3[V*]2XL$"5<&E.PD461Q_[+4X)0"_@)
MW=:)!\@)%^2.P_!I(U^,[QJ@6P3U>Z ZPZK>/Q_Y_/XGN'P5D6&?@'[3:&W>
M0F+@%KK$?WWI&;@YQW=UO3,(1JDE5)!JIO%G:TC#L"=]%A,*^@;6\LQ^Y'A6
M6-K:_(2?,4$SS2GEWECAR%K_0E;ZEB%INON)=$3BZI-M<:W?PWPOL#].[G:-
M 7&* %$%V(NG4C6*77%?[?8LQ_/$BXR-U_VE1#W?U1PV.G$7@OOV;YCN8^7
MR&:7MM+T-/LOAP/V;=4(W?4M\*S@H_.69&?/&1WX&;6"00=?MC-\?W8;@PN0%'!9.H
M*O??(/' $]:=\K/7ZH?\)]+45$M76#ELW6_(L'(_:1PNW7#D@G[]
MTH.>11?FD-1F7QT#JC3>Y7)PS;G!#4B_41W<,$-@/(<$XMV(CM+<&K(D= Y^CENZ9"$/?[D$]+.0[/"Y-SKL0:IMD,].5\AM*+F:NNLU'0/\R0IB4P^:_6ZH#3=@)#F>I0N=>_& 6FW;]>A[-VO$Q]MC:<+D
M--(6RH9;I\?2*TW9D-7W'6K;V9SA\BWU&V<8E]1>AG57"%:?9LXZ#4C683JC
MNP)Y!/'1TOFH+@'M.#B#FBGJRD
MV*IDB(G^R$\70T]9>;@OABZ.+4::/>N(-<]ZW_8F1E 'G\AGO/=Z(MR1V@J_!YN/+NZ2;7X7Z)4F\)N1-V+[.N&2HX7%WN5^[2+;/6,MXK>UOE[>6=
M7+S.MZ#GG:MB8J+VH]VK6-R?'6^1M:3GE9FMDKHR,Y*MW.4=OCR^9/*.0.1M
M&M8MG67HRT5SY7?F%5@X.LCMJS:,5/=XSLSJBX/'+Q:]RK#5U8\^BM^;J!UX\>
M)ISYG61X-:*+\M6"84KJ\Q-C-7LCI6UX)^L&;6/KV8;(<[F4Y7LB/%T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MK]L9+&9HEJ8M8B@_G3H2WWP,M0SA46%'K=C",H=G\^AWY^I'"]RH?4CEO=DY7.3,??0$(^([P([@%\]7"7,.R
M2[KO)V8;*K5UUWAYR>F5EIX48RD]87'JPNWY"[A[9COCE--RUP$
M>4@#*2'EL#CH*-HO@4UKY'MLN:PQ_7P!1.]"R@>0P\?8Z/P2PMB/?77N+LR?5*KJR_-3$6^/#OPKGBD$&7B
M[\3DEV+[:M-#68/GE+]/M[I;:/)X5RSLN^
M'/#R46_X\O[];^^+C'-^B_?1!=^?GX\7G#RI?,#6A3OQ%"$ RZ(+=VZ73%2#
M=D=C8&GI[N"YVTZ$!--;I)QBQ,LF&YD8*A*U[/M=!5$ R&0MPE1S32%>;44T
MM<1+5%(V$ZB*_G- +OJ0E]FY'C&0CS?P-?HB4[96*(6:F76IC"X3'BE,%?HV
MI;J 7F*L<7[6^TXB=@%+]'K58G[GG7BP'F+\HM\2]]C;%:U45RU_L3L*8@,>
MXEGU[U!^Z!N;5+.W9""?92GU1QH6G*:
M)UC/G%#_N( 1[,(SDJ229\EG;G8>8/PBL8XH\(/(/[\KJ??'V39 DG>6CZY0
M#N/5[F%])=FNG7/61RCM\^<1QATD)_K=C*JF80Z^'F=
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MR9"9(>9SA=]U)7$(6URGQGUU;H5!"T,.D9[S M8I#0MJQ5=US1_O^9O@2VZ!-"9/3-7D$KT%@?RE&T:DFY6EMFAMJ6A)K1BJ(K%*N_@*_&^SQR605&U2P4O/J ).:W%W@6C@U:*[_,-A-+4.E
M>OF:>++9Z/R?6:5O"X2+BW1GO^SG\^K=6-"#5R>;I#[:CN!-RVK.XO\F:O9^
ME&W13\QT+^U=MLL:/]K)C&OR4Z?86\!?WG>GL@+;,F8SH'9W=X,"RZHZQG4FU5<:-=:FRTH6&
MQ%FXX66VM[I71+,=HP.=4MYFZWF5&/J];S/,PJN8AJ.J#(?#%QCE
M1[R?+58F2138H)E&2TR+31*>JMN8%QN^,M4;W)Z[1KL'TK2C$1QT;5(4OE)+@1H-PK(I83QX /:.FGU:O9)CK$V.!/[A[E
MGN]JW5ZP>$J*><\'OG^<*-IW,T3HW]Z%;/KM/[TAV43MS591EGZHEM9*?B1_0_:XH*+3^K)5;KR-TEV[)^M4#,6K#%P+Y,)*8RRR HN03*FKN 61W+
ME5&W&:N""[ABG/JX-4>++0IT>_58X2-IR2;>X J'_8EEFOS!P\/5G6, ;PA2
M5-N))H9+@$!5,4_CYA@J29)U$H5%.
M'@/L:>K'@"]4=:C#1_"6Q0(2WXU<.>>[A>,%SW]SVCR<_/F"2NX\XO(?0".^
M^-_CXT$.%*=1P/E;O\4[[:P!#;.1$,/\,[$2!RH]A0WR(SBS?8AMRU1SM84-
MJ%W1_>JTB^O;W5CWJ]\>;7+CUGT*^O?*^!_SLR3>7@U;S\DN.CC2?LK/^I)R
M42,\<MSZ7XBR&Z&Y":Z[?D3X3J\']8P@DV#UR7S3ES1C96HHH4]0(#Y=8FV&GQY W#
MY>:R>>!WB1!VG+9:IF?43D_9VP\C1%E;B0>NO%V-Q?WG,_YTW@M;5TG;:6IN
M?L=E:>1$%V,C?_&!Z^'*EO)3L88K%XPGM_7,QY1$RUST$ .*E;'#"4QUF3F]
M$$OYX\!UPS,$I;F:
M&[?W!^=/6?V,#^22X%F.C9:+%,:2E6, BS1-$3;8D6F)
MA81_<7/ VLA$[V:#3<8QY;RPZ*;8*9'0)HEWR,)5DZEWMBHGN3F)]E##\[)M""HC&J1C5%))':<3B2*]L8.+Z9ZO[H7?(%AG%=M^#RJ,Y
M0X+OC:;K^*WR/-WILM-8F3 >1>\RVN,?98I4Y,CVL6 934KR#$NR\/9*RDJF
M[Y>[V;-II2M=3)D=FLLJ\ VO9*_B:S+>^Z,]V[QF8@2WAT>I$@^%7IF:NWXI
MB"D)C4]&Q2M*
M*._O*@ZG?KNNXC]HV%VTFD7GYI-9DA7)%Y2QQ3^ 5VZ'(@.2B#V0O08\Y^(9
MNU5)=\&Y2,V7/"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M8_OYP!W][AO)"Y>&]Y7/MT0O.N,?]PAW3\S"!YYLC*()ZQ7-ZD9<[F>X6
MB?9.MRQ;G+9RXDNKLV"(O^#E&Q\&U8)-[WF-4H$D$+YVG0&<4*UNV][*OHD:
MIHJ]M?X^-=8:??%@XM!T?6B%\%TJ,I>CY/M$\5+W_T?;>\MC4KO(B"(0+8B74"ZU(A(%Q$!"1"((KUETQ40I(86 E*E1;J 2 ?I))$NDE #
MI-RX]]ON_?;WG??<\YX_5GYD9JVYQGC&,\8<(XO,X>V___I[P#F+1Z:1TP^?
M=X6V=5_KT&8Q77\C<:U0E'MLJ<3*!.$ZF$:(UXO^*-9O^>6P=L])7W%0POEC
MRBQAK_(-;)-OAETBQ4X'@U/A B(G_ M*[R@*\-(/LBMQC^4S\FL+KEQ__SH5
MTW"3FVXC*X+DD\6PM-^OK[LQ\]8E6NF7KU]9>U/M,6S=\S)B^U105A@6,2#VZ$_,SDSD7ZDW4+R>=
M(A9BX6'SHN,U[QRM\65N;@&EKF@/.YFU/4^)48MZCF@8GZ7C8TXWWO+$DNL%
MKWZS*]C:RZ!GY>-)L1 IY'E3/!IG\CP_LNR<>3&"+0^G5Y[++1/,ZY%:X9.A
M+ 4>DW0V+J!5DJN/,*]0]M=#"QFMUY_B^O13F3_Z*QULF&.3:Z.H1]88OF5Z:@=Q>7OF]GRN.CYN^
MM/O<+2O]*G,&WJ5IG=Z?XB98;NY$(6V_-HF$\F^]=!(%J=-:3,':]^*VON!>
MC%K:3GM#HM:B@H:^*_)P9L2;H5Z[X(,"[9[) _]!F]G':VP;U(!)UKIW-$U BB<$3/1
MIK*3/C/8?>9^!K_IW2$&R9+;+GX(H?ZSN6SU',6)=MU5.M6<
M.V:=JU".6Y\?QRC-EXYHLY8_646^G?05[W?TR09\?> T=+VD^V(G9MVRTR'?
M0J:.\UOP(X%M7TH]G01GNJSD_E XKE^TP%))4E>FKX'/DT^&GM\D7@M?%V>L0^)QDB8Y$;'"7+;[ZY/%.JYF^$"!J3]G+YJ5QT]!PGD9=;>%I((]6YX
M>?8G*;LYNV40^:)5!"]0AGE'WZXNI9L[HM\!,EGC?==G-8(8&;B;*[O?.:#=79@^:C%3*[QPU+AC(U")-WKDJ&WEDW$8:Z
MMYZ/%KV=E=DM=_[\3;<7;'8P!1Y?C09H5=CAG0S1IZ18'^(
M$[_C6V::]$Z\VR1<1TDQQ.IYT8FVAUP)8:]Z*M3D!PUOYI\2CCJ=[
MS[57F(?R]R]S$PWV\K ^:/32+#-80T-;GNXMC]=]3#(V*/HQ':-[ Y6W7A%$
M%Q:B1.QO ].W7H$*#"-5E41#*6(#3MXXG5II&>R6^9C3"*EH)&/&Q.[.V5$:
M+PO"A>N/54$*X7%8$!A7E5A9+Z6^8I>
MBO@@J^G,(V&V+>NR,+=CO?3DY?3JL"M!POULR-QQ,&]LYVB[,2JJQ"*-C@G_
M1EG/VJ%R!&EZ<=5DR7BI8&.\S*IM1];-I 5T'NK#K:^0&FLIX2F&/_+#YB?
M/$_))/OUD%^D4P%::FQ*1QOPHTU92ER@& )9YQVFZ2(XQ-RRC]4P(N)3>W3
M(96//1-EDH-0:_N-;U,_G-3>YQ9E>K!Y05?U\83:=9W.XOLK#%S73H?>/LU8
M?E.+[K0*J1^>\OIS3*(/0EFT;^F\]ELO =>O2OJH[GM8]IK@[V$HJ!A[84DA+J?T-I8_$W3XO(9A(G[@!WPP[Z #!X=BEY$-:9NQ3E7
MC_KJ5-"](BGYO[@2:3CLY6<4H2*3C.'"N5VPF;*1V_'U$#M$HVT,F:0Q'8!?+8V?IC@1BY)PC]X:4'8!/=(8L&;EU\+3:$C0]?+?$'/GL"S
M'IM=SF$AEA!D8+&3Z@($H^@K#51 >+@3A@QLSY8>IP+\1=[AZ,$,4ST((JQS
M%+KAXXB%_?B&K!EX?NW#U/K9OAGS4(C,X^SY'"J ?A!WK?Y8F?@6B\3I>YYS
MC_@Y2TP_/I]WC9^5\>F3B+JKVW)G&02=H$6<0MV8W LUA9&0
M:/P>7R2+_L5U%>^T2Y!P!G/N]NO/"Y4MWNGM%HR5]7F;92&X;7;Y!F.V?_@N
M12 U6*0$@/$>A(B3=8SWPP-K?,0M8;@%>NBWQ0)5)28?/Z+,':4E%T TN@-E7Z.=8O=3/%1$4K%J)[>PG*\4ZJK1
MX[B8_?,F-N]$!XR8[.RF#9@S?(\SY>7/C8]VHI83M*B 4$.29<3@G0^$@X2M
M&D_!KHS]= R*T0T],W&?F-Z1)A<;?Z-#MWY$]9NT[$^DM SR1V[3*+9QSDFM
M^96PT1<8'?0NX:"CK9SY!+'#'O^,P/YJI)8*^$%?6^WIHN]UK36S!)TJ:/=-
MSREEP'7EQXY"PHZV(*8TV ;KU1D?I(-'1>ZA^(GIQL.JYZ4N$8'Z.??%7197
MZAY,S)&NIQ$Z1!*&HAY]>_(X4H3KL=/.(PN^7:)AG4"A\DB7<M3I545Y->N4/S!WTR)@A@.=;;U[LTT_XKVZK6)??RJ_D+-IVJ,A(),D6"LD@C
M_N@>1Q]A*=7*C?/:W#;QUUN%IT6B_'G3MSY:K)L#BJ8 GH!D1+7PX/,:SF1X#B\9I$PK)Y=90]%FIRS=,X0*0Y_V:>'(7
M%9"@:N6I8/K M=$[YMBVH2D5%VLQBF'5:WV'73@+L0=.+U#.KX3,[A8B3
M9(Y2H@"FE>T;GW;T]Y7G
M8%*6.%3W'D&K$.=+;"(PR7)M\(CCYY'8J&8#&%-],3'H^6<%C[)5 =&@$V([
M80[&(SB_/AT9NT)%''&/Z +SUVYU;'AD@D_.#V+IF_K1YS6"N&/P
MKC[SF=%/$!_#,@-DV>=W/CMR98F8=6":^P]8$-%MQN%\115V_;JXEJ/:ZXII
M7PL.BS!9BW9Q/"U,MOZI _9-Z-JXCTY8A,0W9PH@MF<^@(QV7H?UTA9W$QV"][1(+<[XKFE^YH>KEE.,A:+ GEGFFK!U](O)E",<:
MB%%5\=B"=*>V;E1AX=1J?[''#:5*8K+^F"_LTH*MMI_ Q\*YP5/KC[JQ7\60
M%19?Z37KJD<4CET%"2'AF!P %$BN:Y6$B$SJCK2*NB[4=J5W!#$:=G?H*0D
M\*>(*(/LZ9Z.?5,;?<_WWX@) 4]]^WNE/3$\\1DRR4T_?N\]$P*Q@6H37SOA
MW-2%IXB#]C7$:,6!KMU6I?K&!-"E%O*L"'W+;^OZ9_?&GCHZZ^Z=-@Z0.;1;
MEI6*FY2B2)(,1_>V6(AYHSW61QZ4:Z[ KNFPT9EYV1BGNH\)VQ,KG1R<=?4J
M]BA_EP V_XGT]#J3N>GYO+DV%=METQ&B#ROW?5^)881A&KT$PCXY^TH';U0;
M;BF^*\AY70]1U:5EB^RSG\G.NJ*P5LL:D\Z[N*3/S6#/S!K5:3G@,VO!RMW_
M.FR;)."2UG\JW;2]FZWX6%7++#.%'^1B< <98(SBM#CNM>BJH>-6:KH/Y%/0>,:< M*_70!5'X/>+IH?*#=2#)/E"S1OS>=_.M[D#/Z]?8G#$_(JGSG64'C3<$LQ$UVM$T)AEH=YM:35NYW[ 7P5,BB]>9V5ZD
MV4M.^KYVRY77ESO/EO'2ID6DST+LS-RN<UE"
M\$)TLW^>^[0%VEL=K9J6+=XXX2DK)30&?5ZO'MP3S:I7CV[\.")U/IK3F&-3
ML?/%B^5I&$<"6P);)/>#89;G >UGIOT!YQZ:ZSP\87&_/_3]I*MF[ZA5&ZG&CR;]^Z2W61*J4G9YKI%O-9LOF&AWOV.8R7Q8RX]]HSDK/PEB\'M
M6:5+#Y7+Q#\%29FK'K!D8I]GW7658E<>_G*M]II9Y=ZUDN?]K'=2K;#"*GPU
M.( QNOB]!PSJRW4C.!+F-)GV%GG*;<7G*SP
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M.P)#4!R1N>YEQ6O3!IME72Z<,W[\&O1%M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MD=ZL3Y)Y!^Y:8K]HC[\.$&RQQU^MY)('=;UU81O=]UX??*8+ITS'> ;X!
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M:JO6YBZ/5A+<+P@ZZ_4C'Q-_M]FF7:"2G0537"R;IW6^+DMH[\]N42PB,Y?"Q$;E]J=D^RLMM4-D*EVG#FL
MOB40J4^:ME'YKFQ'L8'
MJ)?AN#>1R#VR]?M7JT'^8Q=V2P4%7=8O:,K=KR-Y%' ]W&Y] (ESW2]%;X 53H3VM5MJQ:=!F(W
M:7YF@$L_JHKO$WW97BX1XUOUX"BEBHE]_%:WGX=C852WUH-FRXBII(FZ'[:?
MK;G@;Z:DM=VNJ?GFS"G[%M4P MI#HC%3!:;K[X5X,KRPO;$E]H:;)= A4P=N_V!OZ !-^6/>9W AU5?P)^J_K;
M5^#7R'M'L'AU=+)C-17 AMXM@A5>T60S!UC^VO'/\=>.?[!)-!RT"V*V_/6+
M+RJ@S1F$.U[D) <1=Z@ #?Q><"2 "NBU2:4"(OFI@&+%P7ZH*Q60[$VK;6)_
M_>2KB(VDD1?0;Y:*-K.;AY;P8,2[+&8I _2@2MI@%8_?CE\K;.*K?U%RT
MD^V293T%VN?(Q#1Y##)UO)!/K>$).S#]A'PS[9]8]]-9D7 FT/^5NM LQ+(C
M1!U_%NGE74I2)>8X%,T0$3JU:6)^C" K/'EQ#"J-DV76?\8SH19TNWD>[N5[
M)KNJ8'9^S=_H1!)],71VE-&&59MA]7BD??D!@T^A;TOS-;]Q]QKK]":7\Q(U
M*35I(G$.:/&?C[F.N$-$!3807+CM>ROBX8^3(4^T'%XCC!BCEE(>9PE:I%>6
MR5CV:W."\SR#<<&[,0;AV^\)HB9/4MA- LBM=W%MT ?5=G:KLI""\O!Y+OMS^&KZ\8L^+X7@CTHD);Q-.T5L,N0*5")9%\^F
M#AIIODT W1[V';RP4?_<+9N)\+,> =RDAS,O+%0FS=OCCR
MHT* /GX LN^OZA^F&H1#1^XLS!(YN^T%\06-R&HK]QZ-,415W<23[=]>6XSZ
M&R#6Y=A$G_CO'SRZW"7HT)\RINJ'"[:Q'U4U+R$V=5IF"P_;S^T:>._9%-?R
M,Y8O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MVGU@;.72T/B@)^EU7_MCY2RU)_PJ>\$%:\MM77BBQU!AA?9Q@D#_M(*QE'6S5*_<+\H=9^)RWUJT8UK">0ZUS-.UZ>.1>@%Q
M/G'5P(2NI8]+W \KQ]8F(CCIX%V+N;.\P*9YO@45Q5@"8Q9TMD[31K1Z2K@@1(N(Z0]@)K86@".C-X')B?H?M\Z1XTCJLZMOA@=3E*PTY41S3SJCC7UW"='?IYW@[+ *9VXP2CC11[1N,@ATJ
M(HF<':N/)S>1/[_"A<%>)J0[(F(CV]
M,$WZL&AUA?I:O.-A*U-=+!BMHRHJ5Y?6/X@?TQ4SN.3HICHQ*),M_=WU.[1*
M5*B16$TPV>_IS+!;Z83QV+MERV?KH[C6)JW)I#IUR<:TMGIY>)SZ.602$/;O+/OD()_:LXGKV564XTJ%0&8N)60';F:O-4BH\"#XURY7F
MPJ'PAI&XI3/LYZW<+.&5[,]DST@U\2QN-W[TS1=-Z[ODUR 22;_S_#G(;WG7
MWL?MG4#F7;++O6-HHVC\'I!EP:KC-)C+[[C&\\[&/?R.O;NU[_TN=11RWK[FI*P0
M$50!)KKLWR-'J]XNM%Y]!DFV(:-\%TZY3V]2 1&JH%*/>@$N]*1BD(%V1RRL
MU"W=DF,__<7FC9SGB37^H=]J:ZZW-TV@E7*)PX3L"4^)(*_8G$OO,^\,.>-;
MHZ74%2:'=U%,L]U51GEKN,U":=_#1PEM'#D$^FX.:]$(OW-[,,8UCNF]W<"GK\HZA$8URMTX0APB.BQT*RH0E)'Z!UNJ
MQ]&%\IRITWFJX@DI$J/(F'9EBVX'N>MA%K*)W1&\2KD*8Z4WLE;@'689/M"1
MO)FFI?LSY) ^<;,P_-131\-"J?IK_6N3.?OWO"4>-$]&^"B/^;G>#UM9E!3U'IW0?5M' ='_ 7O+I56Y+'#:@8H$N0.AUN+O$)8N1YIIG?>VJIR"_0]
M[^;H[.5+OG6_0=_&-?2V)U^ZI:FA8+A@-,\C%O,[,4<(')<5:#$SI[+ P+GQ
M]P;BVU*M1LZI=!AAA%-V^E_-986E4I'V',,ZM:$&[A1YHG<$:KZF,W
M[3M0$5:&YO>N>ERIQI?5T4XU=6("-^=K U6ZO _&I^;>(U02XZ66C :<7*NJDP:
M[R8*UX2*:DF/W8K<+UWBBFEX*E"P/O*\=WVH+"KEG=F&BI6%H$S.AR7#O*S2
M,83%=F"AN+C(SU9'QD[(!>4*Q8K*-U$C6*B,/&-HOJ&R625+Y\JW>\L740:%
M6L]R]2\4*P^]+KPYEN+ D_(> QJ1G;ZZT*:NAM]ZK2X/O4JX-Q%R$3Q]"R/Z
MNO4*E(GP%.Y21"Q;=.F,E_BI)@R5Q<"O3L_;R7=M7_.(_3992\1A4)<\8+7@S94R8E#[M7E$1"L7Y#J6"L#:):W74Y2)][M^F:B$V:39QI[ "8@HG%5&7W3(S<5:A.F/V?./5JXE[$_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MWHD4/ K[DGXCT?"[JK<.%: "U8K4(ZS\ =50+H9SX[ &"CS@8B. 5';D5UI
MUHX1B"EF\R!*H,-D:'?*-TCR3/U(^>Y,;'3,/9=$Z],-V0&%KX3!@Y!6&:A5
M_9@"HSUS-$4=;H$OBIL7P-<5JYJ7\VMT!+*]LK 3U&SV*&H8+5\VBW?6MQ*4
MU^9[]F60S34O.Y\@BA5!O0<33M31.ROO4^;CZE=O9-<[/NESJ?%KR;UTZIYDM1MN&_T'!>U?.,%+]J8VQYMK2A
M)'WL0.E8%MORV#L][@J!E,S8QG9=_;D8/0(T*/61V J;8 HV5UNQ+!O++U[^
M$8-1G9'"W.-7@4091]9FN3I"8+PQI?B?$OH*)=:Q^Q7EB./\]QKE$(_]'G(^
MA0WBKPG7)VHNPJZMG7"M?
M;NQQNGU#E78#ZV!1O@W)#:_2T99S">0L?>J3 ,=$(=&2L("A MJ-HD,4T]M;
M14<]G8G!QW>)IVPB33U]NB\-"J,'L&HGSP$-1_:(/S'C).[BM?Z3,ZW)"F@7
MHC4P <8G_6-W0'T!Q]G9%"3-J0EC"64]O-(K7QH3F@-455;
M?_)L8IQQ>Z7&U=^L;WP"7@H1%(U$J!#N$)]ZW$+>W)7=#$I$P)P7[-0V
M]S-B_&UMUAKC<2T3)8X>JC>F"SOC;^3SS[RR&L'8>BJ#-QXH3T;N&^B,%S)8
MHDVE\Z/S[1]$6<3A8DO@"5>?(WF2S>:LCG7&PS"&SF_0%Y]_T7PPL/2@K\&"
MF*'X#)+Q1K0W9&8))CVC=H#+^K&?<
MGJNNJI66.S^!:N:8:C+GA8QELS;B?;>OOHU ED(TM&LG%NN?*[.Z,=Z:$[K[
M6(L[VMP6>O><('SG=V4J0-6RB)B#O7>4T[%%!Q7&[]5.I"X"S[EGH&)^.C1E
MB(R1[ ATG=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MI2M*N;2IO-TC6A$6-$P%,/U.3D>O2A-,J8 +MW$ N5$ 48P\5L+,A0@5TM( HCT$91Y('.[8T"GN%]%DK=:$!4)%D"@?I(%L=
MCX*KFGJ5(^)]WVSZ?FMF],9D!L7>BG7$X!1VW.DZAVN;$QM[3EI]%F9Z?*>U
M"(W7!4[Y\[FCV2&?V@@OLG0N,UWW%1A'&K$TO$AQ[]G52
M2<$I/C$=,4)VC?@B<.2N4G?
MC,$CD205FM)4P'M4EQ%)TG>!M&AD.?Z=XK*+6-"C\5XYE84.66 2%O9%&8K%?[1]T0OH7=MF))51 ^%/:^7T\
M(*S(LYX=VI*%CX?MZ, ZS^!H,^PEPS"_'GY>!PX$LY/%8!T%(*>MHPLD,UIT
MK#>@ I88@?@UYJD@2BB:'81'CL(.-;3_521FXLMF&!6@_L&+=&N4"EC6.$3E
MH0N9B;Z1/UIHG@2.R2%:K*%)N?E_)6/4VP[@ )QV)T4J8. *%7"1D_9F98)V
MV\A &.DS3''7I!65I*->-'[+B IX
MR[S<2B,:"#,"_'! /A,B 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MTE-P>/ZIC .W"K&4[WA\N$\OUQT$+G/ 19OSM33$D[<_R3**+I$FAOG%NQRKXV=72O>!XD4KB-%=&\SB?2+Z[[_?Q"=1=F&"-
MY6XDS#I"\Y'&@\8KB-MM9 :&P;H@*J:M/^LAD7I0QTE4P,^5[2W2;UX7.;)[A&FJ="D2@TTV1G-)\[10QDE2 >Z[ '>N
M0ZUI[IBO#1KLV(5UT!S7.02-3_K;( 6,AV-I)+:5HP) M(-XET85"*SS+.$4
M!?H=383\HK'+3I F3,>%M/9K$<#2D0Y[87B"T:]VLLO;,12:P_V+8I,X;#P?
M[=[,(_\GLH'QJ["I+-K;7@+-?2[$\\%DF6E)PA\S^E !\J)=.20)!6]2,X@6
M)BNX:)&#Q@?25=BO9A&G(*]HD?(YF*1J^JO3Z6%S'KH 1/0%_1@MS6A.-DAA(?T*)I'DMSU_6 G(YKIR2 SY7XL7\'?QM_P7/O]F6AA#KGVV%+O)V,A_NT"R-P=)\5RYG8).=?.6_4>R7N6G!\/R?8[!?
MO: HO\)Y:@=P9^=79 &39_\'=;^"EA\3:XG$/YF2\]M\J8L14"<%D"Y2?/#?Z<=Z!^T _9W[*+_:1Z7OYOG5\B3C "M+/^*Z3E_-,EX
M.7\9-IB53@4PL]&@C*-XB:'6F/] B18"P_YT M"OQB\PA3_$RX+]P]Z_&/3O
MS.B*6J/_8\:]/V:<_#7C]J\9V1!_0>__M3F6_FF.D!P:M6D88KI4 RXE<_;>L(?M/:_S]PC78'RZC[O.'>5$T\T)#_AWOB-Q)_I?_4X-I
MNU$!IV/)&4,7LT6(->^S?E)R2%NAB;=ITJ33
M4RZ#HD [N#\B"XCB"#+=1[W/=S]B[DN+H02#Z@:35 -HBPC\6.48>H7\/@J7
M2QDAFH#2V?M1Y#'?.!$$/S%LT5:COL&]BW8B*S=%C^-J-^EF#69[0/[#TU&-4I6-0-$GS59
M%M$='FSHUFI[;9!6&1"YOUJ=3>HW\#U,"/297#N$?PD<.NEI3RL.0(8IA7]<
M:]QP*FYG3?^W\[6!#V$Y(36>QM]@H!5]38"2>\+"Y.%P;2".1%8Q+7Y_6@)1
M20'WQ9>-GB(=[Q7FO61U3^@XI )4#$IOP< KAGDO>?\\UR35]!M,=HDVAMVBM*\-%PK;8#B0IX)\T&F"M;(ZW^*?JZV(D;)3] Z=OO 2H7K/_9*:- E',
M=VPRK/U&(3M>I'EOF]5]11DXNKVF6VODM48J&;M_TO./&VC].?O(,$UV;0?B
M#FGM!@JQ@S#^[9RYD0,)GPR/?PC\U
M2HL!&/RI5/[?-+(6.]'TQ[GQ99/ E;41VB57S-4BMREFGO9O@"L+2)HFM,F
M@XYZ>[9'8V)N)+;S'WY/R)Z!^WS7?/
M7A@]_(7H]'^#J+CK'PWGF?_.G%NPJMH\JO3 R1F7W2QPBX>41F#>_$APP:RTH68&
M>UJOUN%A,:K&>.!^%A5
MEQ 1M, R/P.F!=#I?1Z71*>S*4ZWF3>L!FE9%G@T$7QR-J1]FJ-E$3Z]@SF(
M;PX(1D%@^Q7$;G5E[IJ6DZ.WQRE+5K>!PG$==2CBMT3/00[K.'M"V>)
M<*-DD]KPHG$D"MN-7-94$_^(A"-\!SL)E,R&E' UW(X3]5C0O=
MJ0 N11 <>!YZ K.5L+FX*=#9@:_&@CX-\D&?3I*T Q9M I;P39"-]AVH(D$[
MM$;,^DJNO;5[*^^D'[_(.G;0M&ZL@A/!!'Q*
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MXNB[?RV /#)@AI/,(' %R
MUT6[!GGQS>L7W<:BHH$7?>&GWPFPM=80(KN\(M ,K>R0A)&#KK.'TSN?&BTC
M*!QN2JT<^'(5 \3^TZH26UW%O:ZBMT6W@7.7'Y[8O'UU^-^KV/\3QXEM;3CH
M.RVTNW@="P%K."E9K6R3$WM_/;J^#/OT&?U#5Y\*L.!N:PNEB#A0 0Y[H#W@
M:;:P19>1M(R>4PG,*"S='DIX<\=RMQ7]:H%X*/TMLUM'U?'R]U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MHK@S$]^0E,B7'N20;M$,MD#V4EC(HTI'NA?!2HE6-*/R5M(_[8$\+)X_[8(OZ9)W\?VHP^6M_N?.P.-BJ
M-P%&85>A J@ *5JR&8;N!NTJ$]&TI.P=C I(HQ7;XIVPH9]P"N\Z;.<^K+,'
M@UY-HGDW9H:9EI\@]C?^ 87!!GD11+O->116EG+ICWV#AW!8F@@2?K2:^L'P
M7]XORC2*ILTN:,!;P7Z#\
M%W#=R=(F,_VJ)UO_!1RI?X+3-'GFA/W'L%EK"=8F[Z)Q
M6GL4/(@VM4H*M8+D*F9/''1L?83V@0A@+[#\#.&W*3U3 I_2C1'T:=1 TZHS%_.?$3E^C
M20M$\M(HKU[^'_7/R,E?$,/T:'^^^GMT^0\Y:,1=?BO85B'P2XRYYU2WMUHHJ67EC'AT5 '7 7>%-Q(&X3M7 #WG\*&$"L.^7 _E@X3 PZ$/6Z"QE 'WJ
MJ8Q+]C+6*YS"G.016U+0T)!A.2(]M9018+64ILN5YI\X]6V[,\D BF9[%F[/
MG1N&5(5ZHZU1*JI5'2H" ^TY-<^?^BU_S_ P0Z*0Z-OXG2X)6QC\RS.S;?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MKN[NC1J]^]N4^?49C3MVDW[+%M3U%.4P%34G@7REMD&7'UO_]L&\4.FGV><\Q 8WOQ[Z"\D 38MAK6ZYAM$;1W
M,^?.L"8[,9?\]'_G O1P(\Y^.NR
MQY=,J(#QB&?/'J*C_UXSGJ%Y#&+/.EBNY8CF3L[6V\+X_N%W&S[;EI0+OV*D
MR/&B[+&DBC\EO_4*:N7^2AV,"4V&><^Z\$WNTBQ]AA8SDX/QG.34=[>H ..%
MBY,[)40<0I1TL 8>HO#!>N7N?!W<^$;VK]\J\0T,7B$P)^1L/_,&[TOT'L.&
M%)^NH5I &A.^P)M.HZW/Q=1OO/AMPRS>(&\28:T-?>1QMMS>@N@>F=7X%[W7751SJD8\G/>6^$BML64\TQ#;$'O^M>Y9MM!MQ'NP0N-^!;8V#NL=P_]SR8&0>QF:O6TJ:_)5KTZ]2VC+[;<@+$VI2@KH9.
M^R:X/1#[/(,F>+6C9G;V8SZ.VO,"Z68AX$4'O,NG#:/HP+@C%9(AX6=R<6:L
M&S3('Q,[''1)&CFPV9WS?BVP:HS?PHVT$5KMMCEE%"7W>^>R*>IUW(?9L[?D
MV[%ROF(3^RF"859!';<^?DVU&CM:TC9AR6L)O\#N??UIDK<]8PACOTO89\RK
M+TM&:E^WOP*_7"P,1F/]E!;5Y@LRTQ+0O-?Y5@KO? .K6*]6CM>-SJCL=V:>AO&Y3@UM;Q(WE\_KX/T1O'G #F0KO(1H$8:PR>K0+ZI23Q
MX3U9GO7Z.@L8BR_X@H9?F1OKPM1LN8 ,/J())D@LZ^"I"O+HSV'N\?;TYO.Y
M.ZRYDG,2Y)+###4F)N>3;A+4DWTP2&W,0AN8 VI&['6=GEN*R$5Z!-H6>7*V
M#0BOS][&R)\II+S,%FJNJM?-M?+C=C1+[]\.!NY%GDP3,8UWU: /;\>YZW:S
MKK0_6@NR?A"CWH?4F2CXCHMM>"[3D[O"#(,G8H_J9$_%QMLJBC^L4B@1QZ6JZIF4A"),RDV2[L/85G:Y5Q+D
MXW8H0;MYZ-\H3%!6MJ\#+NZFO,::JB)TRFD:,-&LX,#;#'Q\TYMG,V8 [5DYGR'%X);2>@EX;ASGW
MHZ)SF)J52HFFW2K 3:>2D$%CF >QC@KHO#$O./Q4T7E$ >EB';$\/3]I,/:P
M,7M$VT[@G#2N+N&QS[/'LJ8R0I_::R78Q;!K?67YG"HI9N(FJ5 M$+/^]$==
M,^-W]YHN8I1-,K*$M;R;)41J(L\LIUY[$!M1Y#+6^VNX#?,!M[JG_R C$98;LBRAZ4X1K4/Z"\.W5Z%R;0$*Q>B&M1!)#$B
M+]ZE"\BN?F*P -(*BA7@B,48H-IS^*67!KHBXVL'6:T?@.+ /2\X.1UUAJ$W
MO6\4;!/]CZ]VR?S U+H6?OR8=3,]"#?Y8P]ONCA !?QJSQ78$T,"Y4,F,5NO
M5$\@26H3/YOM H)QS-'JJNCJ&"J@VUY@DL3*9NK6"(SO%6#.4*C*Z/WA
MZ!%[O-><>J8CZID/Q*S8T2L^%!ENWW;3LGW X:9M:9(1+_[Y*XK.N<;IC9;?=@\YU>*!;5LY]%+[,AOF[=< /Q<+A0 YDP33F&S^
MNE6L6S_#FL%8YT@!%-#C*K0+2,X" $XGZ:J>2#!DHA-R%')=S] JRYVUF=JP
M]IM/#? K:$&2I#U5IPT_.GB5KDZG>/=&>*B9&C;6MWQ(>;4\TQ?_LK-T
M;X$>RC$/(E3DY/:[>!>[<5ADI$=#=3UG.H3;VB8]2
M+^8%JMUM3D5"99%K'@KVP-O[-W\F*AS;] >190VO?['S1>K?UG:2":WI=F'#!Z39O,KB
M%%$W=VVL>!9;&)5ZTXA.[UEJQM%H?E38XVD]O5#+_8UTJ>I(R64KIJ LDQ)%
M4]'"R*Z."\7]Z>RAYFM# U4L*#&)ZP&!G4ND7=S-,7>_QRE7M$Q@:=SMN/G@7[P7\%NW+_M=#C:4W.UO!U5SMB$]88LY2DI''*7:FU)0#P?"]7D@F\>U
M[NW5M!,UQRTGPHJ"!9P:XW\6QH@+3"_J#*F&F&A4@S!&/ZKQ!UB!C\>Z$,?V
M%]8N<:TB) EBKW\!T0;#&=WL5$IT-)EL9715"5]JK?7#>#[M#K)H(0Q\^;TU
MW:G4OMH\=64NYT7GRLK/?<:,KCY:PD^S#(*?5B?%6A%*,53J1DJ-"(Y:9%JNZS?>;H
M? ,3,]82"ZL7US,06F&E6,E'XI/Y=^*M3&NH *5V/:Q6@KB0CO'C[+L)VCJ"
M 1Q"2?Z:CT.5WN+"A=[DJ8X(Z75KFSN',G-S[](I'BEAD*R?! 3(852 J]M.ZAT?+,&\R9[/I'5Q-/GP:1"SB61U,+U1#LB3&_M:ESQEJZ,HF63\QDYDC]^S!<0&SMM%8R E+T==3(X%87O7>QU$YML_6[Z?=X7!PVD2[M:V&T?37
MY$_8)=$W$_W/UM,K2S?&.Q:??3L:]9@Q-5OKCA#,?-NG/^OOUBL<1E1OOC;<
MV:_0+VX2H?UZL"JYMK&Q]7 RD@-^N%+[PPJ]@3XMBT/2R_495EI50OA^GK7M#O8V)T#I3Y.% .A9M#R?+NZZN1C@S7[*XP-I#"&JWO*A(3N^ ,PWZD]_BC"*M52W%/4L]C%MUI;+8L7W>'NED-6^R:=HR:9\")!<,2?CN4RNEMHIWU%T?_&P<6(^7['\(R1!M^4KT]GYT&C&)37+/RG+QLY#V6R2*-!=;=#H2V/+O%-W.=/[&O5C:_:$DJF\=
M_\,E$KDIUBV37)@SFEQVNJ2WY\ DJWC,/(2+T/.2Y(;O[YR<9R!&8I#Z[0*2
MH[D?/K8,U8:'>R$W:WD?-U%7WJS5U^#W9D#)B&'D5&=TWP!;5_"[D#65H
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M]2&R9Y.Q!M=7])O3OFZ G%MJ=(W;YH-]6O5OZ%2_O60Y==UGW7RA$_
MYF^G]C<^3"H*#RLTM?A_2@2[H[^E"UR^,?Q&P>Y#7;R;&K*[0.-)_$/]**,K
M&69F4FH@3$\W.#RG!K$I>\P!%8[]E)XMC@>UY5P8P,2"6*"W$]1 M@3M**@:
M1C+X3H]=ZU#-S)P6:X';9#9'WM.59GQ]\TMX5Z*ZXV[B)X'CRI2'#0\RDQJ=6C1:I"<-FVA/>+VJ?.R:_W7?'.
MQC']1(_T&R6O!QK@YY,F/MWO>HYU'>MTMM5(Z/5.N:+!>$>Y 8-O>,(HY:EJ
M;EU[M70\^U+A3*%%^G>S:*GKN@P$_=/XS_@!!H*JO*;"$Q.=PHC['[JDGE[0
MYXM!\8:6OX_1^"0Z@M92YX4J$F\?:T)MR26M G;$ZT;,)*L88(R]&/&FMR?.
MB]7.S?H@AJ16L8&>L>#IBA_O.;(;6.JLLQY UC S<.QW&$<)I>TO,D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M6*&LQ<=,[Q,7$L&% BR:5$"D$M6Y^3$TBRN<3\_62B8!&QI]V"(H6/J"5<&+W=6#/FW!2IH])L;?"SY?%3S:KS
M)?U.^V*RAO&^UNT_1<#UY96)#%DU\H$Y%H-5#V+N>_?)O3EBPVD^UZNY!@GT
M&\TLN=%2:!^B&Z1N[6ULM+:'SH1-PW]TXJ7W$UZW7K+30VJ0T5UPH&2;_-MIOO([]+=]9OB5\M\N4['_""9XG$]E+.CS8KED)ZVH\%(!1CWE&XQ4=M\[-+8
MVKQP9<0M-^>6X:>;,D]S6VIC;LUHN;&\[.I\O)A4=N YV>X%@-XF(#:7"&6=
M]JP@/)PRZ$^1R)AINV$O-H&I):#ABK!+Q!A)-;#=&&EPTU->LSZB5Z1AV%>\
M?#-;UT+2:A,;5I!"!3P)V.V'3^7OG\S1'MO#I;*SJ(Q@B./IO>9VC7:^(]!-R+U]RA//[,]JS2976NIVO\Q4
M-*#3;>B=2N+3K
M#I BJ&)T)U9\HGW^G<2;&+]M@).P'VD0>2K@WL0XR?=_^'!;0((*^.BDLD"N:ZV8K!^_XMEMP/KKV7XS1ZP397X!#-X>.N*($4-U,6\\_/_UI5". #/Q"VQJ9@9#MWD2I*:/
ML21:T@18Z :'H=F;30FR&%27;%BK/%XT?(\* !#]>[*Y&FH(-!$4!SG< HMR
M<-%0.6^%"8*KO2B^:QPY%]?*&V]ML0PNP6/1N W[I4 S.2*TPFQ'M9Y95<2&03KP0>/XFGG\@T<[%RJ&(\XVV]K*
ML7TO*/78$DFV"+&32'VV5U6R2$AEM[5=;_M8;I1JK4:$M&J11/-?W\>M&-&!3B#2?(@EIX=8I,V21!==T!F!TVE$XB*!'Y8
M3M ,(HI$4@$W@"*T
MU.(A[/L"B8X*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M3,R5L]C3[=KXCD;'>W6'? "I8D_L3*RH1RI+B5RU]^%\+?
M71JE]%5NL&3UR*<6+!*3(<=O:UP:;!]\6NAQ6[!6-#O 1B@,%N(TIW7)I+I.
M3XUY@0+EB[Z$9(_F*P(-LYA3P X5D\B6\@X ;J^OVN[UO9T]X)\*WL_!<""F
MOO9H-MM^9E&BH!W]D%]K>]!1?'R(Q?EMYG+]HRUAONR\:OA3L]&&;?OYHL1\KOZO@]:
MIYX%QZ7;*AB+P3-D/%%=5UMCDO7CO\[/++"^OZ'/BZK7"BX-ECKR.)ZQ5,'%
M94K'G(OOH8W8/8TIE^\+B#NGF[Z@^;T:IVB2-](8KY9;0_*B!6H_<(&HEN=:
M=QF(/:M M 9IV*8'62#8@QGKQN2BR&O[9NCX-JB(
M.C))^@00QGC;ADB)PXVM!X//+&8+OQ:)40I!"DR2\FLKG2;K6PZJRZ=[O+NF
M1Q4)]JCL8$7)\.B83H ?VKHVP!('%VX'.D+ YMUDD6W%))RK(+=WM%]\IK']M>+V7E95]OS2HVHERJL#K$+0XJALY&D0@'I/9E&G"^DFT+>+9W3U.
M].%,_O0%4W5!.?C$2.I>Y;(E=TX>RM2E;;1"WA267JJ0"F^R.NIT]FJE%O72
M^6[/2N,[S827K4IJANF]]Z]TP#_=HP^]&\+6I@>@$391V47IJC\$A;1N7\48
M1[H4[\FQS^)<%GB]U9#
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M$!"N&"BU5:LV$Y)5#GU@*")VI_H$OOQ60/JO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M(E2#K(+*XQ**M4GOYWQP/1*N=GI]BGMBU@37=X2^D$$GZ.(R*JK;@C>VBI+YN_RJ(S"Z"F,")&K/[X)2XYE\T\M(7G9
M8LC(MVG6"$"'/BP!H"0NL+\ P0 L8 1D02HZ7[5BGYD0:NDEQH?705K\HD
M]>%!7\*]Y.O7K2Z\]#OKU!"3EHPJ,NY;,8[W5XE#_LG]K99C_GCN NCN@FAE
M\8MY*S]KAB@ZR$(#_J1RV,<*_=**\)[IMU1P6]8'8:_HPS?=NS?I$__B'GI7+
M!MM?@8I*X!!$*^ATAK>3N?RW?O[2EOLN
MM/0/DBK90#BW9Q%P2WPQ$147L^5+I:V83^>ZL?K:XRP=$K.J@'HMC"T*
MW(*<\$)DQ:NK%4_/>-E68E&^^*ZLJ^.G*S- #?5#!"7?%Q,FG#IW!2@&IVP\
M[KY_=[4NM^*78R<=+$Y?D'QJ]B+7W?-$K!SWC:5;WP0:+FA+NGL2G"4+E#IL
M<(YMS0?W5< )Y; J!:R=:4"G+0'K$&LR$OQ*3G&./.'^-]6MP[1\W,K'N@5<*@4\V\:F>0#<]99N[,((C2F9O59\/?W19_JF_9*PRZ_$AL'L
M=XB;,F<\W6N)"2Z!:B87UR#4T$ZR4*0D$$OU?SY])K\/(@ 8W(DX4%H2+MNT
MS'6:^$H?JT?$OD)/^)CU<+W-0466%S9B/?@[E!X6JT>!&B
M"V,2NMJUP[W%8N:5@I5V RVLKR?EV9O"$QYBBY4=;UN9&7Y,G7=HO5^::3['
M-"TS$P^NRWZ1)]_<*A@(=<)MV7":O1CJ_&ASZ=+'IJ!C#%*74-*
M-<9'--*'T4^M3M"'1%K4,4^.M:]>5.Q5LQDCYMWG@=]A\I92$WENL]?F.L_Z
MB&1M N$[YB+BV)44_(<@O::HV'33:-M1#0*\<^)[ RW*^]&;T6:CBJ7L-4+@
MA9?2OI9VK8W#*N[*80'*RM+J;H]M-4!W[WH*PFXJE%0]2CTV^>)ITH_WLW/5
M8HN7IF<6EJ(LWWS'\3PNC2/H#MSQ'2J.*Q8=P%DN?=&#OL[C5O?@ZFO"(=2R
MRQ$6I3B?%+%LNRYJ#>"P"<=9D![XG;]"@ 77ZN2?5Q"J78J9X]3V?EW,J:X
MZX#'20>6?2_D@ 7/?&Z%')2PS*GK3\+C5W8/0:=5.GI]J&6UM)NT YML<-PI+'3I&?,ZOHDO'?X/7G3>VW!P3],)]^P^! D ;G#
M!H\6:<\_R9 I.*WGB$\D3)68^K+\
MC[?!6O6)GK@/2L)E%[\L4X>M*RM46GRHJ _W%&VJGYD/D[S_2O!+O@A/K):?
MKI?ZF!;9NI2:[BMO2)".R-6(14YHC V_M>7AA FZ5:J$A:VY]Q]?:Z7/6D"YTU6;.6:(+*=QL!8F)ACAY822)>9:&0"%C
MBDBX!SD!)%^&T?;843=V$>-,GK*W0NS2J"#_BK;*YX7[9I.&DK;,22,.-:;C
M]A,FAG((.LE299PB4_N/>[E( H9E3EYL3DLNK[VXG @4SHGBRSV:I?9U:6S@
MJ^/'S$<>+_YVX!ZM>.@9-O\FU9*[&+JPS,84$,R5BI5+$MP1]3DDJ,])+B51U/>=?YE;"R7!PX&1:8@!VF*6W4B_ ]JMR SL=+/U<,FZVG[+JA@)B71:' I>[&HNMI8;?D[H/W:SNPL)
MF7O)L?8^HJ@QV.==;S=704)^6_J__/1;'Z%7\PF9%8*J7HK@,!>UH\5LU
M_Y?0WE\+.FTLZ"MUHM4-#/(57*)!U'T#LV'<;7"HV
MH;*8V>I93(<^P-7 M2C!GT?1#D!R'R"'H7F7!T6,5T)$#ZM'ZIPI23@I:W?@'HOCVU5CG!ME*P%SG
M$)#GF?8.P\F6!%[3^I-7?#]RL2'S;P
MH3Y$^WY+7OCX(CJTNH9\[Q DB=*','$42]"R5@#J W-N-A[;*K"87?HU\61>
M=1))(@A#O>;X.-UTU_9#K::90)Y=EAM
MAR$R$:N%Y)'\K=Q!:]4U+O.\]4H.##OH>V&*&JXMSKJ9 ?N4JX_3,S>":92*
M#I0CM']_P%#W-K6X8JUX7_4=K!*GW77G%57GMEIZ5E^K,.DI306[6L+4H!3$
ML72"E-BR3 ([$=?F@0,LWR&DFKSUSV69#"FEBKJ:J]VJ]U6Y7?\LJFCY3FJ7
M2"IM>_Y;%KU@LG^VZ@^&VYRZ+ODQP36%JD))X4)!S[*E-?./TS\[6'J@_"M1
MC[C?&'"+0#Q&"']JZG^H;!MF=;@JIT+Y
M6?JZ:UENLRW28M3/!V#.#+3-N^QK!L3WF&(*V2NZ&Q$[U;"X])SB+O^!T &)3KD\?KQ+;LV*[,
M4MI2SM"G8@OKR3O%MH+NRSH?S, PLHJ2T_C*/''C@1&OY\MH*%],AV=0
M![4Q_EA"-2SV&DU5:-G5YQO&P:94U+;[KD(?OKU)?;D;8IJA6\49K+-; ?Z2
M2-,O98I0,1W7D&)H[F6D"%MPFG67X;&?PG$S^F/%<>
MM=F&).4WJ>&_RAN79980Y<5N:>TAEG>8KT;$SL6DD75UYW&_5%>28M5_MKARX,26V78Y('65&XXG#,3#;X:/17$!6VY[='VG6"=<1ZY;)7="SE&K-6M]3
MI:46->\S1\5#B V!'_3@+B;^XKK09^Q>,K$AII63'KX>OW4($D("#=24)&6V
M+*:]'[A4!5RX,TJ$B+:56SYJY1B-Y'IE?GX"#4>.7)9N'Z-L(VB&I3+"+Z9W
M&Q#I)H+1D6K2%S/$5ZG>$0A%'@\E@9):\/(;@I*U*DE%U_1AVV"/HNN\;?JK
MOI)T65TS_LW<++Y;(_.\MGR_(A4_'O+ #W*0PT\W
MN$+Q!"+-1?NT 5B2HJY /E)24^53B,H?TIP#&+=#$!?[L\BT7FT*15H-2,%[
M92*LFZ#/)BYK63!:L02)=0X$EZ/(D[G.T#UL$])Y::=+BI/+QUA]67';36],
MF'V._5Y:%G LL:P$^FGD=IZ+UPIBF"P$(S,GI,I;$[&>$OSF=]E@",_BV*BJ
MM=09F&S[/C>CI$.CYEQI&7.OJ"USVHYJS;PQ85%5$UGUQFIHVP-6-&RKM>#'I
M['&D&.L8L\,!,,2C.>Z,5JVR.!BA'1A>C6#,454T<"I&A:\3N
M]FJ<&9 \27:JX'R;$_E%N]&A1 ;/2D(?K2G'):[
M+CK4J>)_2P]OZ=#%C[4YHZ+(9Q23Z8 4$9VM%6U6 0<\Z7"MV:V7X]$=+[OR
M/1@=5W8Q&QLV3(C)&F9>+=J5$@\LU$VV]K;@+P_:EXXT(@VUGNO0)U%KYU)B
M9[B;M9B)7=+')J,]$ZGK"9?]_%9(4HH4TQ3J*MR&V/#ZC:^1L
MH5B-']=G'C=#\3\C:4]\E_?D8O0EM9);S[',QX+S[&!,CC@";9 5&%B*COO>
MW3$AUZFC+G&:) 4W:!3.M!4)(MK!*!)<%3&-YV=["HNBA\AU8T^)ZPGZ_ QU
MLK Z^)?(&P@[;$DC:B J38)G[V\
M3^(6+UQQ':7T6U*ZUL9HG@O;"8"A#Z-GFX\1U== $QHY!-WW?ZZ&[J%QR3W=
M.8@J3&+&&5I
M8R->].-KG,C3?*E^L&/\9JS\:(RBV=>PF !BH7F?GY#/H,NHGS7.:+&FT0_<
M@YH[%_?IX;BE6,9@X3-+]6(L3M(%G 3M\8P/0_D2? M((?8)X*T=4+IO@<:Y- !1C)EV)$=[_N+VW'9N/T;*
M]2-.08UJ&/ZQM.0>I^$'W#MFH>6FEXG[$?=]WCZCVF4KGO4J..8)H/8M%V=>
MRW7)_S!'&@-/PZAD7N?E<&&9U"Z(V/BGZ5/,G=@0Q4E[DKF$]:"&#N'[VZ&+
M]E1R+7M@@)3H\^7B$_L#@M,Z<1T]-H"Z&&&NE?23FWQDAF41>,F$Z#]N8>.'35^BJ]&.'"8_9;YB2\ 3T_
M<_3:(..11+G5<48$K?OI%OCL.!IJ6 ]$T%2>V45?':0-B+1EV[57.(18\B]I
MA:=,5I]OKHT;' /C=<<[@LJG'%';)D$:G>87&92%*T4,($$TP5[70M<;40VS'O$(50S@NS:%[JTQX?*>ZYM&E!DC.!P[!,R9 ZMJA]1F*'&T.TN8LL
M3!72/?O)]=E>'SR)]OL<&)NIR,6M*1RK&]1S:9:I%H#5'FJWZZ3E%G(FQ''-
MJD@"UVR T+D448##A2\OJ,WEXFBS"O[#:47NG?#+/T;-@SCS?]-"\3MW7GUG
MJ OJ/I&/:%&;LTN9!0C,1%I6YUMC65(MLS\Y\B;M\M7ID(V%%).6EI!!P\[(
MOQ9T@VU[KVJ..C@_Y7DW]G)L_.Z"2YD EYZI&9^>LGC(H"T)15W\B/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MHL;JRM+HHH8/8HCCLL4(F8QL*]2X8KGLNEST_\/#P0*/-U=5\
MGF\J@+/.R%W?\+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MTG<6(6.TE _0G_R$O-[Y!S\/0?\D:")TMN9MMA2;Q%K:#<+T0UE1F"YR8:16*/4GCU..-D)\R;HY5\W*E41FVJ0=@I8N6Q'A
MS6_("P5L??*<4986:_,0U#W&\ED'=\<-6&Q\/P3E8X"]0Q!6VFEFL_]H%4CF
MWZ?^O_"OA=,>AZ"CCK:6S3[BGOO,KB;F#^BVF9[8(:C,QYNM^RWNOM$O^J8-
M3)QK_C>,+IN"<9]7W%>/Y#QQ-R6VE4?JK=?V=$R*Q=:N74+!FH[E0=S841MA@P@C:"[TDRM@X0 Z%YN?^%1PV7=8==SRA<]_D\ /1S_+U!+ P04 " 7
MBME:"!.Z.=*C #2K #0 &EM86=E7S P,BYJ<&>LNG=4$__;+1HZBA!
M>@M2!*4I55H"(DT$1)J @(H( 2$B+6!(!*0W@:^@H!3I D:DA)H H8B((%5!
M@21(%4BDC1#"X7?O7>\]]YSWK'/7^;V3M?^8-9\U:^U/GGGVWL_,T;>C>1#O
M53-+,Q 3$Q/H]O$/=#0#,OG7V;]U_.LF_^X]F(XZ07R<3#G,8!8F&1 S'Q,+
M']-1#P@" C&Q_=\+0/_/P<3,PLK&SL%YXB37\8)&7A S$PL+,RL+&QLKZ_'5
MJ./K(%8^-OXS%XW93]O=X9 )$E"/SBSFE+UMY,\J*)X[KZFEK7-)5\_DBJF9N87E57L'1R?GFRZN7O>\[_OXPOV"0T+#PI$1
MD;%/X^(3$I.2L[+_>9Z3^^)EWIN2TK+RBLJJMQ_J&QJ;<,TMK=W$GMZ^_H\#
MGT;'QB65U9I?[:V=W;W@+_[_^+%!&+Y#^K_*2^^8U[,
MK*PLK!S_XL7$'/ZO!7RL;&M7T\*R6F2Y&G_HO9_,?O_1RSF_XC9?Q#[?WE-@TZQ,!W_>2Q\(!B(P5!\DPSZ
MG_&B7Z0O^%L(ZRXKI6*,KLBT[3QX _T-QCI/VZ,K34WN#*B:I]@^\:']@Q:=
M&";ZPZ02GV;,#V(EM9I'BJ?(7GP@^[ZKY9BG$9%4NH'/GH]PCSI5^
M:0H^2IW=]_A^F2@W8&R^,*95,+Z-XK96?-A8/8T,)[I*I57\6&6M\&*DEUF#>MU/.$*0G"__VGK]3%>II9 MM(\,_R::ZURTY9"N7H_I.0&I50 +\')Y;.]M22\GG=<&?(O]<[%R"](ZG!XT5
M#R^#RHTN;H1M_?EC,\)N9F,K5;#]55$%URPM]9#)4%@.Y":QSOKJ/MYY"GT.
MP%Z9@"K2H;3R5]-GRV>Y:=@DM"!RTSR>U 1\-T/C W'!'N=/951@NSO?B=$
MWO\"1W5<_20WWC!I,6CJ*MHMC$=PR953&/A(J?\/V*I)!_1FJF3/'UEE[C*N-^PFJ+P\$L;8F=( BVX09+
MYGIT[.K%R9PG)Q7?_"]QYN6N$E],[ZTBU%_OF+1B&EV^[E4(5@CPIP6A/-\A
M8SMGSWV=Z2KD;Y?7'ZA&7EVDJ>+GBJT,JLJ06.*4T97IIMC*[DHQDLS9/FK'
MJZY[)X?7RXR_/#(642K@W ^#77/^,M>@A<\G>3(#^12GW&)X[AP_F@_0Z6F=
MBM4RO.I2DUDNAOH5GB212OG/U<>D^,
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M=J%4"8ST%; U -&E(UK.#ME&!J(47\/_94=(WE.V;-GO],'?D
M5EE[':_*TWS&4&*GX3#%+(4"2<+PM@N2CT"QKK>$9_4/\U&6H=4FD'1*X14@
MG/(-Y4WZVQ"%Z)[V3,R9W5TTO#MEWAQK-T8WO5/N#I]TKA5L[.FICUN#^2!B
M9]6I.&A*M 0H?).GTPD979,P$LW?'6;F94IXPB7R&&Z,@#E9V9&7^W
MUU:>+6.U.90>L=<=K_\1%E99Z,Q@:]7WITO0/%[.#^F8 H+8%:@Z=;&1NMEM
MMS)]OY;B:/43UCLK1$VKQ>>AO#E2UKF6?ZN>24(@'@0NU+>._5RT/4=ZVOR;
M(8'^"F'%*_OK)22@)>A6U/[4T'7Y^WF;EJ,;NWY\TZZ?FW*%WW<]? 8MKB ^
MHO7LQQ?@G*(7KLN?#[_.@:MD,F(!G?(J@$$Q>JY&EJ "'EVIA&;Z.5]0Y3VG
MVV8CQBR7OI"#/V[W<8@:!F5/EZH6/;.YH".QW3\90Y1XQM0O1ZDM##:"L*QZZ!U6A6!3"QL)R-MMTZZ'\_[=:Z[RZS"UY7G<4T6"TBLI"=Y[GO&;@NP1/&48 QBV%%!%8 (
MRK>0)-R3 ?&;#&ME+RQ!ZI-M8T)A/*:5*!5:8=S.@:&>?\8)TX>S@<\IAJ>-
M<9G*H?GFN)88*W@1]ALF66\QDY21X*$_U=BL@MB.TN_.FYA@%*(=OGMT*]]/
MA(^6Q'O*VODMO.37-]$HX5(@_M.HNS,1+=+BO;5]*&5!:8HA_] OK15H%K^5Q93-D0"#;_)K
M0-MH'*0C$#'?^<^"&Y@-\-CLS4LUEQOPG>Y/"GP0\!HD;OHY\K)%9^RO,Z"I
MK]IV0VP-0GNG.\9I)F+6P=*.CY,$'0P^)S*?>?[AE_VO&[W.T4[](/#5:Z>6
M6HK8WB0K@OY[O!W[T0L*S[E)2M;TR8&_]DH6M&MYO?"(S]&!OS?Q)),<1:9F
MJO<(A.-)($M:]HR-02TKV;[N3JVP'?84)GMRF65;]Y\"O3$%J'\5:M?FM-8K4![P>EI\.5-N7.:"#FW*V^S9"U/ZYS_<'Z^
MY,(OQ^XZ274]M*C_+'\SS3SC_@3LGMH)(+83PBD'Y!X8]",J?R)A/=K0DYBD
M5K.V=];O@!(KJO7<;NC.1DHI<#4 9DO3VI;IOQ9@>?NT;DL\?&U#[3N82!#4
M!"?/-5+HSNWYKI.-X"0\=_XUFGQY=# )>](_T@'-/-IC2W+77CP"W5!B:W@W
MXO>H;+QE/.?AE]\M1>#V+E9F'N,%/BLC7=$EF@CL^6T@V_,K7:7$#RU#XRGS
M+UF.5$G[4E&UBJMQFK*MJ\\8:FE]%M>"J-_AAS2J%K+JF0^O+FL0;>17"NADU_R0X("5E+LYEM8?=&YAIAH^M1$4WIP'REM3.5#CU64D^R:(% L]MK_>YZ7]=SN%>G!8Y TVCY
MW&N)MKA\?,=7.P[XO
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MOR%MYDCKPS%Y7U'60625<**:0LIMX0D&&J6NOGK:+T$QPY8?TN[B&EAS,W-,APLUW_W>NF4QK#)8E^-T_VQ+%8,;
MI=1"^^QY.A JB51=(LM=[#TEI9-/S+,'\@1P9E8W\NK=\ANSIG5\S[R %4JP
M]J3+RMN6];5=5[V8_EWE+W]PQN"*D932@3'JT@1>AM(HC3@:5#B7?;"8VAO+<^5#>$Z>7JH4N7:\B?-DC/K6X[$PM/&M2VZ%\^695)VKA]E%-+6GJ.!WJM@WLZO0"^V%74% 8'\7]%2"B;$^4NY6@Y1L
M6U2@!>H?L4A37S6#[VX[\A7NWR19SN<,FR%:RXQ4LE_=!CW.8K=&=1SHNT_K
M)&)\-\^[R:@P#-8N#.VZ]1)\?T$EJ/,G(F0^,DS[EAS][SK,+)QQ5 "QK :-
MA%/>!1>B1L=8LH)2=Q5DMRBI!44^EQ:";!18# J+Y&C; DQQ9!6$#74RLQI(
M<'[A!G<5RGUK,'9/Y[9O;0%#8PL638I=*9G670%+-,-UE@B!>!WE@G>)$
M%>[R=V>Q&*<(N]H0:!J]DY,J52M;G=GPUG97H5C_RI]EC>OM=4.G=$X3H?US
MEFTH3*(,29BXO*"?5<=E4I!$XGHQ>3\9B9+WT=E=2L.2;H&Z9XS>
M-^-\'GV-P#6MR7RJD869N\R8PA&( (08,,\WHRI5T
M+_#_6NT%N86"#92'W@NOB\=@ZI1.I/4*TE-!+J
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MCDSWE:V8/Q5A[\8*;MXU\%GT*K"QXBN( -5QO7JU#H)M.EG7#KRD+LY^$ET"G,F&=\?I-E1]=P-!2;D?>731
MY5:^H:4][U0'H$!Q)@Y+?)O["<];T'-D/*M@\,-X@!+&N3E>P,/W6^E[_U:G
MRI$A7_X;UV^=R?ET_^_ZAO=EL2>&#UX7FUD.]!F)2+;L2NY#(O^6[,84S/4*
MSW&AP= ]&!\=CL"\M.D2+,.U,FFC?O$-2I)O2K-SL%:UE24TIL,3AEZ?E G/%BOP#^&M^B.C7O)>Z37>;KY09'6Z?_V<:AG-MOLZ4MQ^''7*0(T:,QJ L)GB_OS^ARJ.
M4JO..+#Q_ "'JMZTR5>>5M+-6[**+F_44'Y@Q#%SO?);$1MGT7F9)WR7TXID
M0,QOL)]*("$L?1'_*'+HZFX.>V)7T:4%.Q*0UM^\GGOT?$9@\D"2H)^)1@ I$%_HTQ49<'+48;UM4_1=FZ336FF1D?>\CE/.\/
MFM/Q91%*3(*M@C-BEIHUF>>"EA4J*J;H>RN>&HP16DTKKM-4-7F0-M:=I1R7
M?.M,\MB-9[4MM^Y]3+S[@I\I;BYMXB4!%L<8Z\"NM# _47);QD*_'EG95"':"H0Q_YEX/Y)-0PDT,T;;FMM:(.%P27:O:_8<;M>H3P-+Y=W&5"P:S=OYG+_&248\FR'CAAO:QNI"%*R;2^N:6YO6#FZOO&L?F"
MC5^?ZW]>R_G:D_7CEO92SGVG+).<^Y=JGV3NM?+V"A>N2;Z:7\^X%=WE7H%RII>$Z>/:I':Z4A*:Q6BUK;?E<)^J[^LJJ.)F&
MUF1RM]MW*2ZK)D]EI][^/MO$6=7GM0P!E#!-<,&SU9@\G#1Z!.IF(T5E\6[*
M=_R3$DY6L0$K:I]M&-T](:;E<_*[E-6!A:='14_9&&/4YCDLFB%NL^_/)_]J
M*H&R^=3KP&TFZ[J'N<3E2^^NM@^@;--M4E MUCX*-1073PGOW(8G.1 ^><0+.@(V4QK[1/4C")K2[OW5;R4)9
M?]7B(FAO];E&Q8UK1T)2Y<[.6K-<;M,BAG;RJ3D'ZSU.P>K0C"P1.W>)(/C*MP>DJSYG2Z:CQ=80\OH*$X(U)G?+@IP46:DYK=U3\P0JLA,5^P25(V1]H(O-[
M7-EKJU#@*XKO%&-59?O'1[6Q,FGJ$\GCG+0?B*"-CP
MH3ZMDC7Y_-14 V?T/N"&54#R_LP(MR! 9I<-I1R 2(ZFF-%X?$0\U&-_.KYS6B" =/EAME7\J)3-BW1/<6X&,^3)+
MOE<_,?ES0R7'G.^20H8;E:,;P8RZ^+Z@OVM:PC5TZ.!$:%1@A/M9;;CW9SF?GI5D$;]U?5@C3=M.M^7$^:UHI@\_OZZJKY )49.3&KC]RDVX2Q%8V-/'N5;JJJJSGSQ,WXZ!8ZAP9
M%X,_#W_D5\ ]2<8_=EG\,!F27UD^1C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M@6/CGB'1;D>@Y#RYJ4BSN*BHDCFZ9:Y%O8YK0GSC$+_OMG)WIT]Y=K<4"ZOYK;J7_N)FWK1_"'.K':^^VC6W^1M24G=S=:]*YX.'ZX\J,
M9=:YVM(L=J.;JCN/8J7OW6]12YQ5S.XN.$F3(GB3#@BB/]W@61AOP,TJ3O5=
MNRDF1&AZ\%JRQ@O7V0VR@U75DLPLUQVY^@MIKD\N>483!-7PTL!=-S!O%_MK
MFFRWV> UVL9K=IY"^9^]=MK<6$74%VC.6/K!8)QHH6F0,4+,<-K,@#E'&\(G*E9L=6RD^H1JCODZ_T'\W"
M$P":UZ -<@JXVEF>6_JM;TCL;_#/0'5W"]MVINB!@;4CT.K_'([_'6#S";X=
MD)ZL%2DVFDX\'58)5")9R- 42H"/T=?7;CTZTU*YW..1";MLK[*-I:HJNW;C
M"B0O+F:LWQ$3#/BLM"+FI6KM[8:Z3/VM]Q0O.7:BQ:(V!),X?6RVD0DD7.*S ;GPPIFP--+BXXBE6)>#2^EF
M^[O3C,$;N)@]&WS3N+)J0&]OXWK:9QVA8&.9F.S>X, _;H-M\_[ DB L* AE9IE^A1!(+4Q7*MF&U,TVHJJ;@&=4P_W3@U0-,LR&E$-1%
M_KBQ]'BP&BOH81I\MKBL/T(S7FD8C/1;G+'.=!S5+<')@)B(]*!)S6$QX,>Q
M#KRMFT"K(+=L&JC#"5H_.;H'RK$)=)TRI!>9_24ES>KZE(%+I4&D0V3/0*EV
M?MERV89\SJ[O^.&KUQ.;L^*';^@GJOUVI<1H@H0DABC09IM3QEL>YZ6,W-MO+-E9//'D,S,6V)50DZ88[K,S9,[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MMOB2KB%%R&L>E?TS^60_ 149-/V@=4RL*2./>2:6Z]US7?%1]:JH7PHNY?P02
M1IHXXFB()Z%@/J EY!MW8T'5G6IB"1U!1;](48P'\P"U%&L8V2PNH(6(M.JG
MS1FLG/W6R#T@ BG^ISO10O^A,:N7[+,+ZDR@^8<:!8HLE"&=ZX?%:!7X/CJC
M1+6*ZM,UN>M?OL8PI.7D5^#ZP *#@NTGIROB4$I><@P):JGP;V_G\1V?YO:F
M_.";*Z:"\E(=\\-/YKCH@M[5,]^1=X==Q@VN$FB.0$:O'\J6;"ND>P-[EE#C
M#X.WMB8E_7WPO.1#].52(5HEE\? K]C7WVY'QD [>)"KD5Z$6@-%CUA)F'%T
MH8(,^!BHMMM)J!@/V#W7UQ82,]
ML^+\33F!GWLL[S519YH)%X>R?DS]6OH]5H$*!J)H5KL2@#T%B59"YG=^!<+)
MSAET61KXYEBC[YM1S4,,\5%3'15+_OR47VN89\T&)\4UKE6NABG]+&NVI4)Q
M/*RCE0R 8^F.FMSA$B- L'N.POL W,!Y>'B N(LVSTS9P]K ;V?N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M4)3&?:Z->5?*VY5P642"UUSZ5:P#H3[ 8#!MZ+2HR!4CZ=2M7KB=T2G3:<[UPMP*EE<\)P:D2A?&EO_7K^G^CP#WYA 5E<@L
M,+^TLD-9L\'F'8'\L$E05<"8JD\&]T)8FY(.C.NVK/28P@M)?$U5D)#
M Z$I2UP\_W%S^8'*YP_3EGS'VL6LDG_/RPABB?"TV]XMR%*!9@]:Z_?0\"Q@,!V^UQHZR[6,UP)"*?53J AP//X44$*'$&
M<4Q+TL$KF_/-&]I92I@?XRE"&)AI;E4NAX5?KRFO]SDLH;L)IZ$$
M*]U0)A\PS#-T)- R#TO<=VJ9AP"F&]L9)Y#F7<+XL_&3)S:TN&9FUH9/<1F'
M0]L>U)57^_U1'/.Z&&T$*7D2H\YCJFTI*"P77?"JM^Z4Y$Y;1FY/7GZ1YR'&3RI&PLK/K#P*NSIW Z4HX[M?3)/U5N
M5;5G/W1'O97;NCO[#>-G>Q*9M=6+YQ[;1B2B16A?TDA1XBX-[Z<,(/+/MTPH
M3!B?HM4<;>'M2%?BD>[:C87(9/H7*G8],TJG4X7+GI;>>#:6%DDA'6+3L2@3X>A +0RW/UZR
MCC;NP3>%,B%U"-N.[[G7)N4P153DO_"ITY T,@\.C,>_J#NL9$"L:\3@A
MM&K=I$H["BHR7+L:R51/_3Q[$<-M3,X7YW)W'@[)/W"^^LKV'K,2PCG>-&V*
ME64E[URBI6>^J*2%[O!#).@1IT'DV/)_ZJ)*E4M$95]1"IJW=_:O_]3SR>S'
M:FTAUJUIL;T0%C2O/^:T@58Y$'RCFM4OS3%U(7F;LEQ*P=<^[)[1F')U&R+9AV&.P! [DDZ:M:DD64#,Y,#?J"X?/D
MIBL=UC6L!WYA@)-=SR.]G)J!;"Q2B;0S%Z^BU>%U%:@FK?.KR W1P%V[SCE.
MTS-(/Z4.!_A4N"W\?-*Z=VN3^G=$CH&[\"YV\C09\O2WUL_@3F$83Z.DR6[\
M!QHBL6$=TAMI4""0,#_T&E\G/F>)[67R;XN"PE4:LQ<P^F>%O& N6[KH(.
MCD"RHA][1:5*CC,8=.?/'EUKKBOXC8<_=\W:PR'_B-*;,\A !-<:%X7[H?\T
MJK4I"4,Z IWB"IO0BE)P&%W?:.2*,IOD:')[[!^M5%KWU_P5[K#&0+C"K^#2
M1+L5.1\"7&XX O'25:ES<0';&$YD!\H2$463-6Z>:- @RQ$^I(M7THVH3T?+
M1Z4ON.D*A??I]W$:07O?M!]'0FS/,"?=E?H\(8T.KL17%/F=GOU>,NP?5#$[
MO2KF_:-)+Z>P&=Y/[*-1S/^E+0=<&R'M!^E72_"0!>Z0HYQ[],P3VFV4LQU;J7VEK1[O[XSM<%G;S(H_WHU9,,L(]CDY
MS&=T[[)9T+.HL&00=3BQD!FE0#,Q^QH"$UZ5DB.,AN2[Z8OG:U3V[#*D<0T%
MGU;<7&*LG&UQ7&E0]@RG]V)H[ ./>5=/(YP&^Q\ XZ461UVSJAJH!LA_>NA7
M:9!>I4*>6?^@X2+W-:@B]0, MA5SG^.BUJPF8-7W*/0W@]YQ'U^E:Y[2>3-A
M5EBQLA6N/
M.<>)P'87LK5LWX5>6'(9C?X"-Q8H-F>7;$X]K&WGYD[*M(]!=<.PZ*67X9&\5P)BQQ?"8S ^QKX(%!H[%.!8E"TF\0Y.?BZUW
MGEAWW'%!R+:UM^$0'_+K1$[JG<#MJNW>;Y;YD'[3\ =]+\6YA$>]D+\^I.5MBMXONOI=MZN+183)@I4I]H:=969,E,;^=>:O=G^KMAZA/=JE+C!)%SQY\LA8
MM_\J\G;0L (.K3?"_/^=:IPU6@V:PDI"&T"$I3]8,+!'C9RB]!.'S$E]Q63K
MX.XPL8+JHE4=UYPX1(5MQ,-6]EJ?VBYO.;U_3L]8PD-#O07"K]*>+0O:#GI,
MWD_%B!V2VU_=CLZ>>;^T8NMT2MV0X&',T2S[*AGT=Y.MKH#M;_5O;BMYZ$R$@5Y9?$G%ZH4U,9O*IH&W2(SSC,^N3LO(NYJOOU41*NT5
MEBP:1F0G"D',AN8C[M1^I_N_Q[VG::<%!R,0
MW#^<\N -R9N7FW&9:K6!L8-R.+?OMC\:?J9\,=+576 YU+O.T4-C]$,AC/$Q
MNI=:CYKH3Y3]UT8U;DL2)EDXK%7<'P\9,5"H<(<+H45P8W<_N)_=,Q_7/%C[
MMF/6VKBUL:$*G99/HUC,87J.0!_H'HHTX>1V\U":?E]8/;*PK_"D@=_=!%OJ
M@4GI#]29ZYJ&>@.S/1\#0I7>3+6VO/;XM7"^J4\QM_#=?DBIM,2]$%VIOB<&
MB/G^[D0H#X#QI-*E9"8,KA6M[GEJV)CF99_+;WQ\!B'>_^E78O]U.)<5-?J0A_/2I:ZN8=3)J#.@F..TDCDE
MNV($&4[H*004;=?5J!R,DZ84PO=A:^HX08HAA22X4Z\5"%)-;+U*D-G=<]1_
M5OA$ ^B&Y'/:<)K+S1\SPP]; UN2&B&Z)>^WY"X3]T%U65:)TGF^'I,1TLF6
MM66A66XN\FD>5G /'>3L3MVJ#&!S0-VOZA/RY?T;8BU\KV0"41#4B='J=6? _>GW!J+B#OL^C8Q0&#D[1>
MS9<4@C4+RM#?AGY2J+Y5#)"QD11NN
M7& 335F7D9]LV%&'9M\WCI\T64FOM$473(9O'X060D.-JX37PJ2Q_21H^N6+OE_>TW]_V
MX:=9]YR7%5V,IDVGB8T\27W+^J<&N*FI"VY=$ED6 D_0RD>@+@?"?#&AH?#W
M'%D<_!3"R8#,(&5@HO#JL]DTHFO.C&?V]9C%U='NWTA/HWH7>Y-"J^:.]&EK
MGUX9?876 OGW9GD&.NL8XJ4=$88D\O2!Q^Z6W<1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MU&$Q:];=+5ESS=,FTA<'!>KJY3);GX?(W^3U9>'J]E <:?M>9#95A\F0ZQ=OYCF31Y<&U>97!PEG^-]?H8<.C! 3#!),&,IPVH"]E1L-XR]
M_3R>@ZJL,PD5P4V$ICG;C"*TN-(NM^\?F:Z>0ND"D.TC@!C^[WM:8P*17@^ 72\8*M,.(E6%8R;3M )?V2@_G*8J!
M768Z/'\5E&RNZ,#47-=I-_[J]!2'!+OTJU.I/@4PZ.N$]5C:"$=C^A%H-_ P
MW^!NC:N7VFYX'SB]54-VQI*Y6BN^B@1^BKM6?\Y+,[Q .\G=(4W']V#8?90T
MI9EF;]Z2L\H5Y6S3,>;37%=@Y;]\!M^4,PE_L%'M,M>@3I$J8M'\2'$BAJ>=K=2T&+#M;HW\!M<+0M;;A^N+TQ)1R>/1BD45^GR?3CBLBI@@JY@DM?*GLW_[^@1D//RQF&.IT&>IW3>H)/]V!)<+X\8I %8J;VM_9&C"NY[?&D--#
M[9?]R&NJ#Q$;-AG9CI+ZLF8WKJ5+3!Q5.W==OS9*Q?,\>A3#HK694D6=ZIWC
M:;>'SQ>F0MA0?@;!U#G/R8;O6@AN6ZV?J=,*R09*Y#3M$P'O AL0IX%'JP?7
MFO.^+'(-0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MQ--^=LA@8NO].%(*MS^'4E_T#BE". "*".M7?:M[GR4Z7!))*5O&*HSS1I$+ 1M-MW<<(2"A!OK&8
MKY^@BU:;>RG6:YC[A\D-E7UTZ=)2R*#ST80ISCT98%0(H.0/(68DP>HW".2,
MA%GQ<<9Y..X1($M1BVXW1PA(Z1[G MIKPO%*6!&4:/E!ZM;"(W':V'G.F"0H$XLFMAQ2ZC_,*7:'$S_[GL2260>L.BZ;?U2GO";<6K"4DRS%K@_;S2>'K3*3AY".0
M(%25;DBMR;M?6X8Z5T^52",?BM^JF]1\C5[KBPQ@%,O7<-CF7,'E7Q6"(]0-
MWKE:LD,=1?=A]"/0*^=/MEVG+--]MU:>%90;&P/\#:K /YPE:-;<;?QB9.4=/CK]L:?]\VGQP@_0$],QBNN>)(7B5
MZ=+MQ[1O^P<9KAZ-OR \#'EX(=\&ZJ%F@(9]TQ@*3+&VZN)P:G40\C@SKHFL
M3:\**I5HR/#VBM+X-JB<(JXUU)#/8A[K4M@Y_#7+H@#(2\M+"4G;%K'K1BQ/+^HX(L:TAGP.>P/4JQR(XAR#F_M]
M!#HX_Q..%Z#95-\$J6%+<^S7U>2%G,
MKNNL"MWF"+]81+F.R<(QTQ#^!AR[J:'
M)22U[]5=PHF5!:JT\U?DXNA6J'2BT4C%18/AIFL))W!$V/P_$.YV82J1#%FW
MHU:0=9XVK/OO]@/F-.8!M"+],8VM9_\(E +50-KVYNRY5L2V!_E'524M4"=J
MJ.*#XFEM "DTI*MU9H#\EVC2RN_M- 4'4W:X\KOKFE:-DGMYR^O'B<=SIL+Q+*6WD&KO
MF92#*[C\.[8+PD.7?+-2%;9:_+)VHZ@MSRKJX*E=0W'W?,X/5X(96HGN"#RF
MVA[G[$3T690#S>GE/)85Z6R;?7TR].?=E;OQ(B.\[WN*_N8Z3_'_CA\='=?<
ML[]Z)DY='::+.G,$8@L')&N !.(D7A>P/;B,.@U$4-P]IDRIL+Z,9-BI'1@8
MI4UC6U_HTV>*>F=S$@B;N0'VVX^:K-]%!J*G^$N3C8O S^EV[S!=U_!M$ _&.R/>L]$S&JT+)/0?5S+=A1:VB$F'<8_9C&J"N0#776[%%?M5Z.GFF.U5
MO8Z%V-_!?\T41>HOG2_S7WX!FR_%"!)\TB[W$^>HUPG?JWL(;,KO N_6XX M
M:L%W#76%][MAGPL!X53K'
M$2CF"8J=^GRS5\5Y'IV&16J0YXB>/%<_(&/[,2SMM[[.K@I[\#FZE$QH#?&L
M"#N]_W"];Y==AG\()Y9[!*(Z8@&%W&2\Q.Q/@$#.R9?'EY6YFV+I9VCA3W?\
M"Q.E?.-N['7O%Q('!T\TGM@)#_A?LFD
MP)B!; L:YFGCP+3 _34B-^?#VO=84
M,UB&\ (6S75@CQY:HYGOCA^^P#,C"SN/0.]W"12K /L;AZGMUT/A>)DU"#AK
MEA-E3FOKE!)KT0'/!US53>M[8R H+MPVIOP][L-Z&&*Y>GZN#PQ"A0$(DFWR
MW"F4,9R,8$,2KR78C89:F9^Z7OCSQ\K4R-+G#Q.::W%98]?K7]]P>_S"7537
M%;1S7I'#X'^4$ UZ:H/US.CRZ:R-'H,):T07P+<:_
M6A!+S$-1FTNW.>4@*"E=:,+:57?CKMO@6_Q,]*1ARMA.$8>=N<<__\GL6U)O
M''U["?3LXD=1B5>APT>@ZNVB$XKEFQZZ?<&I\R&7=G96K+<$J)S#>!A0;,1O
M9Q?Q]9E%J#2SY3R%-;8@M*G!XC7 5%
M"4)>7'S%-U4I^^2A#;M%O^C/U% Y'M\M84B$NM?_#]#AZ.= 65'%94W*4>XH?%'@L2SB[R*M\TJQ=LUZ<]Z%:PO*AK4A=[.);7
M-VG@,S\'-JFXY<\X1YU-8*^[A!OUF6A\K6.38M]\)Y.G4/Y7S[F(M2O%]G%K &DWV&G (ZX4 Y\KZNPF\2&%+Z@,//FH;,F^P/U(X*=30V>X%G:?
MOXGJT.J^7O:Z(&"+Y4>#O=<-Y.*9LJ2K?X>[AVQW QII-R SVIL6"40=PH?"
MSD+ #D:M5R T4U7ZG]RA:K70B$B;/P"7/B$QMA?GG)/WE 8!K&9G]2W>F(AW
M>H,.ZVGF/<=JRD^@,IZ3,P1\(SVJR=:7O_03\PR'/MNO[O>N_RY7,BE?&4G"
MWK<4R=Q]407 ;_-V>+-P?8+_[K"7% O D83AO,J8*=&AZR%8U
M#G][]"B70NR..X>S'76OC__'#%P[5ZQG^O'R_KU>L;[9Z46:00MJ+*/]"'1[
MCOV')V/8DZO=C8+E_O$#*+0X CTEV@)!9(C8"H;F 2><>&?@\G9PWLK_>Z.M
MOL/[" -US:&F/T.2W^K<;BY.S[<1^N>K
M=6$_907=/]M8@R(4NK&I_YK!"_86/ _%E %8XV01E.V\IX#K4"F20M18__YK
M+=)PU%PYY8Q3Z/@#_->*GXBTXD*8XF8#3 *IU+.G]SPWGNY"*N3U\/U=7?U]
MN77VY5MW>*KE22VNQTHO%^OEGS\W[3;?.F>WQM?^528'0E%4\KZD8=Z<"WA%8-_R/R:^(!RK R>K=LPNR%FO
MMQ5;FUU3A'KYO9ZY;Q\9/:-NMC3U?N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MPY':<>MN]D^NRXE%H\I9[DQ*7W*GJEY)Z7S1^3]#Y@*5 ?91A;NWDPOQ WW>_*LH2].
MXB5\IV&Q#%$Z @B^&[@YG("Z2%9[.C6*?$S&16\WEV+J_=$"4XOI8+[>.R(!
M/E9M.>LO\X;N70=_.P)]/P)U[F%XT/R /K'U>RKP\K>X&RUDQ2#M/8FZ/.>?^,'CO%]XL)MQF&A<;P.OGN13YP8AKF_S$B&=7TY0+@VS-)DAUWJ/
M0XTL:;C'5AS%5/Y##
M+K$W\2Z(/"/JBP"R_Z5QY0=?/E/FVD\M2>3<+9KD9Z!>!;"
M-RQ7;:?F-$OG3Z\8<9E>D6=KBL[INL0J<3MNB2,Z>XXUG/E#");/-W)A_SD^
MHP;NVM"J18'O-T0&'#925G)7BZ<_'=[.,?$/J31I;.^2=SC?^Y H+1[B@/9Y
M5"%QW%CG=Y=>/;'H>\2!%6B;$EU:&=^A1*_J2I7D'7=F+NOH9Q4LNLK:%%;F
M".GYT$NL% [)MXZW/XD\XOSRT'S9"/:B"/0,)D6L194<^#%&Q3Q_5QQM@\',JV(;&>6J:?/6G+R!!J8TEIY'JL_G#X6F^0>7#"=K->VMQ *#X6R#BI\R
M/9TAGK;&V0S,>;K>L34H]B7P87S!TYZ[YP[_00NNS8I]-3#2*A1FC$SAI"Z.
MJ882.'M#J9\FOQM<. XM9WP7QK=7L)N!6?IN<.ONJXP@8[%X$,09TZ6'\:X^
MKHB#>0IRAOQ@;@;3T-]?E=&S.M]>X13LI3\[/;SEID6!TBL0A8.HABS'HVF,>JGL$#IA4N*!6 K1A(L$TW+@%F
M>@C@!SL*-&B9UZ/E3#_N(OD_P/'40&_[==NSCE ]+&[X;
M"!^8,\;GP&@>NM*X^V^Z2Q'Z\ZP@?@PJC:RW/#]H6$;("*T>()"D<.-,?P+9
M:E^-U;!U*@-!>Y(YKP_T&)VP>F2,KJ;:TSEF/ \0:;GQ;N.&Y@\^G5N>L[<4
MTZT]>Z9W_F[)ORAN'0]5>@8:?%O)T8^A.F.X@ Q[0(GZN(^&=':F[1$]8X]
M#9Y$3)*G&(JOU.66QZP_AF=;O"UCW6WJ_1.+_?C"XHBDJENNG/>WG)3;'[QD
M&88%SLWX[RH"4PMB.L!I!1.U5"5D[;@.?''^6V#U?JAHZX372'33JT6F/ER@N#.H= :V3;A"#1?
M@&D(3SP"^8!_;^./0'&QH?ZETT"N![5GU15Q&G[L5U6)J[A]N4BX<+VY7+Q_
MVX-!YN;;C3NPWV5E#.*_9I^P"O08IAY"+'RZS%#,6;:D@,& PN6O=.=RO_=M
MYF_A>CT/75-^\PWDOW_66RY>6FKLX"+2MD\*=/@:?P+0(MIQ/240K4P:YI2/+FNXJ(#;E)S4.A2:[FC7MC8G]X#]'?>&'X8&*#I#AJ;HT:#$)PJ-=)WN93&:WMB'WS!I4*8G:33Y:[===
MTEKP;/)9E_4^4& ,H[6 EL.LV3.3O\UR2<,L0, )-3)$ OBPJR+M#,6QY>D/?+BYO\#W;D%9$B&!0+7: [X6N] M#CN@:O2;0#\MN\]IL-8??9HZ
ME[YS!#K>22ZHU!$(3MQ]@9(GP4X!@1L3/5"(9=9G/XU949^6Z/(_$R>O<_PV
MJ"NI-I8IS;Q:DR%>A"S%A5YL0(A*N216LX4^J#9SL>CSIY60#F,Q7= C$$()
M$:NM_ #C#9N)W'2EJ74?JBU:JY$PZUPE72K'BZ"YY3'QWQ'QZ\D
MJY6E:_IDBDSID&O!9$\Z?QO9G CC7SX"":&EZ4Z'B<=AR(BZU%TH#"B1^Y.\
M:1XM5.$>_$4\8YB*2T(ID%]?UIY4H);BRN>N%EYIS?NE(O!R(/S91W3,<4/
M 6)+/9YUDRTT!>+;_CY"/2[5@)NVU"T65_("J^)#527X5*X&]0:=NH^\31B9
MWM!O3"PJD*YKB^, 02HK;;Z^;EF2#M-=V6'1W:N88J+6]UU'F0$!U#TR6WT?
M%9CIDA*B^8D$+X !"TU]2>N21'Z+FP6_MYD_6CIT/,.D1JI_U;9H>:',>KUTOO7C+$/=]W8?GSL/PJC-/_CZ1>6+X*1EH
MQG1=@=UM6CFX K!2&/E^44>@]>YM5@H7%$^)%P]C4)'S6YXB:G0!I5W5EUERAV]0S+6RO''EXYF6H@.JDTP.S.HW
MWTMN>9ZG\Q[OS4?&9Q@_7MX?=J(='@$CJIW625=#*5&/0+[Y+-\#H6
M7N(O)4)C^\>H2_O]Q[IWKRM=BMUY^G&%Y:+#3B'5#V3=WXE%B<4O_>T='TOO)GY)7K7!JOV$ YTCPP!0;L"-3E
MC?%2BYY5:J.ROR8'("C@])"UBH:)XR8U[4.7FYP\W>VJ_\)[DORS?%BE]&N[
ML*6WUO#W!6=A;E'V%@*@PK$N3IF+(=1C$J"2* 5\RRCC+/KK$8BW ?8T4JC:
MYV'37F3@ZUI189>\3\YY"LF+R&O:3_KES ?RO%T$7SB/>+X_ M%/S\TC?L=1
M"417ITP2MW /C!_18 U=ZB_DI9N6W?3SD)EH//C(3W%,_[*X^G/FZFA)>QY)
MY;?*%>],NXVR@AN?C:"\"$!ML[//+.A #_WU ?^5Z\)$.\V::ZEI'RZTE9KJ
MVPX.]G6]!PV9Z] E3E#9)WW7-QA,J*CZEM=+%BKOME]#N?)?JB3J\$T;:Z9H
M$=_]NF:4UO$Q7OT>J_/&1RHN/MH>DJ#)>B91SG?_H;[M7)?08"J5YV+!#B!Z
MK MZ8YH'"$ 11^??'?W2;_V^L8TV6R__(PB^*S.Z-S@>X&2!K;5N,4_KSTD*
MUWQ4VZ;W=CTB5UJ2ZWCG47C.OK&EW8##DNNER3'WJ.V/Y;@;NGM[3 ;A!A\9
MEMT6:=(W+KX*18./2V0+/:"7T^A?AC*C9O1YQN;L974T2$G3"I\JY)K_%$DK
MR_*OEE=7MA.]/* <]"GQR2=CT[,$O_QNAOA=4KMAL2":4\^L8 884,M_Q',5
MZ[G! _07HJP +FHL13BNT9:%;@4@YC>% &?GAH+I)=OQ;25VWZ>T!GY+GV")
MCV3N>K4VY(F67&)Z<1*TAN*@'('845;4] 1*(1.RQ/PX?;<;W\O=-T\,
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M+/GO$8@AAMN]+\=T8$07'Y#V8@@IQ$6^O";-M!\9T48>P.+X9,BR.S^K'Y\D11:\JBOJ/_\;:FX=#^8?QOR.BK-EW(X1"*EL8
M,TFVA+38F4IBB$G(8,S(OD\(12B[;&5?AHFQ5+*.);N9*?MD)M(3@^/[.^MYW>NZ_S^.-M>5Y^_[_1R25HRU%,/=K'X548_?; 1MKV%Q!=(/!C1#D^[Y=T('-&65U?DN]-62C5YWGGK\MHMZ-U1Z7',_
M]-I$Y;VQ^BJX66O,GM58_=Y+/F28>R K7D>$](Y'Z*.^2OEG@S)6W__>-2L>
MU*/J.E^4-$CD/2G>*2N#65V<_#G9QV.Q$SN!];(69NH TE3M\..:P $1OM@#7@)2/"RQ6Z\T4=.B&=N@E2M_9_AT]O3,#9*"#CN#.0^ZA;TE
M;G1,+X1_3*;O$%3E*DW9AY%KB#AQ>^:=-KK[S^5N=0F7E7P>CGC\17(%S0.>
M-V33FKKA\R?VHX :+E;SWXLY^%I6A(K^":I _[FZA:.4J>ONH#A(DYP
M 5#J"H$FEZWMP"0#"+&NRA-:;F4SJ_.G =5;:OZV#%RL?)/#=KOHK8QB'V'Y
MS#7[']I/O"H>I\N#[]*S: ;47/_N;!WB'CQ& RAT'&:JT!LW*4%QV[G7]<,D
M3<8Z%%"N2'XG[^S@U@0M/'TG1[HFJPKB_BC%&SA-PD\TO@27% "6]&;OD,VX
M1;I25(XK0SAZ/K?&RV;55F!N;4M* G*BSXSJH[7*5OI8*=W9&#)UGPZT7B-L/ON4K<1,I(97_347KX@9#X6;HI*
MN"TWT[:D:'4G'!,&K.]0@:Q .JZ[E1 #D21C0< WM#()J@;-84
M&S)@UG3%]D*O)^T-]1-9 NU=6@U;)A-GCZ_7IQG[L9-6??:NKLN<8!R"^H3;
MZUK&(>9NY4SA$4TM.E92%FXY^+Q-0(?!$'M0--N'"$_5 R% 0!(%40E=]([[.;)1G ([L>88N]-^
M"(I9WDJ,V^Z?L_,M]_=0OI.V_K4=;2YQR9/P:3-RU'5-(A(-HV>O2;0"+G]4
MFCL5_ E+6=.VWH^5+D"?@6% 9LUP JJ
ME */92(H6-#J]!&43"52/&*9!N#XAR)YIR:/Q(HO'[=W$&]C6E553V9IJ4N_
M>\5]S)=0J?L_.1_<.Z(CP) QV0WCA]RM08$=Z6?R8] NBS@A%,Z(,8@3C2./
M_1C65/&D5>,%*1_ZD:"6.L:?*N* NX_$O\R(D_'9-N)NA. ]G8,A=>_W8:6+
M?R/.TZKK/34MVJZ-JA4+KDQK[:TW2IRI/T<1>TS3TLFZ64LJN-AW_$?.B!MW
MD?O!MV0R3 2PO@DT%'H%Y$COMY%#822![GM0Y75+\=A7#/UY?
M<7?+AT 6=4)LI/HJO1G8GX6GP[=&EOTOS4*XCB6
M&:Y!J*UDRWI:55SPI2S:Q;RG7O_/<3/C5K7UQP.CQMS@Y8.S;6UT^@MXDFI:/I/683\"_F^=Z=RZXS Q(O\,]8/LM?.S>
MJ4L5*7D)H!JI<\^OIF?/\:&RD<4'RYONZA^R^
M Q$F["8;BW1]G#,GR Z$:Q6/^!&HI!298O)4XWE^]7%T$QTJEDXAT+13#1%(
MI!MUDW=ZVA19ZN#0QWT)9?5U:>GTF>(J?.V_O[<:OO4Z>*A#DE5._1I?0-\
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MN/J>?F4WSV0((9FHM,)7[5B
M/F['O!QRKN(OROAK5[.W8SF>22_O;]LE,(,6#T&LJSHA?4EXBP(@R+JN,?-7
M<(./R41?P$6%:&K"V2*':D6D6O>S'<87U<%CW=7+/BB[C1)PM\S)B0,UYWJ-
M.:8W([.)P3Y!%K,XAWID+GJ='I.O #AH3WEJGQ)J?"4_;0ZAUYN??@*"YCIY
M%EB?5S42DW]@\CZU;W!1WJSK'',*POLCKU17C3S'7?UQR7/72!&?+(('6S?Z
M52M-);^UO'_#?BS5!SN2<9XYW$C]M@\$\63TD4Y7OI/N/9D#E3'*E8X",)MT@&O_@,I-=/F$.[_+64/)+R;LP+V+
MJ2$D_ $B:">D.M_]/6+R!7RU-;E(=#J,5I^HU3Z7.VMN4/5-\+2*JD:GG+E0
MPI//7Y_P&IL'N2.#V28F+_3X(_V$7C@[S9JD&T($Y4U5-8SD(/[&M3\].+U9!OPY.6MMG&^5A5@>I<:8:."V5O]A\RK^\VO/ZV (*XGUA,<@R? (6#TLKN/8^HMN:Z3CR%PJ=3:OJ)UQZ)0K:ISGU\(5VN^-HJ8>GC:&(/!_+<[84U#T"/)3M>2H8,Y3N3L@WT(UKHM'(4E37Q*^)*<'NOWJ'H#B?7X'Q2/6?T=EK
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MPL81<9GE8:+:_PXT79@_>U(H)\"^X6>*@Z._=.'U
MCWU^^:\X52]O+
M77!8)/-^T??Y5:C""'=+&LDFFGK)^))*A7GZ+>;MHR%>'$VJ.E0+$.R!MF8_HV$2((&4.:BG:/2\]M@T6%#O_]HW*N=?R)!$+!W+JN^:FUNAQ6HG93X<[
M$54[W5'%**M:B[E8E%_;V?O_>\-&0+_T@Y;1\OXSK
M<8S)T8VT<;&^,$\"H+R_T.7F3Y20%]?]2O"B(-/54%@JG !ONA;
M,Q+HQJ=>2Z)CI8TW93:_SKWQK1DPJCSH# E,0VL-'X(6JPGUT$BZX#>1MRMSU']]7KBX&RXB2(+[SX(.IQF%HKV^EHXT"R=3SEF9S'+$9@V-R'WD;<62$
M$L$#'"LAVF4=!19G*I%KC@,A.GM:Q27)E)RV 9/=1\<.08X3#=JC,LMV$X$6
M20-AY?,:EO[*O5>C;K)L_+0PBC2XF8W7^PA2$HS
MG]NA/',+W@0@:V;60QJS/#BY9^&L(Y::.#K
M(O"@[0$'2KN2Z\B? ;UIGUM?5C./U*UX)[ED;,MAS5,XL9;Q'V#T(1="J
MR8EJ(L 45>[Z/W?"8C66;JW+8K-W#17V]WTTAQ%#!6E.3KO#(FG*>>V#DM]223SIW,N\A!> )&ZME/QUX'Q[@6E*9NB!IUP,$J7;WOQB74-#)R=[+:4W D?@Y["=,)/
M(%71/HST(QP7PT@"I+[,$!732D-Z#3GV.=[0FV+IW9-W4;L"HG?+U=BS4>+Q
M;0ON+>?/Z)+;2?LC>P$+*WJB&PY[-X9JG)UF$%QT];[6T%DKH5Z>S1BDYKI6
M=TK;C[0E%)O?K^,I[!N_L;H8$.8[F&ZR.25J.$8%5!BLUT8#U7S>M4YJ]0ZC
MD4MOD@G=<+YF$AZ[([@*-JZ")5.^=N-B]-S K ]8)G;Q*;^B:
M:/5-'Y_T;HGNS?BW6VK?KIE_",?$'84/3/5/,FSGS'[F1N#*+[EQ-0PG2D)\
M8OWGFZ[L:\>^FMX L36"'V5"GL@'ND8JK?7O@RW'7'75M_>XIN2.NV7^[AVE
MO;O=7_F(M*67ZZ]<365Q2MHTC?6QF>%6;@A^4^A56-I1=%[4T9IME>V2;? AJW([MZA"G
MD>?8L+.25K ]I-/V30[(O#!]< 3'ZZE?ETPT)3W52$W->:"/@[];A5]DBN_'
M$![E1T#5&-AN]1-,G5'U(]F[T*/7E]BP((5*FU?S=[&T<&A+6W+RX=F4#[7F
M0V2V)=EFZJDUI!F#%^8'4O_0A$#C-Q.$ J1AN_.1P[?+"L)A K#%Y@5VO =E
MM:0UUU]MH*2\R&OW\1?A;AOC8)ZO#O!@^$-"Q$5_=\CPFTG2W^G S'>(8+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M:U[;_AM[8NF7!J.QA4];7/!/87R8A5$\M"6UO2=N+CJ']+=K[A;?&:XH&!LO+76A&?J&HW]<[GYW_W"6[<_/"Q71@F$.%
M4G,,T.A[9CN-3,:?)2^((G:R_!:FOZ.R3#],;-!JWAU_@(]8L(F@*%<7L,65
M7G-P^Z),U.K"34TNBITS[<1&3SD?X747%QF?]!&C4>JWE4L=B;\?HUOC7A .
M>8(9 K,8?F6* M^Q 4)4AT%GAZXA 4C^CDV3K+JMP7\F)VLM;F"CAWFL 4%-RQ8ICVA7E3:Y(P
MX-4\Y>:Q !=6D]$.J=G55I]\(I(WF??D.XGBFICZ=>_04-JMWPX/6S(I_XKL
M?P8_ZS5Z$W8(*D;H/8LO^8Z0T$K.RRA&9'ZP7YWVS?<1KDI.SJWW%FZO*JX_
MEVJ$Y+Y>+F53EGRE*V&T(/S4FV/8H:8E+]C%YG]'0%G/)SUD]1URNZAWWB18
M"DP_P$2^$;@(?YTO0_ <2I+P^=O7SDKP4@;%# O?T'5'^/=GPJ3]5=MT[
M"Z?01O>1-2N[\]%^"I6J6J^6]F1RU9JFE(S#EI!IM]Z"2Z[OQ4NYFW.S'K-3
M^OFY]RGQH[S8*OS2P9@,-Z,O<;LF:@L-&RF:T"*<9/H"6,J'B6GI*
M5F 0./&A@%652*'P?&J@6M+TC? JRFR$4/UUNV\-UC/YGT*TLJ8V(2R,\W"Q
M/@HVKD.\&< 6KMAXAQS5CEH7V(% KIEY\>R<@Z:,:U5)1SK']&CHMMDGYC<+AD_C 0O4N<+S--,"^:3GZIX9_KN.Y>X'CVH'<<$!N:->T.[/6*V+3
M.N>NBY6!-N-'[4O/OU^'9[/FWX+0863X%&XG>Z0@NZ\+(YE.[FV@N*CLO/@P
M@?8B"+J/GR95,6]3PV#=,*[ZMF0%DR'-2X@/"PY.\_9QC^A?7?5,:DZ)_UK>
MSX"85P&%B]<\R,<&T&KD']%4YSS)A$X$S!N?6B:TEF3M9C?U5
MJS#ZR]7D2M/B[Q ?H;_'@E_Q!W'G+91B9F4D)^H7>.97%K@A097]-8!2GXPV
M/N(3XI&T7#\YI4TFDIIS5MU7*6+ZMXL>@JMO T5AZ!33H @$:/)&'S]UM/.L7BPJ7 UO:_$8!P7V9?\Z_$9/+XI0=+"[]V%
M" //(;7PR22):WG.E357P)<\P;6$/A?PIPYMTI\PT6ZH%@.9A#
M$/)9HD]VPWCZ:F;- ZF$DXALV]Q2@Z9X41.1BY8>E.!?]W,L!!&"/?J=2+E?
M 'C':[]PFV:W.'!0$>HOTT3?[ HI?>X;F,^/ZE(+)=H^NSD'1.ZI]XED&RMKOD!@])ZZV8I@X:!@84#W&H>Y8C^N#S80T8L+:-*6G>&7$KDL; ;#U@ HX^/
M-$@BA=:T]1[EO$?947U>CZOYUCNM>[?8[6%O?-@2^#WX,""&QLXS>D-::QLW
M;;M)G.Y+86HHOF8(4G IU1A5YM41O#S]@$>R*UOQ7M;^VDYH!V[X9%R=Q:FFF-5T@&%:'A9/*%.XIU&7X"\Q4L4<_'C4CS@M-S4"D,
MJ +*S18@D/GXF7=J6TA0W54)D=PR1\LJA'?IJBT_8.[;X)W(=VIV5;0I2"=H
MO=!^=6O!_'BS.:9[/QE_G J+AK$&U(" Y:X0;)16,FOWP>6T&6M2X )@?A\_
MW( 5\=J=C\3BJ\<\JH9;IL%\!X:?'8#E70Y8B
MJ2YN/7GGZ8WOJ(E(=B"4V+1;&E=_E+X\*WQDROW+OCN8JO!M2?EKIS@HGC-@85!N +;+CN&!1CZOQ%]^M
M=TC@>B5*N[UU SG:6UL9N1EM.2:C?RY/6M5]B*#,6SQJ3?IR!5R5T)V46A]A
M*#YX<;-'K^,8?9(V1Y_?LJ[_C==EJ-P>K5$:1ALLXL2<5S*I-X!"BII'CS_
M859'^I7VL.'CN-;"*?O9^4YA<@1_(;9[WK2I3KEA)9^+X F605\!2&5H@[$.
M?J_YD_2>+&*83@]I#L@^& 6+K.S2)MHK/=,1$AV)W%M= 7LEHP_SS<M ?'SKPJ:0:SKVR;H&PR[6+PI>8AUY> ""2H&/-HC
M0N490]W8>!UM)=N);>L3G@)3W]NSHC3G'^#L\?B.%%TM[S*DH'E<\>RSVH]=
M^Q%7+G\>Y#6=(.@2'A>_ -(=LL\6M%F5P?PFN6F^R6/X\6E&^9_#>T:&@R% MJ_^6"M,&$%[$Q0=E2M"^KLD(,>;C
MQ%!!%-/(3:MHRCYW\]!+=;)IHAWIX9."=>.)TWA2=<%\LD"68CN<&([M@KV[
MQY(K>GUU1?4>*^L;$"^'$O.9)*OXIR&IW!9JJ31*>E^9=
M("VR-D23[5 JJY
MT<']=5&:V-=*CP[ <:%>G<:WJ,X'S!P1AV"]=0Q4B&&;MNTN3 T@I(,)[J:YI3&)R*(\'9MK4&J/H=+===7"9EGRGC-0 S?_-@V==XF2?
M083HZ(?>HSX?O-R#/@3MR6<<@F)0@'M<8?Q@.J8VKE=^R^1CF>BYH6\)W[A\
MIZ/>I"6@9$\Y8+[!>2$ZB/?>4/ P#6_(D/-1) ? )=%WFL<@V%!DE0)WP$S.
MV(2O8HJR/-YS_F< 4'5&^63R^$[VO]C%_!Y$AP"J:\^(X?X><.LZ4&&DH3PH
M.M$6FMG(3G6MGG[VWYOK;4F_@]>_R+Z9_)(OT\$)./6('FG96O4_!O+$[#M0Z7&T+J/$P,$A
M(%^*J>S]+#O4\KJ]R\,FAF@4DC^PAG4=%9HLPQSB1%J\ '%,7'CSVTJR-8;[
MQ!\.2,HAR!7OH]B#GMM37H.JCF.X -^MGMHUG4Z/<34\N'J]L)\!CN^0<7+]
MPO><:4RQN%I^)K.MW)/+Z^_.[X)OWQ+]SL6^#M\U^7\^MNLMBR1],+B\8LB1
M]/S-\[0K0YIKRJQY$_@S9*3 XR,(2B0Z79ZEOQLURVMF]G';$3
MT_73#I3!45:3B/4E<*)UZ#H;_GLW4*56=-'G MT[BEMKXEP?B#B4-!GN>4E%[M!3MN3LZ];U3"OT,0[*"5>21F(AK6LD+@3,&^
MG?R\D3S=\Q N]NPAR2ADW5K(KRR/)V)0_F&BQK'H\"=F"KQOI3TV3M.QY'W<
MAO?>Q1EO,!]>,/2]>B>-=:"C9X%AH6TY%N\3$VI)W_(_:C)_9:PYYB%=M
MP6D:%R&4CJ-4&7V;W@SB(")!X$<.\] /%L@/9UONM6ABXH9
MI0!V$=O9+FIU+:+_!N"V:*'B.7SNK1G^8HD;\LR51_T\14D=HI&NA"LR:(P0
M6HTE#D L'KO>>(6.C&6Y=V3EZFS$%24#,^?MY=_>W5!.^J/$(RI_"023_]"Q
MD7TQ:+\]::# 0*%Z!0D:Z[-RS#NYP;>+ST$/=K/MNA$RM;KH"Y5@MLN&\+K
M'YN("?!9\4E)L0RU[*,&,"8'HY=X) \XFX[ GSG^6)SMS>N; ]KT5Z;)J74[-D^N'">:5'[M;_B>#=K7;@*MXN?/:WOC&>E6QZ4N\Y[0Y6;EEO@E,"\V+J \JDQEN:4\[I8,&CPF!SKE/_+$
M 0A%=PSI V!_LB&^V^F63FU<*3?&CX&XK ZZ_D_QU6U=:_@&C]@UR.P&K19
MO/9A1:*G-ZVNUXI&FQ\6?(^PGW%A55-]S7LK]_I:W3GX,N[N+
M">AZFS;[4$JPGO7YN#GDA:GK?,8_>;K\3BE0K!0)$68(]NT>@KKYI)Q1Z<9T
MG1C!3ATLUW8-^ZJ,-I#!X+(9HT%TU8D$4;7Q]Z:%4\1B9PL*XH^GK\]C:M[)
M4YTM0F&)NR>;3AR%&!H,$MD3*@B*AV3YFQC6$;IXYM!#IQ:-MIOWAEI+IQ$Q0V_.QA6O!G#F@1-Z\!87??
M^/P=J7MI%[]CP%F&\P2]*BS2P;?^&H.3R0+$J1;3D7$=LB:WCX;ORR=CV5%+
M,#:@8$DI(WU/)!G]5,KK6U R7^@"1U;U>D;N^.XSR0;@]@/8[2BJ"3
M05^WBSI9TU6%%!AVYM'']%X"'Q+M049*.4Q=K]&9\JVB59^.+_C6X]FW6
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MY,T>K'#^"2"T%P%Y:M#XM.3OTG5*R@4>GC $#1EP00@7=;FOHR+&<1&L$-&[5!V4J3#L[NLY8(+$G;R]U
M9\F=M9'VNR(S9RR[2I+&&NV'C/Z?G6Y878S*;YEQ5//RD59")X=D=/=?0071
M5R8A#A08/R*DM9>'*5WV!B2\(ASZHVT\[X/L^V_@.X4Z)TTJE+@@PC268KLICY(E#4!/3S1MY
MG](L:A--?>F9=[J^M@YW>Q2TIWJ4(**[*BLZ*KW M:6=M.OK%,N?\^E5_>H]
MN%,H_>X#-8YNB:R76@LL_0BEZ$ U&9'4PM%JSM'G@P$9ZLBVK8G7,D=>@Y0&;+9.SQ]F9$-O0YX^ID3P>W]W_;^%UW*7P":.N)
MC3\#OK]YGDK^:(@U;,WKU1H+^'+OOJK_+)$E05?;;F0:OK%')YA-!M)"34:J
MZS]2VCG5^5!91J0&BW4XE_>S"YX(\BO%#OKVT^J\P!.:;!(/@X:-N9<$'*^.
MOC?KF'N^ E,W2OTG8#TV.LSQ91C30V!9)&E573*0[.;.WH:RQ>S\P]M52E\7
M!=PO]2]:5$AV/JUQ#R4W/Z_]V!:ENG OSMRDL&V@&\V)W+3]"R\+$E=>]69_$F5QE$_[BDD)GMVU1B*%Q256Q\$(E*4$!%
M-;\(D^$W"=W:/KBS"!K4'^9XB2(L]D6@$5@RCY--T]@VS>-3UQ(?[SH&/+ZI
MZ>,Z8]G18&%@=*V%T'#?X%=BV4R?Q-SJ7T7[O&L.I/XWP1G+60NUL9U[-.3-
MR>HC>XVQ0>7&#HC^# ZS$3?ZSY@B'T?39!^Y43F1-$2ML*OGZS<-83IF5Z"$US12.PA-@;D3HL#T).\.[H,OX]8Q?Y+O_UDW4&N8(2/)
M:O?6DJL,RP Q%65ZPT!*N;SK=_.2$P-%.9FR\AXF&P&XB Z.869P"=.,)#MQ
MFH')(K,N(@)/:N6L/I@(4,2'64JZ-*;9QMH18G80U;*$EB-:'=)-"O_I/?G!
MX/C_?N!\8DA,_(?'FWN!S# 8/YP?,W; -7:>:7Q4L$7G@=O=>2I H$XXWIV^
M10'1-;T#J4@>Q/SI5I*6/EQ@)3M8T=)D?B),LZ=\VJE'M!'N_L5.&VWU'Y<[IMR;+\@(/.G@1'@<5_S#1(0.DWV"8Q/IPZ]G-:.Z]4VA,
M=^A.-7.:=?/*A FP(U]$,0^=&K;$(RT\B[^,RO
ME?ID+:Z%=8PL_II/I@QX1(UMM"T:)VH]W"*!M3C8=""*/%UTPKDP.Y\)* H^,)?@2-^)M"+0=QII-N,C"K>?F
M0R\LZ3!J$ [BXE>!FKE%YR/.F4B?X^/Q6A#ND':">V'YF?<+G.(A'\E\@!EF
MI!@-SD3]2*?]=?0I*7__13-NV+G>=JV>)>L]AM2AUG+X
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M&Q62'XVW9+1UKAU.ZB43,J^FLN*JJD?E?8K1*
M)2[AF?3^@PGL,3) ]*>+$OG(-;Q>,B<,& _IEV=9.$OT2=>>&)^O[U
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MRZ"M+QR[=^K*;Q(HQ=18RB-_[";'CX='M,DG8LDEER]S1\++++LKM3-U.RS"->9(Z@SOIS-0'N.@"I%N)#K&+3<3^_M*6\"#*IXRLXN
M\XM;@F3 ;[_P8P=EE5<>THO^3+W@OM]1EICF/A_!RW[! @@)!G/])3@,7L--RJ,4C(YO^ZA).K/">F=[+*5[(3
MODX_JW+W*YFKPO^>'MK1_^PXO2K7VH3Z=2_X=.JP!7>BG*\"OY/F38ZH56Q=
M39@@0C<#CF[$!.0-.=F.^V_I[%LMCE5H\2G9X?+YM;3L)
M612\O?[*=\);Y(':W"E:67W-%)$,C:X"K+NS83$*'R>8HDC*C OK39S#A.-#
MJ'ZJ!R-PIU+B$.3;5+:>WB,TV=3Z?LY%],KZ!?3R_,I;O@SR?A+!(S%,UC-S
MGB-[YCJ<$Y75R>_@A$KO?F(L&@.!5QK5 +@;1C)EXJ*W)]XYK7I8UA6]YC>7
M$"A%WMG/A)Y<=SW=P##^&_7H8*&VF5Z\(1'=V%(]!6X"5,Q;A_%:9=MG!=66[5^]F8C%6WSEB9,$LA%(+>5:676G_VP[X>@19'MX7*Z7[7^N'?&E*',B$F5:L*%G>F.M6 HTFR[+-?H7W^;!%WKX=W#?,MG/_XM
M"$Z/6=XX!)UJ0"9H[\3>&8=;1O9)[&=,Y-=XGT+@4!/\G=6."Z[G:TH2_4I<
MV[MQ!A7Z(K"KM^Z%'GC \OSGPZ%/D%-.BT6MFO,RZ9W% >6^:#6(5_9@=9/V
M!4#>4>]OM&;N^3](RU]9[U#8.^I!):LBMXWM]V@)J9@QF5##]*&TY20;W1Q;GH!8OR^R65AKNK0P:W7+.^YMA+8]OOEK5^FC
MC?15^T,0F"1T\QCWH@?;W[X:[-9TYO_+QK9%\O(@ZGQF HBYMD]0PR/]WF,^
MWT3K9YG6,1(Q8S*B>K85%'UIZUOT^+3,]$!&HE7KU8]DEL6CB
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MM"_,=% 8.:_NEJ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M?0G_[#O)Q1>] [6H3I<1J/13'5[OP8X+P.]UM&U]H[^HUN9M9)R=6_QU#?*C0O"HO38,.
ML]Y_>R"#\NYJ):YUZ+?3U?MRU7LEV%]3^"00$F>:<.I5<@#-NV1-(KM88,V_F>3>T7Y]ZS]]"S^V]#2
M6;XA!9!>^BCAG.:/_:(&<#R8&RKAQ/0"TK63*; HJ I#I)PA0_SD-_5]?JU5
M*8%MGHLTCSTUQ4;2HMTFB@H@''-[-D[-N1J4$YKK8GZ4H'(6DH]J^OFM^)KK:2#]W9K-T=HP&^FO!*[.3SL1P @H9 P/8Q@1\TZTM-3&J.#BYE5''D08
MR.:$MIWXE3=YFT1S/44.ASG^0MN\=01BB%U9$O/Y/A0?QZ^'H-NC 2=_O<7=
M&:L?N#!C6K8FDFEEW#V1>MBF%-=[M^7[ZH^G8^#]P3:@!$,T3[&@GL,,\]GJ!N/63XXAC>E+Y'.9\:^&X-
MPT,W_OFC]<:EE;SSI,HYS<1VG2]W&5+O2=5&1=36=(H.#78(.O$W&6)0 D12
M#.8SE.*@[+->A%.!R&-#B@1R&%5.?UU\&?F
MQ-*629I3\\WK41F@??0CZ5?<4F"W)&H'K^[J<.1PTM9N5GR]FM+=X6T?:Q>2
M)LVNFS3G"/C?P+7JZ;=?EC7D5GK"P$RYJ
M68MA)O.D&>S1[H5>,G) >;4AOM]O2. L;WKZ,S"ZN.^TUQA4VD,[4'0V,_?\M=DT9JH[\+->]$JW;V@+<(#GW<+]P,-=."-@40RV9%TS'5/E5WC+
M-UXM8'6QD6B_2DLJ[CCQZ%%C*CF:U8X%\?)!;B:*)
MM M6KHB;!Z]3(E?TEF$UL'Q-4+W-_QV!_@<&+<.%H6< _<7EYQ!3A@Y%I&(_
M3L4IU3TM"MG1RHU5YY:U:3W\)/MW4=?9%CWYD_E4.VZL&Q]I81$=-BBCS41 ]:K7YJ\@;O5\3M3,G$OO*IV>G(_
M] 77Q22Y\._W6+;Z/B'% .^=JOUB)I+QE^C8$QL'%6$*CO1UP2/M&IML)[4=
ME^.UFM4:<'$=^A\2=+Q?JW(+K$(E1]7/"VC(.:TI"K"DFJYT&W%]^O1I,4F*
M"M8.GOOTV8 =1!7^UW,(8OM["(H(02GMR-#O=-A^#*6J)\HHC];/P*11'8CB
MIE%Q'R$S32S72G=1.#*_7[M ?N+&"64O"&0M6@MPC1@7%.!Q?[7Q M.;&V]8/*[*E!?UZ?C>\=]_LK,2WKS
MAO+@N2$VGQ@0#X2"8#[DYM]32K*@#P2
M.>-=*$Q:?)OL?_]X5ASD+$_F^[^"L[)9M[S7[WS[D+#/,E&?*(VU& NPO#7K
MLNK8$/WK=;FC!AX1=+_,R0(1["W?^^5M]U]AD=+@G5C J'SJ"_W65F>>!JE!G7T]RR[(59$.C]ME?[ O5S#GHG,J*/\<%54%ES+2+NB>QD6H#//:K!O;15\"!(_=SF<\YVY+.OV
MC^5JO917M%O_W[M*&XJO&PN!1M\NI[2'^'>*Z0Z:G!2#N*6\S %]8@N_9,)[
M\J_>LVJXWCY/>A*O7A>A3>3B)W7JJ
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MON_VO[A6K_";*^-T-U@^B2NDAX,^#X;XD3K.6]/(\[Q1SIIOQ6E^6[LK#
MGOM7NM,!U%# $?"ZH>ZAN'G^!$4&-+X$,9&M]7/VK)][H2LJTI&TS<;@80K6
M$M5PL;T%TSW?GN:?H=2=5;3)[K")V*(T;0PP^G:MQR8%'((D'5?MME;G%4A,,"R1A@Y:%!VN?"Q*G!<7F!GRQMZ_!%]]MJ/S+%ZZ
M^^F)WRR[+R1_?CD$02C90PWALL=E<[M3YL+79_U'WPE\6/2Y!V*+;'A^^ML#(;R\QE;L.:E]C'-?$'>H +_9FT$7FIL 3 ]D O'>';%CDSGS+@*.;K Q$7
MQ>&MW=XZ ^65OOQ52-_Z,E_I2I_S#(3:;&I8>=*]M/2^K/?_"RE%:IB77\D@EZ=ZQIT_NY"688G1G>?7MEF1R^?JLGV/!>)4]* I+
MG:]@F,"2"-Q,)%5:WAX@W4=0?/P_82[14PH]#'Y]]&WE'WF4WCG]I_U/3VY'
MO%X?>PZZD>[HVFIR&EPB$1"4.N.DQF3,SJM5G@SV$V*?%_\U+N1LR69B?N.4
MN?*CA-E^^6O1=W/COH"&_X<@T04M/J2&7[B$*<4-9F93SX4<2/LME,*R='M
MUVI_4".>$C=E62)!0EMOJ,V+>:#!<]=>F%UBD7["Y\R:E&]=:@//AS>J@AN=
MY\\#W# /,::T4E0!D$N>P4GP6%F&2.Y_MN]M.@C^#S[P)DR/P+KUBC
M,?S91W^Y?6W_:?W(LFILR-^70[ ]N'"M_ 5?4 $^VSJ9P'6:CC_0R>J;%[/F
MF 8RK3EF4P=J&YJJL.+;QT7?EESXR[W%O?LGR
M?Y9:1I9_4=C*[\<].:G\]E0PA_S8__15*^%EF/"!$NJ_O1WBIC#3G!'8G7D@
M0\>\VLT]!$U1-5QF<[_P5$5'2;ZPQI;-6?(DO[RV$5I.M3WMCV,#X'M60&P/
M%$;_2T0F@-DA3G2[;AD]^D0A93-FDR+M;32IBK]?O'I2>+ZJ4'P;\5!/)S'
MX!)E\!#D,*)^)R/&7&8B.$-!F66'1YBUO\'0!I^:]MYPM$[Y?LA
M=555%2[S4:/U3K(UVN_*OWZ,2)5/8]G>%]Y"=N*F[8AP\8*1TR3(1:H!GWT;
MKOL9Y@RIP5)ZJ8ZNG@@!EV$?H=(_'2A/^CC4K\,%IFZX-3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MDF?1MX?)MP&L9_*[M^>;P5F(=2,1I'VU'"K(:,Z3OQ"*V=JOMJ4(BC2/J\PLQ'B\^7_,C"GPQZ/YMS':QKH6-E>Q]")I.M][/K=%:B&PZX-Y_
MBS'(C\SCK6>8=H/C#J3H@_'5A&BFQON^MM[61: ('#WY;:DR^GT49PKPL]6]V,%S;W@+I.XY'F7;O*E2 ;AP=->S5H:(W
MJZTWZZH]SK1R;QQ'P\I6!8-%6F4RBL+R0O5SY,LLGBEUV46M'H)J>W%[5] /
M@#I&4]\6< BR!-P9WEU@'A^TZ-N5#G4&F+@^X&9$TO1>!_.OYI^"*)5H90Q\
M&9<)[!PK7H"F!S2&RIET[0LO2N(2\WD":9+DDB;Z%C$[O^M'QK8U"""1*V.O
M1W;)@&N=4=@KC/PH+=%@M>3BERJER4$F+0]-\D857Q>_Y4%&P6OSN_(C
M,6?'($%O^411Z7VB!^!&>@2JCR*:V$"01.%NT,.JNG5> '#SL8;^^.(/H\=_
MG U4N/!QJ(5'J^
MO2"&BYT\*H,^3$FL3FMQ()-9S)'%>*J!%53(39?T^1/RF>XLXQ37PAPOIS^]"/&SM:9]ZW(?\UWSU:^
MB^$-B>SL_'SP<=C91":97=#;2)>/_Q2=_>,.^U\=Q60%D]D6L
M9OEJ_TXHT$DGD#>)+DY=,"XT_#V@3R70G-YZ824[P$-(V?$#:53?56 RN +E
M1$UY76R6-@?F6P\YGO2L0RUZ?GY4A:7$^YRM^8V[^R>!_NY6;!3D+$5=Q LG
M@>B0&-52\_U7%)",&2J>LGS6OW2=T9U$DWB[]=#X7]SL2>&?X#J37(IR!S_*
MWX61_.?/?[TX_,\7,SAMPC][[O:5',?Q PVO6^@KQWKL/]J'^##$4*ZPZ;]W&9),#A@O^D*=URX'4]US
M<[ &4666/P.;LI TKY&V6GEU?J.JJ"/GZY;.Y"JN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M;[0!SQFNTTZO U]M0%P\D!S1H]9\5W?F!<(V
MAYF*;=/L)29J"E%P"\+$G_WK1*/A^C;$^MR[Y]]&!PY@[[O1,<+SS!]1S$LPTNHI_R5!A'Q7J!AVG?DB"M#P?\1),UG6AN
M%@R=[XMI?TVC$E_F4>R+FI.K1.P+VYHCECA0;)5WT1I'+O3RQ1$$-3>GP8N;
MWSN$@4+34;PI/?$6?;-G7\:[78.B0QRBA?I86# >.*[JG*Q"'2U+$P:G*WPE
MLP[[^=$(I&V$I^';8Z@W?6@CD6J=T*&S_Q9M7NW]9 7.Q33M44\7G("T#JD1B%89X+IG#:3[J;;F)9,'L+<_-NJ(-NY4^>]X_KH_G3IT_A T
M;,V)?D;_55X U-@P)I(KT7+C4!E'PS#J.E^<"-5Z% WST'G%@,\ ! ZBWD[&
MA>AL+IK2S=9S-0+.QC[Z<5=881[@B$DX&Y,CF$P+ZI'O/=!B6"M59RUI41_MZL&P_A[\UA-P #G68]88]*#"!5]?1;?#QKL@O/LU.!7S]&&
M=+\<4:+!);T$!BX:#,:<0OOHE3+/'8)D5O+4\Z^D"4UL/);P]K$PW[O%7M?:
M.MIPPD?K\O:^U26XU9AEA?W"N3HGY\]"V3O9H+-\1E]DJ%5J4D&'(,5PJ-1^
M/3J,(?KI)F9(E,#U[6_K4LN>":!.G,1('MMYLN%(V:N+&;4Z)4W*\@^0"_O3NHK4^N^ONE-1V74?X]&M.>8&$T5X$]2J=S
MMS&7FBQ)1L9J@;D0-=H-_N][LV]\G%[7RRL^/K.RUB11]/L-XIE 4F]^:4AF
M=,&ZP&K=6K9[3*$V+DRFHM@BU%MZ+!M3R-EJ%/;P-[MW:-F$N;!27&5"]2MB7^;5-&-U<6AN-VF�\C,+CT6FYF"_8Q^"SM^8V*IJ:0O4[#V\3?8K6,-HI
MF]:Y@23RS+74>G_4AJI86I08]3O+/S ?[2)CX=.P_:JK.I!!R?W?6OOV<";\
MM_\5(I*M.5MM'VQ3A+")60R/S_/7\[N>[^^/Y_D^?]Q_OJ_K?;VN^WW?]^NZ[]?[=NDJ
M4R %,NZPW/HG116A^)2?!GN -/U]@'=*>99:-,_>X.H+V*"M_F2\X7&)N;7/
ML,$SI#'F&;&EWM7X6'\Q<:1\^PPO<)@GRQ@PM-A2SJ'##T(] ]XN0+234:O[
M 5+"\^]&;XA0XNM"*/^22@#IR?7U"$0[I&3%#Y[=[+;@"W:C>MKWFF07!ZUJWU2>$_.9S'ZW52V
M_MC:O/*3^=_#@I)TG4/@!(.(T>]LMW3>+7-*D5OC$DAW_,5X,T+CW:/69%]"
M\MH,0Y[ %A
M2O.JR.X_Z\"M&-%74>IDZ U"M("!"Q%;.5;R(7EF+5BE;-B4,+(,PH@JFA44;P8MVXJXI''_M[Z5U$BMIW;NZWHY80#O.G>#C>?4#V.0S!V77F@43X)BX/"5KQ=*
M2='&B,Y"@E.+,< 0MDIWFT-JC*K70L.7KQ>IFXGF9E&QX7XAX:*#S4U. U$*
M"9V0B#8QK+D *Y^3LE/ 4V?),FW20+IM XB*22!B%0Q/3I[365Y7L@;+U3^[J[,L\WEZU_X&<+8AXR=9M0A)VE8=7PS.BA7_UB"]&0._4;;Y%ASKGF1@"#_N5FA@MR/;)[4Y4?Y"?OO_J
MCBL@G1FCB!'@6K"*M]TG0 H8/59P?+,HNBU@LU-I!!>H$PRD!IO3#,E1TV:'
M'FLO5=,,+J2IE6L+L^L!%I'2]RJR0][?U"O??OU#MS#P/.[[PM7AB*0&F"E^2F[MWL%Z_.[NZ7O!^[).JQIK9VEO]@N\^#%7Y\[$?
MS#/ R[IBW:+!NX=I2#KXH-V+@$WH/,>O_SC&KRHYAYZ"GRVBZ!#OU/! :WT-
MN\:-XQLF8;Y-29UEABS".#1TPM515^M""QW[-V.WM6E:Y0QK$!/$3&M^"N@:.XTLTPX)IEO;.7_M_#M3:UM3\]4JL5_2\00.I\(I]
MYLOSCX($_L0"*..OU0C'?^A=$_)^"" #8LH^QFD\GQ6T.%WA$U_Z-.M-BK9,1VG^08Z=7G71V*.<2]A;%ZY+SXM&6[]FXHV*B+TE%];085,(;N#_)=:5NJ: C""T\WV:HC.9\QWS22]#+N!,(M!Y%,&7S X'FQ>P8D4:A_&R(7Y?2'$^C-TGRKA&CB20PJ7) L1HU@E/7093;M
MN Z,9Q#F:MKRAXAT&MFT_!-C%3M@\/;3=GO-A\D-__(\(P$4,U?H@^:2E:-U
MY.]6]6J3H4O]H%907QS(;'P/<'M]$P?9JVF-96K#>Y@Z[QHO=&XP2IBK?R4=@1[*#P@9=KNRM2W[4CU)T[,[-?WLS7L;XAINV$XSD'R\2XLQO_[TI=-VS,*$ACDJC 4IG=
M9YY&=9I8HB6C+ 6D1UFW?V"KUIIC.[[>(<%9H3B>MW_\?=M\1*.NX6 6H?0=
M/J2N VX]%KYCY#027J+EY6 S45??M RYUI$M_^QR51\#J*3O!]M=1*,Y3ACKK:S=I+RO)MSDL.>W5[JU5V09??PG:LB405NQ;FUM\J0I,2;PF FX&$@/M/$)_H;!489Q!?(/\'O\3ZG*X_T?R4$\9OSM.X;1KZ'1J(NF&N)3%;4[1374KU3H#/1/K7 !HMWI.Y>R?1B$]\%)8*%SXME+*CF#/T3U/W3^.:D8."#L>\O:&7U"$"^9Z?--;ZJR^=T$%6D]D>M'LG$LY+
MG1;$V00]ZE.W95ZYNN$]<%*IY9M+@7\4:ZF_5NV;*H!7)8KV:^+UGH$A[&5\@KE#-?M%#&"NGL'%7:2^O@X>R/JPL3 3XNA:^^4''[5J/A^6%KK=+W2-TQ.J+CY^M[]
MGA< "<&K -XV5\EO%IP);WHVOPRLX>F0N$#ZCB#CCSV 8%.6#FR<:!+)+$N3
M?\R6,JTOKUD\S[V]!W!L;&$1$NKI[<-A!L1W1HV+8&1KBA92[RWAQTV3X_C'
M>P#?@FQPPA9HO-"X/[U3HU_84S4;]89WA:WMW"[#AT;,WF_W=N]N^^TL!:",
M!3 :LZF^XNBIA!VFE/S$O,M"*#5JI,7(ZM>$P/??:\[>N?70Z:QQ?Z'? 6VV'XDM@ H,L-E2.PKD[EO$O,_9I0;7A7;D$L
M:%6QL)Q,>&$8;8.!$[/"!F5FG-Z]^_/^":=WW^B.@H:5O/MM!PP1/(NP3M:[DX7[;L/QMO84SO_.@7^]E5=Y$C?;.*F]J[P?[=DJ:?7K[07H<)S.
MKD2PI!?,@UJY7-'0)?T]&RL]T6Z29W*0AUWHX+-J'#9 :5Y^8RF=DE;ECI#1
MI6>U%(?7/2BDK__FU3QJOZD;^.V15>!LYL/8JX!YHL5+Q*[\J$'.T049YJ>K
MPTV?@%J0INLW;+4#5=,GOQZ= +Q)D1)32QKX(*SU0@ELOA,ZM 3Y[ZVH_['=
M?!C^3^? ,62&8,[9?)G;IO)B]_J!JRMK"K::[]J*%6!187FPC)(G+U,FI_F/
M(^HU']>%7*DY_K7B!,#9/3.=.]NOTOSYF1IRLNQ06!1MK4%"7.B/ H3 :L:<=4EO* P6F4T-3@!N("I;Q=T[_I+X>.,!";&CUM]K2OFY
M2?<*@BWP#)E#F3+#:*QE"[%XLI_<%I3+F(*Y>VEZVFJDP*: *W6,MM:&N[I>
MMZ*0#"$M0S1F8"F1::VY(JW"S[C"*.
M(:FUH:$"/?RVR!\.8C$C;IT2D^MXOIB14IDM%4^:M6V59?QD_-\Y/]YTC&G%RV +5B9TBZ"4XD47"$A%(OSN!>>C@7IFTT.O#%
M!RT*X:>/PRZP<#/%4-WYHJP+QJJ.@G4!WEJLS]AJ49@'6R:Y$F$?=*Y\?,,>
MYC"V_A7XQ'RB-7MK#HWSYE/YK.%Q5>IWC[0JY7,1J1G?T^'B7-0S(])$.L[S
M9Q^)F/^CE,:@8%?JU[6T"C(&G^&(FT'K)W\3][V1!,LD/
M_O43G?.:&9NYBN=:S_1>\.;C-M=R7=ZWZ:2'1[OTFLHFFIO\T]!."9\8"1,5
M<7M7]L<8$+6A=)6Q[",3R(*EWDJXDGV^>4L45?$%T0*_/597]U-[0EC$S,R_
M;OG&^6-G>P)SU9(S^9UE'TR(O$L'<&MQ\TU=&Y-E#=Q;QU];(#'KOEO+=>)0[GIGV2V,@+&$(/:KO+?QSEC0E[EOT!4
M9^%:.=6X2XH'S6Z&QO\P.ZJU5LT$]SA(\12X>$8\W>L:Y>JM.J2RZLZSYH[;
M'E4-]BXPGTBV)NMDUH'9Y0*C9HC&#_J46I$Y&M1V.7Q%T@OOQZ0VNC=;1D2 Q?P)9.Z6'SJ>3[4
MZPH]Z'HZ^I.-7C%@P_1?*9F,E_I;]P!+([938L-[@+. 7^ T%1ES$5:C;:(K
MNZJIY1!O,/CE#T[+VB)(@RW-7<88/#AX:GSC]:;C0=I76&=W5Q6Z *LB
MP5V=C26OIL6H%KW?E6Y@JR3?RC-^9BY*MPN;LIP]BO=#YP$[AG*($#4O-)Q>
MA7WP>"8X,C1D5OKP6>UC5T>6M_CZ.Q7&,%[;E]"PGN+NOS.00PF=('=#!05"
MP\1Z2<9R[.6QE6 #X&5%SQ];U5^J"Z$1
MD#P+C/UI#JZ\@AF0&=4+VA!Y>;AP#^ Z?M*O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M:UA[ &F,);OO"9O &>"#!9BCK$Q*H+H
MI?[&2U*FT=4IOH5 RY[:R-N^B9#QYNO%NTQC;[W82T"#)7N00/.;!.K'SXI"
M*.WE%\V$^.L ">.;US,%' $*QNJ9;H-[@":W;@6\W((3FM)M"LJOY5FR6DHB
M[RCGOP(8E*5ZBXP+QW8[L>;)6IGVB+JO&OG^1?J"IN!4U;>=!-WE^Q=!178-
M<0F*F8=N@EQ_6P:Y/-5[MK5BQGFP!XF3Q:GJG"M036%C.V(DQBXM#CS$J>;GH4+)CDF6HOT$'5%+#2,^6
MA'KQGY-?OO,Y]==B30'A_PX?_J^FY/\R#N2\\_Q16>I,0_?OFV20_M_Z9;_G
M"5T@U=/OI8.9BT9'#EZSDU.YYC'3%2W_-]23Y@TUS[,N^_2!KXDZ*
M7?D#.S[UN-\VKED)[U0C<>M6UF35=HHF,839^Z( ^L-
M542YZ9-G4$RBC.R(PZU7T"&404M$BVRNGB?5TT&8>&U C2<8\9QW8Z>,:'.N
M\W89HSW ;2BZGONK.R2@],S.$QXR7/TW.(B;S)J#M..E,1J4<"-_N#-;%OML
M_7201K'U[=17 +!KVQ[ ^V$,/ LSL'U;\\FV&<;*4F"J:_M<]G"7S_'BE:AD
MRGHCOV/?JY\0^^^KW;IK28_Y)W)28I5]V)K)AG@)C-4(#B2_L'NMJHV&!RG"IN+YV-*Y?ZNZ$K6KJP\H[QA7QJVNV"TD.Q62H2
MG<;]M0AP(R'IQ%M6VP#P:9GB[ID%V4F0Y*]M/O6L>6JCYH<.G'ZO9/-SYJ E/F94KP($L6>ONAH!WM^4]-9)P,B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M&6/C/S1T.DCA_ZY?&3>SDK@+F)LNH%P)K+SL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M*9@R[)O><$:[:9^[*.1
M9^1B@-S+M&OLEG;S0U'13L0SK!;JG<;19KWAOOX;%(5MI;S9P3<-!2^%.21L
M[ &>(%T_&C-)SVW:Q'
M&4UCS@?5D!&TO .+\IJI80Z2[O75C(Y@6TK30!RZ651ME^;M/"Y">NJ1B0F_?"%GQA\2VN!; 8-:CHIN-4N(]@/!3
MKED01?IOK9C/>P!AG+E=);>ZARHU+3(9UF&M9.7+4?[B7?
M?7UD%;A\/
MHC-ULXLDBXY@WNCY%*+T^G=Q 5@H1M7_ MAQ*)-GATD2>7P;[P$07N+=7(7K5EZ22NE*>HLV@,1K&)ZNA7U(!'\WXH& Q6
M;F3"GI!B^>N+/0-/M-S)7Q3HF^CGXU/Y(V3TY=I(VFU X%,]'KYI[8#ZVZ%K
M29E/\T+._]"G=/S[Q.Z_V E IG*99XR*Y=\W$,LOB@\#OR>?2G"OS':_8U5X
M6-WW],@ WVLK-=.WKC:7,UN/5*O+[+_%(A(C%^PWR=8H_L6S:,[3RK)JKC4_
M>7*NT@OU^5%#"##UG.2!GW?:1EI\GQQWX65;N89Z=.&#M_\5&OU!G%
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M]KKYSW)(;"7ZEV0FOE=YNYG<
M*1DSQL+X<+T8.4)+/.,3&IKTNF=RLU[MM9E'M
MOUB9"T5D)!?;CP8=^;(=J=]\__P]8V.-*,60,L^0A5Z Z?]OTNRQC_/!V>_?
MEG_:#6E2\DL[$.N._'<-M>7R0FCJ_.R!V?PXP>'K!4X7Q=\Y/R"HSIZ]I+IB
M9AUU+SHY1GR0_8OSN(B175ECQT3>8OV.#6IA7>*2=++(WOH9/6?8UX#&:"'T
M WM%JYTBN:_/+P)79F)*76T_TWW![4%R\P$KQLXF_2<:LZ:G+JH?/_X9^216
MB'L7 OXYOT] 3STUO#X9TW4AYR8'56<3PJFM_A@0KI4=LABZ&+DZD_CH\+=9BX5QLH*;H,GB_0@?\UECP*[BT8*M_[-MS&?U
MOLE\?'3@O?'G*.5,,27NUMT*O"9W;!8NQ3/F(IA[ 4NN,N'*=/!Z##9,%,1
MJ"<(8L^96P^;IHQI;T2U0V@PV-+S::\7I2IGOI_._'A8@V^<_"HDKC_TO.>1
M;V< A#?'AT"ES:=B"QUJMM+W621E^2Y(W9+AH/"%>VVH9^;0*H^/Z2"!GNTM
M/M&ZI0^^FN?U8@3*?V -D2HF HQ9?5)*&DXIZWV$].*V_I.)2+0RSMPEL6_7A%1S^I^&.+OMUY]\>P D6!2]NT1N
ML\DR+#OB#^VMSL+<>MD?6<1DNI+9V:I%/1M>V,.5;2+8_/=L@QX!J(2GHZB ;<7IM>&W)MH6@FKZ("
MKV59- 0$;FY=50JU]VT^$_DRECRI-@GN!*A8CGB+J"QKL5SG8:RJ1"1;Q+*]
MK.\!]4Y??*W'QTV0ME4@U%6H/W9Z22K1@0'14%C:WAM(Q3K*)1)#!DM?E3?N)C4_YM99(T5*"0$6Q
M9TN1;)MU=95E[:^[^]$1SEI\M4@VS,VB2%+"::!I>BK/ IJZ8VX16<"&>[#".M_)HN/U5.^TPRUBIEKNV*'D%
M+V<.2N]WV""'>D-6__(+N=6V*B&"*[,AVQ0KC=D6X$MM]%,Q(8]N,];45EUDCY*WQUF\:C0D_U80'L+H0364-#O]TJJL?0\07CQ &='
M>AXN!CJ+5F ^:VF.HH./?46GS/2T]7!C/65V XU,KS5*-S=_*X[>P9&='()-
MJ5.TS_'Y@6^O-JCK26N.V/S> X"F_KOMXHG920FA\0F")DO+JRYNY(T99688;4;]@ZM9;AHTY/+;>
MKF0)'>.%1#)4E+B8Q4UO_5_!*R>'9V.%.HBU-0NC_6*
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M";_(U#Y\5/E"F^L31H?S[AP'(CMPL>34)&@$S8L2B]?3\3,48P%#HX)(+!UDLP=&,''D-ZZ% ;7!15IYD!'N5V%
M>*FH*9@80CZLHBI_/>I\=G?-L]OC/?A*U]#\[L-XB+< "\O)YJ+8+5$T!S[/
MI<'0ZA_*2NPKA:4G6'V-C(PTGAGSWMX6]\JW'?^!8/[ ',Q;Z!"OZESN%_8])S*K*\P_4\ZWV7+Q/@!O<9*?--FEOY
M*57B,X!AKT6#EJS/A L,E,Y )J37EXK4)&5H[RKM\XP^/=T_C/G%+/O2V.6M
M,[Y[8FFK.G5C2EY)MD5>PP89BE0EF(8_,\O%Z/-60K,.P3L=[OE.J*;
M*"?WEO2":Y27:S=5 ?F%]M&M"K)]$IDW34.7PC.,BKS-QT%GN0K,X&Q#VNKA
M'RX+G6>QC-V4::5AHL[1E#31^HR;8MV7BS!:;FR6725@R<'_-:*SO*[L;+FY(.C+(0#<#M=PAFGDHLRO-
MA9"=4WVMZX4:):Z_]1Z$><^,%CH(^M;M]W@KC
MS9 /W]E!Y8+Q/$LFF)\[TQ!I-MO
MBU?_&"D\F8T\3>U#6A7> 'FP)>D/GOSSGT!1,HAOFEOF.M%$DN*V4:YP(?@%
MJC?V.3J1X?6]L#V4.64$M8?VC?^])+MUGQM62(U^*6$SZ@L*!LJJXZ'A8WP=(V2?1(O-36.AILMZZU:=8RLK'<@79JMO**L
M6E'6LVY1]MZC*^R
MK) C\D/6#<'8T2+;,47LHY?KU:)!J(A W85\+=I..NP^!2A&S9-(ECJP+ML%
M3XB8$>;9L6'DS6G=HEX]GO,DSPBWDVMEM'U(A+JUWK-\ZPD1<+3#;:._DO!J6JV!6EK#Y!3*>4HV%<\_Q-&SY'DSO0K
MZU(PB-D26G#J-)BE0X9+M 8?&,2\)F;XSY^-$7R'(RH2ABRS+ =:LH&>,7/ELF
MB!S$%)M"HNK0?K#V9ZB[G?O>?MN9YK8;6)T.??7X;Q23)
MP@) ZJQ [P/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M2LXIIZ+@UL79.$' 2X T%\MY711Y'\ZD+SW]3\ 4$L#!!0 ( !>*V5J3
MBI^[418! /@Q 0 - :6UA9V5?,# S+FIP9^2[>503V1\O6,@2%B$@JVP%
MHJ(BX@*B&%,JK;BT1ML%%24J*B)J5*2)&E,H0EC$N/R4=B,J*@IB5$!<8HJ0
M -JV J(@H26;W;A 4]5JN))*98KWWGDS;^:=.7/FS7^#E@BINKG?[;.D$LL[
MBQ9R73AOP3S(RLH*VD#_@2R=4.S@3_]+7X.+_*^N866IA=SLK2*&A%A;C8"&
MN%E9NUE95! ,05:V__4$Z+]]60VQMK&U8]@[.#K1)U2[0D.LK*V'V%C;VMK8
MT(\>HA^';-QLAP5/FFWGOFPC8\0>C\F'3UZQ#YES3^'Y2PL^M?8;[CAH=.F;LN,BHJ='3IL?$_C1W7MS\!0N7KUBY*G[UFK5)F[=L3=Z6LCUM
M7_JO&?S]![*.9N>(M.J6JOJ'QV?/?7[>^>=O6_JY#K=,;/OSU=_?'3Y^)?[]^^V[L!S\&!N.R@JS_
M>^C_T[CM*1Q"IOR">V[:V^+H-3)2-XH8#.V_1/;_++ C_Z\B^^^!_>]QJ:&AUE9T\:S=
M( 2B'J/:&^@#8X$%LL'-Q]ECJ=8B8<#IAICNG"5BG1CB3]JUJEX03\#U S5D
M2+%]\ZY_,E^>+1S]Z-_U
M;WLV&6= WDUMTKTZ@S]+Z?)Y2ZE8L9?!04-;M?ZIIE,>X'OWPS%_*XG'W2'8
M(D1[QP+=\WIB@6R'F+/EXZDFH7/[OB8GMF)ERP (Q8D)S[V7HC$WO?1\EU2JH/2@/MA:J+1"^K"DK<1@((V#*OM$TYR.W
MIN8H.P!3:)RH5F_$_YO4FGHI869L[_)'7M.TTQ\GL0_'@MUGN&H)24DY\)H1IKVA-]<0M4B^5*[B+YV#:)-W_J(??%M!2)Z'G$9URXS[%05,I4W;_I,M>'DC0S>AD$"7@IV$;Y-Q?[L\],-A[?I0P_YF1+?: O&2AL/JS*&2W[3NA+,%
MZ@DQ+?P35M]U$#=ND=,>3D,7QV'_>2V!1E@12S!!OI"C?B#-*U@0="XPI9HPQ-+J!];DN4
MN-/7L!I/)B@XSK?@)*CNO7!+>^"<)0,HG-ZYNN3H8T;(',L
MT4AZ!:!;Q6!L46\'[F<\28R^5RYLPNPI3X$=P5.((4$8F*%GYJ&>7A9()1SZ
MFK6(X'+?[J "/R[6V^$UH@3HBSPD6##AT?,@6T3([Z<MNZ>$1"E6PRLLT%&>]MOCY!R?8'*;I+=ASO!T]U]0QJ
MF"IF&WWFZK62*=LV2GY?=,G)J#3G(MI;6$UI[P*=]-T,@Z1W/;Y<[]WSQ11!
M!N)]^=1P"U07<,B >O)+:E$7M]^C?)4PZ\5PPMJEGO6FH4"FT:9'["GYM94TRH.IDXPE0;]K%]S-.O _2]1SU
M!6U3-C7N2TD\6*[59 <&M\U:[W?& A4MRH%G6BMLY][EBB,B-?F:RIH"F15N4L6$UB,YOG=.ZSFBP#%M[%# 5+*#FLD]
M>&NC?O+M?8C;L_E6=^=OT![F5I?H+Q5ELX3MJ
M+5!R"MLE<"3AMS;EXK_Y(\>50!]&Q^]N)$IO"FLU#U[V]XREVU,%>(R>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MM=)A'[.X"4PW](^R^:$K&]Y?PM+M+U'\-2F([HUI3]8+$N%0$+$-V(=I*7W+IK0ON9D9M/[/K13!1?V@0)
M6[@X%ST.WV]4/%TF#"%WX/$]^<@6J1>H_!G?V2UBCWS/=Y_C&UV_47LI;"V"
MB[\DTM%FORJW0/:GP+/"KK"ZBUE5F<(RZH4&C\?>O3 ^!"##"/&
M?:V-$==S'8A6
MHHZFG RFF>1<\TDDI<^;JA6RB?@\]C1R@OF\#"5:E<4C";@6"ZQ12ITX6MAC
MFSR L,LV'(I/P._B ^ NNV);G.B^,G!$LU_0/0="TW/:%$VU%8^D4_Z;L%%2
MS2A@VU*:3[B&8_X/FR6()+I5FLZ,>KD+$7I\/!4*3BLT.V(@/"Z'M0K1_2*8
M3OW9))*-Y.3((NBM$XJ@;WM4<63)SNC*?=#&4N)B'KKV_R#TV8LV.EPXN;T:<_[SD-FU'P.TY;0R1..!05&
MOOE">I_;9RK2?%O&-8TB86 BKBIKA3;M/!:,OQ<M6$24@!^GI$8$__:Y;;BVC]6GY(!P#NG>K>]NT#!):UQM7/"6[<=_W:@M4HGS!B9;EP%OG:0A/&$VEP%*N*V_;6@05Q>5?+V/A5B@#5P0
MVM\;9[("'6Q'?FH==Y@LS30=5<1A2MA>&8E=X+[&T!(LK-TV\A^&6]WZZ_QSXDTTP3:"1G6Z#MN8)1IA!*H0E M_2!
M,5TUMX2O+! M=1VL;J3"]S/JDTU)]1?%8,'$6>J],,'[T)=,6ZCWW :-'FJ%]GUQWP%MA
M@88%P-KT#Q*F/+1C>]>XNWAF6UQ](4>?G"M;F*>S0':I6?6A"P+=\,RE&CR_
MK#MTA/P?\UT+I+TLJ4SNFMO@%^N]N;1"PG[26$&L9HV6>;RIG"'1^R_->I15M&8U/1#4TV5 M<64-ZBBG'
M],O@JW$;>(8QT!UP'N4%/N%-QM.5X@5R )>F4-9@'VOJ/MAU^\N*@#AJF-0M
M8!WS[DX+="[C\J9K^U'2L\D8;RZ18CRLP\_8#9;I(M25>KBN+X>&05D:'J$_
M7F1R P4*=6CO8IH1J&$SEZOD0?3_C@GM*$OPL!I(2J,OWV7.WF0N8LTT):X6)#QNH[SX3QJ^X!?J#@CSM-+ +G(N$=VP
MM8E/^F]6['9TU?I:H^$%[:TUY*/<.J2WO=
M\-)YX*24GMLSD8?8[0T2:^$H<@0HP0WZK5D&7H 85)4T!MJU507K+=!0P0SB
MADS!*3#^!W\8!P51>J8,OV(*2[M/Z\-!?57I)4)XN_]Q4@-0PR4I,K
M]P99QJ,!\
M$=->*V:;+R':,L2NFF&^QUI@FBI8:/Y/E$2DN=M@ZR%LC;!)+VXMP4GSK4KGA5'$7,JLZ[\A['U#L3HX Y%M67L(&#"NRF'V833
M O#^,CGTK05*D1Y?I7$03@2,!J0R6;4SD7FL:VJ+8+BN(K5!,U3HN?W?"'*9
M[PCV;9I$<\FE[.1LUB^7I^U:X_V1$X J,E#M18TSK7D"01H7G"$\H^!LQ"<*
M/6*!?'A534M/6>D+U 'P2ASA3"2G&*!L@37,'.A? 8YZ8DY#TWA.H$0@UQ,1"QJ'5_-= *I
MM8B3S%GW -3?2[\M$0F#"5JLU8_V3CMY]625S?!NUER3L_!M.Q=?HJ'93G==
MW&.!""LJE'H#/\A0P3X".[SJ5_5JPKL>@R0^Y%24^44>.!SZ^"2R<'UM2'"L
M6W;X">9[+).+KV*^DQ@O@^_IID@R#&3K$S1Y[ORT>*(H,[F="N0W*2@&J-$6
M^B%J^600:CB4^I-8:8%$
M'5C3"49C_UB#)J]1VTU?<M\=$-F?>/^;L%3]_^ ZZ7W&_J#6:2'AS*WD3$THAA^_T=&6I"!I^ BA1$$=T%
MN\)GXW%*,M1/@*J<$*Y2S2Q?Q8Z"/X&1 I^O6INB81FL1QXL/SP)5R4G._78&(>K42L'H6
M?[DIE!V,_!N6G#B2AK3ID+G=?(H&H4JAH_D*QN-VM.+/B;_/#&@ZL74_K1Z=]L-MVC9\LF7C2<+Z%ZT(BCK]7X"::%-X)ENMF!I")
MU[PVHZ785@T8C_9,,L63"7B_0GR4ZRK8Q%II*.>YOQ<$O65EX)@^5"FV(?FO
M68&=@K@[Y#!"FE\5/D6I<1T?V1P[J74U8C.N&Z+F J5QH?FV(,Z4B"KVH,GV
MU!"2\YKE3JMGLM37W_)G'-LXAX]_Y[#I)WZE7D.ZOZA%?9$M,!@;*"X3JHK4:+XLP8 <
MMT!5T75]+M0+V$ZV43O35C#E&MRAG-_"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M^DFP$Z03F'%"J]R:_]6(-G^C.8TK?&.![O<7?$.'PV[FM/>D8BTXLV1T7!,O@^UAO$NYN? YF7R%WF"]2P6L$/^%>MS(.E2RXV:'^?&!)
M>0DHG=]D[*?M\.74P^D6R!F4SIJV/EZI'@@K]X!B[AT@-Q-2TBLMGW!OXREB0G49:0.B\78MDL]VX(?HN(I"5)^L2G];+;'[%!@**J6I;=C02'@8
M."P+T_7;NSS53R[0I;_P/V/?]85F_\WF(C:;A%]C.[EJ)X,%4JX$MGI.I\A8
M3L3U!E\1OB12?0-Z^Q284ZJU[Q*1W@M7HQMJ\F5S7 2K5V0]_H/!N@L'\M/R?C+#K9-70?S$53^YR%M1(_-$5S6.(C'RI\:8%M[55S6:MR ,F3+16I,!<+5"/LN SNO3FL#6\Y8[5"!)G7T.%Z\HR!>$3/2_R)
ML>8Q:-^BYV1A?M\7SU!*[$KP":([H%'/4$D]$C&V"\Y1AGO/XOE\20PKM&TG
M1_DRC,*^H1?FC'2MJ>X[PAXAF$0\O6(E"R 8BAA]1"YKBK3LG[W'2G?#8WF_1?R[C)8(-C?,CZFA
MPFM*\Z5+8W+:BHD?M(:G(D0&L=SAAK3.?>=K76T <5$CM9#CJWM\C&<^E]S-(>@F<:EB!(
MJZ:E"CG"=P\13XZN,,S6/7B+Z*(8>UH6XI'NI_S/A@Q?BQ>@8$Q?+W)5^">"
MKT&RG6ZD:#PH?Z$2K90J^PHL$$2+JM2Z38WU:RU0?I18Q,5/\PN4 ]+MZL'(=D:16':OTKZ#'_6,^G/0&J=R.A(HQR;<0#DFX-'&U2#+M(D,(I">ZD.F
M:8)5.$/QXI(]N18??4^$%OOU8R9G_8=1O_G8Y']TZ"8L
M<_"%&UX@23_O$9J:%;-[*&>UL!$.0+?3D ?\%-A]CC)"[)Y2'/&&%8WBTCE/
M?9<\)1*4 ^.>F\7T*6Y4H_.&VAU_KLGQV 7]*##2[',DCUYHJ07:]GZ&%FZ4
M'L$>Q/<$FS9^Z6(113F([B#]Z/3(G7X*#<0>38[$D;SY/#>F#2C0,_(MD&X2
M,>\17MFW=^+\'YB.-8W12K/)%0Q?RNW,[Z,MA?Y\U!!]]'@9NMTY62^IZX/Y7U2^TMRH];O_X1P-=";B1-^P[-M=0X?$&OJ&
M@07K=/&P-=6LH=DSUI0*#NJ\,[]QP8C2/&0+ L:ZG"/<=?(K1)C1A%^3.X$$
M/&[6&U;(G9V$1,5S^0(SJVFQ=/228/[O@MFT^2GHV[OZ[J85P0,&RFF1CBLN
M1LR7:=[T,5^FE5^7O_DN9?NE> +./F>:($@ L6:1CGM,.(Z8JU%@>4X&7A;F
M2>ZL %)J[#Y>[JUKY#(:71G9LC&",.WD_3O?^'T4/J::NVA'W_#%N (L
MQZV5&(0EO]#X"*+?L)),"53KP.TX ^>(MPI/1%@@LDL5I3WOLZ5F<7U8O3S4?1[45DBK:ZK]+T"/UF"\)M:/;F]2P#NM-
M,*#ONA5>Z/U2T07*5:-V;PCTJVT6AEH@U5]'!&RPCTF*J8F;!.&Z#M#W.Y'*8KFB ?+JSCWBTBW25UL!U=?/&Q SL0VV\%W$Z#@4,K+WWA9%.C=S&3
M>O^VIZGG+?Y"GYP?50UWEOY4R78AZ*PDT>D\UYR[\\YM.6W879$* :'=V4+F=@U^&+AKN\5D+#VK;I_55('Y@OFN8(M9>FUJE!C,3\=<
MMW=M)+S#];L[9^U\$FO] M'FPM7=O0P33]A =TN[B<,%0FZ^$:F*;T1%16V)
M'BW?7KHKU5ZGM1&N'1\'YF6ZG*A/OX%3"['<7$WPAD5'CLA1.O\WZ1@7",,%
M[N9;M"*UG#Z=;YD*]M,FS-,\T5OH4]6+:FF>BVE$1_HDEUD#F,_RR5[40]>_-\YXQY[(GPGM\FBV5+
MAY;SN;VW\&3#4TFOQN2&*E9WFS-IT[H +$$[%BT%"PB-<25N+LV2\8@L+5I(
M+KK./[WV==3*U^FTHU]/[RM=L%//9(![)^^=T(SY"$W"4B-HK"(]XK1-/MIH##S]GR3'EL[:QVZ:<(>
M/>P%T#382>+"KU[PKJSD,G V'1*^US 'AQBI#.VI(+R-5>9CB/8J1O\NQ3E:
M;PT>]!M7X+^ Y8U(Y5F)+GQ2U&9PCH91J2=H5W[1Q6]@(6*W:7^NV7-/GO3C
M.>%-.6"F3> @Y7#+-)4?M\Q\G(PCW-=)*,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M"Q+?1CHQVE-ML M7)K) #VJF5+_B,86?$H]HAVB!5MM/P+]X&HMX;XY8N6T_OH"G WTB+_R&;0J>4JX3S) W'A/LQ?0"L1U=8-(M7MFVQX::NL4=G;J=UO9#_O[Y)F/;!F$GJAB-\"Y(P1A-3Y:.>_Q\5\%!'9J[
M[,]+UOI5HBTZ9#@_33' R[>/>=A*"V38_8[&=UOJE>V/E["XNG]_7W-\_XKW
M>)%" L)_1F L10S&=/?TISCWU2V".Y[4"J=AP,W0NTC;K;) P^SO"+U ='R;
M/%PP%S3,;SC&FJF7]DC!7/;PG4R]U/&35;LNC=P6IM!UW;]3V]7PG
MOACW J5IAF".^4*D!JS,,$H\*R+#IU#N+==.WX:'\T-,[FOW"L9@:KIGQLWW
M[\B<;].N#*3UKVFY8*JY!M/6)-HB]_L:Q#X"MEE.>7RF)H%@0J,TGO?LKIM]
MD\\S;F\31%\#T:J8\M0-TGPR5G]I!4#K"C)_GV?OK[7ND68C>+P%ZL!T<3VM
M)D]0:BPU7^[4M"B;=!MG5AZ*575#SJ*74^--I8U:XG4UO)/UI_+9Y)5:<#9R&YB'N]=E%>0R1
M?,0G!+\BGZ30(X=K/WMN4P&&V 0'6-J0"HM4&'D"V9'FE;:ZW"=QB[?/P[0"J+N',')^Q8D]Z=AI7V:
M!-B<,WJ%"H2A.V
M*$;2P'-R7J1$:;LUEN%UVN04*]L%6"KVQZIS'^_%;H!WAZ
MQG%!@D'L)5B-SP)%6HQ!NH,]!K@P<.H;N8\KJN_^7 R#0U<^BTO(&;-/=(UX
M,S5X*.279>AE'N8&R#V%KQ$G00@AT4J/[9/ Y$3BGW-FJ0[U^'BM.KLW"YH\
MY:O=\C,;?K\6J/(,_3$>/#?Y"]NQRK[>Z?@4X^U6MC?U/G$L.&20@E!.+3-3
M./:!^0@K24L[O6:)@S""#,)?'>?*-W!$D\2>VC,SF?^T
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M4HX%)AB@E$,OL=RH?$"K_,LW^&*$[>9EJ/E":
M1ZZBG:OR.U@[>\P?P]?,^V!S9F,ORD2UQ7"5II:&(YP7=UA2][A15>ADC,3%
MC85^QB.@4/?;XNXC+,9M_A?=<2:Y.$'2$]'[?O6V0/<=KDIE6>W]NY%6 W$T
MNNXUWV+'"%42_&=I 4);<]CC8Q\AT/X,ID\JY=Z:OCYT.4; 8@&L>XJN
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M 4+[%!'Y7=- G $+%,S=+_?@2^/PT'IZCKN&@7 ":>#:L-WYG6LLD)C# :]
M-.<; S?FW?%ZYMAY]^'[YVKY3"+$^-U\>9\4C*WI=3=-!7'UB>Z/@)N6"4;U
MT:X@%;%1A![]UOD^@?(Z\/EJDW*@GQRY;FKU%=?)+*3ER5\)#"+!V =HN62[
MV%Q*.M#?W4$T,<.(FFNH8,&GIUO*SBL8"+:XS.;RB;%/9H_)_*
M:ZGRD->123JIF[ 9\3F>?0T&I;(46@%KR)4A=1>3E%NQN562CE2C6$:G+4NP
M$F!,!3>@4S"-@$DWWT8M5\2*W;/S>N'H/H-]Z[YCY(1GH51HR5#[?V8O/WP>
M^FB!MC31PJA16H!:(]I\C:M\G+"%@@!J:.I,KM>X5=%Y2J0U33;C#C@I9--H
M.$T%,P&\$G\2P-#Y\=-Z-F"YK'F77;_D3-O"K1+2[EVQ&Z'[VD8X$5S0-AV7
MA_%OS%RDTQ2,9]D2"?IYAW&I/C27LA>,).1E?WC7P<.H\=L.>!2[X6T/NH?:
MG-H\Q DRM6$!0HANZ&I-MM 553PX'YJ+)F.!*0.E/1(BSB L-\U?\U[]:8O<
M]1,U*IQ6V%2Y(=VWZT!2BLVIO?;K!#2/V0BBZ3P[TDG9#Y*,"G,NB_8;-G^T
MHSL0-Y)GOL,.(K>!2<2+!#939CXMR-!*\HLGXW_??BSMA?4!J?5)*M_1U5K%
M]>F!S#$9?ZU9XGV"^3&B%JEI[&DBX$9N-4=9Z-W0?R C#TNZX RO!>^3I2!M
M%=[CZYTE6Z!]R6T\$"<6S"SK"3-PK(&H[O'BKJ?7@4C1_8NI7.GEB(R03T,5
MNUC15VC3AR_FYB(N5% 77=>[:"\7KS3F$:)CF"X8C#*$:7*+I[YAV7G/!P*!
MMT[3,X6(K,E-KW?2A3LIN[S3#(I^_M;E>#?I1;M,N#%"Q*V.J%VDR?R%C\P%
MI70*UIDE.VC7A@20H;K")9_57;^;%K3+0FZO(9?@\TY=3NW^"==D8]4R>MX<
M&.'7^P#"EH(I1\I'4<]H6B O0;4U')'>E@Z\Y2Q3L
M,"/D8GCFZO>FDE'W')<\E3'8?YSW+]RQ4>0^U]
MG"W0G>+DMQH?1%LNL69/&KS_A&R/4&<8X\U7JZ1'$H.!VRT^HJ18-) S#TO<
M6 OT\.'BL6]E2;J*,2D2+R2YMO(V[VE@!.&H(53%]:;MQO-J$@###H1PQWJD5JW@>GS'7JL)M4PU:"7/;6N_<
M"Z:=UQZ\EN(-NG&[JM=0TEN30T %W
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M5<53W[+FZJTN'4RP'CY\E<.K9KNYB^C1F004G&41*CALYIEVV
MGC9"KVEE*@N[RL_I[(D_3^=-L/X.V"E## %CTR0]7-?LK8DNT/2PDY)":I+
MBGX\DQ]A'$2KOP6_FG\3.OW)#!!P@;5IXB<+5,DH$"R[P9_<7ZMQ([=HN4,_
M^2*%WLJ!555QHN\5:4KUV+=VK,WHAY1@SG5(>$GX@I:5TG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MN_VD1[N^IG>1GM>1O!IK%DPW\&BZ=OJ.#C]4:>(H0@NMJ6%7DIJ.?CTNM8WQ)[@VCHSH/4@AKRN&]:0^9;LX5[#EX6=@BN=]W--(Y?C7.:$!SU$4B%@_7
M+"6\C^TK#(E[(]N)-S5^\;- &[\,!+_](\ZYMNM7>6NBR11(5VT#LH6ICJV7
MV"+)!YMR#] ^-3).)3VJ9A9$/OJ.Y01.Q#.42$%@< LY\7RCR@K/: PMV0.2?S#!]Y8%RC\H/S5KO+?3C^^FE1KJ3Q1?RGQ70#D>",>T%PZ(>KZ7"A:
M)/R+0E-)91D6A\Z^:ZZ41P,LCA ?]5-9ZSFBJL6[P?Y(IHOS>+%#!!DZW>TF
M='>Y. %TF,($PC9L.Q<$A1Z31>$)JM/\..-F7%2X3RQ67[_TX+<=PF&TNB']
M\-"<;Q535@5@^HQKGQ_;M9Q8$#I\TWS&MX-S/98R&'KFM/\A#WB+WR.F!-;=3#JQL>%2>_>QUU>';B?18=J_],>?,W$T+X+'3H]8B, BH
MOI2AW V4=152?AQG?;)JP)=_>H%O:
M[AD)OIZ9^;BF00)"BU1]GOQ U2):66UHDS%-:\C13ZL>P.I?$\, 4UIZ/'U1
MX9B+$W_%*^[(/>-OC?0_=M%.Y]]/@4;;BZOXYI);!MK_T\A28O_HM'HC+IR"^9E#?3/R"56\]0V3H7O!#ZF#\R//;MLV8SF']3G*C?O-IRNU;!B$6
M(?HSQQ(ED;<*?R?#]7U@0D1M+K)A9IKQ.UB &U28!PLN$0A:Y3:+\5>&!GKB
M.(462%\";@B]^&D-,7?.!!.3\%=Y^F")-S\IEA@F0AWO'GHVRPG?^L@TFAP/
MYM)M>XA&U%U40Z-B@)%'^8-8RKZ%,&CEE;J$PJ" L/H#NZEV7$-K_HN$?A9K
MCH_;B?2SZK0M7"I6BQH?1RM"#+M^L#UC;H%#IV;5UGZ9!7],UVKR8:8L]2:_8!8N.B[SUJ-N
MX)=E2?J7UK.)XUGZ\(2Z\X>779JA\EU2>*![WLFTS/OC_(],MXZZ9Z!Y.K9V
MK=T5O=07E"B+F7C#68>V* ODF1K#%0EFIF0*UR^/;^L(.7:R[M2+XKU\Z=])
ML\S%;%OA,PS?G=&S6,OMD.@T(LJ5S]6+2/<:P\I^U4[K6B.RH9+X^TI):@\+
MN0,T/<&T/6A?^FDD6C=;/_ZN?>FO>U-I?:C%N.YR)S"OR3@<'"2*M!)%7][:
M:-K(J".6L?U EFDY:-)'B)#-6)9P#-Z5]1^BJ$'#Y%N=$=")#C9R'<#!!A'E
M-L4"N;>-?S@B$SDD'D2KR_(="3:,_I6W'] :;5N'T4CL*_MWQ;
MSYT[>9XJ[83(.B3KH?6/2Z8TNA$Y1<9$4(^7&YM.N0(QOQ^*$RYBNV-LPL/9Q!^^N3"[_?W,8?RE_=>#M[ZU]V%-^<<0\>CVC]?
M2)TZR>UT#U2!!$5@$-AXFS]!8^A3#%:C42O)2N\[*K&)B.P;QI^BPM3R*8"#
M-ZXE.'F8SA>/RUURJJ17=X)_+66HZB)T@*>^H,\1T9S?3:_7F\)]T-\[];Q&
MA&WAJ=.,TUJQ9%J.J.0![=68-6WL)#K,=9OZ^6MRQ[Z?T!XNF!^O?#=\G:0W
M9S\ACJ#\0#V1RA%FM7%94 <0/769":GFQ@
MNJ0FVA,3!F]-BX^P1W^DD=J^/^_V.K,>FB'VU\LR%M*;Z2 #WJ+:6VHQZ3Y/
MH\-R@Q?-Y"T%Z$[3'*8K[83MYW8W.H?4HO@E?I;VWT^A/RU]_&UAG.@%6K>P
M@YA\WV;KEL;B3QB^/B*K&,&;>@FB1,=5FI,3!V_N;Z(E0;=J .G-.,0W!MJ#
M%\3A?0]?G<0/*MAT+<;)@]IB4S/.KRTM./6+5?SDG^SJ-"_/:'JNTY.7A&M(
M]P*%!:K:)/P=4^,7&2_#OK/-U_H$L\LM4'U&F07:3DZF5-VQ
ML,OQ4WX*@ZJ#"^*LIC_SL#)G4QK:1?\B=J+J8YH4O*RNH2"6L#9*S&7HML+8
MU:W44.$KV.F?JG+8#60M:MGWL)D!+>QMLMV"9-IY/1'TA- 0(>@69%B7,1I[YN8K2(X.FB5>'PO&EOJ1<&
MZ=!MC[>U5#^=X;VA9.BDX>',_73>Z>0H=LD67^?GFXP!X)-I
M>"IBQTHE9LQJJ=;X?:*5SW'9/D&VD1G 99QWK.2+6VG?O
MC[4!VE[86M-)E5!.#-Q/5]I3,&B#"0O4^\@43BZ@IXL90.[!N3E(M)6/6$B80KP8'M8U 2M?V_A=U6][CKPOA3MVS('Y<]_#@66P%SB"]OAK+@(Y'
M%*FXE37D,*Z^NY%+-Z^U/()<"A ]XL/G&G,!]UHAIQYV2N?M,C9!0V1[&:.Q>!H.)%@-4PF#,=R>YUJ).D$W5:R'G3^R1\J):%&4U)[_^%T"
M$"L2H_%?;^RCA1"B"MIP"%LBGSX2L@^QT3I2T>@6K,/)^ *\-P6ABI^%DX7U
M6'5?KP/>2HL@%PNTJTF=U^:"X0
M&Q8[?C7-H(:YE)I"ZKAKJ0NH-@=V0S?3NHW.?PSE%-&3I^ULRDETQ)N,KPH(
MAHY='-WM:GO,
M^EMWO07RH=R!TXH6V4P#[>PQIB! SQSV3P%M0@I8>W2H\^>N$&CWOH"0A+:6
M[[\FU;J5NQU[8"LMO"$T2^C$/UCWP'?>.;,TPQ#ASV]5Z0PM@HGE;Y_-R-S8,(O7;:U?H<$Y%8CQ
M#-U5ZD'>.M&ZKURB3EU!=.FBUZY041YPM+_N,5/+Q7]D.$3U5CA)0[)QF
MB@A1''7]W=N'S0ZATV'7^CM^DMT -G.'D'+"8D$?D#TQZ
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M$=$Z6C%DD;&Z)C!7D*)KM1&?_.8F8RZZ:[S;UOJ<]DW&S.4>0ED*4&\_@TKJ-^&D=?*2[C1=U$N_7=IVY
M]E?16I SX%51+EA&;)O>E.\BN_U$YK'4CO'=0N]-K\D46@LF$)H&3GYQ4"L9
MC&MT4E$4ZL57JLY+?7=EE6RK+9()QJ@9/HW$?7'1[D9]M53+8% WN.*?6H]7& I.O@ F0M&W-?/=7_&9K765>BE!9M4O+RJ/<4VUR":&]TN9GSA*.%M3 C$NY<3IN(T&/I
MW$*)#ROT%KGXM1R*:.#ZD^'$N1:ACV Z44;&TL-W6.@/D'IU/#E*X\H*%+@D
MU(OB5CRO7?952KIBNL0*T^;!ES\>E/98(-,2ZJ5ZZQG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M.Y[U-@<^?(KOKC :SP<6%[OAGU.$OH^\V8&M<:)]TGL?,YZ?B@JPG7I_
M6^G(4\\\MO'7>K:P@O\JZ!Z\=7NUU3MM-AH(]$,$X@_?7;@"2U3%]>8C^6/.L]N\7)Z3S
M7*VVH@^BKF:@I?+5P_9;2V\NF^5_FI\VZ]!6V/5E2M)LP8-F_?V[M/YYP3A\^8MSX35ZC^[4LYOO91\<'_2M;,QB6<3^G:N.^E[*G^BQXY@1XX>9O(/UJ]=]S@T
M?Y]SB.K\3&W]JT*]<\C/;[Z5*X],'%AU/V#UL0]VOU@]MQ[9GC 7VCT16-=.
M!%S*]9G,5K<(M;.G]>+1V8*H*TR77PTFN"=NSG/_;R'MU_=I.L["6ZC?31[P
M!E-$A_"Y$?V&W-UGFCKI^$4#G).Z*1\R])+#=0E<9NG1<'+*Y=FZD]MW8KK
MFI:JAX(95880T\B@I=.@FS:['6;(MU_1]HF*'7';HX\S,F7#=8C-NZ;=$W95
ML$;IWHGB(,M /5Z^[MJ<_A\.+6'5[_F.]=FI]=-PF"GMQ_<3'K^1\'(K(%,W3B&HG+QP-QHH;R [SO
MXI[PD)]?4QU"):)>>V+IT*,VHQ8X!ST/NJ2*3YH+[=?D"0. =_WCX^+;_%)%
MH#N1*-69"@HJ&+\0C.PJL=OVQY[*C.:H]9M>'L]7U/@W?+YV\5>[:BDYX^KV
MF@,KJ9*K*0?H]A?]D]TFSMA__5-[SM4/*?L]GLW?'[3FNS7H6@!XE&D-T7"M^F"+FI\?,HRP_
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M^FMX53@\Q^UC3,RND=ESH5.S'%W"Z#([COG_T1'V=?#S#,@P"]2M:A@_P2^BE-S?_M'.;@.2_+4&UZ/-5%1)CMJIM(6@Q_:69\G.OY
MPVQ^JN>$O:(ZVVD;S>6*2G6M7>+>OF$TC4YZFO;)>.>24&[&!K3PYM_KQ@"[2^XLO9]U,NW$GKDRR17(([NT;^*^OK?9J&?/\.#@@#9GZT_F:7#ZQ-
M&2K)-_\VVE%-LT#9T::#JM/H'[QU X?*I9S2&AYUE_'1F=[ U*?Z^:BA.^&_
M;< ")4@X=9?,3_2< 9=4%/BC=9EL"W050[ : 2U69[^D3:8U-O"FKUM2Z"#-U >5OUF3YQI_*_[N_-%4JAI_[%G\"7F+!7V;MCU%W4&V&!4J\39L"<)K*.J^A&#!^F8E]E#9QP/SOV( S[02UR\HEG?*1%NCR
MWS46Z' C.<:Z;R#L:SLG1%NBWKD??3/&)$LXNC7D#
ML]DW3,O\'W8HZ0P<^54FZ=V9%HAM)P\DDU15 ..CK2?.,-),\7%Z!?V$>RR0
M(U(C6# 8)H\.4PR6IDG0%JZD^4O7R O4S.K_DN3OL'G73-2QX'_M(4K+G]EZ[L#P:@[I4O)_K#XDS%S&+<;P4WPQE?6XE&)("&F- (YLY7-G/WIX
MH==]7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MS ;$3>%KV(EBHG6Q1*PB,)CZTP*=FT*YBP>\!C?H8('(()2NEVXBPMY$^'32O0NF6HX:0IC*I#\8N?SV(;V@2#;9(U^'E:0V)K(UDKF&M P4),%T0@
M<'OIP@O4B'GF+
MZ,8-#LGG<:D&RN(SESIX&9C]J0"5J3Q$78
MZ?ORSKWK'ZG!C_!JLF(::U&U$^6&,;=+_#"=#Q!++,!T,XP5T
M0X;1&_D)T^O0.CA1BJ<9^HX+(X7-<&4=_U7JXN@$/)DV3MH2V"'] N)L@>JG
M7^>74YY<>HN'?1M%U1I7$/(3$!.IRH$)#Q%==-/@O23\%+C(CVM@:F^^HKG^K*4^IV6Z/(+:0:G95?![_\VZ>QN74?K-I88J%GLZ,9\3)]^A3:'
MW8#(6KZ-7F5OE,_6&![B$YO558+[,G%6&2XX@B$7(7?8!\V!@8
M2-4#L04:EB@/[.^^>WGF?^NCBR8@ZKMZ;
MZRDM<"UO*/JN0_T0H"E],+GUKMG20F1CP%@W>-F4*3^-AUD5D9^Y6[#P\
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M <25");2=+M'SW3XJ':A2<5AE:3D(]NO33"3F$6&M@A#!&LI53MK^Y*+Z
M=KJ;TO3'Z'\9%FAY#?+[4 V>%M][;E+;Z M:9D]&6MJ=M>8L54:1Q$6PA:YR
MSG%$SS%GZ:TLD),?%9J($6N^=W]:*:/-*&.\L%UN_;IW'\=:^%)R#SDBF)F<
M;C0QF0#6-1V315]'MZ'OGEXEYY&'MC$W=@.:MI RR3#!')".PPIVH(A&T2EE
M@F6$J-XYN<[H.[-;QM0D2N$D['L@QB-M
M0KA##1I7$H%/"6OC";JVI^,&[_(U&.JYN/@CQI![\LN5&ORW X/@12>*%TK-
M*Z.2!C_8E(]L2Y@Y@7[VW50C/8%/>,SMYYO(43&O#B?C<"+U>[N,AO+9?:Z
M)@DI^-_8>].X)J[_;3@6)2)"0$04)*.BHE*-"DC%F-%2C4LU6A=<*JFE"HB6
MMFB)$C,*0EC$U%JE;D2E2A4U(B NF"$+I*W5H @(M"236%$!F5$,!S*9W">]
M?_?_S?U[7CYOGL_S(I /)#/G?)?K>UUGF[/)F8R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M=M,:3// =,O_>=3,!_:YLMH^=->-AEZ[ZI9T+G4BM@6XP#?CO_1_8/2$(QS0+JE/-: LJ&1F#&FJ8T:3B%;5"JN;%X_'#[HB0995
M4(8N$Q53(W.CV)G2& L"-K3/H=CZ8 [T3!"0NS925F^%)(.GP<&5ZB@G:Y2)
M\7MT'-L _J'6F)VL[C(K1QXWMU GFWB'$FHX!_J8$&I[87%R^U@ 4\%CL>(<
MTU TWT5N2:4FL#FO>I !=70+S%3K*RHQ0Y"+D0; >_YD#
MM;M\>MS05WJ>KSQ[T.C:JMIJS_/_EU(1=/%K6:#,H/Z/E4P+)&F1<]]A8E/(S#CH],-/GP^'//O;Z[_F )
M+0'G'0HKEL6,)_MH'B<(TRLT^P)RI'R,2)3\*1&[PKG4=3+#L#XM,]/?UE?G
M\7[+^UZY2Y$9<(E[)UN-EK]+$KGDM[V1]9CI4GL>$NS(I'T_Z>9=TZR\Z^T19S?=-7%@\1-0+10(IC N,5MZ?_FT!<=C% 03>656T1@KIOM/A573IKTIU0:3@LTG]F4\UXQ4L+9\(2>2P4M
M8S1/(Q7NX%B-;'P]^F\^U>U#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M'#S$+B+5)K^T'QO^?TKW^Q"+*+=];O6_$]E-@FE/U+- RR3AU ]QN4'DM/Y0W83?5DT&I6:V@8G2R#TAA+8M/@.OJ'MU@EF.TVI?(^566^1'1765V=?2[B#(OGV'FOL4O6FHQ7,9/OA-YB-!
M-.WC#(%-652L^= CM
MH<]0 KE/(H?QFW@YE+SCD*YC5! #>]B%;LJ&7SAF^_-4\LE+KMU_\7C%7\G1
MLO(]\)+#.NK$K7<+H7_[ _;T]$]IB>[(1%]^\]PFJ/E/I9Z6B%8(:UV;;3W?
MG_6S7#4-CQ"S:M_408O3ZS"!21I$"6=.C,5\TO"S7*TMH"%3&G55 A7P#)7/ .?K2CH*M#'>,QREU7O-F!\]MQE/P%MX*TA#'C_(HI#?
M-=(39%X082.W1&D9/@2. 8Z\.N:"=+&3EM(6-LRV_=*J^T#[EV5IFIAM1F6]+=Q?N9D'CZ?<7TY1$?]-/@GI3^SV
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M+.:'___C_Y_[.#NAQ6&D%:^&Y3$IF&5:"IAHM(95"XL>Q\LASPMZL15@43OE'T2-2F&R%0@FVTMN8D9A^K8EMP2KV_PN?G"8TO6QKY+=[)\(9N:[&2]3 3]3E8V4BT+I$3NF
M?&HBCTNEFH^Y=4ILW!O6)-&)>=6!T"*4Q0$
M,HFE>\Y.ZUG9^!79E]][>DOZDN3.$1Z5M^=$D2GYH2ECSSS_:1"3H(:E*".)
M1DC(G7(V312X.R[+YC)/$&_\*V2XK$D90&-D@P$O[SC(C*"AL,@J(7$]_*OO
M>4Q; @XZ60$QEA=RHF?8.ZJJCCM\KD;#>KY>:>"!$*7-T.UEP8;1_N RB9MC
MM3T^D@=FM,;88C-:#8>KMY5*CEFCNL=;C2U]-=AH:0R):[CC'TNG0O6BQHB9
ME)*>P(Q"R1^AS)L;2>U2TOYAM@L-,I_7")O7)? /SI9S$@T#]VV)M"J+6.<[O1EKP#?58&;V(3-&91J'/OV"T+JT(2YB+M*@NID6C]*APVY^/WT-J
M?V4 .2B;3GEU'%8C]')R5\<1UV7T\69C'6<0S2--6IPC_0J$."IA-8*ZG+PN
MG4^T*WNG*VNBL3:LE'N-@B&X>B12GJ)1Y2D]U..DMW$=4^WU8=U*W<-V P8)FB4?)0D'H4L$H ?)8'2R!ZG@; CYA'QDYB#".^L![
M]KZ>0SBY9$SU/(N*#>16[' O[.-@P029$;DES.-/NB)%*T$!V;&N0<9C'CI9
MY3WT=!'G*WHS2#4K1W>*O3'+KE] )N/'<>> !?QU70M4/Q0RP\[:-_$THV5#
M]Y<3V+/IS%AHD!.5H!SF3.ERZ%8B@:S^5V]>MO#P8J3:>?48;Z0\>6(
MF^[!W,'(C>(VU"(H-AOQ[YPEC%MHB;FN?ZBAF1G,.(4'2;:58
M[5K,DF[E>0Y7.8:.?K3O"]]^7D)$PZ:VSQ\J*AP_I0+O?CH]?7U!;/;HK=E-
M7+3>8>A'ZAOSO _\STBC6NV Y?J+E-9"VP 56B -LT^CYY6#? LBWS=':5&,
M:HF3%;#M7>76'7$B2;GJ'Q(A?"NMU8\9#19 !W?[X!L"@C,1T'"9YBN?U
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M)\M\&B\7'+7O ^\L\K;>E"PNXC@M_4K@_!F8:PLW=4VB0GVP
M1.,8B4H?:CD0:@BSX)[#1UPQ)()09EA?*HDM=93M41X2#V&"I./(#]%RI4XU
MF!X+\'0R1)-OQMSH)8X+$041RH+VF62?_*MH:<@GAG: P6J/_@1X<18/@&::VV2&/TI%/(G1YE]Z\MH%3U!/>6QD_4\KMFU
M^2(@B)EXMT..O?RFHS/.#U)$]PYHG*\J/>]=B]_@.-U[?YF3M0JWKW/\TU'7
MD]77>JV]3-'/^=9R7>VX:ZMAT=$7\!3<,A8%'_(<01Q(Y*"2@HGZXN;MOT.8
MH8.#)*Q<+K_.%YKGH[I >4YO.55(2)@_71+HT ] VL&,N#JH
M(&3]W)=L?IIW_O7.'O$+V=SF-VGT")XF>O)%LL_V \BGK+9PL(5JMBTA$3D?
M4C3/6,OD,C(3)A^>*/:7N(Z!M*%:K*7/]DT@CSZXQ^@:).926
M@5AFF5#/Z_?I1/]K\(M69(IY5R,ZT1Z1_YGR,&QCSG_:/^@JY XLB.0EI!U9)/2CDCG-?%A8-H\'0?0
M9#0;'?L56&=%_.E/@<8>"Z7G[\4@Q8)K'9OKF !#CF!ZHBPB6I4C&XUI%>2K
MN=PA;HGCK"V"R;(_T2'%I# ;WX&S9'^(APBFT)O('MHOP78.E),EVN\AKH4>
M5K,E:ZP\@R(+J^ MS3CXMHH.>"(>*DFO86OBYG&'D%@N2LR"B6/LCC4_)D3#Z(6AS(A95H0CP9A1
M@@BQOY/U]0_%=6/?U85O\>J@?=,9[]%/99,@DQW=TZO(&U#4<3B;H-YX"64V
M#]VYPHWQ*V"O--('JN=;4RF$&3'H_)[GE.:<(*%#2/LK";%.E2FNDMMMHOD+&7;X*_??D+/^]M+KF*8:)3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M1\E"Z #S-:P2S1X'T"O+"56+LE8Y4N#6"D(6DXA!,59F5'M12/MF6E!\IRLMS.3Q63VL6,]!.[A]_OU!"U.KC.VM6GOH@>O.ED$)CE6UVK0804Z
M:\D!^EMJIFOQ$F7(M4WM%1"P]PFK;!=JH,/.U1P>A/*\'8C+3TM'URKZ<3B6/%^;+^,Q#052C; XG
MHXA#-A^A_2Y)0BR&+(UK!+4[31^CGT@OA.]KQ1\<-/M94(\9:T?HWLUCABVT
MSZ*C72>Q[/"$GD"&2Y=:'BYK-1)&'6>,I$J+^ME$51WODP4)G*ZQ#MIW8!G4;.;/_TW1:H2%U[SBH>E247ORSR)[$N$UE8TXZ
M5/LG4MYC]1AI$.!M"/5X:[2=^+Z*6KP+"LTX5W_AMS[H3?%)'.#98G/>][C18:[[9:!$5"/^(H&*
ME4>@KGUXQ,Q.Q5,W?:EC(VHVF?IC#%USG:RO.FJ1@8KJO>)_HL2O?X>0SSA9
M?W#1K49[J&N30N-%ZQ_L'%/'0+EM=MZ4M%PKQU+CY9^
M ;98C'+9:-!!\(!(X+?CE$/U;+MYWH:'I ?KA8+I1,="@:5?D=RCU(!1'/6[OG+-=&FVBTQYOM5.9$*KB2J9F 5
MI3Y*5M-K&W38P2XI-&^X< ]CT[,H
M)TL1 ?;@PP"ZY6GUK&^MN"<=P?T0_A5Q>U7T$66B<[E>%*>@4@5*>K>DUB4L
M:\2?ISI9YW>RPL(,[9QF]6A@K4.\JQ.\E9> KD86\I0?9)DW;W[R0HI[_-+K
M0,$]A\+B1T#F',],[=YI9;M8)C9P /9I;NNTZO"%455CK(JWJ/'SO++_OG",
MAU#=S/Y] \Q'OZC:>& \*F=0,?,T[D,J0M( 2M2%UD*A0WMROF(=N=K!(C(-$XU,"]O[=3W-*L:^N>JQX!\O6G>K2J0]A@)RL!
M\>'1_N6N7=>?X1G92&8\XX_7/11_1G%5]NG0IKZP7G"ZC1S)YG4@"=+EY8R/
MT<+\[;IUY+N2;FA=.V:XW"N:!S;7<48Y?*E!OVOTF
M*>RJ%T1*YC'^;!TDRQKDV?F5E?<^@=>0ZY$@ONN8H%FD*DNZ1C/Q;0SG:SMZ
M1_E'K?] %8S#GX$CB:JRU=TC43F][B* R8Z[)B"KI]LC#52\\+$T*!XRAL):
M@0_4AF54P'JFULG*P_16/>J+524+7[6]_3'S&Q>MOL)@5:^M5QY:IKL'C]*:/FN^SE]4\BSI1)KR[;#JI^Y0KHSLH[,QB]+Z>>>1,_O9MM.6
M K:U1"X5VT/ICQSGJN>1)HNP.Y:TVN(=Y7MM'(45^Y3, _M2T>65S(QNX!OM9DL-/()1@$;M.T3\2(L)0TSA$7W+6R4+F
MJXWPI_B]5UTJLU]67?2_6ZKJ[K2EG3;4,W\)D#O-5R?=N7/;<<+)VGX6L?53
M[$/7\6W+>S)'B2MY]!0\&-/NNLRT8>0Q)PLZ="/88S9V;X'^,X)ULLGD'>Y4
MYF\#O:Y#\2.]=:O9P68\[EAW37--M>PS=<4X6=ZZ(\T+&OE1T,MX8!\]\BGS
M1&Z/7?MD+^H'0><;[+?-P3CQZ;[APX;/O]?%O,"F1,:]8^9#W%"M=NRHC84D
M7 %#LO,IMLFKR/B8^=2U( *$M+1EWP]]OD>S+\PZX]QX[C?ZI@IQ]B:CUV$*%.38GY;TXJT\PVG$!W2XZC%2&
M'J(W)ESO'+A^_!RTSC F@*/@1@&Q52J)92::?''B>ZZBW6DW@*W'K
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MG0(1.229RP(-9DZ@9)F.&8'F!$;!M,XQ^,I9J>*/*1LDU/+=$:-FC%Z6;2)5!%"21KX7UY:C4==I9AG1NXVXLIY6#
M/!OHH]>BGLR'V"[LMX085^_0MY.Q/QM?-55CMAI'=82HM9G #JJ#D]N#P-%=
M#KE].].$5!PIMW!\) ^8$?-C&K)!Q]$9=,D=_#OI;PM&IHJ++8S@5'
MPBU"VJ_05@#B[7.8/TP5#QW9M1P42!-*9+W"RLCJ,Z.F&_*S/%GQ[18+-S7&'CBKNA&X/[E
ML!"47)6.HTX6\F&NL ^?;>?7EG6D4U'
MD1CC9WQFLG"ZH"@=]J;3'F8-R-JC>&:LBX.)E^52.U'KFZK7N0X>J$")E:^B
M<2TM2=,) J#(/?:TR1M"PY S3\XW5Z0[8FM,09'W@C#(3$BHQ?,"FPKW4FMW
M*%LWH=T&J&X7T)QSE&L&_(HK,H^9F*2Z[[X;U,_C=!7:UZX@L*SVF7*;%/R>
M:G:RC@0^4A3#CK#I<9NH)^K0Y$"#@%LO]76R8E!Z,M3^^>GP+21^O04)-HZC
M. +Q!&QH'V_7.C+M*Y!+81O ]&+748ODKX*0)+'?[K]C&!^3%WBG:[5AA+\
M@2TT:M7C83]09K%JV'-,^YNJ,5D$IBMT#Y;WM&36>9$JB^RH!M*(>>E4QR#42A@MV59'YLGA^VENR#,OW?I2)D=-NW%HZ\W9M2'L$L!YAGS65Q
M4UUG5F^L#B>5FDWH0682+0!WK+MK*USG5FBETV9B!Q&/-GR0C%CHD8H/'FAW_XUYX#LNV2D+*4[G8#<80GUJ,H>
M+MWYF(^0*1N;(E+RU.,:!8')K>N/F^?'"PV0BY _=+3I!5RW2R@QT?_=(EF'
MB[)EG)09E(.907026$YVVG:"5ZE6#EM,(CYM;F,OQ%DF(IAM@V'B#K'K=P/3*K8M4@=@K[==C>U;:KU(/>S)>G\/RPY@1C5(
M=T8X6>$+JBGUV2NOVP.@ CCLE;[T<23NW=EU^';(@Z=K#WOIYI71;$QS63R:
M\8,DUF[_8@<^2C9)$D[LE^<(?*4S;CQ6\1,L!6&Z?>LO0E7EHM:B9%;+#A&ZS2D6Y[X#B\YR&RX8F?[2X(+O[]2E):Z[=/=XL/%PU[\GYYS)7B
M74\C+NSY;O$-Q:U/M@7I,OZZ/"WF9,\K![:I:(U=((/YA%2[3FO\!>BL/6R)
MGV4)X%E,A[EC0%0\R5M,'MH>- TE*['OT3\70=IZ8M#U2'$BEY5>IYCVDAB8O!F@N=BGPO[*#_$'
MUX#/[B=\"H[9)TC8,8Z3ZD#I&,<]@;=T#D#((*UL"JDN(;S85EX&U/XA?F9W
M$LG@Y$B%CCNW>?*5URR\W*Q;X:#4," Z=*3I\U,=$6>7VR:03+X%]!K!U!7=
M5;4\;K)Z- [EEYN3Y36=_$JZ\>ENQ:!711,>T[[F)F.60N=G5G V2/+UDZ1C
MU8/;'*6EK^-XW_&_7+/N7,V[TQB88NH.L:9D-F'^?%\S[^"IE1?)$MLMTKX08&N:I-LLXZU>R$9*J:BX%DZ@VOUK/M&"L+AC4"X/DZ9: JB PP&&769T
M5'*<+UEX6,VE+-_AJ;)G6)!ZAG2Z0ZE2SY-RFV7#DS9Q,FG_4NG'U%AQ8(0X
M^#4I^67&&9[4BWRG"86U+T\:47H=&+:X:>-7&7-;-J^KKU9Y@%]>CQ=I!^1:
M%9BD'TB02V==DK4,!&1+(UW'Y)\G[59W)6%J3=><$M,1^"'I"BOJ^R__+_@%
M,@O_2!M.!=2USZ4&G^K+%!Z@88DAE1*5-FPC_E.I0A,
MT1M(!$_@%?^OO[[FB\XC2;WUW=OX1 IO3JC;5E[B2VIF\DW!==VJ(/NW=M\#QJK
M,_K6R1VMU[/;%H>?F]]D&#=D^H^_WIF@W@U$3E;HM6;>PKM1?$EOCSJ+=^63,)N6GCWOMR?=3-@ =^?+UJ3N;5[E?ON(K0RW???]<
M]8?WRG^&_!S["/'$=BI;9C^P77-MAPWRXGV1JW[IS#S/WVWE6R,&]8KTJ@(D0(TP3>+R%.U'TOGFC0)O.B7?\GW!
M95#4LZ$1([Y<:%$,HF=244=T2=$KT1L5U_RV']S^XZCO![\^V!B_T]IA:E':
MGH 'E-@ )06/AG@HWR36\MK8-.09](/&Z41[4B#+.SU
M*8W IPDGPL$>2XBEGA^M=JT$6%X[#LP/,'R+U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MN2./OQ?2R)IHE>NA #-R[H+FB+\]US7WMFS#-_ 003P41,UP;C\.:WV,>].= HO!I3PYDEH!]
M?/2J)%:_K]YUF.\D&8<*R)Y(E@:'+-CN:RYER3*EOJ"*ZH$AT;6'?&!USR2,
M'TC#@ G2YNB4W.D1XIQ]HL/50O+-GW.NUNR0+WN\Q^@%U'T?4P%9MTB]>FQ?^M3()_5)4@/L+YM-C&@53Z#691'7]:]Q7%O+2R1K.7TX^:J[=%)O-
MP(@AOX9*;6ASEF!"0:A^P)3S_N\ QF]>=YBXN7%Y/..[V33LHS65F1(^[H_&
MGUVNB^XX)(6L:<@$N=[6VJ'%_.CQ]YLBT5:Q^M(-)VE H:THMX@,P=0\C+JT:>N9^N.H#OP)^%$?*,ZA"R4X-6&+HZ+H 8#9?[
MN#J86#'":.G+N-4",-VI'2\'5IYTLL;?6)J[>MU2SQ_.G2E:P.Z'G%LCQ?[A
MH;=PA\)UNN?[6."-CRM]+V(\TZR<8;3K1.O+LF>"F:0H9[=B%(C_G$K(NEZ1
MXI,8^)OZ9K5!VS/H<-*FF_0=Z]EJ;X-__\:%+Z<77J"/#LPB8QF/8Q1NE7MI-I7)A:A0$3<1]:2'0;7DB+"E!^I&(/X2]Y!E"^7%3K**#S.I;YU7'_7Z"-I
MAZ(>+$EU+75;1QFA>B6FO3(/=.!?B4&HHE;4YE9C-3#^()],(=+DU0LI3.0X
MK?;'M,\I[N6+.Y1!:))7O 8GBR3I9E,&6B8-L\8[;O/##@-='48>AMILVLK]
MPD93N9@>"0NSJ4;U;,U:QT^1X@Q\1.1]T2I2VM5?^$$1[@O'WQ*^X4\C)0.JKL? 4'2"2K ,\PQI.X.?+P&669DAY9:D[I"K$H
M USGBT=@;=X(.U\)^^ C'4,B>L17[251$ J%8"8T!&9#<_:(\KGC*52G!$LB
MQ."V;CTDP9.183@10,72$XH9WT#OU+H4U/RCJ>)K!6'*9*91H?F,'UBN,_E&
MQ$--U6K(B3R;ONP)E.%*U^1(Z;_J6+N-NJ='R3R8;:A#[EJ6PQPR@F7AKC7C
M=(@";.3.B>S/1(^]^+P_JN.S6_;8@>D=+=ASUZD\]>D#"9<9K!PM%]'^89^
MJ82))0ER65P)LWS@'-!8,$7TI;*K+[D3& TE//*^9P3LDR#3_I$$L<#6XYX5
M8KEX6&49E!,+0$Q=/.K#C[5\O%*44>TA/HX'06C M,+YKN;/)#IT#81;&N3U^7R#IY+HDU7V4&-ZGZ3C%>@>)Y7H1B.IC5E%V;ZQE
M+B5DKO&XL?TKF@=N8AH^3)&\/6J+ZF:N.PQ?RILS-P&=!
M1ZNB S)=FT &FQU7>SFY,AZ,N0#B4A7Y3G0+%%C*BCM;[Y!5!U!B!FD!IK71
MPNQ"9H37YD".K7Q7_M=+_SY[,5-V)O9Y'QV ,*M#[%"1M RE.,R9WGTLY@M9
M@.QO)^M&87>#?97,J![R)$*CDHPB_V5FD<*#PO<.A%/
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M)9W;L9GBWG$M)SVND9\ C<-% _!M;O8H*';Q6\?[NI'+X!TSNLXZPG
MEQH.TU#J@L\ZEIA/[& V_GI.H.*A!EIA2FD3VVC'65DT\P#V0>T&TNNX0=3D
MDQ<2<5($4:>E<'$5M4*OI<."W:&10UO\UNGMF/AZR5&R2TT'-,.I?.K+PI!0P6:'KR5-R\6VB#,R?
MF? :(A+O97-<%&4XM!L9(M-LFQ*0:2&&P:_T%*?^< +.6?NYZ8YSI2+M:,U;G+_G2R%+JS8:CB@9">6\YX
MB)VLQ6/LX3#J[CS!P:GALALT[.T[]+<.'R?+:'CG9 4*8&E?@1K_$7=":>W]
M[Z6KF,D*D)I C\"9P^$V:'M=ZD7H'';5?IP#0OO']M\88$KH
M1+O0 1V*'L>N1_VW^Z+$0R6YS,D:F&EL44(._0AV3E^/;)#!>%<^3_U/I_ZG
M):]C* 7C@<*>-9%]=:*6F$\>HU^*6Q[IA!16*QZ;J)[1\*$Z,''>GC:O(+-8
MP5]T+FE3\1*?>KM'PO\.PN!GRON1GH;:&8=<]M$OC""29AC=$*7TMVS$Z*AI:QV_!_JW]#/H".VI\@SW!7KUC!$[6JW>T52FN*W0$M#&R>XRXXZWJ
M?>U__?9_=8U;FQH&BA]]1/8?*ZQ300A8=,= #\!F"JM>&3=!;T.?_%_.B%R^
M"CKM(W@;ZTV\D!D=:DL8?>,IO/"HAH^?^T]W//YKG^+3C 7C8)N=+'%X&V8^
M@[Y5.%G/5,S#-',:4ZKBK%X/:Q^@!Y7#Q]VL9/D.
M]R2\0G?LZ0NE+F3^[&1-=+*"9 _P"J7.))^#!-$8B5@,&3)/2:;K5#*=TH^_
MT/QW^C)2<-_U;(D))-F7(W1X8RN3.WIFMS'[F S\"HRPNB\I3AV"::;)I
MD@Y+25>:Q73(Y$X/L7-H@>/M(S(A3QI#]/A@VCC^<,&X-...MYTI^>(RM LG&WM5@T$/U!6=%$Y@78A]PP9)
MJGX4!DMZO 2)<_P:J6A;KI/Q@=MGI!9TO:@W'Z2?K;_9IM#=-9$']Z7SG![]]_T=;*FE]FPSO<#3'#80"4IKN4\
MBS'M"NL@(U'*D;MD_:B2O1X6?9E2DS@1US[RKBC0*H%R<#8O1PYXB$8G#2 TR&R(,<1:3"%VQ/,
M:06N+52>B$8]C>R#0'Z#4AY4S^8,PQX*N?."%PSHWC'JA+=^RFADWB,K# >Q
M"G5@^Y;9-T,59NG)DD4[KO%3+:+, 52[']$%%(TEYU]W+9 2Z3'R*#V[N?K;
M8A EA-9JJQ-P*0X=ICRDYD!4=#T=-22%'E_D3N)9HCRMY+%<+^8^:J[?'[7R*9Z(M2T+7F80/?T2$D\>6<4(IB^B.NID(=8/1\>3O[^\
MS6_N&T2)]M]Q_N.6V9SF*T:^Y]>+OC&"W$-$7XVV^AWBYT'$W),@V<3/9WG&.:\0^^=)3@
MVUV/_&$U;Z@B>_$1TO%S"I.NQKUZ>.75IN]O1FXM?1D:V\#:=O^Q=]7%MBS#!S\@@^92QMR%*=C=%$M?Y84KUPQ-%G\U9.K]"R+*3!Q3FP/]KV4OQOQD13JQH%+D"U*6L,ZC%ZR9^U^
MU/;+U#S=/G'7-KM0:,4/*R@=AX*8MN=D
M=\LXR=DE;><=YL6/HFR? [9](?.GR0>[V<4@TN#Z:C^JQ[)=17E:Y(<$WJ\#
M+Q9JD)9.G< =1%T 3H& =N2KO*RZ446<1"]#N0F7 #':@])0K2,?ZMT\WBW
M]>NPD6D#:-<]JEB'E2/=7N;]'(LP>W=/:[+M-)6F[PD")@O]_:E^DE%M-60W,#Z5*+6: ]:)V;MQ;Q!#V&A_06#]ED=_'1^^MK9^+V5+QGE]5.3261IJ(^B>R$:^BA7J"/-19--?-,I5Y5@]A<6K+97C!>(->
MLEJ17^/6LS^ *K>R=2D9:8(/R!XZ+#C!(MME-C67G;%R=HI*=U"B@Y%[&+KSE<F75UAF>_E3EC&L8W86&R;JB#V
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MA?(*)5BJHL/-CM&O-[5\&0F)-BC4<4>MMVO>Z)(WHRPJE9 56U.LU=UA#0-T YS ?L<[#L^)"R.]>!49V@O2-S0&6X-.2
M!M08TI@/8EKJUZ/6" JMC_]:G@8\D# KEE\HHIKKWGA.5)6-*\)4$_M3--=K*O#DO(LK[U3$QAZX#TJQWPBMLP?+9,:"J$N2-D*NY^6Z)DWRZ-!<:4CHH06M'[/2L\_:=TI'/XUXMOL>>@#W
MW<,[W$#'4<*:!OO\%K"9^,LTPG"$[V$V<20]=02:)9+IUIP3G_1
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MT2^CVS,I$3,2/?A )?'LWD<:COS^V0*!B3(:3/)V'_".,+8T"X&?
M%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M.+-_;\]@.@RM=(H%Z<]XB968)8Y7#CGZM>B0>"BV%2V72IH%@S\7TWY@NCT9(@O'K/"@5X'?
MX^TQR:V&[M7GO<9*HF"3RK/S"1& W?+9C8X!I7J4A,;5UE/*(ZF$>)ADYUM.
MY',E*?H;)9IKTE5M\XB '-Q\P52^^#2)611=JRW*K('Y]PT*P020"I7O" %?
M*@%;?H&8K(+7F>\:C&="8XBXR!0V**_CCO^=O+X0?,UB#WHD^W0C\Q"MV/./
M2F.WMWI?-<_K$7]R%!*B$ZNXV-+]5O1+:8AVW9"/:I4%@.AECNP :R"-M=8$=6I7K
MV-*Y5DR^[]%ELH/Q=SW;,@OSA.$00X?6RSZ4[GHL*I#K>G),%2*=DH-I5:Z-
MA9HB=X@*L>9;V(M?Z$VUF )BL"R]@74B?(&0C5>*:NH%,TNGD$]]0989^%
M^?9;[!82M?71:UK[Q)[Y
M7X=6'%M5CU 0-D1^(%(,0HW=4R_2F]6!*=I\*!9!G,FR[N6K)!+0B\EIH/GU
MRH..J^%&\KLE/?AGF<8M/!RG^!V::1#3$L=)]$=&"2;MXPY#%OZ
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M.?>5DU6[IAC^J.IMP!Z(2#^#9"=K6XK5P%SMWH'_^01O"&*\=CM9/WWJ>O[!30UEA2$ESYTR4Y_R
MSK'1WF ]&U47:,R*_)M7(YAV@Q3G1WIRRA,%H4W\61#QLH[(?YW]0V0XT7 -
M[.P<-WS6&LNLS*H?%QH[.KITU#W(*T5=W7:1='/CU]73[9_\#>;5H:,C5"V'
M@%B#DE<4=;M08GNF:X%4M C:;HX=H2>+1U>CUOUNVH+;4?0$"&=S0T.1XKCQ
MCZ=7+RS><3?X[X>.JX%UA;\FI<6V;FFL/7%M1^2NM/Q#T(@??OH*]N,Q1)$5MMRCWZA*[])DDZI/&/1"^IA6:8-?JZZ6;'N*Z] US%0^,M/I\R9O+W4)/?:93EC0;-PW2#V%.:8)^]44-AMD,I>?O0'%FPI$VC])G9H4$_
M$.EX/A)7(V9ZNTEBES173VRKCK\T[,5[%9@FU\]%MZ>TN-4&LF'Z)#Q0'N'.
MJ6>&TLL=Q97W-Z]JB'"RW)+PX?R-5+X.'U:Y)5P3-U2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M 593%$CV'>*'EK0F2=8I?0*KN[JB?2[V.R,\E!28^V7TV?/FXX4,?[UJ]
M'#D-3O[L_@7G+)J(]O/P&]"D)Q0Y3M; (RM"M-=)QG;^EHQ^-D* ?Q8B[(5?T9#6K[G'9H_NL7^1[_*!K/F1UCMX#\37:>]
M7.VA9.ICE/NQ7:JDZ**CD2^*+RVZ_.I4]NE)[8KO=]]?WV!?M^S8Q=MNGUW'(UZ]-LSL\^@?HX9:RVQ%8.C!.> R9.3KPZ2Q%L-MK
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M%8VJKN406TX^X:<0!5%UHS;UZ;T"+.X'2YB'[>$4M*J[GF7T1:9-?]*/N5"\R:DW^6,H($1V2H&ULEZ39GH)_+C,F)7E^CU=*#26%
M&)M5=9WF-_26$6'EYOTB3;108P0K>\^N6> H-N0);M\NOE8U7TI/C7UV(8CWZ[H%/ KF=&+W6R/%.6D8+CO!Q./M_U?-<"9&1%*>M3IYYK;(@8S%MUU;+,?BI;ZL3KNW8] "4;Z0.[N6O@%[SOGMS=L^GNW?9A\J,
MW](KJL%9]]/6H3TS^)M_E2[/A$U<3!7285XM]]T0H%T1+_1R7OJZ.KN,,E\ZJ9R;)'L:Q
MR<*#*H&G5$0ET!%(MCH29"XAHPKH%;_0NQY725#B316I^KSQ9A'2P18B9&$&
M/XG(MK&Q]BJ\TNI+B'-Q=7@Q$%JZ*M&]L1@F$XND7]8OHB=P)L<8\#CWI(.MH&&=D_7#]^>=K+A !7,@T>V%\5DZL\+-E@*+9(P9=T0L7(3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MU8DT<7/.P-B^_H&KM5=Q/;N3GE3N?R>JGO%^G<;
M7D%BQ$D1792Y=!"D<^8BL2?V90]']D P"V"$PA^$K07%5(S5H!7GJ%D4^W#U
M-BI0V[ !<*R\06#GCKO"(X)Q]%RPW.*5PHP87_K:1!Z'<#.&.$:L<6WY&(GE
M2]<\P=>ANY2'\#*E0=G:L,6108>1QPA,P7PDX5@7EU$?-^LP=]>.4-TD3"MW
M_,QGVR-<^T"L6*9L#OB;4,BY!!B
MN!]K_QQ]1T$4!J>80M?3F$*P!,6A4>(*8U[U&!*S_>HH08F 2D=A%[SV?#J(
M.EE&&33S4=M1AY+_[[E18_@IEN!DPDA/#&R&CI2H="92#E8!8TT[U")7CHHE
MTG"R4).294-&2N=91&S07*N>"M@I,8O?*XZQP^?1&7T9/;;V/$.'"(<["<*F4FBLFRMX/.81L*E58F@8IG[C&;
MX^??M8Z5W7F5V8PN][>7VG?+=+B7VH?VH)1U#C81T.T+]7F WGA862G/H5?;
M5TI$:\FT+#1!U?*.\1=W)UV5AKE665)1FD">3@$@,:WB)Q K0ID1/D)Z@AG3
M+G6MQ*PBE?3X?G^P;N'MU8M&#G+ 9-)<$;/Y893M^K=;]T*.9E'5(O)HU4.KR/>R8#P5H#.-!&'VY,OS9Q5Y>)Y V@KIF4:-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M>^_[^=;SKF>]_[Q_@)*5F=F'Z_I=O]^>O:]KZ8.(XW'1KC*%J.EI2YMJH#-Q1>3U;Z_B"(OM41'TU_MJIM=^37SN[>\59!%7+E^U5JPW;:NP"F1/UX$
M4LA[,QKE!VV]E5 AT#]U5G1YO+9';;YD\Z9O:Z>?#OKSMZ6A/\SA_[5*LM=U:1$\IBF[+M+9WAV*8B;QMK!#!PGR1 ('68/,[>IA=]2:MVBR(I8A;=G!-!
MI6GZ UD DH->"\=$6+0=1A+?)-7[ R9FJ9:I)O$L=-!18[S&>*MC+QHH'L&,
M>82GJ.N5=H$J'%OHG%*NM^0I0JGR/0I/; ?X' LB3?6ILS8UU.UQ3I,75^']
MF%6ZX91ECU*EW4E0/_421DE[R1?S!(]NRZR=;;&D2B!'J]EAKC/B8MDE93S=4!ZO;W]-&Y5//^O].^N;4)\['YT&5QRS\-_$XJN'G\MS&WO[];#O5'
MO=,1 V;Z'=Q.)]G-U43VY*ZF,E6L,Y'[V,AS=1+>
M/P)_[GFIZ0-3;N6 #4A*[6XM0,M)4
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M5;U'W20:#U*8)#&&'F=*]=%9+$3'FF@8%(K8VR6JGENU<)>]*'#
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M6O[0S<]#XV'O]=G:Q, W<$H,JARV!ZW.8B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M#;=WM6L[P\(/AC)])'X7#YX"Q2>U;K*[0!>:.K?<$U86^9>5/,(DM;%$U^\DQ>)_+
ME)_]PNLCC]&XJ$N-8.QM_(?OW6"2724R$GQWZYNY
M\]X299/PD"_AP/S8[$SB4O[A;(;1N8N=@= CV^UHD61U=$N83GI2U1SSXH,.
M)TT:,\/^8\>##XKMZ#KC"H?IJRY'-;Y".-YU+.(6"HF20#PV!BJ@\ IT\#C"
MJA2'@,=.%.N#E&QW2 QAN,/XD"!'<&MFT52G7N6S5SP,FP66D%(O[E4)M%\\
MWYB+I:O!%P0YWC2,B74F*/Y AW)):W*8SVAE6[ESE#R\BAU?.XEX"B^!PEZ'
MO$8\)GD[I\M1!P7..\4MK(@F]!V!(%C%3R;>^H&3-A/_+M^[>HFHB"!A%&V.WT*_7;QP_<9D%X5JN:V0@7SLS6@D!2VIA@4U6: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MV3\L1I5K>4-MG\$%+%Z,+L?)Q:P9>;<]'FcGX!]M#&'F+'+]U\T[?A*A
M!W*G_4Q^EYE4UYDV<<_7W3S^I$TI4 M72?UCZ!2;M;+MFO7#(HS1IP&O=J+IWK@/'4QM#O#%$+#G1",6BP^:0SVVK6C@MBEQ:^FGNGD5.D3J#?;@9+]'HF6*4MR07*JD0_;M_9.1C[-O4"FXY-+;" )6B9T154!W5<3B.)L/)27'_>=1EM^;L4
M9699^G*YHB^B7HI:OSO.V$IN7VC%38M*-//7F>1M6I02T+0?O:I-TKQJ"J-_TNG\'EW6KK0==SM^^FXPN&!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MX?-D'!3HO/^9Z6ZLNL'.[F^%#E^UB8)W%\53MK?963,9B06\2S2H,JX7$<-K*4MJD?RZQ30!GS4;QY#IFL6*PO/<6RKP,17/G
MBY:X]I"S!AB_WW7V@#.N13',]=-634.)P>(I'M.J"S"+D+7V2\%DS2]DQA9Z
M K/A]\W9F3<7U!$D,FZ.FQ,#1UGO;]S'_Y"U9!6$W?^>M2+>KW*$\O$3W-U6C)8EJ9Z+<**$JJ/6U"C^%*?[251Q\E996)UI:?"DE=QD,
M2J( D03>13_M\K<%N>VORY'K1L,CS66")OG?.X
M])9*6>CO?D:>6MV$4-MSM#/"Y]8#"_3*6GZ^SXR%OX&$S<7E[-CP 7UXK]'_
MM?VU7#XI==D/5V^_Q5/2^PJN6?![Y4 T=,T5U.N#<=5L4V#N]1YO-;E(.9[)
M!BH>>C%N-RC^_K0[ER(L64(O6I97FD?PES6VB$>#]LL>_N3Q^P?(L-3JG4GY
MHO23KJLSZ'4WK)H!X&=Y0JK?UTU!M,219(E7,1DRHM6XD)VU6[S8E>>'@V]E
M]1K3K;MJ?ZCW9BTES#F0=U>=ES&#E0/Q/4SM[A.KDZS"<#L]QWP)PQA9Q)M\*]T)G1I
MA"H'*IZ1M?=@R!#AM%O";[\]+(7N]#Q1GE$3[RAVF-Q;H%8(3T;I*#HN:G (
M2BG-[Y+H8+9OJS-*57^8#-^/A19CW'I4" 19PJKN9-V QF;*2_2DC7MT(S"Y
MZ]I[CG^^QS-V$I5!_GJE3:F?)Z@L]&7K:&4F&P),519JMUSC'&H_>9EO(*X0
MC$^,C5\E:\"A&B%=Q:*1 L;'9#=6=O-Z*1Y(O45;Z,#*FYMKP2O+M@UA^K,%H5"ESVX@EIWHQC7KR;1#P&H[5#PJ^@'"AXX6-,TGLZO>RPW
MU C'T9ONZ11W=]A,WJU-P>P]J-$_TQ%OPU/?=2T4Y&J7)-E&8ZM7VS1^"7+]
M_=9VAVY<">UWOIO7#W$877R"'&YD1@1M,5X/[9H!;=V:I7!CC4!&$MZ@L>9Z
M-V_(9NB@<7 Y*Q,EMS"K I#4KY":,J:S3[CD^)+JL%_OS('
M=?..(SE2"L*I7D^;F%"D70*6=O.H7^2G6:]P,/O3_<7<"P0BJI-9Z%8E'HZ\
M'MDQ>S(?&(_0B7A%N5#QEQL#(/M;?&$MV\ ZK%O? US:QW!_="[F4AQ-;JT(8K
MHT^T1#;3ROR0AS(F,C)?M#R5;%^TG,N OIP[/31B9Q$3?*1S7S>O9;H-$>!_
MMTX%?/H'F!K[2SN8SP8884&!5M:UN_WVZ<8BF_1;KV]G>#+%VI',*;@OC--:I
MR<1^ DPTL_-1QZ-NWK4PZE8W;U'8-T2Y2A7']GRH\,1FUXE'83-U8"9LY'QJ
MOR;=CNP[$I=KW/->TK.E_ZF.Q>924T [__.M#<2K#X,K7N6/3D5;8ZIQM3+;%UZYX*"W9#WIO/VD!#'_L#8*^_O1QWA3BLA'QL5XA3!
M1LFY1DW0S785*L8!,]G1EDK?M?FJJA O^:F.%75$LC0'O2;8HPB5-[)^X=5W
MT1[R%'(WW6P(S[IYO3U1Z@_4U0,O'[B(S9/UW2"Q2?W W KA"$D?4-8I%TU@
M>E.-C@)Z7MI^KF_$S1YMB]_+8[M'\-[JWP ;LJV5!*I5>!:#[SRM=B74&87;0L%C;GR/_]L.$KYG $%+*A4#*77[ZI[K
M\;*B?-8/2P)J4M6#;8@GLA7]L#54AU([?K;K+&%[!N38^$8[ZM.#/E_ZT^J?
MZ''91"QA/:GV4@1)J#.3CO/MIOU;\8)X4PZ32AFLZ!Y%/_:!@9Q?K&'DFWI%
M-F R3ME!2QGQ %:%=PRE](=F$_5\DHUP5TPV_CT&3![FWL\ R#NH1P_'T>;7MN#[_R
MO'D&W>%8&+# =7K*%/NVV.\\)6A1(B\O7EG!>DN\0(:$WDRDD!+WZF)P=-Z>
M6;_8TI=/JEX9M_+1CFD'J\)O?C&U1TS!A3Z]L?>4FI6$.N \7)4XOH'47:!J
MZ1D.9G3S9&C75+0>^J=W2HW4Y7UHIG@(^VSABCL[!.V^SL@S3^CTPK\[V2$)
M-7-W;"_OE824?C?X_ORI0::A9JES>;5'1^7*#95EQR7S=+>?E(+2EM.=$B;UP6I;YKI>EUD%S)P&K1%VX#P*[-%XPGAR9!54%NS]>%,"NX/1;EF>^D
M#9L% ]C'4!RA[H&MJ=7V+O[T "W55T3F8J'6VH X
M/4U#KK9W%KTFR-TV*JZ:G;1DE: <)WNXM'@+%"E) F8F,:2;]V[68X)TM_?%3%3-3,P1_-RON+T$.&PQ::Z2]-T:HW>6&!=32@\YQ6(KKM#;,&2,70)VR
MMX"93;WZN'S28?#PJ8I9#)*<7U_.9#\#62?EGVFWG/$Y*?]3OAP;:;> 7[5)
MI?)55U]$2!H.&H4371?%0T!G-,BB%QD0OJE*\G2-P7_>>>SKVJUJ+VRD;+_%
M)9',\P2V5!YD!:GW^>!D@J$.@!^*["3[HC[;D4-5W7
MN:.;]_ .:T) 7N($V)U\J'[U;A\__8.]KP:Y["3X:8'F7C@8K:F6%"0*Z4]/
MTT>MG56W)35";TDVX?Z-ZY>-K"?[L,F36I*=X8Q>SFRD1QTHYA(Q4B;G6GZ[
M&RG)+6*]U%EV@Q/;RN63L51I((?2CR27XD"2TOGW]$:?^[ YC\O)#V^/\+IY
MHQ 05J;.>]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M)0F!/-*9\/$,9"9.TG0A# A]'?@+C#L14+8C/!==I:[_V\3VW^<M)6>XA!=E?"6:A.?%XT_;<7(*J+:BMV0>AO[17/T^>:OKC^!I;;%7!SD" S:'];?Q]867S IW^RTL^OMJZJ-5"
M_8BO DIG2O6RCV&ZF WML:SKIUN76A^V4*V*$>:(6RL%L]@:;EGM8FN#QN$)
M:?T,&$0?!,:X^(]S61577:I7N2OC';'?3]I?%&V3Y" >S"9ZD6,SP.VJ#'Q
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M&Z>#0AM05KA#U*-ZM*0*I40U]^C-#6R 2E($!-)A=AJBHJQ"0^U8R#/=*Y@G]6JMEH])?M3'UHCBUJ?!B<-ZZPH\B0SGT*8003D?FU*2FI75=U#
M;)]&/(^I(MS?XP-Q@UB>5QD0DJ5B))*JE:$&"W6(6; &_/F6.%N=CGV+<3)
M0D6#-$@;&+E'NX,.-VQ;&M" :::!6
M1CGU<,*P&74,1.CAD&-=[.:=#>5RJ2Y6-M[X#-RTKTH%X>.H]M!W$GNGEKP"Z;,J?TN+^>H*/,*.E+>T(@Z[=.P"R)?7,"
M\KY.MN]CVFRPE*Q5MKO9-/M0 1.)7UB_$\\G2)[V81F,,(.F@!I%+P_MA&++:'^G3#R,>] 6VVERQ8 WH7>U4./WJJU[U\UK;#1(*4FX4EK*81D4,8/6
MTL@^)IP.K-F96& /]\2XU\2JGOA&^>&:!D$.?KT4DN.(DU:+,DK"C'!CO9K0
MEPNG##4?2$&H!:J&I"JUYU8\6SRVC@T$UPWZ3A@DJ<-YHN54!HGGL*. 0((.
M0DDX4?I JSH/X0[^REIN(LRXC?(,+FF_;$WB+D%[FO/SY8K:R&[>]9\.V9T%
M/HX?GG!' /TNZX:MWSDY8PUTK)HK?,M2-MMYRRL9VVI.LM29C)XR&S;<[IYF[C=_"#<^<7KPH&@XXQ\D2V2"<%+'%MXOJC* P)5R>>!N=UP4G"\73?8;VG3AV&>')0*%E&AV0I!@#E$M=YA0#,70[V
M4=MMJO8Q=KS?>Z!IZG?'FUGHS
MWPD$>'6Z3=.>2\U5@S&'VW>RGSS0+CD#BD@B\RRE-*K%/@\9 15+XGN8
MJ2<8*8BS/K1*>J4TQ.W=RJWIKL)7=_.^26*A,RCD$35R&=N_MS-.OL:(]A?A
MIT W3R(>#D(@->57=/1I;))'5I8W#=6":%J26/M>%8B-IW4'+W$P HE(%)+_
MWA2XX3P6/Z4LC/?UYF6_W:#%Q<[UF#NEJ7B^U.!88&9]L8V_4?XU
M\^*^Y!)0-C"@PR#MCY((-2OO)+>6?0J<2RGL*Q3021G,NL_(S<_H>!::W-ZO
MFM;C C&R0@[#"MJ7[1%#F6)<9=KESCA,?JM.'(S-M)]X%UI9>E)W$#M2T[Q4''XNK%H[EB(O"K)NLHY>\+*?]8YR1N:*93I$\
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MN2[+[[(P9O=/%DZP5R>.?30Q/RX6*JQ>7X'#%]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M###N5;L+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MD2=XHG%NOS$'8 R _5ZE[AJ&E*E9'[4G%!WVAY",;6,K\7M-2=>HC.QY=SI?'"83K(U%=!%QINFR@*?*DC:OW4=8H.Q7>:MZAX;MA.^BB%8
MG.M8NW9*6GJH8RWX*:U6Y@Y";;NI3N8389@P>.4";F?N=DV/&]I9^MMW;8*V
MB,LP0,QVG8VX)[$E_DP$*"9A:X",1BO8";]1AYYW*'5#DRTE+R^1A!?4A)[O
M98+)O_%S)R$>4H OH05Y7QZ?R Y4#Y*_KM?BW\]_W:EJY^ULW[W74>+*0$CI\!1@S2PNL'*CS#:\+WL\/I\OULB&03U5HS
M43YM#CU=8Q!X,&$@^(P\2%J])D'F+AM=U!)^5>RGU'=O!K'%XA6T[VA
MDY5[&N8^%@TG.R!1"+=*>KP*$&1^,JYIZ)?<"_7_=I=B.[IY[?QNWLA.!]+-
MN_:0AK^76VRN](D:?!.^YK7E*;J*;6)-3]!KT(;>.L+;!ZSLYJW%-VSZP%86
M_M:,4@&L2!>"5SZ"?,B_0!>L,!5&7 '!3DEC/#:,;LX5+;)-VV5RQZ8Z-[U4
M7\2FT98]?$<MCTC&YZTCDU97]J >V]"\;MXZ0EC_5/&(@#$Z>:6$C,T1]:8'0996M(8N7DGC
M^\OP'E@M"]\GZG7,3Q!%(?4!DKBFG5);=S7/'
M!!?D.*G.+'7)$;^#OXX1A_9[V0,X_^W(GF8_:7?M[>:U[&9A@ ;SF?!N7G/!
MC#8G>@.*@"X?NQ2,,E9)02
MWAN9GEMO(S.=,OTQ<"XY=@7MF74ZDX[+Q+[%%I&SZ%D6_U6[=?["M2DME!EF#.YED[,@3#RVCDO9!3G!W&4BRW4Z*H6/WEG&9VF*IS2KK]+#KQ_MA
MLVYZL94/E8Z!X.\+YF&A5ZXR1_\W3&CMZ$!, A:&YV\Z#89<2L1B'S-!]D T3]HG3965,5NV3R%P_?3WT>JB&,JL[U %
M/'IM,+)">J>.OU^[5)0HVIJA-T ST,0KF0P9WFIM!H)I%-'-*XSX6MO-R[@)L6G]19D-Z8&F1+-Y>#=O F'PW%)HM$4'S9XNN!'R
M0U]V'[&ZX\,D03W!WA' F7GWL+>ORMGG]>0&4UN<MGWZU-TRFCTJ\<"MGROU/6TX(WEQ^0EA/JM,GF;PN/!5H(+:"6*VZZK5&#B(SGZE/#6^::HWT@XI5Z;:P90WO0>XRHFUJ-*
MW5BPQNZ*(W7[3C,P(F:+MM#$,@@J2M*LEPY5/"@<30TQ*=]W%#1- >FG$"\L
MVBP:#"74X!8N//HF5U0(R^T",!+//0EBJ--VOE[:(+&JVX=?5#PX8LJ=)-L-
MPY3. Z3:1Q73D39SKHBOD6_$ECW03B?;4TCS7DR,DTMP/:1$_NZLCXA-%R7,
M@RQM'=MH+NSG.HMMPBE^36&@TC$7^B-D=_;MD/.EN [9BJM3]/)?Y:]].6[@::;<:VYT7L'84(
MSE6FH)*HCS]M/E&];35WQ;64ZSO *$D[:L-S U"#)L\B8%*=4W#]0BK!3M2@?4")+2FS3-)V
M"9< ;\I0I?85Q5B;OD/+^0[)E&8]0?WX73\;$77RZ/WLALWF(-3TAIDZ*:CG
MPJ6C3_1_MR1W=,_;OM_D\EQMI=B?:LYN8X> U&A:>#%"Y=':-)(.R<'+<'(T';=W9\\=KI2N>70D$\0=X-'1
M^_/.RV4U")]8+QL$DA:736[0Y6F8H91_CG9:6M&5&E',KZU2[VU7@K;=O'9P
M;\4A7W;'H2Z(P;U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M*
MQS*!E/B0%75C^&;B*A-C#_<"P? .>2=I&;L.&8Q]3N%ZS0=?;,RKNMU778N?
MX95WI53LW.-K*@.>6]H(>EMS%>)^<>,EW=!6?Z)$H]]UM"-[:=2BS>R?U/S+
M3>/6414KKGQ!)?1:,OSSW5?;,ZHLU/MHD19V>'="$WW0HFXZ,)&&LW[7.4+\G9X+@[]\T)>\*&9;A]$=$A;I%4P&#?P
M7T%0.9PO'I:RS5*69%#G"B< E5VU[\CDC#/K$]T>LK[@;E5A($WD$V300_R%
M.]5<6>A+=>9@JTW,DI4WXPXK&A&>@L]^7%3-PGI873+;7Z8VUV5L"A#0,5 @
M^,6W!-O]N9>+OJ) DA@H5W+E&#@6W7@CA!W-LMH%?NCUZ:&L9SGTCK5R7'+E
MT59))KR?QT^JHJ?NFR;.>ZP8*)_X94G9M06_/2Z]/5(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MN3>,KKMIK=V\*K/#3KF:X*.S==ZD.F!5<)Q-Q^D23V9
M^93N*I1V"A$MR.?*<6O'8M%.<:MN@)G;J=879\9"M4C02^3%[*R&GL;W;N?Q
MRM\):F:[U* ;2"F*G2.8>4^T"/7ZQ3-,1.G..R=B0VNQJ=:P&'.E6"CS/3YM
M5C"RJ[)2M?"8WZ7G$M8S%0[5K VZ*8]T8U*0DNTUQQ?9]BN+RK(+:,].J[_A
MN+2F(2AO@$?X7+I$?@[DS5PBRIKC-?2'.2;DCY!\= VZ-P!M*X;8;LQ:#>KI
M$.?W9NMTR%1[TSZ0I$GK.ZL4?##R(K/8#(ME_=?PXQ,'-%EK]=R6>!IX&;ERE241.XY26G:>YQ?ALE!M$TU9"46H@6T<](K
MZ5/QZ(?:M:[] B8BG/G!E?(Q>3H;PM7^1:PF\*5H";D(HJI*M,H=>MC/?]Q_$4ON\BL5:3_P,HKMA67M?4DPXBVEJI$R"O8EO4]8CCB[ZBYFNX=5G7
MX*0EM9&O=$$_C%-/?O_!LAU2ZJIX"P4C;]MV-Y1A$O9P>!TST9RIKJF8Q"&EM'5S1E<6=6FY"YQ!@?\2L(&!>W/XM(GO-4+"(7?<:JF:9J9ZHL%SKJ)$,D+M5/ !V^*#,#)(//3M''$RI]T<M6L.GEW&UH(4>5">,<$9NY2MO)\+D6>AE\HE%3.[4$^X6:A'1D%JAOI[4WNB,
M81\C[FW,G#5629[P$TI70CX5+2R"JD">^V=+TP#*DOVV6"[_<2>0%_ZJ6B0=
ML+PI?7^7GAV\Z>]UUVX^[&"-.U)MZ;N,8AYMM[7M9/ R#X>F\: N9*%FTXD^46DPT3C#9UAIK1F-2JLMLFVFIEK@S\65T,HBF
M#,Z$S\5N8)7"3[Z+Q)65U'FV&D2)A]H-!E)NS.J[\,D+R'^A*++^W,T;S(Y7
MW&] C<=#;5*]RN,U*Z(0([X/[\'VEVMR0$\-8C1)G'':%GOTXFXTU-1*?4C9!I_N=F@'J"=8U7U:H'Q4#14-XI&]HM'
M/GO=(%7BUY=K9^GXE$Q9D]VO3O$)^!W@52BE88877- %TJF?]>_7X_X\&Q04
MH]7M0^SN;W?R]1V]$EZI>S +G9%,U"-V"#,6.KK*$^L'5MOO0=Q! UNDO;33
M3W7S[J!FQ5B5%\@P6+RTJW!;,;4[QK6 ?J*]'&E4-J0;$73N<3DIX
M\#Z,3XK5YW#]U"1H2WU:Q('LXR<1!?R*0C<((ES]ZOMEW,H_LE?D0W*;1 1N
MK'>),;Y+86+[3:--K!=:[[1M*Z8#222;%3+?4IO5=+BQ<%S=I]JU9^2ICC0@
MO8C!@&Y4@7AA)-T7]C*XB]NSV+^U2HP@'+2.AJBDJ2H<2*F8?Z@"UQ'CU[U1
MF+_?&%YS9K5#\R[!!!UH;=#B<[YNW8V-Q[A79*^KO\?YVL(81<.=^[L
MYM7S:#Y[?"N7K^$N#L9E9YR0%W$9"Y+EVZL2(QZ) Y,#FBO;$XW+(4?+"RN#
M0M!='E_Q^H@X#?6*!RGBX5&C>2] ^IQFM*F7&W.P15.GRD>HV5*5L!_MG\'X
M0$MB?5PENA%R$VG>PTY8P: NM2B0%KUN\@4H+?F*?M:(39+0JQMXT5,7$!253>O9ZL1M4K8"FL2SD.O\*DE!U-(;%%Q48P"X1NC](D
M KER)DJI\-5O4-N5SI#!K508+^[4Q84S?%N*!RWHO7-L]: >B;E79_[+AVUP
MJCE)WQ!J/ZS4;K)9]A(]=>.P>,IHN+7PG/RM%&RW3E]4]9/8][&)6:RF)]>6
M)BJGNU)46A!'3YL'4L]@JPB09B^()&-SF-ASM&PQL3/S++5U)A2D.?[8O9,-N%4C/4T#C_'R#Y;I1C^_% YC>:VRX)_LGT8.=
M#$5+@17//**N0H+ --9K>IQC#[BB$+8H)K/UE"9CTO0$#A[[RU'6:PT$7TDN
M/I8H:C$YH_'*"(4G>R?4N0X;#(X[HUO1ZY8L[4I*8TUB0M3>6*S-%4R:5%C0
MK]BX1TP@:?)4*=&G 6,"FHHO,!*V0CR*!Y:I_/;.WLB?^B'4*JLWVSNK"*5B
M,JBT"O9:!HHV4:=)'/76C00IE3M: "$)/-^D<\I;,%#@OP$I%T$)88C14H4ZN4:_&HWKY3Q=I5T\X;?%C2B\6S^
M)JW,Z08F.CR5CME0O:]Q;*==$&P/GU58+![:)3M(W(]],!GUT^YRQJ0(QZ/4
M?<0;77L[U(#0&\7#0'!5B#-8+PPULV.@5>K#3MM'?"MLH8$1Q$5VYYN$]2'ZQ'_=MVG()#\]/8%+ '<6$_[&X_\K;$3>^-/4!W5EWPJ
MQ4B=+@@+-0OV*O.V]J'U4+YM9690_*KG2PWZ3H>01R=EI+6'&@/4<-3?A./ZZ;_"ZRLAMU5+9'77Q1,5)CP(
MJKMT62QE,G;LM0P2]T_1#7M(7)^T::(-7BMQ:VJMX[+5=!HLC5+)XZ#0]W:V
M_W![>#WAT+M.LD(L%M+K.:M'@QT[D:C0)?+!2A4]G)GL=1<@429#Z*5RYCAV/3S-@T2*M\@:]S,1/B
M.J/CL?<4O>C8/0H$(C0KH@]7R?9W=>9C.RZL%TX#&OJ@7<:,"Q(8<"H_O'J>
M#*7V ;RR<"H=395G89$_3EL03!>68Y&DRDO>6)4HI/!,T?3+\I)J=G3=UO1
M@\Z'8@LN) *5]$F$ZL-NL,O0%M)TQ"46,*"J6H;7TWS^^P!+H@M^EF7R2S&'GCQJ3W.]$RO5\W[QND\3-QN&!W
MN#.4P9# ORB2_H%[8]6_>;%PBMC?Q.P/-M0W?P%'M'JU692F":>,%7B!. J<
MCJR4]<9&@@,V3;Y?9U=6EEF/"\#$1;?I>X4EI^&D&52]$'!NHO7/;IXRPC4?
M;4^!)(T8JA@&!J(-)L<<4$+Q]>JK,CU17^3X%J33X3 NUH0ED,W5E_BDS+@)
MJ6:'F8D434$1:<#F4T0-+Y6.T2L$5+*L_SMJ'RUE%AUZXT=LV63%&PU&G%J@
MRL++U&TF&^JFJ$.]B8VHDNA?)FF,;[5%&H[S;;&& ]9[2$5A)+W_/.S@8;VN
M'^V91]EA@#ZZP>+.]I,;A/[VBDSZR,?J37:ZQN08[BJ)"$NP;US
MYC(V] K[ !"GES-CZ<,.C6&+*\-U15#PV\="[)"YH[^[)+ZB)JKW?*2SH
M436,1-JWPN<[MM:+4@!'JLNB:M1@9".
M2K31S(V"3$F4RBID UA3(:*<=5T=1R=!_=%P#EL&MM#\92[U^_1@&U$M>*KZ
MLDX;:IOG9JO+B;B]&.S29]BOTK&Y2L>L]-"_U&[8EZYC6Q$PTM3N1J$)KG/L
M@&3=:->)V,I+:,7VPL%TMM<%"_8" I(,D_L&-(:B#WSX0/G?@6\!CB'!%C@)PB++4H$-T0HP/3MIE62C4
MBB\P<)@D^K0V:/:*A.C+U=R9J*6M#X1$8IFU4TVW1KIV(B]#NXZY?F2C%$8H
MCYO;4FSXGL0P5XG8 Z@2P6J4&>2C_XGP*9VF&;)>ZB<>BNL?4TF.V+V"MCG6
M Y3=Z68S[U5$0?*PIGJ-[21"Y1Z7)C;K[1%,R=T!#UX]^ES99FFIMNB%\MN7!Y%UH[(>)KEQ("?\USVLLXZ-D%W;SG+Z0,5QF/"'?2"-?CYZ2V%'+
M;NSF34/K.QQ-M!IBT%ZBQ%B!^"J,>*ERGRB4ZJB 1B?(5/MBT>3TP)K$H;3P
M-K3%@ZRWMM723QOS,M-77ZO:D^Q2%Q'=.Y?].:B/AL0LE\9JU-*I0'+P;/;0B(0VG8VZQBFP9RB1ET
M$C-<_68LB'.ZLUYL&7MBT()@YIEH+=0;,Q[]P@:^XC8/6 O1TEB#A0\$;&!/
MUJ"/QS-+;X^Z"R5$]CG7$9R,.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M YA/784,[O1+5HP# BN:J_,'91=?*1#744BLL7EF;.'IUJ9 \7 S049REMJK',K>QA=Z/1"O/8=O5E5&'
M(05?MW(7ZX/O$?9SG2Z+*6:6@C1J;HV%RMU#.4ESSO;QO5[L7C:@9RI;MG6!
MI/0-@UN1%UMLFH8\QU.S-I ZK=<)@.\6:FRSM;#@8K+%$]OBG*XP$8/$ [%Y
M#[#/+N*_=W")"F10E/SI7J/@%A\RJG]&WT0LUHUW%1.;\7T!GM(2UPA%>D!YB7@5^<$U*:IM1N]4"MXMO_E+ZDD&V@RIDY.#F)CF-^@N,\,6Y^
MJ.N[F%QWF1KV;A\@:\FSJ]IG.E?)KC7".?(AU*;B'_.6;UF5UD):9LJ4E
MV_.U ALJ3 DPNJ#[OAO2;+#0,KQEQCT,>FU_W,YW>9OR$+!!!*WDSTM<9J#V
MZ]NB]:XV^:="-A^UE">B 5_M'V:/Z+,HXQXVE2NE0CNG83BX;>W($/I2D34>[E5LI*YN:T'@(EJJ%$T\(]]J
M26[P?5FR(Z^,_FI_U:<_;CMU_EE%;[?@'D5UB*RU [T_$;8*(39T]&?O7;=<
MV\Y,(+*9!.K6W#ILH:T@X*T1N:;)9V+M!1-M?!5J@\&XWP]T7ZZB90;ZLA 8
MV+7QG4?#&W=GV,[J!"#
M8*!<0*+Y1/(;+,R^D':+@4A:SHQ J!SY)+!"_JO/X[UH[9'< :[_'._AKDA[
M9[OL!!-^!9"H>N'M'FA2[@WY_V+N1(9!RL#!#4=
MX(R$8S?.5/;;;MZ'(S>;R]("B/:%SCCYC\Z*!ZW2JVI]>BRY';)!3_EI[C>>
M=,OT]*X4H@<"B6>[>@BNWV%#ALAW50:QP?+'*ZA.9C]"'7L3%=?U;.&,79)P
M(]N#_=+-4>/208:"T;7^)O6"-8XFY;&5
M\@(30Q%54OI+%2C)($W,(@M5#)B49HLJ<92K"$W>E%(9K\Z#BNN@_J; @/;@
MCOZ)_1D4)%%(32*?BMS-"* GCJ!#'(D'N2/5H8_9@1HOH*Q!HZ5MLJOIZ")V
MTD:IY$DWKZ!W^IH_T!WL6)0J8L?C#X=R&SFR3]>@S!\/_YT%EFW[" T/_WD/
M?IWH=*?ZKW3G.$6#)8A8&U[O;HNM%/3%QKK*F7DTOT;A"0BKVE,^MVKI;O:/
M)CF\GTH8[=VVP
M7$4+M--)(@NGYHM=8$_Z\4ETERM;I=!=*M&[*@;=UQ&P),?K'Z6;^[:O3!Z'YN 7+.TW^"R3G0:
M=#RJ=W.;QCD[I; ?MS)_D9&6E%,_G4_GEO)R13M,%9OXCN^HV"JD/V@T=/,$
M.D_V?EW?K6\2>E U5T6)PAY;:MF=#5)/N
M0SQ*D7V(MW:A/2R0JVG ^LKO.D,K=HJO:G#]'%<&"0T15Y/5^+7;@P+^PV@@
M//W+K)B[?NCF5?:9=%LR$X+\;$7USM!:Z_3S=N2@]=WL?5;\#@/L-^6)S?[.L4S.QA^@O\-/I4[@ ],0JUEA^9?Q[&
MZ1&F=O)$"[SN4FM4407NU;B^2WQX=>J%US32E]M'7+R\2A V<]&^IV
MS%/0.GU0#_8;V#C+=W+GES3?("F07C&U)VVG\&J41ZQ2*_V3R'7G+X!IMB1F
M'"0M@T"^?)FWWUR$7&U!O6YMI3*PC;2+/0QI 9QAY[IX.6+@#CU!ZGF;(JK1/O+4BL3A8+4]/:0*^J/ 8M3C\I#S$T#:/4^5,H32ZVI)L7C&=2H:XIHT\(W@YTG2.L)W0C@(7:;H?LOZ^B
M2ET:FUDJRT5*N#UPD?+4Q;6BD0ZD#0%?$Z6"_>RT?Y8,[1MKZ-C#]J?8/-A>
M2)JY+=1PSB>RWJGDQB.,Z-\P"*+AUC]#]7^$?0_=U;\0+92!R+]2B^3_G^M3
M7B -1QU58(ASE/P;/)M'06ORU=X9
M_Z)/W?&?II^Y4FT>]$^_?('\&P]&_M6BG%/E_D9Q(/C%JNX/253ED0)=.2D+
M:(F*S15-O1#]1U-R5\V1F]M_W/8^;_HR;4_*P8RZ[,E44@F,23L,M[\YBYIJEIS#/+67^+VE[%/;OTK+M,6/4^M:@;GH('_RW=CF3'=/.Z68GC+M+?T4$U;DB9[&YYF48D[WR]CXV[\Q[/^QEOSR\;O;N>^JN>^&+-&(!ML2>VHINGDG:-3)S0VEB4E8[.K[?B9;I_M0A?O'):KP9IF[=S\*NN@C..H^E)
MSO&88.]K?>>\6WM?UWT+TLCV!_<\#7_=W-KX*F//L9XZ\ZD,K_\J9<)__+A5
M*Z9B8Z@B(YJ5* ;1]MG?WJ#,55*!%"0LFOR]X'J]JV1[?=G*\=D(/95RM:S<
M-OW$H1_OS?'4QM&?T456W*AY.M=N5)9*O8ZJ!/+&"D7P0R:)RK"M/5[.+%),
M#Q!K!8\H47_,YY3\K7[GV0YP
MJ-5/^%VISOW[36DK0Q8->3)IY::YS8.NE?.T U6U!<*
M,M=W[L0SV0G)?E/!/NKZRPYVU,XEX"G1H! ^^XN16,\^_$
MQ,^HZO\A[=VCFCB_O]$@2D3 < ^@)"HJ*FJ\@"C&C)M*%,8,RA"N*=JE:J5>$=%3!605F("N1!;:U$0$/Q*,I-65$!F6HU/S22MUCKGC[/>M<[[_C%K\0>$F3U[?RY/]K,?E/ALJ 3UH%:*:=DR%U0)&C(OOF5N
M)=3'J'A\ODE>I/)CG*]JAOPS-HZM/<5PG)C<-)F1P#AKI*V[Z19TCSEPZOI6
M9+&M4>(,:G7?^ \S7M_KG=\1+@++[)-:?_3<4//?=E7/K;N.T,B.$0T[OOMJ
MCI-M^5.17#T"-5V%Z'(<=#EX .&252MH4"VJ:A8Z(ZL-6H7?[PNP4P>H#7?*
M=ITLY;(:CZYANN4*+$?QL,+=9[G&%8+H,P.')5MNF68\2+)DF2KQ'^1XM(6X.//+_ M!JN
M2E90M%4]^@@>9N#[%)%:V7.UR=*0H_@/]\YV<%E?.;X#R31_]1_T88A)ECOO
M:Q8#/#)P_!CC\P,OL&BS8KHBKQ?IC-U9F%.G( #5_%1'?EG/N9AVX2WJR5_S
M=69L]7=;4R6N(/E22AG.*HQZ%8#NG1VO>?L;BLW^_
MUZ;<1LHLM;JBNKPS"TNSM]H@.P;C_[$?_]B3%.K<:)LYKL3Y>+ ?'X9#F*,?$RYU$Q0KS
M=ZXA$^32W"#;0]O98<8>Z*C\KK'@7;@XOW>LY_[[O[U0ER"9MXWGQ09!^(\'
M%BM7*%1MSY%AAJZX.82XGWLQ:61M\.V*#S94-$?P)7T#:8BOC7Z$9*@@<1K8
M1+:U-[6:!GDZ](5H=/0Q:CNR)2-XMC\Y?13>E7+KSOZK0_Z/K=JQ.X/A^L?C]+QDBWY0HJ"BC^H_9X:AGRJM2>;1QBJK.D<\TOG$O)C,C(W,O] 6%@CY.#"%1(00-6.=O&"[ON_3RR3,_Z=>
M5]H$?/ZV&EXA%[MS]_];T&IWC;0**8]S?]B^4YLN&&8\41U43G@\S
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M*2PS13<_SJF*4FA%3-&/Z2_KYLM;M'#1]1RAEC;^:^NF=[(9F;WO]XG%_VC^M
MDQ$W.K[4-IBUO$UFRL@4_F5G_L EUBF>C[_SRSW;CTC$M=6+7W_Z6!:NT-HG
M]TX7*889"<4,F^LEU6@AF"H=$(]Q2B(,NONIP>];R]3!MXHH-KX 6O9I7X4]
M6&&=,LQXD):-WM*5\F-%7M92;$^?V8'F+AA?U][O>7NZ_;_B7@VW"9_$:
ML]VUVLI=PSJ5:>(&ODUJCP6#)/Y>IJ-6AS2LE\1M1)OGJ'>''?N'AR8_\!YF
MV#7VF4!VTW[64/R#Q8+G"FYU2"(0[I.0UB)!&+7PB7!W-1C2W-\TS#!\^ D*
MZ50R=;0^%S\O:9[]!MJ5T#?M=.IJ=90Q'VM_1=7[MA>K1S\Y'WG2OZ_E9\\02E'6*>IG^8X3LT0!*B
MSX89/Z$:M4NSP?$-&:?7-LW9?#C+[L:UCDZ]/4L908;J49\/(Q;5@C2B"L\J
M&O?F;WCG9L_#KIS*JE8Z0$>KX59]XT1 N[:1GVQW!=.N_BYZW5-5Q ^D]=FC
MM:VVP_TBXOC[D&#!@^H/56N(!BD%C9:N>))QV-_K8=[JMO!'[F:5[RYK?.Q2
M;B$;#4)-=<,,?W.*)%CRB.L,)9^?])&[KU,R#70CT7C,8N>C&:MFQ&_+#:"T"S*=X7YUFTU_6>4+S.N/6/Q0^0%32Y(T-/Z);RU#^W!OQ"=Q[:Z
M_SBJ9?$GR8>G2[FT/G%5FV@[<4>:&[ 3OKR*-.AM\2F1LM NR$^)>5SU%-"KHW)RMY JL=DHK<)$'4M"MA3URJA0D[/3SG?/ISZYK3__7[/-_MFUR_ 6:',::R+H#35NV>_[SX_V_G;"Q"DOXU2G+HPHGD9?
M87V\4FY=0Y,Z5YS)U@\52;B$[VG:R/'3R7VOTT(_'PDSL09+)!7*F?H;;:&6
M$O^2+BP+JM;Z#[J,@'3Y' 2\"ZA3-YF+%BTYZGR!+2/P\/J7M8N>7VG&W=N1]YK+3[T27A
M2]BZLQ[O@T[GX<$\8=?[P\O_4]#0V!:1$]?Q_OSJ]",_>S[Z\>NOFSC3G&_^
M/\!-(W:9J([5#'4;-'+B1R0#7#2)\CFLR)!U]TB>C(J^!J>O;50OSFT?]1=H
M7C0^_]&(9;N<7'*7:(J!6F=L4 QL,YW/T20&D!6#*XEHK602V5N$B7Q!='2G
M*@1\TVO62X)(#"*.]?=RPV#MMJ?\=2?XLW^;>W/$>C0RHDM))%(I.H.2#(?YF(*V>R9ROAKB2] K.%30R%;FRW,R_R&41*<(^I*L+HLX7^G
MOQO/\&8(SETJ_O?="TLA6)-#=L7:S@[RDU,SR:I5!.<\&:KC,.I_ZA!G[F0U
M1]V[82NYVM]3>75?V<64UQ__Y2J1'_B\EZ-ZY
MFJUN_?VIM]\_.I?0[W,]=6;X^=CUO]7.WI07QMBPB#_Q\V;2IM:4=MNTMMYB7; [1N<*;;X;),GZOLES;9SX1AS#:5!1_%R'P67P;4^$MA57D*E-QVWRM9 %XH0!R+7?,^R6K=C789SSC+[K ]8+SUA%VE\"*Y6WJAA^^
M-*4_8H2EXR*=W)GB !0?*D:]D955L+!)SJ(BJ^$J?>6TCC]>>+"6/AU4==U\
MF[4GV8D1.&;1>/>^DM?LLIZ\I_;O05B'[8]0&:P_PK.)CA&W^*6@7.$%;,)6\W+BQ4A;8I0[&7L7I!
M(''PWL6;?@T-C20DB[ *Q\(YZYP]3G?5O]RT"@Y\Y--LN+G1:272349:+@,F
MD:6K4+' .9+.!7=R085I&1F_\>F'HOJ):#*=;':?8&Y3:,O(&9X9$:2Z,*.&
M<6K7NI='-#ZR*Z__[Y3\QTU4S!GU %R^27$:R+%G(G4U8M[VJ.4C74P%GK.LH#*.F.)Q$IEGN!V[YV^NUGQOM/TR[EC@G[2S9.TJFN56OE
MA5FH&Y5*)FOM7/(_;)3Y_I',M3=X3>9NE*QMR3;DVOT8(Z.YQ ^@2OM))0V<
MTJ#Z_NU GLN#!$RF9S&H'<0MP7QP$(_AZ57LQF<1-3.Z=K3-M02*J46*_?;@
MCJ.FTIO]9[?M>M3MU8.?GTE"5/DYU3*7TVWKT#UIEU>V;;MW\OO?CE[^*^E=.&/32M__[2N^
MB#I,T*\MA/($>J)?$_24Z"NAOB6TAMZQA+IP3I753<>90DCJ+Z=&O6.]_%OQ
M[GC)V T+?QW)/7 I%SI#O]5HR[FGZ"Y1_C"C-EZ*FLX(%H-#9)@I66OLIH5W
MA9[E]0(T-M\72?EQF&UM)1."=T66SFDN 3/L+2(BEA5D?WQVRWGSO^C^PY&X6"-_SK;((??WK1[V)]E5
M4IX8W<\::W\F".F@I?)+-UVH%O)2X]=)49Z$A>YAC78L8IGEOG!MIWW"GR\1OK'['N!4O:R3\HS
MV\Y *1XAYE455^VMV:RF)%/K,0;BU<;W^>]1A-SG:$!YXQ4JQE"(8J,6D1^+
M6#H(;-U!)IB, R763>#%Y[83"-N\6-[SCQ9E9 SUG+04D!5ZGML.N$$$/ 7C
MJ(50[:OO)-Z 99\NZXG$6W5#OL@$DD7[(Q;+\SC."P:#:FP)R2O.\C*U!T+M
M!^?3Q5<%-C+_^> XU]Q6"8EIGV:L&W6U:B#/S"NL] ?QI-74(K^$;"$-4ON$
M>ADU75@,W6TH1:))%#N7&K4B;>UOZKK%M\;FP%'*BUER'6[&/^CRSO$=H64]'YR1XA+M>&F%I@MF<+ABL$(R'H1MX?CL;M-8*974?5V([]I^US;%?Y>\FU=*+L.QYL.1IOR(XN5._A'N,X/8'NGK,>R _1
M9V]08.VT8@AD1BUB5G$KL^,':)H=Y=P7N'S@*_Y>
M@HNK6XZ3:;BX_+V,2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M]H [N!>IX_HXFD$O[N]U^1/TZR&B&,0ZMJ5T_\,8#]?)V:B?6ZM$-+FZHN0D2XHG]P-*^>=F#I:WY;G =>X^AP-?[:M2G
MT&9Q3XCED.UR#7\EZ6,2ZUJE:M^,88;[+S3V*(78XL'Y<8U/OO>JOE=1G9@;
M&%[JI9@V[^;Q,W%;+]_,1?DBC_>LGGYM4LU+H%*C1 ,*3)3["1K81J!V=E;S'4)N][XE]T/B0!G.!:N1JXB*
M$FD)G_Z4T3%[0@?RK%^"^994V_<709%)]B+-?*QW&O BLX<9EJ, )M!+/A>,OKSCJ>1XK:F4K">9[]J)M[&/Q5ER=J0RS9MLU@BF.<<[#C&!XL>4$<.45J+B@9-4=M_54LZ$S)UNVB#+WY.9C\8^RJU]JR8VJ9\GK0)B3%:ZO6IP
M$['!@*G+]I(QL@)^PK?FEZ,RSHLV$E.KKKRV1[;5-5B_"MU.[+547^$5OP]H
M/N[QY]Y3W]^YP'JH."IRA4S7( \HC4M'7S 3%IE#]8JCE3X@YU*#3CWJM9I=
MUW&/;!A4F$3=D:N)KD)URJR0I9W4QA62/XQ^$?4D5\L: \]!M.8MK>5B;&'G
MRJ1/2ZRI^[D^]BF2AZJ 7YY*6))G44R=J.C^*KGMSC5)ZUEHH,LL*QMFC,@,
M3FO.;H1+ECXSZ(V^-%HK]CY4@21MN]\W&$BEH21;5JA:Z/S<$AUH26*''I[%I3V;K5/<\-IMJC0)A5.4SCB;\I-:G,$A'&6"V"VV*Q0+7Q+?(@\('V8<4>\A]GZ"R\5TX7:Z
MW+$L%@:A7XSHF21MVW!LF_TK,\/O"U]GDRQ??0<=9)FA?#6QNK4[ULP:A
M!49W"2,ET;'7.7X_Q[=BV0/B>=M$ _)B
MD><:1PWXI$Y =5<1-:X8B+.NIJ8!&2XN%=T5:\2MJIF@.O89,M\T5-+3=50PC34R+6KH: 8+Q$K2#
M=E)?BYM-RS!9[[K6GA>6Y/:#N]5JT$^T]?QQB"Q(2'W'WW3%S*UU##'X^&>R
M/']")#73R4!-,@\-+C1(1<.,YN5HLM@SQ3Z>9#8-%4-C5(M2NE .PB*B#4'R
M? $/]EE_EYCUL?Q]3;(N:?/]@ZG/X%/##(S=-IN_X@J\KOF%,L[\U^M'^;E.K8CCPH'R=9XY#.2V]Q8-A]K-2A*H#%? "MUDZA=C<1C:.%CLT1;N,P+UH2*IA.YJ_&S>:'3ATJ%!%%*DU>EMUUR#J1V@<6
M6S?:VXQ!ZI2R^2U1,AVO$*V5#T"8V N)ACPC!L7-D(]@&BPVO;J#J7N@..*C
M%,*F3V11,Y>$:G5BXC=SV$VPFD=-OL*J@9+%8'KT@,BZ 7;AM920N+?ZBC1)^C4!X6:2&]MD?-E8NZ,K<.;XQZG5EM?CD]+$/D@XH5W?$8JYAF.R&39LYO*D:U#IZY7L++[:D\GY9^ Z3K$^JX8$W&
MK+CZO0_"+J>H)N][DL$=M&SGX[6V$2:@'SUEWP3++<9!,Y)A;+?'E CZ<8$C6W3<,7"178!"M1F XM(5+
MW%9&(2MD_@"R^\C=P"UXF"&834JI*5RBK/.C%*6S](6,Q@\(RP1&DT@OZPFU
MR,DJROOR*A"?93[L;#G>I5QR%=6N@'UTG"A[)Q"3D2T]H3K92#@WK0IKJ3$I
M6+Q29:!!IMR&/(E@"/9%K%2^<+7M (TG7V2B['_45$)L5Q9(1
M\HW"0'B^QCZ]/4+HE%_+M\=>A5A
M?&&US";HST\E%#JT3JTYZ(:SM87PV+A 3G!R3:7%*S+;T^
MOOF3?P3+#_D3;%O]SX*[9QG49IL,VFM\$1\#&JRS007>I1DJ\J\<"8363/L3
MHR=_$;.0\N=$P2H:NXM9C_
M^2^3OW,-K;?=H!.FIQUGZUE@NN#(;6J"[;**UV\,$+C#9JWH;K2.YT8E$O93
MU@6O:5:)4-!ZV.YE!+&JB2#V%K*:6,LJK#*SJM*EX_ L:W-(
MRG%0$RU]L;/WN-Q'T*P^KSK%'=QKG:]^O@!)![OD/:>'&4&\ 43!3IV0^%SR
M1Z2H6S2NT%K%'?-K-\G,[0T0*Q>T'=,,,Y?-PPH^>2T7*P
M TT=>KY.=_;#[Z(ZM#A>OT7DSASH-C_@6G[A<,A?0"FR^Q*(M_M/).1290+&
M&BL_-TH9=,';?PT-@KP7G[@]H8;V%(Z?[5I&Z_CG5)RM^ET]KRQ+'3S,H/_/
M/B-'TO+)T-P:#-(M.T"D2>XMU\M>L#B2CO].CJA!1OP2I3[V05R M9UX;'[J5&(US"X/"7N>N":4F7J1QRK<]D(JO]OXYPNQH_C+=@GYB:8W2K&$&
M>S::RI)*YA(+3I&Q6%_SR[3M0'R#5>B\G.S2+U<3LK(X9,Z?4PO/>LL]4MYEQ"=;(FJM$O\P+K-TBJOBL<_$!HHXE[IRX]LL;TISG&M:B)M7(.LHG&AUI+
M80=??%,FX[C8+C39?E+C%SOM(\M'FB*?.1_!\K32ES;*NOA#32$QBM19,9CRY5WT%XF''$VQZGD8#;E*?9@VH>3,.^DA#MZ@.MW4D[P*/=5D$J%*P*
M?"L:5W]8H$U\JAJW'52L%?DGOOET[YSM;O&]TCCTW@M-(ZUG0?0C7G%T_IUJ
M=,_WDTLXTVUWT'W<$PC PS##S:!9W1V:1\A9U=Y]6/C9"YOLF&RW*Y U6
M-]N^'W7NU%[!A)%R-^;SWJEA]7&M2UFOW!RP1@=[%/O.4\D$N&$M#>)Q8)WE
MV,^VXCINOF0QD)$^EOPGRMTWJ6C;5>'@94)!RUCO#\;\H 9JIFP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M0\#Y<5>VM$61:R0V50\%VGN_,3HCP63[QCN@[#8M^%-AF7J?^FCVAA+K2GD!UU,0S,H[*RP4'E,NPXP@&>+""9HK0&CWUM)UX+T'
M7:KV@/;SNOO,,7VZ-%8^&FCGP)_Z3+V7#@AF1&.H;^KV&X3?OSMW>$2V''%&
MO_CKO4?"E-_,UBG_^>XR4]M'>]!3DF8+_1P307OD8 RQGZ9G\IV"^.#H/7"]
M*K?$&'YY57Y.PO&WT%YDG5/XA^M_#/\QPG#!5?,M%UL?@EG.XP,-Z$,X<
M9GQQ.$EK][7=L,_<"83F>)W;!["-/"C3B(ZI62I_H#:S"NJ/9LH]0;*ECJS2
MLZ39?1J%].R6GP2C9<5EY ]PM48RB8
MMH%6Q[*5GCL22N*Y.;:HII*;04 /+%]EJ\M$O:@#C00XN'ML$7Z'R+B!LD=N
MXA8$W/AS!+JJ7OQ"81$0QG(ED^A*M%T5C$F51('3?%9DKF.*A1MSN;V3W JN
MNRA,YU>L<>.U7@8/I].I%O,)OG#*5>D2\8]8[YB9-3!$6,V+[:UTHCO.+4P%
M19=22O<3)C;8?$3:F#MY?Z4'^47W;Z^)K1S_]=\.,7>K"
M[2LPQ0C!"4/+[-Q1$[CC07\S5 <-J&GY4T._BALPJDN<"!18'/C6/-33F& [
MK5R#RXI[%,74H2L(C:I%4*'=;_]9J.R/!K.(_5U$NZ+/[NTOF#%*4>3\];M_
M5[6;%+2C)A+,HQKR)2,ES]A<%]5LY "8A6*0% V$4M :A6H-ZVX@KB2$X""
M;+3/^C@8B"G 5NY821CR%?W0DUE,;HE9HV)#)"+5MJ5C:VTQ7:BI!KWK?P-'
MO2EV>X38 ZXR;R@BQYGHQ&4CXTE1J9*'/0Z)[93PMP/VU@[F4>5!W'$0*ZKS
M,AG=8'-.ZNN'_/BII;U^Q)'?2\/ZGZ-?RI^_!@:\2TOS>(KQF+->/8):A,M\
MD9V.:<]3L^-[E$Q,YC27OB/C9I*QI>>&Z:\XP0RG(D*CZH[[YJ==+$>_5MHR&Y*%/8W:I7LP5LT*Y3+:PEQ)37+2219!;Q-YE>#&X$M%*R]#RT2D?4S-89.PN]TQQD-1G@7Y
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ME23W*)6 /V8@B41#L3(6$XV5C^9M3N,H2?!KMKQ.JF=Q7AM]$*^;R-?$XU?U5ZC)MAO*@U:>HB5&M)5LT R&./KN
M9>9]3Y6T,1SS-B9,Z]B^910L(:'\NH)A1LDQU=R%Z!GE"N*M:#09ZEEL^M@\))5$VGYP/_NQ5!4%/\)YI<*!CYF.9D*I) (LQ@]UHJER'V0.
MT4"%2..>MI8( E'-7+)"+UEBUC\BG06N?K8E _^S^KF %?L)S6>@(?9P6PEJ
MNK"=-?#2.I\604->:9)(,GYPV2U)5]!(K@\_B4S']Y69#R;'1_$&?C&S6'".
M/2@2FQ[$U2C2"
M;*8-$28\(O!*Z7- +BT!FB,-,I]^$6OE4'E$^A4*(H5%T)W,(8_^T\;G@EF_
M!FTBU\TELG^]DJ_XZ7_N59 [QK%:_[]U*8Z@J>H>M@%U15-YS]E8MN@;9#^0F86'RYKK[*G50=)Z="?XQG%W3-OY$N-0Q74[[:6VM<]V-Z0]Y/SL/
MW0PCYFM1(LY8)/'OL$^ ?3;;Y%2"=2D2(^ZIMH]Q(CYBTCR[YSKZC3HW)Q,-
ME@CZ(WSB.]18A./7:Y;3)L2GI1/)%191PE,KEV+5+^T070"KJ#1,=%3]D]30
MVEUM^J::[*)5WST#+7SR.*SV]S5)NFR6]GS\YLS-UAQL'^I=SQ
MSON<#P^Y76SCW?WJH<[YP]_%5"6@*7&4@)#J9#*)!XAG-XN+/[$UK24B7_L"
M9#0(LZYZVY7HQAD-3I*7+8<$4\1%E:PZ8M5)_!J08X<#HX]07ZJ\258A%7X'
M7 >'5"N7^PD2@&/!>7<7-MOYFV\MW_Z% .2TJQ9'Y.EU,DXZ.BCTJX?9L( Q67"-$P@H08J(F?;63VH&QH
MSU /*\[6\![M,9AD+5"!RJ7] ZN[;X/M1U4(+,29FH-BP\>N2O\ZMO$-U00X+2L,4?&5!S4^\4OY\7.WVYP@G9HA)/ 9M#I#P>K7F?GD95)]XG$S3
MV2.DELBV#S)/.*]),(/TKU:\&6;M=B_4"79FVFD>MCZYOI^LI#9,:#F<9SD*% G:_?7RG9+(7Z6SW-/K"6H];0
MCJ;A6#0U<:JJ#,1:L^U/1'4*+6VZ.&93N8*HY/6,$X(5IL.H!;'].'1P=KZE
M\?IKBWW3K+^#"$]=HB^S^1\@3^K /52[K[J#[HQ
MU&TCL^63=,#+^CFRUM8 [7ME6.3UXD+M.;0YLF$H65H8%:2F5VJQKAMR$1\B 6Z+-^*_**Q]17@V$U7$GJC
M&)#36F! !<*(9$L!K6\6ZU#6A\)8N[(5-+1F)SOKPX,5XS?7\DDC-J:
MY"8!YQFR#&>5H 'V6;Y=RHA+0+J%+@\ZT"0F=H-C4\N2OIGYQ6M[L+T="D)I
MG@H]U3 80D?>C7BIE^I%H^ TX0-2D2?AOKD?3TW)MM?6P'G:2A8Q.^]"RC"#
M^#Z8:??GEF4:/5,X7"OS#$;3,,FJ:-#.V,HJ15-$8+IL, P_GV;J:A(>XSJK
MIMI;U5P%]*4XGULK'V1CMG7;'&>O>L-NFMZY8.MAD35062\LVR,!U=??).?J/+W=3*C033\?\^MGR5MTI5W&5"6(!S9140>M[4XPM9PA^DROSA&/M/>93?)N@^42P=4=)Q?CB:=P6:%JBJ@P^U7&:1(M0<9S
M-79?X8#(3Y%7(2Y:%E1)8\?1),GS*%:++*]W$L@AG;$-#22=KC(:K"%_U6(D
MN<,^^EQKKL2%% YRB3Y,E*MMP4T[XOO1\F'& ;?S(98JF24.'"+6&5"V<@76.@*$X#*#./AUU)!6[@+B3>*C
M_&]O IFVDOE,N2R3=$XD6JFI]X=*>4H/_',$PACO^/.OS"\K/I=FYCE:'],$
MX]*B4'U8// CF9M)@U9M.$2HK0?ZLU>P_,&WRJ\>8[O^''KHDKMP)V0?W8HK1M-53H41T8-,K-D:M?]3
MY, $-;M.X8_,BE*WY+R,MHQ\0BV^!,;9_63ES&*I%'&Z2,4)1A'_DE\#:;-@
MLO0HVJ N1P_VLP)@&;9.
M!$?JXSD."RK5J280R85\")/[P6GZ/;1,I>M7LX0.)I.:LK:;Z#WRW>:]WR .
M8%C_ -RX0M 4#:TF,L@3 /DDHC?41MTMSXYK*)Y%=?K%C.9OWI10M.$\C&B493XEH=![R!&D;B8(;*,G^C':>P=RFQ,5U,4Z9)@FGOPR7>TX@I-34
MJ1 0\F?SC3_ENZ_M/!KL$E)BUQR4T,IMVC84SS%<(Z86SI
M85+\D'5D&%Q"O[)REF[>_5_!)KSLL!I+E#/A9 UM7G./S_W\46(]S2LCSRGO
M@I.8B/,:,R/.X;
M*F=X3,QB^MNQF47 -FO(CT(J) GLY9?QDKW/G9FRBAQ7'8RX9?L4VWYB!R5K Q!#38W>*)
MKB;4336>BB$53<9Q<'+T,WXZZ=RD9BNGW*16@H@DMI-D9GP3RS)%42.4$=N_$*,<1,O,U?4U;=_7?2M(L=7ZED!F)-499I[J6._"/
M=3Z\V/ 3_,_G!#IXF'36?(K6M3+@E4J/FR#6$FBKB6@=WP_5A^9)YD86\^/-
MFVZAFA47]]LG$D>ZE$$N,4/'?H W^F7;OK!=1?>H?:CU(,_JBWP&(+-Z#++P
M&;J'5=PC*ZQYS_*%N9M)5,H7$68#Y!ZAR$]<2)0I+% Q$MXS^^=>?]))152J
M]IQ,+AJ8I+E9>_S?_DC*UVHIZA)$[.MX^H.NNGN,PNH /ZWM,^1EM&6@_J,,X=H:30O<8MR3!.TCR&ZBBHTO_5XSECV
MK*F+D%%LF4DD4TXDF09.$&"3TFUM"(^M\4AK^@X6;P$B?%8"'ET@X2,'GZJ<
MX9"_A+XR%B( Q;TTNQY]3&A;MM\$-Y"YU2Z,$VMSLQL&:!TU\A%I&'A#IIL4
M1
MF9=D:;=D+WT2:_=L=8=9:QP]@7K1K1%KVF2O/A8X]LMR[PGU7!K4[J%:-9OB
M531!'NK4=:(7:MK5_"R9:)1[P^FFZ'PU31*T&EZ#O8PU2:5UPG+'/!Y/H7X3
M-C02U0P2,("(=-H''?_O4>#2UL;WY4_S+6L(&OJC#[V2$D'
MUQE->>"FY\P"6;PRE2LP6K:U*1=7P[DI'I?@&B5$NGNX.M*]6QI>2W2P57;.?4IDN< -M5*'F84JJY9BW-H$&&$B2P
M&A'>OT.X2/&8I"U/E =-!\M6]3^R@3S#Y0SJ6WFC 0BZW+*PU:))AM[YFN[Z/\MTG,6M"/SK4OZ&WHG$?:K
M5L';3LX,HD]*.=> 8V\-,6%FH3M0K"'..>&VB5D7VJ0ER#M%&'BGL2/3P,QF;E5]U9.R-0X00D^IWSM_:!GTIE$9%G\&/V5] ]5'P
MD9X8Y'O4]>#&ZW\5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M8#K1WQ+T3D'CXZBT^]?)JF(J\C889B20K"(J4N&$#3,\6KX!HNCD"2>: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M]8XD7Y4C7+/8:VK#U".V1OI&"B61'?/Y(>$> 3:[).I
M*)!,!,'7U7JA%/7F3S$YODZJA;3BDMY D(<)2[=$11=ELKK3#;U3R*XC5)()
M92%+@-E4,S(==W+,LM3O-BO&P$GZJ(WD_G>[F@^_8H'I!3=(GE[MQBP0!%,[
MP1K3N&'&B[9AAB5:,)><*B.TNF]$XS]P1Z= '&9Y>/"(WY%501_S^&'88#JV
MY20=_86SG]I^6B"KT-U<8K;,HX&F&(@L>E)A$!;MGU9[T0[EM+@T:UG.?M01K8"]IMBPC664)L?=L%S*'>E1#+8D"HN6H:CSIV:[>+PP '^-G
MCG@WZS;(T?0N%+%0,>=3U"E&M<_?I6HB9JAG,(/7W:KWE+2):@^!/BL/IFFO
M631BO\PZ!Q3T8;,;"2Y>01OU$5181Y=.P.324< FBDO/$)!4N:,W3.1-"XO1
M7/MT'\P+\TYK@O;*0)APT"?+Q V"S^'R)E$QS4BJ,%AK0.NE>F@,Y4W0"K,)
M'?L&&HWNY78GXR@UH]6S_Y.H#,6F>>"'[S\/MB5I6F[B[RS[& Y/WG#.K:0.*T+5-KM@"4,R8#XVVAX&3YLX;F:8'8M5JE@/*@BJM>*QJH=RS+[^H.&BI!9N#O-?:-_J\HWKIYIVW;=^4\>B_;3!Q$?
MT^.D)I4?>)24D\3+@TQG$CV(=]6X3,KMJ9QTM]UQX$711]42TK5C'7S=A4ZP
MFYE+1X^2Y;O^2B/4CQF8D/(JPM"\JN;948G;=V\E?>0#8 6C"X.=I!$&0M3GPN=*)B;'>I6&M +Q@SI+$O;.=8X;6)X
M74>&7&J?3DY5T\';Z9AYL*:SY8C9;]6TWUQG7C=HE$*ZJG,JA*!!04TEX@<2
MK)]1&SIGVL.1+VV52G8-2*?M+#/#QL.A%K2;9F@2_-/2DY@;T5JHB6%IM-AO
MO;#4[FWT/!9':^31Y_2O9OS$^.T9:CIE])ZM%)H5=Y&OB9T-N?QOS6(0VJ5?
M4T=G>/[V.^2J,V2D9;PX/WMA0UTGA'V!:A;R?M;WHC[ZSVT;^2K*U$2P-1DF"[A+#3B9/-J+OZ2_%(^^/H]2 R\PJUBOAKF#'8
MPE]#VY1[-\A:W0I\;KM](JJ)ZIW8$YV'S#>%F,F3YK$+3G]81 NG6FC,.V0Q
MC7E%E:[ E3S9(G*ID^6C#,$"! &RJAV M1:J=MTL[NNIK=RJTJ=R/]N WYMTI+?_^:&9U#1[$ Q&"MWJ# JD==)/-!EB4G1FSY
MGA [EC<$*TR#0HWMY99/Z)U'SR]"D<
MRK6'VN2"D6^-HR$L!9E&JK7&PMXQ7>^%A8WU)6HVO$X.5O[0S76%&\.NG^;6
MJ5G*)3=!0I/=G?BC 2]+:.GIDO)YF(V90%;^MD1HX/R_MRWG:0[M89/Q?ZH$8:SJ2;+N,I@[UI*\$"J)5)W<2^ &F16([+9E.
M18)#9@C$;U<4UI5PB^5$PXLVLOP26?T;KKZ&OO@QQ_=&S_
MS=')8R3!((^.'0(,YEEBG6/LI8?)6 35]@T,YE@]8*VE& AQ40!8;.K3B;V0
M#=.ML=1HL,PD+ZTMV1_M8_I-CZ$XVX5P9V*%H2N;MIAHL9T%?#"9RV-<*,T6Z14EQ@ DR^QL$CJG
M?(.Z1\C\J@J149@P, W+='0UKB?/",MC]"@=G-6D2J,^@K$D#PLHS<$K#>8_E!;%[T1,,E0W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MJ_6S-D3/R/5F56T(.!5:<1?4$EWQTDTQ$,X\RALKS;KUYFQ3/?EEWK>VM[P4^*S(N+/NY(%AT3C]M[;V*'P7M2IKR_P.Y(M$5J\O0\KBXUINTAN.$[(S5*Z+HLK)Q,_]G36WI\5Q6.G)+IU\*&9?]^]\L6_
M:W;=BD'BK+0E:9XB"$(V?[\=87;40,D1Y$1;-1W&$2CC<MTQ327WTS>N:UF!&BLV)NREI?^!I[Z=O@'=^Q.F3>\,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MP2F5/7#S<_BG5_>A[CZ[ZT?R)(U*7&]D
MW<] =B$M<0X9/7#RIJ3U1.+;W@A0:]YD:AW_1NZCS#2W,OOOLRV//TK'UA"O
MN$"X>PTR\<8 *3HF6I:/3"'=#MR\Y91'1COV;1/!U0YU
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M2:SEN. 7ZQ@P9$EK.Z"<7M(YLG=F1R%]X8Z>GF&""V6_;6?,G688=BR75HJF AGK:X#U68>
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M<""1;'?MLKJ^,8ZF0Y9C>B6_#LLQ6M,&G5(M<+)@5QFVFQK%^)#8$XE<=N;$=:T,=C?\]I.AQBXG8S3313EO?.M%WF
MMBWQ9(V#$\ZL7ZD7*9#J A.TN?R<>QO-]@P8)QMI;24BC\(4W"%TE?]20)YM4
M(T!J=:14->.-O+O7C;A7@LL\ *H[R](O26B1>)!5.E8 7*%=8QYR Q68O2PT
M[V-+HZ$2V?+?$R@Z[($G+*TF:0MM*>#V%;0?U4??Z4#-\O1-FH))L\_
M#@P&^Y0GQM@NJ2X=GU?I\J3^)6OI&67 9;U@RM8_4\?<.M#D;&%9\@A1$Z^D
MUTD%O*S+'F-N1B:2;#@*82/)T.)X;;9"%A&L[AEF/)?XN=UZHYH0!4:T[W3%
MNL0^^6.HGS8EMJ% P!Z0WG6W5R,>"]A9[9*=RLYU'W[AC3LU8Q^GJT2>UE1-/"-U'[7Z0U54(
MFRT3@#FT3.5*K7AJGXA,!+5XZTC)HTH_VUE$;%;TS&\Z^TJ-Y_!\7H^*: 4I
MHOQ9V.-ODYX*0N!677LT5'(@$NR^)EM+E!X'-]089Z58;A]/,\5<],"LD2!^
M4^*?B%9!LX4\DU3Y40+O+CLN#J@5YO
M\D^!-V$B904) V\NZ"5VX/)PR%:FS?&PX[
M#WNGR,&@\:!5$R32B:6?5C7> B4K"9[.YJQ-#&U_SRWD^!&61MP#U6W_\@B^
M\*_GGQ[YCRW.^.U?JP8E8J#G3)/QS(7F*V_G[M^^PU@K+7QOA8*00^2U&S=?
M"]BVQ^($P5,YJLT+ICZ
M<7!W=:K_:;/EW+GF.V^-M;-O$!H-))7["Q;=.V7BL?OO@+[USY1"[#0Y7^X/
M%&O(^_!)K60NN?X3+3CX$;C0':[2/NSU^+H\Z(',MR!NUQY J"(FRG57YIF[97G!> =H^ZB"F*A Y5(%GZ7D%E>$=$0\RY=NEANS/
M!.X<=_+,2USF /ZF[>R2B:>>!U_@#.(L,'5HX/AUVDBIIN1I.>&$M#1#6#3,
M"!#,VIZF<@5JDMLL".G,E,DX44^IPV3#\H[,@RQ]E.1B#;*0K"K.D+'2:.^<
M>,@TXH"F;,*[P-V.F0KV1ZU7D;V$V)*E^P#B2.-2MATHK#)4178@7H0/7811[UXCS_")>*7LG$%^M4/VS4W-](7?L5K1YA@3:S[:[
MDK(2=6J-<#O9=^R=>K]; KM=I;N8*16,!?D8PS[-()9?.S^0V?D>/64(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M$BM%JFB1RJ5JR )Q$LY@%RBV)+,I,\+"!YFJL)N,PSO\/O['\Q^9JWU_7R?
MO?9:N*&,6D^#4;\&6A)\BG""(XB3DA++-_>&UCM9DJ/W!V"(J_GT"_F%M 7'%8!'JNLH\$]Z[Y& !LAW]_/ 8@KF'D!5J5V]1LS+%Q2+7KF)R\?=I4I\>
M>%\P;>1'1/;DBO3*YZB8 9:!])8U6/*ZS:*V:#>%M\"@ AR(M@8G8D2Z1&&[
MR 6L?8M6J/! ,ZNU,UTWD("X:"*PYGV2)$MVKI8+_Z-/I?=.UX]ABWP%"^'P
M:CIL;!<02: ^I(27DO15]YQQ(U(W-;Z9T7'3Q$X9.C%FZ2J>L5E6+QMTZ&V[
M2J8:#8K@"17D\-%;U!**E&H$^#/P$&QMZ$'_.^LSWU]J
MYTII1'BX6VK3QW-!N5[O^!N!WRE,9B,QZ=1.7$&:V!L84*ZN1)TO6AHD9H/E
M\"HMMC$+$]7M CGDRG>$8\'T Y+?]U&M-#DU0*XT/"#ZM/IU46SA'41"KB41'?JJ/J[.<2N\0X;N8Q2*W"3Y$;FDFA./O\1"L*8_G@Z>C
MUSS%+.YH5CE)RM&)_#O;
M)957(FVL(OK<=5'C2>F6,&AQ6OQP*SL(9!$Z@ZDQM8F=XCS'8^I+K7LG1J8M%K\?0&9O%8&MZN%TY<''WCX!,1B"'M$^X2B[XBL%LH9^22O&!9D91OK$(\60K2[^R0
M*U[S=>YG'AT'KGSZP'P?:9U'Q@(+(9M\2B"*#.18#7JJRBWKCTP*.G5
M\==KB?W&DDSO\[2 ]<))A,VH@%AA#-"PIA__)&OSO_S-E4W=\/K[IB=7GLPV
MI-5-M-/5T51',UOMFV%]A#D=#%M"M8\_(S0_2YGS\NAY:# [O-5+>D68]KGLQX,DJ@>.9I5>V;O&.;[*RI2V>>XHL
M$P[I,S9XR6A\*(L&L#=R=$J?[A1G8=^M@ASA#=/JX$F",_X';[NP> O^1'EF
M/F_+YR$EGL\8&=&GJ@:0+Z'7U6U\;]!S#W2,[>^F[,B<1B)&K:*6@@E+>>E)
MP;'SY^FO?_+S6$KP@(:#?SA(; &'S,UG.E)6'R4.$MJ*1QYGMPDV!:HI14^*C6![#$V/FG7?. >@<08IT"@S8$A!->AKNGS(["$B'!
M2X^@7.>@[AH\\0N);80 O[8VY2'A)6OC_FM;Q(!VA:PUF/+KM"X?I#KY#M.5
MM=2JH9=X5XMH08/(D>KQC,HG(_"(7?CO*@4I0$T>[P1.\.;;9!B;"V38<]*G
M%KJ"*LW"X*EO?,\LV6<[V##QQF]R4Z]F#6IBD%MF%S6>'IZ4@#I4
M53:8H*1\I4:!RR=AD

3J@YH<:5($=5%HP4#NO9+%Q=2 :MZ1N99#1T^O*(S$-PS/1&B&6_A^CXIX*,927$6"M_WIH3Z2A4>LZD^RZAP[0P
M,SE+$WEG%''CN:'J)9)_P9^#4S2,")H:P>4C>%OG)6OE7W$??#K4>)2@B+U6
MW?'H!-\?[*Q:(%LR1*ZS!O$#7V5E.$QAFB$'>:S,*ZV: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M_241/Z8/<8BEL;RZCD&!,V+^%ED2A+Q)P(;']Q.N5G2H"E5YD\:$3TDTE
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ME9+HUB'^#:B8M-)DC'(#F9%L6>G(+,Y$R=C 0W!OSC'J_PN*=BJD-JORASPAM$88XI6M7T0(C
M3,J(UK/]:>-W5*_8?O7XWJ<*&O$92.I$'L0(1B R!H2CWS%UG80X"AQB% 7'
M, _XZ,ZI"OB+09#$#:TF?4BE;50/+]R<=YWO[>#P+6G^:>+%11HBDZ2OV#Z-
MQ'W(#4G;R?=- >4B_*O'Z0] 4RR1_ZEM,: 99W05*S=&H3REM$&3Q3QS_\
M #XWZ=E.0/?[2UF*:)WFI#QQ)\??CE/'68(CC2U3I
MN1HV%O79Y&3C;R?G3U]"C@F*$I'W2U&E8RQ>]AAM#L.HRD/W)#68HI2K]28W
M=DN#)+F2">QWVK6NP7*^AKW,G6[Z)P/7M '$%W8WG:YN^.>N.<9$:0?RMPS/^^N?HCQ\?1&\#K81H\G_X_D^)_S17C<:+7/G!DA!JT421=J-O0\\MV2&@
M:_LM/(_3]E?M7K6%@T^2TR@..&I1+W@7?_13QLEJ)=][4S,FFIN>*WG65%R$\[:6;*I=BIL:
MX:-@LS62S 1^UCW4K]J@7X E=F#,?-0-3Z&0JJ/C^'DNVE-4G\C2OS:Q54&
MR>L;2\QJAMKVMV?5F14N*X^TV7W))5\7D*C=XPR)RH_$!'([WMLF<
M^= @"!."&H)M:!6YD$[X(Y'8E0SLEFZ2Q,#[> +BM [-+LX*Q"![IB?D]K[_
MY],6^^2 )M+-;3*T'B@MLJ(0:"$WZPTIE:Z>1EK9RXE:)2\*O[JECQ],&WO(
M,VO"EN0.! _@BMR&KN*S'L(E8UKOWGTO3N\U7&*^' J:EB,GN240BTLMAW=,
MWX8#<*N.+>BEW"7I'9 SWT&BLF07U'^78FR1XD^JCU"=",Y:BL.
MJ8(6#UCXGM=JE7^$G374-!5)?H^B[%NM7[ZK<#?R0F5I\OMIY[Z%[+XZR8LY
M8ZDM?<(HRNIB2!Q;;5O/=;7%;(T[2(1<#.IR,M1L)/?A3>T_PANX'9 ;&"GB
M^SS[\K=WM_9)3H_ ])U"+6;"+=?M=YR]9:5Z?]I]U*4)TK,U]%<.$!31CF9[(#
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MF0[D1!GDFKX1CNK)=&2Z +ILR@SJ0AVU6)RO"286DG%X?#G^LOW<<'$=KHK
M4_5G:+V27430A1E<]EI=X"=&=@OR,W<\PAJ:GK*$@+,]4ZYBPMQ)D[OFS#TP
M@8G:E4FT@KV#ZL^!,SOIF&9:XFLM7/>GZ3=,[>[X?Z_\+%%T%.\W[1('7/LQ
M%]Z (<#7])Y+^$7UU3_M&H3:ACSQZD(M?;N*-OM1
MBW\^D<(GDICN9'"&*%I4EMI1\=F,3Y&&3059(
M^Q1!FJ"83HW9>=+.HZ9ZQO@#W#()-]&RK# 'R#I":X"Z96@#L>Z7B@W$P*4-
MZ(2K>ISI^6Z0>?'2)MZR<967>!VB+4IT\X@014VF0)A["?KM\B@_HU,82KD F']_!""$?=WU&%4BA$
MSLQ7%"RS61IAF])\&YX_?46[2*)NT7((5GOX["V>B^Q8!LLPQ.DF,PC=Y"4C
M?-3290_2+0?P"05=R\&C>&*J6*=TU$>C[SDZBD7+7/%6]'.7^!7-6C&#J!Y?
M85&[SCH^ENS([UZ18&G53,\] NQ#D*'B2N?5XE
M^??ULJE(!/\@D;<>;F-[XG?5^Z,%+,E]I"3V&2Z"9*UMLOI7$.HB+1L^TJ=UD+S4:3<0Y6U=7G ,/BDWAW\FL)/\:4H2;^(6:%W8[OT(
MZI(S)XYR[:D9$>$/-:O&T+ZA.=9'=R75NG-\%8=6O_/;ZKJ_;[1&D2L][]3=
M.3#*WKXQR;K_W\OW+MC)8-R)7L3D0.U(/G*2.%:A=B47!#/GOJ&MMN=;I+2>
MVRA9J_.P)BA9OW85V,S8W+VXW7ZB(OW/FU@"Z<;":$8M[9]HEMY>P=R^HO_?GOQ8-AE+VLENK=I&Y8TH"I"A%GJ3>=?)9:N91%\FGK=3%L=E4[
MY,"5DQRT=LG!-+X3J*!606\K^-V:,]9MDL;ACI25SL_^E,A0H^[MH2?8$'K8
M9CJ[G[]\3\[H"8_V9=^7V7
MX1?+"<[E;Z>YF%C7G+CCZD["(.=66/2)"GE ^6XB17%^LLMMU&EY/[Q^Z8&\
MGT:@T=V9BW\;6?]K;IWC7Y\(XR07Z(ALG:S.>&&X7\N05&X%]EBMTSO:Z68)
M64"47$<@Q4DH@;\"8;& YC,W#OK!\-/H82R[Y*.SUI<0%M!G6T+3N<"Z2[M[
M=FO0O'K0B>N2IBL:)'",-;#S'KQT^@>M)[R][[_UB*U$MRU#V")SI.:"FV9/
M(3I1!X$KY%%0BWKO$;J0<48&&MS4E*Z>O53WFFE%=)%'LTS9J'^*JGJ3^ TL&D+\(N\,(?I W&YV&Y=G8[XI]W
MA,&H1.$7$40Y.1%EXA-G3
MA':*VQ"[3+43N%;#.YN(%&:=^.J-'7[?T2RT9ZW>);?N_W^'^4$S;_X/4$L#
M!!0 ( !>*V5I MP,0FQ4! (TU 0 - :6UA9V5?,# T+FIP9^RZ>513
M:;\U&$1$10B(B( 0%04M!!Q %#!142E$3"$E* @I166(F%)$(H0<%1$0,0XE
ME% 0%95"AJA,RI ("<0)PQP(2DBBHD#,.0SA0)*3/KYOW_OU=]_J[KK?[;Y_
M].JPLEB0[0#&>-=.GYT8'1T=S"_H#T;;A_'Z_M=_Z?5]
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MX7\)V;\#^Q^X1)AYNCIH\G1-, 2,A@\7J@YJ,0U;.,V(0^
M'WG+-"0<[J%YZ,OU5+MI(?#)DQ"!Q[:#BZ3#^RL=<9+XMP^YJP+V^JXIYUKKDH40>7OK!7'E9B[E01-/7,("!NT).933-!+)G:#''F!?I
MFZ'LD4^J_327FUPO+FFA%E-.6UM$7IB-K(57%%)O'J@%'V@QJ2<.E5^5[]X
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MS2F@-S*G5L+H$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MP$C/P;X0VZCWEM?D[JX!O2_2G9L2'3D-[M[X2S
ML8--@UPM!FVL%C1KZ72^V"J.TQ/?1'H:E J@N\Q"-D4%\R_7 5)GW3QS*:>9
MD,XTDH"%*6I]\!UZTJKRDRR:*5B=5J$*^7TB0Z434Q3IGII6\6&;PJ_B^;,N
M1\!]4).''KB0:6.KR:@+4FVE"W#5SAEX#YJNII9N0O/3W/VFCI"Q4BSU1^Y*
M"/I?\C=WRBH["4>)YTA&<:'K?845?O;>[/8)RGQJ_]B/^6@ (4@>^
M$/_:*_ 6\ZX&"S1X:#%DRE52!5%.1DMZ+^P#>>]O<\7-I+\&*OC)B*7:[&E;
MG3/Y3K2E?O*$8E9T<$M385K?^O/<+-]O6B"*)(A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M*2G"*]_:=JM[_G6I2^<"F.C3[K3,-].;9QZ8L-7FJ$@6/A"O-B,K5\-3(%MV:3 TG8+\3AJO#(H1P)$ECK+G"^H@\",)BUF3E/>35(?;@%U/3_!)?Y,8$Y5
M/D$:&OOP6W9 5J2CG"]R.A2L7J+)XAPBB?JVP&>UF%DC<#@?*"===2D-4&Z$
M^U0_1XLK>,'W(K.ZR<,O44_V
MG%EMMJ@\:F&#G2I,H?DE[NH=>AUC%A/S<-C*>F%$>.^\GQ]X;,IK#\N,ZW_(WHITC
MH2;*4N5Q:+*;X "5%;689QE_#HC"7;59 2J:Q?/4)'B.C#*#FMO,G'6"9C/-
M.H=?2B/D\D4[_KBIQG=7QG@$5'?0]DE>M1ON]9%6A2O)MVT)Q]!M8\[(JK-0A_($A$U1;X)MP+Z^D=OS?=,"[3./C 4
MK5Q71DBOBRA2N]V0\O<"*=.X5%M L"C U],2TY&E;\F[. ,#&@QO;6R>+D_BEW)E!!>X%)$XB:%=0LT.1!Q^83:
M7"(8T6*J^JGAW'Q'%2GCQ!&DH[,BU\XW:<5'U?93T<8^J^?ORI(FWC2LN],]
MW$6/&%0P H+7LD9V0=QE&[E\"W5"3IZ_LES6DP4481KX.BJ?<",@7BNA:<.
ME+CC,?3;Y(;L_,V@B(IKIF\,]?(&*5E.<8MM6(PV8);F(A#A?,5F)8R##*3V&2?JO,#&L:T=[/545@/!H.X[%7%FN&(7'$09
M<79_)I0K];Y8<5-"TAFNN;+-[.;NNKIG,1O(N6M.(5\P)4SY1(T$ +-3<]-,NPE]I(L[$5F)6ODS8#8"-XVN+^59DVOTF(.PWPP
MP!_2*Q$)4RLU1-]"5RMFD47X@SICD##
M3ORB(5RYOGQ0Y:5VUSS#>U"3I87<*DT.(1([BV8'ZT$&+YB6SDZ?(6(*A^R@
MQ9@6IM=ME1#-X,/MD_X5S[I<#&=-V6W("7@=LWK"AU6:'$0F[ 1\.15:C-H,
MJ]RAN547 ?(E#![.G,KGB4WPSI%[J>6-=&/8'AQN A:I_7'G'.6'GV5+]U07
MPK9[(,/^6Z!R.;OJ!L$L>F&X'W'-CY],PO:S/>$I-,I'8$MG[?BS:GK_335B W]K4C0!)C1!3:;X=R[U.' KLR\EDET!!G >Q-#'8(O.%M'
M)73_[H+-,-Z/S[[[OH>T?^-VHU=@IW@>XH$TB,$ <;+8E*ZC-@<5M:0*=E0M+913?J_SQ)F=:4>(+8K>,255

((L$KF#R! 6T%O)4,Z?)S@M2+=M!@>=O3.<;]I:MV(@D](0E+_Q.?B.L_G#5:94B]&%=_K'%T:Y?\A\2R*W2JLN
M&'X;MKID/[%"%8#V[B^86GI9 /I,GT#Q*Z%K+@(+KE9;.SI 3(D (/M
M%$:S!7?T7I#08J! TAS1A_=4 G<^?T6%T-SMUYMQ_P&DC[2(C;QC('RN]A6B-"!A>W58OAAQN#D9<\HB<#&^RX<+>09]SX0IGIZ
M)"86#KG?(X5$!>,S@6AA$'U)[>/V@]ZNKT8YR^-P>G21&"22^GR1N0$RIB[2
MD.^A>8Y?##1LF^#,A?LD@JOX1M5'+"]97ML_H.X_0!QIOMM%. WT-N(D@S-K$DN8<9Q]JJ0(9NE;>/#B:K2,Z.;B8V(0;>BHF59V^GB W7U
M.Y;DM-V2^2S0578,<-1F'8JDR'^Q[2M@O5NA*@=TV(F]SZOCH8!F2D
M2W0W>'?VF7AS]Y-"M8548-0W)(\IJF??)1?X/@Q^+=DSF?V+* A
M5(LYBA4Q>7@'V L$?H(?##"N=*.-[ND#45[DF\&?0"(?F+,MMIFX^(M[$BK(' O[#T:5N^0DM2^O,M^[^_R+.:3? 5-.! "OY',%#!P8QKG*
M>M6#PK3G)>9N#QP9(P_]6#'T^KI.D1;E?H;X!RG#RI%&C8@MVM)Y)!S=F%HM)M@':-<;=V[^53!Z@Z%&;"08T<]"N0#KK>3O-
M08(U@$]'3F=5)]D]9,]K_;"SLA!#[T(+TYP03;F"DC*@-N4,B.7FT'!0^X0@
M/0POI/_@Q"J&X[=TU#D_?!_%MH +I!RC2&/O^U=N^2G%2+>]6MZGN/-:6<@1)"!>$[]>MM@@&0H&S5W. <$UQB/IYL_DHSE/AA9:07,;8A,?&-
M8Y'!984/#?HY\X]%'%]@X")'%[^&WL(!
M=PM0KI^%2D1"%V).VPTRTO!K-CP9^$ /V3_AY[!'2%]/%?,L-_,R(TM79@2V
M.P<%IF^=LZ3Q7>#[EUU3 M5&H,$",4-:@>H(5(=(6>H%ILJMN4W])E"UW/\>
M7*X,A^PS)S3D76V>?@.9X;MKF4U!.7N8 Q3+D(:B^\*<$^>6^Y%V_?82']2S
M_]6B6804SL S9H6XB07;3XZ0I(Q+*%O1%VDQ7!K21ZI@7@:.$%)W@D/!U2]"
M"4UX76AV&VT?]-G%SD$3TIACMXM4+JPM^(9X1QUD)N=<]31X-%0U7/A5]F-%EOQ!O6\&<\D.6Y89FHM)%-4=^MHVFS96;6]4.Q$7\.=5">U5;^>"L'B4P>IAEH'@)HHBNKY13PV&>@!Y4,XL=N
M([&@8B>$+U!YAR"M]@UA>/@\5,#+2?GM3(WS!;IU4X$.MAGX]>;"O)NWSJBVX!T"E0)ZKVDSGBHUHFR"2D@%E"L_5Z4@I:70C.!1[^5!;
M7"B)V*[VD]W^(RJC! @/)FVX7EC=^[ESPGJ/04CZP-/J9\\NS3EZU5T]?1,Q
M&$;G[6@5*2TP*&P9C,KM.7SN+]F6K$:^Y@_VVB@M9J':7S)>6M9_,T5\Y,0QM14D @M*.OKS?R3'J49]5/_#\I)D##&2""E(FKJ!YA@;@&@BY]
M,1DPK?.2D/KBE3%PGI1B]'5]T^J<^',T"ZDA?;(I 2E8/;GPJVL^X^BO)G?.
M-IP+G_?)W^IVJI(,=S/! Y2^#.7U;(D3FS.7%H\>4P0R&[285,Y\@=*_(TZ
MBYI69T^+DT]?MRO\P>GN\1B7%Y[#QU+L?CIF,+?V'+:X#KU'CZ))P^-H.C!6
MY!BFUMV#2KO>!(
MEG".U"'J7*)#\8'!O(L;RDW?A0 -1X%#5N+>FWR@\H&01S+_0IK#-J/M;<-C
MU?LS>+AYM*@[L$S"Y%DG!G>XD"ESU5M!IZ([/D5?LE?%%P?;L4X_+@_^>O/@
MAZ4!.D?5*^$ T!F9FZ1R 1HV<0:R"?HT ABAS >9YVA+90S1#T)E%^@V4GL2
M?(?KL^(&AJV 6.FNC.0 FAOD=EFQVD5@1*60_':.JOA"9%Y-JG]U?597^J]-
MRT&&,V Q:KDN@"@@W>#"9*[1F>'M!-J3Z#
M;II);DPHNXN* 6D"-2L0BKA"MOYLPW'Q.) 6V^Z*YX7F@.(I9/LEW%A7*6"]8C&!A$_:BC1V8"^=RF?-0<^#1
M#,+E+Q(*KYZVQO_(QO5R2YK*B+):@V?'N]]) ZB"P^4[Z1 H5)NQE-9"((*3
M0:I,X?#R8G=IY!UWT3)3^S@K8Y:<[,"%_>VH(MW!Y
MK3!&7E%KP-+C;F \;&&)=BE\^0@5KV0B,Q10%;* 9B%UDT)?/0AU4VZ0_!"
M,8>V&[[U@-Z6OPF.CWWXU5+<*)Y!SC< D_+JFYH?Q!4)XL+U+SL==QK/W#.X
MY\+HRG'X!-(QLRK_B"/(X+%ZO)"YSA .F9-;2.M1@$->)9[.!*F;A2S2G^D$GP3(%P"UC&QGEN/AD=)2AU0R9-29R\UN%^>S)L^
M<<,U)L@O.: J-; SWQH_KJN,V(NNU4E_G3,XTJ;:1Z/ 461HKZJ9]%1X;AF4
MG8GHTGZ$O2&MM(LP0:-I*;M]*/97=BT:A%S-LX_H\A>1EZ1YG$CKH#U($S3155=#:O);)VS
MNX*KCI[
M> W="T'U_1-%,^N*2"P?@_*!7K%R$(Z2 6FDQS@>KIM^W?38NZ(WZ,6WUT\M\Y<\J>L5;U"0C)91-H!'9WD55I>" MIL+^P>B;#$R@$
MP.W+X18)![;GOR!> *PY$93+N/)4!A"!G?N5HT<9QZ87;,/*-JJM"[YV#\M(
ML_,,]M78-PK;0U]%''.^$V%X-*_A]2V,AG[O\DK,?\?[T>19X[5!1WYI6[>@
MV;?DS[WK'MQ,V/7">_FNH=%F^8(C/PX'KKR#/4>()L%V_!%_531MU_F",Z&%#_1YE&*Y_>Y5W76Q P2KJ!KKOLTMGU-Q&8@5EM,C/8RO623_N1FO,/*YY/6REIFCSZ//H;DA'-#20K$V! HDC18N:J5^=<^)(_
M#ZS;N_7^%E%*0QV[Z]L))_J'HN&$B4^?N]B=E:&!Y-LWO".N?]A67=>V16^!
M_W_K&\>KX(!4>O+1Q/@8^Q$K:6*18QGE3I8OZ6K-PC?,)_W6KI1Y:^$-GWW-
M;I7ZKCYF811R:$GM*U\MQN0J-1ZYHM^,@Y/&.4B\JWK;T$U-85!WF<<'M*RWF/-FT+"E1BV&X[DPN'%((("W&5H4J@32^IX<6LU-7AE7CITE:C$<.0;I6
M8*3%M)V#4>N$96=K,>\^MJR#67^[@R]1:#&Z4\(P!7XGEM+Q'I7YWA+Q9A2?HOZ_[_8/[/P1! ZF JXMZW$MJR$+"U\B$@ZZLB&Z\OGO,PS[#FV5=T._ 0VR_,4"]>_F&<0.V;LTXD>F
M436=Q+!@2;IWIWUR^'3"Y.6;P;0M$5*W(ID)$@F](BU&4C@BD^)$AMYJJ7MZFW/J+.QUXA55#2[T"E=?GS6FF^4G),6-^>:OBD)&.8,R?J)X;)T$)Q
M;T+HV,ZY;2J?44WQF6$8UZI0[]PD$4^OP2T"))/M6LS4^[:_Z(I6QG>QBC6C
MX36YGCY@[+YV9#5U4)9U5W783QKJB.;AHI6$Q&7-I;_B&)^FS*2F2M]50@Y-
M8U%%#VGK(<,437YY$MCT1?\HUA@MWO\0F6_5QN?6AS3&^Q93FXF+OG;GT(*"\^^2R6N"5/JW-:C>YH7G6VLQ!3I0
M*H)+M\.28'8:3!P0F-!_P6#9T;)IP[N0/M"/""M(EU#D]4&^!/A6>DW2ZO'15+/CJ
M3DH;'\[#2]LE#ZL[9/G38I$]BBTFZAHJG'R "&;/?,(5R_M5S,7CS-[))B]I
M'O]B>[\6LQNW&&]M^:\G]OZ7Q D'@OAB>/G.2@EE'DT7(HU40^92_:9,@LR9QT@7SREH!:(8*36D
M$;*4@R6+]3S7ZE^A>M PJUB4P:E#8QA[868C4)2;-I1P^I#B#-A/*WP7O./Z0&28]=+Z7:*KD4TVBV
M"?QF0 YP\78QV(-@70X^KR3:I;#?*W
M>S5'O !H6,-V^D#F&*I=P3/DS%,*'BH$NZ0?@&;4E56*4P!]]H(O-=@&HLB
M!^B, R:1!&/:(5^W.3*WS??0U<,T;%RT&O$K.0@AU;75S)'F$O95=!1R;
M7%"!S&Y3[7Q/C6WH7P^7E,.&<82^'5I,.&$!S0X\S<9"A M8?J)
M"3F6.XDSKC!TX FG@30*;DNKVNS^4'?-;K;5C>'F>4XT^X=PMB_E_@EL^/E4IYVJ*5ROBBO?CC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M#CM9VI@!>2\#^JN'<">ZS> [8NC+/M3!V*(C9:"3#51YO&CZ\QV3W)MT:&@JBPE)(AU6>/S43P+&+C&K')#T:^'*7P"%IUO_NH-8(0<)V'U5LL(/& !
M-5ER>@W-$V)72CGZ<,+DSO:ZCMJ^#T_K=?]%587_%=S3+@7YE>'\$N!@M,B=9%1C)M*+0C>" AHS$60_MG"G\NHV^F&HT^7/'LLK'D'[F9TMM^'G]&&-/!$LOL8J&PW!=3I7/;)SG;BWZ\.)_=%LA[E^Z[1_R2:Q9A,L@@.HO
M)/6WXJF7&J86,W"[0.;6J$C%NT!!S09B/6JVE#\RK(JFM_>;@&6YDO-%N\6S
M.4=# B]TD-B=B/#P<19^K7H[.L3O"?8\5>TF]4X[IQQC3UV9X28'C@+PBCU,
ME7M-#KN*?P$"I <3C]0L']U5?;1\RXZSMMUH:?LJT,'MBC'#'^3_#'N!S%%:6
MN#PL5885G5+Q<941S>(9:DM-#B&"E4*RH87&E-)?YR]MXT2Q4H4<8V29#UB)
M-U$'PN8RHO&7^!S@"LVUJ"6JI"E.@EOP1I)1;Q#M)XK86S P>1%Q/D#;#V]6'8X"9GK&J@CJPQUJ.YI#O!27PK&L.]4_H_T$[=
M0^X7I,+QV=;"FZ')/[=RJDMIQ=1O./FMER[.GP4!Z@5SK9BB,U:*5,X3S@N*$2T2#I$]JS.?4Z^Y,]$2("G,I"^/KED0
M& NS]X_'2OR\7["=.L0!EF5/'$O.R.,IE!@7_Q;S%Z)LM:FI,@MEPX\Q\^CZ72Q;6DV()$'+(X*C'(;XZR(^K#"AX36T$R)E&U&#]0
MD%Z1;@>Y4QF\P*=-)S5Y'^U:&K?/95NH'<=."UE>TZ?^P8)N* OJ2P5J@KLY
MRH*/_+48_:O46,+H+V&.!"+#?2GA!LW]PQ3=\Q@G$\L0SZ*%JMQII^%RT)PO
M_@4M.;[$G*$.'7 \-8B6GE[*1\122'$<*3O].^&+5=E7\RJ;Y6D1F>L&N>Q;
M'\<-LJ9#DMPG_KZ7.*\)G4(('X&3?R'Y_D) @8H=.A/Q@[ 6MY-8OT.\2,V6(]Z3)ORAGE[]8!# :_PD71 <84[CW_WJ&OU+?'FU;DOZ_CV.K
M%I/,]]R$5I.>%)J H?OGX6PXMGI,O:GI^U8V#:5Q'6'U>._)N< Q#3:%4B
M?R$NQ*YM]P0:I]N"SDSNZWV.MWS[ZG/$&R=;#S?*BAG9I'Y"CP"9FQJE.H0*
M#P-.U&P@HMZKT9_F]Q0R'**>HEA$):AK?@*UF"N>7A)3W6$#2>Y6^CL:_MBZ
MC,@M8[1ZIAUQ:K=S/W&R0XOQ,D/.B<$=P-1.YQ'4[?U"2<=-/T=L6QUP+_2T
M&'5*'%$UE\RM#W=NQY&)QCN%*P@55>9&SQ?_<27Y+NKL1H8YX_']EFA1$UC V+X]/\B=Y,YU
MP/[O46:V/##3H!.&Y^&NT%A/7N* @F&QNLO_7V\+_9X6X4O\X^_.>XR0N\MA
M&HUPVIDX\;2'PA"0,(6(?!%4>>*"B0@3(OY_(CQ#S^M3U7V: 0L= D:C$YCPA2Z[QXY*J*2X(C)A1(])__].O_#^T6
M'GJ\4.TJOG1_3">#HEZE242"$46\.I/44 NH9SV7VR*&2J%K**5I>HVFA.9&
MUF)F/^A/)RO+P61TU?3SG6JW>^20DUK,G"!UN>4[+0:>C?_MGU6'^V<8WY7^
MS3!Z_Z,=MDZD?F^DVVJ1/ZF=I/8J+T,5E)B*;CP/J==B6O;A(*-WM5J,=Y*$
MI5X_/:G%N/[\/^WW;VES%\DD6'F\I$CW6JYW@R81?ADJ'G4%9L4S)\G8']'B
M3YIH"5/QIO?_&Z[^)P]Z,SCPSY:09:HR-:4B,S8"CM)PMA_R]BTF)(2Z:YZ/T18]'L T?FIT1FW+E..F:Y[H4[8YVT3??IC2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M;Y#)J/.66'M)\2FJ"/7Q-O;&X7BM^24F^7KG-(Y^MDV81.8^!S/XEN97$:QZO^:JD^=6U;JA?FO-M3H3L$_"3Z%O
MB@YV9N!-82NE&\G"!^SOGY3J4FU_NBEU2Z_S8<$%P9V>(<5](87)K%ME(Q6H
M#?HJ[.@3BS3$ORCFO\CR4BWF\=G\0SBU^6&R0!=I]8_68IX"ETYK,9=)%?LF
MY2?)$*Z9K@??R%_4ZBHVH'^[H*FM$]^:+?#HJ_XBH^E[/MJ\UB\$@P
MBV=MU3@9MK!C-?"T3J^PO[*<#UW38BXPAKY_]V^.)I]#6848;Q=5OP#FJO7
ME,+&+^ICK5YE M!7XEC8V&*ZUV8%2?\@/MON"3G:TUL_M2#EP07RQD]I?+M>
MT_'8OZ"/?RUV7=3EJ-DP.K[TYD&#EPC1<@]EMN8^BF<1TK/!,C 96K^UE68*
MA4CM2J5]8DP39-=!L@32V/.B.:8C$Z&ZVR#G<]^<8R8(V"'=%S5Y5_.*PH)#
M'W=P?0T*SV +@BL=K.,:";U.$@U'Q,$3=2)^@B>$'B\
MB_K&J\/1M?X41;>W6BGFQ;B%;4A Z?"7-L6WBC>=YC7'\@")*B3#)RF?!+N%
M'+RQRI: 5N2EU-\9-H"$.,P<;=L5/@@%BG,W#@JOGCR00%%;?2H=MLS.B$F5
MDR7%X1*QJ>%*H.E.%^3<1ULO*4VTC;A<'6Y9]6WS)IF+ODK_]@!]!AIW7E38
MXDZ:?;R4U1OA#>DISK'GJP_!H1*LZ1>FL>=F?09MK11[&:CH?J+:P651;7EA
M*^&3,D>'ADMI,(TPM'?.FG$@N_?!$>5W(7S:GSU4[@*^FJ)2Y\@)M-MX/60@:2[Y"C8W@^G
M^D!VN7>(?U*#> G-N871"?0[0O?4WQX'_X87_KUJU4&XG^D)7PG@/NM;+PIO04MO>Q+OW0BIO0VMC'\2J+%9%A>'!ONM^VBZ0P(+EMR^,2+0#G_\FI'
MS\U'SYX=0+6IF@11TNN"*26*XRRG^>OO'0@[\/ZKR<$F@GI!(C(W"IT<>IAV
M]8J"8)H'E-HHQO; *C[34NUW;YAD1I(:,=RNJI.BC'(?A<)&'=M 3NI=D)@\
M7I6Z]^;N3M=ADBEIM)KTZ@2U:S'\DX7\9C_>$'6PF_?NS
M/CH RY"Y_@/B=(Z1PA67SGGBUB"V07J"2.69G)'G]G*B%#"E%O!$<0KN,';V
M5QLC4)SV&9Y-.2V8%8*TB@CG*UZ.,PW4!UHG8JQ^JAHKG=@.LC-/1M@41BEW
M V"H!KOE"6Q?2,4JW5H]5Q30;. GH)7L HS;";/NAZB=GT'9+\2I>'LX/BD"
M'./F+X8)#ZS7-^*,I=#N&F6]U"_\9V$E!_85C5H'\7.NYI\HC9#G(H8]PEV/
M<=_K^/PO002P<$(@M3HY!A=36O+JIJ%W#LPV8$ M3DK^ !KO='&2/D7B+82^M/P?Q'SU<@\VB7^E0VE(+LN9^#J*5>(4N-6(@ 0&
M 0MH.II;$\S>+KHU?!4=J/VX+D(4P9AF"5\?8%VNR3[W+B56M2M,4]X4R#0]
M[4O0)2>D7F$VNG_BIY&XP=GGU'$2>VB>Y5O+G34Y5Y.3'D5.]A]0Z:#5ZXL>
MO,=A2V=%C+[DTBUHUF:2D@%[08K@&&_>DZBLR01[+DZ7M@-T2\MOXF;%N),*VM]F?-)40F_YM=*@!R$IYI*TN0.IG+LENQNI&LM>VTF(+1+3=("6#OIS>FB"06T5(Q3.I!0?A
M1.D;W.Q^;I34BC&#^FYV14O OJZ*J);/R25P0$B,>R,>)\.JS10_PQS(6R+@
M)7DK@0Z7(L_OQ&B4BLS5 >ZQ>#%A2-_/7L<::Z*W*7)*>
M3W%4_LK.&%K ([YA=\G@SALK1HN'67]#6V"5V/7-JX&!Y_DKNQ"W]T@K80%^
M1N\P9[YG#-@G'7P!7 US!0NO.KH0+:AO!H KR)(&""=9V7["%7LI?V7'\;H@
M4*^B-LE\%X04W0>.PLP7+?=A2@"8G5H21V88?V6Z(!TD<&\H0-">(
MTT TKGH"X907X235-IH9=%"\*(ZP*(RVOA-OI5Y;#EL]A$.::U*4Z871S/D5
MM0K,E[)^*_M["[OTD!??[MYB'S\T'R&)#8[.K!)2(WP^8
M,J8L:\?+$K=]UV9Q+8?'>$H--(4=^"NH!YB:':10]X\[SR&=1JU6,
M/*0I[Q!Z/ 4YB#G0L-W3 ,R6*$8L9(L\-]]3!T!N+]!LDRJQ(]:J+31]X1'(
M/N4X#5"MHT5#"XNDF5A^F 5461?[1M(2%-2.7P[?Y"H3GO:%)F4IMJ6+VN6Z
M(;[OH@F@O^*<>;^MYH\ZPP*$:[DM\\XHK3LK55P18>461R6$F624(HLD'!.+.*S^L)(]KPX;_LCN^LD5+:4CG]B]
M?T>RG]-B#B&0%+\2!2*@$>";N*MUNI"'TAO*;B+ULII)3ZNY@MZ@/2#ABA9#
MQEI$XW!QV#E4>^D1ID7JY;HXU8_V7&>3:&0]M&+P2EE$^>.*Y$9W0+G._: @
M:>;"T7XNF,K']C%_@E^I=J("T<*%!?.6^#O8\*FX@Z 7'D(S8=HUS
M#-5K8%^IGP??_=CY.%G>+H'_,RB?(_6+4(4'"-4!FEOW+5QC]FU-V=I+*N;\
M:_L!_T'^_V3^8OP4QX^H!RG4Y@Y\G D=1[;!<#1,]=K"R)KJ%"V&PIK3M2]KC\;E"4ZZ8>%51T<4") L^E+%&- _@Y+T=X6U&.XN>/FBW
M6;5R(IU-U D@C@?H?!'/KM-7'1XF@<0/6&D$8RD46%]\D&8!5H_X6\(A/PL=
M8TI.&UBQS,-@?F.[>/A,\.H@?ZS^AS>&O ?2)S?<5$'(TA[A1H$\27+W0B$C
M>7KRL!'A8[3B"MTU]3[04#_]N2A>ZF"B"J&>$"(F+./^R&?H)-_*HJLLW2[%
ME6@Q+[OZD/GKN!R;WX*GXSL4YALLR NGLIX(65X05RF"IPKIG;@J?;FI:DMD
M][HHMA5\%W)KJJF^6/K O+MZ6&*0F+>,^Z*='%B3/>T5;4XW[A@1J!R.+!IW
M'=4 /L#_?9 #_MU\:&B"S^V7D1M_8S06#"D$TU/ZW3C4BT6,1>T ?+R_CQLK
M$Z9HDNO][G3U![0/,PXRWJA\2V;$**2ER2_7G7T_,0IN6O;\^]/N!H[EYWK[
M]'NX2N"2G"!9#.T3IVPAS)F(PG>A11(YR>FS"H<"QY1,.=/V:OXQ(J;MGT].
MKB4=0DW<9\!C0=!X]M]3*/\%VSW\?W2+=EC8+3QT$Q%&ES;$N@8O1AW+/2&J
ML\(>+J9H,1>+,_N4JD'K87UOE)D2)^H/#_/\&2(Q]PR?BZS@@-^PC4D)1#>5
MV^[6;V/5J"$"/FX@5JT7_0?'V/;?;N^;T./&330?\5*%P9&II_W$WX7"!\4O
M;$ @+>4\$^0)U&,R?;,6:BQB.-D]H80L&2(.]TP$-^R'+MI2!APPS7;28IY<
M--2P1JDL8-I;Y)GO\4JPX'^V]TW_K]O[!UOO]]?8(8IKGE[5)*9ZDUK$^K]\
M1"24HI,W^3'?S^?ZP F\W1^VSXOI8&T<.FL-0_&GNE4V]LNT6)V
M > >+:97-*R,T3#H\VGS;DH-4]/$D@JQ2<4LH2UXJ?!XSFVTJUDRU%U7E&!+
M7T,GS'//5%PY=7\P9]!VV,9?]=)S:04UO#'EPC5/5TERZL8KUQ]L^]E7E<'X
ML)"?XYGU-O%2N.!WYK9(YFQ9EW[J/MY_O*UX'4I@T?@OF;I)RGB7Z)*9?
MRKI9)QM^$:MH47'2 '&UL-W).YOB!>0)4@+I/>MNABF^%2TTASCBJ+W?O@P-1GH%K3P3/ W
MQD/X.N?S7@:IU>EA5PR%<^'+5LVW%1D#S(Q ZUU:3$A=^WB/"YEE]G6Z0IF0
M+8H+**,&$"&C8K*RCS1%:U68C/QW>(F
MQ-;K_E:@L!>EAD?EG1D]T?Y 7XA\I9>04&?=M TA0./*PXW 0CBE]'Y(QJ4G
M-V0)7I2B[6/]Q7],=O+1/L37R0QS#&NW+^2
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M'&M4.X:ZJ;:)9 SP:O#E@"A1XA8:S&!-((6X_2UV.KJ=6GE?3@;PL6,N672O#]&
M9T_3'YR2=_S$Z8AA"V:5B)4].PE&]YXGD?<+ZWS_]"T>GK[575G\-L/Z78';
M=,=\DT]W;%M39B8<.[=.Y:8JU6+NY$@]UVHQML0FG,J"9J_%/!)SS?H6/?R)
MMUJ>0KGU2D3?NPG)A\OL&Z7'T+EK-GH[5DJ:M,A_JM9Z=S0X_.'\X(RX#"M6X;EA1]UNL[ABHJ'1'D/?P_OF!!7]FAJ>3DC02MT/T67;=NW3R[(GC'$CY:7&4W]*XD/B[+W0,Q,BHV+ZT(Q85VGTXRJUS>=:1=
M3CK<1\YJ+^T,.J0Z:\JU%H1MIPZ8_J:D,T9UGW;2+>$$[AYA7")CT7O-C8[=
MX&!::9P!:S80P04*X':A#[O]^+(T^()*GI ;XE,
M?;:WE@&&WA)G$[MLRI_ <5%HE.6))T>+DA@CFRJZEUB*[&]^L3J@FW\K@9).
M,/Y477.)8@[?ECN?.-3E[+AP^'/NOJN1_=:11KVWP_6M=R9,?G8-#3D(&:IK
MRIX7#26PB]>MCK=,Z6J(SUG OV41III-HF1O+EXP$?;G7&NAYI,6TYIREG6!
M\/$$C$ZL\.YT-%5,25+"D5];ZND^XL\XAYL5&GJ>]S.SP3##2Q1X%[*6+NE
M'.I-/Q^\A(.B$//QZ7$\KWL@P72M_[72I:N+/MT[FVG_>\,\7[2IHG2/+]1B
M1L&05UI,UJVO^-GP68J,O-2Q[+G>P\(-E0^I9ZS(MVL?H<_7P37Q^HM)9+^G1Z@,-O^*!"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MMHI&%[A7FTT^' EO(*K!LLH$0?^VG
M:^*ET:VY4G.>3RDKAM3$7I[5K @(C0XA3"F*1>[O'U8RSBXY."[K,'LS5%-6
M*368B@M-0";W=3M?/\KT_P-1[O\MY2KAT2\1K3,M4EVFWX ;70Q7:S%''3D3NJ!9?.F\ON53)T(F W[U&9PDJFM407H#?QY#WL.5
M:64_ XUOZ;$7"-(+(+:0M>L]*NPC*;_=O;;6X-,C2M2IDY^6(.;9^MN\AI",L>$*16T=W:LZ3.IDZ,DI9'O5^J D55YY5R6_^0C)>.WT[7&P2H0K.5
MG+2*C /V70\ZD YS4>"K4C;@LA.)?K)[D7'U/.YO>_=8;B&<^4.+2?![M/DE
MW[7C:[\3E)]]?ZM$[L:S_)QWKV_H)[+^[JI3Z8?*MIXTXP4EJF;;7][$WSU%
M];0D1GS18I9L]O:#[2.*HW5]VNJ./?8[642U14R*6TA>&[HM\V]+K9U]:]N/
MAG#@'YWIKQY]/2-Z6/XGTU"317KJ6"C">QE?]RQLRE^MMCL?K[0H53HBV8\BE<%EUQ\%NX$EHJ/RW^R[%E^%2WW82]3>.?U#7>H0Z::8
M;Y61E;6USA44TZ&L4P_>![>%3=V8J3A_)?\6FK*'Y5*#KQ.9)Q!58-?$',^^
M^IW Q W>@C29YK$G2!I9@?E4[&(%W,18:0X%!B:,^ ^[C6O
MAW(C?BKD4^QH/O8@Q/?_IO'=%B,EAKW_^Q!OT-#*QM)MA>
MY4']U;JM&SV-]]MX5OK)G:C&=Q#SWYFKT)K(VB,E#;#\06=N*:%91 MB@C>J
M,A]M*"6'4R+^C,2=>,R^)/J\2N$BF#=T[-O+:&1U>TG!LZY?.MA=YJ)C3T,H
MS)91\9ON55XS B5IG\S2N;OTOP5!V;_8? P*> "_::[9>MTT!?@[/S?")*FGYXFXV/ --L7)]-CD+]YSP"X8@[P4V/POJIU?Y9?7Z=:FSL
M8A\)L&ZPZ4S8FB=MBKKU]Y=^]U\:7'.0^X;2DH82.!8YZ'*,P]9BLA,&/$/O
M[H?#FRSYE\8_').%EKM60=G;1H%EX>Z00K>I@I5\0'U/JE5;JAWH&5E/]-1M=[,1]GB0E:TX[&#HP="ZFP<%FVJ>U]#M\^7-_'V3/R^O6C^:O&4>4 -@/SMD
M@DSU);K]-&HMK23,=W4*4)R4L&;+%FD2?B4NT!'69.^]?&&O[)
MV!_-AATZU1:@2-B<MLFC?HY:B#U%:3%2&?$-W;# R]A9-U?: &4:]?3.MR_9T\SWV4 ?O3#;%!8:M
M@2I7'O?>QPC?\ )\1#>ZC
M_OT>VJ)VA4+6(8-R&URJV:8+J[/I5LLZ CIH07=[AJ==1$>8X#6200S)%SS-
M]>> @[U'5&:W'K0,OOIX-OVSC3,X#9-XT\S4P$'5+L/-CM^.3RPV(,D-0O+<
MMK$M"WN!C'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M-W_$4U6;&/+%$R;7Q?]4A.TQ;*.HG^\&Y2KF_G\4IK
M++'K]!M4\* J,RCR]X[LM_M'N0]%,JM>*)7.*>G/_]*:VZ4>49L+C_XKB .3<]D0OZ#LXE (N L.J$8E(;4
M;\\L1SWX*<=O2=E024!7PIT?XDF3V5K,-K,&>#V"I]L"O7N%:#OAP+SX-B^W
M7/,WI\3U&5?WT./DTT*S@9?'3-5>FLXW6HRY%X_V? #@W6P,]08HI[ )[XU8
M5LFL+#O#Q6F'UDW91%)[=_LZ@Y[G1JY,GBJH3Q"FX&VBZ*O;EZ)$M,N-^?]0D?M&HBRKOAS?>-;7=BM-^OO(S)/ :>4/-YOK)M#@3Y9]U&89[A@84
MH^KJ4;'3UAMM/BL;-.^3#LH^&9YGVI_QU&*F_S?*WCV>Z?___U\)E5#)(;)5
M*I53Y50:*QTD:451Q)+$K%ER6LQ6R3E6*8I80G-63I-FMGMELW_7^?'__?-ZO[^7R^OWA+Z?'\_ZXWV_WZ^VQ^_/Y]!IQ=?7BF>@B6389
MV>.2G7V&\Q[ZY[6_OO"^UF#6H7\AB=H3F <[;WCIP)6@+[;G;(2[Y;J*:2HL
MQ*"_\!U0,>T\[DK3Z3,_!SV4B@"A:BW(Q4W%QQ7C3.@$HX=/CJX0&;XZ*TBI
M %_[@TFD0H3V3XFQ=D_W1;!Y38K3BT-EETK_6;
MQLDQ@V,2-0;8*SNE%;RK:6*:>ZO 1A@9A-R/VG:'D6'\C0@U2&F5#PI/^II=
MA!B<",_L&,HIG) QFY]_>!Y3C!MD?Z2YOYI]FO2<(MI&7[]6IJHEB9):?M@[M F!1DKBKY+ 4U(Y9W=TYV><=@+$Q20Y>G<(<.XY<6ED*6$GZ7Q79VD.((
MM3ZRWM0B@#P5-2TNZ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MK!:-'-_<;X/MZ#Q$FY^YAXVN3@M8#_+=JF@@)G%:\,UFMM7(C([P\Q"N35UAC/3=364#QEB3>PG%_=Y#*2A8 OGB
MVH58)07])#7)O%=8,WOY:9VWO?8V K((<_#2RNWBP.C^#28@!98]R^
M"2:TP,FPKR^%R_I9(B!X/((H .XM][33280N],TJ1OGXF!*A""J_S!(WNRR*]ZHJ$3K#N+$2W=DX&>R74AIM33D8
MI?B+GC#@A/C@9?>9S%KH&P8X(]:>?[*DFQ3Q#?
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M.+&UAPM704RZIMW"QMKSEVM=Y(\D(!1]1QB^5OJP?FS<4Y+]?["(B-R'!6&+,@-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M.J?$SH4#?I[:U+[Y3/"M8[:*IV1$>A,"'L!W:&.()5 ,GW *J$/RDHYQVL? ^WN@RQ NIKG=PTH2*<=A
M--V!6@M\W;IQ]AB>KI.!XP'$EF_8'.<*/BF*Z0)$EXRC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M'(8*P!VUZ\+K>&)+9UMMSV-BZV3=,,[H7U#%5C@\@:LKKVUOU>Y_EM<0N6@G-E:-S]H+M(AL &\.(XZZ
MAL#!Q-%5S>GQ4M#&F[-0RP+_11J$'QI-_CY@F*Z8D"T 9Z#E^^D\C"X6[M Y
M;[(>L!IUI71#]03:)SXXJ5>^520!^N2IJH>0=5B^0J,4]"D :!?;83!Q+T8/
M\O2_S9=I KXB>4F'&R49;]T@K,@30I'&QK=OX&
M.9K\ATL_YWU+JZW1Z[F=3G[LHJWIE_T+5[<$/6[\*7CH&B?>*04]212=DJ6'
M$Y_]-SV"5W"/2=9P1$8%BI(-!$C@I(#"L[ ^+#[1 OOO4G2E2KID0+. N,]>
MB=\K=NFM7GJBM*W+,@M8.&\OT27QN5Z83X4@U, DQHW]<%XUOE;U+GYKXZ*5,(J#4E6V
M%P0T<6:*RL8T:BVR>1W'S@MV]J>$!87E#ES"LETZ9ZI*C/MWFU?>V'=0L?!O
MUX#YT)?4Q7=D>O>!9R(%04_#.$.D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ME*K@M\LMNF.V@L-5 I?"U_S RE/K'X9[VMQ!L ?@1L^F][R32A4@IJB70=#JN'QY/4YZVU3=:C;-9UONXUJ]O+/2__K&7Y
M:P%YO/K)A#,M)_>80HJ/^1S"__?@!.OB RN?JA_I,7E>URF:Y_%XW-'E6HD^
M]O!P;"-FTW@H1'56C.&6J8L1?'82[KAP+TXIYQC?B=V:7IU3X,=R_WM;2\:5
M:L&-C.'O\VB]"]W4P#*_L'#>]P;.!]+ZR1ZDS.S4VSS_AS4_)?Q#MHB7F/3A
M-P2MFS\%-],14?@MD4]F6\-?2I3Z38R./_%CKQ-;*[8LH\[5,.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M(GI$5B(QYB7!0.*5[AM,,[2V,KB5=[ZV-\1CK]+T 52'#:N?A33N,EM.4/K8;I8(L!,[Q0P&N@5E@TD,#:JA2!O!D^":.RTZZ&!L2E-K%92(?;S8HO%
M4II,>_F+C4-@62R>66'#/+JI6V^2@31NXJ1,HI!@C9YYAAJ6?%YFNNIV30P=
M447\VX3XH\E#3%>)CN .$.+#L^)#^(DM69N[:0;8-,YHS!-18VUJ8G Y#LI7
M*>%)00EX&)6XXSZ\6WHG"%1
M=9GH*I!E,J#40%AU,[A,B=P4B3K+/VX9+A[AG6/B[$NQLTVD]2%)0V!*G4 E
M-I\U'F[-O.O=4VK3,,S6]+L16$I U%'!?LJNGOE.@MY/FVGMS\L=5.;'@^"_69IH.O)U6 R26X&YI@#4&GR+)EMM[MOLUU0/PH53J'FJU<15T_< ITZ'ZI%X/6-/N":?@5YWPT'K0:!#%HE*E+0
MQP@>>3E5AIC+1ZCR1\ ;8<-9D'+6(P)'4[ (INO@3;U[Z,U7G&7>];]5-U)>
M9(MEG ,"^9;2Y;/9'*L+2()KGWF
M1&6D9!??9Z8*A/,V6+YH[QF.+-RD)7RYG$GR(WQE<
MXD/<9K[W!8#)&U@MMA,$U=.T8ILI3F-K2LMU5(9![4KO (,,1I9U1F%>6U18A1J%:59;H;]#U!QBC"<12@?6 F37>BL#4D'
M?V"426D^PQQ!M!" O9:M[%43$*W@#AN>$".PIM^%XFN)43CO;$K"@JH<*DLN
MBJ/8@@%[X+8+UEX"/F^ M"[[ML*4JV0"H]E=5K:U%X.S?S/)*F$VGG(R68ER
M8__($=(%\HQI.C]*B.=CXB7RV-@&VF$@A&NB#;0UI&9MKM!9MXH<]S\2R_;Y['=4E1O%="TQKOM]DM:)FN)*VGZ4TLLBR(PQE%)T#SLH:]
M:G8Y;846OXT8@W>"M\X^_,9B&Q ZCL,:X=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MIL6LC;&-VH4369"Z&C1^TM4JM2IW O;=;OJPDJ
M> 8@UY%5]P1J^H^L#TT<&:&Z#L].;1.93J;'MI*J 52;OLB21WXXO4TFY:WG
M0I,@C?6/X,U.^+'Y+6I9C?1S=]>N-NS>E_ +RFP=^=-TDQ%YU]LFT7,-7TEB
M2Y*YL"DZMDP*.D]7/*?X^%\36@1LVD"@TTQ?@U?&,KBJ#VY6)DY''+'1%1U
M=7X*RV6Y^0\9=MR(GR"*?(0P"[B7%4>=%!W 8@F\!QW$GU$1SFNJ0-UUWC\LX*GLI(A;KME?A&
MEV0+-J=MH_NE3(Q[E*L@]5XA:O<\ZGVOW#CB
M_X=.M!#^?E"$20*O3N1ZO+;C8]K2/-<(U/QK=Y&'#Z/=FZTLDW&F(7R)#**L
M5._A3!4>"Y2:%6(@=4T+I
MEH$F0O.$R'4,MK;J(&X;DC_:+(%T%E/WLM#S;M7B"M^NX7BH=0NJ>@MD,@IIGUM7&C^4M5'MMGSUU:+X>2Z Z*C&_#.%H"
M_BKUO\_89RQ>4L?\R2<#]E.H-ALU? .[PH52*/9U9ZP#YF4&#^?=7SEY$R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M ETC?%>!X#>O;K$>?I>VO5L?0'-FD^B;:%O]\(J)#MD%4]>D 6!;RBKQBO";B[ 2F[7A2@W'[6HF>(A5C[:2<4Z(ABKLR2$*9J5QAP
MB)"H;\0D]N:*E#9"7,VL)YR?(91??A%R4+)CC=AM, K90'S5!K_)I=L'?\_=M4&/=;;G>+=]R(U5H4].V9J_K[K;<=O;8>"(2>AR
M*<_OBF: -K5BF+Q4)G/4PLM_GP ]WGE.\;Y,*#[0?1@R'8F419?"LY3IB-OY
M_Q>?T@:I2(W!+Z>__LJ^>.%[S6RZ^M5IHH$N )/7JG:.KN.(MNJDXA<8W_8GARA:R.$( 49,>W;()O_#YF:;.]MD^[
MY_2[/G/5! N63]5('J=.K[$=%9)CJN;0_T'M_9_,IB[AT+*Z\61O,$6\("G#AF6&LLHU":K+Q>AXBO4 Y_PQA(K-SF/#\+CT
M9[GI,5'*(V4\8C1M@X!XC[J!HV1 U/:WE.S]T$W;"E1M1N(3LE!4QVO4+-%(HITB4]QU_F+;;)1$ M@AH=7U4Q8\67?7U\"M[V<_9A8YK.+<^\B3F$3J(\:LG5,E9,ENU[[%1M]CL.
M F+SZ[K/?[S'M#W94:\5;E_>\)K4,F=2],&*V2K;>*O?PF'2U5*M>Q&0A?^$'WH(@9>I_W+GL
M/UNH@5*0-S.)OK"W;TSN]T#C)5FHW!O_Z-"YS_ELL.\S$O!4=FU&^T*71,M#
M"YW6'2SYN=+-;H>\TG<[+1J--AR KP!)0:%8'N$U,P'KSGG9 W@W51 :AP"!
M(FO>444TU>\)ZQXIK_IMEL_T*91=.DS_NUIF-J[ZLSAV\P]9/G%<':6@$RG"
M>[+O_3XC!8TXU_O7A[(HVXH[NNL5V=.;NU-\M4]Z,G/7SP5U*-
MJ-COR0SP+F6Z?+-%C:E]2+RP_.EC5](?O^@M3)<1PX&GA,;2#$FB_K2<+)8C+Z2@+WF@\(>N%('A-LP,+^%'^X[S;2&W/-F+
MZ)'RY30U\7B=2D,]S/)3;:YVTN*S34J%GI5[/87J[VO[Q$]\%?15A:0?MTL'
M< S> ,58T^;BO_M_A1.:[>L>-47DNS=WZ+3+US%G1K!Y]M=2LCH_Q\.6*\39
MJ1/"F5\S)F7NY[(NKF8ZPVDN%W\Y8P[MO; RJ'X5\_E__TT(O^B-%/3ZD^B(
M+)1WWA!^[SD")IVX$RO>.TX?*\=WP@!/)$G\V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MUKX> )H_V6+1[LU%R&'MFMW"GS^X-9&EVVWN$*Q1;4(^:D2UW/"ET^A9U*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MCR1[6;@EU55-2.8&M]QA_+M@@$L"^0.<07Z_5QT?]D ?L))IN%
MSWS(+=8_0^][AG92=KU0I2%PD&].HJWQP
M=7.J=DCTLT\QEP;:'2K6QE/?_=I+AM;FMUJ.UO_;C $M1?ZG>H;9:P@_7TNZ
M8<(+5)F<%6(XF4'ZPI#>&F71<7R/BM+>9S))G3TB-W+U_0ZLPH_I*S,WSY!V
M0V$_,-H DJ]VGB9@M.7;M;%9QC_&Z1N##0A5EX'?1Q5&)4:J31NJ9;UV=MR^&_E6X?6,N[!1+QG"CW)UI'6!.KC=$!V_?]: B1[4MQ]=RCE)T=EM,AA)Q X-_J&6.Y(D_FA]K<&^;IP.)VEK^RN_]%7]PB6;U'R69JR)N:[[T6[P
MOI7*ED?Z%I)<1KI[C8UF9EZ_6+T6U0[[MS%85$8U>FX6;$&A2P'4T?[M#ID6
M'%?W;K-VX&>:X_NHM:>)XUXX0$HD11BCI7*SN]:W,ZNWH\W>I>[^0J[_
MUXM:PLV+7?\D\$UD@#)GC>^4$8WK*RFHSY&?]9X-^'J<>J8L.H'O69?7HR=1
MJP/)_2Y;9W?WZC9"7?R%:8;RHDXK31,GWVM"=15TJ\M81'1B0!?&34[#9,#
M?H=P.#W@^IH,&]6:3Z-4$\8AY]^[%8>6GN5J"C5#+<^="$)%R'T?=&=L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MEL2<\-WEO134JUD?TB #N$,39]=:3FN*'+RB]K!Y=4J8KMKMO"+_Y8&[D0WYWP?\-2PM7-\V!2*#-L>,Z,0UOX.J''EZ +QF3>I)6& CG<_,
M\">MM='!$B]%$CR!B.%!;_<#R-L9C/78B!/]LT:REOE"KWO7VP]9>\COTN63
M#Z$'-Y5_3%#H^$!,ERWY?XN5W3](VHII38D\/W+YJ8MV;#34](X7IL@=52U,
M\P1W#[4.N%=F&21Z^+F9URKT&9%C]K#^N%EO2!WK:?19E/BI1[S2<(Z
M/PM6?QHZ__LE_\?C;H2!RDEKVY.IPA[XA]C%ZCWYIV0F]<6U'?9R#DH/3X4"
MA'_99.!9I 0I:+\GA!\F.<;6A4U5L*6@"?GAO;P!87#O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M^"+*\/R5EF*J$W3.]NW,E_/&$$66_&-2=Q(PPDD&?MDH-%*
MGA@W!7%)N-[GV7ZQHGMZ9II].0$Y<&$_8_-+.-0IUMX#]5F&;_]6W^Y3+8?9
MXEC\82GHNU\O;$&.KWP;QO^:GH(K^2ML\O!SN+!L$/X-##1 ,V6JZ=,XSVS.
M\QG#N@N2=X*'Y&EYF:15D5M$HIO?@=^G=@JQ2O577SS(4JFYPK/VPEGLK^3T
MRLUDGNV6K0G^H;P7?97V]L.]Z3+#TNS[W*$YEM>O#A14OJ#J6VK=OZ
M/A.?)_PV4'T@!2E/>_;OABIS=E97:&^\[*:ZSB^FNQ6^9CD?>[%RX$B%%'1C
M$.O4+YSXS/IUS279H?OC197>WV6 +QHN2381/I=9@+\WE(MGQJ2@F-!>*6B,
M*\MGHMA8#)."OL[MPMJ.IQ4L=+E N?C=,:,WKQ2 F>UQ,>/5[G %P).!>,M2E=PAH=;:YOSTZ$)C5"F4/CN1RDI?^C>G?R!MJWNF<[HGONO[G$1_*\LTO(6
MQ/3?P2-VK!3T9[!+"EHW72 %=;5(>B" !R #LLQ!4.1A_:7WLKZ^O(K)0(#H
M/_<(9/76OB@KK 4=?HAL5YNL)H[?95?"I_W%W#?VYTINO7G$OJ^;%
MP8]_"\ENN*W>X]@Y*O#9KFV69=Q78F.&3?]F3B+.QYA03O*'=_FD-"SNR?K1
M"$"3Y;.:(KSS6:<>./J&H [Z
M^20$?[FYPTESVU)^*?PTW^3^?,8'4:+JNC&7,-=Q#F#B899YR*NNFN_WP,]6
MY_:!ZBS(XQ*FXW-YM,W2850T=[W[QW^?G N!?!Z'?]_=3ZS#V9V3TEP.?+'%
MF>>6G^"271B)'CNCA!)*FQ$\F<5<)=I*BJ=9([J:W
MI#,>H4R[[I*0IQ4USXQ+B\FTZB^SZO,3)J%V52=UOD!,?5O^/0KM&9AU.F(UZZFR=!*'M2$ SZ$];1(UO'+I'2G(U]&^MPC?!:ML6KG/548$JWV_
M/1?+!0"PEOB4AZ.W/E.2<#L 90*A&(=2DFVI,+':@K1Y8>!J/Q[:?8 #M>9,
M_UM9=\^;6EU-C0\P'%T_Y&X7HL@R*MOZONKE
MB=W[XZ<#7L>,=-_.*PG(COEE@W6A3F!B("HAFVE=^G?%^K>-,56D]8XD5:1:
M0U@A0(&_[UKX(!JX\[0MXDX!4@UQ:<)U[CI[G&GIDG#IJ_R=LG_)SA\"AR$K
MAI :+'5V%'4;(=L-*?"K9IUHBS6+2 (K[VV]3J-T3YO]V1YA,C7I7G0J %V9
M9EL==J[MCI9K55),:OPP71$(K!1%*C:!=;IX/1NDH(JMMU[0N9YKOTH)5ND[OJW_V\2]$VXZ.;-'-6DE!TX>:/\V-_BT8,L>NWGW9%A;7
MC"/(^DX2N84-<9?SY75 1M<4E)[YVW;>'%F(?C]3(NLZ=\[*'9^H5_=I,O!&
M[=EZ@':^M76SZ^=]W^"ZDS%TOF54E;7M[)5>\39.DMVE7G3EM.6YWEF<>0[;
MWY(5D$E0R"-?&O1_XM9F/?*"[*]1G9Y,VH!#4H3]K!@Y=P&/_F]E(GRP["YT
M@Y>W2B89"VM,#4U=ZF/$315/52H;?ZW'WI_8[/6^+SM:_4QM2:]:.YI0M]]D]PZGM:XB59!.?'@O=EC=. _.K8_, PI'NX?WC;A9)7KYOD&XW Q9-U5!D
M6SFW3V%&@U/E4']:P)5/OZ$95,M_W?[R#>8H+?2Y0UB>I*U,AS!QL8C9-X?_
M6IMMFR-,6GZSJ5HS3*R?!7:R?.M\GZUR*:#AS\D#[B#U'?O^@(T4/!06F\,/
M SVM;NU(B85@NL(_:RLS^/U"1F.6.9.1D7\F?6?Y)\O#M@V*C1-V9LIBEPV]VH!V^XXIC7=E@]WR&?JOY<*G2MA\F='(_@,M2P'M#+! PA\FKZC6=7ETY6E4YL_.3]AD"V/X"D03Z@MBEN&$J\
MLV/YLSW"&GLF@$^.T5P;Q"$H/S3SO 43[$X$V0W2:PC10AGRO5;5 FHN(VO#
MQ#LD>^ZWGWSDZ(/:15E^(5QYF*7/SU%]%HO]G@:\'WM>?!\U!"D/&O2H<\\]/X%@=[$N?%:XS1.)MRY?^&\M6O>DS7PTS2_E/
M=*2X<)O+;QOI#)BD&=LTPO>;XCY!>$_ TH=1!YGX>K8!Q,N:9@@5)'[
MI+NYSNJR[1$&:=6]-7._+-+4FM4@X]LZ*/9%)Q%@H'^.<:0ZK=GMRSD_6V$D
M6$G95;3=I:8W0 JB9%RI@_^)\U\T*#:SA+/6[$P!3@0HV'S(&_(+[R?G>@ZZ
M>\#)5\R?EG^7@G(;PKLRV2RZ/^/S+H-?MY]> V3(3(JLTP$0+[:.):+QH;[0\O':1JPW:_3KA[]?_W-"UX7^.F_X^=7KB
M_SMN6E*4%*K&7/SS]?].76[^^\HG*>A_QB[1BE+0A<4FJ]&TQF78Q[_COZ8S
MA/BL0WQV$PP$5' U'QJ7&HKW#W=L%#6'_^Q/'9F;&E^Z8A1B79>7+F:FN=[?
MC\3EQHNT %=A KT+N@'-(VX&FEKQ"EW4+:2--.9P
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M<%Y CH/J%-3Z54]AJ 8<1[F+_>*3M/YN=S) ,N/+XFGR4&R.ZW][,,51XJH\T[69(L;P]OKC-[91QV>MGUVUU286Q
M]1)UT8GH'UG@[NNDTWT+F/5(IA.R7\WS:.GDVRL-!:A4RGEW.Z/4O'SD8EAX
MY/2/LR4AWB'F*6G)3L4K^G)B5.=>5RP7[8)R^ON2:G]N#%R\UW;TH6L*SO+O
MK-U?\/JL&$U8FK["N
MLA1C-VF#)O![L3+^)"G9@+$4+B1I-)W=F+6Q>U??0BJ%DC7#=<=ZFB5_53I\
MRX>:)1DY97BMHB%YQB&:DK%XX!-B!5(*JFIK9H E;7BYY6S\9B1!T1M(X=%U
M[8<3(:LFAG;WB=TYCF$MFG0UL3W?_2A?F"A#VU4GEYY26,1XLTQC3<&J=U0W
MBX=#VVOK!A3N[8>\"?,KPVPOKR ^BF-^6>89%!D&;-^6OEEK59:%S85'+S82
M?E3>I[:V<2R;4#K?0I1,5@$W3 /24=_:-%[XL] OT\/B0N#JW]C(?M5,@S.]
M:)Q#"8J55->?FABD.U2X\YFX' 02EP#Q?]]V)[!K-#+@.>!L^9;14U#7892U
M+:^^5FZB=C$:M\>X@,/8!) :\8;O! SB0M%N,2P(D^<'5B%Q%5X4C1THBRF;
MK[N.=1J5["TZ?()0@L.(SJ$D.LNY.!,^Q;839UF(51#.M6PL$C_$[&SAU#@T:%C^_H5+!&S$QY7;^3$]+Z,DE
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M&1M[HDMLG^T_!!&H9/H4C5E])86\05FYY&R$>^6/ASTVTQ2&O3VMO6M$CGFJE>JA=\OL+LY]@1SZI/(>L(E_&)6-C^J/LPE_$16&IHS;00U>>4V;K7R
MVS%N[OW9QO3(\E+2ZRM#90GBT\R@\>/P(%3QE88PVJ'<'7(\3!*IFMQ"B('P
M*1OPRF,NM0SA+OI[[(-PG9R+,"2"UA+G8Z'8O)($)WA^6R\VT\##\5X3<5''EMRK5AY[J
M[P5AB:4X]S+DD@:%<] <$I,^FT35RQFST;Z-P9WG*>,C%2^A\6UG6C,Y<%6D
M6]+DNR<\XAN<'3]%MAKP42XB5J+*S$*[.O:OJB7'S _:_^RO-$!%6A[OYX;I
MMT=J?S-Z><7@>([_S7,-M>C#C?B-FMHGB]"MR)Y'\_U=+ -GGK1-+X5F1Y _.Z,<,;?YAZX3GLN5;KZQ;B JY\[U/7_6+@\W
MAV^@C-W:[ZG&)TCLRE@0R>=YR%(!38U)^[]',_+_ZQN=BO8"9BMX%U^Q$1)'
M,^4C8C5;)";\T0=5:(?&(8T4YR@[8C-X>X*"AXY]ROF:WN#GTSQ:KR=KS4I_
MBS33G*JZW,:92TU\.415;Q(V-%U\4F#2R-][D=.*<
M.405K,;H,#Z6"]^(NYG :Z)HM]*YP6"='O'!I:L6M8SX77V[]#UZ*C^\UXMI
MD8(=?^='V\B5%',8&I'8 /1LE(]3"L=K63(V2-_ZAIN7%PK3TX.&&H$T%
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MYG-6Z!]"6&CK8-:R*9&9/F?RO\=/)[_]O\YE@U? AMNT@-2Q=+^DKOJ7W2\4]+CRDAC_6'YF4G(YOA(?F-/7%;:S*S+VOHH%ZMB4*J@K3T 7+#\+APEWC^6_&9&L'0>YD7:<6#^F:H(?*+"6(4![$!R&C2IC>R
M'V3I=NOUFHO8,NFB/>ROF%B:O )$-+DP KEH_]&+G95))R=/+2LQYS/U/;O,
M'34]>Z9"T&H7RVO>]LUWG.T_/&@C,Y&U#UON(".0^_P"C,CWL@YY/]=ZH?4G
MY\8$/TAD(F$L/O9#A? )]:X:>&U'8Q.E\3#PYDX=>_Z%VI,DPIN6B.')U9I3
MGEJTVK>] 49OWG=;P .5FQ]=25G7LW$%7X9JHX(X ,ZU3*@LD\/MIDM6I8MCR6VAB^WQ=\ CJ%D'3Z!H$IUY70XZ9K8(=[ACO-+B_BD\[U4>^YAN4 .
M006(.-_[,[E[B=?XNG]R*(3 6G1^NUP$->'O8C0M763<-9F7@A2.<1$0SPSN
M3H%FBZ-B&VT[WSB*XY[AO3.SJ>TU=N5O)UK:A8B4@N\H3M!_XK7/N5A(\(/#E_T!YW
M)/54U9KUE*^7:S,(T71EUY9:>!(:I\S9+4:\9DWLR<7F8B/@:!2\4K!EJ6Z(
MK/"XZ(UOCTQ4Z'V^'^8&%H6L7&%)=,UC/[DNK\>9:8&&EV=.^;36/_ZQ^BGD
M]J8- (DLTQ<9\"^VP46&BU+0TCWLVKH:Y4+%6@F4.&;0C/^O@5MC;+O%=S95A%FW2#V\V*]IY9FNF^,T1:[765%$RR9-$QO'_+=.V/H[-PW;6QN
MLNM00'*F4Q;&UBB4KL%&<
MMO@RFQW?W!$XI_= ?)G8T$:+'UKFC21$YG9P.C!-67L%D+@JU0T-07G?_-Q.
MED5L*GU;6E*,?PND'.N".G*644WXG3V&(715U)+/2&*IWU)>^H3VC:+MJ=ED?Y>SV@8E-L+^.^C9J\^U=E0_N?CRSL[)%IR)R$JLRK_QWKL8Z\T)NSOO
M4&?5U"!T,W2SBZFL,W'@_T"H;!6<($?I\TM35CCHKC52@&P!J@>FMMW6T&JW_B0'A?@"&<72[$Z7%FB5E;TQHAY>QX"(\K@N'VEG?C @7N9_LD
M%L!;X.I$[6@C41%+<.;_T,YD-'];^" %J8JAO>8&OC9R_)@/7@+%-M:4Z1A"
M->3P'>ON2>$TG;)[!M
MI_FDF!M=,CCA0.Z)SM2K3;3@I&&R#1GGOXDB3NH'N;1KAKO%CN%
M<%U*SKL36?))=:"T9&;&:.1J2D7_;*Q$#K>9/_NP$KYEC+361GMQE8!4ASXQ)CID!*=LX+0,HLR+@IMMOU*?'RNF7LY>"8S=/=A>EOJ%NO2S '9LOFS#?T_51F1B,0WT/RKB,)D^=N43
M)A2'939!8H*-/<^/;5+5Q5).]U$M7PUA79OMA:CJI56=_DQM=$PF,BPD4/[EQQNGJ._C*M3;D;;X2[+?!MFCQ(W>-;BK+9R'>-A>IQ8;I ,.IKK;/_'G>^^I^L<$P0]TO
MM0+K.3.^M1?GG?\=&7:HXL-C^+A)7&6FJ6?G@J.F6T]Q5:3>Q8K4)J?NA=4:
MW)[SY;5@QXZG;RDJ =="8XSS;F"_K;P@UTIIHLN=7?KUA;:YQ^1D-<[$?"&+
M3![X,5YF>=^QDK8A\Z9QR0Q:S%;VO'RIP^?P$?95:M7]:0OKV@-W\=M%O2^B;?? ,CP3Y3J ZJ'H*@I39.VC5EBI-A0%CO:VL\BWJMR][GOW@Q\-Z1I
M(.=+3!WCJ0>"VX6I!XJSTR:5785W!;1$D0-@QZ&1.
M6=,K=BP0._2;F>@ A29R/SPN P_%HRR;:.BK38:+6J&>0]V:&;TL
M"")-& YLN,7D8NZSU_EHDQZB<4'YG_3O5NYQ/R?H/>H#-@SUV+4QI*/KE81]
M(";@?/R/L66%M+\6@YR$EFQSQ\'X(92D::,0I<-P33O.H+48+I^59_ZK/P>E
M&,M&*H>OX+PT9DGD[&T6769%[ &*EY=:@=R+23/J?V6%-<;3-WSL%\0*$
M) >O\DJ)5$EI47889C9@MHB/=9E%'FZV$C[&Y(S3P)TAEWMJJKC3CM@XYI/V)-6"TDE;UX@)2^*/-H57OA*GH4IXU"ED@'$>C-V%&*U9!MR
M2(U_HK2*.ZLD1@@HR?.DC4":V_VF,]VT51/IH6D\F.)86-?)D-UB0K%]83OY
MTM$"P_2 Z-*Q].CH*2>/:=?EG0)$K)FJ)A#AS&[S!-7
M]/+[O#^14-:1;:
M5VCJ]&XS!Y+JN*;;R5C8_:FR*>B>?"SA].K@:?!(=__(S(9=SPMV%')V*>P*
M!XD;^^C#!9K@]?RV^%>"M'O!NJHM!5Q8M(4$TH.A'N6:K/'#@_F89L@F#VQ$
MZWYLK(? -=K,:*.HC:Y06:::RZIJNPNKI.[D$K6QE,8L'7XP'=6'\< STH1I
M BBB2K>L8G:_&O1".
M$D%I7!,/J:V@8A?&S%^4+*R!A2CI1>XDX_0 CYSQVJ''N6(KOF-J&I>PWAW(
M:7:[CM?H#C!+"FO>Y]$0HI*3CTRFG4GOJ&JIU'19/)M[Z<=175;UM8/O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M7,H$>OM(P.HFY%QC:F3F\CG6:BN:C699C +M8,HHDE7)2EF)FU
M97,6I+_$KMWS_WB7Q4OY&^:O#[I2$ =:Y[R@1Z*.?*F 323]WL$^3S>B)<(39B4_7?'8P9
M/I("!)A'W#]N:3MA_.SZSTE#+>0P9*,\25HUI6.8K&#P E*Y.C>D%.,+2N#6D>2FUY=[C"TK&;[
ML?&=G@>[82AE'8Y"%2=2SQ:X6#K>.9ZE(PCIAA?YTTR!-"EH-3%.[%.*#;)'
M0=;O),>40$TY9:H[2FP*LG]89.^L+D-JQ40\)\>R?):S:(H'9M*&I: FA>L"
M@EC_71'6TO:(Q&PK$; /RS!)<0\QO!]P64FQ'=T2@$2LP6N-TTPI B%I6%7A
M* ^%M%*RTS;P?<[9.%?'[SV]/$[[S\M^W_8D,V>NEH/DQ@X&B9OQ:0B% DH)\,K@0
M2:8\*,*(=V#@[*<=@5:MEWV>5;?HJ+C8GSWI;2MWZOV?SDV2O>*>'BD(35=K
M$86S)1^S# 4FL->BTJWJ98H")P0GI^*X):Q.,@P27L0(#MR=#-KX$0'MY'FD3+O?1@&GVT]U+,8V703.#QLYM$BV4SK1YE*0^A7LL6.U H42#*?$LZD9
MK!-UH3_@:LK%.N(Q@4+:&Y3VF93BQ]_]W2(S)QY8B)[*_=88E:S5$M20&$&W4J TTD58(?+!DFC]=GL<1'T4'._&GV_6W\*DI#:X)DDW9H3BGN?!_T
M/-F-L3T_Q2ZF$;VK"\_<60.19=0*O '@RT,T$17$)_EE<6(8MPZ&>/O>M%;#@0%>BQ)N-P\IQKCZ^N_(57GOUX.!>QQK858B.TQA=OE3R7:*&,ZVU
M-QH!(H;_H/,$4>(CJ7W40WGF&< 5GIN'N)/_K !+?_MRLA"V67
M?J M M,G^P7(*K$)?X@X3(S%JW?A-(<'P8>;.\76'-%A V7]LPDC,R.2Z]64
M6)62_$$/#W^37S\#E.F*^&'5HV6?V1HR_O[%(XK 5+045.!2ABB\^ _CP7,I
MC1(%(%8_!FH-151J$J>F\_X/;6\:U536M W'IA49 ZB@($1%066(RJ00$FT;
M$!%Q9)2D%9$A0AQ @2B(H1!2"LMM- 0$)EDB PAC(D0AE9$YD1 "4E49))S
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MKRQWYS]#OA;>1GO*7JTE1*YL);?")=ND*JNPK[5Y4C5=LIJ&" &LEJ%
MO1&RB@:B-Q!YQ_XRJ-"+N:C[L?U^C15M].Q7VF3(6^1.PB,5PB1&#G4$3_ W[_*R'Z#[,AF-M?UE!9895Y(WK70G74Q;
M=.?")9'#'FV"+:;E$=_ %O$J;&X@$0:)_F$-U'\Z/+'.2+CQE_%*?(E3<^!'
MO2C+KS-+MN]NSP0YV6S:PYL,J[$>=;R2W*(%:TA2,4%ZJ
M1E[W?=*96^GIPWHG1M=""96'R?ZK,,1O;;NW-\H#A(!UEFM=)%YW%NM5(Q[@
MPJ4M.$66T92V6WM;/SD0GHA&I(P(XS*;@DCRP+F=RZRMT+[@=60*VOU#3)P\
MM=[L+OIR,.4S^5'T?7*S-?N#.OA5^HHE6\BS&,$C.^?M2)=!E> FMT^13,GN
M55@R9IY(EAD $ O!95L?ID*G5V':Y,^ ]'MLHP0@5F%9C"@5DM;+T'U*OR+7C_;B)C_F>!WZPD6'O<*3S+"Z3MJ
MZC,VS^1#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MZU73MUYK&.Z.*MK%>D1<\_Y[(Q&H[YK\# 7T?VAO-N9R^T/HUC&2YM>^;I1H!A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M+=.O^2^-,H4J1] (+R\LWK/P7J.>>90>IYVU;\#"/6@Z%*M F C\KB G$D"@[8D%A&@(VBY&JM]NO(ME$8;#[WS(-GU_-;0J/<3!,\4LM>S-L=NDVVXUN;67Y:1]^]_35Q94_-HR]T]
M'4MS1Y&IGRRJ7;GMD<=B]EGBT*.%&M:_'_O4Z"= 2O[ #3M(7Z7'K<(6G"5F
M.:HV/^K?X9]P@W4/+,@MGMD>XZ\,7$N/HM,KBQR!194'M_^,6M%6L&%*:05(0N\4L.%+KD4!G1QIUK3IUVUO28+V"#\O<;/81&.BI6@MG84#*<
MZ-7*,J:U#NL0$QMHMA"+JVP.H*04 C^FF%UC\%E C654AVHB5Z0*NCL5I8<2G2.0OJ"LW?+,EMO
M&5TCF#25>$,"D8J^<+:9'S>,X+C,-&"2M T:A%%GYA;;5F%O97Q3-5F0A9SQ
MS,X3NJQ!IT=5#IL)9NYB$RCWW6UZH8N18YK]WKL)4*"#^
MDRN6I !LO?]\[T&$2MU4!\NH [V%I NQPX2S*=>\I%RRIK%?)91_467P;P#Q
MXCY?)&#&W/+!J+RQ3&TM:^<%^?S9YL[:SZ?A*U_BCX0];_WH(
MTU6P$&!DJOT0L9*["INF'Y'YBDR!+>P&[M^B[.RHS2 C2ZEY=,=@HXV@&.5+
M'PI(??D$.F/B=:*'UJI=M/9P2_\UB0KL D?!3*E#8:OT"=$DB^0APFSTZ;PH?S^/BZJTX#=1-S2*R'K'#
MM2]:%Z^WO1)(2;@N\+@JI+9&KP.8B<'V] *JQH3VND*_<)-X^7+9@JF0C)0[
M4$ 9UJW'W5Z%26:*5F&Q"+!02H4+^5(U]AJ9&QYQ>ZD]*]G8^<(S=#9E&HV
M]DX)-[%C24&^ H+"Y+#?_>DOYO!X+((!>8DPB=D6X)?T,$&96;M51-@]U.[L
MGT%R[*?T4\";S."=/Z.X0\Z=T">([+(#7UAV#5:T#++K&;TO-AR8U
MK;7:O)#JP]BA$6)V?XLG,R7]1*9CW]6%)DMG16>$0ZV32>#7]EO][P*U&7]%
MPRM!"N4#N*Y*T*/ %APC^>N2KR*3?D6DR\L _V\;Z04?Z28VECA_T.)3]$^0
M!9@RWHK3RDL2UT-5P4'H'2.'/Q#A8_;N5(I4<8(6]R'4]J1"Q\FG4<.Y=VM]
MFF*LS42_QRJ5AZ-6>J+>V!J]C-8D_]T!EDA?,;JE.2RY'/C!?SBKT__@(>@Y
M$OPS?(1AK,5[-T[T5K0);_KJSLQC %_,2(G1I$MON[\--QLZIO(G?--X1*ZD\/$XJ265=C/4@3);Y"U!3>$3 JEQ=>@=_>$\C>Q
M*?H B:^HTRIJ6_(8H),V%4Y%="=;& (/^J.W$I7:T'H (I'DNMFEK[]LGWT/[MO9T[6;@*6VM:61EUP(@M4Q0"PE-0'@3$'08".H(ZDN#'4_JI=I_-/],
MZR Z$^P4(%ON ;?*B@)PFR1[1/0-[J1CS,'O$T[6SSSJN%/
MMV;\55_PF&SY)./-XR>&]SXLF^/\>(:U%Z^,;5V6J$(#G7>6+Y$\M^Q5_6[Y
M=ZU4.JF0JVA6N6C1XB-&!:U"PC7RT KZ 59IJB^+:BU
M8ZCGA@+VE>;NG^_<5\7/K_^?+X6LPF+8M,T@5^MV5JDB0(+,-'A_QQ%^J F IZ(IRK%E+I?ENL#GHXI5T#3O"S>) 7K_L
M<+SOSQE;Q^5'XGU,SPCN0'M=1KZ>JEM)1JM+AS+D7ZC@O0$:-2ZAE-C?G$J<
MY:2-ZD,7!5UN;3W0F:_G!Y!!6F?Z&M[S)@$7D8GD_^4:D#Y'\P_)*OJ:T(P)V@1 P[WL2[ AD)&X@,\J8C?F/AH9@-
M'G9Y@3@%.TJ;LX,7U$L/K'>)"XV7*.&?= "8#K@0OHY8L'BFLB\$(B%+1HD\
MCA3.'K28,9NUO2G.Y,[CABD"9/-ZU@;OJ>B-4(6@6\9+[*'M10EU)I\>",51,J)IQ8%BA+*GDXH<1UYHGRNT->!X0!0A9OT$%M'#B#([E>H1
M+U>(D9-:C,VL/)>:7 93OQ/!W2@SD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M-?C%9W"&0;\SNJ=RP)BU7V(+^4O5:[FFQA;O,8+95FI21$=+F9P($7\5%27
M4<1]) PW>%[7Z51?_XN(=&K^X)?7>EJUB:_># N7>",,0E(V4G;F_F0*>6T(
M6\X_0YPDPB@1.]HBTN\;2VY^F)+"@<78W$1]>J!4E0TL=Q=/1,S&STI,!$G>
M1UUXV[53RDH"M3,?/^GQO?N;8L<8N;W4$G,5DW1HM\!)!N(V>ROL%3^2!5[W
MOUT]>B?[F5$K2UFB ]6%18&T:1R#TA9T\ B8V6:Y>(2T!M#5G@/-Z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MLXJ%4I<7I_ZJ=AN;M5"6@)[%VR#!*C6 !5^+DHD8UN*CM>9/9FY*<^A>"'+ #H7]>!D.SWBV]Z#M*S4U!ALOF 2#>8]N'XJ#MH,- 1TS">#ER[]5$>7&#J^'*W_X3NJE:W=UU">"
MN'L(^>A][R?YVNC.93>):W\K9O-"0V2<#,G.-O7;8;-]0
MC\9F,(7VY";Y6;JTCBV]BW\A7?O]80U[)9VP\3_/:H9A'__!2?XSG@Y&'R0N
MND$^ +U->DBFBKNDHR#"NV=Z.H4Z1E,Z&FXIBW1<3@]6KQBTNFL]@)TR$
M=>R4V;-9(0U064A#Y$AFID?9D\?POW'JJ[#@9",!CT./05LG-?<1BTCN@Z&1
MNF=/]%F4N7J@U+(WX"/)6R1+,N=E3M.8]"R,"_Z0O?LJZJS 9>U$=]AF%RVH
MY(5FUT5=0+[ZGQ;[CP#6G1$V(P@O]IJPSNINAFMX!40;@H4O;)Q5ET^"A3$+
MZTVDVM*>:.0@2GV,GX#>7]?$[I\Q3^HO]?>/:M=%Y$U\^@//9L!R=IG$NM-@&_ZGL_H#?Z(!*VIM.\%>N4DWU;[Y^"J%N%-O\ -;@:4B^:V1*L2\787A,8F>UVN@!M%4N(1-X:]9
MO' @,#!L#T(%XMR(N"S78< ^W'Z@(<(G[-,^C!Z^#?U?6>UKW],HEF'?'8T/
M6W(*\9/6 D9%!@L[TO\AZC^%LT_U0MT(WE]U]-/>#E1^[Y7D;+--=? =QW(Z
M=NQ[*)_\.#@W^VV7,NV!=H=D$]*I%TFX:DKVH^E]KO(G:[&V07(=-=&[0$2L
MN2VAA0Q'R8D(=V@J"\C$*WU=<0#1%JDW4_[&DD+6]CCF@
M#5<=A471_R5%40%GQ>_!V69"PC"/TR0GO@2RVR(;"+&+;+5J(_H:B&TWL%!<
M.@./%0Z$$K9 VBVOIK" 58S/@$4=ZI!@A=RJ*:Y?C%_H5B0RJJE*",6 C.Y$
M&?Y%KCPF^_.5I;WUEHQR_UO/_7E8!*^@WY1T*%RH@C@'8FD%785>95FKL/CJ
M9-,O"HTVJL7%[G@Y3LWBTLW.MD+?1L-=NK[\IA=^4',@P4-QMA9I,BES+;0H3S,H-OYN\04]FS 4;,/L;S0)\-LSLL*WA@@[WY(,=#1=NL8U(
M,KS63T_!3$> 3&F^9Q,L.@(ZH4]T:YG:OL-,0%6A[!U1S.W;KMQ,=2Y)G;T?
M1C^)BT?OKTDE1>\=^)A<5FJ^P(B,?UJ==*(/N6V@U(-+?H\P^/)&X2S94?\,
M>]]/+#^@_0YXNM%"4!<4;>RO-ER3\&2S\1M].^/1ZXJ\J7-WQ'%SH^#@_S-NZ6!)3V'NO-X0AEV,[(_?<'H3%I9N1V(RCV\
M+#_TZ52MN\[+E2_[;S>0DW18%T3WD[R:XC#P-M6\4#%!.? KGH4XMXP.^19,
MT#H]$(SI8U]?A6TWQRUD97[X)LZ8PTPCDLCSKJ3O(P5C3OQGI. /DMOH>!DH
MY($;7YH,L) #Y:%[RD*\K!H00X?^())GR+[Q4>F+'W8R*U*K*B5\ ]&Y7"A)
M5&282$1Y/^O855M=OV@A<*P]_&Y6PWU#PD+5>&)9Z\MI2E'P8J,7F.>1\M<<*\'P)-JJYC]9[;B
M#Q+8_!)^I1\B[\?ZKL2 !&EB=QP;Z F@209/_]?_I^2?JK)CR/JX/#YPDO[M
M9Q)I%59)SR%/YD"^N(>S.:0+NYNCD<3 =<.MQ]#PM[['?KZS3-L\XOCU0=7'
M+/1B5]V-Y"6E[_$90&_O;-(1/7@.O11D'N()VVGB-'+,"/>(S#;YS9GN=(GQ
MQ;^RC_S=K%]FYW(72WNF_3Z"_GK%#1R/F4?$HY5 ESNDLX4U90+:9G]K>ESC
MD:=E'[]D#QCW?BAN061D$7;_GJ"VHT:D"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MPY=]MMC8BV)CIL\Y,?JVT6RV*&!_S\<,QM
ME#[(Q6V5$+S(R6@UQF-2>&YX*5KIZVZ$*@H1DPKJ_[4B/&)[(*)'?@"C3MHD
MH"7HK05QMTD!A2ZE1*=V[5VSE$;'IR/O)M-N!D:8%JHS!JYJCMO55P[D:MWJ
M"0K5^O+AHN7R36/"6#JBLK#9V\&^G[2K&')S&VS<\F0X0.TS2Z,.7$PV
ME6 NUZ.68M\W3(Q!.?RHI.FE]OR<2<\3G=<+I["(!F;O0I)3\H[)I5%LMU2-
M-BPO32J\QP8Z5V'0WWG_+^M;B4METDDP_U$K;]$R
M(RXUJ,1["@C0#F6T5VIQAE7*&\A1I0Y/B-$C)_LT(G,/>.Q,>-2'J!IO"4<;
MNY,NIW/Z$0G<#.?V.-9N:IN>CX-%O:4FQ,MO&_-GJ[T
MF-$-FB7DU-YV0+E^,9!Q*L/OK7Z>3 B0D@.K,.F!W?\@DGM__"_FP6]#?R^<
MW7)DZ2L4O4E _J$ WQPR$M^^L 'L;#DIAY3M4-$O>/;/ZPU2S4/MT7_-SV)W
M 54M-)UQL'MF70UMB\0P*(2]<1[)J("L$;?0JB2SX5LR(MFQI=-G@N9S&/$;
M<83C";_?J"]$*D!Y3A1/8#9^OJ1)RZ/?5#_-O7Q^Q=X,?ZTT;5$S/3QYIYF^
M^[OFHKQV>N$Q9FM9;=XY!=22+)\8L;D<@=VNXO6Y*UL(S"X+BRR#,H85OHU2Y]Z\H"J;.__3R7"
MS6EBQ$J&KN$0L#1I60<]B +=P\D:Z)WV-?P-"WLL'C,P6X?_E)RZ+MQ"9C)H
MMC7KAPT?>)P^X,#VQZF2$'E0!K]=.SKU&LEI77(Q%&31Y;H*NS 8>J]GP>1X
MMQN[_VDC-]2ICI3YWNUDY<":_9KH8W+!0OS]?ZFW4:I+&_E/^D^0S-#T>3-P
M&=.*@*^MNHCN2T
MV!(AGR+93B=:M5E?]NRF-#I?,0_".64?W:A5$];?IL0Q3["M+E8W+MO.S#(5
M[UDVF*+OTAEW8@\9C:'SGKR%HE=AS>E:V"U]OOV$:9(1(K'QH@%U7>$N?@+2
M(NC:-^O6I3=THM2[>05V%;-OXH6=,ZR:_@3?<6=92YA $N@I4&B'H6^%(A#$=AGEK%\MU8P)OT
M4$&)5BV51LWB@.NMG:XTTDGQ\HRY\2K&1%PQU$
M34I"<]:ZJO1V[-::--ZQP>!0;V+;I4K=@)D/U%^MR[AW;*6T BC&JR]D)5"L
ME.QUO&>\%I ^LBBGAG ',?\"2X4;'_F-WJNRJ: ^>O#SU<3'L\R]-_G^B_1=
MD(=,J8AV^O)>'F;I+J1:B1'($%3>4%1X+W[K[VBEF-]M;H);%R;Z)[K""1S^
M>@DQLY6\^5>$-LG0WTUH6R.,5O)YC0%N$XTWK,)V;;UVG1;\K0L6Y2"B*OKK
M'0+2V +XQHE]^%$]4#7+-+/$?]',.4@U+^"0M[CK9I MHZW*9NWM/VRKZSW/NN8R9#-V@EN3O94-A([F";HT5RRZ,)SA-+9([ND0,1X[]?(9,=%<
M>UP<.\-/M'>('">R:=>%T^+)%H*5T1WVZP)1RTS!!XK *4[A56Q).?\'3FEYZWEA=E<+Q
M:K4^^<3B?90%7&%B'4()2ECH"CLY8 X&T+WKERUH'.I:CI"L.-4M^+N 1]HB
M>X,8R,>CKI;=B-Z*-G/:"!K0MW\K^%\J;CX@VDK01RY@$N'A,3?*MGY:I\[/,;F
M1LZ<%;FEX^#?W83 .41L-AP2F#+ DFF,=N.>X$XP>OZX2[-0D"E5PZRY/R-C
MBO?-(-&6[@&Y*:0VY,6)M@3*&0*EP5.;Y'MF%]2!2.$S@:<4[
M^XPW"<5R%XLGP M'5=K:LL:64<4*&K\_UA?YD\>R96Q8U (
M>4H02AV8#HQ8H=\E:;(VL\#0A5)M-"6_$S$T!I[(-AZ )X^QM:X1.T[4W>UH
M$Z=S:V[5G%UF_HOSP!1)FS&5!OD%4-Y1VIC\G4]]*!RH!T] [V0J1 5IYHD.
M71I\4LM%_=&47-VI,+TP'12.8#&ZPJ8.C #MF.W.9B(R!:W=_%3BWC>OU*WB06SO;T.C=O Y80>FM%.A"-V]LZTW_3WIE+[Q
M=L^9A4=_9%RHUZ*4+VQ,.GXL5 ?O>'$6(U!8R2%_KBM.; 7TL]R\R]6C#C1JKKUXQTW5V'GGZS"%@##V_(+SSJ:,=4P>8Q,H1QYH_]X
M/X?_.+^.CS,=GG/(_]%H!?BG.RD0R*K#W=>27L?(AU$PP!U(>0-3JKFO&_6U
MOR@'3I<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M(:U8VC5&'UYSZ0]F!U+!.OY=IM2JM35N:
M*&/E$LQOC.C#LZ^L_([^J7$4;D;TMZ0PP8(G>GG(Z5+@^V-0ER>+0O:6.!$^OEQ:1G666^,R 2#[T"]D?L62:K;$*
MXR!78:(=U!\DMP^9^(CM5S(9G]A6F'4D+1]T6=G(U-*'C%WY/,K.P06_GJNH
M'7/08PDZQ*9[P] D6KN"8C=HO)!'#B@) -^]#M5DT6 C&,U>DE.>;Z>[[O>O\EMSA@V"J)'K+BX_T\;MES(#C4JF]V047. =^@
M$]_UB1KFF^\> /7:-9_$_PM-AF6NG&,O=*W"YC=@Y0$CZ2\TW578]/]77SN0
M/$:CCFG(,-3@U1KC$L#OHGZMRBI,::MH248W#8'(%L167R[:JHS63E8M\TA1N"CPKD^]>"-ZL$QN2FZ'M&*PU=#[2J%,&T1YR)&[Y0=
M)6CFYG=&AA4ZA-0P:WCB98:20MGLM++6K9I%I7"?O5C/ZAV1WOU/_?G6[Z/_
MQL'*RTK-9]Q>O"S^'('H$JPHG>8N3)AW69CZ6"Y]HA6,M)65_L+K<-GA).I2
M-FE/$B6?5+$Z#^[*6EFIB#NY^/\^#-6PXROIZ)^)P;J!)@A!06P 7@C7)A*$
MEA57'^)-9,B)6#?9"V6VN-%]#*IK,H(?"_@:=IK%!,$4K@KRM/D6;)!ZA!'/
M>#6_Y/("%^L9UMID)L@[VY\M_,P/9*H'
M:G^HB?A4<3%(: 3M8C& CVW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MC6"9BX@->1R2O(-+S#Q;SV2.!%WSBW1R'^:N"+591:J,K1IE/QK_/\"![9MLW)1ST9ENZOHZ'"13WTDD"K.7@C>\LVA]>^4ZUE/#PZ_O8JVM&K5F& 950^2
MS@8]FQ);E^?"4TC1S(C[>FK+6]UNR. 43T\UOL4&_KCPS>CN1L/A7MY,<78Q7IL233F8<;.'K:J7%-]J\C3I@VX%Q688YNRCEYB/G?WEKQ/V/\Z;DS
M+'DH8]D>*,CU+78_)MU-5HG*[CS#X)HG6^\7'B,@]9:=&BC2G=GZ R&UTR-G
MN6/?Y[ =G] ,Z\-N^*D+AX).^+6P-L-N>[5(=>Q,,$.ID1/J>Q5VSFZY\>08
M^Z- 2;;E3L\%(T*\GOE=)2$9>A@OH1
M,_-)65AO9\-5F/W _(>&_B_LWB\?NG-N9G536$J!T?LHOPZ0;(5L.!ZM#:[Q
M.A;:8#[XL#?WH?,1B[)?A.U3B]K1CP7>1YWTE*K27!9X+ -F,CKL+#9<2%>9
MC-XXT._(S=C$SG3I6\"7&&&@Q3[#P8?+9_KG-\SD!*3WVW$K3>
MM96\"(W)]YRRWM5^Y[K/$W]/O3M/W?TK)_=-IFN*TZS)DN-MTS;0*?-FLA\[_'W!U.B.09(;/3!Z.P_IN>PV&(P=/\O^4RJ>M;9ROV#XOE&? KIRVVPC[O[_9W;W2P_HAF*.2DGD_J4+_*FP;E4H3GZ]&K)SE
M*T]]??R_=ZKM1L8ND?]G)-OGE)*0-.LKN>$[W5)WE65U<=H*.>*D;YJ[O8>,
MQU9A:_;RS<_#N.E%H%"T4-A"W](-;^O69,=5=Z\GWBZ_
M4T3T_#0J:M_'#T0?8.-MYH$W606>T([)8[-8[KDTKQ'B+ZW]6_IGEV.OQ-[=
M[_IJ*]4N](HWY]/A5XK5"M8[V-NKFD(Z!EC$^^\TTA? M>;\_@I0'C\K*%D14G+-J<9@_Z9A?;3/"P>E':
M[:%J?T^^U:$=FL(!I]F*6'>2+QLB !VMN W3+(U 9&&U&&L"&"3(0HF%ZFA3
MKE3'R3!FC,MP/NB-G42HS^1!X8*LO<(7;71\QAM:*#)=Z?CX!%5+VILG&&]=
MA<6LPE111X'%UI<^8(8@I!.S2262$Y;A2A'IK!BU9BPLQAHF+7N*W+GEU4YD
MN+-J'CEGY*7@O3%>JOT\SKDR+BV1?,'Z3<)828-.+8.MC(^PS$3$
M-SJ$"W"*WD2;=G72D5X3<[B",]U!($,PHC_)#@>Y:_,H\YJ)!#5BHE.R_11Q
M-*:&2_:CQHV:@NFQD@#A>E) *1\ZZL$$T5F%@:LP-0F.+/A*GW#[.I6MG>D-
MY(^R(W.GK*(WUW/IIA*ST%"_O9]/.?ZL":7M]CZ,ONTAEZMMF&O;QK[8&Z( EZ9PY(^=/Q:(IT6_7XY[\.#,I0[_FQKO'%& PV>>UF[*[9^8
M1Q@W/[!5R1_R)=&KL(I%#FZI"+WYE'P)GDD;&K8L+@JWXOW4TOYI(:=/Y,'8
MZG!R;7YWWLH[6>9?P_M@"2(A?A04.&;-]9Q6C>UGJT"$A
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MGH(QTM? 'L.1\O5T#VFQ^($LS,T7L+]W:9X:\?$S9A\XL.FOAE^C7?]R
MK"Y$_9Y4>S/FT8<,$'F//7>:'(!8WHO5684-6@%O;MM2<0.JJ4\"ZY\,82?)
M0V(K+8IS_Z44T9D!S5'+1],A4^'75=[DWGKV6T7-8T&<MXYCT.XU:@(. WA'E)#.W%.-J>D(/='MCT[YV$GY,4>!@N+K3R", S?4V0L[V)[UQ%/)J!.Z0IEMZ#\P_(:[C%KXI7>+
MH[K\&<7'\=]:%>VOS*W"HC[*SQU)_XW^8($PA!B3L@5EB!<9?T0;8U3,=X<(
M1=!;D%;?EOURJ/
M;].["]![IUB:$!)4:G>C*30Z U,B28TCU[
MI![0>TR?"H@4*I5T:Q#S6E@_Q]C5I1AE$5J'R^[? CNW7IF.U$I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M4_C\P #0G7=.N_(__!)YTZ3L55< "G#Z,.PW/346A6GF
M"/('%Y,MNF$J.BT1NH6Q)#OAK-ID6L1.K"*X!\3<&^\)=?YE@N'ET+^@8 Y=
MW(>_]B;#C4*RS3?,6+)ZM$T^AL@3OV8#>-+%NU_'M*A7ZJ&#]5?RA3?Q(IM0<@L9;B$F(U'; RL3X(2ORXKM2U]9,;Y#4JLQO0)5DF-[DO,.R?6Z9>V@Y%E
M'3,(@1(A6>:M6>N]WA)33X&X5KX2,:G=;1W/9<1WS,3,N>MZ9)SOT]>@R+M[V5=<\K!.=]ZTE;H\S$,\[RP6?=XW]+. >F^;8-HDY=@WVD_
ML%"8E=5%HUZ.MTR/ #7("=@/44$1$N#1!M+%OH8XA.,3H^_>3>COCO+TXP[2XX-(O,H30XI&.
M^/GF3"[59#TMH(>'KV6PZ,^MV*32F+7XIXT.L&A:%Q2$)"DE
MNRR;_5J1?H9K@7B^O7YY7?I%9?%,6!$VGM45(.>R]8#+7J48,=D<<1]U=/G2
M1#9B)8NU6=H+2HS &?[=1H+\/8+DB,]FX$J6D!878960Z7+DNM#;Y@PO.?]-
M[7!:83ZG ,+9&\Q-G-MBO\2IZ=, I2>?A0SNE]7\F^)EN2RJXG)5'?)JR
MN1WKX9-FF+BO;V=%)07WQ_C*0ZE6H R:2.HAT=N:@66.-9HB6)$7+-!:733]
MK4UH%/,16Z>3 XTVY4A*J-$V.$*KGM,SC]2X-%%"-+Y
M5K1F3(L-G-;5&)X2JN2GM^ V3(6-*H'R*2;&(7BDAK^V7WPHG,)7R>4QX'J2
M$VD=;4Y/&(44M^/ ZWI>#,ZNGO<4++7.?Y3UN"9M*%A_RMSR'?8HCJ"-4]F<(:]).N^PEUU[VQE3L&B..6WK"+\6CYQOK4MHCH1T^[PF41
M#.?AI!)B:!RT:G7>%QZ@\YF4PZ]:C-_%:N"9PS=/6J4SSQ[1G>=KH'=U
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M4;!0\G (T4U,A9P!G7,07BCR MU/#*&\\LN5)S/#K6Y8GM/IQT]"F1()1/> *ZW0]Q5A*ZM:FL&SE?G=;A4GN=:EEJQ Q>>[8-
M!0MY70&@'2LD-Z'-L48+I7>E#\2C&U;N2^%$G*@@:?GPYQEP!R9^6.MN]^UM
MM750+H@X ]S+5DL3M6KG%\;I--?SXY$H(R2EVA!$]4*>1LX&"M56?=-/-![_
MU@F+HJ;MSX*@ CEX<:N1BH'20X/300)K\KWJ/?-)WF>QM=E?1H>N_E;/*SMIKJF;/.[[3:/??@'''1()D+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M% R0S(+\479"PL]0@] V+19.*6MTL'LI2Z>_M9-'#: [F..:H,Z+V_PTBI.HL@BK\A(I/+DCM:_&:HJI-E=T$AG]"F9E;#TQI?_G-J-\$XT>(G2.=Z$&;8/WKI7DBA$K 4GY:
M#)HAPJCC-;7W8E6.]UE1.(N>,Y]BUM$O%N*Q^L"G!T4>GB\MLP294^]UG[:^
M>K5F7BEM6'(Y^7/'"G5/ELNGB
M Z8-P'^L@+9U$F(20C'RD'XK=E=OXWZRR,3-L=)C&F55Z/W6_<*D&_+FVL9(
MALH9(<^E?WKZ-9\P0/_B=VRZ>LJK)&M0%"OSG=Y8:N]"2_JS\_>#7E_?-&Y5[_F\<+[:%NKU@QQ\3/M;*.[*Y>K3H<9>[%>@+Q[YF0]R.<\D-)D6K(NO5=E*(Y&=
M.C.&WCVSQA;>9JMAOQ782J2HP%"OMQ$A%_KK,[G6TN(A-F0&0>I!F$3UN7)U*TP]-Y!DG,1/GK;
M ,JIA-CC[?FR=,JZ]4]X\FT]FV>KL&:[>95#Y@D,>*S>P;[^5JD^4 M\*?L^
M_+'/?$^T;+,.8"@W 4QU8U/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M,DX\!?C26OA#?.$,]2[JB.EC:.V)4QXE$,T#9"?.M.?E
M^:.W5-3=?2FJ3S^5;)&4NG9ZS4=U^^AWLCCM7C5-%SKJ"60S#:I4LTK;@I3>
M06&X092)4,FH"%E&,!]9@;=ZFH@SG_DO-<7E$P+""['#V!<@]HCJ'+AE!SD3
M/AT+/(O2[FQ>3.>KFTIT@D+2N5@MJA!YGW0H5ZONL2^8G\+6C"V92,>:54!Y
M]'?OB>QV3[_['\"UM 34+\&$>.85I_C;Z. !S%@A#A[2@,=W'7V!-JE)$0ES
M %7:4]R4MFJ6,*[G/"55E(4[C"^Y[B@>D*/23 M>B.T5?TU]7,#
M=9C?7.\W8W5Q^6!@]M;!,HLLK^GZX"RA5Y9+"[MY *QY2M'S%K?PW"DHX)V51&#D>IM08(12[/W=CNXK!6*+):-.B,6>0Z:P[4F
MPY@'XSY-G88R0MA'VT;$,ZQ(#H>9*+]?T+7;B.;$2O86]ULA<6-(QGV-CN*N_W2IP]U3>/;\**
M?JT>,)UGJP=:[V+E^?K/#?NOB]I<_ZW\G-QGNX.W3C8?1?9\V!J-^? 5:_1#
M[Q(*#'X<1-RE3;(,90AX!9*MN?#(8;V7I*W#)XLV-QBT[BW]J/NW7?JE"YZO
M6C1WG'E^@7/M%W7"CNZ/&9)R+F:LF*\M+^I0*633(OT9Q'%FY0+YFQ@S>N,>SO;P]9-8$Z@)F./\TBMG*J].A,RH5^[B*>G6Q0??[1N.[ETG)96J_;W[ZR$MEJYF<\I>?S>0V
MIAB)R!NEG%5855ARX_%L0U"+$UK'#9+NP9)\'L2QA7B\[$UU QW'BAD)H9''
M)$-)AN'%D)(LWHXW)6T)Q5O%E4J.CDW9C!QTGBFK_QTN!XW(R.H! /-B
M%99,VX3^Z9UD&U0HHF\B&4$!/J"BAV2/*C4D>_O75(Z*2MSCPIJR4&'X;\=(
M7I=YV&VLFDA_9$CR)5?T^8H_HF*7T:00@-_1I.4&&L8:T^=7]!W!M=)DPCIF
M:'ZST.E#-5SW#:.4&'GL0?IAC2D.KG\'@^UB=AJ/F+'X[9=M7VT18L.5[&H,
MPADTY7%#Q-XC67UOFB'.K,"$BA>'M[8&"YTML:!TW SU3JB(+F6T*T;IV
M3Z'#1+Y''&Y3IZ!,H_]$_SBCIWHJZ>9["7SE$4M! @,Q]TEG@<*69$&RFW M
M/79&MWW<\*>18R@[>JV54[R'G++1),]O<66FZ.%+ C^=9Y:NFJ^$8W@'6X^*(6OF_
M@->6]->N-2@:E3^ON4);A0'94.XJK+-^IE$_54!5W-NQ=M&;8AX)1=T!5]!J.)]KJQECCS)(21_BKMW*.:'>8)4V*:2N,1M(B().[YL=1QX-\R.EYR/O.B[OX9+9[A_J5;:;'RQQQ">;[E<)*EE'I@-=<_L
M.=2=T?C#(GY:"'!?&O]D4VU332P]^*"T
MZ^ZAJ^?+15*;T#3XMP#W8?,&L6N"PRC3WRJ+=@$'OE[9T"9']=N9JN:O-
M2;+HDR5['5F\"9PZK&?RX7O*/(W\4\;YW ''Y_^&ECM,K
MB _RJ>8(Q)"'?<6R[9Z];\V(84)*VCZ%<:DA2'IW$4-DHT>;X*.8YUGI,Z="
MJ,E'6^IGIS_?DSCW2M\MT>/01L=EG$RRS6WZ)?Q^T%-?Y.UCCV$74FM5DK^:
M_<]S*C>I I\VC:%"[0YMWNN3.==45F&*D8+'/Z= VQ"^9I#O,
M&R/FOC,3XH9(JC=<8M#[1+G2Q=8+T62*!?(M)@BSI(WQY4MV2$W)7]O*T\5Q
M*T^BMTA?8U3+I8:2TS0/"NMWWB+IY0RN?YEYB7G:6<'3(.,C&J
MS4(98HA< 3VZLA5+M0ZWN3,?/[K)4BW0Z-F$]FOL>M#I\Q(VGU X&3$8^XB2
MB++!1PFRO'X!C2&=++?_7FS>-**&MJ*"J)R5JI.U,-^$O)<1.,FF)/%I4)FE
MQ$R9%:ZC^8F0L?R-:-/ ^MM+FMS >?>SW(+?^'NC>+2ZJ/^D
M,RD1+ ><:7C2TI3,U,R!4M&<0,&A'BMR+AR8*N?8NQ1WBGCP/7?_YSV?\]R<
MBW/!A3?LO=9OK>\@>Z^E4AIJM#-K_C3H@R=ZE5GE*.[KR*YW:DS^,2?[R?H9
MO0_3%8:T5KDYSI)]MYIX9>!VVA+FT:42TIUOJ-F^E?%_DH#"U" L% MO6(Z :(U7N>150][*MJ%"Q
MZSJ7,1K?&W.^?I>37CHK^:*72=+L+LK.0L5-6Q*F,Y/NZ/TV7MY0(OA)$IPC
M?HYR\I5IBI6U%V%X@CYTX;1,20EXI@K_/_/7*8$/8&0)E*^12[MU4ZA2,)0D
MN;>0CS*0=?!4Z/!DDM95>C8:[C->9YM0ILN>DXNH1'KH0F"K3WQZ=E&K8F;A
M5]Z@\GE2Y%5N>OZ6TBQB2M&6'V]>K:NJ5W[__#MG-658$&3&@$RR=^L]\;'34CX>R%2I3D\K#S8QUFBFT3':H;V^Q ^8Z[]]L6'
M'GN3\]PW#!T!)IU5>#6O-"77;H[.D_5+VW5;.3)\572LI'L1EIM65H6#")7D9H/R5827*J '=#U H('2$M"F1 V06_ ?!9*L1H*+A\CFH'P6"(<
M8G0T$\WI,D[_]TZK-&1K5G5EA'9F@M2T.,2&.R/+M)5\>_/>L+8F(VU$JA7.
M-TF91TG1"_ER=Z9*" (68?&H#>,,AVZI@R :VZ2K03A0TTG4?"^4$V$228W.
M5.7ZA=RT06D#A7?X)#6\<*)U]W!M+5!6_?#5H0_BX -'+#%)I$O]
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M1FNAQESFI/0PYSL$8JT@9]D:$F#0)AE6I!R0=Z+O(DR=QB.NJ !Q9
MZDBTI)791Y3@39NS/KWA\[2@S.;;@134=C90TIXITP2&J4*S15C50-#UKQ,U
MN>M K3[N3EXOB?^M46@Q,@4&)F2;@4&B6BA\
MP&LY)E$>Q>]F+CR6@41^6C6(N8>J\$+ (*O#3OAUA'N*F/
M361>;KY!W!K,XRJ*66CM=
M':Z-\Y9YA1TOO;D\M\)0-64'#";[9 S/M6C<0T;,DUCX#Z5?K;K4N.FCX][
M7Y+^AP23<[G6"\\'$\Y1=<_]I;7MBBF+%#=Y1/5@SK.KS7OW-'U+AGW/Q"S0
M:]9"F1*LPM.'?$[JGE%2(ZB+H H^NOXO8"1B3BT#9B7AG?;60FSB7$(E+E"$
M2/1?"04^&QBMLRP1&@PYMQ+M01.*H$S1^(J>5=GR?RQM.VHM-^C\."(U9I. $^BO''^R)+]>U@_&/Z)-/K*>D_K4]TAW1^.T7]2=::O-
M#WF#=RD-L.4.9A(W 9<+SA>,O3Z814VFFZ6X!;"K?3AQ,T/*9QM@,Y3_]YZ@
M&7>1^,\0RZP=/ 6X^.D!;+(N0DUFCO<441*MD'&=D('/6^CA\[.R3]>'OA".
M YDI#18A4_!XZ7FM9MXAP4E!WGSH4:0<3'W:4V_X:;+K/-D+%R;:);&"<(@U(MR'W$I^B&R"Q[R[5\#^>/>=0-/8E2\=T?").TO5Z@VU3S-&4=!=4Y^3(U3DI#
MM>KGZZ#NGJ%4T=/+#1U--@CZ(DRR"&N]7H27GYHN GB3I_\$M19JMK8Q(PF$^.-GPRS:L?4#?[WO!]\;&WIQ6>FO!S ,LEW/5<<"O]642;B.SXN]K
MG2'JJRW]-QQGUQJ]<$IC *TDO(>\0&/^#E+
MNF<-NX8]MR#OUM&@A4P2D +5+L(X.O].OA^\G<0U$# G)_+P 7*ZU9@)"^&X
M@K8MF)4$J\ZV-,&">TNFK?\6<"1QFK)V5"BT6*>"=NFJFOAXP=#9E]F[4^*G
MVG&RGASQ05WI%SR>6N/I"$C470T3FD)I[#
MI@@Q.GA7)Q#)K@]],F4A=90[([6)81AXF5HTOGN8Z]UQ/>]U_=NJFB$[6"3O
MO\2 M> NPIK=Y8ZW!HB,M5_:"BV-EI\=)Y$);[@N$J_BX3F"L-[8T =2!T9]
M"E9.*]H,6D1X&50^5OI@=C^SJKH.F)K,FDT0AS4XVF=]LYD:]3=>A-U-DG%0
M>I AGTFQ=17-+\)4(''+\%[@-%'O,P'Q,M3(_K,<9N,RC78_% 7U2VU--%W>
M0*Z7^ B#<91=?8 LJ6CT=MH_"3LL8+?GOQ*YB07D).:EO@TOE>5=&MAZ/\-\
MN>@#E%:Y=T-YE&B]L"%_B:Q("[7@W\'$30M96K:M ^)J^D@L:AM(L%_)WXU\
M^%UZ>'"9PKKUMW&!U.[XX8RSO3T/UBKM-MRC?T:N7V?6WG[VJ)--U$_SS8"=E.03[>47]<7]I
MR5/[\Y^_:6Q52/N/6J%^WHG8)5NS\,1^6[ (@QA%J\^@E3NNC95-^*\"(D:6
M5CDH!-][K>MO!A:^JNGSP200]N*,CEGMZ""59-VY>QKZ(M*0+&I%0AF2+$.&Z//B9CCP=L5:1/PT6H,4&-S'_40M'+=[
M1/L:T6&HJK>Y\T)5U/L /%WMCN4]!=I_O//?R%7$801,ZEDL17ZVH-,,@O0Y
MK?"X833$*T"F-)A&!5YZ3M@'78\(*(*RO<&KKQ^X"OQ0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M?!!4\TDL.#!OWF[V]X&,^ZO9;7JJCFK[]SQ:FAP;QD9M6MA,/M(U#XJ87_)=F?%_+1P20%XH?<=6_ S!9#N-"D6.#R\UW?#&TE9.L!6C[B
MEUD./1+;NXO*CK8=J@!&XL/X2K.9RT/+#EY.9Q^O;.RY6E;ZXU<]=H#&/^UO
ML)#?X$F3?WVD0.Z93M=&HX4?F6D$[5LO0NY]'0[R6'J5)?CFINGR,MVT*[ZN
M\CHXVG?+@N"(1X8):C^;/WO@^CC&0?,_*/EO4XZR-9SYK<&17,7,4F1+&=(=
M1+ ZL,GMP_E%09X,"SJHW5L8;UN*SY;\@2P$U*\#;#1]Y<]8T/M\C)*B@D[C+1[(QR0[;-4-7[MX5C637]54"?I5N&XN]NC3/]NBS+-#[N-U>!>
M-HCJQWI+P"/Q>WC_%XEE" :OWKN.C:;\U%*[I1?_RTFQRQ&91-"K6"A+$[<=
M>#ZQ"*L\&RC312\@/GXR \[S8D[JR^\N+CVV&,E4^-ON,_K-L??
M2\%97-AT:PT;\7,1=NO'4<'@VLU"%_7OE+32[]=NM<=*5PTMY,WOC]<+ .7$
MMGU7_=]7 7&L9SCMB7I0][YO)\9]K,_M?JJV%O/_3O,EZ"K*E!D?]S63S3 "
MT2T.2D+% KF%;=&/),_XA3?)X#B-()FRK*_G2E6*1?C26S5!APAH053C0=D_
MK-6G.[9\'^KQ4&\UKS'3Q-^,E?.[.J1M^.#;A/,BD3 06)F1!HA=.J7.M!#]>$Z2-"3+4PY.NLG33*7@_ML_R@*BPF]G
MS+V/@$G^BU)Y:D6%MB,FQX0D32BJR5^YDV$)B82Z*0S-$)*6%78Y/KSIH5]H
MIL7S$'T95L*$<[3"45 Q[]40-S@S
MJH[V/Z;I_CR:L&7A1005+O7K)&B#N4CU4*+V9SJ6/*LB^KBOF:A:T1>!TR"X
M]=U0#LTYU>X"!,9+]PIJ&TZ:%&_YO0T8+LD/W4XSJ=0_NNRGQ?GYX#M4R$7.
M/]_..\<2S8M-C:_J8Q"#SS;P4UE_-BRK$F2VRM2]B?VF9Z#/5DQUV<>C(R)4
MK:2M :"TVBR?ES>+\JWAH^TBL\ -+XV3,I7?O_NG9ECRRY>CEMMC/-"P=L-;
MQ[CM/]3'JM_D'HGV'PJ%5.4\M8U/^4IUEGO'9-0&B-0^1XF+P*D%UZ%H0L0*R!*K
M$<18J5^8'UK@C7_8YBXWDB^",RR*L5]]G23@X%"'_7N5LD>];/8*F9* !&U#
M3@Z)$/'4*G);H^+OU@S9JH6,0G ]5LMR!KO&?V!X^Y@'=D!M"'^9)3[1'883
M]#U+LS2?O#ICB/1_2[VBZV/]]ZGHPAWPZ__562O#H:TX5LY![&HO7TA)U'*;
ME\90P5-$N+M6&?*"S)?#P-5XP4#.=@LLBQO1'A\QY>X6[>X2Z]=ETM!G\H"T
M(BC#<[=/"&,'O3_.)BU?2(.VBB<'^-0X:N5(6^@\QQ##IW'=3W3*I5)\C08>
MZ4OOH>7WAH59/EB$^=U=V."WM".P(:#M9UUY!491ZG_*%KG7A98)E2BLNZ[Y?!]-8=PO!*D$,K&@'->>1+=A*
M+TXK#1']>DA.-OFD(E(P[Q5
MB16/7^B 333=;+WF=[J/C4,$Z4?O[K!_R"^:H\D-I,2;L7$1-O;YA!*LCC15
M]C:PA5D!K?]&522<;W=<$">^EM=Z\ 3&S^O7J9"P(QAJCV;!XB21[TRMH"W#\B3NRW9?POYA?Q;S'*
MB,R46][Y;8?+0^PV@J;)/\]W$DT)%Z #)?@';%9D.'2I(0QP9,OT^J61EH]*
MAK?5]M_X:-??JF]R7\#3&-ODAO3OV=+GX]!1\(!)@C!>)(U@(P2H5M'0'= W
M'>5P+MCN;\VO(;?_&J]^/NE8XO-.SZGHDGI%=Y$?O^!SKTW&R7@8X&V.#MN1
M2A)L6\AT7+D/+MU(TDG\3?I^;R/#>&7SPZ"]G!5 ^W?T9FY1:M=(BYEPGJ?D
M*CPOPAHMPJZ\%PPAVDZ,4J+D!5C.N!B&VC93\N34\OJ_C&[Y?AB./,MCDLA??L+;%^@^-LLPGI*/)_!.9@U&49:0'WQ&7S#;L&3>W5B/R#XQ(<8&J$"
MYK!:B7Z;\4C4&'JH.VPZRM5MS813][3<5XQV%$QX^%^EAN?C\WV[I!@)&4/_
M\O/M:U U\]+++\LB=)!38<>Q1KYSY91Y16*/WMY2ZA%-6)*_H2_< :?X6 C Z5Q*F5N-3U[3_ZQBW5OD5^W@FZ"\6DT8WS*)+
M%UP:"M:(^ZC5R]W+L9?W6KKQV]Z?LE:!WLP0UI79:6E=L@#_T%O@.D]5MW29/P21GQ^T-")UF78%MMAYX&(CC_TU2@6JB.L
M[H?!U@$;9@M:Z'^3(MAS]57H* 4Z3^)FRNXB*D=DVDSUI<%-2UN%D?.GY&7D
M*"'(X:!&N#23['8WU_W7_#W$SI-8N?1C*\MZF--J"U0T4 91%F&?AO^W+YK:
M]B?Z'?SQ2UH121"_" O!SJTBMU*CD;RGCF]*'TY[=3("U"*,C%U:@ SE2,Z+MPTH*%F'/R)-_Y*B!
M:R');D[G'+UYLV8PYD_\__,['/R2>15BSWW[O[)Y7W\MNWDK<3WLZ*.U>P4QY]_1GI,N+\+N+,*J1IJRX48^+NM-G$/XR18Y3$[8TLV\.VIK82HZ)!4.G#<\N/_#/R.#@,'^/+;DJ$()F F"Z[O
M4G)80#7X^F6,^Z+.\'M!0K&^3ZC^S9*P+?2/"[EY%Y;[CTD^7E_Y(^>ESQ W
MJ&:AU_ZAO!6
MT!V4VC.4^&WWBRVSD%7(-35)C V#$-NM]R?21*YQ$B:GJ2KXP/W]MZ.$8AB[K)DUO)ZR5GUX*J"LOLU9$Z$*A'!E.0W)91M85(I>&L+<,0K?%LM4'
MYG>'R'2 ]AB"'XT0"+;?J0IS;V-LZ9?N+,5WJ>P[#,6+J'HY-P;P):UR)=*
M%G3L\XMJSAC>)E<]RG#X 0$&CO4>:KX.*AP#M,/AZPND^HH'4O0(T1SG(AOOM]RZ4"1T"_4&5MMIBJ&[>O4$ Q]3P25O51
M\>N-ZHK.$>!CP0=C=K_[V_X+<[93I"K>PAJJ AH0+@V"'[GN+#?3P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M^OZINQB4SISZWSV"EY7@X6-7&D>YCJI#^#
M)Y12QDBOY=E84&UOLM'')C*V>-6P*:OE[E<5&*8ADJ]81*18V$I>@V>*4AG&
MX^'CG:/$@% B@ED1A[<[?233[4C9"/YGJN+8+5(2 L!@8M%:Q/526\BQ!$\1
M'G_(Q\3)U >FZ(49*0%6C#B5:G\'&23?C\;H0_=#-#)Q&VMA(H!40N7'$NX
M=-F$,N][+,KAF,ZO?SR[_K<21O7/N\G1JQB0(X&JG/YED5K+)C/4?'P=+X6&
MW#]@6/!4?6"@=>>EY,_[P>;U&,ITR87$57O;GZQ[N#D522%L62J*^2.+L*^G
M -[2))^(%374*FZK,6*U=.T&XZ>(1)(Z=L^IZS4R[79T-RUD";SP 9(,@)?,
M, YE[X?T\#(4Z$=.S$! &,8FTR_H"L+&//R)&)'@??/Y JT-UQQ3 W.>&76
M_0*E>*(]P0(T97$,7$I:!53U07R(^&3FP;=5]-Y-)&6(Y@C>I%HT]$MNQS\^
M,N.@^/YG?BX+-*WRYL^;_SA@0" )Q)!I$8NY N()(U-E1A!;Z!R'$&T$MW+FRK_1[%:5YV*8>8@JG,"PCY=S^8_.8A*HH6C)53WH23"JW7AV!UNP0TBNJ
M[88R8[_U-!B_C$9+F%R<+!XC5][7E[8T_'Z;_Z]VVX]8CW>6K8X$X"Q_X]C6
MZMR=4'^XL(NQH\_^@'!OPW7!3(_TNMP=U06F3[]E[,:S!MR ].SGWE)/H*RH
M%;$>PZ_G*03+Z\SWRD(7=@]5(Z^B$[H@HP%./9JZ6'1$90!
M08,L(9&4(/UV]]>5AZDE'19=G@J._74M=@
M9 0L?#KX=1?UY+\*^>2_ GL&OQ*W[9'W09V5O:R+;*.O/USBW*JN9G/.:%Z%
M+8CZDT&DW*#]+L%XW(#?VUKQ;C M0U,1.O[X(4X8+S:;'?BW-
MC!RA=M!"^ T;!4QN(&MNI,7B6!!"X2HEW=X/D6Q_1[0(2TR26 SK?;;:I8P@
M;TZ3(P8EX+O"YICCJUU
M.&"-3*"J-5B R .*H1.&3IU5?Y;&'8_=G]"I_'HLD^O(\R9.#JYV%SQ>A/&S
MJ(JE--3VZH="9M+-.N?V-$P;":!+S:Z7>X?4W2P3H+4G2!KV%W+5@>E((X3Q
M_KOMPO:6'%\A,:DTE.P)ML67?OD"745HV[(7D.Y =;Y$Z=_@2ODWG< ($4N+
MCRR8ES^:M0RK0>0"*%847]-*71/,5'O60T2.4M<1G/.@B;8Y>8@JMJTZ634M
M.*V/^2X! E>Q@3='!-><,#+LF\:L#JYT%#8>=+DZ_..K2;JK/E6JZMQGC*,QA]Z:7&3G-KIA:>,N^$T/XREM56\(IPM!J\^00L%$I&'($^M$.HSM+70IXX;1-WNZ7T6B&- 48+]7LLGQ8R"&?%_B^FV+#MP95I93D[I==^!
MK]S#8;B5Q2T>$IO/;CK4RQ47%PJY?;KX1W5_.LWC5$,__1\SODOWRG5X,,UR
M_[ 6M.Z LY+,$M'B//X"_K=TS]YOE.L]YU+[305I"$DF(,L31=$!3M-[WU;_
MG20-.$1C;-I(^0!P$J9W%3 %9Q^@OV';#3_M"G^G5$@(@UP%E'2C90U0A$AO
M)B5L^6P+$][@9L]5FM[MJ4*:,$VSQ=\ _)X0*YA"GNZ2[@M[B0]!D[GBEIS0-H9>WP9=(].4%HVQBL&)
MK$>TG"*_Z&W_"3^L\&S9ZN] >)L'3\5J*J 5JQ-FCP1B!9L(-@ RILS>]\5[
M/D?%%<$N\Q58^5MU6LFEM*J*'L$;?BM7-Y)_PLXR 0Y^2<<>,A"P,HBQ$E9V#N$M77-G5-5.'7+G&N5T*#4J5NVYUB_
M#?>TTRK9WF"TEM2OD.#)O[UOFY6"(,W@$/W0:Q*-\6\6^3=7*O3?B-KG
M9L-M/U85;SXU:1%6%F9Q8L41\[#G09-5\Y$K%@K[W>)S82Y7]GB^LT=LA8X%
MR/JA7R:P%IZ>]T960%U5ITJUZ]:=5HN;=7E4BUDC7PLS6
M_]\*!&)1!4L*Y./U7/7/Z&#M8M7M.V)DA(B,[=ZSX80".ICZ-8I-I:\EK=T((M)EIGC];@&YQ6^W\' J5G6&
MHAI; 2+(57#OXMA5'M>SY@>CG0Z[GR[R]0GQN5-L]
MRLF9HN5*3RPDVB\#CV-2[?QKA#0#'[RG)*FOS)J6QM"J9E1E\=I*\@@:740-
M/(8M296$'Q"DP%>_SPLBVE?;V-P?LV7L[JZJ=_ \VEN5DOUQNWB8^)\2/3)
M@DPID].$C7S>"BC)/DQDJ-#,);65N+:"MBG(*W2XP5DI$32AR#%OCI-":[!0
M2A";TV9R2.R;M?G'Y7]ZB"4022A=H(&E48;5-BD2A:"W\0,OO(7RW.Y3)9R)"B#L3?F/!K/&'
M7R9*KMWXZ,F6&?9,?YVR5D$-CZ-ILO\4S)?)_"P=>DW&#^&XUYE3KBGY165#
MP@,AYS)/U/D&Y9%O]!LHD *_CG7^28<_V+#P^1<\+@$]A:/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MSI$I8YE9)CE D5^O-5,'"FTYY3MNM!>TJ<<5T3
M;O"@S463C2]";.<*Y(2R>S!4OX9L[UT$)4^MI%> ]DDBL9:F(#34BZ'G;]D0D>,I2*"5'U L@?M&RYWF(.1P'2@2Z#8QUQ*.
M01-\= )VI=3U&5[4G*L'D%+MMX45#$+U;/VB1'JV'#"S_.G\M,OLEM<3*&LP
M39Q*;US51$"^@-K9#+U^*T-;MEW;DW,;YD;^F[\AM@U[G4\R&A=^%Y*O5/J;
M7Y"$J[RIS@BE(B->1OWI1;[KGJIZEP3[$[5;'83?V5J!)7Z^7\M"MS-U\N\=
MV6C ]H>KGDX_<_M#7 4]CJ8<0C* BPWH'DV=U^=/J*I0P+2*-8(O4"9IC@QT5S6FQ^4A980Q9#G
MBMA57_M:'H:!F/..\L^&!DN/$:XF
MX5E7!%HKJ#J\.=\/SSP(XLB$,\_P&7[KWO9:*:=\5)6(V%E3A3E""Q-7AP"7
M-XP:<#633S5:ILO4-NH79K9^M6#L':NCD8DF5(V0.=/$" O?YGO,Q/*&97P_
MPQG$&KE"P)%ENOB';;=_%@M2RHYR/$";E]:^4XAVHXT@,?,6+CAP!O$?-M>7CD$,Y8>/K"KER2]O4M3$9KH$/$#K?M88;_IDC
MWNW\ KVYP4N2(:/M^KYZ-F==?FX1L0^QJCTR=#7V)%0SOXJP 1KA,]?BX2VR
MS=#]0+YXY5A=8((]\KF\VN?\$ZQ(,.9=) J!IS95OW\1?%('Z&^%KQC.,6NM
MUIW=;5-B'!R9=/V<1#G?==KTO\40M7GG9I=O+?6;$O1>[U#//Z!Q>&5=X2#]
M%>NY]3TU?=\-+@&I^*+F(WV^BS#*FTHM%]1>J'CS^6;UF@2"?L4Y2MV MO^?*^@N%MM2J?^[ZLD@*>M<.8"$ODCKBYH&EBEEAV#+U[5R@0\E= )- "F:N
MXD$2P0WDG1IV&\.6"6:0!"@H\2YGRLM:>&Q_>[Y0R&D572L.GY>2+I#Y8M;0A%)MRUH,=:4M8[/)XA;NDI-Z5V!((M#1!PM*'PUFKNJ7_J"NZ&V!F*QFPE-^L85(OM^8+AHLS8&]1$]Q TD&M.W%K12W!TH&>D.62R4[#*>,I)X%'EF!N0[='0"*)2
M2H:#ZR1,D9_;E!4I>8Z71MBK79T3-D/^C_5RITA>+U8,98@D4_^?S=B'%YY)
M=T;PR^#"E45Q%SM1)@.E#'6PO[7,8_XTE _B#OXFF%J*UT.L>:^>0!">4'9/
MNBWKQ[C7#1XYJ=BA?@M"0_Z%.V7+0IFJ,CW"WAYK<=INO*-@Q5P^Y.R2TBK9
M96" UGF_$9R):S-<8S9T"IVHX3\T82?+NQ1U7>B'.'4OF+MO/!?_#]M['ZI6= ]B_:,%(?Z1O9"T3(?YXN:X%_=M]Y7^Y8 2)-?>M:GN \W
MTI#0-EF)D+20@4LDS=W0SL6A@^_M&M:&=%/3X2WH1,MUW\+<*J1[O[A6JVF^
MLWCT)Z8\0"YMR,P@Y.I680*CDZB&'<)GMC&,P8L5 Y"X[8!YIE>40]TU#OOI
M??4:E?;U =4PI6[/?_S[3L->/[QX%78_*=E%?M"Y&:1#9VE;WOO&,HLZJMJ!0_W"$L+Q.D(%M(;@5\;:4<$9 4?7&>[;\%3+W@Q9M%%LV3LOS&[7C2&Z^.3^-'%AZA^XS'M.S[>.CF9U.9/,0T78:,^2TL=XL6I\CQ]5GI/7+T(NWM%]I&G*C408MH_M\#(+@!D2V8+0@#TQBKC%H7=HO4P/2'PK23-GZ?KPTL;VC90I?\!Q/8KWQ
M\\83H\T\&\E'H_>=Z,=-9]M2JU)>B'BDHG^D=,]N @]_1_?M*G"6Z3)VRNDDW/G? 3V#!_QO#ZY'=$2#WYSFY=H\P\,XR,7^ELA1S_R@E(5.
MJ-RIG#/HY(S8>::#=I7NP7@3,IH
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MMPI&G4G-P>HZ6EM\CU8THAGI&X_ A1ZB.;23 9\"U3)EMIQLK6P^%'@!YZ40U
M*2DG(FR?T+J((H3<0*2@/T9FA^]O[N\_\06O>0RH26-H0C\'^*:)!$M#-E9U%NE7(8X15(ZN/&*3'"68 +Y1J)3?S"@,+[9%]F&]GQTNAOO;I5OGG >
MN]JK/3"/Q/*PO&(:VPI_<5CKYFW[R)WH+S>F[A^FYR<_@,?RUH@8%0Q,@C_,
MS?-(YR6@/(7(6 .\;.ANV'J/0;6\MB]\JI1^!;0AHFRF%HM,)*-O"/QZ/.Q'DDH%]9&,1-)FE:&1V]UG[QU8Q&VZO KK&\PM_%CJ5V8^,&@
M_*""IM'P<<2J&X8!_$M@:+69A%..9BG-16!5),Z0&E _2%H(;IHK-+'
M6XJJ!G*+@8G66,D-<(%.39V28@JA!\-=\X=J&< >>L)%TH R4P'"G/0-HDDW
M"E*FZ17=-WPO9>_OO#1O;FQE\94M-SL;.JL:CG[I/=5L]-"C(S0L.
MNY%,6_/NJ8A@"+E??]E>ZD^PA6Z]#+TIF4NG*KY!WY7N-2D.#"B]56/71SW_
MTKG =]"WE89Y%<*-E[WO#63T(?.O;S_&BD&KEJ/Y%2@KZ)*(F0H'8_F?BE7C
MBX@?>&N9P9C54E27O6NAWWM!F9D7%&";8LTAZP>V8"?-Y/D3^M->XO-9J$T]
MTULZIWL!)'N=O8MHI\YK>]2-#G$1^A(-VFK:!N?J2IY60RY"[)UA-M">UAF+W@4EO>SRS"UD\8;?TL,\>W"PI+BO&N^S/9/IN'MT*DJ$N"1EL?X$=E
M%#Q6ZFWYJ#BZJ*7.NKBAV]P*WBTW'F0C!>:&<:(Z\.A;IWGK5MS.MYC'=%-;7>4P_9-?W<+:V5!X7"3S^"4(<)J1RX=!-T7K!5BAK6A&[QJM56.W$Y($&^4&//-'--1]&HI%]?);W _"_>8/N*-Z69<68_
M]AH&*8!%+#3@/<];A[>!)^I0*TUH GC";FDH@&8_1FV$1H2?*((%A0- 43+A
MI(BRVJ1>V+B=PZIK;^GIW] G50\(C'B&#V^2(=]4]4JO"[Y*'851.&5V68@.
MPQO@R-:,S3N&_,+?7H2URZT+8_VX?G]:.9S%5)#:09'@Y0X,,)*(,IY@UCSB
M348+&C&MLFT@.=:D5V9X%KIYY,%O3^"%+0K5&3'@.B:VL+!*J3W7U?ZSAZJ
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M&.(U60\/.,DTE'U$5)GD\8>M4XS60J8O@K+*JGRKW6*-U#L@K<\IH
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MN\<$'@0967??B#9MY^HF_^QO-3+NHKO6(]=ZC9'9M"P@6O5DJ?S
M :ZX5=\CO] Y;P _X=EICQ91-,Z.>43Z_$@++5;QZ)Z]T"ZH8=M_*[^MCZ[S?ZZ%6!$47S#;J6D*_:V ;^Y>+D OAZL'F(S9Y0;X!TV[?SH?/6V
MQA.OU+UGL8H,3;\A_,")>B@,D/W\+=SR]#8I'6<"7$ZR[D^_TKLBY;QPHM;<
M5Z9AYI2[YYM.)1F[:\\[6.H))0&:S8&VDEH1V@3WA4<18;ZB3_?E^'>':"NG
M>&56Y7B[ ,Y^%X'5(A"[IU#;6E\-RCXCX#M[@28R6(:A=2A6^35%=?&8V51R*;DI2VZ6HZ2Y%ZB.O$#2;W!#2R1G 5M8QD[
M9$.95-BD;-,8P^@ARV@[U#&/@N+I^Y )5"TK^'(,:#1R$'(4&;I<^437KDD2
M2T^>CQ*\)^C49%F]%YK$'\W:7Q.V05&ZJ00T,"2#CPZ;IK"R
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M[F25PQH"+UVB39#@#:X@NRG++?>1<$\$%1ZL<]ND4DA)DKOV\_GCMM"XA,__]W)!J"K!=>4K3)YO%A(>))P.8%!:W'@ID5X;HGR&GQOT*U;$[/.BS
M&Y6MFS@5L6U&N2."6R/)W5!;&>'U\\EAK"JRZ:,9VS9W[=*FLX8M LIJ_/.1
MEMO^M?PA=%/6&3*9CMO5]ROL\DB+#RKMN>'VT.BK_^S+WO:L5_OX*YSQFT2'
MUI9S,<1(V3L2X(Y,I-*+VBDK">@J:"\?O0S2;$&O8%C@2TY%+<)2?'HY+>N(
MY@0=:*2,H XFW!&DV6"5H*M(;:F#ZT=+]FE*2\5H'3Q)<%?BFPDME2X]5T\G=N9NJB6?!#E-2\^^EM<*E:/0BA!2@+M#M/ :8VCVH3:-,ZLSE]XR
MJE\E/2]:B&P.#^6MI4U3W@1GWN;$-QQX@2_G_N1&I1W_QP\U>J"P9LJ3?(,3
MDZ5%7-\(,,CRV!U):X*R_H%\9EV C">"40(B/]2SKX^QB0[\T=].2RBCNW(J
MFQ<>/]^-_U*YH?2?0]6OI2LJ,R0_NIV@J+#PXK-M,=J4A9O+$P_V(='52OOCR.3],K90
MC/ GF&8+9N,FY6HMX'2F/S#;0E*4GNM?R4MN\ L0%&/9#/-+D*:P3(G5USWF
MJ4^L+QG"GYKPZ).:%;KB)Q) 92,,['WS
MY:)*S0JG#)6P&5J@+:5!'6!PFJFJ4HM@U6KF.MG.,2-S,/WARQ#>6GNSZ+Q7
M0=4^\;E)9>-VC)J @N&%VO)19N4G^O.S$,D+L&4SM4M[PVO>S5$K&Z;[)*@?+>, ;8M<4-M[_2V2XJN&R.+AWV61>B/N)]YR"^O+,7[
M#)P&1N*LI[#-F3?K,N]8TN&J7X<'\*=&/+!OV&AR1%)57 TPX++"J<^QZ+WN
MDRM3%UL?N!O"B+:AB[ :Y-1#@?B+\T%HY&4(T4CN_2O!6,FO/@8,[P6Y-L\Y
MM\Z3E*6[ZZ I(2M$9,69LF0O#]7XJ _?*2"_!*KI-Y\)GD1!B>%,%5DG[)P%/OH8KQ[RSU\MXM<
MIN&.X^+UY?IO8QGD[ ],0,?-SO/%B399"4]T$V1;\-\&&.76RM-WN[9=3IG-
MH[ O=54%(8X 7:-%?OH_R+CP_#'GC_UEY3-F#X7*%G:N2K[[[D?BM@S1$C>E
MM6$+?GE*I2YE;P8'B8:_VX/#"Q V]6[P<'S_H:2CPB$'K2[7E07E"\0*J7BN?
M8]0NP.GC8UL9&^1H527; )K&HE9)-P"QZ*DM\R&0DR&I'67?4,V4O4M&QE,K
M0[S';NKJ5'"$&+5@+C9A-<6WCU[;A4M=LJ?HI!WCMTW),AVI#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M_[P!19!SX>$+%21^GI'IPB/4#L+!!XLP#!"9TK#Z.?$C4YD0Q>M
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M&K?_HUU9\YE&U^[,FOO%VJMGG*ZMQN?.U@U]RB[VASP=F3VE8NMYS!L\>7*6^O4:_6^9<7?3FYYDCMK;M(W)!S95
M/(-)_X'"Y"G:W&.!OHA-02-D.Z46J/7]I$L\ ^DN('!J6]&H_[YNJ>N+T6%=
ML/\.8[7T6)]L9]#M0?TM"=22H%P=R 4L.0X]$D5OF;1RZAX!Q$E5[ZY:_K1Z
M<9?T*(("6<"3B'*S2U_:=ZTD%^143M-+ BQ3,L'P1A6_S5?TL-@)0FDC97[+2CC','M0TZROWUZQ]65/8[4K1N,TJ3
MM1JMP<*O'NHL(.,%PY>!L7ZXN\+%@,NM.[_-:C$KP7:$9;]()6&A<^-#Q^NQ9
M[NC4]1?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M]D)WBBMD#)T,/KR;_<&8#;^AN%VL4]MO^4Y9H\XPF!AT[!KDJ GL,JFO\NO16S=T.V\
M@>MBCE!B:)H4/P_-%U#98]:+L+7!-;=M$V:RJ2M'(^UHY.F!>YV\@2!N6>LK
M[$"PZNPOY]O5OYPJ?5TC#3(TWWDI@/F2W7+I^)AP>>G!?AR7(N>#J7T%S;00
M="4G1J8M/1S+DAD"3CE MQ"57T!PA!SDIY2D@WP)F1T#^UL1*LZ Z&SVZ5N$
MC:#^0-MKMS(HT*V?<+(8[\@"O-]?SA$WP04CVYT1 K0PA!)DN\
M&A\NH6+2;_H;@HPD<-]1L#U5IMX*9#IU6C)T"8M2.<-@S+WEHZ7OH.^;"7V1)I9"YIV#6_,JKNR^W 1/H MN39NA*@$Z(,>7*._
M^R)1ZRMGCVOIX!L!WR%:3"\E.<%H9N'
M]8&M3@$428[+,Q9+N-Q#N#7O#N$D]-= WV/J&BL_I=8ZRWA^XVX6+\QH.X@J N/E
MA/KUM^#LL#J4!AZ'I_MO[V,82+=4@.(XBTFYVU<#:](L"0=>?OG(-UA76O@
M_9"(6(0U>S"O+,)TH8,BX2-&/.#94H=ARYUWJ+"&+;<.*M-R]%F$'0 C)'=1
MNGAC(3G67CE8*=5HX&R?-9ILM!942J)34G+W )%D68=.DM3\A2JI;^W="P+TSBIK3D>JUMAG X6$1M"3F4>=_%XLWE>1>/6MN8!H.H8DS)(-Z9%6E;^?'E,';H+)[DDBOQ
MGFFTB]9L6?/K7?H#__';J)S"4?V"#Z6\T.YGM=7AWS^-QA@=F#>2GB6E4V$R
M?8*;W#"7][=UA]X^/)692' +%#0Z-E?+D048SH\4X'3815" >\8/T9'NT@;G
MO/$YPDU$Z--#<[=YT30OOT,A:@LGS]8D$*SE]11\V^..(,ST*" CY^^OSK S
M2BKR'N.BLK4KCB<,=QRO:"VD[@S]W.WP=FB'A\ON!Z'%SY8G;_W_Y*/HDL;<
MO6+9O9\6583R%\N'8M5T>7O$9U4X,82]YG,)>5M*.R)>'KMZ]0DR]<"[L'\&
MVH>6Q> (YV:L1ZU.**4-2;YY5UWZUH4D"3U?'##W0
MM[:U.ZMX8C]/9W1@V6^?AW)MV=H2JD:OJW:JG->;-RJRJ#XQ5JV/OXO;_*?R
MK#>[:Y]>=E!+\D_3/AV_':RW[UBDU!^[4/.B\T+-BM_53FGKOS/**LU[C
M1;YTYM^8QY^*+08[-\_'?#"?)U[1[TP1U,0_K\N%!OQ=(B+V<>Q<7QU3+SM2;H3=.2>IL'.92Y[V_ FC9N28;]UH4!![V]+"XO"9.D%W[V6$083;Z?G"_;Q
M,_:8!!@(SYS,5+H<6>Y].MF#N4:*5,VY5%!EBPQ6?%04?&J@/,^BRE;EDLK"
MH_*""A/>R"KK,*M'C^(WN=>G6'C*KW_6."U-F-$%K7YUOBRA X!+[XTYDG9U2(SG%:80UO1R[-_
M^OHJ"@8W"A^E'M?PRC^W[MIIN]?G"I?N^UUGZ89NMAD.UON]E"Y4T$6'$5+;X$2HTN\BB@V/3L!4B9A<)LVNV(M,T9I%-(0F57RHC
MBI F12+-8!S:6QFGW91D3D4.PYH2*^;P7_I_^7W_'SZL+W.MZWWN^WV>YWV?
M>UWSO&\RE!#_F7 1=[[-T+6SFMR[%]#W_Q\\0>)) 1Q(S+A>@+_BJ0*67$.7
MC+)7OU.P[\H>(Q@A./G\:OJ)77\[W!T:H@<^&J!,WEV3<;]E0[2#ME*(U*H [I+14 7WFD+"2B1QI,EGLC$H&8ZQ8[1SD'+--!M?1?WHHKL].+-/U[9J+%*2)0.4Q;[Y #%W1(..IQH"EJM L9T.?!!HGSSL,Z/
MID#Y3IX84FS *Y=7J(!TDQ:.7!:M/IN7*4?KUPL-MUH+GP P5,'-1@%B7*XTHFBK@:WLQ9M#'1D91FHW*0&4N"E3C I?1RA04FNA
M_P<:/J#P(6GU6XG2](?M4>7]'T/U:$E-#9#.Q3HS!KGMO#1'KN>I7%YJ=)1Q
M'%DM_%,=J!?<%!_P7YE,[VYPL;)-3CR"6BRG>Q7$H.0/0"W$(XP4.]?E\NU9
M]3(OAK7IL[5S?[6.%@(*J(1C-MPQVD].?47]Y_*3WUQ]O#N?\LGJ.PV^7)Z^>KR647]DE/U.&TZ-HMQ/70$K\58_JQ-E\K!;-?9'4M?BK@D:7T]M438Y"O<^HL-!@GLT)\U5 U$M^+5UJ2"K/&:F[!H:W&!'X9CQ4I;KZAI
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M+R]58G/:LEXJKD,Q>9X49+C^
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M7CHJ3W1\Q8%"Y=^HA68MCGQ]H2$?MI?$7_V2B19./I"C5^JSYG8] TNF]]%O,6GZ&+P!%X0;WK#SKBNE18%@72W$(
M(J<9MIE["_SJLW]-O9+SPE[B$^TNG>M&%U$!S1;%3GQ#S3B!!+%TXZ3-)I:E\*/.,
MPD%@-*JO-M-N\#53?HY_(QE\,M<9W,+C6:;/Z&6U3*@ Z^)GM,#F36X3D)L
MD&Y],RL[NOK6$X3BOGRS]@HFXOUQW$/KY5!N_WU@'IL)!RL=QN\UHU+>0G:-
M]A7-GZD_XUJD*F#9BB1:TC&===M[Q2.6\0MV7WY7C
M_F7;?BWCE\ 6&TU+:;(0R:D]HJW- F>OTV[FJ+7*_?]ZUHMXJ
M1XIO\%[-;TNK_6TU3WY ]]MGU[B_3&FK,$=*FFXJUW@\4 $V='ODMKW3MI:LRG:Y3'IKK&'&W2^U8)-SXIF9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MDGI<8N<3TUS5O)M8ASOC'ZX!'Q=7("7SMZX@Q,/PT+!APX#<7MQ%
M.#JWI_$9S,F>"7U9_0U:0F+?$.L0$HS9G=MNB*7:(?WF[#X[]$53I\B&/E96
M#&NZ%OB/&^/^]Q^O]@-Z;1JFWF-\]>US[;NB4G$3&^1>[0!Q;]#JWM''S^X\? KZB +*J!FH-/RD'6TYA6M'BMQ1VERD]9_42S=LK;N,[F3L0MP(,6
M.3/[VMM-0]_?3<-@[=V+;RL&XY+?:D5)MB"QF&G:)'(Y5CF,)3\BTL#[/^[XEL;2R[,JR+-.KAGB\[F!LR+9RTS&O2.UC
M=X=\1/Z'!M3'"VTD$YSWY-FC_7>^LAC6,6?4'MI6'_S4)_==NVOJRW?'B6A[
MW(+=JL?L2KO:29>:4?_' WZ?N)[A,E@B)J8R-D5O"]^,0&(3DA[UY)1X?NFW
M4.=S5S-&'T75-M78QE>.'VFPL=,RWE6Z_35 (_Q@HM-6M63KOB^>>GN>#WKO
M-S_XZ[)-IW9M0O!^GIKO0B+CC:!NNMT4%"6VMC*UO<+T,EV$[;6?W4;:%+VG,?2#VENZ_J7\]OR5^72X#+9W/7X):K%RW*@>'
M09GMFS19T.P?MM#.1"V,%PM="^$*2:ME ?#HY,U,$]X/:V$>@GYVHY;%LD43TM9"?"30$4^KR/)DLO^2<:\
MG-#/&N>H_?8FJDE&NB2!:TO;"M[D#S^\HX_'TI4WA"1D/2^;CH='PY'U8*8*
MB)"N%LW]J5Q&]T,<8):8F0I&?C#W4MRE4]GV<-$](4F'>E,RW:9=?MWIB3$%U@R%S^@&Y^5D)P(ZNW;0W[W#A;<>24OQNN!&<&'J48T@\@U7"YI#-5
M:?V982R#6CAI.[0N,$Q>5U$##@S$QRBMD$0QZ4+3[M()QN;^=?R2Q@'E6FK^
MKJQVAA:_"5<>'E-8798O,>FJ-@GK30@E$\*YJ"":C4'F9&93?#&S70$)*6V@
M2A87VU//UAI(^P
MQJ*^O@\MJ9:[BY[?-*^(I>7N!9)"88QHI!SNXCZA4@)NMJ;Z/Y?A+KHMUH#+;4S1!^NN_?VB1IE&=>V:]&"ZOWA9F2R\>+T*R*C[<-?#
M=IU"^_]RE=BKK^894(^G)7TJZ7+4G!H.)>T8]M=H(T4'+*-NC#ZYYE]7MV_Q
MZGFIY_; 3=U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M..D)M')TG^UA?]_5H\OX:[7MY Z^-K8K5.$MPR-)X1T"]W['W>15>3N+<$^?[8#>)ZB75 [%IH;R)^T=R- Z\-C8F4?!FW8D
M%-Y_7%/G2XZ^MB_N70C7M*[NVBVK4X?TM(\>4@%-SB>7+[=2C\JT*EYZMANVMR:.X83T]TM!S8WLU 6?MTAJ1\$9YA(&('?O=]G-
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MK.GF^9&7)82YBCN<>X_#D^"ZT79]5S2!?9J
MV(X)V=VCB*HWVKJ,VSCQ+KR9_^B2+PC+-O1"?1?U;SO[LFMK(HQJG?_!5!+ P04 " 7BME:?=F,9B[F #7 0$ #0 &EM86=E7S P
M-2YJ<&?LNWE<$^F>+QS<$!#")B@(:45%&S&M;"U+HJ*B(L:E&Q2$M"*R"6D7
M)$I(J<@NQA5:;(B(B(@0V94E(82 +6V'/0)*-A79I$HEE*12N47WN3/OS)PS
M[WGO?3]SYX\+'UR2RE//;_LN3X+FE4:*,]RY;<M?^MK9I'_W36T-(TXH_DX>);';*UEN%E&6K.-M#3-. (.IS7WKPMP?_O2FC5[
MSMQYVO-U=/6P"ZH,<;.T9L^>-6?VW+ESYF#/QF//X^88S35>NF[3/).]A[67
MG3!=?^%:WGR;S67\A?LZP.4.1TY>U-$U,U^TV&+%2MM5J[]U=')V^7Z#J^>6
MK=N\MN_8N?^''WW]#AST#SX:DIEV_M9M8OM[/OY=\O>%#XL.A1>45E577-TV>U38)F84OK\]]>='9U]_2*7_7UR^2*
MM^_>#WT8'H$^??XRJ9R"OT[/Q*6%F_TOH?_=N(RPN&;-F3-[CO9,7%JS8FM,)HS=^FZ><:;]FH?/F&R;/V%^::;K^65\75L'/:!"X^<[- U6^XH6P'-A/9G
M9/]<8!?_ER+[E\#^-:Y^W(+96ECQ9AOAR+AIEBP4,=5#]19""4I/=:$&%\U;
MP'Q-+LNZZ$Y0D9 ?U'?=G0H9"^ JT'-K1Q5E43AA?E5<9(;)YN36MENG!G=EKTY>?.Y05._UR/",Q6Z_MZ5%*'W$.P#\.A-H[*/>K,T@.C).=7)MP
MLKD&=YQRJ9VQ!^2,J<%D66PSD$8VJK)RV%&92U@"5VP#DQ._E%#\67S7F"_F
M?M6U5ZK.9;;)! \HM*K35BB9@@Q4QXV&>IM._J,%>Q,>J3!7;P.GU)*VS6X"&K?G2;>'*XELRM+@WL2PN;CC>@VS19XQ$2I
MPMBG+":2M4M&<,'B]M ?<]1@S/2X/AGU[A35)OI9&EA OFP/DV:R&NDI687\F]S;0:0%9WU
M9V5V/K'-M5DI]>:RI]'N/T)FJXE1O2VMF^MJKO=%3]@/!F;N^6/T:P$XBNH,
MJWZF ZC.E,H#6=+-"Q&EU,8V\Y()X*$Z:K^+T-JLNZH$W]Q?E

MQO'U=)19Z432AU@XQ8],R">ZN&:<0"*.]RE+60J%)&ISTG3?> )D%
M9>8]9(H_(W/2E<K?+Z!][
M[L5F)$3AQ?A4 /2E];&4AT%V(VT^XQ TT4Q-!Q:3EC-%J#'\,OXP2)02,^HC
MY>DBK3=PQ O%#W"'G#B;'K EDY)L;=SK9%FM/QD,DB0 \XX#4K:U SS75(,S9AHS7PVZ5/34[X7T28L8>Z!UH)A/Q$<\&MJ01CD]U7W"\M*&$$IN_=4;G8G>!8]CK\Y$$1,_CV\6"_KQ4*FD $KWI+-B6'
M:G"7LME-Y &7@^J;V$Q=!!@$&)"1\6@+R0,.!0'A/F;7S["W3T<]54;N;U-D
M%CX,0TF@ER#>.B[KR0Z^"D (9N4]/*8'U-;@Y&ARV
MH@/]-B]8=#EW YRJFL=\0S9!US B82VIN'V2D"K.M6Z LEB%'4ZT^9MBBR.J
M^Y-NE&Z-G_M%S"EI/NX7]+1&WVW[U>MKA) EE,K)L;$4GQ?G#"+-P=Q4CDBFRO@"RJW80W.VK'$J,1]KX*7\MVFV!#(
M6!+8':-GQS+VE'U_M 8^]OEW]Q]LZKJ&0M0XJ&:\1^5*MY1/C/6!-GNA6V@)
M9*NL (?2&%%@L!M]P0_O;[BB>T?.6?0'QD$#$F^04*P\!, /G52Q"+/10)DU+XN99_Z-N\8=2Z=
MY@_%9R7VMOK5U\)KIPE7*D<#(@-]Y<'%R#I>9M?.WE\WCUK71"TH20P4O"?#
M*T(1$YI2] QR&9\M9P^P=G4C! 7Q KO<1XR8."A=H*#'RNS+4Q)=>_-F=A3<
M5Q!_>?'=].;K5/C$RO/ZY?WA8L,7"^Q7W6U6'X0#L)%\@.TL'OD)'KB+Z(-^
M0H+YCD>PI*56+, G\TRJ>$FY9'"*3\ KU+OM\.]]=K@E%S]1T*(- ,0NL:\
M::Z6'*VIOW)P[2W[']\^S7:Z(0&D]]C5VS)46F@+V8H<\29T(UOH BQ@K,PB
MF8+GSY:$0,FLJIR@MB8)OM[IH4_TRU/VI25R^WV_C]X((+CJ&P^B]!]JO7A?
M_=0WL!%D$ZJL>,GD8-&K.XK"L3NJ^!$3YDL-CO %;PYS6ON3QWVDG'G,QJ"Y
MG:2%<(TO9)[,=6-8L3S;$:_BR/Z/5>IG43&1X,=XB_>>"Z;K*?;7)[C5:"Y/
M6@24Y9:H &838,7#:F, 7Q0WH8Y0Z;7[$=9SQ4Z;;X3WQUY!5I2$!(B7G
M]I+1J/#BU^%7P_W('WQ;7GA$59F$QZQX6GES]F>3+3P-+B'%?;4,?Y%:900-
MC;6I=O0QMO0BEH\9V]4I[D1P8B<<:7N!NX2.#E&Z#[KK0 /--9FDY6+&#IF5
M[0']A[R4Z.#J*WJ6PO*#'_U742>H_314;ZYJ$?,YV00#:YK\3#ZT'X,0P<2<
M XR-\+-\9!GL 6G+>[+X;&TXN]_>:VM]CC&;_FV'S4XY]- /QO52X<<,$IH9/<%R&B(R50SH;RU5600R=-'5D,5R@HX
M3TY+'G14_^HH22;-M3AV1Q'O)>N]560_.9%6RJ 5ANE:>E9=E33'[*D]5G3J
MS).1<^99 '\3:HD!^G:4R.RD5D\T40R1Y>HR=!EB#$WQ[:M9=]74$D.(O
M4'&(]Z,W"(G7A<06,7NM7(#S^]XPDFIS&\Y59N^SH^YH/V.3GY
MHV5MAMICVJT<> TPME#E.BR9Y\0A,/R@>7DAJNT,VV[F>L0PJQ$KGCM-T<>U
M@4E_C.Y.ZQ4):H%+E7IW[KPY\B52V=L[;2]?\?G-]B?;MK[7><=<@^TTBOP3
M5C"+PDNGV8M@MKQ'626G)EKKP./R'+LFZASF2KAX'^P WI#OSBD<8>I!0.O3
M2O:"^X3Y1[HK&_8>K:L06WO$[;KXLK1J?N8?;]YHM\R%JA@87"BP."UJDO@D2*[7>NY=/VTY;ZN[M'LN;-
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M$_0:BU=036%K[!Z#R\ :(;!X*Q0J0%W*U%ME66/7!*^9)S:7MX>G&1/'#\EB@M?<-4'$UC\(-X1@B'V]R8 JWHZN:+F?%6#
MBQ=0%D\5X8_BD8'_=S;/G&.<^KP:G1_[8WKFR
M6]9SJKKKF]F?,2U5ABTDX.E+87.HM7EPG3H+B.#@&=L@K^1[L$)%@*FR*E93
M /N2!H=G'/(1CD\(6.FU;]X5#*56X>>$KZ^/-:0_DJ^*<5%MRRGT\I@M7:S:!?"/\@Y+^H+E-9>9.H@G1!#:QPHE>J-N6_.
MG+@?H<&9.6EPNF'G6FY))Y]6U:%BM"/[E,G"])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M)"!<@P,YC+U2#\KN*LB>=24ZQJ[.;3O#+?+!2X^N-X^/+BMBGQT "WBE*92V$=Q80^;**,QW)RF-XEG6B)BJ1VEJSYHL$E2DRK\ NLUC&6
ME@X-9D)MA#WCPA4-WJ@>7H/3+P%=FH+6UK57QJCOH19T-^&ZD=Z.L)J.U_[A39)F7W%_
MY?3"W+(3>&4FY\&!X8?RN*>?M%1O5!L ?B"6QOZ+G^6^R3*B)5PHDZ22C.CS
MB.E<%S"VE9V(.L)+Y0UD*5(M>N@%>>[L< ?N!?!2&$N_O>_G+)X.(#BO--EV
MI=(1:$DOH=;)E#&\X0,%+\M=NXMG_%^5<4V1+Z!;%,0?MG\<54I4Z-H+.$.B9D@5 _!_
M9"[&5.S\4O)/J[&Y3!YT4U^N8B7EZL'%D!I9SZNDII,MYTT^W^F4([7XX\&'LLB3WIROWXQ(CI1]I2CGJZ^3PU@6*.:!GFPM;"7VD5%=
M(VD=ZQ5KLXI9!^DI,]4/F(1 AA;LI0C4DWW, J7T8"45%"M#Y(^:'@__6*;RE9PG0[L??:+X('H/8[9A_Y!!OTT. S42^#A>ZB(-]N= KFT
M$HRJ D2I9A:/6 F X9>9'O"# ^-+#M!9.R!LQ'VL18)MV_FFCOL?_!C5_K4&,1,K:^$)E3G:ECL'9H-NS4%+X!,AM[Q3(XQ ].%RAUQ 8C:X()^A5;3Y>'QYK4+BPZD+G?<'7V);(D^+OFB)O86UC
MS/Q#LIA\C-7GJ3"_R'5EK.O%Z&!"2*VN&7>"C+MVB1]_25G>R[!7X!?R;9,8
MFT+F9<0^4K-W=1]W?"K,>8EDAY\-W.%U[;H.PQS5,U*Y(.%0ZWBLR@QM[V>/
M%<@U.'B5RU@(&" @F'YAI0'E+N36SP?62[
M1/O#<4&PJ7W"4< /B6Y AB/UGY"-X*L85L"Z<$B")C):(N
M\ V^I,)EW(,HL,.(6$RH,N>G>[L=K*2E4<#W8,KIY\>KM.)D'R8CYSJC2YTU
MN/#^C$*S.#+H*QDHE@^-)9C!"1VF$JA[1
M!<2N:%<'I92Q$5I[.\2CH>?C'6E<%'77M9+K8?F949OG/ NM_AQ,:Q7!-N(Q
M3$S.7::^K<%%L>8%(AMA(]4^V XC-#E^-B,(8Z$>C+#)X_IY$4I>>6MB#,6<
M;1GNA;FF*,MF\R*@--)P;8&,G3S];< .#6[^^HC:F&>?A'G7@'UD:1FY;&K<
M!)J@J*\"X=0^DYW@Q&4@;.(56?$[P8JQ&.0U^Y?D)A8@!\'$-P5)60K:_.%!
MF^ZC2>*=D)/R6L&'IAM0]2QKU"H\@T\#MHH6]374 ?$%_3B4],_(638D\!G$1 =R+:Y*+0&%*6[6SZ$
MF2CD[BVS(L5Y[.S_/B8L^"GW4+^:X_.T+GU/S1?J H ?.L%<@?91P;U 'W43
M6%HH*]+@CE$30J'*(:CD8,04<823"R!B^6\%))-I,7-6&MC4)3$
MD]F ;ZYD@!Q!=A*+[AX>>6_$]:;ULF=/H14E%73;\1F#.7M.6,QD;WJ2T H41LY"M,@EC('+H$&A*1%O)XJ/8K6F\!#F ?11L@/G!*'4MYE
M*V49K+1[9D7E6YYFBK=?7!P5MX4SV N;W]$#$[2S(VPZ9"\A] RUM95S*VQ]2<]J=XLA>9?T WX4LK=/@M+AVC'GJ]'I[U8^(-S2'72D9GQNI?6E2
ME'+.A8\GP#3I[@*H5-5L<:LT&111H,%;,GJ]7K BO6YUO4M!85+)DK/BJ3/*
MSNO1/U(&R 2>M(+PQ&M, 64)J;.YMHS-4+)R2F#'6? *.0K1+J#F6/\E@!72
M7>BWF7$>6B0GQD9P=T)L/MW*ZH^!.GW L#\]A=M[V/HP"QJ<4EJJ'[_'M(_LE3%P_4Y3K#%SF89TQ?DOERM@*=X#CR\ OKF*!1(=.E1.:U=16ZQ6]%O =
M8.S5<<0[-#YFR:[H=Q4'CW15,)7-,+E5],I3^0P.AC!O?5"Z&CBFP0W4*=/A
M>%4L$@+Y":E)+NQR7NO$7(:MFET/R&AI]R+U:;*A<9^S\A*' ,@OD=KHRBR+
M+]@$G"V0^(L*^]:8[M7N!#P+#F4KT]."7C74:7102Y@4%UG*#A:4_8;1]8G3GMEUI06Y[@!ZT_&)Y5
M_3D\U[1]TF/_OC=1H:=FQ[F,\U7'Z7Y*9W4R=RVS[]R#Q"(XJ;61C#_-6_B!
M:5A;P][6/M)I6!4Z=QUS'LL:S6,U]0C9*;J*9\T%*:C!AG[5;G'(%9CR(MS"]_(>@C6[KJ
M?0IV#^K0+'88)!?!-X1FM6:.Q42389)QIS$F%,_$MN]ZWQM^C].%A[_5'CL1
MJXIC"@B5MF,U]T?-9#!W=QC[,/R"3RM,CQ""H,"SYH3@JMKX\HB8][&Y^[!_T;6CR2#)^:RSY/TF&(SDI,ZDTD20"0%
MWWH-Q!JSR6.X=:&+O3$X(A@5=$V4D,M04J1_9M:C$>8JD)K\,?W-8&1-K]+Y
M6/\.9> M*0_>:P#J\U!=0%7F]EAT9JZ$M:2MGCH LZ&34_+D%"=[9X#P+5D0J!T(F:=\$>G!S$ OWYX8?KM
MY;P,R^>5+,R+Z&4H"(G ;-Y15B(/I&3$*J/5]^I7%"&NH*T0Z)^2$]/=M>03
M?85>F,+KNG^ 7B-$YW71'K!]H2V#JSM/+S7MMZ^L>+.T^T5 8,28693MZ,1%
M7@6[%:\/\(_S(B7]A!9 OPJ;T@3T._5%KC9C+2AJ65S)61">36$QXN_!";L:
MH,(D=[?PJ!,&G'Q)Q"?_P9'LTN2'N^WO/F5Y/[URT/[&;D>M"=(,$K4 ?'*]
MI.-ETA*2'P5X ?C;M;L3F<;A#6/F'XBAF>ORIAVWZMY[&%:>\_APTLV07*AC4ACU!-[DXS4F2KBQG
M=HBM;3&)2 ;/$,]K< LGB?W:0E^2+C17MNKS'S"TN/?Q(7.#;->'P7C 9U1E7A83QRK(0X_VRFE3>,9IEJYQSD0WZX@V1
MG^%GLH#T^'GC[D9@IJ(UZ+O>TQ)+^L7^J1^?5N>Y73%
MB>E0511CC?H!QIDT^%M>$P5>[MSM.+J8&SA
M(0LGE/.?J6^. U%;X,XNID@"/JDG@ARJ&) 900EP0B/5>%(=Z&B+^5I6O<&T
M(<1*^/@EH$C^K.=MCTVS6?LAQ[,'>MZ5@>:H;IV*@'9K<";U9T&\3#L#BM#H,UYR>)*:YSLYHQW+!V!YUXE^NU%NS[%MD+G\M=U_G8%MLW_& 3?:KVAP[1
M6=J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MY\:R"P7V9]T=("]9*XMAPT'MJ]ZZ8OFQ!3]J<%F21/(3VG@/2%9^AT5(02(JU;_44R%M.0LQF5#RU0]0.\9V
M]2\6-/UPP'!2@TNFFKF?>MS_87KHPC>]1$>U\[0&MZ4RFV!^WR0HX(UW9/$;
MR[G9H.=B-%F#^XF8JL%53K1,&#+;":;,[YDMKN9CP5*V*;T0$UB)G@7TBZ+M
M->I\])OAZG[W<\P\!8LU'9U>%&'F6UN5,7ZA#/SMK@004XXF ]9(QJ#P,F287%^"5!]-B
MSEW#)Z(>;^/UB5VWB2K^2%R2O]-B8:9S&XPQ[5PC]1/&&AZX']\W6]D)29KP
M6LQ>]I.I,?5#) X$QOW SXW6WXA)B^AW9(4I]?9%D20S.*\8L2CO64OC3-2;
M._4F&!3+O.G>](N#BRL?Z(JCEGT&JJ*OJ7Y"160PP(.B%,/[57I(%"9K3 >9
MS1;:C:^BF>9P5F/MHDIH6Y&BC6?L/8NO$_\:
M3BC+&F]0;7J%"8*? !K[B@97\3$/)"O,QR^H%L$)RE#UKQI<2 :AQ=7V,A+_
M@'Y*0#+H^3*!C["VAZS3YJ5K9\2H/7=WZ#^[M;7A5E?K.MVR;Z_B.]F8(^7[
MDF8AB^&%*@(['3#B+F5V$2QY8?B+9Z@+OSP'0JE]Q7*S @4AE610455#,41H
M+&ELDGTI5OLD+HZ]YQ>M.,[FPT\RCI;I9ZULN+,?ZYH*5. /C.7)V .[1^7C
MSS%;RC8Y ,]NL@N72LP#DC=5[I&!N_-9SBR-F:U9'$]5)MW1/0'WGJV
M[O?RW^B_%7J>6HV8PJTJ$T90)SH?V^2ZM>Z8?6'VE\$BJ7B,)B->RIX:MU3A
M&)$U(&T\#C1O=?WYXOLAF7,#6.H3O!&,O<)=%#BRPZPH3O[]9-R!>Y#>UKAS
M%0,#+\-/7(!,E#,G'@^1 $R@'N&D$RP=@0RV*M "GC9XO1-K_IZ&MY=.+^JI[*A^X4\ O:%;38>=_HL*ND]:1MS_)Y(W;W0E-F
M3\^!9][^"U6G,FT8.%BL\L*G3HO/N^NK'$FB?LNM,$MM%+UJZP6,K864B-\XD+#[PDC0]UKN7DQP3_]G&6@L%.>^%.KM! J6]/J]TH)
MNG""G"8@+H8=9$D%$&\/R&ME)U -N3H1YY+Y+W5^RO*%;\B*R4O@:"T.W;6E
M_WUO"+?S[;(X;\%RSX_7X'P9T->F_#ASWLB#5TG&#ZI6H9A!JF()>/UWY-P,
MD#KSAN(;+^5K6"PEI+$K.2WX)'16][T;+MC".LE\M[I:P>+,Y5<2!*87U-0Z]H@4PF3SS-!DUU."L#\)VS6)?*HYK!9>$]M8[%:YA
M&M^*YF!HN@1H,K_+2;G2\ #'[$7TL82TH4)R)5&(3R;KSIS!!X/O\Z%'G_W+
M81,%)P68Q;5!2' U#(D>/^U:@[L ]D)SSGQ$MW]]$ISZ)D1-UIJ7*P/.=_Y
M^+8ZHP@>0O6H6 NYPS(Y\3RZ'+XMYXW3M.D?Q3(:BV0;QM-G (^1.7 \M!Z5
MK3F.$N@J11!;-HS8R #SJK'>WE/A8G%$]>MV/=HAHGR$$SX\YW1ZTP+>JC\L0L98^!&H#]47B/@96AP3W@7N,8'@H)*GQ6B
MO^O+(5J:DWWT\P;>I;6GQ]=Z-Q#'S_C9O# K6<,DQF$,]U9=BBX.!RJG
MQLB8NDI03L,JJ>0*4.62P0B1-D1*L\8W2#E)U#)R,R&)9^(>*!-9;H5FR]_7
M 06CS&\Q6TK1I818YQE'GO-Y[>+?FNS8IN=2G4W_> 2'9F/@"=L5CL6K[!$?
M"&BB61Y"#D.L-*X9'. -\5IB81O04TYMP03R O !+])*>9N#'.A%\+*!.K)N
M^/25:S\S-D74=-12[FU=6[W1._ZW:3PHD(M\.!:,!;3F.-SRGL9+H\/W,DA[J])>M_T(O)H;>JMP:X]6S)U=/;=._TCYZT&
MA^KJJRR10'!JW$TAL618J&_RI'>#M*%),:9JD@<7P%M5?AA"N)/!F7ZHU
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M!T45>TQ[3[>YB)8D;?,C%7
MWKR="AX@3[OJZVEP"[+X(C0$H[V4JSSI$^#+:0MS=#$Q@8V\$,MZ3"WZSE!/
M:G V4^;HLLT8!&-CU]$>1H6/<@V SW9>R)9$+)@$#2[_;CL/_(VQ1(-[[\LS
M>'AW31WQ&7!-E?[W]IC_]Y:B)O^PQRPPZS7ON5KX=_;2\7>#%3Q:I;>V[2/U
M_V-0<[-"IHB?R"< ^7(BO(:@MIJ'19'D+1W2X-97 O]QG4AP)&U66[DJZROA
M*0\R-D?,\.B5!"P&P0KPE 9WVY_\=Q:J@F.V:H7TQ;MY0&RZS.*\_<2PM];"7%]4/MCAU7P
MWO@'IN*?#K:%!^[B]7%DO'%/50 <*Q,)WT'69: $R[T!ZHR$0:$)#(='E#RX
M5?X@!W1K9"Z'W@*Z7_0C>OPG=E(-!S]4UV[+>]AO6E?16M0C%+.5O)4)=,TF!;3FM@@-(,7@>>DG*$$ZR@;^! R,Y'GMO<%3MV;/? ?]TPCX'DE&=A#S>!89'.'%<.])V_. IU1IZ@!(SK*$9;C*4%RR=I\ZL
MWR&/7VF9X]RJO,##O,ISYJKA0?.GR<)]]/5D@P/T92^\\V3CGD(QM_ :5/T8KMJA6)%#);AG ]]DH5E8]H)MCB11(R7VQMVN<4%=1/;OK%D65*%[6R*V=]\*M]\\W4?_,QZLN^B-KU;>Y!&9?;7+JY,#$Y:A";'??GZ;T5TA7%LM]OA7Q!TDP
M5:Z:Z"_<"3L5MW+\Z=Y"DB-H/UA(NQ^>G7ECX:.1Z:;AY( HN'!\$'GCL?1
M)0TW9HX=5C(%J*WZ(G<.(T)]GVN*OO#/S(',E;GP%#BA$+=0^MV4-R%>(]Z,
M'B 57W#D&#BZ2O@>)ELAX2VVD)+FNO9V4<14=?;RH"4-F1^W;]D3<+_$-$WK
M,_GO @,+3L6C>O,V$*KF);)5R[ 9YB2>.)B[ (MP'YTBYXT-08"R%(Z"\EOR
MFU!=S"=^ASB O"LD8TFX]7PX'31IU."62)I<@20-3A86B=J#0$;]#@7+),SE
M:H0Q7-@X\_ZLITQ_F="BZP!\U527;BQ0
MX5%=6]4^9%&[#!JL@ *H8#M!G:71_27E%RYY7RGQ'^0MD-N*Q=7T)\@!\%&F/@9R6%/I -(,%-^#XM&75&LD%A*T]M.2W*.@8*4KV-J"
MGSTBF3W0M$\D(_8GM#AS%X((>4YI#,W"2S&Q:)"^1YTNN(9L[JG7D5(6C/IF
MW^]G78RQ]U5YUE74C9!6 7PBUY!>"1W&P!
M7(Y&;1C!M>KKJ!5,;*W5;M0']OM3GQ1U9$-*;,3J7KJB68IUIY4> T1:T_,SB=Y2<5_ TLV>& _7_W0T1WH,X)=
MU.YVV2/,A0!_00S5MR8=" T"_9DN?4'GKQ4JU>2-ACKL=AT[;#2*#>$Y!G&'?)%$'TH/D#
M[WBO .41.,S]K(H!%RN302=.ZP'R3X3S5"/4]C?PE#<4S;M/IRG,FS'#--TF
MZTU55Y7"T6Y6)S]+:Q)+)QLH+:AS/=CL;_526-!0DA91\S-EV4Y=F%;!C+XS
MT3[%^0>H0T#,%IPD1^CKD95;,+*BZLJ?47#H"P"[D@:D#VI#+AM_I@I.J/!+:P/R8?-^4$V, \4MP2M? ()"\\OPPA[[)VMS!TL*&*$P<6T>QI8
M,PZJCD:RGXC&)J4JXB72<@MB,Y!J;<&6<>L !<&4+JS?XC@Q&W8F)TL,C]=O
MDKM1RT:FAMS_F+1JX!TB<\C$8(Z&)" A6CD9>\&A%B4DM\A?E,FWC91'H[9NU"AMV%MNA1>@L^!4&7XAX@$EEF;(%T+$"X@39-?L4T!W$Y+[[>4B+7JN78.#*F#W
M%?S\0;J?('=EQ_%Q\^G-/63I50)(J2/VL^5>+"GL8'U#Y4#DQU.E'($D>3^=
MTV+XB@XHWX,9AMXVRN>1U":=;@X%1S5$_OSTIB4'$-=OI;*8F(F3D&NYX8[-J D3.PVPJR$:.7
MR'[5:L:WZKMC)!=ZOJ!?DE[OI;+[0%H*4M-)AH=@;\_.T^S^0OFQ.V"%H%\D
MB KP@U-IML):"V*=0/NH@62&GJB')9MI,4,*]CJ(3TS&"KTY4$M"3+O!@/EBF0?LY*22(N"-U>N%0X.;C: J1-,VY>2
MOQ<4-JP4>,UJ*=IM84T>2T$LT=R%+ZD@%3$"=C>HV4P#)![.4FT2RG[AVL*A
MTII6FB'=K&3 '(BX"XX]G ?36FXPMB?_B(UZ6"2@-R(.MK#B7HBH#/?=5E4'<_-A\0:2++N9G6\MTJ58KFPXGNV7<0P,;:3JPB(Y14A(/AG$+?H>,BB(U>#F5Q?++"F6Z:=LTYF#
MV9M9[I%\I8@"[53&3L.%\*//"SE-M\L/((?O,@@-#Q[ZJ5C%;-#ASK%QJ6SYS'KP0K)/'CN\O0I:K\]RI"K(6L@.N
M@8*EY'%>T6@N7EP?]9#A DV-11V67V3/(ZU&+,&I)(0M=EN&VW0?K?AY/HC_I]&&6]@)A!!>Q;4ROU??YAT^K%K^@;L(0Y-6$;R2D,B+
M"-?@(B5SD3UP43#DUBA9=!@F*B3I+M-_5$GM]PM)R^%8_/FU,>3Y]EDI42%7
MFI;:IC,VQ!>VJO,69K-O:G#2F[RR9(PZ!_241]6U:]P!J275"#D7+*4E4MTTJJ.(9A5/ RPQ?*NH#:T=E>B?;^'ULW=C]&3G#H9@.>>T^M86.XDFO-S0%FT?[1!-HB9J8@$*&/)RBW,/4U.(KN>ZY070U(;Q+*M9,93J!@
M#QRI"..%/GKH$Y',8/\"V0H-"^P)S'V,[>"K94
M*!J6R24'-+A+(T/-SMF'LH.*#A_)ZG6>,A>O"R\+K&+,A=I0G2EP2"IN8@](
M&L]8VU$(C*WJ:T[L5Q.*(0'UGT0OY
M]#K/GDF)+IS[ZH/_9;']:<;IFJ!EO,0'9<]T*?HQ+R1.7R1,=NK /^\^G@NT
MEA'>[/+!\LU ,KX>G0[=4'"W_[_*7-P[7S[&?8=Z?23^(X'V'Y=B6NW=>/#_
MNL#_6A?X7URH?[661&1)ZLPUVXP!P9ZP+5NV_$&6;466/'NSQ/;EM5W:34]_
M[LA?C7[$0%O_5+8$61*/77RQTKGHA&K'AU/G*P3O,"&3 [O\]%/F('7MUD^
M;.&'#O6O5P3:N*-B^[H7!;2!I"YLH^>!W[ZB_63E
M:;8E;Y(DCGR;C;YWQVSFG,?J1)1(GY!["3 K#*CE/.&%"OW.@"DZ4
MO[1RTFN(E -I]QLKRVK+JBP#=N,38@P7O9CX9@NB /B+,7S+H9-"^8"QJ8(,
MQ=0?BX-:D15!3PLM+$K.E7*9EQYO*]Z.W$:V[J4.)",;V*A.JP:W):"9#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M&+]NT$)UX6O71%DS(1M[.TQBY+ 76YQ7&+@5')R! _[<]
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M9E[D0U2K<*R7M&8-6?=TB>X 7\DA)C+TR8'X%)%B_42>#UOH>-+/0J<
M3&R*LCW8.5[O%0]FHL.,I0;%IY:LUN\^'K5R$C_SN>Y#/&D>NARB76!$EB#Q
M3VF+&!M@=A243H&L+X"?99(D&H,"[6X53&==7%/%(]1<8AC)QEWDE1:$!*>7
M 8U,K\OC,1_RP3_RX_)$CE$GE ]Y!03X%!DQ8:$I-:ED<(2.19:=39;]/O,.
M%7EZV>!R#("Q'D CPOY6N9KD\D+'=EF<)R0;%2)
MA[WJ(\'+B'Y=N[LEV"8=NE"_P9R/\855 $*I@J-DX^9-3$)Y%[).JG:3K[PS
MKT'VH=+MEZK0VY/F-^(MCBD65B:M3++%.7J^T&3TFBA*'KA-TOQ=^+4"829G?4FS-['=]49F$K"
M8/>B$\#_7G$T"S7EI"X^?#I[KP:GM[^%P=?364M^'SX^ZWDD^PXZ?QPKYY?T
MENEMETAX^M7P0?K8!O?[[N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M6MFSKHH.!&&S:Z>+P0U5'G31+Z 7XAWWHNR#KOR-%%
MHJ$5G,33'&-D8]86<"HQ=E D?^[NE'^(SMG>#<3*5;??94O/^AG[36[X!Q#Y
M=_'0;P;U9@ME;[JC7G:)"SV__@1CH#;77/V$9 97*/#-9 -D?V4/@Z+:"#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M)9-V'?^KL3MI1W(CZ!"AO*D>I0D:XON%;V(MI2"9WQ[I\F(3A!\9GS?JT=/]_2QW=E1>IIM
M"(1&LDZM_ +]H/FXD=,OT:=I-?TO
MU8$84&63I;^FOT#,H)5>%+@VUV$::.\:QAJA M7IQ-HDT4&.P5DXNH;^PHG@
MA[5I\>4OUO>1"JO%+<[>7XRTP;
MD%M4!..""A.CW'5 L8PC4)N)]_40%6*GG+B]'0QS*0M/#VAF.D,&97/.<=*0
MPS&1G AS<=/V=YFKWZI^"'IY%FNS+>IZ)_W=0WY9RHN]-"*-^RWM<%JOAS\A>^$$L/JS-),GMTN/$^E^=? D"S+V[P479P"=BT848_3Z3W;3<1@K
MN0!\5PH!+(P9)K^B7":M?\UD0S\:Y% \M JP9S%3R=]P)PFVDQ^RYD&QC!!;
MWFLLV,=#[&A794'DL(3"V^2^VWIPQ&]XM!T]4@I('U*K>Z8N8,9\4*&8LQ[>
MW^0:RU>;[ZHGZW&-^^$*_RX@E+>D#RZ4'N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M> O8-36MCNK:>B,5'9ZFS(=Y"H,M@HBR?_ELX: I#W)BI2/!#WZOZ1=*TH_VKKV4=GV;I+MLYG>+9RK\2<75H]^(
MQOHJO5A!I%+@G2P&X+KU?SY]TIUW<7 Y_@^R? 3^_M?%N;7VA'-+".9P!("WE54WQRMJ!X]5LZH31&[VX#%\N24^E6YZV ZPUM65Q=%;OX$QPJK_5P37XRZLJ:/,T-N
M]8:>QZBGD% ])2!P:46.HXI"W
M@J5%QRNLG^5O@OP:N>90SKN7 OK-5KGE#_7F6>+T.WYGQB7A[Q_
M+%EX);)ZKA+X+IN#++14CGMX5Z )&R:>#$&G]*+&<1T'UE;W;[VU^%^S-45-9#^XXK1_4X]UU_['Z*S&D7]
MKFS#( 99W#O1[%Q3
MW?4F/,NEMJKAY8.BJ+6W'\Y2NN:VZ:6GFDR/46 ;%\3DZI/94DRH!*S^RVTL
M_>60*;N4%]=I/(1ZA PCA%&3JURLP&2LP.0H1KPT4)]D %\-SQ8G,M4P^4Y5I]S3;A'485[T9:"Y)3%S^M32^$I-N&_F89?G4Y"JQEVJ@;,(CCF<-$
M(0'OOA6ZL[^705 0YR)><*0\P_KS1K#+ZE0CSPRU8UUFNK>S#UHO5!WAI#*7
MM0RNCMHWA:[,WMY++C]-A.^_JW7JHKMI6,>M>&'87"0REBFOLU8>9J:R-,K<3S@3@Y98U\X6I/9_[Y(GEB;KO+R;GM.284\C'A5D3]4YS<:3LT ^5O7F*NQ:\E_A/P(6*24%CB\)_*[^^!\BP72E R
M9'9_93.A6) >1#V-Z'O1GY7
MR*<9'Y_0X,SWMU"3D9>DI_DC$R)(@_MF&K-VP.^HS0?.^&_ 7Z)J3Z,MGV+L
M4/.Q!\!(]?G1WU1M<"F?1I[\62LLM/D?;\CJ[@!?X\I4-:Z5]JQ*81?<^O'_Z9,(G\F7=>U4/Q/
M;1S8UFW.-MA>OM%XC1$F9?U:J(,8"MXN%'>R_C-!1\9R(Y*3TOXE"_]V3OZ1
MT?F/L0L!:08;W.U]QEP/I#:G]38?*OK3))*JA_YH13)L)HX/P&(R]AC?"AO5
MW#.YWX%KDVE@9//5@(COZ$V2O=5_-C;Q2V([PRG_I0X&O,6P;5W:9OS4J=9_
M:TV%,9@GQL,V?HA)SD4;AAGTC8[9_+]>/;$ ^+UK='@W%;;!8LZR:9O)"*)
MUW(NM\X XJ7"KG]GMFPH_DP8'F'6/5^/X-WS]?JH0.0@8KUUD",R(L(<;9J/;(-10"?0);F
M]J+?@F;7(K'0,Y7^7?3VB#,2L*H^!+VZ!B'>EVP$WD:B.N-Y-]@?XS[]V[#C
M_]_"_DO98JVS!D/E&P -4SKK$>!]^)>7?\E;[5X"-NFA$&$K$/W7 0#P/P\
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M$OTU9#A^2I)![-TW6:G"=29R/(61I!@'<_=..9 RK%XR4
M]BI0,\GEDK*31AD59UNI#3K5)RR#Q\HG6D0W8G_)#8'M-:5G-E).%/<_!V1'X1=3(C/?6M,[]7*#,X>H@0:2<__:M\TC?PQ5#:QU^F7E-VQ^$J5' HU;)R7-WD5+U1W@&'PNZ8P+7B^6[:U86E P;
M61W3KJOJ+''*L>Y4;:SNC 9.QMY2[OBJ&E2 Q.C_N*Y2["N+@,U\\MUJ9/GI7W02XM^BJ85OHX>LK9&8HQFH,,
MB-CWNVX]_1"">/'H53I=:=,
M_9R0+?J?HO.B&_S>GVT=Z$]N)"[HQWH(,*6G]9V.VAUHN3MA ?EO\EJR]I+*ML*V[>.D2P[HN]!(7?@)+>&/1Z77?96$0T9:\"M+P>+25G%
M6E8W(E]U?O$(WMP56L<:M_@V<-1AD,ZF-M2P/#OM?Y]8YM__XD:!8B#/\]OG
M;(L=4+$LM_8>V?/1K^[G(UOO8QJD^W^.WTQ+C'VMX'T8UKA[)(PPE]1T??DEAF(:UA^;,MFPN]6GKKRFY[1ENMW#\1ZTQS#M8/ S
MZ\,IVY!7L+>T+LZT)P9O-7@GS)$V_L.-W6C3)V13U +_.$$)?""0?E$I41$W
M]TZ.4YIMH3A >%8J0GFT"-PDVS"\(XQK(_ZBYYWBI.>!;[88O&%P+]>KWS;0_ =>Y\9G
M*NWIE> WBT66K+;/48_[/]^$*\"K3S D* 'YKLAO"M&\CTNLV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M'J#EXJ\-/Q,>%'T2E2.*#%$(^ PGO+Q(>2<;UJ&+2#7Z+%PS(%+C
M5O%)44P9)N>6>SL# V$^8R06\A$)6F?QFE(.A7):#QVM_'5%B>Y"?HD.Q,\4
M\U+RAM5^1OAN_AI:=3DB<'XVO$:Y&%2!F@6N]9-YX\9&$86S>S.+>I9110LG
MC_-MS="P5I]%WYLP0=2/F.EI_H<'AN(SO-'?565_FI!N5+]JL4:+K$0*%FFV
M\^<^LGD/@[B/X-.073T-UL%'3$\C6-1XS";]N7'7GZT]X!.-$N3.M>YK*]-NTYV-WY4_XLZ]Q9Z$7I8G\E&44O#5U*]"5#=K2&FQSQX9[9\DBZ]%X
MM\L^>GQJ^EGW19P);UK,LLUW-J+X^SA?!9>62S[#'64%VJ7D(]NV(NW($[YF
M7.JV[H&W*3%Z^?[&#F2*8ET< T1B'!'LEHRC?-#P),,%*_\&0A%XUAP
MEE%@5A-HPO'XL >4^+BS_M U4"/L<:V$JLR,A80Z'7L]Q(0_1HWX8R^+M.WM
M%L>74>]\>'@A 7OPY+"\:+-TAD@+PI">*WIS33'X23D,[>?DP]&R,]X7S)M8
ML^$TH*ADO1+7Z'Y5*:+ROQ$BYP\MU9OM^95Z95][Z+<21Z=MUNGS*\O_?,79PL,K]UHYCT9%BD;W:"-4S?9C(I/&XMGAHW%#S("9(>Y6J';)8YB7 H_MSVU*-,)
MLG*N\H]@9;
M&*6A B2&CP"[(2N7#NQ1F5<[AW"&_QQ"N5_=LZ
MLAZG>Q0M&,R%0$@2\+_/4C&% @ND(B2$8.)HED85F(3@9T5[?8%/ .(6UJF:
M[64^36J!?OP6S#X37@=(_+4G#"F/)_$<@F"'BQ["",D=N83[
M6D1#G;>@8L(Z(9MUEH09^7HIU-WBO5_F>7I')9^:CVU>N./L/E5=YPAE!YL,(&77AB4.$94)GKV
MS=S+>#ZO^K?^M/;%UAF#9OS&%BSZ5JQ?OE.?RP5WRZR2T',;'G_MGI92:H5/Q7/<*8@.>TT?(<$[YW/_Y2W!;0S13[B^3M@'X-MR]\2H$\V*K(CK
MR6F$DO92FIB5L":(-@'TT2;=J=U^?Q0A-YE12:KK7JRKI(%SD7NRU
M'&?];B7<9=">58&.' 6JDK9_/="2Y:Z;Z:&8=/$%'XM%&TZT<"%XI5L-LJD5)*_>LUEK; K<=YFY8\M81K/+/[YK4-^3R[\<1II0?;:
M L0FODR:RW<66:'KEU&"C:)=M/%13M<-1C1>*A)1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MH!H^7I:8#C_R,K:A068E^7:(-*U,#O2?9
MRCFV7/^ZKDOV7*,0(RF>6^1\_N"Z0[R.POM'FT\>)*"R( .]GT/'GP.NO;S,]+M%H483P:743].IU-D+L?4,Q7,""O$'?I[Y@.P24IHM7;+TJ\0TU[RNKN?!,YW
MOZ?_OC#=3$'*67S_D\&G*O.,!RM-G1"UO:AS/DB==";4//XLTVAIF&\U_O[^
M#X.F7I[@?"*\+?$WJU FB>D9,Q48VC>$J'RWW\.C;,B)*.5D@ &*L.AF(_AK
MH'8/A+LU6%W<<(*J3=G7U *B/[XQ"0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MH5&%CY[#FT1JF!C,>CMWYVOWJ[Q?GMB&45K_M9[_OW,,LI3]>XRJOGTE&CWO-X#D48IJ!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M$Z)%*$0=T!'&XA'H*[5TVYZ+#K$)O]W,-974NB]CJ#X0)V.B06Y!!6Y8P-C
MDQ'=S!]4R&89=0&GO8P:CSF6:0E:<1*?Z<$7"L6:!,_O3')-]^S&OO^&2PN=
M\GS83=U)V4_#4 XDH2-K-I!=D45'C9ZD6*3S=#D7I95,1"Z.(:-,0G(TBO]1
MGG/AL%WDKMZ>7\$O/\QNW*;M\AVXJJWPYH7>;^][J)O;F3]G@JS2UC;,-XE,=30KJG[4$HU74G.L *<)*0G/
M(74M.V82<'F1J7?FI<:H+".*(?F=A)?%HC[>L4"$HP15PF4@M*<]!#?6256#
MUB_$,(K(@=+VQTJ!QLH"#T4^JJO
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M-+%GB&0G5RGUYU>QNB;L1*;G=.%_56::B"
MV[MZX/K^AAKU911A'57P78?81#2DU7V&_JJB1V+0'1@6Q2(#[%\8A]J0(L)S
M/'XS9:M6/>YPBRS)'P";-%*"BX^H@^-0X9S"J$B;#6MCQ(7X,IPF;:(L9D'T
M=![* %K?]H*8CYQBQ+'5F:?'2>@N-@[9:S'J7]BOY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M#2F)SX/\UI"*M$-JE+_WN=0&UBAZ.?&M/:Q,-1L%%Q^.ZZ2*Q3384=7:]NX
MU\XOZ?"-DUN"R5AK=]W\KORJ)7'&N[DS)8^IBO\?<&B1-'0OP6:E54=\.XRY
M/3NQ:@4YM+I6R(%928S46&5GNH%,MQIL1&-":ODM*/_;S]64W4Q&']]+N?L'
M=SI/,OOB\.]%05$9E?P-@<;H9]$>6C8P*UABB!Z1[Y9%((9U9(8662.^Z@ ,
MT:UJKZJV(60@EYN]:/"#N1FWDV(M"#I'$SNB,9OION3SN;"DXN[C72OC"=SR8>_T!F]MO +6F9UB-'-O>D[CQ#&8
M9_,$$B;/.9MA!$X[A!E>1$T=]//R6+
MGBL5DDIBZ@]",HWK]'"8\8JGW:)=H8T1+*VSN ,J\Q7=SS'A,UCC/N+2S4!K
M9KBJQ8> *\(!P[86@\_(RX41M'2K,1'SB>GA=T8?JTG>@SN(NZBTOW=F2V8WNB^ -H[-C5-URT?>X+^WM2Y,7
M$FW!;79.?RGVO'_WV7K_O'N<4Z /CN2<4LI
MS]NGX,B0=DT5$A)J\Z>N/G\.:S_YR0T7RWS"5O3NS7,FJJ
M98\H)! C6C>O@B_6+UQ:-4:#M%H]WX%/-3:_!UWR22,Y3C3)OH$!)W>C>(1[
M+SJU;6*]S]TQ*6C^67DL*/SPY(7I6^(T1!(A.S9%(SL.E,;T)MD+4?-X6';,
MX)4YRFT9==V=."_6BNA;BY=MPN<9M%:TV3*J5B/42?ZL>$"'[\L")# &P@%D
MQ5=NN&(J;XW/S77$E=?R#!;H4WKIXP=$;34')"S;$#X.4[Y)O;B'$/F"MZ-!O:#9D'59LDJAK)M0IT+S_]AO%E&?5MUE6UO7.8'M"7*DZS\-EV1_=--IC7X*O@TF?NR$U0UK),@[T _X=4';+62%-C
MX0:*13O-$Q_E)"IZM$_C7894
MC2IT;I85B([P8RM!:WUIXD2RA6V/-A2\OK-$-=(YMK7>VZKO6MLV_Q/>61.##N]@_^_N86A0+#JTOH>FC:'W<,'>T:?I.W2+?IGN>
ML!%*M +T8K(Z81->M1@/4RN(JK)81JV[N<2XA]LYF6K2627MSY/>?1)KSZW6
M:M3C,- >]DN>+N0R6U A;(C)6@
M$KW :T'P=ZGZKI(@VL,^>K2?T-ZYK!HM$.1YIB)$;,&]"O_*RZ0D!:OGPS_/2S7>.1O'K9*QQEC@2T2Q&SMT-AA]I&V^
M1OV294+=03[-.Z2U*CQ0)E#-VV4A2T['F[#-6IW59L"JOW,RY^")27T]@P(O
M[=3.=TY6/I*;;YW&N:[FKL9>)_TQSI=;.>FA@;GT#M8ZHM&%;)F/=.MU"K[E52+9*?E1/>,::+5A0C1V)=J[?Y^L63M\6:QJJ#0:9VTVW:[=&2BH;YK
MCIS]JZ_-G=W!@9BM$3>-*U;TA!C0^G8,6T*T;$_1;@(Z*[S*H)#\!+-Z#+<6U'M ,>"17Y6UB52&
MG#WM#FQ<)=C^GY9'#*-J=.)O3HLO.G>+MD.V_"(0'99?HZQNW%./D2[$6I.X
M_MQUBA*M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M30_%D*F8=A[$U$]:VQ]-(,FNXK38772ST-@)XAM-9M@(_;./RYA;[F$
M[K8 1.'R"6WSO]0H^=MJ=E(L=R68D(XNY]'#!M53?O3M$5&0CL;E<2'AJP;5'=?O.7FYS@THA!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M?CNW=!I87_G"#]H5@G?RT@;.3[=4EZ8TAM.']\4-H8M>=0I"=*X<7A"._AZ. V8/M]]]G;-MOD%M#C!,E+OY>3U32XW>1)"BU>*9-W2-B$7,#JS_2&%X<=8# W)FU_2K"A!7
M>L> O8$ML+=D7$0CHTB[";T)WB1\7",_P :FAJC?4E=W5!W.(W!2/&V!@L>^?"=:_=]>
MMTJ"5 CL68Y'B*-GEFJ%K3CB_)\_B4QOH1
MSGPG6!"6T9C[]8GF]_$,!<,$BZM]$E^/<J=I=X;8&ID/_&]I):
M5>L*!:P_+;J^B
M7KU_\9=JP+J$04G'V,>ZC>FG*+]^_3Q:$_]YH?#/(7H$D6\EVD6;L "X(::N
M_TS 1P%1]&&5$TD$@5T4O>D.;VYVUBGQ:&Q5=-B]2WE/W65#[IZ_HB$?8+O!
MLVF),;3*'1,C3*L"'5EDY\S/0OE(82267HJY%!.61U> NIHMZ"I]Q$C#MJ_)6O6IRJVE_9.Q1%O \#DO>5T\UY[NAUX_X>06>1E@1Q58A'N1
M#!HZYB=;T9W$*6E54<@20;3Z*&*9VV/%3F#5,:?$A,DG?2"O"Z*+U7E FOT[
M8=G-TA_.)$5J.TZS_29.!G*VZG*C'X'H:491^EXFEH!1E-\@Z92(%:U[CLUR
M2GA7HPOY%O6/.QE-:Z4-/ .E68N&9;9F>J7D7%+?%4)OXDAJ]%9WP7%W
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MNCQY\78U%MK#N^1[4U4 X0SS-C6.*(XF3]YP.)QV\
M&*LFMM#QSVI4GW;IQO"\1#L-V(06[6"F$")$*R,9Y>/GJ-_LE_QKV=$U>Z&@
ME] RBM==2>(,R\&G@ 'CGK@2/5FR-C<\&2#6$4OV%H$R/768C10CCM[JB82D
MM4,,/Q_W7.*D?U]W"E+F:H&ZOYYS0G/XG[GX?A&/OQ>@/:!NN4%[K\ML'#S(
M,VJ0IB&RHDHRPUUQ6+'*%OBVR**IEK!#%ZDR-4!-EG?F>(5I%MVK1B8K$I9U
ME:_H3@%NC1LP-JZ;-VFQ_B0QFSQFO.6YJ,MXL2
M[R+:8N7))ZM=5X>FI?19 7*"A^(@IFH.&=S"!
M?"H&L?J?!=JP#@,Z"NLBW5AN"G--( 'O( +T<<1>/ F.%^P1;<=?%W4/"Q-_
MBI91 JVI2JC%6W1H&14? JU?1ETBQ6*6W(#SJ*!=_PX ZW^6W1Y#)A9>>U[>
M:2[A* R&#%7^O>V.A4ZRO8YK9%7!JI.O/CQZLXEZ>!RG*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M9:Y?,OM0T<0'=\G=#@$RYWR%N[.J1&UQ$S;
ME3UYMQYGQHJ[7KN# !U@@:)?^MUCF=K\K>^+N]"#0-T_\E6YZF\. Y;H/T4.__]K?
M3]!?NTWNJ-37)VQ5K3UU<6_V66)BF>)8*\'U&[0-B//#\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M)VKDWE/XHJW?#LUS:QZ\0V.:=VK:2__"_GW :J?]G$W__9\;\IS57*MKB)P\7"B7F^_J!(^OXSJ/%$78OH""CH^*MINB FJSEWR&V?_I(_^-Q1_P;\Q
M%L^J**LC1*FXA?JUT.I==&L 8J07Q:" ;&=J3)1S[QOH\ZIS?S(F._%Q?/J-
M:6^T.GY::_6$0]*![;*/_X0!E2Q\"3%49$"V9Q'EMD-PZN8.6)8#507H1>H4
M^N'#$S4DRR$M(-$,8.U*=W_=QQ*\TCR,%ET,/[P'
MTC74/D2*+13_"^NG'6FC2UBTARRCKK>KB53M\8DD#]BF\Z4PM8=@/Q6%5K'(N1=6:BI'M->W3H2J]@PI'F)$^ \T').\DV961./1(I;[$2"IJ
MXB#YO4A0%^@Z7J'[T.TU=,U?X(P)86)N8F_0;CAB27E0:%U24UA-;R:YH+DA
M!A$=ST8;T&O(5K:/"BI?602XDG(AVS.@?4AZ&9!=WMG!8HI5F5X+]NBQ05$;
M4\3,SSJX&Y.;:.\*S6I%LIV;]M3BM,:6CL$7A:E;Z:?>[K?FXB.=FWKM-Q/#
M^V)R-JO?R>NM(%6K[FV='[M+U=U. 7O(5]@L8T;D^NY2NBS-P\/INTI2CJD$B_AG#U+W=.%#
MS$;:@M.$_JIIB?H^;3RXZZU@<-J^H_ ,38=FC(Z8M_G4KM].ZRLY335)Q#!H
M@3TO]IAMN?/JU%SY^ZW*$C=C^PP%[V3NA"5*',*_P /G2H6O9O!NY$O"9&=N
M5U;T,HIS"7+P]*>)3_M9T54=R&=,B!NK)KW2R4%_M<&6M(PA3W>.ISAI_7"#
M:;J];C:43>!(ZLDZ#:"HH?_..3DTCD8;?DP.XMU$^&1"D]W&&R(9>V@>Q?2U11X5E:Z]7B9,"_5)UYZ :\XJ33WGCO$49D66!B
MV$+O%D#WX2/H2BM_(9#2@V X28\IA\?[BLIB0EWV<%LU3U3S#&UM(0DKR'L;G]]]W_(U2GCVHIBYW1HDT5OBS'-'4TT*3'BIII[UU/WN3N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MWT;:ZO59\9RP^[?931]18I:4
M,)8VW"!"QNTK/X=.ZVJ+[BM1ZB>,ZH8>IXS><(+;YUM48;FF#@.U 8#[-KW9?LF8KZ.."%?M.?S[[(<3-V!(!74-.W_?PD%JB+Y
MIEKVTC;:!D0I]D%&RZCGI_"M_V>&>*Y?QF)4[?28=;"50,JS0CUK>BMOO_>;L;/AD+)7^;?BC$=,\(YV8\#,
M;>,%[6CH7HT4K+;A![P-M+MH-]N;O$T0)G/S@=V2M#TO+PX=X"&)"KT754TXR5.-%LMEE-R\5K/,./W]H
MRU_LD<0TE14@"DM7)N'KAN$,<>N(_ 6R>@SP<(#B-)T
M%:;@Q^[!FY=1]>XCPZ)S-@@8FP3&M#8Q:#_R<4M6]64JL'NSYEQGE1EC:0A/' WUD)&Y/G]+J]XN^
M,>:/B*1HG!* M(S:M5.L0[4!I]3W'32\M^B<690Q^FJQ<,T'4#LB8MHLK1S<
M\4 3LQKKH&K<^/P>(U(D+[8E/NYNG,/M$/& ."T $*;!.T=929LC*7)05*5Q8V(MC%XZWV>$$4);*[(_<0'6!VX9I>5IPQ\%A\Z93C;LQ;OIA9CQ[P&IB4BHC#@8
MO@=%'LSG]B,0*P5(O;%3J8>!+?%4_;VO'"KB9$:RWJ^3Z,$#3R%G43@)C;0C
MGM4R2@7_SY@P^$4$OM**LX0;\:$8R NKNHSZ@I3.O\-BU3CS?^Y260TNBB@&
M9%DBHU#AJ>(2J,$P^C-ONJ?)CR +!8E4T'4',)O&CFV'S$"ENWZQ.C(45^"C
MU'U6ZDF15F@H>T?),/^J\$5=$0F)U)=[MGVKP$/X4\1YS/8Y%W4BQK+#Z+T3M.4CNX034\XZ+Y.:T+WPX)XT*=O_7A*>)
M-C$D::TM2,7":NXTGLNEX6+,U'C),JKA/K0OT!N)?D=M%E,8M%Q:646TH2 \! [N6 7]ME?+7)
M7:"/-F8&CMF+E!G\N[?PG&.PJO+LRO%IM7FS/8)UKG/\E^B5*?:\.MXVM3Q+_*,AEU U::GFA<@_E*&<MOV6J+0I\TFG7]7H[A;,A3/'OJ]_\!1\"7-TN2QT2U8^N66W:$"!>*#@L8A=1
MR%#P9:6/[%!/D@\PS'TQ9_:/K:=Y:VR';D_0?JP+-,X+! +C;HA-XJ%3*T\F
M,3.*0/C0.V,9%8OY5[C,X:'KA-X!@"I&4=%JA0V 6_CY)LO__:(\H[$+>$_[
MX=:J5'.B*..J:^J4A"FZE+P8667)Z8:Z@$S;PK$3.V$YD.@[ZM"QSX@ 5$G]
M8%1]11U69J.D=G;@5Y(_/*)=^X)6#'34EL-XKL4?@3U]M&4?V?7(M7J&J_SK"<,.[X$IZ6+M%I6@;K>Y3G.EF= 8JV/D_XNS:?[/^-)$R
MG>^+]#$)P!7I8UE('[,\HI'\/WBMOX=V O5[UH)[0\YT?.S6?TM>DRIZ7K@!
M+(N$$4RK4]><3MW>2OF[A/:0ZHZ0%CWY#/!.;RT=?%N[.&I*.#-MDM>K]?US4H>J0C9"[>NC_5H_H(;V:9TOE 7I4S\%N*-@Y8C? XR8:).%EU\Z
MY?)!9W1XJK3B7,!=#?GG_LLHUD-AK^S5TQJY*8&M$CW_F6MHP%=&M6[R"/$<&:.-Q\?_KL7J!M>'M84+D]")+=FV-'N8RD_=WZU?MF)4M[,T75ONO1&%\@/9)[I4:QM5%GOS7ZW
MZEW+#\C5,D4*:F4/D)^UOM@T\9R/6D*V]<\;LH"WXQ274:^2ZY=1T"%$+C56
ML47*\7Q_+"9D6#QR'B]-4:4+][?_MZW^?U8TU+NREE;#6;]4&A/6C0A$ZNPL
M@Q&:+-:,4TXU$+$3UW/5UW.C)[F%R5N[?:OVSFYPWL+6AK[$R9RPT,Z9[.M%;[/!Y <*5<_B9?&JH;&T<8D1-9D @O3.SJB4-A("%'Q8];J/7C4ZZ&$453\
M]8FBCW3"T=^4@VZWPWH$4KR;C[?E]?PR;W(]@KG"D"<[(RICO79$S2)Q.E;O
M<*/Q+7S/I.6_<[4K@QU_-LPG?_O?Q]5_78A/DQC8$
MSEQT/?6I23NG22MTRIJ,9]$VD>\08AC% WEMZ["IXU/OT/C6U?*^OT5(:?P=?6QX%4XR1/8;H9X@SMMZ9F#TN(AO*CQM%1RFLKN744HBE+,90EW;;#Q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MBG.GFN?""AK1<37;HT=/II+$U^??G%^'U=Z1N'8!UE"K[,T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M&'RY [;@$C;I->03&V@RSK6)%;/W_2:EW>JIM\*\W#B_*AN+K:S8!BZP@M)ASLDF^7 /U<*=?D*<)<:!,^=SZRT^J7M7?_O@0
MXU/+;[%_TJU\+<[MGE3;?>+FM8^>O=XS-I;E1%14=8TVW_*F1G1
MG9083C6$;#G/AFL]#U'<0/6J]9R+5BY)>I C43R_9COLA7Y-/NLQI-(%&P&+
MCF#)L!162ZD^C[3)\O6%"0W-[JK5?LGKKM+3H#2PD)]5!.T7X(B0EAV4HA>3
MUEGE[,.MG)Q=W>#*):DZN1O#GD"$-1B>Z 44-T;VK3S73*TPKV7$VM5@2[H@OKO7(#S;!QF/]8LZ^VN,-4>%3CF0'*)]#QKJM6E)F5 NN)\"6C)&HH
M(.OWU7BI=\$)JD]+%2=_ZCX.RU]3<>^]KBNOF/:YZP:#3Q(A/J KD:.R)&/S
M=[I&T0>XLX?=L1-3>N+A\,(1RGG(C4MX,"8VL$![K[X7=O^EP#0LEMQ1/H?[
M5F:^KBP ?N8./WN:9L7W"TJY5_.-CD_( IM&F--K!7_5 EGD-;@
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MKD$L:?Q\9KJS@V&@&S-;JSWD0/X3_>>*A]+6;TS9LOLT?MG+PLZ_PF?O4GW>[N0?V!K/A_'<)R^;&,\A5AOMJ'#_WK>)8ZJ7$5-PTHYDK
M6Y8Z(/]&L;K ?K+/A9CCB'%[PK/J:F^T*ZXJ;J5VN0OS@N5?JDJ:SOTI2STB
M$,^A3_4S6] /\*JB0^/+*(4:C%$C1@[J/]6Q#:"%QW,58[B8".UZ/-JW6O(<
MM!_(F4='[IM(JU6Q=8(66M:9:>%+BM;?^)&\,S\6HQN^5$O-MJ#)]$/*Q[A9A/%648G$Z%ZS3CVH4 UH$4)=>-RAQ L!'SQ/ERJ)^=$WWG'P+
MV#'\]")\O<2XNF]PF[MFKRR24)2KD/#:"+//$7MP&25IPC.LO,S-VURSRB@*
MWHPUS6/3\L><;,#@\!SQ8D3'A"DJ(8I\ X5H6%W@X:*&O]$Z CP-M+A74B@/
MI9UWMKPN))S\W<\J^%0OJ<)K/I*613LM-KF04X?R8?^!=XK]8O>:-> .(U9J
M$@AU@5ZYMQDMQNLR9V/^YMZ\'OB*'#LJ$"MT:\]#'1FYJ25=\IMD Y6%;/5(&PUKG'* 1.+/'8X&O/Q52%
M+H;@W#?/@VLCHGS_Y"](B_\:L^)?[9K:8=6/UA_HN_4AS@"_%E:&#H/XD<:T
M$;8J%&H.ZD5MB^";0ZL GX:*$RD\DQ1?,Q !3V\[]GB22U2.1YF*?[A^\(YZ
M^\[2PLWDZ,8==-8RZE)EM_8R*CIWCR;M]-A+=)V?\"GMIGQUQUZJ&A14RU@O
MDG?'E$2$UNPKJZ,KPO:@^P GEUG:Y)@\H,
M(\M3:3\YJ\GI1?>P+,6ULL')/H)+;>;8?Z33B1N64=?Q,7CI4GJO$+??M*!/Q!O)!,AB-VPG='6+;@=H1;VK4QYP:\WG59_14'2":#;!]J"Q]HF9/A[ZS
M9W;I[.8;3GO&:?(/4K>"<@O0+.;"TCS&5]UU90H12!!%8Z
M?:QL/_G=I'5ESZ89U>/.?Z4W28'D
MA%1V).2WC+K*Y":*TFDR>P:2L^#UM/FM+I@\,SU8;S;\7"YUG*I(.3\D>MY#
MW90KNGED-/6&6!%4C(Z9P6V&EC 12S^H*F E9'510Z$GH_42>*2]M#;KF^\D
M"UCHFF&XY[4H?"04]UX<,G/7^84O#7BT7I/6HO> J(X-0C"^YZ,UJ,0M9)E(
MZBKQ*8!,$3AZ%(H?B=6NHZI5@Z,/X;4C>_2DQYDRI7D$<7+@!%J!5N>538ZY
M",5D]T]JU0=JY!3<M[MO%U2'XC;>643?PT$Y4Q(4XTOUEU&9]YWYZ'Y/S;F*3^0@^O.*'AB1DF4L/
M6[DQUE'_V#WIY[M0$_^@TZ< K6]&+;[ )7Z!8P(57XOHS@SE:_'#D*TIIK=8%.XKZD]BZB(U1NQ
MEB%&5/@Z643(-3A=?YX)'3P%:M"YU6[U%3)EA>0;Y%3"U(\D?,_YLQGR>S1?
MUN7RFAO;Q;W'T!K+J%-)(5CG$5(X3!J9#:/)5!T&M1J2LN*PP=M\SIAC7G<8H62)4%.Z.FV 2>+[$%KU[2UQ3;"J Q')=23+J5(YH\*"G*M=S00
M";X553,&>!JR9I%$3_H&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MD%Q&*9.K*0>HVZ#=L[5X>8KI"*%4EQV&/0P>T!HAA"5=K^19!>\6]0EMJ]T#L66+L=>DECK[+G5%M.+^;>(I2/!""^/J(LT[SVZBA4R/IU.N8E*3.31P
M&67ZT33+P:I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M%C:+H%R]C*HGO]FTC'*$.'GD+$YU0=1+M8/_A?3@Y:==K1]Z5L-<4KRMQ!>D@K)/+&S1'417&&9L1JG>^*&8!U%2"&.X\
M;6,I,<9K&;6.P7+'82;Z).J#[\ZXZ^? YU]#LZ=!^WIK22= XAY.Z412XGW]
M89FQ>$L_KJE;@XI7WJ3*F;0,*-2A:$F/[P#1!>;0<"U1I:0P*I =4T**,EHB
M]L-H6CY9]5R\%4!@J9O55204<9=1XI!/O7^-!-"R, 9YY5ASH(*77IZ-+E*=
M?JK5BOUU+CK52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MEZ5;2D2__3\_I^>_3O>=W]X/W <'K>P
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MNWAC[:H6:B/8PW]_9U[-N(;UGT_#N,CD>A0-*+R4M!YUW]A:'!Y>&7M8-#-U[!)^:_]N_"K;D:2^#
MJ:9A+K/M:IQ/9>-7TNT6N?T6=-JGGWG?IOG;6I]5KVH/>2PV4B%DL8 C!!,*
M!8J9PS+UJ&U^Z4D;*8?#934&N!6%U^'-T5*MY@"/40CX]D8J\:M&>BDF9.]#H-.U\]Q-H/39FIB;DT)6>5WJ+^(I17"M?-X)<<@2WRS="7)U0W#
MR7+"$3#J)L4<8W6RR"G>060*IM9+O9
M\3J6'O-ZJ3TZ?J8Z^%KD@(]+C\,XHP(HC(LD.K09A$495A+ZJQ,<9PO2<\E'
M%.C?R'_BC=P=%A#COBN-'BU;U(8;!AZJ7;A TU;0C %V,B&:S_L:RILU9P4.
M?6QJ[;+XF4Q]R=:%7@\I-<;.+Q$+B$0N35Z#,Y_?&:+R\R,^%J?Q(VP!83"6
MP8N-F,LZ,B-%-WAD%BMRW C;ET\X)(,I0@M;I]ZVL_Q*+_%;\(9&#D7?-M)T)'-3,W[YRIHVH PTFP5=BFJAY[T8H Z,/XKC1O[*JYHYK!N9"'%TC-N\HU
M_,^:S[G &))GQ]
M;L3!/8>5^A@M49M?)HQ2:%&"%A"MQV)D)^=V< N=Z%/C..VQ.^/&^0N(A#4]
M7_WKUOIK&D3[7%DQ@FE!:8)AV/X'3@OKSK&:J1O=67!CH D^SXR!2G
MWY]=R5Z)L9($G/E"5'2?30OH/-7]8VTJ[B=]E"!T6AM*5+Z'D,@5G$S?(<29MC-"XBA)S5GDQ#?2/_/W^@.Z0)7[E:133R%#]]>*H&:
MC!@S=,59MBL\/H;Z6#Q]&;*6HH0:CM4D(Y;ZZURZ+F2LG_Z2EF$FM)#>YM6.08;^O7VCF4XL/#885^ZM*(/0R5/%\[ID')#W:UM'='$-]$.*-R?O$%MR0]<"IJ_%OP9-GG9S7"(?/6I/1-NW:@W:$HXG
MFNSOJM!<^W7:S+OM6Y-X1BF8I:TD6=7$=PG-%-X+H9VN*6P5;P.UH->RG3K\
MWWGML!=0+#U?*D;=S+;L"(==2UUD,=1.W&_P42X4=R$;P:L&EC+$K\Z'1\C5
MH>B&#'E]P$&1.T_JA-M+D]RB!>-GUP(TB;L,K2#\^K$]]M=O,DZQOV;NK*1]
MF^5IP-H+"%6O^<)?]I:*! L3R[A:QWW1D[K(>*Z59^[(EE#SK3504#&$J\TH
MRQ+C8D6:#O@$0;@,G;PU;'!-=8>M,%_#W:KHP"VCA6BZU'O3-"@X4,X7LA,+(%] 4.]C(VE5P[^B'^R-+ #0C(H
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MYH&&?(4ZJ/5"W((V\7S,EZC#NPM&7PR,CDN]E0ZSXW%4<_RJOT
MW5@^UXK]*C49I[V5WT !AY")5!M(#N#V*D&#O$DUAO"@Q;0[Y \>_!RB/3)S
M-9^=BG$%[K1(K5-^27!-4N-3LD#I&C7\6\^+7 '5#X\ET?,F]3,"9T)\)%YW
M+;NTR?(/5/X_X*_,V_C=OR9P9-8JP8)*YOV,(2#8DRESQ_Q@-W-3 6P+'.CR
MZ*2)\_SP$_E2QRZ?QJZ 498&YC#@7X?% 5F\FZWB9\Q B%X:EKTF8[P!NQHT
MK2;<6/V\:S4P$U_.8*X(&*6NJAAZ-/^4%X)2H7Y &5,MRM;?5-'()"?$)Q>@DX,O/@-0"K4:X&KX":Y_9"<[7&/@T#A*,"CB$@JO=+3\8$
M/*XI>R91[>2HYD!>/M7=$1 E\/M#M5'M>65F_+&%I[7J2/YQ%+0//M/8J[F
M<%E^E4:F[D2F$JCO" BDDIQ_(X8#8P,YI%B%,^?,_P#I*UAU;=<"XL&C!80Y
MOB 5$B=36DX@::/WLT6NE3?3G3JJ?^
M3]O&U[G^H8;56>^I*'"]/UJ;?+77(]%X)]+GZ=E>AUKC@.;>?RRL-6V?5_X9
M?.B2$E"]GZ)_;?BG)%$B80&Q&T<_)/\'NOJI[8%K0<$-A1KL#=+X-JCEH805
M&+08KPW%UGD';JONL<78.%8\(G:)A&:G/ T&9$#
M//8;NA]] 2?-_[V $#_"K>"N470-+H6.@9=%M5@5*%K*[!L6+R 8#U_2/=)=
M>RJ81I!M^26-QS(\_WZ#*E06OW\!L818Q?*X.3S1F/LL+W0+;-I#V?^(<@2T/'R<3.*S
MI6UTZMI.43UU>;MB)?4]2D-A"3DU?>N'Z#)!*F:SU(S00-W864'31"MV!BUH]#Y:><2A747MPE@3;J"Q?LA[3E_V!-B@=\E;IEGQ')#17O8W [R$Y&X
MYVML3!%98YKP/5QA&YJ.0D:BDHU[FNH]$C&>#Z'"O<#0"X-7.2DN>RJ[%!;-
M)XD&9=5+WJ"NX";H<]N?W"/1#<1V1FE2_,H_PEM]?VDXL@N'BBM<.$@X29*AV1*4T;6_)*,%/=1":\\UM_K/PQ>#)3-.0S" =U4
M=61SC
M="1M[GA\3[CAD8#FTG4[C.GPW_18VD0B[+: Z!9)PA&75*9WS6<=_:H<9>+Y
MBPL(+U1R--A?KY3##UG\(@)TFM#7KTC,XBGT KFKT)M
M^; =Z)/$T06UAB55C+98V%,<[N32 P<7C-^;M1UHO0-Y\^OO^:72G1+0@[H%
MHUM"G6,F#*H$MP88'HE_I%K#,5" E-8?+"FM5EGI\N-HRAGQ#*A4.1P5H*E.5F\W&_/)\1+T=5A&94LS44:0TP'@&<30?LJ2
M>K^2,0CT#!:=8T59-,M7IBQC;@>M8VN5,E$8C028^U#QEO7B!84'E$PVTL9.
M@>GGHZ'KN*G5T!2.?E6%5NL?T:8*^9D@-2@T0;A25@IIT]&]"O0@5-S(0Y9B
MUXPQ\L(&=>@R>:S"G!\='%. GNB1(;5%8UB+S@K1(437AKP?T)>61?
M[HQ1)*D?>1 PG&1*6%K0I>F/U5TP 6341O'4(MF&+J8\/8H5T.+.@TA1M]!MA:6$B[$\L"-@O^2Y3#B9U#1#X*DR"TQ>%"?%Q7#W(X_<>BF'1ISV+9K-%
MS^03(WPU23Y/U5_AAC/ZX::%&SI#'MT,*N/]BDT,&MO%15S]/\C/J.VMWC#J;N^#L.FSEGW 2&XOI:),:4/W_-3508
MW(!"I\)$0&9;P2>R6"D*JWA (JWNDBWK:QMC 2'YM3X@6J$3NU+1I>AKFUY
MP+]C.@(^*'6#M38PKFBF-:#G]RE,#ZG9XY2JM:_;]-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M^C&Y3A-#CG(%F/P1%0SH#2EMCNHFZ,MC11NN0BV1$EP(;^U2
MK(?7@VU\N3H9Z9/ZB;6H.5HZQU;%@WX:)B8H7:@P4)E-\;C3X5L;_/)GDC'X
MH,B<4#_!38[M$W)50S7NAN6KE]EO57ZP%2LUIB.7: .#B&-W7RP@U)4=C+LN
M9T?[,,<7$,^9$S^1C;0X(06G]8=C5;8V] (C4^++Z,=^KI$SZJ?6L%4'TKKP
M9.M5_$2D4E+A3)2%JRV>I\,YH_7 .@&SF\3F7WPRXBCH-3<%K>Y=ET;+M8C<
M;=M
MH8!=IE7_''' Z.8GM\@$[[-
MPY"JC!P!Y_3LV9S\4&VR_P$#7KA@Z$5W22']0/S8\>$]#]AOY7W\Z6]0GZS5
M9]JSAW-)6?GF?*#U8 %)V$O0IGAW_#9KP%&LA,R4:H $F=0KK('N[-7=4[B;
MEX7I-\,E(+XA %G/W= =R5(;][G'7MR0:B!+T,MC=F3LRS?45DI"NX-JUD[)XQ@9^B(OU,^RVR-*QA5A[/\8^)1M<3
M$J[ZAP1NAHC 7*,Q*M9\AB^<"+3MQ!PK#9F-'E':'#R,64#.
MC\M>2U"CF "$-THNQ.)O&+M=@%QG3H@YJF354F4W5)MJNSVZQ<0._]>
MEACD,H.TR,WV%L&Z@NF;8/JD$Z#%E](92B7YO>E"J/EFL)1]DW,)^%JGN5S0
MP%7I9+ME290"I[A.0THR12XB]_M7?J_P]'^3*"V>Q_.%,4.WK1-PSR,U7M9YBFM.8WE"4+B*=.CM/=Q2V F4,X; I=.VJ8<;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M))@ID_.9B4KR+\*H/B03)*YM#'B1U+]X^P3&2M*6M3VQ\MJ_&JC5+JRS,R_+) **J>BZ0?Z E2\4]6F:K@_>J7FL*V7"V5I2PH
MRJYE*"/83I]B:X%5$_G \GX9_DV8D<*LGV'K)I(^S+"0XHR^?X:"]KT\B$_\
M^Z+E.JHL8AS>HT14TW0"&#SI"JQ7V$#,1IZF8C5Q1H$!4S/%!!.*0V55>SCG
M#"#"5R>3_1NPZX&CYFO!=L PJ8)7?F+,BZPE:[S*K9#(D0'0*9(./P?*/"S
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M'3*:/MEC/S@3;]_J 1JZM9^CA#_,S/3MF4JYW*/KV^UB6?H15A:*
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M+!/RG,0PI7QRAS@J"8,K:"Z 7!H5)J!!FEBCI:5_3IV[9LM-#)9NI#[[\#. E;A 'Q8F<&.-F:>I==POQ?\AP VG* X7F/9OD7]HJZB(^[P
M^_6B^8K9:;86E#BW'EY4!3T#U/ ,R2=SMWPI*F'Q-QRT#PY*/TY1+SO1L(#8
M>D"99"&W9+=K?]3-LB8.@XP& HIVEA3+,\1<,F<@&7"P9,=K]@IVO"TI0J[5
M_)CHUUN:4]'+/+DVA_UQ;591/B.P(3J?S/1I_Q%_N(@<=;AGBO",D"J0HN&[
M2JW>I&A$)N!F2R.-$MIE+>GSJ^-N%.[KX!C74MZ\ZL>OZ;:77R7V+XS86P[P+%\AUSKK#G?#IWT6[0
M17(B&]G%]FJLICZ0!H0U5$=6)>0!\GCK#HI7<6O12*#.2Y#.E\DT?8Z!=IF2
M%.2ASDF,[]+\ J)Q07X9T0_-<-AIU\8W?JO&64#\&[Q<^,5.-_ZB[ 4FY1-X
ML3R>JMJU$2;.N01 40>@(L6Z=DJD%*].08-MB10-J4;*#HGU],S-B'$P&'3K
MDEX'.B$YG^O8;3] <(.NZ,L3!'BB/"B[)G;:?KZMBOK;O7"G@Q MCYP[7CO[M50-T8GG?_"XJ>% -!?GR""1T5G]LSY
M9V*\\4/0)V&*GY-_34U0.+UG/@NQ'0H_OUO5'VL!ICI6O6M2N S\E=9?>+B7
M$RNE350!*ON==7W)BX5+7S$.[3\!,1JWW]MQMMS@9^/+*Z[W7/KI9FZ:,5^W
M(V8%<913\%1$^^5-CSJ>5[\9:_YL6G
MT]Z=_ +#.."S';+(,HK=ZST?APLV>3WI-@71&@V^C0D;GY4.U :![M(E!OPC
MO3_"O0)["!.5V%6IG1\=2TO&]KJ_1.P[9IF\4EEI8G'!FYL[,!>9MOZ#N>>Z9\20J3;=O%O<6OC.WMZ5S[-M.T6BTM*:%Z31S>MWP#91:96?(X'.S
M]WX^DY9=\O1/<5_WO;5^VLSNE4-_*,6WXEJVDS+8I2#J?P[-C>4%(V<7DT4+
M"*VJ>IHB-%3Q/\=W;<)9%K%[1?_J,R'_M,DYQ_\^95/_+9?[_8\)4OAU(F@]7>BFM^;]Q(^HR&NPLTOZ?$XO_MPO]Y]"E
M-W!J^KS7 J(Z;)SVT1T'= YN:YM?48R?]]55.F6VG'""]1$W_:=G6;5U2I7E
M[9>:H+]TNW??FDK^ D)_WP+"-R6+EE1.L9E;"1L"WCP[GF0IE"X9."]S"5\^
M?*B+:DMQCX_J$!UF' G ;J=)UELM\;G0V'K-9=49A=W:8Y]R965/1+UMN.D[L#>MWW/)[::-EQK;F_6*K.*/?S'W;[(_O:+];?*10[O-?8-2;1@"#%*"
MT^[+PM4'&K=7,-8?3-$1$D8O>"YOEK0&-M7[&3>9-G^)R=PGL"_=X=/Y\=JJ
M[I*)H=^=UVYC08>=#>>1.!,<,/5KQ^:A7.8_6IXZ[=P4XKQNL56G_9O;HLJR
MRZ,9YRYH$G-""#[:<4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M&6X;%Y\3]MBO[^VB[091EV\%[MFR+&-PS:Y&F[A_V?MH>3,78G3":4-W/L=FU:MKZPL]X]\(SFX*?-&>[76/89Q3'QMAE"CA?P@SRBU
MZ_!?GD5%>[
M-:O=30_5K;Z^YO=U58LN7[L:M,K<.?OB=QU*X)SBH$<=87JO8A5M+!QX=UNA
M.K(O&9]*=?C^#2$RIEJN:-QC<;06=,->_B//\H];?SKW[J%^&%1_V5O*V8O!
M@[%S9T7NKSMM'"J$YJHH]VV%?NG?ER4YM5'7=;>+EM][+JU!0*UYU/]
MB]J-.I9_NFZY7Y!Z3&3Z].UE3UT[M[VWMQ9BSL3O7JF6*H"U)3@=I:CM&UP-
M?&64]EE6[VDZ$QVL]S27'.W]#%QZ+MF:%"[Z!R\%W:&MO@G3@=W,^BO'^T/$1Z8%$=:U;SGI>7,^9VC?^YKJM$V]_G
M^+N6Q^R_U+PDG[?KUK5][6&B4R;FVJK]C@K6\3U^H)<8<7+M)_1?Z.'O
M]Y<.(U+XII_3NBP%]Y4E+[&=-W(%ZEM T NE2J9QT*/]LVG11(OIH7H=JWU_
M6298,+Y2BIH*=BQB!=Z5.?_WTV 'A6K(ABV#VZ&/2S^COOE1+4WO11[B0'FH
M[:NW*V8.]SYWGY"+1W]DQESA>(%7*A@QSG._E_>X-Q(2-2+L8XY,B[Q8^%]G
M_3[Z['XE2$.WW"QIM_4V!,KU<*")4B)9[U%:_V%9L,*M_]:752Y3N'>0U-KD?>6X-VRD_P4EY2?X)[D)Q?L\9
MSKO8>D:I7FJKC'O*.(IU$&>VXF[EJZ"31>A&9H)4^J$M@-O%=F L>R9-^U;Z
M-?$/HS(?DW3+V%TH%[RQIV[#!LO;;QWWFS)JS(RNO3T*1*W?L%-=3
M?#% 2 K_:B_7)A-<>L_9\9Y[]E0^+JB-.A.1L;0XF!URVW-)7Y++H_&K9S.+
M^^,) Y\^NFRXUOP-8 &Y$>A9CW
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M-T(^76O>Z'5VNX7%/6^U52L6;2MS(RPA>\?H?.M/#WJY&-AZYDGOJY+3AM9=)\KLRY_O8U?BRGN>+X-_Z_&0A>O)(:"W>99A:/&
M,14EEZLOWUOE8:2C]JQS53)16Y..ZYL]Q@DCGKFK>GY)D,62RNS\_(^AATJB
MJJFL*WI!I+O1A:Z7M;2P/=^3O+__YQ?%JP-V4OY9_,$K/6+5>W$XLN??9CD?H7'S!OFG H<
MO(#HPMT(_<1:;+_E)M*,MKZK6Z2HWL?0$N5 Z45T99U"S]$$1K4X&9:=[#Q.R-1ALV\R&'=3HL"LY?[IO
M?LN/5_+J[C&#IP3?$WTGFO1Z9RYF$G.S]5[&[QM:X[C_9-IZRW,FOY4XZ[BO
M\M&^*":IBHA>(20)3FM;LBJ=C/4>#S:''7F
M"I-'O(0&+FQ'_IN8[.BG+8=.=;X/N3>[]'Z&O^_HK,_'W*Y)'=W"D/;&B*/'
M^Y)H9T>U7Z>;>BN&:=12\S":6IZR]7/,R:0@4X9^^U!WH]YM/
MVI9MW7P[/OO,+O]+;H^>W]*PO2+Z%R6.]2BDVBU1UV]$&!Z?=DZ@M3+ .)V'WG9"'BZJVG_NRU.4/T[6N5Y#_-5,T@';=6/V(21/.N')&!.9)7=:;
MWZ35'6[>J9;WQW1)&%,9$>/XQ_EA4=RU$#^J>*3TSPC_GXHM\#[##+QPTOIY
M=9BW^3H3:@?QTL4P:[7->.NR76K5H4+7U-+@BRMO>_S:.
MA@=_#G&N2*W*];MPG/+AHL\_J?PG:1TSD*#:
M0_@X>XH?_MBNF*1:DW*W?%/H!1O[J&8]FR'-_3U[O?:5QJKL,_EB^M'9_.Y<
M>;0F=F_\CH]2-.F[^YFB5^F'7,>9CGN.7K^F\NMKG?!KV%1?*?0Z++[DN6OU"[@[*2(6M,[6[9<"D2!*(5'^L3D B) L6$!,69Q
MTD>D9*ZCUV6L%)=M/3J
MP (BD;II,%2HE^Z9$ZH+GX)N55W=S2G/KIL0_EJ>ON_-JQ>O7E9 NQ
M]=8B>749*^C)Z(SSY4)B,.WDY\Y]\II4T F]W.F
MI>G#,J=C4*38EO2[LQU;@M(*=3X<;H>>^%F>LG6"!J[IV?ACP/C3[JZVSA\I
MCGROY^M]W9:I-H(NE?=)/J=:@HOPN"UN[41V[LYE?T[A7\WAP^Y8<%WM#JGASH_.R*N
MG;[RZ'Z68X/Y_K+5=P:_S5 (G*72SOVE'[!!0Y+XSIXAWK^J9?/Y%17)FX3"
M7?>FG_;?#[<5TT][3X_EQ^.!^%4(K2W[Q'<\R5'_O8VM^3!9YW]B(P9V>TE3/7Y[,KM9689+TNML'M8J>5@WPGB3/@YFL3J7$S!NS%I7W,*+W+K]>1XI4XY9KOG0^]LKT=8"]GN
M8? -%\UW:O3W54IZ4 _ J[U]F;1>L-/<8?N2TU>M68<2?3Z[E>CKDEDKS.0)/+CF(7(_??_3JL3M^&J9A]O[O%6WD._JQ::33GQSTZY(FYU[^"Z=4^-S'OXU6WJE)B9&YTLCYAZK
M_FB\J_?4Z3XCBIQW-'*7RP:S-XOW2Y01/C""FW*FG%:&LP8T7$"DE]/J[K;3
M1B*@9J7TBY8J71 Z1*6OF*_81"L!%A!SU6P%_:2WB;CRIMXDR&IM#8^77.-? )>0=^SO_\YN38TV[6^[%HCL]M5Z7 *[]=QM7>..AJTL;%8?LV9*4'Z(F2?KMWP8.[1/QC9_5-MH,$9()%>@WO&M^3=?+T0R1CCUR,9DIQ19%B%2A2X<81[H=
M!JC?F@['V!RO[H1WYKO-@,0]WP]U@5)5+XV"O*& VT331XB8W:X7IQ6K +Y_
MP&#_>,;.AOQD@!BUM7_,4: M;%G\I"G(MN&U_9WWJM*$R:]]CY*NZ .G5V>\
M5U@ \W^E;QX8OQI>/NW=*XA:/#2][&S5"T[&CK"M,99-YX@7HR[^MN(!LG7C
MLR=G/NHLZNHXOCGLJDO;Y[6%A5=N]UMUU>I/_IV4N%I8=D![U6\'7MWJ392NZ7NM^DJ#YDKH#2_)(:WP7@=W?([KUK.BHH"YRISYC.E-2L-2HOU=(H
M/7+QXI.Q7N]O+4M^J[SH837)MZK@=*Y2R^D@Z!-95<$3M6R*/3C34*,BC:M8
M0%RCZE-P@$\#RCR4UT>U?NYL&,NY4B@*I:[H_FK\_<"-H8FPRGM.FV\/_;P<
M=F[&:97+;TD+B&,-92-_IM@T]Y8G-I;:=CN?#BL2?H@\6WZ=7<@\L&53NE?&
MAUZ31$N/+9/A)BWV;YHT,A!C167A\.[M25RSWLR%M[Z4PCNNRSIO/7F__-XI=<-Z9PV')P55^3_3AW:?#>JV'[HW\S;)
MX\&-1?QE#Y-\31__U#>JW+S+S$K_?;.4A'R\3#ATV[)4\WV'O^:!=QZ/+M,X;D+3?6?C=Y5W'CBN7Z6[?SMEXH* D,O1QX;)P!G?+<&37X5N7MR<._.=^Z
M9Y^P _.XT-6^76)E\N9L_&F?Q#=.1>RV&'?%MX4M7 'F#VKG-%OD-\0;@6;$3EOX0[X
M"P?ZC,K*5M[;7N-5RZM$373(LGPQ. DAV=P U&)?E(U0C?J)QM;]'F-<^^XI
MDAZY[D.3V^Y\_X'0&:2$N0RJ.MKM8&87E*<**+BUR4\YYQ;]R-?_0M#FKJ=@
MH9,2O"&Y2:K&F&(NAX+>!*X0<**D\SY',OK"R_'+H;.=_C5!1VHJLK>SO\3;
M8DUB+3>Y"9P0)M&GUF98',>N@(:!%XW[Q?J=F),%N\LH^X$E"PA=CK8$O:(*
MM@ATZJ4L,AN\AX8/9.N#>K>@.YHZ'\*#]GD&'8HVJ(HC1M$:XUQ9ZD,ZK0(Z'(;GB=,:I.-R:\(*15ZFD_EL&\N1%M>+";XDLJO#B=8GCP
M=>33]!.+2GLP\NW3EBG'K^(:%A#QU?+ZK&")>8I,(\9%JA4'C->*]'YHKOW0
M&_W* D R*^3Z9)^ZP$U,GZM1*+(1*$_1M/-%'\I9$0P6 F;(0T/Z!9F6]JN74!J?FD8=655M_WM"^D5X[XY70$%\3LW!&?M#7D?LQ)VETS?,[$2V%^Q.^]'#B_U\2H/RZPE+DGW
M(9HZ?GZ_UZ =;Y^YM#O)^L[)+_%+5 IS.55^4(IXP,0/R$Z)+"VI&D2#FO+8
M*=;$//IPM^2E8..4ID?]C*.37V\&[^/LD5&A^8,8FDWH%ZV6([=8E?8'A,YR
M)HR2M"T/Y3KVPKOS_,D>>SM_! 1Y"]SR51L?+$W/^MU4!/[O4S]QO+%HW8^[0I%0%U)VP#\1\*(=8;ZCI%;TME^)ER,4A5.?V-4 [Z):84_;"07#]!QL))6U]E+('_6*,WTJ^C;\[QJ\?-+_E
M]U00D3?=NK_<@P ]&+W_2I#CA9[>M[U6L.9;2\K.@^)#9H6K5F@]2?JL+!?6
M@*BURK^CUKAZY ARTF3I B(I\:/%J.5>*6&R+NYZ^8GG*D-ZPH)7(B/8#8BZ
M2=DJ9>N/"]]Z(FM%U>!&84Q!8:E'P63VNL\OPG>X^OY868$6;?A4OEFOHHIH
MQW;LJ]V.,,]R_<-O+"-\LOMQ>#3I(F:/]MMTB:*KY2*4$0_]SP2&'9OE?=:;KQKU,L'X9KO/_KJ7CUR"O#QW4/:+WM+_LM
MM3A\J1/^SY/7+W2J[#([I@]^9MZ^*%C"$&Z$Z T)3J^ND,G8]$QWLB;7AS*73BQ"=1+M!JL7^N.EM$2J1N?#W@B6/I3&]VXZ$3]\"'3+$F\KJ &)P!"S<',->"(;E:@4
MA^7VMDM:KD0%ZW<;EH2KUEU#4G)?^B/U0YR,';.D^WZ,:^>/&9_+^!R5CKX8
M_IO0JX8Q>"(SP+5A/CMPNM6@5Q)07G7';&M(L&OXZ]8PCV=)O=%9!SYTFLSU
MAVEBI4-'][$=-/=H.]S0!CV;0"\2#J'#[KUJ:E\_KO_,DLON!B0U18
MR6B:I> Y\18GROM(#L^CNS/UON7-!QH+"&+KBKHO#/T/VD^%QF?S@Y[0'A$%
MMP;]YW._66SMB^I9+Y,G6\-]#QQ(^9SV^<2=M4UWGZV^0J"^3=KW=AQ0:V3VO98V\N8.0;K3
M1=!J$%F+U02UF$"T+Z0J*[60LFY4D'1#,IA\6UKCK'4J&N,I*8K Z9.CCST%
M*^,>C[2[+J%:I)1[[OFP_5SD\=0LAW>X$4^]1? 8.4BQ+$>:Y4TP8S>2DG&:
MV-7$[*W@8+$L@,#?1$&E\[,UNV%\%* K0]:9H'3&LE8)B
M)=C_X>G8U9,D=MDETWU8Q\0R3%U1< AGPYDKRU'K=$84->0.#!4Z(QG)HUK\,*Y/'E6GZ*[_QL
M>Q9?6/>]8)(T-64"$HM7(!$EO<8F0
M6%W16%- V0[()T;%K.N]7'6\P7BVQ4L!9_\C_S!C9!+LD]\WQGM5R0'W(@W,
M]6Y3=T)$Y24O0%62EI@C,TV$2OV9>IIN:#ME"V@OY.:(MUMZD)*%^$9V;* -
M]!U-T\7:T3]0%/CFA(#]5Q>\(^X2D=CC7ZHL$8<'[Y:&==H-!Q2
MYR@X]QQ^0GD;/S2B]]+;.FSID6/7MU.E5;T37-Y'C."L?#QX/<6*IEQ/T1_RXKYZ$V$A+'7Z$H;61*_I-!K;8'ACT
M;_%8&7YL;4;(0Y(=0(=UU!J,MKS:J ;PS+1"JD%T$?O$#3]0[B.G>P?11,.9[HCS1R_
M[6#8]#,\F(]X1!*39MI6(.&;"6FBD>GU3M*;O&-0;.L\I:Q/W[>J0@NAZMWC?HUG)6^(718EH![!4!
MA]#0NFP&X$U+HCH!9])O<-" 7.+>Q#;]M>D >V)&9F8W+CW[.@\^#P37$:YG
M.#[(&0P+_+4*"-UHOJ6#N]H//EQ^8WR_HAVT&J;_T6X?OKAK7X^EH.(0TF,!
M<>,:K78+=R<<#<7-[8>O0F$RWC(R\RA86&?F+Q%MY_,O"-N2O EZ,>PCSP/^(+M[5%?VVH^;O"43D+1:
M,X5#'X7<_JA:B2LR3?+A>O[((*X2G(FEJ#^&+@]+6$SK^7SN.O@T#W*?LX;<
M^IMF"W( 7*UCMFDOO%V2=7:N?BMT3U"O0(&!Q8_ZB,T7<_R?7V8]GYELF(N&
M_:"*N2U0]%&&!)6D,"3WOCL&Q.>A@U" &QK"#"1$JZO[BZ?M/8S
M1T#L.9P_&2\92I29F'F/4':\ K5>2:-=+TI>P9:UN%!D__CT9\A)UB9,^B9X
MX^U,X[?%&XBT;2.B"?K4-I%NI":RCFO86<&\,8U2Y=H@DXP=V8]">"8.^-1J
M9BKFV$/D]4'52N/IY CMH.+G8X$:8,M=&"==H=HP@IX0Z\#;D4?>5QB0 >-M#Z5)'3-S"*,ZG\:&_8A3[)>XDX0^I#1]XJ2X"[A!8S@;-J#ICIO)+ *CP4]$
MQ^S!;B97-0KGIV_8EQ*:N!NJ!9$F>-T^*,BMJINC?]:Z"A4$G$\$Y =UWD1<
MSD:WFEDKEIO,Q3@UM,41EFWD;#\C;:4=>U8I*+%'0F=$28&FH'L3;U$HKD*0
MR%7SH^P3A'"#"XBXDHR9^K]'JZ*XVCTEJ];$[!EPSX7MYXMY
MXD+4K_TK%D-VHKI*['*FU+"!AB '-?%T.;OGUL,'.J<6$'V\0[U8/?@B&-R(
MCP7)0?79SIVY4'XA; 62E!D3'V@.#$^JG*%D(T!4 M:2>/74;NKYO.=_JP@X
M2K.^I!6J0,=1MY/Q32AC>!-FYQR>VH%2QUI30H&VFQ&X1)_>] 6$)M68V#M<
M+T).M:VDX*$L&2EAQA"W\L=.DUT58$5A L8='0MO%X]P=BNIFH_5[(P@Z#5'
M!_>$+B" @RP3_AS>?_U*!5 QSPGU2ISY#'
M#WZ='?92CF\P:%%O8#PYDUH6SUI++V;ICEXX;JL2ROD@3K^==1
M52$-\7_8A[L*]H)NR\+5)/$I4KQ^&.%Y86KY WN"&7_N3%4=4VCR1H'#FO86
M=DS9H!'PHHI* 0<-JAQA> (B9EE%P([&R[?"9JH?&=OE^1^"?BX@5'\'A^D4
MW0("Y.75A8F4>BS#KH)LFLR70VC0BU\=Q==@FU&;495V>:A8&"\)=V_PR(,/
MO *H/91(92?VCZ/,J)LI
M5'#H,>@BX4,^,C1=L<5$8SY8\K6"#1\P1.GA@B'N,G*4!)^,\44FEY<:UHM>
MT.LT6J()#"P"V-E(7]6%75V:,A7X^_33]]RTN:-* GH(3990G'MA;2EI$07+
M>D-X3JCG]86$_DFQ5_0+(L)5ZNFUQE7TKXJ5'[CK;^ U1EIIXDS6(FB\[E K
MR2F!BB+S&[ HYJ'GF5ZI\YCAZ1WS)0N(,!)*26M6MF<#3Q>P&JA3ZZ0GG%:90NJ0GG>_!HYO; -J@ZG<()ZUHFD3GD]/J\5?"B.C8
M"C:],H.;]8?!MZ\]LI_?O7_ANH"F,:%8!5'\H!=2=F($08B??L&H$SCS)A@R
MDREP"KL,*I18S#E0W_L%OA S&"1UB. "M0#,QJI!V]CI.! S&BQQ FX!]7/]
M^]>)S1GY"XA:%'PESS5*BM:$NJ8O 57U:'WRUNF_ ._'.M0VM!1'1RVW1Z=F
MVP&TE'*VNN(#5P]42[PHEJL1#0/-!)B=Q<2KM3\>),P*W0.IB9E*V62]UI\>52! U_3MK^L(S <5:DMGBZ25YP6X@"4E- /2Z
MKF[NZ.O*5^::78IM(=7FC$+A'LRX$E+] _0JQ8"O5Q/O'!-:1YM$ 6G3;;W4
M1? 6+G2I,$1A-,\2-%VF:@M@M3*HJ9ZEK]A*CI6T3:K*%A!+87W@!!M,@536BR/QQK&UE6NDS8U&(MIG3:;_"VD_Z\/KH4$X@ L6P9_MH"0AMK2:9+YP7UMV7SV(\A7JAQM0RA5(9WQOB?MX;B:U:\R*)=#EEIY%Q80RS&>3\B%8OP-# V(
MYJ,68]9+E%5.K59Y53+I(/ 4VCFW#\7 .H#(N' [^'!1H!^4)F->MZ@ V W;
MRUM2-IAYU5\ZX7]B8V745I<-D%()RJUOD!809S-I6K +%$G,@]<#R+J=*HU"
M#DU#^0^)?2MOVY?NK9SA\?C\ZZO9],GB'/^U$^\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MTXMQQZW(H <6_M81E980&=GYQIM5T!W)=$[IEYU47(B26^I2E-<$359+",)@R0H
M9871)9/\04-^3+ K\!Z[L3N2W18
MH.3Q5.>LX=IQUK5 K]J\VL+]Q;65X7O6< W!'=-*RKEQ;]R)A;)GJ1.Y5E"8
MVC5.0&Y8==R'M#DK\G"CL: 6I0EY33^"KHC]<6B
M%,WDKA(HS.B^^8/AO ;RKJ1UQ=FJ6L=9E@9?IC6)?;J4S.63(4
M'OFHCN*=C>PA-!JKW2AOZPN26$_,%(V8(]I_:)(:L7J=F/U23W?)/C U$_35
MR@'5)'+A'90*]/IPY\.>C66MM2^ X 38I7B>Y)F3^T2ZNH6U5JCUR&6'TJEJB
MG.*#2Z"X6@TTQ3]Z!:Y5BM\%A&(Y7BGF1":V$6W+R)E2\S@IVICR!^C$9^F2
M7TN0J5_A,\#6.B=1%;44D!\"'?.*0K,MP+\)!B6Z8D4-LH&P&/+V\-0-;*?L
M+!QY2F;L[X%W2B:/3,6TSFVAG)U_R8F\ E81H&<2O-K^'!@[GZTP#,-I8;25
MI!#/6X$Q)($,F5JJPM@/XC54S2*3N:M$(;.I+$F_9IAG%V4K\GHN,)A6'"),
M3XXT43( WF&>%W]G%_(NQE,YV.? @Z^+1V>JZ0W,I;CK]CRAC;2M8M+CF"MVP4:P1E711KNGAU5Y 2,X*3PZFKE4RI SL54S#5+X'T)'1A/$EC)-NI
MEV)8V(:,CV@IQ.TGNRC4);(L#7'P9#[@)Y+2XB)L4=-_@[VE,AS"CBXQ\_-G
MQXOZA2F-+Z3;?[ ,H!?U?O1ZTLI08>_C,-LO-04\:8V70G]MW]22;3!?CA/G1*G/.?].<2HE,XZ#0HAT&.QE7II#P<MQ#U_=V),R.DE+#\]G\U9^83,:WBJZ#3??$-62]"Q K[Y7]$II%,>;Q_PGU8R
MU(TL/_)915.]4J60[,.139>Y2WL)TJB;M-/R9,7:7NS2$&,1@Q;2A@@@FXO>
MF*/ QCP9"@45!KR$/($[9(>WZ B"-GDW=QO3K%EB\M(:K',6CZ4WCC$..A*G"KA#VY54(P\@OAFKP"%(4RFC[L.Y]#.08R:[%K0;MFM3D=8"KPAQ"UU^@K"=:TB,YEPN&!H\7Q&\/@K\!2IF-FH[O7D"<,;.0T!.P
MMO!*:+>,94:.$HO@C?AE$%X2,%V1"[DTH#07$,%OJ08NH(TG>+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M?]R3^\\_5* IYT.LGKT&]][+N)8J:U28Q_IUD0X)0WT&30RB+/T_R /5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M>(#',:"PD990Z4Q+:O&UNBOBUW?)GM_8\0K-J[+E9R0X
M;6CQ+*I/HW:6'F]21S/!6$EQ2M8,V?QS=<[M%3&VLB@$HM((BAA7$")$1603T@HT 4(*1'8Q[484FD1$-@$CLBG&!,C6-B)*
M( @(V;11%E.E@"4D8>+O/W,QSS,7<_%_YF(NSMU9JLYWON]]WZKSG;-1^\?<
MSYMH-"%')[NYNAF;OX!8Q;27_T:1*;B&!2LT>+YZOS36U1O2.,SY;G=)T76Y
MAE &3P2S06H.&A\C/$GEV(N/ACHP !G@3Q\
M0T16$UL;5:A&PID^?3.JB&"XHAH7Q<+T:1[2\OUG]8JW))1$E73@)C<41?<%
MMS:G59\43XRZ-C6_15'QSY_3$F]%]TX4?V',E7LC?"S>(W.^FJTW/:SE_=]7
M%J/^N?+G2GW>;^L>9O_2JEA )"Q*#RJX9&I,WQFL_*ZZAXE3Z"B7J!ZR
M(QB#5:%@O3C74&"RF)W'#(^0>=C["STM3A&[@ON4)J#E<, ;Q@=+=H&%; '!
M=73@TO2PDSQM=2\OE12V+:&?N[S#BA0+H697JVZKMQ$%O%$,3 4C.M7;(''!%\_5+^/E+_9L
MK8+^S8H',X\W#7A:8B53%^,F46H;GK24W#=A7BO5KAJ:B#] 0!\D./T@U']!
M>/Y*4>O.@_3C\/6+%7 \QW*&W<'/D8K*[FL"W>LL>8^! $)QR*Y"(/)%M(('
MZ#K=E+R<8N(D/D)/K7$,>(W8)@S,X;35>1TKZGG]K"E[%9GR0K/0_R1WSX[:
M@1$93;5B&V(CC^8F:E+HP\">-\K%,KVN^KV*H_ F"4"Y./+^_7A1F_?E#A2G
M)Y=FP5HB/YPN/S*\M$C^3^O-5UL7$));R$;_UD*R-9S9(7+[?D7I(&7GNHRB
MH:I,B^,B9405<B"+GM=K4+B L=L:9OOM1E(@M*^T7GD =,V:=K1K'[6%=D/(@L16:#G9H!D5=:.K6G[QPX5[Z
M?0]FNLTN*1[>8C\Y4@^;2,;RF[&+R+VA%@,L)UA'.L"EZ!,-)B1X+M*46+)'
MJ-X63=LE9*WX[+F.S@FPO/5K--)D!I/#VES0&3!1\R!P(H80N_7O#9'%8X6
MI!8 L?5XSE!5%C-)5E"8VI$BGIP5KU0>J23>E!8URM(687.^B_4!:62WA&(!
MG_L47#5$PB>![?B)N1S."/9044Q!9'CZTJK$&ZA[/V^V^64!H2KRM F&@X=W
M@_I#0R0WNE0('PKQX=.V],%=?\IIB00]*N)NV'_%^7
MEF^AGVUX$FN3FN :\)CZ\^B#R]'DOUWF"+G3.&3V7#M/5 +78HW(;KN _L9F4H/BX*FC>C#HF!ZOA.PK"U29+,FI#CKT>UUU&!2P_B*
MH%?IJP7MJ.'G$IU"\A:EL^H.>:G2$GXA'8X-TUC+TMF]IU&Y^@5HF.&I.T'7
M(D5(%3KPF/0[UV_I5-,@R41N5>K#F_-6/MU6(T1 I\#)?-[R"F8F&_"HV@;81C),A<&P=H]J8MU5IX1)<,I?V.6((%??)(89*RRG=*+S9+J'1.C=7]O/U5VPA%3+-043 1/7JD
MXT)/%SBP8XZ:0U[W#M8$R:LE>"$S1'9GJCDM0M[,N(*3'0\>+9IK!Q6YTQY[
M\4N)F&--CXN7"*>?LPUQ+^_A@NO:ZI)8,1MV Q;:"=" Y!5P./+J,*VY\0"F4:<7T9CXF4J'R\XV96K'_[ LHFV5,CM=&M*XB3U#]? @*33-N%U0,=^]CF, 2:?F69.EW<#>%!M3=#M'S R(E[&R&\KHHE$3XA%WZ34CBY@2KP"OI'FO>5544I69>W]/:E;GVM0
M+M-*]EUI1IE-!ETSU Y$:ONM7,**<4MS1B:A7KD-;+E2O*$<0O%G#\TE79X> 3CFP75%
M3KFWCQDA0UH04;PA=AYY#?QDGF>S#3I'MU!O'H*K#KO1LQEH[23I;Y!C3G[O
M1Z:9?;IS"- ^Q\[\&%8Y'HKL=]:W/ZKC_^(9JD9.@>TQDX6016>,)"U>FMDA
ME& 5SAG$=RE /+WW5$)$E=PL$I
M9< 3W"Z]WWD(]#D-Z0C%G OQ-%SQB;Q6Q#RM=@4]2R6%[ERU,M@E$G$O$;MU$8";71:K1<(G48E4 <
M/5VLI0R44):2#K9!(BH@J]?CC&Z&T#42O,E$<& G:CD\SPL@+P91N:Q=,6ZA
MI%L\A+UR4S<9&")OIM.G#
M<^&)X<.-O:&BN5VQ<7'&SU$: M*@F/P.<60:T6RO/ R&"W*9_E('?20V$#"&
M:[W>*/>7P8&\HE$7<#0/LN-8;GA>!L?+D%DD"SD.AS+_[.93D#!RZ9\!G+_[
MT:)0,
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MI7,Y\5]#/?T CMRSH"XJ@+ZMQ'#!< I_F1KC9U,NQUB-!S^J@D)QS7WKX8PZN$RY>ZCB=7E2O/'?I_NW?JF_
MO49O^9&_;<\)0=3DF?GMRNV@.$\#]PN(K-!5U,[0;:!/)R;'M-4@(&6I#2N?/(WWQOE XOZ9\W'QT.=A?>N>R^[S#4U+7R3@7CT[!NMW(OVPT
M&NLR9_QG[O_:1ZV3/)E?C&\5^*@ &O9K@%NEL8%[0$H'
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M; MK645W\C:-X[);>R9G)(1KECV3$X^Z(.,Q0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M$'&LMB(A7V!AIO"E*S:<9"*6/>\FF_EL:HH,)N7&$+QI]HGVLCZ#T*H,5'72SR9F@
M1 >Q14A(-L:(9"5E&'O%5+V,6O&BN=AB7^N-DST>! UV,50Y]?:LYSF2[G+.
M1;#D"&P?_T"CF@3?(AU!,0Z.)8!)QQO]S>7MXWH\$^VQ ?E2::=SVBHB?^ I'8QO>AP$Z_;D,>S?:-$V8I+.Z<4Q?(
MNX;]M;GT9223FD]MHSD:N=D:3.#Z$2Q)H6"6NDPRM=WQ8!19!PK,FKD;/N\Q
MW>CS":.G42 5F">!/'86VU+#YK$RLV]$$\GZ2HH])8Y!MU'D$)QW\2OL>] 3JSNI^ F_N'?%\6XT?.15\W^')L\_G-7.61OXGT+(U';TG
M&:P4!D%(#C(_F,IG+X$+N.KU4,N+6@:O0)S3AN3@V%;1<]D5LKQ'SCP6R,^H
MX-1&!?<-@-%42YOKC""!]>C-&-MQ&#>+5)4H]4$OP<\= 9E2Q_-CDAQ*TT#O
M#%8K1KT=$N_@U"PM. "*,\Z]&%A -)%,JH@IZP'8)U:)V9+49CV=LJ\J
MS"YD$&>D]9'E^#--6/V:;4"8=M23]3-X]*PY0;Y:GU@NM[YV72Z^0M[1^RAP
M'^B:G8@U@@6=@6[^W;=2,HGT R _\Q&QS,E_S^U'";=OO6L<:69JF%2@TA0[
M&PEW0W1O50D350^/>83<#1+[K" T(9I(:'+
M/H!C7(\=G9X;- @<-ZTZO^3DM./YEY/GYN-QL7^S-$^()_-31AM1!4PL.,$E
M_PJM /T%Z3/Z\=P%A EK'9$:W!\[8Y@SU\/QB#CM^P=RG6][KBGT9@P&V?NN8R2# Y,-8&H[?17S"#31J4;V,S%RA>7)H'>PZ-L^
M*">_#NTN*^CRT#D$=M,UH"BIGFF\%S(A(EOT3B4,DL[4U!+OBMI]5U6N<$>0
M1!I5>;QG,$Y^"&Y(/4MY#=61:4DY:,]P#'9H<*', 8/+:&G:N/P_+@M\N>TG?>HKVZJ];3F,>.A;D_>
M)HQH"^;L.038+\%_^P)B-AUB7R%I>-'J >4F&7(P_JBJ:EH5(ZW*MR0CLNM_5Q<80*B;N<;:*M0CJ:QIDS&RMM[&'L->4>R #O/6$S:^0>4;U)[<6!E0@P*SM5SG2V9/-'PP3'V76O.QYY*WQXC>J EF,@ROL:C9[^TPY'./S&.37RMC6T39&
MD>C%()6';_R>O56!=@!D0?4H5,("(I.VN0^][&+]/Y6X4NLF?H9(XF.;GGR-
MJG'C>-6U9K$AT0?7.P/DZ1D6)EK'^.P85EI#7VJK2)@"?\@P';T^269H\Q[W
MJ;:*F,0).PY3)079?7&5?H'^!Y._=I@X=?4J$9K%
MX>D.LQE*@I"T2XI$*M%]";AJ)TIZ*$J$-I0M($S]979.-.MGX&BYS,_].5[?
MOVR\N/O5 "IU+!Q>^>H]\9H-8]F#^0.:;,>.D^I).X(!LVOC6Z$
MJ7+*BNC94<-^9CBX@)"M;\W9TCP5QJ/&XX)\9(1LEEX?T]6%)JHICQK:'(5(
MON3&^AG'3V,'JWZ#?#@*4QR,.O6T1$KE,G*1%F3D)RK9$WJO7@:RN81M,AG>*"IT$7/@B](]NK :+N.]RI#&X[61-?'5'1JR\[N=-<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M%Q"\EAD[FVFM>0]O\HXA#>=,!B2E%CI&1*'\REWT1M4M3%0MN]B78*X)1JM&*5QN2)5%JJSN36?[.0B;:?.XE4/[F'QQ?O5%@)C2)AZ^9!I>'[-9T>VI![3
M$"[3-LQC.2+>">[.[R*EY;G;A (YMNMGQ7T2PSOU"/*=(_C2(C%X'#6H^VT1
MTEAY)*W]SR<_?W-:E1_20K.5#M>OGI;3?+7_$O5AP*.HP5#2TD1%WNII)'B?
MY2P08@3VG/ESI\+@JH/35G>NG#9D13*R--3NMUN]VS4*7O5PYTB=!=>?W9<[.J_[:NO1K,]UF^_4_V6"UY\9X/O#IN#)2>^J
M@_P..ZYG<#3PN#].<*9DI[T4R>U;O0C[:M1\:*<.(S3SQN9WJJ= 1._OSI35
M)N^ SMJ?N3JOFA%I2=XDC2;6?P'JJ"^/[M0LYL"?^4-W@S'25I8FQ+S!"9!P
MM'H=\,UA-S+D"-Y64X- TEI W&N]A@'[_Y.C%T"!8Q7IUC.$U5KOZ5F L:%Z
MO$EKIM_L*TKIHIC\L8#80[$"I ]ABF;$>B0XS&X<4RU!_SQ?H5:&64!L_Z_*
M5NIA#<[+:@A3%"OH&EV793=V0P?0U^ _#2[^IX&KIL$MK5DS,TBA=$7^
M5^^K?_9>J.F] @F^IS<.?5,UR*]AQF^3]LW] 59&:D]N=I"+X3C*X(0ZT^9_
M>\B#O]_7]=K/H'E0 SM%V
M[$:>>8M?K:F9H'Z]@)@VA<;4EOA\I/)E+W*8,9MT^.0X#8T ^M?!]T:(GQ<0
M2^_UC.U&AKW%6U5-CM(GYZ)2106[+SD,I_WNB\.QXH8(,CR,:!_SG/C)_9Y=N;/JJ>L2-:UNB'"5;M
M6D 4GX#L'O>H=)NT9A>;?5VC>HJ)&'#?UR"_C-VS@-#5V#(N%<99UTS,7R M
M6K>XGWGQIA"CR[+-4/Q%Q'EX;-2>R'?X()^/("UQ>#K.M4*^(MI:#@:TJ$M)5KM'.LCF6Q8E9M-_VCX1AO/H"TBKK$ \=CPP3T^5(VD^22#HAY
M/8?B+VM-]YM](P'-R$[SQ!/]Z #NF*Y:&RH2=OS\AXSEILH8C"D46-JN@>^#
MLX)T902=XV9?A2=TIGMFW&>NP$0ALYYL\V9!+O^^=H4M^+[,18=P\R;7M 0U
M[8J F[-9<.2D&6%&MTW_<5)Y-63YM:30]4Q,HS^$(UH;U.6?'OP6D1E!"E+_O1-HW\
MU51K,B'PNCT?_XMOA_%$T-;X#(V-12RW15C[ ^D).NK@*J7>E^;;&H%OW+YE
MCI7,5QA,[$[P\-L@[F$?NKC;IL8[.0-ND'J)Y$=MIJ13@4A*UP'/C?"1:XJF
M:.N+_(R'9=/SP[^[J;#8:,3TN$-/&$R1)B_QYE=18I$G[$&;XW>_2]36O]'!
MAI^;@C&6K>IEB7CUWGL&<_D20'J6&*8F.Q.4QN-L99:/<@MV.=##K]?$L1 -
M"/Q9KF(!\6$S0E']
M2(NU%HY*/T$-N'[W]@E,0[/6C5>(?V..4ZY^^')&>+5%:ZI^[!K1]J[KPP//
MWQRHU!E*7K57:W78U:1[>DZ!7RMD2'B+H=+4S@?>-7^6+&K#9V!.:[PA O]N
M?I8&OP!Q7+:^TD]# LGFJOND>"GJ"LU5Z.0^SS; ^]=U27R9?FEE<(ZOF^.U
M"A-<=%MNSL$,_8_3JU1[W[(E3X"&K34/AS^Y4?,\UW_^JB-4HAC$+$]=$FZ
M;$9,DDV-I<>RUN&5"!;\K))XZ%M[\0 _U5#_%+I+4JM_@D' AY>V^2=?),1N
MU)D(,?LQF*J!(E=501UZ%6@E"Q'SNVU[.O!-WSGTW 6$.MP!S.=;A<,+IIH)Z^5TA@.MPG'N!_[?7[H3QYP?X9M'B*D=FT=$8_]63O9-RS
M>CNU;L/\JNA0:\@^=X:RDO0;:*^TL[&'"5)58*?8F*Q+PH,ZW&7WX.[DZBA@
MZM"V],FIQG1 92W;P9O&&&615WE=IBB&34!N^!K/SA!42\O!:U' M+PWP7=J\%9?M-9XK(I@3;^ \M!("F'W.#O,A;@Y5!<]Z,1?HF;2-(.VVW'")
M#Z3-CZGAR/SWSN\&Z1R*1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M'ZTDP%-@.:]1',URS>=( >TZ&^H9&GXLSBJ=QX\$;ZF-,
MP744CQ);?,>'G^=07R:2AU/LIX!JTDGXA(2=!32VE*3-!P"=,S!]?I]R*2R'
M KU %)^0[M+&&_NY22P';XDYHW_,#Z9(&*M(9"@I>P,;_)ZODB]
M Z._O@US:VF,6K'QGF$^.QR -V"XV*$QK&:TF[#?_GZ2GP293E[:# &3"DVT
M&NWSM"M('FH*B[>>QB]8FB[NH#DI.DT5=U+LX>KP.]R1J%:#\9*Q@HT FW';'3Q#^6)
M^?-*HNJ1)NH5M /+U1LI>72SQ'!(P?-5-(EUX:/?CC0]OBE=0&1,_^V,-1D=
M-XZ>HY7)AF.=Q][$Y6M0M,=(WM/Q/\61M3R/P9*,;#/J"0P]K8GS"L,/]4*ZVWDJ&N>-HJG9J!Y8*ZD*"AGQ]@
M]\L*#>>Q_D_[9*S,QTWPCGE?3*XSJ@ P\K1Y%Z/>!=^4\A_WH4W 5'E2 =GT
M,T:/,XM,5OE"=DUA@\F-C*J]WI9+@R*AC#-;1Y%S0MLIU0&= 6]^>1W<@_E,:@\Q@'GT->"J)%:NLG-SDIMB?'74+-*$&4W:U]]N+J
M:(?*4L)1R*!^BS^0-+8_^5',]O&Y]\*N6M^VLQ%^U,'(_[ZLIO]3T5 <\Z"1
M<<^5T)+2L!KL_=%H-Y?R,S'U.)>7TT&*V/7-E*#"K/Z;VA5.Y8?YS5\
M/=G5@/N(U%4NAQL?$"?V0 %5T!BW>#;K_DA0"%:R7]8O/A1U]HW"Z=_&8AS%
MN"OETV5)]'KGXY'G8J[X(NZ6K;F?OB-!,IM_:3HXIS\R<0\B="@/+EF*"BRA65U;0'1^7NG*'[_N=::M!C'YE?;WG?L4"Z#
M>X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MP-BW<]0Q> &QOY]I]\<9G[_G\4YU59T&QR-=<"Z
M8D!_P'P4_D/?UR7OC&?AO:Z:D@*M";FP)KES'?N(TA*NE>EOQOQ"M?@I+.T>3[:Q'7/W@]_M5SMF&]:9:LU?V>)G\.;F:?P[/?'=T^+S')79H64K$
MDF[3PSHZD _GYX=.:[B'$[P8$CJ7QG/FKI54X>N^M_!%_XXOR5OW;?HKRD0K
MU];DV^6C![FO-[>F)]"-B81VM>';Q,((M?$(X >*KE=.T#8D5]R=4>WE]Z]]
M*BKV>X;^U^U!)^YU$#_<_63-T0,;M1<&_P=02P,$% @ %XK96N8H?>1Q
MK0 \<4 T !I;6%G95\P,#8N:G!G[+M]5!/7VRX\B!45,2H*"D)J%:$B
MIBI(Y6NT5!&I1NL' D*J:/D24XM(@)!1$:(BI,JO4K$2$1$5,"(@EH^,$"!:
MBD&^ D$(253D(S(C$ 9F,CGC[SWK.<]9ZWG7.NN_K
MNJ]K]L;09>@'%NS<[KL=,#(R GZBO@%##^#]^=/_T=?GA_R?/L/(\!Q8.-OH
MQQF'C(V^ F8L-#)>:&2H!^@ 8/3%_W,#\-^_C&88S_QBELGL.7--J1O*%P S
MC(R-9\PT_N*+F3.IJTG4=6#FPB\6K5B_=9;YWB,F7YU:O.'MXVMDU<:COYZ?,]?"3Z[68W[^^W;??9X;MSW_X#!_T/
M!02&'CO^M#QX^*2TK?UKQ[*_*.DE]0Z/TQMW20V-?UY7$: \7\,_;\:?)Y7$8SXC[?L'#F%RO6SUJT=:_)
MD5/F7VTX-WOQ=U=S2VKGK-SX([+DZ*^OYUJLM8V#_8UP*8)ZQ$35YQ@L!$"#HV?%$DW"\4(!-#^CMQTFN 'FH//', .2T&8#^
MXTX#1)+, +"\ISL2/LR GAZ&9!$& -D@^(^SV_EOZ=\YS&#_5Y?NG+7'CTL)
MG= &#O\Q]F:N0[_]9/^[^W_]_;_?]V^KN?-X?)Z$'ZVJLD @"PF=/CU@2,&
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M\Y1\>@ ='V250'-(([(77NJU JIUY=GP7L/SWV(XDM9@1M$]EL %*8_?HU8_YHC3)](LK=>AFR_%:K;Y8V#]1#JW'&ZT-/$I]6$.-^0
M]#ONQUVF_X-MKZ85<>[(?%!:77"0+WI;5D\?Z:%C65AIHU4JMU";_[Q3="+GD7O>Y77
M0C-88P:@4^MGUURV8=7&7='S6J&FZFM3YII!6=NPEM4F;)#QX2>3&>0&J/8X
M=*R7IMN$&2/R.N43VG-/2,.LHU_BF;1.[!"O">1N?3TR?K.G*9WI7R,.]JQV
MNL\*-J="'[\O?XF)K\)D95WU$94!N"!\J+P6.]
MH(99K^6-;4,W/4 -@)I*I6K6O8#@WD'(A+>B>Z/H[%H>G=5K80%\/5MUR/&!
MLQ%F9%?_S9-5;4%UGZ '&;[<#) N-U[,/!4]&W)+Y$#O1%FG7*^V$8[38?H<
M Q &=J_L9XU4X/,X0C7K GSX;"]4;HI(^^V)E]V>M;K,(U>61BN)E.
M+O9Y'AVDFLC(+\!"U062*BJ$!B \TNWGK,+(RO(_-@^&1/6SYO.DX!/6R"7\
M%^[I-%TD%HVS*FH%F,,5^FPXK-=/LRKNFZF0^:AMRAT#<'PPQ['L>7LZ/W7D
MYH&VC'/J!;,>/%1T18ZX+KE-JZ/"PIHM_HH;CUU5@1?HLXEOR8W8[YIX%VO6
M/,ZO[E5!B;TA2=9^9%?UIHJLKK84?M>)3\S=XC]$^>1ZJ-;9 +#!;@/PO#*K
M?C2-51IVT<.SGT9K>COMNQ/\*Z!::]&*=KB_"'KRZ(%92LV%!%$][;+5K4>">] +^QUD-V)Y)58P4G78
M #3Q^2<@-2L?XC,?<(_C!WD2 U#"3H'Z[U:"(SA:H,O3WR,W\=JFP4;:!:N*
M9/%:CL]^!*J%4K(FLX678-4*=-N-:MB*]X3[;6Q4WMTAMU^B_0]:'%Q)W[15
MS_N2-].IH;S^XJ68$V-^Y$.'=PWU?4+R(06W3%[3S;A/4S>;_L4;F!K7T<^Z
MZ%=Q@[ X?-6'20CQ8W?%[=3_RVM!>()4VXVLU/W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M^1M)W>0;>P::H9XNK;)-V-3J!3>RKRF5BQ;N/JOBI2W:H=W-T?&4%8G4T":DR_$
M*_0UX$EEUPR9;JU>2*Q'E,\-P).?850F$2XBG/(B?^'N+\5*\K#YLOHSV07\
MB="D!Q'DTI8L]S+1[(C*GUH-0/E:T<0I_0-]?C+"NWJ/6*W/A,-HV.I- M5H
M5Z(J3OM2#?6TJ3I+-+(TQ4#Z>'!B/63.^Q*[,[;OR>MQX05X9K7WL=U"! ]N
M*WHDT_D:7\U3QE($$_$^51FF^+F"_X\!.*"[Q!6X#PY!*W^4CR?B'J2,5MKNPV4;DVCB[':+I]B+*>KMBH>X )$+G:-1D^F6ZN!NNC8U2C9SU6B)3A2J09
MG*<5TP,BX\AE6$/!H;-@!;+^_*]Q &@)GU"FLDR];,E.V(I<2LJR M_G(SE-
M:AJ_C)K<,Y;(4"7S8E$_>K849YQ;EUIQO"!RTTJF_*0!4-$MIZ__V=4J.F&T
M^JQ7$'X\==+G62G$(+WRM638:@#E4CC1@_@\/1U8&C]NN0SQOO2BODD='.S,QM*2V]-OV^(8/G@W03MXJ
M/47F8;?\^[.T)8B)6O1MZR8;04548 DR<($;41QIE9P$DPOTWT;^<+KGEG?R,NLI T C9<)Y<"1K,52[
MS,,.A;PSI2'S$(A85-JHM,['6&$/>R/&B)_DQ.S3T:R=6&Q$W#$S ] 5:]JZ
MNVC]6 3D\!8Q(OZR:Z[^>W1>Y]@J:/A8!@M\Z0F^.B5[M[>XHW3#]JQ-KSY!
M#P7-Y?7*W:=(GP1]76DKCT8JZ"7K:O C*\+Q1CX>F(W-@?_A5B*;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M8"Y!?1K!F623
MY3U*$^([U%/8Q?XL)1E$V"-%9&7JCI7XZD_UH:L6&$V%NHZXX $*CK2!13OI
M-7\H$^NA",R8$M 1M&4<7D]@RZ[&F\AW'Q4M](L54#1,RO#YM[?/IYS"BCU;
M^Q=*7U[=(0Q+?;>Z G>^&J3V]6H:, #W^A7!P?HTTDY/*8>A*'Q)^RJ. 3C)
M5DBY/>\-P$7(@^'4#HW5:7!& 3:&^:OHQ$*FRE4BR K!'4,*KS$%[>Y^Y#5
M)>$ 3A+^(8SRHK/:'RQN+C"0)?^M7!HM5]/D$\;0S*K=>*;[U)/? T0
M+S/"?U:^W;6<9&V8^G6*]*4\BDQXU#$MXN8QUTUCF].:]6_$'!QD-?4,YSA.
M?D>?0RS3%\%'96FPE0NCVUW%'Q%I9-W>NG<8 V$]'R,V(B2L:H(NTM!^&)$(EZR:-RRJ0L*M)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MX3=2HJMB8EE#]KB_?N.'R"68*[H)[^MJ"C%!-04;8AH/0&KCXQL5 Y>)M/*!%V3NIAV, +LOC,6A&W+Y6C\,(H]9L:V
MP9&#O'FKL@L/<3F8+"\I@]);'<4,E]?W0PX-UHU0(8@82-_3EWQ^ \VQWQ7A
M:RG],?.5/NNT8 G7"C$9*5>-"NC( 1F_;Q[Z%ISM7!/WW'86:GN5([\WRL(2
M[PZ[YI8%Z?U&A C_IMZC/_*Z?\.6S:N,IPI2PW^^%GXD,?%&L0'0#/G%MO8"$X1K/_!T=O7TNU+PWK1)+*#Z:5J9#/L(*GSIFUROV!;B"?J',C_)_SWF@
M_G=B[]U#O&:4_*?/#"O/Y^Y"XE]/^+E[^JL@+4O='.7M14.]*C3NC/(AJX.Y
M.6\_2*_0J5G$5K/J_+%SJ+]:EL$@%W--L.1^T3FAL0O-FE/:("Q[7RJ*8,WT
M,CG<%WEA$%Q8':T"YQV*#%F!"9/2W"5W"9#\YY5)($#T!Z6%TA0_ON_5\HEJ
MZ=>?W*&F/HJ_P9T6XMM3B':/JS+E>OP .YWV#-1=RCKTDZL; \.=CQ6MSXF4:HG!;]NV/G_<4;NOF>N$?B?O![643IPYI'\F7OE!^$10"Y[U8N@SX"C9
M;*XCYJIF)I^Q(JQ&^@!T=4U86%PN=QM[C>:E&&$N390Q2Y61>.'S&P)0_TS/.+5[C33SUS_ZY2E0@?'-]_+BC@#JEG'
MI42]R_)!5C&;.(JYHSZZ1"Q-34^&EW&7/>+8JQDI=J\U*#V58=MN3?;DQZE!7T4L1[J54#';GT+-;W?R!(9 .1[QGE&,7>W/A>*:O8[@( I1?!Q
M^$+?EVU>%IP"M6U-A(H%;,5]B'TM;&=HSJV@>EMM%&/V6, *PQD8W9*8G%K@V*K.<"A;GZ7@IJJH)&E'A 9 X@+_:(06(:Z0N+
MB-TFYV-[#XYZTW_"(V\6[Q\,2M4Z'BQK078\!^BR\X0)-OQO>77):S$MQ?;;
MFVI!BL?F^UA%HYX)&<
MU.I3;.>6JESX2?8RNT]WKKF+)I3HP,U"^*D!J)=H%0(%95#FJ>'R:'L-$6$
MOOB!,C_EG/W$;&S><2P"-^/P>;A50[\M>MW=V*ABU_UMY%A$]O;SZV^YP5_>E%+4)*R58:N4(QWX#B4I$0)>7W&3] 7B
MU;P6TEC ZABO*G2R5[VZ%?^(4_>Q=4 R[4NVD=TUR*#;[F351M[^P<#@WR>1
MMPMH=;*RH+6-/=I-U%31/XV^)PV :%_4BSN^N>E75V<[M(%G"-<,=2)FT%K2@J%*4 <^ 0T$^SPNAC2PKXH8^Q@+Z/4W4_ PP4L#OM..EZF%<@M+,)1_]3#&S_#7=;NM88;T$$$W,'RZEF?'0#LCR]MY5D2-NCQ+,*/I+,P5SRH
MC3P\G7"69]]#@&A9GRGS\MMH ['O28/:P=S'!,UEK7*BW I54\^DA;<8&2$1\-2\@<3O J3;D/L<+M3:Y]"@\F.%$%(\0 A.NOC1D ^15226S%;D6KA-@*?C(QQW5D@C)J==M'1&,; !IF.2'#A?92ZD
M&X5U/V%&J+FN5U\#]0O)!9@/,DJ9<]YJ\B5KGM<:\H7MU^?K/IK%2%C6!+V_
MJ:G9_SN$%,5#]_5\;_3W+.('LW/?-N2XOP6@;WBG[=XSW3QU!F!X'\5Z^PP
M"_IADOK4_MNN>4W6/1XQJZY-K3_LPQ":&!/3!F CJPV6@)2;U>VHTI<1M3IY**OGK$?33:-=L(@)#LM_&@4>Q)GS?L,73!/&#")1U$&D64 UM\2.E>MO&1_[LFY Q94+,P2<5^CD]49>DORGV(ARK]3>I0LGEY#6('9"LA@OZ
MWPAKCM6TI*E66R1BB9M0 .IZ4HY[HPEW%ML+VK2RBLPEM7B_UZR\^X NM^(0?7+[^MQ@9 ^&/"/ =G%'=&92M/=4_FI*06H*[MFE.=6]ERXL3IGFCZR)F$FN+\?.VD+F5T^DQQF!"[OO"%+)!,!ONOL,S+1*FL
MQ[&Z%+5?(81M%;M3\[QU0)]=?5PGP=.:Z9HP27&83VDEY>TK1I_8&H#?$UF-
MPMF,D:L45[_4/X;Z_[0Z6!#F,C BQVF87X/M^@[G%Q=:(GD@UH$^T7UJ_1!(
ME?Y+"UJ+/!MWO'@KE$]@1D2\2[N3:[>XY^3DAJ.L$BEC^N-FC7"L,8:9\7WV
M)\6K945]Y"=2Z?1R'C#>.1=J,^;Y35Z5/'[G;7
MQ=4@\BL47-D9RAD&X.AHJI=+"WC$B:4YSJ^CS8A@F9-?DNWD3'16>C]:& $M
M\_J2;'.]'AC&'SE1;CVBC/"BM\G^EH?YUD9OC,#H4O$J_2V(BI ]2)@S?BS3
M7^698<.: FT<\K5OY![.'BXHI8^N/V5:*=3>F$1L:V=_0AZ^].J
M(?C#]"/7&LO"W8CMG5Z+B!.(E/B2OO"T>_#*/9T>]O$/ Y7,>SV<
M3+_23F?ADY J!X><4M/[[B7:P#8?XB< W+Q[\\<#2<[[#^*9;K"0_8O*?,<
M BN6)Y)YV60%V%\"SN(MY)BJE-H"_$=B+2*7"!36NC\3P;.VB[ IU_K9_(L3
MK*XVU281,KSC-6&O%M*P%7&FO>QZ[Y&$C =J_??)^6E*;4SRO=_6E\NZK77&
M&)B(L'4[*=GS!"?-T1:(5JX#*Q
M/O0!A]=4:VLCQE>X0;JKK64U:RB'M6/66?!ZE,P8>R5Y3E(1N(^!P6UB6PP.
MZ/1@]"N7AT3$'?1:COI?]-@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M#K3E,C6,BTI;+T^]J Y>R(V:V;1]*-EZ!:JX/]6BP,S
M-?:, X\Q&LXD*/5W_@[&#M%?(N?R_G&B\#[2.B&T(2RQE/XDDQ#DW?-G&%MC
M$[JC'&.BS_I0U)BTL!/PB\%R7\>'E'6<^.!@C#0UB+] 80F,;?.7YM!0DV23
M#.YZMD8VJ^#26O")J-JW'V\J;')G+>U6'*,4A:#>O[,"ZO:?HC@CMU3;\"LK
M/)6R3FGQN164?U_UZQ2RK6>9:(2NB3OO9<%30,A> 68_2=G<=*$)N60P9%8+
MV)^3;:+U?1@8/AWR('/Q$GDM4.U\^W&V*(5*
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MAK%F$]LZUSE3ZGTH.Z3P7A?-Q'H](I'(SR2>HX)U#R+N*/[Z2X8<6
MY@!@9GI@*]ML2'&=7Z07_M#IG+1O3TOL3?MOY44%??JEO#7J%9B!>*C+LCPLN >Q.3]HS,/1T%S>29-*HQTXM1YAOF5)-=5
MV*ZB>.) 13<#4A])U.<9@#T?;WE&3;KK/"E1H7Q.TFO0T09ALK!$?*Z?=D59
M(:NGLI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M+NU! /2")9F.(U)\J=F61G[DV4&UWW]>J[T20B]#I/6L]&M1?M0U4%SN2X>B.B5'(5QW0_V85,7JGVC+CS :)<6YLHYGYD)<1<$EF1*EY[YZQ7
M)OVII=9!N( 25/YTM18EI5#BLL JW>C3'QNR, 9@+]^?2GV91^+]0"=724@Q &>TBL1YIDRA"M6=TO\SBNAU&^Q,;8OQQ?77B/0V^<[N-36HI_?B1VT2RA7E@0F?3LO=B%ZDT5
MMA#G\KJ@4D;RJ)MIEE_9P
M0[%S=X>?7L]25%SRMO> L:%YMAV;U?W[+IIJ#Y2'DD)HUGR/ U\D/D,W/JBD'F0@_X21,DG:3L&*3
MZZV$6.WE?L+[ 0NK.DA%6VU]PR78O]'M7FX1EC&FMWQ1\ZQSG;B[,)A6 KVP
MP/>*JXJF'8R[> Y<'B9'LX=5(84H0VV1*XH4SB"L55"J<$ZLV1JY'_)N\FPU
MO1\7:04TZ%AO]Z'/7J%JM[BJC'R)SJ*0^*6H1%Y"G*#P=H[73#'W
M9^Q=$:?P>5Q6H"=9DSM(VK1P-R=IFM)M.U_))$JDE.NM2K-QW8,E)Q4D76LC
MO_MV4"N5GMYC\B3R\R,:X07ET875K:FW7"M4F%TBK2.$QLJG5
M@UFH?]P;=>^CU"U]XB*,VCXZ+: )I[ZPB<)9?[F,^R=#_04P53(DPMG$9B0L
M&8XPB]GZFC3O"AKD&?^5*N(WQ7LE'SE#GU0&)GQ<$MR;V)[EKH4^,
M(0]*4@9\^$J\\,Y93_&8[B:&)_6+^*SY2O7VBGR.M\JD7A^J\:FKVD7;V4IL
M+N30U-*+$WZ]8?6V]HA.1)EH<_K3(3+F9EO!MK%'CPE_2E=ZZ2J
M<:P56GMMZN-4U&6#%\MF_@EY:O-S7PR[HB]J#3-9_?$Z1Y"&2&@OL!<\X6"&X<5]/<(4G,V8><8*>/F
MKI<\YCO7YO6&@]W@$5OZDY7?EUE!.K[;?8_.T>?*GF%=H_X&:5U0.WJ>;CW!
M-.9ZMKYK7U>]7H7+3#%6@[^2%FO:%%5;&,S=@-(NC<1Z>M="5';%0>@WR"AQ
M7ORGO[1LCTDG;&0 3LIZC'44?7OG$MO);,TLBPXK6Q#&R[QZG[!J!%50"]\$=$V=P#&IH%ACMCSSVJL'EG,S]E6+4_Y+'5IVHO'=(J( _X?I;.C_FR-4_(UBAPX<6[S'IRRX@
MEIA3?DWN?%-F-DPO.YA;_&%Z0-+KK8(N.WWTL.[O'D 'SDVD.WR8/"-VK2(E
M9 OJ5:5;/JA$?HOTB/ >#ED&:OWQ[7X0[CFD RVX6^]&P4\*4F#5/+VP7#_#
MB?%]!V\9AV, \A6#!RL?I1W=7O$3]'8YI%HY3&5],@OMLF;XH0+-%\I+6B\K3DZ/E#>_Q1DVPX*>]RUIXT+'S\2>T]@$U>68EK2=UDM?$4JVM.AO511>^0[<"U*I"W']_N@R6I8.P.V/$G7T*5,HS=MU3>(Y[O'KR?8IKV#X!&*[WB-TI%--\B6MI*'B..[OQV,1Z 4$-DCZO'KA^H.
M\>80=MBDFC:/Z_):6[TU'W-E9M9-S_]+0^=70I><>-)"J*X&%5/"M(,6"$#/]4<>Z:^RRYE,Q+LT=#1VO-TR-]1T.U:\;Q@]!4NUDSZ./$V9!>PS
M[>*!MAG&R>GW$W++U@K^V*=D@==;-Z.DS"9: 2M?PM4(1IL"U#8&LM\&O]^"66PLX;RLINR._H+$[Z#(-%&"NX5X!E\MD_*-6%,#:T$^)CWC$:.AG5O ^T?\=:M&I&2L3O>I>O?&R\B:<9D U@^>18.9R__0#K(N78J:";7!ZE60&?'J3H?!2E(
M#\3FO2#?U*^J2;^1B<\7)L9%087+*;%Z]\^Q*_34#[=I1>+UO%YZN51K5(#9
M;\4>H 6'4'^^V!KK4ZKYYYWA$9KIAU^@NB-AL3HEC3/6J.,MI;* &LUP=ER2
M=SU+4=U-AB1JZ H_#2S@>?KA/W(RU7$7057N1Q?*NMVA7\Y>?%!L+5];O555
MQ1I)LL>_DE$U^%(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M&X$M.,S DO8BE\*%!F"%F3UYCG5"-(_BMX+.NO&_:O>9S[HS5>5F(Q8@3G*'](BO-N8E5MRR^C-J!FH*'75<5N@,]G^U]Y^Q0[C@Y($Z!Z.(UG3C92*+_M%!NEQ/[H9D%W H?HW92PVUD2XKD-2&@7VO"<&,^#?70L?@,C&C$.0GOY]=I$
M5;,X+3\^<+0^D55R,]BOWE+XZ9L0,X_N@('=='0->'3@MS60"=E"7^I%ISS2
MP C:/[K, /Q$+,!RU>G&4IX3!K'SPC=V-6L$\X,CK,29&J?5HR.@PG:IW*M7
M-4J+I"NLXHBIZ6QTR,'XX^K/^^)X;^+HEM7K416Y>8=PJ8<+\EZC6AM"P?6"
M:>WCK0^X8$UEJ64"*WT\,]0 6)K@VZ=;V\C5ME]1B+C?$;W6M@*5TRT*Z
M2Z9+F7C71[4S]3NO^Z>$Y?)4BN!O6RB1 Q31K4W8+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MSO!U-2#N,?;PS['A,MZ?5.LX.CAU ;4=<$6QN]6B?]L6VBF%9_<"6("(9 =$UKF0C[5URQ0&&N>ZS/
MH\C*6_(KP<&NGM+LX%I&G0KM%Y@.3L_/4C%-.![#='0R5@7.H:"XZ_/.H7+Z
M5!KG+%0OSV1Y[MUBVZQ2*LPUS&1RB:B6.1?[.+838T6@<74&P&;$@V$KS!_P
MP8I5IC!64,VD(FQ)7-CV4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M)Z#'#+BT#)SZPUFC+\RW3>BM-K-MDU41!*1B 2%)OP5CYG60.8,RC8S77*M_ZV%PWS!8V4H4MAZ]7))QK&Q\9.% ->Z;$\&9A4VBBJD!"2Z.@Y&&F<4\W5D':A04?+&#+ZM7.
M->O4-,M!DBK+O^W!@R>)'];"I25QE#'\3=0#6GVRM!?P)[2)2&=(2VSQ_:$AZN*4\W798F[W[03[G?!/I 9>*BIU,=/R!T0F6E$5I
MYCK]73$=IM(I'5Q>#BXCW)^)DW]$Z:EK/3:KV*;TBVY/!5&Z76L&U!:BS[9F
M+_:G,^[HOC&?MO"7'MCF^I3HPO"M,I]6+)JQIYQ*"95+6PH_Z/^QDSV4+
M!Q-XR?D87O=4EQT\D#I^:]UHH^X@B/S&R9;B\T=QD*2JQ@*J*!<6Z*0)?Z'>
MNBE]B7@#1Z0*NRQ>Q0U_UNG".)>SX2F6A@A_:",8_M?SK(QG5+)[&?T3Q _."RSFVR?8Q%?[V%_AUECPZ2+5>'P#*>R*3^!O@4CBJV
MTFS5WWETTCEZ!H0%*,Z4QJ15A:R%U'Y)HZJ^G+\>X=OT,'2"10NGS^2ZW^-&
M7;-QU1UM]Q@])[M;_L[^FZQD8XF86,.]EHA$E3;YXC0)?2,RH$4[D:UM93W-_:N,IT:FI!]6'P'3+W'3<4_YG7)G9_JK_M/+J$
M>X#L*M<_$%4S8O MNDJGSPA,ITODKG%'I?JY^.Z2LK(V Z .IJ#&
M*AE?,K9M,5!U57PZWF:5?O2&O0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M5UYM$Q]R[-@T'DJ,?1[AY?]X*_@_'S=O%;Y/VBCCTL8:YIW)4@IZQX>G$A.FP[*!
MV,6%8[\*)YHVO]0(?P&7M[HVE?+V_:-O#XX!Y04#6[Z@1GJP:[1D>HIG 8$
MSR>;P7!6(\N1BCV#GD(%HN.J-4^:3L 3<#7XEP$ !S*V/%EU]>[K2H\-T,-K
M7E\: "^Q\!;@=CGL#V'?XBJ20DPM%?Z-2KK,JYMP,&K?=^SJ"@-P&*7R*QA\
MC<=\2/($;\WM^=WFFT'JCP/:;*@Y@V@QU."RBZX\^H"W@A/5Z)QQ*0:E>/XN
MIZ_8?'OFG:Q;508@&1S>3$7,OC,W8,7Q/H%UPM!=_=<88WO;O$ #1![Q-.3<5T9K=^55A5'4X-ISB3Y)!"LCHIW"@\GQRPG[Q!
MU"1-Z2,N]Y0VKO]_#>W_QLM7ASO_TV%)&L&BCZ^2GGG"TN4Z40AF'98W1%^P
MJ.?08Z3O0;&T7[ \F.O50IQR*K)=(A<[0#\9@(:%^=CCO@$F;ME3O,X /('*
M(/4!?:&.IKW\:>[>Y6MA\:?),9*7DY/S+Z/IKT\A Y*^+TM*GV)W2/.;4M*A
MA4M+*L+8/JV$-67J%F%Y/I78_6B/]7'ZM$>1(;37;/%7K$!.(C4CR!\1RN[
M1X7Y4)V=ON3N8$+#S\.L+W@+H;JJQ)^1HFP[(B[D&WGU*?7W6.YM W"2:];)
M\++$V/79S+/5 3K'42WMXB8W"I%J(:4K!(2=L7Z# 2"/3DR-=Z(;V7[LS3*O
MX_5B[A@D?Z?LH2;QW9H;;R76OAN\K:NAX;O7&..X;!H'/]%J2-GP!)5PO'/<
M8Y@C(E7Y4#74@O4A,YRM\=Q'G?]462%HL!!_3373*-#(3/29(8BP)[;93V]2
M'[($M2C^[/G==[6.%_O[O9YJ/5WS5-YH\=B@BH3%7(TNA)/6X
MS;H^95V(&?*>WR]<'F4U<4MYD1NOIJMW J^MY8U]BU!*'1>++^+]"7K3G>P3[C,B2XNMRZ\_R6EQ$O&JYIZ_%B4MJIO
MTE8HCY113X)\VUZ2?W?$!O68K!W32I:W9]MOT5EV#Z\U_Z6!BX_6D'
MPX7I-3N:\-,+BH*'A,>>M!@ C73WYY?RO@A9!'UP#(/N0B^.GO4ZU^FU@+L
M\HW.F[)MP-]T4F
M+X*EQ#;*\+_P'Z%W3?L^*&-U&X#^U+13=SC2D*=M$V^?8>4%7=[L>-1*/N*U
M"1&7H-:'$*7.HECGJ!S!';5NC:UM>TA96_5&2@ 7K_DD\>]TB<1ZU'"M)78J
MMXM[/O/.TW*7=@CA2#V)_1B9YEX'4_V#;$1@5.) _E15HT51QYQ[DB>Q_EG90<7
M9V2I10NB;"U+T91[-M&32.-?ON_5@(6BP]?\+#/A:!:\5.I=6H;5:2ARO5?><:6UFM92"S"];HI*I.
MBLWFS!)2?EQ+GM.+ D(V8:$(\SEMZQZRK],9H@7V#BE[MYGNP0O:ODSF6J(EN7I9%Y3SS(=XWKR=VT25Q"2S%B*A1J.=3*1NJIF'>!N#M
M0X[_SE*8[&J%GCK64Q5I!R>%MY8#]A,OX_.H4 ;$YG4%8EGU5L&=OX?&LW4L
MK-!EE!88 $5$6G7R"UB!%.T>2_+5G*KO^;K+
MB$@"F@T%>B47L9IR,3 @<\1!^)5N&Q9^+3GO0>%@UZF8B]Z3M4,1@MHCX2HBZ=H+J7<]A%>LL6-I7K)E337>17?+8!N5BK#WH]Q56K'I35@7G
M8=^8VF4@]>.X-5C"XK"9KR%5,':P55Z_/!+ZO'3ZV(4[B8RJ:!+Z%=;"ZF4J
M*#5G%588HQH68#^L$W\YE+,*B2[6_74;8TF@#W&\#<@DL=*R3A)$X>"R=$2(
M^@QMP0IWTC\M)=N+T^C=C9+M[9D2:%&;^BN.9 \&:V@7;,T02%)C73M;)V[; $V>?#SOZ&1=@:@*]2[HTPX(C095'8G4&07PJ* VG?6C97B-0=CJT5S
MR->L>6P7NIGD 2=9[PS#V8Z[)RAW.6M!&N446<3#RA]6,3N>6IU\86
M[;IQBIO,W/=1\"YG/3XC.M7I-9^8B57$:]BVWD?R,5!BF6.)5(L7">IX#N44
MI%5+VIVA61\T6G^>+?GF\QN]"BQ-SR"_ Q6P AXM )8-6TVFG;9L\[**LO5H=VEJ8LWJPNB2A ;A98:'ZUUL_EA=7.4 X63J.+I,
MGXF[^[9#I> 3J!QZ2VNM]JZ%38GUCR(@6BQK::1X5=LCWNJH/H?'R$ JL40%
M83]P#Q1!=:XZS^6!6$*K#L=!K2*C*C:NDMX(Z[.D[#%B6JE3D6+\F M"H@ZC9*.%77DB?WTWE
M81C&K!T@(1MU.C#9/;D)>?$FGUU9Y(; J_G%H?SOBHI0W1YA1'3 KJBXKJQ#]GT>KC98RMB
M\CS!)B/?C$K2I:/EZ0P_U*3>.BB=7G>PLB"Y &.IX&4!&*W>E17U1/SY'Y0F
M&P(%BE>Y!F"V >!#Y1Z.#_4"G(X'/EVM_X-8&%7(23B&93VRYXN_].N'YG,9
M\I6ORZQQO9_:I(&I%8S<,FG@;Y.[,$RZPQ/BNIW M(25ZRD3W3=!2$Z"+A"F^\3!&>PZ5]@DTGC_*][2JVX@CC.18UGQ.IIO9@*ZB
MP2RH'CQ)MJ#W^/VR\5W>!S$6:K[+ %Q]^$E:!RH4^7M06BJY.(3KB36[$HXB
M&B?QT#76\J3D_>UV2'2Z+KF(J^.95U:UGBAO]JNW7=I)?B[E_'HZC4M'
M1G&J9^B/AR)LOZ'\+)O82=+0BO,J1$:L- >SH+N89&N%?)S=&WS( /RL[![*
MRK%&?TZFQ(OR@X]$O*;U))776%88?BB@:VA:6D'7<;@O;5HWZ4=O.M7'ZR>D
M>L_QT2WT.P; E&N.Y%:;(FML$K]'N*XHEJ>:P@2/.*7D K_!"<9%2^%BAC/;
MFM@L[8%5/X573,>E^.A2BS\OQUN(R(5[N;P<)WP/13UIW WM1>-X$KU^\KKM
MMZU$4'Y?.'T^=[-F6?$XM!AJ<'_(X?MBODD/.%Y_2T=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M_N$X_R3]'V@ZC#X]!1?L[FIT,!X*$J2 M_<+=JW.O,3Z(GZ0JI)=K' O]AOR'[!AQ21BCFW#")+PU[1Y!OV:;U;<,)G0*
MH_*QW>#BP"X#$/IANO%!_/$XC2.\H._M,*M;>:RL':0*?N G.[W\Q<6]JRAW
MPU'KZVTGPT@6&Q;^M5C'S((^3MD75;!>-?U%@'.!:=MI<&8S:ET[O>364X%>
MH*)@J[@0>#@[12[\O.B)KRZ)5VGW-?QY#*K;]B@P,-(&5!_040KKT'!@B T&
MN5YF7!M0=]Y4U9@%9[,\ET?RNQ^6&W_LDHZ=VWMO5TT.C(L*/6G3P"
M=BO'YF[ZMO^].+:U>"V#4:0M#]XYL+/UT;KJPN+O7DGP@],RLL99.)4D;H?>
MVNB%/>@C [ ?8]\>+.4HF-K!C2IP#H?50.]*2!$1^V.@$] _)O6N9_R5/ST1
MM\'OG0S >M;XW\#': HN?:HCI3M.OBK,/Q0^^6./5"WX$E/NZ72N.3I&+DST
MJ^H9Q:Z]GVYM@<(CE&-3@<6(]'G4[23XP,T]+;$!+ENC'@;U8'E^MT!'$O*'ROW"V+B6]MR]7?_MT\SZ4;!8Y(G')!$/$X8W]V%Z>'N/3432AI]M;R*FDXJFE_=]B=K)IU=GA>F4V!_0R8A.$/U&-E8,+^7:/48R!*C/H9M!S_YZ
MC(34Y"FPD&_5FD8%2,1C_!!*MA=HW?"1/VE3E_'+0*G*739[T)6U=%3GM^K0;-V0Y_G/6;8QR>:DT;"=C[4?RI9[2$8OTX4.;-EWGAI%V(>7=W9B[2GZQ
M2.0!Z7_7F4;OJT]((M/S7XIFV_.99-_K\>B@NLF$'6)2]D3<#KY=J1?>&Q2B
M:_"?FN,SA,CD3JOVA/DEHL@S(:L$DFSHH@%0^^MJ5G'<_47J HTI)R8ZKOW#(M1!7MF:G/LJS^=3@ICMG#9[P;/P#^5MKNDSQRV
MM25?5M6(K6(_\G76LA%]T)[V^%8!L>N#<=LC\7)L!N71>M_4O,O)SU>\"?R<
MW7$Z\;_7^D9JP@Z5=KA$P=IF5RV,#D844.[2?+=^\\,S) T+-M/5W!M4K$KX
M5Z?.UJ$%:J, 2UWV_$[V ]+[KN!*<30#TD@/&P"_*O)EVR=GT3B8_XMBH"Z)
MOI5L31VH=TMY7Y&OP)(;K#8);;-T'UP8IABXO_3U!+M\2%YA 8KI@6Z\K[<
MNU?2'4618]""E?)UV8GO1/U.*TK!K6-(U!4
M+*6613N!"7U0K=BXA>? F:%@,\B%P;\R-NZOZ'1A5GS>UQV@+QV!D>M00>3A
M(;?>G$S]9TL%CHA&'L'=L1T]V,\]A]J.W%1_WV?9PO4NZHJR,FL_,[TI.7M._JYO)JN8X[MQ1E2B"4=9GY2':7\_)\H.:RU7-2[[!X57% 4"4Q?EU*X/V__^N.)]TA#PZU7
MN0_#)Z=U GN!,ZQE&0T: /10P%"? ]GYN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M@'^OMG[V%U5L0W;6+ >0NC74S)X,R1-G\Q^0$'!B6("2W ^8;9JC "_(Y\R
M,KCN7DO,3TZZ55)GC]?URN;O;<:8:M^M88T(9?%*ZK6KON:-@ZVL)Q:<=?#J
M_QAP^P^..U[Z81]_&-X#'$ 3@G?A*"?2!JJDD:"_FIHUQW_0%"3U.T 2:YVB
M$?"E+GM9]? N<0>I#W3R':QAR!4V"S,J9S58)N+;!WQ&
MBNZ1![MN4@K99W4A 7NXO4621IA43/%A;N3%AVM20T^L1%L(22;QJ
M[]'#U=:/M>FVT8=$M%99Z;YS+P?XD3A6F_EFA-OLYVP^]&@EW4DZ) ";II&C==\RY,1O$4X$!FMMM>&36&]CWY(*PKM3FX.QG[!B[H$8^)@:6>CGZ._:N(2* LF5T'9[83O'E2A
M0N?M?2=!V;%R6JMYJSD,_V" MPF:(/-4Q\M!V0=K^WA.[52*RGSP 5:T
MM9$*[5VK[0=CC^G3A!'IU,X,UD6,*: 7O8Q1W1M9YL+D;C.&?8T5?0@YU5*VJ
MS+8!])Z4PE,W3& X3N.4+B]HFUMU(DV2S=%%$OQ5^H>41*0:,X*MA?B?-B=_
MK,O;+SRLMA7#^TZO17;N$[L!-5[Q >AZ<*BA@@4'Z:@S:0^CS9_1]_TL6U)4
M3 U0K^_BPVL-F#C:K@H\"PM0;1_VVG"L%_U'*A22H:/E0:2SIBRS2S5%6BK4#\EXV!>_M"/X889@CF:%DM7
M1NO3U67/MQD+' AZ\KD) %K'ZVOV,VD^<_[0NYUS/L5!!&5IVKCVILN"GW3,
MK,*RCCN4,@EXDD9H*P@K**S+E#F2C#8*<,A;G,)88S4U:RK"9FP"!1G\O\"G
MU*S68L(7]U54?61=F12B'RN;'!J_M6.0&1-!"C8U^/N"<8>8*)WUB1
MO*?Z4*]G]U1/"=>8CMM;ZNB@8\+EUXF8B)\I486W&S3*@:/=>2.@LI.?]F"460GNIX\Q->\W45FZG.@
MQY3;47&AC ][M<.Y>>Z2X/O5#U34K#7=L+<>J!L)CRM9J=)=9L)K47NQIT(9
M$=JWE,\&OY_FJ[?S@:'7Y1UAX_'G#<\_)WN@Q1BE1_FM)=Z6I3]5-&K!O1V+KNRIL [:12"5\YK0?J]3@-S<%CZ&20THS&/7>[A]_U>'
M%^_04LB)-#_!THC?6\"5(NG[596UQV0A*RC;DS,(RA53*?97[!KN+7L5%9[!
M1/V]ZX!!0_/9(PWJJ*KDU(H1:O7])O6&*TGQE)G3#I&_.ESF#_$&4]#SWT>C
MF='Z.4S#M DLN'YA?*L+XCG'VN-GP0DKWAF^M>W)Q1!/5L.V 0N.7W+J*DQL
M#O1K0P]A8E>V9">YRIK?8T0L./^GA+,A=VGR
M]K3Q(J3HSC1Y*'1%+#@(#L[O0ALDYC1-&TMML.".-38V!YH_4T]%#'FT$'+0
MCPY_F:D2"^Q_"#)+/@UQF.[DP\C(2[6H.46-/@-JUG7R"%D%YUA:X[W)3T@B
MD?(1GC.]"YM#/?&)Y]\/FI'D=EKP\#:JY[\FHPKP5TV_BSS-U'A.K4M^V62! J:R\M*0ESV
M]E%ZCB._6S,"#J3#6YJN A/%)MMM_/(JZO1Q\WU&>R3.G5)O#29ZLX&.9Q0ZOX/;K(W<'%KD<;ZAL&HNL1M'PI
M*S4Y)C7E^I0/ACI,-SRR$O6?P+3=JU#\.:]&UDJ*MTDG^[+ YU<>=5 FGSF-
M\?1$+&7XMMYP[\N+JRY()0]HQBMO ^)6+MNK/.+<5/B3=['$]]-Q^%V>3Y9WOX$R*;'%S,Z_AKU/<+YK5"*B8"RFRKPM^[
MZHW\2=ZT$>8 +[#^0GZPE IZ'(BZH.)( 2;J27L@? S8:E.]7(TVP[,<#V*_
M3;:O-WL"<3VH_HL$?HB5_SP(?MMK;$=I%\H?(T;[%*11C4GP9TR_I(>L[$9X1"ZRJET6+^:MXG$;$-ACR>4)7X
M2'P!N>L6W6&'=81-C9@6O$TZ@^G@B-M'L/)OL0W4=%!TI5(\O-*@/PB1]4NZ
MPA[/T\/4A_B#8T61T(V[&8V[S8'(YW2_[Z,MN,7(9282H'/:6C)4D>$P-##E
M]!I-/T/].!\P1C--Z1;<*QHMSQ-1CB*L.?IC&82>FN9-6%?$Q%,UUAKW"Z+#WJ@7UMR>2US'9.I^#,:$UKUT
MU,]54!2Y)Q\3?'O0IC30U!AZ[8I)F[8$8J/+E<=@5R?QX/?J+](B>[IE]?9
MM)4]8 P6Y69,+Y+7.&,P_K:-^< X?-!5 ^E
M-+BS:.>3^)O\A[UH3X+]!1O]V6+VL+N63YG#PK7M$;HJ EVQF,[?J?SXC9$7
M=G52.W7*SYQK4^\=F1Y@LN-"AQCE94'F.TG(MRT#M T=P%BO7L"?5Y(=
MZ:'6T=KO";F$.'Z15,EOE:PMB%,\)$*D5JX1&+??*#H,1=Z)M> <
MZ.MCW-KN3YU6@\<@>0C6M&PA'GQ.<2Y,@4,RTL(FWAK@;N.N/#(2MJW#R5,H%1T^4/J*1>"U&4@M&@D.M?X9\!)"W^H%"HY+U!P8"I,$"J8UR
M55Q!B5MOJ=^I8&+O*L'M'9HKRFE\@>@4&)6
MH&E8#\(DD 57X=/,DJ<\ O^Z0/0\7^JL'JO]?<#^XJM=4J'#"75T"V\3=JO,
M5N12"A.Z*,G(94&!_#>N45N9T6CYMD6PA"]!.#2L%L!GG=_K3.71I*XRADL!/^!/Z 30A^UZ[C?%V-]7KH(9^)YD$
MJ;MG+#C%7&CS>*<1V4(FP8[([\?%'U:KP]IO)]NZ!EZ:,81[_RPO0#<,7>83
MIJ(V8UZVP-4C!""\X ?4_)%4L9!4UZ-U7.*W,K Z]VEMK]9,^F@Q#6:\SBCA
M(S^>V'I'-$[/'26\3&FIV]*:JO9H,SB[](-CB@"5!3=44[R48$INM!K/8Q7@
MU%U>LXIUAKY@-.)@M:K@9[KW]8 /L%_+MH@ =F_7\^Z(N9'],2^I%QAS0D$]^]8-?!J-Y
MVD-I'XT^^,*"JVL&;B!;1Q[>:IKOG-OIR]/,5Q8MYKQP-VZ***F] "N8V,6%1-:$XL4.V:W(_6-%Z7SAM?9Q4%>M4.:_WCX6,HZ=
M )@>,CH].$,^2 $7DNL<#)T=AD&SQ(,+TQG\6WZW%[JVL_"H,S0]M5XPP?(=S<\EK#V&!\D7_/;Z\\SI![3YA@A/E%MS+E%;QDN1$56=[6 .FF"MR
M6QD;"Y1#JR5:Z_KRMRVXG)\[86*M7C),3-J3\I3UVFQ&3IA3S* "4')UM@_T*U$/C[L@G]1.RHWRA1#DURULRR-NATHUG>EXTAG(O@C=CPPMN])ZR+A%*
M^Q28<3VZ&X;9SP$/X2(^#?9G3Z(;1;-)X,J7L>B'U?7GEI2GF\E$?+5A=:)>
M.H50-!QYS P;E*9C0+>*[IZ>%],Z$J8OL^!^T>$EBL+OZX6F0S>PQALF(%[H
MH?-WU&>,$3'JB7SPB:EW?Z7PU8SY(@@BC$2T0#N[1:D(^NPO[^W['P_\/_,I
M]N'AC A0O ^^??UM*B"?!4TFPD!Y?ZX0,K-07K;NKO;?:JFF2],A:M!DW)*< BVK&UU=DS=:9;S;*0S\4.89E:L#:#B;D.%I4_N9)MP3T/8S?_,$+H
M3B:_1QD"LCR# :["9_P.DEMEHPRSVR&MY3YIOBTORF-4A><_RX7V=E6LK&IUNST6DS6NCKY"-#UICTL&+J.
MCX8.J"8> V_1"?&C+-SAC'SA-D.X_DXJ6EQ)*S\L,$65RYPB4+ 9&'_/DP/]
M_H[V[ !E!K52L$8:R+J&%*%-["TV.W&M5IP?N !=%5W8@D;J0-YP-I _; %
M1[/@)$/S0N5A<((S#;84#K5M:C1D^Y5>] !@"^Z3A)=[;4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M5UAOR81=I>E%B(=4F+/9$](QE[R.^U/8;E]BWS.C],3;A19.:K;,FY6;R
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M\17%?% QAO+94 :]U1Q*,"I,+%7I/]YM<8^1P:=VU'L00>W9FTPU_BCVQ+CK1"R@6U4-4U0D?1:TD$-?H$[1GQ1?I(R\
M+5Y?7_#8^9.+'A]E1&/:@=G9[-'F1VR75>RLO&<#GZ48W'0G E^!G; >YE].
M )8WN4K).5'+^^D?R&[3E=X'MWCRKB$DF*X(BPYB^2RK@K>HL[BAU18!#',^Q8*8JLATMW2^: T1N7@J2>;$%
M-^92DGBT(K%XP:[W]O[;(X1Z&?.YF=PQ)(/I.;UQ0<38"'-\K4!/XZ?8SR%N
MP%'"'HK60T^#WHZ1WO:4.-/0EA%PQ=%=>HXM=,I_XB44*D$9E>8129R?:6(J
M*M+L#6^,,%;PUM$N"I_?%XUAG/'1R+S[AGH+[GK9:S;,!V-B,"6)CS-G*],_
MZ/'M0.:*].?QUM1KM_C(2$^[SXJY"^;/GFHSXG4L!4UO8
M"%A-G6F5$O(E>-A19J]>^M"&Z07D\5Q4X]52/^+LP!+F"OI&U7BFM%-H%TG;
M/[<6W<19FA'F-L!CF5Z3;M!1'R*_P.2>(
MSM".M_IZJK;B+T:B]\2KKRTGP@4=N\NL,3S_O#F?[.F[?9J*C8EM!0>&V.WK"#)@#
MJBZ,T!A]2"Z+.S5 )#2B&-US%XISM$Q,GE8Q+I?31-+I./ZJ&3AF5&(7Q\+/
MUEIP,WXV42I.CE0%MOO9'&E4Z9O<=>5.P23SZ6)0NK-YIQE SQS6<>QJ'R -
M66=2KP]'T8-J>]!5BB&_LWK6AFHIS47%J&)!ORLDVF7-W5H%P0X\ ;;XO[A<
M%ALNT/."9 T5$5*2\I)JKL..\8[*<(Z^KY(V@;&^=M]Z9\])=DG1*H ,ENY:N*,*# 7B4-%1/ZP,C=50N#@Y <.**"E@S'E-3G"
M,[7XI1 8I0H\[^'9?" N^#=B<.UZO5CMPID3AOT@A#G]RVX"R1KAY5^V$<#
M)E[T"93?
M*PY5+P5DM_AH:PU6E];U!0/W' *5P_= *BU+AZY!BCKL0RTX?-.^VQ3[*/NJ
MK1&3)@.\)N4T-RU$F56&Y!V3ODX,-2\JE]GN_+KCLEZ8)D<_IJ]%;CM$J [JM5_D<,$,18X"U[3#V-0I]<<][71 TMC 143%,[!:Q_6W)=_K=-?QT?4
M(R6PK13\66)'_%0QLJ->W766^Q.\5L;\V72KH%0QLCHS,K.-L;-)=7:$+<]P
M":]"NQ]@%9)FWMV(%;]:Y[P4J'TL) '5"&OV5#QJ?YC_JU*J%K:%.+:@;KF/
MTLB9OOLJXQKP/_N2*?>B8L-U['-)$829)MH#A2ERG""W*\J#CZT3Z84$I!-_>[U]SVW$[WB)&!T):O?=:P[N5
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M-><&2J-/;&.L*3!8,SN8<TT'"[E:9N!XF@_<2X#-O:01
MXP7TZ.IT.8O='!O&@?C/\07@">9/I]/:4BRX93S'*:QLPPE#2&,;PYZ;.[/-
MIYT/-RL&3E^UX#X7>ZHQ26?!&7.*7HSS%I$EMJKSVZ*?S;_)-1@Q/UPM4K[>
M.M;7T#'E?8LS3O*=!?O @<:EI;_2D$.$AG[W*?.)YAP3%V?!%9#]_9Z/7?4S;_
M<1#^*=?_)$ F[-XK2XW[/ELQ\J]!IG+[?^9'3_X?Z:.W+#B[YUBUA>5C%HPC
M'RJ.P$*>ZGNHXL3(^_?-Z!H^MQMO?8T.PIS3&W;IL"[X:].C*S@7O1XY2_%:BB7HF=ID=N2\'!,7PTY 0_N:=HS
MQALN?CSV!E3,;%=$Q?[9&B-%/(*ZDUX^]SG%/+:HX-CJA&\7Q\\H01%1+(3;
MJ!8<0I/5\B2HQ @KKD_L9"K?LN9.0YB*\0M_G7.#>J%HF]H6'.%[(P&Q!RC$*^WX+"7<.(K\>!;5!-XK=NF!O:I4@ER>!_2
M7%I'=C0.;/9=?X_&W%.K_K+\QDLP3G$E#1BJ2DF.C?T>*;L=_7*JL"R#*F<.
MSDF9V7"R.>3$5N]SOKX,1_C= :(;[*!"F1RP)4C:'-UJ\N/ N^G[,&'97* _
M94WMX0Q7 +(#HQC1=;D>LC+B;P)])",EUGGC -V[(I:W3C52=?>$@R%[3CFG
MC8\.+'C2?U*W!-!V!E>X7,,G1)+/$3WH7ZG)Y^%#MO_GCD/QPSQS8S?$D/ "?$(48 ]UF8.I^167? AU+^8'*^Y%D"=U&)6@C+F4>
MS8C8V^\&[U"[[^SD*/>5*AP$/VE!YTAK)R8<0X6JCH=Z1^O,*&#-\"P-[D_B
M0!@%4DYSCO> ,91-9)\AG8
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MS,A+L. VN_34,B&M!?>4\ #KQ1!AZ.&CTM2R.V9SD*JU_'56O-SDRQ,N#,E#!AW#IT" )95H#/(9ZJ"@E7)KTH>3
MMNH]LM>#<]>"\#M((I MMW+,B1-S?-/7I? EHYAKG52WJR%D\K:H@1PX3&H;(' (/$=<1B=!&. N'C4?
M= @M2Y#;+M($UJ #C9B:)Y@PH_C;#Q;M2GX ;P$ZQ%K*LZ>[]O@NE,^=37$&U$N9'N<\^5#0.O0Y8CBC32\7OD]WZN6+
MTB@E3E![*L*_JV%"N^(W>^;_Z%_8#+:CWZ288@3"(5%;^!ZNU,UFE)HY-P[=
M.48=+;9IY\6]4+8PL!@CBV90?"/">H@S,4>!Z4?]_($H 7G
M[TZ?XE.!G$+OG.0\"KH,L)D$AAV$N3JF'43B4,-2\H2(-
MLYD]5+[L4G6?)V=F#KH,QHV0Y9(Z58P2D49N$#T.JHSE+_>&#K2S<+Y4,.;&
MKNO^-Z#R-L!6Z^$<2UC&KZUAF?[P$JX:HICVW)"8/WID#LMD8[CR&J8AQ0Q/
MZ-(7:I=SL\15T$J22L#T*%HM^9(#('/B7I#:QWQP][ 7RRX
M&G!R>7?2O3V9O;Y!:HG^BFHD]Q;$:H]:B(&K?K<#YL3]/:@O
M;5;8KB_8=J6 *U']EE!)D8,<2$-H_%)4K
MQ>>@._L\">_1SGKR/SAZY 3JK3[;SSH'!UR'TH,&LLK8D[SM?50E4./)6@8^
M=U6RSJ9XD[G>K2^3F=GB;:B[?D[I(4;)EP UUG&)\4MU?
M&]SL@OICYEN-A]=?B38#9E*P0]A+3*VZE:DHMS"'\_-/L'M/M/^=669\%]Y[OEM(G2E!"*^:L3[#WJ0R.7Y+8N)&"H
MD&-R!FO3<4M='UEPM>(LHC.\H,>3 'W6%%1)3^Z&MQQ3%;2@Z_KIZSPY2V,;
M@"STHT$XL#>ID;0,:30'''D@XE0LQ:02:-Y,*S]DCNFMQT,G.;G!"M%=%7I0TU?2]N(T&[="_I8;?HVX'EF*0:HN]0V[)]&+E2$A0RBQ7E&_2YR"LR
M;#>&=;M2"EV4/=((CRS@+;KWW4D'"PYV ? Z_,).>==^-QM_]:&LLMNTQ(,#
M7GD1,C"[-C[.C'BW1VUUX,(A343/YLTLS'$^B;B07[X?J>M$"D_I]#V?IV(+SNRJ/P>U-+Y6*+*!ZF1TV)K*],V"922[_@8-0'[K/RTN_]+
M8/R3ORQ*]J%WD;- [#;B=L"N=^ ?H4.8/]],.NO\;D&'L_N6$^'L"]%2ZON1
MT R-+[-G J+DKN .NW#"N28JIOM64O%3DOE5O;S'-Q,'FAJE*1V<' MN^7&5
M'KO+Q8SKK"6^>#G_S'*HM)V%]R1P*0VG;L3(W:(/J\(R:XI"XB :J)0LTPGM
M7D^^WP?*8LMBPS(H E;6I6&_,#^O9+;5$;JZ_,+MX
MD3$]H&T4+IGR!4\X8N)3D0)2K?X=NCQ%'JJ[\H&64\Y8S7A)7L)SHJ\5$Q>Q
M'R,QAU3M[#8\CB9H+?$@+;?@OH-:V\.<\5!NC-PVH@TK25(1 6)C3M/;P65(
MB[B@RQ]W;$ZZ,.5_M9/1&[4:4L@LN'.L&H* Z01[]OM^>!-*ETVJJ'D5\/#A
M-:H]S>EQH'2ERL-D#P<_$6F!F6+?XNW%KJ_$S[KH5S7<.5 7=1P4:I T1&/>
MA8Z4K(+D*FJ'!)\D64C+;!W9I&X7_NQ+DOE]&\Q9NUOM1I.)@$E0WX'?33!_KP_(M>"X*.A3
MD>%<=&]*; JMB'<:R[I!23B63'4!)@VL>1V2!IYO,\>808X%%WY5_WO'W-8)
M[ K#&NLFOW>M8/I]:\J4J503W!%EWZ0*.U]+?C<**!GRY1VJ$!"F"D&X(3)Q
M9@=,N>;*S7_-%T;I='/*#Z5]O%XMY_V(=>#)WC'SHCMCZHF(D8S\%Z(; %K^
MW!3VY,''1S88VUC-\]7(#I@F^*\JK[7_S]9DO;?M58EU7B1*IV7--/YYZX:\
M$Y-T1X>IV2TFME3-VJXISM'T<%/'RB>TGMKR,TMAU$QNJLR\QK6V6M9:)K+1*"^&KOL%[#B%S/53#;:,3&#@6'9A1,+&_]^#<"\
MYS@!?(Z)E F6B$V(HAE6/7*;^V-XY00#3!E'G;'/!YK9H\)'_!S N79=]J.A
M@[%_'LFT:Y:'1"M#B:M%H*)WCJ#VX:U%STA8:;@W%EP=@5U,(.EX5+E8K#;<
MS#[XL.';*[$)=T(L.%]M8T1%*!T<+ABSX*8_0'Z"HLV+Z 159'/MQ*\8?1 W
M*GK:]7>B!]:CSU05Q0+$)W8;66U6(J7Y:6$O'0B_6,>7DZI5@BQ?0*J@T/C)
MS@6EL:=]0?'K8J8^BR:00MTVFH9"X-M'[]M8JC!F-1;3:!VV?V&JOE/MMLHZP"V>(!_BU 7%3]D<(E!MKHXLR9@^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MZ_)1YVRC@9,+4MSL"#50&Y]Y0UING$MIEUVMPFJ%AP@&6YIBY-J/[]*]^J[BKYG\4!;X'DNOBXE)-4U(=-?QF;?O.&)7GQ-;
MM^$V(NWB&1X;U]82I L:@.46TCB60>BQ\B31V1#E6)\X'@>//,2_!=B77X36_
M9E"4_#J&VF LB?G]>[1>;L%5B)A[%_18$U ;+#C#/+.6;R"C:!B@%TUB?T/@
M64(\D6G!@=E0F/^+) (%G.4C<*F2BF#WSK\L1&I, ((2I(%#PCO8!]GPQH4W
MS >4@CEB2:QPS#2Q79GC,"7NPP#-+PW9?B_]$)_74%M]OZZ^J;&I+>'(M!.L/42S-V/!4_O956I9U5X6BSMO'FM0ORI#"BPR]A^VDA,_#H+0KHN*R>NXS
MY\7B_!M;![Y&9S @$6->?D%H-',_Y@8.W)J^M!3L/QQ)8J'\4Y++&9H_(9O'
M1"?F\4O2/+^53^=Y/;=W(>5WNQ1H@5)22:MLV$;KW[_RS4UPNC3?HYJI08G:
M!<8J3Y_+')@^U5#&W=[5?O85 2O6:N?:(U1OO+CS4RR\B]'BM\54,J+>DJE*01-3I?"40KL+_3/=WO%4N;28&W128OBRP?QDC\,W@7'?:N' 4
MJ/'1P P>]23((G<4Z:W#//S:6?03I"1Y9T0JQWM*-2"*QC!U-<.XX/YU'O'TW<^.;79P\V"2TZ)23"?E]9CI??[M/>,?#?D0 R"Z=2FOD^_(EBGKB1O-L5K0# ,M/_G@_];*^_1<%#,7DF<3Z% &
M <5"2U6J9/=@@8G!_CN%_^2?/X7G/2%XE[29ZG_5.V]_R_C&!E#07LP9=@/F
MT[KS,ZK(Q5V.';>9:,/VIG(.Y5>P# 4F5IGLG?2#RZV *D53X7J]H(7G7AT"
MM#M_>)_TD'KWZ.)J,4%MN,8@[Q/4?AN7^#^M%2'^:SSHBW^E)?VTO@FC(ZR0
MBDDPG!/J\<\9WN[_/F&R,(+]5$1\O=.MXS3F;319E]*2?C/[49I/*@L8JETML."H8<4,?E3&[84CC/_=[59Z*%E*E(_$
M$?]IS*[-$"75Q0AFNDPM+/V+=1+-S1^-^XV@+"-!.UXOY*:"/JGIMCC5HG,%C<&)TEFWVIQ]5&5J=-HW+A(%-5S!!T^[S!M2X0MS:A$7)CA.%.B_C/D$A4XX2J$OH;C]<6NH^/98$+\>.P\DF7N&#I; &=,,9RM
M-L^9!(?4XH42 V57=PUH.UGG[*S2%QW[\X2/;ZB^(2J[M%WOM/2%!&4HW8 )
M,V'>3N##65L;()783A*7JV;/2\GO3 V87+*;/,JF3$LSRX9W=94P8RRX3WB2
M>1BH 6J(M;7_G'"WW?3KMGKC3HW.\^G:K.D!M'?^Q4B\]T&D'V7YDD_UM4W-!2G&^SLU=R7_,1[$.M[QVFVUX(QGP\8-P\2#6$VONY!:%32NR3=:<-OU
M',4*2@2E/**+./W^W&:O)1&Y$8C'003)&VL>JW17GK+@I@3#7 UZTH([2?V)
M8MX.DXN^Z%DQ2\V.\LR1MQ/PE>X? 9-IX%!5BC2]$6,&CQ$G7F.C PGYG./S
M#D[%_+N0(_YM2"3W'X*-60=R31:<[O;"^__X"(,A0I!^;@%4)YXS%GJU\M_ 1ZM01\\D;4KE^T4&O!$6N?09U[AZ6$E3-4X]E7 1;<&4Q 4>[;3K>D6P"
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M:.BR&J 7PU))J]-*J3+?3(4*H:QYLG>4V.,CS!2MOD0#3+ AM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M"G(9?MWQT:L> 28>L= <7# !.8QNZ#.%+C\X0/OND 4EPP>P%
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MR1%CI\1Q4Y(231OGN2%\GAW8TH=MJ)=>P3J5&8]N6(W)=1;'2W\[_F%&D=5XBMG-AQIZCXGO)7LL?763&B.S]=C;
M?:KTTD?X:H4=]PIH3D&V?$;H>#8=]-%-+$0>7L)H ]-% C%;Y%(+_)W#V\3W
MCJOXYYI(T@C61:HMQ&QS>.NF'/W&I!MCK=4(P[O,AW6 U5-,^"Q]3/4FIIC
M;!)Y3Y/X _62_?/TM1E5:/K3>&7&5O0R)D4%O25<9OM9;&WS?!@2%_5FT0T7]9XVD45N#P7WBIA\WN+_WU._X*'4@JG"LK<
M?8TGU')<+;CUZ8S(9H0BX0W1,7%2&8K9Y%L@$O52/GYB/#UUQ1@1:>)1HQX*
MJ.QYKSD[[GG/CW]D-J_+D3S[#=DAOP8>F/K,R64H^SH"MC#K" %&EOH>H88U
MQWH.YOV7/#$ D^?E!5V"M6(.>4+7L=&:BYE>\!AXQZ7-XWS4^]VG&!F;=G*4
MQ7N7\@=-P!XLJ)ES#](9;XD5FZJHQ;XUPM&OI]05F(V?E%ZY?=\:?667!7O.U94P6IZT 1&RL"3\]\=WC$B3DU#*.$LO@Y
MS&RIMZXOTTZR="*8.6^[/BWL,3_[CCI1QCZ#OM_% 5L^*?'L=_?D0%_YEA^Q
MX*I/;592/=S<*Y4>))B&-(C0#1+DU$;\UA'62"Z[ *W!N!:OR?'>T(;IAM9HQI3#\&&J=TLU?-ZZ LDB/=785Q4 ANY)^C-"6%]W><-.!/%S#R1XAJ)SO
M($RD.>:2!;>R M\!4FKZ/(L#.*;C7Z8;.6=XBRC.&R",^1?H&H>9^+@ZDS#'
M,S[F$#-8,W>#JWK-,6VX'4_E5R>970G+7B*7T T.3'AW=>K03[Y!^X9CGKK,
M@?T)4R9YO@2).QN1>!(%M.!KZSXZ;"(&ICLF)O&+Z0LNM1-JOI/@R(>:ZK)"
M @YGHRN$T*Y9WNM4A'D+/!D.MOM5@,=?@IUL/0A_G>SGL;N?T9&<00AK/T7C
MZU/OJ_1,>=?^UBCUK@MJU3R( $K*%$P]!,QFOS'6ET0D/XN2S/,EH$MQ9'L-N$B5K;U*56C;_7MN8//
MU"D#_',/;OM38/YJ4(ZXSEAGE&5SYNVQ\LJM1R-QG@_PK[O>30QP,0VG F.U
M?-C$$A&Z->0+H)UUCF;ZK!FI^4*O2CZ'J#
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M5\#Q#V.N3YJ(%7%8F5F*
M8!Y?,]&;>4T7M_$6_S60K5G5;4,:-39]SONX^T +Z2/:Q6#.@RDL&#D_S\L/
M6W !C36--7/1.K2>$\85$]U.-&3GQO3>4%T;8-ATNXV).;[>E#+AC4F]"3 =
M:["F*(^9]YK2#1R[[KD;O;H*[_T/@Y]6W)NMF!W/;U',>(NP6G?G@O-C&::8
MESE:\@KZ[KI^WWWRXE.M7S?G"]N=%]>K+M]+L<>8E%MOG@*N2K<4U_YP_J!6N'YD27,0+4M/!15A#P\)C5'4'(3*< EJI0/78OU.21Y
MR:G^/D-O&V%*[&UPVT;-^316$Q%Q!"*UA!/.^>X MVH*+"X]$N.8 I60*-.XXRCE/_.@$^F%5[SU\=NT2H/IUA,+GYD7RD'!1F2R/
MX%_=HRT^,%-,;"T"C#:FL&-X :?VJTMQO%5HU\-Z%:]*VHD$/#;H&PYI"?']
MQ,%8Y))>8MEPA@3S/A!/_1RI_B G+3");M+@JDX&AM$NY0N9UKZG$+3JL[!1!J%V(JZ,G=5Y>F0T(;^BMJ')V"V[POIFYC
M./;J\,M?![F8F-63^H)"P2G)9'%SQN1"J!,:3,I5-\IWN[RX8L'9-26,,7S0
M*N,/Q&9>28+^QB1 5MWC+*-5P4=D&'[M4G&$?,H9$XN)Q38'J5LTC3/YQ#0&F26==7WFU3G>5_MQ)3C%OFR/I#,MN#"C
MC%OK%O0AMW@EDG2!H1C&..E'3&"V52KO\'>J!5%-M*"T.>%%EWJ;A220O$_+YW6$LT"&#I"T?BM>\Q#JVT/,2_,8JBW?C=.!.B07G
MS%Y75(14O?!CL/R-89^*_QCL7H,D",F:)\JM,5H-;P.9C ^W/35^*'?44.A7
M<,6!V$S!!.KLYEF>(+6$K[538DC#Z2F;+O(Q!A X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MG$U>!DBWJF.R :E]3U,J&Q(&_VQN3MF&_X@QOWMSGP](,.'LH(&>?7D150L2?9MI;_JQWXKKM7L4>@F7P6AABK8QWP
M0^WL'-@%@Z0CJMH)_>G?O-RV'GSJI\G1Y 5W /;$Y4=H!]H;"EKG?HER5K$Z
M^$NFG#_JA@GV9SP;YVP4=M2'7!5\R6ZI>TK>T.E>4W)KT=(E_M9 >AW:C0N@D\4IYJ--HK5ZG-J/W #6G$$_IZ0J94U2S^E?@XQDE7H5U^8F1=
M/U#G6>PNF@EUH+[D5_,K$PZ0.)VZA8]U7>F'K8^2"I!QEKT.ND/+;BML[ZB^
M-UU ^%XSY[7D^1(^-%\E KL_L^!M& S^R>^@KR[>]/%H#;+@QL;]TMN6IV($P@XA< G9 %]M'6-$R>0N_'!U&^&$FM3*P:?VW-S&6-WGI2@5PO2H.%;TU##JY_/=\5LM^L-K$^,V-)S8(5$ !546W-*^O(3:E*O;M5J4C^E2,BN]\K'!F/DJ#06$\[M^)WQLQ/?@1PCX;Q0?K@P^WRM2X1'52EL6&CX Z,T$%/C'(22Z5I[&A0"QEBC
MG(L!*[F^.O6TH0"_U8#I.;V2A7*]3OS[W23_$U-LUL,E*^8LEPW7*.9>[,1N
M:Z 2*4=8&N- I-<1@\L4FGYZBJG"O32?EES+N$JL(@B<>/P\\&N6*I"0OPR2
MC^+/,=Z>#BN"#ZD\HNK13J[UJ;<*81;Z24/3@&<)..U4&3F-22).YSMHM+X!
M:;5':H13PN:,5>8-C)Y"R0Q;/=Q"MD^ZV=2?Y C4T!(%)01N@??()HAZ+R-?
M&-J+=:T=UF>*M#GLN;Z5587\N "IM.#>._\D"08P(5TP$734@LNB'Y)RG&D4
M?S4WT^L)'(2)";O8TP[ZS,HCR!59AZ;5<$5RLL8
M*.'J,\SPR1V"_]U$\=ORM\^/:4"AC*)1H._$JP>);Z-/T&U9+?/!@"/]FRL2
MJMW^^A"[Y*S\7>8];TZ\:&QD:LGIU\.D3&I?TP"#[&0CIN#J+@F0MVIQU8Y3Y2Y7 ?7-R'L%\@/BA>NP6*->;V\(G1&;7W=7W>SM;P*/6;[*[H4(8Z'M2NU-\_&>81B)N_SE\W>0-',T1PN[7ILD)'SZ]?!SD,,Q
MPF?]_[\7A2^X8:L=/@W((:RI0=-(77A,LE'P% *C7F'4M^_>#\,_IJ=8<'[I
M_7^\@;<8,U&G],0N7+ID1J%V(&19<.\WK9M:D];<+]EJ*H-RB%^$IWO5O#7.;([:R^AD>9+F"\\D;%C%3SX_,XZ*I]M*G6!
MU5BGY9P"A;N1RPB3X>G2)ES SM0U,B$.D3 T/,G=]RK8C$2WZ,')M#UWYI#B
M:'T( "!Q[TXG&5E'>X*91<<9-.$<)I!*_$!GUD2/Z_7G_]+7A1&G#.;SJZ.^
M>Q D').PC4Z/;)_"5(>(0//PG>^$L_$=6Y) DKB7OXBQD_X%>)YEUQ0C>PF^
M^6"]!:=?FG?-2'AI(IY4NEMQ\L:ZKD%R,Y6AKUUN*NQG/<0[1'H:9PGV/=25G\,+V\? _,D2-N7R7A1X5^'
MY?XZ3NB!W$%LC/"F&G%1Z7=ZD]8 3!@/.'Q!()$P_?[V7::!*87/'H_[DI7$
M )Z+;O_[M-C_0&KLWX__(GDAX '4$['@7A$P5B_)L&;$*0Q3(]?__ G8#XR6
M@*J]N<)!$D;69_>I]\<'1" EOOYWCT;N2B#,S?&64;Q!M4'&Q(///S<$])'@
MO!+"&PON.3D0ZXGMX'X?_#E?/]GM:!E[)#%6']SHGH9]*T:N(#\^^:,Q@VC!P5H;3'IQH(0A7AER%3PIS.<_(%['
MF/\./2@F7>K:R*FE,:4I>43171@05P)CM&'(71YI%,04L70F?I=/=Y'3B?P948< @178H[U:1>I^..6CN$*\81GC >[N0
M\E';W7*44<.R.P(*+C.17ZVC.E.D7^#D4>KJ(V769Z*GCO(=#P>MXIMBLN!]
M9=.EVZV3J+.(9ICG>GW")XZ\Y[QUE]TG%MR:?N&,N2[2@CM^Z:E@!=CY7X!0
M!.]@+J/EMC)65E^T3FBXJB29FV6Y75[7 AJ5B\A1WL./+M+V+1@BG
MD(LGL09YB'0PBM-0Y_YPF6QHX 6*SL^_: T1*4^YUX8$'&RHP>Q C7DK6I"<
MDH*I*.=0:[+F'TPVAF^@O !>=4#_.?3YT)4B:5Z:7"[)MS[K[@(HOMM4\N&UY>X8A?(["CFOUF+%)0EO\ JF0P^#N2/E@Y(/G"S5J<^?6!N)0;2PTHE
M/57]Z0OR?0G]8'WUN,A?Q4HG9!.=^#78;];=$.HKR\F_/N.L@,\[!+J8).X>
M:UDF;<=)_JP3LO%5#M_Z+$VW;[_Z:'Y-]L._C7T"YNP##J&G++@)(^-J9>+U
M#\Z0.>23R2CK;.#_Q7X8^\OCCRF03ZT;5\=NO+YD'[?+X,V&:YF*/K.\#ZWO
M2D+QUN<8V;
M576B)N'<+8UH2R>2EB+GB\JLLQ3"UY(S! )]O;K37W//V8_0/D0FKE5%MO'Y
MW:> L5G%5XU"TZGLVQ+PB?71(O.+3>FM'E<.@+.P<$258-WZ^AF_"'&)ZD]R
MB@A1+\J\.UT(G$M*Q^Y"[/F0UWJW=5A)ICSH8OP,NR+-'+=#_ZN],P]KZMKW
M_K9JJ:4:1VA!2)W .L4!12&PM511*<89!26UJ$QB#D>1 "';BHJ"DBI5*@AQ
M8A"$B( H4RI3M!2B! B#$),(&$),PI#L9._LW)6>\]Q[SWGN>9[W?9_[Q_O'
M^0,),=E[[;5^P^>[U]J_Y<*XPG9,W4=SM>QM6&ZMC7Z;;AFC]?P>_"4L3C"V^J6AL-ROEN[X;9JG/7I!&B?XF3W4,J+&ENXS0R]\
MU5\I#6-KA[*^O[(GN.4ZDG]M45G6%$0HWSBC=>PHQ[%3R(,#8]FS=5?EAOM=RW/.K]:6//==#V^1K '5[YBA6HKP<"?51W/J#=#,UBNP3K$<$KTD5].R?FS
M?$,(7[N*G"AM@&(K$AGC%#-DN2,/\_AA!K5M7$UFU5-^R$4Y<7BM*H!@/3HM-4.;R(;/]8(Y((,TT'J$^]IN#FY#-]]YRSS9
M+2,OH=@Q2TSN]:= Y!!VI#[H(@UC%.R299.<[4HZMR(E.Z9@R-:84_PP,-RN
M\6[4@$1I=[Z/I<\".1HDL+-FR.Z_ K5+%4T6$=<8.+^#ND^6N=W7+U"\HHBA
M5J^ Q:;[1/QRM_AD+]#'.[+BIHT+8[(DEELDZ$OH+__Z<>3_
ME4>2=_D()L_T_@O<+D 1>+1GXHDM=M72+SZ/>$7G\M9A+"[4\).=:99_A]&Y$/!K#-%Q?T-T.+9K<9;LWP1%:[Q]PS
M0SD=9LAT(L4]ZF[VYL[H7#78YL'M03
M@4:DS,;5S\VWZ>V'-+>+"3$#I@)5%IE?H>G7=]-,'A_*NT/F!E_U?KIDSM$(
MS,YUQ Q%8<_C:>Q?!\5CV;W/H^^!=E2/7(D<%&+>L-QHW&D536Z@)*ULO,2=
MS5X\-X7%O]2WVB0D_-8(1$GR\7 EL*W5OC('OP/B(I9DCMM\DSP>%#S.M2SA>G BH%MAG+(IN)'(D&)!2NQP6/@TZ,7FKT-]T^B.3%RN')
M?6LVDB*2'GX2_(ICVGMFA/NX3H@;V?P[GUS/&'!B"5=[<$=%Q('X4P0[,^^+
MY&H'N7?2TLMLH3- 4]&89V_>A+8]TM5DDL"]SX?&"T,XG8H"N6.O,E"^,6Q"R0+"R?L=D105P[S9!M:2;.8 P2,LJJD:>JS="0W@4:^B;OS0WO;:X/N%5)6X6&/_?4SOM7N?R_?M+_
M2+ZJMHLR0P>!.,A5=6&O/@/Q,T!W&6Z+YQ+L1$0+AMR#SM"^S-*."T0+^N[U
M/K]&DOQL"*0;\+\BN[RV)O7 BAOUQ62#2@>C& ;4*+V&?0ML1%X++E\M+"2,I.9ZDMW$M83"TL2B1B%4?MQPV(F*1 V>FS0ZP4&_#=7'KY-YK ==@)>FK68GTC$CY-F*,M?
MD_$LO-JH*XI=^S1Q\%RWQPBY3YW2$2,T55O*:<9Y; D:E>A7<@RA\ZCLV\3I
MYI>5^JK0?C-4. KW<_JOG(9O0%O_P&IBJ!^)HUPE9M%DK1G;BRN1B>J1*@F%
M QN_&)4 P/BVR)1!+8\VM>T24-: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M YJT1I67+*$[SE-)*/_'8BQ*>$I1?=
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MDH*P%:EQ;WFMP&N8*TI_1V3+&-WKA/4:)CD0/4P^BT?:7L!#YM1*R-<"D#2-A9I,388$!F^6;HY0]F*.BVN'ZIO=<7WSS9LE7PRX+KE/G3(A"Y
M>/AFX$U7Q."LW)?>T2W-'$@!5$CAEA[:'$K566Y<M#(E5#VOS0A'KJEE:.K"#>+\#J;KX9UI& P]THAF2W4B0?BR6'=XM)&:H/A5M
M>\(W0TEM&]PZ7W(#?QK+5:-NW ]^;Y 5!JG\/3FA[]QIE_S%NIO<^^'I48GX7KN:NWD<
M-#WL:;31F]R]3S/J7?ZC;\3<;P;>'FJ:^[,IZ[,_,:VGYJX9VGD??;.H,".@
M>>H?-DA0"KVOZU5XN$=BMQ7MB3_RTK+LXN?$7-X/I.H:IT#6YQJ;YY@SMBOL3SI#RK5&)8 :^2>N=/)67-,R*L!3X%]8A8>B%4&!RO9:R"J\)L0FDK96%
M2XEOC7!VW+J[FG+=9JWS%5@*:T]F2]T94PZQZ&Y?5%B!(V:C[B^F*X#^*:50
MR5+U>;Z&MYG(SK.?(:6CC]8R4LC=B GYG;OBR^.&>=?M;\W'EA6#UK[WRK6F
MC_''?"BHJ9%FN8EQ-]B%-W#RO2^K.B!65E6%0F'S=V1V%34^Y-L=P_
MP<_E31Q?(7C'&!:]ZW%G?"4!JDTM\[G,7N_?]"[BE&Q=FCQS&IG4%^*YJ$23
MF=O-EP68H3E^B8S23&?,>:?H,2Q:MO0/@B1AOWR*3(:/,[Y@A;X9B_=I"%PO
M+OI1._ \M[LW .7\AF@CP;B&H!ERI!P).1@2R[D0L0R'S=#G9FB'Z)3I1@Q2
M@(D'U9TGQ.PF#\^O'F!P9B3#UB<91L N#"(@;M:13&
M,,@L^WMIJ CI-+<[H%&([6!.?.=1GF#9DJYFY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M)GMS">,R>1)RC#89=99%<1/&#P?)O%-.$+8'F.4O[ 8>:BF;6A\AIMOMW+%-8H*J6COMU.M=4ZM+W2>M%$3T$WJ3XU(ZBF(4//[P""SB& .YIKLML2;(
M:=21=KNY^N-\;&_-T4#OS$B.9?8\EX)9C;; D[)/E NOU= D/@12IVA>]#\N
M0/KO/U%LB..=(7"YQ&EAU_0[2#N!87(&0\-OJ]U@=^
MAMU"OM:?)8/%$9!P;!)I56]?3UGF%;-R29O9 92)_.S&W<7U$X/L U_62&9F>*NZSP
M9V&N'=R1Z:)GK=5+K61^YP@[IO=OL;V6<:'X::?=89$HMV)X_D,E'XR).E,_
M]U+$ZM-L42MP%9C(K+H/C$1RP/=$T^$+4>Y/JLN6UEI,DA;HT)O-!83WZX]" QCWD?
M^U18G^58T5X6$6[9M6%D+M$A:KF;&[S]482M%*Y-+@RL%>[N6#NIY)G&6_>'
MVP4NQX5M3:_J&=$1( >H\YSBL6AB(]$Q#Y$,?135NHMGU9I^L(<)[6MN/>L@[HK^\5[])QP+UD1. \CXS^=I@R[?Z]P8V>:'EIFB@Q?
M^-T]S*2_:ZYCQ@6 +[Y=B88'MBU*WBL:5RVQ)LT,(W??/+,_G7Z)!3"6PO\
MAX/DDK #C.]^=[_:)P=[7!A/NGO[MGW/KZ*:(1QQ)ISF'+M_X>AHU:]] W!?
M]]MMM%-\0D]L7=C,M+7CX]I -O4NB.$/6?6Y5&&=3#)3 6>/YK'49FU)?Z,2>KDE]
MOE8[,*1KF#T7J27GAQ!VVJE/4\]LPN;HKQ#B@B%R]T2R=F#'ZJ4RLM.7W4C)
MPK]/H1O*1
M'M3YG1_(]O?YNK?IC1G.EUV4UM;Q7@?+VD][6.VHTC@,%!<,9MSP&HS^0:D[HZ@WFD-S5S\,]%/:ITWF4*=5NPU17^XY.%P[AWMNDV
MJ -$RAV>\XLK,<0T^33/,,D,_>%J)6]((LNW]FH9L\L_F6>52=S0O; \-Z@L
MCE#5T,;"F2Q^2MES=B*G@/("\L$!QV?Q.Q2,S7DYQ*OMFW>VTGURD2>P:4*]D8BSGC9BA8(6!\
M][^YL]K2-YXS4/>Z/D_TUCO>)+2\/EUPOFJ5S#=XV$Z83(6ES7L:7;NG/I.U
M=HBVO3D1M=S+[9)EAU_=Q8RJDTOC=#D%U;" %S\?M%GTL')]J
M?Z!55E$L=HF[@N3$I^XOJ1G GK=Y7+I#*JW:A$UA,=[DM.^:UPHXGE;QK#+Y
MA5^:GS\O9=X;-?P4ELZNK*Q\<\([ 0^7%7XKV%;9MI9!0M<03A5THY6N,34[
MZ?=J4S+A'*KW2_<5)U59@63@R3TBCM-]_@7"IK"N"K&-/#%BH"YYBA7QL+KXA?_07-D!VN#*4?1R_(K(^^'O?U/OB:
M51W7X,CF%"C)(RN'*FB=O.)C\3**\;/0.H*^Y,MQX:5=S3&KF:,'1LNLK:_:
M[WV&G:D>5-IYJ,0]\)/Q\$I ;2IKX/&O+0\T7MY?D%HP=H?TB.6-.:(]OYDA
MAZI9FEF-?2LU'N67J4=D'N2Z-'_N1564K]_VU^RN;*6= *_I5-20J\6P+,M2
M8T5*)D2PYD;8O3H_D,O6A1TFZ[9I$SDYE@4+TO;<*R[D"4)>N-TD?X%J@C1^
M3VW-JI(VEXA80%[: (6G[6N0CH?YI8PB%2R=I0'.WG":5UOS?4U'54S^%L4C
MIG!GNW?/N_;YJ3O3]F8A*DMI6C1N;RDP7/8-CDG
M*?5P8*"OEM(PBY8O41AS2A:U5/,.T1Z&V9SA!Y6VKP!<\HPO>D:\:MLP?H=4
M7(3\(+Q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M&2FL74M\:[#@1JLW?,B%DZ\ERS[SO]BL32>TF#[.L1-4(=,Z&/6-7"[)1\6T-ZM0HXJC$\16;B,]Y0.1)9B?C'5&7- N0UVM@T]KEKN!=Q#)DD @ZXBR.&KE'#/
M:^8GHQM+- Z#G+6,KY#:@Y8"LC,#_E8^$/3/^62,@OFE+.WO9&V3Y9U0N^2Q
M]LF^/%WXK1+;LT^D&EG'$5_SBS0MO
M"L[O=*HN\LI!$X8!/E]3:)5N#Z8S><,L?W_T<7PEL23.P;)?A^8:$A8]>\)8
M2RJV"-]M2T)OHOM%@&<*=7;K4MS2HN*"@I:
MVY IOCB,NYL*HPL/A/(_N%W5)[MD4A7=T;H$]\W3
M>C[G,5-WBJL.1ID>RJY^Z_'C4"-6GT8^ACGDZLH[.<9@7=35WCZN&?JAH"5^
M?(Q^.6O>ZRCU5/0B@!V7.#-DI:3W]-ECP9<^E@4XN.YTI?? W3?3?=46N?1^
M@\[7BWBK-AY];24&?C5KL-YU.KIF>UO-"M115.^Y6'N2&_I(P+C/O/]2Q+95
MVM20JEK9"T(]R1A)E]C#+Z<>C,X=ZB.!8/6TP,1!3)SNJEPI8SA:ZR[W/D\7
M$)]V4)T(^[2#VLV)B2NHVX[P H2\$&):^[*Q^( _Z]JWE0+OG1<.6C'=#!GL
MHO8$(V#HDT8MWB167CPKK[7)UNA(9"?4Y^:XFXP"0X4*5
MSP[^CY9IVM-JP^1($^=UNZ]KX\U8WT=N)V\@V@7>HHAQFBHCP,-:D)YS8W)6
M,8 )Q]C"[.PTR\67NP%T(IMBH?'>4[K-Z+5[=9K%.<7O(OQVF^ZOY3[!732W
MHXW$#1D/W=Q05!SS /=N+\WH(8\MM]YMYRO1U8 NG^7KET&RK$&O;UHKX>&S
M]/+5?8<4%8RD&OM#0T\C0\7[*Q8)\$4VQO[!1/5RU@93(<\_=('7W^IJ11,S
M'9QI[55 $LX[[+?R^GC&]O1^SP5OF^_V'J*C?QV@.1Z.KZSM
MOM O[CDY3B,='C1]CNVN>='.+^$/@!0TB_7#/AWZD_1YU,+VX$19W1 _#&-5
M/$#F1-'*??.0NWU(6#P/7.I)$:\0+ET\\4.AC\Y:VUS$B=!1OD(]QJ_"@$.2
MFG9>5^YMK=H@Y2<:F\47QY")Z$O_0*[*N@?88=8\RXZ#?Y8M7&H"6#@SX1#2
MP.NB'$#]I Y! HH\DQ2H87-DM-G,=>)#EK)L#39DS0UF0ETT/8AH:BWE/K[J
M]0)1=*27XRFQ7-W^ MT:$TA5X=
M!.(TW-'>#'W?&N53R7^,A"#U%1CA9+<%]/NF %B%&+XXM6N;7)WH=U.OJRCB
M:%/W/>WP%)JJ@V.TJ7NS!/5I-LRJTHKV0KA?A^VHJ:QL<^&J'!''.XY?%U0&
M"XER\D@3AX:(>@JGWE [FXP5 .1&58$O3,\UD_?!LDY\HQSPMSP_!-V'4D[Y P!/S8;',-?<(D:#"KT+,IV;(J#!#["+P\:SG09P^]HS#P49Y
MKB)08M';PWU\1$JI3_0R0\N$]36]S]91@RRK6D1RK?/P'P'$UL$&*\O"=DWI
M*N$SS J0>\=9JA?XR*^^CG2^PK*0CM;8CF)OL/[M@6SV6(M!TTI-\!8M+3U$9D7)%![ADQ0\,%O8 KEIENP1^NL(#3
MU!5$F*'?W>CH=O[Q+P!?3JY9!CL@TN#NK%,@A"R!-/$\,T25@&\J6T^ 9OT5
MD?"(ZK@F9H;NA[3%W$G$$ELS].0N$!DOJ5GKY0ZA7,W/[#_X8]]Y+@8M*+-4
MDX:VBR<[%DU-^F%]%\RD&W\H^_)!!T#WFV
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M/:VPW PM_O#GMRUO+O_SS6S+FWD37^B0#C
M%.-\,V2#:!3=0,U.]F =Q%9=,T,+ V2_Z3FR0AZ#\5B.+Y[XVVID\!%=;^Q(
M\^1ZNL<\K39-F8L8E1_(Z'8S=-P3EC6Q#@';/.8/)+:*0ZO]M6^9Z5=[(J2\
M(9&LVU\8:SQU%R-*)[R#3_'IQO!PH7*+6LM,;VW&B]8B1;H_(3X-5(R%XU6 :-Z (L,?YDP*L-[^2,KX,9,;H@94@/W#JP!
MPN)\I6XO1XU/1>NM &+DEV;(X]1&LMM5>;NP"@1-;NU5GJDYD:C@MMT.P@GR%H&M$#X(%TOO<+ALN.@$Y8JE\+OM^V3CTJ'/\&.8O3?!UT6ATI6_O0*P.6B9F/L!'LUJ7XV*=,L9XY*28,$FL8DN
M2*81NS@[WL9&;B0O>T/?[RUG=%[T=#*E(R&?OA1^!/2WE-YO2A1G^R<+Z(^+
MV$A7@NX\PE.1PD$TG<3F[RB=,+*_XTAC_&5@9%RBS/Z@]P;] C/T"#&VCP^S
MW4P)LTS1PV78%D\2_L3T(.*'P;E -9+PK-ZP8^A/&$0QJKN\=1R$CKX*/UF-
M?+ RZI4-$(N9U-P9W(-GL7]94AE?GXICU]]M=;$E/$6=1=%]PMB',1\
MNU^8H6?P23P6.TB_Q-?L Y\&)O'%G',4+1/B$M_XHHS:\L4''0@V3-CETBW7I3'IEX3K3OOP\;O,"@/@H[P%Z$O'"=G7 *LV>W
M._(K306J'SQOFZ$&D*G$[_5W2)?@=W$PSS!8O?XA08RJ3*M:EGYDH <1S?>B
MVT2#&2JS1$=:=ZL(*)A;?J,/[Z.W0$?]OF>4:*"7!0WFIF'^_E@LZF=9M46JWWSU.9X:R#IHA^'L[K 5.(FN^GX.9H6)8%6HI>A3^(-)"+ZM:(EZ<([?!#Q5?+B)M01I63SQW>$Z(MT,28II$J*>JQ^H,8 !OPM.^DR%32?$
MT]:8(>_X<"/2L)33\@M.,T/G#E'P3HDJ4IBK2LP!S=U%!Z#\B=H,_4C#1K>8
M(1U0QORU>@&^G(8N*C=]*53%@)8D9INAT6^\_Z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MZ>>"" RMK"\O(.?TP.2T@\D=+%??2%#?A2>$M4<(+.M1RXCT^#CZ@GX)M1@
MVT"Z0)^&A/AZO2 F$B\KQ57.,N$Y^6Z-OH[K5_28X9D)2+X27'P$4!!
MJ>DC^\$%11&_W_2<988N9FM)"11/,FL2D'F#W%+E$+.D-3^LFJ5[<
MQW>^(>QQCU9+B1_L3(:NE[3;<5XKZT@!:1H(P I_7B=?%MF2;4K=2!:N854Z
M--9?7YJMR^ST(VSI5VL@25=/3K&&+$NL8WPJ&2)/':=UKT:^9.U]@V_+[@MDEF\RW:5N
MEM,^5_"M
M!$6=1G71VL$&SB1@E&D:2R51Q_!TM-#&/N09;NEV[XX8.@#+P_J:!OH+J5M]$?4WP#2)^@Z!L)8XY+$SY;O3[P.",
M<$XI(BSR0(8=6FM:VZJ6:I+(YRN<55-B-)6_62;(!+;^GR;<06DRIVJMUSYT
MNM$V_P15(Z.9P]1W,\8]%%CC2OL#]Q9]M\\:.H@#J9+\6[JK*LO30SG'"R\>MS
MP.@ZY,):TG#SFGWM+!"]YEUU.DN]_J_NQ-W0G3'%1H^KMVV&EF16N\7NZ?9^
M93#MB$.X FW>ASN31^E$+&D4;M),X"N?JE^ZB8;U"@(C;#H' VFMBL5WIK "F5Q",1N2S!#EI8[.&Y92]%V>NM/JXF8MEK'69#^2TP)P%T3SNW?W<, !T/,DZLG3-[ @4$PU'+P@^Y]W^^VK5K
MXTS#WS_CDA7,,F09!%(T2MEW_][9A;T]']E?F:$OV'13E.4Z80,>MF3Q)_2U
M )GN@Q3=>.T!B\MM&RPWX(A=2A*T[YKVJD&0"\+LYZG-B %MU&.44Z=1BJL=@\LMI29 UTVA"AE_/@U]2V6I/)#OMGC"@8]*4>L%]]C38P]R
M7O8=.N7)?A_(2.-*FL5PFF'LSI2T@9:/D5?.C(\UK-XLE+\TZLV0)]$^EIB(
M'*-?[EOZ9J!C+$YH92DC_Z&C>]P,]:Q5YCE;:MT#8?84EHN&807_ S43WD&T
M/Z)]00@]-VB]+T14!62'LZVPR8UIII(5W!@9O*#^C#^BR^Z[%AJ5KX"/$*_?
MG(BR5](,EUY;7=CR#-\ !TH&>_HNV\*M.?ZR\/WCMA/C7'A[ABH!X'E:"4@G.S/XV.>[MBK;
MPK=#,Y![@FRE> _ *B"<9U96EMS-]/P=,U' 7S_S<$;R>M6UZPI(>]8
M@QONNG%SQ^>,I;*;D)D@ZJP15UF=*L3=1%'JJ1Q2!J"0V3$VKFF.*UVY76Z!
MJ=$Z\IA2/1; 0],BT;V[B#^0&4C)N&I_!%V*KW.T??R,WW%RD9;QT:4GSB?
MO:'^GE7X?)?X(W7+@0?*
MP0!@1\#:Z"G>'9D;I^[KD11^;KWNQ54PI&UQB!&+=]]3$%"GO-]<%*+KF^>[
M:+27PD@]K:/L,UQQ4
M^I>3B@F] N11,1$U]GTL:?B:2VQ#NQEJ-$-S0XR%M\MM_?RICK9EV-1,0?>C
M1ZKEI[FJ K+*^JT$9(F5?/1&Y/[[(*0-_Z7;,U^AYM9]^A@X C[Y'+3.>/#OGW2W1,\MCGZV5G/4\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M$E#/5X_;__TX$U2P-1)*Z79]=YA[Z;3D'-G1M^NPL*<,<MW_3(#$Z#.B5P>:F6D43=)^-W.\OBL_-*RK3>R=/*XDW<>PD_Y0UUG\D4[WM"
MB(>7OO< N(](AES-4+490O(F2BC\,$[WJ;UO6%;2:A]=(OH"N8,OK2BO0$_=
M?\MLVC-")9\*#M>YTYX@0I4N,RC&Q'TP9'?-[>F-;.2E(^C#6OZM5'NM;4/6G,0Z8G$;E7$_ $4.5A2?$S;:-13V9_95BS"8<%KG&AW+YG$,GROH
M(U\J#SG^4Q<-I9'GUJPYS"P_H.T?K%?;A 4NUZY(R_W0MT"\UKHR0#&N(H,$
M\KU&EQ9MV0V1&?N[P/)LR#4:330F1+-CB)=*8<:0W<6"@C"_]+[B_"&[OO(\
MG\BH_/#T"^UMQJ+BO,!@56Q.872<*5L'@MY* AX4$H!9NXX_!.X31P"BY9O4
MF&GCM'L9?[[8\K<60FY))_^QK=#0-Y5_?\GXVS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MM1CKD/MA1KO48'[VIT*?13U02KTH!A=P8R?EG;X=GU"QG)LH2=21='^>=:18Q
MXUG1?(M&(&GZM\T!.2NH)6UUY4.?KYK5PRS<_I@3PYC,*<_$$#"0$Y9M_,#N/6^^O91(XMSH-
M'M4:!B5C[[)V_Z-A^ORG&LPN-Q3-LU1,'A5S1H5M)N]%4-2I@![UM_=<1[5K;+A5@N?.P7@&CZ8OO3!P&'#I:2\;&N+@O.;@<0.IT0 M*K$L=/P,4;MA%/28@CSX..:1,+D;(9F>?_[E/\^Y;]/^?_[*:=\79[0DJA?A12"DX4.(5TZ
M\HW9NS:2S5W_ 5!+ P04 " 7BME:* \&Z:-& 0!D90$ #0 &EM86=E
M7S P-RYJ<&>DNGM83'L8]SWI,"HUTHE.PPXA-:A$I84V(0P[=%*#-JED-DJ#
M:59)34D&;=I.C20A&>FTI5K55&,[[*+#U*3FM$F:T5ID6LR:-<_RO,_UO/^\
M?SS7^TS77,U<,]>:WWW_[OM[?[YK+7V_7D::OFG]QO4D P,#TA[BCZ0?) 7]
M?/=_]?AYD/_;8QCHFTE64PT"INPT-/B%-,7*P-#*0-]&HI)(!L;_SQ=(_^MA
M,,70R-B$/-74S)SX0LUTTA0#0\,I1H;&QD9&Q*=IQ.M_,L1FV49%XNGNJZM;+'][0T\UVO?T=.F9G;V,V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MASER?OC%"\FI9_?GRH(2DPZ+?3=O=)V[Z+_S?\^MJ>:.&-K+R M-I"H$?%6BGX_T_
MZD1,"J?93Y>=H2M\E! I:F9,CXA,Z!N>TYL.#"8IS*T>/(DEI[UU.K_AQ]9Q
MW)Q1.BJ%?].3)"$:?\1>2'<)@B'-*=3Z 5HOW-W%L44[8Q#>V28W-$$R'H[,
M?.:W?,S"OEE/ZE\>1X>OE.A)7KLJ6-XW3J=2_H7.\^$UM$%S&4/5J 58?,TA
MW6/.4KP+= #V0E;L5>A5K3_^^L?GBS*J&;:RB[WFSB?)*G&;,[G%978G-G=F
MC^H1MN:)L"W "T75A[PW R]4S@+(X8M]&33K=C:W1WQH']T,Q/5+*>=&B\
MGR<'6F_&=5QQ60 _?P/$03DNL]Z.-ZQ3.'LIG*\VX6^AANYO[8'44+DJ6QLC
MV]!RRTQ:RM:CB5XB .FP/5/JP>,M]DJ+ K*?OLL.M^QQ*2H"*%B7KXJDZ58 %H+#*%8H9W
M^WW3DSJVI(I^A+42AVMRTA4%G'B Q2('\N#A#Z]85:+C(&77/^S515.G?.[A
M36<8;=G\N/_IOX!QPSSM%%P:.8E9A\CXJA"%=,"P_1J0#QT T(6 4)H;>;?R
M :N[^5K=&=R#[=87Z(&*.@+=$=Z9#$@2X"$?MEMP,U:7F@@G\@7_'Y'&G.0'L#;H\WNF [27L8#A8=1]Q; ')G*74//M"%GRY
M\RS&?.C+93/VP\G]1Q3/*)9HV1:WTT=9MZ1!8[F@3"!]?(;Q9&N>-@YHMUB'
M4UB\CC#^-&]G3\"4=5NI."Q 3OZ+/!0$6D=@WGXL\7A 2FSJ4T?AV O-;+4/
MPE6O(0H509UEG?V%FDS=;2".:L&2M@&S.&0T;PUZ2H!9H$*X6\2W9$?(:$YH
MY)OKN:CUZ8OL=PJ?:DG$=L%;^8/CLOYJECM
MMK,S\X:@?+P?\+V';*6O^WT \Q 7@[7H2N@!2>1 +=>UJV*BU1^TU"1!:)@>-
M1O6DJK#69Z^90K(F#^4=D3OO>J$GM84Q9@7LC 7UI*G?"@<[+GF/3^UWV?G'
M@^:ES_>D+90QT(7+2Q%SQ8C*_&$D%@K!9:.-TNL.=D'Q8W/6H/X
M*@X\@\O7/FE$R+F8:_G8AFN\+%4 M7QIMH^'3-WX]$[UT&MD0
ML7:Z*X&F>+\#F(]MK&"[ZXH#Y[! .:.UW(+:&EDQR<-"$&I;T>Q&.%^0"M,\6JFM? [NH&A]JB]>H%$9;VFHWH^.:6(37 IEA
M5KH+G #,"?VG&!5&PAWE#[ 9/M;MH]<8"KYQ.\7O_+4D^1>^/-G/MSE3^]FHC0A_HQ$V#M.O9 -&>]R/B8SS>S&&@\_FJ;J1<(5+7:;TK_^YV&![1
MI*.#I6F7QH7D37G1?EF%F'O%44)*3 KU))NW=P]WS/V>L8W2(SC+AR.I_0R9
MN .:P;9"P+.XZ[L8-H M<8$[ZDZQ^N3;[@]I:OQ[/KN-,09IBN%&^)AFM>XVQQ=;V5O]C&'-#D!=E;R<
M0.L^P1Z\[^TZ/%\^ULC8V'/X4,M@>?@?E#^VRDKF6F%\UB1N>D(;1?SRB+I4
MZ_N)\61<;:K=C'GKRO6D>.IT]GJ8FA] UNZ,Q)QUA8( R0T!A] *)BWVYF'
M=&PNN9TSK5%/^HN+N?J5:03]*D"1- R5,24%,GY>"A]UHW4(!I3RI@S?G(#$
M$UIW%E=.RV1[I@@ =7VC0'A1WNBVV65.7_8US\D5->28'LHKSM%4]AW#[X.Z
M0DA6HR?5QD"$2E7J!)S%[$2F28*>5$<1\NS8LV%^"TW%),=?VWI1X:7=&A5/
MEF6),=<]ZL8GB=]]+KT^=\FFTC^,>@1O9L#A%G&;B6UCLFB:OXC_68F1=QL1
M?@>U.JZ=DBXA+K&VI@Z$P#15;:\V\Q6';=OS11L?/X
MH->,#1+0CT,EAM OT"$(C:>A\[:6*FC9/Q[EP[]T:O[0\;GJ?XI;'GZD[NW"
MO? 7FJ)YS.SCP[-K\&'\;9\@2U-^D)ADW&!-A- Z_U9=HHP^$(R;%6H!O!DD
M-;F@07)>NY023%9_UVYF;]8]"G3&3!">L-%:M'W_-JL?XVZ.2M,T9=-M=\^#-7=O-ZU#JPBI2"]4,#H8J-LA/>G)@;J'*"BC=4@E6A'5J&DE6J(8
M:7T&D0=12*XG93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M]W&\ST$L>$+!=,8^C,7;"@SP!Q)/MM=Y)G[)4Y1AUIFXV2RE '5[
MQFFKTY,HS&_CTXG"] <2^28$._P9$%*,OFP=MLS4E.BN8BL%,6,N3EW)?"OP
M52$2VG)MGKQ;O*TG^?5BY\BW0J8F(N"'H)7?[Z[)0%_+&>@"<=LHM%]PGF_<
M-(=]4,?S 0<*Y.0<()$N8>)VT@Y^;O?P8$PBM3]F,?RM4,//Q);*Z99C3[LQ
MMWN? N?W^FS7"/_U(W'$8,M2X-!&/8E)Z1^3VZO)%1\="KD-L0J+11: Z"1[
MV$;5T;MHETR?0[:.!-&>3C9N7(
M@TGM^[C3U%/H7/$VAR@PP3?@]P(M(<)&(#V_B*K+ ./&LZ!JBDJGI XH%<$M%).#
M>A*YAF*!=N_L2HG_]D:VQ;-SOKH]Y"_3&_N/GM.A5[SY!ZA?]8BED%
MR2F\P"4^M7GQZHEUMF&1=[Z/+
M\GS6P2EM8^ AZ@ ^)_B3Y91S2\A]U"F K!8D4W%31.N*BZ&:Y5M?& 6(92@1<"<1ZBR0VK-/E82$Q/O4"H5THP^EOR&6$QF"5Y?[-FE)VUKWK)@
MP.MH[".FYC&A;:-LI(Z5^L^F A:-Z3* +M^;#XSV\47II]K\!6P
MEZ)5#XMT#PC\G68UR_6''W3Y(\&:?S04XBK[ JD7<(*W='%-G@P@-J+KO"114AP*U]-
MX 14B_G_6Y3\Y82AI&DJFDFD?4Q7#Q[L'$C%S5A>;AQ+-:VP%F(M:
M*0._LOAKGR)V5^6\3,EGWJGX1^A(VZY@K2%N!^2H/&B6R=@4SF\M5PU)G+^'
MP);?P0,40\Q,=PV?BWYZJ:3E<'[!W[A,N]Y&$/Q26$^2%?)\I.?PN75P;TD$
M*NT(DGMXF8ZK2G+2P8V Q):
M)%J3YML"28(Z)@&+0!<6% 27Y7[;*$=J2DN_]97+0;O1Y9%'Q-C21_&3?=PU
M?L?62_[J/=\EJ%Z";481K1M'@GNA[5H'HAO7%&K"=?>3KF_678C2'$!%6C^V
M!8K(>5R@AMQ*MT:9NYX$VB#G"Q3R"J()_!5,,_1%AV0MGWYN_2LJO)DI\5V'6A!Y['W;L%#K09=M26R5PJ&)H*1;.=[Z'?>68/OXM3UZB_-0CE-O>-#_0$1\4^\Q83-"Z'>N4L"2TXR'EU=:UV2,?I3Q(]I11%8N_
MIM:&M>M)F4W.:/%#+$QW$0.("96#FQ.A,)14$MKA$=0V\ 1-4T3'">OZJ)+E
M#$L?YS]&=B)9DPZ[+N^_EW!GPM@K,NL]$32*B\+#=P"NO?#R\5XKP)IHE%["XX50A8)9#XQFC45L@^]0>]S6)#
M;:&BT?WF[$MMENZ:+-UI0K,[M?;A_*WR )52;?Y>N*[QWY-WBF@(INU_IR!J0VF!N1
M.2MP%N=%C#\:EJ(UP?83J(!T;D7B\AH<'TCCBTQA;LLSFL$HU5HM6,S\FEJ,
M\J)JC>+[\5X]Z=>8E38SJ:77]"3,WEHS ZYK3R0&G5]3!7)^E?T&5,"$?2-1
M@I[-0D0BS9-A+V>QGK3/PB"EHZFAIM+U5NP[R^/@_D[)H-*W
MG8XNHF V81H&DETGUQ); %8),J$#0\?D\R_OE[?L+8_8S=X(-PY7*=PKHMI/
MB'(+MS5&!97F2Q%W\^K]M9G89TXWE3!XMJM[OU(X*8W9#N ,6%J%OC[_2;#CU(;DTJYEI')-_*.3A7&M>E)5MRLI#]O!K=%
M'KC_8-1? "D.>>G^!-G0[Y0!2%DH)*S"(BYF VK.(/ST<6_J&M';?/#]U\C6*;X&((.W^XJ'@96FHN59L[2BVET6#<)ZDD_+=#K:/DBZNI5+!E
M/;%G9: C9DATNZ?N&BCC2Z=PYA I-*H&[3[:$W/1MFENB';IF)[DY/-,.CW1
MKX@7)ZMPEW^^\+JL/^;@^A=$1[=&*'0!-]U:,]621X^/W T; &> LK\)>T07
MG)':-83"W':^%<:\YR8$[>/U)$O.(O:A+HX5.MD&5HT(J=3A)P-U61@38:Q[
MXT.=>K!08U\7I(WRXVMB+C'M-Z7MN+ M#DO376_R106X^3HMA=/MX@ [X\4P
M5!
M6"FZD-$"#-AKB+XZ'8+2-6YO\*6L, T?A9!@!DQ57Z6V\4SZV>[='"I[+Q+(
M*Q]FE2A2SXQ3L'DC';BY75WPQNY_4[;L&(@?>323Q%%SWE+A<$:_0,- 1=1F
MBA.+JP!R Q>_8[DVZTDSJFE3V4O0> 4_1XPO@[GGO_D_R
MR%J;&K9/&?)V OQKZ5Q; NF-\W7E@4OQYP"\%MMB<6)2]/.MGZK[2M:>D;[U.5#S[:]U,3M28/@EP]D[M''V=^B5/QM<;L@^C/
MW8R""]N24ELI"O T9 ;)"D$3:'\%69FO'B[TEHRW44T^7=N$\D)J:N:BF>KZ
MK,LW"9G#-J\'GCS4N8_R44^J"D$*-&5$H@YAQU$J;-XLIEHUN;%:MMSM"W$V4]%1.@"XL9UN=9%R.-;P@?B-AMMZ,G=(=1W =9.N55OJN&T+?3YSDO
MP)I4E3D\KDG7E4&_2P==Y9"Z'3$/1D_<8U'E9.$@)'=\MW>O[OLT!RT8)C$V)O7?:ZT#_>"3@ ,J>\*L!82>Z:'$3]8T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M]:K_IKC'X::)VF2\AV]+X,V@O<9)5X:!L)M)CU)#2F'D@XWD!7.3@D.E\)9 OK<3Y9AH2\IM>5>I%OLG0_!%@",!P<[E778
M#'([4"=2E1YYR'*5NZEZ$;Y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MX)KN@>LF-L^.1FQ[OIH\1E&U$(5%F 8P$M0A>SBQ:B491V(/LD("GM$:T%.QQ])F-D.5B6(OSU5-N&_>6HN6RR';1A6R+C6;@IQD ZSBU-E3.YD/7X
MA)ZD_+5#NU3IR>'^,=TDS&](9CVE_P+CUI*I:J
M7<2>@DQRV8Y(J.:FKL*#LX@5M@;M5# ,^%,C6+$RJ=!C^J?82'3G_9@!28+#
MHV*%!SW$(>:RAH+^^4U0&#!'ZT1LZE9\ 3JF,4;SD'$-2W<7VX[P-"FZ*F]*
MCK2ZDQ>0BDPVIT)F(V^@NI33/O2!0ADOVZ?3 @6$@5.U%KUWB\L3R)O?8CM+
MTWA:-ZU;*/YF%DD[*4_%[$8B=<75#'111\'O8GZ5BC#?ZWE*BT09KPVR8I/1
M/$6C>>NP&6QY]5BB@-6I:+K(\9:?4.:I3[Z/X,S,+/UT[>Y?O@=%.^8Z:*\H
M<3.I=BG;&*Y3J67,?#P $;31S@.SH/W@5+PKQK$.#8-IHKHZR'Y"J_;L&J8:
MH8Z_5O9\LZ!NZ[G3X'?ELDS]:YGF\)^BQ5/_P?Z&=!?UI*0A2SI*$S2[:FEH
M":,+2GH>.)L=J>-SEATL\H"?H/[M?EG2K(J E7(]B>NV(7$>]M(>5
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MG%!W91?A@[;?<1Q74U3KWQR&ZAIV@OMO)KD."."<^P4[6[,!0&$\8L#UI5&LQ@=D=S,!O<[B6'U)E<5[6XAE1!B-FI1
M=F69T3M2F'_/!6G0C\L(3:W4!K+"E-SFSH$QAK@FBI(#53-:F3;8(?24S0];
ML<:5F(#'"^/+TM]1^D51J,0HJAJ&8&F>.%9LKJ>,GT#*D=%ELR-!01_1&D$-%G5+M_#^R-3WYZ
MX.VDK>'[_WBO(4/V?%TC88^D@R.:*;K20%>\[22_F4J0W13H=^9YJJ&/VE=!
M.1^P\$%"'6N73P^17GT2;NF=>
MXFS0%4%[(72!;RLH\97YE*DJM"LXA* ]OMG)Q0-NQFG.=7D2'A8R9Q.&Y/2Q
M3C@CA5&#\G";R3,-VW4EB*$VE>A4S\*R>&4(_L*7Y?K39=X!JIB8?6@S?SKN
M!;8$3S#SB,+DIG,L\?:RL+Z&A0\&,!JB3"C -BVK+]I3@)C>DK45QT_5LE4
M-R7SR(]\MH0)5_0EIZ_9#[+KB-^=)+HJ0,#>6,8Z2K5AQWP-B)*A 7%PX3;J
ME";7?)KR6Y;DGD-5Q'B:M$9]#5($JS*T?PRP
M\G!S'>P6I/L+HRMXYKC4Q8'0-3TI'73P)JPFRQ>?GI8:7@4[EV5/\+E^CRZS
MZ#F+&YCW=(_&J1( 6:0G!8FZ/[[VTCCJ;A=HLHF%F:%/F)E?@N24 8HL-1];
MB2B^2'=TK8.$@$T,F_9F(FV^&$@"DCP>148OP%];]).BSI)T1G =9N>HF8'0
M5.5*RJ ->V-?@Q?\3#YRGM[::7^0LQAFYE;SMO&]KN*$K63[WVG5?JN
M:"$L;'$-FB9,0>-_75
M)K'&9/;JTS]26]5K7XH;PRB=9:+^A@G%GN%WVYB#! 4X//
MJJ#_PA&H_QCQYF[QO1%\?BT;B;F_5SN5\U8Z$S<"6[9SYL9+G]BK#>"7BCHU
M6>NZ1NN/S0>J1]2^I82+^8Z<5+R5#8/[657"IST-5%FCN5"L)WU9B*:S"K51
M.^9K:[>0.!#;Y>>TP5L9L_"E6 #J+P-GL#<[C'0 Y 3SYR%\+ML
MX0P&OQW<)9Z@9A=YBI.3_.E(8.-=\RC(:VUWG5?"WFS3.<%7?\H]X>0?5A$O
M?FURQ?MB*+V8\4.6YXB]&3>H=5ESOSL745F65N
M!,)+HO6D1%:00TSYG5'&'K=-KBMAIA5.E$_U?C%A,&32U\$;4/_%?J#J9!Q/
MM@+>!9Z0.0%SG#%:MKLM3C6==OM4S\]/J!U_"]UBMIG8YVVQ?;?Q_\F0Q1=+STFG >C,L#M+T6]Y(7"H05CPTN1N5?\+F-^AV],K?;=FYR5J#!89+J@WWC]R=AWY8B>A)OW
M2)%[X.#C"2I*6A31#"D>.H_.Y:G/$K55JVC0+[[Y&4.5T
M-I/6WV!5C J$1=ZP%7+^EKW;9OA]9[XWS3)\S"_[6,VV*P%[+AUA'& Q-+=0
M0$F36"OH*H%<8+U[F)V ;I%)S5E?147V!6O%2:H)MFSQVW9Q\8%JP04@2'@O('J5228\ &9?_Q#G[.B \ <5'Y?QTK.BV[:SHY#F(
M+VZW/L HA8FN\V![Z4FVQJ63FEF]V>5U9H&?JRZ5N;Q6\GE C0Y2%Q**O1N-
ME3%YD52AP)F]\N=E-T[G\&PT_@%&[R-X1\JE3N-XLRZ)M6X[D.CAB@J^2NL^
MM%YWN/93S.R>ZR$.3W\CD2X8Z'[;SA#1,.MRS5UT@/#+=V!Z*R2):@/@;3PC
M+!J]K W -B#4,TT6>%>1+VPO(N;@F.8&(DK': 39S1MI8V;R[0*6>:N#A%3)
M6K$#G8NMO)M09#N[Z,R'IH1,3:'N<0%N6A-'++B2^?.2QP'=;5K@\L&KX.\K
M?5:1V"1NZXB"A\T&X=?VX+3 %HV6Y@02*6EK;UB[ 0ESS;RTFCP9A5%AZBAC
M%?X6J YKI0^$R$;RFE:Q3R!T;+;4/(!BD24^&[#AD,^6K19^YB^?A;B'E"26
MN#*^IJ4FQK9J9AFY@#=I1N_P'FIM&&9;IGF),H]IH_ WD$F@"?X3/\']#(G[
M9M0>[MS=O;BX >'FLIWC%*O"Y.<%#X8^NFU[ M\MN>=J=JK\W%
M[TNUZUE2):@FY,4H6U>K)S&A\]1:<=MUIB.K0).'!+M$Y.QW]]@/@24G+G"IV1S?W(Q[RPN9/E0U%]YME9ZTIRD_CTD *)-0_,V(@QN
M,M7V8V$\>)O%#WZ,S"\X,8VE/7#Q861D@F1+ERAV;VK"":=LIY,IMM@.C*F[
M!27RS_-KR6V\@>O-,2L(KSH+GM1LT.4&DEB=MB0CS$.37"]JTXQ:?7+S0%(V"#92R0&&90T0UM,+HAJ;('R4&F[&Y[D[3 K#%
M#C=@_=QWL4J$N&E*=47@018Q=9..:3@(-3,@B)Q+3[^XJU-TTD)=J"D[8X&7
M[JE-5?[6W9%\<^N7;\E_K#9*!W_?$?:!J2Y!S(EA1[ATHS;T/6(M'VY4T/,
M&S .&.@,?P9WGL../&L+7(0P<@)\B_/6(<%G)<]G-S6.:-?O%!Y+JLFSA JE
ME3$%"LJ92:B2JG94=J*+P\X%G'C$Z0$- ]8HH5PJ"5\Q%F-!.,[ I:S37ULR
M1==J(3AXTQLRER)\*NIDJDFK-=
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M+9"D?71W\-CIU:[? ]&+VOU@RWKH -UTY/4L40/3MJ9IT]*F"GTVU:O(GJAM JG9452&-@G8>NG:\86/9 *M
MM-G9_5V3+9MZ7>:+V6LUL]$#0(*>E O41-<(5%Y(=WCWM\YS+K]T8;&(8M'S5#%;V]CY%=^7NRM4'(?"FZ(9FGMO1^/1^.7_"J-#P=W 3-TI,2@-/4*>PT
MV%K.;:?-+,O&$K6;6)]'Y**6"J?1^M(QUK,.NUV984^[^CZ]6'Z^<_:
M^?2@%^+N%.P%V')JL> ;7<+ IW:7C$)V@#PX&BW4_(,$MIN/MJ?='+2IXJK%5Q[8_J?>S+ OA>UL[.X@#3(6)EAS!OU2VZ2HNPBSKI)1
MU)4(I-"-J":U*S$WW4/@@. MQ>C9EQOKNR?XE$^;MO[IJ5JS>NMJLF;Q_[J[< 12IQ#;OT27#^RE6;%\6R%B
M9]M#!-R3HO/>B3=/M>;:9[+C%3F>$Z?MY^ZWXFLXS?RZX)_78]S4W=J5A"9UMO'L/H)5(E6W=CHKJ(. E,+, '\P);:8
M5:9YA);?G(UZM=<6'Q^S+S+;XAH&10>D>[\BO6[,H_:#Z,(K%V_'<)JIM9[%
M8.EH6.%Q:E5P!Z52^LEO2P76!R+KQL@Z&_6[1O!]\[DB/WCURO$!&FY6JIW.
M>><2T-?DC+_2DV9ZM_9]_O8.*N;(U (.QC58 =C0(E/)=3;Z!#,;+9#:,(AIN9N@4S00LN1
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MA'*.<BL"=X/-#[CO?"C8&C/Z]AS*6V":M'FD9GXIW\2W ]3IZ.TT
M0!GM?&X[<1-<*#4$$LMQS!0U;58X!&P74-_;!&LEAPA;^N%JLY?[7'ZLAI[!7=V4 8?=>*F&^%NW"Q&
M3ZH3J>U!A-&L)]5>AH31YO*;_];<>@V_#$>9)[1KHE%@5U= 1-RI8B)(M'MW
MSZ'#WQ&3$AYZ.2+?53OWZX,N\F3;_^JE5\-S=&7X5#11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M&X7K4&/D-LZT1(DJ:G5&HMHB;Y[GW6$Q5-*!=D&^3E.1&*M?IPX3M*0O::46+T+6T_Z>G'5;!Z(EJF^BRK)MFBN-G09[7^>/->.!#(P.[H,
M^OSC" %CH)#3Z/_M%F7M]R'+$YVEB>(O%0@Y1'<;BN]$%Z6JB9H:!6H9:BO85\85 OU\#8B6RZ46&%5<
MD>R?!S@.HPR=]8ZW*8FO*;]!M1_(T <3"UV).?8$+V:S>%%!RG9 %,+MI.;8!-7W ,BM:MT:LQA9T9U,F<82;*^LML<7]UBF;-D1 7M=6@T\K7='W]>C3XEP0YG]89J+
M:-@M+*S7FSZ3[:^KQ*D_SX^>"US&/H92Y)V21 70G+9G.(95ITE[AF;=EB;$
MD-YP -9)[48_3L&]!+\X36UY:;3,Z4:WGG2 :*P291,?3L3- &T RUHI(+QB
M *<_9BHZ2\[+"31$"M0U05']T\,>2^Z6U-5"- <$;NW8O/27B;]#- =-ZQ\12< ^6SJ&H+[5IL@>Y*
MDPV:IW3KX%L'R2DD]%!_>'3"6LEX:&-#;TW%;]W!7M)UJXT;NW?3K4_YWE"5RCH/,*U;8(0SZI?@J+-&S=739A-(R-T)T(71G<2IW.
M^"B="L3S[%!SY60SC^<@RE1OK2QG1Z KD5CA3(1\^B'O1PS1Y5._=P-/:K;0
MR-KP\^Z?*>AB6R5:_C]/7?JPK?ILZ'")@JSN+$.%'2>) D3DY9\ ,\SY(:N@
MQ2]:]H^>M+;'YUDQV O^1^GZ8X'A1&<+G[ /JB$E)(D542O%V4UN\=VMN#9?R;-A+^Y=G++*G?$$%N4F#WKLZ]Y150\]=CA<-;/[6]+2:T+ZO(E'8$WV
MVI%*U$L;BMGHBMFA2%VS="I&F"Y3>BX0Q\MAP.6!2R)TF:&5A:U%OG:WX7@P
ML;'2SO?5\Y.C Z3,&WN/8=F
M<4A\>M73O;$(7?YZ)#._K*/S3'UC&=9([.DZ65[(,YW;$2?YT8TD#?"8@=E<
M;PXDZ:X LGIB2%"-U]P?Z&G=6!3,;_WQ<+W%+D8. 6U.$0=Q4_B/:J(?
MM!]5B5%-_)\S%MB?))ZIB_H>>84;X7?[#BNQG<M93;CL\38?H6:&0)WGL%H)=*QX;F(B2"%N??.QY/++QZM_]BYYX[5G-C_\25^DO^X4&1!T1CJ[A+R>%WJ-!<%M)O9M'J4$* 2#4AL>2:V
M Q7!SQ@P(.2?Y2Q'QY4&"KH9>]W;AG4GM_(KI/'#*Y[5/'YN:+CAL5-&@8X#
MML1"\80;Q%]28;KT?. *I%"8".;5QYV?T &RZ+IT'XLPK9M0\KD$.?V1Y=>)
MSWC-?N3-- O/CQC_EO^KTB'._\2\U4L"[+7[":7S F0/8+1,$Y&W'1:(TGRC
MNP#Y4F86P?>XXQCN6(GFRAW=:YX0Q#XI'T >YM]ZSQ4,50='QH#PV=QV^5GJ,Z<1T4L/:X"[Z69R&BH77EC]]D!!VTB2_
M[/B$AT"_ XZL0=QTJ?8HW@F1P:0QBV#- U3]
MD.V#,N%8W%2IA+B@;8 'I9E/>%%2X,*Q[^CU6V";*KX^Z_(X5\!ZV[!&X4'?
MT1NP\\X '(QM0G3!1'@'/Q"=P:7CP[RC\_Y.Q_^-6?&5%+77%SMQ#KSC^\-X
M8.;L!7-)*^<6I%-\8 %F+\1-F)B*8<
M^M.O,,>GO"7^;J2>E#B,SDD>]$E\F44]W$/KN/+W/N/\;* &;(;RI7:!
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M^&E\>E]*;HTZ;BU\^/JQ6)/2AX_-4J*W?IBH+4YE>2P]X'MU^>DUM6SY4D4)/I]9VGO/^[MK3L$K1B2[@J9>FW4)/#S.JP\YRN2C
M09$)/88KY,Q&2Y0BM5R;!K9L:)J)\C5JM$IKQ09TZM7^C80W0%>GY,*6I[V;B'L'?Y 8MHZO7\4A3)&JV!PGM2QN$S=-=";1DC2@APG#8\$RP)6A:6MQ:\?OV418#?[YBU2XGM9.3C#L&EHS.P'3 DW'NB))YJ75VQ:)SN-[4!L;W,'YPHT?TIVM2[L6_J"LD)
MNH1*9,<16ZG]>3MQ*U@YTC;. V<$ BQSS3:$T9+F)2>?Q;W'_&*>*K6K#$7\
M?GQN;W5C5)O=+C_FX+&TCH*;7@%I"PRUO\/BG*2 *'F%=7NDQ?/&-P$;;X\Z
MX)GW-II'M=P;_?'ZP7#$.UT!#CS\NC\EX<3LC#K#^X';RSEO +, ?^U:5K#F
M]UYLB^=U)$_$,>[CN+)H0OL^WUW;6&6M,0Z]BU4!0&N9'2SI?
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M$L\&-X7'UJ\=@^S#C-NAQO@YY(
MSP;.QIAHI8)YFC,# 0ARBJ=P_7Q;!?EUN&OV6/03M #6DX37LPOD?"L4C#@
M?P^Q-#,H+9E2-O=MB%L>.TXYR.AY2W?#JFHKL>O*]PJBVOV($O5-
MX@ "M7N2UAUU#ES MXMFKWE5>'*B::J>E)7!.I:"6..VES_42BFBLY4M/<'9
M09:W9AP%MM^[1;D1X*Q=@DU'TQ"AHDZ]4$;HN83#12#EX0)YFKT"S%?^W3/2
MPPZ]PUK;,X">VO)LB)T\MK3L=V,[TY;?-OSQCKU?R4==J9@U74'C-2W -B(\
M585\552;U/[2*MT>$7KO]U>A *6W"+\AJ2..*FV[4FG-[ZPLR4\7RI@3=DE3AL A_GP]KUB"57
M09N%^D8UH$DE$MVE;GEG3@IH/%;DU!- EZ]>Z4?.@6H,9D\$A E&"74GJTIO
MHU+-*32OA&T#-V4J*0.AK8&S8;=FTXE9/JOF=\KCLK#HI+CXAP<=UA?<23#<
MLMSA0K4A/M_O<.FY*],LIVKMSI+>L]?(7U/;))Z5M;?T+B79S[\386&A,';Y"B;F)5#>*V$X7@
M(,TAN#,+.W$O?,QO?N&]X81KDV<78\ZW6&?-6Q06Y!8'>NZWUW0Z')-[/^W1
M)]&.[H: ^GW/_WXNZ0?*DK>1_ZO+ F5G^? 6JHFT?\R/HA*5#,;$,Z97X&[H
MQO<(U!8O@]W.+_X6]#!B"%OU5A 0GDQ0(J7N6S<6X-U(.W_5IQ\+)XIE U$L
M@8&^['W(N(AY%JCB9@?L1"B**[SEA8C#A_%0Y-= 1^1O!Z9F=0\6)JMPB^AF
M^S]*O.)PE' 4H_4Z_"])_>$]3LL'W"<49TG8*Y2@:J-;NDS.M^!V1[$V8)[I?P9N*UHF*R(@HF^,4,5#!Q^;$=1"@-S$^4XI&V4'[',@Y >ON
M+XC9NE5QBC(+;/$"]PJHG'^+['1_?H,&1"T7B;H$'UBD-@?.>E,JKEX5U,)9
MX$)X@C-"(>[Y)J71MV,Y9Z'OF<#[ EJN2<7])4PU]^+,LSI#HLU78:8_;Q/7
M<7$G_-_A5;K+F(]V);J(FB&U\^2(D:#6R/>/RA5;@A1V%:P-SQ!*?L/.BL23
MA3DUD,T5*M-E3H^/U_W1XB!W)S%AGHB<+=:3]M(&PCJ&3=!".$RVZ[JM]*99HPPA:$7SD=J@O YJ?]'2V9\TU^IR4BI2?^M)*5]RY8KD\$7=[0UO)UIT
MA7>,0Q]S_MR^FNJ"OY%6@BI(RWC'FH:_I4[UIN3![*6]/KI3+7;#<_&^\R_7
M]+"#2RUM.C^UF9YM!SDVI(),Q2P/SF)67;M%K')\NK5SV0 ^&UO3%]561&M\_':"7KCI
M<=*O%WMLHXD)1R<$0 2@KN.8M;"-X%UF!G6ZM_2L+X?<$PAPNO@SL5A$J/20
M"LL=RRE&!W] N9X\#9#9,"^1]4(<8P\?SM.39DPM.&Q_KLD!U9."N6U%4Y&1;!\F&:T2BI?M%IH(;B7N*CSN5W'SI<2VH5V7WVVR
M<\^)Y_Y_V4UL6F"H &WQ%N")VSEP/V2)=\3,0ZGRQEA-(IQ=6'(P9@;*.''L
MP>Y^UJY!X3F14.Q"[1WW,5"8.P<)Q:GA;VNH:J_[)1ME<6UCP\,"OE5'5PW(84WRM23S&\/AHK9L0JJ%18:Y7\Q]0[/GC6L)T4S[:7Y
MWI+!Y9?W^81/-+KO2S\S HZFV!A\X;4!_>.:H^A]^V9_"A6C=3<$,[6>K)+U
MB* YQY-9LX*2$;!&7N'9O>%MBH>KZF1Z8D>W*JEBL4U"5#/I)O?X5F?"/09I
M/1,B1]0>BK00^?*\8X\X_2YVC^$X-?6>N8ZSLFD1*W;]6V:#__Z[";69NZ.<
M9X_^.%Z>NE'L7==-<"
M[1.IAIRIG^X_8-V.XAFPE_15-+7?1SEOMOZ=_'7_O7Y)NB2[M"S![]&&CO(K
MS1] ^2"U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MLI'RL+V%LF@>(9.'.>WX,E@L DQ8?!F=6P.:XV\9,[WY/+Y#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M;_,O_PSZXD IFQ\VT9M]-@CY?S6MO]?5A$;2%;4H1<&PX](=FLTB2\)=A2QYL5G[!^>CG8<.7.25BC.J+SZ,(2I.
M/EW997[8^_#SFDJ1@ K_R$560RFH>PG]%T*?IR!X%8O*;R5]['0[*:.M
M0(8; ZBH74!F,,+L\% 2Y[ .M74JB*QZ__VH^,*:W\O_=EA7RFVG7IMHA"*C'N)8U+[#4TFNC*P%>Z#8U-1F_.Q3_M[(VW-7U6:A7I'UEEJ*)T+4LN2
MSCD\62CO&R2&XG7?QHF*K.Q!C2%!?$DR-XSZ@LJ2.[,-(X_:?MM6$H)<4GI9
M7BQ]%)36[Y#+L?YE/MU0A A9)9$3-&?I+10D2[.+*M^GH]\GR&M';'>FJ7R8JI#2HH4K/F$G<,,^AQ$A2';0\RT7*>#.=XS+O8,WIW
M^3S<)7GS&-]J,YDKZ!<&)UYS6#E$Y!@L:#"[VB'(60+7/7W1'MU[;K:Z6J-.
MF9[&/#XD/LG^:Z--98G7G_P* FI;2X46JPG'' M>YZ\HUIY
MNK)*)EH\ECF3HO@MBV: ]*%6,@Z!N&+$F
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MZH3VUT]*J-D@T=:@=ISW/3(1FZ\#&KZ!-7LM]UR.QVHOCU
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M^!!'[>5U&9J3 /K"2P+WK_U_H0#_GS 26$Z=PTXB2]2$Z)ZB?Q\839\:IX:
MVLD\\9]E^T]2 4Q.&_6W_R0;^[]*M9U8,.7W2?^_RI;W'Z3:KS^J-9V]]#^3
M[7\BU?^?UT]0$/"17-;%0O6N;N93^ @OD5_T:3[S.(UL):!U'^#Q<<:QV&%V
M6OL,'"RA5MC+0Q(&:T@X:'UN> ^?S>"KCD!. Q6^@;6#1NB.M4]OFJ;[^)C%VMV7TVG3RQ&,"2_X_>7?_]S^^?[&=2 /*O&\]E%^HW
M6GY.E=81#W2C7D7A3&*;DR;\'&DZ_92Z?V^[O#AIU?N@X(&[I=LWW?[I[(4;
MQO64(9)B[O$T1VG?M^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MJ&\Q3,/N!/D-VZ/&+]9P!CGHML,5W<,XSC01J#)@MMH!2!RA"8:[ =B/,;K#1VZ4DLJ8-/0^;BW?EG:DZ];G[
M4-DTLW@5&1(R1K^3N:V!IC.ON[#B#,N?M)'= V@J[$35#R"G?I"%"J
M!.&]H-J=>(6(./> L[[^E]2A.YEG(($,&OP-FHH'OP;AR!+H2V8&1L03UORF
M#Q_QVAZ.VG[0 2=]#\WJ@%,AJ!H/MKNFL[CW$^9."(1,X%S", N^ \V0)25X
M,-_9JAK/I*%D.VQ1F@[PRH5QF?2F1=A!_+ITT]G?)+ _!UFS*KR.'T6X$I&,
MS-W<((IV$+.),()_\A_D]>J(5
M/#?1*QPLN,);1Y]Y+3$DKV2L1][*()LP6WUD!IY41;_JG"8LHN>]OAB_KQ:'
MF.25_A%;7.OAS^F%8^I4F'E_8<&SM6_6;:Z2K\%7WXB/N\GB+![>K0@H@A1!
M%^R56*,6S&(M:3\(#Z0MN)C\("&,N[W%R
MW'9 $RK^//UA)2*22E*=K1RT.YG"D&>)R0>/ISDO^;,I"?C"%K.QQ2&:8T@P
M**Z1LI/=?#3NZ HD!09E4,,BIC7!##J'#&E"!Q>6*MD"R,B9=MWV&V4EKKSE
M4&_MCS&!OF 3DTCL"UX'/Z_E__"#A;92"37VHD=@^Z$%? $[70=\74Y+XWV-
MG"\,Q^EK6N2S@$CF/"1(:><'G^PNYY@@UWL4KUZT7JJK5"Y.WSZL6=MW?ZDO
MTX:(RP3[Q-DI_^6-YX0SAPB-U^Z1; /?Y*);/ ST!93 7Y
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MVW3:H/OW-I0&\<;:U1[\?3'R!3K@ES;LE Q&'
M>U7%2)H *I^Y4KOB"9TS6)'1(.H/%$( 7I0,D)E&,U=2$[Y A@G,3U* TDU*
M?LK":TX:Z1/ZT%$E074TM^ ^/;"AVATK>N\7J 2QQ4\U_@QW'N( "P6VR[09
MS!_0(TJ6@+.<$=:)>L#)3:Y8+IS5+-["?HK\^ =C#>QWK:)0NTUC)5Q%K])X
M'5$N+'B:3?)IEY=_$6]WO29T+F!$S)VC'ZD.OC77N-&O1KMY7ZM3NI<@QZ9C
M?1'3VG\TV+IM.J69GXM >\#%*5?38
ML.#E1/AP(A%;QED<$=K(-(?E3 LDP(ECB"0?U1!5CU_EAU/A M^[Z3/79JI4
M)4O3*=JOISO^M7$A2^&)ZYB"9'"1.ZH<9)$TFU+O"K%(4*A$'!,-KD!L(=,P
MSC+R8@8%60UG]C1;EB071HHEJ(^;#U0@&??+U(L(MCKP.+SZ84GAH]O7GO'.
M2R>0M30AVW944D:\5$N5M?MN%&:,_=G%3S3G+H$IT#2AU@!$ :I0U:C^M4@M11PZR>BI 525[B:>2XF7@
M=897^/F3,FB9Z!%C*Z_;S>-14'_BS?$]73&'X"?! _YC 9!ZX3,?MB)H\\M@.>A+)X#5+^QEABES9"2$(>UZ'F$W
MI/]@ ^U[85 P&C_CFGEYSQ^:GU\3YS9\_ -/@#+S149SQ!1H+*GGKL(B93*
M.4:?R?:HB%:X
M[&V_5(?]\0U;?Q*4#BL.*+G^<)5MY/-SG4&(2_2O,V*E;Z&&;FA)4;E2-L$23S1PYB,71M*>TLS&HF(&N@RS%1U #8!37]C"]<+$G[Z6676U 1LJ'E-=.LR^T0%'>AN: P
MJ(^Q;BSF*U+IC8C,G'V?O[+L)II!@QG5M/1I3FH\B)H6A5.73;]DUIM@RRSX*U=CA/ZO7]T,?Q"X:M:;0U@Z%&[F5;.V5EAF8S^B,R- BF?1FO'FZD79,LD;OI:W9\H'LV+F6V=6?\
MWGJV@F\Q$H]0%HU9Q@4Y^'0X17FNVWZ(^E""8\[!IWQC-Q>-%V*N^B4J=I#:
M6$=J$A_A"L#4>%;#F]JXAY%,4X1=B)ITDU<90@*>MO:/Q1\1CPT=GM]NZA"J)V**@/+9Y2=I<>X^RUA/*NFMMM5'A>?0$:5UV1EIY
M@L\9_1^5IOF-X1[#%>K_SME.24O!&Q(2LU:@ID;5%_OI,7$!"ZI\,IVP\SW7?V;,HMUY\M+\YK9ZEV[:(#
M+8@O/J>?]F&M\R#GRALIA<4QJ) D4XW(EEAC@ YHB@J5V3?R5T1"%K4>^HH0
MW+N12,UF@;I.<:UC@EMKE? (7S2RVVTG1[$=L'A=8J JQ6/_";H?21\D]=.D
MYI?= @=W,]REQ*N9[";"%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MYKH]OD$2\LWIBK%Z?+7E7&AX*%Y^-
MN7W6)UQ X4NT]PKN&^\$F(EXP5J@KZT"I6D/M??YTL=HHKW"74J;'T:L[+D&
MA:]U*B9AQHZ>JJW*U56L&/;B?B@BD84MDT)/Z?U^M*M+MK_1V&_EMG/G=OV>
MPB&/_1")S9CW,(!ACW '<3C$,$;ZN<>">@/I>8(<.YC;Q.Z;D=I?16,+PX+7
M=\743!8@&9BQ@_;H.*6++[7! 8+LWBJ.(FJ_[?ESY+GGJ9M7EB=$MCI.-E50'])44\:P%IS(,9R8LH>$N.[U]@?\,T)>=UZ(O*O>>\VVR&X
M,\]O8 =VNQTAHJ:9)&0WZA&Y(5U&,O:9ZZ]@$BGFY41/R,^TETQ3D2/4<[6E
M=1W%S*;"7GU0K#[A4!AZ=:5%\!HM'XJ KLZURLF5<:_/D.=U.(O$D2I?Y.2&
M@BCIA G]V8SJ(((G%0,?66MMNUO7:/7\<[H(V0 KGP8W9$?@9'K2MNM
MCG9$G[J0/D1!'+P4I4H?U3EM(=F>L0XF" C)8M(EAKZ,:(&"2%KA^_>2,;Z!
M,X%%M)1CUA&8N9)_98*[+Z]H/-BN[9SP&K_M8(NJ"AON]>" /NC0@G8O8%Y7:=<%Y04AA>.,BV;)AIJCX6YQBCR
M<_(?C5CQRZ+?[FMO\>NU6'".":;R81^?0)'9N"6$FCYN[CB$L/*.ATF6.ALD
M$J1T3K-XP:>S[S)D_;BJMG:?=;8.2O0/VESR=W,=9E/Y@[=S
MYO>XG7^\,U0ID75B6Y ZW,FO!#S.#Y$2+")L]9"M<3*MPYYVYTB'09(;0>9.
M.Q+D=;BC!3H]QN\[GO*:^Z9_0CPT9)0CJ1#=("]F#E"7DK]E_CFP!IG0;&6^
MRP2;H!7(Y.O,*C:N+X(Y&E +2Q0D)5OJ7IR=I -20N J0>5"T6NR:0^Z\[&A
MPYZNF[FRMRNRYG,2>[!O<&=R1 ^9"[9%^6$&!D.[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M"?Q L.>@EHP#D<79>1%'B49+C%&P?9JRA$'BM=<:?[^S#MYH=^%."KW4M>GRFG\;Z#ZK^/L8D,5C+S\"03W\UI9MK#=:++,:)K]Y3(XA:A
MFGUU0]1$U :GLJ$$2HI=XTKM%4=VR],M'[Y_UPA]?0;0TO#Y ]']2E:3J)>D
MHBGY[&F';%I3%9-0W5I!63IP7%L]V4B%;R#)1^ /.?R$!&$_:5ICLZ[C0!?M
M%Y>(#%K],#'W+I*N^7ZNNR T>!M[N=7+0\ [#4DWUK>\U;Y@K'>=/YHPT9QQE_[?OE*B\\
MUE[0 ?_":7'(OWD[GE0&?V,5*')AM@Y8&#^"\F7>F12$$8J:&-!^QWEY,9QP
MQE4'A(]Q6C0$[KF7#P@=>QPFMV'$97/T7@?DM<[QL$OJ81WPW7?FF(')W,'*
MTP.<2E:#"X6J,(R=X_RAL'#H.J#]_B%_,RB%Y[I=!]7H &DY>5E<7#..E=PO
M?!&JUKBK\33Z[SL)60?P;\MXR^1WM MHIB3:Q2=:]8[=^C^3]<0J/[4G$A9T-]39 (;4OC&LH4:$Y"S!T"OZ(#DV\LD
MC="+[X)9.Y"NY/NAVLW2T.&=#'RD!4/:.C"$RH[GRYLNP,FJJTB<\BOBXE'<
MX<[6>JRYE5#DK;US_FDPNI5#N3SR]G'@QMN?K +O'7BNU+O0L1J HJ+_^5SD
M?]S> V*6BS:!M>M6Y%_]6GSLT>[<&V>\5V6\N;YQV^W=>O=CFG_9&/;56U,I
M>9WV$3C'$C/2FHG6O.7T*JT:5#,"B3R=25**3GB/!KO,G80SUEYW
MZO@[B-DF(7SZ50>TDHPAZHG9*_V)S_8P0@BQ\ML2J(0)@D9.V$W)OT
M!K?C(NE\RL1[?_K#]Z$=VLT_VE#V#K?7D B86/+"Y7I^8)2#BHVXK*I!+NL
M8:;1'3(TWA,0Y5S605PKY$8 :M[U82>2*3VR:MS+7Y+31X9<)E#'ZJ=@76/HY+U4I]ZA(A3VPY,'9N>EI+0(Z>*7PZ6KV!$_MTO7NS5N/PV'MXYG#G9\5\J*S#_89ONWZV.>S[?"2GX/^V/OK+]\O8(+,5MQ+
M_+A7> MJNAE6&K>1Y*&>F^LG#7'4XIA?TXX9([\,.92/88Z#D<3&%0Q7XM:#
MUB'A@);179%.^K)%-._R\+;J8W%?"=78_JNZG=)P=!&2RL<^39R]>-]KU
M:=N\URV;ON+;@F$TQ&&B@;K@?42PL3:K?"WF3O]3I#7#D>BMX^]'J?JU+D^&
MV0H:_@^A#DB=J(%"$;HMP?7E!)*KK!FJ$E+%@?LY!Y$9I?DA)3F+1LJ*A"4-
M.B "'FZHLY7T8,O&'2:0;*HMAZ8T5^66K&!LXP:,S+C@XK&#_<-M^@/]1P.BZH;1R\PWX3J 5"6^J8\F\]>-^L?%\(>P[;C9KMPK7,@C2YXI,FB"VH6V?%-40=6A_H@(Q#X=)M!O)(O[^AOSP;J6+60*WBB-W-
MY5>)99XT\[OAQ+N1"V[@Y&QZ]#1G&#D2OL$Q#W3KQEV<:*&=&!;.HL\^3J=_
MRNPF/.OW#M461M*@?%SF]30GS5^)M\=1[&Y=QD\7?H6]GCA5/ V52HRIGOG'
M^Y"$1O/GX[?'EH7_XG4RYN\(:H@.8//E)?PH[!TX9806;OGT[M,[BS.O*F^W
M*.Y5SASP/D^Z-1R(J_/WZG(-#7VI'K-0[]=S8=0HO\1,;A9.CD[M#V9Y9C4]/7D1LZWB8RT9QR>C3CS'6H>UYG+XA^U7,=E?3C#G
M-JE_AU&3B54S;ZNTWY_Z20=4NQI!\R;/CTY0+T%E)9S'5:_!Y)MJ\M4)^V1'
M5+)Y5_MP#FVJ\*\/01^TK/'^"J8:JE^+BI!#DBJ5B*^:9*-.+#4T/3Y;BNAK
M/!F+V[!%Z(8V9W:J:U!.83Y]SX#CP0%?4M-FR;'W4$0D<4JJY2"J8;@Y9Z)M
MGDJ_-UH'J!>$$Y$U>%:;I?JHK$CJ^2,0_I$_N[ V!+/T43']>G6 Z92[#E 1
ME* .6*L#1).AJ%.!?+HF%'5,)^@ P.T ;I\38 >8TUZ1,0_2"-MNU
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M%U\]"P/[,\]Q\D:VQ M5U&N.X'.1BJ1*3_]08(=Y4"MRQ.HR4-F]Y;XXFP%][I;\85#B)W2,M%/CFUL]4I"/;7
MXX5Y!'#[M>'MS/>2YTW-=3%#!B(QL2$V4U4J3?=LD"RK,.!M''4I/(ZPL%.V%KPMKKZ/\3QO_!FLB+R_4(R)>%M>=D07[^D7,/5?\3O7X,7N
MKK1F:[2%FY<19\CPH,@+YMRH2%RC$F*K>*9*4U5Q>,%H NJ](] 3[T$S>FF
MJ(G, 2\9^ORN\CA(%FE_5=8:\W9=R_Z)_ ^XIV)@&5K8+L=%%?5RO")#
MV_D1),->^AU**0RF3* GB:^A:Y/C.:M@4)!(\5+:7ZFUDEGMS2:W:%PU O$^
M3F&$Y46H(KIP&T'!WC-[J)E37B!_/;"JF^3FKNSW4IIE/:.^C_PR;FYKK/1*
M88RSC8,B+9LDZ!Y:M/MN+4O1 ]T%8ODG7^B !_M8> 6.PE?[:YC&,$/[532(
MFH13T>3@37C!L=> M'00=Z_3?VL[-VF3FX@\$+&SE0Q?/X6U<\KZB7=DO*NX
MYTME[/'%PL+!U'.ELT
M>S!1[5F$F_L2CSP9^Z,67TPWUUJ;RP^C7:JN>DV]87DT2TD2S+C>RQW\\&-W
ML^3/G@M-HHE-R=<&%G7TWN6/V*2.W?Z:H\.^-M2Z0")0P<-_/L$+DTV1EOSVJ?2J&5O
M(KD>Y*P+H9&A*EZUA0X@=]FC3E7R&1VP,V0'CKFH."KZMD^^/&>CNZ)J; BQH 1O1 >MFN"DZ8%XY9!DV*DM,T("^;1NMOV1_A:G=)6+44Y:PK&"D$H3O1G3G$-NAO[][AA0>K=4!OP6S'_L)(C5[
MF:*(>AP_G0VCXB"KP) >/53)&L?BG%49#81^@>H;F"U(U!MJ[)\= A21<^E15:;4L/"2I3VJ-_J<"^F:H!FQZG+,I2.J71\B+X@M<'/8)^
M^I3D;B?@EW&2^IL#TBO4$;:.< E'>F&HSNHUTZ+5S0ILHECU#]#S_&%F<;XX
M(!@OI*!J8F%DYKYB;;$V6P=\$[2N UNE=4AF#;J7@U]/8*OPM)5\I+)KM=(+
MM;L73[R$6H5HLW!D.F]M;9(SP3K2=@N2HO'N1WWX&L?&8+TJ4,_MM#20J#]N%NN7*;PR[;M&A%?D/G[O
M/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M>D 95M/F6:;4%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M>*^O()K1JM&] ?M?G\TPGI!Z:S350X.DRY]6P\(R"EN^X9_4Z][??PW_![JYJ6%I] G[H(
MX<%.TEFH7:GE]-L.7NR,_0D#"G;O8/5/\Z
M)/!ABJ"IHTX4=,&_,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M-,?H>3X]M?8G55^7N)'@[\>; JR)(9H3Y14:>WRF\O4Q(B-MR81 777-"4<
M$:-^OZN38@)(\O'!WV*HN%!GR65#V40!T[S5[< #A#;7[:F6!#8&A7@IKR;'
MQ4DG;#X@3,WCU$'1BZ!1S+$#=7,^\.P&6W[S;G(!]JYZ7S$.6*2AUQA;(Q,*
MQZ'ESKY?"126U&0\K2'TN(\F(_S(/<):2'
MJCJTR5.0<:1D*8.B\1[%-B+7;X>I.4GH@?,P2;;E+BB EH;I@)'XW>U13H$3
M9'C'%K3()*EF
MT#R>':6$7J@AXC7E2H/(IZ:=1N/C&1/L2"]0<547?]MS$SX8'P +%-N*'41L%E?$+Z/\N,0KN=*\J;D)MNEK\K*-*0KBK-%NS@)(3*2
M(M+7TY*--L@GM(4WNGCSWO.;5O LD>\%#?&3[Y'=]/[MWWPTSK8_1->
MJQ?9%*@J>GKW<1Y*PL6K^_A#_?JF9VAX.;'(]-&ZDL0.]6K:I>D6RG+/(1(+
M7SRVEDJ_T&S)3YOV<0]IM%05%RZ),/.3G"LKQ]Y@[XC*=5M"KQ?@]L(58%R&
M%#]E^"A#%1[V.&BN<+.7$>9##6MT %[83N:'9R8.XPN06K='UY0EZH"-[JY"
M[!1Q:EBM^!Y!S\4 HCI*E7L*+ =EI[5WTP]AJTW?CU/+(H[Y^_L^] ^')<(ADG4X\UO\
MZA<=#>JCJ5*1/MUS#_RI5%LG,PR4N_5J:XZNF&M@EEI2^.S6(VL_!Z*B16/L
M890?=5JS%V&^);GIYZ'.K=$O>0L9^SF>,/?R^BF^')([^*Z20*'C0?C4TI5*
M NJ[L)#NS#@RBV6LZG*CD=+M1L[].>ZA SR)8K/C=&A/IU.QY[XW[14^8,GVM0-,D>V&CJ&N,]U3W*OJ(SD9
M,06C%RTGKCEG?R7MXJ,*[YZNHPCCH52YF[WT&FJ?CV#B;6]P=9N7EF8)L:7E;1/GRNO\L%4_':/;
MR5V+MABI,"#=QKCC=D4Z&SCW[X2*WQ%!CO\:+K: B6?&6XS'L_DF5;5M7(N6$!C6KQ!?F3NIB:/G%N?.3B]QOC376(%ZXUQ3!KIW/;?"P,#'%^S0&@EL
MSF]?[OCOSA@6'TB]CK6;I'S$>U5/2DI^8VRP^4MXP3!K@FES#/G<$4Q;FD94
MF_([IK(]]X%]U#XJ;3#25!!)_9KAF8?P=\!N.=8P[ZF,8!PP,A-L\0I^'VS6
M%U3 >;L2I?N+S++(S#LF,N:7#V,F*[C<:.B9MVG)E6+4[7ZX<$CP:$?^ Q.*LIK+#H_T" Y)Y2S\0Y$DZ $\'C3U'NEQ/9,JD
M6BX4L@URA(*-N6LJ3;UKJB%N? J15S]SIL
M/!5^\1#._8ZWZM.(\J&A126VG[YFFGX(OZ@FY\K2N"OZD3L-DPA9M+NMPL?=
MKG$+7\SO/::YF%T2)!Y55W*TOZ?[82=P[FK_=)K3]VGR1]@H5[8BVM$_"
MR]!=[6B45/0B;'-]N!3Z:I1IW6WT5#JI(B+9U) FAE'FX[NJ>4+5QM3FR/S@@RA9>B*6** "/ 1U_E1I)M,AKBP=>BZ^;=KC'\5#=*J QMY)GCG;3RXK6CKDR<6:PL)BF$[I'EK3C)>" I/4MV@2EI;IZ:(WV27CI5MK!N
MJ.Z09PM57E2SM*1'*NR[JGZ@JS"!'<'CYRO=W[Z/31.=7!]$1T.M_,
MJI@946_3 >^M?#@YJ);%W]*3K>'6-XAKI,
M@O@TV5IS#G0Z)W K@\303]E+M&F:'Q*Y.@"H]ON6CW-)]&TIV6'DLPZ8>B=H
M,B=JDG6 ]?G^A=4 HL$6$\/#;80-)K0"?^&G /KHHQR!=YL\O<5 9"CSN:;
M=MW:M=W^@;V-K^DP6,5NYE_)69\E_8EGK7S'*M8FMZYWHWV;$#(NLE%\37FZDFLTPO#RSO\(&=OR0=V+D<.!1;,).!J8E#WJ^.
M,7=Y(I>WJO25,]QDG@/69WGQEDSK,U@@'QTL%(DW#[W]%^]HF73"0!+0BVY%
M3O]\ ;NK9,M.Z@GP*O(G]%Q?57"=O;5=?V$2>:"SPGWSKH[/T^Y^AYZWEQ<:
MT,H'QEQ3/E2DIV2_M'!Q\^5[R[\ZH$X-%*K)@0?0@([:XF:
M+71]F;["3U:S.4O#3KEG2VEX:WO^5[]&HL5T.L_HA?Y5?8&B\/[]I5_/CQ-C
M+<%V2$5"J(S=#\JB=8"5LT%<%+>(O)B^-R+'2)OMYO##JC0JLD/.Y9>35P[<
MN.WF,>1+.5S_(=W>YVWBA4>C8@JK/ LD( F^;:B[M(Z$N46#A-X Y()GQSY]
ML\Q]:2':[(1^[,ML@T6PY;\1H+),ND'R]GM\RBLJ8>O]=[YF.S &HE?,[RM@7"5H8U#GK\9"5YC%KP.-[>%KD:_C4Y,:Y?/D_',M;__.T7-)]V1@GVXRP]<
MYTS".7KMT\=P&8M_BG!E25^C=&Y 52OJ7B!41;D(!LR?!_.5))B7K,^UQU8E
MUF">[>5K2Y+L;HM\3_>MN2N=S1V:BMJ(/RV[B'WT$59"(]6"/!R'CN?Y=[A\.=+!G!4?T,G+@9B1T=%TJI]E@?L6+#
M7M(<;S6.I3#3$"8'(UB[$WXOS!SG+.E4J)X70@&YGN(1LBPB;BDHJ_+G"F?,W0
M\,$<84&IVS5'YL*YF]R$GW*@2Y)*4KKXG20\[36_G'/52906;'MC2N-8E2[?
M]?N0P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MNK3$F4/PBE%E4:\PS:^/-TB6E"_.=C+VXM$.>GE&_J]_?"GKU[Y^"_DH4.ZX"2;92=M--]UG]?\!KV=-JJ XZ9-@9GNT/4
M/_SX],FAU54WR-8C.0LK7W39]GOQ$1I4'!B\,W(!+[\ 7%3PND?1J%(G(FE
MIF2HTE5,_MDIKOY'"G^2*,7B>]IX5HB]5'%!.I'LYGWAV9A9?,9UQW,D^:IN
M-Z\'H\'+.POF0-_D[AKXW)WPA)"Y=[_U\P3A^.]YRH5YM2] 2!;$FOFO*:,XIGTJECOI[.!YPW:>ZT+A"Q@_EY4.4NM*.\FT^==N\<:R6
M$D.M/+JK6!GZVC+C$AKJ1+:JJNQQ/^\8637LK3."OZ
M#>J-5ABUBPZT0^.3[@Y%M8@/?$&@'*LTB[_;]!;C%"$/>S"3MX>:JI>HC[(+
MV 8C,SFV%$7[QD B'Q]_&ZBQW]_!_^00GMG$0^S@-*]N$V]H!9+W[C:5
M@ 0W?-G&-= !?X3Z5RCM>]'3X;$)B5I.<5@\6^6;VX6#!35CJNG"I2;$2]9\
M5PHN8JQ]7JG43P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MY^F)%\"'9LSX>O3M-0<*_C,I1!81M-__-3)59A,^UR1
M]=;S6$77B6XW#VU=;&CSOT!9R&#=!?D6CG)+AP[XVWCS]2^9MJ(V;"^A9P)9
M[;, P<-EP5?G^6FOV&\P/CLY[8\9HB#GQL)XOT%2 _4&C#HC7AK7$5=^MZGX!SO#JM47X>=Q4/*I\#[SG/2:96J0FS:-:XJ+Y5'TM1,TW13Z@=TJ79&,DIFW@MT4MA\ZP\J$&%YSG[G_>Y6:XNJ1N/A'^%<\^F:#J<7'L:1R0/9;0+S9_GM#8473
MKWXJ+NJ+"[6I(/Q4:4'-U/9$EHQP#9^FGK@4/5()9UQ!/;GA\89-6M:5J;AH
M*\6Z2?_:GJ*I1'N/6J5A!LHG*FAR;2#O[K,^"6;=*"EW3NF:D6M#<:JG'QY?
MA6YX@]=VQ)P_WJL)39<93T@(9J&NU:Q=,#G0#Z7V,%
M(QHQO.%QS%+?)U/0;(ZS1?&[TC497'_ZS:CM8_?BA>(BQ?IR4*ZQC<[R=1M5
MQ_JNF]10G0-$,G/YD1 982ER6S0TD!$%R0C7+<&F8U&?OU5Z]>9V1B>2_-MT
MP L45)$60XT9#?QS2J-B&4&.<<15&>JZL_JM&9QR\P;%&E&CBXLJOIE] ?=Y
M@?HXCWA'JL+C9Y&UF)7VN60*6A0>3V$5%560%%QD-^\-#OJ_(<[.'^-59.2C
M\?#R %:3#\$B<#1^%62$!A:%]1R]B)FW-TV1]ML@[TQMU)=C2&6HKSA!S>:9A7HS%#@J4D$]6=EWQZ!2%EAAI66U%=RM. #76'
M_)7VK.)S6).4JC",P)4JKI"HJJXYVU#P8- !'NXONY3V-\!3D'$$9QD#+R :
MGQ?=Y'41F5?KAN*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M,%@J2A9GNV<4?L_-[T'VU#MKQ 2+6U@')(J#6M7H=
MM>::W72P,6=-]Y2/UM;794>&/[R3FX1ZT 8_;*"30.E&."KCQEQSZ;)&\"0F
M>J$\FI<8&UN TY^YYP'4%V'@%P/+N^%A4'EHDC/A*L\4R2NB^S7F&,.2:ZL[
MH79G]KS1"SK@Q*@J?J97!U0X1P5BU+,4L0+\FSCWLDC;6.WYX$6A2CW5EC+E
M]Y&6- 4I-%3JP%Z&$)N_H*2JBAZ^U!2OA\E27D:HE#\_*)&++:,J]/#MY]&8]>)/;AXE3&&.76NTQ'",7['SX[N[>6(D;]?SJI?/NVBUV<1FRQET%=0W
MMWF?ZS)@PY][&("N(7XQ[8HN%,EOQN_7[\[,$')9.98O.XM0[]#S%^*T=4H]
M2D493$V&I.MX^/20E(^O7OI-SW0@_[D.R,4+V&ZHW)DFGYA-@?X@8O8+RTN8
MK@S;4N5RLM6KGG*G5[<=(.2^5U[81KJKC:<_S$?7F&42Q'@VLCN=^ 0YA*TC
MS"Z$&@LQ#Z*XK[-P. 6GE];]XY8#>+P8ZA4(XF0&U!MFYBHLN [L6XG4:]FA
M,JM "I(/E\*86\/,,\FE>1YY=+8@-M.P
M"Y&
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M=,#V%@)J,@JAR52G/JR'6+:@.#OEBF1%K?T296^XTBM0A-TCS4+J<8T.V%E5/_?JS;F;YM^MU1OAK".H%_I#@QR?N<>,;D_
MD14XCKB<2,)K4.0P#8FMN0=0V_^9C%VZ1T3LYW8=+&3_8]#9?LQ2HPK2 0_[!W4 :DKGS&T%X\ ]DA?C
M6T1(4 Y!(OP\5P4.X6-1)OL+ .+.N/U0Z_<"G*ZIJ3I@9=L_I=YJK[BDV5!V
MEI*>0X#4PR=E-Y.Q0:@E'_SW/&*V#C HJ]>LROASTI!U_8=70SV>]5IWY 'A
M(?,=?VI)Q]Q[/?.A+X:DN_I:O?4@_D$'?#%D_,VOU)=7_SEW-1^_6K/K)XW^
M=?!CRQQS^Z2/OIR:H( 5N HG=4"3'(8^?_R2/_?PQ.OSNM]S9(0&6V\*<"&41_7;R,?)DXM>3[74@JO<7\X)=Y;0:;(
ML\G09NQ8NI7/8/P)?QV0\Y^L>%0@&X0Z>/T@D,PF59#)]D]XJ2U
MS"Z>+S^):0/V3E7=EJC8R#?FOR^\F^\QMRF&]@'*PPWT@%VI ^[W=/IUJUH2
MH_DG<&,.CS$YJF235S0#^8F@BF[@R'9A%
M87,6.F?]-M0Q/;*RK$WA=BA.J#['4MR'I@M'#;ABC>I$9(N0:,G8\.N;F">S
MO#,<&1M4$"/^AOXP0-5GDLA7OCS %W":A2V:XF,>>?_P)][%N7>_:S.@D4H$
M]]L%P?8ZX.-JXIP'36C-)/HXG2_$Z2;Z"+M<.WZI>*#>WO]WQ,8!_]WXZXA;Z&#,YPQ?JO; M7^?)0F8/_\4(SM249?6#!'4*DB?!'D X8OI/@3-OBO)_.5@5ZCPLKT^7P#5N
MQ#);VN_:#-G-;&A$GWU6C4,=P[A_!^]9/'@-T+G@7???!.\;Z"RA[W0I.QTC
MC+,16.GU[PU#EG?^%Y?V7U7]GTP+))K\(W3V9@[T/3R_A9/_,'IR5?O42U E
MK.I0RGAQ_^GB;S&MMPZ55>Q,(%S;05ERT77/^Z']<-6[@P,M/VDNL#=.K;K4?5TI0=9"0NIEZM+3
MB$<<+F5J@/ZUD(Y!Y71EWOG\^I*=48:-&0,KPEHWY.6+?>\=_F73"HO@?6%%
MSQB_3+L2IF0/KSO\^M6KMS1J&\,Y;TRLJBD,%Y-3.NO(+$R)./P]2)
MCPQCXV*>#@29EKTH>U$NJ+W9_Z/TMQME\WMJ/7+ID5Z=TQ-+(RTOICX,NV?N
MFE-1&.%26;G%.\K)2S>9[O_RX4,_.SGF68LBKT# BNS%G
M9?J],KSLLP3B6C5+0&49I[TE'-86.">N&_G P=W>6/&')B:C7E(EY+"P)0>=
MJ<2EU>_*\W;%M/?JT8X@EY1^*ME+?BD26$CG#!;(Z4O46XJ5-[=M>H2>U.9%
M:YX?G?1$MM"\5!F""5;\;Z<*9$9YC]FF$87--ZJ/6E=U4@V9*QANR#:I 0%
M-\ WV8.;'GBQN/UYYV;X[KM 6Z.Q/2BB[<"CWF$TL*\VZ.+[;W+P!,O2CM21UN-]"V65[0F_?M$^:-#-?\;
M;>\>UL3UO8_&HJ(B1J6"@A"M%U0$V@JB7#(B*BIBO(*"$"E%+A%3*TB D%$1
M$!%3:Y46"Q$14;E$Y%81$B% M CA'@A*2*)R2V3")0S)9'(F_7W/.9]^VNMSWG.^?V7?[)G]MYKO>M]9Z^]5CZ9-'&ST\[_#(_[]IK7$KYZ#$)K-LP*>_CN
MGJM@)G1*"^23SK8A+CIMZN5R^\4C5G.5I*N()U4J3L[>UBXMYW @]O7-Z8-(@@A\39SV4.:EO^]G%81/
M32TM*)7OG?Y$MB$,0@KQRJ-.ZW4X>]0O 22-"L4.L^"9O\K;V=(]!EAI@4OA
M)\J7,L,DY$(D-!98J?2\6FT(B>M$^4E163'U:K>B]]EWI,R5 :.^ZHP^4&+%
M$2!'U>?1-Y:Q0XPWVEP@B-LK5/U^:XJ[G'9.AKG.4KD4,T=R(S/Y1Q%\@6\>
MR4?4(SKB"['T5D^@X*A.EW "(H>.2.'N-&5X KR55\*F]X#'68
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MNMZ6T$_ 0&X F73?GZG>R%W(E89(C4TU'?56EFAG>TU4EATGN'TJW>E4:M-D=;X,BSG\GK;9JMR,1YY[X%V\XIOB4V)#"'*/<''1G1FM_$.MQF4/!DL-*R
M@7CR4W5E:445M]/*DFASK2QH+8=N[L85<7IC*.'A.ARY=YAO-65$KP8+0)MF
M':Z2KL/QA3.6%"]>U:)*J<+/TJ#.SXV?.E6SXY27:48>BQ@O*&'-7"A[/C7
M(%^:ZWIO367U"QJC1\D[;]M54U]YR#U6J.M$29*?@*N&TQQ]"(XRS1V+1.\[FS+LN7&$?S&&.'=;$*[J_OC858O6501
M@]X92(=RI;L;[TYC :RX.DP=+OSL:F$[B'PU31YB8*#,=.$:O=?A.J81WB2[
M*"8C0UR6S'I,T^'\[^V'+^>.5-$#S;APVN/PN(!.$RQV02E:)KID2T%"FL9+
M[K<^"TW5%DFT+FB=NO;^0L)2^NH7D/Y#\D+ZWA?=LHGRUV4S(:V?';A?_8DI
MC*KJTK+VR7LOQ3.6]M4NVMLQVJ)\'>Y,>)S/'=5;7^.GM'N!PL*S#N^# [L<
M PA>:>BZN,#M;V5E2O7A6&G1!5ZV[]4R2OKL'G%$H)GF^*>2\.B'X:[#.MS$M+;H<;A8WR?G
M/M^Q\12-W&A:>HIW09+^8XO4+4YM#(FQ()4]UQMWP8CP+LH;/56Y]+=U&0(=#CC%;'Q85'3!76F=[!C3YDIZ$)&Y
MJ'+EGI$ ^Q/EX]::;3I<1DXX&J_QL<6'8JNWWE!NB"S]738@4* :C(0].D!_
M&T,P/#;8MUP@&1/(^/(:XWN,9JY!S'!%^-IL@TKL#=*,3A![T5_ =HY015 8
MB7GL=GU7M8%?),Q:9I_6+./G\=.&&L^!(8/A-X0B$""7YBM"-%MI_@/V&(88
MCXJ7(\ #2APYT581[6WG;=] .'==ICDRH3537 QMF^=[S*5F^V&<8=5AE1&@GCM,AK]J!V>^X/R 1>$6[5U@J!S&6.]LH@-&F'V8
M\-FQWF TC9R$V8:'C(2&4$X3F9HY+*U!%!M9$@X@E[WTPQB&851@=0M_;=QLKD55'GYR_G*TKJP&:WPM_MP4S9K:M,@9B"/#QF6(#L[[5WM!UA+:8F\
M_H5MR/&G0W%;M>R?@^'P^%M=-:6OJ4*
M[HP&%)&^Q[M=UVF9#S$^<^0%=SFCB_5?(RWN.14F5']*
MD33':WZT))PHUU@54<)5X@4Z7&@O&-;S_GM#H1T'P;MJW3J!J0_A!G(!;-'#L&WZZI\*A,>P788( @5ODI:H*WA*>ACED#$;;,]^UG.
ME4UK7+0FF#!1VLDT/A/ A/&RCH0K O1RE2\ZKXR%[F"GHY9HF_@YP /Q_6$5
M!*O)FN.?'>\QOR2_HUBM%-[GH*W5Y2C?B?S]
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M,0KZD\VG>*!OC= 7/7Y2VRU%A'@:M#39:##[.
M+U1F8O\VSM)L!MLH$!>=I^_H^K8(ET#XFYMB7G$MV4@+Y311)CTT_'#UJI%&2R^UI!;0P-O
M5(-@+G($(O'ZC&TDW:FY(Z85ZD>EA;!4*-\"B_K'1S7F8Z_ A<4H9C;S,))O
M;1ZMHKL7A*MO8D\R";!!UYD#$8/^JK?:.[T7P;I1B+5R4&/12&Y"EQP>5C,<
M/X!+B$3&6W"IH_&F)G]MOD("!Z_U4=(J)?0X_'7[PFB%!R]8D6W2YM;=3F/LA6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MQ"%V55,UQD\T<9><.':4V*Q7W(9DP8EDP6&2I Z#KX
MVN1PB8:,K,L$ WP5*88K?9_!OJH'VEOT%8MJ@G(1:FN[Y87&P%7*W=J:YI0;
M^5<$)[J)?-5++Q*<%UO2P7D3GC^Q@^#_-RC(_;N#TR7_X@\$J%?\G*\UY1IA
M(2ZED87\V6J(Z=G_\KQ-NTHKWF4?O)-7+1YOW#89^36H8,YH;3X)_@$)X1:J
M/[5W/GB2X(!L,\+T7&7&*1VNIP#=T8S;K?'EG^48P&&J;M&/!X P]F7E;EM.
M!F6V#MM6=P[C$BTG5R>(O\H)7U!)R;N@FLE+V>*B$2Z6?>Y7+11N6OQR2$58R-F.T]\
M+;E/QI@/SW'/"GH/%[/7D])1BQ/?5W72Q5OM$/^/>8;]6U"]]%^1V+-G,R8?+/+ @;1]F.I?,,/[%R#^)UQC7FK>4OO#V*,A
M#5Z-O6D[PBR=8,VM9:[[I$9>K$G2M0?MZGH:8_H5NKI$LYXE(M.0O]P=?NH(=HLKE3F\X';J$J)U1G7\!)H3+68K3K(KJ:67>
M1OSCL\A>&L(UN\]35-A=ARMS]0Y6R2C:.Q+%KI'<_>TOAJ_C5-LY7]/N$.?1
M>-(RPGPZP2D5,7M*X[IWNYIIG^0EI'AW(-O9X/MSU57G>O5L\W0^=#TE<_1+]\#GMQVF?(R^B=4?(\:&Z[J>UGD-[;[66>Y49^E
M2Y9'AW8!9R%3FB$O)IK3^B1T<<76%Q<>(3N$Y>FD8]UVKNLN: M"SQ<&)+ ;
M,@-OJ^PQ3 CM[QEQ%O>,S0#*32M-'BT8HOLJQU2GEM%H;_*.X=]=0U!]$3=#POBR]D(=3GJ0].4L,4^S(S 0
MK,L-KS:!Q#Q3(M#A:/R=_FQKF_/O5H8IA]JJ#[DZ42@2-__=K8V&USBO[2=9
M\%[N\TFV'#.PPYM]]P4K9;O^Z&9L'\X47RX;-80/)ZBH1DTK_4Y-T \^0S'S
MN/KCYT_MT E6"3F"Z/32&=?J( _=;[K<*^.
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MF>,K#LK-_\S]^"B#,C145A -0BY3IDTO]A_J_
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MO,TV4A&Y6:XH.JVQK&$A5Z)JUO]UI.KC' /DG6MKU:;/< VI<>_R9[UM!F]#I27*WP@\#7EE'+9&'+ ,=*#4Q"0I[^G'84[O/O+
M6:RBB!]@D(>N4RY\,VB=C&Q_3+MY0I;Q.IN20/"JKGY9/HJM4%:-LY GG@T,
MY! 6$%UIA '\C3+0$.;5D2&NZVX9YNBC_1;*AW['S/-KLT)?L1:!DH@(;'.?
MQ:Y7-1V"BO(>Y3P<,;\(E(,54=I3HM;5+!SH;SA6%.F6YY7;T*'8X WF&<@4/1^4U2LA'BKNVL:"-:H (S
MP@)N&,&HX<%[[Q E03J'56L9/)!QA6A+LV:K'-&L'#C%%]+ATARTN_ *\@+P
M]$*PONSG6=,M1M(MJ$CYY.@<@J=?K4^^SLZ%DZW#?^38NZ7L. JE9[QS562IU/ ^JX901>>GP]
MNEWX.8JP,*P[+N^MF>@F-^1GAS7A\3F#N[L%!OLZ$(_;TJ(-Z>2]YK\:$F8-
MN<[M/RT?5^0"+'E@8TFI.N
M$U<'](M#T4VV)CS^P2ZZY2,,-=E>7> GVW9.BM):'OYDE+"8LQX>]!(BA#P/
M;$?ZC%0QVD?R77&V;\V+LS +40>FYX[T+WKY\GE-\\V7^BL;@>#W$>;G#-4Q
MVV4K!V+(I4Q%#A2JNMX^A@5AB2W$NLJQ#E/2]V*@FBL)^%1#20"2$7M(S&>L
MA1+Z"V)BXH/S,0\.TLR]39$:^VM6D&73
M/ TIA6,F+ .-:,P&L\R\[I2\\.Q5RO7VKFZ4F/ $?>?.0#$M3M383QN6BG&V-^!88J,?1@Y<74/&0SG*4TDNQ)A(2UB:I*; %34;,PQJ;G\&]/
M*(2R]\(;9[&(+7%\X:3^\?T08V$KXA^K?>9[Q+PRS9'B!ISO6/3K-^WZ+[!7
M0)CEW8JX14J+")+ >U*Q,>*EO3.E"&TP!]/1#?1C+*GG91WNC/;(^'B'N](X
MOWX,SH"#-9YK#D.LE$G%EF/MU38H2UM2$'>)<07ND*74ZG IX*)),"UP.YR$
M(>=M<:*$.MPY^Y1QM!TL=9+W0?TZW"O4E0-C*.L6*GT8N(%J,E*A7DDPEI]K28^@
M+W:(-#K<@1R6LI:0;Z0;'.Y$[!\.4T+I(D[T=PZE[QEM7$/.5S0L0NEP.,:W
M]*^J8/WI\Z!<(V6F.CG*-75<*)V6+!J9YIGZWM-/.)2[[].'V+2SIZ>X32"(3B>]CUY"_0M?35RD\Y,F ^+M+'@9?L><6$M05_K)Y_"3F*=THB8:=2#/#NMMJWI-/>SN6^X^6;!.))J_9DC("#8%K.YPCRZD6876+L=#!4PS=-UN!N3%O'<
M2SJVZ^:>>7R ?A2$V3,A
M6D"0AP-MN!;<$+'(0W6\RCM42KZ0-'-MM@5\\$_^$:7AE;%R*PPEC3T/=#GH6EG #=!T ]FDVE#I68]:_%$-,3+,
M1-Q2=,6HF*OT*M8,/'@-A;\P[@T8\3,XBE &(R9H!:J.1(K@17!AZ6T6#GQ0RU#K<
M2<@RA36 7QY!F)B2@5=EZ$8M1>-QO]-A#-X]%?C;X,_H,P0#Q(GM@J8Q.(RT
MT*\'?OI)0(9K\?7$*>!MC%Z6 7
M?Y[Z(DJQ!5W/'9_7;5/4P:50<;10GVJE=3)J3KO2=Z1]:I1I%N9,C_$+O),#
M3S1:K85J6,G5'D_IWNU19#ACJ,*9V6N'N#\<1O4?J[D="27D+?2+6A;#&?V3
M.PRLK":$8NI\90PYY!G<.^!24'-!8CG89\?AAVN+^*H4;(TMQF92: )O9XS8
M_THL"CQ,=7 ZE-?\>]N[OGUF]Y;5+TT=R& .-Y\S[$8W:Q^XKBNB3=0%?M5.
MMY%Z-1OR?D1.=#EZVS1FIK# )[1$:5[1H&C2TEI.GE@#QRC 7NT46MD45^=9'VO#CK-#HA%E2YZ&L\,D]T.6@F@C_ LEIT ]H#3:L.WF;))W*&199Y
MXA2,EF_1%FCOJ!;,N/_"%L^XOAU$T)7@U# 70_]'+'@*%_^H1/FS_9M<"WJB2WKA,:!C"\#%YWPZPECX#OD4QZQ,928&/V5%B/QY.A+KH**'P%$+%%5
MT:"*JZI$O+QI 5_^3Z4&+EB[:1N\!>,VLV9*T0Q@;!$P=-/@]N0 2O!#&-J[
MDB3@#/=RLM3=9XW'1ESCP,A:P&H3'!0(QMZS?56&#,%_VAPWGIOZA871"O^*MFP[3U'2HFXYL!?=9 *-SVT5^':]U"TI^:
M_H8Z#HBA+G)IBM84, ('[&KTQ68 R5-N*%Z]F6&* 58 !C*_1#^SFOC;WQQB
MMS:/@R$G@%]!C(4&AX,M,I$9)DV_T>'<;*/EZFB4-[C<=4+=:E@,W];$1L5R)?@VQ P#_/$6<2-+N09Z
MZ PB-2.9-?VIP7Q5S"1"^90&B"+VGD6,"RF@L6*2;0PGNE<*R_=M5MBQ\[%P
MGI_JZJ1BSV<]T^N;(?!<>Q1+SE;\3Y+<55[=<;-Z]DU"J6']V-Q1J_E<;M9%W^**%W?"0S)5D135*<+))_YK9/&G$K8%\-<;JN*K6%51".,.7%;I1-&JE0
M7EL<1K2 Q#>PJ%8 + DC$MH1#PHE_YWH?;C/Q*E1\X"/V;>?!HAHP:_4YU@A
MQ;1O&\=\.B:S7 [J<*F'NJA .3;[U',9.PC':)X^I,5PZ*YN>P?!_+Q/3RBJ
M@L>(O3:Q."SN7(Z*/>E%+N\%^8KIG@OY(]RI9=4ZW&.JV]^W4?BF?Y8^ 93N
M!$T)4LK$Z6KBTVGS*?ZU*:^L([Q K:HDEJ("RA-^YGOH<#M+-'B$-SDVM,(:/L7#CXYIM8%LP5(E^,2I&+,(&^ EO( =8!'<[M !JK+5#S M4/F%KG2ZC('"%WQM,3MKS$(/RF0,-LY#&WA[&_0MZ"5I6TAIB@D@7#BGS_W\[RP4(U!(ZM:#6:7.R&.
M)/F''@#ZP]4N 6@KQP;]PUE)$"6J?H$-"QDMH(5#D8V4FS3F:.M1:]Z0S K]
M2&E->"X=']4N%:([$O"D\0T&BJ*M_0(-L'_^H^$)L/Z>Y]UN+S?[ ]K7:%.I
M$TCAYX]VLV=\,%_[7\DYC\!T^D2HY@BCY7#/<(406.YJ=_MD3[CJ>5\3A1T+
MO3LY[ ..JZ*V]+&%W<68R/IODQXRZ*?_Y_JDW\6&-NX (>\\X;]Y OJ(I1F
M:$WMC;'E7?^7C^&FNV[VQ2!7RF:XPRQ58$9C@@NX9CC01$:]EEF(Z
MY(BA1&%S*(W$%5:[R]+(S_1MGC$AJ&7&0(,2A;A'?Z^>?CZ?'%QO7JFZ^1@H
MCV+#OX1)?Q67.\G[K^ K;
M?!XTLJU:;(HX,;VZ0DN4/CF2FJ.*;!/-^B)MBC8'4QNAY/,%$>8QB'M;:IDU:^%?RM&OKE7RUKX.=J+.6O$R@4Z]X0:_90<3'JNW)V?/)EE+VW([P&D
M7MKR'/G[(4#]$
M#3NK[:%$]])N5^I3'8X2V(/-U5TU5AF@+Y'ZD#4S!\P9'/T3]L7<<%KB1I':
MO< K F(+P;KZJDY'XS/B8\\TNU1Q28-JT]M/PYTN!AIV1!O9V+I@$00U@=#<
M)R.9OM29A3^$BVFC*M\T'HB/(BUDM'X#?X%997:Z%&\T1-P (7X/U1\_I4L]
M5( I2$EXN0L5H.^49J*)46W!#JNT :;(?Y?2_D9QE'=H[5W&E]"=P3HMP+]K
MM;;:G,S:6A*:-VK.3W.UB E7+0D*29"\Q^_KXCZ/QH'ECN3)1>^$.703.#5&
M&?QJ@E9Y'#K(&GCY&CE<2"/KRS]LZ@9=2&TH/U:B/3*F-42!M[!+VW7)O+]6ZSLFRUJ.R.4D5]^8^@?I'ZMQ<1UL%BU@0VZMZ:R89T3>EW2*U
ML2BH :2FGH@WHU?@-R4V0NC:.]7F5>\Y3"63%XZ_YAHB9:X(\']C^A*X_9CV
M4Z^6[576F-)\,TOEY0V(AUL-1NPWB='+F2 Z?U*@S/VS4H>[?X:ESTS:@E!J
MN?^(#5'_-/C_]H]KLJ23KNE.I!@#]'(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M%0L]V$[P+67E@.]-AWACPG[MXT)D1>[(K0ASIW2Y@YO-L3\2&P(-NVW9FZMYPH5^J,N#R'PB? 03CS(!_;C5/9+:$)]X?BQ*PXGJPD#-H+Y=,\NZ_;)! ^O
MJG*.\H;SS5OW^REF<7E=;!5!=5[_M4WE9>Q_J*-*RW;O&B5)].V(/8K@Z48&
M3EEYM9KP0 S;V2^,6!J1O;3+KKQYH3_,(WP/<8HP&:O%%.A\G]\C 6FD#O=U
MT8;^N 4SW%UPDF8KCMO+4:B(D? .&]FU-UN%V=CA?R(T"E8Q>FH:7G"^* 5^"70"@7-^SKMZY2$?Z8
MLM6I:M)\NL^QB0 40WAD0,S-[GWP5+$1]'@L)=>RM\R%#?XIF)\6$9B(5IGZ"0GGGBQ"G\LYS983D6V^>##.V==O-Q7CJO/[;T5*"
MH@BO 7:W3EF,OB3!O])B-$?=&FT.8SPD86,^/#O;"K*[]?0]W;_3 :X."5U7
MG)%'@J3]8XI,=Z>+C_BHM:\HY7K4O1H##7 8?:O/O%#V5W-/*(7RMC>*RC_Q4^W+ J%:28'_HCVM+MU3D'MRN-=W+;LTX0F@1_F/R%'"!FK-'-_!S_8Q(Z^P6DN%P6E9Q/D[^WI/\X$AF)1
M$&.MJAC?K!G9+74FZ3]0B#V;*BI04<^ <#7#9.,G=$B;$>@*/@H$6_%HM@Z7
MY?*_R:,$?V?.%;W'Q1HG+QT.8Y3VY@&%B\]WH*Z%YX=9:/F_#)@I+O>4?RS'
MS 6B4;/;1*.(AH5Y#LQ\^>/[]Q2G8(
M^J-_=^6;.X8K)P1?^OZ&O?QNCC-BI3PE-GP(@?7VBRAM)_QAU'AG_/;RK/7;
MSJWE0$U[DNQV2WX-GWQCW.4[<'I=EJ X2CVPU#\GZE -&&^?=
MS*(Z=BG>?5Z3W-[?_>[=>](/@V'';W;&WOCAXF/!2MF$C2K0B;"MKL3;BAOC[S'GTHTZSKTRX)%+*R\5LPU3HEW<7Y74P 486:30L'7 !1]KISK@
M@ \6UR<%?:/U55W".A!/GP==?*HFWP0C2-<"K> UN1%;C[ JAOH7=Z5V<:QI
M]PI.AW,7E;&6X"LF]U27;'MW(;#VX9 SD%269<*S6OZLL@UQDKAM$O,8*SLP
MG=3ID=L[#/:H295"(23[R=AYPX.J_VGYF;P
M9_*FM2J4_.=O+1_MD288H<$RY:B^,"Y&=\!>06VVO383" 73C2%#J;B!;47WZT1LI.FA?.+*BN?=
MQ/4!R 9H]^?$)R=& TWA"T%/1>F^&H]C 4<;_/*>H*]G*_A4C%_/V:1EGI5S
M[,DPBV_E"CER7XT9]"%>\!7B6F2]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M&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M:G>"9K3_66U7P#7/-*,N^188)
MUNPLKJ!R=,><+Q7LC[D3'YMT.%N -:7#F;S__5PO@F& +W]&-7E_SH/K&W"8
M=5RB#FM*F PWD+\R)N_!I6UCJ81%]'7*1,E@.N=+6-3BHL,9(CM:[>C;V0D/
M5KFFI8EG9H_/*LQV#8HBW?VR@G)&+$Y.4KL"R4QUP6GKGHB=DK
MJD@PX)D6S;Q*,.5*"!VVUG"($E]O9:'#W8KG9Z^&8YERS6HEOH[;:[4*\ZL4
M7OZ!KH-4N,N9U1>B>8-8 NR9T;YVCF?G&>H5<45E'3O5E"_O7ZA]BGP#O!J[
M9G6(\!W&\$H&;/P%2^D;E-NM@>'^M5"^BIO")&7L+3'XV=@Z/LQPXJ.R;\",
M3^Z]HL/)65:NLV+O#RU]GY#)PW8YJ?\%-$BN("B'SB$>&(TUP2\T$"!'T2UH
MT^S3D^R-R;NJDBWNA=X<$4GMM]JDQ3+:9G=KM^APW8/7T0%'2R+/]UEU>WF
MG>!HA[W"NQS->B+JZ^\-Z"MI:"Y_?^],W5C.S-XU5[[>X3ACJ-&WYEK-,:.U
M>_LW@J47'Q-GTSY]]K^G8<\3?.V^GN4DQU7?^BT]4^(>%5I&=M5?8O
M<_=$Y3;;%\9ZCFT7#([I*Y<8%KOH"R=W3^<5:V3VM> -<>G!%UM3,;?HSAEP
MV1XR7DATV6N-Z\GM0ZD4'APA2.U;>#Q:W,
MZ!/\F=$ VP*W.. U7HA1_W4[^J!@=,&MK\,E1\*K-?<<0'@'AO+1Y\W48_IO8;_W$K3;E.1G9&C_]Z&PDP9L6)IRU[_D
MR\-\OO7 IU9BWC7^$UD-8S9# )0-O@+G(X:PKX1L@NRM;(T>,X*#-5OJ_:R>
MW(>;%")B2>C3P)/O1?IMCSF5L+ %A(2$4D"[+(N 17RK;_]7FB&%VM?Y#\%>U>_H-O4T^W=,4A8#9T"UC3. SG,-T1^Q6B..0GDSQ@XHNT!U
MJ#91MF:JA6[3YQ:O&MMAE:),E%IB.A<+&_G7RXH,/+KMSKGZ8US"J($:JWT2
MG!>F9I1$AX?&L"/$/17.V;DJ2TS8BC#-'\.-&W_OH?J99-Q/VW*4VTJW?@I[
MU6>OK%2NT[-D,^V3XK"8#/.&[A(=[BO//@QQL\!0,BVN@Z07EDN,[8^WM6Z/2":CUBJ?]J[0%8*C"XR MBB3:1)H]4O+>?7/@JM9J"W9$I3AT5$5^3M'G
M;>K3TMS.!_J'*JU51&9=E?45*G'KJ5-PL)?^0]O)KLV?':A?DA+8]!WP+?0W
M*<$J0@A"US%!-YH9HZJ\%FUL_=<%Y*1H_UHMMJI?/\,1.Z!SI4[7JC?FCIK=
M99A4O*@IGZ#*JYUB\D8S?>Z=#XTBOLD3151X:HC3&F<^NDY=28(S51B^1T9E
M8S0XVP]$M*'_OYT=8(.5KY[9WH-@R32XSF^K3X7BG&!@UGO2) I'%M*;_E1>XY4]@H@E[
MUU=&5$P(_]^__W6+"?^TG4O$M!Y@L!\;#6=+><6ES!G'P@7 7+JNO!K3R@L&
MZZV.W555/"/AU;ZC0^?;'__;6RC)(I+J=RVKVEM#1(*AZ13.VG!U8TTQ;M9VUE+]T,&\GG.J>,FMB37OX G ?B&R\11YXEK>F(>GQ$U'S$V\+SKL@EWI_\
MCB5_"91KB\>4,B!CV87_G,T]3-)0J+UY#N^WBJC7U4>U-WFD\KLNZ8:-1P7&
M?%4 "ZEA+^:09E2EC!^^0YO*6M=O]VQF88+^$P0P=JE@KJE[@_#8C@.&1H-N$M_+4%&H(/1.6]]]MD*M8*,1LX5;!?LRXOBZ.(XEDJC-A8M2.DXQ,WG97_H0%K<>$L_$X&GNMMK%@=GX911G1V&?JYO*VQ]=UI(GQ2\\
M,2S6)X!7JACY>2-53W"'#$MA@NR8>)DC:#),G$-*FO#.>T_+]8*H*5-OHOM-N^7\>+RD34Q<8^*PK4I^CS,><6YQ2#E@F1,X>U;QQTWZ]Y#2>9HMZ [F.9P5<)R%X+K5!GVCQ?E7,X77K>$+H?DPX*XY4R1-J_%IJN-"/YT$P^ "
M12"^'2P#I;YH\OG7#>>=@09"K^=>Y1>4BV"9U7V5R!5ME 9212#\?&R__@IIF3VW;/=[LM ?4S)4W,15Y6*1+;(^KIP+:IFXY4!:A@+Y@HIJ4IXBJB\3-)"<4O7JF:P/3N
MQY0?D[1%JA2IUU_G\?NDS7/;6_3%:7>B+:T3
MCX>)JYQ9JN*B[#LU$$D:,M@@F.TM+M.,+/"EO*HGST^+A/B939PSQ1BO()RZ
M*646+J42L@+_#+[>.*8!&EB3RU9,L0.A2H6E9@.\1QQ8VMV_GK$Z7,21?F$BU3$1<(2$S7R)UC>FT=M#9,7GG4K"GF+^#@76P;+YF*99[_
M\9N\_=^\%OA_\)..7/*O\HI2!DKNC3R-)(-6M"DIY[R^F::^C-!0X1 6/EM,_0)MQ^UV%"18J#AO3'X^90R@\U-BK]PN6/]I0V,;MMY$(%'7;?&$_OG=9CP
MI9.IBH,Q@]"_:J1HS6YF\0_WM_LEU!L+QHN !(+7:F[HVJ35L]"4$MTTFQ'J_%_;^
ME?W$M'1!OQ,/ KL#&4)QJ4/&T:_H?FUB)U]"M;/A=7HJM[VFV@:-';V.4YO\
M?P;/&^-,9%ROV+_H0\+^XS=E$/@'BG@BCGRY NPH=A:U!K>X.J3!Q^M*H6D[0_1?DQB(_$Z7%/_%O@\?)Z\O8]^NON3DMMP;UV;JYEE"D^PB)9]%)HX
MU,QL8"\;M5IIEMF0SYQ[6U\V([0?)C3Z?"4DM:>D@!^^-#S7SE9$:QP:OG(%
MS:*B:!\K,] =Q&^UH/2.8 :A-/K+0N7:0EH?:H)?RNC(4/_"(*#"#,FB._J*
M)C6SL:AN1P_*NPMT'T?@W4%5!-84.^#&K=%3L87Q8&+:/Z*3#RR-NX9G*0:6\"\9NHWF%)X/G]X
MJ_E?I2+]IC]V.2KB:[>:#R8"$O]1QMINVRA-0MLS =+FBXV]52CYNI3Y ":8=RB^J,>9(@#9#D1Z>B=F^D;D##,^34[3K?0Y3,
M,SFYM-/PA7WM"E$4JZ!'5C
M>$9']EJ(?75=6Z'#\L+)!+-CFEU.SL0GL86TE.-.()0X*"M@,H-UI7;K&Y3-/O%XE-T^ST0FZ?#S0WC+IY," [HM#;7WZF(N!BX;EMH0)K5KT*6KL;D'QP;I<.ZK T*8_-%UW0R7XM\BG"? M*T2:8OA,SHG) 8EF&8N+&'6U]SNFD'XT)S_^K@O%,T,WS@5L*D6!M
M-N(E>4DRA&^K"H6.]O/W48*"I.GF@E<@]H"K0E+IB]+J]D@[@;Z+J,AJ.=JB
M69>?(E!=)*F.9UUN]@#J\3T5T_7H"N69'&54=W*&KY#"8W,@Q\86>[!
M^*BTY?/H@2XF\E6^@K-,$YV7A][!L.&MS?'29UUJWQT$/_I&Y9W!>C"9N%#9
MDB=1 '69[%0'0=E(-N$F67'"85C^>0RO.OUR6HAPYG/
MV-<"9:%R]@!AP;#5XG;.UR?[3X0O>>>_.S8VEY:KF/#O#PC$>'$ V+#Q%O;W
M&+I)A]R2\OA?X6?69.C_K\C7]O$1.:$B6X>K(HQNMDV(14'F\+^/1-([^6^-
M MC?SV4F\<]Q?6E0909A)F)B$G/T$P8R -Y8^^TI9$F8I+Q/1;A&KHYEU(^S
M%'@CI'D.<\S,DB/4O"/\(G/PS43%XA5$"^1P#7R$:#%:).MU,,(OYQ>#P320
M?YB79Y<#/K!M/'U=H&+CT29@UN#6[G$\<3EC YW6R5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MS:(,B*\1J)!5Q@=:HO31D]AM"'2#!.B"^3+!"@H!3R5NHILHP5=XPU&".1C&3!%-W[#G7T(N2,A?#F,Q04$/
MBHV17(AY ,LP8%U(805!&MA?H+E"9U5;Z)F-UXBD4PL>D8U%B01S'GRZ>CM250T[&N:@\IN& D\&L-OH\K
M#9**\<,B5A)B(V7/W/"-#=(L16PJ._>/!%K#EZ6@D1\]$&8JF9Z0X35';QMT
M2;,A&>9*P*6P1V._63NC(2?= UT,ZB^:G)3:>J [:>W/SW=?M$()I]/"@ <%U3.%80(,8M'TY9 XD?ZZVD!&6P!.O=+AE>G^91[@Z1<*#==](
MB[Q(4.,+[8N"<$ DQB.A3V#_X^U1!6\CU-YGWZ']'.M.>@)$E;"Q"9YA7XN[
M62-CB@SYA%)!(VD!A;$&OA!M,1S%DA?9*$1[=;CK/'3=\7M!O=SH(,L" PL[79=MKO31,NF&";(WG+5A_8[P;P,ZG.4;S5Z\R$]8GVGU)$^'RX%E)S"""[$;LLW0
M-]6M4[8 NIBZA&;>H0%\.BYU.9(5_@)%@M6+5\,H#FUG6&AS,6HWPED*9:2Z
M.F'C):-KNEW7.5US/5DXM/7HJ)D5OLO> 32U]*^+LWNAKPS'&[5TUN'VO>Q<
MQ%*:'&B?(B\+][UKSF&V5_OTH0N,H$^?1;;QQV%?)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MYLW=J4KR :AF:OH&<2':IM;A>J+8)B+,_HIIMTG/A:X>W]O3746,W*?X9MSYZ9-Q[:L@ET!48MC)'8
MV $W_P/*FAYA-" /N'!8V1@UHM+/QNE?>9SMHY*?+FIUD4B:(Y*^_C)1W.N_-;S^MPRU.<.?'@O@+-5O0M&M;&,(N19CMI,]T631&ID52PK.#S>-:VYYD0=3)2@S[Z14U*'(M5I.W()I:"1(
M*L#3HB+1[E+7J/MX>[#OKK"NTD^<,H7'(5ZP4%;C*14K"))(0QYC-C28A&PD
M,G/1%O,SS ):L;#>N:)=U.__!;7?4]_:R/ZX,+-R#$=!YK /:(H@O
M-4QBV-&W0X8-)(-3[T[!@-0S:1(C]C]Z[[3_2FT)G"SG]U*!%@IODM0S(?%)
ME8ZR5O2]AZ7>@>!21JNZL^3=J"GW--JF?536;+$/3HS4X:SY%D
M/WW]K4T/8S'R=2MQ'K(1CH'2ZHZ,9&0OAX,D:>!\VL6)>C.?2M''SZR0"['1
MX3$% ;TK%]E=>J5F'IDUU/D_\62[/X6*H'?&QQ0YDBR/!D)I*-.1:3S#@N[0
MUV1@YF2!+(FE,BM[X<0!]$FXU.NE/TDS#SZ*+K5T#49!FY$%'GD]E!].P?%'
MTIK;J]V#'M,N'*ITG5]4O8\2G]MOHL-=IFL9R9?<7%Y9;7D&7QZ@SH4G]O^\
M?7+,G!:\0^EV]2<@:[:/NB4CE)Y#6M%CIVP=--RV*O/SZ +MIY;$YN@68>X
M02U/QXD%T,MC2GZM]HAT!S[K/"1N].,G*\[]J+\5;>'UC6)R>+K\PN6WM#0>
MT4IYYE9,#NT>3^V9ZN#_.C19A_,43M8 )SNHMI_3$IZ*1OZ<"7Q3*WB[\MFK
M-^^VL!JI(FMTWMA >A ;(6DVC,HP&+D6Z)6^ ]FBG!WC/%C[?@\*F5P4'7\$
M2E9!QX=Q$Y+W)(T-&]E/DTU_<1V'4##!<8AN '=!&\$(2Q,9F9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M%J:*&1WL1'0SW:,:KAEP(1G2YRNM2B2$&\1U+X5R23MG)8W%R_ )/M%:
M[7]1/C>M<)@;66I]D#MK(C:81V6'/!:SPT;-NVTE-D15&*ZUV
M?^04G;/?G-E9B6#JX=*(^YQ+KXW;+UFCO#9? PW!"Y.!"1CG7-V^->W!5Y\3
M+/;N&;F^:AQ
M]N 5FV8Y8R/-Y)!2<(-CY4^[V82: +@PQG(ED%8V<6W1Y0=PW2>T8V]55=7+
MV;,>$_ 1ET++!BBAX,%4R71:Y*.!L)SBSZ92CN6[8S\2YN3,L*'U:<
M >\FC/*C[$5XO=TY,*^:H[=E"<3!W?"@+0(LF%JCZJ. RYH>AOD)4JG$U\+K
M2]L*RVP)QSG42AP5_7/OVDOXRIJIIV\^6%QSE>"S/LPT#<:NX&?/FGGF/+A\
M^LW]!>2>."?MK$D!8BK2X<:7$7K\/+6SRM@(#@M$'S:-VQLS6@GSZ">5I'KQ
MG"A@9;@9=ZGKZG!M?B'MT+TT&UANFWZ?\Z+#NL;=JC3D46! [Z-'(@I71>TK
M[*J[<6[*.[3>;_WEW @U6O18Y#_LMY69P([(2#Z>;>']54OO9[9=W^U[[I:%
M'Z])*B[]@2XV(O14;6+.&(3C0&$Z>[+TD0[WW9"W#O=UI*6VA15&&CX#:H^_
MPK2&J>LL=C@+[YA@5F\J*KZC]+.)I9O$GK4;"^KZ>9HWV*!BA:\BE-R61*.M
M:PYMV'GKIWD+/@H;F+A>NCLDY+FP3<)_H@D;T)5*L[0HX]4AE7?*$PSJS._>
MRATU"X][>)+:,4;?K2<<&_OGG]TJ;S6DBZRN%M1,>EL:QI@G%,<.LGOXY#J6
M-C47;+7 [/J5!1GU**#&GUFHM/ACJ3\-Z7L8'CDQ;TWB#]]>O+A2MB:GT9@V
MV(!G @LXB\*FU8/U)-.3,-7C.=3(E5D4':%]#BE)V0-]_*.JZ_/NY@>W8J,*
M8L(::T]LT>;L:'%?9?5$R\QQ"K#>2U!)PL!)&^+&/M_E^#ZIG)0H(QK=)3:7?Y/NU*[]AF.7(ROX?B[&K^P2EN??%I3KE77F7D&M^&
MJ3N0P:>./Y$:]P7&L6,\O @O(35H8WPA,4]LUDM+\8/Z,ZALBJEIR?L=W9D)
M@]=<]TF,_(MWIC5M*8:/UCO35OUDL:_%?626'/R[L9#D MM]NN7 ;."4M]E$YM"+1LM_#O"FDM^Y[;73;JT^UXIZ*F)M)ZOW$4,Z'0R,7K
MI21_^,/(@8JB\>*Y/Q()]/V0;SU[?GB_*Q1Z35ZNPRV,H/RXNKOHPXF<>W)?
MWPK?M.C?$]+D3G^'#I(KDG$]#.BF(C9GW_8L<5CD9+OO)0-9&(
M>Y$>F<:;>V_S2GS9I@]+\[>_MB !2;'E65^M?6$24?6=[;/QS_3FG:+5\U==
ML4L]'4DZ=8Y_2MF(6VV^]9HA#*T;L>,T=OIC]@SB0.6XF'3+GM;X6)
M<*[J'KQQ %SN/4!=2AMO:6JH 'O'LS;OCDXXO]F\,;$0OKUOUM1XRR\3UOY+.FTCWYJ%&[Z]9^VR[D9,X0Q_QFQT'.'T+'A",=^TM**KL: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M]H$8>^/8.XQ#SM-/+UGDIN^_[[^;G2X)Q02P.ZU@2/H)QU-R?7"'AHHL^_]5;TZO&A7RSB/S^P
ME?_&.?YV=NHUCV7O@T2$J3_6?@CPY+.Z:T36Y;[2V:Q22:75PXGJY.3[S]O&
MWJW?59%);[M[*O.!R=TW9?0AA^VOLM;2IOK.?U_G1" P5J8_J.AI+DL8+<:]
MZY,'_7\,Z:S($NY(8D>+FMQV88Z76[,FTO.*:*A?6
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M&[MY"XM@Q:AL;K[QZ,295U[",96C'K>'(JMHLBGII*6PMY\_%&_HR?\BZ,IE%6F?<0+
M@*<-%7T>*K\=H=FTM=3]TM'K#^CG&RT.LIBW>H[:1KF9^A[X<8OU]UWXN$Z;Y1"WO[OP\6AU[-*:W<\)[6
M=8BPW=WX,DJ_CPQ(. YP/!F\#/F;X[&XK$G4P8C7[C%I>
MGY86'OW#E' 2!S)M\8?<^9^3M:6HMN\V&GU,7MT:/AC\XMX#29YQC,4JL2/_!&M(]9DL;L1>V +C@NH"/F!S!H84<>]-4N'XQ7 0D<$BYV
M]00 @#?H"5MQ(J6+9PRD?2-,[N:8?!6>^[MQ\5 9>7S1+=5AMA03*Q%MV\[B
M4ZUNKSXMXKJ+90MU'T/8>@+M>_81W3,VF5Q#FG<8.>O;D@,G#\K/:[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M%6QQ./%JKSFBA :4^37
MNF?H5A7#P1=; 5Y%72)4/9X[HM7WA=\&\5+*62-A>P-\);Q8FH[N!YZ=4AROH"A"?!'-I?O<,>F!6!>8MN
MGO]U$T$1JR?8BG\CXZK;04A_PI*JZ$F"JG>AP5 FZC*
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MI+2>9(.>?\;V@VC7W"[0!^.=]R,7U*YF05] PD?2
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M[[1R->Z(\<-W4*M_*W7QYB6?0[>DU%7?HZ>R]QRDRH,%TW\@AY*X2-->E
M:;5 '68%6S\O[.DWE$QPT9UE14% YZC!2,7@,NU>="]R]R&;A 3#XAMV&?P73[[+/25^UUX. ]Y-*X"$@?172(B;"K-B%I1-J8G7&'4V]TMMT?YS8*(IV]TQ7E1,O%#JT]44UT6U9+MV4$A\EF^-3_"L05(+'1'K:A(>/:;
MN,VX$R/V,MHYBZH@L8ZJ)]3]:)'NL;NDUA'3QN1*'^FK^;I>\#,NQ,?L"(%+
M'UR<.?F*/D-9L^BEUG&CL/,A:@9.H!=:(^R_BV'M1#PX>60JC@"1.X\E<8LX
MG;W&6^:\J=43RHGU)CUK"(#Z?6/#.MGZJ]8=-_[(Z5T_]9[1]S.,43NQ%Z[4
MZ3]=@0KU[\TDV67YZ\;0RM>-$P3/IUXY/P'"+.8!A@HEU'O3RA(\2FF>-X>'+''_MF)7F]@3WR%B\6M \.LC4=T\S^X"R6WW\<=_4OGQ?5\:U-<\1PSVZ=+RM/M08
M#E/24F.DB3BIT!.4110'2+P5Z8;Y1\25)?#D,I0Y M3VSH/ E%-E7+.,Z7V8
M>S%6"\$?A,Z/36FU7W? 0SU82?1%]X4,36\: ;6!]01TCEPUGD97?;D4JJ89
M\"7&XP]L9#]_EE4T82F\H.B*0NOWHMD+-F"5CR+CX(9FJ.('P5TXKSUFXLZ:Z2EG+'IE:ME\Z?5[RI F0FM>"OK0(O(!"F)?@DC^U]U#>NWO5!'?0&&$RF5_1?%>='[S'&
M5?Y%\5&QC*=$-8[DED60'R^=;1 #/0@.VU:*W%3='@0CI7,1D[K>U>WLK7"Z
MRJSH_'TBXATS;-O)*F@3E]KXQ7H\N@[F]4\4-P,E+RM'R0*WM\]B6=N_!1@E@!P1$9^::8NJE%T\[E&XSM@X[2DI!B+!ZRS00A?J2?,
M9>W=U%/0+R(V_&V,[BPMQB\)_56@!1+P EMNJ(R]RIZ!ZY/IPRE/R[Q\ZF91O)ZQ$G9^.-MIYT#IKJG^U?:# [K"5/QU-X'Y6NN0D =F J:C_%2XY@)J+LR-(_5\*8Q,W"_
M)G0[XAM&*33/N@)&1X7 8]H\D70=HS4?8[&E7WGW6M>QJ,G!J6C(7K'_:D*!F0V>\KG8
M6I3,E/50#O.1LP'EB.X1 X"*3MZ'@0QW!CFAW:Z6U=#2JHPJ&;!=+YK>RG>_
M ,S5$YB'#"?/J;%NU,=MH ]F>>[@M\U<:@B9U,DA&I\+3A,9#U32:UWW+.'E
ML-T@W6N4BIQ7 ;89 72X(4.[BJ55!J2?8GLRV+_+DE,HN-0(J+,+?/;D4:3L
MC^:$57;/C_Q,K@$1YZ_7.&340_QAF$W@$=G>2K$9UC1!OR*@V=&1-S7E-N)Y
ME L,Z-F ERRRG#SW>R5!XC@=BLI,= \F1& +6]VJ@[ YA9YZ@O7CMMT/
M-V-_\K[S)#_3,C8%7PKX- K\>'/MXKE/>L+U3:0KZWF0GUAF'U*IRUD ^W!7
MNOM.<\B,B[D9IZYV^DLFC\_#X@".NEU0!EP)9J8!!+]:R:,):Y$16P],8FLX)I'
M.LYOI6R("?X-H; ]GV.OF_WWV-SB.(B@L1Y$*/ZXS?+6N5/@_J4YQ->D[O6:
M;<@8?#=8ESTD,NME&=>*B A=QSW'9*Z,\7-IP&:WC4:=E03M)6QI65G6FL.ZH'4YX%'1":@BW4*?'$Q^ 79*57I"[5"L^GT>3HV]FX-4 ;51
M]!JJ13NZ,:8@I%]D#V\KA9EJ.M?F0#WTLJ3U)#:?=2'"\)S6Y>/O9H#_XQSB
M"] ,C\-UG-7O]819J(\*)*#SRN\JN?7#"517TBQB!MM?!9@A-^@0,1&E*TDI
M]#)+QP75Q>^SU&!*:%W@[ES=1=FA#PV9RGJ[=GX!8_>EW ^@(I,W#P44MJ-D
M I);J_F]'[-M^@W)5.C(]7M)6$M']S>QK2XQR_]-G!=^W,K@1/%>4,J;G\"75!1M)7?YYBRY/]R8QK8RPC74C)CA.H=5/;V'6+&;K.TR-/SMS(_R])5^)=?*.T,U%3!10K=ES%#PI[&L]83Z2F8=:1J>]AV]X+"K[C1+=G#K
M&%=F7$==T8*[=%_(DK\_1!.-6/DUO3/*!"4(RYV,[!RM><18,>- IT!'^EW2
MV5S+/;:)E% 9BUK$:OZBST)^=0A0.2><$@;EL63)@MU["
M3Z42!96"-G[TZLMF7&&U3ZBC/^2H*9=/D@BGJ0 NF(^UXPU7N]HUT:=%XE9=+"C3D0#0Z2*L-JX
MZFN%*E-O[9Y5PM9.EO\N_RM_!2PI))88 -U[1V2"4?JN)@Z#SYW0PE.[0G\]04BQR-Q-NH9*RA3YO49U\KJ
ML3_QK!'^IY>)QDN7@JU!B27(A,@='DZ]VR"?S5[&9^V4-+:+9^-P/II%IU=7
MPHN_W(1/=$\6=D[O2U?R+0OZ)_S2Z9&!O+28HW=Z\B72Q4D\8
M)&KW]MKOURC.L%RG=5-7*]EWW
MS%V<3K="&7# =JBCSM5?(OM2]9A5%5):A3!@L^YZSMJFL?GN\N1 UQP(:1T=
M6N_K$7*+ABZ8R''B]MEB%5#=3E3=&\*[U "9*A?"- TO/ T*[(*!684IC39P-VK;-+"=Y-$_Q,+8@(
MG[A.M5"1D"7<(4,UGM38] [.DB!T&7PN446S9\^%DVY#$U&T_<40F,'VAD"5
MZ_NB"VK3D/;:>GY9!J.!1"0;W5V2QY%5I'8<+I,=BJ $C-H6QP/^F%L_ ;7'
M'TIQE^08S7-DVXD^H,>\OB902<$,&(E[4PM:N@=/)X;BR9>7HW2)&
M;>6MW*+PL%\JRR!-87Z?+/LVC@O'$W+YZ,ZU:;)DG)DT%H=GSTDU
MV8]8P$!#"+$#I:D]L]:J2 U@(L]:2%?1S%G9FN'#?Z^S#I!#5Q@3![.4-//9
MNL*J[5@CJ2MNLUT61]-ZCIS?#S9M'HBO3<98-:BB/G<4%_8%E%<$ '.$D4"IN^YLK2QCJ%Z0=#V?,,%/C/[7'RMQ
MR5LG)BU")ZM%1'":;@5:WPS#;6KW+6Y!TQ)=O@#'\M;=M2L'L(JG':^VS?/=#P_7$M$"VM=UQ+!^>BMSXI;1C-'Y*ZW;'-2VGHKU,)#PH
M@V3;*^MA)1P,!K E[PIZ$PH5CZ4\!AW:3;I:])"5?P :3D>!,-BD02.WGH\D
M%OBHY(XIG/GAC@MAZ27*#@4O.5#0HS&]=24:3[[IM8%W(]3,)(NZ2Z._[N_?
M)CZ-T]GZC7K"KWR9_6;8+!,F*[D)'$NVU]U=F4I=6_(+W=K&WN4X?@9*?9I%
M#BS)"UEYXGGU!5<3[9;OX[NKX6G/Q \[#T4D[# ]41 3_R[AMA*;&9::Q9P-I0M?<;VN^RMN>9@+4A*$9CNBHQ[R5 79'D>_,U=1\!#6>K'0RW"U"AI:I&0"#X*%ZT1_M-.
M.2-:C3#5P^F5I2S#.KOQ%-%<&8N(IY>Y0J]8)7-*7^.VCFC=F?;A!KO,9*'W
MH\BBIV#MUL=@9&3EJ6?Y6E\-7^%S42!. HTP*URK?%]!%G"G(!:;H/+\LX^2
MM;,Z)M;=CCC1L2[J[/%'O))C05,C"@9NVN^82F+\ER3Y_[R 5<#1?WH[-#X(
MD(.-O(M1-9^MM>^*O.'@F'2@;\%\Q.(B=ARV6'V#@AR$MS*Q6'(JC?KX;6Z@+:Q)H.M
MEGLF7X2 6#QG#@34\RJ.-Q2OQX=\V=&R!.:E4TP>H;_H"O]CHVM2MFL'Q535
MS3="KHW43#2F41L+(T#HCRZP3B*Q7M+0BAW[.-(B:GUF@^.\/&G2;&NRC9!<
M!8^(X"#^(_(.%6]HNCQU865V \G\L)[PTCFDK*KD_?WC\?GT.&(>@7/P,!H
M!TCHW$S P(U+0C+5? D_F2Z(K0&-4#+L?)6ZL <\U5>9? TS98TT4%<@ZU7B
ME'6'6S'G3N2<=D=+C.DBUAML2>]DK28)YDR2B;L$VSGM>H(@GQM#[$K>TB)D
M0*'*]?4.H9IGS2(KK(D^0T";PGK0H*VU U/Q,,]L<'2$;%)6#O-?P.Z9G='W
M6+0&JF/W0WP(&?3M'B$;=%M;.--0L]+DX"LY@D?>W4WR4KD0:
M]!77PB3SD/@2Z4%XZWT2O K[^('3$9O?C^!QH*O4#_J5[56"
MN"I8[ 63QY:Y:M;33^5MY,FZBVK);?POK9X$_:&KPBQ,7,]*Q-_N<&X\CI#Q
M\.;OZZ[C$UG'V_?L=ZIAA_B45.:]H\E5&$2\S+&J3J[CRC)QX5_243.7LEXI
M=YR\Z;WI%&5& 2L3FT-R9&]I62$NC3%E8'-<2,1@/>$WQ%LBC CDX]2-J2=8
M.'$G=VZ>),M(.\2Z["]((Y19"QI0%L-3!O8TL9DJJ76X;%3C,5Y'1':)E?80
M+T'4\4!/>#43F+T"5.5 O!3J0E-_;$D%KXLT9D4Z.Z G3,/,<&X2ERDASF&[
M0YQ<:'P_O+CQ*A]UUI@4VML*C\7BJ?QD#_*ZY<=+ARUOCF ?W_W\X";_F1;M
MI/5UEWIK5W&DO\L1DST"9+,"]%3>RHX63TW_2^ Y0#2+^/+]^_A@XX[J=JQ&
M=4'G?:12R_I ^27&RW]GVXSVZ:&7"12)9N=D84X351%.I3)M+HH880!&H_&D RVH#S1>.WY+M$@(9;47%=(MMW>31JU,8RJ##3]'-6@+J@:2K2.DDNQ54"OLD[-- M$:70[P:/2&M(L0*)M61
M98:-XMGL'9.;\\K*WI/9+HHW)"+.DP,EV&*.%?3L9NZ K+Q83UBP$C@LFLNV
M1X*AH\DQ??3XL@E$8V5'1Z_1A^I<1
M[1+)9-WM@+]:W)ZM#3$-TYIPWA.57L8UV&K(D0O3MD"\#.H*5KXR'UW\U3])
MJZROJ/MHK9J_D(R5" WF]S$68O5[\%>.LY!&$J^"9+2Q7)J%"V#DQ*4A=+4._P4#JF+
M-#B<8DVR9?L7,NS._M;(;&KU(-L2:[?,D UQ(]W,19S9K<;UE/-.T[R%E4)H"&)=WD(5=OA8!;DTX2
M]-OMOO\XP\47WH&3!MQ>)>Z[&:.O:5V9F@MWZS$C&)4;4XCKKV*VW2QP,Q*O
M2D\G @>@).[#^+]9<4T]N@HM$#AY^;MV"">?2;F/6+D'('PR\;:D@0(ELZM*
M$P\QKPIIZF$3-@FRSE0#=D&1UHY+.X#2AB)=WC'5",\\ H0]L=;6LB"2[1_$
M=#=VLSVU,[#R7H!%&4
MK2INROJ096*H8\@@# :V,ZIW2P^4S/_6#EA%>]X5(AO":H6GFD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MD!BYK-_5V5_>&G;S\CB7.FI :+?7DA_=F@-0M#!Z^&I-QHJEGWCR+7Z,\X%8Y$!>P89KEWDW3+ \&-_#S#I?DM><>BUJ4P#[]
ML2>H=KM7PZ$+(R.DLYOL_G60K-$DZ@F;LYSU!"-K$ TF=MM(%@ZZ]Z C.;PG;@P)7(TQ-L-MGO_W^OE=JM]_6$
MIO\XIY'%Q[_H\V]?(D3M/23^GU\$_T?/349M5NDX-EDG3WX-)Z]&Y\1X7]#U
M<'#4%H]%*(SQWY_ZMV?\/^OJ_ZU&_LT,S?^;H?XO/N__UK>)RM44^R[()6G3
M O_+(T+!VLUX5\Q=>L*+ 1JV,HV #KSIS6-OIKY*
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M+/8\YFE?3=R(K1?<+LRH!S9[YI);D:Y3-CUD^-=2-M _DI0[;^TNAY4'5>330/GZ!WN_%F15# QO$4?I$1[YKX)KA63[ %%.4\:!^Y
MLT-%>B&VX?2(H=W$*6Q;W1TJE?6HNW;"$*&IB.@B<"Z;%'4^AJ$))M<%7.02
M\803\*BS)UT7M+OF99FS$V']J&TNUL8K-7JNXF=D$_$ "2\7/:T
M@^$@L7N@O4+&KPVV>]_9&]R?O;YL7A<8=NCJA7G:CI'E['B%'%DY/E2-MK8[FB#@IG=$Y4LTB^-5=)3T96\C>##4F4J*T1]C!)54VMWK=JR#=Y^\\7;J2
M61XH&Q1^L/%@)D)&[O%[>U<1/Y"ZN=A,DO8WU$XGP*E_O;C8>; 8$FMNPQ7U
MM(N!C8WR,G0SDG!68?(M6NMU83"PPA:3Z@E<8DD\[1FC(T@CT@DXLSDO ('/
M4(3V&/8:,,5FHB<1HE)JSLJM!8U19]@8LR"9L0IK)KSR>!J_-GD*^,5$E_LL
MGL^;./LI[J>>,%2CG8:]%0O&A[P?H*QV@$EWP%Z+'3 ;U*HMX";17-:-H=Y%+4):G'NA=$A;;5+G/;3A:)!O6UGAMI\!X63DMM:3TT8J\VGD
M(T[#J(V+$F@ T@,;AUP50!?7%VZ4\"[K"65)I8[N])001SW!;V'[0-U\!R"H
MI%74&/;8'MM0O>C&U7WB,5VX\6 %.L<%FUFO)B)+/X\W$)/EMM09"%T!-'*O
M8/,04/W.OI9CW_%L[)U+@WPZ=5$@=Y!G&[$^KHV+Z@E@G?B@GL!__9.G>8S[
M,HQT*_BHI1&IRU-I,P@K<#X,3!.NAZN4ZP=[8&_UH^>JG@L[VZ+!=)(5T$KQ
M5H+$P,.'LJCCV.SN>:-]FA7C_+=%#%6>%+68(59< Z #?BX[VV+(27)+/>%H
M%;<+5'_.OFX_K6TLRZFV4E0,Y>^O-)[)?$KF6UH\-N3^?>G>9>/K+*F"F8K9
MZ?
M-V5#T*?Y66T72;U#@\O"SL='$=_?B@VP+N8(XT'IV?T,GX#@B4G"OFO,]VH\
M(-TK'SCDO[CO[=Q&+S.NQN&CJ)QIWFM/^_\3-"\A4_D*8$NGBHZ;E&)
MMXJ?>NL.4$.:ZD.:Z!-NAA/VET#Q66WY9W59H;&%D883T?Q'I+!;6GG8=[R7
M#A2@-8@.PAG_(%+M";8YLOWB1R14$]L\K"=$$%/WYD0,GH"YJ5%\REJ(N5GX
M\PS9;0 8HL^]2YC>V&F?[[:*.HI/82$YF42D3%,XK)O-S&>1:T2.4/73B,[P
MB0-9F1U8,.UK7]KH\J7/?I],KW9Z0C1&>AOP.0.'"&XB2 ).#MZA'BK22]^ H)LO2$5(I?:&@.KMEX
M!]223& ]P12G?X<&<36*^(.E%5]YCG'@Q,C0)BNAMW8F)G&T:':G6^(:)3D1
M]516F]6JM(?:QZ3VR+!O\VBU1].7_A_?OVL;4H\?#S=JZM"[RKE86AQQ]'R*='VVM-M[7T8J^_M]:+/)Z75157[FF_T7TD/^WUW6W[;,\Y
M_.-T[?8("5FQYBX?6?QUJ&O6:ON.&QHFDO"YJ]&J3O5[=,G6)UI;Z03+G@74
MO_3R^52!1]32@)H>AF:'+H5MJJ5P6N26"]K=:3.(!DAZ'<\0/:T$$SGS(/E5
MMC'D(^$LPFJ01GAM0[;E9(%Y$WE$QPOP-P38W0H*V <*[NI(AK8YQ(];<>\[
MCS4P,WC3HAO&J4N1U X]8>;;_3QHF-[9BJ4\PNV:"-31L,@!R$2S7YM^"K2X/I'B$3S!"F&OOXR>?\/DXZUZ0G69MC_Q0NM:%:/X-[')5]0 2<5=R_9:7?8;:5?U.P"K46E<%G"):HK-UN;@/T:9S
M/F2[P;PZIB'6$+( ODHGC$FM$6*C73D?YAU"KKE2ML(WE,,U[RQJ*T_E*KG)
MI)FHN;$F(%G@X%]/ZHHK^LMXX47@"8C$Y@^&50%07K3TYV<]PMR%H$M<1G]"N:%+DK?@M"*4*^R?Y"B^^Q?D2=0=SW5J8G,9#/SD(KZWLE#/4^-$E4N
MS7D,S!+"\AYE^->^Z+=;]K+U)7!//@TX!MS;2'[15 @QAQ9F?/:0&5=+:++A-UCX$7-K%R!Q.\L2:H>CP))3YDT533D4N/
MD7\1+?LK:_N<-KP@8,EB92^]N I\9]E*U+TCS08RT<4WB:BG6K/ZIS&Z+-YI
MLE:LZC&2?'T+1#
M84-.V@V1U%DMH^*9J!U"@PIW(7]P;-E[A%7%36+5CF<1L?CP;CNN^A"SB_5P
MP"[I3X)5AG8Y3A5_P6,O*\ /.: 67Z$+N'5 M[?:.7WR%W!0U=@H[AH^ FW-
M@>0OY"FX0[H1!6S[RA*M6?*C2\]8Z4<816X1LFN/ .71^!O:0[-B"-A#/4'9
MRRO.'A)#>675G3\T^ C\80O; 3W!.^PGJ?Z O6:J+K5=)7LG,D?B3WU7K3_8
M7L(2-RX,>DR8K%]W@8;XF@1K_WBZJ=^3]"761_<<"-<3B.QU2$<1>YKN.6MY\/$AR-,0]80;L]'+[G@K$J
MT_68U;D\77Y!7V!(AHZ?\8]SIS!4 9#8&W7E@"(#MWXXT-VA2?FP&*F AE7C
M*0(@)7M!)8,"ZU:JD7G]X.#Q,HEE',A\6,!'OI*PGIK2#
MV.N2O^VHA7E7[0A8@GARZ'=&$9='7'X:=>%_3-^A>(9-L.X*\"MQ5H1'0Y6*
M>*77H<7-SW#7\_:8C'UZ0@/5LZ2DU:W;Y4+5W<(WA6)D9W+GX,D51<_N\2K-
MUQ.N@4;85'RXVT5KD5:<:(35F-(TE^ B/:&1BT1)NR_4\/!,<>D[96-,:-$W
MP%2XX!&;+D1H2M"^)^0;[VA)L]N /6U&OZ/%!R*:R'FY^MXM\=7\@F3"3IJ'R!.8TZUITF5,7J49ULB;)<09TRSR98J5BM@U(+$3?)5T5QON
M##:W]SH[U![@'?"!\@NH*MQ;]CEVBH%N.HNDH>#YY +J!WU-GKSQY(5H.LQ-
M8@?=#T)XDCAYLF@!J_' WQU"SPNE@Y78K9-HN&K$I_IK%+1XGL+ZT[^&&E$+
MM<:MIAL*V,5<":SG6;)Q(@[\<,_VJM2>IK]E#A9'J0%[3@=0;%3-Q]IYEE0C
M9%B3@/>YCK6$?*7Y6]R)FXIA0Q97A9/?L6QN!#0@P7 !M\K-ES+_P\"C6^#Z3GBN'=A!EM&C*C\B) [(U?%C&*L13L7\DE^.F:U/&"7OYKP>L?<'&)5M+Q+
M3\!FW"ABA\/&@WVYW\1F E(&9P[TB;H"]I%X$AU9*G5]B".DZQ-HEQ05=O'3
MP":<0@P=/$Z5U73^_OKWLT,D:!CLE#+1Z\%KP_+1QC3(2)&#^Y
M,%8(YVH"D5=ZPK3#>!+3JL7U-"+) G>,3> )\#)HBZWN%\UM8F^] (4IDNNX
MLUA "QN&%ITF+7?Q'-XVK=8$+K(VHT_YI+*@YF/C@GBY\^^+I-SVN0">4IT
M^C!N2@,](0I,SW9%G)[BS=(XAIRW8B/@I)8W(X*S"$E7\9)#/)&S%PK17Z%&
M3=&7U$<('ER9DG<1:7V@>< N//,,K;+Z*W$/ X $
M; XWY=Z9\P!\8.SKW\#K/#TA&06 HX"Q,5^37 %T5
M+T0SD%?J?W#,8Y] O*#D.M!J^&19-=A 7=H4<_=2+L.C5\S0D ;UA/+^N39?
M]\S,]5U4T>O*Y5*6P3::FU!^6IGIKVI-&G)=[>KT JSX77=;K#2'C1+R',@X
MA3 CNZ[X/A;L7U]Q+I"D2=0\SP<9H3L^1 \/OE_1>-_-8&*%&*+Q.^M%7VNB
M%HL_YZ-XFB VBS]% E\%9R:^#H9JI['" J'&)'0SU%&+MF\9UX]F+/JPHXG3$AN4%\BQOG#\?&BHEK:JIF1K%O\RVP*7QCG;,ZR/Y"G4!
MNEL(,=-0$^V>K4^1LRHCOC+JH'9S&V;3)W(202?RPY3#)M]"]R*A\<<>!YYJ
M&21+4;^RIAGO7:24PT\YS>7BZM3-E$-6.09)7TY-&[+@1 _=)>YRR92-KVI*#+L&$W 3CL@UIT:-8>[Z7.[$L"
M]JJX*>(WV)QBN5=B !>;@=,MJY]
M*I-NSGH^) =NW1$/N<#BH _HXGR6O2;QPV@1<3=B#ZD;Y"8H"!/KSHG-!CE.
MB+J.LT#K7&^+UES&_Q/_NZO4F%X&^%X.!P
M-ZBI:T;]X=#Z&XCX$)B,+1(@,2#'N6DLWBD JL[[4O3LFR:ISJ2;9-;[53*Q
M^W[^[!JJZB+U$>Y6%S@-Y_%HG!FPJR$.K-T+VU"K0:7+P!#B;X_-&-/:K+A>
MJR<8C<;_ NXV!R>8^PG\&V[3\4B,/G%.,D!Q+%F-J>#NA%J0K+R67-9@.92
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M'V9OA+\F^7TO>A2,/UYGW*DLM:?K!E1V,,?M[:?S+5D]T6BO)K
M7^?AYMJK?HN!T,VXV4VQS_S]=.G T2AZ';8 "LF$U+6QF"OTU".F(U4(,-5<
MAR.1E8OL:DLC8NVRX+FW9N)HG L'L;7LFM2[RDGSQJ5,M#+YE%5K;45U\5.0A$WB]-TP:LN&S:($P,6'4SP\,O>L:VQ";/;UU/LR5R FH
M3]-V..RJ@#E*0K(8=W[7+KY6 'RR4/K'LCF:5083'GC&X';6WU;3$NPVXG/6
MWJ@GS*!Q/;3XF/=O&'T!!+[]@(M.<2=W:VN,:^@!Q#NG,R+0*_%[?@$]F,5O
M_*/F4<2$7W%E956E<[WWX+G F)O/CNC:-LTXT"_/PK'"GK,^I(9\$;/'FD/6
MPC827VDW60G4R*>P+]S86M9&V?H,<6YP-!=6PV%)KBLGBY:5CE61B'(](2>"
MNN"3GL"8]>E>0#M0.GY-M#B27LHMS@8V4=;G](]S')GFUW\K]VB>NX>F81AM"5W^M@-0O0F;!XLO"@/R53Y12:U90HVAC6UE47,T_-G$AA4"ZO,EDV_]ZO
ME5=T%_6$7U-/?2U-5AI=[+C5E/JLR+\A9*.%CX&"=C:2'3B]S'GNHI.O7FSL
M0]\B1'784#*\%E>+X$S$6?,8N:^E?J/BZOWR>N2-YD7;?(2F(!LA!TES<)R(
M4DMMLI;(1G940WP-)SWT\2&$TRXYV$3QTMV*"5X^PM^W6FBAW<2.;0$89 >L
M_30[#$D]K]V)^N/M>;(7(L/0645]3]$'1P+2!?\Z7-.[J HV3F #BKL])IAS
M("F!661\U8U/[&OM6_BHA52S]B18?ZOYIQ1]1Z4,C<'T,7X#'5D\/K05IN$>(A#CV6@*XJUY@=S5
M1K+G(\E:FQKXK.:F"$G(Z38!+M++(CK-BI&M?(KW\=C"/CE4
M..94$!FX[6:N\>+3-R&Z#"<^';H\MKMV.];E%ZKU9_LB6[6;48+N =487:]+
M!W\%B$A@"VB(ML5LS:(;M(55K F#B7A\=LK1@?
MP*G&1>O6&&BOP_::@[B!SJ#SH1 Q;*.B)U))B-,+S*;R[V*8E$;9#)LT'+1;
MR7TD(IO]E0+->)I
M93M<^0O+*].V"VGJDL7E5039$2Y2\/SE_&NY]SZ%&?YTU^5$W^69(H:82:N"
M- <]A^07L??_@_R$O.NMQ4;HZ>FP]4VS2RJZ VI9W2)R[W,DK0/Z;CG.ZUCY
M3.BE)\R9/ "N=9&$WI\BRD-:M?NPC_(2,%E/. 5>QNQT]T5+T:/-' MTE^[*
MHC*D7EV]=DL+^QB4H,PMVX4\Y1=>W+OS(K@U#)LQK+4S$T]SJ\&J-L*T.MK/F/E@4Q<*\!?$SFL+$G=:
M:!:7'K(;41*3A]I5QR*BOB)O&O?$%YS]8WZYJ:J)N?*5<>)'["])Z,]O+=@Z
MSD>J2Y.>\-MP@IWQD/2)C!6JSA_J@VT4Y>DP5^F31K&'Y:IUEZ EK8J;P^E#
M; ,W\DXT/EM-#P5K3E%(,4JF*5BS#O53
M@3(?M4TMSQ"EZ/@B>U:LRKA>;-I_ZYSSMHIV"DGEZ4)/Q=RK@DWVMF)=^?+#
M,AQ!P]?=B7XA>W\_RX6P_"+G6?Y_<(5S/ZDSOPWCV=[*A^LQIB?M$8>C+OY6!-B/OJ?LA&M2<&UU
M,:B&5Q[#KXVR4'#KI"D3]&3*1K6\ZV@?JT5 (Z(6CI:.J^#\.J;=(=V-Q@F?
M>E//.LG.-J"UC#N8M>8?_G1VF*[*G=;)4]*'K&*T)]&8!!5Q:#'.CDT@GT$I
MTS)[.E0W0:_A)1X4V^/T8^:/;DFO@X<-NE_6FWL_4";O%RV$9WCLU;IF;\+>
MO2& 6R_VP7/'LKU32\.1]?CYU(5[OV0>!W5F)Y_\CZW798#/4<-@O
M'R@^4&M-]E3X?4+>@$R:R!_CF2#C#1Z"K,P4]L9S)P6ZF=_[I0U7'XS["8W>
M[/_[Q-35^V,D 4I:$G49]A'7T>Q8XY089O<-=6P=UXQ-Q$TC9L5J[-)KLEV@
MQD1Q*=4)M8,_E_1&WAFNJS[8N*65*1!;1(Q77.GS2+HW<3#S87Q&],6YJYV<
M%+SZR:6=BE3@N/ABB)GNOI"II7RCV^L)$7QDN31)M!C)5'R5#!LAL75QFM.2(>XA&?E?$F"^88;H7W B,;(NFP6]O&R7(\:&*XX80+$W'F#89;B56O(C(^
M3][]NY@T>X:M9C*G??7ZI_[\=ZYV"4Z#*'CD&];C9BJC3T%<]B%M*B2&J9D.1UC)M;+8U*+OW]G ^<(([_J@IROROA&O 73!5
M#.V5RF@!NE1QF%_0$42GW82$::ZG:^C("+R*55$[,9[ F8.8J*QQ=%6M+%82
MS09Z%Y;#0&*,BYZ0RILML'=8TA0IGL[V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M6TI#S)SMQL+XGBRAG!\"[!X5O,>I@V@.M="'TO
MCC"HP#J;AU=NS=<$-S=.. QWI[3^>'B1U3_7+.V_KW1/(T \V5K-<<10>X1-
MOJOX.K0 :O1%^%"E^G KNI=\92R]:%]#(S:':-H37]*Z7QN2GN4])!\C-K([
M&@$BH$B70[[,*[S9;%N8H90.QBC$IFP?Y/RS/FP%%) ZA/JH/0>&S5@\"1N)
M^]+>,A)L%S-T39&OI7SZ?=7:RP!M:0[QSS)FI[-F79,P6$MCC6Q'B$I?DA6G
ML]+]_27MSLC4&#[.PUJ:AUT#WP]O;CL;CV.$I\/VTDB[?Z O1H6%:QW7,-0_
MQ8K+ .1S.W<[73,7 <]J6$4HKXR5V\@3?<6\F"OUA K/,$!&"M3%/+@(> #A
M4F01GA:K-$4P,9%-ASLT$=#P5>$!A=B8%:IL3U"9DH]T"%UPHE[[#Y3QI!0:
M3W)G%#IL!LN?LCU/<"1Y$>KALTWERE%'KM8>>XV1=+=1;ZT]BZE(OBQM*I7$)5\1#%_!;-(&=C:-]3C5\7ZLPIEK1/$N#'SYU
MO,ZU&B]$@ON/O68KM:%9$/]-MZ$CLU(0&7(;/!7ZC=?'4[[F0SV;D.93@#=]*UJYCY4JPUM?^\$98-8H5OYQ@<:>W\CX@&=6T$T"[]U[J#=;M8BLS4&I)U[-\UYY?+NM)MT
M1/!)=+(D3D\XP@F&]_[733:6>W?\F!H+9@%MOO/._+303%SS4,OY9PS>(-T-
M(ELD6#$\E[T-KOX8%WN%8J#LP46!4U5\OAWG^LF5[ZJ?[?SR [7W=5AA^$]_
M[+D%ANL,%. Q>G+VHF;40 5DX+,Y^M-M&-<]>%;X3B6SNFFW9_ D<=.&'IML8K=F]>=XYA 6_KLP$[:V\HGXOGW[K&2KT6!RB)Q>!19PQ1$D+'I["D=9>14
M4&"4\Q@H04/AC42-N)9[T6AP3D6ZW/ICNR^-V&M[0OW.^YGSB55.B!]USZJ6YZ_$/_71D@#NO%DA=\;F.XIKDJQ%?+!(2EF(QSE
M5_WG60[$6QF+\L:'CN&8GZ YIR?T?+](%< G!$I3)[\DLIT]JB=%J2;,.
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M[EEUQD5%[.)A,T#M:NP-:"YT@IU>?%6%I:,^D%KYK CG?[O$%I10'-)P-MQJ:ZNWCVA-5D$TJP^M:#[]_L]=CVYYU<1E%AO[BK_#4@F+O,]>M D21.:>99$2U:H3XC8'<6M @')R-36>-;X8XQ2IRBHR/
M+JF88#;,AFWJ#E(7>.#LXIUG3=R)_(<&N"_''YFE*J7B0JMF-QA.GXMUA\R
MI#@*R.Q]D)M0K#H972=.'&51U[ ]('*M="I";B"5GKMT(5;9732E6^+Q/0_V
M\8&H=U5W@X*!>LXJ)/U17T*]QX$LK#3WW'S#BM.$/FJZ#WR7G?>"?_V9T9W:6IGW@6-:F.;^;S+OD'\0":EM4I$P (S0X)AEU3=!O4?9^J0/,6$P+O"+_FH??OI\*G'(T6SG>../X\ZH%4U3
M#L6^L.MHL[N0P#8> O\5TM1-!XYHOE(^I.^.'XB6 ZH<%6;6L/?@Q1J\;=JO#$;[(UX
MNLB9O1_A*9@&B,4+NC5&.81&(9D0?[^.1UV"QL/.-=PI#G8=BN&Z"[0D +J)
M9V,1O%%>$'D+L!Y[V@-G0Z#'[1QBKYYP25X<\(+?]49Q1$Z@VK%^
M5;76G/DF-X]>)O#[==(I&XUIR'4^*[,N>T'+=S930QHB%<=7U<<]:=F$4ZA#
M6G/"C6#^8)=V+;I$=Q.S0$B*X5J'V6[R62@ B7B*+') VZ?R-C;S\;?*M=8E
M='/DZ>%.^L!)X64F?&_6T:.F0**>,$]DS]Y7W.8F-D2TVV%INI"D)$\9"%G3
M[-87=5+H\Z@;&:^UYJR"LCK2A%1;6A*9?>R^>F_KBIEJ/]_:U:_VHEUL?'HN
M<[%.NA6;H5V!% $1TN0[#87:$U@3G31Y;9LEIR';!CFMO"T\IG5"@E[MA= 3MF5R\*B;$:^I4LB17\KXYJQRKF
ME)^\M+*/OLFDTV!0Y$$.>R:(?P*3)AR#-I8)'UT%-]4SYH>:R[DXW^[NT6^T#$DU%
M^8;BXWK"5M*IUH;-AG\$."$)"/DQ>A;)UWJ -4NC7P$G+P I=!NM5RODM\\-E'ML4U$IX5\$PKB7\U5)-];7T>9P6L7EC8,ZV%"#HV$29H/$
M[H:0A@]]S-0'=4
MHA@V\BF,M"L2)Z++S H?]YAH=9O9G@\V%_32U4S9]__%WIL'-;'U_8-!5%3$
MB" @"%%141'CPJ* B<@51"Y$14% B(K*)N:J(!%"FD5 6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M2 @B"XGNK_70C1QR1[NO!9W7U::!<:@%PQ.K@F7CH
M!@Q#K86ZYM'D+W_*]_%NO@(_,B7.'X%S@AM=O "-:A0X.UR.&7HQ[!6-KRCK
MWW4MZ:=XG-"$B6&6Y27 FSS)CIYP:P74+*E#Z(4>O %ZSBMHSF#)>&W"HFIY@9-5RH;U!R[KR&Z^W[KVZ9MUU5(DWY2Q#?$/EUXLVD;/D[#
MP+WI\^FL*#]>E1+51.0P^?Y)MBH3D0B;X1Q);Q+KR7?4#2A1/#MV!2<25E?PGU%EL2? "7RLO:="G$%IVH)BY.^3W,Y'=(RJ HQJ0Z^N)V9A%.%
MAL'K$])H173]'K"HA;L.MT:^OH:MEF(;)M%EA3/7R@E%Y$C>7%+5GDOG>=/3
M79 C;,2%:%D>3EWG7%# >366D5ZVQM7M,P>7B^J/+FR#DF20BODU8'9<^JSW
M(SEZ-5"M-A3=UQ^TY14*^=GED?>UU/KDIN<%PFO!]H
MWET:HH(/[+TB%+8EI$1A*X7GSJT:@L\GRK4KI"6OH6%,:SX.)[MU>#E';IQE#U6M&^XU1IA%*MP"5YVCDB[HT,U;?L;RJ;8+6067E;0T]23>9IS
MJT1FN_"ZB4DZZ,:G"7,D:#Y6I *RVYG+E*@ THBSM%Z1@@CR>%Y+@VG+H/4J
M.IC$YA_DLL1W,O)2A8PJ,P?Q66_N,H&:QXKG1ZU]OMF9U4;C"YT[;=0'3M57
M5#1X1S[>Y>=<=R+BPE]&)BII.NGGM!+TC%-^:SU-$)9L_M-PIF2_TY8YZ0NZ
M9&=5TBV+]6DAHMD]G2.]"U/"BXPW<32(ROI"5Z,!?9VO" -0B9K #I=^'E\M.07\F4M^#!/FG>;$H#G[>RU.,1RM_%IAC); / 4Z5X&4U3%0X@(>D*$T D@AJL]2QS!
M-"E10]GFD#\XV62)6RY1$_+&NW0AVK%:R#\GH'8L1W)8!FN*;C@:80;J[23H
M7WMGZ!A!D$74ABR$1N1U$C6@B%YX'C;4M_=;[KFHZ: ,LN3NZ0>WF-YU"RY+Q7+90OCJ#EJ#5)M4_SZYDKO@S--^B[N#Z
MLYG&I9X"1(<"AH?B,K7RAS2>AR]^B0(0L2Q9\)0 >!R_!+(?9[;3DN@ZC1BX
M6X=9R9!K$:6/%86V>T" Q56?8:AAEE .*;*%HEWR@^$\$?%(8W\59MTP^4[0
M4XI''NBP=#>J UCXS@QZ.D%/P8"GNN)]K:%,F3MEIZ*P/IC/A+:T)=XKK7<&
M1UC9.F 9N+;C'FQ,)K5ZU<18!!-6$J>\PD#PLVBHK)
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M<,5>8W19D]MQZ'D\HNO"%)4E65]WTU8^W,=:"6M413B-OA,4ZU#'%ES./4&<$ZD<:.$?!@F
MJ@P1*7@FN+:TW%;S!@^/'N8"+4!4!+9RX>,N7SK?;/?XF/\!03/91 HI7IAW
MH05CEK50VCCV7A^Y4VHGH748.C=3]<&L')I\!]X MCOEBI3<+BPJG4L_=S.TQV*WV+3RQ7HV'70E162VU[G$Y(P%2#H[^Y'V(V<,B
M0V="C[#]?H %,+,S6$UH^3S5_C?CL@\..34)\H.!RRHJ0/@^:4EQM[-&K>!F
MM_V2MH+@8.MHNMO%=,2];\4J=VA;IH>C" D599X-QNILRVP90$7WHJM#_5?*T*7?3K'YG"K
MU%J!5&:%B9!4" W)C_90G"0$5@;MMA]3 A?Q#(C"[>
M&1H:\Q>UL5 JRU;)45$=43S2RJ KS]VZ0VUFG)]':8?/X_Y$@HW6*H ?H/'Y
M[B8EZN-Z28>=^]*L')^2'^]S/7^UT"L1D>">\R%(+;W??ML%OO!=J9JY)DI[
MT5%5"9JHJ&(&8!9]I1O);7+E+B"]_:ZME<1O'!UO>U#":($-NZ^8XUMOTVW<\Y7U#7BC/S&!RHPP_KW<@H,=YL-Z;M-H6[\9KPVA'*T5M>^_HADEM%9G*>9YHT=OVMRTL^]X-Y7W?ZCL-;**P+N5E?:5(%,:XNU<_B4H2
M7D7M1I#Z[YMG; JABKX0/^;M,X%W#85]'X.NM06'Z([HBV^Z#*WS[ARUU]M)
M>$=U^VL;_O9S:;\BQX*YF+(<\;2H4Y^"7$\
MM]: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M<0CO7^^20]G;>YGN*XFBL136$V?T"0E;V/4$ORM:0178MH=_F"]1M+>0FN;5%56N$;^"X[#W8T#_*3.TTZA[_>.3]_4N56E4_OD
MG!?M7J/FKKFA.5G<[HX/1F9FGX@3/E0U:B/RDQG[8K.LONRW<2)V :O@,6;-1^8Z
M6[,)&9.CQ1N1KY=8R=LC--AY$H#P^;\*.&J3.U
MH9MS3I7ZKEE4\[)"@;N_[.R:UM_1@DDG4#=&CB>]")S'QLFW/Q5PM@CG.$:9
M+\CAA_MVAHY(J_&!_3.9IC;K/7W_>HC-BSYZHC[KM7Y$5V(E9LV9][E0HF.W
MW"YW2M4JPKTFAQ-4ZS)<=:!:UST][D09_IS-W?V?9IKYS%3NL#\"$O.IJZCO
MX%40A5ZS]<_(8LHM!'4_EOLJ,NH])MT,L_^#G?'@:>!Y&H>\?\O6E+[67&N5!*($I3YH9 $5A1AC.A."NRF%>(:^17
MH0I>UUUKK#!-$C=!8A%740=\5X-A.8V)$C_$G["BU&1^L(YAWNW*O:$B_[.@
M(+(![UX&CKT(9:P-RM@-O]G?KQ.-/Y,'.L9-2LSH29= (/Z+9!<]6&J*7ON1
M?./75Q+#APUYF,N5$I4*N+OL[ QJ_-QX:/L?.$/P365-68CJ+][JD9*H2^="
MWV.%.ADQ==Y/PX,O:P^5*%$CWQV>H/H=MOKX4M]N;;",]"87)0BG[ZJ&[().W-9%_T+'%&MOZ(U#BW3R8;03YE081+X#X
M%%B'XQ.D?SH1@=W\ K"TZ.(RL>]H(0+2W>!=%!*8F$S=0;%6/)L%$HGJS "
M!^\.^S34'_9E*\-**F+37B!^(^M!B57+6O@]:)J:55WF(1
M6I,NLEM $\/ZCG*76<0[]'+OA&'C??4>?<=H30'H4&=Z^11F-;:XZF?]GIRS
MYOJ[1PNA+U.#T!:)?L#F(.I&V\#'QX5HGR@, ?09S4TK(8MJ5YST;:AA$&/L+&MHL(6!*BEN /++&CKR#)X696,#&6V&>U_"68_5$M2HJKD2R1H6%.ED!S>:FG5
M&I"!N=/X)A! J)>+R3%]AJH[ZD*#>@<>/"%. 2H0SW.9N$*^!!(4;L8LEFO(
MEI*Q?$*SCU\34;V8NLX^3Q[<1]GX(JB:4Y,Z6W(#UE%KU2"=[)XEU0@\E*A5
M,UPA4SV(>0YFJ^GG'L(7V9C9\'13?8,UL+]")/YCBBJ#&/#=ME&]6Y;)WJM_+AAQ\5HERNA1V/MM#'0DS&9YM.S[:B6QSX>NI=[O#@MQ.V(2PDUD]N[T<+ULXOSQ]/T]79(?XV(.
M?4)-V"QS@0>SMT!F,DM !RWNV* 04)(VMYRA&=2VX>F]/%RXXSSO95,R$'<7G%O'PVD2ZL@ 8CFY453
M%U&[J)O2>+-,D9J,O+ &-0RO0SF.A!,?0N'7&LPJ2MBM(@AHJG7AMDZ+K'CQ
MC^KXIJ-GICD,Z:-\"X2T;1#H[__4K2:MT^YQ>O4\ ?77#WAD@M$],72"J$-%
M-)!Z #'9/QI7D<72AY5@*4W":O7%9 !&+'#B+"A.D:\+R_M41*@.13D%95:^D1:>V3:\TC^:)#1\77FQ]5&3A-6OK7/O_B[5MR]1-A'PE[7
M=7 ?.^EM]:6,/VP'+7VX!L'FU.<7\#O $/*^5M2YY&B
MZA7OGU.,H(Z;[SA9/U1>0.K\51873H0=9GU;I_LFS6_VC1)5BOD$8R8$8UC0
M(Z%Q(]FCU7>YY$/<)3Y]&;G"N1$!B;SW5P<'YYP'0R,[W0+# \.##JVLC7UP
M[HRN:/+ZXQY20BZ1;).YQ('$">R>,J EWPAOJ$EE*5$57A^(6Y_LD[VZ=
M32@]6HDRLO"C0>F"5@QTBJL=MOKT3&RCMB0XRUN_ A75><1IYW5[XQ8E:G//
MD2^=F$PNXV?7YQ/L0_]\OOH?#F/+ 1R=K4;_,?@HBTGZ0*?N!@9@F H(NI4H
M_+MN58.LKQ^!+B)V3J%$,6;DIE^8'(,)?%*]\34>-@Z_6"BTM9>Y4OSA[F3>
MA_2=6R,QB8VZ_+XVNA%NHP$6^@[FQ>UT-<_4<(0=Z&L5<8X]B"D>*$+.'O26
M;S32!8$X\^4X$VHW7FM?,!B'^#)+$W;8JC$3R>6B2UT).!WR;KH(K4-FG=";
M?O%U\M37*+3T@B)C5Z-&31)N$\59HH=$1D?YF31"(U0GL=C9:NG6'.#4 QN1
M,4YJ\'9FHM$J[S2_9X*BA) '09Q&[^.7:'^AG139N$5DDO0WR.,IQ1*L9-?6
M2]/=IK/W2&Z^; ?64.PD'RJN8VV])YB:HT^VBKTE&A+KN)=C:Z_E7FV)91[N
M^=_?5QU!6< ".?XQXS95-XM;,R>ZS)QU4*+\K\TJ4?=!_[X^HX=S\92-8!U,
M4**DB$65V\GV U]];9Z@@_OQEX%HZW1:&#:)D]>,3M#E:E4Y50:7N/&7=$3+
ML=*L3O&DL#)':@
M1$)H0M_&;<3I2J@5B!M0S:GN!'[KF1]]!;056D'1]X
M7 0$!:F&UM'>X?Y\%HV[*<$+WX-:"^.VDCQOPR_&K872^).WG]48K8?NEI*M
M#O?;^CVORM3,,31M]:@V.5$!?R#]7/+ J?>>Z\-[+ON<% ^!RR+=-M^-DNHL
M$,/;0DNI]P@OXI*?M[DK46CYGJ6O^$H6*M3SOM3= S^?IVF^J7@[K27Q49E=A$+W&+AJXT K)_+M\N.2)A2O"L(FPBK!?7
MDB'ZV=93.U!YJ0S^P&P<0^G'+66M4>E0-:>V(:)-)DMO0R<8/V0VX"M\[JQ%L%%7=4^H]#-MN*DH2J%HJ'DQ^^KA-LNH$X1B_*?H!_C
M5E [Z2OA11!KHH8F7^L7 5LIGN.,,7<6TM-Z%OM&Y9T=) E#;3 :9+?#E;4C
MM5TM8RO ]H?^//%R0>'RWDI6Q-YU\5,0ZSTM9&0FPK
M^^EK#*4AW(DU#Z14#7-&B_.LJ)O*7_H<2JC4W3.UX?>+:IL;]=C=IXZK=MA:,@FA71"26RN(NI:[_J#XAI)E!!6&$ O+2[F$1K_9$[*E#MR)WJMM\+.;VW4GLI(&GU]N>G]"4FXL$QF#MHUE?HROAFSP$",5:$+4MGKXTEMTXV< *JKU/%!UT5KNA^M%O$2XE?]O-M4';)!2T9Z@NUF6S7>J#T+UNL.+9A!+XXJ]L6H!WQI;UN5_$Q]
M0OJY._1CX#E>;8K&,!4#69/TO>5'TUIJM;FKA?4V83Q3C(%SCI<2U>)XB9=<
M5V0S_5Y-=D:58BZ333M[?RGKXD[$M46LU58!\]IHD E3V" AM.#7A^K!VF0B
MKR.)BH=L6HTTH!@)D><;\X1LP[\HU6\KJ*RKK9*L?7B/%Y4O^E#X<5?QM\9@(% _'PD,!%?TEO]UT%^B?:&N>2;7@:
MO<$8M*XSB(\+%>%9_CX@_%0:W"&)Z6/RMO6'F>[;_G#Y$L!CVQ.T6HWB+UB5
M(_=X#4V'@-Z\*&9[<">QPEGB8JO)@VP!BS*9%><(.ZDMIG_HK_"0]Q6,L:6S
MM"8@SOJLT?J*/E@+6O2VHT5?RN33U(>;>2&;O: ;;;@MLFL2]-W*HDMERP-+
MR7$R+S"($SOAUM_6IW-=U2+RM+8*#Z\.^'/C,(O,JI*)L?3E%!6P?(38/SE8
M-52_A!=ERKH6S+F+D=&2RX% !5HH>4[N\(3N
M/D?PS(DM<:H%BJ(O?A]P=Y]%V_H?A8S!Q",+>91",#Q'EF(/M;>M(@X[:[GFRI!Q_OL?"HD.:FY47WQ=F%WTJ=/TDBS3,'%=K#FY[#;D@@B.Q
M#/X>[]]DG1A3CU[8$3G(R*&L0%'C417B32C7S>TZV:A$W8UY>5([.W&Q_]<#
M2M1 #5<@-XR@_?C)_O%:MO!QCR/S"CX6J/00!8(UXYNH[ZWQLM;L4U25G]8M%93B'1NW6FXBT:F'=R!5&4NFL[=GMX464!R+H1O'&MDF+RO>CY9GG2Z^]V2M
MJU[(N2^WKTH%E..TIW)YRZ/X-4-RM_"Z$H:L%BI@#ZYHVK$1/=DPXRG6T)OSCJ5LIQA)=ECHWT0@+!9>2,Z5.8 ?B
MPN+H8+$MF>((;W"JF"??7QT^XCHABLX%P]O$@SB-E3T4TS&13;. [KN
MO<*YU>IKJ/LE^';&2)H7F"M#SQ15/"Q<2);DQOCM-60W]D^QP1$;T<,O9W@-R#M3NCH*:A(&($$JD9\93F"
M6LU(4BKD7(2G84,0NV>L@O+X6^,8$+'5UQ*4QN0&^N[(8+5F!)8/E'XHD:YV
MF2Y8UXC_KFG\8&BS&X(V]\NW0UKC)=AFWY5@:M,8\RZA_FT-;Z>@ZA18R9]5$P[JQF;# HXR$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M8)$B76'FU2&,2!QJB_EYB/5 _6$3'(Q3A[D8\ 0A'@!=T$-MW&A3)R'<:<11!P P.A@)5K-=,1CU^@,WPOQY,F8R!FWN$^["EA,4STO5&_!M
MOGCPJUI+QHDRZ\:T!S<41R@V$K/$5%O=<8:>P+K]/M_0J@VGURT_ML\Q"87.FKR0L\J";HRX@X [/_UZK?SORGBC^EU=1_.A]E8PX_(I*THJ@;+4^
M6!_:V]6B/_XC3+S2CO?>5*9U-BOV2Y1[E]#4C]P1X-?@M+A&5F64"-[@T>*O
MV-KDDCUXDW&AIN@507->[$3$\]J5QW(/#S!PWJ-NSCK14C>4;#.VN3Z@_
ML#L7%9&$DF01QQ-;"&L"U'D^ ,\_>A:O85=,G+;,6/J4]W['W+%$]X:=5ZML
MO DO117U_MM:S<3:8D:TF7;/HB5#VG?;5VPYJC704]AXR<"N7ZD _?3/M#ES'5III'0>_I5_+^3H??4#FGG;9SGF3T^;?7]OZ/VGY2-D(!>+EFV!_5M?2
M=_ R*RWR3@*O80^3IZ^;"?>&/M@)\'WWW0C/M%&I5+R(5K&-&-!6X<^SFQ#\
MN*77UN89.8Y'BIX=-6FN4&M;?\'Q1R+OI3[OJ!A+E:.O67)?"88TV5?]>\UM"VWW5V@\3PB:R=BF^L'6'IQN@K?U5 )HJMU5]S1@?BPMERC(
M<"CCU75509$G>X7BXR4/I;%V];V>IPRMOK6&J]PC4U9!]JN/7H \QH_VM\&M+8LG$8PIV:R2S2E'1D:CS*R&)U#@<5G?23?',2O55=C8"E2FCA=2WQ IJ
M78AD5ZR@<]S
M4F&1D\HXX\17>!5T?AR=Z*O9AS.BX$#_!$1=-39U"^:!./F>)X&U^,0K,]^;
M,SZ,.):5.Z/+B;1TMX]ULRLM^6=>XAXBM_\!(B[MHB*[4:>SL(9%B*&OD"]'
M/.*2>XS^%S*,$]U*2Y>/?:U]G:ZU:49MEGNO5//8E%%
M!7 GO:*T#/S! E;,8J*)*QBX]9#C"1?_%E_5UZ!)@G?+F,Z J'3PA\S-N2<^
M^F59@VXQR?E,/-S3'*B"2IN)1T*X#L+C:IID9KB18V60!=C2YUJ!^%Q;-;_S
M@>-T]'"@.VZ%9&%[TE.*S#"Q
MYE??W8/_; 8=T76WWNJ) $%C827VO+GXR0%S "W0"+Z5$WC3(_S13B7*KX]D
M9@:4I\/GXP=K^+2R)U:_,@5EO]!W[)JI.
M>KNE5\>=5X,6=OR->:E.I%ETN5<"\XWQDY&>0'*ZU$>1)0\M"!J*[\RBUQ')^#.@0TS!UQJC70/B7:5BV^/5)>?65C4XS):2J@X>5:):WSS.
M-XL].N^0A.+)3<>YJR!U%@=_FX+F-6!;J-H@G!F8$^"[#IQ]$6&4^"QP,&F:
MY)H$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M,7?#UR6P/"5+?@["R\A-C,5DDPF]M9;>+_S7=S.!;I+#@@RF(FOV8#0R_A' WV5C6OJ\'WH>B*D^29)FXT#3%J?LT
M_(=9^/8,?#EEGBIFBO'7% >5J+P5XQ$;OPCJMNC<;)^F8%1_2>'%Y1:GXCZ,_OKPQF;]'?4Z;%!%.W\)]6O.KO$U*YO^85**:
M7+DT'D(I;TA_APZ NZ98QR1=R1?I'?HO3&!-;'RV^DO$ CKXW*32_4K4+Z"8
M-:H]Y94X1#B13[X3&.&AEK<.)84F,D+NAGRQ[04*9;;$@%=*U$$9O]$.BI,=
M":9NE.3F@+I25Q!.E 3)7]Z$[3)C_A$_'AB$^9Q%,,7*N._U\.(2DAXP3RQ
M&>'44UZY1853CVY/JQUK_\42KP$$$3FU5C2^V6"9;!.U:^[SI4P>]W;52"27
MX\AWH/MX[F8-AMI]6IF&-HC4YQDKGF%OBN)P?IC.?<5.?E3J04V#]==;B[]S399
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MYDT$GS0N4:)ZUD(GE*@$60M3GO,MI&*K?)D2Q6H8Q\"^/?^I<) MWX:- 6:.4+4!7B/(4**V!R!C6 )BX3N,%IK<
M:B'#YVM2M1;+SS/;F'%W3-3\#G2B;EXX*?S(3TFV,^LP"O6$YIH0V(LQ_+0H!
M6F(A743+/7B.L(%XA1+U_1$-.DYM7G1$9NZD]0SNP2^R"E6(VQ@J>A79DS)R'!3.>$M*HI?-R;72I#&*M59JTTX:?3^R*F\ GX-7E2YY2=B\\P5"38M6FN!JS(]PU ,EK:C![I^/@E?I?
MKD8/A!K^8OG()7_S:L_$:>;_LVF@1D$CXX!\31P?WRJ%F!.ABK19)>J.VQ&>
M^MVP8>IVLO5;@U1O7MVP#]G@=%VOD'+"*/-6*=G<<^0,Y.W;;YY6&&CMD]_[
MQVW5J/?$\0[YFC1/";V5>RM0TYKH9H,S-"@8VP[Q'D_=QD4"F?1(HRPIX#?)S8R%?^'">GY#VJ @ARZ>![R
M-?R^B:M/94>\R,G2RWVX7=->V<_YAH16=XP>95^.73AC6C^PUX*D%=2XMD\>
MU+B^4>*BB#LKJ,UNR \LV7C:IF;WA0C2,L@>7GY_W Z,)CO[*A[.:$.J.1#K
M*&3Y"-"2+_]$.=C7:*Q>-A&UC]4*/5_NS]>Z%:XHS+-I''3%27%__P?98OZK
M6CQ!O[N+O]@%&3/E&WODMM6)4H]*T"4O16XG6M!>Z^!U !V9OV6U?'5%4^%Z24*R3/J-W<\L:8/ %G5YID1!K5:QZU9K#3J;>R
M 7K]#T^&3@<&9.B?H?8_\?A_G_
M9QF>LQ+9R2PF->$>0)6M]Q'@7:58GW0ZOMBVC$6$2.S6]L*0?!&@GP47?DQWMM%:'YB2.HM>BL99=MKLK#PJ^,'QUO)G*![. ?<1,TT9_%E"40-WRM)F^SA'$/&V99-E")71W$S@"[%U+]NSJ/FOK@C"6/,AIUK$_T'QU(*,D+>8+N
MUNX.VX]*;0\O;75=%-=2MBNA.7_TWIO.1U3#[O!JF0&'Z_0L ;6>R\BM#
M,SIYE%4
MZKT'WOL]$86(38&NA3'4OB;R/%(M? CM]-7UQ/$L_2['05O3R(/I\HV<)R#[
M3A5^-:U:P!RJR:"^VO4AC2N0;
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M[I$3>++GQO\'FE$B3K6NXKQKR3N>L(.
M4<'XPJ;P>T%NRBPANG''@"MS J-')GJ"V76Z\;.>]19Y9$?>WU!!T71-.%&R
MIX]13(OY%N*:YI?W*(3@WA"R8?V>@65JU60BWXJ%67M^$_>
MDLGXV2[Y'^7L@PXH^70]W%7_$]_S MAWIY[)E?P,E4?)V!/$E$8+N-EH W@Y
M38)OY[XV<[0E@C&-.&_VM\K($OVNHWWF-,C!8-.MR"D".I@<]4!V=+1@?')["?[\B(C*:J*B%1FPB?V$H9\]B*L*'A>KR_TE'@G?
M-K+K;_&#$9YVCISPO8L(?^BY4CE]T%MV%$IV[:^R*Q1@MI^5CZM*7PHB'HGH
MY^L].N255;5Q2M1 U\^OIAC/QCZ*S?)7DJ45S\@11LP Y$_.U^.AF!G]QCY@
MA]RE>X8^;'4*2AQ/W8Y;3#FL
M[R\M'#/TO"G8?TYE_B ?X,BD)\&SV:X-LL.4W0T#0*^:W!C6&B309M\P!6R9
M"6^6=M="E7Z%/GGV#TP5)IERL\^;V@64LSMH230E:E>C&123PY$O@V[XTW_.
M#,@#E:BU\:+[2E1^>(+3-],T"49D!@9+KT!WK5C $OC=O#>.E@,=GF[- %B(
MFX:LCK$I6J1B 3""VP@/;)+!)B:_RD[G9ILK]J\.MVH-FC4;3NNYTR8GEHM%P71OUJ[WB_6V?E.17!%X\*'O
M&55:.3EQ I.Z*H>_FL!(#&TPNQ;K$K4=)$J)D)8,QPK#L[ J@@C?AN*C6]CU
M-XH,Z)J0K#5]@^55BCU_E"2"-S)W$CSZ!Y;JKBC68[=QE^-)@([\D*0FME[U
M&GB96 W-3>@\?1*@_ZEQM?!4R8*T05M) +W,\QU>530DN)#NV,-%AHZYC;,^ZLF[*+Y03O&1#4Y]>6YL;
MA0LY_<)N!),]8,UDD66'8WU_*%V-^2>?JQWUQ\Z(BR<8TOLHQ6&/(X[7?J3<
M^LMY$IA_!3\NH PQF=RW<@ [R-SS#!%P$G0,B)%0R$ \O+.WWJJ4/#710D75
ML.OM>%&;L/KJWMXC90Q#WQ_'O;'J0T-# ETF)P)]1SN(SJFQ]')(X63ZV9:(
MY6O5FVO#LD1]%"-)O774AS])^>2]M9P[; 955A+6OK'WOO[AT!X4IS@ZZ.MS5=[X=C^_8KR#G.EY;^:8!$^'?B9ML
MO"7?1_R]#VAVB2]-FSA)7WE1@DX:X[/.0.%/1J:D&>YQD6#'F8%0HL8PE-@^
MMJNAT=)ZJZU;D55MS9!"M]<5*@[P@+]2VW%MW%3S"DT5)5V=G%6C(+?^?7*N9#5& /:Q-(A*[$7R!LE[8
M6/%?Q_]9[;]4^>?4B7^*45/;Z]CL&3S/X5^EQU7S<\7_U#3X5_&A5?]= _]+
MVU-(__[O5_WYQ60N?M=_V^CS49&)0J)$#?75,!A?@99HPR-6$< M0/P4-B<1
MQ%C%#+X=*=OWCB!>$872=@O_5ZVL?Z\-^N3A1ODVE_]]GTQ8JHZ+^
MEQ5$F)W4?MQ21:X\')QS[6%>(J7ZHB$UR1IN:\0ET62*+0G\P.8/W@WGJ;N%
M6M T,&C?*?T+7MR@S<-^)UT.:5NF++7?C?DK@RZ\A,0XTL"W61_[TXCZQE [
M:[.D9<_1Z*"(5*[0=%S J,*CT54ONV?=;C&"\"%]%6'OX]:ZKW/[_3<@N$K#
MC=![Y9MXUJ N4EW=P"TR,BI\Q\CPB/>3S5W7KK<=7[EQMF1AU\,$V 3HX VCD5$WB^TQG,#U5OH=O YWKX :[Z!YG-J#\Z&E+&O:C5+_C
MV%)SI$.OO,]Z?1P!F@\I49>\@^O,]K(M^^2X5:')*J^!QE.?EM&$GLBH OMFD49Y9 9KC<8%H]">_)K/G#.;?@TJVBTVK/X\NCO65*KKWC7_JA"[N>?'6+K
M:^QIQ1[ZY"',W7!N&4.^EG7*91U6B1I_BJE8T@Q^K!@EAYZ%6[(U&N+L7EO2
M+U;5]I9XMY$K-ERLD0;V61LM+_[*O("!=LQHEE3B:QC"YQKU>X*Z.6TALB7D
M5<7]"O:/H6G..9CF!)U
M(,>)=S_\.>G7GY?M^O"3!>W;5,'O75*D)[%5@596X;4DN;:JU+/B]<#FOO8R
MLW2AYGB ?S^SW Q?;DZO'L4F$3@?Z.>6_I79%++O6)7ZNBW5U7)BN;]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MF1E""T1;O-ACT#2WABXL*%:B@H*-C"1&!5N?
MRI:1#^8.(N=7CF8VF)P:U$A/JN05&^Y//I]CZ"8[+GBQ6ETS1E9R!$7=BAMX7K)[>POWD6TA33SP[8U>[:]?C0AQ8!7OONZMC/:7W%A(Z(=<=5AB1,L+L)X3O9%MG<[0N5\LX,#I3\:HS6.KRGJ%LU%&DZ+:
M@X,C^+5 #N#/5:7NU=J)IK#%1[15H%ANN:Y<9^DMT=7+"^$'?O>=..13)2K-
MQY^G+65=NY1?,!)2Z#71YJC;TOY-="8M^K?EGRX-MGD':7;\'V"&KEL$O(921J,=3Z9?9;45(_"PER$^ALEP\/J.V-2GJGT7CU\T@
MKDT&KX@*?N[$&[67\A2/L13;FJ*"D0!-*FM,M[J7Q[1R^#9Y4F8V>2_, "U"
MUY0QO<7"]V]%38N3A+I2Q#1C4T='1NSXF!&TE#1XOB;3]772!^(0E^5"6M+V
M!Q_TX>PCY\?_W.J7'%*_23K$M1A@<;VEH
M2&3KO"_]*91V"F&W[KW?3 9#0XQ^ELZD[IT:G&[S=Y5IQ+RRCB8(1[F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M'JEXMN<09@/0\EI1QOPZ@3,">!E5_SRK* 6ND.;W=R72H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MAWX"GBAPHRV!^VS*E2A]N9Y;'[RVI!3PELBG!=;;5"&BC7634"=O478<
M[WUIA(RK(G!/;\%4ZBE1GI+$%K$2%3K5QVA$@E37][FV^VC)T_GUP#[G?]"5
M"B^8AZ=%-@+).+V+B%^)!X+0\%]XQ@TW1GRC]=5.^2EP)"\4 ?.K^JE,$EPE
M^K\ .K541@)LKIH.I3_Q@UL[2=.1'_:Y:[&X>@\;@3L9ZLCP"W ?J>MDY_!9
M$6_?I7S$7UV*RYKOF_LG6ME6R-3X70KTO F\QEV)DF<2?-3XV>+,#NM=7:25
M(Y-*U&$,C2?VS=Y\\C?T3T1*E?.H'Y=ZJ%NN_I2'O*@%ADI("FQBGWQ'A]2Q
M%3-O:-XEWUJ"&)MEP]*T>*.6Z/V:+\C(9+[CY:+S$D1O, _%L\A,7"2+,58I
M"+ A0;FBLODQ=O#D+RLVAN3^^C,R\>RJ89A)L#OY;T")^HT^-(9$GJ<5B)ZV
M!"&VG18 MTL8"HT,?UC+G2G/].FUQH_B)^5*E#'AR2IUF4$[<\8RD ZY>"E1
MWT-L9,8=Q!G+,P#/*EB)>C,[VN?94BKNE#Q9J:'?>3;ZP."LJ8NK:UE#0W2Y
MZ6RSLH,:[2Z;E!0?]')JF??M*W%PG#:.G3X+C/FX&*
MR;:?OR;.[6[!\U0'7PZKP6>731WZ2OYP31X)MP%EDQUB0[B+"[I@.,;C><)@
MT$1J'RE.)+\1!
MZTSA+$).AV9ML5.A7@=>8;2AR%\DZ8ER.QY&2U!=VY$@=\D=A8)]>G=-H ,+
M FIG*SG4$K_K<4N>U5=E'_W$4OV[>7U<.V3/P[(("\P3RLYN
MVRW8A!F2"F=X9_:Z/HJYV6 GK-D9LF/\?5 &=OAQ^Y65ES=9?])9J2+_TTJN
M38)7G!A'PC.4V]6*Z+]%));CVB6-PE=MR6M!:U/60E9\? *@9XL%:]JL+2LD
M%ZF=1 -8;SI[,PA7@9,GH;#PHL!Y=_K$P7VPUG<'>M'7^;+!(Q$B[D(*EC\5
MSZEFWE/M;ZQ$J:^0L:AHB562/' BE7@,BGHA@/?US[J8'NNE'&"D8HY9-UM(3>3:!.EO
M"X_>QC.!EW.B[;*CU';\4IPA11=ZM+?.DNT#5#'T%^::,4)MMU4,YX)<;^)0;/OQR$;L'<4M8H89L.PU"@$Z';#^4
MSG.(G^A*T">TT);+'6,[VKK;=KTMP_.EZ5OI$;6G6*Y:CSTVJTZ0HC&5>+FVEC0)RK,2SO'%]_S&_^"N@I=3 $E"
M@437'HH$2:U4/!2?+S\ T<;%2^6V;(K]B^'@;$L08(G7!DI]=];U-9I">->)
MTP.AD9+GB)5@?7MD-O((Q0M\$#PE!F@4439!Y>V?IS)UZ8QX2
M7^'-$HU'T;:.?.8=KDZ(1::AM _ GQEK[TI!HF\M8U>5X#[,G6(V9$]XO'J@W?XD>L7GK8H[^$LAOAA5[D?*.K!8?3P5[]AK'K*W
MF51L[IUE?)19EWFTM][Q!6?,\1+_/=Z9V5 W<"6$XJ)3LMZZI#5]*/#.!M5)
MTDH*$1)-:)BTX-<6S]+T1LZ01_C:.*-:4#&;SBK9-]Z8.9XL7NL+'1Z1F;2:
ME=+U:-H"YF68ZPUR.1'9N0XIM8?S3Q#S='0RXDOBMP.[ZIKONM6Q'09G!R^5ZMI.HE&_?#8#A'^.S]!1VQW&RL8M/!%83Q[R:&SSQ
MC$.F'^\8H7A?XK'"%#&7^$7TG\$,CJ![RH5SS??'?__5R__;8R_A%?=8U)YY
M53$,/$3=PK2*D[+70QZ77A"AF#"KQ#.UK\M>UO2&A/P94UDE\V%SXB>VJ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MP5M'G'M%\2\L.;Y9)$UBV96$MZ-JPW WM-F^O#^,Q$D\2^(\I3OP162K>^7ME9(A[NWJRK:)(=E+\"[._L?GBOC?,YO&(
ME0'T$5/>A2#=1UI?N9KCD1;,!Z8QXR.O$W*69.>;A]?U7G\OG4;7K$R6:7#.
M?5JW;#.CYU'&KI3[S3MC/@H,C"5+E=>%F>?^F5D1-M=MJ74[YW.L,EMF.7#Y(>;P?IG;,^&0?.JV"8BJ%&2\SEG0C!7\WC+7T-+.7NO[_%5HL[4^J0^
M+-;,R2FIRCB[H39KYWA"S\57%YZ\Y0]OZEQ]2R3R/H4ZM;?B#K>SX\_/="QP
M.')R_;P_EY.;BR=TR -4OXA3O";;HTQ/@GMCZT6<&?54AA2S?O]ZJP._.[#"]^W'<[[^\*V&K\-L;TE"_Q(]/7$-W4EO.P@
MF15?GTK//O@ZMOU1+
M6N?$WTQG68HI-3>,$-MG]'Z;BEIT /M06/T%W+QKS=GS1][_O>V7:),'
M@<2R\)C'@0_>2!REL8\XR\Z9.*?QV_,YIR =?\6F+N'YB_)U :H5$)[/X&1Z
M2+(^X=?A],AJS?]; X!\?Z>!I-'-W8ZGX;\8G5]6AU@FSMK;2[JS')LS_IA
M6^ ZXXP,CZK6:-FV;\/_ '.,_P OZ_IC/YVZ!^QEX"MKA-0A^)'QX2ZQI^A^
M8/BEJ7_(,\G4XOL__'GG&V1N<]3Z<5]M^ ?!FG> /#>D>$-+O]M]0\2ZMN9*BF_U9P2.0
M.../RH \<\!_%O0?'WC;XE^!M/LM3M-8^%>N:=I.L2:BMM$-1.K::+U+RS0
MYLP0+'C#9"D$8&/:*YS3],TJSUS5YK/2]/L[R]2WN+^_MK6.&^U"4]#>W"@/
M<8Z#?DXZDUT= !1110!__]E02P,$% @ %XK96BV?>6<;CP XI$ T
M !I;6%G95\P,#@N:G!GK+MW5!/O_R\X"H@TD0XBH!!Z4ZK4?% I 2'2.ZAT
M8D!Z)XK2FX;VH??>I'%*2''B DF^]O]]S=/??NGGOV;G+FCYR9
M/#.O][R?5\DS(?XDK@"WM34@&L"U:]> %Z0W0)P'GOSGT__2ZS^#_*^.<8WX
M!6"X"<1%V[3D9.<8/R)A4U#>F
MIMO ]6MD9-?)R2@HR,E)>T-(^P%R!@K&^P_5;C#IOZ3D]6"6>O
M%H,)+$CZE6<8%34K&SO''7X!02%A$1E9.?E'"HI/GJIK:&I!M V-C$U,SM[.P=')V<75R]O'U\_?P# M]_"(^(C(J.028EIZ2F_9N>45!85%Q26E9>4=_0
MV-3F9V[N?]8V_FUL'AT?')Z=GN/.+
M_^"Z!I#]-^C_0UP,)%S7RM;C(__I1?UT/%)VV 97GE.4'-"I)9Y3_X#[3_0O8_!RSL_Q.R_P;L_\2%!FC)
MKI%N'AD# 8(!*&"&& CV$;Y6; XA@?WA$MO1 J>8?^M??4Y3YCWO/Y><]RD_.-4P/MPLS:(N@S-G[J($+D#O@B91(,I2>"I9A1/A>B1^UI\U_C.Z.5C
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M^BMD*-C_J"_#*599''NI/^/-]4JA>*KI9A,]_0#+B.4BU$D4Y!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MQ+RUEV:&_FDEU9HG+^/M9\VFXA'UW69NRA[ ]
MI<\*2[SQ6GTL\C;O7;0-=-!34#T?4)IBPF%M:30.!&(]6P(UNDK,MB[@(PS154TTSGO515] HNS%UIM(_;/[?W1?FUX[A90D
MZMJBD>&)I*YU_(98,9^^Z.SQ )N95G:(?J/"V&: 8ZD]481Z.7EQRV6M2M@2)18:OCZY;((KK/5'*O$ ZG:\$OD4C4?F ]7I& 58M>JIR>0Q#OZY"MTT
M$/_-0,3"*F+VO7:56RUJ5+-VU/?"+2"]W^IPYW'<])U3SUG"A3'?93&L>4N>
M?0!T7CR2T>"+!TVMU$UBS'[J,%<@GX[R\M$OH&Z$_K3EM4(+#T=_OH1L9!E:VRY J3Q.;*@8\9)Z,72W$9>H&+/?1XP3X:U)J7"R&^A,Y
M>RHVFRMA?GZK5[=&,%0U$FFCJ98BNM]R%5J5Y24+9M
M\>SBFEP7V$L[=Y;JE)1&UE3?S_<2:&"6SJF<0?YVSUEX(T!::^J B-#S!Z*N
M,RZCJ1.&KF?NZ?R_JQV) -_H2/U""(N)8;4A>4E>,M\=60=YUF690E7_'M!.
M1O#>KI(ZB$!&!"+:<21^TLA6?M#
M6Y3;'S%>AE@Q) *_$VVW_D5=<,P1@=Y@02)P+S34+'1>E7^R4W]511"3]H4(
M, 3+8,]B9*..7V+@KAMF,>CO+C'W_BW)7PV1XRAH=GF5MM,![<[TL%RG@]<$AMN9":!$7UG!]?CA;UB(D.(^S<8].6E'$(GQ4$J\SGX"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M_I8MMM3YT;C=96LQ_=H[6Z*7->=,?]HMO[Z^*5SUN(5-GO[NPWLK#@OV'PM!;T/E
M2"H;ZB)O =V961UV6ST$-\FB;KL^B'CA-S_DQ9KM]:H)[))[.]@*][[2WU1SVNTU@1L'-6B=:HQ773+GC35JJT_/R[3M,KX']0@0
M@\OE['?L!,+FU8&(@";*]K73T,G&25]MW9:NILW%EJ"0C6F$LR99RDJ%GD2Q
M1;+P8(K2X9$LS1%D:YKOEJ9 DMM!S,QB:#KNDD#-A:7L:1AW*EK8[G[4T?+)
MSFOU4@B^HP>A/;"!L;'2>]QY\ZRY>:I_2RWZ-X@:.U^+$XD,3W5DM:7V4M_(/<'G"!/^38>A799^IJ.5'EUJ1BJ-\6,SDR
M^)W*S:VFQLDG0>AE&$N Q+"H<\HX^3WHJ+JV[5+44U2N4)")S-JLEH._37F
M=9S^V70HAP72=6W27KN6IUB#R]KX=X-!*RN:@9VE>O'.[1:EF9/D:@12V2=C
M@SU-,#+6Q?T.NX.^9KTG,A-5J;MOM^].LC@]SU59MM@>J&%XR/TK'T.LQ%I,
M3#,<:]VOKR#W)&[%2M/&YQL(O-)2IEW;S0U?YNIFP=LU7FJ^#;9\66E5)*KR
M/5[N"FS=&!\KF:Z:%/AYL?'^I^1%RZ+3S,\4/2"G\P9<+I8'T]*S^<(VBOO6
MC#=G4"E22>?<+F'C6;O_%TM3M!R"J^^&F)SJ3YS/%JV+U9;)<&]Y"\8A:_GJ^7H$>I)*43*^3M"7B#-LG7H
M]+2Q*1U*1^I$P ;ZVUCLC.MQJ8!$EBMH,HL?^M,DQG?&.66WPC!2#)5NLW'R
M;HV'Q26'$MO=@;ERD;2?5%8JA59L/=%K@LWWUS=9GTGUN<95"X6)3VF3T7T<
M GU8U0T.)O<',O+R%X;L6$
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M@S'91E.JTU'CYR.0[@;IG_+@K;VLVU]2P#.AV0A8Q>:I8G9MT01F^=4 LV1\[Z.)EKTF.>,##:IB&V3)&JRU::Y]&=L@-R)-_>^63XH#A4GR
M6A$O)EMA:-'7,[5"/]D2!8]-6;7E0#B/DR!<6WX2B;E5C' !1_%U9>JU3'EO
MRG+$L=*[WSWZ]JD]0#_=K2"!%^+"#FGR'>"3;)\[(O$K!1DN(=CK\A]8H'%3
MWVBQ_QWT7&]J%)<-3Y-90(/K9)Z![U?9V#&-R>=:(^C'VF%24QH9Y4I*OP3F
M+4]MHYMA\:F4M!6&?WR<#&0VRTN%3I+G(8.G'X*J+M R2!YJDM4V7%&V!1@SS4ZFM02B[(,6?L? 7B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M%E\5C7"7[,^Y+YTWS6$^J3&YLY9@N:@SZNV ?/[Q%XM:2)!XITGV[[M_#[3HTQ9II76JYXCJF@/N&)GYV9K!V0J?HWB9I=*-42H!5M2
M]>K?KN+
M6#:,]4Q-ND1=T$JVS6[J([BR-4MU<>;(X?E#S:LZ)Q^_4LO&N.>E\^OU=.LB
MY4XCB4E[B)64X:N,@CE,)P]Z_L9I9N^PXAG]HSQ\:4K
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MU S7'GBWB_PV<+^R'*.>NMF;Z2H#X\6X7CZF>S()E9]7OI0FK%O=2ZZ8K
M08_!M$Q+\X@[8C!=OMEB@$DYH7%B%$R/R6JP?FKUO+2DM6[ H7G#^ATXUFV*WP^V&
ML'T/RYH)$< :H2+A#]ELZ8+U65H%SU+1@]E>"EQUY+.I^O87(95D<M\J2.=L1K'TADPBIQ9_WMIN^6=M3?> ?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MOMX_N8QH/W /=R,"JW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MKWV[?*O&36:>2_/YP5(Y_%Z"6:MYILK@X^7L49$@#;@MR8VUP"FNZ"])&: VI!0Z$7?0T>44.IZ+
MU>.2L!;I&[#EJO&ADA7%V77:DF_.:4SLS,+K"_S?&\6IC-CL#F4[E.B0IW[?
M2W*5@K2SAZXDGCZ^RBQH9-7!ECY^\.'A/G+; ODW[ &D,T2_)C:GHW/G_8^8
MB2L;10M#6("@P^&OD&6$X??(TSU^D8H23DH.&+5!Z9A,3F7&03F_CWMT.:S*
MKOX03 J"V.>HMP3%]DCHK-,,GB)$.>+1M%R>W#IIA,5>UVC:QVMMWH_#(+>O(VH&ZJ&FH1.V6+U<&BOG.XDQJI3BA/1:ET^ZP02Z]HXT@Z:9U6C[
M##,9R^TVSNW-@9>A<:?<*9W
MTF-TM55$A'S8/N;2;*=Y1HE+5@?OY\S.KN]IY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M8SCTJI4W\-TZ=UGV8:[RE^S;1T-7-?NMG^/\]&9K&NE9J%B95J'L+DM1;\JUA]+B(*E!9;S[C$'/P_/UA?80KZ*RYD 1/_R^QP UU3"2<_VU_=HZ3'+
M\?AM"Y!O-^^$&Y\#DC->VECKV\&Y09$GIWGG)6=83(M)PST:&S V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M$^U9H9RX52\,G_;*F.IWP6AEA](EF&D.&]:L);H&A-2I'&?Y
MN?#7XA/D]A,03$F3UE,\:+DWEVG+1@8'6W%GA3',JU?ZQ_;=T:@M5W>,YZKR
M:VGVT/7B:E=.DNI'-HB0B6;G!0^VVN*<M5G2"YFLYM](R)EJF5V+(=>9M;[G.)9;Y^SCI(7L<]
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M?'3"*CRJMB?*$/*:_V2;[F8?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M\[FNM:W1\J>!'$'A/]/GI>S3_>U>O[/R%IQV7IW$6J#UQI;&+;E[2.+JMC CP7P]5( +(6LRMA8-TQ9SWCSBV_AFNX5>5#IWEJ6=+E-FEQZB65KM>/-MF
MF9C 0RMU,.(T%E/<3Q/,&\?,]WP4Q(,;:#^?H^'3;')>P6>SAM>;DPAGG*/_
M4,F;?+F&?'8 %N0Q2\LN%%21I;#Q:_4,KIR7\,Z19Z(*UD>T$=&M'E4C94L
M//&7Z:F %(8D/&;MS.*"55M@CX[HQ?=
M?5J6.N.D:>G$;G";9:E*LN@U*3SY!&42+F^1R3*RG$$?-A55LQ9SFWJ=S'T)
ME9H,O>\OWVMT^*(@%W0Y:/@(&SI+O_J=M#[%13'@F!XM\CF+(Q/<\,*I'T1'0:R=W&OJL),
M5X]2?&_*ATNNPQ@I+SA/%:?M;WUUG93E&;*")[Z5=@51]J. O\O,RC08Z'78UUNY&"Y%2[5'ZDA+FAE>N))A
M\ZT'$M[;?W?W[WTG4[[/*?3M%E69$3)P\# NS7]I.7"B5B9P1GBMBEZ"0%RUV[.G+H,PO8^9GJ6R+?P:V3N^K/*S@=DI.<6E"WT!+\LLYI?-%N=;
MD3252JT&0;!_05:5?J37O =8G]UH::L0/@ALA^I:C=8#@V
MYV)O7E,GG56ZW-]8PK?"/.W>&+Q81T9J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MIAW.@S]_P-5Z% 2/:MIC>:1B+S
MUMI9W#=Y.TK9(1+>&5"=#M&KO^?/5 )Q 6VK&XI>'AZ>809NXB53>DR3FRJI
M\\=@77H\B]+@OVNK+1'7=IZA\WG23C^/KXN.X/U(,^H>;A.3J=2EI':',FRW
M9LV9,)7O,D5GP>(1QCOM0[.KF_?:.V-2R;((+&,J] :&J<69VI!8)%_3EE0E
M.(E8.2M94;2JO#;?FD]SJ [4I_?^,:OV5M'>>@P!7HI7%[M!AJ#5CN4_]#:?
M0)4(GG538D/295DV@HQ3DQ.QL7Z;_OIQ38MHK4.Z(R-27L7U* K4T7*)/72$!!26ADIK;7S_=M0'M1%3 N.[LO3#59_I\+&F8C8'R>5\/X/F3!N<'IA;+HPW?7C*4ZAZ)[27"/ 0
M[B]9TB12+?B#-9('I[9MQ.D+^FC%[YL*VWDQS+KQ&]-^;48;]S_SK1QE?[5Y
MJ7;YB#!"(+_*D4D-D28(+DFAFLU\$ED6YZL,ZN6&,D:UFB4?3C6>I; 4W7"I
MV<.WALZ\.>B!4[27V]S6%2@6->>OL*EV1NZB=.G>*.@)LAE(%)-,GO>&09$5
MO]#2KF'<9%:QN*ET3)S;[X4,R$5)["J->R3/S=U.CCPV))C:GS=$8M"P5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M0FT'9JEUP(W*LQ)?BJYRM3!><&55JE;="[+\-]GM2PR) %K0VXGVO@6%8
MH+E2S=7(_9VBJ3#G<92L,N!IYZ4BSK:)-D^(V921[,!
MTH@PXN$(Y?P5;(ESPNP#-B$)\G/'Y2M3[NYPPM2M]*I^TN66\0'#[2,7CQSL
M6+DPC$_]0 GQYT^7L3J2=UCAN8S*$FP>:%J+NOM>7T N_S#>D'HC!?L#OD&8
M!S*F*D63>D
M#5M)H Y.8S/)M#^BR$EAX^/6Z0.=W[7.J^?T.]<;WG(H-.9,<9>^+68GJE[,?"FOK/6CPTS8L
M_%:5Z>L94^]N5!.B<,E+&+41N\JL#;:11;"YJ-Z;#(8ZE PV!_JC3)J[IR3<
M["/6X#/5C=KQ%%>_/5F6^1Y&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M;_H%5HX87-ONU\S(#'DUW6T)[EG^';P$B3IEO_!P^]&O8>0PGV%S
M(D\$W@TNGQYMK;YJC@,@2&.R)-L1RJB3V/';,/1@2]DS"MX0%*:M;3T>H_A)VE$:A5#MAQ.BO9M1]V)6@#$Q-E6^'%6K_5DYTO[B?J=WA^
M8'7.-81S4P)TPZ#W;WKXL,!U/6!8&5!,VM0/C\\7]DFJ/T[$LQ+6*J-@1QB7
MU:G)<%47Q-Q(^]56EAT) @])S7N4"6R(WH"#[Z/]ILT$MWCLZ01>UUO+D-/5
M>1N>9]GZXJ?C=+&U]MT7K1,US%SY Z%EH0NY+ (X6RR;#6&\[5*N90TRU7/Q
M.I9O2.H)PMW+JVJ81O.H,IM[\G &1!NAX(9YTY-L2A)S\B.MJ@D1Y;=?U?$Q KJC0R:>D,CNPYG!4428F%Y=>/-JVNX>< VL2KHVHR:7U+Y5
MB2@JUL.66!]!&]_&B>'54>=_C^(G!H]$LNS%)J_UW8FX*N$7K'JU@]J=;SD;
M/53M+Q#-U=^^$RN+_W$B>M+M QT\7]9>GFZ0]SLU\63S]:H"TL-3[/SUOVL9MA(M@_V27(/"^+808H$&*H
M&ZJ//( LM>
MY$_+S;T)32,"D8FA$XACQA\(K%HAXK"]IDLD!53M9M1H&M2UM!3);?CORF<9
MQXK>AFJ#0L]DX4$=I+"(AX%7;/U9T0QRW6_.Z^)6C?L @?&'LL]JM5VOC>#G
M6,,?)_/"K]UW^M'SIJI)+?B"<"(UO@U;7E1MLK\D8>_&WG97Q-56BML6OU&>I013[WSZ&>5&E4
MLGV6?3:[S)2NS%2E8P9MLQ,ZZS\7"]7_=-ZXZ-6!39N=RCQTXZ\0;[
MFM9@JT^W_+8#Q28W%9._2?DV_1G(M*481J=I2:-1&MKS,M9TS&W+D'OR^-"-\9Z9W2B_XF5_>$]M6SS79>%R$)IXIL&YS[U%=B,Q1QH3;G%V/[\YIEUMLI\-SS.P;JJ-8F(A3>M5
M)/_K-?9U6T,AWM6H+87Z1\5*<:%VUOFFEV@'Y+%G[,QN!UB*"+CSG"O41B%.
MCHI(OE:A8&[.%ONL]OT=^ 8>E,O1U,'ZCSM&-65NO)
MPR<>7/&+X=E9(^]6+1=U/3D^UGY%M23BL^;ZP1?GDXB3NQ.P$P2!:IG6(_3;
M!6U4GLI0=+"^V%!'IU\=FH_'@Z+Q8:(]61.+I9F_9458:((\(N3]-6T6KQ'\
MIJQVC42CH:G50?DH9>UA6YO$F. $CZ>^.DMOR#M<+M0DU<[H]G9'8UGL:)I?$][FJXO#O9RA=4I=@QW_! [%5+\S_SKX#7B!Y1V:#<
M76AL((>O7'RQOZG!4]"N^0IJ#KZ8[$V!/'C"7>JZ\59D'\\"WMV+2-J,PD5=V$"'Q=/C E#,33$ &],^/Y;B:;V,.,NL- S6AQ+DE32Y?08/X_
M9UVV?N5GI;O5!W+N$;9 L+'?2X]3N-W #?!-%R1HZ=E?6><:'N/4Q9Y; HGJ
MS=.L;(^Y%7Y']QC(TW^7Q F<]51"[^#_F0T5PH5-2!P3@>M1/%J0CS)2N$+]
M@/CL'@/?!I?GEHNV(E*Y(@?'E?^G5B&2N#_)WYJ)\V.)X
M4M8;FB?%[_ERUPV4+9:-N\0'+N.9$!J-4T3 Z5VY&C7_8-L:EQMF2VU4^[5X
MXZ*(RM!G0Q=1H=WUNX>ZCEW?I&$!(W.'\X?0?2=CLRH3!+776?FJ4$6,I/&W
M@@J;<MEWIJ&GHJG>_8F6^9'A1E+'BHA91O'A4EEF=N]]M'KU'Y,6K>_ZD/=A*J#(<8
MP@?1E3(S4S:1W/(4FEQZ,ML*Q51'@T;HN*F&6$CKJ$9.Q2+3(H\,W@H7B4F,
MR&T()O#-O$R=PMQ=8OVAK)PZ._DDQ(,RONFOV''T>I,_Z%#B]U3-1L?,[2')
M%!%SIL[[8BHT*Z5]E;;AN;1XT96_^J'S3J7J?C4+^%W^LRCW&;>FV'+0I]^I
MSQ8[>MP8_1Z.#N+MUKSYCK(UM#A#=!&3F#1*L?
MFS=F,RX1MC#,#?4)EI6I/A]S>=D7UX'!"O/4=BC.3?+7-N']D@@1Z M80Q#T
MC3V'>SP'NEVT]49U5:9;-GWGRB-;^J8&9TY/-GM^]/THU$&/:4#1@B;5NB8U
M;C*%PJ#:D=GO0W-&IE]1V 7;AKDKRDYC(A!Q-$@*G 6%!,[84Y+NY9W%H+!+
M_LM$(-E8]7OIHJ5N]0X(HB(":/P+/R7.HVEZ;3 K$V=2'8,#%EMG[YH)_
MR\I&M$PMAPMC[S;SU&;OQ>2<]10HN9 TVN)\4]?BCN8K7>ZLNJ^;G H5X/_^
MU#6<&+]=OTLP;FYU/ '/=Z,.$Q2;R^BOV:\H6\3H3SGXIFBNY<)XIBL++H,6
M>]/+O;EJ*%:O>3=@:2^F.%R#R2#V=TI-;:EFX?:O!EH]40I3>HN,@>?K*0J/
M9$WDC7FS-D<4;3-D[^L.HA<#ML]NQ5;,PS)4DZI_<MV;NN]14T(/7[?:+V9"WS599 :^:*?*^=MP#3P J<>H;PHZJ!I\Z"/R.=[&U/
M^CT3!:ZCK^M=-0VN8S5CM6V-?@:YC<7:Q55;AJ5R'0J]C+#?OW_HJS/'TT=U
M0B^I\M5"0J-BGUN)P=7I;W$M'7UML7P+;PDOFH>W[&_-PU&8$S@J_?P^!A5N@JK3'$1%H-@:*Q?M2/;N9"BM5U6D
M54WU@?]O"*Q$9,HFQ:K.O&DTTJXK^].\.AV^I-8UV[
M35U_BB:LT(L]+&--_1+U3U0Z#ZH^CS'':'<:#&X=M".KJM@9Z=Z 654Y_RZS
M=O/XIWVQ0)-JFTK'5;P:;Y^D,U/]TVI3L?':NZO3[#)UBJ_ZB8HRR,7Q-.GW
MAT1@Q_J QS2$KQ]Q3=DOTY8GF+LS4R=FR4] 9Y]FZ U\U^*&=]PX=Z(2?Y'G
M/2'OH*X;+[1R90WYGQQ>OQ-S6LQ_O[%=^6D3AYLPJ%,
M-VOA&KLMKHV3E;H**G8&PCN);;#S&%6*V6Y^PI0%*DQ9I7S>^6(\2O4>+F:D
M3[\3Z5]=[T7-0KM)?(&W(7=7LA]PX)+K4@^(?>K$3T^?PM=1G"
MB]LR>+U/L+4:DBWA:JQH:@^#_?XUE-,K*Y@ZE7+N%/,F)3M7["K.P;%);](7
M9G2BLD(R#0JJ*K?5<*6KC#=[* T/;MPD KV.7=*KFG@F>=T)GTMQ/TQ+W.J!
M>%-LWFPMU+XWHM;?>U(@@+=ZXL"O+G*J:L
MAFTK8J#[FD92S[H9#4\-,V-U19HJ].3U+@9^R08Y'X<86CP2A\.KJJMWJE9B
M9B,%*GS@,H^!<7F\*KQTYV#BQ^
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M1EB*16+.F_"MJ41QF6E>I'LJ&WQI8WP9NT\2^6,P_CFI=9A?\#*'L(
M[*QM0^05"Q&XB5BQ'B("O',.J_0)MI3X$/]VO_<$D+^FS736;J)NXZRXJ7YZ
M*_^+NE9_MXT7-T'J-!\5^(#)C>JNC9(+Q&GQ$%726%DONP)DEWW6(.E8AW'^
M7" 8>D!_2CYQC*+ 11KA?-82H^1#929W0-.-G%PZ^I.Z-84^=@0DVAE&QSVX
MQYF)LT.B!]M1W#
M?;*/]YD'W]E]_H&'B"UYGQ4;B-==)3W/@I4-O+MC4H@QR^>$,SPQ\.%=$PR0
M#*3;+S@KK%]T[9S[MT*_-,VD."J? DJG7\'>JCZ*5#Z\&A283*[>V0([Z2]*
M.NG+8YM#DR>TJJHJ1GI2WO[G$1]A#MHB^]MJY+??:/*FUJF\*(@1 @IB\BNV
M4N\(I)?!%*NG310=4QQ\RK;D&YJ_PL6J\H(R*Z,M<781-YM\[X0N?D)4!.\>UC@5VC,.<^I+0YUP+0&G^M'<&RS-LN!:36CMOYP/0\J@GCD65O,#]NB #FEUF8EMPRW6'XLA.7-?8[=C/&-C/8(J;19E])8J
M3D,=C42?,&C+EA]Y0C,_C2C7Z!LD&TUVG F.CE&6RECXFGXV/4*17"P#$4A*
M.0!?O?_/@RYEWZ-M)RC^LQB#U2?9\?\L__R4[T-;$H4YW4$\&,3QG
M(HA3)B@1T*H(EK2= N^\@EQE='/8;[!:_.3N(S#"G6((CJ(7CE=QX-_H;@XB
M,)?30@3*Y1HL,=TD/DLD G"GM+[E_2;$SAW;"]_T$Q:2AZ/\1<&L_P^%;+-4
M??.L"86Y)86Y5H\)Y;TP*G*&L$>R?Q!W\> *_T(21?:'T#P-8#+OQJ;6>!>R
M'O%ML3;O!CDQWOSJZ++1DG#[+08J;7>]2HWP8B_88RT(%ET]WW_QP]G!GP ;
M3OY8]<]KQINTK2^_K+RW-"C<-0P>$9M0@BT)F'*^4A[5Z"X>]SN GJPO]. 9<) VC+[;6\=F^WO-6RX9MQ.ZT/'MC%B
M((X3OQMUHLET06\7!][01@:)WL%=#O%@=4A)-./?ME:L9(+/_JV%]G4:%=_!
M4 R'!I]JVM>T.@X7N=0\[QP5.7UPF3&>[O.CUJ_6TQIE$.+9/!,%CI
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M:B2RG$K;Z ^_@D$C,K&SZMPQ\X^AU=*VGXQDH%B:>KBQ(1L]''&#CMB
M-V*/1^>CQ(H#N)6LO;0:4@GHO47YU^%%4SO[K_>L)-QN_QSB8VEH-KJ:JMT8
M)U -K<9>.9U^F#J)XLW<466?D!TSN5BU6Z2.]MX\]G^)U(N:M-IF_?:^\D.P
MO2@UX;UH)B.RLM2LY,KG2BSHG+Q4C*)H/@XV$T^::_QY:!MMSY34X>8TN_/<
MJ_I0-OIP!+?RRR)TS^^_Z+$Y/ A])_[/C?0:Z25-1M;GY+ZF&OLZ\4:?R?1>
MWU8U/JP-RU%IQ3DDN)#\Z*"ABG@Q9RM;.J7W^\O-OYKK=+RJFU%DC;X^>>6Y:!5T:.\;8FB,&_XR[CVD/ZWPK?$3ISC
MD__Y^&0[3D-##:]('G83=-OS/_]TN1W$8&U4O"LLNET8UZV]'-.@ZOXP7XQ5
MM2*R/44+(]3A7*@@\JD9_=A5O\7^T]E_5J6@F!!4 D&F)]_%[].2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M51?_N\2E_(\MC$(1V7W[Z5WO,>V?\GD/_[9L@$Z^W,U!F%2N+Z.G5GV&!FK?A3[$KF>3+< "
M0]K]$Q^'\9MDK#V?^) $<0#M!'^MRW"]OL$;QQ<0)#H58^WRZ/M#GMTTCK9L3-K32T=5;+17@LS:7.%7LT0^-V)<3>O@&)VW&AWA6;YW0T/9DCL&>>
M.A*! A@E@9E;F C\F0DEPS/@LBOPMW#5JRA.RP%0?+ZK:WOQ6R^V^>/A5!UK
M[:^I0H6[)FQL#]7$4!UAYJ_:19:T#*\>X2B'",RXS%6XY* J[4SU20B3\3O[
M&+/TX$OST_)FN\C6Y(OZIVM\WJ\3+C$*:_S\PD+#XID0VMCO,<.?6[+(%,A2;Q5'.E"M"SY,T1SV)54]:L@OGG2 \7V]2M38'TE65L_W*#
M_!63&1B;=T 2+HDR4I(4N$I'_M]IS6CV-+A=HF<8U#XQ@:F+]1 ^,WST.%_C=]["ZEZ6L1S 'V3]U" W/'P7AJ
MV_6@1(IW,?#5-^6@>;=X$%)[MQF#A C,NPWSD&2UCRGTV_*Q[@N2F7\_ ,:W
MUSKBW+&Y7\ WCSNN.%=/WW&_*W7UZS/H;M$9>WP\[M\\82$V)E'HX_= U)U<
M7Z3JW?6\W@T0$5!$L:.<;YFXK?6\"G&NDO21YI!#VN
M'1Y>D\[V:U_+N*=SMBY9TE0TNMAF!TJH6V,Q;:9ZZ6BLN>A-1")2I/J?8D'7/>H.%=TZQT#"FI@LT^-J+:G[/X
MV$3BCT)2_Y2D!34W=G5!P1(#+Q\^RJCK>^$RN:
MA-2SI9[=6$W;72,"@K('](1N[]PK31F+*WO23 P@ L/U_C#"( _)D6ZBM?&9
M_]W3Q+95N5@H^%P.2H?XV8=!72E!+$V(@%\I$7!#; IFIR*^'I%\A1?J(I1R
M_EA?W8/'+%05T6-$(!48?'%\@""DX%S;4#A^=WP\$6!![)C]0!WO^U@+_D_]
ML(9&+?*4$I82DQ"'!I(7ESQ73YQJ2/[:P#N@%!>"7;-,4/GQTS_1;'+C#970
M179X,9X\)Z981B?/:SKEN.:20%6-T5$Q79$EA#/Q-.'M]$F5_=;DGW2]6:5!T\>;V K[:XO.7;5?9B/M.0XY8_@Y^,]KU5)GM^/&1_=4MNK8+?!!5^\)CRSQ'+@&OU4PJU4F/0UN\=6/
M$YK86BGVQFH;JE_'UMJK#LZ$\==)8QXNOH=/E6/A>I;S$0FBK&4QI_\&J,.$
MM$^W81BGR\D5V@BR0Q9TVISNZR\[CF?9H0MC?
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M1-P^W_O^XS[G^[O/?4ZN.9W;DJTD[&3@TW
MV\.J2JFC\+L43;A+-=EY<+DR'+$R^9$O1+^ U?C4U]NV[P?@M=EL38YXMC3CD=6CV+#7T D11QN< DL*>Y@!OI(/)V0?I,+; X$>\+XBI4;["Q%^-GGQ+
MH:8],M9VX,'79 WS@6KYXZW)94[$^X=B5KS/R>*D.YBE5#3O3?)WW.L_;9/R
MG^Y/VR>C\]3#>JY5(-TN.%<1TB__+ALP#)7LZEU]E):0E<^'GM^C&1Z-4_E?Q/YB:>># !H2L0:6=>YIQ#WA#S#-EMGC]2E]MJ6=C;N7%V?,';
M\:7_[Q=5?VM'9Z6&MR%_GAR"/8^/(JF4BTS8-P4=G&@^M=[QNX[9>E-7*OM[
M;IX3"K7B8[L.K,QS-+XO<'ETH^V^2^Y/1#H*.A*\O=9CQT/6QV_&0M@HKT@6
MR?@Z*7$'3EN42@HPOB
MU $7R)/M,S<3F:SY7H9G';K=MJ%8:ICKW[5F\B*BT=/2J?@@M+EE;[9'O>S=
M"%1-9L1=H:,L>[='3!PMP:C]W/-66F.G)[O(WY[,K/N34T5EZRTXQ:P*5Q8W
M"XP>9FM_UES= C> 4[5B.HTK,08Q"U4?6C;Z6^H[;B$\Q>?G+6A%2L*C_\L;
M80'4*2KW5!@#3)NH2;!>K-%)VT_MM/>=30O6S?$%D&>"WG_:=J$M9 <=4F4,M/Q]/I\]1$ZB=W@UO9U].,7LPKOM)/QNXW9*^PUH*\9]WEMQNU%U71!L&=N)C9'=B5]DV9$M=(>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M03A.]6(!-V).V[FE.4RT(MT>T"
M\)<8ES8#T(ERH;-_<[/4(:EX#P7IY,0;<'Z=9_ZI]@"_Z=MY75=*2WF!_K,:62RVVEJ_J_#[
MW'/7J1B'I*3B'\1?S!SY35%5WRND2G*:,BI-9'*C:6$3B9F,6R>
M@]>BI.H2G "O"Z2SZ.K"["\PPJQ(=S[X^54>"VWM\B2/7F'6F;#EGG$5Y7$DWI/@A2 ?KAF&@NAO4MWK[ZMCYO-R3V _#8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MZJ=3A]SWQU*/M[K5*,(8JCQ,AL0:OMUG#/G=F
MZQ0!I/NU$/THP["S,PI>6U-T58T73W\9)D:$Q,#HJL&;W1R-$_RYPQ!D^KR5
MWSJB+/WD'&!MB71NO6&,^M+6]K"O7S(RT4DYI@O4!F[^75I>]CL8;*L:NL"_
MOF[BTX,IC7.KR>9AVE3=$VTUT#;Z ,D]LLCU((A65GLNPW]AED;. 4D4NE#B
M9O\JU#.NZ.:V9>\)H6"]_V @"RHP#3+8#R^8![H;% PDACX03![-SY$MVO_[
M@?H-,0S!0%A7LP+M$(+T=4NS6[6?]:4/!V-O_WC[F[U^&:ZCB=P92"HB]]/S$'7_!):JM;*K:0&_U,#;3W@E-765=ZY+2_KGM3:W/8NE3*F.3B.\_3&;92)REJHE,UU:;
M&B=]&C4I-2Q)UM%[D:P[-&!#]!@!RNW?2:!0+G)"%WG\'*!=O+PPW,]+05]X
M_NT04BDU^=D@*B=!\SBFZM!T"T54AN]>A")MJ"YD$#!@QS>A)E>FO7FW>UKZ8V/T:ACC3;4UR[8O\,765FOGMS16WV[P%IT#
MFA&#!L++[J@H#0"%EB18%*\ B<_MM* *3^Z/OSW$&<42!(&%TT?!L_I<2K>Y
MM"*Q;[&AK2UMUO;VUJE]@O.$%>/,-^B7(\*7SUDWG;)QU+GRQO;XS'AW#^$X9NDOOJ9HG)C[
M//"18&F"/ZP5&J*J+G^@IN;AOVE6%1.M=$NBDL-<3"IP2="HD!8AX%A2U3:8
M2RN;JI(8L)*9#IG40>]<^5MTNY,5C[H2&,PK#B3.YWA6@ILNK?[^]F_7W-DP
M/2KHTSS0*S3HP:I^7CRDRU^!RW!"BRLI1C%P'*=X^NU'<8)2>T;S:4+ZE]F.
MCJDN2(U&M4R2 UN_R(",<9))HW&"GJA4O$"ZW1/(&"^%25'4Z:Q<[85# A"
MZ50N*Y'[%XWF>""F%W&IY\:-?(;@NY"?*T&#<=WT%'&21XU&VU)J;.$=TO4F
M[W>#7M5N5%Z,YTZ%_NOLFXS@O+P@0;\8)MW26X-O7E=KF .@>B65&LYYXS7B
M?JWP9Y%R/4:\L@4^_S\EK9D(:?Y\#QCK/ 4>K
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MZS;W-KN#4D[&F'("IQ?4W?- BWD0NL! N89W-US0)BDE4:3QM? PF/*0D.:SO6^/U3^/4ON&LG)+U,K*3OYY6M!CTLOP/RK2J_N0<4A#\"#NQF=+AW?#= "8*7 B(DN@5@&B1XN!_@*H_03T1S
MWP45#B/_I+'+;_8K*Z35
M(K^;+ZD&_64[5XDL7')/Q-0,X9VQX9!)X134:WAD$3WET:? 1"MR)%[_TQ;!
M.7?68,*/(&TVA00N1Z\D#!LU-+1]^9(+C,;6&@W,7;+Z"!2 K(H/S/-Y
MLI [^KJ%7D?=1FSFUC?^K/K= *R&_(9\C^LWR[3VX'K@=+O) ]^A@(U>U0LP
MT-&W!=N:(BFM&BYQY4]-T*]XMZ)&ON=U&!J(NQU_
M6G9U3!$\G5 I6:NPC4@Z==R%GCB>I5#94J-1E]38RW^#WRND,H ND-BV+OXN
MBU\[UB$!*NYZ01##8&YN^5E1LXR60"'-H#S-R*+&M=Y5<@<)T6-W+YLU3\_=
M4%+'3JSZ6SO/^PMV,P6V$AOF0&!]^Y3K6OV3EW2=32&3C'S:U7'5<0F?XA*8
MC9D U=4 VHO'1P <,NDWP@?<0ZX1\G9^([_K; "814DEC\MJJU3J0O6>LJK
MJ)(@4B^WD3JX,"M]R#'E=]O2G%Q%]-0[=5L85BQ=\KQN]<^U/TH9P%4[MV#F
MVI><'= ///H==2ISH%V<__L9M)^[[)-*ZIM ^J76_K'PDZX?\_0D%A1>O._]
MDT\SHJ]<5;]N<,P:8Z3YBXS:7R<$V=D2RB9 &?>CGH@Z(S8J.A&#O%MF;_)V*\\G%CIA,8"$_ UY-3WQJW[&Q?28.)$UUMC*XMX*0NM*.0;SBX+6D;N
M=W7([\,CU6XYZU:;!R8Q>]:8>WM['4T^FG7_?J]B,D7
M0C2!XX24;QE(1ZYZ \#Q%(6[;3QE>2$=8)/!3YKVM)7L.H"8XYVE5,)=4N5R
M?A5TF9[)+;>PX# SQ.#Z$%_#N/N:=T-_DQ%FL;DI/73MC:6EL7Y@M\,_K3S@
M3,TV]U.:L!\Q1G)4!O&L<\ KF-'2RP*?)&ZSUN4.C6,$B*BY=40$XT?Z++L9
MR'[X$263\+L/IBJ;W2TMX[3U16--I\JZN\(CY;AZU*PEC'S,:HQ3&LH1.HXH
MS@Y8VH_=?%S[86!2L&\+%&=1Y;=VC=8- )
MH7&*:OF09Q49WGM2T/&L*C#B4-%Z:]N/3C1BQ*ED]@NP+&579&W*VF3NOHIC
M^IC?*5B+>M@+0@_K^+]L)/ YY)%#4/]BFFB H8^Y55B20M/B2NQND*/@'\^X2__N8!8EJ:
M+%S=&/9CGM/20IOG (2^]6[:=_N[ROL%W81H7C-!#]PG4]?
MT1T8>_TF:X5<0-5&-P]&&E'_W%A AKW>0_)/]C,NXS)H6\JDEO'7R^T+=P(=
MT(4,$TOC:I+%ZV$\XXOIKL48^1 1^5.VE2\^ KN"R$8=QLYZ_6\]WH1A1JA>
M5N;Z *VD\NZFGZ>?U5*O4];;XVB88S4F4^PTS$I;SM0.5^9MV6RL]3)$>/F(POR$!QAVM_;U:.]8_Y8Y4].U4TA,S-N/^8[AA1_N!]3[4&D<
MF-+(J*7*#YR#'6@.GKF_0_EN1X\&%N62DI8KM(.QFSD)5&XR_:"[X[P\$1X+
M,\&]_?#F3E?9C)OSB,=S9R_/PR].NU$#;$GA#[D&HAO-[#5I88ID^*+U]C:,
M?1%U.Q"T1!59[,I[,K[E.^2!C_Z1IO7V\%W?Q"!7TFCM !52+W>",
M=\=1>VL_W'0@R,DRMQ:-PQS"-NS&LF$G+PXM4#W=W;D>_E/'W*M \ZJ<7N]SBLD2&[#3I084_B^7:GQ4?H.^*?[NRO*7]XAYXLK9FML$RN_M#MK'OPT$&P'.+*AF8K([S:[0HSYP 0-_D'-Y<[JW:C/TI>F-,'4U!;SH(!NXJ@
M_(TG;#DHO.2[IS#*4[*ZRXUPJLCK #OIG_(%+2S>M@:2J?&^K^NN/)V6F1_A
M(LWW>"+M$P9.'@BV/:.%S()+P(.'_YX#(K(I-U5<9N^D+D=WSW2M36B/UQEJA2KX9/ -"6)!>7)6U'T'9ERPH^:^R$UO/ODG=3C4F:U\XJ#R>=6L
M5$VYODOHVX\E> ^A#X 7EY<3B/^MQ!4<]H/@[:&)YR8Q5F7\.'U(LJC\<\?G
M,^/ HO";T%+EG7FD3[%PT%/C4#.[U%U*V@J:KN!53F-Q(MJBG/FU"@E&2AD*
M^6ZDU;B6:]'HWP@I6&AF)6"7=U(4?0+I\/.Q/G@CVHU&.M5ODN7IYX ^G@?
M[P**2JU>6K?\#YN^63M.;"V)^ZX\*-P]F=Q6@Z$(R^*KV@0,C%E:$Y
M_8S/'A!S8G<<;H>4"?Z69,*M5J0[U7FNMN9:24B4T?FXMTFNZ("(A=$(I>SUVE\=]YPR917F:?+AP+4@VB1__<%342!)6/JG&B;M*T [W
MF(Z&%F96UUO2&O])G$/%GP-L_3R+*SC%JTEW!YR9IX4Z)=9[1:O-<%/RNM=@U)K]A$0W8*@?*6?78/?E)<3N4"-VW)D8L&UX\&>*]UNH<(U2SO7%V_6[.I
M08O-OZ<93U%WS[+>GZT/PP(NW3=H:?4&N;;D^LT7'!*8,YV&0Z5RFXRJ#_YB
MIA2:MNN+*NTB:DLFRPWK'OE,U##E5PW56_J>S?1Z';F9YG0H'R25T@Q^IUPA
MM>(A?<-LGC#>9=M[+]*MEM,-Q$*^-1/\?PYSZ#+N_8."ANK-1;3C<;_10AM].D9[_/9(6(^(H*>7[QY",!)(19]@(Y$K8_3&OH"5(
M+(BI/7IV4'*ZO+QN-/R3SE8K\HA/]D.N:!6(5<:M=8K/&%%#:Q;
M:UW/J0Q3"'MM"Q9LMSPIN1_Q+=#T"O05K4-$; 1*E&VIH*J[R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M7-F*9AA2=V[WD8AIQ6SFR]7)$F,MYAM6_XS)XCI_
MJZWK*Q5$M+2+%A^Z+_ONM\-;HT$IN'WY=J?C&WGB,Z-T8@XCF@Y%B=BBNQI<
M0WA-ILYQV%.RK4J@4=]A:VWIBT+MK554O[D7L%Q>L+ U=?J$##Z,^_GQ ^P&Z?*?0(>EK.AJ/9)6D/H6
M,,C=]0[R$H[[P)V11)<]-<-K%3+N.W_RG7=)W^H<,#L4NL[C+WV6BU2#67[)
M?$ON:_^9B0JP/L9O##W2/#XP">4+2[/<&UK4AT+'9K^K0H>A(1VNW7*;7B.>
M?KUITW*ID%^%A3,U1>[0N$.7LQ3681.5O^<%RI#UT;J
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M:^EM!Z! RNA]P>Q'7**&C$GER@(%LVO=B7[0@[V?8\SO\0U6PM4?=ZE3\-S6C#?M=5WM@1JMU.;SM;0*VDZMJ-EVWW;]2>^M;_,^PR 4; T/[5E4H9QL/*NK%F,F#=K]+YP*6DHN_[A$3)V)763.V3H@+DG3
M)GY#JL--.U50\4A5+[Y9HT_R,F"TJZ,@W8.FAM9X!R"/,FAU5;\#?0V%T^J$
M:(3-4.6P:GY+O%>HPW: _!;4\ISVQ44Z<._IJ*713WP>P<*B-?E66COX?DM>
M7W#)#6M6PPF"60T:9MZ4;BZN-SKN[=X]#F%"W? T"S N>(X2+R5D9 6:)BN;
M=*V(3;D(:BMW"KK_&D22ZU).(5)=HO!0\7LWA'G>!QGLHOYM%2F8'\K;[G"[MB ]&UKBN!9
M!L4)C[@VXEMGP=0USMI3I]2+(AC212%)1J*W_)MD]O\-AC$"@8! ];,X19T7(.8=ISD60,F
MP$#F)>WIQMIOWU[E/D9?G:KV:)4OF3 ^MFM<7"M^UDTOH B$E+0SD?V?;I[>=:8U;@UB:7BU)LNJ2KF?)_G;-
M7?W@4+.^5W7-N7'2W;ZCY1V#[C'^ PUW_*"Q'9R$7KJJ2==]C[PS* OD"N 0
M"O?W;>"OM;?U($L5E#RENUND9-[1;$&W]V8>?0G(M:XXL3'7'="P;5CVP-#<
M$2MP?^.1[Y\DFYV]!$P7UJ<'[B;]:QG-V_Q/2S=?\U1LM)K/*^=L\6KDAR[,
M 5C9.G?^MLF\:-T:L*XO7>?:/N.W83H)2Y96UVL?6\AT7Q>:_#-.Y:D8"%WS
M3E*Z=6 JFH=_=XTXT.5L)TG+RSP8P 5Z$UP">7(KJ=VC7GY<3=EJ[+"B($ B
M&W"2?
M$OW"E"BTL=KA5PNE)GS=E?H*[W:E-;Q5.%678:^[/7S=U]9C;@WCG-FZO?(E
MAA ?XLA?MS=A'+6:+SS"S=+0/J>^[W%(\%O?8PA\,VI."H1Q5B:B5913K$<,
MV6+9'ZGX5#(/C2ACO%:1QV=Y4Y7P3Z\1.7!'5%(ZQ89L"^5I%4_E(O.9$5N3
MZK;-2SO3MT=N^7-<:)^8;FHUKM=@QO%%>U=]U>5_[_>':MFD&TKV;Q>@$.8N
M>QK9T:_M14WK#.:9^M1>229P0'>WET:J2DK'W:LC#'8)Q7>M2]I/Q@QY/B6]V:;MD<
MV&0GTNWN\HKU\77_IM?80W]27;,2:X[,=L21(>K9_>R3T!\Q,GS']EJ>DKH3
MF9-"Y>*X,:?0K:"9>I9ZN1MB\F8VM[&R<6B2C4FEDT6%MAVS0_6'O45
MMADV8V(NJHZY.C8G!&=^#?*(+)O0EZQ7$4K9ELIFCZU3JY8_7LEVB'Y!8P\0
M0@7=H](D$A^Y,+8FA/$!V=Z\Y]A#7[I)W5XA?GVKZLA%?=H=078]Y:%<(5N'
M7J\K#E14-P4ALX214YT&;W%3_66DCUI?FINS^";J/%AS]-_+D[?Y_9U3S"1\
MIDEF$^/ [NG6I9D]7S*<6U10Z6FF9VU79;-KT%,&@^XAY.KXWCF M&"L9=+IDE-1\_$;-M73F#&^)[ID 8Z824-AO;F.;EYQ?N$&T9]S5:Z6(JHXH-HU5W>U2'9G-],CK7
MQ%V#],&2C,8)$RJ9QI ;U(LP@61-1KFHIE[6PDN*HW,SPX21V+5N%4+YV>S
MBM487.R&J"H0AA'+J?6JYFX
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MO^.JXG16^M)]\3]G*_^F_5(^5%9FT7R
M'*1D=M6&U/P@L3(BHZBUBEFD_#K>N5(P:'X(E]_M\Z-I+KAB,^4^K?0%(Q]J]")<\)9]4.U695N\T\WO XJ!D\H6%F*&TS>NPE1/
M^:C35 'R.@):R$I:32Y]'5P\P=K'PY@';)J4>#DM/ZNZOC_BIMZ*BREK&G+U
M_BPO^T3-J2\X0>T^R%.^5)@=*,D/I5!2@M]7R]>\0(\:F/7YA$C[?6FEL]6S
M; 9[C+978$KEH*_PML @(CNY.P_]R235J:<^FD]0Q2!?N[@XI$@IR>?@)XQQ5G+[$)R;CXR8>,#<3
MNLJ6I"5Q482UN$HZR$4->A@.:8M;*^Z4_,V;D2-4B[\CARS1C;$$TO78B4SR
MM\9\3#CI#;']/<[=NGFO/T3^,(V9;IYJU %[]HQW3@U5?/.CY+!)]D
MO![2DTG'&2?E& @R"U8:"$0DB'Q\]3]*Q]Q+,2*I'T5TM\7IH]D.[VE17A>D/E6,!MP+$;Z7I_51+$_O&GZTDIFMI^DT)TUT4))L>Y?3(
MG>V[(:Y#6S:C<8/ 6FG:7M(YMHA-.I".@]/!Z)=#[3CU0XWZVIE;*H-N1WFC
M7;@P:@G_W#50_]%0?//.X)?W50)!20"%]4QM?B[#RE7:FZ7-65B=CQ=1(.%_+69^G'C80V+]EZ).I!] $3]+SN\93M69ZHUO
M+2&.0Q$$*$R=^ +&\
M\R]6Z42U*N=K;GM@X\E, ?_>_B??S5.Z];MEOB:'T,"MVP7Y^ "G'\A91%CNK&D&K^C@M80L9=&A%U6OD3]RO9H1O,V97"L>G96K+KT(
MLLB- =X8%:683J&6>5X2?;2:TCUKL+7;M!S\=7>F4*X^]&XUR%9+0MR)*][5
M23CC;4O+NW[Z"SL0T#O[07Y& J.+V-4N%0>> ]#EBTU3^#2/-U*V')OZDW4V
MZ-!*&]EH:PZ:F+\>=\VE"(ZM'MNW-:A(#N8[1J VTUC80N@%$;[AQV%=ZC^0;1S?X75-FG>8^\W$L5FJ*<&2X_
MGG#!2.(Q[E+L%KWBGSR;:_+>[ZP@4U3SWCOZAIBJS QQZ'L*!==@RM*SCCGA
M3I#<(U2'WZ;?29%2QK(/C:%9,;O]^M/T(S=SLRDI2S9T=G.QN&U(==ZJM][&
M[SK4U)BLYO'?HJ.)H"4I]"Y0[/S6/M70H
MJEC\PAF39SR*S/T1OIO05F=$#?M/AU%4W:.S[E<7J>,$3K:]V)-99$_1(4=^
MA,D0=>(H?DMT409*:)PO-IGV6Z+ZP;1:![KN@<7_/V0+&UT&?
MI&F/NK09)H(BQ1+42;2:JOU%C A$,1'W(]^UFY=5RV.MD?$95P/89LC3L\PU
M/%$-I)U>"'[OF1? 25*ETJP7TU\FQZSUA"F06A!+=2HC2(-[0*R4?'PSP63'
M:&0(XP@VN("D0BI3.F[TEM5EUE)$RK#/Q58GIB31>9,M^[K7K_4DOKY!9?S(H]CH43V=7$#M7I=^7P?NMA
MF9XTUP9*KL^JW\^86RA/"?R.A/5&>666/C$I-6GA2*_B^%D#VF 6>S0@DZK.
M8:!LNN(NVAY_.'=6@_KSFRIU(=JE?N> M_6H#^4'6:>8NH9RF.7TGSI]BGD4\:,DYU33.O'[\JNE#2^[9TO_ZG..="^L;
M_^E[#F B/UL>BT&^CCIQB9-'W?F+)3'4=6-,4@M?"(C6A3H6W5CH[G]M-YKU9=%6+[WI__9-MU=I@6@]_3;G+,.!=:C(I.+(*;1
M+9C*3;GV^6=]Q4(U11V5@VXLE<)R_+.XP<%_;>CLQUU]OS)T$J#=V.;R31ZY
M_QGYGG 8QDS4Z>V@2V[5$)AT)+$TM%NS&,-.R,%_?Y&%VS:G7[1F5(_'P(&5(<2%0IQ?T-\*>[J9.#(6NK3[\5JU@
MZ[0"IW6Q)=WG *\*)56"1XBB#6G,0
M:=BQJ*\K'ZL*#1'3HS4Z;=0 G15K<,Y2Q$DW>A?HZDI &YY$=&_N?'>QXO!9
M6_U(S8;2SQ]]'@&-C.B7=/#;U>$#XB= XA@EL9#W'/!9*.L<4,9R0+:].!?<
MYX",=QCXECX12\V$*IR6XHN.6=4TSP$O#<3/ ;J2&]"6]7%/_[*%,=-*D4H.
MJ]\3F_:>,^##G/'NAU8U((HH>5#U-8KA933S
MF_TZ?U<6X^?-J>[DY[+I"Y48]>O6F9G]#,1;<$&5TEE/T>8
M2$"F!MWBY>Q'=Q/4/*)D5=)KRY@%N+!?>5N.XK9A/L+AYP!GHYM@W(;=0W)\
MW7IN8=FN#M<:&J=>\"-F]/C7EQ#M"[A =10^=$K4FD!>%3,Y>;@+@O>H4CG!
M.%R/7B%%X<"O%,BBF5*1G
MU*:Q"4*7(V]/8)EPP]D*3TGSEV22F+R4ORNKW.U[D:QKEI[EI"TOPVR_!LKD
MC)K$P)!.3#E-!3JL).O0<\!:SSE O>0<@(JG*O U?OY=R\83K7M_&<'/UWWU
M'! ;3+FHO^+3)1?J+7EZZ@O+:0A-&)LK[TTU5I?%@GNF4P=0.M61IP?2"FUU
MJ]VN"IS9;=FRTRW3[R1D.ICC^=: HRK$O-Q
MB.AH-N^62J[G4 UHC4Z6:623Y?0)V-U(KR1![,['_WM>VO_WAACT)(M54D)A
M]\\!"'HV^+I+3,VA$(H;M5A=1#H@1E([U2Z4M+R0H^X"Z/I3RU#[V4'66$JB
M%T\S:G_K"I5FG)B!S^F3!I!WSP&#/->(V 3/-S#]BEGK.6BP;=?^X?2N:Z,N
ML7=/G"FY['C&DC/OZMH5WI(BX@](T\+9W3$ '*_J< X8V-RU/!0^JPGCI%PF
M!B3N:W* R#$AMV8E=
MM#IS<;6H^1-6SE=@=L5KWD@?.CM\#O#PG#'"Z\1J,$(H>D3>F#JU![5DYW.
M3LPV!AAD/W$@J60Q63*1P*T!%&A%MK5TH%K:K&NG+TG<';LU_IUP]1ULY#^-
MPR)5Z5..0))(='U>/=D(%&OM/7%CAXM-Y!5\')4C\,K3[@FU1R&?<+:;*ME(A>J%C50'I2('=R[%)@-7)X?;
M$VC8-M9G3*&_\U+W")>LCM_!V-;=4VD[F#C&HUN$W&Z@ ;D76 0$M,S7@U^H(@78,>4C7"K4U03>/)>L>G*IW[G&JA@3]LQN_X]S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MO13=:%K@T0 TP+/,)@O(^6R"$.6U !7E2ACG1$N00*X13J\G+-JZ
M9$;E#UMS=D,6Z;?S)KZV9RP2"TCMM68V;OG8IUQ#84FRX^4'8.2\]N5S\.T,4:#7K3TG8I.M%_#T';.&K;"7+-)F:
M]8.X*<@,8^2T?,>%"Q#L-CC\D&70O[NC<<'71Z^%WJYT _DCG#RK7)4.084%
M 6S9%RQFU!YQ.+K*I\L(G@.KO7L>%:&DO=5VU84/Q:=V8?-7VQ6#F8Z*[E#O
M*Y8NT5GQ6.UW09]S.*ID-E2L1,R:))ITI(Q:<]D_\/'XF2W6. >NM/HPA1Y[*4BX(+@(;YI=(
MDSI=BV^>G4X7YZ$H2RBM7$N:V<4SWQ'CNKD_V.'_Y(0GRW9.0$#6M)G!,
M.JZP=93-'E6RB\P]*A<9E3G*=,S0+*;G. =\RUM:.&7QVSE3L,7^44*+7SC=
M=>H8[V7-UP:T-"O=9//E'097JF#$B(NK'^^UP!PP5/6O4\QOYY6E+VUY1DC&
MR]EK?:Q*SQ]',9^])6FMU)M2#KR4NG\ 18WNF!>IVR!D.>DUJUP^BB_]U'MD+@_I/K4X"_#$DI8GZ_.J>\L
MH/Y^A3>NROMHIY3)1LA%KD3ES1;2U*]7572O4EVYE7&&W5))_ (51*NJB<(-
M!=?I7K-232WE@;-E4=_@,TS%!DMP2]&KZG5,^711U0QN@T5)AF'\M_7\XQP6
MS Z(AW-IUOF9W&]'OL-WG .2%#0)#^#:1$3^^^P]B]<@VD%X3F_O.=3&/C7
M0PK\N"M",.#5RQ(Z@IR19$RHIF%CP90_5C.G,>12/R8\_HK2U+
M#:LMUE*[6#N%6? F]*/,#Y116K\=&P>OFAC(QS,]'-@=EDAB5%Y.UN],V7I:
MS1?QH^_?:AJ!2Y T'D5ZDBH>2WATJC6O/6$-S47$:/#"5-*=HMZK\7\D#Z)1
M;]J;TB[Y19H%^I(D/'H^3I9.+]^GL>&]*&1H$?="H"G^.963>!RD]HJD8]I$
M#L%W6-E9;0N$!O5W5TF8/$T5N'V6O_NKQQO X,:1',G"&5Y_[S""J)6#AO\:
M,R5JQ3-JX0G2/2VFOP%,\QLW^G,%3NH_?A5+/HDI5YC;I)2NYJ=,E6L&9!WD
M+S-3F47:-/.:PY[O-?$NG :'8'H6-[%%+G9U')^+62?VUT- +7./>M9+-=+(
M%\4D$( W.LM(O7#\#:4*[$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M//P_UMNEI[/:-;M3-UN<OF"8:CXA,3MW-JJ^[.,PRP=; ?B=)?B!@TM1(-DIA&?S4M-,C6FM#CJ]6KO=ZV7X4W3](Q-5KS@'YECEWCO!0;T@AQ/L D*
M<\)HG,%G(7=]ZTE)WUGE;Q;N%4O;5J6RS!;B' UIQ*=5"ADARV.WKMA2IB/@^KAO1I\.)QKM+AZRG^;(6YF&RH?83RD5.Y7ZIJ,BR(F(J'+30[UI"6
ME^N:-H/]F[P"A-&>L:RF'60(FLIN[8QLZ6QO2##B-\TP25*]HAP2"KJ<6TM+1\M<"H3Y.;,[/LT,
M,JTS,3;)D5QAZWUH:"Y 8$G/S.EZ=OJ".K8WS\E$KL1GOF>XUMG6AOCC7$&0+@R#>/KBK>5*@B]5('3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M5-Q1/PC;E\I*YCVT('(/5]0LBUQ
M_K+-[+0 F7M0"1@#&=%?D:Q"PQAPA1CTG3'JZ4%3O*R98$\
MP6Z:AL]6%9VN9BGI\6Z,5B&K_T?#K'57F>S<$Y=*5PZ_9E8?T??(GD^MPIV6
M[1U#?XO* N#\B9R&=8$8]!,%P\YC+P53_0QZYA%E2;.VFAF31.",GCNR_"RU
M5Y.&RAW(@W[22#R*['SDHA3K.RPI;3BEG5C!_?J9T^6O&08UH9D0?1]%C&0?
M0?.#_ 20/WT4.BY24MQRY'ZRX3? $&$MVK4P-_)/WAF=PQ*,&OQ-S!B>=1"8]YSTQJMZ\%4).078AV7=_I3G 5OAB/Z
M^B+//L"7XHI-)-_13U3OTJME>%RN^LFM9\[RVL16;JRZ]B =[Z94[UZ4F/X])7TW=!0^RULY8>AY&*5RM:_N'>^;$G2Y=X6#WMJ9?%_R#R,FW:.V^9?&POG*A'U$KMWXK0\+Q^P'8.R)Z7/$"4G@.MR!)O!(II_T\7"8*.\;Q.;GHZ+;N[T7Z[WGL,JXB2G=V@RHU]JI\?VZ OF
M8Z?_]1,6^"<8#;$2CT4S3^9\Y6$8[Q1I;T.JO)MX^5IK[5=R#Y(Q)HW\[]SO
M3+KFZ[G:][.%ZKIU#3,,MX$5+8WZ=B XD#]L1'!8\&Y*M^Y@L;ZMF-
M&]I-R,8D9JGX>$=EUNZP5GRB1/[7X)MH9 -F(*M-TBE+7)71-S"I$I'F%P])XHQW0OZFK,75R4PV1/!40,!4J"6B0O
MO" );@1ZZK7E0;]-6PBI$NP#?R/>LVP0]C>M+\$/3LR*,Q\JG,@M%\50KY)S
M*G&N=NK$EHRE HV!K05KW,8T%>:/=18.KXR*T=%Y[1CX^SKN[Z^7;V7J\'!:
MT?/US;
ML655,WNO\U'M!1,[)Z_%@B!"+FJ>:K9":Q9,7=NOL577:(R.&MR:[_W?^X2AT_<06\4V/%U[Z[M8'(P**N;??+FNBKT G>S7&CN=B')XUCY))]BS90@@
M,*0O%P=".[9G5[[9_9T(]GD0<7M8C%Y*3J+CB5W*U_0[XLLH'-2LBSQ.,OH*
M;PR(D.*8U446#O9IWO-\HRM--<]L8;RVR85>?D%==^SZ\+T1TI"LYYW5[Q*6(T&+KOULH&,5U?]*H6J!BPM
M&CT+#97T&/+<^1T.58DQR&74W<#EPS(2H0/N&7@.,$%A**SNC]*P0.)4Y["K
ME^2[#\REK7RC"T\P?U[M:;T.0$<[(QXG!77]RXV\]1);QJ3RMHS]^GGR@1]F;]G-3W[#X=+PQ"5_*\RMA@]B>^E/B*18:G:@&\H>2IJETE:= W@A-S4WT0.\)];XZ@5ZBM7)A2(#7;(*
MX-]:[VY>/#?\NK?PR^7P)=F<--83)C,-"W&IL5EX?7*6')VQ?A)ED5;7?'A;
M-18HL:TOD^9]TPG@E;0'\3H'H#M0SCLGU\AYYX ;%@N4:@3GQ9>PLYE]0EQ8
M$BE8JS_P[439TZ1?CHXWKFF)GCZGCF'/ VLG8.>#RRW/ TOIT
ME8*)JR%0N,1HB.O8^<8URTLQ59:WG_H)TCPR?&MH$C918M#M%,H(?I-V[$3"
M4&GZ%W5AW'7D6+Q&:=TZ]?[/_>$N/4DZL]S1DV$K?3:[52@8&EM"#:5SV&9&&ED!!&?B _F2Z'EP*0HUZ@Y2"[4MPMT
M\H17S0D6Q#0X1RDGG- =+[I6)CUHQ\QO<&:(@A5;SBK(ZR3T5]Z;E"M+W- ^
MGOL3J&8($-7Z<_\F@N XY==E$@)<;D(B&X$\<,$*M.V\/-RYJ07H\N'KXSK*
M.NS.N((F*^4-.:3"E:'S**=;_N>'R_:*X$"DJJN4E HSI,EZ4.%/Z;]\$1;?
MS)PY)KRK]$JJ I@*\NP,.E1M9\H1!O5!,UDJ;!)A=ZR8.?QLM?+/R88*#Z,"+8#W%C(1&%P*6PF1$-6@R/PM'+ ^?=C=?K$S_APPU.*&.I0GAQQ#L-]01+V%8X[N"TK_U88_!YRIS$_JG.$J
M$9OW:NY="/^=>]2N9^< @Z54D8MC,S:PP;&$:SPY$A/(^C0\A'X&U-L79$Q3
MDF,2D'3IG6..>-3.(AW' [GY5L*6C,G+V1K7E
M'H';<@^! N\HH^/] BS?C>82YD4FQ?@^42Y"=40!F>X%)DPPT&'IJM>/$\MX
MF.J=_+U:2'OKE*]H(=W[>:>K- *-[1-V@N]BW@K)1#S(3$6B7O(F@813P^C6
M-6BAPU8P<^*Q$$9J'R'#_R7O6?8&-%G<&!E>YBJ C!9RE_5_$N?2K.V7(%YC
M]+"JGB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M)"9D8[A<>$&7>.[9OYI_<)TRYX!7J'OP]0F] Z/8[ML=9/BIXFLJPZ2EM1:;;P$2]6*W 9$^WMTYO\5VKK8%\(>E)('4B 4D_;]4
MD=)$HQL41Z11K)WB:=JLUI)5="?H3I7&+_W.O<$[&6P![P2[8C)J1X,^C(2B
M[;A/M6$*FLQA#.0F-$M#T^9;'-PC\/6@P+L?"F>L?BM)=XWN,O;Z"0*;/P@D
MQ5A)KZQV8GHAS7ZU18TU%(/@[:&_3GL4MU\)2WE$#<
M.#PL5\RKDO#F_OEK \I?T-! 4ZG<7P=RR]OK_@Q/3!WBZ/7J79)YF&=<:L(X
M:.JIQM^0O0-T[5>QK3Z:+2:#]('/Q?C9QY-!N(M\?3=JJ6=K14HUITH2*$VL<^VJ8D
M2FK?I6I-;%6"VM*%UMXAEM8Z]JV1(0FUQ591-:A@,A)4HHJ22FA)"7[>^^>=
M\_YXYYU[[C_WSWO/^=[/]X][Q<6FAS=2>D+6MPX%$O>0M[T7P>W>KV+(NN_A
M$N1GH^59O^9B\:H$]IC\S$ST]H">DTUE%!&YNJM$LNR5^[TM[M^BA 4T/[ !!T /BIIRZ/I2/$#DVW1]F41ZRS(LE7F& (\Q L1FV?_PWF^_8#
M6=(A3#OLM]24=7D4W//#H:03[!U ;A5+WWRB*YS:/QX [FO53L,4]"RYP-^)
MSYUSM)M:ZE@>6I;J,JU"4#>JQE8,X)E#DQ[)BL=/;6\^FA/)9
M\:KNZ';$XW-+=Z8(ZY>!.WD-7@_RQU6W"O+*,.'QH: ,H_
MZ]JSFF@WZ^-DB/>\9U)H]9]FEW&V+_O. 0WBS$2.I+?^829]_F*KC:MI,S8=
M'^?/E62M\=RUZ139\>!.V8;*K$Z]TV@YZ51C#>@[B82-$QT3[*;)\HP>4_^N
MI,?]HFHYBM&;KA44O.L*,_1VTK"M\QN#I-#[BWF]9KM@S*,BM WF2N[M;!2\
MJ!3"S&A\T_C E/NOQ %@O'6?5LH/Z=Y=='_Q3IZ!W)?$'N4/]F[LCWPB!8I+
M\ -=Q^TXIK^ZK:V:E-6,!0=)* JFBJ:B3/U%@1*X&@").YF$_\0
MI0=,C+HM0H2>U1BUZ&K-5)5_C2'W5U7CJE/^E7V^?;=D3@CCJ$&EP9V"@F[5
M0M."<6DJ]$3LJKJYP+B/G7XVH_#E4P@!\HGJK./P"(,!6+[*9G5:/.W&8X=)'"
MS,"7 _V@X#--R/*24^.<3E.6O%B KD46(^"PG1$-/E#1-*'2:J;KN[/J@*!D
M.8,?A%9\;C'JD]\5*@60;L>$SEI\C0SN7>
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MF9)2RLQM*DM\(N;W_A/:.2="&QH-QWW!%6W2Z04[HBD"VP/ V6Y=1^#_6.3KAQ;9JB\5
M].?1_R/%Q^1?)IPZ9+;US!+@7OF^1#3"EN?N>24U^!C;//&[LUJ!U9VT@ 4@
M3NR4Z=T\AM@>OM*M81--NG./C0)LP0@FL-QJT]6C_N* 4>/I5>]R()G?FF#JP-[K7/AC],
MJVVKX,C8YC@6T>-=N$H"7?4!]1T=^>1N/K 1NWG<_'\7D/'CYMJF2X?KO>>+
MO /U /!QM&9?PLOTO6"O;:_)!'(A\(G_KG+<[V[$7\JG&M5T5BX!A70W3KXO
M$4IA7%:;N%*91;SDZW3CYJ^#6X9\&%M=;+E$D8_G@>=8"2"!P^0WC)4+1GC1
MDJ-BKA?N;N;'0^PR73"&@_EV;UN9\OF!>S@_WNU_C@ Y,J!P]T:-U)M+7G#'KD_)B(=C&2AKL5!M\'1^5#$OU3[6EJ&_B1MR_VB_OL5X_\G$_P/ +UFE!,"!+\?PYVBR$7;;K_+6FY)N)9F%ZO_G4\95.2,
MOE"L?]_:FI>8DDV;;[B-%#*Z?N$)84(47*8GHJSB@8PG.^KSG /N+R/$;6W3
ME8:CQ,+57)15PJ^1T:,KRU@]1VP3@>-44S'HR]U\IUMW]4265_?'/PQ!/7['
M7#X_?@#^)-!4XH0> &XHI71S?*"$_LB"P> AK>(GP>
MU,.1U&$WB#\7Q['WL(RH@7P-;.#RW8 LBV6Q%JJC0F?(
M/A5^XW?/\MYQ!?I7];6.W?-\IZTX/YY:32V4W9T,/+?!/ $0CK,JI?_LCZO
M],S\^?V)X3!M!>98W8RJ1*>XMFY+I(;[;-48@V0_V@5K=*1YV#L0/L]M;7Q<
M[?O,-U*8+JW]*9:-MH*:6GL-(1L:>W_!!18\V6QK-!?
M EH-]COTDB,L21,M7UD@QQ-_9]B=G"!)X2ZV-)4';+5'T,-7:/B_MQA)?T^82S=3.N[9ZDN]>G_Z
MY&,QR<&OLE+@RAQ98WU/@E44(O9GI%[)T=P[P4;AQ5#'''OO7Q;6 U%T@+
M(['VL; @TLS&6#I6.$Z)U]'#*'W2Z2:6YM;ICF(4-P_NE95]'5=(":QWUJY_
M[Y-LJ:#5>^GZG,M(&.KZQA>%A&O1AQB^5VTB%/WG:O>O7E,_5MWT?0KO\/2>
MA(2,[-R4H]J8E/I>66T)?VOH\]3P$>>#RL#6;J4JHO-B@N2;B#7L[G8SD
M&NV8U*:'N+R@OAT-B6@P4Y29+$A?*Z9EQ\"@J\#H#P8;0TK>/Q?IVNM,(KOK
M-;>DPYL7Z#S1*"F)VMXRF"NN&4T57:/$IL6>,@AZ^@"C[[;$5'KUIFR0(=_\
MXSTQ82L<8F
M-,O"@/6KF=_8&]X2KC5?':1L"4I :>IU1(*#W_K2GJF6Z'F(**;"LPO-;_\#
MU<\<^FU@8 [2,#2<6TG+:;.#;;1D/6,76J8= $Y&9U)I6CJSWYXU,%S[1)]!
M!JBE82M%$?^,V9P$U-K])<%E<;^(MM<-O/J=>;,.5'K\1\0J9=:BV'+C(08I& ,;N\-
M_LX[-5Q2#"9E.RZ&-8 ?XF(\5R8_"22K4$RL
MOSQ0<&,B M[9F4%_FQ8MT<@F,B T<\E].M)?*4[1PNYA,+"CZC]*&5-7 GZ^]?!T"3+^WS
M:J$.4/O#N%M??[2^/AUB;ZTSPVO5.'905><*6'
M,LUBC76GYBW36PMQ2/HB0RT VB(+$-:LK;6;;=+2T.O-%1^;V_-ZA6HTC"G3K#R^[O$G5H"C9W,
MN:9)$5WPD6E93NB:MN$%MXZHZ-<+?L_9RE?],J9%;!V2>PFO.V'<&O:+WI<7
M^2_846N[OM7\_/Y]2%N^ X_>NW?CB[&&^@]=MY0O4W&0^*L#@2AL6/CE/U0S
M,T+\VY/-&ER-,TNK]QJ@.M<*(ZW@VPC[B:B-5:(K?KSXCC;X1HY[C8C-8@2Z
MMW:J!M1[LT!M% )7R7N0XRLR0 8Q1DWE2AF% TTSC;FF:P.\$M"-]7M0JG_,\ GSAS-JFE>=*89,+5$N0+>2 VX-/9 (-U*D>"SOK45WH2F>$&
MX]N%UJG5-407VCV'>;>V\WP7WV9>1FV%-\U'D'-<9V97AJIZZ%KH[+U!J$D$
M1;JV^TM'< SREN!'/+X-UV==59'\;I( TYZ5][^=?HT]X4F?5D-G65V;G_&Z
MEJ_MTT4_GWKUS./!\XF#B])P]9S[3.*PQH)_/G%Q.J,CP=T[E>] N1!W;Z]
M@, '8H^1#+')W2("1-TI.T>^BS%_XD?HR;D150U$&*NP+O$Q8S (?NLO:*R6
M"\,5M2UCU<_LKZ^9G;1-+PHM1ZT#B2USJ,8,;?I<1@-K 9GM/E'EB'M8Y5H(
MK])31*D_@FLF3N6LC&HF9CO!:H?BXL4YY@LJ*S43VF/3+Q8B"B;#AA8':U=.
MHUP5<.6"6L8LE746<>VN]=8ET(59*0LE'.]$+R&U^VR$NHS@%I_L6PU; F.
ML?%76MS8137FI\V$3*=C"S.=1G9]H#K];.YF;7XU/>V1/.EJKJ*]M65RXHU( F$ SX
MQ9F/2_D*?CEM%[/#>.O3N_WM8XD4L;C?N/3D(,4)'?R%?MU(U[Q2_91J4EM&
M%>1DMM)'K_,ONF<=(NTK'K$+,J70ZF_P-02P,$% @ %XK96D>#+Z%Z) H^,!
M ! !P8FTM,C R-3 S,S$N>'-D[5U;<]LXLG[?7\'UJ3HU6[..?(F323:9
M+5FVL\K8EL:723);6UL0"5F84*1"D+(UO_X ("G><"-%VU .7V8<$9>OT8U&
MH]%HO/OGP]RUEC# R/?>[^R_V-NQH&?[#O+NWN_<7N_VKP?#XMZ^ZN]0%Z, A=*S)RAKX\\6UC:R; 'AXZ@=SZX=P_C=KUYJ%X>)MKW=_?__"
M)F6PC0*(_2BP(:8_6+N[I,&TR4$ :8-OK4^DU8^19QT<60=[;P]^>GNP9]W>
M#,@_R"^LRE_>/>"WV)[!.;"@"^?0"\](MR=P"B(W?+_S+0(NFB+H[%B$+H^4
M#<+=<+6 ^/U.@FD*\.2%']SUUI]ZI/V7.U8(@CL87H(YQ M@PW4%2L0"K\BH
MP GRY]"A%- Z1WN'A_MI1R[ROA:J/$P"E_5SL+=WV*.?)P##M/AB,J_9P4.E
MA_M#UO[^FS=O>NQK6C3"(IK3+PG)2MCWKQQ[2H$P;\ 2$?>A0%!7&PNW>XFR.2E$&2840>#@$9IQTJ"Y9%I0%XGA^"
MD(@O%:F_4+%B/R\6R)OZ/R<_D1_I"+U-^7 %IQ8;L[<4R?L=C.8+EW*'_38+
MX/3]#N'1;LJ%_[I@\H)@3$N P Y\%\KYT5L$_@(&(2(#GA, UD"E=I%0^KE'
M^H3N>89XI\=F34L4+0+XY!21/C&9LXQ=9<+:HGBO2)/,2CJ35FVM^AWT7.53O'P.73NGK&81$=R"'
M4?[?X+_",IFLI! R!OS\YLW1X=X^68*NB92Q!8+\G6\J^X M?VJ=(8^TC(!K
MC7W,FGC7*[>9YV/:982A,_)^9G^7I3II(2DBK5H4G7)%>;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MY\C.95OJ)ME4LY<$-T4$!.P;]M^Y(5$J,=$<=G$;LXS
M2%)*N=Z]+K,I;MCLY2]U.9G6GK>7:NVV>Z,NNAVU^H^'L%J4,2WH"OT"=_,>\BL"F.>Q3.+@?]
M09ZS&J75>O1-F:-)JU;:K)5KUZ(-6[3E;JJJIBJQ]*X@#@-D)_8DF0ST?]1N
M7P*W,DUURJO4[?Y>97Z2%OYN90W'%BC;)-(_MT_;WR[Q95^X4HVKPD]4%C\$*3%Q(Y)?\$D30.4=@@EP4EDP6K?+*V710YEC:
MK)6TRR92TK*5:[KSLB@VXDOJG24#>.F',!VW56DSSB^CGF>'%1V8M671QM:<
M6G7; RFC3HBEOB3]+N$G$! K(!3,-FDYG:WW_LLRS[(FK:3-;G[ILFT<^'.$
ML1^LJ+07.%7^I&'S[U?<(EDC;#IUKBR%X7 ^*ICM[-]J-59Q<-!ZG:6@%/[X
MYW,PP>>APQSGIP\VRSM])&.^M:P;;A
M^#0YD?3NQDSWP[$+;.8Y(%96L@@4E9EN'1TM5_%LT-:M=?-,[;$>K'47S/I+
M.^D8K'&T-@ +% *W)2UT;@D%&T;A# ;QB7">"_F?5=NB
M@XJ3@=5.SIF[>:#R"S%!O0 >N*L&#E0^JF?$0<6OD+1B9MYQ5TZ>GM& 3EO8ZBI,92M%)30F%\5?T*\XK"VK'QCG7&N8E.\1-R ![IOS'.G^$''97!0<1G$;5BD$;8M
M[7P$,DZLH_^&'@Z#B)W/$7-V_?,5PE_Y:U3-FDIKHN)>R (3MK&\=LS/M&$TP_!81DD^7Y7.GRCMP2LEY]&KO;V*B+9;JA)T%8$=&4%%*:AX1W
M%7N>&]ED_1 WV47T-HQPJK)-659E+!+F56Q[6;R3C(?=K*L5%U/EIG8=G3E9
MV0/H1M'4OJ1=94N56CEL;,J^PH=.-L%&SN^*P.NN%H57E)G8E9.1X5A^!T=NS&H3A5
M%FJ45@0@$"963D3E,3G=7&PC1J'*2W5AM;N4<+-R;JJ*6.ALFG8C%SBMY?2I!G_7#&'H.%X_E*'*5ZFE[
MQZM63MVKC-,JKU23%5^.\OB]8VB3\]TJ_WB?E79H-3:\=-#;&9Z/=.I;96"C
M^FH'0#7$O,$9<+>1U#->[!ET(A?Z4WILBQP$@E1W%JP823$-ANK=SJ=&3M(/
M_93OR?KA!(8 N9T';X,CKF0(]M0$#'FFE"?[I6@WV,(5/"91M"A5<41*!ZZ2-)VW,Y8.\O'8>1$% :JUDTJ2LIJ5-*KXIA;C0%%A[A_\H2$WL
MLT)><8%)PYT "P[#]2NI]N35
M.PRZ\16=95%;UY\CS";G PUAV VIX
M.KQ&-9VEO7IYHDY0C93=';-Y=IPX!DI@P4DJ:"S0F\1,E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M4132-]KH X+DOZML=D$)=1F^F'%Y59.Q]EQJ49B3@YK\C\K%]ZJ4XS4[@XJ6KD+PYLVZM+J1;/B
MUU)?A>D\4G57Q:&WA#BD7F"$TY >Z ,BB%&26B/ \(S@(+?@!O)ELM-&]5:
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MV<'U+[WEP_'@R][2N0[ ,HBM_O/S[Y??T)\/J]/]7\_@Q\/)_.IFM;M>?#[ZK+_X=NH=_AF]./G_14Z]-'TC]NOKW\]'KP9G-]\/GQY=CCZM^Z?/HU_=7P9OIJ]_M*'[:F]TMKSY\_KTUO]X/UJBEQ<_33^#XUO[:/(3&GX<
MXN6/JV_.P>_[@^GD7P^75UMF_/;OR;PZ_F;N\MOSJW[^>SDX(_[,PRO@C=?@H.7#Z_&KR\Q7!W,^N__8PVN
MKW9W'\D/?0\#N(DO6J.^AN*MN"EEM75IQ>.8??^@VL/6G[8V_SD7AY-.&\">IL+3:PJVX/3F9*XK3DG66?'9T3>&.
MRSPN_P)7V3"/88!]SY.&=2BR'O2?UXPU@BZ*;[9FQ2B#:NP
MH'IB5]R.H@M<(G). [\)6*G+-=D0*+0#U9K?EV!4&8%-VU,@_5'%1]BF?7E*S$Q%"O!PHSA
M#(VUAI-OAR+J='23N+TI# +HD#&,DPI(P_6X9=7+\E'%RRB7@+0C]CW)==#I
M\ ;D.WFZLP/[D'@R/BLK*7!\8H#4LYQTN5N:FC33BW6JY5V
MVYT1/$JF*\[ZWJP!G2WT4<4=>=8DVU4G"+7-!#*3D'?'#EW]:3B#/!Y+30/]
M!K0$H>(C:R((99LAQI@<+9-?Z+4MHXF+[H JU%N[MHXYV4K6O*+XI/A2P)M_01$M!:)^BJW;
M"FA?NO-M-F'ZGG/JA60.#+VI'\P9DIAATA**"9L\R9:TD/^S3T\X6'-6KKW_
M!ZOZN]X#?@L6"T2H3GZ,?_(\/Z8D'=-WY%M@[O>P=[>80]Y]/C()BH8$]4V!^=)=)6D"OW7;EIOE_ZTNW^P>[C_X@$[.[V?
MFZ"@1$\ KHTBK=<$Q13@"6LNPKLA&6M,VCUXR4> 27G6?;[2'0 +5J<'W1"O
MF]FE/S4;"R<,>K0-VNK!+J'H<%^,1U63_1NO@6A(1WZ C]B_G%";(VD%RHJC
MK%=M+N @;, &4BO'@G4;11[HDHZA_>+.7_8PLG5 E(O3/PH=U^K47CF[8%JG
M7U(C[C>N6D_N"BU!VZG3<5J<_M&<8%H91Y/&'9.Z93;7ZM^!J&[_I$KMT#]T8W.1 GB_0\Q"[+O(H>='U L9)]P;)?D@\3".TIKYK@,#3-/!T$034V2C
ML#_!S*#M49"LS!YR76HRIV4)#9BLIA']^B'PHT7:"2+-9Y97"R04YV%QA%*C>E3(GVP,
M]0IX>34GHJN8I[5?S"0[*F>2[1M($X3^8FFB;2!;0S5-:#F%B01HTOI$XVA4HU02X[7:;X,)*R*38-?+(W-C3B3
MCH%T:D/6T>BEI",&DBM"J"6OG#0+!I(H0ZDAPYR$ OU" *>Y)&M@UK.XL@N8
MP]PMT3[N\V^)]K-;H@8.3@O$Z(T:YVJ<@<,A0ZDQ/8@1MOK[0%]Z<,9!@;8V5IP]29P6NU3,7Y_:]2_'FX=&:C$YQA(M1BC#H62
MR!0#:=5!J^5RR!_ CZ8W_ -X P>@)G"]^9Z>U;+V^&?)!@Y%'=02LSZ^OD+Z
M,(=&#B2%"Q71L$[:ZA@@QQ@ZQ,C$<_36(SV1G\RAHHI(:!Y>PG#HT)PR4T0[
MRCOV[&\1"@RBJ@94(;F5D=E[=K(XD*13!YOCMB%T8.H&+ )*ERZ@=H@J?;$DMK,[&4,1'):6#>>7#T@L ?=X+ $7JR$X+AB!8
M\>B; A=S"8RC)<+TTX3>E:#GDC910BAL3G8-(N3+*S??O<&$BQ!GA]!%$HO.
M^Q8(RT2V1)D#)QL05L(I(B?G\32>) Y6B2Q^ ,@;>2=P$E[#,(P_/29M&PHB
M%ZZ$O,PEY_P1Q:[*D5>29G-9J85>IG6'TP#S&EG[-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MXG;KH9!UD7\PYSLTTW3I;":"M?O9#EEL3E9[.])D 8\W)YA1NN6B*"&MMMI>GM$+AZI,BV".L#HCN /#=_(M9FM,AC'^5)P&NM%M=.@Y6''+=0,^2&B4R6;0D;DJ*612H6ZE4C=0R.QU!#UZ9[Z!%9 QB>P/C_
M0^^)P@*?9&@:4B<9/:(]; @=?$:T"+N5@"8,$AY-QR!XY$.XS89U"-S'0
MTOI7T(9H"1W:#O6\F4NQ#+10"ZIS.]S A_#8):9'2KD3!F_#],>G-8'JH!5M
M[[+,@*.ISOPPB?[FV"7"GF]4%&YKZB"H\71<
MF$F5C91)I.GAU!18R=/GQ#P@>A70IP ,H+H!:)GH%IHK/=/M;ZBPV[.Y?.-&RKL63(TL#9ODXC)I/-JF2.>.="FE$\LF;>:8R)&*::UK&N0F
MF7&CT1XM.D9@,7V2\1J3@U-SK>3H5Z-9K\:KNT(JMAMZ"='B+H3/TUNZVG+(V=])L2HV^#0:GA?1$XN:ICN>I+L-&K@V*VDC-9-Q\
M; Q=P\:3)3[:LH$0P*Z3E%">_,C@\6B"7R@=^4DI>NC6I&&HAUM<'V#*WEC\ K:/MD@N"CW1HQ)([$9?K&ZB.9S$*Q&T]&"Y:/Q[O@/L1DU%+4Q
MB]>.8X 1]J?YU,O96T+YS-W)(R_)RT.%\_O'SUSAA&]GI&9@1Q,X+(Q%,_SR
M-"1TCT33V\)PYCNY_.4K7;H?C_52=++I?T&F2$"W_^L&QKZ+;#(PN=?'"BX$
M4'0A^&47 BBX$ P5CRGN@[8C>=:$@G.
MRWF_S7-)ERQ5O@NRJL8^(SUGIZQ
MTON]ZZ$K.2L-%8*V*&KVG(-N'_1 C.+65BJ/)C-MTK)!9#ITB&4HQK(% 9DJ
M"H06_OJAAFR@US\9.LFT(8LE0G28G[7('G8(Q0\[&#HV+1,F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MIE3U*>G,I&?RV<(VHS7%+T"G9%-J[([QZAQ,TCM2!F/QI7=_). YF:SY\/5OI1+XP7N//1GF45&DE@"++MEF,^-4+X7 +)[ =G:
MPWGOT-"UM'W:Y!>:2C%[YLI)%:I0[7)&A#2,<7K;T5PBE7F\J ?CM0DZ9,(T/74&2F+.LK7A% <*034,'K05BI*?7VYS05#-IJ=2BRX]:WO1('[W
M+*2DU"Q?R3ZG%W8S,L2I,N8T>*+543)*@MJAK[&0)3D]S1>C%&AC0>%2NE6B
MH!P"WAC2OQ&S]>-_F\MM+E)9Y"EGN-34&L_QNL,@G#B%)&_FSW,NW)KLUZ3;
M>!EH-"!;G419\R2@!4-J_&$H30!LU*30I: E\TDU-D:)S,:DM210-"AQRR6*
M1T(3U=ML?$P**-B<-+'#>/OS1=?)":TM.;S?#!X#;1+:L-D*#BN#M8H<=_W5
MJ<8X&"\M2L0+MYP330=KBX2ME5'4/T:.HX9_>SQ$5H@9><]
MJ:2M V$D]+5ZGMK.QD 6S-NIQCV63TMZCL.])QH;@R;:\(6'8B61Z\>_29N
M$.L,B=X="U6+-S"8$XN1XNO?!1!R;D^9+B=<$K3OV6"-UMHW4-H=H48DZ*C3
MSM(_?H+X0]/O-SCW_I!4W+?#"M!=2T'$FMA5EG@6A O8D"46- -)7"(SHWVM<(
M\IVW4AL\CV^B/56PF;/K61Q/!>CS]T\-TM[W%<,GRL&K[T]2#E&]@:OTP1M30! ->-E[9S7TR?NA67)]NB2'KG-DN,;E3B
M#ES*W*$ G[LL^>SW.?FH=.S:] JHN;?SRY?S-2DR^!)J^0ZJB*(;\!!GWAU-
MW2UYX%$,66)/^W1AC6SFHSEGSYZ>^\"[AF'HZL>6QK'O
M?X7.C1_GB3+XH$^.6Z@YM>N3'8^C!*0KQI1^V>C/VL<= BPQ)"%N:0IQZ8S,3XP1.84#DDGR(L[\::B U
M@B^<$X+6B%I);+!*FO'M&A9=0L1GG^(&C-U/R#"+-HLTT2TW*8=AR7C5&*7I
M -($SUD61)K=>_WS%<)?LX?FMHX L[ P!>XJ8#%P$W-'$17?QRP_?V<#7I5BR]J_[RN4@NB5;&=-'1?#L
MS/7O34X"H$V"="L3 ">^,&_#<;)#?O9=,Q>4V')1/]]LD+*N";8)U6DZ;4.G
M?TW@TJ=:!1F0#:5<"Z[4KTEZM .T8%$2S#MJKG[B8)4EZTE2E]!-3'8597WZ
M=P(G!GL;=,!+'M@F>U4[I"^/3LL.UP3NTT9=%_ T35=HZ S4AJP^96XY[6C;
M)T6J[*,\\V&=5Z@U2V!C8=2#*4O^GP6]FY(@EH-)_AXY42>DHS"^[!H1:]M)T>,%)T\J5CAM2;+(9?NYG*4S],BD!6YVM]:,D[FZ>,7,/A^9:FE7H,GF8\QG^L3.:#I(3#]C
MQ;2*569;1H$] Q@*0NN-.L.I8A6O;7GZ^V&6%-!P'2.'+73$;D=P*R^ E2^4
MUM'BP12VYF*'#&(*#/']&\P7Y@L&KD@)6M9[=> (%+#ST+N8/-51TBP"VD.#95
MHS2!W^P]C4MXSSX]NZ[10ZE[D3@U%PS8U0J1*4/V^IX3)\RG=\!,\(#Q@2FN
MO\>Q14[! &#_23X8>RRNAUZTA"1CQ:MOKJJ5@1;K%SI.N7M*)DPZ#B;=N&A#
MUP0A1)$ CNX]Z*2AXMMSA<'+QDJJ"*$LB?@P0.:1W.RXMO4P+DC&XXK."%&S\B[@A@"LF*>P"5T??:\
M[0UX(,V3/] 2C@/_+@#SDM>,?GQ:?;,Y!6)9/_:#P+\G#,47R*.]#+T0$HT:
M#HA*N(,4;6PKF6 BZ(/5(3@N>N-?P058]:>DI4L_9(\]T:!%C*M.J^>F6@NQ
M9K"IH1-Z3":DP4('4MI]&Y-,")#%,T7\10-YO4&S^+U 2S
MT,GCD46#F/TG,/[_T",3?XK"44!7@9,(4I$1]7$",;KSB#9Q:&\#?[[P/;/=
MM8]"KM@"):#@MXC&MR\-#JR4PI3=N\A'C*3^[XI/[ODO9>KB%,V1_/GO,< (
M7]&1W_BU]%;/I7.XQ-JN[>>2'FN65A]'DMG;W%#J_@,J"]Z33#$'$70X6>@U
M0KX93EDP.UG/XK7;0(J*V(1J4!U":1AMFH!E%[AM%M6+QV!%D?0]A_Q"P#A9
M6,P%I/ZW9XYNU<$6+I_^C9]!*XY)L1),B0R4-K
ML\6 2JD?A6,0GTJ809<2GU!_B,)P#:%+"DZDVHD!R@KMTJ*$51AY9HB<#)D\3K9<[^;>-Y2B#%G3R%]#"%,"E*RV)\DE&F+_PEC#7)!-
M7!2P,D-O$9FAVK5A"J<:W9_2"Q?79.>)?4,T!A^45!QIE20\A;5,MN7FT,('
M)KD/<#X:&($^!T0D086\)D9.$AV$6M0EBL0\HHK U/=,3M 2T03&7Q!T'4-Y
MIH]4$H3-:<0L)BH!2M:H_"T=HYDH :A)GHE,J^(2*Y&XQF\^O21!37D3Z1&A
MDZJ3)"F7J>(GAR>-A5]7-HQ77%3B.U[5=^*S(QPS#'4MB&(A/$,!#JD_S9ZQ
M[;(9-/%!J?S.&KXS,WA6$ZP\NB7G[Z 1(<80R,M4^21AF)?O!F$\$%)IQ0+$H^U?O'J@B$4*>"I:?,#0_1!"8WL @AT^MQGE,P@
M1 U0EHIZT!\8,_-+8&2P;6"&LR0'1)BZF10QR5=5Q2--A KOR:(9A'W[6X0P
MBQ48^,'"#$JDV&3B4TBJ!EE:-<0>"**)UB+ UJ2!TMGHT6P(U#=XW<
M\>CC%-/*@EJ-H":/1('W"MH0+6D?9BPC E#29 @?AD9 SW!(<_64M2K@[+E\XZWNF$:3"IR+-1')X]I3L@G0_HLAMC4(^MXL9^'F0A/A7F!)[C/PY=(9#8TPO,2X1)5?_2NR9^/(L'/CGYV8<&MR=:_JYN1&?C7."3K'RF4"^$S!7<5DE!\DILZ9$')7=9)4Z:;08\.1%EN3!KO
M:2=94$VAJ I)R"&$OTX#"--+15>&G42H\8GO,$#;]YR<=]P,@1/"4KT386[D
M@Q*>\J:P<7$/(E2RMRV^$$5RL/?RI1$$5/$HWIE)2A\9AOY(!_TZ7TO?62)L
MBK=:"$LRTV_)JF.3&>3D3H5*F0&-H$T?IWCMS"(!^IX7 =<(P@2@-%XS,^WP
MM$D\:E*'AKD?T D8!P*81 X?FOJQ-F#/M_?VCO33]JTD#T2Y):IE@=Q^.S!0* 38943-$KSP8LJDJHQ%9ZSJQ$/T$[I/?
M2FMP0RL#*Z*8W0X=3>=Q>_%D6&
MQT0FUH0KO><5D+(VM0#:]K4.3L5)JGOZZ;!TR,Y32-,S&L*P 1@K9G/$OHI$&B.7RHIB#7P!+./K5
MU!V?_. K09UXL%/^&2-4M0%+,U&%!%I>B8Y]%]DFJ3T-B,(P(?I0&+&HD]71
M]^C*\,&G0^5[-@S,,5;TD4H#BU2MF#-+:T#5R0UG#F%<4)+3;?'AOC'"J8.Q
M$87F<$T+9(U73 SB'1]7LXSTYI"E@5$94L*K;9!(ZH"4GJ7+L\T,^@89G76P
MRD[BDC="1],TMUI^^S^(@H ,Z/T9'
MS"F.H\#(@6F%'I&%F/4CW':NC%%ZM<"J*:9I@%@XA8ELYX#3FO>RJQLFTJF'
M5V/>)Y5RFM-(>J4PM3BM:URBTA(RL>5XXMM1LC\X]4@?JZ$W]8.Y62M2P,$% @ %XK96M"X]U[L#@ '+8 !0 !P8FTM,C R-3 S,S%?8V%L
M+GAM;.U=;7?:N!+^OK^"F_OEWM-#2:!)FIQF]Q 2NJ0D4%[:M'OV] A;!#5&
M(I)-(+]^)=N\VO([MLGVTZ:LK1D]CS0:C4;C#W_,QEIA"BE#!%\<'+T]/"A
MK! 5X8>+@WZW6.W6&HV#/WXO%'[[\)]BL? 18DB!#M7"8%ZHD?&DJZ!"CP+,
MAH2."__3Q_\O% LC79^8.+)FL4B@;/
M"U]YJS<&+I2/"^7#\_+[\_)AH=^K\7_P7\Q7?ON@(?PX P6N-Z871RL29H-
MJ/:6T(=2^?"P4EH\>& ]>3X3/VP\_UPQGSXZ.SLKF?]W^2A#;@_R9H]*][?-
MKC*"8U!$F.D *T( 0^?,_+%)%*";2/KJ59 ^(?Y57#Q6%#\5C\K%RM';&5,/
M+-P*A0^4:+ #AP53\W-]/H$7!PR-)YI0R/QM1.'PXF R&!<%@(<5JX7_\A]^
MT!\U@AG1D"J0OP2:Z$AW!*%^4! -]SN-C2Y,V)R/"CA 9 Q5P6!)/%62-E+Z
M/7DM&WQ8CF%7YW^/(8ZNZ'8[I5U 6@-L5-?(M 'Z "+?YK.00F$.V9E#*E9KWP$"T%T+M,.WRWB3:DR9B.C=5U[,)Q RR.,J[
M-K43]#FU )L,7S\9: HTCE4LU;U:3&QXK\15%8487$ ;S(4(+IG_0@VH-A$8
M( WI*!X3P=L7G4NT:W6 Z!>@&;"J:;8MC],3:7-)&M^+_B:"YM+GG-/\&Y)4B8XS9W10C&,);R7BWN8#[4N"P5 5R'*O>-^#*HMBF9
M(JP@H(EUQM )G5O+3@_,.MR\QYOLT:2MF3(%:(JAF<.QR?MI]U;(B;7J;R )
M9SK$*EQY+%PNGP,;SYAS@M#%BQH80.WB TI*PX-3?MAK1UZE3&HLTU2A)J,
MZVFZ3N(-TW_2P8Q@,IYS1ZK\KL@=I_)IR6Q)/+'ZJZ@0^F/UB$FJ3.IBO$=1
MG]OCJL,LI] *@LU^9^.@;'IK]I/E)@Q'INM%1%WK1;O
M#RD9^W*JDR"X$(7H8Z>+/U:B./KXZD.D4*;;7E25C ?79Z'1^
M:0R*KLUK>9O7:*2V]!&D2]D*Y'*X^4N/1)G\-4.26\JDV-D45;8HBC7M^"YA
M I"Z<+C3GF7;XO? +DIPL\EYEYA=3'G!75]I,^4@ /B+1^1K433(N0\W@52?
MM[D_I7,C*0SDQ(ISI,2"7(.5+MHR63G_FJXD6.%#3)-W%'G)A4C;#'56W<$> '6F8UK*>
MT2X]$R,G-"A2*QR:"L*'*M41%W5'=+@0,@^"N^S5[-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M#^(R7]\2M,I?"("D_-WM;BO=Q=HIB%FY>/ M@:;9>R*O7ZM8W&[.S
MF"$2T;2YO@)%:E!"LQ*,S"Y]5,
MC@(.TE70$X8%\,[H;%C8&UPG-YE#^_0Y2+*??QOY'=8!^K\ .VXH54HOUVZ,
M&"-T'F>0;[62?S_/"X(%YK$BGQO2A"HM;+.ZV".%P=J]@?S#+.GX F%'R#)B
MUAX9M3XS'9T6:#!;60,I4<4;J7,VCY^M9+_L^?/AW7W[3<.>Y(*NB+>M@;5YDCW$5
M7#3-1+"X;P8"6Q-12(EOCJKHFB'WH;
M&'\16(I[ AKZPYCF,M'05K)^F)S/#:\X$DB)UA"/4MFC^ALYO7,#A>(I,=9
MO_:027+@O;]TG(/%/ 5K6YY3$PQ84U?#8._Z?O;AZICHNZ,B.3"+6(!A-MA'9'@$)1#%)M@_DXU8HTOHKLW40* [+SL"WF61NWEPJ$JJFM>=^K-6Q1%6%
MYZ;\5)UE'TWV<*$*!;3S^"ZQ"9OE8;>_)A:Q9NG=O[[>?CGY^Z][96+,ON'C
M,_7E=/KP;8[[5\;SQU-Z=OJI_+/?FS/M=*J\'&HW>DGOPIN7T\KC[$AIZH??
MZ_5R]U-I.KNL?3NM/NI?9JW^3:5R=E/ZMU8]/K5+EK/7F_FB.*@0-?_8?3S]?ULYJS=Y]Y5V]TOIV/#@Q/GW_>M_ZK'VJ
MG0U/WRA0.SELU:>]E^YUG]P\MZ;HW>W[X3VX["O'@_>H<=-@TS?S)[7\_:@V
M'/PYN^MT;CZWZ)LWM[?]RZM2LT%/KI_;6']_W&PWVYTOZI<_!_"Q>?9P]Z3V
MM?OZ5?GG2Z/?.NF'QO"Y?EAZ.FH-YHV+OPNU;L>J;[RODR? 8':>XR8V
M>?J80J")9"G^#][X,KO*RK8R$Z\RFDV!5-OGV$,4)EQ.I*,>U6V*#YT7X?GZ
M_M'BCXC+F72D$[M-**
M9U'A,+J&KV:W$(H6EY/U'8Z/K,HJAM7K%8\%687&H^W 6#Q#O1"X4B"A4F*)
MB'D-YCXJP@N^MT-Q_^*D_FAT>";\'YW$3 _SU,[*AL_-^:R;.C%KDV])<-JQ
M_!3&3D3;/*2KA!IGSK+H"5 F.U..&-$T*-\3,M@:2BNQUC3 &!HBJ%99EI,J
M 55S>781> EP95'C8/D+%$=88"5W)A>-W7BI<8L8].7A%+R+"IM:9?'PP(/%.6'!2$(\2R]%-S'6Y=>(YA;[X$ANLOX- 4TF,/GWT8.O7$??@)B
MDU")/B'M#NH+@=;^':I"\'6S50O @=?;^?0\ A#@"4G25]VW#^VX9AF?BJXT
MV+_Y$PC71!)V5I(Z<&(?GK>&EP2K3*0%,;-M;I2=$9&,MX:!%U;6)4-^2
M78=ZXS;%OZ7VN5T15;?\5P%*C[2>,:02'W_WM6^]5,F!L^I5F3@(F(E_*3 O
MUUE>5?W9/-W?]8$LZ3NBEA5/^];NIM3,UT8_)K9 2N3JS:KU7X75MW&,3.W:)W#]*+_6"H@[@.VA_C3"+&OJNPJ.O4SDX7\S?IY*]"([WQ>1H)/&)
MIXJ,A_6OQ-IY$.E1Y:E$YDM:<,J\P4R\E/CJ7",UIM9$9AU["4[+.D[)E@+_
M]1V\^&;.YX-X+K7 TXB <*L+',;79]6/_$&'?"3D!,FUB6BH@":M@!]3M%<.R1FO_T'9WK)@3@"3WKTNOQ"?D]$85)\<;'^B<1H8\)2_I+0R@EMY
ML< M+];;)(8]K<_#UY-C>= +;Z]'S)^[QF2B(4@SMVCJ:Z@%M(X'([DMJU'KIL+^$>B*[H^]6MRF9(O'YF=27LS7)^TN9"XI9AN96
M96PTDW_>GF]X+GHUH:6,CY0PMDC#"; :^381K^+[^I>&,ZH_X:5#9J,]*',>
M'VZ65)F(7\&MS1DQQ* ,427:^4YF'G!8>"5=EAGY:!,ALUB,>Q!F#VCQPLZC
M&MN.K7J/\)EW"S!X6,[#1*VZ8SFSDW" MK;^5?7JF%!='$;52(H?SPJA4O2@
MS+\Z>AR>=-^8M#/V,6;2QXRY*U&6&F &KY'5* RJ *K$<7O_VNR,^3'1(Q]?CB4;F$%Y"#(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MP0"3?QPZB;L8RT".E158U9M;O?,0)V(X[%+0AZAVB-N5T%=9[#W^_OGR@7 1/9Y:H_]\(>2$"!VU6*!^0=0
M2P,$% @ %XK96F7 3U-Q6P Q@$& !0 !P8FTM,C R-3 S,S%?9&5F
M+GAM;.V]67/C.!8F^CZ_(J?NR[W1D9U;;=G1=2=DVM%BLI4@52ME6_?@ N$A<0. "QB"J]5&4Z39R#[P 'P%G_^;^>5]&+1X33,(E_
M^.K-WU]_]0+%?A*$\<,/7WV^?3FYG5Y=??6__O\7+_['/__GRYMP8O[[8MILEK?^N&+.^S%Z2+!JQ?_;[;Z_UZ\?+',LO4_7KUZ>GKZNT]^)_5#
MC-)D@WV4TA^\>/F2#%@-.<6(#OB/%S^347_?O/B[>M_O/W^'V]?O_A\
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M1LEBMJ8ZB>R[U(N##PG1782PCW LQ:QX-,*Y!J[/O#1,D\6MOM>UCSX22>'0BR:^GVSBC,Q]3N3GARB58I$SC*ZEB<,L].L4+M(L7!&Z5&H_
M;H*'?-/*L0T>5-\2OD'T\$5WWA>4D#_E)ZGG4YD^A=GRTW0RE9H!8#AM*I?L
MYQN49CCTR]U-,*+_H[KHT8ODT8<,J&GYT"'7TJ?#_BM=()8K+9U[6^\^0F3"
MY"=X@X+KT+L/([(<)7<>:$!]QP-98UE(Z'Q*,E11V,H>$>Q!=$%\3C31(]&2
MC^AG#Y/]D*E"RQU(S]$PQ\DJ3-,$;RD6M[SZ]SH+\TG/Q[!/=\(#D\.&,H^UJ-[^:7UR&,;G@TC,O7R]H'GE^?FZ0S5BN
M'$G)0@?5)_(%]
MT?E:&T:ULSZEA_T-BNBU>^YA:4TG&$KS,B/W67+<)ZLU(D2E;\,]0VB#M5@]
M=]XSU:I2G#6_U'- E&K BZYBM-F3$BT?I&V/G8TU,=9\M9]O\3W)7&\XPFAAE/ 7OZ+5/#L;^4?3M]/X7H0+#
MPL&T[7[Q>TJ!??"@^N"'O*T49B(QK#:1[!YA"ORVO]4',.3=I<"PQ+#: .Y[
MD:FL#_Y0^N#GO#1-#U7@DT1E"G)#Z[J'U-XM"DPS/M<#
M=.?!H*2EV6/HX9#_6%!@%S2@)K$W[N@*O+*^UZ49Y"[D"LPK$=#G!?.7*-A$
M*%G0:WP8A!ZNQ"NW]3CC&&!V&GEI&B["PM%+X/J(O'2#"\= LMB!-TE3E,/9
M/CH4)S>LPS1T^S]2&,$Q4
MS*&,H-]_X5;%G3.B@M9^2"]87\F(R;DCL7O7I]3 (4#9D6;&P#JZJ\-#8NBHIS8 YE8BOWOC@&J5'1
MJ-K74TFF?H4;PG_O27BV2:C<5TT ([\]^(983],*4T-\Q -KOM,NR*O
M[S2CJC%,J_L#"KS4:]X6RIM$X&677HA_\J+-H,D.I:H;A=WPDR@JX_.&3*]W
M./UKDMQ^%ILX0($>5<8MQ./JW@_5Z$\((Z/:#D# @*#NDIVM(ZA;9!0GTSN<_NW^;[3=/[?G"*=)' ^[
M@O%&-/$V)K3(^SN^1 '"-,PWF./D,-FB9J5(S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MG+TBG[PJ?^=5]_,25<.\)BLOC)59+;[>'P,FF%V2(;"_N4MY,"\7*'5/<*2Z#8^W2E?$UQZ423'&_U@QQ%9IV$M>LX0-?=_5=(D5*/$;_Q*[K](M*](OS1H2M.L6F ;4$]PD3R13#5P*"2;%\IL%N?$+TDU_,
M5]8__"3.B,PNHOS7R.I$#T4.1_7O44(N&3]\10Z_VNQ@D(8+G+Y<;**(/)(S
M])#0"*G9HAE8-WD.T^Y>2"LPZ! Y(IGWG,3):DNVQ=NO7[Y^]_+M=Z_RH>EO
M[/_TTD_P;_M?R>4$9J-\J&B7'E,=]DNSL?:H).$XEN)]\[I7?G*; D+YO#R/
MG,OP?'>TF1!B]P"N2U!VJ4/%6H';W;=MN9H1ZV^O#TJP9O8GXQYH3[84X6K;
M>.2A;RI=ZH3CS%K\=Y1UHJ$
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MRP(*C0@RHQVFKI+&I)3(]WK._)Q\;Y5#,?[MK3KT#_Y$Z 4.XGX8)JQS=)_50C&*-!;;$F,S,1:Q]4!8RM<]BB81TF;SCO?,4K<"[J77U-6Q??!M6#WR4MD"IA<)[SJN(H]><-2A%^9 2$
M&))'B^P(C)EMH"J9\)[UJD*YH0%R,0HN/!R'\8,]A=4A?/A:JXM5)1G. WZ
M,;E< )9-R#NJ!Z^Z6B!5PN ]T!7%433^L":'DMSA[X@*EPKZ_B?Z(. GMW+@86L0/\P4O0JP24/^+G<9+OFH&3.X#4+4%4G:Z!M5AJ\52JMH\&Z-/[M,\
MQ=*BS9--?\"C_=:+4$JD^='#7U"MWI6U.?4RX#I21B#LYJ[HAQ$2+:-ZM4H1
MF1%U0Y^C1Q0EN='?MOSX7(Q*B ) S;GVBW9\$36&!BL"$662)DW:EJ6(#R<7
M!D5A"C$5>O^5/9D+E-+H1R^Z1"BU+<,^^BYNVXJBZX50' HP0&AA1LMM@FF&G56!M6F/2FTRP0-$"@QYNE9=9&P^7&L=:,8BF@96PF -7F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M"=W)(\+> RHZ&%F3')OZX9N(A?A5 N-8'133H?-'-@K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M\AASDU*&$C@>C0N&%)!X;70S7R98.G]Q(('CD3(84LV5Y&47GD8A \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M8.^SJ/P%% 37$AY"ZU:8,_99P)QSMC5_.(RC,D/R6\:>^NKTQV1N<<@^)K+
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M>]%IM<5X^9+9&V*/+X@;Y*'RDE9I=*4,9#L=\MZ[B60@=U$VU'FTRTM*JB0/"7%^NG5!.A+ZW/>Y'VG*5HK-IA<
ML6D2''E;$]K9=AYY<486'/6GK^ETIKNJ8).T:#WJ9A%H8'4DYEZ]X@&TB-6F
M)+IGU UA"(=^&;= &*?_H\P_>I%5 Z<>;@\I]$U9R:A("9("I7$AN50T0':.
MX+3AZ@MM65!L^^U9@G'R1.MSUS78+NK2Q0&CQ-W8EH&B#""I4E5V:V
M.$OB(,W3=(@2.D?WY*<;FSX3""^C>&5(PBM.B9)]-];76:-6-+G+>!CF2A:/
M,0I9 .$PD8;T"645Y<)4A +* 4US!^#/^WHL-R$A"H \(#V>8*)1'7N ]QR,
M8M^ H!1GYVB[E+J\G #9&=MM!(JR]H2;/0M=ZYOCERJ8H9%M8CC0XL0:]3WM
MV 3!%N.(I"B2&:]0M;D$F4\>O<@FB])^2NY57AQ\2(@6(9ME2HG-:N1FC1)L5-FV!Y10G]\DF*W6N
M%^W60WKQO(Z\F YLKQS=<$X=J$2E-='<4QHD!&J+96CSG7EIF":+.;F/$;YR
MGONWF_1^RT>?-4:7V&&\KP<9+>LRVQ-9>X7\9XL#W%(*;-H_FX B[]] *L*
MYK@9VD ?"5.8<%>Z?6EV:A*%?NU]P4KRE-Y)_60D-A1@D"&W\;HD>TAM:[K1
M]9:29-'%\TQ.\OW[2E8:@#UE,&$:DR_].K,7:182+A&]&/ZX"1Y0([]B:!(U
M!9E#=#'^.;H2JBZ%__TD)!7*@F=M]
M-XA634!WWA>4D#_58EF?PFQ)F]]HO!_V$_N9$O,]7V+#20RFF$PJIG!'X#@C
M WS1PN]^-$<[05X^E=E>"BK'5SAJ#VE&47B]AJ;!ESF1-<9ZT0X!&WI.)5&0
MBNM3288_IZ9;V*+I/XFD!.'2,+$+DM-TW#0<4NQP/.M;3\R))M-A+R'7^P[$
MF%O'&'BY]&\Z&/Q.'UVMJ'6/EPJ@Q: !"9.7N/Q)#:=6SH)QH>>2D[D+JH_M
M)I9#58+5]7 EL)M8K246[V<4Z>ZDK8C:A_<9_U,8I!6BEZJ2[@/-]4=(A[/
MI5^V7WBLU0_ QJU!X!QAM"8G-03B,X-RY,FS+B+S_;B4A!<=FAI[V$#K,UZVA)39,WY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M1Y\FJS5&2Q2GY)E&U(7M)5SN]X^$F0?$=2ZB"E]N &#>-VR7-E5EW88' X]=G6
M@JI2&IQW@R+:9&CN89&W5K78PV[\;9VV]64O9$3+65*GXOH,Z>/%:2P2=#WP
MHI%Z('9[)TYCP]&,FIR,^+&K[4[A!>T8#@:1('85E:HE/X?D*?B(4N
M4$L[JMWWG.]-=,P?_8>CH_>
M[TE^N4[BHH@/H5.6?'7T#(-SI,W.40'L>FLR&7&Y#:57!\>XP039L0&1Y9#W
MXF#WXYLP_0)XF.E9ABQFG!ZC7(;T1-WW(.UZ(P+8.B"S(V3A]&],B BM-_7HTE.A2Q^-3$GMY 6V:59<3G"PRA&_0.L'9KK6OTXTIR:*F6VT_
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M-5@>HAH!,VS?"&SP/ +*2'/3>3B+X9MC<'=,QTX-_N1X,]"D3
M/NZ*AL'3#<8H]HM(@LA=A4 MW![1NPDNH7()\:I(FUI#%QZ.:<;U'.$RB>3P
M5@Z/Q^-:+UQIE*O$1#,R$5^=B(3ZE?L0EPR8X>.YPM"G/'LSRX@0YO3-A_ZQDH^9LL[3S*7)E1Y%D;D^E- ?AJ'7"LMN8<<(Q2^G=E
M=_=^_YMLE/X(*NK?DJMBN A]+\Z*)I6YN^8JII$&81!Z^ "VBRR/[@H$#*JG
M+RT*EY&8_87.!=M(=@\=;BU].O"MOT3!)JH2'G/QY5*/@X_(HW(M&T+NG**3
M-$5Y/6G%XG.Z*3JKV2)7*M\(V+!8KJ&7TJ)G#:V4MZ(3K0[(^OE8U19WM87 DRT6'*(1.97/:55S77?]E963EW??*X#HL8L<*NWEQ_JAI5/Y(SI:^>F%W
M,$@NZW0""KIKO%/L-<-?J:3[ <6F2'$UZO+M8RG:KOM=]UF5\&#K>D^B&&7^5@:*KT/$Y;+K0LI *_Y'7[\)>!KTI6^0^JCY:AYD,WZ
M\!R@G5:?Z2ON;>AX''G=>*$1\W.B'_RH@VJ&6WH
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MKO:*O:'6',"SMNP37EM1?5G1*;3]UP=(%>5\4>_895 %=IZK':V,',@'D^#BT;5ZV0'75"_3ZC:R\3C
MN0QL 36\D(3'I5N=W_A"\[-Z#^-?K/]%.X;IWVB[5S9SA-,DCI'[SF727#KV
MG0_OFJ$@&,>5P!M%]K4ZR/<(_;5J[3=O+Q>+!:)F4+0#^H:LL:8A=MMU="I=KZ&D"UXLB_0V1>V,/;\Y#P2&NRH,_QAI A/%XG]/I+[JV[GQ2MHYW[
M-08S[5AO:^S6,%Q^1EZ8F]6*\#1;['KY45ZFY&%$"R\\>3A04"'28XY1RHKH
M04(%#J(UAY%M]$$;MG"4)>78GU9>=I-%O2)(KNX-:GM(51(R&725H97%JOG*'"J$0C!J!;%E
M42RLIDA$!7ZDQS45+>1%$63K*:V'ZMZEB&17>R=Q1E;Y193?>'[X*D4/95MO>\XR&0GSZ&]=0]FR-0J69(OL;^Y1R_)3VD+\GVKU589)-4-T]3;< F(R\J9
M6P/G^0%V4*N@9,G4B5T)_V70F'I;<\AN('GA5]"#7!Q&Q?_;ZP-= (9N^_LE
M@!;>)LIM#XG6UU9.;IM2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M/!<, SE[S:+58-29G[DT12I S9ZZ]N4]RY8(WR ?A7GUN12,<<^'(US4?1#
MLMFDT-Z_I*_B9FT0,.["(48H 3$L@ ;?!JKM@H4"'\MM%H"";"1@TMN(6U3%
M"BPTZ
MB=,$P[MD, J"=$Y4N.YJ6YEV$0K":EN/VIN$X1/ V*LEQC-4?D_TU9W&3S%GE K7K>\
M]F$8U^-6IQM,4_ZV J_: )]:V8&.15319P8:4?&&!3*=M6C(BEO):@8'6X952M4-O5ILH?PP4.=J3[)Q,C8;,$/S)_-;KJ-(\5GU4M>X3I\UA);KN6"5M23"#WE.*2F:U13*9XYD4>C71$BP2C2?#[IC##P#EE788-
M+BG-;-N(W.:[O91V;G-9Z1:EN1 ZO9Q:=*V96':NW7 'M_)@R06*5=MB'Y/;
M,CI'Y?_I<[;0YFF]-7&N\KMKQ-;JG:R('>;T1WO0[EV:4JVL5@UR]B4[J61 MEVDF4XO-]D>M'BZ>1';6%X 5=^VT!KQFY< VE<=9T+8L3'?EYS7*2W\!JUH&EA?E];,^>O@+
MJC6HMR:G7@9&OM7Z@365FW9#>"0SI"%8Y^@114G5,MFJ//E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M>R&0,'9&O02@D%MQ(F/4)!3GB9QX?0DG/=XEMG%*X5CC._6!\2F
MDHB>[#3NBBBS$PYE$[+8.;9-R(2\$CDG24Y/A-U5S"P684_J8(;&M[U54*\$
MS[&O#3ES'0JZ7ZQCE:I(AOU6.!LY7-=A6HMVT%\,\08](IRB.^\+2LB?:CU!
M:6_;/.^WCYPK[&B"WG+OE+QB
M"M$5=][S'.$P";I)7>S*,9UO##J>0"E7FA?_KIQ,%QS]J50=0D7>/*NTGU@:
MC6^=]!/A+BHFL,WY0ALJZ\&WG?HCC["3[)MA( .;;TBW'_ ]>$F+VB^[N5\)
MM]RN?4!M6D86YVV6^%^NTG2#@O,-ICDA.4^YMC^WAN)O+NOFTH7#,%G5FK+V#F,0=/6X-R5^$M-;RB+5 "*_H@DI66D[/7B!)
MF_"Q;6@>QJ:BZ//%,EM8SE9I4G5E:S0NQA:X@+J-)Z/3X4M58)#BQM-BRL9IEU=RZ7B:/=P7SH(34EU41^EF"MM.J06NR-UD/_:'=H+^" IBJ#QN4%67E>FOTF7S8L(@?ZX9E(RT,CI>N?MV(
MVVER"K!,<#\_+M&(T8+%QINOK4AN9U[GDL9WSZG?O6LD)OM"V=91"/]F2R5,R_^8O$2TJ'LM 0V7[2MRT47-%.U)M4O($@VRN6L7!"!@BV7%(%2Q.OJ7-^/E%6](=$YZ4-E?QNM4:N[81ASEPSJ ]E:+4*RO+VXUW=K.!8N*RO2UY:6QI(N:+EWR:^7]360L$Y
M6F/DAT69Q!7M29Q6!;ZO5FLOQ)0A\IM55/)E$U:EFOS,8D[;QMI>&?R5HRAOG=\MF]PCG&WGY(E%F=XI-C=MAOGLC/H8 "(NSH4V)7%7[8)%##E7_E)[15;J]KH'
M"UAPT4(8(GK7QX %Z9M4],EJO [FDR
M+A.6)=G/@0-'#.RQTBH@U0^A*7-RWZTQ#NH71\N"E&+*O6$9*EXYK$V%M$VO2[>? >0(JWTP' M%<3/4D",(B;YT&)-TMO?ANB9/-P_)LDQ)VB>9(5O=A
MG"^BU+V8-;$[FC6A2SSF7$IUI>-^?<"X<9V\#)4^$%NA@\F&?ZG5R=QC=#(7
M)S/+!]J(^Z?W!%"H=IIOQ4/HB,"MXC_ODOS'MQO:/01A1Z&XO=RXV34J$N:$
MW/9C;? RC#=>E%9-:E$P2QBI6+JZFNNU4$=LX>0RI&<5Z2$R-
M\E@%Q\!0;S)2WI"[( +A%G NR(SFZ&ZI*A=IL$!-.HQ?-SZ3Z^\#4>AGD>=_
M(3\F_TKNOR$MR/0Q"5!D(C#S/$SI7#>87.%NPX9Y_CY#Y%."_4>16O
M-UE:5HCRPB+IKM9)?+;@M1XW?STV-@/%-.]I$C^26VU("']*,K2+MH<+6C*D
M1S-!4YN]$_EC<17NM()FV3@,,>J"8]7/VT/>T $.\NJ:V7C-@[X/=4BY&%UR
MMNS=[67 3E-BKD.7OPE$H@,[;/5*SJ)[EBL[I\Y8'9(#UK>1#_^EY02H7J@?
M,#EA<-D;X1"NO3$BM;(KGB+$0J^1(0_/>5XC&GU^'CZ& ;G?_AJB*% 6AM3OV?4)%(P6.@_M/%,SF+PW3@#H&,XC)C BX- !IB8X#R_>"*7#@Q2K,;+P,)
MPV@!72$K8U![ PUXGS7V%*_IF\2*.?
M$MJ3C+XIJJ9(J>,MI\+;"(0^$'QQS1&%#1GB[3E0Q_9M1_X08]"-,"STMN3,
MBS.2!STY86,_7'M1%4&D* CX6&Y#&Z'RD,#&4 _.:1*GF4?]'VA=-(@[@-N(
M%%-CV'NJ>(O[9"K<4*C)EJXT2AA^$C+W(WBH,3P'X+@ BH H!S#5F'"\"P&L
MC&OO0;#5F\Y)E]7^\C.)XXT7@3=7SX=CP)PW;TB?2;6]P_,_N:AE!>7'M42M
M^/ 4Q&2FE#>'^D66:SI[BHJ;I%3FK\:8;,LJV&ZL-[/A)9\U_JXH[T$M@
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MZNXW?PF1]< %J@1BW)?=:QCMJ#)@%->5O^ 2V04L0[ Q5Q_PU'Y2CR@!B!IX7;?ZN.\UZP SG
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MWMJA(<&2Z\&L_.*K%55A1X,:*ZH,#L!O)[*GV=/5:8/M!9-'A+T'M(]*K(OT V4%!59WDC1C[KT@\CM*'GU0Q7F;1E_S-E_W/A69C3L8
M3J&E5UIS-A=90XLKV( E1AN5X*1@$IJ-+=J,Z_M#M/AFH3P;JOZ2!NO8PXUA/33YZ&<;7\9A?^^'3;N3>G1?XAM[:TSS*.>\-*Q<8
MWC? @1CG%*Y9(F3T9Y7FJV3'M"A*"N#JXR:A#!5%C4D$0]:^/2Q -7("QL<8--%?Q(THS>EJ&M=:\7NKMSM,)
M.5^KHNN!E^TB?XU9;O8L736Z!4_8+$WV+"FER6@@IR78?YYNK[W[B?_')L0@
M[Y%@ -?W WUB[,L":".F/T[A[./>* Z22?N+XQ-"!Q-#SYMM;'&79%Y$VP2$A'!^;M[[75OXM[$-+ONFUD:MT@/WF(PS]!JK3ORR/;0%R0@(4MC-\2]S.(M]8.=>L[.*R\*H/M]/[IIVE,:0(+=DLMGMW=1C_T&G)2%.N5%./:]?0UB+JL[&IL$[6JC31 UML:
MITO%LH^N1?8 ZKBRUC1;((9KMC;)6'2H,63BU',F*Q&SM5B+)^G46X?DP3'#
M 5$ >%N\5JU)B,>#RVR008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MBR_93\^SSS^^>_?^QU<__?)'O=^]K=?WFS#=TFX^/WS
ME^_^M_KR]^)S\^#1[#+_^^/WB%^_LL__-_??AU8]7Z>/?MG\$;__[9KJX_]?SIYN;
M'_\SPW_[V\>/G\_.7UU?X6\OGN9Q]OTWU_/K^MMZ6VFY7 _'8[Y_-0&[=0&37\<=DM;WY%'BZJYX-!YW_OV.2J +X #^W]5<*MH3-?\\M1M'[KG;8!KQNSS9PLVH!!1M"." J'B:.55>!#K _81H-X_>Z%>
MD87Z)DR_+#!"];9OLHB+QQB%H@% 4E4YM,^;JJ;I?CN.+I*],X?$_RHC
MO6^JIHIWWPACT2\"'" 5E&21+QM=*2#._'(4"J5WVB7 WVHWG_,\BA=Q1D2=
MSI[BPGU8N^%:LS2H\N=4W*9=MAK$I[\=N!(GD*>(VL '%!)ERFNO"CGP FX^
MHSJ/D/3BH)8Q/DU6JR0NPB1-1_/LWO YN3)2LX.VU1@= 4LJ^[(V$!QZR4 ;
M#41@[2I[)M/=M!+GT,'(!+C[_L18(S[-+K(V@SM2921<0@J2JM5'(51L,2@N)C$#^:Q"K\$B> TU[BYL5S<;#/'9KNA$FLAJ+^;
MCFS9_&D2/R*0F]2G)4!BS,A'9#P]-E,8H4*U(FW _B^D#) P8Y(!,/7+2
M@P"DO]!,I;#KCYFZ\I[%!1/T;D9_J\&01'*I'CJC%:XFF,6.+5GY3U;)AEH7
M3UKKW/]%"%]>SJ88=7HTT6AF"H1+[YW3O4KB4H".-5DI@
MJ$HI?6=V+]$_AWG5L^+O S83MCE0IIO<:Q=2K;JN+\C1)LU3#^<0<;YP"D\1,>]<..4FR1FVC/!
M5*P'KLKM6[N
MDKMEB(.YA[/M)'@,TP1KWYM,&N/4P!JPK40N*CNL0^9Y>)A9D<-)C'8C#P>W
MDCG'(F/8)#O_<#4G@(0I86A+K47ZK;$,$J,5^7!P*Y'K"K^6-P\JB7PPB=&*
M?#BXE<@YMB+#N_S3=#(UO)NKR7PXC7'*7 .VEM5BSCS^IY$2A_[=VGUUGY:P;?UEQR?Y4'-A_S*AI"7_A9SR.2Q8;:4YLYTF@/
M<#!4E:1X=C&=^W?/V&<"9LY7O4#4)T3T4<."IVDCJ],=IVXW)(-JN6B-M0ZR?*1[ES*'&*54X4I6@1&T_S?B7&NM)IZ.I.?!HU;,JD)54>?8R8\XG6:$J
M#CQ:H:H"60G5ID&LY*)33ZRJA"+3%5:=QCB5L 9L*Y'S#&(F(IX&RWPXC7'*
M7 .VEMK81^"YJK4A*PIC#RUH%]>]NFN8J<&
MQ !!RI> ./ 6*7D/9M?=46I,N&V,HF>7B/HFU#&'A&3JE;7SWB<--@ZO[4EW
M1\#DZ:#929VPTSXG'9&ZKAJA6:K:&YM4;HZ^@P=<\1 PR,$5*V?IH;KO1P2*
M]O(0]>?1KJ5'?B&>K5%,.#CS(GHMEGAHM,(!]LXX&:8A T5_9H5GLHZ*[LR&ULE@G :T!OEE);!K)@9TH-HW[2!9'[=6\
MVTM(@RBEAW10_L; Y@,+C^O2-+PC[Q!>D3,X1_@!(P2LP:J!R,@/O"'P FJ3
MJST'JG[,EV2VE4ENOR"M/08$;(QO>\,1%E=G&+BA 0MLB#-D )&CV-!J\&JN
MQMXTR!N1]Z#A1WTW'B1A Y4BBG77"*$HZ5>>%^GMRQW,C8]*^T;E P8H&:&\
M(P>*"C3,2'4I#"*#A2+$:R-W8VK=4<6(?X%M54*GOT,[=.E 90M6NM$=$N\]H8#*M0'E!EUI )4 A!4ZD%UW^D2HMQXH[Y)2HI-9QF(KM+6$@H'
M&NXX3*S ,"9>)8#6 H,8G)BA*XK(+^D\UC9M,/K)P?*(M0DB5 D;')UE5' %5%/0XZ2_R>92.3XF42YG1QJE?I? 2ET 8ZE]L$%9P)C:_
M'_M^ZD$%4)7 1E!UQ=T3PJ@V._+?M=16TC5'NLJ"=@>T&:K<)F].X Z*SE3=**P"T@[)^VV=M-1?QJ[N0R-N,D,V[
M\U+ZEKN(@9BQ$M7+#]7NV0=-.<*0%0ML$GA;>@;O^X\3U!"U>RNJ(WYZF[G1BF<(S\?_>Z)<(*VE\D&@^'M_]9I?K8"
MSAP4](?O-HCEM&8Q\Z@1@][Z>HQ+G(N&B89H78)W3\D ^/=?'P?\-30@L;*R
M\.\-5.L0;REC -09'XVP76??]+7V,VX2*8R 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ME_/1*.RVSSJ7MX=&Y<<+]TF^JJD$"UVV*E6.+O #N/4)N[FV[N<..UU^;MP.JQ#N:9=>1KZ%[
MD9B7 UI:)PTFOY3 UA;C=ZPI830(O?@2$7YHB%60SW]GI]Z0=;HE<)+O[[SG
M&X*&R!B@N.9OD)\0JE&8 T0DZ?M4E+2Y 4Z(M/-F_36EB5]V3WB9H;>8=PHY/$KT+I[F3NR ;LU$0ABZ>J8) Q6XCS[(VL]9$
M#.'%J97)I,Q!@M#K?6X27RR0G\T6Y,Q"X4-<,6U5^#TL'/%.YP$/.*ME'2,U
M1.G;A='C.[]$*M6^)D\[ LYC;#] -K.W0 BVZMT"8W\!"Y 6I0*?@^$WHEWOAY=15*9Q9?)UY\
MB[(L I<6$XYQ9,M B #5((:='(FV1)A\KY>>3%]FQ<' R2Q33S&$6XK '#BPDX#Y$6KQ$V77OQ
M[M7DAY7-]E.2T?D^Q.&?H.12N?&.^$8$PU-8_$G1HUY9A,K%,TWHQ#9D;K,U
MPOF$[=V'0,P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M^&.[;6XY5#,*<-->L3:G5SP Z]2$:A$LI]ZQ':D\T,+<2:(?&M21).=)@>86AO')E;5?'VM^F$@WN*_+\_)(^ORE\NH"__LD>^-I13=Y#@XD,Q
MKL]:>_?':O#)9VV0DJ'& BF=M?::.;7$K&2UWF0(4Y_IFNX1R[6M^NB[#131
M8$AJY;_UP6SNXCNC3E;&1)B]:PU*6,2'8\>8=E$+<==?.2@G"2Y54__MH]AF
M'0BT-^+\E,15:86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M0RJH!3?TM^RF?([6\7]:87ASL?GP3IE_V5=)DA21I;[7(C.O>?Z#55>U9FT+2D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MLS9RKL\W]U'H5ZV^P0 S/[.?A"9]H%7PLJ>M/TYFCL-'(FMY?)G?N8
M/77- 8@M@\<;EL'#MC\^[0Q$JCY&1"I6+K?:D_U+#UWR&X&.N]U/'Q2XD0@RJXZX?!6.9#=.$W,AQ
MGB=]CNZ9%6GZ7XG,;UVN=P7,.2!H55T5K3EA.4S)E7Q+4XRD\&9^.KY5WH\"
MM!N]PGG!C&;8MXJR=ER(^' L3J7H0@F4#Z6>PDMC#SI'HHN&H9ZW]81OHH7"5[EY";WR2;OSN.35WU9@:+H'E+CKFQ;_-'##V%\
M%=<;FW4$8S6HV,A$[,8B U:$I4!D64Y,F6*!0<@F%_'0V&5IH0X/7%;3"A6C
M5@,;&D1==LJPO&>;9U83>D#$\4 16XY.:)$]@+86K+7.%HGAYA--,A8#"Q@R
M<1I%("L1LXT<3AD/(L1
M39>W;,?OY\!IV0OVK;$I.@YXIEQJ+7*3.*@S<4>DE?_<=OUK6;YM6;-GO#+7EAULT[FWI1<"P@;Y"1DQ4''82 [HMDRMHGU;!C!3D=0LCIW:N=UJ
M4ILV*Y$0--^8&F^!&J'/<4 F31NKR,DB=(H#5\K,.I(6W5#"G&&*:(
M#?DY/M(#@K!9:SR>1*%/-5;QK.MW:\@NNWY2[3[FG/4&&&386S%)R9B7"4;A
M0WSQ[).C\P'19NL6WPZ]+#CQ^,F)KOU2Z(?3T'US\HBP]X!<2I##PN@DR(,3
M\L SI+:FY#JHP#MU)G:Z$1I,>4JF
M'O8"*G-,SK$YPK=+#T/\DLS/W,1=JR*_JZS'1 !VNS*TB&\0V5PINO.^H(3\
MB7 8IX1S,MA3F"T_32=3X1FL&L$)G15!8N&".HJUUR0'MU
MNQ1E4ZUO6: &NZ\UKSO?\X&YG<"!G";;JRU;L2R;4.GMA@"C+)FW*3F@HWX'
M\NL3+BK9A$ZS(@/E=:H(S5F.IPVY&MC./^=YT]QX8A69NLP9HZMD5-*K])T8['/().X RN^%K&QD=0=QU0^2RO>J!DZ3H'/\O9'XT*Z;^:09#%3
M%B4O7=Z@-,.A7YKGO3C_'^T-_>A%$&N2Y=+!?)
M#5IOL+_T4C1YP*BTUA3TIDE$:Q1@+YK%M\BGSNX0I6<)QLF311TVF%'W91\@
M*ZFIZX9+QV$5_UHZ'LT.JYQM6]V&,[8CL:""@K9#L8 FC!\M#S7)@89Q74!?0=;520>#24MLP=+4XU+N_1L1S3W,7 Z2/\A2T2G.&4DCZ"-L.4>;)S&YFL07)F4T_NR&\1
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M)BS1 \YRI80.8<>%1QG7T99MJ8.4[C8Z]=
MRQ"G&0TQ\Y=(JGIRSX>N<>7?6_99Y^Q9&ZD)?HO\) YJU. :O_=3QZH%AG+_
MQ/6NXSU?,QR$L8>W13RJ937#).ZT/HMAT/&H=IV\_.0-21.7BMQ"OV0ZH]9>MV9X\1'*$@OR31H
M6@NYPNS;-\0/M*4)0 B045P^XC4)!026UOY&K)OH59PAMX2VER?.AG9+S#DZ:W'0]CA-!,2^VI1;(#)I/#&MB%7-R.$7W!@L9 'LI\6\,
MN%X;2VR6G]/IQ3/"?IAZ^8LD_X=[+Z7VXBV]%T_HS;4 -I?2J
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MG',!-H[B&07 !%H^!CR4H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M@TMS FAU_-SOV[PW06#F?3XJP+DXB".Q3_[70Y?R,#]K?TCVRMP=&J=I4-QN0"WV)Y:\^2TD-_A+NT%TIAQ+,Y1_B<3"Q,TP1O\ZH).IMS:PLM
M.*H&+6S H8YUWM<&[]_F&[)P8='A6C_5I#;E%P*L:+52U$;\[*=:U*=:U,X%
MZ]KM,[Y:U*?RKL-T+K^JJPV)GM'V;:O>BTR;)4A\NGW^X@HM:9M@%-2RIUN7"##"\+'M:>#=LVA-D'PNCDJN L"U!AV>O%MC2"+DQ6:<*L,=FE2YE>$XH2#R*?<9X683
MIDNJ+"CC]T4(8@:N;"HM&^Y$]>W ,@
M+MD1CT1ZTD ":O(IEN9&X<.2/',FA%Y5B2>G:;4(#I^+(Q Z&'!A5(AT0&EU
M]DZ"WS=IEFN+N/E8 NQ3R"@CKT(#!@L2^J%4EJBN$])_H2CXB#PZI:!V@RJ+
MJ\VR)<(T5!^C)36)TE+R?K*R=ZG5P^U1[6Q- A36Q#,7671Q/9L"2FG(W^O(
MN!WP>)>XQN\KW23W,X'&Z70^,68)8Y:Z8&*TN^UUIC,XOD97RN:$_-UYUG6-
M";<)UWWK3I2,64<1$$NC5WC.\ZD;;!Q>*G5WBYT1Z2NXVM2]5(LC35'F"73NV7#RLQFJ54Z@>9,1_NS\N0MDU.8C"&[2_& V1GKOH78VY.
MHE>2V6)*[K AR/S6_MBR!C<@8#9D[&?9%,@,9ZK3FQ]?U3>^&";?7\[YTE?7'7O6#.>GTB]<"4=$E;
MI:8+A+'%M=^F>[C+OH,0)%U6=L57_-K
M[SZ]SH)<>UT\^WEBK-@F)7TV]Q.3,52!AE%RM8G1 .>? 4PN
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M/XR:TT\.&+ '4&58FZ4I986S>Y$KX>6R-.6IMP?>G/F:&Q.S:Y#VR/F;]QY-LQRW.&(=A895NOL5#Q41CHGW8993_$D6)O-97
M:_HGN#Q P[BMAZ4@$Q@X^@N^,>A^P$F:DD>UCU N5D+AW 7#*]R/14CHOE(
MHD1OL\3_4MBNSC>87IX0#I/BP9A^0D_Y/P%D 1MG7 (!8F.@K=?Q=*U3P5W0
MM$Y7,:CME4%]!]-.X\'1"(2+@X'J3BUZ58:7@I;:?^HLB4<#X#4 ()9I^735DA_"6K&;
M[A!> MV BK'6GQ5[OQ4(]FT_2B)BP6I&ZK+AFZ02G"C_8*2[7(CF=/]2-7"NF]-F-4
M28"U>>'G!_/K\< MQ '4DDKI0"G)@M]PC(]<.9%5SXG6E$TVH3G%40Y60-PX
MRC9:
M,\_W.[1>>)(9V=X!RVI'50%+"E<6!JC0\)7>3RUFK ^17.,@94*@(R+EE+"N
M-?Y$M%Y/&>JG#/53AOHI0WU/^8[\%J$[B;,P"*--EI=T=A/M8"M^DYJ0JV6%"V+&2G075_G"]X*,G"4"^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M*@@NT!"JB)*WY%G3S$*BD5#V$/X,?0A48/,SUS>D=4#
M!]D(&,@ O2+,T@)QUTF:SN*+YXRHWTV8+NGEB39(OX=T=0,,,LJ%#P5(G"MJ
M+G0Y[RI?-)(71BY+[\/]V!U\>/N0]9F">:P[-6C\<-^7IJY+S/)V//1V^[QO
MBJ>*=2!.W%:L$RQ0(T7I3E7I['KO3E7I3E7I%"6MO2K=GOI9@G'R1*XBZ=GV
MD[="5M4RD[C3F#4I1M/3E49L::4]&B"V0VRTD#H
M=\R7M>LG&\*?%X7>/-LJ= YC?^[4Z,W7YZW&83W3UQY(MI_"5S_G:M7D
M5>(?$(U&N/W?>,V&%_"%\1'.M7Y^2HE-980FWYV]MDG57JP2^S=I( >JL#K\B7\49PBC-;LAZ<7!!;I _S"TF
M1LU -=4]J8\$";*[*XK3I8!B-#'IBZ-@L1=
MM-1X/AZ[;N/@!&H\9+NQT1BOZ3I,592XOR6^CQ!.M;TNKW4Z3N.BW6CF<[RDW
M_I4].U=H60S!$C%R*"$D
M0Y=4*RA+B+^5>-A9T:3D XW$1<%5S)N0O0> ,H?'N58&2$QOUYDN2S4+:'Y@
M7?RQ"6F'T=U/2SZMKQTP8X<3VVEFT< E!&L.8NBJ4-QT[KQGMQ^]P/%;TEK&E"PZKZOS6D]IAQ57P@=W%[_?-T5WOQ Z(VL_4R]+UH
M@I%G-YR*3=V<#1GDNA>NQZ92Z4'08.14AZ)E#WX??1L>8:X3G[N8!5*3J>NE
M56P6/?EMSH50&\JILUB@.RC0]5D;K'(W6:\CP@71JT356K77=RF[,6>)KPUM945\>'&P^_%-F'[YZ,5><3'7F@G ?BLPHR5=VK"X#"F%L#1\HEZ:Q&1!;.=)
MFH9D84R7]!5T%5/@]\U6(:$M*L.Z#L.0E?PN#D8)0P,]4LGNI_J7W#"+_U_%
MM U,.ALU]BO[8T)BZQSP*S[SF_400RFVW8?Q0$,W]93=HG>!LU^&VQ\)@21G+
M\JAHS.A!']QF@O>YM5PQK5+>=9[@(N,PNPPV+ZMV$0F6G%:'!"SV=E 0'&N(
M!<6DQ"U;5:28.H!JDO+;1F4I&*XU*<.$14.-]%IP:KJQN1+,UJD\=2+2IND!
MW8AT)[:=FA&=FA&=FA%)R/'4C.B0FA%)JU@(OI!^JR;[U!R(A$]-B4Y-B4Y-
MB<#"/M5K'T/=77IJ7%S/X&FUM5]V6J@9!F=[>L96^T?O]P0W1%8O FEY]8.8
M<>QO4;&?-3<(#')3KXP;1)1IZ&S8/5A.ZC-V8?
MA[F+=O* $2HJ($Z"(E38BPKU"W2[0$8Z(#^G!F\,"#MS\7 3_X]-F.;D B]#
MEUY8E'*=+>X2T\/RK7#@N$L<6P>57^#J8"]H EHD%*ANJ,G4K7
MFY4WMY9]OQ5!5G=/D]4J*1)UTC,O#=,;NH( JKKGPT,*1QJHFON@$>?ERPKA
M T[2=(X3'Z$ )G]^S)G%P02Y@-"EID>"55X_D
M&Q;!$Z#PMXI*;? ..IQ(9S)$$>5,_K"/MLH$*@BY3/A+NLH=._E*&,1^R;*5]I38];8?B9SLY2T_.TB-WEE)=41STY.5-
M[GN$=OD':H81:%+Q02<8^N!5) 0>O=$DE&*-A% ABF70'M_8M,.ESEI0BX$S6D 7,#;K[V&_/G,%LFFZSJI 3V)HG'&(/3#HB&]@*Y5:O'
M"\]?7CP3=1FF>79?,M]@?^G1FE6HQM>$/ G+7T-SG)_/FF]=5VRNPT(R0
M=6P6EY"T&=3U9AU3/7"V2\96FK ' M>/6+".5%BUDA'\B^@UW5H%#,V\C17I&X00\A3<&C_-QF7B:JG07'FCVR&VNP
MJ@!ZT-&O5?;6Q7CC185]5(L4&@,Z./55D6\" 2OV)(7X=(,QH7,9IKX7_8H\
M?!$'Y_Q:!V+4>P<=Q[+OQT2OAZ/.5^$"T $^>T1GYZC*JF^! 7!X*..^%_(E
M^8D>YT)[3!?5ZE2A[^"AM7YPXU2GOO@<"HUZOC/H.#1./R;B4L"J^-\N4131
MJ@!>O-4H <:PH](]+%A*(7RG4P$59I?+,$)%0(,&,VIML%% WH6@!/I[_4!7
M5]@XHRUQ-(#=&G $=THV$"7D[S7>*:O #_!9/_L7PW3HF[7- ET"( __FCD
M(8!)>Y7&CLFW)*?/C5,-.!H1M($0.VR&8E[^C_+U1A_PC5''AGX3$E!6H"X1
MO#4B@K=C%L';O0AX;78&:A[RQQF^2YZ&^2_[QAS#LZL7CPI]SJ-W$/;Y23/#
MMXBB8/POGS1SA-(EC% U^'# '',%!P :B EWKRY>J.5K9=_!R;PQT^.ZLYKPK
M:/O?NK*X7I-_B>;+)-9A4>@,-@H%TH6@@IGWOI5?PK?(WV BSC=O[^_";&"P
M=V>P44#=A:#R3NGUT-YA+PCCA]OMZCZ)!N'<'&D,]Y+6W"N -3I<*RE>//MY
MU=C!YQ]SP!&M M+5"W9/]V<41?^.R5OL-B^PC((\TU"'F;YOY#%)I1>=2B""[#0%@?R41!MR
M1\6YPP#K"#MOCSB*<[<'C IWSB-57545\1"[=$7Z0A[H*N<./(:CF8],)0V-
M;MO*6Y A6B@^?$3G7N:5]+5X4Y@#CT<4?@AT>(]:8XW
MIL.@A42%.,^+JP;YQ0KA![+-/N#D*5N63GH-T+/'/7R+ A>52@S]+U]%(3SO
MHU2J#O##)= ==$P[@(5)%2NH,Q+\RE_@R28(R;].L@R1>S"E>!EYPYX,G&%'
M<2?BP5*)06]*Y#Y)N3(\;4(!##\.+8'!*=*0CK#FG?QTW[>
M+*ZXFL6!AXMO SQZFK80F^.- :(6W.OT-7HM"TIS-8$@"2^0\_9&?GE+SIP[HPY(L2[>%38
M:WS]EK2H?Z=>:6@(YKNQ1F"=[DR_@EBK8[:D,M@'4!]G%,=B8^(5M-P@9$Z%
MK7^^HF/?>RFBZ^K_ E!+ P04 " 7BME:&A531L;= !(\0H % '!B
M;2TR,#(U,#,S,5]L86(N>&UL[+UM=]PVLB[Z^9Q?@9-][U[V&CN6['AF,GMF
MG]5J24YG9'>/)"M>E H% I5?_Z_3]L0/, D17'TEZ].OS[Y"L#(CP,4W?_EJ\\WKVMWP#\[S__G]>OP0<8P<3+8 #N#F >;WEZSC9@A?9]B5X#399MOO3
MFS>/CX]?^_B;U$<)3.-]XL.4_ *\?HT[++N<)Y!T^"?P(^[U^WT$WKX';T_^
M]/:/?WI[ C[?SO$_\&]HD__]YQ!%7^Z\% ),=Y3^Y:O&2$]W2?AUG-R_>7MR
M\NY-^>%7^9=_>B*_:'W_^(Y^??KMM]^^H7^M/DT1ZT/<[>F;OW^\NO$W<.N]
M1E&:>9%/!DC1GU+ZRZO8]S+*R4&Z /<+\J_7Y6>OR:]>G[Y]_>[TZZM&P!_3N(07L,UH)3_*3OLX%^^2M%V%Q*"Z.\V"5RS"0F3Y UI_R:"]X3U9)!O
MR2"GOR>#_$?QZ]LX\\(K[PZ&7P'R^>?K!7=BW[8Z;+1\8Y-B+6*/1&?6IS%3
MI2^K:2.4A>1?5YB"@@[RE0!JM),"V(VYP*<,1@&LL41ZCOW6-R$!G
M?_D*K9/T]7H?AC_/0R]-8;IM\?: J7S[S6L,[[=_>$-[)5_4/[WVX^3G^A/*0QD*"FZ5_&K-JU1#7ZEP,!>:
M*B=^#N]"JE%P&Z),8?3Z\\U7_UU\#^(U2$D+X.=-P$\>;O2O/^?#_3=HS6&6
MM,7C)7Y)$/YQ8!+%%V_\&&NK7?:Z-9]U$F^5!)O%\K/'DM"$USY)8)3-<-^9
M14BU1GW3D8$QCK*&.I69-P= 5+<"/_\2>/33!FII-KK%1%@%A&
M1A,2MC$A!L/R=G8%9CDN%_
MV]U\Q&18WH&$Q/"VH:H1V8F2O!G8Y>VFLA=)";NC9(:9H;TK72'O#H6(=&8-
M:M'UL(@YOO9M<7WRVOSB^N;\#%WSXO;O_QYL7YQ>5BOKA]Z5JAM$751D1C;J-;
M?CN8H#BXR; BDF7P"8/#9UY(' XU%R?,Q),C(#1GXT44R#+Q5(:)TP;CZ3%6
M.DQ2*,O#MPP>?KJX!<6:?BY\?-OFHY:.GV'D.3 !F(./;6)*:_\V';(F 9A]
M.@<$-OF6T$2-0]"P!+M+X 9&*7J B\B/MPS'XK$.+HRQW_06
MKQ571Y\2(9CFRX\K;%EO+A:WMR\=(XF@40[IQ/.I$UT
MTZ?]]@XFA0XS.S:Q!
ML;:1)9YPK:ML&F)"F@0&+E,*SUX()^/OV<-VG) BEGF<-ZAN)U(0UVU^.[(X
M-7 ]$QT>1S#*TN6Z, ZLNA[9PX^\P@<\CDP:>)[&ZF."*D@_[SH8G>W:?$'V
M-V[.C-OFD[(_.]UHF)^YS"8!$M=R3 @-UYF?HP>Y10Y(<)U=C4J1Q
MO=WI!NQQ(X!WEKAL!KRJG6O/E!H.NBYO:MS")Z@.ETE R+G(DH&09I@TIF'2<8KT6[B8-5@(1!L/)X8V!<]0>Y1!$^%$P&
MJBQR)@)5!FDBJ.Z2^ $%!*ZX![ N&T\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MWO^4N*&AKCYZV/)#7CCS_7@?$6?Z*@Z13WJ5UUH2G8P?1LS37M2U VY6@RRXI,7EBE/I-DAH$KH7R!6_A&O7 1X8[W%*9N7F1S*;%BABD0-/Q$
M>UVV!*ANVG\>Y_BM]I#H.6^VA6PQ0.1^NP_QSOT +]9KZ&>S[!PO@N5Z$:&,
MK(3=#B^ ?&>W"D\ULNSH2UWR>,BM.@&0]@*\# 2X'X)EE/<$O+JKJ3STU$),
M]W6Y,O^4;4FBT.<)[L]O*O2+-$-;/!8YR'R_#^YAOI#D=V_E+FW8@SJ$\5!9
M=-/M4;;YY'N^ A05.K-X&I:GBH/ H@-0]@ :78!'W ?X-)_-F=BSC#QU:9:84V22
MEO(CJ:^"?8C5ZA6B@3\73SL8I4IGE>$^;*FW04IX)]RB'=E4BY:@;,K67Y9!
M)"VF$CMRG#"*=/X$B\PO+IY0,@MFTBFONFW.<:#1][M'9,"CJP7E](MZ
M OF76)5TCYFV%0F7WZ7B8$_-,%:Y?]W$WEZL1TA8W:%DB1'$2;P"UQ!_A'R2
MVZ>ZBJ0_-#J:P"6!JOQEKBA-[I':?;L&(@^!EB$HC[VF@:0(.V>@4T*; &::
M.*L7JN/8L$%"QHY[&3:7AD@2)4IT[J25%6P;9%)3-K+'5PEY3I4=5IAG&1Z
M=+XC3@GK*FZ8$LO*;I @#N"J[R:UHTH+NHU .2:,<&_%'\C)Y968'%MAJ^Q=D7S5V!'.J#[,:S1VKD$<'N9)84'SHW6,)OT 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MBY,D?L0;FOT;',;0ELVZ/@7<5'W1 [;P$4':ISB#U:YSM*>5S%-^E,'D@$%U$N[WEZ'K.\%;S/K)IX("I^3% ]&M&X+P;$(EEV0:28-*:
M$9OG,$$/-%3Y1VQFX\.TGB4LU8VUEZ\RU'"04C<%1=LA<]?Z)JM?D$B^ !#\I #G]Y^\,(]_ [!!,]H8SM3=EP*N]]Y,3=*70TS Z-.+PZ7I0+\H-62+!$=_;.]"ID243""-0M+]-^_+ DIW3.]*V,WHLTQ0>$[A@26)/IQ6XB)$FJ> '"G83MKTCFB"GMK,H/(3[4BIK' >(D?];TH>WQWU>$X
M%/'M6)?M#:OKL;"Z6([39RV(TQ$%T7[,I"T*5C(TL2C "^IR/#UQ7B9T++&\'7]]
MR*6HXY/T3DTL!UJ*Z3P.0R]))U!G;23!O--[_5K:/467_%IKPH,'J_71$GQ*
M'3H8% T>-LHVV) M0_KMU X6WM0.T".NDU;HS!0L&972GK,8CE%Z6+!_25#$,BI6F(2-EU(/FQ]OMW%4
M5JXK!3,%!XBY- P+&#_!Q$MY/(DM4*:]G?C_!Q)5#LTA&F^%249I&B<'ML+[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M7N_*D8W!W'PH>D=1_DMM[M0R^UVSM(-2 D2%XM\1#D6"TQQH,(YR72:UI4JJ-[
MM-54$B7)B'FH)GJ'#P:82R"]Z2#EJ.WBK#NP]9+F'0*XY:'SS_)"Y1/)VM6@1'V\YH:]'A,X@(5;33@Y1PW,2DF8@
M_W0ZT1VR,FXC38H%-A,MKA?8H]O>5YA4<&M,Y-%='[W(NX?M)<&ZM<(E12*W8Q[9DH,LF%Y(X;"DNT5$A+PPP5R>E:4RLYLY<;.B+ D&>IQ:
MQ* \2?9KG\H3-\$"#R9B9R;SD66#4>+!:TCKY:R\)#O<)EZ48MB3M\[6E>,@
M(5:M\"%J>/AK? H>4;8!14> ]#2%_-[JDN_6ZI5@C!$BFR'=N7LLQ48E61+!
MV>$BRE!VN(R351(_H!2/O%S_%1YJ@V>%;?@XBF!X Y,'Y,.4?AB0MC=PYR68
M^/ICVALW#[VE9P:VYVC9Z>9PJA*F#!ZL:2U7PTW'FIG MM9Q%1>>>E9&<]T&>QY#XHI\CI[J1-K,-M1I=FXM.*NON#]ZO\34S1A'Y'B.Z?">+IZ((%S=&M.\&X,@S:0%;CC(';YQJ2Z> 3.U43V$K*2_ZAZ!X;.VN4?=R'&=J%B!@]LQW^
MP2?EMC UUQXW,]A13]ZCD&OW MF\S+]AE)=]98.=<>9^4X.NF/B<>N/V T.>A?$U'&UZL9[TZ8@#VF8;DK7E[:
M"T20(N8(*7^'37L9RL2; F80>)%@B3_ Y/#R#MB/>;Q$L.YVB]A@E)._8YVF-C"0][%9,P'&Q.5;^9XT,TLARAI4^A58^L-IF\
M\VK9'PBJ#E^!/>V CVDG5)UW_BMGW<\D<@=8W2U%X09CS6\OFF2_4PV4'I8
M^ #C^\3;;? 6$0ZL@+67WE&6X0XH^-_ ,$O)OTBXZS<4X>*^K1Q/A21P<-G\
M#)L0+DO(2DF'(&AXGB:^DU:'"?3LJD?VZ+9/=4PJ9!#DD8\GHJV$@FQK(OY\
M#?;BIB>CNEQ=1-@$W;L)")$FR.[92I8L#O[JS)J--G0?K?]RC=(O0V%*$_"D
MR:"$[RT;Y)W&J[0%'HG&;U=O!I;)-*S,$=17";/)EK
MHR0,B!- &_9V3,N//Z3$4S[^&)[^F(\_FE$D;E^ ="EQ_@RD0Y#*6Y!F3;?)
M/@CAB'[H50B++29._&R?D-+(-L'7&M3J>;4Y,@=0Y2=3 0Y+0ET7>F=2HT7Z
M?(HC+_AEGQ+/X<4#W2G7>.^XACL2[A;=K^@C0J<6FB*)#B] U2CE.<'W=RG\
M=4^LL[R/"<6NF2.';[5I,$]?*18/[VS#NC.LF[M:D.(,1L3IT<1 ^P('^S1+9X.!DCA66CYM\4#7=?/$$029 9\\R!DA*!KB+M#
M?D8>U*0;$KN!_W?QZQX]>"%1;K8Q-4B/&V4D21T'>'4SX.,&DRBT+2MX)A2E
M^&"BW_*7@^5@/L0=WX7=#"E'?_3;']]%RC0.+<*7ODG]W23>^'(ER7HPRIZJ
M@;,C[W"5P)V'@N(VU[IFZPX_]OLI:276(81;J(]^!7JW^&[W2XX0F5J*-5&C
M$RFV_?V\ZZ;OP[;U):;"S?XHI(F7["F.7OL2W@[.W&0?K.MN
MI8L(&X"QCTA@E,5P)?;X3E*'LFF1*.\6@6ZE0O<1V0.2[88B\:>NOR^Z5&+3
M45WR"NMJ,3M;7"UN%Q>N/0[2VND8.FGN?@L4D.#2"R$/I=(5T;@?FH8_0AI9
M U/62M$[C[&>2S*$;7[RN*#L^R!Q<MDD%Y.RV98VP",L%M81$N#!]1 1QD'6^AR"+05(D&-B1%_GNK1X9
M\3+U#'_J^E@C#JOL8'WSZ@SKQNII$\&[X_MN=GWQW?+J_.+Z!ES\[?/B]A]O
M7IQ?7"[FB]N7[L'$EE\;/HQYCK\C2*7F[U/"R@27<_FY\O;$S+]2A#E=PQ0F
M#]#:@NP,ZV9!MHG@+,BJN'/QF6.;D2VO-D@8\W*T /N4L!9@&3*8=#G\K'AL
MN!"O8>:A" 877D*RX-OS-_4&=G*M429C>J:I>@OP6;ZBJT9U=C%74L"_^J5_=AT2Q901X_*M-1T#TSJ_M@?83,/#&=P$3#BTM+@%N3$0>.;S3&_FT81B
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M_ U)Y5NG \._I%4?0IH=CR1_O(](,9)%E&]7RX2TM7?('85:-^@"AYL
M+Z#[","B6Y 7F7MSC\=T;GN."K'.R7HTGCJZPAYM BR;N(>*+AS^!P]\=FI:
MW82"942"VVY@EH4TVY6$WM=X(CKOQOM%Y<*WGZ.OP8E[<
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MZDH/KY(M_FTA%43S4SU+.9SHY>Z[R6+_2YZ6ZWR?5(50MLQ2R&+$2_F+# 6P::N;DFJU_SNG#MCMZ'$B4#NL1&#HFL&ED2G_83_/9G/Z\
MB<.@=W11 ;;L !,!MB2Y2L FC?-_%JV=!;*- X(!**NPT(:.'@_+TB-8O?M)-8,RCP=/1%DJV)"4TOSL7U<17T9)\I!UV;]VSM2&-,J#VQB_ KBNB>"934$
MZ"AI-@LUZCVH6\W* E6)&'U
M+'A :7P$*YHQA.5$\:;T*ED?&6F>YP '7M'!,[&E^6#0LZ8YG+3H?!J+9I:G
M:I8[I;#PYTU_U*M"D15^J6%(3$;1.46%'5?8F.I.80R;#YJ,J376=L_TN*6-
MM4NA9V'E\$&@>QUDL//YFWA\81:S NU&.YKR1)N%I4J7:#.//\ZP^ !7=0[N(
MPR,;?6-N\F+*#;9Z_(<<+R3;)?EZZAIR0H Y,0GD84?>73S!Q$MU$>1+OM/-A0IE-"=CT4#]Q$I>J"0BND4\L>.)7MQM9S3.+CR;_,XS<9V7_+'
MF; /DTNTVLY/^G@%(DA]7*C\QB<=3?!8KP<339-7P%Y5):ZSB["'/Z+].S#@
M=$,)!FD?;4DP[>)I+ U#'.G:.A*,M[-3%%M4^3Y__"VB.\#$?1X=
M5'D@IF;1*X) M0T"YDL_C1YX*_!] ]-@ZHCG,T\4KS!!LB\7)@;A4CG "[ XP\>V]0ZZ:ZMM5
MC:F_[GF$KO!!H+F]LUAH97OO#'S$[9TWTK2W=P[59AA_GMO[ %1TM;F(P^-%
MV7(77OZ4",,EO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ME[SP)P.1.I=X6PEA75V'71'^Z-FC92ARDL]M;4X>NU[Z09X54=_M5!D$K(S1LBS1.CU6]0#KL9:1^M-!J6[L.IYE2!HN_?B"%#]Z^89DJ*W?O+!>
MN;@K^2@AN5[UQR&>C'4,EZO&*DL6L\!RNTQGHT[59%XD'5-2>M[5JG?",L*P
M951LA5?(NT-A[^60>-$+>G%2X95/C_*"+RVHL.QA"BM^6&H]& VPQ+I_1)(P
M?CJ65Z!;H+>71ORW(Q_SLLT-4V(9M2,_]+;W?C?.M_<>2MP:;!YHE&>$_5]U43I0HO+08Z<+)1,$D91DUWM- W8?H,B<;B"1Y**^2:0UWQO7]BKK%QF>\O>8B$QPTN76@H8)]W@()=7(5+R
MZ>&$.W_]Y )M?P/UA-UY*0Q6WH'^TI&KBD&(_?0!0R1QH)??P-$O:?$;&*7=
MRLD3\$SQ12UR2'&8<(3@%ZFJ(S+$L781GHCP'D)^=K6%V)#5B7Y-6&Q5^A &
MZ24FEGKM_#8DY7CBI&21%&DL[=&*N,B-C,"U#32M_)TTCG<)=!'5-E>Y+K6D87!
MHL2%TABDBJ,TFE\Z<7-KB%BT6_%F/I9I^SE*H!MK5T9NU*D68M=,*&2=QC+&[!.Z!, K HR1 B69I"&*ZX]TA5*,Q3=,Q4H\S@O
M;&XU*D9$"0<]Q4>.;7-9*92']L&):GIVVOW>)AX^NO@-I2D3437MVDL"LI[)@0Y$4E,
MT"AV:/=J2(TX#IZ*3@"*P&.MDF6224P"*8IO+O0HM] GT+7WD<%6H75N)/Z.[=EZ8W!(CY,J'%K
MQ+#/_M"K!.X\%+#W9X=@[](U/8AW*.0 N_C*S9-#8QBHP9C%D5$,R6XJX$4T
M\WT2=).NO -9*'C#P+])]K"Y;RC;FIK#.#1']2CF0+5L"G9Y6^!% ?#RUE6\
M&9J0%6L&"[:A:\!1(ST]]]+-91@_4F?G9WQ,7T3]!78-L26$_ P&Y'-,"?D?
M27_]X(56[T/'H=;FJ_21:><]>RDZ(%9Z4G4!R#, UVZE40'6WA?&XV@K=L/@
M O L3I+X$=M2Z3STTA2M$0QF:?665^%
M94\>_>)>I_)J823L\"^MU-BG$SC?'&T>1WB%W>V)DR9=KE=>(E+@/JQ;.
M(#EJ6"L#JSXD\7X'L#YR:+Y(2ZNT3>1XH6EC?X)9V?]UP3(R#DF>+H$:46O;
MZ68$M/ >Y\&,!%>S $-:.<2(A%1*= Q-V^!BO'OUCK65XRB:F@('EXU<8M3@
M%2M^F-X^>*CA6W@=,<=32FI(*9#!/=0FG_%NJ-V51^,*;1N_:_^Y#2"$Y3#$1@!
M"%:?GIB%'5BV5L1A!IS E41]B^?)<3(:&1QC;(ID \5M^]EDL()BAX(QG@N+E>/C25<+K%)9S_>K HH2JVFX#\N+:Y @N:=7C?0,4WI9
M+RVR$BYR[!COT?8X;[993[9=I_E0?;'=09'HQ?8$GFQKO-CF/=BVJ>DER9+(
MQR*6T6]&0%IO*[.*N=S#)#BO,U&P6!>3&9D=&;7JT%]$#I):>
MBXL5MBZ,@I>5K, 'G\ [_=F_3:RI#BQ-7A01AO'N=O!W))-E1W.X=&0JB;Z-6EAV*
MYGX T<]G^Q1%,$W)?1$^0'R$)!>S ( I]+^^CQ_>X+84>N0'8KU]0Z'%[]&B
M"< E@@.9\EM0?.PF]F)0& 02XJEIG/;R]Y^Y7_Y'E&WB?;;R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MVCV#36 =Z['[Q"CL((^^&SQ;C>SJ:@YJ_T%469T;;.G&Y\204L=[U)V3
MJV1A74)8ZS#_!ORT[:ZX9\+M&7-P![&=+#IX!D95URSW*;A^TR.27QLTW$G:*Z0[3 Q+YY7?E@G-^LKOV?+^
MY B>^ %]R".%I1>;Q[K4L9DW)MM/#;)VY:6#4#$J$V6:+
M/"7.EZQ >IW04\X$K5:E&"2'I2[S3T'Q+6/5/DO&&T8S%$Z8:YC"Y('IH3[B
MLF4.[L#,8=$QX&L&Q<>N=;Y(?FW\<">I;2(772W79;Z\<[1>PX2<M0_J@P3*L5.FR[RY0I)"#Q:(7UR^E-&'0O?17YXB1XKN&F8(5O'
M*'-X%U!D$<)/@[+?[D,2T@+.X1KYR%'\@*PM!!,O7$3K.-E2Q,[NXGU6/&SWPIL,MX9%@(N*RB//\8B0LD"3VN8]I"D$"OV0*CPC'@E?GR>$H;-5_VMH8_LQ+$7FW
M3Y)DY8)8KB>X8C3(M*_0S0CF18V1CO(P0[Q11]E4GM>.@B'^LM#DWVB;R0VZ
MCQ#>9K'=G@?GTN$6TU
M*C01Q%\2.LPSN4V>DP1SR6&Y7D08DKNX6(8)/C"@ .8EXLNA[2T -:HM!/)NK$,O#U!"S3ZMGB*+(:,:Y'%0^_^"N&SE'*K*PN\EE5%@A5;46Y'!$Y]W/L)L$P=\;M;C?YJX 2<5)7MVU.11!&LS32:A2FO7+=?DTTL_]
M(5'P$7J$E.)I6G4.9-5EN(5/V1D>Y(N$#AU[1,L//48F7^*TU1Z'>NR:(Y%/
MJK% /AC]Z&H2>;J/!+!R?SB&.'3647OT@>$D5HE:?S8KU"M1QGN.U^K#98"^
MEMRJQWC*K%!W#9!Q%) L 2V5WJS:M J$\8R%N@>7H-*05PDI51Z8F;\P]1.T
MR\&;7P^1F@9;8G!@A4HOIJNJ!R1[6YHA;'K8S,FI2:"3H[PNM1PP_^=__/'M
MR;O_:ID"M ]24F#5N)@ \WU"0@<.SNUA0SQU8CM_
MHY>[(]B9U(^(?PE2W-PO#!,F2(<,:6.W[X'DA=P&I>3$3:X +B&IE1%O"=J+
MA'_L\H='!)Z(!OMWO )J.#"[Z&5V=((R"5&VX34T4Z/M/KM5(N"H[2ZC%#E3J#
M*JRVM(XW0(RIHJ<) _2=D37=_?8SY?A_MOWWG!,OF=#G\4O7L]AAC""'^]9,J$S72TUW#!R+86^\+C/%/C33G)+$9R=2A
M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M$]S:HT8/33M4%6M !__@CKKZ0^P[LNYD6B((;[77I6+HV2SF";V)X]X79RWXD%+B-,?+B8*\1&
M?60XGWDAB:2A%77.O.B+O1"#_LCVP^MZ-'"0]SGJ:M<-#(/\!LK'YRD2016
M.]*#8V<'5YYMA+$G/IIYP*U"Z%HW2A'F^O6H#)&\Z,]^HMQHE+.2D2Q@)S5;A?%F,@C+]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M.>5 [_'&LFKFC$:V?$Z*"O.K!N:+D3@YJ":.^4'-_,[,]VFW,?WU
MS7ZW"Q&&C;6CJ1PU]KUM4G1QH$\_*A6[\]2#2O)NGQ[EF6#VM)? WPO3,DD6
M/K2D>:(:BRX2 0WVT2>@AF]/3,-T4!)KQUDQ,&LCD!4=K9+X :7$VV$-6OV1
M[0.J1P,OLWGU@?,+,:[ .AG+F3/3]'.T @GBZ $F&<(Z[U.<51%_!UW;<+@_
MFT^[E"CC/_RUBVBW
MS]+/*;F4(D])Z'F^D?>/O%QDF8Q.KE/'GH.;Q'S'FY#$O>OGE/B7R#.AL]#S
MO[S&?\-TX_-2@GSREX]Q $/' 3,68"M58V4TD1A< XK(X69:/>)RE*7'329
M2>H&ZLN^ MM:L "1QJX-7448M.&MPA5'I:052&0]N^N:"6()_K9%J%64FC[W
M%8QQ$678,DF7CU&>M-+;S6:!9S"AEJ9CV.^M= O'"C (8@,="U,Y>_3L6ZXF)>=..CDO0@Y>A!UAE
M&J]'JL$TG6T\[M09M'@5BH^D5@/1+$.!/W5W4M88@B_@YY?+\738.PW][!9+DNTDS5WK8/'HHP*3)5A8;[L!H(,T@.+],%;4<
MER=S>@4:IY![W!:\(*U?.@P3EI96E>5"BA>Z+HRAC&5>7E^8_OLR3BH5[N?Y
MTV6<&:9#3"TCW@"]TM L%2$L6KHL\S<2#*03XMS0LCH363Q'AQ9NNU^=RS]!H3TTO4U=Q.RP/.6)&AP_VYNOT?I$S"Y"KATL@O
M.9$H3FDYL@Z)?7#?J5WL>0-7?@(VESNJHSDI
M_;?P/T)TO\E@,'N B7M),]+470#BG[ Q1-,?)1"&D,!>W!T=0[4!4O[_*?%-*W:WV8VUO$M=[M'1D-B
M%;3GE.RPD4 PDMUN_TZC*MS !%
M/HT07%RN\.4^2S,O(FFI:1U'.C(Q,<<^=V@,Y/I HDZR_$DE!8W>Z3NT1O\.
MG2/C8D1TIM'DKMYAA[[HJ,9>)M=DP;7668.P_*\R[CZM;JWGS-$@DENKMJE]
M!ZL'V(>OB9RKQ^NZ_+)9?,"$4%8 4R79/'$^5E1EY%(M67=9E1Q*]413XY0W
M&;4+IU)P"E=4K-;64[+S:9$^2'!V-T?740*9="^B>),V"="H\$6# V@.%+5H
M#5X'#MSY'%+XMMU+)+ED<'_VEG\3F@W[MRR0YQOA2]<'HZ3JP\/O8*1>1Y7P(#E-5VL8K\Y?JQ
MO4U(4<73"U=+=T5!E<12@D-^ML;Y8U;I >()8+ZG5UGNGBJ] 0:1H7*=NCJ"
MRY''4S1Y8T!: ]S\Z[ST'KAP[B/2%RLSA%2>26.]$[Z&9(8HS#.WM<*[9@DB
MKT>,1\#A(>JD7T //Z\@"EH,Z% ;P4>* *
M?P>S-(49**+]\%^S//ZLG9W.?93CF) 5E3,9238:"?*Z07-8+V!0E66A%$Z;
MG YL;@)B4B3#S0"*0-ZP+OG%+,'J[@@JEA4O')+!#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MZH W0-=P:B?N:?TW(9<3'4M\A5]B,7
M.)RN0Q98DS)(.E+T4Z6OL*:]>P,[21+2I6(@GY_;,GX\676>;+&F9!ZCT 6>
M:N/P5O\IKEZ^Q&GD:1;1Y^ "
M1I-4*6>J*$^G,YO.$#ORF8&'N*=H"K+C(EH&I^L@("XQSC.0\2CCZ7@:S^;G
MG[NU.E2$S0^?$M$S>?,18NBYN.R\*^F\U4^-43<1,6:ARE&:_..W5@). IT8EEPW>8(F$V*(*X
MEC?L50&Q,L('_\&G_9'Z2^1KOY/QW]F)75Z@)>0D>:5S8UY&DS5QVXP[6D;S
MBHN] D0*SIUQQK&,T5&('HQ/-(.Q\VSRHR*H&^1HSGF=19&KF.,OBG'&L;PH
M1B'ZR+K=^:(8%4'EHAB/\\?8*?"F1)YLC; 7E#U-3-L79)GI\W6< *M**N0F\PYALJ51Y=L3Q-3FV)T22I&Y^A2%*.L9C-%%PN]Y&=$PPWS?QLH+V97
M+E[(#!&EJKOJ/LI+[C:ZIJ"\1'(4:2\N?_0BO5@0UH28=%M5.4H4F$C0XR[!Y?^@7F<9ND(=ABS/]?ZC$N9ED%&=TS2$SX[X*X8.^M? <--"[+]$ X2F)5R=RI;MV1*LGI&3#C9J%T[VX<2#VID.?TN.[&U8=%)^'*
MZ)Y&QA 3.W8.T3NR?Q$/ '9U5I[(95:>L="BYU7DL/KX#D4MV!L/,;'SL";L
M=3V(4X+]6&C1\QN."'NU]?9I/IL?6]VSQIB$82M+[M?!Z_Q_,(C(U^\S%<^Q#&0+^NTI\8^D<#C)[B'Q?]C$,$(S>9#,9E>W)_8F21
M9>[0+[,6T2\F471#4;:"I59E>NU2?K=UJ0:R&.O 9?EZ_!
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M"O9;!0M'L6-'OAHU*F6SZE?%W!K6?.\U3MFI\TA!@9]Y7XJ2).WM$Q"IW
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M+=DP:4_Z^M; ?Y971C98@ZJ6[L&@DR) TJ1(JK"F4R
M '.D_E1P)M:&I.%I#R?4U/X8D@J*[U.MB;I/)CXDZ-5>:UM$5!N1H9,55Z=7DREZ)0V=9;
MI.P(CAY.G>8.-D IVRW-#,-3M=C(56M/Q?G9Q-LUIK2")2.M*46%M79-M99
M>)2(4JGNG$99& :&,@_$LC%M$S@3JT=Y2K/-))!BM#!-">@Y,10-XBNUL.;0
M0E0/CI2.J3^"?3BBVE,/")Z0O6BN$WE;LQQB)V46W)472I5H#[
M) S,,;2M&9RG9'2J*V1-#.N'II=]_@@3V(@WGD5!,0H-.-:/4=?IWU7Y'PU:
M)6+6J_"/1]QM*VR=A+$W>IY&(2 #0/1#V74YJG' KQ?'#B6'MM3\^!U#Y!X!\X1(F?":7LN?,2-.*[&J\58*D;NO8[>SJ%28-7/'FWP#Z$7B!
M(G >AZ&7I&"'33UJY[UT&*DJE$-?]-T)&_B7BTX;RD/A=,!H[,9;W"=DT+:O
MMHU&(^=O1?C2Z)KDG!G;B]H<)D88JQFSN.[.CV3*>+/@S*+/QIZMO@B;C9TN
MP@8A\HN0:::YQ0)#&APL=&<\2L':9;;!0^#=RM?1PXTE8 T:^=@,\( /Q:MC+QK*6 ^JMHBG85FU=;FLJ(BJ5FO3D-:S-)BQOXVJ4LM"RLO]#K3^;_F@ERB2\&[0/4'0"
MYIU*V_:1I27)$F+JS%%W(->Z\"Q.DO@1JSY[#^,:0SIX!%>/S@%6_8'C?:XO
MFO8VUIG)6 OXVYR5$;SW,ABH,)-UEF%E<@8O2+P_.#U]Z?X9FAJ3U4\P;*OC
M&H:$N2LOR0ZN[54>+0[6I@19G$5[BX\8J>>3QR,I>$39!B1Y>[##'2!W!>ZU
MY,\W5T5<&>5$M8C6<;+-7^'M!_OU]L=V%\
M@/ ,1G"-+.8;,*'1YFN.42CF+0[R/M\,Y+R2YUZ*>5<;P"NK0YV1\='% "7J4&=QRD#7-S>:
M7NM),0M?%DD<:":?PHP5ZB;8V)6.%_$(D.;,WG-4)HZ*.MBO8;XN/X JR&N\<'V
M&I*)H1#1)6Z2EE:G?U ?(B< D#F'@AC?1;)?$#PKWB?]YD
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M8Q+>MX+)UHL@B4&ED)1)K3'M*87GM'[S@NQ7Y7W)IS@C)\7["/U;ZO&L6G].-B 9RGCQF[09,5.(>5+>L!%G
M%SVUY6TG "T58?9@)LT?DVNT5I ?W.[BQ$L.M27X.=JG,,"C$]4(TUD45+^9
M)S! [B\?C(EV'I!A.@,)%]PYQ!WCAM2U-L-=9N[-^6,@C^] 'H7))I=YE9'!
MH(2\;?]Q@_S-I[B4%":"RFF1%HN]ES/AF.MK#&*=/"\9@7#.M1+8?C_3@XEQT''1UUM!8'-5*S+#?;O& RW7U+H8LU;F7) <\\J.7!!HW,\I]
M6DXHHDR@A/XGI[;RS0OI#=#N0-F?.TM)6\+5]8H6M[2>?\91P<+>"'+'?VYK
MZRF,^;0(3OU^@1]ZY/M3I8@R[DE/$PC!Y]50WPD3+-D3Z-4Z#WSNOI+@OOD//AS;O_*8X9OX4HR;RR4
M>RCY@51P:@R\J'GO'.WRY+D).=8C5BK: NLUXK"G/9+?9!L(Z@72Z-BQS6J$
M)L$Z4..FB?.DZO\*>7MI-3;")7AQN@G9JDR?A*4L=Y37O;E\9N2QLF8JZ9ZRIH9R^)4*(M6ZLA&XJR7
MCH.6CB6ET]&M>'ZVQ]O(\BY$]WELI?L JA$!QS> 3/AL%,G/6J].;2 748 L.KA9: I3/<]W
M.T$5+:^7=7/-L/KZ' 48SH0E)-E(NKD,XT<9'YM\7W8#[*7IXN&DH<[(MX!^
M[-#IIBRTT@6GQHE1\@A;>/2%%)V^7
MWM^E\-<]B?C)NW%]>-.&!G^_E>>/B:UZFW@!G$4!#:2:[Y.$O$/U#N1NPV*,
MLXB(\92J2N8?$4F\+/OYVX@4[/+OJ*/8\_UD#P,0UIK)\88L(_%.Q/,0+PR2
M!L%= OW\D=(JB7M,H$CBXK@N[$#LKS0#)JL"WAOM\4#_)3^MULXXN)J.9M*K^37HJ2.:] _K8=]4N-D,Z<%Q-1$F^_N+LLO\S*WPR.TRJ=-R88VQT?PVLY
M#C!;=(Z&T';915?/4\Q0H(S9/BOU=_8/'HK2/ 1R&54'M#Q(M.%MO=TD\?Y^
MD[\F72:D@;7MWH!$-T:I/L&" !S,2FJMUC=AX!Z/ [S@EWV:N4QB/":8VB:$
M(2.U@@[+!9>OMK,X_@*#VY@8+-E!0F^+VUM7ST)RA*ENB+(M->T=;0:R&$#:
MT%EJ!AGA5+&!@U/7P<M<(!1- %5&_ "MWH)<#OP4][R7RXSJM=O+@X+:U^4*+2P4/%?GW(&\ %@M FGS-0H1M/ S)H@*#<,J:KX;AHX\%D\U\
MK'!21$[!2F 0M[==O5I$##>S2MX&-!KQH6$_=%A&/E7P\.#\]8ISI)M91*\]
MR*Z$C3ILQ4D#1-3:=DRY@!;N[6>ZH9Y7G_P JT8I QS6"W(,BJ6NPR&>MU:6
MB6N(]R3D%Q=BTGA@-K.Y<; (X$B__C27_Q04@HCMI;RY4]3;(ZBG_AKZ$".'
M>.FE9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M\RI=1(T=>1G/%XZW,"XL,
ML\13QP+:$:^K[<[*38"PU3ER?4@DVA8RKYZMSKR01+?0$.I9%1/CJ/0O8/@!;&#&E#IR;0D<'7
M7HWCM0&G+2HXWOHNT?AQ:N&?P_&M0?>[62R,MT[;N$$UZ[#@AJ401 H)8"2(J,M#%NWAY[Q)7%BDD\)GZ2*/&1XC\AC?RTOM5N%L36H^Y68%#)K/;\@MP98\34Q=&,Q*1+DYSZJ0R+]Z*KL S3Y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MM-R =VISD*]8@= BP#U5'$[GR,@!*6P7J,LM-BF--:EF[6=T!"#P4_H]@VYN=
MQEZ'DL.YI)W,V^G$7=AV] P1Q-<:N!E&E7-;5D4PC3UN>-):CAX2?HH/:Y&/
M=EY8.LHUL2+?E]VX0FFZN.E!,GHJSSL 7IY%Q[FII"RZNE2/"C^T+TOF<91F
M7I2M$KCS#J3K"9S8E8ARUVLR!W-0/HB:R[I7-[2
M9\=7RW9ETT\I2Q0O\KIHGCN'\C1BSF^+=>16Q6"K\,.T*D(YD&-=*$&*N_S(
M8L*D8,E[^NXL-;*MAR50:B?!/ TBI*[@ PS?-FIZ?8=@@NG>,%\4'E$1#1)B/XI[B"0.QF@S\+:9
M17!;+UKG*1G49=]61E)<.8(2D/)#R1#']"Y!>/
MF>6?J#.;6%.T>HTIHH2UW@0O_DGJB/_\
MCS^^/3W]+[#+A?+(%\HSDHCV=>6*\@JJ+S]F.[M^-R8-7(\%_5:T!FV+6\3Y
M2M[<*8ZLZH;6'X\.DP58B$2P I^94$X,;H%%*_"(IC%K 5L_CTNMX.*CJ7@:
M^1 1SLM1 )#/*B
M4XWW .V65J.Y.43HA?Z[B_UG\KX?\M^?HV%$7"O>6Q4 $ITXBHCC4V0:TC^)
MF'XA6B1YH).,K!7IK8X6;F.[1Q0^(?I1^D[#] ?@()RMAG.(A!^3Z.-FT*XJ
M&(;[L+J+#))C&CEO.^^RK(BJ),Q2#!@A_%IWC^FWM?O"AT.%9H"URPAKJM/5'MB$3:9WVAI0L"7@^V]P\A-28AS$YV$BGI= $BFKS&GE('.VI@@]G2]IM2
M%A%Z<:GN E.'),^=H[:C&Z[W40!+\U3%UZ_SS*=UOB"50
M>U?Y,]64?=G3CRC;O/\'])(<7](($+>W?.X4$B/VG:;@$3<"[VEQ8@!SU>#:
M?I023@F.XM'K0&84 *L^\S$AH>1.1Z,2R'AFFB%?R@S:DI1D:3:<5W2 OLZKPAQP[
M=-3+;'^_3^6MS-;GMB,>FX/S,B713\#;DU> 7"NZ-RQ8_*WJ;73GHY?_'/JT
MA]M'&&7P<(EY+BU.?ENK\?@\*KAE,_+OP=MOIB+F02'4)3)$<]5\K]'LDW:Y
MC.3K]8A:6R^!P*?% MNT< 6"!,/C!F;JP3:Z>UC; "(NK5[0%2T/&] ] 3"
M!T1[QLJ H"\HDL//\UE;]JW G13Z7]_'#V^*CVG83OD/@I!O*#H:75D[.M1C
M$09#YGU\PZ9G;Z 3J<
M)-<8(&JX2&AU8T4.#6L4>9%/C@SXG FCU'TE2648=/+$2[!':X^A'4OO*M[=Y2-$86%@]U[6IB\+-5(M3L7N%3',V]'F $@\LX>?02^M4MW83G P3!(WMT'TVL_;@I V!G[>&JSSYI/P%ZC(KDYS(,D512R56]KL\VC&
M!.[*NC$Q^\SU'^!]P0L1RYZP*_D^IYLF13$!#4UPZST1!^3;DV^^D5[V_3:V
MSP$]"CCR(Q\X5^5<%I>KDST;K6VX[NJ]ACC?.Q?G^R%QOI^0.-\/B?.]J3@7
M40"Q#8HRN(()BE5J=C,;VJ_4S2*#6Y^[_-B] T_,^+H"-W=Z6N(V*(,\E>+'
MBB6/RRN]*U'!;%=7>8,%CD"=_%\-O:]-YSZ5"LH[Q!((_
M!H50+7_A7/6<]Z3/%28%I6F<'$AZ,B4 ,)O:OJWET,$+ /JP +OJ\[R8M7L5
M,"2')@:XD]5_8DE3&)Q.)1^)B!!'^4@$) GSD9PZ/\FI"YF1W6)H^AKQ(YT1
MWDT%?")"'(%/0)(0?.^F!CX)(3/ -S1]W> E/$I1-SA=>0M>:]N$RMV:-=1J48MV/ V?N5AZ=UNO&@907*:MZSY^!0XJ)?()8:#2I(UX^3=?UW!- 49;H,W71JK
M.9FKLT'YMI6>>/[:*.OVB>'<'.D6@XS^WO:]KBI=#C9A-0K%,#V#V2.$!*3D
MQO<=A>I4TDIH0J2S9VMP2W,+O\;F 9;>K?<%QO@G6HK=\TFE1A+J3(I6SYY0
M*K%U2W9D]S6L%$W<" /:&)2M0:-Y'M">%QTG7;@,35*38/5.5IXU1B>3:\Q2
MV(?0$95A/>(1?.>A4,M50_,@1?X.?O(ZB'&BJ'J"::N@]E1,M92A X9YD[EI$:9;L:5)1J]"0(,4Z9H9IXH")-@3Q&F^"=5. ZK9=H#F!F;ST
MV_B39(L),,_B)(D?472?GAT^>5N[6HHY^-B;HQAY+!(X6*L_!7<'$.&/>UK,
M";I$(FSCB3M9_0HAH4<">9]JR@2T3"RD2_&DH 0WC52WH(H
ML+AH4Y5BF *T),3;J>TQP (C,^I3''G!+_LTPPB^>* J<(U-WVNX(Z75H_O\
M-MLJ]A1(L@I%>;H$4855#P#2+H!'^@!)V0G8T5[ZMIPK]X@J/+K^$B6>:4!Y
MG[Z^][S=SX5#D/09A\A'>('M!3@.4R'V#Q.(E2WP$;-HX\26DY<M>I%W3ZL3K)+8AT3_DL1/]R1W57 +G[(SW-D7 ;*J2-=#4$2Y'H)&A*O!F/9"
M8O6)Y&W-S=X +=)<]P>J#D'=(_B)] EHIZZTX0@ H0&ZANP\'K(OXV1&_I_B
M1;4(\%_0^H!_G$4!_1C_2!R#7I;: [X&219#6XXW"\.%LXX34(WX"C3&?$5=
MVN6PH!B7M[PFN+KT0:JR^#0EIOI60ED57(;>O<7=A@XWX8V&T#?B'D.ZFSC\
MV5#0VU;N/N5]?P'A'#
M+&NI1P7YL""+^]^">FBN^3:!)38R9@5+
M<4SQ363)'F,_&H&BY[U057>UL=9H=_M[]HM3M.$F7Y!X=W6^.M3U*C.?Z2#5,HOQRH7V12X&J-U!UQ]FF7"\#>41P02[)P7'/
M+R0# 'N!OF.1K'7LJ7HG"Z#Q^\8 $UT#
M!JB2.!RI<5WC=H*_*.?Q=HNR#,)EX N);:"/4>G7'73
MJ(8A]E5SH-;Z(;ZW9[&C&")/O->8B$0]@9EX==]N4!*LO"0[7$3W^'=']:*Q
M!YO,_L(D3VLOH3T!VA4H^F(<(9Q#71(&$IL$GW5&D1?S,"9>9KP<(+J/+I[\
M#8F,)&5E+$;Y<$EPDK&-3P\WUHM);8$)#C!%I\>7L!$WF BV!J6:!M; ]/5RRB4>"2_.*V3MH()#4-KXXF=5(C5
MS&8B"A8!O-CG_-.B "8^'.2A@PY?88B87J49XDW0)(JY>,AQ#7=8&!LOA;/[
M!,(\2CH*YEZZF<=A2-QC7KB,;O*M$\$T#XB%@35-8TRHF_+1IF1SLQSO\*Z2
M@:T7D*!]X('[/:V/#&E&TP>89M2,\\G!=XU\6LN=$7MV']8Z&N
M\^AD#%Z;+*9/,7D!Y86S+0E>LQA*VQK6#=#;1/!VVWLLD7L"1JQZ(Q_MO!!X
MM('C<&VVY'JO@KLS=%0QO4\)JV+ZJL-BXA4,X%T&$"TGXM[:T6.ZFQKJ?3I8
M-=1+3=(#]?-BL7X1]?U=ZB=H1SID*4&FYF]\7M7TQH=]"5NV&/FL
MKLJEL^>E7:,P]K%QD5YB"D@](@]3MUQ?EOG222XT"5G+]&+ST"!!#[>,8=X2
M$)$ OY'5CNA85[E*%:14US248\$X;R6;A96M&4BWGL6 3PDV/VBBE/9F7
MDBP!\MY*]B9Y!--4RF#BD\0RG*YB+P)W-"L(8LK@&8O@Q"!)TIYD"UFNJ>-A
M2;>5].())CY*27*F143_<(?/7<'*.Y!CUXQD2\W=Z_8.0T94.G%:&I',K:U<
MM7?NX!H90AWKU9AY!A[X1>0G$'=]#O/_WVZ2>'^_R7/$IIB4Y;J1+[:1@<#:
MMS-(57G:X;^\>-E?C!^J7M.2J^+P7$!3=@ ."8>#84M1$11O5
M.@PRQ#+=,2"]7&&,\/;D]%N+ )8@QHFE(D.9V""!Q:7;"Q2!<^*-QT9V99^\
M=.\P4P%"%[.2O#&P-\YAY=%9KDG\RF4"8=/$=ZEWM8BSKWQUR.0E9"-!4VO<
MG'-.= -A$Y"T(:W-*DT?8ZGVK]!:)N2@];GM2C?-P8MS<% -7WP4)3FQ>:6T9S&H2RB*FOXMD0B -6X&'D@[]YNH!A;:BD>5,6/?%TDY%16)9'D:+RNAT0*43:OHI5MOHVT1
MGN@%JY7>GZ(P4[J@5]L2>P>GH>U=A$T&+[,8_9AO\BWO+F+^5]5(
M^;,<7>T*EJZ8%'8(!<1HC@*\AY*3'XC+0"QME%ZJEK! C
M*M>/[34H197!9US**E*19@DJ>25IZG#PHBG-7O;P.9S2R&CC2
M'Y];\XY\6.8G[8=?608 G]FEM#DSTSS6S4E( 0F\I.?(U?XN1'ZIG&3$+&IN
M5^ "2GBB;S0AZF%'&TUB-Y$12P6(H9F;9?F'N_QJ+EVNY_LDP3_5-]C63HMB
M*ER%CPMHXB:@)54U=QX*7 =Y2TBU&\$]-%T] ^;BB:02W:-T0SHGAX^[_'(P
MDXY2'.S"O@-*3!#78FDV8P2J6O=/R8FF]EE)3%O+!B&1;O4%:>O6%)L[7EC?
MJ5(7OP1F5'NT#2%%^H05?M.[9Z!2FFPLU>**2)5VZ\: .\XIUG?B*;'$X5Y=_>-8<98Q*[V\9_^AT,@X_0
M2_<)'C"KCH!%W,DRV\ $GQYV"=S **5E5_QX:R_4=QQJW0!\%-HY"Z'A:<:G
M$%IXW?T]P:C0ZEY=CL5+38N3VB17*(+8DL6#(BD;L]_(ZOFV/[XXL@ZWIW#R
MZ;'RN7J\P
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M&1 %8VWC5Z')1K/Q+E
M9NLWLFIS],?G69/DP]<[FG44%9^ZS,K&97:5DXT],TU+Y'.40"]$_X9!!1P2
M1BDA85Y+JV+F$,&1=?UU(W89W.,&+O>B 1&4MS3>Z3_"1_DD""G+]V'8]25$E8:YVK!7;27=49%3EX9&>^A@AT*5#3",(NFYJ
MV5G%HT,V#AJ4"?_MDP;>36XAZGB?I9D7T?RMN/.M*U4@Y'LI;?X$-9Q,5&'MV2"D^K&^0MMM$BH.49841"'AU-PIVP%AXH3XJ>I:/N&8WLIFOLC2^4>&DB.(^ZYS.[M?K[
M,S,*KMY;;40- I,2#/%AWS=?D8P2 ?8[F^@M.9C3_&L.1"QK)1'_2[W$G:O>36";:0Z,3R(7:8(@X^
M2".2I(SFYLX-%!J:[_HQN)JLJKLY.3;HZ(J/WA/:[K=U*JCE^AK>87VTC*YA
M"O&4-N?P 8;QCA9T\IX6$?D0/ %C5(5%8">W2
M%01'DWJ)T'&8IJ?[ZM=,'U%$J"BSZPM!);F5. =G)W2E&56 DV-$1H>H7J O)_;F#Z@FZWQ,"2K/XV0(!DX4LD05<4.
M7>%*AKA!<-WM4Q3ACRFV:%W/B'9"@V*J;ES>1>F)MX\^:7891%+DP"8)I:(4
M*U('SW=%-+C(9(2'5;@"$>-)&G@Q6HNMG]JT"IUM<5X;Q656HA$!,YQH7)YCHT"_\:")/EG*W[0T?FL[Y:ZI$
M\I)]8L66()K/,24W^F ?(58&+K=@5X4(&^-*K-)_73';[4+D$SL8G[+LUJWM
MC6Q?!?=HD#J,IYF7[3%328 <>:,(,#^ZU6O=.)EYPNSXDYFSUGV&USK#>VD<
MX8X/JSBE->C+K(,DS_9Y?#A)+)H7
M%\9F:5Y=V"'83$5>/1K499W6+6NW1,,B6B7Q&F7+A/A(S_>0G,QX1)S#%#.?
MW+D0M_!%A5#GOC\5O'7=_JWYA^;RW]^1')G)%MB?+Z)8DBW?EW'FXE3J[0U04%+,^
MY<#T=?#33&)XYJ4HO29[F@1<. UM;_!L,J123-Z1SP%]*^5NIQ;SGY5JLC-+
MK=WV0X+54EG34D+8[>^M1C*UAN9=#I-OP*XL-CJ%.V$FATMQ]N=DY/EH5: H
M@FQ(!'V,SQ"'RSBITM(VSJ873SO,0M+MP=IYTI1.%WX10YIYS_O*5OCL4#5S
MFXAR)! ):J-HO-!J)<(1
M27:5GFNL"7!S!:>;_-!!?H#U]Q->/EI84UA)ZGPURW4G7M2U#YA-P!2W'A6:
M':29&9'\8<<]65A3JLXU#L34-B95AFH'!0P1THP?_A%EFT9L,8*37$KR%$_1
MGI.FGKN.Z/<@?YZ?-7J;\/ZD@S.U]:3&UI%,OA_B$)/A)8?2^=8ES,V:&2;+
M2=E2-1H'2ZUY50.PHRW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MMUQ?DV7-$N@1]Y;>P$[NZ[I4<&L/[M+:-'2(0+C[Z((&$U8]H$--JXW3[4Y-PI<37$ YT-YQ(E*3U5^AM(ZLU+[SN<
MAK;?5K#)X(8TXX]!\34@GS.UC>T]22R#M.'3P?$ST\Y;\)V&3#$FB>FMFSU%(,GV5L*;K%XNO,]1"GU2D+FQ0ZTP:?CTCL^K:JI%OB^[.(6R2G:
M@Z9=4OMWZK@27\Z=,_Y\_]Y_1K\]./''W[_KY_^[N_V3_^(WG\;_/L/#_?_.$2?S_>/
M'_Z0?/N'O[[]Y?/M(0W_\.#_^R3\/GN3W<#O__V'=U^>3OVK[.2?EY=O;_[Z
MYN'I;/Z/DX?@)O$>DGWPRZ?/G]_=?+GX1_#F_=_PW_[VSZOX\/D?\//L/%C]
M^^___/0K^O?3X>+T;Y?P^W=WV^O;P\GN+'J__I+]\+3\_/V[=]]^_^:'O_\:
M7'UZ^\_#I]F'7Y=OWGV[_-W?3P_H78S6OWS^\H>_GM?_?[_5__^>/?EW\+_SK_=OV'W_DP_/W)\O+A]M\W%Y_C[Q^7#^B;CW]<_]T[
M^^R_O_LC6GR_2!]^=_@U>/O/T_GZ[KNG3]?7W_]MF?SN=Q\_?CX[?W.U2'Y_
M\;B*LC^^OUI=K:Y_"'[X[@Y^N?KV_M.OP>?P[Y?G;W\Y_<,L_MW[]_'O$K3^
M^/LOO_O[]?;&^^-?_@7F-]>O7^N8=JL/"^DU4G]K>7E4 _,"KSXLW+OZ>IRL
M,H^TJ-5U<+>?24FI\;-/!5P_+$1+Y8 J;5I^9I: Z4]"S<'[H3B2
M%EBWA4VI=<;FU6$B7P'RF7,+5L#BJFP*8TYZLERE!X@IPM*HL GNK,/P7D6X __GH"BE3 ]4JG\F:H*>@$/7@97(6>3S.2S**@+.,E+_7!
M/JPFFA@DAQO$3-N!JB&]72V;3L#TE)95A14I3FAFHZM*@MCU0W=H^Q,B2)RCW3MJ!N#!JMIV 'J$BNMI_/H$%5^!O1[4#:8 C*&)-$O!,V8KHZ=?WV[;$3MJ81@])O9M#=8! BB,AK?
M3L*>%+&]$:_!GJ*>P2%\*":_\*6ZL;MMR) D\Z:PT1B4K:>@'%0D5X%'EB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MZ,JOP$_T,X=>0 YGJ_@GQGST3FIU3U386E6HP]+E'P*
MZ+?N7/\"9O?$YV14@;<#8
M#%P9(T."[<9,"^9N\K"C0FSCV58^ &-3."+,ANBPHY^DZ1G46!AR>76:E"1H
M*]&7M3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M$Y87L.=%Y1[1+AR9[-%C0<4VY+C4<]9F,0BXRTM&0C(,Q>\6%$^'/#J\M6MGAK*RJL:G6,TS_\S_^^/;DW7^U]L.J2%++H5>.*; ]IVAZ*D),R;14D8S&
MT;&QX18%G%@C:9J%4CU:"EC0((V#=@TX,TTW=Y:;BJ09EIDT[[02ARWP+G/K
M/:WPTHB#W"_"\JLQL<=O:RDFCDL +WEI_WOPTWG_=LUV&M,A&50)387SU7WG
M]$!BGF^]+S#&/S5"R!]1MB%Y8FKU>(52HC?+9S&*&_I8(UG;RTMRNY;C^[( ("F$VI[FHIAZO=6PILWZP^O1H52_39K/#'H/-\R'EYE/Q]S-$M:
M>$22;2T5YY=U1P+6>$N&=8EG>(>W2N(=3++#"LN6I'@@T4GTF:6KB[PA@AS=
MY@V0-7REMRLZ> 5(G8$\/0@L.^E?[;F]V)-$!>=V3X97VA%OMP&@[:S=K<,N(9)# ?7V4?PH\^FW?.^?HN1%?@-TG1IRI:A@,%09K'5O#4LUD
MEN[*TE8O2P\OP5REA-I;=?W[Z=R"JDJQ2E&GPB+-!T^5M1(3$#5^-F&G8/%I98+>W'B?%)<#Z6RD>)=RL
MSO7G -'OF;'73K:R(;&VMS/AS/643B,/-$D<7-[_'FHU]SG%&VBV@6>AYW_!
MO\9S2U<)\O%O/\8!#!7WOI$'M*78QB5;HAP*S3==#=/96>E8 \&Z&BOB^%
M,1Z@ TXK?/LX0"N5[Q'$T:\1G+]7!(D?V \!%F8'W#
M.-I4)"R:1D9& IN$@SM*4Y'?(U/8^W=[C[ !"BR:&%5"/PT@VX#.-'
M,-OMDMCS-^[#F"Q"72IL?21AFGC$KDB&,1)550[Y'8()R3YF^UG[("%6GVP,
M4<-91'DS&LI.EM #74*;LNED(MEEA=X&L11/-&-8SR%-NXL>8)%LMP'V>CLL
M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M'N$V8[P=CU9\*U6I@D:9[&& -T3C!81MC&T?T>]5-;H1!K!V4S&GE+0CR
M854JK;U/Y=W3G:SI+,A' /D0D]JXQH--Y3T8A^^CG'2JMT=-HMSN.0,D.4N\
M*J9+:BE,=R>0PP%?OTLP9^3-FTITF9RP
MAU*D]IBAD^)&6E5K'HH-![!Y=6!$Z7B6PC3#R<8!BKJ%( XDT[\5R\>:,MNQ"3Z]')79@4:1*'OR'$3NX&3$G*_;X9%!(ZAVMO'V:56J\+LI',@);?
ML4L18[NPE0Q1W*@&VK1A"J15XSQA93\SI3-S50$('4-5ED%Z2I.IK,MU\ BQ
M>3Q2I,Y8(SGV,"@3K&$\5#J7#*(=AC,-*T(;2F)S0D\,VEZ'6[C=Q8F7',[1
M>@U)QC_X.=JG,+CUGJYB8KOCC:3ZS3R! ;)^O#.AT;J'VX!8SH*J>@1!U>4K
ML*== ,Q@$-)NZ1)J_-;/NYY*6>81@-;>/DP9;?*Z[@.,[Q-OMT$^/M FT+.]
M(GCC6T[LS2&#@^/FU\ CGT\%FP/B;.-.-&G5N\DTR7Z^@??$Z&EV.XBFM9?>
MT;GB#BB0WL P2\F_B'GR#46+N&\K2!&2((.2?N)4B_B0$@[!QO T]:[&%I$?
M;R%67N1U=FTA8+L9)@G5:H4S3U>K6H@= ASY>,E[:%MO2C1,2GWE0D JGR^NMPT<0XTKB"TMFFW5UV&)#L-JC"C7<*;QEHTT[U &P=]
M_ NV$=@]ZM[P*8[*6SX\.LTX>!DGCUX2C+1+R [@?K^0I%1KY\!]ORX]'*1W
M0+L'9?\32C$X#DX&-A,55H^TK?2L<+=;AH M#[!+/_"T?PO>+!?H.E:B3XOK@(D>12I1$V&SP-YD0R>X !B*GV#S1B.(@A3Z
MH-U7S^66R36ZWV0:%5J&^[%I#\@0)*C>(FC+JN3BH)"+M-B:15WD6*)UU\:J
M?^Q%0?7K:Y1^^>A%WCUL)RTN,V+3^.)XG6T@LY*RFN%JD1AK-W;VYL19%W4I
MTT8[>N-0_X40 6HJNO6+R^SM5?Y!DC&4W>^4+O_L8[MM,476@T)D*9.I0*RPHJ9IK$NA1? 8MH/2CR=C7;&&UD<.8F9[K35MI?DM!M?0C^])(>PX6JX;1-W Y 'Y\*.7W*.(%%>-UPB?NX@OS:U)=)2)N+2DCC$A
M"0-,=KE/-"7&,?',-]J.)BME6\\_!#_/#WM)*H),G;FUJ+%77U]'S^\P7WG<3GXASHD1W]$*YX&;?)X[MEF7]VM\Q4H^WM%
M]]BZ2Z>;HC$H"/+-&*FQ8>D,*+,'C0_GUH8Q14 /;0#:H'9\ A\%(KK@-M34
MXG*S/Y)RL[[G*]Y;*'8X@8K@++K$U8P'.^E?:$RF0+%(K,,UB+F\.DIU[M&K
MU$^U&/UX->M4N_U>&7D [G%7Z7+]2S*4(#"/4D6W;Q'LOP63(88V[X(&:)XC[M(4^) \!J-
M 6I>W3#*@SIZPJ4 A,Y;+5D&&5S87&.V0LMH;(YI&W2-L7GZD'PQE3=6#/&T
M,=*=CP$4SN(DB1]1=)^>'3YY6]NHX QO-446FP8.4.J/P=T!1/CS/FJ<@$8L
MR#9^!#/6K$; J^,Z4I%A-S:^##7J%8'YUOQ$*OOJU.L]3HA,WBM)K=EVA-?X
M=7L[I$*?W4!A32K5T>S:5S<:MB#*%A<3E-4?!EXHS1*X?BP'L4@3I01KA=6&'J4)K&R8%60E>M
MH2!H;1$W C)XQ0VJ%D4%^.E$)DE(I*HR,##OT6UKQ>*]BGLMJS1O3U 3C2EQ
M::.<:)4,O;A:JE[?])I8.[QU1^8L:_+9I*P('I/+%MZ6B-*A+A%'9K)DN;M@"7$RWG]RF&!IE]OE1Y(H@Z\@:=764#[OGCR-]3_K&CX2?9DL2B6'$4\>S!O
M#4AS@-M_G9?^ &47TTJ/I"C'REQ48)&.12'H7V5ODNK&7OE."6HD0=7%U!1V
M.1692>#(V'@;J6[?A.*13(2O6GEOG H%W0%F]0!**D^F
M&WLJ3X(:KE]%B+6I1""IB*UVMDAR1?NRK++ZEDF $9PMDC-\'HB+5OG!@!%4Y/9 ()(TYTC Y8-Y&4*#_/^.K'X>"5(I^B=S=S\D U;B
M_%$L]F6V@4F>VTY1]KR6MEQ)G/$YMPFQFZ?*9-;:,P*=PSA*QFR%EEF_1*%.J21)4%X$&7 (DTY9.:9$/"H*9972D
M8(%6GRHKG=/057[;H17?!< 4%KV8]TRI,Q:^WF'B4QQYP2_[-,/'X(L'$FT^
M6VMD\DAI(.4]ME$F7&:1Y7]70I_W>/^\T%4CRNBYK;L5A$1O$-+U03D;2:UNMI3J_#$U^M)0U6XHU5:71:7D&16&DHN]ZF1X4//Z)'AWWC>U&"V*MSVA$$4,YS7P_WD>$GH\PV\3!@-;M!@*O:@>VM&$*:#4V%(&T
M[( $8=*K>>+'0FM$"M.F $LFC4-$2GL&($[ /FK^YFM7AIN($5VE-LRTD8],
M@U*D0*,/#"]CQ@T(DMYTF[T#=98
M7JCH';P(BOY?$JD7@$C!+A^#W@)X^2BM/.59C.TB(@R$/]K1%$?@!2GK]Y+\
M*8(9\+UT ]9A_ B(>,"+ E@O08S-*(]BCCP ?J#]?>WN[FH,KO>@-9HDG4+P
M"N5Z[VD'HQ3*0BM$A1&=-SLF5!R#I61-;(4%%(^
MJD9P+&8&I\2RYK+6ML"W1,N0Y'3;;1SE]TZLWW'E3K^EF9OIU\5=W"O ^M#H\SLG/M24Z)1TM(J3_7:3IGF0;F\M\61,@\;69;]34\##G-"6.H.?H\=9:0L_95&[2N!Z'P6PBCZZ>(*)C[ 1I >'
ME(N'70)?YT.!QS*""Y:#34S!Z_!+&C1:M>:J)M\.>B2D!2MW_U]W;]\:-(_O"7X7 !0X2P-F=M\7!>?:OCIUD_5PG;3C.
M#@:#Q4)NL6V=44N]DMI.[Z>_K.*+*(FD*'6'5/9@SR2QQ1*KBB*+]?*K;_?U
M"[5^QU^]AX!FK ?_[WQ1:V5=<(R/6F**ZR@ODHT3UPO[Q4:]!)[>:+ B!43@
MY>J)Y\4]AYBFKIH)LE_<'M.=.Z I]BK,S[UF$)9RWY9XP[J)ZL0]54"GK1:K
MQ!>_Q]Q^N/[&2X6]P;%2%KU.AL(Y;9G8A!UQ/^GLTVK$K%<(6/%84JR5F
MF"N# Z5IZ9)$$EZJD3)=(O9%,5>Z$;<-YSW;WP09=548K(QH2O?BV:;E"0);
MF%I/N9)\KZZ'\S@:9KL58JC>M" E ^.*-G^U2O\+4*F+/YL"QV5R[KS"ME]O)*N.?[!)M6^7@./+ !RY 0T:&;(IQ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M^&&!9$FBJ$)V(F6J3]E?M)>$O\]#KXA(VNSQ/> _=V\-#GFW&?$RP"HK#[H'IF7W6>QRS!&>2BY>^;L;Y
M#GPB"VR*MBEF6P-S3[\V;_-R\X=+(6Q$5E&2JE$8!Q!P'3M%->KFZL/C4%&^
M<@G^Z4 YCK(?UM5=]OC4R(O4;86?MS(N^&]Q:?UHT* R/5; <;(3
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MX0A\>M0]V/)93*PP,UK9Z1EAQW09KD*Z1%2>_7!:DDG.JA$5.[4#75-9,9+[%GOW\H
MBT,-OV6O99K-.2G\U;;* 'GZ@19TF\6-WDU83H,/8^I*#'Q<7-&'IFWSJWW&
MU^P&Q"S&-ID++P1.1U7_*K65IXK,C=O2I(&;,F5'?)IRU 5X)&63T/HI1]WQ
M)@JDK^]9\@QOD^F 'SYK\]W7/=,W8-H<$0)GW$62/!S8=][QC_#U\"IYW=M1
M1S?4Z%L/U7\NKA-2D1YU'\
MK/XKONC5YK4):^)/Y!V_N=1BGZ<^6^R?R)>:"D?Q-J<;8=3Q#8@@>@LWZ^#'
MNDA?F4XA$"S_$?X=2=J)]">R8D+)V>P*WMEND^SQ?8*!6O$IR^?C
M?N7G6O^#[_^\'U;HTV#B[&=Z2N%K\\9=2?@Z9A^J7+M]>+J8IL%LB9VZ< S.
MV'A'B'[W57'X8G]H:MB2KHOW25;A5>M--@EU1_\ $EPVP;O3_*<9+E::FI'%_$OMNI@!W_DQQ#$<+.VI9T^%KK;X4,)
MN^3O]MS,1VKBI?N$+9O92''"BS#?:)'40[Y%^^9LO$PH_ Q6R&)VK2
MM:K/LD@B^"F[/)CON7-#1K"B/2[^41?$",=NE7N)*[)2!]EY]O6XWIK/;O\=
M3$MR_$_S.;<7W73VG6XZAB2%J O$
MAW?W&O"77O1-#:M0QN_O$F%)X[*-GZT)1@Q=V$Z]T[E3I!?Y&_ROE29-:G(L_'SIGW>/-'TD*L/
M%$Y@_7S7\_O*-@$IE0E)B[E>C$K I6E/\456LN% .-5EJK*0-!C*6IB!>L2\
MS58RYBA%U/NH4%QZ]Y3H0O2^;F7/S .13@73_18+0E,TK@?:OFXA&_Q\L?@L
MB;G"CK!6WOWKP&Z^-UD!]^**IIDSZSM1I1\4QY$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MV"/0 O4AL6B'YQB7=GVYI!+Q\/R09,6ZN&;[/E]-?AMH[#/EU4Q9@'$W"+YC+H^60]L+=X1U?>T9I)1L%#@YTYW=%-
M^5AD_[87Z+SO?3J5&K&,PZC+A5,!?68#^R;47&[8AKHN5&B*!RZ^G8THH;%D
M2"BBY\(M JOR' *+N?&MM^/GT/N.*DR'3BP5Z+.W2G[(8C0[#7:?7%\(G8JC
M;_OIF"NS8FG.+@FK'L>$%^,SDA7*6N*,FN\MK3"LZ_%9=:I/VN)N8T5W>)WY
M,#G0FK]D(ECBALE]**$-FDMM(7(2?J]PM8)/]#O0L5$B/GIVB#+TSLMM5JAN^DR;)J?R##!MM7?ME1B"E6H#
ME;M2!5J/K>'S\^P"*RD42GT%>T0O?" VU>H'BP
MF^J,#HCDB,Y+LDM2JO)P5%%CT@V?B?I$P+*5\V!K8E]E4.==,AK-H8JN=+>T
M3%KWD6]P?\:P\?0M]N5=5S#5JP,%3+BD+HOD(3_>LA]!N.@2KY#7;(^OL\<"
MOMB[K/[CLMSMRV+$JVAI*BZ: 2.8$.R^"?L?H.X=M*O9B #[A;^9Y^2\)%*+*29.]F+5/81PA[(+,RR]3RDPE]@913P^)VH6.5!#M
M#OHM5#98K]]L681?X3[(Z%T+P J#'EK3+J!S,YAY#,FNMZLTS>"A)'?>.^4
M_*35$'[_C.D;L#)BD[F%XPCV;3LC7BMKCFWG*)M3]K$# GZGH!4ABVLJT1!F@!M)""WA*P$.C=L$M0:T&#[Q;
MHWXJ=04H%J#*D2B%KYR"*_!&R_5<->V-S9D'V#4C\D[**YB?QOKUP#IR,M97
MCX<4(FBF!I/]'7<>^*H"QTB/0\QOI#O]H<"'S 67\,?D*P#$WU)&ESWUR);
M'7U@!OVZN!-(Z%MT#J Z_^5[/9_[4"N2S@<<'C3T:>;Y"O<.?GLX)H)TXMV=3M9L/WEMM>KO>B8Z\4XC,0V;.+C>_9D=:'BJG )? C_11KJA[P3XUWO&MZL9_3WZ_FJ
M((,0%0$YMMAPU>1+E_^*9,BF[L;,K5#S354N3**@OV9U(8@XCAM>7FUZ S'P&%WO>PB+@+
MT@1_SS"ILDH0@FB&F"^-]^[]99
M>ORL8-A[37#[ZER$0JU\^VAU1&A+5FVG3>CY=-SMKQKU<)PEB=E:-\@S^/75
M.MGZ/"VNW(EAFSOECR\SY)T.GSVCO2%B4_A6?T]3;
M$\_"-@&^J+4B:Z5K;)?2BQN.I;MYKA=HAM<"
M_YL:G RQ 1>V8KS$-'753)#]XO:8[MP_7:XNN[6[9U\S\(I^U7/,Y.Z3!73:
M:K%*?/%[S.V'ZV^\5-@;'"MET>MD*)S3EHE-V-'V$W6S4H?D:+56MQ.M4B:=E5B1=.U@TJ;.4;E$_*ZE?ZMS/MW3:I<5.'3U6%'T5LXP-+N-%5N+H&G)
MDT32=UJ9,74]2SC.I7""N$.7 W7GK:%@?Q"UA7XM'L6'79!^83F0B'^#M'+G
M5J-5')%\^G)6M_7Q)GE8;?YUR*H)WRE3!Q\)/7SXV.6HILO3F%Y,$HB^R3I]
MCO[7,:&MZS'O[7(N7A/8'U&LOP0C;Y1G=MB.Z-S35[,X]4]WTISJAXVX)DR+
M53+BO0+,G[ARW2]$URY6W9H=%U(\?_KX#)VU.E-U&;N*9R+;\_7:K02*KMPS
M[-/?S:9\RB;LO>G&4Z?J/B8=^;V+URI-:9$>K'F_ \6VG9S::,G@>BNI+N73
M]96"6]W39+EPQ9MNW-Z+X,5G$1A]'-_+BC")Y[3581=X+$-=E>NH5@*C"8NU
MK0V'N1M#)!4/&;.ISB:"R"K1>CW8W,:?ACI81"L4.RM\R@-[.68!7CI^VR,B+_';K33JV=&N78E@P*6T13&PM-PH6)'_.P9CH=3[C2[VW'?Y\RA$06_[^A\"0[?B:$/GN.*>W20[W]:S02]2]
M-",L9\H;6#UP.DM(+_9@FJ*_EXD^X6H;HN?WXZ
M,\DDM-VU9E>*"K"&*OI$BSI[IM<(*G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MF L;G1!';:UZ:-,15#+"Z%!%7I();(;HLVH1KU0M4JX\#4[QH:RJ\H4]A)EHR>-C11\!6P>P=?]$K@NQL7:57S^55?,&=FD!PEH\
M\G_AJ'B7% _)N9: 4]@QCNMNGOGM##.&(B-\'7TN!E(WLQG^Q+JC4&Y![Y,_:,G^=L^.SSK9P,._9LW3ITVR&?T6
M! G2"!JD:8F0%T8%RY]B?0<3&.PK:;)L I]>GS=/-#WD 38<8&LBG0".I77
M7L<.IDV5[1M1I-2([:\Y_E?"KB-_K4G?"M6R[>;;=TTR@WTGWR]8Y9,M")CDV>J10MNWL(MJ\"#5W=>-JC,82P_!^HN>GS'9R1\B( Z*'V([/K;F/R,G6<0MKX\Y*D$O>=&
MW7Z?8X.$E VHFVQ#MC2E%4!F,^$=&CC]@4S%A%+#B]B-2@ >PAN459\5!Z!2
M,J8B8]>?I%K[:I^]3D)[J=LI<[\1^_"T6)5>KGC*JA;Y5+#O::$\\,NT!:)1
M[9:Y8K"O@#GB7);RI4_A&R@^>@'+',ZGZ=HEO?#6;CO7+IZOKW*?X'@P*7B3
MY)N#:.8VA#6.F.3NR;%=J1Z"BFB(R.7U*ZVHMNK8&M12;4[YM+X]'&A.2(FIYAD#LNI\MW> [N"I QUJ+MV7Y!TWORW?_.H@2=)/"6Y X66_V
M@./ 8*,X,NJ-Q,720&7C_(?_2&%.' PT[53"X'_$+_R\.[RZFF.DIGT8-_GC
M@0,VWJGJP[E1A7[BBG!NPN2TJB:[XOA'I9=Z]5JJQ]!%9^9&P1MX"^W,R1X+
M] L4S9>B?( D!]A8KXO]H7F'KI9Z_5+P+_I:161=L",JLE>WI,E!H\WNHXPX
M#P:+D+'FLU&!X$Z4L.OU*5\*L55J4>+(5YA9MM[C_=7! U]LO13:L*?]$&VZWJ^U&3^US9P1K"2&R_M(K+!(OIV>HD0(G-Q4[?L\'\/"Z0FKZMK;5V)'XVU.UO0(IH@D2G+9K*@@UOB
M$R<_;$=M3-O](A>'I=F6M1/WPI>$NV/W.809P5B<.&L HW7O=W[H/N:5 =1'
MCY^%KQ*WA$Y=-3[R#VT,3V2AE\1PKK6S(,3.,TGDU+7B%/32SQI3&\J3S%U]
MJ8@&GCF@B^7+:.!Y3OFDL:7%@EWDOFB244]?+
MB+07?AY-;BD+CI8:7B)#A<*;*5))_1;0L-/L][%Z;#UHSR+U[VNEG.LXM_KX6Q9DW%+.@OY.S1T[^;$?.][YCG'M5Q (8GS3M^Q+R:?'O3V6>LN-QEMND
M*7E;@EHC]+UL$T,1G+00;!)=\MEQ7PJ3^D-5'O;7Q6;N(A!D"-*!,I3OQ/H<
M".#$)6 4Y\*]9_?E_5-6I;=)U1Q7Z7/&+N8>IH-Y'31 "6K+FB-)!*WO9S\8
MRN'$Y6 3[!(C+PA(9Z]6\+ 6#%M+_BK\750T)>1M;#0PT&R.$F=7;DL9JO'?@OC<3Y?#(=$U3=,#J@N0\.>\O!4
M_23I+GY-^(5/_RZS=Z9&3Q>SG_OQ?^(2L(5/%ZQ_<^QN*KS+*:'3Q2\1LXA.
M7"HNN2_E\+?-W;.!W<3%LIC"]].D<>*Z<'0U7/**, 3GSK0LI'MX>O#()M3%XE5W(M?*8.PW)F6B3,&NO@U,I#*B0O$(N6E'RR3HY[3UH8AEO5=
M+(N)XM@MG=Z
MHDP7>D)XECB<8DO,KCQ9Y+KQ%-B\131)&Q%VE\.#PAI2\%CK[4H!Z;GO)_IP
MK?DR %RV4'SQ+R%^3 X4/$4VX3<#?7;XE7IV'*H[.N-@/E$]3 -&G(K06 V=
M,7#8[9+JN-ZN.810\0B(WI?,4CRR#YP9SNE)L"5[<(@C8'!6L*UUA].X8.K:
M/ %@.D :)8?FJ:RRYG@A%7M>T%:8/>D0)RPNM:+4?/L#YIG3V69XJ;?9'GV[R1V"'*J$H:+:986@W_?]\E7
M#NB$(*X" 9G]\"V'@*X_EL
M@W*]XC!:KW&=862R*M/#1JV19+,!\I@^RT'^=X>\R?9YQN'\\9D]^^<&BZ E
M4-M+*\>3%#,(\\J:.NZ,6LD[AHIH<\%,WIW"9Q:$K/H/V*M(&O8EP1Y,T!+Q5LQ
M9K$[5HY+3X%-J/8J?5T\T[HIJZG74/1+O.%^B4S0B&B.#!D:*,+"M>K=5MJ%L+>#5Q29[? @O<01@0-FW@EMTLG$\$ W5J'$V%G;O#9MD[?AS6A?A 8 /3S;PDN]QX1!YD8V W\/7XJ*)CF8
M6^^3K$*GS8M.:))<82\SZKC56)/:Q0/7G#/PA&]"A%/V<&\K0+N,A;>GRHF8H*6^X]$WW/P
M:]&17331M 7([W?9XU-30V-YJU7$T_/E[42IIN> 8SHTH [C4Q6\@]#=0YDB
MH/F!W6<*Y29OVWF)YH@9-EQ,*6]WA3<8.#O9-0E_A;C^A-U;ZCW=9-N,]U*4
M3<;PB@.?+?SPL ?;X!F.KPVMF@1<+.R2L]D<*G "$HXP=UO\5GPLKNZ+O[$_
M/O.?$>Z)O,!@#_V:[/8YO9#/__C;7S[^^/.5>%*[T"E,^&W"KV=E0MV^R9DEU9-$_"=PD&?0,"39-CS""!<2U8UK!IP83.7>UUN:9HQ(Z9+S6W7P22
M+FU-=E/KL4@*Z#!D4X"!ZW@*&#M->P$8_E5V.JTS"E$C9$->[((?'+$QA,[C
MKA,:#W=+; ;E-=$DSAFQ25MG,W@$0O41K_A>]TX=MLP_4 $8,@C[CHL?CYS?V?V\^?GQS=26.FR4HQLRU35$N&<4P]"G,AJ:K9UHE
MC[2S6\Z"2WD1!$G"*?:/D,5@'$S@?*#+J4(+O/==;ZL:.QHIK'BQZE9?,WL3
MTC:6C!8DFYVV+ZHO

'5AM3M[ZBO(01/#-$N9TGWSEEP270C[]>14SV7HP
M3Y-P#8PLL5F>2\QXJV:_Y_[HAE^'L(MR+=I6\08B]5.V[T2<>*?Y6F)T\Y$R
MXI1#]^:LH3L\TX2H:QX^ I]WSFY?[;!H7Y.?Z/J:GR+PP%O?559C; \:6O&L
M*ZV3&^*$?T2UV5<#6PEM\/3R;;6AFZ!#7Q(X+>05T7DZ(_74Q3?@1K)W.27V6
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MP@IN(TAM=D]2\"2XFFX.D'(.D2:XV92=OM3H-JC@,@3_XJ5RO6#1 S.:(8MSW99@PW?+DPMK45;5BBJB7C\6B5L]$'851'!@H(9=1$19NW//6B)R+HP,612
MA9WQ\)Z@ OT,;*US'XI;"[W84*8&FV(4P35@9&4@?P?#$4Y'D64YM*8T9C.MQ,!2W@<$(^PTXA&;)^!-]8<=LU9#5YE^'K,;\!W)95GOR"HJN7TM(%J.^C+O\QI)W)_W9<'VN'8FYNS065(G@GA4Z7<8-"G!(('P6PPSG9^9J2QC
M?[/4L>21AS7H)+W\#-0/A6CB-L0[?'
M&HITWF;ECJ;7U["!S#H$!!W""9'K:]R+XGT%-K8&RG#S'P.P&%SRYW-]\P34
M"7[O"%_-&,M]I?F)*/Q!M&##0E[R%PPBB'H"XS/HZ%H;;;N-JH 8G]\&OR%\*]"K15/.@], M0B@D["8*N?$E.MCOJ0W;P'_\R$U7Z;)QL\\59%JA+8'^JF2C;V'L"=+*4X5Q+7O"T7E'%68YC,
M]KG=9 6]AG0BSVRQY2A"S7R")GKMED0&,=;+I'YB,X0_WOWKP&:>4Y[DSK20-&P_M:8Y=[![*D60;!@I#(WA7VA+
ME/S>T*\->0!,F7_$.'5.EH6NZC,)-NP:@)DP$TC;$$Q> _X4^3T1S_TCTA=H
MF[=9#2;>OL%FYQ8PKU>X3/99D^1NWPQ_%$+-\"SYG9L _XAUFW'R8):XE=E
M8I\7M3;J@E$AD@P1= @C1 0EHI$BG%;L).:0D?[S>SEM^M0W4P-RN:P_Z.VC
M)IUJ!]1Z.T2&1W)$TB,:P8CVQG3N^[J=*[_@.^4559"&Z^U*(1?=EGFV 2"Z
M=TD%]]A:PI+XF"0M24S@T."0D"I/RQ!TX:XL?'U&NR3:]GN"8"SVR:F2#KB=
M\\)%"3U\7; ES)8O1NPJ7@?H:#;(/G,^CEP7\,'#QT[DV'BW.3=/@R"?AP0"
M*H3#C:HZHWJ]I[!8WB8YU/[;%,)'@4+D."(&$C$REM?)S4]?&3[M H33YLANFWC3!"-XO^,H9]-N<'M!Z8+ 0([70"4URQ89_>[FP_[XIM8'F909W8\W3+1P3:)5:0Q=*):NK8.'1:-VZQG#_"8M/5Z9U_34I$JD1<$CE=
M(A!8Y"$G 5C:<^_>T&!Y:?U+HO57#K4FVDWF\E!5;!NYK>@^R=(Q@%#Q-!3.
MP>,*Y.X)/=:A-N!&MWW%6507(_P!*K[@2K39,]
MXV]G^$'U-\%/M/@-2?C+" BX;1I!$O4^VU4D^D%[#@GZ>$_/I:>P;E4-:Y;=
MIVCV"-#64"UJK\X&6%\< FMDRPM6T\T>Z8IK!KHH6F]/]*&R#%$#B(P"KN2QC23'-P,;HYCC(?3@8+3!"!0Z+RP
M+GJA8?Q.?S+H H:2SEBR+I3QJH;'NC]Z<-;7B[

M_1WEC :5MAG:"3$9\93/D&]QY _'@>XEB:0=P@\=:M,NNQN+< ;KSMAC_)N;"FF*ZR3B2
MXJ.']!84ZS9P8):VE=7P4>^BH9 !(JY[ZT*5W3I@N?@0U=P"X+G4J/CVKX,E
M2S!\3 8!;K_\X*LV3TE-5<,VVT$B'R3JR6B>HL&YD:DP!NWFF/[S\@B8
M6*(2_"ZK__C(KC95EN3Y<877'IJNJSN:U"4 #Q]OH''8\;[L/W5''S/X4HOF
M?9X\6C=__64$WD9:0D2^#VK.VS<2_DI(^QT\2]K7DM_AQ=&BG-],E/J"^<;Z
M"FD_EH7(KH$6;12;M&7L5L?;M+G3BC]!=:/(+>*CB1A.Q/CXAKP/?P.;SULF
MH5)6!C:F=<<=F.3Q=MS^G <[KIFI<"X$W2^HPJ\MKCR$Z;@I#^E+FO]OV+MP
M/$36!JDUX'K(_M)>H-6%
M0APB'QI2-*,YYMTLVEWM/J()>,+]^I0U]"8K"[=J\#$"S\4_M'I3[G\\1HX"
M2=1B^13)(RH:O<-P9K+#13KY&4U6^
MCZ@78N:=>N4%T5[*FV#(]Q+Q8O)[N[G&NI)_.VEZ6*MGTUE8]\OG[+'(MMF&
M'1E?BO*AIM4S' JXQ;Q#O*MZ_5+P5/WK@IG66#AD;Z_>DB,'C1[?D"]Z$%KE
M2X$I2]@94=&.6VDR4R#F#?PDZ88RAUUH5-;<^W8 @1'#7?X[A-[Z,4RZ6+L\
MUA4SSY+J*#&*74$=^:Q$?![:-E$^%Q,+YF_!SFS(A>Y$X;>N=ARE73S(NB(X
MDL#0_XP6!(%6OR,U#&.N_/PPMU_X&O'GW3TFQ+BB <#!;B4U&_13L)?SY2($^#H 6!X5JXX8V*V)Z
MMK]K@!S^UK2;Q@HF31.!)= T1XX!PATCIG.+^?&N>&0_2R?[W-5%!DD1I$4$
ML;XG?3D7$R/?$ZX<#KD%BF'9VE(;(LYL]S??BJ*! )W3>CI&2P%-V
MX78YCHLADY2Q^>:BXN9&-BQY"G:.0Y]1NJ]51I_Z-7I:"ZO)"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MD)8^/-Q] _ILXB5FG"R]V9!)Z;R=DGC<$CSXWIHJA7>5L?M_3/+&%>++6@@GR()/A8Y5M"=L_FH,?$5<"E/*EI^7U;"=FF_R$Q\L6>M$@MM33R]%>)WT?\<,XF+T_W]5Q%M'ZPLBL4]F^P^4U+@7WEZ2%G+^EF,$+^XE%D
M+P[<%D\5W>+P-S_]\--??OCYYQ__]+5._\]T>H$<=Y,F!:(T+6E! X_F7A(K
MIK >90)K322I>%?066I5JW*RN$*?"_^7'K5<%/8IE$5!MDNQ:#_I>CL4VT7)P]#O,.'_F<\57+MVSQFNST-(]9#_"]?:];%)X6_+.->:=
M H12,ZF@1( 0BJ5)OI9%N3LR^?STRYL??G[STW__&5\ 3[1_>[,IJW^VC^!.
M,W$RH9>GSZ1LVXQJ]@@%^*H'Y%Z,MGBV(R4135@(O8PA7P'%1#8R027/ACE2
MQ#"!6ZM]79B_TH]WEUMRBO0B>,#<0,AV]]M;H>Q)U1N_)NX-Z<#M\DT$04NDR\/"WC%9,(D_'D4P6&$=^Q!,/
MPCK/&-9YDH,7A$$]QJ$E4<5++L'O0AP8)WNFU]!.F@I@G"[84>U7MZ1?CA19
MPND2 !4"RJ1'VEZN%/&Z-$,H]NO3; F'JQ'DP#P R-.Z&Q22%71/ME<-"F B
MQ"/2W3EJ.('Q$6L)1WGK:\Y;' %]=7CI9B_'C6,T#48\+"+C S]$Z/"/:>Z#
MZ(^=P;#'ETB_F0#5(;..\F5"=M@9C/M_>00PL<0&$38J 7D"SBX&5RDQA@/'H'I8!EIY;;68 P'@F*VG"CA*-LQ<6](
M5E8L,1HWYZ&.:%?O,M.YW(>D,W4&^0[;M 6O6G*V)[@OKVA#JUU64'"NE@7/
M&IGF4_#J"Y&*]\"/-^I5\/S$AE9+;!LQ28SFK_3<:@J9#X<%D3=LMIG6CC=ZX1#,L&(V9)3B>:+Y'T[4J=)Z<#X/]36""5*+B+ TJH0%IZQ$P&M*S
ME:>W)*V%YPLJ\'!)0M?RR0*-58J@0A6ZA=RL=F75 '0C #R.W13:B$X'@+N!
MU!5.A>WR=>P4%G]^G1<);WF%^D(+,G%<^,
MEDDRC@ (O4K_]U W&)$LNHF&XX#0I!T,69R]G,UHIZ\';WWE>8LC:-KEMPNYA'#.(QZW>Y^6+-1=-$>AMFK:=L@^]N@<'QX_>C;,V,&H]A;&D.R[;G<>BP^=J?EC-;M.\R&OM-,G-N-?.
M44U87SJ;'JV>(00F3O:K;+NE%?0^JM<%@G'G&/YR.W4%&5@Y5+9$35M*@,[<
MM+06%"B>R+\U.6.Z$,/5PA\>SKN_5]LX"]HF
MJHO2;3HEWYI0R:.L]3$(\CXO87M3P7Q3@%[ N2U6[\& +>T_KZGR\ERDIU+ 8%VMH_)UVQWV+%[ZX9-(WG$!F /
M24/7!6S(D+=S!0D])?;BO$^^7A?P8/9,V4WIL4IVMB]6$"8M9? (<-IP<934
MB48>DV?4"XAX0RQ7P^U9Y)U<(?@AX1]R!SH>UV,G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M(U0#9G43@&R(V.X>.SMFJWZ,_= 9K3(6M>RM,%:5*!1V2U%!.+BA=\/174G)BY)%3BQZXF,B]6:6S1!AH0U09!?NL.EXE
M=B#M-O\"GB17T3XMXZS[>YN%K7"GM:SA9?8< JK7][2RNKI4?3,8Q/QQ L_'
M3D'NSMXB8Q.+H:+F$A;K/$V96^2QD[HQ1\(:.ZT)\RF2#(8Z\*5@EZ8\^S=-
M5>H-&# V?;:/Z_BG,"*6D69AH*\,)Y]A VM)#JNA_C5KGMXFQ1_6['SY('EA
M3Y('>#3ZX3V8O"7@9N8QJ)Q5UA'44G(\VNOBF=9@DZ^@)E;Y :Q]QKMR*M#C8&UU^S_!1&2*"JQLV6]6#6K:HJ8@NU*LO))[H[M8'H32^&CYF2(HA,?W6T"N_U];;*D3D)HP\8VV&@+ Z=%JJ62U1J2C@"0+U)'
MY:<7A-M97AC*=#KOM#U0X+JO05-7?Y%6"I_DA+\+']+34(=(<=&0#\ZYNH90
M"&?3293.K3)_P02IOMYJ4YV<-:(!GNB=7=EO.D7E2ZKHFRF/\>R0Z=(-=_WM
M[?3^A=!Z.S5#)73DP\Y2!>W#<;!]_;#;)=5QO5WO:96 833 HO0$J>&$0".*
ME!&^)Q["QM]
M?8SP&ZNR<2XLGBQK]$G@CPO^X,FHY98V14K!=;ANGFAU3W?[LF*?NI8OYMP6&DD>,Z>?7+2:0?8J/#P^]5/:3!I$BCPQ
MD-:OH1BB3306C="21KMP-M:3W:T*NI(/E:?>*;MI<,8,5HS7^U$H0+T9<^]I5RMF3,.\")@@[J)_^8
M_&]9=9J&:_5'(R'#GUX-&O27SJA/^8^5"3;9;JM
MWT=Q,S&PD<%0^$*[6HP?:AKESZPP3[&$O%_J#;^E+\D*WM[ODJZM"X:KI8/5X,&C;FZ^'GU7>*KR6!X/(O5+'KI9#"W@K*08RZ"9P;S-[399?L$P
M@SO%6DE=%LE#?KQE]C,LO4O,[KLN -.)V=R'W5YV'3%NAKU2.$F-2'*$TX-D
M>X3):DG&<\K-$4!?R_.%&#Y=LF-*:VY@/=/OIQ]^_!]['KVX@>SQ!@*'74ND
MFR89VQ#U9]9\_$T55ES@*W/YU'UY_Y15Z6U2-<=5^IS5966]=LZJ4KLO";Z!
MX"N(?$=$+_NIXAEXW<\C[Y!%C"I0RZ>]*E)M\M2[Q(N+\([/'NJ6(,%\E$YRC H5;TB1:UZD[@*DGFON+.(-G=X4;W( 96F8N5
MOFK&V0ZT&7\I$/<2\ ^5P=[K;>O&QU($B'Y;Z;<*'A:2!D\-]>2SKZF) @H6
MA\X>"TQ@*9HO1?D T#P)NH_VA^9=T;";5KU^*7A%7>M3LIZ<+36BDQ,89X(@
M811%Q2%I:4:KZ9XE@<$>>8(<@]UBNT6N-QDF9&IP0#XEPV+4 /0H:@UPEY6^
M;L;9#K1)ZFE!/@7%HT9)MRN?;^'V,BR3V<+HJ_=$J8:S48SQ=;MEW;4 @ 5'-P,G'ACC(MG38OCR3LL0OF I+#YBEWVI6RGR(=1)?P'>"DT#O]MBS_H.E]R2TWJW, W7TX
M2GCQ^3CP"KWK!Z/#J\K%TD SX_R'B[K0YCH%9+1M!J>YGCR_8?-AEZFQQ$I&
M@>@DNF4*@HCQ9/'F=1!;F2BEY;6U__Q45@VTM'FWV^?ED=*WM*#;S)XC
MXM7O'L *&-TW0)A009D\"-+18]$GB,7LIC]9SL%S/,VM-%0RF[5)@:G=R$4W
M*S!^CN<(DDDG+4,H;IM12DTK8%L:, W$8?S",2U&$CD2-XK5QK+D5NW
MC;+5WV(]Y1"\V7'7ES$CDM'SYCA"%]',2R>/=KO20S0! 1'P'^U!_*/MNU%/
M*IODQX@V_G#>0Z^VF;-@48?>ZW_P%^P/2Q+L#Z."_2%"&F$^44R '=N
MXR\>DIJFM\D1S(X5[(F/"I_4:))W6ZDJ+"G:$B99P7_Y!FF3/2=.DI9Z=//M
M)-F8#_\SB#MX(UTFJLD-IMF@-QN_)M-Q5.MBRJ*Z<3DL&+RY%X<<@\&8C>+<
MC^8:<3(6G2=C%]9)V3)C.@B6!?GA>@3863X0%MON1)C[4"$%;=CNXH]\V\/5Z_O_M<7QYV!X" ?Z;OMENZ:58-P.&MM]<%VTJ2
M?+7?YP)EPJT@4_5,"D5R)>'^_!H.UV'#JDI,ASP<"4[H@FS4E C%.<$-.X5K
M'#N[,SXODK03,]97+J+RYIMJPGP@1%@,P=TW?V-7K+)B,\G_7L)T(2^?[61\
MXYK6':\E19X5+>RBQBM'+CHX(AEFDRQFN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MG(QRUE_DGX9J<(
MQ1[1FBWAT##OI\*Z+Q[#?1YFNR=&>W"8-&:)/&=@EXP"HNW5D[%+6@=3-Q]=
M%@X#12>EXGL8!M!_(2LX8JR\0\SX2@:@#AI=H@@[/Y]H'] M%_.XXQW0W8YMP\X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ML0[,P>QMYY^%S8!W$]D%O[(_(.U
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ME]6[F_7E:4X*\'\#E>A[Y@B74[T,'>&$P]M7*MM33D3[HZBY?6[>9SD $R23[QLU^MX"V]DU@';SE;@RGX-/LVT'<)H&,1EF>@
M:IX.0I= S=RD;1_\PC9I3RY]/O>XFW1[QK\MFZ;M%M*.V," V9JQOXFD(R#_3YNAA]=/
M$A3)"NPGC"9IL8\UJD._7S2OW[PU,'3[S1!G+,Q1?\C1:!OV8,Y]P5N8"N=*
M53ECT+EN71B:D!B1P-L,.A@',59[/Y98F7-&COH*\.$_0A;(5?:MGDX%8! 9(9(&02+C2 S1$D0\F+4EBWC+*= F96N;/M)MRMHG?@G]IIPL]17C
M(X (T%U-DA4T?9=4!3O;K,5S\CE"Q8-Q3M2(RYV+J_.=[V-,K8($KD)XF@6!/WY=[K<]RL F\[]NF;/P$SDZ'K<[MU
M51-29_4B!"A)29>72CO*FUDQGB()=FV\3[YR9%?(O^>HL-<%^Z'LQ\..+%'1
M\F][A)0]3S@5 F0(I\-L*@*_D:3@("M+,:6N1M>.68.;'$6$Y^A][DK6F^J#'/75.-7A:C,/G/V/YH]%CQZMSEB@6DN
M/WH94[67$2CB 5IVG>0WQL(1S]TJ[.C'6!G$99YM'@)^L2*HZ],PV/89R]BV;]_E>";D!&8'%ZFI<@IJ5O8/=@ZV+L'7KXO;BNZ3
M+-4KROTL'XFBGQ4213\KR)Y3D[;0 F!-)O+O9QUY"3&<(Z/.4EHE?'MQ-R;I
M/-R&3F-YQ8US-S@J; R&"EHRQ6;5$5H,V#U7EIHO-H[ 0!^O7@R_GI,O@S//
M0PYQKW-@XQ:;+*>W5E16QJ
M#HY]MK-1@87S4$TLO;VMCX![<,/T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M\>KMDGW@>H#UGD(6T]LDAWFLM@VM6K_2N9KUBI>0!_X6DL!K2*+>O''0
MUL\I/?/A_0T4%.C0N$^^@FOCIQ]^^<5M3D,:AWPR^F$PF+4A0M^;J WIRB12?M;D<'[?45B_ECFR;4L-A0,(7W>?F"6*9?:II>%VQO@'A:\;AB=N*SBDT;0X:@
MSBT,Y_BNKPXU^B%>DU(2(8FB$CG[S8]5LPJGB"ET[5U29QN9-@PVO=X>PEB!
M!P-4M9!-R[C"\9\?+_5-5'AZ?WA[JK* U%- _"!B8>K+'75$7OMJ&T6?_P1>0!_$&
MLM%>X>^7CQ5,/H>\;)'F\^DB,**L7EGF@)0UE-%%"A_:"N>,_ 1TS"F'!]PN
MI./0 _$?;O[J^?A%BOKLK3Z=(8O!6OD9\%VF(*G8T&^6AJ3BR^? +3I)/J=7
M^HO\^UM&EM''#4[F]\ZK[_/K7\JC1#)T0D)1-N9\02_@G*-13N
M^THL;*OCOZ!,MZNR9ZKWL34FDVJ/L)@C/QK[W#6=ON>39V S9W,R&\M)Q
MZIX"A--SF1OP<,)_/I.X[G\],T06O'89T_V3O+[,D[K.MAE-5[6H#;!>)L00
MLE%C2%*+:IEF R=>5LD;> M/-3E
MT&4V+(ZX8_9PE4&2G=TE:CQFK(Y'2_%)I5YD=T;'/J?.(3!O]^5<700\"]N8
MR%]&RM[;4,]?%A3J^=K^Q
M,9&K+0NWN^B(ZZ;)]Q>WG<%86,O\,+0>)*(*%5N%+J DL3-IRV8^Y"NT%WTC
M,BMHJJ=?0UGKKJR:K/;(WM!H=*$RX&1.-#(&')-8]JXWTU8#>*+8 AZV']C6
MN&96P4/3S08TE6[#LY '"4\;\R##[TVFZ??W)CN+(3W>$HA1*_U6+F(]=>
M@"O\2FVTCK[$"/!;?JRJ72_V!BYR?YDLMMYPN*S.F?'H^-*6G>GH_B+/(.-0
M,93;MQ]UM&6;@M5C0TR:T"V*NA/NB][(3W ;32\BX!Y70"J:6G+!WM&Q.]XL+$F]E(\)-(H.L*Y&G
MG YBA]-$%&J[NJ/0%92MG3]HR?Z&L$&0B5<64!W\:9-L5E\S:UZ?&$WD<**-
MQQ)I A0(D(BWP?FQ.+R@^@LF%$H+''-Y+C!,;@\/>;89@]W4QX"MP$=%;X+K
M8J6OB7&V0_6>G&"%W)?W3UF5WB95MIC]1-*<8?'91!W9WZ$>RELUC@M2?;+ILX>[VC*L!_J7N=WI]MPT++[I5XR^,
M<5MGJF #F:J;8_K/R^,#'!D;MF";XUU6__&1S807U -$!'ANV*S;'][1>@^X
M5/U^?:&\CO;>.^2-A#YY*1ODC.*_=0YG(7W_.6
MT7U*O+ITRH11-21^$EV?B8'AZV0V]!8]AJ(YMS_[7LM4:9%]M>9GXWU+,F(>D+(!QE^RA8K*_X7.RH%CP_44Y+1O>O<\O]$7_!7,[SH
MXAK%*/#?+PT1H,N@Y_7())70Z2*&%"*QQ9]6*+J51!9=*&I@U1*M/'"2=I)B\3_B%VY8*O%0/WF8_U?\,IJ3PH>]P:?F+Y/@F+4['2S\CF+& +I!
M-&^E'8V;CP;#!(9?D(H38#\ CU*CD8CN3/#CU&*\3)!2L"^MK?"Z+KI0J.XX
M23L.RUSZN+*]\$CHZM\1IOJ?EI\08D-;B&)3+#Z]+(NFRAX.N&3>'MM'YC"N)"5O;S8=Z/3( ]'4B*5"X'8&/=^,)EY\SMGG'U4!X::T7Q9!]N*M[ [!GU"I+ .]S5WWM,5$MB=)_(D"N6B
MAD0R0,T8]^O)7)!"3]*2PQ?0K\C*FLW;-R*+*)KIME,:(DWM S[V5=?K,66$YB#:&XAZ17P7[GSQN-4_7^"180O;C*=NH/'3Y>H2__Y4YJDX
MMN8Y'LPAW3[]97HEQN4RR5_A*^90I1?W:^UB,%)ZT7DV>DF1:>J#O!8K>V$K
MMCADX'J;9S5X%[4.D2-=&-40\J[?+#.\Q*V,],4^PG%4RY?[>NN!LW<.JK5
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M"+V.KC4?AJQ1$4]1A(YYL:/CABTB*9O
M*U(+,1M+9MV,2" P;FR]KNZRQR>\!F1\94!KA1$8V9JL*\+'D78@=@Z.91JY
M^>F?8C[F\2S9/[[[2:I/5>%:6,H>9+13-<%\UJT(\QMN9K;<__OB7
M'V1=NKL+A5(AO(QH;P.WL'P?NQ[1SO6)K!IF &^A2AM
MJ^?\Z@IVOU(LJ![9X^NE;0^^" 6KF5O5T^,M@*UI+!)Y6R95RM%[&TK7U>?#
MPT;^2ZL085>L-5[ V88TITH'7T/4>PB[M^IOZI3H0,ZX>ME2"W9.D9N^)KZ1
M4D*;3K]2F 1-5VP^R2-M.UD;NT>+ATG"GR9%V[6U2K,"M[+*$':PZ'3F&K3BB6%I&"9BM+(>PEJ W/ 9^^N''__'6'XJ?73K9N/@FKY,E
M?X7TI! 9U-CTLZD^9LO/(^;5^'+JXR^V2RB@ZMI379SS[ONC9K6HFL:XR:L6
M!OH*MVUJ["WD7&-?Z%70!^8<&7FRI9U:VPVF@=ZIV;IF^G8&DI2%H]._X"^HMX$HX54XS-EAPD9=Y!MUMVMHW%:,59'']%"MTL(OOIP-]"?MT1"10BTX%ZM0>"(5@Z%'N2UJ4HG 5]GBQ8K
MVEA 4%VC$T]E$YCM:VZRG *7)/AE_$ FM&<6C:WYVDB"5?<-_0RK!31FFR0<
MFU%XHK1C1,U-!7320M*L7#PS1DL0M3;;LAJ12H.RW)(706W118@VYJW!]ND2
M#+0'?*B@_7!5;BA-K=\S/D3D4Q'O8)W9]C\P RN!A'AU@- >+QMFLSCLF<;=
M3B8UR'3E0 ,-2_0+8$=XRY%:"<"S@*6_'(
M^&5T%3@9LL4R'=P'N\_=_4T8J=S&H9?ESM*AAE.W1 "4#G-0RSO]$\%39HNFI4&6RW$MZ[72;B^NNP<4^,O,QM3$G2Z "A
M?;P!1Z?-2*A59Y"4^=0_HQ*"VWQB(;L7@OQ@^QU38\4<.Y,VZ\3 5V@\O_T^
MSS:8#)1\O1.9)T9,'/4@-@FH>DDU<;!O^I,W2]G"8UA0/BT+_7/V6&1;-J.B
M^5*4#S6MGF%RF)!<"\ K^3UJ=_7UUIRE[E=[5KM4M2%)81E73+*D-XJ5GUXAV[YD1>[^MLN.
MR'BK:!B)=TDA?+G]" KRI)Y&/F#3HZV.HAUD,R1AL_7GRC2H470G2[,@[,=;
MM=9#+)G,. 8=M4I36J2'W7@JJ!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MM)] /A7W#\ MQ:,I[5;WR!K]+&W1@*)CR5 V5HP%SR^?Q'7_>YPCL]."'BIDM\KQ<42CG!'X
M<-$)6('J-2&/&(@&P-^.7\0"FZ2Z84!D3"S!;BO0\B.5WJK/M'K.-M8Z.'Q6
M*^ 6C\=4@VGZ?:G;60SX171.B*X/4&XIQXGXBP/'J2*TB!*?21SW=39#7 &5
M.70\W%;E-FO6%?B=,"WXCOV\+-B]YWC+?@1SEUTM%JIL0+X,FTWAZP!B#%Y(1#)U^TXB7RJJ_6!,^UX.AJ/>'#'']%L(M"FRB7[(/@IDB/4^G*X5.C!AZAGO)='%"8U9V+(&Q$?:7F\/4*Y\^;Z<2\/GU
M"]"CPG*?*IU3\Y/,T@X>-.UX),6<.E[+\6AIAX12M#=W 'G]H:*4ZF;FCH_)QO4/<8G(/C)S8T@X<; <^Z/C'+DI*U@*+S8TV)3;-
M#1]ST4=PBUQ#:>?'K(Q1 01-FA*-,@"[/-UE10;7U"9[IEK3')/Q(8:A!S#I
M#)0XTK$_D!'&S+KQDD8X6P3VR5'G'7O&X#0)#NA1.Z Y^EP$KQC3+IQZ7^+)
M7N]NY^:EEBU86!SW;CME$_:D9G/HG%.F4@#^S(*@T/5)FZ4]9"M06EBG/>BZ
M:#M"VP[=7GM4P+-H!\6*M%FYZ.\Y(^R&[,#WE%7\BUJESUE=5K7;YL3G"0X@
M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M+B53VEM,]/!-HMKMK4QHXS'^59?,[O7GSU(H#&AB)+"LS&S&?KS'J0BF!D+WFY%?/!N
MUYG:(1?3H[,[;_-A:.(M>"4SA[$< ML:NV]PV&V(DN1&F-](PC;Q8!:YG=M0
M.]DT-+W*GC.HI_TMH[D\UD9[G^!((H<2'&OK@Q)^3QEGK;_)^ HC<%!7
MKPAB%W*:/3M+H]:=@JBJ'1 WE&OAPN69L+ MM<@=[^HFVSE2RWK )P52Q*H/GF&6%3H8"A74EE0@-5,@ECO82>(-VR(>I@!I
M<_Q.8&]0;MNZPVU;YX!UR$L ^,K2W; D:$RP:L@.NBH8^0%YN^SY-'JY=PV%14:[*AB)&6
M&OD=Z,4RGN=QKRON%/G-<"&T6ZIJT<)+ZM[GY8LEG <"JIF$4#I $74)%_+
MHMP=F:Q^^N7-#S^_^>F__XR$X8GV;V\V9?7/]A'T1'A.(O 1[IJ+S2LAAZAZ
MS"V,(K\G8ES\2YV/FKMG[:@MS:M9R9NDK^GB"+K6O#ZXV3+GA^L_%@:,'%AE;^=Y2#;/]JCU?&?JR]6>* OG^_O
M5C?7JRA+NYU?QVCHS7IJM'JT"^ O$('[!4_^DEX:YPITR15NG0)=%>T$DR0O<1ENJY/>5P818CF7KM40\
M[-MQD09*;&CA.3]F1;8[[.31?,DNJH\4/$L\KF"[NK<$B*! E$W2TA"AE'@!
M*V\^^[?+B0(*>W:.X>/>5TE1LQ7%?H_)&EJ:M2?VO@\0<:.]A;RPUW2RU1TP
M^PMPT9TB- ^?W>DZB>G0A3WK?46I7/+*@;7&!^H/X/SG@7TCPC'L^ELVGF1R
M1X!=[X)73Y&2$R&/G,J"_+:>?'OH?Y($@^9,W3)R3TF-^:^6V\"E2F]M'2!KV,I]=H8>)678,/:N2],%T=),DYJM$O$.DJB71+;J3Q:2Y0)P)N%_-\7I
MW[PV/6(JS&F2&:3+G$/007<2CIY*TUZK][:PU-@G4#Q,$OXT*7C&'=LS>D6V
MJJ//)LDWAYQCA*59?H#1-*D*M#W91\2?7P(>L446YKW 0WP!0T(R6^^VRC;4
M,]=!-)G%(=84A^ )#C8^AHD-;H[#6O1B @J-R/K]"#'+Y)[(_7S[TS8O=3-S
MX0XQ:!2RW=)-L]XB,B[;6G=)P?%&P0%GS0B$9$ ^DHBA1(TEM>\HAZ"EBJ[>1M33R@+O*V,PK:!55KPN\2^6(]YDFO8[IH08S2]@6D+/CE
MEK\"07H%YE')(1R9"1_]/GNJY%Q91J?J(^#)U<\WQ_W<]D$/\O3YZ14K6=\X
M]_Y7ZV#P-)1005AW3,S*K7?1B9)E[YB01[Z]/&+UX4:0T&BY]QZ*&V;ACPDE
M>/&.7-?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M?7V,M$1HIU*.'4/L\-IBH%]%7PL9$7^YN9H,Y3V[K(_A<5P?PW.19M#%&#R"U<-)IAZ]W0LG!RCNX&!4>#NMB#8HFO#M?(QL.0..
M0]VEIZ9(O+M97V+8HF,\9(4;^WMV:HIXW= JRZ2/*QI,XED%=VKFBH]:0B%C
MCDT=?6]W]!GRN>^3/RCD;&L>]-/6D'!S"O)$TM<##S'##2?*9O(R\9+UB8BN
M!JL)DN_:'>V4 )@'U7"8D-,GYQ\:ZYC-V+!1([?(4)F_PJV!,T\!!MJYQ*0^
MTZ;):>K5"48:'V+,MD)P@LI#Y XX#JC5COA39T 'E-F=,5<5C%D+'R,1W&GQ[WY^U.5N.4ZR)$Y45
M'-\-:@'*BA>.0'?1JG[*]C*VM[?)FV!P FRBOF+U?<%T])#74>1T1 A/.+UX+.AV4&!/=WR YLN?T2*(17%B]
MW0PYF!4^7Z)!H]&=/EOP_I]-$8!.:['XWV)GTF;Q&_@*GBRF-G:5_=+))C<=
ML:UMU9ZH;1Y1V]XXN@?.P9O-@AH51_!#[#T5B<)X-\)T\K%&8N^I:D.!]8%\
ME!E-*,JWX>#)_*6,"B%"VP)W1XCNM2-^1XCAS/N?@(VW:)T'.MOCY#,]ZYP'
M"VXK8&-S_,AV"RCQXQH6[C6[\- L7=[;LBG&)A(KQ#-NK_UI6?[!9
MB>4CM].QL\78YUZ04AE/DL@27)93&1\D9LP27*#S:+79''8'Q+NXHON*;C*L
M%1I3HC:,Z..B]QT;X6?PF?FP'[;>%.(LQ8&^9RS)F_,HU""WU2)#WADF;CZ!
MK!R&="F"E>)?4LWO*1EE(;8Z:,5VR>8!J#LO295:
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M3S9_L!\SB=00DM(
M@IJO[.'-;9+\@E_D.!SA>@OIPM6^Y)C2:XC%9BGE]?*C93^""&:1ZF2P5&18
M[A/GHC>%4<:V1YL2\2EP
MJ^*HZ,::%R]F/4T00ZBT0^?9U0]H?1,H6T.X\/N#M/67U#3K8:H& H(NTH?F
MNF 'Q %[,K56S77!;B5)WMH\3KAY1'=KZ71,1D%)-RJC8M%/9+FOZ5D2"WWL
MRNL+)(6V,*IZRRT5U?;H=R:($9 A>=# 9;OMS;8J,60Q[M:?UM900N;;@_QP=HM/#0_PJ=K$:KD+JG.S#;JF/;-.1+ >V][I.OX$!&?YOZ
M"0_63:^.;N1;M%8N%^2 9*'7"\GQ5>BDU'ZZX:^S55Y%K[LZ57@V-_ZYU1-Z
M+_^_]-CV5;YE1TM9%#2'SC6TJ/&*,(C&V]81(T5VBA8$9S@Q;!\DJ5V8\B B
M9SO,D(%Y.M-QD?(IHS+L=^Z; R;J,8. _A+#"VA7];)E6ZWEYE%=VP?;1>HX'\^-1TTJ.-
MGA^=%,%^RT@,CD%%CBAZY/M09C@56A_:'JQ+6/$NAW.+)5V/,F P(4MNAM4MD+==+Z N%AH,Z""<)*G&RRJ?)X7^R7>*+ /G,O.&VV@#B?[<
M*A#ZI8;+[!5E%E(*/BM[M:PDH9J@DRU$AY\Q.HS7CJ0F*1)B!F8=)2]N%LOF
M3WBRS":' ?5W007RYR9IT% U1_Q +C43# H%QJ)DV%6O+,K=D8GHIU_>_/#S
MFY_^^\]($YYH__9F4U;_;!_!B.'X^X,O4^,T+)% II9MUA"VQ< %V RO$PM\
MRJW/_D*SMKJ)ET\ THZ(Y1RW,&!-FS'Q&2CHQ?=C9@J/=**1CT5OQM6;<%^F1GX"FH+=
M.M>1PE8KS%:WMMBCE#B:"V,2OWUES1!62#@.]D46*=3D;)[0V!R)!/#GB1@@
MFM;$_EQL3 PR89S,!MOZ#0T@1"N7&V:(W#2INQN'I=>&;&D#-+"330_R./@>
MYL?E8&^;(IS 1N8-8$'\S#YA>:;]+:,5$\?3T?W1X#CR,[BBM'O/DQQ,?M_A
M\ 58GV,M/)5I/ZO,F #4ULOR0;A-14V]&V-ED*$SRG;0IOSH'
MH6.B'C4B1A,SV@X\YA\V%H*$Q
MW/YA1A6V]YDEN<.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M]?;^B9G99'))\_9!GCQC9FP=R-H5NL*;R(T@TBLNJ
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MU=^B>$:.#2%J 1A1(UR;-ZC)8@MLJHKMGEU@08$;8 5&X6/8V?, _:K5
M*(2OT:SL2&"X#H[,.AJ709P:WG71K5/RK>1=%X/2K464]/;YZ6]R'LP'_CKT
MK[QS= K0_<_RJ*F,U.)M;?A6%M]OWNZ^:)*8QF15L!:E*DHT2AGU;>+:"5+HSV18,2V@A.ZO,(:^"Y/J<.P@*)
MZ3O1=<%NU3O>;?NA/#1FS,;)>WW6DB4)T"5_V. PEPJ1.EDRX]O^3&&'OOJ
M.5)SC%:VT>%RU;SIT+ZPRIX9%\_V"GLDP>/;M'Y-V"K@RQY\-5H!-ULI:4LL
M>@7;!,;-RIXLN6"&]M_+G+TWSYKCJB@.2>YV$+1/$_YX]!Q1\_S[F[*+RW"A
M@ONGK$IODZHY2I@9VV>"3Q)\E,AG8YZ5PYGW)6SC+9!G$5T*UPW==>+!IB6,
M3Q)\U)@.&5JTPYGW16OC+933%KILG&PZ%5GA#V^- HD9BWH(5YCXXQOT(
M6P-7KI\<@M:ZM'"(]76QJNMRD\$U<1PNLH8#-U$#2$7W904%,.S'-=TG4/PG
M>TFP7;Z6.'AU;$O,PK'YV'6*)V!'B!81&C.4LX<#1JW76[9A.I+0%"8VC"2=
MH9@-@H,C?D C; T_("\Y!/Z &LJH-E 2JJ6#("3P&*0='XEULA=DIR7=('"R
MJ7PLTA3&MC+F
MG2/FUT_?"^:7@T/SA^MM/>E\SUW\]ZNAPU35O"%

2M?"3[X30O].4)(BFX+ )#4E:RG%3:&8+Q/S9
MG2C?H&:+*&=Y>_P$Y6]T[,ZKD"(>CJ3 $8L"YK9P8U:3D_6(8=%WSQBL@ZJ)
M.[Q,*=?_9"814"PTJ20Q<(U#J&6I?G$O 8S[PB?(,:#EV3IHA>VDI8N/
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MGRT*9[L$?3A1X[$F7E$P)'J%SO/R8[)OYDZ2C=Q#!9LWC) X4]E/V#_

M_7]02P,$% @ %XK96H6D6YH=7 1"4& !0 !P8FTM,C R-3 S,S%?
M<')E+GAM;.U][7/;.-+G]^>OR#/WY:ZVLGF;V=EL[=Z5+-M9SSJ6UG8F,WMU
M-463D(0)12HD95OSUQ] BA)) 20 -M&DHB\SB6,"C5\W&HU&O_S]_SPO_1>/
M)(II&/SCNS=_?OW="Q*XH4>#^3^^^W3WM)""1DQ#OQGO[L
MLM^)71J1.%Q'+HGY#UZ\?,D&S(<<1X0/^+<7G]FH/ZV#%V]_>/'V]=_>_O5O
M;U^_^'0_9G]A/TD_^:^_^S3X\N#$Y 6C.XC_\5UAIN>'R/]S&,U?O7W]^MVK
M_!>_RW[S;\_\!Z7??WJ7_O:;]^_?OTK_=?>K,17](AOVS:M?/E[?N0NR=%[2
M($Z2'^#_^UE_FLO^8]>OGG[\MV;/S_'WG<9
M;B]>_#T*?7)+9B]2RO^6;%;D']_%=+GR.4'ISQ81F?WCN]7#\B4'\/6[;(3_
MP7[P6_3;. SBT*<>1_[,\?E"[A:$)-^]X -_NKTJ+6$5;YA4D <:+HG'.?B*
M_]8KZ2"O_C<\E5=,+)?D+F%_7I+ G-#J.*^@(+U;.!%9A+['=M/%US5--O=L
MB+=A]$Z+UIIA.*G J(Z=>''IAT_&<.X&R'"$H._&2=81"6>3%5M")E*8A.[) JTB&T>C5$.0/69$],XG$V9IF-BEZA]])%Q*J*./W+=
M_-TT^J1K3PHG C?
M$GZFDGOG"PG9G](#TG$Y3Y]HLK@9C\9:*U 8#DSELOU\2^(DHNYV=S.,^/^X
M+GIT?'WT508$$A\^Y$K[=-A_!07B5M+BJ;-Q'GS"%LQ^$JV)=TV=!^HS<=3<
M>4H#PAT/3,82RN:Y"1.2S[#1/2+$@T!!?,XTT2/3DH_DLQ.Q_9"80EL[$,S1
M,(W")8WC,-IP+/3(JWX+IZ,NKB=Z6BC] (I_TVR.:^':9;I@3
M/7QJQ@$S[:97TXM+&C #EY]YJ;R0J>^XZ;G!-N-6,;.BB:.
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M;PP(;QX-Z**J>"4Q68+>T%!V2.'>8D"TX',8H \N#$9:6CP&#(7UEP4#M!&)[R48WH%7T/91FT#/(#8@WF@#N%ML>_$,9W1[/V6P?61./$ZRAX&PMD.O%$V_=4I4<+#8IW
MA_$ZBMA:-JU6VS@NC/+:SWA-X_3!YYG[$-JQ2CA4)^C+#6Y3W&M&[& SE>UQ
M0YHK@T"IW_T$RD:XX0+4QXM;[,LM;$[D*JMT5@R% W7(!RJBZTLO7&T4J--HX++TW::H@G7AG[IM9)WP<"T>U\;^>_%,(I?&?$Z =30-#GVF7;';=YQPU4CCW'X@GA,[96MA:TEX
M3G+IT.AGQU^W6FS;6:%1V T_\OUMV%V;Y4F'@Y=)9OW,UH%'/!A5)ARL _U[
M%MW/DZO*)'QG QTN'@M_N_R&9_W9Z2* Z#H)T)5C=B%W=C-A>[?P>7Q",1#_/U
MIE'X2%.=S^-HUTD8;78NDULG:25FIK-U8[[-"+N=>FRB[ +>SFH3#M8!PV[8
MK3J3Z>LPCL=LWVXNP^C)B;Q6"V@S>&,W3M$[JUV\J8^ [3.
M_LACDYG9GDX[#H,D8N;PVO$G#SZ=.ZWM;.7A#?8.IR-FA*2Y"S%Q_SP/'U^Y
M&^\56_#W_ ]\Y=^GJQYO'OC#J)O24O8^C@+O+N'Y)//-.8U=/^2VX^%J#R;)
M'."ZX\*P3_Y,?4X2A_I0C][Y:$ O#HI!T"9KT!W;XCN^R7+41P4+/FM^;S?B
MB\:X0%(F>1DVHKYA+"#PZQZ%3F*T#8O? ?&Z
MYAW="+GFX<#B"12?SXV6H3DV;,;MI"-!X5AZ2CRTW68#9#$#24@FE-9(3R1B:% HO#!ZAV86!_6%_
M87"YV=5P"^!?IN1YH9MBRNP%_I6^MUXR:+4W\ZU:YUZ7UDN>$<.?P=[O]PF;V0[?T2ZF_.XSR+WWG@?C_^([.HOCE
M;.W[O^URI2?[>(1I&%-.^>@A3F^5-9#R@=+L]L1Y#H-PN4F!??GZW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M=FXEG88GMU,EXU9@2P]>+35I^0L+DLB(]^!=B'=:K@@QG$II)0^K2WE'K$D99EIMDB?NR
M^0M+ZCNOI1""F8JM-OHT(BN'>GF&B^U]79U^.-I; M^6J^]Z8&+AF%9#VIL5
MN+:\^]Z =SRTM.V.O D#-R.H$#Y@W4ZNIP+_F%7A:P.24*>JH9,E"EMWTF#U@H%#&UY7*04H'B<-7= Q?TB1Q/L?F3&YWWR3'P5,*D-7>HD%D]8V?S8
M^MF R5(H\5VFEH_:XAG;=RU<.59-#-WRL6K((LS3M$]GJ++;L(>'YAC?,*HA
M 7T[*FO2.AQQ_(FY#5[.G!^)RR=%CXH)H^\>'0SNVI+
M1@^!.]*U8[ONMO17JP785I<'\P]CURG@V __W3EY2 I!IED.LFTFBXD8**MB$(Y]MH;L1C&ZX!,'-&!:**%0>X>63U7 H+2LH0\GW?R[
MZOFV/#>E6;'5J%B$*PZ:,DYP-PG3?;<]KF\97M%C7? _+.MO>G?\E23@'@73A308&[OM#N8&/W(4V'>(5QP(8@M8@:VPF0Y4F WZQ!T9@4G
M,/NRI:UBV489QB[+H0%[(6YG3@9RKUCW1F4@:D V%+LR$/K+3#;=P8O_WU]5
MT_O@L_X.&J(602XE_IF^69;&MWYODMW2,#$=#2-TQ4=7RV]0/OHQ-](85:S=;X*R6@!\9_O>B762P'$O\VQZTDMG >
M(GM.'HD?IA$>MCE=3\7 V-T *7Y@1=9UWNMMC>BBORJ,8W"&8ECWA?!OR0DMLUMV?S8I[46DZ4@ MXQS=E+$UY*\HS,PHB7
M>+'*VNK< U/:0OC@[J1Z7,W*'?$H(K%-+7SP%WR$O;44#&'14@%/R!9^MKR3
MKDTO6Z$++P+CY&(G<*_E\""' I\3-BF/667PV#[11'-CJ3U5W@GQ,MAP[S,>
M!F3.G2=MNMXSO1 Z-(BY[4/B2;"KN4EGC!3N-F4_3*OV^BF,M\0-Y^QZ
MPUVFF=4TB?BW]JZ-(-3V?8L#\:2%"=M**93;NRF8KY4/^LF>ZJJVZ/Y@^> L
MU-!6!UCP$<[]H!YBT=JV,/^E/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M3AU6UN. GMM\2)BU/2V:&W^;:FEX(7Q8801[LLZMIV!(]ED-C@:N8,#4KG/JKY-]JA(*B^MH&)"15@NE@2<:5#U_)G2^8-2-'DGD
MS$G6SMT:A\6SHX=I:K%7@B"4W]NTUEGJR2(>+G_KJ1C84=P J8$WO>YAM*L4
MI93<1>@S8N,LT>J>8?PVC-Y]5\*\F*&D66%HEP*UKV(VF8W32T1\%1P2<$YF
MU*62#"99+:*VD[1*9-GWT]K-N,7RL#M9E_DL#71TL\9K<3\TE'5>E[JL6=M<,)>2?!I$C"8AFPMKG1AD*UTFZMIM1.;>'I[D1 G#7T%L7>31P
MHDUVIEEN+B6<'/DR5R_J%4>:$#S\C+Q2P1?+/!7-C6_VZ7!5B!YZ0D&Y#HQE
MI@HG']!&%8.''^V\)8@MH,'E;IG?NG0A-P;1D 1MQ)$K"U8K"%D7!.'T0^*W
M&#^PH&8H@]IV_UL9 <,ZJ^4X%ISI [PG*-W%(3I\GLI1 3'SP$=26Z/*X'*P
M(A$-N<\A2@ LCYLUUX.3679UF:R3.'$"=IN96V.IG )DP]*8QS68FE\?)&PW
MKB 5$2($@B^K#F6,=GF\E3P XZ>]=&;M W+EC_1.G!^Q=GT)NUFQ(W3,V5T&#Z,)X5T2NE\RQ\;Y.F(J:9JIE513\9\[
M[ *4:Z[[<)J])'U@8KEBPJKP/M-R@KZ::$+.M@43*Z%20G<:\GU(]LUX-"X^
M9I@+@>H$QR $RF!"!?L "8%,>.&D0'F&@>GYUH!"!01UI0HNPT@[@[7=^$.[
MYK5$$RQPJ$-- "@$JA,E%U%-R/OD<9A!U:!8(K!
MW?3:@VJ0$MS^NJ=YDD$*@\8MG^UZ#0ZIIH$H^!C$5)#-="26HS["< G:T,[EBV<2N30F^XH7MKV(FG0-2J^T
M@#\7F3XX(F5Z\.)Z,D[34O-_&X>Q4K$8F'F.VO*L@3<7#0 799?GC9C\#H^=
MA@F/V7.E 'U]FAUJ%/U:.BTG&-1QTA;,7 3ZX,R4RG&%Z@[UA6RF8S=3
MI0CG\@'AZ^Q22Y1+@75@<%0G.&8M<0!F+@6MO9U=:HD*U1UJ"=E,QZXEI CG
M\M'>_=FQELA>]MET\77BM94/K5F.6E\(8MQ3H7%^M-TM2$_5- DW015].+2QJP'[+?[-#3H3K?$>H59:ASD6GM0X72,-IK
M %(UYO,>S^-<"^QS.;+=R'GCM3#RCO
MWB\BF.O(7:@U(.=B8M=[NE_Y-UUBV?C5351N&:"T&W#MW?N%DWRFOG]&;HGK
M.W%,9Y1X]V&QT4]>_=4:]T&('9B^@&95+G)81>>RI?[VVIK0#/N-?@]7SC@#
M%VB6$7@1F+7]4$A7M,C.^B308>[L6EQSOANX-@_YOD6HJ\*!Q5IG8R=>7/KA
MTWMN-W.NR.R>[]/]D1:%U-UBGJE.]68KP$W6"FN4X,Y"?NT95^[ YWUXG@[ZN8.
M#?QBBZEKZCQ0_R @M9Y]-:,@Z]UVO*M#!ZD$GD"N8IA&=8?#',W.$R"$5>WN
M*'O907&LOMF=[0>$2@.X\@.K#J>$W^.[_MOQ2@P*7#&';ZJQ<$NFU'8>!NBE
M#7%G2.__#TY,O*FS27^(=%40$(+K/S-BN0[,&"452A=9EQ OOF3+3M^&)K-R
MI6B;[H &2K#]YRU%00'J7K1ER1=X3A@)+G5*O>E1E(*(DH$+@P+48&46((3A
M4Q 1QZ=,<[&_$#H/<@.0+Y7$_(S#.C*42!NBX=".%V!E&?0$J$SJ-8T3&LR%
MZD-H]=5^/L@]7P\(8,$$M12*'B]&([?[OJB1.+K%S>JTAL0W>.DZJK7!0JY8&G5%LARXO,<>;8*
M'GZQ6PH38T(?>3ENK -7AT*,RYO9/JFWSS1X O5LT(TP32.RMZU@%YP!_J*<*\^._6HWC*ABY;KAF_SAU-ERHV?K93Z(U*<*@;2$83H-C1)B+
M @RVR$?2[GCESHI/[*91!()90X\"$>BR X@:.=CVIGXH@2K.+1Y9JCW5#?V$
MZXC=,7EI'F8],PJ3S=1W@H1)+X\S6_%%CW<1H".V;QY)C"0L *0.QM*%99#!
M^Y#D3<)8S@0;XO ,O66D1]3=AOJQ)?+_\64^.K[5MPL8:O$?&T$4EPF?L"J+
MURX$4WDIDG,4)UV=#C)Y#@,ZZ0K/-&=A%(5/O!=;47?N$BLQ#CM0"I/OJ?[EMWN-ML^VV=AX,5IN1"F^L[) _OIVN:+J@HM@XN\5@+8X.E,:LCH
MR$%1:DO-D9A5EJ*A<&EN'F,HNUD!#:1'JAN2Y,1EKCOB<2)YT4 %#M5]W9]D
MKSK.U*X?JX:W/%*"*7GD8)0]!8-3F#5@PKUC@=G>F+:5(CE#4;_Z.+MOH$*M>-?YYXZ U86<;I.ZU]9SNF\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MN^HN48!F %Z+:JX"-L>Z
M%\]FZM3A6' Z')>;;AH\&,)[F:05M OA@&D)7^G5-;_*^90@[>QFR--GK"AVA4QL'PW87
M@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M "E\947WO/!<;AK:-$=@C]]'Y/4SO &% TD)J;*9M07*D^Z(Z
M16".FQQB['TL) 1WSVK+1XVW1@CS *)V1/$03N#M?GQ+XR\JE\?VDBJB!/58
MKB4()O]" C/V7E4@"_T.JRLZ\KVKPH1A1*;>K1]B\G7-B7_L(C6JB-I-&#AI
M"PB>P)G.-IJQM=Z251BE2=)I&1W4#:Q)(I U+9\)>UNK489?IKV]F,DWNR)W
M!G*S/JQK<+;)JA/ ;/UU_'+N.*O?5 MGE 1YYL0/*3C;45(Y?D7\),Y_POVG
MWZ<"JS"1N;^*Q&Y$5UFYE&H5A\LPZDU8;DLZ<9YM3MA$2QJ0XA4#N<8C(,E8YT0G J?)+8QF9NI;IY=9W8 THSCTN])S)GG?6.W2
MFM92?-[X?/#2UD>Q4Z?XN$Y7#4ZUZ,G6Q3G[<^BSM3C1)FM=N<N%L=CFPU
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M[BK@T2;4HT[4@^VD2R.6X=BJ_8VL^3AE,>
MIZ(1>!^)PYF_[02]>Q0?Q3%)B]P;EJ*$GA%K/^DU^ #'&3# MZV%G'7RXA4V
MEQR)_ 0N'L!Y0P0<*UF'0*2W$N-V,<:,@ HDZ%1!-_>C #2&!M*18J]*KFD6
MG)B]461GEIDJKA\)2\6:]:)0QF<8-HI*(PI0:V6O7+ZE?A0]BE?2HFK@O2>.
MKN,$X'FT1^P;[#EQ3A*'^L2K-G7M;2^*5@3C9B,"=*AHQZY!;'&5QA6@!_&1
M]Z\H2("VY0HW%T[MK9/X4\QU]J5#HY\=?TT*OBA^?1+)$;:3'60-Z#G$]2TZ+#%R",6VZ[HP-)ZV
MQ]3B0U!!=SM^ZP+#@G$P#%+=AAN*B"![RHOI_GU7LT/0H3!M68P4)8"OW'S/
M"TIDMS*;F\=#<2VU40(*$(&EL;5GY(2=VKQ:/C,"^,7XF40NC3FYT!PVF&BP
MK# R.7&R5]"BU$0T9I)PR<1KUZ]BY#()
MZ\5I"T+X$!JA=,FW0;@.51NF-&WDX^N;,@Z7RS!()2C.!VZZT)K?=]K.-K1.
M*ZW1!=U=AE==,EMS^<_I;^NQ4K@4MY\1K_=?BZX\ $"#790L=>R!M9PD3]Q'
MW[AG'W&3E?=G4E>PPXM*J$6(DN;0Z!Y>HX8\YDABU:2JI[ADV,#Q73)L?^IP
M S%M.^"\HLEBZA)L'@\YGK"Q/Y F.L.(\:WO$P3I%=@C_8VU"ZH&IOV+;/8*:M'08!P>\OJ4TE^L'7OLF0 6L&T-Z@U&$$.%)AC^.WU6AD;R]=S&:$.X3)#N9;
M)H5EEW*;6X?)^.A;T:BK2$M,>U +N=3_B"T^61R*=@'1./+>8Z
MY$8YLZAW/QDS4BE^DD=KHH%UQ$"M8XVZ]7#*Z)[-=YU9.[YA=['C5DBM\@P4DO:8^#T4S+20/GAPM]_>-#GJ*(_OF^]UE+]AB&?#UO\:Y.'O;L#F1QI<
M@8Q4[B@QK8^294IK?QSI[43,F%? -D1G3YE;VSV<%0OQI*<(T"&ROQT49] (
M(&D80'=/"LIAB4'(6%_&HJF4E?:X\!DZTNI*3#K(54*6%ANV&%.(H3[4!)6K
M"D,1,E<)?KL, A7L1\_4GF H$X3REM!*0Y2/$G7D+0O'-OYRM.;2[5-GFFRN
M$^\C63Z02$'9U7Z.DQ!K+NZ<9?5X8"0 33M(];(@0"M0*7,F1ORY(;K*!FY7][]-,S#H(7!
M9HZ?;R;CA?H\O$0 ]ZMQUUO$/:MIL#WO=D(]OC$+]I*].ZH>5M38[@OZ_P$BZ\6RW/T9@\!6S4!5U=!6QXMO["TNV)CSI%Z"\CP,*CP0N,&,%]
MG"<+(>H$&\:.S/SW(E6Z=ME?T*QD8>+9 )M0]W>:E8&-9H>LZLDJ,-%@RS),ZW#L6CY$Q#.<.ZV5=<"=H5
M8 #7C+GUG0>""Y\Q;/KLFBG!.5\QE%G%'F_FD7T1$I9%5791U'V-^[2GO"$X
MCVI!P,E,+1=B5F:(\#/LRKTZK!"O&^.*,4D6A-V574+3XF>Q,@\D'PYH/\B6
M#GIM4&;$_N)S%93K02BSI'&( 3&G&0ZX,C/ 1625^:4^%KK?18MW&AB!]1J'
M*DRHS#R%0? ?+[38I@(+8*]N/0-.4K96W8:K'V!(QD,3%E!=L;6VU)KMS-TJ#.(P4M]&X@\'=%+)E@[5+UI3MW%JM@?FARAM?/G;N=R#._U 'G U#Y 2Y0VDJIPG6N.AB$M'OMKT"-)#$R7<7&.-*FYYC=%P
M7'\=LEL+RL'%>F==_6A0C&H9KR.>*[=IBOTV?3S9-A(436GV=*8RH+[?5.G$
MJ8&OB[G:I$/7P6GX>*4T(FZDMXY4*C\\*4L'S*N ZKGVT[MOEK4]
M2L[9XGA0$=-J;(6KE9^K4ZO/3'ID]:[9JKF6J#PJ:;('598F*Q(P#,XMNF061F3D_;[.W)GJ2Q%=VSJ4-6"RL>.+S'9T6>R@.5FP@]L\@[/+;,0L,G).
MMO_GM]UL@\7%YL3I+MS7L7]U;^[*ZJ![Y9 &U+ DX&0:R
M_3B:L5$'IUC;4HWL&077JJVY"/5<>S1FD_8U!L =9[:?>1A*(KGP=K@A*]/V
M(")0Y[I9WDQ5",U=;8\D>@A;]^?:TI,D$7U8)VF)F3"+K)_,IBD4MME<1PJ^
M%2#> D(>UV**VY4MH] R9[&NNX#[%B?F:T_%)O:N(Z&_OK#
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M>0^>3?I#)+D0$(+[^*N]D>KD000S[B-&F;Y/040MDF HD8:Y\^:#CI=#*)
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MO7=(WV^O>\#PH6YU.:0YTPUB2#*F7P1>A>7=U\"XIG$A>+63M,"@\^\C5Z+WSA83L3^E3-!N(P?A$DT5:S4N&C69-"ZB9]/=_^YD/]D"GZ[PN
MU6A'5 L-DIH5\ 62'XA*!5JO%4R#W3O/TU33'-:R$#]'''R#<5(#;]GT%>(0
M#(Q\G!O74:_15_AEE&TB%:"T\5EA)?"=EH8M;*#J&*:"GF8%5MY0*VNO-76H
MIW& R[]%$>$.#L9M75890CAO37=)Z'ZYBN,U\<[7$<\OSRX5//(BSGZ>OLW+
MT% QS=I.@;7!&\4YS:1O#2!*Y5FS77Q9%:DV-JE3SCY,6WX)IRQGPNG
M3O2SXZ\)D]J4,'L!K-6)D<(8.^?[(<+H;WNI\$UFEC/RR[/B^'4ZYW8%6O-<
MH8/0=,V.R\F5QS"@,\IMS&)W,#M+@[ZHJ_EJ >HFF/,Y%*L2.:$3JR'\-02@:/5V[*\'E<#$VV7F3)W$N(!;.^S
M,(K")Z:Y[/&Y,"6*0=Z6J47(#"PN&0M-:P>G0E5IFF.Q^[MD_F'N5RF:!N86
M^%9EB\N*WDN;!W1YGQ9-/LCM*X;1P- J,_@^3!S?;#>7(SG+EJ2"%5W[^5'=
MANJ!@FH/9J?O [,"G0-CL*GC@[D)7YC$>L:I;/X6WJ5M_=;X,Q.G,R?X8M%Z
M.9@9N2AN/7,KILLA;-B9*-LCM]R4%O/"J4@/?O$P+L=%P_1$%%
M!H;"?V7&FSB/RZ:/G0.4TYX6OVOLDF08,K:;P"A8[/!KS;B,W0"")6M&@2D/
MI6NX"I9[8+?IH75="L/"C,.2LI_O*W7FX#868O?8#4\.6/(:[R/7S>K;$^^<
M,%I!(E^Z>KOJ/N^(F
M@)!""*CEUAC"R;%[,7>\8^LD2M8HR+ LVB$AEODKI^";8G(-(W#KO\L6'GC%
MM5L6&BVB^G 'M"E*>AP#C$8Q/5[RMMW3*%R1*-E,?2==]=ZXLVK-J)$S2-M$
M$6FT;C_C<+E:,[G:T6/;V)#,CUV?6F^+5)@NPQ2\)FO/]T']/=@\5*NES$M9
M:B\64TH!M:%8;A(<9W2^OYXFP=LT4R^RYMBWG\]:(P"&&HA='<3A"D[EMY@]DV#XVW(8T.NP>Z;K1F5.]#:QJ>9[3B9,K3
MC433:3S6: W72D$+2['=A^F/[]:\JRS;HCAQME)J,$YI$P;7!-S*D49O&I&N
MR_'C]/I%9Y1XHWC[1&_3U26E89CR'M-2F'F8_!4@
MB)3RMJ5$94D*)Y'.:#@.(U/>:>'4HO]5)0+%DOWSB5GPM,^$IK\?W,?2(#QG.N32E#XB9,=N':&W44
M-:-=@"=L\01Z3F/7#^-UQ/"]H_. G4@NL_L_!>%#3**T%/A5L%HG\;:6HT.S
MA-Z/Q.$?\7L!KP>TVR$'EXON'3J=K0"_>Y_N-MI6V0 59K3 BT,.6GT)DTR/
M895THY_*=HL,;9#@,*U#A-<)X+07=VA*D7()J,8A<(-BZP4[?:QIQ "E;@I/
M8^'AN>?TD7K,1/B5$M\SYI+.:-A/D,TLT\(&I_#)Q3.)7!JWW%PJHR '+ZEP
M2P$*_."0JX"-1.+DUDF4&-9I=>I&4O!#C9H9KX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M4[CG0,,]6P<4'LLUK?LG\_;'Z.G1_/2$A?5HOMU)^TAEA1/X\!O<>Z<5?@J
M@JUATOUKHU3%;@#+0NV?6^33&3U"*@QG<"M&VDDO HLP#4W3STW$1FN@*>YNA.Q6TNG)*'[)9/"\W5$@_DT&S"UA/G/>1NU
MK;#R7H0[7>TNG&"N5/2G]13XS]MZ#&^/*48-S H5.L;*]HM!J>&#Y:+<.4J'
M05PPH#XX-&"&E\K^:AYC6/I2 1- )YL6NW:DS+>D3 (#DT9EE$'M)258(+-E
MH>W0:BQJ*TMT0(Q3A,;<\R4HV MKBUJ,(JZU1@?$="5,S9-P#UENY0:^742A
M W=CDVG3V[=@*J-K=]TXFL:;FHM7,&$G$M4P^J;>0[3//.EKVK+FG +D;4\?>I+'8CZYHIP9$*T,TM:6MT_>!3
M-W^)4GZ^%GZ&W0)15;HY7\3KQGB[J#P&JK- ^!WZV[ >%\1K!PZ?&[+^4#V,
M$0)V\QM-SKW).N'E13P:S#6N>**O<;LYJ5@]Q1N=MWD,GJW1Y;U^_>6_MZ-<@:1AR8(8V[#N$IH#D(IOY(=3]S_D'^/=P5>945XI?
M(_0SH?-%0KS1(XF<.=D'DQ=EY ,GFGA6-Z8V83V\N#5L4'WL :.,@J
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M[[Z_?#?Y]8>'OZS_]9_/OTS^[?]K_'[VXY]3R\?Z/NXM/X4]/DT?Z
M_<>_SGYQSCZY/SS\E5[]=!4__FGSU7O[GS?CV<,_GV]N;W_Z]R3ZTY\^?OQT
M=O[J^BKZR\73-$C^^L/U]'IZ^[/W\S\?R)?K]_.;K]XG_Y?+\[>_OPE>?_UP
M[OP:?_KA[/7HU>SCW>WGU<4__M^+\=WMRY<#V3U:4@A5$/:%I6!0@6W _KM=
M(_>E-#Y,M7H9*MPJ6A+K;:#U^JD@/QU'%Z!.N!$UM/52 ]B1EZ:FJ>9+KTPXA>= ;SI".'#[Z<
MS/'L";,C"N311ZOQ)I>$'8V3Z):;EI4;^6X!V;\J]:HU&;;G)ZG0%C?##Z5W
MW)&_[FDR3N6MSVZUERI%A148\*?X]3'PIX0&V)N/R1-;OHW3E,L42KW\5-D
MR%'K9FQJ @6XIDOW_H>KX)'$"3>$:)PJ=SJCQ'-B9VMD6-B3]!5@:!1/!(3--H39.2Q )BN999!?!5,XPWC_,C]NJ:1TFMVPP#(6PN.
MA:(4GRI8@%:Y5M3;V<>]_UZ):=4OCHI+!W# 9N4;7'Y3"8DIQY2I+;*C?C*[
M#Q/'Y[VD*",Q!3WU06BX8+%LE
MX&!5O"MEA=X2-YP'] \EG2W[$OOEN2-V5?$!RYVU8LONU^BGMC,S/NG%TP_"OIA=;[@?S;5SZU'?M9>UO)&]DEMHYJ%&&'Z"J(.*IX0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ML/,M]3VUM!L$_T0S;9HJY9-O3*,IC-NN2*6)+S[DB7SI&.X-;&G^91804>S;JM,@4MLVV)9L 1X9?]5UC2-<,5S#G."T,WOG'SPZ%MX%;-$BZ"A%$93YZ"C-["I=I>
MP) A?<@G5)MB:GY0E[J.%PNPR"+4>KFY3J;=22=U2RU4G50[>W'/]]&<*DCI_F4#3 )5"S[
MSC%4<+D* WXFYGK4[NNR>'H4.0#3#I4W
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MZE,,51^TQS87"P./UX%8=.MSSITEAN)1>LIABH6[;'-Q0+"%=>AMK@9C\9=JPO1'(,T+0"@S<6BM5^O.TUA
M)A+MYQBD2 ! FXM$:_]@EYZ&:9:TP.:*KY/MKW7H;JB=[AOQ.=1#GD?@ ,2I
MMG<\B$@U\SX(1QJJ%:&,5,Y,Z[64ZF1R3_VG@*;>T5):Z@U)LC2+G?\42!^8
MSSO($Z0C%N0B93U$3W0BBGYF:%,(AQHDX]6!RGG9VDW9R>MA220AGQ'+ P_U
M$##%,6>Z]?(>RH]ENHPW''BHC#?%,6>\CIM1]OH('%C'*3VH-)%7MQR!5/0"TN52T=C,"1^BU%HGVM&3HXYV("$$H(ISM !05LJB$*"AS.N: !"K"I?#^]KHL !A)O ,\7II!S=/
MC#-Y+P)#0U.2A&J1TX)4WD'S^ #'G+G&^;PEYKY +'RDVJX'L.I1J]8]2@,:
MUM16*NU@V+:GY02ZST]*>!U(?6L.[$?L7WFBNG8X;=F/5J#FL*%!VI0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M72>8(0M5'M7@\36$DADYWMJH]UG%NSPLGVZ3OF.[0VJ-B@?*[.J,-CKA%V+6K] !R@4 S6&V^HQJXF2U$R
M:_8G!4B8K-)P@_=>*P8QFM3N@4F; 8MF5>'DD/BH"E"+,CL@16P[CF8W#4P>
M%*_;80E64@?JG 79SP8L'^@.-^4WFI.I'*9PD:YT^_2MD=2N,]K@M+<65"VJ
MW(C"C]L\'I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M0KYY:G)?!^L6A@H_ENR>A/\BF^PMYB)(*+_G1],H?*19=PLQ<7F0&>YS^HL>_O2.,Y^Q6M?_E=#3.'-MG+>8:
M6Q3*$U/!ML>*!'$J97<+)N3L_%E>+%=^N"'DC 1D1BUF4;:A$;^D2P^$OZS2
M6K$=[(DEJEK5=7PL$(Z &'P9Y)NI+*'@GA22N:
M"!V<@6I^6E0*66[!T;?\U$>L-P9]_?.\^W#+9Z ]!L
M;]P2-V13^C1=$..WZW*&\P8U4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M0J(LBM-YN'2HO:?O-C3B7W!;;U@ *M70:E2N;'OO@"\UD*,VBHLJ$,3/@]7+!@8=^V#F6AB0[T.P^P4#3BCI%5E1*E
MG+Y<_.WC8$]I_;"IS,H>_SS-*Z5Y[$0137NZ/#F1I\P9I6&.@V5JB.$VN_E
MPGGDK!;4=?Q11!R[1KQX=B3NP]GH$E MI\_7T&/9M);-CVU,U0I_ TO%QJZF
MK9.Z)J/-;^-1#2]BXOYY'CZ^VOYRRHG\+UR_?I^B71@*V6O?B&IQU4@5:G(2
M1I_ @&=##05XOFJD.*,X2G[CT)X/IS9^;$#RD=;(",$<1/8OZW/2?J
MQ\91-FT/E0:\S U!TQIU*4%D7B6G\4119J!T;!P&*@GLCE-R8*KGA-DQ\=MK
MZ(.BSY"6UPU^5 Q(#73SXF-^]6A?X?)\%P4E\C2P.])G)A*+F[ *T56\?: _
M*'O>Y9L5!+'8UB[\6V%%,D$X"IPDVOWS>?F6S^_XF^T-OZ.'])H)C9[45<8#
M>EROF0KFF5UU I ']P-[&_M:VU8?G+<&#AN;.<[GAPW2!ZS*T8MV\G3M-O&H4H3']('W_0H]L9 "PDP '.C
M&?,BM+,&R4.J:[.GXP0#>'_H/[P_081":-RN/S&A $Y+1J8RQY,/> 2U;(%A^[8 /
M(/U[*,@#@7F82&E5VM$AY:]QBS_J7?P/PS\J2(!6MV>4I7P7L K].RV$VED,VMZ0*NZ32S2 Q4VS311+ANMGJ*L-IEM=PL7%_9%%54#]VN=KVP,J_5;FN-E.!X
M;NUKK4I8>C.'\))9:HFS'%FG0@MVT7O5W:8A A!!%=M^%(51E:]2TD_Q\X"T
MT)9# .ADU/9LC5#OD"C_=D@[H 8!C+0+3LZ4K8?&<1AM^ 56
MBQ_"3P>V2^00P)7\,CV+KLDC\?DZ\B)1_Z0D8D@L-E;MF 8R4/8?M@W3Q!J
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M;10[8]YG " &0]P4>7?CMG8/::(#O1*5=C!461X:<1YMX.9Q3&O'GS!=/L]J<,,U(MS'5>73IB%5XFF-(A!UQM4VFTRUD0+&ED(/=2EI
M46R_N-.N@ED8+;.=_A"NTR80+KL);3/5L]+R!7*VO40_.M&MK48K=K(0]"!'@\W8)L)1>SO A#>:B7%.K%4_<&E2C.N394U7/F3+D(,POQWO
M+3MS*]/BQ_>(]H"899 UJV_"Y)K=:*+[A1-, L+3Q2P_QLDI0 Z!:V9(#7@]
M>&RO4#8*O"*]]XRQZ<]M5Z;6I0O7L]PL!-HXHZ1@GC()!G(NJZ<1H$3AG1()
MCB*1@'L\MUW&XJFSX>+(]!;[2;1FHF207J Y(+J+2CN:6@M 1'& N<[1G488VM&6YZK9M5: #UL=!5
MKTW.:T ,?&-K]:A0K@BV\;)YQIL'/I.;:MJR)F;'T1W#*"'SS1Y>Z6N"IIPR
M GZKF3N?F-'P(7PD$4>M]P*3J52> . 76/+76]=1$(*>EKXS%R;0(@,]A^[ %&PII[;K:=93R\XFE_ [
MQA4[:.:<Z> S-MB7KO94[9PH!A^(ZE&0C7JT02L7@0O(91CQHN)Q3(/Y
ME,Y>^,[>HG-+I
MOC6]E&$,U\L(0"+8D.R.Y&]&LUEZ_9I$M\2)PX =T)MK^H7XF_NP^ENW9$ZY
MZ1,DG:DE*+*.4L+ > :7&(@NB5VH+P"*3O(GX11.8H9P06>A$WF3V3F-&)UA
M%$\8)C&/ >](NRG,=Y06E0K.YE'>79I+W#<9)31.8_GR']Z2F&>391V$.K;.
MU0G >3>W95-I,&(K27^Q67Y*+O;C<+FD24+()+I;/[CYWPJDL\N%%<5C2LE0
MO'*:^LB8,5OY^M%VF%<#)O<+&J49L)N+8,Y^UNF]3CS9<:L@"M*BDE-\FV\0PTF$]#G[H\KB1[H(=Z-9)/I)%SHC!(R[*Z(??CL-U-Z#RX>'87
M3C GMVQ6BU%,4A*0#$!USE6CEN1@XGA@][2-V&YG^Q23T34D#(S1=6#"N3H[
M5()CIM'31@B[A5_$"5VR!?!HIY_67J;E%52BCC36S#HJSJJA'[6'U-Y"]Y'C
M<<&(J,N;F]PMG$@E=T[X&8H?Q!3UM(&.M9FMC@SW19'$S'HT;15M'2.33?>;3N8ZK(=,:@VG>S)114MX,!Z-4>V-!J._:XO2'R;ZO+5J
MBX69O*8G:7D]K$K8.L2YIKXW[B?*Z.Y_%RO*21_?POK@4P)[L?*6N[M\A$&D
M-IE=$*=.5EU$;.-V>"T\F!CI,FA@:I1OA8<(FBN4EE6I"BFZ:[[Y)K.4HO@J
MCM?$L\9:X>1]/!B:F2O&$;+LF.:E-*>?/P8%L>*5M/I1WRRE6F:(%@T71=2I
MN\6)%[>$V>W4W>9<.$'ZOXNO:_KH^&JN%N/RP?%B=#"=0GX"=/'@6C+,#ZZM
M--V2U3IR%TY,1O.(;%T:V7SCT.M:K)4UISM^0/F.^]RB^_;/_%N0WFZU0;4S;0'-0.'!G/[&UDPM?;YU8"6JOM)
M:1BHKJ;9H,2KINSM\9"XHBQ5#=.A#SGW52Z]7'6H"0=B+\EPN0H#KK\F,ZX%
M+9?MDDR/$9FBLXTK3Z42#"U[)NL(LEW,0T9 #T[]6H%O8BQDM:Y)Y-' B3;9
M+MKFI5\ 6IJ-0%^RTK825BT M(J.\8'4F0E54R-Y-V$EN8Q;+.KB4"Q_O5GH_U
MR.)77JQKAM AKX6]%(;(WR[;*YPZU_7F8#[UG#OUG.NHYUPHKFI;TV(NC/IR
MH]%L*1<>%):%";TU>8G@4)^QN'=2PIHF:?!MKY^I%18UFG%.=$O$P="
M*^ 2]-7@/ERQS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MV[[/N!Z0I*4/HZJ/V"K+ 4[6F-],R1$MG31L(OV'!R?FKTN;M(,(?W//2F'@J UM*M%]U]UI&'V.014Z-):XXK;8TLU@
MR4,Y4)21@(QC.I.:$#>O32C(OC64BJO C0B3V7.2_?]^$87K^2)S:L1Y=R=!
M-)<^P<_I(/1)XHWC*-@-GR)P4M>D'OB\L&L6Z
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M>RI5T1U_4M5UA%*)HIP;GOM-2@S?@"%*'H@/>V=:H"+=@9FJI;14,"9!EF6M%\ZP>?NG7%
M!\3A>Z+/A@2Q>-TX\91<0Q!]%@B_0[^TZW%!O/;A!MZ;Z'O%>R),90.]-@;;
M\)*2)\+Q8^1U$1;9I36
MCU5'7.1)W/D1-;I=J8TSB#VC" FP7EM+M!<"WB>[<"+5*?OJF6#2X4%=9\/A1FU$. TLC\]85H6@G;/E"#QX*>GRKZ)
M@NISI$YLMB!-Q-RUMX[XJBOKVMASZ4CF']R>EP()'FG=U8OSE$% XSB,-FEV
M/&Q[V\K@&B_+LB_U76#"]:D^']=];>Q^6IA&BW
M7 6K'(KT+'TJ'3K,TJ&%S*J4?,O%W4J3#H\U9M^NI:43QRTP]7ZJ]M_Z<@YHT7B5=(4Q\+_86_"7,-6, CV/JL4MJ6UL.L$W0JL-=!\0ZP
M GM@C<]OR2HK$\(LG*WC7H &HY,J#X. 30W.M6-
MZQ_[:^O&M8O_T\LU3QBQ:QHON'KBZWK(MR3[TME2)ARD4Q]_7Z4FK9RAP4W?$P3-7&T+SF VP-H*$SA<)\4:,L+QN3DJ<
MU5(T]50):S,HS5@
M8O7*JBC^)_&]C\3AZ_8*EN&V!-LD69"(YQA&9$&".&VAZ89+>^8Z#+5'IB>
M6 A6.Z_#D*&+Z\FX,4Y(RQ9E VK$!I5^7;?$TIYVU1B@@T_T?3!\B /Y:9CR
MNA178W^?B)B2VL0'" +$5D!EJ8[8W]&3DPM$X+'.)/^XB!Y$P(SN%E%^3RG\
M1UKEF.O!^7E#>*2@,E#&N?C$0H \6"IOUVY-=7#E0(%ZN
MM39KZ@3A!$QF8S8553JV#S_"4X]B=X]@66")H;J9^Y&[<&(RFD=$4(%?DK9?
M_09+;(7H"I:$W;GUY.FN9YFBU]HDP"Q,'-_H)"MNS\+-2MEK7?\]UJU4RH*&
MY>)'#XR=>,'[*\;9W/;L[LJ\?=TY!_A /1GHL"MO3S8.8Z7TW/+O]^R8KBP&
MT"W?99Y5]F,V6WR=>*D:O7AVTRS1YIPK3=M!/I5.!I;"*-JQP8T@*"=F*8YD
MH-IJAM;QX2@-@Q7=IBXAJ>6FRC;;3@/!]3"E;NRL*+,OM:^@0S9ZQ&*L6G8 &Y 2=I@V@P&'0C*ER!SS+F5/"R?OBP5+CD!@_R+)(I[S5
MGFE=M1Q6:UZ^4P+KX!-8R_*HGIUK[+=64;O$6(\Z/;E>
MU5G;QB,+D&9BXEZ:S$:>1[/$%]5"B?)O!\&0FJ4C57 ?AT%,VMJHBB[_KGH1"R0;)HL QX8SV7;M%F,ZC<(5B9+-[L'F4TR\47S.7SX][KBVQWP-FGIGWC2)@P[>8*D:.K)QOZ!1
M:J=N,EI#%?-;\-$P."-:+=CSC%[R?D0MYBET]D1V-;W81G<%\VWS@*GON&FPB!-X>6U=Z!J%Y8E&^XFTZA4VCZ)]>=?#
M0_GIS&18L[87(CBTWM!4AD&K$*$L-^F%W(B9N&7K3@V@FF2@Q0XU;09EKU)E
MC83K]K&I&0.'M-62 2W$,2 FIG=666]$)F/8A"N.8W?-<0CP5XZ%Q"!37AX9A)!'>"@X8V21W
M2>A^R7PQY^N(BQV):)C=3^(;\I3^DP*+U,89 I\4$<%H07<,?;YTV='0Y@N@
MM(ZF3YX?6/M&5]$M+RIP\4PBE\99.8$]K=M_57+9FPP[!/Z9X87E *Y*6ZM&
M;G&EDUOO>56[>G.G*RA+\MPC [6W_Q0K-Z0E0PIKAPN5U\H]S=TB@9?MU'L2
M+148(?ZN?^X>(1,DBP;SPVKR(#5$[DB2\!H7Q?R)]#_;?U"QV)3&&8+:4D0$
MJC0,P.LQSGLQEFM-DYU2S,PKJH 57MT2?LO BQ[MU>FI3#N4XTN.VY:5[^T'
M/V\I$:D+]8-,^/405&7MZO,KK=W6R:GVWM*E?*$5?#0,Y29:;8[[*7D>.8+3
M6+W51G"^@?!1Z+WVD-F:OZ!K=/$]_&8(ZDRPTAQTNXUM521**2D..#M;7']0G!PFC#_ILK*C,D7ZYK 4]6(%>FGK<(;&A=[(,_X^%\7
MHUYZ4CI3271W5HQ0 C";<)X2Q\M,;MJGITSQ4Z;X*5.\3QP"RQ07M)@WX^@]
M^RU&_BA(J$?]=9(6.,8)'50@!T9$#
MB6)NZ[JVK95%,:*#Y)8D.K2E5C:W=D^E.X#L7K5:':TRZT^U.OI13\)6K8YO
ML'&VW!W_\R]G5 O0%\88%PJ>]F^:XC[Y'&8:2>>B#]=$@B+E\_
M2JOXV_M)6GO6<1.=VO_"SP:S"\2+ANO4U](I5;ZNX[@:!31@G,:&OD81@N;L
M]=M;U6+"L#R.0BIZH$2;-X 2O\6F%ISK\;?7^,['83%*AB+89;?OFDGG*=$\
M!KN]HCJ%[.B^8QZ\ =LMP@;"9VDZBC5F5U):CH?CHEP7B'IOAGS/NH+$4V?#
M=57!2MX4#&)[YJ8B.=@5 -J*A"KJ.#?R/9V,I#25>$HB07'&#N7@8&)T$ZMRP^A-+C>MW?L3YX"XF7BQ\@GT:-:JW?A9X/4RV( X*[ZFO&<;#6\W-9U&,>3
MX.(Y8M1%N/"FTD1//Z?0B>:B"H[$OM0[$PT(&DJLU_7:H_AK@55<4D59M,B;A=<-^P2DDU@6WL1RF-;1@/WKH%+K21+D:(J3UKL2P8.M8C +OG#P2/USQ
MH2^>5TP#B4,XQ>],*L.@7Q:TF*"&#,KS]WY%9V$4A4_,^HK/-C<..RMLJEGA
MY"C[3$NQBC%#B[BLDF-9=TJFQPWIJ1/K>F;"M=H9K;G9Y5-GFFP,6NZ(/\?V
MD#4!6[]VC*)GM__<7D0SG4W&X?7U6/UNV[X;AC]4M;B6QU *&:+
M"WQ&CMV[^G9.),.I[FY=>3C\TR7Z^641"['9TYX=-&#DY!)D)MR
M!3ONWGEF]+(_L&OV- KGD:-2R*K]'-CFD9"1 -!!-V73?B@-LXY-F0O9WNMH
M>=H>J-2&G5K%R> DJ8WL,+=^KP(F"21.;IG<(5B_I>DQ3 -U'LHP ZR:JM/3D?:<#U2$[5>.%$<\+/]JR&KH*"51^KIV>B!AB CUMF[,H(N0]ORM5*X=T@YXW$T2MH@=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MUM63N+CB_:T<*X/$S/42U!VH%%I?=5)PX#)C.;:1C'E,G..&T&?Q5PV/=M354"
MCDR&[<_57(7G:6B2$7J IX>N4

\+LD6<
MDYC. YY\R)>S,T;53&KX:?N5I:0J+]UP #+>M[-W@?5#3+ZN>;3R(]GW"^Y6
M==\P(%.'*PWFV;3IT]DM6851LFNCBJK,-4G4]K))<%0N7GSX$DDM\
MK]A4\A?T2#V9[8.TJGZM^&#Z$1379-.YH$$22CTL!550#M#%I$X:L+_>UD(BJ0U;52IVBI.%2Q((;EDM)*Q*#GFK5ELAKD&!D9@GRZ4\L5
M4[7?W';%?D;:J>O*J>O*J>N*]:XK%]<3]<2VPB\/ >WBVK"K9YUZVG1SE>
MM6G53:$CQI]ZVP@V]S!ZV]P2-C1U$^*E.NA30*WWN:DA8;!,K(,5.HZQUYJM
ME0<5IIZYMB/:C6CZ!#::1X1D==E&7A:M/2P:AF>X7]MN[*%$ 'PR5R_"E(33C7&^RD=M47'#>Y'+5D_#I?+,,M?B,^M87]B3%IP2P8*6!<@/1Y]B,(XGD:A2XBG%(! ;A*<*NPC%(\
MKD=H-H\7NJFQ_6HMT-, :/:'??!S[:!8UJO*2K6[M.]OT[J@7[ +(F_#U1[I\D@X6D>Z(FU$WY@4
MUMQ-OV%W![;J& S7ZH H5E'3\K1!?FOF!-K3<4W3HP0,Y?)XF"JB9GW:,+\S
MU@Z\2%T6'IF>UNUA%@Z()LQUR]-&^?NV'LW3$^P GF"+5X//-%F$ZR1O)Z+\
MCM<\!K;-K@2V A08H2IYT_8+QUUMD6F4EOQY\^:'UWEO&&6F=C(MOHM521*Z@1SLS5CWU-M:-_P)I5']-A]YAZ-E
M MWEE7.T]FCQ=B&]?9YNGBF+.%QAU-Z\*0V$<5[*5F-\HSR9,B=3YF3*G$R9
MDRDS2%.FXJXIV"(-Q[6V7ZHZ=-MSN+:1M_Y)C.1A$*^("YH*=UH[(^U8LNA>
M2(E8YS +4&@7A<8'/5O'-&"CCD.V;#=I##UKAE<\(E(DF3[*$D"Z3Y[^^RM.
M!Z^ZQO_V_P%02P$"% ,4 " 7BME:/+.CP0AT P#N[AP &0
M @ $ 96$P,C0V-C(S+3(P9E]PM !>*V5I>QIAM+FAT;5!+ 0(4 Q0 ( !>*V5I9A$I8.00 #44 = "
M 0Z$ P!E83 R-#8V,C,P,65X,3,M,5]PM !>*V5J8Z7BVKP, +0, = " 8*( P!E83 R-#8V,C,P
M,65X,C,M,5]P*V5JSS&>R!A U$
M = " 6R, P!E83 R-#8V,C,P,65X.3M+FAT;5!+ 0(4 Q0 ( !>*V5K;MT@GX!H /$; + "
M :V< P!F:6Y?,# Q+FIP9U!+ 0(4 Q0 ( !>*V5I_G7\@8 \ 'P0 +
M " ;:W P!F:6Y?,# R+FIP9U!+ 0(4 Q0 ( !>*V5J)
M^Y6AH]\ +SW - " 3_' P!I;6%G95\P,#$N:G!G4$L!
M A0#% @ %XK96@@3NCG2HP TJP T ( !#:<$ &EM
M86=E7S P,BYJ<&=02P$"% ,4 " 7BME:DXJ?NU$6 0#X,0$ #0
M @ $*2P4 :6UA9V5?,# S+FIP9U!+ 0(4 Q0 ( !>*V5I MP,0
MFQ4! (TU 0 - " 89A!@!I;6%G95\P,#0N:G!G4$L! A0#
M% @ %XK96GW9C&8NY@ UP$! T ( !3'<' &EM86=E
M7S P-2YJ<&=02P$"% ,4 " 7BME:YBA]Y'&M #QQ0 #0
M @ &E70@ :6UA9V5?,# V+FIP9U!+ 0(4 Q0 ( !>*V5HH#P;IHT8!
M &1E 0 - " 4$+"0!I;6%G95\P,#M @ %XK96BV?>6<;CP XI$ T ( !#U(* &EM86=E7S P
M."YJ<&=02P$"% ,4 " 7BME:1X,OH7HD "CXP$ $
M@ %5X0H <&)M+3(P,C4P,S,Q+GAS9%!+ 0(4 Q0 ( !>*V5K0N/=>[ X
M !RV 4 " ?T%"P!P8FTM,C R-3 S,S%?8V%L+GAM;%!+
M 0(4 Q0 ( !>*V5IEP$]3<5L ,8!!@ 4 " 1L5"P!P
M8FTM,C R-3 S,S%?9&5F+GAM;%!+ 0(4 Q0 ( !>*V5H:%5-&QMT $CQ
M"@ 4 " ;YP"P!P8FTM,C R-3 S,S%?;&%B+GAM;%!+ 0(4
M Q0 ( !>*V5J%I%N:'5P $0E!@ 4 " ;9.# !P8FTM
F,C R-3 S,S%?<')E+GAM;%!+!08 %0 5 $X% %JPP !

end



XML
119
ea0246623-20f_psyence_htm.xml
IDEA: XBRL DOCUMENT



xmlns="http://www.xbrl.org/2003/instance"
xmlns:country="http://xbrl.sec.gov/country/2024"
xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
xmlns:dei="http://xbrl.sec.gov/dei/2024"
xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:pbm="http://www.psyencebiomed.com/20250331"
xmlns:srt="http://fasb.org/srt/2024"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:xlink="http://www.w3.org/1999/xlink"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">



0001985062


2024-04-01
2025-03-31




0001985062

dei:BusinessContactMember



2024-04-01
2025-03-31




0001985062

pbm:CommonSharesWithoutParValueMember



2024-04-01
2025-03-31




0001985062

pbm:WarrantsEachExercisableToPurchaseOneCommonShareAtAnExercisePriceOf1150PerShareMember



2024-04-01
2025-03-31




0001985062


2025-03-31




0001985062


2024-03-31




0001985062

pbm:NcacSponsorMember



2025-03-31




0001985062

pbm:NcacSponsorMember



2024-03-31




0001985062

ifrs-full:ParentMember



2025-03-31




0001985062

ifrs-full:ParentMember



2024-03-31




0001985062


2023-04-01
2024-03-31




0001985062


2022-04-01
2023-03-31




0001985062

ifrs-full:OrdinarySharesMember



2022-03-31




0001985062

ifrs-full:IssuedCapitalMember



2022-03-31




0001985062

ifrs-full:WarrantReserveMember



2022-03-31




0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2022-03-31




0001985062

ifrs-full:RetainedEarningsMember



2022-03-31




0001985062


2022-03-31




0001985062

ifrs-full:IssuedCapitalMember



2022-04-01
2023-03-31




0001985062

ifrs-full:WarrantReserveMember



2022-04-01
2023-03-31




0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2022-04-01
2023-03-31




0001985062

ifrs-full:RetainedEarningsMember



2022-04-01
2023-03-31




0001985062

ifrs-full:OrdinarySharesMember



2023-03-31




0001985062

ifrs-full:IssuedCapitalMember



2023-03-31




0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2023-03-31




0001985062

ifrs-full:RetainedEarningsMember



2023-03-31




0001985062


2023-03-31




0001985062

ifrs-full:WarrantReserveMember



2023-03-31




0001985062

ifrs-full:OrdinarySharesMember



2023-04-01
2024-03-31




0001985062

ifrs-full:IssuedCapitalMember



2023-04-01
2024-03-31




0001985062

ifrs-full:WarrantReserveMember



2023-04-01
2024-03-31




0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2023-04-01
2024-03-31




0001985062

ifrs-full:RetainedEarningsMember



2023-04-01
2024-03-31




0001985062

ifrs-full:OrdinarySharesMember



2024-03-31




0001985062

ifrs-full:IssuedCapitalMember



2024-03-31




0001985062

ifrs-full:WarrantReserveMember



2024-03-31




0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2024-03-31




0001985062

ifrs-full:RetainedEarningsMember



2024-03-31




0001985062

ifrs-full:OrdinarySharesMember



2024-04-01
2025-03-31




0001985062

ifrs-full:IssuedCapitalMember



2024-04-01
2025-03-31




0001985062

ifrs-full:WarrantReserveMember



2024-04-01
2025-03-31




0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2024-04-01
2025-03-31




0001985062

ifrs-full:RetainedEarningsMember



2024-04-01
2025-03-31




0001985062

ifrs-full:OrdinarySharesMember



2025-03-31




0001985062

ifrs-full:IssuedCapitalMember



2025-03-31




0001985062

ifrs-full:WarrantReserveMember



2025-03-31




0001985062

ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember



2025-03-31




0001985062

ifrs-full:RetainedEarningsMember



2025-03-31




0001985062

pbm:PsyenceAustraliaPtyLtdMember



2024-04-01
2025-03-31




0001985062

pbm:PysenceBiomedIICorpMember



2024-04-01
2025-03-31




0001985062

pbm:NewcourtAcquisitionCorpMember



2024-04-01
2025-03-31




0001985062

pbm:CashAndCashEquivalentMember



2024-04-01
2025-03-31




0001985062

pbm:RestrictedCashMember



2024-04-01
2025-03-31




0001985062

pbm:OtherReceivablesMember



2024-04-01
2025-03-31




0001985062

pbm:InvestmentInPsyenceLabsLtdMember



2024-04-01
2025-03-31




0001985062

pbm:AccountsPayableAndAccruedLiabilitieMember



2024-04-01
2025-03-31




0001985062

pbm:DerivativeWarrantLiabilitiesMember



2024-04-01
2025-03-31




0001985062

pbm:ConvertibleNoteLiabilityMember



2024-04-01
2025-03-31




0001985062

pbm:DueToNCACSponsorMember



2024-04-01
2025-03-31




0001985062

pbm:DueToPsyenceGroupIncMember



2024-04-01
2025-03-31




0001985062

ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember



2023-03-31




0001985062

ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember



2023-03-31




0001985062

ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember



2022-03-31




0001985062

ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember



2022-03-31




0001985062

ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember



2022-04-01
2023-03-31




0001985062

ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember



2022-04-01
2023-03-31




0001985062


2024-01-25




0001985062

pbm:NcacMember



2024-01-25




0001985062

pbm:NcacMember



2025-03-31




0001985062

pbm:RTOMember



2024-04-01
2025-03-31




0001985062

pbm:NcacMember



2024-04-01
2025-03-31




0001985062

pbm:NcacMember



2025-03-31




0001985062

ifrs-full:ComputerEquipmentMember



2023-03-31




0001985062

ifrs-full:GrossCarryingAmountMember
ifrs-full:ComputerEquipmentMember



2023-04-01
2024-03-31




0001985062

ifrs-full:GrossCarryingAmountMember
ifrs-full:ComputerEquipmentMember



2024-03-31




0001985062

ifrs-full:GrossCarryingAmountMember
ifrs-full:ComputerEquipmentMember



2024-04-01
2025-03-31




0001985062

ifrs-full:GrossCarryingAmountMember
ifrs-full:ComputerEquipmentMember



2025-03-31




0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2023-03-31




0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2023-04-01
2024-03-31




0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2024-03-31




0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2024-04-01
2025-03-31




0001985062

ifrs-full:AccumulatedDepreciationAndAmortisationMember
ifrs-full:ComputerEquipmentMember



2025-03-31




0001985062

ifrs-full:ComputerEquipmentMember



2024-03-31




0001985062

ifrs-full:ComputerEquipmentMember



2025-03-31




0001985062

pbm:InvestorsMember
ifrs-full:TopOfRangeMember
ifrs-full:ConvertibleInstrumentsMember



2024-01-15




0001985062

pbm:FirstTrancheNoteMember
pbm:InvestorsMember



2024-01-25




0001985062

pbm:FirstTrancheNoteMember
pbm:InvestorsMember



2024-01-25
2024-01-25




0001985062


2024-07-31




0001985062


2024-07-31
2024-07-31




0001985062

pbm:SecondTrancheNotesMember



2024-07-31




0001985062

pbm:InvestorsMember
ifrs-full:OrdinarySharesMember



2024-08-20




0001985062

pbm:InvestorsMember
ifrs-full:OrdinarySharesMember



2024-08-01
2024-08-20




0001985062

pbm:InvestorsMember
ifrs-full:WarrantsMember



2024-08-20




0001985062

pbm:InvestorsMember



2024-08-20




0001985062

pbm:InvestorsMember



2024-08-20
2024-08-20




0001985062

pbm:InvestorsMember



2025-03-31




0001985062

pbm:InvestorsMember



2024-04-01
2025-03-31




0001985062

pbm:InvestorsMember
ifrs-full:WarrantsMember



2025-03-31




0001985062

pbm:FirstTrancheNoteMember



2024-09-30




0001985062


2024-09-30
2024-09-30




0001985062

ifrs-full:ConvertibleInstrumentsMember



2024-09-30
2024-09-30




0001985062

ifrs-full:BottomOfRangeMember
ifrs-full:ConvertibleInstrumentsMember



2024-09-30
2024-09-30




0001985062

ifrs-full:TopOfRangeMember
ifrs-full:ConvertibleInstrumentsMember



2024-09-30
2024-09-30




0001985062

ifrs-full:ConvertibleInstrumentsMember



2024-04-01
2025-03-31




0001985062

ifrs-full:ConvertibleInstrumentsMember



2023-04-01
2024-03-31




0001985062

ifrs-full:ConvertibleInstrumentsMember



2022-04-01
2023-03-31




0001985062

ifrs-full:ConvertibleInstrumentsMember



2024-03-31




0001985062

pbm:SharePriceMeasurementInputMember



2024-08-20




0001985062

pbm:ExpectedDividendYieldMeasurementInputMember



2024-08-20




0001985062

pbm:ExercisePriceMeasurementInputMember



2024-08-20




0001985062

ifrs-full:InterestRateMeasurementInputMember



2024-08-20




0001985062

pbm:ExpectedLifeMeasurementInputMember



2024-08-20




0001985062

ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember



2024-08-20




0001985062

pbm:ExpiryDateMeasurementInputMember



2024-08-20




0001985062

pbm:SharePriceMeasurementInputMember



2024-03-31




0001985062

pbm:NotePrincipalAmountMeasurementInputMember



2024-03-31




0001985062

ifrs-full:ConstantPrepaymentRateMeasurementInputMember



2024-03-31




0001985062

pbm:DiscountRateSharesMeasurementInputMember



2024-03-31




0001985062

ifrs-full:DiscountRateMeasurementInputMember



2024-03-31




0001985062

pbm:VolatilityAnnualMember



2024-03-31




0001985062

ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember



2024-03-31




0001985062

ifrs-full:InterestRateMeasurementInputMember



2024-03-31




0001985062

pbm:PublicWarrantsMember



2025-03-31




0001985062

pbm:PrivateWarrantsMember
pbm:DerivativeWarrantLiabilitiesMember



2025-03-31




0001985062

pbm:PublicWarrantsMember
pbm:DerivativeWarrantLiabilitiesMember



2024-03-31




0001985062

pbm:PrivateWarrantsMember
pbm:DerivativeWarrantLiabilitiesMember



2024-03-31




0001985062

pbm:PublicWarrantsMember



2024-04-01
2025-03-31




0001985062

pbm:PublicWarrantsMember



2024-03-31




0001985062

pbm:PrivateWarrantsMember



2024-03-31




0001985062

pbm:DerivativeWarrantLiabilitiesMember



2024-04-01
2025-03-31




0001985062

pbm:DerivativeWarrantLiabilitiesMember



2025-03-31




0001985062

pbm:DerivativeWarrantLiabilitiesMember



2024-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:SharePriceMeasurementInputMember



2025-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:SharePriceMeasurementInputMember



2024-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExpectedDividendYieldMeasurementInputMember



2025-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExpectedDividendYieldMeasurementInputMember



2024-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExercisePriceMeasurementInputMember



2025-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExercisePriceMeasurementInputMember



2024-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
ifrs-full:InterestRateMeasurementInputMember



2025-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
ifrs-full:InterestRateMeasurementInputMember



2024-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExpectedLifeMeasurementInputMember



2025-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
pbm:ExpectedLifeMeasurementInputMember



2024-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember



2025-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember
ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember



2024-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember



2025-03-31




0001985062

ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31




0001985062


2024-01-24




0001985062


2024-01-25
2024-03-31




0001985062

pbm:PublicWarrantsMember



2023-03-31




0001985062

pbm:PrivateWarrantsMember



2023-03-31




0001985062

pbm:PublicWarrantsMember



2023-04-01
2024-03-31




0001985062

pbm:PrivateWarrantsMember



2023-04-01
2024-03-31




0001985062

pbm:PrivateWarrantsMember



2024-04-01
2025-03-31




0001985062

pbm:PrivateWarrantsMember



2025-03-31




0001985062

ifrs-full:WarrantsMember



2024-04-01
2025-03-31




0001985062

ifrs-full:WarrantsMember



2025-03-31




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
ifrs-full:ParentMember



2024-01-25




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
ifrs-full:ParentMember



2024-01-25
2024-01-25




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
ifrs-full:ParentMember



2025-01-25
2025-01-25




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-03-31




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-01-25
2024-01-25




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2025-01-25
2025-01-25




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-01-25




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-09-30




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-09-30
2024-09-30




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-10-25




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-11-26
2024-11-26




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-12-31




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:PGIMember



2024-04-01
2025-03-31




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-09-30




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember
pbm:NCACNoteMember



2024-09-30
2024-09-30




0001985062

pbm:NCACNoteMember



2024-12-31




0001985062

pbm:UnsecuredConvertiblePromissoryNotesMember



2024-04-01
2025-03-31




0001985062

pbm:NCACNoteMember



2025-03-31




0001985062

pbm:NCACNoteMember



2024-03-31




0001985062

pbm:NCACNoteMember



2024-04-01
2025-03-31




0001985062

pbm:NCACNoteMember



2023-04-01
2024-03-31




0001985062

pbm:ELOCMember



2024-08-28
2024-08-28




0001985062

pbm:WhiteLionMember



2025-03-31




0001985062

pbm:ELOCMember



2024-04-01
2025-03-31




0001985062

pbm:ELOCMember



2025-03-31




0001985062

pbm:PsyenceLabsLtdMember



2024-10-28




0001985062

ifrs-full:OrdinarySharesMember



2024-10-28




0001985062


2024-10-28




0001985062


2024-10-28
2024-10-28




0001985062

pbm:PrivatePlacementAndWarrantsMember



2024-12-24




0001985062

pbm:PrivatePlacementAndWarrantsMember



2029-12-24
2029-12-24




0001985062

pbm:PrivatePlacementAndWarrantsMember



2029-12-24




0001985062

pbm:PrivatePlacementAndWarrantsMember



2024-04-01
2025-03-31




0001985062

pbm:PrivatePlacementAndWarrantsMember



2025-03-31




0001985062

pbm:PrivatePlacementAndWarrantsMember



2026-12-24
2026-12-24




0001985062

pbm:FairValueAllocationAssumptionsMember



2025-03-31




0001985062

pbm:PrefundedWarrantsMember
pbm:SharePriceWarrantMember



2025-03-31




0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:SharePriceWarrantMember



2025-03-31




0001985062

pbm:WarrantWith2YearExpiryMember
pbm:SharePriceWarrantMember



2025-03-31




0001985062

pbm:PrefundedWarrantsMember
pbm:ExpectedDividendYieldWarrantMember



2025-03-31




0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExpectedDividendYieldWarrantMember



2025-03-31




0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExpectedDividendYieldWarrantMember



2025-03-31




0001985062

pbm:PrefundedWarrantsMember
pbm:ExercisePriceWarrantMember



2025-03-31




0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExercisePriceWarrantMember



2025-03-31




0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExercisePriceWarrantMember



2025-03-31




0001985062

pbm:PrefundedWarrantsMember
pbm:RiskfreeInterestRateWarrantMember



2025-03-31




0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:RiskfreeInterestRateWarrantMember



2025-03-31




0001985062

pbm:WarrantWith2YearExpiryMember
pbm:RiskfreeInterestRateWarrantMember



2025-03-31




0001985062

pbm:PrefundedWarrantsMember
pbm:ExpectedLifeWarrantMember



2025-03-31




0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExpectedLifeWarrantMember



2025-03-31




0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExpectedLifeWarrantMember



2025-03-31




0001985062

pbm:PrefundedWarrantsMember
pbm:ExpectedVolatilityWarrantMember



2025-03-31




0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExpectedVolatilityWarrantMember



2025-03-31




0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExpectedVolatilityWarrantMember



2025-03-31




0001985062

pbm:PrefundedWarrantsMember
pbm:ExpiryDateWarrantMember



2025-03-31




0001985062

pbm:WarrantsWith5YearExpiryMember
pbm:ExpiryDateWarrantMember



2025-03-31




0001985062

pbm:WarrantWith2YearExpiryMember
pbm:ExpiryDateWarrantMember



2025-03-31




0001985062

ifrs-full:OrdinarySharesMember



2025-03-31




0001985062

ifrs-full:OrdinarySharesMember



2024-03-31




0001985062

pbm:PGIMember



2024-01-25




0001985062

pbm:NcacMember



2024-01-25




0001985062

pbm:ThirdPartyAdvisorsMember



2024-01-25




0001985062

pbm:RTOTransactionMember



2024-01-25




0001985062

ifrs-full:OrdinarySharesMember



2024-03-31




0001985062

ifrs-full:WarrantsMember



2025-03-31




0001985062

ifrs-full:WarrantsMember



2024-03-31




0001985062

pbm:IssuedAndOutstandingWarrantsMember



2024-03-31




0001985062

pbm:IssuedAndOutstandingWarrantsMember



2025-03-31




0001985062

pbm:IssuedAndOutstandingWarrantsMember



2024-04-01
2025-03-31




0001985062

pbm:AugustMember



2025-03-31




0001985062

pbm:DecemberTwenteyFourMember



2025-03-31




0001985062

pbm:DecemberTwentyFourOneMember



2025-03-31




0001985062

pbm:DecemberTwentyFourTwoMember



2025-03-31




0001985062

pbm:ResearchAndDevelopmentExpensesMember



2023-04-01
2024-03-31




0001985062

pbm:PsyenceAustraliaPtyLtdMember



2023-08-21




0001985062

pbm:RHCapitalFinanceCoLLCMember



2024-04-01
2025-03-31




0001985062

pbm:RHCapitalFinanceCoLLCMember



2025-03-31




0001985062

pbm:RHCapitalFinanceCoLLCMember



2023-04-01
2024-03-31




0001985062

country:CA



2024-04-01
2025-03-31




0001985062

country:CA



2023-04-01
2024-03-31




0001985062

ifrs-full:ComputerEquipmentMember



2025-03-31




0001985062

ifrs-full:ComputerEquipmentMember



2024-03-31




0001985062

country:CA
ifrs-full:OtherTemporaryDifferencesMember



2025-03-31




0001985062

country:CA
ifrs-full:OtherTemporaryDifferencesMember



2024-03-31




0001985062

pbm:OtherMember



2025-03-31




0001985062

pbm:OtherMember



2024-03-31




0001985062

country:CA
pbm:NonCapitalLossesCarriedForwardMember



2025-03-31




0001985062

country:CA
pbm:NonCapitalLossesCarriedForwardMember



2024-03-31




0001985062

country:AU
pbm:NonCapitalLossesCarriedForwardMember



2025-03-31




0001985062

country:AU
pbm:NonCapitalLossesCarriedForwardMember



2024-03-31




0001985062

pbm:TaxYear2044Member
country:CA



2025-03-31




0001985062

pbm:TaxYear2044Member
country:AU



2025-03-31




0001985062

pbm:TaxYear2045Member
country:CA



2025-03-31




0001985062

pbm:IndefinitePeriodMember
country:CA



2025-03-31




0001985062

pbm:IndefinitePeriodMember
country:AU



2025-03-31




0001985062

country:CA



2025-03-31




0001985062

country:AU



2025-03-31




0001985062

pbm:InvestmentInPsyenceLabsLtdMember
ifrs-full:Level1OfFairValueHierarchyMember



2025-03-31




0001985062

pbm:InvestmentInPsyenceLabsLtdMember
ifrs-full:Level2OfFairValueHierarchyMember



2025-03-31




0001985062

pbm:InvestmentInPsyenceLabsLtdMember
ifrs-full:Level3OfFairValueHierarchyMember



2025-03-31




0001985062

pbm:InvestmentInPsyenceLabsLtdMember



2025-03-31




0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level1OfFairValueHierarchyMember



2025-03-31




0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level2OfFairValueHierarchyMember



2025-03-31




0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level3OfFairValueHierarchyMember



2025-03-31




0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember



2025-03-31




0001985062

ifrs-full:Level1OfFairValueHierarchyMember



2025-03-31




0001985062

ifrs-full:Level3OfFairValueHierarchyMember



2025-03-31




0001985062

pbm:PrivateWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:PrivateWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:PrivateWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:PrivateWarrantsMember
pbm:WarrantLiabilitiesMember



2024-03-31




0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:PublicWarrantsMember
pbm:WarrantLiabilitiesMember



2024-03-31




0001985062

pbm:IfrsConvertibleDebtMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:IfrsConvertibleDebtMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:IfrsConvertibleDebtMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:IfrsConvertibleDebtMember



2024-03-31




0001985062

pbm:NcacSponsorMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:NcacSponsorMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:NcacSponsorMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:IfrsPromissoryNoteMember
ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:IfrsPromissoryNoteMember
ifrs-full:Level2OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:IfrsPromissoryNoteMember
ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:IfrsPromissoryNoteMember



2024-03-31




0001985062

ifrs-full:Level1OfFairValueHierarchyMember



2024-03-31




0001985062

ifrs-full:Level3OfFairValueHierarchyMember



2024-03-31




0001985062

pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember



2025-03-31




0001985062

pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember
ifrs-full:NotLaterThanOneYearMember



2025-03-01




0001985062

pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember
ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember



2025-03-31




0001985062

ifrs-full:NotLaterThanOneYearMember



2025-03-01




0001985062

ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember



2025-03-31




0001985062

ifrs-full:OrdinarySharesMember
ifrs-full:MajorOrdinaryShareTransactionsMember



2025-04-15




0001985062

ifrs-full:MajorOrdinaryShareTransactionsMember



2025-04-15




0001985062

ifrs-full:MajorOrdinaryShareTransactionsMember
ifrs-full:RestrictedShareUnitsMember



2025-04-17




0001985062

ifrs-full:MajorOrdinaryShareTransactionsMember



2025-05-05
2025-05-05




0001985062

pbm:ELOCMember



2025-03-31




0001985062

pbm:ELOCMember



2024-04-01
2025-03-31



shares


iso4217:USD




iso4217:USD


shares




pure


iso4217:CAD


iso4217:AUD

20-F
false
true
2025-03-31
--03-31
2025
false
false
001-41937
Psyence Biomedical Ltd.
A6
CA
121 Richmond Street West
Penthouse Suite 1300
Toronto
ON
M5H 2K1
Neil Maresky
121 Richmond Street West
Penthouse Suite 1300
Toronto
ON
M5H 2K1
+1 (416)
346-7764
Common shares, without par value
PBM
NASDAQ
Warrants, each exercisable to purchase one Common Share at an exercise price of $6,874.13 per share
PBMWW
NASDAQ
contextRef="c4"
decimals="INF"
id="ixv-20117"
unitRef="shares">568021
No
No
Yes
Yes
Non-accelerated Filer
true
false
false
false
International Financial Reporting Standards
false
true
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has developed and implemented cybersecurity
risk management measures intended to protect the confidentiality, integrity, and availability of its critical systems and information.
The Company’s cybersecurity risk management measures are integrated into its overall enterprise risk management program, and shares
common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal,
compliance, strategic, operational, and financial risk areas.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The cybersecurity risk management measures set
out the foundation of the process for assessing, identifying and managing material risks from cybersecurity threats and provide guidance
for response plan when facing cybersecurity threats. The Company has not engaged assessors or other third parties in connection with such
processes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There can be no assurance that the Company’s
cybersecurity risk management measures and processes, including its policies, controls or procedures, will be fully implemented, complied
with or effective in protecting the Company’s systems and information. The Company has not identified risks from known cybersecurity
threats, including as a result of any prior cybersecurity incidents, that have materially affected the Company, including its operations,
business strategy, results of operations, or financial condition. The Company faces risks from cybersecurity threats that, if realized,
are reasonably likely to materially affect it, including the Company’s operations, business strategy, results of operations, or
financial condition. Many of the laws and regulations regarding cybersecurity, information security, privacy and data protection applicable
to the Company are subject to change and uncertain interpretation, and any failure or perceived failure to comply with such laws and regulations
could result in negative publicity, legal proceedings, suspension or disruption of operations, increased cost of operations, or otherwise
harm the business of the Company.</p>
The Company’s cybersecurity risk management measures are integrated into its overall enterprise risk management program, and shares
common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal,
compliance, strategic, operational, and financial risk areas.
true
false
The Company has not identified risks from known cybersecurity
threats, including as a result of any prior cybersecurity incidents, that have materially affected the Company, including its operations,
business strategy, results of operations, or financial condition
false
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cybersecurity Governance</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board has general oversight power over cybersecurity
issues and has delegated daily supervision responsibility to the Company’s Finance department. The Finance department, consisting
of personnel with relevant expertise in cybersecurity management, overseas the implementation of the Company’s cybersecurity risk
management measures and reports to the Board any material cybersecurity incidents. The Finance department supervises efforts to prevent,
detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal and
external security personnel, threat intelligence and other information obtained from governmental, public or private sources, and alerts
and reports produced by security tools deployed in the IT environment.</p>
The Board has general oversight power over cybersecurity
issues and has delegated daily supervision responsibility to the Company’s Finance department.
The Finance department, consisting
of personnel with relevant expertise in cybersecurity management, overseas the implementation of the Company’s cybersecurity risk
management measures and reports to the Board any material cybersecurity incidents.
1930
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Opinion on the Consolidated Financial
Statements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We have audited the accompanying
consolidated statements of financial position of Psyence Biomedical Ltd. (the “Company”) as at March 31, 2025 and 2024, and
the related consolidated statements of net income (loss) and comprehensive income (loss), changes in shareholders’ equity (deficit),
and cash flows for each of the years in the three-year period ended March 31, 2025, and the related notes (collectively referred to as
the “consolidated financial statements”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In our opinion, the consolidated
financial statements present fairly, in all material respects, the consolidated financial position of the Company as at March 31, 2025
and 2024, and the results of its consolidated operations and its consolidated cash flows for each of the years in the three-year period
ended March 31, 2025, in conformity with IFRS<sup>®</sup> Accounting Standards as issued by the International Accounting Standards
Board.</p>
Toronto, Canada
MNP LLP
6135166
733188
35964
29611
137348
41747
251796
322126
6560274
1126672
11096
5487
745000
7316370
1132159
394270
755202
7657397
200096
901608
1474256
1316236
594366
12104699
61752305
46125397
1065705
-56447204
-57458994
351198
361057
6722004
-10972540
7316370
1132159
483530
80603
7029
342168
954593
1608895
1209847
557904
366435
1623209
1158484
1252510
-3658754
-2751584
-3234869
879344
4268
240
95787
2134
1554
9270
52941
-7317
-2695
26912
41481605
2461025
281500
-3357628
5157397
-694516
306250
-705565
108288
185064
22967
1011790
-51159048
-3206403
-9859
3715
-89828
191982
1001931
-50963351
-3296231
contextRef="c0"
decimals="2"
id="ixv-20220"
unitRef="usdPershares">5.24
contextRef="c0"
decimals="2"
id="ixv-20221"
unitRef="usdPershares">5.24
contextRef="c10"
decimals="2"
id="ixv-20222"
unitRef="usdPershares">-4674.25
contextRef="c10"
decimals="2"
id="ixv-20223"
unitRef="usdPershares">-4674.25
contextRef="c11"
decimals="2"
id="ixv-20224"
unitRef="usdPershares">-394.06
contextRef="c11"
decimals="2"
id="ixv-20225"
unitRef="usdPershares">-394.06
contextRef="c0"
decimals="0"
id="ixv-20226"
unitRef="shares">193043
contextRef="c0"
decimals="0"
id="ixv-20227"
unitRef="shares">193043
contextRef="c10"
decimals="0"
id="ixv-20228"
unitRef="shares">10903
contextRef="c10"
decimals="0"
id="ixv-20229"
unitRef="shares">10903
contextRef="c11"
decimals="0"
id="ixv-20230"
unitRef="shares">8365
contextRef="c11"
decimals="0"
id="ixv-20231"
unitRef="shares">8365
4537055
255188
-3093543
1698700
1397086
1397086
-3206403
-3206403
-89828
-89828
5934141
165360
-6299946
-200445
5934141
165360
-6299946
-200445
contextRef="c28"
decimals="INF"
id="ixv-20250"
unitRef="shares">8365
contextRef="c28"
decimals="INF"
id="ixv-20251"
unitRef="shares">13040
37336416
37336416
contextRef="c28"
decimals="INF"
id="ixv-20254"
unitRef="shares">251
718500
718500
contextRef="c28"
decimals="INF"
id="ixv-20257"
unitRef="shares">746
2136340
2136340
-51159048
-51159048
195697
195697
contextRef="c33"
decimals="INF"
id="ixv-20264"
unitRef="shares">22402
46125397
361057
-57458994
-10972540
contextRef="c33"
decimals="INF"
id="ixv-20269"
unitRef="shares">22402
46125397
361057
-57458994
-10972540
contextRef="c38"
decimals="INF"
id="ixv-20274"
unitRef="shares">586
241379
241379
contextRef="c38"
decimals="INF"
id="ixv-20277"
unitRef="shares">38156
4617286
4617286
682482
682482
contextRef="c38"
decimals="INF"
id="ixv-20282"
unitRef="shares">222292
6410395
6410395
contextRef="c38"
decimals="INF"
id="ixv-20285"
unitRef="shares">1104
192060
192060
contextRef="c38"
decimals="INF"
id="ixv-20288"
unitRef="shares">99540
2084927
2084927
contextRef="c38"
decimals="INF"
id="ixv-20291"
unitRef="shares">35594
722033
722033
contextRef="c38"
decimals="INF"
id="ixv-20294"
unitRef="shares">47679
273179
1468872
1742051
contextRef="c38"
decimals="INF"
id="ixv-20298"
unitRef="shares">100668
1085649
-1085649
1011790
1011790
-9859
-9859
contextRef="c43"
decimals="INF"
id="ixv-20305"
unitRef="shares">568021
61752305
1065705
351198
-56447204
6722004
1011790
-51159048
-3206403
-3357628
5157397
-694516
306250
-705565
300270
185064
-22967
281500
317882
221287
241379
4268
240
-9860
3660
-84499
41481605
2100830
-95601
107622
-109858
70330
-245075
-71665
-360932
-1035498
1659058
-3734238
-2945365
-1592080
9877
5727
-6353
-16230
-5727
1000000
2500000
150000
1172923
6410395
1742051
9152446
2350000
1172923
5401978
-601092
-419157
733188
1334280
1753437
6135166
733188
1334280
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>1. Nature of operations and going concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Psyence Biomedical Ltd. (the <b>“Company”</b>
or <b>“PBM”</b>), is a life science biotechnology company traded on the Nasdaq exchange (NASDAQ: PBM) that is focused on the
development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The Company is working towards developing
psychedelic therapeutics to treat mental health disorders. The Company is currently conducting research through clinical trials to evaluate
the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with a cancer diagnosis in a palliative
care context (the “<b>Clinical Trials</b>”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company’s registered office is at 121
Richmond Street West, PH Suite 1300, Toronto, Ontario M5H 2K1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On November 26, 2024, the Company consolidated
its common shares and warrants on the basis of 75:1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On May 5, 2025, the Company consolidated its common
shares and warrants on the basis of 7.97:1. All prior share capital information has been presented based on these ratios.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Business Combination Agreement and NASDAQ listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 9, 2023 Psyence Group Inc. (“<b>PGI</b>”
or “<b>Psyence Group</b>”) entered into a definitive business combination agreement, as amended (the “<b>Business Combination
Agreement</b>” or “<b>BCA</b>”) with Newcourt Acquisition Corp. (NASDAQ: NCAC), a special purpose acquisition company
(“<b>SPAC</b>”). The agreement aimed to create a public company leveraging natural psilocybin for palliative care treatment.
PGI is a listed Canadian company that contributed its clinical trial activities to the Company as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The transaction concluded on January 25, 2024,
with PBM's listing on NASDAQ. This transaction involved PBM acquiring the SPAC through a merger, thereby making the SPAC a wholly-owned
subsidiary of PBM.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Transaction Overview:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 25, 2024 (the “<b>Closing Date</b>”),
the Company, a corporation organized under the laws of Ontario, Canada, completed the previously announced business combination (the “<b>RTO
Transaction</b>”) as per the BCA (Note 5). The parties involved in the BCA included:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">Psyence Group Inc.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">Newcourt Acquisition Corp., a Cayman Islands exempted company (“<b>NCAC</b>”).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">Newcourt SPAC Sponsor LLC, a Delaware limited liability company (“<b>NCAC Sponsor</b>”).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of Psyence
Group.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">Psyence Biomed Corp., a corporation organized under the laws of British Columbia, Canada (“<b>Original
Target</b>”).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (“<b>Psyence
Biomed II</b>”).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">-</td><td style="text-align: justify">Psyence Australia (Pty) Ltd (“<b>Psyence Australia</b>”)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Key Transactions (collectively, the “<b>Business
Combination</b>”):</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Formation of Subsidiaries</i>: Prior to the
Closing Date, PGI formed three wholly owned subsidiaries: Psyence Biomed II, Psyence Australia and PBM.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Amalgamation</i>: Prior to the Closing Date,
PGI amalgamated with the Original Target. Consequently, PGI transferred shares of Psyence Australia and related business assets previously
owned by the Original Target to Psyence Biomed II.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Share Exchange</i>: PGI contributed Psyence
Biomed II to PBM in a share-for-share exchange (the “<b>Company Exchange</b>”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Merger</i>: Following the Company Exchange,
Psyence (Cayman) Merger Sub merged with Newcourt Acquisition Corp., with Newcourt Acquisition Corp. being the surviving entity. Each outstanding
ordinary share of Newcourt Acquisition Corp. was converted into the right to receive one common share of PBM.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Warrant Conversion</i>: Each outstanding warrant
to purchase Newcourt Acquisition Corp. Class A ordinary shares was converted into warrants to acquire one common share of PBM on substantially
the same terms as the original warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">These Consolidated Financial Statements provide
historical financial information of PBM, reflecting PBM as if it had been historically operating the Clinical Trials conducted by PGI
prior to the Closing Date. The Financial Statements are carve-out statements up to January 25, 2024, the date of listing of PBM.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>2. Basis of presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Statement of compliance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Consolidated Financial Statements, including
comparatives, have been prepared in accordance with IFRS® Accounting Standards as issued by the International Accounting Standard
Board (“<b>IFRS</b>”) on a going concern basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Consolidated Financial Statements were authorized for issue on
June 25, 2025 by the directors of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Consolidated Financial Statements up until
January 25, 2024 were presented on a carve out basis (“<b>Carve-out Financial Statements</b>”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Consolidated Financial Statements have been
prepared on a carve-out basis from the PGI consolidated financial statements for the purpose of presenting the historical financial performance
and cash flows of the Company on a stand-alone basis. The accounting policies applied in the Carve-out Financial Statements are, to the
extent applicable, consistent with accounting policies applied in the PGI consolidated financial statements, and as a result, reflect
the carrying amounts that are included in PGI’s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In determining the perimeter of the Carve-out
Financial Statements, the activities related to the Company’s clinical trials were considered to include the operations of Psyence
Biomed Corp. and Psyence Australia (Pty) Ltd carried out through PGI directly as well as through legal entities of PGI as detailed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In the Carve-out Financial Statements, all intercompany
balances and transactions have been eliminated. The transactions and balances with the remaining PGI operations that are not part of these
Carve-out Financial Statements have not been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Carve-out Financial Statements present the
expenses and cash flows attributable to the clinical trial activities from April 1, 2022 to the Closing Date, and include allocations
of certain transactions and balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company believes the allocation assumptions
applied in the Carve-out Financial Statements to be a reasonable reflection of the utilization of services provided by PGI. However, different
allocation assumptions could have resulted in different outcomes. The allocations are therefore not necessarily representative of the
financial performance or cash flows that would have been reported if the Company operated on its own or as an entity independent from
PGI during the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company believes the basis of preparation
described above results in the Carve-out Financial Statements reflects costs associated with the functions that would be necessary to
operate independently.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Basis of consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">These Consolidated Financial Statements incorporate
the accounts of the Company and its subsidiaries performing Clinical Trials. A subsidiary is an entity controlled by PBM and its results
are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Control exists when an investor is exposed, or
has the rights, to variable returns from the involvement with the investee and has liability to affect those returns through its power
over the investee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The subsidiaries of the Company have been consolidated
commencing the Closing Date and on March 31, 2025 for the purpose of these Consolidated Financial Statements are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name of entity</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Place of incorporation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accounting method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Psyence Australia Pty Ltd.</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Australia</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Consolidated</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Pysence Biomed II Corp.</td><td> </td> <td style="text-align: center">Canada</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Consolidated</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Newcourt Acquisition Corp.</td><td> </td> <td style="text-align: center">Cayman Islands</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Consolidated</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Inter-company balances and transactions are eliminated
upon consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The financial results of subsidiaries up to January
25, 2024 were presented on a carve out basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Basis of measurement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">These Consolidated Financial Statements have been
prepared on a historical cost basis, except for certain financial instruments, which are classified as fair value through profit or loss
(“<b>FVTPL</b>”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Functional and presentation currency</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">These Consolidated Financial Statements are presented
in United States Dollars (<b>“USD $”</b>)<b>,</b> which is also the Company’s functional currency. The Company’s
functional currency before the Closing Date was Canadian Dollars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This changed upon consummation of the BCA at which
time the USD $ represents the currency of the Company's funding and is the currency of the primary economic environment in which the Company
operates in, except for the Company’s Australian subsidiary which has an Australian Dollar functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">See change in accounting policy in note 3 for
further details on the change in the Company’s presentation currency.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The subsidiaries of the Company have been consolidated
commencing the Closing Date and on March 31, 2025 for the purpose of these Consolidated Financial Statements are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name of entity</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Place of incorporation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accounting method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Psyence Australia Pty Ltd.</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Australia</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Consolidated</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Pysence Biomed II Corp.</td><td> </td> <td style="text-align: center">Canada</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Consolidated</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Newcourt Acquisition Corp.</td><td> </td> <td style="text-align: center">Cayman Islands</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Consolidated</td></tr> </table>
Australia
1
Consolidated
Canada
1
Consolidated
Cayman Islands
1
Consolidated
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>3. Material accounting policies </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Financial instruments </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial assets and financial liabilities, including
derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument
or derivative contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Summary of the Company’s classification
and measurements of financial assets and liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Assets and Liabilities</b></span></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Measurement </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other receivables</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in Psyence Labs Ltd</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued liabilities</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative warrant liability</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible note liability</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to NCAC Sponsor</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to Psyence Group Inc</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Classification</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company classifies its financial assets in
the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (“FVTPL”);
ii) those to be measured subsequently at fair value through other comprehensive income (“FVOCI”); and iii) those to be measured
at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual
terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as
those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair
value, gains and losses are either recorded in net loss or other comprehensive income (loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company reclassifies financial assets only
when its business model for managing those assets changes. Financial liabilities are not reclassified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Amortized cost</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This category includes financial assets that are
held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments
of principal and interest ("SPPI") criterion. Financial assets classified in this category are measured at amortized cost using
the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Fair value through profit or loss</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This category includes derivative instruments
as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL.
This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest
(“SPPI”) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or
to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized
in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives
are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Financial assets at fair value through other
comprehensive income</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Equity instruments that are not held-for-trading
can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through
net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable
transaction costs are included in the carrying value of the instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial assets at fair value through other comprehensive
income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Compound financial instrument and derivative
liability</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company determined that the warrants, including
public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured
at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized
in net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Each embedded derivative is measured and presented
separately unless the whole hybrid financial instrument is designated as at FVTPL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Measurement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">All financial instruments are required to be measured
at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that
are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial
assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered
in their entirety when determining whether their cash flows are solely payments of principal and interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial assets that are held within a business
model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal
and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All
other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with
any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial
liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value
are attributable to changes in own credit risk which is recorded in other comprehensive income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Cash and cash equivalents </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cash and cash equivalents include cash on hand
and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three months
at the date of their acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Restricted cash</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Restricted cash comprises a collateral agreement
with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment
certificate with the bank.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Related party transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered
to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be
a related party transaction when there is transfer of resources or obligations between related parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Change in accounting policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to completion of the Business Combination
Agreement and NASDAQ listing as explained in Note 1, on January 25, 2024, the Company decided to change the presentation currency of its
consolidated financial statements from Canadian Dollars to United States Dollars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Board of Directors believe that US Dollar
financial reporting provides more relevant presentation of the Company’s financial position, funding and treasury functions, financial
performance and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">A change in presentation currency represents a
change in accounting policy in terms of IAS 8 – <i>Accounting Policies, Changes in Accounting Estimates and Errors</i>, requiring
the restatement of comparative information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In accordance with IAS 21 – <i>The Effects
of Changes in Foreign Exchange Rates</i>, the methodology followed in restating historical financial information from CDN $ to USD $.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The average and closing rates used in translating
the historical financial information from CDN $ to USD $ for the various periods were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The closing rate used as at March 31, 2024 was
$0.7380, as at March 31, 2023 was $0.7389 and as at March 31, 2022 was $0.8003.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The average rate used for the year ended March
31, 2024 was $0.7415. and for the year ended March 31, 2023 was $0.7559.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The change in presentation currency is a voluntary
change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated
to United States dollars which is disclosed in the tables below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Change in presentation currency</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">March 31, 2023 <br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Restated<br/>
USD <br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold">EQUITY</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Net equity</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(271,275</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">70,830</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(200,445</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET DEFICIT</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(271,275</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">70,830</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(200,445</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; font-weight: bold">Change in presentation currency</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022<br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022<br/> Restated <br/>
USD<br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold">EQUITY</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Net equity</td><td style="width: 1%"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,122,696</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(423,996</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,698,700</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET DEFICIT</td><td style="font-weight: bold"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,122,696</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(423,996</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,698,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Change in presentation currency</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Restated <br/>
USD<br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Expenses</td><td> </td>
<td colspan="2"> </td><td> </td><td> </td>
<td colspan="2" style="text-align: center"> </td><td> </td><td> </td>
<td colspan="2"> </td><td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left">Sales and marketing</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9,292</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(2,263</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7,029</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Research and development</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,126,762</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(517,867</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,608,895</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">General and administrative</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">484,382</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(117,947</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">366,435</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Professional and consulting fees</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,655,663</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(403,153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,252,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss before other items</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,276,099</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,041,230</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,234,869</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left">Other items</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Interest income</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,054</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(500</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,554</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange gain</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,574</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,662</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,912</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET LOSS</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,238,471</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,032,068</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,206,403</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
</table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Change in presentation currency</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Restated <br/>
USD <br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left">Net loss</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(4,238,471</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,032,068</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(3,206,403</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left">Non-cash adjustment:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Share based compensation</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">292,756</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(71,469</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">221,287</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Foreign exchange</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(84,499</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(84,499</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left">Changes in working capital:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Other receivables</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(152,778</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">42,920</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(109,858</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td>Prepaids</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(97,547</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">25,882</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(71,665</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,258,967</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(599,909</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,659,058</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,937,073</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">344,993</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,592,080</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Proceeds received from Psyence Group Inc</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,551,744</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(378,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,172,923</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash provided from financing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,551,744</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(378,821</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,172,923</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Change in cash and cash equivalents</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(385,329</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(33,828</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(419,157</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, start of year</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,191,095</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(437,658</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,753,437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, end of year</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,805,765</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(471,486</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,334,280</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Research and development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Expenditures on research activities, undertaken
with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and
comprehensive loss as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Development expenditures are capitalized only
if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits
are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell
the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect
operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as
incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Provisions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Provisions are recognized when the Company has
a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle
the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required
to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations.
Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash
flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Foreign currency translation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Consolidated Financial Statements are presented
in USD $ which is the Company’s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In each individual entity, a foreign currency
transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency
and the foreign currency at the date of the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">At the end of the reporting period, monetary assets
and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary
assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The resulting exchange gains or losses arising
on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial
recognition, are included in the consolidated statements of net income/(loss) and comprehensive income/(loss) in the year in which they
arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For the purpose of presenting these Consolidated
Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end
of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries
is recorded in reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Income/(loss) per share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company presents basic and diluted income/(loss)
per share data for its common shares. Basic income/(loss) per share is calculated by dividing the profit or loss attributable to common
shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined
by adjusting the income or loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted
for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Share based compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company operates equity settled share-based
remuneration plans for its eligible directors, officers, employees and consultants. All goods and services received in exchange for the
grant of any share-based payments are measured at their fair value unless the fair value cannot be estimated reliably. If the Company
cannot estimate reliably the fair value of the goods and services received, the Company shall measure their value indirectly by reference
to the fair value of the equity instruments granted. For transactions with employees and others providing similar services, the Company
measures the fair value of the services by reference to the fair value of the equity instruments granted. Equity settled share-based payments
under share-based payment plans are ultimately recognized as an expense in profit or loss with a corresponding credit to contributed surplus,
in equity. If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available
estimate of the number of share options expected to vest. Non-market vesting conditions are included in the assumptions about the number
of options that are expected to become exercisable. Estimates are subsequently revised if there is any indication that the number of share
options expected to vest differs from the previous estimate. Any cumulative adjustment prior to vesting is recognized in the current period.
No adjustment is made to any expense recognized in prior period if share options ultimately exercised are different to that estimated
on vesting. Market conditions are considered in the estimate of the fair value of share-based compensation on a grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Income taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Income tax comprises current and deferred tax.
Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders’ equity,
in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also
recognized directly in equity or other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Current tax is the expected tax payable on the
taxable income for the year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect
of previous years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the
amounts and the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Deferred tax is recognized in respect of all qualifying
temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Consolidated Financial
Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively
enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax
assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate
to the same taxation authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Deferred tax assets are recognized to the extent
future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable
that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Accounting Standards Effective January 1, 2024
and issued but not yet effective</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>IFRS 18 Presentation and Disclosure in Financial
Statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In April 2024, the IASB issued <i>IFRS 18 –
Presentation and Disclosure in Financial Statements</i> which will replace <i>IAS 1, Presentation of Financial Statements</i>. The key
new concepts introduced in IFRS 18 relate to the structure of the statement of earnings (loss), required disclosures in the financial
statements for certain earnings or loss performance measures that are reported outside an entity’s financial statements and enhanced
principles on aggregation and disaggregation which apply to the primary financial statements and notes in general. IFRS 18 will apply
for reporting periods beginning on or after January 1, 2027, and also applies to comparative information. The Company is still in the
process of assessing the impact of this standard on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Classification of liabilities as current or non-current
(amendments to IAS 1, presentation of financial statements)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 23, 2020, an amendment was issued to
IAS 1 to address inconsistencies with how entities apply the standards over classification of current and non-current liabilities. The
amendment serves to address whether, in the statement of financial position, debt and other liabilities with an uncertain settlement should
be classified as current or non-current. This amendment is effective on January 1, 2024. The Company adopted the amendment on the effective
date and the adoption did not have a material impact on the Company’s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Non-current liabilities with covenants (amendments
to IAS 1)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The amendments to IAS 1 specify that only covenants
with which an entity is required to comply on or before the reporting date affect the classification of a liability as current or non-current.
In addition, an entity has to disclose information in the notes that enables users of financial statements to understand the risk that
noncurrent liabilities with covenants could become repayable within twelve months. The amendments are effective for annual reporting periods
beginning on or after January 1, 2024, and are to be applied retrospectively. The Company adopted the amendment on the effective date
and the adoption did not have a material impact on the Company’s consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Financial instruments </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial assets and financial liabilities, including
derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument
or derivative contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Summary of the Company’s classification
and measurements of financial assets and liabilities:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Assets and Liabilities</b></span></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Measurement </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other receivables</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in Psyence Labs Ltd</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued liabilities</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative warrant liability</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible note liability</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to NCAC Sponsor</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to Psyence Group Inc</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Classification</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company classifies its financial assets in
the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (“FVTPL”);
ii) those to be measured subsequently at fair value through other comprehensive income (“FVOCI”); and iii) those to be measured
at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual
terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as
those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair
value, gains and losses are either recorded in net loss or other comprehensive income (loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company reclassifies financial assets only
when its business model for managing those assets changes. Financial liabilities are not reclassified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Amortized cost</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This category includes financial assets that are
held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments
of principal and interest ("SPPI") criterion. Financial assets classified in this category are measured at amortized cost using
the effective interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Fair value through profit or loss</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This category includes derivative instruments
as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL.
This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest
(“SPPI”) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or
to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized
in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives
are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Financial assets at fair value through other
comprehensive income</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Equity instruments that are not held-for-trading
can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through
net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable
transaction costs are included in the carrying value of the instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial assets at fair value through other comprehensive
income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Compound financial instrument and derivative
liability</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company determined that the warrants, including
public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured
at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized
in net loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Each embedded derivative is measured and presented
separately unless the whole hybrid financial instrument is designated as at FVTPL.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Measurement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">All financial instruments are required to be measured
at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that
are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial
assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered
in their entirety when determining whether their cash flows are solely payments of principal and interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial assets that are held within a business
model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal
and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All
other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with
any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial
liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value
are attributable to changes in own credit risk which is recorded in other comprehensive income.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Summary of the Company’s classification
and measurements of financial assets and liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Assets and Liabilities</b></span></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td> <td style="width: 1%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Measurement </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other receivables</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in Psyence Labs Ltd</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued liabilities</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized cost</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative warrant liability</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible note liability</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to NCAC Sponsor</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to Psyence Group Inc</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FVTPL</span></td> <td> </td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value</span></td></tr> </table>
Amortized cost
Amortized cost
Amortized cost
Amortized cost
Amortized cost
Amortized cost
FVTPL
Fair value
Amortized cost
Amortized cost
FVTPL
Fair value
FVTPL
Fair value
FVTPL
Fair value
FVTPL
Fair value
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Cash and cash equivalents </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cash and cash equivalents include cash on hand
and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three months
at the date of their acquisition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Restricted cash</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Restricted cash comprises a collateral agreement
with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment
certificate with the bank.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Related party transactions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Parties are considered to be related if one party
has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered
to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be
a related party transaction when there is transfer of resources or obligations between related parties.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Change in accounting policy</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to completion of the Business Combination
Agreement and NASDAQ listing as explained in Note 1, on January 25, 2024, the Company decided to change the presentation currency of its
consolidated financial statements from Canadian Dollars to United States Dollars.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Board of Directors believe that US Dollar
financial reporting provides more relevant presentation of the Company’s financial position, funding and treasury functions, financial
performance and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">A change in presentation currency represents a
change in accounting policy in terms of IAS 8 – <i>Accounting Policies, Changes in Accounting Estimates and Errors</i>, requiring
the restatement of comparative information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In accordance with IAS 21 – <i>The Effects
of Changes in Foreign Exchange Rates</i>, the methodology followed in restating historical financial information from CDN $ to USD $.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The average and closing rates used in translating
the historical financial information from CDN $ to USD $ for the various periods were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The closing rate used as at March 31, 2024 was
$0.7380, as at March 31, 2023 was $0.7389 and as at March 31, 2022 was $0.8003.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The average rate used for the year ended March
31, 2024 was $0.7415. and for the year ended March 31, 2023 was $0.7559.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The change in presentation currency is a voluntary
change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated
to United States dollars which is disclosed in the tables below:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Change in presentation currency</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">March 31, 2023 <br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Restated<br/>
USD <br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold">EQUITY</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Net equity</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(271,275</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">70,830</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(200,445</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET DEFICIT</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(271,275</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">70,830</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(200,445</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
</table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; font-weight: bold">Change in presentation currency</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022<br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022<br/> Restated <br/>
USD<br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold">EQUITY</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Net equity</td><td style="width: 1%"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,122,696</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(423,996</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,698,700</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET DEFICIT</td><td style="font-weight: bold"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,122,696</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(423,996</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,698,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Change in presentation currency</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Restated <br/>
USD<br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Expenses</td><td> </td>
<td colspan="2"> </td><td> </td><td> </td>
<td colspan="2" style="text-align: center"> </td><td> </td><td> </td>
<td colspan="2"> </td><td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left">Sales and marketing</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9,292</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(2,263</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7,029</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Research and development</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,126,762</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(517,867</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,608,895</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">General and administrative</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">484,382</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(117,947</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">366,435</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Professional and consulting fees</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,655,663</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(403,153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,252,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss before other items</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,276,099</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,041,230</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,234,869</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left">Other items</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Interest income</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,054</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(500</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,554</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange gain</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,574</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,662</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,912</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET LOSS</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,238,471</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,032,068</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,206,403</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
</table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Change in presentation currency</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Restated <br/>
USD <br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left">Net loss</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(4,238,471</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,032,068</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(3,206,403</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left">Non-cash adjustment:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Share based compensation</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">292,756</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(71,469</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">221,287</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Foreign exchange</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(84,499</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(84,499</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left">Changes in working capital:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Other receivables</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(152,778</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">42,920</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(109,858</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td>Prepaids</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(97,547</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">25,882</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(71,665</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,258,967</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(599,909</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,659,058</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,937,073</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">344,993</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,592,080</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Proceeds received from Psyence Group Inc</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,551,744</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(378,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,172,923</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash provided from financing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,551,744</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(378,821</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,172,923</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Change in cash and cash equivalents</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(385,329</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(33,828</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(419,157</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, start of year</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,191,095</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(437,658</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,753,437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, end of year</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,805,765</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(471,486</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,334,280</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
0.738
0.7389
0.8003
0.7415
0.7559
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The change in presentation currency is a voluntary
change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated
to United States dollars which is disclosed in the tables below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Change in presentation currency</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">March 31, 2023 <br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Restated<br/>
USD <br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold">EQUITY</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Net equity</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(271,275</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">70,830</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(200,445</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET DEFICIT</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(271,275</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">70,830</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(200,445</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; font-weight: bold">Change in presentation currency</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022<br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022<br/> Restated <br/>
USD<br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold">EQUITY</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Net equity</td><td style="width: 1%"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,122,696</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(423,996</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,698,700</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET DEFICIT</td><td style="font-weight: bold"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,122,696</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(423,996</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,698,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Change in presentation currency</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Restated <br/>
USD<br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Expenses</td><td> </td>
<td colspan="2"> </td><td> </td><td> </td>
<td colspan="2" style="text-align: center"> </td><td> </td><td> </td>
<td colspan="2"> </td><td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left">Sales and marketing</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9,292</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(2,263</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7,029</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Research and development</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,126,762</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(517,867</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,608,895</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">General and administrative</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">484,382</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(117,947</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">366,435</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Professional and consulting fees</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,655,663</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(403,153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,252,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss before other items</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,276,099</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,041,230</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,234,869</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left">Other items</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Interest income</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,054</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(500</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,554</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange gain</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,574</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,662</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,912</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET LOSS</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,238,471</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,032,068</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,206,403</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
</table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Change in presentation currency</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Reported CAD $</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Foreign Currency<br/> Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023<br/> Restated <br/>
USD <br/>
$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: left">Net loss</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(4,238,471</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,032,068</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(3,206,403</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left">Non-cash adjustment:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Share based compensation</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">292,756</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(71,469</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">221,287</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Foreign exchange</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(84,499</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(84,499</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left">Changes in working capital:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Other receivables</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(152,778</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">42,920</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(109,858</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td>Prepaids</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(97,547</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">25,882</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(71,665</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,258,967</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(599,909</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,659,058</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,937,073</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">344,993</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,592,080</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Proceeds received from Psyence Group Inc</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,551,744</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(378,821</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,172,923</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash provided from financing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,551,744</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(378,821</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,172,923</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Change in cash and cash equivalents</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(385,329</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(33,828</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(419,157</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, start of year</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,191,095</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(437,658</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,753,437</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, end of year</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,805,765</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(471,486</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,334,280</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
-271275
70830
-200445
-271275
70830
-200445
2122696
-423996
1698700
2122696
-423996
1698700
9292
-2263
7029
2126762
-517867
1608895
484382
-117947
366435
1655663
-403153
1252510
-4276099
1041230
-3234869
2054
-500
1554
35574
-8662
26912
-4238471
1032068
-3206403
-4238471
1032068
-3206403
292756
-71469
221287
-84499
-84499
-152778
42920
-109858
-97547
25882
-71665
2258967
-599909
1659058
-1937073
344993
-1592080
1551744
-378821
1172923
1551744
-378821
1172923
-385329
-33828
-419157
2191095
-437658
1753437
1805765
-471486
1334280
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Research and development</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Expenditures on research activities, undertaken
with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and
comprehensive loss as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Development expenditures are capitalized only
if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits
are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell
the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect
operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as
incurred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Provisions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Provisions are recognized when the Company has
a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle
the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required
to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations.
Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash
flows.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Foreign currency translation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Consolidated Financial Statements are presented
in USD $ which is the Company’s functional currency.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In each individual entity, a foreign currency
transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency
and the foreign currency at the date of the transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">At the end of the reporting period, monetary assets
and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary
assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The resulting exchange gains or losses arising
on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial
recognition, are included in the consolidated statements of net income/(loss) and comprehensive income/(loss) in the year in which they
arise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For the purpose of presenting these Consolidated
Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end
of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries
is recorded in reserves.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Income/(loss) per share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company presents basic and diluted income/(loss)
per share data for its common shares. Basic income/(loss) per share is calculated by dividing the profit or loss attributable to common
shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined
by adjusting the income or loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted
for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Share based compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company operates equity settled share-based
remuneration plans for its eligible directors, officers, employees and consultants. All goods and services received in exchange for the
grant of any share-based payments are measured at their fair value unless the fair value cannot be estimated reliably. If the Company
cannot estimate reliably the fair value of the goods and services received, the Company shall measure their value indirectly by reference
to the fair value of the equity instruments granted. For transactions with employees and others providing similar services, the Company
measures the fair value of the services by reference to the fair value of the equity instruments granted. Equity settled share-based payments
under share-based payment plans are ultimately recognized as an expense in profit or loss with a corresponding credit to contributed surplus,
in equity. If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available
estimate of the number of share options expected to vest. Non-market vesting conditions are included in the assumptions about the number
of options that are expected to become exercisable. Estimates are subsequently revised if there is any indication that the number of share
options expected to vest differs from the previous estimate. Any cumulative adjustment prior to vesting is recognized in the current period.
No adjustment is made to any expense recognized in prior period if share options ultimately exercised are different to that estimated
on vesting. Market conditions are considered in the estimate of the fair value of share-based compensation on a grant date.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Income taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Income tax comprises current and deferred tax.
Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders’ equity,
in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also
recognized directly in equity or other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Current tax is the expected tax payable on the
taxable income for the year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect
of previous years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the
amounts and the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Deferred tax is recognized in respect of all qualifying
temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Consolidated Financial
Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively
enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax
assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate
to the same taxation authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Deferred tax assets are recognized to the extent
future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable
that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Accounting Standards Effective January 1, 2024
and issued but not yet effective</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>IFRS 18 Presentation and Disclosure in Financial
Statements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In April 2024, the IASB issued <i>IFRS 18 –
Presentation and Disclosure in Financial Statements</i> which will replace <i>IAS 1, Presentation of Financial Statements</i>. The key
new concepts introduced in IFRS 18 relate to the structure of the statement of earnings (loss), required disclosures in the financial
statements for certain earnings or loss performance measures that are reported outside an entity’s financial statements and enhanced
principles on aggregation and disaggregation which apply to the primary financial statements and notes in general. IFRS 18 will apply
for reporting periods beginning on or after January 1, 2027, and also applies to comparative information. The Company is still in the
process of assessing the impact of this standard on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Classification of liabilities as current or non-current
(amendments to IAS 1, presentation of financial statements)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 23, 2020, an amendment was issued to
IAS 1 to address inconsistencies with how entities apply the standards over classification of current and non-current liabilities. The
amendment serves to address whether, in the statement of financial position, debt and other liabilities with an uncertain settlement should
be classified as current or non-current. This amendment is effective on January 1, 2024. The Company adopted the amendment on the effective
date and the adoption did not have a material impact on the Company’s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Non-current liabilities with covenants (amendments
to IAS 1)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The amendments to IAS 1 specify that only covenants
with which an entity is required to comply on or before the reporting date affect the classification of a liability as current or non-current.
In addition, an entity has to disclose information in the notes that enables users of financial statements to understand the risk that
noncurrent liabilities with covenants could become repayable within twelve months. The amendments are effective for annual reporting periods
beginning on or after January 1, 2024, and are to be applied retrospectively. The Company adopted the amendment on the effective date
and the adoption did not have a material impact on the Company’s consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>4. Critical accounting estimates and judgements
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The preparation of consolidated financial statements
in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results
may differ from these estimates. The Company’s management reviews these estimates, judgments, and assumptions on an ongoing basis,
based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical
accounting policies as these require a high level of subjectivity and judgement and could have a material impact on the Company’s
consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Reverse takeover transaction</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The determination of fair values of consideration
paid and net assets acquired is subject to significant estimation. The Company treated the RTO Transaction as a capital transaction equivalent
to the issue of shares of the Company in exchange for the net monetary assets of NCAC. The Company determined that the original shareholders
of PGI became the single largest shareholder of the Company after the RTO Transaction, therefore the Company was the acquiror and NCAC
was the acquiree.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company has determined the RTO Transaction
did not constitute a business combination as defined under IFRS 3, Business Combinations, as NCAC is a non-operating entity that did not
meet the definition of a business under IFRS 3. The excess of the consideration paid over the net liability acquired together with any
transaction costs incurred for the Transaction is expensed as a listing expense in accordance with IFRS 2 Share-Based Payments. The fair
value of the consideration paid was estimated by the closing trading price $2,863.22/share of the Company’s common shares listed
on the NASDAQ on January 25, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Convertible instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The valuation of convertible debt instruments
is subject to significant management estimation. Convertible notes are compound financial instruments which have been designated at FVTPL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The identification of convertible debenture components
is based on interpretations of the substance of the contractual arrangement and therefore requires judgment from management. The separation
of the components affects the initial recognition of the convertible debenture at issuance and the subsequent remeasurement. As the Company
has designated the entire convertible financial instrument as FVTPL given the embedded derivate liability that was contained by the convertible
financial instrument, the debentures have not been separated into debt and derivative components. The fair values attributed to the different
components of a financing transaction, and/or derivative financial instruments, are determined using valuation techniques. The Company
uses judgement to select the methods used to make certain assumptions and in performing the fair value calculations in order to determine
(a) the values attributed to each component of a transaction at the time of their issuance; (b) the fair value measurements for certain
instruments that require subsequent measurement at fair value on a recurring basis; and (c) for disclosing the fair value of financial
instruments subsequently carried at amortized cost. These valuation estimates could be significantly different because of the use of judgement
and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">From time to time, the Company is named as a party
to claims or involved in proceedings, including legal, regulatory and tax related, in the ordinary course of its business. While the outcome
of these matters may not be estimable at the reporting date, the Company makes provisions, where possible, for the estimated outcome of
such claims or proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates, the
difference will be accounted for as a charge to profit or loss in that period. The actual results may vary and may cause significant adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The rebate over the tax claim is subject to inherent
uncertainty and could be subject to being denied and clawed back by the Australian Tax office at a future date. The Company expects that
a claw back of the rebate is highly unlikely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Deferred taxes and Income taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Significant estimates are required in determining
the Company’s income tax provision. Some estimates are based on interpretations of existing tax laws or regulations. Various internal
and external factors may have favourable or unfavourable effects on the Company’s future effective tax rate. These include, but
are not limited to, changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, and results
of tax audits by tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Provisions for taxes are made using the best estimate
of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these
provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from
audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded,
such differences will affect the tax provisions in the period in which such determination is made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Share-based compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Valuation of share-based compensation requires
management to make estimates regarding the inputs for option pricing models, such as the expected life of the option, the volatility of
the Company’s stock price, the vesting period of the option and the risk-free interest rate are used. Actual results could differ
from those estimates. The estimates are considered for each new grant of stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Government grants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Government grants are recognized when there is
reasonable assurance that the Company will comply with the conditions attached to them and the government grants will be received. Grants
are recognized as income when they are received. The Company has recognized the government grant received during the period as research
and development grants as other income in the consolidated statement of income/(loss) and comprehensive income/(loss).</p>
contextRef="c66"
decimals="2"
id="ixv-20453"
unitRef="usdPershares">2863.22
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>5. Reverse takeover transaction with NCAC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 25, 2024 the Company completed the
RTO Transaction (See Note 1). As disclosed in Note 4, the RTO Transaction did not constitute a business combination as defined under IFRS
3, Business Combinations, as NCAC is a non-operating entity that does not meet the definition of a business under IFRS 3. The excess of
the consideration paid over the net liability acquired together with any transaction costs incurred for the Transaction is expensed as
a listing expense in accordance with IFRS 2 Share-Based Payments. The fair value of the consideration paid was determined by the closing
trading price $2,863.22/share of the NCAC’s common shares listed on the NASDAQ on January 25, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Accordingly, upon consummation of the BCA the
Company issued 13,040 common shares in exchange for the outstanding ordinary shares held by NCAC stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The calculation of listing expenses is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Listing Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td>Consideration paid:</td><td> </td>
<td colspan="2" style="text-align: right"> </td><td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 0.125in; width: 88%; text-align: left">Shares issued to NCAC shareholders</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,040</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Total consideration shares issued</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">13,040</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Fair value of the common shares</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,863.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Deemed consideration amount for the common shares issued</td><td style="font-weight: bold"> </td>
<td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">37,336,416</td><td style="font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Net identifiable liabilities acquired:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 0.125in; text-align: left">Cash and cash equivalent</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">203</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-left: 0.125in; text-align: left">Accounts payable and accrued liabilities</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">(2,136,505</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 0.125in; text-align: left">NCAC promissory note (Note 11)</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">(1,413,529</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-left: 0.125in; text-align: left">Derivative warrant liabilities (Note 10)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(595,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Net liabilities acquired</td><td style="font-weight: bold"> </td>
<td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">4,145,189</td><td style="font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Listing expense</td><td style="font-weight: bold"> </td>
<td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">41,481,605</td><td style="font-weight: bold; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The listing expense has been included in the consolidated
statements of net loss and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Transaction expenses included in the consolidated
statements of net loss and comprehensive loss are others costs of $2,461,025 in connection with the RTO Transaction composed of legal,
banking, professional fees and costs related to the settlement of carved-out assets and liabilities from Psyence Group. Some payments
to brokers and advisors were in the Company’s shares upon RTO at the closing trading price on January 25, 2024 (Refer Note 12).</p>
contextRef="c67"
decimals="2"
id="ixv-20454"
unitRef="usdPershares">2863.22
contextRef="c68"
decimals="INF"
id="ixv-20455"
unitRef="shares">13040
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The calculation of listing expenses is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Listing Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td>Consideration paid:</td><td> </td>
<td colspan="2" style="text-align: right"> </td><td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 0.125in; width: 88%; text-align: left">Shares issued to NCAC shareholders</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">13,040</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Total consideration shares issued</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">13,040</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Fair value of the common shares</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,863.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Deemed consideration amount for the common shares issued</td><td style="font-weight: bold"> </td>
<td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">37,336,416</td><td style="font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Net identifiable liabilities acquired:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 0.125in; text-align: left">Cash and cash equivalent</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">203</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-left: 0.125in; text-align: left">Accounts payable and accrued liabilities</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">(2,136,505</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 0.125in; text-align: left">NCAC promissory note (Note 11)</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">(1,413,529</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-left: 0.125in; text-align: left">Derivative warrant liabilities (Note 10)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(595,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Net liabilities acquired</td><td style="font-weight: bold"> </td>
<td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">4,145,189</td><td style="font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Listing expense</td><td style="font-weight: bold"> </td>
<td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">41,481,605</td><td style="font-weight: bold; text-align: left"> </td></tr>
</table>
contextRef="c70"
decimals="INF"
id="ixv-20456"
unitRef="shares">13040
contextRef="c71"
decimals="INF"
id="ixv-20457"
unitRef="shares">13040
contextRef="c71"
decimals="2"
id="ixv-20458"
unitRef="usdPershares">2863.22
37336416
203
2136505
1413529
595358
-4145189
41481605
2461025
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>6. Cash, restricted cash and cash equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cash and cash equivalents include the following
amounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Unrestricted cash held with chartered banks</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6,135,166</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">733,188</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,964</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,611</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,171,130</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">762,799</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unrestricted
cash held with chartered banks and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company entered into a cash collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited Canadian Dollars $50,000 in a guaranteed investment certificate with the bank. Amounts are presented as restricted cash on the consolidated statements of financial position.</span></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cash and cash equivalents include the following
amounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Unrestricted cash held with chartered banks</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6,135,166</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">733,188</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">35,964</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,611</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,171,130</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">762,799</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
6135166
733188
35964
29611
6171130
762799
50000
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>7. Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computer equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Cost</td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">At March 31, 2023</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="width: 88%; text-align: justify">Additions</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,727</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">At March 31, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">5,727</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,877</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; padding-bottom: 1.5pt">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">15,604</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-decoration: underline; text-align: justify">Accumulated Depreciation</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">At March 31, 2023</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Charge for the year</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(240</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">At March 31, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(240</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Charge for the year</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,268</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; padding-bottom: 1.5pt">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,508</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-decoration: underline; text-align: justify; padding-bottom: 1.5pt">Carrying Value</td><td style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">At March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,487</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; padding-bottom: 1.5pt">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,096</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computer equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Cost</td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">At March 31, 2023</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="width: 88%; text-align: justify">Additions</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,727</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">At March 31, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">5,727</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,877</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; padding-bottom: 1.5pt">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">15,604</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-decoration: underline; text-align: justify">Accumulated Depreciation</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">At March 31, 2023</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Charge for the year</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(240</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">At March 31, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(240</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Charge for the year</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,268</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; padding-bottom: 1.5pt">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,508</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-decoration: underline; text-align: justify; padding-bottom: 1.5pt">Carrying Value</td><td style="padding-bottom: 1.5pt"> </td>
<td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">At March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,487</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; padding-bottom: 1.5pt">At March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,096</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
5727
5727
9877
15604
240
-240
4268
-4508
5487
11096
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>8. Accounts payable and accrued liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Accounts payable and accrued liabilities include
the following amounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">261,937</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">562,352</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Accrued liabilities</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">50,481</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">125,951</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1.5pt">Provisions</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">81,852</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,899</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">394,270</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">755,202</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Accounts payable and accrued liabilities include
the following amounts:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Trade payables</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">261,937</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">562,352</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Accrued liabilities</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">50,481</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">125,951</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1.5pt">Provisions</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">81,852</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,899</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">394,270</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">755,202</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
261937
562352
50481
125951
81852
66899
394270
755202
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>9. Convertible note liability</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 15, 2024, in connection with the RTO
Transaction (Note 5), the Company and Psyence Biomed II entered into the Securities Purchase Agreement with the Investors and the NCAC
Sponsor, relating to up to four senior secured convertible notes obligations under which are guaranteed by certain assets of the Company
and Psyence Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up
to $12,500,000 in exchange for up to $10,000,000 in cash subscription amounts (the “<b>Convertible Note Financing</b>”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The First Tranche Notes, for an aggregate of $3,125,000
principal, were delivered by the Company to the Investors on January 25, 2024, in exchange for an aggregate of $2,500,000 in financing,
which occurred substantially concurrently with the consummation of the RTO Transaction. On the original issuance date of the First Tranche
Notes, interest began accruing at 8.0% per annum based on the outstanding principal amount of the First Tranche Notes and is payable monthly
in arrears in cash or in common shares of the Company. The maturity date of the First Tranche Note was January 25, 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Second Tranche Notes, for an aggregate of
$1,000,000 principal, were delivered by the Company to the Investors between May and July 2024, in exchange for an aggregate of $1,250,000
in financing. On the original issuance date of the Second Tranche Notes, interest began accruing at 8.0% per annum based on the outstanding
principal amount of the Second Tranche Notes and is payable monthly in arrears in cash or in common shares of the Company at the Conversion
Price. The maturity date of the Second Tranche Notes is May 31, 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company designated the entire instrument as
FVTPL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On August 20, 2024, the Company and the Investor
entered into an addendum to the Securities Purchase Agreement (the “Addendum”). Under the provisions of the Addendum, the
First and Second Trance Notes would be extinguished by the Company issuing common shares within the conversion limits detailed in the
Securities Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As a consideration to the Investor entering into
the Addendum, the Company issued to the Investor 1,673 common shares valued at $523,000 based on the market price of the common shares
on the date of issuance and 837 warrants to acquire common shares of the Company with a two-year expiry, exercisable at $298.88 per share.
The warrants were valued at $42,528 using the Black-Scholes pricing model with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant Inputs at<br/> August 20, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Share price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">312.62</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.93</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expiry date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 20, 2026</span></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The fair value of shares and warrants issued pursuant
to the Addendum as detailed above, was recorded in the consolidated statements of income/(loss) and comprehensive income/(loss) as part
of the fair value gain on convertible note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On November 27, 2024, the Company and the Investor
entered into the Termination Agreement pursuant to which all obligations, covenants and liabilities of the Company and the Investor under
the Securities Purchase Agreement will be fully and finally terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As a consideration to the Investor entering into
the Termination Agreement, the Company issued to the Investor 18,947 common shares valued at $489,598 based on the market price of the
common shares on the date of issuance and 22,876 warrants to acquire common shares of the Company with nominal exercise price for a one-year
period. The warrants were valued at $639,954 by the reference to the Company’s common share price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The fair value of shares and warrants issued pursuant
to the Termination Agreement as detailed above, was recorded in the consolidated statements of income/(loss) and comprehensive income/(loss)
as part of the fair value gain on convertible note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Between May and September 2024, the Company converted
all outstanding balance of the First and Second Tranche Notes into common shares by issuing 17,536 common shares. The total additions
to equity on conversion were $3,604,688.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company measured the fair value of the convertible
loan liability before each conversion using Monte Carlo valuation model with the following main assumptions: expected dividend yield 0%,
exercise price $224.22- $320.45, risk free interest rate 3.63%- 5.23%, expected life 0.1 – 2.7 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The change in fair value resulted in a fair value
gain of $5,052,708 (2024 – loss of $5,157,397, 2023- <span style="-sec-ix-hidden: hidden-fact-126">nil</span>) which was recorded in the consolidated statements of income/(loss) and
comprehensive income/(loss) as part of the fair value gain on convertible note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2024, the fair value of the convertible
notes was estimated at $7,657,397 using a combined discounted cash flow approach and Monte Carlo simulation with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-align: justify">Share price</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">681.44</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Note principal amount</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">3,125,000</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Prepayment Amount</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">130</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Discount rate shares</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4.43</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Discount rate cash</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">20.83</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Volatility annual</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Volatility daily</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">6.30</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Risk free annual</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4.43</td><td style="text-align: left">%</td></tr>
</table>
12500000
10000000
3125000
2500000
0.08
1000000
1250000
0.08
contextRef="c90"
decimals="0"
id="ixv-20500"
unitRef="shares">1673
523000
contextRef="c92"
decimals="0"
id="ixv-20502"
unitRef="shares">837
298.88
The warrants were valued at $42,528 using the Black-Scholes pricing model with the following assumptions:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant Inputs at<br/> August 20, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Share price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">312.62</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.93</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expiry date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 20, 2026</span></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2024, the fair value of the convertible
notes was estimated at $7,657,397 using a combined discounted cash flow approach and Monte Carlo simulation with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-align: justify">Share price</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">681.44</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Note principal amount</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">3,125,000</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Prepayment Amount</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">130</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Discount rate shares</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4.43</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Discount rate cash</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">20.83</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Volatility annual</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Volatility daily</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">6.30</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Risk free annual</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4.43</td><td style="text-align: left">%</td></tr>
</table>
42528
contextRef="c107"
decimals="2"
id="ixv-20506"
unitRef="pure">312.62
contextRef="c109"
decimals="2"
id="ixv-20507"
unitRef="pure">298.88
contextRef="c110"
decimals="2"
id="ixv-20508"
unitRef="pure">3.93
contextRef="c111"
decimals="2"
id="ixv-20509"
unitRef="pure">2
contextRef="c112"
decimals="1"
id="ixv-20510"
unitRef="pure">17.7
August 20, 2026
contextRef="c95"
decimals="0"
id="ixv-20511"
unitRef="shares">18947
489598
contextRef="c97"
decimals="0"
id="ixv-20513"
unitRef="shares">22876
639954
contextRef="c98"
decimals="0"
id="ixv-20515"
unitRef="shares">17536
3604688
contextRef="c100"
decimals="2"
id="ixv-20517"
unitRef="pure">0
contextRef="c101"
decimals="2"
id="ixv-20518"
unitRef="usdPershares">224.22
contextRef="c102"
decimals="2"
id="ixv-20519"
unitRef="usdPershares">320.45
contextRef="c101"
decimals="4"
id="ixv-20520"
unitRef="pure">0.0363
contextRef="c102"
decimals="4"
id="ixv-20521"
unitRef="pure">0.0523
P0Y1M6D
P2Y8M12D
5052708
5157397
7657397
contextRef="c114"
decimals="2"
id="ixv-20527"
unitRef="pure">681.44
contextRef="c115"
decimals="0"
id="ixv-20528"
unitRef="pure">3125000
contextRef="c116"
decimals="0"
id="ixv-20529"
unitRef="pure">130
contextRef="c117"
decimals="2"
id="ixv-20530"
unitRef="pure">4.43
contextRef="c118"
decimals="2"
id="ixv-20531"
unitRef="pure">20.83
contextRef="c119"
decimals="0"
id="ixv-20532"
unitRef="pure">100
contextRef="c120"
decimals="2"
id="ixv-20533"
unitRef="pure">6.3
contextRef="c121"
decimals="2"
id="ixv-20534"
unitRef="pure">4.43
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>10. Derivative warrant liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company has two classes of warrant liabilities
outstanding: Public Warrants and Private Warrants. As of March 31, 2025, there were 20,762 warrants issued and outstanding, consisting
of 19,808 Public Warrants and 954 Private Warrants (March 31, 2024 – 20,912 Public Warrants and 954 Private Warrants). Each warrant
is exercisable to purchase one common share at a price of $6,874.13 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">During the year ended March 31, 2025, the Company
entered into the Warrant Exchange Agreement. Pursuant to the Warrant Exchange Agreement, the Company issued to the Holder 1,104 Common
Shares in exchange for the surrender and cancellation of 1,104 Public Warrants held by the Holder. The warrants exchange resulted in a
loss of $185,064 which was recorded in the consolidated statements of income/(loss) and comprehensive income/(loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Public Warrants: The fair value of the Public
Warrants is determined based on the observable market price, as they continue to be traded on the Nasdaq under the symbol “PBMWW.”
Changes in fair value during the years ended March 31, 2025 and March 31, 2024, have been recognized in the consolidated statements of
income/(loss) and comprehensive income/(loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Private Warrants: The Company utilizes a Black-Scholes
options valuation model to value the private warrants at each reporting period, using the following main assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant Inputs at<br/> March 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant Inputs at<br/> March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Share price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.78</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">681.44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,874.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,874.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.21</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.21</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59.98</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59.98</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expiry date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2029</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2029</span></td><td style="text-align: left"> </td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">At March 31, 2025 the fair value of the Public
and Private Warrants was $200,096 (March 31, 2024 - $875,000) and $<span style="-sec-ix-hidden: hidden-fact-136">nil</span> (March 31, 2024 - $26,608), respectively. A fair value loss of
$694,516 was recognized on the consolidated statements of income/(loss) and comprehensive income/(loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The expected volatility was based on implied volatility
of the Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2025, the derivative warrant liability
was $200,096 (March 31, 2024 – $901,608 ) reconciled as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; text-align: justify"><b>Derivative warrant liability – Public and Private Warrants</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount<br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: justify">At listing January 25, 2024</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">21,866</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">595,358</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Fair value loss</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">306,250</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Opening balance April 1, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">21,866</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">901,608</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Warrant exchange</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(1,104</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(6,996</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Fair value gain</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(694,516</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 2.5pt">Balance as at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">20,762</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">200,096</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Warrant transactions and the number of warrants
outstanding are summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Public Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Private Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Balance, April 1, 2023</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Issued</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">20,912</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">954</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Balance, March 31, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">20,912</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">6,874.13</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">954</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">6,874.13</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Warrant exchange</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,104</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Balance, March 31, 2025</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,808</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">954</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following warrants were outstanding and exercisable
at March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issue Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiry Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt">January 25, 2024</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 19%; text-align: center; padding-bottom: 1.5pt">January 25, 2029</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 17%; border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 17%; border-bottom: Black 1.5pt solid; text-align: right">20,762</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 17%; border-bottom: Black 1.5pt solid; text-align: right">20,762</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>
contextRef="c4"
decimals="INF"
id="ixv-20535"
unitRef="shares">20762
contextRef="c4"
decimals="0"
id="ixv-20536"
unitRef="shares">20762
contextRef="c122"
decimals="INF"
id="ixv-20537"
unitRef="shares">19808
contextRef="c123"
decimals="INF"
id="ixv-20538"
unitRef="shares">954
contextRef="c124"
decimals="INF"
id="ixv-20539"
unitRef="shares">20912
contextRef="c125"
decimals="INF"
id="ixv-20540"
unitRef="shares">954
contextRef="c0"
decimals="2"
id="ixv-20541"
unitRef="usdPershares">6874.13
contextRef="c0"
decimals="0"
id="ixv-20542"
unitRef="shares">1104
contextRef="c0"
decimals="0"
id="ixv-20543"
unitRef="shares">1104
185064
The Company utilizes a Black-Scholes
options valuation model to value the private warrants at each reporting period, using the following main assumptions:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant Inputs at<br/> March 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant Inputs at<br/> March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Share price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.78</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">681.44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,874.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,874.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.21</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.21</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59.98</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59.98</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expiry date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2029</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 25, 2029</span></td><td style="text-align: left"> </td></tr> </table>
contextRef="c132"
decimals="2"
id="ixv-20546"
unitRef="pure">4.78
contextRef="c133"
decimals="2"
id="ixv-20547"
unitRef="pure">681.44
contextRef="c136"
decimals="2"
id="ixv-20548"
unitRef="pure">6874.13
contextRef="c137"
decimals="2"
id="ixv-20549"
unitRef="pure">6874.13
contextRef="c138"
decimals="2"
id="ixv-20550"
unitRef="pure">4.21
contextRef="c139"
decimals="2"
id="ixv-20551"
unitRef="pure">4.21
contextRef="c140"
decimals="2"
id="ixv-20552"
unitRef="pure">4
contextRef="c141"
decimals="2"
id="ixv-20553"
unitRef="pure">5
contextRef="c142"
decimals="2"
id="ixv-20554"
unitRef="pure">59.98
contextRef="c143"
decimals="2"
id="ixv-20555"
unitRef="pure">59.98
2029-01-25
2029-01-25
contextRef="c126"
decimals="0"
id="ixv-20556"
unitRef="usdPershares">200096
875000
26608
694516
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2025, the derivative warrant liability
was $200,096 (March 31, 2024 – $901,608 ) reconciled as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; text-align: justify"><b>Derivative warrant liability – Public and Private Warrants</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount<br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: justify">At listing January 25, 2024</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">21,866</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">595,358</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Fair value loss</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">306,250</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Opening balance April 1, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">21,866</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">901,608</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Warrant exchange</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(1,104</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(6,996</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Fair value gain</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(694,516</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 2.5pt">Balance as at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">20,762</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">200,096</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
200096
901608
contextRef="c146"
decimals="INF"
id="ixv-20562"
unitRef="shares">21866
595358
306250
contextRef="c5"
decimals="INF"
id="ixv-20565"
unitRef="shares">21866
901608
contextRef="c0"
decimals="INF"
id="ixv-20567"
unitRef="shares">-1104
-6996
-694516
contextRef="c4"
decimals="INF"
id="ixv-20570"
unitRef="shares">20762
200096
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Warrant transactions and the number of warrants
outstanding are summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Public Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Private Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Balance, April 1, 2023</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Issued</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">20,912</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">954</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Balance, March 31, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">20,912</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">6,874.13</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">954</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">6,874.13</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Warrant exchange</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,104</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Balance, March 31, 2025</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,808</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">954</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>
contextRef="c150"
decimals="INF"
id="ixv-20572"
unitRef="shares">20912
contextRef="c150"
decimals="2"
id="ixv-20573"
unitRef="usdPershares">6874.13
contextRef="c151"
decimals="INF"
id="ixv-20574"
unitRef="shares">954
contextRef="c151"
decimals="2"
id="ixv-20575"
unitRef="usdPershares">6874.13
contextRef="c127"
decimals="INF"
id="ixv-20576"
unitRef="shares">20912
contextRef="c127"
decimals="2"
id="ixv-20577"
unitRef="usdPershares">6874.13
contextRef="c128"
decimals="INF"
id="ixv-20578"
unitRef="shares">954
contextRef="c128"
decimals="2"
id="ixv-20579"
unitRef="usdPershares">6874.13
contextRef="c126"
decimals="INF"
id="ixv-20580"
unitRef="shares">-1104
contextRef="c126"
decimals="2"
id="ixv-20581"
unitRef="usdPershares">6874.13
contextRef="c152"
decimals="2"
id="ixv-20582"
unitRef="usdPershares">6874.13
contextRef="c122"
decimals="INF"
id="ixv-20583"
unitRef="shares">19808
contextRef="c122"
decimals="2"
id="ixv-20584"
unitRef="usdPershares">6874.13
contextRef="c153"
decimals="INF"
id="ixv-20585"
unitRef="shares">954
contextRef="c153"
decimals="2"
id="ixv-20586"
unitRef="usdPershares">6874.13
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following warrants were outstanding and exercisable
at March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issue Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiry Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt">January 25, 2024</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 19%; text-align: center; padding-bottom: 1.5pt">January 25, 2029</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 17%; border-bottom: Black 1.5pt solid; text-align: right">6,874.13</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 17%; border-bottom: Black 1.5pt solid; text-align: right">20,762</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 17%; border-bottom: Black 1.5pt solid; text-align: right">20,762</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>
2029-01-25
contextRef="c155"
decimals="2"
id="ixv-20588"
unitRef="usdPershares">6874.13
contextRef="c155"
decimals="INF"
id="ixv-20589"
unitRef="shares">20762
contextRef="c155"
decimals="INF"
id="ixv-20590"
unitRef="shares">20762
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>11. Promissory Notes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 25, 2024, the Company issued an unsecured
convertible promissory note to PGI (the “<b>PGI Note</b>”), in the principal amount of $1,610,657, which is equal to the total
amount owed to PGI in connection with loans that PGI had previously made to the Company. The PGI Note bore no interest, and (i) $150,000
of the principal balance of the PGI Note was paid on the Closing Date and (ii) $1,460,657 of the principal balance of the PGI Note was
payable on the date that is the one-year anniversary after the Closing Date, or January 25, 2025. The proceeds from this loan were received
by the Company prior to the Closing Date. This note is convertible into shares at the option of PGI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 25, 2024, the Company issued an unsecured
convertible promissory note to the NCAC Sponsor (the “<b>NCAC Note</b>”), in the principal amount of $1,615,501, which is
equal to the total amount owed to NCAC Sponsor under certain existing promissory notes previously issued by NCAC to the NCAC Sponsor (the
“<b>Existing Notes</b>”). The NCAC Note bore no interest, and (i) $100,000 of the principal balance of the NCAC Note became
owing on the Closing Date and (ii) $1,515,501 of the principal balance of the NCAC Note was payable on the date that is the one-year anniversary
after the Closing Date, or January 25, 2025. This note is convertible into shares at the option of NCAC Sponsor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Both notes were designated at FVTPL due to the
embedded conversion features, as the conversion prices were not fixed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">At inception on January 25, 2024 the fair value
of the PGI Note was $1,418,675 and the NCAC note was $1,413,529.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>PGI Note: </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On September 30, 2024, the Company entered into
Debt for Equity Exchange Agreement with PGI pursuant to which the Company issued 3,473 of common shares to extinguish $1,307,960 of PGI
Note, representing a conversion price of $298.88 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On October 25, 2024, the Company entered into
Debt for Equity Exchange Agreement with PGI pursuant to which the Company issued 1,414 of common shares to extinguish the remaining balance
of PGI Note representing, a conversion price of $298.88 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In accordance with the Debt for Equity Exchange
Agreements entered into on September 30, 2024 and October 25, 2024, as amended, the Company will need to issue additional shares to PGI
if the Company’s volume weighted average share price for the 10 days prior to November 26, 2024 is lower than $298.88 per share
(“<b>PGI make whole payment</b>”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In December 2024, the Company issued 42,378 common
shares to extinguish the PGI make whole payment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The issuance of shares pursuant to the Debt for
Equity Exchange Agreements resulted in a fair value gain of $327,668 which was recorded in the consolidated statements of income/(loss)
and comprehensive income/(loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>NCAC </b>Note<b>:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On September 30, 2024, the Company entered into
Debt for Equity Exchange Agreement with NCAC Sponsor pursuant to which the Company issued 5,405 of common shares to extinguish the outstanding
balance of NCAC Note, representing a conversion price of $298.88 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In accordance with the Debt for Equity Exchange
Agreements, as amended, the Company will need to issue additional shares to NCAC Sponsor if the Company’s volume weighted average
share price for the 10 days prior to November 26, 2024 is lower than $298.88 per share (“<b>NCAC make whole payment</b>”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In December 2024, the Company issued 46,870 common
shares to extinguish the NCAC make whole payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The issuance of shares pursuant to the Debt for
Equity Exchange Agreements resulted in a fair value gain of $377,897 which was recorded in the consolidated statements of income/(loss)
and comprehensive income/(loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The fair value of the notes was calculated using
a credit adjusted market borrowing rate as at March 31, 2024. The fair value of both notes was $<span style="-sec-ix-hidden: hidden-fact-137">nil</span> as at March 31, 2025 (March 31, 2024
- $2,790,492). A fair value gain of $705,565 was recognized during the year in the statement of comprehensive income (March 31, 2024 ($108,288)).</p>
1610657
150000
1460657
1615501
100000
1515501
1418675
1413529
contextRef="c163"
decimals="0"
id="ixv-20599"
unitRef="shares">3473
1307960
contextRef="c163"
decimals="2"
id="ixv-20601"
unitRef="usdPershares">298.88
contextRef="c165"
decimals="0"
id="ixv-20602"
unitRef="shares">1414
contextRef="c165"
decimals="2"
id="ixv-20603"
unitRef="usdPershares">298.88
contextRef="c166"
decimals="2"
id="ixv-20604"
unitRef="usdPershares">298.88
contextRef="c167"
decimals="0"
id="ixv-20605"
unitRef="shares">42378
327668
contextRef="c169"
decimals="0"
id="ixv-20607"
unitRef="shares">5405
contextRef="c169"
decimals="2"
id="ixv-20608"
unitRef="usdPershares">298.88
contextRef="c170"
decimals="2"
id="ixv-20609"
unitRef="usdPershares">298.88
contextRef="c171"
decimals="0"
id="ixv-20610"
unitRef="shares">46870
377897
2790492
705565
-108288
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>12. ELOC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On August 28, 2024, the Company entered into a
$25 million equity line of credit (ELOC) agreement with White Lion Capital, LLC, which was declared effective by the U.S. Securities and
Exchange Commission (SEC). This agreement allows the Company to sell up to $25 million in shares over a 24-month period, subject to specific
conditions outlined in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As part of the consideration for entering into
the ELOC, the Company issued 3,392 common shares to White Lion at a fair value of $187,500 as a commitment fee. These shares were accounted
for as share issuance costs in the Consolidated Statement of Changes in Shareholders’ Equity/(Deficit).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">During the year ended March 31, 2025, the Company
issued 218,900 common shares for total consideration of $6,692,495. The Company incurred $282,100 in cash settled share issuance costs.</p>
contextRef="c177"
decimals="-6"
id="ixv-20615"
unitRef="usd">25000000
contextRef="c177"
decimals="-6"
id="ixv-20616"
unitRef="usd">25000000
contextRef="c178"
decimals="0"
id="ixv-20617"
unitRef="shares">3392
187500
contextRef="c180"
decimals="0"
id="ixv-20619"
unitRef="shares">218900
6692495
282100
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>13. Psyence Labs Ltd. Share Exchange</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On October 28, 2024, the Company acquired 1,000
shares in Psyence Labs Ltd. (PsyLabs) from PGI, the Company’s parent company. PsyLabs is a private company headquartered in the
British Virgin Islands. PsyLabs is focused on the production of psychedelic active pharmaceutical ingredients and extracts. The Company
issued 3,346 common shares in exchange for the shares in PsyLabs. There was a make whole provision which entitled the PGI to a top-up
in shares if the share price at November 26, 2024 was lower than the issuance price on October 28, 2024. The share price was lower which
triggered the top-up leading to the issuance of an additional 32,248 shares to PGI. The total consideration was 35,594 shares. Based on
the listed share price of PBM’s common shares at the respective dates of issuance, the total fair value of shares issued was $722,033,
which was recorded as the cost of the investment in PsyLabs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Fair Value Assessment</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2025, the Company determined the
fair value of its investment in PsyLabs to be $745,000, based on a recent arm’s length subscription transaction by a third-party
investor at $745 per PsyLabs share. This price was considered to represent a Level 2 input under the fair value hierarchy in accordance
with <i>IFRS 13 – Fair Value Measurement</i>, as it reflects observable market-based pricing for an identical equity instrument
in an active negotiation with a market participant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As a result, the Company recognized an unrealized
fair value gain of $22,967 in the statement of profit or loss and other comprehensive income for the year ended March 31, 2025, in accordance
with <i>IFRS 9 – Financial Instruments</i>, as the investment is classified as a financial asset measured at fair value through
profit or loss (FVTPL).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt; font-weight: bold">Summary of transaction</td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-align: justify">Number of shares in PsyLabs acquired</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Total PBM shares issued</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">35,594</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Total fair value of shares issued</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">722,033</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Fair value of investment at March 31, 2025</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">745,000</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Fair value gain recognized</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">22,967</td><td style="text-align: left"> </td></tr>
</table>
contextRef="c181"
decimals="0"
id="ixv-20622"
unitRef="shares">1000
contextRef="c182"
decimals="0"
id="ixv-20623"
unitRef="shares">3346
contextRef="c183"
decimals="0"
id="ixv-20624"
unitRef="shares">32248
contextRef="c184"
decimals="0"
id="ixv-20625"
unitRef="shares">35594
722033
745000
745
22967
<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt; font-weight: bold">Summary of transaction</td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-align: justify">Number of shares in PsyLabs acquired</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,000</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Total PBM shares issued</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">35,594</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Total fair value of shares issued</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">722,033</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Fair value of investment at March 31, 2025</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">745,000</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Fair value gain recognized</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">22,967</td><td style="text-align: left"> </td></tr>
</table>
contextRef="c4"
decimals="0"
id="ixv-20630"
unitRef="shares">1000
contextRef="c4"
decimals="0"
id="ixv-20631"
unitRef="shares">35594
722033
745000
22967
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>14. PIPE Financing - Private Placement and
Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Private placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On December 24, 2024, the Company completed a private
placement with HC Wainwright &amp; Co., LLC (“HCW”), raising gross proceeds of $<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000
through the issuance of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,679 common shares,</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,792 pre-funded warrants (each exercisable into one common share at a nominal exercise price of $0.000797), and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,942 common share p</span><span style="font-family: Times New Roman, Times, Serif">urchase warrants, comprising:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">125,471 warrants with an exercise price of $15.94 and a 5-year term (expiring December 24, 2029), and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"> </p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">o</td><td style="text-align: justify">125,471 warrants with an exercise price of $15.94 and a 2-year term (expiring December 24, 2026).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The proceeds were allocated between the common
shares and the warrants based on their relative fair values on the date of issuance. The fair value allocation was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt; font-weight: bold">Fair value allocation</td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Component</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Allocated Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-align: justify">Common shares</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">313,628</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Pre-funded warrants</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">511,690</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,174,682</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Total gross proceeds</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">2,000,000</td><td style="text-align: left"> </td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Fair value allocation assumptions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The common shares were estimated using the share
price on date of issuance - $19.37.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The pre-funded warrants and the warrants were
estimated using a Black Scholes valuation model using the following estimates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pre-funded <br/>
warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants with <br/>
5 year expiry</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant with <br/>
2 year expiry</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Share price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19.37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15.94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.63</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.63</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.63</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expiry date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-142">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 24, 2029</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 24, 2026</span></td><td style="text-align: left"> </td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Share Issuance Costs</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company incurred $257,949 in cash settled
share issuance costs, which were allocated proportionately to the equity instruments issued. The portion related to the common shares,
$40,449, was deducted from share capital, and the portion related to the warrants, $217,500, was deducted from the warrant reserve. The
Company also incurred $137,778 in warrant settled issuance costs, 9,409 warrants, which was allocated to warrant reserve.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Pre-funded Warrant Exercise</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">During the year ended March 31, 2025, all 77,792
pre-funded warrants were exercised. An amount of $511,690, representing the fair value originally allocated to the pre-funded warrants,
was reclassified from warrant reserve to share capital upon exercise. An amount of $66,003 of share issuance costs was reallocated to
share capital upon exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">All instruments issued in the private placement
were classified as equity instruments, as they did not contain any contractual obligations to deliver cash or other financial assets and
met the fixed-for-fixed condition.</p>
2000000
contextRef="c185"
decimals="0"
id="ixv-20636"
unitRef="shares">47679
contextRef="c185"
decimals="0"
id="ixv-20637"
unitRef="shares">77792
contextRef="c185"
decimals="6"
id="ixv-20638"
unitRef="usdPershares">0.000797
contextRef="c185"
decimals="0"
id="ixv-20639"
unitRef="shares">250942
contextRef="c186"
decimals="0"
id="ixv-20640"
unitRef="shares">125471
contextRef="c187"
decimals="2"
id="ixv-20641"
unitRef="usdPershares">15.94
P5Y
contextRef="c188"
decimals="0"
id="ixv-20643"
unitRef="shares">125471
contextRef="c189"
decimals="2"
id="ixv-20644"
unitRef="usdPershares">15.94
P2Y
The fair value allocation was as follows:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt; font-weight: bold">Fair value allocation</td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Component</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Allocated Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-align: justify">Common shares</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">313,628</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Pre-funded warrants</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">511,690</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,174,682</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Total gross proceeds</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">2,000,000</td><td style="text-align: left"> </td></tr>
</table>
313628
511690
1174682
2000000
contextRef="c191"
decimals="2"
id="ixv-20651"
unitRef="usdPershares">19.37
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The pre-funded warrants and the warrants were
estimated using a Black Scholes valuation model using the following estimates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pre-funded <br/>
warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants with <br/>
5 year expiry</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant with <br/>
2 year expiry</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Share price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19.37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15.94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.63</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.63</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.63</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expiry date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-142">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 24, 2029</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 24, 2026</span></td><td style="text-align: left"> </td></tr> </table>
contextRef="c192"
decimals="2"
id="ixv-20652"
unitRef="pure">19.37
contextRef="c193"
decimals="2"
id="ixv-20653"
unitRef="pure">19.37
contextRef="c194"
decimals="2"
id="ixv-20654"
unitRef="pure">19.37
contextRef="c198"
decimals="2"
id="ixv-20655"
unitRef="pure">0
contextRef="c199"
decimals="2"
id="ixv-20656"
unitRef="pure">15.94
contextRef="c200"
decimals="2"
id="ixv-20657"
unitRef="pure">15.94
contextRef="c201"
decimals="2"
id="ixv-20658"
unitRef="pure">3.63
contextRef="c202"
decimals="2"
id="ixv-20659"
unitRef="pure">3.63
contextRef="c203"
decimals="2"
id="ixv-20660"
unitRef="pure">3.63
contextRef="c205"
decimals="2"
id="ixv-20661"
unitRef="pure">5
contextRef="c206"
decimals="2"
id="ixv-20662"
unitRef="pure">2
contextRef="c207"
decimals="0"
id="ixv-20663"
unitRef="pure">100
contextRef="c208"
decimals="0"
id="ixv-20664"
unitRef="pure">100
contextRef="c209"
decimals="0"
id="ixv-20665"
unitRef="pure">100
December 24, 2029
December 24, 2026
257949
40449
217500
137778
contextRef="c188"
decimals="0"
id="ixv-20670"
unitRef="shares">9409
contextRef="c189"
decimals="0"
id="ixv-20671"
unitRef="shares">77792
511690
66003
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>15. Share capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>a) Authorized</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company is authorized to issue an unlimited
number of Common Shares, each without par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>b) Issued and outstanding</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On November 26, 2024, the Company consolidated
its common shares on the basis of 75:1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On May 5, 2025, the Company consolidated its common
shares and warrants on the basis of 7.97:1. All common shares and value per share amounts have been updated to reflect the share consolidations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2025, there were 568,021 (March
31, 2024 – <span style="-sec-ix-hidden: hidden-fact-150">22,402</span>) issued and outstanding Common Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; text-align: justify"><b>Common shares</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: justify">Opening balance April 1, 2024</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">22,402</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">46,125,397</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued on conversion of convertible note</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">38,156</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4,617,286</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Shares issued on conversion of convertible note warrants</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">22,876</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">639,954</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued for ELOC</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">218,900</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">6,692,495</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Commitment shares ELOC</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">3,392</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">187,500</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Share issuance costs for ELOC</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(469,600</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Warrant exchange</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,104</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">192,060</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued to third party advisors</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">586</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">241,379</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Shares issued on conversion of PGI promissory notes</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">47,265</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">988,569</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued on conversion of NCAC promissory notes</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">52,275</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,096,358</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Shares issued for PsyLabs share exchange</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">35,594</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">722,033</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued for PIPE financing</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">47,679</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">313,628</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Share issuance costs for PIPE financing</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(40,449</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued for PIPE pre-funded warrants exercised</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">77,792</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">511,690</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Shares issuance costs for PIPE pre-funded warrants exercised</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,995</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 2.5pt">Balance as at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">568,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">61,752,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 25, 2024, because of the completion
of the RTO Transaction, the Company issued 8,365 Common Shares to PGI, 13,040 to the previous shareholders of NCAC and 997 to third party
advisors (see Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Payments to advisors of NCAC was settled in the
Company’s shares upon RTO Transaction at the closing price. Accounts payable of $2,136,340 acquired from NCAC as part of the RTO
Transaction was settled through the issuance of 746 shares at a fair value of $2,863.22 per share on January 25, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">An amount of $1,000,000 owing by the Company for
services provided in relation to the RTO Transaction was settled through the issuance of 251 common shares at a fair value of $2,863.22.
A gain on settlement of $281,500 was included in the consolidated statements of net loss and comprehensive loss relating to this advisor
settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The opening balance of equity is the net parent investment which represents
the net financings that the Company received from PGI to fund its operations through contributions to the clinical trials, cash extended
to the Company’s subsidiaries and the net effect of cost allocations from transactions with PGI, all of which did not require repayments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>c) Income/(Loss) per share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The calculation of basic and diluted income/(loss)
per share is based on the income/(loss) for the year divided by the weighted average number of shares in circulation during the year.
In calculating the diluted loss per share, potentially dilutive shares such as options, convertible debt and warrants have not been included
as they would have the effect of decreasing the loss per share, and they would therefore be anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>d) Warrant Reserve</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2025, there were 261,188 (March
31, 2024 – <span style="-sec-ix-hidden: hidden-fact-151"><span style="-sec-ix-hidden: hidden-fact-152">nil</span></span>) issued and outstanding Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; text-align: justify"><b>Warrants</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Opening balance April 1, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="width: 76%; text-align: justify">Warrants issued for convertible note Addendum</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">837</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">42,528</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Warrants issued for convertible note Termination Agreement</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">22,876</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">639,954</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Convertible note Termination Agreement warrants exercised</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(22,876</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(639,954</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">PIPE financing warrant issuance</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">328,734</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,686,372</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">PIPE financing warrant issuance costs</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">9,409</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">137,778</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Issuance costs for PIPE financing warrants</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(355,278</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">PIPE pre-funded warrants exercised</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(77,792</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(511,690</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Issuance costs for PIPE pre-funded warrants exercised</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,995</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 2.5pt">Balance as at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">261,188</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,065,705</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following warrants were outstanding and exercisable
at March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt">August 20, 2024</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 19%; text-align: center; padding-bottom: 1.5pt">August 20, 2026</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">298.88</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">837</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">837</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2029</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">15.94</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">125,471</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">125,471</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">15.94</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">125,471</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">125,471</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2029</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">19.93</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">9,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">9,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2025, there were 568,021 (March
31, 2024 – <span style="-sec-ix-hidden: hidden-fact-150">22,402</span>) issued and outstanding Common Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; text-align: justify"><b>Common shares</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: justify">Opening balance April 1, 2024</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">22,402</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">46,125,397</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued on conversion of convertible note</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">38,156</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4,617,286</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Shares issued on conversion of convertible note warrants</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">22,876</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">639,954</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued for ELOC</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">218,900</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">6,692,495</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Commitment shares ELOC</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">3,392</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">187,500</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Share issuance costs for ELOC</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(469,600</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Warrant exchange</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,104</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">192,060</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued to third party advisors</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">586</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">241,379</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Shares issued on conversion of PGI promissory notes</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">47,265</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">988,569</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued on conversion of NCAC promissory notes</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">52,275</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,096,358</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Shares issued for PsyLabs share exchange</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">35,594</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">722,033</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued for PIPE financing</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">47,679</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">313,628</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Share issuance costs for PIPE financing</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(40,449</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Shares issued for PIPE pre-funded warrants exercised</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">77,792</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">511,690</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Shares issuance costs for PIPE pre-funded warrants exercised</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,995</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 2.5pt">Balance as at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">568,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">61,752,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
contextRef="c213"
decimals="INF"
id="ixv-20674"
unitRef="shares">568021
contextRef="c213"
decimals="INF"
id="ixv-20675"
unitRef="shares">568021
contextRef="c214"
decimals="0"
id="ixv-20676"
unitRef="shares">22402
contextRef="c34"
decimals="INF"
id="ixv-20677"
unitRef="shares">22402
46125397
contextRef="c39"
decimals="INF"
id="ixv-20679"
unitRef="shares">38156
4617286
contextRef="c39"
decimals="INF"
id="ixv-20681"
unitRef="shares">22876
639954
contextRef="c39"
decimals="INF"
id="ixv-20683"
unitRef="shares">218900
6692495
contextRef="c39"
decimals="INF"
id="ixv-20685"
unitRef="shares">3392
187500
469600
contextRef="c39"
decimals="INF"
id="ixv-20688"
unitRef="shares">1104
192060
contextRef="c39"
decimals="INF"
id="ixv-20690"
unitRef="shares">586
241379
contextRef="c39"
decimals="INF"
id="ixv-20692"
unitRef="shares">47265
988569
contextRef="c39"
decimals="INF"
id="ixv-20694"
unitRef="shares">52275
1096358
contextRef="c39"
decimals="INF"
id="ixv-20696"
unitRef="shares">35594
722033
contextRef="c39"
decimals="INF"
id="ixv-20698"
unitRef="shares">47679
313628
40449
contextRef="c39"
decimals="INF"
id="ixv-20701"
unitRef="shares">77792
511690
-65995
contextRef="c44"
decimals="INF"
id="ixv-20704"
unitRef="shares">568021
61752305
contextRef="c215"
decimals="INF"
id="ixv-20706"
unitRef="shares">8365
contextRef="c216"
decimals="INF"
id="ixv-20707"
unitRef="shares">13040
contextRef="c217"
decimals="INF"
id="ixv-20708"
unitRef="shares">997
2136340
contextRef="c218"
decimals="INF"
id="ixv-20710"
unitRef="shares">746
contextRef="c218"
decimals="2"
id="ixv-20711"
unitRef="usdPershares">2863.22
1000000
contextRef="c219"
decimals="INF"
id="ixv-20713"
unitRef="shares">251
contextRef="c5"
decimals="2"
id="ixv-20714"
unitRef="usdPershares">2863.22
281500
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2025, there were 261,188 (March
31, 2024 – <span style="-sec-ix-hidden: hidden-fact-151"><span style="-sec-ix-hidden: hidden-fact-152">nil</span></span>) issued and outstanding Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; text-align: justify"><b>Warrants</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Opening balance April 1, 2024</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="width: 76%; text-align: justify">Warrants issued for convertible note Addendum</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">837</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">42,528</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Warrants issued for convertible note Termination Agreement</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">22,876</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">639,954</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">Convertible note Termination Agreement warrants exercised</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(22,876</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(639,954</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">PIPE financing warrant issuance</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">328,734</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,686,372</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">PIPE financing warrant issuance costs</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">9,409</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">137,778</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Issuance costs for PIPE financing warrants</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(355,278</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify">PIPE pre-funded warrants exercised</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(77,792</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(511,690</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Issuance costs for PIPE pre-funded warrants exercised</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,995</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 2.5pt">Balance as at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">261,188</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,065,705</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
contextRef="c220"
decimals="0"
id="ixv-20716"
unitRef="shares">261188
contextRef="c220"
decimals="0"
id="ixv-20717"
unitRef="shares">261188
contextRef="c223"
decimals="INF"
id="ixv-20718"
unitRef="shares">837
42528
contextRef="c223"
decimals="INF"
id="ixv-20720"
unitRef="shares">22876
639954
contextRef="c223"
decimals="INF"
id="ixv-20722"
unitRef="shares">-22876
-639954
contextRef="c223"
decimals="INF"
id="ixv-20724"
unitRef="shares">328734
1686372
contextRef="c223"
decimals="INF"
id="ixv-20726"
unitRef="shares">9409
137778
-355278
contextRef="c223"
decimals="INF"
id="ixv-20729"
unitRef="shares">-77792
-511690
65995
contextRef="c223"
decimals="INF"
id="ixv-20732"
unitRef="shares">261188
1065705
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following warrants were outstanding and exercisable
at March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiry Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: center; padding-bottom: 1.5pt">August 20, 2024</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 19%; text-align: center; padding-bottom: 1.5pt">August 20, 2026</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">298.88</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">837</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">837</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2029</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">15.94</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">125,471</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">125,471</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">15.94</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">125,471</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">125,471</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">December 24, 2029</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">19.93</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">9,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">9,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>
2026-08-20
contextRef="c225"
decimals="2"
id="ixv-20735"
unitRef="usdPershares">298.88
contextRef="c225"
decimals="INF"
id="ixv-20736"
unitRef="shares">837
contextRef="c225"
decimals="INF"
id="ixv-20737"
unitRef="shares">837
2029-12-24
contextRef="c226"
decimals="2"
id="ixv-20739"
unitRef="usdPershares">15.94
contextRef="c226"
decimals="INF"
id="ixv-20740"
unitRef="shares">125471
contextRef="c226"
decimals="INF"
id="ixv-20741"
unitRef="shares">125471
2026-12-24
contextRef="c227"
decimals="2"
id="ixv-20743"
unitRef="usdPershares">15.94
contextRef="c227"
decimals="INF"
id="ixv-20744"
unitRef="shares">125471
contextRef="c227"
decimals="INF"
id="ixv-20745"
unitRef="shares">125471
2029-12-24
contextRef="c228"
decimals="2"
id="ixv-20747"
unitRef="usdPershares">19.93
contextRef="c228"
decimals="INF"
id="ixv-20748"
unitRef="shares">9409
contextRef="c228"
decimals="INF"
id="ixv-20749"
unitRef="shares">9409
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>16. Other income </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In the prior year ended, March 31, 2024, the Company
received a research and development rebate of AUD $1,336,622 ($879,344) from the Australian Taxation office. The Company benefits from
the Australian Federal Government’s Research &amp; Development tax incentive program, which provides up to a 43.5% rebate on research
and development expenses in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This rebate represents a government grant aimed
at supporting research and development activities. Therefore, in accordance with <i>IAS 20, Accounting for Governmental Grants and Disclosure
of Government Assistance</i>, the grant is recognized as income when there is a reasonable assurance that the grant will be received and
that the Company will comply with the conditions attached to it. These conditions were satisfied when the Company received the rebate
on October 5, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On August 21, 2023 the Company entered into a
loan agreement via its Australian subsidiary Psyence Australia (Pty) Ltd (the "<b>Borrower</b>"), to borrow up to AUD $1,100,000
by way of a secured loan from RH Capital Finance Co., LLC (“<b>Lender</b>”). The Loan is secured by way of a General Security
Agreement and company guarantee against the assets of the Borrower and the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The loan was granted to the Borrower after it
successfully registered its research and development activities with the Australian Federal Government. The Borrower benefits from the
Australian Federal Government’s Research &amp; Development tax incentive program, which provides up to a 43.5% rebate on research
and development expenses in Australia. The Loan bears interest at 16% per annum subject to a minimum interest chargeable period of 91
days and is repayable at the earlier of: (a) 21 business days after the notice of assessment (in respect of R&amp;D refunds) is issued
by the Australian Taxation Office to the Borrower for the financial year ended June 30, 2023 (b) an event of default and (c) 30 November
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The loan with the Lender was repaid in full on
October 5, 2023 when the Company received the research and development rebate from the Australian Taxation office, which was utilized
to settle the loan payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">$<span style="-sec-ix-hidden: hidden-fact-153">nil</span> (March 31, 2024 - $29,697) in interest expense
was incurred during the year ended March 31, 2025, on this loan. The loan and all outstanding interest was repaid.</p>
1336622
879344
0.435
1100000
contextRef="c231"
decimals="3"
id="ixv-20754"
unitRef="pure">0.435
contextRef="c232"
decimals="2"
id="ixv-20755"
unitRef="pure">0.16
P91D
P21D
29697
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>17. Capital management</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company’s objectives when managing capital
are to safeguard the Company’s ability to continue as a going concern to pursue the development of natural health business, to maintain
a flexible capital structure which optimizes the cost of capital at an acceptable risk level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company manages its capital structure and
adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its
capital structure, the Company may obtain additional funding from equity financing, issue new debt, acquire or dispose of assets or adjust
the amount of cash and cash equivalents on hand. The Company defines capital as the aggregate of its capital stock and borrowings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Total managed capital is as follows as at March
31, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Borrowings</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,447,889</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Share capital</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,752,305</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,125,397</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">61,752,305</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">56,573,286</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">To facilitate the management of its capital requirements,
the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment
and general industry conditions. The annual and updated budgets are approved by the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Management considers its approach to capital management
to be appropriate given the relative size of the Company. There were no changes in the Company’s approach to capital management
during the period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Total managed capital is as follows as at March
31, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">Borrowings</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,447,889</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Share capital</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,752,305</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,125,397</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">61,752,305</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">56,573,286</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
10447889
61752305
46125397
61752305
56573286
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>18. Transactions with related parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">All related party transactions are measured at
the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from
or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments.
The Company incurred the following transactions with related parties during the years ended March 31, 2025 and March 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Compensation to key management personnel</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Key management personnel are those people who
have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management
personnel include the Company’s executive officers and Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Key Management Personnel</td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>March 31, <br/>
2025</b></span></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Short term benefits</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">984,697</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">465,702</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-bottom: 1.5pt">Share based compensation</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,295</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">984,697</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">698,997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Short term benefits consist of consulting fees,
director’s fees, payroll and other benefits paid to key management personnel. Share based compensation is options granted to key
management personnel.</p>
Key management
personnel include the Company’s executive officers and Board of Directors.<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Key Management Personnel</td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>March 31, <br/>
2025</b></span></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Short term benefits</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">984,697</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">465,702</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-bottom: 1.5pt">Share based compensation</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,295</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">984,697</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">698,997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
984697
465702
233295
984697
698997
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>19. Share based compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">During the year ended March 31, 2025, $<span style="-sec-ix-hidden: hidden-fact-156">nil</span> (Year
ended March 31, 2024 - $317,882) was recognized for options and restricted stock units (“RSU’s”) granted by Psyence
Group under professional and consulting fees expenses and general and administrative expenses on the consolidated statements of net loss
and comprehensive loss. No options are outstanding as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This share-based compensation relates only to
the historic carve out pre-combination period and does not relate to options or RSUs in the Company. <span style="-sec-ix-hidden: hidden-fact-157"><span style="-sec-ix-hidden: hidden-fact-158">No</span></span> share options or RSUs have been
issued by the Company during the year.</p>
317882
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>20. Income tax note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The reconciliation of the combined Canadian federal
and provincial statutory income tax rate of 26.5% (2024 – 26.5%) to the effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net Income/(Loss) before recovery of income taxes</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,011,790</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(51,159,048</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Expected income tax (recovery)/expense</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">268,124</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(13,557,148</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Difference in foreign tax rates</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">6,871</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">966</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Listing expense</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">10,992,625</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Non-taxable fair value gain adjustment</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(1,722,146</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Non-deductible loss on loan settlement</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">449,196</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Share issue costs booked to equity</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(246,802</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Other permanent expenses</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,787</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,061,001</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Change in tax benefits not recognized</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,242,970</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">502,556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Income tax (recovery)/expense</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Unrecognized deferred tax asset</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Deferred taxes are provided as a result of temporary
differences that arise due to the differences between the income tax values and the carrying amounts of assets and liabilities. Deferred
tax assets have not been recognized in respect of the following deductible temporary differences:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Unrecognized deductible temporary differences</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%">Equipment</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,508</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">240</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Restricted interest and financing expenses – Canada</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">764,297</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Share issuance costs and others</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">722,097</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">124,132</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Non-capital losses carried forward-Canada</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4,248,226</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,357,347</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Non-capital losses carried forward-Australia</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">431,349</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">164,861</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,170,477</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,646,580</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company’s non-capital loss carry forwards
will expire as noted in the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Year of expiry</b></td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Canada</b></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Australia</b></td><td style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">2044</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,357,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">2045</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,890,879</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Indefinite</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">431,349</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Total</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4,248,226</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">431,349</td><td style="text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The reconciliation of the combined Canadian federal
and provincial statutory income tax rate of 26.5% (2024 – 26.5%) to the effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net Income/(Loss) before recovery of income taxes</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,011,790</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(51,159,048</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Expected income tax (recovery)/expense</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">268,124</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(13,557,148</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Difference in foreign tax rates</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">6,871</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">966</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Listing expense</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">10,992,625</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Non-taxable fair value gain adjustment</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(1,722,146</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Non-deductible loss on loan settlement</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">449,196</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Share issue costs booked to equity</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(246,802</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Other permanent expenses</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,787</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,061,001</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left; padding-bottom: 1.5pt">Change in tax benefits not recognized</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,242,970</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">502,556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Income tax (recovery)/expense</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>
contextRef="c234"
decimals="3"
id="ixv-20771"
unitRef="pure">0.265
contextRef="c235"
decimals="3"
id="ixv-20772"
unitRef="pure">0.265
1011790
-51159048
268124
-13557148
6871
966
10992625
1722146
449196
246802
1787
2061001
1242970
502556
Deferred
tax assets have not been recognized in respect of the following deductible temporary differences:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Unrecognized deductible temporary differences</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%">Equipment</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,508</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">240</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Restricted interest and financing expenses – Canada</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">764,297</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Share issuance costs and others</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">722,097</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">124,132</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Non-capital losses carried forward-Canada</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4,248,226</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,357,347</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Non-capital losses carried forward-Australia</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">431,349</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">164,861</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,170,477</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,646,580</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>
4508
240
764297
722097
124132
4248226
1357347
431349
164861
6170477
1646580
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company’s non-capital loss carry forwards
will expire as noted in the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Year of expiry</b></td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Canada</b></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td>
<td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Australia</b></td><td style="padding-bottom: 1.5pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">2044</td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,357,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">2045</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,890,879</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Indefinite</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">431,349</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: left">Total</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4,248,226</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">431,349</td><td style="text-align: left"> </td></tr>
</table>
1357347
2890879
431349
4248226
431349
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>21. Financial instruments and financial risk
management</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>a) Financial instrument classification and
fair value measurement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial instruments that are recorded at fair
value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance
of the inputs used in making the measurements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The fair value of hierarchy has the fol<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lowing
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 – quoted prices in active markets for identical financial instruments.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"></td><td style="text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 – quoted prices for similar instruments in active markets; quoted prices for identical
or similar instruments in the markets that are not active; and model-derived valuations in
which all significant inputs and significant value drivers are observable in active markets.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"></td><td style="text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 – valuations derived from valuation techniques in which one or more significant inputs
or significant value drivers are unobservable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The table below presents the carrying value of
the Company’s financial instruments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Investment in Psyence Labs Ltd</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">745,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">745,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Derivative warrant liabilities – public warrants</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,096</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,096</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance, March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">200,096</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">745,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">945,096</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Derivative warrant liabilities – private warrants</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">26,608</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">26,608</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Derivative warrant liabilities – public warrants</td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">875,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">875,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Convertible notes</td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">7,657,397</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">7,657,397</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">NCAC Sponsor promissory note</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,474,256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,474,256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">PGI promissory note</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,316,236</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,316,236</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance, March 31, 2024</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">875,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">26,608</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">10,447,889</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,349,497</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The face value of the other financial instruments
approximates the fair value due to the short-term maturity nature of the financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">There were no transfers in and out of level 3
during the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>b) Risk management</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In the normal course of business, the Company
is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial
risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company’s Board of
Directors has overall responsibility for the establishment and oversight of the Company’s risk management framework.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Credit risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Credit risk arises from cash and cash equivalents
held with banks. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing
counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents
by depositing with only reputable financial institutions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Liquidity risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Liquidity risk is the risk that the Company will
not be able to meet its financial obligations as they fall due.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company manages liquidity risk through an
ongoing review of future commitments and cash balances available. Historically, the Company’s main source of funding has been through
investments from its parent. The Company’s access to financing is uncertain. There can be no assurance of continued access to significant
equity or debt funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table set forth the maturity of
the contractual obligations as at March 31, 2025 and after</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual Cash Flows</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than 1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Between 1 and 3 years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Accounts payable &amp; accrued liabilities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">394,270</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">394,270</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">394,270</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">         -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total contractual obligations</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">394,270</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">394,270</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">394,270</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Interest rate risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Interest rate risk is the risk that the fair value
of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has no significant
interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially independent of changes in market
interest rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>Foreign exchange risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Foreign currency risk is the risk that the fair
values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective
functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at March 31, 2025, a 10% fluctuation in foreign
exchange rates would result in a $8,861 impact to net loss and comprehensive loss.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The table below presents the carrying value of
the Company’s financial instruments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Investment in Psyence Labs Ltd</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">745,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">745,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Derivative warrant liabilities – public warrants</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,096</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,096</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance, March 31, 2025</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">200,096</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">745,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">945,096</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Derivative warrant liabilities – private warrants</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">26,608</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">26,608</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">Derivative warrant liabilities – public warrants</td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">875,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">875,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">Convertible notes</td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">7,657,397</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">7,657,397</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="text-align: justify; padding-bottom: 1.5pt">NCAC Sponsor promissory note</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,474,256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,474,256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">PGI promissory note</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,316,236</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,316,236</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Balance, March 31, 2024</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">875,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">26,608</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">10,447,889</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,349,497</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
745000
745000
200096
200096
200096
745000
945096
26608
26608
875000
875000
7657397
7657397
1474256
1474256
1316236
1316236
875000
26608
10447889
11349497
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table set forth the maturity of
the contractual obligations as at March 31, 2025 and after</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
<tr style="vertical-align: bottom">
<td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Carrying Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual Cash Flows</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than 1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Between 1 and 3 years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: justify; padding-bottom: 1.5pt">Accounts payable &amp; accrued liabilities</td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">394,270</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">394,270</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">394,270</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td>
<td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">         -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; ">
<td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total contractual obligations</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">394,270</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">394,270</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">394,270</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
394270
394270
394270
394270
394270
394270
0.10
8861
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>22. Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 15, 2025 the Company issued an additional
15,242 common shares to a third-party consultant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 15, 2025 the Company signed a subscription
agreement to subscribe for an additional 250 shares in Psyence Labs Ltd for total consideration of $500,000 in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 17, 2025 the Company granted 12,711 restricted
stock units (“<b>RSU’s</b>”) to consultants and an employee of the Company. This was granted pursuant to an equity incentive
scheme implemented by the Company to incentivise consultants and employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On May 5, 2025, the Company consolidated its common
shares on the basis of 7.97:1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Subsequent to year end the Company issued 130,000
shares for gross proceeds of $607,050 under the ELOC.</p>
contextRef="c289"
decimals="0"
id="ixv-20833"
unitRef="shares">15242
contextRef="c290"
decimals="0"
id="ixv-20834"
unitRef="shares">250
500000
contextRef="c291"
decimals="0"
id="ixv-20836"
unitRef="shares">12711
7.97:1
contextRef="c293"
decimals="0"
id="ixv-20838"
unitRef="shares">130000
607050
contextRef="c5"
id="hidden-fact-0"
unitRef="usd"
xsi:nil="true"/>
contextRef="c4"
id="hidden-fact-1"
unitRef="usd"
xsi:nil="true"/>
contextRef="c6"
id="hidden-fact-2"
unitRef="usd"
xsi:nil="true"/>
contextRef="c8"
id="hidden-fact-3"
unitRef="usd"
xsi:nil="true"/>
contextRef="c5"
id="hidden-fact-4"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-5"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-6"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-7"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-8"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-9"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-10"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-11"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-12"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-13"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-14"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-15"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-16"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-17"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-18"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-19"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-20"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-21"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-22"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-23"
unitRef="usd"
xsi:nil="true"/>
contextRef="c12"
id="hidden-fact-24"
unitRef="shares"
xsi:nil="true"/>
contextRef="c14"
id="hidden-fact-25"
unitRef="usd"
xsi:nil="true"/>
contextRef="c19"
id="hidden-fact-26"
unitRef="usd"
xsi:nil="true"/>
contextRef="c20"
id="hidden-fact-27"
unitRef="usd"
xsi:nil="true"/>
contextRef="c21"
id="hidden-fact-28"
unitRef="usd"
xsi:nil="true"/>
contextRef="c18"
id="hidden-fact-29"
unitRef="usd"
xsi:nil="true"/>
contextRef="c19"
id="hidden-fact-30"
unitRef="usd"
xsi:nil="true"/>
contextRef="c20"
id="hidden-fact-31"
unitRef="usd"
xsi:nil="true"/>
contextRef="c18"
id="hidden-fact-32"
unitRef="usd"
xsi:nil="true"/>
contextRef="c19"
id="hidden-fact-33"
unitRef="usd"
xsi:nil="true"/>
contextRef="c21"
id="hidden-fact-34"
unitRef="usd"
xsi:nil="true"/>
contextRef="c22"
id="hidden-fact-35"
unitRef="shares"
xsi:nil="true"/>
contextRef="c22"
id="hidden-fact-36"
unitRef="shares"
xsi:nil="true"/>
contextRef="c27"
id="hidden-fact-37"
unitRef="usd"
xsi:nil="true"/>
contextRef="c29"
id="hidden-fact-38"
unitRef="usd"
xsi:nil="true"/>
contextRef="c30"
id="hidden-fact-39"
unitRef="usd"
xsi:nil="true"/>
contextRef="c31"
id="hidden-fact-40"
unitRef="usd"
xsi:nil="true"/>
contextRef="c32"
id="hidden-fact-41"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-42"
unitRef="usd"
xsi:nil="true"/>
contextRef="c30"
id="hidden-fact-43"
unitRef="usd"
xsi:nil="true"/>
contextRef="c31"
id="hidden-fact-44"
unitRef="usd"
xsi:nil="true"/>
contextRef="c32"
id="hidden-fact-45"
unitRef="usd"
xsi:nil="true"/>
contextRef="c30"
id="hidden-fact-46"
unitRef="usd"
xsi:nil="true"/>
contextRef="c31"
id="hidden-fact-47"
unitRef="usd"
xsi:nil="true"/>
contextRef="c32"
id="hidden-fact-48"
unitRef="usd"
xsi:nil="true"/>
contextRef="c30"
id="hidden-fact-49"
unitRef="usd"
xsi:nil="true"/>
contextRef="c31"
id="hidden-fact-50"
unitRef="usd"
xsi:nil="true"/>
contextRef="c32"
id="hidden-fact-51"
unitRef="usd"
xsi:nil="true"/>
contextRef="c29"
id="hidden-fact-52"
unitRef="usd"
xsi:nil="true"/>
contextRef="c30"
id="hidden-fact-53"
unitRef="usd"
xsi:nil="true"/>
contextRef="c31"
id="hidden-fact-54"
unitRef="usd"
xsi:nil="true"/>
contextRef="c29"
id="hidden-fact-55"
unitRef="usd"
xsi:nil="true"/>
contextRef="c30"
id="hidden-fact-56"
unitRef="usd"
xsi:nil="true"/>
contextRef="c32"
id="hidden-fact-57"
unitRef="usd"
xsi:nil="true"/>
contextRef="c35"
id="hidden-fact-58"
unitRef="usd"
xsi:nil="true"/>
contextRef="c35"
id="hidden-fact-59"
unitRef="usd"
xsi:nil="true"/>
contextRef="c40"
id="hidden-fact-60"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-61"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-62"
unitRef="usd"
xsi:nil="true"/>
contextRef="c40"
id="hidden-fact-63"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-64"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-65"
unitRef="usd"
xsi:nil="true"/>
contextRef="c39"
id="hidden-fact-66"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-67"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-68"
unitRef="usd"
xsi:nil="true"/>
contextRef="c40"
id="hidden-fact-69"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-70"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-71"
unitRef="usd"
xsi:nil="true"/>
contextRef="c40"
id="hidden-fact-72"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-73"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-74"
unitRef="usd"
xsi:nil="true"/>
contextRef="c40"
id="hidden-fact-75"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-76"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-77"
unitRef="usd"
xsi:nil="true"/>
contextRef="c40"
id="hidden-fact-78"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-79"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-80"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-81"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-82"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-83"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-84"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-85"
unitRef="usd"
xsi:nil="true"/>
contextRef="c39"
id="hidden-fact-86"
unitRef="usd"
xsi:nil="true"/>
contextRef="c40"
id="hidden-fact-87"
unitRef="usd"
xsi:nil="true"/>
contextRef="c41"
id="hidden-fact-88"
unitRef="usd"
xsi:nil="true"/>
contextRef="c39"
id="hidden-fact-89"
unitRef="usd"
xsi:nil="true"/>
contextRef="c40"
id="hidden-fact-90"
unitRef="usd"
xsi:nil="true"/>
contextRef="c42"
id="hidden-fact-91"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-92"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-93"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-94"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-95"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-96"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-97"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-98"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-99"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-100"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-101"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-102"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-103"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-104"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-105"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-106"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-107"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-108"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-109"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-110"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-111"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-112"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-113"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-114"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-115"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-116"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-117"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-118"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-119"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-120"
unitRef="usd"
xsi:nil="true"/>
contextRef="c11"
id="hidden-fact-121"
unitRef="usd"
xsi:nil="true"/>
contextRef="c64"
id="hidden-fact-122"
unitRef="cad"
xsi:nil="true"/>
contextRef="c72"
id="hidden-fact-123"
unitRef="usd"
xsi:nil="true"/>
contextRef="c77"
id="hidden-fact-124"
unitRef="usd"
xsi:nil="true"/>
contextRef="c108"
id="hidden-fact-125"
unitRef="pure"
xsi:nil="true"/>
contextRef="c105"
id="hidden-fact-126"
unitRef="usd"
xsi:nil="true"/>
contextRef="c134"
id="hidden-fact-127"
unitRef="pure"
xsi:nil="true"/>
contextRef="c135"
id="hidden-fact-128"
unitRef="pure"
xsi:nil="true"/>
contextRef="c147"
id="hidden-fact-129"
unitRef="shares"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-130"
unitRef="shares"
xsi:nil="true"/>
contextRef="c148"
id="hidden-fact-131"
unitRef="shares"
xsi:nil="true"/>
contextRef="c148"
id="hidden-fact-132"
unitRef="usdPershares"
xsi:nil="true"/>
contextRef="c149"
id="hidden-fact-133"
unitRef="shares"
xsi:nil="true"/>
contextRef="c149"
id="hidden-fact-134"
unitRef="usdPershares"
xsi:nil="true"/>
contextRef="c152"
id="hidden-fact-135"
unitRef="shares"
xsi:nil="true"/>
contextRef="c122"
id="hidden-fact-136"
unitRef="usd"
xsi:nil="true"/>
contextRef="c173"
id="hidden-fact-137"
unitRef="usd"
xsi:nil="true"/>
contextRef="c195"
id="hidden-fact-138"
unitRef="pure"
xsi:nil="true"/>
contextRef="c196"
id="hidden-fact-139"
unitRef="pure"
xsi:nil="true"/>
contextRef="c197"
id="hidden-fact-140"
unitRef="pure"
xsi:nil="true"/>
contextRef="c204"
id="hidden-fact-141"
unitRef="pure"
xsi:nil="true"/>

contextRef="c39"
id="hidden-fact-143"
unitRef="shares"
xsi:nil="true"/>
contextRef="c39"
id="hidden-fact-144"
unitRef="shares"
xsi:nil="true"/>
contextRef="c39"
id="hidden-fact-145"
unitRef="shares"
xsi:nil="true"/>
contextRef="c222"
id="hidden-fact-146"
unitRef="shares"
xsi:nil="true"/>
contextRef="c222"
id="hidden-fact-147"
unitRef="usd"
xsi:nil="true"/>
contextRef="c223"
id="hidden-fact-148"
unitRef="shares"
xsi:nil="true"/>
contextRef="c223"
id="hidden-fact-149"
unitRef="shares"
xsi:nil="true"/>
contextRef="c214"
id="hidden-fact-150"
unitRef="shares"
xsi:nil="true"/>
contextRef="c221"
id="hidden-fact-151"
unitRef="shares"
xsi:nil="true"/>
contextRef="c221"
id="hidden-fact-152"
unitRef="shares"
xsi:nil="true"/>
contextRef="c231"
id="hidden-fact-153"
unitRef="usd"
xsi:nil="true"/>
contextRef="c4"
id="hidden-fact-154"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-155"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-156"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-157"
unitRef="pure"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-158"
unitRef="pure"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-159"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-160"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-161"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-162"
unitRef="usd"
xsi:nil="true"/>
contextRef="c0"
id="hidden-fact-163"
unitRef="usd"
xsi:nil="true"/>
contextRef="c10"
id="hidden-fact-164"
unitRef="usd"
xsi:nil="true"/>
contextRef="c239"
id="hidden-fact-165"
unitRef="usd"
xsi:nil="true"/>
contextRef="c247"
id="hidden-fact-166"
unitRef="usd"
xsi:nil="true"/>
contextRef="c249"
id="hidden-fact-167"
unitRef="usd"
xsi:nil="true"/>
contextRef="c253"
id="hidden-fact-168"
unitRef="usd"
xsi:nil="true"/>
contextRef="c255"
id="hidden-fact-169"
unitRef="usd"
xsi:nil="true"/>
contextRef="c258"
id="hidden-fact-170"
unitRef="usd"
xsi:nil="true"/>
contextRef="c259"
id="hidden-fact-171"
unitRef="usd"
xsi:nil="true"/>
contextRef="c262"
id="hidden-fact-172"
unitRef="usd"
xsi:nil="true"/>
contextRef="c263"
id="hidden-fact-173"
unitRef="usd"
xsi:nil="true"/>
contextRef="c265"
id="hidden-fact-174"
unitRef="usd"
xsi:nil="true"/>
contextRef="c268"
id="hidden-fact-175"
unitRef="usd"
xsi:nil="true"/>
contextRef="c269"
id="hidden-fact-176"
unitRef="usd"
xsi:nil="true"/>
contextRef="c271"
id="hidden-fact-177"
unitRef="usd"
xsi:nil="true"/>
contextRef="c272"
id="hidden-fact-178"
unitRef="usd"
xsi:nil="true"/>
contextRef="c275"
id="hidden-fact-179"
unitRef="usd"
xsi:nil="true"/>
contextRef="c276"
id="hidden-fact-180"
unitRef="usd"
xsi:nil="true"/>
contextRef="c278"
id="hidden-fact-181"
unitRef="usd"
xsi:nil="true"/>
contextRef="c279"
id="hidden-fact-182"
unitRef="usd"
xsi:nil="true"/>
contextRef="c286"
id="hidden-fact-183"
unitRef="usd"
xsi:nil="true"/>
contextRef="c288"
id="hidden-fact-184"
unitRef="usd"
xsi:nil="true"/>
0001985062
false
FY